PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Montero-Herradon, S; Garcia-Ceca, J; Zapata, AG				Montero-Herradon, Sara; Garcia-Ceca, Javier; Zapata, Agustin G.			How Many Thymic Epithelial Cells Are Necessary for a Proper Maturation of Thymocytes?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						thymic epithelial cells; thymocyte education; Eph; ephrin; regulatory T-cells	RECEPTOR; GROWTH		[Montero-Herradon, Sara; Garcia-Ceca, Javier; Zapata, Agustin G.] Univ Complutense Madrid, Dept Cell Biol, Fac Biol, Madrid, Spain; [Montero-Herradon, Sara; Garcia-Ceca, Javier; Zapata, Agustin G.] Hosp 12 Octubre Imas 12, Hlth Res Inst, Madrid, Spain	Complutense University of Madrid	Zapata, AG (corresponding author), Univ Complutense Madrid, Dept Cell Biol, Fac Biol, Madrid, Spain.; Zapata, AG (corresponding author), Hosp 12 Octubre Imas 12, Hlth Res Inst, Madrid, Spain.	zapata@bio.ucm.es	García-Ceca, Javier/J-1803-2016; Montero, SARA/AAD-3017-2019; Montero Herradón, Sara/AAZ-5842-2021	García-Ceca, Javier/0000-0002-0940-455X; Montero, SARA/0000-0003-2004-8987; Montero Herradón, Sara/0000-0003-2004-8987; Zapata, Agustin G/0000-0003-0576-2672	Spanish Ministry of Science, Innovation, and Universities [RTI2018-093938-B-I00]; Carlos III Health Institute [RD16/0011/0002]; Regional Government of Madrid [S2017/BMD-3692]	Spanish Ministry of Science, Innovation, and Universities; Carlos III Health Institute(Instituto de Salud Carlos III); Regional Government of Madrid	This research was funded by the Spanish Ministry of Science, Innovation, and Universities (RTI2018-093938-B-I00), the Carlos III Health Institute (RD16/0011/0002, Cell Therapy Network, TERCEL) and the Regional Government of Madrid (S2017/BMD-3692, Avancell).	Alfaro D, 2008, IMMUNOLOGY, V125, P131, DOI 10.1111/j.1365-2567.2008.02828.x; Alfaro D, 2007, EUR J IMMUNOL, V37, P2596, DOI 10.1002/eji.200737097; Alfaro D, 2011, IMMUNOL CELL BIOL, V89, P844, DOI 10.1038/icb.2010.172; Benz C, 2004, EUR J IMMUNOL, V34, P3652, DOI 10.1002/eji.200425248; Cheng M, 2018, NAT IMMUNOL, V19, P659, DOI 10.1038/s41590-018-0128-9; Cosway EJ, 2017, J EXP MED, V214, P3183, DOI 10.1084/jem.20171000; Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154; Garcia-Ceca J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102226; Garcia-Ceca J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00333; Garcia-Ceca J, 2009, EUR J IMMUNOL, V39, P2916, DOI 10.1002/eji.200939437; Hendrix TM, 2010, CELL IMMUNOL, V261, P81, DOI 10.1016/j.cellimm.2009.11.004; Inglesfield S, 2019, TRENDS IMMUNOL, V40, P279, DOI 10.1016/j.it.2019.01.011; Jenkinson WE, 2007, BLOOD, V109, P954, DOI 10.1182/blood-2006-05-023143; Munoz JJ, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00135; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Munoz JJ, 2009, INMUNOLOGIA, V28, P19, DOI [10.1016/S0213-9626(09)70024-1, DOI 10.1016/S0213-9626(09)70024-1]; Osada M, 2006, CLIN DEV IMMUNOL, V13, P299, DOI 10.1080/17402520600935097; Passos GA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00352; Prockop SE, 2004, J IMMUNOL, V173, P1604, DOI 10.4049/jimmunol.173.3.1604; Revest JM, 2001, J IMMUNOL, V167, P1954, DOI 10.4049/jimmunol.167.4.1954; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Wilkinson DG, 2014, CELL ADHES MIGR, V8, P339, DOI 10.4161/19336918.2014.970007	22	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2021	12								618216	10.3389/fimmu.2021.618216	http://dx.doi.org/10.3389/fimmu.2021.618216			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QZ7SF	33763065	gold, Green Published, Green Accepted			2022-12-18	WOS:000630922000001
J	Shabrish, S; Kelkar, M; Yadav, RM; Bargir, UA; Gupta, M; Dalvi, A; Aluri, J; Kulkarni, M; Shinde, S; Sawant-Desai, S; Kambli, P; Hule, G; Setia, P; Jodhawat, N; Gaikwad, P; Dhawale, A; Nambiar, N; Gowri, V; Pandrowala, A; Taur, P; Raj, R; Uppuluri, R; Sharma, R; Kini, P; Sivasankaran, M; Munirathnam, D; Vedam, R; Vignesh, P; Banday, A; Rawat, A; Aggarwal, A; Poddar, U; Girish, M; Chaudhary, A; Sampagar, A; Jayaraman, D; Chaudhary, N; Shah, NT; Jijina, F; Chandrakla, S; Kanakia, S; Arora, B; Sen, S; Lokeshwar, M; Desai, M; Madkaikar, M				Shabrish, Snehal; Kelkar, Madhura; Yadav, Reetika Malik; Bargir, Umair Ahmed; Gupta, Maya; Dalvi, Aparna; Aluri, Jahnavi; Kulkarni, Manasi; Shinde, Shweta; Sawant-Desai, Sneha; Kambli, Priyanka; Hule, Gouri; Setia, Priyanka; Jodhawat, Neha; Gaikwad, Pallavi; Dhawale, Amruta; Nambiar, Nayana; Gowri, Vijaya; Pandrowala, Ambreen; Taur, Prasad; Raj, Revathi; Uppuluri, Ramya; Sharma, Ratna; Kini, Pranoti; Sivasankaran, Meena; Munirathnam, Deenadayalan; Vedam, Ramprasad; Vignesh, Pandiarajan; Banday, Aaqib; Rawat, Amit; Aggarwal, Amita; Poddar, Ujjal; Girish, Meenakshi; Chaudhary, Abhijit; Sampagar, Abhilasha; Jayaraman, Dharani; Chaudhary, Narendra; Shah, Nitin; Jijina, Farah; Chandrakla, S.; Kanakia, Swati; Arora, Brijesh; Sen, Santanu; Lokeshwar, Madhukar; Desai, Mukesh; Madkaikar, Manisha			The Spectrum of Clinical, Immunological, and Molecular Findings in Familial Hemophagocytic Lymphohistiocytosis: Experience From India	FRONTIERS IN IMMUNOLOGY			English	Article						familial hemophagocytic lymphohistocytosis; perforin; degranulation; HLH-targeted therapy; flow cytomertry; NGS		Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of immune dysregulation characterized by hyperactivation of the immune system, excessive cytokine secretion and severe systemic inflammation. HLH is classified as familial (FHL) when associated with mutations in PRF1, UNC13D, STX11, and STXBP2 genes. There is limited information available about the clinical and mutational spectrum of FHL patients in Indian population. This study is a retrospective analysis of 101 molecularly characterized FHL patients over the last 10 years from 20 different referral centers in India. FHL2 and FHL3 together accounted for 84% of cases of FHL in our cohort. Patients belonging to different FHL subtypes were indistinguishable based on clinical and biochemical parameters. However, flow cytometry-based assays viz. perforin expression and degranulation assay were found to be specific and sensitive in diagnosis and classification of FHL patients. Molecular characterization of respective genes revealed 76 different disease-causing mutations including 39 (51%) novel mutations in PRF1, UNC13D, STX11, and STXBP2 genes. Overall, survival was poor (28%) irrespective of the age of onset or the type of mutation in our cohort. Altogether, this article sheds light on the current scenario of FHL in India. Our data reveal a wide genetic heterogeneity of FHL in the Indian population and confirms the poor prognosis of FHL. This study also emphasizes that though mutational analysis is important for diagnostic confirmation of FHL, flow cytometry based assays help significantly in rapid diagnosis and functional validation of novel variants identified.	[Shabrish, Snehal; Kelkar, Madhura; Yadav, Reetika Malik; Bargir, Umair Ahmed; Gupta, Maya; Dalvi, Aparna; Aluri, Jahnavi; Kulkarni, Manasi; Shinde, Shweta; Sawant-Desai, Sneha; Kambli, Priyanka; Hule, Gouri; Setia, Priyanka; Jodhawat, Neha; Gaikwad, Pallavi; Dhawale, Amruta; Nambiar, Nayana; Madkaikar, Manisha] Indian Council Med Research, Natl Inst Immunohaematol, Dept Pediat Immunol & Leukocyte Biol, Mumbai, Maharashtra, India; [Gowri, Vijaya; Taur, Prasad; Desai, Mukesh] Bai Jerbai Wadia Hosp Children, Dept Immunol, Mumbai, Maharashtra, India; [Pandrowala, Ambreen] Bai Jerbai Wadia Hosp Children, Dept Bone Marrow Transplant, Mumbai, Maharashtra, India; [Raj, Revathi; Uppuluri, Ramya] Apollo Hosp, Dept Pediat Hematol Oncol Blood & Marrow Transpla, Chennai, Tamil Nadu, India; [Sharma, Ratna; Kini, Pranoti] Comprehens Thalassemia Care Pediat Hematol Oncol, Mumbai, Maharashtra, India; [Sivasankaran, Meena; Munirathnam, Deenadayalan] Kanchi Kamakoti CHILDS Trust Hosp, Dept Pediat Hematooncol, Chennai, Tamil Nadu, India; [Vedam, Ramprasad] Medgenome Labs Pvt Ltd, Narayana Hlth City, Bommasandra, India; [Vignesh, Pandiarajan; Banday, Aaqib; Rawat, Amit] Post Grad Inst Med Educ & Res, Dept Pediat, Chandigarh, India; [Aggarwal, Amita; Poddar, Ujjal] Sanjay Gandhi Postgrad Inst Med Sci, Dept Clin Immunol & Rheumatol, Lucknow, Uttar Pradesh, India; [Girish, Meenakshi; Chaudhary, Abhijit] All India Inst Med Sci, Dept Pediat, Nagpur, Maharashtra, India; [Sampagar, Abhilasha] KAHERS Jawaharlal Nehru Med Coll, Belagavi, India; [Jayaraman, Dharani] Sri Ramchandra Inst Higher Educ & Res, Dept Pediat, Chennai, Tamil Nadu, India; [Chaudhary, Narendra] All India Inst Med Sci, Dept Pediat, Bhopal, India; [Shah, Nitin; Jijina, Farah] PD Hinduja Hosp, Mumbai, Maharashtra, India; [Chandrakla, S.] Seth GS Med Coll, Dept Haematol, Mumbai, Maharashtra, India; [Chandrakla, S.] King Edward Mem Hosp, Mumbai, Maharashtra, India; [Kanakia, Swati] Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India; [Arora, Brijesh] Tata Mem Hosp, Dept Pediat Oncol, Mumbai, Maharashtra, India; [Sen, Santanu] Kokilaben Dhirubai Ambani Hosp, Mumbai, Maharashtra, India; [Lokeshwar, Madhukar] Kashyap Nursing Home, Mumbai, Maharashtra, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Immunohaemotology (NIIH); Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Sanjay Gandhi Postgraduate Institute of Medical Sciences; All India Institute of Medical Sciences (AIIMS) Nagpur; K.L.E. Academy of Higher Education & Research; Jawaharlal Nehru Medical College, Belgaum; Sri Ramachandra Institute of Higher Education & Research; All India Institute of Medical Sciences (AIIMS) Bhopal; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital	Madkaikar, M (corresponding author), Indian Council Med Research, Natl Inst Immunohaematol, Dept Pediat Immunol & Leukocyte Biol, Mumbai, Maharashtra, India.	madkaikarmanisha@gmail.com	Banday, Aaqib Zaffar/AAN-2592-2020; Chaudhary, Narendra Kumar/AAH-7745-2021; Sampagar, Abhilasha/AAT-3771-2020; Bargir, Umair Ahmed/AAR-4202-2020; Aluri, Jahnavi/AAB-3570-2022; Vignesh, Pandiarajan/AAV-3025-2021; Chaudhary, Narendra/GRJ-7752-2022	Banday, Aaqib Zaffar/0000-0001-5486-4267; Chaudhary, Narendra Kumar/0000-0002-0243-6364; Sampagar, Abhilasha/0000-0001-8604-4167; Bargir, Umair Ahmed/0000-0001-6785-8042; Vignesh, Pandiarajan/0000-0001-8490-5584; Jodhawat, Neha/0000-0002-7752-3956; shabrish, snehal/0000-0002-6407-5082; Yadav`, Reetika/0000-0002-5030-0437	Indian Council of Medical Research (ICMR)	Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR))	Support from Indian Council of Medical Research (ICMR) to NIIH is gratefully acknowledged.	Abdalgani M, 2015, BLOOD, V126, P1858, DOI 10.1182/blood-2015-06-648659; Ammann S, 2014, CLIN EXP IMMUNOL, V176, P394, DOI 10.1111/cei.12306; Ammann S, 2017, J CLIN IMMUNOL, V37, P770, DOI 10.1007/s10875-017-0443-1; Arico M, 1996, LEUKEMIA, V10, P197; Ariffin H, 2005, J PAEDIATR CHILD H, V41, P136, DOI 10.1111/j.1440-1754.2005.00564.x; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; Cetica V, 2016, J ALLERGY CLIN IMMUN, V137, P188, DOI 10.1016/j.jaci.2015.06.048; Chia J, 2009, P NATL ACAD SCI USA, V106, P9809, DOI 10.1073/pnas.0903815106; Chiang SCC, 2013, BLOOD, V121, P1345, DOI 10.1182/blood-2012-07-442558; Chiang SCC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01740; Chiapparini L, 2011, NEUROL SCI, V32, P473, DOI 10.1007/s10072-010-0467-2; Clementi R, 2002, BLOOD, V100, P2266, DOI 10.1182/blood-2002-04-1030; Entesarian M, 2013, BRIT J HAEMATOL, V162, P415, DOI 10.1111/bjh.12371; Filipovich Alexandra H, 2009, Hematology Am Soc Hematol Educ Program, P127, DOI 10.1182/asheducation-2009.1.127; Gholam C, 2011, CLIN EXP IMMUNOL, V163, P271, DOI 10.1111/j.1365-2249.2010.04302.x; Gifford CE, 2014, CYTOM PART B-CLIN CY, V86, P263, DOI 10.1002/cyto.b.21166; Hori M, 2017, J CLIN IMMUNOL, V37, P92, DOI 10.1007/s10875-016-0357-3; Ishii E, 2005, CRIT REV ONCOL HEMAT, V53, P209, DOI 10.1016/j.critrevonc.2004.11.002; Janka GE, 2012, ANNU REV MED, V63, P233, DOI 10.1146/annurev-med-041610-134208; Khazal S, 2018, PEDIATR TRANSPLANT, V22, DOI 10.1111/petr.13101; Kogawa K, 2002, BLOOD, V99, P61, DOI 10.1182/blood.V99.1.61; Lee SM, 2004, J MED GENET, V41, P137, DOI 10.1136/jmg.2003.011528; Lounder DT, 2019, BLOOD ADV, V3, P47, DOI 10.1182/bloodadvances.2018025858; Madkaikar M, 2017, J PEDIAT HEMATOL ONC, V39, P143, DOI 10.1097/MPH.0000000000000597; Madkaikar MR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01248; Marsh RA, 2018, BRIT J HAEMATOL, V182, P185, DOI 10.1111/bjh.15274; Mhatre S, 2014, J PEDIAT HEMATOL ONC, V36, pE524, DOI 10.1097/MPH.0000000000000102; Ohadi M, 1999, AM J HUM GENET, V64, P165, DOI 10.1086/302187; Qian YP, 2014, PEDIATR BLOOD CANCER, V61, P1034, DOI 10.1002/pbc.24955; Rohr J, 2010, HAEMATOL-HEMATOL J, V95, P2080, DOI 10.3324/haematol.2010.029389; Rubin TS, 2017, BLOOD, V129, P2993, DOI 10.1182/blood-2016-12-753830; Shabrish S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/3769590; Sieni E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00167; Sieni E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044649; Sieni E, 2011, J MED GENET, V48, P343, DOI 10.1136/jmg.2010.085456; Spessott WA, 2015, BLOOD, V125, P1566, DOI 10.1182/blood-2014-11-610816; Stadt UZ, 2006, HUM MUTAT, V27, P62, DOI 10.1002/humu.20274; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Strauss-Albee DM, 2017, CYTOM PART B-CLIN CY, V92, P33, DOI 10.1002/cyto.b.21485; Tesi B, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0244-1; Trizzino A, 2008, J MED GENET, V45, P15, DOI 10.1136/jmg.2007.052670; Yoon HS, 2010, HAEMATOL-HEMATOL J, V95, P622, DOI 10.3324/haematol.2009.016949; Zhang KJ, 2014, BLOOD, V124, P1331, DOI 10.1182/blood-2014-05-573105; Zhang KJ, 2011, BLOOD, V118, P5794, DOI 10.1182/blood-2011-07-370148	44	2	2	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2021	12								612583	10.3389/fimmu.2021.612583	http://dx.doi.org/10.3389/fimmu.2021.612583			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QY7BP	33746956	gold, Green Published			2022-12-18	WOS:000630192500001
J	Kohn, M; Lanfermann, C; Laudeley, R; Glage, S; Rheinheimer, C; Klos, A				Kohn, Martin; Lanfermann, Christian; Laudeley, Robert; Glage, Silke; Rheinheimer, Claudia; Klos, Andreas			Complement and Chlamydia psittaci: Non-Myeloid-Derived C3 Predominantly Induces Protective Adaptive Immune Responses in Mouse Lung Infection	FRONTIERS IN IMMUNOLOGY			English	Article						complement; chlamydia; intracellular; adaptive immunity; T-cells; B-cells; C3; bone marrow chimeric mice		Recent advances in complement research have revolutionized our understanding of its role in immune responses. The immunomodulatory features of complement in infections by intracellular pathogens, e.g., viruses, are attracting increasing attention. Thereby, local production and activation of complement by myeloid-derived cells seem to be crucial. We could recently show that C3, a key player of the complement cascade, is required for effective defense against the intracellular bacterium Chlamydia psittaci. Avian zoonotic strains of this pathogen cause life-threatening pneumonia with systemic spread in humans; closely related non-avian strains are responsible for less severe diseases of domestic animals with economic loss. To clarify how far myeloid- and non-myeloid cell-derived complement contributes to immune response and resulting protection against C. psittaci, adoptive bone marrow transfer experiments focusing on C3 were combined with challenge experiments using a non-avian (BSL 2) strain of this intracellular bacterium. Surprisingly, our data prove that for C. psittaci-induced pneumonia in mice, non-myeloid-derived, circulating/systemic C3 has a leading role in protection, in particular on the development of pathogen-specific T- and B- cell responses. In contrast, myeloid-derived and most likely locally produced C3 plays only a minor, mainly fine-tuning role. The work we present here describes authentic, although less pronounced, antigen directed immune responses.	[Kohn, Martin; Lanfermann, Christian; Laudeley, Robert; Rheinheimer, Claudia; Klos, Andreas] Med Sch Hannover, Inst Med Microbiol & Hosp Epidemiol, Hannover, Germany; [Glage, Silke] Med Sch Hannover, Inst Lab Anim Sci, Hannover, Germany	Hannover Medical School; Hannover Medical School	Klos, A (corresponding author), Med Sch Hannover, Inst Med Microbiol & Hosp Epidemiol, Hannover, Germany.	Klos.Andreas@mh-hannover.de			Deutsche Forschungsgemeinschaft (DFG) [KL-603/10-1]; ZIB Ph.D. program from the Hannover Medical School	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); ZIB Ph.D. program from the Hannover Medical School	This research project was funded by the Deutsche Forschungsgemeinschaft (DFG): KL-603/10-1. MK and CL were partially funded by the ZIB Ph.D. program from the Hannover Medical School.	Agrawal P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01117; [Anonymous], 2000, MMWR Recomm Rep, V49, P3; Arbore G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06706-z; Arborea G, 2017, MOL IMMUNOL, V89, P2, DOI 10.1016/j.molimm.2017.05.012; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Baud D, 2011, CLIN MICROBIOL INFEC, V17, P1312, DOI 10.1111/j.1469-0691.2011.03604.x; Bode J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050327; Cheong HC, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7050146; Cooper P D, 1995, Pharm Biotechnol, V6, P559; de la Maza LM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00543-16, 10.1128/cvi.00543-16]; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Dumke R, 2015, EMERG INFECT DIS, V21, P426, DOI 10.3201/eid2103.140927; Dutow P, 2014, J INFECT DIS, V209, P1269, DOI 10.1093/infdis/jit640; Dutow P, 2013, INFECT IMMUN, V81, P3366, DOI 10.1128/IAI.00334-13; Elwell C, 2016, NAT REV MICROBIOL, V14, P385, DOI 10.1038/nrmicro.2016.30; Fankhauser SC, 2014, J IMMUNOL, V192, P1079, DOI 10.4049/jimmunol.1301657; Freeley S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02449; Ghannam A, 2014, MOL IMMUNOL, V58, P98, DOI 10.1016/j.molimm.2013.11.010; Goellner S, 2006, INFECT IMMUN, V74, P4801, DOI 10.1128/IAI.01487-05; HALL RT, 1993, INFECT IMMUN, V61, P1829, DOI 10.1128/IAI.61.5.1829-1834.1993; Hammerschlag MR, 2000, EUR RESPIR J, V16, P1001, DOI 10.1183/09031936.00.16510010; Harkinezhad T, 2009, VET MICROBIOL, V135, P68, DOI 10.1016/j.vetmic.2008.09.046; Hess C, 2016, IMMUNITY, V45, P240, DOI 10.1016/j.immuni.2016.08.003; Juretzek Milnickel I., 2012, MIKROBIOLOGIYA, V24; Kandasamy M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003115; Karsten CM, 2017, J IMMUNOL, V199, P3234, DOI 10.4049/jimmunol.1700710; Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994; Killick J, 2018, SEMIN IMMUNOPATHOL, V40, P37, DOI 10.1007/s00281-017-0644-y; Klos A, 2013, PHARMACOL REV, V65, P500, DOI 10.1124/pr.111.005223; Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027; Knittler MR, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu007; Knittler MR, 2014, INT J MED MICROBIOL, V304, P877, DOI 10.1016/j.ijmm.2014.06.010; Kolev M, 2015, IMMUNITY, V42, P1033, DOI 10.1016/j.immuni.2015.05.024; Kollessery G, 2011, VACCINE, V29, P5904, DOI 10.1016/j.vaccine.2011.06.070; Kopf M, 2002, NAT MED, V8, P373, DOI 10.1038/nm0402-373; Laroucau K, 2009, VET MICROBIOL, V135, P82, DOI 10.1016/j.vetmic.2008.09.048; Laufer J, 2001, MOL IMMUNOL, V38, P221, DOI 10.1016/S0161-5890(01)00044-X; Lausen M, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00087-20; Lausen M, 2018, MICROBES INFECT, V20, P328, DOI 10.1016/j.micinf.2018.04.004; Le Friec G, 2012, NAT IMMUNOL, V13, P1213, DOI 10.1038/ni.2454; Lee Junghwa, 2015, For Immunopathol Dis Therap, V6, P7, DOI 10.1615/ForumImmunDisTher.2015014188; LIN JSL, 1992, INFECT IMMUN, V60, P2547, DOI 10.1128/IAI.60.6.2547-2550.1992; Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018; Lubbers R, 2017, CLIN EXP IMMUNOL, V188, P183, DOI 10.1111/cei.12952; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x; Nakayama Y, 2009, J IMMUNOL, V183, P2921, DOI 10.4049/jimmunol.0801191; Naughton MA, 1996, J IMMUNOL, V156, P3051; Peng Q, 2006, J IMMUNOL, V176, P3330, DOI 10.4049/jimmunol.176.6.3330; Porcella SF, 2015, INFECT IMMUN, V83, P534, DOI 10.1128/IAI.02764-14; Quell KM, 2017, J IMMUNOL, V199, P688, DOI 10.4049/jimmunol.1700318; Rattan A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006248; Rudilla F, 2012, VACCINE, V30, P2848, DOI 10.1016/j.vaccine.2012.02.052; Satpathy G, 2017, INDIAN J OPHTHALMOL, V65, P97, DOI 10.4103/ijo.IJO_870_16; Shekhar S, 2018, CELL MOL IMMUNOL, V15, P377, DOI 10.1038/cmi.2016.68; Sommer K, 2009, FEMS IMMUNOL MED MIC, V55, P206, DOI 10.1111/j.1574-695X.2008.00503.x; STARNBACH MN, 1994, J IMMUNOL, V153, P5183; Stoermer KA, 2011, VIROLOGY, V411, P362, DOI 10.1016/j.virol.2010.12.045; Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001; Strainic MG, 2013, NAT IMMUNOL, V14, P162, DOI 10.1038/ni.2499; Suresh M, 2003, J IMMUNOL, V170, P788, DOI 10.4049/jimmunol.170.2.788; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; West EE, 2020, IMMUNOL REV, V295, P68, DOI 10.1111/imr.12852; West EE, 2018, ANNU REV IMMUNOL, V36, P309, DOI 10.1146/annurev-immunol-042617-053245; Wizel B, 2008, MICROBES INFECT, V10, P1420, DOI 10.1016/j.micinf.2008.08.006	66	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 4	2021	12								626627	10.3389/fimmu.2021.626627	http://dx.doi.org/10.3389/fimmu.2021.626627			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QY4CD	33746963	gold, Green Published			2022-12-18	WOS:000629988600001
J	Sung, MH; Shen, Y; Handel, A; Bahl, J; Ross, TM				Sung, Meng-Hsuan; Shen, Ye; Handel, Andreas; Bahl, Justin; Ross, Ted M.			Longitudinal Assessment of Immune Responses to Repeated Annual Influenza Vaccination in a Human Cohort of Adults and Teenagers	FRONTIERS IN IMMUNOLOGY			English	Article						influenza vaccine; hemagglutination inhibition assay; composite score; repeat vaccination; immune responses		Background: The overall performance of a multiple component vaccine assessed by the vaccine-elicited immune responses across various strains in a repeated vaccination setting has not been well-studied, and the comparison between adults and teenagers is yet to be made. Methods: A human cohort study was conducted at the University of Georgia, with 140 subjects (86 adults and 54 teenagers) repeatedly vaccinated in the 2017/2018 and 2018/2019 influenza seasons. Host information was prospectively collected, and serum samples were collected before and after vaccination in each season. The association between host factors and repeated measures of hemagglutination inhibition (HAI) composite scores was assessed by generalized linear models with generalized estimating equations. Results: The mean HAI composite scores for the entire sample (t = 4.26, df = 139, p < 0.001) and the teenager group (t = 6.44, df = 53, p < 0.001) declined in the second season, while the changes in the adults were not statistically significant (t = -1.14, df = 85, p = 0.26). A mixture pattern of changes in both directions was observed in the adults when stratified by prior vaccination. In addition, the regression analysis suggested an interactive effect of age and BMI on the HAI composite scores in the overall population (beta = 0.005; 95% CI, 0.0008-0.01) and the adults (beta = 0.005; 95% CI, 0.0005-0.01). Conclusions: Our study found distinct vaccine-elicited immune responses between adults and teenagers when both were repeatedly vaccinated in consecutive years. An interactive effect of age and BMI on the HAI composite scores were identified in the overall population and the adults.	[Sung, Meng-Hsuan; Shen, Ye; Handel, Andreas; Bahl, Justin] Univ Georgia, Dept Epidemiol & Biostat, Coll Publ Hlth, Athens, GA 30602 USA; [Handel, Andreas] Univ Georgia, Coll Publ Hlth, Hlth Informat Inst, Athens, GA 30602 USA; [Handel, Andreas; Bahl, Justin] Univ Georgia, Ctr Ecol Infect Dis, Athens, GA 30602 USA; [Bahl, Justin; Ross, Ted M.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA USA; [Bahl, Justin; Ross, Ted M.] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Shen, Y (corresponding author), Univ Georgia, Dept Epidemiol & Biostat, Coll Publ Hlth, Athens, GA 30602 USA.	yeshen@uga.edu	Bahl, Justin/A-4728-2011	Bahl, Justin/0000-0001-7572-4300; Handel, Andreas/0000-0002-4622-1146	University of Georgia Research Foundation; National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services [75N93019C00052]; Georgia Research Alliance as an Eminent Scholar; NIH [U01AI150747]	University of Georgia Research Foundation; National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services; Georgia Research Alliance as an Eminent Scholar; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study received financial support from University of Georgia Research Foundation. This project has been funded by the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under contract 75N93019C00052. TR is also supported by the Georgia Research Alliance as an Eminent Scholar. AH also received partial support from NIH grant U01AI150747. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu RB, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132155; Beyer WEP, 1999, ARCH INTERN MED, V159, P182, DOI 10.1001/archinte.159.2.182; BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; Beyer WEP, 1996, VACCINE, V14, P1331, DOI 10.1016/S0264-410X(96)00058-8; Callahan ST, 2014, J INFECT DIS, V210, P1270, DOI 10.1093/infdis/jiu245; Carlock MA, 2019, HUM VACC IMMUNOTHER, V15, P2030, DOI 10.1080/21645515.2019.1642056; Chambers C, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy211; Cobey S, 2018, CLIN INFECT DIS, V67, P327, DOI 10.1093/cid/ciy097; Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513; Gabriel G, 2014, J INFECT DIS, V209, pS93, DOI 10.1093/infdis/jiu020; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Groenwold RHH, 2009, EUR RESPIR J, V34, P56, DOI 10.1183/09031936.00190008; Hopping AM, 2016, VACCINE, V34, P540, DOI 10.1016/j.vaccine.2015.11.058; Honce R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01071; HOSKINS TW, 1979, LANCET, V1, P33; Karki S, 2018, INT J OBESITY, V42, P1480, DOI 10.1038/s41366-018-0029-x; Keitel WA, 1997, VACCINE, V15, P1114, DOI 10.1016/S0264-410X(97)00003-0; KEITEL WA, 1988, AM J EPIDEMIOL, V127, P353, DOI 10.1093/oxfordjournals.aje.a114809; Khurana S, 2012, J INFECT DIS, V205, P610, DOI 10.1093/infdis/jir791; McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680; Neidich SD, 2017, INT J OBESITY, V41, P1324, DOI 10.1038/ijo.2017.131; Nunez IA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185666; Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661; Paich HA, 2013, OBESITY, V21, P2377, DOI 10.1002/oby.20383; Petrie JG, 2011, J INFECT DIS, V203, P1309, DOI 10.1093/infdis/jir015; R Core Team, 2020, R LANG ENV STAT COMP; Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208; Skowronski DM, 2017, J INFECT DIS, V215, P1059, DOI 10.1093/infdis/jix074; Smith DJ, 1999, P NATL ACAD SCI USA, V96, P14001, DOI 10.1073/pnas.96.24.14001; Thompson MG, 2016, VACCINE, V34, P981, DOI 10.1016/j.vaccine.2015.10.119; WHO Global Influenza Surveillance Network, 2011, MANUAL LAB DIAGNOSIS; Xie H, 2017, CLIN INFECT DIS, V65, P259, DOI 10.1093/cid/cix269	32	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 3	2021	12								642791	10.3389/fimmu.2021.642791	http://dx.doi.org/10.3389/fimmu.2021.642791			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX5DM	33746985	gold, Green Published			2022-12-18	WOS:000629366800001
J	Barni, S; Giovannini, M; Liccioli, G; Sarti, L; Gissi, A; Lionetti, P; Mori, F				Barni, Simona; Giovannini, Mattia; Liccioli, Giulia; Sarti, Lucrezia; Gissi, Anna; Lionetti, Paolo; Mori, Francesca			Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease	FRONTIERS IN IMMUNOLOGY			English	Article						anti-IgE monoclonal antibody; chronic spontaneous urticaria; inflammatory bowel diseases; Crohn&#8217; s disease; omalizumab; adolescent		Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that is often associated with autoimmune or autoinflammatory conditions. Omalizumab is recommended in the treatment of refractory CSU in patients over 12 years of age who do not respond to four standard doses of antihistamines. Omalizumab blocks the mast cells' degranulation, thus interrupting the resulting inflammatory cascade driven by T-helper 2 (Th2) cytokines. The efficacy of omalizumab in controlling CSU and possible associated diseases has been studied in few patients so far. In particular, some case reports describe adults with CSU and concomitant inflammatory bowel diseases (IBD), such as Crohn's disease (CD) or ulcerative colitis (UC). Although the treatment of CD with anti-tumor necrosis factors-alpha (TNF-alpha) seems to be effective in controlling CSU, no cases of the utility of omalizumab in patients with both conditions have been described so far. At the moment, there is no evidence that the pathogenetic mechanisms underlying CD are linked to the same pathways that are inhibited by omalizumab for the treatment of CSU. We present the first pediatric case of refractory CSU and CD in which omalizumab led to CSU remission, even if the follow-up period was limited. In conclusion, our experience shows how CSU could be associated with CD and successfully treated with the monoclonal anti-IgE antibody in a patient on immunosuppressive therapy. However, more data is needed from a larger population.	[Barni, Simona; Giovannini, Mattia; Liccioli, Giulia; Sarti, Lucrezia; Mori, Francesca] Meyer Childrens Univ Hosp, Dept Pediat, Allergy Unit, Florence, Italy; [Gissi, Anna; Lionetti, Paolo] Meyer Childrens Univ Hosp, Gastroenterol & Nutr Unit, Florence, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER	Giovannini, M (corresponding author), Meyer Childrens Univ Hosp, Dept Pediat, Allergy Unit, Florence, Italy.	mattiag88@hotmail.it	Liccioli, Giulia/AAC-3862-2022; Giovannini, Mattia/AAP-2693-2021	Liccioli, Giulia/0000-0002-5216-0423; Giovannini, Mattia/0000-0001-9568-6882	Novartis	Novartis(Novartis)	The research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The publication fee was financed by Novartis. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Bard S, 2008, ARCH DERMATOL, V144, P1662, DOI 10.1001/archdermatol.2008.510; Cardet JC, 2019, J ALLERGY CLIN IMMUN, V143, P923, DOI 10.1016/j.jaci.2019.01.016; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; Comberiati P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01700; dos Santos JC, 2008, INT IMMUNOPHARMACOL, V8, P1433, DOI 10.1016/j.intimp.2008.05.016; Farkas H, 1999, IMMUNOL INVEST, V28, P43, DOI 10.3109/08820139909022722; Freeman HJ, 2000, CAN J GASTROENTEROL, V14, P337, DOI 10.1155/2000/828679; Grieco T, 2018, J DERMATOL TREAT, V29, P10, DOI 10.1080/09546634.2018.1527990; Habal F, 2012, WORLD J GASTROENTERO, V18, P4787, DOI 10.3748/wjg.v18.i34.4787; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Iemoli E, 2017, EUR ANN ALLERGY CLIN, V49, P88; Kaplan AP, 2017, ALLERGY, V72, P519, DOI 10.1111/all.13083; Kolkhir P, 2017, AUTOIMMUN REV, V16, P1196, DOI 10.1016/j.autrev.2017.10.003; Kolkhir P, 2017, J ALLERGY CLIN IMMUN, V139, P1772, DOI 10.1016/j.jaci.2016.08.050; Liutu M, 1998, INT J DERMATOL, V37, P515, DOI 10.1046/j.1365-4362.1998.00328.x; Mansueto Pasquale, 2009, BMJ Case Rep, V2009, DOI 10.1136/bcr.08.2008.0781; Maurer M, 2020, INT ARCH ALLERGY IMM, V181, P321, DOI 10.1159/000507218; Naimeh LG, 2001, ANN ALLERG ASTHMA IM, V86, P511, DOI 10.1016/S1081-1206(10)62898-0; Petagna L, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-00280-5; Peyrin-Biroulet L, 2008, LANCET, V372, P67, DOI 10.1016/S0140-6736(08)60995-2; Sand FL, 2015, DERMATOL THER, V28, P158, DOI 10.1111/dth.12222; Sarti L, 2021, PEDIAT ALLERG IMM-UK, V32, P153, DOI 10.1111/pai.13325; Strober W, 2011, GASTROENTEROLOGY, V140, P1756, DOI 10.1053/j.gastro.2011.02.016; Wilson LH, 2011, J AM ACAD DERMATOL, V64, P1221, DOI 10.1016/j.jaad.2009.10.043; Witten J, 2016, INFLAMM BOWEL DIS, V22, pE12, DOI 10.1097/MIB.0000000000000702; Zuberbier T, 2009, ALLERGY, V64, P1427, DOI 10.1111/j.1398-9995.2009.02178.x	26	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2021	12								635069	10.3389/fimmu.2021.635069	http://dx.doi.org/10.3389/fimmu.2021.635069			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX3KP	33737936	gold, Green Published			2022-12-18	WOS:000629245200001
J	Lightbourn, CO; Wolf, D; Copsel, SN; Wang, Y; Pfeiffer, BJ; Barreras, H; Bader, CS; Komanduri, KV; Perez, VL; Levy, RB				Lightbourn, Casey O.; Wolf, Dietlinde; Copsel, Sabrina N.; Wang, Ying; Pfeiffer, Brent J.; Barreras, Henry; Bader, Cameron S.; Komanduri, Krishna V.; Perez, Victor L.; Levy, Robert B.			Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection	FRONTIERS IN IMMUNOLOGY			English	Article						cyclophosphamide; Treg; corneal transplantation; hematopoietic stem cell transplantation; tolerance		Corneal transplantation (CT) is the most frequent type of solid organ transplant (SOT) performed worldwide. Unfortunately, immunological rejection is the primary cause of graft failure for CT and therefore advances in immune regulation to induce tolerance remains an unmet medical need. Recently, our work and others in pre-clinical studies found that cyclophosphamide (Cy) administered after ("post-transplant," PTCy) hematopoietic stem cell transplantation (HSCT), i.e., liquid transplants is effective for graft vs. host disease prophylaxis and enhances overall survival. Importantly, within the past 10 years, PTCy has been widely adopted for clinical HSCT and the results at many centers have been extremely encouraging. The present studies found that Cy can be effectively employed to prolong the survival of SOT, specifically mouse corneal allografts. The results demonstrated that the timing of PTCy administration is critical for these CT and distinct from the kinetics employed following allogeneic HSCT. PTCy was observed to interfere with neovascularization, a process critically associated with immune rejection of corneal tissue that ensues following the loss of ocular "immune privilege." PTCy has the potential to delete or directly suppress allo-reactive T cells and treatment here was shown to diminish T cell rejection responses. These PTCy doses were observed to spare significant levels of CD4(+) FoxP3(+) (Tregs) which were found to be functional and could readily receive stimulating signals leading to their in vivo expansion via TNFRSF25 and CD25 agonists. In total, we posit future studies can take advantage of Cy based platforms to generate combinatorial strategies for long-term tolerance induction.	[Lightbourn, Casey O.; Copsel, Sabrina N.; Barreras, Henry; Bader, Cameron S.; Levy, Robert B.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Wolf, Dietlinde; Komanduri, Krishna V.; Levy, Robert B.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Wang, Ying; Perez, Victor L.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Miami, FL 33136 USA; [Pfeiffer, Brent J.; Levy, Robert B.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA; [Komanduri, Krishna V.; Levy, Robert B.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Perez, Victor L.] Duke Univ, Foster Ctr Ocular Immunol, Duke Eye Ctr, Durham, NC USA; [Perez, Victor L.] Duke Univ Sch Med, Dept Ophthalmol, Duke Eye Ctr, Durham, NC USA	University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; Duke University; Duke University	Levy, RB (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.; Levy, RB (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.; Levy, RB (corresponding author), Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.; Levy, RB (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.	rlevy@med.miami.edu		Bader, Cameron/0000-0003-3544-0113	NIHRO1 [EY024484-06, R01EY030283-01]; Heat Biologics, Inc. [R41AI149916-01]; Heat Biologics, Inc.; Sylvester Comprehensive Cancer Center; NIH [F31CA216999, F99CA245728]; Kalish Family Foundation	NIHRO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Heat Biologics, Inc.; Heat Biologics, Inc.; Sylvester Comprehensive Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kalish Family Foundation	This work was supported by funds from the NIHRO1 EY024484-06, R01EY030283-01 (RL and VP); R41AI149916-01, and SRA from Heat Biologics, Inc. (RL); SRA from Heat Biologics, Inc. (VP); Sylvester Comprehensive Cancer Center (RL and SC); NIH F31CA216999, F99CA245728 (CB); Kalish Family Foundation (KK). The funder bodies were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Amescua G, 2008, TRANSPLANTATION, V85, P615, DOI 10.1097/TP.0b013e3181636d9d; [Anonymous], 1988, JAMA, V259, P719; Atif M, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1099; Bachmann B, 2010, OPHTHALMOLOGY, V117, P1300, DOI 10.1016/j.ophtha.2010.01.039; Bayer AL, 2011, EUR J IMMUNOL, V41, P3467, DOI 10.1002/eji.201141611; Bayer AL, 2009, BLOOD, V113, P733, DOI 10.1182/blood-2008-08-173179; BERENBAUM MC, 1963, NATURE, V200, P84, DOI 10.1038/200084a0; Boisgerault F, 2009, TRANSPLANTATION, V87, P16, DOI 10.1097/TP.0b013e318191b38b; Browder T, 2000, CANCER RES, V60, P1878; CARDOSO SS, 1978, EUR J CANCER, V14, P1037, DOI 10.1016/0014-2964(78)90058-0; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; Ciba Foundation., 1973, CORN GRAFT FAIL; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Copsel SN, 2020, AM J PATHOL, V190, P2000, DOI 10.1016/j.ajpath.2020.07.012; Copsel SN, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03104; Coster DJ, 2003, EYE, V17, P996, DOI 10.1038/sj.eye.6700634; Cunnusamy K, 2010, INVEST OPHTH VIS SCI, V51, P6566, DOI 10.1167/iovs.10-6161; Cursiefen C, 2003, CORNEA, V22, P273, DOI 10.1097/00003226-200304000-00021; Dana MR, 1996, INVEST OPHTH VIS SCI, V37, P2485; Fang L, 2008, J EXP MED, V205, P1037, DOI 10.1084/jem.20072528; Gain P, 2016, JAMA OPHTHALMOL, V134, P167, DOI 10.1001/jamaophthalmol.2015.4776; Ganguly S, 2014, BLOOD, V124, P2131, DOI 10.1182/blood-2013-10-525873; Hirakawa M, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89278; Huang MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23770; Inomata T, 2017, CORNEA, V36, P491, DOI 10.1097/ICO.0000000000001127; Inomata T, 2016, SCI REP-UK, V6, DOI 10.1038/srep39924; Ito S, 2014, MOL THER, V22, P1388, DOI 10.1038/mt.2014.50; JONES JERRY W., 1963, JOUR SURG RES, V3, P189, DOI 10.1016/S0022-4804(63)80057-8; Kanakry CG, 2017, BLOOD, V129, P1389, DOI 10.1182/blood-2016-09-737825; Kanakry CG, 2014, J CLIN ONCOL, V32, P3497, DOI 10.1200/JCO.2013.54.0625; Kanakry CG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006960; KERSEY JH, 1980, TRANSPLANTATION, V29, P388, DOI 10.1097/00007890-198005000-00008; Khan SQ, 2013, J IMMUNOL, V190, P1540, DOI 10.4049/jimmunol.1201908; Kruisbeek AM., 2004, CURR PROTOC IMMUNOL, DOI [10.1002/0471142735, DOI 10.1002/0471142735]; Le DT, 2012, CANCER RES, V72, P3439, DOI 10.1158/0008-5472.CAN-11-3912; Leventhal JR, 2015, TRANSPLANTATION, V99, P288, DOI 10.1097/TP.0000000000000605; Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood-2004-06-2410; Luznik L, 2012, SEMIN ONCOL, V39, P683, DOI 10.1053/j.seminoncol.2012.09.005; Luznik L, 2010, IMMUNOL RES, V47, P65, DOI 10.1007/s12026-009-8139-0; Luznik L, 2010, BLOOD, V115, P3224, DOI 10.1182/blood-2009-11-251595; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; McCurdy SR, 2017, HAEMATOLOGICA, V102, P391, DOI 10.3324/haematol.2016.144139; NEWMAN DK, 1995, EYE, V9, P564, DOI 10.1038/eye.1995.140; Niederkorn Jerry Y, 2002, Int Rev Immunol, V21, P173, DOI 10.1080/08830180212064; Nishikii H, 2016, BLOOD, V128, P2846, DOI 10.1182/blood-2016-06-723783; Nunes NS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02668; Ross D, 2013, BIOL BLOOD MARROW TR, V19, P1430, DOI 10.1016/j.bbmt.2013.06.019; Sano Y, 1997, INVEST OPHTH VIS SCI, V38, P1130; Shao CY, 2019, TRANSPLANTATION, V103, P182, DOI 10.1097/TP.0000000000002442; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; STREILEIN JW, 1982, INVEST OPHTH VIS SCI, V23, P489; Tahvildari M, 2016, TRANSPLANTATION, V100, P525, DOI 10.1097/TP.0000000000001044; Tan YH, 2012, J IMMUNOL, V188, P5962, DOI 10.4049/jimmunol.1103216; Toomer KH, 2016, J IMMUNOL, V196, P3665, DOI 10.4049/jimmunol.1500595; Wachsmuth LP, 2020, BIOL BLOOD MARROW TR, V26, P230, DOI 10.1016/j.bbmt.2019.09.030; Wachsmuth LP, 2019, J CLIN INVEST, V129, P2357, DOI 10.1172/JCI124218; Winzler C, 2011, CYTOM PART A, V79A, P903, DOI 10.1002/cyto.a.21132; Wolf D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121717; Wolf D, 2017, BIOL BLOOD MARROW TR, V23, P757, DOI 10.1016/j.bbmt.2017.02.013; Wolf D, 2012, TRANSPLANTATION, V94, P569, DOI 10.1097/TP.0b013e318264d3ef; Yamagami S, 2002, CORNEA, V21, P405, DOI 10.1097/00003226-200205000-00014; Yu AX, 2015, DIABETES, V64, P2172, DOI 10.2337/db14-1322; Zhao J, 2010, CANCER RES, V70, P4850, DOI 10.1158/0008-5472.CAN-10-0283	63	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2021	12								636789	10.3389/fimmu.2021.636789	http://dx.doi.org/10.3389/fimmu.2021.636789			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX3RR	33737937	Green Published, gold			2022-12-18	WOS:000629264200001
J	Sturt, AS; Webb, EL; Patterson, C; Phiri, CR; Mweene, T; Kjetland, EF; Mudenda, M; Mapani, J; Mutengo, MM; Chipeta, J; van Dam, GJ; Corstjens, PLAM; Ayles, H; Hayes, RJ; Hansingo, I; Cools, P; van Lieshout, L; Helmby, H; McComsey, GA; Francis, SC; Bustinduy, AL				Sturt, Amy S.; Webb, Emily L.; Patterson, Catriona; Phiri, Comfort R.; Mweene, Tobias; Kjetland, Eyrun F.; Mudenda, Maina; Mapani, Joyce; Mutengo, Mable M.; Chipeta, James; van Dam, Govert J.; Corstjens, Paul L. A. M.; Ayles, Helen; Hayes, Richard J.; Hansingo, Isaiah; Cools, Piet; van Lieshout, Lisette; Helmby, Helena; McComsey, Grace A.; Francis, Suzanna C.; Bustinduy, Amaya L.			Cervicovaginal Immune Activation in Zambian Women With Female Genital Schistosomiasis	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; female genital schistosomiasis; S; haematobium; inflammation; sub-Saharan Africa; genital tract; cervicovaginal lavage (CVL); polymerase chain reaction (PCR)	HIV; HAEMATOBIUM; INFLAMMATION; TRACT	HIV-1 infection disproportionately affects women in sub-Saharan Africa, where areas of high HIV-1 prevalence and Schistosoma haematobium endemicity largely overlap. Female genital schistosomiasis (FGS), an inflammatory disease caused by S. haematobium egg deposition in the genital tract, has been associated with prevalent HIV-1 infection. Elevated levels of the chemokines MIP-1 alpha (CCL-3), MIP-1 beta (CCL-4), IP-10 (CXCL-10), and IL-8 (CXCL-8) in cervicovaginal lavage (CVL) have been associated with HIV-1 acquisition. We hypothesize that levels of cervicovaginal cytokines may be raised in FGS and could provide a causal mechanism for the association between FGS and HIV-1. In the cross-sectional BILHIV study, specimens were collected from 603 female participants who were aged 18-31 years, sexually active, not pregnant and participated in the HPTN 071 (PopART) HIV-1 prevention trial in Zambia. Participants self-collected urine, and vaginal and cervical swabs, while CVLs were clinically obtained. Microscopy and Schistosoma circulating anodic antigen (CAA) were performed on urine. Genital samples were examined for parasite-specific DNA by PCR. Women with FGS (n=28), defined as a positive Schistosoma PCR from any genital sample were frequency age-matched with 159 FGS negative (defined as negative Schistosoma PCR, urine CAA, urine microscopy, and colposcopy imaging) women. Participants with probable FGS (n=25) (defined as the presence of either urine CAA or microscopy in combination with one of four clinical findings suggestive of FGS on colposcope-obtained photographs) were also included, for a total sample size of 212. The concentrations of 17 soluble cytokines and chemokines were quantified by a multiplex bead-based immunoassay. There was no difference in the concentrations of cytokines or chemokines between participants with and without FGS. An exploratory analysis of those women with a higher FGS burden, defined by >= 2 genital specimens with detectable Schistosoma DNA (n=15) showed, after adjusting for potential confounders, a higher Th2 (IL-4, IL-5, and IL-13) and pro-inflammatory (IL-15) expression pattern in comparison to FGS negative women, with differences unlikely to be due to chance (p=0.037 for IL-4 and p<0.001 for IL-5 after adjusting for multiple testing). FGS may alter the female genital tract immune environment, but larger studies in areas of varying endemicity are needed to evaluate the association with HIV-1 vulnerability.	[Sturt, Amy S.; Ayles, Helen; Bustinduy, Amaya L.] London Sch Hyg & Trop Med, Dept Clin Res, London, England; [Webb, Emily L.; Hayes, Richard J.; Francis, Suzanna C.] London Sch Hyg & Trop Med, MRC Int Stat & Epidemiol Grp, London, England; [Patterson, Catriona; Helmby, Helena] London Sch Hyg & Trop Med, Dept Infect Biol, London, England; [Phiri, Comfort R.; Mweene, Tobias; Ayles, Helen] Zambart, Lusaka, Zambia; [Kjetland, Eyrun F.] Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway; [Kjetland, Eyrun F.] Univ KwaZulu Natal, Discipline Publ Hlth, Durban, South Africa; [Mudenda, Maina; Mapani, Joyce; Hansingo, Isaiah] Livingstone Cent Hosp, Dept Obstet & Gynecol, Livingstone, Zambia; [Mutengo, Mable M.] Levy Mwanawasa Med Univ, Inst Basic & Biomed Sci, Lusaka, Zambia; [Chipeta, James] Univ Zambia, Dept Pediat, Lusaka, Zambia; [van Dam, Govert J.; van Lieshout, Lisette] Leiden Univ, Dept Parasitol, Med Ctr, Leiden, Netherlands; [Corstjens, Paul L. A. M.] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, Leiden, Netherlands; [Cools, Piet] Univ Ghent, Fac Med & Hlth Sci, Ghent, Belgium; [McComsey, Grace A.] Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA; [McComsey, Grace A.] Case Western Reserve Univ, Dept Pediat & Med, Cleveland, OH 44106 USA	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Oslo; University of Kwazulu Natal; University of Zambia; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ghent University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University	Sturt, AS (corresponding author), London Sch Hyg & Trop Med, Dept Clin Res, London, England.	amy.sturt@lshtm.ac.uk	Corstjens, Paul/Y-6310-2018	Corstjens, Paul/0000-0002-0004-0526; Hayes, Richard/0000-0002-1729-9892; Patterson, Catriona/0000-0002-4500-7199; Bustinduy, Amaya/0000-0001-6131-4159; Francis, Suzanna Carter/0000-0002-3724-4813; Ayles, Helen/0000-0003-4108-2842; Cools, Piet/0000-0003-2980-5307	Wellcome Trust [205954/Z/17/Z]; Dowager Countess Eleanor Peel Trust; MRC [MR/K012126/1, MR/N023692/1]; UK Medical Research Council (MRC); UK Department for International Development (DFID) under the MRC/DFID Concordat agreement; European Union; National Institute of Allergy and Infectious Diseases (NIAID) [UM1-AI068619, UM1-AI068617, UM1-AI068613]; U.S. President's Emergency Plan for AIDS Relief (PEPFAR); Bill and Melinda Gates Foundation; NIAID; National Institute on Drug Abuse; National Institute of Mental Health; National Institutes of Health; South-Eastern Regional Health Authority, Norway [2016055]	Wellcome Trust(Wellcome TrustEuropean Commission); Dowager Countess Eleanor Peel Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department for International Development (DFID) under the MRC/DFID Concordat agreement(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); U.S. President's Emergency Plan for AIDS Relief (PEPFAR)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); South-Eastern Regional Health Authority, Norway	AB received funding from the Wellcome Trust (Award 205954/Z/17/Z) and the Dowager Countess Eleanor Peel Trust. EW and RH received funding fromMRC Grant Reference MR/K012126/1, and SF received salary from MRC Grant Reference MR/N023692/1. These awards are jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 program supported by the European Union. HPTN 071 (PopART) was supported by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-AI068619, UM1-AI068617, and UM1-AI068613, with funding from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); the International Initiative for Impact Evaluation with support from the Bill and Melinda Gates Foundation; the NIAID, the National Institute on Drug Abuse, and the National Institute of Mental Health, all part of the National Institutes of Health. EK was supported by South-Eastern Regional Health Authority, Norway project #2016055.	Al-Harthi L, 2001, AIDS, V15, P1535, DOI 10.1097/00002030-200108170-00011; Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; Archary D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131906; Arnold KB, 2016, MUCOSAL IMMUNOL, V9, P194, DOI 10.1038/mi.2015.51; Chehimi J, 1997, J IMMUNOL, V158, P5978; Corstjens PLAM, 2020, AM J TROP MED HYG, V103, P50, DOI 10.4269/ajtmh.19-0819; Corstjens PLAM, 2014, PARASITOLOGY, V141, P1841, DOI 10.1017/S0031182014000626; Dessein A, 2004, IMMUNOL REV, V201, P180, DOI 10.1111/j.0105-2896.2004.00195.x; Dupnik KM, 2019, J INFECT DIS, V219, P1777, DOI 10.1093/infdis/jiy742; Dupnik KM, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00291-18; Fallon PG, 2000, J IMMUNOL, V164, P2585, DOI 10.4049/jimmunol.164.5.2585; Francis SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0143109; Fu CL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002605; Gosmann C, 2017, IMMUNITY, V46, P29, DOI 10.1016/j.immuni.2016.12.013; Hayes RJ, 2019, NEW ENGL J MED, V381, P207, DOI 10.1056/NEJMoa1814556; Hegertun IEA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002104; Herold BC, 2013, JAIDS-J ACQ IMM DEF, V63, P485, DOI 10.1097/QAI.0b013e3182961cfc; Jespers V, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0825-z; Jiang YS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089212; Jourdan PM, 2011, AM J TROP MED HYG, V85, P1060, DOI 10.4269/ajtmh.2011.11-0135; Jourdan PM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001170; King CL, 2001, J INFECT DIS, V184, P1176, DOI 10.1086/323802; Kjetland EF, 2006, AIDS, V20, P593, DOI 10.1097/01.aids.0000210614.45212.0a; Kjetland EF, 2005, AM J TROP MED HYG, V72, P311, DOI 10.4269/ajtmh.2005.72.311; Kjetland EF, 1996, ACTA TROP, V62, P239, DOI 10.1016/S0001-706X(96)00026-5; Kjetland EF, 2006, T ROY SOC TROP MED H, V100, P740, DOI 10.1016/j.trstmh.2005.09.010; Kleppa E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098593; Kyongo JK, 2015, CLIN VACCINE IMMUNOL, V22, P526, DOI 10.1128/CVI.00762-14; Kyongo JK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043951; Leutscher PDC, 2005, J INFECT DIS, V191, P1639, DOI 10.1086/429334; Lyke KE, 2006, INFECT IMMUN, V74, P5718, DOI 10.1128/IAI.01822-05; Marsden V, 2015, J IMMUNOL, V194, P4438, DOI 10.4049/jimmunol.1401706; Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298; Masson L, 2014, SEX TRANSM INFECT, V90, P580, DOI 10.1136/sextrans-2014-051601; Mave V, 2016, J INFECT DIS, V214, P65, DOI 10.1093/infdis/jiw096; Mlisana K, 2012, J INFECT DIS, V206, P6, DOI 10.1093/infdis/jis298; Mutapi F, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-139; Mutengo Mable M, 2018, J Parasitol Res, V2018, P9754060, DOI 10.1155/2018/9754060; Obeng BB, 2008, ANN TROP MED PARASIT, V102, P625, DOI 10.1179/136485908X337490; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Passmore JAS, 2016, CURR OPIN HIV AIDS, V11, P156, DOI 10.1097/COH.0000000000000232; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Pillay P, 2016, CYTOJOURNAL, V13, DOI 10.4103/1742-6413.180784; Pillay P, 2014, AM J TROP MED HYG, V90, P546, DOI 10.4269/ajtmh.13-0406; Sturt AS, 2020, ACTA TROP, V209, DOI 10.1016/j.actatropica.2020.105524; Sturt AS, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008337; UNAIDS, UNAIDS GLOB AIDS UPD; van den Biggelaar AHJ, 2002, J INFECT DIS, V186, P1474, DOI 10.1086/344352; van Lieshout L, 2000, ACTA TROP, V77, P69, DOI 10.1016/S0001-706X(00)00115-7; WHO, 2015, FEM GEN SCHIST POCK; Yegorov S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09900-9; Zambian Ministry of Health, 2017, GUID ET CLIN MAN SEX, P1	53	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2021	12								620657	10.3389/fimmu.2021.620657	http://dx.doi.org/10.3389/fimmu.2021.620657			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX3KV	33737927	Green Published, gold			2022-12-18	WOS:000629245800001
J	Sulsenti, R; Frossi, B; Bongiovanni, L; Cancila, V; Ostano, P; Fischetti, I; Enriquez, C; Guana, F; Chiorino, G; Tripodo, C; Pucillo, CE; Colombo, MP; Jachetti, E				Sulsenti, Roberta; Frossi, Barbara; Bongiovanni, Lucia; Cancila, Valeria; Ostano, Paola; Fischetti, Irene; Enriquez, Claudia; Guana, Francesca; Chiorino, Giovanna; Tripodo, Claudio; Pucillo, Carlo E.; Colombo, Mario P.; Jachetti, Elena			Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						prostate cancer; neuroendocrine differentiation; mast cells; drug repurposing; tumor microenvironment; mouse models		A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of androgen receptor pathway. Therefore, effective drugs against both CRPC and NEPC are needed. We have previously described a dual role of mast cells (MCs) in prostate cancer, being capable to promote adenocarcinoma but also to restrain NEPC. This finding suggests that a molecule targeting both MCs and NEPC cells could be effective against prostate cancer. Using an in silico drug repurposing approach, here we identify the antiepileptic drug levetiracetam as a potential candidate for this purpose. We found that the protein target of levetiracetam, SV2A, is highly expressed by both NEPC cells and MCs infiltrating prostate adenocarcinoma, while it is low or negligible in adenocarcinoma cells. In vitro, levetiracetam inhibited the proliferation of NEPC cells and the degranulation of MCs. In mice bearing subcutaneous tumors levetiracetam was partially active on both NEPC and adenocarcinoma, the latter effect due to the inhibition of MMP9 release by MCs. Notably, in TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice subjected to surgical castration to mimic androgen deprivation therapy, levetiracetam reduced onset and frequency of both high grade prostatic intraepithelial neoplasia, adenocarcinoma and NEPC, thus increasing the number of cured mice showing only signs of tumor regression. Our results demonstrate that levetiracetam can directly restrain NEPC development after androgen deprivation, and that it can also block adenocarcinoma progression through the inhibition of some MCs functions. These findings open the possibility of further testing levetiracetam for the therapy of prostate cancer or of MC-mediated diseases.	[Sulsenti, Roberta; Fischetti, Irene; Enriquez, Claudia; Colombo, Mario P.; Jachetti, Elena] Fdn Ist Ric & Cura Carattere Sci IRCCS, Dept Res, Mol Immunol Unit, Ist Nazl Tumori, Milan, Italy; [Frossi, Barbara; Pucillo, Carlo E.] Univ Udine, Immunol Sect, Dept Med, Udine, Italy; [Bongiovanni, Lucia; Cancila, Valeria; Tripodo, Claudio] Univ Palermo, Dept Hlth Sci, Tumor Immunol Unit, Palermo, Italy; [Ostano, Paola; Guana, Francesca; Chiorino, Giovanna] Fdn Edo & Elvo Tempia, Lab Canc Genom, Biella, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Udine; University of Palermo	Colombo, MP; Jachetti, E (corresponding author), Fdn Ist Ric & Cura Carattere Sci IRCCS, Dept Res, Mol Immunol Unit, Ist Nazl Tumori, Milan, Italy.	mariopaolo.colombo@istitutotumori.mi.it; elena.jachetti@istitutotumori.mi.it	Frossi, Barbara/AFL-0800-2022; Cancila, Valeria/AIE-4354-2022; Jachetti, Elena/C-2145-2017; Tripodo, Claudio/AAB-6004-2022; Chiorino, Giovanna/K-5037-2016	Frossi, Barbara/0000-0001-9855-2396; Cancila, Valeria/0000-0002-9502-1191; Jachetti, Elena/0000-0001-6483-7350; Tripodo, Claudio/0000-0002-0821-6231; Sulsenti, Roberta/0000-0002-2247-056X; Chiorino, Giovanna/0000-0002-9502-6400	Associazione Italiana per la Ricerca sul Cancro (AIRC) [14194, 18425]; Fondazione Italo Monzino; Fondazione Cariplo [2018-0213]; Italian Ministry of Health [GR-2016-02362484]; Compagnia di San Paolo [23019]; Fondazione Boschetto; AIRC	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italo Monzino; Fondazione Cariplo(Fondazione Cariplo); Italian Ministry of Health(Ministry of Health, Italy); Compagnia di San Paolo(Compagnia di San Paolo); Fondazione Boschetto; AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Grants from Associazione Italiana per la Ricerca sul Cancro (AIRC; Investigator Grant 14194 and 18425 to MPC), Fondazione Italo Monzino (to MPC), Fondazione Cariplo (2018-0213 to EJ) Italian Ministry of Health (GR-2016-02362484 to EJ), Compagnia di San Paolo (grant ID#23019 to GC), Fondazione Boschetto (to PO). CE has been awarded by a fellowship from AIRC.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Awaad Y, 2007, EPILEPSY BEHAV, V11, P247, DOI 10.1016/j.yebeh.2007.05.006; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078-0432.CCR-13-3309; Bobustuc GC, 2010, NEURO-ONCOLOGY, V12, P917, DOI 10.1093/neuonc/noq044; Cataldi M, 2005, J PHARMACOL EXP THER, V313, P720, DOI 10.1124/jpet.104.079327; Chedgy ECP, 2018, J PATHOL, V246, P244, DOI 10.1002/path.5137; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Eyal S, 2004, EPILEPSIA, V45, P737, DOI 10.1111/j.0013-9580.2004.00104.x; Graca I, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0264-8; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Happold C, 2016, J CLIN ONCOL, V34, P731, DOI 10.1200/JCO.2015.63.6563; Huss WJ, 2007, NEOPLASIA, V9, P938, DOI 10.1593/neo.07562; Jachetti E, 2018, CANCER IMMUNOL RES, V6, P552, DOI 10.1158/2326-6066.CIR-17-0385; Jachetti E, 2017, MOL CANCER THER, V16, P365, DOI 10.1158/1535-7163.MCT-16-0466; Karsenty G, 2009, PROSTATE, V69, P1143, DOI 10.1002/pros.20958; Kaushik I, 2021, SEMIN CANCER BIOL, V68, P279, DOI 10.1016/j.semcancer.2020.03.011; Larkin TM, 2013, J CLIN PHARM THER, V38, P68, DOI 10.1111/j.1365-2710.2012.01361.x; Li FZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1362-1; Lynch BA, 2004, P NATL ACAD SCI USA, V101, P9861, DOI 10.1073/pnas.0308208101; Lyseng-Williamson KA, 2011, CNS DRUGS, V25, P901, DOI 10.2165/11208340-000000000-00000; Ma HT, 2011, ADV EXP MED BIOL, V716, P62, DOI 10.1007/978-1-4419-9533-9_5; Mauri G, 2016, ONCOTARGET, V7, P3905, DOI 10.18632/oncotarget.6678; Mazzoleni S, 2013, STEM CELL TRANSL MED, V2, P678, DOI 10.5966/sctm.2013-0041; Ostano P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031078; Pal S, 2001, CELL CALCIUM, V30, P285, DOI 10.1054/ceca.2001.0236; Paulson L, 2010, EPILEPSY RES, V90, P110, DOI 10.1016/j.eplepsyres.2010.03.015; Pinke KH, 2020, NEURAL REGEN RES, V15, P1995, DOI 10.4103/1673-5374.282238; Pittoni P, 2011, CANCER RES, V71, P5987, DOI 10.1158/0008-5472.CAN-11-1637; Portela-Gomes GM, 2000, AM J PATHOL, V157, P1299, DOI 10.1016/S0002-9440(10)64645-7; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sakata S, 2018, INTERNAL MED, V57, P721, DOI 10.2169/internalmedicine.9300-17; Sanchez PE, 2012, P NATL ACAD SCI USA, V109, pE2895, DOI 10.1073/pnas.1121081109; Siebenhaar F, 2018, TRENDS IMMUNOL, V39, P151, DOI 10.1016/j.it.2017.10.005; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Sills GJ, 2020, NEUROPHARMACOLOGY, V168, DOI 10.1016/j.neuropharm.2020.107966; Stettner M, 2012, EUR J CANCER PREV, V21, P55, DOI 10.1097/CEJ.0b013e32834a7e6f; Terry S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00060; Turanli B, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00500; Wiechno P, 2014, EUR UROL, V65, P516, DOI 10.1016/j.eururo.2013.10.039; Wilcock A, 2019, ALLERGY, V74, P53, DOI 10.1111/all.13657; Xi HB, 2015, BIOL PHARM BULL, V38, P827, DOI 10.1248/bpb.b14-00518; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	47	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 2	2021	12								622001	10.3389/fimmu.2021.622001	http://dx.doi.org/10.3389/fimmu.2021.622001			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX2CV	33737929	Green Published, gold			2022-12-18	WOS:000629156400001
J	Boz, V; Valencic, E; Girardelli, M; Pin, A; Gamez-Diaz, L; Tommasini, A; Lega, S; Bramuzzo, M				Boz, Valentina; Valencic, Erica; Girardelli, Martina; Pin, Alessia; Gamez-Diaz, Laura; Tommasini, Alberto; Lega, Sara; Bramuzzo, Matteo			Case Report: Refractory Autoimmune Gastritis Responsive to Abatacept in LRBA Deficiency	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune gastritis; lymphoproliferation; inflammatory bowel disease; LRBA deficiency; primary immumunodeficiencies; case report; abatacept	INFLAMMATORY-BOWEL-DISEASE; IMMUNE DYSREGULATION; MUTATIONS; ENTEROPATHY; PATIENT; CTLA-4	Primary immunodeficiency (PID) with immune dysregulation may present with early onset gastrointestinal autoimmune disorders. When gastrointestinal autoimmunity is associated with multiple extraintestinal immune system dysfunction the diagnosis of PID is straightforward. However, with the advent of next generation sequencing technologies, genetic defects in PID genes have been increasingly recognized even when a single or no extraintestinal signs of immune dysregulation are present. A genetic diagnosis is especially important considering the expanding armamentarium of therapies designed to inhibit specific molecular pathways. We describe a boy with early-onset severe, refractory autoimmune gastritis and biallelic mutations in the LRBA gene causing a premature STOP-codon who was successfully treated with CTLA4-Ig, abatacept, with long term clinical and endoscopic remission. The case underscores the importance to consider a monogenetic defect in early onset autoimmune disorders, since the availability of targeted treatments may significantly improve patient prognosis.	[Boz, Valentina; Tommasini, Alberto] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy; [Valencic, Erica; Girardelli, Martina; Pin, Alessia; Tommasini, Alberto; Lega, Sara; Bramuzzo, Matteo] IRCCS Burlo Garofolo, Dept Pediat, Inst Maternal & Child Health, Trieste, Italy; [Gamez-Diaz, Laura] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany	University of Trieste; IRCCS Burlo Garofolo; University of Freiburg	Tommasini, A (corresponding author), Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy.; Tommasini, A (corresponding author), IRCCS Burlo Garofolo, Dept Pediat, Inst Maternal & Child Health, Trieste, Italy.	alberto.tommasini@burlo.trieste.it	Boz, Valentina/AAC-6884-2022; Pin, Alessia/AAB-5218-2022; Bramuzzo, Matteo/K-2504-2018; Girardelli, Martina/K-7199-2016	Boz, Valentina/0000-0003-3695-372X; Pin, Alessia/0000-0002-0145-1976; Girardelli, Martina/0000-0003-1186-4907; bramuzzo, matteo/0000-0002-5249-8248	Institute for Maternal and Child Health IRCCS Burlo Garofolo [RC24/17]; Italian Ministry of Health [RF-2016-02362384]	Institute for Maternal and Child Health IRCCS Burlo Garofolo; Italian Ministry of Health(Ministry of Health, Italy)	This study was funded by the Institute for Maternal and Child Health IRCCS Burlo Garofolo, grant RC24/17 and by the Italian Ministry of Health, grant RF-2016-02362384.	Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Azizi G, 2017, EUR ANN ALLERGY CLIN, V49, P235, DOI 10.23822/EurAnnACI.1764-1489.22; Bal SK, 2017, J CLIN IMMUNOL, V37, P790, DOI 10.1007/s10875-017-0446-y; Bratanic N, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0682-5; Burns SO, 2012, J ALLERGY CLIN IMMUN, V130, P1428, DOI 10.1016/j.jaci.2012.07.035; Cagdas D, 2019, J CLIN IMMUNOL, V39, P726, DOI 10.1007/s10875-019-00677-6; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Chen CB, 2020, DIGEST DIS SCI, V65, P3079, DOI 10.1007/s10620-020-06540-8; Cullinane AR, 2013, TRAFFIC, V14, P749, DOI 10.1111/tra.12069; Eren Akarcan Sanem, 2018, JMM Case Rep, V5, pe005167, DOI 10.1099/jmmcr.0.005167; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Garcia-Perez JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00998; Kammermeier J, 2017, J CROHNS COLITIS, V11, P60, DOI 10.1093/ecco-jcc/jjw118; Kiykim A, 2019, J ALLER CL IMM-PRACT, V7, P2790, DOI 10.1016/j.jaip.2019.06.011; Kucuk ZY, 2017, J ALLERGY CLIN IMMUN, V140, P862, DOI 10.1016/j.jaci.2017.02.032; Lega S, 2020, INFLAMM BOWEL DIS, V26, P720, DOI 10.1093/ibd/izz178; Levy E, 2016, CLIN IMMUNOL, V168, P88, DOI 10.1016/j.clim.2016.03.006; Li Q, 2017, AM J HUM GENET, V100, P267, DOI 10.1016/j.ajhg.2017.01.004; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Oz RS, 2019, PEDIATR RHEUMATOL, V17, DOI 10.1186/s12969-019-0388-4; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Pulvirenti F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02546; Revel-Vilk S, 2015, CLIN IMMUNOL, V159, P84, DOI 10.1016/j.clim.2015.04.007; Sansom DM, 2015, SCIENCE, V349, P377, DOI 10.1126/science.aac7888; Sari S, 2016, J CLIN IMMUNOL, V36, P8, DOI 10.1007/s10875-015-0220-y; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Serwas NK, 2015, INFLAMM BOWEL DIS, V21, P40, DOI 10.1097/MIB.0000000000000266; Tafaroji J, 2018, IMMUNOL GENET J, V1, P93; Tegtmeyer D, 2017, PEDIAT ALLERG IMM-UK, V28, P412, DOI 10.1111/pai.12734; Tesch VK, 2020, J ALLERGY CLIN IMMUN, V145, P1452, DOI 10.1016/j.jaci.2019.12.896; Vardi I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01775; Zullo A, 1999, GUT, V45, P77, DOI 10.1136/gut.45.1.77	35	2	2	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 26	2021	12								619246	10.3389/fimmu.2021.619246	http://dx.doi.org/10.3389/fimmu.2021.619246			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU9CO	33717114	Green Published, gold			2022-12-18	WOS:000627578000001
J	Cisani, F; Olivero, G; Usai, C; Van Camp, G; Maccari, S; Morley-Fletcher, S; Pittaluga, AM				Cisani, Francesca; Olivero, Guendalina; Usai, Cesare; Van Camp, Gilles; Maccari, Stefania; Morley-Fletcher, Sara; Pittaluga, Anna Maria			Antibodies Against the NH2-Terminus of the GluA Subunits Affect the AMPA-Evoked Releasing Activity: The Role of Complement	FRONTIERS IN IMMUNOLOGY			English	Article						synaptosomes; AMPA receptors; GluA2 and GluA3 subunits receptor; glutamate exocytosis; complement; C1q complement; cortex; autoimmune diseases	METABOTROPIC GLUTAMATE RECEPTORS; PRESYNAPTIC NMDA RECEPTORS; NERVE-ENDINGS; AUTOANTIBODIES; ENCEPHALITIS; SYNAPTOSOMES; TRAFFICKING; BINDING; PATHOPHYSIOLOGY; INFLAMMATION	Antibodies recognizing the amino-terminal domain of receptor subunit proteins modify the receptor efficiency to controlling transmitter release in isolated nerve endings (e.g., synaptosomes) indirectly confirming their presence in these particles but also allowing to speculate on their subunit composition. Western blot analysis and confocal microscopy unveiled the presence of the GluA1, GluA2, GluA3, and GluA4 receptor subunits in cortical synaptosomes. Functional studies confirmed the presence of presynaptic release-regulating AMPA autoreceptors in these terminals, whose activation releases [H-3]D-aspartate ([H-3]D-Asp, here used as a marker of glutamate) in a NBQX-dependent manner. The AMPA autoreceptors traffic in a constitutive manner, since entrapping synaptosomes with the pep2-SVKI peptide (which interferes with the GluA2-GRIP1/PICK1 interaction) amplified the AMPA-evoked releasing activity, while the inactive pep2-SVKE peptide was devoid of activity. Incubation of synaptosomes with antibodies recognizing the NH2 terminus of the GluA2 and the GluA3 subunits increased, although to a different extent, the GluA2 and 3 densities in synaptosomal membranes, also amplifying the AMPA-evoked glutamate release in a NBQX-dependent fashion. We then analyzed the releasing activity of complement (1:300) from both treated and untreated synaptosomes and found that the complement-induced overflow occurred in a DL-t-BOA-sensitive, NBQX-insensitive fashion. We hypothesized that anti-GluA/GluA complexes in neuronal membranes could trigger the classic pathway of activation of the complement, modifying its releasing activity. Accordingly, the complement-evoked release of [H-3]D-Asp from antiGluA2 and anti-GluA3 antibody treated synaptosomes was significantly increased when compared to untreated terminals and facilitation was prevented by omitting the C1q component of the immunocomplex. Antibodies recognizing the NH2 terminus of the GluA1 or the GluA4 subunits failed to affect both the AMPA and the complement-evoked tritium overflow. Our results suggest the presence of GluA2/GluA3-containing release-regulating AMPA autoreceptors in cortical synaptosomes. Incubation of synaptosomes with commercial anti-GluA2 or anti-GluA3 antibodies amplifies the AMPA-evoked exocytosis of glutamate through a complement-independent pathway, involving an excessive insertion of AMPA autoreceptors in plasma membranes but also affects the complement-dependent releasing activity, by promoting the classic pathway of activation of the immunocomplex. Both events could be relevant to the development of autoimmune diseases typified by an overproduction of anti-GluA subunits.	[Cisani, Francesca; Olivero, Guendalina; Pittaluga, Anna Maria] DIFAR, Dept Pharm, Pharmacol & Toxicol Sect, Genoa, Italy; [Usai, Cesare] CNR, Inst Biophys, Genoa, Italy; [Van Camp, Gilles; Maccari, Stefania; Morley-Fletcher, Sara] Univ Lille, CNRS, UMR 8576, UGSF Unite Glycobiol Struct & Fonct, Lille, France; [Van Camp, Gilles; Maccari, Stefania; Morley-Fletcher, Sara] Sapienza Univ Rome, Univ Lille, CNRS,Int Associated Lab LIA, UMR 8576,UGSF,Prenatal Stress & Neurodegenerat Di, Lille, France; [Van Camp, Gilles; Maccari, Stefania; Morley-Fletcher, Sara] IRCCS Neuromed, Lille, France; [Maccari, Stefania] Univ Sapienza Rome, Dept Sci & Med Surg Biotechnol, Rome, Italy; [Pittaluga, Anna Maria] IRCCS San Martino Hosp, Genoa, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Sapienza University Rome; University of Genoa; IRCCS AOU San Martino IST	Pittaluga, AM (corresponding author), DIFAR, Dept Pharm, Pharmacol & Toxicol Sect, Genoa, Italy.; Pittaluga, AM (corresponding author), IRCCS San Martino Hosp, Genoa, Italy.	pittalug@difar.unige.it	Olivero, Guendalina/AAL-7489-2020	Olivero, Guendalina/0000-0001-8571-3736				Alexander JJ, 2008, J NEUROCHEM, V107, P1169, DOI 10.1111/j.1471-4159.2008.05668.x; Banerjee A, 2016, TRENDS NEUROSCI, V39, P26, DOI 10.1016/j.tins.2015.11.001; Barbon A, 2010, J NEUROCHEM, V114, P397, DOI 10.1111/j.1471-4159.2010.06767.x; Breukel A I, 1997, Methods Mol Biol, V72, P33; Buscarinu MC, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9110299; Carlson NG, 1997, J BIOL CHEM, V272, P11295; Centonze D, 2010, CELL DEATH DIFFER, V17, P1083, DOI 10.1038/cdd.2009.179; CORSELLIS JA, 1968, BRAIN, V91, P481, DOI 10.1093/brain/91.3.481; Dalmau J, 2016, NEUROLOGY, V87, P2471, DOI 10.1212/WNL.0000000000003414; Di Prisco S, 2012, J NEUROCHEM, V121, P428, DOI 10.1111/j.1471-4159.2012.07720.x; Esteban Jose A, 2003, Mol Interv, V3, P375, DOI 10.1124/mi.3.7.375; Fakhoury M, 2015, NEURODEGENER DIS, V15, P63, DOI 10.1159/000369933; Feligioni M, 2006, J NEUROCHEM, V99, P549, DOI 10.1111/j.1471-4159.2006.04087.x; Fukata M, 2018, CURR OPIN NEUROBIOL, V48, P1, DOI 10.1016/j.conb.2017.07.012; Gahring LC, 1997, NEUROLOGY, V48, P494, DOI 10.1212/WNL.48.2.494; GAHRING LC, 1995, MOL MED, V1, P245, DOI 10.1007/BF03401549; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Haglerod C, 2017, NEUROSCIENCE, V344, P102, DOI 10.1016/j.neuroscience.2016.12.042; He XP, 1998, NEURON, V20, P153, DOI 10.1016/S0896-6273(00)80443-2; Henley JM, 2011, TRENDS NEUROSCI, V34, P258, DOI 10.1016/j.tins.2011.02.004; Henley JM, 2003, NEUROSCI RES, V45, P243, DOI 10.1016/S0168-0102(02)00229-8; Hoftberger R, 2018, HAND CLINIC, V145, P285, DOI 10.1016/B978-0-12-802395-2.00020-1; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; Khandaker GM, 2015, LANCET PSYCHIAT, V2, P258, DOI 10.1016/S2215-0366(14)00122-9; Kishore U, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00398; Levite M, 1999, J AUTOIMMUN, V13, P61, DOI 10.1006/jaut.1999.0301; Malina KCK, 2006, NEUROCHEM RES, V31, P1181, DOI 10.1007/s11064-006-9143-6; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Martinez-Martinez Pilar, 2013, Frontiers in Genetics, V4, P181, DOI 10.3389/fgene.2013.00181; Merega E, 2015, NEUROSCI LETT, V600, P50, DOI 10.1016/j.neulet.2015.06.001; Merega E, 2014, J NEUROCHEM, V129, P473, DOI 10.1111/jnc.12650; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Moscato EH, 2014, ANN NEUROL, V76, P108, DOI 10.1002/ana.24195; Musante V, 2008, NEUROPHARMACOLOGY, V55, P474, DOI 10.1016/j.neuropharm.2008.06.056; Musante V, 2008, J NEUROSCI, V28, P12231, DOI 10.1523/JNEUROSCI.3212-08.2008; Olivero G, 2020, CURR NEUROPHARMACOL, V18, P655, DOI 10.2174/1570159X17666191127112339; Olivero G, 2019, MOL NEUROBIOL, V56, P6142, DOI 10.1007/s12035-019-1511-8; Olivero G, 2017, BRIT J PHARMACOL, V174, P4785, DOI 10.1111/bph.14061; Paas Y, 1998, TRENDS NEUROSCI, V21, P117, DOI 10.1016/S0166-2236(97)01184-3; Palese F, 2020, NEUROBIOL AGING, V86, P143, DOI 10.1016/j.neurobiolaging.2019.10.015; Paoletti P, 2013, NAT REV NEUROSCI, V14, P383, DOI 10.1038/nrn3504; PASCHEN W, 1995, J NEUROSCI METH, V56, P21, DOI 10.1016/0165-0270(94)00085-U; PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4; Peng XY, 2015, ANN NEUROL, V77, P381, DOI 10.1002/ana.24293; Pittaluga A, 2006, NEUROPHARMACOLOGY, V50, P286, DOI 10.1016/j.neuropharm.2005.09.004; Pittaluga A, 1997, N-S ARCH PHARMACOL, V356, P29, DOI 10.1007/PL00005025; Pittaluga A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153641; Pittaluga A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01079; Pittaluga A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00295; Raiteri L, 2000, NEUROCHEM RES, V25, P1265, DOI 10.1023/A:1007648229795; RAITERI M, 1974, EUR J PHARMACOL, V25, P411, DOI 10.1016/0014-2999(74)90272-6; Raiteri M, 2000, J NEUROCHEM, V74, P423, DOI 10.1046/j.1471-4159.2000.0740423.x; Rhoads J, 2011, SCHIZOPHR RES, V129, P213, DOI 10.1016/j.schres.2010.12.018; Rogers SW, 1996, MOL MED TODAY, V2, P76, DOI 10.1016/1357-4310(96)88742-9; Salamone A, 2014, NEUROPHARMACOLOGY, V79, P488, DOI 10.1016/j.neuropharm.2013.12.014; Solaro C, 2006, HAEMATOLOGICA, V91, P168; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Stephenson J, 2018, IMMUNOLOGY, V154, P204, DOI 10.1111/imm.12922; Summa M, 2013, NEUROPHARMACOLOGY, V66, P215, DOI 10.1016/j.neuropharm.2012.04.020; Summa M, 2011, NEUROPHARMACOLOGY, V61, P1282, DOI 10.1016/j.neuropharm.2011.07.032; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Trippe J, 2014, NEUROIMMUNOMODULAT, V21, P189, DOI 10.1159/000356519; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; van Coevorden-Hameete MH, 2014, AUTOIMMUN REV, V13, P299, DOI 10.1016/j.autrev.2013.10.016; Varley J, 2018, NEUROPHARMACOLOGY, V132, P71, DOI 10.1016/j.neuropharm.2017.04.046; Whitney KD, 2000, J NEUROSCI, V20, P7307; Wright A, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00034; Zaborowski MP, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/630602; Zuliani L, 2017, NEUROL SCI, V38, pS225, DOI 10.1007/s10072-017-3032-4	70	2	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 26	2021	12								586521	10.3389/fimmu.2021.586521	http://dx.doi.org/10.3389/fimmu.2021.586521			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QV1WM	33717067	Green Published, gold			2022-12-18	WOS:000627768500001
J	Zeber-Lubecka, N; Hennig, EE				Zeber-Lubecka, Natalia; Hennig, Ewa E.			Genetic Susceptibility to Joint Occurrence of Polycystic Ovary Syndrome and Hashimoto's Thyroiditis: How Far Is Our Understanding?	FRONTIERS IN IMMUNOLOGY			English	Review						autoimmune thyroid disease; Hashimoto&#8217; s thyroiditis; polycystic ovary syndrome; genetic variants; association studies; susceptibility loci	REGULATORY T-CELLS; GRAVES-DISEASE; NONCODING RNA; TGF-BETA; ASSOCIATION; POLYMORPHISMS; HORMONE; RISK; AUTOIMMUNITY; INSULIN	Polycystic ovary syndrome (PCOS) and Hashimoto's thyroiditis (HT) are endocrine disorders that commonly occur among young women. A higher prevalence of HT in women with PCOS, relative to healthy individuals, is observed consistently. Combined occurrence of both diseases is associated with a higher risk of severe metabolic and reproductive complications. Genetic factors strongly impact the pathogenesis of both PCOS and HT and several susceptibility loci associated with a higher risk of both disorders have been identified. Furthermore, some candidate gene polymorphisms are thought to be functionally relevant; however, few genetic variants are proposed to be causally associated with the incidence of both disorders together.	[Zeber-Lubecka, Natalia; Hennig, Ewa E.] Ctr Postgrad Med Educ, Dept Gastroenterol Hepatol & Clin Oncol, Warsaw, Poland; [Hennig, Ewa E.] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Genet, Warsaw, Poland	Centre of Postgraduate Medical Education - Poland	Hennig, EE (corresponding author), Ctr Postgrad Med Educ, Dept Gastroenterol Hepatol & Clin Oncol, Warsaw, Poland.; Hennig, EE (corresponding author), Maria Sklodowska Curie Natl Res Inst Oncol, Dept Genet, Warsaw, Poland.	ewa.hennig@pib-nio.pl	Hennig, Ewa E/N-6459-2013	Hennig, Ewa E/0000-0002-6388-2237; Zeber-Lubecka, Natalia/0000-0003-4036-3191	Polish National Science Centre [2016/23/B/NZ2/00696]; Centre of PostgraduateMedical Education [501-1009-12-20]	Polish National Science Centre; Centre of PostgraduateMedical Education	This work was supported by the Polish National Science Centre (grant number 2016/23/B/NZ2/00696) and the Centre of PostgraduateMedical Education (grant number 501-1009-12-20).	Abbott DH, 2019, EXPERT REV ENDOCRINO, V14, P131, DOI 10.1080/17446651.2019.1576522; Ajjan RA, 2015, HORM METAB RES, V47, P702, DOI 10.1055/s-0035-1548832; Akinci B, 2008, ARCH MED RES, V39, P397, DOI 10.1016/j.arcmed.2007.12.001; Al-Saab R, 2014, INT J ENDOCRINOL MET, V12, DOI 10.5812/ijem.17954; Alkhateeb A, 2013, ENDOCRINE, V44, P702, DOI 10.1007/s12020-013-9908-z; Anaforoglu I, 2011, J ENDOCRINOL INVEST, V34, pE259, DOI 10.3275/7681; Angstwurm MWA, 1997, CYTOKINE, V9, P370, DOI 10.1006/cyto.1996.0178; Antonelli A, 2015, AUTOIMMUN REV, V14, P174, DOI 10.1016/j.autrev.2014.10.016; Arduc A, 2015, ENDOCR RES, V40, P204, DOI 10.3109/07435800.2015.1015730; Arnaud-Lopez L, 2008, AM J HUM GENET, V82, P1270, DOI 10.1016/j.ajhg.2008.04.019; Arora Sheetal, 2016, J Hum Reprod Sci, V9, P18, DOI 10.4103/0974-1208.178636; Asvold BO, 2007, J CLIN ENDOCR METAB, V92, P841, DOI 10.1210/jc.2006-2208; Azziz R, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.57; Azziz R, 2016, FERTIL STERIL, V106, P4, DOI 10.1016/j.fertnstert.2016.05.009; Ban Y, 2005, THYROID, V15, P1115, DOI 10.1089/thy.2005.15.1115; Ban Y, 2005, AUTOIMMUNITY, V38, P151, DOI 10.1080/08916930500050319; Ban Y, 2004, GENES IMMUN, V5, P203, DOI 10.1038/sj.gene.6364059; Ban Y, 2001, THYROID, V11, P607, DOI 10.1089/105072501750302967; Ban Y, 2008, J CLIN ENDOCR METAB, V93, P3589, DOI 10.1210/jc.2008-0364; Ban Y, 2010, THYROID, V20, P893, DOI 10.1089/thy.2010.0104; Bao S, 2016, J CLIN RES PEDIATR E, V8, P135, DOI 10.4274/jcrpe.2259; Baric A, 2017, J ENDOCRINOL INVEST, V40, P1061, DOI 10.1007/s40618-017-0660-8; Bedaiwy MA, 2018, J WOMENS HEALTH, V27, P659, DOI 10.1089/jwh.2017.6584; Bedecarrats GY, 2003, J CLIN ENDOCR METAB, V88, P834, DOI 10.1210/jc.2002-020806; Behre HM, 2005, PHARMACOGENET GENOM, V15, P451, DOI 10.1097/01.fpc.0000167330.92786.5e; Ben-Shlomo I, 2014, REPROD BIOMED ONLINE, V28, P669, DOI 10.1016/j.rbmo.2014.02.011; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Benetti-Pinto CL, 2013, FERTIL STERIL, V99, P588, DOI 10.1016/j.fertnstert.2012.10.006; Bernecker C, 2013, HORM METAB RES, V45, P74, DOI 10.1055/s-0032-1323704; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Brand OJ, 2009, HUM MOL GENET, V18, P1704, DOI 10.1093/hmg/ddp087; Brcic L, 2019, J ENDOCRINOL INVEST, V42, P567, DOI 10.1007/s40618-018-0955-4; Brcic L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41850-6; Brcic L, 2017, IMMUNOL INVEST, V46, P625, DOI 10.1080/08820139.2017.1337785; Brcic L, 2016, AUTOIMMUNITY, V49, P480, DOI 10.1080/08916934.2016.1191475; Brix TH, 2000, J CLIN ENDOCR METAB, V85, P536, DOI 10.1210/jc.85.2.536; Brower MA, 2015, J CLIN ENDOCR METAB, V100, pE182, DOI 10.1210/jc.2014-2689; Burn GL, 2011, FEBS LETT, V585, P3689, DOI 10.1016/j.febslet.2011.04.032; Caburet S, 2017, EUR J ENDOCRINOL, V176, pK9, DOI 10.1530/EJE-16-0968; Cadagan D, 2016, REPROD BIOL, V16, P53, DOI 10.1016/j.repbio.2015.12.006; Cai J, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00222; Calvar CE, 2015, MEDICINA-BUENOS AIRE, V75, P213; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Castanet M, 2010, HORM RES PAEDIAT, V73, P423, DOI 10.1159/000281438; Caturegli P, 2014, AUTOIMMUN REV, V13, P391, DOI 10.1016/j.autrev.2014.01.007; Chabchoub G, 2009, ANN HUM BIOL, V36, P342, DOI 10.1080/03014460902817968; Chang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004; Chapman JC, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-47; Chardes T, 2002, IMMUNOGENETICS, V54, P141, DOI 10.1007/s00251-002-0453-9; Chen DJ, 2014, EUR J OBSTET GYN R B, V182, P27, DOI 10.1016/j.ejogrb.2014.08.014; Chen LJ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011558; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen XH, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3916395; Chen ZJ, 2011, NAT GENET, V43, P55, DOI 10.1038/ng.732; Cho WK, 2011, HORM RES PAEDIAT, V76, P328, DOI 10.1159/000331134; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Condorelli RA, 2017, GYNECOL ENDOCRINOL, V33, P665, DOI 10.1080/09513590.2017.1342240; Cooper JD, 2012, HUM MOL GENET, V21, P5202, DOI 10.1093/hmg/dds357; Crespo RP, 2018, ARCH ENDOCRIN METAB, V62, P352, DOI 10.20945/2359-3997000000049; Criswell LA, 2005, AM J HUM GENET, V76, P561, DOI 10.1086/429096; Dallel M, 2018, GENE, V647, P79, DOI 10.1016/j.gene.2018.01.028; Dan Z, 2020, MOL CELL ENDOCRINOL, V499, DOI 10.1016/j.mce.2019.110589; Dapas M, 2019, J CLIN ENDOCR METAB, V104, P3835, DOI 10.1210/jc.2018-02496; Day F, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007813; Day FR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9464; de Medeiros SF, 2018, GYNECOL OBSTET INVES, V83, P105, DOI 10.1159/000485619; De Pergola G, 2018, ENDOCR METAB IMMUNE, V18, P646, DOI 10.2174/1871530318666180406163426; Dechairo BM, 2005, EUR J HUM GENET, V13, P1223, DOI 10.1038/sj.ejhg.5201485; Denny JC, 2011, AM J HUM GENET, V89, P529, DOI 10.1016/j.ajhg.2011.09.008; Deswal R, 2018, SYST BIOL REPROD MED, V64, P12, DOI 10.1080/19396368.2017.1410591; Dharmshaktu P, 2013, ENDOCRINOL DIAB META, DOI 10.1530/EDM-13-0050; Ding XH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00700; Dorris Emma R, 2012, Front Endocrinol (Lausanne), V3, P102, DOI 10.3389/fendo.2012.00102; Du DF, 2013, INT J CLIN EXP MED, V6, P880; Du X, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0864-x; Dumont C, 2009, BLOOD, V113, P3990, DOI 10.1182/blood-2008-09-181180; Duntas LH, 2013, THYROID, V23, P646, DOI 10.1089/thy.2011.0499; Duran C, 2015, ENDOCRINE, V49, P464, DOI 10.1007/s12020-014-0504-7; Einarsdottir E, 2003, EUR J HUM GENET, V11, P81, DOI 10.1038/sj.ejhg.5200903; Enzevaei Anahita, 2014, Iran J Reprod Med, V12, P481; Erdogan M, 2017, J ENDOCRINOL INVEST, V40, P77, DOI 10.1007/s40618-016-0534-5; Eriksen MB, 2012, EUR J OBSTET GYN R B, V163, P39, DOI 10.1016/j.ejogrb.2012.03.020; Eriksson N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034442; Eschler DC, 2011, CLIN REV ALLERG IMMU, V41, P190, DOI 10.1007/s12016-010-8245-8; Escobar-Morreale HF, 2011, FERTIL STERIL, V95, P1048, DOI 10.1016/j.fertnstert.2010.11.036; Fagman H, 2011, J MOL ENDOCRINOL, V46, pR33, DOI 10.1677/JME-10-0084; Farooqi AA, 2018, CELL MOL BIOL, V64, P1, DOI 10.14715/cmb/2017.64.15.1; Ferreira RC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02606; Frohlich E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00521; Fujii A, 2017, THYROID, V27, P111, DOI 10.1089/thy.2016.0345; Furugaki K, 2004, J HUM GENET, V49, P166, DOI 10.1007/s10038-003-0120-5; Gaberscek S, 2015, EUR J ENDOCRINOL, V172, DOI 10.1530/EJE-14-0295; Gammoh E, 2015, GENE, V560, P30, DOI 10.1016/j.gene.2015.01.034; Gao J, 2016, ARCH GYNECOL OBSTET, V294, P1073, DOI 10.1007/s00404-016-4159-x; Gao XR, 2019, FRONT GENET, V9, DOI 10.3389/fgene.2018.00708; Garelli S, 2013, EUR J OBSTET GYN R B, V169, P248, DOI 10.1016/j.ejogrb.2013.03.003; Gianchecchi E, 2013, AUTOIMMUN REV, V12, P717, DOI 10.1016/j.autrev.2012.12.003; Gong LC, 2018, BMC ENDOCR DISORD, V18, DOI 10.1186/s12902-018-0305-8; Goodarzi MO, 2012, J MED GENET, V49, P90, DOI 10.1136/jmedgenet-2011-100427; Goodarzi MO, 2011, FERTIL STERIL, V95, P1736, DOI 10.1016/j.fertnstert.2011.01.015; Gorsic LK, 2017, J CLIN ENDOCR METAB, V102, P2862, DOI 10.1210/jc.2017-00612; Govinden R, 2003, PHARMACOL THERAPEUT, V98, P257, DOI 10.1016/S0163-7258(03)00035-4; Gudmundsson J, 2012, NAT GENET, V44, P319, DOI 10.1038/ng.1046; Gudmundsson J, 2009, NAT GENET, V41, P460, DOI 10.1038/ng.339; Gunning MN, 2017, CLIMACTERIC, V20, P222, DOI 10.1080/13697137.2017.1316256; Ha LX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126505; Hansen PS, 2005, CLIN ENDOCRINOL, V62, P380, DOI 10.1111/j.1365-2265.2005.02230.x; Hatzirodos N, 2011, FASEB J, V25, P2256, DOI 10.1096/fj.11-181099; Hayes MG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8502; Hefler-Frischmuth K, 2010, FERTIL STERIL, V93, P2291, DOI 10.1016/j.fertnstert.2009.01.056; Hepsen S, 2018, J TURK-GER GYNECOL A, V19, P215, DOI 10.4274/jtgga.2018.0001; Heward JM, 2007, J CLIN ENDOCR METAB, V92, P685, DOI 10.1210/jc.2006-2064; Hiam D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101606; Hill RJ, 2002, EXP HEMATOL, V30, P237, DOI 10.1016/S0301-472X(01)00794-9; Hodge SE, 2006, THYROID, V16, P351, DOI 10.1089/thy.2006.16.351; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Hou HF, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/747816; Hu YF, 2018, GENET TEST MOL BIOMA, V22, P224, DOI 10.1089/gtmb.2017.0243; Huang R, 2014, EUR J OBSTET GYN R B, V177, P52, DOI 10.1016/j.ejogrb.2014.04.013; Hughes GC, 2012, AUTOIMMUN REV, V11, pA502, DOI 10.1016/j.autrev.2011.12.003; Hunt PJ, 2001, CLIN ENDOCRINOL, V55, P491, DOI 10.1046/j.1365-2265.2001.01356.x; Hwang JY, 2012, J HUM GENET, V57, P660, DOI 10.1038/jhg.2012.92; Hwangbo Y, 2018, ENDOCRINOL METAB, V33, P175, DOI 10.3803/EnM.2018.33.2.175; Jabrocka-Hybel A, 2018, J ENDOCRINOL INVEST, V41, P1409, DOI 10.1007/s40618-018-0910-4; Jansen E, 2004, MOL ENDOCRINOL, V18, P3050, DOI 10.1210/me.2004-0074; Janssen OE, 2004, EUR J ENDOCRINOL, V150, P363, DOI 10.1530/eje.0.1500363; Ji R, 2013, GENET MOL RES, V12, P1421, DOI 10.4238/2013.April.26.4; Jones MR, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005455; Jones MR, 2016, FERTIL STERIL, V106, P25, DOI 10.1016/j.fertnstert.2016.04.040; Joo YY, 2020, J CLIN ENDOCR METAB, V105, P1918, DOI 10.1210/clinem/dgz326; Kachuei M, 2012, ARCH GYNECOL OBSTET, V285, P853, DOI 10.1007/s00404-011-2040-5; Karakose M, 2017, J TURK-GER GYNECOL A, V18, P85, DOI 10.4274/jtgga.2016.0217; Kerchner A, 2009, FERTIL STERIL, V91, P207, DOI 10.1016/j.fertnstert.2007.11.022; Kichaev G, 2019, AM J HUM GENET, V104, P65, DOI 10.1016/j.ajhg.2018.11.008; Kim CY, 2019, KOREAN J FAM MED, V40, P323, DOI 10.4082/kjfm.18.0075; Kim D, 2016, HORM-INT J ENDOCRINO, V15, P385, DOI 10.14310/horm.2002.1681; Kim JJ, 2022, HUM FERTIL, V25, P128, DOI 10.1080/14647273.2019.1709668; Kokaraki G, 2009, TISSUE ANTIGENS, V73, P199, DOI 10.1111/j.1399-0039.2008.01182.x; Kommagani R, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005937; Kowalczyk K, 2017, EUR REV MED PHARMACO, V21, P346; Krassas GE, 2010, ENDOCR REV, V31, P702, DOI 10.1210/er.2009-0041; Kulkarni R, 2019, J ENDOCR SOC, V3, P2204, DOI 10.1210/js.2019-00169; Kwak SH, 2014, HUM MOL GENET, V23, P4433, DOI 10.1093/hmg/ddu145; Laven JSE, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00023; Lee HJ, 2015, J AUTOIMMUN, V64, P82, DOI 10.1016/j.jaut.2015.07.009; Lee H, 2015, HUM REPROD, V30, P723, DOI 10.1093/humrep/deu352; Lerchbaum E, 2011, HORM METAB RES, V43, P743, DOI 10.1055/s-0031-1286279; Li M, 2019, J CLIN ENDOCR METAB, V104, P1049, DOI 10.1210/jc.2018-00544; Li M, 2012, ENDOCR J, V59, P1041, DOI 10.1507/endocrj.EJ12-0126; Li QL, 2011, HUM GENET, V129, P553, DOI 10.1007/s00439-011-0954-4; Li Y, 2019, LIFE SCI, V228, P167, DOI 10.1016/j.lfs.2019.04.046; Li Y, 2019, MOL HUM REPROD, V25, P638, DOI 10.1093/molehr/gaz014; Li Y, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018720; Liao D, 2018, J ENDOCRINOL INVEST, V41, P1289, DOI 10.1007/s40618-018-0866-4; Lim SS, 2019, OBES REV, V20, P339, DOI 10.1111/obr.12762; Lim SS, 2012, HUM REPROD UPDATE, V18, P618, DOI 10.1093/humupd/dms030; Lin L, 2015, CHINESE MED J-PEKING, V128, P169, DOI 10.4103/0366-6999.149189; Liu AL, 2017, BMC MED GENET, V18, DOI 10.1186/s12881-017-0452-1; Liu XB, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027923; Lopez ER, 2004, EUR J ENDOCRINOL, V151, P193, DOI 10.1530/eje.0.1510193; Louwers YV, 2013, J CLIN ENDOCR METAB, V98, pE2006, DOI 10.1210/jc.2013-2495; Lovelace DL, 2016, DEVELOPMENT, V143, P1893, DOI 10.1242/dev.132761; Luo LM, 2012, ENDOCR J, V59, P439, DOI 10.1507/endocrj.EJ11-0381; Makled AK, 2015, MIDDLE EAST FERTIL S, V20, P86, DOI 10.1016/j.mefs.2014.05.006; Malhotra S, 2009, J BIOL CHEM, V284, P24088, DOI 10.1074/jbc.M109.014209; Maratou E, 2009, EUR J ENDOCRINOL, V160, P785, DOI 10.1530/EJE-08-0797; Marshall JC, 1999, ENDOCRIN METAB CLIN, V28, P295, DOI 10.1016/S0889-8529(05)70071-2; Matana A, 2020, J CLIN ENDOCR METAB, V105, P944, DOI 10.1210/clinem/dgz239; Matana A, 2019, GENOMICS, V111, P737, DOI 10.1016/j.ygeno.2018.04.012; Novais JDM, 2015, GYNECOL ENDOCRINOL, V31, P48, DOI 10.3109/09513590.2014.958990; McAllister JM, 2019, ENDOCRINOLOGY, V160, P1964, DOI 10.1210/en.2019-00013; McAllister JM, 2015, TRENDS ENDOCRIN MET, V26, P118, DOI 10.1016/j.tem.2014.12.004; McAllister JM, 2014, P NATL ACAD SCI USA, V111, pE1519, DOI 10.1073/pnas.1400574111; McCartney CR, 2016, NEW ENGL J MED, V375, P54, DOI 10.1056/NEJMcp1514916; McLeod DSA, 2012, ENDOCRINE, V42, P252, DOI 10.1007/s12020-012-9703-2; Medici M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004123; Menconi F, 2008, P NATL ACAD SCI USA, V105, P14034, DOI 10.1073/pnas.0806584105; Menon M, 2017, J OBSTET GYN INDIA, V67, P61, DOI 10.1007/s13224-016-0914-y; Michalaki MA, 2006, THYROID, V16, P73, DOI 10.1089/thy.2006.16.73; Moleti M., 2018, ANN THYROID, V3, P18, DOI DOI 10.21037/AOT.2018.07.03; Morgante G, 2013, GYNECOL ENDOCRINOL, V29, P967, DOI 10.3109/09513590.2013.829445; Mori M, 2005, J HUM GENET, V50, P264, DOI 10.1007/s10038-005-0246-8; Moulton VR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02279; Muderris II, 2011, ANN SAUDI MED, V31, P145, DOI 10.4103/0256-4947.77500; Muscogiuri G, 2016, ENDOCRINE, V53, P538, DOI 10.1007/s12020-015-0745-0; Muscogiuri G, 2013, OBESITY, V21, P101, DOI 10.1002/oby.20240; Mutharasan P, 2013, J CLIN ENDOCR METAB, V98, pE185, DOI 10.1210/jc.2012-2471; Nandi A, 2016, HORM MOL BIOL CLIN I, V25, P15, DOI 10.1515/hmbci-2015-0051; Ni J, 2014, ENDOCR RES, V39, P180, DOI 10.3109/07435800.2013.879167; Okada R, 2009, ANN NY ACAD SCI, V1163, P262, DOI 10.1111/j.1749-6632.2008.03662.x; Ong KK, 2013, J CLIN ENDOCR METAB, V98, P1435, DOI 10.1210/jc.2012-3761; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; Oryoji D, 2015, J CLIN ENDOCR METAB, V100, pE319, DOI 10.1210/jc.2014-3431; Ott J, 2010, FERTIL STERIL, V94, P2895, DOI 10.1016/j.fertnstert.2010.05.063; Panicker V, 2010, AM J HUM GENET, V87, P430, DOI 10.1016/j.ajhg.2010.08.005; Papoutsoglou P, 2019, CELL REP, V28, P3182, DOI 10.1016/j.celrep.2019.08.028; Pastuszak-Lewandoska D, 2012, ARCH MED SCI, V8, P415, DOI 10.5114/aoms.2012.28593; Patel S, 2018, J STEROID BIOCHEM, V182, P27, DOI 10.1016/j.jsbmb.2018.04.008; Patiroglu T., 2015, I 51 ETFAL T P B L, V49, P255, DOI [10.5350/SEMB.20151005010345, DOI 10.5350/SEMB.20151005010345]; Pau CT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168870; Pearce EN, 2012, J CLIN ENDOCR METAB, V97, P326, DOI 10.1210/jc.2011-2532; Peng HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep17702; Pennell LM, 2012, J AUTOIMMUN, V38, pJ282, DOI 10.1016/j.jaut.2011.11.013; Petrikova J, 2015, BIOMED PAP, V159, P302, DOI 10.5507/bp.2014.062; Petrikova J, 2010, EUR J INTERN MED, V21, P369, DOI 10.1016/j.ejim.2010.06.008; Petrone A, 2001, THYROID, V11, P171, DOI 10.1089/105072501300042901; Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570; Porcu E, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003266; Prodoehl MJ, 2009, MOL HUM REPROD, V15, P829, DOI 10.1093/molehr/gap072; Qiu H, 2014, ENDOCRINE, V45, P198, DOI 10.1007/s12020-013-9985-z; Quintero OL, 2012, J AUTOIMMUN, V38, pJ109, DOI 10.1016/j.jaut.2011.10.003; Radetti G, 2014, ENDOCR DEV, V26, P158, DOI 10.1159/000363162; Raja-Khan N, 2014, REPROD SCI, V21, P20, DOI 10.1177/1933719113485294; Raja-Khan N, 2010, FERTIL STERIL, V94, P2916, DOI 10.1016/j.fertnstert.2010.05.047; Rawlings DJ, 2015, J IMMUNOL, V194, P2977, DOI 10.4049/jimmunol.1403034; Reddy MVPL, 2005, GENES IMMUN, V6, P658, DOI 10.1038/sj.gene.6364252; Reid Sara Pittenger, 2017, Fertil Res Pract, V3, P8, DOI 10.1186/s40738-017-0035-z; ROMANOWSKI Mariana Drechmer, 2015, Arq. Gastroenterol., V52, P117, DOI 10.1590/S0004-28032015000200008; Romitti M, 2018, ENDOCR CONNECT, V7, P1158, DOI 10.1530/EC-18-0309; Rupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00794; Rydzewska M, 2018, AUTOIMMUNITY, V51, P183, DOI 10.1080/08916934.2018.1486824; Santos LR, 2014, J CLIN ENDOCR METAB, V99, pE719, DOI 10.1210/jc.2013-3539; Saran Sanjay, 2016, Indian J Endocrinol Metab, V20, P108, DOI 10.4103/2230-8210.172245; Sasazuki T, 2016, ADV IMMUNOL, V129, P175, DOI 10.1016/bs.ai.2015.08.003; Shen XK, 2015, AUTOIMMUNITY, V48, P129, DOI 10.3109/08916934.2014.962025; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shi XY, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0763-5; Shi XH, 2016, J OBSTET GYNAECOL RE, V42, P844, DOI 10.1111/jog.13002; SHI YF, 1992, J CLIN ENDOCR METAB, V75, P943, DOI 10.1210/jc.75.3.943; Shi YY, 2012, NAT GENET, V44, P1020, DOI 10.1038/ng.2384; Shim U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136609; Simmonds MJ, 2013, NAT REV ENDOCRINOL, V9, P277, DOI 10.1038/nrendo.2013.56; Singla M, 2015, J CLIN DIAGN RES, V9, pAC4, DOI [10.7860/JCDR/2015/13118.5931, 10.7860/JCDR/2015/9982.5443]; Singla Rajiv, 2015, Indian J Endocrinol Metab, V19, P25, DOI 10.4103/2230-8210.146860; Sinha Uma, 2013, Indian J Endocrinol Metab, V17, P304, DOI 10.4103/2230-8210.109714; Sivanadham R, 2018, GENE, V642, P430, DOI 10.1016/j.gene.2017.11.057; Skaaby T, 2015, ENDOCRINE, V50, P231, DOI 10.1007/s12020-015-0547-4; Smyth D, 2004, DIABETES, V53, P3020, DOI 10.2337/diabetes.53.11.3020; Song DK, 2019, CLIN ENDOCRINOL, V90, P586, DOI 10.1111/cen.13936; Song DK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178120; Spritzer PM, 2016, CURR PHARM DESIGN, V22, P5603, DOI 10.2174/1381612822666160720151243; Spritzer PM, 2015, REPRODUCTION, V149, pR219, DOI 10.1530/REP-14-0435; Sun BY, 2020, ONCOL LETT, V19, P595, DOI 10.3892/ol.2019.11182; Tagliaferri V, 2016, EUR J ENDOCRINOL, V175, P433, DOI 10.1530/EJE-16-0358; Tamer G, 2011, THYROID, V21, P891, DOI 10.1089/thy.2009.0200; TANDON N, 1991, CLIN ENDOCRINOL, V34, P383; Teft WA, 2006, ANNU REV IMMUNOL, V24, P65, DOI 10.1146/annurev.immunol.24.021605.090535; Tian Y, 2016, J CLIN ENDOCR METAB, V101, P2178, DOI 10.1210/jc.2015-3776; Ting WH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154394; Tomer Y, 2003, ENDOCR REV, V24, P694, DOI 10.1210/er.2002-0030; Tomer Y, 2015, J AUTOIMMUN, V60, P32, DOI 10.1016/j.jaut.2015.03.006; Tsuchiya Y, 2004, CANCER RES, V64, P3119, DOI 10.1158/0008-5472.CAN-04-0166; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Ueda S, 2014, J CLIN ENDOCR METAB, V99, pE379, DOI 10.1210/jc.2013-2841; Ulrich J, 2018, EXP CLIN ENDOCR DIAB, V126, P198, DOI 10.1055/s-0043-110480; Urbanek M, 2007, J CLIN ENDOCR METAB, V92, P4191, DOI 10.1210/jc.2007-0761; Valkenburg O, 2009, HUM REPROD, V24, P2014, DOI 10.1093/humrep/dep113; Velaga MR, 2004, J CLIN ENDOCR METAB, V89, P5862, DOI 10.1210/jc.2004-1108; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Verma Indu, 2012, Int J Appl Basic Med Res, V2, P17, DOI 10.4103/2229-516X.96795; Vieland VJ, 2008, AM J HUM GENET, V82, P1349, DOI 10.1016/j.ajhg.2008.04.017; Vink JM, 2006, J CLIN ENDOCR METAB, V91, P2100, DOI 10.1210/jc.2005-1494; Wang B, 2019, MOL CELL ENDOCRINOL, V480, P97, DOI 10.1016/j.mce.2018.10.017; Wang B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00396; Wang DG, 2017, IMMUNOL INVEST, V46, P544, DOI 10.1080/08820139.2017.1319382; Wang F, 2017, MOL CELL ENDOCRINOL, V439, P363, DOI 10.1016/j.mce.2016.09.023; Wang XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep41540; Weetman AP, 2012, EUR THYROID J, V1, P243, DOI 10.1159/000343834; Welt CK, 2012, J CLIN ENDOCR METAB, V97, pE1342, DOI 10.1210/jc.2011-3478; Weng XC, 2019, THERIOGENOLOGY, V138, P145, DOI 10.1016/j.theriogenology.2019.07.012; Wild RA, 2011, FERTIL STERIL, V95, P1073, DOI 10.1016/j.fertnstert.2010.12.027; Winer D A, 2012, Int J Obes Suppl, V2, pS4; Wu HJ, 2015, J ASSIST REPROD GEN, V32, P625, DOI 10.1007/s10815-015-0449-7; Xia JY, 2019, KAOHSIUNG J MED SCI, V35, P49, DOI 10.1002/kjm2.12008; Xiao L, 2013, FUNCT INTEGR GENOMIC, V13, P455, DOI 10.1007/s10142-013-0337-0; Xie GB, 2013, REPROD BIOMED ONLINE, V26, P168, DOI 10.1016/j.rbmo.2012.10.014; Xiong YL, 2011, EUR J OBSTET GYN R B, V159, P148, DOI 10.1016/j.ejogrb.2011.07.012; Xu YP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140695; Yang J, 2015, EUR J OBSTET GYN R B, V186, P1, DOI 10.1016/j.ejogrb.2014.11.004; Yang M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00136; Yin DM, 2017, GYNECOL ENDOCRINOL, V33, P332, DOI 10.1080/09513590.2016.1273895; Yin L, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa053; Yu Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2067087; Zaletel K, 2011, CURR GENOMICS, V12, P576, DOI 10.2174/138920211798120763; Zeitlin A, 2008, GENES IMMUN, V9, P358, DOI 10.1038/gene.2008.26; Zhan M, 2014, HUM MOL GENET, V23, P5505, DOI 10.1093/hmg/ddu250; Zhang BJ, 2018, GYNECOL ENDOCRINOL, V34, P875, DOI 10.1080/09513590.2018.1462319; Zhang YB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175708; Zhao H, 2016, BEST PRACT RES CL OB, V37, P56, DOI 10.1016/j.bpobgyn.2016.04.002; Zhao SG, 2015, SCI REP-UK, V5, DOI 10.1038/srep12619; Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007; Zhu K, 2018, REPRODUCTION, V155, P505, DOI 10.1530/REP-18-0015; Zou S, 2013, MOL BIOL REP, V40, P3315, DOI 10.1007/s11033-012-2406-1	293	2	2	3	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 26	2021	12								606620	10.3389/fimmu.2021.606620	http://dx.doi.org/10.3389/fimmu.2021.606620			24	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX9YE	33746952	gold, Green Published			2022-12-18	WOS:000629696500001
J	Farazuddin, M; Landers, JJ; Janczak, KW; Lindsey, HK; Finkelman, FD; Baker, JR; O'Konek, JJ				Farazuddin, Mohammad; Landers, Jeffrey J.; Janczak, Katarzyna W.; Lindsey, Hayley K.; Finkelman, Fred D.; Baker, James R., Jr.; O'Konek, Jessica J.			Mucosal Nanoemulsion Allergy Vaccine Suppresses Alarmin Expression and Induces Bystander Suppression of Reactivity to Multiple Food Allergens	FRONTIERS IN IMMUNOLOGY			English	Article						adjuvant; alarmins; allergy treatment; food allergy; immunotherapy vaccines and mechanisms; vaccine	INNATE LYMPHOID-CELLS; EPICUTANEOUS IMMUNOTHERAPY; PEANUT ALLERGY; ORAL IMMUNOTHERAPY; CELLULAR-IMMUNITY; PROMOTES; TOLERANCE; EFFICACY; IMMUNOMODULATION; SENSITIZATION	We have demonstrated that intranasal immunotherapy with allergens formulated in a nanoemulsion (NE) mucosal adjuvant suppresses Th2/IgE-mediated allergic responses and protects from allergen challenge in murine food allergy models. Protection conferred by this therapy is associated with strong suppression of allergen specific Th2 cellular immunity and increased Th1 cytokines. Here we extend these studies to examine the effect of NE-allergen immunization in mice sensitized to multiple foods. Mice were sensitized to both egg and peanut and then received NE vaccine formulated with either one or both of these allergens. The animals were then subjected to oral challenges with either egg or peanut to assess reactivity. Immunization with NE formulations containing both egg and peanut markedly reduced reactivity after oral allergen challenge with either allergen. Interestingly, mice that received the vaccine containing only peanut also had reduced reactivity to challenge with egg. Protection from oral allergen challenge was achieved despite the persistence of allergen-specific IgE and was associated with strong suppression of both Th2-polarized immune responses, alarmins and type 2 innate lymphoid cells (ILC2). NE-induced bystander suppression of reactivity required IFN-gamma and the presence of an allergen in the NE vaccine. These results demonstrate that anaphylactic reactions to food allergens can be suppressed using allergen-specific immunotherapy without having to eliminate allergen-specific IgE and suggests that modulation of Th2 immunity towards one allergen may induce bystander effects that suppress reactivity to other allergens through the induction of IFN-gamma and suppression of alarmins in the intestine. In addition, these data suggest that a NE vaccine for a single food allergen may lead to a global suppression of allergic responses to multiple foods.	[Farazuddin, Mohammad; Landers, Jeffrey J.; Janczak, Katarzyna W.; Lindsey, Hayley K.; Baker, James R., Jr.; O'Konek, Jessica J.] Univ Michigan, Mary H Weiser Food Allergy Ctr, Ann Arbor, MI 48109 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Allergy Immunol & Rheumatol, Cincinnati, OH USA	University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati	O'Konek, JJ (corresponding author), Univ Michigan, Mary H Weiser Food Allergy Ctr, Ann Arbor, MI 48109 USA.	jjoz@umich.edu			Food Allergy Research and Education New Investigator Award; National Institute for Allergy and Infectious Disease, National Institutes of Health [R01AI145991]; Michigan Food Allergy Research Accelerator (M-FARA)	Food Allergy Research and Education New Investigator Award; National Institute for Allergy and Infectious Disease, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Michigan Food Allergy Research Accelerator (M-FARA)	This project has been funded by a Food Allergy Research and Education New Investigator Award, the National Institute for Allergy and Infectious Disease, National Institutes of Health under Grant R01AI145991, the Michigan Food Allergy Research Accelerator (M-FARA), and a generous gift from Robert and Caren Vondell.	Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Allinne J, 2019, J ALLERGY CLIN IMMUN, V144, P1624, DOI 10.1016/j.jaci.2019.08.039; Andorf S, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0224-7; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Bauer RN, 2015, J ALLERGY CLIN IMMUN, V135, P312, DOI 10.1016/j.jaci.2014.12.1908; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-1; Bielinska AU, 2008, CLIN VACCINE IMMUNOL, V15, P348, DOI 10.1128/CVI.00440-07; Bielinska AU, 2007, INFECT IMMUN, V75, P4020, DOI 10.1128/IAI.00070-07; Bielinska AU, 2016, VACCINE, V34, P4017, DOI 10.1016/j.vaccine.2016.06.043; Bielinska AU, 2014, J IMMUNOL, V192, P2722, DOI 10.4049/jimmunol.1301424; Bielinska AU, 2010, CRIT REV IMMUNOL, V30, P189, DOI 10.1615/CritRevImmunol.v30.i2.60; Broide DH, 2009, ANNU REV MED, V60, P279, DOI 10.1146/annurev.med.60.041807.123524; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Casale TB, 2008, J ALLERGY CLIN IMMUN, V121, P288, DOI 10.1016/j.jaci.2007.11.040; CLASSEN DC, 1987, J CLIN MICROBIOL, V25, P600, DOI 10.1128/JCM.25.4.600-604.1987; Dunkin D, 2017, INFLAMM BOWEL DIS, V23, P1972, DOI 10.1097/MIB.0000000000001273; Eisenbarth SC, 2004, J IMMUNOL, V172, P4527, DOI 10.4049/jimmunol.172.7.4527; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gregory JA, 2016, PLANT BIOTECHNOL J, V14, P1541, DOI 10.1111/pbi.12515; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hamouda T, 2010, HUM VACCINES, V6, P585, DOI 10.4161/hv.6.7.11818; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hussain M, 2018, J ALLERGY CLIN IMMUN, V141, P223, DOI 10.1016/j.jaci.2017.02.035; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Li BWS, 2019, EUR J IMMUNOL, V49, P144, DOI 10.1002/eji.201747421; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Lindell DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021823; Makidon PE, 2012, EUR J IMMUNOL, V42, P2073, DOI 10.1002/eji.201142346; Makidon PE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002954; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Mondoulet L, 2019, ALLERGY, V74, P152, DOI 10.1111/all.13479; Mondoulet L, 2015, J ALLERGY CLIN IMMUN, V135, P1546, DOI 10.1016/j.jaci.2014.11.028; Mondoulet L, 2011, INT ARCH ALLERGY IMM, V154, P299, DOI 10.1159/000321822; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Myc A, 2003, VACCINE, V21, P3801, DOI 10.1016/S0264-410X(03)00381-5; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; O'Konek JJ, 2020, ALLERGY, V75, P872, DOI 10.1111/all.14064; O'Konek JJ, 2018, J ALLERGY CLIN IMMUN, V141, P2121, DOI 10.1016/j.jaci.2018.01.042; OKONEK JJ, 2019, ALLERGY 0805, DOI DOI 10.1111/all.13977; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Passmore C, 2014, HUM VACC IMMUNOTHER, V10, P615, DOI 10.4161/hv.27383; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Rodriguez B, 2012, FEMS MICROBIOL ECOL, V79, P192, DOI 10.1111/j.1574-6941.2011.01207.x; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Starkey MR, 2019, MUCOSAL IMMUNOL, V12, P299, DOI 10.1038/s41385-018-0130-4; Stier MT, 2018, J EXP MED, V215, P263, DOI 10.1084/jem.20170449; Storni F, 2020, J ALLERGY CLIN IMMUN, V145, P1240, DOI 10.1016/j.jaci.2019.12.007; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Wang LF, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-28	61	2	2	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								599296	10.3389/fimmu.2021.599296	http://dx.doi.org/10.3389/fimmu.2021.599296			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5LL	33717078	gold, Green Published			2022-12-18	WOS:000627322300001
J	Ferreira, ACFM; Eveloff, RJ; Freire, M; Santos, MTBR				Ferreira, Ana Cristina Fernandes Maria; Eveloff, Ryan J.; Freire, Marcelo; Santos, Maria Teresa Botti Rodrigues			The Impact of Oral-Gut Inflammation in Cerebral Palsy	FRONTIERS IN IMMUNOLOGY			English	Article						cerebral palsy; inflammation; cytokines; quality of life; caregiver priorities and child health index of life with disabilities; constipation; antiepileptic drug		Background: Oral-gut inflammation has an impact on overall health, placing subjects at risk to acquire chronic conditions and infections. Due to neuromotor disturbances, and medication intake, cerebral palsy (CP) subjects present intestinal constipation, impacting their quality of life (QOL). We aimed to investigate how oral inflammatory levels predicted gut phenotypes and response to therapy. Methods: A total of 93 subjects aging from 5 to 17 years were included in the study, and assigned into one of the 4 groups: CP with constipation (G1, n = 30), CP without constipation (G2, n = 33), and controls without CP with constipation (G3, n = 07) and without CP and without constipation (G4, n = 23). In addition to characterizing subjects' clinical demographics, medication intake, disease severity levels, salivary cytokine levels [TNF-alpha, interleukin (IL)-1 beta, IL-6, IL-8, IL-10], and Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Statistical significance was evaluated by Shapiro-Wilks, Student's T-Test, ANOVA, and ANCOVA analysis. Results: Salivary proinflammatory cytokines were highly correlated with the severe form of gut constipation in G1 (P < 0.001), and out of all cytokines IL-1 beta levels demonstrated highest correlation with all gut constipation (P < 0.05). A significant relationship was found between the type of medication, in which subjects taking Gamma-Aminobutyric Acid (GABA) and GABA+ (GABA in association with other medication) were more likely to be constipated than the other groups (P < 0.01). Cleary salivary inflammatory levels and gut constipation were correlated, and impacted QOL of CP subjects. G1 presented a lower QOL mean score of CPCHILD (49.0 +/- 13.1) compared to G2 (71.5 +/- 16.7), when compared to G3 (88.9 +/- 7.5), and G4 (95.5 +/- 5.0) (P < 0.01). We accounted for gingival bleeding as a cofounder of oral inflammation, and here were no differences among groups regarding gender (P = 0.332) and age (P = 0.292). Conclusions: Collectively, the results suggest that saliva inflammatory levels were linked to gut constipation, and that the clinical impact of medications that controlled gut was reliably monitored via oral cytokine levels, providing reliable and non-invasive information in precision diagnostics.	[Ferreira, Ana Cristina Fernandes Maria; Santos, Maria Teresa Botti Rodrigues] Univ Cruzeiro Sul, Dept Individuals Special Needs, Postgrad Program Dent, Sao Paulo, Brazil; [Eveloff, Ryan J.; Freire, Marcelo] J Craig Venter Inst, Dept Genom Med & Infect Dis, La Jolla, CA 92037 USA; [Freire, Marcelo] Univ Calif San Diego, Sch Med, Dept Infect Dis, La Jolla, CA 92093 USA; [Santos, Maria Teresa Botti Rodrigues] Assoc Assistance Disabled Children, Dept Dent, Sao Paulo, Brazil	Universidade Cruzeiro do Sul; J. Craig Venter Institute; University of California System; University of California San Diego	Ferreira, ACFM (corresponding author), Univ Cruzeiro Sul, Dept Individuals Special Needs, Postgrad Program Dent, Sao Paulo, Brazil.; Freire, M (corresponding author), J Craig Venter Inst, Dept Genom Med & Infect Dis, La Jolla, CA 92037 USA.; Freire, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Infect Dis, La Jolla, CA 92093 USA.	anacristina.ferreira@gmail.com; mfreire@jcvi.org	Freire, Marcelo/AAQ-7519-2020; ferreira, ana cristina f m/R-4533-2018	Freire, Marcelo/0000-0003-4906-7698; ferreira, ana cristina f m/0000-0001-5154-7530	Sao Paulo Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo), FAPESP [2017/15160-4]; U.S. Public Health Service from the National Institutes of Health/National Institutes of Dental and Craniofacial Research/Department of Health and Human [DE 0235804]; JCVI internship fund	Sao Paulo Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo), FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); U.S. Public Health Service from the National Institutes of Health/National Institutes of Dental and Craniofacial Research/Department of Health and Human; JCVI internship fund	This project was supported by the Sao Paulo Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo), FAPESP #2017/15160-4 given to MS and also this work was partially supported by the U.S. Public Health Service Grant DE 0235804 given to MF from the National Institutes of Health/National Institutes of Dental and Craniofacial Research/Department of Health and Human. JCVI internship fund given to RE.	Batool H, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8531961; Bearden DR, 2016, PEDIATR NEUROL, V59, P23, DOI 10.1016/j.pediatrneurol.2016.03.002; Bensi C, 2020, SPEC CARE DENT, V40, P401, DOI 10.1111/scd.12506; Blond BN, 2016, NEUROL CLIN, V34, P395, DOI 10.1016/j.ncl.2015.11.002; Santos MTBR, 2017, INT J PAEDIATR DENT, V27, P364, DOI 10.1111/ipd.12270; Braccialli LMP, 2016, J PEDIAT-BRAZIL, V92, P143, DOI 10.1016/j.jped.2015.05.005; Carlo WA, 2011, J PEDIATR-US, V159, P919, DOI 10.1016/j.jpeds.2011.05.042; Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002; Chapple ILC, 2018, J PERIODONTOL, V89, pS74, DOI 10.1002/JPER.17-0719; CHAVES ES, 1993, J CLIN PERIODONTOL, V20, P139, DOI 10.1111/j.1600-051X.1993.tb00328.x; Chen MJ, 2013, CYTOKINE, V61, P826, DOI 10.1016/j.cyto.2013.01.011; Costa FO, 2019, CLIN ORAL INVEST, V23, P3517, DOI 10.1007/s00784-018-2770-x; Dammann O, 2008, CLIN PERINATOL, V35, P643, DOI 10.1016/j.clp.2008.07.011; Dean A., 2007, OPENEPI OPEN SOURCE; Degasperi G.R., 2018, ADV MICROBIOL-IRVINE, V8, P1, DOI 10.4236/aim.2018.81001; Delacy MJ, 2016, DEV MED CHILD NEUROL, V58, P50, DOI 10.1111/dmcn.13012; Devinsky O, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.24; Dos Santos MTBR, 2005, J ORAL REHABIL, V32, P880; Ertugrul AS, 2013, J PERIODONTAL RES, V48, P44, DOI 10.1111/j.1600-0765.2012.01500.x; Fairhurst C, 2019, DEV MED CHILD NEUROL, V61, P929, DOI 10.1111/dmcn.14113; Ferreira ACFM, 2019, INT J PAEDIATR DENT, V29, P635, DOI 10.1111/ipd.12488; Ferreira MC, 2011, J ORAL PATHOL MED, V40, P576, DOI 10.1111/j.1600-0714.2011.01008.x; Finoti LS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006932; Fiori S, 2019, NEURAL PLAST, V2019, DOI 10.1155/2019/9154282; Gamonal J, 2001, J PERIODONTAL RES, V36, P194, DOI 10.1034/j.1600-0765.2001.360309.x; Godhwani N, 2016, ANN ALLERG ASTHMA IM, V117, P634, DOI 10.1016/j.anai.2016.09.443; Gomes Francisco Isaac Fernandes, 2016, J Oral Maxillofac Res, V7, pe2, DOI 10.5037/jomr.2016.7202; Gunel MK, 2009, EUR J PEDIATR, V168, P477, DOI 10.1007/s00431-008-0775-1; Gutierrez GM, 2019, MED ORAL PATOL ORAL, V24, pE204, DOI 10.4317/medoral.22729; Hu LZ, 2017, J INVEST DERMATOL, V137, P1277, DOI 10.1016/j.jid.2017.01.007; Huang Nasi, 2014, Curr Oral Health Rep, V1, P124; Hyland NP, 2010, FRONT PHARMACOL, V1, DOI 10.3389/fphar.2010.00124; Ickes SB, 2015, J NUTR, V145, P2578, DOI 10.3945/jn.115.214346; Jahromi SR, 2011, SEIZURE-EUR J EPILEP, V20, P343, DOI 10.1016/j.seizure.2010.12.011; JOHANSON JF, 1992, DIGEST DIS SCI, V37, P179, DOI 10.1007/BF01308169; Jozala DR, 2019, J PEDIAT-BRAZIL, V95, P321, DOI 10.1016/j.jped.2018.01.006; Jyonouchi H, 2001, J NEUROIMMUNOL, V120, P170, DOI 10.1016/S0165-5728(01)00421-0; Kardesler L, 2011, INFLAMM RES, V60, P143, DOI 10.1007/s00011-010-0248-7; Khalif IL, 2005, DIGEST LIVER DIS, V37, P838, DOI 10.1016/j.dld.2005.06.008; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203; Li QR, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00120; Liu HY, 2017, J DENT SCI, V12, P388, DOI 10.1016/j.jds.2017.05.003; Maenner MJ, 2016, ANN EPIDEMIOL, V26, P222, DOI 10.1016/j.annepidem.2016.01.001; Malaeb S, 2009, J CHILD NEUROL, V24, P1119, DOI 10.1177/0883073809338066; Martinez AP, 2012, REV LAT-AM ENFERM, V20, P583, DOI 10.1590/S0104-11692012000300021; Meyle J, 2015, PERIODONTOL 2000, V69, P7, DOI 10.1111/prd.12104; Ming Xue, 2018, Child Neurol Open, V5, p2329048X18786799, DOI 10.1177/2329048X18786799; Mlodzikowska-Albrecht J, 2007, PHARMACOL REP, V59, P129; Mugie SM, 2011, BEST PRACT RES CL GA, V25, P3, DOI 10.1016/j.bpg.2010.12.010; NAKAGAWA S, 1994, J CLIN PERIODONTOL, V21, P658, DOI 10.1111/j.1600-051X.1994.tb00783.x; Nelson KB, 1998, ANN NEUROL, V44, P665, DOI 10.1002/ana.410440413; Barros ALO, 2019, SPEC CARE DENT, V39, P380, DOI 10.1111/scd.12400; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Park ES, 2004, ARCH PHYS MED REHAB, V85, P453, DOI 10.1016/S0003-9993(03)00479-9; Pellegrino LA, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-30; Pulgar S, 2019, J MANAG CARE SPEC PH, V25, P817, DOI 10.18553/jmcp.2019.25.7.817; Rezaei F, 2019, J INTERF CYTOK RES, V39, P727, DOI 10.1089/jir.2019.0070; Romeo DM, 2016, DEV MED CHILD NEUROL, V58, P809, DOI 10.1111/dmcn.13137; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Rudick CP, 2019, ORAL DIS, V25, P1879, DOI 10.1111/odi.13030; Sedky NA, 2018, INT J HEALTH SCI-IJH, V12, P4; Selai C, 2005, EPILEPSIA, V46, P50, DOI 10.1111/j.1528-1167.2005.463010.x; Sewell MD, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5474; Sullivan Amy Burleson, 2015, J Patient Exp, V2, P7, DOI 10.1177/237437431500200103; Tan SS, 2020, DEV MED CHILD NEUROL, V62, P132, DOI 10.1111/dmcn.14351; Verrotti A, 2001, CLIN EXP MED, V1, P133, DOI 10.1007/s10238-001-8024-1; Veugelers R, 2010, DEV MED CHILD NEUROL, V52, pE216, DOI 10.1111/j.1469-8749.2010.03701.x; Wimalasundera Neil, 2016, Pract Neurol, V16, P184, DOI 10.1136/practneurol-2015-001184; Yoshida RA, 2019, BRAZ ORAL RES, V33, DOI 10.1590/1807-3107bor-2019.vol33.0033; Zhang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104436; Zhang Q, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/284836; Zhu HH, 2015, INT J CLIN EXP PATHO, V8, P2214; Zhu LX, 2014, PHYSIOL GENOMICS, V46, P679, DOI 10.1152/physiolgenomics.00082.2014	74	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								619262	10.3389/fimmu.2021.619262	http://dx.doi.org/10.3389/fimmu.2021.619262			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QV3LW	33717115	Green Published, gold			2022-12-18	WOS:000627877700001
J	Gamain, B; Chene, A; Viebig, NK; Ndam, NT; Nielsen, MA				Gamain, Benoit; Chene, Arnaud; Viebig, Nicola K.; Ndam, Nicaise Tuikue; Nielsen, Morten A.			Progress and Insights Toward an Effective Placental Malaria Vaccine	FRONTIERS IN IMMUNOLOGY			English	Review						Plasmodium falciparum; placental malaria; VAR2CSA; PfEMP1; vaccine; pregnancy	FULL-LENGTH VAR2CSA; PREGNANCY; PREVENTION; ANTIBODIES; SELECTION; CHILDREN; DOMAINS; ANTIGEN; PFEMP1; RISK	In areas where Plasmodium falciparum transmission is endemic, clinical immunity against malaria is progressively acquired during childhood and adults are usually protected against the severe clinical consequences of the disease. Nevertheless, pregnant women, notably during their first pregnancies, are susceptible to placental malaria and the associated serious clinical outcomes. Placental malaria is characterized by the massive accumulation of P. falciparum infected erythrocytes and monocytes in the placental intervillous spaces leading to maternal anaemia, hypertension, stillbirth and low birth weight due to premature delivery, and foetal growth retardation. Remarkably, the prevalence of placental malaria sharply decreases with successive pregnancies. This protection is associated with the development of antibodies directed towards the surface of P. falciparum-infected erythrocytes from placental origin. Placental sequestration is mediated by the interaction between VAR2CSA, a member of the P. falciparum erythrocyte membrane protein 1 family expressed on the infected erythrocytes surface, and the placental receptor chondroitin sulfate A. VAR2CSA stands today as the leading candidate for a placental malaria vaccine. We recently reported the safety and immunogenicity of two VAR2CSA-derived placental malaria vaccines (PRIMVAC and PAMVAC), spanning the chondroitin sulfate A-binding region of VAR2CSA, in both malaria-naive and P. falciparum-exposed non-pregnant women in two distinct Phase I clinical trials (ClinicalTrials.gov, NCT02658253 and NCT02647489). This review discusses recent advances in placental malaria vaccine development, with a focus on the recent clinical data, and discusses the next clinical steps to undertake in order to better comprehend vaccine-induced immunity and accelerate vaccine development.	[Gamain, Benoit; Chene, Arnaud] Univ Paris, Biol Integree Globule Rouge, INSERM, Paris, France; [Gamain, Benoit; Chene, Arnaud] Inst Natl Transfus Sanguine, Paris, France; [Viebig, Nicola K.] Univ Klinikum Heidelberg, European Vaccine Initiat, Heidelberg, Germany; [Ndam, Nicaise Tuikue] Univ Paris, MERIT, IRD, Paris, France; [Nielsen, Morten A.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, Denmark; [Nielsen, Morten A.] Rigshosp, Dept Infect Dis, Copenhagen, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; University of Copenhagen; Rigshospitalet; University of Copenhagen	Gamain, B (corresponding author), Univ Paris, Biol Integree Globule Rouge, INSERM, Paris, France.; Gamain, B (corresponding author), Inst Natl Transfus Sanguine, Paris, France.	benoit.gamain@inserm.fr	Gamain, Benoit/N-9985-2017; Chene, Arnaud/O-4397-2017	Gamain, Benoit/0000-0002-8255-2145; Chene, Arnaud/0000-0002-6551-4382; Tuikue Ndam, Nicaise/0000-0003-2646-2513	French National Research Agency [ANR-16-CE11-0014-01]; Laboratory of Excellence GR-Ex [ANR-11-LABX-0051]; French Parasitology consortium ParaFrap [ANR-11-LABX0024]; program "Investissements d'avenir" of the French National Research Agency [ANR-11-IDEX0005-02]; Bundesministerium fur Bildung und Forschung, through Kreditanstalt fur Wiederaufbau, Germany [202060457]; Inserm, France; Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland; European Union in the Seventh Framework Programme (FP7-HEALTH-2012-INNOVATION) [304815]; Danish Advanced Technology Foundation [005-2011-1]	French National Research Agency(French National Research Agency (ANR)); Laboratory of Excellence GR-Ex; French Parasitology consortium ParaFrap; program "Investissements d'avenir" of the French National Research Agency(French National Research Agency (ANR)); Bundesministerium fur Bildung und Forschung, through Kreditanstalt fur Wiederaufbau, Germany(Federal Ministry of Education & Research (BMBF)); Inserm, France(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland; European Union in the Seventh Framework Programme (FP7-HEALTH-2012-INNOVATION); Danish Advanced Technology Foundation	This work is supported by the French National Research Agency (ANR-16-CE11-0014-01), grants from Laboratory of Excellence GR-Ex, reference ANR-11-LABX-0051 and the French Parasitology consortium ParaFrap (ANR-11-LABX0024). The labex GR-Ex is funded by the program "Investissements d'avenir" of the French National Research Agency, reference ANR-11-IDEX0005-02. Funding for PRIMVAC and PAMVAC activities were provided by the Bundesministerium fur Bildung und Forschung, through Kreditanstalt fur Wiederaufbau (ref: 202060457), Germany; Inserm and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland. European Union in the Seventh Framework Programme (FP7-HEALTH-2012-INNOVATION; under grant agreement 304815), the Danish Advanced Technology Foundation (under grant number 005-2011-1).	Accrombessi M, 2019, CLIN INFECT DIS, V69, P1385, DOI 10.1093/cid/ciy1073; Accrombessi M, 2018, J INFECT DIS, V217, P1309, DOI 10.1093/infdis/jiy009; Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Ataide R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022491; Avril M, 2008, INFECT IMMUN, V76, P1791, DOI 10.1128/IAI.01470-07; Avril M, 2006, MICROBES INFECT, V8, P2863, DOI 10.1016/j.micinf.2006.09.005; Avril M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016622; Babakhanyan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088173; Barfod L, 2007, MOL MICROBIOL, V63, P335, DOI 10.1111/j.1365-2958.2006.05503.x; Barfod L, 2010, J IMMUNOL, V185, P7553, DOI 10.4049/jimmunol.1002390; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Beeson JG, 2007, AM J TROP MED HYG, V77, P22, DOI 10.4269/ajtmh.2007.77.22; Bewley MC, 2020, J BIOL CHEM, V295, P18589, DOI 10.1074/jbc.RA120.014676; Bigey P, 2011, J INFECT DIS, V204, P1125, DOI 10.1093/infdis/jir499; Bir N, 2006, INFECT IMMUN, V74, P5955, DOI 10.1128/IAI.00481-06; Bordbar B, 2012, VACCINE, V30, P1343, DOI 10.1016/j.vaccine.2011.12.065; Chene A, 2019, EBIOMEDICINE, V42, P145, DOI 10.1016/j.ebiom.2019.03.010; Chene A, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0064-6; Chene A, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1527-8; Clausen TM, 2012, J BIOL CHEM, V287, P23332, DOI 10.1074/jbc.M112.348839; Cutts JC, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1467-6; Dahlback M, 2006, PLOS PATHOG, V2, P1069, DOI 10.1371/journal.ppat.0020124; Dahlback M, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.191510; Dechavanne S, 2015, INFECT IMMUN, V83, P2466, DOI 10.1128/IAI.03116-14; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Desai M, 2018, LANCET INFECT DIS, V18, pE119, DOI 10.1016/S1473-3099(18)30064-1; Doritchamou J, 2017, LAB ANIMAL, V46, P388, DOI 10.1038/laban.1349; Doritchamou J, 2013, VACCINE, V31, P4516, DOI 10.1016/j.vaccine.2013.07.072; Doritchamou JYA, 2016, J INFECT DIS, V214, P577, DOI 10.1093/infdis/jiw197; Duffy MF, 2005, MOL MICROBIOL, V56, P774, DOI 10.1111/j.1365-2958.2005.04577.x; Elliott SR, 2005, INFECT IMMUN, V73, P5903, DOI 10.1128/IAI.73.9.5903-5907.2005; Elliott SR, 2005, INFECT IMMUN, V73, P2848, DOI 10.1128/IAI.73.5.2848-2856.2005; Fievet N, 2001, J INFECT DIS, V183, P1530, DOI 10.1086/320201; Fodjo BAY, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1585-y; Fowkes FJI, 2012, J INFECT DIS, V206, P1612, DOI 10.1093/infdis/jis566; Fried M, 1998, J MOL MED-JMM, V76, P162, DOI 10.1007/s001090050205; Fried M, 1998, J IMMUNOL, V160, P2523; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570; Fried M, 2013, INFECT IMMUN, V81, P487, DOI 10.1128/IAI.01106-12; GALBRAITH RM, 1980, T ROY SOC TROP MED H, V74, P61, DOI 10.1016/0035-9203(80)90012-7; Gamain B, 2005, J INFECT DIS, V191, P1010, DOI 10.1086/428137; Gangnard S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53334-8; Gangnard S, 2015, SCI REP-UK, V5, DOI 10.1038/srep14868; Gnidehou S, 2014, INFECT IMMUN, V82, P2565, DOI 10.1128/IAI.01594-14; Gysin J, 1999, INFECT IMMUN, V67, P6596; Higgins MK, 2008, J BIOL CHEM, V283, P21842, DOI 10.1074/jbc.C800086200; Hounkonnou CPA, 2020, CLIN INFECT DIS, V71, P166, DOI 10.1093/cid/ciz748; Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8; Jafari-Guemouri S, 2021, CLIN INFECT DIS, V73, pE355, DOI 10.1093/cid/ciaa841; Janitzek CM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41522-5; Jaworowski A, 2009, CLIN VACCINE IMMUNOL, V16, P312, DOI 10.1128/CVI.00356-08; Keen J, 2007, PLOS MED, V4, P912, DOI 10.1371/journal.pmed.0040181; Khunrae P, 2010, J MOL BIOL, V397, P826, DOI 10.1016/j.jmb.2010.01.040; Khunrae P, 2009, J MOL BIOL, V393, P202, DOI 10.1016/j.jmb.2009.08.027; Lo Tutterrow Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040049; Magistrado PA, 2011, VACCINE, V29, P437, DOI 10.1016/j.vaccine.2010.10.080; Maubert B, 1997, INFECT IMMUN, V65, P1251, DOI 10.1128/IAI.65.4.1251-1257.1997; Megnekou R, 2005, INFECT IMMUN, V73, P4112, DOI 10.1128/IAI.73.7.4112-4118.2005; Moore Kerryn A, 2017, Lancet Glob Health, V5, pe1101, DOI 10.1016/S2214-109X(17)30340-6; Moormann AM, 1999, J INFECT DIS, V180, P1987, DOI 10.1086/315135; Mordmuller B, 2019, CLIN INFECT DIS, V69, P1509, DOI 10.1093/cid/ciy1140; Muehlenbachs A, 2006, PLOS MED, V3, P2124, DOI 10.1371/journal.pmed.0030446; Ndam NGT, 2005, J INFECT DIS, V192, P331, DOI 10.1086/430933; Ndao CT, 2009, AM J EPIDEMIOL, V170, P847, DOI 10.1093/aje/kwp207; Nielsen MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135406; Nielsen MA, 2009, INFECT IMMUN, V77, P2482, DOI 10.1128/IAI.00159-09; Nunes-Silva S, 2014, SCI REP-UK, V4, DOI 10.1038/srep07373; Obiakor H, 2013, CLIN VACCINE IMMUNOL, V20, P433, DOI 10.1128/CVI.00638-12; Patel JC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04737-y; Pinto VV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017942; Rele S, 2021, HUM VACC IMMUNOTHER, V17, P1122, DOI 10.1080/21645515.2020.1822136; Resende M, 2009, INT J PARASITOL, V39, P1195, DOI 10.1016/j.ijpara.2009.02.022; Saito M, 2020, LANCET CHILD ADOLESC, V4, P761, DOI 10.1016/S2352-4642(20)30099-7; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Salanti A, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-11; Sander AF, 2011, J INFECT DIS, V203, P1679, DOI 10.1093/infdis/jir168; Shulman CE, 1996, T ROY SOC TROP MED H, V90, P535, DOI 10.1016/S0035-9203(96)90312-0; Singh K, 2008, NAT STRUCT MOL BIOL, V15, P932, DOI 10.1038/nsmb.1479; Singh K, 2010, J BIOL CHEM, V285, P24855, DOI 10.1074/jbc.M110.118612; Sirima SB, 2020, LANCET INFECT DIS, V20, P585, DOI 10.1016/S1473-3099(19)30739-X; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Srivastava A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020270; Srivastava A, 2010, P NATL ACAD SCI USA, V107, P4884, DOI 10.1073/pnas.1000951107; Thrane S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0181-1; Turner L, 2013, NATURE, V498, P502, DOI 10.1038/nature12216; Umbers AJ, 2011, J INFECT DIS, V203, P561, DOI 10.1093/infdis/jiq080; van Eijk AM, 2019, LANCET INFECT DIS, V19, P546, DOI 10.1016/S1473-3099(18)30732-1; Verhoeff FH, 1999, ANN TROP MED PARASIT, V93, P119, DOI 10.1080/00034989958609; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466; Walker PGT, 2014, LANCET GLOB HEALTH, V2, pE460, DOI 10.1016/S2214-109X(14)70256-6; WALTER PR, 1982, AM J PATHOL, V109, P330; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization Geneva, 2018, GLOBAL REPORT INSECT	95	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								634508	10.3389/fimmu.2021.634508	http://dx.doi.org/10.3389/fimmu.2021.634508			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5QM	33717176	Green Published, gold			2022-12-18	WOS:000627335800001
J	Lee, L; Alrasheed, N; Khandelwal, G; Fitzsimons, E; Richards, H; Wilson, W; Chavda, SJ; Henry, J; Conde, L; De Massy, MR; Chin, M; Galas-Filipowicz, D; Herrero, J; Chain, B; Quezada, SA; Yong, K				Lee, Lydia; Alrasheed, Nouf; Khandelwal, Garima; Fitzsimons, Evelyn; Richards, Huw; Wilson, William; Chavda, Selina J.; Henry, Jake; Conde, Lucia; De Massy, Marc Robert; Chin, Melody; Galas-Filipowicz, Daria; Herrero, Javier; Chain, Benny; Quezada, Sergio A.; Yong, Kwee			Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma	FRONTIERS IN IMMUNOLOGY			English	Article						multiple myeloma; immune phenotype; PD-1; Ki-67; T cell receptor; autologous stem cell transplant	MINIMAL RESIDUAL DISEASE; CANCER-PATIENTS; SURVIVAL; SUBSETS	The benefit of autologous stem cell transplantation (ASCT) in newly diagnosed myeloma patients, apart from supporting high dose chemotherapy, may include effects on T cell function in the bone marrow (BM). We report our exploratory findings on marrow infiltrating T cells early post-ASCT (day+100), examining phenotype and T cell receptor (TCR) repertoire, seeking correlations with timing of relapse. Compared to healthy donors (HD), we observed an increase in regulatory T cells (CD4+FoxP3+, Tregs) with reduction in CD4 T cells, leading to lower CD4:8 ratios. Compared to paired pre-treatment marrow, both CD4 and CD8 compartments showed a reduction in naive, and increase in effector memory subsets, suggestive of a more differentiated phenotype. This was supported by increased levels of several immune-regulatory and activation proteins (ICOS, PD-1, LAG-3, CTLA-4 and GzmB) when compared with HD. Unsupervised analysis identified a patient subgroup with shorter PFS (p=0.031) whose BM contained increased Tregs, and higher immune-regulatory markers (ICOS, PD-1, LAG-3) on effector T cells. Using single feature analysis, higher frequencies of marrow PD-1+ on CD4+FoxP3- cells and Ki67+ on CD8 cells were independently associated with early relapse. Finally, studying paired pre-treatment and post-ASCT BM (n=5), we note reduced abundance of TCR sequences at day+100, with a greater proportion of expanded sequences indicating a more focused persistent TCR repertoire. Our findings indicate that, following induction chemotherapy and ASCT, marrow T cells demonstrate increased activation and differentiation, with TCR repertoire focusing. Pending confirmation in larger series, higher levels of immune-regulatory proteins on T cell effectors at day+100 may indicate early relapse.	[Lee, Lydia; Alrasheed, Nouf; Fitzsimons, Evelyn; Richards, Huw; Chavda, Selina J.; Henry, Jake; De Massy, Marc Robert; Chin, Melody; Galas-Filipowicz, Daria; Quezada, Sergio A.; Yong, Kwee] UCL, Canc Inst, Res Dept Hematol, London, England; [Khandelwal, Garima; Conde, Lucia; Herrero, Javier] UCL, Canc Inst, Bill Lyons Informat Ctr, London, England; [Wilson, William] Canc Res UK & UCL Canc Trials Ctr, London, England; [Henry, Jake; De Massy, Marc Robert; Quezada, Sergio A.] UCL, Res Dept Hematol, Canc Immunol Unit, Canc Inst, London, England; [De Massy, Marc Robert; Chain, Benny] UCL, Dept Immunol, London, England	University of London; University College London; University of London; University College London; Cancer Research UK; University of London; University College London; University of London; University College London; University of London; University College London	Quezada, SA; Yong, K (corresponding author), UCL, Canc Inst, Res Dept Hematol, London, England.; Quezada, SA (corresponding author), UCL, Res Dept Hematol, Canc Immunol Unit, Canc Inst, London, England.	s.quezada@ucl.ac.uk; kwee.yong@ucl.ac.uk		Herrero, Javier/0000-0001-7313-717X	King Faisal Specialist and Research Centre; Medical Research Council [MR/S001883/1]; Cancer Research UK; Cancer Research UK-University College London (CRUK-UCL) Centre Award [C416/A25145]; UCLH Biomedical Research Centre; MRC [MR/S001883/1] Funding Source: UKRI	King Faisal Specialist and Research Centre; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Cancer Research UK-University College London (CRUK-UCL) Centre Award; UCLH Biomedical Research Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	NA's PhD studentship was funded by King Faisal Specialist and Research Centre. LL is a Clinician Scientist funded by the Medical Research Council (Clinician Scientist Fellow, MR/S001883/1). GK is funded by Cancer Research UK. LC was funded by the Cancer Research UK-University College London (CRUK-UCL) Centre Award [C416/A25145]. SQ is a Cancer Research UK Senior Cancer Research Fellow. KY receives funding from UCLH Biomedical Research Centre.	Alrasheed N, 2020, CLIN CANCER RES, V26, P3443, DOI 10.1158/1078-0432.CCR-19-1714; Attal M, 2017, NEW ENGL J MED, V376, P1311, DOI 10.1056/NEJMoa1611750; Brown RD, 2009, LEUKEMIA LYMPHOMA, V50, P1860, DOI 10.3109/10428190903216804; Busch DH, 2016, SEMIN IMMUNOL, V28, P28, DOI 10.1016/j.smim.2016.02.001; Chung DJ, 2016, CANCER IMMUNOL RES, V4, P61, DOI 10.1158/2326-6066.CIR-15-0055; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Goding SR, 2013, J IMMUNOL, V190, P4899, DOI 10.4049/jimmunol.1300271; Holstein SA, 2016, LANCET HAEMATOL, V3, pE306, DOI 10.1016/S2352-3026(16)30058-8; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Hwang S, 2016, J EXP MED, V213, P1799, DOI 10.1084/jem.20151995; Jia QZ, 2015, INT J CLIN EXP MED, V8, P1803; Jimenez-Zepeda VH, 2015, LEUKEMIA LYMPHOMA, V56, P2668, DOI 10.3109/10428194.2014.1003057; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Kawano Y, 2018, J CLIN INVEST, V128, P2487, DOI 10.1172/JCI88169; Kim H, 2006, BIOL BLOOD MARROW TR, V12, P837, DOI 10.1016/j.bbmt.2006.04.006; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Minnie SA, 2018, BLOOD, V132, P1675, DOI 10.1182/blood-2018-01-825240; Muraro PA, 2014, J CLIN INVEST, V124, P1168, DOI 10.1172/JCI71691; Nakamura K, 2018, CANCER CELL, V33, P634, DOI 10.1016/j.ccell.2018.02.007; Paiva B, 2012, BLOOD, V119, P687, DOI 10.1182/blood-2011-07-370460; Porrata LF, 2001, BONE MARROW TRANSPL, V28, P673, DOI 10.1038/sj.bmt.1703203; Sun YX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00430; Takeuchi Y, 2018, INT IMMUNOL, V30, P13, DOI 10.1093/intimm/dxx073; Thomas N, 2013, BIOINFORMATICS, V29, P542, DOI 10.1093/bioinformatics/btt004; Uddin I, 2019, METHOD ENZYMOL, V629, P465, DOI 10.1016/bs.mie.2019.05.054; Vahidi Y, 2018, CELL ONCOL, V41, P1, DOI 10.1007/s13402-017-0352-6; Vuckovic S, 2019, J CLIN INVEST, V129, P106, DOI 10.1172/JCI98888; Williams KA, 2007, SEMIN IMMUNOL, V19, P318, DOI 10.1016/j.smim.2007.10.004	29	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								618610	10.3389/fimmu.2021.618610	http://dx.doi.org/10.3389/fimmu.2021.618610			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU2RU	33717112	gold, Green Published			2022-12-18	WOS:000627131800001
J	Li, SP; Wang, XH; Zhao, YM; Yang, J; Cui, TJ; Zhao, ZJ; Chen, Y; Zheng, ZH				Li, Shuping; Wang, Xiaohua; Zhao, Yuming; Yang, Juan; Cui, Tianjiao; Zhao, Zhizhuang Joe; Chen, Yun; Zheng, Zhihua			Association of PTPN22-C1858T Polymorphism With Susceptibility to Mycobacterium tuberculosis and Mycobacterium leprae Infection: A Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						PTPN22-C1858T; single-nucleotide polymorphism; tuberculosis; leprosy; Mycobacterium tuberculosis; Mycobacterium leprae	T-CELLS; PTPN22	It was previously published that single-nucleotide polymorphism rs2476601 (PTPN22 [protein tyrosine phosphatase non-receptor type 22]-C1858T) might be related to increased sensibility to Mycobacterium tuberculosis and M. leprae infection. However, the results were inconclusive despite a high degree of similarity between both parameters. Herein, we carried out this meta-analysis to systematically summarize and articulate the correlation between PTPN22-C1858T polymorphism and mycobacterial infection. The susceptibility of PTPN22-C1858T carriers with autoimmune conditions receiving immunosuppressive therapy to M. tuberculosis and M. leprae infection was determined. A systematic retrieval of studies on relevance of PTPN22-C1858T polymorphism to susceptibility of M. tuberculosis or M. leprae infection was performed in Chinese National Knowledge Infrastructure, PubMed and Embase databases. We regarded Odds ratios (ORs) and 95% confidence intervals (CIs) as the determined effect size. Finally, four and two case-control studies on tuberculosis and leprosy, respectively, were included. In all genetic models, without indicated association between PTPN22-C1858T polymorphism and tuberculosis's susceptibility. [C versus T: OR = 0.22 (95% CI: 0.09-0.50, P-H = 0.887); CT versus CC: OR = 0.21 (95% CI: 0.09-0.49, P-H = 0.889); TT+CT versus CC: OR = 0.21 (95% CI: 0.09-0.49, P-H = 0.889)]. A significantly increased risk of leprosy was perceived in patients with the PTPN22-C1858T polymorphism [C versus T: OR = 2.82 (95% CI: 1.02-7.81, P-H = 0.108)]. While the PTPN22-C1858T polymorphism is irrelevant to higher susceptibility to the infection of M. tuberculosis in Caucasians and Asians, it is relevant to increased susceptibility to the infection of M. leprae. However, the results of M. leprae are supposed to interpreted with prudence owing to the limited quantity of studies and heterogeneity. Further well-designed studies with sufficient populations are required to verify our conclusions.	[Li, Shuping; Wang, Xiaohua; Yang, Juan; Cui, Tianjiao; Zheng, Zhihua] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Nephrol, Shenzhen, Peoples R China; [Li, Shuping; Wang, Xiaohua; Yang, Juan; Cui, Tianjiao; Zheng, Zhihua] Sun Yat Sen Univ, Affiliated Hosp 7, Ctr Nephrol & Urol, Shenzhen, Peoples R China; [Zhao, Yuming; Zhao, Zhizhuang Joe; Chen, Yun] Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, Shenzhen, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Zheng, ZH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Dept Nephrol, Shenzhen, Peoples R China.; Zheng, ZH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Ctr Nephrol & Urol, Shenzhen, Peoples R China.; Chen, Y (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, Shenzhen, Peoples R China.	cheny653@mail.sysu.edu.cn; zhzhihua@mail.sysu.edu.cn		Zheng, Zhihua/0000-0003-1025-5384	100 Top Talents Program of Sun Yat-sen University; National Natural Science Foundation of China (NSFC) [31871400]; Shenzhen Science and Technology Innovation Committee of Guangdong Province of China [JSGG20180703155802047, JCYJ20180307150634856]	100 Top Talents Program of Sun Yat-sen University; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Innovation Committee of Guangdong Province of China	This work was supported by the 100 Top Talents Program of Sun Yat-sen University, National Natural Science Foundation of China (NSFC, Grant No. 31871400), the Shenzhen Science and Technology Innovation Committee of Guangdong Province of China (Grant No. JSGG20180703155802047), and the Shenzhen Science and Technology Innovation Committee of Guangdong Province of China (Grant No. JCYJ20180307150634856).	Aliparasti Mohammad Reza, 2013, Indian J Hum Genet, V19, P403, DOI 10.4103/0971-6866.124365; Azarian M, 2008, TRANSPLANTATION, V85, P1859, DOI 10.1097/TP.0b013e31817729c4; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; Bonecini-Almeida MDG, 1998, CELL IMMUNOL, V190, P112; Bongiorno M R, 2008, Travel Med Infect Dis, V6, P311, DOI 10.1016/j.tmaid.2008.05.004; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Bottini N, 2014, ANNU REV IMMUNOL, V32, P83, DOI 10.1146/annurev-immunol-032713-120249; Bray C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02595; Britton WJ, 2004, LANCET, V363, P1209, DOI 10.1016/S0140-6736(04)15952-7; Carrasco-Escobar G, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00647-w; Chapman SJ, 2006, NAT GENET, V38, P499, DOI 10.1038/ng0506-499; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Cohen S, 1999, BLOOD, V93, P2013, DOI 10.1182/blood.V93.6.2013.406k25_2013_2024; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diaz-Gallo LM, 2018, ANN RHEUM DIS, V77, P1454, DOI 10.1136/annrheumdis-2018-213412; Dornelles LN, 2006, CLIN EXP IMMUNOL, V145, P463, DOI 10.1111/j.1365-2249.2006.03161.x; Ferreira RC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02606; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gomez LM, 2005, HUM IMMUNOL, V66, P1242, DOI 10.1016/j.humimm.2005.11.008; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; Hasegawa K, 2004, SCIENCE, V303, P685, DOI 10.1126/science.1092138; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hill RJ, 2002, EXP HEMATOL, V30, P237, DOI 10.1016/S0301-472X(01)00794-9; Hotez PJ, 2009, LANCET, V373, P1570, DOI 10.1016/S0140-6736(09)60233-6; Van Rensburg AJ, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-019-0619-4; Jin Y, 2010, NEW ENGL J MED, V362, P1686, DOI 10.1056/NEJMoa0908547; Krischer JP, 2017, DIABETES CARE, V40, P1194, DOI 10.2337/dc17-0238; Kyogoku C, 2004, AM J HUM GENET, V75, P504, DOI 10.1086/423790; Lamsyah H, 2009, TISSUE ANTIGENS, V74, P228, DOI 10.1111/j.1399-0039.2009.01304.x; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Moller M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02219; Moran AE, 2012, IMMUNOLOGY, V135, P261, DOI 10.1111/j.1365-2567.2011.03547.x; Nahum A, 2008, J ALLERGY CLIN IMMUN, V122, P1220, DOI 10.1016/j.jaci.2008.10.027; Narasimha VR, 2016, INT J MYCOBACT, V5, P346, DOI 10.1016/j.ijmyco.2016.06.014; Orlova Marianna, 2017, Curr Genet Med Rep, V5, P125, DOI 10.1007/s40142-017-0124-7; Pescarini JM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006622; Rani R, 2009, J INVEST DERMATOL, V129, P2726, DOI 10.1038/jid.2009.140; REES RJW, 1974, LANCET, V1, P47; Rieck M, 2007, J IMMUNOL, V179, P4704, DOI 10.4049/jimmunol.179.7.4704; Sauer MED, 2015, CLIN DERMATOL, V33, P99, DOI 10.1016/j.clindermatol.2014.10.001; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; [石学香 Shi Xuexiang], 2014, [中华微生物学和免疫学杂志, Chinese Journal of Microbiology and Immunology], V34, P908; Sartori PVU, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58079-3; Vang T, 2005, NAT GENET, V37, P1317, DOI 10.1038/ng1673; Wang YY, 2013, IMMUNITY, V39, P111, DOI 10.1016/j.immuni.2013.06.013; Wells G., 2014, VIS COMMUN Q; World Health Organization, 2016, GLOBAL LEPROSY STRAT; World Health Organization, 2019, GLOBAL TUBERCULOSIS; Zheng J, 2012, GENES IMMUN, V13, P641, DOI 10.1038/gene.2012.46	50	2	2	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								592841	10.3389/fimmu.2021.592841	http://dx.doi.org/10.3389/fimmu.2021.592841			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU7IF	33717071	Green Published, gold			2022-12-18	WOS:000627452100001
J	Ma, YH; Yan, GL; Guo, JJ; Li, FJ; Zheng, HP; Wang, CX; Chen, YY; Ye, YH; Dai, HL; Qi, ZQ; Zhuang, GH				Ma, Yunhan; Yan, Guoliang; Guo, Junjun; Li, Fujun; Zheng, Haiping; Wang, Chenxi; Chen, Yingyu; Ye, Yuhan; Dai, Helong; Qi, Zhongquan; Zhuang, Guohong			Berberine Prolongs Mouse Heart Allograft Survival by Activating T Cell Apoptosis via the Mitochondrial Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						alloimmunity and transplantation; transplantation immunology; immunoregulation; immunological tolerance and memory; T cell; berberine; heart allograft survival	EXPRESSION; RESPONSES; TRANSPLANTATION; ANTIGEN; REJECTION; CD69; INDUCTION; MECHANISM; SIROLIMUS; RISK	Berberine, which is a traditional Chinese medicine can inhibit tumorigenesis by inducing tumor cell apoptosis. However, the immunoregulatory of effects berberine on T cells remains poorly understood. Here, we first examined whether berberine can prolong allograft survival by regulating the recruitment and function of T cells. Using a major histocompatibility complex complete mismatch mouse heterotopic cardiac transplantation model, we found that the administration of moderate doses (5 mg/kg) of berberine significantly prolonged heart allograft survival to 19 days and elicited no obvious berberine-related toxicity. Compared to that with normal saline treatment, berberine treatment decreased alloreactive T cells in recipient splenocytes and lymph node cells. It also inhibited the activation, proliferation, and function of alloreactive T cells. Most importantly, berberine treatment protected myocardial cells by decreasing CD4(+) and CD8(+) T cell infiltration and by inhibiting T cell function in allografts. In vivo and in vitro assays revealed that berberine treatment eliminated alloreactive T lymphocytes via the mitochondrial apoptosis pathway, which was validated by transcriptome sequencing. Taken together, we demonstrated that berberine prolongs allograft survival by inducing apoptosis of alloreactive T cells. Thus, our study provides more evidence supporting the potential use of berberine in translational medicine.	[Ma, Yunhan; Chen, Yingyu; Zhuang, Guohong] Xiamen Univ, Organ Transplantat Inst, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China; [Yan, Guoliang; Guo, Junjun; Zheng, Haiping; Wang, Chenxi] Xiamen Univ, Sch Med, Xiamen, Peoples R China; [Li, Fujun] Harbin Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Harbin, Peoples R China; [Ye, Yuhan] Xiamen Univ, Zhongshan Hosp, Dept Pathol, Xiamen, Peoples R China; [Dai, Helong] Cent South Univ, Xiangya Hosp 2, Ctr Organ Transplantat, Dept Kidney Transplantat, Changsha, Peoples R China; [Dai, Helong] Clin Res Ctr Organ Transplantat Hunan Prov, Changsha, Peoples R China; [Dai, Helong] Cent South Univ, Clin Immunol Ctr, Changsha, Peoples R China; [Qi, Zhongquan] Guangxi Univ, Med Coll, Nanning, Peoples R China	Xiamen University; Xiamen University; Harbin Medical University; Xiamen University; Central South University; Central South University; Guangxi University	Zhuang, GH (corresponding author), Xiamen Univ, Organ Transplantat Inst, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China.; Dai, HL (corresponding author), Cent South Univ, Xiangya Hosp 2, Ctr Organ Transplantat, Dept Kidney Transplantat, Changsha, Peoples R China.; Dai, HL (corresponding author), Clin Res Ctr Organ Transplantat Hunan Prov, Changsha, Peoples R China.; Dai, HL (corresponding author), Cent South Univ, Clin Immunol Ctr, Changsha, Peoples R China.; Qi, ZQ (corresponding author), Guangxi Univ, Med Coll, Nanning, Peoples R China.	helong68888@csu.edu.cn; zqqi@xmu.edu.cn; zhgh@xmu.edu.cn		Ma, Yunhan/0000-0001-9593-5391	National Natural Science Foundation of China [81771271, 81800664, 82070776]; National Key R&D Program of China [2018YFA0108304]; Natural Science Foundation of Hunan Province of China [2019JJ50842]; Huxiang Young Talents of Hunan Province [2019RS2013]; College Students' Innovative Entrepreneurial Training Plan Program [2020X0736]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Natural Science Foundation of Hunan Province of China(Natural Science Foundation of Hunan Province); Huxiang Young Talents of Hunan Province; College Students' Innovative Entrepreneurial Training Plan Program	The experimental studies were supported by the National Natural Science Foundation of China (81771271, 81800664, and 82070776), National Key R&D Program of China (2018YFA0108304), Natural Science Foundation of Hunan Province of China (2019JJ50842), Huxiang Young Talents of Hunan Province (2019RS2013), and College Students' Innovative Entrepreneurial Training Plan Program (2020X0736).	Aberg F, 2008, LIVER TRANSPLANT, V14, P1428, DOI 10.1002/lt.21475; Arakaki R, 2014, CRIT REV IMMUNOL, V34, P301, DOI 10.1615/CritRevImmunol.2014009988; BERKOWITZ N, 1992, J IMMUNOL, V148, P309; Besancon A, 2018, TRANSPLANTATION, V102, P1496, DOI 10.1097/TP.0000000000002261; Bueno V, 2002, BRAZ J MED BIOL RES, V35, P1247, DOI 10.1590/S0100-879X2002001100001; Chrobak Pavel, 2003, Acta Medica (Hradec Kralove), V46, P131; Cui GL, 2009, J BIOL CHEM, V284, P28420, DOI 10.1074/jbc.M109.012674; Du J, 2017, ANTICANCER RES, V37, P6141, DOI 10.21873/anticanres.12063; Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006; Hsu WH, 2007, ARCH TOXICOL, V81, P719, DOI 10.1007/s00204-006-0169-y; Hu ZL, 2011, ARTHRITIS RHEUM-US, V63, P949, DOI 10.1002/art.30202; Huang PL, 2003, CURR HYPERTENS REP, V5, P473, DOI 10.1007/s11906-003-0055-4; Hwang JM, 2006, ARCH TOXICOL, V80, P62, DOI 10.1007/s00204-005-0014-8; Issa F, 2010, EXPERT REV CLIN IMMU, V6, P155, DOI 10.1586/ECI.09.64; Jeong HW, 2009, AM J PHYSIOL-ENDOC M, V296, pE955, DOI 10.1152/ajpendo.90599.2008; Jiang H, 2006, NEW ENGL J MED, V354, P1166, DOI 10.1056/NEJMra055446; Kasiske BL, 2008, AM J TRANSPLANT, V8, P1384, DOI 10.1111/j.1600-6143.2008.02272.x; Kim EY, 2006, J IMMUNOL, V176, P1026, DOI 10.4049/jimmunol.176.2.1026; Kong WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/nm1135; Kumar R, 2020, LIFE SCI, V244, DOI 10.1016/j.lfs.2020.117346; Li J, 2011, MOL CANCER THER, V10, P1346, DOI 10.1158/1535-7163.MCT-10-0985; Li L, 2017, BIOMED PHARMACOTHER, V95, P1225, DOI 10.1016/j.biopha.2017.09.010; Li YH, 2019, EUR J PHARMACOL, V850, P167, DOI 10.1016/j.ejphar.2019.02.021; Lin RH, 1997, J IMMUNOL, V158, P598; Linn YC, 2012, PHYTOTHER RES, V26, P682, DOI 10.1002/ptr.3617; Liu C, 2014, MOL MED REP, V10, P1323, DOI 10.3892/mmr.2014.2382; Llambi F, 2011, CURR OPIN GENET DEV, V21, P12, DOI 10.1016/j.gde.2010.12.001; Ma YH, 2020, JOVE-J VIS EXP, DOI 10.3791/61103; Mahata S, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-39; Mahmoudi M, 2016, J IMMUNOTOXICOL, V13, P255, DOI 10.3109/1547691X.2015.1058306; Martins RM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010284; NAST CC, 1994, TRANSPLANTATION, V57, P498; OCONNELL PJ, 1993, J IMMUNOL, V150, P1093; Onsager DR, 1999, J HEART LUNG TRANSPL, V18, P448, DOI 10.1016/S1053-2498(99)00016-9; Rad SZK, 2017, IRAN J BASIC MED SCI, V20, P516, DOI 10.22038/IJBMS.2017.8676; Rivas MN, 2009, J IMMUNOL, V183, P4284, DOI 10.4049/jimmunol.0901408; Rutella S, 1999, CYTOMETRY, V38, P95, DOI 10.1002/(SICI)1097-0320(19990615)38:3<95::AID-CYTO1>3.3.CO;2-C; Schowengerdt KO, 2000, TRANSPLANTATION, V69, P2102, DOI 10.1097/00007890-200005270-00023; Stallone G, 2009, TRANSPLANTATION, V87, pS23, DOI 10.1097/TP.0b013e3181a05b7a; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; TU YZ, 1995, TRANSPLANTATION, V59, P177, DOI 10.1097/00007890-199501270-00004; Vajdic CM, 2009, INT J CANCER, V125, P1747, DOI 10.1002/ijc.24439; Wan X, 2018, J IMMUNOL, V201, P1194, DOI 10.4049/jimmunol.1800108; Wang X, 2017, BIOMED PHARMACOTHER, V89, P887, DOI 10.1016/j.biopha.2017.02.099; Wang Y, 2016, INT IMMUNOPHARMACOL, V35, P217, DOI 10.1016/j.intimp.2016.03.041; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260; Wu YQ, 2020, MOL CELL, V78, P42, DOI 10.1016/j.molcel.2020.01.022; Xu LH, 2005, CELL MOL IMMUNOL, V2, P295; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139; Yang J, 2006, ACTA PHARMACOL SIN, V27, P173, DOI 10.1111/j.1745-7254.2006.00257.x; YASUURA K, 1991, TRANSPLANTATION, V51, P896, DOI 10.1097/00007890-199104000-00031; Yuan J, 2015, AM J TRANSPLANT, V15, P2336, DOI 10.1111/ajt.13350; Zhang Y, 2014, J PHARMACOL EXP THER, V349, P417, DOI 10.1124/jpet.114.212795; Zhang ZG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6493; Zheng ZK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4508; Zhu MS, 2020, BMC IMMUNOL, V21, DOI 10.1186/s12865-020-00352-1; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502	57	2	2	11	25	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								616074	10.3389/fimmu.2021.616074	http://dx.doi.org/10.3389/fimmu.2021.616074			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5NX	33732240	Green Published, gold			2022-12-18	WOS:000627329000001
J	Saris, A; Steuten, J; Schrijver, DP; van Schijndel, G; Zwaginga, JJ; van Ham, SM; ten Brinke, A				Saris, Anno; Steuten, Juulke; Schrijver, David P.; van Schijndel, Gijs; Zwaginga, Jaap Jan; van Ham, S. Marieke; ten Brinke, Anja			Inhibition of Dendritic Cell Activation and Modulation of T Cell Polarization by the Platelet Secretome	FRONTIERS IN IMMUNOLOGY			English	Article						platelet immunomodulation; transfusion-related immune modulation; platelet releasate; monocyte-derived dendritic cells; primary dendritic cell; T cell priming	LACNAC-EXPRESSING MONOCYTES	Platelet transfusions are a frequently administered therapy for especially hemato-oncological patients with thrombocytopenia. Next to their primary function in hemostasis, currently there is increased attention for the capacity of platelets to affect the function of various cells of the immune system. Here, we investigate the capacity of platelets to immuno-modulate monocyte-derived dendritic cells (moDC) as well as primary dendritic cells and effects on subsequent T cell responses. Platelets significantly inhibited pro-inflammatory (IL-12, IL-6, TNF alpha) and increased anti-inflammatory (IL-10) cytokine production of moDCs primed with toll-like receptor (TLR)-dependent and TLR-independent stimuli. Transwell assays and ultracentrifugation revealed that a soluble factor secreted by platelets, but not microvesicles, inhibited DC activation. Interestingly, platelet-derived soluble mediators also inhibited cytokine production by human ex vivo stimulated myeloid CD1c+ conventional DC2. Moreover, platelets and platelet-derived soluble mediators inhibited T cell priming and T helper differentiation toward an IFN gamma+ Th1 phenotype by moDCs. Overall, these results show that platelets are able to inhibit the pro-inflammatory properties of DCs, and may even induce an anti-inflammatory DC phenotype, with decreased T cell priming capacity by the DC. The results of this study provide more insight in the potential role of platelets in immune modulation, especially in the context of platelet transfusions.	[Saris, Anno; Steuten, Juulke; Schrijver, David P.; van Schijndel, Gijs; van Ham, S. Marieke; ten Brinke, Anja] Univ Amsterdam, Med Ctr, Dept Immunopathol, Sanquin Res & Landsteiner Lab, Amsterdam, Netherlands; [Saris, Anno] Leiden Univ, Dept Infect Dis, Med Ctr, Leiden, Netherlands; [Zwaginga, Jaap Jan] Sanquin Res, Ctr Clin Transfus Res, Leiden, Netherlands; [Zwaginga, Jaap Jan] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands; [van Ham, S. Marieke] Univ Amsterdam, Swammerdam Inst Life Sci, Amsterdam, Netherlands	University of Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam	ten Brinke, A (corresponding author), Univ Amsterdam, Med Ctr, Dept Immunopathol, Sanquin Res & Landsteiner Lab, Amsterdam, Netherlands.	a.tenbrinke@sanquin.nl		Steuten, Juulke/0000-0002-6647-2233; ten Brinke, Anja/0000-0002-0135-7496; /0000-0002-2177-4836	Sanquin Blood Supply Foundation [PPOC 17-44]	Sanquin Blood Supply Foundation	This work was supported by Sanquin Blood Supply Foundation (grant PPOC 17-44).	Ahmad F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00948; Aslam R, 2008, TRANSFUSION, V48, P1778, DOI 10.1111/j.1537-2995.2008.01791.x; Baran W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01352; Blair P, 2009, BLOOD REV, V23, P177, DOI 10.1016/j.blre.2009.04.001; Blakytny R, 2004, J CELL PHYSIOL, V199, P67, DOI 10.1002/jcp.10454; BLUMBERG N, 1994, ARCH PATHOL LAB MED, V118, P371; Calzetti F, 2018, J ALLERGY CLIN IMMUN, V141, P2276, DOI 10.1016/j.jaci.2017.12.988; Cameron B, 2007, TRANSFUSION, V47, P206, DOI 10.1111/j.1537-2995.2007.01090.x; Ceroi A, 2016, HAEMATOLOGICA, V101, pE72, DOI 10.3324/haematol.2015.135459; Charlton A, 2014, TRANSFUSION MED, V24, P213, DOI 10.1111/tme.12126; Cognasse F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00083; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Czapiga M, 2004, EXP HEMATOL, V32, P135, DOI 10.1016/j.exphem.2003.11.004; Duerschmied D, 2014, THROMB HAEMOSTASIS, V112, P678, DOI 10.1160/TH14-02-0146; Eder AF, 2010, TRANSFUSION, V50, P2288, DOI 10.1111/j.1537-2995.2010.02901.x; Elzey BD, 2005, J LEUKOCYTE BIOL, V78, P80, DOI 10.1189/jlb.1104669; Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8; Esebanmen GE, 2017, IMMUNOL RES, V65, P987, DOI 10.1007/s12026-017-8944-9; Estcourt L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004269.pub3; FROJMOVIC MM, 1982, PHYSIOL REV, V62, P185, DOI 10.1152/physrev.1982.62.1.185; Geiger TL, 2008, TRANSFUSION, V48, P1772, DOI 10.1111/j.1537-2995.2008.01860.x; Greeno E, 2007, TRANSFUSION, V47, P201, DOI 10.1111/j.1537-2995.2007.01089.x; Hagihara M, 2004, J IMMUNOL, V172, P5297, DOI 10.4049/jimmunol.172.9.5297; Hamzeh-Cognasse H, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-54; HEISS MM, 1994, J CLIN ONCOL, V12, P1859, DOI 10.1200/JCO.1994.12.9.1859; Jensen LS, 1996, LANCET, V348, P841, DOI 10.1016/S0140-6736(96)06168-5; Kapur R, 2015, J IMMUNOL, V194, P5579, DOI 10.4049/jimmunol.1500259; Katus MC, 2014, VOX SANG, V107, P103, DOI 10.1111/vox.12146; Ki KK, 2018, PLATELETS, V29, P373, DOI 10.1080/09537104.2017.1306045; Ki KK, 2017, TRANSFUSION, V57, P2878, DOI 10.1111/trf.14320; Kissel K, 2006, TRANSFUSION, V46, P818, DOI 10.1111/j.1537-2995.2006.00802.x; Kolanowski STHM, 2014, INNATE IMMUN-LONDON, V20, P423, DOI 10.1177/1753425913498626; Koupenova M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09607-x; Langer HF, 2007, ARTERIOSCL THROM VAS, V27, P1463, DOI 10.1161/ATVBAHA.107.141515; Maitre B, 2010, J THROMB HAEMOST, V8, P2262, DOI 10.1111/j.1538-7836.2010.03983.x; Mayr WR, 2005, TRANSFUS CLIN BIOL, V12, P357, DOI 10.1016/j.tracli.2005.10.006; Muszynski JA, 2017, TRANSFUSION, V57, P195, DOI 10.1111/trf.13855; Nelson KA, 2019, TRANSFUSION, V59, P3396, DOI 10.1111/trf.15555; Ng MSY, 2018, TRANSFUS MED REV, V32, P144, DOI 10.1016/j.tmrv.2018.04.001; Nguyen XD, 2008, CYTOTHERAPY, V10, P720, DOI 10.1080/14653240802378912; Nishat S, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00186-18; Perros AJ, 2015, J INTERF CYTOK RES, V35, P821, DOI 10.1089/jir.2015.0029; Rachidi S, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai7911; Ramalingam R, 2012, J IMMUNOL, V189, P3878, DOI 10.4049/jimmunol.1201029; Rebulla P., 2017, LANCET, V370, P1391, DOI [10.1007/978-3-319-47462-5_94, DOI 10.1007/978-3-319-47462-5_94]; Riesenberg BP, 2019, J IMMUNOL, V203, P1105, DOI 10.4049/jimmunol.1900594; Roubinian NH, 2019, HEMATOL ONCOL CLIN N, V33, P767, DOI 10.1016/j.hoc.2019.05.003; Sadallah S, 2011, J IMMUNOL, V186, P6543, DOI 10.4049/jimmunol.1002788; Saris A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01251; Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956; Silva-Cardoso SC, 2020, EUR J IMMUNOL, V50, P1598, DOI 10.1002/eji.201948341; Silva-Cardoso SC, 2017, J IMMUNOL, V199, P253, DOI 10.4049/jimmunol.1602020; Singh MV, 2021, J LEUKOCYTE BIOL, V109, P807, DOI 10.1002/JLB.3A0620-460RR; Sprague DL, 2008, BLOOD, V111, P5028, DOI 10.1182/blood-2007-06-097410; Stolla M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00028; Strobl H, 1999, MICROBES INFECT, V1, P1283, DOI 10.1016/S1286-4579(99)00256-7; Sut C, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00042; ten Brinke A, 2007, VACCINE, V25, P7145, DOI 10.1016/j.vaccine.2007.07.031; Tesic N, 2020, IMMUNOL INVEST, V49, P215, DOI 10.1080/08820139.2019.1624768; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Vamvakas EC, 2007, BLOOD REV, V21, P327, DOI 10.1016/j.blre.2007.07.003; Villadangos JA, 2005, SEMIN IMMUNOL, V17, P262, DOI 10.1016/j.smim.2005.05.015; Wandt H, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0809; Xia CQ, 2003, INT IMMUNOL, V15, P1007, DOI 10.1093/intimm/dxg100; Zaal A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00818; Zimmer N, 2020, CANCERS, V12, DOI 10.3390/cancers12123653	66	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								631285	10.3389/fimmu.2021.631285	http://dx.doi.org/10.3389/fimmu.2021.631285			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QX3KU	33737933	Green Published, gold			2022-12-18	WOS:000629245700001
J	Sun, MH; Chen, ZH; Wu, XQ; Yu, YY; Wang, LY; Lu, AP; Zhang, G; Li, FF				Sun, Meiheng; Chen, Zihao; Wu, Xiaoqiu; Yu, Yuanyuan; Wang, Luyao; Lu, Aiping; Zhang, Ge; Li, Fangfei			The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research	FRONTIERS IN IMMUNOLOGY			English	Review						sclerostin; Wnt signaling pathway; aptamers; immune system; B cell malignancies		Wnt signaling is one of the fundamental pathways that play a major role in almost every aspect of biological systems. In addition to the well-known influence of Wnt signaling on bone formation, its essential role in the immune system also attracted increasing attention. Sclerostin, a confirmed Wnt antagonist, is also proven to modulate the development and differentiation of normal immune cells, particularly B cells. Aptamers, single-stranded (ss) oligonucleotides, are capable of specifically binding to a variety of target molecules by virtue of their unique three-dimensional structures. With in-depth study of those functional nucleic acids, they have been gradually applied to diagnostic and therapeutic area in immune diseases due to their various advantages over antibodies. In this review, we focus on several issues including the roles of Wnt signaling and Wnt antagonist sclerostin in the immune system. For the sake of understanding, current examples of aptamers applications for the immune diseases are also discussed. At the end of this review, we propose our ideas for the future research directions.	[Sun, Meiheng; Wu, Xiaoqiu; Yu, Yuanyuan; Wang, Luyao; Lu, Aiping; Zhang, Ge; Li, Fangfei] Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Peoples R China; [Sun, Meiheng; Wu, Xiaoqiu; Yu, Yuanyuan; Wang, Luyao; Lu, Aiping; Zhang, Ge; Li, Fangfei] Hong Kong Baptist Univ, Sch Chinese Med, Inst Integrated Bioinfomed & Translat Sci, Hong Kong, Peoples R China; [Sun, Meiheng; Wu, Xiaoqiu; Yu, Yuanyuan; Wang, Luyao; Lu, Aiping; Zhang, Ge; Li, Fangfei] HKBU Inst Res & Continuing Educ, Inst Precis Med & Innovat Drug Discovery, Shenzhen, Peoples R China; [Chen, Zihao] Chinese Univ Hong Kong, Fac Med, Sch Chinese Med, Hong Kong, Peoples R China; [Lu, Aiping] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China; [Lu, Aiping] Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai, Peoples R China	Hong Kong Baptist University; Hong Kong Baptist University; Chinese University of Hong Kong; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS	Lu, AP; Zhang, G; Li, FF (corresponding author), Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Peoples R China.; Lu, AP; Zhang, G; Li, FF (corresponding author), Hong Kong Baptist Univ, Sch Chinese Med, Inst Integrated Bioinfomed & Translat Sci, Hong Kong, Peoples R China.; Lu, AP; Zhang, G; Li, FF (corresponding author), HKBU Inst Res & Continuing Educ, Inst Precis Med & Innovat Drug Discovery, Shenzhen, Peoples R China.; Lu, AP (corresponding author), China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.; Lu, AP (corresponding author), Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai, Peoples R China.	aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk; fangfeili@hkbu.edu.hk	Yu, YY/ADO-6482-2022; Zhang, Ge/K-9118-2019; Chen, zihao/HGE-3792-2022	Zhang, Ge/0000-0002-7807-7695; chen, zihao/0000-0003-4027-1158; chen, zihao/0000-0002-3004-7243; chen, zihao/0000-0002-7690-8651	National Key Research and Development Program of China [2018YFA0800804]; Interdisciplinary Research Matching Scheme Hong Kong Baptist University [RC-IRMS/15-16/01]; Hong Kong General Research Fund [12101018, 12102518, 12102120]; Theme-based Research Scheme Hong Kong Research Grants Council [TRS/RGC T12-201-20-R]; National Natural Science Foundation Council of China [81703049]	National Key Research and Development Program of China; Interdisciplinary Research Matching Scheme Hong Kong Baptist University; Hong Kong General Research Fund; Theme-based Research Scheme Hong Kong Research Grants Council; National Natural Science Foundation Council of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Key Research and Development Program of China (2018YFA0800804), the Interdisciplinary Research Matching Scheme Hong Kong Baptist University (RC-IRMS/15-16/01), the Hong Kong General Research Fund (12101018, 12102518, 12102120), Theme-based Research Scheme Hong Kong Research Grants Council (TRS/RGC T12-201-20-R), and the National Natural Science Foundation Council of China (81703049).	Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bouaziz W, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0540-6; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Cain CJ, 2012, J BONE MINER RES, V27, P1451, DOI 10.1002/jbmr.1608; Calzada V, 2017, BIOORGAN MED CHEM, V25, P1163, DOI 10.1016/j.bmc.2016.12.026; Catuogno S, 2019, MOL THER-NUCL ACIDS, V18, P981, DOI 10.1016/j.omtn.2019.10.021; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cragg Mark S., 2005, V8, P140; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Danquah MK, 2020, BIOTECHNOL PROGR, V36, DOI 10.1002/btpr.2957; Darmostuk M, 2015, BIOTECHNOL ADV, V33, P1141, DOI 10.1016/j.biotechadv.2015.02.008; Delgado-Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152; Delgado-Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008-5472.CAN-15-1703; Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885; Donham C, 2020, CURR OSTEOPOROS REP, V18, P32, DOI 10.1007/s11914-020-00563-w; Dosen G, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-13; Du JM, 2007, J BIOL CHEM, V282, P15073, DOI 10.1074/jbc.M701654200; Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Ge XJ, 2019, ONCOL LETT, V17, P3727, DOI 10.3892/ol.2019.10047; Genetos DC, 2010, J CELL BIOCHEM, V110, P457, DOI 10.1002/jcb.22559; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Grillo-Lopez AJ, 2002, INT J HEMATOL, V76, P385, DOI 10.1007/BF02982803; Gruszka AM, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111403; Guder C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00058; Haghighi M, 2018, MOLECULES, V23, DOI 10.3390/molecules23040715; Hardy RR, 2007, IMMUNITY, V26, P703, DOI 10.1016/j.immuni.2007.05.013; Haseeb M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111380; Hay KA, 2017, DRUGS, V77, P237, DOI 10.1007/s40265-017-0690-8; He F, 2020, CURR MED CHEM, V27, P2189, DOI 10.2174/0929867325666181008142831; Hernandez P, 2014, BIOCHEM BIOPH RES CO, V446, P1108, DOI 10.1016/j.bbrc.2014.03.079; Hoelzer D, 2014, BLOOD, V124, P3870, DOI 10.1182/blood-2014-03-563627; Horowitz MC, 2012, J BONE MINER RES, V27, P1448, DOI 10.1002/jbmr.1672; Horowitz MC, 2010, BONE, V47, P472, DOI 10.1016/j.bone.2010.06.011; Hu Yan, 2018, Oncotarget, V9, P26605, DOI 10.18632/oncotarget.24902; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Jain N, 2018, LEUKEMIA, V32, P663, DOI 10.1038/leu.2017.215; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kohlberger M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241560; Kovacevic KD, 2018, ADV DRUG DELIVER REV, V134, P36, DOI 10.1016/j.addr.2018.10.008; Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890; Krause U, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.67; Krishna SM, 2017, ARTERIOSCL THROM VAS, V37, P553, DOI 10.1161/ATVBAHA.116.308723; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Li H, 2017, THERANOSTICS, V7, P1204, DOI 10.7150/thno.17069; Li SY, 2018, PATHOLOGY, V50, P74, DOI 10.1016/j.pathol.2017.09.006; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Loots GG, 2018, BONE, V116, P307, DOI 10.1016/j.bone.2018.08.022; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452; McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood-2017-03-773341; Ni SJ, 2021, ACS APPL MATER INTER, V13, P9500, DOI 10.1021/acsami.0c05750; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; Nolan K, 2014, PROTEIN SCI, V23, P999, DOI 10.1002/pro.2485; Novak AJ, 2004, BLOOD, V103, P689, DOI 10.1182/blood-2003-06-2043; Nozari A, 2017, MOL THER-NUCL ACIDS, V6, P29, DOI 10.1016/j.omtn.2016.12.002; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Oden F, 2015, MOL ONCOL, V9, P1348, DOI 10.1016/j.molonc.2015.03.010; Pacifici R, 2010, ARCH BIOCHEM BIOPHYS, V503, P41, DOI 10.1016/j.abb.2010.05.027; Pan QS, 2020, ACS APPL MATER INTER, V12, P400, DOI 10.1021/acsami.9b20707; Parra D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00354; Perosa F, 2005, AUTOIMMUN REV, V4, P526, DOI 10.1016/j.autrev.2005.04.004; Prebet T, 2010, BLOOD, V116, P2315, DOI 10.1182/blood-2010-01-262352; Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140-6736(09)60221-X; Ranheim EA, 2005, BLOOD, V105, P2487, DOI 10.1182/blood-2004-06-2334; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Ryan MC, 2007, MOL CANCER THER, V6, P3009, DOI 10.1158/1535-7163.MCT-07-0464; Schweighoffer E, 2018, CURR OPIN CELL BIOL, V51, P8, DOI 10.1016/j.ceb.2017.10.002; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Shangguan DH, 2007, CLIN CHEM, V53, P1153, DOI 10.1373/clinchem.2006.083246; Shangguan D, 2007, CHEMBIOCHEM, V8, P603, DOI 10.1002/cbic.200600532; Sicco E, 2020, CANCER BIOTHER RADIO, V35, P262, DOI 10.1089/cbr.2019.3402; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Stengel KR, 2017, P NATL ACAD SCI USA, V114, P8608, DOI 10.1073/pnas.1701610114; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Tai YT, 2006, CANCER RES, V66, P6675, DOI 10.1158/0008-5472.CAN-06-0190; Tamura M, 2011, INT J BIOCHEM CELL B, V43, P760, DOI 10.1016/j.biocel.2011.01.021; Tan WH, 2013, CHEM REV, V113, P2842, DOI 10.1021/cr300468w; Tao YM, 2013, DIGEST LIVER DIS, V45, P251, DOI 10.1016/j.dld.2012.10.020; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002; van Dinther M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062295; Wang HY, 2018, BIOCHIMIE, V145, P125, DOI 10.1016/j.biochi.2017.09.006; Wang KM, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-36; Wang SZ, 2011, CLIN EXP METASTAS, V28, P581, DOI 10.1007/s10585-011-9393-9; Wildner S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37624-1; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Wise JF, 2013, BLOOD, V121, P4729, DOI 10.1182/blood-2012-12-471094; Yee CS, 2018, J BONE MINER RES, V33, P1748, DOI 10.1002/jbmr.3467; You L, 2018, CELL PHYSIOL BIOCHEM, V48, P1030, DOI 10.1159/000491971; Zhou Jiehua, 2015, Methods Mol Biol, V1297, P169, DOI 10.1007/978-1-4939-2562-9_12	97	2	3	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								602330	10.3389/fimmu.2021.602330	http://dx.doi.org/10.3389/fimmu.2021.602330			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU2QE	33717084	gold, Green Published			2022-12-18	WOS:000627127500001
J	Thompson, G; McLean-Tooke, A; Lucas, M				Thompson, Grace; McLean-Tooke, Andrew; Lucas, Michaela			Cross With Caution: Antibiotic Cross-Reactivity and Co-Reactivity Patterns in Severe Cutaneous Adverse Reactions	FRONTIERS IN IMMUNOLOGY			English	Article						severe cutaneous adverse drug reactions; antibiotic cross-reactivity; antibiotic co-reactivity; beta-lactam; antibiotics	TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; DRUG ALLERGY; HYPERSENSITIVITY; DRESS	Current understanding of cross-reactivity in severe cutaneous adverse reactions to beta-lactam antibiotics is limited, thereby making recommendations for future prescribing difficult. The underlying immunopathogenesis of these reactions is not completely understood but involves interactions between small molecule drugs, T cells and HLA molecules. Historically, these reactions were considered to be specific to the inciting antibiotic and therefore likely to have minimal cross-reactivity. We assessed patients presenting with non-SJS/TEN severe cutaneous adverse reactions to a tertiary hospital drug allergy clinic. In our case series cross-reactivity or co-reactivity commonly occurred among the beta-lactam antibiotic class, however further research is required to investigate and understand patterns of cross-reactivity. Based on our experience we provide clinicians with a practical algorithm for testing for cross-reactivity in non-SJS/TEN severe cutaneous adverse reactions.	[Thompson, Grace; McLean-Tooke, Andrew; Lucas, Michaela] Sir Charles Gairdner Hosp, Queen Elizabeth II Med Ctr, Dept Clin Immunol, Nedlands, WA, Australia; [Lucas, Michaela] Univ Western Australia, Sch Med, Nedlands, WA, Australia	University of Western Australia; University of Western Australia	Lucas, M (corresponding author), Sir Charles Gairdner Hosp, Queen Elizabeth II Med Ctr, Dept Clin Immunol, Nedlands, WA, Australia.; Lucas, M (corresponding author), Univ Western Australia, Sch Med, Nedlands, WA, Australia.	Michaela.lucas@health.wa.gov.au		Lucas, Michaela/0000-0001-8881-9990				Adler NR, 2017, BRIT J DERMATOL, V177, P1234, DOI 10.1111/bjd.15423; Barbaud A, 2013, BRIT J DERMATOL, V168, P555, DOI 10.1111/bjd.12125; Berot V, 2020, J EUR ACAD DERMATOL, V34, P787, DOI 10.1111/jdv.15986; Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142; Cho YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061243; de Risi-Pugliese T, 2020, J ALLER CL IMM-PRACT, V8, P3185, DOI 10.1016/j.jaip.2020.04.052; El-Ghaiesh S, 2012, J PHARMACOL EXP THER, V341, P597, DOI 10.1124/jpet.111.190900; Feldmeyer L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081214; Goh SJR, 2021, ALLERGY, V76, P150, DOI 10.1111/all.14355; Goldblatt C, 2017, BRIT J CLIN PHARMACO, V83, P224, DOI 10.1111/bcp.13103; Goncalves Marcia, 2020, CONTACT DERMATITIS, P1, DOI DOI 10.1007/978-3-319-72451-5_26-1; Illing PT, 2016, CURR OPIN IMMUNOL, V42, P31, DOI 10.1016/j.coi.2016.05.003; Lin YF, 2014, CLIN INFECT DIS, V58, P1377, DOI 10.1093/cid/ciu126; Phillips E, 2001, ALLERGY, V56, P790, DOI 10.1034/j.1398-9995.2001.056008790.x; Pichler WJ, 2015, INT ARCH ALLERGY IMM, V168, P13, DOI 10.1159/000441280; Romano A, 2020, ALLERGY, V75, P1300, DOI 10.1111/all.14122; Romano A, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0691-4; Romano A, 2016, J ALLERGY CLIN IMMUN, V138, P179, DOI 10.1016/j.jaci.2016.01.025; Romano A, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0594-9; Sassolas B, 2010, CLIN PHARMACOL THER, V88, P60, DOI 10.1038/clpt.2009.252; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Trubiano JA, 2019, J ALLER CL IMM-PRACT, V7, P1341, DOI 10.1016/j.jaip.2018.09.014; Watts TJ, 2018, J ALLER CL IMM-PRACT, V6, P1766, DOI 10.1016/j.jaip.2018.01.011; White KD, 2015, J ALLERGY CLIN IMMUN, V136, P219, DOI 10.1016/j.jaci.2015.05.050	24	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								601954	10.3389/fimmu.2021.601954	http://dx.doi.org/10.3389/fimmu.2021.601954			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5UD	33717082	gold, Green Published			2022-12-18	WOS:000627345800001
J	Venema, WJ; Hiddingh, S; de Boer, JH; Claas, FHJ; Mulder, A; den Hollander, AI; Stratikos, E; Sarkizova, S; van der Veken, LT; Janssen, GMC; van Veelen, PA; Kuiper, JJW				Venema, Wouter J.; Hiddingh, Sanne; de Boer, Joke H.; Claas, Frans H. J.; Mulder, Arend; den Hollander, Anneke, I; Stratikos, Efstratios; Sarkizova, Siranush; van der Veken, Lars T.; Janssen, George M. C.; van Veelen, Peter A.; Kuiper, Jonas J. W.			ERAP2 Increases the Abundance of a Peptide Submotif Highly Selective for the Birdshot Uveitis-Associated HLA-A29	FRONTIERS IN IMMUNOLOGY			English	Article						Birdshot; HLA-A29; ERAP2; autoimmunity; immunopeptidome	PREDICTION; PRECURSORS	Birdshot Uveitis (BU) is a blinding inflammatory eye condition that only affects HLA-A29-positive individuals. Genetic association studies linked ERAP2 with BU, an aminopeptidase which trims peptides before their presentation by HLA class I at the cell surface, which suggests that ERAP2-dependent peptide presentation by HLA-A29 drives the pathogenesis of BU. However, it remains poorly understood whether the effects of ERAP2 on the HLA-A29 peptidome are distinct from its effect on other HLA allotypes. To address this, we focused on the effects of ERAP2 on the immunopeptidome in patient-derived antigen presenting cells. Using complementary HLA-A29-based and pan-class I immunopurifications, isotope-labeled naturally processed and presented HLA-bound peptides were sequenced by mass spectrometry. We show that the effects of ERAP2 on the N-terminus of ligands of HLA-A29 are shared across endogenous HLA allotypes, but discover and replicate that one peptide motif generated in the presence of ERAP2 is specifically bound by HLA-A29. This motif can be found in the amino acid sequence of putative autoantigens. We further show evidence for internal sequence specificity for ERAP2 imprinted in the immunopeptidome. These results reveal that ERAP2 can generate an HLA-A29-specific antigen repertoire, which supports that antigen presentation is a key disease pathway in BU.	[Venema, Wouter J.; Hiddingh, Sanne; de Boer, Joke H.; Kuiper, Jonas J. W.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands; [Venema, Wouter J.; Hiddingh, Sanne; Kuiper, Jonas J. W.] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands; [Claas, Frans H. J.; Mulder, Arend] Leiden Univ, Dept Immunol, Med Ctr, Leiden, Netherlands; [den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands; [den Hollander, Anneke, I] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands; [Stratikos, Efstratios] Natl & Kapodistrian Univ Athens, Dept Chem, Panepistimiopolis, Greece; [Sarkizova, Siranush] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Sarkizova, Siranush] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [van der Veken, Lars T.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Genet, Div Labs,Pharm & Biomed Genet, Utrecht, Netherlands; [Janssen, George M. C.; van Veelen, Peter A.] Leiden Univ, Ctr Prote & Metabol, Med Ctr, Leiden, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen; Radboud University Nijmegen; National & Kapodistrian University of Athens; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Utrecht University; Utrecht University Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kuiper, JJW (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands.; Kuiper, JJW (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands.	J.J.W.Kuiper@umcutrecht.nl	Stratikos, Efstratios/N-2969-2014	Stratikos, Efstratios/0000-0002-3566-2309; van Veelen, Peter/0000-0002-7898-9408	VENI award from the Netherlands Organization for Scientific Research (N.W.O) [016.186.006]; UitZicht [2018-1]; Stichting Lijf en Leven [63]	VENI award from the Netherlands Organization for Scientific Research (N.W.O); UitZicht; Stichting Lijf en Leven	JK is supported by a VENI award from the Netherlands Organization for Scientific Research (N.W.O. project number 016.186.006). WV is supported by UitZicht (project number 2018-1) and Stichting Lijf en Leven (project number 63). The funders had no role in the design, execution, interpretation, or writing of the study.	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Alvarez-Navarro C, 2015, MOL CELL PROTEOMICS, V14, P1770, DOI 10.1074/mcp.M115.048959; Anderson KS, 2011, CANCER IMMUNOL IMMUN, V60, P857, DOI 10.1007/s00262-011-0995-5; Andreatta M, 2013, BIOINFORMATICS, V29, P8, DOI 10.1093/bioinformatics/bts621; Andres AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001157; [Anonymous], 2017, Arthritis Rheumatol, V69, P686, DOI 10.1002/art.40073; Apps R, 2015, J IMMUNOL, V194, P3594, DOI 10.4049/jimmunol.1403234; Birtley JR, 2012, BIOCHEMISTRY-US, V51, P286, DOI 10.1021/bi201230p; Brosch M, 2009, J PROTEOME RES, V8, P3176, DOI 10.1021/pr800982s; Chen HN, 2016, SCI REP-UK, V6, DOI 10.1038/srep28902; Chen LY, 2020, MOL CELL PROTEOMICS, V19, P871, DOI 10.1074/mcp.RA119.001617; Chowell D, 2015, P NATL ACAD SCI USA, V112, pE1754, DOI 10.1073/pnas.1500973112; Coles CH, 2020, J BIOL CHEM, V295, P11486, DOI 10.1074/jbc.RA120.014016; Elahi S, 2019, KLIN MONATSBL AUGENH, V236, P492, DOI 10.1055/a-0829-6763; Evnouchidou I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003658; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; Gaudio PA, 2002, BRIT J OPHTHALMOL, V86, P1439, DOI 10.1136/bjo.86.12.1439; Georgiadis D, 2019, CURR MED CHEM, V26, P2715, DOI 10.2174/0929867325666180214111849; Gfeller D, 2018, J IMMUNOL, V201, P3705, DOI 10.4049/jimmunol.1800914; Giastas P, 2019, P NATL ACAD SCI USA, V116, P26709, DOI 10.1073/pnas.1912070116; Goslee SC, 2007, J STAT SOFTW, V22, P1, DOI 10.18637/jss.v022.i07; Guasp P, 2019, MOL CELL PROTEOMICS, V18, P1491, DOI 10.1074/mcp.RA119.001515; Hahsler M, 2019, J STAT SOFTW, V91, P1, DOI 10.18637/jss.v091.i01; Hassan C, 2014, J PROTEOMICS, V109, P240, DOI 10.1016/j.jprot.2014.07.009; Hassman L, 2017, INVEST OPHTH VIS SCI, V58; Hennig C., 2020, **DATA OBJECT**; Herbort CP, 2017, BRIT J OPHTHALMOL, V101, P851, DOI 10.1136/bjophthalmol-2016-309764; Hussong SA, 2011, INVEST OPHTH VIS SCI, V52, P714, DOI 10.1167/iovs.10-6032; Kammers Kai, 2015, EuPA Open Proteom, V7, P11; Kanaseki T, 2006, IMMUNITY, V25, P795, DOI 10.1016/j.immuni.2006.09.012; Kim Y, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-394; Kuiper J, 2015, PROG RETIN EYE RES, V44, P99, DOI 10.1016/j.preteyeres.2014.11.003; Kuiper JJW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.599558; Kuiper JJW, 2018, HUM MOL GENET, V27, P4333, DOI 10.1093/hmg/ddy319; Kuiper JJW, 2014, HUM MOL GENET, V23, P6081, DOI 10.1093/hmg/ddu307; Kuiper JJW, 2014, HUM IMMUNOL, V75, P570, DOI 10.1016/j.humimm.2014.02.012; Kuiper JJW, 2011, AM J OPHTHALMOL, V152, P177, DOI 10.1016/j.ajo.2011.01.031; Lim YW, 2018, P NATL ACAD SCI USA, V115, pE11701, DOI 10.1073/pnas.1804506115; de Castro JAL, 2016, MOL IMMUNOL, V77, P193, DOI 10.1016/j.molimm.2016.08.005; Marquez A, 2017, J MED GENET, V54, P38, DOI 10.1136/jmedgenet-2016-104144; Mavridis G, 2020, J BIOL CHEM, V295, P7193, DOI 10.1074/jbc.RA120.012976; McFerrin L., 2013, **DATA OBJECT**; Minos E, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0429-8; Mpakali A, 2015, J BIOL CHEM, V290, P26021, DOI 10.1074/jbc.M115.685909; Mulder A, 2010, MOL IMMUNOL, V47, P809, DOI 10.1016/j.molimm.2009.10.004; NUSSENBLATT RB, 1982, AM J OPHTHALMOL, V94, P147, DOI 10.1016/0002-9394(82)90069-1; Ogle, 2020, FSA FISHERIES STOCK; Osorio D, 2015, R J, V7, P4; Papadia M, 2015, INT OPHTHALMOL, V35, P287, DOI 10.1007/s10792-015-0046-x; Papakyriakou A, 2018, J BIOL CHEM, V293, P7538, DOI 10.1074/jbc.RA117.000313; Pulido JS, 2012, EYE, V26, P862, DOI 10.1038/eye.2012.10; Rao XY, 2011, IMMUNOGENETICS, V63, P691, DOI 10.1007/s00251-011-0552-6; Reeves E, 2013, J IMMUNOL, V191, P35, DOI 10.4049/jimmunol.1300598; Rene C, 2015, EUR J IMMUNOL, V45, P3454, DOI 10.1002/eji.201545927; Riley TP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02047; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sanz-Bravo A, 2018, MOL CELL PROTEOMICS, V17, P1564, DOI 10.1074/mcp.RA118.000778; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Storey JD, 2019, QVALUE Q VALUE ESTIM; Wagih O., 2017, **DATA OBJECT**	61	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								634441	10.3389/fimmu.2021.634441	http://dx.doi.org/10.3389/fimmu.2021.634441			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU7IV	33717175	Green Published, Green Submitted, gold			2022-12-18	WOS:000627453700001
J	Yang, PP; Liu, L; Sun, LZ; Fang, P; Snyder, N; Saredy, J; Ji, Y; Shen, W; Qin, XB; Wu, QH; Yang, XF; Wang, H				Yang, Pingping; Liu, Lu; Sun, Lizhe; Fang, Pu; Snyder, Nathaniel; Saredy, Jason; Ji, Yong; Shen, Wen; Qin, Xuebin; Wu, Qinghua; Yang, Xiaofeng; Wang, Hong			Immunological Feature and Transcriptional Signaling of Ly6C Monocyte Subsets From Transcriptome Analysis in Control and Hyperhomocysteinemic Mice	FRONTIERS IN IMMUNOLOGY			English	Article						lymphocyte antigen 6 complex; locus C (Ly6C) monocyte subset; hyperhomocysteinemia; transcription factor; immunological gene; immune checkpoint	INFLAMMATORY MONOCYTE; STEM-CELLS; DIFFERENTIATION; MACROPHAGES; IDENTIFICATION; EXPRESSION; PROTEOMICS; BIOMARKER; ORIGINS; MARKERS	Background Murine monocytes (MC) are classified into Ly6C(high) and Ly6C(low) MC. Ly6C(high) MC is the pro-inflammatory subset and the counterpart of human CD14(++)CD16(+) intermediate MC which contributes to systemic and tissue inflammation in various metabolic disorders, including hyperhomocysteinemia (HHcy). This study aims to explore molecule signaling mediating MC subset differentiation in HHcy and control mice. Methods RNA-seq was performed in blood Ly6C(high) and Ly6C(low) MC sorted by flow cytometry from control and HHcy cystathionine beta-synthase gene-deficient (Cbs (-/-)) mice. Transcriptome data were analyzed by comparing Ly6C(high) vs. Ly6C(low) in control mice, Ly6C(high) vs. Ly6C(low) in Cbs(-/-) mice, Cbs(-/-) Ly6C(high) vs. control Ly6C(high) MC and Cbs(-/-) Ly6C(low) vs. control Ly6C(low) MC by using intensive bioinformatic strategies. Significantly differentially expressed (SDE) immunological genes and transcription factor (TF) were selected for functional pathways and transcriptional signaling identification. Results A total of 7,928 SDE genes and 46 canonical pathways derived from it were identified. Ly6C(high) MC exhibited activated neutrophil degranulation, lysosome, cytokine production/receptor interaction and myeloid cell activation pathways, and Ly6C(low) MC presented features of lymphocyte immunity pathways in both mice. Twenty-four potential transcriptional regulatory pathways were identified based on SDE TFs matched with their corresponding SDE immunological genes. Ly6C(high) MC presented downregulated co-stimulatory receptors (CD2, GITR, and TIM1) which direct immune cell proliferation, and upregulated co-stimulatory ligands (LIGHT and SEMA4A) which trigger antigen priming and differentiation. Ly6C(high) MC expressed higher levels of macrophage (M phi) markers, whereas, Ly6C(low) MC highly expressed lymphocyte markers in both mice. HHcy in Cbs (-/-) mice reinforced inflammatory features in Ly6C(high) MC by upregulating inflammatory TFs (Ets1 and Tbx21) and strengthened lymphocytes functional adaptation in Ly6C(low) MC by increased expression of CD3, DR3, ICOS, and Fos. Finally, we established 3 groups of transcriptional models to describe Ly6C(high) to Ly6C(low) MC subset differentiation, immune checkpoint regulation, Ly6C(high) MC to M phi subset differentiation and Ly6C(low) MC to lymphocyte functional adaptation. Conclusions Ly6C(high) MC displayed enriched inflammatory pathways and favored to be differentiated into M phi. Ly6C(low) MC manifested activated T-cell signaling pathways and potentially can adapt the function of lymphocytes. HHcy reinforced inflammatory feature in Ly6C(high) MC and strengthened lymphocytes functional adaptation in Ly6C(low) MC.	[Yang, Pingping; Liu, Lu; Shen, Wen; Wu, Qinghua] Nanchang Univ, Dept Cardiovas Uiar Med, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Yang, Pingping; Liu, Lu; Sun, Lizhe; Fang, Pu; Snyder, Nathaniel; Saredy, Jason; Yang, Xiaofeng; Wang, Hong] Temple Univ, Lewis Kats Sch Med, Dept Pharmacol, Ctr Metab Dis Res, Philadelphia, PA 19122 USA; [Sun, Lizhe] Xi An Jiao Tong Univ, Dept Cardiovasc Med, Affiliated Hosp 1, Xian, Peoples R China; [Ji, Yong] Nanjing Med Univ, Key Lab Cardiovasc Dis & Mol Intervent, Nanjing, Peoples R China; [Qin, Xuebin] Tulane Univ, Tulane Natl Primate Res Ctr, Sch Med, Covington, LA USA	Nanchang University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Xi'an Jiaotong University; Nanjing Medical University; Tulane University	Wang, H (corresponding author), Temple Univ, Lewis Kats Sch Med, Dept Pharmacol, Ctr Metab Dis Res, Philadelphia, PA 19122 USA.	hong.wang@temple.edu			National Institutes of Health (NIH) [HL82774, HL-110764, HL130233, HL131460, DK104114, DK113775]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by the National Institutes of Health (NIH) grants HL82774, HL-110764, HL130233, HL131460, DK104114, DK113775, and HL131460 to HW.	Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198; Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Ammari M, 2018, THERANOSTICS, V8, P5972, DOI 10.7150/thno.29313; Audzevich T, 2017, P NATL ACAD SCI USA, V114, pE3954, DOI 10.1073/pnas.1616417114; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Autissier P, 2010, J IMMUNOL METHODS, V360, P119, DOI 10.1016/j.jim.2010.06.017; Bain CC, 2014, IMMUNOL REV, V260, P102, DOI 10.1111/imr.12192; Barbieri A, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/729654; Biswas P., 1998, BLOOD, V91, DOI [10.1182/blood.V91.1.258, DOI 10.1182/BLOOD.V91.1.258]; Cencioni MT., 2020, NEUROIMMUNOL NEUROIN, V2020, P277, DOI [10.20517/2347-8659.2020.18, DOI 10.20517/2347-8659.2020.18]; Chang YH, 2017, IMMUNITY, V47, P943, DOI 10.1016/j.immuni.2017.10.014; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Cochain C, 2018, CIRC RES, V122, P1661, DOI 10.1161/CIRCRESAHA.117.312509; Coondoo Arijit, 2011, Indian J Dermatol, V56, P368, DOI 10.4103/0019-5154.84717; Crawford K, 1999, J IMMUNOL, V163, P5920; Croft M., 2014, SEMIN IMMUNOL, V26, DOI [10.1016/j.smim.2014.02.005, DOI 10.1016/J.SMIM.2014.02.005]; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Dai J, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0504-1; del Rio ML, 2010, J LEUKOCYTE BIOL, V87, P223, DOI 10.1189/jlb.0809590; Desplat-Jego S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/628748; Ducros V, 2006, CLIN CHEM LAB MED, V44, P987, DOI 10.1515/CCLM.2006.178; Engel P, 2015, J IMMUNOL, V195, P4555, DOI 10.4049/jimmunol.1502033; Fang P, 2019, ARTERIOSCL THROM VAS, V39, P2097, DOI 10.1161/ATVBAHA.119.313138; Fang P, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0637-x; Fang P, 2014, DIABETES, V63, P4275, DOI 10.2337/db14-0809; Gautier EL, 2014, IMMUNOL REV, V262, P85, DOI 10.1111/imr.12231; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Gorvel Laurent, 2020, F1000Res, V9, DOI 10.12688/f1000research.22877.1; Gundry RL, 2008, PROTEOM CLIN APPL, V2, P892, DOI 10.1002/prca.200780122; Haghverdi L, 2018, NAT BIOTECHNOL, V36, P421, DOI 10.1038/nbt.4091; Hanna RN, 2011, NAT IMMUNOL, V12, P778, DOI 10.1038/ni.2063; Hein RM, 2007, IMMUNOL LETT, V108, P103, DOI 10.1016/j.imlet.2006.11.004; Hettinger J, 2013, NAT IMMUNOL, V14, P821, DOI 10.1038/ni.2638; Huber R, 2014, CELL MOL LIFE SCI, V71, P63, DOI 10.1007/s00018-013-1322-4; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Iwasaki H, 2007, IMMUNITY, V26, P726, DOI 10.1016/j.immuni.2007.06.004; Jakubzick CV, 2017, NAT REV IMMUNOL, V17, P349, DOI 10.1038/nri.2017.28; Janssen WJ, 2011, AM J RESP CRIT CARE, V184, P547, DOI 10.1164/rccm.201011-1891OC; Johnson EN, 2007, CLIN INFECT DIS, V45, P409, DOI 10.1086/520029; Kapellos TS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02035; Kawamoto H, 2009, TRENDS IMMUNOL, V30, P193, DOI 10.1016/j.it.2009.03.001; Kimball A, 2018, ARTERIOSCL THROM VAS, V38, P1102, DOI 10.1161/ATVBAHA.118.310703; Kumanogoh A, 2005, IMMUNITY, V22, P305, DOI 10.1016/j.immuni.2005.01.014; Kumar P, 2018, J AUTOIMMUN, V95, P77, DOI 10.1016/j.jaut.2018.08.007; Kurotaki D, 2013, BLOOD, V121, P1839, DOI 10.1182/blood-2012-06-437863; Langstein J., 1999, BLOOD, V94, DOI [10.1182/blood.V94.9.3161.421k31_3161_3168, DOI 10.1182/BLOOD.V94.9.3161.421K31_3161_3168]; Lau MC, 2017, ANN RHEUM DIS, V76, P261, DOI 10.1136/annrheumdis-2015-208677; Lee DL, 2006, AM J PHYSIOL-HEART C, V290, pH935, DOI 10.1152/ajpheart.00708.2005; Lee PY, 2013, J LEUKOCYTE BIOL, V94, P585, DOI 10.1189/jlb.0113014; Lee PY, 2009, AM J PATHOL, V175, P2023, DOI 10.2353/ajpath.2009.090328; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Li YF, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0406-2; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Lim S, 2017, CANCER RES, V77, P1245, DOI 10.1158/0008-5472.CAN-16-1647; Lin SL, 2009, J IMMUNOL, V183, P6733, DOI 10.4049/jimmunol.0901473; Loughner CL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0074-2; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Ma WJ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0277-y; Mahner S, 2008, BRIT J CANCER, V99, P1269, DOI 10.1038/sj.bjc.6604650; Menezes S, 2016, IMMUNITY, V45, P1205, DOI 10.1016/j.immuni.2016.12.001; Miko E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00846; Mildner A, 2017, IMMUNITY, V46, P849, DOI 10.1016/j.immuni.2017.04.018; Miron RJ, 2016, BIOMATERIALS, V82, P1, DOI 10.1016/j.biomaterials.2015.12.017; Mouhadeb O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02623; Munro DAD, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00837; Nakahara T, 2017, JACC-CARDIOVASC IMAG, V10, P582, DOI 10.1016/j.jcmg.2017.03.005; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Rahman K, 2017, J CLIN INVEST, V127, P2904, DOI 10.1172/JCI75005; Riccardi C, 2018, EXPERT OPIN THER TAR, V22, P783, DOI 10.1080/14728222.2018.1512588; Rugg-Gunn PJ, 2012, DEV CELL, V22, P887, DOI 10.1016/j.devcel.2012.01.005; Saftig P, 2016, NAT CELL BIOL, V18, P1025, DOI 10.1038/ncb3409; Schonfelder T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21273-5; Scott CL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10321; Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110; Sintiprungrat K, 2010, J PROTEOMICS, V73, P602, DOI 10.1016/j.jprot.2009.08.001; Su EW, 2008, CYTOKINE, V44, P9, DOI 10.1016/j.cyto.2008.06.013; Sun LZ, 2020, ARTERIOSCL THROM VAS, V40, P1990, DOI 10.1161/ATVBAHA.120.314037; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014; Wang LQ, 2004, CIRC RES, V94, P1318, DOI 10.1161/01.RES.0000129182.46440.4a; Wang LQ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0351-5; Wei H, 2020, AGING-US, V12, P14376, DOI 10.18632/aging.103480; Wikenheiser DJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00304; Winkels H, 2018, CIRC RES, V122, P1675, DOI 10.1161/CIRCRESAHA.117.312513; Xiao G, 2012, P NATL ACAD SCI USA, V109, P15419, DOI 10.1073/pnas.1206370109; Yang HZ, 2005, IMMUNOLOGY, V115, P189, DOI 10.1111/j.1365-2567.2005.02137.x; Yang JY, 2016, CIRC RES, V119, P1226, DOI 10.1161/CIRCRESAHA.116.308750; Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1; Yaseen NR., 1994, MOL CELL BIOL, V14, DOI [10.1128/MCB.14.10.6886, DOI 10.1128/MCB.14.10.6886]; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Zhan YM, 2005, J CLIN INVEST, V115, P2508, DOI 10.1172/JCI24403; Zhang DQ, 2012, CIRC RES, V111, P37, DOI [10.1161/CIRCRESAHA.112.269472, 10.1161/circresaha.112.269472]; Zhang DQ, 2009, CIRCULATION, V120, P1893, DOI 10.1161/CIRCULATIONAHA.109.866889; Zhang RJ, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101460; Zhao Y, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26461; Zhu YW, 2016, J EXP MED, V213, P167, DOI 10.1084/jem.20150785; Zhuo JM, 2011, TRENDS PHARMACOL SCI, V32, P562, DOI 10.1016/j.tips.2011.05.003	100	2	3	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								632333	10.3389/fimmu.2021.632333	http://dx.doi.org/10.3389/fimmu.2021.632333			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5RB	33717169	gold, Green Published			2022-12-18	WOS:000627337500001
J	Zhang, YM; Liu, XZ; Zhou, XJ; Liu, LJ; Shi, SF; Hou, P; Lv, JC; Zhang, H				Zhang, Yue-miao; Liu, Xing-zi; Zhou, Xu-jie; Liu, Li-jun; Shi, Su-fang; Hou, Ping; Lv, Ji-cheng; Zhang, Hong			A Functional Variant rs3093023 in CCR6 Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population	FRONTIERS IN IMMUNOLOGY			English	Article						IgA nephropathy; CCR6; Th17 cells; genetic association; functional annotation		C-C chemokine receptor 6 (CCR6) is a susceptibility gene of various immune-related diseases, which was suggested to be shared with immunoglobulin A nephropathy (IgAN). In this study, we aimed to identify the functional variants. First, we analyzed the associations of CCR6 common and rare variants detected by multi-platform chips with IgAN susceptibility using imputation and identified 68 significantly associated common variants located in the regulatory region. Among them, rs3093023 showed both statistical significance (rs3093023-A, odds ratio [OR] = 1.15, P = 2.00 x 10(-2)) and the expression quantitative trait loci (eQTL) effect (P = 1.45 x 10(-3)). It was independently replicated (rs3093023-A, OR = 1.18, P = 5.56 x 10(-3)) and the association was reinforced in the meta-analysis (rs3093023-A, OR = 1.17, P = 6.14 x 10(-7)). Although rs3093023 was in a strong linkage disequilibrium with the reported CCR6 functional variant dinucleotide polymorphism, CCR6DNP, the alleles of rs3093023 (G>A) rather than of CCR6DNP were shown differential nuclear protein binding effect by electrophoretic mobility shift assay. The RegulomeDB and JASPAR databases predicted Pou2f1 as the potential transcription factor, which was negatively associated with CCR6 mRNA (r = -0.60, P = 3.94 x 10(-9)). At the mRNA level, the eQTL effect of CCR6 was validated (P = 4.39 x 10(-2)), and CCR6 was positively associated with the expression of CCR4 and IL-17A rather than that of CXCR3 and IFNG. At the protein level, a higher CCR6(+) cell ratio was observed in a risk allele dose-dependent manner in lymphocytes (P = 3.57 x 10(-2)), CD3(+) T cells (P = 4.54 x 10(-2)), and CD4(+) T cells (P = 1.32 x 10(-2)), but not in CD8(+) T cells. Clinical-pathological analysis showed that rs3093023 risk allele was significantly associated with diastolic blood pressure, serum creatinine, and high ratio of tubular atrophy/interstitial fibrosis. Overall, the rs3093023 was prioritized as the function variant in CCR6, which may contribute to IgAN susceptibility by regulating Th17 cells.	[Zhang, Yue-miao; Liu, Xing-zi; Zhou, Xu-jie; Liu, Li-jun; Shi, Su-fang; Hou, Ping; Lv, Ji-cheng; Zhang, Hong] Peking Univ First Hosp, Dept Med, Renal Div, Beijing, Peoples R China; [Zhang, Yue-miao; Liu, Xing-zi; Zhou, Xu-jie; Liu, Li-jun; Shi, Su-fang; Hou, Ping; Lv, Ji-cheng; Zhang, Hong] Minist Hlth China, Key Lab Renal Dis, Beijing, Peoples R China; [Zhang, Yue-miao; Liu, Xing-zi; Zhou, Xu-jie; Liu, Li-jun; Shi, Su-fang; Hou, Ping; Lv, Ji-cheng; Zhang, Hong] Peking Univ, Minist Educ China, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing, Peoples R China	Ministry of Education, China; Peking University	Zhang, H (corresponding author), Peking Univ First Hosp, Dept Med, Renal Div, Beijing, Peoples R China.; Zhang, H (corresponding author), Minist Hlth China, Key Lab Renal Dis, Beijing, Peoples R China.; Zhang, H (corresponding author), Peking Univ, Minist Educ China, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing, Peoples R China.	hongzh@bjmu.edu.cn			National Natural Science Foundation of China [81800636, 82070733]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5-046]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences	This work was supported by National Natural Science Foundation of China [81800636 and 82070733], and CAMS Innovation Fund for Medical Sciences [2019-I2M-5-046].	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Akhtar M, 2019, INT J IMMUNOGENET, V46, P459, DOI 10.1111/iji.12449; Blauvelt A, 2015, BRIT J DERMATOL, V172, P484, DOI 10.1111/bjd.13348; Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Brkic Z, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4578; Cattran DC, 2009, KIDNEY INT, V76, P534, DOI 10.1038/ki.2009.243; Chintalacharuvu SR, 2008, CLIN EXP IMMUNOL, V153, P456, DOI 10.1111/j.1365-2249.2008.03703.x; Delaneau O, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4934; Farahnik B, 2016, DERMATOLOGY THER, V6, P111, DOI 10.1007/s13555-016-0121-x; Feehally J, 2010, J AM SOC NEPHROL, V21, P1791, DOI 10.1681/ASN.2010010076; Furue K, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12846; Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Honczarenko M, 2006, EXP HEMATOL, V34, P1093, DOI 10.1016/j.exphem.2006.05.013; Hsueh Huey-miin, 2003, J Biopharm Stat, V13, P675, DOI 10.1081/BIP-120024202; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Kang EG, 2018, BRIT J DERMATOL, V178, P1427, DOI 10.1111/bjd.16131; Kiryluk K, 2014, NAT GENET, V46, P1187, DOI 10.1038/ng.3118; Kiryluk K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002765; Kochi Y, 2010, NAT GENET, V42, P515, DOI 10.1038/ng.583; Koga T, 2016, ARTHRITIS RHEUMATOL, V68, P1981, DOI 10.1002/art.39665; Koumakis E, 2013, ARTHRITIS RHEUM-US, V65, P3202, DOI 10.1002/art.38136; Krebs CF, 2016, IMMUNITY, V45, P1078, DOI 10.1016/j.immuni.2016.10.020; Krohn S, 2018, J AM SOC NEPHROL, V29, P1210, DOI 10.1681/ASN.2017090949; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lee AYS, 2019, IMMUNOBIOLOGY, V224, P449, DOI 10.1016/j.imbio.2019.01.005; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Li M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8270; Lin FJ, 2012, SCAND J CLIN LAB INV, V72, P221, DOI 10.3109/00365513.2011.652158; Lin JR, 2018, RENAL FAILURE, V40, DOI 10.1080/0886022X.2017.1419972; Lu GY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178352; Lv JC, 2013, AM J KIDNEY DIS, V62, P891, DOI 10.1053/j.ajkd.2013.04.021; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Meng T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108723; Ochi M, 2019, CEN CASE REP, V8, P200, DOI 10.1007/s13730-019-00393-5; Papp KA, 2013, BRIT J DERMATOL, V168, P412, DOI 10.1111/bjd.12110; Peng ZG, 2013, HUM IMMUNOL, V74, P1586, DOI 10.1016/j.humimm.2013.08.001; Ruszkowski J, 2019, CLIN EXP NEPHROL, V23, P291, DOI 10.1007/s10157-018-1665-0; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Scolari F, 1999, J NEPHROL, V12, P213; Segawa Y, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-02015-0; Van Kooten C, 1998, J AM SOC NEPHROL, V9, P1526; Wang F, 2020, KIDNEY INT, V97, P1219, DOI 10.1016/j.kint.2020.01.015; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756; Woltman AM, 2000, J AM SOC NEPHROL, V11, P2044, DOI 10.1681/ASN.V11112044; Wyatt RJ, 2013, NEW ENGL J MED, V368, P2402, DOI 10.1056/NEJMra1206793; Yu XQ, 2012, NAT GENET, V44, P178, DOI 10.1038/ng.1047; Zhang F, 2015, HUM MOL GENET, V24, pR102, DOI 10.1093/hmg/ddv259; Zhou XJ, 2015, ARTHRITIS RHEUMATOL, V67, P3091, DOI 10.1002/art.39268	50	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2021	12								600598	10.3389/fimmu.2021.600598	http://dx.doi.org/10.3389/fimmu.2021.600598			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU5ZF	33717080	Green Published, gold			2022-12-18	WOS:000627359300001
J	Adams, P; Iserentant, G; Servais, JY; Vandekerckhove, L; Vanham, G; Seguin-Devaux, C				Adams, Philipp; Iserentant, Gilles; Servais, Jean-Yves; Vandekerckhove, Linos; Vanham, Guido; Seguin-Devaux, Carole		PhenoCure Study Grp	Cytotoxic CD8+T Cells Expressing CXCR5 Are Detectable in HIV-1 Elite Controllers After Prolonged In Vitro Peptide Stimulation	FRONTIERS IN IMMUNOLOGY			English	Article						HIV controllers; functional cure; viral suppressive capacity; multifunctional CD8(+) T cells; CXCR5 CD8 T cells + plus; elite controllers		Antiretroviral therapy (ART) is not curative as HIV-1 persists in long-lived viral reservoirs. Consequently, patients are dependent on life-long drug adherence with possible side effects. To overcome these limitations strategies of a functional cure aim at ART free viral remission. In this study, we sought to identify detailed subsets of anti-viral CD8(+) T cell immunity linked to natural long-term control of HIV-1 infection. Here, we analyzed HIV controllers and ART suppressed progressors for in vitro viral suppressive capacity (VSC) at baseline and after peptide stimulation. Functional properties and phenotypes of CD8(+) T cells were assessed by IFN-gamma ELISPOT and 18 color flow cytometry. HIV controllers showed significantly increased suppression at baseline as well as after peptide stimulation. IFN-gamma secretion and the proliferation marker Ki67 positively correlated with VSC. Moreover, the detailed phenotype of three distinct multifunctional memory CD8(+) T cell subsets were specific traits of HIV controllers of which two correlated convincingly with VSC. Our results underline the importance of multifunctional CD8(+) T cell responses during natural control. Especially the role of CXCR5 expressing cytotoxic subsets emphasizes potential surveillance in sites of reservoir persistence and demand further study.	[Adams, Philipp; Iserentant, Gilles; Servais, Jean-Yves; Seguin-Devaux, Carole] Luxembourg Inst Hlth, Dept Infect & Immun, Esch Sur Alzette, Luxembourg; [Adams, Philipp; Vanham, Guido] Inst Trop Med, Dept Biomed Sci, Antwerp, Belgium; [Adams, Philipp; Vanham, Guido] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium; [Adams, Philipp; Vanham, Guido] Univ Antwerp, Dept Biomed Sci, Antwerp, Belgium; [Vandekerckhove, Linos] Univ Ghent, Dept Internal Med, Ghent, Belgium	Luxembourg Institute of Health; Institute of Tropical Medicine (ITM); Institute of Tropical Medicine (ITM); University of Antwerp; Ghent University	Adams, P (corresponding author), Luxembourg Inst Hlth, Dept Infect & Immun, Esch Sur Alzette, Luxembourg.; Adams, P (corresponding author), Inst Trop Med, Dept Biomed Sci, Antwerp, Belgium.; Adams, P (corresponding author), Inst Trop Med, Dept Clin Sci, Antwerp, Belgium.; Adams, P (corresponding author), Univ Antwerp, Dept Biomed Sci, Antwerp, Belgium.	Philipp.Adams@lih.lu		Seguin-Devaux, Carole/0000-0003-0636-5222	FNR in Luxembourg [PHD-2015-1-10111126]	FNR in Luxembourg(Luxembourg National Research Fund)	PA received an AFR PhD grant (ID: PHD-2015-1-10111126) from the FNR in Luxembourg.	Akinsiku OT, 2011, JAIDS-J ACQ IMM DEF, V58, P132, DOI 10.1097/QAI.0b013e318224d2e9; Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Altfeld M, 2006, PLOS MED, V3, P1851, DOI 10.1371/journal.pmed.0030403; Banga R, 2016, NAT MED, V22, P754, DOI 10.1038/nm.4113; Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Blankson JN, 2007, J VIROL, V81, P2508, DOI 10.1128/JVI.02165-06; Calin R, 2016, AIDS, V30, P761, DOI 10.1097/QAD.0000000000000987; Carcelain G, 2013, IMMUNOL REV, V254, P355, DOI 10.1111/imr.12083; Chen H, 2009, J VIROL, V83, P3138, DOI 10.1128/JVI.02073-08; Day CL, 2007, J VIROL, V81, P434, DOI 10.1128/JVI.01754-06; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Ferrando-Martinez S, 2012, J VIROL, V86, P3667, DOI 10.1128/JVI.07034-11; Ferre AL, 2010, J VIROL, V84, P10354, DOI 10.1128/JVI.00803-10; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461; Freel SA, 2012, J VIROL, V86, P6835, DOI 10.1128/JVI.00437-12; Freel SA, 2010, J VIROL, V84, P4998, DOI 10.1128/JVI.00138-10; Genovese L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00086; Gurdasani D, 2014, AIDS, V28, P149, DOI 10.1097/QAD.0000000000000049; Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529; Hersperger AR, 2011, BLOOD, V117, P3799, DOI 10.1182/blood-2010-12-322727; Huang SH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01842; Huang SH, 2018, J CLIN INVEST, V128, P876, DOI [10.1172/jci97555, 10.1172/JCI97555]; Julg B, 2010, J VIROL, V84, P5540, DOI 10.1128/JVI.02031-09; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Kloverpris HN, 2013, J VIROL, V87, P2628, DOI 10.1128/JVI.02131-12; Koofhethile CK, 2016, J VIROL, V90, P6818, DOI 10.1128/JVI.00276-16; Kreher CR, 2003, J IMMUNOL METHODS, V278, P79, DOI 10.1016/S0022-1759(03)00226-6; Lecuroux C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059767; Lemieux J, 2016, J IMMUNOL METHODS, V434, P73, DOI 10.1016/j.jim.2016.04.010; Li FS, 2006, VACCINE, V24, P6893, DOI 10.1016/j.vaccine.2006.06.009; Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Minton K., 2013, NAT REV IMMUNOL, V14, P7, DOI [10.1038/nri3596, DOI 10.1038/NRI3596]; Miura T, 2010, J VIROL, V84, P7581, DOI 10.1128/JVI.00286-10; Mylvaganam GH, 2017, P NATL ACAD SCI USA, V114, P1976, DOI 10.1073/pnas.1621418114; Noel N, 2016, J VIROL, V90, P6148, DOI 10.1128/JVI.00419-16; Pannus P, 2019, AIDS, V33, P387, DOI 10.1097/QAD.0000000000002068; Perdomo-Celis F, 2018, JAIDS-J ACQ IMM DEF, V78, P473, DOI [10.1097/qai.0000000000001700, 10.1097/QAI.0000000000001700]; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Peris-Pertusa A, 2010, JAIDS-J ACQ IMM DEF, V55, P29, DOI 10.1097/QAI.0b013e3181e69609; Perreau M, 2013, J EXP MED, V210, P143, DOI 10.1084/jem.20121932; Petrovas C, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2285; Reuter MA, 2017, CELL REP, V21, P3458, DOI 10.1016/j.celrep.2017.11.075; Rutsaert S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35403-6; Sacha JB, 2007, J IMMUNOL, V178, P2746, DOI 10.4049/jimmunol.178.5.2746; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928; Schvachsa N, 2007, J VIROL METHODS, V140, P222, DOI 10.1016/j.jviromet.2006.11.012; Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014; Spentzou A, 2010, J INFECT DIS, V201, P720, DOI 10.1086/650492; Turk G, 2008, J VIROL, V82, P2853, DOI 10.1128/JVI.02260-07; Turk G, 2013, J VIROL, V87, P7445, DOI 10.1128/JVI.00865-13; Warren JA, 2020, ELIFE, V9, DOI 10.7554/eLife.57246; Yang HB, 2012, J INFECT DIS, V206, P552, DOI 10.1093/infdis/jis379; Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006	62	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	11								622343	10.3389/fimmu.2020.622343	http://dx.doi.org/10.3389/fimmu.2020.622343			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QU1EI	33717056	Green Published, gold			2022-12-18	WOS:000627026000001
J	Saravanan, R; Choong, YK; Lim, CH; Lim, LM; Petrlova, J; Schmidtchen, A				Saravanan, Rathi; Choong, Yeu Khai; Lim, Chun Hwee; Lim, Li Ming; Petrlova, Jitka; Schmidtchen, Artur			Cell-Free DNA Promotes Thrombin Autolysis and Generation of Thrombin-Derived C-Terminal Fragments	FRONTIERS IN IMMUNOLOGY			English	Article						thrombin; host defense peptides; cell-free DNA (cfDNA); coagulation; molecular innate immunity; NETs (neutrophil extracellular traps); antimicrobial peptides		Cell-free DNA (cfDNA) is the major structural component of neutrophil extracellular traps (NETs), an innate immune response to infection. Antimicrobial proteins and peptides bound to cfDNA play a critical role in the bactericidal property of NETs. Recent studies have shown that NETs have procoagulant activity, wherein cfDNA triggers thrombin generation through activation of the intrinsic pathway of coagulation. We have recently shown that thrombin binds to NETs in vitro and consequently can alter the proteome of NETs. However, the effect of NETs on thrombin is still unknown. In this study, we report that DNA binding leads to thrombin autolysis and generation of multiple thrombin-derived C-terminal peptides (TCPs) in vitro. Employing a 25-residue prototypic TCP, GKY25 (GKYGFYTHVFRLKKWIQKVIDQFGE), we show that TCPs bind NETs, thus conferring mutual protection against nuclease and protease degradation. Together, our results demonstrate the complex interplay between coagulation, NET formation, and thrombin cleavage and identify a previously undisclosed mechanism for formation of TCPs.	[Saravanan, Rathi; Choong, Yeu Khai; Lim, Chun Hwee; Lim, Li Ming] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Lim, Chun Hwee] Nanyang Technol Univ, Interdisciplinary Grad Sch, NTU Inst Hlth Technol, Singapore, Singapore; [Lim, Chun Hwee; Petrlova, Jitka; Schmidtchen, Artur] Lund Univ, Dept Clin Sci, Div Dermatol & Venereol, Lund, Sweden; [Schmidtchen, Artur] Univ Copenhagen, Bispebjerg Hosp, Wound Healing Ctr, Dept Biomed Sci, Copenhagen, Denmark	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Lund University; University of Copenhagen; Bispebjerg Hospital	Saravanan, R (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.	rathi@ntu.edu.sg		Saravanan, Rathi/0000-0002-3884-6023; Choong, Yeu Khai/0000-0002-2868-3929	Lee Kong Chian School of Medicine, Nanyang Technological University Singapore StartUp Grant; Singapore Ministry of Education [2015-T1-001-82]; Swedish Research Council [2017-02341]; Lee Kong Chian School of Medicine [L0491020]; NTU Institute for Health Technologies, Interdisciplinary Graduate School, Nanyang Technological University Singapore	Lee Kong Chian School of Medicine, Nanyang Technological University Singapore StartUp Grant(Nanyang Technological University); Singapore Ministry of Education(Ministry of Education, Singapore); Swedish Research Council(Swedish Research CouncilEuropean Commission); Lee Kong Chian School of Medicine; NTU Institute for Health Technologies, Interdisciplinary Graduate School, Nanyang Technological University Singapore(Nanyang Technological University)	This work was supported by the Lee Kong Chian School of Medicine, Nanyang Technological University Singapore StartUp Grant, the Singapore Ministry of Education Academic Research Fund Tier 1 (2015-T1-001-82), and the Swedish Research Council (project 2017-02341). RS was supported by the Lee Kong Chian School of Medicine Postdoctoral Fellowship 2014 (L0491020). CL was supported by NTU Institute for Health Technologies, Interdisciplinary Graduate School, Nanyang Technological University Singapore.	Berends ETM, 2010, J INNATE IMMUN, V2, P576, DOI 10.1159/000319909; BERLINER LJ, 1984, MOL CELL BIOCHEM, V61, P159; Bode W, 2006, SEMIN THROMB HEMOST, V32, P16, DOI 10.1055/s-2006-939551; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; Branzk N, 2013, SEMIN IMMUNOPATHOL, V35, P513, DOI 10.1007/s00281-013-0384-6; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; BROWER MS, 1987, BLOOD, V69, P813; Buchanan JT, 2006, CURR BIOL, V16, P396, DOI 10.1016/j.cub.2005.12.039; Chatfield SM, 2018, J IMMUNOL, V200, P1802, DOI 10.4049/jimmunol.1701382; da Cruz DB, 2019, FASEB J, V33, P14270, DOI 10.1096/fj.201901363RRR; Davie EW, 2006, SEMIN THROMB HEMOST, V32, P3, DOI 10.1055/s-2006-939550; Denning NL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02536; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Fuchs TA, 2012, ARTERIOSCL THROM VAS, V32, P1777, DOI 10.1161/ATVBAHA.111.242859; Gould TJ, 2014, ARTERIOSCL THROM VAS, V34, P1977, DOI 10.1161/ATVBAHA.114.304114; GUILLIN MC, 1992, SEMIN THROMB HEMOST, V18, P224, DOI 10.1055/s-2007-1002428; Hansen FC, 2015, J IMMUNOL, V194, P5397, DOI 10.4049/jimmunol.1403009; Huntington JA, 2005, J THROMB HAEMOST, V3, P1861, DOI 10.1111/j.1538-7836.2005.01363.x; Kalle M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051313; Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719; Kasetty G, 2011, ANTIMICROB AGENTS CH, V55, P2880, DOI 10.1128/AAC.01515-10; Lim CH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01554; Malovichko MV, 2013, J BIOL CHEM, V288, P8667, DOI 10.1074/jbc.M112.410829; Napirei M, 2009, FEBS J, V276, P1059, DOI 10.1111/j.1742-4658.2008.06849.x; Narayanan S, 1999, ANN CLIN LAB SCI, V29, P275; Neumann A, 2014, J INNATE IMMUN, V6, P860, DOI 10.1159/000363699; Papareddy P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000857; Petretto A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218946; Petrlova J., 2020, J BIOL CHEM; Petrlova J, 2017, P NATL ACAD SCI USA, V114, pE4213, DOI 10.1073/pnas.1619609114; Puthia M, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax6601; Saravanan R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05242-0; Saravanan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13197-3; Schulz C, 2017, BLOOD, V129, P925, DOI 10.1182/blood-2017-01-757328; Soslau G, 2004, PLATELETS, V15, P155, DOI 10.1080/0953710042000199848; Thakur S, 2015, EUR BIOPHYS J BIOPHY, V44, P337, DOI 10.1007/s00249-015-1027-8; Tsopanoglou NE., 2009, THROMBIN PHYSL DIS; van der Plas MJA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11567; von Kockritz-Blickwede M, 2009, BLOOD, V114, P5245, DOI 10.1182/blood-2009-08-240713	40	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								593020	10.3389/fimmu.2021.593020	http://dx.doi.org/10.3389/fimmu.2021.593020			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT9JO	33717072	Green Published, gold			2022-12-18	WOS:000626903300001
J	Yang, Z; Han, F; Liao, T; Zheng, HF; Luo, ZH; Ma, ML; He, JN; Li, L; Ye, YR; Zhang, R; Huang, ZY; Zhang, YN; Sun, QQ				Yang, Zhe; Han, Fei; Liao, Tao; Zheng, Haofeng; Luo, Zihuan; Ma, Maolin; He, Jiannan; Li, Lei; Ye, Yongrong; Zhang, Rui; Huang, Zhengyu; Zhang, Yannan; Sun, Qiquan			Artemisinin Attenuates Transplant Rejection by Inhibiting Multiple Lymphocytes and Prolongs Cardiac Allograft Survival	FRONTIERS IN IMMUNOLOGY			English	Article						artemisinin; cardiac transplantation; transplant rejection; T cell-mediated rejection; antibody-mediated rejection		Immunological rejection is an important factor resulting in allograft dysfunction, and more valid therapeutic methods need to be explored to improve allograft outcomes. Many researches have indicated that artemisinin and its derivative exhibits immunosuppressive functions, apart from serving as a traditional anti-malarial drug. In this assay, we further explored the therapeutic effects of artemisinin for transplant rejection in a rat cardiac transplantation model. We found that it markedly attenuated allograft rejection and histological injury and significantly prolonged the survival of allograft. Upon further exploring the mechanism, we demonstrated that artemisinin not only attenuated T cell-mediated rejection (TCMR) by reducing effector T cell infiltration and inflammatory cytokine secretion and increasing regulatory T cell infiltration and immunoregulatory cytokine levels, but also attenuated antibody-mediated rejection (ABMR) through inhibition of B cells activation and antibody production. Furthermore, artemisinin also reduced macrophage infiltration in allografts, which was determined to be important for TCMR and ABMR. Moreover, we demonstrated that artemisinin significantly inhibited the function of pure T cells, B cells, and macrophages in vitro. All in all, this study provide evidence that artemisinin significantly attenuates TCMR and ABMR by targeting multiple effectors. Therefore, this agent might have potential for use in clinical settings to protect against transplant rejection.	[Yang, Zhe; Han, Fei; Liao, Tao; Zheng, Haofeng; Luo, Zihuan; Ma, Maolin; He, Jiannan; Li, Lei; Ye, Yongrong; Zhang, Rui; Huang, Zhengyu; Zhang, Yannan; Sun, Qiquan] Sun Yat Sen Univ, Affiliated Hosp 3, Res Inst Organ Transplantat, Guangzhou, Peoples R China	Sun Yat Sen University	Huang, ZY; Zhang, YN; Sun, QQ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Res Inst Organ Transplantat, Guangzhou, Peoples R China.	h_zhengyu@163.com; zhangyannanyn@163.com; sunqiq@mail.sysu.edu.cn	zheng, hao/HHM-6949-2022	Sun, Qiquan/0000-0002-7296-316X	National Natural Science Foundation of China [81970649, 81970650, 81770753, 81800662, 81800663]; National Key R&D Program of China [2018YFA0108804]; Guangdong Basic and Applied Basic Research Foundation [2019A1515011942]; PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China [2018A030310324]; China Postdoctoral Science Foundation [2020M683083]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Guangdong Basic and Applied Basic Research Foundation; PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study was supported by the National Natural Science Foundation of China (No. 81970649, 81970650, 81770753, 81800662, and 81800663); the National Key R&D Program of China (2018YFA0108804); Guangdong Basic and Applied Basic Research Foundation (2019A1515011942); and the PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China (2018A030310324); the China Postdoctoral Science Foundation (2020M683083).	Abe T, 2015, AM J TRANSPLANT, V15, P1192, DOI 10.1111/ajt.13150; Bhagra SK, 2019, HEART, V105, P252, DOI 10.1136/heartjnl-2018-313103; Colvin MM, 2015, CIRCULATION, V131, P1608, DOI 10.1161/CIR.0000000000000093; Dai HH, 2020, SCIENCE, V368, P1122, DOI 10.1126/science.aax4040; Dhital KK, 2015, LANCET, V385, P2585, DOI 10.1016/S0140-6736(15)60038-1; Djamali A, 2014, AM J TRANSPLANT, V14, P255, DOI 10.1111/ajt.12589; [董妍君 Dong Yanjun], 2003, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V23, P676; Fabritius C, 2017, AM J TRANSPLANT, V17, P3199, DOI 10.1111/ajt.14467; Gupta G, 2014, TRANSPLANTATION, V97, P1240, DOI 10.1097/01.TP.0000442503.85766.91; Gupta SK, 2016, CARDIOVASC RES, V110, P215, DOI 10.1093/cvr/cvw030; Halloran PF, 2018, AM J TRANSPLANT, V18, P785, DOI 10.1111/ajt.14600; Hippen BE, 2005, AM J TRANSPLANT, V5, P2248, DOI 10.1111/j.1600-6143.2005.01009.x; Ho WE, 2014, PHARMACOL THERAPEUT, V142, P126, DOI 10.1016/j.pharmthera.2013.12.001; Hou LF, 2011, ARTHRITIS RHEUM-US, V63, P2445, DOI 10.1002/art.30392; Immenschuh S, 2015, TRANSPLANTATION, V99, P56, DOI 10.1097/TP.0000000000000244; Jin OY, 2009, CELL MOL IMMUNOL, V6, P461, DOI 10.1038/cmi.2009.58; Kfoury AG, 2016, J HEART LUNG TRANSPL, V35, P335, DOI 10.1016/j.healun.2015.10.016; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; Ko JH, 2016, P NATL ACAD SCI USA, V113, P158, DOI 10.1073/pnas.1522905113; Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251; Lefaucheur C, 2013, LANCET, V381, P313, DOI 10.1016/S0140-6736(12)61265-3; Li T, 2013, INT IMMUNOPHARMACOL, V16, P306, DOI 10.1016/j.intimp.2013.03.011; Li TF, 2020, J CLIN INVEST, V130, P5397, DOI 10.1172/JCI133008; Li YM, 2013, TRANSL RES, V161, P89, DOI 10.1016/j.trsl.2012.06.001; Liao T, 2020, J HEART LUNG TRANSPL, V39, P481, DOI 10.1016/j.healun.2020.02.002; Liao T, 2018, EBIOMEDICINE, V37, P236, DOI 10.1016/j.ebiom.2018.10.061; Liao T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01334; Loupy A, 2016, AM J TRANSPLANT, V16, P111, DOI 10.1111/ajt.13529; Lund LH, 2017, J HEART LUNG TRANSPL, V36, P1037, DOI 10.1016/j.healun.2017.07.019; Lund LH, 2014, J HEART LUNG TRANSPL, V33, P996, DOI 10.1016/j.healun.2014.08.003; Meier-Kriesche HU, 2000, TRANSPLANTATION, V70, P1098, DOI 10.1097/00007890-200010150-00018; Roemhild A, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3734; Stewart S, 2005, J HEART LUNG TRANSPL, V24, P1710, DOI 10.1016/j.healun.2005.03.019; Sun QQ, 2012, KIDNEY INT, V82, P321, DOI 10.1038/ki.2012.112; Wang JX, 2007, BRIT J PHARMACOL, V150, P652, DOI 10.1038/sj.bjp.0707137; Wang Y, 2016, INT J MOL MED, V37, P1567, DOI 10.3892/ijmm.2016.2579; Wu YW, 2016, CELL MOL IMMUNOL, V13, P379, DOI 10.1038/cmi.2015.13; Yang Z, 2012, CURR MED CHEM, V19, P4541, DOI 10.2174/092986712803251575; Zhao YG, 2012, J IMMUNOL, V189, P4417, DOI 10.4049/jimmunol.1200919	39	2	3	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 24	2021	12								634368	10.3389/fimmu.2021.634368	http://dx.doi.org/10.3389/fimmu.2021.634368			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT7AZ	33717174	Green Published, gold			2022-12-18	WOS:000626742600001
J	Hussen, BM; Nicknafs, F; Hidayat, HJ; Sayad, A; Ghafouri-Fard, S; Taheri, M				Hussen, Bashdar Mahmud; Nicknafs, Fwad; Hidayat, Hazha Jamal; Sayad, Arezou; Ghafouri-Fard, Soudeh; Taheri, Mohammad			A Diagnostic Panel for Acquired Immune-Mediated Polyneuropathies Based on the Expression of lncRNAs	FRONTIERS IN IMMUNOLOGY			English	Article						AIDP; CIDP; lncRNA; ANRIL; MALAT1; CCAT1; CCAT2; CCHE1		Long non-coding RNAs (lncRNAs) have been shown to alter immune responses, thus contributing to the pathobiology of autoimmune conditions. We investigated the expression levels of ANRIL, PICART1, MALAT1, CCAT1, CCAT2, and CCHE1 lncRNAs in acute and chronic inflammatory demyelinating polyneuropathy (AIDP and CIDP). ANRIL, PICART1, MALAT1, CCAT1, CCAT2, and CCHE1 lncRNAs were significantly downregulated in individuals with both AIDP and CIDP compared with unaffected individuals. Gender-based comparisons also verified such downregulations in both male and female subjects compared with sex-matched unaffected controls for all lncRNAs. There was no significant difference in the expression of any of the lncRNAs between cases with AIDP and cases with CIDP. While the expression levels of ANRIL and PICART1 were significantly correlated in healthy subjects (r = 0.86, p = 8.5E-16), similar analysis in cases with AIDP and CIDP revealed no significant correlation. The most robust correlation among patients was detected between ANRIL and MALAT1 lncRNAs (r = 0.59, p = 3.52E-6). ANRIL, MALAT1, and PICART1 had the diagnostic power of 0.96, 0.94, and 0.92 in distinguishing between cases with CIDP and controls, respectively. A combination of all lncRNAs resulted in 0.95 diagnostic power with a sensitivity of 0.85 and specificity of 0.96 for this purpose. Diagnostic power values of these lncRNAs in differentiation between cases with AIDP and controls were 0.98, 0.95, and 0.93, respectively. The combinatorial diagnostic power reached 0.98 for differentiation between cases with AIDP and controls. The six-lncRNA panel could differentiate combined cases with AIDP and CIDP from controls with area under the curve (AUC), sensitivity, and specificity values of 0.97, 0.90, and 0.96, respectively. Collectively, the lncRNA panel is suggested as a sensitive and specific diagnostic panel for acquired immune-mediated polyneuropathies.	[Hussen, Bashdar Mahmud] Hawler Med Univ, Coll Pharm, Pharmacognosy Dept, Erbil, Iraq; [Nicknafs, Fwad; Sayad, Arezou; Ghafouri-Fard, Soudeh] Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran, Iran; [Hidayat, Hazha Jamal] Salahaddin Univ Erbil, Dept Biol, Coll Educ, Erbil, Iraq; [Taheri, Mohammad] Shahid Beheshti Univ Med Sci, Urol & Nephrol Res Ctr, Tehran, Iran	Hawler Medical University; Shahid Beheshti University Medical Sciences; Salahaddin University; Shahid Beheshti University Medical Sciences	Ghafouri-Fard, S (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.; Taheri, M (corresponding author), Shahid Beheshti Univ Med Sci, Urol & Nephrol Res Ctr, Tehran, Iran.	s.ghafourifard@sbmu.ac.ir; mohammad_823@yahoo.com	Sayad, Arezou/AAX-1349-2021; Taheri, Mohammad/AAC-7307-2019	Taheri, Mohammad/0000-0001-8381-0591; Hussen, Bashdar/0000-0003-1060-6527	Shahid Beheshti University of Medical Sciences [21974]	Shahid Beheshti University of Medical Sciences	This study was financially supported (Grant Number 21974) from the Shahid Beheshti University of Medical Sciences.	[Anonymous], 2018, FRONTIERS LAB MED; Brannagan TH, 2011, J PERIPHER NERV SYST, V16, P3, DOI 10.1111/j.1529-8027.2011.00298.x; Cao Y, 2017, INT J ONCOL, V50, P1671, DOI 10.3892/ijo.2017.3918; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; CORNBLATH DR, 1991, NEUROLOGY, V41, P617; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Gaballah HH, 2019, MOL BIOL REP, V46, P657, DOI 10.1007/s11033-018-4521-0; Gholami L, 2020, NON-CODING RNA RES, V5, P60, DOI 10.1016/j.ncrna.2020.04.001; Hadden RDM, 2001, NEUROLOGY, V56, P758, DOI 10.1212/WNL.56.6.758; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; Hu W, 2003, NEUROLOGY, V61, P1774, DOI 10.1212/01.WNL.0000098884.75756.4D; Hur K, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e4; Kaur A, 2018, INT REV IMMUNOL, V37, P229, DOI 10.1080/08830185.2018.1469629; Kieseier BC, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0027-2; Li ZB, 2018, EXP THER MED, V16, P3951, DOI 10.3892/etm.2018.6687; Liu J, 2019, PROSTATE, V79, P105, DOI 10.1002/pros.23716; Liu Z, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01081; Marineau A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040897; Quan SH, 2015, J IMMUNOL, V194, P4175, DOI 10.4049/jimmunol.1401766; Sanjabi S, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022236; Simon Lee S., 1999, American Journal of Medicine, V106, p37S, DOI 10.1016/S0002-9343(99)00115-1; Van der Meche FGA, 2001, EUR NEUROL, V45, P133, DOI 10.1159/000052111; Wang Y, 2017, EXPERT OPIN THER TAR, V21, P103, DOI 10.1080/14728222.2017.1258402; Wolbert J, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132411; Wu J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01847; Wu ZJ, 2017, EUR REV MED PHARMACO, V21, P706; Zhao JM, 2018, NEOPLASMA, V65, P779, DOI 10.4149/neo_2018_171130N778; Zhou X, 2016, RNA BIOL, V13, P98, DOI 10.1080/15476286.2015.1122164	28	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	12								643615	10.3389/fimmu.2021.643615	http://dx.doi.org/10.3389/fimmu.2021.643615			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT3AF	33708228	gold, Green Published			2022-12-18	WOS:000626461800001
J	Matos, MC; Pinheiro, A; Melo-Ferreira, J; Davis, RS; Esteves, PJ				Matos, Maria Carolina; Pinheiro, Ana; Melo-Ferreira, Jose; Davis, Randall S.; Esteves, Pedro Jose			Evolution of Fc Receptor-Like Scavenger in Mammals	FRONTIERS IN IMMUNOLOGY			English	Article						FCR; FCRL; FCRLS; scavenger receptors; CD5L; evolution		Fc receptor-like (FCRL) molecules comprise a large family of receptors, homologous to the receptors for the Fc portion of immunoglobulins (FCR). Within this family, an unusual gene known to exist in mice, rats and dogs, termed FCRLS, encodes a chimeric protein with both Ig-like FCRL and type B scavenger-receptor cysteine-rich (SRCR)-like domains. In mice, FCRLS is located next to the CD5L and KIRREL1 genes. Here, we show that the curious FCRLS gene is actually present across major mammalian groups, but its annotation is generally incorrect or absent. Anchored on mouse FCRLS and FCRL2 genomic sequence alignments, phylogenetic analyses demonstrated that many mammalian sequences currently annotated as FCRL2 cluster with FCRLS, supported by a conserved genetic synteny among organisms. This analysis shows that FCRLS is present in Rodentia, some Carnivora (Canidae and Ursidae), Chiroptera, Arctiodactyla, Proboscidae, and some Primata. Thus, the FCRLS most likely originated in a eutherian mammal ancestor since it is not present in Monotremata or Marsupialia. FCRLS has a peculiar distribution pattern across mammalian lineages, being present in some species, but absent in others from the same family, as in carnivores for example. The most parsimonious hypothesis to explain this FCRLS evolution is that it was convergently lost in several independent mammalian lineages. Analyses of branch-specific nucleotide evolutionary rates, show that FCRL2 and FCRLS have similar ranges of rates across mammals, suggesting that both genes have crucial, but separate functions in the immune system. Bayesian estimates of evolutionary rates for FCRLS in mammalian lineages revealed that carnivores display the highest mutation rate after rodents. Additionally, positive diversifying selection was detected for both FCRL2 and FCRLS. Our results show that the presence of the FCRLS gene is older and more widespread across mammals than previously thought and appears to be functional, being under positive selection. Its precise physiologic role should thus be investigated.	[Matos, Maria Carolina; Pinheiro, Ana; Melo-Ferreira, Jose; Esteves, Pedro Jose] Univ Porto, Ctr Invest Biodiversidade & Recursos Genet CIBIO, Ctr Invest Biodiversidade & Recursos Genet, Lab Associado,InBIO, Vairao, Portugal; [Matos, Maria Carolina; Melo-Ferreira, Jose; Esteves, Pedro Jose] Univ Porto, Dept Biol, Fac Ciencias, Porto, Portugal; [Davis, Randall S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Davis, Randall S.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Davis, Randall S.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA; [Davis, Randall S.] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA; [Esteves, Pedro Jose] Cooperat Ensino Super Politecn & Univ, CITS Ctr Invest Tecnol Saude, CRL CESPU, Gandra, Portugal	Universidade do Porto; Universidade do Porto; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Instituto Superior de Ciencias da Saude Egas Moniz	Esteves, PJ (corresponding author), Univ Porto, Ctr Invest Biodiversidade & Recursos Genet CIBIO, Ctr Invest Biodiversidade & Recursos Genet, Lab Associado,InBIO, Vairao, Portugal.; Esteves, PJ (corresponding author), Univ Porto, Dept Biol, Fac Ciencias, Porto, Portugal.; Esteves, PJ (corresponding author), Cooperat Ensino Super Politecn & Univ, CITS Ctr Invest Tecnol Saude, CRL CESPU, Gandra, Portugal.	pjesteves@cibio.up.pt	Melo-Ferreira, Jose/E-9784-2010; Esteves, Pedro/A-7537-2010	Melo-Ferreira, Jose/0000-0003-4473-1908; Esteves, Pedro/0000-0002-6055-8298	FCT-Foundation for Science and Technology [PTDC/BIA-OUT/29667/2017]; FCT [SFRH/BPD/117451/2016, IF/00376/2015, CEECIND/00372/2018]; NIH/NIAID [AI110553]	FCT-Foundation for Science and Technology(Portuguese Foundation for Science and Technology); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by national funds through FCT-Foundation for Science and Technology-under the project PTDC/BIA-OUT/29667/2017. FCT also supported the postdoctoral fellowships of AP (ref. SFRH/BPD/117451/2016), the FCT Investigator grant of PE (IF/00376/2015) and the Scientific Stimulus contract of JM-F (CEECIND/00372/2018). RD was funded in part by NIH/NIAID award AI110553.	Agarwal S, 2020, CELL REP, V30, P1292, DOI 10.1016/j.celrep.2019.12.099; Akula S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096903; Anisimova M, 2003, GENETICS, V164, P1229; Chistiakov DA, 2007, HUM IMMUNOL, V68, P375, DOI 10.1016/j.humimm.2007.01.013; Chu X, 2011, NAT GENET, V43, P897, DOI 10.1038/ng.898; Davis RS, 2007, ANNU REV IMMUNOL, V25, P525, DOI 10.1146/annurev.immunol.25.022106.141541; Davis RS, 2002, IMMUNOL REV, V190, P123, DOI 10.1034/j.1600-065X.2002.19009.x; de Sousa-Pereira P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109050; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; Ehrhardt GRA, 2011, CURR TOP MICROBIOL, V350, P89, DOI 10.1007/82_2010_88; Fayngerts SA, 2007, IMMUNOGENETICS, V59, P493, DOI 10.1007/s00251-007-0208-8; Finstermeier K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069504; Franco A, 2013, J IMMUNOL, V190, P5739, DOI 10.4049/jimmunol.1202860; Gibson AW, 2009, ARTHRITIS RHEUM-US, V60, P3510, DOI 10.1002/art.24915; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Guselnikov SV, 2002, IMMUNOGENETICS, V54, P87, DOI 10.1007/s00251-002-0436-x; Haage V, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0665-y; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Hammond TR, 2019, IMMUNITY, V50, P253, DOI 10.1016/j.immuni.2018.11.004; Jackson TA, 2010, J IMMUNOL, V185, P7405, DOI 10.4049/jimmunol.1002305; Pond SLK, 2006, MOL BIOL EVOL, V23, P1891, DOI 10.1093/molbev/msl051; KULCZYCKI A, 1990, P NATL ACAD SCI USA, V87, P2856, DOI 10.1073/pnas.87.7.2856; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Kumar S, 2017, MOL BIOL EVOL, V34, P1812, DOI 10.1093/molbev/msx116; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lai XF, 2018, INT IMMUNOPHARMACOL, V63, P311, DOI 10.1016/j.intimp.2018.07.022; Li XR, 2014, CURR TOP MICROBIOL, V382, P275, DOI 10.1007/978-3-319-07911-0_13; Miyazaki T, 1999, J EXP MED, V189, P413, DOI 10.1084/jem.189.2.413; Nielsen R, 1998, GENETICS, V148, P929; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Pinheiro A, 2019, BMC EVOL BIOL, V19, DOI 10.1186/s12862-019-1547-4; Pinheiro A, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140088; Pinheiro A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073934; Pond SLK, 2005, BIOINFORMATICS, V21, P2531, DOI 10.1093/bioinformatics/bti320; PrabhuDas MR, 2017, J IMMUNOL, V198, P3775, DOI 10.4049/jimmunol.1700373; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Rivera J, 2008, ADV IMMUNOL, V98, P85, DOI 10.1016/S0065-2776(08)00403-3; Sanjurjo L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00480; Sarrias MR, 2004, TISSUE ANTIGENS, V63, P335, DOI 10.1111/j.0001-2815.2004.00193.x; Scheffler K, 2006, BIOINFORMATICS, V22, P2493, DOI 10.1093/bioinformatics/btl427; Schreeder DM, 2010, J IMMUNOL, V185, P23, DOI 10.4049/jimmunol.1000832; Shriner D, 2003, GENET RES, V81, P115, DOI 10.1017/S0016672303006128; Stratoulias V, 2019, EMBO J, V38, DOI 10.15252/embj.2019101997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsubata Takeshi, 2012, Infectious Disorders - Drug Targets, V12, P181; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; Wilson TJ, 2012, J IMMUNOL, V188, P4741, DOI 10.4049/jimmunol.1102651; Wlasiuk G, 2010, MOL BIOL EVOL, V27, P2172, DOI 10.1093/molbev/msq104; Yang ZH, 2005, MOL BIOL EVOL, V22, P1107, DOI 10.1093/molbev/msi097; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yang ZH, 2000, MOL BIOL EVOL, V17, P1446, DOI 10.1093/oxfordjournals.molbev.a026245; Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088	54	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	11								590280	10.3389/fimmu.2020.590280	http://dx.doi.org/10.3389/fimmu.2020.590280			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT3HN	33708190	Green Published, gold			2022-12-18	WOS:000626480800001
J	Molehin, AJ; Gray, SA; Turner, C; Davis, J; Zhang, WD; Khatoon, S; Rattan, M; Kernen, R; Peterson, C; Sennoune, SR; Carter, D; Siddiqui, AA				Molehin, Adebayo J.; Gray, Sean A.; Turner, Cheri; Davis, Jennifer; Zhang, Weidong; Khatoon, Sabiha; Rattan, Madison; Kernen, Rebecca; Peterson, Christopher; Sennoune, Souad R.; Carter, Darrick; Siddiqui, Afzal A.			Process Development of Sj-p80: A Low-Cost Transmission-Blocking Veterinary Vaccine for Asiatic Schistosomiasis	FRONTIERS IN IMMUNOLOGY			English	Article						Sj-p80; calpain; Schistosoma japonicum; Asiatic schistosomiasis; veterinary vaccine; water buffalo; Montanide ISA 61 VG	UREA TREATMENT; JAPONICUM; INTERVENTION; CANDIDATE; EFFICACY; MANSONI; TRIAL	Asiatic schistosomiasis caused by Schistosoma japonicum is a neglected tropical disease resulting in significant morbidity to both humans and animals - particularly bovines - in endemic areas. Infection with this parasite leads to less healthy herds, causing problems in communities which rely on bovines for farming, milk and meat production. Additionally, excretion of parasite eggs in feces perpetuates the life cycle and can lead to human infection. We endeavored to develop a minimally purified, inexpensive, and effective vaccine based on the 80 kDa large subunit of the calcium activated neutral protease (calpain) from S. japonicum (Sj-p80). Here we describe the production of veterinary vaccine-grade Sj-p80 at four levels of purity and demonstrate in a pilot study that minimally purified antigen provides protection against infection in mice when paired with a low-cost veterinary adjuvant, Montanide (TM) ISA61 VG. Preliminary data demonstrate that the vaccine is immunogenic with robust antibody titers following immunization, and vaccination resulted in a reduction of parasite eggs being deposited in the liver (23.4-51.4%) and intestines (1.9-55.1%) depending on antigen purity as well as reducing the ability of these eggs to hatch into miracidia by up to 31.6%. We therefore present Sj-p80 as a candidate vaccine antigen for Asiatic schistosomiasis which is now primed for continued development and testing in bovines in endemic areas. A successful bovine vaccine could play a major role in reducing pathogen transmission to humans by interrupting the parasitic life cycle and improving quality of life for people living in endemic countries.	[Molehin, Adebayo J.; Zhang, Weidong; Khatoon, Sabiha; Rattan, Madison; Kernen, Rebecca; Peterson, Christopher; Sennoune, Souad R.; Siddiqui, Afzal A.] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Ctr Trop Med & Infect Dis, Lubbock, TX 79430 USA; [Molehin, Adebayo J.; Zhang, Weidong; Khatoon, Sabiha; Siddiqui, Afzal A.] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Dept Internal Med, Lubbock, TX 79430 USA; [Gray, Sean A.; Turner, Cheri; Davis, Jennifer; Carter, Darrick] PAI Life Sci Inc, Seattle, WA USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Gray, SA (corresponding author), PAI Life Sci Inc, Seattle, WA USA.	sean.gray@pailifesciences.com			SBIR grant [R43AI142908]	SBIR grant	This work was supported by SBIR grant (R43AI142908) to SG (PI) and AS (MPI).	Ahmad G, 2009, PARASITOL RES, V105, P1767, DOI 10.1007/s00436-009-1646-z; Andersen FA, 2005, INT J TOXICOL, V24, P1, DOI 10.1080/10915810500257097; Burke ML, 2009, PARASITE IMMUNOL, V31, P163, DOI 10.1111/j.1365-3024.2009.01098.x; Cao YF, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4680812; Colley DG, 2014, PARASITE IMMUNOL, V36, P347, DOI 10.1111/pim.12087; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Da'Dara AA, 2008, VACCINE, V26, P3617, DOI 10.1016/j.vaccine.2008.04.080; Dai Y, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2036-5; Dai Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120792; Danopoulos E D, 1983, Clin Oncol, V9, P89; Danopoulos E D, 1975, Clin Oncol, V1, P341; DANOPOULOS ED, 1981, CLIN ONCOL, V7, P281; DANOPOULOS ED, 1974, LANCET, V1, P115; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; GORDON CJ, 1988, PHARMACOL BIOCHEM BE, V31, P699, DOI 10.1016/0091-3057(88)90250-X; Gray DJ, 2007, AM J TROP MED HYG, V77, P866, DOI 10.4269/ajtmh.2007.77.866; Guo JG, 2006, AM J TROP MED HYG, V74, P335, DOI 10.4269/ajtmh.2006.74.335; Hams E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00089; Hurst MH, 2000, ANN TROP MED PARASIT, V94, P461, DOI 10.1080/00034983.2000.11813565; Jankovic D, 1999, J IMMUNOL, V162, P345; Jiz M, 2008, INFECT IMMUN, V76, P3164, DOI 10.1128/IAI.00409-08; Jiz MA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00347; Jiz Mario Antonio L. II, 2016, Annals of Parasitology, V62, P295, DOI 10.17420/ap6204.64; Karmakar S, 2014, VACCINE, V32, P1296, DOI 10.1016/j.vaccine.2013.12.057; KNOPF PM, 1977, EXP PARASITOL, V41, P74, DOI 10.1016/0014-4894(77)90131-X; Le L, 2014, PARASITOL RES, V113, P1195, DOI 10.1007/s00436-014-3757-4; Leger E, 2017, PARASITOLOGY, V144, P65, DOI 10.1017/S0031182016001190; Li YQ, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2033-8; Lo NC, 2017, LANCET INFECT DIS, V17, pE64, DOI 10.1016/S1473-3099(16)30535-7; Martin RM, 1998, J IMMUNOL METHODS, V212, P187, DOI 10.1016/S0022-1759(98)00015-5; McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07; McManus DP, 2020, SEMIN IMMUNOPATHOL, V42, P355, DOI 10.1007/s00281-020-00789-x; McManus DP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0013-8; McManus DP, 2010, CLIN MICROBIOL REV, V23, P442, DOI 10.1128/CMR.00044-09; McManus DP, 2009, EXPERT REV ANTI-INFE, V7, P473, DOI [10.1586/eri.09.17, 10.1586/ERI.09.17]; Molehin AJ, 2017, PARASITOL RES, V116, P3175, DOI 10.1007/s00436-017-5634-4; Molehin AJ, 2016, EXPERT REV VACCINES, V15, P619, DOI 10.1586/14760584.2016.1131127; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Peng JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021109; Pennisi E., 2018, SCIENCE, DOI [10.1126/science.aav2480, DOI 10.1126/SCIENCE.AAV2480]; Pennisi E, 2018, SCIENCE, V361, P832, DOI 10.1126/science.361.6405.832; Qiu CH, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-172; Rojo JU, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171677; Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396; Shi Feng, 2019, Zhongguo Xuexichongbing Fangzhi Zazhi, V31, P33, DOI 10.16250/j.32.1374.2018307; Siddiqui AA, 2017, TRENDS PARASITOL, V33, P194, DOI 10.1016/j.pt.2016.10.010; Siddiqui AJ, 2018, ANN NY ACAD SCI, V1425, P19, DOI 10.1111/nyas.13866; Solomon JS, 2004, PROTEIN EXPRES PURIF, V36, P226, DOI 10.1016/j.pep.2004.04.011; Street M, 1999, J IMMUNOL, V163, P4489; Tebeje BM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1799-4; THURSTON JH, 1986, METAB BRAIN DIS, V1, P129, DOI 10.1007/BF00999383; Tu YQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086575; Tucker Matthew S, 2013, Curr Protoc Immunol, V103, DOI 10.1002/0471142735.im1901s103; Wei F, 2010, VACCINE, V28, P5161, DOI 10.1016/j.vaccine.2010.06.012; Wilson RA, 2020, PARASITOLOGY, V147, P507, DOI 10.1017/S0031182020000049; Wilson RA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000290; Wu HW, 2017, VACCINE, V35, P3409, DOI 10.1016/j.vaccine.2017.05.007; You H, 2018, TROP MED INFECT DIS, V3, DOI 10.3390/tropicalmed3020068; Zhang R, 2000, Parasitol Int, V48, P232; Zhang RL, 2001, INFECT IMMUN, V69, P386, DOI 10.1128/IAI.69.1.386-391.2001; Zhang WD, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01246; Zhang WD, 2018, ANN NY ACAD SCI, V1425, P38, DOI 10.1111/nyas.13942; Zhang WD, 2018, J INVEST MED, V66, P1124, DOI 10.1136/jim-2018-000786	63	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	11								578715	10.3389/fimmu.2020.578715	http://dx.doi.org/10.3389/fimmu.2020.578715			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT3BW	33732227	gold, Green Published			2022-12-18	WOS:000626466100001
J	Nan, FL; Zheng, W; Nan, WL; Yu, T; Xie, CZ; Zhang, H; Xu, XH; Li, CH; Ha, Z; Zhang, JY; Zhuang, XY; Han, JC; Wang, W; Qian, J; Zhao, GY; Li, ZX; Ge, JY; Bu, ZG; Zhang, Y; Lu, HJ; Jin, NY				Nan, Fu Long; Zheng, Wei; Nan, Wen Long; Yu, Tong; Xie, Chang Zhan; Zhang, He; Xu, Xiao Hong; Li, Cheng Hui; Ha, Zhuo; Zhang, Jin Yong; Zhuang, Xin Yu; Han, Ji Cheng; Wang, Wei; Qian, Jing; Zhao, Guan Yu; Li, Zhuo Xin; Ge, Jin Ying; Bu, Zhi Gao; Zhang, Ying; Lu, Hui Jun; Jin, Ning Yi			Newcastle Disease Virus Inhibits the Proliferation of T Cells Induced by Dendritic Cells In Vitro and In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						Newcastle disease virus; dendritic cells; antigen presentation; phenotypic maturation; immunosuppression; proliferation of T cells		Newcastle disease virus (NDV) infects poultry and antagonizes host immunity via several mechanisms. Dendritic cells (DCs) are characterized as specialized antigen presenting cells, bridging innate and adaptive immunity and regulating host resistance to viral invasion. However, there is little specific knowledge of the role of DCs in NDV infection. In this study, the representative NDV lentogenic strain LaSota was used to explore whether murine bone marrow derived DCs mature following infection. We examined surface molecule expression and cytokine release from DCs as well as proliferation and activation of T cells in vivo and in vitro in the context of NDV. The results demonstrated that infection with lentogenic strain LaSota induced a phenotypic maturation of immature DCs (imDCs), which actually led to curtailed T cell responses. Upon infection, the phenotypic maturation of DCs was reflected by markedly enhanced MHC and costimulatory molecule expression and secretion of proinflammatory cytokines. Nevertheless, NDV-infected DCs produced the anti-inflammatory cytokine IL-10 and attenuated T cell proliferation, inducing Th2-biased responses. Therefore, our study reveals a novel understanding that DCs are phenotypically mature but dysfunctional in priming T cell responses during NDV infection.	[Nan, Fu Long; Xu, Xiao Hong; Zhao, Guan Yu; Zhang, Ying; Jin, Ning Yi] Jilin Univ, Coll Vet Med, Coll Anim Sci, Changchun, Peoples R China; [Nan, Fu Long; Yu, Tong; Xie, Chang Zhan; Zhang, He; Li, Cheng Hui; Ha, Zhuo; Zhang, Jin Yong; Zhuang, Xin Yu; Han, Ji Cheng; Wang, Wei; Zhao, Guan Yu; Li, Zhuo Xin; Lu, Hui Jun; Jin, Ning Yi] Acad Mil Med Sci, Inst Mil Vet Med, Changchun, Peoples R China; [Zheng, Wei] 964Hosp PLA Joint Logist, Changchun, Peoples R China; [Nan, Wen Long] China Anim Hlth & Epidemiol Ctr, Qingdao, Peoples R China; [Yu, Tong] Yanbian Univ, Coll Agr, Yanji, Peoples R China; [Han, Ji Cheng] Changchun Univ Chinese Med, Acad Workstn, Changchun, Peoples R China; [Qian, Jing] Jiangsu Acad Agr Sci, Inst Vet Med, Nanjing, Peoples R China; [Ge, Jin Ying; Bu, Zhi Gao] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Peoples R China	Jilin University; Academy of Military Medical Sciences - China; China Animal Health & Epidemiology Center; Yanbian University; Changchun University of Chinese Medicine; Jiangsu Academy of Agricultural Sciences; Chinese Academy of Agricultural Sciences; Harbin Veterinary Research Institute, CAAS	Zhang, Y; Jin, NY (corresponding author), Jilin Univ, Coll Vet Med, Coll Anim Sci, Changchun, Peoples R China.; Lu, HJ; Jin, NY (corresponding author), Acad Mil Med Sci, Inst Mil Vet Med, Changchun, Peoples R China.	Zhangying636@126.com; huijun_lu@126.com; ningyik@126.com	xie, chang/GYJ-2493-2022; Zhang, He/GYD-7125-2022	Nan, Fu Long/0000-0002-9415-6406	National Natural Science Foundation of China [31272573]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China (No. 31272573).	Avota E, 2010, MED MICROBIOL IMMUN, V199, P227, DOI 10.1007/s00430-010-0152-3; Burke S, 2020, CANCER IMMUNOL IMMUN, V69, P1015, DOI 10.1007/s00262-020-02495-x; Coughlin MM, 2013, REV MED VIROL, V23, P126, DOI 10.1002/rmv.1735; Ge JY, 2007, J VIROL, V81, P150, DOI 10.1128/JVI.01514-06; Grosjean I, 1997, J EXP MED, V186, P801, DOI 10.1084/jem.186.6.801; Hahm B, 2004, VIROLOGY, V323, P292, DOI 10.1016/j.virol.2004.03.011; Hua J, 2016, INVEST OPHTH VIS SCI, V57, P1457, DOI 10.1167/iovs.15-17551; Huang LL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21363; Jinushi M, 2004, J IMMUNOL, V173, P6072, DOI 10.4049/jimmunol.173.10.6072; Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x; Kumar S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092159; Le Nouen C, 2019, J VIROL, V93, DOI 10.1128/JVI.01216-19; Mandaric S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002846; Mittal SK, 2015, CURR OPIN IMMUNOL, V34, P22, DOI 10.1016/j.coi.2014.12.009; Qeska V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096121; Qian C, 2018, SEMIN IMMUNOL, V35, P3, DOI 10.1016/j.smim.2017.12.002; Qian J, 2017, VET MICROBIOL, V203, P158, DOI 10.1016/j.vetmic.2017.03.002; Qiu XS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148560; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Romanets-Korbut O, 2016, CELL MOL IMMUNOL, V13, P828, DOI 10.1038/cmi.2015.55; Schraml BU, 2015, CURR OPIN IMMUNOL, V32, P13, DOI 10.1016/j.coi.2014.11.001; Servet-Delprat C, 2000, J VIROL, V74, P4387, DOI 10.1128/JVI.74.9.4387-4393.2000; Sun YJ, 2019, J VIROL, V93, DOI 10.1128/JVI.00322-19; Tan L, 2018, VIROLOGY, V518, P126, DOI 10.1016/j.virol.2018.02.011; Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000; Xiang B, 2018, ARCH VIROL, V163, P1407, DOI 10.1007/s00705-018-3745-6; Xu Q, 2020, INT J CANCER, V146, P531, DOI 10.1002/ijc.32694	28	2	2	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	11								619829	10.3389/fimmu.2020.619829	http://dx.doi.org/10.3389/fimmu.2020.619829			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT5FX	33708193	Green Published, gold			2022-12-18	WOS:000626614400001
J	Zheng, WZ; Zhang, SQ; Chen, XB; Jiang, SQ; Li, ZH; Li, MQ				Zheng, Wenzhong; Zhang, Shiqiang; Chen, Xiaobao; Jiang, Shaoqin; Li, Zhihao; Li, Mengqiang			Case Report: Dendritic Cells and Macrophages Capture Sperm in Chronically Inflamed Human Epididymis	FRONTIERS IN IMMUNOLOGY			English	Article						chronic inflammation of genital tract (CIGT); oligozoospermia and asthenospermia; chronic epididymitis; macrophages; dendritic cells		Chronic inflammation of the male genital tract is thought to be a primary etiological factor of male infertility. The abundance and activation of macrophages and dendritic cells in patients with chronic inflammation of genital tract were closely associated with oligozoospermia and asthenospermia. Chronic epididymitis appears to be more important than seminal vesiculitis or prostatitis due to the direct interaction between spermatozoa and epididymal inflammatory cells. In this study, we present a case report of a 41-year-old male with oligoasthenospermia and chronic epididymitis. Hematoxylin-eosin staining and immunofluorescence analyses showed that antigen presenting cells including macrophages and dendritic cells were found capturing spermatozoa in the lumen of cauda epididymis. To our knowledge, this is the first case report that directly observed dendritic cells capturing spermatozoa in the lumen of an inflamed epididymis. This finding directly explains chronic epididymitis as the possible cause of oligospermia in patients.	[Zheng, Wenzhong; Chen, Xiaobao; Jiang, Shaoqin; Li, Zhihao; Li, Mengqiang] Fujian Med Univ Union Hosp, Dept Urol, Fuzhou, Peoples R China; [Zhang, Shiqiang] Sun Yat Sen Univ, Affiliated Hosp 7, Kidney & Urol Ctr, Dept Urol, Shenzhen, Peoples R China	Sun Yat Sen University	Li, MQ (corresponding author), Fujian Med Univ Union Hosp, Dept Urol, Fuzhou, Peoples R China.	limengqiang1976@163.com			Fujian Medical University [2016QH032, 2018QH1044, 2020XH004]; Fujian Natural Sciences Foundation [2017J01203]; Joint Funds for the innovation of science and Technology, Fujian province [2017Y9023]	Fujian Medical University; Fujian Natural Sciences Foundation; Joint Funds for the innovation of science and Technology, Fujian province	This study was supported by the Startup Fund for scientific research, Fujian Medical University (Grant number: 2016QH032); Fujian Natural Sciences Foundation (Grant number: 2017J01203); Joint Funds for the innovation of science and Technology, Fujian province (Grant number: 2017Y9023); Startup Fund for scientific research, Fujian Medical University (Grant number: 2018QH1044); Startup Fund for scientific research of bring in talents, Fujian Medical University (Grant number: 2020XH004).	Colpi GM, 2018, ANDROLOGY-US, V6, P513, DOI 10.1111/andr.12502; Cooper TG, 2002, J CELL SCI, V115, P5; Da Silva N, 2016, CELL TISSUE RES, V363, P97, DOI 10.1007/s00441-015-2270-0; Da Silva N, 2011, REPRODUCTION, V141, P653, DOI 10.1530/REP-10-0493; Duan YG, 2016, ANDROLOGIA, V48, P431, DOI 10.1111/and.12463; Duan YG, 2014, FERTIL STERIL, V101, P70, DOI 10.1016/j.fertnstert.2013.09.006; Fijak M, 2018, HUM REPROD UPDATE, V24, P416, DOI 10.1093/humupd/dmy009; Guiton R, 2013, BASIC CLIN ANDROL, V23, DOI 10.1186/2051-4190-23-8; Hamada A, 2012, INT BRAZ J UROL, V38, P576, DOI 10.1590/S1677-55382012000500002; Hedger MP, 2012, MOL CELL ENDOCRINOL, V359, P30, DOI 10.1016/j.mce.2011.09.031; Hedger MP, 2011, J ANDROL, V32, P625, DOI 10.2164/jandrol.111.012989; HOLSTEIN AF, 1978, ANDROLOGIA, V10, P331; HORAN AH, 1972, J REPROD FERTIL, V30, P417, DOI 10.1530/jrf.0.0300417; Jones R, 2004, BIOL REPROD, V71, P1405, DOI 10.1095/biolreprod.104.031252; Kampf C, 2012, JOVE-J VIS EXP, DOI 10.3791/3620; La Vignera S, 2011, INT J ANDROL, V34, pE330, DOI 10.1111/j.1365-2605.2011.01200.x; Lotti F, 2018, HUM REPROD, V33, P1417, DOI 10.1093/humrep/dey235; Makar Robert S, 2002, Am J Clin Pathol, V117 Suppl, pS95; Michel V, 2015, ASIAN J ANDROL, V17, P756, DOI 10.4103/1008-682X.155770; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Poongothai J, 2009, SINGAP MED J, V50, P336; Schutte B, 2013, ANDROLOGY-US, V1, P822, DOI 10.1111/j.2047-2927.2013.00122.x; Schuppe HC, 2017, DTSCH ARZTEBL INT, V114, P339, DOI 10.3238/arztebl.2017.0339; Smith TB, 2014, ANDROLOGY-US, V2, P755, DOI 10.1111/j.2047-2927.2014.00251.x; Sullivan R, 2016, HUM REPROD UPDATE, V22, P574, DOI 10.1093/humupd/dmw015	25	2	2	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 23	2021	12								629680	10.3389/fimmu.2021.629680	http://dx.doi.org/10.3389/fimmu.2021.629680			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QT5NH	33708220	Green Published, gold			2022-12-18	WOS:000626633700001
J	Hendaoui, I; Lahmar, A; Campo, L; Mebarki, S; Bichet, S; Hess, D; Degen, M; Kchir, N; Charrada-Ben Farhat, L; Hefaiedh, R; Ruiz, C; Terracciano, LM; Tucker, RP; Hendaoui, L; Chiquet-Ehrismann, R				Hendaoui, Ismail; Lahmar, Ahlem; Campo, Luca; Mebarki, Sihem; Bichet, Sandrine; Hess, Daniel; Degen, Martin; Kchir, Nidhameddine; Charrada-Ben Farhat, Leila; Hefaiedh, Rania; Ruiz, Christian; Terracciano, Luigi M.; Tucker, Richard P.; Hendaoui, Lotfi; Chiquet-Ehrismann, Ruth			Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers	FRONTIERS IN IMMUNOLOGY			English	Article						tenascin-W; tenascin-N; tenascin-C; gallbladder cancer; extracellular matrix; tumor stroma	GALLBLADDER; EXPRESSION; CARCINOMA; FAMILY	Extrahepatic cancers of the biliary system are typically asymptomatic until after metastasis, which contributes to their poor prognosis. Here we examined intrahepatic cholangiocarcinomas (n = 8), carcinomas of perihilar bile ducts (n = 7), carcinomas of the gallbladder (n = 11) and hepatic metastasis from carcinomas of the gallbladder (n = 4) for the expression of the extracellular matrix glycoproteins tenascin-C and tenascin-W. Anti-tenascin-C and anti-tenascin-W immunoreactivity was found in all biliary tract tumors examined. Unlike tenascin-C, tenascin-W was not detected in normal hepatobiliary tissue. Tenascin-W was also expressed by the cholangiocarcinoma-derived cell line Huh-28. However, co-culture of Huh-28 cells with immortalized bone marrow-derived stromal cells was necessary for the formation and organization of tenascin-W fibrils in vitro. Our results indicate that tenascin-W may be a novel marker of hepatobiliary tumor stroma, and its absence from many normal tissues suggests that it may be a potential target for biotherapies.	[Hendaoui, Ismail; Campo, Luca; Mebarki, Sihem; Bichet, Sandrine; Hess, Daniel; Chiquet-Ehrismann, Ruth] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Lahmar, Ahlem] Mongi Slim Univ Hosp, Dept Pathol, La Marsa, Tunisia; [Lahmar, Ahlem; Kchir, Nidhameddine; Charrada-Ben Farhat, Leila; Hendaoui, Lotfi] Univ Tunis El Manar, Sch Med, Tunis, Tunisia; [Degen, Martin] Univ Bern, Dept Orthodont & Dentofacial Orthoped, Lab Oral Mol Biol, Bern, Switzerland; [Kchir, Nidhameddine] La Rabta Univ Hosp, Dept Pathol, Tunis, Tunisia; [Charrada-Ben Farhat, Leila; Hendaoui, Lotfi] Mongi Slim Univ Hosp, Dept Diagnost & Intervent Radiol, La Marsa, Tunisia; [Hefaiedh, Rania] Mongi Slim Univ Hosp, Dept Hepatogastroenterol, Tunis, Tunisia; [Ruiz, Christian; Terracciano, Luigi M.] Univ Hosp Basel, Inst Pathol, Basel, Switzerland; [Tucker, Richard P.] Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; [Chiquet-Ehrismann, Ruth] Univ Basel, Fac Sci, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Universite de Tunis-El-Manar; Hopital Mongi Slim; Universite de Tunis-El-Manar; Faculte de Medecine de Tunis (FMT); University of Bern; Universite de Tunis-El-Manar; Hopital La Rabta; Universite de Tunis-El-Manar; Hopital Mongi Slim; University of Basel; University of California System; University of California Davis; University of Basel	Tucker, RP (corresponding author), Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA.	rptucker@ucdavis.edu	Terracciano, Luigi M./AAB-5335-2022	Terracciano, Luigi M./0000-0002-9393-9660; Degen, Martin/0000-0002-4356-3714	Swiss National Science Foundation [31003A_156740]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This work was supported by funds from the Swiss National Science Foundation (31003A_156740) to RC-E.	Aishima S, 2003, MODERN PATHOL, V16, P1019, DOI 10.1097/01.MP.0000086860.65672.73; Alvaro D, 2006, AM J PATHOL, V169, P877, DOI 10.2353/ajpath.2006.050464; Bosman F. T., 2010, WHO classification of tumours of the digestive system; Bourgine P, 2014, STEM CELL RES, V12, P584, DOI 10.1016/j.scr.2013.12.006; Brellier F, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-14; Cherif MH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-637; Chiovaro F, 2015, INT J CANCER, V137, P1842, DOI 10.1002/ijc.29565; Chiquet-Ehrismann R, 2014, MATRIX BIOL, V37, P112, DOI 10.1016/j.matbio.2014.01.007; Chiquet-Ehrismann R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004960; Couvelard A, 1998, HEPATOLOGY, V27, P839, DOI 10.1002/hep.510270328; DEARETXABALA X, 1995, REV MED CHILE, V123, P581; Degen M, 2008, INT J CANCER, V122, P2454, DOI 10.1002/ijc.23417; Degen M, 2007, CANCER RES, V67, P9169, DOI 10.1158/0008-5472.CAN-07-0666; Ehrlich L, 2017, AM J PATHOL, V187, P570, DOI 10.1016/j.ajpath.2016.10.021; HEIKE M, 1995, VIRCHOWS ARCH, V426, P375; HENSON DE, 1992, CANCER, V70, P1493, DOI 10.1002/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO;2-U; Hundal R, 2014, CLIN EPIDEMIOL, V6, P99, DOI 10.2147/CLEP.S37357; Iguchi T, 2009, ONCOLOGY-BASEL, V76, P293, DOI 10.1159/000207506; Kayahara M, 2007, CANCER, V110, P572, DOI 10.1002/cncr.22815; Konstantinidis IT, 2009, ARCH SURG-CHICAGO, V144, P441, DOI 10.1001/archsurg.2009.46; KUSAKA Y, 1988, RES EXP MED, V188, P367, DOI 10.1007/BF01851205; Lowy CM, 2015, CELL ADHES MIGR, V9, P112, DOI 10.1080/19336918.2015.1008331; Macias RIR, 2018, BBA-MOL BASIS DIS, V1864, P1468, DOI 10.1016/j.bbadis.2017.08.002; Martina E, 2010, INT J BIOCHEM CELL B, V42, P1412, DOI 10.1016/j.biocel.2010.06.004; Martina E, 2010, FASEB J, V24, P778, DOI 10.1096/fj.09-140491; Meloty-Kapella CV, 2006, DEV DYNAM, V235, P1532, DOI 10.1002/dvdy.20731; Meloty-Kapella CV, 2008, CELL TISSUE RES, V334, P445, DOI 10.1007/s00441-008-0715-4; Mertens JC, 2018, BBA-MOL BASIS DIS, V1864, P1454, DOI 10.1016/j.bbadis.2017.08.027; Mertens JC, 2013, CANCER RES, V73, P897, DOI 10.1158/0008-5472.CAN-12-2130; Midwood KS, 2016, J CELL SCI, V129, P4321, DOI 10.1242/jcs.190546; Midwood KS, 2011, CELL MOL LIFE SCI, V68, P3175, DOI 10.1007/s00018-011-0783-6; Mikura Ayako, 2009, Congenital Anomalies, V49, P77, DOI 10.1111/j.1741-4520.2009.00227.x; NAGORNEY DM, 1988, SEMIN ONCOL, V15, P106; Neidhardt J, 2003, MOL CELL NEUROSCI, V23, P193, DOI 10.1016/S1044-7431(03)00012-5; Okamura N, 2005, PATHOL INT, V55, P724, DOI 10.1111/j.1440-1827.2005.01891.x; Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Randi G, 2006, INT J CANCER, V118, P1591, DOI 10.1002/ijc.21683; SCHENK S, 1995, INT J CANCER, V61, P443, DOI 10.1002/ijc.2910610402; Scherberich A, 2005, ONCOGENE, V24, P1525, DOI 10.1038/sj.onc.1208342; Scherberich A, 2004, J CELL SCI, V117, P571, DOI 10.1242/jcs.00867; Shimizu T, 2006, WORLD J GASTROENTERO, V12, P6316, DOI 10.3748/wjg.v12.i39.6316; Sithithaworn P, 2002, J HELMINTHOL, V76, P261, DOI 10.1079/JOH2002129; Spenle C, 2020, CANCER IMMUNOL RES, V8, P1122, DOI 10.1158/2326-6066.CIR-20-0074; TERADA T, 1994, HISTOPATHOLOGY, V25, P143, DOI 10.1111/j.1365-2559.1994.tb01570.x; Tucker RP, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-60; Tucker RP, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00053; VANEYKEN P, 1992, HEPATOLOGY, V15, P909, DOI 10.1002/hep.1840150526; Wi Y, 2018, CANCER RES TREAT, V50, P1444, DOI 10.4143/crt.2017.279; YAMADA S, 1992, LIVER, V12, P10; YOSHIDA J, 1994, J NEUROL NEUROSUR PS, V57, P1212, DOI 10.1136/jnnp.57.10.1212; Yoshida T, 2015, CELL ADHES MIGR, V9, P96, DOI 10.1080/19336918.2015.1008332; Zuliani-Alvarez L, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01718-7	53	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	11								630139	10.3389/fimmu.2020.630139	http://dx.doi.org/10.3389/fimmu.2020.630139			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS5QT	33692777	Green Published, gold			2022-12-18	WOS:000625955400001
J	Howard, S; Richardson, S; Benyeogor, I; Omosun, Y; Dye, K; Medhavi, F; Lundy, S; Adebayo, O; Igietseme, JU; Eko, FO				Howard, Simone; Richardson, Shakyra; Benyeogor, Ifeyinwa; Omosun, Yusuf; Dye, Kamran; Medhavi, Fnu; Lundy, Stephanie; Adebayo, Olayinka; Igietseme, Joseph U.; Eko, Francis O.			Differential miRNA Profiles Correlate With Disparate Immunity Outcomes Associated With Vaccine Immunization and Chlamydial Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Chlamydia; immunization; infection; microRNA; immunity; pathology	VIBRIO-CHOLERAE GHOSTS; MESENCHYMAL TRANSITION; GENE-EXPRESSION; GENITAL-TRACT; MICRORNAS; ACTIVATION; MIGRATION; RECEPTOR; INFLAMMATION; PATHOGENESIS	Vaccine-induced immune responses following immunization with promising Chlamydia vaccines protected experimental animals from Chlamydia-induced upper genital tract pathologies and infertility. In contrast, primary genital infection with live Chlamydia does not protect against these pathologies. We hypothesized that differential miRNA profiles induced in the upper genital tracts (UGT) of mice correlate with the disparate immunity vs. pathologic outcomes associated with vaccine immunization and chlamydial infection. Thus, miRNA expression profiles in the UGT of mice after Chlamydia infection (Live EB) and immunization with dendritic cell (DC)-based vaccine (DC vaccine) or VCG-based vaccine (VCG vaccine) were compared using the NanoString nCounter Mouse miRNA assay. Of the 602 miRNAs differentially expressed (DE) in the UGT of immunized and infected mice, we selected 58 with counts >100 and p-values < 0.05 for further analysis. Interestingly, vaccine immunization and Chlamydia infection induced the expression of distinct miRNA profiles with a higher proportion in vaccine-immunized compared to Chlamydia infected mice; DC vaccine (41), VCG vaccine (23), and Live EB (15). Hierarchical clustering analysis showed notable differences in the uniquely DE miRNAs for each experimental group, with DC vaccine showing the highest number (21 up-regulated, five down-regulated), VCG vaccine (two up-regulated, five down-regulated), and live EB (two up-regulated, four down-regulated). The DC vaccine-immunized group showed the highest number (21 up-regulated and five down-regulated compared to two up-regulated and four down-regulated in the live Chlamydia infected group). Pathway analysis showed that the DE miRNAs target genes that regulate several biological processes and functions associated with immune response and inflammation. These results suggest that the induction of differential miRNA expression plays a significant role in the disparate immunity outcomes associated with Chlamydia infection and vaccination.	[Howard, Simone; Richardson, Shakyra; Omosun, Yusuf; Medhavi, Fnu; Lundy, Stephanie; Adebayo, Olayinka; Eko, Francis O.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA; [Benyeogor, Ifeyinwa] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA; [Dye, Kamran] Morehouse Coll, Dept Chem, Atlanta, GA USA; [Igietseme, Joseph U.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA	Morehouse School of Medicine; Emory University; Morehouse College; Centers for Disease Control & Prevention - USA	Eko, FO (corresponding author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA.	feko@msm.edu			National Institutes of Health [R01AI126897]; National Center for Research Resources, National Institutes of Health [1 C06 RR18386]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This research was funded by the National Institutes of Health (R01AI126897) to FE. The investigation was conducted in a facility constructed with support from Research Facilities Improvement Grant #1 C06 RR18386 from the National Center for Research Resources, National Institutes of Health.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Arkatkar T, 2015, IMMUNOLOGY, V145, P534, DOI 10.1111/imm.12470; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Benyeogor I, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5495-6; Biernacka A, 2011, GROWTH FACTORS, V29, P196, DOI 10.3109/08977194.2011.595714; Brunham RC, 2015, NEW ENGL J MED, V372, P2039, DOI 10.1056/NEJMra1411426; Chen YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071076; de la Maza LM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00543-16, 10.1128/cvi.00543-16]; Derrick T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1367-8; Eko FO, 2000, J BIOTECHNOL, V83, P115, DOI 10.1016/S0168-1656(00)00315-1; Eko FO, 2003, VACCINE, V21, P1694, DOI 10.1016/S0264-410X(02)00677-1; Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337; Fang Y, 2020, FISH SHELLFISH IMMUN, V98, P34, DOI 10.1016/j.fsi.2019.12.076; Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Fu G, 2014, TRENDS IMMUNOL, V35, P311, DOI 10.1016/j.it.2014.05.003; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20258-8; Guo J, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0348-x; Gupta R, 2016, ONCOTARGET, V7, P64726, DOI 10.18632/oncotarget.11461; Gupta R, 2015, AM J REPROD IMMUNOL, V73, P126, DOI 10.1111/aji.12281; Hafner LM, 2015, CONTRACEPTION, V92, P108, DOI 10.1016/j.contraception.2015.01.004; Huang F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01327; Igietseme JU, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00585-17; Igietseme JU, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145198; Igietseme JU, 2013, J INFECT DIS, V207, P1095, DOI 10.1093/infdis/jit009; Igietseme JU, 2009, J INFECT DIS, V200, P926, DOI 10.1086/605411; Igietseme JU, 2000, J IMMUNOL, V164, P4212, DOI 10.4049/jimmunol.164.8.4212; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kurata A, 2018, ONCOL REP, V39, P91, DOI 10.3892/or.2017.6093; Li N, 2012, MOL BIOL REP, V39, P4655, DOI 10.1007/s11033-011-1257-5; Li YY, 2015, CANCER RES, V75, P2674, DOI 10.1158/0008-5472.CAN-14-2875; Li ZR, 2017, FASEB J, V31, P3018, DOI 10.1096/fj.201601278R; Lindsey ML, 2015, J AM COLL CARDIOL, V66, P1364, DOI 10.1016/j.jacc.2015.07.035; Liu RH, 2015, CANCER RES, V75, P1703, DOI 10.1158/0008-5472.CAN-14-2108; Liu Xiaofang, 2019, Eur J Immunol, DOI 10.1002/eji.201848007; Liu Z, 2010, MICROBES INFECT, V12, P854, DOI 10.1016/j.micinf.2010.06.002; Lv JF, 2018, BRAIN RES, V1685, P91, DOI 10.1016/j.brainres.2018.01.032; Miguel RDV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162445; Muller T, 2017, VACCINE, V35, P2801, DOI 10.1016/j.vaccine.2017.04.017; Murtaza G, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3494289; Nakasa T, 2008, ARTHRITIS RHEUM-US, V58, P1284, DOI 10.1002/art.23429; Nejad C, 2018, FEBS J, V285, P3695, DOI 10.1111/febs.14482; O'Reilly S, 2017, MOL ASPECTS MED, V54, P89, DOI 10.1016/j.mam.2016.10.001; Oliveros J. C., 2015, VENNY INTERACTIVE TO; Ordas A, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-696; Pais R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178537; Park ST, 2017, BMC WOMENS HEALTH, V17, DOI 10.1186/s12905-016-0356-9; Parker MI, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12673; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Shah N, 2017, MOL NEUROBIOL, V54, P1392, DOI 10.1007/s12035-016-9746-0; Sheedy FJ, 2008, ANN RHEUM DIS, V67, P50, DOI 10.1136/ard.2008.100289; Shyu AB, 2008, EMBO J, V27, P471, DOI 10.1038/sj.emboj.7601977; Skalsky RL, 2010, ANNU REV MICROBIOL, V64, P123, DOI 10.1146/annurev.micro.112408.134243; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Soper DE, 2010, OBSTET GYNECOL, V116, P419, DOI 10.1097/AOG.0b013e3181e92c54; Stallmann S, 2016, CELL MICROBIOL, V18, P761, DOI 10.1111/cmi.12549; Starnbach MN, 2008, NAT REV IMMUNOL, V8, P313, DOI 10.1038/nri2272; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Wang JY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171265; Wang S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11023; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; Workowski KA, 2015, MMWR RECOMM REP, V64, P1; Wu AB, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0462-8; Xin ZL, 2018, AGEING RES REV, V41, P42, DOI 10.1016/j.arr.2017.11.002; Yao Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02205; Yeruva L, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00768-16; Yeruva L, 2014, MBIO, V5, DOI 10.1128/mBio.01241-14; Yu WP, 2018, ONCOTARGETS THER, V11, P7109, DOI 10.2147/OTT.S183600; Zhang T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7861290; Zhou JL, 2013, EXP APPL ACAROL, V59, P339, DOI 10.1007/s10493-012-9604-3; Zhou XK, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0006-9; Zou YT, 2017, CELL SIGNAL, V39, P1, DOI 10.1016/j.cellsig.2017.07.016	74	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	12								625318	10.3389/fimmu.2021.625318	http://dx.doi.org/10.3389/fimmu.2021.625318			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS6UP	33692799	Green Published, gold			2022-12-18	WOS:000626033200001
J	Kulkarni, V; Queiroz, ATL; Sangle, S; Kagal, A; Salvi, S; Gupta, A; Ellner, J; Kadam, D; Rolla, VC; Andrade, BB; Salgame, P; Mave, V				Kulkarni, Vandana; Queiroz, Artur T. L.; Sangle, Shashi; Kagal, Anju; Salvi, Sonali; Gupta, Amita; Ellner, Jerrold; Kadam, Dileep; Rolla, Valeria C.; Andrade, Bruno B.; Salgame, Padmini; Mave, Vidya			A Two-Gene Signature for Tuberculosis Diagnosis in Persons With Advanced HIV	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; tuberculosis; transcriptomics; diagnosis; gene signature	PULMONARY TUBERCULOSIS; XPERT MTB/RIF; EXPRESSION; HOST; BIOMARKERS; PACKAGE; GAMMA; ASSAY; TB	Background: Transcriptomic signatures for tuberculosis (TB) have been proposed and represent a promising diagnostic tool. Data remain limited in persons with advanced HIV. Methods: We enrolled 30 patients with advanced HIV (CD4 <100 cells/mm(3)) in India; 16 with active TB and 14 without. Whole-blood RNA sequencing was performed; these data were merged with a publicly available dataset from Uganda (n = 33; 18 with TB and 15 without). Transcriptomic profiling and machine learning algorithms identified an optimal gene signature for TB classification. Receiver operating characteristic analysis was used to assess performance. Results: Among 565 differentially expressed genes identified for TB, 40 were shared across India and Uganda cohorts. Common upregulated pathways reflect Toll-like receptor cascades and neutrophil degranulation. The machine-learning decision-tree algorithm selected gene expression values from RAB20 and INSL3 as most informative for TB classification. The signature accurately classified TB in discovery cohorts (India AUC 0.95 and Uganda AUC 1.0; p < 0.001); accuracy was fair in external validation cohorts. Conclusions: Expression values of RAB20 and INSL3 genes in peripheral blood compose a biosignature that accurately classified TB status among patients with advanced HIV in two geographically distinct cohorts. The functional analysis suggests pathways previously reported in TB pathogenesis.	[Kulkarni, Vandana; Sangle, Shashi; Kagal, Anju; Salvi, Sonali; Kadam, Dileep; Mave, Vidya] Johns Hopkins Univ Clin Res Site BJGMC JHU CRS, Byramjee Jeejeebhoy Govt Med Coll, Pune, Maharashtra, India; [Queiroz, Artur T. L.; Andrade, Bruno B.] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil; [Queiroz, Artur T. L.; Andrade, Bruno B.] Multinat Org Network Sponsoring Translat & Epidem, Salvador, BA, Brazil; [Gupta, Amita; Mave, Vidya] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Ellner, Jerrold; Salgame, Padmini] Rutgers New Jersey Med Sch, Ctr Emerging Pathogens, Newark, NJ USA; [Rolla, Valeria C.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil	B.J. Govt. Medical College & Sassoon General Hospitals, Pune; Fundacao Oswaldo Cruz; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Fundacao Oswaldo Cruz	Mave, V (corresponding author), Johns Hopkins Univ Clin Res Site BJGMC JHU CRS, Byramjee Jeejeebhoy Govt Med Coll, Pune, Maharashtra, India.; Queiroz, ATL (corresponding author), Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.; Queiroz, ATL (corresponding author), Multinat Org Network Sponsoring Translat & Epidem, Salvador, BA, Brazil.; Mave, V (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD USA.	artur.queiroz@fiocruz.br; vidyamave@gmail.com	Queiroz, Artur/AAT-9330-2021; Rolla, Valeria Cavalcanti/AAI-6078-2021	Rolla, Valeria Cavalcanti/0000-0002-0841-1408; Gupta, Amita/0000-0001-7036-2718	CRDF Global (Country: India) [DAA3-17-63158-1]; Government of India Department of Biotechnology (DBT); Indian Council of Medical Research (ICMR); National Institutes of Health National Institute of Allergy and Infectious Diseases Office of AIDS Research; CRDF Global; National Institutes of Health Baltimore-Washington-India Clinical Trials Unit for National Institute of Allergy and Infectious Diseases Networks [UM1AI069465]; National Institutes of Health [R01A1I097494]; Intramural Research Program of the Oswaldo Cruz Foundation; National Council for Scientific and Technological Development (senior CNPq fellowship-tier 1D), Brazil	CRDF Global (Country: India); Government of India Department of Biotechnology (DBT); Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR)); National Institutes of Health National Institute of Allergy and Infectious Diseases Office of AIDS Research; CRDF Global; National Institutes of Health Baltimore-Washington-India Clinical Trials Unit for National Institute of Allergy and Infectious Diseases Networks; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the Oswaldo Cruz Foundation; National Council for Scientific and Technological Development (senior CNPq fellowship-tier 1D), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF))	The research work was primarily supported by CRDF Global (Award number DAA3-17-63158-1/Country: India). Research data in this manuscript were collected, in part, as part of the Regional Prospective Observational Research for Tuberculosis (RePORT) India Consortium. This work was funded in whole or in part by federal funds from the Government of India Department of Biotechnology (DBT); the Indian Council of Medical Research (ICMR); the National Institutes of Health National Institute of Allergy and Infectious Diseases Office of AIDS Research; CRDF Global; the National Institutes of Health Baltimore-Washington-India Clinical Trials Unit for National Institute of Allergy and Infectious Diseases Networks (UM1AI069465 to VM and AG); and the National Institutes of Health (R01A1I097494 to VM and AG). The work of BBA was supported by the Intramural Research Program of the Oswaldo Cruz Foundation, and the National Council for Scientific and Technological Development (senior CNPq fellowship-tier 1D), Brazil. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the DBT, ICMR, National Institutes of Health, or CRDF Global. Anymention of trade names, commercial projects, or organizations does not imply endorsement by any of the sponsoring organizations. The content of this paper is solely the responsibility of the authors and does not represent the official views of the funders.	Agizew T, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4697-5; Akanbi MO, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0430-6; Anderson ST, 2014, NEW ENGL J MED, V370, P1712, DOI 10.1056/NEJMoa1303657; Blankley S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162220; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Burel JG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00221; Darboe F, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01441; Das R, 2013, P NATL ACAD SCI USA, V110, pE2997, DOI 10.1073/pnas.1301128110; Esmail H, 2018, P NATL ACAD SCI USA, V115, pE964, DOI 10.1073/pnas.1711853115; Gebremicael G, 2018, J INFECT DIS, V218, P1833, DOI 10.1093/infdis/jiy404; Hampel U, 2013, ENDOCRINOLOGY, V154, P2034, DOI 10.1210/en.2012-2201; Iram S, 2015, PAK J MED SCI, V31, P105, DOI 10.12669/pjms.311.6970; Kaforou M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001538; Kassa D, 2016, TUBERCULOSIS, V100, P25, DOI 10.1016/j.tube.2016.06.003; Kebede A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225205; Kroon EE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02637; Lawn SD, 2011, FUTURE MICROBIOL, V6, P1067, DOI [10.2217/FMB.11.84, 10.2217/fmb.11.84]; Leek JJ, 2020, R PACKAGE VERSION 34; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marais S, 2017, J INFECT DIS, V215, P677, DOI 10.1093/infdis/jiw561; Mulenga H, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026612; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Penn-Nicholson A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65043-8; Rajan JV, 2019, CLIN INFECT DIS, V69, P77, DOI 10.1093/cid/ciy835; Ranjbar S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002620; Ross SA, 2014, ANNU REV NUTR, V34, P305, DOI 10.1146/annurev-nutr-071813-105729; Rossato M, 2011, UROL ONCOL-SEMIN ORI, V29, P33, DOI 10.1016/j.urolonc.2008.10.015; Sambarey A, 2017, EBIOMEDICINE, V15, P112, DOI 10.1016/j.ebiom.2016.12.009; Schnettger L, 2017, CELL HOST MICROBE, V21, P619, DOI 10.1016/j.chom.2017.04.004; Sedky M, 2018, EGYPT J CHEST DIS TU, V67, P419, DOI 10.4103/ejcdt.ejcdt_57_18; Singhania A, 2018, NAT IMMUNOL, V19, P1159, DOI 10.1038/s41590-018-0225-9; Soneson Charlotte, 2015, F1000Res, V4, P1521, DOI 10.12688/f1000research.7563.1; Steingart KR, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009593.pub2, 10.1002/14651858.CD009593.pub3]; Sutherland JS, 2014, CLIN MICROBIOL INFEC, V20, pO230, DOI 10.1111/1469-0691.12383; Sweeney TE, 2016, LANCET RESP MED, V4, P213, DOI 10.1016/S2213-2600(16)00048-5; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; Therneau T., 2019, R PACKAGE VERSION 41; Turner CT, 2020, LANCET RESP MED, V8, P407, DOI 10.1016/S2213-2600(19)30469-2; Verma S, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3127-4; Vittor AY, 2014, ANN GLOB HEALTH, V80, P476, DOI 10.1016/j.aogh.2015.01.001; Wang L, 2017, NUCLEIC ACIDS RES, V45, P2318, DOI 10.1093/nar/gkw1286; Warsinske H, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002786; Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zak DE, 2016, LANCET, V387, P2312, DOI 10.1016/S0140-6736(15)01316-1	45	2	2	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	12								631165	10.3389/fimmu.2021.631165	http://dx.doi.org/10.3389/fimmu.2021.631165			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS6QH	33692804	gold, Green Published			2022-12-18	WOS:000626022000001
J	Ledo, C; Gonzalez, CD; Garofalo, A; Sabbione, F; Keitelman, IA; Giai, C; Stella, I; Trevani, AS; Gomez, MI				Ledo, Camila; Gonzalez, Cintia D.; Garofalo, Ailin; Sabbione, Florencia; Keitelman, Irene A.; Giai, Constanza; Stella, Ines; Trevani, Analia S.; Gomez, Marisa I.			Protein A Modulates Neutrophil and Keratinocyte Signaling and Survival in Response to Staphylococcus aureus	FRONTIERS IN IMMUNOLOGY			English	Article						Staphylococcus aureus; protein A; neutrophils; type 1 TNF-&#945; receptor; cell death		The type 1 TNF-alpha receptor (TNFR1) has a central role in initiating both pro-inflammatory and pro-apoptotic signaling cascades in neutrophils. Considering that TNFR1 signals Staphylococcus aureus protein A (SpA), the aim of this study was to explore the interaction of this bacterial surface protein with neutrophils and keratinocytes to underscore the signaling pathways that may determine the fate of these innate immune cells in the infected tissue during staphylococcal skin infections. Using human neutrophils cultured in vitro and isogenic staphylococcal strains expressing or not protein A, we demonstrated that SpA is a potent inducer of IL-8 in neutrophils and that the induction of this chemokine is dependent on the SpA-TNFR1 interaction and p38 activation. In addition to IL-8, protein A induced the expression of TNF-alpha and MIP-1 alpha highlighting the importance of SpA in the amplification of the inflammatory response. Protein A contributed to reduce neutrophil mortality prolonging their lifespan upon the encounter with S. aureus. Signaling initiated by SpA modulated the type of neutrophil cell death in vitro and during skin and soft tissue infections (SSTI) in vivo triggering the apoptotic pathway instead of necrosis. Moreover, SpA induced pro-inflammatory cytokines in keratinocytes, modulating their survival in vitro and preventing the exacerbated necrosis and ulceration of the epithelium during SSTI in vivo. Taken together, these results highlight the importance of the inflammatory signaling induced by protein A in neutrophils and skin epithelial cells. The ability of protein A to modulate the neutrophil/epithelial cell death program in the skin is of clinical relevance considering that lysis of neutrophils and epithelial cells will promote an intense inflammatory response and contribute to tissue damage, a non-desirable feature of complicated SSTI.	[Ledo, Camila; Gomez, Marisa I.] Univ Maimonides, Ctr Estudios Biomed Aplicados & Desarrollo CEBBAD, Dept Ciencias Biol & Biomed, Buenos Aires, DF, Argentina; [Ledo, Camila; Gomez, Marisa I.] Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, DF, Argentina; [Gonzalez, Cintia D.; Garofalo, Ailin; Giai, Constanza] Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Invest Microbiol & Parasitol Med IMPaM, Buenos Aires, DF, Argentina; [Sabbione, Florencia; Keitelman, Irene A.; Trevani, Analia S.] Consejo Nacl Invest Cient & Tecn, Acad Nacl Med, Dept Inmunol, Inst Med Expt IMEX, Buenos Aires, DF, Argentina; [Stella, Ines] Univ Maimonides, Fac Ciencias Salud, Buenos Aires, DF, Argentina; [Trevani, Analia S.; Gomez, Marisa I.] Univ Buenos Aires, Fac Med, Dept Microbiol Parasitol & Inmunol, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Buenos Aires National Academy of Medicine; IMEX - Instituto de Medicina Experimental; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Gomez, MI (corresponding author), Univ Maimonides, Ctr Estudios Biomed Aplicados & Desarrollo CEBBAD, Dept Ciencias Biol & Biomed, Buenos Aires, DF, Argentina.; Gomez, MI (corresponding author), Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, DF, Argentina.; Gomez, MI (corresponding author), Univ Buenos Aires, Fac Med, Dept Microbiol Parasitol & Inmunol, Buenos Aires, DF, Argentina.	gomez.marisa@maimonides.edu		Keitelman, Irene Angelica/0000-0002-7093-5712	Agencia Nacional de Promocion de la Ciencia y la Tecnologia, Argentina [PICT2011-2263, PICT2016-2678, PICT2018-3613, PICT2013/2177, PICT2016/1418]; Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires, Buenos Aires, Argentina [UBACyT 20020150100114BA, UBACyT 20020130100744BA]; Fundacion Cientifica Felipe Fiorellino, Buenos Aires, Argentina	Agencia Nacional de Promocion de la Ciencia y la Tecnologia, Argentina(ANPCyT); Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires, Buenos Aires, Argentina; Fundacion Cientifica Felipe Fiorellino, Buenos Aires, Argentina	This work was supported by grants from the Agencia Nacional de Promocion de la Ciencia y la Tecnologia, Argentina (PICT2011-2263, PICT2016-2678 and PICT2018-3613 to MIG; PICT2013/2177 and PICT2016/1418 to AST) and the Secretaria de Ciencia y Tecnica, Universidad de Buenos Aires, Buenos Aires, Argentina (UBACyT 20020150100114BA to MIG and UBACyT 20020130100744BA to AST). Intramural funding has been provided by the Fundacion Cientifica Felipe Fiorellino, Buenos Aires, Argentina.	Alonzo F, 2013, NATURE, V493, P51, DOI 10.1038/nature11724; Askarian F, 2018, FEMS MICROBIOL REV, V42, P656, DOI 10.1093/femsre/fuy025; Beaumier CM, 2016, VACCINE, V34, P2996, DOI 10.1016/j.vaccine.2016.03.074; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUNCE C, 1992, INFECT IMMUN, V60, P2636, DOI 10.1128/IAI.60.7.2636-2640.1992; Choi KS, 2005, INFECT IMMUN, V73, P8209, DOI 10.1128/IAI.73.12.8209-8218.2005; Claro T, 2013, MICROBIOL-SGM, V159, P147, DOI 10.1099/mic.0.063016-0; Claro T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018748; Classen A, 2011, EXP DERMATOL, V20, P48, DOI 10.1111/j.1600-0625.2010.01174.x; Dabrowska D, 2019, INT REV IMMUNOL, V38, P18, DOI 10.1080/08830185.2018.1540616; Gonzalez CD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131879; David MZ, 2010, CLIN MICROBIOL REV, V23, P616, DOI 10.1128/CMR.00081-09; Dragneva Y, 2001, INFECT IMMUN, V69, P2630, DOI 10.1128/IAI.69.4.2630-2635.2001; DuMont AL, 2013, P NATL ACAD SCI USA, V110, P10794, DOI 10.1073/pnas.1305121110; Falugi F, 2013, MBIO, V4, DOI 10.1128/mBio.00575-13; Foster TJ, 2014, NAT REV MICROBIOL, V12, P49, DOI 10.1038/nrmicro3161; Frank D, 2019, CELL DEATH DIFFER, V26, P99, DOI 10.1038/s41418-018-0212-6; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Garofalo A, 2012, J INFECT DIS, V206, P81, DOI 10.1093/infdis/jis311; Giai C, 2016, J INNATE IMMUN, V8, P284, DOI 10.1159/000443663; Giai C, 2013, INFECT IMMUN, V81, P4200, DOI 10.1128/IAI.00593-13; Gomez MI, 2007, EMBO J, V26, P701, DOI 10.1038/sj.emboj.7601554; Gomez MI, 2006, J BIOL CHEM, V281, P20190, DOI 10.1074/jbc.M601956200; Gomez MI, 2005, J IMMUNOL, V175, P1930, DOI 10.4049/jimmunol.175.3.1930; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Gonzalez CD, 2019, BBA-MOL BASIS DIS, V1865, P2657, DOI 10.1016/j.bbadis.2019.07.004; Greenlee-Wacker MC, 2014, J IMMUNOL, V192, P4709, DOI 10.4049/jimmunol.1302692; Guerra FE, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00286; Jiang LZ, 2016, NAT PROTOC, V11, P655, DOI 10.1038/nprot.2016.028; Jones HR, 2016, SEMIN IMMUNOL, V28, P137, DOI 10.1016/j.smim.2016.03.007; Kennedy AD, 2010, J INFECT DIS, V202, P1050, DOI 10.1086/656043; Kobayashi SD, 2018, J INNATE IMMUN, V10, P432, DOI 10.1159/000487756; Kobayashi SD, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00159; Kobayashi SD, 2009, WIRES SYST BIOL MED, V1, P309, DOI 10.1002/wsbm.32; Kobayashi SD, 2010, J INNATE IMMUN, V2, P560, DOI 10.1159/000317134; Krishna S, 2012, SEMIN IMMUNOPATHOL, V34, P261, DOI 10.1007/s00281-011-0292-6; Krismer B, 2017, NAT REV MICROBIOL, V15, P675, DOI 10.1038/nrmicro.2017.104; Gabelloni ML, 2013, SEMIN IMMUNOPATHOL, V35, P423, DOI 10.1007/s00281-013-0364-x; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Ma XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034970; Malachowa Natalia, 2013, Methods Mol Biol, V1031, P109, DOI 10.1007/978-1-62703-481-4_14; Meagher LC, 1996, J IMMUNOL, V156, P4422; Bertelli AM, 2016, BBA-MOL BASIS DIS, V1862, P1975, DOI 10.1016/j.bbadis.2016.07.016; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mistry RD, 2013, PEDIATR CLIN N AM, V60, P1063, DOI 10.1016/j.pcl.2013.06.011; Nasser A, 2019, MICROB PATHOGENESIS, V131, P259, DOI 10.1016/j.micpath.2019.04.026; National Institutes of Health National Research Council, 1996, GUIDE CARE USE LAB A; Nauseef WM, 2007, METHODS MOL BIOL, V412, P59745, DOI [10.1007/978-1-59745-467-4, DOI 10.1007/978-1-59745-467-4]; Nilsen NJ, 2008, J LEUKOCYTE BIOL, V84, P280, DOI 10.1189/jlb.0907656; Ocana MG, 2008, MOL IMMUNOL, V45, P2087, DOI 10.1016/j.molimm.2007.10.013; Rigby KM, 2012, SEMIN IMMUNOPATHOL, V34, P237, DOI 10.1007/s00281-011-0295-3; Sakamoto E, 2005, J LEUKOCYTE BIOL, V78, P301, DOI 10.1189/jlb.1104690; Salamone G, 2001, J IMMUNOL, V166, P3476, DOI 10.4049/jimmunol.166.5.3476; Salamone GV, 2010, LAB INVEST, V90, P1049, DOI 10.1038/labinvest.2010.77; Sampedro GR, 2017, J INFECT DIS, V215, pS64, DOI 10.1093/infdis/jiw581; Sarkar A, 2012, INFECT IMMUN, V80, P1615, DOI 10.1128/IAI.05219-11; Spaan AN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6438; Tecchio C, 2016, SEMIN IMMUNOL, V28, P119, DOI 10.1016/j.smim.2016.04.003; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Van Den Berg JM., 2001, TRANSFUS MED, V10, P330, DOI [10.1111/rp10.1113-jphysiol.2006.109561, DOI 10.1111/RP10.1113-JPHYSIOL.2006.109561]; van Kessel KPM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00467; Wicki S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.311; Wilke GA, 2010, P NATL ACAD SCI USA, V107, P13473, DOI 10.1073/pnas.1001815107; Woof JM, 2016, BIOCHEM SOC T, V44, P1651, DOI 10.1042/BST20160246; Wright HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058598; YAMAMOTO C, 1993, INFECT IMMUN, V61, P1972, DOI 10.1128/IAI.61.5.1972-1979.1993; Zurek OW, 2015, J INFECT DIS, V212, P934, DOI 10.1093/infdis/jiv124	68	2	3	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	11								524180	10.3389/fimmu.2020.524180	http://dx.doi.org/10.3389/fimmu.2020.524180			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS6ZJ	33692774	Green Published, gold			2022-12-18	WOS:000626045600001
J	Santana, JB; de Almeida, TVVS; Lopes, DM; Page, B; Oliveira, SC; Souza, I; Ribeiro, LEVS; Gutierrez, NAG; Carvalho, EM; Cardoso, LS				Santana, Jordana Batista; de Almeida, Tarcisio Vila Verde Santana; Lopes, Diego Mota; Page, Brady; Oliveira, Sergio Costa; Souza, Irisma; Ribeiro, Luis Eduardo Viana Silva; Gutierrez, Nestor Adrian Guerrero; Carvalho, Edgar M.; Cardoso, Luciana Santos			Phenotypic Characterization of CD4(+) T Lymphocytes in Periportal Fibrosis Secondary to Schistosomiasis	FRONTIERS IN IMMUNOLOGY			English	Article						schistosomiasis; periportal fibrosis; Schistosoma mansoni; CD4(+) T lymphocytes; fibrosis		Schistosomiasis is a parasitic disease that affects about 166 million people around the world. It is estimated that 5%-10% of individuals with schistosomiasis develop severe forms of the disease, which are characterized by pulmonary hypertension, ascites, periportal fibrosis, and other significant complications. The chronic phase of the disease is associated with a Th2 type immune response, but evidence also suggests there are roles for Th1 and Th17 in the development of severe disease. The aim of this study was to evaluate the CD4(+) T lymphocyte profile of patients with different degrees of periportal fibrosis secondary to schistosomiasis. These individuals had been treated for schistosomiasis, but since they live in a S. mansoni endemic area, they are at risk of reinfection. They were evaluated in relation to the degree of periportal fibrosis and classified into three groups: without fibrosis or with incipient fibrosis (WF/IFNE), n=12, possible periportal fibrosis/periportal fibrosis, n=13, and advanced periportal fibrosis/advanced periportal fibrosis with portal hypertension, n=4. We observed in the group without fibrosis a balance between the low expression of Th2 cytokines and high expression of T reg cells. As has already been described in the literature, we found an increase of the Th2 cytokines IL-4, IL-5, and IL-13 in the group with periportal fibrosis. In addition, this group showed higher expression of IL-17 and IL-10 but lower IL-10/IL-13 ratio than patients in the WF/IFNE group. Cells from individuals who present any level of fibrosis expressed more TGF-beta compared to the WF/IFNE group and a positive correlation with left lobe enlargement and portal vein wall thickness. There was a negative correlation between IL-17 and the thickness of the portal vein wall, but more studies are necessary in order to explore the possible protective role of this cytokine. Despite the fibrosis group having presented a higher expression of pro-fibrotic molecules compared to WF/IFNE patients, it seems there is a regulation through IL-10 and T reg cells that is able to maintain the low morbidity of this group.	[Santana, Jordana Batista; de Almeida, Tarcisio Vila Verde Santana; Lopes, Diego Mota; Ribeiro, Luis Eduardo Viana Silva; Gutierrez, Nestor Adrian Guerrero; Carvalho, Edgar M.; Cardoso, Luciana Santos] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil; [Page, Brady] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Oliveira, Sergio Costa] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil; [Oliveira, Sergio Costa; Carvalho, Edgar M.; Cardoso, Luciana Santos] Inst Nacl Ciencia & Tecnol Doencas Trop INCT DT C, Salvador, BA, Brazil; [Souza, Irisma] Inst Saude Irisma Souza, Gandu, Brazil; [Carvalho, Edgar M.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Lab Pesquisas Clin, Salvador, BA, Brazil; [Cardoso, Luciana Santos] Univ Fed Bahia UFBA, Fac Farm, Dept Anal Clin & Toxicol, Salvador, BA, Brazil	Universidade Federal da Bahia; Harvard University; Massachusetts General Hospital; Universidade Federal de Minas Gerais; Fundacao Oswaldo Cruz; Universidade Federal da Bahia	Cardoso, LS (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, Salvador, BA, Brazil.; Cardoso, LS (corresponding author), Inst Nacl Ciencia & Tecnol Doencas Trop INCT DT C, Salvador, BA, Brazil.; Cardoso, LS (corresponding author), Univ Fed Bahia UFBA, Fac Farm, Dept Anal Clin & Toxicol, Salvador, BA, Brazil.	lucianac@ufba.br	Oliveira, Sergio Costa/AAG-5408-2021; Cardoso, Luciana/L-5459-2018	Oliveira, Sergio Costa/0000-0003-4062-5577; Guerrero Gutierrez, Nestor Adrian/0000-0003-4451-9894; Cardoso, Luciana/0000-0001-9195-451X	FAPESB [APP0051/2016]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES) [001]; CNPq/MST/INCT-DT [465229/2014-0]	FAPESB(Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq/MST/INCT-DT	This work was supported by the FAPESB/EDITAL UNIVERSAL, grant number APP0051/2016. This work was also supported by the CNPq/MST/INCT-DT, grant number 465229/2014-0. This study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES)-Finance Code 001.	Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633; Arnaud V, 2008, J INFECT DIS, V198, P418, DOI 10.1086/588826; Bina José Carlos, 2003, Rev. Soc. Bras. Med. Trop., V36, P211, DOI 10.1590/S0037-86822003000200003; Booth M, 2004, J IMMUNOL, V172, P1295, DOI 10.4049/jimmunol.172.2.1295; Cardoso LS, 2010, CLIN EXP IMMUNOL, V160, P266, DOI 10.1111/j.1365-2249.2009.04084.x; Cardoso LS, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/710647; CHEEVER AW, 1994, J IMMUNOL, V153, P753; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; de Jesus AR, 2004, INFECT IMMUN, V72, P3391, DOI 10.1128/IAI.72.6.3391-3397.2004; De Jesus AR, 2000, AM J TROP MED HYG, V63, P1; De Souza Robson Da Paixao, 2012, J Parasitol Res, V2012, P394981, DOI 10.1155/2012/394981; DESSEIN AJ, 1992, IMMUNOL INVEST, V21, P423, DOI 10.3109/08820139209069383; Fabregat I, 2016, FEBS J, V283, P2219, DOI 10.1111/febs.13665; Fallon PG, 2000, J IMMUNOL, V164, P2585, DOI 10.4049/jimmunol.164.5.2585; Farah IO, 2000, J IMMUNOL, V164, P5337, DOI 10.4049/jimmunol.164.10.5337; Fernandes JS, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/703653; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Gryseels B, 2012, INFECT DIS CLIN N AM, V26, P383, DOI 10.1016/j.idc.2012.03.004; Henri S, 2002, J IMMUNOL, V169, P929, DOI 10.4049/jimmunol.169.2.929; Hirsch C, 1996, PARASITOLOGY, V112, P529, DOI 10.1017/S0031182000066105; Kamal SM, 2001, J INFECT DIS, V184, P972, DOI 10.1086/323352; Kamdem SD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02781; Li L, 2015, PARASITOLOGY, V142, P341, DOI 10.1017/S0031182014001115; Louis H, 1998, HEPATOLOGY, V28, P1607, DOI 10.1002/hep.510280621; Mbow M, 2013, J INFECT DIS, V207, P186, DOI 10.1093/infdis/jis654; Meng Yun-chao, 2012, Zhonghua Gan Zang Bing Za Zhi, V20, P698, DOI 10.3760/cma.j.issn.1007-3418.2012.09.012; Mitre E, 2008, J INFECT DIS, V197, P94, DOI 10.1086/524301; Oliveira LFA, 2006, INFECT IMMUN, V74, P1215, DOI 10.1128/IAI.74.2.1215-1221.2006; Ramalingam TR, 2016, J PATHOL, V239, P344, DOI 10.1002/path.4733; Reiman RM, 2006, INFECT IMMUN, V74, P1471, DOI 10.1128/IAI.74.3.1471-1479.2006; Rodrigues V, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002567; Romano A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004306; Rutitzky LI, 2008, J IMMUNOL, V180, P2486, DOI 10.4049/jimmunol.180.4.2486; Rutitzky LI, 2001, P NATL ACAD SCI USA, V98, P13243, DOI 10.1073/pnas.231258498; Santos Germana Titonelli, 2007, Radiol Bras, V40, P377, DOI 10.1590/S0100-39842007000600005; Silva-Teixeira DN, 2004, CLIN DIAGN LAB IMMUN, V11, P627, DOI 10.1128/CDLI.11.3.627-630.2004; Watanabe K, 2007, AM J TROP MED HYG, V77, P676, DOI 10.4269/ajtmh.2007.77.676; Wilson MS, 2007, IMMUNOL CELL BIOL, V85, P148, DOI 10.1038/sj.icb.7100014; World Health Organization (WHO), 2019, SCHIST WHO; Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Zhang YX, 2012, EUR J IMMUNOL, V42, P1523, DOI 10.1002/eji.201141933; Zheng B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00061	44	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 22	2021	12								605235	10.3389/fimmu.2021.605235	http://dx.doi.org/10.3389/fimmu.2021.605235			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS5FY	33692784	Green Published, gold			2022-12-18	WOS:000625927200001
J	Blay-Cadanet, J; Pedersen, A; Holm, CK				Blay-Cadanet, Julia; Pedersen, Alice; Holm, Christian Kanstrup			Cellular Metabolites Regulate Central Nucleic Acid Sensing Pathways	FRONTIERS IN IMMUNOLOGY			English	Review						metabolites; lactate; succinate; itaconate; MAVS; STING; toll-like receptors		Detection of pathogen-derived DNA or RNA species by cellular nucleic acid sensors prompts release of anti-microbial interferons and cytokines. In contrast to their protective anti-microbial functions, inappropriate or excessive activation of nucleic acid sensors can cause inflammatory diseases. Nucleic acid sensing is therefore tightly controlled by regulatory factors acting through both transcriptional and post-transcriptional mechanisms. Recently, it has become clearer that metabolic pathways-previously thought to be unconnected with immune responses-can influence nucleic acid sensing. This regulation can be observed when immune system cells undergo metabolic reprogramming in response to stimulation with pathogen-associated molecular patterns such as lipopolysaccharide from gram negative bacteria. Metabolic reprogramming leads to accumulation and secretion of metabolites, which have been mostly viewed as end-products of processes providing cellular energy and building blocks. However, metabolites have now been identified as important regulators of nucleic acid sensing. This mini-review aims to outline current knowledge on regulation of central nucleic acid sensing pathways by metabolites during metabolic reprogramming.	[Blay-Cadanet, Julia; Pedersen, Alice; Holm, Christian Kanstrup] Aarhus Univ, Dept Biomed, Aarhus, Denmark	Aarhus University	Blay-Cadanet, J; Holm, CK (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.	juliablay@biomed.au.dk; holm@biomed.au.dk			Faculty of Health at Aarhus University - Novo Nordisk Foundation	Faculty of Health at Aarhus University - Novo Nordisk Foundation	JB-C was funded by the Faculty of Health at Aarhus University (Ph.D. Fellowship). AP was funded by Novo Nordisk Foundation.	Ablasser A, 2020, NAT IMMUNOL, V21, P17, DOI 10.1038/s41590-019-0556-1; Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Adeva-Andany M, 2014, MITOCHONDRION, V17, P76, DOI 10.1016/j.mito.2014.05.007; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Bartok E, 2020, IMMUNITY, V53, P54, DOI 10.1016/j.immuni.2020.06.014; Basler T, 2006, J LEUKOCYTE BIOL, V79, P628, DOI 10.1189/jlb.0905520; Choudhuri S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008474; Fekete T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03070; Gao P, 2013, CELL, V153, P1094, DOI 10.1016/j.cell.2013.04.046; Hansen AL, 2018, P NATL ACAD SCI USA, V115, pE7768, DOI 10.1073/pnas.1806239115; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Husain Z, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26383; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Kansanen E, 2011, J BIOL CHEM, V286, P14019, DOI 10.1074/jbc.M110.190710; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004; Larabi A, 2013, CELL REP, V3, P734, DOI 10.1016/j.celrep.2013.01.034; Lee SM, 2016, J THORAC DIS, V8, P1388, DOI 10.21037/jtd.2016.05.55; Li Y, 2008, NAT STRUCT MOL BIOL, V15, P865, DOI 10.1038/nsmb.1447; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Mao Y, 2017, ARTERIOSCL THROM VAS, V37, P920, DOI [10.1161/ATVBAHA.117.309017, 10.1161/atvbaha.117.309017]; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Michelucci A, 2013, P NATL ACAD SCI USA, V110, P7820, DOI 10.1073/pnas.1218599110; Mills EL, 2018, NATURE, V556, P113, DOI 10.1038/nature25986; Mu XM, 2018, CELL CYCLE, V17, P428, DOI 10.1080/15384101.2018.1444305; Mukai K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11932; Olagnier D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05861-7; Paludan SR, 2021, NAT REV IMMUNOL, V21, P137, DOI 10.1038/s41577-020-0391-5; Pankowicz FP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12642; Pantel A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001759; Pozza ED, 2020, SEMIN CELL DEV BIOL, V98, P4, DOI 10.1016/j.semcdb.2019.04.013; Rubic T, 2008, NAT IMMUNOL, V9, P1261, DOI 10.1038/ni.1657; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shang GJ, 2019, NATURE, V567, P389, DOI 10.1038/s41586-019-0998-5; Shin JH, 2011, J PROTEOME RES, V10, P2238, DOI 10.1021/pr101054m; Sugimoto M, 2012, METABOLOMICS, V8, P624, DOI 10.1007/s11306-011-0353-9; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Sun LC, 2018, BBA-REV CANCER, V1870, P51, DOI 10.1016/j.bbcan.2018.06.005; Swain A, 2020, NAT METAB, V2, P594, DOI 10.1038/s42255-020-0210-0; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; van Diepen JA, 2017, DIABETOLOGIA, V60, P1304, DOI 10.1007/s00125-017-4261-z; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang CG, 2019, NATURE, V567, P394, DOI 10.1038/s41586-019-1000-2; Zhang WN, 2019, CELL, V178, P176, DOI 10.1016/j.cell.2019.05.003; Zhou L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20316-8	53	2	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2021	12								635738	10.3389/fimmu.2021.635738	http://dx.doi.org/10.3389/fimmu.2021.635738			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR8VF	33679790	Green Published, gold			2022-12-18	WOS:000625490200001
J	Liu, SY; Liu, NN; Wang, H; Zhang, XW; Yao, YF; Zhang, SQ; Shi, L				Liu, Shuyuan; Liu, Nannan; Wang, Hui; Zhang, Xinwen; Yao, Yufeng; Zhang, Shuqiong; Shi, Li			CCR5 Promoter Polymorphisms Associated With Pulmonary Tuberculosis in a Chinese Han Population	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; CCR5; polymorphism; susceptibility; Chinese Han		Background Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis, is a major public health concern. Chemokines and their receptors, such as RANTES, CXCR3, and CCR5, have been reported to play important roles in cell activation and migration in immune responses against TB infection. Methods To understand the correlations involving CCR5 gene variations, M. tuberculosis infection, and TB disease progression, a case-control study comprising 450 patients with TB and 306 healthy controls from a Chinese Han population was conducted, along with the detection of polymorphisms in the CCR5 promoter using a sequencing method. Results After adjustment for age and gender, the results of logistic analysis indicated that the frequency of rs2734648-G was significantly higher in the TB patient group (P = 0.002, OR = 1.38, 95% CI: 1.123-1.696); meanwhile, rs2734648-GG showed notable susceptibility to TB (P = 6.32E-06, OR = 2.173, 95% CI: 1.546-3.056 in a recessive model). The genotypic frequency of rs1799987 also varied between the TB and control groups (P = 0.008). In stratified analysis, rs2734648-GG significantly increased susceptibility to pulmonary TB in a recessive model (P < 0.0001, OR = 2.382, 95% CI: 1.663-3.413), and the rs2734648-G allele significantly increased susceptibility to TB recurrence in a dominant model (P = 0.0032, OR = 1.936, 95% CI: 1.221-3.068), whereas rs1799987-AA was associated with susceptibility to pulmonary TB (P = 0.0078, OR = 1.678, 95% CI: 1.141-2.495 in a recessive model) but not with extra-pulmonary TB and TB recurrence. A haplotype constructed with the major alleles of the eight SNPs in the CCR5 promoter (rs2227010-rs2856758-rs2734648-rs1799987-rs1799988-rs41469351-rs1800023-rs1800024: A-A-G-G-T-C-G-C) exhibited extraordinarily increased risk of susceptibility to TB and pulmonary TB (P = 6.33E-11, OR = 24.887, 95% CI: 6.081-101.841). Conclusion In conclusion, CCR5 promoter polymorphisms were found to be associated with pulmonary TB and TB progression in Chinese Han people.	[Liu, Shuyuan; Liu, Nannan; Zhang, Xinwen; Yao, Yufeng; Shi, Li] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China; [Wang, Hui; Zhang, Shuqiong] Third Peoples Hosp Kunming, Kunming, Yunnan, Peoples R China; [Yao, Yufeng] Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming, Yunnan, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Diseases	Yao, YF; Shi, L (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China.; Zhang, SQ (corresponding author), Third Peoples Hosp Kunming, Kunming, Yunnan, Peoples R China.; Yao, YF (corresponding author), Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming, Yunnan, Peoples R China.	leoyyf@gmail.com; 1357626082@qq.com; shili.imb@gmail.com			National Natural and Science Foundation of China [31401063]; Special Funds for high-level health talents of Yunnan Province [D-201669, L201615, H-2018014]	National Natural and Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Funds for high-level health talents of Yunnan Province	This work was supported by the National Natural and Science Foundation of China (31401063); and the Special Funds for high-level health talents of Yunnan Province (D-201669, L201615, and H-2018014). The funders had no role in the design of the study, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel L, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0428; Aravindan PP, 2019, LUNG INDIA, V36, P244, DOI 10.4103/lungindia.lungindia_146_15; Azad AK, 2012, INFECT IMMUN, V80, P3343, DOI 10.1128/IAI.00443-12; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; Blanpain C, 1999, BLOOD, V94, P1899; Camargo JF, 2009, J IMMUNOL, V182, P171, DOI 10.4049/jimmunol.182.1.171; Carpenter D, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-15-5; Cliff JM, 2015, IMMUNOL REV, V264, P88, DOI 10.1111/imr.12269; Dallmann-Sauer M, 2018, MAMM GENOME, V29, P523, DOI 10.1007/s00335-018-9765-4; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Galkina E, 2005, J CLIN INVEST, V115, P3473, DOI 10.1172/JCI24482; Gornalusse GG, 2015, P NATL ACAD SCI USA, V112, pE4762, DOI 10.1073/pnas.1423228112; Juffermans NP, 2000, BLOOD, V96, P2649; Kalsdorf B, 2013, EUR J IMMUNOL, V43, P540, DOI 10.1002/eji.201242804; Kauffman KD, 2018, MUCOSAL IMMUNOL, V11, P462, DOI 10.1038/mi.2017.60; Kohlmeier JE, 2011, J EXP MED, V208, P1621, DOI 10.1084/jem.20102110; Li C, 2005, INT J IMMUNOGENET, V32, P99, DOI 10.1111/j.I744-313X.2005.00498.x; Liu SY, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5738-6; Lyadova IV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010469; Mamtani M, 2011, J INFECT DIS, V203, P1590, DOI 10.1093/infdis/jir145; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Mummidi S, 2000, J BIOL CHEM, V275, P18946, DOI 10.1074/jbc.M000169200; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; National Health Commission of the People's Republic of China, 2018, CHIN J INFECT CONTRO, V17, P642; NHFPC, 2018, CHIN J INFECT CONTRO, V17, P367; Ometto L, 2001, J INFECT DIS, V183, P814, DOI 10.1086/318828; Pai M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.76; Picton ACP, 2010, INFECT GENET EVOL, V10, P487, DOI 10.1016/j.meegid.2010.02.012; Pokkali S, 2009, HUM IMMUNOL, V70, P110, DOI 10.1016/j.humimm.2008.11.003; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qiu LY, 2008, J INFECT DIS, V198, P1514, DOI 10.1086/592448; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; WHO, 2021, TUBERCULOSIS	35	2	3	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2021	11								544548	10.3389/fimmu.2020.544548	http://dx.doi.org/10.3389/fimmu.2020.544548			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR5ZY	33679683	Green Published, gold			2022-12-18	WOS:000625297600001
J	Mohapatra, SR; Sadik, A; Sharma, S; Poschet, G; Gegner, HM; Lanz, TV; Lucarelli, P; Klingmuller, U; Platten, M; Heiland, I; Opitz, CA				Mohapatra, Soumya R.; Sadik, Ahmed; Sharma, Suraj; Poschet, Gernot; Gegner, Hagen M.; Lanz, Tobias V.; Lucarelli, Philippe; Klingmueller, Ursula; Platten, Michael; Heiland, Ines; Opitz, Christiane A.			Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production	FRONTIERS IN IMMUNOLOGY			English	Article						liver; hypoxia; tryptophan; TDO2; regulation; AHR activity; hallucination; tryptamine		The liver is the central hub for processing and maintaining homeostatic levels of dietary nutrients especially essential amino acids such as tryptophan (Trp). Trp is required not only to sustain protein synthesis but also as a precursor for the production of NAD, neurotransmitters and immunosuppressive metabolites. In light of these roles of Trp and its metabolic products, maintaining homeostatic levels of Trp is essential for health and well-being. The liver regulates global Trp supply by the immunosuppressive enzyme tryptophan-2,3-dioxygenase (TDO2), which degrades Trp down the kynurenine pathway (KP). In the current study, we show that isolated primary hepatocytes when exposed to hypoxic environments, extensively rewire their Trp metabolism by reducing constitutive Tdo2 expression and differentially regulating other Trp pathway enzymes and transporters. Mathematical modelling of Trp metabolism in liver cells under hypoxia predicted decreased flux through the KP while metabolic flux through the tryptamine branch significantly increased. In line, the model also revealed an increased accumulation of tryptamines under hypoxia, at the expense of kynurenines. Metabolic measurements in hypoxic hepatocytes confirmed the predicted reduction in KP metabolites as well as accumulation of tryptamine. Tdo2 expression in cultured primary hepatocytes was reduced upon hypoxia inducible factor (HIF) stabilisation by dimethyloxalylglycine (DMOG), demonstrating that HIFs are involved in the hypoxic downregulation of hepatic Tdo2. DMOG abrogated hepatic luciferase signals in Tdo2 reporter mice, indicating that HIF stability also recapitulates hypoxic rewiring of Trp metabolism in vivo. Also in WT mice HIF stabilization drove homeostatic Trp metabolism away from the KP towards enhanced tryptamine production, leading to enhanced levels of tryptamine in liver, serum and brain. As tryptamines are the most potent hallucinogens known, the observed upregulation of tryptamine in response to hypoxic exposure of hepatocytes may be involved in the generation of hallucinations occurring at high altitude. KP metabolites are known to activate the aryl hydrocarbon receptor (AHR). The AHR-activating properties of tryptamines may explain why immunosuppressive AHR activity is maintained under hypoxia despite downregulation of the KP. In summary our results identify hypoxia as an important factor controlling Trp metabolism in the liver with possible implications for immunosuppressive AHR activation and mental disturbances.	[Mohapatra, Soumya R.; Sadik, Ahmed; Opitz, Christiane A.] German Canc Res Ctr, DKTK Brain Canc Metab Grp, Heidelberg, Germany; [Sharma, Suraj; Heiland, Ines] UiT Arctic Univ Norway, Dept Arctic & Marine Biol, Tromso, Norway; [Poschet, Gernot; Gegner, Hagen M.] Heidelberg Univ, Ctr Organismal Studies COS, Heidelberg, Germany; [Lanz, Tobias V.; Platten, Michael] German Canc Res Ctr, DKTK Clin Cooperat Unit Neuroimmunol & Brain Tumo, Heidelberg, Germany; [Lanz, Tobias V.; Platten, Michael] Heidelberg Univ, Med Fac Mannheim, Dept Neurol, Mannheim Ctr Translat Neurosci MCTN, Mannheim, Germany; [Lanz, Tobias V.] Stanford Univ, Dept Med, Sch Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA; [Lucarelli, Philippe; Klingmueller, Ursula] German Canc Res Ctr, Div Syst Biol Signal Transduct, Heidelberg, Germany; [Klingmueller, Ursula] German Ctr Lung Res DZL, Translat Lung Res Ctr TLRC, Heidelberg, Germany; [Opitz, Christiane A.] Univ Hosp Heidelberg, Neurol Clin, Heidelberg, Germany; [Opitz, Christiane A.] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); UiT The Arctic University of Tromso; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Stanford University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Opitz, CA (corresponding author), German Canc Res Ctr, DKTK Brain Canc Metab Grp, Heidelberg, Germany.; Opitz, CA (corresponding author), Univ Hosp Heidelberg, Neurol Clin, Heidelberg, Germany.; Opitz, CA (corresponding author), Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany.	c.opitz@dkfz.de	Opitz, Christiane A/I-9507-2012; Platten, Michael/F-2902-2013; Sadik, Ahmed/AAW-4920-2021	Opitz, Christiane A/0000-0001-5575-9821; Platten, Michael/0000-0002-4746-887X; Poschet, Gernot/0000-0002-5344-0865; Gegner, Hagen/0000-0001-7374-7197; Mohapatra, Soumya/0000-0002-4350-6410	BMBF e:Medinitiative [01ZX1402]; European Union [754688]; DFG [406052676, PL-315/5-1]; Liver Systems Medicine network [031L0042]	BMBF e:Medinitiative(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); DFG(German Research Foundation (DFG)); Liver Systems Medicine network	This work was supported by grants from the BMBF e:Medinitiative (GlioPATH, 01ZX1402), the European Union's Horizon 2020 research and innovation programme under Grant 754688 (MESI-STRAT), DFG grant 406052676, PL-315/5-1 and the Liver Systems Medicine network (LiSyM, 031L0042).	Anavi S, 2017, REDOX BIOL, V13, P386, DOI 10.1016/j.redox.2017.06.008; Araujo AM, 2015, ARCH TOXICOL, V89, P1151, DOI 10.1007/s00204-015-1513-x; Asrani SK, 2012, HEPATOLOGY, V56, P1160, DOI 10.1002/hep.25692; Ayabe H, 2018, STEM CELL REP, V11, P306, DOI 10.1016/j.stemcr.2018.06.015; Badawy AAB, 2017, INT J TRYPTOPHAN RES, V10, DOI 10.1177/1178646917691938; Barker SA, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00536; BENDER DA, 1983, MOL ASPECTS MED, V6, P101, DOI 10.1016/0098-2997(83)90005-5; Bergander LV, 2012, MOL ENDOCRINOL, V26, P1542, DOI 10.1210/me.2011-1351; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Cheng YT, 2015, DRUG METAB DISPOS, V43, P1536, DOI 10.1124/dmd.115.063677; Cheong JE, 2018, TRENDS PHARMACOL SCI, V39, P307, DOI 10.1016/j.tips.2017.11.007; Chua YL, 2010, J BIOL CHEM, V285, P31277, DOI 10.1074/jbc.M110.158485; Cursio R, 2008, TRANSPL P, V40, P2042, DOI 10.1016/j.transproceed.2008.05.037; Dean JG, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00232; Doherty DG, 2019, NAT BIOMED ENG, V3, P763, DOI 10.1038/s41551-019-0445-9; Doherty DG, 2016, J AUTOIMMUN, V66, P60, DOI 10.1016/j.jaut.2015.08.020; Fisher CD, 2008, ARCH TOXICOL, V82, P959, DOI 10.1007/s00204-008-0312-z; Flaveny CA, 2010, TOXICOL SCI, V114, P217, DOI 10.1093/toxsci/kfp308; Fuertig R, 2016, BIOANALYSIS, V8, P1903, DOI 10.4155/bio-2016-0111; Gao J, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00013; Greene SL, 2013, NOVEL PSYCHOACTIVE SUBSTANCES: CLASSIFICATION, PHARMACOLOGY AND TOXICOLOGY, P363, DOI 10.1016/B978-0-12-415816-0.00015-8; Grimaldi G, 2018, BIOCHEM BIOPH RES CO, V495, P2356, DOI 10.1016/j.bbrc.2017.12.113; Hara Y, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04334; He R., 2019, AABB ANN M; Heymann F, 2016, NAT REV GASTRO HEPAT, V13, P88, DOI 10.1038/nrgastro.2015.200; Hoops S, 2006, BIOINFORMATICS, V22, P3067, DOI 10.1093/bioinformatics/btl485; Jablonska O, 2010, INT J ANDROL, V33, P405, DOI 10.1111/j.1365-2605.2009.01031.x; Jin UH, 2014, MOL PHARMACOL, V85, P777, DOI 10.1124/mol.113.091165; Kietzmann T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092347; KNELL AJ, 1980, J ROY COLL PHYS LOND, V14, P205; Knolle PA, 2015, MED MICROBIOL IMMUN, V204, P21, DOI 10.1007/s00430-014-0371-0; KODAMA C, 1989, Osaka City Medical Journal, V35, P1; Kubli SP, 2019, P NATL ACAD SCI USA, V116, P3604, DOI 10.1073/pnas.1815126116; Lanz TV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41271; Li XY, 2013, CHEMOSPHERE, V93, P2488, DOI 10.1016/j.chemosphere.2013.08.092; Lohr C., 2013, EFFECTS POLYCHLORINA; Mejia-Garcia A, 2013, XENOBIOTICA, V43, P161, DOI 10.3109/00498254.2012.707790; Mohapatra SR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02762; Moon JO, 2009, AM J PHYSIOL-GASTR L, V296, pG582, DOI 10.1152/ajpgi.90368.2008; Mousseau DD, 1995, PROG BRAIN RES, V106, P277; MOUSSEAU DD, 1994, J NEUROCHEM, V62, P621; Mousseau DD, 1997, J NEUROCHEM, V68, P1200; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Nakamura K, 2007, HUM PATHOL, V38, P1532, DOI 10.1016/j.humpath.2007.03.002; Nasimuzzaman M, 2007, J VIROL, V81, P10249, DOI 10.1128/JVI.00763-07; Nath B, 2012, HEPATOLOGY, V55, P622, DOI 10.1002/hep.25497; Nath B, 2011, HEPATOLOGY, V53, P1526, DOI 10.1002/hep.24256; Okuda T, 2004, MOL CELL BIOL, V24, P3949, DOI 10.1128/MCB.24.9.3949-3956.2004; Opitz CA, 2007, CELL MOL LIFE SCI, V64, P2542, DOI 10.1007/s00018-007-7140-9; Opitz CA, 2020, BRIT J CANCER, V122, P30, DOI 10.1038/s41416-019-0664-6; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Ott M, 2015, GLIA, V63, P78, DOI 10.1002/glia.22734; Owczarek A, 2020, BIOCHIMIE, V171, P31, DOI 10.1016/j.biochi.2020.02.002; PARDRIDGE WM, 1979, J NEURAL TRANSM, P43; Pilotte L, 2012, P NATL ACAD SCI USA, V109, P2497, DOI 10.1073/pnas.1113873109; Platten M, 2019, NAT REV DRUG DISCOV, V18, P379, DOI 10.1038/s41573-019-0016-5; Protzer U, 2012, NAT REV IMMUNOL, V12, P201, DOI 10.1038/nri3169; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roager HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05470-4; Sadok I, 2019, J PHARMACEUT BIOMED, V176, DOI 10.1016/j.jpba.2019.112805; Sartor MA, 2009, ENVIRON HEALTH PERSP, V117, P1139, DOI 10.1289/ehp.0800485; Schadde E, 2017, SURGERY, V161, P666, DOI 10.1016/j.surg.2016.05.018; Schauble S, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1722-9; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Sobotta S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00775; Stavrum AK, 2013, J BIOL CHEM, V288, P34555, DOI 10.1074/jbc.M113.474908; Surani SR, 2016, WORLD J GASTROENTERO, V22, P6008, DOI 10.3748/wjg.v22.i26.6008; Suzuki T, 2014, WORLD J GASTROENTERO, V20, P15087, DOI 10.3748/wjg.v20.i41.15087; Szabo A, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00423; Tamagawa K, 2008, J SURG RES, V148, P158, DOI 10.1016/j.jss.2007.12.787; Tanaka H, 2006, CANCER RES, V66, P11263, DOI 10.1158/0008-5472.CAN-06-1699; Tanos R, 2012, HEPATOLOGY, V55, P1994, DOI 10.1002/hep.25571; Tiegs G, 2010, J AUTOIMMUN, V34, P1, DOI 10.1016/j.jaut.2009.08.008; Wenger RH, 2015, HYPOXIA, V3, P35, DOI 10.2147/HP.S92198; You N, 2017, J BIOINF COMPUT BIOL, V15, DOI 10.1142/S0219720017500202; YOUNG SN, 1980, J NEURAL TRANSM, V47, P153, DOI 10.1007/BF01250597	76	2	2	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2021	12								590532	10.3389/fimmu.2021.590532	http://dx.doi.org/10.3389/fimmu.2021.590532			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR6AJ	33679737	Green Published, gold			2022-12-18	WOS:000625298800001
J	Nourkami-Tutdibi, N; Freitag, K; Zemlin, M; Tutdibi, E				Nourkami-Tutdibi, Nasenien; Freitag, Klemens; Zemlin, Michael; Tutdibi, Erol			Genetic Association With Pseudomonas aeruginosa Acquisition in Cystic Fibrosis: Influence of Surfactant Protein D and Mannose-Binding Lectin	FRONTIERS IN IMMUNOLOGY			English	Article						cystic fibrosis; Pseudomonas aeruginosa; surfactant protein D; SFTPD; mannose-binding protein; MBL; biomarker; gene polymorphisms		Background: Pseudomonas aeruginosa (PA) infection in cystic fibrosis (CF) is associated with poor prognosis. Surfactant protein-D (SFTPD) and mannose-binding lectin (MBL) play a critical role in innate immunity and response to bacterial infections. We investigated serum levels and genetic variants of SFTPD and MBL in CF patients. Method: Thirty-five Caucasian patients homozygous for Delta F508del were genotyped for functional relevant polymorphisms within MBL2 (promoter-221 Y/X, codons 52, 54, and 57) and SFTPD genes (Met11Thr, Ala160Thr, and Ser270Thr). Serum levels of collectins, clinical characteristics, and PA status were correlated with genetic data. Results: Patients age, gender, and PA status did not affect MBL and SFTPD serum concentrations. MBL concentrations were correlated with MBL haplotypes. Patients with chronic Pseudomonas aeroginosa infection (PAC) and MBL insufficiency had a shorter interval between first PA infection and onset of PAC (0.01 vs. 4.6 years, p < 0.04) as well as a lower median age at transition to PAC (9.8 vs. 16.4 years, p < 0.03) compared to MBL sufficient patients with PAC. SFTPD serum level and FEV1% (Spearman r = -0.41, p < 0.03) showed a negative correlation irrespective of PA infection status. The hazard ratio to PA acquisition was increased in carriers of the SFTPD haplotype 11Thr-160Ala-270Ser compared to carriers of the common 11Met-160Thr-270Ser haplotype [HR 3.0 (95%CI: 1.1-8.6), p < 0.04]. Conclusion: MBL insufficiency leads to a shorter interval between first PA infection and onset of chronic infection. Susceptibility to PA acquisition is associated with SFTPD genetic variants with 11Thr-160Ala-270Ser as risk haplotype for early PA infection. This may be due to presence of threonine associated with oligomeric structure of SFTPD and binding ability to bacteria.	[Nourkami-Tutdibi, Nasenien; Freitag, Klemens; Zemlin, Michael; Tutdibi, Erol] Saarland Univ, Hosp Gen Pediat & Neonatol, Med Ctr, Homburg, Germany	Universitatsklinikum des Saarlandes	Nourkami-Tutdibi, N (corresponding author), Saarland Univ, Hosp Gen Pediat & Neonatol, Med Ctr, Homburg, Germany.	nasenien.nourkami@uks.eu		Zemlin, Michael/0000-0001-9528-7419	Saarland University, Medical Faculty (HOMFOR)	Saarland University, Medical Faculty (HOMFOR)	This study was supported by grant for research from Saarland University, Medical Faculty (HOMFOR).	Atochina-Vasserman EN, 2012, BBA-GEN SUBJECTS, V1820, P763, DOI 10.1016/j.bbagen.2011.12.006; Chalmers JD, 2020, LANCET RESP MED, V8, P12, DOI 10.1016/S2213-2600(19)30335-2; Chalmers JD, 2013, LANCET RESP MED, V1, P224, DOI 10.1016/S2213-2600(13)70001-8; Chalmers JD, 2011, GLYCOBIOLOGY, V21, P271, DOI 10.1093/glycob/cwq161; CROUCH E, 1993, J BIOL CHEM, V268, P2976; Cunningham S, 2019, LANCET RESP MED, V7, P995, DOI 10.1016/S2213-2600(19)30405-9; Di Paola M, 2017, MBIO, V8, DOI 10.1128/mBio.02073-17; Fakih D, 2018, RESPIROLOGY, V23, P298, DOI 10.1111/resp.13193; Floros J, 2000, J INFECT DIS, V182, P1473, DOI 10.1086/315866; Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Garred P, 2002, PEDIATR PULM, V33, P201, DOI 10.1002/ppul.10064; Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468; Glas J, 2008, TISSUE ANTIGENS, V72, P21, DOI 10.1111/j.1399-0039.2008.01056.x; Griese M, 1999, EUR RESPIR J, V13, P1455, DOI 10.1183/09031936.99.13614779; Griese M, 2005, PEDIATR PULM, V40, P378, DOI 10.1002/ppul.20295; Griese M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051050; Haerynck F, 2012, HUM IMMUNOL, V73, P1175, DOI 10.1016/j.humimm.2012.08.010; Hartl D, 2006, EUR J CLIN INVEST, V36, P423, DOI 10.1111/j.1365-2362.2006.01648.x; Heidinger K, 2005, IMMUNOGENETICS, V57, P1, DOI 10.1007/s00251-005-0775-5; Hilgendorff A, 2009, ACTA PAEDIATR, V98, P112, DOI 10.1111/j.1651-2227.2008.01014.x; Hsieh MH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01543; Husby S, 2002, IMMUNOLOGY, V106, P389, DOI 10.1046/j.1365-2567.2002.01436.x; Kalia N, 2019, IMMUNOBIOLOGY, V224, P42, DOI 10.1016/j.imbio.2018.10.009; Kiedrowski MR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03067; Kotecha S, 2013, BBA-MOL BASIS DIS, V1832, P2391, DOI 10.1016/j.bbadis.2013.10.002; Krane M, 2003, EUR RESPIR J, V22, P592, DOI 10.1183/09031936.03.00060603; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Lahti M, 2002, PEDIATR RES, V51, P696, DOI [10.1203/00006450-200206000-00006, 10.1023/01.PDR.0000015911.65104.93]; Lee AC, 2018, PAEDIATR RESPIR REV, V27, P18, DOI 10.1016/j.prrv.2018.05.009; Lee Tim W R, 2003, J Cyst Fibros, V2, P29, DOI 10.1016/S1569-1993(02)00141-8; Lenney W, 2015, PAEDIATR RESPIR REV, V16, P35, DOI 10.1016/j.prrv.2015.07.016; Leth-Larsen R, 2005, J IMMUNOL, V174, P1532, DOI 10.4049/jimmunol.174.3.1532; Lin ZW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02256; Mackay RMA, 2016, CHEST, V149, P1165, DOI 10.1016/j.chest.2015.11.012; MADSEN HO, 1995, J IMMUNOL, V155, P3013; McCormick J, 2010, LANCET, V375, P1007, DOI 10.1016/S0140-6736(09)62161-9; Nayak A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00131; Olesen HV, 2010, J CYST FIBROS, V9, P257, DOI 10.1016/j.jcf.2010.03.011; Pifferi M, 2015, PEDIATR PULM, V50, P179, DOI 10.1002/ppul.23026; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Sorensen M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00096; Sorensen GL, 2006, AM J PHYSIOL-LUNG C, V290, pL1010, DOI 10.1152/ajplung.00487.2005; Sorensen GL, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00018; Sorensen GL, 2007, IMMUNOBIOLOGY, V212, P381, DOI 10.1016/j.imbio.2007.01.003; Sosnay PR, 2013, NAT GENET, V45, P1160, DOI 10.1038/ng.2745; VanDevanter DR, 2016, J CYST FIBROS, V15, P147, DOI 10.1016/j.jcf.2015.09.008; Videbaek K, 2019, PEDIATR PULM, V54, P1182, DOI 10.1002/ppul.24346; von Bredow C, 2003, LUNG, V181, P79, DOI 10.1007/s00408-003-1008-z; Wolter DJ, 2019, LANCET RESP MED, V7, P1027, DOI 10.1016/S2213-2600(19)30365-0; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200	51	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2021	12								587313	10.3389/fimmu.2021.587313	http://dx.doi.org/10.3389/fimmu.2021.587313			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS3UM	33679736	Green Published, gold			2022-12-18	WOS:000625827200001
J	Pollastro, S; de Bourayne, M; Balzaretti, G; Jongejan, A; van Schaik, BDC; Niewold, ITG; van Kampen, AHC; Maillere, B; de Vries, N				Pollastro, Sabrina; de Bourayne, Marie; Balzaretti, Giulia; Jongejan, Aldo; van Schaik, Barbera D. C.; Niewold, Ilse T. G.; van Kampen, Antoine H. C.; Maillere, Bernard; de Vries, Niek			Characterization and Monitoring of Antigen-Responsive T Cell Clones Using T Cell Receptor Gene Expression Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						T-cell receptor; adaptive immune receptor repertoire; T cell responses; next generation sequencing; bioinformatics; immunoinformatics	REPERTOIRES	High-throughput T-cell receptor repertoire sequencing constitutes a powerful tool to study T cell responses at the clonal level. However, it does not give information on the functional phenotype of the responding clones and lacks a statistical framework for quantitative evaluation. To overcome this, we combined datasets from different experiments, all starting from the same blood samples. We used a novel, sensitive, UMI-based protocol to perform repertoire analysis on experimental replicates. Applying established bioinformatic routines for transcriptomic expression analysis we explored the dynamics of antigen-induced clonal expansion after in vitro stimulation, identified antigen-responsive clones, and confirmed their activation status using the expression of activation markers upon antigen re-challenge. We demonstrate that the addition of IL-4 after antigen stimulation drives the expansion of T cell clones encoding unique receptor sequences. We show that our approach represents a scalable, high-throughput immunological tool, which can be used to identify and characterize antigen-responsive T cells at clonal level.	[Pollastro, Sabrina; Balzaretti, Giulia; Niewold, Ilse T. G.; de Vries, Niek] Univ Amsterdam, Dept Clin Immunol & Rheumatol, Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam UMC,Locat AMC, Amsterdam, Netherlands; [Pollastro, Sabrina; Balzaretti, Giulia; de Vries, Niek] Univ Amsterdam, Dept Expt Immunol, Amsterdam Infect & Immun Inst AIII, Amsterdam UMC,Locat AMC, Amsterdam, Netherlands; [de Bourayne, Marie; Maillere, Bernard] Univ Paris Saclay, Dept Medicaments & Technol Sante, INRAE, CEA,SIMoS, Gif Sur Yvette, France; [Jongejan, Aldo; van Schaik, Barbera D. C.; van Kampen, Antoine H. C.] Univ Amsterdam, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam Infect & Immun Inst AIII, Amsterdam Publ Hlth Res Inst,Amsterdam UMC,Locat, Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; CEA; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Amsterdam; Vrije Universiteit Amsterdam	de Vries, N (corresponding author), Univ Amsterdam, Dept Clin Immunol & Rheumatol, Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam UMC,Locat AMC, Amsterdam, Netherlands.; de Vries, N (corresponding author), Univ Amsterdam, Dept Expt Immunol, Amsterdam Infect & Immun Inst AIII, Amsterdam UMC,Locat AMC, Amsterdam, Netherlands.	n.devries1@amsterdamumc.nl		Pollastro, Sabrina/0000-0002-0950-7583	Innovative Medicines Initiative Joint Undertaking from the European Union's Seventh Framework Programme (FP7/2007-2013) [115303]; ZonMw, the Netherlands Organisation for Health Research and Development [436001001]	Innovative Medicines Initiative Joint Undertaking from the European Union's Seventh Framework Programme (FP7/2007-2013); ZonMw, the Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115303 (ABIRISK), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution and was also supported by ZonMw, the Netherlands Organisation for Health Research and Development, in the program 2Treat (Grant 436001001).	Afik S, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx615; Becattini S, 2015, SCIENCE, V347, P400, DOI 10.1126/science.1260668; Bethune MT, 2018, P NATL ACAD SCI USA, V115, pE10702, DOI 10.1073/pnas.1810653115; Chemin K, 2016, ARTHRITIS RHEUMATOL, V68, P1124, DOI 10.1002/art.39553; Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383; Di Genova G, 2010, EUR J IMMUNOL, V40, P976, DOI 10.1002/eji.200940017; Eltahla AA, 2016, IMMUNOL CELL BIOL, V94, P604, DOI 10.1038/icb.2016.16; GELDER CM, 1995, J VIROL, V69, P7497, DOI 10.1128/JVI.69.12.7497-7506.1995; Giudicelli W, 2005, NUCLEIC ACIDS RES, V33, pD256, DOI 10.1093/nar/gki010; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Hamze M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00500; Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830; Klarenbeek PL, 2010, IMMUNOL LETT, V133, P42, DOI 10.1016/j.imlet.2010.06.011; Klinger M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074231; Leen A, 2001, J VIROL, V75, P8649, DOI 10.1128/JVI.75.18.8649-8659.2001; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Linnemann C, 2013, NAT MED, V19, P1534, DOI 10.1038/nm.3359; MacQueen J., 1967, 5 BERK S MATH STAT P, V1, P281; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Oakes T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00162; Pira GL, 2004, INT IMMUNOL, V16, P635, DOI 10.1093/intimm/dxh065; Qi Q, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1725; Reddy ST, 2017, NATURE, V547, P36, DOI 10.1038/nature23091; Redmond D, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0335-7; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rodriguez MZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210236; Ruggiero E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9081; Simon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01962; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Whitmire JK, 2006, J IMMUNOL, V176, P3028, DOI 10.4049/jimmunol.176.5.3028; Woodsworth DJ, 2013, GENOME MED, V5, DOI 10.1186/gm502; Zemmour D, 2018, NAT IMMUNOL, V19, P291, DOI 10.1038/s41590-018-0051-0; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593	34	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2021	11								609624	10.3389/fimmu.2020.609624	http://dx.doi.org/10.3389/fimmu.2020.609624			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS3KG	33679697	Green Published, gold			2022-12-18	WOS:000625800600001
J	Shahar, M; Szalat, A; Rosen, H				Shahar, Michal; Szalat, Auryan; Rosen, Haim			Pathogenic Stress Induces Human Monocyte to Express an Extracellular Web of Tunneling Nanotubes	FRONTIERS IN IMMUNOLOGY			English	Article						monocyte; tunneling nanotubes; pathogen-associated molecular pattern; innate immunity; toll like receptor		Actin-based tunneling nanotubes are a means of intercellular communication between remote cells. In the last decade, this type of nanotube was described in a wide variety of cell types and it became widely accepted that communication through these nanotubes is related to response to environmental changes. Few reports, however, are available regarding the expression of similar nanotubes in vivo or in primary cells. Moreover, the functional significance of this intercellular communication for health and disease is largely unknown. In this context, and as a first step in unraveling these questions, we examined the formation of similar nanotubes in primary peripheral human monocytes. To that end, we combined the use of a live cell imaging system along with advanced methods of fluorescent and scanning electron microscopy. This experimental approach reveals for the first time that the bacterial lipopolysaccharide endotoxin induces a transient expression of an unexpected abundance of actin-based tunneling nanotubes associated with vesicles. In addition, it was found that a similar response can be achieved by treating human monocytes with various bacterial and yeast membrane components, as well as with a viral component analog. In all these cases, this response is mediated by distinct complexes of toll-like receptors. Therefore, we suggest that the observed phenomena are related to a broad type of monocyte pathogen response, and raise the possibility that the phenomena described above may be involved in many clinical situations related to inflammation as a new topic of study.	[Shahar, Michal] Hebrew Univ Hadassah Med Ctr, Inst Med Res Israel Canada, Dept Microbiol & Mol Genet, Jerusalem, Israel; [Szalat, Auryan] Hadassah Hebrew Univ Med Ctr, Dept Internal Med, Jerusalem, Israel; [Rosen, Haim] Hebrew Univ Hadassah Med Sch, Inst Med Res Israel Canada, Kuvin Ctr Study Infect & Trop Dis, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Szalat, A (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Internal Med, Jerusalem, Israel.	auryans@hadassah.org.il			Joint Research Fund of the Hebrew University; Hadassah University Hospital [6058105]	Joint Research Fund of the Hebrew University; Hadassah University Hospital	The study was supported by The Joint Research Fund of the Hebrew University and Hadassah University Hospital (Grant Number 6058105).	Abounit Saida, 2015, Curr Protoc Cell Biol, V67, DOI 10.1002/0471143030.cb1210s67; Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279; Ady JW, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00400; Alarcon-Martinez L, 2020, NATURE, V585, P91, DOI 10.1038/s41586-020-2589-x; Antanaviciute I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099196; Astanina K, 2015, SCI REP-UK, V5, DOI 10.1038/srep11453; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Bittins M, 2017, J CELL PHYSIOL, V232, P2271, DOI 10.1002/jcp.25584; Chauveau A, 2010, P NATL ACAD SCI USA, V107, P5545, DOI 10.1073/pnas.0910074107; Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779; Costanzo M, 2013, J CELL SCI, V126, P3678, DOI 10.1242/jcs.126086; D'Aloia A, 2018, EXP CELL RES, V362, P349, DOI 10.1016/j.yexcr.2017.11.036; Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399; Desir S, 2016, ONCOTARGET, V7, P43150, DOI 10.18632/oncotarget.9504; Dieriks BV, 2017, SCI REP-UK, V7, DOI 10.1038/srep42984; Doster RS, 2018, J INNATE IMMUN, V10, P3, DOI 10.1159/000480373; Drab M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060626; Dupont M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00043; Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Goeijenbier M, 2012, J MED VIROL, V84, P1680, DOI 10.1002/jmv.23354; Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Guo R, 2016, J VIROL, V90, P5163, DOI 10.1128/JVI.00036-16; Hanna SJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08950-7; Hashimoto M, 2016, J IMMUNOL, V196, P1832, DOI 10.4049/jimmunol.1500845; Ikeda U, 1998, CLIN CARDIOL, V21, P11, DOI 10.1002/clc.4960210103; Ingersoll MA, 2011, TRENDS IMMUNOL, V32, P470, DOI 10.1016/j.it.2011.05.001; Jackson MV, 2016, STEM CELLS, V34, P2210, DOI 10.1002/stem.2372; Kazzaz NM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00453; Korenkova O, 2020, CELL STRESS, V4, P30, DOI 10.15698/cst2020.02.212; Kumar A, 2017, SCI REP-UK, V7, DOI 10.1038/srep40360; Liu KM, 2014, MICROVASC RES, V92, P10, DOI 10.1016/j.mvr.2014.01.008; Lou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033093; Luchetti F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035766; Marzo L, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00072; Matula Z, 2016, STEM CELLS DEV, V25, P1818, DOI 10.1089/scd.2016.0086; Mittal R, 2019, J CELL PHYSIOL, V234, P1130, DOI 10.1002/jcp.27072; Naphade S, 2015, STEM CELLS, V33, P301, DOI 10.1002/stem.1835; Omsland M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29391-w; Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511; Panasiuk M, 2018, J VIROL, V92, DOI [10.1128/JVI.00090-18, 10.1128/jvi.00090-18]; Parker I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11223-y; Rainy N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.245; Rossol M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2339; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Saenz-de-Santa-Maria I, 2017, ONCOTARGET, V8, P20939, DOI 10.18632/oncotarget.15467; Sartori-Rupp A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08178-7; Sharma M, 2019, J CELL BIOL, V218, P1972, DOI 10.1083/jcb.201807068; Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682; Valdebenito S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101450; Vallabhaneni KC, 2012, STEM CELLS DEV, V21, P3104, DOI 10.1089/scd.2011.0691; Vignais ML, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6917941; Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009; Weil S, 2017, NEURO-ONCOLOGY, V19, P1316, DOI 10.1093/neuonc/nox070	55	2	2	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2021	12								620734	10.3389/fimmu.2021.620734	http://dx.doi.org/10.3389/fimmu.2021.620734			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QS4IP	33679763	gold, Green Published			2022-12-18	WOS:000625863900001
J	Burwick, RM; Lokki, AI; Fleming, SD; Regal, JF				Burwick, Richard M.; Lokki, A. Inkeri; Fleming, Sherry D.; Regal, Jean F.			Editorial: Innate Immunity in Normal and Adverse Pregnancy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate immunity; complement; pregnancy; innate lymphoid cells; infection	IMPLANTATION; SYSTEM		[Burwick, Richard M.] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, Los Angeles, CA 90048 USA; [Lokki, A. Inkeri] Univ Helsinki, Bacteriol & Immunol, Helsinki, Finland; [Lokki, A. Inkeri] Univ Helsinki, Translat Immunol Res Program, Res Programs Unit, Helsinki, Finland; [Lokki, A. Inkeri] Univ Helsinki, Helsinki Univ Hosp, Obstet & Gynecol, Helsinki, Finland; [Fleming, Sherry D.] Kansas State Univ, Div Biol, Manhattan, KS 66506 USA; [Regal, Jean F.] Univ Minnesota, Med Sch, Dept Biomed Sci, Duluth, MN 55812 USA	Cedars Sinai Medical Center; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Kansas State University; University of Minnesota System; University of Minnesota Duluth	Regal, JF (corresponding author), Univ Minnesota, Med Sch, Dept Biomed Sci, Duluth, MN 55812 USA.	jregal@d.umn.edu	Lokki, A. Inkeri/H-4783-2019	Lokki, A. Inkeri/0000-0003-4397-8415	American Heart Association [17GRNT33650049]; NIH [R21HD100840, P20GM103418]; Defense Medical Research and Development Program [W81XWH-18-10716]	American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defense Medical Research and Development Program	This work was funded in part by the American Heart Association 17GRNT33650049 (JR and SF), NIH R21HD100840 (JR), P20GM103418 (SF), and the Defense Medical Research and Development Program under Award No. W81XWH-18-10716 (SF).	Kim MY, 2018, ANN RHEUM DIS, V77, P549, DOI 10.1136/annrheumdis-2017-212224; Makatsariya AD, 2022, J MATERN-FETAL NEO M, V35, P2536, DOI 10.1080/14767058.2020.1786811; MINKOFF H, 1983, OBSTET GYNECOL, V62, P137; Mor G, 2011, ANN NY ACAD SCI, V1221, P80, DOI 10.1111/j.1749-6632.2010.05938.x; Plaks V, 2008, J CLIN INVEST, V118, P3954, DOI 10.1172/JCI36682; Plummer MD, 2021, J DEV ORIG HLTH DIS, V12, P555, DOI 10.1017/S2040174420000896; Regal JF, 2015, MOL IMMUNOL, V67, P56, DOI 10.1016/j.molimm.2015.02.030; Rodrigues C, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.558144; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017	9	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2021	12								646596	10.3389/fimmu.2021.646596	http://dx.doi.org/10.3389/fimmu.2021.646596			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR3RI	33679810	Green Published, gold			2022-12-18	WOS:000625129300001
J	Giehl, E; Kosaka, H; Liu, ZQ; Feist, M; Kammula, US; Lotze, MT; Ma, CR; Guo, ZS; Bartlett, DL				Giehl, Esther; Kosaka, Hiromichi; Liu, Zuqiang; Feist, Mathilde; Kammula, Udai S.; Lotze, Michael T.; Ma, Congrong; Guo, Zong Sheng; Bartlett, David L.			In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						oncolytic virus; CD8(+) T cells; IL-15; adoptive cell therapy (ACT); solid tumor		Adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TIL) achieves durable clinical benefit for patients from whom these cells can be derived in advanced metastatic melanoma but is limited in most solid tumors as a result of immune escape and exclusion. A tumor microenvironment (TME) priming strategy to improve the quantity and quality of TIL represents an important tactic to explore. Oncolytic viruses expressing immune stimulatory cytokines induce a potent inflammatory response that may enhance infiltration and activation of T cells. In this study, we examined the ability of an attenuated oncolytic vaccinia virus expressing IL15/IL15R alpha (vvDD-IL15/R alpha) to enhance recovery of lavage T cells in peritoneal carcinomatosis (PC). We found that intraperitoneal (IP) vvDD-IL15/R alpha treatment of animals bearing PC resulted in a significant increase in cytotoxic function and memory formation in CD8(+) T cells in peritoneal fluid. Using tetramers for vaccinia virus B8R antigen and tumor rejection antigen p15E, we found that the expanded population of peritoneal CD8(+) T cells are specific for vaccinia or tumor with increased tumor-specificity over time, reinforced with viral clearance. Application of these vvDD-IL15/R alpha induced CD8(+) T cells in ACT of a lethal model of PC significantly increased survival. In addition, we found in patients with peritoneal metastases from various primary solid tumors that peritoneal T cells could be recovered but were exhausted with infrequent tumor-reactivity. If clinically translatable, vvDD-IL15/R alpha in vivo priming would greatly expand the number of patients with advanced metastatic cancers responsive to T cell therapy.	[Giehl, Esther; Kosaka, Hiromichi; Liu, Zuqiang; Feist, Mathilde; Kammula, Udai S.; Lotze, Michael T.; Ma, Congrong; Guo, Zong Sheng; Bartlett, David L.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; [Giehl, Esther; Kosaka, Hiromichi; Liu, Zuqiang; Feist, Mathilde; Kammula, Udai S.; Lotze, Michael T.; Ma, Congrong; Guo, Zong Sheng; Bartlett, David L.] UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA; [Giehl, Esther] Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany; [Kosaka, Hiromichi] Kyowa Kirin Co Ltd, Oncol Res Labs Oncol R&D Unit, Shizuoka, Japan; [Feist, Mathilde] Charite Univ Med Berlin, Dept Surg, CCM CVK, Berlin, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Kyowa Kirin Ltd; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Guo, ZS; Bartlett, DL (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.; Guo, ZS; Bartlett, DL (corresponding author), UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA.	GuoxZS@upmc.edu; David.Bartlett@ahn.org		Feist, Mathilde/0000-0002-6107-5490	German Research Foundation (DFG research fellowships) [1408/1-1, 1655/1-1]; UPMC Immune Transplant and Therapy Center; NIH [P30CA047904]	German Research Foundation (DFG research fellowships)(German Research Foundation (DFG)); UPMC Immune Transplant and Therapy Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	EG and MF were supported in part by German Research Foundation (DFG research fellowships 1408/1-1 and 1655/1-1, respectively). This work was supported in part by The UPMC Immune Transplant and Therapy Center. This project used University of Pittsburgh shared core facilities (including the Animal Facility, Genomics Research Core, and Flow Cytometry and Small Animal Imaging services) supported in part by NIH award P30CA047904.	Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Bessard A, 2009, MOL CANCER THER, V8, P2736, DOI 10.1158/1535-7163.MCT-09-0275; Chandran SS, 2017, LANCET ONCOL, V18, P792, DOI 10.1016/S1470-2045(17)30251-6; Cieri N, 2013, BLOOD, V121, P573, DOI 10.1182/blood-2012-05-431718; Corgnac S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01904; Dafni U, 2019, ANN ONCOL, V30, P1902, DOI 10.1093/annonc/mdz398; Demaria S, 2010, J IMMUNOTHER, V33, P335, DOI 10.1097/CJI.0b013e3181d32e74; Downs-Canner S, 2016, MOL THER, V24, P1492, DOI 10.1038/mt.2016.101; Engelhardt JJ, 2012, CANCER CELL, V21, P402, DOI 10.1016/j.ccr.2012.01.008; Epardaud M, 2008, CANCER RES, V68, P2972, DOI 10.1158/0008-5472.CAN-08-0045; Feist M, 2021, CANCER GENE THER, V28, P98, DOI 10.1038/s41417-020-0189-4; FOULDS S, 1993, BRIT J CANCER, V68, P610, DOI 10.1038/bjc.1993.395; Gaston DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081768; Guo ZS, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-018-0495-7; Guo ZS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00555; Han JF, 2020, CANCER IMMUNOL RES, V8, P146, DOI 10.1158/2326-6066.CIR-19-0398; Kim JW, 2016, GASTRIC CANCER, V19, P42, DOI 10.1007/s10120-014-0440-5; Kim KH, 2021, CELL MOL IMMUNOL, V18, P385, DOI 10.1038/s41423-020-0427-6; Kim PS, 2016, ONCOTARGET, V7, P16130, DOI 10.18632/oncotarget.7470; Kowalsky SJ, 2018, MOL THER, V26, P2476, DOI 10.1016/j.ymthe.2018.07.013; Kubicka U, 1996, SCAND J IMMUNOL, V44, P157, DOI 10.1046/j.1365-3083.1996.d01-297.x; Lauer UM, 2018, CLIN CANCER RES, V24, P4388, DOI 10.1158/1078-0432.CCR-18-0244; Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064; Liu ZQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06954-z; Ni J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1219009; Park AK, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz1863; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Peng WY, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-4363; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rohaan MW, 2019, VIRCHOWS ARCH, V474, P449, DOI 10.1007/s00428-018-2484-0; Romee R, 2018, BLOOD, V131, P2515, DOI 10.1182/blood-2017-12-823757; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Schenkel JM, 2016, J IMMUNOL, V196, P3920, DOI 10.4049/jimmunol.1502337; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shaw AR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02103; Singh AK, 2020, LANCET ONCOL, V21, pE168, DOI 10.1016/S1470-2045(19)30823-X; Spranger S, 2016, INT IMMUNOL, V28, P383, DOI 10.1093/intimm/dxw014; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Stephenson KB, 2012, CANCER GENE THER, V19, P238, DOI 10.1038/cgt.2011.81; Stevanovic S, 2019, CLIN CANCER RES, V25, P1486, DOI 10.1158/1078-0432.CCR-18-2722; Sugiura A, 2018, J IMMUNOL, V200, P400, DOI 10.4049/jimmunol.1701041; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Van den Bergh J, 2015, ONCOTARGET, V6, P44123, DOI 10.18632/oncotarget.6536; Van den Bergh JMJ, 2015, CYTOKINE GROWTH F R, V26, P15, DOI 10.1016/j.cytogfr.2014.09.001; Waldmann TA, 2015, CANCER IMMUNOL RES, V3, P219, DOI 10.1158/2326-6066.CIR-15-0009; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Wing A, 2018, CANCER IMMUNOL RES, V6, P605, DOI 10.1158/2326-6066.CIR-17-0314; Wrangle JM, 2018, LANCET ONCOL, V19, P694, DOI 10.1016/S1470-2045(18)30148-7; Yang YP, 2015, J CLIN INVEST, V125, P3335, DOI 10.1172/JCI83871; Zeh HJ, 2015, MOL THER, V23, P202, DOI 10.1038/mt.2014.194; Zeh HJ, 1999, J IMMUNOL, V162, P989	51	2	2	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2021	12								610042	10.3389/fimmu.2021.610042	http://dx.doi.org/10.3389/fimmu.2021.610042			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR3YA	33679747	gold, Green Published			2022-12-18	WOS:000625146900001
J	Hu, J; Liu, T; Han, B; Tan, SS; Guo, H; Xin, Y				Hu, Jie; Liu, Tie; Han, Bo; Tan, Shishan; Guo, Hua; Xin, Yu			Immunotherapy: A Potential Approach for High-Grade Spinal Cord Astrocytomas	FRONTIERS IN IMMUNOLOGY			English	Review						spinal cord astrocytomas; immunotherapy; immune checkpoint inhibitors; CAR-T therapy; therapeutic vaccines therapy; K27M-mutant histone H3		Spinal cord astrocytomas (SCAs) account for 6-8% of all primary spinal cord tumors. For high-grade SCAs, the prognosis is often poor with conventional therapy, thus the urgent need for novel treatments to improve patient survival. Immunotherapy is a promising therapeutic strategy and has been used to treat cancer in recent years. Several clinical trials have evaluated immunotherapy for intracranial gliomas, providing evidence for immunotherapy-mediated ability to inhibit tumor growth. Given the unique microenvironment and molecular biology of the spinal cord, this review will offer new perspectives on moving toward the application of successful immunotherapy for SCAs based on the latest studies and literature. Furthermore, we will discuss the challenges associated with immunotherapy in SCAs, propose prospects for future research, and provide a periodic summary of the current state of immunotherapy for SCAs immunotherapy.	[Hu, Jie; Liu, Tie; Han, Bo; Tan, Shishan; Xin, Yu] Capital Med Univ, Dept Neurosurg, Beijing Tiantan Hosp, Beijing, Peoples R China; [Guo, Hua] Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China	Capital Medical University; Nanchang University	Xin, Y (corresponding author), Capital Med Univ, Dept Neurosurg, Beijing Tiantan Hosp, Beijing, Peoples R China.	hj960803@ccmu.edu.cn						Abd-El-Barr MM, 2018, NEURO-ONCOLOGY, V20, P729, DOI 10.1093/neuonc/nox230; Ahmed N, 2017, JAMA ONCOL, V3, P1094, DOI 10.1001/jamaoncol.2017.0184; Aihara K, 2014, NEURO-ONCOLOGY, V16, P140, DOI 10.1093/neuonc/not144; Alvi MA, 2019, MODERN PATHOL, V32, P1236, DOI 10.1038/s41379-019-0271-3; Bahney J, 2018, ANAT REC, V301, P697, DOI 10.1002/ar.23728; Banan R, 2017, ACTA NEUROCHIR, V159, P403, DOI 10.1007/s00701-016-3062-3; Bartanusz V, 2011, ANN NEUROL, V70, P194, DOI 10.1002/ana.22421; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Carpentier A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6086; Chai RC, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00913-w; Chamberlain MC, 2011, CURR NEUROL NEUROSCI, V11, P320, DOI 10.1007/s11910-011-0190-2; Chen ZH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01004; Chheda ZS, 2018, J EXP MED, V215, P141, DOI 10.1084/jem.20171046; Chow KKH, 2013, MOL THER, V21, P629, DOI 10.1038/mt.2012.210; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Ellis JA, 2015, J NEURO-ONCOL, V123, P27, DOI 10.1007/s11060-015-1769-2; England B, 2013, TUMOR BIOL, V34, P2063, DOI 10.1007/s13277-013-0871-3; Garber ST, 2016, NEURO-ONCOLOGY, V18, P1357, DOI 10.1093/neuonc/now132; Gessi M, 2015, ACTA NEUROPATHOL, V130, P435, DOI 10.1007/s00401-015-1463-7; Goff SL, 2019, J IMMUNOTHER, V42, P126, DOI 10.1097/CJI.0000000000000260; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; Jha P, 2019, NEUROPATHOLOGY, V39, P413, DOI 10.1111/neup.12594; Johnson A, 2017, ONCOLOGIST, V22, P1478, DOI 10.1634/theoncologist.2017-0242; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Klekamp J, 2013, J NEUROSURG-SPINE, V19, P12, DOI 10.3171/2013.3.SPINE121063; Kwok D, 2020, J NEURO-ONCOL, V147, P281, DOI 10.1007/s11060-020-03450-7; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lyon JG, 2017, ADV DRUG DELIVER REV, V114, P19, DOI 10.1016/j.addr.2017.06.006; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Mount CW, 2018, NAT MED, V24, P572, DOI 10.1038/s41591-018-0006-x; Nagaishi M, 2016, BRAIN TUMOR PATHOL, V33, P267, DOI 10.1007/s10014-016-0263-7; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; Ochs K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1328340; Raco A, 2005, NEUROSURGERY, V56, P972, DOI 10.1227/01.NEU.0000158318.66568.CC; Reardon DA, 2016, CANCER IMMUNOL RES, V4, P124, DOI 10.1158/2326-6066.CIR-15-0151; Sampson JH, 2020, NAT REV CANCER, V20, P12, DOI 10.1038/s41568-019-0224-7; Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6; Shankar GM, 2016, ACTA NEUROPATHOL, V131, P147, DOI 10.1007/s00401-015-1492-2; Shows J, 2016, BRAIN PATHOL, V26, P120, DOI 10.1111/bpa.12327; Solomon DA, 2016, BRAIN PATHOL, V26, P569, DOI 10.1111/bpa.12336; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Swartz AM, 2018, EXPERT OPIN BIOL TH, V18, P1159, DOI 10.1080/14712598.2018.1531846; Tobin MK, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15158; Vinci M, 2018, NAT MED, V24, P1204, DOI 10.1038/s41591-018-0086-7; von Maltzahn G, 2011, NAT MATER, V10, P545, DOI [10.1038/nmat3049, 10.1038/NMAT3049]; Walker C, 2011, BRIT J RADIOL, V84, pS90, DOI 10.1259/bjr/23430927; Wang SS, 2019, TRENDS IMMUNOL, V40, P748, DOI 10.1016/j.it.2019.05.009; Weathers SP, 2015, J NEURO-ONCOL, V123, P331, DOI 10.1007/s11060-015-1716-2; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Wilhelm I, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1143544; Wong KK, 2016, ADV IMMUNOL, V130, P191, DOI 10.1016/bs.ai.2015.12.001; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043	53	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2021	11								582828	10.3389/fimmu.2020.582828	http://dx.doi.org/10.3389/fimmu.2020.582828			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR3TJ	33679686	gold, Green Published			2022-12-18	WOS:000625134800001
J	McGowan, E; Rosenthal, R; Fiore-Gartland, A; Macharia, G; Balinda, S; Kapaata, A; Umviligihozo, G; Muok, E; Dalel, J; Streatfield, CL; Coutinho, H; Dilernia, D; Monaco, DC; Morrison, D; Yue, L; Hunter, E; Nielsen, M; Gilmour, J; Hare, J				McGowan, Ed; Rosenthal, Rachel; Fiore-Gartland, Andrew; Macharia, Gladys; Balinda, Sheila; Kapaata, Anne; Umviligihozo, Gisele; Muok, Erick; Dalel, Jama; Streatfield, Claire L.; Coutinho, Helen; Dilernia, Dario; Monaco, Daniela C.; Morrison, David; Yue, Ling; Hunter, Eric; Nielsen, Morten; Gilmour, Jill; Hare, Jonathan			Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth in the Context of a CD8 T-Cell Mediated HIV Response	FRONTIERS IN IMMUNOLOGY			English	Article						CD8 T-cells; HIV; T-cell epitopes; vaccines; machine learning		Predictive models are becoming more and more commonplace as tools for candidate antigen discovery to meet the challenges of enabling epitope mapping of cohorts with diverse HLA properties. Here we build on the concept of using two key parameters, diversity metric of the HLA profile of individuals within a population and consideration of sequence diversity in the context of an individual's CD8 T-cell immune repertoire to assess the HIV proteome for defined regions of immunogenicity. Using this approach, analysis of HLA adaptation and functional immunogenicity data enabled the identification of regions within the proteome that offer significant conservation, HLA recognition within a population, low prevalence of HLA adaptation and demonstrated immunogenicity. We believe this unique and novel approach to vaccine design as a supplement to vitro functional assays, offers a bespoke pipeline for expedited and rational CD8 T-cell vaccine design for HIV and potentially other pathogens with the potential for both global and local coverage.	[McGowan, Ed; Macharia, Gladys; Dalel, Jama; Streatfield, Claire L.; Coutinho, Helen; Gilmour, Jill] Imperial Coll, IAVI Human Immunol Lab, London, England; [Rosenthal, Rachel] Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England; [Fiore-Gartland, Andrew] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Balinda, Sheila; Kapaata, Anne] MRC, Uganda Virus Res Inst MRC UVRI, Entebbe, Uganda; [Balinda, Sheila; Kapaata, Anne] London Sch Hlth & Trop Med LSHTM, Uganda Res Unit, Entebbe, Uganda; [Umviligihozo, Gisele; Muok, Erick] Ctr Family Hlth Res CFHR, Project San Francisco PSF, Kigali, Rwanda; [Dilernia, Dario; Monaco, Daniela C.; Yue, Ling; Hunter, Eric] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA; [Morrison, David] Bitefirst, South Walsham, England; [Nielsen, Morten] Tech Univ Denmark, Dept Hlth Technol, Lyngby, Denmark; [Hare, Jonathan] IAVI, New York, NY USA	Imperial College London; International AIDS Vaccine Initiative; Francis Crick Institute; Fred Hutchinson Cancer Center; Emory University; Technical University of Denmark; International AIDS Vaccine Initiative	McGowan, E (corresponding author), Imperial Coll, IAVI Human Immunol Lab, London, England.; Hare, J (corresponding author), IAVI, New York, NY USA.	ed.mcgowan@isogenica.com; jhare@iavi.org	Muok, Erick/AHD-2170-2022	Macharia, Gladys/0000-0002-5605-5604	IAVI; United States Agency for International Development (USAID)	IAVI; United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR)	This work was funded in part by IAVI and made possible by the support of the United States Agency for International Development (USAID) and other donors. The full list of IAVI donors is available at http://www.iavi.org.The contents of this manuscript are the responsibility of IAVI and do not necessarily reflect the views of USAID or the US Government. This paper was accepted for pre-print with BioRxiv (39).	Altfeld M, 2006, PLOS MED, V3, P1851, DOI 10.1371/journal.pmed.0030403; Amornkul PN, 2013, AIDS, V27, P2775, DOI 10.1097/QAD.0000000000000012; Baalwa J, 2013, VIROLOGY, V436, P33, DOI 10.1016/j.virol.2012.10.009; Baden LR, 2018, J INFECT DIS, V218, P633, DOI 10.1093/infdis/jiy212; Carlson JM, 2014, SCIENCE, V345, DOI 10.1126/science.1254031; Claiborne DT, 2015, P NATL ACAD SCI USA, V112, pE1480, DOI 10.1073/pnas.1421607112; Fiore-Gartland A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147812; Gaiha GD, 2019, SCIENCE, V364, P480, DOI 10.1126/science.aav5095; Goepfert PA, 2008, J EXP MED, V205, P1009, DOI 10.1084/jem.20072457; Guardo AC, 2017, AIDS, V31, P321, DOI 10.1097/QAD.0000000000001276; Joseph SB, 2015, NAT REV MICROBIOL, V13, P414, DOI 10.1038/nrmicro3471; Julg B, 2019, CURR OPIN HIV AIDS, V14, P318, DOI 10.1097/COH.0000000000000556; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kearney M, 2009, J VIROL, V83, P2715, DOI 10.1128/JVI.01960-08; Kunwar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064405; Li GD, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0148-6; Maldarelli F, 2013, J VIROL, V87, P10313, DOI 10.1128/JVI.01225-12; Marsh SGE, 2017, HLA, V90, P188, DOI 10.1111/tan.13090; McGowan E., 2020, UTILIZING COMPUTATIO, DOI [10.1101/2020.08.15.250589, DOI 10.1101/2020.08.15.250589]; McMichael AJ, 2014, NAT IMMUNOL, V15, P319, DOI 10.1038/ni.2844; Michelo CM., 2021, J IMMUNOL METHODS; Monaco DC, 2016, J EXP MED, V213, P2049, DOI 10.1084/jem.20151984; Mothe B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029717; Naarding MA, 2014, J IMMUNOL METHODS, V409, P161, DOI 10.1016/j.jim.2013.11.021; Ngumbela KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002356; Nielsen M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000796; Nielsen M, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0288-x; Ogishi M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00827; Ondondo B, 2016, MOL THER, V24, P832, DOI 10.1038/mt.2016.3; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Rosenthal R., 2020, SELECTIVE HLA RESTRI; Sheet F, 2018, UNIAIDS WEBSITE, P1; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Simek MD, 2009, J VIROL, V83, P7337, DOI 10.1128/JVI.00110-09; Sok D, 2018, NAT IMMUNOL, V19, P1179, DOI 10.1038/s41590-018-0235-7; Spentzou A, 2010, J INFECT DIS, V201, P720, DOI 10.1086/650492; Sunshine J, 2014, J VIROL, V88, P1354, DOI 10.1128/JVI.02361-13; Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737	39	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2021	12								609884	10.3389/fimmu.2021.609884	http://dx.doi.org/10.3389/fimmu.2021.609884			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QR0SI	33679745	Green Published, gold, Green Submitted			2022-12-18	WOS:000624925500001
J	Brilland, B; Vinatier, E; Subra, JF; Jeannin, P; Augusto, JF; Delneste, Y				Brilland, Benoit; Vinatier, Emeline; Subra, Jean-Francois; Jeannin, Pascale; Augusto, Jean-Francois; Delneste, Yves			Anti-Pentraxin Antibodies in Autoimmune Diseases: Bystanders or Pathophysiological Actors?	FRONTIERS IN IMMUNOLOGY			English	Review						pentraxins; autoimmunity; systemic lupus erythematosus; ANCA-associated vasculitis; anti-pentraxin autoantibodies	C-REACTIVE PROTEIN; SERUM-AMYLOID-P; NEUTROPHIL EXTRACELLULAR TRAPS; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FC-GAMMA RECEPTORS; PATTERN-RECOGNITION; APOPTOTIC CELLS; IMMUNE-RESPONSE; TARGETED DELETION	Pentraxins are soluble innate immunity receptors involved in sensing danger molecules. They are classified as short (CRP, SAP) and long pentraxin subfamilies, including the prototypic long pentraxin PTX3. Pentraxins act mainly as bridging molecules favoring the clearance of microbes and dead cells. They are also involved in many other biological processes, such as regulation of complement activation, inflammation and tissue homeostasis. Autoantibodies directed against pentraxins have been reported in various autoimmune diseases, especially in systemic lupus erythematosus and ANCA-associated vasculitis. In this review, we review the main biological characteristics and functions of pentraxins and summarize data concerning autoantibodies directed against pentraxins in the context of autoimmune diseases and discuss their potential pathological role.	[Brilland, Benoit; Subra, Jean-Francois; Augusto, Jean-Francois] CHU Angers, Serv Nephrol Dialyse Transplantat, Angers, France; [Brilland, Benoit; Vinatier, Emeline; Subra, Jean-Francois; Jeannin, Pascale; Augusto, Jean-Francois; Delneste, Yves] Univ Angers, INSERM, CRCINA, Angers, France; [Vinatier, Emeline; Jeannin, Pascale; Delneste, Yves] CHU Angers, Serv Immunol & Allergol, Angers, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Brilland, B (corresponding author), CHU Angers, Serv Nephrol Dialyse Transplantat, Angers, France.; Brilland, B (corresponding author), Univ Angers, INSERM, CRCINA, Angers, France.	benoit.brilland@chu-angers.fr	Brilland, Benoît/AAP-3193-2021; Jean-François, Augusto/L-2887-2015	Brilland, Benoît/0000-0001-9622-4014; Jean-François, Augusto/0000-0003-1498-2132; DELNESTE, Yves/0000-0002-2142-596X; JEANNIN, Pascale/0000-0002-3666-3856	LabEX IGO program (National Research Agency) [ANR-11-LABX-0016-01]; University Hospital of Angers - University of Angers joint program (project 3I-Impact)	LabEX IGO program (National Research Agency); University Hospital of Angers - University of Angers joint program (project 3I-Impact)	This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This work was realized in the context of (i) the LabEX IGO program (National Research Agency; ANR-11-LABX-0016-01) and (ii) the University Hospital of Angers - University of Angers joint program (project 3I-Impact).	Agrawal A, 2009, ADV EXP MED BIOL, V653, P98; Augusto JF, 2009, RHEUMATOLOGY, V48, P442, DOI 10.1093/rheumatology/ken507; Baruah P, 2006, J LEUKOCYTE BIOL, V80, P87, DOI 10.1189/jlb.0805445; Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; Bassi N, 2010, ANN RHEUM DIS, V69, P1704, DOI 10.1136/ard.2009.117804; Bassi N, 2015, CLIN REV ALLERG IMMU, V49, P217, DOI 10.1007/s12016-015-8476-9; Batista NV, 2019, J IMMUNOL, V202, P1807, DOI 10.4049/jimmunol.1701531; Beauvillain C, 2008, CLIN REV ALLERG IMMU, V35, P47, DOI 10.1007/s12016-007-8071-9; Bell SA, 1998, CLIN EXP IMMUNOL, V113, P327; Berthelot JM, 2017, JOINT BONE SPINE, V84, P255, DOI 10.1016/j.jbspin.2016.05.013; Bharadwaj D, 2001, J IMMUNOL, V166, P6735, DOI 10.4049/jimmunol.166.11.6735; Bickerstaff MCM, 1999, NAT MED, V5, P694, DOI 10.1038/9544; Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; Bozza S, 2014, J IMMUNOL, V193, P2340, DOI 10.4049/jimmunol.1400814; Brilland B, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2019.102424; Brilland B, 2020, CLIN REV ALLERG IMMU, V58, P194, DOI 10.1007/s12016-019-08744-x; Brucato A, 2001, ARTHRITIS RHEUM-US, V44, P1832, DOI 10.1002/1529-0131(200108)44:8<1832::AID-ART320>3.0.CO;2-C; de Oliveira THC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01461; Carrizzo A, 2015, CIRCULATION, V131, P1495, DOI 10.1161/CIRCULATIONAHA.114.014822; Comarmond C, 2013, ARTHRITIS RHEUM-US, V65, P270, DOI 10.1002/art.37721; D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137; Daigo K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00378; Daigo K, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.015073; de la Torre YM, 2010, J IMMUNOL, V184, P5055, DOI 10.4049/jimmunol.0901672; Deban L, 2011, CELL TISSUE RES, V343, P237, DOI 10.1007/s00441-010-1018-0; Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433; Eisenhardt SU, 2009, CELL CYCLE, V8, P3885, DOI 10.4161/cc.8.23.10068; Figueredo MA, 2006, J RHEUMATOL, V33, P1980; Firooz N, 2011, LUPUS, V20, P588, DOI 10.1177/0961203310393378; Flossmann O, 2011, ANN RHEUM DIS, V70, P488, DOI 10.1136/ard.2010.137778; Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756; Gatto M, 2016, J AUTOIMMUN, V74, P208, DOI 10.1016/j.jaut.2016.07.002; Geetha D, 2020, AM J KIDNEY DIS, V75, P124, DOI 10.1053/j.ajkd.2019.04.031; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; Gillmore JD, 2004, IMMUNOLOGY, V112, P255, DOI 10.1111/j.1365-2567.2004.01860.x; Guillon C, 2015, PROTEIN PEPTIDE LETT, V22, P248, DOI 10.2174/0929866522666141231111226; Inforzato A, 2013, SEMIN IMMUNOL, V25, P79, DOI 10.1016/j.smim.2013.05.002; Jaillon S, 2009, CELL DEATH DIFFER, V16, P465, DOI 10.1038/cdd.2008.173; Jaillon S, 2007, J EXP MED, V204, P793, DOI 10.1084/jem.20061301; Jaillon S, 2014, INT ARCH ALLERGY IMM, V165, P165, DOI 10.1159/000368778; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jeannin P, 2008, CURR OPIN IMMUNOL, V20, P530, DOI 10.1016/j.coi.2008.04.013; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Jennette JC, 2017, CLIN J AM SOC NEPHRO, V12, P1680, DOI 10.2215/CJN.02500317; Jennette JC, 2013, ANNU REV PATHOL-MECH, V8, P139, DOI 10.1146/annurev-pathol-011811-132453; Jung JY, 2014, J INVEST MED, V62, P890, DOI 10.1097/JIM.0000000000000094; Junker F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01393; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Kruse K, 2010, APOPTOSIS, V15, P1098, DOI 10.1007/s10495-010-0478-8; Lech M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020118; LINARES LF, 1986, CLIN RHEUMATOL, V5, P66, DOI 10.1007/BF02030970; Locati M, 2020, ANNU REV PATHOL-MECH, V15, P123, DOI 10.1146/annurev-pathmechdis-012418-012718; Lominadze G, 2005, MOL CELL PROTEOMICS, V4, P1503, DOI 10.1074/mcp.M500143-MCP200; Lu JH, 2008, NATURE, V456, P989, DOI 10.1038/nature07468; Magrini E, 2016, TRENDS MOL MED, V22, P497, DOI 10.1016/j.molmed.2016.04.007; Mantegazza AR, 2013, TRAFFIC, V14, P135, DOI 10.1111/tra.12026; Mantovani A, 2013, ANN NY ACAD SCI, V1285, P1, DOI 10.1111/nyas.12043; Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103; Mitchell DA, 2002, J IMMUNOL, V168, P2538, DOI 10.4049/jimmunol.168.5.2538; Moalli F, 2011, J IMMUNOL, V186, P5425, DOI 10.4049/jimmunol.1002035; Moalli F, 2010, BLOOD, V116, P5170, DOI 10.1182/blood-2009-12-258376; Mold C, 2002, J IMMUNOL, V169, P7019, DOI 10.4049/jimmunol.169.12.7019; Mold C, 2002, J AUTOIMMUN, V19, P147, DOI 10.1006/jaut.2002.0615; Mold C, 2001, J IMMUNOL, V166, P1200, DOI 10.4049/jimmunol.166.2.1200; Morioka S, 2019, IMMUNITY, V50, P1149, DOI 10.1016/j.immuni.2019.04.018; Ng PML, 2007, EMBO J, V26, P3431, DOI 10.1038/sj.emboj.7601762; O'Neill SG, 2010, ARTHRITIS RHEUM-US, V62, P845, DOI 10.1002/art.27286; Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; POTEMPA LA, 1988, INFLAMMATION, V12, P391, DOI 10.1007/BF00915774; Pradhan V, 2013, Indian J Nephrol, V23, P434, DOI 10.4103/0971-4065.120341; Reading PC, 2008, J IMMUNOL, V180, P3391, DOI 10.4049/jimmunol.180.5.3391; Real JM, 2012, MOL IMMUNOL, V51, P82, DOI 10.1016/j.molimm.2012.02.113; ROBEY FA, 1985, J EXP MED, V161, P1344, DOI 10.1084/jem.161.6.1344; Rodriguez W, 2006, ARTHRITIS RHEUM-US, V54, P325, DOI 10.1002/art.21556; Rosenau BJ, 2006, ANN RHEUM DIS, V65, P674, DOI 10.1136/ard.2005.037895; Rovere P, 2000, BLOOD, V96, P4300; Sangaletti S, 2012, BLOOD, V120, P3007, DOI 10.1182/blood-2012-03-416156; Schlieben DJ, 2005, AM J KIDNEY DIS, V45, P758, DOI 10.1053/j.ajkd.2005.01.001; Shoenfeld Y, 2007, ANN NY ACAD SCI, V1108, P227, DOI 10.1196/annals.1422.025; Simon A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147091; Sjowall C, 2002, J AUTOIMMUN, V19, P155, DOI 10.1006/jaut.2002.0608; Soderberg D, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00256; Son CN, 2018, KOREAN J INTERN MED, V33, P823, DOI 10.3904/kjim.2016.065; Souza DG, 2009, AM J PATHOL, V174, P1309, DOI 10.2353/ajpath.2009.080240; Souza DG, 2002, AM J PATHOL, V160, P1755, DOI 10.1016/S0002-9440(10)61122-4; Suzuki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053133; Szalai AJ, 2003, ARTHRITIS RHEUM-US, V48, P1602, DOI 10.1002/art.11026; Szalai Alexander J, 2004, Clin Dev Immunol, V11, P221, DOI 10.1080/17402520400001751; Talor MV, 2007, CLIN EXP IMMUNOL, V150, P42, DOI 10.1111/j.1365-2249.2007.03453.x; Tan Y, 2011, CLIN J AM SOC NEPHRO, V6, P93, DOI 10.2215/CJN.09051209; Tan Y, 2008, HUM IMMUNOL, V69, P840, DOI 10.1016/j.humimm.2008.09.006; Thakur R, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00192; Tsokos GC, 2011, NEW ENGL J MED, V365, P2110, DOI 10.1056/NEJMra1100359; van Rossum AP, 2004, ARTHRITIS RHEUM-US, V50, P2667, DOI 10.1002/art.20370; Wang H, 2015, CLIN EXP IMMUNOL, V181, P518, DOI 10.1111/cei.12654; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Yuan M, 2017, RENAL FAILURE, V39, P465, DOI 10.1080/0886022X.2017.1308258; Zandman-Goddard G, 2005, ANN RHEUM DIS, V64, P1698, DOI 10.1136/ard.2005.035832	100	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 16	2021	11								626343	10.3389/fimmu.2020.626343	http://dx.doi.org/10.3389/fimmu.2020.626343			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QP5JE	33664737	Green Published, gold			2022-12-18	WOS:000623872000001
J	Granata, F; Duca, L; Brancaleoni, V; Fustinoni, S; De Luca, G; Motta, I; Graziadei, G; Di Pierro, E				Granata, Francesca; Duca, Lorena; Brancaleoni, Valentina; Fustinoni, Silvia; De Luca, Giacomo; Motta, Irene; Graziadei, Giovanna; Di Pierro, Elena			Alternative Pathway Involvement in Protoporphyria Patients Related to Sun Exposure	FRONTIERS IN IMMUNOLOGY			English	Article						protoporphyria; complement system; alternative pathway; phototoxic reaction; global radiation; UV detection		The homeostasis of tissues in a chronic disease is an essential function of the alternative pathway (AP) of the complement system (CS). However, if not controlled, it may also be detrimental to healthy cells with a consequent aggravation of symptoms. The protoporphyria (PP) is a rare chronic disease that causes phototoxicity in visible light with local skin pain and general malaise. In order to establish if there is a systemic involvement of the CS during sun exposure, we designed a non-invasive method with a serum collection in winter and summer from 19 PP and 13 controls to detect the levels of CS protein: Properdin, Factor H (FH), and C5. Moreover, the global radiation data were collected from the regional agency of environmental protection (ARPA). The results show growing values for every protein in patients with PP, compared to control, in both seasons, in particular in summer compared to winter. To reinforce the evidence, we have estimated the personal exposure of patients based on the global radiation data. The main factors of the AP increased over the season, confirming the involvement of the AP in relation to light exposure. The systemic response could justify the general malaise of patients after long light exposure and can be exploited to elucidate new therapeutic approaches.	[Granata, Francesca; Duca, Lorena; Brancaleoni, Valentina; De Luca, Giacomo; Motta, Irene; Graziadei, Giovanna; Di Pierro, Elena] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Med Gen, Milan, Italy; [Fustinoni, Silvia] Univ Milan, Dept Clin Sci & Community Hlth, EPIGET Epidemiol Epigenet & Toxicol Lab, Milan, Italy; [Fustinoni, Silvia] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Environm & Ind Toxicol Unit, Milan, Italy; [Motta, Irene] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Granata, F (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Med Gen, Milan, Italy.	francesca.granata@policlinico.mi.it	Duca, Lorena/K-6909-2012; Brancaleoni, Valentina/I-8442-2019; Duca, Lorena/AAV-5773-2021; Fustinoni, Silvia/I-8773-2012; Di Pierro, Elena/A-3157-2009	Duca, Lorena/0000-0002-2008-3187; Brancaleoni, Valentina/0000-0003-1521-3319; Fustinoni, Silvia/0000-0002-0287-7338; Di Pierro, Elena/0000-0002-1413-1349	Italian Ministry of Health [RC-2020]	Italian Ministry of Health(Ministry of Health, Italy)	The Italian Ministry of Health (RC-2020) supported this work.	Abrahamse H, 2016, BIOCHEM J, V473, P347, DOI 10.1042/BJ20150942; Balwani M, 2017, JAMA DERMATOL, V153, P789, DOI 10.1001/jamadermatol.2017.1557; Blatt AZ, 2016, IMMUNOL REV, V274, P172, DOI 10.1111/imr.12466; Blatt AZ, 2016, J IMMUNOL, V196, P4671, DOI 10.4049/jimmunol.1600040; Brancaleoni V, 2016, CLIN GENET, V89, P20, DOI 10.1111/cge.12562; Chen JY, 2018, MOL IMMUNOL, V102, P58, DOI 10.1016/j.molimm.2018.05.018; Cuny JF, 2019, ANN DERMATOL VENER, V146, P143, DOI 10.1016/j.annder.2018.12.005; da Costa MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02664; de Bataille S, 2016, BRIT J DERMATOL, V175, P768, DOI 10.1111/bjd.14600; Fink C, 2015, J DTSCH DERMATOL GES, V13, P15, DOI 10.1111/ddg.12546; Giang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00639; GOG HWV, 1975, DERMATOLOGICA, V151, P9, DOI 10.1159/000251293; Granata F, 2019, IMMUNOL RES, V67, P382, DOI 10.1007/s12026-019-09097-5; Harrison RA, 2018, SEMIN IMMUNOPATHOL, V40, P15, DOI 10.1007/s00281-017-0661-x; Heiskanen T, 2012, SCAND J PAIN, V3, P201, DOI 10.1016/j.sjpain.2012.05.073; Holme SA, 2006, BRIT J DERMATOL, V155, P574, DOI 10.1111/j.1365-2133.2006.07472.x; Karim Z, 2015, CLIN RES HEPATOL GAS, V39, P412, DOI 10.1016/j.clinre.2015.05.009; Lame IE, 2005, EUR J PAIN, V9, P15, DOI 10.1016/j.ejpain.2004.02.006; Leaker BR, 2017, MUCOSAL IMMUNOL, V10, P408, DOI 10.1038/mi.2016.74; LIM HW, 1984, J CLIN INVEST, V74, P1961, DOI 10.1172/JCI111616; McGeer PL, 2017, NEUROBIOL AGING, V52, P12, DOI 10.1016/j.neurobiolaging.2016.12.017; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Naik Hetanshi, 2019, JIMD Rep, V50, P9, DOI 10.1002/jmd2.12052; Naik H, 2019, MOL GENET METAB, V128, P314, DOI 10.1016/j.ymgme.2019.01.023; PANGBURN MK, 1986, BIOCHEM J, V235, P723, DOI 10.1042/bj2350723; Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; POTTIER RH, 1986, PHOTOCHEM PHOTOBIOL, V44, P679, DOI 10.1111/j.1751-1097.1986.tb04726.x; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Roberts DW, 2018, J NEUROSURG, V128, P1690, DOI 10.3171/2017.1.JNS162061; Schiekofer C, 2012, HAUTARZT, V63, P961, DOI 10.1007/s00105-012-2423-y; Shahini N, 2017, SCI REP-UK, V7, DOI 10.1038/srep42532; Sliney DH, 2016, EYE, V30, P222, DOI 10.1038/eye.2015.252; Smith-Jackson K, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.10.35; Thunell S, 2000, SCAND J CLIN LAB INV, V60, P509, DOI 10.1080/003655100448310; Wahlin S, 2008, LIVER TRANSPLANT, V14, P1340, DOI 10.1002/lt.21527; Wensink D, 2020, JAMA DERMATOL, V156, P570, DOI 10.1001/jamadermatol.2020.0352	38	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 16	2021	12								615620	10.3389/fimmu.2021.615620	http://dx.doi.org/10.3389/fimmu.2021.615620			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QP7XC	33664746	gold, Green Published			2022-12-18	WOS:000624044700001
J	Bailey, EM; Choudhury, A; Vuppula, H; Ortiz, DF; Schaeck, J; Manning, AM; Bosques, CJ; Hoppe, AD				Bailey, Elizabeth M.; Choudhury, Amit; Vuppula, Harika; Ortiz, Daniel F.; Schaeck, John; Manning, Anthony M.; Bosques, Carlos J.; Hoppe, Adam D.			Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fc gamma Receptor Inhibition and Activation in Endosomes	FRONTIERS IN IMMUNOLOGY			English	Article						macrophage; Fc gamma receptor; antibodies; immune complex; autoimmunity; monocyte; inhibitor; single molecule		The inhibition of Fc gamma receptors (Fc gamma R) is an attractive strategy for treating diseases driven by IgG immune complexes (IC). Previously, we demonstrated that an engineered trivalent arrangement of IgG1 Fc domains (SIF1) potently inhibited Fc gamma R activation by IC, whereas a penta-valent Fc molecule (PentX) activated Fc gamma R, potentially mimicking ICs and leading to Syk phosphorylation. Thus, a precise balance exists between the number of engaged Fc gamma Rs for inhibition versus activation. Here, we demonstrate that Fc valency differentially controls Fc gamma R activation and inhibition within distinct subcellular compartments. Large Fc multimer clusters consisting of 5-50 Fc domains predominately recruited Syk- mScarlet to patches on the plasma membrane, whereas PentX exclusively recruited Syk- mScarlet to endosomes in human monocytic cell line (THP-1 cells). In contrast, SIF1, similar to monomeric Fc, spent longer periods docked to Fc gamma Rs on the plasma membrane and did not accumulate and recruit Syk-mScarlet within large endosomes. Single particle tracking (SPT) of fluorescent engineered Fc molecules and Syk-mScarlet at the plasma membrane imaged by total internal reflection fluorescence microscopy (SPT-TIRF), revealed that Syk-mScarlet sampled the plasma membrane was not recruited to Fc gamma R docked with any of the engineered Fc molecules at the plasma membrane. Furthermore, the motions of Fc gamma Rs docked with recombinant Fc (rFc), SIF1 or PentX, displayed similar motions with D similar to 0.15 mu m(2)/s, indicating that SIF1 and PentX did not induce reorganization or microclustering of Fc gamma Rs beyond the ligating valency.Multicolor SPT-TIRF and brightness analysis of docked rFc, SIF1 and PentX also indicated that Fc gamma Rs were not pre-assembled into clusters. Taken together, activation on the plasma membrane requires assembly of more than 5 Fc gamma Rs. Unlike rFc or SIF1, PentX accumulated Syk-mScarlet on endosomes indicating that the threshold for Fc gamma R activation on endosomes is lower than on the plasma membrane. We conclude that the inhibitory effects of SIF1 are mediated by stabilizing a ligated and inactive Fc gamma R on the plasma membrane. Thus, Fc gamma R inhibition can be achieved by low valency ligation with SIF1 that behaves similarly to Fc gamma R docked with monomeric IgG.	[Bailey, Elizabeth M.; Vuppula, Harika; Hoppe, Adam D.] South Dakota State Univ, Dept Chem & Biochem, Brookings, SD 57007 USA; [Bailey, Elizabeth M.; Vuppula, Harika; Hoppe, Adam D.] South Dakota State Univ, BioSyst Networks & Translat Res, Brookings, SD 57007 USA; [Choudhury, Amit; Ortiz, Daniel F.; Schaeck, John; Manning, Anthony M.; Bosques, Carlos J.] Momenta Pharmaceut, Cambridge, MA USA; [Bailey, Elizabeth M.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA	South Dakota State University; South Dakota State University; University of New Mexico	Hoppe, AD (corresponding author), South Dakota State Univ, Dept Chem & Biochem, Brookings, SD 57007 USA.; Hoppe, AD (corresponding author), South Dakota State Univ, BioSyst Networks & Translat Res, Brookings, SD 57007 USA.	Adam.Hoppe@sdstate.edu			Momenta Pharmaceuticals; NSF/EPSCoR [IIA-1355423]; South Dakota Research and Innovation Center, BioSNTR; State of South Dakota BOR CRGP; ASERT-IRACDA program [K12GM088021]	Momenta Pharmaceuticals; NSF/EPSCoR(National Science Foundation (NSF)NSF - Office of the Director (OD)); South Dakota Research and Innovation Center, BioSNTR; State of South Dakota BOR CRGP; ASERT-IRACDA program	This work was supported by funds provided by Momenta Pharmaceuticals as well as the NSF/EPSCoR Cooperative Agreement #IIA-1355423, the South Dakota Research and Innovation Center, BioSNTR, and by the State of South Dakota BOR CRGP to AH. EB was supported through the ASERT-IRACDA program (K12GM088021).	Andrews NL, 2009, IMMUNITY, V31, P469, DOI 10.1016/j.immuni.2009.06.026; Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Bakalar MH, 2018, CELL, V174, P131, DOI 10.1016/j.cell.2018.05.059; Brandsma AM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aaq0891; Chiou SH, 2015, GENE DEV, V29, P1576, DOI 10.1101/gad.264861.115; Cojocaru Manole, 2011, Maedica (Bucur), V6, P330; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Flaherty MM, 2012, TOXICOL SCI, V125, P299, DOI 10.1093/toxsci/kfr278; Flannagan RS, 2012, ANNU REV PATHOL-MECH, V7, P61, DOI 10.1146/annurev-pathol-011811-132445; Freeman SA, 2018, CELL, V172, P305, DOI 10.1016/j.cell.2017.12.023; Freeman SA, 2016, CELL, V164, P128, DOI 10.1016/j.cell.2015.11.048; Garcia-Parajo MF, 2014, J CELL SCI, V127, P4995, DOI 10.1242/jcs.146340; Goodridge HS, 2011, NATURE, V472, P471, DOI 10.1038/nature10071; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Horejsi V, 2014, FEBS LETT, V588, P2392, DOI 10.1016/j.febslet.2014.05.047; Jaqaman K, 2008, NAT METHODS, V5, P695, DOI 10.1038/nmeth.1237; Jaumouille V, 2014, DEV CELL, V29, P534, DOI 10.1016/j.devcel.2014.04.031; Kara S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01320; Li XR, 2014, EXPERT OPIN THER TAR, V18, P335, DOI 10.1517/14728222.2014.877891; Lin J, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0143-2; Lin J, 2013, MICROSC MICROANAL, V19, P350, DOI 10.1017/S1431927612014420; Lopes FB, 2017, J CELL BIOL, V216, P1123, DOI 10.1083/jcb.201608094; Lowell CA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002352; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Murphy KW., 2017, CASEY JANEWAYS IMMUN, V924; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Oates-Whitehead R M, 2003, Cochrane Database Syst Rev, pCD004000, DOI 10.1002/14651858.CD003511; Ortiz DF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9418; Ostrowski PP, 2016, DEV CELL, V38, P135, DOI 10.1016/j.devcel.2016.06.023; Scott BL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02818-8; Tokunaga M, 2008, NAT METHODS, V5, P159, DOI 10.1038/nmeth1171; Ushio A., 2017, WORLD J IMMUNOL, V7, P1, DOI [10.5411/wji.v7.i1.1, DOI 10.5411/WJI.V7.I1.1]; Vega AR, 2018, BIOPHYS J, V114, P1018, DOI 10.1016/j.bpj.2018.01.012; Zhang YX, 2010, P NATL ACAD SCI USA, V107, P19332, DOI 10.1073/pnas.1008248107	35	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2021	11								617767	10.3389/fimmu.2020.617767	http://dx.doi.org/10.3389/fimmu.2020.617767			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QO6AA	33679705	gold, Green Published			2022-12-18	WOS:000623221900001
J	Qin, T; Jia, YJ; Liu, YH; Dai, RX; Zhou, LN; Okada, S; Tsumura, M; Ohnishi, H; Kato, Z; Kanegane, H; Sun, XL; Zhao, XD				Qin, Tao; Jia, Yanjun; Liu, Yuhang; Dai, Rongxin; Zhou, Lina; Okada, Satoshi; Tsumura, Miyuki; Ohnishi, Hidenori; Kato, Zenichiro; Kanegane, Hirokazu; Sun, Xiulian; Zhao, Xiaodong			A Novel Homozygous Mutation Destabilizes IKK beta and Leads to Human Combined Immunodeficiency	FRONTIERS IN IMMUNOLOGY			English	Article						IKK&#946; NF-&#954; B; SCID; protein degradation; protein stability		Mutations in the IKBKB gene cause severe immunodeficiency, characterized clinically by persistent respiratory or gastrointestinal infections. Targeted gene panel sequencing revealed a novel homozygous missense mutation in the IKBKB gene of a patient with immune dysregulation and combined T and B cell functional defects. PBMCs from the patient, Ikbkb Y397H mice, and transfected cells were used to elucidate how the Y395H mutation triggers IKK beta deficiency and impairs immune function. Here, we found that cells from both the patient and Ikbkb Y397H mice lacked or showed decreased levels of IKK beta protein, along with impaired lymphocyte function. IKK alpha and IKK gamma protein expression by human PBMCs harboring the Y395H mutation was normal, but degradation of IKK beta protein was accelerated. Binding of human NF-kappa B to DNA in patient PBMCs fell upon stimulation with TNF-alpha or LPS. Additionally, a structural model of Y395H revealed loss of the hydrogen bond with D389. These data suggest that IKBKB deficiency induces abnormal IKK beta protein degradation, leading to impaired NF-kappa B signaling and immune function. We postulate that the Y395H variant in the IKK beta protein lost the hydrogen bond with D389, thereby affecting interaction between Y395 and D389 and increasing protein instability.	[Qin, Tao] Chongqing Med Univ, Dept Infect, Childrens Hosp, Chongqing, Peoples R China; [Qin, Tao; Jia, Yanjun; Liu, Yuhang; Dai, Rongxin; Zhou, Lina; Zhao, Xiaodong] Natl Clin Res Ctr Child Hlth & Disorders, Chongqing, Peoples R China; [Qin, Tao; Jia, Yanjun; Liu, Yuhang; Dai, Rongxin; Zhou, Lina; Zhao, Xiaodong] Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China; [Qin, Tao; Jia, Yanjun; Liu, Yuhang; Dai, Rongxin; Zhou, Lina; Zhao, Xiaodong] China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China; [Qin, Tao; Jia, Yanjun; Dai, Rongxin; Zhou, Lina; Zhao, Xiaodong] Chongqing Med Univ, Chongqing Key Lab Child Infect & Immun, Childrens Hosp, Chongqing, Peoples R China; [Jia, Yanjun; Dai, Rongxin; Zhou, Lina; Zhao, Xiaodong] Chongqing Med Univ, Dept Rheumatism & Immun, Childrens Hosp, Chongqing, Peoples R China; [Liu, Yuhang] Chongqing Med Univ, Dept Neurol, Childrens Hosp, Chongqing, Peoples R China; [Liu, Yuhang] Chongqing Med Univ, Chongqing Key Lab Translat Med Res Cognit Dev & L, Childrens Hosp, Chongqing, Peoples R China; [Okada, Satoshi; Tsumura, Miyuki] Hiroshima Univ, Dept Pediat, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Ohnishi, Hidenori; Kato, Zenichiro] Gifu Univ, Dept Pediat, Grad Sch Med, Gifu, Japan; [Kato, Zenichiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Struct Med, Gifu, Japan; [Kanegane, Hirokazu] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Child Hlth & Dev, Tokyo, Japan; [Sun, Xiulian] Shandong Univ, Brain Res Inst, Qilu Hosp, Jinan, Shandong, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Hiroshima University; Gifu University; Gifu University; Tokyo Medical & Dental University (TMDU); Shandong University	Zhao, XD (corresponding author), Natl Clin Res Ctr Child Hlth & Disorders, Chongqing, Peoples R China.; Zhao, XD (corresponding author), Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China.; Zhao, XD (corresponding author), China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China.; Zhao, XD (corresponding author), Chongqing Med Univ, Chongqing Key Lab Child Infect & Immun, Childrens Hosp, Chongqing, Peoples R China.; Zhao, XD (corresponding author), Chongqing Med Univ, Dept Rheumatism & Immun, Childrens Hosp, Chongqing, Peoples R China.	zhaoxd530@aliyun.com	Okada, Satoshi/B-8901-2011	Okada, Satoshi/0000-0002-4622-5657	Public Welfare Scientific Research Project of China [201402012]; National Natural Science Foundation of China [81901611]	Public Welfare Scientific Research Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was funded by the Public Welfare Scientific Research Project of China (201402012) and by the National Natural Science Foundation of China (81901611).	Altin JA, 2011, J ALLERGY CLIN IMMUN, V127, P1277, DOI 10.1016/j.jaci.2010.12.1081; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Burns SO, 2014, J ALLERGY CLIN IMMUN, V134, P215, DOI 10.1016/j.jaci.2013.12.1093; Cuvelier GDE, 2019, CLIN IMMUNOL, V205, P138, DOI 10.1016/j.clim.2018.10.019; Darwech I, 2010, J BIOL CHEM, V285, P25522, DOI 10.1074/jbc.M110.121533; de Beaucoudrey L, 2010, MEDICINE, V89, P381, DOI 10.1097/MD.0b013e3181fdd832; Silva RDE, 2014, DOSE-RESPONSE, V12, P110, DOI 10.2203/dose-response.13-015.Silva; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ding Y, 2018, J ALLERGY CLIN IMMUN, V142, P970, DOI 10.1016/j.jaci.2018.04.022; Dion Marie-Lise, 2007, Methods Mol Biol, V380, P197; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Isomura I, 2009, J EXP MED, V206, P3001, DOI 10.1084/jem.20091411; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Liu SP, 2013, J BIOL CHEM, V288, P22758, DOI 10.1074/jbc.M113.482596; Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mousallem T, 2014, BLOOD, V124, P2046, DOI 10.1182/blood-2014-04-571265; Nielsen C, 2014, J CLIN IMMUNOL, V34, P916, DOI 10.1007/s10875-014-0097-1; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Qin T, 2016, IMMUNOL RES, V64, P260, DOI 10.1007/s12026-015-8745-y; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schmidt-Supprian M, 2004, J IMMUNOL, V173, P1612, DOI 10.4049/jimmunol.173.3.1612; Schmidt-Supprian M, 2003, IMMUNITY, V19, P377, DOI 10.1016/S1074-7613(03)00237-1; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Wu JF, 2015, J ALLERGY CLIN IMMUN, V135, P209, DOI 10.1016/j.jaci.2014.06.025	30	2	2	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2021	11								517544	10.3389/fimmu.2020.517544	http://dx.doi.org/10.3389/fimmu.2020.517544			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QO3GT	33658989	gold, Green Published			2022-12-18	WOS:000623033600001
J	Sponaas, AM; Waage, A; Vandsemb, EN; Misund, K; Borset, M; Sundan, A; Slordahl, TS; Standal, T				Sponaas, Anne Marit; Waage, Anders; Vandsemb, Esten N.; Misund, Kristine; Borset, Magne; Sundan, Anders; Slordahl, Tobias Schmidt; Standal, Therese			Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?	FRONTIERS IN IMMUNOLOGY			English	Review						multiple myeloma; T cells; checkpoint therapy; immunomodulating drugs; virus		In this review article we discuss the role of the memory T cells in multiple myeloma (MM) and how they may influence immune responses in patients that received immunomodulating drugs and check point therapy.	[Sponaas, Anne Marit; Waage, Anders; Vandsemb, Esten N.; Misund, Kristine; Borset, Magne; Sundan, Anders; Slordahl, Tobias Schmidt; Standal, Therese] Norwegian Univ Sci & Technol NTNU, Fac Med & Hlth Sci, Ctr Myeloma Res, Dept Clin & Mol Med, Trondheim, Norway; [Waage, Anders; Slordahl, Tobias Schmidt] St Olavs Hosp, Dept Hematol, Trondheim, Norway; [Borset, Magne] St Olavs Hosp, Dept Immunol & Transfus Med, Trondheim, Norway; [Standal, Therese] Norwegian Univ Sci & Technol NTNU, Fac Med & Hlth Sci, Ctr Mol Inflammat Res, Dept Clin & Mol Med, Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Sponaas, AM (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med & Hlth Sci, Ctr Myeloma Res, Dept Clin & Mol Med, Trondheim, Norway.	anne-marit.sponaas@ntnu.no	Borset, Magne/AAY-1713-2021; St Olav Hospital, Medisinsk Klinikk -/AAD-6414-2022		Norwegian Cancer Society; Research Council of Norway; Liaison Committee for education, research and innovation in Central Norway; Cancer Fund at St. Olavs Hospital, Trondheim, Norway, Rakel and Otto Kr. Bruun's legacy	Norwegian Cancer Society(Norwegian Cancer Society); Research Council of Norway(Research Council of Norway); Liaison Committee for education, research and innovation in Central Norway; Cancer Fund at St. Olavs Hospital, Trondheim, Norway, Rakel and Otto Kr. Bruun's legacy	This work was supported by Norwegian Cancer Society, The Research Council of Norway, The Liaison Committee for education, research and innovation in Central Norway, and the Cancer Fund at St. Olavs Hospital, Trondheim, Norway, Rakel and Otto Kr. Bruun's legacy.	Abbott RJM, 2013, J IMMUNOL, V191, P5398, DOI 10.4049/jimmunol.1301629; Alrasheed N, 2020, CLIN CANCER RES, V26, P3443, DOI 10.1158/1078-0432.CCR-19-1714; Appay V, 2004, SEMIN IMMUNOL, V16, P205, DOI 10.1016/j.smim.2004.02.007; Bailur JK, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127807; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Blimark C, 2015, HAEMATOLOGICA, V100, P107, DOI 10.3324/haematol.2014.107714; Borset M, 2020, BLOOD REV, V41, DOI 10.1016/j.blre.2019.100646; Britanova OV, 2016, J IMMUNOL, V196, P5005, DOI 10.4049/jimmunol.1600005; Brown RD, 2009, LEUKEMIA LYMPHOMA, V50, P1860, DOI 10.3109/10428190903216804; Casorati G, 2005, EXP HEMATOL, V33, P212, DOI 10.1016/j.exphem.2004.10.008; Cox B, 2010, BRIT J CANCER, V102, P1665, DOI 10.1038/sj.bjc.6605675; Cunningham MW, 2004, MOL IMMUNOL, V40, P1121, DOI 10.1016/j.molimm.2003.11.023; Dhanji S, 2003, J IMMUNOL, V171, P3442, DOI 10.4049/jimmunol.171.7.3442; Dhodapkar KM, 2008, BLOOD, V112, P2878, DOI 10.1182/blood-2008-03-143222; Dhodapkar MV, 2003, J EXP MED, V198, P1753, DOI 10.1084/jem.20031030; Feyler S, 2009, BRIT J HAEMATOL, V144, P686, DOI 10.1111/j.1365-2141.2008.07530.x; Forte E, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00130; Fulop T, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00271; Ganatra S, 2018, ONCOLOGIST, V23, P879, DOI 10.1634/theoncologist.2018-0130; Goodyear O, 2005, BLOOD, V106, P4217, DOI 10.1182/blood-2005-02-0563; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Guillerey C, 2016, CELL MOL LIFE SCI, V73, P1569, DOI 10.1007/s00018-016-2135-z; Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885; Hislop AD, 2015, CURR TOP MICROBIOL, V391, P325, DOI 10.1007/978-3-319-22834-1_11; Inazawa N, 2017, J MED VIROL, V89, P358, DOI 10.1002/jmv.24621; Jelinek T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02431; Johnson DB, 2019, NAT MED, V25, P1243, DOI 10.1038/s41591-019-0523-2; Jones RJ, 2016, CLIN CANCER RES, V22, P4901, DOI 10.1158/1078-0432.CCR-15-2242; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Kawano Y, 2018, J CLIN INVEST, V128, P2487, DOI 10.1172/JCI88169; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Klarenbeek PL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002889; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Kortum KM, 2015, BLOOD REV, V29, P329, DOI 10.1016/j.blre.2015.03.003; Kovtonyuk LV, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00502; Kramer I, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1139662; Kyto V, 2005, CLIN INFECT DIS, V40, P683, DOI 10.1086/427804; LeBlanc R, 2004, BLOOD, V103, P1787, DOI 10.1182/blood-2003-02-0361; Levy R, 2016, P NATL ACAD SCI USA, V113, pE6437, DOI 10.1073/pnas.1603321113; Long HM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02193; Maasho K, 2005, J IMMUNOL, V174, P4480, DOI 10.4049/jimmunol.174.8.4480; Martinez-Calle N, 2018, HAEMATOLOGICA, V103, pE318, DOI 10.3324/haematol.2017.185777; Massoud R, 2017, J CLIN VIROL, V95, P36, DOI 10.1016/j.jcv.2017.08.006; Mateos MV, 2019, LANCET HAEMATOL, V6, pE459, DOI 10.1016/S2352-3026(19)30110-3; Mateos MV, 2019, BRIT J HAEMATOL, V186, pE117, DOI 10.1111/bjh.15946; McCoy L, 2006, AUTOIMMUNITY, V39, P9, DOI 10.1080/08916930500484799; McKinney EF, 2015, NATURE, V523, P612, DOI 10.1038/nature14468; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; Minnie SA, 2018, BLOOD, V132, P1675, DOI 10.1182/blood-2018-01-825240; Mutlu H, 2011, HEART LUNG, V40, P81, DOI 10.1016/j.hrtlng.2009.12.012; Nakamura K, 2018, CANCER CELL, V33, P634, DOI 10.1016/j.ccell.2018.02.007; Okazaki T, 2006, TRENDS IMMUNOL, V27, P195, DOI 10.1016/j.it.2006.02.001; Okhrimenko A, 2014, P NATL ACAD SCI USA, V111, P9229, DOI 10.1073/pnas.1318731111; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; Perumal D, 2020, CLIN CANCER RES, V26, P450, DOI 10.1158/1078-0432.CCR-19-2309; Puig N, 2020, CANCERS, V12, DOI 10.3390/cancers12123615; Qian JF, 2007, BLOOD, V110, P1587, DOI 10.1182/blood-2007-03-082529; Reynolds JM, 2013, TRENDS IMMUNOL, V34, P511, DOI 10.1016/j.it.2013.06.003; Roberto A, 2015, BLOOD, V125, P2855, DOI 10.1182/blood-2014-11-608406; Rosato PC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08534-1; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9; Sehgal K, 2015, BLOOD, V125, P4042, DOI 10.1182/blood-2014-11-611426; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Sponaas Anne-Marit, 2018, Oncotarget, V9, P32024, DOI 10.18632/oncotarget.25882; Suen H, 2016, LEUKEMIA, V30, P1716, DOI 10.1038/leu.2016.84; Suen H, 2015, LEUKEMIA, V29, P1621, DOI 10.1038/leu.2015.104; Taylor GS, 2015, ANNU REV IMMUNOL, V33, P787, DOI 10.1146/annurev-immunol-032414-112326; Tietze JK, 2012, BLOOD, V119, P3073, DOI 10.1182/blood-2011-07-369736; Torti L, 2017, BLOOD, V130; Usmani SZ, 2019, LANCET HAEMATOL, V6, pE448, DOI 10.1016/S2352-3026(19)30109-7; van Rhee F, 2005, BLOOD, V105, P3939, DOI 10.1182/blood-2004-09-3707; Vuckovic S, 2020, BLOOD ADV, V4, P4593, DOI 10.1182/bloodadvances.2020002237; Weng NP, 2012, NAT REV IMMUNOL, V12, P306, DOI 10.1038/nri3173; Westhrin M, 2020, BLOOD, V136, P2656, DOI 10.1182/blood.2020006045; Whiteside SK, 2018, TRENDS IMMUNOL, V39, P1021, DOI 10.1016/j.it.2018.10.003; Wu TD, 2020, NATURE, V579, P274, DOI 10.1038/s41586-020-2056-8; Yang R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000610; Zahoor M, 2017, BLOOD ADV, V1, P2656, DOI 10.1182/bloodadvances.2017010801; Zavidij O, 2020, NAT CANCER, V1, DOI 10.1038/s43018-020-0053-3; Zelle-Rieser C, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0345-3	81	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2021	12								636375	10.3389/fimmu.2021.636375	http://dx.doi.org/10.3389/fimmu.2021.636375			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QO5RO	33679794	Green Published, gold			2022-12-18	WOS:000623199600001
J	Stein, JV; Ruef, N; Wissmann, S				Stein, Jens, V; Ruef, Nora; Wissmann, Stefanie			Organ-Specific Surveillance and Long-Term Residency Strategies Adapted by Tissue-Resident Memory CD8(+) T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						tissue-resident T cells; epidermal barrier; salivary gland; chemokine; integrin		Tissue-resident CD8(+) T cells (CD8(+) T-RM) populate lymphoid and non-lymphoid tissues after infections as first line of defense against re-emerging pathogens. To achieve host protection, CD8(+) T-RM have developed surveillance strategies that combine dynamic interrogation of pMHC complexes on local stromal and hematopoietic cells with long-term residency. Factors mediating CD8(+) T-RM residency include CD69, a surface receptor opposing the egress-promoting S1P1, CD49a, a collagen-binding integrin, and CD103, which binds E-cadherin on epithelial cells. Moreover, the topography of the tissues of residency may influence T-RM retention and surveillance strategies. Here, we provide a brief summary of these factors to examine how CD8(+) T-RM reconcile constant migratory behavior with their long-term commitment to local microenvironments, with a focus on epithelial barrier organs and exocrine glands with mixed connective-epithelial tissue composition.	[Stein, Jens, V; Ruef, Nora; Wissmann, Stefanie] Univ Fribourg, Dept Oncol Microbiol & Immunol, Fribourg, Switzerland	University of Fribourg	Stein, JV (corresponding author), Univ Fribourg, Dept Oncol Microbiol & Immunol, Fribourg, Switzerland.	jens.stein@unifr.ch		Stein, Jens V/0000-0002-8199-9586	Swiss National Foundation [31003A_172994, CRSII5_170969, CRSK-3_190484]	Swiss National Foundation(Swiss National Science Foundation (SNSF))	The Stein laboratory was funded by Swiss National Foundation grants 31003A_172994, CRSII5_170969 and CRSK-3_190484 (to JS).	Amsen D, 2018, NAT IMMUNOL, V19, P538, DOI 10.1038/s41590-018-0114-2; Ariotti S, 2015, J IMMUNOL, V195, P5285, DOI 10.4049/jimmunol.1500853; Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803; Ariotti S, 2012, P NATL ACAD SCI USA, V109, P19739, DOI 10.1073/pnas.1208927109; Behr FM, 2020, NAT IMMUNOL, V21, P1070, DOI 10.1038/s41590-020-0723-4; Belz Gabrielle T, 2020, F1000Res, V9, DOI 10.12688/f1000research.25234.1; Bergert M, 2015, NAT CELL BIOL, V17, P524, DOI 10.1038/ncb3134; Beura LK, 2018, IMMUNITY, V48, P327, DOI 10.1016/j.immuni.2018.01.015; Brandner JM, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974451; Bromley SK, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108085; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Carbone FR, 2015, J IMMUNOL, V195, P17, DOI 10.4049/jimmunol.1500515; Casey KA, 2012, J IMMUNOL, V188, P4866, DOI 10.4049/jimmunol.1200402; Chang HD, 2018, IMMUNOL REV, V283, P86, DOI 10.1111/imr.12656; Charras G, 2014, NAT REV MOL CELL BIO, V15, P813, DOI 10.1038/nrm3897; Clark GF, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00026; Conrad C, 2007, NAT MED, V13, P836, DOI 10.1038/nm1605; Dijkgraaf FE, 2019, NAT IMMUNOL, V20, P756, DOI 10.1038/s41590-019-0404-3; Dixit D, 2019, IMMUNOL REV, V289, P173, DOI 10.1111/imr.12760; Enamorado M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01751; Fan X, 2016, CELL, V164, P1198, DOI 10.1016/j.cell.2016.02.048; Fernandez-Ruiz D, 2016, IMMUNITY, V45, P889, DOI 10.1016/j.immuni.2016.08.011; Ge CH, 2019, CELL REP, V29, P4236, DOI 10.1016/j.celrep.2019.11.103; Gebhardt T, 2018, IMMUNOL REV, V283, P54, DOI 10.1111/imr.12650; Gebhardt T, 2011, NATURE, V477, P216, DOI 10.1038/nature10339; Gerlach C, 2016, IMMUNITY, V45, P1270, DOI 10.1016/j.immuni.2016.10.018; Gibbons DL, 2011, J IMMUNOL, V187, P2067, DOI 10.4049/jimmunol.1100833; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Halle S, 2016, IMMUNITY, V44, P233, DOI 10.1016/j.immuni.2016.01.010; Hirai T, 2021, IMMUNITY, V54, P84, DOI 10.1016/j.immuni.2020.10.022; Hombrink P, 2016, NAT IMMUNOL, V17, P1467, DOI 10.1038/ni.3589; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; Iijima N, 2014, SCIENCE, V346, P93, DOI 10.1126/science.1257530; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Kadoki M, 2017, CELL, V171, P398, DOI 10.1016/j.cell.2017.08.024; Kehrl JH, 2016, BIOCHEM PHARMACOL, V114, P40, DOI 10.1016/j.bcp.2016.04.005; Khan TN, 2016, J EXP MED, V213, P951, DOI 10.1084/jem.20151855; Kok L, 2020, J EXP MED, V217, DOI 10.1084/jem.20191711; Kopf A, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201907154; Kumar BV, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123568; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Lee SH, 2015, INTEST RES, V13, P11, DOI 10.5217/ir.2015.13.1.11; Lomakin AJ, 2020, SCIENCE, V370, P310, DOI 10.1126/science.aba2894; Low JS, 2020, J EXP MED, V217, DOI 10.1084/jem.20192291; Mackay LK, 2017, TRENDS IMMUNOL, V38, P94, DOI 10.1016/j.it.2016.11.004; Mackay LK, 2016, SCIENCE, V352, P459, DOI 10.1126/science.aad2035; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; Mani V, 2019, SCIENCE, V366, P202, DOI 10.1126/science.aav5728; Masopust D, 2013, NAT REV IMMUNOL, V13, P309, DOI 10.1038/nri3442; Maurice NJ, 2021, J IMMUNOL, V206, P455, DOI 10.4049/jimmunol.2000937; McCully ML, 2018, TRENDS IMMUNOL, V39, P734, DOI 10.1016/j.it.2018.06.003; Milner JJ, 2020, IMMUNITY, V52, P808, DOI 10.1016/j.immuni.2020.04.007; Milner JJ, 2017, NATURE, V552, P253, DOI 10.1038/nature24993; Moalli F, 2018, J EXP MED, V215, P1869, DOI 10.1084/jem.20170896; Moreau HD, 2018, TRENDS IMMUNOL, V39, P632, DOI 10.1016/j.it.2018.04.007; Mueller SN, 2016, NAT REV IMMUNOL, V16, P79, DOI 10.1038/nri.2015.3; Nath AP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210495; Osborn JF, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan6049; Overstreet MG, 2013, NAT IMMUNOL, V14, P949, DOI 10.1038/ni.2682; Pallett LJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200050; Paluch EK, 2016, ANNU REV CELL DEV BI, V32, P469, DOI 10.1146/annurev-cellbio-111315-125341; Pan YD, 2017, NATURE, V543, P252, DOI 10.1038/nature21379; Pascutti MF, 2019, EUR J IMMUNOL, V49, P853, DOI 10.1002/eji.201848003; Pauls K, 2001, J INVEST DERMATOL, V117, P569, DOI 10.1046/j.0022-202x.2001.01481.x; Pfeiffer F, 2008, EUR J IMMUNOL, V38, P2142, DOI 10.1002/eji.200838140; Reilly EC, 2020, P NATL ACAD SCI USA, V117, P12306, DOI [10.1073/pnas.1915681117/-/DCSupplemental, 10.1073/pnas.1915681117]; Reversat A, 2020, NATURE, V582, P582, DOI 10.1038/s41586-020-2283-z; Rosato PC, 2017, CURR OPIN VIROL, V22, P44, DOI 10.1016/j.coviro.2016.11.011; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sasson SC, 2020, CELL MOL IMMUNOL, V17, P113, DOI 10.1038/s41423-019-0359-1; Schenkel JM, 2014, SCIENCE, V346, P98, DOI 10.1126/science.1254536; Schenkel JM, 2014, J IMMUNOL, V192, P2961, DOI 10.4049/jimmunol.1400003; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Sigmundsdottir H, 2008, NAT IMMUNOL, V9, P981, DOI 10.1038/ni.f.208; Skon CN, 2013, NAT IMMUNOL, V14, P1285, DOI 10.1038/ni.2745; Smith CJ, 2015, CELL REP, V13, P1137, DOI 10.1016/j.celrep.2015.09.076; Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852; Stary G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa8205; Stein JV, 2019, IMMUNOL REV, V289, P232, DOI 10.1111/imr.12759; Steinbach K, 2016, J EXP MED, V213, P1571, DOI 10.1084/jem.20151916; Stolp B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz4371; Sung JH, 2012, CELL, V150, P1249, DOI 10.1016/j.cell.2012.08.015; Szabo PA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aas9673; Takamura S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01214; Takesono A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008774; Thom JT, 2015, CELL REP, V13, P1125, DOI 10.1016/j.celrep.2015.09.082; Turner JE, 2018, J AM SOC NEPHROL, V29, P389, DOI 10.1681/ASN.2017060599; Uderhardt S, 2019, CELL, V177, P541, DOI 10.1016/j.cell.2019.02.028; Venturini V, 2020, SCIENCE, V370, P311, DOI 10.1126/science.aba2644; Walsh DA, 2019, J IMMUNOL, V203, P946, DOI 10.4049/jimmunol.1900052; Wein AN, 2019, J EXP MED, V216, P2748, DOI 10.1084/jem.20181308; Wolf K, 2003, BLOOD, V102, P3262, DOI 10.1182/blood-2002-12-3791; Wong MT, 2016, IMMUNITY, V45, P442, DOI 10.1016/j.immuni.2016.07.007; Zaid A, 2017, J IMMUNOL, V199, P2451, DOI 10.4049/jimmunol.1700571; Zaid A, 2014, P NATL ACAD SCI USA, V111, P5307, DOI 10.1073/pnas.1322292111; Zhao ST, 2014, CELL MOL IMMUNOL, V11, P428, DOI 10.1038/cmi.2014.38	100	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 15	2021	12								626019	10.3389/fimmu.2021.626019	http://dx.doi.org/10.3389/fimmu.2021.626019			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QO3EO	33659008	Green Published, gold			2022-12-18	WOS:000623027900001
J	Binder, C; Sellberg, F; Cvetkovski, F; Berg, S; Berglund, E; Berglund, D				Binder, Christian; Sellberg, Felix; Cvetkovski, Filip; Berg, Stefan; Berglund, Erik; Berglund, David			Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity	FRONTIERS IN IMMUNOLOGY			English	Article						NK cell; CD2; siplizumab; spontaneous cytotoxicity; antibody-dependent cell-mediated cytotoxicity; NK alloreactivity		The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc gamma receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2 via monoclonal antibodies in the absence of Fc gamma receptor binding inhibited NK cell activation in allogeneic mixed lymphocyte reaction. In contrast, siplizumab increased NK cell activation in both mixed lymphocyte reaction and autologous lymphocyte culture due to Fc gamma RIIIA binding. However, experiments using purified NK cells did not show an inhibitory effect of CD2 blockade on natural cytotoxicity or antibody-dependent cytotoxicity. Lastly, it was shown that siplizumab induces NK cell fratricide. Concluding, siplizumab is a promising biopharmaceutical drug candidate for depletion of T and NK cells with minimal off-target effects.	[Binder, Christian; Sellberg, Felix; Berglund, David] Uppsala Univ, Dept Immunol Genet & Pathol, Sect Clin Immunol, Uppsala, Sweden; [Binder, Christian; Sellberg, Felix; Cvetkovski, Filip; Berg, Stefan; Berglund, Erik; Berglund, David] ITB Med AB, Res & Dev, Stockholm, Sweden; [Berglund, Erik] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Transplantat Surg, Stockholm, Sweden; [Berglund, Erik] Karolinska Univ Hosp, Stockholm, Sweden	Uppsala University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Binder, C (corresponding author), Uppsala Univ, Dept Immunol Genet & Pathol, Sect Clin Immunol, Uppsala, Sweden.; Binder, C (corresponding author), ITB Med AB, Res & Dev, Stockholm, Sweden.	christian.binder@igp.uu.se						Arduin E, 2015, MOL IMMUNOL, V63, P456, DOI 10.1016/j.molimm.2014.09.017; Ashraf MI, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02279; Binder C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.592553; Binder C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01090; Branco L, 1999, TRANSPLANTATION, V68, P1588, DOI 10.1097/00007890-199911270-00026; Comerci CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047664; Damschroder MM, 2004, MOL IMMUNOL, V41, P985, DOI 10.1016/j.molimm.2004.05.004; Dehoux JP, 2000, TRANSPLANTATION, V69, P2622, DOI 10.1097/00007890-200006270-00024; Demetriou P, 2020, NAT IMMUNOL, V21, P1232, DOI 10.1038/s41590-020-0770-x; Dutertre CA, 2008, J LEUKOCYTE BIOL, V84, P1511, DOI 10.1189/jlb.0608343; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Ferlazzo G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00159; Fogel LA, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4232; Grandjean CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep34382; Grier JT, 2012, J CLIN INVEST, V122, P3769, DOI 10.1172/JCI64837; Haider AS, 2007, J IMMUNOL, V178, P7442, DOI 10.4049/jimmunol.178.11.7442; Harmon C, 2016, AM J TRANSPLANT, V16, P751, DOI 10.1111/ajt.13565; Inoue H, 2002, EUR J IMMUNOL, V32, P2188, DOI 10.1002/1521-4141(200208)32:8<2188::AID-IMMU2188>3.0.CO;2-T; Jawahar S, 1996, CLIN EXP IMMUNOL, V103, P408; Ji WB, 2017, EXP THER MED, V14, P2380, DOI 10.3892/etm.2017.4748; Lo DJ, 2011, AM J TRANSPLANT, V11, P22, DOI 10.1111/j.1600-6143.2010.03317.x; Marquardt N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11632-9; Marquardt N, 2017, J ALLERGY CLIN IMMUN, V139, P1321, DOI 10.1016/j.jaci.2016.07.043; Meehan AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060144; Mikulak J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00946; O'Mahony D, 2007, BLOOD, V110, p1043A; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Paul S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01124; Podesta MA, 2020, AM J TRANSPLANT, V20, P88, DOI 10.1111/ajt.15533; Schleinitz N, 2010, IMMUNOLOGY, V131, P451, DOI 10.1111/j.1365-2567.2010.03360.x; Schlothauer T, 2016, PROTEIN ENG DES SEL, V29, P457, DOI 10.1093/protein/gzw040; Sellberg F, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12839; Silva JP, 2015, J BIOL CHEM, V290, P5462, DOI 10.1074/jbc.M114.600973; Umehara H, 1997, J IMMUNOL, V159, P1200; Umehara H, 2002, MOL IMMUNOL, V38, P587, DOI 10.1016/S0161-5890(01)00099-2; Wang XH, 2018, PROTEIN CELL, V9, P63, DOI 10.1007/s13238-017-0473-8; Watzl C, 2014, ADV IMMUNOL, V124, P137, DOI 10.1016/B978-0-12-800147-9.00005-4	37	2	2	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2021	12								599526	10.3389/fimmu.2021.599526	http://dx.doi.org/10.3389/fimmu.2021.599526			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL8SU	33643309	gold, Green Published			2022-12-18	WOS:000621351600001
J	Hada-Neeman, S; Weiss-Ottolenghi, Y; Wagner, N; Avram, O; Ashkenazy, H; Maor, Y; Sklan, EH; Shcherbakov, D; Pupko, T; Gershoni, JM				Hada-Neeman, Smadar; Weiss-Ottolenghi, Yael; Wagner, Naama; Avram, Oren; Ashkenazy, Haim; Maor, Yaakov; Sklan, Ella H.; Shcherbakov, Dmitry; Pupko, Tal; Gershoni, Jonathan M.			Domain-Scan: Combinatorial Sero-Diagnosis of Infectious Diseases Using Machine Learning	FRONTIERS IN IMMUNOLOGY			English	Article						sero-diagnostics; DNA barcodes; next-generation sequencing; machine learning; phage-display	EPITOPE; ANTIBODIES; VIRUS; HIV	The presence of pathogen-specific antibodies in an individual's blood-sample is used as an indication of previous exposure and infection to that specific pathogen (e.g., virus or bacterium). Measurement of the diagnostic antibodies is routinely achieved using solid phase immuno-assays such as ELISA tests and western blots. Here, we describe a sero-diagnostic approach based on phage-display of epitope arrays we term "Domain-Scan". We harness Next-generation sequencing (NGS) to measure the serum binding to dozens of epitopes derived from HIV-1 and HCV simultaneously. The distinction of healthy individuals from those infected with either HIV-1 or HCV, is modeled as a machine-learning classification problem, in which each determinant ("domain") is considered as a feature, and its NGS read-out provides values that correspond to the level of determinant-specific antibodies in the sample. We show that following training of a machine-learning model on labeled examples, we can very accurately classify unlabeled samples and pinpoint the domains that contribute most to the classification. Our experimental/computational Domain-Scan approach is general and can be adapted to other pathogens as long as sufficient training samples are provided.	[Hada-Neeman, Smadar; Weiss-Ottolenghi, Yael; Wagner, Naama; Avram, Oren; Pupko, Tal; Gershoni, Jonathan M.] Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel; [Ashkenazy, Haim] Max Planck Inst Dev Biol, Max Planck Soc MPG, Tubingen, Germany; [Maor, Yaakov] Kaplan Med Ctr, Inst Gastroenterol & Hepatol, Rehovot, Israel; [Sklan, Ella H.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel; [Shcherbakov, Dmitry] Altai State Univ, Russian Amer Anticanc Ctr, Barnaul, Russia	Tel Aviv University; Max Planck Society; Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Altai State University	Pupko, T; Gershoni, JM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel.	talp@tauex.tau.ac.il; gershoni@tauex.tau.ac.il	Pupko, Tal/HGF-1353-2022; Shcherbakov, Dmitry/U-4763-2019; Ashkenazy, Haim/AAX-6285-2021	Pupko, Tal/0000-0001-9463-2575; Ashkenazy, Haim/0000-0002-5079-4684	Israel Science Foundation; Edmond J. Safra Center for Bioinformatics at Tel Aviv University; Manna Center Program for Food Safety and Security at Tel Aviv University; Dalia and Eli Hurvitz Foundation; Alexander von Humboldt Foundation; Jakov, Miriana, and Jorge Saia Fellowships	Israel Science Foundation(Israel Science Foundation); Edmond J. Safra Center for Bioinformatics at Tel Aviv University; Manna Center Program for Food Safety and Security at Tel Aviv University; Dalia and Eli Hurvitz Foundation; Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Jakov, Miriana, and Jorge Saia Fellowships	This research was supported by two Grants of the Israel Science Foundation to JG. NW, OA, and HA were supported in part by a fellowship from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University. NW was supported in part by the Manna Center Program for Food Safety and Security at Tel Aviv University. OA was supported in part by the Dalia and Eli Hurvitz Foundation. HA was supported in part by Humboldt Research Fellowship for Postdoctoral Researchers from the Alexander von Humboldt Foundation. YM and ES were supported in part by a grant from the Dr. Sima Lior research. SH-N and YW-O were recipients of Jakov, Miriana, and Jorge Saia Fellowships.	Carotenuto P, 1998, AIDS, V12, P1591, DOI 10.1097/00002030-199813000-00005; Chen YH, 1998, IMMUNOL TODAY, V19, P586, DOI 10.1016/S0167-5699(98)01368-1; Claire Moore M, 2009, INTRO W BLOTTING; Enshell-Seijffers D, 2001, Nucleic Acids Res, V29, pE50, DOI 10.1093/nar/29.10.e50; Enshell-Seijffers D, 2001, FASEB J, V15, P2112, DOI 10.1096/fj.00-0898com; Gao F, 2005, J VIROL, V79, P1154, DOI 10.1128/JVI.79.2.1154-1163.2005; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687; Hofer T, 2006, IMMUNOL REV, V211, P295, DOI 10.1111/j.0105-2896.2006.00380.x; HORAL P, 1991, J VIROL, V65, P2718, DOI 10.1128/JVI.65.5.2718-2723.1991; Isnard P, 2019, P NATL ACAD SCI USA, V116, P10899, DOI 10.1073/pnas.1821166116; Kurien BT, 2011, METHODS MOL BIOL, V717, P55, DOI 10.1007/978-1-61779-024-9_3; Liu JP, 2020, CELL, V182, P317, DOI 10.1016/j.cell.2020.05.038; Marvin DA, 1998, CURR OPIN STRUC BIOL, V8, P150, DOI 10.1016/S0959-440X(98)80032-8; Mina MJ, 2019, SCIENCE, V366, P599, DOI 10.1126/science.aay6485; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Ryvkin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041469; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Siman-Tov DD, 2013, ANAL BIOCHEM, V432, P63, DOI 10.1016/j.ab.2012.09.025; Weiss-Ottolenghi Y, 2014, FEBS LETT, V588, P318, DOI 10.1016/j.febslet.2013.11.005; Wine Y, 2015, CURR OPIN IMMUNOL, V35, P89, DOI 10.1016/j.coi.2015.06.009; Xiao Y, 2001, IMMUNOL LETT, V77, P3, DOI 10.1016/S0165-2478(01)00187-0; Xu GJ, 2015, SCIENCE, V348, DOI 10.1126/science.aaa0698	25	2	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2021	11								619896	10.3389/fimmu.2020.619896	http://dx.doi.org/10.3389/fimmu.2020.619896			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL0UU	33643301	gold, Green Published			2022-12-18	WOS:000620797800001
J	Liu, YL; Li, ZM; Wu, YY; Jing, XB; Li, L; Fang, XD				Liu, Yilun; Li, Zhongmin; Wu, Yuanyu; Jing, Xiabin; Li, Lin; Fang, Xuedong			Intestinal Bacteria Encapsulated by Biomaterials Enhance Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						intestinal bacteria; probiotic; immunotherapy; immune cell; biomaterial; oral delivery	PROBIOTIC BACTERIA; TARGETED DELIVERY; CPG MOTIFS; T-CELLS; ALGINATE; NANOPARTICLES; MICROBIOTA; INDUCTION; VIABILITY; SURVIVAL	The human intestine contains thousands of bacterial species essential for optimal health. Aside from their pathogenic effects, these bacteria have been associated with the efficacy of various treatments of diseases. Due to their impact on many human diseases, intestinal bacteria are receiving increasing research attention, and recent studies on intestinal bacteria and their effects on treatments has yielded valuable results. Particularly, intestinal bacteria can affect responses to numerous forms of immunotherapy, especially cancer therapy. With the development of precision medicine, understanding the factors that influence intestinal bacteria and how they can be regulated to enhance immunotherapy effects will improve the application prospects of intestinal bacteria therapy. Further, biomaterials employed for the convenient and efficient delivery of intestinal bacteria to the body have also become a research hotspot. In this review, we discuss the recent findings on the regulatory role of intestinal bacteria in immunotherapy, focusing on immune cells they regulate. We also summarize biomaterials used for their delivery.	[Liu, Yilun; Li, Zhongmin; Wu, Yuanyu; Li, Lin; Fang, Xuedong] Jilin Univ, Dept Gastrointestinal Colorectal & Anal Surg, China Japan Union Hosp, Changchun, Peoples R China; [Jing, Xiabin] Chinese Acad Sci, Changchun Inst Appl Chem, Changchun, Peoples R China	Jilin University; Chinese Academy of Sciences; Changchun Institute of Applied Chemistry, CAS	Fang, XD (corresponding author), Jilin Univ, Dept Gastrointestinal Colorectal & Anal Surg, China Japan Union Hosp, Changchun, Peoples R China.	fangxd@jlu.edu.cn	liu, yi/GXE-9662-2022					Ahmadzadeh M, 2020, MOL BIOTECHNOL, V62, P18, DOI 10.1007/s12033-019-00221-2; Alkotaini B, 2018, CHEMBIOCHEM, V19, P1162, DOI 10.1002/cbic.201800142; Ansari F, 2017, AMB EXPRESS, V7, DOI 10.1186/s13568-017-0442-x; Anselmo AC, 2016, ADV MATER, V28, P9486, DOI 10.1002/adma.201603270; Araya RE, 2016, IMMUNITY, V45, P714, DOI 10.1016/j.immuni.2016.10.007; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Aryana KJ, 2017, J DAIRY SCI, V100, P9987, DOI 10.3168/jds.2017-12981; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Ballas ZK, 1996, J IMMUNOL, V157, P1840; Basu R, 2012, IMMUNITY, V37, P1061, DOI 10.1016/j.immuni.2012.08.024; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Belkacem N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184976; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Belkaid Y, 2013, NAT IMMUNOL, V14, P646, DOI 10.1038/ni.2604; BENGMARK S, 1995, JPEN-PARENTER ENTER, V19, P410, DOI 10.1177/0148607195019005410; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Bleuze M, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151979; Blumberg R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004184; Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108; Capurso L, 2019, J CLIN GASTROENTEROL, V53, pS1, DOI [10.1097/mcg.0000000000001170, 10.1097/MCG.0000000000001170]; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; Cebeci A, 2003, FOOD MICROBIOL, V20, P511, DOI 10.1016/S0740-0020(02)00174-0; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Chen H, 2005, J MICROENCAPSUL, V22, P539, DOI 10.1080/02652040500162162; Chen WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039743; Chiba Y, 2010, IMMUNOLOGY, V130, P352, DOI 10.1111/j.1365-2567.2009.03204.x; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Chow J, 2011, CURR OPIN IMMUNOL, V23, P473, DOI 10.1016/j.coi.2011.07.010; Chowdhuri S, 2016, CHEMBIOCHEM, V17, P886, DOI 10.1002/cbic.201500643; Chua KJ, 2017, CURR OPIN CHEM BIOL, V40, P8, DOI 10.1016/j.cbpa.2017.04.011; Ciorba MA, 2012, GUT, V61, P829, DOI 10.1136/gutjnl-2011-300367; Cong YZ, 2009, P NATL ACAD SCI USA, V106, P19256, DOI 10.1073/pnas.0812681106; Cook MT, 2013, J MATER CHEM B, V1, P52, DOI 10.1039/c2tb00126h; Cook MT, 2012, J CONTROL RELEASE, V162, P56, DOI 10.1016/j.jconrel.2012.06.003; Cremonesi E, 2018, GUT, V67, P1984, DOI 10.1136/gutjnl-2016-313498; Cunningham-Rundles S, 2011, NUTRIENTS, V3, P1042, DOI 10.3390/nu3121042; D'Orazio G, 2015, APPL MICROBIOL BIOT, V99, P9779, DOI 10.1007/s00253-015-6853-1; Dafe A, 2017, INT J BIOL MACROMOL, V97, P536, DOI 10.1016/j.ijbiomac.2017.01.060; Damodharan K, 2017, BIOTECHNOL BIOPROC E, V22, P265, DOI 10.1007/s12257-017-0096-1; de Barros JMS, 2016, EUR J PHARM BIOPHARM, V102, P115, DOI 10.1016/j.ejpb.2016.03.010; de Barros JMS, 2015, INT J PHARMACEUT, V493, P483, DOI 10.1016/j.ijpharm.2015.06.051; de Barros JMS, 2014, J PHARM SCI-US, V103, P2022, DOI 10.1002/jps.23997; De Santis S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00612; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Diab R, 2017, ADV COLLOID INTERFAC, V249, P346, DOI 10.1016/j.cis.2017.04.005; Dilnawaz F, 2010, BIOMATERIALS, V31, P3694, DOI 10.1016/j.biomaterials.2010.01.057; Dong QY, 2013, INT J FOOD SCI TECH, V48, P1339, DOI 10.1111/ijfs.12078; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Dzutsev A, 2015, EUR J IMMUNOL, V45, P17, DOI 10.1002/eji.201444972; Elyaman W, 2009, P NATL ACAD SCI USA, V106, P12885, DOI 10.1073/pnas.0812530106; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; Faith JJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008051; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760; Forsythe P, 2007, AM J RESP CRIT CARE, V175, P561, DOI 10.1164/rccm.200606-821OC; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Gombotz WR, 2012, ADV DRUG DELIVER REV, V64, P194, DOI 10.1016/j.addr.2012.09.007; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015; Gostner JM, 2020, NEUROPSYCHOBIOLOGY, V79, P89, DOI 10.1159/000496293; Grierson P, 2017, J GASTROINTEST ONCOL, V8, P474, DOI 10.21037/jgo.2017.05.01; Haffner FB, 2016, J MATER CHEM B, V4, P7929, DOI 10.1039/c6tb02802k; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hendrikx T, 2019, J INTERN MED, V286, P32, DOI 10.1111/joim.12892; Hengge U R, 2001, Lancet Infect Dis, V1, P189, DOI 10.1016/S1473-3099(01)00095-0; Hill D, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02107; Hold GL, 2016, DIGEST DIS, V34, P244, DOI 10.1159/000443358; Holodniy M, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014764, 10.1371/journal.pone.0025792]; Huda MN, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1489; Huq T, 2017, CARBOHYD POLYM, V168, P61, DOI 10.1016/j.carbpol.2017.03.032; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Jacouton E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01553; Jobin C, 2018, SCIENCE, V359, P32, DOI 10.1126/science.aar2946; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Karimi K, 2009, AM J RESP CRIT CARE, V179, P186, DOI 10.1164/rccm.200806-951OC; Kato K, 2017, CURR MICROBIOL, V74, P987, DOI 10.1007/s00284-017-1272-4; Khosravi A, 2014, CELL HOST MICROBE, V15, P374, DOI 10.1016/j.chom.2014.02.006; Kiang T, 2004, J BIOMAT SCI-POLYM E, V15, P1405, DOI 10.1163/1568562042368112; KOTLER DP, 1990, ANN INTERN MED, V113, P444; Kriegel MA, 2011, P NATL ACAD SCI USA, V108, P11548, DOI 10.1073/pnas.1108924108; Kroemer G, 2018, NAT REV IMMUNOL, V18, P87, DOI 10.1038/nri.2018.4; Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107; Lai WF, 2009, J CONTROL RELEASE, V134, P158, DOI 10.1016/j.jconrel.2008.11.021; Lammers KM, 2003, FEMS IMMUNOL MED MIC, V38, P165, DOI 10.1016/S0928-8244(03)00144-5; Lau K, 2011, J IMMUNOL, V186, P3538, DOI 10.4049/jimmunol.1001864; Lavasani S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009009; Li HT, 2016, LWT-FOOD SCI TECHNOL, V74, P542, DOI 10.1016/j.lwt.2016.08.019; Li J, 2016, P NATL ACAD SCI USA, V113, pE1306, DOI 10.1073/pnas.1518189113; Li W, 2017, FOOD HYDROCOLLOID, V62, P66, DOI 10.1016/j.foodhyd.2016.07.019; Li W, 2016, J AGR FOOD CHEM, V64, P3430, DOI 10.1021/acs.jafc.6b00481; Li XL, 2020, SMALL, V16, DOI 10.1002/smll.201902262; Lin H, 2018, J CLIN INVEST, V128, P1708, DOI 10.1172/JCI120803; Lin JZ, 2008, J BIOSCI BIOENG, V105, P660, DOI 10.1263/jbb.105.660; Liu KH, 2020, INT UROL NEPHROL, V52, P399, DOI 10.1007/s11255-019-02365-1; Lopez P, 2012, VACCINE, V30, P825, DOI 10.1016/j.vaccine.2011.11.115; Lucas C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061310; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Marchesi JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020447; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mei L, 2014, ACS APPL MATER INTER, V6, P5962, DOI 10.1021/am501011j; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; MESSINA JP, 1991, J IMMUNOL, V147, P1759; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Mo X, 2018, CANCER RES, V78, P436, DOI 10.1158/0008-5472.CAN-17-1615; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Nualkaekul S, 2012, CARBOHYD POLYM, V90, P1281, DOI 10.1016/j.carbpol.2012.06.073; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Odamaki T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18391-x; Oh NS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192021; Pardoll D, 2015, SEMIN ONCOL, V42, P523, DOI 10.1053/j.seminoncol.2015.05.003; Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pitt JM, 2016, ANN ONCOL, V27, P1482, DOI 10.1093/annonc/mdw168; Pitt JM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2015.1132137; Pitt JM, 2016, CANCER RES, V76, P4602, DOI 10.1158/0008-5472.CAN-16-0448; Prakash S, 2005, J BIOMED BIOTECHNOL, P44, DOI 10.1155/JBB.2005.44; Qi HB, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0424-4; Qian JW, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1330-2; Raghavan S, 2011, EXPERT REV GASTROENT, V5, P489, DOI [10.1586/egh.11.44, 10.1586/EGH.11.44]; Roager HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05470-4; Robert S, 2014, DIABETES, V63, P2876, DOI 10.2337/db13-1236; Roesch LFW, 2009, ISME J, V3, P536, DOI 10.1038/ismej.2009.5; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Routy B, 2018, NAT REV CLIN ONCOL, V15, P382, DOI 10.1038/s41571-018-0006-2; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Roy S, 2017, NAT REV CANCER, V17, P271, DOI 10.1038/nrc.2017.13; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Ryan PM, 2015, FOOD FUNCT, V6, P679, DOI [10.1039/c4fo00529e, 10.1039/C4FO00529E]; Schwarcz R, 2012, NAT REV NEUROSCI, V13, P465, DOI 10.1038/nrn3257; Seddik HA, 2017, PROBIOTICS ANTIMICRO, V9, P111, DOI 10.1007/s12602-017-9264-z; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Shi LE, 2013, J FOOD ENG, V117, P99, DOI 10.1016/j.jfoodeng.2013.02.012; SHIMADA S, 1986, JPN J CANCER RES, V77, P808; Shlyakhovenko VA, 2003, EXP ONCOL, V25, P119; Singh P, 2018, COLLOID SURFACE B, V168, P156, DOI 10.1016/j.colsurfb.2017.12.014; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Tenaillon O, 2010, NAT REV MICROBIOL, V8, P207, DOI 10.1038/nrmicro2298; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Turroni F, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7110544; Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105; Valladares R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010507; Varankovich NV, 2015, FOOD RES INT, V70, P118, DOI 10.1016/j.foodres.2015.01.028; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Vieira SM, 2018, SCIENCE, V359, P1156, DOI 10.1126/science.aar7201; Wang J, 2017, CAN J ANIM SCI, V97, P214, DOI 10.1139/cjas-2016-0090; Wang J, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01953; Wang TT, 2012, ISME J, V6, P320, DOI 10.1038/ismej.2011.109; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Weecharangsan W, 2008, INT J PHARMACEUT, V348, P161, DOI 10.1016/j.ijpharm.2007.07.011; Wei H, 2010, FEMS MICROBIOL ECOL, V73, P577, DOI 10.1111/j.1574-6941.2010.00924.x; Wei OY, 2004, J PHARM PHARM SCI, V7, P315; Wei PJ, 2016, DRUG DELIV, V23, P2058, DOI 10.3109/10717544.2015.1122672; Wenzel TJ, 2020, MOL CELL NEUROSCI, V105, DOI 10.1016/j.mcn.2020.103493; West CL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0225481; West NR, 2015, CANCER CELL, V28, P687, DOI 10.1016/j.ccell.2015.11.010; Wu RY, 2013, NEUROGASTROENT MOTIL, V25, pE205, DOI 10.1111/nmo.12072; Wurth R, 2015, J FUNCT FOODS, V15, P116, DOI 10.1016/j.jff.2015.02.046; Xie RN, 2020, J PSYCHIATR RES, V122, P70, DOI 10.1016/j.jpsychires.2019.12.013; YAMAMOTO S, 1992, MICROBIOL IMMUNOL, V36, P983, DOI 10.1111/j.1348-0421.1992.tb02102.x; Yeung TW, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00494; Yi AK, 1996, J IMMUNOL, V157, P5394; York A, 2018, NAT REV MICROBIOL, V16, P121, DOI 10.1038/nrmicro.2018.12; Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003; Zhan Y, 2013, CANCER RES, V73, P7199, DOI 10.1158/0008-5472.CAN-13-0827; Zhang H, 2018, ACS SUSTAIN CHEM ENG, V6, P13924, DOI 10.1021/acssuschemeng.8b02237; Zhang YQ, 2007, BIOTECHNOL APPL BIOC, V46, P197, DOI 10.1042/BA2060163; Zhao C, 2020, ACS APPL MATER INTER, V12, P42586, DOI 10.1021/acsami.0c13518; Zhao QQ, 2008, J BIOSCI BIOENG, V105, P65, DOI 10.1263/jbb.105.65; Zheng DW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03233-9; Zheng HZ, 2017, CARBOHYD POLYM, V155, P329, DOI 10.1016/j.carbpol.2016.08.096; Zhou WQ, 2020, TRENDS IMMUNOL, V41, P721, DOI 10.1016/j.it.2020.06.009; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918; Zitvogel L, 2016, CELL, V165, P276, DOI 10.1016/j.cell.2016.03.001	180	2	2	12	51	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2021	11								620170	10.3389/fimmu.2020.620170	http://dx.doi.org/10.3389/fimmu.2020.620170			24	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QL3QQ	33643302	Green Published, gold			2022-12-18	WOS:000620995000001
J	Da'dara, AA; Elzoheiry, M; El-Beshbishi, SN; Skelly, PJ				Da'dara, Akram A.; Elzoheiry, Manal; El-Beshbishi, Samar N.; Skelly, Patrick J.			Vitamin B6 Acquisition and Metabolism in Schistosoma mansoni	FRONTIERS IN IMMUNOLOGY			English	Article						pyridoxal phosphate; PLP; schistosome; parasite; ectoenzyme; alkaline phosphatase	PHOSPHATASE	Schistosomes are parasitic platyhelminths that currently infect >200 million people globally. The adult worms can live within the vasculature of their hosts for many years where they acquire all nutrients necessary for their survival and growth. In this work we focus on how Schistosoma mansoni parasites acquire and metabolize vitamin B6, whose active form is pyridoxal phosphate (PLP). We show here that live intravascular stage parasites (schistosomula and adult males and females) can cleave exogenous PLP to liberate pyridoxal. Of the three characterized nucleotide-metabolizing ectoenzymes expressed at the schistosome surface (SmAP, SmNPP5, and SmATPDase1), only SmAP hydrolyzes PLP. Heat-inactivated recombinant SmAP can no longer cleave PLP. Further, parasites whose SmAP gene has been suppressed by RNAi are significantly impaired in their ability to cleave PLP compared to controls. When schistosomes are incubated in murine plasma, they alter its metabolomic profile-the levels of both pyridoxal and phosphate increase over time, a finding consistent with the action of host-exposed SmAP acting on PLP. We hypothesize that SmAP-mediated dephosphorylation of PLP generates a pool of pyridoxal around the worms that can be conveniently taken in by the parasites to participate in essential, vitamin B6-driven metabolism. In addition, since host PLP-dependent enzymes play active roles in inflammatory processes, parasite-mediated cleavage of this metabolite may serve to limit parasite-damaging inflammation. In this work we also identified schistosome homologs of enzymes that are involved in intracellular vitamin B6 metabolism. These are pyridoxal kinase (SmPK) as well as pyridoxal phosphate phosphatase (SmPLP-Ph) and pyridox(am)ine 5'-phosphate oxidase (SmPNPO) and cDNAs encoding these three enzymes were cloned and sequenced. The three genes encoding these enzymes all display high relative expression in schistosomula and adult worms suggestive of robust vitamin B6 metabolism in the intravascular life stages.	[Da'dara, Akram A.; Elzoheiry, Manal; Skelly, Patrick J.] Tufts Univ, Cummings Sch Vet Med, Dept Infect Dis & Global Hlth, Mol Helminthol Lab, North Grafton, MA 01536 USA; [Elzoheiry, Manal; El-Beshbishi, Samar N.] Mansoura Univ, Fac Med, Dept Med Parasitol, Mansoura, Egypt	Tufts University; Egyptian Knowledge Bank (EKB); Mansoura University	Skelly, PJ (corresponding author), Tufts Univ, Cummings Sch Vet Med, Dept Infect Dis & Global Hlth, Mol Helminthol Lab, North Grafton, MA 01536 USA.	Patrick.Skelly@Tufts.edu	Elzoheiry, Manal/F-8942-2019	Elzoheiry, Manal/0000-0002-5756-3651; Da'dara, Akram/0000-0003-3318-9623	NIH-NIAID [AI056273]; BRI via the NIAID schistosomiasis resource center under NIH-NIAID [HHSN272201000005I]	NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BRI via the NIAID schistosomiasis resource center under NIH-NIAID	This work was funded with support from NIH-NIAID grant AI056273. Infected snails were provided by BRI via the NIAID schistosomiasis resource center under NIH-NIAID Contract No. HHSN272201000005I.	Araujo-Montoya BO, 2011, EXP PARASITOL, V129, P284, DOI 10.1016/j.exppara.2011.07.008; Bhardwaj R, 2011, INFECT IMMUN, V79, P4276, DOI 10.1128/IAI.05431-11; Bhardwaj R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001011; Bhardwaj R, 2009, TRENDS PARASITOL, V25, P256, DOI 10.1016/j.pt.2009.03.004; Braschi S, 2006, MOL CELL PROTEOMICS, V5, P347, DOI 10.1074/mcp.M500287-MCP200; Braschi S, 2006, MEM I OSWALDO CRUZ, V101, P205, DOI 10.1590/S0074-02762006000900032; Castro-Borges W, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000993; CHURCHICH JE, 1990, ANN NY ACAD SCI, V585, P357, DOI 10.1111/j.1749-6632.1990.tb28068.x; Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2; Da'dara A, 2012, J HELMINTHOL, V86, P141, DOI 10.1017/S0022149X12000120; Da'dara A, 2011, BLOOD REV, V25, P175, DOI 10.1016/j.blre.2011.04.002; Da'dara AA, 2015, METHODS MOL BIOL, V1201, P143, DOI 10.1007/978-1-4939-1438-8_8; Da'dara AA, 2014, PEERJ, V2, DOI 10.7717/peerj.316; Elzoheiry M, 2019, MOL BIOCHEM PARASIT, V232, DOI 10.1016/j.molbiopara.2019.111190; Elzoheiry M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01746; Elzoheiry M, 2018, THROMB HAEMOSTASIS, V118, P979, DOI 10.1055/s-0038-1641715; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Faghiri Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010451; Faghiri Z, 2009, FASEB J, V23, P2780, DOI 10.1096/fj.09-130757; FEDDE KN, 1990, AM J HUM GENET, V47, P767; G a M., 2017, VITAMINS FUNDAMENTAL, V5th ed; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Hellmann H, 2010, MOLECULES, V15, P442, DOI 10.3390/molecules15010442; Huang SH, 2019, PLANT SCI, V278, P88, DOI 10.1016/j.plantsci.2018.10.014; Krautz-Peterson G, 2007, J BIOL CHEM, V282, P21767, DOI 10.1074/jbc.M703512200; Krautz-Peterson G, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000932; Krautz-Peterson G, 2010, PARASITOLOGY, V137, P485, DOI 10.1017/S0031182009991168; LEVY MG, 1975, J PARASITOL, V61, P627, DOI 10.2307/3279455; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Mukherjee T, 2011, BBA-PROTEINS PROTEOM, V1814, P1585, DOI 10.1016/j.bbapap.2011.06.018; Musayev FN, 2003, PROTEIN SCI, V12, P1455, DOI 10.1110/ps.0356203; Nation Catherine S, 2020, Virulence, V11, P568, DOI 10.1080/21505594.2020.1770481; Paul L, 2013, NUTR REV, V71, P239, DOI 10.1111/nure.12014; Rofatto HK, 2009, MOL BIOCHEM PARASIT, V166, P32, DOI 10.1016/j.molbiopara.2009.02.006; Said ZM, 2008, AM J PHYSIOL-CELL PH, V294, pC1192, DOI 10.1152/ajpcell.00015.2008; Skelly PJ, 2006, ADV PARASIT, V63, P185, DOI 10.1016/S0065-308X(06)63003-0; Skelly PJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004246; SKELLY PJ, 1994, J BIOL CHEM, V269, P4247; Tucker Matthew S, 2013, Curr Protoc Immunol, V103, DOI 10.1002/0471142735.im1901s103; Wang Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13141-5; Wondrak Georg T, 2012, Subcell Biochem, V56, P291, DOI 10.1007/978-94-007-2199-9_15; Zhang PP, 2016, J BIOL CHEM, V291, P24517, DOI 10.1074/jbc.M116.743815	43	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2021	11								622162	10.3389/fimmu.2020.622162	http://dx.doi.org/10.3389/fimmu.2020.622162			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI7SX	33613557	gold, Green Published			2022-12-18	WOS:000619184700001
J	Zhao, YM; Gao, F; Wu, YB; Shi, JM; Luo, Y; Tan, YM; Yu, J; Lai, XY; Zhang, MM; Zhang, W; Huang, H				Zhao, Yanmin; Gao, Fei; Wu, Yibo; Shi, Jimin; Luo, Yi; Tan, Yamin; Yu, Jian; Lai, Xiaoyu; Zhang, Mingming; Zhang, Wei; Huang, He			Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						KIR; hematopoietic stem cell transplantation; iKIR-HLA model; relapse; survival		Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with malignant hematologic diseases. Killer immunoglobin-like receptor (KIR) expressed by NK cells is closely associated with the transplant outcomes, and it has been widely explored and debated for a few decades. Recently published studies have revealed that inhibitory KIRs (iKIRs) are educated by their cognate human lymphocyte antigen (HLA) ligands, and that decreased iKIR-HLA pairs post-transplantation may indicate a reduced NK cell function and impaired control of the primary disease. However, this theory still needs to be validated by additional clinical studies. Here we conducted a retrospective analysis of 246 patients who received haploidentical (haplo)-HSCT at our treatment center between January 2015 and June 2018. Our data suggests that decreased iKIR-HLA C pair post-HSCT correlated with a significantly higher risk of relapse [hazard risk (HR) = 2.95, p = 0.019] and reduced overall survival (OS) (HR = 3.74, p = 0.001) and disease-free survival (DFS) (HR = 4.05, p = 0.0004) in patients with myeloid disease. In conclusion, decreased iKIR-HLA C pair should be avoided during anti-thymocyte globulin (ATG)-based haplo-HSCT, especially for patients with myeloid disease.	[Zhao, Yanmin; Gao, Fei; Wu, Yibo; Shi, Jimin; Luo, Yi; Tan, Yamin; Yu, Jian; Lai, Xiaoyu; Zhang, Mingming; Huang, He] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China; [Zhao, Yanmin; Gao, Fei; Wu, Yibo; Shi, Jimin; Luo, Yi; Tan, Yamin; Yu, Jian; Lai, Xiaoyu; Zhang, Mingming; Huang, He] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China; [Zhao, Yanmin; Gao, Fei; Wu, Yibo; Shi, Jimin; Luo, Yi; Tan, Yamin; Yu, Jian; Lai, Xiaoyu; Zhang, Mingming; Huang, He] Zhejiang Engn Lab Stem Cell & Immunotherapy, Hangzhou, Peoples R China; [Zhang, Wei] Zhejiang Blood Ctr, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Huang, H (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China.; Huang, H (corresponding author), Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China.; Huang, H (corresponding author), Zhejiang Engn Lab Stem Cell & Immunotherapy, Hangzhou, Peoples R China.	huanghe@zju.edu.cn	zhao, yan/GWC-9174-2022	Gao, Fei/0000-0002-8627-3688	National Natural Science Foundation of China [81670148, 81730008]; Key Project of Science and Technology Department of Zhejiang Province [2019C03016]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of Science and Technology Department of Zhejiang Province	This work was supported by the National Natural Science Foundation of China (81670148 and 81730008) and Key Project of Science and Technology Department of Zhejiang Province (2019C03016).	Aguilar AMO, 2010, J IMMUNOL, V185, P4238, DOI 10.4049/jimmunol.1001494; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Apps R, 2015, J IMMUNOL, V194, P3594, DOI 10.4049/jimmunol.1403234; Armand P, 2014, BLOOD, V123, P3664, DOI 10.1182/blood-2014-01-552984; Babor F, 2019, BONE MARROW TRANSPL, V54, P1847, DOI 10.1038/s41409-019-0543-z; Belanger S, 2012, BLOOD, V120, P592, DOI 10.1182/blood-2012-02-408732; Bosch M, 2012, CYTOTHERAPY, V14, P1258, DOI 10.3109/14653249.2012.715243; Boudreau JE, 2016, IMMUNITY, V45, P280, DOI 10.1016/j.immuni.2016.07.005; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; Cooley S, 2009, BLOOD, V113, P726, DOI 10.1182/blood-2008-07-171926; Gao F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02022; Graczyk-Pol E, 2018, HLA, V92, P42, DOI 10.1111/tan.13386; Grullich C, 2009, BIOL BLOOD MARROW TR, V15, P173, DOI 10.1016/j.bbmt.2008.11.014; Harris AC, 2016, BIOL BLOOD MARROW TR, V22, P4, DOI 10.1016/j.bbmt.2015.09.001; Heidenreich S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00041; Hosokai R, 2017, BIOL BLOOD MARROW TR, V23, P606, DOI 10.1016/j.bbmt.2016.12.638; Impola U, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00405; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Landtwing V, 2016, J CLIN INVEST, V126, P3772, DOI 10.1172/JCI86923; Leung W, 2005, CANCER IMMUNOL IMMUN, V54, P389, DOI 10.1007/s00262-004-0609-6; Leung W, 2004, J IMMUNOL, V172, P644, DOI 10.4049/jimmunol.172.1.644; Luo Y, 2014, BLOOD, V124, P2735, DOI 10.1182/blood-2014-04-571570; Makanga DR, 2020, CANCERS, V12, DOI 10.3390/cancers12071927; Mancusi A, 2015, BLOOD, V125, P3173, DOI 10.1182/blood-2014-09-599993; Manser AR, 2015, IMMUNOL REV, V267, P178, DOI 10.1111/imr.12316; Nowak J, 2019, HLA, V94, P40, DOI 10.1111/tan.13770; Parham P, 2013, NAT REV IMMUNOL, V13, P133, DOI 10.1038/nri3370; Park S, 2015, HUM IMMUNOL, V76, P636, DOI 10.1016/j.humimm.2015.09.009; Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78; Pende D, 2005, BLOOD, V105, P2066, DOI 10.1182/blood-2004-09-3548; Rogatko-Koros M, 2016, ARCH IMMUNOL THER EX, V64, pS63, DOI 10.1007/s00005-016-0438-2; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Russo A, 2018, BLOOD, V131, P247, DOI 10.1182/blood-2017-05-780668; Schellekens J, 2008, MOL IMMUNOL, V45, P2255, DOI 10.1016/j.molimm.2007.11.014; Single RM, 2007, NAT GENET, V39, P1114, DOI 10.1038/ng2077; Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4; Tordai A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218945; Vago L, 2008, BLOOD, V112, P3488, DOI 10.1182/blood-2007-07-103325; Van Elssen CHMJ, 2020, AM J HEMATOL, V95, P1590, DOI 10.1002/ajh.25983; Verheyden S, 2009, CANCER IMMUNOL IMMUN, V58, P855, DOI 10.1007/s00262-008-0601-7; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Yabe T, 2008, BIOL BLOOD MARROW TR, V14, P75, DOI 10.1016/j.bbmt.2007.09.012; Zhao XY, 2007, EUR J HAEMATOL, V78, P338, DOI 10.1111/j.1600-0609.2007.00822.x; Zhao XY, 2019, BLOOD ADV, V3, P4312, DOI 10.1182/bloodadvances.2019000242; Zhao YM, 2019, BIOL BLOOD MARROW TR, V25, P1898, DOI 10.1016/j.bbmt.2019.05.036; Zhao YM, 2014, AM J MED SCI, V347, P439, DOI 10.1097/MAJ.0000000000000186	49	2	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2021	11								614488	10.3389/fimmu.2020.614488	http://dx.doi.org/10.3389/fimmu.2020.614488			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI5DQ	33633734	gold, Green Published			2022-12-18	WOS:000618998400001
J	Omondi, BR; Muthui, MK; Muasya, WI; Orindi, B; Mwakubambanya, RS; Bousema, T; Drakeley, C; Marsh, K; Bejon, P; Kapulu, MC				Omondi, Brian R.; Muthui, Michelle K.; Muasya, William, I; Orindi, Benedict; Mwakubambanya, Ramadhan S.; Bousema, Teun; Drakeley, Chris; Marsh, Kevin; Bejon, Philip; Kapulu, Melissa C.			Antibody Responses to Crude Gametocyte Extract Predict Plasmodium falciparum Gametocyte Carriage in Kenya	FRONTIERS IN IMMUNOLOGY			English	Article						Plasmodium falciparum; gametocytemia; gametocyte extract; antibody response; malaria transmission	MALARIA	Background Malaria caused by Plasmodium falciparum remains a serious global public health challenge especially in Africa. Interventions that aim to reduce malaria transmission by targeting the gametocyte reservoir are key to malaria elimination and/or eradication. However, factors that are associated with gametocyte carriage have not been fully explored. Consequently, identifying predictors of the infectious reservoir is fundamental in the elimination campaign. Methods We cultured P. falciparum NF54 gametocytes (to stage V) and prepared crude gametocyte extract. Samples from a total of 687 participants (aged 6 months to 67 years) representing two cross-sectional study cohorts in Kilifi, Kenya were used to assess IgG antibody responses by ELISA. We also analyzed IgG antibody responses to the blood-stage antigen AMA1 as a marker of asexual parasite exposure. Gametocytemia and asexual parasitemia data quantified by microscopy and molecular detection (QT-NASBA) were used to determine the relationship with antibody responses, season, age, and transmission setting. Multivariable logistic regression models were used to study the association between antibody responses and gametocyte carriage. The predictive power of the models was tested using the receiver operating characteristic (ROC) curve. Results Multivariable logistic regression analysis showed that IgG antibody response to crude gametocyte extract predicted both microscopic (OR=1.81 95% CI: 1.06-3.07, p=0.028) and molecular (OR=1.91, 95% CI: 1.11-3.29, p=0.019) P. falciparum gametocyte carriage. Antibody responses to AMA1 were also associated with both microscopic (OR=1.61 95% CI: 1.08-2.42, p=0.020) and molecular (OR=3.73 95% CI: 2.03-6.74, p<0.001) gametocytemia. ROC analysis showed that molecular (AUC=0.897, 95% CI: 0.868-0.926) and microscopic (AUC=0.812, 95% CI: 0.758-0.865) multivariable models adjusted for gametocyte extract showed very high predictive power. Molecular (AUC=0.917, 95% CI: 0.891-0.943) and microscopic (AUC=0.806, 95% CI: 0.755-0.858) multivariable models adjusted for AMA1 were equally highly predictive. Conclusion In our study, it appears that IgG responses to crude gametocyte extract are not an independent predictor of gametocyte carriage after adjusting for AMA1 responses but may predict gametocyte carriage as a proxy marker of exposure to parasites. Serological responses to AMA1 or to gametocyte extract may facilitate identification of individuals within populations who contribute to malaria transmission and support implementation of transmission-blocking interventions.	[Omondi, Brian R.; Muthui, Michelle K.; Muasya, William, I; Orindi, Benedict; Marsh, Kevin; Bejon, Philip; Kapulu, Melissa C.] KEMRI Wellcome Trust Res Programme, Dept Biosci, Kilifi, Kenya; [Omondi, Brian R.; Mwakubambanya, Ramadhan S.] Egerton Univ, Dept Biochem & Mol Biol, Nakuru, Kenya; [Bousema, Teun] Radboud Univ Nijmegen, Dept Med Microbiol, Med Ctr, Nijmegen, Netherlands; [Drakeley, Chris] London Sch Hyg & Trop Med, Dept Infect Biol, London, England; [Marsh, Kevin; Bejon, Philip; Kapulu, Melissa C.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England	Egerton University; Radboud University Nijmegen; University of London; London School of Hygiene & Tropical Medicine; University of Oxford	Kapulu, MC (corresponding author), KEMRI Wellcome Trust Res Programme, Dept Biosci, Kilifi, Kenya.; Kapulu, MC (corresponding author), Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England.	mkapulu@kemri-wellcome.org	Bousema, Teun/N-3574-2014; Kapulu, Melissa/ABC-1311-2021	Bousema, Teun/0000-0003-2666-094X; Kapulu, Melissa/0000-0003-0321-7128; Omondi, Brian/0000-0003-4611-2721	Bill and Melinda Gates Foundation [OPP1034789]; Wellcome Trust [092741, 107499]; DELTAS Africa Programme via the Wellcome Trust grant [107769]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Wellcome Trust(Wellcome Trust); DELTAS Africa Programme via the Wellcome Trust grant	The AFIRM study was supported by a Bill and Melinda Gates Foundation grant (OPP1034789). The KMLC study was supported by a grant from the Wellcome Trust (092741). BO, MM, andWMare IDeAL scholars whose studentships are funded by DELTAS Africa Programme via the Wellcome Trust grant (107769) to KEMRI-Wellcome Trust Research Programme. PB and MK were supported by a Wellcome Trust grant (107499).	Aguilar R, 2014, BLOOD, V123, P959, DOI 10.1182/blood-2013-08-520767; Alonso PL, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000406; Andagalu B, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-265; Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x; Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029; Bousema JT, 2007, PARASITE IMMUNOL, V29, P309, DOI 10.1111/j.1365-3024.2007.00948.x; Bousema JT, 2006, CURR MOL MED, V6, P223, DOI 10.2174/156652406776055140; Bousema JT, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-18; Bousema T, 2011, CLIN MICROBIOL REV, V24, P377, DOI 10.1128/CMR.00051-10; Coalson JE, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1587-9; Collins KA, 2018, J CLIN INVEST, V128, P1551, DOI 10.1172/JCI98012; Dantzler KW, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3963; Davison AC, 2003, STAT SCI, V18, P141; De Niz M, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat3775; Dinko B, 2016, PARASITE IMMUNOL, V38, P352, DOI 10.1111/pim.12323; Drakeley CJ, 2006, PARASITE IMMUNOL, V28, P185, DOI 10.1111/j.1365-3024.2005.00818.x; Goncalves BP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01270-4; GRAVES PM, 1992, AM J TROP MED HYG, V46, P711, DOI 10.4269/ajtmh.1992.46.711; HAWKING F, 1971, T ROY SOC TROP MED H, V65, P549, DOI 10.1016/0035-9203(71)90036-8; Hosmer DW, 2013, WILEY SER PROBAB ST, P153; Koepfli C, 2018, TRENDS PARASITOL, V34, P378, DOI 10.1016/j.pt.2018.02.009; Koepfli C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126747; Meerstein-Kessel L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18840-7; Muthui Michelle K, 2019, Wellcome Open Res, V4, P66, DOI 10.12688/wellcomeopenres.15186.1; Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006; Nacher M, 2002, J PARASITOL, V88, P97, DOI 10.1645/0022-3395(2002)088[0097:DHCHAS]2.0.CO;2; Ndungu FM, 2002, PARASITE IMMUNOL, V24, P77, DOI 10.1046/j.0141-9838.2001.00440.x; Nilsson SK, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004871; Obaldia N, 2018, MBIO, V9, DOI 10.1128/mBio.00625-18; Ouedraogo AL, 2011, INFECT IMMUN, V79, P4957, DOI 10.1128/IAI.05288-11; Ouedraogo AL, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-281; Ouedraogo AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008410; Pett H, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1584-z; Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031; R Development Core Team, 2018, R LANG ENV STAT COMP; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P29, DOI 10.1016/0035-9203(90)90369-P; Saeed M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002280; Saliba Kathryn Shaw, 2013, Methods Mol Biol, V923, P17; Schneider P, 2004, MOL BIOCHEM PARASIT, V137, P35, DOI 10.1016/j.molbiopara.2004.03.018; Schneider P, 2007, AM J TROP MED HYG, V76, P470, DOI 10.4269/ajtmh.2007.76.470; Schneider P, 2006, INT J PARASITOL, V36, P403, DOI 10.1016/j.ijpara.2006.01.002; Snow RW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128792; Tao DY, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aan4479; Taylor LH, 1997, PARASITOL TODAY, V13, P135, DOI 10.1016/S0169-4758(97)89810-9; Wampfler R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076316; World Health Organization, 2015, GUID TREATM MAL, Vthird	46	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2021	11								609474	10.3389/fimmu.2020.609474	http://dx.doi.org/10.3389/fimmu.2020.609474			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QI0BA	33633729	gold, Green Published			2022-12-18	WOS:000618638800001
J	den Hartog, G; Butcher, LD; Ablack, AL; Pace, LA; Ablack, JNG; Xiong, R; Das, S; Stappenbeck, TS; Eckmann, L; Ernst, PB; Crowe, SE				den Hartog, Gerco; Butcher, Lindsay D.; Ablack, Amber L.; Pace, Laura A.; Ablack, Jailal N. G.; Xiong, Richard; Das, Soumita; Stappenbeck, Thaddeus S.; Eckmann, Lars; Ernst, Peter B.; Crowe, Sheila E.			Apurinic/Apyrimidinic Endonuclease 1 Restricts the Internalization of Bacteria Into Human Intestinal Epithelial Cells Through the Inhibition of Rac1	FRONTIERS IN IMMUNOLOGY			English	Article						intestinal epithelial barrier; invasion; internalization; Rac1; Salmonella Typhimurium; AIEC LF82 strain; apurinic; apyrimidinic endonuclease 1	NF-KAPPA-B; INVASION; DISEASE; COLI; ACTIVATION; INFECTION; DAMAGE; RHO	Pathogenic intestinal bacteria lead to significant disease in humans. Here we investigated the role of the multifunctional protein, Apurinic/apyrimidinic endonuclease 1 (APE1), in regulating the internalization of bacteria into the intestinal epithelium. Intestinal tumor-cell lines and primary human epithelial cells were infected with Salmonella enterica serovar Typhimurium or adherent-invasive Escherichia coli. The effects of APE1 inhibition on bacterial internalization, the regulation of Rho GTPase Rac1 as well as the epithelial cell barrier function were assessed. Increased numbers of bacteria were present in APE1-deficient colonic tumor cell lines and primary epithelial cells. Activation of Rac1 was augmented following infection but negatively regulated by APE1. Pharmacological inhibition of Rac1 reversed the increase in intracellular bacteria in APE1-deficient cells whereas overexpression of constitutively active Rac1 augmented the numbers in APE1-competent cells. Enhanced numbers of intracellular bacteria resulted in the loss of barrier function and a delay in its recovery. Our data demonstrate that APE1 inhibits the internalization of invasive bacteria into human intestinal epithelial cells through its ability to negatively regulate Rac1. This activity also protects epithelial cell barrier function.	[den Hartog, Gerco; Butcher, Lindsay D.; Ablack, Amber L.; Pace, Laura A.; Xiong, Richard; Eckmann, Lars; Crowe, Sheila E.] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA; [Ablack, Jailal N. G.] Univ Calif San Diego, Dept Med, Div Rheumatol, La Jolla, CA USA; [Das, Soumita; Ernst, Peter B.] Univ Calif San Diego, Dept Pathol, Div Comparat Pathol & Med, La Jolla, CA 92093 USA; [Stappenbeck, Thaddeus S.; Crowe, Sheila E.] Washington Univ, Div ImmunoBiol, St Louis, MO 63110 USA; [Ernst, Peter B.] Univ Calif San Diego, Dept Pathol, Ctr Mucosal Immunol Allergy & Vaccine Dev, La Jolla, CA 92093 USA; [Ernst, Peter B.] Chiba Univ, Dept Immunol, Chiba, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Washington University (WUSTL); University of California System; University of California San Diego; Chiba University	Ernst, PB (corresponding author), Univ Calif San Diego, Dept Pathol, Div Comparat Pathol & Med, La Jolla, CA 92093 USA.; Ernst, PB (corresponding author), Univ Calif San Diego, Dept Pathol, Ctr Mucosal Immunol Allergy & Vaccine Dev, La Jolla, CA 92093 USA.; Ernst, PB (corresponding author), Chiba Univ, Dept Immunol, Chiba, Japan.	pernst@health.ucsd.edu			National Institutes of Health [LP: DK07202, SC: DK061769, NIH P30-DK120515, PE: AI079145, SD: DK099275]; Neuroscience Microscopy Shared Facility [P30 (NS047101)]; Chiba University-UC San Diego Center for Mucosal Immunology, Allergy and Vaccine Development	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Neuroscience Microscopy Shared Facility; Chiba University-UC San Diego Center for Mucosal Immunology, Allergy and Vaccine Development	Funding was obtained from the National Institutes of Health (LB and LP: DK07202; SC: DK061769; PE and SC: NIH P30-DK120515; PE: AI079145; SD: DK099275) as well as the Neuroscience Microscopy Shared Facility Grant P30 (NS047101) and the Chiba University-UC San Diego Center for Mucosal Immunology, Allergy and Vaccine Development.	Ando K, 2008, NUCLEIC ACIDS RES, V36, P4327, DOI 10.1093/nar/gkn416; BARRETT KE, 1993, AM J PHYSIOL, V264, pC446, DOI 10.1152/ajpcell.1993.264.2.C446; Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012; Bhattacharyya A, 2009, GASTROENTEROLOGY, V136, P2258, DOI 10.1053/j.gastro.2009.02.014; Boyle EC, 2006, CELL MICROBIOL, V8, P1946, DOI 10.1111/j.1462-5822.2006.00762.x; Brown MD, 2007, J BIOL CHEM, V282, P30265, DOI 10.1074/jbc.M702537200; Bustamante VH, 2008, P NATL ACAD SCI USA, V105, P14591, DOI 10.1073/pnas.0801205105; Carvalho FA, 2009, J EXP MED, V206, P2179, DOI 10.1084/jem.20090741; Chattopadhyay R, 2010, CANCER RES, V70, P2799, DOI 10.1158/0008-5472.CAN-09-4136; Cieza RJ, 2015, INFECT IMMUN, V83, P1904, DOI 10.1128/IAI.03003-14; Criss AK, 2001, J CELL SCI, V114, P1331; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; Das S, 2015, CELL MOL GASTROENTER, V1, P311, DOI 10.1016/j.jcmgh.2015.02.003; Das S, 2011, P NATL ACAD SCI USA, V108, P2136, DOI 10.1073/pnas.1014775108; den Hartog G, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005382; Dierkes R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088520; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Finlay BB, 2000, PHILOS T ROY SOC B, V355, P623, DOI 10.1098/rstb.2000.0603; Gallois A, 2001, J IMMUNOL, V166, P5741, DOI 10.4049/jimmunol.166.9.5741; Gastonguay AJ, 2012, CANCER BIOL THER, V13, P647, DOI 10.4161/cbt.20082; Gibold L, 2016, CELL MICROBIOL, V18, P617, DOI 10.1111/cmi.12539; Hapfelmeier S, 2005, J IMMUNOL, V174, P1675, DOI 10.4049/jimmunol.174.3.1675; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Jeon BH, 2009, ANTIOXID REDOX SIGN, V11, P571, DOI [10.1089/ars.2008.2223, 10.1089/ARS.2008.2223]; Krause-Gruszczynska M, 2007, CELL MICROBIOL, V9, P2431, DOI 10.1111/j.1462-5822.2007.00971.x; Lapaquette P, 2010, CELL MICROBIOL, V12, P99, DOI 10.1111/j.1462-5822.2009.01381.x; Levay M, 2013, J PHARMACOL EXP THER, V347, P69, DOI 10.1124/jpet.113.207266; Martinez-Medina M, 2009, INFLAMM BOWEL DIS, V15, P872, DOI 10.1002/ibd.20860; Mauldin JP, 2013, CURR BIOL, V23, P162, DOI 10.1016/j.cub.2012.11.049; Miquel S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012714; Moon C, 2014, MUCOSAL IMMUNOL, V7, P818, DOI 10.1038/mi.2013.98; Newell DG, 2010, INT J FOOD MICROBIOL, V139, pS3, DOI 10.1016/j.ijfoodmicro.2010.01.021; O'Hara AM, 2006, J IMMUNOL, V177, P7990, DOI 10.4049/jimmunol.177.11.7990; Ohlson MB, 2008, CELL HOST MICROBE, V4, P434, DOI 10.1016/j.chom.2008.08.012; Ozaki M, 2002, FASEB J, V16, P889, DOI 10.1096/fj.01-0664fje; Patel JC, 2006, J CELL BIOL, V175, P453, DOI 10.1083/jcb.200605144; Peery AF, 2012, GASTROENTEROLOGY, V143, P1179, DOI 10.1053/j.gastro.2012.08.002; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Sarkar A, 2017, J INFECT DIS, V216, P1655, DOI 10.1093/infdis/jix528; Scallan E, 2011, EMERG INFECT DIS, V17, P7, DOI 10.3201/eid1701.P11101; Scharl M, 2009, GASTROENTEROLOGY, V137, P2030, DOI 10.1053/j.gastro.2009.07.078; Schenck LP, 2013, NEUROGASTROENT MOTIL, V25, pe441, DOI 10.1111/nmo.12139; Sengupta S, 2011, ONCOGENE, V30, P482, DOI 10.1038/onc.2010.435; Small CLN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2957; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; VanDussen KL, 2015, GUT, V64, P911, DOI 10.1136/gutjnl-2013-306651; Wang RX, 2020, LIFE SCI, V261, DOI 10.1016/j.lfs.2020.118468; Watarai M, 1997, J EXP MED, V185, P281, DOI 10.1084/jem.185.2.281; WELSH MJ, 1985, J CLIN INVEST, V76, P1155, DOI 10.1172/JCI112071; Zhu SA, 2015, ANN RHEUM DIS, V74, P285, DOI 10.1136/annrheumdis-2013-203901	51	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	11								553994	10.3389/fimmu.2020.553994	http://dx.doi.org/10.3389/fimmu.2020.553994			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH1YF	33603730	gold, Green Published			2022-12-18	WOS:000618073100001
J	Ferrant, J; Lhomme, F; Le Gallou, S; Irish, JM; Roussel, M				Ferrant, Juliette; Lhomme, Faustine; Le Gallou, Simon; Irish, Jonathan M.; Roussel, Mikael			Circulating Myeloid Regulatory Cells: Promising Biomarkers in B-Cell Lymphomas	FRONTIERS IN IMMUNOLOGY			English	Article						monocyte; myeloid-derived suppressor cells; lymphoma; biomarker; mass cytometry		The monocyte/macrophage lineage has been shown to be involved in the promotion of a protumoral tumor microenvironment and resistance to treatment in B cell lymphomas. However, it is still poorly described at the single cell level, and tissue samples are not easily accessible. Thus, a detailed analysis of the circulating myeloid cell compartment in the different B lymphomas is needed to better understand the mechanisms of resistance to treatment and identify at risk patients. In this Perspective, we review current knowledge on the phenotypic and functional description of the circulating monocytic lineage in B cell lymphomas and provide first insights into the heterogeneity of these cell populations in health and lymphoma, using mass cytometry. Indeed, the monocytic compartment is a continuum more than distinct subpopulations, as demonstrated by our high-resolution approach, explaining the sometimes confusing and contradictory conclusions on the prognostic impact of the different populations, including monocytes and monocytic myeloid derived suppressor cells (M-MDSC). By identifying S100A9(high) monocytic cells as a potential biomarker in diffuse large B cell lymphoma (DLBCL) in this proof-of-concept preliminary study including a limited number of samples, we underline the potential of circulating myeloid regulatory cells as diagnostic and prognostic biomarkers in B-cell lymphomas.	[Ferrant, Juliette; Le Gallou, Simon; Roussel, Mikael] Univ Rennes, UMR S 1236, Inserm, Rennes, France; [Lhomme, Faustine] Ctr Hosp Univ Rennes, Serv Hematol, Rennes, France; [Le Gallou, Simon; Roussel, Mikael] Ctr Hosp Univ Rennes, Lab Hematol, Pole Biol, Rennes, France; [Irish, Jonathan M.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN USA; [Irish, Jonathan M.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU Rennes; Universite de Rennes; CHU Rennes; Universite de Rennes; Vanderbilt University; Vanderbilt University	Roussel, M (corresponding author), Univ Rennes, UMR S 1236, Inserm, Rennes, France.; Roussel, M (corresponding author), Ctr Hosp Univ Rennes, Lab Hematol, Pole Biol, Rennes, France.	mikael.roussel@chu-rennes.fr			Nuovo-Soldati Foundation (Switzerland); FHU CAMIn (Federation Hospitalo-Universitaire Cancer Microenvironnement et Innovation); comite de la recherche clinique et translationnelle (CORECT), CHU of Rennes; association pour le developpement de l'hematologie oncologie (ADHO)	Nuovo-Soldati Foundation (Switzerland); FHU CAMIn (Federation Hospitalo-Universitaire Cancer Microenvironnement et Innovation); comite de la recherche clinique et translationnelle (CORECT), CHU of Rennes; association pour le developpement de l'hematologie oncologie (ADHO)	This work was supported by a fellowship from the Nuovo-Soldati Foundation (Switzerland) [M.R.], from the FHU CAMIn (Federation Hospitalo-Universitaire Cancer Microenvironnement et Innovation) [J.F.], from the comite de la recherche clinique et translationnelle (CORECT), CHU of Rennes [F.L.], and from the association pour le developpement de l'hematologie oncologie (ADHO) (F.L.).	Ame-Thomas P, 2014, SEMIN CANCER BIOL, V24, P23, DOI 10.1016/j.semcancer.2013.08.001; Amini RM, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5529-0; Azzaoui I, 2016, BLOOD, V128, P1081, DOI 10.1182/blood-2015-08-662783; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bizymi N, 2019, HEMASPHERE, V3, DOI 10.1097/HS9.0000000000000168; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Charbonneau B, 2012, CYTOKINE, V60, P882, DOI 10.1016/j.cyto.2012.08.028; Connors JM, 2015, BLOOD, V125, P1693, DOI 10.1182/blood-2014-07-537480; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Engblom C, 2016, NAT REV CANCER, V16, P447, DOI 10.1038/nrc.2016.54; Ferrant J, 2021, METHODS MOL BIOL, V2236, P57, DOI 10.1007/978-1-0716-1060-2_6; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Giannoni P, 2014, HAEMATOLOGICA, V99, P1078, DOI 10.3324/haematol.2013.091405; Gustafson MP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121546; Gustafson MP, 2012, BRIT J HAEMATOL, V156, P674, DOI 10.1111/j.1365-2141.2011.08902.x; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Hollt T, 2016, COMPUT GRAPH FORUM, V35, P171, DOI 10.1111/cgf.12893; Jitschin R, 2014, BLOOD, V124, P750, DOI 10.1182/blood-2013-12-546416; Jones K, 2013, CLIN CANCER RES, V19, P731, DOI 10.1158/1078-0432.CCR-12-2693; Keane C, 2015, LANCET HAEMATOL, V2, pE445, DOI 10.1016/S2352-3026(15)00150-7; Koh YW, 2014, HEMATOL ONCOL, V32, P178, DOI 10.1002/hon.2106; Ku AW, 2016, ELIFE, V5, DOI 10.7554/eLife.17375; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Kumar V, 2016, IMMUNITY, V44, P303, DOI 10.1016/j.immuni.2016.01.014; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Kusmartsev S, 2003, J LEUKOCYTE BIOL, V74, P186, DOI 10.1189/jlb.0103010; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lin Y, 2011, BLOOD, V117, P872, DOI 10.1182/blood-2010-05-283820; Liu JL, 2015, ONCOL LETT, V9, P1167, DOI 10.3892/ol.2014.2808; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Marchesi F, 2015, HEMATOL ONCOL, V33, P110, DOI 10.1002/hon.2142; Marini O, 2016, ONCOTARGET, V7, P27676, DOI 10.18632/oncotarget.8507; Nagaraj S, 2010, J IMMUNOL, V184, P3106, DOI 10.4049/jimmunol.0902661; Nicholas NS, 2016, BBA-MOL CELL RES, V1863, P471, DOI 10.1016/j.bbamcr.2015.11.003; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Parker KH, 2015, ADV CANCER RES, V128, P95, DOI 10.1016/bs.acr.2015.04.002; Pham LV, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00147; Porrata LF, 2013, BRIT J HAEMATOL, V163, P545, DOI 10.1111/bjh.12531; Porrata LF, 2012, HAEMATOL-HEMATOL J, V97, P262, DOI 10.3324/haematol.2011.050138; Riihijarvi S, 2015, HAEMATOLOGICA, V100, P238, DOI 10.3324/haematol.2014.113472; Romano A, 2015, BRIT J HAEMATOL, V168, P689, DOI 10.1111/bjh.13198; Rossille D, 2017, LEUKEMIA, V31, P988, DOI 10.1038/leu.2016.385; Rossille D, 2014, LEUKEMIA, V28, P2367, DOI 10.1038/leu.2014.137; Roussel M, 2020, CANCER IMMUNOL IMMUN, V69, P407, DOI 10.1007/s00262-019-02464-z; Roussel M, 2017, CANCER IMMUNOL IMMUN, V66, P1103, DOI 10.1007/s00262-017-2036-5; Roussel M, 2017, J LEUKOCYTE BIOL, V102, P437, DOI 10.1189/jlb.5MA1116-457R; Sato Y, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.995541; Schlecker E, 2012, J IMMUNOL, V189, P5602, DOI 10.4049/jimmunol.1201018; Scott DW, 2014, NAT REV CANCER, V14, P517, DOI 10.1038/nrc3774; Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tadmor T, 2015, MAYO CLIN PROC, V90, P756, DOI 10.1016/j.mayocp.2015.03.025; Tadmor T, 2014, HAEMATOLOGICA, V99, P125, DOI 10.3324/haematol.2013.088161; Tadmor T, 2013, HEMATOL ONCOL, V31, P325, DOI 10.1002/hon.2019; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Uhel F, 2019, J ALLERGY CLIN IMMUN, V144, P1125, DOI 10.1016/j.jaci.2019.06.027; Vaidya R, 2014, ANN ONCOL, V25, P2124, DOI 10.1093/annonc/mdu109; van Unen V, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01689-9; von Hohenstaufen KA, 2013, BRIT J HAEMATOL, V162, P465, DOI 10.1111/bjh.12409; Wang JX, 2017, ONCOTARGET, V8, P5414, DOI 10.18632/oncotarget.14289; Wilcox RA, 2011, LEUKEMIA, V25, P1502, DOI 10.1038/leu.2011.112; Wilcox RA, 2012, LEUKEMIA LYMPHOMA, V53, P575, DOI 10.3109/10428194.2011.637211; Wu CY, 2016, CELL PHYSIOL BIOCHEM, V39, P521, DOI 10.1159/000445644; Xiu B, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.56; Xu Z, 2017, FEBS J, V284, P2410, DOI 10.1111/febs.14133; Zarobkiewicz M, 2020, CANCERS, V12, DOI 10.3390/cancers12092614	70	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	11								623993	10.3389/fimmu.2020.623993	http://dx.doi.org/10.3389/fimmu.2020.623993			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH4CB	33603754	gold, Green Published			2022-12-18	WOS:000618222200001
J	Kim, W; Jang, JH; Zhong, X; Seo, H; Surh, YJ				Kim, Wonki; Jang, Jeong-Hoon; Zhong, Xiancai; Seo, Hyungseok; Surh, Young-Joon			15-Deoxy-Delta(12,14)-Prostaglandin J(2) Promotes Resolution of Experimentally Induced Colitis	FRONTIERS IN IMMUNOLOGY			English	Article						cyclopentenone prostaglandin; resolution of intestinal inflammation; macrophage polarization; DSS-induced colitis; STAT3; 15-deoxy-Delta(12,14)-prostaglandin J(2)		Uncontrolled macrophage functions cause failure to resolve gut inflammation and has been implicated in the pathogenesis of inflammatory bowel disease (IBD). 15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), one of endogenous lipid mediators formed from arachidonic acid during the inflammatory process, has been reported to terminate inflammation. However, the pro-resolving effect of 15d-PGJ(2) on intestinal inflammation and underlying molecular mechanisms remain largely unknown. In the present study, we examined the effects of 15d-PGJ(2) on the resolution of dextran sulfate sodium (DSS)-induced murine colitis that mimics human IBD. Pharmacologic inhibition of prostaglandin D synthase (PGDS) responsible for the synthesis of 15d-PGJ(2) hampered resolution of inflammation in the colonic mucosa of mice treated with DSS. Notably, intraperitoneal injection of 15d-PGJ(2) accelerated the resolution of experimentally induced colitis. 15d-PGJ(2) treatment reduced the number of neutrophils and M1 macrophages, while it increased the proportion of M2 macrophages. Moreover, 15d-PGJ(2) treated mice exhibited the significantly reduced proportion of macrophages expressing the pro-inflammatory cytokine, IL-6 with concomitant suppression of STAT3 phosphorylation in the colonic mucosa of mice administered 2.5% DSS in drinking water. Taken together, these findings clearly indicate that 15d-PGJ(2), endogenously generated from arachidonic acid by cyclooxygenase-2 and PGDS activities in inflamed tissue, promotes resolution of intestinal colitis.	[Kim, Wonki; Jang, Jeong-Hoon; Zhong, Xiancai; Surh, Young-Joon] Seoul Natl Univ, Coll Pharm, Tumor Microenvironm Global Core Res Ctr, Seoul, South Korea; [Kim, Wonki; Jang, Jeong-Hoon; Zhong, Xiancai; Surh, Young-Joon] Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul, South Korea; [Seo, Hyungseok; Surh, Young-Joon] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul, South Korea; [Surh, Young-Joon] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Tumor Microenvironm Global Core Res Ctr, Seoul, South Korea.; Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul, South Korea.; Surh, YJ (corresponding author), Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul, South Korea.; Surh, YJ (corresponding author), Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.	surh@snu.ac.kr	Zhong, Xiancai/AAV-2761-2020; Zhong, Xiancai/AAM-3069-2020	Zhong, Xiancai/0000-0001-8312-4057; Zhong, Xiancai/0000-0001-8312-4057; Seo, hyungseok/0000-0002-6632-1208	Global Core Research Center (GCRC) grant [2011-0030001]; BK21 FOUR Program from the National Research Foundation, Republic of Korea [5120200513755]	Global Core Research Center (GCRC) grant; BK21 FOUR Program from the National Research Foundation, Republic of Korea	This study was supported by the Global Core Research Center (GCRC) grant (No. 2011-0030001) and the BK21 FOUR Program (5120200513755) from the National Research Foundation, Republic of Korea.	Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Allen L, 2005, J IMMUNOL, V174, P3643, DOI 10.4049/jimmunol.174.6.3643; Aritake K, 2006, J BIOL CHEM, V281, P15277, DOI 10.1074/jbc.M506431200; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Berndt BE, 2007, J IMMUNOL, V179, P6255, DOI 10.4049/jimmunol.179.9.6255; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Brown RA, 2012, PULM PHARMACOL THER, V25, P185, DOI 10.1016/j.pupt.2012.01.006; Cader MZ, 2013, GUT, V62, P1653, DOI 10.1136/gutjnl-2012-303955; Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571; Courtney PA, 1999, ANN RHEUM DIS, V58, P309, DOI 10.1136/ard.58.5.309; Decara J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00730; Egger B, 2000, DIGESTION, V62, P240, DOI 10.1159/000007822; Elbim Carole, 2009, Open Virol J, V3, P52, DOI 10.2174/1874357900903010052; Ertel W, 1998, J TRAUMA, V44, P767, DOI 10.1097/00005373-199805000-00005; FERRETTI M, 1994, J CLIN INVEST, V94, P449, DOI 10.1172/JCI117345; Fiocchi C, 2008, INFLAMM BOWEL DIS, V14, pS77, DOI 10.1002/ibd.20618; Gandhi UH, 2011, J BIOL CHEM, V286, P27471, DOI 10.1074/jbc.M111.260547; Garside P, 1999, CLIN EXP IMMUNOL, V118, P337; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68; Hine AM, 2019, J IMMUNOL, V203, P593, DOI 10.4049/jimmunol.1900345; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kai Y, 2005, GASTROENTEROLOGY, V128, P922, DOI 10.1053/j.gastro.2005.01.013; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kim EH, 2006, BIOCHEM PHARMACOL, V72, P1516, DOI 10.1016/j.bcp.2006.07.030; Kim SJ, 2021, FEBS LETT, V595, P604, DOI 10.1002/1873-3468.14040; Kolios G, 2004, IMMUNOLOGY, V113, P427, DOI 10.1111/j.1365-2567.2004.01984.x; Korns D, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00057; Kuhl AA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00613; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; LEE SH, 1985, J EXP MED, V161, P475, DOI 10.1084/jem.161.3.475; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li Y, 2012, INFLAMM BOWEL DIS, V18, P1177, DOI 10.1002/ibd.21884; Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879; MacDonald TT, 2011, GASTROENTEROLOGY, V140, P1768, DOI 10.1053/j.gastro.2011.02.047; Medeiros AI, 2009, J EXP MED, V206, P61, DOI 10.1084/jem.20082058; Michlewska S, 2009, FASEB J, V23, P844, DOI 10.1096/fj.08-121228; Migita H, 2005, ARTERIOSCL THROM VAS, V25, P710, DOI 10.1161/01.ATV.0000156482.76228.d1; Mochizuki M, 2005, AM J RESP CRIT CARE, V171, P1260, DOI 10.1164/rccm.200406-755OC; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Nguyen PM, 2015, J INTERF CYTOK RES, V35, P340, DOI 10.1089/jir.2014.0225; Park Yo Han, 2015, J Cancer Prev, V20, P260, DOI 10.15430/JCP.2015.20.4.260; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Ponferrada A, 2007, GASTROENTEROLOGY, V132, P1791, DOI 10.1053/j.gastro.2007.02.032; Rajakariar R, 2007, P NATL ACAD SCI USA, V104, P20979, DOI 10.1073/pnas.0707394104; Rajakariar R, 2006, MOL INTERV, V6, P199, DOI 10.1124/mi.6.4.6; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891; Sanchez-Munoz F, 2008, WORLD J GASTROENTERO, V14, P4280, DOI 10.3748/wjg.14.4280; Scher JU, 2009, J INVEST MED, V57, P703, DOI 10.2310/JIM.0b013e31819aaa76; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Shalhoub J, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-9; Shinohara M, 2016, J ATHEROSCLER THROMB, V23, P655, DOI 10.5551/jat.33928; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675; Takagi T, 2019, ARCH BIOCHEM BIOPHYS, V677, DOI 10.1016/j.abb.2019.108183; Trivedi SG, 2006, P NATL ACAD SCI USA, V103, P5179, DOI 10.1073/pnas.0507175103; Virtue S, 2015, INT J OBESITY, V39, P1151, DOI 10.1038/ijo.2015.34; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Weigmann B, 2007, NAT PROTOC, V2, P2307, DOI 10.1038/nprot.2007.315; Wong SH, 2009, RHEUMATOLOGY, V48, P39, DOI 10.1093/rheumatology/ken412; Wu GD, 2003, GASTROENTEROLOGY, V124, P1538, DOI 10.1016/S0016-5085(03)00345-7; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Yamamoto M, 2000, J IMMUNOL, V164, P4878, DOI 10.4049/jimmunol.164.9.4878	77	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 2	2021	12								615803	10.3389/fimmu.2021.615803	http://dx.doi.org/10.3389/fimmu.2021.615803			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QH4EJ	33633749	Green Published, gold			2022-12-18	WOS:000618228400001
J	Deng, SW; Qiu, K; Tu, RR; Zheng, HP; Lu, W				Deng, Shuwen; Qiu, Ke; Tu, Ranran; Zheng, Haiping; Lu, Wei			Relationship Between Pregnancy and Acute Disseminated Encephalomyelitis: A Single-Case Study	FRONTIERS IN IMMUNOLOGY			English	Article						acute disseminated encephalomyelitis; pregnancy; immunological pathogenesis; T-helper lymphocytes; Immune Tolerance	PLACENTA; AQUAPORINS; WOMAN	The relationship between pregnancy and autoimmune diseases is unclear. This study investigated the possible role of local immune changes and the activation state of the HMGB1/TLR4/Nf-kappa B/IL-6 pathway at the maternal-fetal interface during pregnancy in the pathogenesis of acute disseminated encephalomyelitis (ADEM). Clinical data and blood samples of a patient with ADEM were collected to observe the dynamic changes in lymphocyte populations after an abortion. The expression of HMGB1, TLR4, Nf-kappa B, AQP4, IL-2, IL-4, IL-6, and TNF-alpha in the fetal membrane and placenta was compared between the patient with pregnancy-related ADEM and a woman with a normal pregnancy using Real-time qPCR and western blotting (WB). The patient was diagnosed with ADEM in the early stage of pregnancy after showing limb weakness symptoms. In the third month of gestation, the symptoms worsened, with a disturbance of consciousness and breathing. After the abortion, the patient relapsed with vertigo and visual rotation. Analysis of lymphocyte subsets by flow cytometry showed that B lymphocytes increased, while natural killer T lymphocytes decreased. WB and Real-time qPCR showed that the expression levels of HMGB1, TLR4, Nf-kappa B, AQP4, and IL-6 in the fetal membrane and placenta were higher in the patient with pregnancy-related ADEM than in the woman with a normal pregnancy, while those of IL-2 were lower in the patient than in the woman with a normal pregnancy. The local immune changes and the activation of the HMGB1/TLR4/Nf-kappa B/IL-6 pathway at the maternal-fetal interface may be related to the pathogenesis of ADEM.	[Deng, Shuwen; Tu, Ranran; Zheng, Haiping; Lu, Wei] Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Peoples R China; [Qiu, Ke] Third Hosp Changsha, Dept Neurol, Changsha, Peoples R China	Central South University	Lu, W (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Peoples R China.	luwei0338@csu.edu.cn			National Natural Science Foundation of China [81571181]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Natural Science Foundation of China (#81571181).	Adar T, 2015, DIGEST DIS SCI, V60, P2581, DOI 10.1007/s10620-015-3683-z; Al-Shammri S, 2004, J NEUROL SCI, V222, P21, DOI 10.1016/j.jns.2004.03.027; Bonney EA, 2016, OBSTET GYN CLIN N AM, V43, P679, DOI 10.1016/j.ogc.2016.07.004; Burton GJ, 2018, AM J OBSTET GYNECOL, V218, pS745, DOI 10.1016/j.ajog.2017.11.577; Challis JR, 2009, REPROD SCI, V16, P206, DOI 10.1177/1933719108329095; Chang SH, 2012, MOL THER, V20, P2052, DOI 10.1038/mt.2012.125; Chen KB, 2011, SPINE, V36, P2122, DOI 10.1097/BRS.0b013e318203941c; Chen XR, 2017, J NEUROINFLAMM, V14, DOI [10.1186/s12974-018-1151-3, 10.1186/s12974-017-0917-3]; Cisse FA, 2012, MED SANTE TROP, V22, P103; Dale RC, 2003, NEUROPEDIATRICS, V34, P141; De Falco M, 2007, IN VIVO, V21, P813; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Dong P, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170150; Faas MM, 2017, PLACENTA, V56, P44, DOI 10.1016/j.placenta.2017.03.001; Fei YX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01361; Fominykh V, 2018, J CLIN NEUROL, V14, P327, DOI 10.3988/jcn.2018.14.3.327; Franciotta D, 2006, J NEUROL SCI, V247, P202, DOI 10.1016/j.jns.2006.05.049; Gaudry P, 2006, EUR J OBSTET GYN R B, V124, P123, DOI 10.1016/j.ejogrb.2005.06.031; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; Han XJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010300; Hoftberger R, 2018, HAND CLINIC, V145, P263, DOI 10.1016/B978-0-12-802395-2.00019-5; Hoya M, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12813; Hu ZL, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00465; Ishizu T, 2006, J NEUROIMMUNOL, V175, P52, DOI 10.1016/j.jneuroim.2006.03.020; Kaur G, 2014, PSYCHOSOMATICS, V55, P101, DOI 10.1016/j.psym.2013.05.010; Kidd Parris, 2003, Altern Med Rev, V8, P223; Kothur K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161656; Kothur K, 2016, CYTOKINE, V77, P227, DOI 10.1016/j.cyto.2015.10.001; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee CL, 2011, HUM REPROD, V26, P517, DOI 10.1093/humrep/deq381; Li N, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/6025061; Liu TE, 2013, LEUKEMIA RES, V37, P1322, DOI 10.1016/j.leukres.2013.06.026; Macerollo A, 2016, J NEUROL SCI, V364, P53, DOI 10.1016/j.jns.2016.03.015; Martinez N, 2017, ADV EXP MED BIOL, V969, P199, DOI 10.1007/978-94-024-1057-0_13; Matiello M, 2013, JAMA NEUROL, V70, P1118, DOI 10.1001/jamaneurol.2013.3124; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Pohl D, 2016, NEUROLOGY, V87, pS38, DOI 10.1212/WNL.0000000000002825; Qiu K, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01070; Qu YR, 2018, VIROLOGY, V525, P19, DOI 10.1016/j.virol.2018.09.001; Quick AM, 2005, FASEB J, V19, P170, DOI 10.1096/fj.04-1901hyp; Robinson DP, 2012, HORM BEHAV, V62, P263, DOI 10.1016/j.yhbeh.2012.02.023; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X; Rudolph ME, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00257; Sabayan B, 2007, MED HYPOTHESES, V69, P322, DOI 10.1016/j.mehy.2006.10.061; Salvador NRS, 2019, MULT SCLER RELAT DIS, V34, P59, DOI 10.1016/j.msard.2019.05.007; Savransky A, 2018, MEDICINA-BUENOS AIRE, V78, P75; Shah AK, 2000, J NEUROL SCI, V174, P147, DOI 10.1016/S0022-510X(00)00260-4; Shosha E, 2017, MULT SCLER J, V23, P1808, DOI 10.1177/1352458517740215; Smith KA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00456; Sun L, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-1008-1; Svensson-Arvelund J, 2014, TOXICOL PATHOL, V42, P327, DOI 10.1177/0192623313482205; Taylor EB, 2017, CLIN SCI, V131, P2911, DOI 10.1042/CS20171070; Tenembaum S, 2007, NEUROLOGY, V68, pS23, DOI 10.1212/01.wnl.0000259404.51352.7f; Verma P, 2019, AM J REPROD IMMUNOL, V81, DOI 10.1111/aji.13081; Wang R, 2018, VIROLOGY, V518, P172, DOI 10.1016/j.virol.2018.02.021; Wang X, 2019, J DIABETES INVEST, V10, P375, DOI 10.1111/jdi.12873; Wiegman MJ, 2008, REPROD SCI, V15, P506, DOI 10.1177/1933719107311783; Xu MM, 2017, ADV EXP MED BIOL, V969, P81, DOI 10.1007/978-94-024-1057-0_5; Yang FL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02317; Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648; Yuan J, 2015, J REPROD IMMUNOL, V110, P81, DOI 10.1016/j.jri.2015.05.001; Zhang YW, 2012, FRONT BIOSCI-LANDMRK, V17, P2371, DOI 10.2741/4058	62	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2021	11								609476	10.3389/fimmu.2020.609476	http://dx.doi.org/10.3389/fimmu.2020.609476			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QG9JZ	33597947	gold, Green Published			2022-12-18	WOS:000617896900001
J	Mariscal, A; Milan, M; Baucells, A; Martinez, MA; Guillen, AG; Trallero-Araguas, E; Alvarado-Cardenas, M; Martinez-Martinez, L; Alserawan, L; Franco-Leyva, T; Sanz-Martinez, MT; Vinas-Gimenez, L; Corominas, H; Juarez, C; Castellvi, I; Selva-O'Callaghan, A				Mariscal, Anais; Milan, Milena; Baucells, Andres; Angeles Martinez, Maria; Garcia Guillen, Andrea; Trallero-Araguas, Ernesto; Alvarado-Cardenas, Marcelo; Martinez-Martinez, Laura; Alserawan, Leticia; Franco-Leyva, Teresa; Teresa Sanz-Martinez, Maria; Vinas-Gimenez, Laura; Corominas, Hector; Juarez, Candido; Castellvi, Ivan; Selva-O'Callaghan, Albert			Anti-TIF-1 gamma Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice	FRONTIERS IN IMMUNOLOGY			English	Article						dermatomyositis; cancer; autoantibody; diagnosis; immunoassay		Objectives Anti-TIF-1 gamma autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1 gamma detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1 gamma. Methods We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebron Hospital (Barcelona, Spain) tested for anti-TIF-1 gamma autoantibodies using the Euroline profile and an in-house immunoblot assay. Results A total of 27 anti-TIF-1 gamma were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0.3163. Expected prevalence of anti-TIF-1 gamma autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1 gamma autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1 gamma antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). Conclusion We recommend using a second validated method to confirm Euroline-detected anti-TIF-1 gamma antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1 gamma antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.	[Mariscal, Anais; Baucells, Andres; Angeles Martinez, Maria; Martinez-Martinez, Laura; Alserawan, Leticia; Franco-Leyva, Teresa; Juarez, Candido] Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain; [Milan, Milena; Garcia Guillen, Andrea; Corominas, Hector; Castellvi, Ivan] Hosp Santa Creu & Sant Pau, Rheumatol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain; [Trallero-Araguas, Ernesto] Hosp Valle De Hebron, Rheumatol Unit, Barcelona, Spain; [Alvarado-Cardenas, Marcelo; Selva-O'Callaghan, Albert] Hosp Valle De Hebron, Internal Med Dept, Barcelona, Spain; [Martinez-Martinez, Laura; Juarez, Candido; Castellvi, Ivan; Selva-O'Callaghan, Albert] Univ Autonoma Barcelona, Barcelona, Spain; [Teresa Sanz-Martinez, Maria; Vinas-Gimenez, Laura] Hosp Valle De Hebron, Immunol Dept, Barcelona, Spain	Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron	Mariscal, A (corresponding author), Hosp Santa Creu & Sant Pau, Immunol Dept, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain.	amariscal@santpau.cat	Corominas, Hèctor/P-5045-2019	Corominas, Hèctor/0000-0002-7738-6787; Selva-O'Callaghan, Albert/0000-0003-2823-9761; Juarez, Candido/0000-0003-2235-9893; Vinas-Gimenez, Laura/0000-0003-2913-1154; Franco-Leyva, Teresa/0000-0002-0250-0274; Trallero-Araguas, Ernesto/0000-0003-3365-4521; Sanz Martinez, Maria Teresa/0000-0001-5814-8698				Aggarwal R, 2014, RHEUMATOLOGY, V53, P433, DOI 10.1093/rheumatology/ket383; Bottai M, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2017-000507; Bundell C, 2016, PATHOLOGY, V48, P363, DOI 10.1016/j.pathol.2016.03.012; Cavazzana I, 2016, J IMMUNOL METHODS, V433, P1, DOI 10.1016/j.jim.2016.02.017; Fiorentino DF, 2019, CLIN EXP RHEUMATOL, V37, P1048; Fujikawa K, 2009, SCAND J RHEUMATOL, V38, P263, DOI 10.1080/03009740802687455; Fujimoto M, 2016, J DERMATOL SCI, V84, P272, DOI 10.1016/j.jdermsci.2016.09.013; Hill CL, 2001, LANCET, V357, P96, DOI 10.1016/S0140-6736(00)03540-6; Hohlfeld R, 2006, AUTOIMMUNE DISEASES, 4TH EDITION, P453, DOI 10.1016/B978-012595961-2/50037-8; Kaji K, 2007, RHEUMATOLOGY, V46, P25, DOI 10.1093/rheumatology/kel161; Labrador-Horrillo M, 2012, ANN RHEUM DIS, V71, P993, DOI 10.1136/annrheumdis-2011-200871; Mahler M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00848; Pinal-Fernandez I, 2018, RHEUMATOLOGY, V57, P388, DOI 10.1093/rheumatology/kex413; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; Shimizu K, 2020, J DERMATOL, V47, P64, DOI 10.1111/1346-8138.15128; Tansley SL, 2020, RHEUMATOLOGY, V59, P2109, DOI 10.1093/rheumatology/keaa021; Targoff IN, 2006, ARTHRITIS RHEUM, V54, P3682, DOI 10.1002/art.22164; Tiniakou E, 2017, CLIN REV ALLERG IMMU, V52, P20, DOI 10.1007/s12016-015-8511-x; Trallero-Araguas E, 2012, ARTHRITIS RHEUM-US, V64, P523, DOI 10.1002/art.33379; Trallero-Araguas E, 2010, MEDICINE, V89, P47, DOI 10.1097/MD.0b013e3181ca14ff; Vulsteke JB, 2019, ANN RHEUM DIS, V78, DOI 10.1136/annrheumdis-2017-212915	21	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 1	2021	11								625896	10.3389/fimmu.2020.625896	http://dx.doi.org/10.3389/fimmu.2020.625896			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QJ3OW	33613568	gold, Green Published			2022-12-18	WOS:000619602500001
J	Hait, SH; Hogge, CJ; Rahman, MA; Hunegnaw, R; Mushtaq, Z; Hoang, T; Robert-Guroff, M				Hait, Sabrina Helmold; Hogge, Christopher James; Rahman, Mohammad Arif; Hunegnaw, Ruth; Mushtaq, Zuena; Hoang, Tanya; Robert-Guroff, Marjorie			T-FH Cells Induced by Vaccination and Following SIV Challenge Support Env-Specific Humoral Immunity in the Rectal-Genital Tract and Circulation of Female Rhesus Macaques	FRONTIERS IN IMMUNOLOGY			English	Article						T-FH cells; B cell help; humoral immunity; rhesus macaque; SIV vaccine	FOLLICULAR HELPER-CELLS; TFH CELLS; RESPONSES; HIV-1; ANTIBODIES; INFECTION	T follicular helper (T-FH) cells are pivotal in lymph node (LN) germinal center (GC) B cell affinity maturation. Circulating CXCR5(+) CD4(+) T (cT(FH)) cells have supported memory B cell activation and broadly neutralizing antibodies in HIV controllers. We investigated the contribution of LN SIV-specific T-FH and cT(FH) cells to Env-specific humoral immunity in female rhesus macaques following a mucosal Ad5hr-SIV recombinant priming and SIV gp120 intramuscular boosting vaccine regimen and following SIV vaginal challenge. T-FH and B cells were characterized by flow cytometry. B cell help was evaluated in T-FH-B cell co-cultures and by real-time PCR. Vaccination induced Env-specific T-FH and Env-specific memory (ESM) B cells in LNs. LN Env-specific T-FH cells post-priming and GC ESM B cells post-boosting correlated with rectal Env-specific IgA titers, and GC B cells at the same timepoints correlated with vaginal Env-specific IgG titers. Vaccination expanded cT(FH) cell responses, including CD25(+) Env-specific cT(FH) cells that correlated negatively with vaginal Env-specific IgG titers but positively with rectal Env-specific IgA titers. Although cT(FH) cells post-2(nd) boost positively correlated with viral-loads following SIV challenge, cT(FH) cells of SIV-infected and protected macaques supported maturation of circulating B cells into plasma cells and IgA release in co-culture. Additionally, cT(FH) cells of naive macaques promoted upregulation of genes associated with B cell proliferation, BCR engagement, plasma cell maturation, and antibody production, highlighting the role of cT(FH) cells in blood B cell maturation. Vaccine-induced LN T-FH and GC B cells supported anti-viral mucosal immunity while cT(FH) cells provided B cell help in the periphery during immunization and after SIV challenge. Induction of T-FH responses in blood and secondary lymphoid organs is likely desirable for protective efficacy of HIV vaccines.	[Hait, Sabrina Helmold; Hogge, Christopher James; Rahman, Mohammad Arif; Hunegnaw, Ruth; Mushtaq, Zuena; Hoang, Tanya; Robert-Guroff, Marjorie] NCI, Immune Biol Retroviral Infect Sect, Vaccine Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Robert-Guroff, M (corresponding author), NCI, Immune Biol Retroviral Infect Sect, Vaccine Branch, NIH, Bethesda, MD 20892 USA.	guroffm@mail.nih.gov		Rahman, Mohammad Arif/0000-0002-6120-8943	Intramural Research Program of the National Institutes of Health, National Cancer Institute	Intramural Research Program of the National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.	Abbott RK, 2018, IMMUNITY, V48, P133, DOI 10.1016/j.immuni.2017.11.023; Amet T, 2017, J LEUKOCYTE BIOL, V102, P527, DOI 10.1189/jlb.4A1216-513RR; Anderson SM, 2009, J IMMUNOL, V183, P7314, DOI 10.4049/jimmunol.0902452; Arunachalam PS, 2020, NAT MED, V26, P932, DOI 10.1038/s41591-020-0858-8; Bacher P, 2013, CYTOM PART A, V83A, P692, DOI [10.1002/cyto.a.22317, 10.1002/cyto.22317]; Baiyegunhi O, 2018, J VIROL, V92, DOI 10.1128/JVI.00659-18; Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352; Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886; Barouch DH, 2010, CURR OPIN HIV AIDS, V5, P386, DOI 10.1097/COH.0b013e32833cfe4c; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; Beller A, 2020, EUR J IMMUNOL, V50, P783, DOI 10.1002/eji.201948474; Bentebibel SE, 2015, METHODS MOL BIOL, V1291, P187, DOI 10.1007/978-1-4939-2498-1_16; Bossaller L, 2006, J IMMUNOL, V177, P4927, DOI 10.4049/jimmunol.177.7.4927; Buge SL, 1997, J VIROL, V71, P8531, DOI 10.1128/JVI.71.11.8531-8541.1997; Cardeno A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20740-3; Chan TD, 2009, J IMMUNOL, V183, P3139, DOI 10.4049/jimmunol.0901690; CHENG SM, 1992, J VIROL, V66, P6721, DOI 10.1128/JVI.66.11.6721-6727.1992; Chevalier N, 2015, METHODS MOL BIOL, V1291, P209, DOI 10.1007/978-1-4939-2498-1_18; Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Claireaux M, 2018, MBIO, V9, DOI 10.1128/mBio.00317-18; Cohen K, 2014, J VIROL, V88, P13310, DOI 10.1128/JVI.02186-14; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Curtis AD, 2018, J MED PRIMATOL, V47, P288, DOI 10.1111/jmp.12372; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; DeFranco Anthony L, 2016, F1000Res, V5, DOI 10.12688/f1000research.7717.1; Demberg T, 2008, J VIROL, V82, P10911, DOI 10.1128/JVI.01129-08; Demberg T, 2012, J VIROL, V86, P12591, DOI 10.1128/JVI.00298-12; Demberg T, 2009, INT REV IMMUNOL, V28, P20, DOI 10.1080/08830180802684331; Fazilleau N, 2009, IMMUNITY, V30, P324, DOI 10.1016/j.immuni.2009.03.003; Garcia M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17057-y; Hait SH, 2020, J IMMUNOL, V204, P3315, DOI 10.4049/jimmunol.2000165; Hait SH, 2019, J VIROL, V93, DOI 10.1128/JVI.01687-18; Havenar-Daughton C, 2017, IMMUNOL REV, V275, P49, DOI 10.1111/imr.12512; Havenar-Daughton C, 2016, CELL REP, V17, P2195, DOI 10.1016/j.celrep.2016.10.085; Havenar-Daughton C, 2016, J IMMUNOL, V197, P994, DOI 10.4049/jimmunol.1600320; Haynes BF, 2013, CURR OPIN HIV AIDS, V8, P326, DOI 10.1097/COH.0b013e328361d178; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Heit A, 2017, J EXP MED, V214, P2139, DOI 10.1084/jem.20161794; Hollister K, 2014, HUM VACC IMMUNOTHER, V10, P1985, DOI 10.4161/hv.28659; Hong JJ, 2012, J IMMUNOL, V188, P3247, DOI 10.4049/jimmunol.1103138; Hsu DC, 2017, HUM VACC IMMUNOTHER, V13, P1018, DOI 10.1080/21645515.2016.1276138; Iyer SS, 2015, J IMMUNOL, V195, P994, DOI 10.4049/jimmunol.1500083; Jenkins LMM, 2010, NAT CHEM BIOL, V6, P887, DOI 10.1038/NCHEMBIO.456; Kaji T, 2012, J EXP MED, V209, P2079, DOI 10.1084/jem.20120127; Karnell JL, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00002; Keoshkerian E, 2012, J IMMUNOL METHODS, V375, P148, DOI 10.1016/j.jim.2011.10.004; Klein U, 2003, P NATL ACAD SCI USA, V100, P2639, DOI 10.1073/pnas.0437996100; Kubinak JL, 2015, CELL HOST MICROBE, V17, P153, DOI 10.1016/j.chom.2014.12.009; Kuchen S, 2007, J IMMUNOL, V179, P5886, DOI 10.4049/jimmunol.179.9.5886; Kuhrt D, 2011, J IMMUNOL METHODS, V363, P166, DOI 10.1016/j.jim.2010.09.017; Kulkarni V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01581; Linterman Michelle A, 2016, F1000Res, V5, DOI 10.12688/f1000research.7388.1; Liu DY, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0176-6; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Manrique M, 2009, MUCOSAL IMMUNOL, V2, P536, DOI 10.1038/mi.2009.103; Martin-Gayo E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89574; Matchett WE, 2019, J VIROL, V93, DOI 10.1128/JVI.02016-18; MATSUDA S, 1993, SCAND J IMMUNOL, V38, P428, DOI 10.1111/j.1365-3083.1993.tb02584.x; Mikell I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001251; Mohanram V, 2016, J IMMUNOL, V197, P2316, DOI 10.4049/jimmunol.1600544; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Moukambi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00135; Moysi E, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0437-y; Neumann B, 2015, J LEUKOCYTE BIOL, V97, P19, DOI 10.1189/jlb.1HI0514-243R; Niessl J, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102727; Nutt SL, 2011, NAT IMMUNOL, V12, P472, DOI 10.1038/ni.2019; Onabajo OO, 2018, J CELL MOL MED, V22, P5682, DOI 10.1111/jcmm.13844; Pallikkuth S, 2016, J VIROL, V90, P2718, DOI 10.1128/JVI.02883-15; Patterson LJ, 2004, J VIROL, V78, P2212, DOI 10.1128/JVI.78.5.2212-2221.2004; Perreau M, 2013, J EXP MED, V210, P143, DOI 10.1084/jem.20121932; Petrovas C, 2014, CURR OPIN HIV AIDS, V9, P235, DOI 10.1097/COH.0000000000000053; Pissani F, 2014, TRENDS IMMUNOL, V35, P278, DOI 10.1016/j.it.2014.02.010; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Roider J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01975; Ruprecht RM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040194; Schmitt N, 2014, TRENDS IMMUNOL, V35, P436, DOI 10.1016/j.it.2014.06.002; Schmitt N, 2013, IMMUNITY, V39, P629, DOI 10.1016/j.immuni.2013.09.011; Schultz BT, 2016, IMMUNITY, V44, P167, DOI 10.1016/j.immuni.2015.12.011; Shi JW, 2018, IMMUNITY, V49, P264, DOI 10.1016/j.immuni.2018.06.012; Shulman Z, 2013, SCIENCE, V341, P673, DOI 10.1126/science.1241680; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Stephenson KE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205139; Subbaraman H, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0433-2; Swathirajan CR, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftz044; Tarlinton DM, 2014, NATURE, V509, P573, DOI 10.1038/509573a; Thornhill JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00046; Titanji K, 2010, J CLIN INVEST, V120, P3878, DOI 10.1172/JCI43271; Tuero I, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005101; Tuyishime S, 2018, EBIOMEDICINE, V31, P25, DOI 10.1016/j.ebiom.2018.02.025; Ueno H, 2016, J CLIN IMMUNOL, V36, pS34, DOI 10.1007/s10875-016-0268-3; Vargas-Inchaustegui DA, 2016, J IMMUNOL, V196, P1700, DOI 10.4049/jimmunol.1502137; Vella LA, 2019, J CLIN INVEST, V129, P3185, DOI 10.1172/JCI125628; Velu V, 2016, J IMMUNOL, V197, P1832, DOI 10.4049/jimmunol.1600143; Verma A, 2020, J VIROL, V94, DOI 10.1128/JVI.01737-19; Victora GD, 2014, CURR OPIN IMMUNOL, V28, P90, DOI 10.1016/j.coi.2014.02.010; Xie MM, 2017, EUR J IMMUNOL, V47, P1136, DOI 10.1002/eji.201747034; Xu HB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00085; Yamamoto T, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3964; Zaunders JJ, 2009, J IMMUNOL, V183, P2827, DOI 10.4049/jimmunol.0803548; Zhang J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46533-w; Zhang Y, 2016, IMMUNOL REV, V270, P8, DOI 10.1111/imr.12396; Zhao J, 2003, VACCINE, V21, P4022, DOI 10.1016/S0264-410X(03)00266-4	109	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2021	11								608003	10.3389/fimmu.2020.608003	http://dx.doi.org/10.3389/fimmu.2020.608003			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QF3MV	33584682	Green Published, gold			2022-12-18	WOS:000616803000001
J	Ashoori, MD; Suzuki, K; Tokumaru, Y; Ikuta, N; Tajima, M; Honjo, T; Ohta, A				Ashoori, Matin Dokht; Suzuki, Kensuke; Tokumaru, Yosuke; Ikuta, Naoko; Tajima, Masaki; Honjo, Tasuku; Ohta, Akio			Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events	FRONTIERS IN IMMUNOLOGY			English	Article						PD-1; cancer immunotherapy; immune-related adverse events; contact hypersensitivity; skin; T&#160; cells; CXCR3		Blockade of PD-1, an indispensable physiological immunoregulatory mechanism, enhances immune activities and is widely used in the immunotherapy of cancer. This treatment often accompanies inflammatory complication called immune-related adverse events (irAE), most frequently in the skin. To analyze how skin inflammation develops by the blockade of PD-1-dependent immunoregulation, we studied the exacerbation of oxazolone-induced contact hypersensitivity by PD-L1 blockade. The inactivation of PD-1 signaling enhanced swelling of the skin with massive CD8(+) T cell infiltration. Among PD-1-expressing cells, T cells were the predominant targets of anti-PD-L1 mAb treatment since PD-L1 blockade did not affect skin inflammation in RAG2(-/-) mice. PD-L1 blockade during immunization with oxazolone significantly promoted the development of hapten-reactive T cells in the draining lymph nodes. The enhancement of local CD8(+) T cell-dominant immune responses by PD-L1 blockade was correlated with the upregulation of CXCL9 and CXCL10. Challenges with a low dose of oxazolone did not demonstrate any significant dermatitis; however, the influence of PD-L1 blockade on T cell immunity was strong enough to cause the emergence of notable dermatitis in this suboptimal dosing, suggesting its relevance to dermal irAE development. In the low-dose setting, the blockade of CXCR3, receptor of CXCL9/10, prevented the induction of T cell-dominant inflammation by anti-PD-L1 mAb. This experimental approach reproduced CD8(+) T cell-dominant form of cutaneous inflammation by the blockade of PD-L1 that has been observed in dermal irAE in human patients.	[Ashoori, Matin Dokht; Suzuki, Kensuke; Tokumaru, Yosuke; Ikuta, Naoko; Tajima, Masaki; Ohta, Akio] Fdn Biomed Res & Innovat Kobe, Dept Immunol, Kobe, Hyogo, Japan; [Ashoori, Matin Dokht; Honjo, Tasuku] Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Kyoto, Japan; [Suzuki, Kensuke; Tokumaru, Yosuke] Meiji Seika Pharma Co Ltd, Pharmaceut Res Labs, Yokohama, Kanagawa, Japan	Kyoto University; Meiji Seika Pharma	Ohta, A (corresponding author), Fdn Biomed Res & Innovat Kobe, Dept Immunol, Kobe, Hyogo, Japan.	ohta-a@fbri.org						Akiba H, 2002, J IMMUNOL, V168, P3079, DOI 10.4049/jimmunol.168.6.3079; Albanesi C, 2000, J IMMUNOL, V165, P1395, DOI 10.4049/jimmunol.165.3.1395; Ali OH, 2020, J AM ACAD DERMATOL, V82, P854, DOI 10.1016/j.jaad.2019.08.045; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; Chamoto K, 2020, INT J CLIN ONCOL, V25, P790, DOI 10.1007/s10147-019-01588-7; Chamoto K, 2017, P NATL ACAD SCI USA, V114, pE761, DOI 10.1073/pnas.1620433114; Chow MT, 2019, IMMUNITY, V50, P1498, DOI 10.1016/j.immuni.2019.04.010; Coleman EL, 2020, CLIN DERMATOL, V38, P94, DOI 10.1016/j.clindermatol.2019.10.015; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; El Osta B, 2017, CRIT REV ONCOL HEMAT, V119, P1, DOI 10.1016/j.critrevonc.2017.09.002; Gamradt P, 2019, J ALLERGY CLIN IMMUN, V143, P2147, DOI 10.1016/j.jaci.2018.11.048; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Goldinger SM, 2016, CLIN CANCER RES, V22, P4023, DOI 10.1158/1078-0432.CCR-15-2872; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Haratake N, 2018, J THORAC ONCOL, V13, P1798, DOI 10.1016/j.jtho.2018.05.031; He DG, 2009, J IMMUNOL, V183, P1463, DOI 10.4049/jimmunol.0804108; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317; Hua C, 2016, JAMA DERMATOL, V152, P45, DOI 10.1001/jamadermatol.2015.2707; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Karyampudi L, 2016, CANCER RES, V76, P239, DOI 10.1158/0008-5472.CAN-15-0748; Khan Z, 2020, P NATL ACAD SCI USA, V117, P12288, DOI [10.1073/pnas.1922867117/-/DCSupplemental, 10.1073/pnas.1922867117]; Kim HK, 2006, J LEUKOCYTE BIOL, V79, P686, DOI 10.1189/jlb.0805436; Krempski J, 2011, J IMMUNOL, V186, P6905, DOI 10.4049/jimmunol.1100274; Mahalingam S, 2001, J BIOL CHEM, V276, P7568, DOI 10.1074/jbc.M005773200; Melter M, 2001, CIRCULATION, V104, P2558, DOI 10.1161/hc4601.098010; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Mitsui G, 2003, IMMUNOL LETT, V86, P191, DOI 10.1016/S0165-2478(03)00017-8; Mori T, 2008, J INVEST DERMATOL, V128, P1719, DOI 10.1038/jid.2008.5; Nakae S, 2003, INT IMMUNOL, V15, P251, DOI 10.1093/intimm/dxg028; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Okiyama N, 2014, J AUTOIMMUN, V53, P1, DOI 10.1016/j.jaut.2014.06.005; Panzer U, 2004, TRANSPLANTATION, V78, P1341, DOI 10.1097/01.TP.0000140483.59664.64; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Qin WT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02298; Ramos-Casals M, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0160-6; Ritprajak P, 2010, J IMMUNOL, V184, P4918, DOI 10.4049/jimmunol.0902478; Robinson S, 2020, AM J DERMATOPATH, V42, P292, DOI 10.1097/DAD.0000000000001527; Rogado J, 2019, EUR J CANCER, V109, P21, DOI 10.1016/j.ejca.2018.10.014; Rouzaire P, 2012, EUR J IMMUNOL, V42, P80, DOI 10.1002/eji.201141820; Sadik CD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01934; Salati M, 2018, ANN ONCOL, V29, P283, DOI 10.1093/annonc/mdx640; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Saw S, 2017, EUR J CANCER, V81, P237, DOI 10.1016/j.ejca.2017.03.026; Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002; Sebastiani S, 2002, ARCH DERMATOL RES, V293, P552, DOI 10.1007/s00403-001-0276-9; Strauss L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay1863; Tanaka R, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01308-2; Terme M, 2012, CANCER RES, V72, P2757, DOI 10.1158/0008-5472.CAN-11-3379; Tokuriki A, 2002, J DERMATOL SCI, V28, P234, DOI 10.1016/S0923-1811(01)00172-4; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsushima F, 2003, EUR J IMMUNOL, V33, P2773, DOI 10.1002/eji.200324084; Young A, 2018, CANCER IMMUNOL RES, V6, P1445, DOI 10.1158/2326-6066.CIR-18-0487	56	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2021	11								618711	10.3389/fimmu.2020.618711	http://dx.doi.org/10.3389/fimmu.2020.618711			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QE9MB	33584713	Green Published, gold			2022-12-18	WOS:000616526600001
J	Netherby-Winslow, CS; Ayers, KN; Lukacher, AE				Netherby-Winslow, Colleen S.; Ayers, Katelyn N.; Lukacher, Aron E.			Balancing Inflammation and Central Nervous System Homeostasis: T Cell Receptor Signaling in Antiviral Brain T-RM Formation and Function	FRONTIERS IN IMMUNOLOGY			English	Review						T cell receptor; PD-1; brain-resident memory CD8 T cells; virus; neuroinflammation	PD-1	Tissue-resident memory (T-RM) CD8 T cells provide early frontline defense against regional pathogen reencounter. CD8 T-RM are predominantly parked in nonlymphoid tissues and do not circulate. In addition to this anatomic difference, T-RM are transcriptionally and phenotypically distinct from central-memory T cells (T-CM) and effector-memory T cells (T-EM). Moreover, T-RM differ phenotypically, functionally, and transcriptionally across barrier tissues (e.g., gastrointestinal tract, respiratory tract, urogenital tract, and skin) and in non-barrier organs (e.g., brain, liver, kidney). In the brain, T-RM are governed by a contextual milieu that balances T-RM activation and preservation of essential post-mitotic neurons. Factors contributing to the development and maintenance of brain T-RM, of which T cell receptor (TCR) signal strength and duration is a central determinant, vary depending on the infectious agent and modulation of TCR signaling by inhibitory markers that quell potentially pathogenic inflammation. This review will explore our current understanding of the context-dependent factors that drive the acquisition of brain (b)T-RM phenotype and function, and discuss the contribution of T-RM to promoting protective immune responses in situ while maintaining tissue homeostasis.	[Netherby-Winslow, Colleen S.; Ayers, Katelyn N.; Lukacher, Aron E.] Penn State Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Lukacher, AE (corresponding author), Penn State Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.	alukacher@pennstatehealth.psu.edu		Netherby, Colleen/0000-0001-5676-768X	National Institute of Neurological Disorders and Stroke; National Cancer Institute [R01NS088367, R01NS092662, F32NS106730, T32CA060395]	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the National Institute of Neurological Disorders and Stroke and the National Cancer Institute grants R01NS088367 and R01NS092662 to AL, F32NS106730 to CN-W, and T32CA060395 to KA.	Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005; ALLISON JP, 1982, J IMMUNOL, V129, P2293; Bally APR, 2016, J IMMUNOL, V196, P2431, DOI 10.4049/jimmunol.1502643; Beck ES, 2020, CURR OPIN VIROL, V40, P19, DOI 10.1016/j.coviro.2020.02.005; Becker TC, 2002, J EXP MED, V195, P1541, DOI 10.1084/jem.20020369; Behr FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01770; Beltra JC, 2020, IMMUNITY, V52, P825, DOI 10.1016/j.immuni.2020.04.014; Beura LK, 2018, IMMUNITY, V48, P327, DOI 10.1016/j.immuni.2018.01.015; Boland BS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb4432; Boldison J, 2014, J IMMUNOL, V192, P4541, DOI 10.4049/jimmunol.1301390; BORKOWSKI TA, 1994, EUR J IMMUNOL, V24, P2767, DOI 10.1002/eji.1830241129; Bronke C, 2013, AIDS, V27, P899, DOI 10.1097/QAD.0b013e32835e1616; Casey KA, 2012, J IMMUNOL, V188, P4866, DOI 10.4049/jimmunol.1200402; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Cibrian D, 2017, EUR J IMMUNOL, V47, P946, DOI 10.1002/eji.201646837; Clarke J, 2019, J EXP MED, V216, P2128, DOI 10.1084/jem.20190249; Corgnac S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01904; Corse E, 2011, J IMMUNOL, V186, P5039, DOI 10.4049/jimmunol.1003650; Cortese I, 2019, NEW ENGL J MED, V380, P1597, DOI 10.1056/NEJMoa1815039; Cui WG, 2010, IMMUNOL REV, V236, P151, DOI 10.1111/j.1600-065X.2010.00926.x; Curtsinger JM, 2003, J IMMUNOL, V171, P5165, DOI 10.4049/jimmunol.171.10.5165; Curtsinger JM, 2003, J EXP MED, V197, P1141, DOI 10.1084/jem.20021910; Daniels MA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00617; Dulken B, 2019, NATURE, V571, P205, DOI 10.1038/s41586-019-1362-5; Fernandes RA, 2020, NATURE, V586, P779, DOI 10.1038/s41586-020-2851-2; Fiege JK, 2019, J IMMUNOL, V203, P936, DOI 10.4049/jimmunol.1900093; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Frost EL, 2015, J IMMUNOL, V195, P3520, DOI 10.4049/jimmunol.1501521; Gaide O, 2015, NAT MED, V21, P647, DOI 10.1038/nm.3860; Gane E, 2019, J HEPATOL, V71, P900, DOI 10.1016/j.jhep.2019.06.028; Garber C, 2019, NAT NEUROSCI, V22, P1276, DOI 10.1038/s41593-019-0427-y; Gardiner D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063818; Goldrath AW, 2002, J EXP MED, V195, P1515, DOI 10.1084/jem.20020033; Hendricks J, 2003, J EXP MED, V198, P1369, DOI 10.1084/jem.20030916; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Hirano S, 2012, PHYSIOL REV, V92, P597, DOI 10.1152/physrev.00014.2011; Hofmann M, 2011, P NATL ACAD SCI USA, V108, P16741, DOI 10.1073/pnas.1107200108; Jelley-Gibbs DM, 2005, J EXP MED, V202, P697, DOI 10.1084/jem.20050227; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Judge AD, 2002, J EXP MED, V196, P935, DOI 10.1084/jem.20020772; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim TS, 2010, J EXP MED, V207, P1161, DOI 10.1084/jem.20092017; Konjar S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01683; KUHN K, 1995, MATRIX BIOL, V14, P439, DOI 10.1016/0945-053X(95)90001-2; Kuhns MS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00159; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Landrith TA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00335; Le Floc'h A, 2007, J EXP MED, V204, P559, DOI 10.1084/jem.20061524; Le Floc'h A, 2011, CANCER RES, V71, P328, DOI 10.1158/0008-5472.CAN-10-2457; Lewis-Tuffin LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013665; Liu XL, 2001, J EXP MED, V194, P1339, DOI 10.1084/jem.194.9.1339; Low JS, 2020, J EXP MED, V217, DOI 10.1084/jem.20192291; Mami-Chouaib F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01018; Marasco M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay4458; Martinez RJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00468; Maru S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006318; Masopust D, 2004, CURR OPIN IMMUNOL, V16, P217, DOI 10.1016/j.coi.2004.02.005; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Mockus TE, 2020, J VIROL, V94, DOI 10.1128/JVI.02038-19; Mockus TE, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007365; Pan YD, 2017, NATURE, V543, P252, DOI 10.1038/nature21379; Park SL, 2018, NAT IMMUNOL, V19, P183, DOI 10.1038/s41590-017-0027-5; Park SL, 2017, IMMUNOL CELL BIOL, V95, P857, DOI 10.1038/icb.2017.69; Petrelli A, 2018, J CLIN INVEST, V128, P4669, DOI 10.1172/JCI96107; Phares TW, 2010, J IMMUNOL, V185, P5607, DOI 10.4049/jimmunol.1001984; Phares TW, 2009, J IMMUNOL, V182, P5430, DOI 10.4049/jimmunol.0803557; Prasad S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0860-3; Ray SJ, 2004, IMMUNITY, V20, P167, DOI 10.1016/S1074-7613(04)00021-4; Reilly EC, 2020, P NATL ACAD SCI USA, V117, P12306, DOI [10.1073/pnas.1915681117/-/DCSupplemental, 10.1073/pnas.1915681117]; Ren HM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb5590; Ritzel RM, 2016, J IMMUNOL, V196, P3318, DOI 10.4049/jimmunol.1502021; Saeidi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02569; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schachtele SJ, 2014, GLIA, V62, P1582, DOI 10.1002/glia.22701; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Shwetank, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00783; Shwetank, 2017, IMMUNOL CELL BIOL, V95, P953, DOI 10.1038/icb.2017.62; Siddiqui KRR, 2010, IMMUNITY, V32, P557, DOI 10.1016/j.immuni.2010.03.017; Skon CN, 2013, NAT IMMUNOL, V14, P1285, DOI 10.1038/ni.2745; Smith-Garvin JE, 2010, BLOOD, V116, P5548, DOI 10.1182/blood-2010-06-292748; Smolders J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07053-9; Steinbach K, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5519; Steinbach K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02827; Steinbach K, 2016, J EXP MED, V213, P1571, DOI 10.1084/jem.20151916; Stolley JM, 2020, J EXP MED, V217, DOI 10.1084/jem.20192197; Takahashi C, 1999, J IMMUNOL, V162, P5037; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Topham DJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00515; Turner DL, 2007, J VIROL, V81, P2039, DOI 10.1128/JVI.02167-06; Urban SL, 2020, NAT IMMUNOL, V21, P938, DOI 10.1038/s41590-020-0711-8; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wakim LM, 2012, J IMMUNOL, V189, P3462, DOI 10.4049/jimmunol.1201305; Wakim LM, 2010, P NATL ACAD SCI USA, V107, P17872, DOI 10.1073/pnas.1010201107; Wallin JJ, 2001, J IMMUNOL, V167, P132, DOI 10.4049/jimmunol.167.1.132; Wang Z, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw1217; Weisberg SP, 2019, CELL REP, V29, P3916, DOI 10.1016/j.celrep.2019.11.056; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wu TQ, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aai8593; Youngblood B, 2011, IMMUNITY, V35, P400, DOI 10.1016/j.immuni.2011.06.015	102	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 27	2021	11								624144	10.3389/fimmu.2020.624144	http://dx.doi.org/10.3389/fimmu.2020.624144			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QE9EP	33584727	Green Published, gold			2022-12-18	WOS:000616507100001
J	Lenart, M; Dzialo, E; Kluczewska, A; Weglarczyk, K; Szaflarska, A; Rutkowska-Zapala, M; Surmiak, M; Sanak, M; Pituch-Noworolska, A; Siedlar, M				Lenart, Marzena; Dzialo, Edyta; Kluczewska, Anna; Weglarczyk, Kazimierz; Szaflarska, Anna; Rutkowska-Zapala, Magdalena; Surmiak, Marcin; Sanak, Marek; Pituch-Noworolska, Anna; Siedlar, Maciej			miRNA Regulation of NK Cells Antiviral Response in Children With Severe and/or Recurrent Herpes Simplex Virus Infections	FRONTIERS IN IMMUNOLOGY			English	Article						miRNA; NK cells; Herpes simplex virus; antiviral response; posttranscriptional regulation		Severe and/or recurrent infection with Herpes simplex virus (HSV) is observed in a large group of patients treated in clinical immunology facilities. Atypical and prolonged HSV infection is the most common clinical manifestation of disturbed NK cell development and functions, yet the molecular basis of these disorders is still largely unknown. Since recent findings indicated the importance of miRNA in regulating NK cell development, maturation and functions, the aim of our study was to investigate miRNA expression pattern in NK cells in patients with severe and/or recurrent infections with HSV and analyze the role of these miRNAs in NK cell antiviral response. As a result, miRNA expression pattern analysis of human best known 754 miRNAs revealed that patients with severe and/or recurrent HSV infection had substantially upregulated expression of four miRNAs: miR-27b, miR-199b, miR-369-3p and miR-491-3p, when compared to healthy controls. Selective inhibition of miR-27b, miR-199b, miR-369-3p and miR-491-3p expression in NK-92 cells resulted in profound upregulation of 4 genes (APOBEC3G, MAP2K3, MAVS and TLR7) and downregulation of 36 genes taking part in antiviral response or associated with signaling pathways of Toll-like receptors (TLR), NOD-like receptors, the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and type I IFN-related response. Additionally, flow cytometry analysis revealed that miR-369-3p and miR-491-3p inhibitors downregulated NK cell intracellular perforin expression, while the expression of granzyme B and IFN gamma remained unchanged. Taken together, our study suggests a novel mechanism which may promote recurrence and severity of HSV infection, based on miRNAs-dependent posttranscriptional regulation of genes taking part in antiviral response of human NK cells.	[Lenart, Marzena; Dzialo, Edyta; Kluczewska, Anna; Weglarczyk, Kazimierz; Szaflarska, Anna; Rutkowska-Zapala, Magdalena; Pituch-Noworolska, Anna; Siedlar, Maciej] Jagiellonian Univ Med Coll, Inst Pediat, Dept Clin Immunol, Krakow, Poland; [Surmiak, Marcin; Sanak, Marek] Jagiellonian Univ Med Coll, Dept Internal Med 2, Krakow, Poland	Jagiellonian University; Collegium Medicum Jagiellonian University; Jagiellonian University; Collegium Medicum Jagiellonian University	Siedlar, M (corresponding author), Jagiellonian Univ Med Coll, Inst Pediat, Dept Clin Immunol, Krakow, Poland.	misiedla@cyf-kr.edu.pl	Lenart, Marzena/AGW-9505-2022; Sanak, Marek/AAV-1628-2021; Surmiak, Marcin/GYU-3390-2022	Lenart, Marzena/0000-0001-6176-2891; Sanak, Marek/0000-0001-7635-8103; Surmiak, Marcin/0000-0001-8396-1488	National Science Centre of Poland (NCN) [2013/09/D/NZ2/01660]	National Science Centre of Poland (NCN)(National Science Centre, Poland)	This work was supported by the National Science Centre of Poland (NCN) (grant number 2013/09/D/NZ2/01660).	Alles J, 2019, NUCLEIC ACIDS RES, V47, P3353, DOI 10.1093/nar/gkz097; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beaulieu AM, 2013, IMMUNOL REV, V253, P40, DOI 10.1111/imr.12045; Bezman NA, 2011, J EXP MED, V208, P2717, DOI 10.1084/jem.20111386; Bezman NA, 2010, J IMMUNOL, V185, P3835, DOI 10.4049/jimmunol.1000980; Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074; Buck AH, 2010, RNA, V16, P307, DOI 10.1261/rna.1819210; Catrina AM, 2014, PATHOL ONCOL RES, V20, P153, DOI 10.1007/s12253-013-9678-1; Chen K, 2017, J AUTOIMMUN, V83, P1, DOI 10.1016/j.jaut.2017.03.008; Cheung AKL, 2017, BLOOD ADV, V1, P306, DOI 10.1182/bloodadvances.2016000638; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dong L, 2019, MOL ONCOL, V13, P1605, DOI 10.1002/1878-0261.12527; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Fehniger TA, 2007, IMMUNITY, V26, P798, DOI 10.1016/j.immuni.2007.04.010; Fehniger TA, 2010, GENOME RES, V20, P1590, DOI 10.1101/gr.107995.110; Gregoire C, 2007, IMMUNOL REV, V220, P169, DOI 10.1111/j.1600-065X.2007.00563.x; Hao GJ, 2017, BIOCHEM BIOPH RES CO, V488, P501, DOI 10.1016/j.bbrc.2017.05.075; Haynes LD, 2015, J IMMUNOL, V195, P2157, DOI 10.4049/jimmunol.1402060; He F, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2077-y; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Ishida H, 2011, BIOCHEM BIOPH RES CO, V412, P92, DOI 10.1016/j.bbrc.2011.07.049; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kim N, 2014, J ALLERGY CLIN IMMUN, V134, P195, DOI 10.1016/j.jaci.2014.02.018; Kim N, 2013, BLOOD, V121, P4090, DOI 10.1182/blood-2012-10-461566; Kim TD, 2011, BLOOD, V118, P5476, DOI 10.1182/blood-2011-04-347526; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kim YK, 2016, YONSEI MED J, V57, P5, DOI 10.3349/ymj.2016.57.1.5; LANIER LL, 1988, J IMMUNOL, V141, P3478; Leong JW, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/632329; Li H, 2006, IMMUNOLOGY, V117, P167, DOI 10.1111/j.1365-2567.2005.02275.x; Li P, 2019, BOSNIAN J BASIC MED, V19, P146, DOI 10.17305/bjbms.2018.2865; Liu SY, 2016, CELL MOL IMMUNOL, V13, P700, DOI 10.1038/cmi.2015.52; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Mace EM, 2019, IMMUNOL REV, V287, P202, DOI 10.1111/imr.12725; Manoury B, 2011, EUR J IMMUNOL, V41, P2142, DOI 10.1002/eji.201141858; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020; Orange JS, 2012, J CLIN INVEST, V122, P798, DOI 10.1172/JCI62620; Orange JS, 2006, CLIN IMMUNOL, V118, P1, DOI 10.1016/j.clim.2005.10.011; Sarkar SN, 2004, PHARMACOL THERAPEUT, V103, P245, DOI 10.1016/j.pharmthera.2004.07.007; Sharma S, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1651-1; Sullivan RP, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00044; Sullivan RP, 2012, J IMMUNOL, V188, P3019, DOI 10.4049/jimmunol.1102294; Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x; Wang HW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00293; Wang LQ, 2017, EXP BIOL MED, V242, P1227, DOI 10.1177/1535370217699535; Wang P, 2012, J IMMUNOL, V189, P211, DOI 10.4049/jimmunol.1200609; Xing JJ, 2012, J VIROL, V86, P3528, DOI 10.1128/JVI.06713-11; Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood-2009-06-222794; Zawislak CL, 2013, P NATL ACAD SCI USA, V110, P6967, DOI 10.1073/pnas.1304410110; Zheng CF, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0709-5; Zingoni A, 2004, J IMMUNOL, V173, P3716, DOI 10.4049/jimmunol.173.6.3716	54	2	2	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2021	11								589866	10.3389/fimmu.2020.589866	http://dx.doi.org/10.3389/fimmu.2020.589866			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QD9CW	33679688	Green Published, gold			2022-12-18	WOS:000615808900001
J	Xu, BY; Tang, JH; Lyu, CC; Wandu, WS; Stumpo, DJ; Mattapallil, MJ; Horai, R; Gery, I; Blackshear, PJ; Caspi, RR				Xu, Biying; Tang, Jihong; Lyu, Cancan; Wandu, Wambui S.; Stumpo, Deborah J.; Mattapallil, Mary J.; Horai, Reiko; Gery, Igal; Blackshear, Perry J.; Caspi, Rachel R.			Regulated Tristetraprolin Overexpression Dampens the Development and Pathogenesis of Experimental Autoimmune Uveitis	FRONTIERS IN IMMUNOLOGY			English	Article						experimental autoimmune uveitis (EAU); autoimmunity; inflammatory cytokine; IL-17; IFN&#947; immunoregulation; tristetraprolin (TTP)		Non-infectious uveitis, a common cause of blindness in man, is often mediated by autoimmunity, a process in which cytokines play major roles. The biosynthesis and secretion of pro-inflammatory cytokines are regulated in part by tristetraprolin (TTP), an endogenous anti-inflammatory protein that acts by binding directly to specific sequence motifs in the 3'-untranslated regions of target mRNAs, promoting their turnover, and inhibiting synthesis of their encoded proteins. We recently developed a TTP-overexpressing mouse (TTP Delta ARE) by deleting an AU-rich element (ARE) instability motif from the TTP mRNA, resulting in increased accumulation of TTP mRNA and protein throughout the animal. Here, we show that homozygous TTP Delta ARE mice are resistant to the induction of experimental autoimmune uveitis (EAU) induced by interphotoreceptor retinoid-binding protein (IRBP), an established model for human autoimmune (noninfectious) uveitis. Lymphocytes from TTP Delta ARE mice produced lower levels of the pro-inflammatory cytokines IFN-gamma, IL-17, IL-6, and TNF alpha than wild type (WT) mice. TTP Delta ARE mice also produced lower titers of antibodies against the uveitogenic protein. In contrast, TTP Delta ARE mice produced higher levels of the anti-inflammatory cytokine IL-10, and had higher frequencies of regulatory T-cells, which, moreover, displayed a moderately higher per-cell regulatory ability. Heterozygous mice developed EAU and associated immunological responses at levels intermediate between homozygous TTP Delta ARE mice and WT controls. TTP Delta ARE mice were able, however, to develop EAU following adoptive transfer of activated WT T-cells specific to IRBP peptide 651-670, and naive T-cells from TTP Delta ARE mice could be activated by antibodies to CD3/CD28. Importantly, TTP Delta ARE antigen presenting cells were significantly less efficient compared to WT in priming naive T cells, suggesting that this feature plays a major role in the dampened immune responses of the TTP Delta ARE mice. Our observations demonstrate that elevated systemic levels of TTP can inhibit the pathogenic processes involved in EAU, and suggest the possible use of TTP-based treatments in humans with uveitis and other autoimmune conditions.	[Xu, Biying; Tang, Jihong; Lyu, Cancan; Wandu, Wambui S.; Mattapallil, Mary J.; Horai, Reiko; Gery, Igal; Caspi, Rachel R.] NEI, Lab Immunol, NIH, Bethesda, MD 20892 USA; [Stumpo, Deborah J.; Blackshear, Perry J.] NIEHS, Signal Transduct Lab, POB 12233, Res Triangle Pk, NC 27709 USA; [Blackshear, Perry J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Blackshear, Perry J.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Gery, I; Caspi, RR (corresponding author), NEI, Lab Immunol, NIH, Bethesda, MD 20892 USA.; Blackshear, PJ (corresponding author), NIEHS, Signal Transduct Lab, POB 12233, Res Triangle Pk, NC 27709 USA.; Blackshear, PJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.; Blackshear, PJ (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	geryi@nei.nih.gov; Black009@niehs.nih.gov; rcaspi@helix.nih.gov	Lyu, Cancan/ABC-4635-2021	Mattapallil, Mary/0000-0003-0615-7343; Lyu, Cancan/0000-0003-2078-3471	US Government through NEI; US Government through NIEHS; Intramural Research Program of the NIH, NIEHS; Intramural Research Program of the NIH, NEI	US Government through NEI; US Government through NIEHS; Intramural Research Program of the NIH, NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural Research Program of the NIH, NEI	US Government funding through NEI and NIEHS. Supported by the Intramural Research Programs of the NIH, NIEHS (DS and PB), and NEI (BX, JT, CL, WW, MM, RH IG, RC).	Agarwal Rajeev K, 2012, Methods Mol Biol, V900, P443, DOI 10.1007/978-1-60761-720-4_22; Bayeva M, 2012, CELL METAB, V16, P645, DOI 10.1016/j.cmet.2012.10.001; Becker MD, 2005, DRUGS, V65, P497, DOI 10.2165/00003495-200565040-00005; Brooks SA, 2013, BBA-GENE REGUL MECH, V1829, P666, DOI 10.1016/j.bbagrm.2013.02.003; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440; CASPI RR, 1988, J IMMUNOL, V140, P1490; Dick AD, 2004, PROG RETIN EYE RES, V23, P617, DOI 10.1016/j.preteyeres.2004.06.005; Durrani OM, 2004, BRIT J OPHTHALMOL, V88, P1159, DOI 10.1136/bjo.2003.037226; Grutz G, 2005, J LEUKOCYTE BIOL, V77, P3, DOI 10.1189/jlb.0904484; Ildefonso CJ, 2015, MOL THER, V23, P875, DOI 10.1038/mt.2015.30; Ildefonso CJ, 2015, HUM GENE THER, V26, P59, DOI 10.1089/hum.2014.089; Kato H, 2018, ARTHRITIS RHEUMATOL, V70, P427, DOI 10.1002/art.40380; Kruisbeek Ada M, 2004, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0312s60; Lacomba MS, 2001, OPHTHALMIC RES, V33, P251; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Lai ZW, 2018, LANCET, V391, P1186, DOI 10.1016/S0140-6736(18)30485-9; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Mattapallil MJ, 2015, INVEST OPHTH VIS SCI, V56, P5439, DOI 10.1167/iovs.15-17280; MOCHIZUKI M, 1985, INVEST OPHTH VIS SCI, V26, P1; MOUNTFORD AP, 1994, PARASITE IMMUNOL, V16, P521, DOI 10.1111/j.1365-3024.1994.tb00306.x; Nussenblatt RB, 1996, J AUTOIMMUN, V9, P575, DOI 10.1006/jaut.1996.0077; NUSSENBLATT RB, 1990, INT OPHTHALMOL, V14, P303, DOI 10.1007/BF00163549; Patial S, 2016, TRENDS PHARMACOL SCI, V37, P811, DOI 10.1016/j.tips.2016.07.002; Patial S, 2016, P NATL ACAD SCI USA, V113, P1865, DOI 10.1073/pnas.1519906113; Qiu LQ, 2015, J LEUKOCYTE BIOL, V97, P723, DOI 10.1189/jlb.3A0214-106R; Rizzo LV, 1996, J IMMUNOL, V156, P1654; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sato T, 2018, P NATL ACAD SCI USA, V115, pE6291, DOI 10.1073/pnas.1804701115; Silver P, 2015, J IMMUNOL, V194, P3011, DOI 10.4049/jimmunol.1402650; Steinkamp HM, 2018, J DENT RES, V97, P946, DOI 10.1177/0022034518756889; Sun B, 1997, J IMMUNOL, V159, P1004; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Touchard E, 2018, J CONTROL RELEASE, V285, P244, DOI 10.1016/j.jconrel.2018.07.013; Trickett A, 2003, J IMMUNOL METHODS, V275, P251, DOI 10.1016/S0022-1759(03)00010-3; Vistica BP, 2012, MOL VIS, V18, P1858; Wandu WS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128906	38	2	3	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 25	2021	11								583510	10.3389/fimmu.2020.583510	http://dx.doi.org/10.3389/fimmu.2020.583510			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QD9DY	33569048	Green Published, gold			2022-12-18	WOS:000615811700001
J	Dunne, OM; Gao, X; Nan, RD; Gor, J; Adamson, PJ; Gordon, DL; Moulin, M; Haertlein, M; Forsyth, VT; Perkins, SJ				Dunne, Orla M.; Gao, Xin; Nan, Ruodan; Gor, Jayesh; Adamson, Penelope J.; Gordon, David L.; Moulin, Martine; Haertlein, Michael; Forsyth, V. Trevor; Perkins, Stephen J.			A Dimerization Site at SCR-17/18 in Factor H Clarifies a New Mechanism for Complement Regulatory Control	FRONTIERS IN IMMUNOLOGY			English	Article						analytical ultracentrifugation; complement factor H; inflammation; molecular modelling; X-ray scattering		Complement Factor H (CFH), with 20 short complement regulator (SCR) domains, regulates the alternative pathway of complement in part through the interaction of its C-terminal SCR-19 and SCR-20 domains with host cell-bound C3b and anionic oligosaccharides. In solution, CFH forms small amounts of oligomers, with one of its self-association sites being in the SCR-16/20 domains. In order to correlate CFH function with dimer formation and the occurrence of rare disease-associated variants in SCR-16/20, we identified the dimerization site in SCR-16/20. For this, we expressed, in Pichia pastoris, the five domains in SCR-16/20 and six fragments of this with one-three domains (SCR-19/20, SCR-18/20, SCR-17/18, SCR-16/18, SCR-17 and SCR-18). Size-exclusion chromatography suggested that SCR dimer formation occurred in several fragments. Dimer formation was clarified using analytical ultracentrifugation, where quantitative c(s) size distribution analyses showed that SCR-19/20 was monomeric, SCR-18/20 was slightly dimeric, SCR-16/20, SCR-16/18 and SCR-18 showed more dimer formation, and SCR-17 and SCR-17/18 were primarily dimeric with dissociation constants of similar to 5 mu M. The combination of these results located the SCR-16/20 dimerization site at SCR-17 and SCR-18. X-ray solution scattering experiments and molecular modelling fits confirmed the dimer site to be at SCR-17/18, this dimer being a side-by-side association of the two domains. We propose that the self-association of CFH at SCR-17/18 enables higher concentrations of CFH to be achieved when SCR-19/20 are bound to host cell surfaces in order to protect these better during inflammation. Dimer formation at SCR-17/18 clarified the association of genetic variants throughout SCR-16/20 with renal disease.	[Dunne, Orla M.; Gao, Xin; Nan, Ruodan; Gor, Jayesh; Perkins, Stephen J.] UCL, Div Biosci, Dept Struct & Mol Biol, London, England; [Dunne, Orla M.; Moulin, Martine; Haertlein, Michael; Forsyth, V. Trevor] Inst Laue Langevin, Life Sci Grp, Grenoble, France; [Gao, Xin] UCL, Div Med, London, England; [Adamson, Penelope J.; Gordon, David L.] Flinders Med Ctr, Dept Microbiol & Infect Dis, Bedford Pk, SA, Australia; [Adamson, Penelope J.; Gordon, David L.] Flinders Univ S Australia, Bedford Pk, SA, Australia; [Forsyth, V. Trevor] Keele Univ, Fac Nat Sci, Keele, Staffs, England	University of London; University College London; Institut Laue-Langevin (ILL); University of London; University College London; Flinders Medical Centre; Flinders University South Australia; Keele University	Perkins, SJ (corresponding author), UCL, Div Biosci, Dept Struct & Mol Biol, London, England.	s.perkins@ucl.ac.uk	Forsyth, V. Trevor/A-9129-2010	Forsyth, V. Trevor/0000-0003-0380-3477; Gordon, David/0000-0003-3276-9685	University College London; Institut-Laue-Langevin; CCP-SAS project; EPSRC [EP/K039121/1]; NSF [CHE-1265821]	University College London(General Electric); Institut-Laue-Langevin; CCP-SAS project; EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); NSF(National Science Foundation (NSF))	OD thanks University College London and the Institut-Laue-Langevin for a PhD studentship award. Support for this work was also provided in part by the CCP-SAS project, a joint EPSRC (EP/K039121/1) and NSF (CHE-1265821) grant.	Antolinos AD, 2015, ACTA CRYSTALLOGR D, V71, P76, DOI 10.1107/S1399004714019609; Ballermann BJ, 1998, KIDNEY INT, V53, P1810, DOI 10.1046/j.1523-1755.1998.00943.x; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Blaum BS, 2016, GLYCOBIOLOGY, V26, P532, DOI 10.1093/glycob/cwv170; Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]; Bretthauer RK, 1999, BIOTECHNOL APPL BIOC, V30, P193; Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4; Curtis JE, 2012, COMPUT PHYS COMMUN, V183, P382, DOI 10.1016/j.cpc.2011.09.010; de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005; de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; Dunne O., 2015, THESIS U COLL LONDON; Fenaille F, 2007, GLYCOBIOLOGY, V17, P932, DOI 10.1093/glycob/cwm060; Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038; Glatter O., 1982, SMALL ANGLE XRAY SCA; Incardona MF, 2009, J SYNCHROTRON RADIAT, V16, P872, DOI 10.1107/S0909049509036681; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Kadkhodayi-Kholghi N, 2020, J BIOL CHEM, V295, P16342, DOI 10.1074/jbc.RA120.015132; Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108; Kavanagh D, 2006, BRIT MED BULL, V77-78, P5, DOI 10.1093/bmb/ldl004; Kolodziejczyk R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188127; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Law SKA., 1995, COMPLEMENT INFLAMMAT, V2nd; Morgan HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032187; Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018; Nan RD, 2008, J MOL BIOL, V375, P891, DOI 10.1016/j.jmb.2007.11.015; Okemefuna AI, 2008, J MOL BIOL, V375, P80, DOI 10.1016/j.jmb.2007.09.026; Okemefuna AI, 2009, J MOL BIOL, V391, P98, DOI 10.1016/j.jmb.2009.06.010; Ortega A, 2011, BIOPHYS J, V101, P892, DOI 10.1016/j.bpj.2011.06.046; Osborne AJ, 2018, J BIOL CHEM, V293, P17166, DOI 10.1074/jbc.RA118.004767; Osborne AJ, 2018, J IMMUNOL, V200, P2464, DOI 10.4049/jimmunol.1701695; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Perkins SJ., 1988, NEW COMPREHENSIVE BI, V11B, P143; Perkins SJ, 2020, ADV CHRONIC KIDNEY D, V27, P120, DOI 10.1053/j.ackd.2020.03.002; Perkins SJ, 2016, J APPL CRYSTALLOGR, V49, P1861, DOI 10.1107/S160057671601517X; Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003; Perkins SJ, 2011, METHODS, V54, P181, DOI 10.1016/j.ymeth.2011.01.004; Perkins SJ, 2009, J R SOC INTERFACE, V6, pS679, DOI 10.1098/rsif.2009.0164.focus; Pernot P, 2013, J SYNCHROTRON RADIAT, V20, P660, DOI 10.1107/S0909049513010431; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117; Round A, 2015, ACTA CRYSTALLOGR D, V71, P67, DOI 10.1107/S1399004714026959; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wright DW, 2015, J APPL CRYSTALLOGR, V48, P953, DOI 10.1107/S1600576715007062	53	2	2	10	36	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2021	11								601895	10.3389/fimmu.2020.601895	http://dx.doi.org/10.3389/fimmu.2020.601895			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QB8QF	33552059	gold, Green Accepted, Green Published			2022-12-18	WOS:000614401100001
J	Song, LQ; Xiao, YC; Li, XP; Huang, YM; Meng, GX; Ren, ZH				Song, Liqiong; Xiao, Yuchun; Li, Xianping; Huang, Yuanming; Meng, Guangxun; Ren, Zhihong			Activation of the Nlrp3 Inflammasome Contributes to Shiga Toxin-Induced Hemolytic Uremic Syndrome in a Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						Stx2; hemolytic uremic syndrome; IL-1&#946; Nlrp3; Nlrp3 inhibitor		Objective To explore the role of the Nlrp3 inflammasome activation in the development of hemolytic uremic syndrome (HUS) induced by Stx2 and evaluate the efficacy of small molecule Nlrp3 inhibitors in preventing the HUS. Methods Peritoneal macrophages (PMs) isolated from wild-type (WT) C57BL/6J mice and gene knockout mice (Nlrc4(-/-), Aim2(-/-), and Nlrp3(-/-)) were treated with Stx2 in vitro and their IL-1 beta releases were measured. WT mice and Nlrp3(-/-) mice were also treated with Stx2 in vivo by injection, and the biochemical indices (serum IL-1 beta, creatinine [CRE] and blood urea nitrogen [BUN]), renal injury, and animal survival were compared. To evaluate the effect of the Nlrp3 inhibitors in preventing HUS, WT mice were pretreated with different Nlrp3 inhibitors (MCC950, CY-09, Oridonin) before Stx2 treatment, and their biochemical indices and survival were compared with the WT mice without inhibitor pretreatment. Results When PMs were stimulated by Stx2 in vitro, IL-1 beta release in Nlrp3(-/-) PMs was significantly lower compared to the other PMs. The Nlrp3(-/-) mice treated by Stx2 in vivo, showed lower levels of the biochemical indices, alleviated renal injuries, and increased survival rate. When the WT mice were pretreated with the Nlrp3 inhibitors, both the biochemical indices and survival were significantly improved compared to those without inhibitor pretreatment, with Oridonin being most potent. Conclusion Nlrp3 inflammasome activation plays a vital role in the HUS development when mice are challenged by Stx2, and Oridonin is effective in preventing HUS.	[Song, Liqiong; Xiao, Yuchun; Li, Xianping; Huang, Yuanming; Ren, Zhihong] Chinese Acad Med Sci, State Key Lab Infect Dis Prevent & Control, Natl Inst Communicable Dis Control & Prevent,Res, Chinese Ctr Dis Control & Prevent,Res Unit Discov, Beijing, Peoples R China; [Meng, Guangxun] Chinese Acad Sci, Ctr Microbes Dev & Hlth, Key Lab Mol Virol & Immunol, Inst Pasteur Shanghai,Univ Chinese Acad Sci, Shanghai, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Center for Disease Control & Prevention; National Institute for Communicable Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Le Reseau International des Instituts Pasteur (RIIP)	Ren, ZH (corresponding author), Chinese Acad Med Sci, State Key Lab Infect Dis Prevent & Control, Natl Inst Communicable Dis Control & Prevent,Res, Chinese Ctr Dis Control & Prevent,Res Unit Discov, Beijing, Peoples R China.; Meng, GX (corresponding author), Chinese Acad Sci, Ctr Microbes Dev & Hlth, Key Lab Mol Virol & Immunol, Inst Pasteur Shanghai,Univ Chinese Acad Sci, Shanghai, Peoples R China.	gxmeng@ips.ac.cn; renzhihong@icdc.cn			National Natural Science Foundation of China [81371761, 31170868]; Ministry of Science and Technology of China [2018ZX10301403-003-003, 2018ZX10712-001-006, 2018ZX10305409-003-001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by grants from the National Natural Science Foundation of China (No. 81371761 to ZR and 31170868 to GM) and the Ministry of Science and Technology of China (Grant No. 2018ZX10301403-003-003 to SL and 2018ZX10712-001-006 and 2018ZX10305409-003-001 to ZR).	BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; Fernandez D, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00009; Frank C, 2011, NEW ENGL J MED, V365, P1771, DOI 10.1056/NEJMoa1106483; Fuller CA, 2011, INFECT IMMUN, V79, P1329, DOI 10.1128/IAI.01182-10; Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4; Garg AX, 2003, JAMA-J AM MED ASSOC, V290, P1360, DOI 10.1001/jama.290.10.1360; Haq M, 1998, J AM SOC NEPHROL, V9, P614; He HB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04947-6; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Hoshino J, 2015, AM J NEPHROL, V41, P337, DOI 10.1159/000431333; Ikeda M, 2004, PEDIATR NEPHROL, V19, P485, DOI 10.1007/s00467-003-1395-7; Jiang H, 2017, J EXP MED, V214, P3219, DOI 10.1084/jem.20171419; KAPLAN BS, 1990, PEDIATR NEPHROL, V4, P276, DOI 10.1007/BF00857676; Karpman D, 1997, J INFECT DIS, V175, P611, DOI 10.1093/infdis/175.3.611; Lee MS, 2016, INFECT IMMUN, V84, P172, DOI 10.1128/IAI.01095-15; Litalien C, 1999, PEDIATR NEPHROL, V13, P840, DOI 10.1007/s004670050712; Liu LY, 2015, INFECT IMMUN, V83, P2596, DOI 10.1128/IAI.03071-14; LOUISE CB, 1995, J INFECT DIS, V172, P1397, DOI 10.1093/infdis/172.5.1397; LOUISE CB, 1991, INFECT IMMUN, V59, P4173, DOI 10.1128/IAI.59.11.4173-4179.1991; Mao KR, 2013, CELL RES, V23, P201, DOI 10.1038/cr.2013.6; Marcato P, 2001, J INFECT DIS, V183, P435, DOI 10.1086/318080; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Meng GX, 2009, IMMUNITY, V30, P860, DOI 10.1016/j.immuni.2009.04.012; OBRIEN AD, 1992, CURR TOP MICROBIOL, V180, P65; Pellino CA, 2016, J BACTERIOL, V198, P1621, DOI 10.1128/JB.00918-15; Platnich JM, 2018, CELL REP, V25, P1525, DOI 10.1016/j.celrep.2018.09.071; Rutjes NWP, 2002, KIDNEY INT, V62, P832, DOI 10.1046/j.1523-1755.2002.00502.x; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Song LQ, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00510; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Terajima J, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.EHEC-0011-2013; Timoshanko JR, 2004, J AM SOC NEPHROL, V15, P910, DOI 10.1097/01.ASN.0000115704.86897.F4; Vanaja SK, 2014, P NATL ACAD SCI USA, V111, P7765, DOI 10.1073/pnas.1400075111; VANDEKAR NCAJ, 1992, BLOOD, V80, P2755; vanSetten PA, 1997, KIDNEY INT, V51, P1245, DOI 10.1038/ki.1997.170; Wang Li-li, 2008, Zhonghua Liu Xing Bing Xue Za Zhi, V29, P55; Whyte DA, 2008, PEDIATR REV, V29, P335, DOI 10.1542/pir.29-10-335; Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8; Yukioka H, 1997, Eur J Emerg Med, V4, P165, DOI 10.1097/00063110-199709000-00009	41	2	3	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2021	11								619096	10.3389/fimmu.2020.619096	http://dx.doi.org/10.3389/fimmu.2020.619096			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QB8MS	33552083	gold, Green Published			2022-12-18	WOS:000614392000001
J	Chen, W; Zhang, Y; Zhao, CF; Shao, SX; Zhang, YA; Li, XH; Bai, X; Guo, QY; Liu, QN; Tang, JM; Zhang, L				Chen, Wei; Zhang, Yi; Zhao, Chunfang; Shao, Suxia; Zhang, Yanan; Li, Xuehui; Bai, Xue; Guo, Qianyu; Liu, Qianwen; Tang, Junmin; Zhang, Lei			Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia	FRONTIERS IN IMMUNOLOGY			English	Article						Nocardia rubra cell wall skeleton; high-risk human papillomavirus; cervical intraepithelial neoplasia; CD4(+) T cell; CD8(+) T cell; programmed cell death-1; programmed cell death-ligand 1		The Nocardia rubra cell wall skeleton (Nr-CWS) for external use is an immune enhancer, which has been widely used in human cervix diseases such as cervical erosion, but the mechanism of Nr-CWS enhancing immunity is still unclear. The purpose of this study was to explore the effect and mechanism of Nr-CWS on the local immune status of cervical tissue in patients with high-risk human papillomavirus (HR-HPV) infection and cervical precancerous lesion, cervical intraepithelial neoplasia (CIN). The recruited patients with HR-HPV infection and CIN were treated with Nr-CWS. The specimens were taken from these patients before and after local application of Nr-CWS respectively. The normal control specimens were tested simultaneously. Serial section analysis of immunohistochemistry and co-expression analysis were performed to characterize populations of T cells and the expressions of programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1). The levels of cytokines in local cervical tissue were also detected. Nr-CWS significantly increased T cells including CD4(+), CD8(+) T cells, and reduced the expression of PD-L1 in the patients' local cervical tissues. Co-expression analyses showed that the proportions of PD-1(+)CD4(+) cells in CD4(+) T cells and PD-1(+)CD8(+) cells in CD8(+) T cells decreased after Nr-CWS application. Furthermore, the increase in the number of immune cells was accompanied by increased pro-inflammatory cytokines interleukin-12 (IL-12), interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), and decreased suppressive cytokine IL-10. The results indicate that Nr-CWS, as an immunotherapeutic agent for HR-HPV infection and CIN, plays an immune promoting role related to the upregulation of T cell subsets and the inhibition of PD-1/PD-L1 pathway.	[Chen, Wei; Zhao, Chunfang; Shao, Suxia; Zhang, Yanan; Guo, Qianyu; Liu, Qianwen; Zhang, Lei] Hebei Med Univ, Dept Histol & Embryol, Shijiazhuang, Hebei, Peoples R China; [Zhang, Yi] Weihai Greatest Pharmaceut Res Inst Co Ltd, Dept Med, Weihai, Peoples R China; [Li, Xuehui] Hebei Med Univ, Hosp 1, Dept Gynaecol, Shijiazhuang, Hebei, Peoples R China; [Bai, Xue] Hebei Med Univ, Hosp 4, Dept Gynaecol, Shijiazhuang, Hebei, Peoples R China; [Tang, Junmin] Peking Univ, Hlth Sci Ctr, Dept Histol & Embryol, Beijing, Peoples R China	Hebei Medical University; Hebei Medical University; Hebei Medical University; Peking University	Zhang, L (corresponding author), Hebei Med Univ, Dept Histol & Embryol, Shijiazhuang, Hebei, Peoples R China.; Tang, JM (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Histol & Embryol, Beijing, Peoples R China.	jmtang242@163.com; zhang13903210199@163.com	Chen, Wei/GRX-2231-2022		Technology Development Agreement of Hebei Medical University; Weihai Greatest Pharmaceutical Research Institute Co., Ltd., RP China; Nature Science Foundation of Hebei Province [H2017206078]	Technology Development Agreement of Hebei Medical University; Weihai Greatest Pharmaceutical Research Institute Co., Ltd., RP China; Nature Science Foundation of Hebei Province(Natural Science Foundation of Hebei Province)	This work was supported by Technology Development Agreement of Hebei Medical University and Weihai Greatest Pharmaceutical Research Institute Co., Ltd., RP China, and Nature Science Foundation of Hebei Province [Grant No. H2017206078]. The funder bodies were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; AZUMA I, 1976, GANN, V67, P733; Chen W, 2015, HISTOL HISTOPATHOL, V30, P1487, DOI 10.14670/HH-11-644; Correnti M, 2011, GYNECOL ONCOL, V121, P527, DOI 10.1016/j.ygyno.2011.02.003; Crawford A, 2014, IMMUNITY, V40, P289, DOI 10.1016/j.immuni.2014.01.005; Desravines N, 2020, GYNECOL ONCOL REP, V33, DOI 10.1016/j.gore.2020.100608; Folk A, 2010, VET IMMUNOL IMMUNOP, V134, P33, DOI 10.1016/j.vetimm.2009.10.006; He Y, 2017, Zhonghua Fu Chan Ke Za Zhi, V52, P740, DOI 10.3760/cma.j.issn.0529-567X.2017.11.005; Hochmann J, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760190405; HOZAWA S, 1989, CANCER IMMUNOL IMMUN, V30, P190, DOI 10.1007/BF01669429; Jacobs N, 2003, AM J REPROD IMMUNOL, V49, P6, DOI 10.1034/j.1600-0897.2003.01109.x; Lucena AAS, 2016, IMMUNOL LETT, V169, P98, DOI 10.1016/j.imlet.2015.10.016; Luo M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213062; Maskey N, 2019, CANCER MANAG RES, V11, P7647, DOI 10.2147/CMAR.S217264; Massad LS, 2013, OBSTET GYNECOL, V121, P829, DOI 10.1097/AOG.0b013e3182883a34; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Meng YM, 2019, J CELL PHYSIOL, V234, P15342, DOI 10.1002/jcp.28182; Mezache L, 2015, MODERN PATHOL, V28, P1594, DOI 10.1038/modpathol.2015.108; Munk AC, 2012, GYNECOL ONCOL, V127, P489, DOI 10.1016/j.ygyno.2012.09.010; Ovestad IT, 2010, MODERN PATHOL, V23, P1231, DOI 10.1038/modpathol.2010.109; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Piersma SJ, 2007, CANCER RES, V67, P354, DOI 10.1158/0008-5472.CAN-06-3388; Plummer M, 2007, J INFECT DIS, V195, P1582, DOI 10.1086/516784; Tao YC, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106023; Venuti A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-140; Vijayashree R, 2015, J CLIN DIAGN RES, V9, pEC01, DOI 10.7860/JCDR/2015/12432.5628; Wang GC, 2017, INT J BIOL MACROMOL, V101, P398, DOI 10.1016/j.ijbiomac.2017.03.060; Wang Y, 2018, J INT MED RES, V46, P2398, DOI 10.1177/0300060518764210; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Woo YL, 2008, BJOG-INT J OBSTET GY, V115, P1616, DOI 10.1111/j.1471-0528.2008.01936.x; Yang W, 2017, J OBSTET GYNAECOL RE, V43, P1602, DOI 10.1111/jog.13411; Yang W, 2013, IMMUNOLOGY, V139, P513, DOI 10.1111/imm.12101; Zhang Y, 2017, ONCOL LETT, V14, P7225, DOI 10.3892/ol.2017.7105	33	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 20	2021	11								612547	10.3389/fimmu.2020.612547	http://dx.doi.org/10.3389/fimmu.2020.612547			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QB3XR	33552075	Green Published, gold			2022-12-18	WOS:000614075700001
J	Du, SH; Xiang, YJ; Liu, L; Nie, M; Hou, Y; Wang, L; Li, BB; Xu, M; Teng, QL; Peng, J; Hou, M; Shi, Y				Du, Sheng-hong; Xiang, Yu-jiao; Liu, Lu; Nie, Mu; Hou, Yu; Wang, Ling; Li, Ban-ban; Xu, Miao; Teng, Qing-liang; Peng, Jun; Hou, Ming; Shi, Yan			Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia	FRONTIERS IN IMMUNOLOGY			English	Article						immune thrombocytopenia; immunoproteasome; LMP2; LMP7; Fc&#947; Rs; T cell; treatment	PROTEASOME; CELLS	The immunoproteasome, a special isoform of the 20S proteasome, is expressed when the cells receive an inflammatory signal. Immunoproteasome inhibition proved efficacy in the treatment of autoimmune diseases. However, the role of the immunoproteasome in the pathogenesis of immune thrombocytopenia (ITP) remains unknown. We found that the expression of the immunoproteasome catalytic subunit, large multifunctional protease 2 (LMP2), was significantly upregulated in peripheral blood mononuclear cells of active ITP patients compared to those of healthy controls. No significant differences in LMP7 expression were observed between patients and controls. ML604440, an specific LMP2 inhibitor, had no significant impact on the platelet count of ITP mice, while ONX-0914 (an inhibitor of both LMP2 and LMP7) increased the number of platelets. In vitro assays revealed that ONX-0914 decreased the expression of Fc gamma RI in ITP mice and decreased that of Fc gamma RIII in ITP patients, inhibited the activation of CD4(+) T cells, and affected the differentiation of Th1 cells in patients with ITP. These results suggest that the inhibition of immunoproteasome is a potential therapeutic approach for ITP patients.	[Du, Sheng-hong; Xiang, Yu-jiao; Liu, Lu; Nie, Mu; Hou, Yu; Li, Ban-ban; Xu, Miao; Peng, Jun; Hou, Ming; Shi, Yan] Shandong Univ, Qilu Hosp, Dept Hematol, Cheeloo Coll Med, Jinan, Peoples R China; [Du, Sheng-hong; Wang, Ling; Li, Ban-ban; Teng, Qing-liang] Taian Cent Hosp, Dept Hematol, Tai An, Shandong, Peoples R China; [Nie, Mu] Karolinska Univ Hosp, Karolinska Inst, Div Immunol & Allergy, Dept Med Solna, Stockholm, Sweden; [Peng, Jun; Hou, Ming] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Shandong Prov Key Lab Immunohematol, Jinan, Peoples R China; [Hou, Ming] Shandong Prov Clin Res Ctr Hematol Dis, Jinan, Peoples R China; [Hou, Ming] Shandong Univ, Leading Res Grp Sci Innovat, Dept Sci & Technol Shandong Prov, Cheeloo Coll Med,Qilu Hosp, Jinan, Peoples R China	Shandong University; Karolinska Institutet; Karolinska University Hospital; Shandong University; Shandong University	Shi, Y (corresponding author), Shandong Univ, Qilu Hosp, Dept Hematol, Cheeloo Coll Med, Jinan, Peoples R China.	shiyansjj@163.com			National Natural Science Foundation of China [81170475, 81470285, 81770114, 81770133, 81470284]; Major Research Plan of National Natural Science Foundation of China [91442204]; Natural Science Foundation of Shandong Province [ZR2017PH022, ZR2017PH041]; Major Research Plan of Natural Science Foundation of Shandong Province [ZR2016QZ008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Research Plan of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Major Research Plan of Natural Science Foundation of Shandong Province	This work was supported by grants from the National Natural Science Foundation of China (81170475, 81470285, 81770114, 81770133, 81470284), Major Research Plan of National Natural Science Foundation of China (91442204), Natural Science Foundation of Shandong Province (ZR2017PH022, ZR2017PH041) and Major Research Plan of Natural Science Foundation of Shandong Province (ZR2016QZ008).	Bajnok A, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8045161; Basler M, 2015, CLIN EXP RHEUMATOL, V33, pS74; Basler M, 2018, EMBO REP, V19, DOI 10.15252/embr.201846512; Basler M, 2018, BRIT J PHARMACOL, V175, P38, DOI 10.1111/bph.14069; Basler M, 2014, EMBO MOL MED, V6, P226, DOI 10.1002/emmm.201303543; Basler M, 2012, J IMMUNOL, V189, P1868, DOI 10.4049/jimmunol.1103592; Basler M, 2010, J IMMUNOL, V185, P634, DOI 10.4049/jimmunol.0903182; Borissenko L, 2007, CHEM REV, V107, P687, DOI 10.1021/cr0502504; Chen YY, 2019, THROMB RES, V180, P1, DOI 10.1016/j.thromres.2019.05.010; Chen ZP, 2015, AUTOIMMUNITY, V48, P305, DOI 10.3109/08916934.2015.1016218; Clausen J, 2003, IMMUNOBIOLOGY, V207, P85, DOI 10.1078/0171-2985-00219; D'Souza WN, 2003, J IMMUNOL, V171, P5727, DOI 10.4049/jimmunol.171.11.5727; de Jong A, 2012, METHODS MOL BIOL, V803, P183, DOI 10.1007/978-1-61779-364-6_13; Dhodapkar KM, 2007, J EXP MED, V204, P1359, DOI 10.1084/jem.20062545; Ettari R, 2018, PHARMACOL THERAPEUT, V182, P176, DOI 10.1016/j.pharmthera.2017.09.001; Ferrington DA, 2012, PROG MOL BIOL TRANSL, V109, P75, DOI 10.1016/B978-0-12-397863-9.00003-1; Horvath Curt M, 2004, Sci STKE, V2004, ptr10, DOI 10.1126/stke.2602004tr10; Hu Y, 2012, HUM IMMUNOL, V73, P629, DOI 10.1016/j.humimm.2012.04.015; Kalim KW, 2012, J IMMUNOL, V189, P4182, DOI 10.4049/jimmunol.1201183; Karreci ES, 2016, P NATL ACAD SCI USA, V113, pE8425, DOI 10.1073/pnas.1618548114; Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302; Koerner J, 2017, ONCOTARGET, V8, P50873, DOI 10.18632/oncotarget.15141; Li J, 2018, KIDNEY INT, V93, P670, DOI 10.1016/j.kint.2017.09.023; Liu HJ, 2017, FASEB J, V31, P1756, DOI 10.1096/fj.201601147R; Liu XG, 2016, BLOOD, V128, P852, DOI 10.1182/blood-2016-01-690727; Liu XG, 2011, BLOOD, V117, P2061, DOI 10.1182/blood-2010-07-295477; Mackay LK, 2015, J IMMUNOL, V194, P2059, DOI 10.4049/jimmunol.1402256; Mouzaki A, 2002, BLOOD, V100, P1774, DOI 10.1182/blood.V100.5.1774.h81702001774_1774_1779; Muchamuel T, 2009, NAT MED, V15, P781, DOI 10.1038/nm.1978; Nagayama Y, 2012, CLIN EXP IMMUNOL, V168, P268, DOI 10.1111/j.1365-2249.2012.04578.x; Nie M, 2019, THROMB HAEMOSTASIS, V119, P758, DOI 10.1055/s-0039-1679909; Panitsas FP, 2004, BLOOD, V103, P2645, DOI 10.1182/blood-2003-07-2268; Podolanczuk A, 2009, BLOOD, V113, P3154, DOI 10.1182/blood-2008-07-166439; Radulovic K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065413; Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503; Schmidt C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02386; Schmidt N, 2010, GUT, V59, P896, DOI 10.1136/gut.2009.203554; Semple JW, 2012, CURR OPIN HEMATOL, V19, P357, DOI 10.1097/MOH.0b013e3283567541; Sijts AJAM, 2000, J EXP MED, V191, P503, DOI 10.1084/jem.191.3.503; Talaat RM, 2014, CLIN EXP IMMUNOL, V176, P291, DOI 10.1111/cei.12279; Vachharajani N, 2017, ONCOTARGET, V8, P50447, DOI 10.18632/oncotarget.14579; Wang TT, 2005, HAEMATOLOGICA, V90, P914; Webster ML, 2006, BLOOD, V108, P943, DOI 10.1182/blood-2005-06-009761; Wehenkel M, 2012, BRIT J CANCER, V107, P53, DOI 10.1038/bjc.2012.243; Yan R, 2015, THROMB HAEMOSTASIS, V113, P107, DOI 10.1160/TH14-03-0217; YONG K, 1992, BLOOD, V80, P2897; Zahran AM, 2014, CLIN APPL THROMB-HEM, V20, P61, DOI 10.1177/1076029612454937; ZEIGLER ZR, 1993, BLOOD, V81, P1251; Zhang JB, 2009, HAEMATOL-HEMATOL J, V94, P1326, DOI 10.3324/haematol.2009.007823; Zhao YJ, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154853; Zhong H, 2012, BLOOD, V120, P3326, DOI 10.1182/blood-2012-06-434605; Zufferey A, 2017, J CLIN MED, V6, DOI 10.3390/jcm6020016	52	2	2	5	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 20	2021	11								603278	10.3389/fimmu.2020.603278	http://dx.doi.org/10.3389/fimmu.2020.603278			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QB4HH	33552061	Green Published, gold			2022-12-18	WOS:000614101000001
J	Al Sukaiti, N; Ahmed, K; Alshekaili, J; Al Kindi, M; Cook, MC; Al Farsi, T				Al Sukaiti, Nashat; Ahmed, Khwater; Alshekaili, Jalila; Al Kindi, Mahmood; Cook, Matthew C.; Al Farsi, Tariq			A Decade Experience on Severe Combined Immunodeficiency Phenotype in Oman, Bridging to Newborn Screening	FRONTIERS IN IMMUNOLOGY			English	Article						severe combined immunodeficiency; children; lymphopenia; newborn screening; hematopoietic stem cell transplantation; Omani	DISEASES; DISORDERS; TREC	Introduction Severe combined immunodeficiency (SCID) results from various monogenic defects that impair immune function and brings on early severe and life-threatening infections. The main stay of treatment for SCID is hematopoietic stem cell transplant (HSCT) with near normal survival at 5 years for an early transplant done at or before the age of 3.5 months of life and the patient is maintained free of infections. Although overall rare, it constitutes a major burden on affected children, their families and on the health system especially in communities with a high rate of consanguinity where incidence and prevalence of recessive inborn errors of immunity (IEI) are expected to be high. Method Here, we report the clinical, immunological, and molecular findings in 36 children diagnosed with SCID from a single tertiary center in Oman for the last decade. Results We observed a median annual incidence rate of 4.5 per 100,000 Omani live births, and 91.7% of affected children were born to consanguineous parents. Twenty-three children (63.9%) fulfilled the criteria for typical SCID. The median age at onset, diagnosis and diagnostic delay were 54, 135, and 68 days, respectively. The most common clinical manifestations were pneumonia, septicemia, and chronic diarrhea. Eleven children (30.6%) have received hematopoietic stem cell transplant (HSCT) with a survival rate of 73%. The most frequent genetic cause of SCID in this cohort (n = 36) was (RAG-1), encoding for recombination activating gene (n = 5, 13.9%). Similarly, Major histocompatibility complex type II deficiency accounted for (n = 5, 13.9%) of our cohort. Conclusion Our report broadens the knowledge of clinical and molecular manifestations in children with SCID in the region and highlights the need to initiate newborn based screening program (NBS) program.	[Al Sukaiti, Nashat; Ahmed, Khwater; Al Farsi, Tariq] Royal Hosp, Dept Pediat Allergy & Clin Immunol, Muscat, Oman; [Alshekaili, Jalila; Al Kindi, Mahmood] Sultan Qaboos Univ Hosp, Dept Microbiol & Immunol, Muscat, Oman; [Cook, Matthew C.] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, NSW, Australia; [Cook, Matthew C.] Canberra Hosp, Dept Immunol, Translat Res Unit, Canberra, NSW, Australia; [Cook, Matthew C.] Australian Natl Univ, John Curtin Sch Med Res, NHMRC Ctr Res Excellence, Ctr Personalized Immunol, Canberra, NSW, Australia	The Royal Hospital, Sultanate of Oman; Sultan Qaboos University; Australian National University; John Curtin School of Medical Research; Australian National University; Canberra Hospital; Australian National University; John Curtin School of Medical Research	Al Farsi, T (corresponding author), Royal Hosp, Dept Pediat Allergy & Clin Immunol, Muscat, Oman.	alfarsitq@gmail.com	Cook, matthew/F-4151-2019; Alshekaili, Jalila/L-5129-2019	Cook, matthew/0000-0002-3331-9363; Alshekaili, Jalila/0000-0002-2576-4766				Al Awaidy ST, 2018, ERJ OPEN RES, V4, DOI 10.1183/23120541.00121-2018; Al Yaquobi F, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02027-2017; Al-Herz W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01754; Al-Mousa H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00782; Al-Muhsen S, 2012, ANN NY ACAD SCI, V1250, P56, DOI 10.1111/j.1749-6632.2011.06379.x; Al-Tamemi S, 2016, J CLIN IMMUNOL, V36, P785, DOI 10.1007/s10875-016-0337-7; Aluri J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00023; Barbaro M, 2017, J CLIN IMMUNOL, V37, P51, DOI 10.1007/s10875-016-0347-5; Chien Y-H, 2017, INT J NEONAT SCREEN, V3, P16, DOI [DOI 10.3390/IJNS3030016, 10.3390/ijns3030016]; Chien YH, 2015, J FORMOS MED ASSOC, V114, P12, DOI 10.1016/j.jfma.2012.10.020; Cirillo E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01908; de Pagter APJ, 2015, EUR J PEDIATR, V174, P1183, DOI 10.1007/s00431-015-2518-4; Fazlollahi MR, 2017, J INVEST ALLERG CLIN, V27, P299, DOI 10.18176/jiaci.0147; Fischer A, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.61; Galal N, 2016, J CLIN IMMUNOL, V36, P649, DOI 10.1007/s10875-016-0314-1; Heimall J, 2017, BLOOD, V130, P2718, DOI 10.1182/blood-2017-05-781849; Information. N.C.f.S, 2020, DEM IND; Islam MM, 2017, ANN HUM BIOL, V44, P273, DOI 10.1080/03014460.2016.1224385; Kumrah R, 2020, GENES DIS, V7, P52, DOI 10.1016/j.gendis.2019.07.004; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Lipstein EA, 2010, PEDIATRICS, V125, pE1226, DOI 10.1542/peds.2009-1567; Marciano BE, 2014, J ALLERGY CLIN IMMUN, V133, P1134, DOI 10.1016/j.jaci.2014.02.028; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Picard C., 2015, CURRENT PEDIAT REPOR, V3, P22, DOI [10.1007/s40124-014-0070-8, DOI 10.1007/s40124-014-0070-8, DOI 10.1007/S40124-014-0070-8]; Rajab A, 2014, J COMMUN GENET, V5, P283, DOI 10.1007/s12687-014-0182-4; Rechavi E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01448; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; van der Spek J, 2015, J CLIN IMMUNOL, V35, P416, DOI 10.1007/s10875-015-0152-6; Yao CM, 2013, J CLIN IMMUNOL, V33, P526, DOI 10.1007/s10875-012-9854-1	30	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 15	2021	11								623199	10.3389/fimmu.2020.623199	http://dx.doi.org/10.3389/fimmu.2020.623199			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PZ3PJ	33519828	gold, Green Published			2022-12-18	WOS:000612650600001
J	Machata, S; Sreekantapuram, S; Hunniger, K; Kurzai, O; Dunker, C; Schubert, K; Kruger, W; Schulze-Richter, B; Speth, C; Rambach, G; Jacobsen, ID				Machata, Silke; Sreekantapuram, Sravya; Huenniger, Kerstin; Kurzai, Oliver; Dunker, Christine; Schubert, Katja; Krueger, Wibke; Schulze-Richter, Bianca; Speth, Cornelia; Rambach, Guenter; Jacobsen, Ilse D.			Significant Differences in Host-Pathogen Interactions Between Murine and Human Whole Blood	FRONTIERS IN IMMUNOLOGY			English	Article						whole blood ex vivo model; host-pathogen interaction; Candida albicans; neutrophils; mice	CANDIDA-ALBICANS; STAPHYLOCOCCUS-AUREUS; IMMUNE-RESPONSE; NEUTROPHILS; EPIDEMIOLOGY; INFECTIONS; MODEL; KETAMINE; RECEPTOR; OUTCOMES	Murine infection models are widely used to study systemic candidiasis caused by C. albicans. Whole-blood models can help to elucidate host-pathogens interactions and have been used for several Candida species in human blood. We adapted the human whole-blood model to murine blood. Unlike human blood, murine blood was unable to reduce fungal burden and more substantial filamentation of C. albicans was observed. This coincided with less fungal association with leukocytes, especially neutrophils. The lower neutrophil number in murine blood only partially explains insufficient infection and filamentation control, as spiking with murine neutrophils had only limited effects on fungal killing. Furthermore, increased fungal survival is not mediated by enhanced filamentation, as a filament-deficient mutant was likewise not eliminated. We also observed host-dependent differences for interaction of platelets with C. albicans, showing enhanced platelet aggregation, adhesion and activation in murine blood. For human blood, opsonization was shown to decrease platelet interaction suggesting that complement factors interfere with fungus-to-platelet binding. Our results reveal substantial differences between murine and human whole-blood models infected with C. albicans and thereby demonstrate limitations in the translatability of this ex vivo model between hosts.	[Machata, Silke; Sreekantapuram, Sravya; Dunker, Christine; Schubert, Katja; Krueger, Wibke; Schulze-Richter, Bianca; Jacobsen, Ilse D.] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Res Grp Microbial Immunol, Jena, Germany; [Huenniger, Kerstin; Kurzai, Oliver] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Res Grp Fungal Sept, Jena, Germany; [Huenniger, Kerstin; Kurzai, Oliver] Univ Wurzburg, Inst Hyg & Microbiol, Wurzburg, Germany; [Speth, Cornelia; Rambach, Guenter] Med Univ Innsbruck, Inst Hyg & Med Microbiol, Innsbruck, Austria; [Jacobsen, Ilse D.] Friedrich Schiller Univ Jena, Inst Microbiol, Jena, Germany; [Schulze-Richter, Bianca] Univ Leipzig, Inst Immunol, Coll Vet Med, Mol Pathogenesis,Ctr Biotechnol & Biomed BBZ, Leipzig, Germany	Hans Knoll Institute (HKI); Hans Knoll Institute (HKI); University of Wurzburg; Medical University of Innsbruck; Friedrich Schiller University of Jena; Leipzig University	Jacobsen, ID (corresponding author), Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Res Grp Microbial Immunol, Jena, Germany.; Jacobsen, ID (corresponding author), Friedrich Schiller Univ Jena, Inst Microbiol, Jena, Germany.	ilse.jacobsen@leibniz-hki.de		rambach, gunter/0000-0002-7574-7868; speth, cornelia/0000-0001-5637-5993	funding line Strategic Networking in the Leibniz Association; FWF Austrian Science Fund [P26117-B20]; German Research Foundation (DFG) [TRR 124, 210879364]	funding line Strategic Networking in the Leibniz Association; FWF Austrian Science Fund(Austrian Science Fund (FWF)); German Research Foundation (DFG)(German Research Foundation (DFG))	Part of this project was funded by the funding line Strategic Networking in the Leibniz Association within the framework of the Leibniz Science Campus "InfectoOptics" (Project BLOODi to IJ) in Jena. CS was supported by the FWF Austrian Science Fund (Project Nr. P26117-B20). Work in the lab of OK and IJ was supported by the German Research Foundation (DFG; TRR 124 FungiNet, "Pathogenic fungi and their human host: Networks of Interaction," DFG project number 210879364, Project C3 to OK and C5 to IJ). Funders had no role in study design, analyses and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.	BALWIT JM, 1994, J INFECT DIS, V170, P1033, DOI 10.1093/infdis/170.4.1033; Behnsen J, 2007, PLOS PATHOG, V3, P138, DOI 10.1371/journal.ppat.0030013; Bertling A, 2010, THROMB HAEMOSTASIS, V104, P270, DOI 10.1160/TH09-11-0769; Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987; Chang Y, 2005, TOXICOL APPL PHARM, V204, P27, DOI 10.1016/j.taap.2004.08.011; Cottier F, 2019, MBIO, V10, DOI 10.1128/mBio.02347-19; DAVIDSON JAH, 1995, BRIT J ANAESTH, V74, P315, DOI 10.1093/bja/74.3.315; Doeing Diana C, 2003, BMC Clin Pathol, V3, P3; Duggan S, 2015, CELL MICROBIOL, V17, P1259, DOI 10.1111/cmi.12443; Eberl C, 2019, J INNATE IMMUN, V11, P52, DOI 10.1159/000491030; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3446, DOI 10.1128/IAI.60.8.3446-3447.1992; Ermert D, 2013, J LEUKOCYTE BIOL, V94, P223, DOI 10.1189/jlb.0213063; Ermert D, 2009, J INNATE IMMUN, V1, P181, DOI 10.1159/000205281; Filler SG, 1996, INFECT IMMUN, V64, P2609, DOI 10.1128/IAI.64.7.2609-2617.1996; Fradin C, 2005, MOL MICROBIOL, V56, P397, DOI 10.1111/j.1365-2958.2005.04557.x; Ganguly S, 2018, DRUG METAB DISPOS, V46, P1014, DOI 10.1124/dmd.117.078360; Gazendam RP, 2016, IMMUNOL REV, V273, P299, DOI 10.1111/imr.12454; Grubb SEW, 2008, INFECT IMMUN, V76, P4370, DOI 10.1128/IAI.00332-08; Han YM, 1997, J INFECT DIS, V175, P1169, DOI 10.1086/516455; Heller A, 1998, ACTA ANAESTH SCAND, V42, P518, DOI 10.1111/j.1399-6576.1998.tb05160.x; Horn DL, 2009, CLIN INFECT DIS, V48, P1695, DOI 10.1086/599039; Hunniger K, 2015, J IMMUNOL, V194, P1199, DOI 10.4049/jimmunol.1401845; Hunniger K, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003479; Huertas B, 2017, J PROTEOME RES, V16, P335, DOI 10.1021/acs.jproteome.6b00383; Iliev ID, 2012, SCIENCE, V336, P1314, DOI 10.1126/science.1221789; Jimenez-Lopez C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003741; Kahl BC, 2000, INFECT IMMUN, V68, P5385, DOI 10.1128/IAI.68.9.5385-5392.2000; Koh AY, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040035; Leroy J, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00383; Lionakis MS, 2014, MED MYCOL, V52, P555, DOI 10.1093/mmy/myu029; Lionakis MS, 2011, J INNATE IMMUN, V3, P180, DOI 10.1159/000321157; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; MacCallum DM, 2005, MYCOSES, V48, P151, DOI 10.1111/j.1439-0507.2005.01121.x; Maccallum Donna M, 2012, Int J Microbiol, V2012, P363764, DOI 10.1155/2012/363764; Martinez RM, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.DMIH2-0031-2016; Miralda I, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00217; Mitruka B.J., 1977, J CLIN PATHOL; Mollnes TE, 2002, BLOOD, V100, P1869; Mukaremera L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00629; Nishina K, 1998, ANESTH ANALG, V86, P159, DOI 10.1097/00000539-199801000-00032; Pappas PC, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.26; Perlroth J, 2007, MED MYCOL, V45, P321, DOI 10.1080/13693780701218689; Pfaller M, 2012, DIAGN MICR INFEC DIS, V74, P323, DOI 10.1016/j.diagmicrobio.2012.10.003; RAUSCH PG, 1975, BLOOD, V46, P913; Reimer LG, 1997, CLIN MICROBIOL REV, V10, P444, DOI 10.1128/CMR.10.3.444; Robert R, 2000, INFECT IMMUN, V68, P570, DOI 10.1128/IAI.68.2.570-576.2000; Romani L, 1996, RES IMMUNOL, V147, P512, DOI 10.1016/S0923-2494(97)85216-9; Rudkin FM, 2013, MBIO, V4, DOI 10.1128/mBio.00810-13; Schultz CM, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00784-19; Schulz D, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00152; Sreekantapuram S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00500; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Torosantucci A, 2000, J LEUKOCYTE BIOL, V68, P923; Vazquez JA, 2002, INFECT DIS CLIN N AM, V16, P793, DOI 10.1016/S0891-5520(02)00064-8; Viscoli C, 2016, VIRULENCE, V7, P248, DOI 10.1080/21505594.2016.1152440; Walther A, 2003, CURR GENET, V42, P339, DOI 10.1007/s00294-002-0349-0; Wartenberg A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004824; Watson KG, 2010, CELL MICROBIOL, V12, P1389, DOI 10.1111/j.1462-5822.2010.01511.x; Willcox MDP, 1998, J MED MICROBIOL, V47, P103, DOI 10.1099/00222615-47-2-103; Woth G, 2012, ANN CLIN BIOCHEM, V49, P554, DOI 10.1258/acb.2012.011215; Wozniok I, 2008, CELL MICROBIOL, V10, P807, DOI 10.1111/j.1462-5822.2007.01086.x; Yao Y, 2015, J IMMUNOL, V194, P1211, DOI 10.4049/jimmunol.1402018; Yeung F, 2020, CELL HOST MICROBE, V27, P809, DOI 10.1016/j.chom.2020.02.015; Zavrel M, 2012, EUKARYOT CELL, V11, P129, DOI 10.1128/EC.05206-11	64	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 15	2021	11								565869	10.3389/fimmu.2020.565869	http://dx.doi.org/10.3389/fimmu.2020.565869			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PZ1XF	33519798	Green Published, gold, Green Submitted			2022-12-18	WOS:000612533300001
J	Rutherford, HA; Kasher, PR; Hamilton, N				Rutherford, Holly A.; Kasher, Paul R.; Hamilton, Noemie			Dirty Fish Versus Squeaky Clean Mice: Dissecting Interspecies Differences Between Animal Models of Interferonopathy	FRONTIERS IN IMMUNOLOGY			English	Review						type I interferonopathy; Aicardi-Goutieres syndrome; autoimmune disease; RNASET2; zebrafish; mouse; white matter disorders; leukodystrophy	AICARDI-GOUTIERES-SYNDROME; SYSTEMIC-LUPUS-ERYTHEMATOSUS; I INTERFERON; CYSTIC LEUKOENCEPHALOPATHY; EXONUCLEASE TREX1; IMMUNE-RESPONSES; MUTATIONS; GENE; SAMHD1; MOUSE	Autoimmune and autoinflammatory diseases are rare but often devastating disorders, underpinned by abnormal immune function. While some autoimmune disorders are thought to be triggered by a burden of infection throughout life, others are thought to be genetic in origin. Among these heritable disorders are the type I interferonopathies, including the rare Mendelian childhood-onset encephalitis Aicardi-Goutieres syndrome. Patients with Aicardi Goutieres syndrome are born with defects in enzymes responsible for nucleic acid metabolism and develop devastating white matter abnormalities resembling congenital cytomegalovirus brain infection. In some cases, common infections preceded the onset of the disease, suggesting immune stimulation as a potential trigger. Thus, the antiviral immune response has been actively studied in an attempt to provide clues on the pathological mechanisms and inform on the development of therapies. Animal models have been fundamental in deciphering biological mechanisms in human health and disease. Multiple rodent and zebrafish models are available to study type I interferonopathies, which have advanced our understanding of the human disease by identifying key pathological pathways and cellular drivers. However, striking differences in phenotype have also emerged between these vertebrate models, with zebrafish models recapitulating key features of the human neuropathology often lacking in rodents. In this review, we compare rodent and zebrafish models, and summarize how they have advanced our understanding of the pathological mechanisms in Aicardi Goutieres syndrome and similar disorders. We highlight recent discoveries on the impact of laboratory environments on immune stimulation and how this may inform the differences in pathological severity between mouse and zebrafish models of type I interferonopathies. Understanding how these differences arise will inform the improvement of animal disease modeling to accelerate progress in the development of therapies for these devastating childhood disorders.	[Rutherford, Holly A.; Hamilton, Noemie] Univ Sheffield, Inst Neurosci, Dept Infect Immun & Cardiovasc Dis, Bateson Ctr, Sheffield, S Yorkshire, England; [Kasher, Paul R.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Lydia Becker Inst Immunol & Inflammat, Div Neurosci & Expt Psychol,Sch Biol Sci, Manchester, Lancs, England; [Kasher, Paul R.] Northern Care Alliance, Manchester Acad Hlth Sci Ctr, Geoffrey Jefferson Brain Res Ctr, Manchester, Lancs, England; [Kasher, Paul R.] Univ Manchester, Manchester, Lancs, England	University of Sheffield; University of Manchester; University of Manchester; University of Manchester	Hamilton, N (corresponding author), Univ Sheffield, Inst Neurosci, Dept Infect Immun & Cardiovasc Dis, Bateson Ctr, Sheffield, S Yorkshire, England.	n.m.hamilton@sheffield.ac.uk			MRC Discovery Medicine North (DiMeN) Doctoral Training Partnership [MR/N013840/1]; New Investigator Grant from the MRC [MR/T03291X/1]; Stroke Association [TSA LECT 2017/02]	MRC Discovery Medicine North (DiMeN) Doctoral Training Partnership; New Investigator Grant from the MRC; Stroke Association	HR is supported by a studentship from the MRC Discovery Medicine North (DiMeN) Doctoral Training Partnership (MR/N013840/1). PK is supported by a New Investigator Grant from the MRC (MR/T03291X/1) and the Stroke Association (TSA LECT 2017/02).	AICARDI J, 1984, ANN NEUROL, V15, P49, DOI 10.1002/ana.410150109; Balla KM, 2020, CURR BIOL, V30, P2092, DOI 10.1016/j.cub.2020.04.031; Bartsch K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00587; Baschat A A, 2003, J Matern Fetal Neonatal Med, V13, P381, DOI 10.1080/jmf.13.6.381.384; Beck-Engeser GB, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-91; Behrendt R, 2013, CELL REP, V4, P689, DOI 10.1016/j.celrep.2013.07.037; Benitez-Guijarro M, 2018, EMBO J, V37, DOI 10.15252/embj.201798506; Boxx GM, 2016, CELL HOST MICROBE, V19, P760, DOI 10.1016/j.chom.2016.05.016; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; Crow YJ, 2020, DEV MED CHILD NEUROL, V62, P42, DOI 10.1111/dmcn.14268; Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850; Crow YJ, 2014, NEUROPEDIATRICS, V45, P386, DOI 10.1055/s-0034-1389161; Crow YJ, 2011, ANN NY ACAD SCI, V1238, P91, DOI 10.1111/j.1749-6632.2011.06220.x; Crow YJ, 2003, J MED GENET, V40, P183, DOI 10.1136/jmg.40.3.183; Crow YJ, 2015, AM J MED GENET A, DOI [10.1055/s-0036-1592307, DOI 10.1055/S-0036-1592307]; Dale RC, 2000, NEUROPEDIATRICS, V31, P155, DOI 10.1055/s-2000-7492; De Laet C, 2005, NEUROPEDIATRICS, V36, P399, DOI 10.1055/s-2005-873058; de Vries B, 2010, ANN RHEUM DIS, V69, P1886, DOI 10.1136/ard.2009.114157; DECARLI C, 1993, ANN NEUROL, V34, P198, DOI 10.1002/ana.410340216; Funabiki M, 2014, IMMUNITY, V40, P199, DOI 10.1016/j.immuni.2013.12.014; Gall A, 2012, IMMUNITY, V36, P120, DOI 10.1016/j.immuni.2011.11.018; Garau J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050750; Goldstone DC, 2011, NATURE, V480, P379, DOI 10.1038/nature10623; HAMILTON N, 2020, GLIA 0325, DOI DOI 10.1101/744144; Hartner JC, 2004, J BIOL CHEM, V279, P4894, DOI 10.1074/jbc.M311347200; Hartner JC, 2009, NAT IMMUNOL, V10, P551, DOI 10.1038/ni0509-551a; Haud N, 2011, P NATL ACAD SCI USA, V108, P1099, DOI 10.1073/pnas.1009811107; Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786; Henneke M, 2009, NAT GENET, V41, P773, DOI 10.1038/ng.398; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Hiller B, 2012, J EXP MED, V209, P1419, DOI 10.1084/jem.20120876; Hironaka K, 2015, SCI REP-UK, V5, DOI 10.1038/srep13104; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Kasher PR, 2015, J IMMUNOL, V194, P2819, DOI 10.4049/jimmunol.1403157; KAUFFMAN WM, 1992, AM J NEURORADIOL, V13, P949; Kok FO, 2015, DEV CELL, V32, P97, DOI 10.1016/j.devcel.2014.11.018; Lahouassa H, 2012, NAT IMMUNOL, V13, P621, DOI 10.1038/ni0612-621c; Lai JKH, 2019, DEV BIOL, DOI [10.1101/479188, DOI 10.1101/479188]; Lamers MM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01763; Langevin C, 2013, J MOL BIOL, V425, P4904, DOI 10.1016/j.jmb.2013.09.033; Lee-Kirsch MA, 2007, NAT GENET, V39, P1065, DOI 10.1038/ng2091; Levraud J-P, 2019, J IMMUNOL, DOI [10.1101/693333, DOI 10.1101/693333]; Liddicoat BJ, 2015, SCIENCE, V349, P1115, DOI 10.1126/science.aac7049; Livingston JH, 2014, J MED GENET, V51, P76, DOI 10.1136/jmedgenet-2013-102038; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Luhtala N, 2010, TRENDS BIOCHEM SCI, V35, P253, DOI 10.1016/j.tibs.2010.02.002; Mackenzie KJ, 2016, EMBO J, V35, P831, DOI 10.15252/embj.201593339; Mannion NM, 2014, CELL REP, V9, P1482, DOI 10.1016/j.celrep.2014.10.041; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Namjou B, 2011, GENES IMMUN, V12, P270, DOI 10.1038/gene.2010.73; O'Brown NM, 2019, ELIFE, V8, DOI 10.7554/eLife.47326; O'Connell RM, 2004, J EXP MED, V200, P437, DOI 10.1084/jem.20040712; Oda H, 2014, AM J HUM GENET, V95, P121, DOI 10.1016/j.ajhg.2014.06.007; Parker D, 2011, MBIO, V2, DOI 10.1128/mBio.00016-11; Pokatayev V, 2016, J EXP MED, V213, P329, DOI 10.1084/jem.20151464; Rajshekar S, 2018, ELIFE, V7, DOI 10.7554/eLife.39658; Ramesh V, 2010, DEV MED CHILD NEUROL, V52, P725, DOI 10.1111/j.1469-8749.2010.03727.x; Rasmussen M, 2005, NEUROPEDIATRICS, V36, P40, DOI 10.1055/s-2004-830532; Rehwinkel J, 2013, RETROVIROLOGY, V10, pS28, DOI 10.1186/1742-4690-10-S1-P70; Reijns MAM, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.011; Rice G, 2007, AM J HUM GENET, V80, P811, DOI 10.1086/513443; Rice GI, 2018, NEW ENGL J MED, V379, P2275, DOI 10.1056/NEJMc1810983; Rice GI, 2013, LANCET NEUROL, V12, P1159, DOI 10.1016/S1474-4422(13)70258-8; Rice GI, 2012, NAT GENET, V44, P1243, DOI 10.1038/ng.2414; Rice GI, 2009, NAT GENET, V41, P829, DOI 10.1038/ng.373; Rodero MP, 2016, J EXP MED, V213, P2527, DOI 10.1084/jem.20161596; Rosshart SP, 2019, SCIENCE, V365, P461, DOI 10.1126/science.aaw4361; Rosshart SP, 2017, CELL, V171, P1015, DOI 10.1016/j.cell.2017.09.016; Rossi A, 2015, NATURE, V524, P230, DOI 10.1038/nature14580; Rutherford HA, 2019, FEBS J, V286, P4176, DOI 10.1111/febs.15060; Saili KS, 2017, BIRTH DEFECTS RES, V109, P1680, DOI 10.1002/bdr2.1180; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Sinkevicius KW, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032631; Slavov D, 2000, GENE, V250, P53, DOI 10.1016/S0378-1119(00)00175-X; Stetson DB, 2008, CELL, V134, P587, DOI 10.1016/j.cell.2008.06.032; Tan F, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02156; Tardieu M, 2000, NEUROLOGY, V54, P1089, DOI 10.1212/WNL.54.5.1089; Tonduti D, 2016, EUR J PAEDIATR NEURO, V20, P604, DOI 10.1016/j.ejpn.2016.03.009; Trinchieri G, 2010, J EXP MED, V207, P2053, DOI 10.1084/jem.20101664; van den Pol AN, 2009, NEURON, V64, P17, DOI 10.1016/j.neuron.2009.09.023; Virgin HW, 2014, CELL, V157, P142, DOI 10.1016/j.cell.2014.02.032; Walkley CR, 2012, CURR TOP MICROBIOL, V353, P197, DOI 10.1007/82_2011_150; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; Wenstrom KD, 1998, AM J OBSTET GYNECOL, V178, P546, DOI 10.1016/S0002-9378(98)70436-3; Westerfield M., 2007, ZEBRAFISH BOOK GUIDE; Wu L, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-142; Xu GJ, 2015, SCIENCE, V348, DOI 10.1126/science.aaa0698; Yarlagadda Atmaram, 2009, Psychiatry (Edgmont), V6, P18; Zhao K, 2013, CELL REP, V4, P1108, DOI 10.1016/j.celrep.2013.08.019	92	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 15	2021	11								623650	10.3389/fimmu.2020.623650	http://dx.doi.org/10.3389/fimmu.2020.623650			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PZ1WW	33519829	Green Published, Green Accepted, gold			2022-12-18	WOS:000612532100001
J	Chansard, A; Dubrulle, N; de Molliens, MP; Falanga, PB; Stephen, T; Hasan, M; van Zandbergen, G; Aulner, N; Shorte, SL; David-Watine, B				Chansard, Audrey; Dubrulle, Nelly; Poujol de Molliens, Mathilde; Falanga, Pierre B.; Stephen, Tharshana; Hasan, Milena; van Zandbergen, Ger; Aulner, Nathalie; Shorte, Spencer L.; David-Watine, Brigitte			Unveiling Interindividual Variability of Human Fibroblast Innate Immune Response Using Robust Cell-Based Protocols	FRONTIERS IN IMMUNOLOGY			English	Article						immortalization; HSV-1; FACS; cytokines; human primary cells; NF-kappa B; TLR (Toll like receptors); innate immunity	HERPES-SIMPLEX ENCEPHALITIS; TOLL-LIKE RECEPTOR-3; DERMAL FIBROBLASTS; LIPOPOLYSACCHARIDE; EXPRESSION; PROTEIN; NEMO; AGE	The LabEx Milieu Interieur (MI) project is a clinical study centered on the detailed characterization of the baseline and induced immune responses in blood samples from 1,000 healthy donors. Analyses of these samples has lay ground for seminal studies on the genetic and environmental determinants of immunologic variance in a healthy cohort population. In the current study we developed in vitro methods enabling standardized quantification of MI-cohort-derived primary fibroblasts responses. Our results show that in vitro human donor cohort fibroblast responses to stimulation by different MAMPs analogs allows to characterize individual donor immune-phenotype variability. The results provide proof-of-concept foundation to a new experimental framework for such studies. A bio-bank of primary fibroblast lines was generated from 323 out of 1,000 healthy individuals selected from the MI-study cohort. To study inter-donor variability of innate immune response in primary human dermal fibroblasts we chose to measure the TLR3 and TLR4 response pathways, both receptors being expressed and previously studied in fibroblasts. We established high-throughput automation compatible methods for standardized primary fibroblast cell activation, using purified MAMPS analogs, poly I:C and LPS that stimulate TLR3 and TLR4 pathways respectively. These results were in turn compared with a stimulation method using infection by HSV-1 virus. Our "Add-only" protocol minimizes high-throughput automation system variability facilitating whole process automation from cell plating through stimulation to recovery of cell supernatants, and fluorescent labeling. Images were acquired automatically by high-throughput acquisition on an automated high-content imaging microscope. Under these methodological conditions standardized image acquisition provided for quantification of cellular responses allowing biological variability to be measured with low system noise and high biological signal fidelity. Optimal for automated analysis of immuno-phenotype of primary human cell responses our method and experimental framework as reported here is highly compatible to high-throughput screening protocols like those necessary for chemo-genomic screening. In context of primary fibroblasts derived from donors enrolled to the MI-clinical-study our results open the way to assert the utility of studying immune-phenotype characteristics relevant to a human clinical cohort.	[Chansard, Audrey; Dubrulle, Nelly; Poujol de Molliens, Mathilde; Falanga, Pierre B.; Aulner, Nathalie; Shorte, Spencer L.; David-Watine, Brigitte] Inst Pasteur, UTechS Photon BioImaging, C2RT, Paris, France; [Stephen, Tharshana; Hasan, Milena] Inst Pasteur, UTechS Cytometry & Biomarkers, CRT, Paris, France; [van Zandbergen, Ger] Fed Inst Vaccines & Biomed, Paul Ehrlich Inst, Div Immunol, Langen, Germany; [Shorte, Spencer L.] Inst Pasteur Korea, Pasteur Joint Int Res Unit Ai3D, Seongnam, South Korea; [David-Watine, Brigitte] Inst Pasteur, Unite INSERM 1223, Paris, France; [David-Watine, Brigitte] Inst Pasteur, Unite Biol Genet Paroi Bacterienne, Paris, France; [David-Watine, Brigitte] CNRS UMR2001, Paris, France; [David-Watine, Brigitte] INSERM, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Paul Ehrlich Institute; Institut Pasteur Korea; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Shorte, SL; David-Watine, B (corresponding author), Inst Pasteur, UTechS Photon BioImaging, C2RT, Paris, France.; Shorte, SL (corresponding author), Inst Pasteur Korea, Pasteur Joint Int Res Unit Ai3D, Seongnam, South Korea.; David-Watine, B (corresponding author), Inst Pasteur, Unite INSERM 1223, Paris, France.; David-Watine, B (corresponding author), Inst Pasteur, Unite Biol Genet Paroi Bacterienne, Paris, France.; David-Watine, B (corresponding author), CNRS UMR2001, Paris, France.; David-Watine, B (corresponding author), INSERM, Paris, France.	spencer.shorte@pasteur.fr; brigitte.david-watine@pasteur.fr	David-Watine, Brigitte/ABF-5621-2020; Hasan, Milena/AAO-6610-2021; Gomperts Boneca, Ivo/H-1677-2014	David-Watine, Brigitte/0000-0002-3292-0042; Hasan, Milena/0000-0002-0879-7099; Gomperts Boneca, Ivo/0000-0001-8122-509X; Shorte, Spencer/0000-0002-2125-8663	French Government Agence nationale de la recherche (ANR) [ANR-10-LABX62-IBEID, ANR 10-LBX-73-REVIVE, ANR-10-LABX69-01]; France BioImaging (FBI) [ANR-10-INSB-04-01]; Region Ile de France (Domaine d'interet majeur One Health, DIM1Health); GIS IBiSA (Infrastructures en biologie santeet agronomie); Institut Pasteur	French Government Agence nationale de la recherche (ANR)(French National Research Agency (ANR)); France BioImaging (FBI)(French National Research Agency (ANR)); Region Ile de France (Domaine d'interet majeur One Health, DIM1Health); GIS IBiSA (Infrastructures en biologie santeet agronomie); Institut Pasteur(European Commission)	We are grateful for support from the French Government Agence nationale de la recherche (ANR) programmes: Investissements d'Avenir programme ('Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases'; grant ANR-10-LABX62-IBEID, "Laboratoire Revive"; grant ANR 10-LBX-73-REVIVE, "Laboratoire d'Excellence Milieu interieur"; grant ANR-10-LABX69-01); France BioImaging (FBI; grant ANR-10-INSB-04-01), the Region Ile de France (Domaine d'interet majeur One Health, DIM1Health) and the GIS IBiSA (Infrastructures en biologie santeet agronomie), and the Institut Pasteur.	Altman JB, 2020, P NATL ACAD SCI USA, V117, P17510, DOI 10.1073/pnas.1921324117; Audry M, 2011, J ALLERGY CLIN IMMUN, V128, P610, DOI 10.1016/j.jaci.2011.04.059; Boisson B, 2012, NAT IMMUNOL, V13, P1178, DOI 10.1038/ni.2457; De Chiara G, 2012, MOL NEUROBIOL, V46, P614, DOI 10.1007/s12035-012-8320-7; Desai P, 1998, J VIROL, V72, P7563, DOI 10.1128/JVI.72.9.7563-7568.1998; Duffy D, 2014, IMMUNITY, V40, P436, DOI 10.1016/j.immuni.2014.03.002; Figueroa L, 2012, J IMMUNOL, V188, P4506, DOI 10.4049/jimmunol.1200202; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Guo YQ, 2011, J EXP MED, V208, P2083, DOI 10.1084/jem.20101568; Herman M, 2012, J EXP MED, V209, P1567, DOI 10.1084/jem.20111316; Jolly AL, 2019, MBIO, V10, DOI [10.1128/mBio.00225-19, 10.1128/mbio.00225-19]; Kandasamy S, 2012, J DAIRY SCI, V95, P3852, DOI 10.3168/jds.2011-5251; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kim-Hellmuth S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00366-1; Kuhbacher A, 2017, J INFECT DIS, V215, P1742, DOI 10.1093/infdis/jix153; Le Guezennec X, 2015, MOL VIS, V21, P1151; LeBleu VS, 2020, FASEB J, V34, P3519, DOI 10.1096/fj.201903188R; Long HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093550; Looker KJ, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0114989, 10.1371/journal.pone.0140765]; Melchjorsen J, 2012, REV MED VIROL, V22, P106, DOI 10.1002/rmv.716; Nguyen HN, 2017, IMMUNITY, V46, P220, DOI 10.1016/j.immuni.2017.01.004; Noss EH, 2015, P NATL ACAD SCI USA, V112, P14948, DOI 10.1073/pnas.1520861112; Piasecka B, 2018, P NATL ACAD SCI USA, V115, pE488, DOI 10.1073/pnas.1714765115; Rathi AV, 2010, VIROLOGY, V406, P202, DOI 10.1016/j.virol.2010.07.018; Rodero MP, 2017, J EXP MED, V214, P1547, DOI 10.1084/jem.20161451; Salyer ACD, 2018, HUM VACC IMMUNOTHER, V14, P1686, DOI 10.1080/21645515.2018.1480284; Sancho-Shimizu V, 2011, J CLIN INVEST, V121, P4889, DOI 10.1172/JCI59259; Schaefer L, 2014, J BIOL CHEM, V289, P35237, DOI 10.1074/jbc.R114.619304; Smahi A, 2000, NATURE, V405, P466; Sorrell JM, 2009, INT REV CEL MOL BIO, V276, P161, DOI 10.1016/S1937-6448(09)76004-6; Tabeta K, 2000, INFECT IMMUN, V68, P3731, DOI 10.1128/IAI.68.6.3731-3735.2000; Taura M, 2008, MOL CELL BIOL, V28, P6557, DOI 10.1128/MCB.01202-08; Taura M, 2012, MOL CELL BIOL, V32, P1581, DOI 10.1128/MCB.06454-11; Thomas S, 2015, CLIN IMMUNOL, V157, P277, DOI 10.1016/j.clim.2014.12.004; Urrutia A, 2016, CELL REP, V16, P2777, DOI 10.1016/j.celrep.2016.08.011; Wang JF, 2011, J CELL PHYSIOL, V226, P1265, DOI 10.1002/jcp.22454; West NR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01093; Wolf J, 2012, EXP GERONTOL, V47, P749, DOI 10.1016/j.exger.2012.07.001; Wurfel MM, 2005, J IMMUNOL, V175, P2570, DOI 10.4049/jimmunol.175.4.2570; Yao C, 2015, INT J MOL MED, V35, P1443, DOI 10.3892/ijmm.2015.2146; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522; Zhang SY, 2019, CURR OPIN IMMUNOL, V59, P88, DOI 10.1016/j.coi.2019.03.008	42	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2021	11								569331	10.3389/fimmu.2020.569331	http://dx.doi.org/10.3389/fimmu.2020.569331			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PX1TA	33505391	gold, Green Published			2022-12-18	WOS:000611144200001
J	Hao, JH; Shen, CC; Wei, NN; Yan, MH; Zhang, XG; Xu, GW; Zhang, D; Hou, J; Cao, WJ; Jin, Y; Zhang, KS; Zheng, HX; Liu, XT				Hao, Junhong; Shen, Chaochao; Wei, Nannan; Yan, Minghao; Zhang, Xuegang; Xu, Guowei; Zhang, Dajun; Hou, Jing; Cao, Weijun; Jin, Ye; Zhang, Keshan; Zheng, Haixue; Liu, Xiangtao			Foot-and-Mouth Disease Virus Capsid Protein VP1 Antagonizes TPL2-Mediated Activation of the IRF3/IFN-beta Signaling Pathway to Facilitate the Virus Replication	FRONTIERS IN IMMUNOLOGY			English	Article						foot-and-mouth disease virus; viral protein 1; tumor progression locus 2; interferon regulatory factor 3/interferon-beta; immune escape	INTERFERON REGULATORY FACTOR; TRANSCRIPTION FACTOR; HOST-RESISTANCE; KINASE; TPL-2; ESTABLISHMENT; PROGRESSION; EXPRESSION; INDUCTION; INFECTION	Foot-and-mouth disease (FMD) is a severe, highly contagious viral disease of cloven-hoofed animals. In order to establish an infection, the FMD virus (FMDV) needs to counteract host antiviral responses. Tumor progression locus 2 (TPL2), a mitogen-activated protein kinase, can regulate innate and adaptive immunity; however, its exact mechanisms underlying TPL2-mediated regulation of the pathogenesis of FMDV infection remain unknown. In this study, we confirmed that TPL2 could inhibit FMDV replication in vitro and in vivo. The virus replication increased in Tpl2-deficient suckling mice in association with reduced expression of interferon-stimulated genes interferon-alpha (IFN-alpha) and myxovirus resistance (MX2) and significantly reduced expression of C-X-C motif chemokine ligand 10 (CXCL10), interferon regulatory factor 3 (IRF3), and IRF7, while the phosphorylation of IRF3 was not detected. Moreover, the interactions between TPL2 and VP1 were also confirmed. The overexpression of TPL2 promoted IRF3-mediated dose-dependent activation of the IFN-beta signaling pathway in association with interactions between IRF3 and TPL2. VP1 also inhibited phosphorylation of TPL2 at Thr290, while Thr290 resulted as the key functional site associated with the TPL2-mediated antiviral response. Taken together, this study indicated that FMDV capsid protein VP1 antagonizes TPL2-mediated activation of the IRF3/IFN-beta signaling pathway for immune escape and facilitated virus replication.	[Hao, Junhong; Shen, Chaochao; Wei, Nannan; Yan, Minghao; Zhang, Xuegang; Xu, Guowei; Zhang, Dajun; Hou, Jing; Cao, Weijun; Jin, Ye; Zhang, Keshan; Zheng, Haixue; Liu, Xiangtao] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Natl Footand Mouth Dis Reference Lab, Lanzhou, Peoples R China	Chinese Academy of Agricultural Sciences; Lanzhou Veterinary Research Institute, CAAS	Zhang, KS; Zheng, HX (corresponding author), Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Natl Footand Mouth Dis Reference Lab, Lanzhou, Peoples R China.	vetzks009@163.com; zhenghaixue@caas.cn			National Natural Science Foundation of China [NSFC-31972684]; National Science and Technology Support Plan [2015BAD12B04]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Support Plan	This work was supported by the National Natural Science Foundation of China (NSFC-31972684) and National Science and Technology Support Plan (2015BAD12B04).	Barnes BJ, 2004, J BIOL CHEM, V279, P45194, DOI 10.1074/jbc.M400726200; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chattopadhyay S, 2013, J VIROL, V87, P16, DOI 10.1128/JVI.01853-12; Chevrier N, 2011, CELL, V147, P853, DOI 10.1016/j.cell.2011.10.022; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; Chowdhury FZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092187; de los Santos T, 2006, J VIROL, V80, P1906, DOI 10.1128/JVI.80.4.1906-1914.2006; Du YJ, 2014, J VIROL, V88, P4908, DOI 10.1128/JVI.03668-13; Escalante CR, 2007, MOL CELL, V26, P703, DOI 10.1016/j.molcel.2007.04.022; Feng D, 2010, J IMMUNOL, V185, P6003, DOI 10.4049/jimmunol.1000482; Genin P, 2009, MOL CELL BIOL, V29, P3435, DOI 10.1128/MCB.01805-08; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hedl M, 2016, GUT, V65, P1799, DOI 10.1136/gutjnl-2014-308922; Ho MY, 2014, ONCOTARGET, V5, P3931, DOI 10.18632/oncotarget.2040; Jamal SM, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-116; Kaiser F, 2009, J EXP MED, V206, P1863, DOI 10.1084/jem.20091059; Lazear HM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003118; Li D, 2016, FASEB J, V30, P1757, DOI 10.1096/fj.15-281410; Li D, 2016, CELL CYCLE, V15, P850, DOI 10.1080/15384101.2016.1151584; Li D, 2016, SCI REP-UK, V6, DOI 10.1038/srep21888; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; McNab FW, 2013, J IMMUNOL, V191, P1732, DOI 10.4049/jimmunol.1300146; Meng FS, 2016, GENE DEV, V30, P1086, DOI 10.1101/gad.277533.116; Mielke LA, 2009, J IMMUNOL, V183, P7984, DOI 10.4049/jimmunol.0901336; Panne D, 2007, CELL, V129, P1111, DOI 10.1016/j.cell.2007.05.019; Paton DJ, 2019, VACCINE, V37, P5515, DOI 10.1016/j.vaccine.2019.07.102; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Perugorria MJ, 2013, HEPATOLOGY, V57, P1238, DOI 10.1002/hep.26108; Pulido MR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007135; Robinson MJ, 2007, MOL CELL BIOL, V27, P7355, DOI 10.1128/MCB.00301-07; Schmid S, 2010, J BIOL CHEM, V285, P42013, DOI 10.1074/jbc.M110.165936; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Stafford MJ, 2006, FEBS LETT, V580, P4010, DOI 10.1016/j.febslet.2006.06.004; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Vougioukalaki M, 2011, CANCER LETT, V304, P80, DOI 10.1016/j.canlet.2011.02.004; Wang D, 2012, J VIROL, V86, P9311, DOI 10.1128/JVI.00722-12; Wang XD, 2012, J BIOL CHEM, V287, P18366, DOI 10.1074/jbc.M111.335422; Watford WT, 2010, J IMMUNOL, V184, P105, DOI 10.4049/jimmunol.0803730; Watford WT, 2008, J EXP MED, V205, P2803, DOI 10.1084/jem.20081461; Xiang WW, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501889; Xiao NM, 2009, J IMMUNOL, V183, P7975, DOI 10.4049/jimmunol.0902718; Yang ZB, 2019, ADV MATER TECHNOL-US, V4, DOI 10.1002/admt.201900108; Zhang W, 2019, J VIROL, V93, DOI 10.1128/JVI.00588-19; Zhang W, 2015, J VET SCI, V16, P265, DOI 10.4142/jvs.2015.16.3.265; Zhou Q, 2014, CELL HOST MICROBE, V16, P450, DOI 10.1016/j.chom.2014.09.006; Zhu ZX, 2016, J VIROL, V90, P11106, DOI 10.1128/JVI.01310-16	48	2	3	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 8	2021	11								580334	10.3389/fimmu.2020.580334	http://dx.doi.org/10.3389/fimmu.2020.580334			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU9OI	33488582	Green Published, gold			2022-12-18	WOS:000609627200001
J	Lu, SM; Zheng, K; Wang, JY; Xu, M; Xie, YF; Yuan, S; Wang, C; Wu, YM				Lu, Simin; Zheng, Kang; Wang, Jianye; Xu, Man; Xie, Yafeng; Yuan, Shuai; Wang, Chuan; Wu, Yimou			Characterization of Treponema pallidum Dissemination in C57BL/6 Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Treponema pallidum; C57BL; 6 mice; bacterial dissemination; inflammation; quantitative polymerase chain reaction	EXPERIMENTAL SYPHILIS; IMMUNE-RESPONSE; BINDING; MOUSE	The spirochetal pathogen Treponema pallidum causes 5 million new cases of venereal syphilis worldwide each year. One major obstacle to syphilis prevention and treatment is the lack of suitable experimental animal models to study its pathogenesis. Accordingly, in this study, we further evaluated the responses of mice to Treponema pallidum. Quantitative polymerase chain reaction showed that Treponema pallidum could colonize the heart, liver, spleen, kidneys, and testicles of C57BL/6 mice, and the organism may be able to rapidly penetrate the blood-brain barrier in mice by 24 h after infection. In subsequent rabbit infectivity tests, we observed evident signs of the microorganism in the mouse lymph node suspension. After infection, bacterial loads were higher in the tissues than in the blood of C57BL/6 mice. Moreover, a significant Th1 immune response was recorded by cytokine assays. Flow cytometric analysis suggested an obvious increase in the proportion of CD3(+) T and CD4(+) T cells in the spleen cells in the infected mice. Thus, improving our understanding of the response of C57BL/6 mice for Treponema pallidum will help to comprehensive elucidate the pathogenic mechanisms of this bacterium and lay the foundation for the development of a new research model of Treponema pallidum.	[Lu, Simin; Zheng, Kang; Wang, Jianye; Xu, Man; Xie, Yafeng; Yuan, Shuai; Wang, Chuan; Wu, Yimou] Univ South China, Hengyang Med Coll, Inst Pathogen Biol, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China; [Xie, Yafeng] Univ South China, Affiliated Hosp 2, Clin Lab, Hengyang, Peoples R China	University of South China; University of South China	Wu, YM (corresponding author), Univ South China, Hengyang Med Coll, Inst Pathogen Biol, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China.	yimouwu@sina.com		Wu, Yimou/0000-0001-6883-1677	National Natural Science Foundation of China [81702046]; Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study [2015-351]; General Project in Hunan Province Science and Technology Program [2014TT2025]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study; General Project in Hunan Province Science and Technology Program	This work was supported by the National Natural Science Foundation of China (Grant numbers 81702046), the Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study (2015-351), and the General Project in Hunan Province Science and Technology Program (Grant number 2014TT2025).	Arroll TW, 1999, INFECT IMMUN, V67, P4757, DOI 10.1128/IAI.67.9.4757-4763.1999; Belkum AV, 2007, J MICROBIOL METH, V69, P421, DOI [10.1016/j.mimet.2006.09.021, DOI 10.1016/J.MIMET.2006.09.021]; Boylan JA, 2008, MOL MICROBIOL, V68, P786, DOI 10.1111/j.1365-2958.2008.06204.x; COLLART P, 1971, BRIT J VENER DIS, V47, P389; Dickerson MT, 2012, BIOCONJUGATE CHEM, V23, P184, DOI 10.1021/bc200436x; FEHER J, 1975, LANCET, V2, P896; FIELDSTEEL AH, 1981, INFECT IMMUN, V32, P908, DOI 10.1128/IAI.32.2.908-915.1981; FOLDS JD, 1983, SCAND J IMMUNOL, V18, P201, DOI 10.1111/j.1365-3083.1983.tb00858.x; Fornefett J, 2018, MICROBES INFECT, V20, P101, DOI 10.1016/j.micinf.2017.10.001; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Giacani L, 2010, J IMMUNOL, V184, P3822, DOI 10.4049/jimmunol.0902788; GUEFT B, 1948, Am J Syph Gonorrhea Vener Dis, V32, P59; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Ho EL, 2011, J CLIN INVEST, V121, P4584, DOI 10.1172/JCI57173; KLEIN JR, 1980, NATURE, V283, P572, DOI 10.1038/283572a0; LaFond RE, 2006, CLIN MICROBIOL REV, V19, P29, DOI 10.1128/CMR.19.1.29-49.2006; LaFond RE, 2006, INFECT IMMUN, V74, P6244, DOI 10.1128/IAI.00827-06; LEE RV, 1971, NEW ENGL J MED, V284, P1423, DOI 10.1056/NEJM197106242842508; Lithgow KV, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00195-20; Lithgow KV, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14273; Liu D, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007621; Lukehart SA, 2008, SEX TRANSM DIS, V35, P2, DOI 10.1097/OLQ.0b013e318162c4f2; Lukehart Sheila A, 2007, Curr Protoc Microbiol, VChapter 12, DOI 10.1002/9780471729259.mc12a01s7; Mendell NL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005453; O'Regan AW, 2002, THORAX, V57, P917, DOI 10.1136/thorax.57.10.917; OHTA Y, 1972, J IMMUNOL, V108, P921; Rothschild BM, 2005, CLIN INFECT DIS, V40, P1454, DOI 10.1086/429626; Salazar JC, 2002, MICROBES INFECT, V4, P1133, DOI 10.1016/S1286-4579(02)01638-6; Salazar JC, 2007, INFECT IMMUN, V75, P2954, DOI 10.1128/IAI.00090-07; SAUNDERS JM, 1985, GENITOURIN MED, V61, P221; SCHELL RF, 1975, BRIT J VENER DIS, V51, P19; Shan YY, 2015, J ASSIST REPROD GEN, V32, P1277, DOI 10.1007/s10815-015-0503-5; Silver AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071388; STAMM LV, 1991, INFECT IMMUN, V59, P1572, DOI 10.1128/IAI.59.4.1572-1575.1991; VanVoorhis WC, 1996, J INFECT DIS, V173, P491, DOI 10.1093/infdis/173.2.491; World Health Organization, 2014, REP GLOB SEX TRANSM; Wu Q, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-177; Zhang RL, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151416; Zheng K, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0176-0	39	2	3	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 8	2021	11								577129	10.3389/fimmu.2020.577129	http://dx.doi.org/10.3389/fimmu.2020.577129			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU4CL	33488577	gold, Green Published			2022-12-18	WOS:000609254400001
J	Voss, L; Guttek, K; Reddig, A; Reinhold, A; Voss, M; Schraven, B; Reinhold, D				Voss, Linda; Guttek, Karina; Reddig, Annika; Reinhold, Annegret; Voss, Martin; Schraven, Burkhart; Reinhold, Dirk			Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation	FRONTIERS IN IMMUNOLOGY			English	Article						apoptosis; DNA damage; inhibitor of T cell activation; adefovir dipivoxil; drug repositioning	ACYCLIC NUCLEOSIDE PHOSPHONATES; NITRIC-OXIDE; HISTONE H2AX; APOPTOSIS; PHOSPHORYLATION; PREVALENCE; EXPRESSION	Repositioning of approved drugs for identifying new therapeutic purposes is an alternative, time and cost saving strategy to classical drug development. Here, we screened a library of 786 FDA-approved drugs to find compounds, which can potentially be repurposed for treatment of T cell-mediated autoimmune diseases. Investigating the effect of these diverse substances on mitogen-stimulated proliferation of both, freshly stimulated and pre-activated (48 h) peripheral blood mononuclear cells (PBMCs), we discovered Adefovir Dipivoxil (ADV) as very potent compound, which inhibits T cell proliferation in a nanomolar range. We further analyzed the influence of ADV on proliferation, activation, cytokine production, viability and apoptosis of freshly stimulated as well as pre-activated human T cells stimulated with anti-CD3/CD28 antibodies. We observed that ADV was capable of suppressing the proliferation in both T cell stimulation systems in a dose-dependent manner (50% inhibition [IC50]: 63.12 and 364.8 nM for freshly stimulated T cells and pre-activated T cells, respectively). Moreover, the drug impaired T cell activation and inhibited Th1 (IFN-gamma), Th2 (IL-5), and Th17 (IL-17) cytokine production dose-dependently. Furthermore, ADV treatment induced DNA double-strand breaks (gamma H2AX foci expression), which led to an increase of p53-phospho-Ser15 expression. In response to DNA damage p21 and PUMA are transactivated by p53. Subsequently, this caused cell cycle arrest at G(0)/G(1) phase and activation of the intrinsic apoptosis pathway. Our results indicate that ADV could be a new potential candidate for treatment of T cell-mediated autoimmune diseases. Prospective studies should be performed to verify this possible therapeutic application of ADV for such disorders.	[Voss, Linda; Guttek, Karina; Reddig, Annika; Reinhold, Annegret; Voss, Martin; Schraven, Burkhart; Reinhold, Dirk] Otto von Guericke Univ, Inst Mol & Clin Immunol, Magdeburg, Germany; [Reinhold, Annegret; Schraven, Burkhart; Reinhold, Dirk] Otto von Guericke Univ, Hlth Campus Immunol Infect & Inflammat GC I3, Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Reinhold, D (corresponding author), Otto von Guericke Univ, Inst Mol & Clin Immunol, Magdeburg, Germany.	dirk.reinhold@med.ovgu.de			European Union Program Regional Development Fund of the Ministry of Economy, Science and Digitalisation in Saxony-Anhalt within the Center of Dynamic Systems	European Union Program Regional Development Fund of the Ministry of Economy, Science and Digitalisation in Saxony-Anhalt within the Center of Dynamic Systems	The project was supported by grants from the European Union Program Regional Development Fund of the Ministry of Economy, Science and Digitalisation in Saxony-Anhalt within the Center of Dynamic Systems and the research alliance "Autonomy in Old Age."	ADUMA P, 1995, MOL PHARMACOL, V47, P816; Arrowsmith J, 2011, NAT REV DRUG DISCOV, V10, P1, DOI 10.1038/nrd3375; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; Bieging KT, 2012, TRENDS CELL BIOL, V22, P97, DOI 10.1016/j.tcb.2011.10.006; CHERRINGTON JM, 1995, ANTIVIR CHEM CHEMOTH, V6, P217, DOI 10.1177/095632029500600403; Collier R, 2009, CAN MED ASSOC J, V180, P277, DOI 10.1503/cmaj.082041; De Clercq E, 2005, NAT REV DRUG DISCOV, V4, P928, DOI 10.1038/nrd1877; Devarajan P, 2013, IMMUNOL RES, V57, P12, DOI 10.1007/s12026-013-8448-1; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fontaine HL, 2005, TRANSPLANTATION, V80, P1086, DOI 10.1097/01.tp.0000178305.39231.a2; Furst DE, 2013, LUPUS, V22, P99, DOI 10.1177/0961203312463110; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Goodnow CC, 2007, CELL, V130, P25, DOI 10.1016/j.cell.2007.06.033; Guttek K, 2018, J TRACE ELEM MED BIO, V49, P86, DOI 10.1016/j.jtemb.2018.05.003; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hayter SM, 2012, AUTOIMMUN REV, V11, P754, DOI 10.1016/j.autrev.2012.02.001; Hummel K, 2012, J PEDIATR-US, V161, P652, DOI 10.1016/j.jpeds.2012.03.061; Jacobs BM, 2018, J NEUROL NEUROSUR PS, V89, P1266, DOI 10.1136/jnnp-2017-317411; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan U, 2018, INT REV CEL MOL BIO, V341, P125, DOI 10.1016/bs.ircmb.2018.05.008; Khoury H, 2018, CHEMOTHERAPY, V63, P225, DOI 10.1159/000491705; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koch-Henriksen N, 2010, LANCET NEUROL, V9, P520, DOI 10.1016/S1474-4422(10)70064-8; Kostecka P, 2012, INT IMMUNOPHARMACOL, V12, P342, DOI 10.1016/j.intimp.2011.12.005; Lallana EC, 2011, CURR NEUROPHARMACOL, V9, P468, DOI 10.2174/157015911796557939; Leist TP, 2011, CLIN NEUROPHARMACOL, V34, P28, DOI 10.1097/WNF.0b013e318204cd90; MacPhail SH, 2003, RADIAT RES, V159, P759, DOI 10.1667/RR3003; Malmstrom V, 2005, ARTHRITIS RES THER, V7, pS15, DOI 10.1186/ar1505; Myasoedova E, 2010, ARTHRITIS RHEUM-US, V62, P1576, DOI 10.1002/art.27425; Noble S, 1999, DRUGS, V58, P479, DOI 10.2165/00003495-199958030-00010; Patel A, 2020, INT J CANCER, V147, P1474, DOI 10.1002/ijc.32966; Pisarev VM, 1997, MOL PHARMACOL, V52, P63, DOI 10.1124/mol.52.1.63; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Reddig A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132702; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosenblum MD, 2015, J CLIN INVEST, V125, P2228, DOI 10.1172/JCI78088; Sertkaya A, 2016, CLIN TRIALS, V13, P117, DOI 10.1177/1740774515625964; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Singh V, 2013, CLIN EXP IMMUNOL, V173, P288, DOI 10.1111/cei.12109; U.S. Food and Drug Administration, 2002, HEPS NDA 21 449 PRIN; Van Norman Gail A, 2016, JACC Basic Transl Sci, V1, P170, DOI 10.1016/j.jacbts.2016.03.002; Willitzki A, 2013, CYTOM PART A, V83, P1017, DOI 10.1002/cyto.a.22350; Zidek Z, 1999, EUR J PHARMACOL, V376, P91, DOI 10.1016/S0014-2999(99)00343-X; Zidek Z, 2003, TOXICOL APPL PHARM, V192, P246, DOI 10.1016/S0041-008X(03)00215-1; Zidek Z, 1997, BIOCHEM PHARMACOL, V54, P855, DOI 10.1016/S0006-2952(97)00228-1	48	2	2	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 8	2021	11								616570	10.3389/fimmu.2020.616570	http://dx.doi.org/10.3389/fimmu.2020.616570			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU7YF	33488629	Green Published, gold			2022-12-18	WOS:000609515900001
J	Alvarez, M; Pierini, A; Simonetta, F; Baker, J; Maas-Bauer, K; Hirai, T; Negrin, RS				Alvarez, Maite; Pierini, Antonio; Simonetta, Federico; Baker, Jeanette; Maas-Bauer, Kristina; Hirai, Toshihito; Negrin, Robert S.			Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						Unlicensed NK; allogeneic hematopoietic cell transplantation; chimeras; engraftment; non-myeloablative conditioning regimen	REGULATORY T-CELLS; NATURAL-KILLER-CELLS; DISEASE; GVHD; RECONSTITUTION; SUPPRESSION; EXPANSION; RESPONSES; SURVIVAL; PROTECT	Allogeneic hematopoietic cell transplantation (allo-HCT) is an efficacious and frequently the only treatment option for some hematological malignances. However, it often faces severe morbidities and/or mortalities due to graft versus host disease, and the severity of the conditioning regiment needed, that result in toxicity-related issues poorly tolerable for some patients. These shortcomings have led to the development of less aggressive alternatives like non-myeloablative (NMAC) or reduced-intensity conditioning regiments (RIC). However, these approaches tend to have an increase of cancer relapse and limited persistence of donor-specific chimerism. Thus, strategies that lead towards an accelerated and more durable donor engraftment are still needed. Here, we took advantage of the ability of host-derived unlicensed NK (UnLicNK) cells to favor donor cell engraftment during myeloablative allo-HCT, and evaluated if the adoptive transfer of this cell type can improve donor chimerism in NAMC settings. Indeed, the infusion of these cells significantly increased mixed chimerism in a sublethal allo-HCT mouse model, resulting in a more sustainable donor cell engraftment when compared to the administration of licensed NK cells or HCT controls. We observed an overall increase in the total number and proportion of donor B, NK and myeloid cells after UnLicNK cell infusion. Additionally, the extension and durability of donor chimerism was similar to the one obtained after the tolerogenic Tregs infusion. These results serve as the needed bases for the implementation of the adoptive transfer of UnLicNK cells to upgrade NMAC protocols and enhance allogeneic engraftment during HCT.	[Alvarez, Maite; Pierini, Antonio; Simonetta, Federico; Baker, Jeanette; Maas-Bauer, Kristina; Hirai, Toshihito; Negrin, Robert S.] Stanford Univ, Blood & Marrow Transplantat, Sch Med, Stanford, CA 94305 USA; [Alvarez, Maite] Univ Navarra, Ctr Appl Med Res CIMA, Program Immunol, Pamplona, Spain; [Alvarez, Maite] Univ Navarra, Ctr Appl Med Res CIMA, Immunotherapy Dept, Pamplona, Spain; [Alvarez, Maite] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain; [Alvarez, Maite] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain	Stanford University; University of Navarra; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Alvarez, M; Negrin, RS (corresponding author), Stanford Univ, Blood & Marrow Transplantat, Sch Med, Stanford, CA 94305 USA.; Alvarez, M (corresponding author), Univ Navarra, Ctr Appl Med Res CIMA, Program Immunol, Pamplona, Spain.; Alvarez, M (corresponding author), Univ Navarra, Ctr Appl Med Res CIMA, Immunotherapy Dept, Pamplona, Spain.; Alvarez, M (corresponding author), Navarra Inst Hlth Res IdiSNA, Pamplona, Spain.; Alvarez, M (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	malv015@stanford.edu; negrs@stanford.edu	Alvarez, Maite/ABD-5806-2020; Simonetta, Federico/CAH-2436-2022	Alvarez, Maite/0000-0002-5969-9181; Maas-Bauer, Kristina/0000-0003-1788-2807	National Institute of Health [RO1CA125276, P01CA049605]; AACR-Millennium Fellowship in Lymphoma Research [1540-38-ALVA]; ASBMT New Investigator Award; Marie Sklodowska-Curie fellowship [CINK 746985]; Spanish Association Against Cancer's Investigator grant (2019 AECC Investigator); Geneva University Hospitals; Swiss Cancer League; Fondation Genevoise de bienfaisance Valeria Rossi di Montelera; Dubois-FerriereDinu-Lipatti Foundation; German Cancer Aid; FACSAria II (BD Bioscience) [S10RR025518-01]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR-Millennium Fellowship in Lymphoma Research; ASBMT New Investigator Award; Marie Sklodowska-Curie fellowship; Spanish Association Against Cancer's Investigator grant (2019 AECC Investigator); Geneva University Hospitals; Swiss Cancer League; Fondation Genevoise de bienfaisance Valeria Rossi di Montelera; Dubois-FerriereDinu-Lipatti Foundation; German Cancer Aid(Deutsche Krebshilfe); FACSAria II (BD Bioscience)	This work was supported by the National Institute of Health grants RO1CA125276 and P01CA049605. MA was supported by the AACR-Millennium Fellowship in Lymphoma Research (1540-38-ALVA), the ASBMT New Investigator Award, the Marie Sklodowska-Curie fellowship (CINK 746985), and by the Spanish Association Against Cancer's Investigator grant (2019 AECC Investigator). AP was supported by the ASBMT New Investigator Award. FS was supported by the Geneva University Hospitals, the Swiss Cancer League, the Fondation Genevoise de bienfaisance Valeria Rossi di Montelera and the Dubois-FerriereDinu-Lipatti Foundation. KM-B was supported by the German Cancer Aid. The FACSAria II (BD Bioscience, San Jose) used in this project was obtained through the grant S10RR025518-01.	Alvarez M, 2020, CANCERS, V12, DOI 10.3390/cancers12113189; Alvarez M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127729; Alvarez M, 2016, BLOOD, V127, P1202, DOI 10.1182/blood-2015-08-665570; Alvarez M, 2014, J IMMUNOL, V193, P1709, DOI 10.4049/jimmunol.1400034; Alvarez M, 2013, J IMMUNOL, V191, P688, DOI 10.4049/jimmunol.1300202; Barao I, 2006, P NATL ACAD SCI USA, V103, P5460, DOI 10.1073/pnas.0509249103; Barao I, 2011, BLOOD, V117, P7032, DOI 10.1182/blood-2010-11-316653; Baron F, 2017, EXPERT OPIN BIOL TH, V17, P163, DOI 10.1080/14712598.2017.1269167; Bergerson RJ, 2016, BLOOD ADV, V1, P208, DOI 10.1182/bloodadvances.2016000158; Bertaina A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01342; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; D'Aveni M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00989; Dekker A, 2006, J CLIN ONCOL, V24, P5207, DOI 10.1200/JCO.2006.06.1663; Del Papa B, 2017, BIOL BLOOD MARROW TR, V23, P1847, DOI 10.1016/j.bbmt.2017.07.009; Deng JS, 2017, MOL THER, V25, P416, DOI 10.1016/j.ymthe.2016.11.013; Di Ianni M, 2011, BLOOD, V117, P3921, DOI 10.1182/blood-2010-10-311894; Drylewicz J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0988-4; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Fionda C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1023-5; Gibbons C, 2008, IMMUNOL REV, V223, P334, DOI 10.1111/j.1600-065X.2008.00636.x; Guan QD, 2015, BIOL BLOOD MARROW TR, V21, P1205, DOI 10.1016/j.bbmt.2015.04.015; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Hallett WHD, 2008, BIOL BLOOD MARROW TR, V14, P1088, DOI 10.1016/j.bbmt.2008.08.001; Hirakawa M, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89278; Hongo D, 2014, AM J TRANSPLANT, V14, P2467, DOI 10.1111/ajt.12914; Hotta M, 2019, EUR J IMMUNOL, V49, P179, DOI 10.1002/eji.201847684; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jaiswal SR, 2017, CYTOTHERAPY, V19, P531, DOI 10.1016/j.jcyt.2016.12.006; Kellner Joshua N, 2018, Oncotarget, V9, P35611, DOI 10.18632/oncotarget.26242; Lee SH, 2009, J EXP MED, V206, P2235, DOI 10.1084/jem.20082387; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Ma J, 2003, EUR J IMMUNOL, V33, P2123, DOI 10.1002/eji.200324034; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; NAPARSTEK E, 1992, BLOOD, V80, P1673; Nishikii H, 2016, BLOOD, V128, P2846, DOI 10.1182/blood-2016-06-723783; Olson JA, 2010, BLOOD, V115, P4293, DOI 10.1182/blood-2009-05-222190; Pierini A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15068; Pierini A, 2016, BLOOD, V128, P866, DOI 10.1182/blood-2016-04-711275; Pierini A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9025835; Pierini A, 2015, J IMMUNOL, V195, P347, DOI 10.4049/jimmunol.1402861; Quintarelli C, 2020, LEUKEMIA, V34, P1102, DOI 10.1038/s41375-019-0613-7; Ravi D, 2020, LEUKEMIA, V34, P1291, DOI 10.1038/s41375-019-0663-x; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Schneidawind D, 2015, BLOOD, V125, P3491, DOI 10.1182/blood-2014-11-612762; Schneidawind D, 2014, BLOOD, V124, P3320, DOI 10.1182/blood-2014-05-576017; Shao L, 2020, TRANSPLANTATION, V104, P467, DOI 10.1097/TP.0000000000002996; Shi YF, 2006, CELL RES, V16, P126, DOI 10.1038/sj.cr.7310017; Simonetta F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00465; Sun K, 2012, BLOOD, V119, P1590, DOI 10.1182/blood-2011-08-374314; Swift L, 2019, ONCOTARGETS THER, V12, P1293, DOI 10.2147/OTT.S191478; Tarek N, 2012, J CLIN INVEST, V122, P3260, DOI 10.1172/JCI62749; Venstrom JM, 2009, CLIN CANCER RES, V15, P7330, DOI 10.1158/1078-0432.CCR-09-1720; Yu JL, 2009, BLOOD, V113, P3875, DOI 10.1182/blood-2008-09-177055	53	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 7	2021	11								614250	10.3389/fimmu.2020.614250	http://dx.doi.org/10.3389/fimmu.2020.614250			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU2LH	33488624	Green Published, gold			2022-12-18	WOS:000609137000001
J	Shytikov, D; Rohila, D; Li, D; Wang, PF; Jiang, M; Zhang, MX; Xu, Q; Lu, LR				Shytikov, Dmytro; Rohila, Deepak; Li, Dan; Wang, Pengfei; Jiang, Mei; Zhang, Mingxu; Xu, Qin; Lu, Linrong			Functional Characterization of Ly49(+)CD8 T-Cells in Both Normal Condition and During Anti-Viral Response	FRONTIERS IN IMMUNOLOGY			English	Article						CD8 T-cells; memory phenotype; NK-cell receptors; Ly49 receptors; anti-viral response	CLASS-I RECEPTORS; CUTTING EDGE; EXPRESSION; VIRUS; INFECTION; SURVIVAL; STIMULATION; ACQUISITION; LYMPHOCYTES; ACTIVATION	The role of Ly49(+)CD8 T-cells in the immune system is not clear. Previously, several papers suggested Ly49(+)CD8 T-cells as immunosuppressors, while multiple studies also suggested their role as potent participants of the immune response. The mechanism of Ly49 expression on CD8 T-cells is also not clear. We investigated phenotype, functions, and regulation of Ly49 expression on murine CD8 T-cells in both normal state and during LCMV infection. CD8 T-cells express different Ly49 receptors compared with NK-cells. In intact mice, Ly49(+)CD8 T-cells have a phenotype similar to resting central memory CD8 T-cells and do not show impaired proliferation and cytokine production. Conventional CD8 T-cells upregulate Ly49 receptors during TCR-induced stimulation, and IL-2, as well as IL-15, affect it. At the same time, Ly49(+)CD8 T-cells change the Ly49 expression profile dramatically upon re-stimulation downregulating inhibitory and upregulating activating Ly49 receptors. We observed the expression of Ly49 receptors on the virus-specific CD8 T-cells during LCMV infection, especially marked in the early stages, and participation of Ly49(+)CD8 T-cells in the anti-viral response. Thus, CD8 T-cells acquire Ly49 receptors during the T-cell activation and show dynamic regulation of Ly49 receptors during stimulation.	[Shytikov, Dmytro; Rohila, Deepak; Li, Dan; Wang, Pengfei; Jiang, Mei; Lu, Linrong] Zhejiang Univ, Sch Med, Inst Immunol, Hangzhou, Peoples R China; [Zhang, Mingxu; Lu, Linrong] Zhejiang Univ, Zhejiang Univ Univ Edinburgh Inst, Haining, Peoples R China; [Zhang, Mingxu; Xu, Qin; Lu, Linrong] Zhejiang Univ, Dept Immunol & Rheumatol, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Lu, LR (corresponding author), Zhejiang Univ, Sch Med, Inst Immunol, Hangzhou, Peoples R China.; Lu, LR (corresponding author), Zhejiang Univ, Zhejiang Univ Univ Edinburgh Inst, Haining, Peoples R China.; Lu, LR (corresponding author), Zhejiang Univ, Dept Immunol & Rheumatol, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China.	lu_linrong@zju.edu.cn	Rohila, Deepak/GOV-6206-2022	Xu, Qin/0000-0003-1812-3108; Rohila, Deepak/0000-0001-7138-2702	National Key R&D Program of China [2018YFC1105102]; National Natural Science Foundation of China [31770954, 31930038, 31530019, 81901605, 31700766, 31900628]; Fundamental Research Funds for the Central Universities [2018XZZX001-12]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants from the National Key R&D Program of China (2018YFC1105102), the National Natural Science Foundation of China (31770954, 31930038, 31530019 to LL, 81901605 to MZ, 31700766 to DS, and 31900628 to QX) and the Fundamental Research Funds for the Central Universities (2018XZZX001-12 to LL).	Alter G, 2008, J VIROL, V82, P9668, DOI 10.1128/JVI.00341-08; Anfossi N, 2004, J IMMUNOL, V173, P3773, DOI 10.4049/jimmunol.173.6.3773; Anfossi N, 2004, J IMMUNOL, V173, P7223, DOI 10.4049/jimmunol.173.12.7223; Arlettaz L, 2004, EUR J IMMUNOL, V34, P3413, DOI 10.1002/eji.200324756; Assarsson E, 2000, J IMMUNOL, V165, P3673, DOI 10.4049/jimmunol.165.7.3673; Bjorkstrom NK, 2012, BLOOD, V120, P3455, DOI 10.1182/blood-2012-03-416867; Boelen L, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao2892; Choi TW, 2011, J IMMUNOL, V186, P3911, DOI 10.4049/jimmunol.1004168; Coles MC, 2000, EUR J IMMUNOL, V30, P236, DOI 10.1002/1521-4141(200001)30:1<236::AID-IMMU236>3.3.CO;2-O; Dorfman JR, 1998, J EXP MED, V187, P609, DOI 10.1084/jem.187.4.609; Gati A, 2003, CANCER RES, V63, P7475; Gunturi A, 2003, J IMMUNOL, V170, P1737, DOI 10.4049/jimmunol.170.4.1737; Hermann E, 2010, IMMUNOLOGY, V129, P418, DOI 10.1111/j.1365-2567.2009.03194.x; Holderried TAW, 2013, P NATL ACAD SCI USA, V110, P21089, DOI 10.1073/pnas.1320999110; Huard B, 2000, NATURE, V403, P325, DOI 10.1038/35002105; Jacomet F, 2015, EUR J IMMUNOL, V45, P1926, DOI 10.1002/eji.201545539; Johansson S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006046; Judge AD, 2002, J EXP MED, V196, P935, DOI 10.1084/jem.20020772; Kambayashi T, 2000, J IMMUNOL, V165, P4964, DOI 10.4049/jimmunol.165.9.4964; Kim HJ, 2011, P NATL ACAD SCI USA, V108, P2010, DOI 10.1073/pnas.1018974108; Li ZY, 2019, CANCER IMMUNOL IMMUN, V68, P1303, DOI 10.1007/s00262-019-02363-3; MacDonald HR, 1998, J EXP MED, V187, P2109, DOI 10.1084/jem.187.12.2109; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; McCarron MJ, 2014, J CLIN INVEST, V124, P4375, DOI 10.1172/JCI76179; McMahon CW, 2002, J IMMUNOL, V169, P1444, DOI 10.4049/jimmunol.169.3.1444; Peacock CD, 2004, J IMMUNOL, V173, P478, DOI 10.4049/jimmunol.173.1.478; Peacock CD, 2002, MICROBES INFECT, V4, P1481, DOI 10.1016/S1286-4579(02)00031-X; Peacock CD, 2000, J VIROL, V74, P7032, DOI 10.1128/JVI.74.15.7032-7038.2000; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Roger J, 2001, J IMMUNOL, V167, P6, DOI 10.4049/jimmunol.167.1.6; Ruiz AL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6150; Saligrama N, 2019, NATURE, V572, P481, DOI 10.1038/s41586-019-1467-x; Satooka H, 2017, J IMMUNOL, V199, P3418, DOI 10.4049/jimmunol.1700074; Saurer L, 2004, J IMMUNOL, V172, P4176, DOI 10.4049/jimmunol.172.7.4176; Saurer L, 2003, J IMMUNOL, V171, P6334, DOI 10.4049/jimmunol.171.12.6334; Seregin SS, 2015, J IMMUNOL, V195, P1112, DOI 10.4049/jimmunol.1500084; Skold M, 2000, EUR J IMMUNOL, V30, P2488, DOI 10.1002/1521-4141(200009)30:9<2488::AID-IMMU2488>3.0.CO;2-F; Ugolini S, 2001, NAT IMMUNOL, V2, P430, DOI 10.1038/87740; Uhrberg M, 2001, J IMMUNOL, V166, P3923, DOI 10.4049/jimmunol.166.6.3923; van Stijn A, 2008, J IMMUNOL, V180, P4550, DOI 10.4049/jimmunol.180.7.4550; von Herrath M, 2001, Curr Protoc Immunol, VChapter 19, DOI 10.1002/0471142735.im1910s36; Wojtasiak M, 2004, INT IMMUNOL, V16, P1333, DOI 10.1093/intimm/dxh136; Xu J, 2005, J BIOL CHEM, V280, P24277, DOI 10.1074/jbc.M500727200; Yao YL, 2017, CELL IMMUNOL, V312, P71, DOI 10.1016/j.cellimm.2016.11.005; Young NT, 2001, J IMMUNOL, V166, P3933, DOI 10.4049/jimmunol.166.6.3933; Zhang XQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13032-5	46	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 7	2021	11								602783	10.3389/fimmu.2020.602783	http://dx.doi.org/10.3389/fimmu.2020.602783			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PU2OD	33488602	Green Published, gold			2022-12-18	WOS:000609144500001
J	Jing, X; Korchagina, AA; Shein, SA; Muraoka, WT; Koroleva, E; Tumanov, AV				Jing, Xi; Korchagina, Anna A.; Shein, Sergey A.; Muraoka, Wayne T.; Koroleva, Ekaterina; Tumanov, Alexei V.			IL-23 Contributes to Campylobacter jejuni-Induced Intestinal Pathology via Promoting IL-17 and IFN gamma Responses by Innate Lymphoid Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Campylobacter jejuni; colitis; innate lymphoid cells; interleukin-23; Campylobacteriosis; IL-10	INFLAMMATORY-BOWEL-DISEASE; IMMUNE-RESPONSES; INDUCED COLITIS; HOST-DEFENSE; INFECTION; BIOLOGY; SALMONELLA; RISK; FATE; IL10	Human pathogen Campylobacter jejuni is a significant risk factor for the development of long-term intestinal dysfunction although the cellular and molecular mechanisms remain scantily defined. IL-23 is an emerging therapeutic target for the treatment of inflammatory intestinal diseases, however its role in C. jejuni-driven intestinal pathology is not fully understood. IL-10 deficient mice represent a robust model to study the pathogenesis of C. jejuni infection because C. jejuni infection of mice lacking IL-10 results in symptoms and pathology that resemble human campylobacteriosis. To determine the role of IL-23 in C. jejuni-driven intestinal inflammation, we studied the disease pathogenesis in IL-23(-/-) mice with inhibited IL-10R alpha signaling. These mice exhibited reduced intestinal pathology independent from bacterial clearance. Further, levels of IFN gamma, IL-17, IL-22, TNF, and IL-6 were reduced and associated with reduced accumulation of neutrophils, monocytes and macrophages in the colon. Flow cytometry analysis revealed reduced production of IL-17 and IFN gamma by group 1 and 3 innate lymphoid cells. Thus, our data suggest that IL-23 contributes to intestinal inflammation in C. jejuni infected mice by promoting IL-17 and IFN gamma production by innate lymphoid cells.	[Jing, Xi; Korchagina, Anna A.; Shein, Sergey A.; Muraoka, Wayne T.; Koroleva, Ekaterina; Tumanov, Alexei V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA; [Jing, Xi] Cent South Univ, Xiangya Hosp 3, Dept Gastroenterol, Changsha, Peoples R China; [Muraoka, Wayne T.] Trudeau Inst, Saranac Lake, NY USA	University of Texas System; University of Texas Health San Antonio; Central South University; Trudeau Institute	Tumanov, AV (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA.	tumanov@uthscsa.edu	Tumanov, Alexei/AAR-1607-2021	Tumanov, Alexei/0000-0001-6042-0152; Anna, Korchagina/0000-0003-3633-2392; Muraoka, Wayne/0000-0002-7960-7176	NIH [AI135574, AI111000]; USDA NIFA [2014-67012-22276]; Crohn's and Colitis Foundation [294083]; Max and Minnie Tomerlin Voelcker Fund; William and Ella Owens Medical Research Foundation; UT Health San Antonio [NIH-NCI P30 CA054174-20, UL1 TR001120]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USDA NIFA(United States Department of Agriculture (USDA)); Crohn's and Colitis Foundation; Max and Minnie Tomerlin Voelcker Fund; William and Ella Owens Medical Research Foundation; UT Health San Antonio	This research was supported by grant from NIH (AI135574 and AI111000). WM was supported by USDA NIFA (2014-67012-22276). AT was supported by the Crohn's and Colitis Foundation (SRA#294083), the Max and Minnie Tomerlin Voelcker Fund, and the William and Ella Owens Medical Research Foundation. Data was generated in the Flow Cytometry Shared Resource Facility which is supported by UT Health San Antonio, NIH-NCI P30 CA054174-20 (CTRC at UTHSCSA) and UL1 TR001120 (CTSA grant).	Abt MC, 2015, CELL HOST MICROBE, V18, P27, DOI 10.1016/j.chom.2015.06.011; Ahern PP, 2010, IMMUNITY, V33, P279, DOI 10.1016/j.immuni.2010.08.010; Ahlfors H, 2014, J IMMUNOL, V193, P4602, DOI 10.4049/jimmunol.1401244; Al-Banna NA, 2018, CYTOKINE GROWTH F R, V41, P75, DOI 10.1016/j.cytogfr.2018.03.005; Ang CW, 2000, J NEUROIMMUNOL, V111, P229, DOI 10.1016/S0165-5728(00)00369-6; Ang CW, 2000, J NEUROIMMUNOL, V104, P133, DOI 10.1016/S0165-5728(99)00279-9; Antonelli E, 2012, J CROHNS COLITIS, V6, P154, DOI 10.1016/j.crohns.2011.07.012; Arora Z, 2016, GASTROENTEROL REP, V4, P287, DOI 10.1093/gastro/gov029; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Aschenbrenner D, 2021, GUT, V70, P1023, DOI 10.1136/gutjnl-2020-321731; Aychek T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7525; Becker C, 2006, J IMMUNOL, V177, P2760, DOI 10.4049/jimmunol.177.5.2760; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Brasseit J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00023; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Buonomo EL, 2013, J INFECT DIS, V208, P917, DOI 10.1093/infdis/jit277; Denson LA, 2018, GASTROENTEROLOGY, V154, P2097, DOI 10.1053/j.gastro.2018.02.016; Diefenbach A, 2013, EUR J MICROBIOL IMMU, V3, P143, DOI 10.1556/EuJMI.3.2013.3.1; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Edwards LA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015398; Eken A, 2014, MUCOSAL IMMUNOL, V7, P143, DOI 10.1038/mi.2013.33; Franke A, 2008, NAT GENET, V40, P1319, DOI 10.1038/ng.221; Ghilardi N, 2004, J IMMUNOL, V172, P2827, DOI 10.4049/jimmunol.172.5.2827; Godinez I, 2009, INFECT IMMUN, V77, P387, DOI 10.1128/IAI.00933-08; Gradel KO, 2009, GASTROENTEROLOGY, V137, P495, DOI 10.1053/j.gastro.2009.04.001; Gunasekera DC, 2020, MUCOSAL IMMUNOL, V13, P493, DOI 10.1038/s41385-019-0252-3; Hanzel J, 2020, EXPERT OPIN BIOL TH, V20, P399, DOI 10.1080/14712598.2020.1697227; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Hasegawa M, 2014, IMMUNITY, V41, P620, DOI 10.1016/j.immuni.2014.09.010; Heimesaat MM, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0106-4; Heimesaat MM, 2016, EUR J MICROBIOL IMMU, V6, P124, DOI 10.1556/1886.2016.00008; Helms M, 2006, CLIN INFECT DIS, V42, P498, DOI 10.1086/499813; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Kim MN, 2014, WORLD J GASTROENTERO, V20, P17084, DOI 10.3748/wjg.v20.i45.17084; Klose CSN, 2013, NATURE, V494, P261, DOI 10.1038/nature11813; Koroleva EP, 2015, J IMMUNOL METHODS, V421, P61, DOI 10.1016/j.jim.2015.02.003; Kullberg MC, 2006, J EXP MED, V203, P2485, DOI 10.1084/jem.20061082; Lippert E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007413; Macho-Fernandez E, 2015, MUCOSAL IMMUNOL, V8, P403, DOI 10.1038/mi.2014.78; Malik A, 2014, MUCOSAL IMMUNOL, V7, P802, DOI 10.1038/mi.2013.97; Mansfield LS, 2007, INFECT IMMUN, V75, P1099, DOI 10.1128/IAI.00833-06; Mansfield LS, 2008, MICROB PATHOGENESIS, V45, P241, DOI 10.1016/j.micpath.2008.05.010; McCarthy N, 2001, AM J EPIDEMIOL, V153, P610, DOI 10.1093/aje/153.6.610; Mijac D, 2016, TOHOKU J EXP MED, V240, P15, DOI 10.1620/tjem.240.15; Moschen AR, 2019, NAT REV GASTRO HEPAT, V16, P185, DOI 10.1038/s41575-018-0084-8; Mousavi S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040482; Mukhopadhyay S, 2020, J EXP MED, V217, DOI 10.1084/jem.20180649; Munoz M, 2009, J EXP MED, V206, P3047, DOI 10.1084/jem.20090900; Muraoka WT, 2021, MUCOSAL IMMUNOL, V14, P703, DOI 10.1038/s41385-020-00353-8; Nachamkin I, 2002, MICROBES INFECT, V4, P399, DOI 10.1016/S1286-4579(02)01553-8; Navarro-Llavat M, 2009, DIGESTION, V80, P25, DOI 10.1159/000212076; Neurath MF, 2019, CYTOKINE GROWTH F R, V45, P1, DOI 10.1016/j.cytogfr.2018.12.002; Ouyang WJ, 2019, IMMUNITY, V50, P871, DOI 10.1016/j.immuni.2019.03.020; Pantazi E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00676; Parks OB, 2016, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00085; Phongsisay V, 2016, IMMUNOBIOLOGY, V221, P535, DOI 10.1016/j.imbio.2015.12.005; Poly F, 2004, J BACTERIOL, V186, P4781, DOI 10.1128/JB.186.14.4781-4795.2004; Sands BE, 2017, GASTROENTEROLOGY, V153, P77, DOI 10.1053/j.gastro.2017.03.049; Sun XL, 2013, J IMMUNOL, V190, P357, DOI 10.4049/jimmunol.1201825; Sun XL, 2012, GASTROENTEROLOGY, V142, P86, DOI 10.1053/j.gastro.2011.09.042; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Wang YG, 2010, IMMUNITY, V32, P403, DOI 10.1016/j.immuni.2010.02.011; Wojno EDT, 2019, IMMUNITY, V50, P851, DOI 10.1016/j.immuni.2019.03.011; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Young KT, 2007, NAT REV MICROBIOL, V5, P665, DOI 10.1038/nrmicro1718; Zenewicz LA, 2013, J IMMUNOL, V190, P5306, DOI 10.4049/jimmunol.1300016; Zenewicz LA, 2011, INT IMMUNOL, V23, P159, DOI 10.1093/intimm/dxr001; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720	70	2	2	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 6	2021	11								579615	10.3389/fimmu.2020.579615	http://dx.doi.org/10.3389/fimmu.2020.579615			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PT7MV	33488580	gold, Green Published			2022-12-18	WOS:000608796600001
J	Craig-Mueller, N; Hammad, R; Elling, R; Alzubi, J; Timm, B; Kolter, J; Knelangen, N; Bednarski, C; Glaser, B; Ammann, S; Ivics, Z; Fischer, J; Speckmann, C; Schwarz, K; Lachmann, N; Ehl, S; Moritz, T; Henneke, P; Cathomen, T				Craig-Mueller, Nils; Hammad, Ruba; Elling, Roland; Alzubi, Jamal; Timm, Barbara; Kolter, Julia; Knelangen, Nele; Bednarski, Christien; Glaeser, Birgitta; Ammann, Sandra; Ivics, Zoltan; Fischer, Judith; Speckmann, Carsten; Schwarz, Klaus; Lachmann, Nico; Ehl, Stephan; Moritz, Thomas; Henneke, Philipp; Cathomen, Toni			Modeling MyD88 Deficiency In Vitro Provides New Insights in Its Function	FRONTIERS IN IMMUNOLOGY			English	Article						MyD88; IRAK4; iMac; induced pluripotent stem cells (iPSC); transposon; cell therapy; gene therapy; Toll-like receptor	PLURIPOTENT STEM-CELLS; SLEEPING-BEAUTY; MACROPHAGES; TRANSPOSON; LYMPHOCYTES; INFECTIONS; IPSCS	Inherited defects in MyD88 and IRAK4, two regulators in Toll-like receptor (TLR) signaling, are clinically highly relevant, but still incompletely understood. MyD88- and IRAK4-deficient patients are exceedingly susceptible to a narrow spectrum of pathogens, with similar to 50% lethality in the first years of life. To better understand the underlying molecular and cellular characteristics that determine disease progression, we aimed at modeling the cellular response to pathogens in vitro. To this end, we determined the immunophenotype of monocytes and macrophages derived from MyD88- and IRAK4-deficient patients. We recognized that macrophages derived from both patients were particularly poorly activated by streptococci, indicating that both signaling intermediates are essential for the immune response to facultative pathogens. To characterize this defect in more detail, we generated induced pluripotent stem cells (iPSCs) of fibroblasts derived from an MyD88-deficient patient. The underlying genetic defect was corrected using Sleeping Beauty transposon vectors encoding either the long (L) or the short (S) MYD88 isoform, respectively. Macrophages derived from these iPSC lines (iMacs) expressed typical macrophage markers, stably produced either MyD88 isoform, and showed robust phagocytic activity. Notably, iMacs expressing MyD88-L, but not MyD88-S, exhibited similar responses to external stimuli, including cytokine release patterns, as compared to genetically normal iMacs. Thus, the two MyD88 isoforms assume distinct functions in signaling. In conclusion, iPSC technology, in combination with efficient myeloid differentiation protocols, provides a valuable and inexhaustible source of macrophages, which can be used for disease modeling. Moreover, iPSC-derived macrophages may eventually aid in stabilizing MyD88-deficient patients during pyogenic infections.	[Craig-Mueller, Nils; Hammad, Ruba; Alzubi, Jamal; Timm, Barbara; Bednarski, Christien; Cathomen, Toni] Univ Freiburg, Inst Transfus Med & Gene Therapy, Med Ctr, Freiburg, Germany; [Craig-Mueller, Nils; Hammad, Ruba; Elling, Roland; Alzubi, Jamal; Timm, Barbara; Kolter, Julia; Knelangen, Nele; Bednarski, Christien; Ammann, Sandra; Speckmann, Carsten; Ehl, Stephan; Henneke, Philipp; Cathomen, Toni] Univ Freiburg, Ctr Chron Immunodef CCI, Med Ctr, Freiburg, Germany; [Hammad, Ruba] Univ Freiburg, MD Program, Fac Med, Freiburg, Germany; [Hammad, Ruba] Univ Freiburg, PhD Program, Fac Biol, Freiburg, Germany; [Elling, Roland; Kolter, Julia; Knelangen, Nele; Ammann, Sandra; Ehl, Stephan; Henneke, Philipp] Univ Freiburg, Inst Immunodef, Med Ctr, Freiburg, Germany; [Elling, Roland; Speckmann, Carsten; Henneke, Philipp] Univ Freiburg, Ctr Pediat & Adolescent Med, Med Ctr, Freiburg, Germany; [Glaeser, Birgitta; Fischer, Judith] Univ Freiburg, Inst Human Genet, Med Ctr, Freiburg, Germany; [Ivics, Zoltan] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany; [Fischer, Judith; Speckmann, Carsten; Ehl, Stephan; Henneke, Philipp; Cathomen, Toni] Univ Freiburg, Fac Med, Freiburg, Germany; [Schwarz, Klaus] Univ Ulm, Inst Clin Transfus Med & Immunogenet Ulm, German Red Cross Blood Serv Baden Wurttemberg Hes, Ulm, Germany; [Schwarz, Klaus] Univ Ulm, Inst Transfus Med, Ulm, Germany; [Lachmann, Nico; Moritz, Thomas] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany; [Lachmann, Nico; Moritz, Thomas] REBIRTH Cluster Regenerat & Translat Med, Hannover, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Paul Ehrlich Institute; University of Freiburg; Ulm University; Ulm University; Hannover Medical School	Cathomen, T (corresponding author), Univ Freiburg, Inst Transfus Med & Gene Therapy, Med Ctr, Freiburg, Germany.; Henneke, P; Cathomen, T (corresponding author), Univ Freiburg, Ctr Chron Immunodef CCI, Med Ctr, Freiburg, Germany.; Henneke, P (corresponding author), Univ Freiburg, Inst Immunodef, Med Ctr, Freiburg, Germany.; Henneke, P (corresponding author), Univ Freiburg, Ctr Pediat & Adolescent Med, Med Ctr, Freiburg, Germany.; Henneke, P; Cathomen, T (corresponding author), Univ Freiburg, Fac Med, Freiburg, Germany.	philipp.henneke@uniklinik-freiburg.de; toni.cathomen@uniklinik-freiburg.de	Lachmann, Nico/H-6219-2017; Cathomen, Toni/ABG-8410-2021; Cathomen, Toni/GZL-2702-2022; Fischer, Judith/E-6327-2016	Lachmann, Nico/0000-0002-4245-1497; Cathomen, Toni/0000-0002-7757-4630; Cathomen, Toni/0000-0002-7757-4630; Fischer, Judith/0000-0002-8580-8118; Kolter, Julia/0000-0002-3268-8124; Ammann, Sandra/0000-0003-0385-1890; Alzubi, Jamal/0000-0003-4284-2006	German Federal Ministry of Education and Research [iMacNet-01EK1602, 01GL1746A, IFB-01EO1303]; Else Kroner-Fresenius Foundation; German Research Foundation [HE3127/9, HE3127/12, SFB/TRR167]; Research Commission of the Faculty of Medicine of the Albert-Ludwigs-University of Freiburg [3096997002]; Baden-Wuerttemberg Ministry of Science, Research and Art; University of Freiburg	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Else Kroner-Fresenius Foundation; German Research Foundation(German Research Foundation (DFG)); Research Commission of the Faculty of Medicine of the Albert-Ludwigs-University of Freiburg; Baden-Wuerttemberg Ministry of Science, Research and Art; University of Freiburg	This work was supported by the German Federal Ministry of Education and Research (iMacNet-01EK1602 to TC, PH, NL, and TM, 01GL1746A to PH, and IFB-01EO1303 to TC, PH, and SE), the Else Kroner-Fresenius Foundation (to PH), the German Research Foundation (HE3127/9, HE3127/12, and SFB/TRR167 to PH), and the Research Commission of the Faculty of Medicine of the Albert-Ludwigs-University of Freiburg (3096997002 to TC). The article processing charge was funded by the BadenWuerttemberg Ministry of Science, Research and Art and the University of Freiburg in the funding program Open Access Publishing.	Ackermann M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07570-7; Ackermann M, 2015, EMBO MOL MED, V7, P1388, DOI 10.15252/emmm.201505301; Alsina L, 2014, NAT IMMUNOL, V15, P1134, DOI 10.1038/ni.3028; Alzubi J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12750-4; Ammann S, 2020, J ALLERGY CLIN IMMUN, V145, P434, DOI 10.1016/j.jaci.2019.09.002; Buchholz KR, 2008, INFECT IMMUN, V76, P3150, DOI 10.1128/IAI.00104-08; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cohen RN, 2009, J CONTROL RELEASE, V135, P166, DOI 10.1016/j.jconrel.2008.12.016; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Crow D, 2019, CELL, V177, P1667, DOI 10.1016/j.cell.2019.05.043; Ortuno-Costela MD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246305; Deshmukh SD, 2011, EMBO REP, V12, P71, DOI 10.1038/embor.2010.189; Dettmer V, 2019, HUM GENE THER, V30, P975, DOI 10.1089/hum.2019.025; Dreyer AK, 2015, BIOMATERIALS, V69, P191, DOI 10.1016/j.biomaterials.2015.07.057; Elling R, 2016, J ALLERGY CLIN IMMUN, V137, P1587, DOI 10.1016/j.jaci.2015.09.047; Feuerstein R, 2015, J IMMUNOL, V194, P2735, DOI 10.4049/jimmunol.1402566; French A, 2015, STEM CELLS DEV, V24, P1082, DOI 10.1089/scd.2014.0318; Gay NJ, 2014, NAT REV IMMUNOL, V14, P546, DOI 10.1038/nri3713; Grabundzija I, 2010, MOL THER, V18, P1200, DOI 10.1038/mt.2010.47; Henneke P, 2008, J IMMUNOL, V180, P6149, DOI 10.4049/jimmunol.180.9.6149; Hodge R, 2017, HUM GENE THER, V28, P842, DOI 10.1089/hum.2017.130; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Janssens S, 2003, FEBS LETT, V548, P103, DOI 10.1016/S0014-5793(03)00747-6; Janssens S, 2002, CURR BIOL, V12, P467, DOI 10.1016/S0960-9822(02)00712-1; Katter K, 2013, FASEB J, V27, P930, DOI 10.1096/fj.12-205526; Lachmann N, 2015, STEM CELL REP, V4, P282, DOI 10.1016/j.stemcr.2015.01.005; Laroux FS, 2005, J IMMUNOL, V175, P5596, DOI 10.4049/jimmunol.175.9.5596; Laskowski TJ, 2016, STEM CELL REP, V7, P139, DOI 10.1016/j.stemcr.2016.06.003; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343; Mlambo T, 2018, NUCLEIC ACIDS RES, V46, P4456, DOI 10.1093/nar/gky171; Picard C, 2010, MEDICINE, V89, P403, DOI 10.1097/MD.0b013e3181fd8ec3; Rahman SH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005239; Shi Y, 2017, NAT REV DRUG DISCOV, V16, P115, DOI 10.1038/nrd.2016.245; Themeli M, 2013, NAT BIOTECHNOL, V31, P928, DOI 10.1038/nbt.2678; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; von Bernuth H, 2012, EUR J IMMUNOL, V42, P3126, DOI 10.1002/eji.201242683; Wu CF, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.53	39	2	2	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2020	11								608802	10.3389/fimmu.2020.608802	http://dx.doi.org/10.3389/fimmu.2020.608802			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PO1QC	33424861	Green Published, gold, Green Submitted			2022-12-18	WOS:000604944300001
J	Fall, AKDJ; Dechavanne, C; Sabbagh, A; Guitard, E; Milet, J; Garcia, A; Dugoujon, JM; Courtin, D; Migot-Nabias, F				Fall, Abdou Khadre Dit Jadir; Dechavanne, Celia; Sabbagh, Audrey; Guitard, Evelyne; Milet, Jacqueline; Garcia, Andre; Dugoujon, Jean-Michel; Courtin, David; Migot-Nabias, Florence			Susceptibility to Plasmodium falciparum Malaria: Influence of Combined Polymorphisms of IgG3 Gm Allotypes and Fc Gamma Receptors IIA, IIIA, and IIIB	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; IgG polymorphism; Gm allotypes; Fc gamma receptor; Benin; generalized multifactor dimensionality reduction	SYSTEMIC-LUPUS-ERYTHEMATOSUS; BLOOD-STAGE ANTIGENS; CD32 POLYMORPHISM; COPY NUMBER; ASSOCIATION; ANTIBODIES; IMMUNITY; NEUTROPHILS; SUBCLASSES; CHILDREN	The binding of immunoglobulin (Ig) to Fc gamma receptors (FcgR) at the immune cell surface is an important step to initiate immunological defense against malaria. However, polymorphisms in receptors and/or constant regions of the IgG heavy chains may modulate this binding. Here, we investigated whether polymorphisms located in FcgR and constant regions of the heavy chain of IgG are associated with susceptibility to P. falciparum malaria. For this purpose, a clinical and parasitological follow-up on malaria was conducted among 656 infants in southern Benin. G3m allotypes (from total IgG3) were determined by a serological method of hemagglutination inhibition. FcgRIIA 131R/H and FcgRIIIA 176F/V genotypes were determined using the TaqMan method and FcgRIIIB NA1/NA2 genotypes were assessed by polymerase chain reaction using allele-specific primers. Association analyses between the number of malaria infections during the follow-up and polymorphisms in IgG G3m allotypes and FcgR were studied independently by zero inflated binomial negative regression. The influence of combinations of G3m allotypes and FcgRIIA/FcgRIIIA/FcgRIIIB polymorphisms on the number of P. falciparum infections, and their potential interaction with environmental exposure to malaria was assessed by using the generalized multifactor dimensionality reduction (GMDR) method. Results showed that individual carriage of G3m24 single allotype and of G3m5,6,10,11,13,14,24 phenotype was independently associated with a high risk of malaria infection. A risk effect for G3m6 was observed only under high environmental exposure. FcgRIIIA 176VV single genotype and combined carriage of FcgRIIA 131RH/FcgRIIIA 176VV/FcgRIIIB NA1NA2, FcgRIIA 131HH/FcgRIIIA 176FF/FcgRIIIB NA1NA1, FcgRIIA 131HH/FcgRIIIA 176VV/FcgRIIIB NA2NA2 and FcgRIIA 131HH/FcgRIIIA 176VV/FcgRIIIB NA1NA2 genotypes were related to a high number of malaria infections. The risk was accentuated for FcgRIIIA 176VV when considering the influence of environmental exposure to malaria. Finally, the GMDR analysis including environmental exposure showed strengthened associations with a malaria risk when FcgRIIA/FcgRIIIA/FcgRIIIB genotypes were combined to G3m5,6,11,24 and G3m5,6,10,11,13,15,24 phenotypes or G3m10 and G3m13 single allotypes. Our results highlight the relevance of studying IgG heavy chain and FcgR polymorphisms, independently as well as in combination, in relation to the individual susceptibility to P. falciparum infection. The intensity of individual exposure to mosquito bites was demonstrated to impact the relationships found.	[Fall, Abdou Khadre Dit Jadir; Dechavanne, Celia; Sabbagh, Audrey; Milet, Jacqueline; Garcia, Andre; Courtin, David; Migot-Nabias, Florence] Univ Paris, Inst Rech Dev IRD, MERIT, UMR 261, Paris, France; [Guitard, Evelyne; Dugoujon, Jean-Michel] Univ Paul Sabatier Toulouse III, Lab Anthropol Mol & Imagerie Synth AMIS, CNRS, UMR 5288, Toulouse, France	Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Migot-Nabias, F (corresponding author), Univ Paris, Inst Rech Dev IRD, MERIT, UMR 261, Paris, France.	florence.migot-nabias@ird.fr	courtin, david/A-1584-2017	courtin, david/0000-0002-5263-4430; MILET, Jacqueline/0000-0003-2710-1517; SABBAGH, Audrey/0000-0003-0283-8803; Dechavanne, Celia/0000-0001-8439-9976; Migot-Nabias, Florence/0000-0001-9982-594X	Agence Nationale de la Recherche (ANR) Sante Environnement Sante Travail (SEST 2006) [040 01]; Universite de Paris	Agence Nationale de la Recherche (ANR) Sante Environnement Sante Travail (SEST 2006)(French National Research Agency (ANR)); Universite de Paris	This work was supported by the Agence Nationale de la Recherche (ANR) Sante Environnement Sante Travail (SEST 2006; 040 01). The Universite de Paris awarded a PhD scholarship to AF.	Adamou R, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2831-x; Adu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046197; Aribot G, 1996, AM J TROP MED HYG, V54, P449, DOI 10.4269/ajtmh.1996.54.449; BECK HP, 1995, INFECT IMMUN, V63, P596, DOI 10.1128/IAI.63.2.596-600.1995; Beeson JG, 2016, FEMS MICROBIOL REV, V40, P343, DOI 10.1093/femsre/fuw001; Bux J, 1999, BLOOD, V93, P357, DOI 10.1182/blood.V93.1.357.401k39_357_362; Chen JY, 2014, ARTHRITIS RHEUMATOL, V66, P3113, DOI 10.1002/art.38813; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; Cooke GS, 2003, AM J TROP MED HYG, V69, P565, DOI 10.4269/ajtmh.2003.69.565; Cottrell G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028812; Courtin D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007590; Damelang T, 2019, TRENDS IMMUNOL, V40, P197, DOI 10.1016/j.it.2019.01.005; Dard P, 2001, EUR J HUM GENET, V9, P765, DOI 10.1038/sj.ejhg.5200700; de Taeye SW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00740; Dechavanne C, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002403; Dechavanne C, 2016, SCI REP-UK, V6, DOI 10.1038/srep33961; DELANGE GG, 1989, EXP CLIN IMMUNOGENET, V6, P7; Dugoujon JM, 2004, AM J PHYS ANTHROPOL, V125, P175, DOI 10.1002/ajpa.10405; EDBERG JC, 1994, J IMMUNOL, V152, P5826; FACER CA, 1980, CLIN EXP IMMUNOL, V41, P81; Ferreira MU, 1998, ANN TROP MED PARASIT, V92, P245, DOI 10.1080/00034989859807; FIELD LL, 1989, GENET EPIDEMIOL, V6, P31, DOI 10.1002/gepi.1370060108; Giha HA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-306; Grant AV, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0078-z; Hans Veenu Madaan, 2011, J Oral Sci, V53, P467; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; HUIZINGA TWJ, 1990, BLOOD, V75, P213; Le Port A, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000342; Lefranc MP, 2015, NUCLEIC ACIDS RES, V43, pD413, DOI 10.1093/nar/gku1056; Lefranc Marie-Paule, 2012, Methods Mol Biol, V882, P635, DOI 10.1007/978-1-61779-842-9_34; Lou XY, 2007, AM J HUM GENET, V80, P1125, DOI 10.1086/518312; Maiga B, 2014, SCAND J IMMUNOL, V79, P43, DOI 10.1111/sji.12122; Migot-Nabias F, 2008, J INFECT DIS, V198, P1892, DOI 10.1086/593210; Molokhia M, 2011, RHEUMATOLOGY, V50, P1206, DOI 10.1093/rheumatology/keq456; Munde EO, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2390-0; Nasr A, 2007, SCAND J IMMUNOL, V66, P87, DOI 10.1111/j.1365-3083.2007.01947.x; Omi K, 2002, JPN J INFECT DIS, V55, P167; Omi K, 2002, PARASITOL INT, V51, P361, DOI 10.1016/S1383-5769(02)00040-5; Ouma C, 2006, AM J TROP MED HYG, V74, P573, DOI 10.4269/ajtmh.2006.74.573; Ouma C, 2012, HUM GENET, V131, P289, DOI 10.1007/s00439-011-1076-8; Pandey JP, 2007, PARASITE IMMUNOL, V29, P267, DOI 10.1111/j.1365-3024.2007.00938.x; Pandey JP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-229; Pandey JP, 1996, HUM IMMUNOL, V51, P99, DOI 10.1016/S0198-8859(96)00205-4; PARREN PWHI, 1992, J CLIN INVEST, V90, P1537, DOI 10.1172/JCI116022; Pleass RJ, 2003, BLOOD, V102, P4424, DOI 10.1182/blood-2003-02-0583; Ravetch J, 2010, NAT IMMUNOL, V11, P183, DOI 10.1038/ni0310-183; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Roussilhon C, 2007, PLOS MED, V4, P1791, DOI 10.1371/journal.pmed.0040320; SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297, DOI 10.4269/ajtmh.1991.45.297; SALMON JE, 1995, J CLIN INVEST, V95, P2877, DOI 10.1172/JCI117994; SALMON JE, 1990, J CLIN INVEST, V85, P1287, DOI 10.1172/JCI114566; Shi JF, 2011, BMC CANCER, V11, DOI [10.1186/1472-6750-11-77, 10.1186/1471-2407-11-239]; Sinha S, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-13; van Buuren S, 2011, J STAT SOFTW, V45, P1; van Sorge NM, 2003, TISSUE ANTIGENS, V61, P189, DOI 10.1034/j.1399-0039.2003.00037.x; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Vossebeld PJM, 1997, INT J BIOCHEM CELL B, V29, P465, DOI 10.1016/S1357-2725(96)00160-4; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; Yoo EM, 2010, ENCY IND BIOTECHNOLO, V1, P332, DOI [10.1002/9780470054581.eib044, DOI 10.1002/9780470054581.EIB044]; Zeyrek D, 2008, PEDIAT ALLERG IMM-UK, V19, P20, DOI 10.1111/j.1399-3038.2007.00553.x; Zhao JY, 2014, INFECT GENET EVOL, V23, P169, DOI 10.1016/j.meegid.2014.02.011	63	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2020	11								608016	10.3389/fimmu.2020.608016	http://dx.doi.org/10.3389/fimmu.2020.608016			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PP6FM	33424858	Green Published, gold			2022-12-18	WOS:000605956300001
J	Korniotis, S; D'Aveni, M; Hergalant, S; Letscher, H; Tejerina, E; Gastineau, P; Agbogan, VA; Gras, C; Fouquet, G; Rossignol, J; Chevre, JC; Cagnard, N; Rubio, MT; Hermine, O; Zavala, F				Korniotis, Sarantis; D'Aveni, Maud; Hergalant, Sebastien; Letscher, Helene; Tejerina, Emmanuel; Gastineau, Pauline; Agbogan, Viviane A.; Gras, Christophe; Fouquet, Guillemette; Rossignol, Julien; Chevre, Jean-Claude; Cagnard, Nicolas; Rubio, Marie-Therese; Hermine, Olivier; Zavala, Flora			Mobilized Multipotent Hematopoietic Progenitors Stabilize and Expand Regulatory T Cells to Protect Against Autoimmune Encephalomyelitis	FRONTIERS IN IMMUNOLOGY			English	Article						transcriptome; multiple sclerosis; IL-1 beta; expansion; stability; Tregs; mobilization; multipotent hematopoietic progenitors	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BONE-MARROW; GM-CSF; STEM; TRANSPLANTATION; THERAPY; HOMEOSTASIS; IL-1; GENERATION; IL-1-BETA	Achieving immunoregulation via in vivo expansion of Foxp3(+) regulatory CD4(+) T cells (Treg) remains challenging. We have shown that mobilization confers to multipotent hematopoietic progenitors (MPPs) the capacity to enhance Treg proliferation. Transcriptomic analysis of Tregs co-cultured with MPPs revealed enhanced expression of genes stabilizing the suppressive function of Tregs as well as the activation of IL-1 beta-driven pathways. Adoptive transfer of only 25,000 MPPs effectively reduced the development of experimental autoimmune encephalomyelitis (EAE), a pre-clinical model for multiple sclerosis (MS). Production of the pathogenic cytokines IL-17 and GM-CSF by spinal cord-derived CD4(+) T-cells in MPP-protected recipients was reduced while Treg expansion was enhanced. Treg depletion once protection by MPPs was established, triggered disease relapse to the same level as in EAE mice without MPP injection. The key role of IL-1 beta was further confirmed in vivo by the lack of protection against EAE in recipients of IL-1 beta-deficient MPPs. Mobilized MPPs may thus be worth considering for cell therapy of MS either per se or for enrichment of HSC grafts in autologous bone marrow transplantation already implemented in patients with severe refractory multiple sclerosis.	[Korniotis, Sarantis; Letscher, Helene; Tejerina, Emmanuel; Gastineau, Pauline; Agbogan, Viviane A.; Gras, Christophe; Zavala, Flora] Univ Paris, CNRS, Inst Necker Enfants Malades INEM, INSERM,UMR 8253,U1151, Paris, France; [D'Aveni, Maud; Fouquet, Guillemette; Rossignol, Julien; Hermine, Olivier] Univ Paris, Inst Imagine Lab Cellular & Mol Mech Hematol Diso, INSERM, UMR 1163, Paris, France; [D'Aveni, Maud; Rubio, Marie-Therese] Univ Lorraine, IMoPA, UMR 7365, Vandoeuvre Les Nancy, France; [D'Aveni, Maud; Rubio, Marie-Therese] Univ Lorraine, CHRU Nancy, Hematol Dept, Nancy, France; [Hergalant, Sebastien; Chevre, Jean-Claude] Univ Lorraine, INSERM, NGERE, U1256, Vandoeuvre Les Nancy, France; [Cagnard, Nicolas] Univ Paris, US 024 SFR Necker, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine; CHU de Nancy; Universite de Lorraine; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; UDICE-French Research Universities; Universite Paris Cite	Zavala, F (corresponding author), Univ Paris, CNRS, Inst Necker Enfants Malades INEM, INSERM,UMR 8253,U1151, Paris, France.	flora.zavala@inserm.fr	Hergalant, Sébastien/G-8129-2018; Hermine, Olivier/Q-7072-2018	Hergalant, Sébastien/0000-0001-8456-7992; Tejerina, Emmanuel/0000-0001-8673-1493; Zavala, Flora/0000-0002-2338-6802	CNRS; INSERM; Fondation pour la Recherche sur la Sclerose en Plaques (ARSEP); The Secular Society (TSS); Domaine d'Interet Majeur Biotherapies fellowship from Region Ile de France; ARSEP fellowship; Greek State Scholarship (IKY)	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Fondation pour la Recherche sur la Sclerose en Plaques (ARSEP); The Secular Society (TSS); Domaine d'Interet Majeur Biotherapies fellowship from Region Ile de France; ARSEP fellowship; Greek State Scholarship (IKY)	FZ was supported by core funding fromCNRS and INSERM and by grants received from Fondation pour la Recherche sur la Sclerose en Plaques (ARSEP) and from The Secular Society (TSS). SK and HL were supported by a Domaine d'Interet Majeur Biotherapies fellowship from Region Ile de France. SK was further supported by an ARSEP fellowship and Greek State Scholarship (IKY). VA was supported by a fellowship from The Secular Society (TSS).	Askenase MH, 2015, IMMUNITY, V42, P1130, DOI 10.1016/j.immuni.2015.05.011; Badovinac V, 1998, J NEUROIMMUNOL, V85, P87, DOI 10.1016/S0165-5728(98)00020-4; Bhattacharya P, 2011, J LEUKOCYTE BIOL, V89, P235, DOI 10.1189/jlb.0310154; Brinster C, 2008, J LEUKOCYTE BIOL, V84, P480, DOI 10.1189/jlb.0208085; Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795; Chavakis T, 2019, NAT IMMUNOL, V20, P802, DOI 10.1038/s41590-019-0402-5; Chen CI, 2016, CLIN IMMUNOL, V162, P9, DOI 10.1016/j.clim.2015.10.007; Chougnet CA, 2011, J IMMUNOL, V186, P156, DOI 10.4049/jimmunol.1001505; Cirovic B, 2020, CELL HOST MICROBE, V28, P322, DOI 10.1016/j.chom.2020.05.014; de Jong BA, 2002, J NEUROIMMUNOL, V126, P172, DOI 10.1016/S0165-5728(02)00056-5; Dias S, 2017, IMMUNITY, V46, P78, DOI 10.1016/j.immuni.2016.12.017; DiPersio JF, 2009, BLOOD, V113, P5720, DOI 10.1182/blood-2008-08-174946; Durai R, 2007, INT J ONCOL, V30, P883; Ferreira LMR, 2019, NAT REV DRUG DISCOV, V18, P749, DOI 10.1038/s41573-019-0041-4; Ganesh BB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021949; Garg G, 2019, CELL REP, V26, P1854, DOI 10.1016/j.celrep.2019.01.070; Goschl L, 2019, SEMIN IMMUNOPATHOL, V41, P301, DOI 10.1007/s00281-019-00741-8; Huitinga I, 2000, J NEUROENDOCRINOL, V12, P1186, DOI 10.1046/j.1365-2826.2000.00574.x; Kared H, 2008, BLOOD, V112, P2575, DOI 10.1182/blood-2008-02-140681; Kared H, 2006, IMMUNITY, V25, P823, DOI 10.1016/j.immuni.2006.09.008; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Korniotis S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12134; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Lataillade JJ, 2005, J LEUKOCYTE BIOL, V77, P634, DOI 10.1189/jlb.0504273; Lin CC, 2017, J IMMUNOL, V198, P4553, DOI 10.4049/jimmunol.1700263; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lutterotti A, 2018, CURR OPIN NEUROL, V31, P263, DOI 10.1097/WCO.0000000000000560; Mancardi G, 2018, MULT SCLER J, V24, P245, DOI 10.1177/1352458517742532; Mandolesi G, 2013, J NEUROSCI, V33, P12105, DOI 10.1523/JNEUROSCI.5369-12.2013; Mariottini A, 2020, BIODRUGS, V34, P307, DOI 10.1007/s40259-020-00414-1; Massey JC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00410; Montandon R, 2013, P NATL ACAD SCI USA, V110, pE2199, DOI 10.1073/pnas.1222446110; Mufazalov IA, 2017, EMBO J, V36, P102, DOI 10.15252/embj.201694615; Muraro PA, 2017, NAT REV NEUROL, V13, P391, DOI 10.1038/nrneurol.2017.81; Nash RA, 2003, BLOOD, V102, P2364, DOI 10.1182/blood-2002-12-3908; Openshaw H, 2000, NEUROLOGY, V54, P2147, DOI 10.1212/WNL.54.11.2147; Pare A, 2017, BRAIN BEHAV IMMUN, V62, P1, DOI 10.1016/j.bbi.2016.07.146; Pietras EM, 2015, CELL STEM CELL, V17, P35, DOI 10.1016/j.stem.2015.05.003; Price JG, 2015, NAT IMMUNOL, V16, P1060, DOI 10.1038/ni.3270; Prins M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083835; Ragonnaud E, 2019, CANCER RES, V79, P5826, DOI 10.1158/0008-5472.CAN-19-1058; Ronchi F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11541; Rumore-Maton B, 2008, CLIN DEV IMMUNOL, DOI 10.1155/2008/769795; Schiffenbauer J, 2000, CLIN IMMUNOL, V95, P117, DOI 10.1006/clim.2000.4851; Sekiya T, 2018, CELL REP, V24, P1627, DOI 10.1016/j.celrep.2018.07.008; Tahvildari M, 2019, J IMMUNOL, V203, P2749, DOI 10.4049/jimmunol.1900733; Tang QZ, 2012, CURR OPIN ORGAN TRAN, V17, P349, DOI 10.1097/MOT.0b013e328355a992; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Zavala F, 2002, J IMMUNOL, V168, P2011, DOI 10.4049/jimmunol.168.4.2011; Zhao JL, 2014, CELL STEM CELL, V14, P445, DOI 10.1016/j.stem.2014.01.007	51	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 23	2020	11								607175	10.3389/fimmu.2020.607175	http://dx.doi.org/10.3389/fimmu.2020.607175			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PP6HB	33424854	gold, Green Published			2022-12-18	WOS:000605960400001
J	Immler, R; Lange-Sperandio, B; Steffen, T; Beck, H; Rohwedder, I; Roth, J; Napoli, M; Hupel, G; Pfister, F; Popper, B; Uhl, B; Mannell, H; Reichel, CA; Vielhauer, V; Scherberich, J; Sperandio, M; Pruenster, M				Immler, Roland; Lange-Sperandio, Barbel; Steffen, Tobias; Beck, Heike; Rohwedder, Ina; Roth, Jonas; Napoli, Matteo; Hupel, Georg; Pfister, Frederik; Popper, Bastian; Uhl, Bernd; Mannell, Hanna; Reichel, Christoph A.; Vielhauer, Volker; Scherberich, Jurgen; Sperandio, Markus; Pruenster, Monika			Extratubular Polymerized Uromodulin Induces Leukocyte Recruitment and Inflammation In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						uromodulin; damage associated molecular pattern (DAMP); inflammation; leukocyte recruitment; kidney disease	TAMM-HORSFALL PROTEIN; THICK ASCENDING LIMBS; NEUTROPHIL; GLYCOPROTEIN; ACTIVATION; INJURY; CELLS; IDENTIFICATION; NEPHROPATHY; RECEPTORS	Uromodulin (UMOD) is produced and secreted by tubular epithelial cells. Secreted UMOD polymerizes (pUMOD) in the tubular lumen, where it regulates salt transport and protects the kidney from bacteria and stone formation. Under various pathological conditions, pUMOD accumulates within the tubular lumen and reaches extratubular sites where it may interact with renal interstitial cells. Here, we investigated the potential of extratubular pUMOD to act as a damage associated molecular pattern (DAMP) molecule thereby creating local inflammation. We found that intrascrotal and intraperitoneal injection of pUMOD induced leukocyte recruitment in vivo and led to TNF-alpha secretion by F4/80 positive macrophages. Additionally, pUMOD directly affected vascular permeability and increased neutrophil extravasation independent of macrophage-released TNF-alpha. Interestingly, pUMOD displayed no chemotactic properties on neutrophils, did not directly activate beta 2 integrins and did not upregulate adhesion molecules on endothelial cells. In obstructed neonatal murine kidneys, we observed extratubular UMOD accumulation in the renal interstitium with tubular atrophy and leukocyte infiltrates. Finally, we found extratubular UMOD deposits associated with peritubular leukocyte infiltration in kidneys from patients with inflammatory kidney diseases. Taken together, we identified extratubular pUMOD as a strong inducer of leukocyte recruitment, underlining its critical role in mounting an inflammatory response in various kidneys pathologies.	[Immler, Roland; Steffen, Tobias; Beck, Heike; Rohwedder, Ina; Roth, Jonas; Napoli, Matteo; Hupel, Georg; Uhl, Bernd; Mannell, Hanna; Reichel, Christoph A.; Sperandio, Markus; Pruenster, Monika] Ludwig Maximilians Univ Munchen, Inst Cardiovasc Physiol & Pathophysiol, Walter Brendel Ctr Expt Med, Biomed Ctr, Planegg Martinsried, Germany; [Lange-Sperandio, Barbel] Ludwig Maximilians Univ Munchen, Univ Hosp, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany; [Pfister, Frederik] Friedrich Alexander Univ Erlangen Nurnberg, Inst Pathol, Dept Nephropathol, Erlangen, Germany; [Popper, Bastian] Ludwig Maximilians Univ Munchen, Biomed Ctr, Core Facil Anim Models, Planegg Martinsried, Germany; [Popper, Bastian] Tech Univ Munich, Sch Med, Inst Pathol, Munich, Germany; [Uhl, Bernd; Reichel, Christoph A.] Ludwig Maximilians Univ Munchen, Dept Otorhinolaryngol, Munich, Germany; [Vielhauer, Volker] Ludwig Maximilians Univ Munchen, Univ Hosp, Nephrol Zentrum, Med Klin & Poliklin 4, Munich, Germany; [Scherberich, Jurgen] Ludwig Maximilians Univ Munchen, Teaching Hosp, Klinikum Harlaching, Munich, Germany	University of Munich; University of Munich; University of Erlangen Nuremberg; University of Munich; Technical University of Munich; University of Munich; University of Munich; Munchen Klinik; University of Munich	Pruenster, M (corresponding author), Ludwig Maximilians Univ Munchen, Inst Cardiovasc Physiol & Pathophysiol, Walter Brendel Ctr Expt Med, Biomed Ctr, Planegg Martinsried, Germany.	monika.pruenster@med.uni-muenchen.de	Mannell, Hanna/AAD-4282-2020; Immler, Roland/GRF-6232-2022	Immler, Roland/0000-0002-4086-7528; Napoli, Matteo/0000-0002-8197-9374; Popper, Bastian/0000-0003-1517-695X; Sperandio, Markus/0000-0002-7689-3613; Uhl, Bernd/0000-0002-2615-0803	German Research Foundation (DFG) [SFB914, La 1257/5-1]; FoFoLe-Program of the Medical Faculty, LMU Munich	German Research Foundation (DFG)(German Research Foundation (DFG)); FoFoLe-Program of the Medical Faculty, LMU Munich	This work was supported by the German Research Foundation (DFG) collaborative research grant SFB914, projects B01 (MS), B03 (CAR), and B11 (MP), DFG La 1257/5-1 (BL-S) and by the FoFoLe-Program of the Medical Faculty, LMU Munich (MP and MS).	Bleyer AJ, 2017, ADV CHRONIC KIDNEY D, V24, P86, DOI 10.1053/j.ackd.2016.11.012; Darisipudi MN, 2012, J AM SOC NEPHROL, V23, P1783, DOI 10.1681/ASN.2012040338; Dayang EZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01169; Delgado GE, 2017, J AM SOC NEPHROL, V28, P2201, DOI 10.1681/ASN.2016111162; Devuyst O, 2017, NAT REV NEPHROL, V13, P525, DOI 10.1038/nrneph.2017.101; Di A, 2017, J CELL SCI, V130, P735, DOI 10.1242/jcs.196014; Eckardt KU, 2015, KIDNEY INT, V88, P676, DOI 10.1038/ki.2015.28; Ekici AB, 2014, KIDNEY INT, V86, P589, DOI 10.1038/ki.2014.72; El-Achkar TM, 2013, AM J PHYSIOL-RENAL, V304, pF1066, DOI 10.1152/ajprenal.00543.2012; El-Achkar TM, 2012, AM J KIDNEY DIS, V59, P452, DOI 10.1053/j.ajkd.2011.10.054; El-Achkar TM, 2011, AM J PHYSIOL-RENAL, V300, pF999, DOI 10.1152/ajprenal.00621.2010; FASTH AL, 1988, CLIN IMMUNOL IMMUNOP, V47, P47, DOI 10.1016/0090-1229(88)90144-4; Garimella PS, 2017, AM J KIDNEY DIS, V69, P744, DOI 10.1053/j.ajkd.2016.08.022; Gasparitsch M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226675; Gasparitsch M, 2013, KIDNEY INT, V84, P911, DOI 10.1038/ki.2013.171; Hecquet CM, 2010, ADV EXP MED BIOL, V661, P155, DOI 10.1007/978-1-60761-500-2_10; Hogg N, 2011, NAT REV IMMUNOL, V11, P416, DOI 10.1038/nri2986; HORTON JK, 1990, KIDNEY INT, V37, P717, DOI 10.1038/ki.1990.38; HUANG ZQ, 1993, J CLIN INVEST, V92, P2975, DOI 10.1172/JCI116920; Hutchison CA, 2012, NAT REV NEPHROL, V8, P43, DOI 10.1038/nrneph.2011.168; Immler R, 2020, BIORXIV, DOI 10.1101/2020.07.18.206508; Immler R, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12964; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jennings P, 2007, J AM SOC NEPHROL, V18, P264, DOI 10.1681/ASN.2006020158; Kraus D, 2017, J AM SOC NEPHROL, V28, P1955, DOI 10.1681/ASN.2017040447; Kreft B, 2002, INFECT IMMUN, V70, P2650, DOI 10.1128/IAI.70.5.2650-2656.2002; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; LaFavers KA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw3639; Lange-Sperandio B, 2006, KIDNEY INT, V69, P81, DOI 10.1038/sj.ki.5000017; Leiherer A, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005798; Liu Y, 2010, AM J PHYSIOL-RENAL, V299, pF469, DOI 10.1152/ajprenal.00243.2010; Maydan O, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13654; Micanovic R, 2020, NEPHROL DIAL TRANSPL, V35, P33, DOI 10.1093/ndt/gfy394; Micanovic R, 2018, J AM SOC NEPHROL, V29, P841, DOI 10.1681/ASN.2017040409; Micanovic R, 2015, J AM SOC NEPHROL, V26, P2172, DOI 10.1681/ASN.2014070664; Mo L, 2004, KIDNEY INT, V66, P1159, DOI 10.1111/j.1523-1755.2004.00867.x; Mo L, 2004, AM J PHYSIOL-RENAL, V286, pF795, DOI 10.1152/ajprenal.00357.2003; Mutig K, 2011, J BIOL CHEM, V286, P30200, DOI 10.1074/jbc.M111.222968; Nie MZ, 2018, J BIOL CHEM, V293, P16488, DOI 10.1074/jbc.RA118.003950; Nussbaum C, 2013, J LEUKOCYTE BIOL, V93, P175, DOI 10.1189/jlb.0912468; Pak J, 2001, J BIOL CHEM, V276, P9924, DOI 10.1074/jbc.M008610200; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; Popper B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55079-w; Praetner M, 2018, ARTERIOSCL THROM VAS, V38, P829, DOI 10.1161/ATVBAHA.117.309760; Pruenster M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7915; Rampoldi L, 2003, HUM MOL GENET, V12, P3369, DOI 10.1093/hmg/ddg353; Rampoldi L, 2011, KIDNEY INT, V80, P338, DOI 10.1038/ki.2011.134; Reindl J, 2019, CLIN KIDNEY J, V12, P172, DOI 10.1093/ckj/sfy094; Renigunta A, 2011, J BIOL CHEM, V286, P2224, DOI 10.1074/jbc.M110.149880; Saemann MD, 2005, J CLIN INVEST, V115, P468, DOI 10.1172/JCI200522720; Santambrogio S, 2008, BIOCHEM BIOPH RES CO, V370, P410, DOI 10.1016/j.bbrc.2008.03.099; Scherberich JE, 2018, NEPHROL DIAL TRANSPL, V33, P284, DOI 10.1093/ndt/gfw422; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmid M, 2010, CELL PHYSIOL BIOCHEM, V26, P311, DOI 10.1159/000320554; Schmidt S, 2013, MOL IMMUNOL, V55, P49, DOI 10.1016/j.molimm.2012.11.006; Serafini-Cessi F, 2005, GLYCOCONJUGATE J, V22, P383, DOI 10.1007/s10719-005-2142-z; Siao SC, 2011, MOLECULES, V16, P2119, DOI 10.3390/molecules16032119; Sperandio M, 2006, METHOD ENZYMOL, V416, P346, DOI 10.1016/S0076-6879(06)16023-1; Su SJ, 1997, J IMMUNOL, V158, P3449; THOMAS DBL, 1993, KIDNEY INT, V44, P423, DOI 10.1038/ki.1993.260; Trudu M, 2013, NAT MED, V19, P1655, DOI 10.1038/nm.3384; Uhl B, 2016, BLOOD, V128, P2327, DOI 10.1182/blood-2016-05-718999; Vielhauer V, 2009, AM J PATHOL, V175, P119, DOI 10.2353/ajpath.2009.080590; Wyczanska M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581300	64	2	3	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2020	11								588245	10.3389/fimmu.2020.588245	http://dx.doi.org/10.3389/fimmu.2020.588245			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PN6UC	33414784	Green Submitted, Green Published, Green Accepted, gold			2022-12-18	WOS:000604610900001
J	Yamazaki, T; Biswas, M; Kosugi, K; Nagashima, M; Inui, M; Tomono, S; Takagi, H; Ichimonji, I; Nagaoka, F; Ainai, A; Hasegawa, H; Chiba, J; Akashi-Takamura, S				Yamazaki, Tatsuya; Biswas, Mrityunjoy; Kosugi, Kouyu; Nagashima, Maria; Inui, Masanori; Tomono, Susumu; Takagi, Hidekazu; Ichimonji, Isao; Nagaoka, Fumiaki; Ainai, Akira; Hasegawa, Hideki; Chiba, Joe; Akashi-Takamura, Sachiko			A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza	FRONTIERS IN IMMUNOLOGY			English	Article						antibody gene-vector delivery; adjuvant; RP105; DNA immunization; agonistic antibody; targeting antigen to B cells; cell membrane; influenza	RAT MOUSE HYBRIDOMAS; B-CELLS; VIRUS INFECTION; MONOCLONAL-ANTIBODIES; RP105/MD-1 COMPLEX; CROSS-PROTECTION; NUDE-MICE; CD20 LOSS; MOLECULE; MD-1	Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (alpha RP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (alpha RP105-TM), which could enable the anti-RP105 mAb to link the antigen via the cell membrane. We confirmed the expression of alpha RP105-TM and the antigen hemagglutinin, which is a membrane protein of the influenza virus, on the same cell. We also found that alpha RP105-TM could activate splenic B cells, including both mature and immature cells, depending on the cell surface RP105 in vitro. To evaluate the adjuvanticity of alpha RP105-TM, we conducted DNA immunization in mice with the plasmids encoding alpha RP105-TM and hemagglutinin, followed by challenge with an infection of a lethal dose of an influenza virus. We then obtained partially but significantly hemagglutinin-specific antibodies and observed protective effects against a lethal dose of influenza virus infection. The current alpha RP105-TM might provide adjuvanticity for a vaccine via a simple preparation of the expression plasmids encoding alpha RP105-TM and of that encoding the target antigen.	[Yamazaki, Tatsuya; Biswas, Mrityunjoy; Inui, Masanori; Tomono, Susumu; Takagi, Hidekazu; Ichimonji, Isao; Nagaoka, Fumiaki; Akashi-Takamura, Sachiko] Aichi Med Univ, Dept Microbiol & Immunol, Sch Med, Nagakute, Aichi, Japan; [Kosugi, Kouyu; Nagashima, Maria; Chiba, Joe] Tokyo Univ Sci, Dept Biol Sci & Technol, Tokyo, Japan; [Ainai, Akira; Hasegawa, Hideki] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan	Aichi Medical University; Tokyo University of Science; National Institute of Infectious Diseases (NIID)	Yamazaki, T; Akashi-Takamura, S (corresponding author), Aichi Med Univ, Dept Microbiol & Immunol, Sch Med, Nagakute, Aichi, Japan.	yamazaki13@aichi-med-u.ac.jp; sachiko@aichi-med-u.ac.jp	Hasegawa, Hideki/C-7978-2014; Yamazaki, Tatsuya/AAE-2042-2021		JSPS KAKENHI [19K07491, 19K08500]; Takeda Science Foundation; Daiko Foundation; International Joint Usage/Research Center, the Institute of Medical Science, University of Tokyo [2019-3062]; Aichi Medical University	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Daiko Foundation(Daiko Foundation); International Joint Usage/Research Center, the Institute of Medical Science, University of Tokyo; Aichi Medical University	This review was funded by JSPS KAKENHI Grant Number 19K07491 (to TY), 19K08500 (to SA-T), Takeda Science Foundation (to TY), Daiko Foundation (to SA-T), a grant from the International Joint Usage/Research Center, the Institute of Medical Science, University of Tokyo (ID. no. 2019-3062), and a grant from Unit support, Aichi Medical University (to TY and SA-T).	Ainai A, 2010, J MED VIROL, V82, P476, DOI 10.1002/jmv.21694; Ainai Akira, 2006, Human Antibodies, V15, P139; Allende ML, 2010, J EXP MED, V207, P1113, DOI 10.1084/jem.20092210; Alvarez-Lajonchere L, 2009, HUM VACCINES, V5, P568, DOI 10.4161/hv.5.8.8572; Asanuma H, 2008, BIOCHEM BIOPH RES CO, V366, P445, DOI 10.1016/j.bbrc.2007.11.135; Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660; Beum PV, 2011, J IMMUNOL, V187, P3438, DOI 10.4049/jimmunol.1101189; Bhatia S, 2020, CLIN CANCER RES, V26, P598, DOI 10.1158/1078-0432.CCR-19-0972; Biswas M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030424; Brown DV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172791; Campana S, 2015, IMMUNOL LETT, V168, P349, DOI 10.1016/j.imlet.2015.11.002; Carter PJ, 2018, NAT REV DRUG DISCOV, V17, P197, DOI 10.1038/nrd.2017.227; Chaplin JW, 2013, J EXP MED, V210, P2135, DOI 10.1084/jem.20130188; Chaplin JW, 2011, J IMMUNOL, V187, P4199, DOI 10.4049/jimmunol.1100198; Chen Z, 2000, VACCINE, V18, P3214, DOI 10.1016/S0264-410X(00)00149-3; DANKO I, 1994, VACCINE, V12, P1499, DOI 10.1016/0264-410X(94)90072-8; De Groot AS, 2007, TRENDS IMMUNOL, V28, P482, DOI 10.1016/j.it.2007.07.011; Divanovic S, 2005, NAT IMMUNOL, V6, P571, DOI 10.1038/ni1198; Ebadat S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185967; Erdo-Bonyar S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246152; Fang JM, 2005, NAT BIOTECHNOL, V23, P584, DOI 10.1038/nbt1087; Flingai S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12616; Fujimoto A, 2012, J IMMUNOL METHODS, V375, P243, DOI 10.1016/j.jim.2011.11.007; Gilljam KM, 2020, J IMMUNOL, V204, P2133, DOI 10.4049/jimmunol.1901131; Ginn SL, 2018, J GENE MED, V20, DOI 10.1002/jgm.3015; Giordano D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006743; Ho SCL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063247; Huang Y, 2020, J VIROL, V94, DOI 10.1128/JVI.01432-19; Jennings RT, 2016, INT IMMUNOL, V28, P503, DOI 10.1093/intimm/dxw031; Johansson C, 2006, MICROB PATHOGENESIS, V41, P49, DOI 10.1016/j.micpath.2006.03.004; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; Kitaguchi K, 2005, INT J MOL MED, V16, P683; Kobayashi N, 2004, J GENE MED, V6, P584, DOI 10.1002/jgm.541; Lesinski GB, 2001, J MICROBIOL METH, V47, P135, DOI 10.1016/S0167-7012(01)00290-1; Li GD, 2019, NAT METHODS, V16, P183, DOI 10.1038/s41592-018-0305-7; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Liu SY, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.27; Lopes A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1154-7; Mackay F, 2010, IMMUNOL REV, V237, P205, DOI 10.1111/j.1600-065X.2010.00944.x; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; Matsumoto A, 2009, J GASTROEN HEPATOL, V24, P262, DOI 10.1111/j.1440-1746.2008.05583.x; MISRA DN, 1986, METHOD ENZYMOL, V121, P386; MIYAKE K, 1995, J IMMUNOL, V154, P3333; Miyake K, 1998, J IMMUNOL, V161, P1348; MIYAKE K, 1994, J EXP MED, V180, P1217, DOI 10.1084/jem.180.4.1217; Moyer TJ, 2020, NAT MED, V26, P430, DOI 10.1038/s41591-020-0753-3; Nagai Y, 2005, J IMMUNOL, V174, P7043, DOI 10.4049/jimmunol.174.11.7043; Nagai Y, 2002, BLOOD, V99, P1699, DOI 10.1182/blood.V99.5.1699; Nagai Y, 2012, INT IMMUNOL, V24, P389, DOI 10.1093/intimm/dxs040; Nakayama M, 1986, Nihon Ika Daigaku Zasshi, V53, P534; NOEMAN SA, 1982, J IMMUNOL METHODS, V55, P319, DOI 10.1016/0022-1759(82)90091-6; Nunes-Alves C., 2016, NAT IMMUNOL, V17, pS5, DOI [10.1038/ni.3600, DOI 10.1038/NI.3600]; O'Neill L.A., 2000, SCI STKE, V2000, pRE1, DOI DOI 10.1126/STKE.2000.44.RE1; Qin S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1091-2; REIK LM, 1987, J IMMUNOL METHODS, V100, P123, DOI 10.1016/0022-1759(87)90180-3; Roe K, 2019, J IMMUNOL, V203, P1715, DOI 10.4049/jimmunol.1900549; Samitas K, 2010, ARCH IMMUNOL THER EX, V58, P209, DOI 10.1007/s00005-010-0073-2; Schultz TE, 2017, J LEUKOCYTE BIOL, V101, P183, DOI 10.1189/jlb.2VMR1215-582R; Shen CG, 2019, THERANOSTICS, V9, P210, DOI 10.7150/thno.28434; Skaricic D, 2008, VIROLOGY, V378, P79, DOI 10.1016/j.virol.2008.04.016; Takatsuka S, 2011, J PHARMACOL TOX MET, V63, P250, DOI 10.1016/j.vascn.2010.12.003; TAMURA SI, 1992, J IMMUNOL, V149, P981; Wennerberg E, 2020, METHOD ENZYMOL, V635, P139, DOI 10.1016/bs.mie.2020.01.011; Williams ME, 2006, J IMMUNOL, V177, P7435, DOI 10.4049/jimmunol.177.10.7435; Yamazaki T, 2019, J BIOL CHEM, V294, P6659, DOI 10.1074/jbc.RA118.006375; Yamazaki T, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030035; Yamazaki T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00047; Yamazaki T, 2011, JPN J INFECT DIS, V64, P40; Zhang G, 2000, GENE THER, V7, P1344, DOI 10.1038/sj.gt.3301229; Zhou Y, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02289-w	72	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2020	11								606518	10.3389/fimmu.2020.606518	http://dx.doi.org/10.3389/fimmu.2020.606518			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PN6PF	33414788	gold, Green Published			2022-12-18	WOS:000604598200001
J	Horwitz, DA; Liu, AJ; Bickerton, S; Castaldo, G; Matarese, G; Fahmy, TM; La Cava, A				Horwitz, David A.; Liu, Aijing; Bickerton, Sean; Castaldo, Giuseppe; Matarese, Giuseppe; Fahmy, Tarek M.; La Cava, Antonio			Anti-CD2 Antibody-Coated Nanoparticles Containing IL-2 Induce NK Cells That Protect Lupus Mice via a TGF-beta-Dependent Mechanism	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmunity; systemic lupus erythematosus; NK cells; immune regulation; nanoparticles; immunotherapy; cytokines	NATURAL-KILLER-CELLS; GROWTH-FACTOR-BETA; CD8(+) T-CELLS; SUPPRESSION; GENERATION	We recently reported that the treatment with nanoparticles (NPs) loaded with tolerogenic cytokines suppressed the manifestations of lupus-like disease induced by the transfer of donor CD4(+) T cells from DBA/2 mice into (C57BL/6 x DBA/2)F-1 (BDF1) mice. Although the protective effects were ascribed to the induction of adaptive CD4(+) and CD8(+) T regulatory cells, the results suggested that another population of immune cells could be involved. Here we report that NK cells critically contribute to the protection from lupus-like disease conferred by NPs to BDF1 mice, and that this effect is TGF-beta-dependent.	[Horwitz, David A.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA; [Horwitz, David A.] Gen Nanotherapeut LLC, Santa Monica, CA 90402 USA; [Liu, Aijing; La Cava, Antonio] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; [Bickerton, Sean; Fahmy, Tarek M.] Yale Univ, Dept Biomed Engn, New Haven, CT USA; [Castaldo, Giuseppe; Matarese, Giuseppe] Federico II Univ Naples, Dipartimento Med Mol & Biotecnol Med, Naples, Italy; [Matarese, Giuseppe] CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy; [Fahmy, Tarek M.] Yale Univ, Dept Immunobiol, New Haven, CT USA; [Liu, Aijing] Hebei Med Univ, Dept Rheumatol & Immunol, Hosp 2, Shijiazhuang, Hebei, Peoples R China	University of Southern California; University of California System; University of California Los Angeles; Yale University; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Yale University	Horwitz, DA (corresponding author), Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA.; Horwitz, DA (corresponding author), Gen Nanotherapeut LLC, Santa Monica, CA 90402 USA.; La Cava, A (corresponding author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.	dhorwitz@usc.edu; alacava@mednet.ucla.edu	Matarese, Giuseppe/AAO-4077-2021; Castaldo, Giuseppe/AAC-6782-2022	Matarese, Giuseppe/0000-0001-9429-0616; Castaldo, Giuseppe/0000-0002-4036-0874	NIH [HD97531, AI154935]; Fondazione Italiana Sclerosi Multipla [FISM 2016/R/18, 2018/S/5]; Progetti di Rilevante Interesse Nazionale (PRIN) [2017 K55HLC 001]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fondazione Italiana Sclerosi Multipla(Fondazione Italiana Sclerosi Multipla (FISM)); Progetti di Rilevante Interesse Nazionale (PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN))	Supported in by part by the NIH grants HD97531 and AI154935 to ALC. GM is funded by grants from Fondazione Italiana Sclerosi Multipla (FISM 2016/R/18 and 2018/S/5) and Progetti di Rilevante Interesse Nazionale (PRIN) 2017 K55HLC 001.	ABRUZZO LV, 1983, SCIENCE, V222, P581, DOI 10.1126/science.6685343; Abulaban KM, 2016, LUPUS, V25, P1012, DOI 10.1177/0961203316631629; Becker-Merok A, 2010, J RHEUMATOL, V37, P2039, DOI 10.3899/jrheum.100180; Chatila Talal A., 2008, V94, P16, DOI 10.1159/000154853; Deniz G, 2008, J IMMUNOL, V180, P850, DOI 10.4049/jimmunol.180.2.850; Dinesh R, 2011, GENES IMMUN, V12, P360, DOI 10.1038/gene.2011.4; Gray JD, 1998, J IMMUNOL, V160, P2248; GRAY JD, 1994, J EXP MED, V180, P1937, DOI 10.1084/jem.180.5.1937; HAFLER DA, 1988, J IMMUNOL, V141, P131; He J, 2016, NAT MED, V22, P991, DOI 10.1038/nm.4148; Horwitz DA, 1997, IMMUNOL TODAY, V18, P538, DOI 10.1016/S0167-5699(97)01149-3; Horwitz DA, 2019, TRENDS IMMUNOL, V40, P888, DOI 10.1016/j.it.2019.08.003; Horwitz DA, 2019, ARTHRITIS RHEUMATOL, V71, P632, DOI 10.1002/art.40773; Iikuni N, 2009, RECENT RES DEV RHEUM, P55; Katsiari CG, 2006, AUTOIMMUN REV, V5, P118, DOI 10.1016/j.autrev.2005.08.009; La Cava A, 2018, DUBOIS LUPUS ERYTHEM, P125; La Cava A, 2020, SYSTEMIC LUPUS ERYTH, P69; Li HS, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0421-1; Liang XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155534; Liu LL, 2016, CELL REP, V15, P1088, DOI 10.1016/j.celrep.2016.04.005; McArdel SL, 2016, CLIN IMMUNOL, V164, P10, DOI 10.1016/j.clim.2016.01.008; NABEL G, 1982, J EXP MED, V156, P658, DOI 10.1084/jem.156.2.658; Nishikado H, 2011, J IMMUNOL, V186, P5766, DOI 10.4049/jimmunol.1100370; Ohtsuka K, 1998, J IMMUNOL, V160, P2539; Orange JS, 2006, CLIN IMMUNOL, V118, P1, DOI 10.1016/j.clim.2005.10.011; Rigby MR, 2015, J CLIN INVEST, V125, P3285, DOI 10.1172/JCI81722; SHARPE AH, 1995, CURR OPIN IMMUNOL, V7, P389, DOI 10.1016/0952-7915(95)80115-4; Sobel ES, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3387; Xu AP, 2016, J IMMUNOL, V196, P3631, DOI 10.4049/jimmunol.1501740; Zhang C, 2006, CELL MOL IMMUNOL, V3, P241; Zhang L, 2009, J IMMUNOL, V183, P6346, DOI 10.4049/jimmunol.0901773	31	2	2	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2020	11								583338	10.3389/fimmu.2020.583338	http://dx.doi.org/10.3389/fimmu.2020.583338			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PL8ON	33391260	Green Published, gold			2022-12-18	WOS:000603374100001
J	Tran, LM; Thomson, AW				Tran, Lillian M.; Thomson, Angus W.			Detection and Monitoring of Regulatory Immune Cells Following Their Adoptive Transfer in Organ Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						cell therapy; adoptive transfer; cell tracking; regulatory T cell; mesenchymal stromal cell; regulatory myeloid cell; transplantation	TOLEROGENIC DENDRITIC CELLS; T-CELLS; ALLOGRAFT-REJECTION; SUPPRESSOR-CELLS; EXPRESSION; GENERATION; INFUSION; SURVIVAL; PERSISTENCE; TOLERANCE	Application of cell-based immunotherapy in organ transplantation to minimize the burden of immunosuppressive medication and promote allograft tolerance has expanded significantly over the past decade. Adoptively transferred regulatory immune cells prolong allograft survival and transplant tolerance in pre-clinical models. Many cell products are currently under investigation in early phase human clinical trials designed to assess feasibility and safety. Despite rapid advances in manufacturing practices, defining the appropriate protocol that will optimize in vivo conditions for tolerance induction remains a major challenge and depends heavily on understanding the fate, biodistribution, functional stability and longevity of the cell product after administration. This review focuses on in vivo detection and monitoring of various regulatory immune cell types administered for allograft tolerance induction in both pre-clinical animal models and early human clinical trials. We discuss the current status of various non-invasive methods for tracking regulatory cell products in the context of organ transplantation and implications for enhanced understanding of the therapeutic potential of cell-based therapy in the broad context of control of immune-mediated inflammatory disorders.	[Tran, Lillian M.; Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Surg, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15260 USA; [Thomson, Angus W.] Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Thomson, AW (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15260 USA.; Thomson, AW (corresponding author), Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA 15260 USA.	thomsonaw@upmc.edu			National Institutes of Health (NIH) [R01 AI118777, U01 AI 136779, U19 AI131453, T32 AI074490]; Burroughs Wellcome Fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund)	Work described in this article was supported in part by National Institutes of Health (NIH) grants R01 AI118777, U01 AI 136779, and U19 AI131453 to AT, and by an NIH institutional research training fellowship to LT (T32 AI074490). Additionally, the University of Pittsburgh holds a Physician-Scientist Institutional Award from the Burroughs Wellcome Fund, which supports LMT.	Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341; Alonso-Guallart P, 2019, AM J TRANSPLANT, V19, P2186, DOI 10.1111/ajt.15313; Anderson A, 2008, AM J TRANSPLANT, V8, P2252, DOI 10.1111/j.1600-6143.2008.02376.x; Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134; Boardman DA, 2017, AM J TRANSPLANT, V17, P931, DOI 10.1111/ajt.14185; Burrell BE, 2012, J IMMUNOL, V189, P4705, DOI 10.4049/jimmunol.1202027; Casiraghi F, 2012, AM J TRANSPLANT, V12, P2373, DOI 10.1111/j.1600-6143.2012.04115.x; Casiraghi F, 2008, J IMMUNOL, V181, P3933, DOI 10.4049/jimmunol.181.6.3933; Chandran S, 2017, AM J TRANSPLANT, V17, P2945, DOI 10.1111/ajt.14415; Cheng HY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203624; Dawson NAJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123672; de Kort H, 2012, TRANSPLANTATION, V94, P903, DOI 10.1097/TP.0b013e31826acd01; Divito SJ, 2010, BLOOD, V116, P2694, DOI 10.1182/blood-2009-10-251058; Dons EM, 2010, TRANSPLANTATION, V90, P811, DOI 10.1097/TP.0b013e3181ebf782; Du XX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01326; Dugast AS, 2008, J IMMUNOL, V180, P7898, DOI 10.4049/jimmunol.180.12.7898; Eun SC, 2013, TRANSPL P, V45, P1792, DOI 10.1016/j.transproceed.2013.01.021; Ezzelarab MB, 2016, AM J TRANSPLANT, V16, P1999, DOI 10.1111/ajt.13685; Ezzelarab MB, 2019, TRANSPL IMMUNOL, V56, DOI 10.1016/j.trim.2019.101225; Fu FM, 1996, TRANSPLANTATION, V62, P659, DOI 10.1097/00007890-199609150-00021; Furlan SN, 2020, BLOOD ADV, V4, P1594, DOI 10.1182/bloodadvances.2019001248; Golshayan D, 2007, BLOOD, V109, P827, DOI 10.1182/blood-2006-05-025460; Guo H, 2015, CELL IMMUNOL, V295, P19, DOI 10.1016/j.cellimm.2015.02.006; Hill M, 2011, AM J TRANSPLANT, V11, P2036, DOI 10.1111/j.1600-6143.2011.03651.x; Hoffmann SHL, 2019, THERANOSTICS, V9, P5869, DOI 10.7150/thno.33275; Huang H, 2010, J IMMUNOL, V185, P5003, DOI 10.4049/jimmunol.0903446; Hutchinson JA, 2017, TRANSPL INT, V30, P765, DOI 10.1111/tri.12988; Hutchinson JA, 2011, J IMMUNOL, V187, P2072, DOI 10.4049/jimmunol.1100762; Issa F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053331; Kendal AR, 2011, J EXP MED, V208, P2043, DOI 10.1084/jem.20110767; Lee HW, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1946585; Liu L, 2012, NANOMED-NANOTECHNOL, V8, P1345, DOI 10.1016/j.nano.2012.02.017; Ma AL, 2011, INT IMMUNOPHARMACOL, V11, P618, DOI 10.1016/j.intimp.2010.11.001; Macedo C, 2021, AM J TRANSPLANT, V21, P2372, DOI 10.1111/ajt.16393; Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132; Noyan F, 2017, AM J TRANSPLANT, V17, P917, DOI 10.1111/ajt.14175; Oo YH, 2019, JHEP REP, V1, P286, DOI 10.1016/j.jhepr.2019.08.001; Pan GH, 2016, ONCOTARGET, V7, P12089, DOI 10.18632/oncotarget.7725; Perico N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01359; Pierini A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92865; Podesta MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01287; Raker VK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00569; Rana J, 2020, CELL IMMUNOL, V356, DOI 10.1016/j.cellimm.2020.104193; Riquelme P, 2013, MOL THER, V21, P409, DOI 10.1038/mt.2012.168; Garcia MR, 2010, J CLIN INVEST, V120, P2486, DOI 10.1172/JCI41628; Romano M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00043; Rosborough BR, 2014, TRANSPLANTATION, V97, P367, DOI 10.1097/TP.0b013e3182a860de; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Sato K, 2003, IMMUNITY, V18, P367, DOI 10.1016/S1074-7613(03)00055-4; Sawitzki B, 2020, LANCET, V395, P1627, DOI 10.1016/S0140-6736(20)30167-7; Scalea JR, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00087; Scarfe L, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1076-x; Seng A, 2020, BLOOD ADV, V4, P1325, DOI 10.1182/bloodadvances.2019000965; Sharif-Paghaleh E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025857; Singh K, 2014, AM J TRANSPLANT, V14, P2691, DOI 10.1111/ajt.12934; Smyth LA, 2013, J IMMUNOL, V190, P4848, DOI 10.4049/jimmunol.1200870; Tan JM, 2012, JAMA-J AM MED ASSOC, V307, P1169, DOI 10.1001/jama.2012.316; Taner T, 2005, AM J TRANSPLANT, V5, P228, DOI 10.1046/j.1600-6143.2004.00673.x; Thomson AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00015; Wood KJ, 2012, NAT REV IMMUNOL, V12, P417, DOI 10.1038/nri3227; Xia GL, 2006, TRANSPLANTATION, V82, P1749, DOI 10.1097/01.tp.0000250731.44913.ee; Xia Meng Juan, 2014, J Evid Based Med, V7, P135, DOI 10.1111/jebm.12094; Zhang H, 2015, AM J TRANSPLANT, V15, P1253, DOI 10.1111/ajt.13113; Zhang N, 2009, IMMUNITY, V30, P458, DOI 10.1016/j.immuni.2008.12.022; Zhou YN, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5730674	65	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2020	11								614578	10.3389/fimmu.2020.614578	http://dx.doi.org/10.3389/fimmu.2020.614578			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PK7CA	33381125	gold, Green Published			2022-12-18	WOS:000602596900001
J	Veazey, JM; Eliseeva, SI; Hillman, SE; Stiles, K; Smyth, TR; Morrissey, CE; Tillotson, EJ; Topham, DJ; Chapman, TJ; Georas, SN				Veazey, Janelle M.; Eliseeva, Sophia, I; Hillman, Sara E.; Stiles, Kristie; Smyth, Timothy R.; Morrissey, Charlotte E.; Tillotson, Erika J.; Topham, Dave J.; Chapman, Timothy J.; Georas, Steve N.			Inhibiting Protein Kinase D Promotes Airway Epithelial Barrier Integrity in Mouse Models of Influenza A Virus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Airway epithelial barrier; innate immuity; Antiviral immune response; respiratory tract infections; Protein Kinase D	NF-KAPPA-B; FRONT-LINE; ACTIVATION; IMMUNITY; INNATE; PKD; SP1	Rationale Protein kinase D (PKD) is a serine/threonine kinase family that is involved in a wide array of signaling pathways. Although PKD has been implicated in immune responses, relatively little is known about the function of PKD in the lung or during viral infections. Objectives We investigated the hypothesis that PKD is involved in multiple aspects of host response to viral infection. Methods The selective PKD inhibitor CRT0010166 was administered to C57BL/6 mice prior to and during challenge with either inhaled double-stranded RNA or Influenza A Virus. PKD signaling pathways were investigated in human bronchial epithelial cells treated with CRT0010166, double-stranded RNA, and/or infected with Influenza A Virus. Measurements Total protein and albumin accumulation in the bronchoalveolar fluid was used to asses inside/out leak. Clearance of inhaled FITC-dextran out of the airspace was used to assess outside/in leak. Cytokines and neutrophils in bronchoalveolar lavage were assayed with ELISAs and cytospins respectively. Viral RNA level was assessed with RT-PCR and protein level assessed by ELISA. Main Results PKD inhibition prevented airway barrier dysfunction and pro-inflammatory cytokine release. Epithelial cells express PKD3, and PKD3 siRNA knock-down inhibited polyI:C induced cytokine production. Lung epithelial-specific deletion of PKD3 (CC10-Cre x PKD3-floxed mice) partially attenuated polyI:C-induced barrier disruption in vivo. Mechanistically, we found that PKD promoted cytokine mRNA transcription, not secretion, likely through activating the transcription factor Sp1. Finally, prophylactic CRT treatment of mice promoted barrier integrity during influenza virus infection and reduced viral burden. Conclusions Inhibiting PKD promotes barrier integrity, limit pathogenic cytokine levels, and restrict Influenza A Virus infection. Therefore, PKD is an attractive target for novel antiviral therapeutics.	[Veazey, Janelle M.; Topham, Dave J.; Georas, Steve N.] Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14627 USA; [Eliseeva, Sophia, I; Hillman, Sara E.; Stiles, Kristie; Georas, Steve N.] Univ Rochester, Dept Med Pulm & Crit Care, Rochester, NY 14627 USA; [Smyth, Timothy R.; Georas, Steve N.] Univ Rochester, Dept Environm Med, Rochester, NY 14627 USA; [Morrissey, Charlotte E.] Claremont Mckenna Coll, Dept Biochem, Claremont, CA 91711 USA; [Tillotson, Erika J.] Cornell Univ, Dept Biol, Ithaca, NY USA; [Chapman, Timothy J.] Rochester Reg Hlth, Ctr Infect Dis & Immunol, Rochester, NY USA	University of Rochester; University of Rochester; University of Rochester; Claremont Colleges; Claremont Graduate School; Claremont McKenna College; Cornell University	Georas, SN (corresponding author), Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14627 USA.; Georas, SN (corresponding author), Univ Rochester, Dept Med Pulm & Crit Care, Rochester, NY 14627 USA.; Georas, SN (corresponding author), Univ Rochester, Dept Environm Med, Rochester, NY 14627 USA.	Steve_Georas@urmc.rochester.edu		Chapman, Timothy/0000-0002-2337-2136; Veazey, Janelle/0000-0002-3061-0251	NIH/NHLBI [R01 HL12424, F31 HL14079501, T32 HL066988]; NIH/NIAID [T32AI007285]; NIH/NIEHS [T32 ES007026]	NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The project described was supported by Award Number R01 HL12424 from NIH/NHLBI, F31 HL14079501 from NIH/NHLBI, T32AI007285 from NIH/NIAID, T32 HL066988 from NIH/NHLBI, T32 ES007026 from NIH/NIEHS. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bottero V, 2009, VIROLOGY, V392, P34, DOI 10.1016/j.virol.2009.07.002; Chinnaswamy S, 2016, VIRAL IMMUNOL, V29, P49, DOI 10.1089/vim.2015.0076; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Doyle SL, 2013, J BIOL CHEM, V288, P25066, DOI 10.1074/jbc.M113.469122; Galani IE, 2017, IMMUNITY, V46, P875, DOI 10.1016/j.immuni.2017.04.025; Gan HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101983; Gan HC, 2013, J BIOL CHEM, V288, P37343, DOI 10.1074/jbc.M113.511527; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Guedan A, 2017, J VIROL, V91, DOI 10.1128/JVI.00217-17; Harikumar KB, 2010, MOL CANCER THER, V9, P1136, DOI 10.1158/1535-7163.MCT-09-1145; Ivison SM, 2007, J IMMUNOL, V178, P5735, DOI 10.4049/jimmunol.178.9.5735; Kim YI, 2010, J IMMUNOL, V184, P3145, DOI 10.4049/jimmunol.0903718; Lazear HM, 2015, IMMUNITY, V43, P15, DOI 10.1016/j.immuni.2015.07.001; Matthews SA, 2010, BIOCHEM J, V432, P153, DOI 10.1042/BJ20101188; Olayioye MA, 2013, CELL SIGNAL, V25, P1739, DOI 10.1016/j.cellsig.2013.04.010; Park JE, 2008, J IMMUNOL, V181, P2044, DOI 10.4049/jimmunol.181.3.2044; Park JE, 2009, J IMMUNOL, V182, P6316, DOI 10.4049/jimmunol.0804239; Pulendran B, 2015, CURR TOP MICROBIOL, V386, P23, DOI 10.1007/82_2014_405; Remillard-Labrosse G, 2009, TRAFFIC, V10, P1074, DOI 10.1111/j.1600-0854.2009.00939.x; Rezaee F, 2013, J VIROL, V87, P11088, DOI 10.1128/JVI.01573-13; Rezaee F, 2011, J ALLERGY CLIN IMMUN, V128, P1216, DOI 10.1016/j.jaci.2011.08.035; Roussel E, 2018, J VIROL, V92, DOI 10.1128/JVI.01486-18; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rozengurt E, 2011, PHYSIOLOGY, V26, P23, DOI 10.1152/physiol.00037.2010; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Simon DM, 2006, FASEB J, V20, P1507, DOI 10.1096/fj.05-5410fje; Steiner TS, 2010, CELL IMMUNOL, V264, P135, DOI 10.1016/j.cellimm.2010.05.012; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sumara G, 2009, CELL, V136, P235, DOI 10.1016/j.cell.2008.11.018; Sun YP, 2018, PROTEIN CELL, V9, P832, DOI 10.1007/s13238-017-0503-6; Upadhyay K, 2017, J IMMUNOL, V198, P4448, DOI 10.4049/jimmunol.1601089; Veazey JM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216056; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Xie LS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158865; Xing JJ, 2016, NAT IMMUNOL, V17, P1373, DOI 10.1038/ni.3580; Zou ZP, 2012, J CELL SCI, V125, P4800, DOI 10.1242/jcs.106542	36	2	2	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 14	2020	11								580401	10.3389/fimmu.2020.580401	http://dx.doi.org/10.3389/fimmu.2020.580401			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PK6ZO	33381112	gold, Green Published			2022-12-18	WOS:000602590500001
J	Kleinman, AJ; Xu, CL; Cottrell, ML; Sivanandham, R; Brocca-Cofano, E; Dunsmore, T; Kashuba, A; Pandrea, I; Apetrei, C				Kleinman, Adam J.; Xu, Cuiling; Cottrell, Mackenzie L.; Sivanandham, Ranjit; Brocca-Cofano, Egidio; Dunsmore, Tammy; Kashuba, Angela; Pandrea, Ivona; Apetrei, Cristian			Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques	FRONTIERS IN IMMUNOLOGY			English	Article						romidepsin; histone deacetylase inhibitors; latency reversing agents; human immunodeficiency virus; simian immunodeficiency virus; HIV latency; pharmacokinetics	CD4 T-CELLS; ANTIRETROVIRAL THERAPY; ISOFLURANE ANESTHESIA; DEPSIPEPTIDE FR901228; PERIPHERAL-BLOOD; LATENT INFECTION; VIRAL RESERVOIR; HIV-1 REMISSION; PERSISTENCE; VIREMIA	HIV/SIV persistence in latent reservoirs requires lifelong antiretroviral treatment and calls for effective cure strategies. Romidepsin (RMD), a histone deacetylase inhibitor, was reported to reactivate HIV/SIV from reservoirs in virus-suppressed individuals. We characterized in detail the pharmacokinetics and safety profile of RMD in three SIV-naive rhesus macaques which received two rounds of treatment. In plasma, RMD mean terminal half-life was 15.3 h. In comparison, RMD mean terminal half-life was much longer in tissues: 110 h in the lymph nodes (LNs) and 28 h in gastrointestinal tract. RMD administration was accompanied by transient liver and systemic toxicity. Isoflurane anesthesia induced near-immediate transient lymphopenia, which was further exacerbated and extended with the extensive immune modifications by RMD. The effect of RMD on circulating immune cells was complex: (i) slight increase in lymphocyte death rates; (ii) transient, robust increase in neutrophils; (iii) massive downregulation of lymphocyte surface markers; (iv) important migration of CD3(+) T cells to the gut and LNs; and (v) hindrance to CD8(+) T cell functionality, yet without reaching significance. Our results show that, in contrast to transient plasma concentrations, RMD has a long-term presence in tissues, with multiple immunomodulatory effects and minimal to moderate kidney, liver, and lymphocyte toxicities. As such, we concluded that RMD can be used for "shock and kill" approaches, preferentially in combination with other latency reversal agents or cytotoxic T lymphocyte boosting strategies with consideration taken for adverse effects.	[Kleinman, Adam J.; Xu, Cuiling; Sivanandham, Ranjit; Dunsmore, Tammy; Apetrei, Cristian] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA; [Xu, Cuiling; Sivanandham, Ranjit; Brocca-Cofano, Egidio; Dunsmore, Tammy; Pandrea, Ivona] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Cottrell, Mackenzie L.; Kashuba, Angela] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Pandrea, Ivona; Apetrei, Cristian] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15260 USA; [Pandrea, Ivona; Apetrei, Cristian] Univ Pittsburgh, Sch Publ Hlth, Dept Infect Dis & Immunol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Apetrei, C (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA.; Apetrei, C (corresponding author), Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15260 USA.; Apetrei, C (corresponding author), Univ Pittsburgh, Sch Publ Hlth, Dept Infect Dis & Immunol, Pittsburgh, PA 15260 USA.	apetreic@pitt.edu	Apetrei, Cristian/AAG-9032-2021; Sivanandham, Ranjit/AAF-1770-2020	Apetrei, Cristian/0000-0002-0322-7185; Sivanandham, Ranjit/0000-0001-7431-8415; Kleinman, Adam/0000-0001-6847-2440	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [R01 AI119346]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK113919, R01DK119936, RO1 HL117715, R01 HL123096]; National Heart, Lung and Blood Institute (NHLBI); NIAID; T32 grant Immunology of Infectious Diseases (IID) [AI060525]; T32 grant Pitt AIDS Research Training (PART) grant [AI065380]	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Heart, Lung and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); T32 grant Immunology of Infectious Diseases (IID); T32 grant Pitt AIDS Research Training (PART) grant	This work was funded by grant R01 AI119346 (CA) from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and also from grants R01DK113919 (IP/CA), R01DK119936 (CA), RO1 HL117715 (IP), R01 HL123096 (IP) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Heart, Lung and Blood Institute (NHLBI). AJK was supported in part by the NIAID and T32 grants Immunology of Infectious Diseases (IID) (AI060525) and Pitt AIDS Research Training (PART) grant (AI065380). Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.	Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591; Archin NM, 2009, AIDS RES HUM RETROV, V25, P207, DOI 10.1089/aid.2008.0191; Avalos CR, 2017, MBIO, V8, DOI 10.1128/mBio.01186-17; Badia R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05157-w; Berg SL, 2004, CANCER CHEMOTH PHARM, V54, P85, DOI 10.1007/s00280-004-0766-5; Brocca-Cofano E, 2018, J VIROL, V92, DOI 10.1128/JVI.00576-18; Brocca-Cofano E, 2017, J VIROL, V91, DOI 10.1128/JVI.01051-17; Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445; Chen YN, 2009, XENOTRANSPLANTATION, V16, P496, DOI 10.1111/j.1399-3089.2009.00554.x; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Coull JJ, 2000, J VIROL, V74, P6790, DOI 10.1128/JVI.74.15.6790-6799.2000; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Deeks SG, 2012, NATURE, V487, P439, DOI 10.1038/487439a; Del Prete GQ, 2016, ANTIMICROB AGENTS CH, V60, P1560, DOI 10.1128/AAC.02625-15; Delobel P, 2005, AIDS, V19, P1739, DOI 10.1097/01.aids.0000183125.93958.26; Elliott JH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004473; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Furumai R, 2002, CANCER RES, V62, P4916; Gonder JC, 2007, ILAR J, V48, P1; Gray LR, 2016, MOL PSYCHIATR, V21, P574, DOI 10.1038/mp.2015.111; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; He TY, 2019, J CLIN INVEST, V129, P5474, DOI 10.1172/JCI121208; He T, 2016, J IMMUNOL, V197, P4535, DOI 10.4049/jimmunol.1601539; Hendrix CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055013; Henrich TJ, 2014, ANN INTERN MED, V161, P319, DOI 10.7326/M14-1027; Inada T, 2004, ANAESTHESIA, V59, P954, DOI 10.1111/j.1365-2044.2004.03837.x; JANOSSY G, 1986, CLIN EXP IMMUNOL, V63, P577; Jessen H, 2014, NEW ENGL J MED, V370, P682, DOI 10.1056/NEJMc1308413; Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418; Jones RB, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004287; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Josefsson L, 2013, P NATL ACAD SCI USA, V110, pE4987, DOI 10.1073/pnas.1308313110; Kim HJ, 2011, AM J TRANSL RES, V3, P166; Kleinman AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00734; Kudoh A, 1997, BRIT J ANAESTH, V78, P372, DOI 10.1093/bja/78.4.372; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Lu HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113341; Luzuriaga K, 2015, NEW ENGL J MED, V372, P786, DOI 10.1056/NEJMc1413931; Mackay LK, 2015, J IMMUNOL, V194, P2059, DOI 10.4049/jimmunol.1402256; Mardirossian G, 1999, J NUCL MED, V40, P1524; Margolis DM, 2011, AIDS RES HUM RETROV, V27, P347, DOI 10.1089/aid.2011.0017; Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x; Nagaya Y, 2014, DRUG METAB PHARMACOK, V29, P419, DOI 10.2133/dmpk.DMPK-14-RG-026; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Naughton CA, 2008, AM FAM PHYSICIAN, V78, P743; Nixon CC, 2020, NATURE, V578, P160, DOI 10.1038/s41586-020-1951-3; Ohta Y, 2009, J CLIN BIOCHEM NUTR, V45, P347, DOI 10.3164/jcbn.09-59; Pallikkuth S, 2016, J VIROL, V90, P2718, DOI 10.1128/JVI.02883-15; Pandrea I, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005384; Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174; Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976; PETERSEN CM, 1992, EXP CELL RES, V201, P160, DOI 10.1016/0014-4827(92)90360-K; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; Policicchio BB, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005879; Policicchio BB, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00012; Rothenberger MK, 2015, P NATL ACAD SCI USA, V112, pE1126, DOI 10.1073/pnas.1414926112; Sampey GC, 2018, SMAC MIMETIC AZD5582, P312447, DOI [10.1101/312447, DOI 10.1101/312447]; Sandor V, 2002, CLIN CANCER RES, V8, P718; Schechter ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam5441; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Sivanandham R, 2018, J CLIN INVEST, V128, P5178, DOI 10.1172/JCI99420; Sogaard OS, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005142; Stein JV, 2003, BLOOD, V101, P38, DOI 10.1182/blood-2002-03-0841; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; Tomihari M, 2015, J VET MED SCI, V77, P1227, DOI 10.1292/jvms.14-0611; Tran TA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003305; Tyagi M, 2010, J VIROL, V84, P6425, DOI 10.1128/JVI.01519-09; Uehara S, 2002, J IMMUNOL, V168, P2811, DOI 10.4049/jimmunol.168.6.2811; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wei DG, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004071; Whitney JB, 2014, NATURE, V512, P74, DOI 10.1038/nature13594; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; Winckelmann A, 2017, AIDS, V31, P771, DOI 10.1097/QAD.0000000000001400; Woo S, 2009, CLIN CANCER RES, V15, P1496, DOI 10.1158/1078-0432.CCR-08-1215; Yamamoto T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42253-3; Ylisastigui L, 2004, AIDS, V18, P1101, DOI 10.1097/00002030-200405210-00003	85	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 11	2020	11								579158	10.3389/fimmu.2020.579158	http://dx.doi.org/10.3389/fimmu.2020.579158			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PJ2JN	33362765	gold, Green Published			2022-12-18	WOS:000601601100001
J	Sundqvist, KG				Sundqvist, Karl-Gosta			T Cell MotilityHow Is It Regulated?	FRONTIERS IN IMMUNOLOGY			English	Article						lipoprotein receptor-related protein 1; thrombospondin-1; chemokine receptors; integrins; adhesion; motility	RECEPTOR-RELATED PROTEIN-1; MATRIX-METALLOPROTEINASE-9 MMP-9; LYMPHOCYTE SURFACE; ACTIN FLOW; CHEMOKINES; MIGRATION; ADHESION; THROMBOSPONDIN-1; EXPRESSION; INTEGRINS		[Sundqvist, Karl-Gosta] Karolinska Inst, Div Clin Immunol, Dept Lab Med, Stockholm, Sweden; [Sundqvist, Karl-Gosta] Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Sundqvist, KG (corresponding author), Karolinska Inst, Div Clin Immunol, Dept Lab Med, Stockholm, Sweden.; Sundqvist, KG (corresponding author), Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden.	Karl.Sundqvist@sll.se			Swedish Cancer Foundation; Swedish Research Council	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission)	This work was supported by the Swedish Cancer Foundation and the Swedish Research Council.	ARENCIBIA I, 1987, EXP CELL RES, V172, P124, DOI 10.1016/0014-4827(87)90099-1; BENZEEV A, 1980, CELL, V21, P365, DOI 10.1016/0092-8674(80)90473-0; Bergstrom SE, 2015, IMMUNOLOGY, V144, P687, DOI 10.1111/imm.12424; Bergstrom SE, 2013, IMMUNOLOGY, V140, P441, DOI 10.1111/imm.12154; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Cahalan MD, 2008, ANNU REV IMMUNOL, V26, P585, DOI 10.1146/annurev.immunol.24.021605.090620; Clotworthy M, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-5; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; FLANAGAN J, 1978, NATURE, V273, P278, DOI 10.1038/273278a0; Fooksman DR, 2010, ANNU REV IMMUNOL, V28, P79, DOI 10.1146/annurev-immunol-030409-101308; Friedl P, 1998, EUR J IMMUNOL, V28, P2331, DOI 10.1002/(SICI)1521-4141(199808)28:08<2331::AID-IMMU2331>3.0.CO;2-C; Gowrishankar K, 2012, CELL, V149, P1353, DOI 10.1016/j.cell.2012.05.008; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; HEMLER ME, 1987, J IMMUNOL, V138, P2941; Hons M, 2018, NAT IMMUNOL, V19, P606, DOI 10.1038/s41590-018-0109-z; Ivanoff A, 1999, CLIN EXP METASTAS, V17, P695, DOI 10.1023/A:1006749304315; Ivanoff J, 2005, IMMUNOLOGY, V114, P53, DOI 10.1111/j.1365-2567.2004.02005.x; Jacobelli J, 2010, NAT IMMUNOL, V11, P953, DOI 10.1038/ni.1936; Katakai T, 2013, J IMMUNOL, V191, P1188, DOI 10.4049/jimmunol.1300739; Krummel MF, 2016, NAT REV IMMUNOL, V16, P193, DOI 10.1038/nri.2015.16; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Li SS, 2006, BLOOD, V108, P3112, DOI 10.1182/blood-2006-04-016832; Li SS, 2005, J IMMUNOL, V174, P654, DOI 10.4049/jimmunol.174.2.654; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Liu YJ, 2015, CELL, V160, P659, DOI 10.1016/j.cell.2015.01.007; Liu ZW, 2009, J IMMUNOL, V183, P3616, DOI 10.4049/jimmunol.0804336; Marelli-Berg FM, 2008, J PATHOL, V214, P179, DOI 10.1002/path.2269; Panezai J, 2017, IMMUNOLOGY, V152, P308, DOI 10.1111/imm.12770; Rappel Wouter-Jan, 2017, Curr Opin Syst Biol, V3, P43, DOI 10.1016/j.coisb.2017.03.005; Resovi A, 2014, MATRIX BIOL, V37, P83, DOI 10.1016/j.matbio.2014.01.012; Richter M, 2007, J IMMUNOL, V178, P4506, DOI 10.4049/jimmunol.178.7.4506; Shao DY, 2012, P NATL ACAD SCI USA, V109, P6851, DOI 10.1073/pnas.1203252109; SUNDQVIST KG, 1972, NATURE-NEW BIOL, V239, P147, DOI 10.1038/newbio239147a0; SUNDQVIST KG, 1976, NATURE, V264, P226, DOI 10.1038/264226a0; SUNDQVIST KG, 1993, EXP CELL RES, V206, P100, DOI 10.1006/excr.1993.1125; SUNDQVIST KG, 1987, J IMMUNOL, V138, P825; Talme T, 2016, EUR J IMMUNOL, V46, P1279, DOI 10.1002/eji.201546122; Talme T, 2014, IMMUNOLOGY, V142, P176, DOI 10.1111/imm.12229; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; WANGER L, 1984, IMMUNOLOGY, V52, P519; WIEBKE JL, 1994, LAB INVEST, V70, P392; WILKINSON PC, 1986, IMMUNOLOGY, V57, P281; Winkler B, 2019, COMMUN PHYS-UK, V2, DOI 10.1038/s42005-019-0185-x; Yamada KM, 2019, NAT REV MOL CELL BIO, V20, P738, DOI 10.1038/s41580-019-0172-9	45	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 11	2020	11								588642	10.3389/fimmu.2020.588642	http://dx.doi.org/10.3389/fimmu.2020.588642			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PJ2BL	33362769	Green Published, gold			2022-12-18	WOS:000601580100001
J	Yohannes, DA; de Kauwe, A; Kaukinen, K; Kurppa, K; Maki, M; Anderson, RP; Linnarsson, S; Greco, D; Saavalainen, P				Yohannes, Dawit A.; de Kauwe, Andrea; Kaukinen, Katri; Kurppa, Kalle; Maki, Markku; Anderson, Robert P.; Linnarsson, Sten; Greco, Dario; Saavalainen, Paivi			Effects of In Vivo Gluten Challenge on PBMC Gene Expression Profiles in Diet Treated Celiac Disease	FRONTIERS IN IMMUNOLOGY			English	Article						celiac disease; celiac disease gene expression analysis; celiac disease RNA sequencing; celiac disease transcriptomics; pathway analysis; gluten challenge	INTESTINAL-MUCOSA; PERIPHERAL-BLOOD; MULTIPLE COMMON; GLIADIN; PATHWAY; PEPTIDE; GLUTATHIONE; INCREASES; SCREEN; REGION	The pathological mechanisms that lead to the onset and reactivation of celiac disease (CD) remain largely unknown. While gluten free diet (GFD) improves the intestinal damage and associated clinical symptoms in majority of cases, it falls short of providing full recovery. Additionally, late or misdiagnosis is also common as CD presents with a wide range of symptoms. Clear understanding of CD pathogenesis is thus critical to address both diagnostic and treatment concerns. We aimed to study the molecular impact of short gluten exposure in GFD treated CD patients, as well as identify biological pathways that remain altered constitutively in CD regardless of treatment. Using RNAseq profiling of PBMC samples collected from treated CD patients and gluten challenged patient and healthy controls, we explored the peripheral transcriptome in CD patients following a short gluten exposure. Short gluten exposure of just three days was enough to alter the genome-wide PBMC transcriptome of patients. Pathway analysis revealed gluten-induced upregulation of mainly immune response related pathways, both innate and adaptive, in CD patients. We evaluated the perturbation of biological pathways in sample-specific manner. Compared to gluten exposed healthy controls, pathways related to tight junction, olfactory transduction, metabolism of unsaturated fatty acids (such as arachidonic acid), metabolism of amino acids (such as cysteine and glutamate), and microbial infection were constitutively altered in CD patients regardless of treatment, while GFD treatment appears to mostly normalize immune response pathways to "healthy" state. Upstream regulator prediction analysis using differentially expressed genes identified constitutively activated regulators relatively proximal to previously reported CD associated loci, particularly SMARCA4 on 19p13.2 and CSF2 on 5q31. We also found constitutively upregulated genes in CD that are in CD associated genetic loci such as MEF2BNB-MEF2B (BORCS8-MEF2B) on 19p13.11 and CSTB on 21q22.3. RNAseq revealed strong effects of short oral gluten challenge on whole PBMC fraction and constitutively altered pathways in CD PBMC suggesting important factors other than gluten in CD pathogenesis.	[Yohannes, Dawit A.; de Kauwe, Andrea; Saavalainen, Paivi] Univ Helsinki, Res Programs Unit, Translat Immunol, Helsinki, Finland; [Yohannes, Dawit A.; de Kauwe, Andrea; Saavalainen, Paivi] Univ Helsinki, Dept Med & Clin Genet, Helsinki, Finland; [Kaukinen, Katri] Tampere Univ, Tampere Univ Hosp, Dept Internal Med, Tampere, Finland; [Kaukinen, Katri; Greco, Dario] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Kurppa, Kalle; Maki, Markku] Tampere Univ Hosp, Dept Pediat, Tampere, Finland; [Kurppa, Kalle; Maki, Markku] Tampere Univ, Ctr Child Hlth Res, Tampere, Finland; [Kurppa, Kalle] Seinajoki Univ Consortium, Dept Pediat, Seinajoki, Finland; [Kurppa, Kalle] Seinajoki Cent Hosp, Seinajoki, Finland; [Anderson, Robert P.] Walter & Eliza Hall Inst Med Res, Immunol Div, Melbourne, Vic, Australia; [Linnarsson, Sten] Karolinska Inst, Dept Med Biochem & Biophys, Lab Mol Neurobiol, Stockholm, Sweden; [Greco, Dario] Tampere Univ, BioMediTech Inst, Tampere, Finland; [Greco, Dario] Univ Helsinki, Inst Biotechnol, Helsinki, Finland	University of Helsinki; University of Helsinki; Tampere University; Tampere University Hospital; Tampere University; Tampere University; Tampere University Hospital; Tampere University; Seinajoki Central Hospital; Walter & Eliza Hall Institute; Karolinska Institutet; Tampere University; University of Helsinki	Saavalainen, P (corresponding author), Univ Helsinki, Res Programs Unit, Translat Immunol, Helsinki, Finland.; Saavalainen, P (corresponding author), Univ Helsinki, Dept Med & Clin Genet, Helsinki, Finland.	paivi.saavalainen@helsinki.fi	Saavalainen, Päivi M/E-8621-2011; Linnarsson, Sten/HCH-3909-2022	Kurppa, Kalle/0000-0003-4757-2164; Anderson, Robert/0000-0002-0764-7267; Greco, Dario/0000-0001-9195-9003	Academy of Finland; European Commission; Sigrid Juselius Foundation; Competitive State Research Financing of the Expert Area of Tampere University Hospital; SalWe Research Program INTELLIGENT MONITORING (Tekes - Finnish Funding Agency for Technology and Innovation) [648/10, 3986/31/2013]; SalWe Research Program GET IT DONE (Tekes - Finnish Funding Agency for Technology and Innovation) [648/10, 3986/31/2013]	Academy of Finland(Academy of Finland); European Commission(European CommissionEuropean Commission Joint Research Centre); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Competitive State Research Financing of the Expert Area of Tampere University Hospital; SalWe Research Program INTELLIGENT MONITORING (Tekes - Finnish Funding Agency for Technology and Innovation); SalWe Research Program GET IT DONE (Tekes - Finnish Funding Agency for Technology and Innovation)	This work was supported by the Academy of Finland, European Commission (Marie Curie Excellence Grant), Sigrid Juselius Foundation, the Competitive State Research Financing of the Expert Area of Tampere University Hospital, and by SalWe Research Programs INTELLIGENT MONITORING and GET IT DONE (Tekes - the Finnish Funding Agency for Technology and Innovation grants 648/10 and 3986/31/2013).	Abadie V, 2014, IMMUNOL REV, V260, P221, DOI 10.1111/imr.12191; Amundsen SS, 2007, EUR J HUM GENET, V15, P980, DOI 10.1038/sj.ejhg.5201870; Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Baker SL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173980; Benahmed M, 2007, GASTROENTEROLOGY, V132, P994, DOI 10.1053/j.gastro.2006.12.025; Bhat AA, 2019, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01942; Bragde H, 2018, CELL MOL LIFE SCI, V75, P4385, DOI 10.1007/s00018-018-2898-5; Castellanos-Rubio A, 2018, INT REV CEL MOL BIO, V336, P149, DOI 10.1016/bs.ircmb.2017.07.003; Castellanos-Rubio A, 2010, AUTOIMMUNITY, V43, P131, DOI 10.3109/08916930903225229; Daveson AJM., 2020, GASTROHEP, V2, P22, DOI DOI 10.1002/YGH2.380; Diosdado B, 2004, GUT, V53, P944, DOI 10.1136/gut.2003.018374; Diosdado B, 2007, CLIN GASTROENTEROL H, V5, P574, DOI 10.1016/j.cgh.2006.11.014; Drier Y, 2013, P NATL ACAD SCI USA, V110, P6388, DOI 10.1073/pnas.1219651110; Dubois PCA, 2010, NAT GENET, V42, P295, DOI 10.1038/ng.543; Fuchs V, 2018, UNITED EUR GASTROENT, V6, P567, DOI 10.1177/2050640617751253; Gajulapalli RD, 2017, SAUDI J GASTROENTERO, V23, P253, DOI 10.4103/sjg.SJG_616_16; Garcia-Campos MA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00383; Gazon H, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02686; Goel G, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw7756; Hadjivassiliou M, 2019, CLIN GASTROENTEROL H, V17, P2678, DOI 10.1016/j.cgh.2019.03.014; Han A, 2013, P NATL ACAD SCI USA, V110, P13073, DOI 10.1073/pnas.1311861110; Harley JB, 2018, NAT GENET, V50, P699, DOI 10.1038/s41588-018-0102-3; Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3; Hogg JR, 2016, J VIROL, V90, P7010, DOI 10.1128/JVI.00607-16; Ilus T, 2014, AM J GASTROENTEROL, V109, P1471, DOI 10.1038/ajg.2014.194; Islam S, 2014, NAT METHODS, V11, P163, DOI [10.1038/nmeth.2772, 10.1038/NMETH.2772]; Islam S, 2012, NAT PROTOC, V7, P813, DOI 10.1038/nprot.2012.022; Juuti-Uusitalo K, 2004, J AUTOIMMUN, V22, P249, DOI 10.1016/j.jaut.2003.12.001; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; Kim J, 2019, EXP NEUROBIOL, V28, P74, DOI 10.5607/en.2019.28.1.74; Koehler G, 2014, ROUT EXPLOR DEV STUD, P1; Koskinen LLE, 2008, J MED GENET, V45, P222, DOI 10.1136/jmg.2007.053991; Koskinen LLE, 2009, TISSUE ANTIGENS, V74, P408, DOI 10.1111/j.1399-0039.2009.01359.x; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Leonard MM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215132; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Luettig J, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.977176; Maiuri L, 2010, GUT, V59, P311, DOI 10.1136/gut.2009.183608; Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Monsuur AJ, 2005, NAT GENET, V37, P1341, DOI 10.1038/ng1680; Naluai AT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193764; Nanayakkara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076006; Olivares M, 2018, GUT MICROBES, V9, P551, DOI 10.1080/19490976.2018.1451276; Perricone C, 2013, CLIN REV ALLERG IMMU, V45, P87, DOI 10.1007/s12016-012-8343-x; Plaza-Izurieta L, 2015, EUR J HUM GENET, V23, P1100, DOI 10.1038/ejhg.2014.244; Quinn EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140049; Rebe C, 2009, CIRC RES, V105, P393, DOI 10.1161/CIRCRESAHA.109.201855; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sangineto M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197915; Sergushichev A., 2016, ALGORITHM FAST PRERA, DOI [10.1101/060012, DOI 10.1101/060012]; Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113; Simula MP, 2010, MOL MED, V16, P199, DOI 10.2119/molmed.2009.00173; Singh P, 2018, CLIN GASTROENTEROL H, V16, P823, DOI 10.1016/j.cgh.2017.06.037; Spatola BN, 2014, ALIMENT PHARM THER, V39, P407, DOI 10.1111/apt.12603; Stojiljkovic V, 2007, ANN CLIN BIOCHEM, V44, P537, DOI 10.1258/000456307782268075; Stojiljkovic V, 2012, AN ACAD BRAS CIENC, V84, P175, DOI 10.1590/S0001-37652012000100018; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tempera I, 2016, J VIROL, V90, P345, DOI 10.1128/JVI.02318-15; Trynka G, 2011, NAT GENET, V43, P1193, DOI 10.1038/ng.998; Tye-Din JA, 2019, ALIMENT PHARM THER, V50, P901, DOI 10.1111/apt.15477; Van Belzen MJ, 2003, GASTROENTEROLOGY, V125, P1032, DOI 10.1016/S0016-5085(03)01205-8; van Hees NJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097778; Vorobjova T, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6179243; Withoff S, 2016, TRENDS GENET, V32, P295, DOI 10.1016/j.tig.2016.02.003; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489; Yohannes DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18137-9	69	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 11	2020	11								594243	10.3389/fimmu.2020.594243	http://dx.doi.org/10.3389/fimmu.2020.594243			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PJ2FA	33362776	gold, Green Published			2022-12-18	WOS:000601589400001
J	Soto, M; Ramirez, L; Solana, JC; Cook, ECL; Hernandez-Garcia, E; Charro-Zanca, S; Redondo-Urzainqui, A; Reguera, RM; Balana-Fouce, R; Iborra, S				Soto, Manuel; Ramirez, Laura; Solana, Jose Carlos; Cook, Emma C. L.; Hernandez-Garcia, Elena; Charro-Zanca, Sara; Redondo-Urzainqui, Ana; Reguera, Rosa M.; Balana-Fouce, Rafael; Iborra, Salvador			Resistance to Experimental Visceral Leishmaniasis in Mice Infected With Leishmania infantum Requires Batf3	FRONTIERS IN IMMUNOLOGY			English	Article						Leishmania; Batf3; visceral leishmaniasis; dendritic cells; Batf3 DC+; Th1 responses	CD8-ALPHA(+) DENDRITIC CELLS; T-CELLS; IMMUNE-RESPONSES; INTERLEUKIN-12; PROTECTION; CD8(+); GAMMA	Unveiling the protective immune response to visceral leishmaniasis is critical for a rational design of vaccines aimed at reducing the impact caused by this fatal, if left untreated, vector-borne disease. In this study we sought to determine the role of the basic leucine zipper transcription factor ATF-like 3 (Batf3) in the evolution of infection with Leishmania infantum, the causative agent of human visceral leishmaniasis in the Mediterranean Basin and Latin America. For that, Batf3-deficient mice in C57BL/6 background were infected with an L. infantum strain expressing the luciferase gene. Bioluminescent imaging, as well as in vitro parasite titration, demonstrated that Batf3-deficient mice were unable to control hepatic parasitosis as opposed to wild-type C57BL/6 mice. The impaired microbicide capacities of L. infantum-infected macrophages from Batf3-deficient mice mainly correlated with a reduction of parasite-specific IFN-gamma production. Our results reinforce the implication of Batf3 in the generation of type 1 immunity against infectious diseases.	[Soto, Manuel; Ramirez, Laura; Solana, Jose Carlos] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Dept Biol Mol,UAM, Nicolas Cabrera 1, Madrid, Spain; [Cook, Emma C. L.; Hernandez-Garcia, Elena; Charro-Zanca, Sara; Redondo-Urzainqui, Ana; Iborra, Salvador] Univ Complutense Madrid, Sch Med, Dept Immunol Ophthalmol & ENT, Madrid, Spain; [Reguera, Rosa M.; Balana-Fouce, Rafael] Univ Leon, Dept Ciencias Biomed, Leon, Spain; [Solana, Jose Carlos] Inst Salud Carlos III, WHO Collaborating Ctr Leishmaniasis, Natl Ctr Microbiol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Complutense University of Madrid; Universidad de Leon; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Iborra, S (corresponding author), Univ Complutense Madrid, Sch Med, Dept Immunol Ophthalmol & ENT, Madrid, Spain.	siborra@ucm.es	Iborra, Salvador/J-2863-2015; Álvarez, Manuel Soto/Q-5234-2018; Balana-Fouce, Rafael/AAK-9485-2021; García, Elena Hernández/ABG-9040-2020; Reguera, Rosa M/K-6027-2017; Redondo-Urzainqui, Ana/AAS-8766-2021	Iborra, Salvador/0000-0002-1607-1749; Álvarez, Manuel Soto/0000-0001-6825-841X; Balana-Fouce, Rafael/0000-0003-0418-6116; Reguera, Rosa M/0000-0001-9148-2997; Hernandez Garcia, Elena/0000-0002-9018-5701; Redondo Urzainqui, Ana/0000-0002-5551-4418; Solana, Jose Carlos/0000-0002-0485-6127; Cook, Emma/0000-0002-1415-4049	Ministerio de Ciencia e Innovacion [FISPI11/00095, FISPI14/00366]; Fondo de Investigaciones Sanitarias [ISCIII-RETICRD16/0027/0008-FEDER]; Ministerio de Ciencia e Innovacion (FEDER FUNDING) [RYC-2016-19463, RTI2018-343 094484-B-I00]; Fundacion Ramon Areces; Banco de Santander	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Ministerio de Ciencia e Innovacion (FEDER FUNDING); Fundacion Ramon Areces; Banco de Santander	The research made for this study was supported in Spain by grants from Ministerio de Ciencia e Innovacion FISPI11/00095 and FISPI14/00366 (FEDER FUNDING) and the Fondo de Investigaciones Sanitarias (ISCIII-RETICRD16/0027/0008-FEDER). SI is funded by RYC-2016-19463 and RTI2018-343 094484-B-I00 from Ministerio de Ciencia e Innovacion (FEDER FUNDING). Institutional grants from the Fundacion Ramon Areces and Banco de Santander to the CBMSO are also acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez-Velilla R, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007133; Arnold IC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007866; Ashok D, 2014, EUR J IMMUNOL, V44, P1422, DOI 10.1002/eji.201344242; Ataide MA, 2020, NAT IMMUNOL, V21, P1397, DOI 10.1038/s41590-020-0786-2; Bodhale NP, 2018, CYTOKINE, V112, P12, DOI 10.1016/j.cyto.2018.06.003; Bottcher JP, 2018, TRENDS CANCER, V4, P784, DOI 10.1016/j.trecan.2018.09.001; BUFFET PA, 1995, ANTIMICROB AGENTS CH, V39, P2167, DOI 10.1128/AAC.39.9.2167; Bunn PT, 2018, J IMMUNOL, V201, P3362, DOI 10.4049/jimmunol.1701582; Solana JC, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005644; Carrion J, 2006, PARASITE IMMUNOL, V28, P173, DOI 10.1111/j.1365-3024.2006.00817.x; Cope A, 2011, TRENDS IMMUNOL, V32, P278, DOI 10.1016/j.it.2011.03.010; de Oca MM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005398; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Edelson BT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025660; Engwerda CR, 2000, IMMUNOL TODAY, V21, P73, DOI 10.1016/S0167-5699(99)01549-2; Faleiro RJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002914; Gillespie PM, 2016, VACCINE, V34, P2992, DOI 10.1016/j.vaccine.2015.12.071; Gracie JA, 1996, EUR J IMMUNOL, V26, P1217, DOI 10.1002/eji.1830260605; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Iborra S, 2018, EXPERT REV VACCINES, V17, P323, DOI 10.1080/14760584.2018.1459191; Joshi T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000431; Kaye PM, 2011, CLIN MICROBIOL INFEC, V17, P1462, DOI 10.1111/j.1469-0691.2011.03610.x; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Kaye PM, 2004, IMMUNOL REV, V201, P239, DOI 10.1111/j.0105-2896.2004.00188.x; Lee W, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.157; Li P, 2012, NATURE, V490, P543, DOI 10.1038/nature11530; Loeuillet C, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1413-9; Martinez-Lopez M, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00883; Martinez-Lopez M, 2015, EUR J IMMUNOL, V45, P119, DOI 10.1002/eji.201444651; Mashayekhi M, 2011, IMMUNITY, V35, P249, DOI 10.1016/j.immuni.2011.08.008; Murphy TL, 2013, NAT REV IMMUNOL, V13, P499, DOI 10.1038/nri3470; Nieto A, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-39; Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004; Olekhnovitch R, 2015, TRENDS PARASITOL, V31, P653, DOI 10.1016/j.pt.2015.08.001; Perez-Cabezas B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00478; Perez-Cabezas B, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00030; Polley R, 2006, INFECT IMMUN, V74, P773, DOI 10.1128/IAI.74.1.773-776.2006; Qiu ZJ, 2020, J IMMUNOL, V205, P901, DOI 10.4049/jimmunol.2000228; Rolao N, 2007, EXP PARASITOL, V115, P270, DOI 10.1016/j.exppara.2006.09.013; Sacks DL, 2015, CURR PROTOC IMMUNOL, V108, P1, DOI DOI 10.1002/; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Seillet C, 2013, BLOOD, V121, P1574, DOI 10.1182/blood-2012-07-445650; Stager S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00005; Stager S, 2006, EUR J IMMUNOL, V36, P1764, DOI 10.1002/eji.200635937; Steverding D, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2028-5; Tavares J, 2017, METHODS, V127, P37, DOI 10.1016/j.ymeth.2017.05.008; Thalhofer Colin J, 2010, J Vis Exp, DOI 10.3791/1980; Theisen DJ, 2018, SCIENCE, V362, P694, DOI 10.1126/science.aat5030; Tsagozis P, 2003, PARASITE IMMUNOL, V25, P569, DOI 10.1111/j.0141-9838.2004.00672.x; Uliana SRB, 2018, PARASITOLOGY, V145, P464, DOI 10.1017/S0031182016002523; von Stebut E, 2018, INT J MED MICROBIOL, V308, P206, DOI 10.1016/j.ijmm.2017.11.002; Waithman J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066136; Wilson ME, 2005, MICROB PATHOGENESIS, V38, P147, DOI 10.1016/j.micpath.2004.11.002	53	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 10	2020	11								590934	10.3389/fimmu.2020.590934	http://dx.doi.org/10.3389/fimmu.2020.590934			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PI7MK	33362772	gold, Green Published			2022-12-18	WOS:000601270400001
J	Tinel, C; Vermorel, A; Picciotto, D; Morin, L; Devresse, A; Sauvaget, V; Lebreton, X; Aouni, L; Prie, D; Brabant, S; Avettand-Fenoel, V; Scemla, A; Timsit, MO; Snanoudj, R; Legendre, C; Terzi, F; Rabant, M; Anglicheau, D				Tinel, Claire; Vermorel, Agathe; Picciotto, Daniela; Morin, Lise; Devresse, Arnaud; Sauvaget, Virginia; Lebreton, Xavier; Aouni, Laila; Prie, Dominique; Brabant, Severine; Avettand-Fenoel, Veronique; Scemla, Anne; Timsit, Marc Olivier; Snanoudj, Renaud; Legendre, Christophe; Terzi, Fabiola; Rabant, Marion; Anglicheau, Dany			Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation	FRONTIERS IN IMMUNOLOGY			English	Article						urinary chemokines; CXCL10; BK polyomavirus; kidney transplantation; prognostic biomarker	NONINVASIVE DIAGNOSIS; CHEMOKINE; INFLAMMATION; REJECTION	BK virus (BKV) replication increases urinary chemokine C-X-C motif ligand 10 (uCXCL10) levels in kidney transplant recipients (KTRs). Here, we investigated uCXCL10 levels across different stages of BKV replication as a prognostic and predictive marker for functional decline in KTRs after BKV-DNAemia. uCXCL10 was assessed in a cross-sectional study (474 paired urine/blood/biopsy samples and a longitudinal study (1,184 samples from 60 KTRs with BKV-DNAemia). uCXCL10 levels gradually increased with urine (P-value < 0.0001) and blood BKV viral load (P < 0.05) but were similar in the viruria and no BKV groups (P > 0.99). In viremic patients, uCXCL10 at biopsy was associated with graft functional decline [HR = 1.65, 95% CI (1.08-2.51), P = 0.02], irrespective of baseline eGFR, blood viral load, or BKVN diagnosis. uCXL10/cr (threshold: 12.86 ng/mmol) discriminated patients with a low risk of graft function decline from high-risk patients (P = 0.01). In the longitudinal study, the uCXCL10 and BKV-DNAemia trajectories were superimposable. Stratification using the same uCXCL10/cr threshold at first viremia predicted the subsequent inflammatory response, assessed by time-adjusted uCXCL10/cr AUC (P < 0.001), and graft functional decline (P = 0.03). In KTRs, uCXCL10 increases in BKV-DNAemia but not in isolated viruria. uCXCL10/cr is a prognostic biomarker of eGFR decrease, and a 12.86 ng/ml threshold predicts higher inflammatory burdens and poor renal outcomes.	[Tinel, Claire; Vermorel, Agathe; Picciotto, Daniela; Morin, Lise; Devresse, Arnaud; Lebreton, Xavier; Aouni, Laila; Scemla, Anne; Legendre, Christophe; Anglicheau, Dany] Hop Necker Enfants Malad, AP HP, Dept Nephrol & Kidney Transplantat, Paris, France; [Tinel, Claire; Sauvaget, Virginia; Legendre, Christophe; Terzi, Fabiola; Rabant, Marion; Anglicheau, Dany] French Natl Inst Hlth & Med Res, Necker Enfants Malades Inst, Paris, Paris, France; [Tinel, Claire; Prie, Dominique; Avettand-Fenoel, Veronique; Timsit, Marc Olivier; Legendre, Christophe; Rabant, Marion; Anglicheau, Dany] Paris Univ, Paris, France; [Devresse, Arnaud] Univ Hosp St Luc, Div Nephrol, Brussels, Belgium; [Devresse, Arnaud] Catholic Univ Louvain, Inst Expt & Clin Res, Brussels, Belgium; [Prie, Dominique; Brabant, Severine] Hop Necker Enfants Malad, AP HP, Dept Physiol, Paris, France; [Avettand-Fenoel, Veronique] Hop Necker Enfants Malad, AP HP, Departement Virol, Paris, France; [Timsit, Marc Olivier] Georges Pompidou European Hosp, AP HP, Dept Urol, Paris, France; [Snanoudj, Renaud] Foch Hosp, Dept Nephrol Hemodialysis & Kidney Transplantat, Suresnes, France; [Rabant, Marion] Hop Necker Enfants Malad, AP HP, Pathol Dept, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Hospital Foch; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Anglicheau, D (corresponding author), Hop Necker Enfants Malad, AP HP, Dept Nephrol & Kidney Transplantat, Paris, France.; Anglicheau, D (corresponding author), French Natl Inst Hlth & Med Res, Necker Enfants Malades Inst, Paris, Paris, France.; Anglicheau, D (corresponding author), Paris Univ, Paris, France.	dany.anglicheau@aphp.fr	Terzi, Fabiola/N-5482-2018; Avettand-Fenoel, Véronique/O-6285-2017; Rabant, Marion/ACD-2481-2022	Avettand-Fenoel, Véronique/0000-0002-7022-2990; Rabant, Marion/0000-0001-5696-6478; Tinel, Claire/0000-0003-4595-7570; Picciotto, Daniela/0000-0003-2870-0888; BRABANT, SEVERINE/0000-0002-7590-3963	National Fund for Scientific Research (Belgium); Societe Francophone de Transplantation; Emmanuel Boussard Foundation; Day Solvay Foundation	National Fund for Scientific Research (Belgium)(Fonds de la Recherche Scientifique - FNRS); Societe Francophone de Transplantation; Emmanuel Boussard Foundation; Day Solvay Foundation(Solvay SA)	AD is supported by the National Fund for Scientific Research (Belgium), and AV is supported by the Societe Francophone de Transplantation. The Emmanuel Boussard Foundation supported DA, LA, LM, CT and VS, and DA received funds from the Day Solvay Foundation.	Adam B, 2014, AM J TRANSPLANT, V14, P2137, DOI 10.1111/ajt.12794; Binet I, 1999, TRANSPLANTATION, V67, P918, DOI 10.1097/00007890-199903270-00022; Ding R, 2002, TRANSPLANTATION, V74, P987, DOI 10.1097/00007890-200210150-00016; Drachenberg CB, 2017, AM J TRANSPLANT, V17, P2078, DOI 10.1111/ajt.14314; Dumoulin A, 2011, J CLIN MICROBIOL, V49, P1382, DOI 10.1128/JCM.02008-10; GARDNER SD, 1971, LANCET, V1, P1253; Handschin J, 2020, TRANSPLANT DIRECT, V6, DOI 10.1097/TXD.0000000000000959; Hirsch HH, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13528; Hirt-Minkowski P, 2012, AM J TRANSPLANT, V12, P1811, DOI 10.1111/j.1600-6143.2012.03999.x; Ho J, 2018, TRANSPLANTATION, V102, P521, DOI 10.1097/TP.0000000000001931; Hricik DE, 2013, AM J TRANSPLANT, V13, P2634, DOI 10.1111/ajt.12426; Hu HZ, 2009, TRANSPLANTATION, V87, P1814, DOI 10.1097/TP.0b013e3181a66b3e; Hu HZ, 2004, AM J TRANSPLANT, V4, P432, DOI 10.1111/j.1600-6143.2004.00354.x; Jackson JA, 2011, AM J TRANSPLANT, V11, P2228, DOI 10.1111/j.1600-6143.2011.03680.x; Kariminik A, 2016, INFLAMMATION, V39, P1514, DOI 10.1007/s10753-016-0385-4; Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107; Madden K, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12952; Morel V, 2017, J CLIN MICROBIOL, V55, P1177, DOI 10.1128/JCM.01180-16; Rabant M, 2015, J AM SOC NEPHROL, V26, P2840, DOI 10.1681/ASN.2014080797; Ramos E, 2009, TRANSPLANTATION, V87, P621, DOI 10.1097/TP.0b013e318197c17d; Schaub S, 2009, AM J TRANSPLANT, V9, P1347, DOI 10.1111/j.1600-6143.2009.02645.x; Sharma PM, 2006, J VIROL, V80, P8869, DOI 10.1128/JVI.00510-06; Tinel C, 2020, AM J TRANSPLANT, V20, P3462, DOI 10.1111/ajt.15959; Weseslindtner L, 2020, TRANSPL INT, V33, P555, DOI 10.1111/tri.13584	24	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 10	2020	11								604353	10.3389/fimmu.2020.604353	http://dx.doi.org/10.3389/fimmu.2020.604353			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PI9JG	33362789	Green Published, gold			2022-12-18	WOS:000601397400001
J	Zhang, YX; Li, P; Fang, HY; Wang, GC; Zeng, X				Zhang, Yixi; Li, Pan; Fang, Hongyu; Wang, Guocan; Zeng, Xun			Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress	FRONTIERS IN IMMUNOLOGY			English	Review						chimeric antigen receptor; graft-versus-host disease; host-versus-graft activities; adoptive cell therapy; cancer immunotherapy	NATURAL-KILLER-CELLS; DELTA T-CELLS; VERSUS-HOST-DISEASE; CLASS-I EXPRESSION; NK CELLS; ADOPTIVE IMMUNOTHERAPY; RESTRICTION ENZYMES; BONE-MARROW; DONOR; GRAFT	Chimeric antigen receptor (CAR) therapy has been proved effective in a stream of clinical trials, especially in hematologic malignancies. However, current CAR therapy is highly personalized as cells used are derived from patients themselves, which can be costly, time-consuming, and sometimes fails to achieve optimal therapeutic results due to poor quality/quantity of patient-derived cells. On the contrary, universal CAR therapy, which is based on healthy individuals' cells, circumvents several limitations of current autologous CAR therapy. To achieve the universality of CAR therapy, the allogeneic cell transplantation related issues, such as graft-versus-host disease (GVHD) and host-versus-graft activities (HVGA), must be addressed. In this review, we focus on current progress regarding GVHD and HVGA in the universal CAR therapy, followed by a universal CAR design that may be applied to allogeneic cells and a summary of key clinical trials in this field. This review may provide valuable insights into the future design of universal CAR products.	[Zhang, Yixi; Li, Pan; Fang, Hongyu; Wang, Guocan; Zeng, Xun] Zhejiang Univ, Affiliated Hosp 1,Natl Clin Res Ctr Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis,Sch Med, Hangzhou, Peoples R China	Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases; Zhejiang University	Zeng, X (corresponding author), Zhejiang Univ, Affiliated Hosp 1,Natl Clin Res Ctr Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis,Sch Med, Hangzhou, Peoples R China.	xunzeng@zju.edu.cn	Zeng, Xun/HHM-7791-2022		Major Research Plan of the National Natural Science Foundation of China [91742102]; National Science and Technology Major Project of China [2018ZX10302206]	Major Research Plan of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of China	This work was supported by the Major Research Plan of the National Natural Science Foundation of China (grant number 91742102) and the National Science and Technology Major Project of China (2018ZX10302206).	Abdelhakim H, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5030035; Alderson KL, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/379123; Ali S, 2020, ONCOLOGIST, V25, pE321, DOI 10.1634/theoncologist.2019-0233; Bai S, 2012, CLIN PHARMACOKINET, V51, P119, DOI 10.2165/11596370-000000000-00000; Barber A, 2009, J IMMUNOL, V183, P6939, DOI 10.4049/jimmunol.0902000; Blazquez JL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01601; Boch J, 2009, SCIENCE, V326, P1509, DOI 10.1126/science.1178811; Bogdanove AJ, 2011, SCIENCE, V333, P1843, DOI 10.1126/science.1204094; Bridgeman JS, 2010, J IMMUNOL, V184, P6938, DOI 10.4049/jimmunol.0901766; Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751; Brudno JN, 2016, J CLIN ONCOL, V34, P1112, DOI 10.1200/JCO.2015.64.5929; Burns LJ, 2003, BONE MARROW TRANSPL, V32, P177, DOI 10.1038/sj.bmt.1704086; Cai TY, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.4039.4039; Castellarin M, 2018, GENE THER, V25, P165, DOI 10.1038/s41434-018-0007-x; Cellectis, 2017, CELL REP CLIN HOLD U; Chen KH, 2017, LEUKEMIA, V31, P2151, DOI 10.1038/leu.2017.8; Chen KH, 2016, ONCOTARGET, V7, P56219, DOI 10.18632/oncotarget.11019; Cho JH, 2018, CELL, V173, P1426, DOI 10.1016/j.cell.2018.03.038; Choi BD, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0806-7; Chu YY, 2015, CANCER IMMUNOL RES, V3, P333, DOI 10.1158/2326-6066.CIR-14-0114; Coelho MA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17952-5; Compte E, 2004, EUR J IMMUNOL, V34, P2089, DOI 10.1002/eji.200425227; Conlon KC, 2015, J CLIN ONCOL, V33, P74, DOI 10.1200/JCO.2014.57.3329; Cruz CRY, 2013, BLOOD, V122, P2965, DOI 10.1182/blood-2013-06-506741; D'Aloia MM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0278-6; D'Ippolito E, 2019, CANCER IMMUNOL IMMUN, V68, P1701, DOI 10.1007/s00262-019-02395-9; Davila ML, 2014, INT J HEMATOL, V99, P361, DOI 10.1007/s12185-013-1479-5; Diogo Gomes da Silva MM, 2016, BLOOD, V22, P1851, DOI [10.1182/blood.V128.22.1851.1851, DOI 10.1182/BLOOD.V128.22.1851.1851]; Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026; Eapen M, 2010, LANCET ONCOL, V11, P653, DOI 10.1016/S1470-2045(10)70127-3; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fleming JN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001452; Frey NV, 2008, BEST PRACT RES CL HA, V21, P205, DOI 10.1016/j.beha.2008.02.007; Gaj T, 2012, NAT METHODS, V9, P805, DOI [10.1038/nmeth.2030, 10.1038/NMETH.2030]; Gang M, 2020, BLOOD, V136, P2308, DOI 10.1182/blood.2020006619; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Ghassemi S, 2018, CANCER IMMUNOL RES, V6, P1100, DOI 10.1158/2326-6066.CIR-17-0405; Ghosh A, 2017, NAT MED, V23, P242, DOI 10.1038/nm.4258; Gomes-Silva D, 2017, CELL REP, V21, P17, DOI 10.1016/j.celrep.2017.09.015; Gornalusse GG, 2017, NAT BIOTECHNOL, V35, P765, DOI 10.1038/nbt.3860; Graham C, 2017, ASH ANN M, V130, P887; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Gu Siyi, 2014, Front Immunol, V5, P688, DOI 10.3389/fimmu.2014.00688; Guzman ML, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.765.765; Han JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11483; Hannani D, 2012, TRENDS IMMUNOL, V33, P199, DOI 10.1016/j.it.2012.01.006; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hua JS, 2020, CL LYMPH MYELOM LEUK, V20, P610, DOI 10.1016/j.clml.2020.04.007; Imai C, 2005, BLOOD, V106, P376, DOI 10.1182/blood-2004-12-4797; Ingegnere T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00957; Jain T, 2019, BIOL BLOOD MARROW TR, V25, P2305, DOI 10.1016/j.bbmt.2019.08.015; Jandus C, 2014, J CLIN INVEST, V124, P1810, DOI 10.1172/JCI65899; Jensen MC, 2015, CURR OPIN IMMUNOL, V33, P9, DOI 10.1016/j.coi.2015.01.002; Jiang H, 2014, MOL ONCOL, V8, P297, DOI 10.1016/j.molonc.2013.12.001; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Juch H, 2012, WIEN MED WOCHENSCHR, V162, P196, DOI 10.1007/s10354-012-0070-7; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Kadereit S, 1999, BLOOD, V94, P3101, DOI 10.1182/blood.V94.9.3101.421k04_3101_3107; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526; Klichinsky M, 2020, NAT BIOTECHNOL, V38, P947, DOI 10.1038/s41587-020-0462-y; Koch J, 2013, TRENDS IMMUNOL, V34, P182, DOI 10.1016/j.it.2013.01.003; Kochenderfer JN, 2013, BLOOD, V122, P4129, DOI 10.1182/blood-2013-08-519413; Kohl U, 2018, HUM GENE THER, V29, P559, DOI 10.1089/hum.2017.254; Kolb HJ, 2008, BLOOD, V112, P4371, DOI 10.1182/blood-2008-03-077974; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Krawczyk M, 2004, J IMMUNOL, V173, P6200, DOI 10.4049/jimmunol.173.10.6200; Kudo K, 2014, CANCER RES, V74, P93, DOI 10.1158/0008-5472.CAN-13-1365; Kunzmann V, 2000, BLOOD, V96, P384; Kwoczek J, 2018, TRANSFUSION, V58, P88, DOI 10.1111/trf.14365; Le Page C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038541; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; Legut M, 2015, CELL MOL IMMUNOL, V12, P656, DOI 10.1038/cmi.2015.28; Li XQ, 2019, CURR OPIN HEMATOL, V26, P427, DOI 10.1097/MOH.0000000000000548; Lim WH, 2016, CLIN J AM SOC NEPHRO, V11, P875, DOI 10.2215/CJN.11641115; Liu E, 2018, LEUKEMIA, V32, P520, DOI 10.1038/leu.2017.226; Lohmueller JJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1368604; Lund TC, 2015, NAT REV CLIN ONCOL, V12, P163, DOI 10.1038/nrclinonc.2014.215; MACKINNON S, 1995, BLOOD, V86, P1261, DOI 10.1182/blood.V86.4.1261.bloodjournal8641261; Makanga DR, 2020, CANCERS, V12, DOI 10.3390/cancers12071927; Mardiros A, 2015, CURR OPIN HEMATOL, V22, P484, DOI 10.1097/MOH.0000000000000190; McLellan AD, 2019, IMMUNOL CELL BIOL, V97, P664, DOI 10.1111/imcb.12254; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Mirzaei HR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01850; Mo FY, 2021, NAT BIOTECHNOL, V39, P56, DOI 10.1038/s41587-020-0601-5; Mohning MP., 2019, IDIOPATHIC PULMONARY, DOI 10.1016/B978-0-323-54431-3.00003-2; Montel-Hagen A, 2019, CELL STEM CELL, V24, P376, DOI 10.1016/j.stem.2018.12.011; Muller T, 2008, CANCER IMMUNOL IMMUN, V57, P411, DOI 10.1007/s00262-007-0383-3; Mukherjee S, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai9062; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Netea MG, 2015, NAT IMMUNOL, V16, P675, DOI 10.1038/ni.3178; NIMER SD, 1995, STEM CELLS, V13, P324, DOI 10.1002/stem.5530130402; Olson JA, 2010, BLOOD, V115, P4293, DOI 10.1182/blood-2009-05-222190; Papadouli I, 2020, ONCOLOGIST, V25, P894, DOI 10.1634/theoncologist.2019-0646; Parkhurst MR, 2011, CLIN CANCER RES, V17, P6287, DOI 10.1158/1078-0432.CCR-11-1347; Pegram HJ, 2015, LEUKEMIA, V29, P415, DOI 10.1038/leu.2014.215; Peppa D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001227; Poehlein CH, 2009, EUR J IMMUNOL, V39, P3121, DOI 10.1002/eji.200939453; Poirot L, 2015, CANCER RES, V75, P3853, DOI 10.1158/0008-5472.CAN-14-3321; Qasim W, 2015, BLOOD, V126, P2046, DOI DOI 10.1182/BLOOD.V126.23.2046.2046; Qasim W, 2017, BLOOD, V130; Qasim W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2013; Qin L, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0437-8; Radestad E, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/578741; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reusch D, 2015, GLYCOBIOLOGY, V25, P1325, DOI 10.1093/glycob/cwv065; Rischer M, 2004, BRIT J HAEMATOL, V126, P583, DOI 10.1111/j.1365-2141.2004.05077.x; Ritchie DS, 2013, MOL THER, V21, P2122, DOI 10.1038/mt.2013.154; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rocha V, 2001, BLOOD, V97, P2962, DOI 10.1182/blood.V97.10.2962; Rocha V, 2009, BRIT J HAEMATOL, V147, P262, DOI 10.1111/j.1365-2141.2009.07883.x; Roddie C, 2011, EXPERT OPIN BIOL TH, V11, P473, DOI 10.1517/14712598.2011.554811; Rodgers DT, 2016, P NATL ACAD SCI USA, V113, pE459, DOI 10.1073/pnas.1524155113; Romee R, 2012, BLOOD, V120, P4751, DOI 10.1182/blood-2012-04-419283; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; Rubinstein MP, 2008, BLOOD, V112, P3704, DOI 10.1182/blood-2008-06-160945; Serrano LM, 2006, BLOOD, V107, P2643, DOI 10.1182/blood-2005-09-3904; Sharma R, 2018, IMMUNOL RES, V66, P151, DOI 10.1007/s12026-017-8982-3; Sheldon S, 2006, METH MOL B, V333, P157; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Smith J, 2000, NUCLEIC ACIDS RES, V28, P3361, DOI 10.1093/nar/28.17.3361; Stratton SL, 2010, AM J CLIN NUTR, V92, P1399, DOI 10.3945/ajcn.110.002543; Sun N, 2013, BIOTECHNOL BIOENG, V110, P1811, DOI 10.1002/bit.24890; Tal Y, 2014, ONCOTARGET, V5, P10949, DOI 10.18632/oncotarget.1919; Tang XW, 2018, AM J CANCER RES, V8, P1899; Tasian SK, 2017, BLOOD, V129, P2395, DOI 10.1182/blood-2016-08-736041; Taylor CJ, 2012, CELL STEM CELL, V11, P147, DOI 10.1016/j.stem.2012.07.014; Therapeutics C, 2020, CREATING TRANSFORMAT; Tonn T, 2013, CYTOTHERAPY, V15, P1563, DOI 10.1016/j.jcyt.2013.06.017; Torikai H, 2013, BLOOD, V122, P1341, DOI 10.1182/blood-2013-03-478255; Torikai H, 2012, BLOOD, V119, P5697, DOI 10.1182/blood-2012-01-405365; Tosolini M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284723; Urbanska K, 2012, CANCER RES, V72, P1844, DOI 10.1158/0008-5472.CAN-11-3890; Walsh S, 2003, ANTIMICROB AGENTS CH, V47, P554, DOI 10.1128/AAC.47.2.554-558.2003; Wiebking V, 2021, HAEMATOLOGICA, V106, P847, DOI 10.3324/haematol.2019.233882; Yang YY, 2019, REGEN THER, V11, P139, DOI 10.1016/j.reth.2019.06.006; Yang YM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1209; Yu SN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1057-4; Zhang EH, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0759-3; Zhang T, 2011, CANCER RES, V71, P2066, DOI 10.1158/0008-5472.CAN-10-3200; Zocchi MR, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1278099; Zoine JT, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1593804	145	2	2	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 10	2020	11								604915	10.3389/fimmu.2020.604915	http://dx.doi.org/10.3389/fimmu.2020.604915			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PI7HL	33362790	gold, Green Published			2022-12-18	WOS:000601257500001
J	Martin, RRR; Gonzalez, OG; Gonzalez, CR; Gonzalez, RRR				Rodriguez Martin, Roman R.; Gonzalez Gonzalez, Olivia; Rodriguez Gonzalez, Carolina; Rodriguez Gonzalez, Rene R.			Biomodulina T (InmunyVital(R)) Restores T Cells and Helps Contain COVID-19	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Biomodulina T; InmunyVital; T cells; COVID-19; immunomodulator; immunotherapy; vaccine enhancer; immunosenescence	IMMUNITY		[Rodriguez Martin, Roman R.; Gonzalez Gonzalez, Olivia; Rodriguez Gonzalez, Carolina; Rodriguez Gonzalez, Rene R.] BIOLONG Corp, Miami, FL 33186 USA		Martin, RRR (corresponding author), BIOLONG Corp, Miami, FL 33186 USA.	info@biolonginternational.com						Aiello A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02247; [Anonymous], 2020, US BIOM T PREV INF I; Centers for Disease Control and Prevention (CDC), 2020, AGE 7 BEING FAMILIAL; Chiong Wong R, 1994, TRATAMIENTO ARTRITIS; Christian Lopez LC, 2000, REV CUBANA PEDIATR, V72, P3; Devesa Colina E, 1994, BIOMODULINA T COMO I; Exley AR, 2011, CLIN IMMUNOL, V140, P26, DOI 10.1016/j.clim.2011.03.007; Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960; Gamez ML, 2007, T REV MEX NEUROCI, V8, P28; García Orihuela Marlene, 2014, Rev haban cienc méd, V13, P425; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Jauma AJ, 2011, VACCIMONITOR, V20 Supplement, P1; Jimenez Mesa G, 1991, 22 C PAN ENF DIG 14; Lang PO, 2013, AGE, V35, P609, DOI 10.1007/s11357-012-9393-y; Lara Rodriguez RF, 2003, TRATAMIENTO EXACERBA; Leon Cofino L, 1994, THESIS; Suarez-Formigo GM, 2020, MEDICC REV, V22, P54, DOI 10.37757/MR2020.V22.N3.11; Marsan Suarez V, 2011, REV CUBANA HEMATOL I, V27, P342; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Milke Garcia MP., 2011, ANN HEPATOL S2, V10, pS45; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Molinet Fuertes EJ, 2002, REV CUBA REUMATOL, Vn IV, P68; Rios Hernandez M, 1993, EVALUACION ACTIVIDAD; Rodriguez Martin R.R., 2020, HIST DISCOVERY DEV B, DOI [10.2139/ssrn.3678181, DOI 10.2139/SSRN.3678181]; Rodriguez Martin RR, 1993, REV CUBANA MED MILIT, V22, P108; Rodriguez Martin RR, 1994, REV CUB MED MILITAR, V23, P31; Rodriguez Martin RR, 1997, BIOMODULINA T MULTIP, P60; Rodriguez Martin RR, 1994, REGISTRO SANITARIO B; Rodriguez Martin RR, 1988, REV CUBANA FARM, V22, P72; Rodriguez Martin RR, 1993, REV CUB MED MILITAR, V22, P17; Rodriguez Martin RR, 1996, PERIODICO GRANM 0601; Rodriguez Martin RR, 1989, PERIODICO GRANMA, V25, P1; Saavedra D, 2019, EXP GERONTOL, V124, DOI 10.1016/j.exger.2019.110633; Tufet M, 2007, NAT REV IMMUNOL, V7, P834, DOI 10.1038/nri2197; Vega Sanchez H, 1993, TRATAMIENTO HEPATITI; Vega Sanchez H, 1991, LA HAB CUB 17 C AS L; WILSON AB, 1973, INT ARCH ALLER A IMM, V44, P544, DOI 10.1159/000230959; Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3	38	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2020	11								606447	10.3389/fimmu.2020.606447	http://dx.doi.org/10.3389/fimmu.2020.606447			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PI2OZ		Green Published, gold			2022-12-18	WOS:000600937300001
J	Squire, JD; Vazquez, SN; Chan, A; Smith, ME; Chellapandian, D; Vose, L; Teppa, B; Hanson, IC; Chinn, IK; Forbes-Satter, L; Seeborg, FO; Nicholas, SK; Martinez, CA; Allen, CE; Connors, TJ; Satwani, P; Shtessel, M; Ale, H; Noroski, LM; Rider, NL; Milner, JD; Leiding, JW				Squire, Jacqueline D.; Vazquez, Stephanie N.; Chan, Angela; Smith, Michele E.; Chellapandian, Deepak; Vose, Laura; Teppa, Beatriz; Hanson, I. Celine; Chinn, Ivan K.; Forbes-Satter, Lisa; Seeborg, Filiz O.; Nicholas, Sarah K.; Martinez, Caridad A.; Allen, Carl E.; Connors, Thomas J.; Satwani, Prakash; Shtessel, Maria; Ale, Hanadys; Noroski, Lenora M.; Rider, Nicholas L.; Milner, Joshua D.; Leiding, Jennifer W.			Case Report: Secondary Hemophagocytic Lymphohistiocytosis With Disseminated Infection in Chronic Granulomatous Disease-A Serious Cause of Mortality	FRONTIERS IN IMMUNOLOGY			English	Article						chronic granulomatous disease; hemophagocytic lymphohistiocytosis; sepsis; inflammation; case report; infection; primary immune deficiency	DIFFERENTIAL-DIAGNOSIS; EMAPALUMAB; CHILD	Chronic granulomatous disease (CGD) is a primary immune deficiency due to defects in phagocyte respiratory burst leading to severe and life-threatening infections. Patients with CGD also suffer from disorders of inflammation and immune dysregulation including colitis and granulomatous lung disease, among others. Additionally, patients with CGD may be at increased risk of systemic inflammatory disorders such as hemophagocytic lymphohistiocytosis (HLH). The presentation of HLH often overlaps with symptoms of systemic inflammatory response syndrome (SIRS) or sepsis and therefore can be difficult to identify, especially in patients with a primary immune deficiency in which incidence of infection is increased. Thorough evaluation and empiric treatment for bacterial and fungal infections is necessary as HLH in CGD is almost always secondary to infection. Simultaneous treatment of infection with anti-microbials and inflammation with immunosuppression may be needed to blunt the hyperinflammatory response in secondary HLH. Herein, we present a series of X-linked CGD patients who developed HLH secondary to or with concurrent disseminated CGD-related infection. In two patients, CGD was a known diagnosis prior to development of HLH and in the other two CGD was diagnosed as part of the evaluation for HLH. Concurrent infection and HLH were fatal in three; one case was successfully treated, ultimately receiving hematopoietic stem cell transplantation. The current literature on presentation, diagnosis, and treatment of HLH in CGD is reviewed.	[Squire, Jacqueline D.; Leiding, Jennifer W.] Univ S Florida, Dept Pediat, Div Allergy & Immunol, St Petersburg, FL 33701 USA; [Vazquez, Stephanie N.] Mem Healthcare Syst, Grad Med Educ, Hollywood, FL USA; [Chan, Angela; Shtessel, Maria; Milner, Joshua D.] Columbia Univ, Dept Pediat, Irving Med Ctr, Div Allergy Immunol & Rheumatol, New York, NY 10027 USA; [Smith, Michele E.; Connors, Thomas J.] Columbia Univ, Dept Pediat, Div Crit Care Med, Irving Med Ctr, New York, NY 10027 USA; [Chellapandian, Deepak] Johns Hopkins All Childrens Hosp, Blood & Marrow Transplant, St Petersburg, FL USA; [Vose, Laura; Teppa, Beatriz] Johns Hopkins All Childrens Hosp, Crit Care Med, St Petersburg, FL USA; [Hanson, I. Celine; Chinn, Ivan K.; Forbes-Satter, Lisa; Seeborg, Filiz O.; Nicholas, Sarah K.; Noroski, Lenora M.; Rider, Nicholas L.] Baylor Coll Med, Immunol Sect, Houston, TX 77030 USA; [Hanson, I. Celine; Chinn, Ivan K.; Forbes-Satter, Lisa; Seeborg, Filiz O.; Nicholas, Sarah K.; Martinez, Caridad A.; Allen, Carl E.; Noroski, Lenora M.; Rider, Nicholas L.] Baylor Coll Med, Sect Allergy, Houston, TX 77030 USA; [Hanson, I. Celine; Chinn, Ivan K.; Forbes-Satter, Lisa; Seeborg, Filiz O.; Nicholas, Sarah K.; Martinez, Caridad A.; Allen, Carl E.; Noroski, Lenora M.; Rider, Nicholas L.] Baylor Coll Med, Sect Retrovirol, Houston, TX 77030 USA; [Hanson, I. Celine; Chinn, Ivan K.; Forbes-Satter, Lisa; Seeborg, Filiz O.; Nicholas, Sarah K.; Martinez, Caridad A.; Allen, Carl E.; Noroski, Lenora M.; Rider, Nicholas L.] Texas Childrens Hosp, Houston, TX 77030 USA; [Martinez, Caridad A.; Allen, Carl E.] Texas Childrens Hosp Canc Ctr, Div Pediat Hematol Oncol, Houston, TX USA; [Satwani, Prakash] Columbia Univ, Dept Pediat, Div Hematol Oncol, Irving Med Ctr, New York, NY 10027 USA; [Ale, Hanadys] Joe DiMaggio Childrens Hosp, Div Allergy & Immunol, Hollywood, FL USA	State University System of Florida; University of South Florida; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Columbia University; NewYork-Presbyterian Hospital	Leiding, JW (corresponding author), Univ S Florida, Dept Pediat, Div Allergy & Immunol, St Petersburg, FL 33701 USA.	jleiding@usf.edu	Chellapandian, Deepak/AAH-1857-2020	Chellapandian, Deepak/0000-0003-3518-9790; Chinn, Ivan/0000-0001-5684-5457; Connors, Thomas/0000-0002-0199-7733	 [K23 AI141686]		The authors wish to thank Wilfredo Chamizo, MD, John Hopkins All Children's Hospital, Director of Pathology and Laboratory Medicine for hemophagocytosis images within Figure 2. Work was supported in part by K23 AI141686 (TC).	Akagi K, 2014, J PEDIAT HEMATOL ONC, V36, pE169, DOI 10.1097/MPH.0b013e31828e5dae; Alvarez-Cardona A, 2012, J CLIN IMMUNOL, V32, P207, DOI 10.1007/s10875-011-9616-5; Bode SFN, 2015, HAEMATOLOGICA, V100, P978, DOI 10.3324/haematol.2014.121608; Chinn IK, 2018, BLOOD, V132, P89, DOI 10.1182/blood-2017-11-814244; Crayne CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00119; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Henrickson SE, 2018, J PEDIAT INF DIS SOC, V7, pS18, DOI 10.1093/jpids/piy014; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Hisano M, 2007, J MED MICROBIOL, V56, P702, DOI 10.1099/jmm.0.47071-0; Locatelli F, 2020, NEW ENGL J MED, V382, P1811, DOI 10.1056/NEJMoa1911326; Lounder DT, 2019, BLOOD ADV, V3, P47, DOI 10.1182/bloodadvances.2018025858; Machowicz R, 2017, CRIT REV ONCOL HEMAT, V114, P1, DOI 10.1016/j.critrevonc.2017.03.023; Marsh RA, 2013, PEDIATR BLOOD CANCER, V60, P101, DOI 10.1002/pbc.24188; Martin A, 2009, PEDIATR INFECT DIS J, V28, P753, DOI 10.1097/INF.0b013e31819c6f3a; Morimoto A, 2016, PEDIATR INT, V58, P817, DOI 10.1111/ped.13064; Onrust SV, 1999, DRUGS, V57, P207, DOI 10.2165/00003495-199957020-00006; Parekh C, 2011, PEDIATR BLOOD CANCER, V56, P460, DOI 10.1002/pbc.22830; Rajasekaran S, 2014, PEDIATR CRIT CARE ME, V15, P401, DOI 10.1097/PCC.0000000000000078; Ravelli A, 2015, HEMATOL ONCOL CLIN N, V29, P927, DOI 10.1016/j.hoc.2015.06.010; Risma KA, 2019, J ALLER CL IMM-PRACT, V7, P824, DOI 10.1016/j.jaip.2018.11.050; Scheffler-Mendoza SC, 2014, CLIN IMMUNOL, V154, P112, DOI 10.1016/j.clim.2014.07.004; Sirinavin S, 2004, PEDIATR INFECT DIS J, V23, P882, DOI 10.1097/01.inf.0000137565.23501.03; Tesi B, 2015, J ALLERGY CLIN IMMUN, V135, P1638, DOI 10.1016/j.jaci.2014.11.030; Valentine G, 2014, PEDIATRICS, V134, pE1727, DOI 10.1542/peds.2014-2175; Vallurupalli M, 2019, BLOOD, V134, P1783, DOI 10.1182/blood.2019002289; van Montfrans JA, 2009, PEDIATR BLOOD CANCER, V52, P527, DOI 10.1002/pbc.21851; Wang YN, 2017, CURR OPIN HEMATOL, V24, P54, DOI 10.1097/MOH.0000000000000302	27	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 9	2020	11								581475	10.3389/fimmu.2020.581475	http://dx.doi.org/10.3389/fimmu.2020.581475			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PI2SR	33362767	Green Published, gold			2022-12-18	WOS:000600946900001
J	Kim, SJ; Sin, JI; Kim, MJ				Kim, Sun Jin; Sin, Jeong-Im; Kim, Min Ja			CD8(+) T Cells Directed Against a Peptide Epitope Derived From Peptidoglycan-Associated Lipoprotein of Legionella pneumophila Confer Disease Protection	FRONTIERS IN IMMUNOLOGY			English	Article						Legionella pneumophila; peptidoglycan-associated lipoprotein; peptide epitope; cytotoxic T-lymphocyte; adaptive immunity	MAJOR SECRETORY PROTEIN; LEGIONNAIRES-DISEASE; IMMUNITY; RESPONSES; CYCLOPHOSPHAMIDE; VACCINATION; SEROGROUPS; ANTIBODY; ECOLOGY; MODEL	Legionella pneumophila, an intracellular bacterium, may cause life-threatening pneumonia in immunocompromised individuals. Mononuclear cells and antibodies have been reported to be associated with the host defense response against L. pneumophila. This study is to determine whether Legionella peptidoglycan-associated lipoprotein (PAL)-specific CD8(+) T cells are directly associated with protection against L. pneumophila, with a focus on potential epitopes. Synthetic peptides derived from PAL of L. pneumophila were obtained and tested through in vitro and in vivo cytotoxic T lymphocyte (CTL) assays for immunogenicity. PAL DNA vaccines or a peptide epitope with or without CpG-oligodeoxynucleotides (ODN) was evaluated for protection against L. pneumophila infection in animal models. When mice were immunized with DNA vaccines expressing the PAL of L. pneumophila, they were significantly protected against a lethal challenge with L. pneumophila through induction of antigen-specific CD8(+) CTLs. Of the 13 PAL peptides tested, PAL(92-100) (EYLKTHPGA) was the most immunogenic and induced the strongest CTL responses. When mice were immunized with the PAL(92-100) peptide plus CpG-ODN, they were protected against the lethal challenge, while control mice died within 3-6 days after the challenge. Consistent with lung tissue histological data, bacterial counts in the lungs of immunized mice were significantly lower than those in control mice. Also, the amino acid sequence of PAL(92-100) peptides is conserved among various Legionella species. To our knowledge, this study is the first to demonstrate that PAL(92-100)-specific CD8(+) T cells play a central role in the host defense response against L. pneumophila.	[Kim, Sun Jin; Kim, Min Ja] Korea Univ, Coll Med, Dept Med, Seoul, South Korea; [Sin, Jeong-Im] Kangwon Natl Univ, Sch Med, Dept Microbiol, Gangwon, Gangwon Do, South Korea; [Kim, Min Ja] Korea Univ, Anam Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Seoul, South Korea; [Kim, Min Ja] Korea Univ, Inst Emerging Infect Dis, Coll Med, Seoul, South Korea	Korea University; Korea University Medicine (KU Medicine); Kangwon National University; Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine)	Kim, MJ (corresponding author), Korea Univ, Coll Med, Dept Med, Seoul, South Korea.; Kim, MJ (corresponding author), Korea Univ, Anam Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Seoul, South Korea.; Kim, MJ (corresponding author), Korea Univ, Inst Emerging Infect Dis, Coll Med, Seoul, South Korea.	macropha@korea.ac.kr		KIM, MIN JA/0000-0002-2125-7521	National Research Foundation of Korea (NRF) - Korean government (Ministry of Science and ICT) [NRF-2017R1D1A1B03034363]	National Research Foundation of Korea (NRF) - Korean government (Ministry of Science and ICT)	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT) (No. NRF-2017R1D1A1B03034363).	Abu Kwaik Y, 1998, APPL ENVIRON MICROB, V64, P3127; Bae SH, 2007, CLIN CANCER RES, V13, P341, DOI 10.1158/1078-0432.CCR-06-1838; BLANDER SJ, 1991, J IMMUNOL, V147, P285; BLANDER SJ, 1991, J CLIN INVEST, V87, P1054, DOI 10.1172/JCI115065; Diederen BMW, 2008, J INFECTION, V56, P1, DOI 10.1016/j.jinf.2007.09.010; ENGLEBERG NC, 1991, MOL MICROBIOL, V5, P2021, DOI 10.1111/j.1365-2958.1991.tb00824.x; Fields BS, 2002, CLIN MICROBIOL REV, V15, P506, DOI 10.1128/CMR.15.3.506-526.2002; Fields BS, 1996, TRENDS MICROBIOL, V4, P286, DOI 10.1016/0966-842X(96)10041-X; FOY HM, 1979, LANCET, V1, P767; Ham H, 2011, NAT REV MICROBIOL, V9, P635, DOI 10.1038/nrmicro2602; Han BS, 2018, CLIN EXP VACCINE RES, V7, P119, DOI 10.7774/cevr.2018.7.2.119; Harrison TG, 2001, EUR J CLIN MICROBIOL, V20, P738, DOI 10.1007/s100960100598; Harty JT, 1999, CURR OPIN IMMUNOL, V11, P89, DOI 10.1016/S0952-7915(99)80016-8; HORWITZ MA, 1981, J EXP MED, V153, P398, DOI 10.1084/jem.153.2.398; HORWITZ MA, 1983, J CLIN INVEST, V71, P1686, DOI 10.1172/JCI110923; Huyan XH, 2011, INT IMMUNOPHARMACOL, V11, P1293, DOI 10.1016/j.intimp.2011.04.011; Isberg RR, 2009, NAT REV MICROBIOL, V7, P12, DOI 10.1038/nrmicro1967; Kim MJ, 2003, J CLIN MICROBIOL, V41, P2974, DOI 10.1128/JCM.41.7.2974-2979.2003; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Mobarez AM, 2019, MICROB PATHOGENESIS, V128, P100, DOI 10.1016/j.micpath.2018.12.014; NASH TW, 1984, J CLIN INVEST, V74, P771, DOI 10.1172/JCI111493; Naz RK, 2007, FRONT BIOSCI-LANDMRK, V12, P1833, DOI 10.2741/2191; Shim HK, 2009, EXP MOL MED, V41, P687, DOI 10.3858/emm.2009.41.10.075; Sin JI, 2012, CANCER IMMUNOL IMMUN, V61, P1671, DOI 10.1007/s00262-012-1214-8; Sistigu A, 2011, SEMIN IMMUNOPATHOL, V33, P369, DOI 10.1007/s00281-011-0245-0; Vergis EN, 2000, SEMIN RESP CRIT CARE, V21, P295, DOI 10.1055/s-2000-9934; Weber SS, 2019, EUR J IMMUNOL, V49, P1415, DOI 10.1002/eji.201948106; WIDEN R, 1984, J INFECT DIS, V149, P1023, DOI 10.1093/infdis/149.6.1023; Xu JN, 2012, DIAGN MICR INFEC DIS, V73, P9, DOI 10.1016/j.diagmicrobio.2012.02.013; Yoon WS, 2002, DNA CELL BIOL, V21, P99, DOI 10.1089/104454902753604970; Yu VL, 2002, J INFECT DIS, V186, P127, DOI 10.1086/341087	31	2	3	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2020	11								604413	10.3389/fimmu.2020.604413	http://dx.doi.org/10.3389/fimmu.2020.604413			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PH8HY	33363545	gold, Green Published			2022-12-18	WOS:000600647700001
J	Marichal, T; Boyman, O; Reber, LL				Marichal, Thomas; Boyman, Onur; Reber, Laurent L.			Editorial: Role of Neutrophils in Inflammatory Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neutrophils; inflammation; neutrophil extracellular trap; immunity; models	EXTRACELLULAR TRAPS		[Marichal, Thomas] Univ Liege, Grappe Interdisciplinaire Genoprote Appl GIGA, Immunophysiol Lab, Liege, Belgium; [Marichal, Thomas] Univ Liege, Fac Vet Med, Liege, Belgium; [Marichal, Thomas] WELBIO, Walloon Excellence Life Sci & Biotechnol, Wallonia, Belgium; [Boyman, Onur] Univ Hosp Zurich, Dept Immunol, Zurich, Switzerland; [Boyman, Onur] Univ Zurich, Fac Med, Zurich, Switzerland; [Reber, Laurent L.] Inst Pasteur, INSERM UMR1222, Unit Antibodies Therapy & Pathol, Paris, France; [Reber, Laurent L.] Univ Toulouse, Ctr Physiopathol Toulouse Purpan CPTP, INSERM, UMR 1043,CNRS, Toulouse, France	University of Liege; University of Liege; WELBIO; University of Zurich; University Zurich Hospital; University of Geneva; University of Zurich; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Marichal, T (corresponding author), Univ Liege, Grappe Interdisciplinaire Genoprote Appl GIGA, Immunophysiol Lab, Liege, Belgium.; Marichal, T (corresponding author), Univ Liege, Fac Vet Med, Liege, Belgium.; Marichal, T (corresponding author), WELBIO, Walloon Excellence Life Sci & Biotechnol, Wallonia, Belgium.; Boyman, O (corresponding author), Univ Hosp Zurich, Dept Immunol, Zurich, Switzerland.; Boyman, O (corresponding author), Univ Zurich, Fac Med, Zurich, Switzerland.; Reber, LL (corresponding author), Inst Pasteur, INSERM UMR1222, Unit Antibodies Therapy & Pathol, Paris, France.; Reber, LL (corresponding author), Univ Toulouse, Ctr Physiopathol Toulouse Purpan CPTP, INSERM, UMR 1043,CNRS, Toulouse, France.	t.marichal@uliege.be; onur.boyman@uzh.ch; laurent.reber@inserm.fr	Reber, Laurent L/K-4148-2014	Reber, Laurent L/0000-0003-3384-6769	FRFS-WELBIO (Walloon Excellence in Life Sciences and Biotechnology) [CR-2019s-04R]; Acteria Foundation; ERC Starting Grant [ERC-StG-2018 IM-ID 801823]; Swiss National Science Foundation [310030-172978]; Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie); Clinical Research Priority Program CYTIMM-Z of the University of Zurich; French Institut National de la Sante et de la Recherche Me'dicale (INSERM); ATIP-Avenir program	FRFS-WELBIO (Walloon Excellence in Life Sciences and Biotechnology); Acteria Foundation; ERC Starting Grant(European Research Council (ERC)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie); Clinical Research Priority Program CYTIMM-Z of the University of Zurich; French Institut National de la Sante et de la Recherche Me'dicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); ATIP-Avenir program	TM is supported by the FRFS-WELBIO (Walloon Excellence in Life Sciences and Biotechnology; grant no. CR-2019s-04R), by the Acteria Foundation and by an ERC Starting Grant (grant no. ERC-StG-2018 IM-ID 801823). OB received funding by the Swiss National Science Foundation (310030-172978), the Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie), and the Clinical Research Priority Program CYTIMM-Z of the University of Zurich. LR acknowledges support from the French Institut National de la Sante ' et de la Recherche Me ' dicale (INSERM) and the ATIP-Avenir program.	Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Soehnlein O, 2017, NAT REV IMMUNOL, V17, P248, DOI 10.1038/nri.2017.10	5	2	2	8	29	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 8	2020	11								627939	10.3389/fimmu.2020.627939	http://dx.doi.org/10.3389/fimmu.2020.627939			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PH7YP	33363549	gold, Green Published, Green Accepted			2022-12-18	WOS:000600623400001
J	Kurbatova, EA; Akhmatova, NK; Zaytsev, AE; Akhmatova, EA; Egorova, NB; Yastrebova, NE; Sukhova, EV; Yashunsky, DV; Tsvetkov, YE; Nifantiev, NE				Kurbatova, Ekaterina A.; Akhmatova, Nelli K.; Zaytsev, Anton E.; Akhmatova, Elina A.; Egorova, Nadezhda B.; Yastrebova, Natalya E.; Sukhova, Elena, V; Yashunsky, Dmitriy, V; Tsvetkov, Yury E.; Nifantiev, Nikolay E.			Higher Cytokine and Opsonizing Antibody Production Induced by Bovine Serum Albumin (BSA)-Conjugated Tetrasaccharide Related to Streptococcus pneumoniae Type 3 Capsular Polysaccharide	FRONTIERS IN IMMUNOLOGY			English	Article						Streptococcus pneumoniae type 3; synthetic oligosaccharide; biotinylated oligosaccharide; conjugated oligosaccharide; antigen-binding capacity; vaccine; antibody; opsonophagocytosis	PNEUMOCOCCAL CONJUGATE VACCINE; INNATE IMMUNITY; OTITIS-MEDIA; SEROTYPE; OLIGOSACCHARIDES; IMMUNOGENICITY; PROTECTION; DISEASE; ASSAY; HEXASACCHARIDE	A number of studies have demonstrated the limited efficacy of S. pneumoniae type 3 capsular polysaccharide (CP) in the 13-valent pneumococcal conjugate vaccine against serotype 3 invasive pneumococcal diseases and carriage. Synthetic oligosaccharides (OSs) may provide an alternative to CPs for development of novel conjugated pneumococcal vaccines and diagnostic test systems. A comparative immunological study of di-, tri-, and tetra-bovine serum albumin (BSA) conjugates was performed. All oligosaccharides conjugated with biotin and immobilized on streptavidin-coated plates stimulated production of IL-1 alpha, IL-2, IL-4, IL-5, IL-10, IFN gamma, IL-17A, and TNF alpha, but not IL-6 and GM-CSF in monocultured mice splenocytes. The tetrasaccharide-biotin conjugate stimulated the highest levels of IL-4, IL-5, IL-10, and IFN gamma, which regulate expression of specific immunoglobulin isotypes. The tetra-BSA conjugate adjuvanted with aluminum hydroxide elicited high levels of IgM, IgG1, IgG2a, and IgG2b antibodies (Abs). Anti-CP-induced Abs could only be measured using the biotinylated tetrasaccharide. The tetrasaccharide ligand possessed the highest binding capacity for anti-OS and antibacterial IgG Abs in immune sera. Sera to the tetra-BSA conjugate promoted greater phagocytosis of bacteria by neutrophils and monocytes than the CRM197-CP-antisera. Sera of mice immunized with the tetra-BSA conjugate exhibited the highest titer of anti-CP IgG1 Abs compared with sera of mice inoculated with the same doses of di- and tri-BSA conjugates. Upon intraperitoneal challenge with lethal doses of S. pneumoniae type 3, the tri- and tetra-BSA conjugates protected mice more significantly than the di-BSA conjugate. Therefore, it may be concluded that the tetrasaccharide ligand is an optimal candidate for development of a semi-synthetic vaccine against S. pneumoniae type 3 and diagnostic test systems.	[Kurbatova, Ekaterina A.; Akhmatova, Nelli K.; Zaytsev, Anton E.; Egorova, Nadezhda B.; Yastrebova, Natalya E.] Mechrukov Res Inst Vaccines & Sera, Lab Therapeut Vaccines, Moscow, Russia; [Akhmatova, Elina A.; Sukhova, Elena, V; Yashunsky, Dmitriy, V; Tsvetkov, Yury E.; Nifantiev, Nikolay E.] Russian Acad Sci, ND Zelinsky Inst Organ Chem, Lab Glycoconjugate Chem, Moscow, Russia	Russian Academy of Sciences; Zelinsky Institute of Organic Chemistry	Kurbatova, EA (corresponding author), Mechrukov Res Inst Vaccines & Sera, Lab Therapeut Vaccines, Moscow, Russia.; Nifantiev, NE (corresponding author), Russian Acad Sci, ND Zelinsky Inst Organ Chem, Lab Glycoconjugate Chem, Moscow, Russia.	kurbatova6162@yandex.ru; nen@ioc.ac.ru	Nifantiev, Nikolay E/O-6579-2015; Tsvetkov, Yury/ABG-1841-2021; zaytsev, anton/AAE-7704-2022; Kurbatova, Ekaterina A/M-3460-2018	Nifantiev, Nikolay E/0000-0002-0727-4050; 	Russian Science Foundation [19-73-30017]	Russian Science Foundation(Russian Science Foundation (RSF))	This work was supported by the Russian Science Foundation (grant no. 19-73-30017).	Akata K, 2015, J INFECT CHEMOTHER, V21, P723, DOI 10.1016/j.jiac.2015.07.002; Akhmatova NK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00248; Ananikov VP, 2017, MENDELEEV COMMUN, V27, P425, DOI 10.1016/j.mencom.2017.09.001; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; Argunov DA, 2019, EUR J ORG CHEM, V2019, P4226, DOI 10.1002/ejoc.201900389; Asner SA, 2019, CLIN INFECT DIS, V69, P1574, DOI 10.1093/cid/ciy1139; Badten AJ, 2019, J IMMUNOL, V202; Benaissa-Trouw B, 2001, INFECT IMMUN, V69, P4698, DOI 10.1128/IAI.69.7.4698-4701.2001; Bender JM, 2008, CLIN INFECT DIS, V46, P1346, DOI 10.1086/586747; BRILES DE, 1992, INFECT IMMUN, V60, P111, DOI 10.1128/IAI.60.1.111-116.1992; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Byington CL, 2006, PEDIATR INFECT DIS J, V25, P250, DOI 10.1097/01.inf.0000202137.37642.ab; Chiba N., 2011, JPN J CHEMOTHER, V59, P561; Choi EH, 2016, CLIN VACCINE IMMUNOL, V23, P162, DOI 10.1128/CVI.00591-15; Coffman R L, 1989, Semin Immunol, V1, P55; COLMAN G, 1983, J INFECTION, V7, P248, DOI 10.1016/S0163-4453(83)97169-4; Cywes-Bentley C, 2013, P NATL ACAD SCI USA, V110, pE2209, DOI 10.1073/pnas.1303573110; De Hennezel L, 2001, ANTIMICROB AGENTS CH, V45, P316, DOI 10.1128/AAC.45.1.316-318.2001; Elder MJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00791; Feng SJ, 2019, ACS INFECT DIS, V5, P1423, DOI 10.1021/acsinfecdis.9b00103; Ferreira LMR, 2013, INT REV IMMUNOL, V32, P223, DOI 10.3109/08830185.2013.783831; FINLAND M, 1977, J CLIN MICROBIOL, V5, P154; Galan MC, 2013, CHEM SOC REV, V42, P4599, DOI 10.1039/c2cs35413f; Gening ML, 2015, RUSS CHEM REV+, V84, P1100, DOI 10.1070/RCR4574; Gening ML, 2010, INFECT IMMUN, V78, P764, DOI 10.1128/IAI.01093-09; Grabenstein JD, 2014, VACCINE, V32, P2399, DOI 10.1016/j.vaccine.2014.02.096; Harboe ZB, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000081; Henriques B, 2000, J INFECT DIS, V182, P833, DOI 10.1086/315761; Inostroza J, 2001, CLIN DIAGN LAB IMMUN, V8, P556, DOI 10.1128/CDLI.8.3.556-559.2001; Inverarity D, 2011, J MED MICROBIOL, V60, P793, DOI 10.1099/jmm.0.028803-0; Jansen WTM, 2001, CLIN DIAGN LAB IMMUN, V8, P245, DOI 10.1128/CDLI.8.2.245-250.2001; Jeurissen A, 2004, IMMUNOLOGY, V111, P1, DOI 10.1111/j.1365-2567.2004.01775.x; Jha V, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010018; Kaplonek P, 2018, P NATL ACAD SCI USA, V115, P13353, DOI 10.1073/pnas.1811862115; Kawasaki S, 2015, ANN JPN RESP SOC, V4, P303; Kazakova ED, 2020, J AM CHEM SOC, V142, P1175, DOI 10.1021/jacs.9b11703; KOCHETKOV NK, 1987, TETRAHEDRON, V43, P3109, DOI 10.1016/S0040-4020(01)86852-6; Komarova BS, 2018, J ORG CHEM, V83, P12965, DOI 10.1021/acs.joc.8b01142; Komarova BS, 2015, CHEM-EUR J, V21, P1029, DOI 10.1002/chem.201404770; Krylov VB, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01173; Kurbatova EA, 2016, RUSS CHEM B+, V65, P1608, DOI 10.1007/s11172-016-1488-7; Kurbatova EA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00659; Laverde D, 2020, ACS INFECT DIS, V6, P1816, DOI 10.1021/acsinfecdis.0c00063; Lefeber DJ, 2003, INFECT IMMUN, V71, P6915, DOI 10.1128/IAI.71.12.6915-6920.2003; Leiva LE, 2001, CLIN DIAGN LAB IMMUN, V8, P233, DOI 10.1128/CDLI.8.2.233-240.2001; Linley E, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010004; Martens P, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-21; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; Morimoto K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122247; Namkoong H, 2016, HUM VACC IMMUNOTHER, V12, P336, DOI 10.1080/21645515.2015.1075678; Neelamegham S, 2019, GLYCOBIOLOGY, V29, P620, DOI 10.1093/glycob/cwz045; Ostergaard C, 2004, J INFECT DIS, V190, P1212, DOI 10.1086/423852; Parameswarappa SG, 2016, CELL CHEM BIOL, V23, P1407, DOI 10.1016/j.chembiol.2016.09.016; Paterson GK, 2006, MICROBIOL-SGM, V152, P285, DOI 10.1099/mic.0.28551-0; Plested Joyce S, 2003, Methods Mol Med, V71, P263; Poolman J, 2009, VACCINE, V27, P3213, DOI 10.1016/j.vaccine.2009.03.017; Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9; Reeves RE, 1941, J BIOL CHEM, V139, P511; RomeroSteiner S, 1997, CLIN DIAGN LAB IMMUN, V4, P415, DOI 10.1128/CDLI.4.4.415-422.1997; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; Scott JAG, 1996, CLIN INFECT DIS, V22, P973, DOI 10.1093/clinids/22.6.973; Shiramoto M, 2015, HUM VACC IMMUNOTHER, V11, P2198, DOI 10.1080/21645515.2015.1030550; Shparago N, 1996, INT IMMUNOL, V8, P781, DOI 10.1093/intimm/8.5.781; SNIPPE H, 1983, INFECT IMMUN, V40, P856, DOI 10.1128/IAI.40.3.856-861.1983; Song JY, 2013, J INFECT CHEMOTHER, V19, P412, DOI 10.1007/s10156-013-0601-1; SPERLING AI, 1992, J IMMUNOL, V149, P3200; Stephen-Victor E, 2017, J INFECT DIS, V216, P1281, DOI 10.1093/infdis/jix469; Sugimoto N, 2017, BMC RES NOTES, V10, DOI 10.1186/s13104-016-2353-3; Tsvetkov YE, 2017, RUSS CHEM B+, V66, P111, DOI 10.1007/s11172-017-1708-9; Tsvetkov YE, 2017, PURE APPL CHEM, V89, P1403, DOI 10.1515/pac-2016-1123; Valiante NM, 2003, CELL MICROBIOL, V5, P755, DOI 10.1046/j.1462-5822.2003.00318.x; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; Verkhnyatskaya SA, 2017, EUR J ORG CHEM, V2017, P710, DOI 10.1002/ejoc.201601413; Weinberger DM, 2010, CLIN INFECT DIS, V51, P692, DOI 10.1086/655828; Wong SSW, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00688-19; Xiong CH, 2018, CHEM-EUR J, V24, P8205, DOI 10.1002/chem.201800754; Zamze S, 2002, J BIOL CHEM, V277, P41613, DOI 10.1074/jbc.M207057200	78	2	3	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 4	2020	11								578019	10.3389/fimmu.2020.578019	http://dx.doi.org/10.3389/fimmu.2020.578019			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PG3BN	33343566	gold, Green Published			2022-12-18	WOS:000599614400001
J	Harsh, S; Eleftherianos, I				Harsh, Sneh; Eleftherianos, Ioannis			Flavivirus Infection and Regulation of Host Immune and Tissue Homeostasis in Insects	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						flavivirus; mosquito; Drosophila; immunity; homeostasis; pathophysiology	AEDES-AEGYPTI; VIRUS; DENGUE; PROTEIN; REPLICATION; DROSOPHILA; APOPTOSIS; TROPISMS; BINDING; MIDGUT		[Harsh, Sneh; Eleftherianos, Ioannis] George Washington Univ, Dept Biol Sci, Inst Biomed Sci, Infect & Innate Immun Lab, Washington, DC 20052 USA; [Harsh, Sneh] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY USA	George Washington University; New York University	Eleftherianos, I (corresponding author), George Washington Univ, Dept Biol Sci, Inst Biomed Sci, Infect & Innate Immun Lab, Washington, DC 20052 USA.	ioannise@gwu.edu	HARSH, SNEH/AAE-7485-2022; Harsh, Sneh/GLV-4382-2022		Department of Biological Sciences and Columbian College of Arts and Science at The George Washington University	Department of Biological Sciences and Columbian College of Arts and Science at The George Washington University	We would like to thank the Department of Biological Sciences and Columbian College of Arts and Science at The George Washington University for providing support to our research.	Ahlers LRH, 2019, CELL REP, V29, P1946, DOI 10.1016/j.celrep.2019.10.029; Alonso-Palomares LA, 2019, INTERVIROLOGY, V61, P255, DOI 10.1159/000499128; Anglero-Rodriguez YI, 2017, ELIFE, V6, DOI 10.7554/eLife.28844; Anglero-Rodriguez YI, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02050; Apte-Deshpande A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040401; Bottino-Rojas V, 2018, J BIOL CHEM, V293, P9053, DOI 10.1074/jbc.RA117.001589; Carvalho FA, 2012, J VIROL, V86, P2096, DOI 10.1128/JVI.06796-11; Chong HY, 2019, VIRUS RES, V274, DOI 10.1016/j.virusres.2019.197770; Colpitts TM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002189; Eng MW, 2016, INSECT BIOCHEM MOLEC, V76, P70, DOI 10.1016/j.ibmb.2016.07.004; Fernandez-Garcia MD, 2009, CELL HOST MICROBE, V5, P318, DOI 10.1016/j.chom.2009.04.001; Barletta ABF, 2016, SCI REP-UK, V6, DOI 10.1038/srep19928; Franz AWE, 2015, VIRUSES-BASEL, V7, P3741, DOI 10.3390/v7072795; Girard YA, 2004, VECTOR-BORNE ZOONOT, V4, P109, DOI 10.1089/1530366041210729; Harsh S, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.040816; Harsh S, 2018, J IMMUNOL, V201, P3058, DOI 10.4049/jimmunol.1800597; Huang YJS, 2014, VIRUSES-BASEL, V6, P4703, DOI 10.3390/v6114703; Jupatanakul N, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005187; Li S, 2019, ANNU REV ENTOMOL, V64, P315, DOI 10.1146/annurev-ento-011118-112007; Link N, 2019, DEV CELL, V51, P713, DOI 10.1016/j.devcel.2019.10.009; Linthicum KJ, 1996, MED VET ENTOMOL, V10, P87, DOI 10.1111/j.1365-2915.1996.tb00086.x; Liu B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003137; Liu T, 2018, DEV COMP IMMUNOL, V83, P34, DOI 10.1016/j.dci.2017.12.025; Liu Y, 2018, CELL HOST MICROBE, V24, P57, DOI 10.1016/j.chom.2018.05.022; Martins IC, 2012, BIOCHEM J, V444, P405, DOI 10.1042/BJ20112219; McElroy KL, 2008, VECTOR-BORNE ZOONOT, V8, P675, DOI 10.1089/vbz.2007.0269; Merkling SH, 2013, J INSECT PHYSIOL, V59, P159, DOI 10.1016/j.jinsphys.2012.07.004; Ocampo CB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061187; Paradkar PN, 2012, P NATL ACAD SCI USA, V109, P18915, DOI 10.1073/pnas.1205231109; Plourde AR, 2016, EMERG INFECT DIS, V22, P1185, DOI 10.3201/eid2207.151990; Querenet M, 2015, FLY, V9, P1, DOI 10.1080/19336934.2015.1072662; Ramirez JL, 2010, DEV COMP IMMUNOL, V34, P625, DOI 10.1016/j.dci.2010.01.006; Saldana MA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005760; Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632; Samuel GH, 2018, TRENDS MICROBIOL, V26, P447, DOI 10.1016/j.tim.2017.12.005; Sanchez-Vargas I, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000299; Saraiva RG, 2016, DEV COMP IMMUNOL, V64, P53, DOI 10.1016/j.dci.2016.01.015; Serrato-Salas J, 2018, DEV COMP IMMUNOL, V84, P28, DOI 10.1016/j.dci.2018.01.022; Shah PS, 2018, CELL, V175, P1931, DOI 10.1016/j.cell.2018.11.028; Sim S, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002295; Sim S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002631; Sim S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010678; Soto-Acosta R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006257; Souza-Neto JA, 2009, P NATL ACAD SCI USA, V106, P17841, DOI 10.1073/pnas.0905006106; SRIURAIRATNA S, 1977, AM J TROP MED HYG, V26, P1199, DOI 10.4269/ajtmh.1977.26.1199; Teoh PG, 2014, J VIROL, V88, P7998, DOI 10.1128/JVI.00940-14; Terradas G, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2589-3; Vaidyanathan R, 2006, APOPTOSIS, V11, P1643, DOI 10.1007/s10495-006-8783-y; Wu P, 2019, CELL HOST MICROBE, V25, P101, DOI 10.1016/j.chom.2018.11.004; Xi ZY, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000098; Yasunaga A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003914; Zhang MC, 2013, VIROLOGY, V444, P109, DOI 10.1016/j.virol.2013.06.001; Zhu YB, 2019, NAT MICROBIOL, V4, P2405, DOI 10.1038/s41564-019-0555-x	53	2	2	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2020	11								618801	10.3389/fimmu.2020.618801	http://dx.doi.org/10.3389/fimmu.2020.618801			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PE1NL	33329613	Green Published, gold			2022-12-18	WOS:000598137800001
J	Sharma, V; Wright, KL; Epling-Burnette, PK; Reuther, GW				Sharma, Vasundhara; Wright, Kenneth L.; Epling-Burnette, Pearlie K.; Reuther, Gary W.			Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms	FRONTIERS IN IMMUNOLOGY			English	Article						myeloproliferative neoplasm; metabolism; epigenetic; EZHZ2; HDAC11; JAK2; therapy; stem cell	PRIMARY MYELOFIBROSIS PMF; STAT PATHWAY ACTIVATION; AMINO-ACID-METABOLISM; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; DEACETYLASE INHIBITOR; JAK2 INHIBITOR; PHASE-II; RUXOLITINIB TREATMENT; JAK2V617F EXPRESSION	The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are associated with clonal myelopoiesis, elevated risk of death due to thrombotic complications, and transformation to acute myeloid leukemia (AML). JAK2 inhibitors improve the quality of life for MPN patients, but these approved therapeutics do not readily reduce the natural course of disease or antagonize the neoplastic clone. An understanding of the molecular and cellular changes requisite for MPN development and progression are needed to develop improved therapies. Recently, murine MPN models were demonstrated to exhibit metabolic vulnerabilities due to a high dependence on glucose. Neoplastic hematopoietic progenitor cells in these mice express elevated levels of glycolytic enzymes and exhibit enhanced levels of glycolysis and oxidative phosphorylation, and the disease phenotype of these MPN model mice is antagonized by glycolytic inhibition. While all MPN-driving mutations lead to aberrant JAK2 activation, these mutations often co-exist with mutations in genes that encode epigenetic regulators, including loss of function mutations known to enhance MPN progression. In this perspective we discuss how altered activity of epigenetic regulators (e.g., methylation and acetylation) in MPN-driving stem and progenitor cells may alter cellular metabolism and contribute to the MPN phenotype and progression of disease. Specific metabolic changes associated with epigenetic deregulation may identify patient populations that exhibit specific metabolic vulnerabilities that are absent in normal hematopoietic cells, and thus provide a potential basis for the development of more effective personalized therapeutic approaches.	[Sharma, Vasundhara] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Leukemia, Toronto, ON, Canada; [Wright, Kenneth L.] H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL USA; [Epling-Burnette, Pearlie K.] Ibis Therapeut, Tampa, FL USA; [Reuther, Gary W.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Reuther, GW (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA.	gary.reuther@moffitt.org	Reuther, Gary/AFR-2892-2022		Incyte Corporation; Revolution Medicines, Inc.; Forma Therapeutics; Tolero Pharmaceuticals	Incyte Corporation; Revolution Medicines, Inc.; Forma Therapeutics; Tolero Pharmaceuticals	GR receives research funding from Incyte Corporation and Revolution Medicines, Inc. for projects not related to this manuscript. PE-B received research funding from Incyte Corporation and Forma Therapeutics. PE-B is the Chief Scientific Officer of Ibis Therapeutics and works on drug development unrelated to this manuscript. KW received research funding from Forma Therapeutics and Tolero Pharmaceuticals.	Abdel-Wahab O, 2011, LEUKEMIA, V25, P1200, DOI 10.1038/leu.2011.58; Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032; Ananieva EA, 2018, CURR OPIN CLIN NUTR, V21, P64, DOI 10.1097/MCO.0000000000000430; Andersen CL, 2014, HAEMATOLOGICA, V99, DOI 10.3324/haematol.2013.096669; Arranz L, 2014, NATURE, V512, P78, DOI 10.1038/nature13383; Asher S, 2020, BLOOD REV, V42, DOI 10.1016/j.blre.2020.100715; Bagchi RA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120159; Bartalucci N, 2017, ONCOTARGET, V8, P96710, DOI 10.18632/oncotarget.18073; Bartalucci N, 2013, J CELL MOL MED, V17, P1385, DOI 10.1111/jcmm.12162; Bartalucci Niccolo, 2013, Clin Lymphoma Myeloma Leuk, V13 Suppl 2, pS307, DOI 10.1016/j.clml.2013.07.011; Baumeister J, 2020, LEUKEMIA, V34, P1062, DOI 10.1038/s41375-019-0629-z; Blair HA, 2019, DRUGS, V79, P1719, DOI 10.1007/s40265-019-01205-x; Bogani C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054826; Bora-Singhal N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61295-6; Bose P, 2020, LEUKEMIA LYMPHOMA, V61, P1797, DOI 10.1080/10428194.2020.1749606; Bose P, 2017, CL LYMPH MYELOM LEUK, V17, pS43, DOI 10.1016/j.clml.2017.02.014; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Cao J, 2019, P NATL ACAD SCI USA, V116, P5487, DOI 10.1073/pnas.1815365116; Chachoua I, 2016, BLOOD, V127, P1325, DOI 10.1182/blood-2015-11-681932; Chen E, 2015, BLOOD, V125, P327, DOI 10.1182/blood-2014-04-567024; DeAngelo DJ, 2013, BRIT J HAEMATOL, V162, P326, DOI 10.1111/bjh.12384; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; Deininger M, 2015, BLOOD, V126, P1551, DOI 10.1182/blood-2015-03-635235; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Dhall A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00432; Dunbar Andrew, 2017, Curr Protoc Pharmacol, V77, DOI 10.1002/cpph.23; Elf S, 2016, CANCER DISCOV, V6, P368, DOI 10.1158/2159-8290.CD-15-1434; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Finazzi G, 2013, BRIT J HAEMATOL, V161, P688, DOI 10.1111/bjh.12332; Fiskus W, 2013, MOL CANCER THER, V12, P577, DOI 10.1158/1535-7163.MCT-12-0862; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Grabek J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081901; Gu ZM, 2019, CANCER DISCOV, V9, P1228, DOI 10.1158/2159-8290.CD-19-0152; Guglielmelli P, 2014, BLOOD, V123, P2157, DOI 10.1182/blood-2013-11-536557; Guglielmelli P, 2011, BLOOD, V118, P5227, DOI 10.1182/blood-2011-06-363424; Guglielmelli P, 2011, BLOOD, V118, P2069, DOI 10.1182/blood-2011-01-330563; Harrison CN, 2016, LEUKEMIA, V30, P1701, DOI 10.1038/leu.2016.148; Harrison CN, 2020, ANN HEMATOL, V99, P1177, DOI 10.1007/s00277-020-04002-9; Harrison CN, 2017, LANCET HAEMATOL, V4, pE317, DOI 10.1016/S2352-3026(17)30088-1; Hasselbalch HC, 2019, SEMIN IMMUNOPATHOL, V41, P5, DOI 10.1007/s00281-018-0700-2; Hattori A, 2017, NATURE, V545, P500, DOI 10.1038/nature22314; Hennrich ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06353-4; How J, 2020, CANCERS, V12, DOI 10.3390/cancers12071954; Jacquelin S, 2020, CANCERS, V12, DOI 10.3390/cancers12092381; Jacquelin S, 2018, BLOOD, V132, P2707, DOI 10.1182/blood-2018-04-846220; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Jones CL, 2019, BLOOD, V134, P389, DOI 10.1182/blood.2019898114; Jones CL, 2018, CANCER CELL, V34, P724, DOI 10.1016/j.ccell.2018.10.005; Jutzi JS, 2018, HEMASPHERE, V2, DOI 10.1097/HS9.0000000000000054; Kameda T, 2015, BLOOD, V125, P304, DOI 10.1182/blood-2014-04-555508; Khan I, 2013, LEUKEMIA, V27, P1882, DOI 10.1038/leu.2013.167; Kim E, 2015, CANCER CELL, V27, P617, DOI 10.1016/j.ccell.2015.04.006; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kleppe M, 2018, CANCER CELL, V33, P29, DOI 10.1016/j.ccell.2017.11.009; Kleppe M, 2015, CANCER DISCOV, V5, P316, DOI 10.1158/2159-8290.CD-14-0736; Koschmieder S, 2016, LEUKEMIA, V30, P1018, DOI 10.1038/leu.2016.12; Kreitz J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080805; Kutil Z, 2018, ACS CHEM BIOL, V13, P685, DOI 10.1021/acschembio.7b00942; Kuykendall AT, 2020, CANCERS, V12, DOI 10.3390/cancers12082278; Levine RL, 2007, NAT REV CANCER, V7, P673, DOI 10.1038/nrc2210; Lundberg P, 2014, BLOOD, V123, P2220, DOI 10.1182/blood-2013-11-537167; Lundby A, 2012, CELL REP, V2, P419, DOI 10.1016/j.celrep.2012.07.006; Mager LF, 2015, J CLIN INVEST, V125, P2579, DOI 10.1172/JCI77347; Maher M, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00405; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Marty C, 2016, BLOOD, V127, P1317, DOI 10.1182/blood-2015-11-679571; Mascarenhas J, 2017, LEUKEMIA RES, V53, P13, DOI 10.1016/j.leukres.2016.11.015; Mascarenhas J, 2013, BRIT J HAEMATOL, V161, P68, DOI 10.1111/bjh.12220; Mascarenhas J, 2012, CLIN CANCER RES, V18, P3008, DOI 10.1158/1078-0432.CCR-11-3145; McKenney AS, 2018, J CLIN INVEST, V128, P789, DOI 10.1172/JCI94516; McKerrell T, 2015, CELL REP, V10, P1239, DOI 10.1016/j.celrep.2015.02.005; McLornan DP, 2019, HAEMATOLOGICA, V104, P659, DOI 10.3324/haematol.2018.206151; Mendez-Ferrer S, 2020, NAT REV CANCER, V20, P285, DOI 10.1038/s41568-020-0245-2; Mesa RA, 2015, CL LYMPH MYELOM LEUK, V15, P214, DOI 10.1016/j.clml.2014.12.008; Molle N, 2020, BLOOD, V135, P1062, DOI 10.1182/blood.2019003050; Moreno-Yruela C, 2018, CELL CHEM BIOL, V25, P849, DOI 10.1016/j.chembiol.2018.04.007; Mullally A, 2012, HEMATOL ONCOL CLIN N, V26, P1065, DOI 10.1016/j.hoc.2012.07.007; Mullally A, 2010, CANCER CELL, V17, P584, DOI 10.1016/j.ccr.2010.05.015; Pardanani A, 2011, CURR OPIN HEMATOL, V18, P105, DOI 10.1097/MOH.0b013e3283439964; Pastore F, 2020, CANCER DISCOV, V10, P1742, DOI 10.1158/2159-8290.CD-20-0026; Patel KP, 2015, BLOOD, V126, P790, DOI 10.1182/blood-2015-03-633404; Poisa-Beiro L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68396-2; Quintas-Cardama A, 2012, LEUKEMIA RES, V36, P1124, DOI 10.1016/j.leukres.2012.03.003; Raffel S, 2017, NATURE, V551, P384, DOI 10.1038/nature24294; Rambaldi A, 2010, BRIT J HAEMATOL, V150, P446, DOI 10.1111/j.1365-2141.2010.08266.x; Rampal R, 2014, BLOOD, V123, pE123, DOI 10.1182/blood-2014-02-554634; Rao TN, 2019, BLOOD, V134, P1832, DOI 10.1182/blood.2019000162; Rashkovan M, 2019, GENE DEV, V33, P1460, DOI 10.1101/gad.326470.119; Reddy MM, 2012, LEUKEMIA, V26, P481, DOI 10.1038/leu.2011.225; Saenz DT, 2017, LEUKEMIA, V31, P1951, DOI 10.1038/leu.2016.393; Saenz DT, 2017, LEUKEMIA, V31, P678, DOI 10.1038/leu.2016.260; Sashida G, 2016, J EXP MED, V213, P1459, DOI 10.1084/jem.20151121; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009; Sharma V, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127235; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Shimizu T, 2016, J EXP MED, V213, P1479, DOI 10.1084/jem.20151136; Solary E, 2014, LEUKEMIA, V28, P485, DOI 10.1038/leu.2013.337; Spivak JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232801; Stivala S, 2019, J CLIN INVEST, V129, P1596, DOI 10.1172/JCI98785; Sun L, 2018, EBIOMEDICINE, V33, P157, DOI 10.1016/j.ebiom.2018.06.025; Tefferi A, 2010, LEUKEMIA, V24, P1302, DOI 10.1038/leu.2010.113; Tefferi A, 2009, LEUKEMIA, V23, P905, DOI 10.1038/leu.2009.47; Tefferi A, 2018, AM J HEMATOL, V93, P1551, DOI 10.1002/ajh.25230; Tefferi A, 2015, JAMA ONCOL, V1, P97, DOI 10.1001/jamaoncol.2015.89; Tefferi A, 2014, BLOOD, V124, P2507, DOI 10.1182/blood-2014-05-579136; Tyner JW, 2010, BLOOD, V115, P5232, DOI 10.1182/blood-2009-05-223727; Vainchenker W, 2019, EXPERT REV HEMATOL, V12, P437, DOI 10.1080/17474086.2019.1617129; Vainchenker William, 2018, F1000Res, V7, P82, DOI 10.12688/f1000research.13167.1; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940; Vannucchi AM, 2013, LEUKEMIA, V27, P1861, DOI 10.1038/leu.2013.119; Vannucchi AM, 2015, HAEMATOLOGICA, V100, P1139, DOI 10.3324/haematol.2014.119545; Verstovsek S, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0527-7; Verstovsek S, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0417-z; Verstovsek S, 2015, HAEMATOLOGICA, V100, P482, DOI 10.3324/haematol.2014.115840; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; Villagra A, 2009, NAT IMMUNOL, V10, P92, DOI 10.1038/ni.1673; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Wang YT, 2019, CELL REP, V28, P512, DOI 10.1016/j.celrep.2019.06.026; Werning G, 2008, CANCER CELL, V13, P311, DOI 10.1016/j.ccr.2008.02.009; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Woods B, 2019, CLIN CANCER RES, V25, P5901, DOI 10.1158/1078-0432.CCR-18-4089; Wyspianska BS, 2014, LEUKEMIA, V28, P88, DOI 10.1038/leu.2013.234; Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan DQ, 2012, BLOOD, V119, P3539, DOI 10.1182/blood-2011-03-345215; Yang Y, 2016, BLOOD, V127, P3410, DOI 10.1182/blood-2015-11-679431; Yanginlar C, 2018, BBA-GENE REGUL MECH, V1861, P54, DOI 10.1016/j.bbagrm.2017.12.002; Yi M, 2019, MOL METAB, V20, P1, DOI 10.1016/j.molmet.2018.11.013; Yue LZ, 2020, BLOOD, V135, P191, DOI 10.1182/blood.2019895326; Zhan H, 2016, LEUKEMIA, V30, P2332, DOI 10.1038/leu.2016.114; Zhan HC, 2015, BLOOD CELL MOL DIS, V55, P241, DOI 10.1016/j.bcmd.2015.07.007; Zhang TR, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00862-0; Zhang Y, 2018, STEM CELLS, V36, P1676, DOI 10.1002/stem.2888; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	136	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 30	2020	11								604142	10.3389/fimmu.2020.604142	http://dx.doi.org/10.3389/fimmu.2020.604142			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PE1JX	33329600	gold, Green Published			2022-12-18	WOS:000598128600001
J	Trujillo-Ocampo, A; Cho, HW; Clowers, M; Pareek, S; Ruiz-Vazquez, W; Lee, SE; Im, JS				Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Clowers, Michael; Pareek, Sumedha; Ruiz-Vazquez, Wilfredo; Lee, Sung-Eun; Im, Jin S.			IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA(-)CD62L(+)CD4(+) Invariant NKT Cells With Th-2 Biased Cytokine Production Profile	FRONTIERS IN IMMUNOLOGY			English	Article						ex vivo expansion; human iNKT cells; Th2 polarization of expanded iNKT cells; IL-2; IL-7; IL-15; &#945; GalCer; CD62L(+) iNKT cells	KILLER T-CELLS; ANTITUMOR-ACTIVITY; CANCER-PATIENTS; CD4(+); RECEPTOR; EXPRESSION; SURVIVAL; SUBSETS; HEAD; COMBINATION	Invariant natural killer T (iNKT) cells are innate-like T lymphocytes cells that recognize glycolipid antigens associated with CD1d, non-classical antigen presenting proteins. They can drive either pro-inflammatory (Th-1) or anti-inflammatory (Th-2) immune microenvironment through the production of both Th-1 and Th-2 type cytokines upon activation, thus play a vital role in cancer, infection, and autoimmune diseases. Adoptive cell therapy using ex vivo expanded iNKT cells is a promising approach to enhance anti-tumor immunity or immunosuppression. However, overcoming phenotypic and functional heterogeneity and promoting in vivo persistency of iNKT cells remains to be a challenge. Here, we compared various methods for ex vivo expansion of human iNKT cells and assessed the quality of expansion, phenotype, and cytokine production profile of expanded iNKT cells. While a direct stimulation of iNKT cells in peripheral blood mononuclear cells with agonist glycolipid led to the expansion of iNKT cells in varying degrees, stimulation of enriched iNKT cells by irradiated autologous peripheral blood mononuclear cells or allogeneic dendritic cells resulted in consistent expansion of highly pure iNKT cells. Interestingly, the mode of antigenic stimulation influenced the dominant subtype of expanded iNKT cells. Further, we evaluated whether additional IL-7 or IL-15 during antigenic stimulation with allogeneic dendritic cells can improve the phenotypic heterogeneity and modify cytokine production profile of iNKT cells expanded from 18 consecutive donors. The presence of IL-7 or IL-15 during antigenic stimulation did not affect the fold of expansion or purity of expanded iNKT cells. However, IL-7, but not IL-15, led to a better expansion of CD4(+) iNKT cells, enhanced Th-2 type cytokine production of CD4(+) iNKT cells, and maintained the expansion of central memory (CD45RA(-)CD62L(+)) CD4(+) iNKT cells. Our results suggest the addition of IL-7 during antigenic stimulation with allogeneic dendritic cells can promote the expansion of CD62L(+)Th-2(+)CD4(+) human iNKT cells that can be used as novel immunotherapeutic to control excessive inflammation to treat various autoimmune diseases.	[Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Clowers, Michael; Pareek, Sumedha; Ruiz-Vazquez, Wilfredo; Lee, Sung-Eun; Im, Jin S.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Lee, Sung-Eun; Im, Jin S.] Catholic Univ Korea, Coll Med, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea	University of Texas System; UTMD Anderson Cancer Center; Catholic University of Korea; Seoul St. Mary's Hospital	Im, JS (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.; Im, JS (corresponding author), Catholic Univ Korea, Coll Med, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea.	jim@mdanderson.org		Clowers, Michael/0000-0002-5259-3464; Pareek, Sumedha/0000-0001-6492-3849	National Marrow Donor Program; MD Anderson Institutional Start-Up; NCI [P30CA016672]; American Society of Blood and Marrow Transplantation;  [T32-CA009666]	National Marrow Donor Program; MD Anderson Institutional Start-Up; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Society of Blood and Marrow Transplantation; 	This work was supported by T32-CA009666 (JI), M.D. Anderson Advanced Scholar (JI), New Investigator Award from American Society of Blood and Marrow Transplantation (JI), Amy Strelzer Manasavit Research Scholar from National Marrow Donor Program (JI), and MD Anderson Institutional Start-Up (JI). The South Campus Flow Cytometry & Cell Sorting Core was supported by NCI P30CA016672.	Alves NL, 2009, P NATL ACAD SCI USA, V106, P1512, DOI 10.1073/pnas.0809559106; Baev DV, 2004, BLOOD, V104, P4150, DOI 10.1182/blood-2004-04-1629; Baxevanis CN, 2003, J IMMUNOL, V171, P2953, DOI 10.4049/jimmunol.171.6.2953; Benlagha K, 2005, J EXP MED, V202, P485, DOI 10.1084/jem.20050456; Benlagha K, 2000, SEMIN IMMUNOL, V12, P537, DOI 10.1006/smim.2000.0276; Bricard G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014374; Bricard G, 2009, J IMMUNOL, V182, P5140, DOI 10.4049/jimmunol.0711086; Chan AC, 2013, CLIN EXP IMMUNOL, V172, P129, DOI 10.1111/cei.12045; Chen JW, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/206731; Cheng L, 2014, J HEPATOL, V61, P1297, DOI 10.1016/j.jhep.2014.07.004; Chetoui N, 2010, IMMUNOLOGY, V130, P418, DOI 10.1111/j.1365-2567.2009.03244.x; Crowe NY, 2005, J EXP MED, V202, P1279, DOI 10.1084/jem.20050953; Ding ZC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12488-z; Eger KA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000050; Exley MA, 2017, CLIN CANCER RES, V23, P3510, DOI 10.1158/1078-0432.CCR-16-0600; Fujii SI, 2007, IMMUNOL REV, V220, P183, DOI 10.1111/j.1600-065X.2007.00561.x; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Illes Z, 2000, J IMMUNOL, V164, P4375, DOI 10.4049/jimmunol.164.8.4375; Im JS, 2008, CLIN IMMUNOL, V127, P214, DOI 10.1016/j.clim.2007.12.005; Im JS, 2006, J IMMUNOL, V177, P5226, DOI 10.4049/jimmunol.177.8.5226; Im JS, 2009, IMMUNITY, V30, P888, DOI 10.1016/j.immuni.2009.03.022; Jung YW, 2016, P NATL ACAD SCI USA, V113, P8278, DOI 10.1073/pnas.1602899113; Kinjo Y, 2005, J CLIN IMMUNOL, V25, P522, DOI 10.1007/s10875-005-8064-5; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI200213605; Kunii N, 2009, CANCER SCI, V100, P1092, DOI 10.1111/j.1349-7006.2009.01135.x; Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908; Lin SJ, 2015, CYTOKINE, V76, P348, DOI 10.1016/j.cyto.2015.09.015; Linn YC, 2003, LEUKEMIA LYMPHOMA, V44, P1457, DOI 10.1080/1042819031000083082; Liu DF, 2012, J CLIN INVEST, V122, P2221, DOI 10.1172/JCI59535; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Loza MJ, 2002, EUR J IMMUNOL, V32, P3453, DOI 10.1002/1521-4141(200212)32:12<3453::AID-IMMU3453>3.0.CO;2-D; Matsuda JL, 2002, NAT IMMUNOL, V3, P966, DOI 10.1038/ni837; Molling JW, 2007, J CLIN ONCOL, V25, P862, DOI 10.1200/JCO.2006.08.5787; Molling JW, 2005, INT J CANCER, V116, P87, DOI 10.1002/ijc.20998; Monteiro M, 2013, J IMMUNOL, V190, P805, DOI 10.4049/jimmunol.1201010; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Chuc AEN, 2012, J CANCER RES CLIN, V138, P1427, DOI 10.1007/s00432-012-1251-x; Ngai H, 2018, J IMMUNOL, V201, P2141, DOI 10.4049/jimmunol.1800429; Novak J, 2007, INT REV IMMUNOL, V26, P49, DOI 10.1080/08830180601070229; O'Reilly V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028648; Oh SJ, 2011, J IMMUNOL, V186, P6815, DOI 10.4049/jimmunol.1003916; Oishi Y, 2001, J RHEUMATOL, V28, P275; Osada T, 2005, INT IMMUNOL, V17, P1143, DOI 10.1093/intimm/dxh292; Owen David L, 2017, F1000Res, V6, P32, DOI 10.12688/f1000research.9838.1; Patel O, 2011, J IMMUNOL, V187, P4705, DOI 10.4049/jimmunol.1100794; Rachitskaya AV, 2008, J IMMUNOL, V180, P5167, DOI 10.4049/jimmunol.180.8.5167; Ronchi F, 2008, FRONT BIOSCI-LANDMRK, V13, P4827, DOI 10.2741/3042; Sandberg JK, 2004, P NATL ACAD SCI USA, V101, P7058, DOI 10.1073/pnas.0305986101; Sandberg JK, 2002, J VIROL, V76, P7528, DOI 10.1128/JVI.76.15.7528-7534.2002; Sato N, 2007, P NATL ACAD SCI USA, V104, P588, DOI 10.1073/pnas.0610115104; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Schmid H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01817; Schneidawind D, 2014, BLOOD, V124, P3320, DOI 10.1182/blood-2014-05-576017; Shimizu K, 2007, J EXP MED, V204, P2641, DOI 10.1084/jem.20070458; Shum T, 2017, CANCER DISCOV, V7, P1238, DOI 10.1158/2159-8290.CD-17-0538; Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3; Takami M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02021; Tani-ichi S, 2013, P NATL ACAD SCI USA, V110, P612, DOI 10.1073/pnas.1219242110; Terabe M, 2008, ADV CANCER RES, V101, P277, DOI 10.1016/S0065-230X(08)00408-9; Tian GW, 2016, J CLIN INVEST, V126, P2341, DOI 10.1172/JCI83476; Trujillo-Ocampo A, 2018, CYTOTHERAPY, V20, P1089, DOI 10.1016/j.jcyt.2018.05.007; Tupin E, 2004, J EXP MED, V199, P417, DOI 10.1084/jem.20030997; van der Merwe M, 2013, J IMMUNOL, V191, P5764, DOI 10.4049/jimmunol.1302191; van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490; Vang KB, 2008, J IMMUNOL, V181, P3285, DOI 10.4049/jimmunol.181.5.3285; Yamada D, 2016, STEM CELLS, V34, P2852, DOI 10.1002/stem.2465; Yanagisawa K, 2002, J IMMUNOL, V168, P6494, DOI 10.4049/jimmunol.168.12.6494	67	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 27	2020	11								567406	10.3389/fimmu.2020.567406	http://dx.doi.org/10.3389/fimmu.2020.567406			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC9DN	33329531	Green Published, gold			2022-12-18	WOS:000597298100001
J	Palacios, AM; Grzeschik, J; Deweid, L; Krah, S; Zielonka, S; Rosner, T; Peipp, M; Valerius, T; Kolmar, H				Palacios, Arturo Macarron; Grzeschik, Julius; Deweid, Lukas; Krah, Simon; Zielonka, Stefan; Roesner, Thies; Peipp, Matthias; Valerius, Thomas; Kolmar, Harald			Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies	FRONTIERS IN IMMUNOLOGY			English	Article						B-cell receptor; idiotype; lymphoma; yeast display; vNAR; antibody-drug conjugate	N-GLYCOSYLATION SITES; IGNAR VARIABLE DOMAIN; B-CELL; SOMATIC MUTATION; V-REGION; RECEPTOR; IMMUNOGLOBULIN; BINDING; REARRANGEMENT; GENERATION	The B-cell receptor (BCR) is a key player of the adaptive immune system. It is a unique part of immunoglobulin (Ig) molecules expressed on the surface of B cells. In case of many B-cell lymphomas, the tumor cells express a tumor-specific and functionally active BCR, also known as idiotype. Utilizing the idiotype as target for lymphoma therapy has emerged to be demanding since the idiotype differs from patient to patient. Previous studies have shown that shark-derived antibody domains (vNARs) isolated from a semi-synthetic CDR3-randomized library allow for the rapid generation of anti-idiotype binders. In this study, we evaluated the potential of generating patient-specific binders against the idiotype of lymphomas. To this end, the BCRs of three different lymphoma cell lines SUP-B8, Daudi, and IM-9 were identified, the variable domains were reformatted and the resulting monoclonal antibodies produced. The SUP-B8 BCR served as antigen in fluorescence-activated cell sorting (FACS)-based screening of the yeast-displayed vNAR libraries which resulted after three rounds of screening in the enrichment of antigen-binding vNARs. Five vNARs were expressed as Fc fusion proteins and consequently analyzed for their binding to soluble antigen using biolayer interferometry (BLI) revealing binding constants in the lower single-digit nanomolar range. These variants showed specific binding to the parental SUP-B8 cell line confirming a similar folding of the recombinantly expressed proteins compared with the native cell surface-presented BCR. First initial experiments to utilize the generated vNAR-Fc variants for BCR-clustering to induce apoptosis or ADCC/ADCP did not result in a significant decrease of cell viability. Here, we report an alternative approach for a personalized B-cell lymphoma therapy based on the construction of vNAR-Fc antibody-drug conjugates to enable specific killing of malignant B cells, which may widen the therapeutic window for B-cell lymphoma therapy.	[Palacios, Arturo Macarron; Grzeschik, Julius; Deweid, Lukas; Krah, Simon; Zielonka, Stefan; Kolmar, Harald] Tech Univ Darmstadt, Inst Organ Chem & Biochem, Darmstadt, Germany; [Roesner, Thies; Peipp, Matthias; Valerius, Thomas] CAU Kiel, UKSH, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany; [Grzeschik, Julius] Tech Univ Darmstadt, Biol Technol & Dev, Ferring Pharmaceut Darmstadt Lab, Darmstadt, Germany	Technical University of Darmstadt; University of Kiel; Schleswig Holstein University Hospital; Ferring Pharmaceuticals; Technical University of Darmstadt	Kolmar, H (corresponding author), Tech Univ Darmstadt, Inst Organ Chem & Biochem, Darmstadt, Germany.	Harald.Kolmar@TU-Darmstadt.de	Valerius, Thomas/A-3086-2011; Kolmar, Harald/AAK-8316-2021	Kolmar, Harald/0000-0002-8210-1993; Peipp, Matthias/0000-0002-5088-3804	Department of Protein Engineering and Antibody Technologies at Merck KGaA, Darmstadt; Sektion fur Stammzell-und Immuntherapie, Universitatsklinikum Schleswig-Holstein, Kiel; Deutsche Forschungsgemeinschaft [KO 1390/14-1]	Department of Protein Engineering and Antibody Technologies at Merck KGaA, Darmstadt; Sektion fur Stammzell-und Immuntherapie, Universitatsklinikum Schleswig-Holstein, Kiel; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Department of Protein Engineering and Antibody Technologies at Merck KGaA, Darmstadt and by the Sektion fur Stammzell-und Immuntherapie, Universitatsklinikum Schleswig-Holstein, Kiel. This work was funded in part by Deutsche Forschungsgemeinschaft through grant KO 1390/14-1. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Abdollahpour-Alitappeh M, 2018, ARTIF CELL NANOMED B, V46, P1, DOI 10.1080/21691401.2018.1449119; Armitage JO, 1998, J CLIN ONCOL, V16, P2780, DOI 10.1200/JCO.1998.16.8.2780; Barelle C, 2009, ADV EXP MED BIOL, V655, P49, DOI 10.1007/978-1-4419-1132-2_6; Bekeredjian-Ding I, 2009, IMMUNOLOGY, V128, P311, DOI 10.1111/j.1365-2567.2009.03173.x; Benatuil L, 2010, PROTEIN ENG DES SEL, V23, P155, DOI 10.1093/protein/gzq002; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Bogen JP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01892; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Buatois V, 2018, MOL CANCER THER, V17, P1739, DOI 10.1158/1535-7163.MCT-17-1095; Camacho-Villegas T, 2013, MABS-AUSTIN, V5, P80, DOI 10.4161/mabs.22593; Carnahan J, 2003, CLIN CANCER RES, V9, p3982S; CARROLL WL, 1989, J IMMUNOL, V143, P692; Casi G, 2012, J CONTROL RELEASE, V161, P422, DOI 10.1016/j.jconrel.2012.01.026; Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94; Chao Mark P, 2013, Cancer Manag Res, V5, P251, DOI 10.2147/CMAR.S34273; Chen I, 2011, P NATL ACAD SCI USA, V108, P11399, DOI 10.1073/pnas.1101046108; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Dickgiesser S, 2015, ACS CHEM BIOL, V10, P2158, DOI 10.1021/acschembio.5b00315; Ecker DM, 2015, MABS-AUSTIN, V7, P9, DOI 10.4161/19420862.2015.989042; GREENBERG AS, 1995, NATURE, V374, P168, DOI 10.1038/374168a0; Grzeschik J, 2018, METHODS MOL BIOL, V1701, P147, DOI 10.1007/978-1-4939-7447-4_8; HATZUBAI A, 1981, J IMMUNOL, V126, P2397; Hofmeyer T, 2013, J MOL BIOL, V425, P1302, DOI 10.1016/j.jmb.2012.12.017; Iqbal U, 2010, BRIT J PHARMACOL, V160, P1016, DOI 10.1111/j.1476-5381.2010.00742.x; Kaplon H, 2018, MABS-AUSTIN, V10, P183, DOI 10.1080/19420862.2018.1415671; Konning D, 2017, CURR OPIN STRUC BIOL, V45, P10, DOI 10.1016/j.sbi.2016.10.019; Konning D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10513-9; Konning D, 2016, MAR BIOTECHNOL, V18, P161, DOI 10.1007/s10126-016-9690-z; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kovalenko OV, 2013, J BIOL CHEM, V288, P17408, DOI 10.1074/jbc.M112.435289; Kovaleva M, 2014, EXPERT OPIN BIOL TH, V14, P1527, DOI 10.1517/14712598.2014.937701; Ku M, 2017, BLOOD REV, V31, P23, DOI 10.1016/j.blre.2016.08.001; Kuppers R, 2002, ADV CANCER RES, V84, P277, DOI 10.1016/S0065-230X(02)84009-X; Laventie BJ, 2011, P NATL ACAD SCI USA, V108, P16404, DOI 10.1073/pnas.1102265108; Lim SH, 2011, BLOOD, V118, P2530, DOI 10.1182/blood-2011-01-330357; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Marcus R, 2017, NEW ENGL J MED, V377, P1331, DOI 10.1056/NEJMoa1614598; Marino E, 2012, AUTOIMMUNITY, V45, P377, DOI 10.3109/08916934.2012.665527; McCann KJ, 2006, LEUKEMIA, V20, P530, DOI 10.1038/sj.leu.2404095; Meleshko A. N., 2013, Experimental Oncology, V35, P8; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; Monegal A, 2009, PROTEIN ENG DES SEL, V22, P273, DOI 10.1093/protein/gzp002; Morrison VA, 2014, CLIN INFECT DIS, V59, pS360, DOI 10.1093/cid/ciu592; Morschhauser F, 2014, ASCO M, V32, P8519, DOI DOI 10.1200/JC0.2014.32.15_SUPP1.8519; Moskowitz AJ, 2018, HEMATOL-AM SOC HEMAT, P207, DOI 10.1182/asheducation-2018.1.207; Nuttall SD, 2004, PROTEINS, V55, P187, DOI 10.1002/prot.20005; Oldham RK, 2008, J CLIN ONCOL, V26, P1774, DOI 10.1200/JCO.2007.15.7438; Peipp M, 2008, BLOOD, V112, P2390, DOI 10.1182/blood-2008-03-144600; Ralph DK, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004409; RENSCHLER MF, 1994, P NATL ACAD SCI USA, V91, P3623, DOI 10.1073/pnas.91.9.3623; Schmiedel J, 2008, CANCER CELL, V13, P365, DOI 10.1016/j.ccr.2008.02.019; Seda V, 2015, EUR J HAEMATOL, V94, P193, DOI 10.1111/ejh.12427; Shankland KR, 2012, LANCET, V380, P848, DOI 10.1016/S0140-6736(12)60605-9; Shen ZX, 2019, ELIFE, V8, DOI 10.7554/eLife.42271; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Torchia J, 2016, P NATL ACAD SCI USA, V113, P5376, DOI 10.1073/pnas.1603335113; Toughiri R, 2016, MABS-AUSTIN, V8, P1276, DOI 10.1080/19420862.2016.1214785; van Imhoff GW, 2017, J CLIN ONCOL, V35, P544, DOI 10.1200/JCO.2016.69.0198; Vincke C, 2009, J BIOL CHEM, V284, P3273, DOI 10.1074/jbc.M806889200; VUIST WMJ, 1994, BLOOD, V83, P899; WATKINS BA, 1995, SCAND J IMMUNOL, V42, P442, DOI 10.1111/j.1365-3083.1995.tb03678.x; Zhang JB, 2004, J MOL BIOL, V341, P161, DOI 10.1016/j.jmb.2004.05.069; Zhang LB, 2017, J CONTROL RELEASE, V263, P139, DOI 10.1016/j.jconrel.2016.12.025; Zhu DL, 2002, BLOOD, V99, P2562, DOI 10.1182/blood.V99.7.2562; Zielonka S, 2014, J BIOTECHNOL, V191, P236, DOI 10.1016/j.jbiotec.2014.04.023	66	2	2	2	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2020	11								560244	10.3389/fimmu.2020.560244	http://dx.doi.org/10.3389/fimmu.2020.560244			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PC2GZ	33324393	Green Submitted, Green Published, gold			2022-12-18	WOS:000596827000001
J	Domingues, CS; Cardoso, FD; Hardoim, DD; Pelajo-Machado, M; Bertho, AL; Calabrese, KS				Domingues, Carolina Salles; Cardoso, Flavia de Oliveira; Hardoim, Daiana de Jesus; Pelajo-Machado, Marcelo; Bertho, Alvaro Luiz; Calabrese, Katia Silva			Host Genetics Background Influence in the Intragastric Trypanosoma cruzi Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Trypanosoma cruzi; inbred mice; intragastric infection; host genetic background; proinflammatory cytokines; CD8(+) lymphocytes	ACUTE CHAGAS-DISEASE; CD8(+) T-CELLS; ORAL-TRANSMISSION; BONE-MARROW; EXTRAMEDULLARY HEMATOPOIESIS; SANTA-CATARINA; ACUTE-PHASE; CLASS-I; PARASITE; OUTBREAK	Background Considering the complexity of the factors involved in the immunopathology of Chagas disease, which influence the Chagas' disease pathogenesis, anti-T. cruzi immune response, and chemotherapy outcome, further studies are needed to improve our understanding about these relationships. On this way, in this article we analyzed the host genetic influence on hematological, histopathological and immunological aspects after T. cruzi infection. Methods BALB/c and A mice were intragastrically infected with T. cruzi SC2005 strain, isolated from a patient of an outbreak of Chagas disease. Parameters such as parasite load, survival rates, cytokines production, macrophages, T and B cell frequencies, and histopathology analysis were carried out. Results BALB/c mice presented higher parasitemia and mortality rates than A mice. Both mouse lineages exhibited hematological alterations suggestive of microcytic hypochromic anemia and histopathological alterations in stomach, heart and liver. The increase of CD8(+) T cells, in heart, liver and blood, and the increase of CD19(+) B cells, in liver, associated with a high level of proinflammatory cytokines (IL-6, TNF-alpha, IFN-gamma), confer a resistance profile to the host. Although BALB/c animals exhibited the same findings observed in A mice, the response to infection occurred later, after a considerable parasitemia increase. By developing an early response to the infection, A mice were found to be less susceptible to T. cruzi SC2005 infection. Conclusions Host genetics background shaping the response to infection. The early development of a cytotoxic cellular response profile with the production of proinflammatory cytokines is important to lead a less severe manifestation of Chagas disease.	[Domingues, Carolina Salles; Cardoso, Flavia de Oliveira; Hardoim, Daiana de Jesus; Calabrese, Katia Silva] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunomodulacao & Protozool, Rio De Janeiro, Brazil; [Pelajo-Machado, Marcelo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Patol, Rio De Janeiro, Brazil; [Bertho, Alvaro Luiz] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunoparasitol, Rio De Janeiro, Brazil; [Bertho, Alvaro Luiz] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Plataforma Citometria Fluxo, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Cardoso, FD (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunomodulacao & Protozool, Rio De Janeiro, Brazil.	flaviaoc@ioc.fiocruz.br	Machado, Marcelo Pelajo/I-5359-2012; CARDOSO, FLÁVIA/AEX-9625-2022	CARDOSO, FLAVIA/0000-0002-2026-1836; Hardoim, Daiana de Jesus/0000-0002-2272-2472	Instituto Oswaldo Cruz/Fundacao Oswaldo Cruz	Instituto Oswaldo Cruz/Fundacao Oswaldo Cruz	This work was supported by a grant from Instituto Oswaldo Cruz/Fundacao Oswaldo Cruz. CD was a CAPES scholar. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Rodriguez EVA, 2019, TRENDS PARASITOL, V35, P899, DOI 10.1016/j.pt.2019.08.006; Andersson J, 2003, IMMUNOL LETT, V86, P207, DOI 10.1016/S0165-2478(03)00019-1; Andrade LO, 2002, EXP PARASITOL, V100, P269, DOI 10.1016/S0014-4894(02)00024-3; ANDRADE SG, 1992, T ROY SOC TROP MED H, V86, P624, DOI 10.1016/0035-9203(92)90156-7; Andrade SG, 2011, MEM I OSWALDO CRUZ, V106, P948, DOI 10.1590/S0074-02762011000800009; Anez N, 2013, B MALARIOL SALUD AMB, V53, P1; Arantes JM, 2011, EXP PARASITOL, V128, P401, DOI 10.1016/j.exppara.2011.05.011; Arantes JM, 2006, THESIS; BARR SC, 1991, AM J VET RES, V52, P954; Barreto-de-Albuquerque J, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003849; Ben D, 1990, BLOOD, V75, P1627, DOI [10.1182/blood.V75.8.1627.bloodjournal7581627, DOI 10.1182/BLOOD.V75.8.1627.BLOODJOURNAL7581627]; Barbosa PRB, 2006, INT J CARDIOL, V112, P132, DOI 10.1016/j.ijcard.2005.11.087; Binder D, 1998, J EXP MED, V187, P1903, DOI 10.1084/jem.187.11.1903; BONECINIALMEIDA MD, 1990, MEM I OSWALDO CRUZ, V85, P163, DOI 10.1590/S0074-02761990000200004; Buscaglia CA, 2003, MICROBES INFECT, V5, P419, DOI 10.1016/S1286-4579(03)00050-9; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; Campbell DA, 2004, CURR MOL MED, V4, P549, DOI 10.2174/1566524043360249; Canavaci AMC, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/893634; Cardier JE, 1997, HEPATOLOGY, V26, P165; Cardillo F, 2007, IMMUNOLOGY, V122, P584, DOI 10.1111/j.1365-2567.2007.02677.x; Cardillo F, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv082; Cardoso J.E., 1980, Memorias do Instituto Oswaldo Cruz, V75, P97, DOI 10.1590/S0074-02761980000200009; Caselna TTT, 2008, SINOPSE REUMATOL, V2, P35; dos Santos VRC, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170298; CHAGAS C, 1909, MEM I O CRUZ, V1, P3; Chevillard C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02791; Collins MH, 2011, INFECT IMMUN, V79, P3397, DOI 10.1128/IAI.01080-10; Costa ED, 2017, INT J CARDIOL, V235, P176, DOI 10.1016/j.ijcard.2017.02.101; Coura JR, 2015, MEM I OSWALDO CRUZ, V110, P277, DOI 10.1590/0074-0276140362; Cruz-Robles D, 2004, HUM IMMUNOL, V65, P60, DOI 10.1016/j.humimm.2003.10.008; Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230; da Costa SCG, 2002, HISTOL HISTOPATHOL, V17, P837, DOI 10.14670/HH-17.837; da Silva CV, 2006, MICROBES INFECT, V8, P2120, DOI 10.1016/j.micinf.2006.03.016; DAVIS CE, 1974, J CLIN INVEST, V53, P1359, DOI 10.1172/JCI107684; Deghaide NHS, 1998, DIGEST DIS SCI, V43, P246, DOI 10.1023/A:1018829600200; Domingues CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122566; Dominguez MR, 2012, VACCINE, V30, P2882, DOI 10.1016/j.vaccine.2012.02.037; Esper L, 2014, MICROBES INFECT, V16, P481, DOI 10.1016/j.micinf.2014.03.007; Ferreira BL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00553; Freitas JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005113; Lidani KCF, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00166; Gascon J, 2010, ACTA TROP, V115, P22, DOI 10.1016/j.actatropica.2009.07.019; Georgiades CS, 2002, AM J ROENTGENOL, V179, P1239, DOI 10.2214/ajr.179.5.1791239; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Gutierrez FRS, 2009, PARASITE IMMUNOL, V31, P673, DOI 10.1111/j.1365-3024.2009.01108.x; Hardoim DJ, 2014, THESIS; Henderson SE, 2020, VET CLIN PATH, V49, P382, DOI 10.1111/vcp.12879; Hickman B, 2015, OSMAN ARASTIRMALARI, P1; HOFF R, 1974, J PARASITOL, V60, P527, DOI 10.2307/3278377; Hoft DF, 2007, J IMMUNOL, V179, P6889, DOI 10.4049/jimmunol.179.10.6889; IKEDE B O, 1977, Acta Tropica, V34, P53; Jenne CN, 2013, NAT IMMUNOL, V14, P996, DOI 10.1038/ni.2691; KALOUTSI V, 1994, AM J CLIN PATHOL, V101, P123, DOI 10.1093/ajcp/101.2.123; Kubes P, 2018, ANNU REV IMMUNOL, V36, P247, DOI 10.1146/annurev-immunol-051116-052415; Layrisse Z, 2000, HUM IMMUNOL, V61, P925, DOI 10.1016/S0198-8859(00)00161-0; Lewis MD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29564-7; Lieke T, 2004, INFECT IMMUN, V72, P6817, DOI 10.1128/IAI.72.12.6817-6825.2004; Lima L, 2015, ACTA TROP, V151, P166, DOI 10.1016/j.actatropica.2015.07.015; Macedo AM, 2004, MEM I OSWALDO CRUZ, V99, P1, DOI 10.1590/S0074-02762004000100001; Macedo Andra M, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004118; Maeda FY, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1455-z; Malvezi AD, 2004, FEMS IMMUNOL MED MIC, V41, P69, DOI 10.1016/j.femsim.2004.01.005; Marcili A, 2009, PARASITOLOGY, V136, P641, DOI 10.1017/S0031182009005861; Marcondes MCG, 2000, MICROBES INFECT, V2, P347, DOI 10.1016/S1286-4579(00)00333-6; Marcos P, HEMATOLOGICAL ALTERA; Sanmarco LM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00626; Marinho CRF, 2004, INFECT IMMUN, V72, P2350, DOI 10.1128/IAI.72.4.2350-2357.2004; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Miyazaki Y, 2010, J IMMUNOL, V185, P1150, DOI 10.4049/jimmunol.0900047; MOLDAWER LL, 1989, FASEB J, V3, P1637, DOI 10.1096/fasebj.3.5.2784116; Molyneux DH, 2017, LANCET, V389, P312, DOI 10.1016/S0140-6736(16)30171-4; Monteiro WM, 2010, TROP MED INT HEALTH, V15, P1049, DOI 10.1111/j.1365-3156.2010.02577.x; Monteiro WM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041284; Padilla A, 2007, INFECT IMMUN, V75, P231, DOI 10.1128/IAI.01245-06; Perez AR, 2012, ANN NY ACAD SCI, V1262, P27, DOI 10.1111/j.1749-6632.2012.06627.x; Perez AR, 2007, BRAIN BEHAV IMMUN, V21, P890, DOI 10.1016/j.bbi.2007.02.004; Piron M, 2007, ACTA TROP, V103, P195, DOI 10.1016/j.actatropica.2007.05.019; Pizzi T, 1952, BIOLOGICA, V16, P3; PLOEMACHER RE, 1977, CELL TISSUE RES, V178, P435, DOI 10.1007/BF00219567; RAKUSAN TA, 1989, J INFECT DIS, V159, P127, DOI 10.1093/infdis/159.1.127; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; Roberts AS, 2016, CLIN RADIOL, V71, P807, DOI 10.1016/j.crad.2016.05.014; ROTTENBERG ME, 1995, IMMUNOL LETT, V45, P53, DOI 10.1016/0165-2478(94)00221-C; Rueda K, 2014, BIOMEDICA, V34, P631, DOI [10.7705/biomedica.v34i4.2204, 10.1590/S0120-41572014000400017]; Sambrook Joseph, 2006, CSH Protoc, V2006, DOI [10.1101/pdb.prot3966, 10.1101/pdb.prot3825, 10.1101/pdb.prot4027, 10.1101/pdb.prot3723, 10.1101/pdb.prot3871, 10.1101/pdb.prot4044, 10.1101/pdb.prot4050, 10.1101/pdb.prot4453, 10.1101/pdb.prot3972, 10.1101/pdb.prot4455, 10.1101/pdb.prot4056, 10.1101/pdb.prot4022]; Santos EF, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008445; Sardinha LR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000578; Sathler-Avelar R, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004302; Shikanai-Yasuda MA, 2012, CLIN INFECT DIS, V54, P845, DOI 10.1093/cid/cir956; Silva G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053766; Silva-dos-Santos D, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005507; Steindel M, 2008, DIAGN MICR INFEC DIS, V60, P25, DOI 10.1016/j.diagmicrobio.2007.07.016; Sullivan NL, 2015, J IMMUNOL, V194, P1806, DOI 10.4049/jimmunol.1303163; Sullivan NL, 2011, J IMMUNOL, V187, P1358, DOI 10.4049/jimmunol.1100033; Tarleton RL, 2015, SEMIN IMMUNOPATHOL, V37, P233, DOI 10.1007/s00281-015-0481-9; Filigheddu MT, 2017, MED CLIN-BARCELONA, V148, P125, DOI 10.1016/j.medcli.2016.10.038; THOMSEN AR, 1986, J VIROL, V59, P428, DOI 10.1128/JVI.59.2.428-433.1986; ULICH TR, 1993, RES IMMUNOL, V144, P347, DOI 10.1016/S0923-2494(93)80079-E; VANPUTTEN LM, 1958, BLOOD, V13, P789, DOI 10.1182/blood.V13.8.789.789; Vitelli-Avelar DM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005233; WATIER H, 1992, INFECT IMMUN, V60, P136, DOI 10.1128/IAI.60.1.136-142.1992; WHO, 2020, CHANG DIS AM TRYP; World Health Organization, 2018, GLOB DISTR CAS CHAG; Young HA, 1997, BLOOD, V89, P583, DOI 10.1182/blood.V89.2.583; Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021; Zingales B, 2018, ACTA TROP, V184, P38, DOI 10.1016/j.actatropica.2017.09.017; Zingales B, 2012, INFECT GENET EVOL, V12, P240, DOI 10.1016/j.meegid.2011.12.009	107	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 24	2020	11								566476	10.3389/fimmu.2020.566476	http://dx.doi.org/10.3389/fimmu.2020.566476			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB4IT	33329529	gold, Green Published			2022-12-18	WOS:000596287100001
J	Liu, YJ; Chen, R; Liang, RY; Sun, BB; Wu, YA; Zhang, LJ; Kaufman, J; Xia, C				Liu, Yanjie; Chen, Rong; Liang, Ruiying; Sun, Beibei; Wu, Yanan; Zhang, Lijie; Kaufman, Jim; Xia, Chun			The Combination of CD8 alpha alpha and Peptide-MHC-I in a Face-to-Face Mode Promotes Chicken gamma delta T Cells Response	FRONTIERS IN IMMUNOLOGY			English	Article						chicken gamma delta T cells response; CD8/pMHC-I interaction; face-to-face mode; cCD8 alpha alpha/pBF2(star)1501; cCD8 alpha alpha/pBF2(star)0401	CD8 CORECEPTOR; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; ALPHA-3 DOMAIN; ANTIGEN; BINDING; COMPLEX; RECOGNITION; MOLECULE; AFFINITY	The CD8 alpha alpha homodimer is crucial to both thymic T cell selection and the antigen recognition of cytotoxic T cells. The CD8-pMHC-I interaction can enhance CTL immunity via stabilizing the TCR-pMHC-I interaction and optimizing the cross-reactivity and Ag sensitivity of CD8(+) T cells at various stages of development. To date, only human and mouse CD8-pMHC-I complexes have been determined. Here, we resolved the pBF2(star)1501 complex and the cCD8 alpha alpha/pBF2(star)1501 and cCD8 alpha alpha/pBF2(star)0401 complexes in nonmammals for the first time. Remarkably, cCD8 alpha alpha/pBF2(star)1501 and the cCD8 alpha alpha/pBF2(star)0401 complex both exhibited two binding modes, including an "antibody-like" mode similar to that of the known mammal CD8/pMHC-I complexes and a "face-to-face" mode that has been observed only in chickens to date. Compared to the "antibody-like" mode, the "face-to-face" binding mode changes the binding orientation of the cCD8 alpha alpha homodimer to pMHC-I, which might facilitate abundant gamma delta T cells to bind diverse peptides presented by limited BF2 alleles in chicken. Moreover, the forces involving in the interaction of cCD8 alpha alpha/pBF2(star)1501 and the cCD8 alpha alpha/pBF2(star)0401 are different in this two binding model, which might change the strength of the CD8-pMHC-I interaction, amplifying T cell cross-reactivity in chickens. The coreceptor CD8 alpha alpha of TCR has evolved two peptide-MHC-I binding patterns in chickens, which might enhance the T cell response to major or emerging pathogens, including chicken-derived pathogens that are relevant to human health, such as high-pathogenicity influenza viruses.	[Liu, Yanjie; Chen, Rong; Liang, Ruiying; Sun, Beibei; Wu, Yanan; Zhang, Lijie; Xia, Chun] China Agr Univ, Dept Microbiol & Immunol, Coll Vet Med, Beijing, Peoples R China; [Liu, Yanjie] Chinese Acad Agr Sci, Inst Apicultural Res, Minist Agr, Key Lab Insect Pollinator Biol, Beijing, Peoples R China; [Kaufman, Jim] Univ Cambridge, Dept Pathol, Cambridge, England; [Kaufman, Jim] Univ Cambridge, Dept Vet Med, Cambridge, England	China Agricultural University; Chinese Academy of Agricultural Sciences; Institute of Apicultural Research, CAAS; Ministry of Agriculture & Rural Affairs; University of Cambridge; University of Cambridge	Xia, C (corresponding author), China Agr Univ, Dept Microbiol & Immunol, Coll Vet Med, Beijing, Peoples R China.; Kaufman, J (corresponding author), Univ Cambridge, Dept Pathol, Cambridge, England.; Kaufman, J (corresponding author), Univ Cambridge, Dept Vet Med, Cambridge, England.	jfk31@cam.ac.uk; xiachun@cau.edu.cn		Xia, Chun/0000-0002-3444-0624	National Natural Science Foundation of China [31572493, 31972683]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (grant nos.: 31572493 and 31972683).	Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; ARSTILA TP, 1993, J IMMUNOL, V151, P6627; Berndt A, 2006, INFECT IMMUN, V74, P3967, DOI 10.1128/IAI.01128-05; Cheroutre H, 2008, IMMUNITY, V28, P149, DOI 10.1016/j.immuni.2008.01.005; Cole DK, 2012, IMMUNOLOGY, V137, P139, DOI 10.1111/j.1365-2567.2012.03625.x; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; DAVIDSON NJ, 1992, INT IMMUNOL, V4, P1175, DOI 10.1093/intimm/4.10.1175; Dockree T, 2017, IMMUNOL CELL BIOL, V95, P68, DOI 10.1038/icb.2016.85; Erf GF, 1998, VET IMMUNOL IMMUNOP, V62, P339, DOI 10.1016/S0165-2427(97)00070-6; Fenzl L, 2017, DEV COMP IMMUNOL, V73, P175, DOI 10.1016/j.dci.2017.03.028; FORSDYKE DR, 1991, J THEOR BIOL, V150, P451, DOI 10.1016/S0022-5193(05)80439-4; Gakamsky DM, 2005, BIOPHYS J, V89, P2121, DOI 10.1529/biophysj.105.061671; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Gao GF, 2000, IMMUNOL TODAY, V21, P630, DOI 10.1016/S0167-5699(00)01750-3; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Huang J, 2007, J IMMUNOL, V179, P7653, DOI 10.4049/jimmunol.179.11.7653; Hunt HD, 1998, IMMUNOGENETICS, V47, P456, DOI 10.1007/s002510050383; Hutchinson SL, 2003, J BIOL CHEM, V278, P24285, DOI 10.1074/jbc.M300633200; Jiang N, 2011, IMMUNITY, V34, P13, DOI 10.1016/j.immuni.2010.12.017; KAUFMAN J, 1992, J IMMUNOL, V148, P1532; Kaufman J, 2018, TRENDS IMMUNOL, V39, P367, DOI 10.1016/j.it.2018.01.001; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Koch M, 2007, IMMUNITY, V27, P885, DOI 10.1016/j.immuni.2007.11.007; Laugel B, 2007, J BIOL CHEM, V282, P23799, DOI 10.1074/jbc.M700976200; Laursen AMS, 2018, VIROLOGY, V522, P56, DOI 10.1016/j.virol.2018.06.014; Li YL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00206; Liaw HJ, 2007, J IMMUNOL, V178, P3023, DOI 10.4049/jimmunol.178.5.3023; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; Liu YJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24788; Liu YW, 2003, IMMUNITY, V18, P205, DOI 10.1016/S1074-7613(03)00027-X; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; Luhtala M, 1998, POULTRY SCI, V77, P1858, DOI 10.1093/ps/77.12.1858; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; Merry AH, 2003, J BIOL CHEM, V278, P27119, DOI 10.1074/jbc.M213056200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; Purbhoo MA, 2001, J BIOL CHEM, V276, P32786, DOI 10.1074/jbc.M102498200; Raeesi V, 2017, J ANIM BREED GENET, V134, P405, DOI 10.1111/jbg.12265; Robert J, 2010, DEV COMP IMMUNOL, V34, P915, DOI 10.1016/j.dci.2010.05.011; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SEKIMATA M, 1993, J IMMUNOL, V150, P4416; Shekhar S, 2012, VET IMMUNOL IMMUNOP, V147, P1, DOI 10.1016/j.vetimm.2012.03.016; Shi Y, 2011, MOL IMMUNOL, V48, P2198, DOI 10.1016/j.molimm.2011.05.009; Shore DA, 2005, ADV EXP MED BIOL, V564, P71; SOWDER JT, 1988, J EXP MED, V167, P315, DOI 10.1084/jem.167.2.315; Sun BB, 2013, ACTA CRYSTALLOGR F, V69, P122, DOI 10.1107/S1744309112050300; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; van den Berg HA, 2007, J THEOR BIOL, V249, P395, DOI 10.1016/j.jtbi.2007.08.002; Van Laethem F, 2007, IMMUNITY, V27, P735, DOI 10.1016/j.immuni.2007.10.007; VEILLETTE A, 1991, EUR J IMMUNOL, V21, P397, DOI 10.1002/eji.1830210222; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wallny HJ, 2006, P NATL ACAD SCI USA, V103, P1434, DOI 10.1073/pnas.0507386103; Wang R, 2009, J IMMUNOL, V183, P2554, DOI 10.4049/jimmunol.0901276; Wilson DB, 2004, MOL IMMUNOL, V40, P1047, DOI 10.1016/j.molimm.2003.11.022; Wooldridge L, 2005, J BIOL CHEM, V280, P27491, DOI 10.1074/jbc.M500555200; Wooldridge L, 2010, J IMMUNOL, V185, P4625, DOI 10.4049/jimmunol.1001480; Yin YY, 2009, IMMUNITY, V31, P849, DOI 10.1016/j.immuni.2009.12.002; Zamoyska R, 1998, CURR OPIN IMMUNOL, V10, P82, DOI 10.1016/S0952-7915(98)80036-8; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; Zhang JH, 2012, J IMMUNOL, V189, P4478, DOI 10.4049/jimmunol.1200885	67	2	2	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2020	11								605085	10.3389/fimmu.2020.605085	http://dx.doi.org/10.3389/fimmu.2020.605085			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB7EY	33329601	Green Published, gold			2022-12-18	WOS:000596481200001
J	Wan, L; Jin, ZQ; Hu, B; Lv, KK; Lei, L; Liu, YH; Song, Y; Zhu, Y; Gong, HL; Xu, MM; Du, YY; Xu, Y; Liu, HY; Wu, DP; Liu, YJ				Wan, Li; Jin, Ziqi; Hu, Bo; Lv, Kangkang; Lei, Lei; Liu, Yonghao; Song, Yuan; Zhu, Ying; Gong, Huanle; Xu, Mimi; Du, Yuanyuan; Xu, Yang; Liu, Haiyan; Wu, Depei; Liu, Yuejun			IL-Y Aggravates Murine Chronic Graft-Versus-Host Disease by Enhancing T and B Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						IL-Y; T cell response; B cell response; Tfh cell; Treg cells; chronic graft-versus-host disease	CONSENSUS DEVELOPMENT PROJECT; GERMINAL CENTER FORMATION; FOLLICULAR HELPER-CELLS; CLINICAL-TRIALS; CHRONIC GVHD; EFFECTOR; CRITERIA; CGVHD	IL-Y, a synthetic member of IL-12 cytokine family, was found to exert potent immunosuppressive effects by inhibiting the differentiation and activation of Th1 and Th17 cells. However, the role of IL-Y in the development of chronic graft-versus-host disease (cGVHD) remains unknown. Here, using murine models of scleroderma-like and lupus-like cGVHD, we examined the function of IL-Y in the pathogenesis of cGVHD by hydrodynamically injecting minicircle-IL-Y expressing plasmids (MC IL-Y). In contrast with the reported immune suppressive function of IL-Y, administration of MC IL-Y enhanced cGVHD severity reflected by deteriorated multi-organ pathologic damages. In lupus-like cGVHD model, urine protein and the serum anti-dsDNA antibody (IgG) were significantly upregulated by IL-Y treatment. Further study demonstrated that IL-Y impacts both donor T and B cell response. In T cells, IL-Y inhibited the generation of CD4(+)Foxp3(+) regulator T (Treg) cells during the development of cGVHD. IL-Y may also increase the infiltration of pathogenic TNF-alpha producing CD4(+) and CD8(+) T cells through IL-27R alpha in recipient spleens, as this effect was diminished in IL-27R alpha deficient T cells. Moreover, IL-Y enhanced the differentiation of ICOS+ T follicular helper (Tfh) cells. In B cells, the percentage of germinal center (GC) B cells in recipient spleens was significantly upregulated by MC IL-Y plasmid administration. The levels of co-stimulatory molecules, MHC-II and CD86, on B cells were also enhanced by IL-Y expression. Taken together, our data indicated that IL-Y promoted the process of cGVHD by activating pathogenic T and B cells.	[Wan, Li; Jin, Ziqi; Hu, Bo; Lv, Kangkang; Lei, Lei; Gong, Huanle; Xu, Mimi; Du, Yuanyuan; Xu, Yang; Wu, Depei; Liu, Yuejun] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1,Inst Blood & Marrow Transplanta, Suzhou, Peoples R China; [Wan, Li; Jin, Ziqi; Hu, Bo; Lv, Kangkang; Lei, Lei; Gong, Huanle; Xu, Mimi; Du, Yuanyuan; Xu, Yang; Wu, Depei; Liu, Yuejun] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China; [Liu, Yonghao; Song, Yuan; Zhu, Ying; Liu, Haiyan] Natl Univ Singapore, Yoo Loo Lin Sch Med, Inst Life Sci, Immunol Programme, Singapore, Singapore; [Liu, Yonghao; Song, Yuan; Zhu, Ying; Liu, Haiyan] Natl Univ Singapore, Yoo Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore	Soochow University - China; Soochow University - China; National University of Singapore; National University of Singapore	Wu, DP; Liu, YJ (corresponding author), Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1,Inst Blood & Marrow Transplanta, Suzhou, Peoples R China.; Wu, DP; Liu, YJ (corresponding author), Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China.; Liu, HY (corresponding author), Natl Univ Singapore, Yoo Loo Lin Sch Med, Inst Life Sci, Immunol Programme, Singapore, Singapore.; Liu, HY (corresponding author), Natl Univ Singapore, Yoo Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.	micliuh@nus.edu.sg; wudepei@medmail.com.cn; liuyuejun@suda.edu.cn	Liu, Haiyan/ABD-8689-2021; Xu, Yang/GOH-1228-2022	Liu, Haiyan/0000-0002-4652-469X; Xu, Yang/0000-0003-4643-2098	National Key R&D Program of China [2017YFA0104502, 2017YFA0104500]; National Nature Science Foundation of China [81500146, 81730003]; National Science and Technology Major Project [2017ZX09304021]; Jiangsu Social Development Program [BE2018651]; Jiangsu Natural Science Foundation [BK20150356]; Jiangsu Provincial Key Medical Center [YXZXA2016002]; Jiangsu Medical Outstanding Talents Project [JCRCA2016002]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Suzhou Science and Technology Development Project [SYS2019021]; Translational Research Grant of NCRCH [2020WSC05]	National Key R&D Program of China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project; Jiangsu Social Development Program; Jiangsu Natural Science Foundation(Natural Science Foundation of Jiangsu Province); Jiangsu Provincial Key Medical Center; Jiangsu Medical Outstanding Talents Project; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Suzhou Science and Technology Development Project; Translational Research Grant of NCRCH	This study was supported by the great form the National Key R&D Program of China (2017YFA0104502, 2017YFA0104500), National Nature Science Foundation of China (Grant No. 81500146, 81730003), National Science and Technology Major Project (2017ZX09304021), Jiangsu Social Development Program (BE2018651), Jiangsu Natural Science Foundation (BK20150356), Jiangsu Provincial Key Medical Center (YXZXA2016002), Jiangsu Medical Outstanding Talents Project (JCRCA2016002), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Translational Research Grant of NCRCH (2020WSC05), Suzhou Science and Technology Development Project (SYS2019021).	Alho AC, 2016, BLOOD, V127, P646, DOI 10.1182/blood-2015-10-672345; Bastian David, 2018, J Immunol Res Ther, V3, P151; Belle L, 2016, BLOOD, V128, P2068, DOI 10.1182/blood-2016-02-698241; Busca A, 2007, AM J HEMATOL, V82, P45, DOI 10.1002/ajh.20752; Chen X, 2007, BLOOD, V110, P3804, DOI 10.1182/blood-2007-05-091074; Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Cutler CS, 2017, BLOOD, V129, P22, DOI 10.1182/blood-2016-08-686659; Deng RS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00880-2; Flores RR, 2015, EUR J IMMUNOL, V45, P3114, DOI 10.1002/eji.201445403; Flowers MED, 2015, BLOOD, V125, P606, DOI 10.1182/blood-2014-08-551994; Flynn R, 2014, BLOOD, V123, P3988, DOI 10.1182/blood-2014-03-562231; Forcade E, 2016, BLOOD, V127, P2489, DOI 10.1182/blood-2015-12-688895; Hasegawa M, 1997, J RHEUMATOL, V24, P663; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; Johnston HF, 2014, BIOL BLOOD MARROW TR, V20, P1089, DOI 10.1016/j.bbmt.2014.04.028; Khoder A, 2014, BLOOD, V124, P2034, DOI 10.1182/blood-2014-04-571125; Le HT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00181; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; MacDonald KPA, 2017, J CLIN INVEST, V127, P2452, DOI 10.1172/JCI90593; Malard F, 2017, BLOOD, V130, P2186, DOI 10.1182/blood-2017-05-786137; Matsuoka K, 2010, J CLIN INVEST, V120, P1479, DOI 10.1172/JCI41072; McDonald-Hyman C, 2016, BLOOD, V128, P1013, DOI 10.1182/blood-2016-05-715896; Murdaca G, 2014, IMMUNOTHERAPY-UK, V6, P283, DOI 10.2217/imt.13.173; Nishimori H, 2012, BLOOD, V119, P285, DOI 10.1182/blood-2011-01-332478; Pidala J, 2014, BONE MARROW TRANSPL, V49, P324, DOI 10.1038/bmt.2013.97; Pidala J, 2018, HAEMATOLOGICA, V103, P531, DOI 10.3324/haematol.2017.171199; Pidala J, 2011, BLOOD, V117, P4651, DOI 10.1182/blood-2010-11-319509; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; Rozmus J, 2011, BIOL BLOOD MARROW TR, V17, P1804, DOI 10.1016/j.bbmt.2011.05.011; Sakoda Y, 2007, BLOOD, V109, P1756, DOI 10.1182/blood-2006-08-042853; Shao L, 2015, ANN HEMATOL, V94, P1493, DOI 10.1007/s00277-015-2394-z; Socie G, 2014, BLOOD, V124, P374, DOI 10.1182/blood-2014-01-514752; Srinivasan M, 2012, BLOOD, V119, P1570, DOI 10.1182/blood-2011-07-364414; Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493; Wang RX, 2012, J BIOL CHEM, V287, P36012, DOI 10.1074/jbc.M112.390625; Wu T, 2013, J IMMUNOL, V191, P488, DOI 10.4049/jimmunol.1300657; Wu YX, 2018, BLOOD, V131, P1974, DOI 10.1182/blood-2017-06-789321; Zeiser R, 2006, BLOOD, V108, P390, DOI 10.1182/blood-2006-01-0329; Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472; Zhang CY, 2006, BLOOD, V107, P2993, DOI 10.1182/blood-2005-09-3623; Zhao DC, 2008, BLOOD, V112, P2129, DOI 10.1182/blood-2008-02-140277	46	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 23	2020	11								559740	10.3389/fimmu.2020.559740	http://dx.doi.org/10.3389/fimmu.2020.559740			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PB7EZ	33329519	gold, Green Published			2022-12-18	WOS:000596481300001
J	Gendron, RL; Paradis, H; Ahmad, R; Kao, KN; Boyce, D; Good, WV; Kumar, S; Vasquez, I; Cao, T; Hossain, A; Chakraborty, S; Valderrama, K; Santander, J				Gendron, Robert L.; Paradis, Helene; Ahmad, Raahyma; Kao, Kenneth; Boyce, Danny; Good, William V.; Kumar, Surendra; Vasquez, Ignacio; Cao, Trung; Hossain, Ahmed; Chakraborty, Setu; Valderrama, Katherinne; Santander, Javier			CD10(+) Cells and IgM in Pathogen Response in Lumpfish (Cyclopterus lumpus) Eye Tissues	FRONTIERS IN IMMUNOLOGY			English	Article						lumpfish (Cyclopterus lumpus L; ); eye; immune response; infection; cluster of differentiation 10; immunoglobulin M	SEA LICE; SCLERAL OSSICLES; STEM-CELLS; IN-VITRO; B-CELLS; NEPRILYSIN; FISH; TUBEDOWN-1; CARTILAGE; EVOLUTIONARY	Lumpfish (Cyclopterus lumpus), a North Atlantic "cleaner" fish, is utilized to biocontrol salmon louse (Lepeophtheirus salmonis) in Atlantic salmon (Salmo salar) farms. Lumpfish require excellent vision to scan for and eat louse on salmon skin. The lumpfish eye immune response to infectious diseases has not been explored. We examined the ocular response to a natural parasite infection in wild lumpfish and to an experimental bacterial infection in cultured lumpfish. Cysts associated with natural myxozoan infection in the ocular scleral cartilage of wild adult lumpfish harbored cells expressing cluster of differentiation 10 (CD10) and immunoglobulin M (IgM). Experimental Vibrio anguillarum infection, which led to exophthalmos and disorganization of the retinal tissues was associated with disruption of normal CD10 expression, CD10(+) cellular infiltration and IgM expression. We further describe the lumpfish CD10 orthologue and characterize the lumpfish scleral skeleton in the context of myxozoan scleral cysts. We propose that lumpfish develop an intraocular response to pathogens, exemplified herein by myxozoan and V. anguillarum infection involving novel CD10(+) cells and IgM(+) cells to contain and mitigate damage to eye structures. This work is the first demonstration of CD10 and IgM expressing cells in a novel ocular immune system component in response to disease in a teleost.	[Gendron, Robert L.; Paradis, Helene; Ahmad, Raahyma; Kao, Kenneth] Mem Univ, Div Biomed Sci, Fac Med, St John, NF, Canada; [Boyce, Danny; Kumar, Surendra; Vasquez, Ignacio; Cao, Trung; Hossain, Ahmed; Chakraborty, Setu; Valderrama, Katherinne; Santander, Javier] Mem Univ, Dept Ocean Sci, Marine Microbial Pathogenesis & Vaccinol Lab, St John, NF, Canada; [Good, William V.] Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA	Memorial University Newfoundland; Memorial University Newfoundland; The Smith-Kettlewell Eye Research Institute	Gendron, RL (corresponding author), Mem Univ, Div Biomed Sci, Fac Med, St John, NF, Canada.	rgendron@mun.ca	Santander, Javier/AAU-9423-2020; Vasquez, Ignacio/GOG-8683-2022; Kumar, Surendra/C-9238-2011	Kumar, Surendra/0000-0001-5396-5509	Vitamin Research Fund, Ocean Frontier Institute; Canada First -Ocean Frontier Institute; Medical Research Foundation of the Faculty of Medicine; School of Graduate Studies, Memorial University; NSERC [RGPIN-2018-05942]; Dr. Joe Brown Aquatic Research Building (JBARB)	Vitamin Research Fund, Ocean Frontier Institute; Canada First -Ocean Frontier Institute; Medical Research Foundation of the Faculty of Medicine; School of Graduate Studies, Memorial University; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Dr. Joe Brown Aquatic Research Building (JBARB)	This work was funded through grants from the Vitamin Research Fund, Ocean Frontier Institute (2017), Canada First -Ocean Frontier Institute (Module J3), Medical Research Foundation of the Faculty of Medicine (2016), through leverage funds from School of Graduate Studies, Memorial University, NSERC-Discovery (RGPIN-2018-05942), and through support from the Dr. Joe Brown Aquatic Research Building (JBARB). Canada Foundation for Innovation.	Ahmad R, 2019, J FISH BIOL, V94, P297, DOI 10.1111/jfb.13892; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], **DATA OBJECT**; Arredondo JL, 2008, J FORENSIC SCI, V53, P928, DOI 10.1111/j.1556-4029.2008.00757.x; Auer-Grumbach M, 2016, AM J HUM GENET, V99, P607, DOI 10.1016/j.ajhg.2016.07.008; Barrett LT, 2020, INT J PARASITOL, V50, P787, DOI 10.1016/j.ijpara.2019.12.005; Bene MC, 2005, IMMUNOL LETT, V98, P9, DOI 10.1016/j.imlet.2004.10.008; Bilal S, 2016, FISH SHELLFISH IMMUN, V53, P77, DOI 10.1016/j.fsi.2016.09.063; BLACKER RW, 1983, J FISH BIOL, V23, P405, DOI 10.1111/j.1095-8649.1983.tb02921.x; BOOMKER J, 1981, ONDERSTEPOORT J VET, V48, P185; Boyce D, 2018, CLEANER FISH BIOL AQ; Calderwood W. L., 1891, Journal of the Marine Biological Association, V(2), P43; Cavin JM, 2012, J VET DIAGN INVEST, V24, P516, DOI 10.1177/1040638712440990; Chakraborty S, 2019, J FISH DIS, V42, P1057, DOI 10.1111/jfd.13010; Costello MJ, 2009, P ROY SOC B-BIOL SCI, V276, P3385, DOI 10.1098/rspb.2009.0771; Costello MJ, 2009, J FISH DIS, V32, P115, DOI 10.1111/j.1365-2761.2008.01011.x; Cronin TW, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0030; Davenport, 1985, FAO FISHERIES SYNOPS, V147, P1; Department of Fisheries and Aquaculture Government of Newfoundland and Labrador, LUMPF EM SPEC PROF S; Diep CQ, 2011, NATURE, V470, P95, DOI 10.1038/nature09669; Ding LJ, 2020, STEM CELLS, V38, P261, DOI 10.1002/stem.3112; Erkinharju T, 2019, J FISH DIS, V42, P1731, DOI 10.1111/jfd.13101; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fisheries and Oceans Canada, 2017, FISH OC CAN MAN DIS; Franz-Odendaal TA, 2006, ZOOLOGY, V109, P75, DOI 10.1016/j.zool.2005.10.001; Franz-Odendaal TA, 2008, ANAT REC, V291, P161, DOI 10.1002/ar.20639; Franz-Odendaal TA, 2007, J EXP ZOOL PART B, V308B, P709, DOI 10.1002/jez.b.21185; Franz-Odendaal TA, 2006, DEV DYNAM, V235, P1244, DOI 10.1002/dvdy.20718; Freeman MA, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-49; Gendron RL, 2006, MOL VIS, V12, P108; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Gendron RL, 2010, INVEST OPHTH VIS SCI, V51, P5267, DOI 10.1167/iovs.09-4527; Geven EJW, 2017, DEV COMP IMMUNOL, V66, P73, DOI 10.1016/j.dci.2016.06.025; Hamre LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073539; Hansson AS, 2002, ARTHRITIS RES, V4, P296, DOI 10.1186/ar425; Hara H, 2006, MOL VIS, V12, P977; Hasby EA, 2013, INT OPHTHALMOL, V33, P125, DOI 10.1007/s10792-012-9651-0; Haugland GT, 2018, CLEANER FISH BIOL AQ, V1st, P258; HOLLANDER Z, 1988, BLOOD, V71, P528; Imsland AK, 2014, AQUACULTURE, V424, P18, DOI 10.1016/j.aquaculture.2013.12.033; Jahed A, 2007, J COMP NEUROL, V503, P209, DOI 10.1002/cne.21385; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kennedy J, 2016, ICES J MAR SCI, V73, P1160, DOI 10.1093/icesjms/fsv244; Kitagaki M, 2007, VET PATHOL, V44, P458, DOI 10.1354/vp.44-4-458; Kobayashi I, 2016, DEV COMP IMMUNOL, V58, P86, DOI 10.1016/j.dci.2016.01.003; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msv279, 10.1093/molbev/msw054]; Lorance P, 2015, IUCN RED LIST THREAT; Maguer-Satta V, 2011, STEM CELLS, V29, P389, DOI 10.1002/stem.592; Mumford S., 2007, FISH HISTOLOGY HISTO; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; Pietrak M, 2020, PARASITOL RES, V119, P879, DOI 10.1007/s00436-019-06542-0; Powell A, 2018, REV AQUACULT, V10, P683, DOI 10.1111/raq.12194; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Ronneseth A, 2015, DEV COMP IMMUNOL, V52, P132, DOI 10.1016/j.dci.2015.05.010; Rosen S, 2013, FISH RES, V148, P64, DOI 10.1016/j.fishres.2013.08.002; Salinas I, 2011, DEV COMP IMMUNOL, V35, P1346, DOI 10.1016/j.dci.2011.11.009; Santander J, 2011, FISH SHELLFISH IMMUN, V31, P1142, DOI 10.1016/j.fsi.2011.10.009; Scholz F, 2017, J FISH DIS, V40, P757, DOI 10.1111/jfd.12554; Scott, 1988, CANADIAN B FISHERIES, V219; Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199; Sharpe RW, 1996, ARCH OPHTHALMOL-CHIC, V114, P1421; SHIPP MA, 1991, BLOOD, V78, P1834; Soding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408; SUGIMOTO T, 1991, INT J CANCER, V48, P277, DOI 10.1002/ijc.2910480221; Torlakovic E, 2005, J PATHOL, V205, P311, DOI 10.1002/path.1705; Vasquez I, 2020, FISH SHELLFISH IMMUN, V104, P557, DOI 10.1016/j.fsi.2020.06.005; Wall DS, 2004, INVEST OPHTH VIS SCI, V45, P3704, DOI 10.1167/iovs.03-1410; Wheater P. R., 1979, FUNCTIONAL HISTOLOGY; Whittaker BA, 2018, PEERJ, V6, DOI 10.7717/peerj.5974; Wilson TM, 2019, ACTA VET HUNG, V67, P81, DOI 10.1556/004.2019.009; Witten PE, 2009, BIOL REV, V84, P315, DOI 10.1111/j.1469-185X.2009.00077.x; WITTENBERG JB, 1974, BIOL BULL-US, V146, P137, DOI 10.2307/1540403; Yu YY, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007251; Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478	74	2	2	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 20	2020	11								576897	10.3389/fimmu.2020.576897	http://dx.doi.org/10.3389/fimmu.2020.576897			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	PA2EG	33329544	Green Published, gold			2022-12-18	WOS:000595445300001
J	Samson, JM; Menon, DR; Vaddi, PK; Williams, NK; Domenico, J; Zhai, ZL; Backos, DS; Fujita, M				Samson, Jenny Mae; Menon, Dinoop Ravindran; Vaddi, Prasanna K.; Williams, Nazanin Kalani; Domenico, Joanne; Zhai, Zili; Backos, Donald S.; Fujita, Mayumi			Computational Modeling of NLRP3 Identifies Enhanced ATP Binding and Multimerization in Cryopyrin-Associated Periodic Syndromes	FRONTIERS IN IMMUNOLOGY			English	Article						NLRP3; cryopyrin-associated periodic syndrome; NLRP3-AID; familial cold autoinflammatory syndrome; Muckle-Wells Syndrome; chronic infantile neurologic cutaneous and articular syndrome; neonatal-onset multisystem inflammatory disease	MUCKLE-WELLS-SYNDROME; COLD AUTOINFLAMMATORY SYNDROME; KERATOENDOTHELIITIS FUGAX HEREDITARIA; AMINO-ACID SUBSTITUTIONS; RICH REPEAT DOMAIN; ARTICULAR SYNDROME; SOMATIC MOSAICISM; CIAS1 MUTATIONS; PYRIN DOMAIN; GENETIC-HETEROGENEITY	Cyropyrin-associated periodic syndromes (CAPS) are clinically distinct syndromes that encompass a phenotypic spectrum yet are caused by alterations in the same gene, NLRP3. Many CAPS cases and other NLRP3-autoinflammatory diseases (NLRP3-AIDs) are directly attributed to protein-coding alterations in NLRP3 and the subsequent dysregulation of the NLRP3 inflammasome leading to IL-1 beta-mediated inflammatory states. Here, we used bioinformatics tools, computational modeling, and computational assessments to explore the proteomic consequences of NLRP3 mutations, which potentially drive NLRP3 inflammasome dysregulation. We analyzed 177 mutations derived from familial cold autoinflammatory syndrome (FCAS), Muckle-Wells Syndrome (MWS), and the non-hereditary chronic infantile neurologic cutaneous and articular syndrome, also known as neonatal-onset multisystem inflammatory disease (CINCA/NOMID), as well as other NLRP3-AIDs. We found an inverse relationship between clinical severity and the severity of predicted structure changes resulting from mutations in NLRP3. Bioinformatics tools and computational modeling revealed that NLRP3 mutations that are predicted to be structurally severely-disruptive localize around the ATP binding pocket and that specific proteo-structural changes to the ATP binding pocket lead to enhanced ATP binding affinity by altering hydrogen-bond and charge interactions. Furthermore, we demonstrated that NLRP3 mutations that are predicted to be structurally mildly- or moderately-disruptive affect protein-protein interactions, such as NLRP3-ASC binding and NLRP3-NLRP3 multimerization, enhancing inflammasome formation and complex stability. Taken together, we provide evidence that proteo-structural mechanisms can explain multiple mechanisms of inflammasome activation in NLRP3-AID.	[Samson, Jenny Mae; Menon, Dinoop Ravindran; Vaddi, Prasanna K.; Williams, Nazanin Kalani; Domenico, Joanne; Zhai, Zili; Fujita, Mayumi] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA; [Backos, Donald S.] Univ Colorado, Skaggs Sch Pharm, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA; [Fujita, Mayumi] Univ Colorado, Dept Immunol, Anschutz Med Campus, Aurora, CO 80045 USA; [Fujita, Mayumi] Denver VA Med Ctr, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Fujita, M (corresponding author), Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA.; Backos, DS (corresponding author), Univ Colorado, Skaggs Sch Pharm, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA.; Fujita, M (corresponding author), Univ Colorado, Dept Immunol, Anschutz Med Campus, Aurora, CO 80045 USA.; Fujita, M (corresponding author), Denver VA Med Ctr, Aurora, CO 80045 USA.	donald.backos@cuanschutz.edu; mayumi.fujita@cuanschutz.edu	Vaddi, Prasanna/AAS-5213-2021; Menon, Dinoop Ravindran/AAC-3620-2021; Ravindran Menon, Dinoop/F-9247-2014	Ravindran Menon, Dinoop/0000-0002-6335-9227	Veterans Affairs Merit Review Award [5I01BX001228]; Cancer League of Colorado; NIH/NCI [R01 CA197919]	Veterans Affairs Merit Review Award(US Department of Veterans Affairs); Cancer League of Colorado; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been supported, in whole or in part, by Veterans Affairs Merit Review Award 5I01BX001228 (to MF), NIH/NCI R01 CA197919 (to MF), and Cancer League of Colorado (to MF).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Aganna E, 2002, ARTHRITIS RHEUM-US, V46, P2445, DOI 10.1002/art.10509; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 2007, ARTHRITIS RHEUM-US, V56, P1273, DOI 10.1002/art.22491; Aksentijevich I, 2006, ARTHRITIS RHEUM, V54, P2703, DOI 10.1002/art.22022; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Arostegui JI, 2004, ARTHRITIS RHEUM-US, V50, P4045, DOI 10.1002/art.20633; Assrawi E, 2020, J INVEST DERMATOL, V140, P791, DOI 10.1016/j.jid.2019.06.153; Awad Fawaz, 2019, ACR Open Rheumatol, V1, P267, DOI 10.1002/acr2.1039; Bae JY, 2011, J BIOL CHEM, V286, P39528, DOI 10.1074/jbc.M111.278812; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Berman N, 2014, JCR-J CLIN RHEUMATOL, V20, P451, DOI 10.1097/RHU.0000000000000190; Boschan C, 2006, AM J MED GENET A, V140A, P883, DOI 10.1002/ajmg.a.31148; Bryan NB, 2009, J IMMUNOL, V182, P3173, DOI 10.4049/jimmunol.0802367; Burillo-Sanz S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39113-5; Canoui E, 2013, CLIN IMMUNOL, V148, P299, DOI 10.1016/j.clim.2013.05.020; Caroli F, 2007, RHEUMATOLOGY, V46, P473, DOI 10.1093/rheumatology/kel269; Carta S, 2015, P NATL ACAD SCI USA, V112, P2835, DOI 10.1073/pnas.1424741112; Chang Z, 2014, ARTHRITIS RHEUMATOL, V66, P3227, DOI 10.1002/art.38811; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chen YH, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00247; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Choi YH, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039927, 10.1371/journal.pone.0046688]; Coll RC, 2019, NAT CHEM BIOL, V15, P556, DOI 10.1038/s41589-019-0277-7; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Cordero MD, 2018, J AUTOIMMUN, V91, P13, DOI 10.1016/j.jaut.2018.03.002; Cuisset L, 2011, ANN RHEUM DIS, V70, P495, DOI 10.1136/ard.2010.138420; Dalgic B, 2007, PEDIATR NEPHROL, V22, P1391, DOI 10.1007/s00467-007-0500-8; Damiano JS, 2004, BIOCHEM J, V381, P213, DOI 10.1042/BJ20031506; de Alba E, 2009, J BIOL CHEM, V284, P32932, DOI 10.1074/jbc.M109.024273; de Jesus AA, 2020, J CLIN INVEST, V130, P1669, DOI 10.1172/JCI129301; de Koning HD, 2015, J ALLERGY CLIN IMMUN, V135, P561, DOI 10.1016/j.jaci.2014.07.050; de Sa DC, 2016, AN BRAS DERMATOL, V91, P566, DOI 10.1590/abd1806-4841.20165577; Dode C, 2002, AM J HUM GENET, V70, P1498, DOI 10.1086/340786; Dunn JH, 2012, CANCER LETT, V314, P24, DOI 10.1016/j.canlet.2011.10.001; EROGLU FK, 2016, CLIN EXP RHEUMA S102, V34, pS11; Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Frenkel J, 2004, ARTHRITIS RHEUM, V50, P2719, DOI 10.1002/art.20295; Gaggiano C, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/3293145; Gattorno M, 2007, ARTHRITIS RHEUM, V56, P3138, DOI 10.1002/art.22842; Gattorno M, 2019, ANN RHEUM DIS, V78, P1025, DOI 10.1136/annrheumdis-2019-215048; Goldbach-Mansky R, 2011, CURR RHEUMATOL REP, V13, P123, DOI 10.1007/s11926-011-0165-y; Granel B, 2003, DERMATOLOGY, V206, P257, DOI 10.1159/000068883; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Harapas CR, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0750-4; He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959; Hoffman HM, 2003, HUM GENET, V112, P209, DOI 10.1007/s00439-002-0860-x; Hoffman HM, 2001, J ALLERGY CLIN IMMUN, V108, P615, DOI 10.1067/mai.2001.118790; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hornung V, 2010, EUR J IMMUNOL, V40, P620, DOI 10.1002/eji.200940185; Hu J, 2017, CHINESE MED J-PEKING, V130, P586, DOI 10.4103/0366-6999.200537; Hu ZH, 2013, SCIENCE, V341, P172, DOI 10.1126/science.1236381; Hull KM, 2003, CURR OPIN RHEUMATOL, V15, P61, DOI 10.1097/00002281-200301000-00011; Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001; Izawa K, 2012, DNA RES, V19, P143, DOI 10.1093/dnares/dsr047; Jeru I, 2010, ARTHRITIS RHEUM-US, V62, P1176, DOI 10.1002/art.27326; Jesus AA, 2008, J CLIN IMMUNOL, V28, P134, DOI 10.1007/s10875-007-9150-7; Jesus AA, 2012, J CLIN IMMUNOL, V32, P922, DOI 10.1007/s10875-012-9688-x; Kanariou M, 2009, KLIN PADIATR, V221, P379, DOI 10.1055/s-0029-1239572; Karacan I, 2019, RHEUMATOL INT, V39, P911, DOI 10.1007/s00296-019-04252-5; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Kilcline C, 2005, ARCH DERMATOL, V141, P248, DOI 10.1001/archderm.141.2.248; Koike Ryuji, 2007, Mod Rheumatol, V17, P496, DOI 10.1007/s10165-007-0616-5; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Koska J, 2008, J CHEM INF MODEL, V48, P1965, DOI 10.1021/ci800081s; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009; Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899; Krieger E, 2012, METHODS MOL BIOL, V819, P405, DOI 10.1007/978-1-61779-465-0_25; Krieger E, 2009, PROTEINS, V77, P114, DOI 10.1002/prot.22570; Kubota K, 2013, J CLIN IMMUNOL, V33, P325, DOI 10.1007/s10875-012-9805-x; Kuemmerle-Deschner JB, 2017, ARTHRITIS RHEUMATOL, V69, P2233, DOI 10.1002/art.40208; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Labrousse M, 2018, CRIT REV CL LAB SCI, V55, P432, DOI 10.1080/10408363.2018.1488805; Lainka E, 2010, KLIN PADIATR, V222, P356, DOI 10.1055/s-0030-1265181; Lamkanfi M, 2017, NATURE, V548, P534, DOI 10.1038/548534a; Lasiglie D, 2017, J RHEUMATOL, V44, P1667, DOI 10.3899/jrheum.170041; Latour I, 2018, PEDIATR DERMATOL, V35, pE337, DOI 10.1111/pde.13619; Lechtenberg BC, 2014, CURR OPIN STRUC BIOL, V29, P17, DOI 10.1016/j.sbi.2014.08.011; Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588; Li CF, 2017, SCI CHINA LIFE SCI, V60, P1436, DOI 10.1007/s11427-017-9246-4; Li L, 2003, PROTEINS, V53, P693, DOI 10.1002/prot.10460; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Liu WM, 2013, J INVEST DERMATOL, V133, P518, DOI 10.1038/jid.2012.317; Louvrier C, 2020, J ALLERGY CLIN IMMUN, V145, P1254, DOI 10.1016/j.jaci.2019.11.035; MacDonald JA, 2013, IUBMB LIFE, V65, P851, DOI 10.1002/iub.1210; Maharana J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209420; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Maksimovic L, 2008, RHEUMATOLOGY, V47, P309, DOI 10.1093/rheumatology/kem318; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Mao LM, 2018, J CLIN INVEST, V128, P1793, DOI 10.1172/JCI98642; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matsubara T, 2006, ARTHRITIS RHEUM-US, V54, P2314, DOI 10.1002/art.21965; Matsubayashi T, 2006, ACTA PAEDIATR, V95, P246, DOI 10.1080/08035250500341451; Matsushima N, 2019, PROTEIN PEPTIDE LETT, V26, P108, DOI 10.2174/0929866526666181208170027; McKusick V.A., 1998, MENDELIAN INHERITANC; Mensa-Vilaro A, 2016, ARTHRITIS RHEUMATOL, V68, P3035, DOI 10.1002/art.39770; Milhavet F, 2008, HUM MUTAT, V29, P803, DOI 10.1002/humu.20720; Mirault T, 2006, ARTHRITIS RHEUM-US, V54, P1697, DOI 10.1002/art.21807; Nair SB, 2019, CLIN RHEUMATOL, V38, P403, DOI 10.1007/s10067-018-4225-9; Nakagawa K, 2015, ANN RHEUM DIS, V74, P603, DOI 10.1136/annrheumdis-2013-204361; Nakanishi H, 2017, P NATL ACAD SCI USA, V114, pE7766, DOI 10.1073/pnas.1702946114; Neocleous V, 2016, J GENET, V95, P761, DOI 10.1007/s12041-016-0691-5; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; Ocampo V, 2018, JCR-J CLIN RHEUMATOL, V24, P158, DOI 10.1097/RHU.0000000000000629; Ohnishi H, 2012, J CLIN IMMUNOL, V32, P221, DOI 10.1007/s10875-011-9629-0; Omoyinmi E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181874; Oroz J, 2016, J BIOL CHEM, V291, P19487, DOI 10.1074/jbc.M116.741082; Pal A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41211-3; Perko D, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/293417; Pierce B, 2007, PROTEINS, V67, P1078, DOI 10.1002/prot.21373; Pontillo A, 2010, AUTOIMMUNITY, V43, P583, DOI 10.3109/08916930903540432; Rentzsch P, 2019, NUCLEIC ACIDS RES, V47, pD886, DOI 10.1093/nar/gky1016; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rosen-Wolff A, 2003, EUR J HAEMATOL, V71, P215, DOI 10.1034/j.1600-0609.2003.00109.x; Rusmini M, 2016, ANN RHEUM DIS, V75, P1550, DOI 10.1136/annrheumdis-2015-207701; RUUSUVAARA P, 1987, ACTA OPHTHALMOL, V65, P159; Sahdo B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075457; Saito M, 2005, ARTHRITIS RHEUM-US, V52, P3579, DOI 10.1002/art.21404; Saito M, 2008, BLOOD, V111, P2132, DOI 10.1182/blood-2007-06-094201; Salehzadeh F, 2019, CLIN MED INSIGHT-CAS, V12, DOI 10.1177/1179547619854705; Salsano E, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-29; Savic S, 2012, CURR OPIN RHEUMATOL, V24, P103, DOI 10.1097/BOR.0b013e32834dd2d5; Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z; Shepard M K, 1971, Birth Defects Orig Artic Ser, V7, P352; Shi CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167636; Shihab HA, 2013, HUM MUTAT, V34, P57, DOI 10.1002/humu.22225; Sonmez HE, 2017, INT IMMUNOL, V29, P393, DOI 10.1093/intimm/dxx020; Stack JH, 2005, J IMMUNOL, V175, P2630, DOI 10.4049/jimmunol.175.4.2630; Stehlik C, 2004, J EXP MED, V200, P551, DOI 10.1084/jem.20032234; Stojanov S, 2004, PEDIATRICS, V114, pE124, DOI 10.1542/peds.114.1.e124; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; Tassi S, 2010, P NATL ACAD SCI USA, V107, P9789, DOI 10.1073/pnas.1000779107; Toplak N, 2012, ANN RHEUM DIS, V71, P1177, DOI 10.1136/annrheumdis-2011-200549; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Turunen JA, 2018, AM J OPHTHALMOL, V188, P41, DOI 10.1016/j.ajo.2018.01.017; Vajjhala PR, 2012, J BIOL CHEM, V287, P41732, DOI 10.1074/jbc.M112.381228; Van Gijn ME, 2018, J MED GENET, V55, P530, DOI 10.1136/jmedgenet-2017-105216; VLAGOPOULOS T, 1975, ANN ALLERGY, V34, P366; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wakhlu A, 2017, INT J RHEUM DIS, V20, P1873, DOI 10.1111/1756-185X.12710; WANDERER AA, 1979, HOSP PRACT, V14, P136, DOI 10.1080/21548331.1979.11707566; WATTS RA, 1994, BRIT J RHEUMATOL, V33, P1184; Webb B, 2017, METHODS MOL BIOL, V1654, P39, DOI 10.1007/978-1-4939-7231-9_4; Wu D, 2017, CLIN RHEUMATOL, V36, P965, DOI 10.1007/s10067-016-3523-3; Wu ST, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-17; Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8; Yuksel S, 2014, INT IMMUNOL, V26, P71, DOI 10.1093/intimm/dxt046; Yuksel S, 2018, J DTSCH DERMATOL GES, V16, P1250, DOI 10.1111/ddg.13640; Zeft A, 2007, ANN RHEUM DIS, V66, P843, DOI 10.1136/ard.2006.064899; Zhang LM, 2015, SCIENCE, V350, P404, DOI 10.1126/science.aac5789; Zhang Q, 2015, GENET MOL RES, V14, P13968, DOI 10.4238/2015.October.29.17	155	2	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2020	11								584364	10.3389/fimmu.2020.584364	http://dx.doi.org/10.3389/fimmu.2020.584364			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ7UD	33329557	Green Published, gold			2022-12-18	WOS:000595125500001
J	Shao, S; Hao, CY; Bin Zhan; Zhuang, QH; Zhao, L; Chen, Y; Huang, JJ; Zhu, XP				Shao, Shuai; Hao, Chunyue; Bin Zhan; Zhuang, Qinghui; Zhao, Limei; Chen, Yi; Huang, Jingjing; Zhu, Xinping			Trichinella spiralis Calreticulin S-Domain Binds to Human Complement C1q to Interfere With C1q-Mediated Immune Functions	FRONTIERS IN IMMUNOLOGY			English	Article						Trichinella spiralis; calreticulin S-domain; binding site; complement C1q; classical complement activation; immune evasion; neutrophil; neutrophil extracellular traps	NEUTROPHIL EXTRACELLULAR TRAPS; HYDROGEN-PEROXIDE; EOSINOPHILS; HELMINTHS; EVASION; LARVAE; SITE	Helminths develop strategies to escape host immune responses that facilitate their survival in the hostile host immune environment. Trichinella spiralis, a tissue-dwelling nematode, has developed a sophisticated strategy to escape complement attack. Our previous study demonstrated that T. spiralis secretes calreticulin (TsCRT) to inhibit host classical complement activation through binding to C1q; however, the C1q binding site in TsCRT and the specific mechanism involved with complement-related immune evasion remains unknown. Using molecular docking modeling and fragment expression, we determined that TsCRT-S, a 153-aa domain of TsCRT, is responsible for C1q binding. Recombinant TsCRT-S protein expressed in Escherichia coli had the same capacity to bind and inhibit human C1q-induced complement and neutrophil activation, as full-length TsCRT. TsCRT-S inhibited neutrophil reactive oxygen species and elastase release by binding to C1q and reduced neutrophil killing of newborn T. spiralis larvae. Binding of TsCRT-S to C1q also inhibited formation of neutrophil extracellular traps (NETs), which are involved in autoimmune pathologies and have yet to be therapeutically targeted. These findings provide evidence that the TsCRT-S fragment, rather than the full-length TsCRT, is a potential target for vaccine or therapeutic development for trichinellosis, as well as for complement-related autoimmune disease therapies.	[Shao, Shuai; Hao, Chunyue; Zhuang, Qinghui; Zhao, Limei; Chen, Yi; Huang, Jingjing; Zhu, Xinping] Capital Med Univ, Sch Basic Med Sci, Dept Med Microbiol & Parasitol, Beijing, Peoples R China; [Bin Zhan] Baylor Coll Med, Dept Pediat, Natl Sch Trop Med, Houston, TX 77030 USA	Capital Medical University; Baylor College of Medicine	Zhu, XP (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Med Microbiol & Parasitol, Beijing, Peoples R China.	zhuxping@ccmu.edu.cn			National Natural Science Foundation of China [81672042]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a grant from the National Natural Science Foundation of China (81672042).	Almzaiel AJ, 2013, LIFE SCI, V93, P125, DOI 10.1016/j.lfs.2013.06.003; Barnado A, 2016, J LEUKOCYTE BIOL, V99, P265, DOI 10.1189/jlb.5BT0615-234R; BASS DA, 1979, J CLIN INVEST, V64, P1558, DOI 10.1172/JCI109616; Chen Y, 2012, METHODS MOL BIOL, V844, P115, DOI 10.1007/978-1-61779-527-5_8; Cheng YL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01566; de Bont CM, 2019, CELL MOL IMMUNOL, V16, P19, DOI 10.1038/s41423-018-0024-0; Dupouy-Camet J, 2000, VET PARASITOL, V93, P191, DOI 10.1016/S0304-4017(00)00341-1; Freudenstein-Dan A, 2003, J PARASITOL, V89, P1129, DOI 10.1645/GE-96R; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; Ghai R, 2007, IMMUNOBIOLOGY, V212, P253, DOI 10.1016/j.imbio.2006.11.001; GOODMAN EB, 1995, J LEUKOCYTE BIOL, V58, P168, DOI 10.1002/jlb.58.2.168; Gottstein B, 2009, CLIN MICROBIOL REV, V22, P127, DOI 10.1128/CMR.00026-08; Holers VM, 2014, ANNU REV IMMUNOL, V32, P433, DOI 10.1146/annurev-immunol-032713-120154; Huang L, 2016, TRENDS PARASITOL, V32, P798, DOI 10.1016/j.pt.2016.05.004; Ishiwata K, 2007, EXP PARASITOL, V117, P80, DOI 10.1016/j.exppara.2007.03.019; Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294; Kasper G, 2001, PARASITE IMMUNOL, V23, P141, DOI 10.1046/j.1365-3024.2001.00366.x; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kuna P, 1996, CLIN IMMUNOL IMMUNOP, V81, P48, DOI 10.1006/clin.1996.0156; Lee KH, 2017, AUTOIMMUN REV, V16, P1160, DOI 10.1016/j.autrev.2017.09.012; Leffler J, 2014, ANN RHEUM DIS, V73, P1601, DOI 10.1136/annrheumdis-2014-205287; LEID RW, 1988, ADV PARASIT, V27, P131, DOI 10.1016/S0065-308X(08)60354-1; Leigh LEA, 1998, BIOCHEM J, V330, P247; Lund ME, 2016, SCI REP-UK, V6, DOI 10.1038/srep37789; Mendlovic F, 2004, J PARASITOL, V90, P891, DOI 10.1645/GE-3325RN; Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847; Mihara Keiko, 2015, Curr Protoc Cell Biol, V68, DOI 10.1002/0471143030.cb0430s68; Naresha S, 2009, MOL BIOCHEM PARASIT, V166, P42, DOI 10.1016/j.molbiopara.2009.02.007; Nayak A, 2010, IMMUNOL LETT, V131, P139, DOI 10.1016/j.imlet.2010.03.012; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Pednekar L, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00567; Rajamanickam A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00207; Ramirez-Toloza G, 2020, TRENDS PARASITOL, V36, P368, DOI 10.1016/j.pt.2020.01.007; Ramirez-Toloza G, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01667; Rincon E, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4957-6; Riss T.L., 2004, ASSAY GUIDANCE MANUA, V1, P1, DOI DOI 10.1016/J.ACTHIS.2012.01.006; Segal Y, 2018, IMMUNOL RES, V66, P637, DOI 10.1007/s12026-018-9051-2; Shao S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00532; Sollberger G, 2018, DEV CELL, V44, P542, DOI 10.1016/j.devcel.2018.01.019; Sorensen OE, 2016, J CLIN INVEST, V126, P1612, DOI 10.1172/JCI84538; Stuart GR, 1996, FEBS LETT, V397, P245, DOI 10.1016/S0014-5793(96)01156-8; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; Suchitra S, 2005, BBA-GEN SUBJECTS, V1722, P293, DOI 10.1016/j.bbagen.2004.12.020; Sun SY, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3561-1; Thielens NM, 2017, MOL IMMUNOL, V89, P73, DOI 10.1016/j.molimm.2017.05.025; Trouw LA, 2017, NAT REV RHEUMATOL, V13, DOI 10.1038/nrrheum.2017.125; VENTURIELLO SM, 1993, PARASITE IMMUNOL, V15, P559; VERSTUYF A, 1995, J STEROID BIOCHEM, V53, P431, DOI 10.1016/0960-0760(95)00089-I; Wang M, 2017, PARASITOL RES, V116, P2065, DOI 10.1007/s00436-017-5544-5; Wu ZY, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02164; Yadav S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106413; Yang XD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096454; Zhao LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00636	54	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2020	11								572326	10.3389/fimmu.2020.572326	http://dx.doi.org/10.3389/fimmu.2020.572326			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ7QR	33329535	Green Published, gold			2022-12-18	WOS:000595116500001
J	Tong, H; Feng, H; Hu, X; Wang, MF; Song, YF; Wen, XL; Li, YR; Wan, XP				Tong, Huan; Feng, Hao; Hu, Xiang; Wang, Meng-fei; Song, Yun-feng; Wen, Xiao-li; Li, Yi-ran; Wan, Xiao-ping			Identification of Interleukin-9 Producing Immune Cells in Endometrial Carcinoma and Establishment of a Prognostic Nomogram	FRONTIERS IN IMMUNOLOGY			English	Article						endometrial carcinoma; &#947; &#948; T cells; interleukin-9; nomogram; survival analysis	CANCER	Background Interleukin-9 (IL9) plays a critical role in immunity and the pathogenesis of endometrial cancer (EC), especially endometrioid EC (EEC). This study aimed to identify the IL9+ immune cell subsets and their pleiotropic functions and establish an optimized prognostic nomogram towards the promotion of personalized treatment of EEC. Methods 1,417 EC patients were involved in the present study. 143 patients from the tertiary gynecology centers in Shanghai between 2013 and 2019 were recruited, and the study protocol was approved by the Institutional Review Board (IRB) of Shanghai First Maternity and Infant Hospital. The genomic data of the other 1,274 patients were extracted from the TCGA and the MSKCC datasets, respectively. Immune and stromal scores were calculated using the ESTIMATE R tool, and the tumor infiltration of immune cells was analyzed using the TIMER platform. Metascape and GEPIA datasets were used for bioinformatic analysis. P < 0.05 was considered statistically significant. All statistical analyses were performed with GraphPad Prism and R studio. Results 552 genes that were correlated with leukocyte infiltration, lymphocyte activation, and regulation of innate immune response were up-regulated in the high immune score group. More IL9+ cell infiltration was detected in the highly and moderately differentiated EC (p = 0.04). High IL9+ lymphocyte infiltration was related to a better overall survival (p = 0.0027). IL9 positive cell clusters included ILC2s, V delta 2 gamma delta T cells, mast cells, macrophages, and Th9 cells. Parameters such as FIGO stage, IL9 score, V delta 2 + gamma delta T cell infiltration, classification of differentiation, and diabetes mellitus were assigned a weighted number of points in the nomogram for a specific predicted 3-, 5- and 10-year overall survival (OS). IL9-IL9R axis played a vital role in EEC, IL9R positive cell subgroups were also identified, and the related function was analyzed in the present study. Additionally, PR (Progesterone Receptor, or PGR) expression was relevant to a higher density of IL9+ lymphocyte infiltration. However, PGRMC1 (Progesterone Receptor Membrane Component 1) was negatively relevant to IL9R (p = 4.26e-8). Conclusion We observed a significant infiltration of IL9+ cells and the overrepresentation of IL-9R in tissue specimens of patients in EC cases. The nomogram incorporating the IL9 could accurately predict individualized survival probability in EEC. Additionally, this study not only established a prognostic nomogram but also assist in the firmer understanding of the relevance of the IL9-IL9R axis and IL9-producing cells in EC immunity.	[Tong, Huan; Hu, Xiang; Wang, Meng-fei; Song, Yun-feng; Wen, Xiao-li; Wan, Xiao-ping] Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Clin & Translat Res Ctr, Shanghai, Peoples R China; [Feng, Hao] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Liver Surg, Shanghai, Peoples R China; [Feng, Hao] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Munich, Germany; [Li, Yi-ran; Wan, Xiao-ping] Tongji Univ, Sch Med, Dept Gynecol, Shanghai Matern & Infant Hosp 1, Shanghai, Peoples R China	Tongji University; Shanghai Jiao Tong University; University of Munich; Tongji University	Wan, XP (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Clin & Translat Res Ctr, Shanghai, Peoples R China.; Feng, H (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Liver Surg, Shanghai, Peoples R China.; Feng, H (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Munich, Germany.; Wan, XP (corresponding author), Tongji Univ, Sch Med, Dept Gynecol, Shanghai Matern & Infant Hosp 1, Shanghai, Peoples R China.	surgeonfeng@live.com; wanxiaoping@tongji.edu.cn	FENG, Hao/N-8975-2016	FENG, Hao/0000-0003-4066-8104	Shanghai Jiao Tong University (SJTU) Cross-disciplinary project [YG2017QN54]; National Natural Science Foundation, China [81702545, 81672574, 81902388]; Shanghai Natural Science Foundation [18ZR1424200]	Shanghai Jiao Tong University (SJTU) Cross-disciplinary project; National Natural Science Foundation, China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai)	This study was supported by the Funding Program from Shanghai Jiao Tong University (SJTU) Cross-disciplinary project (HF, YG2017QN54), National Natural Science Foundation, China (HT, 81702545), Shanghai Natural Science Foundation (HF, 18ZR1424200), National Natural Science Foundation, China (XPW, 81672574), National Natural Science Foundation, China (HF, 81902388).	Bruchard M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00656; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; Geng YT, 2016, SCI REP-UK, V6, DOI 10.1038/srep39482; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; Gomez-Lopez N, 2016, IMMUNOL CELL BIOL, V94, P79, DOI 10.1038/icb.2015.63; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Kadel Sapana, 2018, Immunohorizons, V2, P74, DOI 10.4049/immunohorizons.1800008; Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048; Le Gallo M, 2014, CLIN CHEM, V60, P98, DOI 10.1373/clinchem.2013.205740; Leonard WJ, 2019, IMMUNITY, V50, P832, DOI 10.1016/j.immuni.2019.03.028; Lewin SN, 2010, OBSTET GYNECOL, V116, P1141, DOI 10.1097/AOG.0b013e3181f39849; Li TB, 2017, NAT METHODS, V14, P61, DOI 10.1038/nmeth.4083; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Lippitz BE, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1093722; Longoria Teresa C, 2015, Gynecol Oncol Res Pract, V2, P11, DOI 10.1186/s40661-015-0020-3; Lu Y, 2012, J CLIN INVEST, V122, P4160, DOI 10.1172/JCI65459; Mariani A, 2008, GYNECOL ONCOL, V109, P11, DOI 10.1016/j.ygyno.2008.01.023; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Park JY, 2015, ONCOLOGIST, V20, P270, DOI 10.1634/theoncologist.2013-0445; Peters C, 2016, P NATL ACAD SCI USA, V113, P12520, DOI 10.1073/pnas.1607136113; Purwar R, 2012, NAT MED, V18, P1248, DOI 10.1038/nm.2856; Qayum AA, 2019, J IMMUNOL, V203, P1111, DOI 10.4049/jimmunol.1900272; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Turei D, 2016, NAT METHODS, V13, P965, DOI 10.1038/nmeth.4077; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Wang H, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01212; Wui-Jin KM, NAT COMPR CANC NETW; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; You FP, 2017, INT IMMUNOPHARMACOL, V52, P163, DOI 10.1016/j.intimp.2017.08.031; Zar JH, 1999, BIOSTATISTICAL ANAL, V4th, P523; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	36	2	2	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2020	11								544248	10.3389/fimmu.2020.544248	http://dx.doi.org/10.3389/fimmu.2020.544248			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ8NF	33329510	Green Accepted, gold, Green Published			2022-12-18	WOS:000595175400001
J	Villa, A; Capo, V; Castiello, MC				Villa, Anna; Capo, Valentina; Castiello, Maria Carmina			Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency	FRONTIERS IN IMMUNOLOGY			English	Review						RAG genes; gene therapy; non-genotoxic conditioning; severe combined immunodeficiency; hematopoietic stem cell transplantation; Omenn syndrome; leaky SCID	SEVERE COMBINED IMMUNODEFICIENCY; HUMAN HEMATOPOIETIC STEM; IMMUNOGLOBULIN-SECRETING CELLS; GENE-THERAPY; GRANULOMATOUS-DISEASE; ADJUNCTIVE THERAPY; ANTI-CD45 ANTIBODY; OMENN-SYNDROME; T-CELLS; TRANSPLANTATION	Genetic defects in recombination activating genes (RAG) 1 and 2 cause a broad spectrum of severe immune defects ranging from early severe and repeated infections to inflammation and autoimmune manifestations. A correlation between in vitro recombination activity and immune phenotype has been described. Hematopoietic cell transplantation is the treatment of care; however, the availability of next generation sequencing and whole genome sequencing has allowed the identification of novel genetic RAG variants in immunodeficient patients at various ages, raising therapeutic questions. This review addresses the recent advances of novel therapeutic approaches for RAG deficiency. As conventional myeloablative conditioning regimens are associated with acute toxicities and transplanted-related mortality, innovative minimal conditioning regimens based on the use of monoclonal antibodies are now emerging and show promising results. To overcome shortage of compatible donors, gene therapy has been developed in various RAG preclinical models. Overall, the transplantation of autologous gene corrected hematopoietic precursors and the use of non-genotoxic conditioning will open a new era, offering a cure to an increasing number of RAG patients regardless of donor availability and severity of clinical conditions.	[Villa, Anna; Capo, Valentina; Castiello, Maria Carmina] IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy; [Villa, Anna; Capo, Valentina; Castiello, Maria Carmina] Consiglio Nazl Ric IRGB CNR, Ist Ric Genet & Biomed, Milan, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR)	Villa, A (corresponding author), IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy.; Villa, A (corresponding author), Consiglio Nazl Ric IRGB CNR, Ist Ric Genet & Biomed, Milan, Italy.	villa.anna@hsr.it	Castiello, Maria Carmina/K-9767-2016; Capo, Valentina/ABG-3418-2020	Castiello, Maria Carmina/0000-0003-2581-9648; Capo, Valentina/0000-0002-1851-1429	EU [755170-2]; Telethon Core grant E2 project [RF-PE- 2016-02363691];  [PRIN 2017 5XHBPN]	EU(European Commission); Telethon Core grant E2 project; 	This work was sponsored in part by EU H2020 grant RECOMB (755170-2), Telethon Core grant E2 project, RF-PE- 2016-02363691 and PRIN 2017 5XHBPN.	Abd Hamid IJ, 2018, J CLIN IMMUNOL, V38, P727, DOI 10.1007/s10875-018-0540-9; Agarwal R., 2019, BIOL BLOOD MARROW TR, V25, pS92, DOI [10.1016/j.bbmt.2018.12.172, DOI 10.1016/J.BBMT.2018.12.172, DOI 10.1016/j.bbmt.2018.12.172]; Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536; Bulkhi AA, 2019, EXPERT REV CLIN IMMU, V15, P1033, DOI 10.1080/1744666X.2020.1670060; Burtner CR, 2015, HUM GENE THER, V26, P399, DOI 10.1089/hum.2015.021; Capo V, 2021, HAEMATOLOGICA, V106, P74, DOI 10.3324/haematol.2019.238261; Capo V, 2018, J ALLERGY CLIN IMMUN, V142, P928, DOI 10.1016/j.jaci.2017.11.015; Cassani B, 2010, J EXP MED, V207, P1525, DOI 10.1084/jem.20091928; Castagnoli R, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00295; Castiello MC, 2021, J ALLERGY CLIN IMMUN, V147, P309, DOI 10.1016/j.jaci.2020.04.033; Chen Y, 2012, BLOOD, V119, P1130, DOI 10.1182/blood-2011-09-380436; Chhabra A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aae0501; Chou J, 2012, J ALLERGY CLIN IMMUN, V130, P1414, DOI 10.1016/j.jaci.2012.06.012; Cohen S, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-110188; Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726; Czechowicz A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08201-x; de Bruin LMO, 2018, BLOOD, V132, P281, DOI 10.1182/blood-2017-12-820985; De Ravin SS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3480; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Delmonte OM, 2020, BLOOD, V135, P610, DOI 10.1182/blood.2019000923; Delmonte OM, 2018, J CLIN IMMUNOL, V38, P646, DOI 10.1007/s10875-018-0537-4; Dever DP, 2016, NATURE, V539, P384, DOI 10.1038/nature20134; Dimitrova D, 2020, BIOL BLOOD MARROW TR, V26, P94, DOI 10.1016/j.bbmt.2019.08.018; Dvorak CC, 2014, PEDIATR TRANSPLANT, V18, P602, DOI 10.1111/petr.12309; Dvorak CC, 2014, PEDIATR TRANSPLANT, V18, P609, DOI 10.1111/petr.12310; Ehl S, 2005, J CLIN INVEST, V115, P3140, DOI 10.1172/JCI25221; Farmer JR, 2019, J ALLER CL IMM-PRACT, V7, P1970, DOI 10.1016/j.jaip.2019.02.038; Ferrari S, 2020, NAT BIOTECHNOL, V38, P1298, DOI 10.1038/s41587-020-0551-y; Fischer A, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.61; Gao CY, 2019, BLOOD ADV, V3, P2700, DOI 10.1182/bloodadvances.2019000516; Garcia-Perez L, 2020, MOL THER-METH CLIN D, V17, P666, DOI 10.1016/j.omtm.2020.03.016; Geier CB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133220; Gennery AR, 2020, BRIT MED BULL, V135, P4, DOI 10.1093/bmb/ldaa017; Genovese P, 2014, NATURE, V510, P235, DOI 10.1038/nature13420; Gentner B, 2019, MOL THER, V27, P1; Giblin W, 2009, BLOOD, V113, P2965, DOI 10.1182/blood-2008-07-165167; Hacein-Bey-Abina S, 2014, NEW ENGL J MED, V371, P1407, DOI 10.1056/NEJMoa1404588; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Haddad E, 2018, BLOOD, V132, P1737, DOI 10.1182/blood-2018-03-840702; Haines HL, 2015, BIOL BLOOD MARROW TR, V21, P288, DOI 10.1016/j.bbmt.2014.10.010; Heffner GC, 2018, MOL THER, V26, P320, DOI 10.1016/j.ymthe.2017.09.025; Heimall J, 2017, BIOL BLOOD MARROW TR, V23, P379, DOI 10.1016/j.bbmt.2016.12.619; Henderson LA, 2013, J ALLERGY CLIN IMMUN, V132, P969, DOI 10.1016/j.jaci.2013.06.032; Kato T, 2015, J CLIN IMMUNOL, V35, P280, DOI 10.1007/s10875-015-0146-4; Khiong K, 2007, J CLIN INVEST, V117, P1270, DOI 10.1172/JCI30513; Kuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052; Lagresle-Peyrou C, 2006, BLOOD, V107, P63, DOI 10.1182/blood-2005-05-2032; Lagresle-Peyrou C, 2008, MOL THER, V16, P396, DOI 10.1038/sj.mt.6300353; Li ZZ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08202-w; Liu A, 2006, BLOOD, V108, P1123, DOI 10.1182/blood-2006-01-0061; Lum SH, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0883-1; Marrella V, 2007, J CLIN INVEST, V117, P1260, DOI 10.1172/JCI30928; Nakamae H, 2009, CANCER RES, V69, P2408, DOI 10.1158/0008-5472.CAN-08-4363; Neven B, 2017, CLIN INFECT DIS, V64, P83, DOI 10.1093/cid/ciw675; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Palchaudhuri R, 2016, NAT BIOTECHNOL, V34, P738, DOI 10.1038/nbt.3584; Patel NC, 2008, J ALLERGY CLIN IMMUN, V122, P1185, DOI 10.1016/j.jaci.2008.10.030; Pearse B.R., 2019, BIOL BLOOD MARROW TR, V25, pS29, DOI [10.1016/j.bbmt.2018.12.101, DOI 10.1016/J.BBMT.2018.12.101]; Petrillo C, 2019, HUM GENE THER, V30, P1133, DOI 10.1089/hum.2019.016; Petrillo C, 2018, CELL STEM CELL, V23, P820, DOI 10.1016/j.stem.2018.10.008; Pietras EM, 2016, NAT CELL BIOL, V18, P607, DOI 10.1038/ncb3346; Pike-Overzet K, 2011, LEUKEMIA, V25, P1471, DOI 10.1038/leu.2011.106; Pike-Overzet K, 2006, NATURE, V443, pE5, DOI 10.1038/nature05218; Pike-Overzet K, 2014, J ALLERGY CLIN IMMUN, V134, P242, DOI 10.1016/j.jaci.2014.04.033; Polito L, 2013, TOXINS, V5, P1698, DOI 10.3390/toxins5101698; Rigoni R, 2020, J ALLERGY CLIN IMMUN, V146, P1165, DOI 10.1016/j.jaci.2020.04.005; Rigoni R, 2016, GUT MICROBES, V7, P503, DOI 10.1080/19490976.2016.1228517; Rigoni R, 2016, J EXP MED, V213, P355, DOI 10.1084/jem.20151116; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; Schiroli G, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0820; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Schuetz C, 2014, BLOOD, V123, P281, DOI 10.1182/blood-2013-01-476432; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Severe N, 2019, CELL STEM CELL, V25, P570, DOI 10.1016/j.stem.2019.06.003; Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140-6736(09)60945-4; Tirosh I, 2019, J ALLERGY CLIN IMMUN, V143, P726, DOI 10.1016/j.jaci.2018.04.027; Tisdale JF, 2019, BLOOD, V134, DOI 10.1182/blood-2019-125968; van der Burg M, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00373; van Til NP, 2014, J ALLERGY CLIN IMMUN, V134, P243, DOI 10.1016/j.jaci.2014.04.032; van Til NP, 2014, J ALLERGY CLIN IMMUN, V133, P1116, DOI 10.1016/j.jaci.2013.10.009; van Til NP, 2012, MOL THER, V20, P1968, DOI 10.1038/mt.2012.110; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2019, IMMUNOL REV, V287, P73, DOI 10.1111/imr.12713; Walter JE, 2015, J CLIN INVEST, V125, P4135, DOI 10.1172/JCI80477; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927; Xue XK, 2010, BLOOD, V116, P5419, DOI 10.1182/blood-2010-07-295949; Yates F, 2002, BLOOD, V100, P3942, DOI 10.1182/blood-2002-03-0782; Zonari E, 2017, STEM CELL REP, V8, P977, DOI 10.1016/j.stemcr.2017.02.010	89	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 19	2020	11								607926	10.3389/fimmu.2020.607926	http://dx.doi.org/10.3389/fimmu.2020.607926			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ7PX	33329604	gold, Green Published			2022-12-18	WOS:000595114500001
J	Cimini, FA; Barchetta, I; Ceccarelli, V; Chiappetta, C; Di Biasio, A; Bertoccini, L; Sentinelli, F; Leonetti, F; Silecchia, G; Di Cristofano, C; Baroni, MG; Velotti, F; Cavallo, MG				Cimini, Flavia Agata; Barchetta, Ilaria; Ceccarelli, Valentina; Chiappetta, Caterina; Di Biasio, Alberto; Bertoccini, Laura; Sentinelli, Federica; Leonetti, Frida; Silecchia, Gianfranco; Di Cristofano, Claudio; Baroni, Marco Giorgio; Velotti, Francesca; Cavallo, Maria Gisella			Granzyme B Expression in Visceral Adipose Tissue Associates With Local Inflammation and Glyco-Metabolic Alterations in Obesity	FRONTIERS IN IMMUNOLOGY			English	Article						Granzyme B; visceral adipose tissue; inflammation; glyco-metabolic alterations; obesity	FACTOR-KAPPA-B; IMMUNE CELLS; ATHEROSCLEROSIS; INVOLVEMENT; DYSFUNCTION; ADIPOCYTES; INDUCTION; PROTEASES; CLEAVAGE; MARKER	Granzyme B (GrB) is a serine protease produced by immune and non-immune cells, able to promote multiple processes, like apoptosis, inflammation, extracellular matrix remodeling and fibrosis. GrB expression in visceral adipose tissue (VAT) was associated with tissue damage, local inflammation and insulin resistance in obesity murine model, but there is no data in humans. Aim of this study was to explore the expression of GrB in VAT from obese subjects in relation to adipose tissue injury, inflammation, metabolic alterations and GrB circulating levels. For this purpose, 85 obese individuals undergoing bariatric surgery and 35 healthy subjects (as control) were recruited at Sapienza University, Rome, Italy. Study participants underwent clinical work-up and routine biochemistry. mRNA expression of GrB in VAT and of a panel of VAT inflammatory markers was analyzed by real-time PCR. Serum GrB levels were measured by Elisa Affymetrix EBIO. We observed that 80% of obese patients expressed GrB mRNA in VAT, and GrB VAT expression was associated with the presence of local inflammation and glucose homeostasis alterations. Moreover, GrB serum levels, which were higher in obese subjects compared to non-obese healthy individuals, were associated with GrB expression in VAT and glyco-metabolic impairment. Our data show, for the first time in humans, that obese subjects with "sick" fat and altered glucose tolerance exhibit GrB expression in VAT, and suggest that GrB might contribute to obesity-related VAT inflammatory remodeling and glucose homeostasis dysregulation. Moreover, increased circulating GrB levels might represent a possible peripheral marker of VAT dysfunction in metabolic diseases.	[Cimini, Flavia Agata; Barchetta, Ilaria; Ceccarelli, Valentina; Bertoccini, Laura; Sentinelli, Federica; Cavallo, Maria Gisella] Sapienza Univ Rome, Dept Expt Med, Rome, Italy; [Chiappetta, Caterina; Di Biasio, Alberto; Leonetti, Frida; Silecchia, Gianfranco; Di Cristofano, Claudio] Sapiens Univ Rome, Dept Med Surg Sci & Biotechnol, Rome, Italy; [Baroni, Marco Giorgio] Univ Aquila, Dept Clin Med Publ Hlth Life & Environm Sci MeSVA, Laquila, Italy; [Baroni, Marco Giorgio] IRCCS Neuromed, Neuroendocrinol & Metab Dis, Pozzilli, Italy; [Velotti, Francesca] Tuscia Univ, Dept Ecol & Biol Sci DEB, Viterbo, Italy	Sapienza University Rome; University of L'Aquila; IRCCS Neuromed; Tuscia University	Cavallo, MG (corresponding author), Sapienza Univ Rome, Dept Expt Med, Rome, Italy.; Velotti, F (corresponding author), Tuscia Univ, Dept Ecol & Biol Sci DEB, Viterbo, Italy.	velotti@unitus.it; gisella.cavallo@uniroma1.it	Baroni, Marco Giorgio/AIA-6973-2022; Cimini, Flavia Agata/AAC-1985-2019; Baroni, Marco Giorgio/AAH-3476-2020	Cimini, Flavia Agata/0000-0001-7630-7349; Baroni, Marco Giorgio/0000-0002-3224-6078; di Biasio, Alberto/0000-0002-0661-5861; Di Cristofano, Claudio/0000-0003-2891-5598	Sapienza University of Rome, Italy	Sapienza University of Rome, Italy	This work was supported by grants from Sapienza University of Rome, Italy (MC).	Amer Diabet Assoc, 2009, DIABETES CARE, V32, pS13, DOI 10.2337/dc09-S013; Asghar A, 2017, CELL IMMUNOL, V315, P18, DOI 10.1016/j.cellimm.2017.03.001; Barchetta I, 2019, J ENDOCRINOL INVEST, V42, P1257, DOI 10.1007/s40618-019-01052-3; Barchetta I, 2017, J ENDOCR SOC, V1, P660, DOI 10.1210/js.2017-00108; Barchetta I, 2016, CLIN SCI, V130, P1753, DOI 10.1042/CS20160348; Burhans MS, 2019, COMPR PHYSIOL, V9, P1, DOI 10.1002/cphy.c170040; Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200; Chamberlain CM, 2007, CAN J PHYSIOL PHARM, V85, P89, DOI 10.1139/Y06-090; Choy JC, 2004, ARTERIOSCL THROM VAS, V24, P2245, DOI 10.1161/01.ATV.0000147162.51930.b7; Choy JC, 2003, MODERN PATHOL, V16, P460, DOI 10.1097/01.MP.0000067424.12280.BC; Cimini FA, 2021, DIABETES-METAB RES, V37, DOI 10.1002/dmrr.3358; Cimini FA, 2019, CYTOKINE, V115, P104, DOI 10.1016/j.cyto.2018.11.019; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; El Mesallamy HO, 2014, J INTERF CYTOK RES, V34, P179, DOI 10.1089/jir.2013.0059; Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3; Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2; Guzik TJ, 2017, CARDIOVASC RES, V113, P1009, DOI 10.1093/cvr/cvx108; Hammarstedt A, 2018, PHYSIOL REV, V98, P1911, DOI 10.1152/physrev.00034.2017; Hiebert PR, 2012, TRENDS MOL MED, V18, P732, DOI 10.1016/j.molmed.2012.09.009; Ikemoto T, 2009, J CARDIOL, V54, P409, DOI 10.1016/j.jjcc.2009.06.009; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; Jiao P, 2009, DIABETES, V58, P104, DOI 10.2337/db07-1344; Tinahones FJ, 2013, DIABETES CARE, V36, P513, DOI 10.2337/dc12-0194; Kim WJ, 2007, IMMUNOL LETT, V111, P57, DOI 10.1016/j.imlet.2007.05.004; Kobashi C, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-25; Lee YS, 2014, CELL, V157, P1339, DOI 10.1016/j.cell.2014.05.012; Lee YH, 2014, BBA-MOL BASIS DIS, V1842, P358, DOI 10.1016/j.bbadis.2013.05.011; Lin D, 2016, BIOCHEM PHARMACOL, V119, P8, DOI 10.1016/j.bcp.2016.05.005; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Murahovschi V, 2015, DIABETES, V64, P856, DOI 10.2337/db14-0444; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Oztas E, 2016, EUR J OBSTET GYN R B, V198, P89, DOI 10.1016/j.ejogrb.2016.01.009; Russo L, 2018, IMMUNOLOGY, V155, P407, DOI 10.1111/imm.13002; Saito Y, 2011, J CARDIOL, V57, P141, DOI 10.1016/j.jjcc.2010.10.001; Shen Y, 2016, AM J PATHOL, V186, P87, DOI 10.1016/j.ajpath.2015.09.010; Skjelland M, 2007, ATHEROSCLEROSIS, V195, pE142, DOI 10.1016/j.atherosclerosis.2007.05.001; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Surmi BK, 2010, VASC PHARMACOL, V52, P27, DOI 10.1016/j.vph.2009.12.004; Trapani JA, 2003, CURR OPIN IMMUNOL, V15, P533, DOI 10.1016/S0952-7915(03)00107-9; Trayhurn P, 2013, PHYSIOL REV, V93, P1, DOI 10.1152/physrev.00017.2012; VELOTTI F, 1992, EUR J IMMUNOL, V22, P1049, DOI 10.1002/eji.1830220426; Wensink AC, 2015, J IMMUNOL, V194, P491, DOI 10.4049/jimmunol.1401214; Wyszynski DF, 2005, AM J CARDIOL, V95, P194, DOI 10.1016/j.amjcard.2004.08.091; Yamaguchi R, 2015, LIFE SCI, V143, P225, DOI 10.1016/j.lfs.2015.11.010; Yang HW, 2010, J IMMUNOL, V185, P1836, DOI 10.4049/jimmunol.1000021; Zatterale F, 2020, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01607	46	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 18	2020	11								589188	10.3389/fimmu.2020.589188	http://dx.doi.org/10.3389/fimmu.2020.589188			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OZ2JB	33312176	Green Published, gold			2022-12-18	WOS:000594757700001
J	Huo, CY; Tian, JJ; Cheng, JL; Xiao, J; Chen, MY; Zou, SM; Tian, HY; Wang, M; Sun, HL; Hu, YX				Huo, Caiyun; Tian, Jijing; Cheng, Jinlong; Xiao, Jin; Chen, Mingyong; Zou, Shumei; Tian, Haiyan; Wang, Ming; Sun, Huiling; Hu, Yanxin			Safety, Immunogenicity, and Effectiveness of Defective Viral Particles Arising in Mast Cells Against Influenza in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						mast cells; defective viral particles; immunogenicity; protective immune reaction	DENGUE VIRUS-INFECTION; A VIRUS; INTERFERING PARTICLES; RIG-I; RNA; REPLICATION; RESPONSES; VACCINE	Mast cells play pivotal roles in the pathogenesis of influenza A virus (IAV) infections. Defective viral particles (DPs) often arise during IAV replication, which can interfere with the replication of infectious viruses and stimulate the antiviral response of host cells. Therefore, DPs are expected to have immune-protective functions in clinic. However, the potent immunogenicity and effectiveness of DPs arising in mast cells during IAV replication have not been reported. In the present study, we showed that DPs generated in the human mastocytoma cell line HMC-1 following H1N1 infection were safe to mice after vaccination. Compared with lung adenocarcinoma cells, A549, DPs generated in infected mast cells had much better immunostimulatory activity, enhancing both humoral and cellular immunity of hosts. Notably, they could significantly increase the expression of immune-associated cytokines, especially the IFN-gamma. Due to the robust immunogenicity, thus DPs generated in infected mast cells could stimulate the robust protective immune reaction effectively to fight against lethal IAV re-challenge after vaccination, which result in the high survival, decreased lung injury as well as inhibition of viral replication and inflammatory response in lungs. This study is the first to illustrate and explore the safety, immunogenicity, and effectiveness of DPs arising in mast cells against influenza as favorable potential vaccination. The results provide insight into the advances of new prophylactic strategies to fight influenza by focusing on DPs generated in mast cells.	[Huo, Caiyun; Tian, Jijing; Cheng, Jinlong; Chen, Mingyong; Tian, Haiyan; Wang, Ming; Hu, Yanxin] China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol Minist Agr, Beijing, Peoples R China; [Huo, Caiyun; Sun, Huiling] Beijing Acad Agr & Forestry Sci, Inst Anim Husb & Vet Med, Beijing Key Lab Prevent & Control Infect Dis Live, Beijing, Peoples R China; [Xiao, Jin] Zhongmu Inst China Anim Husb Ind Co Ltd, Minist Agr, Key Lab Vet Bioprod & Chem Med, Beijing, Peoples R China; [Zou, Shumei] Natl Inst Viral Dis Control & Prevent, Collaborat Innovat Ctr Diag & Treatment Infect Di, Chinese Ctr Dis Control & Prevent, Key Lab Med Virol,Natl Hlth & Family Planning Com, Beijing, Peoples R China	China Agricultural University; Beijing Academy of Agriculture & Forestry; Ministry of Agriculture & Rural Affairs; Chinese Center for Disease Control & Prevention; National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases	Hu, YX (corresponding author), China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol Minist Agr, Beijing, Peoples R China.; Sun, HL (corresponding author), Beijing Acad Agr & Forestry Sci, Inst Anim Husb & Vet Med, Beijing Key Lab Prevent & Control Infect Dis Live, Beijing, Peoples R China.	sunhuiling01@163.com; 07033@cau.edu.cn		Cheng, Jinlong/0000-0003-3106-7964	National Natural Science Foundation of China [31772702]; Chinese Universities Scientific Fund [2018TC044]; Talent Cultivation Program of China Agricultural University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Universities Scientific Fund; Talent Cultivation Program of China Agricultural University	Research reported in this publication was supported by the National Natural Science Foundation of China (Grant no. 31772702) and the Chinese Universities Scientific Fund (Grant no. 2018TC044) as well as the Talent Cultivation Program of China Agricultural University.	Boergeling Y, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004924; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Boyce JA, 2007, IMMUNOL REV, V217, P168, DOI 10.1111/j.1600-065X.2007.00512.x; Brown MG, 2009, J LEUKOCYTE BIOL, V85, P71, DOI 10.1189/jlb.0308167; Chen LH, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax001; Dimmock NJ, 2008, J VIROL, V82, P8570, DOI 10.1128/JVI.00743-08; Duhaut SD, 2002, J GEN VIROL, V83, P403, DOI 10.1099/0022-1317-83-2-403; Easton AJ, 2011, VACCINE, V29, P2777, DOI 10.1016/j.vaccine.2011.01.102; Frensing T, 2014, APPL MICROBIOL BIOT, V98, P8999, DOI 10.1007/s00253-014-5933-y; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Garcia-Briones MM, 2004, VIROLOGY, V322, P264, DOI 10.1016/j.virol.2004.01.027; HORNE RW, 1960, VIROLOGY, V11, P79, DOI 10.1016/0042-6822(60)90056-8; Hu YX, 2012, J VIROL, V86, P3347, DOI 10.1128/JVI.06053-11; Huo CY, 2020, INT J NANOMED, V15, P661, DOI 10.2147/IJN.S221667; Huo CY, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00386; Jolly S, 2004, VET IMMUNOL IMMUNOP, V97, P125, DOI 10.1016/j.vetimm.2003.08.014; Kell AM, 2015, VIROLOGY, V479, P110, DOI 10.1016/j.virol.2015.02.017; King CA, 2000, J VIROL, V74, P7146, DOI 10.1128/JVI.74.15.7146-7150.2000; Laske T, 2016, VIRUS RES, V213, P90, DOI 10.1016/j.virusres.2015.11.016; LAZZARINI RA, 1981, CELL, V26, P145, DOI 10.1016/0092-8674(81)90298-1; Lee J, 2017, ARCH VIROL, V162, P13, DOI 10.1007/s00705-016-2966-9; Lopez CB, 2011, CURR OPIN IMMUNOL, V23, P495, DOI 10.1016/j.coi.2011.06.003; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; MENG D, 2016, FRONTIERS MICROBIOLO, V0007, P02130, DOI DOI 10.3389/fmicb.2016.02130; Meng D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/160859; Mercado-Lopez X, 2013, VACCINE, V31, P5713, DOI 10.1016/j.vaccine.2013.09.040; Ngunjiri JM, 2013, J INTERF CYTOK RES, V33, P99, DOI 10.1089/jir.2012.0070; Olsen B, 2006, SCIENCE, V312, P384, DOI 10.1126/science.1122438; Scott PD, 2011, J GEN VIROL, V92, P2122, DOI 10.1099/vir.0.034132-0; Scott PD, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-212; Sun Q, 2009, POULTRY SCI, V88, P554, DOI 10.3382/ps.2008-00468; Sun Y, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005122; Tapia K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003703; van den Hoogen BG, 2014, J GEN VIROL, V95, P1625, DOI 10.1099/vir.0.066100-0; VONMAGNUS P, 1951, ACTA PATHOL MIC SC, V29, P157; Xiao C, 2007, ANTIVIR RES, V76, P11, DOI 10.1016/j.antiviral.2007.04.002; Xie JJ, 2014, BBA-MOL BASIS DIS, V1842, P2479, DOI 10.1016/j.bbadis.2014.04.017; Xin YZ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9595718; Xue J, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00326; Yoneyama M, 2015, CURR OPIN IMMUNOL, V32, P48, DOI 10.1016/j.coi.2014.12.012; Zhao HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04792-7	41	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 13	2020	11								585254	10.3389/fimmu.2020.585254	http://dx.doi.org/10.3389/fimmu.2020.585254			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OV8CR	33304349	Green Published, gold			2022-12-18	WOS:000592431200001
J	Gonzalez-Tajuelo, R; Gonzalez-Sanchez, E; Silvan, J; Munoz-Callejas, A; Vicente-Rabaneda, E; Garcia-Perez, J; Castaneda, S; Urzainqui, A				Gonzalez-Tajuelo, Rafael; Gonzalez-Sanchez, Elena; Silvan, Javier; Munoz-Callejas, Antonio; Vicente-Rabaneda, Esther; Garcia-Perez, Javier; Castaneda, Santos; Urzainqui, Ana			Relevance of PSGL-1 Expression in B Cell Development and Activation	FRONTIERS IN IMMUNOLOGY			English	Article						PSGL-1 (CD162); B cells; development; activation; pulmonary arterial hypertension	SELECTIN GLYCOPROTEIN LIGAND-1; HEMATOPOIETIC STEM-CELL; P-SELECTIN; DIFFERENTIATION; COMMITMENT; RECEPTOR; LINEAGE; GLOMERULONEPHRITIS; IDENTIFICATION; PROLIFERATION	PSGL-1 is expressed in all plasma cells, but only in a small percentage of circulating B cells. Patients with systemic sclerosis (SSc) show reduced expression of PSGL-1 in B cells and increased prevalence of pulmonary arterial hypertension. PSGL-1 deficiency leads to a SSc-like syndrome and SSc-associated pulmonary hypertension in female mice. In this work, the expression of PSGL-1 was assessed during murine B cell development in the bone marrow and in several peripheral and spleen B cell subsets. The impact of PSGL-1 absence on B cell biology was also evaluated. Interestingly, the percentage of PSGL-1 expressing cells and PSGL-1 expression levels decreased in the transition from common lymphoid progenitors to immature B cells. PSGL-1(-/-) mice showed reduced frequencies of peripheral B cells and reduced B cell lineage-committed precursors in the bone marrow. In the spleen of WT mice, the highest percentages of PSGL-1(+) populations were shown by Breg (90%), B1a (34.7%), and B1b (19.1%), while only 2.5-8% of B2 cells expressed PSGL-1; however, within B2 cells, the class-switched subsets showed the highest percentages of PSGL-1(+) cells. Interestingly, PSGL-1(-/-) mice had increased IgG(+) and IgD(+) subsets and decreased IgA(+) population. Of note, the percentage of PSGL-1(+) cells was increased in all the B cell subclasses studied in peritoneal fluid. Furthermore, PSGL-1 engagement during in vitro activation with anti-IgM and anti-CD40 antibodies of human peripheral B cells, blocked IL-10 expression by activated human B cells. Remarkably, PSGL-1 expression in circulating plasma cells was reduced in pulmonary arterial hypertension patients. In summary, although the expression of PSGL-1 in mature B cells is low, the lack of PSGL-1 compromises normal B cell development and it may also play a role in the maturation and activation of peripheral naive B cells.	[Gonzalez-Tajuelo, Rafael; Gonzalez-Sanchez, Elena; Silvan, Javier; Munoz-Callejas, Antonio; Castaneda, Santos; Urzainqui, Ana] Hosp Princesa, Inst Invest Sanitaria Princesa IIS Princesa, Fundacio Invest Biomed FIB, Immunol Dept, Madrid, Spain; [Vicente-Rabaneda, Esther; Castaneda, Santos] Hosp Princesa, Inst Invest Sanitaria Princesa IIS Princesa, Fundacio Invest Biomed FIB, Rheumatol Dept, Madrid, Spain; [Garcia-Perez, Javier] Hosp Princesa, Inst Invest Sanitaria Princesa IIS Princesa, Fundacio Invest Biomed FIB, Pulmunol Dept, Madrid, Spain; [Castaneda, Santos] Univ Autonoma Madrid UAM, EPID Future, Catedra UAM Roche, Madrid, Spain	Hospital de La Princesa; Hospital de La Princesa; Hospital de La Princesa	Urzainqui, A (corresponding author), Hosp Princesa, Inst Invest Sanitaria Princesa IIS Princesa, Fundacio Invest Biomed FIB, Immunol Dept, Madrid, Spain.	urzainquimayayo@gmail.com	Urzainqui, Ana/HDN-9549-2022	Urzainqui, Ana/0000-0001-9326-6112; Gonzalez-Sanchez, Maria Elena/0000-0003-0448-7023	Ayudas MHER (ayuda Fundacion Cajasol 2018); Spanish Instituto de Salud Carlos III (ISCIII) (European Regional Development Fund, Fondos FEDER) [FISPI17-01819, FIS-PI12-01578, AC17-00027]; Spanish Ministry of Health (European Regional Development Fund, Fondos FEDER) [FISPI17-01819, FIS-PI12-01578, AC17-00027]	Ayudas MHER (ayuda Fundacion Cajasol 2018); Spanish Instituto de Salud Carlos III (ISCIII) (European Regional Development Fund, Fondos FEDER); Spanish Ministry of Health (European Regional Development Fund, Fondos FEDER)	This work was supported by Ayudas MHER (ayuda Fundacion Cajasol 2018) and by Spanish Ministry of Health and Instituto de Salud Carlos III (ISCIII) (cofinanced by European Regional Development Fund, Fondos FEDER) (grant numbers, FISPI17-01819, FIS-PI12-01578, AC17-00027).	Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Arinobu Y, 2007, CELL STEM CELL, V1, P416, DOI 10.1016/j.stem.2007.07.004; Azab AK, 2012, BLOOD, V119, P1468, DOI 10.1182/blood-2011-07-368050; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; Brink R, 2014, CURR OPIN IMMUNOL, V28, P97, DOI 10.1016/j.coi.2014.03.001; Bullard DC, 1999, J IMMUNOL, V163, P2844; Chan TD, 2012, IMMUNITY, V37, P893, DOI 10.1016/j.immuni.2012.07.017; Clark MR, 2014, NAT REV IMMUNOL, V14, P69, DOI 10.1038/nri3570; Clark MR, 2005, CURR TOP MICROBIOL, V290, P87; Gonzalez-Tajuelo R, 2020, ARTHRITIS RHEUMATOL, V72, P477, DOI 10.1002/art.41100; Gonzalez-Tajuelo R, 2017, SCI REP-UK, V7, DOI 10.1038/srep41841; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; He XD, 2006, J IMMUNOL, V177, P8748, DOI 10.4049/jimmunol.177.12.8748; Herzog S, 2009, NAT REV IMMUNOL, V9, P195, DOI 10.1038/nri2491; ITOH K, 1995, J IMMUNOL, V154, P4341; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kumar Ritu, 2014, Biomed J, V37, P269, DOI 10.4103/2319-4170.128734; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Levesque JP, 1999, IMMUNITY, V11, P369, DOI 10.1016/S1074-7613(00)80112-0; Mansson R, 2008, BLOOD, V112, P1048, DOI 10.1182/blood-2007-11-125385; Martinez-Agosto JA, 2007, GENE DEV, V21, P3044, DOI 10.1101/gad.1602607; Mauri C, 2017, J CLIN INVEST, V127, P772, DOI 10.1172/JCI85113; Muz B, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/417586; Nunez-Andrade N, 2011, J PATHOL, V224, P212, DOI 10.1002/path.2850; OGARRA A, 1992, EUR J IMMUNOL, V22, P711, DOI 10.1002/eji.1830220314; Perez-Frias A, 2014, ARTHRITIS RHEUMATOL, V66, P3178, DOI 10.1002/art.38808; Roessler S, 2006, SEMIN IMMUNOL, V18, P12, DOI 10.1016/j.smim.2005.12.001; Rolink AG, 2004, IMMUNOL REV, V197, P41, DOI 10.1111/j.0105-2896.2004.0101.x; Rosenkranz AR, 1999, J CLIN INVEST, V103, P649, DOI 10.1172/JCI5183; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; Saze Z, 2013, BLOOD, V122, P9, DOI 10.1182/blood-2013-02-482406; Seita J, 2010, WIRES SYST BIOL MED, V2, P640, DOI 10.1002/wsbm.86; Shur I, 2002, J CELL BIOCHEM, V87, P51, DOI 10.1002/jcb.10267; Silvan J, 2018, J INVEST DERMATOL, V138, P2123, DOI 10.1016/j.jid.2018.04.003; Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48; Singbartl K, 2000, CRIT CARE MED, V28, P2507, DOI 10.1097/00003246-200007000-00053; Stohl W, 2020, J IMMUNOL, V204, P2416, DOI 10.4049/jimmunol.1900057; Urzainqui A, 2007, J IMMUNOL, V179, P7457, DOI 10.4049/jimmunol.179.11.7457; Xu ZM, 2005, ANN NY ACAD SCI, V1050, P146, DOI 10.1196/annals.1313.119; Zarbock A, 2011, BLOOD, V118, P6743, DOI 10.1182/blood-2011-07-343566	41	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2020	11								588212	10.3389/fimmu.2020.588212	http://dx.doi.org/10.3389/fimmu.2020.588212			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OV5XP	33281818	Green Published, gold			2022-12-18	WOS:000592282800001
J	Martinez, APG; Abreu, PAE; Vasconcellos, SD; Ho, PL; Ferreira, VP; Saggu, G; Barbosa, AS; Isaac, L				Martinez, Adriana Patricia Granados; Abreu, Patricia Antonia Estima; de Arruda Vasconcellos, Silvio; Ho, Paulo Lee; Ferreira, Viviana P.; Saggu, Gurpanna; Barbosa, Angela Silva; Isaac, Lourdes			The Role of Properdin in Killing of Non-Pathogenic Leptospira biflexa	FRONTIERS IN IMMUNOLOGY			English	Article						properdin; Leptospira; complement system; alternative pathway; bacteria killing ability	COMPLEMENT DEFICIENCY STATES; ALTERNATIVE PATHWAY; IMMUNE EVASION; PATTERN-RECOGNITION; ACTIVATION; PROTEIN; BINDING; CELLS; C3B; THROMBOSPONDIN	Properdin (P) is a positive regulatory protein that stabilizes the C3 convertase and C5 convertase of the complement alternative pathway (AP). Several studies have suggested that properdin can bind directly to the surface of certain pathogens regardless of the presence of C3bBb. Saprophytic Leptospira are susceptible to complement-mediated killing, but the interaction of properdin with Leptospira spp. has not been evaluated so far. In this work, we demonstrate that properdin present in normal human serum, purified properdin, as well as properdin oligomers P2, P3, and P4, interact with Leptospira. Properdin can bind directly to the bacterial surface even in the absence of C3b. In line with our previous findings, AP activation was shown to be important for killing non-pathogenic L. biflexa, and properdin plays a key role in this process since this microorganism survives in P-depleted human serum and the addition of purified properdin to P-depleted human serum decreases the number of viable leptospires. A panel of pathogenic L. interrogans recombinant proteins was used to identify putative properdin targets. Lsa30, an outer membrane protein from L. interrogans, binds to unfractionated properdin and to a lesser extent to P2-P4 properdin oligomers. In conclusion, properdin plays an important role in limiting bacterial proliferation of non-pathogenic Leptospira species. Once bound to the leptospiral surface, this positive complement regulatory protein of the AP contributes to the formation of the C3 convertase on the leptospire surface even in the absence of prior addition of C3b.	[Martinez, Adriana Patricia Granados; Isaac, Lourdes] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil; [Abreu, Patricia Antonia Estima; Ho, Paulo Lee; Barbosa, Angela Silva] Butantan Inst, Lab Bacteriol, Sao Paulo, Brazil; [de Arruda Vasconcellos, Silvio] Univ Sao Paulo, Fac Vet Med & Anim Sci, Lab Bacterial Zoonoses, Sao Paulo, Brazil; [Ferreira, Viviana P.; Saggu, Gurpanna] Univ Toledo, Dept Med Microbiol & Immunol, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA	Universidade de Sao Paulo; Instituto Butantan; Universidade de Sao Paulo; University System of Ohio; University of Toledo	Isaac, L (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, Brazil.	louisaac@icb.usp.br	Barbosa, Angela S/I-3518-2013; Isaac, Lourdes/I-7186-2012	Barbosa, Angela S/0000-0002-6458-9489; 	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil [2017/12924-3]; FAPESP [2012/23708-6]; Conselho Nacional de Pesquisa e Desenvolvimento Cientifico (CNPq), Brazil [141874/2012-0]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Pesquisa e Desenvolvimento Cientifico (CNPq), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil (Proc #2017/12924-3)). AG received student fellowships from FAPESP (2012/23708-6) and Conselho Nacional de Pesquisa e Desenvolvimento Cientifico (CNPq), Brazil (Proc. 141874/2012-0).	Agarwal S, 2010, J IMMUNOL, V185, P507, DOI 10.4049/jimmunol.0903598; Alves da Silva PYO, 2020, MICROBES INFECT, DOI 10.1016/j.micinf.2020.07.005; Barbosa AS, 2006, INFECT IMMUN, V74, P6356, DOI 10.1128/IAI.00460-06; Barbosa AS, 2018, CURR TOP MICROBIOL, V415, P215, DOI 10.1007/82_2017_47; Barbosa AS, 2009, INFECT IMMUN, V77, P1137, DOI 10.1128/IAI.01310-08; Castiblanco-Valencia MM, 2016, IMMUNOBIOLOGY, V221, P679, DOI 10.1016/j.imbio.2016.01.001; Castiblanco-Valencia MM, 2012, J INFECT DIS, V205, P995, DOI 10.1093/infdis/jir875; Chen JY, 2018, MOL IMMUNOL, V102, P58, DOI 10.1016/j.molimm.2018.05.018; Choy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041566; Cortes C, 2011, INFECT IMMUN, V79, P724, DOI 10.1128/IAI.00980-10; de Paula PF, 2003, SCAND J IMMUNOL, V58, P572, DOI 10.1046/j.1365-3083.2003.01326.x; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FEARON DT, 1979, P NATL ACAD SCI USA, V76, P5867, DOI 10.1073/pnas.76.11.5867; Ferreira VP, 2010, IMMUNOBIOLOGY, V215, P932, DOI 10.1016/j.imbio.2010.02.002; Fraga TR, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00623; Fraga TR, 2014, J INFECT DIS, V209, P876, DOI 10.1093/infdis/jit569; Gaarkeuken H, 2008, AM J PHYSIOL-RENAL, V295, pF1397, DOI 10.1152/ajprenal.90313.2008; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; Harboe M, 2017, P NATL ACAD SCI USA, V114, pE534, DOI 10.1073/pnas.1612385114; HIGGINS JMG, 1995, J IMMUNOL, V155, P5777; Kemper C, 2008, P NATL ACAD SCI USA, V105, P9023, DOI 10.1073/pnas.0801015105; Kemper C, 2010, ANNU REV IMMUNOL, V28, P131, DOI 10.1146/annurev-immunol-030409-101250; Kemper C, 2008, MOL IMMUNOL, V45, P4048, DOI 10.1016/j.molimm.2008.06.034; Kouser L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00093; Li SJ, 2010, INNATE IMMUN-LONDON, V16, P80, DOI 10.1177/1753425909105580; Meri T, 2005, MICROB PATHOGENESIS, V39, P139, DOI 10.1016/j.micpath.2005.07.003; Moreno-Torres A, 2019, MICROBES INFECT, V21, P377, DOI 10.1016/j.micinf.2019.03.001; NOLAN KF, 1992, BIOCHEM J, V287, P291, DOI 10.1042/bj2870291; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; Schejbel L, 2009, CLIN IMMUNOL, V131, P456, DOI 10.1016/j.clim.2009.02.008; SJOHOLM AG, 1990, APMIS, V98, P861; Skattum L, 2011, MOL IMMUNOL, V48, P1643, DOI 10.1016/j.molimm.2011.05.001; SMITH CA, 1984, J BIOL CHEM, V259, P4582; Spitzer D, 2007, J IMMUNOL, V179, P2600, DOI 10.4049/jimmunol.179.4.2600; Tsao N, 2006, BIOCHEM BIOPH RES CO, V339, P779, DOI 10.1016/j.bbrc.2005.11.078; Tyson KR, 2008, J IMMUNOL, V180, P3964, DOI 10.4049/jimmunol.180.6.3964; Vincent AT, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007270; Xu W, 2008, J IMMUNOL, V180, P7613, DOI 10.4049/jimmunol.180.11.7613	39	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 10	2020	11								572562	10.3389/fimmu.2020.572562	http://dx.doi.org/10.3389/fimmu.2020.572562			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OU6IZ	33240263	gold, Green Published			2022-12-18	WOS:000591631500001
J	Yuan, SM; Hu, XF; Zhao, YQ; Wang, ZB				Yuan, Shumin; Hu, Xiufeng; Zhao, Yanqiu; Wang, Zibing			Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy; immune checkpoint inhibitor; PD-1; non-small cell lung cancer; B cells	PEMBROLIZUMAB	Introduction In murine cancer models, B cells are unnecessary for efficacy of PD-1 inhibitor. However, we do not know whether this applies to clinical settings, especially in patients with non-small-cell lung carcinoma (NSCLC). Case presentation We report on the case of an advanced lung adenocarcinoma patient without oncogenic driver mutations whose disease progressed on second-line bevacizumab-containing chemotherapy regimens. These previous treatments resulted in profound thrombocytopenia and increased number of B cells; both effects were hard to alleviate. The patient was diagnosed with marginal zone B-cell lymphoma by flow cytometry immunophenotyping. After five cycles of rituximab in combination with lenalidomide treatment, the percentage of B cells rapidly declined to undetectable levels and the lymphoma regressed completely. However, because masses in the lung gradually increased, this patient was subsequently treated with a PD-1 inhibitor. The patient's condition stabilized, and the mass shrank to reach partial response, with progression free survival exceeding 15 months and no serious adverse events. Conclusion The present case proves the efficacy of PD-1 inhibitor in metastatic lung adenocarcinoma in the absence of B cells. Immune checkpoint inhibitions are thus a choice for patients with B cell deficiencies, such as X-linked agammaglobulinemia, immunoglobulin deficiencies, and common variable immunodeficiency, diseases that have historically been excluded from clinical trials for oncologic drugs.	[Yuan, Shumin; Wang, Zibing] Zhengzhou Univ, Affiliated Canc Hosp, Dept Immunotherapy, Zhengzhou, Peoples R China; [Yuan, Shumin; Hu, Xiufeng; Zhao, Yanqiu; Wang, Zibing] Henan Canc Hosp, Zhengzhou, Peoples R China; [Hu, Xiufeng; Zhao, Yanqiu] Zhengzhou Univ, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University	Wang, ZB (corresponding author), Zhengzhou Univ, Affiliated Canc Hosp, Dept Immunotherapy, Zhengzhou, Peoples R China.; Wang, ZB (corresponding author), Henan Canc Hosp, Zhengzhou, Peoples R China.	zlyywzb2118@zzu.edu.cn			National Natural Science Foundation of China [81972690, 81000914, 81272526]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Grant No. 81972690, 81000914, and 81272526).	Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Damsky W, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0613-1; Das R, 2018, J CLIN INVEST, V128, P715, DOI 10.1172/JCI96798; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Leonardi GC, 2018, J CLIN ONCOL, V36, P1905, DOI 10.1200/JCO.2017.77.0305; MacIsaac J, 2018, TRANSFUSION, V58, P2729, DOI 10.1111/trf.14841; Munn DH, 2016, CURR OPIN IMMUNOL, V39, P1, DOI 10.1016/j.coi.2015.10.009; Qin ZH, 1998, NAT MED, V4, P627, DOI 10.1038/nm0598-627; Wagner G, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1774314; Yanaba K, 2008, IMMUNOL REV, V223, P284, DOI 10.1111/j.1600-065X.2008.00646.x; Zinzani PL, 2017, BLOOD, V130, P267, DOI 10.1182/blood-2016-12-758383	12	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 6	2020	11								563622	10.3389/fimmu.2020.563622	http://dx.doi.org/10.3389/fimmu.2020.563622			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OT9YN	33240259	gold, Green Published			2022-12-18	WOS:000591194200001
J	Nisini, R; Oggioni, MR; Rossolini, GM; Fraziano, M				Nisini, Roberto; Oggioni, Marco R.; Rossolini, Gian Maria; Fraziano, Maurizio			Editorial: Exploiting Novel Combined Host- and Pathogen-Directed Therapies for Combating Bacterial Multidrug Resistance	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						multidrug resistance; bacteria; host-directed therapy; pathogen-directed therapy; innate immunity			[Nisini, Roberto] Ist Super Sanita, Dept Infect Dis, Rome, Italy; [Oggioni, Marco R.] Univ Leicester, Dept Genet & Genome Biol, Leicester, Leics, England; [Oggioni, Marco R.] Univ Bologna, Dipartimento Farm & Biotecnol, Bologna, Italy; [Rossolini, Gian Maria] Careggi Univ Hosp, Clin Microbiol & Virol Unit, Florence, Italy; [Fraziano, Maurizio] Univ Roma Tor Vergata, Dept Biol, Rome, Italy	Istituto Superiore di Sanita (ISS); University of Leicester; University of Bologna; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Rome Tor Vergata	Fraziano, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Rome, Italy.	fraziano@bio.uniroma2.it	Nisini, Roberto/M-4363-2015; Oggioni, Marco Rinaldo/K-3839-2016	Nisini, Roberto/0000-0003-1077-423X; Oggioni, Marco Rinaldo/0000-0003-4117-793X	Italian Cystic Fibrosis Research Foundation (FFC) [19/2019]	Italian Cystic Fibrosis Research Foundation (FFC)(Ministry of Health, ItalyItalian Cystic Fibrosis Research Foundation)	This work was supported by the Italian Cystic Fibrosis Research Foundation (FFC#19/2019).	Courvalin P, 2016, CLIN MICROBIOL INFEC, V22, P405, DOI 10.1016/j.cmi.2016.01.012; Happel KI, 2004, SEMIN RESP CRIT CARE, V25, P43, DOI 10.1055/s-2004-822304; Hutchings MI, 2019, CURR OPIN MICROBIOL, V51, P72, DOI 10.1016/j.mib.2019.10.008; Kaufmann SHE, 2018, NAT REV DRUG DISCOV, V17, P35, DOI 10.1038/nrd.2017.162; Tagliabue A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01068	5	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 4	2020	11								616486	10.3389/fimmu.2020.616486	http://dx.doi.org/10.3389/fimmu.2020.616486			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OU4BP	33250904	gold, Green Published			2022-12-18	WOS:000591475100001
J	Chen, LP; Li, JH; Ye, ZH; Sun, BH; Wang, L; Chen, Y; Han, J; Yu, MP; Wang, Y; Zhou, Q; Seidler, U; Tian, DA; Xiao, F				Chen, Liping; Li, Junhua; Ye, Zhenghao; Sun, Binghua; Wang, Lu; Chen, Yu; Han, Jian; Yu, Meiping; Wang, Ying; Zhou, Qi; Seidler, Ursula; Tian, De'an; Xiao, Fang			Anti-High Mobility Group Box 1 Neutralizing-Antibody Ameliorates Dextran Sodium Sulfate Colitis in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						colitis; anti-high mobility group box 1 neutralizing-antibody; toll-like receptor 4; macrophage; colonic barrier	INFLAMMATORY-BOWEL-DISEASE; INTESTINAL INFLAMMATION; HMGB1; RESPONSES; MUCOSAL; INNATE; PROMOTES; INJURY; DAMAGE; ROLES	High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein in mammals. When released into the extracellular space, it acts as a damage-associated molecular pattern. This study investigates whether increased HMGB1 levels are found in the intestinal mucosa of ulcerative colitis (UC) patients, and whether an anti-HMGB1 neutralizing-antibody (HnAb) can inhibit the intestinal inflammation elicited by dextran sulfate sodium (DSS) in mice. Because toll-like receptor 4 (TLR4) is implicated in HMGB1-mediated immune cell activation, DSS colitis was also elicited in TLR4-deficient mice in the presence and absence of HnAb. The expression of HMGB1 in UC patients was examined. HnAb was administered via intraperitoneal injection to TLR4 deficient mice and their wild-type littermates, both being induced to colitis with DSS. Finally, the protective effect of HnAb and TLR4 deficiency were evaluated. In UC patients, HMGB1 was up-regulated in the inflamed colon. When administered during DSS application, HnAb alleviated the severity of colitis with a lower disease activity index, limited histological damages, and reduced production of proinflammatory cytokines. This antibody also limited colonic barrier loss, decreased colonic lamina propria macrophages and partially reversed the DSS treatment-associated dysbiosis. The protective effect of this antibody was enhanced in TLR4-deficient mice in some aspects, indicating that both additional HMGB1-mediated as well as TLR4-mediated inflammatory signaling pathways were involved in the induction of colitis by DSS. HnAb ameliorated colitis via macrophages inhibition and colonic barrier protection. It may therefore be a novel treatment option in colitis.	[Chen, Liping; Ye, Zhenghao; Sun, Binghua; Chen, Yu; Han, Jian; Yu, Meiping; Zhou, Qi; Tian, De'an; Xiao, Fang] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan, Peoples R China; [Li, Junhua] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Nephrol, Tongji Med Coll, Wuhan, Peoples R China; [Wang, Lu] Huazhong Univ Sci & Technol, Inst Organ Transplantat, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Wang, Lu] Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Wang, Lu] Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Wang, Lu] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Wang, Ying] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Pathol, Tongji Med Coll, Wuhan, Peoples R China; [Seidler, Ursula] Hannover Med Sch, Dept Gastroenterol, Hannover, Germany; [Sun, Binghua] Zhengzhou Univ, Affiliated Hosp 1, Dept Gastroenterol, Zhengzhou, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Huazhong University of Science & Technology; Hannover Medical School; Zhengzhou University	Xiao, F (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan, Peoples R China.	xiaofang@tjh.tjmu.edu.cn			National Natural Science Foundation of China [81470807, 81873556, 81470994]; Wu Jieping Medical Foundation [320.6750.17397]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wu Jieping Medical Foundation	This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81470807 to FX, 81873556 to FX, 81470994 to JL) and Wu Jieping Medical Foundation (grant number 320.6750.17397 to FX).	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Anggayasti WL, 2017, FEBS LETT, V591, P282, DOI 10.1002/1873-3468.12545; Bianchi ME, 2017, IMMUNOL REV, V280, P74, DOI 10.1111/imr.12601; Chen QJ, 2016, ACTA PHARM SIN B, V6, P183, DOI 10.1016/j.apsb.2016.02.004; Chen XY, 2017, IMMUNOL RES, V65, P666, DOI 10.1007/s12026-017-8894-2; Chen XY, 2016, INNATE IMMUN-LONDON, V22, P696, DOI 10.1177/1753425916669862; Chen XH, 2019, DEV COMP IMMUNOL, V92, P77, DOI 10.1016/j.dci.2018.09.006; Cheng MJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00837; Choy MC, 2017, INFLAMM BOWEL DIS, V23, P2, DOI 10.1097/MIB.0000000000000955; Cote-Daigneault J, 2015, UNITED EUR GASTROENT, V3, P419, DOI 10.1177/2050640615590302; Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385; Eissa N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01131; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Guo XH, 2015, INT IMMUNOPHARMACOL, V29, P454, DOI 10.1016/j.intimp.2015.10.015; Jiang J, 2018, EXP CELL RES, V367, P81, DOI 10.1016/j.yexcr.2018.03.025; Ju ZL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103992; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Li XX, 2018, INT J NANOMED, V13, P1399, DOI 10.2147/IJN.S151825; Liu YF, 2017, P NATL ACAD SCI USA, V114, pE3796, DOI 10.1073/pnas.1700909114; Maaser C, 2019, J CROHNS COLITIS, V13, P144, DOI 10.1093/ecco-jcc/jjy113; Maeda S, 2007, BIOCHEM BIOPH RES CO, V360, P394, DOI 10.1016/j.bbrc.2007.06.065; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Munyaka PM, 2016, J BASIC MICROB, V56, P986, DOI 10.1002/jobm.201500726; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0; Palone F, 2014, INFLAMM BOWEL DIS, V20, P1448, DOI 10.1097/MIB.0000000000000113; Paudel YN, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.172487; Rezasoltani S, 2019, IRAN J MICROBIOL, V11, P1, DOI 10.18502/ijm.v11i1.696; Ringel Y, 2015, GUT MICROBES, V6, P173, DOI 10.1080/19490976.2015.1044711; Ruder B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081887; Sann H, 2013, LIFE SCI, V92, P708, DOI 10.1016/j.lfs.2013.01.028; Soufli I, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0063-6; VanPatten S, 2018, J MED CHEM, V61, P5093, DOI 10.1021/acs.jmedchem.7b01136; Vermeire S, 2018, THER ADV GASTROENTER, V11, DOI 10.1177/1756283X17750355; Vijayakumar EC, 2019, CURR DRUG TARGETS, V20, P1474, DOI 10.2174/1389450120666190618125100; Vitali R, 2011, AM J GASTROENTEROL, V106, P2029, DOI 10.1038/ajg.2011.231; Wang FC, 2015, WORLD J GASTROENTERO, V21, P7764, DOI 10.3748/wjg.v21.i25.7764; Wu CP, 2019, EUR REV MED PHARMACO, V23, P7543, DOI 10.26355/eurrev_201909_18871; Wu WR, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01804; Xiao L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00268; Yamasaki H, 2009, MOL MED REP, V2, P23, DOI 10.3892/mmr_00000056; Yang RK, 2006, MOL MED, V12, P105, DOI 10.2119/2006-00010.Yang; Yang ZP, 2018, P NATL ACAD SCI USA, V115, P11054, DOI 10.1073/pnas.1804094115; Zhang YG, 2019, AUTOPHAGY, V15, P1935, DOI 10.1080/15548627.2019.1596485; Zhao JJ, 2019, CURR GENE THER, V19, P100, DOI 10.2174/1566523219666190621111604; Zhu XR, 2015, J CLIN INVEST, V125, P1098, DOI 10.1172/JCI76344	46	2	2	7	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2020	11								585094	10.3389/fimmu.2020.585094	http://dx.doi.org/10.3389/fimmu.2020.585094			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ3IX	33193406	gold, Green Published			2022-12-18	WOS:000588682000001
J	Gotti, M; Defrancesco, I; D'Angelo, M; Basso, S; Crotto, L; Marinelli, A; Maccalli, C; Iaconianni, V				Gotti, Manuel; Defrancesco, Irene; D'Angelo, Mario; Basso, Sabrina; Crotto, Luca; Marinelli, Alfredo; Maccalli, Cristina; Iaconianni, Vincenzo			Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers	FRONTIERS IN IMMUNOLOGY			English	Review						CAR-T cells; CAR-T process; CAR-T Unit; CAR-T Specialist; JACIE; GMP; ATMP	IMMUNE INFILTRATION; THERAPY; MALIGNANCIES; IMMUNOSCORE; CYTOKINE; SURVIVAL; TUMORS; TRIAL; CARS	Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell malignancies. In consideration of their complexity, the use of CAR-T requires dedicated clinical setting and health care practitioners with expertise in the selection, treatment, and management of toxicities and side effects. Such issue appears particularly important when contextualized in the rapid progress of CAR-T cell treatment, translating into a constant need of updating and evolution. Moreover, the clinical grade manufacturing of CAR-T cells is complex and implies articulated regulatory and organizational aspects. The main goal of this review is to summarize and provide an accurate analysis of the clinical, logistic, and regulatory requirements of CAR-T cell centers. Finally, we describe a new occupational figure called "CAR-T specialist" devoted to the establishment and coordination of the required facilities and regulatory landscape in the context of cancer centers.	[Gotti, Manuel] Fdn Ist Ricovero & Cura Carattere Sci IRCCS Polic, Div Hematol, Pavia, Italy; [Defrancesco, Irene] Univ Pavia, Dept Mol Med, Pavia, Italy; [D'Angelo, Mario] Osped Pediat Bambino Gesu IRCCS, Dept Oncohematol Cell & Gene Therapy, Rome, Italy; [Basso, Sabrina] Fdn IRCCS Policlin San Matteo, Pediat Hematol Oncol Unit, Pavia, Italy; [Basso, Sabrina] Fdn IRCCS Policlin San Matteo, Cell Factory, Pavia, Italy; [Crotto, Luca] FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy; [Marinelli, Alfredo] Univ Federico II, Operat Unit OU Neuroncol, Naples, Italy; [Marinelli, Alfredo] IRCCS Neuromed Ist Neurol Mediterraneo Pozzilli I, Pozzilli, Italy; [Maccalli, Cristina] Sidra Med, Res Dept, Lab Immune & Biol Therapy, Doha, Qatar; [Iaconianni, Vincenzo] ICMED, Sesto San Giovanni, Italy	University of Pavia; IRCCS Bambino Gesu; IRCCS Fondazione San Matteo; IRCCS Fondazione San Matteo; IRCCS Fondazione del Piemonte per l'Oncologia; University of Naples Federico II; Sidra Medical & Research Center	Gotti, M (corresponding author), Fdn Ist Ricovero & Cura Carattere Sci IRCCS Polic, Div Hematol, Pavia, Italy.	mdrgotti@gmail.com	Defrancesco, Irene/AAC-4789-2022					Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004; Bagley SJ, 2020, PHARMACOL THERAPEUT, V205, DOI 10.1016/j.pharmthera.2019.107419; Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170; Bindea G, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27456; Bindea G, 2011, SEMIN IMMUNOPATHOL, V33, P335, DOI 10.1007/s00281-011-0264-x; Brentjens RJ, 2007, CLIN CANCER RES, V13, P5426, DOI 10.1158/1078-0432.CCR-07-0674; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Burnet F M, 1971, Transplant Rev, V7, P3; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; Chicaybam L, 2020, GENE THER, V27, P85, DOI 10.1038/s41434-020-0121-4; Chmielewski M, 2014, IMMUNOL REV, V257, P83, DOI 10.1111/imr.12125; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; DeRenzo Christopher, 2018, Am Soc Clin Oncol Educ Book, V38, P830, DOI 10.1200/EDBK_200773; Frey Noelle, 2019, Biol Blood Marrow Transplant, V25, pe123, DOI 10.1016/j.bbmt.2018.12.756; Fridman WH, 2011, CURR TOP MICROBIOL, V344, P1, DOI 10.1007/82_2010_46; Gargett T, 2016, MOL THER, V24, P1135, DOI 10.1038/mt.2016.63; Gauthier J, 2017, CURR RES TRANSL MED, V65, P93, DOI 10.1016/j.retram.2017.08.003; Grada Z, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.32; Graham C, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100155; Grosser R, 2019, CANCER CELL, V36, P471, DOI 10.1016/j.ccell.2019.09.006; Grupp SA, 2011, CURR TOP MICROBIOL, V344, P149, DOI 10.1007/82_2010_94; Guedan S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96976; Harrer DC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235942; Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141; Jindal V, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1149-9; Jindal V, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1131-6; June CH, 2007, J CLIN INVEST, V117, P1204, DOI 10.1172/JCI31446; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Kansagra Ankit J, 2019, Biol Blood Marrow Transplant, V25, pe76, DOI 10.1016/j.bbmt.2018.12.068; Klebanoff CA, 2005, TRENDS IMMUNOL, V26, P111, DOI 10.1016/j.it.2004.12.003; Kochenderfer JN, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2016.71.3024; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388; Kohn DB, 2011, MOL THER, V19, P432, DOI 10.1038/mt.2011.1; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Leuci V, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1423167; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Locke FL, 2017, MOL THER, V25, P285, DOI 10.1016/j.ymthe.2016.10.020; Lonez C, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017075; Mahadeo KM, 2019, NAT REV CLIN ONCOL, V16, P45, DOI 10.1038/s41571-018-0075-2; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2015, BLOOD, V125, P4017, DOI 10.1182/blood-2014-12-580068; Mihm MC, 1996, LAB INVEST, V74, P43; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Quintarelli C, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1433518; Ruella M, 2016, J CLIN INVEST, V126, P3814, DOI 10.1172/JCI87366; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9; Tang J, 2018, ANN ONCOL, V29, P84, DOI 10.1093/annonc/mdx755; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621; Vonderheide RH, 2003, IMMUNOL RES, V27, P341, DOI 10.1385/IR:27:2-3:341; Wang MH, 2020, NEW ENGL J MED, V382, P1331, DOI 10.1056/NEJMoa1914347; Watanabe K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02486; Wilkie S, 2012, J CLIN IMMUNOL, V32, P1059, DOI 10.1007/s10875-012-9689-9; Yakoub-Agha I, 2020, HAEMATOLOGICA, V105, P297, DOI 10.3324/haematol.2019.229781; Yang JC, 2016, ADV IMMUNOL, V130, P279, DOI 10.1016/bs.ai.2015.12.006; You FT, 2016, SCI CHINA LIFE SCI, V59, P386, DOI 10.1007/s11427-016-5024-7; Yu SN, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0444-9; Zhang CC, 2017, MOL THER, V25, P1248, DOI 10.1016/j.ymthe.2017.03.010	68	2	2	3	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2020	11								565236	10.3389/fimmu.2020.565236	http://dx.doi.org/10.3389/fimmu.2020.565236			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ4RT	33193333	gold, Green Published			2022-12-18	WOS:000588773300001
J	Guo, YL; Song, ZF; Li, CF; Yu, YY; Dai, HY; Luo, XX; Wang, YJ; Wang, JW; Gao, MC				Guo, Yongli; Song, Zhifeng; Li, Chenfeng; Yu, Yueyang; Dai, Haiyue; Luo, Xiuxin; Wang, Yujiao; Wang, Junwei; Gao, Mingchun			A Novel Type-I Interferon Family, Bovine Interferon-Chi, Is Involved in Positive-Feedback Regulation of Interferon Production	FRONTIERS IN IMMUNOLOGY			English	Article						bovine IFN-&#967; molecular characterization; antiviral activity; JAK-STAT signaling pathway; positive feedback regulation	EXPRESSION; GENERATION; DISCOVERY; RECEPTORS; PROTEIN	Interferon-chi (IFN-chi) is a type of function-unknown IFN. IFN-chi in bovines (BoIFN-chi) has evolved as a multigene family. This family comprises four IFN-chi subtypes, two of which are functional genes, which we demonstrated to (i) have antiviral and antiproliferative activities, (ii) be highly sensitive to trypsin, and (iii) remain stable with changes in pH and temperature. BoIFN-chi is a key intermediate in antiviral response, PAbs against BoIFN-chi s could downregulate the transcriptional activation of ISGs induced by poly(I:C), and BoIFN-chi s could be induced upon virus infection at the early and late phase. Additionally, BoIFN-chi s bind with type-I IFN receptors, induce transcription of interferon regulatory factor 7 (IRF7), interferon-stimulated genes (ISGs), and type-I IFNs as well as myxovirus resistance protein 1 (Mx1) expression. Expression of ISGs and activation of IFN-stimulated response element (ISRE) induced with BoIFN-chi s could be downregulated significantly by the Janus kinase (JAK) 1 and signal transducers and activators of transcription (STAT) 1 inhibitor. The promoters of BoIFN-beta, nuclear factor-kappa B, and ISRE could be activated with BoIFN-chi s, and the BoIFN-chi promoter could be activated by other type-I IFNs. Overall, BoIFN-chi could be induced with virus infection and signal through the JAK-STAT pathway to form a positive-feedback regulation of IFN production. These findings may facilitate further research on the role of IFN-chi in innate immune responses.	[Guo, Yongli; Song, Zhifeng; Li, Chenfeng; Yu, Yueyang; Dai, Haiyue; Luo, Xiuxin; Wang, Yujiao; Wang, Junwei; Gao, Mingchun] Northeast Agr Univ, Coll Vet Med, Harbin, Peoples R China; [Guo, Yongli] Anim Dis Prevent & Control Ctr Heilongjiang Prov, Harbin, Peoples R China	Northeast Agricultural University - China	Wang, JW; Gao, MC (corresponding author), Northeast Agr Univ, Coll Vet Med, Harbin, Peoples R China.	jwwang@neau.edu.cn; gaomingchun@neau.edu.cn			China Agriculture Research System [CARS-36]; National Natural Science Foundation of China [32002296]	China Agriculture Research System; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by China Agriculture Research System (CARS-36) and National Natural Science Foundation of China (32002296).	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Detournay O, 2013, J INTERF CYTOK RES, V33, P746, DOI 10.1089/jir.2012.0130; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; Gao MC, 2012, APPL MICROBIOL BIOT, V93, P1271, DOI 10.1007/s00253-011-3815-0; Guo YL, 2017, DEV COMP IMMUNOL, V67, P213, DOI 10.1016/j.dci.2016.09.018; Guo YL, 2015, GENE, V558, P25, DOI 10.1016/j.gene.2014.12.031; Ismail A, 2014, DERMAT RES PRACT, V2014, DOI 10.1155/2014/847545; Krause CD, 2005, PHARMACOL THERAPEUT, V106, P299, DOI 10.1016/j.pharmthera.2004.12.002; Li SF, 2019, MICROB PATHOGENESIS, V127, P79, DOI 10.1016/j.micpath.2018.11.040; Luo XX, 2015, MOL IMMUNOL, V66, P357, DOI 10.1016/j.molimm.2015.04.009; Oritani K, 2001, CYTOKINE GROWTH F R, V12, P337, DOI 10.1016/S1359-6101(01)00009-0; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Rutherford MN, 1997, J INTERF CYTOK RES, V17, P1, DOI 10.1089/jir.1997.17.1; Sang YM, 2010, PHYSIOL GENOMICS, V42, P248, DOI 10.1152/physiolgenomics.00198.2009; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Shao JW, 2015, MOL IMMUNOL, V64, P163, DOI 10.1016/j.molimm.2014.11.011; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Walker AM, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-187; Wang JM, 2010, J IMMUNOL, V185, P1720, DOI 10.4049/jimmunol.1000114; Zhao Panpan, 2014, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V33, P287, DOI 10.1089/mab.2013.0092	22	2	2	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2020	11								528854	10.3389/fimmu.2020.528854	http://dx.doi.org/10.3389/fimmu.2020.528854			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ4UW	33193303	gold, Green Published			2022-12-18	WOS:000588781400001
J	Monasterio, G; Castillo, F; Astorga, J; Hoare, A; Terraza-Aguirre, C; Cafferata, EA; Villablanca, EJ; Vernal, R				Monasterio, Gustavo; Castillo, Francisca; Astorga, Jessica; Hoare, Anilei; Terraza-Aguirre, Claudia; Cafferata, Emilio A.; Villablanca, Eduardo J.; Vernal, Rolando			O-Polysaccharide Plays a Major Role on the Virulence and Immunostimulatory Potential of Aggregatibacter actinomycetemcomitans During Periodontal Infection	FRONTIERS IN IMMUNOLOGY			English	Article						periodontitis; Aggregatibacter actinomycetemcomitans; lipopolysaccharide; LPS; O-polysaccharide; O-PS; T-lymphocytes; bone resorption	ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; PORPHYROMONAS-GINGIVALIS; SEROTYPE-B; AGGRESSIVE PERIODONTITIS; BONE LOSS; LIPID-A; ANTAGONISTS INHIBIT; ALVEOLAR BONE; LIPOPOLYSACCHARIDE; ANTIGEN	Aggregatibacter actinomycetemcomitans is a Gram-negative oral bacterium with high immunostimulatory and pathogenic potential involved in the onset and progression of periodontitis, a chronic disease characterized by aberrant immune responses followed by tooth-supporting bone resorption, which eventually leads to tooth loss. While several studies have provided evidence related to the virulence factors of A. actinomycetemcomitans involved in the host cell death and immune evasion, such as its most studied primate-specific virulence factor, leukotoxin, the role of specific lipopolysaccharide (LPS) domains remain poorly understood. Here, we analyzed the role of the immunodominant domain of the LPS of A. actinomycetemcomitans termed O-polysaccharide (O-PS), which differentiates the distinct bacterial serotypes based on its antigenicity. To determine the role of the O-PS in the immunogenicity and virulence of A. actinomycetemcomitans during periodontitis, we analyzed the in vivo and in vitro effect of an O-PS-defective transposon mutant serotype b strain, characterized by the deletion of the rmlC gene encoding the alpha-L-rhamnose sugar biosynthetic enzyme. Induction of experimental periodontitis using the O-PS-defective rmlC mutant strain resulted in lower tooth-supporting bone resorption, infiltration of Th1, Th17, and Th22 lymphocytes, and expression of Ahr, Il1b, Il17, Il23, Tlr4, and RANKL (Tnfsf11) in the periodontal lesions as compared with the wild-type A. actinomycetemcomitans strain. In addition, the O-PS-defective rmlC mutant strain led to impaired activation of antigen-presenting cells, with less expression of the co-stimulatory molecules CD40 and CD80 in B lymphocytes and dendritic cells, and downregulated expression of Tnfa and Il1b in splenocytes. In conclusion, these data demonstrate that the O-PS from the serotype b of A. actinomycetemcomitans plays a key role in the capacity of the bacterium to prime oral innate and adaptive immune responses, by triggering the Th1 and Th17-driven tooth-supporting bone resorption during periodontitis.	[Monasterio, Gustavo; Castillo, Francisca; Astorga, Jessica; Terraza-Aguirre, Claudia; Cafferata, Emilio A.; Vernal, Rolando] Univ Chile, Periodontal Biol Lab, Fac Dent, Santiago, Chile; [Monasterio, Gustavo; Villablanca, Eduardo J.] Karolinska Inst, Div Immunol & Allergy, Dept Med, Stockholm, Sweden; [Monasterio, Gustavo; Villablanca, Eduardo J.] Univ Hosp, Stockholm, Sweden; [Monasterio, Gustavo; Villablanca, Eduardo J.] Ctr Mol Med, Stockholm, Sweden; [Hoare, Anilei] Univ Chile, Oral Microbiol Lab, Fac Dent, Santiago, Chile; [Terraza-Aguirre, Claudia] Univ Montpellier, Inst Regenerat Med & Biotherapies IRMB, Montpellier, France; [Cafferata, Emilio A.] Univ Cient Sur, Sch Dent, Dept Periodontol, Lima, Peru; [Vernal, Rolando] Univ Chile, Dept Conservat Dent, Fac Dent, Santiago, Chile	Universidad de Chile; Karolinska Institutet; Universidad de Chile; Universite de Montpellier; Universidad Cientifica del Sur (CIENTIFICA); Universidad de Chile	Vernal, R (corresponding author), Univ Chile, Periodontal Biol Lab, Fac Dent, Santiago, Chile.; Vernal, R (corresponding author), Univ Chile, Dept Conservat Dent, Fac Dent, Santiago, Chile.	rvernal@uchile.cl	Vernal, Rolando/A-6285-2008; Hoare, Anilei P/F-5232-2018; Chea, Emilio A. Cafferata/AAP-9007-2020; Villablanca, Eduardo/E-1380-2016	Vernal, Rolando/0000-0002-1391-320X; Chea, Emilio A. Cafferata/0000-0001-9243-1382; Villablanca, Eduardo/0000-0001-9522-9729	Chilean Governmental, Agencia Nacional de Investigacion y Desarrollo (ANID) [FONDECYT 1181780]; ANID [CONICYT 21170297]	Chilean Governmental, Agencia Nacional de Investigacion y Desarrollo (ANID); ANID	This study was financially supported by grant FONDECYT 1181780 from the Chilean Governmental, Agencia Nacional de Investigacion y Desarrollo (ANID). GM is a recipient of a Ph.D. Scholarship CONICYT 21170297 from ANID.	Aberg CH, 2009, J CLIN PERIODONTOL, V36, P815, DOI 10.1111/j.1600-051X.2009.01457.x; AMANO K, 1989, INFECT IMMUN, V57, P2942, DOI 10.1128/IAI.57.10.2942-2946.1989; Asikainen S, 1999, PERIODONTOL 2000, V20, P65, DOI 10.1111/j.1600-0757.1999.tb00158.x; Asikainen S, 1997, CLIN INFECT DIS, V25, pS227, DOI 10.1086/516211; Assuma R, 1998, J IMMUNOL, V160, P403; BRONDZ I, 1989, INFECT IMMUN, V57, P3106, DOI 10.1128/IAI.57.10.3106-3109.1989; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chen C, 2010, MOL ORAL MICROBIOL, V25, P207, DOI 10.1111/j.2041-1014.2010.00567.x; Cortelli JR, 2012, EUR J CLIN MICROBIOL, V31, P1311, DOI 10.1007/s10096-011-1444-2; Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337; Darveau RP, 2004, INFECT IMMUN, V72, P5041, DOI 10.1128/IAI.72.9.5041-5051.2004; Diaz-Zuniga J, 2015, J PERIODONTAL RES, V50, P824, DOI 10.1111/jre.12270; Diaz-Zuniga J, 2017, ARCH ORAL BIOL, V78, P26, DOI 10.1016/j.archoralbio.2017.02.008; Diaz-Zuniga J, 2015, J PERIODONTOL, V86, P108, DOI 10.1902/jop.2014.140326; Diaz-Zuniga J, 2014, J CLIN PERIODONTOL, V41, P242, DOI 10.1111/jcpe.12205; Duan X, 2016, J PERIODONTAL RES, V51, P196, DOI 10.1111/jre.12298; Dutzan N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0797; Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520; Fine DH, 2007, J CLIN MICROBIOL, V45, P3859, DOI 10.1128/JCM.00653-07; Gaffen SL, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aau4594; Garlet GP, 2005, MICROBES INFECT, V7, P738, DOI 10.1016/j.micinf.2005.01.012; Garlet GP, 2008, MICROBES INFECT, V10, P489, DOI 10.1016/j.micinf.2008.01.010; Gaudino SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00360; Graves DT, 2011, J DENT RES, V90, P143, DOI 10.1177/0022034510385236; Graves DT, 1998, J PERIODONTOL, V69, P1419, DOI 10.1902/jop.1998.69.12.1419; Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873; Haubek D, 2008, LANCET, V371, P237, DOI 10.1016/S0140-6736(08)60135-X; Hensel JA, 2019, LAB INVEST, V99, P93, DOI 10.1038/s41374-018-0137-1; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; Jia R, 2013, J DENT RES, V92, P247, DOI 10.1177/0022034513475625; Jiao YZ, 2014, TRENDS MICROBIOL, V22, P157, DOI 10.1016/j.tim.2013.12.005; Kim TS, 2009, J PERIODONTOL, V80, P2020, DOI 10.1902/jop.2009.090241; Kirikae T, 1999, INFECT IMMUN, V67, P1736; Konig MF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaj1921; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Lima HR, 2010, J CLIN PERIODONTOL, V37, P248, DOI 10.1111/j.1600-051X.2009.01531.x; Madeira MFM, 2013, MOL ORAL MICROBIOL, V28, P415, DOI 10.1111/omi.12034; Marolda Cristina L., 2006, V347, P237; MASOUD H, 1991, EUR J BIOCHEM, V200, P775, DOI 10.1111/j.1432-1033.1991.tb16244.x; Melgar-Rodriguez S, 2016, MOL ORAL MICROBIOL, V31, P162, DOI 10.1111/omi.12112; Miyazaki Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02901; Monasterio G, 2019, J PERIODONTAL RES, V54, P513, DOI 10.1111/jre.12654; Monasterio G, 2018, J PERIODONTOL, V89, P1249, DOI 10.1002/JPER.17-0563; Nakamura H, 2008, ORAL MICROBIOL IMMUN, V23, P190, DOI 10.1111/j.1399-302X.2007.00410.x; NISHIHARA T, 1995, INFECT IMMUN, V63, P1893, DOI 10.1128/IAI.63.5.1893-1898.1995; PAGE RC, 1991, INFECT IMMUN, V59, P3451, DOI 10.1128/IAI.59.10.3451-3462.1991; Perry MB, 1996, INFECT IMMUN, V64, P1215, DOI 10.1128/IAI.64.4.1215-1219.1996; Repeke CE, 2010, BONE, V46, P1122, DOI 10.1016/j.bone.2009.12.030; Rogers JE, 2007, J PERIODONTOL, V78, P550, DOI 10.1902/jop.2007.060321; Shiau HJ, 2014, PERIODONTOL 2000, V64, P81, DOI 10.1111/prd.12033; Shiau HJ, 2010, J PERIODONTOL, V81, P1505, DOI 10.1902/jop.2010.100045; TAKAHASHI T, 1991, INFECT IMMUN, V59, P18, DOI 10.1128/IAI.59.1.18-23.1991; Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600-0765.2005.00814.x; Tanamoto KI, 1997, J IMMUNOL, V158, P4430; Tang G, 2012, MOL ORAL MICROBIOL, V27, P70, DOI 10.1111/j.2041-1014.2011.00632.x; Tang GY, 2010, J BACTERIOL, V192, P1395, DOI 10.1128/JB.01453-09; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; van der Reijden WA, 2008, J CLIN PERIODONTOL, V35, P487, DOI 10.1111/j.1600-051X.2008.01218.x; van Panhuys N, 2014, IMMUNITY, V41, P63, DOI 10.1016/j.immuni.2014.06.003; Vega BA, 2019, TOXINS, V11, DOI 10.3390/toxins11090489; Vernal R, 2008, J PERIODONTAL RES, V43, P689, DOI 10.1111/j.1600-0765.2007.01073.x; Wang L, 2008, P NATL ACAD SCI USA, V105, P9331, DOI 10.1073/pnas.0710441105; Yamaguchi N, 1996, INFECT IMMUN, V64, P2563, DOI 10.1128/IAI.64.7.2563-2570.1996; YAMAGUCHI N, 1995, INFECT IMMUN, V63, P4589, DOI 10.1128/IAI.63.12.4589-4594.1995; Yang BH, 2016, MUCOSAL IMMUNOL, V9, P444, DOI 10.1038/mi.2015.74; Yang HW, 2004, J PERIODONTOL, V75, P592, DOI 10.1902/jop.2004.75.4.592; Yoshida Y, 1998, INFECT IMMUN, V66, P107, DOI 10.1128/IAI.66.1.107-114.1998; Zambon J J, 1988, Adv Dent Res, V2, P269; ZAMBON JJ, 1983, INFECT IMMUN, V41, P19, DOI 10.1128/IAI.41.1.19-27.1983; Zhao CJ, 2020, J PERIODONTOL, V91, P1085, DOI 10.1002/JPER.19-0470; Zughaier S, 2006, VACCINE, V24, P1291, DOI 10.1016/j.vaccine.2005.09.039	73	2	2	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2020	11								591240	10.3389/fimmu.2020.591240	http://dx.doi.org/10.3389/fimmu.2020.591240			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ4YN	33193431	Green Published, gold			2022-12-18	WOS:000588791000001
J	Perdiguero, P; Gomez-Esparza, MC; Martin, D; Bird, S; Soleto, I; Morel, E; Diaz-Rosales, P; Tafalla, C				Perdiguero, Pedro; Gomez-Esparza, Maria C.; Martin, Diana; Bird, Steve; Soleto, Irene; Morel, Esther; Diaz-Rosales, Patricia; Tafalla, Carolina			Insights Into the Evolution of the prdm1/Blimp1 Gene Family in Teleost Fish	FRONTIERS IN IMMUNOLOGY			English	Article						B lymphocyte-induced maturation protein (Blimp1); homolog of Blimp1 in T cells (Hobit); teleost fish; B&#160; cells; plasmablasts	TRANSCRIPTION FACTOR BLIMP-1; B-CELL; EXPRESSION PROFILES; DIFFERENTIATION; MATURATION; REPRESSOR; TROUT; IDENTIFICATION; HETEROGENEITY; LYMPHOCYTES	In mammals, Blimp1 (B lymphocyte-induced maturation protein 1) encoded by the prdm1 gene and its homolog Hobit (homolog of Blimp1 in T cells) encoded by znf683, represent key transcriptional factors that control the development and differentiation of both B and T cells. Despite their essential role in the regulation of acquired immunity, this gene family has been largely unexplored in teleosts to date. Until now, one prdm1 gene has been identified in most teleost species, whereas a znf683 homolog has not yet been reported in any of these species. Focusing our analysis on rainbow trout (Oncorhynchus mykiss), an in silico identification and characterization of prdm1-like genes has been undertaken, confirming that prdm1 and znf683 evolved from a common ancestor gene, acquiring three gene copies after the teleost-specific whole genome duplication event (WGD) and six genes after the salmonid-specific WGD. Additional transcriptional studies to study how each of these genes are regulated in homeostasis, in response to a viral infection or in B cells in different differentiation stages, provide novel insights as to how this gene family evolved and how their encoded products might be implicated in the lymphocyte differentiation process in teleosts.	[Perdiguero, Pedro; Gomez-Esparza, Maria C.; Martin, Diana; Soleto, Irene; Morel, Esther; Diaz-Rosales, Patricia; Tafalla, Carolina] Anim Hlth Res Ctr CISA INIA, Madrid, Spain; [Bird, Steve] Univ Waikato, Sch Sci, Biomed Unit, Hamilton, New Zealand	University of Waikato	Diaz-Rosales, P; Tafalla, C (corresponding author), Anim Hlth Res Ctr CISA INIA, Madrid, Spain.	diaz.patricia@inia.es; tafalla@inia.es	MOREL, ESTHER/AAC-7286-2021; Díaz-Rosales, Patricia/GPG-6820-2022; Jimenez, Pedro Perdiguero/H-5234-2015; Bird, Steve/K-4822-2014; Tafalla, Carolina/J-8074-2014; Diaz-Rosales, Patricia/H-9679-2013	MOREL, ESTHER/0000-0002-4768-082X; Jimenez, Pedro Perdiguero/0000-0002-5471-9550; soleto, irene/0000-0002-8005-2411; Bird, Steve/0000-0003-2937-8579; Tafalla, Carolina/0000-0002-0860-2976; Diaz-Rosales, Patricia/0000-0001-6965-3702; Martin Lorenzo, Diana/0000-0003-3065-2870	European Research Council (ERC) [2016 725061 TEMUBLYM]; Spanish Ministry of Science, Innovation and Universities [AGL2017-85494-C2-1-R]; Comunidad de Madrid [2016-T1/BIO-1672]	European Research Council (ERC)(European Research Council (ERC)); Spanish Ministry of Science, Innovation and Universities; Comunidad de Madrid(Comunidad de Madrid)	This work was supported by the European Research Council (ERC Consolidator Grant 2016 725061 TEMUBLYM), by the Spanish Ministry of Science, Innovation and Universities (project AGL2017-85494-C2-1-R) and by the Comunidad de Madrid (grant 2016-T1/BIO-1672).	Abos B, 2016, SCI REP-UK, V6, DOI 10.1038/srep30004; Alinikula J, 2011, EUR J IMMUNOL, V41, P2404, DOI 10.1002/eji.201141553; Baxendale S, 2004, NAT GENET, V36, P88, DOI 10.1038/ng1280; Behr FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01770; Berthelot C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4657; Bikoff EK, 2009, CURR OPIN GENET DEV, V19, P379, DOI 10.1016/j.gde.2009.05.005; Braga FAV, 2015, EUR J IMMUNOL, V45, P2945, DOI 10.1002/eji.201545650; Bromage ES, 2004, J IMMUNOL, V173, P7317, DOI 10.4049/jimmunol.173.12.7317; Castro RAO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104055; Castro R, 2014, VACCINE, V32, P1160, DOI 10.1016/j.vaccine.2013.11.062; Crotty S, 2010, NAT IMMUNOL, V11, P114, DOI 10.1038/ni.1837; DELUCA D, 1983, EUR J IMMUNOL, V13, P546, DOI 10.1002/eji.1830130706; Diaz-Rosales P, 2009, FISH SHELLFISH IMMUN, V27, P414, DOI 10.1016/j.fsi.2009.06.008; Glasauer SMK, 2014, MOL GENET GENOMICS, V289, P1045, DOI 10.1007/s00438-014-0889-2; Granja AG, 2019, FISH SHELLFISH IMMUN, V85, P9, DOI 10.1016/j.fsi.2017.10.003; Granja AG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174249; John SA, 2009, EXP CELL RES, V315, P1077, DOI 10.1016/j.yexcr.2008.11.015; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; Kallies A, 2004, J EXP MED, V200, P967, DOI 10.1084/jem.20040973; Kallies A, 2009, IMMUNITY, V31, P283, DOI 10.1016/j.immuni.2009.06.021; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kim SJ, 2015, IMMUNOL RES, V63, P113, DOI 10.1007/s12026-015-8694-5; Kim SJ, 2011, J EXP MED, V208, P2193, DOI 10.1084/jem.20110658; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu CH, 2016, FISH PHYSIOL BIOCHEM, V42, P467, DOI 10.1007/s10695-015-0152-8; Mackay LK, 2016, SCIENCE, V352, P459, DOI 10.1126/science.aad2035; Martin-Martin A, 2020, DEV COMP IMMUNOL, V109, DOI 10.1016/j.dci.2020.103715; Martins G, 2008, ANNU REV IMMUNOL, V26, P133, DOI 10.1146/annurev.immunol.26.021607.090241; Montero J, 2011, J VIROL, V85, P4046, DOI 10.1128/JVI.02519-10; Nakanishi Teruyuki, 2015, Biology-Basel, V4, P640, DOI 10.3390/biology4040640; Nutt SL, 2007, NAT REV IMMUNOL, V7, P923, DOI 10.1038/nri2204; Ochiai K, 2008, INT IMMUNOL, V20, P453, DOI 10.1093/intimm/dxn005; Ochiai K, 2006, J BIOL CHEM, V281, P38226, DOI 10.1074/jbc.M607592200; Ohtani M, 2006, FISH SHELLFISH IMMUN, V20, P409, DOI 10.1016/j.fsi.2005.04.007; Ramirez-Gomez F, 2012, J IMMUNOL, V188, P1341, DOI 10.4049/jimmunol.1101938; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Shin H, 2009, IMMUNITY, V31, P309, DOI 10.1016/j.immuni.2009.06.019; Soleto I, 2019, FISH SHELLFISH IMMUN, V89, P309, DOI 10.1016/j.fsi.2019.04.001; Soleto I, 2017, FISH SHELLFISH IMMUN, V64, P210, DOI 10.1016/j.fsi.2017.03.023; Soro PG, 1999, J IMMUNOL, V163, P611; Sun XJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001499; Tafalla C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00295; Takizawa F, 2011, DEV COMP IMMUNOL, V35, P752, DOI 10.1016/j.dci.2011.02.008; Tellier J, 2016, NAT IMMUNOL, V17, P323, DOI 10.1038/ni.3348; Tunyaplin C, 2004, J IMMUNOL, V173, P1158, DOI 10.4049/jimmunol.173.2.1158; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; van Gisbergen KPJM, 2012, NAT IMMUNOL, V13, P864, DOI 10.1038/ni.2393; Wu LT, 2019, DEV COMP IMMUNOL, V98, P137, DOI 10.1016/j.dci.2019.05.002; Zhao HB, 2014, MOL BIOL REP, V41, P617, DOI 10.1007/s11033-013-2899-2; Zwollo P, 2005, J IMMUNOL, V174, P6608, DOI 10.4049/jimmunol.174.11.6608	55	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2020	11								596975	10.3389/fimmu.2020.596975	http://dx.doi.org/10.3389/fimmu.2020.596975			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ4TC	33193451	Green Published, gold			2022-12-18	WOS:000588776800001
J	Teixeira, AF; Cavenague, MF; Kochi, LT; Fernandes, LG; Souza, GO; de Souza, AF; Vasconcellos, SA; Heinemann, MB; Nascimento, ALTO				Teixeira, Aline F.; Cavenague, Maria F.; Kochi, Leandro T.; Fernandes, Luis G.; Souza, Gisele O.; de Souza Filho, Antonio Francisco; Vasconcellos, Silvio A.; Heinemann, Marcos Bryan; Nascimento, Ana L. T. O.			Immunoprotective Activity Induced by Leptospiral Outer Membrane Proteins in Hamster Model of Acute Leptospirosis	FRONTIERS IN IMMUNOLOGY			English	Article						Leptospira; leptospirosis; vaccine; recombinant proteins; immunoprotection; immunogenicity	PROTECTIVE IMMUNITY; INTERROGANS; INFECTION; VACCINE; PLASMINOGEN; ANTIBODIES; ROLES; IGG1	Leptospirosis is a zoonotic disease of worldwide distribution, affecting both humans and animals. The development of an effective vaccine against leptospirosis has long been pursued but without success. Humans are contaminated after direct contact with the urine of infected animals or indirectly by contaminated water or soil. The vaccines available consist of inactivated whole-bacterial cells, and the active immunoprotective antigen is the lipopolysaccharide moiety, which is also the basis for serovar classification. However, these vaccines are short-lasting, and protection is only against serovars contained in the preparation. The search for prevalent antigens, present in pathogenic species of Leptospira, represents the most cost-effective strategy for prevention of leptospirosis. Thus, the identification of these antigens is a priority. In this study, we examined the immunoprotective effect of eight leptospiral recombinant proteins using hamster as the challenge model. Animals received subcutaneously two doses of vaccine containing 50 mu g of each recombinant protein adsorbed on alum adjuvant. Two weeks after the booster, animals were challenged with virulent leptospires and monitored for 21 days. All proteins were able to induce a specific immune response, although significant protective effects on survival rate were observed only for the proteins Lsa14, rLIC13259, and rLIC11711. Of these, only rLIC13259 and rLIC11711 were found to be highly prospective in promoting renal clearance. The sterilizing potential of both proteins will be further investigated to elucidate the immunoprotective mechanisms involved in leptospirosis control. These are the first proteins involved with human complement components with the capacity to protect against virulent challenge and to eliminate the bacteria from the host.	[Teixeira, Aline F.; Cavenague, Maria F.; Kochi, Leandro T.; Fernandes, Luis G.; Nascimento, Ana L. T. O.] Inst Butantan, Lab Desenvolvimento Vacinas, Sao Paulo, Brazil; [Cavenague, Maria F.; Kochi, Leandro T.] Univ Sao Paulo, Inst Ciencias Biomed, Programa Posgrad Interunidades Biotecnol, Sao Paulo, Brazil; [Souza, Gisele O.; de Souza Filho, Antonio Francisco; Vasconcellos, Silvio A.; Heinemann, Marcos Bryan] Univ Sao Paulo, Lab Zoonoses Bacterianas, Dept Med Vet Prevent & Saude Anim VPS, Fac Med Vet & Zootecnia, Sao Paulo, Brazil	Instituto Butantan; Universidade de Sao Paulo; Universidade de Sao Paulo	Nascimento, ALTO (corresponding author), Inst Butantan, Lab Desenvolvimento Vacinas, Sao Paulo, Brazil.	ana.nascimento@butantan.gov.br	Heinemann, Marcos Bryan/AAI-9390-2020; Fernandes, Luis Guilherme Virgilio/AAW-1777-2021; Nascimento, Ana L. T. O./E-8488-2012; Kochi, Leandro/GQZ-3638-2022	Heinemann, Marcos Bryan/0000-0001-6444-9788; Fernandes, Luis Guilherme Virgilio/0000-0001-8794-9021; Nascimento, Ana L. T. O./0000-0003-4851-0870; Kochi, Leandro Toshio/0000-0002-1522-1506; Teixeira, Aline/0000-0002-1171-8312	FAPESP [2014/50981-0, 2018/08131-0, 2018/09652-4, 2017/06731-8, 2016/11541-0]; CNPq [301229/2017-1]; Fundacao Butantan	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Butantan	The following Brazilian agencies: FAPESP (grant 2014/50981-0), CNPq (grant 301229/2017-1) and Fundacao Butantan, financially supported this work; MC, LK, LF, and AT have fellowships from FAPESP (2018/08131-0; 2018/09652-4; 2017/06731-8 and 2016/11541-0, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler B, 2010, VET MICROBIOL, V140, P287, DOI 10.1016/j.vetmic.2009.03.012; Atzingen Marina V, 2012, Open Microbiol J, V6, P79, DOI 10.2174/1874285801206010079; Bharti AR, 2003, LANCET INFECT DIS, V3, P757, DOI 10.1016/S1473-3099(03)00830-2; Boey K, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007499; Cavenague MF, 2019, INT J MED MICROBIOL, V309, P116, DOI 10.1016/j.ijmm.2018.12.005; COE JE, 1995, IMMUNOLOGY, V86, P141; Conrad NL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005441; Costa F, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003898; Coutinho ML, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001422; Dellagostin OA, 2011, HUM VACCINES, V7, P1215, DOI 10.4161/hv.7.11.17944; ESCRIBANO MJ, 1982, J IMMUNOL METHODS, V52, P63, DOI 10.1016/0022-1759(82)90350-7; Faine S, 1999, ANTIMICROBIAL, P272; Fernandes LGV, 2017, INT J INFECT DIS, V57, P61, DOI 10.1016/j.ijid.2017.01.032; Figueredo JM, 2017, MICROBIOL-SGM, V163, P37, DOI 10.1099/mic.0.000411; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; Forthal DN, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0019-2014; Haake DA, 2002, CLIN INFECT DIS, V34, pE40, DOI 10.1086/339942; Haake DA, 2015, CURR TOP MICROBIOL, V387, P65, DOI 10.1007/978-3-662-45059-8_5; Hartwig DD, 2013, CLIN VACCINE IMMUNOL, V20, P747, DOI 10.1128/CVI.00034-13; Heesterbeek DAC, 2018, J INNATE IMMUN, V10, P455, DOI 10.1159/000491439; Kao D, 2017, EUR J IMMUNOL, V47, P2070, DOI 10.1002/eji.201747208; Kochi LT, 2019, VIRULENCE, V10, P734, DOI 10.1080/21505594.2019.1650613; Koizumi N, 2004, VACCINE, V22, P1545, DOI 10.1016/j.vaccine.2003.10.007; LaRocca TJ, 2008, CURR TOP MICROBIOL, V319, P63; LaRocca TJ, 2009, P NATL ACAD SCI USA, V106, P10752, DOI 10.1073/pnas.0901858106; Martinez R, 2004, REV PANAM SALUD PUBL, V15, P249, DOI 10.1590/S1020-49892004000400005; Monaris D, 2015, CLIN VACCINE IMMUNOL, V22, P965, DOI 10.1128/CVI.00285-15; Nascimento ALTO, 2004, BRAZ J MED BIOL RES, V37, P459, DOI 10.1590/S0100-879X2004000400003; Oliveira TL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142821; Pereira PRM, 2017, INT J MED MICROBIOL, V307, P297, DOI 10.1016/j.ijmm.2017.05.006; Rossini AD, 2020, J MICROBIOL IMMUNOL, V53, P163, DOI 10.1016/j.jmii.2018.12.012; Rostamian M, 2017, J MICROBIOL IMMUNOL, V50, P160, DOI 10.1016/j.jmii.2015.05.007; Santi I, 2009, J INFECT DIS, V200, P564, DOI 10.1086/603540; Santos JV, 2018, MOL CELL PROBE, V37, P12, DOI 10.1016/j.mcp.2017.10.004; Saylor K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00283; Silva EF, 2007, VACCINE, V25, P6277, DOI 10.1016/j.vaccine.2007.05.053; Socolovschi C, 2011, INT J INFECT DIS, V15, pE710, DOI 10.1016/j.ijid.2011.05.017; Techawiwattanaboon T, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030095; Teixeira AF, 2019, VACCINE, V37, P3961, DOI 10.1016/j.vaccine.2019.05.087; Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600; Verma R, 2015, ACTA TROP, V152, P103, DOI 10.1016/j.actatropica.2015.08.018; Zhang L, 2015, EXPERT REV VACCINES, V14, P1509, DOI 10.1586/14760584.2015.1081067	42	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2020	11								568694	10.3389/fimmu.2020.568694	http://dx.doi.org/10.3389/fimmu.2020.568694			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ4SS	33193344	Green Published, gold			2022-12-18	WOS:000588775800001
J	Wang, YY; Petrikova, E; Gross, W; Sticht, C; Gretz, N; Herr, I; Karakhanova, S				Wang, Yangyi; Petrikova, Emilia; Gross, Wolfgang; Sticht, Carsten; Gretz, Norbert; Herr, Ingrid; Karakhanova, Svetlana			Sulforaphane Promotes Dendritic Cell Stimulatory Capacity Through Modulation of Regulatory Molecules, JAK/STAT3-and MicroRNA-Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						sulforaphane; dendritic cells; T cells; regulatory molecules; STAT3; miRNAs; pancreatic cancer	NF-KAPPA-B; UP-REGULATION; CANCER; B7-H1; STAT3; ACTIVATION; INHIBITION; EXPRESSION; TARGET; DIFFERENTIATION	Introduction The broccoli isothiocyanate sulforaphane was shown to inhibit inflammation and tumor progression, also in pancreatic cancer, while its effect on tumor immunity is poorly understood. We investigated the immunoregulatory effect of sulforaphane on human dendritic cells alone and in presence of pancreatic tumor antigens, as well as underlying molecular mechanisms. Methods Sulforaphane-treated human dendritic cells were matured in vitro with a cytokine cocktail, and the expression of regulatory molecules was examined by flow cytometry. The subsequent T-cell response was analyzed by T-cell proliferation assay and CD25 expression. To confirm the findings, dendritic cells pulsed with pancreatic cancer-derived tumor antigens were used. To identify the involved pathway- and microRNA-signaling in sulforaphane-treated dendritic cells, inhibitors of various signaling pathways, western blot analysis, microRNA array, and bioinformatic analysis were applied. Results Sulforaphane modulated the expression of the costimulatory CD80, CD83 and the suppressive B7-H1 molecules on dendritic cells and thereby promoted activation of T cells. The effect was verified in presence of pancreatic tumor antigens. Phosphorylation of STAT3 in dendritic cells was diminished by sulforaphane, and the inhibition of JAK/STAT3 led to downregulation of B7-H1 expression. Among the identified top 100 significant microRNA candidates, the inhibition of miR-155-5p, important for the expression of costimulatory molecules, and the induction of miR-194-5p, targeting the B7-H1 gene, were induced by sulforaphane. Conclusion Our findings demonstrate that sulforaphane promotes T-cell activation by dendritic cells through the modulation of regulatory molecules, JAK/STAT3- and microRNA-signaling in healthy conditions and in context of pancreatic cancer-derived antigens. They explore the immunoregulatory properties of sulforaphane and justify further research on nutritional strategies in the co-treatment of cancer.	[Wang, Yangyi; Petrikova, Emilia; Gross, Wolfgang; Herr, Ingrid; Karakhanova, Svetlana] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Mol OncoSurg Grp, Sect Surg Res, Heidelberg, Germany; [Sticht, Carsten; Gretz, Norbert] Heidelberg Univ, Med Fac Mannheim, Med Res Ctr, Mannheim, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Karakhanova, S (corresponding author), Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Mol OncoSurg Grp, Sect Surg Res, Heidelberg, Germany.	karakhanova@uni-heidelberg.de	Herr, Ingrid/AAA-2276-2022	Gross, Wolfgang/0000-0002-5431-7594	German Cancer Aid (Deutsche Krebshilfe) [111299]; German Research Council [DFG HE 3186/15-1]; Heidelberger Stiftung Chirurgie; Dietmar Hopp Stiftung; Klaus Tschira Stiftung; Hanns A. Pielenz Stiftung; China Scholarship Council	German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); German Research Council(German Research Foundation (DFG)); Heidelberger Stiftung Chirurgie; Dietmar Hopp Stiftung; Klaus Tschira Stiftung; Hanns A. Pielenz Stiftung; China Scholarship Council(China Scholarship Council)	This study was supported by grants from the German Cancer Aid (Deutsche Krebshilfe 111299), German Research Council (DFG HE 3186/15-1), Heidelberger Stiftung Chirurgie, Dietmar Hopp Stiftung, Klaus Tschira Stiftung and the Hanns A. Pielenz Stiftung. Y. Wang was supported by a stipend from the China Scholarship Council.	Alumkal JJ, 2015, INVEST NEW DRUG, V33, P480, DOI 10.1007/s10637-014-0189-z; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Barton BE, 2006, EXPERT OPIN THER TAR, V10, P459, DOI 10.1517/14728222.10.3.459; Bazhin AV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02129; Bazhin AV, 2014, CANCER IMMUNOL IMMUN, V63, P59, DOI 10.1007/s00262-013-1485-8; Bellone G, 2009, INT J ONCOL, V34, P1701, DOI 10.3892/ijo_00000301; Burnett JP, 2017, CANCER LETT, V394, P52, DOI 10.1016/j.canlet.2017.02.023; Caparros E, 2006, BLOOD, V107, P3950, DOI 10.1182/blood-2005-03-1252; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Cho YS, 2016, CAN J PHYSIOL PHARM, V94, P1220, DOI 10.1139/cjpp-2015-0150; Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067; Chou HS, 2012, TRANSPLANTATION, V93, P272, DOI 10.1097/TP.0b013e31823ffd39; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Dunand-Sauthier I, 2011, BLOOD, V117, P4490, DOI 10.1182/blood-2010-09-308064; Eren E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00036; Esashi E, 2008, IMMUNITY, V28, P509, DOI 10.1016/j.immuni.2008.02.013; Fan P, 2016, CANCER LETT, V373, P130, DOI 10.1016/j.canlet.2016.01.038; Fukunaga A, 2004, PANCREAS, V28, pE26, DOI 10.1097/00006676-200401000-00023; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Geisel J, 2014, J IMMUNOL, V192, P3530, DOI 10.4049/jimmunol.1300556; Ghebeh H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-57; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hahm ER, 2010, CANCER PREV RES, V3, P484, DOI 10.1158/1940-6207.CAPR-09-0250; Hatfield P, 2008, J IMMUNOTHER, V31, P620, DOI 10.1097/CJI.0b013e31818213df; Herr I, 2013, WIEN MED WOCHENSCHR, V163, P80, DOI 10.1007/s10354-012-0163-3; Kallifatidis G, 2009, GUT, V58, P949, DOI 10.1136/gut.2008.149039; Kallifatidis G, 2011, MOL THER, V19, P188, DOI 10.1038/mt.2010.216; Karakhanova S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.998519; Karakhanova S, 2011, J LEUKOCYTE BIOL, V89, P837, DOI 10.1189/jlb.1209788; Karakhanova S, 2010, EUR J IMMUNOL, V40, P254, DOI 10.1002/eji.200939289; Kehl T, 2020, NUCLEIC ACIDS RES, V48, pD142, DOI 10.1093/nar/gkz1022; Keir ME, 2007, CURR OPIN IMMUNOL, V19, P309, DOI 10.1016/j.coi.2007.04.012; Kogure A, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0500-6; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kumar R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179012; Lee BN, 2006, CANCER-AM CANCER SOC, V107, P999, DOI 10.1002/cncr.22092; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li XQ, 2018, BIOMED PHARMACOTHER, V103, P473, DOI 10.1016/j.biopha.2018.03.121; Li YY, 2010, CLIN CANCER RES, V16, P2580, DOI 10.1158/1078-0432.CCR-09-2937; Liang Jie, 2019, Advances in Biological Regulation, V71, P79, DOI 10.1016/j.jbior.2018.11.006; Liang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02584; Liu P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12855-w; Liu Y, 2008, CLIN IMMUNOL, V129, P471, DOI 10.1016/j.clim.2008.07.030; Liu Y, 2009, CANCER IMMUNOL IMMUN, V58, P687, DOI 10.1007/s00262-008-0591-5; Lozanovski VJ, 2020, INVEST NEW DRUG, V38, P776, DOI 10.1007/s10637-019-00826-z; Matta BM, 2012, J IMMUNOL, V188, P5227, DOI 10.4049/jimmunol.1103382; Meliilo JA, 2010, J IMMUNOL, V184, P2638, DOI 10.4049/jimmunol.0902960; Muller L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147742; Nefedova Y, 2005, J IMMUNOL, V175, P4338, DOI 10.4049/jimmunol.175.7.4338; Neoptolemos JP, 2018, NAT REV GASTRO HEPAT, V15, P332, DOI 10.1038/s41575-018-0005-x; Park JH, 2012, BMB REP, V45, P311, DOI 10.5483/BMBRep.2012.45.5.311; Park SJ, 2004, J IMMUNOL, V173, P3844, DOI 10.4049/jimmunol.173.6.3844; Perrot I, 2007, J IMMUNOL, V178, P2763, DOI 10.4049/jimmunol.178.5.2763; Phuah NH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/804510; Pinzon-Charry A, 2007, BRIT J CANCER, V97, P1251, DOI 10.1038/sj.bjc.6604018; Pinzon-Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440-1711.2005.01371.x; Qu XQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121574; Reddy SA, 2015, INT IMMUNOPHARMACOL, V24, P440, DOI 10.1016/j.intimp.2014.12.037; Rosso SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/nn1374; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Singh SV, 2009, CANCER RES, V69, P2117, DOI 10.1158/0008-5472.CAN-08-3502; Slaby O, 2013, NUTR CANCER, V65, P247, DOI 10.1080/01635581.2013.756530; Smyth LA, 2015, IMMUNOLOGY, V144, P197, DOI 10.1111/imm.12390; Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239; Tahata S, 2018, CANCER PREV RES, V11, P429, DOI 10.1158/1940-6207.CAPR-17-0268; Turner ML, 2011, J IMMUNOL, V187, P3911, DOI 10.4049/jimmunol.1101137; Versteven M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00394; Wagner CJ, 2010, EUR J IMMUNOL, V40, P2882, DOI 10.1002/eji.201040422; Wolfle SJ, 2011, EUR J IMMUNOL, V41, P413, DOI 10.1002/eji.201040979; Yin LB, 2019, MOL THER-ONCOLYTICS, V14, P74, DOI 10.1016/j.omto.2019.03.011; Zhang CY, 2016, MOL NUTR FOOD RES, V60, P1427, DOI 10.1002/mnfr.201500918; Zhou HB, 2010, BLOOD, V116, P5885, DOI 10.1182/blood-2010-04-280156	72	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 30	2020	11								589818	10.3389/fimmu.2020.589818	http://dx.doi.org/10.3389/fimmu.2020.589818			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OQ3JB	33193420	Green Published, gold			2022-12-18	WOS:000588682400001
J	Sivasami, P; Li, CR				Sivasami, Pulavendran; Li, Chaoran			Derivation and Differentiation of Adipose-Tissue Regulatory T Cells: A Stepwise, Multi-Site Process	FRONTIERS IN IMMUNOLOGY			English	Review						adipose tissue; Tregs; immunometabolism; tissue&#8211; Treg precursor; obesity<bold; >	INSULIN-RESISTANCE; ACCUMULATION; INFLAMMATION; POPULATION; FAT	CD4(+) Foxp3(+) regulatory T cells (Tregs) not only enforce peripheral tolerance and restrain self-reactive immune responses, but also maintain organismal homeostasis and safeguard the function of parenchymal tissues. A paradigmatic tissue-Treg population resides in the visceral adipose tissue (VAT) and regulates organismal metabolism by interacting with adipocytes and local immunocytes. Compared with their lymphoid-tissue counterparts, VAT-Tregs have a distinct T cell receptor (TCR) repertoire and transcriptional profile, allowing them to maintain and function in the unique tissue microenvironment. However, when, where, and how VAT-Tregs acquire their distinct features and what signals drive their phenotypic diversification have just started to be unraveled. Here we summarize the recent advances in our understanding on the mechanisms of VAT-Treg derivation and differentiation. We discuss the origin and life history of VAT-Tregs, review the identification and characterization of a VAT-Treg precursor population in the secondary lymphoid organs, and highlight a stepwise reprogramming model of VAT-Treg differentiation that involves multiple stages at distinct locations. Lastly, we discuss whether a similar process may also be involved in the differentiation of Tregs from other non-lymphoid tissues and the imperative questions that remain to be addressed.	[Sivasami, Pulavendran; Li, Chaoran] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Emory University	Li, CR (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.	chaoran.li@emory.edu	SIVASAMI, PULAVENDRAN/AAW-9601-2021		Emory University School of Medicine	Emory University School of Medicine	This work was supported by the startup fund from Emory University School of Medicine for CL.	Ali N, 2017, IMMUNOLOGY, V152, P372, DOI 10.1111/imm.12791; Bapat SP, 2015, NATURE, V528, P137, DOI 10.1038/nature16151; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Delacher M, 2020, IMMUNITY, V52, P295, DOI 10.1016/j.immuni.2019.12.002; Eller K, 2011, DIABETES, V60, P2954, DOI 10.2337/db11-0358; Fan XY, 2018, J EXP MED, V215, P2796, DOI 10.1084/jem.20181442; Fernandes RA, 2020, ELIFE, V9, DOI 10.7554/eLife.58463; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Frias AB, 2019, J IMMUNOL, V203, P658, DOI 10.4049/jimmunol.1900358; Han JM, 2015, J IMMUNOL, V194, P4777, DOI 10.4049/jimmunol.1500020; Ilan Y, 2010, P NATL ACAD SCI USA, V107, P9765, DOI 10.1073/pnas.0908771107; Ito M, 2019, NATURE, V565, P246, DOI 10.1038/s41586-018-0824-5; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Kolodin D, 2015, CELL METAB, V21, P543, DOI 10.1016/j.cmet.2015.03.005; Li CR, 2020, IMMUNOL REV, V295, P114, DOI 10.1111/imr.12850; Li CR, 2018, CELL, V174, P285, DOI 10.1016/j.cell.2018.05.004; Miragaia RJ, 2019, IMMUNITY, V50, P493, DOI 10.1016/j.immuni.2019.01.001; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Pratama A, 2020, J EXP MED, V217, DOI 10.1084/jem.20190428; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Spallanzani RG, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw3658; Sullivan JM, 2019, J IMMUNOL, V202, P31, DOI 10.4049/jimmunol.1800917; Vasanthakumar A, 2020, NATURE, V579, P581, DOI 10.1038/s41586-020-2040-3; Vasanthakumar A, 2015, NAT IMMUNOL, V16, P276, DOI 10.1038/ni.3085; Whibley N, 2019, NAT IMMUNOL, V20, P386, DOI 10.1038/s41590-019-0351-z; Zeng Q, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02075	29	2	2	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 29	2020	11								599277	10.3389/fimmu.2020.599277	http://dx.doi.org/10.3389/fimmu.2020.599277			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OP8XY	33193452	gold, Green Published			2022-12-18	WOS:000588375300001
J	Sheller, R; Ojodu, J; Griffin, E; Edelman, S; Yusuf, C; Pigg, T; Huston, A; Fitzek, B; Boyle, JG; Singh, S				Sheller, Ruthanne; Ojodu, Jelili; Griffin, Emma; Edelman, Sari; Yusuf, Careema; Pigg, Trey; Huston, Alissa; Fitzek, Brian; Boyle, John G.; Singh, Sikha			The Landscape of Severe Combined Immunodeficiency Newborn Screening in the United States in 2020: A Review of Screening Methodologies and Targets, Communication Pathways, and Long-Term Follow-Up Practices	FRONTIERS IN IMMUNOLOGY			English	Review						severe combined immunodeficiency; newborn screening (NBS); United States; communication pathways; long-term follow-up; education		Severe combined immunodeficiency (SCID) is T cell development disorders in the immune system and can be detected at birth. As of December 2018, all 53 newborn screening (NBS) programs within the United States and associated territories offer universal screening for SCID. The Association of Public Health Laboratories (APHL), along with the Immune Deficiency Foundation (IDF), surveyed public health NBS system laboratory and follow-up coordinators regarding their NBS program's screening methodologies and targets, protocols for stakeholder notifications, and long-term follow-up practices. This report explores the variation that exists across NBS practices, revealing needs for efficiencies and educational resources across the NBS system to ensure the best outcomes for newborns.	[Sheller, Ruthanne; Ojodu, Jelili; Griffin, Emma; Edelman, Sari; Yusuf, Careema; Pigg, Trey; Singh, Sikha] Assoc Publ Hlth Labs, Newborn Screening & Genet Dept, Silver Spring, MD 20910 USA; [Huston, Alissa; Fitzek, Brian; Boyle, John G.] Immune Deficiency Fdn, Towson, MD USA		Sheller, R (corresponding author), Assoc Publ Hlth Labs, Newborn Screening & Genet Dept, Silver Spring, MD 20910 USA.	ruthanne.sheller@aphl.org			Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS)	Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS)	The development of this Request for Proposals (RFP) application is supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) as part of an award totaling $2.97 million with 0% percentage financed with nongovernmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the US Government.	Association of Public Health Laboratories (APHL), 2018, EXP REACH SCID TEST; Baker MW, 2010, PUBLIC HEALTH REP, V125, P88, DOI 10.1177/00333549101250S211; Immune Deficiency Foundation, 2018, IMM DEF FDN AW 4 MIL; Kavanagh PL, 2008, AM J MED GENET C, V148C, P15, DOI 10.1002/ajmg.c.30160; Kemper AR, 2008, GENET MED, V10, P259, DOI 10.1097/GIM.0b013e31816b64f9; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Mann MY, 2006, PEDIATRICS, V117, pS296, DOI 10.1542/peds.2005-26331; Ojodu J, 2018, INT J NEONAT SCREEN, V4, DOI 10.3390/ijns4010001; PerkinElmer, 2017, PERKINELMER ANN 1 CO; Puck JM, 2019, IMMUNOL REV, V287, P241, DOI 10.1111/imr.12729; Raspa M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00885; Sontag MK, 2018, INT J NEONAT SCREEN, V4, DOI 10.3390/ijns4020016; van der Burg M, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00373	13	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2020	11								577853	10.3389/fimmu.2020.577853	http://dx.doi.org/10.3389/fimmu.2020.577853			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OP4JG	33193375	Green Published, gold			2022-12-18	WOS:000588046600001
J	Bedocs, P; Szebeni, J				Bedocs, Peter; Szebeni, Janos			The Critical Choice of Animal Models in Nanomedicine Safety Assessment: A Lesson Learned From Hemoglobin-Based Oxygen Carriers	FRONTIERS IN IMMUNOLOGY			English	Review						nanopharmaceuticals; hypersensitivity reactions; anaphylactic shock; hemorrhagic shock; trauma; porcine CARPA model; cardiopulmonary distress; pulmonary hypertension	CROSS-LINKED HEMOGLOBIN; PEGYLATED LIPOSOMAL DOXORUBICIN; INDUCED COMPLEMENT ACTIVATION; IRON-OXIDE NANOPARTICLES; PULMONARY-HYPERTENSION; BLOOD SUBSTITUTES; IN-VITRO; HYPERSENSITIVITY REACTIONS; INFUSION REACTIONS; PORCINE	Intravenous injection of nanopharmaceuticals can induce severe hypersensitivity reactions (HSRs) resulting in anaphylactoid shock in a small percentage of patients, a phenomenon explicitly reproducible in pigs. However, there is a debate in the literature on whether the pig model of HSRs can be used as a safety test for the prediction of severe adverse reactions in humans. Given the importance of using appropriate animal models for toxicity/safety testing, the choice of the right species and model is a critical decision. In order to facilitate the decision process and to expand the relevant information regarding the pig or no pig dilemma, this review examines an ill-fated clinical development program conducted by Baxter Corporation in the United States 24 years ago, when HemeAssist, an alpha alpha (diaspirin) crosslinked hemoglobin-based O-2 carrier (HBOC) was tested in trauma patients. The study showed increased mortality in the treatment group relative to controls and had to be stopped. This disappointing result had far-reaching consequences and contributed to the setback in blood substitute research ever since. Importantly, the increased mortality of trauma patients was predicted in pig experiments conducted by US Army scientists, yet they were considered irrelevant to humans. Here we draw attention to that the underlying cause of hemoglobin-induced aggravation of hemorrhagic shock and severe HSRs have a common pathomechanism: cardiovascular distress due to vasoconstrictive effects of hemoglobin (Hb) and reactogenic nanomedicines, manifested, among others, in pulmonary hypertension. The main difference is that in the case of Hb this effect is due to NO-binding, while nanomedicines can trigger the release of proinflammatory mediators. Because of the higher sensitivity of cloven-hoof animals to this kind of cardiopulmonary distress compared to rodents, these reactions can be better reproduced in pigs than in murine or rat models. When deciding on the battery of tests and the appropriate models to identify the potential hazard for nanomedicine-induced severe HSR, the pros and cons of the various species must be considered carefully.	[Bedocs, Peter] Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, Bethesda, MD 20814 USA; [Bedocs, Peter] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Bedocs, Peter] Def & Vet Ctr Integrat Pain Management, Rockville, MD USA; [Szebeni, Janos] Semmelweis Univ, Nanomed Res & Educ Ctr, Dept Translat Med, Budapest, Hungary; [Szebeni, Janos] SeroScience Ltd, Budapest, Hungary; [Szebeni, Janos] Univ Miskolc, Fac Hlth, Dept Nanobiotechnol & Regenerat Med, Miskolc, Hungary	Uniformed Services University of the Health Sciences - USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Semmelweis University; University of Miskolc	Szebeni, J (corresponding author), Semmelweis Univ, Nanomed Res & Educ Ctr, Dept Translat Med, Budapest, Hungary.; Szebeni, J (corresponding author), SeroScience Ltd, Budapest, Hungary.; Szebeni, J (corresponding author), Univ Miskolc, Fac Hlth, Dept Nanobiotechnol & Regenerat Med, Miskolc, Hungary.	szebeni.janos@med.semmelweis-univ.hu		Bedocs, Peter/0000-0002-4159-1391	European Union Horizon 2020 [825828, 952520]	European Union Horizon 2020	JS acknowledges the financial support by the European Union Horizon 2020 projects 825828 (Expert) and 952520 (Biosafety), and the logistic support by the Applied Materials and Nanotechnology, Center of Excellence, Miskolc University, Miskolc, Hungary.	Alayash AI, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7010002; Bawa R, 2008, NANOETHICS EMERGING; Bedocs P, 2014, ANESTH ANALG, V119, P1094, DOI 10.1213/ANE.0000000000000396; Bugna S, 2016, NANOMED-NANOTECHNOL, V12, P845, DOI 10.1016/j.nano.2015.12.364; Buscema M, 2017, J CONTROL RELEASE, V264, P14, DOI 10.1016/j.jconrel.2017.08.010; Calabrese LH, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1396-8; Chen JY, 2009, CLINICS, V64, P803, DOI 10.1590/S1807-59322009000800016; deFigueiredo LFP, 1997, J TRAUMA, V42, P847; Dezsi L, 2019, MOLECULES, V24, DOI 10.3390/molecules24183283; Dezsi L, 2014, J CONTROL RELEASE, V195, P2, DOI 10.1016/j.jconrel.2014.08.009; FDA/NIH, 2008, HEM BAS OX CARR CURR, DOI [10.1038/nbt0708-721a, DOI 10.1038/NBT0708-721A]; Fulop T, 2019, J CONTROL RELEASE, V309, P333, DOI 10.1016/j.jconrel.2019.07.005; Fulop T, 2018, J CONTROL RELEASE, V270, P268, DOI 10.1016/j.jconrel.2017.11.043; HESS JR, 1994, ARTIF CELL BLOOD SUB, V22, P361, DOI 10.3109/10731199409117867; HESS JR, 1995, ARTIF CELL BLOOD SUB, V23, P277, DOI 10.3109/10731199509117944; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; Hess JR, 1996, TRANSFUS MED REV, V10, P276, DOI 10.1016/S0887-7963(96)80003-4; HESS JR, 1991, J APPL PHYSIOL, V70, P1639, DOI 10.1152/jappl.1991.70.4.1639; HESS JR, 1992, BIOMAT ARTIF CELL IM, V20, P499, DOI 10.3109/10731199209119675; Hoy SM, 2018, DRUGS, V78, P1625, DOI 10.1007/s40265-018-0983-6; Jahr JS, 2011, CHEMISTRY AND BIOCHEMISTRY OF OXYGEN THERAPEUTICS: FROM TRANSFUSION TO ARTIFICIAL BLOOD, P301; Kasperovic P., 2016, US patent application, DOI 10.1016/j.addr.2011.06.017, Patent No. [#20160122759, 20160122759]; Kozma GT, 2019, ACS NANO, V13, P9315, DOI 10.1021/acsnano.9b03942; Kozma GT, 2020, ADV DRUG DELIV REV, DOI [10.1016/j.addr.2020.ext, DOI 10.1016/J.ADDR.2020.EXT]; Kuznetsova NR, 2012, J CONTROL RELEASE, V160, P394, DOI 10.1016/j.jconrel.2011.12.010; Matviykiv S, 2017, PROC SPIE, V10162, DOI 10.1117/12.2258378; Merkel OM, 2011, BIOMATERIALS, V32, P4936, DOI 10.1016/j.biomaterials.2011.03.035; Moghimi SM, 2019, J PHARMACOL EXP THER, V370, P581, DOI 10.1124/jpet.119.258012; Moghimi SM, 2018, NANOMEDICINE-UK, V13, P973, DOI 10.2217/nnm-2018-0064; Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007; NELSON D, 1992, BIOMAT ARTIF CELL IM, V20, P253, DOI 10.3109/10731199209119640; NELSON D, 1992, BIOMAT ARTIF CELL IM, V20, P423, DOI 10.3109/10731199209119662; Orfi E, 2019, INT J NANOMED, V14, P1563, DOI 10.2147/IJN.S187139; Povsic TJ, 2013, EUR HEART J, V34, P2481, DOI 10.1093/eurheartj/ehs232; Schmidt C, 2008, NAT BIOTECHNOL, V26, P721, DOI 10.1038/nbt0708-721a; Shafiq A, 2020, MATHEMATICS-BASEL, V8, DOI 10.3390/math8010104; Silverman TA, 2009, ANESTHESIOLOGY, V111, P946, DOI 10.1097/ALN.0b013e3181ba3c2c; Silverman TA, 2009, TRANSFUSION, V49, P2495, DOI 10.1111/j.1537-2995.2009.02356.x; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Szebeni J, 2006, AM J PHYSIOL-HEART C, V290, pH1050, DOI 10.1152/ajpheart.00622.2005; Szebeni J, 2000, J LIPOSOME RES, V10, P467, DOI 10.3109/08982100009031112; Szebeni J, 1999, CIRCULATION, V99, P2302, DOI 10.1161/01.CIR.99.17.2302; Szebeni J, 2000, AM J PHYSIOL-HEART C, V279, pH1319, DOI 10.1152/ajpheart.2000.279.3.H1319; Szebeni J., 2018, PREC NANOMED, V1, P63, DOI DOI 10.29016/180427.1; Szebeni J, 2007, J LIPOSOME RES, V17, P107, DOI 10.1080/08982100701375118; Szebeni J, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8040082; Szebeni J, 2018, NAT NANOTECHNOL, V13, P1100, DOI 10.1038/s41565-018-0273-1; Szebeni J, 2018, DRUG DISCOV TODAY, V23, P487, DOI 10.1016/j.drudis.2018.01.025; Szebeni J, 2012, ADV DRUG DELIVER REV, V64, P1706, DOI 10.1016/j.addr.2012.07.005; Szebeni J, 2012, J CONTROL RELEASE, V160, P382, DOI 10.1016/j.jconrel.2012.02.029; Szebeni J, 2012, NANOMED-NANOTECHNOL, V8, P176, DOI 10.1016/j.nano.2011.06.003; Szebeni J, 2011, ADV DRUG DELIVER REV, V63, P1020, DOI 10.1016/j.addr.2011.06.017; Unterweger H, 2017, INT J NANOMED, V12, P5223, DOI 10.2147/IJN.S138108; Urbanics R, 2015, EUR J NANOMED, V7, P219, DOI 10.1515/ejnm-2015-0011; Wang YXJ, 2017, QUANT IMAG MED SURG, V7, P88, DOI 10.21037/qims.2017.02.09; Weinhandl ED, 2014, PHARMACOEPIDEM DR S, V23, P1003, DOI 10.1002/pds.3655; Wibroe PP, 2017, NAT NANOTECHNOL, V12, P589, DOI [10.1038/nnano.2017.47, 10.1038/NNANO.2017.47]; Winslow RM, 2006, VOX SANG, V91, P102, DOI 10.1111/j.1423-0410.2006.00789.x; Winslow RM, 2000, VOX SANG, V79, P1; Winslow RM, 2007, SEMIN HEMATOL, V44, P51, DOI 10.1053/j.seminhematol.2006.09.013; Zamboni WC, 2018, ADV DRUG DELIVER REV, V136, P82, DOI 10.1016/j.addr.2018.09.012	61	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 26	2020	11								584966	10.3389/fimmu.2020.584966	http://dx.doi.org/10.3389/fimmu.2020.584966			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OO4ZK	33193403	gold, Green Published			2022-12-18	WOS:000587388400001
J	Pind, AAA; Estupinan, JLM; Magnusdottir, GJ; Del Giudice, G; Jonsdottir, I; Bjarnarson, SP				Pind, Audur Anna Aradottir; Estupinan, Jenny Lorena Molina; Magnusdottir, Gudbjorg Julia; Del Giudice, Giuseppe; Jonsdottir, Ingileif; Bjarnarson, Stefania P.			LT-K63 Enhances B Cell Activation and Survival Factors in Neonatal Mice That Translates Into Long-Lived Humoral Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						neonatal vaccination; adjuvant; B cell subsets; BAFF-R; BCMA; plasma cell survival; APRIL (TNFSF13); BAFF; B-cell activating factor	HEAT-LABILE ENTEROTOXIN; FOLLICULAR DENDRITIC CELLS; BONE-MARROW; PLASMA-CELLS; IMMUNOLOGICAL MEMORY; ANTIBODY-RESPONSES; STROMAL CELLS; BAFF; APRIL; TACI	Adjuvants enhance magnitude and duration of immune responses induced by vaccines. In this study we assessed in neonatal mice if and how the adjuvant LT-K63 given with a pneumococcal conjugate vaccine, Pnc1-TT, could affect the expression of tumor necrosis factor receptor (TNF-R) superfamily members, known to be involved in the initiation and maintenance of antibody responses; B cell activating factor receptor (BAFF-R) and B cell maturation antigen (BCMA) and their ligands, BAFF, and a proliferation inducing ligand (APRIL). Initially we assessed the maturation status of different B cell populations and their expression of BAFF-R and BCMA. Neonatal mice had dramatically fewer B cells than adult mice and the composition of different subsets within the B cell pool differed greatly. Proportionally newly formed B cells were most abundant, but they had diminished BAFF-R expression which could explain low proportions of marginal zone and follicular B cells observed. Limited BCMA expression was also detected in neonatal pre-plasmablasts/plasmablasts. LT-K63 enhanced vaccine-induced BAFF-R expression in splenic marginal zone, follicular and newly formed B cells, leading to increased plasmablast/plasma cells, and their enhanced expression of BCMA in spleen and bone marrow. Additionally, the induction of BAFF and APRIL expression occurred early in neonatal mice immunized with Pnc1-TT either with or without LT-K63. However, BAFF(+) and APRIL(+) cells in spleens were maintained at a higher level in mice that received the adjuvant. Furthermore, the early increase of APRIL(+) cells in bone marrow was more profound in mice immunized with vaccine and adjuvant. Finally, we assessed, for the first time in neonatal mice, accessory cells of the plasma cell niche in bone marrow and their secretion of APRIL. We found that LT-K63 enhanced the frequency and APRIL expression of eosinophils, macrophages, and megakaryocytes, which likely contributed to plasma cell survival, even though APRIL(+) cells showed a fast decline. All this was associated with enhanced, sustained vaccine-specific antibody-secreting cells in bone marrow and persisting vaccine-specific serum antibodies. Our study sheds light on the mechanisms behind the adjuvanticity of LT-K63 and identifies molecular pathways that should be triggered by vaccine adjuvants to induce sustained humoral immunity in early life.	[Pind, Audur Anna Aradottir; Estupinan, Jenny Lorena Molina; Magnusdottir, Gudbjorg Julia; Jonsdottir, Ingileif; Bjarnarson, Stefania P.] Natl Univ Hosp Iceland, Dept Immunol, Landspitali, Reykjavik, Iceland; [Pind, Audur Anna Aradottir; Estupinan, Jenny Lorena Molina; Magnusdottir, Gudbjorg Julia; Jonsdottir, Ingileif; Bjarnarson, Stefania P.] Univ Iceland, Fac Med, Sch Hlth Sci, Reykjavik, Iceland; [Del Giudice, Giuseppe] GSK Vaccines, Siena, Italy	University of Iceland; GlaxoSmithKline	Bjarnarson, SP (corresponding author), Natl Univ Hosp Iceland, Dept Immunol, Landspitali, Reykjavik, Iceland.; Bjarnarson, SP (corresponding author), Univ Iceland, Fac Med, Sch Hlth Sci, Reykjavik, Iceland.	stefbja@landspitali.is		Bjarnarson, Stefania P/0000-0003-3823-6329	University of Iceland; Icelandic Research Fund [130675051-53]; Landspitali Science Fund [A-2015-083, A2015-084, A-2016-067, A-2017-069]	University of Iceland; Icelandic Research Fund; Landspitali Science Fund	AA was a recipient of a doctoral study grant from the University of Iceland Research Fund (2015-18). This study was financially supported by grants from the Icelandic Research Fund (130675051-53), The University of Iceland Research Fund (2014-17) and the Landspitali Science Fund A-2015-083, A2015-084, A-2016-067, A-2017-069.	Alp OS, 2015, EUR J IMMUNOL, V45, P975, DOI 10.1002/eji.201445295; [Anonymous], 2018, LEV TRENDS CHILD MOR; [Anonymous], 2018, 2018 ASS REP GLOB VA; Balazs M, 2002, IMMUNITY, V17, P341, DOI 10.1016/S1074-7613(02)00389-8; Batten M, 2000, J EXP MED, V192, P1453, DOI 10.1084/jem.192.10.1453; Belnoue E, 2008, BLOOD, V111, P2755, DOI 10.1182/blood-2007-09-110858; Belnoue E, 2012, J IMMUNOL, V188, P1283, DOI 10.4049/jimmunol.1103169; Bjarnarson SP, 2005, EUR J IMMUNOL, V35, P1037, DOI 10.1002/eji.200425850; Bjarnarson SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072588; Bjarnarson SP, 2012, J IMMUNOL, V189, P1265, DOI 10.4049/jimmunol.1200761; Bortnick A, 2018, EUR J IMMUNOL, V48, P815, DOI 10.1002/eji.201747229; Bossen C, 2006, SEMIN IMMUNOL, V18, P263, DOI 10.1016/j.smim.2006.04.006; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Chang HD, 2018, IMMUNOL REV, V283, P86, DOI 10.1111/imr.12656; Chu VT, 2012, EUR J IMMUNOL, V42, P130, DOI 10.1002/eji.201141953; Chu VT, 2007, J IMMUNOL, V179, P5947, DOI 10.4049/jimmunol.179.9.5947; Connell TD, 2007, EXPERT REV VACCINES, V6, P821, DOI 10.1586/14760584.6.5.821; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Giuliani MM, 1998, J EXP MED, V187, P1123, DOI 10.1084/jem.187.7.1123; Goenka R, 2014, J EXP MED, V211, P45, DOI 10.1084/jem.20130505; Gomez MR, 2010, J IMMUNOL, V185, P7180, DOI 10.4049/jimmunol.1002319; Haberland K, 2018, EUR J IMMUNOL, V48, P822, DOI 10.1002/eji.201747227; Hannesdottir SG, 2008, SCAND J IMMUNOL, V68, P469, DOI 10.1111/j.1365-3083.2008.02165.x; Hauser AE, 2002, J IMMUNOL, V169, P1277, DOI 10.4049/jimmunol.169.3.1277; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Huard B, 2008, J CLIN INVEST, V118, P2887, DOI 10.1172/JCI33760; Jakobsen H, 2002, INFECT IMMUN, V70, P1443, DOI 10.1128/IAI.70.3.1443-1452.2002; Jakobsen H, 2001, J INFECT DIS, V183, P1494, DOI 10.1086/320202; Kanswal S, 2008, J IMMUNOL, V181, P976, DOI 10.4049/jimmunol.181.2.976; Kaur K, 2007, BLOOD, V110, P2948, DOI 10.1182/blood-2007-01-069245; Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999; Lightman SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00965; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; McCarron MJ, 2017, BLOOD, V129, P2749, DOI 10.1182/blood-2017-01-761643; Mohr E, 2016, CURR OPIN IMMUNOL, V41, P1, DOI 10.1016/j.coi.2016.04.004; Moon EY, 2007, IMMUNOBIOLOGY, V212, P637, DOI 10.1016/j.imbio.2007.06.002; Moreaux J, 2009, EUR J HAEMATOL, V83, P119, DOI 10.1111/j.1600-0609.2009.01262.x; Muthukkumar S, 2000, J IMMUNOL, V165, P4803, DOI 10.4049/jimmunol.165.9.4803; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/ERV.12.140, 10.1586/erv.12.140]; Olafsdottir TA, 2007, SCAND J IMMUNOL, V66, P426, DOI 10.1111/j.1365-3083.2007.01970.x; Pihlgren M, 2006, J IMMUNOL, V176, P165, DOI 10.4049/jimmunol.176.1.165; Pihlgren M, 2003, J IMMUNOL, V170, P2824, DOI 10.4049/jimmunol.170.6.2824; Pillai S, 2009, NAT REV IMMUNOL, V9, P767, DOI 10.1038/nri2656; Pind AAA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02214; Pizza M, 2001, VACCINE, V19, P2534, DOI 10.1016/S0264-410X(00)00137-7; Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494; Pracht K, 2017, EUR J IMMUNOL, V47, P1389, DOI 10.1002/eji.201747019; Rahman ZSM, 2004, J IMMUNOL, V173, P6179, DOI 10.4049/jimmunol.173.10.6179; Rauch M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005456; Reijmers RM, 2011, BLOOD, V117, P6162, DOI 10.1182/blood-2010-12-325522; Rozanski CH, 2011, J EXP MED, V208, P1435, DOI 10.1084/jem.20110040; Ryan EJ, 2000, J IMMUNOL, V165, P5750, DOI 10.4049/jimmunol.165.10.5750; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Stephenson I, 2006, J VIROL, V80, P4962, DOI 10.1128/JVI.80.10.4962-4970.2006; Suzuki K, 2010, IMMUNITY, V33, P71, DOI 10.1016/j.immuni.2010.07.003; SZU SC, 1994, INFECT IMMUN, V62, P4440, DOI 10.1128/IAI.62.10.4440-4444.1994; Tokoyoda K, 2010, NAT REV IMMUNOL, V10, P193, DOI 10.1038/nri2727; Tokoyoda K, 2009, EUR J IMMUNOL, V39, P2095, DOI 10.1002/eji.200939500; Tokoyoda K, 2009, IMMUNITY, V30, P721, DOI 10.1016/j.immuni.2009.03.015; Van TC, 2011, NAT IMMUNOL, V12, P151, DOI 10.1038/ni.1981; Vono M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00381; Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760; Wilmore JR, 2017, EUR J IMMUNOL, V47, P1386, DOI 10.1002/eji.201746944; Winter O, 2010, BLOOD, V116, P1867, DOI 10.1182/blood-2009-12-259457; Wuorimaa T, 2002, SCAND J IMMUNOL, V56, P111, DOI 10.1046/j.1365-3083.2002.01124.x; Xu J, 2012, NEOPLASMA, V59, P341, DOI 10.4149/neo_2012_044; Zaretsky AG, 2017, CELL REP, V18, P1906, DOI 10.1016/j.celrep.2017.01.067; Zehentmeier S, 2014, EUR J IMMUNOL, V44, P2306, DOI 10.1002/eji.201344313	72	2	2	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 23	2020	11								527310	10.3389/fimmu.2020.527310	http://dx.doi.org/10.3389/fimmu.2020.527310			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OM4VL	33193301	Green Published, gold			2022-12-18	WOS:000586024400001
J	Dubey, A; Dahiya, S; Rouse, BT; Sehrawat, S				Dubey, Abhishek; Dahiya, Surbhi; Rouse, Barry T.; Sehrawat, Sharvan			Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; therapy; sdAb; immunoregulation; viruses	ANTIBODY-DEPENDENT ENHANCEMENT; REGULATORY T-CELLS; VIRUS-INFECTION; PATHOGEN RECOGNITION; SPIKE PROTEIN; DOMAIN; CORONAVIRUS; IMMUNITY; MACROPHAGES; DISEASE	COVID-19 has become difficult to contain in our interconnected world. In this article, we discuss some approaches that could reduce the consequences of COVID-19. We elaborate upon the utility of camelid single-domain antibodies (sdAbs), also referred to as nanobodies, which are naturally poised to neutralize viruses without enhancing its infectivity. Smaller sized sdAbs can be easily selected using microbes or the subcellular organelle display methods and can neutralize SARS-CoV2 infectivity. We also discuss issues related to their production using scalable platforms. The favorable outcome of the infection is evident in patients when the inflammatory response is adequately curtailed. Therefore, we discuss approaches to mitigate hyperinflammatory reactions initiated by SARS-CoV2 but orchestrated by immune mediators.	[Dubey, Abhishek; Dahiya, Surbhi; Sehrawat, Sharvan] Indian Inst Sci Educ & Res Mohali, Dept Biol Sci, Mohali, India; [Rouse, Barry T.] Univ Tennessee, Coll Vet Med, Biomed & Diagnost Sci, Knoxville, TN USA	Indian Institute of Science Education & Research (IISER) - Mohali; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Sehrawat, S (corresponding author), Indian Inst Sci Educ & Res Mohali, Dept Biol Sci, Mohali, India.	sharvan@iisermohali.ac.in		Dubey, Abhishek/0000-0002-1037-0174	DBT [BT/PR20283/BBE/117/258/2016]; IISERM	DBT(Department of Biotechnology (DBT) India); IISERM	The work in the lab of SS is supported by Intramural funding from IISERM and the extramural grant from DBT (BT/PR20283/BBE/117/258/2016).	[Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; [Anonymous], LANCET RESP MED; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Biswas M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030424; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Casanova JL, 2020, CELL, V181, P1194, DOI 10.1016/j.cell.2020.05.016; Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x; Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7; Cho HJ, 2020, J INFECT PUBLIC HEAL, V13, P1678, DOI 10.1016/j.jiph.2020.05.001; Chun J, 2010, CLIN NEUROPHARMACOL, V33, P91, DOI 10.1097/WNF.0b013e3181cbf825; Crotta S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003773; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Dasaraju PV, 1996, MED MICROBIOLOGY, V4th; de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25; Dohla M, 2020, SARS COV 2 ENV SAMPL, DOI 10.1101/2020.05.28.20114041; DROBYSKI WR, 1994, NEW ENGL J MED, V330, P1356, DOI 10.1056/NEJM199405123301905; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Duarte JN, 2016, J IMMUNOL, V197, P4838, DOI 10.4049/jimmunol.1600692; Egloff C, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104447; Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1; Felsenstein S, 2020, CLIN IMMUNOL, V220, DOI 10.1016/j.clim.2020.108588; Flipse J, 2016, SCI REP-UK, V6, DOI 10.1038/srep29201; Flipse J, 2013, TRAFFIC, V14, P25, DOI 10.1111/tra.12012; Franchimont D, 2002, J IMMUNOL, V168, P2212, DOI 10.4049/jimmunol.168.5.2212; Franklin R, 2020, HOMOLOGOUS PROTEIN D, DOI [10.1101/2020.04.10.20053207, DOI 10.1101/2020.04.10.20053207]; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; Halstead SB, 2010, LANCET INFECT DIS, V10, P712, DOI 10.1016/S1473-3099(10)70166-3; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Han WZ, 2020, J MED VIROL, V92, P461, DOI 10.1002/jmv.25711; Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2; Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hohdatsu T, 1998, J VET MED SCI, V60, P49, DOI 10.1292/jvms.60.49; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36; Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI [10.1038/s41594-020-0469-6, 10.1038/s41594-020-00527-9]; Ingram JR, 2018, ANNU REV IMMUNOL, V36, P695, DOI 10.1146/annurev-immunol-042617-053327; Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Kaur M, 2019, TOXICON, V172, P15, DOI 10.1016/j.toxicon.2019.10.240; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Koff WC, 2020, NEW ENGL J MED, V383, P804, DOI 10.1056/NEJMp2006761; Konwarh R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01531; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kumar D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01521; Laporte M, 2017, CURR OPIN VIROL, V24, P16, DOI 10.1016/j.coviro.2017.03.018; Lee JS, 2020, NAT REV IMMUNOL, V20, P585, DOI 10.1038/s41577-020-00429-3; Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Li JY, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198074; Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044; Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763; Mabry R, 2010, PROTEIN ENG DES SEL, V23, P115, DOI 10.1093/protein/gzp073; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11; Metcalf TU, 2015, AGING CELL, V14, P421, DOI 10.1111/acel.12320; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; Ng KW, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.05.14.095414, DOI 10.1101/2020.05.14.095414]; Nguyen VK, 1999, MOL IMMUNOL, V36, P515, DOI 10.1016/S0161-5890(99)00067-X; Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x; Oja AE, 2020, BIORXIV, DOI [10.1101/2020.06.18.159202, DOI 10.1101/2020.06.18.159202]; Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008; Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914; Rahimkhoei V, 2021, CELL BIOCHEM FUNCT, V39, P4, DOI 10.1002/cbf.3576; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Saif LJ, 2004, DEV BIOLOGICALS, V119, P129; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schoot TS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01333; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Sehrawat S, 2008, J IMMUNOL, V180, P7636, DOI 10.4049/jimmunol.180.11.7636; Sehrawat S, 2020, MICROBES INFECT, V22, P400, DOI 10.1016/j.micinf.2020.07.002; Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5; Stadler K, 2008, AM J RESP CELL MOL, V39, P142, DOI 10.1165/rcmb.2007-0217OC; Swee LK, 2013, P NATL ACAD SCI USA, V110, P1428, DOI 10.1073/pnas.1214994110; Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; van der Heide Verena, 2020, Nat Rev Immunol, V20, P408, DOI 10.1038/s41577-020-0362-x; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1056/NEJMc2004973, 10.1101/2020.03.09.20033217]; Veiga-Parga T, 2013, IMMUNOL REV, V255, P182, DOI 10.1111/imr.12085; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6; Walter JD, 2020, BIORXIV, DOI 10.1101/2020.04.16.045419; Wang CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16256-y; Wong LDSY, 2020, J ALLER CL IMM-PRACT, V8, P3251, DOI 10.1016/j.jaip.2020.08.026; Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101; Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027; Zhang GH, 1999, INFECT IMMUN, V67, P1353, DOI 10.1128/IAI.67.3.1353-1358.1999	105	2	3	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2020	11								581076	10.3389/fimmu.2020.581076	http://dx.doi.org/10.3389/fimmu.2020.581076			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OL4UX	33193385	gold, Green Published			2022-12-18	WOS:000585338200001
J	dos Santos, AG; Watanabe, EH; Ferreira, DT; Oliveira, J; Nakanishi, ES; Oliveira, CS; Bocchi, E; Novaes, CTG; Cruz, F; Carvalho, NB; Sato, PK; Yamashiro-Kanashiro, EH; Pontillo, A; de Freitas, VLT; Onuchic, LF; Shikanai-Yasuda, MA				Gomes dos Santos, Alexandra; Watanabe, Elieser Hitoshi; Ferreira, Daiane Tomomi; Oliveira, Jamille; Nakanishi, Erika Shimoda; Oliveira, Claudia Silva; Bocchi, Edimar; Novaes, Cristina Terra Gallafrio; Cruz, Fatima; Carvalho, Noemia Barbosa; Sato, Paula Keiko; Yamashiro-Kanashiro, Edite Hatsumi; Pontillo, Alessandra; de Freitas, Vera Lucia Teixeira; Onuchic, Luiz Fernando; Shikanai-Yasuda, Maria Aparecida			A Specific IL6 Polymorphic Genotype Modulates the Risk of Trypanosoma cruzi Parasitemia While IL18, IL17A, and IL1B Variant Profiles and HIV Infection Protect Against Cardiomyopathy in Chagas Disease	FRONTIERS IN IMMUNOLOGY			English	Article						T; cruzi parasitemia; cardiomyopathy; Chagas disease; HIV; IL1 B; IL6; IL17 A and IL18 polymorphisms	INTERLEUKIN-6 IL-6 GENE; AMERICAN TRYPANOSOMIASIS; NITRIC-OXIDE; SERUM-LEVELS; T-CELLS; ASSOCIATION; BLOOD; EXPRESSION; CYTOKINE; DNA	Background Chagas disease caused by Trypanosoma cruzi (T. cruzi) affects approximately six million individuals worldwide. Clinical manifestations are expected to occur due to the parasite persistence and host immune response. Herein we investigated potential associations between IL1B, IL6, IL17A, or IL18 polymorphism profiles and cardiomyopathy or T. cruzi parasitemia, as well as the impact of HIV infection on cardiopathy. Methods Two hundred twenty-six patients and 90 control individuals were analyzed. IL1B rs1143627 T>C, IL6 rs1800795 C>G, IL17A rs2275913 G>A, IL18 rs187238 C>G, and IL18 rs1946518 C>A SNVs were analyzed by real-time PCR and T. cruzi parasitemia by PCR. Results Our data revealed association between a cytokine gene polymorphism and parasitemia never previously reported. The IL6 rs1800795 CG genotype lowered the risk of positive parasitemia (OR = 0.45, 95% CI 0.24-0.86, P = 0.015). Original findings included associations between IL17A rs2275913 AA and IL18 s1946518 AA genotypes with decreased risk of developing cardiomyopathy (OR = 0.27, 95% CI 0.07-0.97, P = 0.044; and OR = 0.35, 95% CI 0.14-0.87, P = 0.023, respectively). IL18 rs1946518 AA and IL1B rs1143627 TC were associated with reduced risk for cardiomyopathy severity, including NYHA (New York Heart Association) class >= 2 (OR = 0.21, 95% CI 0.06-0.68, P = 0.009; and OR = 0.48, 95% CI 0.24-0.95, P = 0.036, respectively) and LVEF (left ventricular ejection fraction) <45% for IL18 rs1946518 AA (OR = 0.22, 95% CI 0.05-0.89, P = 0.034). A novel, unexpected protective effect of HIV infection against development/progression of cardiomyopathy was identified, based on a lower risk of developing cardiopathy (OR = 0.48, 95% CI 0.23-0.96, P = 0.039), NYHA class >= 2 (OR = 0.15, 95% CI 0.06-0.39, P < 0.001), and LVEF < 45% (OR = 0.03, 95% CI 0.00-0.25, P = 0.001). Digestive involvement was negatively associated with NYHA >= 2 and LVEF < 45% (OR = 0.20, 95% CI 0.09-0.47, P < 0.001; and OR = 0.24, 95% CI 0.09-0.62, P = 0.004, respectively). Conclusions Our data support a protective role of IL17A AA, IL18 AA, and IL1B TC genotypes against development/progression of cardiomyopathy and a modulatory effect of the IL6 CG genotype on the risk of parasitemia in Chagas disease. Notably, HIV infection was shown to protect against development/progression of cardiopathy, potentially associated with a synergistic effect of HIV and highly active antiretroviral therapy (HAART), attenuating a Th1-mediated response in the myocardium. This proposed hypothesis requires confirmation, however, in larger and more comprehensive future studies.	[Gomes dos Santos, Alexandra; Oliveira, Jamille; Oliveira, Claudia Silva; de Freitas, Vera Lucia Teixeira; Shikanai-Yasuda, Maria Aparecida] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil; [Watanabe, Elieser Hitoshi; Onuchic, Luiz Fernando] Univ Sao Paulo, Fac Med, Dept Med, Div Mol Med, Sao Paulo, Brazil; [Watanabe, Elieser Hitoshi; Ferreira, Daiane Tomomi; Nakanishi, Erika Shimoda; Sato, Paula Keiko; Yamashiro-Kanashiro, Edite Hatsumi; de Freitas, Vera Lucia Teixeira; Onuchic, Luiz Fernando; Shikanai-Yasuda, Maria Aparecida] Univ Sao Paulo, Fac Med, Dept Med, Div Nephrol, Sao Paulo, Brazil; [Ferreira, Daiane Tomomi; Nakanishi, Erika Shimoda; Sato, Paula Keiko; Yamashiro-Kanashiro, Edite Hatsumi; de Freitas, Vera Lucia Teixeira; Shikanai-Yasuda, Maria Aparecida] Univ Sao Paulo, Fac Med, Hosp Clin, Lab Immunol LIM 48, Sao Paulo, Brazil; [Bocchi, Edimar; Cruz, Fatima] Univ Sao Paulo, Fac Med, Hosp Clin, Heart Inst, Sao Paulo, Brazil; [Novaes, Cristina Terra Gallafrio; Carvalho, Noemia Barbosa] Univ Sao Paulo, Fac Med, Hosp Clin, Div Infect Dis, Sao Paulo, Brazil; [Yamashiro-Kanashiro, Edite Hatsumi] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil; [Pontillo, Alessandra] Univ Sao Paulo, Inst Ciencias Biomed ICB, Dept Immunol, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Shikanai-Yasuda, MA (corresponding author), Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.; Onuchic, LF (corresponding author), Univ Sao Paulo, Fac Med, Dept Med, Div Mol Med, Sao Paulo, Brazil.; Onuchic, LF; Shikanai-Yasuda, MA (corresponding author), Univ Sao Paulo, Fac Med, Dept Med, Div Nephrol, Sao Paulo, Brazil.; Shikanai-Yasuda, MA (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Lab Immunol LIM 48, Sao Paulo, Brazil.	lonuchic@usp.br; masyasuda@yahoo.com.br	Sato, Paula K./K-6625-2012; Freitas, Vera/J-3007-2012; Pontillo, Alessandra/ABC-6266-2020; Shikanai Yasuda, Maria Aparecida/AAX-7693-2020	Sato, Paula K./0000-0002-3951-2316; Freitas, Vera/0000-0003-1112-081X; Pontillo, Alessandra/0000-0002-7883-0640; Shikanai Yasuda, Maria Aparecida/0000-0003-3864-041X; Gomes dos Santos, Alexandra/0000-0001-5061-4551	Sao Paulo Research Foundation (FAPESP) [12/50273-0, 19/06363-4]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - Programa Institucional de Bolsas de Iniciacao Cientifica (CNPq - PIBIC) [100793/2016-9, 157966/2015-1]; FAPESP (Technical Training Scholarship) [2014/071003]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - Programa Institucional de Bolsas de Iniciacao Cientifica (CNPq - PIBIC)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESP (Technical Training Scholarship)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by Sao Paulo Research Foundation (FAPESP) [#12/50273-0]; and by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - Programa Institucional de Bolsas de Iniciacao Cientifica (CNPq - PIBIC) [AGS #100793/2016-9 from January to July 2016], and JOR #157966/2015-1 from September to December 2015]; and by FAPESP (Technical Training Scholarship [CSO #2014/071003 from May of 2014 to March 2015] and Secretary of Administration of Sao Paulo State Secretary [DTF #from March of 2014 to February of 2016], and for IL18 analyses by Sao Paulo Research Foundation (FAPESP) [#19/06363-4].	Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Andreani G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008246; Apt W, 2016, ACTA TROP, V162, P155, DOI 10.1016/j.actatropica.2016.06.025; Balagopal A, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw118; Barbaro G., 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P337, DOI 10.2174/1568006054553444; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Basquiera AL, 2003, HEART, V89, P1186, DOI 10.1136/heart.89.10.1186; Bellera CL, 2015, EUR J MED CHEM, V93, P338, DOI 10.1016/j.ejmech.2015.01.065; Bennett JA, 2002, HEART LUNG, V31, P262, DOI 10.1067/mhl.2002.124554; Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740; Bocchi EA, 2017, J AM COLL CARDIOL, V70, P1510, DOI 10.1016/j.jacc.2017.08.004; Borges DC, 2013, IMMUNOLOGY, V138, P145, DOI 10.1111/imm.12022; BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030; Buschenfelde CMZ, 1997, CLIN EXP IMMUNOL, V110, P378, DOI DOI 10.1046/J.1365-2249.1997.4471463.X; Cai CW, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005902; Castilho Vanessa V S, 2018, BMC Res Notes, V11, P825, DOI 10.1186/s13104-018-3927-z; Chandrasekar B, 1998, AM J PATHOL, V152, P925; Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200; Chen DY, 2009, LUPUS, V18, P29, DOI 10.1177/0961203308094559; Chien Y, 2016, ONCOTARGET, V7, P87161, DOI 10.18632/oncotarget.13552; Collins LM, 2001, PSYCHOL METHODS, V6, P330, DOI 10.1037//1082-989X.6.4.330; Correa J. D., 2012, Mediators of Inflammation, V2012, P846052, DOI 10.1155/2012/846052; D'Avila DA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208133; Guedes PMD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000604; Dutra WO, 2008, CURR OPIN INFECT DIS, V21, P287, DOI 10.1097/QCO.0b013e3282f88b80; Dziedziejko V, 2012, POSTEP HIG MED DOSW, V66, P409, DOI 10.5604/17322693.1000980; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Erdmann H, 2013, IMMUNOBIOLOGY, V218, P910, DOI 10.1016/j.imbio.2012.10.005; Eslick GD, 2009, INT J CARDIOL, V137, P81, DOI 10.1016/j.ijcard.2008.05.017; Esper L, 2014, MICROBES INFECT, V16, P481, DOI 10.1016/j.micinf.2014.03.007; Espinoza JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026229; Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Florez O, 2006, HUM IMMUNOL, V67, P741, DOI 10.1016/j.humimm.2006.06.004; Furucho CR, 2008, TROP MED INT HEALTH, V13, P1527, DOI 10.1111/j.1365-3156.2008.02172.x; Gao WD, 2002, INT J PARASITOL, V32, P167, DOI 10.1016/S0020-7519(01)00322-8; Giannitrapani L, 2011, OMICS, V15, P183, DOI 10.1089/omi.2010.0093; Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0; GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298; Hall SK, 2004, ARTHRITIS RHEUM-US, V50, P1976, DOI 10.1002/art.20310; Hasan FT, 2017, J INFECT DIS MED, V2, P3, DOI [10.4172/2576-1420.1000117, DOI 10.4172/2576-1420.1000117]; Iannello A, 2010, J INFECT DIS, V201, P608, DOI 10.1086/650314; Jurecekova J, 2017, NEOPLASMA, V64, P148, DOI 10.4149/neo_2017_119; Keating SM, 2015, INT J CARDIOL, V199, P451, DOI 10.1016/j.ijcard.2015.07.040; Kim SW, 2011, GUT, V60, P1527, DOI 10.1136/gut.2011.238477; Rodriguez DAL, 2015, GENES IMMUN, V16, P536, DOI 10.1038/gene.2015.42; Rodriguez DAL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004583; Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531; Lopez L, 2006, REV ESP CARDIOL, V59, P50, DOI 10.1157/13083649; Lorente L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111861; Luft T, 2002, J IMMUNOL, V168, P713, DOI 10.4049/jimmunol.168.2.713; Magalhaes LMD, 2013, J INFECT DIS, V207, P661, DOI 10.1093/infdis/jis724; Matos CS, 2014, MEM I OSWALDO CRUZ, V109, P374, DOI 10.1590/0074-0276130385; Guedes PMM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001630; Miyazaki Y, 2010, J IMMUNOL, V185, P1150, DOI 10.4049/jimmunol.0900047; Muller U, 2001, J IMMUNOL, V167, P3346, DOI 10.4049/jimmunol.167.6.3346; Nogueira LG, 2015, CYTOKINE, V73, P79, DOI 10.1016/j.cyto.2015.01.037; Nogueira LG, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/914326; Norman FF, 2011, ANN TROP MED PARASIT, V105, P425, DOI 10.1179/1364859411Y.0000000033; O'Brien LC, 2014, MOL MED, V20, P221, DOI 10.2119/molmed.2014.00034; Okuhara Y, 2017, INT J CARDIOL, V243, P396, DOI 10.1016/j.ijcard.2017.04.082; Petersen CA, 2003, INFECT IMMUN, V71, P4441, DOI 10.1128/IAI.71.8.4441-4447.2003; Dias JCP, 2016, REV SOC BRAS MED TRO, V49, P3, DOI 10.1590/0037-8682-0505-2016; Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813; Rassi A, 2006, NEW ENGL J MED, V355, P799, DOI 10.1056/NEJMoa053241; Reddy VS, 2008, J CELL PHYSIOL, V215, P697, DOI 10.1002/jcp.21348; Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335; Reis PG, 2017, J IMMUNOL RES, V2017, P7, DOI DOI 10.1155/2017/1017621; Rodrigues DBR, 2005, REV SOC BRAS MED TRO, V38, P483, DOI 10.1590/S0037-86822005000600007; Sabino EC, 2015, EUR J HEART FAIL, V17, P416, DOI 10.1002/ejhf.220; Sakai K, 2008, J INFECT DIS, V197, P1752, DOI 10.1086/588196; Samarani S, 2016, CYTOKINE, V82, P38, DOI 10.1016/j.cyto.2016.01.006; Sanchez E, 2009, HUM MOL GENET, V18, P3739, DOI 10.1093/hmg/ddp301; Sangenito LS, 2018, INT J ANTIMICROB AG, V52, P185, DOI 10.1016/j.ijantimicag.2018.03.021; Sangenito LS, 2016, INT J ANTIMICROB AG, V48, P703, DOI 10.1016/j.ijantimicag.2016.09.017; Sangenito LS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113957; Sanmarco LM, 2017, BBA-MOL BASIS DIS, V1863, P857, DOI 10.1016/j.bbadis.2017.01.006; Sartori AMC, 2007, ANN TROP MED PARASIT, V101, P31, DOI 10.1179/136485907X154629; Sedaghat AR, 2009, CLIN INFECT DIS, V49, P1763, DOI 10.1086/648081; SILVA JS, 1993, AM J TROP MED HYG, V49, P589, DOI 10.4269/ajtmh.1993.49.589; Sousa GR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172833; Sousa GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087082; Strauss M, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007859; Talar-Wojnarowska R, 2009, DIGEST DIS SCI, V54, P683, DOI 10.1007/s10620-008-0390-z; de Freitas VLT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001277; Torres OA, 2010, TISSUE ANTIGENS, V76, P131, DOI 10.1111/j.1399-0039.2010.01478.x; Xiao H, 2018, EUR HEART J, V39, P60, DOI 10.1093/eurheartj/ehx261; Zhang L, 1999, J INFECT DIS, V180, P480, DOI 10.1086/314889; Zidan HE, 2015, IMMUNOGENETICS, V67, P665, DOI 10.1007/s00251-015-0876-8; Zingales B, 2012, INFECT GENET EVOL, V12, P240, DOI 10.1016/j.meegid.2011.12.009	92	2	2	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2020	11								521409	10.3389/fimmu.2020.521409	http://dx.doi.org/10.3389/fimmu.2020.521409			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OL5SO	33193300	Green Published, gold			2022-12-18	WOS:000585399700001
J	He, YD; Xu, RN; Zhai, B; Zhou, S; Wang, XQ; Wang, RX				He, Youdi; Xu, Ruonan; Zhai, Bing; Zhou, Shan; Wang, Xiaoqian; Wang, Renxi			Gm614 Protects Germinal Center B Cells From Death by Suppressing Caspase-1 Transcription in Lupus-Prone Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Gm614; lupus; GC B cells; cell death; caspase-1	PRISTANE-INDUCED LUPUS; APOPTOSIS; EXPRESSION	Only a few signaling pathways have been reported in germinal center (GC) B-cell proliferation and death. In this study, we showed that a novel uncharacterized Gm614 protein is highly expressed in GC B cells from lupus-prone mice. Critically, ablation of this GC B-cell-specific Gm614 promoted GC B-cell death and mitigation of autoimmune symptoms, whereas overexpression protected GC B cells from death and exacerbated autoimmune symptoms. We demonstrated that mechanistically, nuclear-localized Gm614 reduced caspase-1 expression in GC B cells by binding with caspase-1 promoter to suppress its activation. Our results suggest that Gm614 protects GC B cells from death by suppressing caspase-1 transcription in autoimmune diseases. This may provide some hints for targeting the cell proliferation involved in autoimmune diseases.	[He, Youdi; Xu, Ruonan; Zhou, Shan; Wang, Renxi] Capital Med Univ, Collaborat Innovat Ctr Brain Disorders, Minist Sci & Technol, Beijing Inst Brain Disorders,Lab Brain Disc, Beijing, Peoples R China; [He, Youdi] Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurol, Beijing, Peoples R China; [Zhai, Bing] Chinese Peoples Liberat Army China Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Nanlou Div, Dept Geriatr Hematol, Beijing, Peoples R China; [Wang, Xiaoqian] Staidson Beijing Biopharmaceut Co Ltd, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Wang, RX (corresponding author), Capital Med Univ, Collaborat Innovat Ctr Brain Disorders, Minist Sci & Technol, Beijing Inst Brain Disorders,Lab Brain Disc, Beijing, Peoples R China.	renxi_wang@ccmu.edu.cn		Wang, Renxi/0000-0003-4130-3334	National Natural Science Foundation of China [82071758, 31770956, 81704151]; Natural Science Foundation of Beijing Municipality [7182121]; Beijing Municipal Commission of Education [KM201710025014]; China Postdoctoral Science Foundation [2019M664000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing Municipality(Beijing Natural Science Foundation); Beijing Municipal Commission of Education(Beijing Municipal Commission of Education); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study was supported by grants from National Natural Science Foundation of China (82071758, 31770956, 81704151), Natural Science Foundation of Beijing Municipality (7182121), Beijing Municipal Commission of Education (KM201710025014), and China Postdoctoral Science Foundation Funded Project (2019M664000).	Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Cassese G, 2001, EUR J IMMUNOL, V31, P2726, DOI 10.1002/1521-4141(200109)31:9<2726::AID-IMMU2726>3.0.CO;2-H; Chandra V, 2015, TRENDS IMMUNOL, V36, P527, DOI 10.1016/j.it.2015.07.003; Christiane S., 2012, SCI CAIRO, V2012, DOI [10.6064/2012/215308, DOI 10.6064/2012/215308]; Chtanova T, 2004, J IMMUNOL, V173, P68, DOI 10.4049/jimmunol.173.1.68; CHU JL, 1993, J EXP MED, V178, P723, DOI 10.1084/jem.178.2.723; Dorner T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3433; Dominguez-Sola D, 2015, IMMUNITY, V43, P1064, DOI 10.1016/j.immuni.2015.10.015; Fang Y, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5848-1; Fillatreau S, 2003, J EXP MED, V197, P195, DOI 10.1084/jem.20021750; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Freitas E, 2017, CLIN RHEUMATOL, V36, P2403, DOI 10.1007/s10067-017-3811-6; Hofmann K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00835; Igarashi K, 2007, J BIOCHEM, V141, P783, DOI 10.1093/jb/mvm106; Incorvaia E, 2013, AUTOIMMUNITY, V46, P128, DOI 10.3109/08916934.2012.748752; Jackson SW, 2016, J EXP MED, V213, P733, DOI 10.1084/jem.20151724; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Leiss H, 2013, LUPUS, V22, P778, DOI 10.1177/0961203313492869; Luzina IG, 2001, J LEUKOCYTE BIOL, V70, P578; Ma N, 2015, CLIN IMMUNOL, V160, P142, DOI 10.1016/j.clim.2015.05.016; Ma N, 2014, CELL IMMUNOL, V289, P140, DOI 10.1016/j.cellimm.2014.03.017; Ma N, 2014, J IMMUNOL, V192, P4192, DOI 10.4049/jimmunol.1302132; Macanovic M, 1996, CLIN EXP IMMUNOL, V106, P243, DOI 10.1046/j.1365-2249.1996.d01-839.x; Melnikov VY, 2002, J CLIN INVEST, V110, P1083, DOI 10.1172/JCI200215623; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Nagata S, 2010, ANN NY ACAD SCI, V1209, P10, DOI 10.1111/j.1749-6632.2010.05749.x; Okazaki Il-mi, 2007, Adv Immunol, V94, P245, DOI 10.1016/S0065-2776(06)94008-5; Recaldin T, 2016, CLIN EXP IMMUNOL, V183, P65, DOI 10.1111/cei.12702; Rieux-Laucat F, 2003, CELL DEATH DIFFER, V10, P124, DOI 10.1038/sj.cdd.4401190; Sander S, 2015, IMMUNITY, V43, P1075, DOI 10.1016/j.immuni.2015.10.021; Sarkar A, 2006, AM J RESP CRIT CARE, V174, P1003, DOI 10.1164/rccm.200604-546OC; Tellier J, 2017, EUR J IMMUNOL, V47, P1276, DOI 10.1002/eji.201747168; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Wang XQ, 2018, MOL MED REP, V17, P1660, DOI 10.3892/mmr.2017.8048; Wang XQ, 2016, MOL IMMUNOL, V71, P54, DOI 10.1016/j.molimm.2016.01.011; Xing C, 2015, J LEUKOCYTE BIOL, V97, P547, DOI 10.1189/jlb.3A0414-213RR; Xu RN, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0635-7; Xu RN, 2010, EUR J IMMUNOL, V40, P1079, DOI 10.1002/eji.200940015; Zhai B, 2020, CLIN TRANSL ONCOL, V22, P1463, DOI 10.1007/s12094-019-02280-y; Zhai B, 2019, LEUKEMIA LYMPHOMA, V60, P2541, DOI 10.1080/10428194.2019.1590572; Zhang Y, 2016, IMMUNOL REV, V270, P8, DOI 10.1111/imr.12396; Zhang Y, 2017, IMMUNOLOGY, V150, P478, DOI 10.1111/imm.12701	44	2	2	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 21	2020	11								585726	10.3389/fimmu.2020.585726	http://dx.doi.org/10.3389/fimmu.2020.585726			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK3QQ	33193409	Green Published, gold			2022-12-18	WOS:000584569000001
J	De Souza, A; Tavora, FA; Mahalingam, D; Munster, PN; Safran, HP; El-Deiry, WS; Carneiro, BA				De Souza, Andre; Tavora, Fabio A.; Mahalingam, Devalingam; Munster, Pamela N.; Safran, Howard P.; El-Deiry, Wafik S.; Carneiro, Benedito A.			Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						glycogen synthase kinase-3 (GSK3); glycogen synthase kinase-3 (GSK-3) inhibitor; COVID; COVID-19; 9-ING-41; GSK-3b inhibitor; GSK-3 inhibitor; SARS-CoV21	CANCER CELLS; SYNTHASE; INJURY		[De Souza, Andre; Safran, Howard P.; El-Deiry, Wafik S.; Carneiro, Benedito A.] Brown Univ, Div Hematol Oncol, Lifespan Canc Inst, Warren Alpert Med Sch, Providence, RI 02912 USA; [Tavora, Fabio A.] Argos Lab, Fortaleza, Ceara, Brazil; [Mahalingam, Devalingam] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA; [Munster, Pamela N.] Univ Calif San Francisco, Dept Med Hematol Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [El-Deiry, Wafik S.] Brown Univ, Dept Pathol & Lab Med, Alpert Med Sch, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Northwestern University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Brown University	Carneiro, BA (corresponding author), Brown Univ, Div Hematol Oncol, Lifespan Canc Inst, Warren Alpert Med Sch, Providence, RI 02912 USA.	benedito_carneiro@brown.edu						CARNEIRO BA, 2020, J CLIN ONCOL S, V38, DOI DOI 10.1200/JCO.2020.38.15_suppl.3507; Cuzzocrea S, 2007, INTENS CARE MED, V33, P880, DOI 10.1007/s00134-007-0595-1; Ding L, 2019, CLIN CANCER RES, V25, P6452, DOI 10.1158/1078-0432.CCR-19-0799; Ducloyer M, 2020, INT J LEGAL MED, V134, P2209, DOI 10.1007/s00414-020-02390-1; Dugo L, 2006, SHOCK, V25, P485, DOI 10.1097/01.shk.0000209545.29671.31; Dugo L, 2005, CRIT CARE MED, V33, P1903, DOI 10.1097/01.CCM.0000178350.21839.44; Hilliard TS, 2011, ANTI-CANCER DRUG, V22, P978, DOI 10.1097/CAD.0b013e32834ac8fc; Huang WC, 2009, IMMUNOLOGY, V128, pe275, DOI 10.1111/j.1365-2567.2008.02959.x; Jeffers A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55176-w; Jellestad L, 2014, EUR J PHARMACOL, V724, P175, DOI 10.1016/j.ejphar.2013.12.029; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Rudd CE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01638; Sahin I, 2019, CANCER BIOL THER, V20, P1047, DOI 10.1080/15384047.2019.1595283; Schwensen HF, 2021, J CLIN PATHOL, V74, P400, DOI 10.1136/jclinpath-2020-206879; Tavora F, 2020, AM ASS CANC RES AACR; Taylor A, 2018, CANCER RES, V78, P706, DOI 10.1158/0008-5472.CAN-17-0491; Taylor A, 2016, IMMUNITY, V44, P274, DOI 10.1016/j.immuni.2016.01.018; Zhang T, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P496, DOI 10.3760/cma.j.cn112147-20200311-00312	18	2	2	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2020	11								595289	10.3389/fimmu.2020.595289	http://dx.doi.org/10.3389/fimmu.2020.595289			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OI4LD	33193448	Green Published, gold			2022-12-18	WOS:000583251300001
J	Hayashi, RJ				Hayashi, Robert J.			Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						transplantation; preparative; childhood and adolescence; hematopoeific stem cells; engrafted survival outcomes	STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; CHRONIC GRANULOMATOUS-DISEASE; SEVERE APLASTIC-ANEMIA; SEVERE COMBINED IMMUNODEFICIENCY; INTENSITY CONDITIONING REGIMEN; ANTI-THYMOCYTE GLOBULIN; TOTAL-BODY IRRADIATION; ANTITHYMOCYTE GLOBULIN	The variables that influence the selection of a preparative regimen for a pediatric hematopoietic stem cell transplant procedure encompasses many issues. When one considers this procedure for non-malignant diseases, components in a preparative regimen that were historically developed to reduce malignant tumor burden may be unnecessary. The primary goal of the procedure in this instance becomes engraftment with the establishment of normal hematopoiesis and a normal immune system. Overcoming rejection becomes the primary priority, but pursuit of this goal cannot neglect organ toxicity, or post-transplant morbidity such as graft-versus-host disease or life threatening infections. With the improvements in supportive care, newborn screening techniques for early disease detection, and the expansion of viable donor sources, we have reached a stage where hematopoietic stem cell transplantation can be considered for virtually any patient with a hematopoietic based disease. Advancing preparative regiments that minimize rejection and transplant related toxicity will thus dictate to what extent this medical technology is fully utilized. This mini-review will provide an overview of the origins of conditioning regimens for transplantation and how agents and techniques have evolved to make hematopoietic stem cell transplantation a viable option for children with non-malignant diseases of the hematopoietic system. We will summarize the current state of this facet of the transplant procedure and describe the considerations that come into play in selecting a particular preparative regimen. Decisions within this realm must tailor the treatment to the primary disease condition to ideally achieve an optimal outcome. Finally, we will project forward where advances are needed to overcome the persistent engraftment obstacles that currently limit the utilization of transplantation for haematopoietically based diseases in children.	[Hayashi, Robert J.] Washington Univ, Sch Med, Div Pediat Hematol Oncol, St Louis, MO 63130 USA	Washington University (WUSTL)	Hayashi, RJ (corresponding author), Washington Univ, Sch Med, Div Pediat Hematol Oncol, St Louis, MO 63130 USA.	hayashi_r@wustl.edu	hayashi, robert james/AAH-2077-2019	hayashi, robert james/0000-0002-1140-1139				AlDawsari G, 2020, BONE MARROW TRANSPL, V55, P1485, DOI 10.1038/s41409-020-0809-5; Aldenhoven M, 2015, BIOL BLOOD MARROW TR, V21, P1106, DOI 10.1016/j.bbmt.2015.02.011; Allen CE, 2018, BLOOD, V132, P1438, DOI 10.1182/blood-2018-01-828277; Anurathapan U, 2020, BIOL BLOOD MARROW TR, V26, P1106, DOI 10.1016/j.bbmt.2020.01.002; Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004; Bae Keun Wook, 2012, Korean J Hematol, V47, P44, DOI 10.5045/kjh.2012.47.1.44; Beam D, 2007, BIOL BLOOD MARROW TR, V13, P665, DOI 10.1016/j.bbmt.2007.01.082; Behfar M, 2019, TURKISH J PEDIATR, V61, P407, DOI 10.24953/turkjped.2019.03.013; Bernardo ME, 2012, BLOOD, V120, P473, DOI 10.1182/blood-2012-04-423822; Bhatt ST, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28030; Bhatt ST, 2019, BIOL BLOOD MARROW TR, V25, P556, DOI 10.1016/j.bbmt.2018.10.008; Boelens JJ, 2007, BONE MARROW TRANSPL, V40, P225, DOI 10.1038/sj.bmt.1705718; Bonfim C, 2016, BIOL BLOOD MARROW TR, V22, P1257, DOI 10.1016/j.bbmt.2016.03.007; Bonifazi F, 2020, BONE MARROW TRANSPL, V55, P1093, DOI 10.1038/s41409-020-0792-x; Boucher AA, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0313-y; Burroughs LM, 2020, BLOOD, V135, P2094, DOI 10.1182/blood.2019002939; Burroughs LM, 2017, BIOL BLOOD MARROW TR, V23, P1669, DOI 10.1016/j.bbmt.2017.06.002; Cappelli B, 2019, HAEMATOLOGICA, V104, pE543, DOI 10.3324/haematol.2019.216788; Cesaro S, 2020, BONE MARROW TRANSPL, V55, P1796, DOI 10.1038/s41409-020-0863-z; Chan AY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00239; Chang YJ, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.00150; Chen Y, 2018, BONE MARROW TRANSPL, V53, P770, DOI 10.1038/s41409-018-0175-8; Choudhary D, 2019, J PEDIAT HEMATOL ONC, V41, pE296, DOI 10.1097/MPH.0000000000001475; Connelly JA, 2018, J PEDIAT INF DIS SOC, V7, pS31, DOI 10.1093/jpids/piy015; Dalal I, 2000, BONE MARROW TRANSPL, V25, P613, DOI 10.1038/sj.bmt.1702215; Darrigo LG, 2019, PEDIATR TRANSPLANT, V23, DOI 10.1111/petr.13552; de Heredia CD, 2008, BONE MARROW TRANSPL, V41, P627, DOI 10.1038/sj.bmt.1705946; Dimitrova D, 2020, BIOL BLOOD MARROW TR, V26, P94, DOI 10.1016/j.bbmt.2019.08.018; Dufour C, 2015, BRIT J HAEMATOL, V169, P565, DOI 10.1111/bjh.13297; Eapen M, 2019, LANCET HAEMATOL, V6, pE585, DOI 10.1016/S2352-3026(19)30154-1; Ebens CL, 2018, BIOL BLOOD MARROW TR, V24, P765, DOI 10.1016/j.bbmt.2017.11.031; ElGohary G, 2020, BONE MARROW TRANSPL, V55, P1906, DOI 10.1038/s41409-020-0897-2; Farzin A, 2007, BRIT J HAEMATOL, V136, P633, DOI 10.1111/j.1365-2141.2006.06460.x; Fioredda F, 2018, BRIT J HAEMATOL, V183, P110, DOI 10.1111/bjh.15495; Gilman AL, 2017, BLOOD ADV, V1, P1215, DOI 10.1182/bloodadvances.2017005462; Gooptu M, 2018, BIOL BLOOD MARROW TR, V24, P2216, DOI 10.1016/j.bbmt.2018.07.002; Goussetis E, 2015, TRANSPL INFECT DIS, V17, P201, DOI 10.1111/tid.12358; Gungor T, 2014, LANCET, V383, P436, DOI [10.1016/s0140-6736(13)62069-3, 10.1016/S0140-6736(13)62069-3]; Gupta A, 2020, BIOL BLOOD MARROW TR, V26, P486, DOI 10.1016/j.bbmt.2019.11.014; Gyurkocza B, 2014, BLOOD, V124, P344, DOI 10.1182/blood-2014-02-514778; Hagen P, 2014, BONE MARROW TRANSPL, V49, P1498, DOI 10.1038/bmt.2014.183; Hamid IJA, 2017, BLOOD, V129, P2198, DOI 10.1182/blood-2016-11-748616; Hansen MD, 2008, BONE MARROW TRANSPL, V41, P349, DOI 10.1038/sj.bmt.1705926; Harris AC, 2018, BLOOD ADV, V2, P1198, DOI 10.1182/bloodadvances.2018016956; Hassan A, 2012, BLOOD, V120, P3615, DOI 10.1182/blood-2011-12-396879; Heimall J, 2017, BLOOD, V130, P2718, DOI 10.1182/blood-2017-05-781849; Henig I, 2014, RAMBAM MAIMONIDES ME, V5, DOI 10.5041/RMMJ.10162; Horan JT, 2015, BIOL BLOOD MARROW TR, V21, P900, DOI 10.1016/j.bbmt.2015.01.015; Hsieh MM, 2014, JAMA-J AM MED ASSOC, V312, P48, DOI 10.1001/jama.2014.7192; Huttunen P, 2020, PEDIATR HEMAT ONCOL, V37, P355, DOI 10.1080/08880018.2020.1738604; Kang HJ, 2016, BIOL BLOOD MARROW TR, V22, P1455, DOI 10.1016/j.bbmt.2016.04.003; Khandelwal P, 2021, TRANSPLANTATION, V105, P891, DOI 10.1097/TP.0000000000003327; King AA, 2015, AM J HEMATOL, V90, P1093, DOI 10.1002/ajh.24183; Kothari A, 2015, BIOL BLOOD MARROW TR, V21, P1321, DOI 10.1016/j.bbmt.2015.03.019; Koura DT, 2013, BIOL BLOOD MARROW TR, V19, P1638, DOI 10.1016/j.bbmt.2013.09.003; Krishnamurti L, 2019, AM J HEMATOL, V94, P446, DOI 10.1002/ajh.25401; Kroger N, 2016, NEW ENGL J MED, V374, P43, DOI 10.1056/NEJMoa1506002; Kumaki S, 2013, INT J HEMATOL, V98, P355, DOI 10.1007/s12185-013-1408-7; Langenhorst JB, 2019, BLOOD ADV, V3, P2179, DOI 10.1182/bloodadvances.2018029421; Lum SH, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0883-1; Lum SH, 2017, BONE MARROW TRANSPL, V52, P846, DOI 10.1038/bmt.2017.5; Lum SH, 2020, BLOOD, V135, P954, DOI 10.1182/blood.2019002690; Luo Y, 2019, BONE MARROW TRANSPL, V54, P1668, DOI 10.1038/s41409-019-0502-8; Maheshwari S, 2014, BONE MARROW TRANSPL, V49, P366, DOI 10.1038/bmt.2013.188; Majhail Navneet S, 2017, Hematol Oncol Stem Cell Ther, V10, P220, DOI 10.1016/j.hemonc.2017.05.009; Mallhi KK, 2020, BIOL BLOOD MARROW TR, V26, P1332, DOI 10.1016/j.bbmt.2020.03.018; Manor U, 2019, IMMUNOL RES, V67, P166, DOI 10.1007/s12026-019-09081-z; Martin HR, 2013, BIOL BLOOD MARROW TR, V19, P616, DOI 10.1016/j.bbmt.2013.01.010; McCune JS, 2002, BONE MARROW TRANSPL, V30, P167, DOI 10.1038/sj.bmt.1703612; Mehta PA, 2017, BLOOD, V129, P2308, DOI 10.1182/blood-2016-09-743112; Mehta RS, 2016, VIRULENCE, V7, P901, DOI 10.1080/21505594.2016.1208866; Mellgren K, 2019, BIOL BLOOD MARROW TR, V25, P2045, DOI 10.1016/j.bbmt.2019.06.018; Mohty M, 2002, Hematology, V7, P157, DOI 10.1080/10245330210000013898; Monaco F, 2019, HAEMATOLOGICA, V104, P1221, DOI 10.3324/haematol.2018.199398; Morecki S, 2001, BONE MARROW TRANSPL, V28, P243, DOI 10.1038/sj.bmt.1703118; Morillo-Gutierrez B, 2016, BLOOD, V128, P440, DOI 10.1182/blood-2016-03-704015; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Nelson AS, 2016, BIOL BLOOD MARROW TR, V22, P884, DOI 10.1016/j.bbmt.2016.01.026; Ngwube A, 2015, PEDIATR BLOOD CANCER, V62, P1270, DOI 10.1002/pbc.25458; Oevermann L, 2019, BONE MARROW TRANSPL, V54, P743, DOI 10.1038/s41409-019-0598-x; Orchard PJ, 2019, BLOOD, V133, P1378, DOI 10.1182/blood-2018-11-887240; Page Kristin M, 2019, Biol Blood Marrow Transplant, V25, pe363, DOI 10.1016/j.bbmt.2019.09.003; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Paix A, 2018, CRIT REV ONCOL HEMAT, V123, P138, DOI 10.1016/j.critrevonc.2018.01.011; Parta M, 2017, J CLIN IMMUNOL, V37, P548, DOI 10.1007/s10875-017-0422-6; Raymond GV, 2019, BIOL BLOOD MARROW TR, V25, P538, DOI 10.1016/j.bbmt.2018.09.036; Rosales F, 1999, BONE MARROW TRANSPL, V23, P861, DOI 10.1038/sj.bmt.1701758; Sabloff M, 2011, BLOOD, V117, P1745, DOI 10.1182/blood-2010-09-306829; Sanders J E, 1999, Pediatr Transplant, V3 Suppl 1, P23; Sauer M, 2009, BONE MARROW TRANSPL, V43, P375, DOI 10.1038/bmt.2008.328; SCHMITZ N, 1988, BLOOD, V72, P1567; Shaw P, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00434; Shenoy S, 2018, BIOL BLOOD MARROW TR, V24, P1216, DOI 10.1016/j.bbmt.2018.01.023; Shenoy S, 2016, BLOOD, V128, P2561, DOI 10.1182/blood-2016-05-715870; Shenoy S, 2016, ANN NY ACAD SCI, V1368, P122, DOI 10.1111/nyas.13019; Shiratori S, 2021, BONE MARROW TRANSPL, V56, P129, DOI 10.1038/s41409-020-0985-3; Simons L, 2019, STEM CELL TRANSL MED, V8, P650, DOI 10.1002/sctm.18-0248; Slatter MA, 2018, BIOL BLOOD MARROW TR, V24, P529, DOI 10.1016/j.bbmt.2017.11.009; Soiffer RJ, 2017, J CLIN ONCOL, V35, P4003, DOI 10.1200/JCO.2017.75.8177; Souillet G, 2003, BONE MARROW TRANSPL, V31, P1105, DOI 10.1038/sj.bmt.1704105; Sun L, 2019, BIOL BLOOD MARROW TR, V25, P1592, DOI 10.1016/j.bbmt.2019.03.028; Svahn J, 2016, AM J HEMATOL, V91, P666, DOI 10.1002/ajh.24373; Szpecht D, 2012, ARCH IMMUNOL THER EX, V60, P225, DOI 10.1007/s00005-012-0174-1; Tan PL, 2006, PEDIATR BLOOD CANCER, V46, P630, DOI 10.1002/pbc.20538; Tang XF, 2020, BONE MARROW TRANSPL, V55, P1875, DOI 10.1038/s41409-020-0864-y; Tolar J, 2008, BONE MARROW TRANSPL, V41, P531, DOI 10.1038/sj.bmt.1705934; Triplett BM, 2012, BIOL BLOOD MARROW TR, V18, P1911, DOI 10.1016/j.bbmt.2012.07.014; Turki AT, 2020, AM J TRANSPLANT, V20, P677, DOI 10.1111/ajt.15642; Tuysuz G, 2019, BIOL BLOOD MARROW TR, V25, P2017, DOI 10.1016/j.bbmt.2019.05.039; van den Broek BTA, 2018, BLOOD ADV, V2, P49, DOI 10.1182/bloodadvances.2017010645; van der Stoep MYEC, 2017, BRIT J HAEMATOL, V179, P772, DOI 10.1111/bjh.14960; Walker I, 2016, LANCET ONCOL, V17, P164, DOI 10.1016/S1470-2045(15)00462-3; Wehr C, 2015, J ALLERGY CLIN IMMUN, V135, P988, DOI 10.1016/j.jaci.2014.11.029; Yoshida N, 2014, HAEMATOLOGICA, V99, P1784, DOI 10.3324/haematol.2014.109355; Yuan JJ, 2017, ONCOTARGET, V8, P10871, DOI 10.18632/oncotarget.14719	115	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 19	2020	11								567423	10.3389/fimmu.2020.567423	http://dx.doi.org/10.3389/fimmu.2020.567423			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OI4LF	33193340	gold, Green Published			2022-12-18	WOS:000583251500001
J	Ricciardi, L; Giurato, G; Memoli, D; Pietrafesa, M; Dal Col, J; Salvato, I; Nigro, A; Vatrella, A; Caramori, G; Casolaro, V; Stellato, C				Ricciardi, Luca; Giurato, Giorgio; Memoli, Domenico; Pietrafesa, Mariagrazia; Dal Col, Jessica; Salvato, Ilaria; Nigro, Annunziata; Vatrella, Alessandro; Caramori, Gaetano; Casolaro, Vincenzo; Stellato, Cristiana			Posttranscriptional Gene Regulatory Networks in Chronic Airway Inflammatory Diseases: In silico Mapping of RNA-Binding Protein Expression in Airway Epithelium	FRONTIERS IN IMMUNOLOGY			English	Article						airway epithelium; chronic inflammation; COPD; posttranscriptional gene regulation; RNA binding proteins; severe asthma	CELL LUNG-CANCER; INITIATION-FACTOR; HELICASE RHAU; G-QUADRUPLEX; TRANSCRIPTION FACTORS; THERAPEUTIC TARGET; NUCLEAR IMPORT; ACTIVATION; COPD; SENESCENCE	Background: Posttranscriptional gene regulation (PTGR) contributes to inflammation through alterations in messenger RNA (mRNA) turnover and translation rates. RNA-binding proteins (RBPs) coordinate these processes but their role in lung inflammatory diseases is ill-defined. We evaluated the expression of a curated list of mRNA-binding RBPs (mRBPs) in selected Gene Expression Omnibus (GEO) transcriptomic databases of airway epithelium isolated from chronic obstructive pulmonary disease (COPD), severe asthma (SA) and matched control subjects, hypothesizing that global changes in mRBPs expression could be used to infer their pathogenetic roles and identify novel disease-related regulatory networks. Methods: A published list of 692 mRBPs [Nat Rev Genet 2014] was searched in GEO datasets originated from bronchial brushings of stable COPD patients (C), smokers (S), non-smokers (NS) controls with normal lung function (n = 6/12/12) (GEO ID: GSE5058) and of (SA) and healthy control (HC) (n = 6/12) (GSE63142). Fluorescence intensity data were extracted and normalized on the medians for fold change (FC) comparisons. FCs were set at >= |1.5| with a false discovery rate (FDR) of <= 0.05. Pearson correlation maps and heatmaps were generated using tMEV tools v4_9_0.45. DNA sequence motifs were searched using PScan-ChIP. Gene Ontology (GO) was performed with Ingenuity Pathway Analysis (IPA) tool. Results: Significant mRBP expression changes were detected for S/NS, COPD/NS and COPD/S (n = 41, 391, 382, respectively). Of those, 32% of genes changed by FC >= |1.5| in S/NS but more than 60% in COPD/NS and COPD/S (n = 13, 267, 257, respectively). Genes were predominantly downregulated in COPD/NS (n = 194, 73%) and COPD/S (n = 202, 79%), less so in S/NS (n = 4, 31%). Unsupervised cluster analysis identified in 4 out of 12 S the same mRBP pattern seen in C, postulating subclinical COPD. Significant DNA motifs enrichment for transcriptional regulation was found for downregulated RBPs. Correlation analysis identified five clusters of co-expressed mRBPs. GO analysis revealed significant enrichments in canonical pathways both specific and shared among comparisons. Unexpectedly, no significant mRBPs modulation was found in SA compared to controls. Conclusions: Airway epithelial mRBPs profiling reveals a COPD-specific global downregulation of RBPs shared by a subset of control smokers, the potential of functional cooperation by coexpressed RBPs and significant impact on relevant pathogenetic pathways in COPD. Elucidation of PTGR in COPD could identify disease biomarkers or pathways for therapeutic targeting.	[Ricciardi, Luca; Giurato, Giorgio; Memoli, Domenico; Pietrafesa, Mariagrazia; Dal Col, Jessica; Nigro, Annunziata; Vatrella, Alessandro; Casolaro, Vincenzo; Stellato, Cristiana] Univ Salerno, Dept Med, Surg & Dent Scuola Med Salernitana, Salerno, Italy; [Salvato, Ilaria; Caramori, Gaetano] Univ Messina, Pulmonol, Dept Biomed Sci Dent & Morphol & Funct Imaging BI, Messina, Italy; [Casolaro, Vincenzo; Stellato, Cristiana] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	University of Salerno; University of Messina; Johns Hopkins University	Stellato, C (corresponding author), Univ Salerno, Dept Med, Surg & Dent Scuola Med Salernitana, Salerno, Italy.; Stellato, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	cstellato@unisa.it	Casolaro, Vincenzo/E-9144-2010; Ricciardi, Luca/AAO-2455-2020	Casolaro, Vincenzo/0000-0001-9810-0488; Dal Col, Jessica/0000-0002-0042-2161; Ricciardi, Luca/0000-0002-0687-6367	Fondazione con il Sud [Brains2South 2015 PDR-0224]; Regione Campania, POR FESR 2014/20 RarePlatNet Project [Az. 1.2, CUP B63D18000380007]; POR Campania FESR 2007-2013-RETE DELLE BIOTECNOLOGIE IN CAMPANIA Project Terapie Innovative di Malattie Infiammatorie croniche, metaboliche, Neoplastiche e Geriatriche - TIMING (University of Salerno, CS); FARB 2018/19 (University of Salerno)	Fondazione con il Sud; Regione Campania, POR FESR 2014/20 RarePlatNet Project; POR Campania FESR 2007-2013-RETE DELLE BIOTECNOLOGIE IN CAMPANIA Project Terapie Innovative di Malattie Infiammatorie croniche, metaboliche, Neoplastiche e Geriatriche - TIMING (University of Salerno, CS); FARB 2018/19 (University of Salerno)	Fondazione con il Sud (Grant: Brains2South 2015 PDR-0224 to JD), Regione Campania, POR FESR 2014/20 RarePlatNet Project (Az. 1.2, CUP B63D18000380007) (to VC), POR Campania FESR 2007-2013-RETE DELLE BIOTECNOLOGIE IN CAMPANIA Project Terapie Innovative di Malattie Infiammatorie croniche, metaboliche, Neoplastiche e Geriatriche - TIMING (University of Salerno, CS); FARB 2018/19 (University of Salerno, VC, and CS).	Abdelmohsen K, 2008, BIOL CHEM, V389, P243, DOI 10.1515/BC.2008.022; Ammous Z, 2008, CHEST, V133, P1344, DOI 10.1378/chest.07-2245; Anantharaman A, 2017, FEBS LETT, V591, P2890, DOI 10.1002/1873-3468.12795; Anderson P, 2010, NAT REV IMMUNOL, V10, P24, DOI 10.1038/nri2685; Antonicka H, 2015, CELL REP, V10, P920, DOI 10.1016/j.celrep.2015.01.030; Arif A, 2009, MOL CELL, V35, P164, DOI 10.1016/j.molcel.2009.05.028; Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2019, AM J RESP CRIT CARE, V200, P556, DOI 10.1164/rccm.201810-1975TR; Barnes PJ, 2017, ANNU REV PHYSIOL, V79, P517, DOI 10.1146/annurev-physiol-022516-034314; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Booy EP, 2012, NUCLEIC ACIDS RES, V40, P4110, DOI 10.1093/nar/gkr1306; Booy EP, 2015, RNA REMODELING PROTE, P125, DOI [10.1007/978-1-4939-2214-7_9, DOI 10.1007/978-1-4939-2214-7_9]; Booy EP, 2014, NUCLEIC ACIDS RES, V42, P3346, DOI 10.1093/nar/gkt1340; Boudhraa Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00345; Carolan BJ, 2006, CANCER RES, V66, P10729, DOI 10.1158/0008-5472.CAN-06-2224; CAVAZZA T, 2016, FRONT CELL DEV BIOL, V3; Chalupnikova K, 2008, J BIOL CHEM, V283, P35186, DOI 10.1074/jbc.M804857200; Chen GF, 2008, P NATL ACAD SCI USA, V105, P4352, DOI 10.1073/pnas.0712276105; Cho SJ, 2010, NUCLEIC ACIDS RES, V38, P2256, DOI 10.1093/nar/gkp1229; Coelho MB, 2015, EMBO J, V34, P653, DOI 10.15252/embj.201489852; Crucs S, 2000, MOL CELL, V5, P457, DOI 10.1016/S1097-2765(00)80440-2; Damianov A, 2016, CELL, V165, P606, DOI 10.1016/j.cell.2016.03.040; Dardenne E, 2014, CELL REP, V7, P1900, DOI 10.1016/j.celrep.2014.05.010; Dardenne E, 2012, NAT STRUCT MOL BIOL, V19, P1139, DOI 10.1038/nsmb.2390; Duclos GE, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw3413; Durham AL, 2015, LUNG CANCER, V90, P121, DOI 10.1016/j.lungcan.2015.08.017; Dutertre M, 2010, CANCER RES, V70, P3760, DOI 10.1158/0008-5472.CAN-09-3988; Fan JS, 2011, J IMMUNOL, V186, P2482, DOI 10.4049/jimmunol.0903634; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Gehring NH, 2017, TRENDS BIOCHEM SCI, V42, P369, DOI 10.1016/j.tibs.2017.02.004; Germann S, 2012, ONCOGENE, V31, P4536, DOI 10.1038/onc.2011.618; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Giri B, 2011, NUCLEIC ACIDS RES, V39, P7161, DOI 10.1093/nar/gkr234; Harashima A, 2010, GENE DEV, V24, P2640, DOI 10.1101/gad.1965010; Hassibi S, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.congress-2019.PA2374; He YW, 2009, CELL MOL LIFE SCI, V66, P1239, DOI 10.1007/s00018-008-8532-1; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Hitti E, 2016, CANCER RES, V76, P4068, DOI 10.1158/0008-5472.CAN-15-3110; Hong S, 2017, J CANCER PREV, V22, P203, DOI 10.15430/JCP.2017.22.4.203; Honig A, 2002, MOL CELL BIOL, V22, P5698, DOI 10.1128/MCB.22.16.5698-5707.2002; Houssaini A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.93203; Howe E, 2010, BIOMEDICAL INFORMATICS FOR CANCER RESEARCH, P267, DOI 10.1007/978-1-4419-5714-6_15; Huang WW, 2012, NUCLEIC ACIDS RES, V40, P1033, DOI 10.1093/nar/gkr849; Ishmael FT, 2008, J IMMUNOL, V180, P8342, DOI 10.4049/jimmunol.180.12.8342; Ishmael FT, 2011, J IMMUNOL, V186, P1189, DOI 10.4049/jimmunol.1001794; Ito K, 2009, CHEST, V135, P173, DOI 10.1378/chest.08-1419; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Jin M, 2018, CHEST, V154, P266, DOI 10.1016/j.chest.2018.05.022; Kapasi P, 2007, MOL CELL, V25, P113, DOI 10.1016/j.molcel.2006.11.028; Kechavarzi B, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r14; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Khabar KSA, 2010, CELL MOL LIFE SCI, V67, P2937, DOI 10.1007/s00018-010-0383-x; Kuo CHS, 2017, AM J RESP CRIT CARE, V195, P443, DOI 10.1164/rccm.201512-2452OC; Lande-Diner L, 2013, P NATL ACAD SCI USA, V110, P16021, DOI 10.1073/pnas.1305980110; Lattmann S, 2011, NUCLEIC ACIDS RES, V39, P9390, DOI 10.1093/nar/gkr630; Lattmann S, 2010, NUCLEIC ACIDS RES, V38, P6219, DOI 10.1093/nar/gkq372; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Lessel D, 2017, AM J HUM GENET, V101, P716, DOI 10.1016/j.ajhg.2017.09.014; Li K, 2017, CANCER LETT, V400, P194, DOI 10.1016/j.canlet.2017.02.029; Li X, 2017, MOL CELL, V67, P214, DOI 10.1016/j.molcel.2017.05.023; Lin C, 2014, ONCOTARGETS THER, V7, P315, DOI 10.2147/OTT.S57023; Lu JY, 2006, GENE DEV, V20, P3174, DOI 10.1101/gad.1467606; Martinez-Nunez RT, 2018, J IMMUNOL, V201, P251, DOI 10.4049/jimmunol.1701798; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; Meier M, 2013, J BIOL CHEM, V288, P35014, DOI 10.1074/jbc.M113.512970; Mercado N, 2015, THORAX, V70, P482, DOI 10.1136/thoraxjnl-2014-206084; Migneault Francis, 2019, Cell Physiol Biochem, V52, P984, DOI 10.33594/000000068; Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC; Mooney SM, 2010, J BIOL CHEM, V285, P30443, DOI 10.1074/jbc.M110.143792; Mooney SM, 2010, BIOCHEMISTRY-US, V49, P1, DOI 10.1021/bi901263m; Moore AE, 2014, WIRES RNA, V5, P549, DOI 10.1002/wrna.1230; Morchikh M, 2017, MOL CELL, V67, P387, DOI 10.1016/j.molcel.2017.06.020; Mukhopadhyay R, 2009, TRENDS BIOCHEM SCI, V34, P324, DOI 10.1016/j.tibs.2009.03.004; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; Nakamura H, 2011, MOL CELL BIOL, V31, P1997, DOI 10.1128/MCB.01424-10; Newman M, 2017, J MOL BIOL, V429, P3121, DOI 10.1016/j.jmb.2016.11.033; Nie JW, 2015, CELL REP, V13, P723, DOI 10.1016/j.celrep.2015.09.043; Ning JF, 2013, ONCOL RES, V21, P67, DOI 10.3727/096504013X13747716581417; Nyati KK, 2020, TRENDS IMMUNOL, V41, P255, DOI 10.1016/j.it.2020.01.004; Oliveros J. C., 2015, VENNY INTERACTIVE TO; Paci P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60228-7; Patial S, 2016, TRENDS PHARMACOL SCI, V37, P811, DOI 10.1016/j.tips.2016.07.002; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Pon JR, 2016, ONCOTARGET, V7, P2297, DOI 10.18632/oncotarget.6223; Pont AR, 2012, MOL CELL, V47, P5, DOI 10.1016/j.molcel.2012.04.019; Rahman MA, 2013, SCI REP-UK, V3, DOI 10.1038/srep02931; Ravi A, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00547-2019; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; Ricciardi L, 2018, INT J CHRONIC OBSTR, V13, P3173, DOI 10.2147/COPD.S166284; Rishi AK, 2003, J BIOL CHEM, V278, P33422, DOI 10.1074/jbc.M303173200; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Samaan S, 2014, NUCLEIC ACIDS RES, V42, P2197, DOI 10.1093/nar/gkt1216; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Sauer M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10432-5; Seo WY, 2013, NUCLEIC ACIDS RES, V41, P8526, DOI 10.1093/nar/gkt644; Sexton AN, 2011, MOL CELL BIOL, V31, P736, DOI 10.1128/MCB.01033-10; Sharma DK, 2016, J NUCLEIC ACIDS, V2016, DOI 10.1155/2016/8235121; Shin S, 2007, J CELL BIOCHEM, V101, P1252, DOI 10.1002/jcb.21250; Shishkin SS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030745; Skibinski DAG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36703-7; Stellato C, 2007, J ALLERGY CLIN IMMUN, V120, P1247, DOI 10.1016/j.jaci.2007.10.041; Stelzer G, 2016, CURR PROTOC BIOINFOR, V54, p1 30 31, DOI [10.1002/cpbi.5, DOI 10.1002/CPBI.5]; Sun Y, 2006, NUCLEIC ACIDS RES, V34, P6314, DOI 10.1093/nar/gkl914; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Teplova M, 2015, Q REV BIOPHYS, V49, DOI 10.1017/S0033583515000207; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7; USMANI O, 2018, RESP RES, V19; Vaughn JP, 2005, J BIOL CHEM, V280, P38117, DOI 10.1074/jbc.C500348200; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang IX, 2013, CELL REP, V5, P849, DOI 10.1016/j.celrep.2013.10.002; Wang ZH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138780; Yamaguchi A, 2016, SCI REP, V6, P1, DOI DOI 10.1038/srep35195; Zambelli F, 2013, NUCLEIC ACIDS RES, V41, pW535, DOI 10.1093/nar/gkt448; Zhang QS, 2006, RNA, V12, P1116, DOI 10.1261/rna.58806; Zhang W, 2016, J CELL SCI, V129, P4025, DOI 10.1242/jcs.192096; Zuo WL, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01442-9	121	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 16	2020	11								579889	10.3389/fimmu.2020.579889	http://dx.doi.org/10.3389/fimmu.2020.579889			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OL8VU	33178205	Green Published, gold			2022-12-18	WOS:000585610900001
J	Chen, LF; Chi, HB; Kinashi, T				Chen, Lanfen; Chi, Hongbo; Kinashi, Tatsuo			Editorial: Hippo Signaling in the Immune System	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Hippo signaling; immune response; MST1/2 kinases; YAP/TAZ; NDR1/2			[Chen, Lanfen] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Chi, Hongbo] St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Kinashi, Tatsuo] Kansai Med Univ, Inst Biomed Sci, Dept Mol Genet, Hirakata, Osaka, Japan	Xiamen University; St Jude Children's Research Hospital; Kansai Medical University	Chen, LF (corresponding author), Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.; Chi, HB (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.; Kinashi, T (corresponding author), Kansai Med Univ, Inst Biomed Sci, Dept Mol Genet, Hirakata, Osaka, Japan.	chenlanfen@xmu.edu.cn; hongbo.chi@stjude.org; kinashi@takii.kmu.ac.jp	Chi, Hongbo/M-9397-2018	Chi, Hongbo/0000-0002-9997-2496	National Key R&D Program of China [2017YFA0504502]; National Natural Science Foundation of China [8192506, 81830046, U1905208]; National Institutes of Health [AI140761, AI105887]; Ministry of Education, Science, Sport, and Culture of Japan [15K21524, 19H03229, 22111003]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Education, Science, Sport, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	LC was supported by grants from National Key R&D Program of China (2017YFA0504502) and The National Natural Science Foundation of China (8192506, 81830046, U1905208). HC was supported by National Institutes of Health grants (AI140761 and AI105887). TK was supported by Grant-in Aid for Scientific Research (15K21524, 19H03229), Grant-in-Aid on Innovattive Areas (22111003) from the Ministry of Education, Science, Sport, and Culture of Japan.		0	2	2	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2020	11								587514	10.3389/fimmu.2020.587514	http://dx.doi.org/10.3389/fimmu.2020.587514			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK0WT	33163003	Green Published, gold			2022-12-18	WOS:000584374100001
J	Kumarasingha, R; Ioannidis, LJ; Abeysekera, W; Studniberg, S; Wijesurendra, D; Mazhari, R; Poole, DP; Mueller, I; Schofield, L; Hansen, DS; Eriksson, EM				Kumarasingha, Rasika; Ioannidis, Lisa J.; Abeysekera, Waruni; Studniberg, Stephanie; Wijesurendra, Dinidu; Mazhari, Ramin; Poole, Daniel P.; Mueller, Ivo; Schofield, Louis; Hansen, Diana S.; Eriksson, Emily M.			Transcriptional Memory-Like Imprints and Enhanced Functional Activity in gamma delta T Cells Following Resolution of Malaria Infection	FRONTIERS IN IMMUNOLOGY			English	Article						RNA-Seq; memory; Plasmodium; chabaudi; &#947; &#948; T cell	PLASMODIUM-CHABAUDI MALARIA; IMMUNE-RESPONSE; ALPHA-BETA; MEDIATED-IMMUNITY; CLINICAL MALARIA; NK CELLS; CD4(+); DIFFERENTIATION; INTERLEUKIN-17; PARASITEMIA	gamma delta T cells play an essential role in the immune response to many pathogens, including Plasmodium. However, long-lasting effects of infection on the gamma delta T cell population still remain inadequately understood. This study focused on assessing molecular and functional changes that persist in the gamma delta T cell population following resolution of malaria infection. We investigated transcriptional changes and memory-like functional capacity of malaria pre-exposed gamma delta T cells using a Plasmodium chabaudi infection model. We show that multiple genes associated with effector function (chemokines, cytokines and cytotoxicity) and antigen-presentation were upregulated in P. chabaudi-exposed gamma delta T cells compared to gamma delta T cells from naive mice. This transcriptional profile was positively correlated with profiles observed in conventional memory CD8(+) T cells and was accompanied by enhanced reactivation upon secondary encounter with Plasmodium-infected red blood cells in vitro. Collectively our data demonstrate that Plasmodium exposure result in "memory-like imprints" in the gamma delta T cell population and also promotes gamma delta T cells that can support antigen-presentation during subsequent infections.	[Kumarasingha, Rasika; Ioannidis, Lisa J.; Abeysekera, Waruni; Studniberg, Stephanie; Wijesurendra, Dinidu; Mazhari, Ramin; Mueller, Ivo; Schofield, Louis; Hansen, Diana S.; Eriksson, Emily M.] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Kumarasingha, Rasika; Ioannidis, Lisa J.; Abeysekera, Waruni; Studniberg, Stephanie; Wijesurendra, Dinidu; Mazhari, Ramin; Mueller, Ivo; Hansen, Diana S.; Eriksson, Emily M.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Poole, Daniel P.] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, Parkville, Vic, Australia; [Schofield, Louis] James Cook Univ, Sch Vet & Biomed Sci, Townsville, Qld, Australia; [Schofield, Louis] James Cook Univ, Australian Inst Trop Hlth & Med, Smithfield, Qld, Australia	Walter & Eliza Hall Institute; University of Melbourne; Monash University; James Cook University; James Cook University	Eriksson, EM (corresponding author), Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.; Eriksson, EM (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.	eriksson@wehi.edu.au	Poole, Daniel/AET-6645-2022	Poole, Daniel/0000-0002-6168-8422	NHMRC [APP106722]; NHMRC Senior Research Fellowship [1043345]	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by NHMRC grant APP106722 (EE). This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. IM is supported by an NHMRC Senior Research Fellowship (#1043345). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brandes M, 2005, SCIENCE, V309, P264, DOI 10.1126/science.1110267; Brugat T, 2014, CELL MICROBIOL, V16, P687, DOI 10.1111/cmi.12212; D'Ombrain MC, 2008, CLIN INFECT DIS, V47, P1380, DOI 10.1086/592971; D'Ombrain MC, 2007, EUR J IMMUNOL, V37, P1864, DOI 10.1002/eji.200636889; Davey MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04076-0; Guenot M, 2015, INFECT IMMUN, V83, P3816, DOI 10.1128/IAI.00446-15; Hamada S, 2008, J IMMUNOL, V181, P3456, DOI 10.4049/jimmunol.181.5.3456; Hernandez-Castaneda MA, 2020, J IMMUNOL, V204, P1798, DOI 10.4049/jimmunol.1900725; Hoft DF, 1998, J IMMUNOL, V161, P1045; Howard J, 2017, J INFECT DIS, V215, P1569, DOI 10.1093/infdis/jix149; Jagannathan P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10624-3; Jagannathan P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009793; Jensen KDC, 2008, IMMUNITY, V29, P90, DOI 10.1016/j.immuni.2008.04.022; Kobayashi F, 2007, EXP PARASITOL, V117, P368, DOI 10.1016/j.exppara.2007.05.002; Kopac J, 1999, INFECT IMMUN, V67, P57, DOI 10.1128/IAI.67.1.57-63.1999; Kreslavsky T, 2009, P NATL ACAD SCI USA, V106, P12453, DOI 10.1073/pnas.0903895106; Kumarasingha R, 2020, BIORXIV, P0505078717, DOI [10.1101/2020.05.05.078717, DOI 10.1101/2020.05.05.078717]; LANGHORNE J, 1995, INT IMMUNOL, V7, P1005, DOI 10.1093/intimm/7.6.1005; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Malhotra N, 2013, IMMUNITY, V38, P681, DOI 10.1016/j.immuni.2013.01.010; Mamedov MR, 2018, IMMUNITY, V48, P350, DOI 10.1016/j.immuni.2018.01.009; McCarthy DJ, 2009, BIOINFORMATICS, V25, P765, DOI 10.1093/bioinformatics/btp053; Medeiros MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081409; Melandri D, 2018, NAT IMMUNOL, V19, P1352, DOI 10.1038/s41590-018-0253-5; Melichar HJ, 2007, SCIENCE, V315, P230, DOI 10.1126/science.1135344; Murphy AG, 2014, J IMMUNOL, V192, P3697, DOI 10.4049/jimmunol.1303420; ODONOVAN SM, 1993, J EUKARYOT MICROBIOL, V40, P152, DOI 10.1111/j.1550-7408.1993.tb04896.x; Phipson B, 2016, ANN APPL STAT, V10, P946, DOI 10.1214/16-AOAS920; Pitard V, 2008, BLOOD, V112, P1317, DOI 10.1182/blood-2008-01-136713; Ribeiro S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00015; Ribot JC, 2012, J IMMUNOL, V189, P1202, DOI 10.4049/jimmunol.1200268; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Russ BE, 2014, IMMUNITY, V41, P853, DOI 10.1016/j.immuni.2014.11.001; Ryan-Payseur B, 2012, J IMMUNOL, V189, P1285, DOI 10.4049/jimmunol.1200641; Schofield L, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0883-8; Schroeder JT, 2008, J ALLERGY CLIN IMMUN, V121, P486, DOI 10.1016/j.jaci.2007.09.049; Seixas E, 2002, PARASITE IMMUNOL, V24, P131, DOI 10.1046/j.1365-3024.2002.00446.x; Seixas EMG, 1999, J IMMUNOL, V162, P2837; Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819; Sheridan BS, 2013, IMMUNITY, V39, P184, DOI 10.1016/j.immuni.2013.06.015; Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466; Simonian PL, 2006, J IMMUNOL, V177, P4436, DOI 10.4049/jimmunol.177.7.4436; Stanisic DI, 2014, J INFECT DIS, V210, P295, DOI 10.1093/infdis/jiu083; Sun JC, 2010, IMMUNOL REV, V236, P83, DOI 10.1111/j.1600-065X.2010.00900.x; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Tan ACL, 2012, ANTIVIR RES, V94, P168, DOI 10.1016/j.antiviral.2012.03.009; Teirlinck AC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002389; TSUJI M, 1994, P NATL ACAD SCI USA, V91, P345, DOI 10.1073/pnas.91.1.345; Tyler CJ, 2017, J IMMUNOL, V198, P3417, DOI 10.4049/jimmunol.1700003; Uematsu S, 2006, NAT IMMUNOL, V7, P868, DOI 10.1038/ni1362; van der Heyde HC, 2006, INFECT IMMUN, V74, P2717, DOI 10.1128/IAI.74.5.2717-2725.2006; VANDERHEYDE HC, 1995, J IMMUNOL, V154, P3985; Weidanz WP, 2010, INFECT IMMUN, V78, P4331, DOI 10.1128/IAI.00539-10; Weidanz WP, 1999, J IMMUNOL, V162, P7383; Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401; Yanez DM, 1999, INFECT IMMUN, V67, P446; Zaidi I, 2018, J IMMUNOL, V200, P1533, DOI 10.4049/jimmunol.1701799	63	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2020	11								582358	10.3389/fimmu.2020.582358	http://dx.doi.org/10.3389/fimmu.2020.582358			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK1OS	33154754	Green Published, Green Submitted, Green Accepted, gold			2022-12-18	WOS:000584421700001
J	Yasumura, J; Shimizu, M; Toma, T; Yashiro, M; Yachie, A; Okada, S				Yasumura, Junko; Shimizu, Masaki; Toma, Tomoko; Yashiro, Masato; Yachie, Akihiro; Okada, Satoshi			Clinical Significance of Serum Soluble TNF Receptor I/II Ratio for the Differential Diagnosis of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome From Other Autoinflammatory Diseases	FRONTIERS IN IMMUNOLOGY			English	Article						familial Mediterranean fever; Kawasaki disease (KD); soluble tumor necrosis factor receptor; systemic juvenile idiopathic arthritis (sJIA); tumor necrosis factor receptor associated periodic syndrome (TRAPS)	JUVENILE IDIOPATHIC ARTHRITIS; WILD-TYPE; FEVER; MUTANTS	Objectives: Genetic analysis of TNFRSF1A can confirm the diagnosis of tumor necrosis factor receptor-associated periodic syndrome (TRAPS), but interpretation of the pathogenesis of variants of unknown significance is sometimes required. The aim of this study was to evaluate the clinical significance of serum soluble tumor necrosis factor receptor type I (sTNFR-I)/II ratio to differentiate TRAPS from other autoinflammatory diseases. Methods: Serum sTNFR-I and sTNFR-II levels were measured using an enzyme-linked immunosorbent assay in patients with TRAPS (n = 5), familial Mediterranean fever (FMF) (n = 14), systemic juvenile idiopathic arthritis (s-JIA) (n = 90), and Kawasaki disease (KD) (n = 37) in the active and inactive phase, along with healthy controls (HCs) (n = 18). Results: In the active phase, the serum sTNFR-I/II ratio in patients with s-JIA, KD, and FMF was significantly elevated compared with that in HCs, whereas it was not elevated in patients with TRAPS. In the inactive phase, the serum sTNFR-I/II ratio in patients with s-JIA and FMF was significantly higher compared with that in HCs, and the ratio was lower in TRAPS patients than in patients with s-JIA and FMF. Conclusions: Low serum sTNFR-I/II ratio in the active and inactive phase might be useful for the differential diagnosis of TRAPS and other autoinflammatory diseases.	[Yasumura, Junko; Okada, Satoshi] Hiroshima Univ, Dept Pediat, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Shimizu, Masaki; Toma, Tomoko; Yachie, Akihiro] Kanazawa Univ, Grad Sch Med Sci, Dept Pediat, Kanazawa, Ishikawa, Japan; [Yashiro, Masato] Okayama Univ Hosp, Dept Pediat, Okayama, Japan; [Shimizu, Masaki] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Child Hlth & Dev, Tokyo, Japan	Hiroshima University; Kanazawa University; Okayama University; Tokyo Medical & Dental University (TMDU)	Yasumura, J (corresponding author), Hiroshima Univ, Dept Pediat, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan.	junko-ma562@hiroshima-u.ac.jp	Okada, Satoshi/B-8901-2011	Okada, Satoshi/0000-0002-4622-5657				Dickie LJ, 2012, ANN RHEUM DIS, V71, P2035, DOI 10.1136/annrheumdis-2011-201197; DIEZRUIZ A, 1995, EUR J HAEMATOL, V54, P1, DOI 10.1111/j.1600-0609.1995.tb01618.x; Lobito AA, 2006, BLOOD, V108, P1320, DOI 10.1182/blood-2005-11-006783; Manki Akira, 2006, Allergol Int, V55, P337, DOI 10.2332/allergolint.55.337; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Newburger JW, 2004, PEDIATRICS, V114, P1708, DOI 10.1542/peds.2004-2182; Petty RE, 2004, J RHEUMATOL, V31, P390; Rebelo SL, 2006, ARTHRITIS RHEUM-US, V54, P2674, DOI 10.1002/art.21964; Shimizu M, 2010, RHEUMATOLOGY, V49, P1645, DOI 10.1093/rheumatology/keq133; Simon A, 2010, P NATL ACAD SCI USA, V107, P9801, DOI 10.1073/pnas.0914118107; Turner MD, 2012, BIOSCIENCE REP, V32, P105, DOI 10.1042/BSR20110089; Yasumura J, 2016, MOD RHEUMATOL, V26, P798, DOI 10.3109/14397595.2014.924894; Yousaf N, 2005, ARTHRITIS RHEUM-US, V52, P2906, DOI 10.1002/art.21268; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040	14	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2020	11								576152	10.3389/fimmu.2020.576152	http://dx.doi.org/10.3389/fimmu.2020.576152			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OK1BR	33162992	Green Submitted, gold, Green Published			2022-12-18	WOS:000584387200001
J	Johnson, BZ; McAlister, S; McGuire, HM; Palanivelu, V; Stevenson, A; Richmond, P; Palmer, DJ; Metcalfe, J; Prescott, SL; Wood, FM; de St Groth, BF; Linden, MD; Fear, MW; Fear, VS				Johnson, Blair Z.; McAlister, Sonia; McGuire, Helen M.; Palanivelu, Vetrichevvel; Stevenson, Andrew; Richmond, Peter; Palmer, Debra J.; Metcalfe, Jessica; Prescott, Susan L.; Wood, Fiona M.; Fazekas de St Groth, Barbara; Linden, Matthew D.; Fear, Mark W.; Fear, Vanessa S.			Pediatric Burn Survivors Have Long-Term Immune Dysfunction With Diminished Vaccine Response (vol 11, 1481, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						non-severe burn injury; immunity; vaccination; mass cytometry; acute trauma; systemic			[Johnson, Blair Z.; Palanivelu, Vetrichevvel; Stevenson, Andrew; Linden, Matthew D.; Fear, Mark W.] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia; [McAlister, Sonia; Richmond, Peter; Palmer, Debra J.; Metcalfe, Jessica; Prescott, Susan L.; Wood, Fiona M.] Univ Western Australia, Sch Med, Perth, WA, Australia; [McAlister, Sonia; Richmond, Peter] Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, Perth, WA, Australia; [McGuire, Helen M.; Fazekas de St Groth, Barbara] Univ Sydney, Ramaciotti Facil Human Syst Biol, Sydney, NSW, Australia; [McGuire, Helen M.; Fazekas de St Groth, Barbara] Univ Sydney, Charles Perkins Ctr, Discipline Pathol, Sydney, NSW, Australia; [Palmer, Debra J.; Metcalfe, Jessica; Prescott, Susan L.] Telethon Kids Inst, Ctr Allergy & Immunol Res, Perth, WA, Australia; [Wood, Fiona M.] Dept Hlth WA, Perth, WA, Australia; [Fear, Vanessa S.] Telethon Kids Inst, Genet & Rare Dis, Perth, WA, Australia	University of Western Australia; University of Western Australia; Telethon Kids Institute; Wesfarmers Limited; University of Sydney; University of Sydney; Telethon Kids Institute; Telethon Kids Institute	Fear, MW (corresponding author), Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.	mark@fionawoodfoundation.com	Fear, Vanessa S/AAF-9805-2020; Fear, Mark/H-9170-2014; Richmond, Peter C/G-3379-2012	Fear, Vanessa S/0000-0001-8363-6685; Richmond, Peter C/0000-0001-7562-7228; McGuire, Helen/0000-0003-2047-6543				Johnson BZ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01481	1	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 9	2020	11								598646	10.3389/fimmu.2020.598646	http://dx.doi.org/10.3389/fimmu.2020.598646			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OF3AH	33163008	Green Published, gold			2022-12-18	WOS:000581084600001
J	Ullah, I; Bibi, S; Ul Haq, I; Safia; Ullah, K; Ge, L; Shi, XT; Bin, M; Niu, HX; Tian, JH; Zhu, BD				Ullah, Inayat; Bibi, Shaheen; Ul Haq, Ijaz; Safia; Ullah, Kifayat; Ge, Long; Shi, Xintong; Bin, Ma; Niu, Hongxia; Tian, Jinhui; Zhu, Bingdong			The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01(E) and MVA85A	FRONTIERS IN IMMUNOLOGY			English	Review						subunit vaccine; tuberculosis; M72; AS01(E); MVA85A; immunogenicity; safety; systematic review; meta-analysis	T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS; HEALTHY-ADULTS; PHASE-II; BCG; IMMUNITY; VACCINATION; PROTECTION; CD4(+); TRIAL	Background: Tuberculosis (TB) is a severe infectious disease with devastating effects on global public health. No TB vaccine has yet been approved for use on latent TB infections and healthy adults. In this study, we performed a systematic review and meta-analysis to evaluate the immunogenicity and safety of the M72/AS01(E) and MVA85A subunit vaccines. The M72/AS01(E) is a novel peptide-based vaccine currently in progress, which may increase the protection level against TB infection. The MVA85A was a viral vector-based TB subunit vaccine being used in the clinical trials. The vaccines mentioned above have been studied in various phase I/II clinical trials. Immunogenicity and safety is the first consideration for TB vaccine development. Methods: The PubMed, Embase, and Cochrane Library databases were searched for published studies (until October 2019) to find out information on the M72/AS01(E) and MVA85A candidate vaccines. The meta-analysis was conducted by applying the standard methods and processes established by the Cochrane Collaboration. Results: Five eligible randomized clinical trials (RCTs) were selected for the meta-analysis of M72/AS01E candidate vaccines. The analysis revealed that the M72/AS01E subunit vaccine had an abundance of polyfunctional M72-specific CD4+ T cells [standardized mean difference (SMD) = 2.37] in the vaccine group versus the control group, the highest seropositivity rate [relative risk (RR) = 5.09]. The M72/AS01E vaccinated group were found to be at high risk of local injection site redness (RR = 2.64), headache (RR = 1.59), malaise (RR = 3.55), myalgia (RR = 2.27), fatigue (RR = 2.16), pain (RR = 3.99), swelling (RR = 5.09), and fever (RR = 2.04) compared to the control groups. The incidences of common adverse events of M72/AS01E were local injection site redness, headache, malaise, myalgia, fatigue, pain, swelling, fever, etc. Six eligible RCTs were selected for the meta-analysis on MVA85A candidate vaccines. The analysis revealed that the subunit vaccine MVA85A had a higher abundance of overall pooled proportion polyfunctional MVA85A-specific CD4+ T cells SMD = 2.41 in the vaccine group vs. the control group, with the highest seropositivity rate [estimation rate (ER) = 0.55]. The MVA85A vaccinated group were found to be at high risk of local injection site redness (ER = 0.55), headache (ER = 0.40), malaise (ER = 0.29), pain (ER = 0.54), myalgia (ER = 0.31), and fever (ER = 0.20). The incidences of common adverse events of MVA85A were local injection site redness, headache, malaise, pain, myalgia, fever, etc. Conclusion: The M72/AS01(E) and MVA85A vaccines against TB are safe and had immunogenicity in diverse clinical trials. The M72/AS01(E) and MVA85A vaccines are associated with a mild adverse reaction. The meta-analysis on immunogenicity and safety of M72/AS01(E) and MVA85A vaccines provides useful information for the evaluation of available subunit vaccines in the clinic.	[Ullah, Inayat; Bibi, Shaheen; Shi, Xintong; Niu, Hongxia; Zhu, Bingdong] Lanzhou Univ, Lanzhou Ctr TB Res, Sch Basic Med Sci, Lanzhou, Peoples R China; [Ullah, Inayat; Bibi, Shaheen; Shi, Xintong; Niu, Hongxia; Zhu, Bingdong] Lanzhou Univ, Inst Pathogen Biol, Sch Basic Med Sci, Lanzhou, Peoples R China; [Ullah, Inayat; Bibi, Shaheen; Shi, Xintong; Bin, Ma; Niu, Hongxia; Tian, Jinhui; Zhu, Bingdong] Lanzhou Univ, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Lanzhou, Peoples R China; [Bibi, Shaheen] Northwest Normal Univ, Sch Life Sci, Lanzhou, Peoples R China; [Ul Haq, Ijaz] Northwest Normal Univ, Coll Chem & Chem Engn, Lanzhou, Peoples R China; [Safia] KMU, Hayatabad Med Complex, Pakistan Inst Community Ophthalmol PICO, Peshawar, Pakistan; [Ullah, Kifayat] COMSATS Univ Islamabad, Dept Biosci, Islamabad, Pakistan; [Ge, Long] Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China	Lanzhou University; Lanzhou University; Lanzhou University; Northwest Normal University - China; Northwest Normal University - China; COMSATS University Islamabad (CUI); Lanzhou University	Zhu, BD (corresponding author), Lanzhou Univ, Lanzhou Ctr TB Res, Sch Basic Med Sci, Lanzhou, Peoples R China.; Zhu, BD (corresponding author), Lanzhou Univ, Inst Pathogen Biol, Sch Basic Med Sci, Lanzhou, Peoples R China.; Tian, JH; Zhu, BD (corresponding author), Lanzhou Univ, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Lanzhou, Peoples R China.	tjh996@163.com; bdzhu@lzu.edu.cn			National Major Science and Technology Projects [2018ZX10731301-004-004]; program of Gansu Provincial Key Laboratory of Evidence Based Medicine and Clinical Translation [20150105]; Fundamental Research Funds for the Central Universities [lzujbky-2018-85]	National Major Science and Technology Projects; program of Gansu Provincial Key Laboratory of Evidence Based Medicine and Clinical Translation; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Major Science and Technology Projects (2018ZX10731301-004-004). It also got the support the program of Gansu Provincial Key Laboratory of Evidence Based Medicine and Clinical Translation (20150105) and the Fundamental Research Funds for the Central Universities (lzujbky-2018-85).	Allie N, 2013, SCI REP-UK, V3, DOI 10.1038/srep01809; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Day CL, 2013, AM J RESP CRIT CARE, V188, P492, DOI 10.1164/rccm.201208-1385OC; Dendouga N, 2012, VACCINE, V30, P3126, DOI 10.1016/j.vaccine.2012.01.088; Dillon DC, 1999, INFECT IMMUN, V67, P2941, DOI 10.1128/IAI.67.6.2941-2950.1999; Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134; Farham BJCME, 2011, CONT MED ED, V29, P481; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Garber DA, 2012, J VIROL, V86, P12605, DOI 10.1128/JVI.00246-12; Ge MQ, 2012, J IMMUNOL, V189, P2099, DOI 10.4049/jimmunol.1103474; Gideon HP, 2011, IMMUNOL RES, V50, P202, DOI 10.1007/s12026-011-8229-7; Gillard P, 2016, TUBERCULOSIS, V100, P118, DOI 10.1016/j.tube.2016.07.005; Glatman-Freedman A, 2006, TUBERCULOSIS, V86, P191, DOI 10.1016/j.tube.2006.01.008; Hawkridge T, 2008, J INFECT DIS, V198, P544, DOI 10.1086/590185; Higgins J, 2008, COCHRANE HDB SYSTEMA, P187, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Idoko OT, 2014, TUBERCULOSIS, V94, P564, DOI 10.1016/j.tube.2014.07.001; Kagina BMN, 2010, AM J RESP CRIT CARE, V182, P1073, DOI 10.1164/rccm.201003-0334OC; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Knoop KA, 2009, J IMMUNOL, V183, P5738, DOI 10.4049/jimmunol.0901563; Kumarasamy N, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000013120, 10.1097/md.0000000000013120]; Kumarasamy N, 2016, MEDICINE, V95, P1, DOI 10.1097/MD.0000000000002459; Leroux-Roels I, 2013, VACCINE, V31, P2196, DOI 10.1016/j.vaccine.2012.05.035; Lewinsohn DA, 2011, IMMUNOL REV, V240, P25, DOI 10.1111/j.1600-065X.2010.00997.x; Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; LIVINGSTON PO, 1994, VACCINE, V12, P1275, DOI 10.1016/S0264-410X(94)80052-2; Lyadova IV, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/854507; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394; Minassian AM, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000223; Moncunill G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01008; Montoya J, 2013, J CLIN IMMUNOL, V33, P1360, DOI 10.1007/s10875-013-9949-3; Mueller H, 2008, CYTOKINE, V43, P143, DOI 10.1016/j.cyto.2008.05.002; Ndiaye BP, 2015, LANCET RESP MED, V3, P190, DOI 10.1016/S2213-2600(15)00037-5; Nowak A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005353; Ota MOC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002461; Pathan AA, 2012, VACCINE, V30, P5616, DOI 10.1016/j.vaccine.2012.06.084; Pathan AA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001052; Penn-Nicholson A, 2015, VACCINE, V33, P4025, DOI 10.1016/j.vaccine.2015.05.088; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; Phuah JY, 2012, AM J PATHOL, V181, P508, DOI 10.1016/j.ajpath.2012.05.009; PIC AYPICJD, 2011, U FAC DET PAG DU WEB; Sander CR, 2009, AM J RESP CRIT CARE, V179, P724, DOI 10.1164/rccm.200809-1486OC; Satti I, 2014, LANCET INFECT DIS, V14, P939, DOI 10.1016/S1473-3099(14)70845-X; Scriba TJ, 2011, J INFECT DIS, V203, P1832, DOI 10.1093/infdis/jir195; Skeiky YAW, 1999, INFECT IMMUN, V67, P3998, DOI 10.1128/IAI.67.8.3998-4007.1999; Spertini F, 2013, TUBERCULOSIS, V93, P179, DOI 10.1016/j.tube.2012.10.011; Stenger S, 2005, ANN RHEUM DIS, V64, P24, DOI 10.1136/ard.2005.042531; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; Thacher EG, 2014, AIDS, V28, P1769, DOI 10.1097/QAD.0000000000000343; THORNTON JR, 1980, BRIT MED J, V280, P293, DOI 10.1136/bmj.280.6210.293-a; van den Berg RA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00564; Van der Meeren O, 2018, NEW ENGL J MED, V379, P1621, DOI 10.1056/NEJMoa1803484; Velayati AA, 2016, INT J MYCOBACT, V5, P66, DOI 10.1016/j.ijmyco.2015.12.001; Von Eschen K, 2009, HUM VACCINES, V5, P475, DOI 10.4161/hv.8570; Vordermeier HM, 2009, INFECT IMMUN, V77, P3364, DOI 10.1128/IAI.00287-09; Warris A, 2001, NEW ENGL J MED, V344, P1099, DOI 10.1056/NEJM200104053441415; Whelan KT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005934; Williams A, 2005, INFECT IMMUN, V73, P3814, DOI 10.1128/IAI.73.6.3814-3816.2005; World Health Organization, 2019, SUBST AB GLOB STAT R	62	2	3	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2020	11								1806	10.3389/fimmu.2020.01806	http://dx.doi.org/10.3389/fimmu.2020.01806			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OI6DA	33133057	Green Published, gold			2022-12-18	WOS:000583365400001
J	Rovirosa, L; Ramos-Morales, A; Javierre, BM				Rovirosa, Llorenc; Ramos-Morales, Alberto; Javierre, Biola M.			The Genome in a Three-Dimensional Context: Deciphering the Contribution of Noncoding Mutations at Enhancers to Blood Cancer	FRONTIERS IN IMMUNOLOGY			English	Review						spatial genome architecture; 3D chromatin organization; DNA loops; noncoding mutations and epimutations; enhancers; blood cancer; hematopoietic malignancies	ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTORS; SEQUENCING REVEALS; CPG METHYLATION; GENE; DNA; EXPRESSION; PROMOTER; BINDING; CHILDHOOD	Associations between blood cancer and genetic predisposition, including both inherited variants and acquired mutations and epimutations, have been well characterized. However, the majority of these variants affect noncoding regions, making their mechanisms difficult to hypothesize and hindering the translation of these insights into patient benefits. Fueled by unprecedented progress in next-generation sequencing and computational integrative analysis, studies have started applying combinations of epigenetic, genome architecture, and functional assays to bridge the gap between noncoding variants and blood cancer. These complementary tools have not only allowed us to understand the potential malignant role of these variants but also to differentiate key variants, cell-types, and conditions from misleading ones. Here, we briefly review recent studies that have provided fundamental insights into our understanding of how noncoding mutations at enhancers predispose and promote blood malignancies in the context of spatial genome architecture.	[Rovirosa, Llorenc; Ramos-Morales, Alberto; Javierre, Biola M.] Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst IJC, 3D Chromatin Org Grp, Badalona, Spain; [Javierre, Biola M.] Inst Hlth Sci Res Germans Trias & Pujol IGTP, Badalona, Spain	Institut de Recerca Contra la Leucemia Josep Carreras (IJC); Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP)	Javierre, BM (corresponding author), Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst IJC, 3D Chromatin Org Grp, Badalona, Spain.; Javierre, BM (corresponding author), Inst Hlth Sci Res Germans Trias & Pujol IGTP, Badalona, Spain.	bmjavierre@carrerasresearch.org	JAVIERRE, BIOLA M/A-2974-2017	JAVIERRE, BIOLA M/0000-0002-8682-6748; Rovirosa Mulet, Llorenc/0000-0003-2986-9001; Ramos-Morales, Alberto/0000-0002-6355-0136	AGAUR of the Catalan Government (Generalitat de Catalunya) [2019FI-B00017]; Jose' Carreras Leukamie-Stiftung [08R/2019]; FEDER/Spanish Ministry of Science and Innovation [RTI2018-094788-A-I00]; La Caixa Banking Foundation Junior Leader project [LCF/BQ/PI19/11690001]; Jose Carreras Leukamie-Stiftung [08R/2019]; European Hematology Association Advance Research Grant	AGAUR of the Catalan Government (Generalitat de Catalunya); Jose' Carreras Leukamie-Stiftung; FEDER/Spanish Ministry of Science and Innovation; La Caixa Banking Foundation Junior Leader project; Jose Carreras Leukamie-Stiftung; European Hematology Association Advance Research Grant	LR is funded by AGAUR project number 2019FI-B00017 of the Catalan Government (Generalitat de Catalunya). AR-M is funded by the Jose ' Carreras Leukamie-Stiftung (08R/2019). BJ is funded by FEDER/Spanish Ministry of Science and Innovation (project number RTI2018-094788-A-I00), by La Caixa Banking Foundation Junior Leader project (LCF/BQ/PI19/11690001), by the Jose Carreras Leukamie-Stiftung (08R/2019), and by the European Hematology Association Advance Research Grant. The funder bodies were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.	Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Amano T, 2009, DEV CELL, V16, P47, DOI 10.1016/j.devcel.2008.11.011; Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; Belver L, 2019, CANCER DISCOV, V9, P1774, DOI 10.1158/2159-8290.CD-19-0471; Bhatia S, 2002, BLOOD, V100, P1957, DOI 10.1182/blood-2002-02-0395; Burren OS, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1285-0; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chiarle R, 2011, CELL, V147, P107, DOI 10.1016/j.cell.2011.07.049; Chowdhary S, 2019, CELL REP, V26, P18, DOI 10.1016/j.celrep.2018.12.034; Cornish AJ, 2019, BLOOD ADV, V3, P21, DOI 10.1182/bloodadvances.2018026419; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Dall'Agnese A, 2019, MOL CELL, V76, P453, DOI 10.1016/j.molcel.2019.07.036; De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384; Deng WL, 2012, CELL, V149, P1233, DOI 10.1016/j.cell.2012.03.051; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Ferrando AA, 2004, LANCET, V363, P535, DOI 10.1016/S0140-6736(04)15542-6; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Fudenberg G, 2016, CELL REP, V15, P2038, DOI 10.1016/j.celrep.2016.04.085; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; GASTON K, 1995, NUCLEIC ACIDS RES, V23, P901, DOI 10.1093/nar/23.6.901; Gery S, 2005, BLOOD, V106, P2827, DOI 10.1182/blood-2005-01-0358; Hao N, 2019, CELL REP, V26, P2419, DOI 10.1016/j.celrep.2019.02.002; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Hnisz D, 2016, SCIENCE, V351, P1454, DOI 10.1126/science.aad9024; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jan M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004315; Jin FL, 2013, NATURE, V503, P290, DOI 10.1038/nature12644; Jin GX, 2011, EMBO J, V30, P2281, DOI 10.1038/emboj.2011.136; Kadan-Lottick NS, 2003, JAMA-J AM MED ASSOC, V290, P2008, DOI 10.1001/jama.290.15.2008; Khurana E, 2016, NAT REV GENET, V17, P93, DOI 10.1038/nrg.2015.17; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Klein IA, 2011, CELL, V147, P95, DOI 10.1016/j.cell.2011.07.048; Kloetgen A, 2020, NAT GENET, V52, P388, DOI 10.1038/s41588-020-0602-9; Kon A, 2013, NAT GENET, V45, P1232, DOI 10.1038/ng.2731; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Levasseur DN, 2008, GENE DEV, V22, P575, DOI 10.1101/gad.1606308; Li KL, 2020, CANCER DISCOV, V10, P724, DOI 10.1158/2159-8290.CD-19-1128; Li Y, 2020, NUCLEIC ACIDS RES, V48, P3119, DOI 10.1093/nar/gkaa098; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Liu Y, 2020, NAT GENET, V52, P811, DOI 10.1038/s41588-020-0659-5; Long HK, 2016, CELL, V167, P1170, DOI 10.1016/j.cell.2016.09.018; Mann IK, 2013, GENOME RES, V23, P988, DOI 10.1101/gr.146654.112; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Maurano MT, 2015, CELL REP, V12, P1184, DOI 10.1016/j.celrep.2015.07.024; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Mazumdar C, 2015, CELL STEM CELL, V17, P1, DOI 10.1016/j.stem.2015.09.017; Mullenders J, 2015, J EXP MED, V212, P1833, DOI 10.1084/jem.20151323; Mumbach MR, 2016, NAT METHODS, V13, P919, DOI 10.1038/nmeth.3999; Nora EP, 2017, CELL, V169, P930, DOI 10.1016/j.cell.2017.05.004; Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663; Perez-Andreu V, 2015, BLOOD, V125, P680, DOI 10.1182/blood-2014-09-595744; Perez-Andreu V, 2013, NAT GENET, V45, P1494, DOI 10.1038/ng.2803; Perry MW, 2011, P NATL ACAD SCI USA, V108, P13570, DOI 10.1073/pnas.1109873108; Polak P, 2015, NATURE, V518, P360, DOI 10.1038/nature14221; Pollock BH, 2000, J CLIN ONCOL, V18, P813, DOI 10.1200/JCO.2000.18.4.813; Qian MX, 2019, JNCI-J NATL CANCER I, V111, P1350, DOI 10.1093/jnci/djz043; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Rao SSP, 2017, CELL, V171, P305, DOI 10.1016/j.cell.2017.09.026; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Sanborn AL, 2015, P NATL ACAD SCI USA, V112, pE6456, DOI 10.1073/pnas.1518552112; Shen Y, 2012, NATURE, V488, P116, DOI 10.1038/nature11243; Speedy HE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11582-2; Speedy HE, 2014, NAT GENET, V46, P56, DOI 10.1038/ng.2843; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Vijayakrishnan J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03178-z; Viny AD, 2015, J EXP MED, V212, P1819, DOI 10.1084/jem.20151317; Walsh KM, 2013, BLOOD, V121, P4808, DOI 10.1182/blood-2013-04-495390; Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Wei Z, 2013, CELL STEM CELL, V13, P36, DOI 10.1016/j.stem.2013.05.010; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Weintraub AS, 2017, CELL, V171, P1573, DOI 10.1016/j.cell.2017.11.008; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Wutz G, 2017, EMBO J, V36, P3573, DOI 10.15252/embj.201798004; Yang H, 2020, NONCODING GERMLINE G, DOI [10.1101/2020.02.23.961672, DOI 10.1101/2020.02.23.961672]; Young K, 2020, EXP HEMATOL, V89, P61, DOI 10.1016/j.exphem.2020.07.012; YUN H, 2019, BLOOD S, V134, DOI DOI 10.1182/blood-2019-122413; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111; Zhao JK, 2017, LECT N BIOINFORMAT, V10229, P336, DOI 10.1007/978-3-319-56970-3_21; Zhou Y, 2013, BLOOD, V122, P4199, DOI 10.1182/blood-2013-02-483875	93	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2020	11									10.3389/fimmu.2020.592087	http://dx.doi.org/10.3389/fimmu.2020.592087			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ON0LO	33117405	gold, Green Published			2022-12-18	WOS:000586404300001
J	Chernomordik, F; Cercek, B; Lio, WM; Mihailovic, PM; Yano, J; Herscovici, R; Zhao, XN; Zhou, JC; Chyu, KY; Shah, PK; Dimayuga, PC				Chernomordik, Fernando; Cercek, Bojan; Lio, Wai Man; Mihailovic, Peter M.; Yano, Juliana; Herscovici, Romana; Zhao, Xiaoning; Zhou, Jianchang; Chyu, Kuang-Yuh; Shah, Prediman K.; Dimayuga, Paul C.			The Role of T Cells Reactive to the Cathelicidin Antimicrobial Peptide LL-37 in Acute Coronary Syndrome and Plaque Calcification	FRONTIERS IN IMMUNOLOGY			English	Article						acute coronary syndrome; T cells; atherosclerosis; cathelicidin; LL-37; mCRAMP	ATHEROSCLEROSIS; PSORIASIS; RESPONSES; DISEASES; MEMORY; ARTERY	The human cationic anti-microbial peptide LL-37 is a T cell self-antigen in patients with psoriasis, who have increased risk of cardiovascular events. However, the role of LL-37 as a T cell self-antigen in the context of atherosclerosis remains unclear. The objective of this study was to test for the presence of T cells reactive to LL-37 in patients with acute coronary syndrome (ACS). Furthermore, the role of T cells reactive to LL-37 in atherosclerosis was assessed using apoE-/- mice immunized with the LL-37 mouse ortholog, mCRAMP. Peripheral blood mononuclear cells (PBMCs) from patients with ACS were stimulated with LL-37. PBMCs from stable coronary artery disease (CAD) patients or self-reported subjects served as controls. T cell memory responses were analyzed with flow cytometry. Stimulation of PBMCs with LL-37 reduced CD8+ effector T cell responses in controls and patients with stable CAD but not in ACS and was associated with reduced programmed cell death protein 1 (PDCD1) mRNA expression. For the mouse studies, donor apoE-/- mice were immunized with mCRAMP or adjuvant as controls, then T cells were isolated and adoptively transferred into recipient apoE-/- mice fed a Western diet. Recipient mice were euthanized after 5 weeks. Whole aortas and hearts were collected for analysis of atherosclerotic plaques. Spleens were collected for flow cytometric and mRNA expression analysis. Adoptive transfer experiments in apoE-/- mice showed a 28% reduction in aortic plaque area in mCRAMP T cell recipient mice (P < 0.05). Fifty six percent of adjuvant T cell recipient mice showed calcification in atherosclerotic plaques, compared to none in the mCRAMP T cell recipient mice (Fisher's exact testP= 0.003). Recipients of T cells from mice immunized with mCRAMP had increased IL-10 and IFN-gamma expression in CD8+ T cells compared to controls. In conclusion, the persistence of CD8+ effector T cell response in PBMCs from patients with ACS stimulated with LL-37 suggests that LL-37-reactive T cells may be involved in the acute event. Furthermore, studies in apoE-/- mice suggest that T cells reactive to mCRAMP are functionally active in atherosclerosis and may be involved in modulating plaque calcification.	[Chernomordik, Fernando; Cercek, Bojan; Lio, Wai Man; Mihailovic, Peter M.; Yano, Juliana; Herscovici, Romana; Zhao, Xiaoning; Zhou, Jianchang; Chyu, Kuang-Yuh; Shah, Prediman K.; Dimayuga, Paul C.] Cedars Sinai Med Ctr, Dept Cardiol, Oppenheimer Atherosclerosis Res Ctr, Smidt Heart Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Dimayuga, PC (corresponding author), Cedars Sinai Med Ctr, Dept Cardiol, Oppenheimer Atherosclerosis Res Ctr, Smidt Heart Inst, Los Angeles, CA 90048 USA.	Paul.Dimayuga@cshs.org	Mihailovic, Peter Marko/ABG-5713-2020		American Heart Association Innovative Research Grant [17IRG33410704]; Joe Weider Foundation; Academic Affairs Department, Cedars Sinai Medical Center; Lidia Kitner Scholarship for Advanced Cardiovascular Training; Milovicz grant for the Development of the Future Generation of Leaders in Medicine; Working Group in Acute Cardiac Care of the Israel Heart Society; Eleanor and Harold Foonberg Endowed Chair in Cardiac Intensive Care Fund; Heart Foundation; Petersen Foundation; Steinberg Foundation; Spielberg Fund; Annenberg Foundation	American Heart Association Innovative Research Grant(American Heart Association); Joe Weider Foundation; Academic Affairs Department, Cedars Sinai Medical Center; Lidia Kitner Scholarship for Advanced Cardiovascular Training; Milovicz grant for the Development of the Future Generation of Leaders in Medicine; Working Group in Acute Cardiac Care of the Israel Heart Society; Eleanor and Harold Foonberg Endowed Chair in Cardiac Intensive Care Fund; Heart Foundation; Petersen Foundation; Steinberg Foundation; Spielberg Fund; Annenberg Foundation	The study was supported by in part an American Heart Association Innovative Research Grant #17IRG33410704 (PD). Additional support was provided by The Joe Weider Foundation (PD); Academic Affairs Department, Cedars Sinai Medical Center; the Lidia Kitner Scholarship for Advanced Cardiovascular Training; the Milovicz grant for the Development of the Future Generation of Leaders in Medicine; the Prof. Arieh Roth Scholarship from the Working Group in Acute Cardiac Care of the Israel Heart Society (FC); Eleanor and Harold Foonberg Endowed Chair in Cardiac Intensive Care Fund (BC); and The Heart Foundation, Petersen Foundation, Spielberg Fund, Annenberg Foundation, Steinberg Foundation (PKS).	Albiero M, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0368-7; Alexandre-Ramos DS, 2018, BIOMED PHARMACOTHER, V108, P1584, DOI 10.1016/j.biopha.2018.10.014; Ammirati E, 2012, J AM HEART ASSOC, V1, P27, DOI 10.1161/JAHA.111.000125; Brossart P., 2020, CLIN CANCER RES, V26; Cautela J, 2020, CAN J CARDIOL, V36, P476, DOI 10.1016/j.cjca.2019.11.035; D'Amelio P, 2015, OSTEOPOROSIS INT, V26, P2785, DOI 10.1007/s00198-015-3189-8; Davidovici BB, 2010, J INVEST DERMATOL, V130, P1785, DOI 10.1038/jid.2010.103; Doring Y, 2017, CIRC RES, V120, P736, DOI 10.1161/CIRCRESAHA.116.309692; Doring Y, 2012, CIRC RES, V110, P1052, DOI 10.1161/CIRCRESAHA.112.265868; Doring Y, 2012, CIRCULATION, V125, P1673, DOI 10.1161/CIRCULATIONAHA.111.046755; Edfeldt K, 2006, ARTERIOSCL THROM VAS, V26, P1551, DOI 10.1161/01.ATV.0000223901.08459.57; Fernandez DM, 2019, NAT MED, V25, P1576, DOI 10.1038/s41591-019-0590-4; Flammer AJ, 2012, EUR HEART J, V33, P1989, DOI 10.1093/eurheartj/ehr425; Grundy SM, 2019, J AM COLL CARDIOL, V73, pE285, DOI 10.1016/j.jacc.2018.11.003; Hardiman G, 1996, GENE, V172, P199, DOI 10.1016/0378-1119(96)00109-6; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; Mangold A, 2015, CIRC RES, V116, P1182, DOI 10.1161/CIRCRESAHA.116.304944; Mihailovic PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213025; Mihailovic PM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187432; Milioti N, 2008, CLIN DEV IMMUNOL, DOI 10.1155/2008/723539; Mitchell JD, 2018, JACC-CARDIOVASC IMAG, V11, P1799, DOI 10.1016/j.jcmg.2017.09.003; Nakahara T, 2017, JACC-CARDIOVASC IMAG, V10, P582, DOI 10.1016/j.jcmg.2017.03.005; Nandalur KR, 2005, AM J ROENTGENOL, V184, P295, DOI 10.2214/ajr.184.1.01840295; Nilsson J, 2008, J INTERN MED, V263, P464, DOI 10.1111/j.1365-2796.2008.01945.x; Paine A, 2018, CALCIFIED TISSUE INT, V102, P559, DOI 10.1007/s00223-017-0380-2; Pennock ND, 2013, ADV PHYSIOL EDUC, V37, P273, DOI 10.1152/advan.00066.2013; Prodanovich S, 2009, ARCH DERMATOL, V145, P700, DOI 10.1001/archdermatol.2009.94; Puri R, 2015, J AM COLL CARDIOL, V65, P1273, DOI 10.1016/j.jacc.2015.01.036; Saigusa R, 2020, NAT REV CARDIOL, V17, P387, DOI 10.1038/s41569-020-0352-5; Salamah MF, 2018, BLOOD ADV, V2, P2973, DOI 10.1182/bloodadvances.2018021758; Santilli S, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0947-0; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; van Dijk RA, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001403; Vandamme D, 2012, CELL IMMUNOL, V280, P22, DOI 10.1016/j.cellimm.2012.11.009; VanderLaan PA, 2004, ARTERIOSCL THROM VAS, V24, P12, DOI 10.1161/01.ATV.0000105054.43931.f0; Vieyra-Lobato MR, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3758713; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05244-y; Yu YT, 2018, ONCOL LETT, V15, P8187, DOI 10.3892/ol.2018.8378; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zhang L, 2009, J IMMUNOL, V183, P6346, DOI 10.4049/jimmunol.0901773; Zhang ZF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013985; Zhao HJ, 2012, J ATHEROSCLER THROMB, V19, P357, DOI 10.5551/jat.10108	45	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2020	11								575577	10.3389/fimmu.2020.575577	http://dx.doi.org/10.3389/fimmu.2020.575577			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OF3BM	33123157	gold, Green Published			2022-12-18	WOS:000581087700001
J	Jacobs, B; Schlogl, S; Strobl, CD; Volkl, S; Stoll, A; Mougiakakos, D; Malmberg, KJ; Mackensen, A; Aigner, M				Jacobs, Benedikt; Schloegl, Sebastian; Strobl, Carolin Dorothea; Voelkl, Simon; Stoll, Andrej; Mougiakakos, Dimitrios; Malmberg, Karl-Johan; Mackensen, Andreas; Aigner, Michael			The Oncometabolite 5 '-Deoxy-5 '-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation	FRONTIERS IN IMMUNOLOGY			English	Article						NKG2C; CD16 signaling; 5 '-deoxy-5 '-methylthioadenosine; NK cells; tumor escape mechanism	S-ADENOSYLMETHIONINE; IN-VIVO; METHYLTHIOADENOSINE; EXPRESSION; MTAP; CANCER; 5'-METHYLTHIOADENOSINE; CYTOMEGALOVIRUS; METHYLATION; CYTOKINE	Tumor cells develop various mechanisms to escape immune surveillance. In this context, oncometabolites secreted by tumor cells due to deregulated metabolic pathways, have been in the spotlight of researchers during the last years. 5 '-Deoxy-5 '-methylthioadenosine (MTA) phosphorylase (MTAP) deficiency in tumors results in the accumulation of MTA within the tumor microenvironment and thereby negatively influencing immune functions of various immune cells, including T and NK cells. The influence of MTA on T cell activation has been recently described in more detail, while its impact on NK cells is still largely unknown. Therefore, we aimed to illuminate the molecular mechanism of MTA-induced NK cell dysfunction. NK cell cytotoxicity against target cells was reduced in the presence of MTA in a dose-dependent manner, while NK cell viability remained unaffected. Furthermore, we revealed that MTA blocks NK cell degranulation and cytokine production upon target cell engagement as well as upon antibody stimulation. Interestingly, the immune-suppressive effect of MTA was less pronounced in healthy donors harboring an expansion of NKG2C(+)NK cells. Finally, we demonstrated that MTA interferes with various signaling pathways downstream of the CD16 receptor upon NK cell activation, including the PI3K/AKT/S6, MAPK/ERK, and NF-kappa B pathways. In summary, we revealed that MTA blocks NK cell functions like cytotoxicity and cytokine production by interfering with the signaling cascade of activating NK cell receptors. Specific targeting of MTA metabolism in MTAP-deficient tumors therefore could offer a promising new strategy to reverse immune dysfunction of NK cells within the tumor microenvironment.	[Jacobs, Benedikt; Strobl, Carolin Dorothea; Voelkl, Simon; Stoll, Andrej; Mougiakakos, Dimitrios; Mackensen, Andreas; Aigner, Michael] Friedrich Alexander Univ Erlangen Nuremberg FAU, Dept Internal Med Hematol & Oncol 5, Univ Hosp Erlangen, Erlangen, Germany; [Schloegl, Sebastian] Gen Hosp Furth, Dept Anesthesiol Intens Care & Pain Therapy, Furth, Germany; [Malmberg, Karl-Johan] Karolinska Inst, Ctr Infect Med, Dept Med, Stockholm, Sweden; [Malmberg, Karl-Johan] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Canc Immunotherapy, Oslo, Norway; [Malmberg, Karl-Johan] Oslo Univ Hosp, Dept Canc Immunol, Inst Canc Res, Oslo, Norway	University of Erlangen Nuremberg; Karolinska Institutet; University of Oslo; University of Oslo	Jacobs, B (corresponding author), Friedrich Alexander Univ Erlangen Nuremberg FAU, Dept Internal Med Hematol & Oncol 5, Univ Hosp Erlangen, Erlangen, Germany.	benedikt.jacobs@uk-erlangen.de		Volkl, Simon/0000-0003-2193-3048; Strobl, Carolin/0000-0003-2257-6281	DFG-funded KFO 262 Tumor metabolism as modulator of immune response and tumor progression Project P3	DFG-funded KFO 262 Tumor metabolism as modulator of immune response and tumor progression Project P3	This work was supported by the DFG-funded KFO 262 Tumor metabolism as modulator of immune response and tumor progression Project P3 (to AM, MA, BJ, and CS).	Alspach E, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a028480; Andreu-Perez P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-265; Avila MA, 2004, INT J BIOCHEM CELL B, V36, P2125, DOI 10.1016/j.biocel.2003.11.016; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Bertino JR, 2011, CANCER BIOL THER, V11, P627, DOI 10.4161/cbt.11.7.14948; Biggar KK, 2015, NAT REV MOL CELL BIO, V16, P5, DOI 10.1038/nrm3915; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Blanchet F, 2005, J EXP MED, V202, P371, DOI 10.1084/jem.20050176; Bottcher M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1445454; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Cichocki F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02078; COWARD JK, 1977, J MED CHEM, V20, P500, DOI 10.1021/jm00214a008; DELLARAGIONE F, 1983, BIOCHEM J, V210, P429, DOI 10.1042/bj2100429; Cruz-Munoz ME, 2019, J LEUKOCYTE BIOL, V105, P955, DOI 10.1002/JLB.MR0618-224RR; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; FERRO AJ, 1981, BIOCHEM BIOPH RES CO, V100, P523, DOI 10.1016/S0006-291X(81)80208-2; Foley B, 2012, J IMMUNOL, V189, P5082, DOI 10.4049/jimmunol.1201964; FREDHOLM BB, 1984, SCAND J IMMUNOL, V20, P511, DOI 10.1111/j.1365-3083.1984.tb01033.x; GALLETTI P, 1981, FEBS LETT, V126, P236, DOI 10.1016/0014-5793(81)80250-5; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; Henrich FC, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1184802; Hevia H, 2004, HEPATOLOGY, V39, P1088, DOI 10.1002/hep.20154; Hori Y, 1998, INT J CANCER, V75, P51, DOI 10.1002/(SICI)1097-0215(19980105)75:1<51::AID-IJC9>3.0.CO;2-0; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2019, PROTEIN SCI, V28, P1947, DOI 10.1002/pro.3715; Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962; Keyel PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104210; Kim GG, 2007, J IMMUNOL METHODS, V325, P51, DOI 10.1016/j.jim.2007.05.013; Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214; Li TWH, 2012, CARCINOGENESIS, V33, P427, DOI 10.1093/carcin/bgr295; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Limm K, 2014, EUR J CANCER, V50, P2714, DOI 10.1016/j.ejca.2014.07.005; Liu LL, 2017, CANCER IMMUNOL RES, V5, P654, DOI 10.1158/2326-6066.CIR-16-0296; Liu LL, 2016, CELL REP, V15, P1088, DOI 10.1016/j.celrep.2016.04.005; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Lokshin A, 2006, CANCER RES, V66, P7758, DOI 10.1158/0008-5472.CAN-06-0478; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008-5472.CAN-15-1022; Luetke-Eversloh M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004441; Luetke-Eversloh M, 2014, EUR J IMMUNOL, V44, P2074, DOI 10.1002/eji.201344072; Marjon K, 2016, CELL REP, V15, P574, DOI 10.1016/j.celrep.2016.03.043; Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944; Meyer S, 2010, EXP DERMATOL, V19, pE251, DOI 10.1111/j.1600-0625.2010.01072.x; Moreno B, 2006, ANN NEUROL, V60, P323, DOI 10.1002/ana.20895; Muntasell A, 2013, EUR J IMMUNOL, V43, P1133, DOI 10.1002/eji.201243117; Nandagopal N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00187; Stevens AP, 2009, J CELL BIOCHEM, V106, P210, DOI 10.1002/jcb.21984; Stevens AP, 2008, J CHROMATOGR B, V876, P123, DOI 10.1016/j.jchromb.2008.10.038; Strobl CD, 2020, MOL CANCER THER, V19, P409, DOI 10.1158/1535-7163.MCT-19-0189; Su CY, 2014, EJSO-EUR J SURG ONC, V40, P1143, DOI 10.1016/j.ejso.2014.04.017; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Theorell J, 2011, J IMMUNOL METHODS, V366, P106, DOI 10.1016/j.jim.2011.01.014; Veal N, 2004, AM J PHYSIOL-GASTR L, V287, pG352, DOI 10.1152/ajpgi.00316.2003; Veeramani S, 2011, BLOOD, V118, P3347, DOI 10.1182/blood-2011-05-351411; Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110	59	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2020	11								2128	10.3389/fimmu.2020.02128	http://dx.doi.org/10.3389/fimmu.2020.02128			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OF2PL	33123121	gold, Green Published, Green Submitted			2022-12-18	WOS:000581056400001
J	Lodde, V; Floris, M; Beerman, I; Munk, R; Guha, R; Steri, M; Orru, V; Abdelmohsen, K; Crompton, PD; Gorospe, M; Idda, ML; Cucca, F				Lodde, Valeria; Floris, Matteo; Beerman, Isabel; Munk, Rachel; Guha, Rajan; Steri, Maristella; Orru, Valeria; Abdelmohsen, Kotb; Crompton, Peter D.; Gorospe, Myriam; Idda, Maria Laura; Cucca, Francesco			Evolutionarily Selected Overexpression of the Cytokine BAFF Enhances Mucosal Immune Response AgainstP. falciparum	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; BAFF; gene regulation; evolution; immune regulation	MIGRATION INHIBITORY FACTOR; PLASMODIUM-FALCIPARUM; MALARIA; ACTIVATION; EXPRESSION; CHILDREN; FAMILY	We have previously shown that a variant of theTNFSF13Bgene that we calledBAFF-varincreases the production of the cytokine BAFF, upregulating humoral immunity and increasing the risk for certain autoimmune diseases. In addition, genetic population signatures revealed thatBAFF-varwas evolutionarily advantageous, most likely by increasing resistance to malaria infection, which is a prime candidate for selective pressure. To evaluate whether the increased soluble BAFF (sBAFF) production confers protection, we experimentally assessed the role ofBAFF-varin response to malaria antigens. Lysates of erythrocytes infected withPlasmodium falciparum(iRBCs) or left uninfected (uRBCs, control) were used to treat peripheral blood mononuclear cells (PBMCs) with distinct BAFF genotypes. The PBMCs purified fromBAFF-vardonors and treated with iRBCs showed different levels of specific cells, immunoglobulins, and cytokines as compared withBAFF-WT.In particular, a relevant differential effect on mucosal immunity B subpopulations have been observed. These findings point to specific immune cells and molecules through which the evolutionary selectedBAFF-varmay have improved fitness duringP. falciparuminfection.	[Lodde, Valeria; Floris, Matteo; Cucca, Francesco] Univ Sassari, Dept Biomed Sci, Sassari, Italy; [Lodde, Valeria; Floris, Matteo; Steri, Maristella; Orru, Valeria; Idda, Maria Laura; Cucca, Francesco] CNR, Ist Ric Genet & Biomed, Monserrato, Italy; [Beerman, Isabel] NIA, Epigenet & Stem Cell Unit, Translat Gerontol Branch, NIH, Baltimore, MD 21224 USA; [Munk, Rachel; Abdelmohsen, Kotb; Gorospe, Myriam] NIA, Lab Genet & Genom, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Guha, Rajan; Crompton, Peter D.] NIAID, Malaria Infect Biol & Immun Sect, Lab Immunogenet, NIH, Rockville, MD USA	University of Sassari; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Cucca, F (corresponding author), Univ Sassari, Dept Biomed Sci, Sassari, Italy.; Idda, ML; Cucca, F (corresponding author), CNR, Ist Ric Genet & Biomed, Monserrato, Italy.	marialaura.idda@irgb.cnr.it; fcucca@uniss.it	Guha, Rajan/AAH-7054-2021; Floris, Matteo/ABH-1274-2020; Steri, Maristella/AAX-8760-2020; Guha, Rajan/AAK-3442-2021	Floris, Matteo/0000-0003-4385-9336; Steri, Maristella/0000-0001-5869-3872; Guha, Rajan/0000-0003-0252-3721	NIA-IRP (NIH); NIAIDIRP (NIH); LEGGE REGIONALE 7 AGOSTO 2007 [CRP-79015]; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health	NIA-IRP (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAIDIRP (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); LEGGE REGIONALE 7 AGOSTO 2007; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health	This work was supported by the NIA-IRP (NIH), the NIAIDIRP (NIH), and by LEGGE REGIONALE 7 AGOSTO 2007, N. 7 (CRP-79015). RG and PDC are supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.	Arora V, 2004, MOL IMMUNOL, V41, P449, DOI 10.1016/j.molimm.2004.03.004; Awandare GA, 2006, CLIN IMMUNOL, V119, P219, DOI 10.1016/j.clim.2005.12.003; Awandare GA, 2007, INFECT IMMUN, V75, P201, DOI 10.1128/IAI.01327-06; Bostrom S, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-109; Boyle MJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax4489; Chaisavaneeyakorn S, 2002, J INFECT DIS, V186, P1371, DOI 10.1086/344322; Chege D, 2014, JAIDS-J ACQ IMM DEF, V65, P517, DOI 10.1097/QAI.0000000000000056; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016; de Salles EM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006595; Deroost K, 2016, FEMS MICROBIOL REV, V40, P208, DOI 10.1093/femsre/fuv046; Dey S, 2012, J BIOL CHEM, V287, P26630, DOI 10.1074/jbc.M112.341255; Fernandez-Arias C, 2013, J IMMUNOL, V190, P3363, DOI 10.4049/jimmunol.1103812; Frank PG, 2008, AM J PHYSIOL-HEART C, V295, pH926, DOI 10.1152/ajpheart.00779.2008; Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57; Gorfu G, 2009, CURR MOL MED, V9, P836, DOI 10.2174/156652409789105525; Greta EW, 2009, J IMMUNOL, V23, P1; GROUX H, 1990, RES IMMUNOL, V141, P529, DOI 10.1016/0923-2494(90)90021-P; Idda ML, 2019, CELL CYCLE, V18, P708, DOI 10.1080/15384101.2019.1580496; Idda ML, 2018, NUCLEIC ACIDS RES, V46, P12040, DOI 10.1093/nar/gky866; Israelsson E, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-175; Kumsiri R, 2010, ACTA TROP, V116, P217, DOI 10.1016/j.actatropica.2010.08.012; Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7; LaMonte GM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08349-0; Lang TL, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00577; Lee EY, 2009, AUTOIMMUN REV, V8, P379, DOI 10.1016/j.autrev.2008.12.002; Lied GA, 2011, SCAND J IMMUNOL, V73, P1, DOI 10.1111/j.1365-3083.2010.02470.x; Liu ML, 2011, ONCOL LETT, V2, P583, DOI 10.3892/ol.2011.300; Liu XQ, 2012, EUR J IMMUNOL, V42, P3291, DOI 10.1002/eji.201242689; Long CA, 2016, CURR OPIN MICROBIOL, V32, P96, DOI 10.1016/j.mib.2016.04.006; Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572; Obeng-Adjei N, 2015, CELL REP, V13, P425, DOI 10.1016/j.celrep.2015.09.004; Perez-Mazliah D, 2015, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00671; Plebanski M, 2000, CURR OPIN IMMUNOL, V12, P437, DOI 10.1016/S0952-7915(00)00117-5; Portugal S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004079; Sabry A, 2007, CLIN RHEUMATOL, V26, P1819, DOI 10.1007/s10067-007-0580-7; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528; Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311; Sullivan RT, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1190-0; Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52; Tognotti E, 1998, LANCET, V264, P640, DOI [10.1016/s0140-6736(54)90416-x, DOI 10.1016/S0140-6736(54)90416-X]; Torre D, 2002, LANCET INFECT DIS, V2, P719, DOI 10.1016/S1473-3099(02)00449-8; Treml JF, 2009, CELL BIOCHEM BIOPHYS, V53, P1, DOI 10.1007/s12013-008-9036-1; Ubillos I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00966; Uchechukwu C., 2017, J CLIN CELLULAR IMMU, V08, P4, DOI [10.4172/2155-9899.1000519, DOI 10.4172/2155-9899.1000519]; Walther M, 2006, J IMMUNOL, V177, P5736, DOI 10.4049/jimmunol.177.8.5736; WENISCH C, 1995, J CLIN IMMUNOL, V15, P69, DOI 10.1007/BF01541734; Yu W, 2010, BIOINFORMATICS, V26, P145, DOI 10.1093/bioinformatics/btp618	48	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 6	2020	11								575103	10.3389/fimmu.2020.575103	http://dx.doi.org/10.3389/fimmu.2020.575103			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OC9HX	33123155	Green Published, gold			2022-12-18	WOS:000579466900001
J	Ranzenigo, M; Pastori, C; Siracusano, G; Pariani, E; Uberti-Foppa, C; Lopalco, L				Ranzenigo, Martina; Pastori, Claudia; Siracusano, Gabriel; Pariani, Elena; Uberti-Foppa, Caterina; Lopalco, Lucia			Virological and Serological Discordant Profiles in COVID-19 Pneumonia: Two Atypical Clinical Cases	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; viral RNA; PCR; antibodies; neutralizing antibodies; NP; spike protein		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is primarily diagnosed through viral RNA positivity in nasopharyngeal swabs, and it is associated with the early detection of specific immunoglobulins to SARS-CoV-2 proteins. We describe two moderate coronavirus disease 2019 (COVID-19) patients with WHO score 4/5 at the time of hospitalization, pneumonia, and oxygen saturation <94% and with a strong discrepancy between viral RNA and antibodies to SARS-CoV-2. One patient was positive for viral RNA but completely negative for binding and neutralizing antibodies, whereas the second patient was negative for viral RNA but with high levels of both neutralizing and binding antibodies. This observation is relevant to better understand the pathogenesis of this novel infection.	[Ranzenigo, Martina] Ist Sci San Raffaele, Clin Infect Dis, Milan, Italy; [Pastori, Claudia; Siracusano, Gabriel; Lopalco, Lucia] Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, Milan, Italy; [Pariani, Elena] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Uberti-Foppa, Caterina] Univ Vita Salute San Raffaele, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Vita-Salute San Raffaele University	Lopalco, L (corresponding author), Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, Milan, Italy.	lopalco.lucia@hsr.it	Foppa, Caterina Uberti/ABH-3089-2020; PARIANI, ELENA/M-3491-2016	Foppa, Caterina Uberti/0000-0001-5271-9138; PARIANI, ELENA/0000-0001-5681-3455				[Anonymous], 2020, INDEPENDENT; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Centers for Disease Control and Prevention (CDC), 2020, 2019 NOV COR 2019 NC; Cervia C, SYSTEMIC MUCOSAL ANT, DOI [10.1016/j.jaci.2020.10.040, DOI 10.1016/j.cell.2020.05.015, 10.1101/2020.05.21.108308, DOI 10.1101/2020.05.21.108308]; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783; Li DS, 2020, KOREAN J RADIOL, V21, P505, DOI 10.3348/kjr.2020.0146; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Park WB, 2015, EMERG INFECT DIS, V21, P2186, DOI 10.3201/eid2112.151421; Siracusano G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01049; To Kelvin Kai-Wang, 2021, Clin Infect Dis, V73, pe2946, DOI 10.1093/cid/ciaa1275; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Xiao AT, 2020, J INFECTION, V81, P174, DOI 10.1016/j.jinf.2020.03.012; Yu HQ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01526-2020; Zeng FY, 2006, FEBS LETT, V580, P5612, DOI 10.1016/j.febslet.2006.08.085	18	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 2	2020	11								580867	10.3389/fimmu.2020.580867	http://dx.doi.org/10.3389/fimmu.2020.580867			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OD1HW	33133098	Green Published, gold			2022-12-18	WOS:000579606600001
J	Sato, PK; Busser, FD; Carvalho, FMD; dos Santos, AG; Sadahiro, A; Diogo, CL; Kono, ASG; Moretti, ML; Luiz, OD; Shikanai-Yasuda, MA				Sato, Paula Keiko; Busser, Felipe Delatorre; Carvalho, Flavia Mendes da Cunha; Gomes dos Santos, Alexandra; Sadahiro, Aya; Diogo, Constancia Lima; Kono, Adriana Satie Goncalves; Moretti, Maria Luiza; Luiz, Olinda do Carmo; Shikanai-Yasuda, Maria Aparecida			Polymorphism in the Promoter Region of theIL18Gene and the Association With Severity on Paracoccidioidomycosis	FRONTIERS IN IMMUNOLOGY			English	Article						paracoccidioidomycosis; Paracoccidioidesspp; single nucleotide polymophism; IL18; IL12A; IFNGR1; clinical forms of paracoccidioidomycosis	GENE POLYMORPHISM; IMMUNE-RESPONSE; RECEPTOR GENES; HLA ANTIGENS; IFN-GAMMA; INTERLEUKIN-18; IL-18; SUSCEPTIBILITY; BRASILIENSIS; EXPRESSION	Paracoccidioidomycosis (PCM) is an important endemic, systemic disease in Latin America caused byParacoccidioidesspp. This mycosis has been associated with high morbidity and sequels, and its clinical manifestations depend on the virulence of the infecting strain, the degree and type of immune response, infected tissues, and intrinsic characteristics of the host. The T helper(Th)1 and Th17/Th22 cells are related to resistance and control of infection, and a Th2/Th9 response is associated with disease susceptibility. In this study, we focused on interleukin(IL)-12p35 (IL12A), IL-18 (IL18), and IFN-gamma receptor 1 (IFNGR1) genetic polymorphisms because their respective roles have been described in human PCM. Real-time PCR was employed to analyzeIL12A-504 G/T (rs2243115),IL18-607 C/A (rs1946518), andIFNGR1-611 A/G (rs1327474) single nucleotide polymorphisms (SNP). One hundred forty-nine patients with the acute form (AF), multifocal chronic (MC), or unifocal chronic (UC) forms of PCM and 110 non-PCM individuals as a control group were included. In the unconditional logistic regression analysis adjusted by ethnicity and sex, we observed a high risk of theIL18-607A-allele for both AF [p= 0.015; OR = 3.10 (95% CI: 1.24-7.77)] and MC groups [p= 0.023; OR = 2.61 (95% CI: 1.14-5.96)] when compared with UC. TheIL18-607A-allele associated risk for the AF and MC groups as well as the protective role of theC-allele in UC are possibly linked to higher levels of IL-18 at different periods of the course of the disease. Therefore, a novel role ofIL18-607 C/A SNP is shown in the present study, highlighting its importance in the outcome of PCM.	[Sato, Paula Keiko; Busser, Felipe Delatorre; Carvalho, Flavia Mendes da Cunha; Gomes dos Santos, Alexandra; Diogo, Constancia Lima; Shikanai-Yasuda, Maria Aparecida] Univ Sao Paulo, Hosp Clin, Fac Med, Lab Med Invest Immunol LIM48, Sao Paulo, Brazil; [Sato, Paula Keiko; Busser, Felipe Delatorre; Diogo, Constancia Lima; Shikanai-Yasuda, Maria Aparecida] Univ Sao Paulo, Inst Trop Med, Fac Med, Sao Paulo, Brazil; [Carvalho, Flavia Mendes da Cunha; Gomes dos Santos, Alexandra; Shikanai-Yasuda, Maria Aparecida] Univ Sao Paulo, Dept Infect & Parasit Dis, Fac Med, Sao Paulo, Brazil; [Sadahiro, Aya] Univ Fed Amazonas, Inst Ciencias Biol, Dept Parasitol, Manaus, Amazonas, Brazil; [Kono, Adriana Satie Goncalves] Univ Sao Paulo, Hosp Clin, Infect Dis Div, Sao Paulo, Brazil; [Moretti, Maria Luiza] Univ Estadual Campinas, Hosp Clin, Fac Ciencias Med, Campinas, Brazil; [Luiz, Olinda do Carmo] Univ Sao Paulo, Fac Med, Dept Prevent Med, Sao Paulo, Brazil; [Carvalho, Flavia Mendes da Cunha] Univ Sao Paulo, Hosp Clin, Lab Med Invest Immunopathol Schistosomiasis & Oth, Struct Biol Unit,Fac Med, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Federal de Amazonas; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade de Sao Paulo	Sato, PK; Shikanai-Yasuda, MA (corresponding author), Univ Sao Paulo, Hosp Clin, Fac Med, Lab Med Invest Immunol LIM48, Sao Paulo, Brazil.; Sato, PK; Shikanai-Yasuda, MA (corresponding author), Univ Sao Paulo, Inst Trop Med, Fac Med, Sao Paulo, Brazil.; Shikanai-Yasuda, MA (corresponding author), Univ Sao Paulo, Dept Infect & Parasit Dis, Fac Med, Sao Paulo, Brazil.	paula.s@hc.fm.usp.br; masyasuda@yahoo.com.br	Sato, Paula K./K-6625-2012; Shikanai Yasuda, Maria Aparecida/AAX-7693-2020; Luiz, Olinda do Carmo/C-6075-2012	Sato, Paula K./0000-0002-3951-2316; Shikanai Yasuda, Maria Aparecida/0000-0003-3864-041X; Luiz, Olinda do Carmo/0000-0002-2596-3626; Gomes dos Santos, Alexandra/0000-0001-5061-4551	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 2012/25192-7]; Fundacao Faculdade de Medicina; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); FAPESP [2014/07801-1]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Fundacao Faculdade de Medicina; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 2012/25192-7) and Fundacao Faculdade de Medicina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. FC was supported by grants from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and FB was supported by grants from FAPESP (2014/07801-1).	Affandi JS, 2013, DIS MARKERS, V34, P445, DOI [10.1155/2013/246017, 10.3233/DMA-130991]; Anyona SB, 2011, INFECT IMMUN, V79, P4923, DOI 10.1128/IAI.05601-11; Aristizabal BH, 1998, INFECT IMMUN, V66, P5587, DOI 10.1128/IAI.66.11.5587-5591.1998; Awomoyi AA, 2004, THORAX, V59, P291, DOI 10.1136/thx.2003.013029; Bakr NM, 2018, IUBMB LIFE, V70, P165, DOI 10.1002/iub.1714; Balarin M A, 1993, Rev Soc Bras Med Trop, V26, P141, DOI 10.1590/S0037-86821993000300002; Bellissimo-Rodrigues F, 2011, AM J TROP MED HYG, V85, P546, DOI 10.4269/ajtmh.2011.11-0084; Benard G, 2001, CYTOKINE, V13, P248, DOI 10.1006/cyto.2000.0824; Benard G, 2008, MYCOPATHOLOGIA, V165, P209, DOI 10.1007/s11046-007-9065-0; Blotta MHSL, 1999, AM J TROP MED HYG, V61, P390, DOI 10.4269/ajtmh.1999.61.390; Bozzi A, 2006, HUM IMMUNOL, V67, P931, DOI 10.1016/j.humimm.2006.07.014; Bozzi A, 2009, CYTOKINE, V48, P212, DOI 10.1016/j.cyto.2009.07.011; Bulat-Kardum L, 2006, SCAND J IMMUNOL, V63, P142, DOI 10.1111/j.1365-3083.2005.01694.x; Caixeta CA, 2018, MYCOPATHOLOGIA, V183, P785, DOI 10.1007/s11046-018-0272-7; Calich VLG, 2008, FEMS IMMUNOL MED MIC, V53, P1, DOI 10.1111/j.1574-695X.2008.00378.x; Calich VLG, 2019, VIRULENCE, V10, P810, DOI 10.1080/21505594.2018.1483674; CALICH VLG, 1987, INFECT IMMUN, V55, P1919, DOI 10.1128/IAI.55.8.1919-1923.1987; Calich VLG, 1998, RES IMMUNOL, V149, P407, DOI 10.1016/S0923-2494(98)80764-5; Cao W, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-018-0729-z; Carvalho FMC, 2016, INFECT GENET EVOL, V43, P245, DOI 10.1016/j.meegid.2016.05.025; Castelar L, 2010, TISSUE ANTIGENS, V76, P126, DOI 10.1111/j.1399-0039.2010.01471.x; Chen WJ, 2006, CLIN INFECT DIS, V42, P1561, DOI 10.1086/503843; Corvino CL, 2007, CLIN EXP IMMUNOL, V147, P483, DOI 10.1111/j.1365-2249.2006.03308.x; de Castro LF, 2018, J INFECTION, V77, P137, DOI 10.1016/j.jinf.2018.03.004; de Castro LF, 2013, J INFECTION, V67, P470, DOI 10.1016/j.jinf.2013.07.019; de Moraes-Vasconcelos D, 2005, CLIN INFECT DIS, V41, pE31, DOI 10.1086/432119; DEMESSIAS IJT, 1991, COMPLEMENT INFLAMMAT, V8, P288, DOI 10.1159/000463198; DERESTREPO FM, 1983, SABOURAUDIA, V21, P35; Dhiman N, 2010, CYTOKINE, V50, P24, DOI 10.1016/j.cyto.2009.12.002; Estfanous SZK, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/3273645; Falleti E, 2007, J INTERF CYTOK RES, V27, P239, DOI 10.1089/jir.2006.0062; Feriotti C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00786; FRANCO M, 1987, J MED VET MYCOL, V25, P5; Calich VLG, 2008, MYCOPATHOLOGIA, V165, P223, DOI 10.1007/s11046-007-9048-1; Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0; GOLDANI LZ, 1991, MYCOPATHOLOGIA, V114, P89, DOI 10.1007/BF00436427; GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298; Haas SL, 2009, J CLIN IMMUNOL, V29, P620, DOI 10.1007/s10875-009-9302-z; Han M, 2011, MICROBIOL IMMUNOL, V55, P388, DOI 10.1111/j.1348-0421.2011.00332.x; Hasan FT, 2017, J INFECT DIS MED, V2, P3, DOI [10.4172/2576-1420.1000117, DOI 10.4172/2576-1420.1000117]; Hirankarn N, 2007, TISSUE ANTIGENS, V70, P160, DOI 10.1111/j.1399-0039.2007.00865.x; Matos GI, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-33; Jannuzzi GP, 2019, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00426; Jouanguy E, 2000, J CLIN INVEST, V105, P1429, DOI 10.1172/JCI9166; Karra VK, 2015, CYTOKINE, V73, P277, DOI 10.1016/j.cyto.2015.02.015; Ketelut-Carneiro N, 2015, J IMMUNOL, V194, P4507, DOI 10.4049/jimmunol.1402321; LACERDA GB, 1988, J MED VET MYCOL, V26, P253; Rodriguez DAL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004583; Loures FV, 2011, INFECT IMMUN, V79, P2470, DOI 10.1128/IAI.00375-10; Lozano VF, 2011, MEM I OSWALDO CRUZ, V106, P220, DOI 10.1590/S0074-02762011000200017; Marazzi MG, 2010, INT J INFECT DIS, V14, pE167, DOI 10.1016/j.ijid.2009.03.025; Martinez R, 2017, J FUNGI, V3, DOI 10.3390/jof3010001; Martinez R, 2015, REV INST MED TROP SP, V57, P11, DOI 10.1590/S0036-46652015000700004; Mendonca MS, 2015, MEM I OSWALDO CRUZ, V110, P781, DOI 10.1590/0074-02760150197; Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0; Neves ED, 2012, REV SOC BRAS MED TRO, V45, P757; Oliveira SJ, 2002, MICROBES INFECT, V4, P139, DOI 10.1016/S1286-4579(01)01521-0; Pan LP, 2012, J MED VIROL, V84, P26, DOI 10.1002/jmv.22251; Neto TAP, 2019, MYCOSES, V62, P186, DOI 10.1111/myc.12866; Pinzan CF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010757; Rezaeifar A, 2013, SCAND J INFECT DIS, V45, P584, DOI 10.3109/00365548.2013.794301; Alves ABRM, 2018, MED MYCOL, V56, P332, DOI 10.1093/mmy/myx050; Rodrigues DR, 2014, CYTOKINE, V69, P102, DOI 10.1016/j.cyto.2014.05.009; Romano CC, 2005, CLIN IMMUNOL, V114, P86, DOI 10.1016/j.clim.2004.09.005; Rosenzweig SD, 2004, CLIN IMMUNOL, V112, P113, DOI 10.1016/j.clim.2004.03.018; Sadahiro A, 2007, MED MYCOL, V45, P35, DOI 10.1080/13693780600999132; Sakai K, 2008, J INFECT DIS, V197, P1752, DOI 10.1086/588196; Samarani S, 2016, CYTOKINE, V82, P38, DOI 10.1016/j.cyto.2016.01.006; Santos RS, 2017, BIOL SEX DIFFER, V8, DOI 10.1186/s13293-017-0151-9; Severo Luiz Carlos, 1998, Revista Iberoamericana de Micologia, V15, P88; Shankar J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028402; Shi BJ, 2017, CLIN INVEST MED, V40, pE176, DOI 10.25011/cim.v40i5.28623; Shikanai-Yasuda MA, 2017, REV SOC BRAS MED TRO, V50, P715, DOI 10.1590/0037-8682-0230-2017; Shin JG, 2015, MOL MED REP, V12, P1568, DOI 10.3892/mmr.2015.3544; Velez DR, 2009, HUM GENET, V126, P643, DOI 10.1007/s00439-009-0713-y; Vieira GD, 2014, REV SOC BRAS MED TRO, V47, P63, DOI 10.1590/0037-8682-0225-2013; Vinh DC, 2009, CLIN INFECT DIS, V49, pE62, DOI 10.1086/605532; Vokurka J, 2009, ARCH ORAL BIOL, V54, P172, DOI 10.1016/j.archoralbio.2008.09.002; Wang J, 2010, EUR J CLIN MICROBIOL, V29, P1291, DOI 10.1007/s10096-010-0985-0; Zerbe CS, 2005, CLIN INFECT DIS, V41, pE38, DOI 10.1086/432120	80	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2020	11								542210	10.3389/fimmu.2020.542210	http://dx.doi.org/10.3389/fimmu.2020.542210			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA1YQ	33117339	Green Published, gold			2022-12-18	WOS:000577590300001
J	Rahmati, M; Ledee, N				Rahmati, Mona; Ledee, Nathalie			Targeted Endometrial Scratching: An Example of Endometrial Diagnosis Usage in Reproductive Medicine	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						embryo implantation; endometrial scratching; repeated implantation failure; endometrial receptivity; reproductive medicine	ANTIGEN-PRESENTING CELLS; NATURAL-KILLER-CELLS; IMPLANTATION FAILURE; DENDRITIC CELLS; LOCAL INJURY; EMBRYO IMPLANTATION; DECIDUALIZATION; PREGNANCY; ANGIOGENESIS; IMPROVE		[Rahmati, Mona] London Womens Clin, London, England; [Ledee, Nathalie] Hop Cochin, Ppiniere Paris Sante Cochin, MatriceLAB Innove, Paris, France; [Ledee, Nathalie] Hop Bluets, Ctr Assistance Med Procreat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Ledee, N (corresponding author), Hop Cochin, Ppiniere Paris Sante Cochin, MatriceLAB Innove, Paris, France.; Ledee, N (corresponding author), Hop Bluets, Ctr Assistance Med Procreat, Paris, France.	nathalie-ledee@orange.fr						Blois SM, 2008, J MOL MED, V86, P837, DOI 10.1007/s00109-008-0342-2; Blois SM, 2011, J REPROD IMMUNOL, V88, P86, DOI 10.1016/j.jri.2010.11.002; Blois SM, 2004, BIOL REPROD, V70, P1018, DOI 10.1095/biolreprod.103.022640; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2002, BLOOD, V100, P3633, DOI 10.1182/blood-2001-12-0293; Dong ZM, 2009, CURR PHARM DESIGN, V15, P365, DOI 10.2174/138161209787315783; Donoghue JF, 2019, HUM REPROD, V34, P2456, DOI 10.1093/humrep/dez194; Gellersen B, 2014, ENDOCR REV, V35, P851, DOI 10.1210/er.2014-1045; Gnainsky Y, 2015, REPRODUCTION, V149, P75, DOI 10.1530/REP-14-0395; Gnainsky Y, 2010, FERTIL STERIL, V94, P2030, DOI 10.1016/j.fertnstert.2010.02.022; Guven S, 2014, EUR J OBSTET GYN R B, V173, P58, DOI 10.1016/j.ejogrb.2013.11.005; Haahr T, 2019, HUM REPROD, V34, P2083, DOI 10.1093/humrep/dez167; Kammerer U, 2005, CHEM IMMUNOL ALLERGY, V89, P96, DOI 10.1159/000087951; Karimzade MA, 2010, ARCH GYNECOL OBSTET, V281, P499, DOI 10.1007/s00404-009-1166-1; Koedooder R, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0653-x; Lash GE, 2016, J REPROD IMMUNOL, V116, P50, DOI 10.1016/j.jri.2016.04.290; Laskarin G, 2007, AM J REPROD IMMUNOL, V58, P255, DOI 10.1111/j.1600-0897.2007.00511.x; Ledee N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01032; Ledee N, 2017, J REPROD IMMUNOL, V119, P23, DOI 10.1016/j.jri.2016.11.007; Ledee N, 2016, AM J REPROD IMMUNOL, V75, P388, DOI 10.1111/aji.12483; Ledee-Bataille N, 2004, FERTIL STERIL, V81, P59, DOI 10.1016/j.fertnstert.2003.06.007; LEDFORD BE, 1976, BIOL REPROD, V15, P529, DOI 10.1095/biolreprod15.4.529; LEJEUNE B, 1982, J REPROD FERTIL, V66, P519; Lensen S, 2019, NEW ENGL J MED, V380, P325, DOI 10.1056/NEJMoa1808737; Li WT, 2019, HUM REPROD, V34, P2372, DOI 10.1093/humrep/dez207; Liang Y, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/757184; Manaster I, 2008, J IMMUNOL, V181, P1869, DOI 10.4049/jimmunol.181.3.1869; Moreno I, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2018.02.012; Petitbarat M, 2010, FERTIL STERIL, V94, P1141, DOI 10.1016/j.fertnstert.2009.10.049; Plaks V, 2008, J CLIN INVEST, V118, P3954, DOI 10.1172/JCI36682; Rodriguez AC, 2019, HORM CANCER-US, V10, P51, DOI 10.1007/s12672-019-0358-9; Safdarian L, 2011, IRAN J REPROD MED, V9, P285; Valdes CT, 2017, FERTIL STERIL, V108, P15, DOI 10.1016/j.fertnstert.2017.05.033; van Hoogenhuijze NE, 2019, HUM REPROD OPEN, V2019, DOI DOI 10.1093/hropen/hoy025; Vitagliano A, 2019, FERTIL STERIL, V111, P734, DOI 10.1016/j.fertnstert.2018.12.008; Xie XM, 2005, BIOL REPROD, V73, P510, DOI 10.1095/biolreprod.104.033951	36	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2020	11								589677	10.3389/fimmu.2020.589677	http://dx.doi.org/10.3389/fimmu.2020.589677			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB9MH	33101322	gold, Green Published			2022-12-18	WOS:000578786200001
J	Uebele, J; Habenicht, K; Ticha, O; Bekeredjian-Ding, I				Uebele, Julia; Habenicht, Katharina; Ticha, Olga; Bekeredjian-Ding, Isabelle			Staphylococcus aureusProtein A Induces Human Regulatory T Cells Through Interaction With Antigen-Presenting Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Staphylococcus aureus; Treg-regulatory T cell; Ig-binding proteins; protein A; tolerance; immune suppression; immune evasion; human	PROTEIN-A; ANTIBIOTIC-RESISTANCE; B-CELLS; AUREUS; SUPERANTIGEN; INFECTION; BACTERIAL; ANTIBODY; PROLIFERATION; ACTIVATION	Despite continuous exposure and development of specific immunity,Staphylococcus aureus(Sa) remains one of the leading causes of severe infections worldwide. Although innate immune defense mechanisms are well understood, the role of the T cell response has not been fully elucidated. Here, we demonstrate that Sa and one of its major virulence factors protein A (SpA) induce human regulatory T cells (Tregs), key players in immune tolerance. In human PBMC and MoDC/T cell cocultures CD4(+)CD25(+)CD127(dim)Tregs were induced upon stimulation with Sa and to a lower extent with SpA alone. Treg induction was strongly, but not exclusively, dependent on SpA, and independent of antigen presentation or T cell epitope recognition. Lastly, soluble factors in the supernatant of SpA-stimulated MoDC were sufficient to trigger Treg formation, while supernatants of MoDC/T cell cocultures containing Sa-triggered Tregs displayed T cell suppressive activity. In summary, our findings identify a new immunosuppressory function of SpA, which leads to release of soluble, Treg-inducing factors and might be relevant to establish colonization.	[Uebele, Julia; Habenicht, Katharina; Ticha, Olga; Bekeredjian-Ding, Isabelle] Paul Ehrlich Inst, Div Microbiol, Langen, Germany	Paul Ehrlich Institute	Bekeredjian-Ding, I (corresponding author), Paul Ehrlich Inst, Div Microbiol, Langen, Germany.	isabelle.bekeredjian-ding@pei.de			Paul-Ehrlich-Institut	Paul-Ehrlich-Institut	This research was funded by the Paul-Ehrlich-Institut. It received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.	Ali A, 2015, J INFECT DIS, V212, P1308, DOI 10.1093/infdis/jiv212; Anderson AL, 2006, INFECT IMMUN, V74, P1196, DOI 10.1128/IAI.74.2.1196-1203.2006; Antonanzas F, 2015, PHARMACOECONOMICS, V33, P285, DOI 10.1007/s40273-014-0242-y; Armbruster NS, 2016, INT J MED MICROBIOL, V306, P666, DOI 10.1016/j.ijmm.2016.09.002; Bekeredjian-Ding I, 2007, J IMMUNOL, V178, P2803, DOI 10.4049/jimmunol.178.5.2803; Bekeredjian-Ding I, 2017, CURR TOP MICROBIOL, V409, P385, DOI 10.1007/82_2015_5004; Bjorkander S, 2016, SCI REP-UK, V6, DOI 10.1038/srep22083; Broker BM, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010031; Brown AF, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005226; Bunker JJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9356; Cao R, 2012, APPL ENVIRON MICROB, V78, P4942, DOI 10.1128/AEM.00803-12; DeDent AC, 2007, J BACTERIOL, V189, P4473, DOI 10.1128/JB.00227-07; Dey I, 2020, MICROB PATHOGENESIS, V139, DOI 10.1016/j.micpath.2019.103903; Dey I, 2017, MICROB PATHOGENESIS, V113, P248, DOI 10.1016/j.micpath.2017.10.033; Domogalla MP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01764; DOSSETT JH, 1969, J IMMUNOL, V103, P1405; Dryla A, 2005, CLIN DIAGN LAB IMMUN, V12, P387, DOI 10.1128/CDLI.12.3.387-398.2005; Falugi F, 2013, MBIO, V4, DOI 10.1128/mBio.00575-13; FORSGREN A, 1969, ACTA PATHOL MIC SC, V75, P481; Fowler VG, 2014, CLIN MICROBIOL INFEC, V20, P66, DOI 10.1111/1469-0691.12570; Giersing BK, 2016, VACCINE, V34, P2962, DOI 10.1016/j.vaccine.2016.03.110; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Goodyear CS, 2003, J EXP MED, V197, P1125, DOI 10.1084/jem.20020552; Harden JL, 2012, IMMUNOL INVEST, V41, P738, DOI 10.3109/08820139.2012.676122; Heim CE, 2015, J IMMUNOL, V194, P3861, DOI 10.4049/jimmunol.1402689; Karauzum H, 2017, CURR TOP MICROBIOL, V409, P419, DOI 10.1007/82_2016_1; Kim HK, 2016, P NATL ACAD SCI USA, V113, P5718, DOI 10.1073/pnas.1524267113; Klein E, 2007, EMERG INFECT DIS, V13, P1840, DOI 10.3201/eid1312.070629; Kolata JB, 2015, J INFECT DIS, V212, P830, DOI 10.1093/infdis/jiv128; LARSSON A, 1992, HYBRIDOMA, V11, P239, DOI 10.1089/hyb.1992.11.239; Ledo C, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00259; Lee J, 2018, J IMMUNOL, V200, P669, DOI 10.4049/jimmunol.1602109; Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703; Mancini F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147767; Nguyen MT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02234-4; Misstear K, 2014, J INFECT DIS, V209, P1479, DOI 10.1093/infdis/jit636; Montgomery CP, 2014, INFECT IMMUN, V82, P2125, DOI 10.1128/IAI.01491-14; O'Brien EC, 2019, TRENDS MOL MED, V25, P171, DOI 10.1016/j.molmed.2018.12.010; O'Halloran DP, 2015, INFECT IMMUN, V83, P1598, DOI 10.1128/IAI.03122-14; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Palmqvist N, 2005, MICROBES INFECT, V7, P1501, DOI 10.1016/j.micinf.2005.05.008; Parcina M, 2013, J IMMUNOL, V190, P1591, DOI 10.4049/jimmunol.1201222; Pauli NT, 2014, J EXP MED, V211, P2331, DOI 10.1084/jem.20141404; Rabe H, 2014, IMMUNOLOGY, V141, P467, DOI 10.1111/imm.12209; Richardson JR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00995; Richardson JR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02603; Rodriguez-Perea AL, 2016, CLIN EXP IMMUNOL, V185, P281, DOI 10.1111/cei.12804; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakoulas G, 2008, CLIN INFECT DIS, V46, pS360, DOI 10.1086/533592; Sakr A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02419; Schlatterer K, 2018, MBIO, V9, DOI 10.1128/mBio.01851-18; Schmidt A, 2015, SURG INFECT, V16, P428, DOI 10.1089/sur.2014.045; Schreiner J, 2013, J IMMUNOL, V190, P3417, DOI 10.4049/jimmunol.1202563; Sharabi A, 2018, NAT REV DRUG DISCOV, V17, P823, DOI 10.1038/nrd.2018.148; SJODAHL J, 1977, EUR J BIOCHEM, V78, P471, DOI 10.1111/j.1432-1033.1977.tb11760.x; Stich N, 2010, TOXINS, V2, P2272, DOI 10.3390/toxins2092272; Stoll H, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00321; Sun L, 2015, CYTOKINE, V75, P249, DOI 10.1016/j.cyto.2015.01.030; Taylor AL, 2010, J IMMUNOL, V185, P6591, DOI 10.4049/jimmunol.1002416; Tebartz C, 2015, J IMMUNOL, V194, P1100, DOI 10.4049/jimmunol.1400196; Ticha O, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01951; Uebele J, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006387; van Belkum A, 2009, J INFECT DIS, V199, P1820, DOI 10.1086/599119; Verma ND, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00190; Wiese L, 2013, J INFECTION, V67, P199, DOI 10.1016/j.jinf.2013.04.018; Yu N, 2012, INFLAMMATION, V35, P1773, DOI 10.1007/s10753-012-9496-8; ZHAO YX, 1995, J IMMUNOL, V155, P5736; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957	69	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2020	11								581713	10.3389/fimmu.2020.581713	http://dx.doi.org/10.3389/fimmu.2020.581713			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA2IF	33117390	Green Published, gold			2022-12-18	WOS:000577615200001
J	Hua, J; Chen, Y; Fu, B; Chen, X; Xu, XJ; Yang, SH; Chen, C; Xu, YJ				Hua, Juan; Chen, Yan; Fu, Bin; Chen, Xu; Xu, Xue-jun; Yang, Shuang-Hui; Chen, Cong; Xu, Ya-jing			Downregulation of p53 by Insufficient CTCF in CD4(+)T Cells Is an Important Factor Inducing Acute Graft-Versus-Host Disease	FRONTIERS IN IMMUNOLOGY			English	Article						aGVHD; CD4(+)T cell; p53; CTCF; P300	TUMOR-SUPPRESSOR P53; T-CELLS; EPIGENETIC REGULATION; TRANSCRIPTION FACTOR; EXPRESSION; ARTHRITIS; MARROW; CANCER	Recent evidence indicates that p53 plays a protective role against various systemic autoimmune diseases by suppressing pro-inflammatory cytokine production and reducing the number of pathogenic T cells. However, whether abnormal p53 expression participates in the development of acute graft-versus-host disease (aGVHD) remains unclear. In this study, we demonstrated that p53 was downregulated in CD4(+)T cells from patients with aGVHD compared with the non-aGVHD group. Furthermore, we confirmed that low expression of CCCTC-binding factor (CTCF) in CD4(+)T cells from aGVHD cases is an important factor affecting histone H3K9/K14 hypoacetylation in thep53promoter and p53 downregulation. Restoring CTCF expression in CD4(+)T cells from aGVHD patients increased p53 amounts and corrected the imbalance of Th17 cells/Tregs. Taken together, these results provide novel insights into p53 downregulation in CD4(+)T cells from aGVHD patients.	[Hua, Juan; Chen, Yan; Fu, Bin; Chen, Xu; Xu, Xue-jun; Yang, Shuang-Hui; Chen, Cong; Xu, Ya-jing] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha, Peoples R China	Central South University	Xu, YJ (corresponding author), Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha, Peoples R China.	xyyajingxu@csu.edu.cn			National Natural Science Foundation of China [81974002, 81570165]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Nos. 81974002 and 81570165).	Carlson MJ, 2009, BLOOD, V113, P1365, DOI 10.1182/blood-2008-06-162420; Chen Y, 2013, CHINESE J CANCER RES, V25, P389, DOI 10.3978/j.issn.1000-9604.2013.07.01; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Duffy MJ, 2014, CANCER TREAT REV, V40, P1153, DOI 10.1016/j.ctrv.2014.10.004; Fierabracci A., 2016, INT J MOL SCI, V17; Fulton LM, 2012, J IMMUNOL, V189, P1765, DOI 10.4049/jimmunol.1200858; Gates LA, 2017, J BIOL CHEM, V292, P14456, DOI 10.1074/jbc.M117.802074; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; Hou CH, 2008, P NATL ACAD SCI USA, V105, P20398, DOI 10.1073/pnas.0808506106; Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-424; Kawashima H, 2013, J IMMUNOL, V191, P3614, DOI 10.4049/jimmunol.1300509; Kim LK, 2014, MOL CELL, V54, P56, DOI 10.1016/j.molcel.2014.02.004; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; Leech M, 2008, CLIN EXP IMMUNOL, V152, P345, DOI 10.1111/j.1365-2249.2008.03629.x; Li XP, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130413; Liu YJ, 2013, BIOL BLOOD MARROW TR, V19, P1421, DOI 10.1016/j.bbmt.2013.06.013; Majumder P, 2008, J EXP MED, V205, P785, DOI 10.1084/jem.20071843; Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454; Martin PJ, 2012, BIOL BLOOD MARROW TR, V18, P1150, DOI 10.1016/j.bbmt.2012.04.005; Mendez-Catala CF, 2013, NEOPLASIA, V15, P898, DOI 10.1593/neo.121948; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Mustafa M, 2015, BIOCHEM BIOPH RES CO, V467, P828, DOI 10.1016/j.bbrc.2015.10.058; Park JS, 2013, ARTHRITIS RHEUM-US, V65, P949, DOI 10.1002/art.37841; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Schuijers J, 2018, CELL REP, V23, P349, DOI 10.1016/j.celrep.2018.03.056; Simelyte E, 2005, ARTHRITIS RHEUM-US, V52, P1876, DOI 10.1002/ART.21099; Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509; Takatori H, 2014, CRIT REV IMMUNOL, V34, P509, DOI 10.1615/CritRevImmunol.2014012193; Vostrov AA, 2002, J BIOL CHEM, V277, P1619, DOI 10.1074/jbc.M109748200; Watanabe M, 2014, IMMUNITY, V40, P681, DOI 10.1016/j.immuni.2014.04.006; Wolff D, 2013, BIOL BLOOD MARROW TR, V19, P767, DOI 10.1016/j.bbmt.2013.01.018; Xiao TJ, 2015, CELL REP, V12, P1704, DOI 10.1016/j.celrep.2015.08.005; Xu YJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03078; Xu YJ, 2015, CLIN IMMUNOL, V161, P278, DOI 10.1016/j.clim.2015.08.012; Zeiser R, 2016, BRIT J HAEMATOL, V175, P191, DOI 10.1111/bjh.14295; Zhang SZ, 2011, FASEB J, V25, P2387, DOI 10.1096/fj.10-175299; Zhao M, 2016, J AUTOIMMUN, V69, P64, DOI 10.1016/j.jaut.2016.03.001; Zitzer NC, 2018, J IMMUNOL, V200, P4170, DOI 10.4049/jimmunol.1701465	39	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2020	11								568637	10.3389/fimmu.2020.568637	http://dx.doi.org/10.3389/fimmu.2020.568637			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB7RC	33133081	gold, Green Published			2022-12-18	WOS:000578663200001
J	Khoenkhoen, S; Adori, M; Pedersen, GK; Hedestam, GBK				Khoenkhoen, Sharesta; Adori, Monika; Pedersen, Gabriel K.; Hedestam, Gunilla B. Karlsson			Flow Cytometry-Based Protocols for the Analysis of Human Plasma Cell Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						plasma cell differentiation; Blimp-1; PRDM1; IRF4; Pax5; CVID; common variable immunodeficiency; B cell proliferation	COMMON VARIABLE IMMUNODEFICIENCY; MEMORY B-CELLS; ANTIBODY-RESPONSES; UP-REGULATION; BLIMP-1; REPRESSION; TRANSCRIPTION; EXPRESSION; MUTATIONS; IL-21	Humoral immunity is established after differentiation of antigen-specific B cells into plasma cells (PCs) that produce antibodies of relevant specificities. Defects in the development, activation, or differentiation of B cells severely compromises the immune response. Primary immunodeficiencies are often characterized by hypogammaglobulinemia and the inability to mount effective antigen-specific antibody responses, resulting in increased susceptibility to infections. After IgA deficiency, which is most often asymptomatic, common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency, but in most cases the underlying genetic causes are unknown or their roles in disease pathogenesis are poorly understood. In this study, we developed a protocol forin vitrostimulation of primary human B cells for subsequent analyses of PC differentiation and antibody production. With this approach, we were able to detect a population of CD38(+)IRF4(+)Blimp-1(+)cells committed to PC fate and IgG production, including when starting from cryopreserved samples. The application of functional assays to characterize PC differentiation and possible defects therein in B cells from patients suffering from primary antibody deficiencies with late B cell defects could increase our understanding of the disease pathophysiology and underlying mechanisms.	[Khoenkhoen, Sharesta; Adori, Monika; Pedersen, Gabriel K.; Hedestam, Gunilla B. Karlsson] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	Karolinska Institutet	Khoenkhoen, S; Hedestam, GBK (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.	sharesta.khoenkhoen@ki.se; gunilla.karlsson.hedestam@ki.se	Hedestam, Gunilla Karlsson/AAN-9616-2021	Pedersen, Gabriel/0000-0001-6872-3975	Karolinska Institutet Doctoral grant; Swedish Research Council [532 2017-00968]; Fondation Dormeur, Vaduz	Karolinska Institutet Doctoral grant; Swedish Research Council(Swedish Research CouncilEuropean Commission); Fondation Dormeur, Vaduz	This work was supported by a Karolinska Institutet Doctoral grant to SK and a Distinguished Professor grant from the Swedish Research Council (agreement 532 2017-00968) to GK. The work was also supported by a generous equipment grant from the Fondation Dormeur, Vaduz.	Arjunaraja S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00913; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Banko Z, 2017, J IMMUNOL, V198, P1512, DOI 10.4049/jimmunol.1600218; Bogaert DJA, 2016, J MED GENET, V53, P575, DOI 10.1136/jmedgenet-2015-103690; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Boztug H, 2016, J CLIN IMMUNOL, V36, P533, DOI 10.1007/s10875-016-0306-1; Garcia-Morato MB, 2018, J ALLERGY CLIN IMMUN, V141, P1924, DOI 10.1016/j.jaci.2017.12.995; Caron G, 2015, CELL REP, V13, P1059, DOI 10.1016/j.celrep.2015.09.051; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Cohen SB, 2019, J ALLERGY CLIN IMMUN, V143, P797, DOI 10.1016/j.jaci.2018.10.005; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Cunningham-Rundles C, 2012, HEMATOL-AM SOC HEMAT, P301, DOI 10.1182/asheducation-2012.1.301; Delogu A, 2006, IMMUNITY, V24, P269, DOI 10.1016/j.immuni.2006.01.012; Diehl SA, 2008, J IMMUNOL, V180, P4805, DOI 10.4049/jimmunol.180.7.4805; Ding BB, 2013, J IMMUNOL, V190, P1827, DOI 10.4049/jimmunol.1201678; Durandy A, 2013, NAT REV IMMUNOL, V13, P519, DOI 10.1038/nri3466; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Good KL, 2007, P NATL ACAD SCI USA, V104, P13420, DOI 10.1073/pnas.0703872104; Good KL, 2009, J IMMUNOL, V182, P890, DOI 10.4049/jimmunol.182.2.890; Guerin A, 2018, ELIFE, V7, DOI 10.7554/eLife.32340; Halliley JL, 2015, IMMUNITY, V43, P132, DOI 10.1016/j.immuni.2015.06.016; Hodgkin PD, 1996, J EXP MED, V184, P277, DOI 10.1084/jem.184.1.277; Jolles S, 2013, J ALLER CL IMM-PRACT, V1, P545, DOI 10.1016/j.jaip.2013.09.015; Klemann C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00297; Kometani K, 2013, IMMUNITY, V39, P136, DOI 10.1016/j.immuni.2013.06.011; Kuehn HS, 2017, BLOOD, V130, P1553, DOI 10.1182/blood-2017-05-782177; Le Gallou S, 2012, J IMMUNOL, V189, P161, DOI 10.4049/jimmunol.1200301; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lin WHW, 2015, CELL REP, V13, P2203, DOI 10.1016/j.celrep.2015.10.072; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Meyts I, 2016, J ALLERGY CLIN IMMUN, V138, P957, DOI 10.1016/j.jaci.2016.08.003; Minnich M, 2016, NAT IMMUNOL, V17, P331, DOI 10.1038/ni.3349; Rosel AL, 2015, J ALLERGY CLIN IMMUN, V135, P198, DOI 10.1016/j.jaci.2014.06.022; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Setz CS, 2018, CELL REP, V24, P391, DOI 10.1016/j.celrep.2018.06.035; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Sharfe N, 2018, J ALLERGY CLIN IMMUN, V142, P618, DOI 10.1016/j.jaci.2017.10.033; Sogkas G, 2018, J ALLERGY CLIN IMMUN, V142, P1650, DOI 10.1016/j.jaci.2018.06.039; Sundling C, 2010, J EXP MED, V207, P2003, DOI 10.1084/jem.20100025; Tang P, 2018, J CLIN IMMUNOL, V38, P88, DOI 10.1007/s10875-017-0462-y; Tangye SG, 2003, J IMMUNOL, V170, P261, DOI 10.4049/jimmunol.170.1.261; Taubenheim N, 2005, J IMMUNOL, V175, P5498, DOI 10.4049/jimmunol.175.8.5498; Tellier J, 2016, NAT IMMUNOL, V17, P323, DOI 10.1038/ni.3348; Thaventhiran JED, 2020, NATURE, V583, P90, DOI 10.1038/s41586-020-2265-1; Vinuesa CG, 2005, NAT REV IMMUNOL, V5, P853, DOI 10.1038/nri1714; Warnatz K, 2008, CYTOM PART B-CLIN CY, V74B, P261, DOI 10.1002/cyto.b.20432	52	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2020	11								571321	10.3389/fimmu.2020.571321	http://dx.doi.org/10.3389/fimmu.2020.571321			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB7HR	33133085	gold, Green Published			2022-12-18	WOS:000578638700001
J	Munang'andu, HM; Salinas, I; Tafalla, C; Dalmo, RA				Munang'andu, Hetron M.; Salinas, Irene; Tafalla, Carolina; Dalmo, Roy Ambli			Editorial: Vaccines and Immunostimulants for Finfish	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccines; immunostimulants; antigens; correlates of protection; immune training			[Munang'andu, Hetron M.] Norwegian Univ Life Sci, Fac Vet Med, Oslo, Norway; [Salinas, Irene] Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; [Tafalla, Carolina] Ctr Invest Sanidad Anim, Inst Nacl Invest Agr, Anim Hlth Res Ctr, Madrid, Spain; [Dalmo, Roy Ambli] Univ Tromso, Tromso, Norway	Norwegian University of Life Sciences; University of New Mexico; Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA); UiT The Arctic University of Tromso	Munang'andu, HM (corresponding author), Norwegian Univ Life Sci, Fac Vet Med, Oslo, Norway.	hetroney.mweemba.munangandu@nmbu.no	Munang'andu, Hetron Mweemba/C-5926-2014; Dalmo, Roy Ambli/AAN-5157-2021; Dalmo, Roy Ambli/B-8437-2011; Tafalla, Carolina/J-8074-2014	Munang'andu, Hetron Mweemba/0000-0002-1021-6396; Dalmo, Roy Ambli/0000-0002-6181-9859; Dalmo, Roy Ambli/0000-0002-6181-9859; Tafalla, Carolina/0000-0002-0860-2976				Anderson Douglas P., 1992, Annual Review of Fish Diseases, V2, P281, DOI 10.1016/0959-8030(92)90067-8; Balado M, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01766; Bowden TJ, 2008, FISH SHELLFISH IMMUN, V25, P373, DOI 10.1016/j.fsi.2008.03.017; Dawood MAO, 2018, REV AQUACULT, V10, P950, DOI 10.1111/raq.12209; FAO (Food and Agriculture Organization of the United Nations), 2018, STAT WORLD FISH AQ; Gudding R, 2014, FISH VACCINATION, P1, DOI 10.1002/9781118806913; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; Munang'andu HM, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00406; Munang'andu HM, 2019, FISH SHELLFISH IMMUN, V85, P132, DOI 10.1016/j.fsi.2018.03.060; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Neutra MR, 1999, CURR TOP MICROBIOL, V236, P17; Tafalla C, 2013, FISH SHELLFISH IMMUN, V35, P1740, DOI 10.1016/j.fsi.2013.02.029	12	2	2	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2020	11								573771	10.3389/fimmu.2020.573771	http://dx.doi.org/10.3389/fimmu.2020.573771			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB7CP	33117370	Green Published, gold			2022-12-18	WOS:000578625500001
J	Pattinson, DJ; Apte, SH; Wibowo, N; Rivera-Hernandez, T; Groves, PL; Middelberg, APJ; Doolan, DL				Pattinson, David J.; Apte, Simon H.; Wibowo, Nani; Rivera-Hernandez, Tania; Groves, Penny L.; Middelberg, Anton P. J.; Doolan, Denise L.			Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8(+)T Cell Responses but Differ in Capacity to Induce CD4(+)T Cell Responses and Antibody Responses	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; vaccine; T cells; virus-like particle; capsomere; murine polyomavirus; chimeric; Plasmodium yoelii	CYTOTOXIC T-LYMPHOCYTES; RTS,S/AS01 MALARIA VACCINE; CIRCUMSPOROZOITE-PROTEIN; PLASMODIUM-YOELII; PROTECTIVE IMMUNITY; MURINE MALARIA; DNA; MICE; IMMUNOGENICITY; POLYOMAVIRUS	Despite extensive research, the development of an effective malaria vaccine remains elusive. The induction of robust and sustained T cell and antibody response by vaccination is an urgent unmet need. Chimeric virus-like particles (VLPs) are a promising vaccine platform. VLPs are composed of multiple subunit capsomeres which can be rapidly produced in a cost-effective manner, but the ability of capsomeres to induce antigen-specific cellular immune responses has not been thoroughly investigated. Accordingly, we have compared chimeric VLPs and their sub-unit capsomeres for capacity to induce CD8(+)and CD4(+)T cell and antibody responses. We produced chimeric murine polyomavirus VLPs and capsomeres each incorporating defined CD8(+)T cell, CD4(+)T cell or B cell repeat epitopes derived fromPlasmodium yoeliiCSP. VLPs and capsomeres were evaluated using both homologous or heterologous DNA prime/boost immunization regimens for T cell and antibody immunogenicity. Chimeric VLP and capsomere vaccine platforms induced robust CD8(+)T cell responses at similar levels which was enhanced by a heterologous DNA prime. The capsomere platform was, however, more efficient at inducing CD4(+)T cell responses and less efficient at inducing antigen-specific antibody responses. Our data suggest that capsomeres, which have significant manufacturing advantages over VLPs, should be considered for diseases where a T cell response is the desired outcome.	[Pattinson, David J.; Apte, Simon H.; Groves, Penny L.; Doolan, Denise L.] QIMR Berghofer Med Res Inst, Infect Dis Programme, Brisbane, Qld, Australia; [Pattinson, David J.; Doolan, Denise L.] James Cook Univ, Ctr Mol Therapeut, Australian Inst Trop Hlth & Med, Cairns, Qld, Australia; [Wibowo, Nani; Rivera-Hernandez, Tania; Middelberg, Anton P. J.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld, Australia; [Middelberg, Anton P. J.] Univ Adelaide, Sch Chem Engn, Adelaide, SA, Australia	QIMR Berghofer Medical Research Institute; James Cook University; University of Queensland; University of Adelaide	Pattinson, DJ; Doolan, DL (corresponding author), QIMR Berghofer Med Res Inst, Infect Dis Programme, Brisbane, Qld, Australia.; Pattinson, DJ; Doolan, DL (corresponding author), James Cook Univ, Ctr Mol Therapeut, Australian Inst Trop Hlth & Med, Cairns, Qld, Australia.	David.pattinson@jcu.edu.au; Denise.doolan@jcu.edu.au	Rivera-Hernandez, Tania/AAG-7511-2020; Apte, Simon/H-2798-2016	Apte, Simon/0000-0003-3105-0820; Pattinson, David/0000-0003-0806-6832; Rivera-Hernandez, Tania/0000-0002-3582-9973; Middelberg, Anton/0000-0001-5922-5704; Doolan, Denise/0000-0001-7354-8817	National Health and Medical Research Council (NHMRC) [1037304]; Australian Infectious Diseases UQ-QIMR; NHMRC Principal Research Fellowship [1023636]; Australian Postgraduate Award	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian Infectious Diseases UQ-QIMR; NHMRC Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government)	This research was funded by the National Health and Medical Research Council (NHMRC) Program grant #1037304 and by an Australian Infectious Diseases UQ-QIMR Seed funding grant. DD was supported by a NHMRC Principal Research Fellowship #1023636. DP was supported by an Australian Postgraduate Award.	Ahlborg N, 2000, INFECT IMMUN, V68, P2102, DOI 10.1128/IAI.68.4.2102-2109.2000; Alonso PL, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000406; Aubert RD, 2011, P NATL ACAD SCI USA, V108, P21182, DOI 10.1073/pnas.1118450109; BRILES DE, 1981, NATURE, V294, P88, DOI 10.1038/294088a0; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHAROENVIT Y, 1991, J IMMUNOL, V146, P1020; Chuan YP, 2008, J BIOTECHNOL, V134, P64, DOI 10.1016/j.jbiotec.2007.12.004; Chuan YP, 2008, BIOTECHNOL BIOENG, V99, P1425, DOI 10.1002/bit.21710; Chuan YP, 2014, BIOCHEM ENG J, V90, P255, DOI 10.1016/j.bej.2014.06.005; Ding H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016563; Dobano C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10195-z; Doolan DL, 2000, J IMMUNOL, V165, P1453, DOI 10.4049/jimmunol.165.3.1453; Doolan DL, 2001, INT J PARASITOL, V31, P753, DOI 10.1016/S0020-7519(01)00184-9; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; Dorn DC, 2008, VIRAL IMMUNOL, V21, P12, DOI 10.1089/vim.2007.0085; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; GRILLOT D, 1990, EUR J IMMUNOL, V20, P1215, DOI 10.1002/eji.1830200604; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Hill AVS, 2010, HUM VACCINES, V6, P78, DOI 10.4161/hv.6.1.10116; Hovenden M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003306; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kawano M, 2014, VIROLOGY, V448, P159, DOI 10.1016/j.virol.2013.10.010; Kent SJ, 1998, J VIROL, V72, P10180, DOI 10.1128/JVI.72.12.10180-10188.1998; Kogot JM, 2012, BIOTECHNIQUES, V52, P95, DOI 10.2144/000113810; Kumada Y, 2010, J BIOSCI BIOENG, V109, P583, DOI 10.1016/j.jbiosc.2009.11.005; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Lipin DI, 2008, J CHROMATOGR A, V1190, P204, DOI 10.1016/j.chroma.2008.03.032; MAJARIAN WR, 1984, J IMMUNOL, V132, P3131; Mazeike E, 2012, VIRUS RES, V163, P2, DOI 10.1016/j.virusres.2011.08.003; Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394; Miao J, 2006, VACCINE, V24, P6187, DOI 10.1016/j.vaccine.2006.05.099; Michel ML, 2010, PATHOL BIOL, V58, P288, DOI 10.1016/j.patbio.2010.01.006; Middelberg APJ, 2011, VACCINE, V29, P7154, DOI 10.1016/j.vaccine.2011.05.075; Moore AC, 2004, IMMUNOL REV, V199, P126, DOI 10.1111/j.0105-2896.2004.00138.x; Ohlschlager P, 2003, J VIROL, V77, P4635, DOI 10.1128/JVI.77.8.4635-4645.2003; Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257; Pattinson DJ, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00215; Rivera-Hernandez T, 2013, VACCINE, V31, P1950, DOI 10.1016/j.vaccine.2013.02.013; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Schussek S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15354-0; Seth A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117203; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; Stanley M, 2006, VACCINE, V24, P106, DOI 10.1016/j.vaccine.2006.05.110; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; Szomolanyi-Tsuda E, 1998, CURR OPIN IMMUNOL, V10, P431, DOI 10.1016/S0952-7915(98)80117-9; Thones N, 2008, J VIROL, V82, P5472, DOI 10.1128/JVI.02482-07; Thomsen AR, 1996, J IMMUNOL, V157, P3074; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; TSUJI M, 1990, J EXP MED, V172, P1353, DOI 10.1084/jem.172.5.1353; Visciano ML, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-4; Vuola JM, 2005, J IMMUNOL, V174, P449, DOI 10.4049/jimmunol.174.1.449; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WEISS WR, 1993, J IMMUNOL, V151, P2690; WEISS WR, 1992, J IMMUNOL, V149, P2103; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; White MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061395; WHO, 2019, WORLD MALARIA REPORT; Wibowo N, 2014, VACCINE, V32, P3664, DOI 10.1016/j.vaccine.2014.04.043; Wibowo N, 2013, CHEM ENG SCI, V103, P12, DOI 10.1016/j.ces.2012.04.001	63	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2020	11								564627	10.3389/fimmu.2020.564627	http://dx.doi.org/10.3389/fimmu.2020.564627			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB7CS	33133076	gold, Green Accepted, Green Published			2022-12-18	WOS:000578625800001
J	Souza, PR; Walker, ME; Goulding, NJ; Dalli, J; Perretti, M; Norling, LV				Souza, Patricia R.; Walker, Mary E.; Goulding, Nicolas J.; Dalli, Jesmond; Perretti, Mauro; Norling, Lucy, V			The GPR40 Agonist GW9508 Enhances Neutrophil Function to Aid Bacterial Clearance DuringE. coliInfections	FRONTIERS IN IMMUNOLOGY			English	Article						GPR40; neutrophil; resolvins; bacteria; resolution; lipoxins	INFLAMMATION; RECRUITMENT; RESPONSES; PROMOTES; SURVIVAL; CELLS	G-protein-coupled receptor 40 (GPR40) is known to play a role in the regulation of fatty acids, insulin secretion, and inflammation. However, the function of this receptor in human neutrophils, one of the first leukocytes to arrive at the site of infection, remains to be fully elucidated. In the present study, we demonstrate that GPR40 is upregulated on activated human neutrophils and investigated the functional effects upon treatment with a selective agonist; GW9508. Interestingly, GPR40 expression was up-regulated after neutrophil stimulation with platelet-activating factor (10 nM) or leukotriene B-4(LTB4, 10 nM) suggesting potential regulatory roles for this receptor during inflammation. Indeed, GW9508 (1 and 10 mu M) increased neutrophil chemotaxis in response to the chemokine IL-8 (30 ng/ml) and enhanced phagocytosis ofEscherichia coliby approximately 50% when tested at 0.1 and 1 mu M. These results were translatedin vivowhereby administration of GW9508 (10 mg/kg, i.p.) duringE. coliinfections resulted in elevated peritoneal leukocyte infiltration with a higher phagocytic capacity. Importantly, GW9508 administration also modulated the lipid mediator profile, with increased levels of the pro-resolving mediators resolvin D3 and lipoxins. In conclusion, GPR40 is expressed by activated neutrophils and plays an important host protective role to aid clearance of bacterial infections.	[Souza, Patricia R.; Walker, Mary E.; Goulding, Nicolas J.; Dalli, Jesmond; Perretti, Mauro; Norling, Lucy, V] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London, England; [Dalli, Jesmond; Perretti, Mauro; Norling, Lucy, V] Queen Mary Univ London, Ctr Inflammat & Therapeut Innovat, London, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Norling, LV (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London, England.; Norling, LV (corresponding author), Queen Mary Univ London, Ctr Inflammat & Therapeut Innovat, London, England.	l.v.norling@qmul.ac.uk	Souza, Patricia/GLQ-8979-2022	Souza, Patricia/0000-0003-3826-6261; Dalli, Jesmond/0000-0001-6328-3640; Norling, Lucy/0000-0001-5316-9115	Brazilian Program Science Without Borders [238277/2012-7]; Versus Arthritis Senior Fellowship [22235]; Barts Charity [MGU0443]; William Harvey Research Foundation -; Wellcome Trust [107613/Z/15/Z, 101604/Z/13/Z]; Royal Society [107613/Z/15/Z]; European Research Council (ERC) under the European Union [677542]; National Institutes of Health Research	Brazilian Program Science Without Borders; Versus Arthritis Senior Fellowship; Barts Charity; William Harvey Research Foundation -; Wellcome Trust(Wellcome Trust); Royal Society(Royal Society of London); European Research Council (ERC) under the European Union(European Research Council (ERC)); National Institutes of Health Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by the Brazilian Program Science Without Borders 238277/2012-7 to PS and MP. LN is supported by a Versus Arthritis Senior Fellowship (22235) and Barts Charity project grant (MGU0443). MP and LN acknowledge the support of the William Harvey Research Foundation. JD is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (107613/Z/15/Z) and by European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant no: 677542). We also acknowledge funding for the ImageStream platform; Wellcome Trust Infrastructure Grant 101604/Z/13/Z. This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the National Institutes of Health Research.	Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Burant CF, 2012, LANCET, V379, P1403, DOI 10.1016/S0140-6736(11)61879-5; Cash JL, 2013, EMBO REP, V14, P999, DOI 10.1038/embor.2013.138; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Dalli J, 2018, METHODS MOL BIOL, V1730, P59, DOI 10.1007/978-1-4939-7592-1_4; Dalli J, 2017, CRIT CARE MED, V45, P58, DOI 10.1097/CCM.0000000000002014; Dalli J, 2015, NAT MED, V21, P1071, DOI 10.1038/nm.3911; Dalli J, 2014, EMBO MOL MED, V6, P27, DOI 10.1002/emmm.201303503; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; Gagnon L, 2018, AM J PATHOL, V188, P1132, DOI 10.1016/j.ajpath.2018.01.009; Hardy S, 2005, J BIOL CHEM, V280, P13285, DOI 10.1074/jbc.M410922200; Inoue A, 2019, CELL, V177, P1933, DOI 10.1016/j.cell.2019.04.044; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Janes KA, 2006, NAT REV MOL CELL BIO, V7, P820, DOI 10.1038/nrm2041; Jones HR, 2016, SEMIN IMMUNOL, V28, P137, DOI 10.1016/j.smim.2016.03.007; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Ma SK, 2014, INT J MOL MED, V34, P1117, DOI 10.3892/ijmm.2014.1874; Mena SJ, 2016, INNATE IMMUN-LONDON, V22, P479, DOI 10.1177/1753425916656765; Morris T, 2010, P NATL ACAD SCI USA, V107, P8842, DOI 10.1073/pnas.1000373107; Motwani MP, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.94463; Nagatake T, 2018, J ALLERGY CLIN IMMUN, V142, P470, DOI 10.1016/j.jaci.2017.09.053; Norling LV, 2012, ARTERIOSCL THROM VAS, V32, P1970, DOI 10.1161/ATVBAHA.112.249508; Norris PC, 2018, PROSTAG LEUKOTR ESS, V138, P81, DOI 10.1016/j.plefa.2016.01.001; Ou HY, 2013, AM J PHYSIOL-ENDOC M, V304, pE668, DOI 10.1152/ajpendo.00419.2012; Padovan MG, 2020, CURR OPIN CLIN NUTR, V23, P76, DOI 10.1097/MCO.0000000000000633; Ross JT, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1407; Sekheri M, 2020, P NATL ACAD SCI USA, V117, P7971, DOI 10.1073/pnas.1920193117; Speight A, 2010, P BR PHARM SOC, V8, DOI [10.1016/s0165-2478(97)87332-4, DOI 10.1016/S0165-2478(97)87332-4]; Yamada M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27408-y; Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015	31	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2020	11								573019	10.3389/fimmu.2020.573019	http://dx.doi.org/10.3389/fimmu.2020.573019			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OB7AF	33133087	Green Submitted, gold, Green Published			2022-12-18	WOS:000578619300001
J	Usmani, SS; Raghava, GPS				Usmani, Salman Sadullah; Raghava, Gajendra P. S.			Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						coronavirus; COVID-19; SARS-CoV-2; vaccine candidates; immunoinformatic	ANTIBODY-DEPENDENT ENHANCEMENT; VIRUS-INFECTION; SARS; NEUTRALIZATION; COVID-19		[Usmani, Salman Sadullah; Raghava, Gajendra P. S.] Indraprastha Inst Informat Technol, Dept Computat Biol, New Delhi, India	Indraprastha Institute of Information Technology Delhi	Raghava, GPS (corresponding author), Indraprastha Inst Informat Technol, Dept Computat Biol, New Delhi, India.	raghava@iiitd.ac.in	Raghava, Gajendra P.S./AAA-2413-2022; Usmani, Salman Sadullah/GNP-3395-2022; Raghava, Gajendra/B-1717-2009	Raghava, Gajendra P.S./0000-0002-8902-2876; Usmani, Salman Sadullah/0000-0001-6624-4428; 				Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Callaway Ewen, 2020, Nature, DOI 10.1038/d41586-020-01247-2; Chary MA, 2020, J MED TOXICOL, V16, P284, DOI 10.1007/s13181-020-00777-5; Chaudhary K, 2016, SCI REP-UK, V6, DOI 10.1038/srep22843; Cohen J., 2020, SCIENCE, DOI [10.1126/ science.abc0006, DOI 10.1126/SCIENCE.ABC0006]; Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Dhanda SK, 2017, BRIEF BIOINFORM, V18, P467, DOI 10.1093/bib/bbw025; Dhanda SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/263952; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Du LY, 2008, VACCINE, V26, P1644, DOI 10.1016/j.vaccine.2008.01.025; Fast E., 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.03.03.962332(2020)606, DOI 10.1101/2020.03.03.962332(2020)606, 10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]; Fierz W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01120; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gorlani A, 2013, CURR HIV RES, V11, P421, DOI 10.2174/1570162X113116660062; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; GUPTA S, 2013, PLOS ONE, V8, DOI DOI 10.1371/JOURNAL.PONE.0073957; HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527; Hasan MM, 2020, BIOINFORMATICS, V36, P3350, DOI 10.1093/bioinformatics/btaa160; Hotez PJ, 2020, NAT REV IMMUNOL, V20, P347, DOI 10.1038/s41577-020-0323-4; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang J, 2007, VACCINE, V25, P6981, DOI 10.1016/j.vaccine.2007.06.047; Iwasaki A, 2020, NAT REV IMMUNOL, V20, P339, DOI 10.1038/s41577-020-0321-6; Jain A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54405-6; Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11; Jones Lora, 2020, BBC NEWS; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Kumar V, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01270; Lin JT, 2007, ANTIVIR THER, V12, P1107; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Martin-Acebes MA, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00044; Maurer-Stroh S, 2019, BIOINFORMATICS, V35, P3020, DOI 10.1093/bioinformatics/btz029; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X; Nagpal G, 2017, SCI REP-UK, V7, DOI 10.1038/srep42851; NCBI, 2020, SEV AC RESP SYNDR CO; Netland J, 2010, VIROLOGY, V399, P120, DOI 10.1016/j.virol.2010.01.004; Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20; Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x; Patiyal S., 2020, WEB BASED PLATFORM C, DOI [10.31219/osf.io/xegzu, DOI 10.31219/OSF.IO/XEGZU]; Rees V., 2020, EUR PHARM REV; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343; Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337, DOI 10.55563/clinexprheumatol/xcdary; See RH, 2008, J GEN VIROL, V89, P2136, DOI 10.1099/vir.0.2008/001891-0; Sharma NC, 2020, LIVEMINT APR, V27, P2020; Shi Yun, 2020, Zhonghua Yufang Yixue Zazhi, V54, P614, DOI 10.3760/cma.j.cn112150-20200317-00366; Sutton TC, 2015, VIROLOGY, V479, P247, DOI 10.1016/j.virol.2015.02.030; Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367; The World Health Organization, 2020, DRAFT LANDSC COVID 1; Tirado SMC, 2003, VIRAL IMMUNOL, V16, P69, DOI 10.1089/088282403763635465; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657; Usmani SS, 2018, ADV PROTEIN CHEM STR, V112, P221, DOI 10.1016/bs.apcsb.2018.01.006; Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678; Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090; Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9; World Health Organization, 2020, COR DIS COVID 19; Xinhua, 2020, XINHUA; Yang Limin, 2020, Sheng Wu Gong Cheng Xue Bao, V36, P593, DOI 10.13345/j.cjb.200094; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102; Yoo JK, 2013, J ALLERGY CLIN IMMUN, V132, P1263, DOI 10.1016/j.jaci.2013.06.006; Yoon KJ, 1996, VIRAL IMMUNOL, V9, P51, DOI 10.1089/vim.1996.9.51; Zhang D, 2020, COVID 19 INFECTION I, DOI [10.1101/2020.03.24.20042655., 10.1101/2020.03.24.20042655]; Zhou ZM, 2006, VACCINE, V24, P3624, DOI 10.1016/j.vaccine.2006.01.059	71	2	4	5	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2020	11								561851	10.3389/fimmu.2020.561851	http://dx.doi.org/10.3389/fimmu.2020.561851			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NZ1PQ	33133071	gold, Green Published			2022-12-18	WOS:000576863700001
J	Kathamuthu, GR; Moideen, K; Sridhar, R; Baskaran, D; Babu, S				Kathamuthu, Gokul Raj; Moideen, Kadar; Sridhar, Rathinam; Baskaran, Dhanaraj; Babu, Subash			Diminished Frequencies of Cytotoxic Marker Expressing T- and NK Cells at the Site ofMycobacterium tuberculosisInfection	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculous lymphadenitis; cytotoxic markers; lymph nodes; NK cells; CD4(+)and CD8(+)T cells	NATURAL-KILLER-CELLS; REQUIRE GRANZYME-B; MYCOBACTERIUM-TUBERCULOSIS; RAPID INDUCTION; PERFORIN; LYMPHOCYTES; APOPTOSIS; RESPONSES	Tuberculous lymphadenitis (TBL) individuals exhibit reduced frequencies of CD8(+)T cells expressing cytotoxic markers in peripheral blood. However, the frequencies of cytotoxic marker expressing CD4(+), CD8(+)T cells, and NK cells at the site of infection is not known. Therefore, we measured the baseline and mycobacterial antigen specific frequencies of cytotoxic markers expressing CD4(+), CD8(+)T cells, and NK cells in the LN (n= 18) and whole blood (n= 10) of TBL individuals. TBL LN is associated with lower frequencies of CD4(+)T cells expressing cytotoxic markers (Granzyme B, CD107a) compared to peripheral blood at baseline and in response to PPD, ESAT-6, and CFP-10 antigen stimulation. Similarly, lower frequencies of CD8(+)T cells expressing cytotoxic markers (Perforin, Granzyme B, and CD107a) were also present in the TBL LN at baseline and following (except perforin) antigen stimulation. Finally, at baseline and after antigen (PPD, ESAT-6, and CFP-10) stimulation, frequencies of NK cells expressing cytotoxic markers were also significantly lower in TBL LN compared to whole blood. Hence, TBL is characterized by diminished frequencies of cytotoxic marker expressing CD4(+), CD8(+)T cells, and NK cells at the site of infection, which might reflect the lack of protective immune responses at the site ofMycobacterium tuberculosisinfection.	[Kathamuthu, Gokul Raj; Moideen, Kadar; Babu, Subash] Natl Inst Res TB, Natl Inst Hlth, Int Ctr Excellence Res, Chennai, Tamil Nadu, India; [Kathamuthu, Gokul Raj; Baskaran, Dhanaraj] Natl Inst Res TB NIRT, Chennai, Tamil Nadu, India; [Sridhar, Rathinam] Govt Stanley Med Hosp, Chennai, Tamil Nadu, India; [Babu, Subash] NIAID, Parasit Dis Lab, NIH, Bethesda, MD USA	Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kathamuthu, GR (corresponding author), Natl Inst Res TB, Natl Inst Hlth, Int Ctr Excellence Res, Chennai, Tamil Nadu, India.; Kathamuthu, GR (corresponding author), Natl Inst Res TB NIRT, Chennai, Tamil Nadu, India.	gokul.r@nirt.res.in	Babu, Subash/GXG-4746-2022		Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health	Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health	This research work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health.	Afonina IS, 2011, MOL CELL, V44, P265, DOI 10.1016/j.molcel.2011.07.037; Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Bruns H, 2009, J CLIN INVEST, V119, P1167, DOI 10.1172/JCI38482; Canaday DH, 2001, J IMMUNOL, V167, P2734, DOI 10.4049/jimmunol.167.5.2734; Cerwenka A, 2016, NAT REV IMMUNOL, V16, P112, DOI 10.1038/nri.2015.9; Parra JAC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00967; Cohnen A, 2013, BLOOD, V122, P1411, DOI 10.1182/blood-2012-07-441832; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Cullen SP, 2008, CELL DEATH DIFFER, V15, P251, DOI 10.1038/sj.cdd.4402244; Esin S, 2015, J INNATE IMMUN, V7, P11, DOI 10.1159/000363321; Fontanilla JM, 2011, CLIN INFECT DIS, V53, P555, DOI 10.1093/cid/cir454; Gabrielli S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1376595; Garand M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00257; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Grotzke JE, 2005, MICROBES INFECT, V7, P776, DOI 10.1016/j.micinf.2005.03.001; Handa U, 2012, J INFECT DEV COUNTR, V6, P6, DOI 10.3855/jidc.2090; He YK, 2017, CELL MOL IMMUNOL, V14, P321, DOI 10.1038/cmi.2016.26; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Joeckel LT, 2011, CELL DEATH DIFFER, V18, P1112, DOI 10.1038/cdd.2011.5; Kamath AB, 2004, J EXP MED, V200, P1479, DOI 10.1084/jem.20041690; Kathamuthu GR, 2019, TUBERCULOSIS, V118, DOI 10.1016/j.tube.2019.101856; Krzewski K, 2013, BLOOD, V121, P4672, DOI 10.1182/blood-2012-08-453738; Kumar MM, 2010, CELL IMMUNOL, V265, P146, DOI 10.1016/j.cellimm.2010.08.004; Kumar NP, 2014, TUBERCULOSIS, V94, P482, DOI 10.1016/j.tube.2014.06.007; Lazarevic V, 2002, AM J RESP CRIT CARE, V166, P1116, DOI 10.1164/rccm.2204027; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lin PL, 2015, SEMIN IMMUNOPATHOL, V37, P239, DOI 10.1007/s00281-015-0490-8; Lord SJ, 2003, IMMUNOL REV, V193, P31, DOI 10.1034/j.1600-065X.2003.00044.x; Omoto Y, 2010, J DERMATOL SCI, V59, P129, DOI 10.1016/j.jdermsci.2010.05.004; Ottenhoff THM, 2005, TUBERCULOSIS, V85, P53, DOI 10.1016/j.tube.2004.09.011; Prezzemolo T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00180; Romee R, 2013, BLOOD, V121, P3599, DOI 10.1182/blood-2012-04-425397; Sada-Ovalle I, 2006, CLIN IMMUNOL, V121, P314, DOI 10.1016/j.clim.2006.08.011; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; Smith SM, 2000, INFECT IMMUN, V68, P7144, DOI 10.1128/IAI.68.12.7144-7148.2000; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839; Walzl G, 2011, NAT REV IMMUNOL, V11, P343, DOI 10.1038/nri2960; Woodworth JS, 2008, J IMMUNOL, V181, P8595, DOI 10.4049/jimmunol.181.12.8595	41	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								585293	10.3389/fimmu.2020.585293	http://dx.doi.org/10.3389/fimmu.2020.585293			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA7RQ	33101317	Green Published, Green Accepted, gold			2022-12-18	WOS:000577978900001
J	Lee, JY; Madany, E; El Kadi, N; Pandya, S; Ng, K; Yamashita, M; Jefferies, CA; Gibb, DR				Lee, June Young; Madany, Emaan; El Kadi, Najwa; Pandya, Sumaarg; Ng, Kessandra; Yamashita, Michifumi; Jefferies, Caroline A.; Gibb, David R.			Type 1 Interferon Gene Signature Promotes RBC Alloimmunization in a Lupus Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						RBC alloimmunization; type 1 interferons; lupus; transfusion; autoimmunity	BLOOD-CELL ALLOIMMUNIZATION; I INTERFERON; PERIPHERAL-BLOOD; RHEUMATOID-ARTHRITIS; EXPRESSION SIGNATURE; SYSTEMIC-SCLEROSIS; RECEPTOR; ERYTHEMATOSUS; ACTIVATION; PRISTANE	Red blood cell (RBC) transfusion exposes recipients to hundreds of unmatched minor RBC antigens. This exposure can lead to production of alloantibodies that promote clinically significant hemolytic events. Multiple studies have reported an increased frequency of RBC alloimmunization in patients with autoimmunity. However, cellular and molecular mechanisms that underlie autoimmunity-induced alloimmunization have not been reported. Patients with systemic lupus erythematosus (SLE) have a high frequency of alloimmunization and express a type 1 interferon (IFN alpha/beta) gene signature. Thus, we utilized the pristane-induced lupus mouse model to test the hypothesis that inflammation in lupus promotes RBC alloimmunization, and to examine the potential role of IFN alpha/beta. Intraperitoneal injection of pristane, a hydrocarbon oil, led to autoantibody production, glomerulonephritis, and pulmonary hemorrhage in wild type (WT) mice. Pristane treatment significantly induced serum IFN alpha and expression of multiple interferon-stimulated genes (ISGs) in peripheral blood and peritoneal fluid cells, including inflammatory macrophages. Following transfusion with allogeneic RBCs expressing the KEL glycoprotein, pristane-treated WT mice produced significantly elevated levels of anti-KEL IgM and anti-KEL IgG, compared to untreated mice. Pristane induced comparable levels of inflammatory cells and cytokines in mice lacking the IFN alpha/beta receptor (IFNAR1(-/-)) or the IFN alpha/beta-inducing transcriptions factors (IRF3/7(-/-)), compared to WT mice. However, pristane-treated IFNAR1(-/-)and IRF3/7(-/-)mice failed to produce ISGs and produced significantly lower levels of transfusion-induced anti-KEL IgG, compared to WT mice. Thus, pristane induction of a lupus-like phenotype promoted alloimmunization to the KEL RBC antigen in an IFN alpha/beta-dependent manner. To our knowledge, this is the first examination of molecular mechanisms contributing to RBC alloimmunization in a model of autoimmunity. These results warrant further investigation of the role of IFN alpha/beta in alloimmunization to other RBC antigens and the contribution of the IFN alpha/beta gene signature to the elevated frequency of alloimmunization in patients with SLE.	[Lee, June Young; Madany, Emaan; El Kadi, Najwa; Pandya, Sumaarg; Ng, Kessandra; Yamashita, Michifumi; Gibb, David R.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Jefferies, Caroline A.] Cedars Sinai Med Ctr, Div Rheumatol, Dept Internal Med, Los Angeles, CA 90048 USA; [Gibb, David R.] Cedars Sinai Med Ctr, Div Transfus Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Gibb, DR (corresponding author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA.; Gibb, DR (corresponding author), Cedars Sinai Med Ctr, Div Transfus Med, Los Angeles, CA 90048 USA.	david.gibb@cshs.org	Jefferies, Caroline/AAI-1543-2021; YAMASHITA, Michifumi/AFT-3479-2022	Jefferies, Caroline/0000-0002-8879-6722; 	NIH/NHLBI [5 K08 HL141446]; American Society of Hematology Scholar Award [5283]; National Blood Foundation [R13672]	NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Society of Hematology Scholar Award; National Blood Foundation	This work was funded by NIH/NHLBI (5 K08 HL141446), the American Society of Hematology Scholar Award (5283) and the National Blood Foundation (R13672) to DRG.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arneja A, 2016, HAEMATOLOGICA, V101, pE440, DOI 10.3324/haematol.2016.149278; Assassi S, 2010, ARTHRITIS RHEUM-US, V62, P589, DOI 10.1002/art.27224; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Baechler EC, 2007, MOL MED, V13, P59, DOI 10.2119/2006-00085.Baechler; Banchereau J, 2006, IMMUNITY, V25, P383, DOI 10.1016/j.immuni.2006.08.010; Bao WL, 2009, BLOOD, V113, P5624, DOI 10.1182/blood-2008-12-193748; Bave U, 2005, ARTHRITIS RHEUM-US, V52, P1185, DOI 10.1002/art.20998; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Bronson PG, 2012, CURR OPIN IMMUNOL, V24, P530, DOI 10.1016/j.coi.2012.07.008; Calabro S, 2016, J EXP MED, V213, P887, DOI 10.1084/jem.20151720; Chowdhary VR, 2007, RHEUMATOLOGY, V46, P1405, DOI 10.1093/rheumatology/kem117; Coro ES, 2006, J IMMUNOL, V176, P4343, DOI 10.4049/jimmunol.176.7.4343; CROCKER PR, 1989, J EXP MED, V169, P1333, DOI 10.1084/jem.169.4.1333; Crow MK, 2003, AUTOIMMUNITY, V36, P481, DOI 10.1080/08916930310001625952; Evers D, 2016, BRIT J HAEMATOL, V175, P956, DOI 10.1111/bjh.14307; Gibb DR, 2017, TRANSFUSION, V57, P2595, DOI 10.1111/trf.14288; Gibb DR, 2017, J IMMUNOL, V199, P1041, DOI 10.4049/jimmunol.1700401; Gibb DR, 2016, EBIOMEDICINE, V9, P77, DOI 10.1016/j.ebiom.2016.06.008; Han GM, 2003, GENES IMMUN, V4, P177, DOI 10.1038/sj.gene.6363966; Hendrickson JE, 2008, TRANSFUSION, V48, P1869, DOI 10.1111/j.1537-2995.2008.01801.x; Hendrickson JE, 2006, TRANSFUSION, V46, P1526, DOI 10.1111/j.1537-2995.2006.00946.x; Hendrickson JE, 2010, TRANSFUSION, V50, P642, DOI 10.1111/j.1537-2995.2009.02481.x; Hermida Micely D R, 2017, BMC Res Notes, V10, P695, DOI 10.1186/s13104-017-3019-5; Higgs BW, 2011, ANN RHEUM DIS, V70, P2029, DOI 10.1136/ard.2011.150326; Holt S, 2004, NEPHROL DIAL TRANSPL, V19, P2403, DOI 10.1093/ndt/gfh333; Hudson KE, 2010, BLOOD, V115, P3989, DOI 10.1182/blood-2009-08-238568; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Karafin MS, 2018, BRIT J HAEMATOL, V181, P672, DOI 10.1111/bjh.15182; Kirou KA, 2005, ARTHRITIS RHEUM-US, V52, P1491, DOI 10.1002/art.21031; Lee PY, 2008, J IMMUNOL, V180, P5101, DOI 10.4049/jimmunol.180.7.5101; Lee PY, 2008, J EXP MED, V205, P2995, DOI 10.1084/jem.20080462; Lerut E, 2007, TRANSFUSION, V47, P28, DOI 10.1111/j.1537-2995.2007.01060.x; Liu D, 2019, TRANSFUSION, V59, P3243, DOI 10.1111/trf.15482; Martinez-Pomares L, 2012, TRENDS IMMUNOL, V33, P66, DOI 10.1016/j.it.2011.11.001; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Moise KJ, 2012, OBSTET GYNECOL, V120, P1132, DOI [10.1097/AOG.0b013e31826d7dc1, http://10.1097/AOG.0b013e31826d7dc1]; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nickel RS, 2016, TRANSFUSION, V56, P107, DOI 10.1111/trf.13379; Olsen NJ, 2004, ANN RHEUM DIS, V63, P1387, DOI 10.1136/ard.2003.017194; Papay P, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2011.11.028; RAMSEY G, 1995, TRANSFUSION, V35, P582, DOI 10.1046/j.1537-2995.1995.35795357881.x; Reeves WH, 2009, TRENDS IMMUNOL, V30, P455, DOI 10.1016/j.it.2009.06.003; Ryder AB, 2016, BRIT J HAEMATOL, V174, P483, DOI 10.1111/bjh.13781; Ryder AB, 2014, TRANSFUS MED HEMOTH, V41, P406, DOI 10.1159/000368995; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Satoh M, 2000, J IMMUNOL, V165, P1036, DOI 10.4049/jimmunol.165.2.1036; Stowell SR, 2014, TRANSFUSION, V54, P179, DOI 10.1111/trf.12217; Telen MJ, 2015, TRANSFUSION, V55, P1378, DOI 10.1111/trf.12940; U. D. O. H. A. H. S. (FDA), 2014, FATALITIES REPORTED; Yazdanbakhsh K, 2012, BLOOD, V120, P528, DOI 10.1182/blood-2011-11-327361; York MR, 2007, ARTHRITIS RHEUM-US, V56, P1010, DOI 10.1002/art.22382; Yu J, 2007, AM J HEMATOL, V82, P691, DOI 10.1002/ajh.20959; Zhuang HY, 2014, ARTHRITIS RHEUMATOL, V66, P140, DOI 10.1002/art.38189	54	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								584254	10.3389/fimmu.2020.584254	http://dx.doi.org/10.3389/fimmu.2020.584254			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA7XG	33101313	gold, Green Published			2022-12-18	WOS:000577993500001
J	Narducci, MG; Tosi, A; Frezzolini, A; Scala, E; Passarelli, F; Bonmassar, L; Monopoli, A; Accetturi, MP; Cantonetti, M; Cappellini, GCA; De Galitiis, F; Rosato, A; Picozza, M; Russo, G; D'Atri, S				Narducci, Maria Grazia; Tosi, Anna; Frezzolini, Alessandra; Scala, Enrico; Passarelli, Francesca; Bonmassar, Laura; Monopoli, Alessandro; Accetturi, Maria Pina; Cantonetti, Maria; Antonini Cappellini, Gian Carlo; De Galitiis, Federica; Rosato, Antonio; Picozza, Mario; Russo, Giandomenico; D'Atri, Stefania			Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab	FRONTIERS IN IMMUNOLOGY			English	Article						cutaneous T-cell lymphoma; PD-1 blockade therapy; immune sub-populations; Ki67 proliferation index; granzyme B	MYCOSIS-FUNGOIDES; INTERNATIONAL-SOCIETY; EUROPEAN-ORGANIZATION; CUTANEOUS-LYMPHOMAS; TASK-FORCE; CONSORTIUM; CRITERIA; BLOOD; PD-1	Despite the recent availability of several new drugs in hemato-oncology, T-cell lymphomas are still incurable and PD-1 blockade could represent a therapeutic chance for selected patients affected by these malignancies, although further studies are required to understand the biological effects of anti-PD-1 mAbs on neoplastic T-cells and to identify biomarkers for predicting and/or monitoring patients' response to therapy. Sezary Syndrome (SS) represents a rare and aggressive variant of cutaneous T cell lymphoma (CTCL) with a life expectancy of less than 5 years, characterized by the co-presence of neoplastic lymphocytes mainly in the blood, lymph nodes and skin. In this study we analyzed longitudinal blood samples and lesional skin biopsies of a patient concurrently affected by SS and melanoma who underwent 22 nivolumab administrations. In blood, we observed a progressive reduction of SS cell number and a raise in the percentage of normal CD4+ and CD8+ T cells and NK cells over total leukocytes. Eight weeks from the start of nivolumab, these immune cell subsets showed an increase of Ki67 proliferation index that positively correlated with their PD-1 expression. Conversely, SS cells displayed a strong reduction of Ki67 positivity despite their high PD-1 expression. On skin biopsies we observed a marked reduction of SS cells which were no more detectable at the end of therapy. We also found an increase in the percentage of normal CD4+ T cells with a concomitant decrease of that of CD8+ and CD4+ CD8+ T cells, two cell subsets that, however, acquired a cytotoxic phenotype. In summary, our study demonstrated that nivolumab marked reduced SS tumor burden and invigorated immune responses in our patient. Our data also suggest, for the first time, that Ki67 expression in circulating neoplastic and immune cell subsets, as well as an enrichment in T cells with a cytotoxic phenotype in lesional skin could be valuable markers to assess early on treatment SS patients' response to PD-1 blockade, a therapeutic strategy under clinical investigation in CTCL (NCT03385226, NCT04118868).	[Narducci, Maria Grazia; Frezzolini, Alessandra; Scala, Enrico; Passarelli, Francesca; Bonmassar, Laura; Monopoli, Alessandro; Accetturi, Maria Pina; Antonini Cappellini, Gian Carlo; De Galitiis, Federica; Russo, Giandomenico; D'Atri, Stefania] IDI IRCCS, Ist Dermopat Immacolata, Rome, Italy; [Tosi, Anna; Rosato, Antonio] Univ Padua, Oncol & Immunol Sect, Dept Surg Oncol & Gastroenterol, Padua, Italy; [Cantonetti, Maria] Univ Roma Tor Vergata, Dept Hematol, Rome, Italy; [Rosato, Antonio] Veneto Inst Oncol IOV IRCCS, Padua, Italy; [Picozza, Mario] IRCCS Fdn Santa Lucia, Lab Neuroimmunol, Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Padua; University of Rome Tor Vergata; IRCCS Istituto Oncologico Veneto (IOV); IRCCS Santa Lucia	Russo, G (corresponding author), IDI IRCCS, Ist Dermopat Immacolata, Rome, Italy.; Picozza, M (corresponding author), IRCCS Fdn Santa Lucia, Lab Neuroimmunol, Rome, Italy.	m.picozza@hsantalucia.it; g.russo@idi.it	Picozza, Mario/J-7094-2018; Tosi, Anna/H-7160-2014; Rosato, Antonio/E-8626-2010	Tosi, Anna/0000-0002-4890-0169; Rosato, Antonio/0000-0002-5263-8386; Picozza, Mario/0000-0002-2529-6456	AIRC [IG 17048_2015]; Italian Ministry of Health [PE-2016-02364102]; Associazione Volontari per il Policlinico Tor Vergata, ONLUS	AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Associazione Volontari per il Policlinico Tor Vergata, ONLUS	This study was supported by the AIRC (IG 17048_2015 to MN), Italian Ministry of Health (Grant PE-2016-02364102 to GR), and Associazione Volontari per il Policlinico Tor Vergata, ONLUS.	Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Anand K, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000104; Bar-Sela Gil, 2015, JAAD Case Rep, V1, P99, DOI 10.1016/j.jdcr.2015.02.009; Choi J, 2015, NAT GENET, V47, P1011, DOI 10.1038/ng.3356; Cristofoletti C, 2019, LEUKEMIA, V33, P1231, DOI 10.1038/s41375-018-0305-8; Cristofoletti C, 2013, BLOOD, V122, P3511, DOI 10.1182/blood-2013-06-510578; Dulphy N, 2009, J INVEST DERMATOL, V129, P359, DOI 10.1038/jid.2008.256; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Failla CM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225731; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Fountain E, 2019, LEUKEMIA LYMPHOMA, V60, P1079, DOI 10.1080/10428194.2018.1516879; Franklin C, 2017, EJSO-EUR J SURG ONC, V43, P604, DOI 10.1016/j.ejso.2016.07.145; Hodgins JJ, 2019, J CLIN INVEST, V129, P3499, DOI 10.1172/JCI129338; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Jelinek T, 2017, IMMUNOLOGY, V152, P357, DOI 10.1111/imm.12788; Khodadoust MS, 2020, J CLIN ONCOL, V38, P20, DOI 10.1200/JCO.19.01056; Kocikowski M, 2020, CANCERS, V12, DOI 10.3390/cancers12040804; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Malachowski Stephen J, 2020, JAAD Case Rep, V6, P16, DOI 10.1016/j.jdcr.2019.11.005; Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749; Olsen EA, 2011, J CLIN ONCOL, V29, P2598, DOI 10.1200/JCO.2010.32.0630; Ono K, 2019, ANN HEMATOL, V98, P219, DOI 10.1007/s00277-018-3406-6; Osa A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.59125; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Phillips T, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0201-6; Ratner L, 2018, NEW ENGL J MED, V378, P1947, DOI 10.1056/NEJMc1803181; Rauch DA, 2019, BLOOD, V134, P1406, DOI 10.1182/blood.2019002038; Saulite I, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1738797; Scarisbrick JJ, 2015, J CLIN ONCOL, V33, P3766, DOI 10.1200/JCO.2015.61.7142; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shen KN, 2017, ANN HEMATOL, V96, P687, DOI 10.1007/s00277-017-2929-6; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Tesio M, 2016, ONCOGENE, V35, P3887, DOI 10.1038/onc.2015.462; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Wang CY, 2014, CANCER IMMUNOL RES, V2, P846, DOI 10.1158/2326-6066.CIR-14-0040; Wang LH, 2015, NAT GENET, V47, P1426, DOI 10.1038/ng.3444; Wartewig T, 2017, NATURE, V552, P121, DOI 10.1038/nature24649; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Willemze R, 2019, BLOOD, V133, P1703, DOI 10.1182/blood-2018-11-881268; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Wong MT, 2015, CELL REP, V11, P1822, DOI 10.1016/j.celrep.2015.05.022; Zheng Yixuan James, 2018, JAAD Case Rep, V4, P540, DOI 10.1016/j.jdcr.2018.01.016	42	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								579894	10.3389/fimmu.2020.579894	http://dx.doi.org/10.3389/fimmu.2020.579894			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA5ZX	33072126	gold, Green Published			2022-12-18	WOS:000577864000001
J	Natynki, A; Tuusa, J; Hervonen, K; Kaukinen, K; Lindgren, O; Huilaja, L; Kokkonen, N; Salmi, T; Tasanen, K				Natynki, Antti; Tuusa, Jussi; Hervonen, Kaisa; Kaukinen, Katri; Lindgren, Outi; Huilaja, Laura; Kokkonen, Nina; Salmi, Teea; Tasanen, Kaisa			Autoantibodies Against the Immunodominant Bullous Pemphigoid Epitopes Are Rare in Patients With Dermatitis Herpetiformis and Coeliac Disease	FRONTIERS IN IMMUNOLOGY			English	Article						bullous pemphigoid; dermatitis herpetiformis; coeliac disease; epitope analysis; blistering skin disease	AUTOIMMUNE-RESPONSE; COLLAGEN XVII/BP180; IGA; PREVALENCE; DISORDERS; XVII	Dermatitis herpetiformis (DH) is an extraintestinal manifestation of coeliac disease (CD). Patients with DH have an elevated risk of development of another autoimmune blistering skin disease, bullous pemphigoid (BP). In this study we investigated whether patients with DH and CD (mean age for both 49 years) have circulating autoantibodies against BP180, the major BP autoantigen. ELISA tests showed that only a few DH (3/46) and CD (2/43) patients had BP180-NC16A IgG autoantibodies. Immunoblotting found that more than half of the DH samples contained IgG autoantibodies against full-length BP180. Epitope mapping with 13 fusion proteins covering the BP180 polypeptide revealed that in DH and CD patients, IgG autoantibodies did not target the NC16A or other epitopes typical of BP but recognized other intracellular and mid-extracellular regions of BP180. None of the analyzed DH and CD patients with either ELISA or immunoblotting positivity had IgG or IgA reactivity against the cutaneous basement membrane in indirect immunofluorescence analysis or skin symptoms characteristic of BP. Although only a minority of middle-aged DH patients had IgG autoantibodies against the immunodominant epitopes of BP180, our results do not exclude the possibility that intermolecular epitope spreading could explain the switch from DH to BP in elderly patients.	[Natynki, Antti; Tuusa, Jussi; Lindgren, Outi; Huilaja, Laura; Kokkonen, Nina; Tasanen, Kaisa] Univ Oulu, Oulu Univ Hosp, Dept Dermatol, PEDEGO Res Unit,Med Res Ctr Oulu, Oulu, Finland; [Hervonen, Kaisa; Salmi, Teea] Tampere Univ Hosp, Dept Dermatol, Tampere, Finland; [Hervonen, Kaisa; Kaukinen, Katri; Salmi, Teea] Tampere Univ, Fac Med & Hlth Technol, Celiac Dis Res Ctr, Tampere, Finland; [Kaukinen, Katri] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland; [Lindgren, Outi] Univ Oulu, Oulu Univ Hosp, Dept Pathol, Med Res Ctr Oulu, Oulu, Finland	University of Oulu; Tampere University; Tampere University Hospital; Tampere University; Tampere University; Tampere University Hospital; University of Oulu	Tasanen, K (corresponding author), Univ Oulu, Oulu Univ Hosp, Dept Dermatol, PEDEGO Res Unit,Med Res Ctr Oulu, Oulu, Finland.	kaisa.tasanen@oulu.fi		Salmi, Teea/0000-0001-7459-4938; Hervonen, Kaisa/0000-0002-6759-8399; Kokkonen, Nina/0000-0003-0913-4892	Academy of Finland; Sigrid Juselius Foundation; University of Oulu Graduate School; Medical Research Center, Oulu University Hospital (MRC Oulu); Competitive State Research Financing of the Expert Area of Tampere University Hospital	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); University of Oulu Graduate School; Medical Research Center, Oulu University Hospital (MRC Oulu); Competitive State Research Financing of the Expert Area of Tampere University Hospital	This study was supported by research grants from the Academy of Finland, the Sigrid Juselius Foundation, the University of Oulu Graduate School, the Medical Research Center, Oulu University Hospital (MRC Oulu) and the Competitive State Research Financing of the Expert Area of Tampere University Hospital.	Antiga E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01290; Cornaby C, 2015, IMMUNOL LETT, V163, P56, DOI 10.1016/j.imlet.2014.11.001; Di Zenzo G, 2008, CLIN IMMUNOL, V128, P415, DOI 10.1016/j.clim.2008.04.012; Di Zenzo G, 2011, J INVEST DERMATOL, V131, P2271, DOI 10.1038/jid.2011.180; Didona D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00779; Feliciani C, 2009, BRIT J DERMATOL, V161, P306, DOI 10.1111/j.1365-2133.2009.09266.x; Forsti AK, 2014, BRIT J DERMATOL, V171, P1223, DOI 10.1111/bjd.13189; Franzke CW, 2004, J BIOL CHEM, V279, P24521, DOI 10.1074/jbc.M308835200; Hervonen K, 2012, BRIT J DERMATOL, V167, P1331, DOI 10.1111/j.1365-2133.2012.11105.x; Hofmann S, 2002, J INVEST DERMATOL, V119, P1065, DOI 10.1046/j.1523-1747.2002.19529.x; Hofmann SC, 2009, J INVEST DERMATOL, V129, P1730, DOI 10.1038/jid.2008.424; Horvath B, 2010, EXP DERMATOL, V19, P648, DOI 10.1111/j.1600-0625.2010.01080.x; Jaskowski TD, 2009, J INVEST DERMATOL, V129, P2728, DOI 10.1038/jid.2009.142; Kokkonen N, 2017, J INVEST DERMATOL, V137, P71, DOI 10.1016/j.jid.2016.09.010; Kromminga A, 2000, J AUTOIMMUN, V15, P293, DOI 10.1006/jaut.2000.0437; Lai YC, 2016, J EUR ACAD DERMATOL, V30, P2007, DOI 10.1111/jdv.13660; Liu ZQ, 2019, J AM ACAD DERMATOL, V80, P774, DOI 10.1016/j.jaad.2018.06.006; Mansikka E, 2019, J INVEST DERMATOL, V139, P2108, DOI 10.1016/j.jid.2019.03.1150; Mansikka E, 2017, J CLIN GASTROENTEROL, V51, P235, DOI 10.1097/MCG.0000000000000533; Messingham KAN, 2016, J INVEST DERMATOL, V136, P721, DOI 10.1016/j.jid.2015.12.005; Nishie W, 2020, ACTA DERM-VENEREOL, V100, P102, DOI 10.2340/00015555-3399; Persson MSM, 2021, BRIT J DERMATOL, V184, P68, DOI 10.1111/bjd.19022; Plaquevent M, 2019, J INVEST DERMATOL, V139, P835, DOI 10.1016/j.jid.2018.10.045; Ress Krista, 2014, BMC Res Notes, V7, P310, DOI 10.1186/1756-0500-7-310; Saffari H, 2018, INT J DERMATOL, V57, P534, DOI 10.1111/ijd.13925; Salmi TT, 2019, CLIN EXP DERMATOL, V44, P728, DOI 10.1111/ced.13992; Salmi TT, 2011, BRIT J DERMATOL, V165, P354, DOI 10.1111/j.1365-2133.2011.10385.x; Salmi T, 2020, ACTA DERM-VENEREOL, V100, P115, DOI 10.2340/00015555-3401; Sardy M, 2002, J EXP MED, V195, P747, DOI 10.1084/jem.20011299; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Schulze F, 2013, DERMATOLOGY, V226, P217, DOI 10.1159/000349982; Schumann H, 2000, AM J PATHOL, V156, P685, DOI 10.1016/S0002-9440(10)64772-4; Tasanen K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01238; Toyonaga E, 2017, J INVEST DERMATOL, V137, P2552, DOI 10.1016/j.jid.2017.07.831; Tuusa J, 2019, J INVEST DERMATOL, V139, P293, DOI 10.1016/j.jid.2018.09.010; van Beek N, 2014, BRIT J DERMATOL, V170, P943, DOI 10.1111/bjd.12739; Varpuluoma O, 2019, J INVEST DERMATOL, V139, P600, DOI 10.1016/j.jid.2018.10.010; Varpuluoma O, 2018, J INVEST DERMATOL, V138, P1659, DOI 10.1016/j.jid.2018.01.027; Zone JJ, 2004, J INVEST DERM SYMP P, V9, P47, DOI 10.1111/j.1087-0024.2004.00840.x; Zone JJ, 2011, J IMMUNOL, V186, P4474, DOI 10.4049/jimmunol.1003273	40	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								575805	10.3389/fimmu.2020.575805	http://dx.doi.org/10.3389/fimmu.2020.575805			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OA7FG	33072118	Green Published, gold			2022-12-18	WOS:000577945500001
J	Skeate, JG; Segerink, WH; Garcia, M; Fernandez, DJ; Prins, R; Luhen, KP; Voss, FO; Da Silva, DM; Kast, WM				Skeate, Joseph G.; Segerink, Wouter H.; Garcia, Mauricio; Fernandez, Daniel J.; Prins, Ruben; Luhen, Kim P.; Voss, Feline O.; Da Silva, Diane M.; Kast, W. Martin			Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering	FRONTIERS IN IMMUNOLOGY			English	Article						human papillomavirus; alpha-defensins; theta-defensins; infection; innate-immunology; sexually transmitted infection (STI)	HERPES-SIMPLEX-VIRUS; ANTIMICROBIAL ACTIVITIES; HEPARAN-SULFATE; CONDOM USE; ALPHA; TYPE-16; HPV; ASSOCIATION; PREVALENCE; LEUKOCYTES	Persistent infection with high-risk human papillomavirus (hrHPV) genotypes results in a large number of anogenital and head and neck cancers worldwide. Although prophylactic vaccination coverage has improved, there remains a need to develop methods that inhibit viral transmission toward preventing the spread of HPV-driven disease. Defensins are a class of innate immune effector peptides that function to protect hosts from infection by pathogens such as viruses and bacteria. Previous work utilizing alpha and beta defensins from humans has demonstrated that the alpha-defensin HD5 is effective at inhibiting the most common high-risk genotype, HPV16. A third class of defensin that has yet to be explored are theta-defensins: small, 18-amino acid cyclic peptides found in old-world monkeys whose unique structure makes them both highly cationic and resistant to degradation. Here we show that the prototype theta-defensin, rhesus theta defensin 1, inhibits hrHPV infection through a mechanism involving capsid clustering that inhibits virions from binding to cell surface receptor complexes.	[Skeate, Joseph G.; Segerink, Wouter H.; Garcia, Mauricio; Fernandez, Daniel J.; Prins, Ruben; Voss, Feline O.; Kast, W. Martin] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90007 USA; [Luhen, Kim P.; Da Silva, Diane M.; Kast, W. Martin] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA; [Da Silva, Diane M.; Kast, W. Martin] Univ Southern Calif, Keck Sch Med, Dept Obstet & Gynecol, Los Angeles, CA USA	University of Southern California; University of Southern California; University of Southern California	Kast, WM (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90007 USA.; Kast, WM (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.; Kast, WM (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Obstet & Gynecol, Los Angeles, CA USA.	martin.kast@med.usc.edu		Voss, Feline/0000-0002-9422-4296; Prins, Ruben/0000-0003-0831-4189	NIH [R01 CA074397, P30 CA014089]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by NIH grant R01 CA074397 (to WK). Several experiments were facilitated through the Norris Comprehensive Cancer Center FACS & Immune Monitoring and Cell & Tissue Imaging core facilities that are supported by a NIH grant P30 CA014089.	BASSO V, 2019, SCI REP UK, V0009; Becker M, 2018, J VIROL, V92, DOI 10.1128/JVI.02106-17; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Breitwieser GE, 2008, INT J BIOCHEM CELL B, V40, P1467, DOI 10.1016/j.biocel.2008.01.019; Buck CB, 2006, P NATL ACAD SCI USA, V103, P1516, DOI 10.1073/pnas.0508033103; Buck CB, 2007, CURRENT PROTOCOLS CE, V26, P1, DOI DOI 10.1002/0471143030.CB2601S37; Campbell CMP, 2013, J INFECT DIS, V208, P373, DOI 10.1093/infdis/jit191; Chang TL, 2005, J CLIN INVEST, V115, P765, DOI 10.1172/JCI200521948; Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193; CLIFFORD G, 2006, VACCINE S3, pS3/26; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; Conway MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016405; Da Silva DM, 2014, VIROLOGY, V452, P279, DOI 10.1016/j.virol.2014.01.031; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; Day PM, 2008, J VIROL, V82, P12565, DOI 10.1128/JVI.01631-08; de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5; de Sanjose S, 2018, JNCI CANCER SPECT, V2, DOI 10.1093/jncics/pky045; Doss M, 2012, J IMMUNOL, V188, P2759, DOI 10.4049/jimmunol.1101335; Doss M, 2009, J IMMUNOL, V182, P7878, DOI 10.4049/jimmunol.0804049; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; Garcia AE, 2008, INFECT IMMUN, V76, P5883, DOI 10.1128/IAI.01100-08; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gulati Neetu M, 2019, Pathog Immun, V4, P196, DOI 10.20411/pai.v4i2.314; Holly MK, 2017, ANNU REV VIROL, V4, P369, DOI 10.1146/annurev-virology-101416-041734; Jemal A., 2019, CA-CANCER J CLIN, V69, P7, DOI [DOI 10.3322/caac.21551, DOI 10.3322/CAAC.21551]; Kaliff Malin, 2018, Oncotarget, V9, P18786, DOI 10.18632/oncotarget.24666; Kines RC, 2009, P NATL ACAD SCI USA, V106, P20458, DOI 10.1073/pnas.0908502106; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; Kobayashi K, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090241; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Li YL, 2017, J MED CHEM, V60, P1916, DOI 10.1021/acs.jmedchem.6b01689; Mahal BA, 2019, CANCER EPIDEM BIOMAR, V28, P1660, DOI 10.1158/1055-9965.EPI-19-0038; McElrath MJ, 2017, CURR OPIN HIV AIDS, V12, P278, DOI 10.1097/COH.0000000000000365; Mikulicic S, 2019, PAPILLOMAVIRUS RES, V7, P135, DOI 10.1016/j.pvr.2019.03.004; Nguyen TX, 2003, PEPTIDES, V24, P1647, DOI 10.1016/j.peptides.2003.07.023; Ozbun MA, 2019, PAPILLOMAVIRUS RES, V7, P188, DOI 10.1016/j.pvr.2019.04.009; Paz-Zulueta M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4033-2; Porter EM, 1997, INFECT IMMUN, V65, P2396, DOI 10.1128/IAI.65.6.2396-2401.1997; Quinones-Mateu ME, 2003, AIDS, V17, pF39, DOI [10.1097/01.aids.0000096878.73209.4f, 10.1097/00002030-200311070-00001]; Roberts JN, 2007, NAT MED, V13, P857, DOI 10.1038/nm1598; Schaal JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051337; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider JJ, 2005, J MOL MED, V83, P587, DOI 10.1007/s00109-005-0657-1; Seidel A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009737; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Selsted ME, 2007, CURR PHARM DESIGN, V13, P3061, DOI 10.2174/138161207782110363; Skeate JG, 2016, J GEN VIROL, V97, P422, DOI 10.1099/jgv.0.000341; Surviladze Z, 2015, J GEN VIROL, V96, P2232, DOI 10.1099/vir.0.000147; Surviladze Z, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002519; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Taylor JR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30051-2; Tongaonkar P, 2011, J LEUKOCYTE BIOL, V89, P283, DOI 10.1189/jlb.0910535; Tota JE, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.19.00370; Tran D, 2002, J BIOL CHEM, V277, P3079, DOI 10.1074/jbc.M109117200; Tran D, 2008, ANTIMICROB AGENTS CH, V52, P944, DOI 10.1128/AAC.01090-07; Wang J, 2015, B MALAYS MATH SCI SO, V38, P415, DOI 10.1007/s40840-014-0028-6; Wiens ME, 2017, MBIO, V8, DOI 10.1128/mBio.02304-16; Wiens ME, 2015, J VIROL, V89, P2866, DOI 10.1128/JVI.02901-14; Wilson SS, 2013, J MOL BIOL, V425, P4965, DOI 10.1016/j.jmb.2013.09.038; Winer RL, 2006, NEW ENGL J MED, V354, P2645, DOI 10.1056/NEJMoa053284; Woodham AW, 2014, J IMMUNOL, V192, P4748, DOI 10.4049/jimmunol.1303190; Woodham AW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043519; Yasin B, 2004, J VIROL, V78, P5147, DOI 10.1128/JVI.78.10.5147-5156.2004	63	2	2	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2020	11								561843	10.3389/fimmu.2020.561843	http://dx.doi.org/10.3389/fimmu.2020.561843			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY6EO	33154746	gold, Green Published			2022-12-18	WOS:000576480400001
J	He, Q; Jiang, L; Cao, KL; Zhang, LX; Xie, XC; Zhang, SY; Ding, XQ; He, YQ; Zhang, MM; Qiu, TY; Jin, XX; Zhao, C; Zhang, XY; Xu, JQ				He, Qian; Jiang, Lang; Cao, Kangli; Zhang, Linxia; Xie, Xinci; Zhang, Shuye; Ding, Xiangqing; He, Yongquan; Zhang, Miaomiao; Qiu, Tianyi; Jin, Xuanxuan; Zhao, Chen; Zhang, Xiaoyan; Xu, Jianqing			A Systemic Prime-Intrarectal Pull Strategy Raises Rectum-Resident CD8+T Cells for Effective Protection in a Murine Model of LM-OVA Infection	FRONTIERS IN IMMUNOLOGY			English	Article						mucosal immune response; rectum TRM; prime-pull vaccination strategy; HIV; Listeria monocytogenes	CD8(+) T-CELLS; HIV-1 VACCINE; IMMUNODEFICIENCY-VIRUS; LYMPHOCYTE RESPONSE; MUCOSAL IMMUNITY; CHOLERA-TOXIN; GENITAL-TRACT; DOUBLE-BLIND; MEMORY; IMMUNIZATION	As the entry sites of many pathogens such as human immunodeficiency virus (HIV), mucosal sites are defended by rapidly reacting resident memory T cells (TRM). TRMs represent a special subpopulation of memory T cells that persist long term in non-lymphoid sites without entering the circulation and provide the "sensing and alarming" role in the first-line defense against infection. The rectum and vagina are the two primary mucosal portals for HIV entry. However, compared to vaginal TRM, rectal TRM is poorly understood. Herein, we investigated the optimal vaccination strategy to induce rectal TRM. We identified an intranasal prime-intrarectal boost (pull) strategy that is effective in engaging rectal TRM alongside circulating memory T cells and demonstrated its protective efficacy in mice against infection ofListeria monocytogenes. On the contrary, the same vaccine delivered via either intranasal or intrarectal route failed to raise rectal TRM, setting it apart from vaginal TRM, which can be induced by both intranasal and intrarectal immunizations. Moreover, intramuscular prime was also effective in inducing rectal TRM in combination with intrarectal pull, highlighting the need of a primed systemic T cell response. A comparison of different pull modalities led to the identification that raising rectal TRM is mainly driven by local antigen presence. We further demonstrated the interval between prime and boost steps to be critical for the induction of rectal TRM, revealing circulating recently activated CD8+ T cells as the likely primary pullable precursor of rectal TRM. Altogether, our studies lay a new framework for harnessing rectal TRM in vaccine development.	[Zhao, Chen; Zhang, Xiaoyan; Xu, Jianqing] Fudan Univ, Shanghai Med Coll, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China; Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai, Peoples R China	Fudan University; Fudan University	Zhao, C; Zhang, XY; Xu, JQ (corresponding author), Fudan Univ, Shanghai Med Coll, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China.	chen_zhao72@163.com; zhangxiaoyan@shphc.org.cn; xujianqing@shphc.org.cn	Zhao, Chen/A-9987-2011; Zhang, Shuye/ABG-7815-2021	Zhang, Shuye/0000-0002-4749-6790; Zhang, Miaomiao/0000-0003-4657-5320; He, Yongquan/0000-0001-5193-942X	National Natural Science Foundation of China [81672018, 81561128008]; National Basic Research Program of China (973 program) [2014CB542502]; National 13th Five-Year Grand Program on Key Infectious Disease Control [2017ZX10202102]; Shanghai Pujiang Program [19PJ1409100]; National 13th FiveYear Grand Program on Key Infectious Disease Control and Prevention [2017ZX10304402-002-007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 program)(National Basic Research Program of China); National 13th Five-Year Grand Program on Key Infectious Disease Control; Shanghai Pujiang Program(Shanghai Pujiang Program); National 13th FiveYear Grand Program on Key Infectious Disease Control and Prevention	This work was sponsored by the National Natural Science Foundation of China (81672018 and 81561128008), the National Basic Research Program of China (973 program #2014CB542502), the National 13th Five-Year Grand Program on Key Infectious Disease Control (2017ZX10202102), Shanghai Pujiang Program (19PJ1409100), and National 13th FiveYear Grand Program on Key Infectious Disease Control and Prevention (2017ZX10304402-002-007).	Anderson KG, 2012, J IMMUNOL, V189, P2702, DOI 10.4049/jimmunol.1201682; Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803; Ariotti S, 2012, P NATL ACAD SCI USA, V109, P19739, DOI 10.1073/pnas.1208927109; Belyakov IM, 1998, J VIROL, V72, P8264, DOI 10.1128/JVI.72.10.8264-8272.1998; Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320; Beura LK, 2018, NAT IMMUNOL, V19, P173, DOI 10.1038/s41590-017-0029-3; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Cauley LS, 2013, MUCOSAL IMMUNOL, V6, P14, DOI 10.1038/mi.2012.96; Cuburu N, 2019, J IMMUNOL, V202, P1250, DOI 10.4049/jimmunol.1800219; Cuburu N, 2015, J VIROL, V89, P83, DOI 10.1128/JVI.02380-14; Cuburu N, 2012, J CLIN INVEST, V122, P4606, DOI 10.1172/JCI63287; Galvez-Cancino F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1442163; Genesca M, 2009, J INTERN MED, V265, P67, DOI 10.1111/j.1365-2796.2008.02051.x; Gherardi MM, 2004, J IMMUNOL, V172, P6209, DOI 10.4049/jimmunol.172.10.6209; Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6; Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757; Haddadi S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02075; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HogenEsch H, 2002, VACCINE, V20, pS34, DOI 10.1016/S0264-410X(02)00169-X; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; HOLMGREN J, 1993, VACCINE, V11, P1179, DOI 10.1016/0264-410X(93)90039-Z; Huang MB, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010030; Huang XG, 2007, VACCINE, V25, P8874, DOI 10.1016/j.vaccine.2007.08.066; Iijima N, 2015, TRENDS IMMUNOL, V36, P556, DOI 10.1016/j.it.2015.07.002; Kelley CF, 2017, MUCOSAL IMMUNOL, V10, P996, DOI 10.1038/mi.2016.97; Kim JH, 2015, ANNU REV MED, V66, P423, DOI 10.1146/annurev-med-052912-123749; Klavinskis LS, 1999, J IMMUNOL, V162, P254; Li JH, 2016, NATURE, V533, P110, DOI 10.1038/nature17947; Masopust D, 2010, J EXP MED, V207, P553, DOI 10.1084/jem.20090858; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Mueller SN, 2010, J IMMUNOL, V185, P2182, DOI 10.4049/jimmunol.1001142; Pizzolla A, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam6970; Ramirez JC, 2003, ARCH VIROL, V148, P827, DOI 10.1007/s00705-003-0006-z; Ren YQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep18099; Reynolds MR, 2005, J VIROL, V79, P9228, DOI 10.1128/JVI.79.14.9228-9235.2005; Schenkel JM, 2013, NAT IMMUNOL, V14, P509, DOI 10.1038/ni.2568; Sheridan BS, 2014, IMMUNITY, V40, P747, DOI 10.1016/j.immuni.2014.03.007; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Srivastava R, 2017, J VIROL, V91, DOI 10.1128/JVI.00278-17; Tan HX, 2018, MUCOSAL IMMUNOL, V11, P994, DOI 10.1038/mi.2017.89; Tsai HC, 2015, CRIT REV IMMUNOL, V35, P135, DOI 10.1615/CritRevImmunol.2015012295; UDDBACK IEM, 2016, SCI REP UK, V0006; Wakim LM, 2012, J IMMUNOL, V189, P3462, DOI 10.4049/jimmunol.1201305; Wan YM, 2014, VACCINE, V32, P2173, DOI 10.1016/j.vaccine.2014.02.056; Xie XC, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01630; Zammit DJ, 2006, IMMUNITY, V24, P439, DOI 10.1016/j.immuni.2006.01.015; Zens KD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85832	47	2	2	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2020	11								571248	10.3389/fimmu.2020.571248	http://dx.doi.org/10.3389/fimmu.2020.571248			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX7BS	33072113	gold, Green Published			2022-12-18	WOS:000575862500001
J	Faber, H; Kurtoic, D; Krishnamoorthy, G; Weber, P; Putz, B; Muller-Myhsok, B; Weber, F; Andlauer, TFM				Faber, Hans; Kurtoic, Dunja; Krishnamoorthy, Gurumoorthy; Weber, Peter; Puetz, Benno; Mueller-Myhsok, Bertram; Weber, Frank; Andlauer, Till F. M.			Gene Expression in Spontaneous Experimental Autoimmune Encephalomyelitis Is Linked to Human Multiple Sclerosis Risk Genes	FRONTIERS IN IMMUNOLOGY			English	Article						experimental autoimmune encephalomyelitis (EAE); myelin oligodendrocyte glycoprotein (MOG); T helper cell (Th); multiple sclerosis; risk genes; gene expression	T-CELL RESPONSES; MICROBIOTA; MODELS	Recent genome-wide association studies have identified over 230 genetic risk loci for multiple sclerosis. Current experimental autoimmune encephalomyelitis (EAE) models requiring active induction of disease may not be optimally suited for the characterization of the function of these genes. We have thus used gene expression profiling to study whether spontaneous opticospinal EAE (OSE) or MOG-induced EAE mirrors the genetic contribution to the pathogenesis of multiple sclerosis more faithfully. To this end, we compared gene expression in OSE and MOG EAE models and analyzed the relationship of both models to human multiple sclerosis risk genes and T helper cell biology. We observed stronger gene expression changes and an involvement of more pathways of the adaptive immune system in OSE than MOG EAE. Furthermore, we demonstrated a more extensive enrichment of human MS risk genes among transcripts differentially expressed in OSE than was the case for MOG EAE. Transcripts differentially expressed only in diseased OSE mice but not in MOG EAE were significantly enriched for T helper cell-specific transcripts. These transcripts are part of immune-regulatory pathways. The activation of the adaptive immune system and the enrichment of both human multiple sclerosis risk genes and T helper cell-specific transcripts were also observed in OSE mice showing only mild disease signs. These expression changes may, therefore, be indicative of processes at disease onset. In summary, more human multiple sclerosis risk genes were differentially expressed in OSE than was observed for MOG EAE, especially in T(H)1 cells. When studying the functional role of multiple sclerosis risk genes and pathways during disease onset and their interactions with the environment, spontaneous OSE may thus show advantages over MOG-induced EAE.	[Faber, Hans; Kurtoic, Dunja; Weber, Peter; Puetz, Benno; Mueller-Myhsok, Bertram; Weber, Frank; Andlauer, Till F. M.] Max Planck Inst Psychiat, Munich, Germany; [Krishnamoorthy, Gurumoorthy] Max Planck Inst Biochem, Martinsried, Germany; [Mueller-Myhsok, Bertram] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England; [Andlauer, Till F. M.] Tech Univ Munich, Sch Med, Dept Neurol, Klinikum Rechts Isar, Munich, Germany; [Faber, Hans] Schon Klin Bad Aibling Harthausen, Bad Aibling, Germany; [Andlauer, Till F. M.] Sana Kliniken Landkreises Cham GmbH, Neurolog Klin, Cham, Germany	Max Planck Society; Max Planck Society; University of Liverpool; Technical University of Munich	Muller-Myhsok, B; Andlauer, TFM (corresponding author), Max Planck Inst Psychiat, Munich, Germany.; Muller-Myhsok, B (corresponding author), Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.; Andlauer, TFM (corresponding author), Tech Univ Munich, Sch Med, Dept Neurol, Klinikum Rechts Isar, Munich, Germany.; Andlauer, TFM (corresponding author), Sana Kliniken Landkreises Cham GmbH, Neurolog Klin, Cham, Germany.	bmm@psych.mpg.de; till.andlauer@tum.de	Andlauer, Till/AAV-1893-2020; Krishnamoorthy, Gurumoorthy/O-1650-2013	Andlauer, Till/0000-0002-2917-5889; Krishnamoorthy, Gurumoorthy/0000-0002-7798-6707	German Federal Ministry of Education and Research (BMBF) through the DIFUTURE consortium of the Medical Informatics Initiative Germany [01ZZ1804A]; European Union's Horizon 2020 Research and Innovation Programme (grant MultipleMS) [EU RIA 733161]; BMBF through the Integrated Network IntegraMent, under e:Med Programme [01ZX1614J]; European Research Council starting grant (GAMES) [635617]; German research foundation (DFG) [SFB TR-128]; Max Planck Society	German Federal Ministry of Education and Research (BMBF) through the DIFUTURE consortium of the Medical Informatics Initiative Germany(Federal Ministry of Education & Research (BMBF)); European Union's Horizon 2020 Research and Innovation Programme (grant MultipleMS); BMBF through the Integrated Network IntegraMent, under e:Med Programme(Federal Ministry of Education & Research (BMBF)); European Research Council starting grant (GAMES); German research foundation (DFG)(German Research Foundation (DFG)); Max Planck Society(Max Planck SocietyFoundation CELLEX)	TA was supported by the German Federal Ministry of Education and Research (BMBF) through the DIFUTURE consortium of the Medical Informatics Initiative Germany (grant 01ZZ1804A) and by the European Union's Horizon 2020 Research and Innovation Programme (grant MultipleMS, EU RIA 733161). TA and BM-M were supported by the BMBF through the Integrated Network IntegraMent, under the auspices of the e:Med Programme (grant 01ZX1614J). GK was supported by the European Research Council starting grant (GAMES; 635617), German research foundation (DFG) SFB TR-128 (Project A1), and by the Max Planck Society.	Andlauer TFM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501678; [Anonymous], 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1494; Ashbaugh JJ, 2013, J IMMUNOL, V190, P4525, DOI 10.4049/jimmunol.1203214; Ben-Nun A, 2014, J AUTOIMMUN, V54, P33, DOI 10.1016/j.jaut.2014.06.004; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; Berer K, 2017, P NATL ACAD SCI USA, V114, P10719, DOI 10.1073/pnas.1711233114; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; Blankenhorn EP, 2011, ANN NEUROL, V70, P887, DOI 10.1002/ana.22642; Cao YH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8038; Domingues HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015531; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Glatigny S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028977; Gregersen JW, 2006, NATURE, V443, P574, DOI 10.1038/nature05133; Hiltensperger M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029637; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Hollenbach JA, 2015, J AUTOIMMUN, V64, P13, DOI 10.1016/j.jaut.2015.06.010; Hoppmann N, 2015, BRAIN, V138, P902, DOI 10.1093/brain/awu408; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Hurst EW, 1932, J HYG-CAMBRIDGE, V32, P33, DOI 10.1017/S0022172400017800; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Jelcic I, 2018, CELL, V175, P85, DOI 10.1016/j.cell.2018.08.011; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Krishnamoorthy G, 2007, J MOL MED, V85, P1161, DOI 10.1007/s00109-007-0218-x; Krishnamoorthy G, 2006, J CLIN INVEST, V116, P2385, DOI 10.1172/JCI28330; Kular L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04732-5; Lehmann-Horn K, 2013, THER ADV NEUROL DISO, V6, P161, DOI 10.1177/1756285612474333; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI [10.1002/0471142735.im1501s77, 10.1002/0471142735.im1501s88]; Molnarfi N, 2013, J EXP MED, V210, P2921, DOI 10.1084/jem.20130699; Moutsianas L, 2015, NAT GENET, V47, P1107, DOI 10.1038/ng.3395; Patsopoulos NA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003926; R Development Core Team, 2018, R LANG ENV STAT COMP; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Stromnes IM, 2008, NAT MED, V14, P337, DOI 10.1038/nm1715	38	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 18	2020	11								2165	10.3389/fimmu.2020.02165	http://dx.doi.org/10.3389/fimmu.2020.02165			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY5XN	33072080	Green Published, gold			2022-12-18	WOS:000576462100001
J	Sato, N; Garcia-Castillo, V; Yuzawa, M; Islam, MA; Albarracin, L; Tomokiyo, M; Ikeda-Ohtsubo, W; Garcia-Cancino, A; Takahashi, H; Villena, J; Kitazawa, H				Sato, Nana; Garcia-Castillo, Valeria; Yuzawa, Mao; Islam, Md Aminul; Albarracin, Leonardo; Tomokiyo, Mikado; Ikeda-Ohtsubo, Wakako; Garcia-Cancino, Apolinaria; Takahashi, Hideki; Villena, Julio; Kitazawa, Haruki			ImmunobioticLactobacillus jenseniiTL2937 Alleviates Dextran Sodium Sulfate-Induced Colitis by Differentially Modulating the Transcriptomic Response of Intestinal Epithelial Cells	FRONTIERS IN IMMUNOLOGY			English	Article						immunobiotics; intestinal inflammation; Lactobacillus jenseniiTL2937; PIE cells; immunotranscriptomic response	INFLAMMATORY-BOWEL-DISEASE; ACTIVATED PROTEIN-KINASE; INNATE IMMUNITY; CACO-2 CELLS; TNF; INTERLEUKIN-10; APOPTOSIS; RECEPTOR; NECROPTOSIS; PROBIOTICS	Immunobiotics have emerged as a promising intervention to alleviate intestinal damage in inflammatory bowel disease (IBD). However, the beneficial properties of immunobiotics are strain dependent and, therefore, each strain has to be evaluated in order to demonstrate its potential application in IBD. Our previousin vitroandin vivostudies demonstrated thatLactobacillus jenseniiTL2937 attenuates gut acute inflammatory response triggered by Toll-like receptor 4 activation. However, its effect on colitis has not been evaluated before. In this work, we studied whether the TL2937 strain was able to protect against the development of colitis in a dextran sodium sulfate (DSS)-induced mouse model and we delved into the mechanisms of action by evaluating the effect of the immunobiotic bacteria on the transcriptomic response of DSS-challenged intestinal epithelial cells.L. jenseniiTL2937 was administered to adult BALB/c mice before the induction of colitis by the administration of DSS. Colitis and the associated inflammatory response were evaluated for 14 days. Mice fed withL. jenseniiTL2937 had lower disease activity index and alterations of colon length when compared to control mice. Reduced myeloperoxidase activity, lower production of pro-inflammatory (TNF-alpha, IL-1, CXCL1, MCP-1, IL-15, and IL-17), and higher levels of immunoregulatory (IL-10 and IL-27) cytokines were found in the colon of TL2937-treated mice. In addition, the treatment of porcine intestinal epithelial (PIE) cells withL. jenseniiTL2937 before the challenge with DSS differentially regulated the activation of the JNK pathway, leading to an increase in epithelial cell integrity and to a differential immunotranscriptomic response. TL2937-treated PIE cells had a significant reduction in the expression of inflammatory cytokines (TNF-alpha,IL-1 alpha,IL-1 beta,IL-6, IL-15), chemokines (CCL2, CCL4, CCL8, CXCL4, CXCL5, CXCL9, CXCL10), adhesion molecules (SELE, SELL, EPCAM), and other immune factors (NCF1, NCF2, NOS2, SAA2) when compared to control cells after the challenge with DSS. The findings of this work indicate that (a)L. jenseniiTL2937 is able to alleviate DSS-induced colitis suggesting a potential novel application for this immunobiotic strain, (b) the modulation of the transcriptomic response of intestinal epithelial cells would play a key role in the beneficial effects of the TL2937 strain on colitis, and (c) thein vitroPIE cell immunoassay system could be of value for the screening and selection of new immunobiotic strains for their application in IBD.	[Sato, Nana; Garcia-Castillo, Valeria; Yuzawa, Mao; Islam, Md Aminul; Albarracin, Leonardo; Tomokiyo, Mikado; Ikeda-Ohtsubo, Wakako; Villena, Julio; Kitazawa, Haruki] Tohoku Univ, Grad Sch Agr Sci, Food & Feed Immunol Grp, Sendai, Miyagi, Japan; [Sato, Nana; Yuzawa, Mao; Islam, Md Aminul; Tomokiyo, Mikado; Ikeda-Ohtsubo, Wakako; Kitazawa, Haruki] Tohoku Univ, Int Educ & Res Ctr Food Agr Immunol CFAI, Grad Sch Agr Sci, Livestock Immunol Unit, Sendai, Miyagi, Japan; [Garcia-Castillo, Valeria; Garcia-Cancino, Apolinaria] Univ Concepcion, Fac Biol Sci, Lab Bacterial Pathogen, Concepcion, Chile; [Islam, Md Aminul; Villena, Julio] Bangladesh Agr Univ, Fac Vet Sci, Dept Med, Mymensingh, Bangladesh; [Albarracin, Leonardo] CERELA Natl Council Sci & Technol Res, Lab Immunobiotechnol, Reference Ctr Lactobacilli, San Miguel De Tucuman, Tucuman, Argentina; [Albarracin, Leonardo] Tucuman Univ, Fac Exact Sci & Technol, Lab Comp Sci, San Miguel De Tucuman, Tucuman, Argentina; [Takahashi, Hideki] Tohoku Univ, Grad Sch Agr Sci, Lab Plant Pathol, Sendai, Miyagi, Japan; [Takahashi, Hideki] Tohoku Univ, Int Educ & Res Ctr Food Agr Immunol, Grad Sch Agr Sci, Plant Immunol Unit, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Universidad de Concepcion; Bangladesh Agricultural University (BAU); Tohoku University; Tohoku University	Villena, J; Kitazawa, H (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Food & Feed Immunol Grp, Sendai, Miyagi, Japan.; Kitazawa, H (corresponding author), Tohoku Univ, Int Educ & Res Ctr Food Agr Immunol CFAI, Grad Sch Agr Sci, Livestock Immunol Unit, Sendai, Miyagi, Japan.; Villena, J (corresponding author), Bangladesh Agr Univ, Fac Vet Sci, Dept Med, Mymensingh, Bangladesh.	jcvillena@cerela.org.ar; haruki.kitazawa.c7@tohoku.ac.jp	Ikeda-Ohtsubo, Wakako/AAJ-2909-2021	Ikeda-Ohtsubo, Wakako/0000-0001-8489-1936; Garcia, Valeria/0000-0002-6197-4648; Kitazawa, Haruki/0000-0003-4586-5553	ANPCyT-FONCyT [PICT-2016-0410]; Japan Society for the Promotion of Science (JSPS); Food Science Institute Foundation (Ryoushoku-kenkyukai); project of NARO Bio-oriented Technology Research Advancement Institution (research program on the development of innovative technology) [01002A]; Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan [16H06429, 16K21723, 16H06435]; JSPS Core-to-Core Program, A. Advanced Research Networks entitled Establishment of international agricultural immunology research core for a quantum improvement in food safety;  [19H00965]	ANPCyT-FONCyT(ANPCyTFONCyT); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Food Science Institute Foundation (Ryoushoku-kenkyukai); project of NARO Bio-oriented Technology Research Advancement Institution (research program on the development of innovative technology); Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS Core-to-Core Program, A. Advanced Research Networks entitled Establishment of international agricultural immunology research core for a quantum improvement in food safety; 	This study was supported by ANPCyT-FONCyT Grant PICT-2016-0410 to JV. This study was supported by a Grant-in-Aid for Scientific Research (A) (19H00965) and Open Partnership Joint Projects of JSPS Bilateral Joint Research Projects from the Japan Society for the Promotion of Science (JSPS), and the Food Science Institute Foundation (Ryoushoku-kenkyukai) to HK. This research was supported by grants from the project of NARO Bio-oriented Technology Research Advancement Institution (research program on the development of innovative technology, No. 01002A) to HK. This study was also supported by grants for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan (16H06429, 16K21723, and 16H06435) to HT. This work was also supported by JSPS Core-to-Core Program, A. Advanced Research Networks entitled Establishment of international agricultural immunology research core for a quantum improvement in food safety.	Albarracin L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00543; Albarracin L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00057; Araki Y, 2006, ONCOL REP, V16, P1357; Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147; Canna SW, 2017, J ALLERGY CLIN IMMUN, V139, P1698, DOI 10.1016/j.jaci.2016.10.022; Chang KW, 2015, FOOD FUNCT, V6, P3334, DOI [10.1039/c5fo00513b, 10.1039/C5FO00513B]; Claes IJJ, 2010, CLIN EXP IMMUNOL, V162, P306, DOI 10.1111/j.1365-2249.2010.04228.x; Coccia M, 2012, J EXP MED, V209, P1595, DOI 10.1084/jem.20111453; Colombel JF, 2001, GUT, V49, P42, DOI 10.1136/gut.49.1.42; Cui Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148241; Danese S, 2019, GUT, V68, P40, DOI 10.1136/gutjnl-2017-314562; de Souza HSP, 2016, NAT REV GASTRO HEPAT, V13, P13, DOI [10.1038/nrgastro.2016.186, 10.1038/nrgastro.2015.186]; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Friedrich M, 2019, IMMUNITY, V50, P992, DOI 10.1016/j.immuni.2019.03.017; Ganji-Arjenaki M, 2018, J CELL PHYSIOL, V233, P2091, DOI 10.1002/jcp.25911; Goretsky T, 2012, AM J PATHOL, V181, P1306, DOI 10.1016/j.ajpath.2012.06.016; Gunther C, 2013, GUT, V62, P1062, DOI 10.1136/gutjnl-2011-301364; Gunther C, 2011, NATURE, V477, P335, DOI 10.1038/nature10400; Hagiwara C, 2002, J GASTROEN HEPATOL, V17, P758, DOI 10.1046/j.1440-1746.2002.02791.x; Hayes CL, 2014, BENEF MICROBES, V5, P79, DOI 10.3920/BM2013.0039; Hosoya S, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-111; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Ishizuka T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152416; Jeon YD, 2016, MOLECULES, V21, DOI 10.3390/molecules21040523; Kobayashi H, 2016, BENEF MICROBES, V7, P769, DOI 10.3920/BM2016.0095; Kojouharoff G, 1997, CLIN EXP IMMUNOL, V107, P353, DOI 10.1111/j.1365-2249.1997.291-ce1184.x; Kotlarz D, 2012, GASTROENTEROLOGY, V143, P347, DOI 10.1053/j.gastro.2012.04.045; Kuhn KA, 2018, MUCOSAL IMMUNOL, V11, P357, DOI 10.1038/mi.2017.55; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Levy M, 2013, PEDIATRICS, V132, pE779, DOI 10.1542/peds.2012-3344; Lopetuso LR, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00181; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Martin R, 2017, FEMS MICROBIOL REV, V41, pS49, DOI 10.1093/femsre/fux035; Mitsuyama K, 2006, INT J MOL MED, V17, P449; Mohamadzadeh M, 2011, P NATL ACAD SCI USA, V108, P4623, DOI 10.1073/pnas.1005066107; Moue M, 2008, BBA-GEN SUBJECTS, V1780, P134, DOI 10.1016/j.bbagen.2007.11.006; Mudunuri U, 2009, BIOINFORMATICS, V25, P555, DOI 10.1093/bioinformatics/btn654; Murofushi Y, 2015, MOL IMMUNOL, V64, P63, DOI 10.1016/j.molimm.2014.10.027; Nava P, 2010, IMMUNITY, V32, P392, DOI 10.1016/j.immuni.2010.03.001; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Pabst R, 2020, CELL TISSUE RES, V380, P287, DOI 10.1007/s00441-020-03206-9; Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; Racedo S, 2006, MICROBES INFECT, V8, P2359, DOI 10.1016/j.micinf.2006.04.022; Reinisch W, 2006, GUT, V55, P1138, DOI 10.1136/gut.2005.079434; Rodrigues VF, 2018, CYTOKINE, V111, P72, DOI 10.1016/j.cyto.2018.08.003; Roy PK, 2008, WORLD J GASTROENTERO, V14, P200, DOI 10.3748/wjg.14.200; Samak G, 2015, BIOCHEM J, V465, P503, DOI 10.1042/BJ20140450; Schreiber S, 2000, GASTROENTEROLOGY, V119, P1461, DOI 10.1053/gast.2000.20196; Shimazu T, 2012, INFECT IMMUN, V80, P276, DOI 10.1128/IAI.05729-11; Siegmund B, 2001, P NATL ACAD SCI USA, V98, P13249, DOI 10.1073/pnas.231473998; Siegmund B, 2001, AM J PHYSIOL-REG I, V281, pR1264, DOI 10.1152/ajpregu.2001.281.4.R1264; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; Stokes William S, 2002, ILAR J, V43 Suppl, pS31; Su LP, 2013, GASTROENTEROLOGY, V145, P407, DOI 10.1053/j.gastro.2013.04.011; Suda Y, 2014, BMC IMMUNOL, V15, DOI 10.1186/1471-2172-15-24; Sudirman S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205252; Trivedi PJ, 2018, J CROHNS COLITIS, V12, pS641, DOI 10.1093/ecco-jcc/jjx145; Tsukida K, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0160-1; Villena J, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-53; Villena J, 2012, CLIN VACCINE IMMUNOL, V19, P1038, DOI 10.1128/CVI.00199-12; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Wirtz S, 2011, GASTROENTEROLOGY, V141, P1875, DOI 10.1053/j.gastro.2011.07.040; Xia JG, 2014, NUCLEIC ACIDS RES, V42, pW167, DOI 10.1093/nar/gku443; Yamamoto M, 2000, J IMMUNOL, V164, P4878, DOI 10.4049/jimmunol.164.9.4878; Zhao HY, 2016, INT IMMUNOPHARMACOL, V39, P121, DOI 10.1016/j.intimp.2016.07.020; Zhao Q, 2018, INFLAMM RES, V67, P663, DOI 10.1007/s00011-018-1155-6	68	2	2	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 17	2020	11								2174	10.3389/fimmu.2020.02174	http://dx.doi.org/10.3389/fimmu.2020.02174			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY4AK	33042131	gold, Green Published			2022-12-18	WOS:000576334300001
J	Wennink, RAW; Pandit, A; Haasnoot, AMJW; Hiddingh, S; Ayuso, VK; Wulffraat, NM; Vastert, BJ; Radstake, TRDJ; de Boer, JH; Kuiper, JJW				Wennink, Roos A. W.; Pandit, Aridaman; Haasnoot, Anne-Mieke J. W.; Hiddingh, Sanne; Ayuso, Viera Kalinina; Wulffraat, Nico M.; Vastert, Bas J.; Radstake, Timothy R. D. J.; de Boer, Joke H.; Kuiper, Jonas J. W.			Whole Transcriptome Analysis Reveals Heterogeneity in B Cell Memory Populations in Patients With Juvenile Idiopathic Arthritis-Associated Uveitis	FRONTIERS IN IMMUNOLOGY			English	Article						juvenile idiopathic arthritis; juvenile idiopathic arthritis associated uveitis; RNA sequencing; B cell; memory B cell	RISK-FACTORS; COMPLICATIONS; CHILDREN	Purpose Patients with juvenile idiopathic arthritis (JIA) are prone to developing chronic anterior uveitis (JIA-U+). Although several risk factors for JIA-U+ have been identified, the underlying etiology is poorly understood. Histopathological studies demonstrate B cell infiltrates in eye tissues of patients with JIA-U+. Methods We performed transcriptome profiling of peripheral blood CD19-positive B cells taken from 14 cases with JIA-U+, 13 JIA cases without uveitis (JIA-U-), and five healthy controls. Deconvolution-based estimation was used to determine the immune cell fractions for each sample. Results Deconvolution results revealed that naive B cells made up on average 71% of the CD19-positive cell fractions analyzed. Differential expression analysis identified 614 differentially expressed genes (DEGs) between the groups at nominal significance and six genes at a false discovery rate of 5% (FDR < 0.05). Head-to-head comparison of all JIA-U- versus JIA-U+ revealed no DEGs in the CD19+ B cell pool (FDR < 0.05). However, principal component analysis based on a panel of key genes for B cell subsets revealed that JIA-U+ cases bifurcate into distinct clusters, characterized by markedly disparate expression for genes associated with specific memory B cell populations. CIBERSORT analysis of the overall transcriptome of the new uveitis cluster identified an increased proportion of memory B cells. Conclusion These data show that JIA-U- and JIA-U+ have a globally similar transcriptome considering the global peripheral CD19-positive B cell pool. However, heterogeneity in B cell memory genes among cases with uveitis suggests a role for specific memory B cell subsets in the etiology of JIA-U+.	[Wennink, Roos A. W.; Haasnoot, Anne-Mieke J. W.; Ayuso, Viera Kalinina; de Boer, Joke H.; Kuiper, Jonas J. W.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands; [Wennink, Roos A. W.; Pandit, Aridaman; Haasnoot, Anne-Mieke J. W.; Hiddingh, Sanne; Radstake, Timothy R. D. J.; Kuiper, Jonas J. W.] Univ Utrecht, Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [Wulffraat, Nico M.; Vastert, Bas J.] Univ Med Ctr Utrecht, Dept Pediat Rheumatol, Utrecht, Netherlands; [Radstake, Timothy R. D. J.] Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Wennink, RAW (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands.; Wennink, RAW (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands.	r.a.w.wennink@umcutrecht.nl	Pandit, Aridaman/ABH-1221-2021; Wulffraat, Nico M/AAE-8929-2020; Vastert, Sebastiaan J/AAE-5742-2022	Pandit, Aridaman/0000-0003-2057-9737; Wulffraat, Nico M/0000-0001-9548-5562; Vastert, Sebastiaan J/0000-0002-4226-0949	Dutch Ophthalmology Foundation "UitZicht"; ODAS stichting	Dutch Ophthalmology Foundation "UitZicht"; ODAS stichting	This research was supported by the Dutch Ophthalmology Foundation "UitZicht" and ODAS stichting.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Angeles-Han ST, 2013, J RHEUMATOL, V40, P2088, DOI 10.3899/jrheum.130302; Ayuso VK, 2015, INVEST OPHTH VIS SCI, V56, P6770, DOI 10.1167/iovs.15-17351; Ayuso VK, 2014, SURV OPHTHALMOL, V59, P517, DOI 10.1016/j.survophthal.2014.03.002; Ayuso VK, 2010, AM J OPHTHALMOL, V149, P994, DOI 10.1016/j.ajo.2010.01.016; Barcelos F, 2018, RHEUMATOL INT, V38, P1063, DOI 10.1007/s00296-018-4018-0; Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Bolt IB, 2008, J RHEUMATOL, V35, P703; Cassidy J, 2006, PEDIATRICS, V117, P1843, DOI 10.1542/peds.2006-0421; Corcione A, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2824; de Groot-Mijnes JDF, 2015, OPHTHALMOLOGY, V122, P1270, DOI 10.1016/j.ophtha.2015.01.006; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Edelsten C, 2002, BRIT J OPHTHALMOL, V86, P51, DOI 10.1136/bjo.86.1.51; Glaesener S, 2014, ARTHRITIS RHEUMATOL, V66, P2590, DOI 10.1002/art.38736; Glass DR, 2019, INTEGRADED MULTIOMIC, DOI [10.1101/801530, DOI 10.1101/801530]; Haasnoot AMJW, 2019, EXPERT REV CLIN IMMU, V15, P657, DOI 10.1080/1744666X.2019.1593139; Haasnoot AMJW, 2018, ARTHRITIS RHEUMATOL, V70, P1155, DOI 10.1002/art.40484; Haasnoot AMJW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164312; Heiligenhaus A, 2007, RHEUMATOLOGY, V46, P1015, DOI 10.1093/rheumatology/kem053; Heiligenhaus A, 2011, RHEUMATOLOGY, V50, P1390, DOI 10.1093/rheumatology/ker107; Hu Q, 2019, ATLAS INFILTRATED B, DOI [10.1101/695601, DOI 10.1101/695601]; Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marasco E, 2018, ARTHRITIS RHEUMATOL, V70, P606, DOI 10.1002/art.40410; Miserocchi E, 2016, BRIT J OPHTHALMOL, V100, P782, DOI 10.1136/bjophthalmol-2015-306790; Monaco G, 2019, CELL REP, V26, P1627, DOI 10.1016/j.celrep.2019.01.041; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Numata M, 2015, LEUKEMIA RES, V39, P906, DOI 10.1016/j.leukres.2015.05.013; Petty RE, 2004, J RHEUMATOL, V31, P390; Sanz I, 2008, SEMIN IMMUNOL, V20, P67, DOI 10.1016/j.smim.2007.12.006; Sen ES, 2015, NAT REV RHEUMATOL, V11, P338, DOI 10.1038/nrrheum.2015.20; Shao Y, 2010, IMMUNOL LETT, V129, P78, DOI 10.1016/j.imlet.2010.02.002; Smith JR, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.2; Souto-Carneiro MM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2718; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Van Nieuwenhove E, 2018, MACHINE LEARNING IDE, DOI [10.1101/382499, DOI 10.1101/382499]; Walscheid K, 2019, OCUL IMMUNOL INFLAMM, V27, P788, DOI 10.1080/09273948.2018.1467464; Walscheid K, 2018, CLIN IMMUNOL, V190, P84, DOI 10.1016/j.clim.2017.09.014; Wildschutz L, 2019, J AUTOIMMUN, V100, P75, DOI 10.1016/j.jaut.2019.03.004	40	2	2	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 17	2020	11								2170	10.3389/fimmu.2020.02170	http://dx.doi.org/10.3389/fimmu.2020.02170			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY4HY	33042130	Green Published, gold			2022-12-18	WOS:000576353900001
J	Amani, SA; Lang, ML				Amadou Amani, Souwelimatou; Lang, Mark L.			Bacteria That Cause Enteric Diseases Stimulate Distinct Humoral Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Review						humoral immune response; plasma cell; memory B cell; antibodies; enteric bacteria	CLOSTRIDIUM-DIFFICILE TOXIN; MEMORY B-CELL; CITROBACTER-RODENTIUM INFECTION; ANTIBODY-SECRETING CELL; CHAIN FATTY-ACIDS; CD4(+) T-CELLS; LIPOPOLYSACCHARIDE O-ANTIGEN; SHIGELLA-FLEXNERI 2A; IMMUNOGLOBULIN-A; IN-VIVO	Bacterial enteric pathogens individually and collectively represent a serious global health burden. Humoral immune responses following natural or experimentally-induced infections are broadly appreciated to contribute to pathogen clearance and prevention of disease recurrence. Herein, we have compared observations on humoral immune mechanisms following infection withCitrobacter rodentium, the model for enteropathogenicEscherichia coli, Vibrio cholerae, Shigellaspecies, Salmonella entericaspecies, andClostridioides difficile. A comparison of what is known about the humoral immune responses to these pathogens reveals considerable variance in specific features of humoral immunity including establishment of high affinity, IgG class-switched memory B cell and long-lived plasma cell compartments. This article suggests that such variance could be contributory to persistent and recurrent disease.	[Amadou Amani, Souwelimatou; Lang, Mark L.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Lang, ML (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.	mark-lang@ouhsc.edu			NIH [AI134719]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The ideas developed in this article were derived from work supported by NIH award AI134719 to ML.	Abt MC, 2015, CELL HOST MICROBE, V18, P27, DOI 10.1016/j.chom.2015.06.011; Aktar A, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006399; Aktar A, 2016, CLIN VACCINE IMMUNOL, V23, P427, DOI 10.1128/CVI.00647-15; Alam MM, 2011, CLIN VACCINE IMMUNOL, V18, P844, DOI 10.1128/CVI.00562-10; Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832; ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; Amani SA, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00829-19; Antharam VC, 2013, J CLIN MICROBIOL, V51, P2884, DOI 10.1128/JCM.00845-13; ARONSSON B, 1985, INFECTION, V13, P97, DOI 10.1007/BF01642866; Azman AS, 2013, J INFECTION, V66, P432, DOI 10.1016/j.jinf.2012.11.013; Azrad M, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty066; Bai X, 2020, J IMMUNOL, V204, P2754, DOI 10.4049/jimmunol.2000046; Bardhan P, 2010, EMERG INFECT DIS, V16, P1718, DOI 10.3201/eid1611.090934; BARTHOLD SW, 1978, VET PATHOL, V15, P223, DOI 10.1177/030098587801500209; Bauer MP, 2014, CLIN MICROBIOL INFEC, V20, P1323, DOI 10.1111/1469-0691.12769; Belzer C, 2011, EUR J MICROBIOL IMMU, V1, P311, DOI 10.1556/EuJMI.1.2011.4.7; Bergan J, 2012, TOXICON, V60, P1085, DOI 10.1016/j.toxicon.2012.07.016; Bergstrom KS, 2012, CELL MICROBIOL, V14, P475, DOI 10.1111/j.1462-5822.2012.01750.x; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; Bhowmick R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109107; Bhuiyan TR, 2009, INFECT IMMUN, V77, P1888, DOI 10.1128/IAI.01101-08; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Bougneres L, 2004, J CELL BIOL, V166, P225, DOI 10.1083/jcb.200402073; Bouillaut L, 2015, ANTIMICROB AGENTS CH, V59, P4199, DOI 10.1128/AAC.00275-15; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; Bourque DL, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00594-17; Bridgman SL, 2016, MICROBES INFECT, V18, P543, DOI 10.1016/j.micinf.2016.05.001; BUYSSE JM, 1987, J BACTERIOL, V169, P2561, DOI 10.1128/jb.169.6.2561-2569.1987; CDC, 2013, ANT RES THREATS US; Charles A, 2001, IMMUNOBIOL IMMUNE SY, V5; Clare S, 2013, INFECT IMMUN, V81, P723, DOI 10.1128/IAI.00969-12; COHEN D, 1989, J CLIN MICROBIOL, V27, P162, DOI 10.1128/JCM.27.1.162-167.1989; COHEN D, 1991, J CLIN MICROBIOL, V29, P386, DOI 10.1128/JCM.29.2.386-389.1991; Cohen D, 2019, HUM VACC IMMUNOTHER, V15, P1401, DOI 10.1080/21645515.2019.1606971; Conlan JW, 1996, INFECT IMMUN, V64, P1043, DOI 10.1128/IAI.64.3.1043-1047.1996; Corbishley A, 2014, INFECT IMMUN, V82, P5117, DOI 10.1128/IAI.02462-14; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Cunha BA, 1998, CRIT CARE CLIN, V14, P329, DOI 10.1016/S0749-0704(05)70398-5; Cunningham AF, 2007, J IMMUNOL, V178, P6200, DOI 10.4049/jimmunol.178.10.6200; D'Aoust JY, 2007, FOOD MICROBIOLOGY: FUNDAMENTALS AND FRONTIERS, THIRD EDITION, P187; Devera TS, 2016, INFECT IMMUN, V84, P194, DOI 10.1128/IAI.00011-15; Drudy D, 2004, FEMS IMMUNOL MED MIC, V41, P237, DOI 10.1016/j.femsim.2004.03.007; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; Ellis CN, 2015, INFECT IMMUN, V83, P1089, DOI 10.1128/IAI.02765-14; Fachi JL, 2019, CELL REP, V27, P750, DOI 10.1016/j.celrep.2019.03.054; FASANO A, 1995, J CLIN INVEST, V95, P2853, DOI 10.1172/JCI117991; Finkelstein R.A., 1996, MED MICROBIOLOGY; FINLAY BB, 1991, J CELL SCI, V99, P283; Flach CF, 2007, INFECT IMMUN, V75, P2343, DOI 10.1128/IAI.01900-06; FORMAL SB, 1991, J INFECT DIS, V164, P533, DOI 10.1093/infdis/164.3.533; FOSTER JW, 1991, J BACTERIOL, V173, P5129, DOI 10.1128/jb.173.16.5129-5135.1991; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; Frankel G, 1996, INFECT IMMUN, V64, P5315, DOI 10.1128/IAI.64.12.5315-5325.1996; Gal-Mor O, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00391; Galyov EE, 1997, MOL MICROBIOL, V25, P903, DOI 10.1111/j.1365-2958.1997.mmi525.x; Garber JJ, 2018, CELL MOL GASTROENTER, V5, P273, DOI 10.1016/j.jcmgh.2017.11.015; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; Gaytan MO, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00129; Gebert A, 1996, INT REV CYTOL, V167, P91, DOI 10.1016/S0074-7696(08)61346-7; Ghaem-Maghami M, 2001, INFECT IMMUN, V69, P5597, DOI 10.1128/IAI.69.9.5597-5605.2001; Giacomin PR, 2015, J EXP MED, V212, P1513, DOI 10.1084/jem.20141831; Gibson DL, 2008, CELL MICROBIOL, V10, P618, DOI 10.1111/j.1462-5822.2007.01071.x; Gopinath S, 2012, TRENDS MICROBIOL, V20, P320, DOI 10.1016/j.tim.2012.04.004; GORDEN J, 1993, INFECT IMMUN, V61, P364, DOI 10.1128/IAI.61.1.364-367.1993; Guo XH, 2014, IMMUNITY, V40, P25, DOI 10.1016/j.immuni.2013.10.021; Gutzeit C, 2014, IMMUNOL REV, V260, P76, DOI 10.1111/imr.12189; Hall IC, 1935, AM J DIS CHILD, V49, P390, DOI 10.1001/archpedi.1935.01970020105010; Harris AM, 2009, INFECT IMMUN, V77, P3850, DOI 10.1128/IAI.00369-09; Hess J, 1996, J IMMUNOL, V156, P3321; Heyman D, CONTROL COMMUNICABLE; Higgins LM, 1999, INFECT IMMUN, V67, P3031, DOI 10.1128/IAI.67.6.3031-3039.1999; Hing TC, 2013, GUT, V62, P1295, DOI 10.1136/gutjnl-2012-302180; Hopkins RJ, 2018, GASTROENTEROL REP, V6, P21, DOI 10.1093/gastro/gox041; Huang X, 2017, ASS IMMNOL, V18, P8; Hussack G, 2010, TOXINS, V2, P998, DOI 10.3390/toxins2050998; Ishida Y, 2004, J IMMUNOL, V172, P3018, DOI 10.4049/jimmunol.172.5.3018; Islam D, 1997, INFECT IMMUN, V65, P739, DOI 10.1128/IAI.65.2.739-749.1997; Jafari NV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069846; Janoir C, 2016, ANAEROBE, V37, P13, DOI 10.1016/j.anaerobe.2015.10.009; Jayasekera CR, 2008, J INFECT DIS, V198, P1055, DOI 10.1086/591500; Jiminez JA, 2017, MSPHERE, V2, DOI [10.1128/mSphere.00243-17, 10.1128/msphere.00243-17]; Johal SS, 2004, J CLIN PATHOL, V57, P973, DOI 10.1136/jcp.2003.015875; JOHNSON S, 1992, J INFECT DIS, V166, P1287, DOI 10.1093/infdis/166.6.1287; Johnston PF, 2014, INFECT IMMUN, V82, P522, DOI 10.1128/IAI.01273-13; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; Kamada N, 2015, CELL HOST MICROBE, V17, P617, DOI 10.1016/j.chom.2015.04.001; Karpman D, 2002, PEDIATR NEPHROL, V17, P201, DOI 10.1007/s00467-001-0792-z; Kelly CP, 2012, CLIN MICROBIOL INFEC, V18, P21, DOI 10.1111/1469-0691.12046; Kelly CP, 2011, J MED MICROBIOL, V60, P1070, DOI 10.1099/jmm.0.030015-0; KELLY CP, 1994, J CLIN INVEST, V93, P1257, DOI 10.1172/JCI117080; Kelly CP, 1996, ANTIMICROB AGENTS CH, V40, P373, DOI 10.1128/AAC.40.2.373; Khan MA, 2006, INFECT IMMUN, V74, P2522, DOI 10.1128/IAI.74.5.2522-2536.2006; Khanna S, 2012, AM J GASTROENTEROL, V107, P89, DOI 10.1038/ajg.2011.398; Kim DW, 2008, MOL IMMUNOL, V45, P3295, DOI 10.1016/j.molimm.2008.02.013; Kim MH, 2013, GASTROENTEROLOGY, V145, P396, DOI 10.1053/j.gastro.2013.04.056; Konradt C, 2011, CELL HOST MICROBE, V9, P263, DOI 10.1016/j.chom.2011.03.010; Kum WWS, 2010, CELL MICROBIOL, V12, P1250, DOI 10.1111/j.1462-5822.2010.01466.x; Kupz A, 2014, INFECT IMMUN, V82, P4997, DOI 10.1128/IAI.02192-14; LABREC EH, 1964, J BACTERIOL, V88, P1503, DOI 10.1128/JB.88.5.1503-1518.1964; Lamas A, 2019, ANTIBIOTICS-BASEL, V8, DOI 10.3390/antibiotics8040265; Lavergne V, 2013, J INFECTION, V66, P129, DOI 10.1016/j.jinf.2012.11.001; Lebeis SL, 2007, J IMMUNOL, V179, P566, DOI 10.4049/jimmunol.179.1.566; Lee SJ, 2012, IMMUNOL LETT, V148, P138, DOI 10.1016/j.imlet.2012.10.009; Leung DT, 2011, CLIN VACCINE IMMUNOL, V18, P1317, DOI 10.1128/CVI.05124-11; Linterman MA, 2014, ELIFE, V3, DOI 10.7554/eLife.03180; Liu YW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01411; Luperchio SA, 2001, MICROBES INFECT, V3, P333, DOI 10.1016/S1286-4579(01)01387-9; Luperchio SA, 2000, J CLIN MICROBIOL, V38, P4343, DOI 10.1128/JCM.38.12.4343-4350.2000; Maaser C, 2004, INFECT IMMUN, V72, P3315, DOI 10.1128/IAI.72.6.3315-3324.2004; Mabbott NA, 2013, MUCOSAL IMMUNOL, V6, P666, DOI 10.1038/mi.2013.30; MacLennan CA, 2008, J CLIN INVEST, V118, P1553, DOI 10.1172/JCI33998; Manne C, 2019, P NATL ACAD SCI USA, V116, P7425, DOI 10.1073/pnas.1818242116; Mastroeni P, 2000, INFECT IMMUN, V68, P46, DOI 10.1128/IAI.68.1.46-53.2000; MATHAN MM, 1995, GASTROENTEROLOGY, V109, P422, DOI 10.1016/0016-5085(95)90329-1; MAURELLI AT, 2001, FOODBORNE DIS HDB, V1, P323; McBroom AJ, 2007, MOL MICROBIOL, V63, P545, DOI 10.1111/j.1365-2958.2006.05522.x; McSorley SJ, 2000, INFECT IMMUN, V68, P3344, DOI 10.1128/IAI.68.6.3344-3348.2000; McSorley SJ, 2002, IMMUNITY, V16, P365, DOI 10.1016/S1074-7613(02)00289-3; MITCHELL MJ, 1987, INFECT IMMUN, V55, P1610, DOI 10.1128/IAI.55.7.1610-1615.1987; Mittrucker HW, 2000, J IMMUNOL, V164, P1648, DOI 10.4049/jimmunol.164.4.1648; Monaghan TM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074452; Monira S, 2010, EUR J CLIN NUTR, V64, P1116, DOI 10.1038/ejcn.2010.123; Mykoniatis A, 2003, GASTROENTEROLOGY, V124, P683, DOI 10.1053/gast.2003.50101; Nelson EJ, 2009, NAT REV MICROBIOL, V7, P693, DOI 10.1038/nrmicro2204; Nizet V, 2006, CURR ISSUES MOL BIOL, V8, P11; Nothelfer K, 2014, J EXP MED, V211, P1215, DOI 10.1084/jem.20130914; Nuding S, 2014, ANTIMICROB AGENTS CH, V58, P5719, DOI 10.1128/AAC.02542-14; OAKS EV, 1986, INFECT IMMUN, V53, P57, DOI 10.1128/IAI.53.1.57-63.1986; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; Okuda J, 2005, BIOCHEM BIOPH RES CO, V333, P531, DOI 10.1016/j.bbrc.2005.05.145; ORR N, 1992, J CLIN MICROBIOL, V30, P2165, DOI 10.1128/JCM.30.8.2165-2168.1992; Osbelt L, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008448; Papapietro O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2816; Patel SM, 2012, CLIN VACCINE IMMUNOL, V19, P842, DOI 10.1128/CVI.00037-12; Perez-Shibayama C, 2014, J IMMUNOL, V192, P5192, DOI 10.4049/jimmunol.1302526; Petty NK, 2010, J BACTERIOL, V192, P525, DOI 10.1128/JB.01144-09; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; Puhar A, 2013, IMMUNITY, V39, P1121, DOI 10.1016/j.immuni.2013.11.013; Pulimood AB, 2008, J GASTROEN HEPATOL, V23, P752, DOI 10.1111/j.1440-1746.2008.05325.x; Qadri F, 2004, GUT, V53, P62, DOI 10.1136/gut.53.1.62; Qadri F, 1997, INFECT IMMUN, V65, P3571, DOI 10.1128/IAI.65.9.3571-3576.1997; Qadri F, 2003, INFECT IMMUN, V71, P4808, DOI 10.1128/IAI.71.8.4808-4814.2003; Rabbani GH, 1999, DIGEST DIS SCI, V44, P1547, DOI 10.1023/A:1026650624193; Rahman A, 2013, CLIN VACCINE IMMUNOL, V20, P1592, DOI 10.1128/CVI.00347-13; Raqib R, 1997, INFECT IMMUN, V65, P5338, DOI 10.1128/IAI.65.12.5338-5341.1997; Raqib R, 2002, SCAND J IMMUNOL, V55, P414, DOI 10.1046/j.1365-3083.2002.01079.x; Raqib R, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-111; Rashu R, 2019, MICROBES INFECT, V21, P176, DOI 10.1016/j.micinf.2018.12.002; Ravindran R, 2005, J IMMUNOL, V175, P4603, DOI 10.4049/jimmunol.175.7.4603; Ruchaud-Sparagano MH, 2007, CELL MICROBIOL, V9, P1909, DOI 10.1111/j.1462-5822.2007.00923.x; Rydstrom A, 2007, J IMMUNOL, V178, P5789, DOI 10.4049/jimmunol.178.9.5789; Salazar-Gonzalez RM, 2006, IMMUNITY, V24, P623, DOI 10.1016/j.immuni.2006.02.015; Salgado-Pabon W, 2013, P NATL ACAD SCI USA, V110, P4458, DOI 10.1073/pnas.1300981110; Sanada T, 2012, NATURE, V483, P623, DOI 10.1038/nature10894; Sanchez-Hurtado K, 2008, J MED MICROBIOL, V57, P717, DOI 10.1099/jmm.0.47713-0; Sansonetti PJ, 2007, IMMUNITY, V26, P149, DOI 10.1016/j.immuni.2007.02.004; Sansonetti PJ, 2000, IMMUNITY, V12, P581, DOI 10.1016/S1074-7613(00)80209-5; Sansonetti PJ, 1996, INFECT IMMUN, V64, P2752, DOI 10.1128/IAI.64.7.2752-2764.1996; Sansonetti PJ, 1999, INFECT IMMUN, V67, P1471, DOI 10.1128/IAI.67.3.1471-1480.1999; Satchell KJF, 2003, MICROBES INFECT, V5, P1241, DOI 10.1016/j.micinf.2003.08.007; Saul-McBeth J, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00161; Savidge TC, 2003, GASTROENTEROLOGY, V125, P413, DOI 10.1016/S0016-5085(03)00902-8; Sellge G, 2010, J IMMUNOL, V184, P2076, DOI 10.4049/jimmunol.0900978; Shah HB, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138137; Simmons CP, 2003, INFECT IMMUN, V71, P5077, DOI 10.1128/IAI.71.9.5077-5086.2003; Simmons CP, 2002, J IMMUNOL, V168, P1804, DOI 10.4049/jimmunol.168.4.1804; Simon JK, 2011, CLIN IMMUNOL, V139, P185, DOI 10.1016/j.clim.2011.02.003; Simon JK, 2009, VACCINE, V27, P565, DOI 10.1016/j.vaccine.2008.10.081; Solomon K, 2013, THER ADV INFECT DIS, V1, P19, DOI 10.1177/2049936112472173; Spahn TW, 2008, SCAND J IMMUNOL, V67, P238, DOI 10.1111/j.1365-3083.2007.02063.x; Sperandio B, 2008, J EXP MED, V205, P1121, DOI 10.1084/jem.20071698; Srinivasan A, 2007, J IMMUNOL, V178, P6342, DOI 10.4049/jimmunol.178.10.6342; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; TESH VL, 1991, J INFECT DIS, V164, P344, DOI 10.1093/infdis/164.2.344; Tobar JA, 2006, INFECT IMMUN, V74, P6438, DOI 10.1128/IAI.00063-06; Tsolis RM, 1999, INFECT IMMUN, V67, P4879, DOI 10.1128/IAI.67.9.4879-4885.1999; Vallance BA, 2003, INFECT IMMUN, V71, P3443, DOI 10.1128/IAI.71.6.3443-3453.2003; Vallance BA, 2002, INFECT IMMUN, V70, P2070, DOI 10.1128/IAI.70.4.2070-2081.2002; Van Nhieu GT, 2005, CURR OPIN MICROBIOL, V8, P16, DOI 10.1016/j.mib.2004.12.006; Van Nhieu GT, 1999, EMBO J, V18, P3249, DOI 10.1093/emboj/18.12.3249; Vanaja S. K., 2013, ENTEROHEMORRHAGIC OT; Wahid R, 2013, CLIN IMMUNOL, V148, P35, DOI 10.1016/j.clim.2013.03.009; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; WARNY M, 1994, INFECT IMMUN, V62, P384, DOI 10.1128/IAI.62.2.384-389.1994; WASSEF JS, 1989, INFECT IMMUN, V57, P858, DOI 10.1128/IAI.57.3.858-863.1989; Way SS, 1998, INFECT IMMUN, V66, P1342, DOI 10.1128/IAI.66.4.1342-1348.1998; Wiles S, 2004, CELL MICROBIOL, V6, P963, DOI 10.1111/j.1462-5822.2004.00414.x; Wiles S, 2006, INFECT IMMUN, V74, P5391, DOI 10.1128/IAI.00848-06; WILSON KH, 1985, J INFECT DIS, V151, P355, DOI 10.1093/infdis/151.2.355; Worley MJ, 2006, P NATL ACAD SCI USA, V103, P17915, DOI 10.1073/pnas.0604054103; Yang WJ, 2019, J IMMUNOL, V203, P282, DOI 10.4049/jimmunol.1801068; Yoshida M, 2006, J CLIN INVEST, V116, P2142, DOI 10.1172/JCI27821; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720; Zimmermann K, 2012, GUT MICROBES, V3, P42, DOI 10.4161/gmic.19344; Zychlinsky A, 1996, INFECT IMMUN, V64, P5357, DOI 10.1128/IAI.64.12.5357-5365.1996; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	197	2	2	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 16	2020	11								565648	10.3389/fimmu.2020.565648	http://dx.doi.org/10.3389/fimmu.2020.565648			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY3CT	33042146	gold, Green Published			2022-12-18	WOS:000576272800001
J	Iwamoto, Y; Anno, T; Koyama, K; Shirai, R; Kaneto, H; Tomoda, K				Iwamoto, Yuichiro; Anno, Takatoshi; Koyama, Katsumasa; Shirai, Ryo; Kaneto, Hideaki; Tomoda, Koichi			Rapidly Exacerbating Autoimmune Hemolytic Anemia Together With Marked Cytokine Storm Triggered by Pneumonia Infection: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						pneumonia; autoimmune hemolytic anemia; hypercytokinemia; cytokine storm; Th2-dominant conditions	INTERLEUKIN-18; PATHOGENESIS; TH1	Background:Autoimmune hemolytic anemia (AIHA) is caused by hemolysis induced by the reaction of autoantibodies with red blood cells. AIHA is usually classified as either warm antibody or cold antibody-mediated AIHA. In addition, AIHA caused by infection is classified as secondary AIHA. It is well-known that alteration of various cytokine levels is closely associated with a variety of disorders such as infectious diseases. In addition, it is known that IL-10/ IL-12 imbalance is an indicator of Th2-dominat conditions and a progressive marker of AIHA. Case presentation:A 82-year-old Japanese man was brought to the emergency room with pneumonia and heart failure. After admission, we started antibiotics therapy. Next day, he had symptoms of jaundice and his total bilirubin level was elevated. Five days after admission, his inflammation markers were further elevated and he had hemolytic anemia. We finally diagnosed him as severe warm-type AIHA associated with pneumoniae infection. Seven days after admission, his severe leucocytosis was further aggravated, and then he suddenly had cardiac arrest and respiratory failure, and finally died of multiple organ failure. Unfortunately, we failed to rescue him from severe AIHA induced by pneumonia infection. Conclusions:Herein, we report a subject with pneumonia-triggered warm-type AIHA together with marked cytokine storm. IL-18 levels were markedly elevated without elevation of IL-12 levels. In addition, IL-10/IL-12 imbalance was observed. These data suggest that once marked cytokine storm is induced, infection-induced AIHA is exacerbated very rapidly.	[Iwamoto, Yuichiro; Anno, Takatoshi; Koyama, Katsumasa; Shirai, Ryo; Tomoda, Koichi] Kawasaki Med Sch, Dept Gen Internal Med 1, Okayama, Japan; [Kaneto, Hideaki] Kawasaki Med Sch, Dept Diabet Endocrinol & Metab, Kurashiki, Okayama, Japan	Kawasaki Medical School; Kawasaki Medical School	Anno, T (corresponding author), Kawasaki Med Sch, Dept Gen Internal Med 1, Okayama, Japan.	anno-t@umin.ac.jp	ANNO, TAKATOSHI/M-9425-2018	ANNO, TAKATOSHI/0000-0002-7862-3385				Ahmad E, 2011, J INVEST ALLERG CLIN, V21, P297; Fagiolo E, 2002, AUTOIMMUNITY, V35, P39, DOI 10.1080/08916930290005891; Jager U, 2020, BLOOD REV, V41, DOI 10.1016/j.blre.2019.100648; Khan FY, 2009, BRAZ J INFECT DIS, V13, P77, DOI 10.1590/S1413-86702009000100018; Michel M, 2011, EXPERT REV HEMATOL, V4, P607, DOI 10.1586/EHM.11.60; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Narita M, 2001, CLIN DIAGN LAB IMMUN, V8, P1028, DOI 10.1128/CDLI.8.5.1028-1030.2001; Parker V, 2017, ARCH PATHOL LAB MED, V141, P305, DOI 10.5858/arpa.2015-0444-RS; Singh A, 2017, J CLIN DIAGN RES, V11, pSR1, DOI 10.7860/JCDR/2017/27895.10646; Tanaka H, 2002, CHEST, V121, P1493, DOI 10.1378/chest.121.5.1493	10	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2020	11								574540	10.3389/fimmu.2020.574540	http://dx.doi.org/10.3389/fimmu.2020.574540			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NY1WL	33042156	gold, Green Published			2022-12-18	WOS:000576188400001
J	Adel-Patient, K; Guinot, M; Guillon, B; Bernard, H; Chikhi, A; Hazebrouck, S; Junot, C				Adel-Patient, Karine; Guinot, Marine; Guillon, Blanche; Bernard, Herve; Chikhi, Amina; Hazebrouck, Stephane; Junot, Christophe			Administration of Extensive Hydrolysates From Caseins andLactobacillus rhamnosusGG Probiotic Does Not Prevent Cow's Milk Proteins Allergy in a Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						food allergy; prevention; hydrolyzed formulas; probiotic; cow's milk; mouse model	REGULATORY T-CELLS; ORAL TOLERANCE; BETA-LACTOGLOBULIN; CHOLERA-TOXIN; BALB/C MICE; FORMULA; CHILDREN; IGE; SENSITIZATION; BINDING	Background Early nutrition may influence the development of food allergies later in life. In the absence of breastfeeding, hydrolysates from cow's milk proteins (CMP) were indicated as a prevention strategy in at risk infants, but their proof of effectiveness in clinical and pre-clinical studies is still insufficient. Thanks to a validated mouse model, we then assessed specific and nonspecific preventive effects of administration of extensive hydrolysates from caseins (eHC) on the development of food allergy to CMP. The additional nonspecific effect of the probioticLactobacillus GG(LGG), commonly used in infant formula, was also assessed. Methods Groups of young BALB/cByJ female mice were pretreated by repeated gavage either with PBS (control mice), or with PBS solution containing non-hydrolyzed milk protein isolate (MPI), eHC or eHC+LGG (eq. of 10 mg of protein/gavage). All mice were then experimentally sensitized to CMP by gavage with whole CM mixed with the Th2 mucosal adjuvantCholera toxin. All mice were further chronically exposed to cow's milk. A group of mice was kept naive. Sensitization to both caseins and to the non-related whey protein beta-lactoglobulin (BLG) was evaluated by measuring specific antibodies in plasma and specificex vivoTh2/Th1/Th17 cytokine secretion. Elicitation of the allergic reaction was assessed by measuring mMCP1 in plasma obtained after oral food challenge (OFC) with CMP. Th/Treg cell frequencies in gut-associated lymphoid tissue and spleen were analyzed by flow cytometry at the end of the protocol. Robust statistical procedure combining non-supervised and supervised multivariate analyses and univariate analyses, was conducted to reveal any effect of the pretreatments. Results PBS pretreated mice were efficiently sensitized and demonstrated elicitation of allergic reaction after OFC, whereas mice pretreated with MPI were durably protected from allergy to CMP. eHC+/-LGG pretreatments had no protective effect on sensitization to casein (specific) or BLG (non-specific), nor on CMP-induced allergic reactions. Surprisingly, eHC+LGG mice demonstrated significantly enhanced humoral and cellular immune responses after sensitization with CMP. Only some subtle changes were evidenced by flow cytometry. Conclusion Neither specific nor nonspecific preventive effects of administration of casein-derived peptides on the development of CMP food allergy were evidenced in our experimental setup. Further studies should be conducted to delineate the mechanisms involved in the immunostimulatory potential of LGG and to clarify its significance in clinical use.	[Adel-Patient, Karine; Guinot, Marine; Guillon, Blanche; Bernard, Herve; Chikhi, Amina; Hazebrouck, Stephane; Junot, Christophe] Univ Paris Saclay, Serv Pharmacol & Immunoanal, Dept Medicaments & Technol Sante DMTS, CEA,INRAE, Gif Sur Yvette, France; [Chikhi, Amina] Univ Oran 1 Ahmed Ben Bella, Lab Physiol Nutr & Securite Alimentaire, Oran, Algeria	CEA; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Adel-Patient, K (corresponding author), Univ Paris Saclay, Serv Pharmacol & Immunoanal, Dept Medicaments & Technol Sante DMTS, CEA,INRAE, Gif Sur Yvette, France.	karine.adel-patient@cea.fr		LESAGE-GUINOT, Marine/0000-0002-8338-1181; HAZEBROUCK, Stephane/0000-0003-4828-7031	INRAE (Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement); Mead Johnson Nutrition	INRAE (Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement); Mead Johnson Nutrition	This study obtained financial support from INRAE (Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement) and from Mead Johnson Nutrition through a collaborative research contract that did not have any influence on study protocol, data collection, and result analysis.	Abbring S, 2019, CLIN EXP ALLERGY, V49, P1013, DOI 10.1111/cea.13399; Adel-Patient K, 2005, ALLERGY, V60, P658, DOI 10.1111/j.1398-9995.2005.00767.x; Adel-Patient K, 2011, ALLERGY, V66, P1312, DOI 10.1111/j.1398-9995.2011.02653.x; Adel-Patient K, 2000, J IMMUNOL METHODS, V235, P21, DOI 10.1016/S0022-1759(99)00210-0; Adel-Patient K, 2012, J AGR FOOD CHEM, V60, P10858, DOI 10.1021/jf3031293; Aitoro R, 2017, PEDIAT ALLERG IMM-UK, V28, P230, DOI 10.1111/pai.12687; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; Blanc F, 2008, MOL NUTR FOOD RES, V52, pS166, DOI 10.1002/mnfr.200700283; Brody EP, 2000, BRIT J NUTR, V84, pS39, DOI 10.1017/S0007114500002233; Canani RB, 2017, J ALLERGY CLIN IMMUN, V139, P1906, DOI 10.1016/j.jaci.2016.10.050; Canani RB, 2013, J PEDIATR-US, V163, P771, DOI 10.1016/j.jpeds.2013.03.008; Canani RB, 2012, J ALLERGY CLIN IMMUN, V129, P580, DOI 10.1016/j.jaci.2011.10.004; Chikhi A, 2019, PEDIAT ALLERG IMM-UK, V30, P370, DOI 10.1111/pai.13017; Cortes-Perez NG, 2017, BENEF MICROBES, V8, P433, DOI 10.3920/BM2016.0174; Cosenza L, 2015, BENEF MICROBES, V6, P225, DOI 10.3920/BM2014.0158; Dadar M, 2019, INFLAMM RES, V68, P125, DOI 10.1007/s00011-018-1208-x; Davisse-Paturet C, 2019, PEDIAT ALLERG IMM-UK, V30, P614, DOI 10.1111/pai.13094; Flom JD, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051051; KAWASAKI Y, 1992, BIOSCI BIOTECH BIOCH, V56, P195, DOI 10.1271/bbb.56.195; Kostadinova AI, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01303; Lambers TT, 2015, FOOD SCI NUTR, V3, P81, DOI 10.1002/fsn3.196; Lowe AJ, 2011, J ALLERGY CLIN IMMUN, V128, P360, DOI 10.1016/j.jaci.2010.05.006; Matsubara T, 2018, PEDIAT ALLERG IMM-UK, V29, P433, DOI 10.1111/pai.12887; Mohanty DP, 2016, SAUDI J BIOL SCI, V23, P577, DOI 10.1016/j.sjbs.2015.06.005; Mosconi E, 2010, MUCOSAL IMMUNOL, V3, P461, DOI 10.1038/mi.2010.23; Negroni L, 1998, J IMMUNOL METHODS, V220, P25, DOI 10.1016/S0022-1759(98)00150-1; Nielsen SD, 2019, FOODS, V8, DOI 10.3390/foods8030091; Oh S, 2000, BIOSCI BIOTECH BIOCH, V64, P516, DOI 10.1271/bbb.64.516; Osborn DA, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003664.pub6; Phelan M, 2009, INT DAIRY J, V19, P643, DOI 10.1016/j.idairyj.2009.06.001; Rekima A, 2017, CLIN EXP ALLERGY, V47, P565, DOI 10.1111/cea.12864; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Smit JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028917; Tordesillas L, 2017, J ALLERGY CLIN IMMUN, V139, P189, DOI 10.1016/j.jaci.2016.03.057; van Esch BCAM, 2011, PEDIAT ALLERG IMM-UK, V22, P820, DOI 10.1111/j.1399-3038.2011.01205.x; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; von Berg A, 2017, Allergol Select, V1, P28, DOI 10.5414/ALX01462E; von Berg A, 2013, J ALLERGY CLIN IMMUN, V131, P1565, DOI 10.1016/j.jaci.2013.01.006	38	2	2	4	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								1700	10.3389/fimmu.2020.01700	http://dx.doi.org/10.3389/fimmu.2020.01700			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX7ZH	33042105	gold, Green Published			2022-12-18	WOS:000575923800001
J	Florez-Alvarez, L; Blanquiceth, Y; Ramirez, K; Ossa-Giraldo, AC; Velilla, PA; Hernandez, JC; Zapata, W				Florez-Alvarez, Lizdany; Blanquiceth, Yurany; Ramirez, Katherin; Ossa-Giraldo, Ana Claudia; Velilla, Paula A.; Hernandez, Juan C.; Zapata, Wildeman			NK Cell Activity and CD57(+)/NKG2C(high)Phenotype Are Increased in Men Who Have Sex With Men at High Risk for HIV	FRONTIERS IN IMMUNOLOGY			English	Article						CD57(+); NKG2C(high)NK cell; HIV; natural resistance; men who have sex with men; Highly exposed seronegative; cytotoxicity	NATURAL-KILLER-CELLS; HUMAN CYTOMEGALOVIRUS-INFECTION; IFN-GAMMA PRODUCTION; INTERFERON-GAMMA; CUTTING EDGE; ACTIVATION; RESISTANCE; PROTECTION; DIFFERENTIATION; CYTOTOXICITY	Introduction The HIV-exposed seronegative (HESN) status is for individuals who remain seronegative despite repeated exposure to HIV. One of the main cohorts within this group is men who have sex with men (MSM). Studies of this cohort have revealed different immunological and genetic mechanisms that can explain the phenomenon of natural HIV resistance. NK cells' higher effector capacity is related to natural resistance to HIV. Besides, a new population of NK cells with adaptive features was described recently. These cells are increased in some HESN cohorts and appear to be involved in better control of viral replication in primarily HIV-infected subjects. The present study evaluated the role of NK cells in the natural resistance to HIV-1 infection in MSM. Methodology Phenotypic and functional features were evaluated in NK cells from two groups of MSM, at different risks of HIV infection, according to the number of sexual partners. The production of IFN-gamma and beta-chemokines was included in the analysis, as well as the cytotoxic capacity and adaptive NK cell frequency. Genetic features, such as HLA and KIR allele frequencies, were also explored. Results High-risk MSM exhibit an increased frequency of fully mature and CD57(+)/NKG2C(high)NK cells. These individuals also show higher cytotoxic capacity and IFN-gamma production in response to K562 stimuli. NK cells with a CD107a(+)/IFN-gamma(+)functional profile were found more frequently and displayed higher IFN-gamma production capacity among high-risk MSM than among low-risk MSM. The protective alleleHLA-B*18was only present in the high-risk MSM group as well asHLA-B*39. The protective phenotypeKIR3DL1/S1-HLA-B*Bw4, in a homozygous state, was particularly abundant in the high-risk population. Notably, some of these functional features were related to higher frequencies of mature and CD57(+)/NKG2C(high)NK cells, which, in turn, were associated with a higher number of sexual partners. Conclusion The changes observed in the NK cell compartment can be driven by the magnitude of sexual exposure and immunological challenges of high-risk individuals, which could influence their resistance/susceptibility to HIV infection.	[Florez-Alvarez, Lizdany; Blanquiceth, Yurany; Ramirez, Katherin; Velilla, Paula A.; Zapata, Wildeman] Univ Antioquia, Fac Med, Grp Inmunovirol, Medellin, Colombia; [Florez-Alvarez, Lizdany; Ossa-Giraldo, Ana Claudia; Hernandez, Juan C.; Zapata, Wildeman] Univ Cooperat Colombia, Fac Med, Grp Infettare, Medellin, Colombia	Universidad de Antioquia; Universidad Cooperativa de Colombia	Zapata, W (corresponding author), Univ Antioquia, Fac Med, Grp Inmunovirol, Medellin, Colombia.; Zapata, W (corresponding author), Univ Cooperat Colombia, Fac Med, Grp Infettare, Medellin, Colombia.	wildeman.zapatab@campusucc.edu.co	Hernandez, Juan C./C-1621-2018; Zapata, Wildeman/ABE-5082-2020	Hernandez, Juan C./0000-0002-9200-5698; Zapata, Wildeman/0000-0002-7351-8738; Florez Alvarez, Lizdany/0000-0001-5443-8647; Ossa-Giraldo, Ana/0000-0003-4660-9359	Universidad de Antioquia; COLCIENCIAS [111577757209]; Universidad Cooperativa de Colombia [INV2193]	Universidad de Antioquia; COLCIENCIAS(Departamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias); Universidad Cooperativa de Colombia	This work was supported by the Universidad de Antioquia, COLCIENCIAS (code 111577757209) and Universidad Cooperativa de Colombia (code INV2193).	Alter G, 2009, J VIROL, V83, P6798, DOI 10.1128/JVI.00256-09; Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762; Beziat V, 2012, EUR J IMMUNOL, V42, P447, DOI 10.1002/eji.201141826; Bjorkstrom NK, 2011, J EXP MED, V208, P13, DOI 10.1084/jem.20100762; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Boudreau JE, 2016, J IMMUNOL, V196, P3398, DOI 10.4049/jimmunol.1502469; Boulet S, 2010, J IMMUNOL, V184, P2057, DOI 10.4049/jimmunol.0902621; Bryceson YT, 2009, BLOOD, V114, P2657, DOI 10.1182/blood-2009-01-201632; BUKOWSKI JF, 1983, J IMMUNOL, V131, P991; CDC, 2013, HIV SURVEILLANCE S, V13; Chaix J, 2008, J IMMUNOL, V181, P1627, DOI 10.4049/jimmunol.181.3.1627; Chaudhari DV, 2013, IMMUNOL LETT, V156, P1, DOI 10.1016/j.imlet.2013.09.002; Chung AW, 2011, JAIDS-J ACQ IMM DEF, V58, P127, DOI 10.1097/QAI.0b013e31822c62b9; de Silva E, 2004, FEMS MICROBIOL LETT, V241, P1, DOI 10.1016/j.femsle.2004.09.040; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Drews E, 2018, CLIN TRANSL IMMUNOL, V7, DOI 10.1002/cti2.1039; Farquhar C, 2004, AIDS RES HUM RETROV, V20, P692, DOI 10.1089/0889222041524616; Fehniger TA, 2007, IMMUNITY, V26, P798, DOI 10.1016/j.immuni.2007.04.010; Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198; Florez-Alvarez L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02290; Foley B, 2012, BLOOD, V119, P2665, DOI 10.1182/blood-2011-10-386995; Gondois-Rey F, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.22; Goodier MR, 2014, BLOOD, V124, P2213, DOI 10.1182/blood-2014-05-576124; Guma M, 2006, J INFECT DIS, V194, P38, DOI 10.1086/504719; Gupta A, 2012, BMC INFECT DIS S1, V12, pO16, DOI DOI 10.1186/1471-2334-12-S1-O16; de Sorrentino AH, 2013, IMMUNOLOGY, V140, P273, DOI 10.1111/imm.12137; Tieu HV, 2014, SEX TRANSM DIS, V41, P200, DOI 10.1097/OLQ.0000000000000090; Horton RE, 2010, J INFECT DIS, V202, pS377, DOI 10.1086/655971; Jiang YJ, 2013, J CLIN IMMUNOL, V33, P1376, DOI 10.1007/s10875-013-9930-1; Jiang YJ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-405; Le Garff-Tavernier M, 2010, AGING CELL, V9, P527, DOI 10.1111/j.1474-9726.2010.00584.x; Lima JF, 2014, JAIDS-J ACQ IMM DEF, V67, P463, DOI 10.1097/QAI.0000000000000350; Liu LL, 2016, CELL REP, V15, P1088, DOI 10.1016/j.celrep.2016.04.005; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Liu SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035020; Lohman-Payne B, 2012, AIDS, V26, P2007, DOI 10.1097/QAD.0b013e328359b7e0; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006; Luetke-Eversloh M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004441; Marmor M, 2001, J ACQ IMMUN DEF SYND, V27, P472, DOI 10.1097/00126334-200108150-00009; Martini F, 2005, INT J IMMUNOPATH PH, V18, P269, DOI 10.1177/039463200501800209; Min-Oo G, 2014, J EXP MED, V211, P2669, DOI 10.1084/jem.20141172; Montoya CJ, 2006, CLIN IMMUNOL, V120, P138, DOI 10.1016/j.clim.2006.02.008; Nielsen CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00422; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Payne R, 2014, P NATL ACAD SCI USA, V111, pE5393, DOI 10.1073/pnas.1413339111; Petitdemange C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002268; Pines HA, 2017, AIDS BEHAV, V21, P3026, DOI 10.1007/s10461-017-1855-x; Quillay H, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0271-z; Raulet DH, 2006, SEMIN IMMUNOL, V18, P145, DOI 10.1016/j.smim.2006.03.003; Reeves RK, 2015, NAT IMMUNOL, V16, P927, DOI 10.1038/ni.3227; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Scott-Algara D, 2003, J IMMUNOL, V171, P5663, DOI 10.4049/jimmunol.171.11.5663; Song RJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003867; Tomescu C, 2015, JAIDS-J ACQ IMM DEF, V68, P264, DOI 10.1097/QAI.0000000000000470; Trecarichi Enrico M, 2006, AIDS Res Ther, V3, P22, DOI 10.1186/1742-6405-3-22; Valenzuela-Ponce H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23849-7; Vega JA, 2017, BIOMEDICA, V37, P267, DOI 10.7705/biomedica.v37i3.3237	59	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								537044	10.3389/fimmu.2020.537044	http://dx.doi.org/10.3389/fimmu.2020.537044			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX9II	33042136	Green Published, gold			2022-12-18	WOS:000576015000001
J	Lafuente, EM; Niedergang, F; Rosales, C				Lafuente, Esther M.; Niedergang, Florence; Rosales, Carlos			Editorial: Phagocytosis: Molecular Mechanisms and Physiological Implications	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						phagocytosis; phagosome; CR3; necrotic debris; efferocytosis; macrophages; microglia; opsonins			[Lafuente, Esther M.] Univ Complutense Madrid, Sch Med, Dept Immunol Ophthalmol & Otorhinolaryngol, Madrid, Spain; [Niedergang, Florence] Univ Paris, CNRS, Inst Natl Rech Med, UMR8104,U1016, Paris, France; [Rosales, Carlos] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico	Complutense University of Madrid; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidad Nacional Autonoma de Mexico	Lafuente, EM (corresponding author), Univ Complutense Madrid, Sch Med, Dept Immunol Ophthalmol & Otorhinolaryngol, Madrid, Spain.; Niedergang, F (corresponding author), Univ Paris, CNRS, Inst Natl Rech Med, UMR8104,U1016, Paris, France.; Rosales, C (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico.	melafuente@med.ucm.es; florence.niedergang@inserm.fr; carosal@biomedicas.unam.mx	ROSALES, CARLOS/AAA-5206-2019; LAFUENTE, ESTHER M/AAA-3149-2019; Lafuente, Esther M/K-5684-2014	ROSALES, CARLOS/0000-0003-2568-5723; Lafuente, Esther M/0000-0001-8466-1022					0	2	2	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								586918	10.3389/fimmu.2020.586918	http://dx.doi.org/10.3389/fimmu.2020.586918			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX9IV	33072133	Green Published, gold			2022-12-18	WOS:000576016300001
J	Li, HY; Fu, QH; Wang, S; Chen, RJ; Jiang, XW; Zhu, P; He, JG; Li, CZ				Li, Haoyang; Fu, Qihui; Wang, Sheng; Chen, Rongjian; Jiang, Xiewu; Zhu, Peng; He, Jianguo; Li, Chaozheng			TNF-Receptor-Associated Factor 3 in Litopenaeus vannamei Restricts White Spot Syndrome Virus Infection Through the IRF-Vago Antiviral Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						Litopenaeus vannamei; TRAF3; NF-kappa B; IRF; WSSV	C-TYPE LECTIN; MOLECULAR CHARACTERIZATION; FUNCTIONAL-ANALYSIS; SIGNALING PATHWAY; INNATE; TRAF6; IMMUNITY	Tumor necrosis factor receptor (TNFR)-associated factors (TRAFs) are vital signaling adaptor proteins for the innate immune response and are involved in many important pathways, such as the NF-kappa B- and interferon regulatory factor (IRF)-activated signaling pathways. In this study, the TRAF3 ortholog from the shrimpLitopenaeus vannamei(LvTRAF3) was cloned and characterized. LvTRAF3 has a transcript of 3,865 bp, with an open reading frame (ORF) of 1,002 bp and encodes a polypeptide of 333 amino acids, including a conserved TRAF-C domain. The expression of LvTRAF3 in the intestine and hemocyte was up-regulated in response to poly (I:C) challenge and white spot syndrome virus (WSSV) infection. RNAi knockdown of LvTRAF3in vivosignificantly increased WSSV gene transcription, viral loads, and mortality in WSSV-infected shrimp. Next, we found that LvTRAF3 was not able to induce the activation of the NF-kappa B pathway, which was crucial for synthesis of antimicrobial peptides (AMPs), which mediate antiviral immunity. Specifically, in dual-luciferase reporter assays, LvTRAF3 could not activate several types of promoters with NF-kappa B binding sites, including those from WSSV genes (wsv069,wsv056, andwsv403),DrosophilaAMPs or shrimp AMPs. Accordingly, the mRNA levels of shrimp AMPs did not significantly change when TRAF3 was knocked down during WSSV infection. Instead, we found that LvTRAF3 signaled through the IRF-Vago antiviral cascade. LvTRAF3 functioned upstream of LvIRF to regulate the expression ofLvVago4andLvVago5during WSSV infectionin vivo. Taken together, these data provide experimental evidence of the participation of LvTRAF3 in the host defense to WSSV through the activation of the IRF-Vago pathway but not the NF-kappa B pathway.	[Li, Haoyang; Fu, Qihui; Wang, Sheng; He, Jianguo; Li, Chaozheng] Sun Yat Sen Univ, Sch Marine Sci, State Key Lab Biocontrol, Southern Marine Sci & Engn Guangdong Lab Zhuhai, Guangzhou, Peoples R China; [Chen, Rongjian; Jiang, Xiewu] Guangdong Hisenor Grp Co Ltd, Guangzhou, Peoples R China; [Zhu, Peng] Beibu Gluf Univ, Guangxi Key Lab Beibu Gulf Marine Biodivers Conse, Qinzhou, Peoples R China	Southern Marine Science & Engineering Guangdong Laboratory; Sun Yat Sen University	He, JG; Li, CZ (corresponding author), Sun Yat Sen Univ, Sch Marine Sci, State Key Lab Biocontrol, Southern Marine Sci & Engn Guangdong Lab Zhuhai, Guangzhou, Peoples R China.	lichzh5@mail.sysu.edu.cn		li, haoyang/0000-0002-9243-2489	Key-Area Research and Development Program of Guangdong Province [2018B020204001]; National Key Research and Development Program of China [2018YFD0900600, 2018YFD0900500]; National Natural Science Foundation of China [31802326, 31930113]; Guangdong Natural Science Funds for Distinguished Young Scholars [2016A030306041]; Tip-top Scientific and Technical Innovative Youth Talents of Guangdong Special Support Program [2016TQ03N504]	Key-Area Research and Development Program of Guangdong Province; National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds for Distinguished Young Scholars; Tip-top Scientific and Technical Innovative Youth Talents of Guangdong Special Support Program	This research was supported by Key-Area Research and Development Program of Guangdong Province (2018B020204001); National Key Research and Development Program of China (2018YFD0900600 and 2018YFD0900500), National Natural Science Foundation of China (31802326 and 31930113); Guangdong Natural Science Funds for Distinguished Young Scholars (2016A030306041), and Tip-top Scientific and Technical Innovative Youth Talents of Guangdong Special Support Program (2016TQ03N504). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen XJ, 2014, PROTEIN CELL, V5, P369, DOI 10.1007/s13238-014-0026-3; Dhillon B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00104; Gottipati S, 2008, CELL SIGNAL, V20, P269, DOI 10.1016/j.cellsig.2007.08.009; Grech A, 2000, MOL IMMUNOL, V37, P721, DOI 10.1016/S0161-5890(00)00098-5; Hacker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998; Huang BY, 2016, FISH SHELLFISH IMMUN, V48, P12, DOI 10.1016/j.fsi.2015.11.027; Huang XD, 2010, VIROLOGY, V406, P176, DOI 10.1016/j.virol.2010.06.046; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lee KA, 2018, CELL HOST MICROBE, V23, P338, DOI 10.1016/j.chom.2018.01.011; Letunic I, 2015, NUCLEIC ACIDS RES, V43, pD257, DOI 10.1093/nar/gku949; Leu JH, 2009, CURR TOP MICROBIOL, V328, P197; Li CZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01785; Li CZ, 2019, FISH SHELLFISH IMMUN, V84, P558, DOI 10.1016/j.fsi.2018.10.043; Li CZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15078; Li CZ, 2014, DEV COMP IMMUNOL, V42, P174, DOI 10.1016/j.dci.2013.08.012; Li CZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047442; Li HY, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007109; Li HY, 2017, SCI REP-UK, V7, DOI 10.1038/srep45821; Li HY, 2015, FISH SHELLFISH IMMUN, V43, P257, DOI 10.1016/j.fsi.2014.12.024; Li M, 2014, DEV COMP IMMUNOL, V46, P231, DOI 10.1016/j.dci.2014.04.014; Li YW, 2014, DEV COMP IMMUNOL, V44, P217, DOI 10.1016/j.dci.2013.12.011; Liu SQ, 2013, ELIFE, V2, DOI 10.7554/eLife.00785; Muroi M, 2008, J LEUKOCYTE BIOL, V83, P702, DOI 10.1189/jlb.0907629; Nicholas K., 1997, GENEDOC TOOL EDITING; Paradkar PN, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002823; Preiss A, 2001, MECH DEVELOP, V100, P109, DOI 10.1016/S0925-4773(00)00506-2; Sasai M, 2010, MOL IMMUNOL, V47, P1283, DOI 10.1016/j.molimm.2009.12.002; Stockhammer OW, 2010, MOL IMMUNOL, V48, P179, DOI 10.1016/j.molimm.2010.08.011; Suzuki N, 2006, TRENDS IMMUNOL, V27, P566, DOI 10.1016/j.it.2006.10.003; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Tanji T, 2005, TRENDS IMMUNOL, V26, P193, DOI 10.1016/j.it.2005.02.006; Tassanakajon A, 2011, MAR BIOTECHNOL, V13, P639, DOI [10.1007/s10126-011-9381-8, 10.1007/s10126-010-9288-9]; Wajant H, 2003, ANALOGIES DROSOPHILA, P47, DOI [10.1007/978-3-642-18670-7_3, DOI 10.1007/978-3-642-18670-7_3]; Wang PH, 2015, DEV COMP IMMUNOL, V48, P291, DOI 10.1016/j.dci.2014.03.013; Wang PH, 2011, DEV COMP IMMUNOL, V35, P105, DOI 10.1016/j.dci.2010.08.013; Xie Ping, 2013, J Mol Signal, V8, P7, DOI 10.1186/1750-2187-8-7; Zhai YJ, 2015, DEV COMP IMMUNOL, V49, P1, DOI 10.1016/j.dci.2014.11.006; Zhang X, 2016, MOL CELL, V64, P803, DOI 10.1016/j.molcel.2016.10.002	38	2	2	4	23	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2020	11								2110	10.3389/fimmu.2020.02110	http://dx.doi.org/10.3389/fimmu.2020.02110			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NX7ZX	33042123	Green Published, gold			2022-12-18	WOS:000575925400001
J	Maluf, S; Salgado, JV; Cysne, DN; Camelo, DMF; Nascimento, JR; Maluf, BVT; Silva, LDM; Belfort, MRD; Silva, LA; Guerra, RNM; Salgado, N; Nascimento, FRF				Maluf, Selma; Salgado, Joao Victor; Cysne, Dalila Nunes; Camelo, Daniel Monte Freire; Nascimento, Johnny Ramos; Maluf, Bianca Vitoria T.; Silva, Luis Douglas Miranda; Belfort, Marta Regina de Castro; Silva, Lucilene Amorim; Guerra, Rosane Nassar Meireles; Salgado Filho, Natalino; Nascimento, Flavia Raquel F.			Increased Glycated Hemoglobin Levels in Patients WithHelicobacter pyloriInfection Are Associated With the Grading of Chronic Gastritis	FRONTIERS IN IMMUNOLOGY			English	Article						Helicobacter pylori; glycated hemoglobin; prediabetes; chronic gastritis; cytokines; inflammation	HELICOBACTER-PYLORI INFECTION; INSULIN-RESISTANCE; SYDNEY SYSTEM; PREVALENCE; METABOLISM; DIAGNOSIS; IMMUNE; GENE	Background Recent studies have found an association betweenHelicobacter pyloriinfection and prediabetes. WhetherH. pylori per seor host factors are involved in the disturbance of glycated hemoglobin needs further investigation. The aim of this study was to determine the association of glycated hemoglobin levels with endoscopic diagnosis and the inflammatory response inH. pyloriinfection. Methods A cross-sectional study was carried out in 88 dyspeptic non-diabetic adults who underwent esophagogastroduodenoscopy. The diagnosis ofH. pyloriinfection was performed through urease test and histopathological exam. Cases were initially distributed into two groups: control (withoutH. pyloriinfection,n= 22) and HP (patients withH. pyloriinfection,n= 66). HbA1c was measured to determine prediabetes status according to the American Diabetes Association criteria, and then the groups were subdivided into non-prediabetic (n= 14), prediabetic (n= 8), non-prediabetic HP (n= 26) and prediabetic HP (n= 40) groups. Gastric mucosa was histologically evaluated to determineH. pyloridensity and inflammatory activity according to Sydney System. To investigate the balance of anti-inflammatory and pro-inflammatory cytokines we measured interleukin 10 (anti-inflammatory) and Tumor Necrosis Factor-a (pro-inflammatory) in the plasma or in the gastric mucosa. Results Patients withH. pyloriinfection had higher mean HbA1c levels than those withoutH. pyloriinfection. However, increased HbA1c levels were not associated withH. pylori-related factors but with the bacterial density, the intensity of inflammation and the activity of the chronic gastritis. In addition,H. pyloriinfectionper sedid not alter IL-10 and TNF-alpha neither in the plasma nor in the gastric mucosa, but the bacterial density was negatively correlated with systemic and local IL-10 expression. Although no correlation was found between systemic cytokines and HbA1c levels, local anti-inflammatory cytokine was correlated with HbA1c levels. Conclusion Long-termH. pyloriinfection is associated with prediabetes. This association is not related to the presence ofH. pylori per sebut depends on the extent of bacterial colonization and the degree of both local inflammation and activity of the chronic gastritis.	[Maluf, Selma; Nascimento, Johnny Ramos; Silva, Luis Douglas Miranda; Belfort, Marta Regina de Castro] Univ Fed Maranhao, Hlth Sci Grad Program, Sao Luis, Maranhao, Brazil; [Maluf, Selma] Univ Fed Maranhao, Univ Hosp, Gastroenterol Serv, Sao Luis, Maranhao, Brazil; [Maluf, Selma; Cysne, Dalila Nunes; Camelo, Daniel Monte Freire; Nascimento, Johnny Ramos; Maluf, Bianca Vitoria T.; Silva, Lucilene Amorim; Guerra, Rosane Nassar Meireles; Nascimento, Flavia Raquel F.] Univ Fed Maranhao, Dept Pathol, Immunophysiol Lab, Sao Luis, Maranhao, Brazil; [Salgado, Joao Victor] Univ Fed Maranhao, Dept Physiol Sci, Sao Luis, Maranhao, Brazil; [Silva, Lucilene Amorim; Guerra, Rosane Nassar Meireles; Nascimento, Flavia Raquel F.] Univ Fed Maranhao, Dept Pathol, Sao Luis, Maranhao, Brazil; [Salgado Filho, Natalino] Univ Fed Maranhao, Dept Med 1, Sao Luis, Maranhao, Brazil	Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade Federal do Maranhao	Nascimento, FRF (corresponding author), Univ Fed Maranhao, Dept Pathol, Immunophysiol Lab, Sao Luis, Maranhao, Brazil.; Nascimento, FRF (corresponding author), Univ Fed Maranhao, Dept Pathol, Sao Luis, Maranhao, Brazil.	nascimentofrf@yahoo.com.br	Salgado, João Victor/C-1156-2013; Nassar Meireles Guerra, Rosane/F-7992-2014	Nassar Meireles Guerra, Rosane/0000-0002-9865-9262; Salgado, Joao Victor/0000-0003-4287-4251	FAPEMA (Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do MaranhAo); CNPq (Conselho Nacional de Desenvolvimento em Pesquisa); CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)	FAPEMA (Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do MaranhAo)(Fundacao de Amparo a Pesquisa e Desenvolvimento Cientifico do Maranhao (FAPEMA)); CNPq (Conselho Nacional de Desenvolvimento em Pesquisa)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	We thank the Brazilian funding agencies FAPEMA (Fundacao de Amparo a Pesquisa e ao Desenvolvimento Cientifico e Tecnologico do MaranhAo), CNPq (Conselho Nacional de Desenvolvimento em Pesquisa), and CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) for financial support and author fellowships. We thank to IECT Biotechnology (FAPEMA). We are also grateful to Dr. Gyl Eanes for technical assistance.	Abadi ATB, 2017, WORLD J GASTROENTERO, V23, P2870, DOI 10.3748/wjg.v23.i16.2870; Acharya Anirudh Balakrishna, 2015, J Indian Soc Periodontol, V19, P388, DOI 10.4103/0972-124X.150876; Acharya Anirudh Balakrishna, 2015, J Indian Soc Periodontol, V19, P188, DOI 10.4103/0972-124X.148644; Aroor AR, 2013, METABOLISM, V62, P1543, DOI 10.1016/j.metabol.2013.07.001; Arora P, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-95; Cefalu WT, 2019, DIABETES CARE, V42, pS13, DOI 10.2337/dc19-S002; Chen Y, 2012, J INFECT DIS, V205, P1195, DOI 10.1093/infdis/jis106; Dai YN, 2015, WORLD J GASTROENTERO, V21, P5407, DOI 10.3748/wjg.v21.i17.5407; VINAGRE Ruth Maria Dias Ferreira, 2018, Arq. Gastroenterol., V55, P122, DOI [10.1590/s0004-2803.201800000-21, 10.1590/S0004-2803.201800000-21]; Draz U, 2018, J PAK MED ASSOC, V68, P939; Franceschi F, 2014, NAT REV GASTRO HEPAT, V11, P234, DOI 10.1038/nrgastro.2013.243; Hamed Sherifa Ahmed, 2008, J Stroke Cerebrovasc Dis, V17, P86, DOI 10.1016/j.jstrokecerebrovasdis.2007.10.006; Han X, 2016, DIABETES-METAB RES, V32, P95, DOI 10.1002/dmrr.2677; He C, 2014, WORLD J GASTROENTERO, V20, P4607, DOI 10.3748/wjg.v20.i16.4607; Horikawa C, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/250620; Hosseininasab Nodoushan S, 2019, ADV BIOMED RES-INDIA, V8, DOI 10.4103/abr.abr_37_18; Hsieh MC, 2013, EUR J CLIN INVEST, V43, P949, DOI 10.1111/eci.12124; Htun NSN, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006332; Ibrahim A, 2010, SAUDI J KIDNEY DIS T, V21, P694; Jeon CY, 2012, DIABETES CARE, V35, P520, DOI 10.2337/dc11-1043; Ladeira Marcelo Sady Plácido, 2003, J. Bras. Patol. Med. Lab., V39, P335, DOI 10.1590/S1676-24442003000400011; Moon SW, 2012, CLIN ENDOSC, V45, P392, DOI 10.5946/ce.2012.45.4.392; Parente JML, 2006, AM J TROP MED HYG, V75, P509, DOI 10.4269/ajtmh.2006.75.509; Parihar V, 2015, UNITED EUR GASTROENT, V3, P432, DOI 10.1177/2050640615573374; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; Roca-Rodriguez MM, 2016, DIABETES METAB, V42, P130, DOI 10.1016/j.diabet.2015.11.003; Saxena M, 2013, MOL BIOL REP, V40, P6271, DOI 10.1007/s11033-013-2739-4; Saxena M, 2012, BIOCHEM GENET, V50, P549, DOI 10.1007/s10528-012-9499-z; So WY, 2009, DIABETES RES CLIN PR, V86, P89, DOI 10.1016/j.diabres.2009.08.010; Stolte M, 2001, CAN J GASTROENTEROL, V15, P591, DOI 10.1155/2001/367832; TYTGAT GNJ, 1991, J GASTROEN HEPATOL, V6, P223, DOI 10.1111/j.1440-1746.1991.tb01469.x; Vaz Coelho Luiz Gonzaga, 2018, Arquivos de Gastroenterologia, V55, P97, DOI 10.1590/S0004-2803.201800000-20; Wang C., 2010, INT J ENDOCRINOL, V2010, P10, DOI [10.1155/2010/515136, DOI 10.1155/2010/515136]; Wang Shao-zhen, 2009, Zhonghua Yi Xue Za Zhi, V89, P958; Wang YK, 2015, WORLD J GASTROENTERO, V21, P11221, DOI 10.3748/wjg.v21.i40.11221; Wang Z, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/7965317; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Weyer C, 2000, DIABETES, V49, P2094, DOI 10.2337/diabetes.49.12.2094; Yang GH, 2014, J GASTROEN HEPATOL, V29, P1794, DOI 10.1111/jgh.12617; Yang Z, 2015, WORLD J GASTROENTERO, V21, P12593, DOI 10.3748/wjg.v21.i44.12593; Yokota SI, 2015, HELICOBACTER, V20, P334, DOI 10.1111/hel.12217; Zamani M, 2018, ALIMENT PHARM THER, V47, P868, DOI 10.1111/apt.14561; Zaterka S, 2007, HELICOBACTER, V12, P82, DOI 10.1111/j.1523-5378.2007.00474.x; Zhou XY, 2015, J GASTROENTEROL, V50, P1027, DOI 10.1007/s00535-015-1051-6; Zojaji Homayon, 2013, Gastroenterol Hepatol Bed Bench, V6, P36	45	2	2	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2020	11								2121	10.3389/fimmu.2020.02121	http://dx.doi.org/10.3389/fimmu.2020.02121			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NW7AI	33013895	Green Published, gold			2022-12-18	WOS:000575168400001
J	Zeng, X; Tsui, JCC; Shi, M; Peng, J; Cao, CY; Kan, LLY; Lau, CPY; Liang, YH; Wang, LY; Liu, L; Chen, ZW; Tsui, SKW				Zeng, Xi; Tsui, Joseph Chi-Ching; Shi, Mai; Peng, Jie; Cao, Cyanne Ye; Kan, Lea Ling-Yu; Lau, Carol Po-Ying; Liang, Yonghao; Wang, Lingyi; Liu, Li; Chen, Zhiwei; Tsui, Stephen Kwok-Wing			Genome-Wide Characterization of Host Transcriptional and Epigenetic Alterations During HIV Infection of T Lymphocytes	FRONTIERS IN IMMUNOLOGY			English	Article						HIV infection; gene expression; DNA methylation; genome; apoptosis	DNA METHYLATION; GENE; EXPRESSION; INDUCTION; APOPTOSIS; PROTEINS; PROMOTER; CELLS	Background and methods:Host genomic alterations are closely related to dysfunction of CD4(+)T lymphocytes in the HIV-host interplay. However, the roles of aberrant DNA methylation and gene expression in the response to HIV infection are not fully understood. We investigated the genome-wide DNA methylation and transcriptomic profiles in two HIV-infected T lymphocyte cell lines using high-throughput sequencing. Results:Based on DNA methylation data, we identified 3,060 hypomethylated differentially methylated regions (DMRs) and 2,659 hypermethylated DMRs in HIV-infected cells. Transcription-factor-binding motifs were significantly associated with methylation alterations, suggesting that DNA methylation modulates gene expression by affecting the binding to transcription factors during HIV infection. In support of this hypothesis, genes with promoters overlapping with DMRs were enriched in the biological function related to transcription factor activities. Furthermore, the analysis of gene expression data identified 1,633 upregulated genes and 2,142 downregulated genes on average in HIV-infected cells. These differentially expressed genes (DEGs) were significantly enriched in apoptosis-related pathways. Our results suggest alternative splicing as an additional mechanism that may contribute to T-cell apoptosis during HIV infection. We also demonstrated a genome-scale correlation between DNA methylation and gene expression in HIV-infected cells. We identified 831 genes with alterations in both DNA methylation and gene expression, which were enriched in apoptosis. Our results were validated using various experimental methods. In addition, consistent with ourin silicoresults, a luciferase assay showed that the activity of thePDX1andSMAD3promoters was significantly decreased in the presence of HIV proteins, indicating the potential of these genes as genetic markers of HIV infection. Conclusions:Our results suggest important roles for DNA methylation and gene expression regulation in T-cell apoptosis during HIV infection. We propose a list of novel genes related to these processes for further investigation. This study also provides a comprehensive characterization of changes occurring at the transcriptional and epigenetic levels in T cells in response to HIV infection.	[Zeng, Xi] Huazhong Agr Univ, Hubei Engn Technol Res Ctr Agr Big Data, Agr Bioinformat Key Lab Hubei Prov, Coll Informat, Wuhan, Peoples R China; [Zeng, Xi; Shi, Mai; Cao, Cyanne Ye; Kan, Lea Ling-Yu; Lau, Carol Po-Ying; Liang, Yonghao; Wang, Lingyi; Tsui, Stephen Kwok-Wing] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Tsui, Joseph Chi-Ching] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China; [Peng, Jie; Liu, Li; Chen, Zhiwei] Univ Hong Kong, Acquired Immunodeficiency Syndrome AIDS Inst, Hong Kong, Peoples R China; [Tsui, Stephen Kwok-Wing] Chinese Univ Hong Kong, Hong Kong Bioinformat Ctr, Hong Kong, Peoples R China; [Tsui, Stephen Kwok-Wing] Chinese Univ Hong Kong, Ctr Microbial Genom & Prote, Hong Kong, Peoples R China	Huazhong Agricultural University; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Tsui, SKW (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.; Tsui, SKW (corresponding author), Chinese Univ Hong Kong, Hong Kong Bioinformat Ctr, Hong Kong, Peoples R China.; Tsui, SKW (corresponding author), Chinese Univ Hong Kong, Ctr Microbial Genom & Prote, Hong Kong, Peoples R China.	kwtsui@cuhk.edu.hk	Liu, Li/ABA-8315-2020; Shi, Mai/ABE-2296-2021; Tsui, Stephen Kwok-Wing/E-4385-2015	Liu, Li/0000-0003-2566-7357; Shi, Mai/0000-0002-2798-3268; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259	Huazhong Agricultural University [2662019QD019]; National Natural Science Foundation of China [31900479]; Health and Medical Research Fund of the Food and Health Bureau [14130302]; Research Grants Council of the Hong Kong Special Administrative Region [HKU5/CRF/13G]	Huazhong Agricultural University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Health and Medical Research Fund of the Food and Health Bureau; Research Grants Council of the Hong Kong Special Administrative Region(Hong Kong Research Grants Council)	This work was supported by the research grants from Huazhong Agricultural University (2662019QD019) and the National Natural Science Foundation of China (31900479), the research grant from the Health and Medical Research Fund of the Food and Health Bureau (Reference no.: 14130302), and the Collaborative Research Fund from the Research Grants Council (Reference no.: HKU5/CRF/13G) of the Hong Kong Special Administrative Region.	Abbas AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006098; Aissani B, 2014, GENES IMMUN, V15, P424, DOI 10.1038/gene.2014.42; Akari H, 2001, J EXP MED, V194, P1299, DOI 10.1084/jem.194.9.1299; Anders S, 2012, GENOME RES, V22, P2008, DOI 10.1101/gr.133744.111; Anderson Jenny L, 2004, Curr HIV/AIDS Rep, V1, P47, DOI 10.1007/s11904-004-0007-x; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; Barisoni L, 2000, KIDNEY INT, V58, P173, DOI 10.1046/j.1523-1755.2000.00152.x; Barnitz RA, 2010, J VIROL, V84, P6410, DOI 10.1128/JVI.02273-09; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chandel N, 2013, J LEUKOCYTE BIOL, V93, P623, DOI 10.1189/jlb.0812383; Corley MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep33310; Coyle-Rink J, 2002, VIROLOGY, V299, P240, DOI 10.1006/viro.2002.1439; Cummins NW, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.77; Cunliffe VT, 2016, METHOD CELL BIOL, V135, P361, DOI 10.1016/bs.mcb.2016.05.005; Dabrowska A, 2008, J IMMUNOL, V181, P8460, DOI 10.4049/jimmunol.181.12.8460; Dao LTM, 2017, NAT GENET, V49, P1073, DOI 10.1038/ng.3884; de la Rica L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r99; Doitsh G, 2017, NATURE, V544, P124, DOI 10.1038/nature22066; Dong J, 2013, EUR J IMMUNOL, V43, P793, DOI 10.1002/eji.201242858; Eldeen MB, 2006, J NEUROIMMUNOL, V176, P174, DOI 10.1016/j.jneuroim.2006.04.004; Hamidi T, 2015, EPIGENOMICS-UK, V7, P247, DOI [10.2217/epi.14.80, 10.2217/EPI.14.80]; Hervouet Eric, 2013, Cells, V2, P545, DOI 10.3390/cells2030545; Huan TX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12228-z; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang YL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005397; Jin YM, 2012, NAT MED, V18, P580, DOI 10.1038/nm.2685; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jorgensen BG, 2019, J NEUROGASTROENTEROL, V25, P377, DOI 10.5056/jnm19077; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lienhard M, 2014, BIOINFORMATICS, V30, P284, DOI 10.1093/bioinformatics/btt650; Liu S, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1202797; Long E, 2009, VIRCHOWS ARCH, V455, P159, DOI 10.1007/s00428-009-0791-1; Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1; Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110; Minarovits J, 2015, PATHO EPIGENETICS IN, P879, DOI [10.1007/978-3-319-24738-0, DOI 10.1007/978-3-319-24738-0]; Organization WH, 2018, SUMM GLOB HIV EP; Pan YB, 2018, CLIN EXP MED, V18, P1, DOI 10.1007/s10238-017-0467-0; Pasquereau S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040064; Pion M, 2013, AIDS, V27, P2019, DOI 10.1097/QAD.0b013e32836253fd; Schachter J, 2015, IMMUNOBIOLOGY, V220, P589, DOI 10.1016/j.imbio.2014.12.004; Scharer CD, 2013, J IMMUNOL, V191, P3419, DOI 10.4049/jimmunol.1301395; Selliah N, 2001, CELL DEATH DIFFER, V8, P127, DOI 10.1038/sj.cdd.4400822; Siangphoe U, 2015, JAIDS-J ACQ IMM DEF, V70, P479, DOI 10.1097/QAI.0000000000000800; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Theron AJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01461; Tokarev Andrey, 2011, Cell Logist, V1, P90; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Verhofstede C, 2012, CURR OPIN HIV AIDS, V7, P432, DOI 10.1097/COH.0b013e328356f6f2; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Wei JD, 2012, J ORTHOP RES, V30, P1058, DOI 10.1002/jor.22046; Xue J, 2017, FEBS J, V284, P97, DOI 10.1111/febs.13955; Yndart A, 2015, ACS CHEM NEUROSCI, V6, P1600, DOI 10.1021/acschemneuro.5b00156; Zhang XY, 2016, EPIGENETICS-US, V11, P750, DOI 10.1080/15592294.2016.1221569; Zhang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep10806; Zheng M, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14080921	57	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2020	11								2131	10.3389/fimmu.2020.02131	http://dx.doi.org/10.3389/fimmu.2020.02131			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV9BL	33013899	gold, Green Published			2022-12-18	WOS:000574607300001
J	Shi, Y; Ruan, HF				Shi, Yan; Ruan, Hefei			Toward a Membrane-Centric Biology	FRONTIERS IN IMMUNOLOGY			English	Article						plasma membrane; lipid rafts; evolution; receptor ligand model; lipid interaction; receptor activation mechanism	LIGAND-INDEPENDENT ACTIVATION; TGF-BETA RESPONSIVENESS; LIPID RAFTS; PLASMA-MEMBRANE; CHOLESTEROL DEPLETION; CELLULAR CHOLESTEROL; RECEPTOR; CELLS; MODEL; PROTEINS	With advancements of modern biophysical tools and superresolution imaging, cell biology is entering a new phase of research with technological power fitting for membrane dynamics analyses. However, our current knowledge base of cellular signaling events is mostly built on a network of protein interactions, which is incompatible with the essential roles of membrane activities in those events. The lack of a theoretical platform is rendering biophysical analyses of membrane biology supplementary to the protein-centric paradigm. We hypothesize a framework of signaling events mediated by lipid dynamics and argue that this is the evolutionarily obligatory developmental path of cellular complexity buildup. In this framework, receptors are the late comers, integrating into the pre-existing membrane based signaling events using their lipid interface as the point of entry. We further suggest that the reason for cell surface receptors to remain silent at the resting state is via the suppression effects of their surrounding lipids. The avoidance of such a suppression, via ligand binding or lipid domain disruption, enables the receptors to autonomously integrate themselves into the preexisting networks of signaling cascades.	[Shi, Yan; Ruan, Hefei] Tsinghua Univ, Tsinghua Peking Univ Joint Ctr Life Sci, Beijing, Peoples R China; [Shi, Yan; Ruan, Hefei] Tsinghua Univ, Dept Basic Med Sci, Beijing, Peoples R China; [Shi, Yan; Ruan, Hefei] Tsinghua Univ, Inst Immunol, Beijing, Peoples R China; [Shi, Yan; Ruan, Hefei] Tsinghua Univ, Sch Med, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China; [Shi, Yan] Univ Calgary, Snyder Inst, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada	Tsinghua University; Tsinghua University; Tsinghua University; Tsinghua University; University of Calgary	Shi, Y (corresponding author), Tsinghua Univ, Tsinghua Peking Univ Joint Ctr Life Sci, Beijing, Peoples R China.; Shi, Y (corresponding author), Tsinghua Univ, Dept Basic Med Sci, Beijing, Peoples R China.; Shi, Y (corresponding author), Tsinghua Univ, Inst Immunol, Beijing, Peoples R China.; Shi, Y (corresponding author), Tsinghua Univ, Sch Med, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China.; Shi, Y (corresponding author), Univ Calgary, Snyder Inst, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.	yanshiemail@mail.tsinghua.edu.cn	Ruan, Hefei/GRX-6919-2022		joint Peking-Tsinghua Center for Life Sciences; National Natural Science Foundation of China General Program [31370878]; State Key Program [31630023]; Innovative Research Group Program [81621002]; CIHR [PJT-156334, PJT-166155]; NSERC [RGPIN/03748-2018]; China Postdoctoral Science Foundation [2019M650718]	joint Peking-Tsinghua Center for Life Sciences; National Natural Science Foundation of China General Program(National Natural Science Foundation of China (NSFC)); State Key Program; Innovative Research Group Program; CIHR(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	YS was supported by the joint Peking-Tsinghua Center for Life Sciences, the National Natural Science Foundation of China General Program (31370878), State Key Program (31630023), and Innovative Research Group Program (81621002), by grants from CIHR (PJT-156334 and PJT-166155) and NSERC (RGPIN/03748-2018). HR was supported by China Postdoctoral Science Foundation (No. 2019M650718).	Baumgart T, 2007, P NATL ACAD SCI USA, V104, P3165, DOI 10.1073/pnas.0611357104; Blouin CM, 2016, CELL, V166, P920, DOI 10.1016/j.cell.2016.07.003; Chen CL, 2008, J CELL PHYSIOL, V215, P223, DOI 10.1002/jcp.21303; Chen CL, 2007, J CELL SCI, V120, P3509, DOI 10.1242/jcs.006916; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Contreras FX, 2012, NATURE, V481, P525, DOI 10.1038/nature10742; Crow KD, 2006, MOL BIOL EVOL, V23, P887, DOI 10.1093/molbev/msj083; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Fanjul-Fernandez M, 2010, BBA-MOL CELL RES, V1803, P3, DOI 10.1016/j.bbamcr.2009.07.004; Fessler MB, 2011, J IMMUNOL, V187, P1529, DOI 10.4049/jimmunol.1100253; Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gajate C, 2015, J LEUKOCYTE BIOL, V98, P739, DOI 10.1189/jlb.2MR0215-055R; Gu RX, 2019, J CHEM THEORY COMPUT, V15, P2064, DOI 10.1021/acs.jctc.8b00933; Harris SD, 2011, MOL MICROBIOL, V79, P1123, DOI 10.1111/j.1365-2958.2010.07525.x; Holstein TW, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007922; Honigmann A, 2014, ELIFE, V3, DOI 10.7554/eLife.01671; Irwin ME, 2011, J CELL PHYSIOL, V226, P2316, DOI 10.1002/jcp.22570; Jackson SK, 2008, J LEUKOCYTE BIOL, V84, P86, DOI 10.1189/jlb.0907601; Jury EC, 2007, SEMIN CELL DEV BIOL, V18, P608, DOI 10.1016/j.semcdb.2007.08.002; Lambert S, 2006, J INVEST DERMATOL, V126, P954, DOI 10.1038/sj.jid.5700168; Li M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026999; Liongue C, 2013, JAK STAT, V2, DOI DOI 10.4161/JKST.22756; Lozano MM, 2016, J AM CHEM SOC, V138, P9996, DOI 10.1021/jacs.6b05540; Machta BB, 2011, BIOPHYS J, V100, P1668, DOI 10.1016/j.bpj.2011.02.029; Mahammad S, 2010, BBA-MOL CELL BIOL L, V1801, P625, DOI 10.1016/j.bbalip.2010.02.003; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; Mu LB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06744-7; Murai T, 2011, J BIOL CHEM, V286, P1999, DOI 10.1074/jbc.M110.184010; Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013; Quistad SD, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.58; Razzaq TM, 2004, IMMUNOLOGY, V113, P413, DOI 10.1111/j.1365-2567.2004.01998.x; Ritchie K, 2003, MOL MEMBR BIOL, V20, P13, DOI 10.1080/0968768021000055698; Rouquette-Jazdanian AK, 2007, CELL SIGNAL, V19, P1404, DOI 10.1016/j.cellsig.2007.01.015; Scheidt HA, 2005, BIOPHYS J, V89, P2504, DOI 10.1529/biophysj.105.062018; Sezgin E, 2017, FEBS J, V284, P2513, DOI 10.1111/febs.14139; Shapira KE, 2018, MOL BIOL CELL, V29, P2494, DOI 10.1091/mbc.E18-03-0175; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Smoak KA, 2010, CELL METAB, V11, P493, DOI 10.1016/j.cmet.2010.04.006; Song DK, 2019, NAT MICROBIOL, V4, P97, DOI 10.1038/s41564-018-0290-8; Swamy M, 2016, IMMUNITY, V44, P1091, DOI 10.1016/j.immuni.2016.04.011; Thomas S, 2004, MOL IMMUNOL, V41, P399, DOI 10.1016/j.molimm.2004.03.022; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; von Tresckow B, 2004, J IMMUNOL, V172, P4324, DOI 10.4049/jimmunol.172.7.4324; Yutin N, 2009, BIOL DIRECT, V4; Zhang M, 2005, J IMMUNOL, V174, P1479, DOI 10.4049/jimmunol.174.3.1479	48	2	2	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2020	11								1909	10.3389/fimmu.2020.01909	http://dx.doi.org/10.3389/fimmu.2020.01909			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV3WR	33013841	gold, Green Published			2022-12-18	WOS:000574256800001
J	Zhang, YD; Li, XP; Zhou, KK; Zhou, MK; Xia, K; Xu, YL; Sun, XZ; Zhu, YJ; Cui, CY; Deng, CH				Zhang, Yadong; Li, Xiangping; Zhou, Kuikui; Zhou, Mingkuan; Xia, Kai; Xu, Yunlong; Sun, Xiangzhou; Zhu, Yingjie; Cui, Chunyan; Deng, Chunhua			Influence of Experimental Autoimmune Prostatitis on Sexual Function and the Anti-inflammatory Efficacy of Celecoxib in a Rat Model	FRONTIERS IN IMMUNOLOGY			English	Article						experimental autoimmune prostatitis; chronic prostatitis; chronic pelvic pain (CP; CPP) syndrome; sexual dysfunction; depression; celecoxib; serotonin	PELVIC PAIN SYNDROME; PROINFLAMMATORY CYTOKINES; PREMATURE EJACULATION; PSYCHOLOGICAL-FACTORS; SYNDROME CP/CPPS; MEN; EXPRESSION; SEROTONIN; BEHAVIOR; PEPTIDE	Experimental autoimmune prostatitis (EAP) is a well-established model induced by an autoimmune response to prostate antigen. The symptomatic, pathological, and immunological characteristics of EAP animals are highly consistent with human chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), which makes EAP an ideal model for this disease. Here, we investigate the influence of EAP on male rat sexual function and the efficacy of anti-inflammatory therapy with celecoxib. EAP rat models were established using male Wistar rats. Rats were randomly assigned to a normal control group, an EAP model group, or an EAP model with celecoxib treatment group (celecoxib group). Behavioral changes, sexual behavioral changes, and erectile function were estimated using an open-field test, a sucrose consumption test, mating experiments, and by intracavernous pressure/mean arterial pressure ratio (ICP/MAP). Histological changes in the prostate were observed by HE staining, and the serum inflammatory factors IL-1 beta and TNF-alpha levels were measured by enzyme-linked immunosorbent assay. In addition, serotonin (5-hydroxytryptamine, 5-HT), 5-HT(1A)receptor, 5-HT(2C)receptor, and serotonin transporter (SERT) expression levels in the hippocampus and spinal cord (T13-L1, L5-S2) were examined by immunohistochemistry and western blot analysis. Results showed that EAP rats exhibited characteristics of depression, decreased sexual drive, premature ejaculation, and increased threshold of penile erection. Moreover, all these changes were effectively alleviated by celecoxib. Significant increases in prostatic interstitial infiltration by inflammatory cells and in serum IL-1 beta and TNF-alpha levels were observed in EAP rats, and these were partially reduced by celecoxib. Additionally, the expression pattern of serotonin system regulators in the hippocampus and spinal cord were altered in EAP model rats, including a decrease in 5-HT levels and an increase in 5-HT(1A)receptor levels. In conclusion, autoimmune prostatitis impaired rat sexual function, and this was effectively prevented by anti-inflammatory therapy with celecoxib. Moreover, a serotonin system disorder in the central nervous system was likely mediated via inflammation in EAP rats.	[Zhang, Yadong; Li, Xiangping; Zhou, Mingkuan; Xia, Kai; Sun, Xiangzhou; Deng, Chunhua] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol & Androl, Guangzhou, Peoples R China; [Zhou, Kuikui; Xu, Yunlong; Zhu, Yingjie] Chinese Acad Sci, Shenzhen Hong Kong Inst Brain Sci, Shenzhen Fundamental Res Inst,Brain Cognit & Brai, Shenzhen Inst Adv Technol,Shenzhen Key Lab Drug A, Shenzhen, Peoples R China; [Cui, Chunyan] Sun Yat Sen Univ Canc Ctr SYSUCC, Imaging & Minimally Invas Intervent Ctr, Guangzhou, Peoples R China	Sun Yat Sen University; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Deng, CH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol & Androl, Guangzhou, Peoples R China.; Cui, CY (corresponding author), Sun Yat Sen Univ Canc Ctr SYSUCC, Imaging & Minimally Invas Intervent Ctr, Guangzhou, Peoples R China.	cuichy@sysucc.org.cn; dengchh@mail.sysu.edu.cn			National Natural Science Foundation of China [31900735]; Guangzhou Regenerative Medicine and Health Guangdong Laboratory Grant [2018GZR110105006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Regenerative Medicine and Health Guangdong Laboratory Grant	This work was supported by the National Natural Science Foundation of China (Grant No. 81671449). KZ was supported by Guangzhou Regenerative Medicine and Health Guangdong Laboratory Grant (Grant No. 2018GZR110105006) and the National Natural Science Foundation of China (Grant No. 31900735).	Alexander RB, 1998, UROLOGY, V52, P744, DOI 10.1016/S0090-4295(98)00390-2; Anisman H, 2008, PROG NEUROBIOL, V85, P1, DOI 10.1016/j.pneurobio.2008.01.004; Anothaisintawee T, 2011, JAMA-J AM MED ASSOC, V305, P78, DOI 10.1001/jama.2010.1913; Benedetti F, 2011, J AFFECT DISORDERS, V132, P297, DOI 10.1016/j.jad.2011.02.024; Breser Maria L, 2017, Front Immunol, V8, P898, DOI 10.3389/fimmu.2017.00898; Cellerino A, 2005, MED HYPOTHESES, V65, P179, DOI 10.1016/j.mehy.2004.10.020; Chen CS, 2013, PROSTATE, V73, P391, DOI 10.1002/pros.22580; Motrich RD, 2006, J INFECTION, V53, P175, DOI 10.1016/j.jinf.2005.11.007; de Jong TR, 2006, NEUROSCI BIOBEHAV R, V30, P893, DOI 10.1016/j.neubiorev.2006.01.001; DEPIANTEDEPAOLI M, 1985, AM J REPROD IM MIC, V7, P32; Donadio AC, 1997, CLIN IMMUNOL IMMUNOP, V85, P158, DOI 10.1006/clin.1997.4427; Du HX, 2019, NEUROPSYCH DIS TREAT, V15, P2231, DOI 10.2147/NDT.S211288; Hoxha M, 2016, PHARMACOL RES, V103, P132, DOI 10.1016/j.phrs.2015.11.012; Ihsan AU, 2017, BIOMED PHARMACOTHER, V91, P687, DOI 10.1016/j.biopha.2017.05.004; KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P247, DOI 10.1016/0149-7634(81)90005-1; KEETCH DW, 1994, J UROLOGY, V152, P247, DOI 10.1016/S0022-5347(17)32871-9; Keith IM, 2001, J UROLOGY, V166, P323, DOI 10.1016/S0022-5347(05)66153-8; Kouiavskaia DV, 2009, J UROLOGY, V182, P2483, DOI 10.1016/j.juro.2009.07.067; Ku JH, 2005, UROLOGY, V66, P693, DOI 10.1016/j.urology.2005.04.050; Lehrer S, 2019, DISCOV MED, V28, P205; Lewitus GM, 2009, BIOL PSYCHIAT, V65, P283, DOI 10.1016/j.biopsych.2008.07.014; Liang CZ, 2010, UROLOGY, V76, P962, DOI 10.1016/j.urology.2010.01.061; Lundh D, 2013, SCAND J UROL, V47, P521, DOI 10.3109/21681805.2013.769460; Magistro G, 2016, EUR UROL, V69, P286, DOI 10.1016/j.eururo.2015.08.061; Mehik A, 2001, BJU INT, V88, P35, DOI 10.1046/j.1464-410x.2001.02259.x; Melman A, 2005, UROLOGY, V66, P1127, DOI 10.1016/j.urology.2005.06.070; Mesripour Azadeh, 2019, J Complement Integr Med, V17, DOI 10.1515/jcim-2019-0016; Mirone V, 2014, EUR UROL, V65, P733, DOI 10.1016/j.eururo.2013.08.018; Motrich RD, 2007, SCAND J IMMUNOL, V66, P217, DOI 10.1111/j.1365-3083.2007.01971.x; Nadler RB, 2000, J UROLOGY, V164, P214, DOI 10.1016/S0022-5347(05)67497-6; Nickel JC, 2013, WORLD J UROL, V31, P709, DOI 10.1007/s00345-013-1121-4; Olivier B, 2006, INT J IMPOT RES, V18, pS14, DOI 10.1038/sj.ijir.3901330; Patel K, 2009, CURR OPIN INVEST DR, V10, P681; Riegel B, 2014, J PSYCHOSOM RES, V77, P333, DOI 10.1016/j.jpsychores.2014.09.012; Rivero V, 2002, CLIN IMMUNOL, V105, P176, DOI 10.1006/clim.2002.5281; Rudick CN, 2008, AM J PHYSIOL-REG I, V294, pR1268, DOI 10.1152/ajpregu.00836.2007; Wang WL, 2018, BIOMED PHARMACOTHER, V108, P1894, DOI 10.1016/j.biopha.2018.10.010; Wilson MJ, 2004, EXP MOL PATHOL, V77, P7, DOI 10.1016/j.yexmp.2004.02.004; Zhang YD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153054; Zhang YQ, 2002, PAIN, V98, P287, DOI 10.1016/S0304-3959(02)00026-X; Zhao WP, 2009, BRAZ J MED BIOL RES, V42, P963, DOI 10.1590/S0100-879X2009005000021; Zhu CB, 2006, NEUROPSYCHOPHARMACOL, V31, P2121, DOI 10.1038/sj.npp.1301029	42	2	3	6	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 9	2020	11								574212	10.3389/fimmu.2020.574212	http://dx.doi.org/10.3389/fimmu.2020.574212			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NV3XA	33013933	Green Published, gold			2022-12-18	WOS:000574257700001
J	Vardi, I; Chermesh, I; Werner, L; Barel, O; Freund, T; McCourt, C; Fisher, Y; Pinsker, M; Javasky, E; Weiss, B; Rechavi, G; Hagin, D; Snapper, SB; Somech, R; Konnikova, L; Shouval, DS				Vardi, Iddo; Chermesh, Irit; Werner, Lael; Barel, Ortal; Freund, Tal; McCourt, Collin; Fisher, Yael; Pinsker, Marina; Javasky, Elisheva; Weiss, Batia; Rechavi, Gideon; Hagin, David; Snapper, Scott B.; Somech, Raz; Konnikova, Liza; Shouval, Dror S.			Monogenic Inflammatory Bowel Disease: It's Never Too Late to Make a Diagnosis	FRONTIERS IN IMMUNOLOGY			English	Article						CTLA4; common variable immunodeficiency; enteropathy; inflammatory bowel disease; LRBA; monogenic; whole exome sequencing	LRBA DEFICIENCY; IMMUNE DYSREGULATION; REFERENCE VALUES; MUTATIONS; GENETICS; CHILDREN; SPECTRUM	Background:More than 50 different monogenic disorders have been identified as directly causing inflammatory bowel diseases, typically manifesting in the first years of life. We present the clinical course and immunological work-up of an adult patient who presented in adolescent years with an atypical gastrointestinal phenotype and was diagnosed more than two decades later with a monogenic disorder with important therapeutic implications. Methods:Whole exome sequencing was performed in a 37-years-old patient with a history of diarrhea since adolescence. Sanger sequencing was used to validate the suspected variant. Mass cytometry (CyTOF) and flow cytometry were conducted on peripheral blood mononuclear cells for deep immunophenotyping. Next-generation sequencing of theTCRBandIgHwas performed for global immune repertoire analysis of circulating lymphocytes. Results:We identified a novel deleterious c.1455C>A (p.Y485X) mutation inLRBA. CyTOF studies demonstrated significant changes in immune landscape in the LRBA-deficient patient, including an increase in myeloid derived suppressor cells and double-negative T cells, decreased B cells, low ratio of naive:memory T cells, and reduced capacity of T cells to secrete various cytokines following stimulation, including tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma). In addition, this patient exhibited low frequency of regulatory T cells, with a reduction in their CTLA4 expression and interleukin (IL)-10 secretion. Finally, we show marked oligoclonal expansion of specific B- and T-cell clones in the peripheral blood of the LRBA-deficient patient. Conclusions:LRBA deficiency is characterized by marked immunological changes in innate and adaptive immune cells. This case highlights the importance of advanced genetic studies in patients with a unique phenotype, regardless of their age at presentation.	[Vardi, Iddo; Werner, Lael; Pinsker, Marina; Weiss, Batia; Shouval, Dror S.] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Pediat Gastroenterol Unit, Ramat Gan, Israel; [Vardi, Iddo; Werner, Lael; Barel, Ortal; Freund, Tal; Javasky, Elisheva; Weiss, Batia; Rechavi, Gideon; Hagin, David; Somech, Raz; Shouval, Dror S.] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Vardi, Iddo; Barel, Ortal; Javasky, Elisheva; Rechavi, Gideon] Sheba Med Ctr, Sheba Canc Res Ctr, Genom Unit, Ramat Gan, Israel; [Vardi, Iddo; Barel, Ortal; Javasky, Elisheva; Rechavi, Gideon] Wohl Inst Translat Med, Sheba Med Ctr, Ramat Gan, Israel; [Chermesh, Irit] Technion Israel Inst Technol, Rambam Hlth Care Campus, Dept Gastroenterol, Haifa, Israel; [Freund, Tal; Hagin, David] Tel Aviv Sourasky Med Ctr, Dept Med, Allergy & Clin Immunol Unit, Tel Aviv, Israel; [McCourt, Collin; Konnikova, Liza] UPMC Childrens Hosp Pittsburgh, Dept Pediat, Div Newborn Med, Pittsburgh, PA USA; [Fisher, Yael] Technion Israel Inst Technol, Rambam Hlth Care Campus, Inst Pathol, Haifa, Israel; [Pinsker, Marina] Bar Ilan Univ, Inst Nanotechnol & Adv Mat, Ramat Gan, Israel; [Snapper, Scott B.] Boston Childrens Hosp, Div Gastroenterol Hepatol & Nutr, Boston, MA USA; [Snapper, Scott B.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Somech, Raz] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Pediat Immunol Serv, Ramat Gan, Israel; [Somech, Raz] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Pediat Dept Ward A, Ramat Gan, Israel; [Somech, Raz] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Jeffrey Modell Fdn Ctr, Ramat Gan, Israel; [Konnikova, Liza] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA; [Konnikova, Liza] Univ Pittsburgh, Dept Dev Biol, Pittsburgh, PA USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Rambam Health Care Campus; Technion Israel Institute of Technology; Bar Ilan University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Shouval, DS (corresponding author), Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Pediat Gastroenterol Unit, Ramat Gan, Israel.; Shouval, DS (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	dror.shouval@gmail.com	Hagin, David/GRS-3442-2022; Fisher, Yael/HGE-9861-2022	Konnikova, Yelizaveta/0000-0003-4804-5497	Leona M. and Harry B. Helmsley Charitable Trust; Wolpow Chair in IBD Research and Treatment; Translational Research Program (Boston Children's Hospital)	Leona M. and Harry B. Helmsley Charitable Trust; Wolpow Chair in IBD Research and Treatment; Translational Research Program (Boston Children's Hospital)	DS and SS were supported by the Leona M. and Harry B. Helmsley Charitable Trust. SS was also supported by the Wolpow Chair in IBD Research and Treatment and the Translational Research Program (Boston Children's Hospital).	Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Apoil PA, 2017, DATA BRIEF, V12, P400, DOI 10.1016/j.dib.2017.04.019; Azizi G, 2018, IMMUNOL INVEST, V47, P457, DOI 10.1080/08820139.2018.1446978; Azizi G, 2017, PEDIAT ALLERG IMM-UK, V28, P478, DOI 10.1111/pai.12735; Bal SK, 2017, J CLIN IMMUNOL, V37, P790, DOI 10.1007/s10875-017-0446-y; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Bisset LR, 2004, EUR J HAEMATOL, V72, P203, DOI 10.1046/j.0902-4441.2003.00199.x; Bolton C, 2020, J CROHNS COLITIS, V14, P142, DOI 10.1093/ecco-jcc/jjz112; Bratanic N, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0682-5; Burnett DL, 2017, IMMUNOL CELL BIOL, V95, P775, DOI 10.1038/icb.2017.50; Cagdas D, 2019, J CLIN IMMUNOL, V39, P726, DOI 10.1007/s10875-019-00677-6; Charbit-Henrion F, 2018, J CROHNS COLITIS, V12, P1104, DOI 10.1093/ecco-jcc/jjy068; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Chen H, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005112; Crowley E, 2020, GASTROENTEROLOGY, V158, P2208, DOI 10.1053/j.gastro.2020.02.023; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Gervassi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107816; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Graham DB, 2020, NATURE, V578, P527, DOI 10.1038/s41586-020-2025-2; Habibi S, 2019, J ALLER CL IMM-PRACT, V7, P2379, DOI 10.1016/j.jaip.2019.04.011; Iguchi A, 2019, INT J HEMATOL, V110, P364, DOI 10.1007/s12185-019-02686-y; Kammermeier J, 2017, J CROHNS COLITIS, V11, P60, DOI 10.1093/ecco-jcc/jjw118; Kammermeier J, 2014, J MED GENET, V51, P748, DOI 10.1136/jmedgenet-2014-102624; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kiykim A, 2019, J ALLER CL IMM-PRACT, V7, P2790, DOI 10.1016/j.jaip.2019.06.011; Konnikova L, 2018, MUCOSAL IMMUNOL, V11, P1684, DOI 10.1038/s41385-018-0047-y; Labrosse R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01167; Lega S, 2020, INFLAMM BOWEL DIS, V26, P720, DOI 10.1093/ibd/izz178; Lev A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01672; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li MX, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1257; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Ono S, 2017, J CLIN IMMUNOL, V37, P85, DOI 10.1007/s10875-016-0348-4; Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0; Quaranta M, 2018, GASTROENTEROLOGY, V155, P231, DOI 10.1053/j.gastro.2018.03.069; Revel-Vilk S, 2015, CLIN IMMUNOL, V159, P84, DOI 10.1016/j.clim.2015.04.007; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Seidel MG, 2018, J ALLERGY CLIN IMMUN, V141, P770, DOI 10.1016/j.jaci.2017.04.023; Serwas NK, 2015, INFLAMM BOWEL DIS, V21, P40, DOI 10.1097/MIB.0000000000000266; Shamriz O, 2018, EUR J PEDIATR, V177, P1163, DOI 10.1007/s00431-018-3171-5; Shouval DS, 2016, GASTROENTEROLOGY, V151, P1100, DOI 10.1053/j.gastro.2016.08.055; Tesch VK, 2020, J ALLERGY CLIN IMMUN, V145, P1452, DOI 10.1016/j.jaci.2019.12.896; Uhlig HH, 2016, INFLAMM BOWEL DIS, V22, P202, DOI 10.1097/MIB.0000000000000614; Uhlig HH, 2014, GASTROENTEROLOGY, V147, P990, DOI 10.1053/j.gastro.2014.07.023; Vlkova M, 2019, J IMMUNOL, V202, P93, DOI 10.4049/jimmunol.1800102; Zheng CF, 2019, INFLAMM BOWEL DIS, V25, P756, DOI 10.1093/ibd/izy289	51	2	2	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 4	2020	11								1775	10.3389/fimmu.2020.01775	http://dx.doi.org/10.3389/fimmu.2020.01775			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NU4TS	33013830	Green Published, gold			2022-12-18	WOS:000573636400001
J	Yeh, YH; Hsieh, MY; Lee, WI; Huang, JL; Chen, LC; Yeh, KW; Ou, LS; Yao, TC; Wu, CY; Lin, SJ				Yeh, Yu-Hsin; Hsieh, Meng-Ying; Lee, Wen-, I; Huang, Jing-Long; Chen, Li-Chen; Yeh, Kuo-Wei; Ou, Liang-Shiou; Yao, Tsung-Chieh; Wu, Chao-Yi; Lin, Syh-Jae			Distinct Clinical Features and Novel Mutations in Taiwanese Patients With X-Linked Agammaglobulinemia	FRONTIERS IN IMMUNOLOGY			English	Article						X-linked agammaglobulinemia (XLA); Bruton's tyrosine kinase (BTK); contiguous gene deletion syndrome (CGS); TIMM8A; DDP1gene; deafness-dystonia-optic neuronopathy syndrome (DDON); Mohr-Tranebjaerg syndrome (MTS)	PRIMARY IMMUNODEFICIENCY DISEASES; TYROSINE KINASE MUTATIONS; DELETION SYNDROME; CELL-DEVELOPMENT; GENETIC-ANALYSIS; BTK; DYSTONIA; TIMM8A; IDENTIFICATION; DEFICIENCY	Background:X-linked agammaglobulinemia (XLA) is caused by a mutation of the Bruton's tyrosine kinase (BTK) gene and is the most common genetic mutation in patients with congenital agammaglobulinemia. The aim of this study was to analyze the clinical features, genetic defects, and/orBTKexpression in patients suspected of having XLA who were referred from the Taiwan Foundation of Rare Disorders (TFRD). Methods:Patients with recurrent bacterial infections in the first 2 years of life, serum IgG/A/M below 2 standard deviations of the normal range, and <= 2% CD19+B cells were enrolled during the period of 2004-2019. The frequency of infections, pathogens, B-lymphocyte subsets, and family pedigree were recorded. Peripheral blood samples were sent to our institute forBTKexpression and genetic analysis. Results:Nineteen (from 16 families) out of 29 patients hadBTKmutations, including 7 missense mutations, 7 splicing mutations, 1 nonsense mutation, 2 huge deletions, and 2 nucleotide deletions. Six novel mutations were detected: c.504G>T [p.K168N], c.895-2A>G [p.Del K290 fs 23*], c.910T>G [p.F304V], c.1132T>C [p.T334H], c.1562A>T [p.D521V], and c.1957delG [Del p.D653 fs plus 45 a.a.]. All patients withBTKmutations had obviously decreasedBTKexpressions.Pseudomonassepsis developed in 14 patients and led to both Shanghai fever and recurrent hemophagocytic lymphohistiocytosis (HLH). Recurrent sinopulmonary infections and bronchiectasis occurred in 11 patients. One patient died ofpseudomonassepsis and another died of hepatocellular carcinoma before receiving optimal treatment. Two patients with contiguous gene deletion syndrome (CGS) encompassing theTIMM8A/DDP1gene presented with early-onset progressive post-lingual sensorineural Deafness, gradual Dystonia, and Optic Neuronopathy syndrome (DDON) or Mohr-Tranebjaerg syndrome (MTS). Conclusion:Pseudomonas sepsis was more common (74%) than recurrent sinopulmonary infections in Taiwanese XLA patients, and related to Shanghai fever and recurrent HLH, both of which were prevented by regular immunoglobulin infusions. Approximately 10% of patients belonged to CGS involving theTIMM8A/DDP1gene and presented with the DDON/MTS phenotype in need of aggressive psychomotor therapy.	[Yeh, Yu-Hsin; Lee, Wen-, I; Yeh, Kuo-Wei; Ou, Liang-Shiou; Yao, Tsung-Chieh; Wu, Chao-Yi; Lin, Syh-Jae] Chang Gung Univ, Coll Med, Div Allergy Asthma & Rheumatol, Taoyuan, Taiwan; [Yeh, Yu-Hsin; Lee, Wen-, I; Yeh, Kuo-Wei; Ou, Liang-Shiou; Yao, Tsung-Chieh; Wu, Chao-Yi; Lin, Syh-Jae] Chang Gung Univ, Coll Med, Dept Pediat, Taoyuan, Taiwan; [Hsieh, Meng-Ying] Chang Gung Univ, Coll Med, Div Pediat Neurol, Taoyuan, Taiwan; [Lee, Wen-, I; Huang, Jing-Long] Chang Gung Univ, Coll Med, Primary Immunodeficiency Care & Res PICAR Inst, Chang Gung Mem Hosp, Taoyuan, Taiwan; [Huang, Jing-Long; Chen, Li-Chen] New Taipei Municipal TuChen Hosp, Dept Pediat, New Taipei, Taiwan	Chang Gung University; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University	Lee, WI (corresponding author), Chang Gung Univ, Coll Med, Div Allergy Asthma & Rheumatol, Taoyuan, Taiwan.; Lee, WI (corresponding author), Chang Gung Univ, Coll Med, Dept Pediat, Taoyuan, Taiwan.; Lee, WI (corresponding author), Chang Gung Univ, Coll Med, Primary Immunodeficiency Care & Res PICAR Inst, Chang Gung Mem Hosp, Taoyuan, Taiwan.	wen2707@gmail.com			Chang-Gung Medical Research Progress [CMRPG4B0051-3, CMRPG3H1518, CMRPG3G0441]; National Science Council [NSC 99-2314-B-182A-096-MY3, NSC 102-2314-B-182A039-MY3, MOST 106-2314-B-182A-147, NMRPG3C6071, NMRPG3G0381, PMRPG3H0051]; Taiwan Foundation for Rare Disorders (TFRD)	Chang-Gung Medical Research Progress; National Science Council(Ministry of Science and Technology, Taiwan); Taiwan Foundation for Rare Disorders (TFRD)	This work was supported by Chang-Gung Medical Research Progress (Grants CMRPG4B0051-3, CMRPG3H1518, and CMRPG3G0441), the National Science Council (Grants NSC 99-2314-B-182A-096-MY3, NSC 102-2314-B-182A039-MY3, MOST 106-2314-B-182A-147, NMRPG3C6071, NMRPG3G0381, and PMRPG3H0051), and Taiwan Foundation for Rare Disorders (TFRD).	Aadam Z, 2016, J CLIN IMMUNOL, V36, P187, DOI 10.1007/s10875-016-0251-z; Arai T, 2011, J HUM GENET, V56, P577, DOI 10.1038/jhg.2011.61; Brooimans RA, 1997, J MED GENET, V34, P484, DOI 10.1136/jmg.34.6.484; Brookes JT, 2008, INT J PEDIATR OTORHI, V72, P121, DOI 10.1016/j.ijporl.2007.08.019; BRUTON OC, 1952, PEDIATRICS, V9, P722; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chen XF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004544; Chuang CH, 2014, GUT, V63, P736, DOI 10.1136/gutjnl-2013-304786; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; Conley ME, 2005, IMMUNOL REV, V203, P216, DOI 10.1111/j.0105-2896.2005.00233.x; Conley ME, 2002, J PEDIATR-US, V141, P566, DOI 10.1067/mpd.2002.127711; Haire RN, 1997, AM J HUM GENET, V60, P798; Han SP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01953; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Jo EK, 2003, J HUM GENET, V48, P322, DOI 10.1007/s10038-003-0032-4; Jyonouchi H, 2008, EUR J PEDIATR, V167, P317, DOI 10.1007/s00431-007-0493-0; Kanegane H, 2001, J ALLERGY CLIN IMMUN, V108, P1012, DOI 10.1067/mai.2001.120133; Lee WI, 2007, ANN ALLERG ASTHMA IM, V99, P433, DOI 10.1016/S1081-1206(10)60569-8; Lee WI, 2011, IMMUNOBIOLOGY, V216, P1286, DOI 10.1016/j.imbio.2011.06.002; Lee WI, 2005, BLOOD, V105, P1881, DOI 10.1182/blood-2003-12-4420; Lim LM, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-150; Lopez-Granados E, 2005, J ALLERGY CLIN IMMUN, V116, P690, DOI 10.1016/j.jaci.2005.04.043; Lopez-Herrera G, 2014, J LEUKOCYTE BIOL, V95, P243, DOI 10.1189/jlb.0513307; Lougaris V, 2020, J ALLERGY CLIN IMMUN, V146, P429, DOI 10.1016/j.jaci.2020.03.001; Lougaris V, 2014, J ALLERGY CLIN IMMUN, V133, P1644, DOI 10.1016/j.jaci.2013.12.1085; Marron TU, 2012, J ALLERGY CLIN IMMUN, V129, P184, DOI 10.1016/j.jaci.2011.10.009; Nomura K, 2000, BLOOD, V96, P610; Noordzij JG, 2002, J CLIN IMMUNOL, V22, P306, DOI 10.1023/A:1019982206951; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; Pizzuti A, 2004, NEUROLOGY, V62, P1021, DOI 10.1212/01.WNL.0000115174.96423.A8; Richter D, 2001, PEDIAT ALLERG IMM-UK, V12, P107, DOI 10.1034/j.1399-3038.2001.0129999107.x; RYSER O, 1988, J CLIN IMMUNOL, V8, P479, DOI 10.1007/BF00916954; Schultz KAP, 2008, PEDIATR BLOOD CANCER, V51, P293, DOI 10.1002/pbc.21573; Sediva A, 2007, J CLIN IMMUNOL, V27, P640, DOI 10.1007/s10875-007-9123-x; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Shaker M, 2016, ANN ALLERG ASTHMA IM, V116, P578, DOI 10.1016/j.anai.2016.03.014; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; Stray-Pedersen A, 2000, J CLIN IMMUNOL, V20, P477, DOI 10.1023/A:1026416017763; Szaflarska A, 2018, CENT EUR J IMMUNOL, V43, P139, DOI 10.5114/ceji.2018.77383; Tangye SG, 2020, J CLIN IMMUNOL, V40, P65, DOI 10.1007/s10875-020-00763-0; Tsai MH, 2014, PEDIATR INFECT DIS J, V33, pE7, DOI 10.1097/INF.0b013e3182a72ee0; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad; Yip KL, 2000, HUM MUTAT, V15, P385, DOI 10.1002/(SICI)1098-1004(200004)15:4<385::AID-HUMU21>3.0.CO;2-D	43	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 4	2020	11								2001	10.3389/fimmu.2020.02001	http://dx.doi.org/10.3389/fimmu.2020.02001			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NU4HX	33013854	gold, Green Published			2022-12-18	WOS:000573604600001
J	Kawabe, M; Yamamoto, I; Yamakawa, T; Katsumata, H; Isaka, N; Katsuma, A; Nakada, Y; Kobayashi, A; Koike, K; Ueda, H; Tanno, Y; Koike, Y; Miki, J; Yamada, H; Kimura, T; Ohkido, I; Tsuboi, N; Yamamoto, H; Kojima, H; Yokoo, T				Kawabe, Mayuko; Yamamoto, Izumi; Yamakawa, Takafumi; Katsumata, Haruki; Isaka, Nao; Katsuma, Ai; Nakada, Yasuyuki; Kobayashi, Akimitsu; Koike, Kentaro; Ueda, Hiroyuki; Tanno, Yudo; Koike, Yusuke; Miki, Jun; Yamada, Hiroki; Kimura, Takahiro; Ohkido, Ichiro; Tsuboi, Nobuo; Yamamoto, Hiroyasu; Kojima, Hiromi; Yokoo, Takashi			Association Between Galactose-Deficient IgA1 Derived From the Tonsils and Recurrence of IgA Nephropathy in Patients Who Underwent Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						IgA nephropathy; tonsillectomy; galactose-deficient IgA1; recurrent glomerulonephritis; kidney transplantation	STEROID PULSE THERAPY; RENAL-TRANSPLANTATION; TONSILLECTOMY; IMPACT; GLOMERULONEPHRITIS; RECIPIENTS; INDUCTION; DISEASE	Background:Recurrence of IgA nephropathy (IgAN) in the transplanted kidney is associated with graft survival, but no specific treatment is available. Tonsillectomy (TE) reportedly arrests the progression of IgAN in the native kidney. Thus, we conducted a single-center retrospective cohort study to evaluate the effect of TE prior to IgAN recurrence. Methods:Of the 36 patients with biopsy-proven IgAN who underwent kidney transplantation, 27 were included in this study. Nine patients underwent TE at 1 year after kidney transplantation (group 1), and the remaining 18 did not undergo TE (group 2). Results:The rate of histological IgAN recurrence was significantly lower in group 1 than in group 2 (11.1 vs. 55.6%, log-rankp= 0.046). In addition, half of the recurrent patients in group 2 exhibited active lesions, compared to none in group 1. Serum Gd-IgA1 levels decreased after TE in group 1, whereas they remained stable or increased slightly in group 2. In the recurrent cases, IgA and Gd-IgA1 were found in the germinal center in addition to the mantle zone of tonsils. Finally, mesangial IgA and Gd-IgA1 immunoreactivity was reduced after TE in some cases. Conclusion:Our data suggest that TE at 1 year after kidney transplantation might be associated with the reduced rate of histological IgAN recurrence. TE arrested or reduced serum Gd-IgA1 and mesangial Gd-IgA1 immunoreactivity. Therefore, we generated a hypothesis that serum Gd-IgA1 derived from the tonsils may play a pivotal role in the pathogenesis of IgAN. Based on these findings, we need to conduct verification in a prospective randomized controlled trial.	[Kawabe, Mayuko; Yamamoto, Izumi; Yamakawa, Takafumi; Katsumata, Haruki; Katsuma, Ai; Nakada, Yasuyuki; Kobayashi, Akimitsu; Koike, Kentaro; Ueda, Hiroyuki; Tanno, Yudo; Ohkido, Ichiro; Tsuboi, Nobuo; Yamamoto, Hiroyasu; Yokoo, Takashi] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan; [Isaka, Nao; Kojima, Hiromi] Jikei Univ, Sch Med, Dept Otorhinolaryngol, Tokyo, Japan; [Koike, Yusuke; Miki, Jun; Yamada, Hiroki; Kimura, Takahiro] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan	Jikei University; Jikei University; Jikei University	Yamamoto, I (corresponding author), Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan.	izumi26@jikei.ac.jp	Nakada, Yasuyuki/AAI-2877-2021					Adachi M, 2018, AURIS NASUS LARYNX, V45, P1206, DOI 10.1016/j.anl.2018.04.009; Allen PJ, 2017, KIDNEY INT, V92, P461, DOI 10.1016/j.kint.2017.03.015; Berthelot L, 2015, KIDNEY INT, V88, P815, DOI 10.1038/ki.2015.158; Berthoux F, 2008, TRANSPLANTATION, V85, P1505, DOI 10.1097/TP.0b013e3181705ad4; Chang S, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00092; Choy BY, 2003, NEPHROL DIAL TRANSPL, V18, P2399, DOI 10.1093/ndt/gfg373; Clayton P, 2011, AM J TRANSPLANT, V11, P1645, DOI 10.1111/j.1600-6143.2011.03667.x; Cosio FG, 2017, KIDNEY INT, V91, P304, DOI 10.1016/j.kint.2016.08.030; D'Amico G, 2000, AM J KIDNEY DIS, V36, P227, DOI 10.1053/ajkd.2000.8966; Harabuchi Y, 2019, IMMUN INFLAMM DIS, V7, P86, DOI 10.1002/iid3.248; Hirano K, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.4772; Hirano K, 2016, CLIN EXP NEPHROL, V20, P425, DOI 10.1007/s10157-015-1170-7; Hotta O, 2001, AM J KIDNEY DIS, V38, P736, DOI 10.1053/ajkd.2001.27690; Katsumata H, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0858-9; Kawamura T, 2014, NEPHROL DIAL TRANSPL, V29, P1546, DOI 10.1093/ndt/gfu020; Kennoki T, 2009, TRANSPLANTATION, V88, P935, DOI 10.1097/TP.0b013e3181b75374; Kobayashi A, 2015, NEPHROLOGY, V20, P31, DOI 10.1111/nep.12463; Koshino K, 2013, CLIN TRANSPLANT, V27, P22, DOI 10.1111/ctr.12194; McDonald SP, 2006, TRANSPLANTATION, V82, P759, DOI 10.1097/01.tp.0000230131.66971.45; Moroni G, 2013, NEPHROL DIAL TRANSPL, V28, P1305, DOI 10.1093/ndt/gfs472; Pascual J, 2007, TRANSPLANTATION, V83, P1429, DOI 10.1097/01.tp.0000264554.39645.74; Sato Y, 2014, TRANSPL IMMUNOL, V30, P12, DOI 10.1016/j.trim.2013.11.001; Suzuki H, 2019, CLIN EXP NEPHROL, V23, P26, DOI 10.1007/s10157-018-1582-2; Trimarchi H, 2017, KIDNEY INT, V91, P1014, DOI 10.1016/j.kint.2017.02.003; Wada Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206865; Wyld ML, 2016, TRANSPLANTATION, V100, P1827, DOI 10.1097/TP.0000000000001093; Xie YS, 2003, KIDNEY INT, V63, P1861, DOI 10.1046/j.1523-1755.2003.00935.x; Yaginuma T, 2011, CLIN TRANSPLANT, V25, P28, DOI 10.1111/j.1399-0012.2011.01456.x; Yamakawa T, 2015, NEPHROLOGY, V20, P36, DOI 10.1111/nep.12470; Zhang K, 2019, KIDNEY BLOOD PRESS R, V44, P1196, DOI 10.1159/000502579	30	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 3	2020	11								2068	10.3389/fimmu.2020.02068	http://dx.doi.org/10.3389/fimmu.2020.02068			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0GP	33013875	gold, Green Published			2022-12-18	WOS:000570547700001
J	Liu, SJ; Tian, SC; Zhang, YW; Tang, T; Zeng, JM; Fan, XY; Wang, C				Liu, Si-Jing; Tian, Si-Cheng; Zhang, Yun-Wen; Tang, Tian; Zeng, Ju-Mei; Fan, Xiao-Yong; Wang, Chuan			Heterologous Boosting WithListeria-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; vaccine; Listeria monocytogenes; Listeria ivanovii; multistage	T-CELL RESPONSES; LISTERIA-MONOCYTOGENES; TUBERCULOSIS; VACCINE; IMMUNITY; EXPRESSION; ANTIGENS; IVANOVII; VECTOR; EVOLUTION	While Baccillus Calmette-Guerin (BCG) is used worldwide, tuberculosis (TB) is still a global concern due to the poor efficacy of BCG. Novel vaccine candidates are therefore urgently required. In this study, two attenuated recombinantListeriastrains, LM Delta-msvand LI Delta-msvwere constructed by deletion ofactAandplcBand expression of a fusion protein consisting of T cell epitopes from fourMycobacterium tuberculosis(Mtb) antigens (Rv2460c, Rv2660c, Rv3875, andRv3804c). The safety and immunogenicity of the two recombinant strains were evaluated in C57BL/6J mice. After intravenous immunization individually, both recombinant strains entered liver and spleen but eventually were eliminated from these organs after several days. Simultaneously, they induced antigen-specific cell-mediated immunity, indicating that the recombinantListeriastrains were immunogenic and safein vivo. LM Delta-msvimmunization induced stronger cellular immune responses than LI Delta-msvimmunization, and when boosted with LI Delta-msv, antigen-specific IFN-gamma CD8(+)T cell responses were notably magnified. Furthermore, we evaluated the protection conferred by the vaccine candidates against mycobacterial infection via challenging the mice with 1 x 10(7)CFU of BCG. Especially, we tested the feasibility of application of them as heterologous BCG supplement vaccine by immunization of mice with BCG firstly, and boosted with LM Delta-msvand LI Delta-msvsequentially before challenging. Combination immune strategy (LM Delta-msvprime-LI Delta-msvboost) conferred comparable protection efficacy as BCG alone. More importantly, BCG-vaccinated mice acquired stronger resistance to Mycobacterial challenge when boosted with LM Delta-msvand LI Delta-msvsequentially. Our results inferred that heterologous immunization withListeria-based recombinant strains boosted BCG-primed protection against pulmonary mycobacterial infection.	[Liu, Si-Jing; Tian, Si-Cheng; Zhang, Yun-Wen; Tang, Tian; Zeng, Ju-Mei; Wang, Chuan] Sichuan Univ, West China Sch Publ Hlth, Chengdu, Peoples R China; [Liu, Si-Jing; Tian, Si-Cheng; Zhang, Yun-Wen; Tang, Tian; Zeng, Ju-Mei; Wang, Chuan] Sichuan Univ, West China Hosp 4, Chengdu, Peoples R China; [Liu, Si-Jing; Tian, Si-Cheng; Zhang, Yun-Wen; Tang, Tian; Zeng, Ju-Mei; Wang, Chuan] Sichuan Univ, West China Sch Publ Hlth, Dept Publ Hlth Lab Sci, Food Safety Monitoring & Risk Assessment Key Lab, Chengdu, Peoples R China; [Fan, Xiao-Yong] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Key Lab Med Mol Virol MOE MOH, Shanghai, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Fudan University	Wang, C (corresponding author), Sichuan Univ, West China Sch Publ Hlth, Chengdu, Peoples R China.; Wang, C (corresponding author), Sichuan Univ, West China Hosp 4, Chengdu, Peoples R China.; Wang, C (corresponding author), Sichuan Univ, West China Sch Publ Hlth, Dept Publ Hlth Lab Sci, Food Safety Monitoring & Risk Assessment Key Lab, Chengdu, Peoples R China.; Fan, XY (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Key Lab Med Mol Virol MOE MOH, Shanghai, Peoples R China.	xyfan008@fudan.edu.cn; wangchuan@scu.edu.cn			National Natural Science Foundation of China [31570924]; International Cooperation Project of Sichuan Province Science and Technology Department [2017HH0080]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Cooperation Project of Sichuan Province Science and Technology Department	This work was also supported by the National Natural Science Foundation of China (grant number 31570924) and International Cooperation Project of Sichuan Province Science and Technology Department (grant number 2017HH0080).	Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285; Andersen P, 2007, TRENDS MICROBIOL, V15, P7, DOI 10.1016/j.tim.2006.11.008; Angelakopoulos H, 2002, INFECT IMMUN, V70, P3592, DOI 10.1128/IAI.70.7.3592-3601.2002; Basaraba RJ, 2006, VACCINE, V24, P280, DOI 10.1016/j.vaccine.2005.07.103; Bishai W, 2013, NAT MED, V19, P410, DOI 10.1038/nm.3153; Brennan MJ, 2012, VACCINE, V30, P2811, DOI 10.1016/j.vaccine.2012.02.036; Buchrieser C, 2011, J BACTERIOL, V193, P6787, DOI 10.1128/JB.06120-11; Buddle BM, 2003, INFECT IMMUN, V71, P6411, DOI 10.1128/IAI.71.11.6411-6419.2003; Caccamo N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005528; Commandeur S, 2011, EUR J IMMUNOL, V41, P2925, DOI 10.1002/eji.201141602; Condotta SA, 2012, ADV IMMUNOL, V113, P51, DOI 10.1016/B978-0-12-394590-7.00005-1; Cruz A, 2010, J EXP MED, V207, P1609, DOI 10.1084/jem.20100265; Frehel C, 2003, MICROBIOL-SGM, V149, P611, DOI 10.1099/mic.0.25986-0; Haile M, 2005, CURR OPIN INFECT DIS, V18, P211, DOI 10.1097/01.qco.0000168380.08895.9a; Hoft DF, 2012, VACCINE, V30, P2098, DOI 10.1016/j.vaccine.2012.01.048; Houghton J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080047; Hu ZD, 2017, MOL THER, V25, P1222, DOI 10.1016/j.ymthe.2017.02.018; Jia QM, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00245-17; Jiang MJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57245-6; Johnson PV, 2011, MICROBIOL IMMUNOL, V55, P304, DOI 10.1111/j.1348-0421.2011.00322.x; Kaufmann SHE, 2010, LANCET, V375, P2110, DOI 10.1016/S0140-6736(10)60393-5; Le DT, 2012, CLIN CANCER RES, V18, P858, DOI 10.1158/1078-0432.CCR-11-2121; Leong ML, 2009, INFECT IMMUN, V77, P3958, DOI 10.1128/IAI.01274-08; Lin PL, 2012, J CLIN INVEST, V122, P303, DOI 10.1172/JCI46252; Lin QQ, 2015, J BIOTECHNOL, V196, P20, DOI 10.1016/j.jbiotec.2015.01.008; Ma JL, 2017, EBIOMEDICINE, V22, P143, DOI 10.1016/j.ebiom.2017.07.005; Ma JL, 2016, ONCOTARGET, V7, P63804, DOI 10.18632/oncotarget.11542; Maciag PC, 2009, VACCINE, V27, P3975, DOI 10.1016/j.vaccine.2009.04.041; Mahdy SE, 2019, APPL MICROBIOL BIOT, V103, P1919, DOI 10.1007/s00253-018-09605-x; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Marin ND, 2013, TUBERCULOSIS, V93, P155, DOI 10.1016/j.tube.2012.12.002; Mauder N, 2006, J BACTERIOL, V188, P7941, DOI 10.1128/JB.00473-06; Miki K, 2004, INFECT IMMUN, V72, P2014, DOI 10.1128/IAI.72.4.2014-2021.2004; Reece ST, 2011, VACCINE, V29, P8740, DOI 10.1016/j.vaccine.2011.07.144; Ryan AA, 2009, J IMMUNOL, V182, P7172, DOI 10.4049/jimmunol.0801694; Salman Ahmed M, 2014, Egypt J Immunol, V21, P75; Scortti M, 2007, MICROBES INFECT, V9, P1196, DOI 10.1016/j.micinf.2007.05.007; Sherrid AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011622; Starks H, 2004, J IMMUNOL, V173, P420, DOI 10.4049/jimmunol.173.1.420; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; Vazquez-Boland JA, 2001, MICROBES INFECT, V3, P571, DOI 10.1016/S1286-4579(01)01413-7; Wang C, 2014, J MOL MICROB BIOTECH, V24, P191, DOI 10.1159/000363450; Wang XC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122560; Yin YL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00407; Yin YL, 2012, RES MICROBIOL, V163, P540, DOI 10.1016/j.resmic.2012.07.008	45	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2020	11								2036	10.3389/fimmu.2020.02036	http://dx.doi.org/10.3389/fimmu.2020.02036			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NP9DT	32983151	gold, Green Published			2022-12-18	WOS:000570471400001
J	Marklin, M; Fuchs, AR; Tandler, C; Heitmann, JS; Salih, HR; Kauer, J; Quintanilla-Martinez, L; Wirths, S; Kopp, HG; Muller, MR				Maerklin, Melanie; Fuchs, Alexander R.; Tandler, Claudia; Heitmann, Jonas S.; Salih, Helmut R.; Kauer, Joseph; Quintanilla-Martinez, Leticia; Wirths, Stefan; Kopp, Hans-Georg; Mueller, Martin R.			Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia	FRONTIERS IN IMMUNOLOGY			English	Article						CLL; NFAT2; NFATc1; LCK; Richter's transformation; anergy; BCR	B-1 CELLS; B-CELLS; EXPRESSION; RECEPTOR; BCR; CLL; ANERGY; MOUSE; ACTIVATION; INDUCTION	Most patients with chronic lymphocytic leukemia (CLL) exhibit an indolent disease course and unresponsive B cell receptors (BCRs) exemplified by an anergic phenotype of their leukemic cells. In up to 5% of patients, CLL transforms from an indolent subtype to an aggressive form of B cell lymphoma (Richter's syndrome), which is associated with worse disease outcome and severe downregulation of NFAT2. Here we show that ablation of the tyrosine kinase LCK, which has previously been characterized as a main NFAT2 target gene in CLL, leads to loss of the anergic phenotype, thereby restoring BCR signaling, which results in an acceleration of CLL. Our study identifies LCK as a main player in mediating BCR unresponsiveness and its role as a crucial regulator of anergy in CLL.	[Maerklin, Melanie; Fuchs, Alexander R.; Heitmann, Jonas S.; Wirths, Stefan; Kopp, Hans-Georg; Mueller, Martin R.] Univ Tubingen, Dept Hematol Oncol & Clin Immunol & Rheumatol, Tubingen, Germany; [Maerklin, Melanie; Tandler, Claudia; Heitmann, Jonas S.; Salih, Helmut R.] Univ Hosp Tubingen, Clin Collaborat Unit Translat Immunol, German Canc Consortium DKTK, Tubingen, Germany; [Kauer, Joseph] Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Tubingen, Germany; [Quintanilla-Martinez, Leticia] Univ Tubingen, Dept Pathol, Tubingen, Germany; [Kopp, Hans-Georg] Robert Bosch Hosp Stuttgart, Dept Mol Oncol & Thorac Oncol, Stuttgart, Germany; [Mueller, Martin R.] KRH Klinikum Siloah, Klinikum Reg Hannover, Dept Hematol Oncol & Immunol, Hannover, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Bosch; Robert Bosch Krankenhaus	Muller, MR (corresponding author), Univ Tubingen, Dept Hematol Oncol & Clin Immunol & Rheumatol, Tubingen, Germany.; Muller, MR (corresponding author), KRH Klinikum Siloah, Klinikum Reg Hannover, Dept Hematol Oncol & Immunol, Hannover, Germany.	martin.mueller@krh.eu	Märklin, Melanie/AAN-9222-2021	Märklin, Melanie/0000-0002-2920-3894; Kopp, Hans-Georg/0000-0002-0825-8888; Salih, Helmut/0000-0002-6719-1847	DFG [MU 3340/1-1, MU3340/1-2]; Deutsche Krebshilfe grant [111134, 70113496]	DFG(German Research Foundation (DFG)); Deutsche Krebshilfe grant(Deutsche Krebshilfe)	This work was supported by the DFG grant MU 3340/1-1 and MU3340/1-2 (MRM) and the Deutsche Krebshilfe grant 111134 (HS, MRM) and 70113496 (MM).	ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; Apollonio B, 2013, BLOOD, V121, P3879, DOI 10.1182/blood-2012-12-474718; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Dal Porto JM, 2004, IMMUNITY, V21, P443, DOI 10.1016/j.immuni.2004.07.018; Duckworth A, 2014, BLOOD, V123, P3277, DOI 10.1182/blood-2013-11-539049; Duhren-von Minden M, 2012, NATURE, V489, P309, DOI 10.1038/nature11309; Fuchs AR, 2018, JOVE-J VIS EXP, DOI 10.3791/58270; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 2018, BLOOD, V131, P2745, DOI 10.1182/blood-2017-09-806398; Holler C, 2009, BLOOD, V113, P2791, DOI 10.1182/blood-2008-06-160713; Jain N, 2019, NEW ENGL J MED, V380, P2095, DOI 10.1056/NEJMoa1900574; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Le Roy C, 2012, BLOOD, V120, P356, DOI 10.1182/blood-2011-12-397158; Marklin M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00830-y; Majolini MB, 1998, BLOOD, V91, P3390, DOI 10.1182/blood.V91.9.3390.3390_3390_3396; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Merrell KT, 2006, IMMUNITY, V25, P953, DOI 10.1016/j.immuni.2006.10.017; Mockridge CI, 2007, BLOOD, V109, P4424, DOI 10.1182/blood-2006-11-056648; Muller DJ, 2019, J LEUKOCYTE BIOL, V105, P531, DOI 10.1002/JLB.2AB0218-076RR; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Muzio M, 2008, BLOOD, V112, P188, DOI 10.1182/blood-2007-09-111344; Packham G, 2014, HAEMATOLOGICA, V99, P1138, DOI 10.3324/haematol.2013.098384; Paterson JC, 2006, HAEMATOLOGICA, V91, P772; Quach TD, 2011, J IMMUNOL, V186, P4640, DOI 10.4049/jimmunol.1001946; Simonetti G, 2014, BLOOD, V124, P1010, DOI 10.1182/blood-2014-05-577122; Stevenson FK, 2014, SEMIN HEMATOL, V51, P158, DOI 10.1053/j.seminhematol.2014.05.003; Swords R, 2007, MED ONCOL, V24, P17, DOI 10.1007/BF02685899; Talab F, 2013, MOL CANCER RES, V11, P541, DOI 10.1158/1541-7786.MCR-12-0415-T; Theofani E, 2018, BLOOD ADV, V2, P877, DOI 10.1182/bloodadvances.2017015321; Till KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17021-w; Ulivieri C, 2003, EUR J IMMUNOL, V33, P441, DOI 10.1002/immu.200310019; VonKnethen A, 1997, LEUKEMIA LYMPHOMA, V26, P551; Woyach JA, 2013, BLOOD, V121, P3781, DOI 10.1182/blood-2013-03-489849; Zaborsky N, 2019, LEUKEMIA, V33, P957, DOI 10.1038/s41375-018-0260-4	38	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2020	11								1995	10.3389/fimmu.2020.01995	http://dx.doi.org/10.3389/fimmu.2020.01995			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NS8EU	32983140	Green Published, gold			2022-12-18	WOS:000572489900001
J	Tille, A; Lehnert, T; Zipfel, PF; Figge, MT				Tille, Alexander; Lehnert, Teresa; Zipfel, Peter F.; Figge, Marc Thilo			Quantification of Factor H Mediated Self vs. Non-self Discrimination by Mathematical Modeling	FRONTIERS IN IMMUNOLOGY			English	Article						complement system; complement regulator factor H; non-self recognition; immune evasion; self-tolerance; mathematical modeling; hybrid differential equation approach	ALTERNATIVE COMPLEMENT PATHWAY; RABBIT ERYTHROCYTES; C5 CONVERTASE; ACTIVATION; C3B; EVASION; SYSTEM; DEPOSITION; REGULATORS; PROPERDIN	The complement system is part of the innate immune system and plays an important role in the host defense against infectious pathogens. One of the main effects is the opsonization of foreign invaders and subsequent uptake by phagocytosis. Due to the continuous default basal level of active complement molecules, a tight regulation is required to protect the body's own cells (self cells) from opsonization and from complement damage. A major complement regulator is Factor H, which is recruited from the fluid phase and attaches to cell surfaces where it effectively controls complement activation. Besides self cells, pathogens also have the ability to bind Factor H; they can thus escape opsonization and phagocytosis causing severe infections. In order to advance our understanding of the opsonization process at a quantitative level, we developed a mathematical model for the dynamics of the complement system-termedDynaCoSys model-that is based on ordinary differential equations for cell surface-bound molecules and on partial differential equations for concentration profiles of the fluid phase molecules in the environment of cells. This hybrid differential equation approach allows to model the complement cascade focusing on the role of active C3b in the fluid phase and on the cell surface as well as on its inactivation on the cell surface. TheDynaCoSys modelenables us to quantitatively predict the conditions under which Factor H mediated complement evasion occurs. Furthermore, investigating the quantitative impact of model parameters by a sensitivity analysis, we identify the driving processes of complement activation and regulation in both the self and non-self regime. The two regimes are defined by a critical Factor H concentration on the cell surface and we use the model to investigate the differential impact of complement model parameters on this threshold value. The dynamic modeling on the surface of pathogens are further relevant to understand pathophysiological situations where Factor H mutants and defective Factor H binding to target surfaces results in pathophysiology such as renal and retinal disease. In the future, this DynaCoSys model will be extended to also enable evaluating treatment strategies of complement-related diseases.	[Tille, Alexander; Lehnert, Teresa; Figge, Marc Thilo] Hans Knoell Inst, Appl Syst Biol, Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany; [Tille, Alexander; Zipfel, Peter F.; Figge, Marc Thilo] Friedrich Schiller Univ Jena, Inst Microbiol, Fac Biol Sci, Jena, Germany; [Zipfel, Peter F.] Hans Knoell Inst, Infect Biol, Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany	Hans Knoll Institute (HKI); Friedrich Schiller University of Jena; Hans Knoll Institute (HKI)	Figge, MT (corresponding author), Hans Knoell Inst, Appl Syst Biol, Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany.; Figge, MT (corresponding author), Friedrich Schiller Univ Jena, Inst Microbiol, Fac Biol Sci, Jena, Germany.	thilo.figge@leibniz-hki.de			International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS); Deutsche Forschungsgemeinschaft through the FungiNet under DFG project [210879364, CRC/TR124]	International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS); Deutsche Forschungsgemeinschaft through the FungiNet under DFG project(German Research Foundation (DFG))	This work was financially supported by the International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS) and by theDeutsche Forschungsgemeinschaft through the CRC/TR124 FungiNet under DFG project number 210879364 (project B4 to MTF and project C6 to PZ).	Abreu AG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00452; Berends ETM, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0203-8; Conrad EC, 2013, J INNATE IMMUN, V5, P114, DOI 10.1159/000345705; Dasari P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02573; Dasari P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01635; Dennhardt S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01459; Dinasarapu AR, 2012, UCSD MOL PAGES, V1, P1, DOI [10.6072/H0.MP.A004235.01, DOI 10.6072/H0.MP.A004235.01]; EZZELL JL, 1992, SCAND J IMMUNOL, V36, P79, DOI 10.1111/j.1365-3083.1992.tb02943.x; FARRIES TC, 1988, BIOCHEM J, V252, P47, DOI 10.1042/bj2520047; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FEARON DT, 1977, J EXP MED, V146, P22, DOI 10.1084/jem.146.1.22; Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308; Flaherty D, 2012, IMMUNOLOGY PHARM, P87, DOI [10.1016/B978-0-323-06947-2.10011-2, DOI 10.1016/B978-0-323-06947-2.10011-2]; Hallstrom T, 2008, J IMMUNOL, V181, P537, DOI 10.4049/jimmunol.181.1.537; Hallstrom T, 2010, TRENDS MICROBIOL, V18, P258, DOI 10.1016/j.tim.2010.03.007; Heinrich V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00578; Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200; Hirayama H, 1996, BIOSYSTEMS, V39, P173, DOI 10.1016/0303-2647(96)01617-6; HONG KS, 1991, J IMMUNOL, V146, P1868; Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200; Hunniger K, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003479; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Kaur H, 2017, J FUNGI, V3, DOI 10.3390/jof3030041; Korotaevskiy AA, 2009, MATH BIOSCI, V222, P127, DOI 10.1016/j.mbs.2009.10.003; Laabei M, 2019, J INNATE IMMUN, V11, P3, DOI 10.1159/000492944; Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2; Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824; Lehnert T, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00608; Liszewski MK, 2008, VACCINE, V26, pI22, DOI 10.1016/j.vaccine.2008.11.001; Liu B, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001059; Luo SS, 2010, J IMMUNOL, V185, P2164, DOI 10.4049/jimmunol.1001011; Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651; Markiewski MM, 2008, J CELL MOL MED, V12, P2245, DOI 10.1111/j.1582-4934.2008.00504.x; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Meri S, 2016, FEBS LETT, V590, P2418, DOI 10.1002/1873-3468.12284; Meri T, 2002, INFECT IMMUN, V70, P5185, DOI 10.1128/IAI.70.9.5185-5192.2002; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657; NEWMAN SL, 1985, J EXP MED, V161, P1414, DOI 10.1084/jem.161.6.1414; Noris M, 2008, CLIN EXP IMMUNOL, V151, P199, DOI 10.1111/j.1365-2249.2007.03552.x; Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001; Ogden CA, 2006, CURR DIRECT AUTOIMMU, V9, P120; Pangburn MK, 2008, VACCINE, V26, pI15, DOI 10.1016/j.vaccine.2008.11.023; PANGBURN MK, 1983, BIOCHEMISTRY-US, V22, P178, DOI 10.1021/bi00270a026; PANGBURN MK, 1986, BIOCHEM J, V235, P723, DOI 10.1042/bj2350723; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; PANGBURN MK, 1983, J IMMUNOL, V131, P1930; PANGBURN MK, 1983, ANN NY ACAD SCI, V421, P291, DOI 10.1111/j.1749-6632.1983.tb18116.x; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; Pathak A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05494-w; Pedersen DV, 2017, EMBO J, V36, P1084, DOI 10.15252/embj.201696173; Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003; Rawal N, 1998, J BIOL CHEM, V273, P16828, DOI 10.1074/jbc.273.27.16828; Ricklin D, 2012, IMMUNOBIOLOGY, V217, P1057, DOI 10.1016/j.imbio.2012.07.016; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Sagar A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187373; SAHU A, 1994, J BIOL CHEM, V269, P28997; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; Singh DK, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00094; Takizawa F, 1996, FEBS LETT, V397, P269, DOI 10.1016/S0014-5793(96)01197-0; Thorgersen EB, 2019, HEPATOLOGY, V70, P725, DOI 10.1002/hep.30508; Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wong EKS, 2013, MOL IMMUNOL, V56, P199, DOI 10.1016/j.molimm.2013.05.224; Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755; Wu PF, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.74; Zewde N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198644; Zewde N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152337; Zipfel PF, 2007, MOL IMMUNOL, V44, P3850, DOI 10.1016/j.molimm.2007.06.149; Zipfel PF, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02166; Zipfel PF, 2013, MOL IMMUNOL, V56, P152, DOI 10.1016/j.molimm.2013.05.222; Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620; Zipfel PF, 2008, VACCINE, V26, pI67, DOI 10.1016/j.vaccine.2008.11.015	73	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2020	11								1911	10.3389/fimmu.2020.01911	http://dx.doi.org/10.3389/fimmu.2020.01911			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0UK	33013842	Green Published, gold			2022-12-18	WOS:000570583600001
J	Cavani, L; Braz, CU; Giglioti, R; Okino, CH; Gulias-Gomes, CC; Caetano, AR; Oliveira, MCD; Cardoso, FF; de Oliveira, HN				Cavani, Ligia; Braz, Camila Urbano; Giglioti, Rodrigo; Okino, Cintia Hiromi; Gulias-Gomes, Claudia Cristina; Caetano, Alexandre Rodrigues; Oliveira, Marcia Cristina de Sena; Cardoso, Fernando Flores; Oliveira, Henrique Nunes de			Genomic Study ofBabesia bovisInfection Level and Its Association With Tick Count in Hereford and Braford Cattle	FRONTIERS IN IMMUNOLOGY			English	Article						babesiosis; cross-validation; genetic parameters; genomic selection; genome-wide association studies	RHIPICEPHALUS BOOPHILUS MICROPLUS; BABESIA-BOVIS INFECTION; BOS-INDICUS CATTLE; SAO-PAULO STATE; GENETIC-PARAMETERS; IMMUNE-RESPONSE; WIDE ASSOCIATION; NITRIC-OXIDE; FULL PEDIGREE; IFN-GAMMA	Bovine babesiosis is a tick-borne disease caused by intraerythrocytic protozoa and leads to substantial economic losses for the livestock industry throughout the world.Babesia bovisis considered the most pathogenic species, which causes bovine babesiosis in Brazil. Genomic data could be used to evaluate the viability of improving resistance againstB. bovisinfection level (IB) through genomic selection, and, for that, knowledge of genetic parameters is needed. Furthermore, genome-wide association studies (GWAS) could be conducted to provide a better understanding of the genetic basis of the host response toB. bovisinfection. No previous work in quantitative genetics ofB. bovisinfection was found. Thus, the objective of this study was to estimate the genetic correlation between IB and tick count (TC), evaluate predictive ability and applicability of genomic selection, and perform GWAS in Hereford and Braford cattle. The single-step genomic best linear unbiased prediction method was used, which allows the estimation of both breeding values and marker effects. Standard phenotyping was conducted for both traits. IB quantifications from the blood of 1,858 animals were carried using quantitative PCR assays. For TC, one to three subsequent tick counts were performed by manually counting adult female ticks on one side of each animal's body that was naturally exposed to ticks. Animals were genotyped using the Illumina BovineSNP50 panel. The posterior mean of IB heritability, estimated by the Bayesian animal model in a bivariate analysis, was low (0.10), and the estimations of genetic correlation between IB and TC were also low (0.15). The cross-validation genomic prediction accuracy for IB ranged from 0.18 to 0.35 and from 0.29 to 0.32 using k-means and random clustering, respectively, suggesting that genomic predictions could be used as a tool to improve genetics for IB, especially if a larger training population is developed. The top 10 single nucleotide polymorphisms from the GWAS explained 5.04% of total genetic variance for IB, which were located on chromosomes 1, 2, 5, 6, 12, 17, 18, 16, 24, and 26. Some candidate genes participate in immunity system pathways indicating that those genes are involved in resistance toB. bovisin cattle. Although the genetic correlation between IB and TC was weak, some candidate genes for IB were also reported in tick infestation studies, and they were also involved in biological resistance processes. This study contributes to improving genetic knowledge regarding infection byB. bovisin cattle.	[Cavani, Ligia; Braz, Camila Urbano; Oliveira, Henrique Nunes de] Sao Paulo State Univ Unesp, Sch Agr & Vet Sci, Jaboticabal, Brazil; [Giglioti, Rodrigo; Okino, Cintia Hiromi; Oliveira, Marcia Cristina de Sena] Empresa Brasileira Pesquisa Agr, Embrapa Pecuaria Sudeste, Sao Carlos, Brazil; [Gulias-Gomes, Claudia Cristina; Cardoso, Fernando Flores] Empresa Brasileira Pesquisa Agr, Embrapa Pecuaria Sul, Bage, Brazil; [Caetano, Alexandre Rodrigues] Empresa Brasileira Pesquisa Agr, Embrapa Recursos Genet & Biotecnol, Brasilia, DF, Brazil	Universidade Estadual Paulista; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)	Cavani, L; Braz, CU (corresponding author), Sao Paulo State Univ Unesp, Sch Agr & Vet Sci, Jaboticabal, Brazil.	ligiacavani@hotmail.com; camila_urbano@yahoo.com.br	Braz, Camila Urbano/P-4304-2016; Okino, Cintia/N-9601-2019; Giglioti, Rodrigo/AAA-1381-2019; OLIVEIRA, HENRIQUE/HHN-1128-2022; Giglioti, Rodrigo/I-6431-2017; Oliveira, Márcia Cristina de Sena/K-3995-2014; OLIVEIRA, HENRIQUE N/C-5303-2009	Okino, Cintia/0000-0002-3692-3902; Giglioti, Rodrigo/0000-0002-1700-0547; OLIVEIRA, HENRIQUE/0000-0002-3181-1223; Giglioti, Rodrigo/0000-0002-1700-0547; Oliveira, Márcia Cristina de Sena/0000-0002-7038-4607; OLIVEIRA, HENRIQUE N/0000-0002-3181-1223	Sao Paulo Research Foundation [2015/13024-0, 2016/07216-7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES) [001]	Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	Sao Paulo Research Foundation supported this work (grant number 2015/13024-0 and grant number 2016/07216-7). Also, this study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES) - Finance Code 001.	Abbas A.K., 2018, CELL MOL IMMUNOL; ADAMS AEM, 1995, MOL CELL BIOL, V15, P69, DOI 10.1128/MCB.15.1.69; Aguilar I, 2010, J DAIRY SCI, V93, P743, DOI 10.3168/jds.2009-2730; [Anonymous], 1992, BAYESIAN STAT; Ayres DR, 2015, J APPL GENET, V56, P107, DOI 10.1007/s13353-014-0238-5; Bagnall N, 2009, PARASITE IMMUNOL, V31, P177, DOI 10.1111/j.1365-3024.2008.01092.x; Barendse W, 2010, Patent application, P1, Patent No. [WO2007051248-A1, 2007051248]; Barros SL, 2005, MEM I OSWALDO CRUZ, V100, P613, DOI 10.1590/S0074-02762005000600003; Benavides MV, 2007, VET PARASITOL, V150, P54, DOI 10.1016/j.vetpar.2007.08.022; Berry DP, 2011, IRISH VET J, V64, DOI 10.1186/2046-0481-64-5; Biegelmeyer P, 2017, LIVEST SCI, V202, P96, DOI 10.1016/j.livsci.2017.05.019; Bilhassi TB, 2014, TICKS TICK-BORNE DIS, V5, P234, DOI 10.1016/j.ttbdis.2013.11.002; Bock R, 2004, PARASITOLOGY, V129, pS247, DOI 10.1017/S0031182004005190; Bock RE, 1997, AUST VET J, V75, P337, DOI 10.1111/j.1751-0813.1997.tb15706.x; Brown WC, 2001, VET PARASITOL, V101, P233, DOI 10.1016/S0304-4017(01)00569-6; Brown WC, 2006, VET PARASITOL, V138, P75, DOI 10.1016/j.vetpar.2006.01.041; Budeli MA, 2009, S AFR J ANIM SCI, V39, P321; Buling A, 2007, VET PARASITOL, V147, P16, DOI 10.1016/j.vetpar.2007.03.031; Burrow HM, 2001, LIVEST PROD SCI, V70, P213, DOI 10.1016/S0301-6226(01)00178-6; Cardoso FF, 2015, J ANIM SCI, V93, P2693, DOI 10.2527/jas.2014-8832; Cavani L, 2019, THESIS; Chesnais JP, 2016, J DAIRY SCI, V99, P2413, DOI 10.3168/jds.2015-9970; Clayton D., 2014, SNPSTATS SNPMATRIX X; Constantinoiu CC, 2010, INT J PARASITOL, V40, P865, DOI 10.1016/j.ijpara.2010.01.004; de los Campos G, 2013, GENETICS, V193, P327, DOI 10.1534/genetics.112.143313; Domingues R, 2014, GENET MOL RES, V13, P4013, DOI 10.4238/2014.May.23.12; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]; Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233; Gelman A, 1992, STAT SCI, V7, P136, DOI 10.1214/ss/1177011136; Gianola D, 2015, ANNU REV ANIM BIOSCI, V3, P19, DOI 10.1146/annurev-animal-022114-110733; Giglioti R, 2016, TICKS TICK-BORNE DIS, V7, P657, DOI 10.1016/j.ttbdis.2016.02.011; Giglioti R, 2018, VET PARASITOL, V250, P78, DOI 10.1016/j.vetpar.2017.12.010; Goff WL, 2006, PARASITE IMMUNOL, V28, P221, DOI 10.1111/j.1365-3024.2006.00830.x; Goff WL, 2003, PARASITE IMMUNOL, V25, P185, DOI 10.1046/j.1365-3024.2003.00625.x; Goff WL, 2002, VET IMMUNOL IMMUNOP, V84, P237, DOI 10.1016/S0165-2427(01)00413-5; Goff WL, 2001, PARASITE IMMUNOL, V23, P463, DOI 10.1046/j.1365-3024.2001.00402.x; Grisi L, 2014, REV BRAS PARASITOL V, V23, P150, DOI 10.1590/S1984-29612014042; GUGLIELMONE AA, 1995, VET PARASITOL, V57, P109, DOI 10.1016/0304-4017(94)03115-D; Habier D, 2013, GENETICS, V194, P597, DOI 10.1534/genetics.113.152207; Hayes BJ, 2009, J DAIRY SCI, V92, P433, DOI 10.3168/jds.2008-1646; HEIDELBERGER P, 1983, OPER RES, V31, P1109, DOI 10.1287/opre.31.6.1109; Hoff JL, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5941-5; Hunfeld KP, 2008, INT J PARASITOL, V38, P1219, DOI 10.1016/j.ijpara.2008.03.001; Jonsson NN, 2008, VET PARASITOL, V155, P1, DOI 10.1016/j.vetpar.2008.03.022; Jonsson NN, 2014, PARASITE IMMUNOL, V36, P551, DOI 10.1111/pim.12140; Legarra A, 2009, J DAIRY SCI, V92, P4656, DOI 10.3168/jds.2009-2061; Legarra A, 2008, GENETICS, V180, P611, DOI 10.1534/genetics.108.088575; LIN CS, 1988, MOL CELL BIOL, V8, P4659, DOI 10.1128/MCB.8.11.4659; Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Mapholi NO, 2016, TICKS TICK-BORNE DIS, V7, P487, DOI 10.1016/j.ttbdis.2016.02.005; Martin P, 2018, J DAIRY SCI, V101, P2724, DOI 10.3168/jds.2017-13554; McCosker P. J., 1981, Babesiosis. (Internat. Conf. on malaria and babesiosis, Mexico City, 30 Apr. -- 4 May 1979)., P1; Meuwissen THE, 2001, GENETICS, V157, P1819; Misztal I., 2002, P 7 WORLD C GEN APPL; More DD, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6360-3; NARI A, 1995, VET PARASITOL, V57, P153, DOI 10.1016/0304-4017(94)03117-F; Neto LRP, 2011, VET PARASITOL, V180, P165, DOI 10.1016/j.vetpar.2011.05.048; Oh-Hora M, 2008, CURR OPIN IMMUNOL, V20, P250, DOI 10.1016/j.coi.2008.04.004; Oliveira- Sequeira TCG, 2005, INT J PARASITOL, V35, P105, DOI 10.1016/j.ijpara.2004.09.002; Parenti A, 2016, BRIT J PHARMACOL, V173, P953, DOI 10.1111/bph.13392; Piper EK, 2010, INT J PARASITOL, V40, P431, DOI 10.1016/j.ijpara.2009.09.009; Piper EK, 2009, CLIN VACCINE IMMUNOL, V16, P1074, DOI 10.1128/CVI.00157-09; Plummer M., 2006, R NEWS, V6, P7, DOI DOI 10.1159/000323281; Neto LRP, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-55; Porto-Neto LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113284; R Core Team, 2013, R PROJECT STAT COMPU, DOI 10.9774/GLEAF.978-1-909493-38-4_2; Raszek MM, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00030; Reck J, 2009, RES VET SCI, V86, P56, DOI 10.1016/j.rvsc.2008.05.007; Robbertse L, 2018, TICKS TICK-BORNE DIS, V9, P976, DOI 10.1016/j.ttbdis.2018.03.034; Saatchi M, 2012, GENET SEL EVOL, V44, DOI 10.1186/1297-9686-44-38; Salem GH, 1999, MOL CELL PROBE, V13, P107, DOI 10.1006/mcpr.1998.0223; Sasaki S, 2000, ONCOGENE, V19, P3739, DOI 10.1038/sj.onc.1203716; Shinomiya Hiroto, 2012, Int J Cell Biol, V2012, P213492, DOI 10.1155/2012/213492; Shoda LKM, 2000, INFECT IMMUN, V68, P5139, DOI 10.1128/IAI.68.9.5139-5145.2000; Soares-Silva M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00183; Sollero BP, 2017, GENET SEL EVOL, V49, DOI 10.1186/s12711-017-0325-2; Taylor JF, 2014, AQUACULTURE, V420, pS8, DOI 10.1016/j.aquaculture.2013.02.017; Thompson-Crispi KA, 2012, J DAIRY SCI, V95, P401, DOI 10.3168/jds.2011-4452; Thompson-Crispi KA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-559; Turner LB, 2010, ANIM PROD SCI, V50, P235, DOI 10.1071/AN09135; Van Eenennaam AL, 2014, ANNU REV ANIM BIOSCI, V2, P105, DOI 10.1146/annurev-animal-022513-114119; VanRaden PM, 2008, J DAIRY SCI, V91, P4414, DOI 10.3168/jds.2007-0980; VanRaden PM, 2009, J DAIRY SCI, V92, P16, DOI 10.3168/jds.2008-1514; Veerkamp RF, 2011, J DAIRY SCI, V94, P4189, DOI 10.3168/jds.2011-4223; Vestweber D, 2007, IMMUNOL REV, V218, P178, DOI 10.1111/j.1600-065X.2007.00533.x; Visscher PM, 2012, AM J HUM GENET, V90, P7, DOI 10.1016/j.ajhg.2011.11.029; Wang H, 2012, GENET RES, V94, P73, DOI 10.1017/S0016672312000274; Wang YH, 2007, AUST J EXP AGR, V47, P1397, DOI 10.1071/EA07012; WHARTON R H, 1970, Journal of the Australian Entomological Society, V9, P171; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Xu XY, 2017, J EXP MED, V214, P209, DOI 10.1084/jem.20160068; Zare Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088380; Zhang Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012648	95	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 28	2020	11								1905	10.3389/fimmu.2020.01905	http://dx.doi.org/10.3389/fimmu.2020.01905			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0BI	33013839	Green Published, gold			2022-12-18	WOS:000570533600001
J	Wu, BC; Skovbakke, SL; Masoudi, H; Hancock, REW; Franzyk, H				Wu, Bing C.; Skovbakke, Sarah L.; Masoudi, Hamid; Hancock, Robert E. W.; Franzyk, Henrik			In vivoAnti-inflammatory Activity of Lipidated Peptidomimetics Pam-(Lys-beta Nspe)(6)-NH(2)and Lau-(Lys-beta Nspe)(6)-NH(2)Against PMA-Induced Acute Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						peptidomimetics; anti-inflammatory; phorbol 12-myristate 13-acetate; sterile inflammation; formyl peptide receptors; edema; neutrophils; reactive oxygen and nitrogen species	FORMYL-PEPTIDE RECEPTORS; HOST-DEFENSE PEPTIDES; ANTIINFLAMMATORY ACTIVITY; NEUTROPHIL ACTIVATION; SKIN INFLAMMATION; KERATINOCYTES; RECOGNITION; DERMATITIS; RESOLUTION; RESPONSES	Host Defense Peptides (HDPs) are key components of innate immunity that exert antimicrobial, antibiofilm, and immunomodulatory activities in all higher organisms. Synthetic peptidomimetic analogs were designed to retain the desirable pharmacological properties of HDPs while having improved stability toward enzymatic degradation, providing enhanced potential for therapeutic applications. Lipidated peptide/beta-peptoid hybrids [e.g., Pam-(Lys-beta Nspe)(6)-NH2(PM1) and Lau-(Lys-beta Nspe)(6)-NH2(PM2)] are proteolytically stable HDP mimetics displaying anti-inflammatory activity and formyl peptide receptor 2 antagonism in human and mouse immune cellsin vitro. Here PM1 and PM2 were investigated for theirin vivoanti-inflammatory activity in a phorbol 12-myristate 13-acetate (PMA)-induced acute mouse ear inflammation model. Topical administration of PM1 or PM2 led to attenuated PMA-induced ear edema, reduced local production of the pro-inflammatory chemokines MCP-1 and CXCL-1 as well as the cytokine IL-6. In addition, diminished neutrophil infiltration into PMA-inflamed ear tissue and suppressed local release of reactive oxygen and nitrogen species were observed upon treatment. The obtained results show that these two peptidomimetics exhibit anti-inflammatory effects comparable to that of the non-steroidal anti-inflammatory drug indomethacin, and hence possess a potential for treatment of inflammatory skin conditions.	[Wu, Bing C.; Hancock, Robert E. W.] Univ British Columbia, Ctr Microbial Dis & Immun Res, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Skovbakke, Sarah L.] Tech Univ Denmark, Dept Biotechnol & Biomed, Biotherapeut Glycoengn & Immunol, Lyngby, Denmark; [Masoudi, Hamid] St Pauls Hosp, Dept Pathol & Lab Med, Fac Med, Vancouver, BC, Canada; [Franzyk, Henrik] Univ Copenhagen, Dept Drug Design & Pharmacol, Fac Hlth & Med Sci, Copenhagen, Denmark	University of British Columbia; Technical University of Denmark; St. Paul's Hospital; University of Saskatchewan; University of Copenhagen	Hancock, REW (corresponding author), Univ British Columbia, Ctr Microbial Dis & Immun Res, Dept Microbiol & Immunol, Vancouver, BC, Canada.	bob@hancocklab.com		Franzyk, Henrik/0000-0002-2822-1927; Skovbakke, Sarah Line/0000-0002-4673-4419	Canadian Institutes for Health Research [FDN-154287]; Michael Smith Foundation for Health Research Innovation to Commercialization Program; John Richard Turner Fellowship; Carlsberg Foundation	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research Innovation to Commercialization Program; John Richard Turner Fellowship; Carlsberg Foundation(Carlsberg Foundation)	Research reported in this publication was supported by grants to RH from the Canadian Institutes for Health Research FDN-154287 and the Michael Smith Foundation for Health Research Innovation to Commercialization Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Canadian Institutes for Health Research. RH holds a Canada Research Chair in Health and Genomics and a UBC Killam Professorship. BW is supported by the John Richard Turner Fellowship. SS was supported by a grant from the Carlsberg Foundation.	Afacan NJ, 2012, CURR PHARM DESIGN, V18, P807, DOI 10.2174/138161212799277617; Bitschar K, 2017, J DERMATOL SCI, V87, P215, DOI 10.1016/j.jdermsci.2017.06.003; Bonke G, 2008, SYNTHESIS-STUTTGART, P2381, DOI 10.1055/s-2008-1067171; Boutayeb Abdesslam, 2005, Int J Equity Health, V4, P2, DOI 10.1186/1475-9276-4-2; Bralley EE, 2007, J MED FOOD, V10, P636, DOI 10.1089/jmf.2006.244; Bralley EE, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-1; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen KQ, 2017, J AUTOIMMUN, V85, P64, DOI 10.1016/j.jaut.2017.06.012; de la Fuente-Nunez C, 2016, BBA-BIOMEMBRANES, V1858, P1061, DOI 10.1016/j.bbamem.2015.12.015; De Vry CG, 2005, J INVEST DERMATOL, V125, P473, DOI 10.1111/j.0022-202X.2005.23831.x; Dorward DA, 2015, AM J PATHOL, V185, P1172, DOI 10.1016/j.ajpath.2015.01.020; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; Calou IBF, 2008, BIOL PHARM BULL, V31, P1511, DOI 10.1248/bpb.31.1511; Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39; Gabor Miklos, 2003, Methods Mol Biol, V225, P129; Habib SH, 2010, DIABETES METAB SYND, V4, P41, DOI 10.1016/j.dsx.2008.04.005; Hancock R. E. W., 1996, Clin Microbiol Infect, V1, P226; Hancock REW, 2016, NAT REV IMMUNOL, V16, P321, DOI 10.1038/nri.2016.29; Haney EF, 2013, BIOPOLYMERS, V100, P572, DOI 10.1002/bip.22250; Hansen AM, 2019, AMINO ACIDS, V51, P205, DOI 10.1007/s00726-018-2656-x; Hazeldine J, 2015, INJURY, V46, P975, DOI 10.1016/j.injury.2015.03.028; He HQ, 2017, MOLECULES, V22, DOI 10.3390/molecules22030455; Hemshekhar M, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9030040; Jahnsen RD, 2012, J MED CHEM, V55, P7253, DOI 10.1021/jm300820a; Jimenez-Estrada M, 2006, J ETHNOPHARMACOL, V105, P34, DOI 10.1016/j.jep.2005.09.039; Kielland A, 2009, FREE RADICAL BIO MED, V47, P760, DOI 10.1016/j.freeradbiomed.2009.06.013; Kretschmer D, 2010, CELL HOST MICROBE, V7, P463, DOI 10.1016/j.chom.2010.05.012; Lee JH, 2014, CHEM RES TOXICOL, V27, P34, DOI 10.1021/tx400315u; Li LZ, 2016, J LEUKOCYTE BIOL, V99, P425, DOI 10.1189/jlb.2RI0815-354RR; Lim KM, 2015, ARCH DERMATOL RES, V307, P219, DOI 10.1007/s00403-014-1529-8; Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812; Liu MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090613; Lukens JR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00315; Mansour SC, 2014, TRENDS IMMUNOL, V35, P443, DOI 10.1016/j.it.2014.07.004; McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Molchanova N, 2017, MOLECULES, V22, DOI 10.3390/molecules22091430; Nedoszytko B, 2014, POSTEP DERM ALERGOL, V31, P84, DOI 10.5114/pdia.2014.40920; Nijnik A, 2009, Emerg Health Threats J, V2, pe1, DOI 10.3134/ehtj.09.001; Olsen CA, 2010, CHEMBIOCHEM, V11, P152, DOI 10.1002/cbic.200900618; Ortega-Gomez A, 2013, EMBO MOL MED, V5, P661, DOI 10.1002/emmm.201202382; Peschel A, 2013, NAT REV MICROBIOL, V11, P667, DOI 10.1038/nrmicro3110; Prevete N, 2015, PHARMACOL RES, V102, P184, DOI 10.1016/j.phrs.2015.09.017; Rock KL, 2010, ANNU REV IMMUNOL, V28, P321, DOI 10.1146/annurev-immunol-030409-101311; Rotem S, 2009, BBA-BIOMEMBRANES, V1788, P1582, DOI 10.1016/j.bbamem.2008.10.020; Rutkowski Ryszard, 2007, Pol Merkur Lekarski, V23, P131; Skovbakke SL, 2015, J MED CHEM, V58, P801, DOI 10.1021/jm501341h; Skovbakke SL, 2018, CURR PHARM DESIGN, V24, P1100, DOI 10.2174/1381612824666180403123233; Skovbakke SL, 2016, BIOCHEM PHARMACOL, V119, P56, DOI 10.1016/j.bcp.2016.09.004; Skovbakke SL, 2015, BIOCHEM PHARMACOL, V93, P182, DOI 10.1016/j.bcp.2014.11.004; Sun J, 2015, INT IMMUNOPHARMACOL, V25, P235, DOI 10.1016/j.intimp.2015.02.007; Vagner J, 2008, CURR OPIN CHEM BIOL, V12, P292, DOI 10.1016/j.cbpa.2008.03.009; van der Plas MJA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11567; Winther M, 2018, BASIC CLIN PHARMACOL, V122, P191, DOI 10.1111/bcpt.12903; Wu BC, 2017, J IMMUNOL, V199, P3592, DOI 10.4049/jimmunol.1700985; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zuckermann RN, 2009, CURR OPIN MOL THER, V11, P299	60	2	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 28	2020	11								2102	10.3389/fimmu.2020.02102	http://dx.doi.org/10.3389/fimmu.2020.02102			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ0FM	32983167	Green Published, gold			2022-12-18	WOS:000570544700001
J	Jorgensen, SF; Fevang, B; Aukrust, P				Jorgensen, Silje F.; Fevang, Borre; Aukrust, Pal			Commentary: Gut Antibody Deficiency in a Mouse Model of CVID Results in Spontaneous Development of a Gluten-Sensitive Enteropathy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						CVID; mouse model; gut microbiota; enteropathy; celiac disease; primary immunodeficiency; dysbiosis; gluten sensitivity	COMMON VARIABLE IMMUNODEFICIENCY; B-LYMPHOCYTES; MICROBIOTA; SELECTION; RECEPTOR		[Jorgensen, Silje F.; Fevang, Borre; Aukrust, Pal] Oslo Univ Hosp, Div Surg Inflammatory Dis & Transplantat, Internal Med Res Inst, Oslo, Norway; [Jorgensen, Silje F.; Fevang, Borre; Aukrust, Pal] Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, Dept Rheumatol Dermatol & Infect Dis, Oslo, Norway; [Jorgensen, Silje F.; Fevang, Borre; Aukrust, Pal] Univ Oslo, Inst Clin Med, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Jorgensen, SF (corresponding author), Oslo Univ Hosp, Div Surg Inflammatory Dis & Transplantat, Internal Med Res Inst, Oslo, Norway.; Jorgensen, SF (corresponding author), Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, Dept Rheumatol Dermatol & Infect Dis, Oslo, Norway.; Jorgensen, SF (corresponding author), Univ Oslo, Inst Clin Med, Oslo, Norway.	s.f.jorgensen@medisin.uio.no						Biagi F, 2012, AM J CLIN PATHOL, V138, P185, DOI 10.1309/AJCPEIILH2C0WFYE; Fagarasan S, 2010, ANNU REV IMMUNOL, V28, P243, DOI 10.1146/annurev-immunol-030409-101314; Jorgensen SF, 2016, MUCOSAL IMMUNOL, V9, P1455, DOI 10.1038/mi.2016.18; Jorgensen SF, 2019, J CLIN IMMUNOL, V39, P30, DOI 10.1007/s10875-018-0574-z; Jorgensen SF, 2016, AM J GASTROENTEROL, V111, P1467, DOI 10.1038/ajg.2016.329; Kawamoto S, 2014, IMMUNITY, V41, P152, DOI 10.1016/j.immuni.2014.05.016; Kawamoto S, 2012, SCIENCE, V336, P485, DOI 10.1126/science.1217718; Lorenz RG, 2003, J IMMUNOL, V170, P5475, DOI 10.4049/jimmunol.170.11.5475; Malamut G, 2010, AM J GASTROENTEROL, V105, P2262, DOI 10.1038/ajg.2010.214; Mohammed AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02484; Shulzhenko N, 2011, NAT MED, V17, P1585, DOI 10.1038/nm.2505; Sutherland DB, 2012, CURR OPIN IMMUNOL, V24, P261, DOI 10.1016/j.coi.2012.03.005; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Thaventhiran JED, 2020, NATURE, V583, P90, DOI 10.1038/s41586-020-2265-1; Venhoff N, 2013, J CLIN IMMUNOL, V33, P909, DOI 10.1007/s10875-013-9892-3; Wei M, 2011, NAT IMMUNOL, V12, P264, DOI 10.1038/ni.1991; Yazdani R, 2020, J INVEST ALLERG CLIN, V30, P14, DOI 10.18176/jiaci.0388	17	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2020	11								1921	10.3389/fimmu.2020.01921	http://dx.doi.org/10.3389/fimmu.2020.01921			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NP8AJ	32983117	Green Published, gold			2022-12-18	WOS:000570393400001
J	Padua, TA; Souza, MC				Padua, Tatiana Almeida; Souza, Mariana Conceicao			Heme on Pulmonary Malaria: Friend or Foe?	FRONTIERS IN IMMUNOLOGY			English	Review						hemolysis; MA-RD; Plasmodium; heme; severe malaria; HO-1	RESPIRATORY-DISTRESS-SYNDROME; PLASMODIUM-VIVAX MALARIA; ACUTE LUNG INJURY; CEREBRAL MALARIA; HEMOZOIN; PATHOGENESIS; HEMOGLOBIN; THERAPY; BERGHEI; MODEL	Malaria is a hemolytic disease that, in severe cases, can compromise multiple organs. Pulmonary distress is a common symptom observed in severe malaria caused byPlasmodium vivaxorPlasmodium falciparum. However, biological components involved in the development of lung malaria are poorly studied. In experimental models of pulmonary malaria, it was observed that parasitized red blood cell-congested pulmonary capillaries are related to intra-alveolar hemorrhages and inflammatory cell infiltration. Thus, it is very likely that hemolysis participates in malaria-induced acute lung injury. During malaria, heme assumes different biochemical structures such as hemin and hemozoin (biocrystallized structure of heme insidePlasmodiumsp.). Each heme-derived structure triggers a different biological effect: on the one hand, hemozoin found in lung tissue is responsible for the infiltration of inflammatory cells and consequent tissue injury; on the other hand, heme stimulates heme oxygenase-1 (HO-1) expression and CO production, which protect mice from severe malaria. In this review, we discuss the biological mechanism involved in the dual role of heme response in experimental malaria-induced acute lung injury.	[Padua, Tatiana Almeida; Souza, Mariana Conceicao] Fundacao Oswaldo Cruz, Inst Drug Technol Farmanguinhos, Lab Appl Pharmacol, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz	Souza, MC (corresponding author), Fundacao Oswaldo Cruz, Inst Drug Technol Farmanguinhos, Lab Appl Pharmacol, Rio De Janeiro, Brazil.	mariana.souza@fiocruz.br	Souza, Mariana/GQQ-6648-2022; Souza, Mariana/C-1677-2015	Souza, Mariana/0000-0002-6933-9227	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [407835/2017-2]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, grant 407835/2017-2.	Amani V, 1998, INFECT IMMUN, V66, P4093; Ascenzi P, 2005, IUBMB LIFE, V57, P749, DOI 10.1080/15216540500380871; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Basu S, 2017, INDIAN J PEDIATR, V84, P521, DOI 10.1007/s12098-017-2332-2; Brasil P, 2017, LANCET GLOB HEALTH, V5, pE1038, DOI 10.1016/S2214-109X(17)30333-9; Carvalho LJM, 2000, EXP PARASITOL, V95, P1, DOI 10.1006/expr.2000.4508; Claser C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12017-8; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; Das D, 2018, FEBS LETT, V592, P2458, DOI 10.1002/1873-3468.13165; de Souza JB, 2010, PARASITOLOGY, V137, P755, DOI 10.1017/S0031182009991715; Deroost K, 2013, AM J RESP CELL MOL, V48, P589, DOI 10.1165/rcmb.2012-0450OC; Egan TJ, 2008, MOL BIOCHEM PARASIT, V157, P127, DOI 10.1016/j.molbiopara.2007.11.005; Epiphanio S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000916; Farrugia G, 2014, GASTROENTEROLOGY, V147, P303, DOI 10.1053/j.gastro.2014.04.041; Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049; Franke-Fayard B, 2005, P NATL ACAD SCI USA, V102, P11468, DOI 10.1073/pnas.0503386102; Frimat M, 2019, TOXINS, V11, DOI 10.3390/toxins11110660; Fujiwara T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/278536; Giribaldi G, 2010, INFECT IMMUN, V78, P4912, DOI 10.1128/IAI.00455-10; Haydoura S, 2011, PARASITOL INT, V60, P114, DOI 10.1016/j.parint.2010.10.005; Huy NT, 2006, PARASITOL INT, V55, P75, DOI 10.1016/j.parint.2005.10.003; Hwang J, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu034; Immenschuh S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00146; Jaramillo M, 2005, J IMMUNOL, V174, P475, DOI 10.4049/jimmunol.174.1.475; Krugliak M, 2002, MOL BIOCHEM PARASIT, V119, P249, DOI 10.1016/S0166-6851(01)00427-3; Lacerda MVG, 2012, CLIN INFECT DIS, V55, pE67, DOI 10.1093/cid/cis615; Leopold SJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204832; Liu ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034280; Londhe C, 2014, J VECTOR DIS, V51, P339; Maguire GP, 2005, J INFECT DIS, V192, P1966, DOI 10.1086/497697; Maknitikul S, 2018, EXP BIOL MED, V243, P395, DOI 10.1177/1535370218757458; Maknitikul S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181674; Malaria S, 2014, TROP MED INT HEALTH, V19, P7, DOI [10.1111/tmi.12313, 10.1111/tmi.12313_2]; Matthews K, 2017, INTEGR BIOL-UK, V9, P519, DOI [10.1039/c7ib00039a, 10.1039/C7IB00039A]; Mohan Alladi, 2008, Journal of Vector Borne Diseases, V45, P179; Mohapatra Biranchi Narayan, 2014, J Assoc Physicians India, V62, P14; Oliyier M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00025; Padua TA, 2018, J LEUKOCYTE BIOL, V103, P657, DOI 10.1002/JLB.3A1016-435RRR; Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; Pereira MLM, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00161; Pereira MLM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4158698; Phillips MA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.50; PHU NH, 1995, T ROY SOC TROP MED H, V89, P200, DOI 10.1016/0035-9203(95)90496-4; Quaye IK, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00096; Ramos WM, 2010, BRAZ J INFECT DIS, V14, P410, DOI 10.1590/S1413-86702010000400017; Riviello ED, 2016, AM J RESP CRIT CARE, V193, P52, DOI 10.1164/rccm.201503-0584OC; Schaer DJ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00415; Schmidt HM, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.101072; Seilmaier M, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-422; Sigala PA, 2014, ANNU REV MICROBIOL, V68, P259, DOI 10.1146/annurev-micro-091313-103537; Son SM, 2012, DIABETES METAB J, V36, P190, DOI 10.4093/dmj.2012.36.3.190; Souza MC, 2013, RESP PHYSIOL NEUROBI, V186, P65, DOI 10.1016/j.resp.2012.12.008; Souza MC, 2015, CURRENT TOPICS MALAR, P85; Sulaiman H, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-341; Taylor WRJ, 2012, CHEST, V142, P492, DOI 10.1378/chest.11-2655; Pham TT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00416; Umbreit J, 2007, AM J HEMATOL, V82, P134, DOI 10.1002/ajh.20738; Van den Steen PE, 2010, AM J RESP CRIT CARE, V181, P957, DOI 10.1164/rccm.200905-0786OC; Vinchi F, 2016, BLOOD, V127, P473, DOI 10.1182/blood-2015-08-663245; WHO, 2019, WORLD MALARIA REPORT; WHO, 2018, WORLD MAL REP 2018	62	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 25	2020	11								1835	10.3389/fimmu.2020.01835	http://dx.doi.org/10.3389/fimmu.2020.01835			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ1CK	32983096	Green Published, gold			2022-12-18	WOS:000570604600001
J	Pereira, NZ; Branco, ACCC; Manfrere, KCG; de Lima, JF; Yoshikawa, FSY; Milanez, HMBPM; Pereira, NV; Sotto, MN; Duarte, AJD; Sato, MN				Pereira, Natalli Zanete; Branco, Anna Claudia Calvielli Castelo; Manfrere, Kelly Cristina Gomes; de Lima, Josenilson Feitosa; Yoshikawa, Fabio Seiti Yamada; Milanez, Helaine Maria Besteti Pires Mayer; Pereira, Naiura Vieira; Sotto, Miriam Nacagami; Duarte, Alberto Jose da Silva; Sato, Maria Notomi			Increased Expression on Innate Immune Factors in Placentas From HIV-Infected Mothers Concurs With Dampened Systemic Immune Activation	FRONTIERS IN IMMUNOLOGY			English	Article						DAMPs; inflammation; cord blood; HIV-infection; placental tissue; newborns	HMGB1; REPLICATION	Innate immunity is one of the main protection mechanisms against viral infections, but how this system works at the maternal-fetal interface, especially during HIV infection, is still poorly known. In this study, we investigated the relationship between pregnancy and innate mechanisms associated with HIV immunity by evaluating the expression of DAMPs, inflammasome components and type I/III IFNs in placenta and serum samples from HIV-infected mothers and exposed newborns. Our results showed that most of these factors, including HMGB1, IL-1, and IFN, were increased in placental villi from HIV-infected mothers. Curiously, however, these factors were simultaneously repressed in serum from HIV-infected mothers and their exposed newborns, suggesting that pregnancy could restrict HIV immune activation systemically but preserve the immune response at the placental level. An effective local antiviral status associated with a suppressed inflammatory environment can balance the maternal immune response, promoting homeostasis for fetal development and protection against HIV infection in neonates.	[Pereira, Natalli Zanete; Branco, Anna Claudia Calvielli Castelo; Manfrere, Kelly Cristina Gomes; de Lima, Josenilson Feitosa; Yoshikawa, Fabio Seiti Yamada; Duarte, Alberto Jose da Silva; Sato, Maria Notomi] Univ Sao Paulo, Lab Invest Dermatol & Imunodeficiencias LIM56, Inst Med Trop, Fac Med,FMUSP, Sao Paulo, Brazil; [Pereira, Natalli Zanete; Pereira, Naiura Vieira; Sotto, Miriam Nacagami] Univ Sao Paulo, FMUSP, Fac Med, Dept Dermatol, Sao Paulo, Brazil; [Branco, Anna Claudia Calvielli Castelo] Univ Sao Paulo, Inst Ciencias Biomed, Sao Paulo, Brazil; [Yoshikawa, Fabio Seiti Yamada] Chiba Univ, Div Mol Immunol, Med Mycol Res Ctr, Chiba, Japan; [Milanez, Helaine Maria Besteti Pires Mayer] Univ Estadual Campinas, Dept Tocoginecol, Campinas, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Chiba University; Universidade Estadual de Campinas	Sato, MN (corresponding author), Univ Sao Paulo, Lab Invest Dermatol & Imunodeficiencias LIM56, Inst Med Trop, Fac Med,FMUSP, Sao Paulo, Brazil.	marisato@usp.br	Pereira, Nátalli Zanete/U-7291-2019; Branco, Anna Cláudia/AAP-7618-2021; Milanez, Helaine Maria Besteti Pires Mayer/ABH-1521-2021; Yamada Yoshikawa, Fabio Seiti/F-3049-2014	Pereira, Nátalli Zanete/0000-0002-8875-9470; Branco, Anna Cláudia/0000-0001-7861-6890; Yamada Yoshikawa, Fabio Seiti/0000-0002-6112-7107	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/18837-1, 2012/21364-8]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Grant nos. 2012/18837-1 and 2012/21364-8 and LIM HCFMUSP.	Afran L, 2014, CLIN EXP IMMUNOL, V176, P11, DOI 10.1111/cei.12251; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Caine EA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07993-2; Cervantes CAC, 2016, SCI REP-UK, V6, DOI 10.1038/srep25875; Doyle T, 2015, NAT REV MICROBIOL, V13, P403, DOI 10.1038/nrmicro3449; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Kwon JY, 2018, CELL MOL IMMUNOL, V15, P1010, DOI 10.1038/s41423-018-0050-y; Lamkanfi M, 2010, J IMMUNOL, V185, P4385, DOI 10.4049/jimmunol.1000803; Li JL, 2012, J NEUROSCI RES, V90, P399, DOI 10.1002/jnr.22758; Lin SJ, 2012, J INFECT DIS, V205, P745, DOI 10.1093/infdis/jir843; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lv S, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171675; Maharaj NR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170063; Nowak P, 2006, CYTOKINE, V34, P17, DOI 10.1016/j.cyto.2006.03.010; Paiardini M, 2013, IMMUNOL REV, V254, P78, DOI 10.1111/imr.12079; Pereira NZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084917; Pfeifer C, 2016, CURR OPIN HIV AIDS, V11, P138, DOI 10.1097/COH.0000000000000239; Report Global, 2018, UNAIDS REP GLOB AIDS; Roider JM, 2016, CURR OPIN HIV AIDS, V11, P146, DOI 10.1097/COH.0000000000000231; Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314; Sandstrom TS, 2017, CYTOKINE GROWTH F R, V37, P1, DOI 10.1016/j.cytogfr.2017.04.004; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Simard JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072138; Suh WK, 2003, NAT IMMUNOL, V4, P899, DOI 10.1038/ni967; Trinh QD, 2016, CLIN LAB, V62, P2305, DOI 10.7754/Clin.Lab.2016.150928; Wang X, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00210; Zhang CL, 2013, ACTA BIOCH BIOPH SIN, V45, P1055, DOI 10.1093/abbs/gmt109	28	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 25	2020	11								1822	10.3389/fimmu.2020.01822	http://dx.doi.org/10.3389/fimmu.2020.01822			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ1DP	32983090	Green Published, gold			2022-12-18	WOS:000570607700001
J	Toledo, NPL; Li, HZ; Omange, RW; Dacoba, TG; Crecente-Campo, J; Schalk, D; Kashem, MA; Rakasz, E; Schultz-Darken, N; Li, QS; Whitney, JB; Alonso, MJ; Plummer, FA; Luo, M				Toledo, Nikki P. L.; Li, Hongzhao; Omange, Robert W.; Dacoba, Tamara G.; Crecente-Campo, Jose; Schalk, Dane; Kashem, Mohammad A.; Rakasz, Eva; Schultz-Darken, Nancy; Li, Qingsheng; Whitney, James B.; Alonso, Maria J.; Plummer, Francis A.; Luo, Ma			Cervico-Vaginal Inflammatory Cytokine and Chemokine Responses to Two Different SIV Immunogens	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; SIV; vaccine; mucosal inflammation; pro-inflammatory cytokine; chemokine(s); non-human primates	T-LYMPHOCYTE RESPONSES; GENITAL INFLAMMATION; HIV-1 INFECTION; IMMUNE ACTIVATION; ANTIGEN-DRIVEN; CELLS; ACQUISITION; EPITOPES; VACCINES; CD4(+)	Studies have shown that vaccine vectors and route of immunization can differentially activate different arms of the immune system. However, the effects of different HIV vaccine immunogens on mucosal inflammation have not yet been studied. Because mucosal sites are the primary route of HIV infection, we evaluated the cervico-vaginal inflammatory cytokine and chemokine levels of Mauritian cynomolgus macaques following immunization and boost using two different SIV vaccine immunogens. The PCS vaccine delivers 12 20-amino acid peptides overlapping the 12 protease cleavage sites, and the Gag/Env vaccine delivers the full Gag and full Env proteins of simian immunodeficiency virus. We showed that the PCS vaccine prime and boosts induced short-lived, lower level increases of a few pro-inflammatory/chemotactic cytokines. In the PCS-vaccine group only the levels of MCP-1 were significantly increased above the baseline (P= 0.0078, Week 6;P= 0.0078, Week 17;P= 0.0234; Week 51) following multiple boosts. In contrast, immunizations with the Gag/Env vaccine persistently increased the levels of multiple cytokines/chemokines. In the Gag/Env group, higher than baseline levels were consistently observed for IL-8 (P= 0.0078, Week 16;P= 0.0078, Week 17;P= 0.0156, Week 52), IL-1 beta (P= 0.0234, Week 16;P= 0.0156, Week 17;P= 0.0156, Week 52), and MIP-1 alpha (P= 0.0313, Week 16;P= 0.0156, Week 17;P= 0.0313, Week 52). Over time, repeated boosts altered the relative levels of these cytokines between the Gag/Env and PCS vaccine group. 18 weeks after final boost with a higher dosage, IP-10 levels (P= 0.0313) in the Gag/Env group remained higher than baseline. Thus, the influence of vaccine immunogens on mucosal inflammation needs to be considered when developing and evaluating candidate HIV vaccines.	[Toledo, Nikki P. L.; Li, Hongzhao; Omange, Robert W.; Kashem, Mohammad A.; Plummer, Francis A.; Luo, Ma] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada; [Dacoba, Tamara G.; Crecente-Campo, Jose; Alonso, Maria J.] Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CIMUS, Campus Vida, Santiago De Compostela, Spain; [Schalk, Dane; Rakasz, Eva; Schultz-Darken, Nancy] Wisconsin Natl Primate Res Ctr, Sci Protocol Implementat Unit, Madison, WI USA; [Kashem, Mohammad A.; Plummer, Francis A.; Luo, Ma] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada; [Li, Qingsheng] Univ Nebraska, Sch Biol Sci, Nebraska Ctr Virol, Lincoln, NE USA; [Whitney, James B.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA	University of Manitoba; Universidade de Santiago de Compostela; Public Health Agency of Canada; University of Nebraska System; University of Nebraska Lincoln; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Luo, M (corresponding author), Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.; Luo, M (corresponding author), Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada.	ma.luo@canada.ca	; Omange, Were/F-1454-2016	Dacoba, Tamara/0000-0003-0770-6340; Kashem, Mohammad/0000-0002-6472-3676; Omange, Were/0000-0002-0421-110X	NIH [R01AI111805]; National Microbiology Laboratory, Public Health Agency of Canada; Children's Hospital Research Institute of Manitoba; University of Manitoba, Faculty of Graduate Studies	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Microbiology Laboratory, Public Health Agency of Canada; Children's Hospital Research Institute of Manitoba; University of Manitoba, Faculty of Graduate Studies	This work was supported by an NIH grant (R01AI111805), and A-based funding from National Microbiology Laboratory, Public Health Agency of Canada. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Children's Hospital Research Institute of Manitoba and the University of Manitoba, Faculty of Graduate Studies provided travel grant for NT to attend scientific conferences (HIVR4P).	Arnold KB, 2016, MUCOSAL IMMUNOL, V9, P194, DOI 10.1038/mi.2015.51; Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089; Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106; Biancotto A, 2008, BLOOD, V111, P699, DOI 10.1182/blood-2007-05-088435; Cobleigh MA, 2012, J VIROL, V86, P4253, DOI 10.1128/JVI.05991-11; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Estcourt MJ, 2005, EUR J IMMUNOL, V35, P2532, DOI 10.1002/eji.200535184; Fauci AS, 2014, SCIENCE, V344, P49, DOI 10.1126/science.1250672; Gorse GJ, 2012, CLIN VACCINE IMMUNOL, V19, P649, DOI 10.1128/CVI.00038-12; Gosmann C, 2017, IMMUNITY, V46, P29, DOI 10.1016/j.immuni.2016.12.013; Haglund K, 2002, J VIROL, V76, P7506, DOI 10.1128/JVI.76.15.7506-7517.2002; Haglund K, 2002, J VIROL, V76, P2730, DOI 10.1128/JVI.76.6.2730-2738.2002; Honda M, 2009, J IMMUNOL, V183, P2425, DOI 10.4049/jimmunol.0900581; Kashem MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00272; Kenway-Lynch CS, 2014, J VIROL, V88, P9442, DOI 10.1128/JVI.00774-14; Lajoie J, 2012, MUCOSAL IMMUNOL, V5, P277, DOI 10.1038/mi.2012.7; Li HZ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202997; Li HZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186079; Li HZ, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0174-7; Luo M, 2012, J VIROL, V86, P1166, DOI 10.1128/JVI.05721-11; Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298; McKinnon LR, 2018, NAT MED, V24, P491, DOI 10.1038/nm.4506; McKinnon LR, 2015, JAIDS-J ACQ IMM DEF, V68, P6, DOI 10.1097/QAI.0000000000000389; Ochsenbein AF, 2000, P NATL ACAD SCI USA, V97, P13263, DOI 10.1073/pnas.230417497; Passmore JAS, 2016, CURR OPIN HIV AIDS, V11, P156, DOI 10.1097/COH.0000000000000232; Peng B, 2005, J VIROL, V79, P10200, DOI 10.1128/JVI.79.16.10200-10209.2005; Poetsch JH, 2019, J INFECT DIS, V219, P556, DOI 10.1093/infdis/jiy565; Rolland M, 2007, PLOS PATHOG, V3, P1551, DOI 10.1371/journal.ppat.0030157; Stephenson KE, 2012, J VIROL, V86, P11434, DOI 10.1128/JVI.01779-12; Wesa Amy, 2002, BMC Immunol, V3, P14, DOI 10.1186/1471-2172-3-14; Wilson CC, 2003, J IMMUNOL, V171, P5611, DOI 10.4049/jimmunol.171.10.5611	31	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 25	2020	11								1935	10.3389/fimmu.2020.01935	http://dx.doi.org/10.3389/fimmu.2020.01935			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NQ1AW	32983121	Green Published, gold			2022-12-18	WOS:000570600500001
J	Szikora, B; Marx, A; Jani, PK; Pipek, O; Muller, V; Csabai, I; Kacskovics, I				Szikora, Bence; Marx, Anita; Jani, Peter K.; Pipek, Orsolya; Mueller, Viktor; Csabai, Istvan; Kacskovics, Imre			FcRn Overexpression Expands Diversity of the Humoral Immune Response in bFcRn Transgenic Mice	FRONTIERS IN IMMUNOLOGY			English	Article						B cell repertoire; next generation sequencing; FcRn overexpression; humoral immune response; monoclonal antibody production	B-CELL REPERTOIRE; PERIPHERAL-BLOOD; RECEPTOR; ANTIBODY; VACCINATION; EXPRESSION; TRANSPORT; NUMBER	The neonatal Fc receptor (FcRn) plays key roles in IgG and albumin homeostasis, maternal IgG transport, and antigen presentation of IgG-opsonized antigens. Previously, we reported that transgenic (Tg) mice that overexpress bovine FcRn (bFcRn) have augmented T-dependent humoral immune response with increased IgG protection, higher level of antigen-specific antibodies, greater number of antigen-specific B cells, and effective immune response even against weakly immunogenic epitopes. In this study we analyzed the diversity of the humoral immune response of bFcRn Tg mice, using a length distribution analysis (spectratyping) and next generation sequencing (NGS) of the immunoglobulin heavy chain variable regions. Our analysis showed that in response to immunization with ovalbumin or transfected cells that expressed a unique membrane protein, our Tg animals developed a more diverse plasma cell repertoire than controls, which manifested in greater numbers of different clones, and clusters with fewer highly expanded large clones, as identified by the variable region (CDR3) of the immunoglobulin heavy chain. The increased antibody diversity in Tg mice after immunization was observed at both IgM and IgG levels, indicating that the increased humoral immune diversity in Tg mice is due to a higher number of both activated, antigen-specific naive and isotype switched B cells. We thus demonstrated that the BCR repertoire of the immunized bFcRn Tg animals is more diverse compared to wild type mice, which likely makes these Tg mice a better choice for monoclonal antibody production against challenging antigens, including the extracellular regions of cell membrane proteins.	[Szikora, Bence; Marx, Anita; Kacskovics, Imre] Eotvos Lorand Univ, Inst Biol, Dept Immunol, Budapest, Hungary; [Jani, Peter K.; Kacskovics, Imre] ImmunoGenes Ltd, Budakeszi, Hungary; [Pipek, Orsolya; Csabai, Istvan] Eotvos Lorand Univ, Inst Phys, Dept Phys Complex Syst, Budapest, Hungary; [Mueller, Viktor] Eotvos Lorand Univ, Inst Biol, Dept Plant Systemat Ecol & Theoret Biol, Budapest, Hungary	Eotvos Lorand University; Eotvos Lorand University; Eotvos Lorand University	Kacskovics, I (corresponding author), Eotvos Lorand Univ, Inst Biol, Dept Immunol, Budapest, Hungary.; Kacskovics, I (corresponding author), ImmunoGenes Ltd, Budakeszi, Hungary.	imre.kacskovics@ttk.elte.hu	Szikora, Bence/AAG-3544-2021	Marx, Anita/0000-0001-8969-5766; Szikora, Bence/0000-0002-0766-5684	National Research, Development and Innovation Fund of Hungary [FIEK_16-1-2016-0005, VEKOP-2.3.3-15-2017-00021]	National Research, Development and Innovation Fund of Hungary	Project no. FIEK_16-1-2016-0005 and VEKOP-2.3.3-15-2017-00021 have been implemented with the support provided from the National Research, Development and Innovation Fund of Hungary.	Ademokun A, 2011, AGING CELL, V10, P922, DOI 10.1111/j.1474-9726.2011.00732.x; Agarwal A, 1996, J IMMUNOL, V157, P2779; Baker K, 2014, FRONT IMMUNOL, V5, DOI [10.3389/fimmu.2014.00408, 10.3389/fimmu.2014.00664]; Baranyi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076839; Bender B, 2007, TRANSGENIC RES, V16, P613, DOI 10.1007/s11248-007-9108-9; BRAMBELL FW, 1969, P NUTR SOC, V28, P35, DOI 10.1079/PNS19690007; BRAMBELL FW, 1964, NATURE, V203, P1352, DOI 10.1038/2031352a0; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Cervenak J, 2015, IMMUNOL REV, V268, P269, DOI 10.1111/imr.12364; Cervenak J, 2011, J IMMUNOL, V186, P959, DOI 10.4049/jimmunol.1000353; Chaaya N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50714-y; Csardi G., 2006, INTERJOURNAL COMPLEX, V1695, P5; Dudok B, 2015, NAT NEUROSCI, V18, P75, DOI 10.1038/nn.3892; Even J, 1996, HUMAN ANTIGEN T CELL, P162; Foreman AL, 2008, AUTOIMMUNITY, V41, P80, DOI 10.1080/08916930701619656; Galson JD, 2015, EBIOMEDICINE, V2, P2070, DOI 10.1016/j.ebiom.2015.11.034; Georgiou G, 2014, NAT BIOTECHNOL, V32, P158, DOI 10.1038/nbt.2782; Greiff V, 2014, BMC IMMUNOL, V15, DOI 10.1186/s12865-014-0040-5; Hutchings CJ, 2010, MABS-AUSTIN, V2, P594, DOI 10.4161/mabs.2.6.13420; JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116; Lemos APC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028869; Li R, 2020, SCI CHINA LIFE SCI, V63, P1240, DOI 10.1007/s11427-019-9576-2; MagurranAE, 2004, MEASURING BIOL DIVER; Miqueu P, 2007, MOL IMMUNOL, V44, P1057, DOI 10.1016/j.molimm.2006.06.026; Muller DJ, 2019, J LEUKOCYTE BIOL, V105, P531, DOI 10.1002/JLB.2AB0218-076RR; Rettig TA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190982; RODEWALD R, 1984, J CELL BIOL, V99, pS159, DOI 10.1083/jcb.99.1.159s; Rohatgi S, 2008, J IMMUNOL METHODS, V339, P205, DOI 10.1016/j.jim.2008.09.017; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Schneider Z, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00357; Shi B, 2014, THEOR BIOL MED MODEL, V11, DOI 10.1186/1742-4682-11-30; Shugay M, 2014, NAT METHODS, V11, P653, DOI [10.1038/nmeth.2960, 10.1038/NMETH.2960]; Simchoni N, 2015, J IMMUNOL, V194, P3035, DOI 10.4049/jimmunol.1402690; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Six A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00413; Tabibian-Keissar H, 2016, EUR J IMMUNOL, V46, P480, DOI 10.1002/eji.201545586; Tak PP, 2017, ANN RHEUM DIS, V76, P1924, DOI 10.1136/annrheumdis-2017-211351; Vaeth M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14714; Vegh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036286; Vegh A, 2011, MABS-AUSTIN, V3, P173, DOI 10.4161/mabs.3.2.14462; von Boehmer L, 2016, NAT PROTOC, V11, P1908, DOI 10.1038/nprot.2016.102; Ward ES, 2009, ADV IMMUNOL, V103, P77, DOI 10.1016/S0065-2776(09)03004-1; Weinstein JA, 2009, SCIENCE, V324, P807, DOI 10.1126/science.1170020; Yaari G, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0243-2; Yan Q, 2019, INT J MOL MED, V43, P243, DOI 10.3892/ijmm.2018.3946	46	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 21	2020	11								1887	10.3389/fimmu.2020.01887	http://dx.doi.org/10.3389/fimmu.2020.01887			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM7TH	32973781	Green Published, gold			2022-12-18	WOS:000568296400001
J	Wu, CY; Du, XY; Tang, LL; Wu, JH; Zhao, W; Guo, XK; Liu, DY; Hu, W; Helmby, H; Chen, GJ; Wang, ZJ				Wu, Chenyun; Du, Xinyue; Tang, Lili; Wu, Jianhua; Zhao, Wei; Guo, Xiaokui; Liu, Dengyu; Hu, Wei; Helmby, Helena; Chen, Guangjie; Wang, Zhaojun			Schistosoma japonicumSjE16.7 Protein Promotes Tumor Development via the Receptor for Advanced Glycation End Products (RAGE)	FRONTIERS IN IMMUNOLOGY			English	Article						schistosome; calcium binding protein; colorectal cancer; RAGE; inflammation	SUPPRESSOR-CELLS; S100 PROTEINS; GLOBAL BURDEN; CANCER; CARCINOGENESIS; INFLAMMATION; MACROPHAGES; INFECTIONS; ROLES; MODEL	Schistosome infection contributes to cancer development, but the mechanisms are still not well-understood. SjE16.7 is an EF-hand calcium-binding protein secreted fromSchistosoma japonicumeggs. It is a neutrophil attractant and macrophage activator and, as such, plays an important role in the inflammatory granuloma response in schistosomiasis. Here, we show that SjE16.7 binds to host cells by interacting with receptors for advanced glycation end products (RAGE). This ligation leads to activation of the NF-kappa B signaling pathway, an increase in the generation of reactive oxygen species, and production of the pro-inflammatory cytokines IL-6 and TNF-alpha. Using a mouse model of colorectal cancer, we demonstrate that intraperitoneal injection of SjE16.7 promotes colorectal cancer progression along with systemic myeloid cell accumulation. Thus, our results identify a new helminth antigen contributing to tumor development in the mammalian host.	[Wu, Chenyun; Du, Xinyue; Wu, Jianhua; Zhao, Wei; Guo, Xiaokui; Chen, Guangjie; Wang, Zhaojun] Shanghai Jiao Tong Univ, Sch Med, Dept Immunol & Microbiol, Shanghai, Peoples R China; [Wu, Chenyun; Guo, Xiaokui; Wang, Zhaojun] Shanghai Jiao Tong Univ, Sch Med, Chinese Ctr Trop Dis Res, Sch Global Hlth, Shanghai, Peoples R China; [Tang, Lili; Liu, Dengyu] Guangxi Med Univ, Dept Basic Med, Nanning, Peoples R China; [Hu, Wei] Fudan Univ, Sch Life Sci, Shanghai, Peoples R China; [Helmby, Helena] London Sch Hyg & Trop Med, Dept Infect Biol, London, England	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Guangxi Medical University; Fudan University; University of London; London School of Hygiene & Tropical Medicine	Chen, GJ; Wang, ZJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Immunol & Microbiol, Shanghai, Peoples R China.; Wang, ZJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Chinese Ctr Trop Dis Res, Sch Global Hlth, Shanghai, Peoples R China.	guangjie_chen@163.com; zjwang@sjtu.edu.cn	Helmby, Helena/ABE-1649-2020; Wang, Zhaojun/GKS-9141-2022	Helmby, Helena/0000-0003-0761-7348; Wang, Zhaojun/0000-0003-2853-1850	innovative research team of high-level local universities in Shanghai; Natural Science Foundation of Shanghai [19ZR1428500]; National Natural Science Foundation of China [81471971, 81971486]	innovative research team of high-level local universities in Shanghai; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by innovative research team of high-level local universities in Shanghai, Natural Science Foundation of Shanghai (19ZR1428500) and National Natural Science Foundation of China (81471971 and 81971486).	Ahmad S, 2018, SEMIN CANCER BIOL, V49, P44, DOI 10.1016/j.semcancer.2017.07.001; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Brindley PJ, 2015, TRENDS CANCER, V1, P174, DOI 10.1016/j.trecan.2015.08.011; Callejas BE, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180935; Chonov Dimitur Chavdarov, 2019, Open Access Maced J Med Sci, V7, P2391, DOI 10.3889/oamjms.2019.589; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Fang Y, 2015, ACTA TROP, V149, P49, DOI 10.1016/j.actatropica.2015.05.016; Fenwick A, 2012, PUBLIC HEALTH, V126, P233, DOI 10.1016/j.puhe.2011.11.015; Goyette J, 2011, AMINO ACIDS, V41, P821, DOI 10.1007/s00726-010-0528-0; Hamid HKS, 2019, AM J TROP MED HYG, V100, P501, DOI 10.4269/ajtmh.18-0807; Heijmans J, 2013, ONCOGENE, V32, P1202, DOI 10.1038/onc.2012.119; Tong HV, 2017, EBIOMEDICINE, V15, P12, DOI 10.1016/j.ebiom.2016.11.034; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Idorn M, 2014, CANCER IMMUNOL IMMUN, V63, P1177, DOI 10.1007/s00262-014-1591-2; Ishida K, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00223; Kierdorf K, 2013, J LEUKOCYTE BIOL, V94, P55, DOI 10.1189/jlb.1012519; Kumari N, 2016, TUMOR BIOL, V37, P11553, DOI 10.1007/s13277-016-5098-7; Leclerc E, 2009, BBA-MOL CELL RES, V1793, P993, DOI 10.1016/j.bbamcr.2008.11.016; Marx J, 2008, SCIENCE, V319, P154, DOI 10.1126/science.319.5860.154; Mayer DA, 2007, ADV PARASIT, V65, P239, DOI 10.1016/S0065-308X(07)65004-0; Montfort A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01818; MOSER D, 1992, MOL BIOCHEM PARASIT, V51, P229, DOI 10.1016/0166-6851(92)90073-S; Murata M, 2018, ENVIRON HEALTH PREV, V23, DOI 10.1186/s12199-018-0740-1; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Palanissami G, 2018, HORM CANCER-US, V9, P295, DOI 10.1007/s12672-018-0342-9; Parker KH, 2015, ADV CANCER RES, V128, P95, DOI 10.1016/bs.acr.2015.04.002; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Ranasinghe SL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52609-4; Riehl A, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-12; Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267; Salim OEH, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-68; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Sinha P, 2008, J IMMUNOL, V181, P4666, DOI 10.4049/jimmunol.181.7.4666; Snider AJ, 2016, METHODS MOL BIOL, V1438, P245, DOI 10.1007/978-1-4939-3661-8_14; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Srikrishna G, 2012, J INNATE IMMUN, V4, P31, DOI 10.1159/000330095; Toyoshima Y, 2019, CANCER IMMUNOL RES, V7, P1944, DOI 10.1158/2326-6066.CIR-18-0766; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; Vennervald BJ, 2009, PARASITE IMMUNOL, V31, P686, DOI 10.1111/j.1365-3024.2009.01163.x; Wu CY, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002703; Young ND, 2012, NAT GENET, V44, P221, DOI 10.1038/ng.1065; Zhao P, 2018, ONCOL LETT, V15, P3820, DOI 10.3892/ol.2018.7735	44	2	4	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 21	2020	11								1767	10.3389/fimmu.2020.01767	http://dx.doi.org/10.3389/fimmu.2020.01767			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM7TO	32973746	Green Published, Green Accepted, gold			2022-12-18	WOS:000568297100001
J	Zarate, MA; Nguyen, LM; De Dios, RK; Zheng, LJ; Wright, CJ				Zarate, Miguel A.; Nguyen, Leanna M.; De Dios, Robyn K.; Zheng, Lijun; Wright, Clyde J.			Maturation of the Acute Hepatic TLR4/NF-kappa B Mediated Innate Immune Response Is p65 Dependent in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						liver; innate immunity; LPS; NF-kappa B; Rela(p65); Nfkb1(p50)	NF-KAPPA-B; ICAM-1 EXPRESSION; P50 HOMODIMERS; HUMAN NEWBORN; ACTIVATION; BINDING; LIVER; PHOSPHORYLATION; PROTEIN; INFLAMMATION	Compared to adults, neonates are at increased risk of infection. There is a growing recognition that dynamic qualitative and quantitative differences in immunity over development contribute to these observations. The liver plays a key role as an immunologic organ, but whether its contribution to the acute innate immune response changes over lifetime is unknown. We hypothesized that the liver would activate a developmentally-regulated acute innate immune response to intraperitoneal lipopolysaccharide (LPS). We first assessed the hepatic expression and activity of the NF-kappa B, a key regulator of the innate immune response, at different developmental ages (p0, p3, p7, p35, and adult). Ontogeny of the NF-kappa B subunits (p65/p50) revealed a reduction inRela(p65) andNfkb1(p105, precursor to p50) gene expression (p0) and p65 subunit protein levels (p0 and p3) vs. older ages. The acute hepatic innate immune response to LPS was associated by the degradation of the NF-kappa B inhibitory proteins (I kappa B alpha and I kappa B beta), and nuclear translocation of the NF-kappa B subunit p50 in all ages, whereas nuclear translocation of the NF-kappa B subunit p65 was only observed in the p35 and adult mouse. Consistent with these findings, we detected NF-kappa B subunit p65 nuclear staining exclusively in the LPS-exposed adult liver compared with p7 mouse. We next interrogated the LPS-induced hepatic expression of pro-inflammatory genes (Tnf,Icam1, Ccl3, andTraf1), and observed a gradually increase in gene expression starting from p0. Confirming our results, hepatic NF-kappa B subunit p65 nuclear translocation was associated with up-regulation of theIcam1gene in the adult, and was not detected in the p7 mouse. Thus, an inflammatory challenge induces an NF-kappa B-mediated hepatic innate immune response activation across all developmental ages, but nuclear translocation of the NF-kappa B subunit p65 and associated induction of pro-inflammatory genes occurred only after the first month of life. Our results demonstrate that the LPS-induced hepatic innate immune response is developmentally regulated by the NF-kappa B subunit p65 in the mouse.	[Zarate, Miguel A.; Nguyen, Leanna M.; De Dios, Robyn K.; Zheng, Lijun; Wright, Clyde J.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Sect Neonatol,Dept Pediat, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Zarate, MA (corresponding author), Univ Colorado, Sch Med, Childrens Hosp Colorado, Sect Neonatol,Dept Pediat, Aurora, CO 80045 USA.	miguel.zarate@cuanschutz.edu			National Institutes of Health [R01-HL132941, R01-HL132941-02S1]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by the National Institutes of Health grants R01-HL132941 (CW) and R01-HL132941-02S1 (MZ).	Adkins B, 2013, IMMUNOL RES, V57, P246, DOI 10.1007/s12026-013-8439-2; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Benedicto A, 2017, ONCOL LETT, V14, P3883, DOI 10.3892/ol.2017.6700; Bernal GM, 2014, AGING-US, V6, P931, DOI 10.18632/aging.100702; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Butler B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01555; Cao SJ, 2006, J BIOL CHEM, V281, P26041, DOI 10.1074/jbc.M602222200; Chelvarajan RL, 2004, J LEUKOCYTE BIOL, V75, P982, DOI 10.1189/jlb.0403179; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cho RL, 2016, AM J PHYSIOL-LUNG C, V310, pL639, DOI 10.1152/ajplung.00109.2014; Christian F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5010012; COCHRAN JB, 1995, SHOCK, V4, P450; Cuenca AG, 2013, AM J PERINAT, V30, P105, DOI 10.1055/s-0032-1333412; Cusumano V, 1997, J INFECT DIS, V176, P168, DOI 10.1086/514019; Dowling DJ, 2014, TRENDS IMMUNOL, V35, P299, DOI 10.1016/j.it.2014.04.007; ESSANI NA, 1995, BIOCHEM BIOPH RES CO, V211, P74, DOI 10.1006/bbrc.1995.1780; Fakler CR, 2000, INFLAMM RES, V49, P63, DOI 10.1007/s000110050560; FARHOOD A, 1995, J LEUKOCYTE BIOL, V57, P368, DOI 10.1002/jlb.57.3.368; FITZGERALD M, 1988, ANN CLIN LAB SCI, V18, P229; Fowler T, 2011, MOL CELL, V44, P348, DOI 10.1016/j.molcel.2011.09.014; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GALE RP, 1987, THYMUS, V10, P45; Gao B, 2008, HEPATOLOGY, V47, P729, DOI 10.1002/hep.22034; Gao ZG, 2009, J BIOL CHEM, V284, P18368, DOI 10.1074/jbc.M109.007260; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gieling RG, 2010, HEPATOLOGY, V51, P922, DOI 10.1002/hep.23385; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Henneke P, 2003, J PERINAT MED, V31, P176, DOI 10.1515/JPM.2003.024; Hentzen ER, 2000, BLOOD, V95, P911, DOI 10.1182/blood.V95.3.911.003k36_911_920; Hodyl NA, 2011, EXPERT REV CLIN IMMU, V7, P579, DOI [10.1586/eci.11.51, 10.1586/ECI.11.51]; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kassed CA, 2002, EXP NEUROL, V176, P277, DOI 10.1006/exnr.2002.7967; Kawagoe T, 2008, NAT IMMUNOL, V9, P684, DOI 10.1038/ni.1606; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kohda A, 2016, J BIOL CHEM, V291, P20739, DOI 10.1074/jbc.M116.719302; Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014; Krappmann D, 1997, IMMUNOBIOLOGY, V198, P3, DOI 10.1016/S0171-2985(97)80022-8; Le Rouzic V, 2011, INFLAMMATION, V34, P576, DOI 10.1007/s10753-010-9265-5; Levy O, 2005, J ENDOTOXIN RES, V11, P113, DOI 10.1179/096805105X37376; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Levy O, 2014, NEONATOLOGY, V105, P136, DOI 10.1159/000356035; Lim CA, 2007, MOL CELL, V27, P622, DOI 10.1016/j.molcel.2007.06.038; Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; MANCUSO G, 1994, INFECT IMMUN, V62, P2748, DOI 10.1128/IAI.62.7.2748-2753.1994; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; McKenna S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02210; McKenna S, 2016, J INNATE IMMUN, V8, P386, DOI 10.1159/000445541; Mebius RE, 2001, J IMMUNOL, V166, P6593, DOI 10.4049/jimmunol.166.11.6593; Morein B, 2002, VET IMMUNOL IMMUNOP, V87, P207, DOI 10.1016/S0165-2427(02)00078-8; Naito M, 1997, MICROSC RES TECHNIQ, V39, P350, DOI 10.1002/(SICI)1097-0029(19971115)39:4<350::AID-JEMT5>3.0.CO;2-L; NAITO M, 1990, J LEUKOCYTE BIOL, V48, P27, DOI 10.1002/jlb.48.1.27; Nakagaki BN, 2018, J HEPATOL, V69, P1294, DOI 10.1016/j.jhep.2018.08.018; Nguyen L, 2019, INNATE IMMUN-LONDON, V25, P144, DOI 10.1177/1753425918823900; O'Shea JM, 2008, BIOCHEM SOC T, V36, P603, DOI 10.1042/BST0360603; Ou JH, 1997, NITRIC OXIDE-BIOL CH, V1, P404, DOI 10.1006/niox.1997.0136; Papa S, 2009, BIOL CHEM, V390, P965, DOI 10.1515/BC.2009.111; Paxian S, 2002, GASTROENTEROLOGY, V122, P1853, DOI 10.1053/gast.2002.33651; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; PORTER PJ, 1966, J LAB CLIN MED, V68, P455; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rahman Arshad, 2011, Proc Am Thorac Soc, V8, P497, DOI 10.1513/pats.201101-009MW; Rana SA, 2012, HORM BEHAV, V62, P228, DOI 10.1016/j.yhbeh.2012.03.015; Roger T, 2016, P NATL ACAD SCI USA, V113, pE997, DOI 10.1073/pnas.1514018113; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Schreiber J, 2006, P NATL ACAD SCI USA, V103, P5899, DOI 10.1073/pnas.0510996103; Schwabe RF, 2006, GASTROENTEROLOGY, V130, P1886, DOI 10.1053/j.gastro.2006.01.038; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Strunk T, 2011, J MATERN-FETAL NEO M, V24, P25, DOI 10.3109/14767058.2010.482605; Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52; TAKEI F, 1985, J IMMUNOL, V134, P1403; Tang T, 2010, J BIOL CHEM, V285, P4637, DOI 10.1074/jbc.M109.068007; Trinh DV, 2008, J MOL BIOL, V379, P122, DOI 10.1016/j.jmb.2008.03.060; UHR JW, 1962, J EXP MED, V115, P685, DOI 10.1084/jem.115.4.685; Wang HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Wilson CL, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms7818, 10.1038/ncomms9901]; Wynn JL, 2008, BLOOD, V112, P1750, DOI 10.1182/blood-2008-01-130500; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yang L, 2003, J BIOL CHEM, V278, P30881, DOI 10.1074/jbc.M212216200; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; ZELLER WP, 1991, SURG GYNECOL OBSTET, V173, P375; Zhao J, 2008, P NATL ACAD SCI USA, V105, P7528, DOI 10.1073/pnas.0800152105; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	94	2	3	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 21	2020	11								1892	10.3389/fimmu.2020.01892	http://dx.doi.org/10.3389/fimmu.2020.01892			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM5VF	32973783	gold, Green Published			2022-12-18	WOS:000568163900001
J	Abreu, CB; Bordon, KCF; Cerni, FA; Oliveira, IS; Balenzuela, C; Alexandre-Silva, GM; Zoccal, KF; Reis, MB; Wiezel, GA; Peigneur, S; Pinheiro, EL; Tytgat, J; Cunha, TM; Quinton, L; Faccioli, LH; Arantes, EC; Zottich, U; Pucca, MB				Abreu, Caio B.; Bordon, Karla C. F.; Cerni, Felipe A.; Oliveira, Isadora S.; Balenzuela, Carla; Alexandre-Silva, Gabriel M.; Zoccal, Karina F.; Reis, Mouzarllem B.; Wiezel, Gisele A.; Peigneur, Steve; Pinheiro-Junior, Ernesto L.; Tytgat, Jan; Cunha, Tiago M.; Quinton, Loic; Faccioli, Lucia H.; Arantes, Eliane C.; Zottich, Umberto; Pucca, Manuela B.			Pioneering Study onRhopalurus crassicaudaScorpion Venom: Isolation and Characterization of the Major Toxin and Hyaluronidase	FRONTIERS IN IMMUNOLOGY			English	Article						scorpion venom; Rhopalurus crassicauda; toxin; electrophysiology; nociception; neurotoxin; pro-inflammatory toxin	TITYUS-SERRULATUS VENOM; ELECTROPHYSIOLOGICAL CHARACTERIZATION; PHOSPHOLIPASE A(2); SCORPION; RHOPALURUS; PURIFICATION; PROTEINS; INSIGHTS; CHANNEL; TS6	Scorpionism is responsible for most accidents involving venomous animals in Brazil, which leads to severe symptoms that can evolve to death. Scorpion venoms consist of complexes cocktails, including peptides, proteins, and non-protein compounds, making separation and purification procedures extremely difficult and time-consuming. Scorpion toxins target different biological systems and can be used in basic science, for clinical, and biotechnological applications. This study is the first to explore the venom content of the unexplored scorpion speciesRhopalurus crassicauda, which inhabits exclusively the northernmost state of Brazil, named Roraima, and southern region of Guyana. Here, we pioneer the fractionation of theR. crassicaudavenom and isolated and characterized a novel scorpion beta-neurotoxin, designated Rc1, and a monomeric hyaluronidase.R. crassicaudavenom and Rc1 (6,882 Da) demonstrated pro-inflammatory activitiesin vitroand a nociceptive responsein vivo. Moreover, Rc1 toxin showed specificity for activating Na(v)1.4, Na(v)1.6, and BgNa(v)1 voltage-gated ion channels. This study also represents a new perspective for the treatment of envenomings in Roraima, since the Brazilian scorpion and arachnid antivenoms were not able to recognizeR. crassicaudavenom and its fractions (with exception of hyaluronidase). Our work provides useful insights for the first understanding of the painful sting and pro-inflammatory effects associated withR. crassicaudaenvenomings.	[Abreu, Caio B.; Balenzuela, Carla; Alexandre-Silva, Gabriel M.; Zottich, Umberto; Pucca, Manuela B.] Univ Fed Roraima, Med Sch, Boa Vista, Parana, Brazil; [Bordon, Karla C. F.; Cerni, Felipe A.; Oliveira, Isadora S.; Wiezel, Gisele A.; Arantes, Eliane C.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept BioMol Sci, Sao Paulo, Brazil; [Zoccal, Karina F.; Reis, Mouzarllem B.] Barao Maua Univ Ctr, Ribeirao Preto, Brazil; [Reis, Mouzarllem B.; Faccioli, Lucia H.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Sao Paulo, Brazil; [Peigneur, Steve; Pinheiro-Junior, Ernesto L.; Tytgat, Jan] Katholieke Univ Leuven, Toxicol & Pharmacol, Leuven, Belgium; [Cunha, Tiago M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Sao Paulo, Brazil; [Quinton, Loic] Univ Liege, MolSys Res Unit, Mass Spectrometry Lab, Liege, Belgium	Universidade Federal de Roraima; Universidade de Sao Paulo; Universidade de Sao Paulo; KU Leuven; Universidade de Sao Paulo; University of Liege	Pucca, MB (corresponding author), Univ Fed Roraima, Med Sch, Boa Vista, Parana, Brazil.	manu.pucca@ufrr.br	Bordon, Karla/AEZ-0436-2022; Faccioli, Lúcia Helena/AGH-5297-2022; Pinheiro-Junior, Ernesto/I-9481-2014; Oliveira, Isadora/U-7727-2019; Bordon, Karla C. F./G-7393-2012; Reis, Mouzarllem Barros/O-7635-2017; Pucca, Manuela Berto/D-7899-2012	Bordon, Karla/0000-0001-6540-2295; Faccioli, Lúcia Helena/0000-0002-4999-8305; Pinheiro-Junior, Ernesto/0000-0001-6050-8285; Oliveira, Isadora/0000-0002-2036-1191; Bordon, Karla C. F./0000-0001-6540-2295; Reis, Mouzarllem Barros/0000-0002-7074-6532; Pucca, Manuela Berto/0000-0003-2594-7068; Alexandre Silva, Gabriel Melo/0000-0002-5547-5754	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, The National Council for Scientific and Technological Development) [307155/2017-0, 306479/2017-6]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001, 88881.186830/2018-01]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation) [2017/04724-4, 2019/10173-6, 2017/14035-1, 2017/03580-9, 2018/21233-7, 2016/04761-4, 2017/02314/3, 2017/00586-6]; F.W.O. Vlaanderen [GOC2319N, GOA4919N]; BOF, KU Leuven [CELSA/17/047]; KU Leuven fund [PDM/19/164]; Programa Institucional de Apoio a Pesquisa (Pro-Pesquisa-UFRR)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, The National Council for Scientific and Technological Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); F.W.O. Vlaanderen(FWO); BOF, KU Leuven(KU Leuven); KU Leuven fund; Programa Institucional de Apoio a Pesquisa (Pro-Pesquisa-UFRR)	We thank Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, The National Council for Scientific and Technological Development, grant nos. 307155/2017-0 and 306479/2017-6); the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES, Finance Code 001, scholarship no. 88881.186830/2018-01 to EP-J); and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation, grant nos. 2017/04724-4 and 2019/10173-6 and scholarships no. 2017/14035-1 to FC, nos. 2017/03580-9 and 2018/21233-7 to IO, no. 2016/04761-4 to EP-J, no. 2017/02314/3 to MR, and no. 2017/00586-6 to GW). JT was funded by GOC2319N and GOA4919N (F.W.O. Vlaanderen) and CELSA/17/047 (BOF, KU Leuven). SP is a postdoctoral fellow supported by KU Leuven funding (PDM/19/164). MP acknowledges funding support from the Programa Institucional de Apoio a Pesquisa (Pro-Pesquisa-UFRR).	Abbas A.K., 2018, CELL MOL IMMUNOL; Ahmadi S, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050118; Batista CVF, 2007, COMP BIOCHEM PHYS C, V146, P147, DOI 10.1016/j.cbpc.2006.12.004; BJORK W, 1963, J BIOL CHEM, V238, P2487; Boldrini-Franca J, 2017, BBA-GEN SUBJECTS, V1861, P824, DOI 10.1016/j.bbagen.2016.12.022; Bordon K.C.F., 2015, SCORPION VENOMS TOXI, V4, P411, DOI [10.1007/, DOI 10.1007/978-94-007-6404-0_7]; Bordon KCF, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0042-7; Cardoso FC, 2018, BRIT J PHARMACOL, V175, P2138, DOI 10.1111/bph.13962; Cerni FA, 2014, TOXINS, V6, P892, DOI 10.3390/toxins6030892; Cerni FA, 2016, PEPTIDES, V80, P9, DOI 10.1016/j.peptides.2015.06.004; CEVALLOS MA, 1992, TOXICON, V30, P925, DOI 10.1016/0041-0101(92)90392-I; Chippaux J P, 2006, Med Trop (Mars), V66, P215; Chippaux JP, 2012, DRUG DES DEV THER, V6, P165, DOI 10.2147/DDDT.S24754; Cologna CT, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-018-0141-3; Conde R, 1999, FEBS LETT, V460, P447, DOI 10.1016/S0014-5793(99)01392-7; Cupo P, 2015, REV SOC BRAS MED TRO, V48, P639, DOI 10.1590/0037-8682-0387-2015; Cupo P, 2015, REV SOC BRAS MED TRO, V48, P642, DOI 10.1590/0037-8682-0237-2015; de Oliveira GH, 2016, J VENOM ANIM TOXINS, V22, DOI 10.1186/s40409-016-0081-8; Dhananjaya BL, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1, DOI 10.1134/S0006297910010013; Diaz-Garcia A, 2019, IRAN J BASIC MED SCI, V22, P759, DOI 10.22038/ijbms.2019.33308.7956; Diaz-Garcia Alexis, 2015, J Venom Res, V6, P11; Dib-Hajj SD, 2009, BRAIN RES REV, V60, P65, DOI 10.1016/j.brainresrev.2008.12.005; DICAPORIACCO L, 1947, MONIT ZOOL ITAL, V56, P20; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Esposito LA, 2017, B AM MUS NAT HIST, P1; Fox JW, 2008, FEBS J, V275, P3016, DOI 10.1111/j.1742-4658.2008.06466.x; Fox JW, 2013, TOXICON, V62, P75, DOI 10.1016/j.toxicon.2012.09.009; Fukuhara YDM, 2003, TOXICON, V41, P49, DOI 10.1016/S0041-0101(02)00208-8; Garcia-Gomez BI, 2011, TOXICON, V58, P18, DOI 10.1016/j.toxicon.2011.04.011; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; Incamnoi P, 2013, TOXICON, V61, P62, DOI 10.1016/j.toxicon.2012.10.012; Isbister GK, 2003, TOXICON, V41, P877, DOI 10.1016/S0041-0101(03)00065-5; Kendellen MF, 2014, ONCOGENE, V33, P1297, DOI 10.1038/onc.2013.64; Laustsen AH, 2018, TOXICON, V146, P151, DOI 10.1016/j.toxicon.2018.03.004; Lenarducci Ângelo Ricardo I. P., 2005, Biota Neotrop., V5, P173, DOI 10.1590/S1676-06032005000200015; Louati H, 2013, TOXICON, V72, P133, DOI 10.1016/j.toxicon.2013.06.017; Lourenco WR, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-017-0138-3; Lourenco Wilson R., 1997, Biogeographica (Paris), V73, P181; Mikaelian AG, 2020, DRUG DES DEV THER, V14, P881, DOI 10.2147/DDDT.S231008; Ministerio da Saude do Brasil, 2020, DATASUS DOENC AGR NO; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nelsen DR, 2014, BIOL REV, V89, P450, DOI 10.1111/brv.12062; Oliveira-Mendes BBR, 2018, BIORXIV PREPRINT, DOI [10.1101/487298, DOI 10.1101/487298]; Peigneur S, 2019, FASEB J, V33, P3693, DOI 10.1096/fj.201801909R; Polikarpov I, 1999, J MOL BIOL, V290, P175, DOI 10.1006/jmbi.1999.2868; Pucca MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02090; Pucca MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01598; Pucca MB, 2015, BIOCHIMIE, V115, P8, DOI 10.1016/j.biochi.2015.04.010; Pucca MB, 2015, TOXINS, V7, P2534, DOI 10.3390/toxins7072534; Pucca MB, 2016, TOXICON, V119, P244, DOI 10.1016/j.toxicon.2016.06.014; Pucca MB, 2015, TOXICON, V108, P272, DOI 10.1016/j.toxicon.2015.10.015; Pucca MB, 2014, TOXICON, V90, P326, DOI 10.1016/j.toxicon.2014.08.064; Pucca MB, 2012, J IMMUNOTOXICOL, V9, P173, DOI 10.3109/1547691X.2011.649220; Pucca MB, 2014, TOXINOLOGY, P1, DOI 10.1007/978-94-007-6647-1_20-1; Torrez PPQ, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0350-2018; RAMANAIAH M, 1990, BIOCHEM INT, V20, P931; RAMANAIAH M, 1990, BIOCHEM INT, V20, P301; Reis MB, 2019, TOXICON, V167, P174, DOI 10.1016/j.toxicon.2019.06.219; de Oliveira-Mendes BBR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007048; ROCHAT H, 1970, FEBS LETT, V10, P349, DOI 10.1016/0014-5793(70)80470-7; Rodriguez-Ravelo R, 2014, PEPTIDES, V53, P42, DOI 10.1016/j.peptides.2013.10.010; Rodriguez-Ravelo R, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-13; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz EF, 2008, TOXICON, V51, P1499, DOI 10.1016/j.toxicon.2008.03.029; Schwartz EF, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-119; Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161; Smith JJ, 2013, CELL MOL LIFE SCI, V70, P3665, DOI 10.1007/s00018-013-1315-3; Souza WMP, 2019, TCR, V3, P1, DOI [10.24966/TCR-3735/100011, DOI 10.24966/TCR-3735/100011]; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Teruel Rolando, 2008, Euscorpius, V70, P1; Utkin Yuri N, 2015, World J Biol Chem, V6, P28, DOI 10.4331/wjbc.v6.i2.28; Uzawa S., 1932, J BIOCH, V15, P1, DOI [10.1093/oxfordjournals.jbchem.a125167, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A125167]; Valdez-Cruz NA, 2004, EUR J BIOCHEM, V271, P1453, DOI 10.1111/j.1432-1033.2004.04047.x; Valerio A. A., 2002, Journal of Protein Chemistry, V21, P495, DOI 10.1023/A:1022414503995; Verano-Braga T, 2013, J PROTEOME RES, V12, P3460, DOI 10.1021/pr4003068; Williams HF, 2019, TOXINS, V11, DOI 10.3390/toxins11060363; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886; Zoccal KF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10760; Zoccal KF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088174; Zoccal KF, 2013, TOXICON, V61, P1, DOI 10.1016/j.toxicon.2012.10.002; Zoccal KF, 2011, TOXICON, V57, P1101, DOI 10.1016/j.toxicon.2011.04.017	81	2	3	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2020	11								2011	10.3389/fimmu.2020.02011	http://dx.doi.org/10.3389/fimmu.2020.02011			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM7LV	32973807	gold, Green Published			2022-12-18	WOS:000568276900001
J	Cai, SZ; Chen, Y; Lin, SY; Ye, C; Zheng, F; Dong, LL				Cai, Shaozhe; Chen, Yu; Lin, ShengYan; Ye, Cong; Zheng, Fang; Dong, Lingli			Multiple Processes May Involve in the IgG4-RD Pathogenesis: An Integrative Study via Proteomic and Transcriptomic Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						IgG4-related disease (IgG4-RD); proteomic analysis; WGCNA (Weighted Gene Co-expression Network Analyses); enrichment analysis; IgG4-RD pathogenesis	IGG4-RELATED DISEASE; AUTOIMMUNE PANCREATITIS; IMMUNE-RESPONSES; T-CELLS; PLATELETS; EXPANSION; BIOMARKER; PATHWAY; SYSTEM	Immunoglobulin G4-related disease (IgG4-RD) is a newly defined disease entity, while the exact pathogenesis is still not clear. Identifying the characters of IgG4-RD in proteomic and transcriptomic aspects will be critical to investigate the potential pathogenic mechanisms of IgG4-RD. We performed proteomic analysis realized with iTRAQ technique for serum samples from eight treatment-naive IgG4-RD patients and eight healthy volunteers, and tissue samples from two IgG4-RD patients and two non-IgG4-RD patients. Transcriptomic data (GSE40568 and GSE66465) was obtained from the GEO Dataset for validation. The weighted correlation network analysis (WGCNA) was applied to detect the gene modules correlated with IgG4-RD. KEGG pathway analysis was used to investigate pathways enriched in IgG4-RD samples. As a result, a total of 980 differentially expressed proteins (DEPs) in tissue and 94 DEPs in serum were identified between IgG4-RD and control groups. Three hundred fifty-four and two hundred forty-seven genes that most correlated with IgG4-RD were detected by WGCNA analysis in tissue and PBMC, respectively. We also found that DEPs in IgG4-RD samples were enriched in several immune-related activities including bacterial/viral infections and platelet activation as well as some immune related signaling pathways. In conclusion, we identified multiple processes/factors and several signaling pathways that may involve in the IgG4-RD pathogenesis, and found out some potential therapeutic targets for IgG4-RD.	[Cai, Shaozhe; Chen, Yu; Lin, ShengYan; Ye, Cong; Dong, Lingli] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Rheumatol & Immunol, Tongji Med Coll, Wuhan, Peoples R China; [Zheng, Fang] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Immunol, Tongji Med Coll, Wuhan, Peoples R China; [Zheng, Fang] Chinese Acad Med Sci, NHC Key Lab Organ Transplantat, Minist Educ, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College	Dong, LL (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Rheumatol & Immunol, Tongji Med Coll, Wuhan, Peoples R China.; Zheng, F (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Immunol, Tongji Med Coll, Wuhan, Peoples R China.; Zheng, F (corresponding author), Chinese Acad Med Sci, NHC Key Lab Organ Transplantat, Minist Educ, Wuhan, Peoples R China.	zhengfangtj@hust.edu.cn; tjhdongll@163.com		Cai, Shaozhe/0000-0001-6778-9745	National Natural Science Foundation of China (NSFC) [81771754, 31670876]; Tongji Hospital Clinical Research Flagship Program [2019CR206]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Tongji Hospital Clinical Research Flagship Program	This study was supported by grants from the National Natural Science Foundation of China (NSFC Nos. 81771754 and 31670876), and Tongji Hospital Clinical Research Flagship Program (2019CR206).	Al-Mujaini Abdullah, 2018, Oman Med J, V33, P97, DOI 10.5001/omj.2018.20; Asada M, 2010, PANCREAS, V39, P224, DOI 10.1097/MPA.0b013e3181bab5e2; Aslam B, 2017, J CHROMATOGR SCI, V55, P182, DOI 10.1093/chromsci/bmw167; Beyer G, 2014, UNITED EUR GASTROENT, V2, P165, DOI 10.1177/2050640614532457; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Chen Y, 2018, ARTHRITIS RHEUMATOL, V70, P1853, DOI 10.1002/art.40556; Chuang HC, 2016, ADV IMMUNOL, V129, P277, DOI 10.1016/bs.ai.2015.09.006; Della-Torre E, 2015, ANN RHEUM DIS, V74, P2236, DOI 10.1136/annrheumdis-2014-205799; Ebbo M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183844; Flannagan RS, 2012, ANNU REV PATHOL-MECH, V7, P61, DOI 10.1146/annurev-pathol-011811-132445; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Habets KLL, 2013, EUR J CLIN INVEST, V43, P746, DOI 10.1111/eci.12101; Hart PA, 2013, GUT, V62, P1771, DOI 10.1136/gutjnl-2012-303617; Havenar-Daughton C, 2016, P NATL ACAD SCI USA, V113, P2702, DOI 10.1073/pnas.1520112113; Heeringa JJ, 2018, J ALLERGY CLIN IMMUN, V141, P1831, DOI 10.1016/j.jaci.2017.07.024; Herter JM, 2014, J THROMB HAEMOST, V12, P1764, DOI 10.1111/jth.12730; Higgs BW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17602-9; Jones GW, 2016, IMMUNOLOGY, V147, P141, DOI 10.1111/imm.12554; Kaplanski G, 2018, IMMUNOL REV, V281, P138, DOI 10.1111/imr.12616; Khosroshahi A, 2015, ARTHRITIS RHEUMATOL, V67, P1688, DOI 10.1002/art.39132; Kiyama K, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0584-4; Lam FW, 2015, COMPR PHYSIOL, V5, P1265, DOI 10.1002/cphy.c140074; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Li J, 2013, PHARMACOL THERAPEUT, V138, P441, DOI 10.1016/j.pharmthera.2013.03.003; Lim PS, 2015, IMMUNOLOGY, V146, P508, DOI 10.1111/imm.12510; Lin W, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1231-2; Maehara T, 2012, ANN RHEUM DIS, V71, P2011, DOI 10.1136/annrheumdis-2012-201477; Mahajan VS, 2014, ANNU REV PATHOL-MECH, V9, P315, DOI 10.1146/annurev-pathol-012513-104708; Mattoo H, 2017, AUTOIMMUNITY, V50, P19, DOI 10.1080/08916934.2017.1280029; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Moriyama M, 2016, IGG4 RELATED DIS, P75, DOI [10.1007/82_2016_40, DOI 10.1007/82_2016_40]; Nakajima A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126582; Pasoto SG, 2014, CURR OPIN RHEUMATOL, V26, P528, DOI 10.1097/BOR.0000000000000084; Rawlings DJ, 2017, NAT REV IMMUNOL, V17, P421, DOI 10.1038/nri.2017.24; Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956; Shiokawa M, 2016, GUT, V65, P1322, DOI 10.1136/gutjnl-2015-310336; Shirakashi M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28405-x; Stone JH, 2012, ARTHRITIS RHEUM-US, V64, P3061, DOI 10.1002/art.34593; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Tsuboi H, 2014, ARTHRITIS RHEUMATOL, V66, P2892, DOI 10.1002/art.38748; Tsuboi H, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3924; Umehara H, 2012, MOD RHEUMATOL, V22, P21, DOI 10.1007/s10165-011-0571-z; Wallace ZS, 2015, ANN RHEUM DIS, V74, P190, DOI 10.1136/annrheumdis-2014-205233; Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981; Wen B, 2014, PROTEOMICS, V14, P2280, DOI 10.1002/pmic.201300361; Yoshida H, 2015, ANNU REV IMMUNOL, V33, P417, DOI 10.1146/annurev-immunol-032414-112134; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang YL, 2017, CANCER BIOL MED, V14, P90, DOI 10.20892/j.issn.2095-3941.2016.0086; Zhu L, 2014, J THROMB HAEMOST, V12, P1156, DOI 10.1111/jth.12612	50	2	2	5	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 20	2020	11								1795	10.3389/fimmu.2020.01795	http://dx.doi.org/10.3389/fimmu.2020.01795			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM9JO	32973752	Green Published, gold			2022-12-18	WOS:000568407000001
J	Petrilli, JD; Muller, I; Araujo, LE; Cardoso, TM; Carvalho, LP; Barros, BC; Teixeira, M; Arruda, S; Riley, LW; Queiroz, A				Petrilli, Jessica D.; Mueller, Igor; Araujo, Luana E.; Cardoso, Thiago M.; Carvalho, Lucas P.; Barros, Bruna C.; Teixeira, Mauricio; Arruda, Sergio; Riley, Lee W.; Queiroz, Adriano			Differential Host Pro-Inflammatory Response to Mycobacterial Cell Wall Lipids Regulated by theMce1Operon	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; lipid-induced responses; mce1 operon; mycobacterial cell wall lipid; inflammation	NUCLEAR RECEPTORS; MYCOLIC ACIDS; PPAR-GAMMA; T-CELLS; TUBERCULOSIS; INHIBITION; MUTANT; ALPHA; MICE; TR4	The cell wall of wild-type (WT)Mycobacterium tuberculosis(Mtb), an etiologic agent of tuberculosis (TB) and a Mtb strain disrupted in a 13-gene operonmce1(Delta mce1) varies by more than 400 lipid species. Here, we examined Mtb lipid-induced response in murine macrophage, as well as in human T-cell subpopulations in order to gain an insight into how changes in cell wall lipid composition may modulate host immune response. Relative to WT Mtb cell wall lipids, the non-polar lipid extracts from Delta mce1 enhanced the mRNA expression of lipid-sense nuclear receptors TR4 and PPAR-gamma and dampened the macrophage expression of genes encoding TNF-alpha, IL-6, and IL-1 beta. Relative to untreated control, WT lipid-pre-stimulated macrophages from healthy individuals induced a higher level of CD4(-)CD8(-)double negative T-cells (DN T-cells) producing TNF-alpha. Conversely, compared to WT, stimulation with Delta mce1 lipids induced higher mean fluorescence intensity (MFI) in IL-10-producing DN T cells. Mononuclear cells from TB patients stimulated with WT Mtb lipids induced an increased production of TNF-alpha by CD8(+)lymphocytes. Taken together, these observations suggest that changes inmce1operon expression during a course of infection may serve as a strategy by Mtb to evade the host pro-inflammatory responses.	[Petrilli, Jessica D.; Mueller, Igor; Araujo, Luana E.; Barros, Bruna C.; Arruda, Sergio; Queiroz, Adriano] Inst Goncalo Moniz, Lab Avancado Saude Publ, Salvador, BA 40296, Brazil; [Cardoso, Thiago M.; Carvalho, Lucas P.; Teixeira, Mauricio] Inst Goncalo Moniz, Lab Pesquisa Clin, Salvador, BA, Brazil; [Riley, Lee W.] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Queiroz, A (corresponding author), Inst Goncalo Moniz, Lab Avancado Saude Publ, Salvador, BA 40296, Brazil.	adrianoqs@gmail.com	Arruda, Sergio/AAO-3987-2021; Queiroz, Adriano/AAQ-1164-2020	Queiroz, Adriano/0000-0003-0080-6509; Cardoso, Thiago/0000-0002-0074-9789	NIH [FIC R25TW009338]; Research Program for SUS-PPSUS/BA [SUS 0027/2018]; Oswaldo Cruz Foundation/FIOCRUZ; CAPES Ph.D. scholarship; GHES fellowship	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Program for SUS-PPSUS/BA; Oswaldo Cruz Foundation/FIOCRUZ; CAPES Ph.D. scholarship(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); GHES fellowship	This work was supported by NIH FIC R25TW009338 Global Health Equity Scholarsby and in part by the Research Program for SUS-PPSUS/BA [SUS 0027/2018]. JP was a recipient of a Ph.D. fellowship from Oswaldo Cruz Foundation/FIOCRUZ and MT was a recipient of a CAPES Ph.D. scholarship. AQ was a recipient of the GHES fellowship.	Alaynick WA, 2008, MITOCHONDRION, V8, P329, DOI 10.1016/j.mito.2008.02.001; Almeida PE, 2012, PPAR RES, V2012, DOI 10.1155/2012/383829; Forrellad MA, 2014, TUBERCULOSIS, V94, P170, DOI 10.1016/j.tube.2013.12.005; Antonelli LRV, 2006, INFECT IMMUN, V74, P6317, DOI 10.1128/IAI.00890-06; Barral DC, 2007, NAT REV IMMUNOL, V7, P929, DOI 10.1038/nri2191; BEKIERKUNST A, 1969, J BACTERIOL, V100, P95, DOI 10.1128/JB.100.1.95-102.1969; BLOCH H, 1950, J EXP MED, V91, P197, DOI 10.1084/jem.91.2.197; Cantrell SA, 2013, J MICROBIOL, V51, P619, DOI 10.1007/s12275-013-3092-y; Casali N, 2006, J BACTERIOL, V188, P441, DOI 10.1128/JB.188.2.441-449.2006; Casali N, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-60; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dkhar HK, 2014, J IMMUNOL, V193, P295, DOI 10.4049/jimmunol.1400092; Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1; Eoh H, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.84; Galagan JE, 2013, NATURE, V499, P178, DOI 10.1038/nature12337; Gilleron M, 2004, J EXP MED, V199, P649, DOI 10.1084/jem.20031097; Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Korf H, 2009, J CLIN INVEST, V119, P1626, DOI 10.1172/JCI35288; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahajan S, 2012, J IMMUNOL, V188, P5593, DOI 10.4049/jimmunol.1103038; Ojha AK, 2008, MOL MICROBIOL, V69, P164, DOI 10.1111/j.1365-2958.2008.06274.x; PABST MJ, 1988, J IMMUNOL, V140, P634; Pandey AK, 2008, P NATL ACAD SCI USA, V105, P4376, DOI 10.1073/pnas.0711159105; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Queiroz A, 2017, REV SOC BRAS MED TRO, V50, P9, DOI 10.1590/0037-8682-0230-2016; Queiroz A, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv066; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sequeira PC, 2014, PATHOG DIS, V70, P132, DOI 10.1111/2049-632X.12110; Shimono N, 2003, P NATL ACAD SCI USA, V100, P15918, DOI 10.1073/pnas.2433882100; Tornheim JA, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TNMI7-0028-2016; Uchida Y, 2007, CELL MICROBIOL, V9, P1275, DOI 10.1111/j.1462-5822.2006.00870.x; WHO, 2021, GLOB TUB REP; ZHANG L, 1991, J IMMUNOL, V146, P2730	35	2	3	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 18	2020	11								1848	10.3389/fimmu.2020.01848	http://dx.doi.org/10.3389/fimmu.2020.01848			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM2OO	32973761	gold, Green Published			2022-12-18	WOS:000567941500001
J	Warrender, AK; Kelton, W				Warrender, Annmaree K.; Kelton, William			Beyond Allotypes: The Influence of Allelic Diversity in Antibody Constant Domains	FRONTIERS IN IMMUNOLOGY			English	Review						allotypes; Fc receptor; antibody constant domain; antibody alleles; antibody polymorphism; antibody effector functions; heavy chain diversity; immunoglobulin diversity	NEONATAL FC-RECEPTOR; HUMAN IGG1; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN-G; GAMMA RECEPTORS; GENETIC-MARKER; AFFINITY; VARIANTS; CELL; GM	Polymorphic diversity in antibody constant domains has long been defined by allotypic motifs that cross react with the sera of other individuals. Improvements in sequencing technologies have led to the discovery of a large number of new allelic sequences that underlie this diversity. Many of the point mutations lie outside traditional allotypic motifs suggesting they do not elicit immunogenic responses. As antibodies play an important role in immune defense and biotechnology, understanding how this newly resolved diversity influences the function of antibodies is important. This review investigates the current known diversity of antibody alleles at a protein level for each antibody isotype as well as the kappa and lambda light chains. We focus on evidence emerging for how these mutations perturb antibody interactions with antigens and Fc receptors that are critical for function, as well as the influence this might have on the use of antibodies as therapeutics and reagents.	[Warrender, Annmaree K.; Kelton, William] Univ Waikato, Te Huataki Waiora Sch Hlth, Hamilton, New Zealand	University of Waikato	Kelton, W (corresponding author), Univ Waikato, Te Huataki Waiora Sch Hlth, Hamilton, New Zealand.	wkelton@waikato.ac.nz		Kelton, William/0000-0002-5513-6429	Marsden Fund Fast Start award [MFP-UOW1905]	Marsden Fund Fast Start award(Royal Society of New ZealandMarsden Fund (NZ))	This work was made possible by a Marsden Fund Fast Start award MFP-UOW1905 (to WK).	All Us Res Program Investigators, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMsr1809937; Atherton A, 2000, EUR J IMMUNOL, V30, P2540, DOI 10.1002/1521-4141(200009)30:9<2540::AID-IMMU2540>3.3.CO;2-J; Bannas P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01603; Bartelds GM, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3208; Bastida-Corcuera FD, 1999, VET IMMUNOL IMMUNOP, V71, P115, DOI 10.1016/S0165-2427(99)00095-1; Ben Mkaddem S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00811; Bis JC, 2018, MOL PSYCHIATR, P1859; Bradbury A, 2015, NATURE, V518, P27, DOI 10.1038/518027a; Browning SR, 2018, CELL, V173, P53, DOI 10.1016/j.cell.2018.02.031; Calonga-Solis V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01161; Cen SY, 2020, TRANSFUSION, V60, P688, DOI 10.1111/trf.15663; Chen XJ, 2018, SCIENCE, V362, P700, DOI 10.1126/science.aap9310; Dard P, 2001, EUR J HUM GENET, V9, P765, DOI 10.1038/sj.ejhg.5200700; de Taeye SW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00740; Dechavanne C, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002403; Dimitrov JD, 2020, TRENDS IMMUNOL, V41, P379, DOI 10.1016/j.it.2020.03.006; Dugoujon JM, 2004, AM J PHYS ANTHROPOL, V125, P175, DOI 10.1002/ajpa.10405; Giha HA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-306; Giuntini S, 2016, CLIN VACCINE IMMUNOL, V23, P698, DOI 10.1128/CVI.00193-16; Goldberg JL, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000590; Gorski MM, 2016, BLOOD, V127, P2924, DOI 10.1182/blood-2015-12-685735; GRUBB R., 1956, ACTA PATHOL ET MICROBIOL SCAND, V39, P195; Howie HL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94532; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Janda A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00022; Jefferis R., 1998, ENCY IMMUNOLOGY, P74, DOI [10.1006/rwei.1999.0021, DOI 10.1006/RWEI.1999.0021]; Jefferis R, 2009, MABS, V1, P332, DOI 10.4161/mabs.1.4.9122; JOHNSON WE, 1977, CLIN IMMUNOL IMMUNOP, V7, P97, DOI 10.1016/0090-1229(77)90034-4; Jonsson S, 2017, NAT GENET, V49, P1182, DOI 10.1038/ng.3897; Jung ST, 2013, ACS CHEM BIOL, V8, P368, DOI 10.1021/cb300455f; Khatri I., 2020, BIORXIV, V22, P172, DOI [10.1101/2020.04.09.033530, DOI 10.1101/2020.04.09.033530]; KUNKEL HG, 1969, NATURE, V223, P1247, DOI 10.1038/2231247a0; Labrijn AF, 2011, J IMMUNOL, V187, P3238, DOI 10.4049/jimmunol.1003336; Lazar GA, 2006, P NATL ACAD SCI USA, V103, P4005, DOI 10.1073/pnas.0508123103; Lefranc MP, 2015, NUCLEIC ACIDS RES, V43, pD413, DOI 10.1093/nar/gku1056; Lefranc Marie-Paule, 2012, Methods Mol Biol, V882, P635, DOI 10.1007/978-1-61779-842-9_34; Lewis KB, 2009, MOL IMMUNOL, V46, P3488, DOI 10.1016/j.molimm.2009.07.009; Lu JH, 2015, P NATL ACAD SCI USA, V112, P833, DOI 10.1073/pnas.1418812112; Moore GL, 2010, MABS-AUSTIN, V2, P181, DOI 10.4161/mabs.2.2.11158; Moraru M, 2015, J IMMUNOL, V195, P1676, DOI 10.4049/jimmunol.1500872; Nagelkerke SQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02237; NAKAO Y, 1980, CLIN EXP IMMUNOL, V42, P20; Namboodiri AM, 2008, VIRAL IMMUNOL, V21, P273, DOI 10.1089/vim.2008.0008; Natsume A, 2008, CANCER RES, V68, P3863, DOI 10.1158/0008-5472.CAN-07-6297; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nordstrom JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3069; Oganesyan V, 2014, J BIOL CHEM, V289, P7812, DOI 10.1074/jbc.M113.537563; Pandey JP, 2008, HUM IMMUNOL, V69, P158, DOI 10.1016/j.humimm.2008.01.019; Pandey JP, 2019, J ALZHEIMERS DIS, V70, P917, DOI 10.3233/JAD-190265; Pandey JP, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27317; Pandey JP, 2014, IMMUNOBIOLOGY, V219, P113, DOI 10.1016/j.imbio.2013.08.005; Pandey JP, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-6; Pandey JP, 2012, HUM IMMUNOL, V73, P1155, DOI 10.1016/j.humimm.2012.07.340; Pandey JP, 2012, J INFECT DIS, V206, P143, DOI 10.1093/infdis/jis317; Pandey JP, 2004, J VIROL, V78, P4561, DOI 10.1128/JVI.78.9.4561-4565.2004; Pritsch O, 1996, J CLIN INVEST, V98, P2235, DOI 10.1172/JCI119033; Puca AA, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-018-0134-7; Ramesh A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01407; Ramsland PA, 2011, J IMMUNOL, V187, P3208, DOI 10.4049/jimmunol.1101467; Redpath S, 1998, IMMUNOLOGY, V93, P595; Richards JO, 2008, MOL CANCER THER, V7, P2517, DOI 10.1158/1535-7163.MCT-08-0201; Richardson SI, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008064; Rispens T, 2014, J BIOL CHEM, V289, P6098, DOI 10.1074/jbc.M113.541813; Rispens T, 2010, EUR J PHARM SCI, V40, P62, DOI 10.1016/j.ejps.2010.03.001; Robinson WH, 2015, NAT REV RHEUMATOL, V11, P171, DOI 10.1038/nrrheum.2014.220; Rodriguez OL, 2020, BIORXIV PREPRINT, DOI [10.1101/2020.04.19.049270.:2020.04.19.049270, DOI 10.1101/2020.04.19.049270.:2020.04.19.049270]; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Saito S, 2019, PROTEIN SCI, V28, P900, DOI 10.1002/pro.3598; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Shah IS, 2017, MOL IMMUNOL, V92, P28, DOI 10.1016/j.molimm.2017.10.001; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Stapleton NM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1608; Stavenhagen JB, 2007, CANCER RES, V67, P8882, DOI 10.1158/0008-5472.CAN-07-0696; Su CTT, 2018, ANTIBODIES, V7, DOI 10.3390/antib7020020; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; Tatarewicz SM, 2012, J IMMUNOL METHODS, V382, P93, DOI 10.1016/j.jim.2012.05.009; Ternant D, 2016, J IMMUNOL, V196, P607, DOI 10.4049/jimmunol.1501780; Torres M, 2008, TRENDS IMMUNOL, V29, P91, DOI 10.1016/j.it.2007.11.004; Torres M, 2007, J BIOL CHEM, V282, P13917, DOI 10.1074/jbc.M700661200; VANLOGHEM E, 1984, VOX SANG, V46, P195; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Webster CI, 2016, MABS-AUSTIN, V8, P253, DOI 10.1080/19420862.2015.1128605; ZOUALI M, 1995, IMMUNOL TODAY, V16, P399, DOI 10.1016/0167-5699(95)80009-3	84	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 18	2020	11								2016	10.3389/fimmu.2020.02016	http://dx.doi.org/10.3389/fimmu.2020.02016			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NM7LK	32973808	gold, Green Published			2022-12-18	WOS:000568275800001
J	Swieboda, D; Littauer, EQ; Beaver, JT; Mills, LK; Bricker, KM; Esser, ES; Antao, OQ; Williams, DT; Skountzou, I				Swieboda, Dominika; Littauer, Elizabeth Q.; Beaver, Jacob T.; Mills, Lisa K.; Bricker, Katherine M.; Esser, E. Stein; Antao, Olivia Q.; Williams, Dahnide T.; Skountzou, Ioanna			Pregnancy Downregulates Plasmablast Metabolic Gene Expression Following Influenza Without Altering Long-Term Antibody Function	FRONTIERS IN IMMUNOLOGY			English	Article						influenza; pregnancy; immunology; hormones; cellular immunity; humoral immunity; B cell; metabolism	PLASMACYTOID DENDRITIC CELLS; 2009 H1N1 INFLUENZA; A VIRUS; CYTOKINE PRODUCTION; IMMUNE-SYSTEM; T-CELLS; INFECTION; RESPONSES; WOMEN; IMMUNOGENICITY	While the majority of influenza-infected individuals show no or mild symptomatology, pregnant women are at higher risk of complications and infection-associated mortality. Although enhanced lung pathology and dysregulated hormones are thought to underlie adverse pregnancy outcomes following influenza infection, how pregnancy confounds long-term maternal anti-influenza immunity remains to be elucidated. Previously, we linked seasonal influenza infection to clinical observations of adverse pregnancy outcomes, enhanced lung and placental histopathology, and reduced control of viral replication in lungs of infected pregnant mothers. Here, we expand on this work and demonstrate that lower infectious doses of the pandemic A/California/07/2009 influenza virus generated adverse gestational outcomes similar to higher doses of seasonal viruses. Mice infected during pregnancy demonstrated lower hemagglutination inhibition and neutralizing antibody titers than non-pregnant animals until 63 days post infection. These differences in humoral immunity suggest that pregnancy impacts antibody maturation mechanisms without alterations to B cell frequency or antibody secretion. This is further supported by transcriptional analysis of plasmablasts, which demonstrate downregulated B cell metabolism and post-translational modification systems only among pregnant animals. In sum, these findings corroborate a link between adverse pregnancy outcomes and severe pathology observed during pandemic influenza infection. Furthermore, our data propose that pregnancy directly confounds humoral responses following influenza infection which resolves post-partem. Additional studies are required to specify the involvement of plasmablast metabolism with early humoral immunity abnormalities to best guide vaccination strategies and improve our understanding of the immunological consequences of pregnancy.	[Swieboda, Dominika; Littauer, Elizabeth Q.; Beaver, Jacob T.; Mills, Lisa K.; Bricker, Katherine M.; Esser, E. Stein; Antao, Olivia Q.; Williams, Dahnide T.; Skountzou, Ioanna] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; [Swieboda, Dominika; Littauer, Elizabeth Q.; Beaver, Jacob T.; Mills, Lisa K.; Bricker, Katherine M.; Esser, E. Stein; Antao, Olivia Q.; Williams, Dahnide T.; Skountzou, Ioanna] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA	Emory University; Emory University	Skountzou, I (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.	iskount@emory.edu		Bricker, Katherine/0000-0003-3339-0175; Littauer, Elizabeth/0000-0001-6054-6943; Swieboda, Dominika/0000-0001-6456-4954	Centers of Excellence for Influenza Research and Surveillance through the National Institutes of Health [HHSN272201400004C]	Centers of Excellence for Influenza Research and Surveillance through the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the Centers of Excellence for Influenza Research and Surveillance through the National Institutes of Health (HHSN272201400004C Pilot Project 2 to IS and R.W.C.).	Carey MA, 2005, J IMMUNOL, V175, P6878, DOI 10.4049/jimmunol.175.10.6878; Chan JFW, 2011, CLIN VACCINE IMMUNOL, V18, P305, DOI 10.1128/CVI.00363-10; Chan KH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013757; Cuthbert MF, 1977, CLIN EFFECTS PROSTAG; Denison FC, 1998, HUM REPROD, V13, P3560, DOI 10.1093/humrep/13.12.3560; Ding J, 2008, STEROIDS, V73, P289, DOI 10.1016/j.steroids.2007.10.012; Dulyachai W, 2010, EMERG INFECT DIS, V16, P343, DOI 10.3201/eid1602.091733; Escribese MM, 2008, BLOOD, V112, P4574, DOI 10.1182/blood-2008-04-148692; Esser ES, 2016, J CONTROL RELEASE, V236, P47, DOI 10.1016/j.jconrel.2016.06.026; Forbes RL, 2012, J INFECT DIS, V206, P646, DOI 10.1093/infdis/jis377; Gao RB, 2013, AM J PATHOL, V183, P1258, DOI 10.1016/j.ajpath.2013.06.023; Gordon CL, 2010, CLIN INFECT DIS, V50, P672, DOI 10.1086/650462; Grimaldi CM, 2006, J IMMUNOL, V176, P2703, DOI 10.4049/jimmunol.176.5.2703; Gu J, 2007, LANCET, V370, P1137, DOI 10.1016/S0140-6736(07)61515-3; Hayward AC, 2014, LANCET RESP MED, V2, P445, DOI 10.1016/S2213-2600(14)70034-7; Heltzer ML, 2009, J LEUKOCYTE BIOL, V85, P1036, DOI 10.1189/jlb.1108710; Hmiel LK, 2015, ANAL BIOANAL CHEM, V407, P79, DOI 10.1007/s00216-014-8108-x; Jackson LA, 2011, J INFECT DIS, V204, P854, DOI 10.1093/infdis/jir440; Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152; Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0; JEWETT JF, 1974, NEW ENGL J MED, V291, P256; Kalil AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2539-x; Kawaguchi A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173008; Kay AW, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00289; Kay AW, 2014, P NATL ACAD SCI USA, V111, P14506, DOI 10.1073/pnas.1416569111; Kim HM, 2012, VIRAL IMMUNOL, V25, P402, DOI 10.1089/vim.2012.0007; Kraus TA, 2012, J CLIN IMMUNOL, V32, P300, DOI 10.1007/s10875-011-9627-2; Krishnan L, 1996, J IMMUNOL, V156, P644; Le Gars M, 2016, J INFECT DIS, V214, P1666, DOI 10.1093/infdis/jiw448; Le Goffic R, 2006, PLOS PATHOG, V2, P526, DOI 10.1371/journal.ppat.0020053; Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114; Littauer EQ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02455; Littauer EQ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006757; Lockwood CJ, 2014, AM J PATHOL, V184, P2549, DOI 10.1016/j.ajpath.2014.05.025; LoMauro A, 2015, BREATHE, V11, P297, DOI 10.1183/20734735.008615; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu FX, 2002, CLIN EXP IMMUNOL, V128, P10, DOI 10.1046/j.1365-2249.2002.01780.x; Marcelin Glendie, 2011, J Virol, V85, P11208, DOI 10.1128/JVI.00654-11; MCGREGOR JA, 1984, AM J OBSTET GYNECOL, V149, P856, DOI 10.1016/0002-9378(84)90604-5; Mizumura K, 2003, CLIN EXP ALLERGY, V33, P1244, DOI 10.1046/j.1365-2222.2003.01750.x; Montuschi P, 2003, THORAX, V58, P585, DOI 10.1136/thorax.58.7.585; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033; Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; O'neil, 2013, MERCK INDEX ENCY CHE; Ostensen M, 1999, ANN NY ACAD SCI, V876, P131, DOI 10.1111/j.1749-6632.1999.tb07630.x; Pazos MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040502; Polgar B, 2004, BIOL REPROD, V71, P1699, DOI 10.1095/biolreprod.104.030437; Priddy K D, 1997, J Obstet Gynecol Neonatal Nurs, V26, P388, DOI 10.1111/j.1552-6909.1997.tb02720.x; Raj RS, 2014, REPROD SCI, V21, P1434, DOI 10.1177/1933719114537720; Reichetzeder C, 2016, CELL PHYSIOL BIOCHEM, V39, P919, DOI 10.1159/000447801; Richardson K, 2011, AIDS, V25, P595, DOI 10.1097/QAD.0b013e32834411a8; Robinson DP, 2012, HORM BEHAV, V62, P263, DOI 10.1016/j.yhbeh.2012.02.023; Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149; Sacks GP, 2001, PLACENTA, V22, P550, DOI 10.1053/plac.2001.0686; Schlaudecker EP, 2012, J INFECT DIS, V206, P1670, DOI 10.1093/infdis/jis592; Schumacher A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00196; SEIFERT B, 1978, ACTA BIOL MED GER, V37, P955; Skountzou I, 2006, VACCINE, V24, P6110, DOI 10.1016/j.vaccine.2006.05.014; Sperling RS, 2012, OBSTET GYNECOL, V119, P631, DOI 10.1097/AOG.0b013e318244ed20; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szekeres-Bartho J, 2010, AM J REPROD IMMUNOL, V64, P77, DOI 10.1111/j.1600-0897.2010.00833.x; Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006; Uchide N, 2002, BIOL PHARM BULL, V25, P239, DOI 10.1248/bpb.25.239; Uchide N, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/270670; van den Heuvel MJ, 2005, IMMUNOL INVEST, V34, P273, DOI 10.1081/IMM-200064488; van der Sluijs KF, 2004, J IMMUNOL, V172, P7603, DOI 10.4049/jimmunol.172.12.7603; van Nieuwenhoven ALV, 2002, FERTIL STERIL, V77, P1032, DOI 10.1016/S0015-0282(02)02976-X; van Riel D, 2016, SEMIN IMMUNOPATHOL, V38, P719, DOI 10.1007/s00281-016-0580-2; Vanders RL, 2013, J INFECT DIS, V208, P1062, DOI 10.1093/infdis/jit296; WALLACE GD, 1979, AM J VET RES, V40, P1169; WEEMS YS, 1992, PROSTAGLANDINS, V43, P203, DOI 10.1016/0090-6980(92)90090-G; Who/Cds/Csr/Ncs, 2002, WHO MAN AN INFL DIAG; Xu C, 2013, J CLIN ENDOCR METAB, V98, P2975, DOI 10.1210/jc.2012-2829; YAWN DH, 1971, J AMER MED ASSOC, V216, P1022, DOI 10.1001/jama.216.6.1022; Young BC, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.11.037; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zenclussen AC, 2001, AM J REPROD IMMUNOL, V45, P289, DOI 10.1111/j.8755-8920.2001.450504.x; Zheng R, 2012, HUM IMMUNOL, V73, P906, DOI 10.1016/j.humimm.2012.06.005	81	2	2	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 14	2020	11								1785	10.3389/fimmu.2020.01785	http://dx.doi.org/10.3389/fimmu.2020.01785			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NJ5OR	32922392	gold, Green Published			2022-12-18	WOS:000566092700001
J	Taylor, MD; Brewer, MR; Nedeljkovic-Kurepa, A; Yang, YH; Reddy, KS; Abraham, MN; Barnes, BJ; Deutschman, CS				Taylor, Matthew D.; Brewer, Mariana R.; Nedeljkovic-Kurepa, Ana; Yang, Yihe; Reddy, Kalpana S.; Abraham, Mabel N.; Barnes, Betsy J.; Deutschman, Clifford S.			CD4 T Follicular Helper Cells Prevent Depletion of Follicular B Cells in Response to Cecal Ligation and Puncture	FRONTIERS IN IMMUNOLOGY			English	Article						cecal ligation and puncture; sepsis; long-term effects; B cells; T follicular helper cells; CD4 T cells; T cell memory; adaptive immunity	MARGINAL ZONE; SEPSIS; ACTIVATION; APOPTOSIS; MODELS; BTK	Recent studies have demonstrated that induction of a diverse repertoire of memory T cells ("immune education") affects responses to murine cecal ligation and puncture (CLP), the most widely - used animal model of sepsis. Among the documented effects of immune education on CLP are changes in T cell, macrophage and neutrophil activity, more pronounced organ dysfunction and reduced survival. Little is known, however, about the effects of CLP on B cell responses, and how these responses might be altered by immune education. Importantly, effective B cell responses are modulated by IL21 produced by CD4(+)/CXCR5(+)/PD1(+) T follicular helper (Tfh) cells. We examined the B cell population in control and immune educated mice 24 h and 60 days after CLP. Education alone increased Tfh cells. Twenty-four hours after CLP, Tfh cells were depleted. However, this reduction was less pronounced in immune educated mice than in controls and the percentage of CD4 T cells expressing a Tfh phenotype increased in the animals. CLP did not alter splenic architecture and decreased numbers of follicular, marginal, and germinal center B cells. CLP induced changes were not, however, noted following CLP in immune educated mice. At 60 days post - CLP, numbers of follicular, germinal center and marginal zone B cells were increased; this increase was more pronounced in immune educated mice. Finally, while CLP reduced the induction of antigen specific B cells in controls, this response was maintained following CLP in immune educated mice. Our data suggest that preexisting Tfh assists in rescuing the B cell response to CLP.	[Taylor, Matthew D.; Brewer, Mariana R.; Abraham, Mabel N.; Deutschman, Clifford S.] Northwell Hlth, Cohen Childrens Med Ctr, Div Crit Care Med, New Hyde Pk, NY 11040 USA; [Taylor, Matthew D.; Brewer, Mariana R.; Abraham, Mabel N.; Deutschman, Clifford S.] Zucker Sch Med Hofstra Northwell, Dept Pediat, Hempstead, NY 11549 USA; [Taylor, Matthew D.; Brewer, Mariana R.; Nedeljkovic-Kurepa, Ana; Abraham, Mabel N.; Deutschman, Clifford S.] Feinstein Inst Med Res, Sepsis Res Lab, Manhasset, NY 11030 USA; [Yang, Yihe; Reddy, Kalpana S.] Zucker Sch Med Hofstra Northwell, Dept Pathol, Hempstead, NY USA; [Barnes, Betsy J.] Feinstein Inst Med Res, Inst Mol Med, Manhasset, NY USA	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Northwell Health; Northwell Health	Taylor, MD (corresponding author), Northwell Hlth, Cohen Childrens Med Ctr, Div Crit Care Med, New Hyde Pk, NY 11040 USA.; Taylor, MD (corresponding author), Zucker Sch Med Hofstra Northwell, Dept Pediat, Hempstead, NY 11549 USA.; Taylor, MD (corresponding author), Feinstein Inst Med Res, Sepsis Res Lab, Manhasset, NY 11030 USA.	mtaylor15@northwell.edu	Deutschman, Clifford/AAN-2742-2021; Brewer, Mariana/AAG-9273-2019		NIH NIGMS [R01GM121102, K08GM132794]; Thrasher Research Fund Early Career Award [14734]	NIH NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Thrasher Research Fund Early Career Award	MT received funding from the NIH NIGMS K08GM132794 and Thrasher Research Fund Early Career Award 14734. CD received funding from the NIH NIGMS R01GM121102.	Abcejo AS, 2009, CRIT CARE MED, V37, P1729, DOI 10.1097/CCM.0b013e31819dee81; Abolins S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14811; Allman D, 2008, CURR OPIN IMMUNOL, V20, P149, DOI 10.1016/j.coi.2008.03.014; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Cariappa A, 2001, IMMUNITY, V14, P603, DOI 10.1016/S1074-7613(01)00135-2; Duan SX, 2020, SHOCK, V54, P70, DOI 10.1097/SHK.0000000000001478; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Huggins MA, 2019, CELL REP, V28, P1729, DOI 10.1016/j.celrep.2019.07.028; Kil LP, 2012, BLOOD, V119, P3744, DOI 10.1182/blood-2011-12-397919; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; MEAKINS JL, 1977, ANN SURG, V186, P241, DOI 10.1097/00000658-197709000-00002; Osuchowski MF, 2018, INFECTION, V46, P687, DOI 10.1007/s15010-018-1183-8; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Shankar-Hari M, 2017, CRIT CARE MED, V45, P875, DOI [10.1097/CCM.0000000000002380, 10.1097/ccm.0000000000002380]; Shrum Bradly, 2014, BMC Res Notes, V7, P233, DOI 10.1186/1756-0500-7-233; Sjaastad FV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02532; Taylor MD, 2020, EUR J IMMUNOL, V50, P1838, DOI 10.1002/eji.202048570; Taylor Matthew D, 2018, Immunohorizons, V2, P67, DOI 10.4049/immunohorizons.1800003; Warren HS, 2015, P NATL ACAD SCI USA, V112, pE345, DOI 10.1073/pnas.1414857111; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; Zimmermann M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00829	23	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2020	11								1946	10.3389/fimmu.2020.01946	http://dx.doi.org/10.3389/fimmu.2020.01946			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI7NT	32903485	Green Published, gold			2022-12-18	WOS:000565536500001
J	Han, Q; Han, YL; Wen, HY; Pang, Y; Li, QW				Han, Qing; Han, Yinglun; Wen, Hongyan; Pang, Yue; Li, Qingwei			Molecular Evolution of Apolipoprotein Multigene Family and the Original Functional Properties of Serum Apolipoprotein (LAL2) inLampetra japonica	FRONTIERS IN IMMUNOLOGY			English	Article						apolipoprotein; LAL2; lamprey; antibacterial; immune system	A-I; STAPHYLOCOCCUS-AUREUS; IMMUNE-RESPONSE; PROTEIN; GENE; LAMPREY; LIPOPROTEINS; METABOLISM; EXPRESSION; INFECTION	Apolipoprotein (APO) genes represent a large family of genes encoding various binding proteins associated with plasma lipid transport. Due to the long divergence history, it remains to be confirmed whether these genes evolved from a common ancestor through gene duplication and original function, and how this evolution occurred. In this study, based on the phylogenetic tree, sequence alignment, motifs, and evolutionary analysis of gene synteny and collinearity, APOA, APOC, and APOE in higher vertebrates may have a common ancestor, lamprey serum apolipoprotein LAL1 or LAL2, which traces back to 360 million years ago. Moreover, the results of immunofluorescence, immunohistochemistry, and flow cytometry show that LAL2 is primarily distributed in the liver, kidney, and blood leukocytes of lampreys, and specifically localized in the cytoplasm of liver cells and leukocytes, as well as secreted into sera. Surface plasmon resonance technology demonstrates that LAL2 colocalizes to breast adenocarcinoma cells (MCF-7) or chronic myeloid leukemia cells (K562) associated with lamprey immune protein (LIP) and further enhances the killing effect of LIP on tumor cells. In addition, using quantitative real-time PCR (Q-PCR) and western blot methods, we found that the relative mRNA and protein expression oflal2in lamprey leukocytes and sera increased significantly at different times after stimulating withStaphylococcus aureus, Vibrio anguillarum, and Polyinosinic-polycytidylic acid (Poly I:C). Moreover, LAL2 was found to recognize and bind to gram-positive bacteria (Staphylococcus aureusandBacillus cereus) and gram-negative bacteria (Escherichia coli) and play an important role in the antibacterial process. All in all, our data reveals a long, complex evolutionary history for apolipoprotein genes under different selection pressures, confirms the immune effect of LAL2 in lamprey sera against pathogens, and lays the foundation for further research regarding biological functions of lamprey immune systems.	[Han, Qing; Han, Yinglun; Wen, Hongyan; Pang, Yue; Li, Qingwei] Liaoning Normal Univ, Coll Life Sci, Dalian, Peoples R China; [Han, Qing; Han, Yinglun; Wen, Hongyan; Pang, Yue; Li, Qingwei] Liaoning Normal Univ, Lamprey Res Ctr, Dalian, Peoples R China; [Han, Qing; Han, Yinglun; Wen, Hongyan; Pang, Yue; Li, Qingwei] Dalian Polytech Univ, Collaborat Innovat Ctr Seafood Deep Proc, Dalian, Peoples R China	Liaoning Normal University; Liaoning Normal University; Dalian Polytechnic University	Pang, Y; Li, QW (corresponding author), Liaoning Normal Univ, Coll Life Sci, Dalian, Peoples R China.; Pang, Y; Li, QW (corresponding author), Liaoning Normal Univ, Lamprey Res Ctr, Dalian, Peoples R China.; Pang, Y; Li, QW (corresponding author), Dalian Polytech Univ, Collaborat Innovat Ctr Seafood Deep Proc, Dalian, Peoples R China.	pangyue01@163.com; liqw@263.net			Chinese National Natural Science Foundation [31772884]; Project of Department of Ocean and Fisheries of Liaoning Province [201805]; Program of Science and Technology of Liaoning Province [2019-MS218]; Science and Technology Innovation Fund Research Project [2018J12SN079]	Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Project of Department of Ocean and Fisheries of Liaoning Province; Program of Science and Technology of Liaoning Province; Science and Technology Innovation Fund Research Project	This work was funded by Chinese National Natural Science Foundation Grant (No. 31772884), The Project of Department of Ocean and Fisheries of Liaoning Province (No. 201805), Program of Science and Technology of Liaoning Province (No. 2019-MS218), and Science and Technology Innovation Fund Research Project (No. 2018J12SN079).	Berbee JFP, 2010, J LIPID RES, V51, P1943, DOI 10.1194/jlr.M006809; BOGUSKI MS, 1986, J BIOL CHEM, V261, P6398; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Catapano AL, 2014, CARDIOVASC RES, V103, P372, DOI 10.1093/cvr/cvu150; Concha MI, 2004, EUR J BIOCHEM, V271, P2984, DOI 10.1111/j.1432-1033.2004.04228.x; Grunfeld C, 1999, J LIPID RES, V40, P245; Han YL, 2014, ACTA BIOCH BIOPH SIN, V46, P623, DOI 10.1093/abbs/gmu039; Hanada Y, 2011, J BIOL CHEM, V286, P39360, DOI 10.1074/jbc.M111.278416; Huang GR, 2014, P NATL ACAD SCI USA, V111, P13469, DOI 10.1073/pnas.1405414111; Huebbe P, 2017, AGEING RES REV, V37, P146, DOI 10.1016/j.arr.2017.06.002; Kamareddine L, 2016, J INNATE IMMUN, V8, P314, DOI 10.1159/000443883; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; LI WH, 1988, J LIPID RES, V29, P245; Liu JQ, 2019, BMC EVOL BIOL, V19, DOI 10.1186/s12862-019-1519-8; LUO CC, 1986, J MOL BIOL, V187, P325, DOI 10.1016/0022-2836(86)90436-5; Ma J, 2004, ACTA BIOCH BIOPH SIN, V36, P419, DOI 10.1093/abbs/36.6.419; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Mangaraj M, 2016, INDIAN J CLIN BIOCHE, V31, P253, DOI 10.1007/s12291-015-0513-1; Mohapatra A, 2016, FISH SHELLFISH IMMUN, V55, P717, DOI 10.1016/j.fsi.2016.06.045; Morita S, 2016, BIOL PHARM BULL, V39, P1, DOI 10.1248/bpb.b15-00716; NONAKA M, 1984, J IMMUNOL, V133, P3242; Omae Y, 2013, J BIOL CHEM, V288, P25542, DOI 10.1074/jbc.M113.495051; Pang Y, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0358-y; Pang Y, 2017, CELL COMMUN SIGNAL, V15, P1, DOI 10.1186/s12964-017-0202-1; Pang Y, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1270-6; PARKER TS, 1995, INFECT IMMUN, V63, P253, DOI 10.1128/IAI.63.1.253-258.1995; Pei GY, 2016, DEV COMP IMMUNOL, V54, P66, DOI 10.1016/j.dci.2015.08.011; Phillips MC, 2013, J LIPID RES, V54, P2034, DOI 10.1194/jlr.R034025; PONTES M, 1987, BIOCHEMISTRY-US, V26, P1611, DOI 10.1021/bi00380a019; Rahman MM, 2006, J INSECT PHYSIOL, V52, P754, DOI 10.1016/j.jinsphys.2006.04.003; Ramasamy I, 2014, CLIN CHEM LAB MED, V52, P1695, DOI 10.1515/cclm-2013-0358; Staczek S, 2018, J INSECT PHYSIOL, V105, P18, DOI 10.1016/j.jinsphys.2017.12.009; TADA N, 1993, MOL CELL BIOCHEM, V119, P171, DOI 10.1007/BF00926868; Villarroel F, 2007, FISH SHELLFISH IMMUN, V23, P197, DOI 10.1016/j.fsi.2006.10.008; Wang DY, 2019, FISH SHELLFISH IMMUN, V92, P196, DOI 10.1016/j.fsi.2019.05.062; Wang L, 1994, Yi Chuan Xue Bao, V21, P81; Wang W, 2019, COMP BIOCHEM PHYS B, V238, DOI 10.1016/j.cbpb.2019.110329; Wang ZL, 2018, DEV COMP IMMUNOL, V79, P75, DOI [10.1016/j.dci.2017.09.018, 10.1]; Wei JG, 2015, FISH SHELLFISH IMMUN, V43, P396, DOI 10.1016/j.fsi.2015.01.006; Wu FF, 2013, J IMMUNOL, V190, P922, DOI 10.4049/jimmunol.1200876; Xu R, 2017, FISH SHELLFISH IMMUN, V71, P286, DOI 10.1016/j.fsi.2017.06.061; Xue Z, 2012, IMMUNOL LETT, V148, P1, DOI 10.1016/j.imlet.2012.08.005; Yang YJ, 2017, DEV COMP IMMUNOL, V67, P464, DOI 10.1016/j.dci.2016.09.007; Zdybicka-Barabas A, 2011, COMP BIOCHEM PHYS B, V158, P90, DOI 10.1016/j.cbpb.2010.10.001	45	2	2	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2020	11								1751	10.3389/fimmu.2020.01751	http://dx.doi.org/10.3389/fimmu.2020.01751			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI4PT	32849624	Green Published, gold			2022-12-18	WOS:000565336500001
J	Takano, T; Kotaki, R; Park, J; Yoshida, T; Wakatsuki, Y; Tanokura, M; Miyakawa, T; Takahashi, K; Nakajima-Adachi, H; Hachimura, S				Takano, Tomohiro; Kotaki, Ryutaro; Park, Jihyun; Yoshida, Tadashi; Wakatsuki, Yoshio; Tanokura, Masaru; Miyakawa, Takuya; Takahashi, Kyoko; Nakajima-Adachi, Haruyo; Hachimura, Satoshi			Age-Dependent Decrease in the Induction of Regulatory T Cells Is Associated With Decreased Expression of RALDH2 in Mesenteric Lymph Node Dendritic Cells	FRONTIERS IN IMMUNOLOGY			English	Article						aging; regulatory T cells; dendritic cells; RALDH2; retinoic acid; epigenetic regulation	TRANS-RETINOIC ACID; ANTIGEN; BETA; GENERATION; MIGRATION; MICE; IL-6	A decline in immune function with aging has been reported. Regulatory T cell (Treg) induction is known to decrease with age, and elucidating the underlying mechanism is important for preventing age-related diseases due to age-related chronic inflammation. In the intestine, dendritic cells (DCs) play an important role in inducing Tregs specific to oral antigens, and they efficiently induce Tregs via production of retinoic acid (RA), a vitamin A metabolite, catalyzed by the enzyme retinaldehyde dehydrogenase 2 (RALDH2). We have previously reported that in the mesenteric lymph node (MLN), a secondary lymphoid tissue in which immune responses to oral antigens are induced, four DC subsets express different levels of CD11b, CD103, and PD-L1, and we have reported that the CD11b(-)CD103(+)PD-L1(high)subset expresses the highest levels of the RALDH2 gene and induces Tregsin vitro. We examined Treg induction in young and aged mice using a Treg induction model by administering a food antigen, and we found that antigen-specific Treg induction was decreased in aged mice. We further investigated the MLN DCs, and a significant decrease in RALDH2 gene expression was observed in MLN DCs from aged mice. As factors, we found that the proportion of the CD11b(-)CD103(+)PD-L1(high)subset was decreased in aged mice compared with that in young mice and that RALDH enzyme activity was decreased in the CD11b(-)CD103(+)PD-L1(high)and CD11b(+)CD103(+)PD-L1(high)subsets. Furthermore, analysis of the methylation of the RALDH2 gene promoter region revealed that CpG motifs were more methylated in the MLN DCs of aged mice, suggesting that RALDH2 expression was suppressed by epigenetic changes. Finally, we found that RA treatment tended to increase Treg induction. These results suggest that the regulation of RA production may be involved in the age-related decrease in antigen-specific Treg induction.	[Takano, Tomohiro; Kotaki, Ryutaro; Park, Jihyun; Tanokura, Masaru; Nakajima-Adachi, Haruyo; Hachimura, Satoshi] Univ Tokyo, Res Ctr Food Safety, Tokyo, Japan; [Park, Jihyun; Tanokura, Masaru; Miyakawa, Takuya] Univ Tokyo, Dept Appl Biol Chem, Tokyo, Japan; [Yoshida, Tadashi] Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Tokyo, Japan; [Wakatsuki, Yoshio] Kyoto Univ, Dept Clin Bioregulatory Sci, Grad Sch Med, Kyoto, Japan; [Takahashi, Kyoko] Nihon Univ, Coll Bioresource Sci, Dept Appl Biol Sci, Fujisawa, Kanagawa, Japan	University of Tokyo; University of Tokyo; Tokyo University of Agriculture & Technology; Kyoto University; Nihon University	Hachimura, S (corresponding author), Univ Tokyo, Res Ctr Food Safety, Tokyo, Japan.	ahachi@mail.ecc.u-tokyo.ac.jp	YOSHIDA, Tadashi/G-1124-2013	Tanokura, Masaru/0000-0001-5072-2480; Takano, Tomohiro/0000-0003-4267-1147	Japan Society for the promotion of Science (JSPS) [18H02152, 23228003]; Food Science Institute Foundation	Japan Society for the promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Food Science Institute Foundation	This research was supported by a Grant-in-Aid for Scientific Research (B) (Grant number 18H02152), and a Grant-in-Aid for Scientific Research (S) (Grant number 23228003) from the Japan Society for the promotion of Science (JSPS) and a grant from the Food Science Institute Foundation.	Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554; Bai AP, 2009, J LEUKOCYTE BIOL, V86, P959, DOI 10.1189/jlb.0109006; Baylis Daniel, 2013, Longev Healthspan, V2, P8, DOI 10.1186/2046-2395-2-8; Bermudez EA, 2002, ARTERIOSCL THROM VAS, V22, P1668, DOI 10.1161/01.ATV.0000029781.31325.66; Bian F, 2019, MUCOSAL IMMUNOL, V12, P897, DOI 10.1038/s41385-018-0127-z; Bollrath J, 2013, SEMIN IMMUNOL, V25, P352, DOI 10.1016/j.smim.2013.09.002; Carpentier M, 2013, EUR J IMMUNOL, V43, P2598, DOI 10.1002/eji.201343532; Chougnet CA, 2011, J IMMUNOL, V186, P156, DOI 10.4049/jimmunol.1001505; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Coombes JL, 2007, SEMIN IMMUNOL, V19, P116, DOI 10.1016/j.smim.2007.01.001; Darrigues J, 2018, GERONTOLOGY, V64, P28, DOI 10.1159/000478044; FARIA AMC, 1993, IMMUNOLOGY, V78, P147; Forsey RJ, 2003, MECH AGEING DEV, V124, P487, DOI 10.1016/S0047-6374(03)00025-3; Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Hong K, 2014, IMMUNOL LETT, V162, P34, DOI 10.1016/j.imlet.2014.06.011; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jagger A, 2014, GERONTOLOGY, V60, P130, DOI 10.1159/000355303; Jang MH, 2006, J IMMUNOL, V176, P803, DOI 10.4049/jimmunol.176.2.803; Jones MJ, 2015, AGING CELL, V14, P924, DOI 10.1111/acel.12349; Lu L, 2014, P NATL ACAD SCI USA, V111, pE3432, DOI 10.1073/pnas.1408780111; Molenaar R, 2011, J IMMUNOL, V186, P1934, DOI 10.4049/jimmunol.1001672; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nakajima-Adachi H, 2006, J ALLERGY CLIN IMMUN, V117, P1125, DOI 10.1016/j.jaci.2006.01.016; Nakajima-Adachi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172795; Nolting J, 2009, J EXP MED, V206, P2131, DOI 10.1084/jem.20090639; Ohoka Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096512; Paidassi H, 2011, GASTROENTEROLOGY, V141, P1813, DOI 10.1053/j.gastro.2011.06.076; Paolisso G, 1998, AM J PHYSIOL-ENDOC M, V275, pE294, DOI 10.1152/ajpendo.1998.275.2.E294; Park J, 2014, BIOSCI BIOTECH BIOCH, V78, P976, DOI 10.1080/09168451.2014.910099; Ruedl C, 2000, J IMMUNOL, V165, P4910, DOI 10.4049/jimmunol.165.9.4910; Schulz O, 2009, J EXP MED, V206, P3101, DOI 10.1084/jem.20091925; Scott CL, 2011, TRENDS IMMUNOL, V32, P412, DOI 10.1016/j.it.2011.06.003; Shiokawa A, 2017, IMMUNOLOGY, V152, P52, DOI 10.1111/imm.12747; Tanaka Y, 2017, MUCOSAL IMMUNOL, V10, P79, DOI 10.1038/mi.2016.46; WEI J, 1992, LIFE SCI, V51, P1953, DOI 10.1016/0024-3205(92)90112-3; Worthington JJ, 2011, GASTROENTEROLOGY, V141, P1802, DOI 10.1053/j.gastro.2011.06.057; Xia SJ, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8426874; Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277	40	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2020	11								1555	10.3389/fimmu.2020.01555	http://dx.doi.org/10.3389/fimmu.2020.01555			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI4LY	32849526	gold, Green Published			2022-12-18	WOS:000565326600001
J	Vakkilainen, S; Kleino, I; Honkanen, J; Salo, H; Kainulainen, L; Grasbeck, M; Kekalainen, E; Makitie, O; Klemetti, P				Vakkilainen, Svetlana; Kleino, Iivari; Honkanen, Jarno; Salo, Harri; Kainulainen, Leena; Grasbeck, Michaela; Kekalainen, Eliisa; Makitie, Outi; Klemetti, Paula			The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia	FRONTIERS IN IMMUNOLOGY			English	Article						clinical trial; combined immunodeficiency; immunization; MMR; RMRP; vaccination; varicella zoster virus	VARICELLA VACCINE; RNASE-MRP; RMRP; IMMUNODEFICIENCY; MUTATIONS; PHENOTYPE; CHILDREN; AMISH	Background: Live viral vaccines are generally contraindicated in patients with combined immunodeficiency including cartilage-hair hypoplasia (CHH); however, they may be tolerated in milder syndromes. We evaluated the safety and efficacy of live viral vaccines in patients with CHH. Methods: We analyzed hospital and immunization records of 104 patients with CHH and measured serum antibodies to measles, mumps, rubella, and varicella zoster virus (VZV) in all patients who agreed to blood sampling (n= 50). We conducted a clinical trial (identifier: NCT02383797) of live VZV vaccine on five subjects with CHH who lacked varicella history, had no clinical symptoms of immunodeficiency, and were seronegative for VZV; humoral and cellular immunologic responses were assessed post-immunization. Results: A large proportion of patients have been immunized with live viral vaccines, including measles-mumps-rubella (MMR) (n= 40, 38%) and VZV (n= 10, 10%) vaccines, with no serious adverse events. Of the 50 patients tested for antibodies, previous immunization has been documented with MMR (n= 22), rubella (n= 2) and measles (n= 1) vaccines. Patients with CHH demonstrated seropositivity rates of 96%/75%/91% to measles, mumps and rubella, respectively, measured at a medium of 24 years post-immunization. Clinical trial participants developed humoral and cellular responses to VZV vaccine. One trial participant developed post-immunization rash and knee swelling, both resolved without treatment. Conclusion: No serious adverse events have been recorded after immunization with live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular immune response to live viral vaccines. Immunization with live vaccines may be considered in selected CHH patients with no or clinically mild immunodeficiency.	[Vakkilainen, Svetlana; Makitie, Outi; Klemetti, Paula] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland; [Vakkilainen, Svetlana; Makitie, Outi; Klemetti, Paula] Helsinki Univ Hosp, Helsinki, Finland; [Vakkilainen, Svetlana; Makitie, Outi] Folkhalsan Res Ctr, Inst Genet, Helsinki, Finland; [Vakkilainen, Svetlana; Honkanen, Jarno; Makitie, Outi] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland; [Kleino, Iivari; Kekalainen, Eliisa] Univ Helsinki, Translat Immunol Res Program, Helsinki, Finland; [Salo, Harri] Univ Helsinki, Childrens Hosp, Clinicum, Helsinki, Finland; [Kainulainen, Leena] Univ Turku, Turku Univ Hosp, Dept Pediat & Adolescents, Turku, Finland; [Grasbeck, Michaela] Kymenlaakso Cent Hosp, Dept Pediat, Kotka, Finland; [Kekalainen, Eliisa] Helsinki Univ Hosp, Div Clin Microbiol, HUSLAB, Helsinki, Finland; [Makitie, Outi] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Makitie, Outi] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Makitie, Outi] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Folkhalsan Research Center; University of Helsinki; University of Helsinki; University of Helsinki; University of Turku; University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Vakkilainen, S (corresponding author), Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland.; Vakkilainen, S (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.; Vakkilainen, S (corresponding author), Folkhalsan Res Ctr, Inst Genet, Helsinki, Finland.; Vakkilainen, S (corresponding author), Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland.	svetlana.vakkilainen@helsinki.fi	, eliisa.kekalainen@helsinki.fi/G-6140-2010; Vakkilainen, Svetlana/O-1768-2014	, eliisa.kekalainen@helsinki.fi/0000-0001-6045-108X; Kleino, Iivari/0000-0001-6219-8575; Kainulainen, Leena/0000-0002-7776-3626; Vakkilainen, Svetlana/0000-0002-4573-3297	Sigrid Juselius Foundation; Academy of Finland; Folkhalsan Research Foundation; Novo Nordisk Foundation; Helsinki University Hospital Research Funds; Swedish Childhood Cancer Foundation; Foundation for Pediatric Research; Doctoral School in Health Sciences at the University of Helsinki	Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); Folkhalsan Research Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Helsinki University Hospital Research Funds; Swedish Childhood Cancer Foundation(European Commission); Foundation for Pediatric Research; Doctoral School in Health Sciences at the University of Helsinki	This work was supported by the Sigrid Juselius Foundation to OM, the Academy of Finland to OM, the Folkhalsan Research Foundation to OM, the Novo Nordisk Foundation to OM, the Helsinki University Hospital Research Funds to OM, the Swedish Childhood Cancer Foundation to OM, the Foundation for Pediatric Research to OM, and the Doctoral School in Health Sciences at the University of Helsinki to SV.	Bacchetta J, 2009, PEDIATR NEPHROL, V24, P2449, DOI 10.1007/s00467-009-1256-0; Buchbinder D, 2019, J CLIN IMMUNOL, V39, P81, DOI 10.1007/s10875-018-0581-0; Eisner JM, 2006, J AM ACAD DERMATOL, V54, pS8, DOI 10.1016/j.jaad.2005.03.055; Fedeli U, 2002, J HOSP INFECT, V51, P133, DOI 10.1053/jhin.2002.1222; Harrington WE, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1522; Horn J, 2010, HUM IMMUNOL, V71, P916, DOI 10.1016/j.humimm.2010.06.002; Ip W, 2015, J CLIN IMMUNOL, V35, P147, DOI 10.1007/s10875-015-0135-7; Kennedy RB, 2019, VACCINE, V37, P1775, DOI 10.1016/j.vaccine.2019.02.030; Kostjukovits S, 2017, J ALLERGY CLIN IMMUN, V140, P612, DOI 10.1016/j.jaci.2017.02.016; Kostjukovits S, 2017, J MED GENET, V54, P365, DOI 10.1136/jmedgenet-2016-104279; Kreth HW, 2008, BIODRUGS, V22, P387, DOI 10.2165/0063030-200822060-00005; LUX SE, 1970, NEW ENGL J MED, V282, P231, DOI 10.1056/NEJM197001292820501; MAKITIE O, 1993, EUR J PEDIATR, V152, P211, DOI 10.1007/BF01956147; MCKUSICK VA, 1965, B JOHNS HOPKINS HOSP, V116, P285; Michalik DE, 2008, J INFECT DIS, V197, P944, DOI 10.1086/529043; Otani N, 2009, J IMMUNOL METHODS, V351, P71, DOI 10.1016/j.jim.2009.09.010; PIERCE GF, 1982, J IMMUNOL, V129, P570; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rider NL, 2009, CLIN IMMUNOL, V131, P119, DOI 10.1016/j.clim.2008.11.001; Rogler LE, 2014, HUM MOL GENET, V23, P368, DOI 10.1093/hmg/ddt427; SAULSBURY FT, 1975, J PEDIATR-US, V86, P868, DOI 10.1016/S0022-3476(75)80216-2; Slifka MK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00956; Smith JG, 2001, CLIN DIAGN LAB IMMUN, V8, P871, DOI 10.1128/CDLI.8.5.871-879.2001; Sobh A, 2016, J ALLER CL IMM-PRACT, V4, P1066, DOI 10.1016/j.jaip.2016.09.012; Thiel CT, 2005, AM J HUM GENET, V77, P795, DOI 10.1086/497708; Vakkilainen S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01581; Vakkilainen S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02468; Vatanavicharn N, 2010, J APPL GENET, V51, P523, DOI 10.1007/BF03208884	28	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2020	11								2020	10.3389/fimmu.2020.02020	http://dx.doi.org/10.3389/fimmu.2020.02020			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI4QM	32849667	Green Published, gold			2022-12-18	WOS:000565338400001
J	Zhao, J; Su, M; Lin, YJ; Liu, HY; He, ZX; Lai, LJ				Zhao, Jin; Su, Min; Lin, Yujun; Liu, Haiyan; He, Zhixu; Lai, Laijun			Administration of Amyloid Precursor Protein Gene Deleted Mouse ESC-Derived Thymic Epithelial Progenitors Attenuates Alzheimer's Pathology	FRONTIERS IN IMMUNOLOGY			English	Article						Alzheimer's disease; amyloid-beta; thymic epithelial cells; embryonic stem cells; amyloid precursor protein; T cells	BRAINS CHOROID-PLEXUS; T-CELL DEVELOPMENT; IMMUNE-SYSTEM; DISEASE PROGRESSION; MEMORY IMPAIRMENTS; GLATIRAMER ACETATE; COGNITIVE FUNCTION; BETA-PROTEIN; STEM-CELLS; CNS	Alzheimer's disease (AD) is a devastating neurodegenerative disorder and the most common cause of dementia in older adults. Although amyloid-beta (A beta) plaque deposition and chronic neuroinflammation in the central nervous system (CNS) contribute to AD pathology, neither A beta plaque removal nor anti-inflammatory therapy has shown much clinical success, suggesting that the combinational therapies for the disease-causative factors may be needed for amelioration. Recent data also suggest that systemic immunity in AD should be boosted, rather than suppressed, to drive an immune-dependent cascade needed for A beta clearance and brain repair. Thymic epithelial cells (TECs) not only play a critical role in supporting T cell development but also mediate the deletion of autoreactive T cells by expressing autoantigens. We have reported that embryonic stem cells (ESCs) can be selectively induced to differentiate into thymic epithelial progenitors (TEPs)in vitrothat further develop into TECsin vivoto support T cell development. We show here that transplantation of mouse ESC (mESC)-TEPs into AD mice reduced cerebral A beta plaque load and improved cognitive performance, in correlation with an increased number of T cells, enhanced choroid plexus (CP) gateway activity, and increased number of macrophages in the brain. Furthermore, transplantation of the amyloid precursor protein (APP) gene deleted mESC-TEPs (APP(-/-)) results in more effective reduction of AD pathology as compared to wild-type (APP(+/+)) mESC-TEPs. This is associated with the generation of A beta-specific T cells, which leads to an increase of anti-A beta antibody (Ab)-producing B cells in the spleen and enhanced levels of anti-A beta antibodies in the serum, as well as an increase of A beta phagocytosing macrophages in the CNS. Our results suggest that transplantation of APP(-/-)human ESC- or induced pluripotent stem cell (iPSC)-derived TEPs may provide a new tool to mitigate AD in patients.	[Zhao, Jin] Guizhou Med Univ, Tissue Engn & Stem Cell Res Ctr, Sch Basic Med Sci, Guizhou Prov Key Lab Regenerat Med,Dept Immunol, Guiyang, Peoples R China; [Zhao, Jin; He, Zhixu] Chinese Acad Med Sci, Key Lab Adult Stem Cell Translat Res, Guiyang, Peoples R China; [Su, Min; Lin, Yujun; Liu, Haiyan; Lai, Laijun] Univ Connecticut, Dept Allied Hlth Sci, Storrs, CT 06269 USA; [He, Zhixu] Zunyi Med Univ, Dept Pediat, Affiliated Hosp, Zunyi, Guizhou, Peoples R China; [Lai, Laijun] Univ Connecticut, Stem Cell Inst, Storrs, CT 06269 USA	Guizhou Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; University of Connecticut; Zunyi Medical University; University of Connecticut	He, ZX (corresponding author), Chinese Acad Med Sci, Key Lab Adult Stem Cell Translat Res, Guiyang, Peoples R China.; Lai, LJ (corresponding author), Univ Connecticut, Dept Allied Hlth Sci, Storrs, CT 06269 USA.; He, ZX (corresponding author), Zunyi Med Univ, Dept Pediat, Affiliated Hosp, Zunyi, Guizhou, Peoples R China.; Lai, LJ (corresponding author), Univ Connecticut, Stem Cell Inst, Storrs, CT 06269 USA.	hzx@gmc.edu.cn; laijun.lai@uconn.edu		Zhao, Jin/0000-0003-1442-6873; lin, yujun/0000-0002-8937-1259	NIH [1R01AI123131]; Connecticut Regenerative Medicine Research Fund [16-RMB-UCONN-02]; Guizhou Medical University Graduate Student Innovation Program [Guiyi YJSCXJH [2019] 001]; National Natural Science Foundation of China [81871313]; Guizhou Province Science and Technology Project [Qian Ke He [2016]4002, [2019]5406]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Connecticut Regenerative Medicine Research Fund; Guizhou Medical University Graduate Student Innovation Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guizhou Province Science and Technology Project	This work was supported by grants from NIH (1R01AI123131, to LL), Connecticut Regenerative Medicine Research Fund (16-RMB-UCONN-02, to LL), Guizhou Medical University Graduate Student Innovation Program (Guiyi YJSCXJH [2019] 001, to JZ), National Natural Science Foundation of China (81871313, to ZH), and Guizhou Province Science and Technology Project (Qian Ke He [2016]4002, [2019]5406, to ZH).	Akiyama H, 1996, NEUROSCI LETT, V219, P115, DOI 10.1016/S0304-3940(96)13197-9; Alzheimer's Association, 2016, Alzheimers Dement, V12, P459; Anderson G, 2012, TRENDS IMMUNOL, V33, P256, DOI 10.1016/j.it.2012.03.005; Arsenault D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017397; Arvanitakis Z, 2008, NEUROLOGY, V70, P2219, DOI 10.1212/01.wnl.0000313813.48505.86; Aspinall R, 2010, J COMP PATHOL, V141, pS111, DOI 10.1016/j.jcpa.2009.10.022; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Baruch K, 2016, NAT MED, V22, P135, DOI 10.1038/nm.4022; Baruch K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8967; Beers DR, 2008, P NATL ACAD SCI USA, V105, P15558, DOI 10.1073/pnas.0807419105; Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d; Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103; Chidgey A, 2007, SEMIN IMMUNOL, V19, P331, DOI 10.1016/j.smim.2007.10.006; Ciofani M, 2007, ANNU REV CELL DEV BI, V23, P463, DOI 10.1146/annurev.cellbio.23.090506.123547; Clinton LK, 2007, NEUROBIOL DIS, V28, P76, DOI 10.1016/j.nbd.2007.06.013; Cohen SJ, 2015, BEHAV BRAIN RES, V285, P105, DOI 10.1016/j.bbr.2014.08.002; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951; Dorshkind K, 2009, CURR OPIN IMMUNOL, V21, P404, DOI 10.1016/j.coi.2009.07.001; Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240; Eisele YS, 2016, ACTA NEUROPATHOL, V131, P5, DOI 10.1007/s00401-015-1516-y; ElKhoury J, 1996, NATURE, V382, P716; Guenette S, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00087; Hamley IW, 2012, CHEM REV, V112, P5147, DOI 10.1021/cr3000994; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HOUSSAINT E, 1990, IMMUNOL TODAY, V11, P357, DOI 10.1016/0167-5699(90)90141-U; Hu R, 2017, STEM CELL TRANSL MED, V6, P121, DOI 10.5966/sctm.2016-0012; James DG, 2000, POSTGRAD MED J, V76, P457, DOI 10.1136/pmj.76.898.457; Koronyo Y, 2015, BRAIN, V138, P2399, DOI 10.1093/brain/awv150; Koronyo-Hamaoui M, 2009, J NEUROCHEM, V111, P1409, DOI 10.1111/j.1471-4159.2009.06402.x; Kunis G, 2015, J NEUROSCI, V35, P6381, DOI 10.1523/JNEUROSCI.3644-14.2015; Kunis G, 2013, BRAIN, V136, P3427, DOI 10.1093/brain/awt259; Labow RS, 2001, J BIOMED MATER RES, V54, P189, DOI 10.1002/1097-4636(200102)54:2<189::AID-JBM5>3.0.CO;2-8; Lai LJ, 2012, J CLIN INVEST, V122, P3552, DOI 10.1172/JCI46055; Lai LJ, 2011, BLOOD, V118, P3410, DOI 10.1182/blood-2011-03-340794; Lai LJ, 2011, CANCER RES, V71, P61, DOI 10.1158/0008-5472.CAN-10-3198; Lai LJ, 2009, STEM CELLS, V27, P3012, DOI 10.1002/stem.238; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Lynch HE, 2009, TRENDS IMMUNOL, V30, P366, DOI 10.1016/j.it.2009.04.003; Maras PM, 2014, MOL PSYCHIATR, V19, P811, DOI 10.1038/mp.2014.12; Marsh SE, 2016, P NATL ACAD SCI USA, V113, pE1316, DOI 10.1073/pnas.1525466113; Martin BK, 2008, ARCH NEUROL-CHICAGO, V65, P896, DOI 10.1001/archneur.2008.65.7.nct70006; Melchior B, 2010, ASN NEURO, V2, P157, DOI 10.1042/AN20100010; Mildner A, 2011, J NEUROSCI, V31, P11159, DOI 10.1523/JNEUROSCI.6209-10.2011; Miller AH, 2010, BRAIN BEHAV IMMUN, V24, P1, DOI 10.1016/j.bbi.2009.09.009; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Mondino A, 1996, P NATL ACAD SCI USA, V93, P2245, DOI 10.1073/pnas.93.6.2245; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Naert G, 2013, J MOL CELL BIOL, V5, P284, DOI 10.1093/jmcb/mjt028; Parker D C, 1993, Semin Immunol, V5, P413, DOI 10.1006/smim.1993.1047; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.immunol.11.1.331; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Raposo C, 2014, J NEUROSCI, V34, P10141, DOI 10.1523/JNEUROSCI.0076-14.2014; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rosenzweig N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08352-5; Schwartz M, 2008, TRENDS PHARMACOL SCI, V29, P287, DOI 10.1016/j.tips.2008.03.006; Schwartz M, 2019, DIALOGUES CLIN NEURO, V21, P21; Schwartz M, 2017, SCIENCE, V357, P254, DOI 10.1126/science.aai8231; Schwartz M, 2014, J AUTOIMMUN, V54, P8, DOI 10.1016/j.jaut.2014.08.002; Schwartz M, 2014, EMBO J, V33, P7, DOI 10.1002/embj.201386609; Seach N, 2012, J IMMUNOL METHODS, V385, P23, DOI 10.1016/j.jim.2012.07.023; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Simard AR, 2006, MOL PSYCHIATR, V11, P327, DOI 10.1038/sj.mp.4001809; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Song YH, 2016, EUR J IMMUNOL, V46, P1518, DOI 10.1002/eji.201546196; St-Amour I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-54; STOUT RD, 1989, J IMMUNOL, V142, P760; Stover KR, 2015, BEHAV BRAIN RES, V289, P29, DOI 10.1016/j.bbr.2015.04.012; Su M, 2017, CELL IMMUNOL, V322, P84, DOI 10.1016/j.cellimm.2017.10.007; Su M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09882; Su M, 2015, J AUTOIMMUN, V58, P36, DOI 10.1016/j.jaut.2015.01.002; Sun LG, 2010, AGING CELL, V9, P347, DOI 10.1111/j.1474-9726.2010.00559.x; Swain SL, 2009, J GERONTOL A-BIOL, V64, P183, DOI 10.1093/gerona/gln068; Taub DD, 2005, IMMUNOL REV, V205, P72, DOI 10.1111/j.0105-2896.2005.00275.x; Theriault P, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0125-2; Weiner HL, 2006, NAT REV IMMUNOL, V6, P404, DOI 10.1038/nri1843; Wigginton JE, 2001, J IMMUNOL, V166, P1951, DOI 10.4049/jimmunol.166.3.1951; WISNIEWSKI HM, 1991, ACTA NEUROPATHOL, V81, P588, DOI 10.1007/BF00310142; Wolf SA, 2009, J IMMUNOL, V182, P3979, DOI 10.4049/jimmunol.0801218; Wyss-Coray T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006346; Yeung ST, 2015, BRAIN RES BULL, V117, P10, DOI 10.1016/j.brainresbull.2015.07.001; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Zediak VP, 2005, SEMIN IMMUNOL, V17, P337, DOI 10.1016/j.smim.2005.05.004; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	87	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 11	2020	11								1781	10.3389/fimmu.2020.01781	http://dx.doi.org/10.3389/fimmu.2020.01781			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NI4JO	32849642	gold, Green Published			2022-12-18	WOS:000565320400001
J	Oria, RB; Empadinhas, N; Malva, JO				Oria, Reinaldo B.; Empadinhas, Nuno; Malva, Joao O.			Editorial: Interplay Between Nutrition, the Intestinal Microbiota and the Immune System	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						gut microbiota; nutrients; inflammation; immune system; intestinal barrier function; autoimmunity			[Oria, Reinaldo B.] Univ Fed Ceara, Inst Biomed, Sch Med, Dept Morphol,Lab Tissue Healing Ontogeny & Nutr, Fortaleza, Ceara, Brazil; [Empadinhas, Nuno] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal; [Empadinhas, Nuno] Univ Coimbra, CIBB, Coimbra, Portugal; [Malva, Joao O.] Univ Coimbra, Fac Med, CIBB, ICBR, Coimbra, Portugal; [Malva, Joao O.] Univ Coimbra, Fac Med, Inst Pharmacol & Expt Therapeut, Coimbra, Portugal	Universidade Federal do Ceara; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra	Oria, RB (corresponding author), Univ Fed Ceara, Inst Biomed, Sch Med, Dept Morphol,Lab Tissue Healing Ontogeny & Nutr, Fortaleza, Ceara, Brazil.	reinaldo70.oria@gmail.com	Empadinhas, Nuno/G-3118-2011; Malva, Joao/L-3557-2014	Empadinhas, Nuno/0000-0001-8938-7560; Malva, Joao/0000-0002-5438-4447; Oria, Reinaldo/0000-0002-6914-5481	Santa Casa da Misericordia de Lisboa-Mantero Belard Neurosciences Prize 2016 [MB-40-2016]; FEDER-CENTRO 2020-CENTRO-01-0145-FEDER-000012 (HealthyAging 2020); COMPETE; FCT [POCI-01-0145-FEDER-029221, UIDB/04539/2020, Pest-C/SAU/UI3282/2013-2014, CNC.IBILI UID/NEU/04539/2013]; PT2020/COMPETE 2020; FCT/FUNCAP [POCTI-FEDER-02/SAICT/2017/31699]; Brazilian CAPES-PROCAD [144494]; CNPq-PVE	Santa Casa da Misericordia de Lisboa-Mantero Belard Neurosciences Prize 2016; FEDER-CENTRO 2020-CENTRO-01-0145-FEDER-000012 (HealthyAging 2020); COMPETE; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); PT2020/COMPETE 2020; FCT/FUNCAP; Brazilian CAPES-PROCAD; CNPq-PVE	The authors would like to acknowledge funding from Santa Casa da Misericordia de Lisboa-Mantero Belard Neurosciences Prize 2016 (MB-40-2016), FEDER-CENTRO 2020-CENTRO-01-0145-FEDER-000012 (HealthyAging 2020) and COMPETE and FCT (POCI-01-0145-FEDER-029221 and UIDB/04539/2020), Pest-C/SAU/UI3282/2013-2014 and CNC.IBILI UID/NEU/04539/2013 with national funds PT2020/COMPETE 2020 and FCT/FUNCAP (POCTI-FEDER-02/SAICT/2017/31699), Brazilian CAPES-PROCAD (071/2013 # 144494) and CNPq-PVE grants.		0	2	2	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 6	2020	11								1758	10.3389/fimmu.2020.01758	http://dx.doi.org/10.3389/fimmu.2020.01758			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF5CG	32849628	gold, Green Published			2022-12-18	WOS:000563313500001
J	Wu, JH; Wang, X; Lin, LY; Li, XM; Liu, SX; Zhang, W; Luo, LH; Wan, ZY; Fang, MY; Zhao, Y; Wang, XD; Mai, HR; Yuan, XL; Wen, FQ; Li, CG; Liu, X				Wu, Jinghua; Wang, Xie; Lin, Liya; Li, Xuemei; Liu, Sixi; Zhang, Wei; Luo, Lihua; Wan, Ziyun; Fang, Mingyan; Zhao, Yi; Wang, Xiaodong; Mai, Huirong; Yuan, Xiuli; Wen, Feiqiu; Li, Changgang; Liu, Xiao			Developing an Unbiased Multiplex PCR System to Enrich theTRBRepertoire Toward Accurate Detection in Leukemia	FRONTIERS IN IMMUNOLOGY			English	Article						immune repertoire; TRB; multiplex PCR system optimization; minimal residual disease; leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; INFILTRATING IMMUNE CELLS; LYMPHOBLASTIC-LEUKEMIA; RESIDUAL DISEASE; TCR; DIVERSITY; CHILDREN; CANCER; MEMORY	Accurate T cell receptor repertoire profiling has provided novel biological and clinical insights in widespread immunological settings; however, there is a lack of reference materials in the community that can be used to calibrate and optimize the various experimental systems in different laboratories. In this study, we designed and synthesized 611 T cell receptor (TCR) beta chain (TRB) templates and used them as reference materials to optimize the multiplex PCR experimental system to enrich theTRBrepertoire. We assessed the stability of the optimized system by repeating the experiments in different batches and by remixing the TRB templates in different ratios. These TRB reference materials could be used as independent positive controls to assess the accuracy of the experimental system, and they can also be used as spike-in materials to calibrate the residual biases of the experimental system. We then used the optimized system to detect the minimal residual disease of T cell acute lymphoblastic leukemia and showed a higher sensitivity compared with flow cytometry. We also interrogated how chemotherapy affected the TCR repertoire of patients with B-cell acute lymphoblastic leukemia. Our result shows that high-avidity T cells, such as those targeting known pathogens, are largely selected during chemotherapy, despite the global immunosuppression. These T cells were stimulated and emerged at the time of induction treatment and further expanded during consolidation treatment, possibly to fight against infections. These data demonstrate that accurate immune repertoire information can improve our understanding of the adaptive immunity in leukemia and lead to better treatment management of the patients.	[Wu, Jinghua; Luo, Lihua] Univ Chinese Acad Sci, BGI Educ Ctr, Shenzhen, Peoples R China; [Wu, Jinghua; Wang, Xie; Lin, Liya; Li, Xuemei; Zhang, Wei; Luo, Lihua; Wan, Ziyun; Fang, Mingyan; Zhao, Yi; Liu, Xiao] BGI Shenzhen, Shenzhen, Peoples R China; [Liu, Sixi; Wang, Xiaodong; Mai, Huirong; Yuan, Xiuli; Wen, Feiqiu; Li, Changgang] Shenzhen Childrens Hosp, Hematol & Oncol Dept, Shenzhen, Peoples R China; [Zhang, Wei] City Univ Hong Kong, Dept Comp Sci, Hong Kong, Peoples R China; [Liu, Xiao] Neoimmune, Shenzhen, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Beijing Genomics Institute (BGI); City University of Hong Kong	Liu, X (corresponding author), BGI Shenzhen, Shenzhen, Peoples R China.; Li, CG (corresponding author), Shenzhen Childrens Hosp, Hematol & Oncol Dept, Shenzhen, Peoples R China.; Liu, X (corresponding author), Neoimmune, Shenzhen, Peoples R China.	licg6336@sina.com; airson_LIU@163.com	Mai, Huirong/AAH-3768-2021; Liu, Xiao/P-2732-2015	Liu, Xiao/0000-0002-8073-0534; Fang, Mingyan/0000-0001-7185-6445; Zhang, Wei/0000-0002-6968-6974; Luo, Lihua/0000-0002-2129-4226	National Natural Science Foundation of China [31800765]; Science, Technology and Innovation Commission of Shenzhen Municipality [JCYJ20170817145404433]; Sanming Project of Medicine in Shenzhen [SZSM201512033]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science, Technology and Innovation Commission of Shenzhen Municipality; Sanming Project of Medicine in Shenzhen	This project has been funded by the National Natural Science Foundation of China under No. 31800765, the Science, Technology and Innovation Commission of Shenzhen Municipality under No. JCYJ20170817145404433, and Sanming Project of Medicine in Shenzhen (SZSM201512033).	Ansell SM, 2001, J CLIN ONCOL, V19, P720, DOI 10.1200/JCO.2001.19.3.720; Barnes TA, 2017, BRIT J CANCER, V117, P451, DOI 10.1038/bjc.2017.220; Becattini S, 2015, SCIENCE, V347, P400, DOI 10.1126/science.1260668; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Cha E, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008211; Eyrich M, 2009, BRIT J HAEMATOL, V147, P360, DOI 10.1111/j.1365-2141.2009.07862.x; Freeman JD, 2009, GENOME RES, V19, P1817, DOI 10.1101/gr.092924.109; Gao K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02064; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gomez-Tourino I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01925-2; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Haining WN, 2005, BLOOD, V106, P1749, DOI 10.1182/blood-2005-03-1082; Hogan SA, 2019, CANCER IMMUNOL RES, V7, P77, DOI 10.1158/2326-6066.CIR-18-0136; Hopkins AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122092; Hou DN, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00336; Huang C, 2019, J AUTOIMMUN, V97, P100, DOI 10.1016/j.jaut.2018.10.018; Keane C, 2017, CLIN CANCER RES, V23, P1820, DOI 10.1158/1078-0432.CCR-16-1576; Keane C, 2013, AM J HEMATOL, V88, P273, DOI 10.1002/ajh.23398; Khan TA, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501371; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Liu X, 2019, ANN RHEUM DIS, V78, P1070, DOI 10.1136/annrheumdis-2019-215442; Liu X, 2018, CELL BIOL TOXICOL, V34, P441, DOI 10.1007/s10565-018-9426-0; Liu Xiao, 2016, PLoS One, V11, pe0152464, DOI 10.1371/journal.pone.0152464; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Ramsay AG, 2012, BLOOD, V120, P1412, DOI 10.1182/blood-2012-02-411678; Rezvany MR, 2003, BLOOD, V101, P1063, DOI 10.1182/blood-2002-03-0746; Riches JC, 2013, HEMATOL ONCOL CLIN N, V27, P207, DOI 10.1016/j.hoc.2013.01.003; Riches JC, 2013, BLOOD, V121, P1612, DOI 10.1182/blood-2012-09-457531; Robins H, 2013, CURR OPIN IMMUNOL, V25, P646, DOI 10.1016/j.coi.2013.09.017; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rosati E, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0379-9; Rubelt F, 2017, NAT IMMUNOL, V18, P1274, DOI 10.1038/ni.3873; Shifrut E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00379; Six A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00413; van Tilburg CM, 2011, BRIT J HAEMATOL, V152, P201, DOI 10.1111/j.1365-2141.2010.08478.x; Vardi A, 2016, CLIN CANCER RES, V22, P167, DOI 10.1158/1078-0432.CCR-14-3017; Wang CL, 2010, P NATL ACAD SCI USA, V107, P1518, DOI 10.1073/pnas.0913939107; Wang LL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02194; Wang T, 2017, CANCER IMMUNOL RES, V5, P148, DOI 10.1158/2326-6066.CIR-16-0107; Wood B, 2018, BLOOD, V131, P1350, DOI 10.1182/blood-2017-09-806521; Woodsworth DJ, 2013, GENOME MED, V5, DOI 10.1186/gm502; Wu D, 2014, CLIN CANCER RES, V20, P4540, DOI 10.1158/1078-0432.CCR-13-3231; Wu D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003656; Wu JH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00403; Yin Q, 2017, J IMMUNOL, V198, P1740, DOI 10.4049/jimmunol.1601190; Zhang W, 2015, GENETICS, V201, P459, DOI 10.1534/genetics.115.176735; Zhao X, 2019, ALLERGY EUR J ALLERG, V75, P681, DOI [10.1111/all.14014, DOI 10.1111/ALL.14014]	47	2	2	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 6	2020	11								1631	10.3389/fimmu.2020.01631	http://dx.doi.org/10.3389/fimmu.2020.01631			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF5HQ	32849555	gold, Green Published			2022-12-18	WOS:000563327700001
J	Pattyn, J; Van Keer, S; Teblick, L; Van Damme, P; Vorsters, A				Pattyn, Jade; Van Keer, Severien; Teblick, Laura; Van Damme, Pierre; Vorsters, Alex			Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine	FRONTIERS IN IMMUNOLOGY			English	Article						humaan papillomavirus; HPV vaccination; HPV antibodies; urine; HPV serology	HUMAN-PAPILLOMAVIRUS; IMMUNOGENICITY; PERFORMANCE; SAMPLES; GIRLS	The potential of first-void (FV) urine as a non-invasive method to monitor human papillomavirus (HPV) vaccination has been reported, mainly focusing on urine as a sample to assess HPV DNA. Besides HPV DNA, vaccine-induced HPV antibodies originating from cervicovaginal secretions were recently shown to be detectable in FV urine as well. This presents a novel opportunity for non-invasive sampling to monitor HPV antibody status in women participating in large epidemiological studies and HPV vaccine trials. The simultaneous assessment of both HPV infection and immunogenicity on a non-invasive, readily obtained sample is particularly attractive.	[Pattyn, Jade; Van Keer, Severien; Teblick, Laura; Van Damme, Pierre; Vorsters, Alex] Univ Antwerp, Fac Med & Hlth Sci, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst VAXINFECTIO, Antwerp, Belgium	University of Antwerp	Pattyn, J (corresponding author), Univ Antwerp, Fac Med & Hlth Sci, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst VAXINFECTIO, Antwerp, Belgium.	jade.pattyn@uantwerpen.be	vorsters, alex/A-9605-2012	vorsters, alex/0000-0002-0265-058X; van damme, pierre/0000-0002-8642-1249; Teblick, Laura/0000-0002-7484-0956; Van Keer, Severien/0000-0003-1842-7478	Royal Belgian Academy of Medicine (GSK grant); Research Foundation Flanders [1240220N]	Royal Belgian Academy of Medicine (GSK grant); Research Foundation Flanders(FWO)	JP is supported by a Ph.D. fellowship of the Royal Belgian Academy of Medicine (GSK grant). SV is supported by a junior postdoctoral fellowship of the Research Foundation Flanders (1240220N).	Arbyn M, 2018, J CLIN VIROL, V107, P52, DOI 10.1016/j.jcv.2018.08.006; Cuzick J, 2017, CANCER EPIDEM BIOMAR, V26, P1053, DOI [10.1158/1055-9965.EPI-16-0960, 10.1158/1055-9965.epi-16-0960]; Draper E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061825; Einstein MH, 2014, HUM VACC IMMUNOTHER, V10, P3455, DOI 10.4161/hv.36117; Franceschi S, 2018, VACCINE, V36, P4816, DOI 10.1016/j.vaccine.2018.02.002; Franceschi S, 2016, INT J CANCER, V139, P518, DOI 10.1002/ijc.30092; Handisurya A, 2016, BRIT J CANCER, V114, P409, DOI 10.1038/bjc.2015.462; Kemp TJ, 2008, VACCINE, V26, P3608, DOI 10.1016/j.vaccine.2008.04.074; Leeman A, 2017, BJOG-INT J OBSTET GY, V124, P1356, DOI 10.1111/1471-0528.14682; Louie KS, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00043-18, 10.1128/msphere.00043-18]; Mestecky J, 2005, AM J REPROD IMMUNOL, V53, P208, DOI 10.1111/j.1600-0897.2005.00267.x; Nardelli-Haefliger D, 2003, JNCI-J NATL CANCER I, V95, P1128, DOI 10.1093/jnci/djg018; Parker KH, 2018, VACCINE, V36, P2705, DOI 10.1016/j.vaccine.2018.03.034; PATHAK N, 2014, BMJ BRIT MED J, V349; Pattyn J, 2020, J MED VIROL, V92, P3774, DOI 10.1002/jmv.25841; Pattyn J, 2019, EXPERT REV ANTI-INFE, V17, P755, DOI 10.1080/14787210.2019.1668776; Pattyn J, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100185; Rowhani-Rahbar A, 2009, J INFECT DIS, V200, P1452, DOI 10.1086/606026; Scherpenisse M, 2013, HUM VACC IMMUNOTHER, V9, P314, DOI 10.4161/hv.22693; Schwarz TF, 2010, HUM VACCINES, V6, P1054, DOI 10.4161/hv.6.12.13399; Senkomago V, 2016, J CLIN VIROL, V74, P26, DOI 10.1016/j.jcv.2015.11.005; Stanley M, 2006, VACCINE, V24, P106, DOI 10.1016/j.vaccine.2006.05.110; Tshomo U, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0744-2; Turner TB, 2016, HUM VACC IMMUNOTHER, V12, P1403, DOI 10.1080/21645515.2015.1103936; Van Keer S, 2019, J CLIN VIROL, V117, P11, DOI 10.1016/j.jcv.2019.05.004; Vorsters A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6252	26	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 5	2020	11								1657	10.3389/fimmu.2020.01657	http://dx.doi.org/10.3389/fimmu.2020.01657			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF3QT	32849573	gold, Green Published			2022-12-18	WOS:000563213600001
J	Cantoni, C; Granata, S; Bruschi, M; Spaggiari, GM; Candiano, G; Zaza, G				Cantoni, Claudia; Granata, Simona; Bruschi, Maurizio; Spaggiari, Grazia Maria; Candiano, Giovanni; Zaza, Gianluigi			Recent Advances in the Role of Natural Killer Cells in Acute Kidney Injury	FRONTIERS IN IMMUNOLOGY			English	Review						inflammation; natural killer (NK) cells; tubular epithelial cells; acute kidney injury; innate immunity	INNATE LYMPHOID-CELLS; TUBULAR EPITHELIAL-CELLS; HUMAN NK CELLS; HUMAN CYTOMEGALOVIRUS-INFECTION; CLINICAL-PRACTICE GUIDELINE; TOLL-LIKE RECEPTORS; CLASS-I MOLECULES; ISCHEMIA-REPERFUSION; TISSUE-RESIDENT; RENAL ISCHEMIA	Growing evidence is revealing a central role for natural killer (NK) cells, cytotoxic cells belonging to the broad family of innate lymphoid cells (ILCs), in acute and chronic forms of renal disease. NK cell effector functions include both the recognition and elimination of virus-infected and tumor cells and the capability of sensing pathogens through Toll-like receptor (TLR) engagement. Notably, they also display immune regulatory properties, exerted thanks to their ability to secrete cytokines/chemokines and to establish interactions with different innate and adaptive immune cells. Therefore, because of their multiple functions, NK cells may have a major pathogenic role in acute kidney injury (AKI), and a better understanding of the molecular mechanisms driving NK cell activation in AKI and their downstream interactions with intrinsic renal cells and infiltrating immune cells could help to identify new potential biomarkers and to select clinically valuable novel therapeutic targets. In this review, we discuss the current literature regarding the potential involvement of NK cells in AKI.	[Cantoni, Claudia] IRCCS Ist Giannina Gaslini, Lab Clin & Expt Immunol, Integrated Dept Serv & Labs, Genoa, Italy; [Cantoni, Claudia; Spaggiari, Grazia Maria] Univ Genoa, Dept Expt Med DIMES, Genoa, Italy; [Cantoni, Claudia; Spaggiari, Grazia Maria] Univ Genoa, Ctr Excellence Biomed Res CEBR, Genoa, Italy; [Granata, Simona; Zaza, Gianluigi] Univ Hosp Verona, Dept Med, Renal Unit, Verona, Italy; [Bruschi, Maurizio; Candiano, Giovanni] IRCCS Ist Giannina Gaslini, Lab Mol Nephrol, Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; University of Genoa; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Genoa; IRCCS Istituto Giannina Gaslini	Zaza, G (corresponding author), Univ Hosp Verona, Dept Med, Renal Unit, Verona, Italy.	gianluigi.zaza@univr.it	Zaza, Gianluigi/K-3827-2018; Cantoni, Claudia/J-8732-2018; Bruschi, Maurizio/E-7090-2016	Cantoni, Claudia/0000-0001-6471-1424; Bruschi, Maurizio/0000-0001-6036-1500; SPAGGIARI, GRAZIA MARIA/0000-0002-0981-3265	Compagnia di San Paolo [ROL 20729]; Renal Child Foundation	Compagnia di San Paolo(Compagnia di San Paolo); Renal Child Foundation	This work was supported by the following grants: Compagnia di San Paolo (ID ROL 20729) (CC, GS, and GC); funds from Renal Child Foundation (MB and GC).	Allam R, 2012, J AM SOC NEPHROL, V23, P1375, DOI 10.1681/ASN.2011111077; Anders HJ, 2010, J AM SOC NEPHROL, V21, P1270, DOI 10.1681/ASN.2010030233; Arase H, 2001, J IMMUNOL, V167, P1141, DOI 10.4049/jimmunol.167.3.1141; Ardolino M, 2011, BLOOD, V117, P4778, DOI 10.1182/blood-2010-08-300954; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Ascon DB, 2006, J IMMUNOL, V177, P3380, DOI 10.4049/jimmunol.177.5.3380; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Barrow AD, 2018, CELL, V172, P534, DOI 10.1016/j.cell.2017.11.037; Barrow AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00909; Barry R, 2015, NEPHRON, V131, P221, DOI 10.1159/000441425; Basile DP, 1996, AM J PHYSIOL-RENAL, V270, pF500, DOI 10.1152/ajprenal.1996.270.3.F500; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Baychelier F, 2013, BLOOD, V122, P2935, DOI 10.1182/blood-2013-03-489054; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bellora F, 2010, P NATL ACAD SCI USA, V107, P21659, DOI 10.1073/pnas.1007654108; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bjorkstrom NK, 2016, NAT REV IMMUNOL, V16, P310, DOI 10.1038/nri.2016.34; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Bonventre JV, 2011, J CLIN INVEST, V121, P4210, DOI 10.1172/JCI45161; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Bottino C, 2005, TRENDS IMMUNOL, V26, P221, DOI 10.1016/j.it.2005.02.007; Brandt CS, 2009, J EXP MED, V206, P1495, DOI 10.1084/jem.20090681; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Cameron GJM, 2019, J PATHOL, V248, P9, DOI 10.1002/path.5242; Campbell JJ, 2001, J IMMUNOL, V166, P6477, DOI 10.4049/jimmunol.166.11.6477; Cao Q, 2018, J AM SOC NEPHROL, V29, P961, DOI 10.1681/ASN.2017070774; Carrega P, 2014, J IMMUNOL, V192, P3805, DOI 10.4049/jimmunol.1301889; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Castriconi R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02324; Cen C, 2017, SHOCK, V47, P52, DOI 10.1097/SHK.0000000000000721; Cerwenka A, 2001, IMMUNOL REV, V181, P158, DOI 10.1034/j.1600-065X.2001.1810113.x; Cerwenka A, 2016, NAT REV IMMUNOL, V16, P112, DOI 10.1038/nri.2015.9; Chen GE, 2011, NEPHROL DIAL TRANSPL, V26, P3873, DOI 10.1093/ndt/gfr234; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; Cibrian D, 2017, EUR J IMMUNOL, V47, P946, DOI 10.1002/eji.201646837; Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x; Colonna M, 2009, IMMUNITY, V31, P15, DOI 10.1016/j.immuni.2009.06.008; Cong JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01416; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Cooper MA, 2010, IMMUNOL REV, V235, P297, DOI 10.1111/j.0105-2896.2010.00891.x; Cortez VS, 2014, J IMMUNOL, V192, P4487, DOI 10.4049/jimmunol.1303469; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Crinier A, 2018, IMMUNITY, V49, P971, DOI 10.1016/j.immuni.2018.09.009; Cuff AO, 2016, J IMMUNOL, V197, P4283, DOI 10.4049/jimmunol.1601424; Cupedo T, 2009, NAT IMMUNOL, V10, P66, DOI 10.1038/ni.1668; De Maria A, 2011, P NATL ACAD SCI USA, V108, P728, DOI 10.1073/pnas.1012356108; Della Chiesa M, 2014, J IMMUNOL, V192, P1471, DOI 10.4049/jimmunol.1302053; Demmers MWHJ, 2014, TRANSPLANTATION, V97, P1110, DOI 10.1097/TP.0000000000000108; Diefenbach A, 2017, IMMUNITY, V46, P327, DOI 10.1016/j.immuni.2017.03.008; Du C, 2006, AM J TRANSPLANT, V6, P2256, DOI 10.1111/j.1600-6143.2006.01478.x; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; El-Gazzar A, 2013, J IMMUNOL, V191, P1509, DOI 10.4049/jimmunol.1301071; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Feng L, 2006, TRANSPL P, V38, P2195, DOI 10.1016/j.transproceed.2006.06.013; Ferlazzo G, 2004, J IMMUNOL, V172, P1455, DOI 10.4049/jimmunol.172.3.1455; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Freud AG, 2006, J EXP MED, V203, P1033, DOI 10.1084/jem.20052507; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Fuchs A, 2013, IMMUNITY, V38, P769, DOI 10.1016/j.immuni.2013.02.010; Gaggero S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1470730; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Gomez H, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000052; Gregoire C, 2007, IMMUNOL REV, V220, P169, DOI 10.1111/j.1600-065X.2007.00563.x; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Guan QN, 2010, TRANSPLANTATION, V89, P1320, DOI 10.1097/TP.0b013e3181d8e9dc; Guia S, 2020, TRENDS IMMUNOL, V41, P436, DOI 10.1016/j.it.2020.03.002; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Hanna J, 2006, NAT MED, V12, P1065, DOI 10.1038/nm1452; Harmon C, 2016, EUR J IMMUNOL, V46, P2111, DOI 10.1002/eji.201646559; Hayakawa Y, 2006, IMMUNOL REV, V214, P47, DOI 10.1111/j.1600-065X.2006.00454.x; Hervier B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01263; Horowitz A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006702; Horton NC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00031; Huang QS, 2015, J AM SOC NEPHROL, V26, P2199, DOI 10.1681/ASN.2014050479; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Hudspeth K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00069; Huntington ND, 2007, NAT REV IMMUNOL, V7, P703, DOI 10.1038/nri2154; James M, 2013, AM J KIDNEY DIS, V61, P673, DOI 10.1053/j.ajkd.2013.02.350; Jang HR, 2015, NAT REV NEPHROL, V11, P88, DOI 10.1038/nrneph.2014.180; Jang HR, 2009, CLIN IMMUNOL, V130, P41, DOI 10.1016/j.clim.2008.08.016; Jha V, 2014, NAT REV NEPHROL, V10, P550, DOI 10.1038/nrneph.2014.160; Juelke K, 2010, BLOOD, V116, P1299, DOI 10.1182/blood-2009-11-253286; Killig M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00142; Kim HJ, 2013, J IMMUNOL, V191, P2657, DOI 10.4049/jimmunol.1300358; Kim HJ, 2012, P NATL ACAD SCI USA, V109, pE13, DOI 10.1073/pnas.1112256109; Kim S, 2002, NAT IMMUNOL, V3, P523, DOI 10.1038/ni796; Koch J, 2013, TRENDS IMMUNOL, V34, P182, DOI 10.1016/j.it.2013.01.003; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; Kruse PH, 2014, IMMUNOL CELL BIOL, V92, P221, DOI 10.1038/icb.2013.98; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Lam RA, 2013, ANN MED, V45, P384, DOI 10.3109/07853890.2013.792495; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Law BMP, 2017, KIDNEY INT, V92, P79, DOI 10.1016/j.kint.2017.02.006; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335; Lee S, 2011, J AM SOC NEPHROL, V22, P317, DOI 10.1681/ASN.2009060615; Leemans JC, 2005, J CLIN INVEST, V115, P2894, DOI 10.1172/JCI22832; Li L, 2008, KIDNEY INT, V74, P1526, DOI 10.1038/ki.2008.500; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Lopez-Botet M, 2000, SEMIN IMMUNOL, V12, P109, DOI 10.1006/smim.2000.0213; Lopez-Botet M, 2014, SEMIN IMMUNOL, V26, P145, DOI 10.1016/j.smim.2014.03.002; Lopez-Verges S, 2011, P NATL ACAD SCI USA, V108, P14725, DOI 10.1073/pnas.1110900108; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Lugli E, 2016, EUR J IMMUNOL, V46, P1809, DOI 10.1002/eji.201545702; Luo L, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-91; Maghazachi AA, 2010, CURR TOP MICROBIOL, V341, P37, DOI 10.1007/82_2010_20; Marquardt N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11632-9; Marquardt N, 2015, J IMMUNOL, V194, P2467, DOI 10.4049/jimmunol.1402756; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Melsen JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00262; Michel T, 2016, J IMMUNOL, V196, P2923, DOI 10.4049/jimmunol.1502570; Moffett A, 2014, J CLIN INVEST, V124, P1872, DOI 10.1172/JCI68107; Moore PK, 2018, AM J KIDNEY DIS, V72, P136, DOI 10.1053/j.ajkd.2017.11.021; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Moretta L, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00087; Muntasell A, 2013, EUR J IMMUNOL, V43, P1133, DOI 10.1002/eji.201243117; NAGLER A, 1989, J IMMUNOL, V143, P3183; Narni-Mancinelli E, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam9628; Noiri E, 1999, KIDNEY INT, V56, P74, DOI 10.1046/j.1523-1755.1999.00526.x; Palevsky PM, 2013, AM J KIDNEY DIS, V61, P649, DOI 10.1053/j.ajkd.2013.02.349; Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570; Parodi M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00719; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; Peng H, 2017, SEMIN IMMUNOL, V31, P3, DOI 10.1016/j.smim.2017.07.006; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; Persy VP, 2003, KIDNEY INT, V63, P543, DOI 10.1046/j.1523-1755.2003.00767.x; Pesce S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00510; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; POLLACK SB, 1994, J LEUKOCYTE BIOL, V55, P398, DOI 10.1002/jlb.55.3.398; Pulskens WP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003596; Rabb H, 1997, KIDNEY INT, V51, P1463, DOI 10.1038/ki.1997.200; Radi ZA, 2018, TOXICOL PATHOL, V46, P930, DOI 10.1177/0192623318799976; Raulet DH, 2006, SEMIN IMMUNOL, V18, P145, DOI 10.1016/j.smim.2006.03.003; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Riedel JH, 2017, J AM SOC NEPHROL, V28, P2068, DOI 10.1681/ASN.2016080877; Riggan L, 2019, TRENDS IMMUNOL, V40, P909, DOI 10.1016/j.it.2019.08.005; Romagnani C, 2007, J IMMUNOL, V178, P4947, DOI 10.4049/jimmunol.178.8.4947; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Rosental B, 2011, J IMMUNOL, V187, P5693, DOI 10.4049/jimmunol.1102267; Rosin DL, 2011, J AM SOC NEPHROL, V22, P416, DOI 10.1681/ASN.2010040430; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shigeoka AA, 2007, J IMMUNOL, V178, P6252, DOI 10.4049/jimmunol.178.10.6252; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Simoni Y, 2017, IMMUNITY, V46, P148, DOI 10.1016/j.immuni.2016.11.005; Sivori S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00105; Sojka DK, 2014, SEMIN IMMUNOL, V26, P127, DOI 10.1016/j.smim.2014.01.010; Sojka DK, 2014, ELIFE, V3, DOI 10.7554/eLife.01659; Song H, 2015, INT J MOL MED, V36, P1180, DOI 10.3892/ijmm.2015.2317; Spits H, 2016, NAT IMMUNOL, V17, P758, DOI 10.1038/ni.3482; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Tessmer MS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001254; Thoren FB, 2012, J IMMUNOL, V188, P1668, DOI 10.4049/jimmunol.1102002; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Tsuboi N, 2002, J IMMUNOL, V169, P2026, DOI 10.4049/jimmunol.169.4.2026; Turner JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00587; Turner JE, 2018, J AM SOC NEPHROL, V29, P389, DOI 10.1681/ASN.2017060599; Vacca P, 2018, IMMUNOL LETT, V201, P14, DOI 10.1016/j.imlet.2018.11.004; Vacca P, 2011, TRENDS IMMUNOL, V32, P517, DOI 10.1016/j.it.2011.06.013; Victorino F, 2015, J IMMUNOL, V195, P4973, DOI 10.4049/jimmunol.1500651; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; von Strandmann EP, 2007, IMMUNITY, V27, P965, DOI 10.1016/j.immuni.2007.10.010; Walzer T, 2007, NAT IMMUNOL, V8, P1337, DOI 10.1038/ni1523; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; Wee YM, 2019, BMB REP, V52, P554, DOI 10.5483/BMBRep.2019.52.9.193; Weizman OE, 2017, CELL, V171, P795, DOI 10.1016/j.cell.2017.09.052; Wensveen FM, 2015, NAT IMMUNOL, V16, P376, DOI 10.1038/ni.3120; Wu HL, 2007, J CLIN INVEST, V117, P2847, DOI 10.1172/JCI31008; Wu HL, 2010, J AM SOC NEPHROL, V21, P1878, DOI 10.1681/ASN.2009101048; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; Yang C, 2020, ELIFE, V9, DOI 10.7554/eLife.51339; Yeang HXA, 2017, J IMMUNOL, V198, P1417, DOI 10.4049/jimmunol.1601818; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; Yu JH, 2013, TRENDS IMMUNOL, V34, P573, DOI 10.1016/j.it.2013.07.005; Zhang BZ, 2008, J AM SOC NEPHROL, V19, P923, DOI 10.1681/ASN.2007090982; Zhang N, 2013, IMMUNITY, V39, P687, DOI 10.1016/j.immuni.2013.08.019; Zhang ZX, 2015, TRANSPLANTATION, V99, P916, DOI 10.1097/TP.0000000000000665; Zhang ZX, 2010, J IMMUNOL, V185, P967, DOI 10.4049/jimmunol.0903245; Zhang ZX, 2008, J IMMUNOL, V181, P7489, DOI 10.4049/jimmunol.181.11.7489; Zuk A, 2016, ANNU REV MED, V67, P293, DOI 10.1146/annurev-med-050214-013407	193	2	2	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2020	11								1484	10.3389/fimmu.2020.01484	http://dx.doi.org/10.3389/fimmu.2020.01484			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ND8RD	32903887	Green Published, gold			2022-12-18	WOS:000562169000001
J	Luo, JM; Shi, XW; Lin, Y; Cheng, N; Shi, YF; Wang, YH; Wu, BQ				Luo, Jinmei; Shi, Xiaowei; Lin, Ying; Cheng, Na; Shi, Yunfeng; Wang, Yanhong; Wu, Ben-Quan			Cytomegalovirus Infection in an Adult Patient With Neuromyelitis Optica and Acute Hemorrhagic Rectal Ulcer: Case Report and Literature Review	FRONTIERS IN IMMUNOLOGY			English	Review						case report; cytomegalovirus; immunocompetent; neuromyelitis optica; acute hemorrhagic rectal ulcer	CMV; BIOPSIES	Background:Previous infectious or inflammatory events may be involved in the pathogenesis of neuromyelitis optica (NMO), potentially by triggering an autoimmune response. Cytomegalovirus (CMV)-related NMO (CMV-NMO) is rarely reported. Acute hemorrhagic rectal ulcer (AHRU) is a rare disease with a largely unknown pathogenesis. Herein, we reported a co-NMO and AHRU case associated with CMV infection. In addition, we review previously reported cases of CMV-NMO and CMV-AHRU. Case presentation:A 40-year-old female diagnosed with aquaporin4 (AQP4)-IgG(+)NMO and a poor response to high-dose intravenous methylprednisolone and immunoglobulin, followed by three rounds of plasma exchange was transferred to Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. She developed repeated acute lower gastrointestinal hemorrhage from the third day of admission. Abdominal computed tomography angiography (CTA) and interventional angiography did not detect any bleeding vessel. Bedside colonoscopy revealed a large ulcer-like lesion at 10 cm above the anus. Rectal biopsy pathology confirmed a CMV infection on day 23 post-admission, and cerebrospinal fluid (CSF) pathogen gene sequencing detected CMV gene copies on day 25 post-admission. After 2 weeks of treatment with ganciclovir and sodium phosphinate, the patient's lower gastrointestinal bleeding stopped, and her limb muscle strength and visual acuity gradually improved. After 4 weeks of antiviral therapy, colonoscopy showed that the intestinal wall of the original lesion was smooth. Hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) of a biopsy specimen was negative for CMV, her right eye vision was normal, and limb muscle strength had recovered. Serum AQP4-IgG was negative, and lesions on brain magnetic resonance imaging (MRI) manifested shrinkage. Conclusions:The benefits of antiviral therapy remain unclear; however, clinicians should be aware of the possibility of CMV-related NMO, if NMO was refractory to high-dose intravenous methylprednisolone, immunoglobulin, and plasma exchange. Moreover, clinicians should consider the possibility of CMV-related AHRU when recurrent acute lower gastrointestinal bleeding occurs in a patient.	[Luo, Jinmei; Shi, Xiaowei; Shi, Yunfeng; Wang, Yanhong; Wu, Ben-Quan] Sun Yat Sen Univ, Dept Internal Med, Med Intens Care Unit, Affiliated Hosp 3, Guangzhou, Peoples R China; [Luo, Jinmei; Shi, Xiaowei; Shi, Yunfeng; Wang, Yanhong; Wu, Ben-Quan] Sun Yat Sen Univ, Dept Internal Med, Div Resp Dis, Affiliated Hosp 3, Guangzhou, Peoples R China; [Lin, Ying] Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 3, Guangzhou, Peoples R China; [Cheng, Na] Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 3, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wu, BQ (corresponding author), Sun Yat Sen Univ, Dept Internal Med, Med Intens Care Unit, Affiliated Hosp 3, Guangzhou, Peoples R China.; Wu, BQ (corresponding author), Sun Yat Sen Univ, Dept Internal Med, Div Resp Dis, Affiliated Hosp 3, Guangzhou, Peoples R China.	wubq@mail.sysu.edu.cn			Guangdong Science and Technology Plan Project [2017A020215177]	Guangdong Science and Technology Plan Project	This work was supported by grants from the Guangdong Science and Technology Plan Project (2017A020215177). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banati M, 2013, EUR J NEUROL, V20, P1492, DOI 10.1111/ene.12072; Bate SL, 2010, CLIN INFECT DIS, V50, P1439, DOI 10.1086/652438; Bruscolini A, 2019, EXPERT REV NEUROTHER, V19, P1127, DOI 10.1080/14737175.2019.1648210; DELANCY H, 1974, SURGERY, V76, P830; Duan TJ, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1333-z; Jung JH, 2017, J DIGEST DIS, V18, P521, DOI 10.1111/1751-2980.12513; Juric-Sekhar G, 2017, HUM PATHOL, V60, P11, DOI 10.1016/j.humpath.2016.09.009; Karigane D, 2014, J INFECT CHEMOTHER, V20, P325, DOI 10.1016/j.jiac.2013.12.004; Kezuka Takeshi, 2013, Nippon Ganka Gakkai Zasshi, V117, P270; Komai T, 2018, GASTROENT RES PRACT, V2018; Liao XY, 2016, GASTROENTEROL RES, V9, P92, DOI 10.14740/gr725e; Limaye AP, 2008, JAMA-J AM MED ASSOC, V300, P413, DOI 10.1001/jama.300.4.413; Maneerattanaporn Monthira, 2012, J Med Assoc Thai, V95 Suppl 2, pS48; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; Meesing A, 2018, EXPERT REV CLIN PHAR, V11, P773, DOI 10.1080/17512433.2018.1501557; Muroishi T, 2018, J CLIN NEUROSCI, V48, P93, DOI 10.1016/j.jocn.2017.10.074; Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866; Sahoo MK, 2013, J CLIN MICROBIOL, V51, P3700, DOI 10.1128/JCM.01605-13; Simner PJ, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00472-18; Smith DM, 2016, CLIN INFECT DIS, V63, P1517, DOI 10.1093/cid/ciw612; Tran C, 2007, J INTERN MED, V261, P500, DOI 10.1111/j.1365-2796.2007.01794.x; Tseng CA, 2004, DIS COLON RECTUM, V47, P895, DOI 10.1007/s10350-004-0531-1; Varrin-Doyer M, 2012, ANN NEUROL, V72, P53, DOI 10.1002/ana.23651; Wang F, 2011, EUR J RADIOL, V80, P445, DOI 10.1016/j.ejrad.2010.06.024; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Zhong XN, 2018, J CLIN NEUROSCI, V47, P14, DOI 10.1016/j.jocn.2017.10.005	26	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2020	11								1634	10.3389/fimmu.2020.01634	http://dx.doi.org/10.3389/fimmu.2020.01634			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF6VV	32849558	gold, Green Published			2022-12-18	WOS:000563434700001
J	Wu, RQ; Zhang, DF; Zanvit, P; Jin, WW; Wang, H; Chen, WJ				Wu, Ruiqing; Zhang, Dunfang; Zanvit, Peter; Jin, Wenwen; Wang, Hao; Chen, WanJun			Identification and Regulation of TCR alpha beta(+)CD8 alpha alpha(+)Intraepithelial Lymphocytes in Murine Oral Mucosa	FRONTIERS IN IMMUNOLOGY			English	Article						TCR alpha beta(+)CD8 alpha alpha(+); intraepithelial lymphocytes; unconventional immune cells; TGF-beta; oral mucosa	FACTOR T-BET; TGF-BETA; INTRAEPITHELIAL LYMPHOCYTES; LICHEN-PLANUS; CELLS; ALPHA	TCR alpha beta(+)CD8 alpha alpha(+) intraepithelial lymphocytes (IELs) are abundant in gastrointestinal (GI) tract and play an important role in regulation of mucosal immunity and tolerance in the gut. However, it is unknown whether TCR alpha beta(+)CD8 alpha alpha(+) IELs exist in the oral mucosa and if yes, what controls their development. We here identified and characterized TCR alpha beta(+)CD8 alpha alpha(+) IELs from the murine oral mucosa. We showed that the number and function of TCR alpha beta(+)CD8 alpha alpha(+) IELs were regulated by TGF-beta. We further revealed that oral TCR alpha beta(+)CD8 alpha alpha(+) IELs could be altered under systemic inflammatory conditions and by antibiotic treatment at the neonatal age of the mice. Our findings have revealed a previously unrecognized population of oral IELs that may regulate oral mucosal immune responses.	[Wu, Ruiqing; Zhang, Dunfang; Zanvit, Peter; Jin, Wenwen; Wang, Hao; Chen, WanJun] Natl Inst Dent & Craniofacial Res, Mucosal Immunol Sect, NIH, Bethesda, MD 20892 USA; [Wu, Ruiqing; Wang, Hao] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Capital Medical University	Chen, WJ (corresponding author), Natl Inst Dent & Craniofacial Res, Mucosal Immunol Sect, NIH, Bethesda, MD 20892 USA.	wchen@dir.nidcr.nih.gov		Zhang, Dunfang/0000-0001-7545-9930	Intramural Research Program of the National Institutes of Health; National Institute of Dental and Craniofacial Research; National Natural Science Foundation of China [81470759]	Intramural Research Program of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the Intramural Research Program of the National Institutes of Health and the National Institute of Dental and Craniofacial Research. RW was supported by a grant from the National Natural Science Foundation of China (31800651). HW was supported by the National Natural Science Foundation of China (81470759).	Bai JP, 2009, J INTERF CYTOK RES, V29, P381, DOI 10.1089/jir.2008.0089; Chen QM, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/45327; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cheroutre H, 2011, NAT REV IMMUNOL, V11, P445, DOI 10.1038/nri3007; CHRIST M, 1994, J IMMUNOL, V153, P1936; Dan HX, 2010, INFLAMMATION, V33, P76, DOI 10.1007/s10753-009-9160-0; Eskan MA, 2012, NAT IMMUNOL, V13, P465, DOI 10.1038/ni.2260; Gladiator A, 2013, J IMMUNOL, V190, P521, DOI 10.4049/jimmunol.1202924; Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785; Hall BE, 2010, LAB INVEST, V90, P543, DOI 10.1038/labinvest.2010.5; Klose CSN, 2014, IMMUNITY, V41, P230, DOI 10.1016/j.immuni.2014.06.018; Konkel JE, 2017, IMMUNITY, V46, P660, DOI 10.1016/j.immuni.2017.03.015; Konkel JE, 2011, NAT IMMUNOL, V12, P312, DOI 10.1038/ni.1997; Lefrancois L, 2001, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0319s17; Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607; Mayans S, 2014, IMMUNITY, V41, P207, DOI 10.1016/j.immuni.2014.07.010; Montufar-Solis D, 2006, J IMMUNOL METHODS, V308, P251, DOI 10.1016/j.jim.2005.10.008; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; Reis BS, 2014, IMMUNITY, V41, P244, DOI 10.1016/j.immuni.2014.06.017; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Scully C, 2008, BRIT J ORAL MAX SURG, V46, P15, DOI 10.1016/j.bjoms.2007.07.199; Tu E, 2014, CYTOKINE GROWTH F R, V25, P423, DOI 10.1016/j.cytogfr.2014.07.014; Vasconcelos RM, 2016, J DENT RES, V95, P725, DOI 10.1177/0022034516641890; Wang H, 2013, INFLAMMATION, V36, P696, DOI 10.1007/s10753-013-9594-2; Wang YG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7511; Wu RQ, 2014, INT J ORAL SCI, V6, P125, DOI 10.1038/ijos.2014.48; Zanvit P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9424; Zhang X, 2015, NAT MED, V21, P895, DOI 10.1038/nm.3914; Zhu J, 2013, NATURE, V497, P494, DOI 10.1038/nature12110	29	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2020	11								1702	10.3389/fimmu.2020.01702	http://dx.doi.org/10.3389/fimmu.2020.01702			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NF6HE	32849598	gold, Green Published			2022-12-18	WOS:000563395500001
J	Zhang, X; Liu, ZT; Wu, ST; Sun, MS; Wei, JG; Qin, QW				Zhang, Xin; Liu, Zetian; Wu, Siting; Sun, Mengshi; Wei, Jingguang; Qin, Qiwei			Fish RIP1 Mediates Innate Antiviral Immune Responses Induced by SGIV and RGNNV Infection	FRONTIERS IN IMMUNOLOGY			English	Article						grouper; RIP1; SGIV; RGNNV; interaction	SINGAPORE GROUPER IRIDOVIRUS; ORANGE-SPOTTED GROUPER; MOLECULAR-CLONING; CELL-DEATH; DNA VIRUS; PROTEIN; TRAF2; TRIF; TRADD; PHOSPHORYLATION	Receptor interacting protein 1 (RIP1) is an essential sensor of cellular stress, which may respond to apoptosis or cell survival and participate in antiviral pathways. To investigate the roles of fish RIP1 in Singapore grouper iridovirus (SGIV) and red-spotted grouper nervous necrosis virus (RGNNV) infection, a RIP1 homolog from orange-spotted grouper (Epinephelus coioides) (EcRIP1) was cloned and characterized. EcRIP1 encoded a 679 amino acid protein that shares 83.28% identity with that ofPerca flavescensand contained a homologous N-terminal kinase (S-TKc) domain, a RIP isotype interaction motif (RHIM), and a C-terminal domain (DD). EcRIP1 was predominantly detected in immune tissues, and its expression was induced by RGNNV or SGIV infectionin vitro. Subcellular localization showed that EcRIP1 was distributed in the cytoplasm with point-like uniform and dot-like aggregation forms. Overexpression of EcRIP1 inhibited SGIV and RGNNV replication and positively regulated the expression levels of interferon (IFN) and IFN-stimulated genes and pro-inflammatory factors. EcRIP1 may interact with grouper tumor necrosis factor receptor type 1-associated DEATH domain protein (EcTRADD) to promote SGIV-induced apoptosis, and interact with grouper Toll/interleukin-1 receptor (TIR) domain containing adapter inducing interferon-beta (EcTRIF) and participate in Myeloid Differentiation Factor 88 (MyD88)-independent toll-like receptor (TLR) signaling. EcRIP1 may also interact with grouper tumor necrosis factor receptor-associated factors (TRAFs) as intracellular linker proteins and mediate the signaling of various downstream signaling pathways, including NF-kappa B and IFN. These results suggest that EcRIP1 may inhibit SGIV and RGNNV infection by regulating apoptosis and various signaling molecules. Our study offers new insights into the regulatory mechanism of RIP1-related signaling, and provides a novel perspective on fish diseases mediated by RIP1.	[Zhang, Xin; Liu, Zetian; Wu, Siting; Sun, Mengshi; Wei, Jingguang; Qin, Qiwei] South China Agr Univ, Joint Lab Guangdong Prov & Hong Kong Reg Marine B, Coll Marine Sci, Guangzhou, Peoples R China; [Zhang, Xin; Liu, Zetian; Wu, Siting; Sun, Mengshi; Wei, Jingguang; Qin, Qiwei] Guangdong Lab Lingnan Modern Agr, Guangzhou, Peoples R China; [Qin, Qiwei] Qingdao Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China	South China Agricultural University; Qingdao National Laboratory for Marine Science & Technology	Wei, JG; Qin, QW (corresponding author), South China Agr Univ, Joint Lab Guangdong Prov & Hong Kong Reg Marine B, Coll Marine Sci, Guangzhou, Peoples R China.; Wei, JG; Qin, QW (corresponding author), Guangdong Lab Lingnan Modern Agr, Guangzhou, Peoples R China.; Qin, QW (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao, Peoples R China.	weijg@scau.edu.cn; qinqw@scau.edu.cn	wei, jing/GXA-1455-2022		National Natural Science Foundation of China [31772882]; Open Fund of Key Laboratory of Experimental Marine Biology, Chinese Academy of Sciences [KF2018NO3]; National Key R&D Program of China [2018YFD0900501, 2018YFC0311302]; China Agriculture Research System [CARS-47-G16]; Science and Technology Planning Project of Guangdong Province, China [2015TQ01N118]; National High Technology Development Program of China (863) [2014AA093507]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Open Fund of Key Laboratory of Experimental Marine Biology, Chinese Academy of Sciences; National Key R&D Program of China; China Agriculture Research System; Science and Technology Planning Project of Guangdong Province, China; National High Technology Development Program of China (863)(National High Technology Research and Development Program of China)	This work was supported by grants from the National Natural Science Foundation of China (31772882), Open Fund of Key Laboratory of Experimental Marine Biology, Chinese Academy of Sciences (No. KF2018NO3), National Key R&D Program of China (2018YFD0900501 and 2018YFC0311302), China Agriculture Research System (CARS-47-G16), Science and Technology Planning Project of Guangdong Province, China (2015TQ01N118), and National High Technology Development Program of China (863) (2014AA093507).	Billie Au PY, 2007, ADV EXP MED BIOL, V597, P32; Chung JY, 2007, ADV EXP MED BIOL, V597, P93; Cusson-Hermance N, 2005, J BIOL CHEM, V280, P36560, DOI 10.1074/jbc.M506831200; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Gang MH, 2003, GENES DEV, V17, P873, DOI [10.1101/gad.106240312654725, DOI 10.1101/GAD.106240312654725]; GRAVELL M, 1965, ANN NY ACAD SCI, V126, P555, DOI 10.1111/j.1749-6632.1965.tb14302.x; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Guo ML, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00121; He M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27597; Hegde A, 2002, AQUACULTURE, V213, P55, DOI 10.1016/S0044-8486(02)00092-3; Hoebe K, 2006, TRENDS MOL MED, V12, P187, DOI 10.1016/j.molmed.2006.03.008; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang XH, 2013, FISH SHELLFISH IMMUN, V34, P1094, DOI 10.1016/j.fsi.2013.01.010; Huang XH, 2011, APOPTOSIS, V16, P831, DOI 10.1007/s10495-011-0616-y; Huang XH, 2009, AQUACULTURE, V292, P172, DOI 10.1016/j.aquaculture.2009.04.019; HUANG YH, 2011, BMC GENOMICS, V0012; Iwamoto T, 2005, J GEN VIROL, V86, P2807, DOI 10.1099/vir.0.80902-0; Ji JF, 2018, J IMMUNOL, V200, P573, DOI 10.4049/jimmunol.1701149; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Li J, 2011, J IMMUNOL, V187, P3962, DOI 10.4049/jimmunol.1100816; Liang B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246335; Meylan E, 2005, TRENDS BIOCHEM SCI, V30, P151, DOI 10.1016/j.tibs.2005.01.003; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Michallet MC, 2008, IMMUNITY, V28, P651, DOI 10.1016/j.immuni.2008.03.013; MORI KI, 1992, VIROLOGY, V187, P368, DOI 10.1016/0042-6822(92)90329-N; Park GB, 2015, J CELL MOL MED, V19, P1042, DOI 10.1111/jcmm.12495; Qin QW, 2003, DIS AQUAT ORGAN, V53, P1, DOI 10.3354/dao053001; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Song WJ, 2004, J VIROL, V78, P12576, DOI 10.1128/JVI.78.22.12576-12590.2004; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200; Wang SW, 2014, J VIROL, V88, P13047, DOI 10.1128/JVI.01744-14; Wei JG, 2017, FISH SHELLFISH IMMUN, V71, P295, DOI 10.1016/j.fsi.2017.09.063; Wei JG, 2017, FISH SHELLFISH IMMUN, V60, P6, DOI 10.1016/j.fsi.2016.11.008; ZHANG X, 2019, FRONT CELL INFECT MI, V0009; Zhang X, 2018, FISH SHELLFISH IMMUN, V74, P517, DOI 10.1016/j.fsi.2018.01.018; Zhou ZX, 2017, GENE, V626, P41, DOI 10.1016/j.gene.2017.05.011	42	2	3	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2020	11								1718	10.3389/fimmu.2020.01718	http://dx.doi.org/10.3389/fimmu.2020.01718			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ND8QY	32849607	Green Published, gold			2022-12-18	WOS:000562168500001
J	Cren, M; Nziza, N; Carbasse, A; Mahe, P; Dufourcq-Lopez, E; Delpont, M; Chevassus, H; Khalil, M; Mura, T; Duroux-Richard, I; Apparailly, F; Jeziorski, E; Louis-Plence, P				Cren, Mailys; Nziza, Nadege; Carbasse, Aurelia; Mahe, Perrine; Dufourcq-Lopez, Emilie; Delpont, Marion; Chevassus, Hugues; Khalil, Mirna; Mura, Thibault; Duroux-Richard, Isabelle; Apparailly, Florence; Jeziorski, Eric; Louis-Plence, Pascale			Differential Accumulation and Activation of Monocyte and Dendritic Cell Subsets in Inflamed Synovial Fluid Discriminates Between Juvenile Idiopathic Arthritis and Septic Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						juvenile idiopathic arthritis; septic arthritis; monocytes; dendritic cells; CD141 cDC; CD123 pDC; multiparametric flow cytometry	RHEUMATOID-ARTHRITIS; T-CELLS; CHILDREN; PD-L2; EXPRESSION; BLOOD; INFECTION; INDUCE; IMPACT; CD64	Despite their distinct etiology, several lines of evidence suggest that innate immunity plays a pivotal role in both juvenile idiopathic arthritis (JIA) and septic arthritis (SA) pathophysiology. Indeed, monocytes and dendritic cells (DC) are involved in the first line of defense against pathogens and play a critical role in initiating and orchestrating the immune response. The aim of this study was to compare the number and phenotype of monocytes and DCs in peripheral blood (PB) and synovial fluid (SF) from patients with JIA and SA to identify specific cell subsets and activation markers associated with pathophysiological mechanisms and that could be used as biomarkers to discriminate both diseases. The proportion of intermediate and non-classical monocytes in the SF and PB, respectively, were significantly higher in JIA than in SA patients. In contrast the proportion of classical monocytes and their absolute numbers were higher in the SF from SA compared with JIA patients. Higher expression of CD64 on non-classical monocyte was observed in PB from SA compared with JIA patients. In SF, higher expression of CD64 on classical and intermediate monocyte as well as higher CD163 expression on intermediate monocytes was observed in SA compared with JIA patients. Moreover, whereas the number of conventional (cDC), plasmacytoid (pDC) and inflammatory (infDC) DCs was comparable between groups in PB, the number of CD141(+)cDCs and CD123(+)pDCs in the SF was significantly higher in JIA than in SA patients. CD14(+)infDCs represented the major DC subset in the SF of both groups with potent activation assessed by high expression of HLA-DR and CD86 and significant up-regulation of HLA-DR expression in SA compared with JIA patients. Finally, higher activation of SF DC subsets was monitored in SA compared with JIA with significant up-regulation of CD86 and PDL2 expression on several DC subsets. Our results show the differential accumulation and activation of innate immune cells between septic and inflammatory arthritis. They strongly indicate that the relative high numbers of CD141(+)cDC and CD123(+)pDCs in SF are specific for JIA while the over-activation of DC and monocyte subsets is specific for SA.	[Cren, Mailys; Nziza, Nadege; Duroux-Richard, Isabelle; Apparailly, Florence; Louis-Plence, Pascale] Univ Montpellier, INSERM, IRMB, Montpellier, France; [Nziza, Nadege] Arthrit R&D, Neuilly Sur Seine, France; [Carbasse, Aurelia; Mahe, Perrine; Jeziorski, Eric] Univ Montpellier, CHU Montpellier, Pediat Dept, Montpellier, France; [Dufourcq-Lopez, Emilie] Univ Montpellier, CHU Montpellier, IRMB, Montpellier, France; [Delpont, Marion] Univ Montpellier, Pediat Orthoped Surg Unit, CHU Montpellier, Montpellier, France; [Chevassus, Hugues; Khalil, Mirna] Univ Montpellier, Ctr Invest Clin, CHU Montpellier, Montpellier, France; [Chevassus, Hugues; Khalil, Mirna] INSERM, CIC1411, Montpellier, France; [Mura, Thibault] Univ Montpellier, Clin Res & Epidemiol Unit, CHU Montpellier, Montpellier, France; [Apparailly, Florence] Univ Montpellier, Clin Dept Osteoarticular Dis, CHU Montpellier, Montpellier, France; [Jeziorski, Eric] Univ Montpellier, INSERM, PCCI, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Apparailly, F; Louis-Plence, P (corresponding author), Univ Montpellier, INSERM, IRMB, Montpellier, France.; Apparailly, F (corresponding author), Univ Montpellier, Clin Dept Osteoarticular Dis, CHU Montpellier, Montpellier, France.	florence.apparailly@inserm.fr; pascale.plence@inserm.fr	mura, Thibault/X-7279-2019; Louis-Plence, Pascale/H-1553-2015; Jeziorski, Eric/AAI-3530-2021	mura, Thibault/0000-0001-6420-1336; Louis-Plence, Pascale/0000-0001-7701-5241; Jeziorski, Eric/0000-0003-0318-3044; APPARAILLY, Florence/0000-0003-1762-084X	INSERM; University of Montpellier; Fondation de l'Avenir [AP-RMA-16-033]; CHU Montpellier [AOI ARTEMIS UF9361-2]; Region Occitanie; Arthritis RD [2015/1454]; ANRT (Association Nationale Recherche Technologie)	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Montpellier; Fondation de l'Avenir; CHU Montpellier; Region Occitanie(Region Occitanie); Arthritis RD; ANRT (Association Nationale Recherche Technologie)(French National Research Agency (ANR))	This work was supported by institutional funding from INSERM and University of Montpellier, by funding from Fondation de l'Avenir (N. AP-RMA-16-033), CHU Montpellier (AOI ARTEMIS UF9361-2 to EJ), Region Occitanie (DIANE). NN received a fellowship from Arthritis R&D (convention Cifre N. 2015/1454) and ANRT (Association Nationale Recherche Technologie).	Al-Qwbani M, 2016, CLIN PEDIATR, V55, P1328, DOI 10.1177/0009922816629620; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Aupiais C, 2017, ARCH DIS CHILD, V102, P316, DOI 10.1136/archdischild-2016-310594; Aupiais C, 2015, ARCH DIS CHILD, V100, P742, DOI 10.1136/archdischild-2014-307490; Boltjes A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00131; Canavan M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.95228; Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010; Cavanagh LL, 2005, ARTHRITIS RES THER, V7, pR230, DOI 10.1186/ar1467; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; de Jager W, 2007, ANN RHEUM DIS, V66, P589, DOI 10.1136/ard.2006.061853; de Padilla CML, 2007, ARTHRITIS RHEUM, V56, P1658, DOI 10.1002/art.22558; Dutertre CA, 2019, IMMUNITY, V51, P573, DOI 10.1016/j.immuni.2019.08.008; Fjaertoft G, 1999, PEDIATR RES, V45, P871, DOI 10.1203/00006450-199906000-00016; Fjaertoft G, 2007, SCAND J INFECT DIS, V39, P525, DOI 10.1080/00365540601113693; Ganguly D, 2013, NAT REV IMMUNOL, V13, P566, DOI 10.1038/nri3477; Gaur P, 2017, CLIN EXP IMMUNOL, V187, P234, DOI 10.1111/cei.12880; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Gottenberg JE, 2006, P NATL ACAD SCI USA, V103, P2770, DOI 10.1073/pnas.0510837103; Gregorio A, 2007, RHEUMATOLOGY, V46, P308, DOI 10.1093/rheumatology/kel225; Groselj-Grenc M, 2009, INTENS CARE MED, V35, P1950, DOI 10.1007/s00134-009-1637-7; Guignant C, 2011, CRIT CARE, V15, DOI 10.1186/cc10112; Hanabuchi S, 2010, J IMMUNOL, V184, P2999, DOI 10.4049/jimmunol.0804106; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Hofer TP, 2015, BLOOD, V126, P2601, DOI 10.1182/blood-2015-06-651331; Kavousanaki M, 2010, ARTHRITIS RHEUM-US, V62, P53, DOI 10.1002/art.25037; Kim OY, 2010, CRIT CARE, V14, DOI 10.1186/cc8959; Kinter AL, 2008, J IMMUNOL, V181, P6738, DOI 10.4049/jimmunol.181.10.6738; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lesterhuis WJ, 2011, MOL IMMUNOL, V49, P1, DOI 10.1016/j.molimm.2011.09.014; Li Song, 2013, J Clin Cell Immunol, V4; Li Y, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3017; Loke P, 2003, P NATL ACAD SCI USA, V100, P5336, DOI 10.1073/pnas.0931259100; Macaubas C, 2010, CLIN IMMUNOL, V134, P206, DOI 10.1016/j.clim.2009.09.010; Martin-Gayo E, 2010, BLOOD, V115, P5366, DOI 10.1182/blood-2009-10-248260; Messal N, 2011, MOL IMMUNOL, V48, P2214, DOI 10.1016/j.molimm.2011.06.436; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; MUKHERJEE R, 2015, SCI REP UK, V5; Nziza N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121521; Oppegaard O, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-278; Petty RE, 2001, J RHEUMATOL, V28, P927; Prakken B, 2011, LANCET, V377, P2138, DOI 10.1016/S0140-6736(11)60244-4; Reynolds G, 2016, ANN RHEUM DIS, V75, P899, DOI 10.1136/annrheumdis-2014-206578; RONNBLOM LE, 1991, ANN INTERN MED, V115, P178, DOI 10.7326/0003-4819-115-3-178; Rossol M, 2012, ARTHRITIS RHEUM-US, V64, P671, DOI 10.1002/art.33418; Segura E, 2013, IMMUNITY, V38, P336, DOI 10.1016/j.immuni.2012.10.018; Skrzeczynska J, 2002, SCAND J IMMUNOL, V55, P629, DOI 10.1046/j.1365-3083.2002.01092.x; Smiljanovic B, 2018, ANN RHEUM DIS, V77, P300, DOI 10.1136/annrheumdis-2017-211649; Smolewska E, 2008, ANN RHEUM DIS, V67, P762, DOI 10.1136/ard.2007.077669; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; Tanaka S, 2009, J BONE JOINT SURG BR, V91B, P1237, DOI 10.1302/0301-620X.91B9.22051; Throm AA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121544; van Bon L, 2014, NEW ENGL J MED, V370, P433, DOI 10.1056/NEJMoa1114576; Van Krinks CH, 2004, RHEUMATOLOGY, V43, P453, DOI 10.1093/rheumatology/keh115; Villadangos JA, 2008, IMMUNITY, V29, P352, DOI 10.1016/j.immuni.2008.09.002; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wall C, 2015, AUST FAM PHYSICIAN, V44, P213; Wedderburn LR, 2000, ARTHRITIS RHEUM-US, V43, P765, DOI 10.1002/1529-0131(200004)43:4<765::AID-ANR7>3.0.CO;2-B; Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3; Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355; Yoon BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109775; Zhong XM, 2007, EUR J IMMUNOL, V37, P2405, DOI 10.1002/eji.200737461	63	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 31	2020	11								1716	10.3389/fimmu.2020.01716	http://dx.doi.org/10.3389/fimmu.2020.01716			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC9RQ	32849606	Green Published, gold			2022-12-18	WOS:000561548300001
J	Nicolai, O; Potschke, C; Raafat, D; van der Linde, J; Quosdorf, S; Laqua, A; Heidecke, CD; Berek, C; Darisipudi, MN; Binder, CJ; Broker, BM				Nicolai, Oliver; Poetschke, Christian; Raafat, Dina; van der Linde, Julia; Quosdorf, Sandra; Laqua, Anna; Heidecke, Claus-Dieter; Berek, Claudia; Darisipudi, Murthy N.; Binder, Christoph J.; Broeker, Barbara M.			Oxidation-Specific Epitopes (OSEs) Dominate the B Cell Response in Murine Polymicrobial Sepsis	FRONTIERS IN IMMUNOLOGY			English	Article						CASP; polymicrobial sepsis; B cell response; polyreactive antibodies; oxidation-specific epitopes	ASCENDENS STENT PERITONITIS; CD4(+) T-LYMPHOCYTES; NATURAL ANTIBODIES; MARGINAL-ZONE; MEMORY B; PROFOUND DEPLETION; INDUCED APOPTOSIS; INNATE; BACTERIAL; ACTIVATION	In murine abdominal sepsis by colon ascendens stent peritonitis (CASP), a strong increase in serum IgM and IgG antibodies was observed, which reached maximum values 14 days following sepsis induction. The specificity of this antibody response was studied in serum and at the single cell level using a broad panel of bacterial, sepsis-unrelated as well as self-antigens. Whereas an antibacterial IgM/IgG response was rarely observed, studies at the single-cell level revealed that IgM antibodies, in particular, were largely polyreactive. Interestingly, at least 16% of the IgM mAbs and 20% of the IgG mAbs derived from post-septic mice showed specificity for oxidation-specific epitopes (OSEs), which are known targets of the innate/adaptive immune response. This identifies those self-antigens as the main target of B cell responses in sepsis.	[Nicolai, Oliver; Poetschke, Christian; Raafat, Dina; Quosdorf, Sandra; Laqua, Anna; Darisipudi, Murthy N.; Broeker, Barbara M.] Univ Med Greifswald, Inst Immunol & Transfus Med, Dept Immunol, Greifswald, Germany; [Raafat, Dina; Heidecke, Claus-Dieter] Alexandria Univ, Fac Pharm, Dept Microbiol & Immunol, Alexandria, Egypt; [van der Linde, Julia] Univ Med Greifswald, Dept Gen Surg Visceral Thorac & Vasc Surg, Greifswald, Germany; [Berek, Claudia] German Rheumatism Res Ctr DRFZ, Berlin, Germany; [Binder, Christoph J.] Med Univ Vienna, Ctr Mol Med, Dept Lab Med, Austrian Acad Sci, Vienna, Austria; [Nicolai, Oliver] ZAS Zent Arch Serv GmbH, Neubrandenburg, Germany; [Poetschke, Christian] Salutes Pharma GmbH, Barleben, Germany; [Laqua, Anna] Univ Hosp Schleswig Holstein, Dept Hematol, Kiel, Germany	Greifswald Medical School; Egyptian Knowledge Bank (EKB); Alexandria University; Greifswald Medical School; Deutsches Rheuma-Forschungszentrum (DRFZ); Austrian Academy of Sciences; Medical University of Vienna; University of Kiel; Schleswig Holstein University Hospital	Broker, BM (corresponding author), Univ Med Greifswald, Inst Immunol & Transfus Med, Dept Immunol, Greifswald, Germany.	broeker@uni-greifswald.de	Raafat, Dina/ABD-2266-2021	Binder, Christoph J./0000-0001-8313-7050; Raafat, Dina/0000-0002-3610-9863	German Research Foundation [RTG 840]; DFG (German Research Foundation) [393148499]; Open Access Publication Fund of the University of Greifswald	German Research Foundation(German Research Foundation (DFG)); DFG (German Research Foundation)(German Research Foundation (DFG)); Open Access Publication Fund of the University of Greifswald	This work was financially supported by the German Research Foundation (RTG 840; grants to ON, CP, and JL). We acknowledge support for the Article Processing Charge from the DFG (German Research Foundation, 393148499) and the Open Access Publication Fund of the University of Greifswald.	Barnay-Verdier S, 2011, INTENS CARE MED, V37, P957, DOI 10.1007/s00134-011-2192-6; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; Binder CJ, 2016, NAT REV IMMUNOL, V16, P485, DOI 10.1038/nri.2016.63; Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876; Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381; Burbelo PD, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-97; Busse M, 2008, GUT, V57, P188, DOI 10.1136/gut.2007.121616; Cabrera-Perez J, 2015, J IMMUNOL, V194, P1609, DOI 10.4049/jimmunol.1401711; Calis J, 2013, NEW ENGL J MED, V369, P2062, DOI [10.1056/NEJMc1312359, 10.1056/NEJMra1208623]; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800; COUTINHO A, 1974, J EXP MED, V139, P74, DOI 10.1084/jem.139.1.74; de Vinuesa CG, 1999, EUR J IMMUNOL, V29, P1314; Ehlers M, 2006, J EXP MED, V203, P553, DOI 10.1084/jem.20052438; Ehrenstein MR, 2010, NAT REV IMMUNOL, V10, P778, DOI 10.1038/nri2849; Fitzpatrick F, 2019, BMJ QUAL SAF, V28, P758, DOI 10.1136/bmjqs-2019-009445; Fleischmann C., 2015, INTENSIVE CARE MED E, V3, pA50, DOI DOI 10.1186/2197-425X-3-S1-A50; Genestier L, 2007, J IMMUNOL, V178, P7779, DOI 10.4049/jimmunol.178.12.7779; Gentile LF, 2013, SHOCK, V39, P113, DOI 10.1097/SHK.0b013e318277109c; Grasset EK, 2015, P NATL ACAD SCI USA, V112, pE2030, DOI 10.1073/pnas.1421227112; Holtfreter S, 2009, CLIN VACCINE IMMUNOL, V16, P1607, DOI 10.1128/CVI.00263-09; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; Hotchkiss RS, 2002, J IMMUNOL, V168, P2493, DOI 10.4049/jimmunol.168.5.2493; Inoue S, 2010, J IMMUNOL, V184, P1401, DOI 10.4049/jimmunol.0902307; Joubert B, 2019, REV NEUROL-FRANCE, V175, P420, DOI 10.1016/j.neurol.2019.07.004; Kantor AB, 1997, J IMMUNOL, V158, P1175; Kelly-Scumpia KM, 2011, J EXP MED, V208, P1673, DOI 10.1084/jem.20101715; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Lanzavecchia A, 2006, IMMUNOL REV, V211, P303, DOI 10.1111/j.0105-2896.2006.00403.x; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; Maier S, 2004, SHOCK, V21, P505, DOI 10.1097/01.shk.0000126906.52367.dd; Malfussi H, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00221; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875; Mohr A, 2012, EUR J IMMUNOL, V42, P341, DOI 10.1002/eji.201141692; Montes CL, 2007, J LEUKOCYTE BIOL, V82, P1027, DOI 10.1189/jlb.0407214; NICOLAI O, 2020, FRONT IMMUNOL, V0011; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; Palma J, 2018, CENT EUR J IMMUNOL, V43, P466, DOI 10.5114/ceji.2018.81354; Panda S, 2015, J IMMUNOL, V194, P13, DOI 10.4049/jimmunol.1400844; Panda S, 2013, EMBO J, V32, P2905, DOI 10.1038/emboj.2013.199; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Peck-Palmer OM, 2008, J LEUKOCYTE BIOL, V83, P1009, DOI 10.1189/jlb.0807528; Potschke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081752; Portocala R, 1988, Virologie, V39, P207; Rivera-Correa J, 2018, TRENDS IMMUNOL, V39, P515, DOI 10.1016/j.it.2018.04.003; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Sakakibara S, 2020, INT IMMUNOL, V32, P27, DOI 10.1093/intimm/dxz057; Savage HP, 2015, ANN NY ACAD SCI, V1362, P132, DOI 10.1111/nyas.12799; Schmoeckel K, 2015, SHOCK, V43, P192, DOI 10.1097/SHK.0000000000000267; Shlomchik MJ, 2012, IMMUNOL REV, V247, P52, DOI 10.1111/j.1600-065X.2012.01124.x; SIGOUNAS G, 1994, J CLIN IMMUNOL, V14, P134, DOI 10.1007/BF01541346; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sjaastad FV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02532; De La Rica AS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.59; Sursal T, 2013, SHOCK, V39, P55, DOI 10.1097/SHK.0b013e318276f4ca; Suthers AN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00775; Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009; Tiller T, 2010, J EXP MED, V207, P2767, DOI 10.1084/jem.20100171; Tiller T, 2009, J IMMUNOL METHODS, V350, P183, DOI 10.1016/j.jim.2009.08.009; Tinsley KW, 2003, J IMMUNOL, V171, P909, DOI 10.4049/jimmunol.171.2.909; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; WANG SD, 1994, J IMMUNOL, V152, P5014; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Weismann D, 2012, BBA-BIOMEMBRANES, V1818, P2465, DOI 10.1016/j.bbamem.2012.01.018; Yang Y, 2007, P NATL ACAD SCI USA, V104, P4542, DOI 10.1073/pnas.0700001104; Zantl N, 1998, INFECT IMMUN, V66, P2300, DOI 10.1128/IAI.66.5.2300-2309.1998; Zouali M, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00063	72	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 31	2020	11								1570	10.3389/fimmu.2020.01570	http://dx.doi.org/10.3389/fimmu.2020.01570			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC9SH	32849533	Green Published, gold			2022-12-18	WOS:000561550000001
J	Ram, DR; Arias, CF; Kroll, K; Hueber, B; Manickam, C; Jones, RA; Smith, ST; Shah, SV; Varner, VH; Reeves, RK				Ram, Daniel R.; Arias, Christian F.; Kroll, Kyle; Hueber, Brady; Manickam, Cordelia; Jones, Rhianna A.; Smith, Scott T.; Shah, Spandan, V; Varner, Valerie H.; Reeves, R. Keith			Characterization of Rhesus Macaque Liver-Resident CD49a(+)NK Cells During Retrovirus Infections	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer; HIV; non-human primate; macaque; SIV	NATURAL-KILLER-CELLS; NK CELLS; ALPHA-2-BETA-1 INTEGRIN; RECOGNITION SITE; TISSUE-RESIDENT; RECEPTORS; RESPONSES; IMMUNITY; MEMORY	CD49a(+)tissue resident NK cells have been implicated in memory-like NK cell responses, but while this population is well-characterized in mice and in humans, they are poorly described in non-human primates (NHP) which are particularly critical for modeling human viral infections. Others and we have shown that memory-like NK cells are enriched in the liver and because of the importance of NHP in modeling HIV infection, understanding the immunobiology of CD49a(+)NK cells in SIV-infected rhesus macaques is critical to explore the role of this cell type in retroviral infections. In this study mononuclear cells isolated from livers, spleens, and peripheral whole blood were analyzed in acutely and chronically lentivirus-infected and experimentally-naive Indian rhesus macaques (RM). NK cells were then identified as CD45(+)CD14(-)CD20(-)CD3(-)NKG2A/C(+)cells and characterized using multiparametric flow-cytometry. Our data show that in RM, CD49a(+)NK cells increase in the liver following retroviral infections [median = 5.2% (naive) vs. median = 9.48% (SIV+) or median = 16.8% (SHIV+)]. In contrast, there is little change in CD49a(+)NK frequencies in whole blood or spleens of matched animals. In agreement with human and murine data we also observed that CD49a(+)NK cells were predominantly Eomes(low)T-bet(low), though these frequencies are elevated in infected animal cohorts. Functionally, our data suggests that infection alters TNF-alpha, IFN-gamma, and CD107a expression in stimulated CD49a(+)NK cells. Specifically, our analyses found a decrease in CD49a(+)CD107a(+)TNF alpha+IFN gamma-NK cells, with a simultaneous increase in CD49a(+)CD107a(+)TNF alpha-IFN gamma+NK cells and the non-responsive CD49a(+)CD107a(-)TNF alpha-IFN gamma-NK cell population following infection, suggesting both pathogenic and inflammatory changes in the NK cell functional profile. Our data also identified significant global differences in polyfunctionality between CD49a(+)NK cells in the naive and chronic (SHIV+) cohorts. Our work provides the first characterization of CD49a(+)NK cells in tissues from RM. The significant similarities between CD49a(+)NK cells from RM and what is reported from human samples justifies the importance of studying CD49a(+)NK cells in this species to support preclinical animal model research.	[Ram, Daniel R.; Kroll, Kyle; Hueber, Brady; Manickam, Cordelia; Jones, Rhianna A.; Smith, Scott T.; Shah, Spandan, V; Varner, Valerie H.; Reeves, R. Keith] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA; [Arias, Christian F.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Reeves, R. Keith] MIT & Harvard, Ragon Inst, Massachusetts Gen Hosp, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute	Reeves, RK (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.; Reeves, RK (corresponding author), MIT & Harvard, Ragon Inst, Massachusetts Gen Hosp, Cambridge, MA 02139 USA.	rreeves@bidmc.harvard.edu		Reeves, R. Keith/0000-0003-3157-2557	National Institutes of Health [P01 AI120756, UM1 AI124377, R01 AI120828, R01 AI143457]; Harvard Center for AIDS Research Grant [P30 AI060354]; NIH [T32 AI007387]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Center for AIDS Research Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health Grants Nos. P01 AI120756, UM1 AI124377, R01 AI120828, R01 AI143457 (all to RR) and the Harvard Center for AIDS Research Grant No. P30 AI060354. DR was also supported, in part, by NIH training Grant No. T32 AI007387.	Angelo LS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00469; Carcamo C, 2006, EXP CELL RES, V312, P374, DOI 10.1016/j.yexcr.2005.10.025; Costa-Garcia M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00687; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Eble JA, 2006, J BIOL CHEM, V281, P25745, DOI 10.1074/jbc.M509942200; Erokhina SA, 2018, IMMUNOL CELL BIOL, V96, P212, DOI 10.1111/imcb.1032; Fennessey CM, 2013, CURR OPIN HIV AIDS, V8, P280, DOI 10.1097/COH.0b013e328361cfff; Foreman TW, 2017, ILAR J, V58, P151, DOI 10.1093/ilar/ilx015; Gaynor LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00467; Ghofrani J, 2019, EUR J IMMUNOL, V49, P1153, DOI 10.1002/eji.201847931; Goda S, 2006, AM J PATHOL, V169, P445, DOI 10.2353/ajpath.2006.050676; Hammer Q, 2018, NAT IMMUNOL, V19, P453, DOI 10.1038/s41590-018-0082-6; Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; Kruse PH, 2014, IMMUNOL CELL BIOL, V92, P221, DOI 10.1038/icb.2013.98; Labonte ML, 2004, CLIN EXP IMMUNOL, V138, P205, DOI 10.1111/j.1365-2249.2004.02625.x; Li HR, 2019, AM J REPROD IMMUNOL, V81, DOI 10.1111/aji.13101; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Mandal Arundhati, 2015, Hematol Oncol Stem Cell Ther, V8, P47, DOI 10.1016/j.hemonc.2014.11.006; Marquardt N, 2015, J IMMUNOL, V194, P2467, DOI 10.4049/jimmunol.1402756; Marriott AC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157887; Martrus G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182532; Mohr EL, 2018, J PEDIAT INF DIS SOC, V7, pS60, DOI 10.1093/jpids/piy120; Moiseeva EP, 1999, J VASC RES, V36, P47, DOI 10.1159/000025625; Moncla LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078750; Nikzad R, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aat8116; Osuna CE, 2017, J INFECT DIS, V216, pS928, DOI 10.1093/infdis/jix540; Paust S, 2011, NAT IMMUNOL, V12, P500, DOI 10.1038/ni.2032; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Peng H, 2017, SEMIN IMMUNOL, V31, P3, DOI 10.1016/j.smim.2017.07.006; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; PerezVillar JJ, 1996, EUR J IMMUNOL, V26, P2023, DOI 10.1002/eji.1830260909; Ram DR, 2019, J VIROL, V93, DOI 10.1128/JVI.00731-19; Ram DR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007104; Reeves RK, 2015, NAT IMMUNOL, V16, P927, DOI 10.1038/ni.3227; Reeves RK, 2010, BLOOD, V115, P4439, DOI 10.1182/blood-2010-01-265595; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Scanga CA, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018564; Sinkovics JG, 2005, INT J ONCOL, V27, P5; Sojka DK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00960; Sojka DK, 2014, ELIFE, V3, DOI 10.7554/eLife.01659; Stotesbury C, 2020, J IMMUNOL, V204, P1582, DOI 10.4049/jimmunol.1900927; Suzuki K, 2007, NATURE, V446, P680, DOI 10.1038/nature05652; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; van Hall T, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0761-3; Yeang HXA, 2017, J IMMUNOL, V198, P1417, DOI 10.4049/jimmunol.1601818; ZHANG C, 2019, NAT COMMUN, V0010; Zutter MM, 2007, IMMUNOBIOLOGY, V212, P343, DOI 10.1016/j.imbio.2006.11.013	48	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 31	2020	11								1676	10.3389/fimmu.2020.01676	http://dx.doi.org/10.3389/fimmu.2020.01676			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC9QP	32849583	Green Published, gold			2022-12-18	WOS:000561545600001
J	Tang, YH; Guo, FY; Lei, AH; Xiang, J; Liu, PQ; Ten, WY; Dai, GZ; Li, RH				Tang, Yanhong; Guo, Fangyi; Lei, Aihua; Xiang, Jing; Liu, Pengqin; Ten, Wenyou; Dai, Guozhi; Li, Ranhui			GrpE Immunization Protects AgainstUreaplasma urealyticumInfection in BALB/C Mice	FRONTIERS IN IMMUNOLOGY			English	Article						nucleotide exchange factor (GrpE); Ureaplasma urealyticum; immunogenicity; immune protection; BALB; c mice	REAL-TIME PCR; UREAPLASMA-UREALYTICUM; GENITAL-TRACT; MYCOBACTERIUM-TUBERCULOSIS; MOUSE MODEL; T-CELLS; IMMUNITY; INFECTION; RESPONSES; PATHOGENICITY	Nucleotide exchange factor (GrpE), a highly conserved antigen, is rapidly expressed and upregulated whenUreaplasma urealyticuminfects a host, which could act as a candidative vaccine if it can induce an anti-U. urealyticumimmune reaction. Here, we evaluated the vaccine potential of recombinant GrpE protein adjuvanted by Freund's adjuvant (FA), to protect againstU. urealyticumgenital tract infection in a mouse model. After booster immunization in mice with FA, the GrpE can induced both humoral and cellular immune response after intramuscular injection into BALB/c mice. A strong humoral immune response was detected in the GrpE-immunized mice characterized by production of high titers of antigen-specific serum IgG (IgG1, IgG2a, and IgG3) antibodies. At the same time, the GrpE also induced a Th1-biased cytokine spectrum with high levels of IFN-gamma and TNF-alpha after re-stimulation with immunogen GrpEin vitro, suggesting that GrpE could trigger the Th1 response when used for vaccination in the presence of FA. Although GrpE vaccination in the presence of a Th1-type adjuvant-induced had readily detectable Th1 responses, there wasn't increase inflammation in response to the infection. More importantly, the robust immune responses in mice after immunization with GrpE showed a significantly reducedU. urealyticumburden in cervical tissues. Histopathological analysis confirmed that tissues of GrpE-immunized BALB/c mice were protected against the pathological effects ofU. urealyticuminfection. In conclusion, this study preliminarily reveals GrpE protein as a promising new candidate vaccine for preventingU. urealyticumreproductive tract infection.	[Tang, Yanhong; Guo, Fangyi; Dai, Guozhi] Univ South China, Chenzhou Hosp, Hengyang, Hunan, Peoples R China; [Tang, Yanhong; Guo, Fangyi; Lei, Aihua; Dai, Guozhi; Li, Ranhui] Univ South China, Med Coll, Inst Pathogen Biol, Pathogen Biol Inst,Hunan Prov Key Lab Special Pat, Hengyang, Hunan, Peoples R China; [Tang, Yanhong; Guo, Fangyi; Xiang, Jing; Ten, Wenyou; Dai, Guozhi] First Peoples Hosp Chenzhou, Chenzhou, Hunan, Peoples R China; [Liu, Pengqin] First Peoples Hosp Huaihua, Huaihua, Hunan, Peoples R China	University of South China; University of South China	Dai, GZ (corresponding author), Univ South China, Chenzhou Hosp, Hengyang, Hunan, Peoples R China.; Dai, GZ; Li, RH (corresponding author), Univ South China, Med Coll, Inst Pathogen Biol, Pathogen Biol Inst,Hunan Prov Key Lab Special Pat, Hengyang, Hunan, Peoples R China.; Dai, GZ (corresponding author), First Peoples Hosp Chenzhou, Chenzhou, Hunan, Peoples R China.	daigz008@126.com; ranhui81@163.com			National Natural Science Foundation of China [31500156]; University of South China Innovation Foundation for Postgraduate [193YXC034]; Hunan Science and Technology Innovation Project [2018SK50302]; Research Project of Hunan Provincial Health and Wellness Commission [B2019003]; Chenzhou Science and Technology Bureau Science and Technology Development Plan Project [zdyf201844]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of South China Innovation Foundation for Postgraduate; Hunan Science and Technology Innovation Project; Research Project of Hunan Provincial Health and Wellness Commission; Chenzhou Science and Technology Bureau Science and Technology Development Plan Project	This project was supported by the National Natural Science Foundation of China (Grant No. 31500156), the University of South China Innovation Foundation for Postgraduate (GrantNo. 193YXC034), the Hunan Science and Technology Innovation Project (Grant No. 2018SK50302), the Research Project of Hunan Provincial Health and Wellness Commission (Grant No. B2019003), and the Chenzhou Science and Technology Bureau Science and Technology Development Plan Project (Grant No. zdyf201844).	Aguilo N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16085; Armand M, 2014, J INFECTION, V68, P62, DOI 10.1016/j.jinf.2013.08.005; Barry MA, 1997, VACCINE, V15, P788, DOI 10.1016/S0264-410X(96)00265-4; Bastek JA, 2011, CLIN PERINATOL, V38, P385, DOI 10.1016/j.clp.2011.06.003; BECK L, 1989, CELL IMMUNOL, V123, P1, DOI 10.1016/0008-8749(89)90263-3; Beeton ML, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00137-18; Bourigault ML, 2013, AM J CLIN EXP IMMUNO, V2, P124; Bracher Andreas, 2015, Subcell Biochem, V78, P1, DOI 10.1007/978-3-319-11731-7_1; Cao X, 2007, DIAGN MICR INFEC DIS, V59, P109, DOI 10.1016/j.diagmicrobio.2007.04.014; Cayabyab MJ, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00154; Conrad TA, 2016, INFECT IMMUN, V84, P467, DOI 10.1128/IAI.01171-15; Deetjen P, 2014, J CLIN MICROBIOL, V52, P695, DOI 10.1128/JCM.02990-13; Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491; Fairley SJ, 2013, INT J NANOMED, V8, P2085, DOI 10.2147/IJN.S44155; Fernando GJP, 1998, SCAND J IMMUNOL, V47, P459; FURR PM, 1989, J MED MICROBIOL, V29, P111, DOI 10.1099/00222615-29-2-111; Glaser K, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00484; Glass JI, 2000, NATURE, V407, P757, DOI 10.1038/35037619; Guo FX, 2018, BIOCONJUGATE CHEM, V29, P761, DOI 10.1021/acs.bioconjchem.7b00320; Harmala LAE, 2002, J IMMUNOL, V169, P5622, DOI 10.4049/jimmunol.169.10.5622; Harrison C, 2003, CELL STRESS CHAPERON, V8, P218, DOI 10.1379/1466-1268(2003)008<0218:GANEFF>2.0.CO;2; Hartley MG, 2004, INFECT IMMUN, V72, P4109, DOI 10.1128/IAI.72.7.4109-4113.2004; Hwang SH, 2018, INT J BIOL MACROMOL, V107, P2695, DOI 10.1016/j.ijbiomac.2017.10.160; KIM WS, 2018, SCI REP, DOI DOI 10.1038/S41598-018-32799-Z30258084; Kong FR, 2000, J CLIN MICROBIOL, V38, P1175, DOI 10.1128/JCM.38.3.1175-1179.2000; Kwon KW, 2017, SCI REP-UK, V7, DOI 10.1038/srep44151; Li YM, 2019, APPL MICROBIOL BIOT, V103, P941, DOI 10.1007/s00253-018-9513-4; Liang MX, 2016, APPL MICROBIOL BIOT, V100, P6385, DOI 10.1007/s00253-016-7494-8; Lu CX, 2013, MICROBES INFECT, V15, P329, DOI 10.1016/j.micinf.2013.02.001; Lu CX, 2012, VACCINE, V30, P475, DOI 10.1016/j.vaccine.2011.10.059; Mallard K, 2005, J MICROBIOL METH, V60, P13, DOI 10.1016/j.mimet.2004.08.005; Marciani DJ, 2003, DRUG DISCOV TODAY, V8, P934, DOI 10.1016/S1359-6446(03)02864-2; Marks E, 2007, INFECT IMMUN, V75, P4638, DOI 10.1128/IAI.00465-07; Morrison SG, 2000, INFECT IMMUN, V68, P6979, DOI 10.1128/IAI.68.12.6979-6987.2000; Normann E, 2009, PEDIATR RES, V65, P430, DOI 10.1203/PDR.0b013e31819984ce; O'Meara CP, 2014, CURR MOL MED, V14, P396, DOI 10.2174/15665240113136660078; O'Meara CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061962; Qie YQ, 2009, SCAND J IMMUNOL, V69, P342, DOI 10.1111/j.1365-3083.2009.02231.x; Radonic A, 2009, J CHEMOTHERAPY, V21, P465, DOI 10.1179/joc.2009.21.4.465; Rittenschober-Bohm J, 2018, NEONATOLOGY, V113, P1, DOI 10.1159/000480065; Senthamaraikannan P, 2016, J INFECT DIS, V214, P1597, DOI 10.1093/infdis/jiw408; Shah SS, 2012, PRINCIPLES PRACTICE, P1000; Shan PN, 2016, MED SCI MONITOR, V22, P3722, DOI 10.12659/MSM.897360; Shan YY, 2015, J ASSIST REPROD GEN, V32, P1277, DOI 10.1007/s10815-015-0503-5; Shekhawat SD, 2016, J INFECT PUBLIC HEAL, V9, P143, DOI 10.1016/j.jiph.2015.07.003; Silwedel C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1413-8; Sweeney EL, 2017, CLIN MICROBIOL REV, V30, P349, DOI 10.1128/CMR.00091-16; Uyeda S, 2016, ASIAN PAC J ALLERGY, V34, P314, DOI 10.12932/AP0734; Vancutsem E, 2011, J MOL DIAGN, V13, P206, DOI 10.1016/j.jmoldx.2010.10.007; Viscardi RM, 2002, INFECT IMMUN, V70, P5721, DOI 10.1128/IAI.70.10.5721-5729.2002; von Chamier M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044047; Wang XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161214; Wilkinson KA, 2005, J IMMUNOL, V174, P4237, DOI 10.4049/jimmunol.174.7.4237; Xiao L, 2010, J CLIN MICROBIOL, V48, P2715, DOI 10.1128/JCM.01877-09; Yi JY, 2005, MOL CELL PROBE, V19, P255, DOI 10.1016/j.mcp.2005.04.002; Yoder BA, 2003, PEDIATR RES, V54, P797, DOI 10.1203/01.PDR.0000091284.84322.16; ZHANG Y, 2018, J CLIN LAB ANAL, V0032; Zhu GX, 2011, CAN J MICROBIOL, V57, P987, DOI [10.1139/w11-098, 10.1139/W11-098]	58	2	4	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 31	2020	11								1495	10.3389/fimmu.2020.01495	http://dx.doi.org/10.3389/fimmu.2020.01495			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC9QV	32849509	gold, Green Published			2022-12-18	WOS:000561546200001
J	Fastres, A; Pirottin, D; Fievez, L; Marichal, T; Desmet, CJ; Bureau, F; Clercx, C				Fastres, Aline; Pirottin, Dimitri; Fievez, Laurence; Marichal, Thomas; Desmet, Christophe J.; Bureau, Fabrice; Clercx, Cecile			Characterization of the Bronchoalveolar Lavage Fluid by Single Cell Gene Expression Analysis in Healthy Dogs: A Promising Technique	FRONTIERS IN IMMUNOLOGY			English	Article						single-cell RNA-sequencing; dog; bronchoalveolar lavage fluid; cell; lung	IN-VITRO MATURATION; T-CELLS; MONOCLONAL-ANTIBODIES; DENDRITIC CELLS; MAST-CELL; MACROPHAGES; TRANSCRIPTOME; TECHNOLOGIES; GENERATION; MONOCYTES	Single-cell mRNA-sequencing (scRNA-seq) is a technique which enables unbiased, high throughput and high-resolution transcriptomic analysis of the heterogeneity of cells within a population. This recent technique has been described in humans, mice and other species in various conditions to cluster cells in populations and identify new subpopulations, as well as to study the gene expression of cells in various tissues, conditions and origins. In dogs, a species for which markers of cell populations are often limiting, scRNA-seq presents with elevated yet untested potential for the study of tissue composition. As a proof of principle, we used scRNA-seq to identify cellular populations of the bronchoalveolar lavage fluid (BALF) in healthy dogs (n= 4). A total of 5,710 cells were obtained and analyzed by scRNA-seq. Fourteen distinct clusters of cells were identified, further identified as macrophages/monocytes (4 clusters), T cells (2 clusters) and B cells (1 cluster), neutrophils (1 cluster), mast cells (1 cluster), mature or immature dendritic cells (1 cluster each), ciliated or non-ciliated epithelial cells (1 cluster each) and cycling cells (1 cluster). We used for the first time in dogs the scRNA-seq to investigate cellular subpopulations of the BALF of dog. This study hence expands our knowledge on dog lung immune cell populations, paves the way for the investigation at single-cell level of lower respiratory diseases in dogs, and establishes that scRNA-seq is a powerful tool for the study of dog tissue composition.	[Fastres, Aline; Clercx, Cecile] Univ Liege, Fac Vet Med, Dept Clin Sci, FARAH, Liege, Belgium; [Pirottin, Dimitri; Fievez, Laurence; Marichal, Thomas; Desmet, Christophe J.; Bureau, Fabrice] Univ Liege, Lab Cellular & Mol Immunol, Dept Funct Sci & GIGA Inflammat Infect & Immun, Liege, Belgium	University of Liege; University of Liege	Fastres, A (corresponding author), Univ Liege, Fac Vet Med, Dept Clin Sci, FARAH, Liege, Belgium.	afastres@uliege.be			Fonds Speciaux de la Recherche from the University of Liege	Fonds Speciaux de la Recherche from the University of Liege	This work was supported by a grant from the Fonds Speciaux de la Recherche from the University of Liege.	Alcover A, 2018, ANNU REV IMMUNOL, V36, P103, DOI 10.1146/annurev-immunol-042617-053429; Ardain A, 2020, IMMUNOLOGY, V159, P245, DOI 10.1111/imm.13143; Byrneee AJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20191236; Caughey GH, 2016, EUR J PHARMACOL, V778, P44, DOI 10.1016/j.ejphar.2015.04.045; Clercx C, 2002, J VET INTERN MED, V16, P229, DOI 10.1892/0891-6640(2002)016&lt;0229:AIIOCE&gt;2.3.CO;2; Condliffe AM, 1996, IMMUNOLOGY, V89, P105, DOI 10.1046/j.1365-2567.1996.d01-711.x; Cunningham F, 2019, NUCLEIC ACIDS RES, V47, pD745, DOI 10.1093/nar/gky1113; Davie K, 2018, CELL, V174, P982, DOI 10.1016/j.cell.2018.05.057; DIRSCHERL P, 1995, VET IMMUNOL IMMUNOP, V48, P1, DOI 10.1016/0165-2427(94)05414-N; Emidio NB, 2019, TRENDS BIOCHEM SCI, V44, P387, DOI 10.1016/j.tibs.2019.01.004; Faldyna M, 2007, VET IMMUNOL IMMUNOP, V119, P56, DOI 10.1016/j.vetimm.2007.06.022; Farnsworth DR, 2020, DEV BIOL, V459, P100, DOI 10.1016/j.ydbio.2019.11.008; Finke MD, 2013, TOP COMPANION ANIM M, V28, P97, DOI 10.1053/j.tcam.2013.06.003; Gavins FNE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00354; Gibbings SL, 2017, AM J RESP CELL MOL, V57, P66, DOI 10.1165/rcmb.2016-0361OC; Gibbings SL, 2015, BLOOD, V126, P1357, DOI 10.1182/blood-2015-01-624809; Godlove J, 2007, EXP GERONTOL, V42, P412, DOI 10.1016/j.exger.2006.11.015; Gundra UM, 2014, BLOOD, V123, pE110, DOI 10.1182/blood-2013-08-520619; Haque A, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0467-4; Haran KP, 2020, VET PATHOL, V57, P241, DOI 10.1177/0300985819900352; He LQ, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.160; Herderschee J, 2015, J LEUKOCYTE BIOL, V98, P23, DOI 10.1189/jlb.6RU0115-020R; Hidalgo LG, 2008, AM J TRANSPLANT, V8, P627, DOI 10.1111/j.1600-6143.2007.02128.x; Huang P, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/1701059; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Islam S, 2011, GENOME RES, V21, P1160, DOI 10.1101/gr.110882.110; Kabashima K, 2018, IMMUNOL REV, V282, P114, DOI 10.1111/imr.12639; Kiselev VY, 2019, NAT REV GENET, V20, P273, DOI 10.1038/s41576-018-0088-9; Kockx M, 2018, J MOL MED, V96, P361, DOI 10.1007/s00109-018-1632-y; Lesley R, 2006, P NATL ACAD SCI USA, V103, P10717, DOI 10.1073/pnas.0601539103; Li XC, 2017, IMMUNOL LETT, V183, P86, DOI 10.1016/j.imlet.2017.01.010; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Ling XB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091483; Lischke T, 2012, J IMMUNOL, V189, P234, DOI 10.4049/jimmunol.1102034; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; McQuattie-Pimentel AC, 2018, AM J RESP CELL MOL, V58, P5, DOI 10.1165/rcmb.2017-0328ED; Mercier E, 2011, VET J, V187, P225, DOI 10.1016/j.tvjl.2009.12.007; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Mould KJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126556; Muraro MJ, 2016, CELL SYST, V3, P385, DOI 10.1016/j.cels.2016.09.002; Nelson WR, 2014, SMALL ANIMAL INTERNA, V5th, P263; Out TA, 2002, IMMUNOLOGY, V105, P499, DOI 10.1046/j.1365-2567.2002.01383.x; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Patel VI, 2018, CRIT REV IMMUNOL, V38, P303, DOI 10.1615/CritRevImmunol.2018026459; Proserpio V, 2016, IMMUNOLOGY, V147, P133, DOI 10.1111/imm.12553; Rabiger FV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02748; Rajamaki MM, 2001, AM J VET RES, V62, P13, DOI 10.2460/ajvr.2001.62.13; Rodriguez-Perea AL, 2016, CLIN EXP IMMUNOL, V185, P281, DOI 10.1111/cei.12804; Rogulski K, 2005, ONCOGENE, V24, P7524, DOI 10.1038/sj.onc.1208897; Sattasathuchana P, 2014, ANIM HEALTH RES REV, V15, P76, DOI 10.1017/S1466252314000012; Schyns J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11843-0; See P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02425; Spuzak J, 2008, MEDICINE, V10, P321; Stifano G, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-015-0554-8; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Stubbington MJT, 2017, SCIENCE, V358, P58, DOI 10.1126/science.aan6828; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suryawanshi H, 2020, CARDIOVASC RES, V116, P1446, DOI 10.1093/cvr/cvz257; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Trombetta AC, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0891-z; VAIL DM, 1995, AM J VET RES, V56, P282; van de Laar L, 2016, IMMUNITY, V44, P755, DOI 10.1016/j.immuni.2016.02.017; Varricchi G, 2018, IMMUNOL REV, V282, P8, DOI 10.1111/imr.12627; Vegh P, 2018, BRIEF FUNCT GENOMICS, V17, P265, DOI 10.1093/bfgp/ely003; Volkova OY, 2007, HYBRIDOMA, V26, P78, DOI 10.1089/hyb.2006.043; Wolkow PP, 2018, INT IMMUNOPHARMACOL, V57, P165, DOI 10.1016/j.intimp.2018.02.015; Xin HM, 2009, CAN J MICROBIOL, V55, P859, DOI [10.1139/w09-041, 10.1139/W09-041]; Yi HY, 2013, HISTOCHEM CELL BIOL, V140, P65, DOI 10.1007/s00418-013-1105-x; Zalewska M, 2014, PROTEOMICS, V14, P1343, DOI 10.1002/pmic.201300496; Zhu JF, 2006, CELL RES, V16, P3, DOI 10.1038/sj.cr.7310002	70	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 30	2020	11								1707	10.3389/fimmu.2020.01707	http://dx.doi.org/10.3389/fimmu.2020.01707			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC9YO	32849601	gold, Green Published			2022-12-18	WOS:000561566300001
J	Napimoga, MH; Formiga, WDD; Abdalla, HB; Trindade-da-Silva, CA; Venturin, CM; Martinez, EF; Rossaneis, AC; Verri, WA; Clemente-Napimoga, JT				Napimoga, Marcelo Henrique; Dantas Formiga, Weslley Danny; Abdalla, Henrique Ballassini; Trindade-da-Silva, Carlos Antonio; Venturin, Camila Motta; Martinez, Elizabeth Ferreira; Rossaneis, Ana Carolina; Verri Jr, Waldiceu A.; Clemente-Napimoga, Juliana Trindade			Secreted Osteoclastogenic Factor of Activated T Cells (SOFAT) Is Associated With Rheumatoid Arthritis and Joint Pain: Initial Evidences of a New Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; SOFAT; rheumatoid arthritis; pain; osteoclast	HYPERNOCICEPTION; INDUCTION; CYTOKINES; DISEASE; LIGAND	Rheumatoid arthritis (RA) has an inflammatory milieu in the synovial compartment, which is regulated by a complex cytokine and chemokine network that induces continuously degenerative and inflammatory reactions. The secreted osteoclastogenic factor of activated T cells (SOFAT) is a unique cytokine and represents an alternative pathway for osteoclast activation. In this study, we examined whether SOFAT is able to induce joint pain and investigated the presence of SOFAT in a Collagen-induced Arthritis (CIA) model and in human subjects. Here, we found that an intra-articular stimulation with SOFAT (1, 10, 100, or 1,000 ng/10 mu l) in the knee joint significantly decreases the mechanical threshold in the hind paw of mice (p< 0.05). Moreover, after a second injection of SOFAT, the mechanical threshold decrease was sustained for up to 8 days (p< 0.05). In the CIA model, the immunohistochemical assay of knee joint showed positivity stained for SOFAT, and the mRNA and protein expression of SOFAT were significantly higher in the affected-group (p< 0.05). Besides, the mRNA of RANKL, IL-1 beta, IL-6, and IL-15 were significantly higher in the affected-group (p< 0.05). Finally, SOFAT was detected in the synovial fluid of RA patients, but not in OA patients (p< 0.05). In conclusion, SOFAT is up regulated in inflammatory milieu such as RA but not in non-inflammatory OA. SOFAT may be a novel molecule in the complex inflammatory phenotype of RA.	[Napimoga, Marcelo Henrique; Dantas Formiga, Weslley Danny; Abdalla, Henrique Ballassini; Trindade-da-Silva, Carlos Antonio; Clemente-Napimoga, Juliana Trindade] Fac Sao Leopoldo Mandic, Inst Pesquisas Sao Leopoldo Mandic, Laboratoy Neuroimmune Interface Pain Res, Campinas, SP, Brazil; [Venturin, Camila Motta; Martinez, Elizabeth Ferreira] Fac Sao Leopoldo Mandic, Inst Sao Leopoldo Mandic, Campinas, SP, Brazil; [Rossaneis, Ana Carolina; Verri Jr, Waldiceu A.] Univ Estadual Londrina, Dept Ciencias Patol, Londrina, Brazil	Faculdade Sao Leopoldo Mandic; Faculdade Sao Leopoldo Mandic; Universidade Estadual de Londrina	Napimoga, MH (corresponding author), Fac Sao Leopoldo Mandic, Inst Pesquisas Sao Leopoldo Mandic, Laboratoy Neuroimmune Interface Pain Res, Campinas, SP, Brazil.	marcelo.napimoga@slmandic.edu.br	Clemente-Napimoga, Juliana T/E-5163-2013; WA, Verri/I-1330-2013; Napimoga, Marcelo/S-2434-2019; da Silva, Carlos Antonio Trindade/I-4250-2013; da Silva, Carlos Antonio Trindade/AAN-6561-2020; Abdalla, Henrique Ballassini/M-2565-2014	Clemente-Napimoga, Juliana T/0000-0003-1068-3039; WA, Verri/0000-0003-2756-9283; Napimoga, Marcelo/0000-0003-4472-365X; da Silva, Carlos Antonio Trindade/0000-0002-5669-4190; da Silva, Carlos Antonio Trindade/0000-0002-5669-4190; Abdalla, Henrique Ballassini/0000-0002-7517-2830	Sao Paulo Research Foundation, FAPESP, Brazil [2013/09524-2, 2017/22334-9]; Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, CAPES, Brazil [001]; PPSUS Grant, Brazil [041/2017, 48.095]; Programa de Apoio a Grupos de Excelencia (PRONEX) - SETI (Secretaria da Ciencia, Tecnologia e Ensino Superior)/Araucaria Foundation, Brazil; MCTI (Ministerio da Ciencia, Tecnologia e Inovacao)/CNPq, Brazil; Parana State Government, Brazil [014/2017, 46.843]	Sao Paulo Research Foundation, FAPESP, Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, CAPES, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); PPSUS Grant, Brazil; Programa de Apoio a Grupos de Excelencia (PRONEX) - SETI (Secretaria da Ciencia, Tecnologia e Ensino Superior)/Araucaria Foundation, Brazil; MCTI (Ministerio da Ciencia, Tecnologia e Inovacao)/CNPq, Brazil; Parana State Government, Brazil	This study was financially supported by Sao Paulo Research Foundation, FAPESP (#2013/09524-2 and 2017/22334-9), Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (Research Productivity Fellowships were awarded to MN, JC-N, EM, and WV), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, CAPES (#001), PPSUS Grant (agreement 041/2017, protocol 48.095); Programa de Apoio a Grupos de Excelencia (PRONEX) grant supported by SETI (Secretaria da Ciencia, Tecnologia e Ensino Superior)/Araucaria Foundation and MCTI (Ministerio da Ciencia, Tecnologia e Inovacao)/CNPq; and Parana State Government (agreement 014/2017, protocol 46.843), Brazil.	[Anonymous], 2017, LANCET, V389, P1076, DOI DOI 10.1016/S0140-6736(17)30765-1; Baslund B, 2005, ARTHRITIS RHEUM-US, V52, P2686, DOI 10.1002/art.21249; Candido-Soares LE, 2019, APPL IMMUNOHISTO M M, V27, P448, DOI 10.1097/PAI.0000000000000648; Cross M, 2014, ANN RHEUM DIS, V73, P1316, DOI 10.1136/annrheumdis-2013-204627; Fattori V, 2016, PHARMACOL RES, V112, P84, DOI 10.1016/j.phrs.2016.01.027; Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006; Fournier C, 2005, JOINT BONE SPINE, V72, P527, DOI 10.1016/j.jbspin.2004.12.012; Garlet GP, 2010, J DENT RES, V89, P1349, DOI 10.1177/0022034510376402; Gillespie MT, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2141; Goncalves WA, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03120; Jarry CR, 2016, MOL MED REP, V13, P4252, DOI 10.3892/mmr.2016.5045; Jarry CR, 2013, HUM IMMUNOL, V74, P861, DOI 10.1016/j.humimm.2013.04.013; Jin Y, 2018, EXP THER MED, V16, P3377, DOI 10.3892/etm.2018.6643; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kitas GD, 2011, ANN RHEUM DIS, V70, P8, DOI 10.1136/ard.2010.142133; Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705; Miyabe Y, 2019, NAT REV RHEUMATOL, V15, P731, DOI 10.1038/s41584-019-0323-6; Napimoga MH, 2015, INT IMMUNOPHARMACOL, V26, P378, DOI 10.1016/j.intimp.2015.04.033; Ogata A, 2019, MOD RHEUMATOL, V29, P258, DOI [10.1080/14397595.2018.1546357, 10.1080/14397595.2018.1533514]; Ogawa Y, 2003, ARTHRITIS RHEUM-US, V48, P3350, DOI 10.1002/art.11322; Pap T, 2015, NAT REV RHEUMATOL, V11, P606, DOI 10.1038/nrrheum.2015.95; Rifas L, 2009, ARTHRITIS RHEUM-US, V60, P3324, DOI 10.1002/art.24877; Ruiz-Miyazawa KW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32334-0; Smolen JS, 2016, LANCET, V388, P1984; Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1; Staurengo-Ferrari L, 2017, FREE RADICAL BIO MED, V108, P487, DOI 10.1016/j.freeradbiomed.2017.04.016; Su ZL, 2013, MOL MED REP, V8, P113, DOI 10.3892/mmr.2013.1476; Verri WA, 2008, P NATL ACAD SCI USA, V105, P2723, DOI 10.1073/pnas.0712116105; Verri WA, 2007, EUR J IMMUNOL, V37, P3373, DOI 10.1002/eji.200737488; Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001; Verri WA, 2006, P NATL ACAD SCI USA, V103, P9721, DOI 10.1073/pnas.0603286103; Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91; Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	35	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2020	11								1442	10.3389/fimmu.2020.01442	http://dx.doi.org/10.3389/fimmu.2020.01442			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC7AS	32849501	gold, Green Published			2022-12-18	WOS:000561368700001
J	Vittoraki, AG; Fylaktou, A; Tarassi, K; Tsinaris, Z; Petasis, GC; Gerogiannis, D; Kheav, VD; Carmagnat, M; Lehmann, C; Doxiadis, I; Iniotaki, AG; Theodorou, I				Vittoraki, Angeliki G.; Fylaktou, Asimina; Tarassi, Katerina; Tsinaris, Zafeiris; Petasis, George Ch; Gerogiannis, Demetris; Kheav, Vissal-David; Carmagnat, Maryvonnick; Lehmann, Claudia; Doxiadis, Ilias; Iniotaki, Aliki G.; Theodorou, Ioannis			Patterns of 1,748 Unique Human Alloimmune Responses Seen by Simple Machine Learning Algorithms	FRONTIERS IN IMMUNOLOGY			English	Article						HLA; patterns detection; allorecognition; transplantation; monitoring; PCA; descriptive statistics; machine learning	DONOR-SPECIFIC ANTIBODIES; CLASS-I EPITOPES; HLA-DR; HLAMATCHMAKER	Allele specific antibody response against the polymorphic system of HLA is the allogeneic response marker determining the immunological risk for graft acceptance before and after organ transplantation and therefore routinely studied during the patient's workup. Experimentally, bead bound antigen- antibody reactions are detected using a special multicolor flow cytometer (Luminex). Routinely for each sample, antibody responses against 96 different HLA antigen groups are measured simultaneously and a 96-dimensional immune response vector is created. Under a common experimental protocol, using unsupervised clustering algorithms, we analyzed these immune intensity vectors of anti HLA class II responses from a dataset of 1,748 patients before or after renal transplantation residing in a single country. Each patient contributes only one serum sample in the analysis. A population view of linear correlations of hierarchically ordered fluorescence intensities reveals patterns in human immune responses with striking similarities with the previously described CREGs but also brings new information on the antigenic properties of class II HLA molecules. The same analysis affirms that "public" anti-DP antigenic responses are not correlated to anti DR and anti DQ responses which tend to cluster together. Principal Component Analysis (PCA) projections also demonstrate ordering patterns clearly differentiating anti DP responses from anti DR and DQ on several orthogonal planes. We conclude that a computer vision of human alloresponse by use of several dimensionality reduction algorithms rediscovers proven patterns of immune reactivity without any a priori assumption and might prove helpful for a more accurate definition of public immunogenic antigenic structures of HLA molecules. Furthermore, the use of Eigen decomposition on the Immune Response generates new hypotheses that may guide the design of more effective patient monitoring tests.	[Vittoraki, Angeliki G.] Gen Hosp Athens G Gennimatas, Natl Tissue Typing Ctr, Athens, Greece; [Vittoraki, Angeliki G.] Gen Hosp Athens G Gennimatas, Immunol Dept, Athens, Greece; [Fylaktou, Asimina; Petasis, George Ch] Hippokrateion Hosp, Immunol Dept, Natl Peripheral Histocompatibil Ctr, Thessaloniki, Greece; [Tarassi, Katerina] Evangelismos Gen Hosp, Immunol Histocompatibil Dept, Athens, Greece; [Tsinaris, Zafeiris] Univ Thessaly, Dept Comp Sci & Biomed Informat, Lamia, Greece; [Gerogiannis, Demetris] Univ Ioannina, Dept Comp Sci & Engn, Ioannina, Greece; [Kheav, Vissal-David; Carmagnat, Maryvonnick; Theodorou, Ioannis] Hop St Louis, Lab Immunol, Paris, France; [Lehmann, Claudia; Doxiadis, Ilias] Univ Hosp Leipzig, Inst Transfus Med, Lab Transplantat Immunol, Leipzig, Germany; [Iniotaki, Aliki G.] Laikon Gen Hosp, Med Sch Athens, Nephrol & Transplantat Unit, Athens, Greece; [Theodorou, Ioannis] Ctr Immunol & Malad Infect UPMC UMRS CR7, Inserm U1135, CNRS ERL 8255, Paris, France	Evangelismos Hospital; University of Ioannina; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Leipzig University; Laiko General Hospital; National & Kapodistrian University of Athens; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm)	Vittoraki, AG (corresponding author), Gen Hosp Athens G Gennimatas, Natl Tissue Typing Ctr, Athens, Greece.; Vittoraki, AG (corresponding author), Gen Hosp Athens G Gennimatas, Immunol Dept, Athens, Greece.	avittor2@yahoo.com	Doxiadis, ilias/AAH-9875-2020		Hellenic Society for Immunology [9/29.01.2019]	Hellenic Society for Immunology	This work was supported by the Hellenic Society for Immunology (HSI Ref: 9/29.01.2019).	Chang CJ, 2019, HUM IMMUNOL, V80, P661, DOI 10.1016/j.humimm.2019.04.002; Cios KJ, 2002, ARTIF INTELL MED, V26, P1, DOI 10.1016/S0933-3657(02)00049-0; Cross AR, 2016, HUM IMMUNOL, V77, P1092, DOI 10.1016/j.humimm.2016.04.003; Duquesnoy RJ, 2012, INT J IMMUNOGENET, V39, P1, DOI 10.1111/j.1744-313X.2011.01042.x; Duquesnoy RJ, 2009, TISSUE ANTIGENS, V74, P117, DOI 10.1111/j.1399-0039.2009.01271.x; Duquesnoy RJ, 2007, HUM IMMUNOL, V68, P12, DOI 10.1016/j.humimm.2006.10.003; Duquesnoy RJ, 2004, TRANSPL INT, V17, P22, DOI 10.1111/j.1432-2277.2004.tb00379.x; El-Awar N, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/3406230; El-Awar NR, 2007, TRANSPLANTATION, V84, P532, DOI 10.1097/01.tp.0000278721.97037.1e; Friendly M, 2002, AM STAT, V56, P316, DOI 10.1198/000313002533; Geneugelijk K, 2020, IMMUNOGENETICS, V72, P119, DOI 10.1007/s00251-019-01140-x; Geneugelijk K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00321; Giuliani A, 2017, DRUG DISCOV TODAY, V22, P1069, DOI 10.1016/j.drudis.2017.01.005; Iniotaki-Theodoraki A, 2001, TRANSPL P, V33, P461, DOI 10.1016/S0041-1345(00)02094-7; Iniotaki-Theodoraki AG, 2003, TRANSPLANTATION, V75, P1601, DOI 10.1097/01.TP.0000061611.51612.09; Kosmoliaptsis V, 2016, AM J TRANSPLANT, V16, P2139, DOI 10.1111/ajt.13707; Kramer CSM, 2019, TRANSPL INT, V32, P16, DOI 10.1111/tri.13362; Lashari S.A., 2018, MATEC WEB C, V150; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Loupy A, 2012, NAT REV NEPHROL, V8, P348, DOI 10.1038/nrneph.2012.81; Ntokou ISA, 2011, TRANSPL INT, V24, P1084, DOI 10.1111/j.1432-2277.2011.01312.x; Papassavas AC, 2000, TRANSPLANTATION, V70, P323, DOI 10.1097/00007890-200007270-00016; RODEY GE, 1994, HUM IMMUNOL, V39, P272, DOI 10.1016/0198-8859(94)90270-4; Schnaidt M, 2011, TRANSPLANTATION, V92, P510, DOI 10.1097/TP.0b013e31822872dd; Simmons DP, 2016, HUM IMMUNOL, V77, P1128, DOI 10.1016/j.humimm.2016.09.008; Siu JHY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02548; Steiner NK, 2001, TISSUE ANTIGENS, V57, P373, DOI 10.1034/j.1399-0039.2001.057004373.x; Tait BD, 2009, NEPHROLOGY, V14, P247, DOI 10.1111/j.1440-1797.2008.01074.x; VANROOD JJ, 1963, J CLIN INVEST, V42, P1382; Yamamoto F, 2019, HUM IMMUNOL, V80, P668, DOI 10.1016/j.humimm.2019.04.004	30	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2020	11								1667	10.3389/fimmu.2020.01667	http://dx.doi.org/10.3389/fimmu.2020.01667			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NC6ZU	32849576	Green Published, gold			2022-12-18	WOS:000561366300001
J	Nemes, E; Khader, SA; Swanson, RV; Hanekom, WA				Nemes, Elisa; Khader, Shabaana A.; Swanson, Rosemary, V; Hanekom, Willem A.			Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB	FRONTIERS IN IMMUNOLOGY			English	Review						tuberculosis; NK cells; trained immunity; B cells; Th17 Cells	MYCOBACTERIUM-TUBERCULOSIS INFECTION; HEMATOPOIETIC STEM-CELLS; NATURAL-KILLER-CELLS; BCG VACCINATION; IFN-GAMMA; CONFERS PROTECTION; TRAINED IMMUNITY; CALMETTE-GUERIN; INNATE IMMUNITY; FUNCTIONAL-ROLE	The current tuberculosis (TB) vaccine, Bacille Calmette-Guerin (BCG), is effective in preventing TB in young children but was developed without a basic understanding of human immunology. Most modern TB vaccine candidates have targeted CD4(+)T cell responses, thought to be important for protection against TB disease, but not known to be sufficient or critical for protection. Advances in knowledge of host responses to TB afford opportunities for developing TB vaccines that target immune components not conventionally considered. Here, we describe the potential of targeting NK cells, innate immune training, B cells and antibodies, and Th17 cells in novel TB vaccine development. We also discuss attempts to target vaccine immunity specifically to the lung, the primary disease site in humans.	[Nemes, Elisa] Univ Cape Town, Dept Pathol, Div Immunol, South African TB Vaccine Initiat, Cape Town, South Africa; [Nemes, Elisa] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa; [Khader, Shabaana A.; Swanson, Rosemary, V] Washington Univ, Dept Mol Microbiol, Sch Med, St Louis, MO 63110 USA; [Hanekom, Willem A.] Africa Hlth Res Inst, Durban, South Africa	University of Cape Town; University of Cape Town; Washington University (WUSTL); Africa Health Research Institute	Hanekom, WA (corresponding author), Africa Hlth Res Inst, Durban, South Africa.	willem.hanekom@ahri.org		Hanekom, Willem/0000-0003-3070-6154; Swanson, Rosemary/0000-0003-3455-8857; A Khader, Shabaana/0000-0002-9545-4982	Washington University School of Medicine [NIHgrantHL105427, AI111914-02, AI134236-02, AI123780]	Washington University School of Medicine	This work was supported by Washington University School of Medicine, NIHgrantHL105427, AI111914-02, AI134236-02, and AI123780 to SK.	Aguilo N, 2016, J INFECT DIS, V213, P831, DOI 10.1093/infdis/jiv503; Ahmed M, 2017, VACCINE, V35, P4983, DOI 10.1016/j.vaccine.2017.07.073; Ahmed M, 2017, J LEUKOCYTE BIOL, V101, P1373, DOI 10.1189/jlb.4A0616-270R; Andersen P, 2019, NAT REV IMMUNOL, V19, P550, DOI 10.1038/s41577-019-0174-z; Ardain A, 2019, NATURE, V570, P528, DOI 10.1038/s41586-019-1276-2; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Baldridge MT, 2010, NATURE, V465, P793, DOI 10.1038/nature09135; Barthelemy A, 2016, MBIO, V7, DOI 10.1128/mBio.01440-16; Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004; Parra JAC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00967; Chowdhury RR, 2018, NATURE, V560, P644, DOI 10.1038/s41586-018-0439-x; Coscolla M, 2015, CELL HOST MICROBE, V18, P538, DOI 10.1016/j.chom.2015.10.008; Darrah PA, 2020, NATURE, V577, P95, DOI 10.1038/s41586-019-1817-8; Darrah PA, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0113-9; de Bree C, 2018, NEW ENGL J MED, V379, P1969, DOI 10.1056/NEJMc1811046; Dhiman R, 2009, J IMMUNOL, V183, P6639, DOI 10.4049/jimmunol.0902587; Dijkman K, 2019, NAT MED, V25, P255, DOI 10.1038/s41591-018-0319-9; Domingo-Gonzalez R, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92973; Esin S, 2013, SCAND J IMMUNOL, V77, P460, DOI 10.1111/sji.12052; Esin S, 2015, J INNATE IMMUN, V7, P11, DOI 10.1159/000363321; Feng CG, 2006, J IMMUNOL, V177, P7086, DOI 10.4049/jimmunol.177.10.7086; Fortune SM, 2020, TUB IMM EV SANT FE N; Fu XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151721; Fuge O, 2015, RES REP UROL, V7, P65, DOI 10.2147/RRU.S63447; Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6; Geddes K, 2011, NAT MED, V17, P837, DOI 10.1038/nm.2391; Geldenhuys HD, 2012, EUR J CLIN MICROBIOL, V31, P529, DOI 10.1007/s10096-011-1344-5; Gideon HP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004603; Gonzalo-Asensio J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01803; Gopal R, 2012, EUR J IMMUNOL, V42, P364, DOI 10.1002/eji.201141569; Griffiths KL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13894; Griffiths KL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078312; Guglani L, 2010, CURR OPIN HIV AIDS, V5, P120, DOI 10.1097/COH.0b013e328335c2f6; Haahr S, 2016, INT J EPIDEMIOL, V45, P2122, DOI 10.1093/ije/dyw244; Hansen SG, 2018, NAT MED, V24, P130, DOI 10.1038/nm.4473; Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192; Houghton BB, 2013, BJU INT, V111, P977, DOI 10.1111/j.1464-410X.2012.11390.x; Junqueira-Kipnis AP, 2003, J IMMUNOL, V171, P6039, DOI 10.4049/jimmunol.171.11.6039; Kauffman KD, 2018, MUCOSAL IMMUNOL, V11, P462, DOI 10.1038/mi.2017.60; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Kaushal D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9533; Khader SA, 2005, J IMMUNOL, V175, P788, DOI 10.4049/jimmunol.175.2.788; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Khader SA, 2019, J CLIN INVEST, V129, P3482, DOI 10.1172/JCI128877; Kleinnijenhuis J, 2015, T ROY SOC TROP MED H, V109, P29, DOI 10.1093/trstmh/tru168; Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005; Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628; Kupz A, 2016, J CLIN INVEST, V126, P2109, DOI 10.1172/JCI84978; Laddy DJ, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00776-17; Li Q, 2012, EUR REV MED PHARMACO, V16, P2029; Lin PL, 2014, NAT MED, V20, P75, DOI 10.1038/nm.3412; Lockhart E, 2006, J IMMUNOL, V177, P4662, DOI 10.4049/jimmunol.177.7.4662; Lu LL, 2019, NAT MED, V25, P1175, DOI 10.1038/s41591-019-0519-y; Lu LL, 2019, NAT MED, V25, P977, DOI 10.1038/s41591-019-0441-3; Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Martinez Barricarte R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau675930578351; McGeachy MJ, 2011, NAT IMMUNOL, V12, P521, DOI 10.1038/ni.2044; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Monin L, 2015, MUCOSAL IMMUNOL, V8, P1099, DOI 10.1038/mi.2014.136; Monteiro M, 2013, J IMMUNOL, V190, P805, DOI 10.4049/jimmunol.1201010; Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/nejmoa1714021, 10.1056/NEJMoa1714021]; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Nieuwenhuizen NE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01147; Nikitina IY, 2018, J IMMUNOL, V200, P2090, DOI 10.4049/jimmunol.1701424; Ogongo P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00992; Passos ST, 2010, J IMMUNOL, V184, P1776, DOI 10.4049/jimmunol.0901843; Penn-Nicholson A, 2015, VACCINE, V33, P4025, DOI 10.1016/j.vaccine.2015.05.088; Portevin D, 2012, CELL MICROBIOL, V14, P1734, DOI 10.1111/j.1462-5822.2012.01834.x; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Rolandelli A, 2017, SCI REP-UK, V7, DOI 10.1038/srep40666; Ronacher K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02209; Roy A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4643; Sakai S, 2014, J IMMUNOL, V192, P2965, DOI 10.4049/jimmunol.1400019; Sallin MA, 2018, NAT MICROBIOL, V3, P1198, DOI 10.1038/s41564-018-0231-6; Satti I, 2014, LANCET INFECT DIS, V14, P939, DOI 10.1016/S1473-3099(14)70845-X; Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962; Shahbazian LM, 2004, CRIT CARE MED, V32, P1740, DOI 10.1097/01.CCM.0000132900.84627.90; Shen HB, 2018, CELL MOL IMMUNOL, V15, P216, DOI 10.1038/cmi.2017.128; Slight SR, 2013, J CLIN INVEST, V123, P712, DOI 10.1172/JCI65728; Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4; Stensballe LG, 2017, ARCH DIS CHILD, V102, P224, DOI 10.1136/archdischild-2016-310760; Suliman S, 2016, J IMMUNOL, V197, P1100, DOI 10.4049/jimmunol.1501996; SUTHERLAND I, 1979, TUBERCLE, V60, P225, DOI 10.1016/0041-3879(79)90003-5; Tait DR, 2019, NEW ENGL J MED, V381, P2429, DOI 10.1056/NEJMoa1909953; Tanner R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01317; Thomas ZRM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002790; Tran AC, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e24; Treerat P, 2017, MUCOSAL IMMUNOL, V10, P1069, DOI 10.1038/mi.2017.15; Vely F, 2016, NAT IMMUNOL, V17, P1291, DOI 10.1038/ni.3553; Venkatasubramanian S, 2017, MUCOSAL IMMUNOL, V10, P1031, DOI 10.1038/mi.2016.105; Verrall AJ, 2020, J INFECT DIS, V221, P1342, DOI 10.1093/infdis/jiz147; Wagstaffe HR, 2018, CLIN TRANSL IMMUNOL, V7, DOI 10.1002/cti2.1010; Walk J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08659-3; Woodworth JS, 2019, MUCOSAL IMMUNOL, V12, P816, DOI 10.1038/s41385-019-0145-5	96	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 24	2020	11								1452	10.3389/fimmu.2020.01452	http://dx.doi.org/10.3389/fimmu.2020.01452			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NB5VW	32793199	Green Published, gold			2022-12-18	WOS:000560580600001
J	Ariza, ME				Ariza, Maria Eugenia			Commentary: Antibodies to Human Herpesviruses in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						EBV - Epstein-Barr Virus; Human herpesvirus (HHV)-6; Varicela zoster virus (VZV); Herpes Simplex virus type 1 and type 2 (HSV-1/2); Cytomegalovirus (CMV); Human herpesvirus 7 (HHV-7); Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)	EPSTEIN-BARR-VIRUS; RESPONSES; EBV		[Ariza, Maria Eugenia] Ohio State Univ, Wexner Med Ctr, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Ariza, Maria Eugenia] Ohio State Univ, Wexner Med Ctr, Inst Behav Med Res, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ariza, ME (corresponding author), Ohio State Univ, Wexner Med Ctr, Dept Canc Biol & Genet, Columbus, OH 43210 USA.; Ariza, ME (corresponding author), Ohio State Univ, Wexner Med Ctr, Inst Behav Med Res, Columbus, OH 43210 USA.	maria.ariza@osumc.edu			National Institutes of Health [R01 A1084898]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health grant R01 A1084898 to MA.	Blomberg J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01946; Buchwald D, 1996, J MED VIROL, V50, P25, DOI 10.1002/(SICI)1096-9071(199609)50:1&lt;25::AID-JMV6&gt;3.0.CO;2-V; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; Burbelo PD, 2019, FUTURE VIROL, V14, P39, DOI 10.2217/fvl-2018-0145; Burbelo PD, 2015, TRANSL RES, V165, P325, DOI 10.1016/j.trsl.2014.08.006; Cameron B, 2010, J MED VIROL, V82, P1684, DOI 10.1002/jmv.21873; DILUCA D, 1995, J CLIN MICROBIOL, V33, P1660, DOI 10.1128/JCM.33.6.1660-1661.1995; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; Halpin P, 2017, J MED VIROL, V89, P1636, DOI 10.1002/jmv.24810; HELLINGER WC, 1988, JAMA-J AM MED ASSOC, V260, P971; Hickie I, 2006, BRIT MED J, V333, P575, DOI 10.1136/bmj.38933.585764.AE; HOLMES GP, 1987, JAMA-J AM MED ASSOC, V257, P2297, DOI 10.1001/jama.257.17.2297; Kristiansen MS, 2019, BRAIN BEHAV IMMUN, V80, P551, DOI 10.1016/j.bbi.2019.04.040; LEVINE PH, 1992, ARCH INTERN MED, V152, P1611, DOI 10.1001/archinte.152.8.1611; Loebel M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179124; MANIAN FA, 1994, CLIN INFECT DIS, V19, P448, DOI 10.1093/clinids/19.3.448; Oakes B, 2013, CLIN INFECT DIS, V56, P1394, DOI 10.1093/cid/cit086; Pellett PE, 2013, FIELDS VIROLOGY, P1802; Reeves WC, 2000, CLIN INFECT DIS, V31, P48, DOI 10.1086/313908; Sairenji T, 1995, INTERVIROLOGY, V38, P269, DOI 10.1159/000150450; Shikova E, 2020, J MED VIROL, V92, P3682, DOI 10.1002/jmv.25744; STRAUS SE, 1988, NEW ENGL J MED, V319, P1692, DOI 10.1056/NEJM198812293192602; SWANINK CMA, 1995, CLIN INFECT DIS, V20, P1390, DOI 10.1093/clinids/20.5.1390; TOBI M, 1982, LANCET, V1, P61; Vider-Shalit T, 2007, J VIROL, V81, P9536, DOI 10.1128/JVI.02636-06; Wallace HL, 1999, CLIN DIAGN LAB IMMUN, V6, P216, DOI 10.1128/CDLI.6.2.216-223.1999; Xu GJ, 2015, SCIENCE, V348, DOI 10.1126/science.aaa0698	28	2	2	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2020	11								1400	10.3389/fimmu.2020.01400	http://dx.doi.org/10.3389/fimmu.2020.01400			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NA8KS	32793195	Green Published, gold			2022-12-18	WOS:000560067300001
J	Ramirez-Toloza, G; Aguilar-Guzman, L; Valck, C; Ferreira, VP; Ferreira, A				Ramirez-Toloza, Galia; Aguilar-Guzman, Lorena; Valck, Carolina; Ferreira, Viviana P.; Ferreira, Arturo			The Interactions of Parasite Calreticulin With Initial Complement Components: Consequences in Immunity and Virulence	FRONTIERS IN IMMUNOLOGY			English	Review						Trypanosoma cruzi; complement; calreticulin; C1q; host-parasite interaction; host immune evasion	TRYPANOSOMA-CRUZI CALRETICULIN; LECTIN PATHWAY ACTIVATION; CELL-SURFACE CALRETICULIN; SCHISTOSOMA-MANSONI; LEISHMANIA-DONOVANI; REGULATORY PROTEIN; MOLECULAR CHARACTERIZATION; TRICHINELLA-SPIRALIS; BINDING-PROTEIN; CDNA-CLONE	Because of its capacity to increase a physiologic inflammatory response, to stimulate phagocytosis, to promote cell lysis and to enhance pathogen immunogenicity, the complement system is a crucial component of both the innate and adaptive immune responses. However, many infectious agents resist the activation of this system by expressing or secreting proteins with a role as complement regulatory, mainly inhibitory, proteins.Trypanosoma cruzi, the causal agent of Chagas disease, a reemerging microbial ailment, possesses several virulence factors with capacity to inhibit complement at different stages of activation.T. cruzicalreticulin (TcCalr) is a highly-conserved, endoplasmic reticulum-resident chaperone that the parasite translocates to the extracellular environment, where it exerts a variety of functions. Among these functions, TcCalr binds C1, MBL and ficolins, thus inhibiting the classical and lectin pathways of complement at their earliest stages of activation. Moreover, the TcCalr/C1 interaction also mediates infectivity by mimicking a strategy used by apoptotic cells for their removal. More recently, it has been determined that these Calr strategies are also used by a variety of other parasites. In addition, as reviewed elsewhere, TcCalr inhibits angiogenesis, promotes wound healing and reduces tumor growth. Complement C1 is also involved in some of these properties. Knowledge on the role of virulence factors, such as TcCalr, and their interactions with complement components in host-parasite interactions, may lead toward the description of new anti-parasite therapies and prophylaxis.	[Ramirez-Toloza, Galia] Univ Chile, Fac Vet Med & Livestock Sci, Dept Prevent Vet Med, Santiago, Chile; [Aguilar-Guzman, Lorena] Univ Chile, Fac Vet Med & Livestock Sci, Dept Pathol, Santiago, Chile; [Valck, Carolina; Ferreira, Arturo] Univ Chile, Fac Med, Dept Immunol, ICBM, Santiago, Chile; [Ferreira, Viviana P.] Univ Toledo, Coll Med & Life Sci, Dept Med Microbiol & Immunol, Toledo, OH 43606 USA	Universidad de Chile; Universidad de Chile; Universidad de Chile; University System of Ohio; University of Toledo	Ramirez-Toloza, G (corresponding author), Univ Chile, Fac Vet Med & Livestock Sci, Dept Prevent Vet Med, Santiago, Chile.; Ferreira, A (corresponding author), Univ Chile, Fac Med, Dept Immunol, ICBM, Santiago, Chile.; Ferreira, VP (corresponding author), Univ Toledo, Coll Med & Life Sci, Dept Med Microbiol & Immunol, Toledo, OH 43606 USA.	galiaram@uchile.cl; viviana.feffeira@utoledo.edu; aferreir@med.uchile.cl	RAMIREZ, GALIA/H-9500-2013	RAMIREZ, GALIA/0000-0001-8415-7918; Ferreira, Viviana/0000-0001-8923-5671	University of Toledo Biomedical Research Innovation Program, Toledo, Ohio, USA; VID, University of Chile; FONDECYT-Chile [1130099]; CONICYT-REDES [170126]	University of Toledo Biomedical Research Innovation Program, Toledo, Ohio, USA; VID, University of Chile; FONDECYT-Chile(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); CONICYT-REDES	The University of Toledo Biomedical Research Innovation Program (VF), Toledo, Ohio, USA; VID, University of Chile (AF); FONDECYT-Chile 1130099 (AF), and CONICYT-REDES 170126 (GR-T).	Abello-Caceres P, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2764-5; Alvarez JP, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.10.012; Andrighetto S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246336; ANZIANO DF, 1972, INFECT IMMUN, V6, P860, DOI 10.1128/IAI.6.5.860-864.1972; Beucher M, 2003, PROTEIN EXPRES PURIF, V27, P19, DOI 10.1016/S1046-5928(02)00562-4; Bivona AE, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165658; Bossard G, 2016, INFECT GENET EVOL, V45, P320, DOI 10.1016/j.meegid.2016.09.020; Cardoso MS, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00659; Castillo C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002376; Cestari I, 2012, J IMMUNOL, V188, P1942, DOI 10.4049/jimmunol.1102053; Cestari ID, 2008, J INFECT DIS, V198, P1276, DOI 10.1086/592167; Cestari ID, 2009, MOL IMMUNOL, V47, P426, DOI 10.1016/j.molimm.2009.08.030; Chaibangyang W, 2018, ACTA TROP, V187, P175, DOI 10.1016/j.actatropica.2018.08.009; Chaibangyang W, 2017, KOREAN J PARASITOL, V55, P643, DOI 10.3347/kjp.2017.55.6.643; Crawford KE, 2012, PLACENTA, V33, P416, DOI 10.1016/j.placenta.2012.02.003; Cruz P, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.12.001; Debrabant A, 2002, INT J PARASITOL, V32, P1423, DOI 10.1016/S0020-7519(02)00134-0; Eggleton P, 2016, EXPERT OPIN THER TAR, V20, P1137, DOI 10.1517/14728222.2016.1164695; El Gengehi N, 2000, J PARASITOL, V86, P993, DOI 10.1645/0022-3395(2000)086[0993:ASMKBI]2.0.CO;2; Evans-Osses I, 2014, FEBS LETT, V588, P956, DOI 10.1016/j.febslet.2014.01.054; Feng MY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05211-7; Ferreira CAS, 2002, EXP PARASITOL, V101, P25, DOI 10.1016/S0014-4894(02)00032-2; Ferreira V, 2004, J IMMUNOL, V172, P3042, DOI 10.4049/jimmunol.172.5.3042; FISCHER E, 1988, IMMUNOLOGY, V65, P299; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Gao JL, 2008, PARASITOL RES, V102, P737, DOI 10.1007/s00436-007-0826-y; Ghebrehiwet B, 2004, MOL IMMUNOL, V41, P173, DOI 10.1016/j.molimm.2004.03.014; Ghebrehiwet B, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101338; Gonzalez A, 2015, AM J TROP MED HYG, V92, P887, DOI 10.4269/ajtmh.14-0497; Gonzalez E, 2011, PARASITOL RES, V108, P439, DOI 10.1007/s00436-010-2085-6; Rivas EG, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00358; Gu VY, 2008, MOL HUM REPROD, V14, P309, DOI 10.1093/molehr/gan017; Gupta SK, 2007, PROTEOMICS, V7, P816, DOI 10.1002/pmic.200600725; HONG YQ, 1992, EXP PARASITOL, V74, P290, DOI 10.1016/0014-4894(92)90152-Z; HOUEN G, 1994, ACTA CHEM SCAND, V48, P905, DOI 10.3891/acta.chem.scand.48-0905; HUGGINS MC, 1995, MOL BIOCHEM PARASIT, V71, P81, DOI 10.1016/0166-6851(95)00038-3; Arias JI, 2018, ARCH DERMATOL RES, V310, P639, DOI 10.1007/s00403-018-1851-7; IIDA K, 1989, J EXP MED, V169, P881, DOI 10.1084/jem.169.3.881; Joshi M, 1996, MOL BIOCHEM PARASIT, V81, P53, DOI 10.1016/0166-6851(96)02676-X; Joshi R, 2019, GENE, V714, DOI 10.1016/j.gene.2019.144004; Kasper G, 2001, PARASITE IMMUNOL, V23, P141, DOI 10.1046/j.1365-3024.2001.00366.x; KHALIFE J, 1994, PARASITOLOGY, V108, P527, DOI 10.1017/S0031182000077398; Kim TK, 2015, TICKS TICK-BORNE DIS, V6, P91, DOI 10.1016/j.ttbdis.2014.10.002; Kipnis T L, 1988, Mem Inst Oswaldo Cruz, V83 Suppl 1, P571, DOI 10.1590/S0074-02761988000500069; Klabunde J, 2000, EXP PARASITOL, V95, P231, DOI 10.1006/expr.2000.4539; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Kumari S, 2008, VACCINE, V26, P5700, DOI 10.1016/j.vaccine.2008.08.021; Lopez NC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000730; Lukacsi S, 2020, FEBS LETT, V594, P2695, DOI 10.1002/1873-3468.13743; Ma LZ, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2516-7; McAllister M, 2019, PARASITOL RES, V118, P1147, DOI 10.1007/s00436-019-06246-5; Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847; Molina MC, 2005, MOL BIOCHEM PARASIT, V140, P133, DOI 10.1016/j.molbiopara.2004.12.014; Moreau C, 2016, IUCRJ, V3, P408, DOI 10.1107/S2052252516012847; Muniz J, 1945, REV BRASIL MED, V2, P994; Nareaho A, 2009, VET PARASITOL, V159, P263, DOI 10.1016/j.vetpar.2008.10.037; Naresha S, 2009, MOL BIOCHEM PARASIT, V166, P42, DOI 10.1016/j.molbiopara.2009.02.007; Ng YL, 2018, AM J TROP MED HYG, V99, P1518, DOI 10.4269/ajtmh.18-0415; NORRIS KA, 1994, INFECT IMMUN, V62, P236, DOI 10.1128/IAI.62.1.236-243.1994; NORRIS KA, 1991, J IMMUNOL, V147, P2240; Norris KA, 1998, INFECT IMMUN, V66, P2460, DOI 10.1128/IAI.66.6.2460-2465.1998; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Oladiran A, 2010, DEV COMP IMMUNOL, V34, P396, DOI 10.1016/j.dci.2009.11.005; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Plouffe DA, 2004, J FISH DIS, V27, P277, DOI 10.1111/j.1365-2761.2004.00541.x; Pritchard DI, 1999, PARASITE IMMUNOL, V21, P439, DOI 10.1046/j.1365-3024.1999.00238.x; Ramirez G, 2011, TRENDS PARASITOL, V27, P115, DOI 10.1016/j.pt.2010.12.007; Ramirez G, 2011, IMMUNOBIOLOGY, V216, P265, DOI 10.1016/j.imbio.2010.04.001; Ramirez MI, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12672; Ramirez-Toloza G, 2020, TRENDS PARASITOL, V36, P368, DOI 10.1016/j.pt.2020.01.007; Ramirez-Toloza G, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01667; RUBIO M., 1956, BOL CHILENO PARASITOL, V11, P62; Valdez FJS, 2013, MOL IMMUNOL, V53, P198, DOI 10.1016/j.molimm.2012.08.001; Sanchez-Valdez FJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002696; SANTORO F, 1980, J IMMUNOL, V124, P2886; Schcolnik-Cabrera A, 2019, APOPTOSIS, V24, P245, DOI 10.1007/s10495-019-01532-0; SCHENKMAN S, 1986, J IMMUNOL, V137, P1623; Sosoniuk E, 2014, MOL IMMUNOL, V60, P80, DOI 10.1016/j.molimm.2014.03.014; Sosoniuk-Roche E, 2017, IMMUNOBIOLOGY, V222, P529, DOI 10.1016/j.imbio.2016.10.020; Souto-Padron T, 2004, HISTOCHEM CELL BIOL, V122, P563, DOI 10.1007/s00418-004-0724-7; Stuart GR, 1996, FEBS LETT, V397, P245, DOI 10.1016/S0014-5793(96)01156-8; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; Suchitra S, 2008, PARASITE IMMUNOL, V30, P371, DOI 10.1111/j.1365-3024.2008.01028.x; Suchitra S, 2005, BBA-GEN SUBJECTS, V1722, P293, DOI 10.1016/j.bbagen.2004.12.020; Sun R, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004310; TAMBOURGI DV, 1993, INFECT IMMUN, V61, P3656, DOI 10.1128/IAI.61.9.3656-3663.1993; Toledo V, 2010, BIOL RES, V43, P287, DOI [10.4067/S0716-97602010000300004, /S0716-97602010000300004]; Tsuji N, 1998, MOL BIOCHEM PARASIT, V97, P69, DOI 10.1016/S0166-6851(98)00131-5; Vaithilingam A, 2012, INFECT IMMUN, V80, P2008, DOI 10.1128/IAI.06287-11; Valck C, 2010, MOL IMMUNOL, V47, P1516, DOI 10.1016/j.molimm.2010.01.019; Verneret M, 2014, J INNATE IMMUN, V6, P426, DOI 10.1159/000358834; VOST BRM, 2013, LANCET, V386, P743, DOI DOI 10.1016/S0140-6736(15)60692-4; Wallis R, 2010, IMMUNOBIOLOGY, V215, P1, DOI 10.1016/j.imbio.2009.08.006; Wang WA, 2012, INT J BIOCHEM CELL B, V44, P842, DOI 10.1016/j.biocel.2012.02.009; Weinberger K, 2017, AM J TROP MED HYG, V96, P295, DOI 10.4269/ajtmh.16-0642; Ximenez C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181962; Ximenez C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/127453; Yadav S, 2018, INT J BIOL MACROMOL, V117, P1157, DOI 10.1016/j.ijbiomac.2018.06.011; Yadav S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106413; Zhao LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00636	101	2	2	3	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2020	11								1561	10.3389/fimmu.2020.01561	http://dx.doi.org/10.3389/fimmu.2020.01561			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NB8DJ	32793217	gold, Green Published			2022-12-18	WOS:000560744000001
J	Liu, CH; Yang, CY; Wang, MQ; Jiang, S; Yi, QL; Wang, WL; Wang, LL; Song, LS				Liu, Conghui; Yang, Chuanyan; Wang, Mengqiang; Jiang, Shuai; Yi, Qilin; Wang, Weilin; Wang, Lingling; Song, Linsheng			A CD63 Homolog Specially Recruited to the Fungi-Contained Phagosomes Is Involved in the Cellular Immune Response of OysterCrassostrea gigas	FRONTIERS IN IMMUNOLOGY			English	Article						tetraspanin; phagosomes recruitment; receptor; innate immune response; Crassostrea gigas	C-TYPE LECTIN; ARGOPECTEN-IRRADIANS; MEMBRANE-PROTEINS; TETRASPANIN; CD81; LIPOPOLYSACCHARIDE; ACTIVATION; EXPRESSION; RECEPTOR; OYSTER	Cluster of differentiation 63 (CD63), a four-transmembrane glycoprotein in the subfamily of tetraspanin, has been widely recognized as a gateway from the infection of foreign invaders to the immune defense of hosts. Its role in Pacific oysterCrassostrea gigasis, however, yet to be discovered. This work makes contributions by identifyingCgCD63H, a CD63 homolog with four transmembrane domains and one conservative CCG motif, and establishing its role as a receptor that participates in immune recognition and hemocyte phagocytosis. The presence ofCgCD63H messenger RNA (mRNA) in hepatopancreas, labial palps, gill, and hemocytes is confirmed. The expression level of mRNA in hemocytes is found significantly (p< 0.01) upregulated after the injection ofVibrio splendidus.CgCD63H protein, typically distributed over the plasma membrane of oyster hemocytes, is recruited to theYarrowia lipolytica-containing phagosomes after the stimulation ofY. lipolytica. The recombinantCgCD63H protein expresses binding capacity to glucan (GLU), peptidoglycan (PGN), and lipopolysaccharide (LPS) in the presence of lyophilized hemolymph. The phagocytic rate of hemocytes towardV. splendidusandY. lipolyticais significantly inhibited (p< 0.01) after incubation with anti-CgCD63H antibody. Our work further suggests thatCgCD63H functions as a receptor involved in the immune recognition and hemocyte phagocytosis against invading pathogen, which can be a marker candidate for the hemocyte typing inC. gigas.	[Liu, Conghui; Yang, Chuanyan; Yi, Qilin; Wang, Lingling; Song, Linsheng] Dalian Ocean Univ, Liaoning Key Lab Marine Anim Immunol, Dalian, Peoples R China; [Liu, Conghui; Wang, Mengqiang; Jiang, Shuai; Wang, Weilin] Chinese Acad Sci, Inst Oceanol, Key Lab Expt Marine Biol, Qingdao, Peoples R China; [Liu, Conghui; Yang, Chuanyan; Yi, Qilin; Wang, Weilin; Wang, Lingling; Song, Linsheng] Dalian Ocean Univ, Liaoning Key Lab Marine Anim Immunol & Dis Contro, Dalian, Peoples R China; [Yang, Chuanyan; Yi, Qilin; Wang, Weilin; Wang, Lingling] Dalian Ocean Univ, Dalian Key Lab Aquat Anim Dis Prevent & Control, Dalian, Peoples R China	Dalian Ocean University; Chinese Academy of Sciences; Institute of Oceanology, CAS; Dalian Ocean University; Dalian Ocean University	Wang, LL; Song, LS (corresponding author), Dalian Ocean Univ, Liaoning Key Lab Marine Anim Immunol, Dalian, Peoples R China.; Wang, LL; Song, LS (corresponding author), Dalian Ocean Univ, Liaoning Key Lab Marine Anim Immunol & Dis Contro, Dalian, Peoples R China.; Wang, LL (corresponding author), Dalian Ocean Univ, Dalian Key Lab Aquat Anim Dis Prevent & Control, Dalian, Peoples R China.	wanglingling@dlou.edu.cn; lshsong@dlou.edu.cn	Liu, Conghui/AAA-7192-2021	liu, cong hui/0000-0002-8374-2047	National Key RD Program [2018YFD0900606]; National Science Foundation of China [U1706204, 41961124009]; Modern Agro-Industry Technology Research System [CARS-49]; Fund for Outstanding Talents and Innovative Team of Agricultural Scientific Research from the Ministry of Agriculture and Rural Affairs in China; AoShan Talents Cultivation Program - Qingdao National Laboratory for Marine Science and Technology [2017ASTCP-OS13]; Liaoning Climbing Scholar; Dalian High Level Talent Innovation Support Program [2015R020]; Research Foundation for Talented Scholars in Dalian Ocean University;  [XLYC1902012]	National Key RD Program; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Modern Agro-Industry Technology Research System; Fund for Outstanding Talents and Innovative Team of Agricultural Scientific Research from the Ministry of Agriculture and Rural Affairs in China; AoShan Talents Cultivation Program - Qingdao National Laboratory for Marine Science and Technology; Liaoning Climbing Scholar; Dalian High Level Talent Innovation Support Program; Research Foundation for Talented Scholars in Dalian Ocean University; 	This research was supported by the National Key R&D Program (2018YFD0900606), grants (Nos. U1706204 and 41961124009) from the National Science Foundation of China, earmarked fund from Modern Agro-Industry Technology Research System (CARS-49) and the Fund for Outstanding Talents and Innovative Team of Agricultural Scientific Research from the Ministry of Agriculture and Rural Affairs in China, the Distinguished Professor of Liaoning (to LS), AoShan Talents Cultivation Program Supported by Qingdao National Laboratory for Marine Science and Technology (No. 2017ASTCP-OS13), Liaoning Climbing Scholar (to LS), the Distinguished Professor of Liaoning (XLYC1902012), Dalian High Level Talent Innovation Support Program (2015R020), and the Research Foundation for Talented Scholars in Dalian Ocean University (to LW).	Artavanis-Tsakonas K, 2006, P NATL ACAD SCI USA, V103, P15945, DOI 10.1073/pnas.0607528103; Artavanis-Tsakonas K, 2011, INFECT IMMUN, V79, P1098, DOI 10.1128/IAI.01135-10; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Cao A, 2003, AQUACULTURE, V216, P1, DOI 10.1016/S0044-8486(02)00140-0; Chang YG, 2007, J CELL SCI, V120, P3053, DOI 10.1242/jcs.006361; Charrin S, 2009, BIOCHEM J, V420, P133, DOI 10.1042/BJ20082422; Cheng SF, 2006, J VIROL METHODS, V135, P173, DOI 10.1016/j.jviromet.2006.03.016; Costa MM, 2009, FISH SHELLFISH IMMUN, V26, P515, DOI 10.1016/j.fsi.2009.02.001; Dijkstra S, 2001, J NEUROIMMUNOL, V114, P151, DOI 10.1016/S0165-5728(01)00240-5; Figdor CG, 2010, TRENDS IMMUNOL, V31, P91, DOI 10.1016/j.it.2009.11.005; Garcia-Espana A, 2008, GENOMICS, V91, P326, DOI 10.1016/j.ygeno.2007.12.005; Green LR, 2011, INFECT IMMUN, V79, P2241, DOI 10.1128/IAI.01354-10; Gueguen Y, 2006, J BIOL CHEM, V281, P313, DOI 10.1074/jbc.M510850200; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Huang SF, 2005, GENOMICS, V86, P674, DOI 10.1016/j.ygeno.2005.08.004; Jiang S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01280; Jiang S, 2016, PEERJ, V4, DOI 10.7717/peerj.2590; Jing X, 2011, FISH SHELLFISH IMMUN, V30, P851, DOI 10.1016/j.fsi.2011.01.007; Jones EL, 2011, BIOCHEM SOC T, V39, P506, DOI 10.1042/BST0390506; Konno A, 2010, ZOOL SCI, V27, P204, DOI 10.2108/zsj.27.204; Lau YT, 2018, FISH SHELLFISH IMMUN, V78, P18, DOI 10.1016/j.fsi.2018.04.019; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Little KD, 2004, MOL BIOL CELL, V15, P2375, DOI 10.1091/mbc.E03-12-0886; Liu R, 2013, J INVERTEBR PATHOL, V114, P144, DOI 10.1016/j.jip.2013.07.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo M, 2012, FISH SHELLFISH IMMUN, V33, P294, DOI 10.1016/j.fsi.2012.05.009; Lv Z, 2019, DEV COMP IMMUNOL, V98, P42, DOI 10.1016/j.dci.2019.04.004; Mantegazza AR, 2004, BLOOD, V104, P1183, DOI 10.1182/blood-2004-01-0104; Meyer-Wentrup F, 2007, J IMMUNOL, V178, P154, DOI 10.4049/jimmunol.178.1.154; Monk Peter N., 2012, Infectious Disorders - Drug Targets, V12, P4; Morga B, 2011, DEV COMP IMMUNOL, V35, P323, DOI 10.1016/j.dci.2010.10.005; Moribe H, 2004, J CELL SCI, V117, P5209, DOI 10.1242/jcs.01403; Patnaik BB, 2013, INT J MOL SCI, V14, P20744, DOI 10.3390/ijms141020744; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Pols MS, 2009, EXP CELL RES, V315, P1584, DOI 10.1016/j.yexcr.2008.09.020; Priyathilaka TT, 2017, FISH SHELLFISH IMMUN, V69, P173, DOI 10.1016/j.fsi.2017.08.020; Ribeiro-Sobrinho AP, 2005, J MED MICROBIOL, V54, P413, DOI 10.1099/jmm.0.45728-0; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Sanyal M, 2009, INT IMMUNOL, V21, P1225, DOI 10.1093/intimm/dxp090; Song LS, 2015, FISH SHELLFISH IMMUN, V46, P65, DOI 10.1016/j.fsi.2015.03.013; Suzuki M, 2009, J IMMUNOL, V182, P6485, DOI 10.4049/jimmunol.0802797; Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031; Tanguy A, 2004, GENE, V338, P121, DOI 10.1016/j.gene.2004.05.019; Todres E, 2000, INSECT MOL BIOL, V9, P581, DOI 10.1046/j.1365-2583.2000.00222.x; Wang B, 2010, J FISH DIS, V33, P15, DOI 10.1111/j.1365-2761.2009.01079.x; Wang LL, 2019, DEV COMP IMMUNOL, V91, P1, DOI 10.1016/j.dci.2018.09.021; Wang XW, 2013, DEV COMP IMMUNOL, V39, P27, DOI 10.1016/j.dci.2012.04.009; Wang Y, 2019, FISH SHELLFISH IMMUN, V88, P135, DOI 10.1016/j.fsi.2019.01.048; Wootton EC, 2003, FISH SHELLFISH IMMUN, V15, P195, DOI 10.1016/S1050-4648(02)00161-4; Wright MD, 2004, TISSUE ANTIGENS, V64, P533, DOI 10.1111/j.1399-0039.2004.00321.x; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Wright MD, 2000, PROTEIN SCI, V9, P1594, DOI 10.1110/ps.9.8.1594; Xu JC, 2016, DEV COMP IMMUNOL, V61, P1, DOI 10.1016/j.dci.2016.03.015; Yang CY, 2014, FISH SHELLFISH IMMUN, V38, P221, DOI 10.1016/j.fsi.2014.03.025; Yang SB, 2010, DEV COMP IMMUNOL, V34, P538, DOI 10.1016/j.dci.2009.12.014; Yu MJ, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7893490; Yu YH, 2007, J IMMUNOL, V179, P8425, DOI 10.4049/jimmunol.179.12.8425; Zhang HA, 2011, FISH SHELLFISH IMMUN, V30, P17, DOI 10.1016/j.fsi.2009.12.019; Zhang HA, 2010, FISH SHELLFISH IMMUN, V29, P149, DOI 10.1016/j.fsi.2010.02.024; Zhu XJ, 2019, FISH SHELLFISH IMMUN, V86, P459, DOI 10.1016/j.fsi.2018.11.055; Zhuang SF, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M700341200	64	2	2	2	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2020	11								1379	10.3389/fimmu.2020.01379	http://dx.doi.org/10.3389/fimmu.2020.01379			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MZ7XW	32793193	gold, Green Published			2022-12-18	WOS:000559341100001
J	Machado, A; Pouzolles, M; Gailhac, S; Fritz, V; Craveiro, M; Lopez-Sanchez, U; Kondo, T; Pala, F; Bosticardo, M; Notarangelo, LD; Petit, V; Taylor, N; Zimmermann, VS				Machado, Alice; Pouzolles, Marie; Gailhac, Sarah; Fritz, Vanessa; Craveiro, Marco; Lopez-Sanchez, Uriel; Kondo, Taisuke; Pala, Francesca; Bosticardo, Marita; Notarangelo, Luigi D.; Petit, Vincent; Taylor, Naomi; Zimmermann, Valerie S.			Phosphate Transporter Profiles in Murine and Human Thymi Identify Thymocytes at Distinct Stages of Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						thymus; phosphate transporters; glucose transporters; metabolism; human; mice; aging	APE LEUKEMIA-VIRUS; PRE-T CELLS; BASAL GANGLIA CALCIFICATION; RETROVIRUS RECEPTOR; BETA-SELECTION; GLUT4 TRANSLOCATION; GENE REARRANGEMENT; THYMIC DEVELOPMENT; CELLULAR RECEPTOR; GLUTAMINE UPTAKE	Thymocyte differentiation is dependent on the availability and transport of metabolites in the thymus niche. As expression of metabolite transporters is a rate-limiting step in nutrient utilization, cell surface transporter levels generally reflect the cell's metabolic state. The GLUT1 glucose transporter is upregulated on actively dividing thymocytes, identifying thymocytes with an increased metabolism. However, it is not clear whether transporters of essential elements such as phosphate are modulated during thymocyte differentiation. While PiT1 and PiT2 are both phosphate transporters in the SLC20 family, we show here that they exhibit distinct expression profiles on both murine and human thymocytes. PiT2 expression distinguishes thymocytes with high metabolic activity, identifying immature murine double negative (CD4(-)CD8(-)) DN3b and DN4 thymocyte blasts as well as immature single positive (ISP) CD8 thymocytes. Notably, the absence of PiT2 expression on RAG2-deficient thymocytes, blocked at the DN3a stage, strongly suggests that high PiT2 expression is restricted to thymocytes having undergone a productive TCR beta rearrangement at the DN3a/DN3b transition. Similarly, in the human thymus, PiT2 was upregulated on early post-beta selection CD4(+)ISP and TCR alpha beta(-)CD4(hi)DP thymocytes co-expressing the CD71 transferrin receptor, a marker of metabolic activity. In marked contrast, expression of the PiT1 phosphate importer was detected on mature CD3(+)murine and human thymocytes. Notably, PiT1 expression on CD3(+)DN thymocytes was identified as a biomarker of an aging thymus, increasing from 8.4 +/- 1.5% to 42.4 +/- 9.4% by 1 year of age (p< 0.0001). We identified these cells as TCR gamma delta and, most significantly, NKT, representing 77 +/- 9% of PiT1(+)DN thymocytes by 1 year of age (p< 0.001). Thus, metabolic activity and thymic aging are associated with distinct expression profiles of the PiT1 and PiT2 phosphate transporters.	[Machado, Alice; Pouzolles, Marie; Kondo, Taisuke; Taylor, Naomi; Zimmermann, Valerie S.] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Machado, Alice; Gailhac, Sarah; Fritz, Vanessa; Craveiro, Marco; Lopez-Sanchez, Uriel; Taylor, Naomi; Zimmermann, Valerie S.] Univ Montpellier, Inst Genet Mol Montpellier, CNRS, Montpellier, France; [Pala, Francesca; Bosticardo, Marita; Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Petit, Vincent] Metafora Biosyst, Paris, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Taylor, N; Zimmermann, VS (corresponding author), NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.; Taylor, N; Zimmermann, VS (corresponding author), Univ Montpellier, Inst Genet Mol Montpellier, CNRS, Montpellier, France.	taylorn4@mail.nih.gov; valerie.zimmermann@igmm.cnrs.fr	Bosticardo, Marita/ABA-2688-2021; Taylor, Naomi/H-4016-2014	Bosticardo, Marita/0000-0002-1771-4523; Pala, Francesca/0000-0003-4537-9061; Kondo, Taisuke/0000-0002-8545-1251; Craveiro, Marco/0000-0002-7405-4621; , Valerie/0000-0001-8919-0071; Lopez-Sanchez, Uriel/0000-0003-4937-7055	French national (ANR) research grant (PolarATTACK); French national (ANR) research grant (GlutStem); ARC; AFM; FRM; ANRS; Sidaction; French laboratory consortiums (Labex) EpiGenMed; French laboratory consortiums (Labex) GR-EX; intramural NIH research program	French national (ANR) research grant (PolarATTACK)(French National Research Agency (ANR)); French national (ANR) research grant (GlutStem)(French National Research Agency (ANR)); ARC(Australian Research Council); AFM(Association Francaise contre les Myopathies); FRM(Fondation pour la Recherche Medicale); ANRS(ANRSFrench National Research Agency (ANR)); Sidaction; French laboratory consortiums (Labex) EpiGenMed; French laboratory consortiums (Labex) GR-EX; intramural NIH research program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding was obtained from the French national (ANR) research grants (PolarATTACK and GlutStem), ARC, AFM, FRM, ANRS, and Sidaction, the French laboratory consortiums (Labex) EpiGenMed and GR-EX, and the intramural NIH research program.	Ahamed JA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3119jc4; Almeida L, 2016, SEMIN IMMUNOL, V28, P514, DOI 10.1016/j.smim.2016.10.009; Bejarano-Garcia JA, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.411; Aspinall R, 2000, J CLIN IMMUNOL, V20, P250, DOI 10.1023/A:1006611518223; Aw D, 2010, J COMP PATHOL, V141, pS45, DOI [10.1016/j.jcpa.2009.10.004, 10.1019/j.jepa.2009.10.004]; Aw D, 2009, AGING-US, V1, P146, DOI 10.18632/aging.100027; Aydin OF, 2018, CLIN PEDIATR, V57, P761, DOI 10.1177/0009922817737083; Badou A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00243; Balciunaite G, 2005, EUR J IMMUNOL, V35, P1292, DOI 10.1002/eji.200425822; Beck L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009148; Beck L, 2009, J BIOL CHEM, V284, P31363, DOI 10.1074/jbc.M109.053132; BERNER YN, 1988, ANNU REV NUTR, V8, P121, DOI 10.1146/annurev.nu.08.070188.001005; Bhandoola A, 2007, IMMUNITY, V26, P678, DOI 10.1016/j.immuni.2007.05.009; Blom B, 2006, ANNU REV IMMUNOL, V24, P287, DOI 10.1146/annurev.immunol.24.021605.090612; Bon N, 2018, J BIOL CHEM, V293, P2102, DOI 10.1074/jbc.M117.807339; Bottger P, 2006, AM J PHYSIOL-CELL PH, V291, pC1377, DOI 10.1152/ajpcell.00015.2006; BREKELMANS P, 1994, CELL IMMUNOL, V159, P331, DOI 10.1006/cimm.1994.1319; Brewer PD, 2014, J BIOL CHEM, V289, P17280, DOI 10.1074/jbc.M114.555714; Byskov K, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-7; Cabon L, 2018, CELL DEATH DIFFER, V25, P983, DOI 10.1038/s41418-017-0035-x; Carr EL, 2010, J IMMUNOL, V185, P1037, DOI 10.4049/jimmunol.0903586; Carrasco YR, 1999, BLOOD, V94, P3491, DOI 10.1182/blood.V94.10.3491.422k30_3491_3498; Chaudhry MS, 2016, IMMUNOL REV, V271, P56, DOI 10.1111/imr.12418; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; Cretenet G, 2016, SCI REP-UK, V6, DOI 10.1038/srep24129; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Eil R, 2016, NATURE, V537, P539, DOI 10.1038/nature19364; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; Essletzbichler P, 2014, GENOME RES, V24, P2059, DOI 10.1101/gr.177220.114; Famili F, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2016-0095; Farrow EG, 2010, NAT REV NEPHROL, V6, P207, DOI 10.1038/nrneph.2010.17; Festing MH, 2009, GENESIS, V47, P858, DOI 10.1002/dvg.20577; Fischer AM, 2005, IMMUNITY, V23, P431, DOI 10.1016/j.immuni.2005.08.013; Forand A, 2016, CELL REP, V17, P1905, DOI 10.1016/j.celrep.2016.10.039; Forand A, 2013, BLOOD, V121, P666, DOI 10.1182/blood-2012-05-427302; Forster IC, 2013, MOL ASPECTS MED, V34, P386, DOI 10.1016/j.mam.2012.07.007; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Giovannini D, 2013, CELL REP, V3, P1866, DOI 10.1016/j.celrep.2013.05.035; GODFREY DI, 1994, J IMMUNOL, V152, P4783; Hayashi K, 2013, J IMMUNOL, V191, P4080, DOI 10.4049/jimmunol.1300923; Heng TSP, 2005, J IMMUNOL, V175, P2982, DOI 10.4049/jimmunol.175.5.2982; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Hoffman ES, 1996, GENE DEV, V10, P948, DOI 10.1101/gad.10.8.948; Imamura T, 2003, MOL CELL BIOL, V23, P4892, DOI 10.1128/MCB.23.14.4892-4900.2003; Janas ML, 2010, J EXP MED, V207, P247, DOI 10.1084/jem.20091430; Jensen N, 2013, J MOL NEUROSCI, V51, P994, DOI 10.1007/s12031-013-0085-6; Juntilla MA, 2008, IMMUNOL LETT, V116, P104, DOI 10.1016/j.imlet.2007.12.008; Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; Kelly AP, 2007, EMBO J, V26, P3441, DOI 10.1038/sj.emboj.7601761; Kim Felix J, 2004, Retrovirology, V1, P41, DOI 10.1186/1742-4690-1-41; Kim FJ, 2000, J BIOL CHEM, V275, P23417, DOI 10.1074/jbc.C901002199; Kimata M, 2010, BONE, V47, P938, DOI 10.1016/j.bone.2010.08.006; Kinet S, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-31; Klysz D, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab2610; Kondo K, 2019, INT IMMUNOL, V31, P119, DOI 10.1093/intimm/dxy081; Kongsfelt IB, 2014, EXP CELL RES, V326, P57, DOI 10.1016/j.yexcr.2014.05.014; Koumakis E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37551-1; KOZAK SL, 1995, J VIROL, V69, P3433, DOI 10.1128/JVI.69.6.3433-3440.1995; Krueger A, 2006, J EXP MED, V203, P1977, DOI 10.1084/jem.20060731; Kuro-O M, 2011, KIDNEY INT, V79, pS20, DOI 10.1038/ki.2011.26; Kvainickas A, 2017, J CELL SCI, V130, P382, DOI 10.1242/jcs.196758; Laval J, 2013, J IMMUNOL, V190, P6043, DOI 10.4049/jimmunol.1201755; Legati A, 2015, NAT GENET, V47, P579, DOI 10.1038/ng.3289; Lemos RR, 2015, HUM MUTAT, V36, P489, DOI 10.1002/humu.22778; Lepletier A, 2017, FRONT HORM RES, V48, P19, DOI 10.1159/000452903; Liu L, 2013, EXP HEMATOL, V41, P432, DOI 10.1016/j.exphem.2013.01.004; Loisel-Meyer S, 2012, P NATL ACAD SCI USA, V109, P2549, DOI 10.1073/pnas.1121427109; Lopez-Sanchez U, 2020, J BIOL CHEM, V295, P9366, DOI 10.1074/jbc.RA119.011376; Lopez-Sanchez U, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43255-x; Macedo MF, 2004, IMMUNOLOGY, V112, P543, DOI 10.1111/j.1365-2567.2004.01915.x; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Mao CC, 2007, J IMMUNOL, V178, P5443, DOI 10.4049/jimmunol.178.9.5443; Masle-Farquhar E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00549; McGargill MA, 2009, J IMMUNOL, V183, P4838, DOI 10.4049/jimmunol.0902208; Michigami T, 2013, CONTRIB NEPHROL, V180, P14, DOI 10.1159/000346776; Min D, 2007, BLOOD, V109, P2529, DOI 10.1182/blood-2006-08-043794; Min H, 2004, J IMMUNOL, V173, P245, DOI 10.4049/jimmunol.173.1.245; Nakaya M, 2014, IMMUNITY, V40, P692, DOI 10.1016/j.immuni.2014.04.007; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; OLAH Z, 1994, J BIOL CHEM, V269, P25426; Oliveira NM, 2006, J VIROL, V80, P3104, DOI 10.1128/JVI.80.6.3104-3107.2006; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Palmer DB, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00316; Penido MGMG, 2012, PEDIATR NEPHROL, V27, P2039, DOI 10.1007/s00467-012-2175-z; Pobezinsky LA, 2012, NAT IMMUNOL, V13, P569, DOI 10.1038/ni.2292; Prockop SE, 2004, J IMMUNOL, V173, P1604, DOI 10.4049/jimmunol.173.3.1604; Ribeiro VSG, 2010, J IMMUNOL, V185, P4993, DOI 10.4049/jimmunol.1002273; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; Roy S, 2017, MOL CELL, V67, DOI 10.1016/j.molcel.2017.05.02028602638; Schwarz BA, 2007, J IMMUNOL, V178, P2008, DOI 10.4049/jimmunol.178.4.2008; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Sumaria N, 2017, CELL REP, V19, P2469, DOI 10.1016/j.celrep.2017.05.071; Swainson L, 2005, P NATL ACAD SCI USA, V102, P12867, DOI 10.1073/pnas.0503603102; Taghon T, 2006, IMMUNITY, V24, P53, DOI 10.1016/j.immuni.2005.11.012; Tai XG, 2014, CELL CYCLE, V13, P501, DOI 10.4161/cc.27787; Thapa P, 2019, THORAC SURG CLIN, V29, P123, DOI 10.1016/j.thorsurg.2018.12.001; THOMAN ML, 1995, MECH AGEING DEV, V82, P155, DOI 10.1016/0047-6374(95)01597-S; Trampont PC, 2010, NAT IMMUNOL, V11, P162, DOI 10.1038/ni.1830; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; Vicente R, 2010, SEMIN IMMUNOL, V22, P270, DOI 10.1016/j.smim.2010.04.016; Vodnala SK, 2019, SCIENCE, V363, P1417, DOI 10.1126/science.aau0135; Wang C, 2012, NAT GENET, V44, P254, DOI 10.1038/ng.1077; Xiao SY, 2017, J IMMUNOL, V199, P2701, DOI 10.4049/jimmunol.1600934; Yang Q, 2010, IMMUNOL REV, V238, P12, DOI 10.1111/j.1600-065X.2010.00956.x; Yong CS, 2017, FEBS LETT, V591, P3104, DOI 10.1002/1873-3468.12849; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; Yu Q, 2003, J EXP MED, V197, P475, DOI 10.1084/jem.20021765; Zhang Y, 2019, J MOL CELL BIOL, V11, P1, DOI 10.1093/jmcb/mjy052	116	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 22	2020	11								1562	10.3389/fimmu.2020.01562	http://dx.doi.org/10.3389/fimmu.2020.01562			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MZ7ZP	32793218	gold, Green Published			2022-12-18	WOS:000559345600001
J	Pino, M; Uppada, SB; Pandey, K; King, C; Nguyen, K; Shim, I; Rogers, K; Villinger, F; Paiardini, M; Byrareddy, SN				Pino, Maria; Uppada, Srijayaprakash Babu; Pandey, Kabita; King, Colin; Nguyen, Kevin; Shim, Inbo; Rogers, Kenneth; Villinger, Francois; Paiardini, Mirko; Byrareddy, Siddappa N.			Safety and Immunological Evaluation of Interleukin-21 Plus Anti-alpha 4 beta 7 mAb Combination Therapy in Rhesus Macaques	FRONTIERS IN IMMUNOLOGY			English	Article						anti-alpha 4 beta 7; IL-21; immune activation; T-cell homing; macaques; rhesus macaques; combined immune intervention	SIMIAN IMMUNODEFICIENCY VIRUS; CD4(+) T-CELLS; INTEGRIN ALPHA(4)BETA(7); IMMUNE ACTIVATION; ANTIRETROVIRAL THERAPY; SIV INFECTION; ANTIBODY; TRANSMISSION; INFLAMMATION; EXPRESSION	Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections compromise gut immunological barriers, inducing high levels of inflammation and a severe depletion of intestinal CD4(+)T cells. Expression of alpha 4 beta 7 integrin promotes homing of activated T cells to intestinal sites where they become preferentially infected; blockade of alpha 4 beta 7 with an anti-alpha 4 beta 7 monoclonal antibody (mAb) prior to infection has been reported to reduce gut SIV viremia in rhesus macaques (RMs). Interleukin-21 (IL-21) administration in antiretroviral therapy-treated, SIV-infected RMs reduces gut inflammation and improves gut integrity. We therefore hypothesized that the combination of IL-21 and anti-alpha 4 beta 7 mAb therapies could synergize to reduce inflammation and HIV persistence. We co-administered two intravenous doses of rhesus anti-alpha 4 beta 7 mAb (50 mg/kg) combined with seven weekly subcutaneous infusions of IL-21-IgFc (100 mu g/kg) in four healthy, SIV-uninfected RMs to evaluate the safety and immunological profiles of this intervention in blood and gut. Co-administration of IL-21 and anti-alpha 4 beta 7 mAb showed no toxicity at the given dosages as assessed by multiple hematological and chemical parameters and did not alter the bioavailability of the therapeutics or result in the generation of antibodies against the anti-alpha 4 beta 7 mAb or IL-21-IgFc. Upon treatment, the frequency of CD4 memory T cells expressing beta 7 increased in blood and decreased in gut, consistent with an inhibition of activated CD4 T-cell homing to the gut. Furthermore, the frequency of T cells expressing proliferation and immune activation markers decreased in blood and, more profoundly, in gut. The combined IL-21 plus anti-alpha 4 beta 7 mAb therapy is well-tolerated in SIV-uninfected RMs and reduces the gut homing of alpha 4 beta 7(+)CD4 T cells as well as the levels of gut immune activation.	[Pino, Maria; King, Colin; Nguyen, Kevin; Shim, Inbo; Paiardini, Mirko] Emory Univ, Yerkes Natl Primate Res Ctr, Div Microbiol & Immunol, Atlanta, GA 30322 USA; [Uppada, Srijayaprakash Babu; Pandey, Kabita; Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Rogers, Kenneth; Villinger, Francois] Univ Louisiana Lafayette, New Iberia Res Ctr, New Iberia, LA USA; [Paiardini, Mirko] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA; [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	Emory University; University of Nebraska System; University of Nebraska Medical Center; University of Louisiana Lafayette; New Iberia Research Center; Emory University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Paiardini, M (corresponding author), Emory Univ, Yerkes Natl Primate Res Ctr, Div Microbiol & Immunol, Atlanta, GA 30322 USA.; Byrareddy, SN (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.; Paiardini, M (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.; Byrareddy, SN (corresponding author), Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.; Byrareddy, SN (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	mirko.paiardini@emory.edu; sid.byrareddy@unmc.edu	Uppada, Srijayaprakash/AAD-7728-2021	Pino Claveria, Maria/0000-0003-4954-5215	National Institute of Allergy and Infectious Diseases [R01 AI129745]; Yerkes National Primate Research Center Base Grant [NIH-DRR-00165]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Yerkes National Primate Research Center Base Grant	National Institute of Allergy and Infectious Diseases Grant R01 AI129745 (SB/MPa) and Yerkes National Primate Research Center Base Grant NIH-DRR-00165 supported this work.	Abbink P, 2019, SCIENCE, V365, P1029, DOI 10.1126/science.aaw8562; Amiot A, 2019, ALIMENT PHARM THER, V50, P40, DOI 10.1111/apt.15294; [Anonymous], 2019, GASTROENTEROL HEPATO, V15; Ansari AA, 2011, J IMMUNOL, V186, P1044, DOI 10.4049/jimmunol.1003052; Arijs I, 2018, GUT, V67, P43, DOI 10.1136/gutjnl-2016-312293; Arjonen A, 2012, TRAFFIC, V13, P610, DOI 10.1111/j.1600-0854.2012.01327.x; Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566; Askari JA, 2009, J CELL SCI, V122, P165, DOI 10.1242/jcs.018556; Battat R, 2019, HUM VACC IMMUNOTHER, V15, P2482, DOI 10.1080/21645515.2019.1591139; Battat R, 2019, DRUG SAFETY, V42, P617, DOI 10.1007/s40264-018-00783-1; Berg J, 2019, SCIENCE, V365, P991, DOI 10.1126/science.aaz2722; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Brandes A, 2019, Z GASTROENTEROL, V57, P843, DOI 10.1055/a-0903-2938; Byrareddy SN, 2016, SCIENCE, V354, P197, DOI 10.1126/science.aag1276; Byrareddy SN, 2014, NAT MED, V20, P1397, DOI 10.1038/nm.3715; Calenda G, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007776; Calenda G, 2018, J IMMUNOL, V200, P810, DOI 10.4049/jimmunol.1701150; Casey KA, 2007, J IMMUNOL, V178, P7640, DOI 10.4049/jimmunol.178.12.7640; Cicala C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S2; Cicala C, 2009, P NATL ACAD SCI USA, V106, P20877, DOI 10.1073/pnas.0911796106; Di Mascio M, 2019, SCIENCE, V365, P1025, DOI 10.1126/science.aav6695; Hileman CO, 2017, CURR HIV-AIDS REP, V14, P93, DOI 10.1007/s11904-017-0356-x; Hunt PW, 2016, J INFECT DIS, V214, pS44, DOI 10.1093/infdis/jiw275; Iannello A, 2010, J IMMUNOL, V184, P114, DOI 10.4049/jimmunol.0901967; Iwamoto N, 2019, SCIENCE, V365, P1033, DOI 10.1126/science.aaw7765; Kader M, 2009, MUCOSAL IMMUNOL, V2, P439, DOI 10.1038/mi.2009.90; Kwa S, 2011, BLOOD, V118, P2763, DOI 10.1182/blood-2011-02-339515; Martinez-Picado J, 2016, CURR OPIN HIV AIDS, V11, P417, DOI 10.1097/COH.0000000000000287; McGary CS, 2017, IMMUNITY, V47, P776, DOI 10.1016/j.immuni.2017.09.018; Micci L, 2015, J CLIN INVEST, V125, P4497, DOI 10.1172/JCI81400; Micci L, 2012, BLOOD, V120, P3925, DOI 10.1182/blood-2012-04-420240; Pallikkuth S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003471; Pallikkuth S, 2011, VACCINE, V29, P9229, DOI 10.1016/j.vaccine.2011.09.118; Rasmussen TA, 2018, LANCET HIV, V5, pE221, DOI 10.1016/S2352-3018(18)30040-7; Sengupta S, 2018, IMMUNITY, V48, P872, DOI 10.1016/j.immuni.2018.04.030; Sivro A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam6354; Sneller MC, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax3447; Spolski R, 2014, NAT REV DRUG DISCOV, V13, P381, DOI 10.1038/nrd4296; Stieh DJ, 2016, CELL HOST MICROBE, V19, P529, DOI 10.1016/j.chom.2016.03.005; Tamilarasan AG, 2019, FRONTLINE GASTROENTE, V10, P409, DOI 10.1136/flgastro-2018-101054; Uzzan M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau4711; White L, 2007, BLOOD, V109, P3873, DOI 10.1182/blood-2006-09-045278; Williams LD, 2011, J VIROL, V85, P2316, DOI 10.1128/JVI.01476-10	43	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 17	2020	11								1275	10.3389/fimmu.2020.01275	http://dx.doi.org/10.3389/fimmu.2020.01275			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MU6TO	32765488	gold, Green Published			2022-12-18	WOS:000555803700001
J	Lumbreras, J; Subias, M; Espinosa, N; Ferrer, JM; Arjona, E; de Cordoba, SR				Lumbreras, Javier; Subias, Marta; Espinosa, Natalia; Maria Ferrer, Juana; Arjona, Emilia; Rodriguez de Cordoba, Santiago			The Relevance of the MCP Risk Polymorphism to the Outcome of aHUS Associated With C3 Mutations. A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						C3; MCP risk polymorphism; atypical hemolytic uremic syndrome; de novomutation; case report	HEMOLYTIC-UREMIC SYNDROME; COMPLEMENT C3; DISEASE; SUSCEPTIBILITY; REGULATORS; GENETICS	Thrombotic microangiopathy (TMA) has different etiological causes, and not all of them are well understood. In atypical hemolytic uremic syndrome (aHUS), the TMA is caused by the complement dysregulation associated with pathogenic mutations in complement components and its regulators. Here, we describe a pediatric patient with aHUS in whom the relatively benign course of the disease confused the initial diagnosis. A previously healthy 8-year-old boy developed jaundice, hematuria, hemolytic anemia, thrombopenia, and mild acute kidney injury (AKI) in the context of a diarrhea without hypertension nor oliguria. Spontaneous and complete recovery was observed from the third day of admission. Persistent low C3 plasma levels after recovery raised the suspicion for aHUS, which prompted clinicians to discard the initial diagnosis of Shigatoxin-associated HUS (STEC-HUS). A thorough genetic and molecular study of the complement revealed the presence of an isolated novel pathogenic C3 mutation. The relatively benign clinical course of the disease as well as the finding of ade novopathogenic C3 mutation are remarkable aspects of this case. The data are discussed to illustrate the benefits of identifying the TMA etiological factor and the relevant contribution of the MCP aHUS risk polymorphism to the disease severity.	[Lumbreras, Javier; Espinosa, Natalia] Hosp Univ Son Espases, Serv Pediat, Unidad Nefrol Infantil, Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca, Spain; [Subias, Marta; Arjona, Emilia; Rodriguez de Cordoba, Santiago] Ctr Invest Biol Margarita Salas & Ciber Enfermeda, Madrid, Spain; [Maria Ferrer, Juana] Hosp Univ Son Espases, Serv Inmunol, Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca, Spain	Hospital Universitari Son Espases; Institut Investigacio Sanitaria Illes Balears (IdISBa); Hospital Universitari Son Espases; Institut Investigacio Sanitaria Illes Balears (IdISBa)	Lumbreras, J (corresponding author), Hosp Univ Son Espases, Serv Pediat, Unidad Nefrol Infantil, Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca, Spain.; Subias, M (corresponding author), Ctr Invest Biol Margarita Salas & Ciber Enfermeda, Madrid, Spain.	javier.lumbreras@ssib.es; m.subias@cib.csic.es			Spanish Ministerio de Economia y Competitividad-FEDER [SAF2015-66287R]; Autonomous Region of Madrid [S2017/BMD-3673]	Spanish Ministerio de Economia y Competitividad-FEDER; Autonomous Region of Madrid	SR was supported by the Spanish Ministerio de Economia y Competitividad-FEDER (SAF2015-66287R) and the Autonomous Region of Madrid (S2017/BMD-3673).	Exeni RA, 2018, PEDIATR NEPHROL, V33, P2057, DOI 10.1007/s00467-017-3876-0; Cavero T, 2019, KIDNEY INT, V96, P995, DOI 10.1016/j.kint.2019.05.014; de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103; Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066; Ferreira E, 2016, NEFROLOGIA, V36, P72, DOI 10.1016/j.nefro.2015.07.007; Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083; Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702; Goodship THJ, 2017, KIDNEY INT, V91, P539, DOI 10.1016/j.kint.2016.10.005; Martinez-Barricarte R, 2015, MOL IMMUNOL, V66, P263, DOI 10.1016/j.molimm.2015.03.248; Martinez-Barricarte R, 2010, J CLIN INVEST, V120, P3702, DOI 10.1172/JCI43343; Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528; Nester CM, 2015, MOL IMMUNOL, V67, P31, DOI 10.1016/j.molimm.2015.03.246; Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3; Osborne AJ, 2018, J IMMUNOL, V200, P2464, DOI 10.4049/jimmunol.1701695; Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201; Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; de Cordoba SR, 2016, IMMUNOBIOLOGY, V221, P709, DOI 10.1016/j.imbio.2015.05.015; de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021; Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281; Schramm EC, 2015, BLOOD, V125, P2359, DOI 10.1182/blood-2014-10-609073; Siomou E, 2016, PEDIATR NEPHROL, V31, P513, DOI 10.1007/s00467-015-3267-3; Vieira-Martins P, 2016, TRANSFUS APHER SCI, V54, P212, DOI 10.1016/j.transci.2016.04.011; Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1111/j.1523-1755.1998.00824.x	24	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2020	11								1348	10.3389/fimmu.2020.01348	http://dx.doi.org/10.3389/fimmu.2020.01348			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MW0XJ	32765494	Green Published			2022-12-18	WOS:000556770600001
J	Rossello, A; Steinle, A; Poggi, A; Zocchi, MR				Rossello, Armando; Steinle, Alexander; Poggi, Alessandro; Zocchi, Maria R.			Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						metzincin; NKG2D; NKG2DL; CD30; Hodgkin lymphoma; ADAM10 exocyte; platelets	NKG2D LIGANDS; EXPRESSION; DISINTEGRIN; INHIBITION; MICA		[Rossello, Armando] Univ Pisa, Dept Pharm, ProInLab, Pisa, Italy; [Steinle, Alexander] Goethe Univ, Inst Mol Med, Frankfurt, Germany; [Steinle, Alexander] Frankfurt Canc Inst, Frankfurt, Germany; [Poggi, Alessandro] IRCCS Policlin San Martino, Mol Oncol & Angiogenesis Unit, Genoa, Italy; [Zocchi, Maria R.] IRCCS San Raffaele Sci Inst, Div Immunol Transplants & Infect Dis, Milan, Italy	University of Pisa; Goethe University Frankfurt; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Zocchi, MR (corresponding author), IRCCS San Raffaele Sci Inst, Div Immunol Transplants & Infect Dis, Milan, Italy.	zocchi.maria@hsr.it			Italian Ministry of Health; AIRC [IG-17074]	Italian Ministry of Health(Ministry of Health, Italy); AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was partly supported by funds from the Italian Ministry of Health 5x1000 2015-2016 to AP, AIRC IG-17074 to MZ.	Camodeca C, 2016, EUR J MED CHEM, V111, P193, DOI 10.1016/j.ejmech.2016.01.053; Chitadze G, 2013, INT J CANCER, V133, P1557, DOI 10.1002/ijc.28174; Dreymueller D, 2017, PLATELETS, V28, P354, DOI 10.1080/09537104.2016.1203396; Duffy Michael J, 2011, Clin Proteomics, V8, P9, DOI 10.1186/1559-0275-8-9; Duffy MJ, 2009, CLIN CANCER RES, V15, P1140, DOI 10.1158/1078-0432.CCR-08-1585; Eichenauer DA, 2007, CANCER RES, V67, P332, DOI 10.1158/0008-5472.CAN-06-2470; Gibb DR, 2011, MOL IMMUNOL, V48, P1319, DOI 10.1016/j.molimm.2010.12.005; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Hansen HP, 2016, ONCOTARGET, V7, P30523, DOI 10.18632/oncotarget.8864; Lambrecht BN, 2018, NAT REV IMMUNOL, V18, P745, DOI 10.1038/s41577-018-0068-5; Madoux F, 2016, SCI REP-UK, V6, DOI 10.1038/s41598-016-0013-4; Matthews AL, 2017, BIOCHEM SOC T, V45, P719, DOI 10.1042/BST20160290; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Orme JJ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1744980; Pham DH, 2017, ANTICANCER RES, V37, P5507, DOI 10.21873/anticanres.11981; Poggi A, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27089; Reiss K, 2009, SEMIN CELL DEV BIOL, V20, P126, DOI 10.1016/j.semcdb.2008.11.002; Romero Y, 2020, CANCER IMMUNOL IMMUN, V69, P43, DOI 10.1007/s00262-019-02437-2; Saftig P, 2015, PROG NEUROBIOL, V135, P1, DOI 10.1016/j.pneurobio.2015.10.003; Saftig P, 2011, EUR J CELL BIOL, V90, P527, DOI 10.1016/j.ejcb.2010.11.005; Saha N, 2019, CANCER LETT, V467, P50, DOI 10.1016/j.canlet.2019.10.003; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; Tosetti F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1421889; Venkatesh HS, 2017, NATURE, V549, P533, DOI 10.1038/nature24014; Waldhauer I, 2008, CANCER RES, V68, P6368, DOI 10.1158/0008-5472.CAN-07-6768; Wetzel S, 2017, BBA-MOL CELL RES, V1864, P2071, DOI 10.1016/j.bbamcr.2017.06.005; Zocchi MR, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1123367; Zocchi MR, 2012, BLOOD, V119, P1479, DOI 10.1182/blood-2011-07-370841	29	2	2	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2020	11								1483	10.3389/fimmu.2020.01483	http://dx.doi.org/10.3389/fimmu.2020.01483			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MW0WD	32765514	Green Published, gold			2022-12-18	WOS:000556767400001
J	Lee, K; Jang, SH; Tian, H; Kim, SJ				Lee, Kyungwoo; Jang, Su Hwa; Tian, Hong; Kim, Sun Jung			NonO Is a Novel Co-factor of PRDM1 and Regulates Inflammatory Response in Monocyte Derived-Dendritic Cells	FRONTIERS IN IMMUNOLOGY			English	Article						PRDM1; NonO; IL-6; inflammation; dendritic cells	TRANSCRIPTIONAL REPRESSOR BLIMP-1; B-LYMPHOCYTES; PLASMA-CELLS; T-CELLS; EXPRESSION; DIFFERENTIATION; PROTEIN; HOMEOSTASIS; MATURATION; PRDI-BF1	Proper expression of the transcription factor, Positive regulatory domain 1 (PRDM1), is required for maintaining homeostasis of human monocyte derived-dendritic cells (MO-DCs). The molecular mechanisms and gene targets of PRDM1 in B and T lymphocytes have been identified. However, the function of PRDM1 in dendritic cells (DCs) remains unclear. We investigate co-regulators of PRDM1 in MO-DCs identified by mass spectrometry (MS) and co-immunoprecipitation (Co-IP). Notably, non-POU domain-containing octamer-binding protein (NonO) was found to be a PRDM1 binding protein in the nucleus of MO-DCs. NonO is recruited to the PRDM1 binding site in the promoter region of IL-6. Knockdown of NonO expression by siRNA lessened suppression of IL-6 promoter activity by PRMD1 following LPS stimulation. While NonO binding to PRDM1 was observed in human myeloma cell lines, an effect of NonO on IL-6 expression was not observed. Thus, loss of NonO interrupted the inhibitory effect of PRDM1 on IL-6 expression in MO-DCs, but not plasma cells. Moreover, MO-DCs with low expression of PRDM1 or NonO induce an increased number of IL-21-producing T-FH-like cellsin vitro. These data suggest that low level of PRDM1 and NonO lead to enhanced activation of MO-DCs and the regulation of MO-DC function by PRDM1 is mediated through cell lineage-specific mechanisms.	[Lee, Kyungwoo; Jang, Su Hwa; Tian, Hong; Kim, Sun Jung] Feinstein Inst Med Res, Inst Mol Med, Manhasset, NY 11030 USA; [Jang, Su Hwa] Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Biomed Sci, Seoul, South Korea	Northwell Health; Hanyang University	Kim, SJ (corresponding author), Feinstein Inst Med Res, Inst Mol Med, Manhasset, NY 11030 USA.	SJKim@northwell.edu		Jang, Su Hwa/0000-0002-3022-6612	US National Institute of Health [R01 AR065209]	US National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant from the US National Institute of Health (R01 AR065209 to SK, SJ, HT, and KL).	Ancelin K, 2006, NAT CELL BIOL, V8, P623, DOI 10.1038/ncb1413; Angelin-Duclos C, 2000, J IMMUNOL, V165, P5462, DOI 10.4049/jimmunol.165.10.5462; Carotta S, 2014, J EXP MED, V211, P2169, DOI 10.1084/jem.20140425; Chan YH, 2009, J IMMUNOL, V183, P7039, DOI 10.4049/jimmunol.0901543; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; Chang DH, 2002, MECH DEVELOP, V117, P305, DOI 10.1016/S0925-4773(02)00189-2; Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039; Diehl SA, 2012, IMMUNOL CELL BIOL, V90, P802, DOI 10.1038/icb.2012.17; Fairfax KA, 2007, J IMMUNOL, V178, P4104, DOI 10.4049/jimmunol.178.7.4104; Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473; Goudot C, 2017, IMMUNITY, V47, P582, DOI 10.1016/j.immuni.2017.08.016; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; Hatzi K, 2015, J EXP MED, V212, P539, DOI 10.1084/jem.20141380; Jang SH, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89569; Kallies A, 2006, NAT IMMUNOL, V7, P466, DOI 10.1038/ni1321; KELLER AD, 1992, MOL CELL BIOL, V12, P1940, DOI 10.1128/MCB.12.5.1940; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kim SJ, 2017, NAT IMMUNOL, V18, P1016, DOI 10.1038/ni.3793; Kim SJ, 2014, MOL MED, V20, P707, DOI 10.2119/molmed.2014.00231; Kim SJ, 2011, J EXP MED, V208, P2193, DOI 10.1084/jem.20110658; Li WJ, 2020, NUCLEIC ACIDS RES, V48, P4827, DOI 10.1093/nar/gkaa213; Lord CA, 2009, J IMMUNOL, V182, P2948, DOI 10.4049/jimmunol.0801692; Martins GA, 2006, NAT IMMUNOL, V7, P457, DOI 10.1038/ni1320; Melnikov SV, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124125; Minnich M, 2016, NAT IMMUNOL, V17, P331, DOI 10.1038/ni.3349; Nagy M, 2002, BRIT J HAEMATOL, V116, P429, DOI 10.1046/j.1365-2141.2002.03271.x; Nish SA, 2014, ELIFE, V3, DOI 10.7554/eLife.01949; Park Y, 2013, MOL CELLS, V35, P61, DOI 10.1007/s10059-013-2273-1; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roberts NA, 2017, J IMMUNOL, V199, P1250, DOI 10.4049/jimmunol.1600941; Robertson EJ, 2007, DEVELOPMENT, V134, P4335, DOI 10.1242/dev.012047; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Smith MA, 2011, J BIOL CHEM, V286, P7893, DOI 10.1074/jbc.M110.165431; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Su ST, 2009, MOL CELL BIOL, V29, P1421, DOI 10.1128/MCB.01158-08; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Yadav SP, 2014, HUM MOL GENET, V23, P2132, DOI 10.1093/hmg/ddt609; Yang R, 2016, J EXP MED, V213, P2281, DOI 10.1084/jem.20160417; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000; Zhang C, 2007, ARTERIOSCL THROM VAS, V27, P1760, DOI 10.1161/ATVBAHA.107.144881; Zhou XJ, 2011, ANN RHEUM DIS, V70, P1330, DOI 10.1136/ard.2010.140111	43	2	4	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 10	2020	11								1436	10.3389/fimmu.2020.01436	http://dx.doi.org/10.3389/fimmu.2020.01436			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	NA8TH	32765503	gold, Green Published			2022-12-18	WOS:000560090900001
J	Benedicenti, O; Wang, TH; Morel, E; Secombes, CJ; Soleto, I; Diaz-Rosales, P; Tafalla, C				Benedicenti, Ottavia; Wang, Tiehui; Morel, Esther; Secombes, Christopher J.; Soleto, Irene; Diaz-Rosales, Patricia; Tafalla, Carolina			Type I Interferon Regulates the Survival and Functionality of B Cells in Rainbow Trout	FRONTIERS IN IMMUNOLOGY			English	Article						teleost fish; B cells; interferon (IFN); IgM; phagocytosis	ONCORHYNCHUS-MYKISS; ANTIVIRAL PROTECTION; ANTIBODY-RESPONSES; MX PROTEINS; IFN-GAMMA; EXPRESSION; GENE; IDENTIFICATION; IGD; CYTOKINES	Interferons (IFNs) orchestrate antiviral responses in jawed vertebrates and can be classified into three types based on different aspects of their genomic organization, structure and receptors through which they signal and function. Generally, type I and type III IFNs include cytokines that directly induce an antiviral response, whereas type II IFNs are well-known for their immunomodulatory role during viral infections. In mammals, type I IFNs have been shown to also regulate many aspects of B cell development and differentiation. Yet, these functions have been only faintly investigated for teleost IFNs. Thus, in the current study, we have examined the effects of a model type I rainbow trout IFN molecule (IFNa) on blood naive (IgM(+)IgD(+)) B cells, comparing them to those exerted by type II IFN (IFN gamma). Our results demonstrate that IFNa increases the survival of naive rainbow trout B cells, in the absence of lymphoproliferative effects, by rescuing them from spontaneous apoptosis. Additionally, IFNa increased the phagocytic capacity of blood IgM(+)IgD(+)B cells and augmented the number of IgM-secreting cells in blood leukocyte cultures. IFN gamma, on the other hand, had only minor effects up-regulating IgM secretion, whereas it increased the phagocytic capacity of IgM(-)cells in the cultures. Finally, given the recent identification of 9mxgenes in rainbow trout, we have also established which of these genes were transcriptionally regulated in blood naive B cells in response to IFNa. This study points to a previously undescribed role for teleost type I IFNs in the regulation of B cell responses.	[Benedicenti, Ottavia; Morel, Esther; Soleto, Irene; Diaz-Rosales, Patricia; Tafalla, Carolina] Anim Hlth Res Ctr CISA INIA, Madrid, Spain; [Wang, Tiehui; Secombes, Christopher J.] Univ Aberdeen, Sch Biol Sci, Scottish Fish Immunol Res Ctr, Aberdeen, Scotland	University of Aberdeen	Tafalla, C (corresponding author), Anim Hlth Res Ctr CISA INIA, Madrid, Spain.	tafalla@inia.es	Díaz-Rosales, Patricia/GPG-6820-2022; MOREL, ESTHER/AAC-7286-2021; Tafalla, Carolina/J-8074-2014; Diaz-Rosales, Patricia/H-9679-2013	MOREL, ESTHER/0000-0002-4768-082X; soleto, irene/0000-0002-8005-2411; Tafalla, Carolina/0000-0002-0860-2976; Diaz-Rosales, Patricia/0000-0001-6965-3702	European Research Council (ERC) [2016 725061 TEMUBLYM]; Spanish Ministry of Science, Innovation and Universities [AGL2017-85494-C2-1-R]; Comunidad de Madrid [2016-T1/BIO-1672]	European Research Council (ERC)(European Research Council (ERC)); Spanish Ministry of Science, Innovation and Universities; Comunidad de Madrid(Comunidad de Madrid)	This work was supported by the European Research Council (ERC Consolidator Grant No. 2016 725061 TEMUBLYM), by the Spanish Ministry of Science, Innovation and Universities (project AGL2017-85494-C2-1-R) and by the Comunidad de Madrid (Grant No. 2016-T1/BIO-1672).	Abos B, 2018, J IMMUNOL, V201, P465, DOI 10.4049/jimmunol.1701546; Abos B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082737; Aggad D, 2009, J IMMUNOL, V183, P3924, DOI 10.4049/jimmunol.0901495; Araki K, 2013, FISHERIES SCI, V79, P213, DOI 10.1007/s12562-012-0590-5; Arpin C, 1998, J EXP MED, V187, P1169, DOI 10.1084/jem.187.8.1169; Badr G, 2010, CELL IMMUNOL, V263, P31, DOI 10.1016/j.cellimm.2010.02.012; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; Belmonte R, 2014, INFECT IMMUN, V82, P4518, DOI 10.1128/IAI.02196-14; Braun D, 2002, INT IMMUNOL, V14, P411, DOI 10.1093/intimm/14.4.411; Castro R, 2014, J IMMUNOL, V192, P1257, DOI 10.4049/jimmunol.1302471; Chang CJ, 2015, VACCINE, V33, P2442, DOI 10.1016/j.vaccine.2015.03.093; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; DELUCA D, 1983, EUR J IMMUNOL, V13, P546, DOI 10.1002/eji.1830130706; Edholm ES, 2010, J IMMUNOL, V185, P4082, DOI 10.4049/jimmunol.1000631; Fink K, 2006, EUR J IMMUNOL, V36, P2094, DOI 10.1002/eji.200635993; Ganassin RC, 1998, FISH SHELLFISH IMMUN, V8, P457, DOI 10.1006/fsim.1998.0153; Granja AG, 2019, FISH SHELLFISH IMMUN, V85, P9, DOI 10.1016/j.fsi.2017.10.003; Granja AG, 2015, J IMMUNOL, V195, P1825, DOI 10.4049/jimmunol.1500322; Green NM, 2009, J IMMUNOL, V183, P1569, DOI 10.4049/jimmunol.0803899; Green R, 2018, MAMM GENOME, V29, P593, DOI 10.1007/s00335-018-9755-6; Haller O, 2018, ANNU REV VIROL, V5, P33, DOI 10.1146/annurev-virology-092917-043525; Holzinger D, 2007, J VIROL, V81, P7776, DOI 10.1128/JVI.00546-06; Hua J, 2006, ARTHRITIS RHEUM-US, V54, P1906, DOI 10.1002/art.21890; Kang S, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e33; Kiefer K, 2012, IMMUNOL CELL BIOL, V90, P498, DOI 10.1038/icb.2012.10; Koelsch K, 2007, J CLIN INVEST, V117, P1558, DOI 10.1172/JCI27628; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Le Bon A, 2006, J IMMUNOL, V176, P2074, DOI 10.4049/jimmunol.176.4.2074; Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1; Lee AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02061; Li J, 2006, NAT IMMUNOL, V7, P1116, DOI 10.1038/ni1389; Manry J, 2011, J EXP MED, V208, P2747, DOI 10.1084/jem.20111680; Mitani Y, 2001, GENES CELLS, V6, P631, DOI 10.1046/j.1365-2443.2001.00448.x; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; O'Brien TR, 2014, J INTERF CYTOK RES, V34, P829, DOI 10.1089/jir.2013.0136; Perdiguero P, 2019, CELL REP, V29, P4223, DOI 10.1016/j.celrep.2019.11.101; Pereiro P, 2019, FISH SHELLFISH IMMUN, V90, P150, DOI 10.1016/j.fsi.2019.04.002; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Purcell MK, 2009, FISH SHELLFISH IMMUN, V26, P293, DOI 10.1016/j.fsi.2008.11.012; Ramirez-Gomez F, 2012, J IMMUNOL, V188, P1341, DOI 10.4049/jimmunol.1101938; Redmond AK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01558; Robertsen B, 2019, DEV COMP IMMUNOL, V90, P80, DOI 10.1016/j.dci.2018.09.004; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Secombes CJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00209; Simon R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00584; Sobhkhez M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188456; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Svingerud T, 2012, J IMMUNOL, V189, P5912, DOI 10.4049/jimmunol.1201188; Tang XQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01622; Verhelst J, 2013, MICROBIOL MOL BIOL R, V77, P551, DOI 10.1128/MMBR.00024-13; Wang TH, 2016, ONCOTARGET, V7, P10917, DOI 10.18632/oncotarget.7295; Wang TH, 2011, IMMUNOGENETICS, V63, P235, DOI 10.1007/s00251-010-0508-2; Wang TH, 2011, J IMMUNOL, V186, P708, DOI 10.4049/jimmunol.1001203; Wang TY, 2019, FISH SHELLFISH IMMUN, V90, P413, DOI 10.1016/j.fsi.2019.04.303; Wolf AI, 2011, J CLIN INVEST, V121, P3954, DOI 10.1172/JCI57362; Xu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10728; Yabu T, 2011, J BIOCHEM, V150, P635, DOI 10.1093/jb/mvr108; Young HA, 1996, J INTERF CYTOK RES, V16, P563, DOI 10.1089/jir.1996.16.563; Zhang YA, 2010, NAT IMMUNOL, V11, P827, DOI 10.1038/ni.1913; Zou J, 2005, J IMMUNOL, V175, P2484, DOI 10.4049/jimmunol.175.4.2484; Zou J, 2007, J IMMUNOL, V179, P3859, DOI 10.4049/jimmunol.179.6.3859; Zou J, 2014, J IMMUNOL, V193, P2273, DOI 10.4049/jimmunol.1301796	65	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 9	2020	11								1494	10.3389/fimmu.2020.01494	http://dx.doi.org/10.3389/fimmu.2020.01494			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MU3MJ	32733485	gold, Green Published			2022-12-18	WOS:000555576200001
J	Anania, JC; Westin, A; Heyman, B				Anania, Jessica C.; Westin, Annika; Heyman, Birgitta			IgG Suppresses Antibody Responses to Sheep Red Blood Cells in Double Knock-Out Mice Lacking Complement Factor C3 and Activating Fc gamma-Receptors	FRONTIERS IN IMMUNOLOGY			English	Article						FcgR; complement-immunological term; IgG-mediated immune suppression; Rhesus prophylaxis; antibody feedback	MEDIATED IMMUNE SUPPRESSION; ANTIGEN-MODULATION; ERYTHROCYTE CLEARANCE; HEMOLYTIC-DISEASE; HAPTEN ANTIBODIES; EPITOPE MASKING; IN-VIVO; MECHANISM; ALLOIMMUNIZATION; PREVENTION	Antigen-specific IgG antibodies, passively administered together with erythrocytes, prevent antibody responses against the erythrocytes. The mechanism behind the suppressive ability of IgG has been the subject of intensive studies, yet there is no consensus as to how it works. An important question is whether the Fc-region of IgG is required. Several laboratories have shown that IgG suppresses equally well in wildtype mice and mice lacking the inhibitory Fc gamma IIB, activating Fc gamma Rs (Fc gamma RI, III, and IV), or complement factor C3. These observations consistently suggest that IgG-mediated suppression does not rely on Fc-mediated antibody functions. However, it was recently shown that anti-KEL sera failed to suppress antibody responses to KEL-expressing transgenic mouse erythrocytes in double knock-out mice lacking both activating Fc gamma Rs and C3. Yet, in the same study, antibody-mediated suppression worked well in each single knock-out strain. This unexpected observation suggested Fc-dependence of IgG-mediated suppression and prompted us to investigate the issue in the classical experimental model using sheep red blood cells (SRBC) as antigen. SRBC alone or IgG anti-SRBC together with SRBC was administered to wildtype and double knock-out mice lacking C3 and activating Fc gamma Rs. IgG efficiently suppressed the IgM and IgG anti-SRBC responses in both mouse strains, thus supporting previous observations that suppression in this model is Fc-independent.	[Anania, Jessica C.; Westin, Annika; Heyman, Birgitta] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden	Uppsala University	Heyman, B (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.	birgitta.heyman@imbim.uu.se		Anania, Jessica/0000-0002-2973-6578	Uppsala University; Swedish Research Council [2015-02605, 2018-02409]; Olle Engkvist Byggmastare Foundation; Ollie and Elof Ericsson's Foundation; Gurli and Edward Brunnberg Foundation; Agnes and Mac Rudberg's Foundation; King Gustaf V:s 80 Years Foundation [FAI-2017-0374]	Uppsala University; Swedish Research Council(Swedish Research CouncilEuropean Commission); Olle Engkvist Byggmastare Foundation; Ollie and Elof Ericsson's Foundation; Gurli and Edward Brunnberg Foundation; Agnes and Mac Rudberg's Foundation; King Gustaf V:s 80 Years Foundation	This work was supported by Uppsala University, The Swedish Research Council (#2015-02605 and 2018-02409), Olle Engkvist Byggmastare Foundation, King Gustaf V:s 80 Years Foundation (FAI-2017-0374), Ollie and Elof Ericsson's Foundation, Gurli and Edward Brunnberg Foundation, and Agnes and Mac Rudberg's Foundation.	Bergstrom JJE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00238; Bergstrom JJE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143841; Bernardo L, 2016, BLOOD, V128, P1076, DOI 10.1182/blood-2016-01-692178; Bernardo L, 2015, J IMMUNOL, V195, P2224, DOI 10.4049/jimmunol.1500790; Branch DR, 2006, TRANSFUSION, V46, P1316, DOI 10.1111/j.1537-2995.2006.00898.x; Brinc D, 2007, BRIT J HAEMATOL, V139, P275, DOI 10.1111/j.1365-2141.2007.06764.x; BRUGGEMANN M, 1982, CELL IMMUNOL, V71, P365, DOI 10.1016/0008-8749(82)90270-2; Carlsson F, 2009, SCAND J IMMUNOL, V70, P77, DOI 10.1111/j.1365-3083.2009.02274.x; CEROTTINI JC, 1969, J IMMUNOL, V102, P1008; CHAN PL, 1973, IMMUNOLOGY, V24, P289; CLARKE CA, 1967, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5570.7; Cruz-Leal Y, 2018, J IMMUNOL, V200, P1295, DOI 10.4049/jimmunol.1700874; ENRIQUEZRINCON F, 1984, IMMUNOLOGY, V52, P129; Getahun A, 2009, SCAND J IMMUNOL, V70, P277, DOI 10.1111/j.1365-3083.2009.02298.x; HEYMAN B, 1988, EUR J IMMUNOL, V18, P1739, DOI 10.1002/eji.1830181113; HEYMAN B, 1984, J IMMUNOL, V132, P1136; JERNE NK, 1963, SCIENCE, V140, P405, DOI 10.1126/science.140.3565.405; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Karlsson MCI, 2001, SCAND J IMMUNOL, V53, P381, DOI 10.1046/j.1365-3083.2001.00886.x; Karlsson MCI, 2001, J IMMUNOL, V167, P5558, DOI 10.4049/jimmunol.167.10.5558; Karlsson MCI, 1999, P NATL ACAD SCI USA, V96, P2244, DOI 10.1073/pnas.96.5.2244; Liu JC, 2016, BLOOD, V128, P3159, DOI [10.1182/blood-201606-724732, 10.1182/blood-2016-06-724732]; Maier CL, 2018, BLOOD ADV, V2, P2986, DOI 10.1182/bloodadvances.2018018408; Mener A, 2019, TRANSFUSION, V59, P371, DOI 10.1111/trf.14939; Mener A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00676; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; POLLACK W, 1968, TRANSFUSION, V8, P151, DOI 10.1111/j.1537-2995.1968.tb04895.x; QUINTANA IZ, 1987, EUR J IMMUNOL, V17, P1343, DOI 10.1002/eji.1830170919; Shi QQ, 2015, J NEUROSCI, V35, P13029, DOI 10.1523/JNEUROSCI.1698-15.2015; SINCLAIR NR, 1968, NATURE, V220, P1049, DOI 10.1038/2201048a0; SINCLAIR NR, 1969, J EXP MED, V129, P1183, DOI 10.1084/jem.129.6.1183; Smith T, 1909, J EXP MED, V11, P241, DOI 10.1084/jem.11.2.241; Sorman A, 2014, MOL IMMUNOL, V61, P79, DOI 10.1016/j.molimm.2014.06.010; Stowell SR, 2015, HAEMATOLOGICA, V100, pE394, DOI 10.3324/haematol.2015.128603; Stowell SR, 2013, J IMMUNOL, V191, P5013, DOI 10.4049/jimmunol.1300885; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TAO T, 1966, NATURE, V212, P208, DOI 10.1038/212208a0; Urbaniak SJ, 2000, BLOOD REV, V14, P44, DOI 10.1054/blre.1999.0123; Xu H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33087-6; Yu HH, 2014, J IMMUNOL, V193, P2902, DOI 10.4049/jimmunol.1302287; Zimring JC, 2007, BLOOD, V110, P2201, DOI 10.1182/blood-2007-04-083097; Zimring JC, 2005, BLOOD, V106, P1105, DOI 10.1182/blood-2005-03-1040	45	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2020	11								1404	10.3389/fimmu.2020.01404	http://dx.doi.org/10.3389/fimmu.2020.01404			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MS1EZ	32733467	Green Published, gold			2022-12-18	WOS:000554029200001
J	Vincent, CM; da Silva, CSJ; Wadhawan, A; Dionne, MS				Vincent, Crystal M.; Simoes da Silva, Carolina J.; Wadhawan, Ashima; Dionne, Marc S.			Origins of Metabolic Pathology inFrancisella-InfectedDrosophila	FRONTIERS IN IMMUNOLOGY			English	Article						Drosophila; Francisella; metabolism; pathophysiology; immune response	DROSOPHILA-MELANOGASTER; IMMUNE-RESPONSE; TETRACYCLINE ANTIBIOTICS; RESISTANCE; PEPTIDOGLYCAN; COSTS; TOLL; IMD; ACTIVATION; LONGEVITY	The origins and causes of infection pathologies are often not understood. Despite this, the study of infection and immunity relies heavily on the ability to discern between potential sources of pathology. Work in the fruit fly has supported the assumption that mortality resulting from bacterial invasion is largely due to direct host-pathogen interactions, as lower pathogen loads are often associated with reduced pathology, and bacterial load upon death is predictable. However, the mechanisms through which these interactions bring about host death are complex. Here we show that infection with the bacteriumFrancisella novicidaleads to metabolic dysregulation and, using treatment with a bacteriostatic antibiotic, we show that this pathology is the result of direct interaction between host and pathogen. We show that mutants of the immune deficiency immune pathway fail to exhibit similar metabolic dysregulation, supporting the idea that the reallocation of resources for immune-related activities contributes to metabolic dysregulation. Targeted investigation into the cross-talk between immune and metabolic pathways has the potential to illuminate some of this interaction.	[Vincent, Crystal M.; Dionne, Marc S.] Imperial Coll London, MRC Ctr Mol Bacteriol & Infect, London, England; Imperial Coll London, Dept Life Sci, London, England	Imperial College London; Imperial College London	Vincent, CM; Dionne, MS (corresponding author), Imperial Coll London, MRC Ctr Mol Bacteriol & Infect, London, England.	crystal.vincent@imperial.ac.uk; m.dionne@imperial.ac.uk			MRC [MR/R00997X/1]; Wellcome Trust [207467/Z/17/Z]; BBSRC [BB/P000592/1] Funding Source: UKRI; MRC [MR/P028225/1] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funders have funded this research by paying salaries (CV, CS, and MD) and consumables but were not involved in the design of this project. Open access fees will be paid via institutional open access funds. This work was supported by MRC Research Grant MR/R00997X/1 and Wellcome Trust Investigator Award 207467/Z/17/Z.	Al-Anzi B, 2009, NEURON, V63, P329, DOI 10.1016/j.neuron.2009.07.021; Andersson DI, 2010, NAT REV MICROBIOL, V8, P260, DOI 10.1038/nrmicro2319; Barisch C, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006095; Cao Y, 2013, P NATL ACAD SCI USA, V110, pE1752, DOI 10.1073/pnas.1306220110; Chambers MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050679; Chatzispyrou IA, 2015, CANCER RES, V75, P4446, DOI 10.1158/0008-5472.CAN-15-1626; Chen F, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00275; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; Clark RI, 2013, CELL, V155, P435, DOI 10.1016/j.cell.2013.09.007; DiAngelo JR, 2009, P NATL ACAD SCI USA, V106, P20853, DOI 10.1073/pnas.0906749106; Dionne MS, 2008, DIS MODEL MECH, V1, P43, DOI 10.1242/dmm.000307; Dionne MS, 2006, CURR BIOL, V16, P1977, DOI 10.1016/j.cub.2006.08.052; Dionne MS, 2003, INFECT IMMUN, V71, P3540, DOI 10.1128/IAI.71.6.3540-3550.2003; Duneau D, 2017, ELIFE, V6, DOI 10.7554/eLife.28298; Fernando MDA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004117; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Gyuranecz M, 2010, ZOONOSES PUBLIC HLTH, V57, P417, DOI 10.1111/j.1863-2378.2009.01238.x; Herker E, 2012, J BIOL CHEM, V287, P2280, DOI 10.1074/jbc.R111.300202; Issa N, 2018, MOL CELL, V69, P539, DOI 10.1016/j.molcel.2018.01.029; Jacot A, 2004, EVOLUTION, V58, P2280; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kelly CD, 2011, BIOL J LINN SOC, V104, P38, DOI 10.1111/j.1095-8312.2011.01714.x; Khalil S, 2015, JOVE-J VIS EXP, DOI 10.3791/52613; Krejcova G, 2019, ELIFE, V8, DOI 10.7554/eLife.50414; Lau GW, 2003, INFECT IMMUN, V71, P4059, DOI 10.1128/IAI.71.7.4059-4066.2003; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Libert S, 2006, AGING CELL, V5, P533, DOI 10.1111/j.1474-9726.2006.00251.x; McKean KA, 2001, P NATL ACAD SCI USA, V98, P7904, DOI 10.1073/pnas.131216398; McMillan LE, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.173336; Moret Y, 2000, SCIENCE, V290, P1166, DOI 10.1126/science.290.5494.1166; Moule MG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001065; Nehme NT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014743; Okin D, 2012, CURR BIOL, V22, pR733, DOI 10.1016/j.cub.2012.07.029; Pandey UB, 2011, PHARMACOL REV, V63, P411, DOI 10.1124/pr.110.003293; Pean CB, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms14642; Pham LN, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030026; Radlinski LC, 2018, MBIO, V9, DOI [10.1128/mbio.01471-18, 10.1128/mBio.01471-18]; Roth SW, 2018, CELL REP, V22, P2550, DOI 10.1016/j.celrep.2018.02.033; Sadd BM, 2006, P ROY SOC B-BIOL SCI, V273, P2571, DOI 10.1098/rspb.2006.3574; Shang YL, 2016, PROTEIN CELL, V7, P159, DOI 10.1007/s13238-016-0250-0; Sharrock J, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037259; Tanji T, 2005, TRENDS IMMUNOL, V26, P193, DOI 10.1016/j.it.2005.02.006; Traven A, 2019, EMBO REP, V20, DOI 10.15252/embr.201947995; Troha K, 2019, WIRES DEV BIOL, V8, DOI 10.1002/wdev.344; Vonkavaara M, 2008, CELL MICROBIOL, V10, P1327, DOI 10.1111/j.1462-5822.2008.01129.x; zur Wiesch PS, 2010, ANTIMICROB AGENTS CH, V54, P2085, DOI 10.1128/AAC.01460-09	47	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 8	2020	11								1419	10.3389/fimmu.2020.01419	http://dx.doi.org/10.3389/fimmu.2020.01419			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MS1EM	32733472	Green Published, gold			2022-12-18	WOS:000554027900001
J	Giles, AR; Calcedo, R; Tretiakova, AP; Wilson, JM				Giles, April R.; Calcedo, Roberto; Tretiakova, Anna P.; Wilson, James M.			Isolating Human Monoclonal Antibodies Against Adeno-Associated Virus From Donors With Pre-existing Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						adeno-associated virus; human monoclonal antibody; memory B-cell; single cell cloning; vector engineering; gene therapy; epitope mapping	MEMORY B-CELLS; NEUTRALIZING ANTIBODIES; GENE-THERAPY; SOMATIC HYPERMUTATION; CLINICAL-TRIAL; RESPONSES; EPITOPE; VECTORS; LIVER; TRANSDUCTION	With the advent of single B-cell cloning technology, we can isolate antibodies against virtually any antigen to study the interaction of a given pathogen with the immune system and develop novel therapeutic strategies. Antibodies directed against the capsid of adeno-associated viruses (AAV) are a significant obstacle to effectively leveraging AAV as a gene-delivery vector in seropositive individuals. In order to design next-generation vectors that can evade neutralization by these antibodies, studies have mapped the epitopes of mouse monoclonal antibodies generated by immunization with AAV. Although these studies provide critical information regarding capsid immunogenicity, they cannot address (1) differences in the antibody repertoire generated in humans following AAV natural infection; or (2) how reactions can vary when generated in response to vector administration. Here, we isolated and evaluated a panel of novel, fully human anti-AAV antibodies by cloning single memory B cells from a seropositive normal donor. We have validated the utility of this approach to study AAV immunology. Our goal is to leverage this knowledge to design novel AAV variants that can effectively transduce target tissues in individuals with AAV-neutralizing antibodies.	[Giles, April R.; Calcedo, Roberto; Tretiakova, Anna P.; Wilson, James M.] Univ Penn, Dept Med, Perelman Sch Med, Gene Therapy Program, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Wilson, JM (corresponding author), Univ Penn, Dept Med, Perelman Sch Med, Gene Therapy Program, Philadelphia, PA 19104 USA.	wilsonjm@upenn.edu	Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131	National Institutes of Health [5P01 HL059407-18]; Defense Advanced Research Projects Agency (Department of Defense) [64047-LS-DRP.01]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defense Advanced Research Projects Agency (Department of Defense)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA))	This work was funded by the National Institutes of Health (5P01 HL059407-18 to JW) and the Defense Advanced Research Projects Agency (Department of Defense; 64047-LS-DRP.01 to JW).	Ahmed Y, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0178-3; Amara K, 2013, J EXP MED, V210, P445, DOI 10.1084/jem.20121486; Ameri H, 2018, J CURR OPHTHALMOL, V30, P1, DOI 10.1016/j.joco.2018.01.006; Araten DJ, 2005, CANCER RES, V65, P8111, DOI 10.1158/0008-5472.CAN-04-1198; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Boutin S, 2010, HUM GENE THER, V21, P704, DOI 10.1089/hum.2009.182; Bowles DE, 2012, MOL THER, V20, P443, DOI 10.1038/mt.2011.237; Calcedo R, 2009, J INFECT DIS, V199, P381, DOI 10.1086/595830; Calcedo R, 2011, CLIN VACCINE IMMUNOL, V18, P1586, DOI 10.1128/CVI.05107-11; Calcedo R, 2009, J VIROL, V83, P2623, DOI 10.1128/JVI.02160-08; Chirmule N, 1999, GENE THER, V6, P1574, DOI 10.1038/sj.gt.3300994; Corsiero E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114575; Crowe JE, 2019, J IMMUNOL, V202, P368, DOI 10.4049/jimmunol.1801459; D'Avola D, 2016, J HEPATOL, V65, P776, DOI 10.1016/j.jhep.2016.05.012; Di Niro R, 2012, NAT MED, V18, P441, DOI 10.1038/nm.2656; Dismuke DJ, 2013, CURR GENE THER, V13, P434; Drake JW, 1998, GENETICS, V148, P1667; Flotte TR, 2011, HUM GENE THER, V22, P1239, DOI 10.1089/hum.2011.053; Gao GP, 2004, J VIROL, V78, P6381, DOI 10.1128/JVI.78.12.6381-6388.2004; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Giles AR, 2018, J VIROL, V92, DOI 10.1128/JVI.01011-18; Gunisetty S, 2019, INT J INFECT DIS, V84, pS57, DOI 10.1016/j.ijid.2019.01.018; Gurda BL, 2013, J VIROL, V87, P9111, DOI 10.1128/JVI.00622-13; Gurda BL, 2012, J VIROL, V86, P7739, DOI 10.1128/JVI.00218-12; Hoy SM, 2019, DRUGS, V79, P1255, DOI 10.1007/s40265-019-01162-5; Huang JH, 2013, NAT PROTOC, V8, P1907, DOI 10.1038/nprot.2013.117; Huttner NA, 2003, GENE THER, V10, P2139, DOI 10.1038/sj.gt.3302123; IJspeert H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00410; Krause JC, 2011, J IMMUNOL, V187, P3704, DOI 10.4049/jimmunol.1101823; Kwong PD, 2009, CELL HOST MICROBE, V6, P292, DOI 10.1016/j.chom.2009.09.008; Limberis MP, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006299; Lochrie MA, 2006, J VIROL, V80, P821, DOI 10.1128/JVI.80.2.821-834.2006; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; Martin A., 2014, MOL BIOL B CELLS, V2nd ed, P363, DOI DOI 10.1016/B978-0-12-397933-9.00020-5; McCraw DM, 2012, VIROLOGY, V431, P40, DOI 10.1016/j.virol.2012.05.004; Meffre E, 2001, J EXP MED, V194, P375, DOI 10.1084/jem.194.3.375; MELNICK JL, 1965, J BACTERIOL, V90, P271, DOI 10.1128/JB.90.1.271-274.1965; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Mendell JR, 2015, GENE TRANSFER CLIN T; Milholland B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15183; Mingozzi F, 2013, BLOOD, V122, P23, DOI 10.1182/blood-2013-01-306647; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Moskalenko M, 2000, J VIROL, V74, P1761, DOI 10.1128/JVI.74.4.1761-1766.2000; Nandin IS, 2017, J EXP MED, V214, P2471, DOI 10.1084/jem.20170633; Rouers A, 2017, EBIOMEDICINE, V21, P158, DOI 10.1016/j.ebiom.2017.05.029; Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930; Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3; Smith MJ, 2017, JOVE-J VIS EXP, DOI 10.3791/55382; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; Thwaite R, 2015, GENE THER, V22, P196, DOI 10.1038/gt.2014.103; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009; Tseng YS, 2015, J VIROL, V89, P1794, DOI 10.1128/JVI.02710-14; Wang LL, 2015, MOL THER, V23, P1877, DOI 10.1038/mt.2015.179; Wang TT, 2018, CURR OPIN IMMUNOL, V53, P124, DOI 10.1016/j.coi.2018.04.026; Wardemann Hedda, 2013, Methods Mol Biol, V971, P93, DOI 10.1007/978-1-62703-269-8_5; Wobus CE, 2000, J VIROL, V74, P9281, DOI 10.1128/JVI.74.19.9281-9293.2000; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Wu Z, 2006, J VIROL, V80, P11393, DOI 10.1128/JVI.01288-06; Yu L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00250	60	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2020	11								1135	10.3389/fimmu.2020.01135	http://dx.doi.org/10.3389/fimmu.2020.01135			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR2CV	32733434	gold, Green Published			2022-12-18	WOS:000553398600001
J	Hua, Y; Liu, DD; Zhang, DY; Wang, X; Wei, Q; Qin, WT				Hua, Ye; Liu, Dadong; Zhang, Danyi; Wang, Xu; Wei, Qing; Qin, Weiting			Extracellular AMP Suppresses Endotoxemia-Induced Inflammation by Alleviating Neutrophil Activation	FRONTIERS IN IMMUNOLOGY			English	Article						AMP; A1R; p38 MAPK; neutrophils; endotoxemia	METABOLISM; MIGRATION; SEPSIS; HEALTH	Intracellular adenosine monophosphate (AMP) is indispensable for cellular metabolic processes, and it is interconverted to ADP and/or ATP or activates AMP-activated protein kinase (AMPK). However, the specific biological function of extracellular AMP has not been identified. We evaluated the effect of extracellular AMP usingin vivoandin vitromodels of endotoxemia. We found that AMP inhibited inflammation and neutrophil activation in lipopolysaccharide (LPS)-induced endotoxemic mice. The effects of extracellular AMP were abolished by an adenosine 1 receptor (A1R) antagonist but were not influenced by inhibiting the conversion of AMP to adenosine (ADO), indicating that AMP inhibited inflammation by directly activating A1R. In addition,in vitroexperiments using LPS-stimulated mouse neutrophils showed that AMP inhibited LPS-induced reactive oxygen species (ROS) production, degranulation, and cytokine production, while the effects were reversed by an A1R antagonist. Further research showed that AMP regulated LPS-stimulated neutrophil functions by inhibiting the p38 MAPK pathway. These findings were also confirmed in primary neutrophils derived from healthy human blood. Moreover, we collected serum samples from septic patients. We found that AMP levels were increased compared with those of healthy volunteers and that AMP levels were negatively correlated with disease severity. Together, these data provide evidence that extracellular AMP acts on A1R to suppress endotoxemia-induced inflammation by inhibiting neutrophil overactivation and that the p38 MAPK signaling pathway is involved.	[Hua, Ye; Wang, Xu] Jiangsu Univ, Inst Oncol, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China; [Liu, Dadong] Jiangsu Univ, Dept ICU, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China; [Zhang, Danyi] Jiangsu Univ Zhenjiang, Dept Lab Med, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China; [Wei, Qing] Jiangsu Univ, Dept Gen Surg, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China; [Qin, Weiting] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Shanghai, Peoples R China	Jiangsu University; Jiangsu University; Jiangsu University; Shanghai Jiao Tong University	Wei, Q (corresponding author), Jiangsu Univ, Dept Gen Surg, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China.; Qin, WT (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Shanghai, Peoples R China.	1140329223@qq.com; winnie1900@126.com			Postgraduate Research and Innovation Project of Jiangsu Province [CXZZ12_0708]	Postgraduate Research and Innovation Project of Jiangsu Province	The present study was founded by the Postgraduate Research and Innovation Project of Jiangsu Province (Grant No. CXZZ12_0708).	Ansari HR, 2009, AM J PHYSIOL-HEART C, V297, pH1032, DOI 10.1152/ajpheart.00374.2009; Boison D, 2011, CURR TOP MED CHEM, V11, P1068, DOI 10.2174/156802611795347609; Bosmann M, 2013, TRENDS IMMUNOL, V34, P129, DOI 10.1016/j.it.2012.09.004; Boxio R, 2004, J LEUKOCYTE BIOL, V75, P604, DOI 10.1189/jlb.0703340; Brinkmann V, 2012, J CELL BIOL, V198, P773, DOI 10.1083/jcb.201203170; Brown KA, 2006, LANCET, V368, P157, DOI 10.1016/S0140-6736(06)69005-3; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; de Oliveira S, 2016, NAT REV IMMUNOL, V16, P378, DOI 10.1038/nri.2016.49; Deaglio S, 2011, ADV PHARMACOL, V61, P301, DOI 10.1016/B978-0-12-385526-8.00010-2; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Hajishengallis G, 2015, J LEUKOCYTE BIOL, V98, P539, DOI 10.1189/jlb.3VMR1014-468R; Heidrich F, 2010, CURR CARDIOL REV, V6, P337, DOI 10.2174/157340310793566073; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kovach MA, 2012, CURR OPIN INFECT DIS, V25, P321, DOI 10.1097/QCO.0b013e3283528c9b; Liu XW, 2012, NAT IMMUNOL, V13, P457, DOI 10.1038/ni.2258; Ma F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02854; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mirouse V, 2011, FEBS LETT, V585, P981, DOI 10.1016/j.febslet.2010.12.025; Mondal S, 2017, ASSAY DRUG DEV TECHN, V15, P330, DOI 10.1089/adt.2017.815; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rittiner JE, 2012, J BIOL CHEM, V287, P5301, DOI 10.1074/jbc.M111.291666; Sonego F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00155; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Takahashi HK, 2007, EUR J PHARMACOL, V564, P204, DOI 10.1016/j.ejphar.2007.02.005; Vincent JL, 2013, LANCET, V381, P774, DOI 10.1016/S0140-6736(12)61815-7; Wang X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00399; Wang X, 2016, ONCOTARGET, V7, P74247, DOI 10.18632/oncotarget.12093; Xu XH, 2017, INFLAMM RES, V66, P353, DOI 10.1007/s00011-016-1021-3; Yamaguchi H, 2014, ELIFE, V3, DOI 10.7554/eLife.02172; Yang QL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061498	31	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2020	11								1220	10.3389/fimmu.2020.01220	http://dx.doi.org/10.3389/fimmu.2020.01220			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR2FZ	32733440	gold, Green Published			2022-12-18	WOS:000553406800001
J	Sarcevic, J; Cavelti-Weder, C; Berger, CT; Trendelenburg, M				Sarcevic, Jelena; Cavelti-Weder, Claudia; Berger, Christoph T.; Trendelenburg, Marten			Case Report-Secondary Antibody Deficiency Due to Endogenous Hypercortisolism	FRONTIERS IN IMMUNOLOGY			English	Article						hypogammaglobulinemia; lymphocytopenia; immune deficiency; secondary antibody deficiency; endogenous hypercortisolism	HYPOGAMMAGLOBULINEMIA; THERAPY	Therapeutic corticosteroids have an immunosuppressive function involving several pathways, including lymphocytopenia and hypogammaglobulinemia. While these effects have been well-described in patients that received corticosteroids for therapeutic reasons, the effects of endogenous corticosteroids on the immune system are less well-understood. Here, we describe a 21-year old patient with hypercortisolism due to an ACTH producing thymic tumor. In this patient, we observed a decrease in some of the immunoglobulin classes, and in specific B and T cell populations that resembled effects caused by corticosteroid treatment. IgG levels were restored following treatment and normalization of the hypercortisolism.	[Sarcevic, Jelena; Berger, Christoph T.; Trendelenburg, Marten] Univ Basel, Univ Hosp Basel, Div Internal Med, Basel, Switzerland; [Cavelti-Weder, Claudia] Univ Hosp Basel, Div Endocrinol Diabet & Metab, Basel, Switzerland; [Berger, Christoph T.] Univ Basel, Dept Biomed, Translat Immunol, Basel, Switzerland; [Trendelenburg, Marten] Univ Basel, Dept Biomed, Clin Immunol Lab, Basel, Switzerland	University of Basel; University of Basel; University of Basel; University of Basel	Sarcevic, J (corresponding author), Univ Basel, Univ Hosp Basel, Div Internal Med, Basel, Switzerland.	jelena.sarcevc@usb.ch		Trendelenburg, Marten/0000-0001-7036-8386; Cavelti-Weder, Claudia/0000-0002-0650-6091				BERGER W, 1978, ANN ALLERGY, V41, P67; BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455; GRAHAM BS, 1984, ANN INTERN MED, V101, P334, DOI 10.7326/0003-4819-101-3-334; GRIGGS RC, 1972, J ALLERGY CLIN IMMUN, V49, P267, DOI 10.1016/0091-6749(72)90094-2; HAMILOS DL, 1992, ANN ALLERGY, V68, P472; Kawano T, 2002, INT ARCH ALLERGY IMM, V128, P240, DOI 10.1159/000064258; POSEY WC, 1978, J ALLERGY CLIN IMMUN, V62, P340, DOI 10.1016/0091-6749(78)90134-3; SETTIPANE GA, 1978, J ALLERGY CLIN IMMUN, V62, P162, DOI 10.1016/0091-6749(78)90101-X; Wirsum C, 2016, J CLIN IMMUNOL, V36, P406, DOI 10.1007/s10875-016-0264-7	9	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 7	2020	11								1435	10.3389/fimmu.2020.01435	http://dx.doi.org/10.3389/fimmu.2020.01435			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR2FT	32733476	Green Published, gold, Green Accepted			2022-12-18	WOS:000553406200001
J	Grunebaum, E; Campbell, N; Leon-Ponte, M; Xu, XB; Chapdelaine, H				Grunebaum, Eyal; Campbell, Nicholas; Leon-Ponte, Matilde; Xu, Xiaobai; Chapdelaine, Hugo			Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity Required for Immune and Neurological Development	FRONTIERS IN IMMUNOLOGY			English	Article						deficiency; gene therapy; mutations; partial; purine nucleoside phosphorylase	STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; ADENOSINE-DEAMINASE; INTRACELLULAR DELIVERY; MUTATIONS; PATIENT; DIAGNOSIS; CORRECTS; DELAY	Introduction:Complete or near complete absence of the purine nucleoside phosphorylase (PNP) enzyme causes a profound T cell immunodeficiency and neurological abnormalities that are often lethal in infancy and early childhood. We hypothesized that patients with partial PNP deficiency, characterized by a late and mild phenotype due to residual PNP enzyme, would provide important information about the minimal PNP activity needed for normal development. Methods:Three siblings with a homozygousPNPgene mutation (c.769C>G, p.His257Asp) resulting in partial PNP deficiency were investigated. PNP activity was semi-quantitively assayed by the conversion of [14C]inosine in hemolysates, mononuclear cells, and lymphoblastoid B cells. PNP protein expression was determined by Western Blotting in lymphoblastoid B cells. DNA repair was quantified by measuring viability of lymphoblastoid B cells following ionizing irradiation. Results:A 21-year-old female was referred for recurrent sino-pulmonary infections while her older male siblings, aged 25- and 28- years, did not suffer from significant infections. Two of the siblings had moderately reduced numbers of T, B, and NK cells, while the other had near normal lymphocyte subset numbers. T cell proliferations were normal in the two siblings tested. Hypogammaglobulinemia was noted in two siblings, including one that required immunoglobulin replacement. All siblings had typical (normal) neurological development. PNP activity in various cells from two patients were 8-11% of the normal level. All siblings had normal blood uric acid and increased PNP substrates in the urine. PNP protein expression in cells from the two patients examined was similar to that observed in cells from healthy controls. The survival of lymphoblastoid B cells from 2 partial PNP-deficient patients after irradiation was similar to that of PNP-proficient cells and markedly higher than the survival of cells from a patient with absent PNP activity or a patient with ataxia telangiectasia. Conclusions:Patients with partial PNP deficiency can present in the third decade of life with mild-moderate immune abnormalities and typical development. Near-normal immunity might be achieved with relatively low PNP activity.	[Grunebaum, Eyal] Hosp Sick Children, Div Immunol & Allergy, Toronto, ON, Canada; [Grunebaum, Eyal; Leon-Ponte, Matilde; Xu, Xiaobai] Hosp Sick Children, Dev & Stem Cell Biol Program, Toronto, ON, Canada; [Campbell, Nicholas; Chapdelaine, Hugo] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada; [Campbell, Nicholas; Chapdelaine, Hugo] Montreal Clin Res Inst, Montreal, PQ, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Grunebaum, E (corresponding author), Hosp Sick Children, Div Immunol & Allergy, Toronto, ON, Canada.; Grunebaum, E (corresponding author), Hosp Sick Children, Dev & Stem Cell Biol Program, Toronto, ON, Canada.	eyal.grunebaum@sickkids.ca		Chapdelaine, Hugo/0000-0001-6256-0271	Campbell Chair for Immunology Research	Campbell Chair for Immunology Research	This work was supported in part by The Campbell Chair for Immunology Research (EG).	Al-Dirbashi OY, 2015, LYMPHOSIGN J, V2, P135, DOI DOI 10.14785/lpsn-2014-0024; Arpaia E, 2000, J EXP MED, V191, P2197, DOI 10.1084/jem.191.12.2197; Aytekin C, 2010, EUR J PEDIATR, V169, P311, DOI 10.1007/s00431-009-1029-6; Baguette C, 2002, J PEDIAT HEMATOL ONC, V24, P69, DOI 10.1097/00043426-200201000-00018; Brodszki N, 2015, JIMD REP, V24, P83, DOI 10.1007/8904_2015_444; Broome CB, 1996, J PEDIATR-US, V128, P373, DOI 10.1016/S0022-3476(96)70285-8; Carpenter PA, 1996, BONE MARROW TRANSPL, V17, P121; Celmeli F, 2015, PEDIATR TRANSPLANT, V19, pE47, DOI 10.1111/petr.12413; Cohen A, 2000, IMMUNOL ALLERGY CLIN, V20, P143, DOI 10.1016/S0889-8561(05)70139-9; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Dalal I, 2001, CLIN GENET, V59, P430, DOI 10.1034/j.1399-0004.2001.590608.x; Delicou S, 2007, PEDIATR TRANSPLANT, V11, P799, DOI 10.1111/j.1399-3046.2007.00772.x; Dror Y, 2004, PEDIATR RES, V55, P472, DOI 10.1203/01.PDR.0000111286.23110.F8; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11725, DOI 10.1021/bi961969w; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Fekrvand S, 2019, IMMUNOL INVEST, V48, P410, DOI 10.1080/08820139.2019.1570249; Furman RR, 2007, SEMIN ONCOL, V34, pS29, DOI 10.1053/j.seminoncol.2007.11.004; GIBLETT ER, 1975, LANCET, V1, P1010, DOI 10.1016/S0140-6736(75)91950-9; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Grunebaum E, 2013, CURR OPIN ALLERGY CL, V13, P630, DOI 10.1097/ACI.0000000000000006; Ho MC, 2010, P NATL ACAD SCI USA, V107, P4805, DOI 10.1073/pnas.0913439107; Honig M, 2007, BLOOD, V109, P3595, DOI 10.1182/blood-2006-07-034678; Jentsch-Ullrich K, 2005, CLIN IMMUNOL, V116, P192, DOI 10.1016/j.clim.2005.03.020; Liao P, 2008, J GENE MED, V10, P1282, DOI 10.1002/jgm.1261; Mansouri A, 2012, NEUROBIOL DIS, V47, P201, DOI 10.1016/j.nbd.2012.04.001; MARKERT ML, 1987, J CLIN IMMUNOL, V7, P389, DOI 10.1007/BF00917017; Martin J, 2016, FETAL PEDIATR PATHOL, V35, P120, DOI 10.3109/15513815.2016.1139020; Myers LA, 2004, J PEDIATR-US, V145, P710, DOI 10.1016/j.jpeds.2004.06.075; Parvaneh N, 2008, CLIN BIOCHEM, V41, P350, DOI 10.1016/j.clinbiochem.2007.11.007; RICH KC, 1979, AM J MED, V67, P172, DOI 10.1016/0002-9343(79)90100-1; RIJKSEN G, 1987, PEDIATR RES, V21, P137, DOI 10.1203/00006450-198702000-00006; Shah N, 2019, ANN INDIAN ACAD NEUR, V22, P231, DOI 10.4103/aian.AIAN_430_17; Sikpi MO, 1998, RADIAT RES, V150, P627, DOI 10.2307/3579885; Somech R, 2013, IMMUNOL RES, V56, P150, DOI 10.1007/s12026-012-8380-9; Sun X, 2002, J PEDIATR-US, V140, P724, DOI 10.1067/mpd.2002.123879; Timms PM, 1996, CLIN CHEM, V42, P985; Toro A, 2006, J CLIN INVEST, V116, P2717, DOI 10.1172/JCI25052; Toro A, 2006, CELL IMMUNOL, V240, P107, DOI 10.1016/j.cellimm.2006.07.003; Walker PLC, 2011, NUCLEOS NUCLEOT NUCL, V30, P1243, DOI 10.1080/15257770.2011.630852; WATSON AR, 1981, ARCH DIS CHILD, V56, P563, DOI 10.1136/adc.56.7.563; Whitmore KV, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00314; Wroblewski JM, 2002, J IMMUNOL METHODS, V264, P19, DOI 10.1016/S0022-1759(01)00565-8; Yeates L, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00143; Yu YM, 2009, J IMMUNOL METHODS, V350, P29, DOI 10.1016/j.jim.2009.07.008	44	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2020	11								1257	10.3389/fimmu.2020.01257	http://dx.doi.org/10.3389/fimmu.2020.01257			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MQ8CD	32695102	gold, Green Published			2022-12-18	WOS:000553120100001
J	Kostinov, MP; Akhmatova, NK; Khromova, EA; Kostinova, AM				Kostinov, Mikhail Petrovich; Akhmatova, Nelli Kimovna; Khromova, Ekaterina Alexandrovna; Kostinova, Aristitsa Mikhailovna			Cytokine Profile in Human Peripheral Blood Mononuclear Leukocytes Exposed to Immunoadjuvant and Adjuvant-Free Vaccines Against Influenza	FRONTIERS IN IMMUNOLOGY			English	Article						vaccines against influenza; subunit immunoadjuvant vaccine; subunit vaccine; split vaccine; cytokine response	ALVEOLAR MACROPHAGES; T-CELL; RESPONSES; VIRUS	Background:In the last decade, adjuvant-containing vaccines, exerting different effects on the immune system, including the production of cytokines, which are one of the most important regulatory systems of the body, are introduced into practice. Objectives:An effect of the immunoadjuvant polymer-subunit and adjuvant-free vaccines against influenza on the cytokine profile of mononuclear leukocytes in 27 healthy women was studied. Methods:The study of cytokine profile in human peripheral blood mononuclear leukocytes exposed to vaccines against influenza virus was determined by flow cytometry method (Cytomix FC-500, Beckman Coulter, USA) using the Multiplex-13 test system (Bender MedSystems, Austria). Results:It was established that all the studied vaccines leaded to somewhat increased levels of Th1/Th2/Th17/Th9/Th22 cytokines in the culture fluid of peripheral blood mononuclear leukocytes (PBML), which indicates the activation of both humoral and cellular immunity. An immunoadjuvant vaccine has been shown to be superior in activating the synthesis of Th1 (IL-12, INF-g, IL-2, IL-6, IL-1 beta, TNF-alpha) cytokines, IL-9 and IL-22, while the subunit vaccine was superior in activating the synthesis of IL-4, and split vaccine-of IL-5. Conclusions:Immunoadjuvant vaccine is superior in terms of inducing cellular immune effectors to a greater extent compared to subunit and split vaccines.	[Kostinov, Mikhail Petrovich; Akhmatova, Nelli Kimovna; Khromova, Ekaterina Alexandrovna] II Mechnikov Res Inst Vaccines & Sera, Dept Immunol, Moscow, Russia; [Kostinov, Mikhail Petrovich] Sechenov First Moscow State Med Univ, Dept Immunol, Moscow, Russia; [Kostinova, Aristitsa Mikhailovna] NRC Inst Immunol FMBA Russia, Dept Immunol, Moscow, Russia	Russian Academy of Medical Sciences; Research Institute of Vaccines and Sera Mechnikov, RAMS; Sechenov First Moscow State Medical University; NRC Institute of Immunology FMBA of Russia	Khromova, EA (corresponding author), II Mechnikov Res Inst Vaccines & Sera, Dept Immunol, Moscow, Russia.	kate.khromova@mail.ru	Kostinov, Mikhail P/J-8296-2018; Kostinova, Aristitsa/GQO-8886-2022; Khromova, Ekaterina/AAO-6381-2020	Khromova, Ekaterina/0000-0002-4003-9976; Kostinov, Mikhail/0000-0002-1382-9403				[Anonymous], 2010, TSITOKINY VOSPALENYE; Avdeeva Zh. I., 2009, TIKHOOKEANSKIY MED Z, V3, P19; Becher PM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193844; Ben-Sasson SZ, 2013, COLD SH Q B, V78, P117, DOI 10.1101/sqb.2013.78.021246; Bulgakova VA, 2010, MED COUNCIL, V9-10, P46; Bullens DMA, 2001, SCAND J IMMUNOL, V53, P455, DOI 10.1046/j.1365-3083.2001.00900.x; Chan RWY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051057; Cherdantsev AP, 2018, GUIDELINES DOCTORS, V3rd, P143; Cherdantsev AP, 2014, GUIDELINES DOCTORS, V2nd; Cherdantsev AP, 2011, MED ALMANAC, V4, P120; Chromova E. A., 2016, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P61; Chromova E. A., 2016, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P23; Chuchalin AG, 2016, VACCINES; Degen WGJ, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P65, DOI 10.1016/B978-0-12-804019-5.00004-9; Divangahi M, 2015, TRENDS IMMUNOL, V36, P307, DOI 10.1016/j.it.2015.03.005; Dyakonova VA, 2004, INT IMMUNOPHARMACOL, V4, P1615, DOI 10.1016/j.intimp.2004.07.015; Hauber HP, 2004, INT ARCH ALLERGY IMM, V134, P79, DOI 10.1159/000078384; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Ivanov VV, 2012, N CAUCASUS MED GAZ, V4, P70; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; [Караулов А.В. Karaulov A.V.], 2019, [Эпидемиология и вакцинопрофилактика, Epidemiologiya i vaktsinoprofilaktika], V18, P101, DOI 10.31631/2073-3046-2019-18-4-101-119; [Хайдуков Сергей Валерьевич Khaidukov S.V.], 2013, [Медицинская иммунология, Meditsinskaya immunologiya], V15, P503; Khaitov RM, 2014, ALLERGOLOGY IMMUNOLO; Khromova EA, 2017, MED IMMUNOL, V19, P71, DOI [10.15789/1563-0625-2017-0, DOI 10.15789/1563-0625-2017-0]; Kostinov M. P., 2017, Pediatriya (Moscow), V96, P91; [Костинов М.П. Kostinov M.P.], 2011, [Вопросы гинекологии, акушерства и перинатологии, Gynecology, Obstetrics and Perinatology, Voprosy ginekologii, akusherstva i perinatologii], V10, P44; Kostinov MP, 2018, INFLUENZA THERAPEUTI, P83, DOI 10.5772/intechopen.71939; Kostinov MP, 2017, VACCINES, P67; Kostinov MP, 2016, GUIDANCE CLIN IMMUNO, V1st; Kostinov MP, 2019, GUIDELINES VACCINATI; Kostinov MP, 2015, J VACCINES VACCIN, V6, P5, DOI [10.4172/2157-7560.1000297, DOI 10.4172/2157-7560.1000297]; Kozlov V, 2009, PRACTICAL ASPECTS DI; Li CF, 2017, IMMUNITY, V46, P446, DOI 10.1016/j.immuni.2017.02.012; Lim R, 2017, J REPROD IMMUNOL, V122, P28, DOI 10.1016/j.jri.2017.08.004; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Medunitsyn NV, 2017, MED IMMUNOL, V19, P275, DOI [10.15789/1563-0625-2017-3-275-284, DOI 10.15789/1563-0625-2017-3-275-284]; Moskalev AV, 2015, GEN IMMUNOLOGY BASIC, P351; Murphy K, 2017, JANEWAY'S IMMUNOBIOLOGY, 9TH EDITION, P345; Paul WE, 2015, CYTOKINE, V75, P3, DOI 10.1016/j.cyto.2015.01.038; Spitaels J, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040033; Staumont-Salle D, 2008, J ALLERGY CLIN IMMUN, V121, P962, DOI 10.1016/j.jaci.2007.12.1165; Tarbaeva D. A., 2011, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P71; [ТАРБАЕВА Долгорма Александровна TARBAYEVA D.A.], 2012, [Акушерство и гинекология, Akusherstvo i ginekologiya], P67; Thomas M, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060312; Wang P, 2017, SCIENCE, V358, P1051, DOI 10.1126/science.aao0409; Wolk K, 2006, CYTOKINE GROWTH F R, V17, P367, DOI 10.1016/j.cytogfr.2006.09.001; Zeng H, 2015, J VIROL, V89, P4655, DOI 10.1128/JVI.03095-14; Zverev VV, 2015, FEDERAL CLIN GUIDELI, V41, P1	52	2	3	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2020	11								1351	10.3389/fimmu.2020.01351	http://dx.doi.org/10.3389/fimmu.2020.01351			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MQ8BZ	32695114	Green Published, gold			2022-12-18	WOS:000553119700001
J	Piatosa, B; Wolska-Kusnierz, B; Tkaczyk, K; Heropolitanska-Pliszka, E; Grycuk, U; Wakulinska, A; Gregorek, H				Piatosa, Barbara; Wolska-Kusnierz, Beata; Tkaczyk, Katarzyna; Heropolitanska-Pliszka, Edyta; Grycuk, Urszula; Wakulinska, Anna; Gregorek, Hanna			T Lymphocytes in Patients With Nijmegen Breakage Syndrome Demonstrate Features of Exhaustion and Senescence in Flow Cytometric Evaluation of Maturation Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						Nijmegen Breakage Syndrome; T lymphocyte maturation; flow cytometry; primary immune deficiency; immune senescence; immune exhaustion	RECENT THYMIC EMIGRANTS; CELL DIFFERENTIATION; DNA-REPAIR; MRN COMPLEX; 2 SUBSETS; MEMORY; EXPRESSION; CD4(+); NBS1; INSTABILITY	Patients with Nijmegen Breakage Syndrome (NBS) suffer from recurrent infections due to humoral and cellular immune deficiency. Despite low number of T lymphocytes and their maturation defect, the clinical manifestations of cell-mediated deficiency are not as severe as in case of patients with other types of combined immune deficiencies and similar T cell lymphopenia. In this study, multicolor flow cytometry was used for evaluation of peripheral T lymphocyte maturation according to the currently known differentiation pathway, in 46 patients with genetically confirmed NBS and 46 sex and age-matched controls. Evaluation of differential expression of CD27, CD31, CD45RA, CD95, and CD197 revealed existence of cell subsets so far not described in NBS patients. Although recent thymic emigrants and naive T lymphocyte cell populations were significantly lower, the generation of antigen-primed T cells was similar or even greater in NBS patients than in healthy controls. Moreover, the senescent and exhausted T cell populations defined by expression of CD57, KLRG1, and PD1 were more numerous than in healthy people. Although this hypothesis needs further investigations, such properties might be related to an increased susceptibility to malignancy and milder clinical course than expected in view of T cell lymphopenia in patients with NBS.	[Piatosa, Barbara; Tkaczyk, Katarzyna; Grycuk, Urszula] Childrens Mem Hlth Inst, Histocompatibil Lab, Warsaw, Poland; [Wolska-Kusnierz, Beata; Heropolitanska-Pliszka, Edyta] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland; [Wakulinska, Anna] Childrens Mem Hlth Inst, Dept Oncol, Warsaw, Poland; [Gregorek, Hanna] Childrens Mem Hlth Inst, Dept Microbiol & Clin Immunol, Warsaw, Poland	Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Memorial Health Institute	Piatosa, B (corresponding author), Childrens Mem Hlth Inst, Histocompatibil Lab, Warsaw, Poland.	b.piatosa@ipczd.pl		Wakulinska, Anna/0000-0002-2561-0636	European Union's Horizon 2020 research and innovation program under the ERANET Cofound [643578]; National Centre for Research and Development (NCBiR) under the ERA-NET-E-Rare-3, JTC 2015 [ERA-NET-ERare/I/EuroCID/04/2016]	European Union's Horizon 2020 research and innovation program under the ERANET Cofound; National Centre for Research and Development (NCBiR) under the ERA-NET-E-Rare-3, JTC 2015	This project received funding from the European Union's Horizon 2020 research and innovation program under the ERANET Cofound action no. 643578 and was supported by the National Centre for Research and Development (NCBiR) under the ERA-NET-E-Rare-3, JTC 2015 (Grant No. ERA-NET-ERare/I/EuroCID/04/2016).	AKBAR AN, 1988, J IMMUNOL, V140, P2171; Akbar AN, 2011, NAT REV IMMUNOL, V11, P289, DOI 10.1038/nri2959; Moro-Garcia MA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00107; Appay V, 2004, SEMIN IMMUNOL, V16, P205, DOI 10.1016/j.smim.2004.02.007; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Bai YL, 2003, MOL CANCER RES, V1, P1058; Berland A, 2019, J ALLERGY CLIN IMMUN, V143, P325, DOI 10.1016/j.jaci.2018.05.028; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Campbell JJ, 2001, J IMMUNOL, V166, P877, DOI 10.4049/jimmunol.166.2.877; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerosaletti KM, 1998, AM J HUM GENET, V63, P125, DOI 10.1086/301927; Chattopadhyay PK, 2009, J LEUKOCYTE BIOL, V85, P88, DOI 10.1189/jlb.0208107; CHRZANOWSKA KH, 1995, AM J MED GENET, V57, P462, DOI 10.1002/ajmg.1320570321; Chrzanowska KH, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-13; Cieri N, 2013, BLOOD, V121, P573, DOI 10.1182/blood-2012-05-431718; Davis T, 2015, BIOGERONTOLOGY, V16, P43, DOI 10.1007/s10522-014-9530-3; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dembowska-Baginska B, 2009, PEDIATR BLOOD CANCER, V52, P186, DOI 10.1002/pbc.21789; Derhovanessian E, 2011, J GEN VIROL, V92, P2746, DOI 10.1099/vir.0.036004-0; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Fritsch RD, 2005, J IMMUNOL, V175, P6489, DOI 10.4049/jimmunol.175.10.6489; Garcia-Perez MA, 2001, CLIN DIAGN LAB IMMUN, V8, P757, DOI 10.1128/CDLI.8.4.757-761.2001; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gladkowska-Dura M, 2008, J PATHOL, V216, P337, DOI 10.1002/path.2418; Greenberg Steven A, 2019, Oncotarget, V10, P1399, DOI 10.18632/oncotarget.26659; Gregorek H, 2002, CLIN EXP IMMUNOL, V130, P319, DOI 10.1046/j.1365-2249.2002.01971.x; Gregorek H, 2010, CLIN IMMUNOL, V135, P440, DOI 10.1016/j.clim.2010.01.008; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Helmink BA, 2009, J EXP MED, V206, P669, DOI 10.1084/jem.20081326; Henson SM, 2009, BLOOD, V113, P6619, DOI 10.1182/blood-2009-01-199588; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; HINTZEN RQ, 1993, J IMMUNOL, V151, P2426; Hou YY, 2012, CELL BIOCHEM FUNCT, V30, P233, DOI 10.1002/cbf.1840; Howlett NG, 2006, DNA REPAIR, V5, P251, DOI 10.1016/j.dnarep.2005.10.004; Ibegbu CC, 2005, J IMMUNOL, V174, P6088, DOI 10.4049/jimmunol.174.10.6088; Junge S, 2007, EUR J IMMUNOL, V37, P3270, DOI 10.1002/eji.200636976; Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756; Larbi A, 2014, CYTOM PART A, V85A, P25, DOI 10.1002/cyto.a.22351; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; Lugli E, 2013, J CLIN INVEST, V123, P594, DOI 10.1172/JCI66327; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Mahnke YD, 2012, CYTOM PART A, V81A, P935, DOI 10.1002/cyto.a.22201; Meijers RWJ, 2017, J CLIN IMMUNOL, V37, P133, DOI 10.1007/s10875-016-0363-5; Michalkiewicz J, 2003, CLIN EXP IMMUNOL, V134, P482, DOI 10.1046/j.1365-2249.2003.02285.x; Okada R, 2008, INT IMMUNOL, V20, P1189, DOI 10.1093/intimm/dxn075; Pastink A, 1999, MUTAT RES-FUND MOL M, V428, P141, DOI 10.1016/S1383-5742(99)00042-3; Pera A, 2017, J LEUKOCYTE BIOL, V101, P555, DOI 10.1189/jlb.4A0316-112R; Piatosa B, 2012, CYTOM PART A, V81A, P835, DOI 10.1002/cyto.a.22108; Piatosa B, 2010, CENT EUR J IMMUNOL, V35, P168; Prochazkova J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005645; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Romero P, 2007, J IMMUNOL, V178, P4112, DOI 10.4049/jimmunol.178.7.4112; Saidi A, 2010, MOL CELL BIOL, V30, P5572, DOI 10.1128/MCB.00917-10; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schmueck-Henneresse M, 2015, J IMMUNOL, V194, P5559, DOI 10.4049/jimmunol.1402090; Seidemann K, 2000, ANN ONCOL, V11, P141, DOI 10.1023/A:1008391923792; SUGITA K, 1992, J IMMUNOL, V149, P3208; Takata H, 2006, J IMMUNOL, V177, P4330, DOI 10.4049/jimmunol.177.7.4330; Takeshita M, 2015, CLIN IMMUNOL, V159, P107, DOI 10.1016/j.clim.2015.04.010; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; Tanaskovic S, 2010, IMMUNOL CELL BIOL, V88, P321, DOI 10.1038/icb.2009.108; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; van Engelen BGM, 2001, HUM IMMUNOL, V62, P1324, DOI 10.1016/S0198-8859(01)00345-7; van Lier RAW, 2003, NAT REV IMMUNOL, V3, P931, DOI 10.1038/nri1228; WANG ECY, 1994, EUR J IMMUNOL, V24, P2903, DOI 10.1002/eji.1830241148; WEEMAES CMR, 1994, INT J RADIAT BIOL, V66, pS185; Wolska-Kusnierz B, 2015, J CLIN IMMUNOL, V35, P538, DOI 10.1007/s10875-015-0186-9; Wood KL, 2009, FRONT BIOSCI-LANDMRK, V14, P3771, DOI [10.2741/3487, 10.2735/3487]; Xu WL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081742	71	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2020	11								1319	10.3389/fimmu.2020.01319	http://dx.doi.org/10.3389/fimmu.2020.01319			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MQ8BW	32695108	Green Published, gold			2022-12-18	WOS:000553119400001
J	Prabakaran, P; Glanville, J; Ippolito, GC				Prabakaran, Ponraj; Glanville, Jacob; Ippolito, Gregory C.			Editorial: Next-Generation Sequencing of Human Antibody Repertoires for Exploring B-cell Landscape, Antibody Discovery and Vaccine Development	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						B-cell receptor repertoire; next generation sequencing; antibodyome; immunoglobulin; B-cell clonotypes; vaccination; immunogenetics; immunoinformatics			[Prabakaran, Ponraj] Sanofi, Biol Res, Framingham, MA 01701 USA; [Glanville, Jacob] Distributed Bio, San Francisco, CA USA; [Ippolito, Gregory C.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA	Sanofi-Aventis; University of Texas System; University of Texas Austin	Prabakaran, P (corresponding author), Sanofi, Biol Res, Framingham, MA 01701 USA.	prabakaran.ponraj@sanofi.com	Ippolito, Gregory C./AAR-2930-2021; Ponraj, Prabakaran/D-6325-2011	Ippolito, Gregory C./0000-0002-7565-7002; Ponraj, Prabakaran/0000-0002-4049-4813	NIH [AI135682, AI119368]; William and Ella Owens Medical Research Foundation; PATH Malaria Vaccine Initiative	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); William and Ella Owens Medical Research Foundation; PATH Malaria Vaccine Initiative	The editors thank all reviewers for their time and constructive feedback on submitted manuscripts. This Research Topic would not have been be possible without the support of the Frontiers in Immunology editorial team. We thank Prof. Thomas L. Rothstein for his helpful comments and support. PP thanks Dr. Partha Chowdhury and Dr. Maria Wendt for their support and encouragement. GI wishes to acknowledge his grant support during this period, including NIH grants AI135682 and AI119368, The William and Ella Owens Medical Research Foundation, and the PATH Malaria Vaccine Initiative.	Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004; DeKosky BJ, 2016, P NATL ACAD SCI USA, V113, pE2636, DOI 10.1073/pnas.1525510113; Dimitrov DS, 2010, MABS-AUSTIN, V2, P347, DOI 10.4161/mabs.2.3.11779; Georgiou G, 2014, NAT BIOTECHNOL, V32, P158, DOI 10.1038/nbt.2782; Glanville J, 2009, P NATL ACAD SCI USA, V106, P20216, DOI 10.1073/pnas.0909775106; Havenar-Daughton C, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0381; Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195; Krawczyk K, 2019, MABS-AUSTIN, V11, P1197, DOI 10.1080/19420862.2019.1633884; Kwong PD, 2017, IMMUNOL REV, V275, P108, DOI 10.1111/imr.12480; Naso Michael F, 2014, Curr Drug Discov Technol, V11, P85; Ponraj P, 2018, NATURE, V557, P166, DOI 10.1038/d41586-018-05065-5; Prabakaran P, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107831; Prabakaran Ponraj, 2012, Front Microbiol, V3, P277, DOI 10.3389/fmicb.2012.00277; Robinson WH, 2015, NAT REV RHEUMATOL, V11, P171, DOI 10.1038/nrrheum.2014.220; Soto C, 2019, NATURE, V566, P398, DOI 10.1038/s41586-019-0934-8; Vaisman-Mentesh A, 2018, METHODS MOL BIOL, V1701, P463, DOI 10.1007/978-1-4939-7447-4_26	17	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2020	11								344	10.3389/fimmu.2020.01344	http://dx.doi.org/10.3389/fimmu.2020.01344			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	QD5GK	32714328	Green Published, gold			2022-12-18	WOS:000615546200001
J	Wilhelmson, AS; Rodriguez, ML; Johansson, I; Eriksson, ES; Stubelius, A; Lindgren, S; Fagman, JB; Fink, PJ; Carlsten, H; Ekwall, O; Tivesten, A				Wilhelmson, Anna S.; Rodriguez, Marta Lantero; Johansson, Inger; Eriksson, Elin Svedlund; Stubelius, Alexandra; Lindgren, Susanne; Fagman, Johan Bourghardt; Fink, Pamela J.; Carlsten, Hans; Ekwall, Olov; Tivesten, Asa			Androgen Receptors in Epithelial Cells Regulate Thymopoiesis and Recent Thymic Emigrants in Male Mice	FRONTIERS IN IMMUNOLOGY			English	Article						androgens; T cells; thymus; thymic epithelial cells; mice	BONE-MARROW; RECONSTITUTION; TESTOSTERONE; EXPRESSION; GENE	Androgens have profound effects on T cell homeostasis, including regulation of thymic T lymphopoiesis (thymopoiesis) and production of recent thymic emigrants (RTEs), i. e., immature T cells that derive from the thymus and continue their maturation to mature naive T cells in secondary lymphoid organs. Here we investigated the androgen target cell for effects on thymopoiesis and RTEs in spleen and lymph nodes. Male mice with a general androgen receptor knockout (G-ARKO), T cell-specific (T-ARKO), or epithelial cell-specific (E-ARKO) knockout were examined. G-ARKO mice showed increased thymus weight and increased numbers of thymic T cell progenitors. These effects were not T cell-intrinsic, since T-ARKO mice displayed unaltered thymus weight and thymopoiesis. In line with a role for thymic epithelial cells (TECs), E-ARKO mice showed increased thymus weight and numbers of thymic T cell progenitors. Further, E-ARKO mice had more CD4(+)and CD8(+)T cells in spleen and an increased frequency of RTEs among T cells in spleen and lymph nodes. Depletion of the androgen receptor in epithelial cells was also associated with a small shift in the relative number of cortical (reduced) and medullary (increased) TECs and increased CCL25 staining in the thymic medulla, similar to previous observations in castrated mice. In conclusion, we demonstrate that the thymic epithelium is a target compartment for androgen-mediated regulation of thymopoiesis and consequently the generation of RTEs.	[Wilhelmson, Anna S.; Rodriguez, Marta Lantero; Johansson, Inger; Eriksson, Elin Svedlund; Fagman, Johan Bourghardt; Tivesten, Asa] Univ Gothenburg, Inst Med, Dept Mol & Clin Med, Wallenberg Lab Cardiovasc & Metab Res, Gothenburg, Sweden; [Stubelius, Alexandra; Carlsten, Hans] Univ Gothenburg, Ctr Bone & Arthrit Res CBAR, Inst Med, Gothenburg, Sweden; [Stubelius, Alexandra; Lindgren, Susanne; Carlsten, Hans; Ekwall, Olov] Univ Gothenburg, Inst Med, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden; [Lindgren, Susanne; Ekwall, Olov] Univ Gothenburg, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden; [Fink, Pamela J.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA; [Wilhelmson, Anna S.] Univ Copenhagen, Danish Stem Cell Ctr DanStem, Biotech Res & Innovat Ctr BRIC, Finsen Lab,Rigshosp,Fac Hlth Sci, Copenhagen, Denmark; [Stubelius, Alexandra] Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, Sweden; [Fagman, Johan Bourghardt] Univ Gothenburg, Inst Clin Sci, Dept Surg, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Washington; University of Washington Seattle; Rigshospitalet; University of Copenhagen; Chalmers University of Technology; University of Gothenburg	Tivesten, A (corresponding author), Univ Gothenburg, Inst Med, Dept Mol & Clin Med, Wallenberg Lab Cardiovasc & Metab Res, Gothenburg, Sweden.	asa.tivesten@medic.gu.se	Wilhelmson, Anna S/HCI-9867-2022	Wilhelmson, Anna S/0000-0003-0640-0251; Bourghardt Fagman, Johan/0000-0002-1527-5280; Ekwall, Olov/0000-0002-4506-9955	Swedish Research Council; Swedish Heart-Lung Foundation; Avtal om Lakarutbildning och Forskning (ALF) research grant in Gothenburg; Marianne and Marcus Wallenberg Foundation; AFA Insurance; Novo Nordisk Foundation; National Institutes of Health (NIH) [R01 AI 064318, R21 AI 132960]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Avtal om Lakarutbildning och Forskning (ALF) research grant in Gothenburg; Marianne and Marcus Wallenberg Foundation; AFA Insurance; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the Swedish Research Council, the Swedish Heart-Lung Foundation, Avtal om Lakarutbildning och Forskning (ALF) research grant in Gothenburg, the Marianne and Marcus Wallenberg Foundation, AFA Insurance, the Novo Nordisk Foundation and the National Institutes of Health (NIH R01 AI 064318 and R21 AI 132960).	Abramson J, 2017, ANNU REV IMMUNOL, V35, P85, DOI 10.1146/annurev-immunol-051116-052320; Bennett AR, 2002, IMMUNITY, V16, P803, DOI 10.1016/S1074-7613(02)00321-7; Bourghardt J, 2010, ENDOCRINOLOGY, V151, P5428, DOI 10.1210/en.2010-0663; Calderon L, 2012, CELL, V149, P159, DOI 10.1016/j.cell.2012.01.049; Chen YW, 2010, FASEB J, V24, P5043, DOI 10.1096/fj.10-168724; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; Dulos GJ, 2001, INT IMMUNOPHARMACOL, V1, P321, DOI 10.1016/S1567-5769(00)00029-1; Dumont-Lagace M, 2015, SCI REP-UK, V5, DOI 10.1038/srep12895; Fink PJ, 2013, ANNU REV IMMUNOL, V31, P31, DOI 10.1146/annurev-immunol-032712-100010; Hale JS, 2006, P NATL ACAD SCI USA, V103, P8447, DOI 10.1073/pnas.0601040103; Heng TSP, 2005, J IMMUNOL, V175, P2982, DOI 10.4049/jimmunol.175.5.2982; Kelly RM, 2008, BLOOD, V111, P5734, DOI 10.1182/blood-2008-01-136531; Ketelhuth DFJ, 2016, CIRC RES, V118, P668, DOI 10.1161/CIRCRESAHA.115.306427; Kocar IH, 2000, CLIN EXP IMMUNOL, V121, P448; Lai KP, 2013, MOL ENDOCRINOL, V27, P25, DOI 10.1210/me.2012-1244; Leposavic G, 1996, PHARMACOL BIOCHEM BE, V54, P269, DOI 10.1016/0091-3057(95)02165-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Olsen NJ, 2011, J INVEST MED, V59, P32; Olsen NJ, 2001, ENDOCRINOLOGY, V142, P1278, DOI 10.1210/en.142.3.1278; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Roden AC, 2004, J IMMUNOL, V173, P6098, DOI 10.4049/jimmunol.173.10.6098; Rodrigues PM, 2018, J IMMUNOL, V200, P1389, DOI 10.4049/jimmunol.1701112; Seminog OO, 2015, AUTOIMMUNITY, V48, P125, DOI 10.3109/08916934.2014.968918; Sutherland JS, 2005, J IMMUNOL, V175, P2741, DOI 10.4049/jimmunol.175.4.2741; Tedeschi SK, 2013, CLIN IMMUNOL, V149, P211, DOI 10.1016/j.clim.2013.03.003; Venables T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11879-2; Wilhelmson AS, 2018, ARTERIOSCL THROM VAS, V38, P1519, DOI 10.1161/ATVBAHA.118.311252; Williams KM, 2008, BLOOD, V112, P3255, DOI 10.1182/blood-2008-04-153627	28	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 29	2020	11								1342	10.3389/fimmu.2020.01342	http://dx.doi.org/10.3389/fimmu.2020.01342			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MR0IL	32714327	gold, Green Published			2022-12-18	WOS:000553277300001
J	Froehlich, M; Schwaneck, EC; Gernert, M; Gadeholt, O; Strunz, PP; Morbach, H; Tony, HP; Schmalzing, M				Froehlich, Matthias; Schwaneck, Eva C.; Gernert, Michael; Gadeholt, Ottar; Strunz, Patrick-Pascal; Morbach, Henner; Tony, Hans-Peter; Schmalzing, Marc			Autologous Stem Cell Transplantation in Common Variable Immunodeficiency: A Case of Successful Treatment of Severe Refractory Autoimmune Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						common variable immunodeficiency; primary immunodeficiencies; autoimmunity; autologous stem cell transplantation; autoimmune encephalitis	MULTIPLE-SCLEROSIS; T-CELLS; THYMIC OUTPUT; COMPLICATIONS; REPERTOIRE; EXPERIENCE; MANAGEMENT; PHENOTYPES; DIAGNOSIS; CHILDREN	Common variable immunodeficiency (CVID) is the most common primary immunodeficiency in adults. It is associated with hypogammaglobulinemia, recurring infections and autoimmune phenomena. Treatment includes immunoglobulin substitution and immunosuppressants. Autoimmune neurological manifestations of CVID are rare and occur predominantly as granulomatous disease. We report the case of a 35-year-old woman with CVID who developed autoimmune encephalitis as demonstrated by double cerebral biopsy. Infectious or malignant causes could be excluded. Despite intensive immunosuppressive therapy with common regimens no significant improvement could be achieved. Ultimately, an autologous hematopoietic stem cell transplantation (HSCT) was performed, resulting in lasting complete remission of the encephalitis. To our knowledge, this is the first report of refractory autoimmune phenomena in CVID treated by autologous HSCT.	[Froehlich, Matthias; Schwaneck, Eva C.; Gernert, Michael; Strunz, Patrick-Pascal; Tony, Hans-Peter; Schmalzing, Marc] Univ Wurzburg, Med Klin & Poliklin 2, Schwerpunkt Rheumatol Klin Immunol, Wurzburg, Germany; [Gadeholt, Ottar] Rheumatol Schwerpunktpraxis Wurzburg, Wurzburg, Germany; [Morbach, Henner] Univ Wurzburg, Kinderklin & Poliklin, Wurzburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Wurzburg	Froehlich, M (corresponding author), Univ Wurzburg, Med Klin & Poliklin 2, Schwerpunkt Rheumatol Klin Immunol, Wurzburg, Germany.	froehlich_m@ukw.de	Gadeholt, Ottar/AAM-1030-2021; Gernert, Michael/ABB-4777-2020	Gernert, Michael/0000-0003-0074-4459; Strunz, Patrick-Pascal/0000-0002-3168-7074				Abati E, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01031; Abbott JK, 2015, IMMUNOL ALLERGY CLIN, V35, P637, DOI 10.1016/j.iac.2015.07.009; Abrahamsson SV, 2013, BRAIN, V136, P2888, DOI 10.1093/brain/awt182; Alexander T, 2016, CLIN EXP RHEUMATOL, V34, pS53; Arandi N, 2013, SCAND J IMMUNOL, V77, P405, DOI 10.1111/sji.12040; Arruda LCM, 2016, CLIN IMMUNOL, V169, P47, DOI 10.1016/j.clim.2016.06.005; Atkins HL, 2016, LANCET, V388, P576, DOI 10.1016/S0140-6736(16)30169-6; Ayano M, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1823-0; Azizi G, 2018, SCAND J IMMUNOL, V87, DOI 10.1111/sji.12663; Balashov D, 2015, BIOL BLOOD MARROW TR, V21, P1955, DOI 10.1016/j.bbmt.2015.07.008; Bateman EAL, 2012, CLIN EXP IMMUNOL, V170, P202, DOI 10.1111/j.1365-2249.2012.04643.x; Bertaina A, 2014, BLOOD, V124, P822, DOI 10.1182/blood-2014-03-563817; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Boursiquot JN, 2013, J CLIN IMMUNOL, V33, P84, DOI 10.1007/s10875-012-9778-9; Castagnoli R, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00295; Cull G, 2017, Mult Scler J Exp Transl Clin, V3, p2055217317700167, DOI 10.1177/2055217317700167; Darlington PJ, 2013, ANN NEUROL, V73, P341, DOI 10.1002/ana.23784; de Kleer I, 2006, BLOOD, V107, P1696, DOI 10.1182/blood-2005-07-2800; Delemarre EM, 2016, BLOOD, V127, P91, DOI 10.1182/blood-2015-06-649145; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; Elfeky R, 2019, J ALLERGY CLIN IMMUN, V144, P280, DOI 10.1016/j.jaci.2019.01.030; European Society for Immunodeficiencies, COMM VAR IMM DIAGN C; Fischer A, 2017, J ALLERGY CLIN IMMUN, V140, P1388, DOI 10.1016/j.jaci.2016.12.978; Fox TA, 2018, BLOOD, V131, P917, DOI 10.1182/blood-2017-09-807487; Henes J, 2021, HAEMATOLOGICA, V106, P375, DOI 10.3324/haematol.2019.230128; Knight AK, 2006, AUTOIMMUN REV, V5, P156, DOI 10.1016/j.autrev.2005.10.002; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Massey JC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00410; Moore J, 2002, ARTHRITIS RHEUM, V46, P2301, DOI 10.1002/art.10495; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679; Muraro PA, 2017, JAMA NEUROL, V74, P459, DOI 10.1001/jamaneurol.2016.5867; Oliveira MC, 2016, BONE MARROW TRANSPL, V51, P501, DOI 10.1038/bmt.2015.299; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Shah RM, 2018, J ALLERGY CLIN IMMUN, V141, P1417, DOI 10.1016/j.jaci.2017.07.008; Snowden JA, 2012, BONE MARROW TRANSPL, V47, P770, DOI 10.1038/bmt.2011.185; Sun W, 2004, BRAIN, V127, P996, DOI 10.1093/brain/awh117; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wehr C, 2015, J ALLERGY CLIN IMMUN, V135, P988, DOI 10.1016/j.jaci.2014.11.029	40	2	2	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 25	2020	11								1317	10.3389/fimmu.2020.01317	http://dx.doi.org/10.3389/fimmu.2020.01317			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ML0OT	32670291	Green Published, gold			2022-12-18	WOS:000549177100001
J	Weilhammer, DR; Dunkle, AD; Boone, T; Gilmore, SF; Khemmani, M; Peters, SKG; Hoeprich, PD; Fischer, NO; Blanchette, CD; Driks, A; Rasley, A				Weilhammer, Dina R.; Dunkle, Alexis D.; Boone, Tyler; Gilmore, Sean F.; Khemmani, Mark; Peters, Sandra K. G.; Hoeprich, Paul D.; Fischer, Nicholas O.; Blanchette, Craig D.; Driks, Adam; Rasley, Amy			Characterization ofBacillus anthracisSpore Proteins Using a Nanoscaffold Vaccine Platform	FRONTIERS IN IMMUNOLOGY			English	Article						nanoscaffold; nanolipoprotein particle (NLP); vaccine; spore antigens; anthrax; monophosphoryl lipid A (MPLA)	BACILLUS-ANTHRACIS; NANOLIPOPROTEIN PARTICLES; PROTECTIVE ANTIGEN; SUBOPTIMAL AMOUNTS; CROSS-PRESENTATION; SUBUNIT VACCINES; SURFACE PROTEIN; SPORE; EXOSPORIUM; IMMUNITY	Subunit vaccines are theoretically safe and easy to manufacture but require effective adjuvants and delivery systems to yield protective immunity, particularly at critical mucosal sites such as the lung. We investigated nanolipoprotein particles (NLPs) containing the Toll-like receptor 4 agonist monophosphoryl lipid A (MPLA) as a platform for intranasal vaccination againstBacillus anthracis. Modified lipids enabled attachment of disparate spore and toxin protein antigens. Intranasal vaccination of mice withB. anthracisantigen-MPLA-NLP constructs induced robust IgG and IgA responses in serum and in bronchoalveolar and nasal lavage. Typically, a single dose sufficed to induce sustained antibody titers over time. When multiple immunizations were required for sustained titers, specific antibodies were detected earlier in the boost schedule with MPLA-NLP-mediated delivery than with free MPLA. Administering combinations of constructs induced responses to multiple antigens, indicating potential for a multivalent vaccine preparation. No off-target responses to the NLP scaffold protein were detected. In summary, the NLP platform enhances humoral and mucosal responses to intranasal immunization, indicating promise for NLPs as a flexible, robust vaccine platform againstB. anthracisand potentially other inhalational pathogens.	[Weilhammer, Dina R.; Dunkle, Alexis D.; Gilmore, Sean F.; Peters, Sandra K. G.; Hoeprich, Paul D.; Fischer, Nicholas O.; Blanchette, Craig D.; Rasley, Amy] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA 94550 USA; [Boone, Tyler; Khemmani, Mark; Driks, Adam] Loyola Univ Med Ctr, Dept Microbiol & Immunol, Chicago, IL USA; [Dunkle, Alexis D.; Blanchette, Craig D.] Genentech Inc, Dept Biol Technol, San Francisco, CA 94080 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Roche Holding; Genentech	Rasley, A (corresponding author), Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA 94550 USA.	rasley2@llnl.gov	Fischer, Nicholas/AAE-2409-2019; Gilmore, Sean/AAX-1554-2020	Fischer, Nicholas/0000-0001-7575-4390; Peters, Sandra/0000-0002-4616-0160; Rasley, Amy/0000-0002-4767-6628; Weilhammer, Dina/0000-0002-7618-4702	NIH/NIAID [R01AI093493-01]; Laboratory Directed Research and Development [11-ERD-016]; U.S. Department of Energy by Lawrence Livermore National Security, LLC, Lawrence Livermore National Laboratory [DE-AC52-07NA27344]	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Laboratory Directed Research and Development; U.S. Department of Energy by Lawrence Livermore National Security, LLC, Lawrence Livermore National Laboratory(United States Department of Energy (DOE))	Funding for this research was provided by the NIH/NIAID (R01AI093493-01 to AD) and Laboratory Directed Research and Development (11-ERD-016 to AR). This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Security, LLC, Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.	Bielinska AU, 2007, INFECT IMMUN, V75, P4020, DOI 10.1128/IAI.00070-07; Blanchette CD, 2010, BIOCONJUGATE CHEM, V21, P1321, DOI 10.1021/bc100129s; Boone TJ, 2011, MICROB PATHOGENESIS, V51, P255, DOI 10.1016/j.micpath.2011.06.005; Bozue JA, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.TBS-0021-2015; Brahmbhatt TN, 2007, INFECT IMMUN, V75, P5240, DOI 10.1128/IAI.00884-07; Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001; Brossier F, 2002, INFECT IMMUN, V70, P661; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Chromy BA, 2007, J AM CHEM SOC, V129, P14348, DOI 10.1021/ja074753y; Corthesy B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00185; Cote CK, 2012, J MED MICROBIOL, V61, P1380, DOI 10.1099/jmm.0.045393-0; Cybulsk RJ, 2008, VACCINE, V26, P4927, DOI 10.1016/j.vaccine.2008.07.015; D'Amelio E, 2015, ENVIRON INT, V85, P133, DOI 10.1016/j.envint.2015.09.009; Datta SK, 2010, P NATL ACAD SCI USA, V107, P10638, DOI 10.1073/pnas.1002348107; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Fischer NO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093342; Fischer NO, 2013, J AM CHEM SOC, V135, P2044, DOI 10.1021/ja3063293; Fischer NO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011643; Fischer NO, 2010, BIOCONJUGATE CHEM, V21, P1018, DOI 10.1021/bc100083d; Fischer NO, 2009, BIOCONJUGATE CHEM, V20, P460, DOI 10.1021/bc8003155; Frankel AE, 2009, FRONT BIOSCI, V14, P4516, DOI 10.2741/3544; Friedlander AM, 1999, JAMA-J AM MED ASSOC, V282, P2104, DOI 10.1001/jama.282.22.2104; Friedlander AM, 2000, CURR CLIN TOPICS INF, V20, P335; Gauthier YP, 2009, INFECT IMMUN, V77, P1197, DOI 10.1128/IAI.01217-08; Gilmore SF, 2017, ACS SYM SER, V1271, P131; Giorno R, 2007, J BACTERIOL, V189, P691, DOI 10.1128/JB.00921-06; Glomski IJ, 2007, J IMMUNOL, V178, P2646, DOI 10.4049/jimmunol.178.5.2646; Goel AK, 2015, WORLD J CLIN CASES, V3, P20, DOI 10.12998/wjcc.v3.i1.20; Hahn UK, 2006, VACCINE, V24, P4569, DOI 10.1016/j.vaccine.2005.08.031; Hassani M, 2004, CLIN IMMUNOL, V111, P1, DOI 10.1016/j.clim.2003.09.010; Iwasaki A, 2016, ANNU REV IMMUNOL, V34, P575, DOI 10.1146/annurev-immunol-032414-112315; Kuchtey J, 2005, J IMMUNOL, V175, P2244, DOI 10.4049/jimmunol.175.4.2244; Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106; Mallozzi M, 2008, FEMS MICROBIOL LETT, V289, P110, DOI 10.1111/j.1574-6968.2008.01380.x; Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487; Pitt MLM, 1999, J APPL MICROBIOL, V87, P304, DOI 10.1046/j.1365-2672.1999.00897.x; Plotkin SA, 2009, CLIN VACCINE IMMUNOL, V16, P1709, DOI 10.1128/CVI.00290-09; Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006; Reichelt P, 2006, PROTEIN EXPRES PURIF, V46, P483, DOI 10.1016/j.pep.2005.09.027; Severson KM, 2009, J BACTERIOL, V191, P7587, DOI 10.1128/JB.01110-09; Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x; Steichen C, 2003, J BACTERIOL, V185, P1903, DOI 10.1128/JB.185.6.1903-1910.2003; Steichen CT, 2007, MOL MICROBIOL, V64, P359, DOI 10.1111/j.1365-2958.2007.05658.x; Steichen CT, 2005, J BACTERIOL, V187, P5868, DOI 10.1128/JB.187.17.5868-5876.2005; Sylvestre P, 2002, MOL MICROBIOL, V45, P169, DOI 10.1046/j.1365-2958.2000.03000.x; Thompson BM, 2007, J BACTERIOL, V189, P6704, DOI 10.1128/JB.00762-07; Uchida M, 2012, BIOCHEM BIOPH RES CO, V421, P323, DOI 10.1016/j.bbrc.2012.04.007; Weilhammer D, 2017, VACCINE, V35, P1475, DOI 10.1016/j.vaccine.2017.02.004; Weilhammer DR, 2013, BIOMATERIALS, V34, P10305, DOI 10.1016/j.biomaterials.2013.09.038; Welkos S, 2002, J MED MICROBIOL, V51, P821, DOI 10.1099/0022-1317-51-10-821; Williams DD, 2004, J BACTERIOL, V186, P566, DOI 10.1128/JB.186.2.566-569.2004; Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069	52	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 23	2020	11								1264	10.3389/fimmu.2020.01264	http://dx.doi.org/10.3389/fimmu.2020.01264			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MK3GU	32714323	Green Published, gold, Green Submitted			2022-12-18	WOS:000548672700001
J	Aksentijevich, I; Soriano, A; Hernandez-Rodriguez, J				Aksentijevich, Ivona; Soriano, Alessandra; Hernandez-Rodriguez, Jose			Editorial: Autoinflammatory Diseases: From Genes to Bedside	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoinflammatory diseases; genotype; phenotype correlations; inflammasome; ubiquitinopathies; hyperinflammatory state; epigenetics; dermatopathology; treatment	INFLAMMASOME; ACTIVATION		[Aksentijevich, Ivona] NHGRI, Inflammatory Dis Sect, Bethesda, MD 20892 USA; [Soriano, Alessandra] Arcispedale S Maria Nuova IRCCS, Azienda Unita Sanit Locale Reggio Emilia, Dept Internal Med & Med Specialties, Div Internal Med, Reggio Emilia, Italy; [Hernandez-Rodriguez, Jose] Univ Barcelona, Clin Unit Autoinflammatory Dis & Vasculitis, Res Unit, Dept Autoimmune Dis,Hosp Clin,IDIBAPS, Barcelona, Spain	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); IRCCS Arcispedale S. Maria Nuova; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Aksentijevich, I (corresponding author), NHGRI, Inflammatory Dis Sect, Bethesda, MD 20892 USA.; Soriano, A (corresponding author), Arcispedale S Maria Nuova IRCCS, Azienda Unita Sanit Locale Reggio Emilia, Dept Internal Med & Med Specialties, Div Internal Med, Reggio Emilia, Italy.; Hernandez-Rodriguez, J (corresponding author), Univ Barcelona, Clin Unit Autoinflammatory Dis & Vasculitis, Res Unit, Dept Autoimmune Dis,Hosp Clin,IDIBAPS, Barcelona, Spain.	aksentii@mail.nih.gov; soriano.alessandra@gmail.com; pephernan@gmail.com	Soriano, Alessandra/AAB-3057-2021	Soriano, Alessandra/0000-0002-4554-8198				[Anonymous], 1997, CELL, V90, P797, DOI DOI 10.1016/S0092-8674(00)80539-5; Bernot A, 1997, NAT GENET, V17, P25; BOURONCLE BA, 1957, AM J MED, V23, P502, DOI 10.1016/0002-9343(57)90330-3; HELLER H, 1958, ARCH INTERN MED, V102, P50, DOI 10.1001/archinte.1958.00260190052007; Hoffman HM, 2003, HUM GENET, V112, P209, DOI 10.1007/s00439-002-0860-x; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; SIEGAL S, 1949, GASTROENTEROLOGY, V12, P234, DOI 10.1016/S0016-5085(49)80034-5	10	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 19	2020	11								1177	10.3389/fimmu.2020.01177	http://dx.doi.org/10.3389/fimmu.2020.01177			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MK2SZ	32636839	Green Published, gold			2022-12-18	WOS:000548636800001
J	Dolcino, M; Friso, S; Selmi, C; Lunardi, C				Dolcino, Marzia; Friso, Simonetta; Selmi, Carlo; Lunardi, Claudio			Editorial: Role of Epigenetics in Autoimmune Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						epigenetic; autoimmune diseases; DNA methylation; micro RNA; biomarkers			[Dolcino, Marzia; Friso, Simonetta; Lunardi, Claudio] Univ Verona, Dept Med, Verona, Italy; [Selmi, Carlo] IRCCS, Humanitas Clin & Res Ctr, Rheumatol & Clin Immunol, Milan, Italy; [Selmi, Carlo] Humanitas Univ, Dept Biomed Sci, Milan, Italy	University of Verona; Humanitas University	Lunardi, C (corresponding author), Univ Verona, Dept Med, Verona, Italy.	claudio.lunardi@univr.it	Selmi, Carlo/ABG-4899-2021	Selmi, Carlo/0000-0002-0323-0376				Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Dolcino M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091349; Dolcino M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080816; Dolcino M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030320; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Generali E, 2017, J AUTOIMMUN, V83, P51, DOI 10.1016/j.jaut.2017.04.005; Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109	7	2	2	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 19	2020	11								1284	10.3389/fimmu.2020.01284	http://dx.doi.org/10.3389/fimmu.2020.01284			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MK2SS	32636847	Green Published, gold			2022-12-18	WOS:000548636100001
J	Borger, JG; Le Gros, G; Kirman, JR				Borger, Jessica G.; Le Gros, Graham; Kirman, Joanna R.			Editorial: The Role of Innate Lymphoid Cells in Mucosal Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						ILC; NK cell; mucosal; immunity; lung; gastrointestinal tract; genitourinary tract			[Borger, Jessica G.] Monash Univ, Alfred Res Alliance, Cent Clin Sch, Dept Pathol & Immunol, Melbourne, Vic, Australia; [Le Gros, Graham] Malaghan Inst Med Res, Allerg & Parasit Dis Programme, Wellington, New Zealand; [Kirman, Joanna R.] Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand	Monash University; Malaghan Institute; Victoria University Wellington; University of Otago	Borger, JG (corresponding author), Monash Univ, Alfred Res Alliance, Cent Clin Sch, Dept Pathol & Immunol, Melbourne, Vic, Australia.	jessica.borger@monash.edu		Le Gros, Graham/0000-0002-5721-0442; Borger, Jessica/0000-0003-0704-1254	CASS Foundation Medicine/Science Grant	CASS Foundation Medicine/Science Grant	This work was supported in part with funds from the CASS Foundation Medicine/Science Grant (JB).	Burkhard SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094196; De Grove KC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145961; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365	4	2	2	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 17	2020	11								1233	10.3389/fimmu.2020.01233	http://dx.doi.org/10.3389/fimmu.2020.01233			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MH6ZU	32625212	Green Published, gold			2022-12-18	WOS:000546875400001
J	Van Laethem, F; Saba, I; Lu, JH; Bhattacharya, A; Tai, XG; Guinter, TI; Engelhardt, B; Alag, A; Rojano, M; Ashe, JM; Hanada, K; Yang, JC; Sun, PD; Singer, A				Van Laethem, Francois; Saba, Ingrid; Lu, Jinghua; Bhattacharya, Abhisek; Tai, Xuguang; Guinter, Terry I.; Engelhardt, Britta; Alag, Amala; Rojano, Mirelle; Ashe, Jennifer M.; Hanada, Ken-ichi; Yang, James C.; Sun, Peter D.; Singer, Alfred			Novel MHC-Independent alpha beta TCRs Specific for CD48, CD102, and CD155 Self-Proteins and Their Selection in the Thymus	FRONTIERS IN IMMUNOLOGY			English	Article						MHC-independent; thymic selection; MHC restriction; tolerance; coreceptors	MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL-RECEPTORS; NEGATIVE SELECTION; RECOGNITION; AFFINITY; ADHESION; DIVERSE; RESTRICTION; DETERMINES; ACTIVATION	MHC-independent alpha beta TCRs (TCRs) recognize conformational epitopes on native self-proteins and arise in mice lacking both MHC and CD4/CD8 coreceptor proteins. Although naturally generated in the thymus, these TCRs resemble re-engineered therapeutic chimeric antigen receptor (CAR) T cells in their specificity for MHC-independent ligands. Here we identify naturally arising MHC-independent TCRs reactive to three native self-proteins (CD48, CD102, and CD155) involved in cell adhesion. We report that naturally arising MHC-independent TCRs require high affinity TCR-ligand engagements in the thymus to signal positive selection and that high affinity positive selection generates a peripheral TCR repertoire with limited diversity and increased self-reactivity. We conclude that the affinity of TCR-ligand engagements required to signal positive selection in the thymus inversely determines the diversity and self-tolerance of the mature TCR repertoire that is selected.	[Van Laethem, Francois; Saba, Ingrid; Bhattacharya, Abhisek; Tai, Xuguang; Guinter, Terry I.; Alag, Amala; Rojano, Mirelle; Ashe, Jennifer M.; Singer, Alfred] NCI, Expt Immunol Branch, NIH, Rockville, MD 20850 USA; [Lu, Jinghua; Sun, Peter D.] NIAID, Struct Immunol Sect, Immunogenet Lab, Rockville, MD USA; [Engelhardt, Britta] Univ Bern, Theodor Kocher Inst, Fac Bern, Bern, Switzerland; [Hanada, Ken-ichi; Yang, James C.] NCI, Surg Branch, NIH, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Bern; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Singer, A (corresponding author), NCI, Expt Immunol Branch, NIH, Rockville, MD 20850 USA.	singera@nih.gov			Intramural Research Program (IRP) of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research; National Institute of Allergy and Infectious Diseases (NIAID)	Intramural Research Program (IRP) of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The funding of this work is provided by the Intramural Research Program (IRP) of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research and the National Institute of Allergy and Infectious Diseases (NIAID).	Adams JJ, 2016, NAT IMMUNOL, V17, P87, DOI 10.1038/ni.3310; ALLEN PM, 1994, CELL, V76, P593, DOI 10.1016/0092-8674(94)90497-9; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brzostek J, 2017, TRANSPLANTATION, V101, P1535, DOI 10.1097/TP.0000000000001654; Clements CS, 2006, CURR OPIN STRUC BIOL, V16, P787, DOI 10.1016/j.sbi.2006.09.004; COULIE PG, 1991, EUR J IMMUNOL, V21, P1703, DOI 10.1002/eji.1830210718; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; Ding ZM, 1999, J IMMUNOL, V163, P5029; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; Gao J, 2017, CANCER SCI, V108, P1934, DOI 10.1111/cas.13324; Gerwin N, 1999, IMMUNITY, V10, P9, DOI 10.1016/S1074-7613(00)80002-3; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; HONG X, 1992, J IMMUNOL, V149, P2650; Huseby ES, 2006, NAT IMMUNOL, V7, P1191, DOI 10.1038/ni1401; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Katsamba PS, 2006, ANAL BIOCHEM, V352, P208, DOI 10.1016/j.ab.2006.01.034; Kerry SE, 2003, J IMMUNOL, V171, P4493, DOI 10.4049/jimmunol.171.9.4493; La Gruta NL, 2018, NAT REV IMMUNOL, V18, P467, DOI 10.1038/s41577-018-0007-5; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lu JH, 2020, J IMMUNOL, V204, P3351, DOI 10.4049/jimmunol.1901084; Lu JH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08906-7; Maier MK, 2007, EUR J IMMUNOL, V37, P2214, DOI 10.1002/eji.200737072; McArdel SL, 2016, CLIN IMMUNOL, V164, P10, DOI 10.1016/j.clim.2016.01.008; Moran AE, 2012, IMMUNOLOGY, V135, P261, DOI 10.1111/j.1365-2567.2011.03547.x; Morris GP, 2012, NAT IMMUNOL, V13, P121, DOI 10.1038/ni.2190; Pobezinsky LA, 2012, NAT IMMUNOL, V13, P569, DOI 10.1038/ni.2292; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Schmits R, 1996, J EXP MED, V183, P1415, DOI 10.1084/jem.183.4.1415; Schurpf T, 2011, EMBO J, V30, P4712, DOI 10.1038/emboj.2011.333; Springer TA, 2012, CURR OPIN CELL BIOL, V24, P107, DOI 10.1016/j.ceb.2011.10.004; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Stepanek O, 2014, CELL, V159, P333, DOI 10.1016/j.cell.2014.08.042; Tikhonova AN, 2012, IMMUNITY, V36, P79, DOI 10.1016/j.immuni.2011.11.013; Van Laethem F, 2013, CELL, V154, P1326, DOI 10.1016/j.cell.2013.08.009; Van Laethem F, 2012, TRENDS IMMUNOL, V33, P437, DOI 10.1016/j.it.2012.05.006; Van Laethem F, 2007, IMMUNITY, V27, P735, DOI 10.1016/j.immuni.2007.10.007; Vidal K, 1999, J IMMUNOL, V163, P4811; Wang BM, 2009, SCIENCE, V326, P871, DOI 10.1126/science.1177627; Wiest DL, 1996, IMMUNITY, V4, P495, DOI 10.1016/S1074-7613(00)80415-X	43	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 16	2020	11								1216	10.3389/fimmu.2020.01216	http://dx.doi.org/10.3389/fimmu.2020.01216			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MG6AC	32612609	gold, Green Published			2022-12-18	WOS:000546111500001
J	Barroso, R; Morrison, WI; Morrison, LJ				Barroso, Ruben; Morrison, W. Ivan; Morrison, Liam J.			Molecular Dissection of the Antibody Response: Opportunities and Needs for Application in Cattle	FRONTIERS IN IMMUNOLOGY			English	Review						B cell; immunoglobulin; bovine; single cell analysis; ultralong HCDR3 domain	EXCEPTIONALLY LONG CDR3H; BOVINE MONOCLONAL-ANTIBODIES; B-CELL ACTIVATION; THEILERIA-PARVA; LIGHT-CHAIN; V-H; INFECTED LYMPHOCYTES; ANTIGEN; IGM; GENERATION	Improving understanding of the bovine adaptive immune response would equip researchers to more efficiently design interventions against pathogens that impact upon food security and animal welfare. There are features of the bovine antibody response that differ substantially from other mammalian species, including the best understood models in the human and mouse. These include the ability to generate a functionally diverse immunoglobulin response despite having a fraction of the germline gene diversity that underpins this process in humans and mice, and the unique structure of a subset of immunoglobulins with "ultralong" HCDR3 domains, which are of significant interest with respect to potential therapeutics, including against human pathogens. However, a more detailed understanding of the B cell response and the production of an effective antibody response in the bovine is currently hampered by the lack of reagents for the B cell lineage. In this article we outline the current state of knowledge and capabilities with regard to B cell and antibody responses in cattle, highlight resource gaps, and summarize recent advances that have the potential to fundamentally advance our understanding of this process in the bovine host.	[Barroso, Ruben; Morrison, W. Ivan; Morrison, Liam J.] Univ Edinburgh, Roslin Inst, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland; [Barroso, Ruben] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Birmingham	Morrison, LJ (corresponding author), Univ Edinburgh, Roslin Inst, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.	Liam.Morrison@roslin.ed.ac.uk		Morrison, Liam/0000-0002-8304-9066; Barroso, Ruben/0000-0003-3737-5538	Bill and Melinda Gates Foundation [OPP1108042, OPP1126862]; BBSRC [BB/J004227/1, BBS/E/D/20002173]; BBSRC [BBS/E/D/20002174] Funding Source: UKRI	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Funding related to this article was provided by the Bill and Melinda Gates Foundation (Awards OPP1108042 and OPP1126862). The Roslin Institute is funded by the BBSRC (BB/J004227/1 and BBS/E/D/20002173).	ANDERSON DV, 1987, VET IMMUNOL IMMUNOP, V15, P223, DOI 10.1016/0165-2427(87)90085-7; BALDWIN CL, 1988, INFECT IMMUN, V56, P462, DOI 10.1128/IAI.56.2.462-467.1988; Baumgarth N, 2017, J IMMUNOL, V199, P3387, DOI 10.4049/jimmunol.1700943; Berens SJ, 1997, INT IMMUNOL, V9, P189, DOI 10.1093/intimm/9.1.189; Bishop GA, 2001, IMMUNOL RES, V24, P97, DOI 10.1385/IR:24:2:097; Buza J, 1997, IMMUNOLOGY, V92, P226, DOI 10.1046/j.1365-2567.1997.00330.x; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Chong AS, 2018, AM J TRANSPLANT, V18, P779, DOI 10.1111/ajt.14669; Deiss TC, 2019, CELL MOL IMMUNOL, V16, P53, DOI 10.1038/cmi.2017.117; DeKosky BJ, 2015, NAT MED, V21, P86, DOI 10.1038/nm.3743; Dobbelaere DAE, 2003, CURR OPIN MICROBIOL, V6, P377, DOI 10.1016/S1369-5274(03)00085-7; Dong JH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00558; Ekman A, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-22; Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533; Elsik CG, 2016, NUCLEIC ACIDS RES, V44, pD834, DOI 10.1093/nar/gkv1077; Goldstein LD, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0551-y; Good KL, 2006, J IMMUNOL, V177, P5236, DOI 10.4049/jimmunol.177.8.5236; Guergnon J, 2006, APOPTOSIS, V11, P1263, DOI 10.1007/s10495-006-7702-6; Haakenson Jeremy K, 2019, Immunohorizons, V3, P478, DOI 10.4049/immunohorizons.1900058; Harwood Naomi E, 2010, F1000 Biol Rep, V2, P87, DOI 10.3410/B2-87; Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216; Ingram JR, 2018, ANNU REV IMMUNOL, V36, P695, DOI 10.1146/annurev-immunol-042617-053327; Jourdan M, 2009, BLOOD, V114, P5173, DOI 10.1182/blood-2009-07-235960; Juleff N, 2009, J VIROL, V83, P3626, DOI 10.1128/JVI.02613-08; Kaminski DA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00302; KEMP SJ, 1990, ANIM GENET, V21, P153, DOI 10.1111/j.1365-2052.1990.tb03220.x; KENNEDY HE, 1988, J GEN VIROL, V69, P3023, DOI 10.1099/0022-1317-69-12-3023; Klein AM, 2015, CELL, V161, P1187, DOI 10.1016/j.cell.2015.04.044; Koren S, 2018, NAT BIOTECHNOL, V36, P1174, DOI 10.1038/nbt.4277; Koti M, 2008, DEV BIOLOGICALS, V132, P307, DOI 10.1159/000317176; Koti M, 2010, MOL IMMUNOL, V47, P2119, DOI 10.1016/j.molimm.2010.02.014; Kuchen S, 2007, J IMMUNOL, V179, P5886, DOI 10.4049/jimmunol.179.9.5886; Liljavirta J, 2013, MUCOSAL IMMUNOL, V6, P942, DOI 10.1038/mi.2012.132; Liljavirta J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099808; Ma L, 2016, J IMMUNOL, V196, P4358, DOI 10.4049/jimmunol.1600158; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; McDaniel JR, 2016, NAT PROTOC, V11, P429, DOI 10.1038/nprot.2016.024; MEIROM R, 1993, VET IMMUNOL IMMUNOP, V36, P179, DOI 10.1016/0165-2427(93)90106-E; MORRISON WI, 1989, VET IMMUNOL IMMUNOP, V20, P213, DOI 10.1016/0165-2427(89)90003-2; Muir Luke, 2017, Wellcome Open Res, V2, P97, DOI 10.12688/wellcomeopenres.11386.2; NAESSENS J, 1992, EUR J IMMUNOL, V22, P1713, DOI 10.1002/eji.1830220708; Nene V, 2016, PARASITE IMMUNOL, V38, P724, DOI 10.1111/pim.12388; Newman J, 2003, J IMMUNOL METHODS, V272, P177, DOI 10.1016/S0022-1759(02)00499-4; Nguyen A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01553; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Parng CL, 1996, J IMMUNOL, V157, P5478; Pasman Y, 2016, SCAND J IMMUNOL, V84, P28, DOI 10.1111/sji.12443; Pasman Y, 2017, DEV COMP IMMUNOL, V67, P495, DOI 10.1016/j.dci.2016.08.020; Pasman Y, 2010, VET IMMUNOL IMMUNOP, V135, P306, DOI 10.1016/j.vetimm.2009.12.012; Pritchard GH, 2018, J LEUKOCYTE BIOL, V103, P269, DOI 10.1002/JLB.4MR0517-215R; Rahe MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171171; Ren JS, 2019, MOL IMMUNOL, V112, P123, DOI 10.1016/j.molimm.2019.04.026; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; REYNOLDS JD, 1983, EUR J IMMUNOL, V13, P627, DOI 10.1002/eji.1830130805; Rodriguez-Zhurbenko N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00483; Rosen BD, 2020, GIGASCIENCE, V9, DOI 10.1093/gigascience/giaa021; Saini SS, 2003, INT IMMUNOL, V15, P845, DOI 10.1093/intimm/dxg083; Saini SS, 1999, EUR J IMMUNOL, V29, P2420, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2420::AID-IMMU2420&gt;3.0.CO;2-A; Schwartz JC, 2018, IMMUNOGENETICS, V70, P317, DOI 10.1007/s00251-017-1033-3; Shamimuzzaman M, 2020, NUCLEIC ACIDS RES, V48, pD676, DOI 10.1093/nar/gkz944; Smulski CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02285; Sok D, 2017, NATURE, V548, P108, DOI 10.1038/nature23301; SPOONER RL, 1989, IMMUNOLOGY, V66, P284; Stanfield RL, 2018, ADV IMMUNOL, V137, P135, DOI 10.1016/bs.ai.2017.12.004; Stanfield RL, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf7962; Tsui C, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800060; Vadnais ML, 2016, CURR OPIN STRUC BIOL, V38, P62, DOI 10.1016/j.sbi.2016.05.004; von Schubert C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000499; Waltari E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01452; Walther S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164567; Wang F, 2013, CELL, V153, P1379, DOI 10.1016/j.cell.2013.04.049; WORTIS HH, 1995, P NATL ACAD SCI USA, V92, P3348, DOI 10.1073/pnas.92.8.3348; Xu BL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044719; Zhao YF, 2006, DEV COMP IMMUNOL, V30, P175, DOI 10.1016/j.dci.2005.06.012; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zimin AV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r42	77	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 12	2020	11								1175	10.3389/fimmu.2020.01175	http://dx.doi.org/10.3389/fimmu.2020.01175			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MD3CW	32595642	Green Published, gold			2022-12-18	WOS:000543850300001
J	Ganesan, LP; Cragg, MS; Vidarsson, G				Ganesan, Latha P.; Cragg, Mark S.; Vidarsson, Gestur			Editorial: Roles of Fc Receptors in Disease and Therapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						antibody; Fc gamma receptor (Fc gamma R); immune response; disease; therapy			[Ganesan, Latha P.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Cragg, Mark S.] Univ Southampton, Antibody & Vaccine Grp, Ctr Canc Immunol, Canc Sci,Fac Med, Southampton, Hants, England; [Vidarsson, Gestur] Univ Amsterdam, Sanquin Res & Landsteiner Lab, Dept Expt Immunohematol, Amsterdam UMC, Amsterdam, Netherlands	University System of Ohio; Ohio State University; University of Southampton; University of Amsterdam	Ganesan, LP (corresponding author), Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA.	ganesan.13@osu.edu	Vidarsson, Gestur/A-9909-2009; Cragg, Mark S/E-5965-2010	Vidarsson, Gestur/0000-0001-5621-003X; Cragg, Mark S/0000-0003-2077-089X					0	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 12	2020	11								1232	10.3389/fimmu.2020.01232	http://dx.doi.org/10.3389/fimmu.2020.01232			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MD3DH	32655559	Green Published, gold			2022-12-18	WOS:000543851400001
J	Gupta, A; Narayan, B; Kumar, S; Verma, SK				Gupta, Ankit; Narayan, Bineet; Kumar, Subodh; Verma, Shailendra Kumar			Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis	FRONTIERS IN IMMUNOLOGY			English	Article						cellular immune response; humoral immune response; LcrV-HSP70; plague; yersiniosis; Yersinia enterocolitica; Yersinia pestis; Yersinia pseudotuberculosis	HEAT-SHOCK PROTEINS; V-ANTIGEN; PROTECTIVE IMMUNITY; PNEUMONIC PLAGUE; PESTIS; IMMUNOGENICITY; ADJUVANT; SAFETY; LCRV; IMMUNIZATION	To counteract the deadly pathogens, i.e.,Y. pestis, Y. enetrocolitica, andY. pseudotuberculosis, we prepared a recombinant DNA constructlcrV-hsp70encoding the bivalent fusion protein LcrV-HSP70. ThelcrVgene ofY. pestisandhsp70domain II DNA fragment ofM. tuberculosiswere amplified by PCR. ThelcrVamplicon was first ligated in the pET vector using NcoI and BamHI restriction sites. Just downstream to thelcrVgene, thehsp70domain II was ligated using BamHI and Hind III restriction sites. The in-frame and the orientation of cloned lcrV-hsp70 were checked by restriction analysis and nucleotide sequencing. The recombinant bivalent fusion protein LcrV-HSP70 was expressed inE. coliand purified by affinity chromatography. The vaccine potential of LcrV-HSP70 fusion protein was evaluated in formulation with alum. BALB/c mice were vaccinated, and the humoral and cellular immune responses were studied. The fusion protein LcrV-HSP70 induced a strong and significant humoral immune response in comparison to control animals. We also observed a significant difference in the expression levels of IFN-gamma and TNF-alpha in LcrV-HSP70-immunized mice in comparison to control, HSP70, and LcrV groups. To test the protective efficacy of the LcrV-HSP70 fusion protein against plague and Yersiniosis, the vaccinated mice were challenged withY. pestis, Y. enterocolitica, andY. pseudotuberculosisseparately. The bivalent fusion protein LcrV-HSP70 imparted 100% protection against the plague. In the case of Yersiniosis, on day 2 post challenge, there was a significant reduction in the number of CFU ofY. enterocoliticaandY. pseudotuberculosisin the blood (CFU/ml) and the spleen (CFU/g) of vaccinated animals in comparison to the LcrV, HSP70, and control group animals.	[Gupta, Ankit; Narayan, Bineet; Kumar, Subodh; Verma, Shailendra Kumar] Def Res & Dev Estab, Div Microbiol, Gwalior, India	Defence Research & Development Organisation (DRDO); Defence Research & Development Establishment (DRDE)	Verma, SK (corresponding author), Def Res & Dev Estab, Div Microbiol, Gwalior, India.	vermask@drde.drdo.in		Kumar, Subodh/0000-0002-8764-3361	Defense Research and Development Establishment (DRDE), Ministry of Defense	Defense Research and Development Establishment (DRDE), Ministry of Defense	The necessary funding and facilities to complete these studies were provided by Defense Research and Development Establishment (DRDE), Ministry of Defense, Govt. of India.	Amemiya K, 2009, VACCINE, V27, P2220, DOI 10.1016/j.vaccine.2009.02.016; Batra L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003322; Bottone EJ, 1997, CLIN MICROBIOL REV, V10, P257, DOI 10.1128/CMR.10.2.257; Bowen W, 2019, VACCINE, V37, P5708, DOI 10.1016/j.vaccine.2019.07.103; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; Chain PSG, 2004, P NATL ACAD SCI USA, V101, P13826, DOI 10.1073/pnas.0404012101; Chiuchiolo MJ, 2006, J INFECT DIS, V194, P1249, DOI 10.1086/507644; Chu K, 2016, HUM VACC IMMUNOTHER, V12, P2334, DOI 10.1080/21645515.2016.1175261; Cornelis GR, 2002, J CELL BIOL, V158, P401, DOI 10.1083/jcb.200205077; DeBord KL, 2006, INFECT IMMUN, V74, P4910, DOI 10.1128/IAI.01860-05; Dennis DT, 2004, PEDIATR INFECT DIS J, V23, P69, DOI 10.1097/01.inf.0000106918.18570.dd; Frey SE, 2017, VACCINE, V35, P6759, DOI 10.1016/j.vaccine.2017.09.070; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; Guiyoule A, 2001, EMERG INFECT DIS, V7, P43, DOI 10.3201/eid0701.010106; Hart Mary Kate, 2012, Adv Prev Med, V2012, P731604, DOI 10.1155/2012/731604; Hauser H, 2003, METHODS, V31, P225, DOI 10.1016/S1046-2023(03)00136-1; Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006; Huang Q, 2000, J EXP MED, V191, P403, DOI 10.1084/jem.191.2.403; Huang SS, 2014, INT J NANOMED, V9, P813, DOI 10.2147/IJN.S56260; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Levy Y, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0087-z; Levy Y, 2011, VACCINE, V29, P6866, DOI 10.1016/j.vaccine.2011.07.059; Lin JS, 2010, VACCINE, V29, P357, DOI 10.1016/j.vaccine.2010.08.099; Mueller CA, 2005, SCIENCE, V310, P674, DOI 10.1126/science.1118476; Overheim KA, 2005, INFECT IMMUN, V73, P5152, DOI 10.1128/IAI.73.8.5152-5159.2005; Pechous RD, 2016, TRENDS MICROBIOL, V24, P190, DOI 10.1016/j.tim.2015.11.008; Pettersson J, 1999, MOL MICROBIOL, V32, P961, DOI 10.1046/j.1365-2958.1999.01408.x; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Prentice MB, 2007, LANCET, V369, P1196, DOI 10.1016/S0140-6736(07)60566-2; Price JL, 2013, INT J TOXICOL, V32, P327, DOI 10.1177/1091581813497405; Robert J, 2003, DEV COMP IMMUNOL, V27, P449, DOI 10.1016/S0145-305X(02)00160-X; Sing A, 2005, P NATL ACAD SCI USA, V102, P16049, DOI 10.1073/pnas.0504728102; SKRZYPEK E, 1995, J BACTERIOL, V177, P2530, DOI 10.1128/jb.177.9.2530-2542.1995; Smiley ST, 2008, EXPERT REV VACCINES, V7, P209, DOI 10.1586/14760584.7.2.209; Srivastava PK, 2001, VACCINE, V19, P2590, DOI 10.1016/S0264-410X(00)00492-8; Sun W, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0105-9; Suzue K, 1997, P NATL ACAD SCI USA, V94, P13146, DOI 10.1073/pnas.94.24.13146; Suzue K, 1996, J IMMUNOL, V156, P873; Verma S. K., 2013, Journal of Clinical and Cellular Immunology, V4, P1000151; Verma SK, 2019, VACCINE, V37, P19, DOI 10.1016/j.vaccine.2018.11.057; Verma SK, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01053; Verma SK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00602; Wang XY, 2013, EXPERT REV VACCINES, V12, P677, DOI [10.1586/erv.13.42, 10.1586/ERV.13.42]; Wang YF, 2002, J IMMUNOL, V169, P2422, DOI 10.4049/jimmunol.169.5.2422; WHO, 2005, PLAGUE, P267; Williamson ED, 2011, VACCINE, V29, P4771, DOI 10.1016/j.vaccine.2011.04.084; Williamson ED, 2009, VACCINE, V27, pD56, DOI 10.1016/j.vaccine.2009.07.068; Williamson ED, 1997, VACCINE, V15, P1079, DOI 10.1016/S0264-410X(96)00303-9	48	2	4	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 12	2020	11								988	10.3389/fimmu.2020.00988	http://dx.doi.org/10.3389/fimmu.2020.00988			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MD3AK	32595634	Green Published, gold			2022-12-18	WOS:000543843900001
J	Galgano, D; Soheili, T; Voss, M; Torralba-Raga, L; Tesi, B; Cichocki, F; Andre, I; Rettig, J; Cavazzana, M; Bryceson, Y				Galgano, Donatella; Soheili, Tayebeh; Voss, Matthias; Torralba-Raga, Lamberto; Tesi, Bianca; Cichocki, Frank; Andre, Isabelle; Rettig, Jens; Cavazzana, Marina; Bryceson, Yenan			Alternative UNC13D Promoter Encodes a Functional Munc13-4 Isoform Predominantly Expressed in Lymphocytes and Platelets	FRONTIERS IN IMMUNOLOGY			English	Article						UNC13D; primary immunodeficiency; familial hemophagocytic lymphohistiocytosis type 3; intronic mutation; alternative intronic promoter; isoform; lymphocyte cytotoxicity	TRANSCRIPTIONAL REGULATION; INTRONIC MUTATIONS; EXOCYTOSIS; PROTEINS; FUSION; LYSOSOMES; SECRETION; INVERSION; EFFECTOR; SPECTRUM	Autosomal recessive mutations in genes required for cytotoxicity are causative of a life-threatening, early-onset hyperinflammatory syndrome termed familial hemophagocytic lymphohistiocytosis (FHL). Mutations inUNC13Dcause FHL type 3.UNC13Dencodes Munc13-4, a member of the Unc13 protein family which control SNARE complex formation and vesicle fusion. We have previously identified FHL3-associated mutations in the first intron ofUNC13Dwhich control transcription from an alternative transcriptional start site. Using isoform specific antibodies, we demonstrate that this alternative Munc13-4 isoform with a unique N-terminus is preferentially expressed in human lymphocytes and platelets, as compared to the conventional isoform that was mostly expressed in monocytes and neutrophils. The distinct N-terminal of the two isoforms did not impact on Munc13-4 localization or trafficking to the immunological synapse of cytotoxic T cells. Moreover, ectopic expression of both isoforms efficiently restored exocytosis by FHL3 patient-derived Munc13-4 deficient T cells. Thus, we demonstrate that the conventional and alternative Munc13-4 isoforms have different expression pattern in hematopoietic cell subsets, but display similar localization and contribution to T cell exocytosis. The use of an alternative transcriptional starting site (TSS) in lymphocytes and platelets could be selected for increasing the overall levels of Munc13-4 expression for efficient secretory granule release.	[Galgano, Donatella; Voss, Matthias; Torralba-Raga, Lamberto; Bryceson, Yenan] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Stockholm, Sweden; [Soheili, Tayebeh; Andre, Isabelle; Cavazzana, Marina] IMAGINE Inst, UMR 1163, INSERM, Human Lymphohematopoiesis Lab, Paris, France; [Tesi, Bianca] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden; [Tesi, Bianca] Karolinska Inst, Ctr Mol Med, Dept Mol Med & Surg, Stockholm, Sweden; [Cichocki, Frank] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; [Andre, Isabelle; Cavazzana, Marina] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Paris, France; [Rettig, Jens] Saarland Univ, Ctr Integrat Physiol & Mol Med, Cellular Neurophysiol Lab, Homburg, Germany; [Cavazzana, Marina] Hop Necker Enfants Malad, Assistance Publ Hop Paris, Biotherapy Dept, Paris, France; [Cavazzana, Marina] Grp Hosp Univ Ouest, Assistance Publ Hop Paris, INSERM, Biotherapy Clin Invest Ctr, Paris, France; [Bryceson, Yenan] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway; [Soheili, Tayebeh] Smart Immune Plc, Paris, France; [Voss, Matthias] Univ Kiel, Inst Biochem, Kiel, Germany	Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Minnesota System; University of Minnesota Twin Cities; UDICE-French Research Universities; Universite Paris Cite; Universitatsklinikum des Saarlandes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Bergen; University of Kiel	Bryceson, Y (corresponding author), Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Stockholm, Sweden.; Bryceson, Y (corresponding author), Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway.	yenan.bryceson@ki.se	Andre, Isabelle/F-6263-2013; Rettig, Jens/K-5103-2013; Tesi, Bianca/AAH-6304-2021; Bryceson, Yenan/D-2121-2018	Andre, Isabelle/0000-0002-3905-9910; Rettig, Jens/0000-0001-6160-3954; Tesi, Bianca/0000-0002-8253-2507; Bryceson, Yenan/0000-0002-7783-9934; Voss, Matthias/0000-0002-4217-3175; Galgano, Donatella/0000-0003-0889-0362	European Union [794830 794830 -CL_Exocytosis]; Swedish Research Council; Swedish Foundation for Strategic Research; Swedish Cancer Foundation; Swedish Children's Cancer Foundation; Knut and Alice Wallenberg Foundation; Karolinska Institute Research Foundation; European Federation of Immunology Societies (EFIS)	European Union(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Cancer Foundation; Swedish Children's Cancer Foundation; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Karolinska Institute Research Foundation(Karolinska Institutet); European Federation of Immunology Societies (EFIS)	This project was funded by the European Union's Horizon 2020 research and innovation program under the Marie SkLodowska-Curie grant agreement No 794830 794830 -CL_Exocytosis to DG and by the Swedish Research Council, Swedish Foundation for Strategic Research, Swedish Cancer Foundation, Swedish Children's Cancer Foundation, Knut and Alice Wallenberg Foundation, the Karolinska Institute Research Foundation to YB. For the microscopy data, DG was supported by a fellowship from the European Federation of Immunology Societies (EFIS).	Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Calvo V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00684; Chehab T, 2017, MOL BIOL CELL, V28, P1688, DOI 10.1091/mbc.E17-02-0128; Cichocki F, 2014, J EXP MED, V211, P1079, DOI 10.1084/jem.20131131; Crozat K, 2007, J EXP MED, V204, P853, DOI 10.1084/jem.20062447; Davuluri RV, 2008, TRENDS GENET, V24, P167, DOI 10.1016/j.tig.2008.01.008; de la Roche M, 2016, NAT REV IMMUNOL, V16, P421, DOI 10.1038/nri.2016.54; de Saint Basile G, 2011, ANN NY ACAD SCI, V1246, P64, DOI 10.1111/j.1749-6632.2011.06307.x; de Saint Basile G, 2010, NAT REV IMMUNOL, V10, P568, DOI 10.1038/nri2803; Dustin ML, 2012, J CLIN INVEST, V122, P1149, DOI 10.1172/JCI58705; Elstak ED, 2011, BLOOD, V118, P1570, DOI 10.1182/blood-2011-02-339523; Entesarian M, 2013, BRIT J HAEMATOL, V162, P415, DOI 10.1111/bjh.12371; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Higashio H, 2008, J IMMUNOL, V180, P4774, DOI 10.4049/jimmunol.180.7.4774; Johnson JL, 2016, J BIOL CHEM, V291, P3423, DOI 10.1074/jbc.M115.705871; Kohn RE, 2000, MOL BIOL CELL, V11, P3441, DOI 10.1091/mbc.11.10.3441; Mace EM, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00421; Man KNM, 2015, ELIFE, V4, DOI 10.7554/eLife.10635; Marshall MR, 2015, J CELL BIOL, V210, P135, DOI 10.1083/jcb.201411093; Meeths M, 2014, EXP CELL RES, V325, P10, DOI 10.1016/j.yexcr.2014.03.014; Meeths M, 2011, BLOOD, V118, P5783, DOI 10.1182/blood-2011-07-369090; Menager MM, 2007, NAT IMMUNOL, V8, P257, DOI 10.1038/ni1431; Messenger SW, 2018, J CELL BIOL, V217, P2877, DOI 10.1083/jcb.201710132; Neeft M, 2005, MOL BIOL CELL, V16, P731, DOI 10.1091/mbc.E04-10-0923; Qian YP, 2014, PEDIATR BLOOD CANCER, V61, P1034, DOI 10.1002/pbc.24955; Ren QS, 2010, BLOOD, V116, P869, DOI 10.1182/blood-2010-02-270934; Rodarte EM, 2018, J BIOL CHEM, V293, P345, DOI 10.1074/jbc.M117.816884; Rudd E, 2008, J MED GENET, V45, P134, DOI 10.1136/jmg.2007.054288; Schulert GS, 2018, ARTHRITIS RHEUMATOL, V70, P963, DOI 10.1002/art.40438; Seo JY, 2013, ANN HEMATOL, V92, P357, DOI 10.1007/s00277-012-1628-6; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Singh RK, 2013, FEBS J, V280, P892, DOI 10.1111/febs.12081; Sleiman M, 2017, METHODS MOL BIOL, V1584, P157, DOI 10.1007/978-1-4939-6881-7_11; Soheili T, 2017, BLOOD ADV, V1, P2781, DOI 10.1182/bloodadvances.2017012088; Soheili T, 2016, BLOOD, V128, P2859, DOI 10.1182/blood-2016-07-729871; Sudhof T. C., 2011, CSH PERSPECT BIOL, V3, P3, DOI DOI 10.1101/CSHPERSPECT.A005637; Vacik T, 2017, PROTOPLASMA, V254, P1201, DOI 10.1007/s00709-016-1071-y; Vacik T, 2011, GENE DEV, V25, P1783, DOI 10.1101/gad.17227011; Wang YN, 2017, CURR OPIN HEMATOL, V24, P54, DOI 10.1097/MOH.0000000000000302; Woo SS, 2017, MOL BIOL CELL, V28, P792, DOI 10.1091/mbc.E16-08-0617; Wood SM, 2009, BLOOD, V114, P4117, DOI 10.1182/blood-2009-06-225359; Zhang JZ, 2019, AUTOPHAGY, V15, P1738, DOI 10.1080/15548627.2019.1596475; Zhou KM, 2013, ELIFE, V2, DOI 10.7554/eLife.01180	47	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2020	11								1154	10.3389/fimmu.2020.01154	http://dx.doi.org/10.3389/fimmu.2020.01154			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC6BO	32582217	gold, Green Published			2022-12-18	WOS:000543370100001
J	Gress, K; Bass, JA; Funk, RS; Morrow, RP; Hasenkamp, R; Shakhnovich, V				Gress, Kyle; Bass, Julie A.; Funk, Ryan S.; Morrow, Ryan P.; Hasenkamp, Rachel; Shakhnovich, Valentina			Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunogenicity; children; inflammatory bowel disease; TNF-alpha; infliximab; adalimumab; biologics; anti-drug antibodies	CROHNS-DISEASE; ANTIBODY PHARMACOKINETICS; DOSE INTENSIFICATION; INFLIXIMAB; CHILDREN; THERAPY		[Gress, Kyle] Georgetown Univ, Sch Med, Washington, DC USA; [Bass, Julie A.; Morrow, Ryan P.; Hasenkamp, Rachel; Shakhnovich, Valentina] Univ Missouri, Sch Med, Dept Pediat, Kansas City, MO 64108 USA; [Bass, Julie A.; Morrow, Ryan P.; Hasenkamp, Rachel; Shakhnovich, Valentina] Childrens Mercy Kansas City, Kansas City, MO 64108 USA; [Funk, Ryan S.] Univ Kansas, Med Ctr, Dept Pharm Practice, Kansas City, KS 66103 USA	Georgetown University; University of Missouri System; University of Missouri Kansas City; Children's Mercy Hospital; University of Kansas; University of Kansas Medical Center	Shakhnovich, V (corresponding author), Univ Missouri, Sch Med, Dept Pediat, Kansas City, MO 64108 USA.; Shakhnovich, V (corresponding author), Childrens Mercy Kansas City, Kansas City, MO 64108 USA.	vshakhnovich@cmh.edu		Gress, Kyle/0000-0002-9142-2553	CTSA [KL2TR002367]; NIGMS: COBRE grant [P20GM130423];  [NCATS: L40 TR000598]	CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIGMS: COBRE grant; 	Support for this work was provided, in part, through NCATS: L40 TR000598 (VS PI) and CTSA (#KL2TR002367) awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute (RF PI), and NIGMS: COBRE grant (#P20GM130423) awarded to the Kansas Institute for Precision Medicine (RF PI).	AbbVie HUMIRA (adalimumab) injection solution for subcutaneous use, 2008, HDB THER ANTIBODIES, V3, P696, DOI [10.1002/9783527619740.ch27, DOI 10.1002/9783527619740.CH27]; Alten R, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2018-000876; [Anonymous], 1997, PUBLICACIONES ARQUEO, V50, P1; Bendtzen K, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00109; BUTTE NF, 1995, AM J CLIN NUTR, V62, P1047; Curci D, 2019, J PEDIATR GASTR NUTR, V69, P474, DOI 10.1097/MPG.0000000000002410; Fasanmade AA, 2011, CLIN THER, V33, P946, DOI 10.1016/j.clinthera.2011.06.002; Fasanmade AA, 2009, EUR J CLIN PHARMACOL, V65, P1211, DOI 10.1007/s00228-009-0718-4; Gisbert JP, 2009, AM J GASTROENTEROL, V104, P760, DOI 10.1038/ajg.2008.88; Goldman JL, 2012, ANN PAEDIAT RHEUM, V1, P120, DOI DOI 10.5455/apr.042120121033; Gunn GR, 2016, CLIN EXP IMMUNOL, V184, P137, DOI 10.1111/cei.12742; Kang E, 2018, PEDIATR GASTROENTERO, V21, P329, DOI 10.5223/pghn.2018.21.4.329; Kothari Mansi M, 2017, World J Gastrointest Pharmacol Ther, V8, P155, DOI 10.4292/wjgpt.v8.i3.155; Lee SK, 2014, PHARMACOLOGY, V93, P225, DOI 10.1159/000362562; Levitt DG, 2017, CLIN EXP GASTROENTER, V10, P147, DOI 10.2147/CEG.S136803; Lila AM, 2019, RHEUMATOL INT, V39, P1537, DOI 10.1007/s00296-019-04359-9; Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178; Mitrev N, 2017, ALIMENT PHARM THER, V46, P1037, DOI 10.1111/apt.14368; Ordas I, 2012, CLIN PHARMACOL THER, V91, P635, DOI 10.1038/clpt.2011.328; Rosen MJ, 2015, JAMA PEDIATR, V169, P1053, DOI 10.1001/jamapediatrics.2015.1982; Schellekens H, 2005, NEPHROL DIAL TRANSPL, V20, P3, DOI 10.1093/ndt/gfh1092; Shakhnovich V, 2020, CTS-CLIN TRANSL SCI, V13, P219, DOI 10.1111/cts.12717; Smolen JS, 2017, RHEUMATOLOGY, V56, P1771, DOI 10.1093/rheumatology/kex254; Steenholdt C, 2014, GUT, V63, P919, DOI 10.1136/gutjnl-2013-305279; Steenholdt C, 2013, THER DRUG MONIT, V35, P530, DOI 10.1097/FTD.0b013e31828d23c3; Strand V, 2017, BIODRUGS, V31, P299, DOI 10.1007/s40259-017-0231-8; U.S. HHS FDA, 2014, GUID IND IMM ASS THE; Vande Casteele N, 2017, FRONTLINE GASTROENTE, V8, P236, DOI 10.1136/flgastro-2016-100692; Vasudevan A, 2019, INFLAMM BOWEL DIS, V25, P1462, DOI 10.1093/ibd/izy399; VERMEIRE S, 2018, THERAP ADV GASTROENT, V11, P1, DOI DOI 10.1177/1756283X17750355; Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170; Yoo DH, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-0981-6; Zitomersky NL, 2015, INFLAMM BOWEL DIS, V21, P307, DOI 10.1097/MIB.0000000000000284	33	2	2	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2020	11								1148	10.3389/fimmu.2020.01148	http://dx.doi.org/10.3389/fimmu.2020.01148			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC6AX	32582213	Green Published, gold			2022-12-18	WOS:000543368400001
J	Pelst, MP; Hobart, C; Wallaeys, C; De Rooster, H; Gansemans, Y; Van Nieuwerburgh, F; Devriendt, B; Cox, E				Pelst, Michael P.; Hoebart, Clara; Wallaeys, Charlotte; De Rooster, Hilde; Gansemans, Yannick; Van Nieuwerburgh, Flip; Devriendt, Bert; Cox, Eric			Adjuvanting Allergen Extracts for Sublingual Immunotherapy: Calcitriol Downregulates CXCL8 Production in Primary Sublingual Epithelial Cells	FRONTIERS IN IMMUNOLOGY			English	Article						sublingual; epithelium; Dermatophagoides farinae; Toll-like receptor; calcitriol; CXCL8; dog; sublingual immunotherapy	HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; ANTIGEN-SPECIFIC TOLERANCE; KERATINOCYTE STEM-CELLS; CYTOKINE PRODUCTION; RECEPTOR 2; VITAMIN-D; CANINE KERATINOCYTES; DENDRITIC CELLS; RELEASE	Application of allergens onto the sublingual epithelium is used to desensitize allergic individuals, a treatment known as sublingual immunotherapy. However, the response of sublingual epithelial cells to house dust mite allergen and potential tolerance-promoting adjuvants such as Toll-like receptor (TLR) ligands and calcitriol has not been investigated. In order to study this, primary sublingual epithelial cells were isolated from dogs and culturedin vitro. After 24-h incubation with aDermatophagoides farinaeextract, aDermatophagoides pteronyssinusextract, TLR2 ligands (FSL-1, heat-killed Listeria monocytogenes, Pam3CSK4), a TLR3 ligand (poly I:C), a TLR4 ligand [lipopolysaccharide (LPS)], and calcitriol (1,25-dihydroxyvitamin D-3), viability of the cells was analyzed using an MTT test, and their secretion of interleukin 6 (IL-6), IL-10, CXCL8, and transforming growth factor beta 1 (TGF-beta 1) was measured by enzyme-linked immunosorbent assay. Additionally, to evaluate its potential effect as an adjuvant, sublingual epithelial cells were incubated with calcitriol in combination with aD. farinaeextract followed by measurement of CXCL8 secretion. Furthermore, the effect ofD. farinaeand calcitriol on the transcriptome was assessed by RNA sequencing. The viability of the sublingual epithelial cells was significantly decreased by poly I:C, but not by the other stimuli. CXCL8 secretion was significantly increased byD. farinaeextract and all TLR ligands apart from LPS. Calcitriol significantly decreased CXCL8 secretion, and coadministration withD. farinaeextract reduced CXCL8 concentrations to levels seen in unstimulated sublingual epithelial cells. Although detectable, TGF-beta 1 secretion could not be modulated by any of the stimuli. Interleukin 6 and IL-10 could not be detected at the protein or at the mRNA level. It can be concluded that aD. farinaeextract and TLR ligands augment the secretion of the proinflammatory chemokine CXCL8, which might interfere with sublingual desensitization. On the other hand, CXCL8 secretion was reduced by coapplication of calcitriol and aD. farinaeextract. Calcitriol therefore seems to be a suitable candidate to be used as adjuvant during sublingual immunotherapy.	[Pelst, Michael P.; Devriendt, Bert; Cox, Eric] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Lab Immunol, Merelbeke, Belgium; [Hoebart, Clara] Med Univ Vienna, Ctr Physiol & Pharmacol, Vienna, Austria; [Wallaeys, Charlotte] VIB Ctr Inflammat Res, Ghent, Belgium; [Wallaeys, Charlotte] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium; [De Rooster, Hilde] Univ Ghent, Fac Vet Med, Small Anim Dept, Merelbeke, Belgium; [Gansemans, Yannick; Van Nieuwerburgh, Flip] Univ Ghent, Lab Pharmaceut Biotechnol, Fac Pharmaceut Sci, Ghent, Belgium	Ghent University; Medical University of Vienna; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University; Ghent University	Cox, E (corresponding author), Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Lab Immunol, Merelbeke, Belgium.	eric.cox@ugent.be	Van Nieuwerburgh, Filip/H-9697-2015; de Rooster, Hilde/AAX-9497-2020; Devriendt, Bert/AAM-6666-2021	Van Nieuwerburgh, Filip/0000-0001-8815-5485; de Rooster, Hilde/0000-0001-8087-256X; Devriendt, Bert/0000-0002-3222-8769; Pelst, Michael/0000-0002-1779-4738; Hoebart, Clara/0000-0001-7165-7104; Gansemans, Yannick/0000-0001-5018-044X; Cox, Eric/0000-0003-4281-2990	PhD Fellowship of the Research Foundation - Flanders [FWO - 1S23718N]; Research Foundation - Flanders	PhD Fellowship of the Research Foundation - Flanders; Research Foundation - Flanders(FWO)	This study was funded by a PhD Fellowship of the Research Foundation - Flanders (FWO - 1S23718N). BD is supported by a postdoctoral grant of the Research Foundation - Flanders.	Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Allam JP, 2008, ALLERGY, V63, P720, DOI 10.1111/j.1398-9995.2007.01611.x; Arlian LG, 2011, INT ARCH ALLERGY IMM, V156, P171, DOI 10.1159/000323351; Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; BARKER JNWN, 1991, AM J PATHOL, V139, P869; Calderon MA, 2015, J ALLER CL IMM-PRACT, V3, P843, DOI 10.1016/j.jaip.2015.06.019; Calenic B, 2010, J PERIODONTAL RES, V45, P703, DOI 10.1111/j.1600-0765.2010.01284.x; Chermprapai S, 2018, VET IMMUNOL IMMUNOP, V206, P35, DOI 10.1016/j.vetimm.2018.11.009; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Choi HJ, 2015, ALLERGY, V70, P1569, DOI 10.1111/all.12764; Divekar R, 2015, CURR OPIN ALLERGY CL, V15, P98, DOI 10.1097/ACI.0000000000000133; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Gniadecki R, 1996, J INVEST DERMATOL, V106, P510, DOI 10.1111/1523-1747.ep12343866; GREWE M, 1995, J INVEST DERMATOL, V104, P3, DOI 10.1111/1523-1747.ep12613446; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hill PB, 2001, VET IMMUNOL IMMUNOP, V81, P169, DOI 10.1016/S0165-2427(01)00298-7; Ibisch C, 2007, VET RES COMMUN, V31, P835, DOI 10.1007/s11259-007-0004-9; Jang YH, 2017, J INVEST DERMATOL, V137, P2354, DOI 10.1016/j.jid.2017.03.042; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Kang SW, 2012, J IMMUNOL, V188, P5276, DOI 10.4049/jimmunol.1101211; Kawahara K, 2015, BBA-MOL CELL BIOL L, V1851, P414, DOI 10.1016/j.bbalip.2014.07.008; Kieckens E, 2017, VET MICROBIOL, V202, P29, DOI 10.1016/j.vetmic.2016.03.013; Klukowska-Rotzler J, 2013, VET DERMATOL, V24, P54, DOI 10.1111/j.1365-3164.2012.01096.x; Koizumi Y, 2016, ALLERGOL INT, V65, pS30, DOI 10.1016/j.alit.2016.05.006; Kondo M, 2014, J BIOMED MATER RES A, V102, P1829, DOI 10.1002/jbm.a.34849; Lehmann B, 2004, EXP DERMATOL, V13, P11, DOI 10.1111/j.1600-0625.2004.00257.x; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Lian LH, 2012, J INVEST DERMATOL, V132, P1346, DOI 10.1038/jid.2011.482; Lombardi V, 2008, CLIN EXP ALLERGY, V38, P1819, DOI 10.1111/j.1365-2222.2008.03056.x; Correa APFL, 2007, VET PARASITOL, V143, P267, DOI 10.1016/j.vetpar.2006.08.023; Lutay N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086466; Maeda S, 2009, VET IMMUNOL IMMUNOP, V131, P298, DOI 10.1016/j.vetimm.2009.04.012; Maina E, 2016, VET DERMATOL, V27, P361, DOI 10.1111/vde.12358; MANNING AM, 1995, GENE, V155, P307, DOI 10.1016/0378-1119(94)00903-6; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; MATSUMOTO K, 1991, BIOCHIM BIOPHYS ACTA, V1092, P311, DOI 10.1016/S0167-4889(97)90006-9; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Moingeon P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/623474; Molero-Abraham M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01434; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Murakami Daisuke, 2006, J Artif Organs, V9, P185, DOI 10.1007/s10047-006-0342-3; Park WJ, 2015, ARCH VIROL, V160, P1397, DOI 10.1007/s00705-015-2395-1; Pedersen AE, 2004, IMMUNOL LETT, V91, P63, DOI 10.1016/j.imlet.2003.11.004; R Core Team, 2019, R LANG ENV STAT COMP; Radulovic Suzana, 2010, Cochrane Database Syst Rev, pCD002893, DOI 10.1002/14651858.CD002893.pub2; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Russo RC, 2014, EXPERT REV CLIN IMMU, V10, P593, DOI 10.1586/1744666X.2014.894886; Sakamoto M, 2016, VET DERMATOL, V27, P184, DOI 10.1111/vde.12301; Santoro D, 2015, EXP DERMATOL, V24, P317, DOI 10.1111/exd.12660; Satitsuksanoa P, 2016, ALLERGY, V71, P1425, DOI 10.1111/all.12899; Schmidt LM, 2011, J IMMUNOL, V186, P2095, DOI 10.4049/jimmunol.1002414; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shibata S, 2008, J VET MED SCI, V70, P853, DOI 10.1292/jvms.70.853; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Taylor RC, 2006, J ALLERGY CLIN IMMUN, V117, P1148, DOI 10.1016/j.jaci.2006.02.014; Thirion-Delalande C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183398; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Van Overtvelt L, 2008, INT ARCH ALLERGY IMM, V145, P152, DOI 10.1159/000108140; White AG, 2014, VET DERMATOL, V25, P493, DOI 10.1111/vde.12164; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Yamazoe K, 2007, J VET MED SCI, V69, P611, DOI 10.1292/jvms.69.611; Zhang D, 2013, INT J MOL MED, V32, P203, DOI 10.3892/ijmm.2013.1353	66	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2020	11								1033	10.3389/fimmu.2020.01033	http://dx.doi.org/10.3389/fimmu.2020.01033			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC5XH	32582164	Green Published, gold			2022-12-18	WOS:000543359000001
J	Van Bockstal, L; Bulte, D; Van den Kerkhof, M; Dirkx, L; Mabille, D; Hendrickx, S; Delputte, P; Maes, L; Caljon, G				Van Bockstal, Lieselotte; Bulte, Dimitri; Van den Kerkhof, Magali; Dirkx, Laura; Mabille, Dorien; Hendrickx, Sarah; Delputte, Peter; Maes, Louis; Caljon, Guy			Interferon Alpha Favors Macrophage Infection by Visceral Leishmania Species Through Upregulation of Sialoadhesin Expression	FRONTIERS IN IMMUNOLOGY			English	Article						Leishmania; sialoadhesin; CD169; macrophages; IFN-alpha; type I IFN	INNATE IMMUNE-RESPONSE; SIALIC ACIDS; ANTIBODY-BINDING; I INTERFERONS; IDENTIFICATION; RESIDENT; SIGLECS; MICE; PROTECTION; MONOCYTES	Type I interferons (IFNs) induced by an endogenousLeishmaniaRNA virus or exogenous viral infections have been shown to exacerbate infections with New World CutaneousLeishmaniaparasites, however, the impact of type I IFNs in visceralLeishmaniainfections and implicated mechanisms remain to be unraveled. This study assessed the impact of type I IFN on macrophage infection withL. infantumandL. donovaniand the implication of sialoadhesin (Siglec-1/CD169, Sn) as an IFN-inducible surface receptor. Stimulation of bone marrow-derived macrophages with type I IFN (IFN-alpha) significantly enhanced susceptibility to infection of reference laboratory strains and a set of recent clinical isolates. IFN-alpha particularly enhanced promastigote uptake. Enhanced macrophage susceptibility was linked to upregulated Sn surface expression as a major contributing factor to the infection exacerbating effect of IFN-alpha. Stimulation experiments in Sn-deficient macrophages, macrophage pretreatment with a monoclonal anti-Sn antibody or a novel bivalent anti-Sn nanobody and blocking of parasites with soluble Sn restored normal susceptibility levels. Infection of Sn-deficient mice with bioluminescentL. infantumpromastigotes revealed a moderate, strain-dependent role for Sn during visceral infection under the used experimental conditions. These data indicate that IFN-responsive Sn expression can enhance the susceptibility of macrophages to infection with visceralLeishmaniapromastigotes and that targeting of Sn may have some protective effects in early infection.	[Van Bockstal, Lieselotte; Bulte, Dimitri; Van den Kerkhof, Magali; Dirkx, Laura; Mabille, Dorien; Hendrickx, Sarah; Delputte, Peter; Maes, Louis; Caljon, Guy] Univ Antwerp, Fac Pharmaceut Biomed & Vet Sci, Lab Microbiol Parasitol & Hyg LMPH, Antwerp, Belgium	University of Antwerp	Caljon, G (corresponding author), Univ Antwerp, Fac Pharmaceut Biomed & Vet Sci, Lab Microbiol Parasitol & Hyg LMPH, Antwerp, Belgium.	guy.caljon@uantwerpen.be	Delputte, Peter/A-1062-2008	Delputte, Peter/0000-0003-3972-616X; VAN BOCKSTAL, Lieselotte/0000-0002-8882-8261; Mabille, Dorien/0000-0003-3530-0567; Bulte, Dimitri/0000-0002-2783-4860	Fonds Wetenschappelijk Onderzoek (FWO, Belgium); DOCPRO4 Ph.D. fellowship of the UA [33265]; UA research funds [TT-ZAPBOF 33049, TOP-BOF 35017]; FWO [1136417N]	Fonds Wetenschappelijk Onderzoek (FWO, Belgium)(FWO); DOCPRO4 Ph.D. fellowship of the UA; UA research funds; FWO(FWO)	This project was supported by the Fonds Wetenschappelijk Onderzoek (FWO, Belgium). LV is a Ph.D. fellow of the FWO (1136417N). DB is supported by a DOCPRO4 Ph.D. fellowship of the UA (33265). GC is supported by UA research funds (TT-ZAPBOF 33049 and TOP-BOF 35017). LMPH is a partner of Excellence Center Infla-Med (www.uantwerpen.be/infla-med).	Abongomera C, 2017, CLIN INFECT DIS, V65, P1703, DOI 10.1093/cid/cix607; Adaui V, 2016, J INFECT DIS, V213, P112, DOI 10.1093/infdis/jiv354; Agallou M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02749; Akiyama H, 2017, J VIROL, V91, DOI 10.1128/JVI.00972-17; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Atayde VD, 2019, NAT MICROBIOL, V4, P714, DOI 10.1038/s41564-018-0352-y; Beattie L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000805; Chang YC, 2014, J MOL MED, V92, P951, DOI 10.1007/s00109-014-1157-y; Chang YC, 2014, GLYCOBIOLOGY, V24, P818, DOI 10.1093/glycob/cwu067; Chatterjee M, 2003, GLYCOBIOLOGY, V13, P351, DOI 10.1093/glycob/cwg027; Chava AK, 2004, BIOL CHEM, V385, P59, DOI 10.1515/BC.2004.008; Chow A, 2013, NAT MED, V19, P429, DOI 10.1038/nm.3057; Chow A, 2011, J EXP MED, V208, P261, DOI 10.1084/jem.20101688; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Davies LC, 2013, NAT IMMUNOL, V14, P986, DOI 10.1038/ni.2705; De Baere MI, 2011, CELL IMMUNOL, V271, P462, DOI 10.1016/j.cellimm.2011.08.016; De Schryver M, 2017, CELL IMMUNOL, V312, P51, DOI 10.1016/j.cellimm.2016.11.009; De Schryver M, 2016, ANTIBODIES, V5, DOI 10.3390/antib5020007; Delputte PL, 2007, J INTERF CYTOK RES, V27, P757, DOI 10.1089/jir.2007.0001; Eberhardt E, 2019, J ANTIMICROB CHEMOTH, V74, P395, DOI 10.1093/jac/dky450; Engwerda CR, 2002, AM J PATHOL, V161, P429, DOI 10.1016/S0002-9440(10)64199-5; Ercoli G, 2018, NAT MICROBIOL, V3, P600, DOI 10.1038/s41564-018-0147-1; Eren RO, 2016, CELL HOST MICROBE, V20, P318, DOI 10.1016/j.chom.2016.08.001; Fontana MF, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006046; Gardinassi LG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005123; Grybchuk D, 2018, P NATL ACAD SCI USA, V115, pE506, DOI 10.1073/pnas.1717806115; Gupta P, 2016, CELL REP, V16, P1749, DOI 10.1016/j.celrep.2016.07.010; Hajjaran H, 2016, ARCH VIROL, V161, P3385, DOI 10.1007/s00705-016-3044-z; Hartley MA, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00099; Hartnell A, 2001, BLOOD, V97, P288, DOI 10.1182/blood.V97.1.288; Heikema AP, 2013, INFECT IMMUN, V81, P2095, DOI 10.1128/IAI.01437-12; Hendrickx S, 2015, PARASITOL RES, V114, P2561, DOI 10.1007/s00436-015-4460-9; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326; Kamhawi S, 2006, TRENDS PARASITOL, V22, P439, DOI 10.1016/j.pt.2006.06.012; Kariyawasam R, 2017, J INFECT DIS, V216, P877, DOI 10.1093/infdis/jix416; Kaur S, 2018, BLOOD, V132, P735, DOI 10.1182/blood-2018-01-829663; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Khatua B, 2013, INDIAN J MED RES, V138, P648; Lantier L, 2014, J INFECT DIS, V209, P457, DOI 10.1093/infdis/jit432; Machelart A, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00115-17; Martinez-Picado J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12412; Mattner J, 2004, J IMMUNOL, V172, P7574, DOI 10.4049/jimmunol.172.12.7574; Mattner J, 2000, EUR J IMMUNOL, V30, P2257, DOI 10.1002/1521-4141(2000)30:8&lt;2257::AID-IMMU2257&gt;3.0.CO;2-U; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Monteiro VG, 2005, PARASITOL RES, V97, P380, DOI 10.1007/s00436-005-1460-1; Oetke C, 2006, MOL CELL BIOL, V26, P1549, DOI 10.1128/MCB.26.4.1549-1557.2006; Parmentier L, 2016, AM J TROP MED HYG, V94, P840, DOI 10.4269/ajtmh.15-0803; Perez OA, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aah5520; Perez-Zsolt D, 2019, NAT MICROBIOL, V4, P1558, DOI 10.1038/s41564-019-0453-2; Phillips R, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000813; Pino M, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0160-x; Preham O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02958; Quirino GFS, 2016, INFECT IMMUN, V84, P2289, DOI 10.1128/IAI.00283-16; Rossi M, 2017, P NATL ACAD SCI USA, V114, P4987, DOI 10.1073/pnas.1621447114; Roy S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004904; Sarasin-Filipowicz M, 2009, MOL CELL BIOL, V29, P4841, DOI 10.1128/MCB.00224-09; Schleicher U, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00079; Tegazzini D, 2016, ANTIMICROB AGENTS CH, V60, P3524, DOI 10.1128/AAC.01781-15; Ueno N, 2012, TRENDS PARASITOL, V28, P335, DOI 10.1016/j.pt.2012.05.002; Van den Kerkhof M, 2018, PARASITOL RES, V117, P3601, DOI 10.1007/s00436-018-6059-4; York MR, 2007, ARTHRITIS RHEUM-US, V56, P1010, DOI 10.1002/art.22382	64	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2020	11								1113	10.3389/fimmu.2020.01113	http://dx.doi.org/10.3389/fimmu.2020.01113			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC5XW	32582193	gold, Green Published			2022-12-18	WOS:000543360500001
J	Blumenthal, A; Martin-Orozco, E; McBride, JW; Carson, DA; Sen, M				Blumenthal, Antje; Martin-Orozco, Elena; McBride, Jere W.; Carson, Dennis A.; Sen, Malini			Editorial: Wnt Signaling in Immune Cell Regulation During Microbial Infection and Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						WNT; immunity; infection; microbe; pathogen; tumor			[Blumenthal, Antje] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia; [Martin-Orozco, Elena] Univ Murcia, Murcia BioHlth Res Inst IMIB, Dept Biochem & Mol Biol & Immunol B, Murcia, Spain; [McBride, Jere W.] Univ Texas Med Branch, Dept Pathol, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA; [McBride, Jere W.] Univ Texas Med Branch, Dept Microbiol & Immunol, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA; [Carson, Dennis A.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Sen, Malini] Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder, Kolkata, India	University of Queensland; University of Murcia; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of California System; University of California San Diego; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Blumenthal, A (corresponding author), Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia.; Martin-Orozco, E (corresponding author), Univ Murcia, Murcia BioHlth Res Inst IMIB, Dept Biochem & Mol Biol & Immunol B, Murcia, Spain.; McBride, JW (corresponding author), Univ Texas Med Branch, Dept Pathol, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA.; McBride, JW (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA.; Carson, DA (corresponding author), Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.; Sen, M (corresponding author), Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder, Kolkata, India.	a.blumenthal@uq.edu.au; emartin@um.es; jemcbrid@utmb.edu; dcarson@ucsd.edu; msen648@gmail.com	Martin-Orozco, Elena/C-2553-2008	Martin-Orozco, Elena/0000-0002-6303-481X					0	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 5	2020	11								1133	10.3389/fimmu.2020.01133	http://dx.doi.org/10.3389/fimmu.2020.01133			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC5YO	32582205	gold, Green Published			2022-12-18	WOS:000543362300001
J	Gericke, C; Mallone, A; Engelhardt, B; Nitsch, RM; Ferretti, MT				Gericke, Christoph; Mallone, Anna; Engelhardt, Britta; Nitsch, Roger M.; Ferretti, Maria Teresa			Oligomeric Forms of Human Amyloid-Beta(1-42) Inhibit Antigen Presentation	FRONTIERS IN IMMUNOLOGY			English	Article						Alzheimer's Disease; antigen presentation; amyloid-beta (A beta) 1-42; microglia; CNS border-associated macrophages; CNS dendritic cells; T-cell activation and proliferation	T-CELLS; DENDRITIC CELLS; CEREBROSPINAL-FLUID; MOUSE MODEL; IN-VIVO; A-BETA; ALZHEIMERS; DISEASE; SYSTEM; BRAIN	Genetic, clinical, biochemical and histochemical data indicate a crucial involvement of inflammation in Alzheimer's disease (AD), but harnessing the immune system to cure or prevent AD has so far proven difficult. Clarifying the cellular heterogeneity and signaling pathways associated with the presence of the AD hallmarks beta-amyloid and tau in the brain, would help to identify potential targets for therapy. While much attention has been so far devoted to microglia and their homeostatic phagocytic activity, additional cell types and immune functions might be affected in AD. Beyond microglia localized in the brain parenchyma, additional antigen-presenting cell (APC) types might be affected by beta-amyloid toxicity. Here, we investigated potential immunomodulatory properties of oligomeric species of beta-amyloid-peptide (A beta) on microglia and putative APCs. We performed a comprehensive characterization of time- and pathology-dependent APC and T-cell alterations in a model of AD-like brain beta-amyloidosis, the APP-PS1-dE9 mouse model. We show that the deposition of first beta-amyloid plaques is accompanied by a significant reduction in MHC class II surface levels on brain APCs. Furthermore, taking advantage of customizedin vitrosystems and RNAseq, we demonstrate that a preparation containing various forms of oligomeric A beta 1-42 inhibits antigen presentation by altering the transcription of key immune mediators in dendritic cells. These results suggest that, beyond their neurotoxic effects, certain oligomeric A beta forms can act as immunomodulatory agents on cerebral APCs and interfere with brain antigen presentation. Impaired brain immune surveillance might be one of the factors that facilitate A beta and tau spreading in AD.	[Gericke, Christoph; Mallone, Anna; Nitsch, Roger M.; Ferretti, Maria Teresa] Univ Zurich, Inst Regenerat Med IREM, Schlieren, Switzerland; [Gericke, Christoph; Mallone, Anna; Nitsch, Roger M.; Ferretti, Maria Teresa] Zurich Neurosci Ctr ZNZ, Zurich, Switzerland; [Engelhardt, Britta] Univ Bern, Theodor Kocher Inst, Bern, Switzerland; [Nitsch, Roger M.] Neurimmune AG, Schlieren, Switzerland	University of Bern	Gericke, C (corresponding author), Univ Zurich, Inst Regenerat Med IREM, Schlieren, Switzerland.; Gericke, C (corresponding author), Zurich Neurosci Ctr ZNZ, Zurich, Switzerland.	christoph.gericke@irem.uzh.ch	Ferretti, Maria Teresa/GLR-0567-2022	Mallone, Anna/0000-0002-7949-9718; Gericke, Christoph/0000-0002-1196-7466	Synapsis Foundation-Alzheimer Research Switzerland; Fidelity Bermuda Foundation	Synapsis Foundation-Alzheimer Research Switzerland; Fidelity Bermuda Foundation	This work was supported by the Synapsis Foundation-Alzheimer Research Switzerland (grant: 'Impaired immune surveillance in Alzheimer's disease: studies on pre-clinical transgenic models and patient-derived samples'). BE was supported by the Fidelity Bermuda Foundation.	Absinta M, 2017, ELIFE, V6, DOI 10.7554/eLife.29738; Ahn JH, 2019, NATURE, V572, P62, DOI 10.1038/s41586-019-1419-5; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bayer AJ, 2005, NEUROLOGY, V64, P94, DOI 10.1212/01.WNL.0000148604.77591.67; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Da Mesquita S, 2018, NATURE, V560, P185, DOI 10.1038/s41586-018-0368-8; De Riva A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00399; Dubrot J, 2014, J EXP MED, V211, P1153, DOI 10.1084/jem.20132000; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Engelhardt B, 2017, NAT IMMUNOL, V18, P123, DOI 10.1038/ni.3666; Esparza EM, 2005, J IMMUNOL, V174, P7875, DOI 10.4049/jimmunol.174.12.7875; Ethell DW, 2006, NEUROBIOL DIS, V23, P351, DOI 10.1016/j.nbd.2006.03.008; Ferretti MT, 2016, BRAIN BEHAV IMMUN, V54, P211, DOI 10.1016/j.bbi.2016.02.009; Ferretti MT, 2012, NEUROBIOL AGING, V33, P1329, DOI 10.1016/j.neurobiolaging.2011.01.007; Fisher Y, 2014, J IMMUNOL, V192, P92, DOI 10.4049/jimmunol.1301707; Garber C, 2019, NAT NEUROSCI, V22, P1276, DOI 10.1038/s41593-019-0427-y; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hawkes Cheryl A, 2007, Expert Rev Neurother, V7, P1535, DOI 10.1586/14737175.7.11.1535; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Izzo NJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111898; Jankowska KI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00025; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Krabbe G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060921; Krawczyk M, 2006, TISSUE ANTIGENS, V67, P183, DOI 10.1111/j.1399-0039.2006.00557.x; Kunkle BW, 2019, NAT GENET, V51, P414, DOI 10.1038/s41588-019-0358-2; Kunkle BW, 2017, JAMA NEUROL, V74, P1113, DOI 10.1001/jamaneurol.2017.1518; Lacal PM, 2013, J PHARMACOL EXP THER, V347, P164, DOI 10.1124/jpet.113.207605; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Lambert JC, 2010, J ALZHEIMERS DIS, V20, P1107, DOI 10.3233/JAD-2010-100018; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Ma QL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01484-6; Martin BK, 2008, ARCH NEUROL-CHICAGO, V65, P896, DOI 10.1001/archneur.2008.65.7.nct70006; Mathys H, 2017, CELL REP, V21, P366, DOI 10.1016/j.celrep.2017.09.039; Meyer PF, 2019, NEUROLOGY, V92, pE2070, DOI 10.1212/WNL.0000000000007232; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Mittal K, 2019, ISCIENCE, V16, P298, DOI 10.1016/j.isci.2019.05.039; Mundt S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau8380; Ousman SS, 2012, NAT NEUROSCI, V15, P1096, DOI 10.1038/nn.3161; Parachikova A, 2007, NEUROBIOL AGING, V28, P1821, DOI 10.1016/j.neurobiolaging.2006.08.014; Patel NS, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-9; Patel TK, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0312-x; PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407; Prokop S, 2019, PROG MOL BIOL TRANSL, V168, P183, DOI 10.1016/bs.pmbts.2019.10.002; Rasmussen MK, 2018, LANCET NEUROL, V17, P1016, DOI 10.1016/S1474-4422(18)30318-1; Rocha N, 2008, EMBO J, V27, P1, DOI 10.1038/sj.emboj.7601945; Schlager C, 2016, NATURE, V530, P349, DOI 10.1038/nature16939; Selkoe DJ, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004457; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; Sokolova A, 2009, BRAIN PATHOL, V19, P392, DOI 10.1111/j.1750-3639.2008.00188.x; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Suter T, 2003, EUR J IMMUNOL, V33, P2998, DOI 10.1002/eji.200323611; Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854; Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004; vom Berg J, 2012, NAT MED, V18, P1812, DOI 10.1038/nm.2965; Westin K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030525; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wilson NS, 2004, BLOOD, V103, P2187, DOI 10.1182/blood-2003-08-2729; Xu J, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0001.2001; Yang T, 2017, J NEUROSCI, V37, P152, DOI 10.1523/JNEUROSCI.1698-16.2016; Yin ZR, 2017, NEUROBIOL AGING, V55, P115, DOI 10.1016/j.neurobiolaging.2017.03.021; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	71	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 5	2020	11								1029	10.3389/fimmu.2020.01029	http://dx.doi.org/10.3389/fimmu.2020.01029			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC2GF	32582162	Green Published, Green Accepted, gold			2022-12-18	WOS:000543111500001
J	Verma, R; Kumar, L				Verma, Rakesh; Kumar, Lalit			Plasma Cells in the Melanoma Tumor Microenvironment-Mechanistic Roles for IgA	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						plasma cells; biomarker; IgA; immune therapies; checkpoint blockade; tumor microenvironment; PD1	PROGNOSTIC-SIGNIFICANCE; ANTI-CTLA-4; THERAPY		[Verma, Rakesh] Yale Univ, Yale Canc Ctr, New Haven, CT 06520 USA; [Kumar, Lalit] All India Inst Med Sci, Dr BR Ambedkar Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi, India; [Kumar, Lalit] All India Inst Med Sci, New Delhi, India	Yale University; All India Institute of Medical Sciences (AIIMS) New Delhi; DR. B.R.A. Institute Rotary Cancer Hospital; All India Institute of Medical Sciences (AIIMS) New Delhi	Verma, R (corresponding author), Yale Univ, Yale Canc Ctr, New Haven, CT 06520 USA.	rakesh.verma@aya.yale.edu			Department of Biotechnology (DBT), Government of India [CBT/PR8348/MED/14/1249/2006]	Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India)	Authors would like to thank Dr. Jake Wang, MD, Resident Physician at Yale University, Yale School of Medicine for helpful comments and suggestions for the manuscript. LK and RV would like to acknowledge the Department of Biotechnology (DBT), Government of India (CBT/PR8348/MED/14/1249/2006).	Bosisio FM, 2016, MODERN PATHOL, V29, P347, DOI 10.1038/modpathol.2016.28; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Das R, 2015, J IMMUNOL, V194, P950, DOI 10.4049/jimmunol.1401686; Frankenthaler A, 2010, MELANOMA RES, V20, P496, DOI 10.1097/CMR.0b013e32833e9f5b; Germain C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00067; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Iglesia MD, 2014, CLIN CANCER RES, V20, P3818, DOI 10.1158/1078-0432.CCR-13-3368; Lohr M, 2013, CANCER LETT, V333, P222, DOI 10.1016/j.canlet.2013.01.036; Mahmoud SMA, 2012, BREAST CANCER RES TR, V132, P545, DOI 10.1007/s10549-011-1620-1; MASCARO JM, 1987, AM J DERMATOPATH, V9, P497, DOI 10.1097/00000372-198712000-00005; ONEILL PA, 1974, IMMUNOL COMMUN, V3, P427, DOI 10.3109/08820137409061123; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Teillaud JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00830; Thumar JR, 2010, ONCOLOGY-NY, V24, P1280	14	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 5	2020	11								979	10.3389/fimmu.2020.00979	http://dx.doi.org/10.3389/fimmu.2020.00979			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MC1UH	32582154	Green Published, gold			2022-12-18	WOS:000543080500001
J	Lecchi, C; Zamarian, V; Borriello, G; Galiero, G; Grilli, G; Caniatti, M; D'Urso, ES; Roccabianca, P; Perego, R; Minero, M; Legnani, S; Calogero, R; Arigoni, M; Ceciliani, F				Lecchi, Cristina; Zamarian, Valentina; Borriello, Giorgia; Galiero, Giorgio; Grilli, Guido; Caniatti, Mario; D'Urso, Elisa Silvia; Roccabianca, Paola; Perego, Roberta; Minero, Michela; Legnani, Sara; Calogero, Raffaele; Arigoni, Maddalena; Ceciliani, Fabrizio			Identification of Altered miRNAs in Cerumen of Dogs Affected by Otitis Externa	FRONTIERS IN IMMUNOLOGY			English	Article						otitis externa; dogs; miRNA; sequencing; biomarkers	MICRORNA; ASSOCIATION; MACROPHAGES; BIOMARKERS	Otitis externa is one of the most common diseases in dogs. It is associated with bacteria and yeast, which are regarded as secondary causes. Cerumen is a biological substance playing an important role in the protection of ear skin. The involvement of cerumen in immune defense is poorly understood. MicroRNAs can modulate the host immune response and can provide promising biomarkers for several inflammatory and infectious disorder diagnosis. The aims of this study were to profile the cerumen miRNA signature associated with otitis externa in dogs, integrate miRNAs to their target genes related to immune functions, and investigate their potential use as biomarkers. Cerumen was collected from healthy and otitis affected dogs and the expression of miRNAs was profiled by Next Generation Sequencing; the validation of the altered miRNAs was performed using RT-qPCR. The potential ability of miRNAs to modulate immune-related genes was investigated using bioinformatics tools. The results pointed out that 32 miRNAs, of which 14 were up- and 18 down-regulated, were differentially expressed in healthy vs. otitis-affected dogs. These results were verified by RT-qPCR. To assess the diagnostic value of miRNAs, ROC analysis was carried out, highlighting that 4 miRNAs are potential biomarkers to discriminate otitis-affected dogs. Bioinformatics showed that cerumen miRNAs may be involved in the modulation of host immune response. In conclusion, we have demonstrated for the first time that miRNAs can be efficiently extracted and quantified from cerumen, that their profile changes between healthy and otitis affected dogs, and that they may serve as potential biomarkers. Further studies are necessary to confirm their diagnostic value and to investigate their interaction with immune-related genes.	[Lecchi, Cristina; Zamarian, Valentina; Grilli, Guido; Caniatti, Mario; D'Urso, Elisa Silvia; Roccabianca, Paola; Perego, Roberta; Minero, Michela; Ceciliani, Fabrizio] Univ Milan, Dipartimento Med Vet, Milan, Italy; [Borriello, Giorgia; Galiero, Giorgio] Ist Zooprofilatt Sperimentale Mezzogiorno, Dipartimento Sanita Anim, Portici, Italy; [Legnani, Sara] Univ Liverpool, Inst Vet Sci, Dept Small Anim Clin Sci, Liverpool, Merseyside, England; [Calogero, Raffaele; Arigoni, Maddalena] Univ Torino, Mol Biotechnol Ctr, Dept Biotechnol & Hlth Sci, Turin, Italy	University of Milan; IZS del Mezzogiorno; University of Liverpool; University of Turin	Lecchi, C (corresponding author), Univ Milan, Dipartimento Med Vet, Milan, Italy.	cristina.lecchi@unimi.it	Roccabianca, Paola/I-6110-2017; Zamarian, Valentina/AAC-1214-2022; Grilli, Guido/K-7650-2017	Roccabianca, Paola/0000-0002-3672-4612; Zamarian, Valentina/0000-0002-3913-0537; Grilli, Guido/0000-0001-6157-7258; Arigoni, Maddalena/0000-0003-4629-3841; Calogero, Raffaele/0000-0002-2848-628X	Italian Ministry of Health [IZS ME 13/15 RC]; Fondo per il Finanziamento delle Attivita Base di Ricerca-FFABR	Italian Ministry of Health(Ministry of Health, Italy); Fondo per il Finanziamento delle Attivita Base di Ricerca-FFABR	This research was provided by Italian Ministry of HealthRicerca Corrente 2015 -IZS ME 13/15 RC. This funding for RTqPCR was provided by Fondo per il Finanziamento delle Attivita Base di Ricerca-FFABR-Lecchi.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Angus JC, 2004, VET CLIN N AM-SMALL, V34, P411, DOI 10.1016/j.cvsm.2003.10.005; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beccuti M, 2018, BIOINFORMATICS, V34, P871, DOI 10.1093/bioinformatics/btx674; Bhattacharya S, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.15; Bloom Paul, 2009, Compend Contin Educ Vet, V31, pE1; Bourely C, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268818003278; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; CHAI TJ, 1980, ANTIMICROB AGENTS CH, V18, P638, DOI 10.1128/AAC.18.4.638; Chen WN, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12766; Cheng ZA, 2013, J CLIN IMMUNOL, V33, P567, DOI 10.1007/s10875-012-9834-5; Cordero F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031630; Curtale G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00799; De Martino L, 2016, ASIAN PAC J TROP BIO, V6, P384, DOI 10.1016/j.apjtb.2015.11.012; Diao WL, 2017, BIOCHEM BIOPH RES CO, V491, P912, DOI 10.1016/j.bbrc.2017.07.135; Dong H, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00186; Eadon MT, 2014, IMMUNOLOGY, V143, P363, DOI 10.1111/imm.12314; Eisenberg E, 2013, TRENDS GENET, V29, P569, DOI 10.1016/j.tig.2013.05.010; Elsik CG, 2009, SCIENCE, V324, P522, DOI 10.1126/science.1169588; Essandoh K, 2016, SHOCK, V46, P122, DOI 10.1097/SHK.0000000000000604; Fan YN, 2018, METHODS MOL BIOL, V1819, P215, DOI 10.1007/978-1-4939-8618-7_10; Feig MA, 2013, J PROTEOMICS, V83, P119, DOI 10.1016/j.jprot.2013.03.004; Garikipati VNS, 2017, CARDIOVASC RES, V113, P938, DOI 10.1093/cvr/cvx052; Ginel PJ, 2002, VET DERMATOL, V13, P151, DOI 10.1046/j.1365-3164.2002.00288.x; Griffin JS, 2007, J VET MED A, V54, P424, DOI 10.1111/j.1439-0442.2007.00938.x; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hussen J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01875; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Kim E, 2018, PEERJ, V6, DOI 10.7717/peerj.5161; Layne EA, 2016, VET IMMUNOL IMMUNOP, V176, P1, DOI 10.1016/j.vetimm.2016.05.008; Lecchi C, 2018, ANIMAL, V12, P366, DOI 10.1017/S1751731117001525; Lecchi C, 2016, ANIMAL, V10, P1213, DOI 10.1017/S1751731115003043; Lecchi C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38365-x; Lee HD, 2016, SCI REP-UK, V6, DOI 10.1038/srep35250; Lee HM, 2016, BMB REP, V49, P311, DOI 10.5483/BMBRep.2016.49.6.056; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Lopetuso LR, 2018, P NATL ACAD SCI USA, V115, pE9362, DOI 10.1073/pnas.1803613115; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu JB, 2016, ARCH BIOCHEM BIOPHYS, V590, P64, DOI 10.1016/j.abb.2015.11.007; Markopoulos GS, 2017, CELL ONCOL, V40, P303, DOI 10.1007/s13402-017-0341-9; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Morris DO, 2002, AM J VET RES, V63, P358, DOI 10.2460/ajvr.2002.63.358; O'Neill Dan G, 2018, Canine Genet Epidemiol, V5, P3, DOI 10.1186/s40575-018-0057-9; O'Neill Dan G, 2017, Canine Genet Epidemiol, V4, P13, DOI 10.1186/s40575-017-0051-7; Pardini Barbara, 2018, Oncotarget, V9, P20658, DOI 10.18632/oncotarget.25057; Paterson S, 2016, J SMALL ANIM PRACT, V57, P668, DOI 10.1111/jsap.12583; Perry LR, 2017, CAN VET J, V58, P168; Rosser EJ, 2004, VET CLIN N AM-SMALL, V34, P459, DOI 10.1016/j.cvsm.2003.10.006; Ruksha TG, 2017, EUR J DERMATOL, V27, P343, DOI 10.1684/ejd.2017.3024; Rumble SM, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000386; Samuels TL, 2016, INT J PEDIATR OTORHI, V88, P104, DOI 10.1016/j.ijporl.2016.06.056; Schmidt WM, 2009, BIOCHEM BIOPH RES CO, V380, P437, DOI 10.1016/j.bbrc.2008.12.190; Schulte LN, 2019, METHODS MOL BIOL, V1912, P3, DOI 10.1007/978-1-4939-8982-9_1; Shokry E, 2017, BIOCHEM MEDICA, V27, P477, DOI 10.11613/BM.2017.030503; Sparber F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01614; Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239; Val S, 2017, PEDIATR RES, V81, P911, DOI 10.1038/pr.2017.25; Vergadi E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02705; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Yoon YJ, 2008, ACTA OTO-LARYNGOL, V128, P871, DOI 10.1080/00016480701785020; Zheng YP, 2019, EUR J PHARMACOL, V862, DOI 10.1016/j.ejphar.2019.172659; Zur G, 2011, J SMALL ANIM PRACT, V52, P254, DOI 10.1111/j.1748-5827.2011.01058.x	64	2	2	2	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 29	2020	11								914	10.3389/fimmu.2020.00914	http://dx.doi.org/10.3389/fimmu.2020.00914			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MB1FF	32547539	gold, Green Published			2022-12-18	WOS:000542352000001
J	Sleiman, M; Stevens, DR; Chitirala, P; Rettig, J				Sleiman, Marwa; Stevens, David R.; Chitirala, Praneeth; Rettig, Jens			Cytotoxic Granule Trafficking and Fusion in Synaptotagmin7-Deficient Cytotoxic T Lymphocytes	FRONTIERS IN IMMUNOLOGY			English	Article						cytotoxic T lymphocytes; cytotoxic granules; granule fusion; granule trafficking; immune synapse; calcium dependence; synaptotagmin	NEUROTRANSMITTER RELEASE; ASYNCHRONOUS RELEASE; MEMBRANE-FUSION; LYTIC GRANULES; CA2+ SENSORS; EXOCYTOSIS; LYSOSOMES; DOMAIN; CELLS; VII	Granules of cytotoxic T lymphocytes (CTL) are derived from the lysosomal compartment. Synaptotagmin7 (Syt7) appears to be the calcium sensor triggering fusion of lysosomes in fibroblasts. Syt7 has been proposed to control cytotoxic granule (CG) fusion in lymphocytes and mice lacking Syt7 have reduced ability to clear infections. However, fusion of CG persists in the absence of Syt7. To clarify the role of Syt7 in CTL function, we have examined the fusion of cytotoxic granules of CD8(+)T-lymphocytes from Syt7 knock-out mice. We have recorded granule fusion in living CTL, using total internal reflection microscopy. Since Syt7 is considered a high affinity calcium-sensor specialized for fusion under low calcium conditions, we have compared cytotoxic granule fusion under low and high calcium conditions in the same CTL. There was no difference in latencies or numbers of fusion events per CTL under low-calcium conditions, indicating that Syt7 is not required for cytotoxic granule fusion. A deficit of fusion in Syt7 KO CTL was seen when a high-calcium solution was introduced. Expressing wild type Syt7 in Syt7 KO lymphocytes reversed this deficit, confirming its Syt7-dependence. Mutations of Syt7 which disrupt calcium binding to its C2A domain reduced the efficacy of this rescue. We counted the cytotoxic granules present at the plasma membrane to determine if the lack of fusion events in the Syt7 KO CTL was due to a lack of granules. In low calcium there were no differences in fusion events per CTL, and granule numbers were similar. In high calcium, granule number was similar though wild type CTL exhibited significantly more fusion than Syt7 KO CTL. The modest differences in granule counts do not account for the lack of fusion in high calcium in Syt7 KO CTL. In Syt7 KO CTL expressing wild type Syt7, delivery of cytotoxic granules to the plasma membrane was comparable to that of wild type CTL. Syt7 KO CTL expressing Syt7 with deficient calcium binding in the C2A domain had significantly less fusion and fewer CG at the plasma membrane. These results indicate that Syt7 is involved in trafficking of CG to the plasma membrane.	[Sleiman, Marwa; Stevens, David R.; Chitirala, Praneeth; Rettig, Jens] Saarland Univ, Ctr Integrat Physiol & Mol Med CIPMM, Cellular Neurophysiol, Homburg, Germany	Universitatsklinikum des Saarlandes	Rettig, J (corresponding author), Saarland Univ, Ctr Integrat Physiol & Mol Med CIPMM, Cellular Neurophysiol, Homburg, Germany.	jrettig@uks.eu	Rettig, Jens/K-5103-2013	Rettig, Jens/0000-0001-6160-3954; Sleiman, Marwa/0000-0002-1954-3203	Deutsche Forschungsgemeinschaft [SFB 894, IRTG 1830]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB 894 and IRTG 1830) (JR).	Bacaj T, 2013, NEURON, V80, P947, DOI 10.1016/j.neuron.2013.10.026; Bai JH, 2004, TRENDS BIOCHEM SCI, V29, P143, DOI 10.1016/j.tibs.2004.01.008; Bossi G, 2002, IMMUNOL REV, V189, P152, DOI 10.1034/j.1600-065X.2002.18913.x; Bradberry MM, 2019, J BIOL CHEM, V294, P10942, DOI 10.1074/jbc.RA119.007929; BURKHARDT JK, 1990, J CELL BIOL, V111, P2327, DOI 10.1083/jcb.111.6.2327; Chakrabarti S, 2003, J CELL BIOL, V162, P543, DOI 10.1083/jcb.200305131; Chang HF, 2016, J IMMUNOL, V197, P2473, DOI 10.4049/jimmunol.1600828; Chen C, 2017, CELL REP, V18, P723, DOI 10.1016/j.celrep.2016.12.067; Chicka MC, 2008, NAT STRUCT MOL BIOL, V15, P827, DOI 10.1038/nsmb.1463; Colvin RA, 2010, NAT IMMUNOL, V11, P495, DOI 10.1038/ni.1878; Courtney NA, 2018, NEURON, V98, P977, DOI 10.1016/j.neuron.2018.04.022; de Saint Basile G, 2010, NAT REV IMMUNOL, V10, P568, DOI 10.1038/nri2803; Fowler KT, 2007, J IMMUNOL, V178, P1498, DOI 10.4049/jimmunol.178.3.1498; Gaffaney JD, 2008, J BIOL CHEM, V283, P31763, DOI 10.1074/jbc.M803355200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Houy S, 2017, ELIFE, V6, DOI 10.7554/eLife.27000; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jaiswal JK, 2004, PLOS BIOL, V2, P1224, DOI 10.1371/journal.pbio.0020233; Lindmark IM, 2002, BBA-MOL CELL RES, V1590, P159, DOI 10.1016/S0167-4889(02)00209-4; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Luo FJ, 2015, J NEUROSCI, V35, P11024, DOI 10.1523/JNEUROSCI.0759-15.2015; Lyubchenko TA, 2001, IMMUNITY, V15, P847, DOI 10.1016/S1074-7613(01)00233-3; MacDougall DD, 2018, J GEN PHYSIOL, V150, P783, DOI 10.1085/jgp.201711944; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Marks MS, 2013, CURR OPIN CELL BIOL, V25, P495, DOI 10.1016/j.ceb.2013.04.008; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; Matti U, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2467; Maximov A, 2008, P NATL ACAD SCI USA, V105, P3986, DOI 10.1073/pnas.0712372105; Melicoff E, 2009, J BIOL CHEM, V284, P19445, DOI 10.1074/jbc.M109.002550; Oheim M, 2019, BIOPHYS J, V117, P795, DOI 10.1016/j.bpj.2019.07.048; Page LJ, 1998, BBA-MOL CELL RES, V1401, P146, DOI 10.1016/S0167-4889(97)00138-9; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; Rozov A, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00028; Sanchez-Ruiz Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027057; Stevens CF, 2003, NEURON, V39, P299, DOI 10.1016/S0896-6273(03)00432-X; Stinchcombe JC, 2000, TRAFFIC, V1, P435, DOI 10.1034/j.1600-0854.2000.010508.x; Sudhof TC, 2014, ANGEW CHEM INT EDIT, V53, P12696, DOI 10.1002/anie.201406359; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Tran HT, 2019, BIOPHYS J, V116, P1025, DOI 10.1016/j.bpj.2019.01.035; Turecek J, 2018, J NEUROSCI, V38, P3240, DOI 10.1523/JNEUROSCI.3207-17.2018; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Voleti R, 2017, P NATL ACAD SCI USA, V114, pE8518, DOI 10.1073/pnas.1710708114; Wang S, 2016, ELIFE, V5, DOI 10.7554/eLife.14211; Xu J, 2009, NAT NEUROSCI, V12, P759, DOI 10.1038/nn.2320; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010; Zhou X, 2018, J PHYSIOL-LONDON, V596, P2681, DOI 10.1113/JP274964	46	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 29	2020	11								1080	10.3389/fimmu.2020.01080	http://dx.doi.org/10.3389/fimmu.2020.01080			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MB1HV	32547563	Green Published, gold			2022-12-18	WOS:000542358800001
J	Zhang, Y; Feng, JB; Fu, HJ; Liu, CH; Yu, ZB; Sun, YN; She, XL; Li, PY; Zhao, CH; Liu, Y; Liu, T; Liu, Q; Liu, Q; Li, GY; Wu, MH				Zhang, Yan; Feng, Jianbo; Fu, Haijuan; Liu, Changhong; Yu, Zhibin; Sun, Yingnan; She, Xiaoling; Li, Peiyao; Zhao, Chunhua; Liu, Yang; Liu, Tao; Liu, Qiang; Liu, Qing; Li, Guiyuan; Wu, Minghua			Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme (vol 9, 1557, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						tumor-associated macrophages; polarization; glioblastoma multiforme; extracellular signal-related kinase 1; 2; AKT			[Zhang, Yan; Feng, Jianbo; Fu, Haijuan; Liu, Changhong; Yu, Zhibin; Sun, Yingnan; Li, Peiyao; Zhao, Chunhua; Liu, Yang; Li, Guiyuan; Wu, Minghua] Cent South Univ, Hunan Prov Tumor Hosp, Changsha, Peoples R China; [Zhang, Yan; Feng, Jianbo; Fu, Haijuan; Liu, Changhong; Yu, Zhibin; Sun, Yingnan; Li, Peiyao; Zhao, Chunhua; Liu, Yang; Li, Guiyuan; Wu, Minghua] Cent South Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Changsha, Peoples R China; [Zhang, Yan; Feng, Jianbo; Fu, Haijuan; Liu, Changhong; Yu, Zhibin; Li, Peiyao; Zhao, Chunhua; Liu, Yang; Li, Guiyuan; Wu, Minghua] Cent South Univ, Key Lab Carcinogenesis & Canc Invas, Key Lab Carcinogenesis, Chinese Minist Hlth,Chinese Minist Educ,Canc Res, Changsha, Peoples R China; [She, Xiaoling] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China; [Liu, Qiang] Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China; [Liu, Qing] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Wu, MH (corresponding author), Cent South Univ, Hunan Prov Tumor Hosp, Changsha, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Changsha, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Key Lab Carcinogenesis & Canc Invas, Key Lab Carcinogenesis, Chinese Minist Hlth,Chinese Minist Educ,Canc Res, Changsha, Peoples R China.	wuminghua554@aliyun.com						Zhang Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01557	1	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 29	2020	11								934	10.3389/fimmu.2020.00934	http://dx.doi.org/10.3389/fimmu.2020.00934			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MB1FL	32547542	gold, Green Published			2022-12-18	WOS:000542352600001
J	Novack, JP				Novack, Jeffrey P.			Designing Cases for Case-Based Immunology Teaching in Large Medical School Classes	FRONTIERS IN IMMUNOLOGY			English	Article						immunology education; case-based learning; medical school education; team-based learning; key concepts; active learning; integrated curriculum		Case-based, interactive sessions for small groups (in a large medical school class of 150 students) reinforces basic immunology concepts by including clinical scenarios that stimulate student learning and consolidate critical concepts. Careful design of cases (designing backwards from the key concepts) leads students through successively more complicated and linked group-work questions. This paper details why cases are effective learning tools, how to design an effective case, how to ask appropriate questions and how to help students apply basic immunology concepts to a case. Each group work session is facilitated and followed by a question and answer presentation by faculty, where student groups are directly asked to answer the questions and also challenged with "bonus questions" not presented with the original case. This allows students to "put together" immunology information into a "story" that they can tell and prevents student frustration by summarizing the results at the end of each case. Case design is carefully discussed including clinical relevancy and accuracy, how to write questions that do not give away the answers, how to emphasize mechanistic questions that allow students to "clinically explain as a physician" the immunological basis for the answers. Additionally, students better understand the role of immunity in both normal and disease states. A case-based approach promotes student learning by re-emphasizing basic concepts in the context of the case and promotes better students understanding of critical immunological concepts.	[Novack, Jeffrey P.] Pacific Northwest Univ, Coll Med, Yakima, WA 98901 USA		Novack, JP (corresponding author), Pacific Northwest Univ, Coll Med, Yakima, WA 98901 USA.	jnovack@pnwu.edu						Brauer DG, 2015, MED TEACH, V37, P312, DOI 10.3109/0142159X.2014.970998; Burgess A, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0550-3; Chen HC, 2015, ACAD MED, V90, P431, DOI 10.1097/ACM.0000000000000586; Chonkar SP, 2018, BMC MED EDUC, V18, DOI 10.1186/s12909-018-1122-5; Dawson P, 2018, STUD HIGH EDUC, V43, P1405, DOI 10.1080/03075079.2016.1258052; Epstein B, 2016, INT J LANG COMM DIS, V51, P44, DOI 10.1111/1460-6984.12184; Freeman S, 2014, P NATL ACAD SCI USA, V111, P8410, DOI 10.1073/pnas.1319030111; James S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02477; Kerchner Michael, 2012, J Undergrad Neurosci Educ, V11, pA27; Kibble JD, 2016, ADV PHYSIOL EDUC, V40, P435, DOI 10.1152/advan.00095.2016; Krupat E, 2016, ACAD MED, V91, P723, DOI 10.1097/ACM.0000000000001004; McLean SF, 2016, J MED EDUC CURRIC DE, V3, P39, DOI [10.4137/JMECDECDECD.S20377, 10.4137/JMECD.S20377]; Michaelsen L., 2007, TEAM BASED LEARNING; Turk B, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-019-1884-4	14	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2020	11								995	10.3389/fimmu.2020.00995	http://dx.doi.org/10.3389/fimmu.2020.00995			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LZ0OD	32536919	gold, Green Published			2022-12-18	WOS:000540930200001
J	Wu, WJ; Tan, Y; Liu, XL; Yu, F; Zhao, MH				Wu, Wen-Jun; Tan, Ying; Liu, Xiao-Ling; Yu, Feng; Zhao, Ming-Hui			C1q A08 Is a Half-Cryptic Epitope of Anti-C1q A08 Antibodies in Lupus Nephritis and Important for the Activation of Complement Classical Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						lupus nephritis; C1q A08; half-cryptic epitope; complement classical pathway; epitope mapping	COLLAGEN-LIKE REGION; C-REACTIVE PROTEIN; RESIDUES 14-26; AUTOANTIBODIES; BINDING; IDENTIFICATION; ERYTHEMATOSUS; LOCALIZATION; INHIBIT; IGG	To investigate the fine epitope(s) of anti-C1q A08 antibodies and their roles in complement activation in lupus nephritis, C1q A08 and related peptides with various amino acid sequences around A08 were synthesized. Anti-C1q A08 antibodies from 10 lupus nephritis patients were purified from plasmapheresis samples, and four monoclonal antibodies against C1q A08 were screened and identified from mouse hybridoma cells, to study the fine epitope(s) of C1q A08 using ELISA and Biolayer Interferometry (BLI). The biofunction of anti-C1q A08 antibodies for complement classical pathway activation was investigated by C3 activation assay. Anti-C1q A08 antibodies and anti-C1q antibodies were also detected in the sera of female BALB/C mice immunized by C1q A08 peptides. None of the anti-C1q A08 antibodies, which were affinity purified from the 10 lupus nephritis patients, could bind intact C1q coated on microtitre plates, neither could the anti-C1q antibodies bind to C1q A08 peptides coupled on resin, indicating that the human anti-C1q antibodies and anti-C1q A08 antibodies may recognize different epitopes of C1q. One of the four C1q A08 mAbs (32-4) bound to the six amino acids of N-terminus of C1q A08, while another C1q A08 mAb (17-9) bound to eight or 10 amino acids of C-terminus of A08. The third and fourth C1q A08 mAb (1A12 and 4B11) bound to the whole sequence of A08. Only 32-4 mAb bound to the intact C1q coating on an ELISA plate, whereas 17-9 mAb, 1A12 mAb, and 4B11 mAb could not. However, using a BLI assay, 17-9 mAb, 1A12 mAb, and 4B11 mAb, but not 32-4 mAb, could bind to intact C1q. Furthermore, 1A12 mAb and 4B11 mAb, but not 32-4 and 17-9 mAb, could inhibit the activation of complement classical pathway. Anti-C1q A08 antibodies were detected in all the female BALB/C mice in the experimental group but not in the control group. Two out of six in the experimental group developed anti-C1q antibodies. C1q A08 is a half-cryptic epitope of C1q involving N-terminal six amino acids of C1q A08, and this is important to the activation of a complement classical pathway, and some anti-C1q A08 antibodies were able to prevent this process. Epitope spreading of C1q occurred in the mice immunized with C1q A08 peptides.	[Wu, Wen-Jun] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China; [Wu, Wen-Jun; Tan, Ying; Liu, Xiao-Ling; Yu, Feng; Zhao, Ming-Hui] Peking Univ, Hosp 1, Dept Med, Renal Div, Beijing, Peoples R China; [Wu, Wen-Jun; Tan, Ying; Liu, Xiao-Ling; Yu, Feng; Zhao, Ming-Hui] Peking Univ, Inst Nephrol, Beijing, Peoples R China; [Wu, Wen-Jun; Tan, Ying; Liu, Xiao-Ling; Yu, Feng; Zhao, Ming-Hui] Minist Hlth China, Key Lab Renal Dis, Beijing, Peoples R China; [Wu, Wen-Jun; Tan, Ying; Liu, Xiao-Ling; Yu, Feng; Zhao, Ming-Hui] Minist Educ China, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing, Peoples R China; [Wu, Wen-Jun; Zhao, Ming-Hui] Tsinghua Peking Ctr Life Sci, Beijing, Peoples R China; [Yu, Feng] Peking Univ, Dept Nephrol, Int Hosp, Beijing, Peoples R China	Tsinghua University; Peking University; Peking University; Ministry of Education, China; Tsinghua University; Peking University	Zhao, MH (corresponding author), Peking Univ, Hosp 1, Dept Med, Renal Div, Beijing, Peoples R China.; Zhao, MH (corresponding author), Peking Univ, Inst Nephrol, Beijing, Peoples R China.; Zhao, MH (corresponding author), Minist Hlth China, Key Lab Renal Dis, Beijing, Peoples R China.; Zhao, MH (corresponding author), Minist Educ China, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing, Peoples R China.; Zhao, MH (corresponding author), Tsinghua Peking Ctr Life Sci, Beijing, Peoples R China.	mhzhao@bjmu.edu.cn	Liu, Xiaoling/HGD-3566-2022	Tan, Ying/0000-0001-8243-4731	National Natural Science Foundation of China [81470932, 81500526, 81670640, 81670639]; Beijing Natural Science Foundation [7172215]; Clinical Medicine Plus X-Young Scholars Project of Peking University; Fundamental Research Funds for the Central Universities	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Clinical Medicine Plus X-Young Scholars Project of Peking University; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants of National Natural Science Foundation of China to Innovation Research Group (No. 81621092), National Natural Science Foundation of China (No. 81470932, No. 81500526, No. 81670640, and No. 81670639), Beijing Natural Science Foundation (No. 7172215), and Clinical Medicine Plus X-Young Scholars Project of Peking University supported by the Fundamental Research Funds for the Central Universities.	ALMEDA S, 1983, J BIOL CHEM, V258, P785; Beurskens FJ, 2015, MOL IMMUNOL, V68, P6, DOI 10.1016/j.molimm.2015.05.010; Bigler C, 2009, J IMMUNOL, V183, P3512, DOI 10.4049/jimmunol.0803573; Chikazawa M, 2016, BIOCHEMISTRY-US, V55, P435, DOI 10.1021/acs.biochem.5b00777; Salgado AD, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/849684; Eggleton Paul, 2014, J Clin Cell Immunol, V5, P210; Flores-Mendoza G, 2018, TRENDS MOL MED, V24, P364, DOI 10.1016/j.molmed.2018.02.003; Ghebrehiwet B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00162; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; Jiang H, 1994, INT WORKSH C1 THE 1, P47; JIANG HX, 1991, J IMMUNOL, V146, P2324; JIANG HX, 1992, J BIOL CHEM, V267, P25597; Kolm R, 2016, J IMMUNOL, V197, P3669, DOI 10.4049/jimmunol.1501876; Ortega LM, 2010, LUPUS, V19, P557, DOI 10.1177/0961203309358187; Pang Y, 2016, KIDNEY INT, V90, P1357, DOI 10.1016/j.kint.2016.08.010; Pang Y, 2014, IMMUNOBIOLOGY, V219, P980, DOI 10.1016/j.imbio.2014.07.004; Radanova M, 2012, IMMUNOBIOLOGY, V217, P684, DOI 10.1016/j.imbio.2011.11.007; Rosenthal A, 2016, U.S. Pa10t Application, P2016, Patent No. [14/933,517, 14933517]; Schaller M, 2009, J IMMUNOL, V183, P8225, DOI 10.4049/jimmunol.0902642; SIEGERT C, 1991, J RHEUMATOL, V18, P230; Siegert CEH, 1999, CLIN EXP IMMUNOL, V116, P4; SORVILLO J, 1985, BIOCHEM J, V226, P207, DOI 10.1042/bj2260207; Thielens NM, 2017, MOL IMMUNOL, V89, P73, DOI 10.1016/j.molimm.2017.05.025; Trendelenburg M, 1999, ARTHRITIS RHEUM, V42, P187, DOI 10.1002/1529-0131(199901)42:1<187::AID-ANR24>3.0.CO;2-U; Trendelenburg M, 2006, NEPHROL DIAL TRANSPL, V21, P3115, DOI 10.1093/ndt/gfl436; Vanhecke D, 2012, ARTHRITIS RHEUM-US, V64, P3706, DOI 10.1002/art.34605; von Boehmer L, 2016, NAT PROTOC, V11, P1908, DOI 10.1038/nprot.2016.102; YING SC, 1993, J IMMUNOL, V150, P169	28	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2020	11								848	10.3389/fimmu.2020.00848	http://dx.doi.org/10.3389/fimmu.2020.00848			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LZ0VC	32536911	Green Published, gold			2022-12-18	WOS:000540948300001
J	Laustsen, AH; Ainsworth, S; Lomonte, B; Kini, RM; Chavez-Olortegui, C				Laustsen, Andreas Hougaard; Ainsworth, Stuart; Lomonte, Bruno; Kini, R. Manjunatha; Chavez-Olortegui, Carlos			Editorial: Novel Immunotherapies Against Envenomings by Snakes and Other Venomous Animals	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						venom; envenoming; antivenom; recombinant antivenom; toxin-neutralization; immunotherapy; antibody discovery; serotherapy			[Laustsen, Andreas Hougaard] Tech Univ Denmark, Dept Biotechnol & Biomed, Lyngby, Denmark; [Ainsworth, Stuart] Univ Liverpool Liverpool Sch Trop Med, Ctr Snakebite Res & Intervent, Liverpool, Merseyside, England; [Lomonte, Bruno] Univ Costa Rica, Inst Clodomiro Picado, Fac Microbiol, San Jose, Costa Rica; [Kini, R. Manjunatha] Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore, Singapore; [Kini, R. Manjunatha] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore; [Chavez-Olortegui, Carlos] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim, Belo Horizonte, MG, Brazil	Technical University of Denmark; Liverpool School of Tropical Medicine; Universidad Costa Rica; National University of Singapore; National University of Singapore; Universidade Federal de Minas Gerais	Laustsen, AH (corresponding author), Tech Univ Denmark, Dept Biotechnol & Biomed, Lyngby, Denmark.; Ainsworth, S (corresponding author), Univ Liverpool Liverpool Sch Trop Med, Ctr Snakebite Res & Intervent, Liverpool, Merseyside, England.; Lomonte, B (corresponding author), Univ Costa Rica, Inst Clodomiro Picado, Fac Microbiol, San Jose, Costa Rica.; Kini, RM (corresponding author), Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore, Singapore.; Kini, RM (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.; Chavez-Olortegui, C (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim, Belo Horizonte, MG, Brazil.	ahola@bio.dtu.dk; stuart.ainsworth@lstmed.ac.uk; bruno.lomonte@ucr.ac.cr; dbskinim@nus.edu.sg; olortegi@icb.ufmg.br		Laustsen, Andreas Hougaard/0000-0001-6918-5574				Bermudez-Mendez E, 2018, TOXINS, V10, DOI 10.3390/toxins10110452; Kini RM, 2018, TOXINS, V10, DOI 10.3390/toxins10120534; Williams DJ, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007059	3	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 22	2020	11								1004	10.3389/fimmu.2020.01004	http://dx.doi.org/10.3389/fimmu.2020.01004			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LX2TV	32670269	Green Published, Green Accepted, gold			2022-12-18	WOS:000539690600001
J	Wang, Q; Li, DH; Zhu, J; Zhang, MY; Zhang, H; Cao, GC; Zhu, LQ; Shi, QP; Hao, JL; Wen, Q; Liu, ZH; Yang, HW; Yin, ZN				Wang, Qian; Li, Dehai; Zhu, Jing; Zhang, Mingyue; Zhang, Hua; Cao, Guangchao; Zhu, Leqing; Shi, Qiping; Hao, Jianlei; Wen, Qiong; Liu, Zonghua; Yang, Hengwen; Yin, Zhinan			Perforin Acts as an Immune Regulator to Prevent the Progression of NAFLD	FRONTIERS IN IMMUNOLOGY			English	Article						perforin; NAFLD; CD4 T cells; IFN-gamma; inflammation	FATTY LIVER-DISEASE; MACROPHAGE POLARIZATION; CELLULAR SENESCENCE; INSULIN-RESISTANCE; INFLAMMATION; EPIDEMIOLOGY; PATHOGENESIS; HOMEOSTASIS; ACTIVATION; MECHANISMS	Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of cirrhosis and major risk factors for hepatocellular carcinoma and liver-related death. Despite substantial clinical and basic research, the pathogenesis of obesity-related NAFLD remains poorly understood. In this study, we show that perforin can act as an immune regulator to prevent the progression of NAFLD. Aged perforin-deficient (Prf(-/-)) mice have increased lipid accumulation in the liver compared to WT mice. With high-fat diet (HFD) challenge, Prf(-/-) mice have increased liver weight, more severe liver damage, and increased liver inflammation when compared with WT controls. Mechanistic studies revealed that perforin specifically regulates intrinsic IFN-gamma production in CD4 T cells, not CD8 T cells. We found that CD4 T cell depletion reduces liver injury and ameliorates the inflammation and metabolic morbidities in Prf(-/-) mice. Furthermore, improved liver characteristics in HFD Prf(-/-) and IFN-gamma R-/- double knockout mice confirmed that IFN-gamma is a key factor for mediating perforin regulation of NAFLD progression. Overall, our findings reveal the important regulatory role perforin plays in the progression of obesity-related NAFLD and highlight novel strategies for treating NAFLD.	[Wang, Qian; Li, Dehai; Zhu, Jing; Zhang, Mingyue; Zhang, Hua; Cao, Guangchao; Zhu, Leqing; Hao, Jianlei; Wen, Qiong; Liu, Zonghua; Yang, Hengwen; Yin, Zhinan] Jinan Univ, Zhuhai Peoples Hosp, Zhuhai Precis Med Ctr, Zhuhai Hosp, Zhuhai, Peoples R China; [Wang, Qian; Li, Dehai; Zhu, Jing; Zhang, Mingyue; Zhang, Hua; Cao, Guangchao; Zhu, Leqing; Hao, Jianlei; Wen, Qiong; Liu, Zonghua; Yang, Hengwen; Yin, Zhinan] Jinan Univ, Fac Med Sci, Biomed Translat Res Inst, Guangzhou, Peoples R China; [Shi, Qiping] Jinan Univ, Affiliated Hosp 1, Guangzhou, Peoples R China	Jinan University; Jinan University; Jinan University	Wang, Q; Yang, HW; Yin, ZN (corresponding author), Jinan Univ, Zhuhai Peoples Hosp, Zhuhai Precis Med Ctr, Zhuhai Hosp, Zhuhai, Peoples R China.; Wang, Q; Yang, HW; Yin, ZN (corresponding author), Jinan Univ, Fac Med Sci, Biomed Translat Res Inst, Guangzhou, Peoples R China.	wangqian@jnu.edu.cn; hengwenyang@jnu.edu.cn; zhinan.yin@yale.edu	Cao, Guangchao/AAB-1263-2020; yang, hengwen/GQH-7922-2022	Cao, Guangchao/0000-0003-2069-3396; Wang, Qian/0000-0003-4755-7001; Hao, Jianlei/0000-0003-4600-3082; yang, hengwen/0000-0002-6418-1985	National Natural Science Foundation of China [31830021, 31800721, 81630025, 31970830]; State Bureau of Foreign Experts Affairs (111 project) [B16021]; Science and Technology Department of the Guangdong Province of China [2018B030312008]; China Postdoctoral Fund [2018M633278]; Traditional Chinese Medicine Bureau of Guangdong Province [2018071]; Guangzhou Municipal Science and Technology Bureau [201904010090]; Health Commission of Guangdong Province [A2019520]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Bureau of Foreign Experts Affairs (111 project); Science and Technology Department of the Guangdong Province of China; China Postdoctoral Fund(China Postdoctoral Science Foundation); Traditional Chinese Medicine Bureau of Guangdong Province; Guangzhou Municipal Science and Technology Bureau; Health Commission of Guangdong Province	This work was supported by the National Natural Science Foundation of China (the Key Program, 31830021), and the State Bureau of Foreign Experts Affairs (111 project, B16021) to ZY and HY. This work was also supported by the Science and Technology Department of the Guangdong Province of China (2018B030312008) to HY, the National Natural Science Foundation of China (grant 31800721 to QWa), the China Postdoctoral Fund (grant 2018M633278 to QWa), the National Natural Science Foundation of China (81630025, 31970830 to JH), the Traditional Chinese Medicine Bureau of Guangdong Province (2018071 to JH), the Guangzhou Municipal Science and Technology Bureau (201904010090 to JH) and the Health Commission of Guangdong Province (A2019520 to JH).	Alisi A, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8162421; Angulo P, 2004, J HEPATOL, V41, P943, DOI 10.1016/j.jhep.2004.08.020; Aravinthan A, 2013, J HEPATOL, V58, P549, DOI 10.1016/j.jhep.2012.10.031; Badovinac VP, 2000, SCIENCE, V290, P1354, DOI 10.1126/science.290.5495.1354; Bertolotti M, 2014, WORLD J GASTROENTERO, V20, P14185, DOI 10.3748/wjg.v20.i39.14185; Bolitho P, 2007, CURR OPIN IMMUNOL, V19, P339, DOI 10.1016/j.coi.2007.04.007; Brown GT, 2016, METABOLISM, V65, P1080, DOI 10.1016/j.metabol.2015.11.008; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Canbakan B, 2008, ANN HEPATOL, V7, P249, DOI 10.1016/S1665-2681(19)31856-3; Cha Ji-Young, 2018, Lab Anim Res, V34, P133, DOI 10.5625/lar.2018.34.4.133; Cuff AO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02180; Freitas-Lopes MA, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6040048; Friedman SL, 2018, NAT MED, V24, P908, DOI 10.1038/s41591-018-0104-9; Glass CK, 2012, CELL METAB, V15, P635, DOI 10.1016/j.cmet.2012.04.001; Hardy T, 2016, ANNU REV PATHOL-MECH, V11, P451, DOI 10.1146/annurev-pathol-012615-044224; Hebbard L, 2011, NAT REV GASTRO HEPAT, V8, P34, DOI 10.1038/nrgastro.2010.191; Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148; Kagi D, 1996, J EXP MED, V183, P2143, DOI 10.1084/jem.183.5.2143; Karagozian R, 2014, METABOLISM, V63, P607, DOI 10.1016/j.metabol.2014.01.011; Kazankov K, 2019, NAT REV GASTRO HEPAT, V16, P145, DOI 10.1038/s41575-018-0082-x; Koike Hiroto, 2001, Research Communications in Molecular Pathology and Pharmacology, V110, P229; Koyama Y, 2017, J CLIN INVEST, V127, P55, DOI 10.1172/JCI88881; Ma C, 2016, NATURE, V531, P253, DOI 10.1038/nature16969; Masi LN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04308-1; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221; Osayande AS, 2017, AM FAM PHYSICIAN, V95, P796; Ovadya Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07825-3; Provinciali M, 2013, CURR PHARM DESIGN, V19, P1699; Revelo XS, 2015, DIABETES, V64, P90, DOI 10.2337/db13-1524; Sagiv A, 2013, ONCOGENE, V32, P1971, DOI 10.1038/onc.2012.206; Saradna A, 2018, TRANSL RES, V191, P1, DOI 10.1016/j.trsl.2017.09.002; Seki E, 2015, HEPATOLOGY, V61, P1066, DOI 10.1002/hep.27332; Shan B, 2017, NAT IMMUNOL, V18, P519, DOI 10.1038/ni.3709; Sica A, 2015, CELL MOL LIFE SCI, V72, P4111, DOI 10.1007/s00018-015-1995-y; Sica A, 2014, HEPATOLOGY, V59, P2034, DOI 10.1002/hep.26754; Spicer S, 2017, SEMIN CELL DEV BIOL, V70, P17, DOI [10.1016/j.semcdb.2017.08.026, 10.1016/j.semcdb.2017.07.033]; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Stojsavljevic S, 2014, WORLD J GASTROENTERO, V20, P18070, DOI 10.3748/wjg.v20.i48.18070; Tacke F, 2017, J HEPATOL, V66, P1300, DOI 10.1016/j.jhep.2017.02.026; Temple JL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060947; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Voskoboinik I, 2006, NAT REV IMMUNOL, V6, P940, DOI 10.1038/nri1983; Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839; Walch M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-14; Wang TQ, 2019, FASEB J, V33, P8490, DOI 10.1096/fj.201802534RR; Zhang S, 2013, HEPATOLOGY, V57, P1620, DOI 10.1002/hep.26166	48	2	2	10	26	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 22	2020	11								846	10.3389/fimmu.2020.00846	http://dx.doi.org/10.3389/fimmu.2020.00846			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LX2SE	32528465	Green Published, gold			2022-12-18	WOS:000539686300001
J	Muhammad, F; Avalos, PN; Mursalin, MH; Ma, JX; Callegan, MC; Lee, DJ				Muhammad, Fauziyya; Avalos, Priscilla N.; Mursalin, M. H.; Ma, Jian-Xing; Callegan, Michelle C.; Lee, Darren J.			Kallistatin Attenuates Experimental Autoimmune Uveitis by Inhibiting Activation of T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune disease; autoimmune uveitis; kallistatin; experimental autoimmune uveitis; T cells	REGULATORY IMMUNITY; MOUSE MODELS; EPIDEMIOLOGY; PREVALENCE; INDUCTION; MICE; GUIDELINES; REMISSION; RECOVERY; DISEASE	Experimental autoimmune uveoretinitis (EAU) is a mouse model of human autoimmune uveitis. EAU spontaneously resolves and is marked by ocular autoantigen-specific regulatory immunity in the spleen. Kallikrein binding protein (KBP) or kallistatin is a serine proteinase inhibitor that inhibits angiogenesis and inflammation, but its role in autoimmune uveitis has not been explored. We report that T cells activation is inhibited and EAU is attenuated in human KBP (HKBP) mice with no significant difference in the Treg population that we previously identified both before and after recovery from EAU. Moreover, following EAU immunization HKBP mice have potent ocular autoantigen specific regulatory immunity that is functionally suppressive.	[Muhammad, Fauziyya; Mursalin, M. H.; Callegan, Michelle C.; Lee, Darren J.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; [Avalos, Priscilla N.; Callegan, Michelle C.; Lee, Darren J.] Univ Oklahoma, Dept Ophthalmol, Dean McGee Eye Inst, Hlth Sci Ctr, Oklahoma City, OK 73190 USA; [Ma, Jian-Xing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA; [Callegan, Michelle C.; Lee, Darren J.] Univ Oklahoma, Oklahoma Ctr Neurosci, Hlth Sci Ctr, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Lee, DJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.; Lee, DJ (corresponding author), Univ Oklahoma, Dept Ophthalmol, Dean McGee Eye Inst, Hlth Sci Ctr, Oklahoma City, OK 73190 USA.; Lee, DJ (corresponding author), Univ Oklahoma, Oklahoma Ctr Neurosci, Hlth Sci Ctr, Oklahoma City, OK 73190 USA.	darren-lee@ouhsc.edu	Lee, Darren/AAH-7297-2019; Mursalin, Md Huzzatul/AAH-8027-2020	Lee, Darren/0000-0002-0036-9620; 	National Institutes of Health (NIH) [EY024951, EY029240]; NIH Core Grant [P30 EY021725, EY018659, EY019309, GM104934, EY028810, EY28066]; Oklahoma Center for the Advancement of Science and Technology [HR16-041]; unrestricted Research to Prevent Blindness grant (New York, NY, USA)	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Core Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Oklahoma Center for the Advancement of Science and Technology; unrestricted Research to Prevent Blindness grant (New York, NY, USA)(Research to Prevent Blindness (RPB))	This work was supported by National Institutes of Health (NIH) EY024951 (DL), EY029240 (DL), NIH Core Grant P30 EY021725, EY018659 (J-XM), EY019309 (J-XM), GM104934 (J-XM), EY028810 (MC), EY28066 (MC), Oklahoma Center for the Advancement of Science and Technology HR16-041 (J-XM), and in part by an unrestricted Research to Prevent Blindness grant (New York, NY, USA).	Caspi RR, 2008, OPHTHAL RES, V40, P169, DOI 10.1159/000119871; CASPI RR, 1988, J IMMUNOL, V140, P1490; Chao J, 1995, BIOL CHEM H-S, V376, P705; Chao JL, 2017, CRIT REV ONCOL HEMAT, V113, P71, DOI 10.1016/j.critrevonc.2017.03.011; Chen J, 2015, CURR MOL MED, V15, P550, DOI 10.2174/1566524015666150731100318; DARRELL RW, 1962, ARCH OPHTHALMOL-CHIC, V68, P502, DOI 10.1001/archopht.1962.00960030506014; Foster CS, 2016, SURV OPHTHALMOL, V61, P1, DOI 10.1016/j.survophthal.2015.07.001; Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014; Heiligenhaus A, 2012, RHEUMATOL INT, V32, P1121, DOI 10.1007/s00296-011-2126-1; Hwang DK, 2012, OPHTHALMOLOGY, V119, P2371, DOI 10.1016/j.ophtha.2012.05.026; Jabs DA, 2000, AM J OPHTHALMOL, V130, P492, DOI 10.1016/S0002-9394(00)00659-0; Jenkins AJ, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-19; Kitaichi N, 2005, J LEUKOCYTE BIOL, V77, P496, DOI 10.1189/jlb.0204114; Kruh J, 2012, DEV OPHTHALMOL, V51, P1, DOI 10.1159/000336183; Lee DJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep37790; Lee DJ, 2015, J LEUKOCYTE BIOL, V97, P1101, DOI 10.1189/jlb.3A1014-466RR; Lee DJ, 2013, J IMMUNOL, V191, P4103, DOI 10.4049/jimmunol.1300182; Lee DJ, 2011, INVEST OPHTH VIS SCI, V52, P8862, DOI 10.1167/iovs.11-8153; Lee FF, 2010, EXPERT OPIN PHARMACO, V11, P1135, DOI 10.1517/14656561003713534; Lerman MA, 2015, PEDIATR DRUGS, V17, P283, DOI 10.1007/s40272-015-0128-2; Li PF, 2014, IMMUNOLOGY, V142, P216, DOI 10.1111/imm.12242; Liu XC, 2013, DIABETES, V62, P4228, DOI 10.2337/db12-1710; Lu SL, 2013, ANTIMICROB AGENTS CH, V57, P5366, DOI 10.1128/AAC.00322-13; Ma JX, 1996, CURR EYE RES, V15, P1117, DOI 10.3109/02713689608995143; Maleki A, 2016, EXPERT REV CLIN IMMU, V12, P775, DOI 10.1586/1744666X.2016.1166052; Malhotra S, 2008, J IMMUNOL, V181, P3955, DOI 10.4049/jimmunol.181.6.3955; McBride JD, 2017, INT J HEMATOL, V105, P748, DOI 10.1007/s12185-017-2205-5; McBride JD, 2014, J INVEST DERMATOL, V134, P1725, DOI 10.1038/jid.2014.40; Namba K, 2002, J LEUKOCYTE BIOL, V72, P946; Natkunarajah M, 2007, BRIT J OPHTHALMOL, V91, P330, DOI 10.1136/bjo.2005.083725; Nguyen QD, 2006, RETINA-J RET VIT DIS, P1; Oswal Kadambari S, 2013, BMC Res Notes, V6, P167, DOI 10.1186/1756-0500-6-167; Reeves SW, 2006, OPHTHALMOLOGY, V113, P302, DOI 10.1016/j.ophtha.2005.10.008; Shen B, 2009, J BIOL CHEM, V284, P35471, DOI 10.1074/jbc.M109.046813; Siddique SS, 2011, EXPERT OPIN INV DRUG, V20, P1497, DOI 10.1517/13543784.2011.617741; Silver P, 2015, J IMMUNOL, V194, P3011, DOI 10.4049/jimmunol.1402650; Skarbez K, 2010, EXPERT REV OPHTHALMO, V5, P557, DOI 10.1586/EOP.10.44; Staal FJT, 2008, EUR J IMMUNOL, V38, P1788, DOI 10.1002/eji.200738118; Staal FJT, 2008, HAEMATOLOGICA, V93, P493, DOI 10.3324/haematol.12917; Suhler EB, 2008, AM J OPHTHALMOL, V146, P890, DOI 10.1016/j.ajo.2008.09.014; Yin H, 2010, HYPERTENSION, V56, P260, DOI 10.1161/HYPERTENSIONAHA.110.152330; Yiu WH, 2016, KIDNEY INT, V89, P386, DOI 10.1038/ki.2015.331	42	2	2	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 21	2020	11								975	10.3389/fimmu.2020.00975	http://dx.doi.org/10.3389/fimmu.2020.00975			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW8PB	32508841	Green Published, gold			2022-12-18	WOS:000539404600001
J	Rahat, MA; Kzhyshkowska, J; Iragavarapu-Charyulu, V				Rahat, Michal A.; Kzhyshkowska, Julia; Iragavarapu-Charyulu, Vijaya			Editorial: Targeting Angiogenesis to Treat Autoimmune Diseases and Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						angiogenesis; autoimmunity; semaphorins; MMPs; EMMPRIN; TRPs; YKL-39; VEGF			[Rahat, Michal A.] Carmel Hosp, Immunotherapy Lab, Haifa, Israel; [Rahat, Michal A.] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel; [Kzhyshkowska, Julia] Heidelberg Univ, Med Fac Mannheim, Inst Transfus Med & Immunol, Mannheim, Germany; [Kzhyshkowska, Julia] German Red Cross Blood Serv Baden Wurttemberg Hes, Mannheim, Germany; [Kzhyshkowska, Julia] Natl Res Tomsk State Univ, Lab Translat Cellular & Mol Biomed, Tomsk, Russia; [Iragavarapu-Charyulu, Vijaya] Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA	Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Ruprecht Karls University Heidelberg; Tomsk State University; State University System of Florida; Florida Atlantic University	Rahat, MA (corresponding author), Carmel Hosp, Immunotherapy Lab, Haifa, Israel.; Rahat, MA (corresponding author), Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel.	mrahat@netvision.net.il						Allen E, 2016, COLD SH Q B, V81, P21, DOI 10.1101/sqb.2016.81.030940; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Gacche RN, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.14; Wu JB, 2018, ONCOTARGETS THER, V11, P6901, DOI 10.2147/OTT.S172042; Yang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00978	5	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 21	2020	11								1005	10.3389/fimmu.2020.01005	http://dx.doi.org/10.3389/fimmu.2020.01005			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LW8PZ	32528478	Green Published, gold			2022-12-18	WOS:000539407200001
J	Wang, MY; Zhou, HH; Zhang, CM; Su, HX; Li, SL; Ji, SR; Liu, EQ; Wu, Y				Wang, Ming-Yu; Zhou, Hai-Hong; Zhang, Chun-Miao; Su, Hai-Xiang; Li, Shuo-Lei; Ji, Shang-Rong; Liu, Enqi; Wu, Yi			A Functional Genetic Variant at the C-Reactive Protein Promoter (rs3091244) Is Not Associated With Cancer Risk in a Chinese Population	FRONTIERS IN IMMUNOLOGY			English	Article						cancer; inflammation; C-reactive protein; genetic variants; cancer risk	POLYMORPHISMS; INFLAMMATION; IMMUNITY; BINDS	Background:The association of genetically elevated levels of circulating C-reactive protein (CRP) with cancer risk has been extensively investigated in European populations; however, there are conflicting conclusions. The tri-allelic rs3091244 is a functionally validated genetic variant, and its allelic frequencies differ significantly between European and Asian populations. Here, we examined the association of rs3091244 with cancer risk in a Chinese population. Methods:rs3091244 was genotyped by Sanger sequencing in 4,971 cancer cases and 2,485 controls. The rs1205 and rs2794521 gene variants were also genotyped using TaqMan assays in subgroups. Results:No association was detected between the genotyped CRP variants and cancer risk, with or without distinguishing cancer types, suggesting that circulating CRP is not causally involved in tumorigenesis in Chinese populations.	[Wang, Ming-Yu; Zhang, Chun-Miao; Li, Shuo-Lei; Ji, Shang-Rong] Lanzhou Univ, Sch Life Sci, MOE Key Lab Cell Act & Stress Adaptat, Translat Med Res Ctr, Lanzhou, Peoples R China; [Zhou, Hai-Hong; Su, Hai-Xiang] Gansu Prov Canc Hosp, Childrens Res Inst, Lanzhou, Peoples R China; [Liu, Enqi; Wu, Yi] Xi An Jiao Tong Univ, Sch Basic Med Sci, MOE Key Lab Environm & Genes Related Dis, Xian, Peoples R China; [Wu, Yi] Xi An Jiao Tong Univ, Affiliated Childrens Hosp, Xian, Peoples R China	Lanzhou University; Xi'an Jiaotong University; Xi'an Jiaotong University	Liu, EQ; Wu, Y (corresponding author), Xi An Jiao Tong Univ, Sch Basic Med Sci, MOE Key Lab Environm & Genes Related Dis, Xian, Peoples R China.; Wu, Y (corresponding author), Xi An Jiao Tong Univ, Affiliated Childrens Hosp, Xian, Peoples R China.	liuenqi@mail.xjtu.edu.cn; wuy@lzu.edu.cn		Ji, Shang-Rong/0000-0001-8595-3756; Wu, Yi/0000-0003-0365-5590	National Natural Science Foundation of China [31671339, 31570749, 31960141]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (grant numbers: 31671339, 31570749, and 31960141).	Allin KH, 2011, CRIT REV CL LAB SCI, V48, P155, DOI 10.3109/10408363.2011.599831; Allin KH, 2010, JNCI-J NATL CANCER I, V102, P202, DOI 10.1093/jnci/djp459; Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305; Chang SN, 2012, J INTERN MED, V272, P305, DOI 10.1111/j.1365-2796.2012.02531.x; Du Clos TW, 2013, ISBN INFLAMM, V2013, DOI 10.1155/2013/ 379040; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hajishengallis G, 2017, NAT IMMUNOL, V18, P1288, DOI 10.1038/ni.3858; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heikkila K, 2010, EUR J CANC, V47, P404, DOI [10.1016/kejca.2010.07.032, DOI 10.1016/KEJCA.2010.07.032]; Kim ES, 2018, ONCOGENE, V37, P28, DOI 10.1038/onc.2017.298; Kim ES, 2014, ONCOGENE, V33, P3583, DOI 10.1038/onc.2013.319; Kim HA, 2009, J RHEUMATOL, V36, P2238, DOI 10.3899/jrheum.090243; Li HY, 2019, CARDIOVASC RES, V115, P440, DOI 10.1093/cvr/cvy181; lidcliadyen JO, 2018, FRONT IMMUNOL, V9, P1351, DOI [10.3389/fimmu.2018.01351, DOI 10.3389/FIMMU.2018.01351]; Ngwa DN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00166; Nimptsch K, 2015, INT J CANCER, V136, P1181, DOI 10.1002/ijc.29086; Nlarkt SC, 2014, PROSTATE, V74, P1034, DOI [10.1002/pros.22820, DOI 10.1002/PROS.22820]; Pathak A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00943; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Schimmack S, 2019, ENDOCR CONNECT, V8, P1007, DOI 10.1530/EC-19-0132; Siemes C, 2006, J CLIN ONCOL, V24, P5216, DOI 10.1200/JCO.2006.07.1381; Slattery ML, 2011, INT J CANCER, V128, P2726, DOI 10.1002/ijc.25721; Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754; Szalai AJ, 2005, J MOL MED, V83, P440, DOI 10.1007/s00109-005-0658-0; Wang XL, 2019, INT J EPIDEMIOL, V48, P767, DOI 10.1093/ije/dyy244; Wen WQ, 2008, CANCER-AM CANCER SOC, V112, P2409, DOI 10.1002/cncr.23453; Wu Y, 2015, BIOL CHEM, V396, P1181, DOI 10.1515/hsz-2015-0149; Yang J, 2007, CANCER CELL, V12, P252, DOI 10.1016/j.ccr.2007.08.008; Zhang SC, 2020, ELIFE, V9, DOI 10.7554/eLife.51317	29	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 14	2020	11								926	10.3389/fimmu.2020.00926	http://dx.doi.org/10.3389/fimmu.2020.00926			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MV2ZB	32477370	gold, Green Published			2022-12-18	WOS:000556230200001
J	Talreja, J; Bauerfeld, C; Sendler, E; Pique-Regi, R; Luca, F; Samavati, L				Talreja, Jaya; Bauerfeld, Christian; Sendler, Edward; Pique-Regi, Roger; Luca, Francesca; Samavati, Lobelia			Derangement of Metabolic and Lysosomal Gene Profiles in Response to Dexamethasone Treatment in Sarcoidosis	FRONTIERS IN IMMUNOLOGY			English	Article						dexamethasone; corticosteroids; gene expression; sarcoidosis; alveolar macrophages; monocytes; RNA-seq	ALVEOLAR MACROPHAGES; CANCER-RISK; PULMONARY; IDENTIFICATION; ACTIVATION; MECHANISMS; INHIBITION; EXPRESSION; INNATE; KINASE	Glucocorticoids (GCs) play a central role in modulation of inflammation in various diseases, including respiratory diseases such as sarcoidosis. Surprisingly, the specific anti-inflammatory effects of GCs on different myeloid cells especially in macrophages remain poorly understood. Sarcoidosis is a systemic granulomatous disease of unknown etiology that occurs worldwide and is characterized by granuloma formation in different organs. Alveolar macrophages play a role in sarcoidosis granuloma formation and progressive lung disease. The goal of the present study is to identify the effect of GCs on transcriptomic profiles and the cellular pathways in sarcoidosis alveolar macrophages and their corresponding blood myeloid cells. We determined and compared the whole transcriptional signatures of alveolar macrophages from sarcoidosis patients and blood CD14(+) monocytes of the same subjects in response to in vitro treatment with dexamethasone (DEX) via RNA-sequencing. In response to DEX, we identified 2,834 genes that were differentially expressed in AM. Predominant pathways affected were as following: metabolic pathway (FDR = 4.1 x 10(-10)), lysosome (FDR = 6.3 x 10(-9)), phagosome (FDR = 3.9 x 10(-5)). The DEX effect on AMs is associated with metabolic derangements involving glycolysis, oxidative phosphorylation and lipid metabolisms. In contrast, the top impacted pathways in response to DEX treatment in blood CD14(+) monocytes were as following; cytokine-cytokine receptor interaction (FDR = 6 x 10(-6)) and transcriptional misregulation in cancer (FDR = 1 x 10(-4)). Pathways similarly affected in both cell types were genes involved in lysosomes, cytoskeleton and transcriptional misregulation in cancer. These data suggest that the different effects of DEX on AMs and peripheral blood monocytes are partly dictated by lineage specific transcriptional programs and their physiological functions.	[Talreja, Jaya; Samavati, Lobelia] Wayne State Univ, Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Detroit, MI 48201 USA; [Talreja, Jaya; Bauerfeld, Christian; Samavati, Lobelia] Wayne State Univ, Detroit Med Ctr, Detroit, MI 48202 USA; [Bauerfeld, Christian] Wayne State Univ, Sch Med, Dept Pediat, Div Crit Care, Detroit, MI 48201 USA; [Sendler, Edward; Pique-Regi, Roger; Luca, Francesca; Samavati, Lobelia] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA; [Pique-Regi, Roger; Luca, Francesca] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA	Wayne State University; Detroit Medical Center; Wayne State University; Wayne State University; Wayne State University; Wayne State University	Samavati, L (corresponding author), Wayne State Univ, Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Detroit, MI 48201 USA.; Samavati, L (corresponding author), Wayne State Univ, Detroit Med Ctr, Detroit, MI 48202 USA.; Samavati, L (corresponding author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA.	ay6003@wayne.edu			Department of Medicine [R01HL113508]; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine	Department of Medicine; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine	This work was supported by a grant (R01HL113508) (LS) as well as the Department of Medicine and the Center for Molecular Medicine and Genetics, Wayne State University School of Medicine (LS).	Aberdein JD, 2013, CLIN EXP IMMUNOL, V174, P193, DOI 10.1111/cei.12170; Abraham DM, 2014, CIRC RES, V114, P938, DOI 10.1161/CIRCRESAHA.113.303238; Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159; Ampasavate C, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22859; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Askling J, 1999, AM J RESP CRIT CARE, V160, P1668, DOI 10.1164/ajrccm.160.5.9904045; Austin S, 2012, J CELL SCI, V125, P4963, DOI 10.1242/jcs.113662; Backlund MG, 2005, J BIOL CHEM, V280, P3217, DOI 10.1074/jbc.M411221200; Ballabio A, 2009, BBA-MOL CELL RES, V1793, P684, DOI 10.1016/j.bbamcr.2008.12.001; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bologna C, 1997, ANN RHEUM DIS, V56, P97, DOI 10.1136/ard.56.2.97; Bonifazi M, 2015, CHEST, V147, P778, DOI 10.1378/chest.14-1475; Brown FC, 2018, CANCER DISCOV, V8, P478, DOI 10.1158/2159-8290.CD-17-1271; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Camus SM, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201812135; Cerrone M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00127-0; Ciriaco M, 2013, J PHARMACOL PHARMACO, V4, pS94, DOI 10.4103/0976-500X.120975; Colletti GA, 2012, J BIOL CHEM, V287, P8082, DOI 10.1074/jbc.M111.285536; Costabel U, 1999, EUR RESPIR J, V14, P735, DOI 10.1034/j.1399-3003.1999.14d02.x; Davies LC, 2013, NAT IMMUNOL, V14, P986, DOI 10.1038/ni.2705; Dawson MI, 2012, BBA-MOL CELL BIOL L, V1821, P21, DOI 10.1016/j.bbalip.2011.09.014; Diskin C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00270; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Endo M, 2007, J BIOL CHEM, V282, P13692, DOI 10.1074/jbc.M610873200; Epelman S, 2014, IMMUNITY, V41, P21, DOI 10.1016/j.immuni.2014.06.013; Fardet L, 2007, RHEUMATOLOGY, V46, P1102, DOI 10.1093/rheumatology/kem062; FAZEL SB, 1992, THORAX, V47, P964, DOI 10.1136/thx.47.11.964; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Flynn JL, 2011, MUCOSAL IMMUNOL, V4, P271, DOI 10.1038/mi.2011.14; Garcia-Gonzalez PA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01350; Godot V, 2006, ALLERGY, V61, P886, DOI 10.1111/j.1398-9995.2006.01065.x; Gottlieb JE, 1997, CHEST, V111, P623, DOI 10.1378/chest.111.3.623; Grafone T, 2012, ONCOL REV, V6, P64, DOI 10.4081/oncol.2012.e8; Grutters JC, 2006, EUR RESPIR J, V28, P627, DOI 10.1183/09031936.06.00105805; Hao XL, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152438; Haworth O, 2007, P NATL ACAD SCI USA, V104, P20647, DOI 10.1073/pnas.0710633105; HAZIOT A, 1993, J IMMUNOL, V150, P5556; Hirokawa N, 2010, NEURON, V68, P610, DOI 10.1016/j.neuron.2010.09.039; Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714; Jonsson F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036034; Judson MA, 2012, RESP MED, V106, P1351, DOI 10.1016/j.rmed.2012.01.013; Kaitaniemi S, 2009, CELL MOL LIFE SCI, V66, P2743, DOI 10.1007/s00018-009-0076-5; Kaskow BJ, 2012, BIOCHEM BIOPH RES CO, V417, P653, DOI 10.1016/j.bbrc.2011.11.099; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; Kingah P, 2016, SARCOIDOSIS VASC DIF, V33, P209; Kotake T, 2008, J BIOL CHEM, V283, P8125, DOI 10.1074/jbc.M710078200; Koyama-Nasu R, 2013, ONCOGENE, V32, P3840, DOI 10.1038/onc.2012.399; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; Lim CY, 2016, J CELL BIOL, V214, P653, DOI 10.1083/jcb.201607005; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Liu PS, 2017, NAT IMMUNOL, V18, P985, DOI 10.1038/ni.3796; Minton K, 2016, NAT REV IMMUNOL, V16, DOI 10.1038/nri.2016.132; Mostafa MM, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-018-0467-2; Muzikar KA, 2009, P NATL ACAD SCI USA, V106, P16598, DOI 10.1073/pnas.0909192106; Nakamura M, 2012, CANCER SCI, V103, P26, DOI 10.1111/j.1349-7006.2011.02108.x; Napolitano G, 2016, J CELL SCI, V129, P2475, DOI 10.1242/jcs.146365; Palmieri EM, 2014, FEBS LETT, V588, P4807, DOI 10.1016/j.febslet.2014.11.015; Papiris SA, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0146-4; Pfaendtner J, 2010, P NATL ACAD SCI USA, V107, P7299, DOI 10.1073/pnas.0911675107; PORTER CD, 1994, BLOOD, V84, P2767; Pu J, 2016, J CELL SCI, V129, P4329, DOI 10.1242/jcs.196287; Rastogi R, 2011, AM J RESP CRIT CARE, V183, P500, DOI 10.1164/rccm.201005-0792OC; Roberts AJ, 2018, BIOCHEM SOC T, V46, P967, DOI 10.1042/BST20170568; Roberts AJ, 2013, NAT REV MOL CELL BIO, V14, P713, DOI 10.1038/nrm3667; Romer FK, 1998, EUR RESPIR J, V12, P906, DOI 10.1183/09031936.98.12040906; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Sogaard KK, 2015, EUR RESPIR J, V45, P269, DOI 10.1183/09031936.00084414; Takahashi S, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-13; Talreja J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02941-4; Talreja J, 2016, J IMMUNOL, V197, P1368, DOI 10.4049/jimmunol.1600258; van de Garde MDB, 2014, J IMMUNOL, V192, P1196, DOI 10.4049/jimmunol.1302138; Warrington TP, 2006, MAYO CLIN PROC, V81, P1361, DOI 10.4065/81.10.1361; West SG, 2018, CURR OPIN RHEUMATOL, V30, P243, DOI 10.1097/BOR.0000000000000489; Willems M, 2016, ONCOTARGET, V7, P66310, DOI 10.18632/oncotarget.11624; Wong CO, 2017, CELL HOST MICROBE, V21, P719, DOI 10.1016/j.chom.2017.05.002; Yashiro T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37894-9; Zahuczky G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021349	79	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2020	11								779	10.3389/fimmu.2020.00779	http://dx.doi.org/10.3389/fimmu.2020.00779			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LT4VQ	32477331	Green Published, gold			2022-12-18	WOS:000537070900001
J	Marchalot, A; Ashi, MO; Lambert, JM; Carrion, C; Lecardeur, S; Srour, N; Delpy, L; Le Pennec, S				Marchalot, Anne; Ashi, Mohamad Omar; Lambert, Jean-Marie; Carrion, Claire; Lecardeur, Sandrine; Srour, Nivine; Delpy, Laurent; Le Pennec, Soazig			Uncoupling Splicing From Transcription Using Antisense Oligonucleotides Reveals a Dual Role for I Exon Donor Splice Sites in Antibody Class Switching	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; class switch recombination; splicing; germline transcripts; I exon; antisense oligonucleotides	RNA-POLYMERASE-II; TARGETED DNA DEAMINATION; AID; REGION; RECOMBINATION; CLEAVAGE; GENE; HYPERMUTATION	Class switch recombination (CSR) changes antibody isotype by replacing C mu constant exons with different constant exons located downstream on the immunoglobulin heavy (IgH) locus. During CSR, transcription through specific switch (S) regions and processing of non-coding germline transcripts (GLTs) are essential for the targeting of activation-induced cytidine deaminase (AID). While CSR to IgG1 is abolished in mice lacking an I gamma 1 exon donor splice site (dss), many questions remain regarding the importance of I exon dss recognition in CSR. To further clarify the role of I exon dss in CSR, we first evaluated RNA polymerase II (RNA pol II) loading and chromatin accessibility in S regions after activation of mouse B cells lacking I gamma 1 dss. We found that deletion of I gamma 1 dss markedly reduced RNA pol II pausing and active chromatin marks in the S gamma 1 region. We then challenged the post-transcriptional function of I exon dss in CSR by using antisense oligonucleotides (ASOs) masking I exon dss on GLTs. Treatment of stimulated B cells with an ASO targeting I gamma 1 dss, in the acceptor S gamma 1 region, or I mu dss, in the donor S mu region, did not decrease germline transcription but strongly inhibited constitutive splicing and CSR to IgG1. Supporting a global effect on CSR, we also observed that the targeting of I mu dss reduced CSR to IgG3 and, to a lesser extent, IgG2b isotypes. Altogether, this study reveals that the recognition of I exon dss first supports RNA pol II pausing and the opening of chromatin in targeted S regions and that GLT splicing events using constitutive I exon dss appear mandatory for the later steps of CSR, most likely by guiding AID to S regions.	[Marchalot, Anne; Ashi, Mohamad Omar; Lambert, Jean-Marie; Carrion, Claire; Lecardeur, Sandrine; Srour, Nivine; Delpy, Laurent; Le Pennec, Soazig] Univ Limoges, Unite Mixte Rech CNRS 7276, INSERM 1262, Limoges, France; [Srour, Nivine] McGill Univ, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ, Canada; [Srour, Nivine] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Srour, Nivine] McGill Univ, Dept Med, Montreal, PQ, Canada	Universite de Limoges; Lady Davis Institute; McGill University; McGill University; McGill University	Delpy, L; Le Pennec, S (corresponding author), Univ Limoges, Unite Mixte Rech CNRS 7276, INSERM 1262, Limoges, France.	laurent.delpy@unilim.fr; soazig.le-pennec@unilim.fr	Delpy, Laurent/O-8408-2016; Ashi, Mohamad Omar/F-8778-2018	Delpy, Laurent/0000-0002-9480-8515; Marchalot, Anne/0000-0002-3042-8206; carrion, claire/0000-0003-3221-6319; Ashi, Mohamad Omar/0000-0002-3749-2198; Lambert, Jean-Marie/0000-0003-4812-6596; SROUR, Nivine/0000-0001-5302-9331	Fondation ARC [PJA 20161204724]; INCa [PLBIO15-256]; ANR [2017-CE15-0024-01]; Ligue Contre le Cancer [CD87, CD19, CD23]; Fondation Francaise pour la Recherche contre le Myelome et les Gammapathies monoclonales (FFRMG)	Fondation ARC; INCa(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation Francaise pour la Recherche contre le Myelome et les Gammapathies monoclonales (FFRMG)	This work was supported by grants from Fondation ARC (PJA 20161204724), INCa (PLBIO15-256), ANR (2017-CE15-0024-01), Ligue Contre le Cancer (CD87, CD19, and CD23) and Fondation Francaise pour la Recherche contre le Myelome et les Gammapathies monoclonales (FFRMG).	Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Ashi MO, 2019, CELL MOL IMMUNOL, V16, P810, DOI 10.1038/s41423-018-0160-6; Basu U, 2011, CELL, V144, P353, DOI 10.1016/j.cell.2011.01.001; Bestas B, 2014, J CLIN INVEST, V124, P4067, DOI 10.1172/JCI76175; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chen J, 2018, CELL RES, V28, P981, DOI 10.1038/s41422-018-0076-9; Conticello SG, 2008, MOL CELL, V31, P474, DOI 10.1016/j.molcel.2008.07.009; Damgaard CK, 2008, MOL CELL, V29, P271, DOI 10.1016/j.molcel.2007.11.035; Daniel JA, 2013, MOL CELL, V50, P309, DOI 10.1016/j.molcel.2013.04.017; de Almeida CR, 2018, MOL CELL, V70, P650, DOI 10.1016/j.molcel.2018.04.001; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Dewaele M, 2016, J CLIN INVEST, V126, P68, DOI 10.1172/JCI82534; Furger A, 2002, GENE DEV, V16, P2792, DOI 10.1101/gad.983602; Hein K, 1998, J EXP MED, V188, P2369, DOI 10.1084/jem.188.12.2369; Hu WJ, 2015, P NATL ACAD SCI USA, V112, P5791, DOI 10.1073/pnas.1506167112; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Jeevan-Raj BP, 2011, J EXP MED, V208, P1649, DOI 10.1084/jem.20110118; Kenter AL, 2012, SEMIN IMMUNOL, V24, P281, DOI 10.1016/j.smim.2012.06.001; Kuang FL, 2009, P NATL ACAD SCI USA, V106, P5288, DOI 10.1073/pnas.0901368106; Kuzin II, 2000, J IMMUNOL, V164, P1451, DOI 10.4049/jimmunol.164.3.1451; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; Marchalot A, 2019, UNCOUPLING SPLICING, DOI [10.1101/850867, DOI 10.1101/850867]; Matthews AJ, 2014, ADV IMMUNOL, V122, P1, DOI 10.1016/B978-0-12-800267-4.00001-8; Moabbi AM, 2012, P NATL ACAD SCI USA, V109, P8505, DOI 10.1073/pnas.1112400109; Mondal S, 2016, P NATL ACAD SCI USA, V113, pE1545, DOI 10.1073/pnas.1601678113; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nowak U, 2011, NAT IMMUNOL, V12, P160, DOI 10.1038/ni.1977; Pavri R, 2011, ADV IMMUNOL, V110, P1, DOI 10.1016/B978-0-12-387663-8.00005-3; Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017; Rouaud P, 2013, J EXP MED, V210, P1501, DOI 10.1084/jem.20130072; Ruminy P, 2007, GENE CHROMOSOME CANC, V46, P735, DOI 10.1002/gcc.20453; Seidl KJ, 1998, INT IMMUNOL, V10, P1683, DOI 10.1093/intimm/10.11.1683; Shaul O, 2017, INT J BIOCHEM CELL B, V91, P145, DOI 10.1016/j.biocel.2017.06.016; Stanlie A, 2012, PLOS GENET, V8, P576, DOI 10.1371/journal.pgen.1002675; Stanlie A, 2010, P NATL ACAD SCI USA, V107, P22190, DOI 10.1073/pnas.1016923108; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; Wang LL, 2009, J EXP MED, V206, P1817, DOI 10.1084/jem.20081678; Yewdell WT, 2017, INT IMMUNOL, V29, P183, DOI 10.1093/intimm/dxx027; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; Zheng SM, 2015, CELL, V161, P762, DOI 10.1016/j.cell.2015.03.020	43	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 8	2020	11								780	10.3389/fimmu.2020.00780	http://dx.doi.org/10.3389/fimmu.2020.00780			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LT7QJ	32477332	Green Published, Green Submitted, gold			2022-12-18	WOS:000537260900001
J	Huang, LT; Li, GH; Yu, Q; Xu, YP; Cvetkovski, S; Wang, X; Parajuli, N; Udo-Inyang, I; Kaplan, D; Zhou, L; Yao, ZR; Mi, QS				Huang, Linting; Li, Gui-Hua; Yu, Qian; Xu, Yingping; Cvetkovski, Steven; Wang, Xuan; Parajuli, Nirmal; Udo-Inyang, Imo; Kaplan, Daniel; Zhou, Li; Yao, Zhirong; Mi, Qing-Sheng			Smad2/4 Signaling Pathway Is Critical for Epidermal Langerhans Cell Repopulation Under Inflammatory Condition but Not Required for Their Homeostasis at Steady State	FRONTIERS IN IMMUNOLOGY			English	Article						Langerhans cells; Smad2; Smad3; Smad4; transforming growth factor-beta 1	TGF-BETA; AUTOCRINE/PARACRINE TGF-BETA-1; SKIN; MICE; ONTOGENY; DELETION	Epidermal Langerhans cells (LCs) are skin-resident dendritic cells that are essential for the induction of skin immunity and tolerance. Transforming growth factor-beta 1 (TGF beta 1) is a crucial factor for LC maintenance and function. However, the underlying TGF beta 1 signaling pathways remain unclear. Our previous research has shown that the TGF beta 1/Smad3 signaling pathway does not impact LC homeostasis and maturation. In this study, we generated mice with conditional deletions of either individual Smad2, Smad4, or both Smad2 and Smad4 in the LC lineage or myeloid lineage, to further explore the impact of TGF beta 1/Smad signaling pathways on LCs. We found that interruption of Smad2 or Smad4 individually or simultaneously in the LC lineage did not significantly impact the maintenance, maturation, antigen uptake, and migration of LCs in vivo or in vitro during steady state. However, the interruption of both Smad2 and Smad4 pathways in the myeloid lineage led to a dramatic inhibition of bone marrow-derived LCs in the inflammatory state. Overall, our data suggest that canonical TGF beta 1/Smad2/4 signaling pathways are dispensable for epidermal LC homeostasis and maturation at steady state, but are critical for the long-term LC repopulation directly originating from the bone marrow in the inflammatory state.	[Huang, Linting; Yao, Zhirong] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Dermatol, Shanghai, Peoples R China; [Huang, Linting; Li, Gui-Hua; Yu, Qian; Xu, Yingping; Cvetkovski, Steven; Wang, Xuan; Parajuli, Nirmal; Udo-Inyang, Imo; Zhou, Li; Mi, Qing-Sheng] Henry Ford Hlth Syst, Dept Dermatol, Ctr Cutaneous Biol & Immunol, Detroit, MI 48235 USA; [Huang, Linting; Li, Gui-Hua; Yu, Qian; Xu, Yingping; Cvetkovski, Steven; Wang, Xuan; Parajuli, Nirmal; Udo-Inyang, Imo; Zhou, Li; Mi, Qing-Sheng] Henry Ford Hlth Syst, Henry Ford Canc Inst, Immunol Res Program, Detroit, MI 48235 USA; [Huang, Linting; Yao, Zhirong] Shanghai Jiao Tong Univ, Sch Med, Inst Dermatol, Shanghai, Peoples R China; [Kaplan, Daniel] Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15260 USA; [Kaplan, Daniel] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA; [Zhou, Li; Mi, Qing-Sheng] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI 48235 USA	Shanghai Jiao Tong University; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Henry Ford Health System; Henry Ford Hospital	Yao, ZR (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Dermatol, Shanghai, Peoples R China.; Mi, QS (corresponding author), Henry Ford Hlth Syst, Dept Dermatol, Ctr Cutaneous Biol & Immunol, Detroit, MI 48235 USA.; Mi, QS (corresponding author), Henry Ford Hlth Syst, Henry Ford Canc Inst, Immunol Res Program, Detroit, MI 48235 USA.; Yao, ZR (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Dermatol, Shanghai, Peoples R China.; Mi, QS (corresponding author), Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI 48235 USA.	yaozhirong@xinhuamed.com.cn; QMI1@hfhs.org	Li, Guihua/AAE-4946-2021	Parajuli, Nirmal/0000-0002-0799-6301	Henry Ford Immunology Program [T71016]; National Natural Science Foundation of China [81630083]	Henry Ford Immunology Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the Henry Ford Immunology Program (T71016) and the National Natural Science Foundation of China (81630083).	Bobr A, 2012, P NATL ACAD SCI USA, V109, P10492, DOI 10.1073/pnas.1119178109; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; Chopin M, 2013, J EXP MED, V210, P2967, DOI 10.1084/jem.20130930; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Doebel T, 2017, TRENDS IMMUNOL, V38, P817, DOI 10.1016/j.it.2017.06.008; Ferrer IR, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aax8704; Ginhoux F, 2010, IMMUNOL CELL BIOL, V88, P387, DOI 10.1038/icb.2010.38; Guilliams M, 2017, NAT REV IMMUNOL, V17, P451, DOI 10.1038/nri.2017.42; Hemmi H, 2001, INT IMMUNOL, V13, P695, DOI 10.1093/intimm/13.5.695; Kaplan DH, 2007, J EXP MED, V204, P2545, DOI 10.1084/jem.20071401; Kaplan DH, 2017, NAT IMMUNOL, V18, P1068, DOI 10.1038/ni.3815; Kaplan DH, 2010, TRENDS IMMUNOL, V31, P446, DOI 10.1016/j.it.2010.08.006; Kel JM, 2010, J IMMUNOL, V185, P3248, DOI 10.4049/jimmunol.1000981; Kellersch B, 2013, BLOOD, V121, P298, DOI 10.1182/blood-2012-06-439786; Mi QS, 2013, INT J BIOCHEM CELL B, V45, P395, DOI 10.1016/j.biocel.2012.11.004; Mi QS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031278; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Romani N, 2010, IMMUNOL REV, V234, P120, DOI 10.1111/j.0105-2896.2009.00886.x; Sere K, 2012, IMMUNITY, V37, P905, DOI 10.1016/j.immuni.2012.07.019; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; Wang YY, 2012, P NATL ACAD SCI USA, V109, pE343, DOI 10.1073/pnas.1115635109; Wang ZN, 2019, J IMMUNOL, V202, P2999, DOI 10.4049/jimmunol.1801578; Xu YP, 2012, J INVEST DERMATOL, V132, P2106, DOI 10.1038/jid.2012.71; Yao Y, 2018, J ALLERGY CLIN IMMUN, V142, P976, DOI 10.1016/j.jaci.2018.04.024; Zahner SP, 2011, J IMMUNOL, V187, P5069, DOI 10.4049/jimmunol.1101880; Zhang X, 2016, ALLERGY, V71, P758, DOI 10.1111/all.12871; Zhang XL, 2017, ONCOTARGET, V8, P112875, DOI 10.18632/oncotarget.22843; Zhang XL, 2016, ONCOTARGET, V7, P37498, DOI 10.18632/oncotarget.9546; Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129	31	2	3	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 7	2020	11								912	10.3389/fimmu.2020.00912	http://dx.doi.org/10.3389/fimmu.2020.00912			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LT2VC	32457763	Green Published, gold			2022-12-18	WOS:000536928800001
J	Medaglini, D; Andersen, P; Rappuoli, R				Medaglini, Donata; Andersen, Peter; Rappuoli, Rino			Editorial: Advanced Immunization Technologies for Next Generation Vaccines	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						ADITEC; immunization technologies; vaccines; adjuvants; vaccine vectors; systems vaccinology; human immunology	IMMUNITY		[Medaglini, Donata] Univ Siena, Dept Med Biotechnol, Siena, Italy; [Andersen, Peter] Statens Serum Inst, Dept Infect Dis Immunol, Copenhagen, Denmark; [Rappuoli, Rino] GSK, Siena, Italy; [Rappuoli, Rino] VAMRes Lab, Toscana Life Sci, Siena, Italy; [Rappuoli, Rino] Imperial Coll, London, England	University of Siena; Statens Serum Institut; GlaxoSmithKline; Imperial College London	Medaglini, D (corresponding author), Univ Siena, Dept Med Biotechnol, Siena, Italy.	donata.medaglini@unisi.it	MEDAGLINI, DONATA/R-1149-2018	MEDAGLINI, DONATA/0000-0003-1729-7325	Commission of the European Communities, Seventh Framework Programme [HEALTH-2011-280873]	Commission of the European Communities, Seventh Framework Programme	We acknowledge the financial support from the Commission of the European Communities, Seventh Framework Programme, contract HEALTH-2011-280873 Advanced Immunization Technologies (ADITEC).	Ciabattini A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01305; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; Li SZ, 2013, SEMIN IMMUNOL, V25, P209, DOI 10.1016/j.smim.2013.05.003; Medaglini D, 2018, VACCINE, V36, P1136, DOI 10.1016/j.vaccine.2017.11.069; Nakaya HI, 2016, P NATL ACAD SCI USA, V113, P1853, DOI 10.1073/pnas.1519690113; Rappuoli R, 2019, J EXP MED, V216, P7, DOI 10.1084/jem.20182160; Rappuoli R, 2014, VACCINE, V32, P4705, DOI 10.1016/j.vaccine.2014.06.071; Rappuoli R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003826	8	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2020	11								878	10.3389/fimmu.2020.00878	http://dx.doi.org/10.3389/fimmu.2020.00878			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LS8JS	32435250	Green Published, gold			2022-12-18	WOS:000536627800001
J	Espino-Paisan, L; Agudo-Jimenez, T; Rosales-Martinez, I; Lopez-Cotarelo, P; Garcia-Martinez, MA; Dominguez-Mozo, MI; Perez-Perez, S; Dieli-Crimi, R; Comabella, M; Urcelay, E; Alvarez-Lafuente, R				Espino-Paisan, Laura; Agudo-Jimenez, Teresa; Rosales-Martinez, Isabel; Lopez-Cotarelo, Pilar; Angel Garcia-Martinez, Maria; Inmaculada Dominguez-Mozo, Maria; Perez-Perez, Silvia; Dieli-Crimi, Romina; Comabella, Manuel; Urcelay, Elena; Alvarez-Lafuente, Roberto			A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; SNP; HHV-6; myelin basic protein; relapse; sex differences; genetic marker	DIAGNOSTIC-CRITERIA; CROSS-REACTIVITY; GUIDELINES; DISEASE; CD69	Myelin basic protein (MBP) is thought to be one of the key autoantigens in multiple sclerosis (MS) development. A recent study described the association of the single nucleotide polymorphism (SNP) rs12959006, within the MBP gene, with a higher risk of relapse and worse prognosis. We aim at studying potential associations of this SNP to MS in an independent population. Clinical data of the first 5 years of the disease were collected retrospectively from 291 MS confirmed patients. MBP polymorphism rs12959006 was genotyped in all patients. Associations with EDSS, number of relapses and serology for Herpesvirus 6 (HHV-6) and Epstein Barr (EBV) viruses were studied. Lymphocyte activation measured by CD69 expression was also analyzed according to sex and rs12959006 genotype. The rs12959006 polymorphism contributed significantly to a higher number of relapses at 5 years after onset only in male patients (rs12959006*TT beta = 0.74 [0.36-1.09]; p = 7 x 10(-5)). Titers of anti-HHV6 IgG antibodies showed also a mild association with relapses, both in male and female patients (beta = 0.01 [0.01-0.02]; p = 3.7 x 10(-8)). Both the genetic variation in MBP and HHV-6 infection aid in predicting a higher number of relapses during the first years of MS. The association described in MBP rs12959006*T is exclusive to male patients.	[Espino-Paisan, Laura; Agudo-Jimenez, Teresa; Rosales-Martinez, Isabel; Lopez-Cotarelo, Pilar; Urcelay, Elena] Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Lab Invest Genet Enfermedades Complejas, Red Espanola Esclerosis Multiple REEM, Madrid, Spain; [Angel Garcia-Martinez, Maria; Inmaculada Dominguez-Mozo, Maria; Perez-Perez, Silvia; Alvarez-Lafuente, Roberto] Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Grp Invest Factores Ambientales Enfermedades Dege, Red Espanola Esclerosis Multiple REEM, Madrid, Spain; [Dieli-Crimi, Romina] Hosp Univ Vall dHebron HUVH, Serv Inmunol, Diagnost Immunol, Vall dHebron Res Inst VHIR, Barcelona, Spain; [Comabella, Manuel] Univ Autonoma Barcelona, Red Espanola Esclerosis Multiple REEM, Hosp Univ Vall dHebron,Inst Recerca Vall dHebron, Serv Neurol Neuroimmunol,Ctr Esclerosi Multiple C, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Espino-Paisan, L (corresponding author), Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Lab Invest Genet Enfermedades Complejas, Red Espanola Esclerosis Multiple REEM, Madrid, Spain.	lauraep80@gmail.com	; Lopez-Cotarelo Garcia de Diego, Pilar/Y-1777-2018	Espino-Paisan, Laura/0000-0001-9136-4106; Alvarez-Lafuente, Roberto/0000-0002-3132-1486; Lopez-Cotarelo Garcia de Diego, Pilar/0000-0003-1578-0110	Plan National de I+D+I, AES 2013-2016 - ISCIII [PI15/00821, PI16/01259]; European Regional Development Fund (ERDF) "A way to make Europe"; Fundacion Ramon Areces [CIVP18A3860]; Fundacion LAIR; REEM: Red Espanola de Esclerosis Multiple [RETICS-REEM RD16/0015/0013]; program "Formacion de Profesorado Universitario" -Ministerio de Educacion, Cultura y Deporte" [FPU16/00969]	Plan National de I+D+I, AES 2013-2016 - ISCIII; European Regional Development Fund (ERDF) "A way to make Europe"; Fundacion Ramon Areces; Fundacion LAIR; REEM: Red Espanola de Esclerosis Multiple; program "Formacion de Profesorado Universitario" -Ministerio de Educacion, Cultura y Deporte"	This work was supported by the projects PI15/00821 and PI16/01259, integrated in the Plan National de I+D+I, AES 2013-2016; funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) "A way to make Europe"; "Fundacion Ramon Areces" (CIVP18A3860) and "Fundacion LAIR". LE-P and MG-M are recipients of a contract from "REEM: Red Espanola de Esclerosis Multiple" (RETICS-REEM RD16/0015/0013; www.reem.es).SPP holds a research contract from the program "Formacion de Profesorado Universitario" -Ministerio de Educacion, Cultura y Deporte" (FPU16/00969).	Axisa PP, 2016, CURR OPIN NEUROL, V29, P345, DOI 10.1097/WCO.0000000000000319; Baranzini SE, 2017, TRENDS GENET, V33, P960, DOI 10.1016/j.tig.2017.09.004; Benedek G, 2017, P NATL ACAD SCI USA, V114, pE8421, DOI 10.1073/pnas.1712288114; Cheng WZ, 2012, FRONT BIOSCI-LANDMRK, V17, P1648, DOI 10.2741/4010; Golden LC, 2017, J NEUROSCI RES, V95, P633, DOI 10.1002/jnr.23955; Gonzalez-Amaro R, 2013, TRENDS MOL MED, V19, P625, DOI 10.1016/j.molmed.2013.07.006; Han ZJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8285653; Martin P, 2010, MOL CELL BIOL, V30, P4877, DOI 10.1128/MCB.00456-10; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Ortega-Madueno I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104836; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Radstake TRDJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005981; Rangachari M, 2013, J AUTOIMMUN, V45, P31, DOI 10.1016/j.jaut.2013.06.008; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Simpson S, 2012, MULT SCLER J, V18, P799, DOI 10.1177/1352458511428081; Tejada-Simon MV, 2003, ANN NEUROL, V53, P189, DOI 10.1002/ana.10425; Ysrraelit MC, 2019, IMMUNOLOGY, V156, P9, DOI 10.1111/imm.13004; Yu L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0927-9; Zhou Y, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.670	21	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 5	2020	11								771	10.3389/fimmu.2020.00771	http://dx.doi.org/10.3389/fimmu.2020.00771			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LS4LL	32431704	gold, Green Published			2022-12-18	WOS:000536357000001
J	van den Bos, R; Cromwijk, S; Tschigg, K; Althuizen, J; Zethof, J; Whelan, R; Flik, G; Schaaf, M				van den Bos, Ruud; Cromwijk, Suzanne; Tschigg, Katharina; Althuizen, Joep; Zethof, Jan; Whelan, Robert; Flik, Gert; Schaaf, Marcel			Early Life Glucocorticoid Exposure Modulates Immune Function in Zebrafish (Danio rerio) Larvae	FRONTIERS IN IMMUNOLOGY			English	Article						cortisol; glucocorticoid receptor; zebrafish; larvae; tail fin regeneration; lipopolysaccharide	STRESS-AXIS; INFLAMMATION; SYSTEM; MODEL; LPS; DYSFUNCTION; EXPRESSION; COMPONENTS; SEPSIS; GENES	In this study we have assessed the effects of increased cortisol levels during early embryonic development on immune function in zebrafish (Danio rerio) larvae. Fertilized eggs were exposed to either a cortisol-containing, a dexamethasone-containing (to stimulate the glucocorticoid receptor selectively) or a control medium for 6 h post-fertilization (0-6 hpf). First, we measured baseline expression of a number of immune-related genes (socs3a, mpeg1.1, mpeg1.2, andirg1l) 5 days post-fertilization (dpf) in larvae of the AB and TL strain to assess the effectiveness of our exposure procedure and potential strain differences. Cortisol and dexamethasone strongly up-regulated baseline expression of these genes independent of strain. The next series of experiments were therefore carried out in larvae of the AB strain only. We measured neutrophil/macrophage recruitment following tail fin amputation (performed at 3 dpf) and phenotypical changes as well as survival following LPS-induced sepsis (150 mu g/ml; 4-5 dpf). Dexamethasone, but not cortisol, exposure at 0-6 hpf enhanced neutrophil recruitment 4 h post tail fin amputation. Cortisol and dexamethasone exposure at 0-6 hpf led to a milder phenotype (e.g., less tail fin damage) and enhanced survival following LPS challenge compared to control exposure. Gene-expression analysis showed accompanying differences in transcript abundance oftlr4bb, cxcr4a, myd88, il1 beta, and il10. These data show that early-life exposure to cortisol, which may be considered to be a model or proxy of maternal stress, induces an adaptive response to immune challenges, which seems mediated via the glucocorticoid receptor.	[van den Bos, Ruud; Cromwijk, Suzanne; Tschigg, Katharina; Althuizen, Joep; Zethof, Jan; Flik, Gert] Radboud Univ Nijmegen, Inst Water & Wetland Res, Dept Anim Ecol & Physiol, Fac Sci, Nijmegen, Netherlands; [Whelan, Robert; Schaaf, Marcel] Leiden Univ, Inst Biol, Anim Sci & Hlth Cluster, Leiden, Netherlands	Radboud University Nijmegen; Leiden University; Leiden University - Excl LUMC	van den Bos, R (corresponding author), Radboud Univ Nijmegen, Inst Water & Wetland Res, Dept Anim Ecol & Physiol, Fac Sci, Nijmegen, Netherlands.	ruudvdbos@science.ru.nl	Flik, Gert/C-8229-2011; Tschigg, Katharina/AAS-9940-2021	Flik, Gert/0000-0001-9285-7957; Tschigg, Katharina/0000-0001-5146-3492; Schaaf, Marcel/0000-0002-5859-8936				Alderman SL, 2009, GEN COMP ENDOCR, V164, P61, DOI 10.1016/j.ygcen.2009.04.007; Alsop D, 2008, AM J PHYSIOL-REG I, V294, pR711, DOI 10.1152/ajpregu.00671.2007; Althuizen J, 2018, THESIS; Alves Rosa F, 2002, CLIN EXP IMMUNOL, V128, P221, DOI [10.1046/j.1365-2249.2002.01828.x, DOI 10.1046/J.1365-2249.2002.01828.X]; Benard EL, 2015, J INNATE IMMUN, V7, P136, DOI 10.1159/000366103; Bernut A, 2014, P NATL ACAD SCI USA, V111, pE943, DOI 10.1073/pnas.1321390111; Best C, 2017, SCI REP-UK, V7, DOI 10.1038/srep40905; Bonga SEW, 1997, PHYSIOL REV, V77, P591, DOI 10.1152/physrev.1997.77.3.591; Budaev SV, 2010, ETHOLOGY, V116, P472, DOI 10.1111/j.1439-0310.2010.01758.x; Champagne DL, 2010, BEHAV BRAIN RES, V214, P332, DOI 10.1016/j.bbr.2010.06.001; Chatzopoulou A, 2016, ENDOCRINOLOGY, V157, P2772, DOI 10.1210/en.2015-2050; Chong SW, 2001, MECH DEVELOP, V109, P347, DOI 10.1016/S0925-4773(01)00520-2; Dai YJ, 2014, ENVIRON TOXICOL CHEM, V33, P11, DOI 10.1002/etc.2406; Dios S, 2014, ZEBRAFISH, V11, P421, DOI 10.1089/zeb.2014.0995; Ferguson GA, 1989, STAT ANAL PSYCHOL ED; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Galindo-Villegas J, 2012, P NATL ACAD SCI USA, V109, pE2605, DOI 10.1073/pnas.1209920109; Gorissen M, 2016, FISH PHYSIOL, V35, P75, DOI 10.1016/B978-0-12-802728-8.00003-5; Goulopoulou S, 2016, PHARMACOL REV, V68, P142, DOI 10.1124/pr.114.010090; Hall CJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4880; Hartig EI, 2016, BIOL OPEN, V5, P1134, DOI 10.1242/bio.020065; Hsu AY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00607; Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269; Kanwal Z, 2013, J IMMUNOL, V190, P1631, DOI 10.4049/jimmunol.1200551; Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448; Konrad FM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.482; Liu WT, 2017, CELL ADHES MIGR, V11, P13, DOI 10.1080/19336918.2015.1134404; Liu Yi-Wen, 2007, Organogenesis, V3, P44; McEwen BS, 2003, HORM BEHAV, V43, P2, DOI 10.1016/S0018-506X(02)00024-7; Meijer AH, 2011, CURR DRUG TARGETS, V12, P1000; Nesan D, 2016, SCI REP-UK, V6, DOI 10.1038/srep22582; Nesan D, 2013, GEN COMP ENDOCR, V181, P35, DOI 10.1016/j.ygcen.2012.10.006; Nesan D, 2012, MOL CELL ENDOCRINOL, V363, P85, DOI 10.1016/j.mce.2012.07.010; Netea MG, 2017, CELL HOST MICROBE, V21, P297, DOI 10.1016/j.chom.2017.02.003; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Novoa B, 2009, FISH SHELLFISH IMMUN, V26, P326, DOI 10.1016/j.fsi.2008.12.004; Odenwald MA, 2013, CLIN GASTROENTEROL H, V11, P1075, DOI 10.1016/j.cgh.2013.07.001; Philip AM, 2017, MOL MED, V23, P134, DOI 10.2119/molmed.2016.00188; Pikulkaew S, 2011, DEV DYNAM, V240, P874, DOI 10.1002/dvdy.22586; Pikulkaew S, 2010, GEN COMP ENDOCR, V165, P215, DOI 10.1016/j.ygcen.2009.06.024; Renshaw SA, 2006, BLOOD, V108, P3976, DOI 10.1182/blood-2006-05-024075; Reyes-Lopez FE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00914; Roehl HH, 2018, INT J DEV BIOL, V62, P473, DOI 10.1387/ijdb.170331hr; RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H; Sepulcre MP, 2009, J IMMUNOL, V182, P1836, DOI 10.4049/jimmunol.0801755; Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150; Sopinka NM, 2017, PHYSIOL BIOCHEM ZOOL, V90, P15, DOI 10.1086/689994; Steenbergen PJ, 2011, PROG NEURO-PSYCHOPH, V35, P1432, DOI 10.1016/j.pnpbp.2010.10.010; Steenbergen PJ, 2017, CHEMOSPHERE, V183, P147, DOI 10.1016/j.chemosphere.2017.05.059; Stewart AM, 2014, TRENDS NEUROSCI, V37, P264, DOI 10.1016/j.tins.2014.02.011; Sullivan C, 2009, J IMMUNOL, V183, P5896, DOI 10.4049/jimmunol.0803285; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2008, EUR J IMMUNOL, V38, P192, DOI 10.1002/eji.200636821; van den Bos R., 2020, BEHAV NEURAL GENETIC, P245, DOI [10.1016/B978-0-12-817528-6.00015-2, DOI 10.1016/B978-0-12-817528-6.00015-2]; van den Bos R, 2019, BEHAV PHARMACOL, V30, P260, DOI 10.1097/FBP.0000000000000470; van den Bos R, 2017, BIOL OPEN, V6, P1692, DOI 10.1242/bio.028969; van den Bos R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175420; van der Vaart M, 2013, DIS MODEL MECH, V6, P841, DOI 10.1242/dmm.010843; VandenBos R, 2019, EFFECTS EARLY LIFE G, DOI [10.1101/2019.12.16.877654, DOI 10.1101/2019.12.16.877654]; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Willi RA, 2019, J HAZARD MATER, V374, P101, DOI 10.1016/j.jhazmat.2019.04.023; Willi RA, 2018, ENVIRON SCI TECHNOL, V52, P877, DOI 10.1021/acs.est.7b06057; Wilson KS, 2013, J PHYSIOL-LONDON, V591, P6209, DOI 10.1113/jphysiol.2013.256826; Xie YF, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037887; Yoseph BP, 2016, SHOCK, V46, P52, DOI 10.1097/SHK.0000000000000565; Zhao YB, 2016, ENVIRON SCI TECHNOL, V50, P10245, DOI 10.1021/acs.est.6b03436	66	2	2	3	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2020	11								727	10.3389/fimmu.2020.00727	http://dx.doi.org/10.3389/fimmu.2020.00727			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	MV7MC	32411141	gold, Green Submitted, Green Published			2022-12-18	WOS:000556536100001
J	Mbongue, JC; Alhoshani, A; Rawson, J; Garcia, PA; Gonzalez, N; Ferreri, K; Kandeel, F; Husseiny, MI				Mbongue, Jacques C.; Alhoshani, Ali; Rawson, Jeffrey; Garcia, Pablo A.; Gonzalez, Nelson; Ferreri, Kevin; Kandeel, Fouad; Husseiny, Mohamed I.			Tracking of an Oral Salmonella-Based Vaccine for Type 1 Diabetes in Non-obese Diabetic Mice	FRONTIERS IN IMMUNOLOGY			English	Article						Salmonella-based vaccine; sleeping beauty; transposons; Type 1 Diabetes; CD103(+)DC; TGF beta; tolerogenic dendritic cells	CD103(+) DENDRITIC CELLS; REGULATORY T-CELLS; SLEEPING-BEAUTY; III SECRETION; TYPHIMURIUM INFECTION; IMMUNE-RESPONSES; INDUCE TOLERANCE; DNA VACCINE; ENTERICA; CTLA-4	Type 1 diabetes (T1D) arises secondary to immune-driven destruction of pancreatic beta-cells and manifests as insulin-deficient hyperglycemia. We showed that oral vaccination with live attenuated Salmonella, which simultaneously delivers autoantigens and a TGF beta expression vector to immune cells in the gut mucosa, provides protection against the progression of T1D in non-obese diabetic (NOD) mice. In this study we employed the Sleeping Beauty (SB) transposon system that is composed of a transposase and transposon encoding the td-Tomato to express red fluorescent protein (RFP) to permanently mark the cells that take up the Salmonella vaccine. After animal vaccination, the transposon labeled-dendritic cells (DCs) with red fluorescence appeared throughout the secondary lymphoid tissues. Furthermore, Sleeping Beauty containing tgf beta 1 gene (SB-tgf beta 1) co-expressed TGF beta and RFP. The labeled DCs were detected predominantly in Peyer's patches (PP) and mesenteric lymph nodes (MLN) and expressed CD103 surface marker. CD103(+) DCs induced tolerogenic effects and gut homing. TGF beta significantly increased programmed death-ligand-1 (PDL-1 or CD274) expression in the DCs in the MLN and PP of treated mice. Also, TGF beta increased cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) levels in CD4(+) cells in MLN and PP. Interestingly, DCs increased in all lymphatic organs of mice vaccinated with oral live Salmonella-based vaccine expressing preproinsulin (PPI), in combination with TGF beta, IL10, and subtherapeutic-doses of anti-CD3 mAb compared with vehicle-treated mice. These DCs are mostly tolerogenic in MLN and PP. Furthermore the DCs obtained from vaccine-treated but not vehicle-treated mice suppressed in vitro T cell proliferation. These data suggest that the MLN and the PP are a central hub for the beneficial anti-diabetic effects of an oral Salmonella-based vaccine prevention of diabetes in rodents.	[Mbongue, Jacques C.; Rawson, Jeffrey; Garcia, Pablo A.; Gonzalez, Nelson; Ferreri, Kevin; Kandeel, Fouad; Husseiny, Mohamed I.] City Hope Natl Med Ctr, Beckman Res Inst, Diabet & Metab Res Inst, Dept Translat Res & Cellular Therapeut, Duarte, CA 91010 USA; [Alhoshani, Ali] King Saud Univ, Coll Pharm, Dept Pharmacol & Toxicol, Riyadh, Saudi Arabia; [Husseiny, Mohamed I.] Zagazig Univ, Fac Pharm, Zagazig, Egypt	City of Hope; Beckman Research Institute of City of Hope; King Saud University; Egyptian Knowledge Bank (EKB); Zagazig University	Husseiny, MI (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Diabet & Metab Res Inst, Dept Translat Res & Cellular Therapeut, Duarte, CA 91010 USA.; Husseiny, MI (corresponding author), Zagazig Univ, Fac Pharm, Zagazig, Egypt.	melsayed@coh.org		Mbongue, Jacques/0000-0002-7123-3480; Elsayed, Mohamed Ibrahim Husseiny/0000-0002-3470-2858	Wanek Family Project to Cure Type 1 Diabetes Program Award (Duarte, CA, United States); Juvenile Diabetes Research Foundation (United States) [JDRF2-SRA-2016-314-S-B]; Global Scholar Program	Wanek Family Project to Cure Type 1 Diabetes Program Award (Duarte, CA, United States); Juvenile Diabetes Research Foundation (United States)(Juvenile Diabetes Research Foundation); Global Scholar Program	This work was supported by the Wanek Family Project to Cure Type 1 Diabetes Program Award (Duarte, CA, United States), and the Juvenile Diabetes Research Foundation (United States) (JDRF2-SRA-2016-314-S-B). AA was a Fulbright Visiting Scholar awarded from the Global Scholar Program.	Abrahams GL, 2006, CELL MICROBIOL, V8, P728, DOI 10.1111/j.1462-5822.2006.00706.x; Achenbach P, 2004, J CLIN INVEST, V114, P589, DOI 10.1172/JCI200421307; Annacker O, 2005, J EXP MED, V202, P1051, DOI 10.1084/jem.20040662; Ashkar AA, 2009, INFECT IMMUN, V77, P214, DOI 10.1128/IAI.01066-08; Atkinson MA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007641; Badami E, 2011, DIABETES, V60, P2120, DOI 10.2337/db10-1201; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Beitnes ACR, 2011, SCAND J IMMUNOL, V74, P186, DOI 10.1111/j.1365-3083.2011.02549.x; Brockmann L, 2017, J IMMUNOL, V198, P1130, DOI 10.4049/jimmunol.1601045; Cheminay C, 2005, J IMMUNOL, V174, P2892, DOI 10.4049/jimmunol.174.5.2892; Cheminay C, 2008, INT J MED MICROBIOL, V298, P87, DOI 10.1016/j.ijmm.2007.08.006; Chemnitz JM, 2004, J IMMUNOL, V173, P945, DOI 10.4049/jimmunol.173.2.945; Chen HQ, 2003, INFECT IMMUN, V71, P4664, DOI 10.1128/IAI.71.8.4664-4673.2003; Chistiakov DA, 2015, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00781; Dai SY, 2014, CELL IMMUNOL, V290, P72, DOI 10.1016/j.cellimm.2014.05.006; Devarajan P, 2013, IMMUNOL RES, V57, P12, DOI 10.1007/s12026-013-8448-1; Farache J, 2013, IMMUNITY, V38, P581, DOI 10.1016/j.immuni.2013.01.009; Fife BT, 2008, IMMUNOL REV, V224, P166, DOI 10.1111/j.1600-065X.2008.00662.x; Figueira R, 2012, MICROBIOL-SGM, V158, P1147, DOI 10.1099/mic.0.058115-0; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Geem D, 2016, CELL MOL GASTROENTER, V2, P274, DOI 10.1016/j.jcmgh.2015.12.009; Grabundzija I, 2013, NUCLEIC ACIDS RES, V41, P1829, DOI 10.1093/nar/gks1305; Gregori S, 2011, BLOOD, V118, P5060; Haga T, 2006, EXP ANIM TOKYO, V55, P405, DOI 10.1538/expanim.55.405; Hansen-Wester I, 2001, MICROBES INFECT, V3, P549, DOI 10.1016/S1286-4579(01)01411-3; Hill M, 2010, CURR OPIN ORGAN TRAN, V15, P738, DOI 10.1097/MOT.0b013e32833f7114; Holzer SU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033220; Hu QH, 2008, J CLIN MICROBIOL, V46, P1330, DOI 10.1128/JCM.01255-07; Husseiny MI, 2005, VACCINE, V23, P2580, DOI 10.1016/j.vaccine.2004.11.035; Husseiny MI, 2007, VACCINE, V25, P185, DOI 10.1016/j.vaccine.2005.11.020; Husseiny MI, 2018, VACCINE, V36, P8008, DOI 10.1016/j.vaccine.2018.10.101; Husseiny MI, 2014, VACCINE, V32, P2300, DOI 10.1016/j.vaccine.2014.02.070; Iliev ID, 2009, MUCOSAL IMMUNOL, V2, P340, DOI 10.1038/mi.2009.13; Jantsch J, 2011, IMMUNOL REV, V240, P185, DOI 10.1111/j.1600-065X.2010.00981.x; Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100; Klocke K, 2016, EUR J IMMUNOL, V46, P770; Kong W, 2012, P NATL ACAD SCI USA, V109, P19414, DOI 10.1073/pnas.1217554109; Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821; Kronenberg D, 2012, DIABETES, V61, P1752, DOI 10.2337/db11-1520; Laniewski P, 2013, POSTEP MIKROBIOL, V52, P281; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343; Mbongue JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00320; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; Milling S, 2010, IMMUNOL REV, V234, P259, DOI 10.1111/j.0105-2896.2009.00866.x; Nakayama M, 2007, J CLIN INVEST, V117, P1835, DOI 10.1172/JCI31368; Pabst O, 2007, J LEUKOCYTE BIOL, V82, P795, DOI 10.1189/jlb.0307144; PLASTERK R H A, 1990, New Biologist, V2, P787; PLASTERK RHA, 1993, CELL, V74, P781, DOI 10.1016/0092-8674(93)90458-3; Raine T, 2006, J IMMUNOL, V177, P2224, DOI 10.4049/jimmunol.177.4.2224; Raker VK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00569; Romo-Tena J, 2013, AUTOIMMUN REV, V12, P1171, DOI 10.1016/j.autrev.2013.07.002; Roncarolo MG, 2014, CURR TOP MICROBIOL, V380, P39, DOI 10.1007/978-3-662-43492-5_3; Saito H, 2011, INT ARCH ALLERGY IMM, V155, P46, DOI 10.1159/000327265; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Schulz O, 2009, J EXP MED, V206, P3101, DOI 10.1084/jem.20091925; Siddiqui KRR, 2008, MUCOSAL IMMUNOL, V1, pS34, DOI 10.1038/mi.2008.43; Singh H, 2014, IMMUNOL REV, V257, P181, DOI 10.1111/imr.12137; Skowera A, 2009, J CLIN INVEST, V119, P2843, DOI 10.1172/JCI35449C1; Sumiyoshi T, 2009, HUM GENE THER, V20, P1607, DOI 10.1089/hum.2009.109; Takiishi T, 2012, J CLIN INVEST, V122, P1717, DOI 10.1172/JCI60530; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Xiong GS, 2010, INT J CANCER, V126, P2622, DOI 10.1002/ijc.24957; Xu X, 2010, INFECT IMMUN, V78, P4828, DOI 10.1128/IAI.00298-10; Yrlid U, 2006, EUR J IMMUNOL, V36, P2639, DOI 10.1002/eji.200636426; Yu H, 2017, P NATL ACAD SCI USA, V114, P10443, DOI 10.1073/pnas.1705599114	67	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2020	11								712	10.3389/fimmu.2020.00712	http://dx.doi.org/10.3389/fimmu.2020.00712			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LO0SS	32411136	Green Published, gold			2022-12-18	WOS:000533340400001
J	Zhang, MH; Slaby, EM; Stephanie, G; Yu, CS; Watts, DM; Liu, HP; Szeto, GL				Zhang, Michael H.; Slaby, Emily M.; Stephanie, Georgina; Yu, Chunsong; Watts, Darcy M.; Liu, Haipeng; Szeto, Gregory L.			Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering	FRONTIERS IN IMMUNOLOGY			English	Article						membrane insertion; drug delivery; immunotherapy; adjuvants; Toll-like receptors; cell engineering; T cells; B cells	TARGETED DRUG-DELIVERY; T-CELLS; CALMETTE-GUERIN; LYMPH-NODE; IMMUNOTHERAPY; INDUCTION; OLIGONUCLEOTIDES; NANOPARTICLES; ACTIVATION; RESPONSES	Cell-based immunotherapies have tremendous potential to treat many diseases, such as activating immunity in cancer or suppressing it in autoimmune diseases. Most cell-based cancer immunotherapies in the clinic provide adjuvant signals through genetic engineering to enhance T cell functions. However, genetically encoded signals have minimal control over dosing and persist for the life of a cell lineage. These properties make it difficult to balance increasing therapeutic efficacy with reducing toxicities. Here, we demonstrated the potential of phospholipid-coupled ligands as a non-genetic system for immune cell engineering. This system provides simple, controlled, non-genetic adjuvant delivery to immune cells via lipid-mediated insertion into plasma membranes. Lipid-mediated insertion (termed depoting) successfully delivered Toll-like receptor (TLR) ligands intracellularly and onto cell surfaces of diverse immune cells. These ligands depoted into immune cells in a dose-controlled fashion and did not compete during multiplex pairwise loading. Immune cell activation could be enhanced by autocrine and paracrine mechanisms depending on the biology of the TLR ligand tested. Depoted ligands functionally persisted on plasma membranes for up to 4 days in naive and activated T cells, enhancing their activation, proliferation, and skewing cytokine secretion. Our data showed that depoted ligands provided a persistent yet non-permanent adjuvant signal to immune cells that may minimize the intensity and duration of toxicities compared to permanent genetic delivery. Altogether, these findings demonstrate potential for lipid-mediated depoting as a universal cell engineering approach with unique, complementary advantages to other cell engineering methods.	[Zhang, Michael H.; Slaby, Emily M.; Stephanie, Georgina; Watts, Darcy M.; Szeto, Gregory L.] Univ Maryland Baltimore Cty, Chem Biochem & Environm Engn, Baltimore, MD 21228 USA; [Zhang, Michael H.; Szeto, Gregory L.] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Yu, Chunsong; Liu, Haipeng] Wayne State Univ, Dept Chem Engn & Mat Sci, Detroit, MI USA; [Szeto, Gregory L.] Univ Maryland, Sch Med, Ctr Biomed Engn & Technol, Baltimore, MD 21201 USA; [Szeto, Gregory L.] Univ Maryland Baltimore Cty, Translat Ctr Age Related Dis & Dispar, Baltimore, MD 21228 USA; [Szeto, Gregory L.] Allen Inst Immunol, Seattle, WA 98109 USA	University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore; Wayne State University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore County	Szeto, GL (corresponding author), Univ Maryland Baltimore Cty, Chem Biochem & Environm Engn, Baltimore, MD 21228 USA.; Szeto, GL (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.; Szeto, GL (corresponding author), Univ Maryland, Sch Med, Ctr Biomed Engn & Technol, Baltimore, MD 21201 USA.; Szeto, GL (corresponding author), Univ Maryland Baltimore Cty, Translat Ctr Age Related Dis & Dispar, Baltimore, MD 21228 USA.; Szeto, GL (corresponding author), Allen Inst Immunol, Seattle, WA 98109 USA.	gszeto@umbc.edu	Yu, Chunsong/X-9117-2019	Yu, Chunsong/0000-0003-4823-7835; Szeto, Gregory/0000-0001-7604-1333; Slaby, Emily/0000-0002-1853-2545	Elsa U Pardee Foundation; UMBC's Undergraduate Research Awards; UMBC Summer Faculty Fellowship; Supplement for Undergraduate Research Experiences; Commercialization & ENTR REsearch (CENTER) Funding Initiative of the Alex Brown Center for Entrepreneurship at UMBC; UMGCC P30 grant under the National Cancer Institute, NIH [P30 CA134274]; Nathan Schnaper Intern Program in Translational Cancer Research [NIH R25CA186872]	Elsa U Pardee Foundation; UMBC's Undergraduate Research Awards; UMBC Summer Faculty Fellowship; Supplement for Undergraduate Research Experiences; Commercialization & ENTR REsearch (CENTER) Funding Initiative of the Alex Brown Center for Entrepreneurship at UMBC; UMGCC P30 grant under the National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nathan Schnaper Intern Program in Translational Cancer Research	This work was supported by a grant from the Elsa U Pardee Foundation (to GLS), UMBC's Undergraduate Research Awards (to ES and GS), UMBC Summer Faculty Fellowship (to GLS), a Supplement for Undergraduate Research Experiences (to GLS and ES), and the Commercialization & ENTR REsearch (CENTER) Funding Initiative of the Alex Brown Center for Entrepreneurship at UMBC (to GLS). GLS is funded in part by the UMGCC P30 grant under award number P30 CA134274 from the National Cancer Institute, NIH. ES was supported in part by the Nathan Schnaper Intern Program in Translational Cancer Research (NIH R25CA186872).	Adams S, 2009, IMMUNOTHERAPY-UK, V1, P949, DOI [10.2217/imt.09.70, 10.2217/IMT.09.70]; Akkaya M, 2018, NAT IMMUNOL, V19, P255, DOI 10.1038/s41590-018-0052-z; Anurathapan U, 2014, MOL THER, V22, P623, DOI 10.1038/mt.2013.262; Avelos AM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00092; Bendigs S, 1999, EUR J IMMUNOL, V29, P1209, DOI 10.1002/(SICI)1521-4141(199904)29:04<1209::AID-IMMU1209>3.0.CO;2-J; Bonifant CL, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.11; Bourquin C, 2008, J IMMUNOL, V181, P2990, DOI 10.4049/jimmunol.181.5.2990; Chou SH, 2013, CANCER IMMUNOL IMMUN, V62, P597, DOI 10.1007/s00262-012-1364-8; Csizmar CM, 2018, CELL CHEM BIOL, V25, P931, DOI 10.1016/j.chembiol.2018.05.009; Davila E, 2002, BLOOD, V100, P2537, DOI 10.1182/blood-2002-02-0401; Dunn KW, 2011, AM J PHYSIOL-CELL PH, V300, pC723, DOI 10.1152/ajpcell.00462.2010; Essand M, 2013, J INTERN MED, V273, P166, DOI 10.1111/joim.12020; Geng DG, 2010, CANCER RES, V70, P7442, DOI 10.1158/0008-5472.CAN-10-0247; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hamley IW, 2014, CHEM COMMUN, V50, P15948, DOI 10.1039/c4cc07511k; Herzig E, 2019, CELL, V179, P880, DOI 10.1016/j.cell.2019.10.002; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200; Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2; Kwong B, 2011, BIOMATERIALS, V32, P5134, DOI 10.1016/j.biomaterials.2011.03.067; Lahoud MH, 2012, P NATL ACAD SCI USA, V109, P16270, DOI 10.1073/pnas.1208796109; LAMM DL, 1991, NEW ENGL J MED, V325, P1205, DOI 10.1056/NEJM199110243251703; Liu HP, 2014, NATURE, V507, P519, DOI 10.1038/nature12978; Liu HP, 2011, ANGEW CHEM INT EDIT, V50, P7052, DOI 10.1002/anie.201101266; Liu XW, 2012, NANO LETT, V12, P4254, DOI 10.1021/nl301877k; Lu HL, 2011, CLIN CANCER RES, V17, P6742, DOI 10.1158/1078-0432.CCR-11-1142; Lu HL, 2011, CLIN CANCER RES, V17, P67, DOI 10.1158/1078-0432.CCR-10-1763; Maniganda S, 2014, ORG BIOMOL CHEM, V12, P6564, DOI 10.1039/c4ob01153h; McHugh MD, 2015, BIOMATERIALS, V59, P172, DOI 10.1016/j.biomaterials.2015.04.003; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Moynihan KD, 2016, NAT MED, V22, P1402, DOI 10.1038/nm.4200; Nayerossadat Nouri, 2012, Adv Biomed Res, V1, P27, DOI 10.4103/2277-9175.98152; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, DOI 10.1038/nrclinonc.2018.20; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Nierkens S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008368; Novis CL, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-119; Olden BR, 2018, J CONTROL RELEASE, V282, P140, DOI 10.1016/j.jconrel.2018.02.043; ONG SW, 1995, ANAL CHEM, V67, P755, DOI 10.1021/ac00100a011; Park K, 2013, ACS NANO, V7, P7442, DOI 10.1021/nn404501g; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Ray A, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00052; Ribas A, 2018, CANCER DISCOV, V8, P1250, DOI 10.1158/2159-8290.CD-18-0280; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Ruella M, 2018, NAT MED, V24, P1499, DOI 10.1038/s41591-018-0201-9; Schroder T, 2008, J MED CHEM, V51, P376, DOI 10.1021/jm070603m; Schubert ML, 2018, INT J CANCER, V142, P1738, DOI 10.1002/ijc.31147; Stewart MP, 2018, CHEM REV, V118, P7409, DOI 10.1021/acs.chemrev.7b00678; Szeto GL, 2015, SCI REP-UK, V5, DOI 10.1038/srep10276; Thomas M, 2018, ANN ONCOL, V29, P2076, DOI 10.1093/annonc/mdy326; Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003; Volpi C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2874; Wang XY, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.15; Wisniewski JR, 2014, MOL CELL PROTEOMICS, V13, P3497, DOI 10.1074/mcp.M113.037309; Wong RM, 2009, IMMUNOL LETT, V127, P60, DOI 10.1016/j.imlet.2009.09.002; Yoshikawa T, 2008, BIOCHEM BIOPH RES CO, V366, P408, DOI 10.1016/j.bbrc.2007.11.153; Yu CS, 2017, MOL PHARMACEUT, V14, P2815, DOI 10.1021/acs.molpharmaceut.7b00335; Yuan YY, 2015, ANGEW CHEM INT EDIT, V54, P11419, DOI 10.1002/anie.201503640; Zhang MH, 2019, LIPID MEDIATED INSER, DOI [10.1101/840876, DOI 10.1101/840876]; Zhang Y, 2011, J IMMUNOL, V186, P1963, DOI 10.4049/jimmunol.1002320; Zhao ZG, 2015, CANCER CELL, V28, P415, DOI 10.1016/j.ccell.2015.09.004; Zheng GX, 2006, CANCER RES, V66, P6793, DOI 10.1158/0008-5472.CAN-06-0435	64	2	3	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2020	11								560	10.3389/fimmu.2020.00560	http://dx.doi.org/10.3389/fimmu.2020.00560			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LL7AD	32425924	Green Submitted, gold, Green Published			2022-12-18	WOS:000531707100001
J	Cheng, CH; Lee, CF; Oh, BC; Furtmuller, GJ; Patel, CH; Brandacher, G; Powell, JD				Cheng, Chih-Hsien; Lee, Chen-Fang; Oh, Byoung Chol; Furtmuller, Georg J.; Patel, Chirag H.; Brandacher, Gerald; Powell, Jonathan D.			Targeting Metabolism as a Platform for Inducing Allograft Tolerance in the Absence of Long-Term Immunosuppression	FRONTIERS IN IMMUNOLOGY			English	Article						mouse; model; transplantation; immunology; metabolism; costimulation blockade; rejection	BELATACEPT-BASED IMMUNOSUPPRESSION; LIVER-TRANSPLANT RECIPIENTS; IN-VIVO; HEART-TRANSPLANTATION; CYCLOSPORINE-A; PHASE-III; REJECTION; DIFFERENTIATION; MECHANISMS; INDUCTION	Transplant tolerance in the absence of long-term immunosuppression has been an elusive goal for solid organ transplantation. Recently, it has become clear that metabolic reprogramming plays a critical role in promoting T cell activation, differentiation, and function. Targeting metabolism can preferentially inhibit T cell effector generation while simultaneously promoting the generation of T regulatory cells. We hypothesized that costimulatory blockade with CTLA4Ig in combination with targeting T cell metabolism might provide a novel platform to promote the induction of transplant tolerance.	[Cheng, Chih-Hsien; Lee, Chen-Fang; Patel, Chirag H.; Powell, Jonathan D.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Res Ctr, Baltimore, MD 21205 USA; [Cheng, Chih-Hsien; Lee, Chen-Fang; Patel, Chirag H.; Powell, Jonathan D.] Johns Hopkins Univ, Sch Med, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD 21205 USA; [Cheng, Chih-Hsien; Lee, Chen-Fang] Chang Gung Univ, Coll Med, Chang Gung Transplantat Inst, Dept Liver & Transplantat Surg,Chang Gung Mem Hos, Taoyuan, Taiwan; [Oh, Byoung Chol; Furtmuller, Georg J.; Brandacher, Gerald] Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Vascularized Composite Allotransplantat Lab, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Chang Gung Memorial Hospital; Chang Gung University; Johns Hopkins University	Powell, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Res Ctr, Baltimore, MD 21205 USA.; Powell, JD (corresponding author), Johns Hopkins Univ, Sch Med, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD 21205 USA.	poweljo@jhmi.edu		Brandacher, Gerald/0000-0001-7790-441X	US National Institutes of Health [R01AI077610]; Bloomberg-Kimmel Institute of Cancer Immunotherapy; DOD [W81XWH-17-10624 RT160075, W81XWH-17-1-0520]	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bloomberg-Kimmel Institute of Cancer Immunotherapy; DOD(United States Department of Defense)	This work was supported by the US National Institutes of Health grant R01AI077610 and the Bloomberg-Kimmel Institute of Cancer Immunotherapy (JP) and DOD grants W81XWH-17-10624 RT160075 (GB) andW81XWH-17-1-0520 (JP).	Adams AB, 2003, IMMUNOL REV, V196, P147, DOI 10.1046/j.1600-065X.2003.00082.x; Azzi JR, 2013, J IMMUNOL, V191, P5785, DOI 10.4049/jimmunol.1390055; Blaha P, 2003, BLOOD, V101, P2886, DOI 10.1182/blood-2002-10-3014; Bocian K, 2010, NEPHROL DIAL TRANSPL, V25, P710, DOI 10.1093/ndt/gfp586; Chambers JW, 2010, J VIROL, V84, P1867, DOI 10.1128/JVI.02123-09; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chen CH, 2010, REPRODUCTION, V140, P105, DOI 10.1530/REP-09-0448; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Cheng CH, 2017, JOVE-J VIS EXP, DOI 10.3791/55105; CORRY RJ, 1973, TRANSPLANT P, V5, P733; Durrbach A, 2016, AM J TRANSPLANT, V16, P3192, DOI 10.1111/ajt.13830; Durrbach A, 2010, AM J TRANSPLANT, V10, P547, DOI 10.1111/j.1600-6143.2010.03016.x; Earl PL, 2001, CURR PROTOC MOL BIOL, V16, pUnit 16, DOI 10.1002/0471142727; Feng S, 2018, GASTROENTEROLOGY, V155, P1838, DOI 10.1053/j.gastro.2018.08.023; Ford ML, 2007, J EXP MED, V204, P299, DOI 10.1084/jem.20062319; Ford ML, 2014, NAT REV NEPHROL, V10, P14, DOI 10.1038/nrneph.2013.183; Fowler M, 2005, TRANSPLANTATION, V79, P768, DOI 10.1097/01.TP.0000152798.03204.5C; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Fung J J, 1990, Clin Transpl, P115; Gardner D, 2014, AM J TRANSPLANT, V14, P1985, DOI 10.1111/ajt.12834; Halloran PF, 2004, NEW ENGL J MED, V351, P2715, DOI 10.1056/NEJMra033540; Hasegawa T, 2007, NAT PROTOC, V2, P471, DOI 10.1038/nprot.2007.48; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Karpe KM, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006750.pub2; Katabathina V, 2016, RADIOL CLIN N AM, V54, P303, DOI 10.1016/j.rcl.2015.09.009; Kawai M, 2005, TRANSPLANTATION, V79, P1073, DOI 10.1097/01.TP.0000153505.73700.32; Klintmalm GB, 2014, AM J TRANSPLANT, V14, P1817, DOI 10.1111/ajt.12810; Kumar D, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00060; LaMattina JC, 2014, TRANSPLANTATION, V97, P133, DOI 10.1097/01.TP.0000438635.44461.2e; Launay M, 2020, AM J TRANSPLANT, V20, P553, DOI 10.1111/ajt.15584; Lee CF, 2015, CELL REP, V13, P760, DOI 10.1016/j.celrep.2015.09.036; Leibler C, 2014, AM J TRANSPLANT, V14, P1173, DOI 10.1111/ajt.12721; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Nankivell Brian J., 2003, New England Journal of Medicine, V349, P2326, DOI 10.1056/NEJMoa020009; Oberhuber R, 2014, JOVE-J VIS EXP, DOI 10.3791/50753; Oh B, 2016, AM J TRANSPLANT, V16, P2612, DOI 10.1111/ajt.13789; Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454; Penninga L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008852.pub2; Pollizzi KN, 2014, NAT REV IMMUNOL, V14, P435, DOI 10.1038/nri3701; Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Suresh M, 2001, J IMMUNOL, V167, P5565, DOI 10.4049/jimmunol.167.10.5565; Suzuki J, 2010, CIRC J, V74, P233, DOI 10.1253/circj.CJ-09-0809; Tanaka M, 2005, CIRCULATION, V112, pI105, DOI 10.1161/CIRCULATIONAHA.104.524777; Timofte I, 2016, TRANSPL INT, V29, P453, DOI 10.1111/tri.12731; Tsu TY, 2002, TRANSPLANTATION, V73, P1325, DOI 10.1097/00007890-200204270-00023; Valenzuela NM, 2017, J CLIN INVEST, V127, P2492, DOI 10.1172/JCI90597; Vincenti F, 2012, AM J TRANSPLANT, V12, P210, DOI 10.1111/j.1600-6143.2011.03785.x; Vincenti F, 2010, AM J TRANSPLANT, V10, P535, DOI 10.1111/j.1600-6143.2009.03005.x; Vincenti F, 2016, NEW ENGL J MED, V374, P333, DOI 10.1056/NEJMoa1506027; Wang CJ, 2015, P NATL ACAD SCI USA, V112, P524, DOI 10.1073/pnas.1414576112; Yang YL, 2003, WORLD J GASTROENTERO, V9, P137, DOI 10.3748/wjg.v9.i1.137	52	2	2	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2020	11								572	10.3389/fimmu.2020.00572	http://dx.doi.org/10.3389/fimmu.2020.00572			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LJ1HR	32328063	gold, Green Published			2022-12-18	WOS:000529923900001
J	Deak, P; Kimani, F; Cassaidy, B; Esser-Kahn, A				Deak, Peter; Kimani, Flora; Cassaidy, Brittney; Esser-Kahn, Aaron			Determining Whether Agonist Density or Agonist Number Is More Important for Immune Activation via Micoparticle Based Assay	FRONTIERS IN IMMUNOLOGY			English	Article						toll-like-receptor; innate immunity; microparticle; activation threshold; In vitro quantification	MOLECULAR-PATTERNS; NANOPARTICLES; QUANTIFICATION; RESPONSES; REVEALS; LIGANDS; INNATE	It is unknown if surface bound toll-like-receptor (TLR) agonists activate cells via density or total molecular number. To answer this question, we developed a TLR agonist surface conjugated polystyrene microparticle (MP) system. Using a library of MPs with varying TLR agonist density and number, we simultaneously observed innate immune cell MP uptake and TNF alpha expression using ImageStream flow cytometry on a cell by cell basis. The data shows that total TLR number and not density drives cellular activation with a threshold of approximately 10(5)-10(6) TLR agonists. We believe that this information will be crucial for the design of particulate vaccine formulations.	[Deak, Peter; Kimani, Flora; Cassaidy, Brittney; Esser-Kahn, Aaron] Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA	University of Chicago	Esser-Kahn, A (corresponding author), Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA.	aesserkahn@uchicago.edu		Deak, Peter/0000-0002-2208-0174	NIH NIAID [7U01AI124286-03, NIH 1 F32 AI147517]	NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH NIAID grants 7U01AI124286-03 and NIH 1 F32 AI147517.	Agnihotri G, 2011, J MED CHEM, V54, P8148, DOI 10.1021/jm201071e; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Demento SL, 2011, TRENDS BIOTECHNOL, V29, P294, DOI 10.1016/j.tibtech.2011.02.004; Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x; Ebrahimian M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01077; Hafner AM, 2013, ADV DRUG DELIVER REV, V65, P1386, DOI 10.1016/j.addr.2013.05.013; Headland SE, 2014, SCI REP-UK, V4, DOI 10.1038/srep05237; Jang Sujeong, 2012, Chonnam Med J, V48, P7, DOI 10.4068/cmj.2012.48.1.7; Leleux JA, 2017, CELL REP, V18, P700, DOI 10.1016/j.celrep.2016.12.073; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Lynn GM, 2019, BIOMACROMOLECULES, V20, P854, DOI 10.1021/acs.biomac.8b01473; Lynn GM, 2015, NAT BIOTECHNOL, V33, P1201, DOI 10.1038/nbt.3371; Madan-Lala R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02804-y; Maguire O, 2011, CYTOM PART A, V79A, P461, DOI 10.1002/cyto.a.21068; Moser BA, 2017, ACS BIOMATER SCI ENG, V3, P206, DOI 10.1021/acsbiomaterials.6b00473; Moser M, 2015, ANAL CHEM, V87, P9376, DOI 10.1021/acs.analchem.5b02173; Pacheco P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060989; Petersen LK, 2011, BIOMATERIALS, V32, P6815, DOI 10.1016/j.biomaterials.2011.05.063; Shalek AK, 2014, NATURE, V510, P363, DOI 10.1038/nature13437; Siefert AL, 2016, BIOMATERIALS, V97, P85, DOI 10.1016/j.biomaterials.2016.03.039; Trevejo JM, 2001, P NATL ACAD SCI USA, V98, P12162, DOI 10.1073/pnas.211423598; Wang Y, 2017, J IMMUNOL, V198; Xue Q, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa2155; Yap WT, 2014, BIOTECHNIQUES, V57, P39, DOI 10.2144/000114190	25	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2020	11								642	10.3389/fimmu.2020.00642	http://dx.doi.org/10.3389/fimmu.2020.00642			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LJ1IE	32328073	Green Published, gold			2022-12-18	WOS:000529925200001
J	Scarpa, R; Pulvirenti, F; Pecoraro, A; Vultaggio, A; Marasco, C; Ria, R; Altinier, S; Compagno, N; Firinu, D; Plebani, M; De Carli, M; Matucci, A; Vianello, F; Vacca, A; Spadaro, G; Quinti, I; Agostini, C; Milito, C; Cinetto, F				Scarpa, Riccardo; Pulvirenti, Federica; Pecoraro, Antonio; Vultaggio, Alessandra; Marasco, Carolina; Ria, Roberto; Altinier, Sara; Compagno, Nicolo; Firinu, Davide; Plebani, Mario; De Carli, Marco; Matucci, Andrea; Vianello, Fabrizio; Vacca, Angelo; Spadaro, Giuseppe; Quinti, Isabella; Agostini, Carlo; Milito, Cinzia; Cinetto, Francesco			Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype	FRONTIERS IN IMMUNOLOGY			English	Article						serum free light chains; common variable immunodeficiency disorders (CVID); lymphoproliferative disease (LPD); diagnostic marker; immunoglobulin; clinical phenotype; non-infectious complications	PREDICTORS; DEFICIENCY	We report on an observational, multicenter study of 345 adult CVID patients, designed to assess the diagnostic value and the clinical association of serum free light chain (sFLC) pattern in Common Variable Immunodeficiency disorders (CVID). Sixty CVID patients were tested twice in order to assess intraindividual variability of sFLC. As control groups we included 138 patients affected by undefined primary antibody defects (UAD), lymphoproliferative diseases (LPDs), and secondary antibody deficiencies not related to hematological malignancies (SID). CVID patients presented lower kappa and lambda chain concentration compared to controls, showing low intraindividual sFLC variability. On the basis of the sFLC pattern, patients were classified into four groups: kappa-lambda+, kappa+lambda-, kappa-lambda-, kappa+lambda+. The most common pattern in CVID patients was kappa-lambda- (51%), followed by kappa-lambda+, (25%), kappa+lambda+ (22%), and kappa+lambda- (3%). In UAD, LPD, and SID groups kappa+lambda+ was the most common pattern observed. By analyzing the possible association between sFLC patterns and disease-related complications of CVID, we observed that patients belonging to the kappa-lambda- group presented more commonly unexplained enteropathy compared to the kappa+lambda+ group and showed higher frequency of bronchiectasis and splenomegaly compared to both the kappa-lambda+ and kappa+lambda+ patients. When compared to the other groups, kappa-lambda- had also lower serum IgG, IgA, and IgM concentrations at diagnosis, lower frequency of CD27+IgD-IgM- switched memory B cells, and higher frequency of CD21(low) B cells, receiving earlier CVID diagnosis. Thus, lower levels of sFLC might be an epiphenomenon of impairment in B cell differentiation, possibly leading kappa-lambda- patients to a higher risk for bacterial infections and chronic lung damage. Based on these results, we suggest adding sFLC assay to the diagnostic work-up of hypogammaglobulinemia and during follow-up. The assay may be useful to differentiate CVID from other causes of hypogammaglobulinemia and to early detect monoclonal lymphoproliferation occurring over years. Moreover, since the sFLC pattern seems to be related to disease phenotypes and clinical manifestations of CVID and after confirmation by further studies, sFLC assay might be considered a promising prognostic tool for identifying patients at higher risk of developing enteropathy and chronic lung damage or splenomegaly. This will allow designing a tailored follow-up for CVID patients.	[Scarpa, Riccardo; Agostini, Carlo; Cinetto, Francesco] Univ Padua, Dept Med DIMED, Padua, Italy; [Scarpa, Riccardo; Agostini, Carlo; Cinetto, Francesco] ULSS2 Marca Trevigiana, Ca Foncello Hosp, Rare Dis Referral Ctr, Internal Med 1, Treviso, Italy; [Pulvirenti, Federica; Quinti, Isabella] Univ Hosp Policlin Umberto I, Dept Infect Dis & Internal Med, Rome, Italy; [Pecoraro, Antonio; Spadaro, Giuseppe] Univ Naples Federico II, Ctr Basic & Clin Immunol Res, Dept Translat Med Sci, Naples, Italy; [Vultaggio, Alessandra; Matucci, Andrea] AOU Careggi, Dept Med Geriatr, Immunoallergol Unit, Florence, Italy; [Marasco, Carolina; Ria, Roberto; Vacca, Angelo] Univ Bari Aldo Moro, Sch Med, Dept Biomed Sci & Human Oncol, Bari, Italy; [Altinier, Sara; Plebani, Mario] Univ Hosp Padova, Dept Lab Med, Padua, Italy; [Compagno, Nicolo; Vianello, Fabrizio] Univ Padua, Dept Med DIMED, Hematol & Clin Immunol, Padua, Italy; [Firinu, Davide] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy; [De Carli, Marco] Azienda Sanitaria Univ Integrata Udine, Dept Internal Med, Udine, Italy; [Quinti, Isabella; Milito, Cinzia] Sapienza Univ Rome, Dept Mol Med, Rome, Italy	University of Padua; ULSS 2 Marca TV; Ospedale Ca' Foncello Treviso; Sapienza University Rome; University Hospital Sapienza Rome; University of Naples Federico II; University of Florence; Azienda Ospedaliero Universitaria Careggi; Universita degli Studi di Bari Aldo Moro; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; University of Cagliari; Hospital Santa Maria della Misericordia; Sapienza University Rome	Cinetto, F (corresponding author), Univ Padua, Dept Med DIMED, Padua, Italy.; Cinetto, F (corresponding author), ULSS2 Marca Trevigiana, Ca Foncello Hosp, Rare Dis Referral Ctr, Internal Med 1, Treviso, Italy.	francesco.cinetto@unipd.it	Alessandra, Vultaggio/K-3201-2014; firinu, davide/AAF-4366-2020; Vacca, Angelo/AAC-9558-2022; Milito, Cinzia/AAP-7075-2020; Cinetto, Francesco/AAE-5328-2019; Cinetto, Francesco/J-7386-2018; Scarpa, Riccardo/HFZ-9793-2022; VIANELLO, FABRIZIO/M-5211-2016; Ria, Roberto/I-4263-2015	Vacca, Angelo/0000-0002-4567-8216; Cinetto, Francesco/0000-0001-8486-5850; Cinetto, Francesco/0000-0001-8486-5850; VIANELLO, FABRIZIO/0000-0002-7174-4651; SCARPA, Riccardo/0000-0002-1085-2333; Ziyadullaev, Shukhrat/0000-0002-9309-3933; Ria, Roberto/0000-0002-1515-0090; Firinu, Davide/0000-0002-5768-391X				Altinier S, 2016, CLIN CHEM LAB MED, V54, P1065, DOI 10.1515/cclm-2015-0910; Altinier S, 2013, CLIN BIOCHEM, V46, P691, DOI 10.1016/j.clinbiochem.2013.01.014; Bin Riaz I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00777; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Bradwell AR, 2001, CLIN CHEM, V47, P673; Chapel H, 2012, J ALLERGY CLIN IMMUN, V130, P1197, DOI 10.1016/j.jaci.2012.05.046; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Clay-Gilmour AI, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0220-x; Compagno N, 2015, J ALLERGY CLIN IMMUN, V135, P1075, DOI 10.1016/j.jaci.2014.10.003; Dispenzieri A, 2009, LEUKEMIA, V23, P215, DOI 10.1038/leu.2008.307; Han XH, 2014, LEUKEMIA RES, V38, P1291, DOI 10.1016/j.leukres.2014.09.006; Hanitsch LG, 2018, J CLIN IMMUNOL, V38, P163, DOI 10.1007/s10875-018-0478-y; Hartono S, 2017, ANN ALLERG ASTHMA IM, V118, P614, DOI 10.1016/j.anai.2017.01.004; Heaney JLJ, 2017, BRIT J HAEMATOL, V178, P220, DOI 10.1111/bjh.14753; Hutchison CA, 2008, CLIN J AM SOC NEPHRO, V3, P1684, DOI 10.2215/CJN.02290508; Jonkman-Berk BM, 2015, CLIN IMMUNOL, V156, P154, DOI 10.1016/j.clim.2014.10.003; Katzmann JA, 2002, CLIN CHEM, V48, P1437; Mannina A, 2016, ANN AM THORAC SOC, V13, P1042, DOI 10.1513/AnnalsATS.201511-728OC; Morabito F, 2011, BLOOD, V118, P6353, DOI 10.1182/blood-2011-04-345587; Portney L.G., 2000, FDN CLIN RES APPL PR, P560; Pulvirenti F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02546; Quinti I, 2012, BLOOD, V120, P1953, DOI 10.1182/blood-2012-05-431064; Quinti I, 2011, J CLIN IMMUNOL, V31, P315, DOI 10.1007/s10875-011-9511-0; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Sala P, 2016, EUR J MED GENET, V59, P219, DOI 10.1016/j.ejmg.2016.02.003; Thio M, 2008, TRENDS PHARMACOL SCI, V29, P170, DOI 10.1016/j.tips.2008.01.004; Unsworth DJ, 2012, J CLIN PATHOL, V65, P1128, DOI 10.1136/jclinpath-2012-201044; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744	28	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2020	11								319	10.3389/fimmu.2020.00319	http://dx.doi.org/10.3389/fimmu.2020.00319			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LE5IC	32296413	Green Published, gold			2022-12-18	WOS:000526751400001
J	Delignat, S; Rayes, J; Dasgupta, S; Gangadharan, B; Denis, CV; Christophe, OD; Bayry, J; Kaveri, SV; Lacroix-Desmazes, S				Delignat, Sandrine; Rayes, Julie; Dasgupta, Suryasarathi; Gangadharan, Bagirath; Denis, Cecile V.; Christophe, Olivier D.; Bayry, Jagadeesh; Kaveri, Srinivas V.; Lacroix-Desmazes, Sebastien			Removal of Mannose-Ending Glycan at Asn(2118) Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells	FRONTIERS IN IMMUNOLOGY			English	Article						hemophilia A; factor VIII; FVIII inhibitors; N-glycosylations; immunogenicity of therapeutic proteins	VON-WILLEBRAND-FACTOR; THERAPEUTIC FACTOR-VIII; IMMUNE-RESPONSE; INHIBITOR DEVELOPMENT; N-GLYCOSYLATION; DEFICIENT MICE; RECEPTOR; EXPRESSION; MECHANISM; DOMAIN	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients. Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4 C T lymphocytes. Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity. Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip. Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4 C T cells by human monocyte-derived dendritic cells. However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4 C T cells by mouse antigen-presenting cells. In agreement with this, the N2118Q mutation did not reduce factor VIII immunogenicity in factor VIII-deficient mice. Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species. Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.	[Delignat, Sandrine; Rayes, Julie; Dasgupta, Suryasarathi; Gangadharan, Bagirath; Bayry, Jagadeesh; Kaveri, Srinivas V.; Lacroix-Desmazes, Sebastien] Univ Paris, INSERM, Ctr Rech Cordeliers, Sorbonne Univ, Paris, France; [Denis, Cecile V.; Christophe, Olivier D.] Univ Paris Saclay, HITh, INSERM, UMR S1176, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Lacroix-Desmazes, S (corresponding author), Univ Paris, INSERM, Ctr Rech Cordeliers, Sorbonne Univ, Paris, France.	sebastien.lacroix-desmazes@crc.jussieu.fr	christophe, olivier/W-4268-2017; Bayry, Jagadeesh/A-6589-2011; Denis, Cecile/A-7649-2011	christophe, olivier/0000-0002-9080-6336; Bayry, Jagadeesh/0000-0003-0498-9808; Denis, Cecile/0000-0001-5152-9156; Rayes, Julie/0000-0003-0499-6880	Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; Universite Pierre et Marie Curie; Agence Nationale de la Recherche [ANR-07-MRAR-028-01, ANR-07-JCJC-0100-01, ANR-07-RIB-002-02]; LFB (Les Ulis, France); Innovative Medicines Initiative Joint Undertaking ABIRISK (Anti-Biopharmaceutical Immunization Risk) project [115303]; European Union	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Universite Pierre et Marie Curie; Agence Nationale de la Recherche(French National Research Agency (ANR)); LFB (Les Ulis, France); Innovative Medicines Initiative Joint Undertaking ABIRISK (Anti-Biopharmaceutical Immunization Risk) project; European Union(European Commission)	This work was supported by the Institut National de la Sante et de la Recherche Medicale, the Centre National de la Recherche Scientifique, the Universite Pierre et Marie Curie, and by grants from the Agence Nationale de la Recherche (ANR-07-MRAR-028-01, ANR-07-JCJC-0100-01, and ANR-07-RIB-002-02), and the LFB (Les Ulis, France) and the Innovative Medicines Initiative Joint Undertaking ABIRISK (Anti-Biopharmaceutical Immunization Risk) project under grant agreement #115303, the resources of which comprise financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and in-kind contributions from EFPIA companies.	Ahlen G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046959; Astermark J, 2013, BLOOD, V121, P1446, DOI 10.1182/blood-2012-06-434803; Badirou I, 2010, J THROMB HAEMOST, V8, P2338, DOI 10.1111/j.1538-7836.2010.04012.x; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; BIHOREAU N, 1991, BIOCHEM J, V277, P23, DOI 10.1042/bj2770023; Burgdorf S, 2006, J IMMUNOL, V176, P6770, DOI 10.4049/jimmunol.176.11.6770; Canis K, 2018, J THROMB HAEMOST, V16, P1592, DOI 10.1111/jth.14204; Cunningham MA, 2003, J THROMB HAEMOST, V1, P2360, DOI 10.1046/j.1538-7836.2003.00415.x; Dasgupta S, 2007, P NATL ACAD SCI USA, V104, P8965, DOI 10.1073/pnas.0702120104; Dasgupta S, 2007, BLOOD, V109, P610, DOI 10.1182/blood-2006-05-022756; Delignat S, 2014, HAEMOPHILIA, V20, P486, DOI 10.1111/hae.12348; Delignat S, 2012, HAEMOPHILIA, V18, P248, DOI 10.1111/j.1365-2516.2011.02679.x; Delignat-Heudier S., 2017, THERAPEUTIC STRATEGI; Dimitrov JD, 2010, BLOOD, V115, P2682, DOI 10.1182/blood-2009-04-216408; EHRENFORTH S, 1992, LANCET, V340, P253, DOI 10.1016/0140-6736(92)90530-G; Gangadharan B, 2017, HAEMATOLOGICA, V102, P271, DOI 10.3324/haematol.2016.148502; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; He LZ, 2007, J IMMUNOL, V178, P6259, DOI 10.4049/jimmunol.178.10.6259; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; Herczenik E, 2012, J ALLERGY CLIN IMMUN, V129, P501, DOI 10.1016/j.jaci.2011.08.029; Jacquemin M, 2003, BLOOD, V101, P1351, DOI 10.1182/blood-2002-05-1369; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; James EA, 2011, J THROMB HAEMOST, V9, P689, DOI 10.1111/j.1538-7836.2011.04202.x; Kannicht C, 2013, THROMB RES, V131, P78, DOI 10.1016/j.thromres.2012.09.011; Lacroix-Desmazes S, 2008, BLOOD, V112, P240, DOI 10.1182/blood-2008-02-124941; Lech M, 2012, INT J MOL SCI, V13, P10113, DOI 10.3390/ijms130810113; Lee LY, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00404; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Linehan SA, 1999, J EXP MED, V189, P1961, DOI 10.1084/jem.189.12.1961; Lundberg K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052875; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Martinez-Pomares L, 2005, LAB INVEST, V85, P1238, DOI 10.1038/labinvest.3700327; Martinez-Pomares L, 2012, J LEUKOCYTE BIOL, V92, P1177, DOI 10.1189/jlb.0512231; Marx I, 2008, ARTERIOSCL THROM VAS, V28, P419, DOI 10.1161/ATVBAHA.107.159442; Matino D, 2015, J CLIN INVEST, V125, P3766, DOI 10.1172/JCI81859; Medzihradszky KF, 1997, ANAL CHEM, V69, P3986, DOI 10.1021/ac970372z; MEULIEN P, 1988, PROTEIN ENG, V2, P301, DOI 10.1093/protein/2.4.301; Navarrete A, 2009, J THROMB HAEMOST, V7, P1816, DOI 10.1111/j.1538-7836.2009.03571.x; O'Sullivan JM, 2016, ARTERIOSCL THROM VAS, V36, P855, DOI 10.1161/ATVBAHA.115.306915; Pack M, 2008, IMMUNOLOGY, V123, P438, DOI 10.1111/j.1365-2567.2007.02710.x; Pajot A, 2004, EUR J IMMUNOL, V34, P3060, DOI 10.1002/eji.200425463; Pavlova A, 2009, J THROMB HAEMOST, V7, P2006, DOI 10.1111/j.1538-7836.2009.03636.x; Repesse Y, 2012, J ALLERGY CLIN IMMUN, V129, P1172, DOI 10.1016/j.jaci.2012.01.048; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; Swystun LL, 2019, J THROMB HAEMOST, V17, P681, DOI 10.1111/jth.14404; van Haren SD, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002246; Varthaman A, 2019, HAEMATOLOGICA, V104, P236, DOI 10.3324/haematol.2018.206383; Wei W, 2018, BIOCHEM J, V475, P873, DOI 10.1042/BCJ20170884; Wroblewska A, 2012, BLOOD, V119, P5294, DOI 10.1182/blood-2011-11-391680; Zheng CL, 2010, BLOOD, V115, P1081, DOI 10.1182/blood-2009-09-241877	50	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 26	2020	11								393	10.3389/fimmu.2020.00393	http://dx.doi.org/10.3389/fimmu.2020.00393			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LE2IM	32273875	gold, Green Published			2022-12-18	WOS:000526546800001
J	Connolly, E; Hussell, T				Connolly, Emma; Hussell, Tracy			The Impact of Type 1 Interferons on Alveolar Macrophage Tolerance and Implications for Host Susceptibility to Secondary Bacterial Pneumonia	FRONTIERS IN IMMUNOLOGY			English	Review						type I IFN; trained immunity; alveolar macrophage; lung viral infection; secondary bacterial pneumonia; epigenome; tolerance	RECEPTOR TYROSINE KINASE; I INTERFERON; VIRUS-INFECTION; INNATE IMMUNITY; DOWN-REGULATION; NK CELLS; INFLUENZA; ALPHA; PROTECTION; MEMORY	That macrophages adapt to environmental cues is well-established. This adaptation has had several reiterations, first with innate imprinting and then with various combinations of trained, tolerant, paralyzed, or primed. Whatever the nomenclature, it represents a macrophage that is required to perform very different functions. First, alveolar macrophages are one of the sentinel cells that flag up damage and release mediators that attract other immune cells. Next, they mature to support T cell priming and survival. Finally they are critical in clearing inflammatory immune cells by phagocytosis and extracellular matrix turnover components by efferocytosis. At each functional stage they alter intrinsic components to guide their activity. Training therefore is akin to changing function. In this mini-review we focus on the lung and the specific role of type I interferons in altering macrophage activity. The proposed mechanisms of type I IFNs on lung-resident alveolar macrophages and their effect on host susceptibility to bacterial infection following influenza virus infection.	[Connolly, Emma; Hussell, Tracy] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England	University of Manchester	Connolly, E; Hussell, T (corresponding author), Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.	emma.connoly@manchester.ac.uk; tracy.hussell@manchester.ac.uk	Hussell, Tracy/O-4630-2014	Hussell, Tracy/0000-0001-7186-6141	Wellcome Trust [202865/Z/16/Z]	Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported in part by grants from the Wellcome Trust (202865/Z/16/Z).	Aegerter H, 2020, NAT IMMUNOL, V21, P145, DOI 10.1038/s41590-019-0568-x; Alberts DS, 2006, GYNECOL ONCOL, V100, P133, DOI 10.1016/j.ygyno.2005.07.117; Bell TJ, 2019, MATRIX BIOL, V80, P14, DOI 10.1016/j.matbio.2018.06.006; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Berg J, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01953-2016; Bordon Y, 2014, NAT REV IMMUNOL, V14, P713, DOI 10.1038/nri3759; Chang MY, 2017, AM J PHYSIOL-LUNG C, V313, pL1069, DOI 10.1152/ajplung.00353.2017; Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684; Delgado-Ortega M, 2013, VET IMMUNOL IMMUNOP, V151, P1, DOI 10.1016/j.vetimm.2012.11.008; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Dickson RP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004923; Didierlaurent A, 2008, J EXP MED, V205, P323, DOI 10.1084/jem.20070891; Doughty LA, 2001, J IMMUNOL, V166, P2658, DOI 10.4049/jimmunol.166.4.2658; Durrant WE, 2004, ANNU REV PHYTOPATHOL, V42, P185, DOI 10.1146/annurev.phyto.42.040803.140421; Eisenreich W, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00042; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Fujimori T, 2015, MUCOSAL IMMUNOL, V8, P1021, DOI 10.1038/mi.2014.129; Furie R, 2015, SEMIN NEPHROL, V35, P509, DOI 10.1016/j.semnephrol.2015.08.012; Gao SJ, 2017, VIROL SIN, V32, P261, DOI 10.1007/s12250-017-4004-9; Gopal R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02151; Grabiec AM, 2017, J ALLERGY CLIN IMMUN, V140, P1144, DOI 10.1016/j.jaci.2017.03.024; Grabiec AM, 2016, SEMIN IMMUNOPATHOL, V38, P409, DOI 10.1007/s00281-016-0555-3; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hall JC, 2010, NAT REV RHEUMATOL, V6, P40, DOI 10.1038/nrrheum.2009.237; Hamada A, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03225; Hertzog P, 2011, J INTERF CYTOK RES, V31, P5, DOI 10.1089/jir.2010.0126; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Kamada R, 2018, P NATL ACAD SCI USA, V115, pE9162, DOI 10.1073/pnas.1720930115; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Khamashta M, 2016, ANN RHEUM DIS, V75, P1909, DOI 10.1136/annrheumdis-2015-208562; Kim YG, 2011, CELL HOST MICROBE, V9, P496, DOI 10.1016/j.chom.2011.05.006; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Kudva A, 2011, J IMMUNOL, V186, P1666, DOI 10.4049/jimmunol.1002194; Kurtz J, 2005, TRENDS IMMUNOL, V26, P186, DOI 10.1016/j.it.2005.02.001; Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025; Lee B, 2015, AM J PHYSIOL-LUNG C, V309, pL158, DOI 10.1152/ajplung.00338.2014; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; LEVINE MI, 1946, AM REV TUBERC PULM, V53, P517; Li WJ, 2012, J VIROL, V86, P12304, DOI 10.1128/JVI.01269-12; MacDonald BA, 2015, ANESTHESIOLOGY, V123, P590, DOI 10.1097/ALN.0000000000000766; MacMicking JD, 2012, NAT REV IMMUNOL, V12, P367, DOI 10.1038/nri3210; Maus UA, 2006, AM J RESP CELL MOL, V35, P227, DOI 10.1165/rcmb.2005-0241OC; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mehta D, 2015, J INTERF CYTOK RES, V35, P925, DOI 10.1089/jir.2015.0072; Mesev EV, 2019, NAT MICROBIOL, V4, P914, DOI 10.1038/s41564-019-0421-x; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Nakamura S, 2011, J CLIN INVEST, V121, P3657, DOI 10.1172/JCI57762; Navarini AA, 2009, P NATL ACAD SCI USA, V106, P7107, DOI 10.1073/pnas.0901162106; Neagos J, 2015, AM J RESP CELL MOL, V53, P872, DOI 10.1165/rcmb.2015-0057OC; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Novakovic B, 2016, CELL, V167, P1354, DOI 10.1016/j.cell.2016.09.034; Park SH, 2017, NAT IMMUNOL, V18, P1104, DOI 10.1038/ni.3818; Penkov S, 2019, TRENDS IMMUNOL, V40, P1, DOI 10.1016/j.it.2018.11.002; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Reder AT, 2014, J INTERF CYTOK RES, V34, P589, DOI 10.1089/jir.2013.0158; Robinson KM, 2013, J IMMUNOL, V191, P5153, DOI 10.4049/jimmunol.1301237; Russell DG, 2019, NAT REV IMMUNOL, V19, P291, DOI 10.1038/s41577-019-0124-9; Rynda-Apple A, 2015, INFECT IMMUN, V83, P3764, DOI 10.1128/IAI.00298-15; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Saka HA, 2012, ANNU REV CELL DEV BI, V28, P411, DOI 10.1146/annurev-cellbio-092910-153958; Sanders RD, 2013, CRIT CARE MED, V41, P1627, DOI 10.1097/CCM.0b013e31827c0c8d; Schliehe C, 2015, NAT IMMUNOL, V16, P67, DOI 10.1038/ni.3046; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Shahangian A, 2009, J CLIN INVEST, V119, P1910, DOI 10.1172/JCI35412; Shepardson KM, 2016, MBIO, V7, DOI 10.1128/mBio.00506-16; Shirey KA, 2019, MBIO, V10, DOI 10.1128/mBio.00810-19; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Sun P, 2019, CURR TOP MED CHEM, V19, P1350, DOI 10.2174/1568026619666190619143706; Tian XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041879; Tighe RM, 2019, MATRIX BIOL, V78-79, P84, DOI 10.1016/j.matbio.2018.01.027; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Wang B, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101300; Wang H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02345; WARR GA, 1983, INFLAMMATION, V7, P93, DOI 10.1007/BF00917815; Williams AE, 2004, J IMMUNOL, V173, P7435, DOI 10.4049/jimmunol.173.12.7435; Yona S, 2013, IMMUNITY, V38, P1073, DOI 10.1016/j.immuni.2013.05.008; Yoshida K, 2015, NAT IMMUNOL, V16, P1034, DOI 10.1038/ni.3257; Zhang FM, 2019, BIOMED PHARMACOTHER, V111, P740, DOI 10.1016/j.biopha.2018.12.103; Zhang Q, 2019, NAT REV IMMUNOL, V19, P417, DOI 10.1038/s41577-019-0151-6; Zhang Y, 2016, BIOCHEM BIOPH RES CO, V478, P1436, DOI 10.1016/j.bbrc.2016.08.142	83	2	2	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 20	2020	11								495	10.3389/fimmu.2020.00495	http://dx.doi.org/10.3389/fimmu.2020.00495			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC8CN	32265937	Green Published, gold			2022-12-18	WOS:000525560500001
J	Deal, C; Thauland, TJ; Stiehm, ER; Garcia-Lloret, MI; Butte, MJ				Deal, Christin; Thauland, Timothy J.; Stiehm, E. Richard; Garcia-Lloret, Maria I.; Butte, Manish J.			Intact B-Cell Signaling and Function With Host B-Cells 47 Years After Transplantation for X-SCID	FRONTIERS IN IMMUNOLOGY			English	Article						SCID; B cell; transplant; chimerism; IL2RG; IL-21; gamma chain; IVIG	SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOLOGICAL RECONSTITUTION; IMMUNE RECONSTITUTION; HUMAN-PAPILLOMAVIRUS; DEFICIENCY; MUTATION; OUTCOMES; IL-21	Introduction: Severe Combined Immunodeficiency (SCID) is a life-threatening immunodeficiency caused by several pathogenic genetic variants, and it is characterized by profound defects in T-cell numbers and immune function. First performed in the late 1960's, hematopoietic stem cell transplantation remains the standard treatment for most cases of SCID. There is a growing number of post-transplant SCID patients, and it is imperative to assess the long-term outcomes of these patients. We have reported here the longest follow-up of a post-transplant SCID patient who, to our knowledge, bears the first gamma chain (gamma c) variant to show intact IL-21 signaling. Case Presentation: The patient presented at 5 months of age with recurrent thrush and Pneumocystis jiroveci pneumonia. In 1971, at the age of 11 months, he received an unconditioned, matched, related donor transplant comprising whole, unprocessed bone marrow. He is now 48 years old without significant illness and has never required immunoglobulin replacement. He exhibits T-dependent vaccine responses. He does suffer from chronic warts and bacterial infections that have worsened in recent years. We confirmed a known pathogenic variant in the IL2RG gene showing a hemizygous variant NM_000206.2:c.675C>A, resulting in p.Ser225Arg. His chimerism studies revealed donor T cells, host B cells, host myeloid cells, and mixed NK cells. Lymphocyte enumeration revealed normal numbers and distribution of B cells. The host B cells carry the pathogenic variant in IL2RG, but, when stimulated with IL-21, they demonstrated intact, gamma c-dependent signaling. Conclusions: Even with host B cells, reconstitution with donor T cells can be sufficient to allow over four decades of survival when B-cell function is intact. Our case demonstrates that satisfactory B-cell function can arise as a consequence of both intact IL-21 signaling due to a hypomorphic gamma c variant, and close HLA matching with the donor to allow for effective T-cell help.	[Deal, Christin; Thauland, Timothy J.; Stiehm, E. Richard; Garcia-Lloret, Maria I.; Butte, Manish J.] Univ Calif Los Angeles, Dept Pediat, Div Immunol Allergy & Rheumatol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Butte, MJ (corresponding author), Univ Calif Los Angeles, Dept Pediat, Div Immunol Allergy & Rheumatol, Los Angeles, CA 90024 USA.	mbutte@mednet.ucla.edu	Butte, Manish/AAM-8604-2020; Butte, Manish/T-8860-2019	Butte, Manish/0000-0002-4490-5595; Butte, Manish/0000-0002-4490-5595	Jeffrey Modell Foundation	Jeffrey Modell Foundation	We thank the patient and family for participating in research. We thank the Jeffrey Modell Foundation for funding research on primary immunodeficiencies including the work presented here. The authors would like to thank the Genome Aggregation Database (gnomAD) and the groups that provided exome and genome variant data to this resource. A full list of contributing groups can be found at: https://gnomad.broadinstitute.org/about.	Borghans JA, 2006, BLOOD, V108, P763, DOI 10.1182/blood-2006-01-009241; Buckley RH, 2013, J CLIN IMMUNOL, V33, P96, DOI 10.1007/s10875-012-9797-6; Chahoud J, 2016, JAMA DERMATOL, V152, P1354, DOI 10.1001/jamadermatol.2015.4530; Dvorak CC, 2019, J ALLERGY CLIN IMMUN, V143, P405, DOI 10.1016/j.jaci.2018.08.027; Fuchs S, 2014, EUR J IMMUNOL, V44, P3129, DOI 10.1002/eji.201444689; GATTI RA, 1968, LANCET, V2, P1366; Haddad E, 2018, BLOOD, V132, P1737, DOI 10.1182/blood-2018-03-840702; Heimall J, 2017, BLOOD, V130, P2718, DOI 10.1182/blood-2017-05-781849; Kamili QUA, 2014, J ALLERGY CLIN IMMUN, V134, P1451, DOI 10.1016/j.jaci.2014.07.009; Karczewski K.J., 2019, GENOMICS, DOI [10.1101/531210, DOI 10.1101/531210]; Laffort C, 2004, LANCET, V363, P2051, DOI 10.1016/S0140-6736(04)16457-X; Lim CK, 2019, ALLERGY ASTHMA CL IM, V15, DOI 10.1186/s13223-018-0317-y; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Miggelbrink AM, 2018, BLOOD, V131, P2967, DOI 10.1182/blood-2017-10-809822; Moon WY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01703; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; Nourizadeh M, 2015, IRAN J ALLERGY ASTHM, V14, P457; Nowak K, 2017, J INVEST DERMATOL, V137, P2120, DOI 10.1016/j.jid.2017.05.024; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Patel NC, 2008, J ALLERGY CLIN IMMUN, V122, P1185, DOI 10.1016/j.jaci.2008.10.030; PEPPER AE, 1995, AM J HUM GENET, V57, P564; Puck JM, 2007, J ALLERGY CLIN IMMUN, V120, P760, DOI 10.1016/j.jaci.2007.08.043; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Recher M, 2011, BLOOD, V118, P6824, DOI 10.1182/blood-2011-06-362533; Sharfe N, 1997, J CLIN INVEST, V100, P3036, DOI 10.1172/JCI119858; Stenson PD, 2014, HUM GENET, V133, P1, DOI 10.1007/s00439-013-1358-4; STIEHM ER, 1972, NEW ENGL J MED, V286, P797, DOI 10.1056/NEJM197204132861501	29	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 20	2020	11								415	10.3389/fimmu.2020.00415	http://dx.doi.org/10.3389/fimmu.2020.00415			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC7SS	32265911	Green Published, gold			2022-12-18	WOS:000525533700001
J	Redlberger-Fritz, M; Kundi, M; Popow-Kraupp, T				Redlberger-Fritz, Monika; Kundi, Michael; Popow-Kraupp, Therese			Heterogeneity of Circulating Influenza Viruses and Their Impact on Influenza Virus Vaccine Effectiveness During the Influenza Seasons 2016/17 to 2018/19 in Austria	FRONTIERS IN IMMUNOLOGY			English	Article						influenza vaccine effectiveness; influenza genetic heterogeneity; influenza virus; genetic variability and vaccine effectiveness; influenza antigenic drift and influenza vaccine effectiveness	UNITED-KINGDOM; SURVEILLANCE; CHILDREN; A(H3N2); CANADA; ADULTS; END	The constantly changing pattern in the dominance of viral strains and their evolving subclades during the seasons substantially influences influenza vaccine effectiveness (IVE). In order to further substantiate the importance of detailed data of genetic virus characterization for IVE estimates during the seasons, we performed influenza virus type and subtype specific IVE estimates. IVE estimates were assessed using a test-negative case-control design, in the context of the intraseasonal changes of the heterogeneous mix of circulating influenza virus strains for three influenza seasons (2016/17 to 2018/19) in Austria. Adjusted overall IVE over the three seasons 2016/17, 2017/18, and 2018/19 were -26, 39, and 63%, respectively. In accordance with the changing pattern of the circulating strains a broad range of overall and subtype specific IVEs was obtained: A(H3N2) specific IVE ranged between -26% for season 2016/17 to 58% in season 2018/19, A(H1N1)pdm09 specific IVE was 25% for the season 2017/18 and 65% for the season 2018/19 and Influenza B specific IVE for season 2017/18 was 45%. The results obtained in our study over the three seasons demonstrate the increasingly complex dynamic of the ever changing genetic pattern of the circulating influenza viruses and their influence on IVE estimates. This emphasizes the importance of detailed genetic virus surveillance for reliable IVE estimates.	[Redlberger-Fritz, Monika; Popow-Kraupp, Therese] Med Univ Vienna, Ctr Virol, Vienna, Austria; [Kundi, Michael] Med Univ Vienna, Dept Environm Hlth, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Redlberger-Fritz, M (corresponding author), Med Univ Vienna, Ctr Virol, Vienna, Austria.	monika.redlberger@meduniwien.ac.at		Redlberger-Fritz, Monika/0000-0001-6265-557X	Sanofi Pasteur; Biomedica; Valneva;  [777363 - DRIVE - H2020-JTI-IMI2-2016-09-two-stage]	Sanofi Pasteur; Biomedica; Valneva; 	DRIVE funding was obtained for protocol development and for data and documentation management during the seasons 2017/18 and 2018/19 (Grant No. 777363 - DRIVE - H2020-JTI-IMI2-2016-09-two-stage). The Austrian Sentinel Physician Surveillance Network was supported by Sanofi Pasteur, Biomedica and Valneva. The supporters had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Belongia EA, 2017, J INFECT DIS, V216, P1477, DOI 10.1093/infdis/jix527; Chiu SS, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.5.1900056; ECDC, ECDC INFL CAS DEF; ECDC ERLI-Net, 2015, INFL VIR CHAR; Fonville JM, 2014, SCIENCE, V346, P996, DOI 10.1126/science.1256427; Gherasim A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179160; Hergens M, 2017, EUROSURVEILLANCE, V22, P32, DOI 10.2807/1560-7917.ES.2017.22.8.30469; Kissling E, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.7.30464; Kissling E, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.1900121; Pebody RG, 2013, EUROSURVEILLANCE, V18, P25; Pebody R, 2017, EUROSURVEILLANCE, V22, P10, DOI 10.2807/1560-7917.ES.2017.22.44.17-00306; Pebody R, 2019, EUROSURVEILLANCE, V24, P23, DOI 10.2807/1560-7917.ES.2019.24.31.1800488; Rambhia KJ, 2019, CLIN INFECT DIS, V68, P1235, DOI 10.1093/cid/ciy748; Redlberger M, 2007, VACCINE, V25, P6061, DOI 10.1016/j.vaccine.2007.05.045; Redlberger-Fritz M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149916; Rondy M, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.9.18-00086; Savage RD, 2015, EUROSURVEILLANCE, V20, P29, DOI 10.2807/1560-7917.ES2015.20.16.21100; Skowronski DM, 2017, EUROSURVEILLANCE, V22, P2, DOI [10.2807/1560-7917.es.2017.22.6.30460, 10.2807/1560-7917.ES.2017.22.6.30460]; Skowronski DM, 2019, EUROSURVEILLANCE, V24, P6, DOI 10.2807/1560-7917.ES.2019.24.4.1900055; Skowronski DM, 2019, CLIN INFECT DIS, V68, P1754, DOI 10.1093/cid/ciy876; Skowronski DM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.5.18-00035; Skowronski DM, 2017, J INFECT DIS, V216, P1487, DOI 10.1093/infdis/jix526; Skowronski DM, 2015, J INFECT DIS, V212, P726, DOI 10.1093/infdis/jiv177; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153; van Doorn E, 2017, VACCINE, V35, P2831, DOI 10.1016/j.vaccine.2017.04.012; World Health Organization, 2014, INFL SEAS FACT SHEET	28	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 17	2020	11								434	10.3389/fimmu.2020.00434	http://dx.doi.org/10.3389/fimmu.2020.00434			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC7VP	32256493	Green Published, gold			2022-12-18	WOS:000525541500001
J	Barron, MR; Gartlon, J; Dawson, LA; Atkinson, PJ; Pardon, MC				Barron, Matthew R.; Gartlon, Jane; Dawson, Lee A.; Atkinson, Peter J.; Pardon, Marie-Christine			Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; lipopolysaccharide; Alzheimer's disease; mouse model; tauopathies; tau isoform imbalance	ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; COGNITIVE DECLINE; TRANSGENIC MODEL; MOUSE MODEL; RISK-FACTOR; TNF-ALPHA; EXON 10; PATHOLOGY; BRAIN	Inflammation is considered a mechanistic driver of Alzheimer's disease, thought to increase tau phosphorylation, the first step to the formation of neurofibrillary tangles (NFTs). To further understand how inflammation impacts the development of tau pathology, we used (hTau) mice, which express all six, non-mutated, human tau isoforms, but with an altered ratio of tau isoforms favoring 3R tau due to the concomitant loss of murine tau (mTau) that is predominantly 4R. Such an imbalance pattern has been related to susceptibility to NFTs formation, but whether or not this also affects susceptibility to systemic inflammation and related changes in tau phosphorylation is not known. To reduce the predominance of 3R tau by increasing 4R tau availability, we bred hTau mice on a heterozygous mTau background and compared the impact of systemic inflammation induced by lipopolysaccharide (LPS) in hTau mice hetero- or homozygous mTau knockout. Three-month-old male wild-type (Wt), mTau(+/-), mTau(-/-), hTau/mTau(+/-), and hTau/mTau(-/-) mice were administered 100, 250, or 330 mu g/kg of LPS or its vehicle phosphate buffer saline (PBS) [intravenously (i.v.), n = 8-9/group]. Sickness behavior, reflected by behavioral suppression in the spontaneous alternation task, hippocampal tau phosphorylation, measured by western immunoblotting, and circulating cytokine levels were quantified 4 h after LPS administration. The persistence of the LPS effects (250 mu g/kg) on these measures, and food burrowing behavior, was assessed at 24 h post-inoculation in Wt, mTau(+/-), and hTau/mTau(+/-) mice (n = 9-10/group). In the absence of immune stimulation, increasing 4R tau levels in hTau/mTau(+/-) exacerbated pS202 and pS396/404 tau phosphorylation, without altering total tau levels or worsening early behavioral perturbations characteristic of hTau/mTau(-/-) mice. We also show for the first time that modulating 4R tau levels in hTau mice affects the response to systemic inflammation. Behavior was suppressed in all genotypes 4 h following LPS administration, but hTau/mTau(+/-) exhibited more severe sickness behavior at the 100 mu g/kg dose and a milder behavioral and cytokine response than hTau/mTau(-/-) mice at the 330 mu g/kg dose. All LPS doses decreased tau phosphorylation at both epitopes in hTau/mTau(+/-) mice, but pS202 levels were selectively reduced at the 100 mu g/kg dose in hTau/mTau(-/-) mice. Behavioral suppression and decreased tau phosphorylation persisted at 24 h following LPS administration in hTau/mTau(+/-) mice.	[Barron, Matthew R.; Pardon, Marie-Christine] Univ Nottingham, Queens Med Ctr, Med Sch, Sch Life Sci,Div Physiol Pharmacol & Neurosci, Nottingham, England; [Gartlon, Jane; Atkinson, Peter J.] Eisai Ltd, EMEA Knowledge Ctr, Hatfield, Herts, England; [Dawson, Lee A.] Cerevance Ltd, Cambridge, England	University of Nottingham; Eisai Co Ltd	Pardon, MC (corresponding author), Univ Nottingham, Queens Med Ctr, Med Sch, Sch Life Sci,Div Physiol Pharmacol & Neurosci, Nottingham, England.	marie.pardon@nottingham.ac.uk		Pardon, Marie-Christine/0000-0003-4737-9479	Medical Research Council through an MRC-CASE Studentship award [MR/K017853/1]; Eisai Ltd.	Medical Research Council through an MRC-CASE Studentship award; Eisai Ltd.(Eisai Co Ltd)	This work was supported by the Medical Research Council (Grant No. MR/K017853/1) through an MRC-CASE Studentship award with Eisai Ltd.	Agostini A, 2020, BRAIN BEHAV IMMUN, V83, P87, DOI 10.1016/j.bbi.2019.09.019; Alford S, 2018, OBES REV, V19, P269, DOI 10.1111/obr.12629; Amdekar S, 2011, J CLIN IMMUNOL, V31, P147, DOI 10.1007/s10875-010-9457-7; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Baglietto-Vargas D, 2014, NEUROBIOL DIS, V62, P407, DOI 10.1016/j.nbd.2013.10.019; Banks WA, 2010, BRAIN BEHAV IMMUN, V24, P102, DOI 10.1016/j.bbi.2009.09.001; Barron M, 2017, EXP GERONTOL, V94, P103, DOI 10.1016/j.exger.2016.12.006; Bhaskar K, 2010, NEURON, V68, P19, DOI 10.1016/j.neuron.2010.08.023; Boutajangout A, 2004, FEBS LETT, V576, P183, DOI 10.1016/j.febslet.2004.09.011; Brier MR, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2362; Chuang YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137177; Clark RA, 2012, J PSYCHOPHARMACOL, V26, P1136, DOI 10.1177/0269881111420313; Connell JW, 2005, MOL BRAIN RES, V137, P104, DOI 10.1016/j.molbrainres.2005.02.014; Conrad C, 2007, J NEUROCHEM, V103, P1228, DOI 10.1111/j.1471-4159.2007.04857.x; Copeland S, 2005, CLIN DIAGN LAB IMMUN, V12, P60, DOI 10.1128/CDLI.12.1.60-67.2005; Cortes N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040956; Cruchaga C, 2013, NEURON, V78, P256, DOI 10.1016/j.neuron.2013.02.026; Cunningham C, 2008, BRAIN BEHAV IMMUN, V22, P1117, DOI 10.1016/j.bbi.2008.05.007; Deacon RMJ, 2002, BEHAV BRAIN RES, V132, P203, DOI 10.1016/S0166-4328(01)00401-6; Dickson D, 2011, J MOL NEUROSCI, V45, P384, DOI 10.1007/s12031-011-9589-0; Erickson MA, 2011, BRAIN BEHAV IMMUN, V25, P1637, DOI 10.1016/j.bbi.2011.06.006; Espinoza M, 2008, J ALZHEIMERS DIS, V14, P1; Ferguson SA, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00416; Geiszler PC, 2016, NEUROSCIENCE, V329, P98, DOI 10.1016/j.neuroscience.2016.05.004; Gendron TF, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-13; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; Ginsberg SD, 2006, J NEUROCHEM, V96, P1401, DOI 10.1111/j.1471-4159.2005.03641.x; Glatz DC, 2006, J NEUROCHEM, V96, P635, DOI 10.1111/j.1471-4159.2005.03552.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Hara M, 2013, ACTA NEUROPATHOL, V125, P565, DOI 10.1007/s00401-013-1097-6; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Hernandez F, 2019, BBA-MOL BASIS DIS, V1865, P2024, DOI 10.1016/j.bbadis.2018.08.010; Holmes C, 2003, J NEUROL NEUROSUR PS, V74, P788, DOI 10.1136/jnnp.74.6.788; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Ingelsson M, 2006, ACTA NEUROPATHOL, V112, P439, DOI 10.1007/s00401-006-0095-3; Irwin DJ, 2016, PARKINSONISM RELAT D, V22, pS29, DOI 10.1016/j.parkreldis.2015.09.020; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kitamura T, 2005, ACTA NEUROL SCAND, V112, P327, DOI 10.1111/j.1600-0404.2005.00488.x; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Lang SC, 2017, J IMMUNOL, V198, P2394, DOI 10.4049/jimmunol.1601472; Laurent C, 2018, BIOMED J, V41, P21, DOI 10.1016/j.bj.2018.01.003; Lee DC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-56; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Liu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084849; Espindola SL, 2018, CELL REP, V23, P709, DOI 10.1016/j.celrep.2018.03.079; Martin L, 2013, AGEING RES REV, V12, P289, DOI 10.1016/j.arr.2012.06.003; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Menden H, 2013, AM J PHYSIOL-LUNG C, V304, pL445, DOI 10.1152/ajplung.00261.2012; Niblock M, 2016, NEUROBIOL AGING, V37, P45, DOI 10.1016/j.neurobiolaging.2015.09.022; Pardon MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19880; Pei Z, 2007, GLIA, V55, P1362, DOI 10.1002/glia.20545; Qian W, 2010, J ALZHEIMERS DIS, V19, P1221, DOI [10.3233/JAD-2009-1317, 10.3233/JAD-2010-1317]; Qin YR, 2016, J IMMUNOL, V197, P3281, DOI 10.4049/jimmunol.1600873; Rossi F, 2018, BEHAV BRAIN RES, V339, P140, DOI 10.1016/j.bbr.2017.11.030; Schoch KM, 2016, NEURON, V90, P941, DOI 10.1016/j.neuron.2016.04.042; Sealey MA, 2017, NEUROBIOL DIS, V105, P74, DOI 10.1016/j.nbd.2017.05.003; Shah K, 2014, J CELL SCI, V127, P2391, DOI 10.1242/jcs.147553; Sheth P, 2009, BIOCHEM J, V421, P59, DOI 10.1042/BJ20081951; Skelly DT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069123; Spulber S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042078; Srinivasan S, 2010, CLIN VACCINE IMMUNOL, V17, P699, DOI 10.1128/CVI.00510-09; Stanevich V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086955; Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Streit WJ, 2009, ACTA NEUROPATHOL, V118, P475, DOI 10.1007/s00401-009-0556-6; Swardfager W, 2010, BIOL PSYCHIAT, V68, P930, DOI 10.1016/j.biopsych.2010.06.012; Sy M, 2011, AM J PATHOL, V178, P2811, DOI 10.1016/j.ajpath.2011.02.012; Teeling JL, 2007, BRAIN BEHAV IMMUN, V21, P836, DOI 10.1016/j.bbi.2007.01.012; Togo T, 2004, ACTA NEUROPATHOL, V107, P504, DOI 10.1007/s00401-004-0842-2; Tsubaki M, 2015, AM J TRANSL RES, V7, P1371; Uematsu M, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-017-0501-1; Umeda Y, 2004, NEUROSCI LETT, V359, P151, DOI 10.1016/j.neulet.2004.01.060; Vagelatos NT, 2013, EPIDEMIOL REV, V35, P152, DOI 10.1093/epirev/mxs012; Varatharaj A, 2017, BRAIN BEHAV IMMUN, V60, P1, DOI 10.1016/j.bbi.2016.03.010; Wang YP, 2016, NAT REV NEUROSCI, V17, P5, DOI 10.1038/nrn.2015.1; Yasojima K, 1999, BRAIN RES, V831, P301, DOI 10.1016/S0006-8993(99)01486-9; Zhan XH, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00042; Zhan XH, 2016, NEUROLOGY, V87, P2324, DOI 10.1212/WNL.0000000000003391; Zhang JF, 2014, NEURON, V82, P195, DOI 10.1016/j.neuron.2014.01.043; Zhang R, 2009, J NEUROIMMUNOL, V206, P121, DOI 10.1016/j.jneuroim.2008.09.017; Zhao YH, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00407; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	85	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2020	11								293	10.3389/fimmu.2020.00293	http://dx.doi.org/10.3389/fimmu.2020.00293			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LB6ZG	32194553	Green Published, gold			2022-12-18	WOS:000524781100001
J	Wu, SY; Zhang, JS; Xue, Q; Liu, J; Huang, BZ; He, ZL; Huang, JN; Zu, SP; Chen, ZX; Zhao, BB; Liao, M; Jiao, PR				Wu, Siyu; Zhang, Junsheng; Xue, Qian; Liu, Jing; Huang, Bingzhong; He, Zhuoliang; Huang, Jianni; Zu, Shaopo; Chen, Zuxian; Zhao, Bingbing; Liao, Ming; Jiao, Peirong			Duck TRIM32 Functions in IFN-beta Signaling Against the Infection of H5N6 Highly Pathogenic Avian Influenza Virus	FRONTIERS IN IMMUNOLOGY			English	Article						duck; TRIM32; STING; IFN-beta; avian influenza virus	RIG-I; IMMUNE-RESPONSES; PROTEIN; ACTIVATION; RECOGNITION; MECHANISMS; ADAPTER; SENSOR; MDA5	In mammals, tripartite motif 32 (TRIM32) is essential for regulating host innate immune responses to viral infections. However, the antiviral effect of TRIM32 in birds has not been reported. Here, we cloned the full-length duck TRIM32 (duTRIM32) cDNA from total spleen RNA of Peking duck. DuTRIM32 consists of 682 amino acids and has 95.5% similarity in amino acid sequences with chicken TRIM32 and 84.9% similarity with human TRIM32, respectively. DuTRIM32 mRNA was found to be ubiquitously expressed in all tested tissues from healthy ducks. Overexpression of duTRIM32 significantly activated the IFN-beta promoter and upregulated the mRNA levels of IFN-beta, IRF7, and Mx, which indicates that duTRIM32 is involved in the type I IFN pathway. Furthermore, duTRIM32 was found to directly interact with duck STING (duSTING) and to contribute to the expression of IFN-beta mediated by duSTING. The mRNA level of duTRIM32 was significantly upregulated in the lungs and spleens of H5N6 highly pathogenic avian influenza virus (HPAIV) infected ducks 3 days post-infection (DPI). Furthermore, overexpression of duTRIM32 could inhibit the replication of H5N6 HPAIV in duck embryo fibroblasts (DEFs). Therefore, these results indicate that duTRIM32 is involved in the type I IFN pathway and exhibit an antiviral effect against H5N6 HPAIV infection.	[Wu, Siyu; Zhang, Junsheng; Xue, Qian; Liu, Jing; Huang, Bingzhong; He, Zhuoliang; Huang, Jianni; Zu, Shaopo; Chen, Zuxian; Zhao, Bingbing; Liao, Ming; Jiao, Peirong] South China Agr Univ, Coll Vet Med, Guangzhou, Peoples R China; [Wu, Siyu; Liao, Ming; Jiao, Peirong] Guangdong Lab Lingnan Modern Agr, Guangzhou, Peoples R China	South China Agricultural University	Liao, M; Jiao, PR (corresponding author), South China Agr Univ, Coll Vet Med, Guangzhou, Peoples R China.; Liao, M; Jiao, PR (corresponding author), Guangdong Lab Lingnan Modern Agr, Guangzhou, Peoples R China.	mliao@scau.edu.cn; prjiao@scau.edu.cn		Liao, Ming/0000-0001-8731-4528; Jiao, Peirong/0000-0001-7750-239X	National Natural Science Foundation of China [U1501212, 31872497]; Natural Science Foundation of Guangdong Province [2016A030308001]; National Key Research and Development Program of China [2016YFD0500207]; Science and Technology Projects of Guangzhou [201904010022]; Earmarked Fund for Modern Agro-Industry Technology Research System [CARS-41-G16]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Key Research and Development Program of China; Science and Technology Projects of Guangzhou; Earmarked Fund for Modern Agro-Industry Technology Research System	This work was supported by grants from the National Natural Science Foundation of China (U1501212, 31872497), the Natural Science Foundation of Guangdong Province (2016A030308001), the National Key Research and Development Program of China (2016YFD0500207), the Science and Technology Projects of Guangzhou (201904010022), and the Earmarked Fund for Modern Agro-Industry Technology Research System (CARS-41-G16).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Arimoto K, 2010, P NATL ACAD SCI USA, V107, P15856, DOI 10.1073/pnas.1004621107; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chen S, 2018, CYTOKINE, V102, P191, DOI 10.1016/j.cyto.2017.09.008; Cheng YQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02224; Di Pietro A, 2013, J VIROL, V87, P4523, DOI 10.1128/JVI.02548-12; Fu BS, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004960; Gack MU, 2014, J VIROL, V88, P5213, DOI 10.1128/JVI.03370-13; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Jiang XM, 2012, NAT REV IMMUNOL, V12, P35, DOI 10.1038/nri3111; Jiao PR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00789; Lang XT, 2017, J EXP MED, V214, P459, DOI 10.1084/jem.20160592; Liu BY, 2017, NAT IMMUNOL, V18, P214, DOI 10.1038/ni.3641; Liu J, 2016, IMMUNITY, V45, P15, DOI 10.1016/j.immuni.2016.06.020; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Nitta S, 2013, HEPATOLOGY, V57, P46, DOI 10.1002/hep.26017; Patil G, 2018, J VIROL, V92, DOI 10.1128/JVI.00905-18; Pertel T, 2011, NATURE, V472, P361, DOI 10.1038/nature09976; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; THAKUR AK, 1981, DRUG CHEM TOXICOL, V4, P297, DOI 10.3109/01480548109018136; Tsuchida T, 2010, IMMUNITY, V33, P765, DOI 10.1016/j.immuni.2010.10.013; Wang P, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004726; Wang SS, 2016, SCI REP-UK, V6, DOI 10.1038/srep32336; Wang YM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005012; Wei LM, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-66; Wei LM, 2013, VET MICROBIOL, V166, P386, DOI 10.1016/j.vetmic.2013.06.019; Xing JJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00101-w; Yang C, 2016, CELL MOL IMMUNOL, V13, P94, DOI 10.1038/cmi.2014.131; Yang K, 2009, J IMMUNOL, V182, P3782, DOI 10.4049/jimmunol.0803126; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang J, 2012, J BIOL CHEM, V287, P28646, DOI 10.1074/jbc.M112.362608; Zhao CY, 2017, CELL REP, V21, P1613, DOI 10.1016/j.celrep.2017.10.020; Zhong B, 2008, IMMUNITY, V29, P538, DOI 10.1016/j.immuni.2008.09.003	36	2	2	1	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2020	11								377	10.3389/fimmu.2020.00377	http://dx.doi.org/10.3389/fimmu.2020.00377			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LC0PU	32184788	Green Published, gold			2022-12-18	WOS:000525033500001
J	Li, CK; Huang, R; Nie, FY; Li, JJ; Zhu, W; Shi, XQ; Guo, Y; Chen, Y; Wang, SY; Zhang, LM; Chen, LX; Li, RT; Liu, XF; Zheng, CM; Zhang, CL; Ma, RLZ				Li, Chaokun; Huang, Rui; Nie, Fangyuan; Li, Jiujie; Zhu, Wen; Shi, Xiaoqian; Guo, Yu; Chen, Yan; Wang, Shiyu; Zhang, Limeng; Chen, Longxin; Li, Runting; Liu, Xuefeng; Zheng, Changming; Zhang, Chenglin; Ma, Runlin Z.			Organization of the Addax Major Histocompatibility Complex Provides Insights Into Ruminant Evolution	FRONTIERS IN IMMUNOLOGY			English	Article						MHC; Addax nasomaculatus; ruminant; chromosome inversion; evolution; DY	CLASS-II PROTEINS; MHC CLASS-I; RETROTRANSPOSONS; SEQUENCE; GENES; RUMEN; POPULATION; GENOMES; BIOLOGY; REPEATS	Ruminants are critical as prey in transferring solar energy fixed by plants into carnivorous species, yet the genetic signature of the driving forces leading to the evolutionary success of the huge number of ruminant species remains largely unknown. Here we report a complete DNA map of the major histocompatibility complex (MHC) of the addax (Addax nasomaculatus) genome by sequencing a total of 47 overlapping BAC clones previously mapped to cover the MHC region. The addax MHC is composed of 3,224,151 nucleotides, harboring a total of 150 coding genes, 50 tRNA genes, and 14 non-coding RNA genes. The organization of addax MHC was found to be highly conserved to those of sheep and cattle, highlighted by a large piece of chromosome inversion that divided the MHC class II into IIa and IIb subregions. It is now highly possible that all of the ruminant species in the family of Bovidae carry the same chromosome inversion in the MHC region, inherited from a common ancestor of ruminants. Phylogenetic analysis indicated that DY, a ruminant-specific gene located at the boundary of the inversion and highly expressed in dendritic cells, was possibly evolved from DQ, with an estimated divergence time 140 million years ago. Homology modeling showed that the overall predicted structure of addax DY was similar to that of HLA-DQ2. However, the pocket properties of P1, P4, P6, and P9, which were critical for antigen binding in the addax DY, showed certain distinctive features. Structural analysis suggested that the populations of peptide antigens presented by addax DY and HLA-DQ2 were quite diverse, which in theory could serve to promote microbial regulation in the rumen by ruminant species, contributing to enhanced grass utilization ability. In summary, the results of our study helped to enhance our understanding of the MHC evolution and provided additional supportive evidence to our previous hypothesis that an ancient chromosome inversion in the MHC region of the last common ancestor of ruminants may have contributed to the evolutionary success of current ruminants on our planet.	[Li, Chaokun; Huang, Rui; Nie, Fangyuan; Li, Jiujie; Zhu, Wen; Shi, Xiaoqian; Guo, Yu; Chen, Yan; Wang, Shiyu; Ma, Runlin Z.] Univ Chinese Acad Sci, Sch Life Sci, Beijing, Peoples R China; [Li, Chaokun; Huang, Rui; Nie, Fangyuan; Shi, Xiaoqian; Guo, Yu; Ma, Runlin Z.] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing, Peoples R China; [Zhang, Limeng; Chen, Longxin; Li, Runting; Ma, Runlin Z.] Zhengzhou Normal Univ, Mol Biol Lab, Zhengzhou, Peoples R China; [Liu, Xuefeng; Zheng, Changming; Zhang, Chenglin] Beijing Zoo, Beijing Key Lab Capt Wildlife Technol, Beijing, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Zhengzhou Normal University	Ma, RLZ (corresponding author), Univ Chinese Acad Sci, Sch Life Sci, Beijing, Peoples R China.; Ma, RLZ (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing, Peoples R China.; Ma, RLZ (corresponding author), Zhengzhou Normal Univ, Mol Biol Lab, Zhengzhou, Peoples R China.	rima@ucas.ac.cn	Zhang, Cheng/GRS-8698-2022; Chen, Longxin/HGD-3900-2022	Li, Chaokun/0000-0001-9037-488X	Chinese Academy of Sciences [153E11KYSB20130101]; National Natural Science Foundation of China [81871130]	Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported in part by grants from the Chinese Academy of Sciences (No. 153E11KYSB20130101 to RM) and the National Natural Science Foundation of China (81871130 to RM). The funding bodies had no role in the design of the study, in the collection, analysis, and interpretation of data, or in the writing of the manuscript.	Adelson DL, 2009, P NATL ACAD SCI USA, V106, P12855, DOI 10.1073/pnas.0901282106; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; de Sa ALA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00696; [Anonymous], 2017, IUCN RED LIST THREAT; Ballingall KT, 2016, CONSERV GENET, V17, P1171, DOI 10.1007/s10592-016-0852-3; Ballingall KT, 2005, ANIM GENET, V36, P237, DOI 10.1111/j.1365-2052.2005.01281.x; Ballingall KT, 2004, IMMUNOGENETICS, V55, P748, DOI 10.1007/s00251-004-0641-x; Bana NA, 2018, MOL GENET GENOMICS, V293, P665, DOI 10.1007/s00438-017-1412-3; Biedrzycka A, 2016, INFECT GENET EVOL, V44, P210, DOI 10.1016/j.meegid.2016.07.014; Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910; Bouckaert R, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006650; Brinkmeyer-Langford CL, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-182; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Chang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168744; Chen L, 2019, SCIENCE, V364, P1152, DOI 10.1126/science.aav6202; Chen Nansheng, 2004, Curr Protoc Bioinformatics, VChapter 4, DOI 10.1002/0471250953.bi0410s05; Devant M, 2016, J ANIM SCI, V94, P3902, DOI 10.2527/jas.2016-0594; Elsik CG, 2009, SCIENCE, V324, P522, DOI 10.1126/science.1169588; Fan GY, 2019, MOL ECOL RESOUR, V19, P944, DOI 10.1111/1755-0998.13003; FAN Z, 2018, GIGASCIENCE, V7, P1, DOI DOI 10.1093/gigascience/giy038; Frazer KA, 2004, NUCLEIC ACIDS RES, V32, pW273, DOI 10.1093/nar/gkh458; Gallus S, 2015, GENE, V571, P271, DOI 10.1016/j.gene.2015.06.064; Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022; Hackmann TJ, 2010, J DAIRY SCI, V93, P1320, DOI 10.3168/jds.2009-2071; Hooper DM, 2017, NAT ECOL EVOL, V1, P1526, DOI 10.1038/s41559-017-0284-6; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Jiang Y, 2014, SCIENCE, V344, P1168, DOI 10.1126/science.1252806; Jones EY, 2006, NAT REV IMMUNOL, V6, P271, DOI 10.1038/nri1805; Jurka J, 2007, ANNU REV GENOM HUM G, V8, P241, DOI 10.1146/annurev.genom.8.080706.092416; Kaufman J, 2018, ANNU REV IMMUNOL, V36, P383, DOI 10.1146/annurev-immunol-051116-052450; Kim CY, 2004, P NATL ACAD SCI USA, V101, P4175, DOI 10.1073/pnas.0306885101; Krause DO, 2013, J ANIM SCI, V91, P331, DOI 10.2527/jas.2012-5567; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Lewin HA, 1999, IMMUNOL REV, V167, P145, DOI 10.1111/j.1600-065X.1999.tb01388.x; Li CK, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5790-2; Li G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-398; Li SB, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0557-1; Li ZP, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix102; Liu JH, 2013, AM J PHYSIOL-REG I, V305, pR232, DOI 10.1152/ajpregu.00068.2013; Luo RB, 2012, GIGASCIENCE, V1, DOI 10.1186/2047-217X-1-18; Mancia A, 2018, MAR GENOM, V41, P1, DOI 10.1016/j.margen.2018.08.004; Nawrocki EP, 2015, NUCLEIC ACIDS RES, V43, pD130, DOI 10.1093/nar/gku1063; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Nei M, 2005, ANNU REV GENET, V39, P121, DOI 10.1146/annurev.genet.39.073003.112240; Nishida AH, 2018, MOL ECOL, V27, P1884, DOI 10.1111/mec.14473; Ohshima K, 2005, CYTOGENET GENOME RES, V110, P475, DOI 10.1159/000084981; Price SA, 2005, BIOL REV, V80, P445, DOI 10.1017/S1464793105006743; Renard C, 2006, GENOMICS, V88, P96, DOI 10.1016/j.ygeno.2006.01.004; Rescigno M, 2010, ADV IMMUNOL, V107, P109, DOI 10.1016/B978-0-12-381300-8.00004-6; Ruan R, 2016, SCI REP-UK, V6, DOI 10.1038/srep22471; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Sotero-Caio CG, 2017, GENOME BIOL EVOL, V9, P161, DOI 10.1093/gbe/evw264; Takahashi K, 2000, J HERED, V91, P198, DOI 10.1093/jhered/91.3.198; Tollefsen S, 2012, J BIOL CHEM, V287, P13611, DOI 10.1074/jbc.M111.320374; Trevisi E, 2014, RES VET SCI, V96, P69, DOI 10.1016/j.rvsc.2013.11.011; Trowsdale J, 2013, ANNU REV GENOM HUM G, V14, P301, DOI 10.1146/annurev-genom-091212-153455; Unanue ER, 2016, ANNU REV IMMUNOL, V34, P265, DOI 10.1146/annurev-immunol-041015-055420; Viluma A, 2017, SCI REP-UK, V7, DOI 10.1038/srep45518; Wan QH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004147; Wang W, 2019, SCI DATA, V6, DOI 10.1038/sdata.2018.305; Wang ZF, 2016, MOL BIOL EVOL, V33, P3144, DOI 10.1093/molbev/msw191; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wellenreuther M, 2018, TRENDS ECOL EVOL, V33, P427, DOI 10.1016/j.tree.2018.04.002; Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292; Yuhki N, 2007, J HERED, V98, P390, DOI 10.1093/jhered/esm056; Zavala-Ruiz Z, 2004, P NATL ACAD SCI USA, V101, P13279, DOI 10.1073/pnas.0403371101; Zhang C., 2018, GIGASCIENCE, V7, P1, DOI [DOI 10.1093/GIGASCIENCE/GIX130, 10.1093/gigascience/gix130]	70	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2020	11								260	10.3389/fimmu.2020.00260	http://dx.doi.org/10.3389/fimmu.2020.00260			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LB6YD	32161588	Green Published, gold			2022-12-18	WOS:000524778200001
J	Huang, TT; Li, Y; Zhou, YX; Lu, BW; Zhang, YM; Tang, D; Gan, Y; He, ZZ; Chen, ZA; Yu, WF; Li, PY				Huang, Tingting; Li, Yan; Zhou, Yuxi; Lu, Bingwei; Zhang, Yueman; Tang, Dan; Gan, Yu; He, Zhengzhou; Chen, Zengai; Yu, Weifeng; Li, Peiying			Stroke Exacerbates Cancer Progression by Upregulating LCN2 in PMN-MDSC	FRONTIERS IN IMMUNOLOGY			English	Article						stroke; cancer; myeloid derived suppressed cell; lipocalin 2; neutrophil (PMN); myeloid cell	SUPPRESSOR-CELLS; LIPOCALIN 2; ACCUMULATION; METASTASIS; EXPANSION; PATHWAY	Acute ischemic stroke (AIS) is common in patients with cancer, and mounting clinical evidence suggests that it may shorten the survival of cancer patients. But how stroke affects the progression of cancer remains unclear. We inoculated B16 tumor cells (2 x 10(5)) subcutaneously before distal middle cerebral artery occlusion (dMCAO) or sham surgery in C57BL/6 mice and found that compared to sham operated mice, dMCAO mice developed significantly increased tumor volume and were accompanied by lower survival rate. To explore the underlying mechanism, we performed RNA-sequencing analysis of the tumor tissue from mice with or without stroke and found prominent upregulation of lipocalin 2 (LCN2) in the tumor from stroke mice compared to those from sham mice. Using quantitative reverse transcription-PCR, we confirmed increased mRNA expression of LCN2 as well as anti-inflammatory cytokines-Arg1, IL-10, and decreased mRNA level of pro-inflammatory cytokines-IL-6, IL-23 in the tumor of cancer-bearing stroke mice. Both immunofluorescence staining and flow cytometry analysis revealed that increased expression of LCN2 was mainly derived from the polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) in the tumor. We also found that stroke reduced the PMN-MDSCs in the peripheral blood, but increased PMN-MDSCs in the tumor of the cancer-bearing mice after stroke. In conclusion, cerebral ischemic stroke may exacerbate cancer progression by increasing LCN2 expression in PMN-MDSCs, which turns out to be a promising therapeutic target to suppress cancer progression after ischemic stroke.	[Huang, Tingting; Li, Yan; Zhou, Yuxi; Lu, Bingwei; Zhang, Yueman; Tang, Dan; He, Zhengzhou; Yu, Weifeng; Li, Peiying] Shanghai Jiao Tong Univ, Renji Hosp, Dept Anesthesiol, Sch Med, Shanghai, Peoples R China; [Gan, Yu] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China; [Chen, Zengai] Shanghai Jiao Tong Univ, Renji Hosp, Dept Radiol, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, WF; Li, PY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Dept Anesthesiol, Sch Med, Shanghai, Peoples R China.	ywf808@yeah.net; peiyingli.md@gmail.com	Zhou, Yuxi/GXH-3588-2022; huang, ting/GRR-3141-2022; Yu, Wei/GZL-3831-2022	Gan, Yu/0000-0002-5769-6809; Li, Peiying/0000-0002-5721-9914; zhang, yueman/0000-0002-8187-3350	National Natural Science Foundation of China (NSFC) [81971096, 81722017, 91957111]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20181805]; NSFC [81971223]; Shanghai Municipal Natural Science Foundation [16ZR1420700]; Shanghai Science and Technology Committee [19411971200]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Natural Science Foundation; Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	PL was supported by the National Natural Science Foundation of China (NSFC) grant (81971096, 81722017, 91957111) and the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20181805). WY was supported by the NSFC (81971223). ZC was supported by Shanghai Municipal Natural Science Foundation (16ZR1420700) and the Medical Guidance Project (19411971200) from Shanghai Science and Technology Committee.	Cestari DM, 2004, NEUROLOGY, V62, P2025, DOI 10.1212/01.WNL.0000129912.56486.2B; Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; Chew V, 2017, P NATL ACAD SCI USA, V114, pE5900, DOI 10.1073/pnas.1706559114; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Gao WF, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0676-z; Gelderblom M, 2015, AGEING RES REV, V24, P77, DOI 10.1016/j.arr.2015.07.004; Gielen PR, 2016, NEURO-ONCOLOGY, V18, P1253, DOI 10.1093/neuonc/now034; Gomez-Chou SB, 2017, CANCER RES, V77, P2647, DOI 10.1158/0008-5472.CAN-16-1986; Huber V, 2018, J CLIN INVEST, V128, P5505, DOI 10.1172/JCI98060; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kumar V, 2017, CANCER CELL, V32, P654, DOI 10.1016/j.ccell.2017.10.005; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Law IKM, 2010, DIABETES, V59, P872, DOI 10.2337/db09-1541; Lee MJ, 2017, J STROKE, V19, P77, DOI 10.5853/jos.2016.00570; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Moschen AR, 2017, TRENDS ENDOCRIN MET, V28, P388, DOI 10.1016/j.tem.2017.01.003; Najjar YG, 2017, CLIN CANCER RES, V23, P2346, DOI 10.1158/1078-0432.CCR-15-1823; Navi BB, 2019, STROKE, V50, P3259, DOI 10.1161/STROKEAHA.119.026143; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Qu P, 2016, CANCER LETT, V380, P253, DOI 10.1016/j.canlet.2015.10.022; Rathore KI, 2011, J NEUROSCI, V31, P13412, DOI 10.1523/JNEUROSCI.0116-11.2011; Ritzel RM, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1426-3; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Wang L, 2018, STROKE, V49, P2733, DOI 10.1161/STROKEAHA.118.021948; Wu L, 2015, J NEUROCHEM, V132, P622, DOI 10.1111/jnc.13023; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Xiao X, 2017, ANNU REV NUTR, V37, P103, DOI 10.1146/annurev-nutr-071816-064559; Yarla NS, 2016, SEMIN CANCER BIOL, V40-41, P48, DOI 10.1016/j.semcancer.2016.02.001	30	2	2	2	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2020	11								299	10.3389/fimmu.2020.00299	http://dx.doi.org/10.3389/fimmu.2020.00299			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	LB7CR	32153594	gold, Green Published			2022-12-18	WOS:000524790000001
J	Yaacob, EN; Norouzitallab, P; De Geest, BG; Bajek, A; Dierckens, K; Bossier, P; Vanrompay, D				Yaacob, Eamy Nursaliza; Norouzitallab, Parisa; De Geest, Bruno G.; Bajek, Aline; Dierckens, Kristof; Bossier, Peter; Vanrompay, Daisy			Recombinant DnaK Orally Administered Protects Axenic European Sea Bass Against Vibriosis	FRONTIERS IN IMMUNOLOGY			English	Article						gnotobiotic; European sea bass larvae; bacterial HSP70; DnaK; immunity; vibriosis; Vibrio anguillarum	DICENTRARCHUS-LABRAX L.; POLY-BETA-HYDROXYBUTYRATE; ARTEMIA-FRANCISCANA; ANTIMICROBIAL PEPTIDES; IMMUNE-RESPONSE; RAINBOW-TROUT; INNATE IMMUNITY; CHALLENGE TEST; MODEL PROTEIN; FISH	Vibrio anguillarum causes high mortality in European sea bass (Dicentrarchus labrax) larviculture and is a hindering factor for successful sustainable aquaculture of this commercially valuable species. Priming of the innate immune system through administration of immunostimulants has become an important approach to control disease outbreaks in marine fish larviculture. This study was conducted to evaluate immunostimulation by Escherichia coli HSP70 (DnaK) in axenic European sea bass larvae in order to protect the larvae against vibriosis. DnaK stimulates the immune response in crustaceans and juvenile fish against bacterial infections. The use of axenic fish larvae allows to study immunostimulation in the absence of an interfering microbial community. At 7 days post-hatching, larvae received a single dose of alginate encapsulated recombinant DnaK. Two non-treated control groups in which animals either received empty alginate microparticles (C1) or no alginante microparticles (C2 and C3) were included in the study. Eighteen hours later, all larvae, except the ones from group C3 (non-infected control) were challenged with V. anguillarum (10(5) CFU, bath infection). Mortality was daily recorded until 120 h post infection and at 18, 24, and 36 h post infection, larvae were sampled for expression of immune related genes. Results showed that V. anguillarum induced an immune response in axenic sea bass larvae but that the innate immune response was incapable to protect the larvae against deadly septicaemic disease. In addition, we showed that administration of alginate encapsulated DnaK to axenic European sea bass larvae at DAH7 resulted in a significant, DnaK dose dependent, upreglation of immune sensor, regulatory and effector genes. Significant upregulation of cxcr4, cas1 and especially of hep and dic was correlated with significant higher survival rates in V. anguillarum infected larvae. In the future recombinant DnaK might perhaps be used as a novel immunostimulant in sea bass larviculture.	[Yaacob, Eamy Nursaliza; Norouzitallab, Parisa; Dierckens, Kristof; Bossier, Peter] Univ Ghent, Lab Aquacuiture & Artemia Reference Ctr, Fac Biosci Engn, Ghent, Belgium; [Yaacob, Eamy Nursaliza; Norouzitallab, Parisa; Vanrompay, Daisy] Univ Ghent, Fac Biosci Engn, Lab Immunol & Anim Biotechnol, Ghent, Belgium; [De Geest, Bruno G.] Univ Ghent, Dept Pharmaceut, Ghent, Belgium; [Bajek, Aline] Ecloserie Marine Gravelines, Gravelines, France	Ghent University; Ghent University; Ghent University	Norouzitallab, P (corresponding author), Univ Ghent, Lab Aquacuiture & Artemia Reference Ctr, Fac Biosci Engn, Ghent, Belgium.; Norouzitallab, P (corresponding author), Univ Ghent, Fac Biosci Engn, Lab Immunol & Anim Biotechnol, Ghent, Belgium.	parisa.norouzitallab@ugent.be	dierckens, kristof/GWM-4184-2022	Norouzitallab, Parisa/0000-0002-1740-0444	Ministry of Higher Education Malaysia (MOHE); Universiti Malaysia Terengganu (UMT); Ghent University [BOF-12-GOA-022]; Research Foundation Flanders, FWO-Vlaanderen, Belgium [FWO 12P2519N]	Ministry of Higher Education Malaysia (MOHE)(Ministry of Education, Malaysia); Universiti Malaysia Terengganu (UMT); Ghent University(Ghent University); Research Foundation Flanders, FWO-Vlaanderen, Belgium(FWO)	EY received a doctoral scholarship from the Ministry of Higher Education Malaysia (MOHE) and the Universiti Malaysia Terengganu (UMT). The present study was financially supported by Ghent University (BOF-12-GOA-022). The authors also acknowledge the Research Foundation Flanders, FWO-Vlaanderen, Belgium [postdoc grant to PN, FWO 12P2519N).	AbouShabana NM, 2018, FISH PHYSIOL BIOCHEM, V44, P1241, DOI 10.1007/s10695-018-0517-x; Alvarez CA, 2016, FISH SHELLFISH IMMUN, V55, P662, DOI 10.1016/j.fsi.2016.06.035; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Balado M, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01766; Barton BA, 2002, INTEGR COMP BIOL, V42, P517, DOI 10.1093/icb/42.3.517; Baruah K, 2017, CELL STRESS CHAPERON, V22, P377, DOI 10.1007/s12192-017-0775-z; Baruah K, 2015, FREE RADICAL BIO MED, V89, P593, DOI 10.1016/j.freeradbiomed.2015.10.397; Baruah K, 2014, DEV COMP IMMUNOL, V46, P470, DOI 10.1016/j.dci.2014.06.004; Baruah K, 2013, FISH SHELLFISH IMMUN, V34, P183, DOI 10.1016/j.fsi.2012.10.025; Baruah K, 2010, FISH SHELLFISH IMMUN, V29, P733, DOI 10.1016/j.fsi.2010.07.011; Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019; Bricknell I, 2005, FISH SHELLFISH IMMUN, V19, P457, DOI 10.1016/j.fsi.2005.03.008; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dierckens K, 2009, ENVIRON MICROBIOL, V11, P526, DOI 10.1111/j.1462-2920.2008.01794.x; Esmaeili A, 2019, FISH SHELLFISH IMMUN, V93, P917, DOI 10.1016/j.fsi.2019.08.045; Franke A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14785-z; Frans I, 2011, J FISH DIS, V34, P643, DOI 10.1111/j.1365-2761.2011.01279.x; Galindo-Villegas J, BIOL EUROPEAN SEA BA, P342, DOI [10.1201/b16043-14, DOI 10.1201/B16043-14]; Galindo-Villegas J, 2013, FISH SHELLFISH IMMUN, V35, P1260, DOI 10.1016/j.fsi.2013.07.046; Galindo-Villegas Jorge, 2006, Suisan Zoshoku, V54, P153; George M, 2006, J CONTROL RELEASE, V114, P1, DOI 10.1016/j.jconrel.2006.04.017; Gombotz WR, 1998, ADV DRUG DELIVER REV, V31, P267, DOI 10.1016/S0169-409X(97)00124-5; Heidarieh M, 2012, FISH PHYSIOL BIOCHEM, V38, P1169, DOI 10.1007/s10695-012-9602-8; Hu B, 2014, AQUACULTURE, V418, P87, DOI 10.1016/j.aquaculture.2013.10.008; Rojo-Cebreros AH, 2018, FISH SHELLFISH IMMUN, V80, P15, DOI 10.1016/j.fsi.2018.05.044; Ina-Salwany MY, 2019, J AQUAT ANIM HEALTH, V31, P3, DOI 10.1002/aah.10045; JEFFERY H, 1993, PHARMACEUT RES, V10, P362, DOI 10.1023/A:1018980020506; Ji Jie, 2015, Biology-Basel, V4, P664, DOI 10.3390/biology4040664; Jiang S, 2019, J IMMUNOL, V203, P1369, DOI 10.4049/jimmunol.1900383; Karakatsouli N, 2012, AQUACULTURE, V364, P48, DOI 10.1016/j.aquaculture.2012.07.033; Khuyen TD, 2017, FISH SHELLFISH IMMUN, V71, P359, DOI 10.1016/j.fsi.2017.10.027; Kumar V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01091; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li X, 2014, DIS AQUAT ORGAN, V108, P211, DOI 10.3354/dao02722; Li YJ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00342; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Magnadottir B, 2006, FISH SHELLFISH IMMUN, V20, P137, DOI 10.1016/j.fsi.2004.09.006; Marques A, 2006, J APPL MICROBIOL, V100, P903, DOI 10.1111/j.1365-2672.2006.02961.x; Meloni M, 2015, FISH SHELLFISH IMMUN, V43, P82, DOI 10.1016/j.fsi.2014.12.016; Mulero I, 2008, DEV COMP IMMUNOL, V32, P1531, DOI 10.1016/j.dci.2008.05.015; Mulero I, 2007, AQUACULTURE, V268, P244, DOI 10.1016/j.aquaculture.2007.04.046; Naka H, 2011, INFECT IMMUN, V79, P2889, DOI 10.1128/IAI.05138-11; Niu YF, 2014, AQUACULTURE, V430, P120, DOI 10.1016/j.aquaculture.2014.04.001; Norouzitallab P, 2015, FISH SHELLFISH IMMUN, V42, P395, DOI 10.1016/j.fsi.2014.11.017; Peddie S, 2002, VET IMMUNOL IMMUNOP, V86, P101, DOI 10.1016/S0165-2427(02)00019-3; Petit J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00280; Qiao G, 2015, FISH SHELLFISH IMMUN, V44, P257, DOI 10.1016/j.fsi.2015.02.009; Rekecki A, 2012, J FISH DIS, V35, P265, DOI 10.1111/j.1365-2761.2011.01342.x; Reyes-Lopez FE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00914; Reyes-Lopez FE, 2015, DEV COMP IMMUNOL, V53, P210, DOI 10.1016/j.dci.2015.06.017; Rivas-Aravena A, 2013, BIOL RES, V46, P407, DOI 10.4067/S0716-97602013000400012; Ryckaert J, 2010, FISH SHELLFISH IMMUN, V28, P228, DOI 10.1016/j.fsi.2009.09.005; Sepulcre MP, 2007, MOL IMMUNOL, V44, P3751, DOI 10.1016/j.molimm.2007.03.021; Shabir U, 2018, MICROB PATHOGENESIS, V114, P50, DOI 10.1016/j.micpath.2017.11.039; Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c; Shirdel I, 2019, FISH SHELLFISH IMMUN, V90, P288, DOI 10.1016/j.fsi.2019.05.010; Situmorang ML, 2016, VET MICROBIOL, V182, P44, DOI 10.1016/j.vetmic.2015.10.024; Skjermo J, 1999, AQUACULTURE, V177, P333, DOI 10.1016/S0044-8486(99)00096-4; Smith N, 2017, M S-MED SCI, V33, P711, DOI 10.1051/medsci/20173308008; Sung YY, 2008, CELL STRESS CHAPERON, V13, P59, DOI 10.1007/s12192-008-0011-y; Swain P, 2009, FISH SHELLFISH IMMUN, V27, P89, DOI 10.1016/j.fsi.2009.04.008; Toranzo AE, 2005, AQUACULTURE, V246, P37, DOI 10.1016/j.aquaculture.2005.01.002; Torrecillas S, 2007, FISH SHELLFISH IMMUN, V23, P969, DOI 10.1016/j.fsi.2007.03.007; Torrecillas S, 2014, FISH SHELLFISH IMMUN, V36, P525, DOI 10.1016/j.fsi.2013.12.029; Touraki M, 2012, J FISH DIS, V35, P513, DOI 10.1111/j.1365-2761.2012.01387.x; Vadstein O, 2013, REV AQUACULT, V5, pS1, DOI 10.1111/j.1753-5131.2012.01082.x; Valero Y, 2020, DEV COMP IMMUNOL, V103, DOI 10.1016/j.dci.2019.103516; Vallejos-Vidal E, 2016, FISH SHELLFISH IMMUN, V56, P34, DOI 10.1016/j.fsi.2016.06.028; Wang W, 2017, AQUAC RES, V48, P1, DOI 10.1111/are.13161; Yaacob EN, 2018, VET IMMUNOL IMMUNOP, V204, P19, DOI 10.1016/j.vetimm.2018.09.001; Yaacob EN, 2017, MAR BIOTECHNOL, V19, P391, DOI 10.1007/s10126-017-9758-4; Yang M, 2019, FRONT MATER, V6, DOI 10.3389/fmats.2019.00225; Zhang AY, 2011, COMP BIOCHEM PHYS B, V159, P109, DOI 10.1016/j.cbpb.2011.02.009; Zhang SC, 2013, DEV COMP IMMUNOL, V39, P72, DOI 10.1016/j.dci.2012.02.009; Zhang ZB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00042	75	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2020	10								3162	10.3389/fimmu.2019.03162	http://dx.doi.org/10.3389/fimmu.2019.03162			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR2YS	32117214	gold, Green Published			2022-12-18	WOS:000517486200001
J	Almeida, CR; Bottazzi, B; De Nardo, D; Lawlor, KE				Almeida, Catarina R.; Bottazzi, Barbara; De Nardo, Dominic; Lawlor, Kate E.			Editorial: Immunomodulation of Innate Immune Cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate immunity; PRRs; immunomodulation; pattern recognition; macrophage polarization			[Almeida, Catarina R.] Univ Aveiro, Inst Biomed iBiMED, Dept Med Sci, Aveiro, Portugal; [Bottazzi, Barbara] Humanitas Clin & Res Ctr, Rozzano, Italy; [De Nardo, Dominic] Monash Univ, Monash Biomed Discovery Inst, Dept Anat & Dev Biol, Melbourne, Vic, Australia; [Lawlor, Kate E.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Melbourne, Vic, Australia; [Lawlor, Kate E.] Monash Univ, Dept Mol & Translat Sci, Melbourne, Vic, Australia	Universidade de Aveiro; IRCCS Humanitas Research Hospital; Monash University; Hudson Institute of Medical Research; Monash University	Almeida, CR (corresponding author), Univ Aveiro, Inst Biomed iBiMED, Dept Med Sci, Aveiro, Portugal.; Bottazzi, B (corresponding author), Humanitas Clin & Res Ctr, Rozzano, Italy.; De Nardo, D (corresponding author), Monash Univ, Monash Biomed Discovery Inst, Dept Anat & Dev Biol, Melbourne, Vic, Australia.; Lawlor, KE (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Melbourne, Vic, Australia.; Lawlor, KE (corresponding author), Monash Univ, Dept Mol & Translat Sci, Melbourne, Vic, Australia.	cra@ua.pt; Barbara.Bottazzi@humanitasresearch.it; dominic.denardo@monash.edu; kate.lawlor@hudson.org.au	Almeida, Catarina R/A-7018-2012	Almeida, Catarina R/0000-0001-6670-6004; Lawlor, Kate/0000-0003-0471-6842; De Nardo, Dominic/0000-0002-7045-4695	COMPETE2020 Programa Operacional Competitividade e Internacionalizacao (POCI) [UIDB/04501/2020, PTDC/BIA-CEL/28791/2017, POCI-01-0145-FEDER-028791, POCI-01-0145-FEDER-030882, PTDC/BIA-MOL/30882/2017]; national funds (OE), through FCT/MCTES; European Research Council (ERC) [669415]; Italian Association for Cancer Research [AIRC-IG]; Italian Association for Cancer Research [5x1000] [21147]; Monash University FMNHS Senior Postdoctoral Fellowship; Australian Research Council Future Fellowship (Canberra, Australia) [FT190100266]; National Health and Medical Research Council (Canberra Australia) [1145788, 1162765, 1181089]; Australian Government IRISS; Victorian State Government OIS	COMPETE2020 Programa Operacional Competitividade e Internacionalizacao (POCI); national funds (OE), through FCT/MCTES; European Research Council (ERC)(European Research Council (ERC)European Commission); Italian Association for Cancer Research [AIRC-IG](Fondazione AIRC per la ricerca sul cancro); Italian Association for Cancer Research [5x1000]; Monash University FMNHS Senior Postdoctoral Fellowship; Australian Research Council Future Fellowship (Canberra, Australia)(Australian Research Council); National Health and Medical Research Council (Canberra Australia)(National Health and Medical Research Council (NHMRC) of Australia); Australian Government IRISS(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government OIS	The activities in CRA laboratory are supported by the projects UIDB/04501/2020, PTDC/BIA-CEL/28791/2017 and POCI-01-0145-FEDER-028791, POCI-01-0145-FEDER-030882 and PTDC/BIA-MOL/30882/2017, through COMPETE2020 Programa Operacional Competitividade e Internacionalizacao (POCI), and by national funds (OE), through FCT/MCTES. The activities in BB laboratory are made possible by funding from the European Research Council (ERC-No. 669415) and the Italian Association for Cancer Research [AIRC-IG and 5x1000 (contract 21147)]. DD was supported by a Monash University FMNHS Senior Postdoctoral Fellowship. KL was supported by an Australian Research Council Future Fellowship (FT190100266, Canberra, Australia), National Health and Medical Research Council Grants (1145788, 1162765, and 1181089, Canberra Australia) and operational infrastructure grants through the Australian Government IRISS and the Victorian State Government OIS.		0	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2020	11								101	10.3389/fimmu.2020.00101	http://dx.doi.org/10.3389/fimmu.2020.00101			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR5CB	32117255	Green Published, gold			2022-12-18	WOS:000517635300001
J	Georgescu, MT; Moorehead, PC; Liu, TY; Dumont, J; Scott, DW; Hough, C; Lillicrap, D				Georgescu, Maria T.; Moorehead, Paul C.; Liu, Tongyao; Dumont, Jennifer; Scott, David W.; Hough, Christine; Lillicrap, David			Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the Fc gamma RIIB Receptor	FRONTIERS IN IMMUNOLOGY			English	Article						hemophilia A-complications; drug therapy; anti-drug antibodies; factor VIII inhibitors; recombinant factor VIII Fc; Fc gamma RIIB; B cell inhibition	IMMUNE TOLERANCE INDUCTION; HEMOPHILIA-A PATIENTS; FUSION PROTEIN; ANTIBODIES; DOMAIN; LIFE	The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication of hemophilia A treatment. The sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune tolerance induction (ITI) which is expensive, difficult to administer and not always successful. Although not fully understood, the mechanism of ITI is thought to rely on inhibition of FVIII-specific B cells (1). Its efficacy might therefore be improved through more aggressive B cell suppression. Fc gamma RIIB is an inhibitory Fc receptor that down-regulates B cell signaling when cross-linked with the B cell receptor (BCR). We sought to investigate if recombinant FVIII Fc (rFVIIIFc), an Fc fusion molecule composed of FVIII and the Fc region of immunoglobulin G1 (IgG1) (2), is able to inhibit B cell activation more readily than FVIII. rFVIIIFc was able to bind FVIII-exposed and naive B cells from hemophilia A mice as well as a FVIII-specific murine B cell hybridoma line (413 cells). An anti-Fc gamma RIIB antibody and FVIII inhibited binding, suggesting that rFVIIIFc is able to interact with both Fc gamma RIIB and the BCR. Furthermore, incubation of B cells from FVIII-exposed mice and 413 cells with rFVIIIFc resulted in increased phosphorylation of SH-2 containing inositol 5-phosphatase (SHIP) when compared to FVIII. B cells from FVIII-exposed hemophilia A mice also exhibited decreased extracellular signal-regulated kinase (ERK) phosphorylation when exposed to rFVIIIFc. These differences were absent in B cells from naive, non-FVIII exposed hemophilic mice suggesting an antigen-dependent effect. Finally, rFVIIIFc was able to inhibit B cell calcium flux induced by anti-Ig F(ab)(2). Our results therefore indicate that rFVIIIFc is able to crosslink Fc gamma RIIB and the BCR of FVIII-specific B cells, causing inhibitory signaling in these cells.	[Georgescu, Maria T.; Hough, Christine; Lillicrap, David] Queens Univ, Dept Pathol & Mol Med, Clin & Mol Hemostasis Res Grp, Kingston, ON, Canada; [Moorehead, Paul C.] Janeway Childrens Hlth & Rehabil Ctr, St John, NF, Canada; [Moorehead, Paul C.] Mem Univ, Fac Med, St John, NF, Canada; [Liu, Tongyao; Dumont, Jennifer] Bioverativ, Cambridge, MA USA; [Scott, David W.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD USA	McMaster University; Queens University - Canada; Memorial University Newfoundland; Uniformed Services University of the Health Sciences - USA	Lillicrap, D (corresponding author), Queens Univ, Dept Pathol & Mol Med, Clin & Mol Hemostasis Res Grp, Kingston, ON, Canada.	david.lillicrap@queensu.ca			Canadian Institute of Health Research [FDN 154285]; USPHS NIH [HL126727]; Canada Research Chair in Molecular Hemostasis	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); USPHS NIH(United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA); Canada Research Chair in Molecular Hemostasis(Canada Research Chairs)	This project was supported in part by a Foundations Grant from the Canadian Institute of Health Research (FDN 154285). DS receives research funding from USPHS NIH grant HL126727. DL was the recipient of a Canada Research Chair in Molecular Hemostasis.	Anikeeva N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13264; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Brackmann HH, 1996, VOX SANG, V70, P30, DOI 10.1111/j.1423-0410.1996.tb01346.x; Carcao M, 2006, HAEMOPHILIA, V12, P7, DOI 10.1111/j.1365-2516.2005.01170.x; Carcao M, 2018, HAEMOPHILIA, V24, P245, DOI 10.1111/hae.13413; Dumont JA, 2012, BLOOD, V119, P3024, DOI 10.1182/blood-2011-08-367813; Gilbert GE, 2012, BLOOD, V120, P1923, DOI 10.1182/blood-2012-01-408245; Gilles JG, 1996, J CLIN INVEST, V97, P1382, DOI 10.1172/JCI118558; Gilles JGG, 2004, BLOOD, V103, P2617, DOI 10.1182/blood-2003-07-2207; Hausl C, 2005, BLOOD, V106, P3415, DOI 10.1182/blood-2005-03-1182; Hay CRM, 2012, BLOOD, V119, P1335, DOI 10.1182/blood-2011-08-369132; Hay CRM, 2011, BLOOD, V117, P6367, DOI 10.1182/blood-2010-09-308668; Hoffman M, 2012, J THROMB HAEMOST, V10, P1478, DOI 10.1111/j.1538-7836.2012.04793.x; Jacob A, 2002, J BIOL CHEM, V277, P23420, DOI 10.1074/jbc.M202485200; Kempton CL, 2009, BLOOD, V113, P11, DOI 10.1182/blood-2008-06-160432; Kis-Toth K, 2018, BLOOD ADV, V2, P2904, DOI 10.1182/bloodadvances.2018024497; Krishnamoorthy S, 2016, CELL IMMUNOL, V301, P30, DOI 10.1016/j.cellimm.2015.12.008; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Leung WH, 2009, IMMUNOL RES, V43, P243, DOI 10.1007/s12026-008-8078-1; Malec LM, 2016, HAEMOPHILIA, V22, pE552, DOI 10.1111/hae.13064; Markovitz RC, 2013, BLOOD, V121, P2785, DOI 10.1182/blood-2012-09-456582; MAUSERBUNSCHOTEN EP, 1995, BLOOD, V86, P983, DOI 10.1182/blood.V86.3.983.983; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Pegon JN, 2012, HAEMATOL-HEMATOL J, V97, P1855, DOI 10.3324/haematol.2012.063297; Peters RT, 2013, J THROMB HAEMOST, V11, P132, DOI 10.1111/jth.12076; Qadura M, 2011, HAEMOPHILIA, V17, P288, DOI 10.1111/j.1365-2516.2010.02397.x; Rodriguez V, 2015, HAEMOPHILIA, V21, pE369, DOI 10.1111/hae.12740; Turecek PL, 2004, HAEMOPHILIA, V10, P3, DOI 10.1111/j.1365-2516.2004.00934.x; Van Helden PMW, 2010, HAEMOPHILIA, V16, P35, DOI 10.1111/j.1365-2516.2010.02215.x; Vollack N, 2017, SCAND J IMMUNOL, V86, P91, DOI 10.1111/sji.12573; Williams EL, 2012, EUR J IMMUNOL, V42, P2109, DOI 10.1002/eji.201142302; Yasuda T, 2008, CELL CYCLE, V7, P3634, DOI 10.4161/cc.7.23.7103	33	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2020	11								138	10.3389/fimmu.2020.00138	http://dx.doi.org/10.3389/fimmu.2020.00138			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KR0AX	32117285	gold, Green Published			2022-12-18	WOS:000517284300001
J	Iwashita, S; Suzuki, H; Goto, A; Oyama, T; Kanoh, H; Kuraishi, T; Fuse, N; Yano, T; Oshima, Y; Dow, JAT; Davies, SA; Kurata, S				Iwashita, Shinzo; Suzuki, Hiroaki; Goto, Akira; Oyama, Tomohito; Kanoh, Hirotaka; Kuraishi, Takayuki; Fuse, Naoyuki; Yano, Tamaki; Oshima, Yoshiteru; Dow, Julian A. T.; Davies, Shireen-Anne; Kurata, Shoichiro			A Receptor Guanylate Cyclase, Gyc76C, Mediates Humoral, and Cellular Responses in Distinct Ways in Drosophila Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						receptor-type guanylate cyclase; humoral immune responses; cellular immune responses; Drosophila; innate immunity	PATTERN-RECOGNITION RECEPTORS; INNATE IMMUNITY; HOST-DEFENSE; PHAGOCYTOSIS; HEMOCYTES; PATHWAY; SIGNALS; GENES; HEMATOPOIESIS; CROQUEMORT	Innate immunity is an evolutionarily conserved host defense system against infections. The fruit fly Drosophila relies solely on innate immunity for infection defense, and the conservation of innate immunity makes Drosophila an ideal model for understanding the principles of innate immunity, which comprises both humoral and cellular responses. The mechanisms underlying the coordination of humoral and cellular responses, however, has remained unclear. Previously, we identified Gyc76C, a receptor-type guanylate cyclase that produces cyclic guanosine monophosphate (cGMP), as an immune receptor in Drosophila. Gyc76C mediates the induction of antimicrobial peptides for humoral responses by a novel cGMP pathway including a membrane-localized cGMP-dependent protein kinase, DG2, through downstream components of the Toll receptor such as dMyD88. Here we show that Gyc76C is also required for the proliferation of blood cells (hemocytes) for cellular responses to bacterial infections. In contrast to Gyc76C-dependent antimicrobial peptide induction, Gyc76C-dependent hemocyte proliferation is meditated by a small GTPase, Ras85D, and not by DG2 or dMyD88, indicating that Gyc76C mediates the cellular and humoral immune responses in distinct ways.	[Iwashita, Shinzo; Suzuki, Hiroaki; Goto, Akira; Oyama, Tomohito; Kanoh, Hirotaka; Kuraishi, Takayuki; Fuse, Naoyuki; Yano, Tamaki; Oshima, Yoshiteru; Kurata, Shoichiro] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi, Japan; [Goto, Akira] Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi, Japan; [Kuraishi, Takayuki] Japan Sci & Technol Agcy, PRESTO, Tokyo, Japan; [Dow, Julian A. T.; Davies, Shireen-Anne] Univ Glasgow, Inst Mol Cell & Syst Biol, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Goto, Akira] Univ Strasbourg, CNRS, Insect Models Innate Immun, M3I,UPR9022, Strasbourg, France; [Kuraishi, Takayuki] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharm, Kanazawa, Ishikawa, Japan	Tohoku University; Tohoku University; Japan Science & Technology Agency (JST); University of Glasgow; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Kanazawa University	Kurata, S (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi, Japan.	shoichiro.kurata.d5@tohoku.ac.jp	GOTO, Akira/V-7847-2017; Yano, Tamaki/AHB-5620-2022	GOTO, Akira/0000-0003-3395-484X; Yano, Tamaki/0000-0002-5576-1128	Ministry of Education, Culture, Sports, Science, and Technology of Japan [MEXT 19H03365, 16H05084, 24390014, 21117005, 21117001, 14657577]; Japan Society for the Promotion of Science (JSPS); Japan Science and Technology Agency (JST); Program for the Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); Strategic International Cooperative program from the Japan Science and Technology Agency; National Institutes of Health [AI07495]; Takeda Science Foundation; Mitsubishi Foundation; Astellas Foundation for Research on Metabolic Disorders; Uehara Memorial Foundation; Naito Foundation; Global COE Research Grant (Tohoku University Ecosystem Adaptability); Biotechnological and Biological Research Sciences Council (UK) [BB/E011438/1]; BBSRC [BB/E011438/1, BB/J019755/1] Funding Source: UKRI	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Program for the Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); Strategic International Cooperative program from the Japan Science and Technology Agency; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Takeda Science Foundation(Takeda Science Foundation (TSF)); Mitsubishi Foundation; Astellas Foundation for Research on Metabolic Disorders; Uehara Memorial Foundation(Uehara Memorial Foundation); Naito Foundation(Naito Memorial Foundation); Global COE Research Grant (Tohoku University Ecosystem Adaptability); Biotechnological and Biological Research Sciences Council (UK); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT 19H03365, 16H05084, 24390014, 21117005, 21117001, and 14657577); the Japan Society for the Promotion of Science (JSPS); Japan Science and Technology Agency (JST); the Program for the Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); the Strategic International Cooperative program from the Japan Science and Technology Agency; the National Institutes of Health (AI07495); the Takeda Science Foundation; the Mitsubishi Foundation; the Astellas Foundation for Research on Metabolic Disorders; the Uehara Memorial Foundation; the Naito Foundation; a Global COE Research Grant (Tohoku University Ecosystem Adaptability); and the Biotechnological and Biological Research Sciences Council (UK) grant number BB/E011438/1 to S-AD and JD.	Ayoob JC, 2004, J NEUROSCI, V24, P6639, DOI 10.1523/JNEUROSCI.1104-04.2004; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; Buchon N, 2014, NAT REV IMMUNOL, V14, P796, DOI 10.1038/nri3763; Buchon N, 2009, P NATL ACAD SCI USA, V106, P12442, DOI 10.1073/pnas.0901924106; Chak K, 2014, DEVELOPMENT, V141, P136, DOI 10.1242/dev.095968; Charroux B, 2009, P NATL ACAD SCI USA, V106, P9797, DOI 10.1073/pnas.0903971106; Crozatier M, 2007, CELL MICROBIOL, V9, P1117, DOI 10.1111/j.1462-5822.2007.00930.x; Crozatier M, 2011, DIS MODEL MECH, V4, P439, DOI 10.1242/dmm.007351; Davies SA, 2006, CELL SIGNAL, V18, P409, DOI 10.1016/j.cellsig.2005.08.011; Defaye A, 2009, J INNATE IMMUN, V1, P322, DOI 10.1159/000210264; El Chamy L, 2008, NAT IMMUNOL, V9, P1165, DOI 10.1038/ni.1643; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Goto A, 2003, DEV BIOL, V264, P582, DOI 10.1016/j.ydbio.2003.06.001; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Haine ER, 2008, SCIENCE, V322, P1257, DOI 10.1126/science.1165265; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V201, P194, DOI 10.1007/BF00188752; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Holz A, 2003, DEVELOPMENT, V130, P4955, DOI 10.1242/dev.00702; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Kambris Z, 2006, CURR BIOL, V16, P808, DOI 10.1016/j.cub.2006.03.020; Kocks C, 2005, CELL, V123, P335, DOI 10.1016/j.cell.2005.08.034; Kurucz E, 2007, CURR BIOL, V17, P649, DOI 10.1016/j.cub.2007.02.041; Lanot R, 2001, DEV BIOL, V230, P243, DOI 10.1006/dbio.2000.0123; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mishra V, 2018, BIOCHEM SOC T, V46, P1729, DOI 10.1042/BST20180472; Momiuchi Y, 2015, J BIOL CHEM, V290, P23816, DOI 10.1074/jbc.M115.664193; Qiu P, 1998, DEVELOPMENT, V125, P1909; Ragab A, 2011, EMBO J, V30, P1123, DOI 10.1038/emboj.2011.4; Sorrentino RP, 2004, GENETICS, V166, P1343, DOI 10.1534/genetics.166.3.1343; Stuart LM, 2008, NAT REV IMMUNOL, V8, P131, DOI 10.1038/nri2240; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Valanne S, 2011, J IMMUNOL, V186, P649, DOI 10.4049/jimmunol.1002302; Zettervall CJ, 2004, P NATL ACAD SCI USA, V101, P14192, DOI 10.1073/pnas.0403789101	40	2	2	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 28	2020	11								35	10.3389/fimmu.2020.00035	http://dx.doi.org/10.3389/fimmu.2020.00035			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KM8FY	32063902	Green Published, gold			2022-12-18	WOS:000514377400001
J	Samarasinghe, AE; Rosch, JW				Samarasinghe, Amali E.; Rosch, Jason W.			Convergence of Inflammatory Pathways in Allergic Asthma and Sickle Cell Disease	FRONTIERS IN IMMUNOLOGY			English	Review						sickle cell disease (SCD); asthma; acute chest syndrome (ACS); respiratory infection; pulmonary inflammation	ACUTE CHEST SYNDROME; EARLY-LIFE; PNEUMOCOCCAL DISEASE; ANTIBIOTIC EXPOSURE; CHILDHOOD ASTHMA; NITRIC-OXIDE; AIRWAY HYPERRESPONSIVENESS; PENICILLIN PROPHYLAXIS; ARGININE METABOLOME; PULMONARY-FUNCTION	The underlying pathologies of sickle cell disease and asthma share many characteristics in terms of respiratory inflammation. The principal mechanisms of pulmonary inflammation are largely distinct, but activation of common pathways downstream of the initial inflammatory triggers may lead to exacerbation of both disease states. The altered inflammatory landscape of these respiratory pathologies can differentially impact respiratory pathogen susceptibility in patients with sickle cell disease and asthma. How these two distinct diseases behave in a comorbid setting can further exacerbate pulmonary complications associated with both disease states and impact susceptibility to respiratory infection. This review will provide a concise overview of how asthma distinctly affects individuals with sickle cell disease and how pulmonary physiology and inflammation are impacted during comorbidity.	[Samarasinghe, Amali E.] Univ Tennessee, Hlth Sci Ctr, Div Pulmonol Allergy Immunol & Sleep, Dept Pediat,Coll Med, Memphis, TN USA; [Samarasinghe, Amali E.] Univ Tennessee, Hlth Sci Ctr, Dept Microbiol Immunol & Biochem, Coll Med, Memphis, TN USA; [Samarasinghe, Amali E.] Childrens Fdn Res Inst, Memphis, TN USA; [Rosch, Jason W.] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Rosch, JW (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	jason.rosch@stjude.org	Samarasinghe, Amali/I-5374-2019; Rosch, Jason/N-8106-2018	Samarasinghe, Amali/0000-0002-3104-2823; Rosch, Jason/0000-0002-1798-1760	NIH, NIAID [1R01-AI125481]; Plough Foundation; ALSAC; NIAID [1U01-AI124302, 1R01-AI110618]	NIH, NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Plough Foundation; ALSAC(American Lebanese Syrian Associated Charities (ALSAC)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	AS was partially funded through the NIH, NIAID 1R01-AI125481, and the Plough Foundation. JR was partially funded through ALSAC, NIAID 1U01-AI124302, and 1R01-AI110618.	Adami AJ, 2018, PEDIATR RES, V84, P426, DOI 10.1038/s41390-018-0031-y; Adamkiewicz TV, 2003, J PEDIATR-US, V143, P438, DOI 10.1067/S0022-3476(03)00331-7; Akinbami Lara J, 2011, Natl Health Stat Report, P1; An P, 2011, J ALLERGY CLIN IMMUN, V127, P1440, DOI 10.1016/j.jaci.2010.12.1114; Andemariam B, 2015, TRANSL RES, V166, P254, DOI 10.1016/j.trsl.2015.03.001; Asosingh K, 2018, J CLIN INVEST, V128, P3116, DOI 10.1172/JCI97720; Asquith KL, 2008, J IMMUNOL, V180, P1199, DOI 10.4049/jimmunol.180.2.1199; Aun MV, 2017, J ASTHMA ALLERGY, V10, P293, DOI 10.2147/JAA.S121092; Bakshi N, 2016, J PAIN RES, V9, P167, DOI 10.2147/JPR.S55571; Belcher JD, 2000, BLOOD, V96, P2451, DOI 10.1182/blood.V96.7.2451.h8002451_2451_2459; Belcher JD, 2017, ANTIOXID REDOX SIGN, V26, P748, DOI 10.1089/ars.2015.6571; Bernaudin F, 2008, HAEMATOL-HEMATOL J, V93, P1917, DOI 10.3324/haematol.13090; Boyd JH, 2006, BLOOD, V108, P2923, DOI 10.1182/blood-2006-01-011072; Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836-200110000-00006; Canalli AA, 2005, HEMATOLOGY, V10, P419, DOI 10.1080/10245330500141259; Carden MA, 2019, HAEMATOLOGICA, V104, P1710, DOI 10.3324/haematol.2018.207357; Carter R, 2014, CELL HOST MICROBE, V15, P587, DOI 10.1016/j.chom.2014.04.005; Chapman DG, 2015, CLIN EXP ALLERGY, V45, P706, DOI 10.1111/cea.12506; Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982; Conran N, 2007, ANN HEMATOL, V86, P255, DOI 10.1007/s00277-006-0246-6; Cox SE, 2018, LANCET HAEMATOL, V5, pE147, DOI 10.1016/S2352-3026(18)30020-6; CROIZAT H, 1994, BRIT J HAEMATOL, V87, P592, DOI 10.1111/j.1365-2141.1994.tb08318.x; Dean D, 2003, J PEDIAT HEMATOL ONC, V25, P46, DOI 10.1097/00043426-200301000-00010; DeBaun MR, 2016, LANCET, V387, P2545, DOI 10.1016/S0140-6736(16)00145-8; DeBaun MR, 2014, AM J HEMATOL, V89, pE212, DOI 10.1002/ajh.23819; Ellison AM, 2012, PEDIATR INFECT DIS J, V31, P534, DOI 10.1097/INF.0b013e3182480fed; Elmariah H, 2014, AM J HEMATOL, V89, P530, DOI 10.1002/ajh.23683; ENWONWU CO, 1990, AM J MED SCI, V300, P366, DOI 10.1097/00000441-199012000-00005; FALLETTA JM, 1995, J PEDIATR-US, V127, P685, DOI 10.1016/S0022-3476(95)70154-0; Field JJ, 2011, CHEST, V139, P563, DOI 10.1378/chest.10-1243; Fukuda JT, 2005, PEDIATR DENT, V27, P186; Furuya Y, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005180; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GILL FM, 1995, BLOOD, V86, P776, DOI 10.1182/blood.V86.2.776.bloodjournal862776; Glassberg J, 2017, AM J HEMATOL, V92, P622, DOI 10.1002/ajh.24742; Gomez E, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/604140; Graido-Gonzalez E, 1998, BLOOD, V92, P2551, DOI 10.1182/blood.V92.7.2551.2551_2551_2555; Green CE, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0505-1; Han MY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120682; Heul AV, 2019, CLIN REV ALLERG IMMU, V57, P350, DOI 10.1007/s12016-018-8719-7; Hirsch AG, 2017, CLIN EXP ALLERGY, V47, P236, DOI 10.1111/cea.12807; Holtzclaw JD, 2004, AM J RESP CRIT CARE, V169, P687, DOI 10.1164/rccm.200302-224OC; Intzes S, 2013, PEDIATR HEMAT ONCOL, V30, P726, DOI 10.3109/08880018.2012.756961; Jiang CY, 2019, INT ARCH ALLERGY IMM, V179, P192, DOI 10.1159/000499043; Karlsson EA, 2017, SCI REP-UK, V7, DOI 10.1038/srep43308; Kauf TL, 2009, AM J HEMATOL, V84, P323, DOI 10.1002/ajh.21408; Kumar RK, 2016, RESPIROLOGY, V21, P842, DOI 10.1111/resp.12760; Langer AL, 2019, ANN HEMATOL, V98, P841, DOI 10.1007/s00277-019-03635-9; Lebensburger JD, 2012, BLOOD, V119, P1915, DOI 10.1182/blood-2011-08-374447; LEIKIN SL, 1989, PEDIATRICS, V84, P500; Lim SH, 2018, AM J HEMATOL, V93, pE91, DOI 10.1002/ajh.25019; Lopez BL, 2003, BRIT J HAEMATOL, V120, P532, DOI 10.1046/j.1365-2141.2003.04109.x; Lunt A, 2014, THORAX, V69, P746, DOI 10.1136/thoraxjnl-2013-204809; MALAVE I, 1993, ACTA HAEMATOL-BASEL, V90, P172; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; McBrien CN, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00093; McCavit TL, 2013, PEDIATR BLOOD CANCER, V60, P935, DOI 10.1002/pbc.24395; Morris CR, 2014, HEMATOL ONCOL CLIN N, V28, P301, DOI 10.1016/j.hoc.2013.11.008; Morris CR, 2013, HAEMATOLOGICA, V98, P1375, DOI 10.3324/haematol.2013.086637; Morris CR, 2009, AM J HEMATOL, V84, P234, DOI 10.1002/ajh.21359; Morris CR, 2000, BRIT J HAEMATOL, V111, P498, DOI 10.1046/j.1365-2141.2000.02403.x; Morris CR, 2005, JAMA-J AM MED ASSOC, V294, P81, DOI 10.1001/jama.294.1.81; Morris CR, 2000, J PEDIAT HEMATOL ONC, V22, P515, DOI 10.1097/00043426-200011000-00009; Murk W, 2011, PEDIATRICS, V127, P1125, DOI 10.1542/peds.2010-2092; Nandedkar SD, 2008, BLOOD, V112, P2529, DOI 10.1182/blood-2008-01-132506; Navalkele P, 2017, J PEDIAT HEMATOL ONC, V39, P341, DOI 10.1097/MPH.0000000000000858; Network GA, 2018, GLOB ASTHM REP 2018; Ojodu J, 2014, MMWR-MORBID MORTAL W, V63, P1155; Ortqvist AK, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6979; Overturf G D, 1999, Adv Pediatr Infect Dis, V14, P191; Pitter G, 2016, EUR J EPIDEMIOL, V31, P85, DOI 10.1007/s10654-015-0038-1; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Pritchard KA, 2012, AM J RESP CELL MOL, V46, P389, DOI 10.1165/rcmb.2011-0097OC; Profita M, 2003, J ALLERGY CLIN IMMUN, V112, P709, DOI 10.1016/S0091-6749(03)01889-X; Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532; Rees DC, 2010, LANCET, V376, P2018, DOI 10.1016/S0140-6736(10)61029-X; Reynolds LA, 2013, EXPERT REV CLIN IMMU, V9, P1019, DOI 10.1586/1744666X.2013.851603; Risnes KR, 2011, AM J EPIDEMIOL, V173, P310, DOI 10.1093/aje/kwq400; Rosch JW, 2010, J CLIN INVEST, V120, P627, DOI 10.1172/JCI39843; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Samarasinghe AE, 2014, IMMUNOL CELL BIOL, V92, P449, DOI 10.1038/icb.2013.113; Santoro JD, 2016, J PEDIAT HEMATOL ONC, V38, pE102, DOI 10.1097/MPH.0000000000000510; Schulfer A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004903; Sobota A, 2010, AM J HEMATOL, V85, P24, DOI 10.1002/ajh.21565; SOLOMONS C, 1972, PEDIATRICS, V49, P933; Stokholm J, 2014, LANCET RESP MED, V2, P631, DOI 10.1016/S2213-2600(14)70152-3; Suara RO, 2001, ANN TROP PAEDIATR, V21, P175, DOI 10.1080/02724930120058278; Szczepanek SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149261; Telen MJ, 2019, NAT REV DRUG DISCOV, V18, P139, DOI 10.1038/s41573-018-0003-2; Toews GB, 2001, EUR RESPIR J, V18, p3S, DOI 10.1183/09031936.01.00266001; Tomaki M, 2002, PULM PHARMACOL THER, V15, P161, DOI 10.1006/pupt.2001.0333; Torres A, 2015, THORAX, V70, P984, DOI 10.1136/thoraxjnl-2015-206780; Utset LV, 2018, AM J HEMATOL, V93, pE101, DOI 10.1002/ajh.25033; van Tuijn CFJ, 2010, AM J HEMATOL, V85, P303, DOI 10.1002/ajh.21638; Yamamoto-Hanada K, 2017, ANN ALLERG ASTHMA IM, V119, P54, DOI 10.1016/j.anai.2017.05.013; Yoshida S, 2018, PEDIAT ALLERG IMM-UK, V29, P490, DOI 10.1111/pai.12902; Zeissig S, 2014, NAT IMMUNOL, V15, P307, DOI 10.1038/ni.2847; Zhang LJ, 2013, RESPIROLOGY, V18, P272, DOI 10.1111/j.1440-1843.2012.02280.x	98	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 24	2020	10								3058	10.3389/fimmu.2019.03058	http://dx.doi.org/10.3389/fimmu.2019.03058			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KJ1XY	32038616	Green Published, gold			2022-12-18	WOS:000511853300001
J	Koblischke, M; Spitzer, FS; Florian, DM; Aberle, SW; Malafa, S; Fae, I; Cassaniti, I; Jungbauer, C; Knapp, B; Laferl, H; Fischer, G; Baldanti, F; Stiasny, K; Heinz, FX; Aberle, JH				Koblischke, Maximilian; Spitzer, Felicia S.; Florian, David M.; Aberle, Stephan W.; Malafa, Stefan; Fae, Ingrid; Cassaniti, Irene; Jungbauer, Christof; Knapp, Bernhard; Laferl, Hermann; Fischer, Gottfried; Baldanti, Fausto; Stiasny, Karin; Heinz, Franz X.; Aberle, Judith H.			CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection	FRONTIERS IN IMMUNOLOGY			English	Article						West Nile virus; flavivirus; CD4 T cell; immunodominance; epitope; West Nile patients	BORNE ENCEPHALITIS-VIRUS; MHC CLASS-II; ENVELOPE GLYCOPROTEIN; 3-DIMENSIONAL STRUCTURE; EPITOPE DOMINANCE; HIV ENVELOPE; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; HLA-DR	West Nile (WN) virus infection of humans is frequently asymptomatic, but can also lead to WN fever or neuroinvasive disease. CD4 T cells and B cells are critical in the defense against WN virus, and neutralizing antibodies, which are directed against the viral glycoprotein E, are an accepted correlate of protection. For the efficient production of these antibodies, B cells interact directly with CD4 helper T cells that recognize peptides from E or the two other structural proteins (capsid-C and membrane-prM/M) of the virus. However, the specific protein sites yielding such helper epitopes remain unknown. Here, we explored the CD4 T cell response in humans after WN virus infection using a comprehensive library of overlapping peptides covering all three structural proteins. By measuring T cell responses in 29 individuals with either WN virus disease or asymptomatic infection, we showed that CD4 T cells focus on peptides in specific structural elements of C and at the exposed surface of the pre- and postfusion forms of the E protein. Our data indicate that these immunodominant epitopes are recognized in the context of multiple different HLA molecules. Furthermore, we observed that immunodominant antigen regions are structurally conserved and similarly targeted in other mosquito-borne flaviviruses, including dengue, yellow fever, and Zika viruses. Together, these findings indicate a strong impact of virion protein structure on epitope selection and antigenicity, which is an important issue to consider in future vaccine design.	[Koblischke, Maximilian; Spitzer, Felicia S.; Florian, David M.; Aberle, Stephan W.; Malafa, Stefan; Stiasny, Karin; Heinz, Franz X.; Aberle, Judith H.] Med Univ Vienna, Ctr Virol, Vienna, Austria; [Fae, Ingrid; Fischer, Gottfried] Med Univ Vienna, Dept Blood Grp Serol & Transfus Med, Vienna, Austria; [Cassaniti, Irene; Baldanti, Fausto] Fdn IRCCS Policlin San Matteo, Microbiol & Virol Dept, Mol Virol Unit, Pavia, Italy; [Cassaniti, Irene; Baldanti, Fausto] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy; [Jungbauer, Christof] Austrian Red Cross, Blood Serv Vienna Lower Austria & Burgenland, Vienna, Austria; [Knapp, Bernhard] Symptoma GmbH, Data Sci Sect, Vienna, Austria; [Laferl, Hermann] Kaiser Franz Josef Spita, Sozialmed Zentrum Sud, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; IRCCS Fondazione San Matteo; University of Pavia	Aberle, JH (corresponding author), Med Univ Vienna, Ctr Virol, Vienna, Austria.	judith.aberle@meduniwien.ac.at	Cassaniti, Irene/J-4849-2018; Baldanti, Fausto/J-4924-2018	Cassaniti, Irene/0000-0002-3385-2088; Baldanti, Fausto/0000-0002-3358-8969; Jungbauer, Christof/0000-0002-2482-7147; Koblischke, Maximilian/0000-0003-1223-4990; Spitzer, Felicia/0000-0001-7269-8346; Stiasny, Karin/0000-0002-1902-8674	Austrian Science Fund FWF [P29881-B30, P29928-B30]	Austrian Science Fund FWF(Austrian Science Fund (FWF))	This study was funded by research grants from the Austrian Science Fund FWF (JA: P29881-B30; KS: P29928-B30).	Aberle JH, 2018, J CLIN VIROL, V108, P126, DOI 10.1016/j.jcv.2018.09.020; Aberle JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140545; Aberle SW, 2018, EUROSURVEILLANCE, V23, P7, DOI 10.2807/1560-7917.ES.2018.23.43.1800545; ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995; Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16; Assarsson E, 2007, J IMMUNOL, V178, P7890, DOI 10.4049/jimmunol.178.12.7890; Backert L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0245-0; Barba-Spaeth G, 2016, NATURE, V539, DOI 10.1038/nature19780; Barrett ADT, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay096; Bradt V, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0133-5; Brien JD, 2008, J IMMUNOL, V181, P8568, DOI 10.4049/jimmunol.181.12.8568; Brown SA, 2003, J IMMUNOL, V171, P4140, DOI 10.4049/jimmunol.171.8.4140; Carmicle S, 2007, MOL IMMUNOL, V44, P1159, DOI 10.1016/j.molimm.2006.06.014; Carugo O, 2001, PROTEIN SCI, V10, P1470, DOI 10.1110/ps.690101; Chaves FA, 2012, J IMMUNOL, V188, P4235, DOI 10.4049/jimmunol.1103640; Chen ZM, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1092-6; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Dai GX, 2001, J BIOL CHEM, V276, P41913, DOI 10.1074/jbc.M106018200; Diamond MS, 2008, IMMUNOL REV, V225, P212, DOI 10.1111/j.1600-065X.2008.00676.x; Dokland T, 2004, STRUCTURE, V12, P1157, DOI 10.1016/j.str.2004.04.024; Eisenlohr LC, 2011, IMMUNOL RES, V51, P237, DOI 10.1007/s12026-011-8257-3; Fae I, 2019, HLA, V93, P89, DOI 10.1111/tan.13439; Gould LH, 2004, J CLIN INVEST, V113, P1102, DOI [10.1172/JCI200421623, 10.1172/JCI21623]; Harrison SC, 2015, VIROLOGY, V479, P498, DOI 10.1016/j.virol.2015.03.043; James EA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005375; Kaiser JA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090823; Kanai R, 2006, J VIROL, V80, P11000, DOI 10.1128/JVI.01735-06; Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y; Kaufmann B, 2010, P NATL ACAD SCI USA, V107, P18950, DOI 10.1073/pnas.1011036107; Kim A, 2015, CURR OPIN IMMUNOL, V34, P9, DOI 10.1016/j.coi.2014.12.005; Klitz W, 2003, TISSUE ANTIGENS, V62, P296, DOI 10.1034/j.1399-0039.2003.00103.x; Knapp B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-241; Koblischke M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02083; Koblischke M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09331-w; Kufareva Irina, 2012, Methods Mol Biol, V857, P231, DOI 10.1007/978-1-61779-588-6_10; Landry SJ, 2008, J VIROL, V82, P1238, DOI 10.1128/JVI.02026-07; Landry SJ, 2017, VIRAL IMMUNOL, V30, P479, DOI 10.1089/vim.2017.0008; Landry SJ, 2000, J THEOR BIOL, V203, P189, DOI 10.1006/jtbi.1999.1056; Lanteri MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022948; Lanteri MC, 2009, J CLIN INVEST, V119, P3266, DOI 10.1172/JCI39387; Luca VC, 2013, J VIROL, V87, P818, DOI 10.1128/JVI.01950-12; Luca VC, 2012, J VIROL, V86, P2337, DOI 10.1128/JVI.06072-11; Ma LX, 2004, P NATL ACAD SCI USA, V101, P3414, DOI 10.1073/pnas.0305892101; Mehlhop E, 2008, CURR TOP MICROBIOL, V317, P125; Mettu RR, 2016, J IMMUNOL METHODS, V432, P72, DOI 10.1016/j.jim.2016.02.013; Miller MA, 2015, NAT MED, V21, P1216, DOI 10.1038/nm.3958; Mirano-Bascos D, 2008, EUR J IMMUNOL, V38, P1231, DOI 10.1002/eji.200738011; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Murray K, 2010, J INFECT DIS, V201, P2, DOI 10.1086/648731; Nybakken GE, 2005, NATURE, V437, P764, DOI 10.1038/nature03956; Oliphant T, 2005, NAT MED, V11, P522, DOI 10.1038/nm1240; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Paul S, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0204-1; Paul S, 2015, J IMMUNOL, V194, P6164, DOI 10.4049/jimmunol.1403074; Pierson TC, 2008, CELL HOST MICROBE, V4, P229, DOI 10.1016/j.chom.2008.08.004; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Rey FA, 2017, CRYSTAL STRUCTURE PR; Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12; Sarri CA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205557; Sarri CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165952; Schwaiger J, 2014, J VIROL, V88, P7828, DOI 10.1128/JVI.00196-14; Sercarz EE, 2003, NAT REV IMMUNOL, V3, P621, DOI 10.1038/nri1149; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Simmons CP, 2005, J VIROL, V79, P5665, DOI 10.1128/JVI.79.9.5665-5675.2005; Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316; Sitati EM, 2006, J VIROL, V80, P12060, DOI 10.1128/JVI.01650-06; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; Stiasny K, 2013, EUROSURVEILLANCE, V18, P26, DOI 10.2807/1560-7917.ES2013.18.43.20614; Stiasny K, 2011, AMINO ACIDS, V41, P1159, DOI 10.1007/s00726-009-0370-4; Stiasny K, 2009, VACCINE, V27, P7021, DOI 10.1016/j.vaccine.2009.09.069; Surman S, 2001, P NATL ACAD SCI USA, V98, P4587, DOI 10.1073/pnas.071063898; Tang YL, 2006, J CLIN VIROL, V36, P177, DOI 10.1016/j.jcv.2006.02.008; Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517; Wang XX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00024-6; Weiskopf D, 2016, J INFECT DIS, V214, P1117, DOI 10.1093/infdis/jiw309	76	2	2	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 23	2020	11								16	10.3389/fimmu.2020.00016	http://dx.doi.org/10.3389/fimmu.2020.00016			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KJ2CZ	32038660	gold, Green Published			2022-12-18	WOS:000511867100001
J	Georgana, I; de Motes, CM				Georgana, Iliana; Maluquer de Motes, Carlos			Cullin-5 Adaptor SPSB1 Controls NF-kappa B Activation Downstream of Multiple Signaling Pathways	FRONTIERS IN IMMUNOLOGY			English	Article						SPSB1; Cullins; NF-kappa B; innate immunity; inflammation; signal transduction; ubiquitin ligase; respiratory viral infection	SOCS-BOX; SPRY DOMAIN; NEGATIVE REGULATOR; POSTTRANSLATIONAL MODIFICATIONS; PROTEINS; FAMILY; IDENTIFICATION; UBIQUITINATION; PROTEOLYSIS; SUPPRESSOR	The initiation of innate immune responses against pathogens relies on the activation of pattern-recognition receptors (PRRs) and corresponding intracellular signaling cascades. To avoid inappropriate or excessive activation of PRRs, these responses are tightly controlled. Cullin-RING E3 ubiquitin ligases (CRLs) have emerged as critical regulators of many cellular functions including innate immune activation and inflammation. CRLs form multiprotein complexes in which a Cullin protein acts as a scaffold and recruits specific adaptor proteins, which in turn recognize specific substrate proteins for ubiquitylation, hence providing selectivity. CRLs are divided into 5 main groups, each of which uses a specific group of adaptor proteins. Here, we systematically depleted all predicted substrate adaptors for the CRL5 family (the so-called SOCS-box proteins) and assessed the impact on the activation of the inflammatory transcription factor NF-kappa B. Depletion of SPSB1 resulted in a significant increase in NF-kappa B activation, indicating the importance of SPSB1 as an NF-kappa B negative regulator. In agreement, overexpression of SPSB1 suppressed NF-kappa B activity in a potent, dose-dependent manner in response to various agonists. Inhibition by SPSB1 was specific to NF-kappa B, because other transcription factors related to innate immunity and interferon (IFN) responses such as IRF-3, AP-1, and STATs remained unaffected by SPSB1. SPSB1 suppressed NF-kappa B activation induced via multiple pathways including Toll-like receptors and RNA and DNA sensing adaptors, and required the presence of its SOCS-box domain. To provide mechanistic insight, we examined phosphorylation and degradation of the inhibitor of kappa B (I kappa B alpha) and p65 translocation into the nucleus. Both remained unaffected by SPSB1, indicating that SPSB1 exerts its inhibitory activity downstream, or at the level, of the NF-kappa B heterodimer. In agreement with this, SPSB1 was found to co-precipitate with p65 after over-expression and at endogenous levels. Additionally, A549 cells stably expressing SPSB1 presented lower cytokine levels including type I IFN in response to cytokine stimulation and virus infection. Taken together, our results reveal novel regulatory mechanisms in innate immune signaling and identify the prominent role of SPSB1 in limiting NF-kappa B activation. Our work thus provides insights into inflammation and inflammatory diseases and new opportunities for the therapeutic targeting of NF-kappa B transcriptional activity.	[Georgana, Iliana; Maluquer de Motes, Carlos] Univ Surrey, Dept Microbial Sci, Guildford, Surrey, England	University of Surrey	de Motes, CM (corresponding author), Univ Surrey, Dept Microbial Sci, Guildford, Surrey, England.	c.maluquerdemotes@surrey.ac.uk	de Motes, Carlos Maluquer/AAF-8092-2021	de Motes, Carlos Maluquer/0000-0003-4712-4601	Asthma UK Innovation Grant [AUKIG2016353]	Asthma UK Innovation Grant	This work was supported by an Asthma UK Innovation Grant (AUKIG2016353) to CM.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Bhinder B, 2012, COMB CHEM HIGH T SCR, V15, P686, DOI 10.2174/138620712803519671; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chen RAJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040022; Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x; Christian F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5010012; Clark K, 2013, NAT REV MOL CELL BIO, V14, P673, DOI 10.1038/nrm3644; D'Cruz AA, 2013, PROTEIN SCI, V22, P1, DOI 10.1002/pro.2185; de Motes CM, 2014, J GEN VIROL, V95, P2038, DOI 10.1099/vir.0.065664-0; de Motes CM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002430; Edwards MR, 2009, PHARMACOL THERAPEUT, V121, P1, DOI 10.1016/j.pharmthera.2008.09.003; Feng Y, 2014, CANCER DISCOV, V4, P790, DOI 10.1158/2159-8290.CD-13-0548; Filippakopoulos P, 2010, J MOL BIOL, V401, P389, DOI 10.1016/j.jmb.2010.06.017; Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933; Georgana I, 2019, PREPRINT, DOI [10.1101/634881, DOI 10.1101/634881]; Georgana I, 2018, J VIROL, V92, DOI 10.1128/JVI.02145-17; Ghosh S, 2012, IMMUNOL REV, V246, P5, DOI 10.1111/j.1600-065X.2012.01111.x; Hayashi R, 2004, EUR J PHARMACOL, V500, P51, DOI 10.1016/j.ejphar.2004.07.011; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Huang B, 2010, CELL SIGNAL, V22, P1282, DOI 10.1016/j.cellsig.2010.03.017; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kedzierski L, 2017, ELIFE, V6, DOI 10.7554/eLife.20444; Kohroki J, 2005, FEBS LETT, V579, P6796, DOI 10.1016/j.febslet.2005.11.016; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kuang ZH, 2010, J CELL BIOL, V190, P129, DOI 10.1083/jcb.200912087; Lewis RS, 2011, J IMMUNOL, V187, P3798, DOI 10.4049/jimmunol.1002993; Linossi EM, 2013, CYTOKINE GROWTH F R, V24, P241, DOI 10.1016/j.cytogfr.2013.03.005; Linossi EM, 2012, IUBMB LIFE, V64, P316, DOI 10.1002/iub.1011; Liu S, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0223-4; Liu S, 2015, J BIOL CHEM, V290, P17894, DOI 10.1074/jbc.M114.607184; Maluquer de Motes Carlos, 2017, J Gen Virol, V98, P3086, DOI 10.1099/jgv.0.000946; Mansur DS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003183; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Masters SL, 2006, NAT STRUCT MOL BIOL, V13, P77, DOI 10.1038/nsmb1034; Morelli M, 2015, MBIO, V6, DOI 10.1128/mBio.02490-14; Neidel S, 2015, J BIOL CHEM, V290, P5991, DOI 10.1074/jbc.M114.624650; Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102; Nishiya T, 2011, J BIOL CHEM, V286, P9009, DOI 10.1074/jbc.M110.190678; Odon V, 2018, J VIROL, V92, DOI 10.1128/JVI.01374-18; Pautz A, 2010, NITRIC OXIDE-BIOL CH, V23, P75, DOI 10.1016/j.niox.2010.04.007; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Rehwinkel J, 2010, CELL, V140, P397, DOI 10.1016/j.cell.2010.01.020; Schaller T, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002439; Schuliga M, 2015, BIOMOLECULES, V5, P1266, DOI 10.3390/biom5031266; Seki Y, 2002, P NATL ACAD SCI USA, V99, P13003, DOI 10.1073/pnas.202477099; Strebovsky J, 2011, FASEB J, V25, P863, DOI 10.1096/fj.10-170597; Sumner RP, 2014, J VIROL, V88, P3092, DOI 10.1128/JVI.02627-13; Sun Y, 2017, VACCINE, V35, P481, DOI 10.1016/j.vaccine.2016.09.030; Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800; Torres AA, 2016, J GEN VIROL, V97, P2346, DOI 10.1099/jgv.0.000525; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Unterholzner L, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002247; Wang DK, 2005, J BIOL CHEM, V280, P16393, DOI 10.1074/jbc.M413897200; Wang F, 2017, CELL RES, V27, P540, DOI 10.1038/cr.2017.7; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Xing JJ, 2016, NAT IMMUNOL, V17, P1373, DOI 10.1038/ni.3580; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	63	2	3	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 21	2020	10								3121	10.3389/fimmu.2019.03121	http://dx.doi.org/10.3389/fimmu.2019.03121			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KH8TJ	32038638	gold, Green Submitted, Green Published			2022-12-18	WOS:000510923000001
J	Sarkander, J; Hojyo, S; Mursell, M; Yamasaki, Y; Wu, TY; Tumes, DJ; Miyauchi, K; Tran, CL; Zhu, JF; Lohning, M; Hutloff, A; Mashreghi, MF; Kubo, M; Radbruch, A; Tokoyoda, K				Sarkander, Jana; Hojyo, Shintaro; Mursell, Mathias; Yamasaki, Yuzuru; Wu, Tsung-Yen; Tumes, Damon J.; Miyauchi, Kosuke; Cam Loan Tran; Zhu, Jinfang; Loehning, Max; Hutloff, Andreas; Mashreghi, Mir-Farzin; Kubo, Masato; Radbruch, Andreas; Tokoyoda, Koji			Enhanced Cell Division Is Required for the Generation of Memory CD4 T Cells to Migrate Into Their Proper Location	FRONTIERS IN IMMUNOLOGY			English	Article						CD4 T cells; memory; bone marrow; cell division; migration	B-CELLS; TRANSCRIPTION FACTOR; BONE-MARROW; BET; ESTABLISHMENT; DIFFERENTIATION; INTERLEUKIN-2; EXPANSION; RECEPTOR; PROTEIN	CD4 T cell memory is fundamental for long-lasting immunity and effective secondary responses following infection or vaccination. We have previously found that memory CD4 T cells specific for systemic antigens preferentially reside in the bone marrow (BM) and arise from splenic CD49b(+)T-bet(+) CD4 T cells. However, how BM-homing memory precursors are generated during an immune reaction is unknown. We show here that BM memory precursors are generated via augmented rates of cell division throughout a primary immune response. Treatment with the cytostatic drug cyclophosphamide or blockade of the CD28/B7 co-stimulatory pathway at the beginning of the contraction phase abrogates the generation of BM memory precursors. We determine that, following a critical number of cell divisions, memory precursors downregulate CCR7 and upregulate IL-2R beta, indicating that loss of CCR7 and gain of IL-2 signal are required for the migration of memory precursors toward the BM.	[Sarkander, Jana; Hojyo, Shintaro; Mursell, Mathias; Yamasaki, Yuzuru; Wu, Tsung-Yen; Cam Loan Tran; Loehning, Max; Hutloff, Andreas; Mashreghi, Mir-Farzin; Radbruch, Andreas; Tokoyoda, Koji] Deutsch Rheuma Forschungszentrum Berlin, Leibniz Inst, Berlin, Germany; [Tumes, Damon J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Tumes, Damon J.] Univ South Australia, Adelaide, SA, Australia; [Miyauchi, Kosuke; Kubo, Masato] RIKEN, Lab Cytokine Regulat, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Zhu, Jinfang] NIAID, Lab Immune Syst Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Loehning, Max] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Expt Immunol & Osteoarthrit Res, Berlin, Germany; [Kubo, Masato] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Pathol, Noda, Chiba, Japan	Deutsches Rheuma-Forschungszentrum (DRFZ); Centre for Cancer Biology; SA Pathology; University of South Australia; RIKEN; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Tokyo University of Science	Tokoyoda, K (corresponding author), Deutsch Rheuma Forschungszentrum Berlin, Leibniz Inst, Berlin, Germany.	tokoyoda@drfz.de	Hutloff, Andreas/D-1781-2014; Mashreghi, Mir-Farzin/S-2911-2019; Löhning, Max/AAL-2967-2021; Zhu, Jinfang/B-7574-2012; Tumes, Damon J/B-9917-2009	Hutloff, Andreas/0000-0002-0572-8151; Mashreghi, Mir-Farzin/0000-0002-8015-6907; Löhning, Max/0000-0001-6382-7281; Zhu, Jinfang/0000-0002-0117-4745; Tumes, Damon J/0000-0001-5709-857X; Radbruch, Andreas/0000-0001-5753-0000	Leibniz Association (International Leibniz Research Cluster ImmunoMemory); German Research Council (DFG) [TO944/2-1, TO944/3-1]; Leibniz Association (Leibniz Graduate School for Rheumatology); Alexander von Humboldt-Foundation; Japan Society for the Promotion of Science	Leibniz Association (International Leibniz Research Cluster ImmunoMemory); German Research Council (DFG)(German Research Foundation (DFG)); Leibniz Association (Leibniz Graduate School for Rheumatology); Alexander von Humboldt-Foundation(Alexander von Humboldt Foundation); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by the Leibniz Association (International Leibniz Research Cluster ImmunoMemory) and by the German Research Council (DFG, TO944/2-1 and TO944/3-1). JS was supported by the Leibniz Association (Leibniz Graduate School for Rheumatology) and SH was supported by the Alexander von Humboldt-Foundation and the Japan Society for the Promotion of Science.	Arsenio J, 2015, TRENDS IMMUNOL, V36, P670, DOI 10.1016/j.it.2015.09.004; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Blair DA, 2011, J IMMUNOL, V187, P2310, DOI 10.4049/jimmunol.1100363; Britschgi MR, 2010, EUR J IMMUNOL, V40, P1266, DOI 10.1002/eji.200939921; Brode S, 2008, CRIT REV IMMUNOL, V28, P109, DOI 10.1615/CritRevImmunol.v28.i2.20; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Corse E, 2011, J IMMUNOL, V186, P5039, DOI 10.4049/jimmunol.1003650; Cossarizza A, 2017, EUR J IMMUNOL, V47, P1584, DOI 10.1002/eji.201646632; Dooms H, 2007, J EXP MED, V204, P547, DOI 10.1084/jem.20062381; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Gasper DJ, 2014, CRIT REV IMMUNOL, V34, P121, DOI 10.1615/CritRevImmunol.2014010373; Haftmann C, 2015, EUR J IMMUNOL, V45, P1192, DOI 10.1002/eji.201444633; Hanazawa A, 2013, IMMUNOL CELL BIOL, V91, P524, DOI 10.1038/icb.2013.36; Hojyo S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00026; Kim C, 2013, IMMUNITY, V39, P508, DOI 10.1016/j.immuni.2013.08.033; Kozai M, 2017, J EXP MED, V214, P1925, DOI 10.1084/jem.20161864; Kuhns MS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00159; Link A, 2007, NAT IMMUNOL, V8, P1255, DOI 10.1038/ni1513; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; Linton PJ, 2000, J IMMUNOL, V165, P5558, DOI 10.4049/jimmunol.165.10.5558; Lord GM, 2005, BLOOD, V106, P3432, DOI 10.1182/blood-2005-04-1393; McKinstry KK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6377; Mollo SB, 2013, J IMMUNOL, V191, P6052, DOI 10.4049/jimmunol.1302033; Nakajima C, 2002, EUR J IMMUNOL, V32, P1792, DOI 10.1002/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-0; Okhrimenko A, 2014, P NATL ACAD SCI USA, V111, P9229, DOI 10.1073/pnas.1318731111; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.3.CO;2-F; Ross SH, 2018, ANNU REV IMMUNOL, V36, P411, DOI 10.1146/annurev-immunol-042617-053352; Sabatino JJ, 2011, J EXP MED, V208, P81, DOI 10.1084/jem.20101574; Sasaki K, 2003, INT IMMUNOL, V15, P701, DOI 10.1093/intimm/dxg066; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shinoda K, 2012, P NATL ACAD SCI USA, V109, P7409, DOI 10.1073/pnas.1118539109; Siracusa F, 2018, P NATL ACAD SCI USA, V115, P1334, DOI 10.1073/pnas.1715618115; Stittrich AB, 2010, NAT IMMUNOL, V11, P1057, DOI 10.1038/ni.1945; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Swain SL, 2006, IMMUNOL REV, V211, P8, DOI 10.1111/j.0105-2896.2006.00388.x; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tokoyoda K, 2009, IMMUNITY, V30, P721, DOI 10.1016/j.immuni.2009.03.015; van Essen D, 2000, J IMMUNOL, V165, P3640; Weber JP, 2015, J EXP MED, V212, P217, DOI 10.1084/jem.20141432; Whitmire JK, 2009, J IMMUNOL, V182, P1868, DOI 10.4049/jimmunol.0802501; Zehn D, 2009, NATURE, V458, P211, DOI 10.1038/nature07657; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007	42	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 15	2020	10								3113	10.3389/fimmu.2019.03113	http://dx.doi.org/10.3389/fimmu.2019.03113			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KH5SV	32010148	gold, Green Published, Green Accepted			2022-12-18	WOS:000510711300001
J	Yeola, AP; Doss, PMIA; Baillargeon, J; Akbar, I; Mailhot, B; Balood, M; Talbot, S; Anderson, AC; Lacroix, S; Rangachari, M				Yeola, Asmita Pradeep; Doss, Prenitha Mercy Ignatius Arokia; Baillargeon, Joanie; Akbar, Irshad; Mailhot, Benoit; Balood, Mohammad; Talbot, Sebastien; Anderson, Ana Carrizosa; Lacroix, Steve; Rangachari, Manu			Endogenous T Cell Receptor Rearrangement Represses Aggressive Central Nervous System Autoimmunity in a TcR-Transgenic Model on the Non-Obese Diabetic Background	FRONTIERS IN IMMUNOLOGY			English	Article						EAE (experimental autoimmune encephalomyelitis); TCR transgenic mice; Treg-regulatory T cell; non-obese diabetic (NOD); allelic exclusion; RAG; FoxP3	MOUSE MODEL; ENCEPHALOMYELITIS; CD4(+); MICE; THERAPIES; INDUCE; EAE	The T cell response to central nervous system (CNS) antigen in experimental autoimmune encephalomyelitis (EAE) permits one to model the immune aspects of multiple sclerosis. 1C6 transgenic mice on the non-obese diabetic (NOD) background possess a class II-restricted T cell receptor (TcR; V alpha 5-V beta 7) specific for the encephalitogenic peptide myelin oligodendrocyte glycoprotein (MOG)([35-55]). It remains to be determined what role is played by allelic inclusion in shaping the TcR repertoire of these mice. Here, we show that 1C6 T cells display substantial promiscuity in their expression of non-transgenically derived V alpha chains. Further, enforced expression of the transgenic TcR in 1C6 x Rag1(-/-) mice profoundly disrupted thymic negative selection and led to a sharp decrease in the number of mature peripheral T cells. 1C6 x Rag1(-/-) mice developed spontaneous EAE at a significant frequency and rapidly developed fatal EAE upon immunization with myelin oligodendrocyte glycoprotein (MOG)([35-55]). Passive transfer of 1C6 x Rag1(+/+) CD4(+) T cells, but not CD8(+) T cells or B cells, partially rescued 1C6 x Rag1(-/-) mice from severe EAE. FoxP3(+) CD4(+) T-reg cells were present in the CNS of immunized 1C6 mice, as well as immunized 1C6 x Rag1(-/-) that had been supplemented with 1C6 CD4(+) T cells. However, they were not observed in 1C6 x Rag1(-/-) that did not receive Rag1-sufficient 1C6 CD4(+). Further, in vivo blockade of T-reg accelerated the onset of symptoms in 1C6 mice immunized with MOG([35-55]), indicating the pertinence of T-reg-mediated control of autoimmune inflammation in this model. Thus, TcR allelic inclusion is crucial to the generation of FoxP3(+) CD4(+) T cells necessary for the suppression of severe CNS autoimmunity.	[Yeola, Asmita Pradeep; Doss, Prenitha Mercy Ignatius Arokia; Baillargeon, Joanie; Akbar, Irshad; Mailhot, Benoit; Balood, Mohammad; Lacroix, Steve; Rangachari, Manu] Univ Laval, CHU Quebec, Ctr Rech, Axe Neurosci, Quebec City, PQ, Canada; [Balood, Mohammad; Talbot, Sebastien] Univ Montreal, Dept Physiol & Pharmacol, Montreal, PQ, Canada; [Anderson, Ana Carrizosa] Harvard Med Sch, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA; [Anderson, Ana Carrizosa] Harvard Med Sch, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA; [Anderson, Ana Carrizosa] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Lacroix, Steve; Rangachari, Manu] Laval Univ, Fac Med, Dept Mol Med, Quebec City, PQ, Canada	Laval University; Universite de Montreal; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Laval University	Rangachari, M (corresponding author), Univ Laval, CHU Quebec, Ctr Rech, Axe Neurosci, Quebec City, PQ, Canada.; Rangachari, M (corresponding author), Laval Univ, Fac Med, Dept Mol Med, Quebec City, PQ, Canada.	manu.rangachari@crchudequebec.ulaval.ca	Anderson, Ana C/ABD-6829-2021	Anderson, Ana C/0000-0002-0877-2932; balood, mohammad/0000-0001-5647-7826	Biomedical Operating Grant from the Multiple Sclerosis Society of Canada [3036]; Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant [RGPIN/036652015]; Multiple Sclerosis Society of Canada	Biomedical Operating Grant from the Multiple Sclerosis Society of Canada; Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant(Natural Sciences and Engineering Research Council of Canada (NSERC)); Multiple Sclerosis Society of Canada	The work was supported by a Biomedical Operating Grant (#3036) from the Multiple Sclerosis Society of Canada to MR. AY was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant (RGPIN/036652015) to MR. PI was previously supported by a Doctoral Studentship from the Multiple Sclerosis Society of Canada. MR is a Junior-2 scholar of the Fonds de recherche du Quebec-Sante.	Akirav EM, 2009, J NEUROSCI RES, V87, P3511, DOI 10.1002/jnr.21981; Anderson AC, 2012, J IMMUNOL, V188, P2084, DOI 10.4049/jimmunol.1102186; Basso AS, 2008, J CLIN INVEST, V118, P1532, DOI 10.1172/JCI33464; Bauer J, 2016, METHODS MOL BIOL, V1304, P211, DOI 10.1007/7651_2014_151; Bautista JL, 2009, NAT IMMUNOL, V10, P610, DOI 10.1038/ni.1739; Bettelli E, 2007, ANN NY ACAD SCI, V1103, P11, DOI 10.1196/annals.1394.021; Boivin N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124802; Coleman MM, 2012, FEMS IMMUNOL MED MIC, V64, P413, DOI 10.1111/j.1574-695X.2011.00927.x; D'Cruz LM, 2005, NAT IMMUNOL, V6, P1152, DOI 10.1038/ni1264; Ellmerich S, 2004, EUR J IMMUNOL, V34, P1839, DOI 10.1002/eji.200324044; Encinas JA, 1999, NAT GENET, V21, P158, DOI 10.1038/5941; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Haghikia A, 2013, TRENDS MOL MED, V19, P309, DOI 10.1016/j.molmed.2013.03.004; Krishnamoorthy G, 2009, NAT MED, V15, P626, DOI 10.1038/nm.1975; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; Madsen LS, 1999, NAT GENET, V23, P343, DOI 10.1038/15525; Matejuk A, 2003, J NEUROSCI RES, V71, P89, DOI 10.1002/jnr.10450; Mayo L, 2014, NAT MED, V20, P1147, DOI 10.1038/nm.3681; O'Connor RA, 2008, J NEUROIMMUNOL, V193, P1, DOI 10.1016/j.jneuroim.2007.11.016; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Pennati A, 2016, J NEUROSCI, V36, P12598, DOI 10.1523/JNEUROSCI.1994-16.2016; Quintana FJ, 2012, NAT IMMUNOL, V13, P770, DOI 10.1038/ni.2363; Rangachari M, 2013, J AUTOIMMUN, V45, P31, DOI 10.1016/j.jaut.2013.06.008; Rangachari M, 2012, NAT MED, V18, P1394, DOI 10.1038/nm.2871; Sinha S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00619; Van de Keere F, 1998, J EXP MED, V188, P1875, DOI 10.1084/jem.188.10.1875; Vargas DL, 2017, J INVEST MED, V65, P883, DOI 10.1136/jim-2016-000339; Waldner H, 2000, P NATL ACAD SCI USA, V97, P3412, DOI 10.1073/pnas.97.7.3412	29	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 15	2020	10								3115	10.3389/fimmu.2019.03115	http://dx.doi.org/10.3389/fimmu.2019.03115			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KG5CR	32010149	Green Published, gold			2022-12-18	WOS:000509965700001
J	Kemps, PG; Zondag, TC; Steenwijk, EC; Andriessen, Q; Borst, J; Vloemans, S; Roelen, DL; Voortman, LM; Verdijk, RM; van Noesel, CJM; Cleven, AHG; Hawkins, C; Lang, V; de Ru, AH; Janssen, GMC; Haasnoot, GW; Franken, KLMC; van Eijk, R; Solleveld-Westerink, N; van Wezel, T; Egeler, RM; Beishuizen, A; van Laar, JAM; Abla, O; van den Bos, C; van Veelen, PA; van Halteren, AGS				Kemps, Paul G.; Zondag, Timo C.; Steenwijk, Eline C.; Andriessen, Quirine; Borst, Jelske; Vloemans, Sandra; Roelen, Dave L.; Voortman, Lenard M.; Verdijk, Robert M.; van Noesel, C. J. M.; Cleven, Arjen H. G.; Hawkins, Cynthia; Lang, Veronica; de Ru, Arnoud H.; Janssen, George M. C.; Haasnoot, Geert W.; Franken, Kees L. M. C.; van Eijk, Ronald; Solleveld-Westerink, Nienke; van Wezel, Tom; Egeler, R. Maarten; Beishuizen, Auke; van Laar, Jan A. M.; Abla, Oussama; van den Bos, Cor; van Veelen, Peter A.; van Halteren, Astrid G. S.			Apparent Lack of BRAF(V600E) Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8(+) T Cells in Langerhans Cell Histiocytosis	FRONTIERS IN IMMUNOLOGY			English	Article						Langerhans Cell Histiocytosis; BRAF; neoantigen; neopeptide; Human Leukocyte Antigen; T cell	MHC CLASS-I; BRAF MUTATIONS; DENDRITIC CELLS; ABUNDANT EXPRESSION; SOMATIC MUTATIONS; IMMUNE-RESPONSES; CANCER; PEPTIDES; EPITOPES; PATHWAY	Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder of hematopoietic origin characterized by inflammatory lesions containing clonal histiocytes (LCH-cells) intermixed with various immune cells, including T cells. In 50-60% of LCH-patients, the somatic BRAF(V600E) driver mutation, which is common in many cancers, is detected in these LCH-cells in an otherwise quiet genomic landscape. Non-synonymous mutations like BRAF(V600E) can be a source of neoantigens capable of eliciting effective antitumor CD8(+) T cell responses. This requires neopeptides to be stably presented by Human Leukocyte Antigen (HLA) class I molecules and sufficient numbers of CD8(+) T cells at tumor sites. Here, we demonstrate substantial heterogeneity in CD8(+) T cell density in n = 101 LCH-lesions, with BRAF(V600E) mutated lesions displaying significantly lower CD8(+) T cell:CD1a(+) LCH-cell ratios (p = 0.01) than BRAF wildtype lesions. Because LCH-lesional CD8(+) T cell density had no significant impact on event-free survival, we investigated whether the intracellularly expressed BRAF(V600E) protein is degraded into neopeptides that are naturally processed and presented by cell surface HLA class I molecules. Epitope prediction tools revealed a single HLA class I binding BRAF(V600E) derived neopeptide (KIGDFGLATEK), which indeed displayed strong to intermediate binding capacity to HLA-A*03:01 and HLA-A*11:01 in an in vitro peptide-HLA binding assay. Mass spectrometry-based targeted peptidomics was used to investigate the presence of this neopeptide in HLA class I presented peptides isolated from several BRAF(V600E) expressing cell lines with various HLA genotypes. While the HLA-A*02:01 binding BRAF wildtype peptide KIGDFGLATV was traced in peptides isolated from all five cell lines expressing this HLA subtype, KIGDFGLATEK was not detected in the HLA class I peptidomes of two distinct BRAF(V600E) transduced cell lines with confirmed expression of HLA-A*03:01 or HLA-A*11:01. These data indicate that the in silico predicted HLA class I binding and proteasome-generated neopeptides derived from the BRAF(V600E) protein are not presented by HLA class I molecules. Given that the BRAF(V600E) mutation is highly prevalent in chemotherapy refractory LCH-patients who may qualify for immunotherapy, this study therefore questions the efficacy of immune checkpoint inhibitor therapy in LCH.	[Kemps, Paul G.; Steenwijk, Eline C.; Andriessen, Quirine; Borst, Jelske; Egeler, R. Maarten; van Halteren, Astrid G. S.] Leiden Univ, Immunol Lab, Willem Alexander Childrens Hosp, Med Ctr, Leiden, Netherlands; [Zondag, Timo C.; van Laar, Jan A. M.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Vloemans, Sandra; Roelen, Dave L.; Haasnoot, Geert W.; Franken, Kees L. M. C.] Leiden Univ, Dept Immunohematol & Blood Transfus, Med Ctr, Leiden, Netherlands; [Voortman, Lenard M.] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, Leiden, Netherlands; [Verdijk, Robert M.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [van Noesel, C. J. M.] Univ Amsterdam, Dept Pathol, Med Ctr, Amsterdam, Netherlands; [Cleven, Arjen H. G.; van Eijk, Ronald; Solleveld-Westerink, Nienke; van Wezel, Tom] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands; [Hawkins, Cynthia; Lang, Veronica; Egeler, R. Maarten; Abla, Oussama] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada; [de Ru, Arnoud H.; Janssen, George M. C.; van Veelen, Peter A.] Leiden Univ, Ctr Prote & Metabol, Med Ctr, Leiden, Netherlands; [Beishuizen, Auke] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol, Rotterdam, Netherlands; [Beishuizen, Auke; van den Bos, Cor; van Halteren, Astrid G. S.] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [van den Bos, Cor] Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Oncol, Med Ctr, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Emma Children's Hospital; University of Amsterdam	van Halteren, AGS (corresponding author), Leiden Univ, Immunol Lab, Willem Alexander Childrens Hosp, Med Ctr, Leiden, Netherlands.; van Halteren, AGS (corresponding author), Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands.	a.g.s.van_halteren@lumc.nl	van Wezel, Tom/Z-3092-2019; van Wezel, Tom/AAL-5626-2021; Franken, Kees/ABA-7095-2021	van Wezel, Tom/0000-0001-5773-7730; Franken, Kees/0000-0002-4747-6060; Voortman, Lenard/0000-0001-9794-067X; van Veelen, Peter/0000-0002-7898-9408; Kemps, Paul/0000-0001-9793-7032; Verdijk, Robert M/0000-0003-1437-214X	Histiocytosis Association of America; Stichting 1000 Kaarsjes voor Juultje; Stichting Kiwanis Run-for-LCH; Histiocytose Nederland; research programme Investment Grant NWO Medium - ZonMw [91116004]; Royal Netherlands Academy of Arts and Sciences	Histiocytosis Association of America; Stichting 1000 Kaarsjes voor Juultje; Stichting Kiwanis Run-for-LCH; Histiocytose Nederland; research programme Investment Grant NWO Medium - ZonMw; Royal Netherlands Academy of Arts and Sciences	This study was financially supported by grants awarded by the Histiocytosis Association of America, Stichting 1000 Kaarsjes voor Juultje, Stichting Kiwanis Run-for-LCH and structural research funding from Histiocytose Nederland (AH). In addition, the peptidomics experiments were financially supported by a research programme Investment Grant NWO Medium with project number 91116004, which is (partly) financed by ZonMw. PK received a Van Walree Travel Grant from the Royal Netherlands Academy of Arts and Sciences.	Alexandrescu S, 2012, INT J CLIN EXP PATHO, V5, P503; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Allen CE, 2010, J IMMUNOL, V184, P4557, DOI 10.4049/jimmunol.0902336; Andersen MH, 2004, CANCER RES, V64, P5456, DOI 10.1158/0008-5472.CAN-04-0937; Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Annels NE, 2003, J EXP MED, V197, P1385, DOI 10.1084/jem.20030137; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Battistella M, 2010, ARCH DERMATOL, V146, P149, DOI 10.1001/archdermatol.2009.360; Bernstrand C, 2003, PEDIATR RES, V54, P30, DOI 10.1203/01.PDR.0000069844.50684.7D; Berres ML, 2014, J EXP MED, V211, P669, DOI 10.1084/jem.20130977; Beyrend G, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0700-3; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Bradley SD, 2015, CANCER IMMUNOL RES, V3, P602, DOI 10.1158/2326-6066.CIR-15-0030; CHAKRABORTY R, 2017, BLOOD S1, V130; Chakraborty R, 2016, BLOOD, V128, P2533, DOI 10.1182/blood-2016-08-733790; Chakraborty R, 2014, BLOOD, V124, P3007, DOI 10.1182/blood-2014-05-577825; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chheda ZS, 2018, J EXP MED, V215, P141, DOI 10.1084/jem.20171046; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; Cintolo JA, 2016, MELANOMA RES, V26, P1, DOI 10.1097/CMR.0000000000000203; da Costa CET, 2005, J EXP MED, V201, P687, DOI 10.1084/jem.20041785; da Costa CET, 2009, GENE CHROMOSOME CANC, V48, P239, DOI 10.1002/gcc.20634; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Meulenaere A, 2017, ONCOTARGET, V8, P80443, DOI 10.18632/oncotarget.19045; De Meulenaere A, 2017, PATHOLOGY, V49, P397, DOI 10.1016/j.pathol.2017.02.002; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Durham BH, 2019, SEMIN CELL DEV BIOL, V86, P62, DOI 10.1016/j.semcdb.2018.03.002; Egeler RM, 2010, IMMUNOL REV, V234, P213, DOI 10.1111/j.0105-2896.2009.00883.x; Egeler RM, 1999, BLOOD, V94, P4195; Egeler RM, 2000, EUR J CANCER, V36, P2105, DOI 10.1016/S0959-8049(00)00296-3; EMILE JF, 1994, J PATHOL, V174, P71, DOI 10.1002/path.1711740202; Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101; Fukuyo Y, 2008, CANCER RES, V68, P6324, DOI 10.1158/0008-5472.CAN-07-6602; Garrido F, 2016, CURR OPIN IMMUNOL, V39, P44, DOI 10.1016/j.coi.2015.12.007; Gatalica Z, 2015, ONCOTARGET, V6, P19819, DOI 10.18632/oncotarget.4378; Geissmann F, 2001, BLOOD, V97, P1241, DOI 10.1182/blood.V97.5.1241; Ghorani E, 2018, ANN ONCOL, V29, P271, DOI 10.1093/annonc/mdx687; GOOD IJ, 1982, J STAT COMPUT SIM, V16, P65, DOI 10.1080/00949658208810607; Goyal G, 2019, BLOOD, V133, P1607, DOI 10.1182/blood-2018-12-893917; Grois N, 2005, BRAIN, V128, P829, DOI 10.1093/brain/awh403; Halbritter F, 2019, CANCER DISCOV, V9, P1406, DOI 10.1158/2159-8290.CD-19-0138; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; Haroche J, 2017, LANCET ONCOL, V18, pE113, DOI 10.1016/S1470-2045(17)30031-1; Hassan C, 2013, MOL CELL PROTEOMICS, V12, P1829, DOI 10.1074/mcp.M112.024810; Heritier S, 2016, J CLIN ONCOL, V34, P3023, DOI 10.1200/JCO.2015.65.9508; Holloway G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18464-x; Hutter C, 2012, BLOOD, V120, P5199, DOI 10.1182/blood-2012-02-410241; Ilieva KM, 2014, MOL CANCER THER, V13, P2769, DOI 10.1158/1535-7163.MCT-14-0290; Inderberg EM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1302631; Jorgensen KW, 2014, IMMUNOLOGY, V141, P18, DOI 10.1111/imm.12160; Kessler JH, 2011, NAT IMMUNOL, V12, P45, DOI 10.1038/ni.1974; Kitamura T, 2019, JOVE-J VIS EXP, DOI 10.3791/58841; Klebanoff CA, 2018, J EXP MED, V215, P5, DOI 10.1084/jem.20172188; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Kvistborg P, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.18851; Lange V, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-63; Leisegang M, 2016, J CLIN INVEST, V126, P854, DOI 10.1172/JCI83465; Lill JR, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201800110; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; McClain KL, 2003, MED PEDIATR ONCOL, V41, P502, DOI 10.1002/mpo.10366; Melief CJM, 2013, CLIN CANCER RES, V19, P4295, DOI 10.1158/1078-0432.CCR-13-1432; Miksch RC, 2017, ONCOTARGET, V8, P114935, DOI 10.18632/oncotarget.22932; Mitchell JM, 2018, CLIN IMMUNOL, V194, P19, DOI 10.1016/j.clim.2018.06.004; Nelson DS, 2014, BLOOD, V123, P3152, DOI 10.1182/blood-2013-06-511139; Nielsen M, 2005, IMMUNOGENETICS, V57, P33, DOI 10.1007/s00251-005-0781-7; Quispel WT, 2015, J INTERF CYTOK RES, V35, P831, DOI 10.1089/jir.2014.0190; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Rollins BJ, 2015, HEMATOL ONCOL CLIN N, V29, P839, DOI 10.1016/j.hoc.2015.06.004; Sahm F, 2012, BLOOD, V120, pE28, DOI 10.1182/blood-2012-06-429597; Saraiva DP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02605; Schofl G, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3575-z; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sconocchia G, 2014, NEOPLASIA, V16, P31, DOI 10.1593/neo.131568; Senechal B, 2007, PLOS MED, V4, P1374, DOI 10.1371/journal.pmed.0040253; Sers C, 2009, INT J CANCER, V125, P1626, DOI 10.1002/ijc.24557; Sharkey MS, 2004, CANCER RES, V64, P1595, DOI 10.1158/0008-5472.CAN-03-3231; SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989; Somasundaram R, 2006, CANCER RES, V66, P3287, DOI 10.1158/0008-5472.CAN-05-1932; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Tan TLR, 1997, J IMMUNOL METHODS, V205, P201, DOI 10.1016/S0022-1759(97)00086-0; Tazi A, 1999, J IMMUNOL, V163, P3511; Tenzer S, 2005, CELL MOL LIFE SCI, V62, P1025, DOI 10.1007/s00018-005-4528-2; TOMOOKA Y, 1986, J CLIN IMMUNOL, V6, P355, DOI 10.1007/BF00915374; Tong CG, 2014, INT J CLIN EXP PATHO, V7, P3166; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Trolle T, 2016, J IMMUNOL, V196, P1480, DOI 10.4049/jimmunol.1501721; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; van der Lee DI, 2019, J CLIN INVEST, V129, P774, DOI 10.1172/JCI97482; van Eijk R, 2013, EXP MOL PATHOL, V94, P121, DOI 10.1016/j.yexmp.2012.06.004; van Gool IC, 2015, CLIN CANCER RES, V21, P3347, DOI 10.1158/1078-0432.CCR-15-0057; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; van Sonderen A, 2017, ANN NEUROL, V81, P193, DOI 10.1002/ana.24858; Veatch JR, 2018, J CLIN INVEST, V128, P1563, DOI 10.1172/JCI98689; Verdegaal EME, 2016, NATURE, V536, P91, DOI 10.1038/nature18945; Wang L, 2003, CANCER RES, V63, P5209; Wang QJ, 2016, CANCER IMMUNOL RES, V4, P204, DOI 10.1158/2326-6066.CIR-15-0188; Wick DA, 2014, CLIN CANCER RES, V20, P1125, DOI 10.1158/1078-0432.CCR-13-2147; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; Yarchoan M, 2017, NAT REV CANCER, V17, P209, DOI 10.1038/nrc.2016.154; Yu RC, 1996, BRIT J DERMATOL, V135, P36; Zeng KX, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1185582	104	2	3	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 10	2020	10								3045	10.3389/fimmu.2019.03045	http://dx.doi.org/10.3389/fimmu.2019.03045			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	KF5FW	31998317	Green Published, gold			2022-12-18	WOS:000509268700001
J	Sindura, KP; Banerjee, M				Sindura, K. P.; Banerjee, Moinak			An Immunological Perspective to Non-syndromic Sensorineural Hearing Loss	FRONTIERS IN IMMUNOLOGY			English	Article						Non-Syndromic Hearing Loss; congenital; immune system; pathogen; immunogenetics; inner ear; environmental factors; host response	HEAT-SHOCK PROTEINS; 26 GENE GJB2; CYTOMEGALOVIRUS-INFECTION; CYTOKINE PRODUCTION; MUTATIONS; POLYMORPHISMS; INDUCTION; INSIGHTS; RUBELLA; INNATE	Conventionally the etiology of congenital Non-Syndromic Hearing Loss has been attributed to mutations in the genes involved in ion homeostasis or the structural compartments of the inner ear. However, this contributes to only a part of the problem, as still the determinants for a large majority of the Non-Syndromic Hearing loss seems to be an enigma. Evidences indicate that pathogens like Rubella, Cytomegalovirus, and many other infections can also result in congenital hearing loss. Additionally, there are variety of factors other than the viral mediators, that can act as stressors to trigger an altered immune response, during the gestational period of the mother. It is also known that non-specific stimulation of the immune system can mimic an infection status. This indicates a strong role for environmental factors toward their contribution to the pathology, possibly by influencing the host immune response. These varieties of known or unknown environmental factors interact with the susceptible variants in immune response genes in defining the threshold for protection or infection in an individual. Considering this background we propose to present this perspective that threshold of the host immune response during the prenatal conditions, in response to environmental stimulus, might be determined by the susceptible variants in immune response genes. This in turn can directly or indirectly influence the genes involved in maintaining the structural components or ion homeostasis, resulting in hearing loss. The threshold of immune response alterations may be heavily dependent on the immunogenetic profile of the mother or the fetus.	[Sindura, K. P.; Banerjee, Moinak] Rajiv Gandhi Ctr Biotechnol, Neurobiol & Genet Div, Thiruvananthapuram, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Banerjee, M (corresponding author), Rajiv Gandhi Ctr Biotechnol, Neurobiol & Genet Div, Thiruvananthapuram, Kerala, India.	moinak@gmail.com	Banerjee, Moinak/X-4471-2018	Banerjee, Moinak/0000-0002-0842-0398; , K P SINDURA/0000-0002-2462-1907	DBT	DBT(Department of Biotechnology (DBT) India)	KS thanks DBT for providing the fellowship.	Abe S, 2000, J MED GENET, V37, P41, DOI 10.1136/jmg.37.1.41; Adams JC, 2002, OTOL NEUROTOL, V23, P316, DOI 10.1097/00129492-200205000-00015; Azaiez H, 2018, AM J HUM GENET, V103, P484, DOI 10.1016/j.ajhg.2018.08.006; Bautista LE, 2005, J HUM HYPERTENS, V19, P149, DOI 10.1038/sj.jhh.1001785; Boppana SB, 2013, CLIN INFECT DIS, V57, pS178, DOI 10.1093/cid/cit629; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chien CY, 2012, AUDIOL NEURO-OTOL, V17, P381, DOI 10.1159/000341815; Choi HS, 2016, EUR ARCH OTO-RHINO-L, V273, P1123, DOI 10.1007/s00405-015-3661-2; CORZO D, 1994, J CLIN PSYCHIAT, V55, P149; Dai P, 2007, GENET MED, V9, P283, DOI 10.1097/GIM.0b013e31804d2371; De Jager PL, 2015, SEMIN IMMUNOL, V27, P51, DOI 10.1016/j.smim.2015.03.003; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; Festuccia N, 2012, CELL STEM CELL, V11, P477, DOI 10.1016/j.stem.2012.08.002; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Fujioka M, 2006, J NEUROSCI RES, V83, P575, DOI 10.1002/jnr.20764; Gao X, 2018, J MED GENET, V55, P298, DOI 10.1136/jmedgenet-2017-104954; Gloddek B, 2002, AUDIOL NEURO-OTOL, V7, P317, DOI 10.1159/000066158; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; Hwa HL, 2003, GENET MED, V5, P161, DOI 10.1097/01.GIM.0000066796.11916.94; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Kasztelewicz B, 2017, EUR J CLIN MICROBIOL, V36, P1811, DOI 10.1007/s10096-017-2996-6; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kennedy RB, 2014, HUM GENET, V133, P1407, DOI 10.1007/s00439-014-1471-z; Kim HJ, 2011, CELL RES, V21, P944, DOI 10.1038/cr.2011.27; Konings A, 2009, EUR J HUM GENET, V17, P329, DOI 10.1038/ejhg.2008.172; Korver AMH, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2016.94; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lee MN, 2014, SCIENCE, V343, P1119, DOI 10.1126/science.1246980; Leichtle A, 2009, INNATE IMMUN-LONDON, V15, P205, DOI 10.1177/1753425909103170; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li Y, 2016, CELL, V167, P1099, DOI 10.1016/j.cell.2016.10.017; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Longo DM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-113; Longo DM, 2012, J IMMUNOL, V188, P1717, DOI 10.4049/jimmunol.1102514; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mehl AL, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e7; Moore JK, 2007, INT J AUDIOL, V46, P460, DOI 10.1080/14992020701383019; Morell RJ, 1998, NEW ENGL J MED, V339, P1500, DOI 10.1056/NEJM199811193392103; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Nolan LS, 2013, NEUROBIOL AGING, V34, DOI 10.1016/j.neurobiolaging.2013.02.009; Okano T, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00205; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; RASKANDERSEN H, 1979, ORL J OTO-RHINO-LARY, V41, P177, DOI 10.1159/000275458; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; Sathyan S, 2017, NEUROBIOL AGING, V58, DOI 10.1016/j.neurobiolaging.2017.06.006; Sathyan S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0354-0; Scott GM, 2012, J INFECT DIS, V205, P1305, DOI 10.1093/infdis/jis186; Shi X, 2017, AM J TRANSL RES, V9, P5611; Smith RJH, 2005, LANCET, V365, P879, DOI 10.1016/S0140-6736(05)71047-3; Srinivas L, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0569-8; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Taniguchi R, 2013, INT J INFECT DIS, V17, pE1092, DOI 10.1016/j.ijid.2013.06.004; TAPPIA PS, 1995, CLIN SCI, V88, P485, DOI 10.1042/cs0880485; THOMAS HIJ, 1992, J MED VIROL, V36, P188, DOI 10.1002/jmv.1890360308; Traherne JA, 2008, INT J IMMUNOGENET, V35, P179, DOI 10.1111/j.1744-313X.2008.00765.x; Travers P, 2001, GARLAND SCI; Tsinaslanidou Z, 2016, AUDIOLOGY NEUROTOL E, V6, P9, DOI 10.1159/000442016; Uchida Y, 2014, IMMUN AGEING, V11, DOI 10.1186/s12979-014-0018-4; Van Dyke AL, 2009, CYTOKINE, V46, P236, DOI 10.1016/j.cyto.2009.02.003; van Well GTJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035837; Vogel Megan E, 2016, Inflamm Cell Signal, V3; Wilson BS, 2017, LANCET, V390, P2503, DOI 10.1016/S0140-6736(17)31073-5; Zhao BY, 1998, J NEUROSCI RES, V52, P7, DOI 10.1002/(SICI)1097-4547(19980401)52:1<7::AID-JNR2>3.0.CO;2-I; Ziemka-Nalecz M, 2017, J NEUROPATH EXP NEUR, V76, P644, DOI 10.1093/jnen/nlx046	67	2	3	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 11	2019	10								2848	10.3389/fimmu.2019.02848	http://dx.doi.org/10.3389/fimmu.2019.02848			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JY2CR	31921123	gold, Green Published			2022-12-18	WOS:000504228900001
J	Srivastava, RM; Marincola, FM; Shanker, A				Srivastava, Raghvendra M.; Marincola, Francesco M.; Shanker, Anil			Editorial: Lymphocyte Functional Crosstalk and Regulation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immune crosstalk; lymphocytes; T-cells; NK cells; dendritic cells; immunotherapy; cancer; infections	NATURAL-KILLER; DENDRITIC CELLS; T-CELLS; NK CELLS; TUMOR; CD4(+); RECEPTOR		[Srivastava, Raghvendra M.] Mem Sloan Kettering Canc Ctr, Immunogenom & Precis Oncol Platform, 1275 York Ave, New York, NY 10021 USA; [Marincola, Francesco M.] Refuge Biotechnol Inc, Menlo Pk, CA USA; [Shanker, Anil] Meharry Med Coll, Sch Med, Dept Biochem Canc Biol Neurosci & Pharmacol, Nashville, TN 37208 USA; [Shanker, Anil] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Host Tumor Interact Res Program, Nashville, TN 37212 USA; [Shanker, Anil] Vanderbilt Univ, Sch Med, Vanderbilt Ctr Immunobiol, Nashville, TN 37212 USA; [Shanker, Anil] Vanderbilt Univ, Sch Med, Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN 37212 USA	Memorial Sloan Kettering Cancer Center; Meharry Medical College; Vanderbilt University; Vanderbilt University; Vanderbilt University	Shanker, A (corresponding author), Meharry Med Coll, Sch Med, Dept Biochem Canc Biol Neurosci & Pharmacol, Nashville, TN 37208 USA.; Shanker, A (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Host Tumor Interact Res Program, Nashville, TN 37212 USA.; Shanker, A (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ctr Immunobiol, Nashville, TN 37212 USA.; Shanker, A (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Inst Infect Immunol & Inflammat, Nashville, TN 37212 USA.	ashanker@mmc.edu			NIH [SC1CA182843, U54 CA163069]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by funds to AS by the following NIH grants: SC1CA182843 and U54 CA163069. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. There was no role of the funding bodies in the design or writing of the manuscript. No writing assistance was utilized in the production of this manuscript.	Arina A, 2007, INT J CANCER, V121, P1282, DOI 10.1002/ijc.22795; Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Hivroz C, 2012, CRIT REV IMMUNOL, V32, P139, DOI 10.1615/CritRevImmunol.v32.i2.30; Kabingu E, 2007, BRIT J CANCER, V96, P1839, DOI 10.1038/sj.bjc.6603792; Kamada T, 2019, P NATL ACAD SCI USA, V116, P9999, DOI 10.1073/pnas.1822001116; Krebs P, 2009, BLOOD, V113, P6593, DOI 10.1182/blood-2009-01-201467; Lee SH, 2009, J EXP MED, V206, P2235, DOI 10.1084/jem.20082387; Lo Russo G, 2019, CLIN CANCER RES, V25, P989, DOI 10.1158/1078-0432.CCR-18-1390; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4; Nakayama M, 2011, P NATL ACAD SCI USA, V108, P18360, DOI 10.1073/pnas.1110584108; Pallet N, 2018, INT REV CEL MOL BIO, V341, P169, DOI 10.1016/bs.ircmb.2018.05.009; Pallmer K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00251; Pfirschke C, 2017, CANCER CELL, V31, P614, DOI 10.1016/j.ccell.2017.04.007; Rieckmann JC, 2017, NAT IMMUNOL, V18, P583, DOI 10.1038/ni.3693; Sabio E, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0661-7; Schietinger A, 2010, J EXP MED, V207, P2469, DOI 10.1084/jem.20092450; Schuster IS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00235; Sconocchia G, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.952197; Seliger B, 2008, TRENDS MOL MED, V14, P550, DOI 10.1016/j.molmed.2008.09.010; Shanker A, 2007, J IMMUNOL, V179, P6651, DOI 10.4049/jimmunol.179.10.6651; Shanker A, 2011, CANCER IMMUNOL IMMUN, V60, P1061, DOI 10.1007/s00262-011-1053-z; Shanker A, 2010, IMMUNOLOGY, V129, P41, DOI 10.1111/j.1365-2567.2009.03150.x; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Srivastava RM, 2013, CLIN CANCER RES, V19, P1858, DOI 10.1158/1078-0432.CCR-12-2426; Tchekneva EE, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0566-4; Waggoner SN, 2012, NATURE, V481, P394, DOI 10.1038/nature10624; Zhao ZB, 2020, CELL MOL IMMUNOL, V17, P178, DOI 10.1038/s41423-019-0199-z	30	2	2	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 10	2019	10								2916	10.3389/fimmu.2019.02916	http://dx.doi.org/10.3389/fimmu.2019.02916			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JY4XS	31921175	Green Published, gold			2022-12-18	WOS:000504420600001
J	Bari, R; Granzin, M; Tsang, KS; Roy, A; Krueger, W; Orentas, R; Schneider, D; Pfeifer, R; Moeker, N; Verhoeyen, E; Dropulic, B; Leung, W				Bari, Rafijul; Granzin, Markus; Tsang, Kam Sze; Roy, Andre; Krueger, Winfried; Orentas, Rimas; Schneider, Dina; Pfeifer, Rita; Moeker, Nina; Verhoeyen, Els; Dropulic, Boro; Leung, Wing			A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy (vol 10, 2001, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						natural killer cells; transduction; baboon envelope; lentivirus; NK cell proliferation; CAR; CX3CR1			[Bari, Rafijul; Roy, Andre; Krueger, Winfried; Orentas, Rimas; Schneider, Dina; Dropulic, Boro] Miltenyi Biotec Co, Lentigen, Gaithersburg, MD 20878 USA; [Granzin, Markus; Tsang, Kam Sze; Leung, Wing] Miltenyi Biotec Inc, Gaithersburg, MD USA; [Pfeifer, Rita; Moeker, Nina] Miltenyi Biotec, Bergisch Gladbach, Germany; [Verhoeyen, Els] Univ Lyon 1, INSERM, CNRS, ENS Lyon,CIRI,U1111,UMR 5308, Lyon, France; [Verhoeyen, Els] Univ Cote Azur, INSERM, U1065, C3M, Nice, France; [Orentas, Rimas] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Orentas, Rimas] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA USA	Miltenyi Biotec; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Bari, R (corresponding author), Miltenyi Biotec Co, Lentigen, Gaithersburg, MD 20878 USA.	rafijul.bari@lentigen.com	Verhoeyen, Els/AAW-4853-2021	Verhoeyen, Els/0000-0001-9224-5491				Bari R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02001; Colamartino ABL, 2019, BIORXIV, DOI [10.1101/625285, DOI 10.1101/625285]	2	2	2	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 4	2019	10								2784	10.3389/fimmu.2019.02784	http://dx.doi.org/10.3389/fimmu.2019.02784			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW8BS	31839796	Green Published, gold			2022-12-18	WOS:000503272800001
J	Coulthard, LG; Woodruff, TM				Coulthard, Liam G.; Woodruff, Trent M.			Commentary: Beyond C4: Analysis of the complement gene pathway shows enrichment for IQ in patients with psychotic disorders and healthy controls	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						complement; immunological terms; neurodevelopment; neuroimmunology; C5aR; synaptic pruning; SERPING1; schizophrenia	EXPRESSION; SYSTEM; PROLIFERATION; CASCADE		[Coulthard, Liam G.] Royal Brisbane & Womens Hosp, Kenneth G Jamieson Dept Neurosurg, Brisbane, Qld, Australia; [Coulthard, Liam G.; Woodruff, Trent M.] Univ Queensland, Fac Med, St Lucia, Qld, Australia	Royal Brisbane & Women's Hospital; University of Queensland	Coulthard, LG (corresponding author), Royal Brisbane & Womens Hosp, Kenneth G Jamieson Dept Neurosurg, Brisbane, Qld, Australia.; Coulthard, LG (corresponding author), Univ Queensland, Fac Med, St Lucia, Qld, Australia.	l.coulthard@uq.edu.au	Woodruff, Trent M/B-4861-2009; Woodruff, Trent/AAS-4629-2020; Coulthard, Liam/I-1980-2016	Woodruff, Trent M/0000-0003-1382-911X; Woodruff, Trent/0000-0003-1382-911X; Coulthard, Liam/0000-0003-3604-901X				Allswede DM, 2018, NEUROPSYCHOPHARMACOL, V43, P525, DOI 10.1038/npp.2017.164; Callezi C, 2000, PHARMACOL REV, V52, P91; Coulthard LG, 2018, MOL IMMUNOL, V101, P176, DOI 10.1016/j.molimm.2018.06.271; Coulthard LG, 2018, TRENDS NEUROSCI, V41, P373, DOI 10.1016/j.tins.2018.03.009; Coulthard LG, 2017, J NEUROSCI, V37, P5395, DOI 10.1523/JNEUROSCI.0525-17.2017; Denny KJ, 2013, J IMMUNOL, V190, P3493, DOI 10.4049/jimmunol.1203072; Gorelik A, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00169; Gorelik A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15096; Hawksworth OA, 2018, SEMIN IMMUNOL, V37, P74, DOI 10.1016/j.smim.2018.02.009; Hawksworth OA, 2017, MOL IMMUNOL, V84, P17, DOI 10.1016/j.molimm.2016.11.010; Holland JF, 2019, GENES BRAIN BEHAV, V18, DOI 10.1111/gbb.12602; Jeanes A, 2015, MOL IMMUNOL, V68, P253, DOI 10.1016/j.molimm.2015.09.004; Kimura A, 2009, IMMUNOBIOLOGY, V214, P165, DOI 10.1016/j.imbio.2009.01.003; Mclin VA, 2008, INT J DEV BIOL, V52, P1123, DOI 10.1387/ijdb.072465v; Nesargikar PN, 2012, EUR J MICROBIOL IMMU, V2, P103, DOI 10.1556/EuJMI.2.2012.2.2; Sekar A, 2016, NATURE, V530, P177, DOI 10.1038/nature16549; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036	18	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 4	2019	10								2853	10.3389/fimmu.2019.02853	http://dx.doi.org/10.3389/fimmu.2019.02853			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW8BV	31867012	gold, Green Published			2022-12-18	WOS:000503273100001
J	Hollmen, M; Zheng, W; Pollard, JW				Hollmen, Maija; Zheng, Wei; Pollard, Jeffrey W.			Editorial: Targeting Myeloid Cells to Fight Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tumor microenvironment; monocyte; macrophage; neutrophil; immunosuppression; immunotherapy			[Hollmen, Maija] Univ Turku, MediCity Res Lab, Turku, Finland; [Zheng, Wei] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Pollard, Jeffrey W.] Univ Edinburgh, MRC Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland; [Pollard, Jeffrey W.] Albert Einstein Coll Med, Dept Dev & Mol Biol, New York, NY USA	University of Turku; Icahn School of Medicine at Mount Sinai; University of Edinburgh; Yeshiva University	Hollmen, M (corresponding author), Univ Turku, MediCity Res Lab, Turku, Finland.	maijal@utu.fi	Hollmén, Maija/B-5831-2017	Hollmén, Maija/0000-0002-3250-7653	MRC [MR/N022556/1] Funding Source: UKRI; Medical Research Council [G1002033, MR/N022556/1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))			0	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 3	2019	10								2835	10.3389/fimmu.2019.02835	http://dx.doi.org/10.3389/fimmu.2019.02835			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW4RX	31849994	Green Published, gold			2022-12-18	WOS:000503041600001
J	Rougeot, J; Torraca, V; Zakrzewska, A; Kanwal, Z; Jansen, HJ; Sommer, F; Spaink, HP; Meijer, AH				Rougeot, Julien; Torraca, Vincenzo; Zakrzewska, Ania; Kanwal, Zakia; Jansen, Hans J.; Sommer, Frida; Spaink, Herman P.; Meijer, Annemarie H.			RNAseq Profiling of Leukocyte Populations in Zebrafish Larvae Reveals a cxcl11 Chemokine Gene as a Marker of Macrophage Polarization During Mycobacterial Infection (vol 10, 832, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						innate immunity; zebrafish; RNAseq; macrophage; mycobacteria; neutrophil; lymphoid progenitor cells			[Rougeot, Julien; Torraca, Vincenzo; Zakrzewska, Ania; Kanwal, Zakia; Sommer, Frida; Spaink, Herman P.; Meijer, Annemarie H.] Leiden Univ, Inst Biol Leiden, Leiden, Netherlands; [Jansen, Hans J.] ZF Screens BV, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Meijer, AH (corresponding author), Leiden Univ, Inst Biol Leiden, Leiden, Netherlands.	a.h.meijer@biology.leidenuniv.nl	K, Z/AAB-4868-2020; Rougeot, Julien/GQI-4130-2022	K, Z/0000-0002-0539-3056; Jansen, Hans/0000-0002-8563-4146				Rougeot J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00832	1	2	3	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 2	2019	10								2720	10.3389/fimmu.2019.02720	http://dx.doi.org/10.3389/fimmu.2019.02720			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW7RG	31832066	gold, Green Published, Green Accepted			2022-12-18	WOS:000503244800001
J	Barrera, E; Chirdo, F; Pantano, S				Barrera, Exequiel; Chirdo, Fernando; Pantano, Sergio			Commentary: p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1-Dependent Mucosal Damage in Small Intestine	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						coarse grained (CG); simulations; celiac disease; p31-43; gliadin peptides; sirah force field			[Barrera, Exequiel; Pantano, Sergio] Inst Pasteur Montevideo, Biomol Simulat Grp, Montevideo, Uruguay; [Chirdo, Fernando] UNLP, CONICET, Inst Estudios Inmunol & Fisiopatol, La Plata, Buenos Aires, Argentina	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur de Montevideo; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata	Pantano, S (corresponding author), Inst Pasteur Montevideo, Biomol Simulat Grp, Montevideo, Uruguay.	spantano@pasteur.edu.uy	Chirdo, Fernando/AAL-7928-2020	Chirdo, Fernando/0000-0002-7099-9142; Pantano, Sergio/0000-0001-6435-4543				Calvanese L, 2019, J PEPT SCI, V25, DOI 10.1002/psc.3161; Castro MFG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00031; Lania G, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0443-1; Machado MR, 2019, J CHEM THEORY COMPUT, V15, P2719, DOI 10.1021/acs.jctc.9b00006	4	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2019	10								2792	10.3389/fimmu.2019.02792	http://dx.doi.org/10.3389/fimmu.2019.02792			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JW0VH	31849971	Green Published, gold			2022-12-18	WOS:000502777300001
J	Gupta, P; Yadav, RP; Baranwal, S				Gupta, Pooja; Yadav, Ravi Prakash; Baranwal, Somesh			Commentary: MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						non-coding RNA; microspheres; Hippo signaling; Wnt; b-signaling; experimental colitis			[Gupta, Pooja] Guru Kashi Univ, Coll Agr, Talwandi Sabo, India; [Yadav, Ravi Prakash; Baranwal, Somesh] Cent Univ Punjab, Sch Basic & Appl Sci, Dept Biochem & Microbial Sci, Bathinda, India	Guru Kashi University; Central University of Punjab	Gupta, P (corresponding author), Guru Kashi Univ, Coll Agr, Talwandi Sabo, India.; Baranwal, S (corresponding author), Cent Univ Punjab, Sch Basic & Appl Sci, Dept Biochem & Microbial Sci, Bathinda, India.	drpoojabaranwal@gmail.com; somesh.baranwal@cup.edu.i		Yadav, Ravi Prakash/0000-0001-9112-986X	DBT Ramalingaswami Fellowship [BT/HRD/02/09/2013]; DST-SERB grant [ECR/2016/000903]; UGC startup grant; Research Seed Money grant from the Central University of Punjab, Bathinda [GP-25]	DBT Ramalingaswami Fellowship; DST-SERB grant; UGC startup grant; Research Seed Money grant from the Central University of Punjab, Bathinda	Research in the SB lab was supported by a DBT Ramalingaswami Fellowship grant (BT/HRD/02/09/2013), DST-SERB (ECR/2016/000903) grant, UGC startup grant, and Research Seed Money (GP-25) grant from the Central University of Punjab, Bathinda.	Chen XD, 2014, BIOMACROMOLECULES, V15, P2166, DOI 10.1021/bm500327m; Li YA, 2017, NANOSCALE, V9, P9317, DOI 10.1039/c7nr00598a; Peng H, 2012, P NATL ACAD SCI USA, V109, P14030, DOI 10.1073/pnas.1111292109; Soroosh A, 2018, AM J PHYSIOL-GASTR L, V314, pG256, DOI 10.1152/ajpgi.00268.2017; Tian YH, 2019, GASTROENTEROLOGY, V156, P2281, DOI 10.1053/j.gastro.2019.02.023; Tian YH, 2017, ELIFE, V6, DOI 10.7554/eLife.29538.001; Yan HJ, 2015, MED SCI MONITOR, V21, P722, DOI 10.12659/MSM.893213; Yu T, 2018, BIOMED PHARMACOTHER, V108, P1162, DOI 10.1016/j.biopha.2018.09.132; Zhang YY, 2010, MED ONCOL, V27, P685, DOI 10.1007/s12032-009-9269-x	9	2	2	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2019	10								2649	10.3389/fimmu.2019.02649	http://dx.doi.org/10.3389/fimmu.2019.02649			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JU6KJ	31849927	Green Published, gold			2022-12-18	WOS:000501783100001
J	Perez, MAS; Bassani-Sternberg, M; Coukos, G; Gfeller, D; Zoete, V				Perez, Marta A. S.; Bassani-Sternberg, Michal; Coukos, George; Gfeller, David; Zoete, Vincent			Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands	FRONTIERS IN IMMUNOLOGY			English	Article						human leukocyte antigen; HLA-I ligand presentation; computational immunology; 3D structure; heuristic search; HLA-I motif-like peptides	MHC CLASS-I; SIGNAL PEPTIDE PEPTIDASE; MASS-SPECTROMETRY; PROTEIN; BINDING; IDENTIFICATION; PREDICTION; PROTEASOME; REVEALS; DEGRADATION	Recent clinical developments in antitumor immunotherapy involving T-cell related therapeutics have led to a renewed interest for human leukocyte antigen class I (HLA-I) binding peptides, given their potential use as peptide vaccines. Databases of HLA-I binding peptides hold therefore information on therapeutic targets essential for understanding immunity. In this work, we use in depth and accurate HLA-I peptidomics datasets determined by mass-spectrometry (MS) and analyze properties of the HLA-I binding peptides with structure-based computational approaches. HLA-I binding peptides are studied grouping all alleles together or in allotype-specific contexts. We capitalize on the increasing number of structurally determined proteins to (1) map the 3D structure of HLA-I binding peptides into the source proteins for analyzing their secondary structure and solvent accessibility in the protein context, and (2) search for potential differences between these properties in HLA-I binding peptides and in a reference dataset of HLA-I motif-like peptides. This is performed by an in-house developed heuristic search that considers peptides across all the human proteome and converges to a collection of peptides that exhibit exactly the same motif as the HLA-I peptides. Our results, based on 9-mers matched to protein 3D structures, clearly show enriched sampling for HLA-I presentation of helical fragments in the source proteins. This enrichment is significant, as compared to 9-mer HLA-I motif-like peptides, and is not entirely explained by the helical propensity of the preferred residues in the HLA-I motifs. We give possible hypothesis for the secondary structure biases observed in HLA-I peptides. This contribution is of potential interest for researchers working in the field of antigen presentation and proteolysis. This knowledge refines the understanding of the rules governing antigen presentation and could be added to the parameters of the current peptide-MHC class I binding predictors to increase their antigen predictive ability.	[Perez, Marta A. S.; Zoete, Vincent] Univ Lausanne, Ludwig Inst Canc Res, Dept Oncol, Comp Aided Mol Engn, Lausanne, Switzerland; [Perez, Marta A. S.; Gfeller, David; Zoete, Vincent] Swiss Inst Bioinformat, Lausanne, Switzerland; [Bassani-Sternberg, Michal; Coukos, George] Univ Lausanne Hosp, Ludwig Inst Canc Res, Dept Oncol, Human Integrated Tumor Immunol Discovery Engine, Lausanne, Switzerland; [Gfeller, David] Univ Lausanne, Ludwig Inst Canc Res, Dept Oncol, Computat Canc Biol, Lausanne, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; Swiss Institute of Bioinformatics; Ludwig Institute for Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Ludwig Institute for Cancer Research; University of Lausanne	Zoete, V (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Dept Oncol, Comp Aided Mol Engn, Lausanne, Switzerland.; Zoete, V (corresponding author), Swiss Inst Bioinformat, Lausanne, Switzerland.	vincent.zoete@unil.ch	Bassani-Sternberg, Michal/AAQ-3413-2020; Coukos, George/ABG-7389-2020; /E-4960-2015	Bassani-Sternberg, Michal/0000-0002-1934-954X; /0000-0002-3963-5965	University of Lausanne, Department of Fundamental Oncology; Ludwig Institute for Cancer Research	University of Lausanne, Department of Fundamental Oncology; Ludwig Institute for Cancer Research	This work was supported by University of Lausanne, Department of Fundamental Oncology and the Ludwig Institute for Cancer Research.	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Admon A, 2019, HUM IMMUNOL, V80, P296, DOI 10.1016/j.humimm.2019.03.004; Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Andreatta M, 2017, NUCLEIC ACIDS RES, V45, pW458, DOI 10.1093/nar/gkx248; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Bakker AH, 2008, P NATL ACAD SCI USA, V105, P3825, DOI 10.1073/pnas.0709717105; Bassani-Sternberet M, 2016, J IMMUNOL, V197, P2492, DOI 10.4049/jimmunol.1600808; Bassani-Sternberg M, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005725; Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404; Bassani-Sternberg M, 2016, CURR OPIN IMMUNOL, V41, P9, DOI 10.1016/j.coi.2016.04.005; Bassani-Sternberg M, 2015, MOL CELL PROTEOMICS, V14, P658, DOI 10.1074/mcp.M114.042812; Bassani-Sternberg M, 2010, P NATL ACAD SCI USA, V107, P18769, DOI 10.1073/pnas.1008501107; Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049; Bendell CJ, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-82; Berlin C, 2015, LEUKEMIA, V29, P647, DOI 10.1038/leu.2014.233; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhasin M, 2004, PROTEIN SCI, V13, P596, DOI 10.1110/ps.03373104; Bianchi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01118; Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910; Brouwenstijn N, 2001, IMMUNITY, V15, P95, DOI 10.1016/S1074-7613(01)00174-1; Caron E, 2015, MOL CELL PROTEOMICS, V14, P3105, DOI [10.1074/mcp.O115.052431, 10.1074/mcp.M115.052431]; Chang LF, 2015, NATURE, V522, P450, DOI 10.1038/nature14471; Chapman DC, 2010, SEMIN CELL DEV BIOL, V21, P512, DOI 10.1016/j.semcdb.2009.12.013; Chong C, 2018, MOL CELL PROTEOMICS, V17, P533, DOI 10.1074/mcp.TIR117.000383; Christianson JC, 2012, NAT CELL BIOL, V14, P93, DOI 10.1038/ncb2383; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Dargel C, 2015, GASTROENTEROLOGY, V149, P1042, DOI 10.1053/j.gastro.2015.05.055; Dong YC, 2019, NATURE, V565, P49, DOI 10.1038/s41586-018-0736-4; Drozdetskiy A, 2015, NUCLEIC ACIDS RES, V43, pW389, DOI 10.1093/nar/gkv332; Dutoit V, 2012, BRAIN, V135, P1042, DOI 10.1093/brain/aws042; Fruci D, 2001, IMMUNITY, V15, P467, DOI 10.1016/S1074-7613(01)00203-5; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gfeller D, 2018, J IMMUNOL, V201, P3705, DOI 10.4049/jimmunol.1800914; Gfeller D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01716; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Guillaume P, 2018, P NATL ACAD SCI USA, V115, P5083, DOI 10.1073/pnas.1717277115; Hassan C, 2015, J BIOL CHEM, V290, P2593, DOI 10.1074/jbc.M114.607028; Jarmalavicius S, 2012, J BIOL CHEM, V287, P33401, DOI 10.1074/jbc.M112.358903; Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kazanov MD, 2011, J PROTEOME RES, V10, P3642, DOI 10.1021/pr200271w; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Koumantou D, 2019, CANCER IMMUNOL IMMUN, V68, P1245, DOI 10.1007/s00262-019-02358-0; Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424; Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Leone P, 2013, JNCI-J NATL CANCER I, V105, P1172, DOI 10.1093/jnci/djt184; Martin J, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-17; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Miles KM, 2011, MOL IMMUNOL, V48, P728, DOI 10.1016/j.molimm.2010.11.004; Milner E, 2013, MOL CELL PROTEOMICS, V12, P1853, DOI 10.1074/mcp.M112.026013; Mommen GPM, 2014, P NATL ACAD SCI USA, V111, P4507, DOI 10.1073/pnas.1321458111; Muller M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01367; MULLER KM, 1994, J BIOL CHEM, V269, P14032; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Oliveira CC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00298; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Parmentier N, 2010, NAT IMMUNOL, V11, P449, DOI 10.1038/ni.1862; Pearson H, 2016, J CLIN INVEST, V126, P4690, DOI 10.1172/JCI88590; Perdigao N, 2015, P NATL ACAD SCI USA, V112, P15898, DOI 10.1073/pnas.1508380112; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pritchard Antonia L, 2015, Pigment Cell Melanoma Res, V28, P281, DOI 10.1111/pcmr.12357; Pymm P, 2017, NAT STRUCT MOL BIOL, V24, P387, DOI 10.1038/nsmb.3381; Rasmussen M, 2014, J IMMUNOL, V193, P4790, DOI 10.4049/jimmunol.1401689; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Rose PW, 2017, NUCLEIC ACIDS RES, V45, pD271, DOI 10.1093/nar/gkw1000; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Sidney J., 2013, CURR PROTOC IMMUNOL, V18, P1; Singh-Jasuja H, 2004, CANCER IMMUNOL IMMUN, V53, P187, DOI 10.1007/s00262-003-0480-x; Tey SK, 2012, BLOOD, V120, P994, DOI 10.1182/blood-2012-01-402404; Trolle T, 2016, J IMMUNOL, V196, P1480, DOI 10.4049/jimmunol.1501721; Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938; Vyas JM, 2008, NAT REV IMMUNOL, V8, P607, DOI 10.1038/nri2368; Walz S, 2015, BLOOD, V126, P1203, DOI 10.1182/blood-2015-04-640532; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Weinschenk T, 2002, CANCER RES, V62, P5818; Wulf M, 2009, METHODS MOL BIOL, V524, P361, DOI 10.1007/978-1-59745-450-6_26	78	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2019	10								2731	10.3389/fimmu.2019.02731	http://dx.doi.org/10.3389/fimmu.2019.02731			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OM4NS	31824508	gold, Green Published			2022-12-18	WOS:000586004000001
J	Russlies, J; Fahnrich, A; Witte, M; Yin, JP; Benoit, S; Glaser, R; Gunter, C; Eming, R; Erdmann, J; Gola, D; Gupta, Y; Holtsche, MM; Kern, JS; Konig, IR; Kiritsi, D; Lieb, W; Sadik, CD; Sardy, M; Schauer, F; van Beek, N; Weidinger, A; Worm, M; Zillikens, D; Schmidt, E; Busch, H; Ibrahim, SM; Hirose, M				Russlies, Juliane; Faehnrich, Anke; Witte, Mareike; Yin, Junping; Benoit, Sandrine; Glaeser, Regine; Guenter, Claudia; Eming, Ruediger; Erdmann, Jeanette; Gola, Damian; Gupta, Yask; Holtsche, Maike Marleen; Kern, Johannes S.; Koenig, Inke R.; Kiritsi, Dimitra; Lieb, Wolfgang; Sadik, Christian D.; Sardy, Miklos; Schauer, Franziska; van Beek, Nina; Weidinger, Anke; Worm, Margitta; Zillikens, Detlef; Schmidt, Enno; Busch, Hauke; Ibrahim, Saleh M.; Hirose, Misa			Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans	FRONTIERS IN IMMUNOLOGY			English	Article						mitochondrial DNA; mitochondrial haplogroup; polymorphisms; autoimmune skin diseases; bullous pemphigoid; mitochondrial function; next generation sequencing	REGULATORY T-CELLS; PARKINSONS-DISEASE; MICROBIOTA; SEQUENCE; GENE; SUSCEPTIBILITY; ORGANIZATION; DIAGNOSIS; VARIANTS; RISK	Bullous pemphigoid (BP) is the most prevalent autoimmune skin blistering disease and is characterized by the generation of autoantibodies against the hemidesmosomal proteins BP180 (type XVII collagen) and BP230. Most intriguingly, BP is distinct from other autoimmune diseases because it predominantly affects elderly individuals above the age of 75 years, raising the question why autoantibodies and the clinical lesions of BP emerges mostly in this later stage of life, even in individuals harboring known putative BP-associated germline gene variants. The mitochondrial genome (mtDNA) is a potential candidate to provide additional insights into the BP etiology; however, the mtDNA has not been extensively explored to date. Therefore, we sequenced the whole mtDNA of German BP patients (n = 180) and age- and sex-matched healthy controls (n = 188) using next generation sequencing (NGS) technology, followed by the replication study using Sanger sequencing of an additional independent BP (n = 89) and control cohort (n = 104). While the BP and control groups showed comparable mitochondrial haplogroup distributions, the haplogroup T exhibited a tendency of higher frequency in BP patients suffering from neurodegenerative diseases (ND) compared to BP patients without ND (50%; 3 in 6 BP with haplogroup T). A total of four single nucleotide polymorphisms (SNPs) in the mtDNA, namely, m.16263T>C, m.16051A>G, and m.16162A>G in the D-loop region of the mtDNA, and m.11914G>A in the mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 gene (MT-ND4), were found to be significantly associated with BP based on the meta-analysis of our NGS data and the Sanger sequencing data (p = 0.0017, p = 0.0129, p = 0.0076, and p = 0.0132, respectively, Peto's test). More specifically, the three SNPs in the D-loop region were negatively, and the SNP in the MT-ND4 gene was positively associated with BP. Our study is the first to interrogate the whole mtDNA in BP patients and controls and to implicate multiple novel mtDNA variants in disease susceptibility. Studies using larger cohorts and more diverse populations are warranted to explore the functional consequences of the mtDNA variants identified in this study on immune and skin cells to understand their contributions to BP pathology.	[Russlies, Juliane; Faehnrich, Anke; Witte, Mareike; Gupta, Yask; Schmidt, Enno; Busch, Hauke; Ibrahim, Saleh M.; Hirose, Misa] Univ Lubeck, Luebeck Inst Expt Dermatol, Lubeck, Germany; [Faehnrich, Anke; Erdmann, Jeanette; Busch, Hauke] Univ Lubeck, Inst Cardiogenet, Lubeck, Germany; [Witte, Mareike; Holtsche, Maike Marleen; Sadik, Christian D.; van Beek, Nina; Zillikens, Detlef; Schmidt, Enno] Univ Lubeck, Dept Dermatol, Lubeck, Germany; [Yin, Junping] Leibniz Ctr Med & Biosci, Res Ctr Borstel, Borstel, Germany; [Benoit, Sandrine] Univ Hosp Wurzburg, Dept Dermatol Venereol & Allergol, Wurzburg, Germany; [Benoit, Sandrine; Glaeser, Regine; Guenter, Claudia; Eming, Ruediger; Kern, Johannes S.; Kiritsi, Dimitra; Sardy, Miklos; Schauer, Franziska; Weidinger, Anke; Worm, Margitta; Zillikens, Detlef; Schmidt, Enno; Ibrahim, Saleh M.] German Autoimmune Bullous Dis Genet Study Grp, Lubeck, Germany; [Glaeser, Regine; Weidinger, Anke] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergol, Kiel, Germany; [Guenter, Claudia] Univ Hosp Dresden, Dept Dermatol, Dresden, Germany; [Eming, Ruediger] Phillips Univ Marburg, Dept Dermatol & Allergol, Marburg, Germany; [Gola, Damian; Koenig, Inke R.] Univ Lubeck, Inst Med Biometry & Stat, Lubeck, Germany; [Kern, Johannes S.; Kiritsi, Dimitra; Schauer, Franziska] Univ Freiburg, Dept Dermatol, Fac Med, Med Ctr, Freiburg, Germany; [Kern, Johannes S.] Univ Melbourne, Royal Melbourne Hosp, Fac Med Dent & Hlth Sci, Dermatol Dept, Melbourne, Vic, Australia; [Lieb, Wolfgang] Christian Albrecht Univ Kiel, Inst Epidemiol, Kiel, Germany; [Lieb, Wolfgang] Christian Albrecht Univ Kiel, Popgen Biobank, Kiel, Germany; [Sardy, Miklos] Semmelweis Univ, Dept Dermatol Venereol & Dermatooncol, Budapest, Hungary; [Sardy, Miklos] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Dermatol & Allergy, Munich, Germany; [Worm, Margitta] Charite Med Univ Berlin, Dept Dermatol Venereol & Allergol, Allergy Ctr Charite, Berlin, Germany	University of Lubeck; University of Lubeck; University of Lubeck; Forschungszentrum Borstel; University of Wurzburg; University of Kiel; Schleswig Holstein University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Philipps University Marburg; University of Lubeck; University of Freiburg; Royal Melbourne Hospital; University of Melbourne; University of Kiel; University of Kiel; Semmelweis University; University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hirose, M (corresponding author), Univ Lubeck, Luebeck Inst Expt Dermatol, Lubeck, Germany.	misa.hirose@uksh.de	Erdmann, Jeanette/P-7513-2014; Ibrahim, Saleh/AAO-9541-2020; Hirose, Misa/A-2858-2014; van Beek, Nina/D-4121-2019; Lieb, Wolfgang/AAC-7650-2022; König, Inke R/A-4544-2009; Sadik, Christian David/G-9593-2014; Busch, Hauke/R-6452-2016	Erdmann, Jeanette/0000-0002-4486-6231; van Beek, Nina/0000-0002-3265-0011; König, Inke R/0000-0003-0504-6465; Sadik, Christian David/0000-0001-6701-048X; Schauer, Franziska/0000-0001-5147-0123; Busch, Hauke/0000-0003-4763-4521; Fahnrich, Anke/0000-0003-1904-9544; Sardy, Miklos/0000-0003-4306-5093; Ibrahim, Saleh/0000-0001-7827-2290; Worm, Margitta/0000-0002-3449-1245	high-performance computer cluster of the University of Lubeck OmicsCluster; Deutsche Forschungsgemeinschaft [EXC306, KFO303, EXC 22167-390884018]	high-performance computer cluster of the University of Lubeck OmicsCluster; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank everyone involved in the collection of blood samples, as well as all volunteers and patients, who donated blood for the study. We also thank Miriam Freitag, Paul Schilf, Christian Schwarm, and Stefanie Wichmann for advice and/or excellent technical assistance. AF and HB acknowledge support through the high-performance computer cluster of the University of Lubeck OmicsCluster. This work was supported by the Deutsche Forschungsgemeinschaft (EXC306, KFO303, MP-II, and EXC 22167-390884018).	ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Antiga E, 2014, J EUR ACAD DERMATOL, V28, P222, DOI 10.1111/jdv.12091; Arakawa M, 2011, EXP DERMATOL, V20, P1022, DOI 10.1111/j.1600-0625.2011.01378.x; Belkaid Y, 2014, SCIENCE, V346, P954, DOI 10.1126/science.1260144; Berod L, 2014, NAT MED, V20, P1327, DOI 10.1038/nm.3704; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Chang YT, 2006, BRIT J DERMATOL, V154, P79, DOI 10.1111/j.1365-2133.2005.06938.x; Claesson MJ, 2011, P NATL ACAD SCI USA, V108, P4586, DOI 10.1073/pnas.1000097107; De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532; Delgado JC, 1996, P NATL ACAD SCI USA, V93, P8569, DOI 10.1073/pnas.93.16.8569; Esmaili N, 2013, IRAN J IMMUNOL, V10, P1, DOI IJIv10i1A1; Fay MP, 2010, BIOSTATISTICS, V11, P373, DOI 10.1093/biostatistics/kxp050; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Freitag J, 2016, IMMUNOL CELL BIOL, V94, P925, DOI 10.1038/icb.2016.77; Gao XH, 2002, CLIN EXP DERMATOL, V27, P319, DOI 10.1046/j.1365-2230.2002.01037.x; Haeberle S, 2018, J ALLERGY CLIN IMMUN, V142, P1831, DOI 10.1016/j.jaci.2018.04.006; Hirose M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24290-6; Hirose M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15377-7; Hirose M, 2015, EXP DERMATOL, V24, P715, DOI 10.1111/exd.12732; HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.1093/biomet/75.2.383; Hudson G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004369; Hubner F, 2016, J INVEST DERMATOL, V136, P2495, DOI 10.1016/j.jid.2016.07.013; Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016; Ivanova R, 1998, GERONTOLOGY, V44, P349, DOI 10.1159/000022041; Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93; Ji FY, 2012, P NATL ACAD SCI USA, V109, P7391, DOI 10.1073/pnas.1202484109; Joly P, 2012, J INVEST DERMATOL, V132, P1998, DOI 10.1038/jid.2012.35; Kibsgaard L, 2017, BRIT J DERMATOL, V176, P1486, DOI 10.1111/bjd.15405; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; MA J, 2014, BMC GENOMICS, V15, DOI DOI 10.1186/1471-2164-15-25724694284; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mills EL, 2017, NAT IMMUNOL, V18, P488, DOI 10.1038/ni.3704; Miodovnik M, 2017, EXP DERMATOL, V26, P1221, DOI 10.1111/exd.13357; Nicholls TJ, 2014, EXP GERONTOL, V56, P175, DOI 10.1016/j.exger.2014.03.027; O'Toole PW, 2015, SCIENCE, V350, P1214, DOI 10.1126/science.aac8469; Okazaki A, 2000, J Dermatol, V27, P149; Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8; Saint-Georges-Chaumet Y, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftv096; Schmidt E, 2015, J DTSCH DERMATOL GES, V13, P713, DOI [10.1111/ddg.12612, 10.1111/ddg.40_12612]; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; SEIGNALET J, 1987, TISSUE ANTIGENS, V30, P190; Shen LS, 2018, HUM MUTAT, V39, P806, DOI 10.1002/humu.23422; Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Tranah GJ, 2012, J ALZHEIMERS DIS, V32, P357, DOI 10.3233/JAD-2012-120466; van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wallace DC, 2018, NAT GENET, V50, P1642, DOI 10.1038/s41588-018-0264-z; Wallace DC, 2015, CELL, V163, P33, DOI 10.1016/j.cell.2015.08.067; Wallace DC, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a021220; Weisenseel P, 2007, ARCH DERMATOL RES, V299, P163, DOI 10.1007/s00403-007-0755-8; Weissensteiner H, 2016, NUCLEIC ACIDS RES, V44, pW58, DOI 10.1093/nar/gkw233; Yardeni T, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw3159; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zakka LR, 2011, AUTOIMMUN REV, V11, P40, DOI 10.1016/j.autrev.2011.07.002	62	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2019	10								2200	10.3389/fimmu.2019.02200	http://dx.doi.org/10.3389/fimmu.2019.02200			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JT8QO	31824475	Green Published, gold			2022-12-18	WOS:000501248300001
J	Bernardini, G; Zabel, BA				Bernardini, Giovanni; Zabel, Brian A.			Editorial: The Role of Chemoattractants in the Tumor Microenvironment	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						chemokines; cancer therapy; cancer metastases; anti-tumor immune response; cancer inflammation; immune suppression; chemokine receptor antagonists			[Bernardini, Giovanni] Sapienza Univ Rome, Inst Pasteur Italia, Fdn Cenci Bolognetti, Dept Mol Med, Rome, Italy; [Zabel, Brian A.] VA Palo Alto Hlth Care Syst, Palo Alto Vet Inst Res, Palo Alto, CA USA	Fondazione Cenci Bolognetti; Sapienza University Rome; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Bernardini, G (corresponding author), Sapienza Univ Rome, Inst Pasteur Italia, Fdn Cenci Bolognetti, Dept Mol Med, Rome, Italy.; Zabel, BA (corresponding author), VA Palo Alto Hlth Care Syst, Palo Alto Vet Inst Res, Palo Alto, CA USA.	giovanni.bernardini@uniroma1.it; bazabel@stanford.edu	Bernardini, Giovanni/GRJ-0070-2022	BERNARDINI, Giovanni/0000-0002-3705-2598					0	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2019	10								2671	10.3389/fimmu.2019.02671	http://dx.doi.org/10.3389/fimmu.2019.02671			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JQ8AS	31781129	Green Published, gold			2022-12-18	WOS:000499162000001
J	Tagliabue, A; Leite, LCC; Leroy, OY; Rappuoli, R				Tagliabue, Aldo; Leite, Luciana C. C.; Leroy, Odile Y.; Rappuoli, Rino			Editorial: A Global Perspective on Vaccines: Priorities, Challenges and Online Information	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccines; antimicrobial resistance; vaccine hesitancy; vaccine education; technological platforms			[Tagliabue, Aldo] CNR, Inst Genet & Biomed Res, Monserrato, Italy; [Leite, Luciana C. C.] Inst Butantan, Sao Paulo, SP, Brazil; [Leroy, Odile Y.] European Vaccine Initiat, Heidelberg, Germany; [Rappuoli, Rino] GlaxoSmithKline, Siana, Italy; [Rappuoli, Rino] Toscana Life Sci, Siena, Italy; [Rappuoli, Rino] Imperial Coll, London, England	Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); Instituto Butantan; GlaxoSmithKline; Imperial College London	Tagliabue, A (corresponding author), CNR, Inst Genet & Biomed Res, Monserrato, Italy.	aldo.tagliabue@gmail.com						Hviid A, 2019, ANN INTERN MED, V170, P513, DOI 10.7326/M18-2101; Pang T, 2018, LANCET, V391, P654, DOI 10.1016/S0140-6736(18)30245-9; Pieper K, 2017, NATURE, V548, P597, DOI 10.1038/nature23670; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528	4	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 12	2019	10								2556	10.3389/fimmu.2019.02556	http://dx.doi.org/10.3389/fimmu.2019.02556			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JQ8NL	31781095	gold, Green Published			2022-12-18	WOS:000499195100001
J	Chen, FH; Liu, X; Fang, HL; Nan, N; Li, Z; Ning, NZ; Luo, DY; Li, T; Wang, H				Chen, Fang-Hong; Liu, Xiong; Fang, Hua-Li; Nan, Nan; Li, Zhan; Ning, Nian-Zhi; Luo, De-Yan; Li, Tao; Wang, Hui			VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment	FRONTIERS IN IMMUNOLOGY			English	Article						HFMD; Enterovirus 71; Coxsackievirus B3; cross-protection; VP1 protein	MOUTH-DISEASE; FOOT; HAND; EPIDEMIOLOGY; VIRUS; IDENTIFICATION; IMMUNIZATION; ANTIBODIES; INFECTION; CHILDREN	Enterovirus and Coxsackievirus are the major viruses that cause hand, foot, and mouth disease (HFMD) outbreaks worldwide. Several studies have shown the potential of viral envelope protein 1 (VP1) on providing protective effects from viral strains of different genotypes. However, whether VP1 has the cross-protection in Enteroviruses or Coxsackievirus has not been studied in-depth. In this study, the vp1 gene of Enterovirus 71 (EV71) and Coxsackievirus B3 (CB3) was inserted into the vector pET22b (+) to form the respective expression plasmids pEVP1 or pCVP1, and then transformed into Escherichia coli strain BL21 (DE3). The recombinant EVP1 or CVP1 protein was overexpressed successfully and effectively purified to homogeneity. Then, we identified that EVP1 and CVP1 protein could generate effectively specific humoral immunity and cellular immunity in mice, what's more, we determined the cross-protection of VP1 between EV71 and CB3 in a murine model. The results showed that immunization with EVP1 could effectively induce specific IgG and secretory IgA against CVP1 and the sera from EVP1-immunized mice could neutralize CB3 with mean titers 1:440. In contrast, no measurable neutralizing antibodies to EV71 were detected in CVP1-immunized mice. Then, newborn BALB/C mice, whose mother was immunized with EVP1 or CVP1, were administered with different lethal doses of EV71 or CB3. The EVP1 immunized group showed a 90% protective efficacy for a CB3 dosage of 120 LD50, but the CVP1 immunized group showed no significantly different protective efficacy against 15 LD50 of EV71 compared with the BSA immunized group. Hence, EVP1 is a promising subunit vaccine candidate against Enterovirus 71 and Coxsackievirus B3 caused HFMD.	[Chen, Fang-Hong; Liu, Xiong; Fang, Hua-Li; Nan, Nan; Li, Zhan; Ning, Nian-Zhi; Luo, De-Yan; Li, Tao; Wang, Hui] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogens & Biosecur, Beijing, Peoples R China; [Chen, Fang-Hong; Fang, Hua-Li; Wang, Hui] Anhui Med Univ, Dept Microbiol, Hefei, Anhui, Peoples R China; [Liu, Xiong] PLA Ctr Dis Control & Prevent, Beijing, Peoples R China	Beijing Institute of Microbiology & Epidemiology; Anhui Medical University	Li, T; Wang, H (corresponding author), Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogens & Biosecur, Beijing, Peoples R China.; Wang, H (corresponding author), Anhui Med Univ, Dept Microbiol, Hefei, Anhui, Peoples R China.	litaobmi@126.com; geno0109@vip.sina.com			National Natural Science Foundation of China [31870156]; National Key Basic Research Program (973) of China [2015CB554202]; Beijing Nova Program [Z181100006218111]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Program (973) of China(National Basic Research Program of China); Beijing Nova Program(Beijing Municipal Science & Technology Commission)	This work was supported by National Natural Science Foundation of China (31870156), National Key Basic Research Program (973) of China (2015CB554202), and the Beijing Nova Program (Z181100006218111).	Andres C, 2019, FUTURE MICROBIOL, V14, P499, DOI 10.2217/fmb-2018-0336; Borkakoty B, 2020, INDIAN J DERMATOL VE, V86, DOI 10.4103/ijdvl.IJDVL_576_17; Cabrerizo M, 2017, J MED VIROL, V89, P435, DOI 10.1002/jmv.24658; Cai K, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3878-6; Carrillo C, 1998, J VIROL, V72, P1688, DOI 10.1128/JVI.72.2.1688-1690.1998; Chen GP, 2016, EPIDEMIOL INFECT, V144, P153, DOI 10.1017/S0950268815001107; Chen HF, 2006, VACCINE, V24, P2944, DOI 10.1016/j.vaccine.2005.12.047; Chen YX, 2013, VACCINE, V31, P425, DOI 10.1016/j.vaccine.2012.10.032; CHUMAKOV M, 1979, ARCH VIROL, V60, P329, DOI 10.1007/BF01317504; Cisterna DM, 2019, REV ARGENT MICROBIOL, V51, P140, DOI 10.1016/j.ram.2018.05.003; Esposito S, 2018, EUR J CLIN MICROBIOL, V37, P391, DOI 10.1007/s10096-018-3206-x; Foo DGW, 2008, CLIN MICROBIOL INFEC, V14, P286, DOI 10.1111/j.1469-0691.2007.01904.x; Guang D, 2007, VIRUS RES, V125, P61, DOI 10.1016/j.virusres.2006.12.005; Henke A, 2001, ANTIVIR RES, V49, P49, DOI 10.1016/S0166-3542(00)00132-7; Huang WC, 2012, J MICROBIOL IMMUNOL, V45, P96, DOI 10.1016/j.jmii.2011.09.025; Huang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep08904; Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829; Li YY, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-246; Liang SD, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-381; Lin YL, 2011, J IMMUNOASS IMMUNOCH, V32, P233, DOI 10.1080/15321819.2011.559297; Liu SL, 2015, REV MED VIROL, V25, P115, DOI 10.1002/rmv.1827; Lukashev AN, 2005, J GEN VIROL, V86, P3281, DOI 10.1099/vir.0.81264-0; Hoang MTV, 2019, INT J INFECT DIS, V80, P1, DOI 10.1016/j.ijid.2018.12.004; Modlin JF, 1997, CURR TOP MICROBIOL, V223, P53; Oberste MS, 2004, J GEN VIROL, V85, P1597, DOI 10.1099/vir.0.79789-0; Shih SR, 2000, J MED VIROL, V61, P228, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;228::AID-JMV9&gt;3.0.CO;2-R; Wang JY, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0134-x; Wang JY, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-017-0011-z; Wieczorek M, 2017, POL J MICROBIOL, V66, P405, DOI 10.5604/01.3001.0010.4889; Wu CN, 2001, VACCINE, V20, P895, DOI 10.1016/S0264-410X(01)00385-1; Wu TC, 2007, J VIROL, V81, P10310, DOI 10.1128/JVI.00372-07; Yoshitomi H, 2018, J MED VIROL, V90, P1712, DOI 10.1002/jmv.25250; Zhao YL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011610; Zuckerman AJ, 1994, HSIUNGS DIAGNOSTIC V, DOI [10.1016/0166-0934(94)90153-8, DOI 10.1016/0166-0934(94)90153-8]	34	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 8	2019	10								2564	10.3389/fimmu.2019.02564	http://dx.doi.org/10.3389/fimmu.2019.02564			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JQ4PG	31787970	Green Published, gold			2022-12-18	WOS:000498929100001
J	Janssen, LMA; Heron, M; Murk, JL; Leenders, ACAP; Rijkers, GT; de Vries, E				Janssen, Lisanne M. A.; Heron, Michiel; Murk, Jean-Luc; Leenders, Alexander C. A. P.; Rijkers, Ger T.; de Vries, Esther			Focusing on Good Responders to Pneumococcal Polysaccharide Vaccination in General Hospital Patients Suspected for Immunodeficiency. A Decision Tree Based on the 23-Valent Pneumococcal IgG Assay	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency; humoral immunodeficiency; pneumococcal polysaccharide response; serotype-specific assay; polysaccharide response; pneumococcal vaccination response; 23-valent IgG assay; VaccZyme (TM)	CLINICAL INTERPRETATION; CAPSULAR POLYSACCHARIDE; ANALYTICAL VARIABILITY; ANTIBODY-RESPONSE; HEALTHY-CHILDREN	Background and Aim: Recently, the 23-valent IgG-assay was suggested as screening assay to identify poor responders to pneumococcal polysaccharide (PnPS)-vaccination with the serotype-specific assay as a second-line test. However, in a low pre-test probability general hospital setting predicting good responders could be more valuable to reduce the number of samples needing serotyping. Methods: Serotype-specific PnPS antibody-assays were performed for suspected immunodeficiency in two Dutch general hospitals (Jeroen Bosch Hospital, 's-Hertogenbosch; Elisabeth Tweesteden Hospital, Tilburg). 23-Valent PnPS antibody-assays were subsequently performed in archived material. Data were analyzed using receiver operating characteristic curves (AUC) and agreement indices (ICC). Results: Sera of 284 patients (348 samples) were included; 23-valent IgG-titres and the corresponding sum of PnPS-serotype specific antibodies showed moderate correlation (ICC = 0.63). In 232 conjugated-pneumococcal-vaccine-naive patients (270 samples), a random 23-valent IgG-titer could discriminate between samples with and without >= 7/11, >= 7/13, or >= 6/9 pneumococcal serotypes when both cut-off values 0.35 and 1.0 mu g/ml were used (AUC 0.86 and 0.92, respectively). All patients with a pre-immunization-titer >= 38.2 mu g/ml and/or post-immunization-titer >= 96.1 mu g/ml and none with a post-immunization-titer <= 38.5 mu g/ml exhibited a good response to PnPS vaccination. Using these breakpoints as screening test to predict good responders, only 24% of patients would require further serotyping, as opposed to 68% if breakpoints to predict poor responders would have been used. Conclusion: In a low pre-test probability setting, the 23-valent IgG-assay proved to be a reliable screening test for good responders in conjugated-pneumococcal-vaccine-naive patients, reducing the overall number of patient samples needing further serotyping, thus reducing overall costs of pneumococcal vaccination response assessment.	[Janssen, Lisanne M. A.; de Vries, Esther] Tilburg Univ, Dept Tranzo, Tilburg, Netherlands; [Janssen, Lisanne M. A.] Amalia Childrens Hosp, Dept Pediat, Nijmegen, Netherlands; [Heron, Michiel; Murk, Jean-Luc; Rijkers, Ger T.; de Vries, Esther] St Elisabeth Hosp Tilburg, Lab Med Microbiol & Immunol, Tilburg, Netherlands; [Leenders, Alexander C. A. P.] Jeroen Bosch Hosp, Lab Med Microbiol, Shertogenbosch, Netherlands; [Rijkers, Ger T.] Univ Coll Roosevelt, Sci Dept, Middelburg, Netherlands	Tilburg University; Elisabeth-TweeSteden Ziekenhuis (ETZ); Jeroen Bosch Ziekenhuis	de Vries, E (corresponding author), Tilburg Univ, Dept Tranzo, Tilburg, Netherlands.; de Vries, E (corresponding author), St Elisabeth Hosp Tilburg, Lab Med Microbiol & Immunol, Tilburg, Netherlands.	e.devries@tilburguniversity.edu	Rijkers, Ger/AAW-6143-2020; Heron, Michiel/F-2653-2010	Heron, Michiel/0000-0003-0576-8652; de Vries, Esther/0000-0003-4311-3550	CSL Behring, Breda, the Netherlands; Sanquin, Amsterdam, the Netherlands	CSL Behring, Breda, the Netherlands; Sanquin, Amsterdam, the Netherlands(Netherlands Government)	The Care Path in 's-Hertogenbosch where part of these sera were collected was financially supported by unrestricted research grants from CSL Behring, Breda, the Netherlands and Sanquin, Amsterdam, the Netherlands.	Balloch A, 2013, J CLIN IMMUNOL, V33, P335, DOI 10.1007/s10875-012-9806-9; Balmer P, 2007, J CLIN PATHOL, V60, P345, DOI 10.1136/jcp.2006.041210; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Borgers H, 2010, CLIN IMMUNOL, V134, P198, DOI 10.1016/j.clim.2009.10.006; Chua I, 2011, J ALLERGY CLIN IMMUN, V127, P1410, DOI 10.1016/j.jaci.2011.01.035; Daly TM, 2015, CLIN VACCINE IMMUNOL, V22, P148, DOI 10.1128/CVI.00735-14; Daly TM, 2014, CLIN VACCINE IMMUNOL, V21, P982, DOI 10.1128/CVI.00235-14; de Vries E, 2012, CLIN EXP IMMUNOL, V167, P108, DOI 10.1111/j.1365-2249.2011.04461.x; Guevara-Hoyer K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00654; Hare ND, 2009, J ALLERGY CLIN IMMUN, V123, P195, DOI 10.1016/j.jaci.2008.09.021; Janssen LMA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02384; Janssen WJM, 2014, J CLIN IMMUNOL, V34, P3, DOI 10.1007/s10875-013-9925-y; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Laboratoriu Translationele Immunologie, 2016, RICHTL INT UITSL RES; Lakshman R, 2003, ARCH DIS CHILD, V88, P648, DOI 10.1136/adc.88.7.648; Lopez B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01862; Ltd TBSG, 2016, COULD VACCZYME PCP I; Meek BA, 2014, BEPALING ANTISTOFFEN; Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002; Paris K, 2007, ANN ALLERG ASTHMA IM, V99, P462, DOI 10.1016/S1081-1206(10)60572-8; Parker AR, 2019, VACCINE, V37, P1350, DOI [10.1016/j.vaccine.2019.01.035, 10.1016/j.vaccine.2019.01.]; Perez E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00450; Perez E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00586; Pickering JW, 2002, AM J CLIN PATHOL, V117, P589; Rose MA, 2013, MED MICROBIOL IMMUN, V202, P285, DOI 10.1007/s00430-013-0292-3; Rubins JB, 1999, INFECT IMMUN, V67, P5979, DOI 10.1128/IAI.67.11.5979-5984.1999; SANDERS LAM, 1993, J ALLERGY CLIN IMMUN, V91, P110, DOI 10.1016/0091-6749(93)90303-W; Schauer U, 2003, CLIN DIAGN LAB IMMUN, V10, P202, DOI 10.1128/CDLI.10.2.202-207.2003; Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119; Stead A, 2002, CLIN EXP IMMUNOL, V130, P325, DOI 10.1046/j.1365-2249.2002.01974.x; Tan CY, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00127-18; The Binding Site Group Ltd, 2014, VACCZYME ANT PCP IGG, P12; TRS R, 2009, REC ASS QUAL SAF EFF; Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003; Zhang XC, 2013, CLIN VACCINE IMMUNOL, V20, P957, DOI 10.1128/CVI.00223-13	35	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 5	2019	10								2496	10.3389/fimmu.2019.02496	http://dx.doi.org/10.3389/fimmu.2019.02496			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JP9BA	31749801	Green Published, gold			2022-12-18	WOS:000498551200001
J	Leisching, GR				Leisching, Gina R.			PI3-Kinase delta gamma Catalytic Isoforms Regulate the Th-17 Response in Tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Review						tuberculosis; IL-17A; PI3-Kinase; Th17; neutrophils; airway inflammation	PHOSPHOINOSITIDE 3-KINASE; BCG VACCINATION; IL-17 FAMILY; HOST-DEFENSE; T-CELLS; PI3K-GAMMA; INFECTION; DIFFERENTIATION; EXPRESSION; INTERLEUKIN-17	Although IL17A plays a protective role at the mucosal surface, when IL17A signaling becomes dysregulated, a pathological response is locally induced. At the early stages of Mycobacterium tuberculosis (M.tb) infection, IL17A contributes to granuloma formation and pathogen containment. In contrast, during disease progression, a dysregulated IL17A hyperinflammatory response drives tissue destruction through enhanced neutrophil recruitment. Cumulative research has implicated the PI3-Kinase pathways as one of the most relevant in the pathophysiology of inflammation. Evidence shows that IL-17A secretion and the expansion of the Th17 population is dependant in PI3-Kinase signaling, with the p110 delta and p110 gamma isoforms playing a prominent role. The p110 gamma isoform promotes disease progression through dampening of the Th17 response, preventing pathogen clearance and containment. The p110 gamma gene, PIK3CG is downregulated in TB patients during late-stage disease when compared to healthy controls, demonstrating an important modulatory role for this isoform during TB. Conversely, the p110 delta isoform induces IL-17A release from pulmonary gamma delta T-cells, committed Th17 cells and promotes neutrophil recruitment to the lung. Inhibiting this isoform not only suppresses IL-17A secretion from Th17 cells, but it also inhibits cytokine production from multiple T-helper cell types. Since increased IL-17A levels are observed to be localized in the lung compartments (BAL and lymphocytes) in comparison to circulating levels, an inhalable PI3K delta inhibitor, which is currently utilized for inflammatory airway diseases characterized by IL-17A over-secretion, may be a therapeutic option for active TB disease.	[Leisching, Gina R.] Stellenbosch Univ, SA MRC Ctr TB Res, DST NRF Ctr Excellence Biomed TB Res, Div Mol Biol & Human Genet,Fac Med & Hlth Sci, Cape Town, South Africa	National Research Foundation - South Africa; Stellenbosch University	Leisching, GR (corresponding author), Stellenbosch Univ, SA MRC Ctr TB Res, DST NRF Ctr Excellence Biomed TB Res, Div Mol Biol & Human Genet,Fac Med & Hlth Sci, Cape Town, South Africa.	gina.leisching@gmail.com			South African Medical Research Council; National Research Foundation of South Africa	South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Research Foundation of South Africa(National Research Foundation - South Africa)	This work was funded by the South African Medical Research Council and the National Research Foundation of South Africa.	Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Azzi J, 2012, DIABETES, V61, P1509, DOI 10.2337/db11-0134; Brace PT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006367; Bucher K, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0185-y; Cavalcanti-Neto MP, 2018, TUBERCULOSIS, V113, P1, DOI 10.1016/j.tube.2018.08.009; Chen FD, 2016, J IMMUNOL, V196, P4390, DOI 10.4049/jimmunol.1501541; Chen XJ, 2018, CELL IMMUNOL, V329, P41, DOI 10.1016/j.cellimm.2018.04.011; Cooper AM, 2009, CURR OPIN IMMUNOL, V21, P378, DOI 10.1016/j.coi.2009.06.004; Coulter F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01252; Cruz A, 2010, J EXP MED, V207, P1609, DOI 10.1084/jem.20100265; Erdmann H, 2018, MUCOSAL IMMUNOL, V11, P1168, DOI 10.1038/s41385-018-0026-3; Ernst JD, 1998, INFECT IMMUN, V66, P1277, DOI 10.1128/IAI.66.4.1277-1281.1998; Fogli LK, 2013, J IMMUNOL, V191, P5318, DOI 10.4049/jimmunol.1390058; Freches D, 2013, IMMUNOLOGY, V140, P220, DOI 10.1111/imm.12130; Gopal R, 2013, MUCOSAL IMMUNOL, V6, P972, DOI 10.1038/mi.2012.135; Gopal R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004099; Han JM, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00245; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harris SJ, 2012, EUR J IMMUNOL, V42, P3394, DOI 10.1002/eji.201242463; Haselmayer P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00233; Huang F, 2007, J IMMUNOL, V179, P6504, DOI 10.4049/jimmunol.179.10.6504; Jones Sarah A, 2012, Nat Immunol, V13, P1022, DOI 10.1038/ni.2450; Keller C, 2006, INFECT IMMUN, V74, P4295, DOI 10.1128/IAI.00057-06; Khader SA, 2008, CYTOKINE, V41, P79, DOI 10.1016/j.cyto.2007.11.022; Khan A, 2017, CLIN EXP PHARMACOL P, V44, P932, DOI 10.1111/1440-1681.12784; Kurebayashi Y, 2012, CELL REP, V1, P360, DOI 10.1016/j.celrep.2012.02.007; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lee SW, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-015-0848-x; Leisching GR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01669; Lesho E, 2011, TUBERCULOSIS, V91, P390, DOI 10.1016/j.tube.2011.07.002; Li Q, 2012, EUR REV MED PHARMACO, V16, P2029; Lombard R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149455; Maertzdorf J, 2011, GENES IMMUN, V12, P15, DOI 10.1038/gene.2010.51; Maxwell MJ, 2012, J AUTOIMMUN, V38, P381, DOI 10.1016/j.jaut.2012.04.001; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; Nagai S, 2013, ANN NY ACAD SCI, V1280, P30, DOI 10.1111/nyas.12059; Nordenmark LH, 2015, ADV THER, V32, P548, DOI 10.1007/s12325-015-0215-3; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2006, J IMMUNOL, V177, P5122, DOI 10.4049/jimmunol.177.8.5122; Park SJ, 2010, EUR RESPIR J, V36, P1448, DOI 10.1183/09031936.00106609; Philips Jennifer A, 2017, Sci Transl Med, V9, DOI 10.1126/scitranslmed.aan6195; Randis TM, 2008, EUR J IMMUNOL, V38, P1215, DOI 10.1002/eji.200838266; Rao VK, 2017, BLOOD, V130, P2307, DOI 10.1182/blood-2017-08-801191; Roller A, 2012, J IMMUNOL, V189, P4612, DOI 10.4049/jimmunol.1103173; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Sapey E, 2014, BLOOD, V123, P239, DOI 10.1182/blood-2013-08-519520; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sauty A, 1999, J IMMUNOL, V162, P3549; Singh S, 2018, J PATHOL, V244, P311, DOI 10.1002/path.5013; Song CJ, 2009, ATHEROSCLEROSIS, V207, P374, DOI 10.1016/j.atherosclerosis.2009.05.007; Song XY, 2013, CELL SIGNAL, V25, P2335, DOI 10.1016/j.cellsig.2013.07.021; Southworth T, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0436-2; Stockley R, 2013, RESP MED, V107, P524, DOI 10.1016/j.rmed.2012.12.009; Stokes CA, 2018, BIOCHEM SOC T, V46, P361, DOI 10.1042/BST20170467; Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004; Umemura M, 2007, J IMMUNOL, V178, P3786, DOI 10.4049/jimmunol.178.6.3786; Way EE, 2016, SCI REP-UK, V6, DOI 10.1038/srep30384; Xu LC, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0909-6; Xu YF, 2010, P NATL ACAD SCI USA, V107, P2950, DOI 10.1073/pnas.0912717107; Ye P, 2001, AM J RESP CELL MOL, V25, P335, DOI 10.1165/ajrcmb.25.3.4424; Yin N, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0772-x; Yoshida YO, 2010, J IMMUNOL, V184, P4414, DOI 10.4049/jimmunol.0903332	64	2	3	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 1	2019	10								2583	10.3389/fimmu.2019.02583	http://dx.doi.org/10.3389/fimmu.2019.02583			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO3IC	31736982	gold, Green Published			2022-12-18	WOS:000497473600001
J	De Pelsmaeker, S; Denaeghel, S; Hermans, L; Favoreel, HW				De Pelsmaeker, Steffi; Denaeghel, Sofie; Hermans, Leen; Favoreel, Herman W.			Identification of a Porcine Liver Eomes(high)T-bet(low) NK Cell Subset That Resembles Human Liver Resident NK Cells	FRONTIERS IN IMMUNOLOGY			English	Article						natural killer cells; NK cells; tissue residency; Eomes; T-bet; liver; pig	MEDIATED LYSIS; EXPRESSION; ANTIBODIES; CXCR6; IL-12; PIG	Natural killer (NK) cells are cells of the innate immunity and play an important role in the defense against viral infections and cancer, but also contribute to shaping adaptive immune responses. Long-lived tissue-resident NK cells have been described in man and mouse, particularly in the liver, contributing to the idea that the functional palette of NK cells may be broader than originally thought, and may include memory-like responses and maintaining tissue homeostasis. Remarkably, liver resident (lr)NK cells in man and mouse show substantial species-specific differences, in particular reverse expression patterns of the T-box transcription factors Eomesodermin (Eomes) and T-bet (Eomes(high)T-bet(low) in man and vice versa in mouse). In pig, compared to blood NK cells which are CD3-CD8 alpha(high) cells, the porcine liver contains an abundant additional CD3-CD8 alpha(dim) NK cell subpopulation. In the current study, we show that this porcine CD3-CD8 alpha(dim) liver NK population is highly similar to its human lrNK counterpart and therefore different from mouse lrNK cells. Like human lrNK cells, this porcine NK cell population shows an Eomes(high)T-bet(low) expression pattern. In addition, like its human counterpart, the porcine liver NK population is CD49e(-) and CXCR6(+). Furthermore, the porcine Eomes(high)T-bet(low) liver NK cell population is able to produce IFN-gamma upon IL-2/12/18 stimulation but lacks the ability to kill K562 or pseudorabies virus-infected target cells, although limited degranulation could be observed upon incubation with K562 cells or upon CD16 crosslinking. All together, these results show that porcine Eomes(high)T-bet(low) NK cells in the liver strongly resemble human lrNK cells, and therefore indicate that the pig may represent a unique model to study the function of these lrNK cells in health and disease.	[De Pelsmaeker, Steffi; Denaeghel, Sofie; Hermans, Leen; Favoreel, Herman W.] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Lab Immunol, Merelbeke, Belgium	Ghent University	Favoreel, HW (corresponding author), Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Lab Immunol, Merelbeke, Belgium.	herman.favoreel@ugent.be	; Favoreel, Herman/H-8712-2013	Hermans, Leen/0000-0002-2476-043X; Favoreel, Herman/0000-0003-4993-6857	Agency for Innovation by Science and Technology in Flanders (IWT-Vlaanderen); F.W.O.-Vlaanderen (FWO-SB) [3S63219]; F.W.O.-Vlaanderen [G.0176.15, G.0196.17N]; Special Research Fund of Ghent University (G.O.A. grant) [01G01317, BOFBAS201800301]; Belgian Science Policy (BELSPO-IAP phase VII BELVIR)	Agency for Innovation by Science and Technology in Flanders (IWT-Vlaanderen)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); F.W.O.-Vlaanderen (FWO-SB)(FWO); F.W.O.-Vlaanderen(FWO); Special Research Fund of Ghent University (G.O.A. grant); Belgian Science Policy (BELSPO-IAP phase VII BELVIR)	SDP was supported by a Ph.D. grant from the Agency for Innovation by Science and Technology in Flanders (IWT-Vlaanderen). SD was supported by a Ph.D. grant from F.W.O.-Vlaanderen (FWO-SB, 3S63219). This research was supported by grants from the F.W.O.-Vlaanderen (grant number G.0176.15 and G.0196.17N), the Special Research Fund of Ghent University (G.O.A. grant 01G01317 and grant BOFBAS201800301) and the Belgian Science Policy (BELSPO-IAP phase VII BELVIR).	Angelo LS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00469; BAILEY M, 1992, J IMMUNOL METHODS, V153, P85, DOI 10.1016/0022-1759(92)90309-H; Burt BM, 2009, J IMMUNOL, V183, P1789, DOI 10.4049/jimmunol.0900541; Cao J, 2013, VET MICROBIOL, V164, P261, DOI 10.1016/j.vetmic.2013.03.001; Crispe I N, 2001, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0321s22; Cuff AO, 2016, J IMMUNOL, V197, P4283, DOI 10.4049/jimmunol.1601424; Dawson HD, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P323; De Pelsmaeker S, 2019, J VIROL, V93, DOI 10.1128/JVI.02107-18; De Pelsmaeker S, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03188; De Pelsmaeker S, 2018, J LEUKOCYTE BIOL, V103, P129, DOI 10.1002/JLB.4A0417-163RR; Ebner F, 2014, DEV COMP IMMUNOL, V46, P333, DOI 10.1016/j.dci.2014.05.005; Grauwet K, 2016, J VIROL, V90, P1522, DOI 10.1128/JVI.02902-15; Grauwet K, 2014, P NATL ACAD SCI USA, V111, P16118, DOI 10.1073/pnas.1409485111; Harmon C, 2016, EUR J IMMUNOL, V46, P2111, DOI 10.1002/eji.201646559; Holmes TD, 2016, SEMIN IMMUNOL, V28, P368, DOI 10.1016/j.smim.2016.05.008; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Hydes T, 2018, IMMUN INFLAMM DIS, V6, P34, DOI 10.1002/iid3.190; JONJIC S, 1984, J IMMUNOL, V133, P647; Lugthart G, 2016, J IMMUNOL, V197, P78, DOI 10.4049/jimmunol.1502603; Lunemann S, 2019, J LEUKOCYTE BIOL, V105, P1331, DOI 10.1002/JLB.1MA1118-428R; Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022; Mair KH, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-13; Mair KH, 2012, EUR J IMMUNOL, V42, P1261, DOI 10.1002/eji.201141989; Male V, 2017, TRENDS IMMUNOL, V38, P307, DOI 10.1016/j.it.2017.02.008; Marquardt N, 2015, J IMMUNOL, V194, P2467, DOI 10.4049/jimmunol.1402756; Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002; Mikulak J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00946; Nikzad R, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aat8116; Peng H, 2017, SEMIN IMMUNOL, V31, P3, DOI 10.1016/j.smim.2017.07.006; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; PESCOVITZ MD, 1984, J IMMUNOL, V133, P368; Pintaric M, 2008, VET IMMUNOL IMMUNOP, V121, P68, DOI 10.1016/j.vetimm.2007.08.009; Powell Ellis J, 2017, J Rare Dis Res Treat, V2, P1; Rodriguez-Gomez IM, 2016, DEV COMP IMMUNOL, V60, P115, DOI 10.1016/j.dci.2016.02.022; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Van Elssen CHMJ, 2014, CLIN CANCER RES, V20, P1095, DOI 10.1158/1078-0432.CCR-13-2302; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Yang H, 1996, IMMUNOLOGY, V88, P577, DOI 10.1046/j.1365-2567.1996.d01-682.x; Yeang HXA, 2017, J IMMUNOL, V198, P1417, DOI 10.4049/jimmunol.1601818; Zhao ZB, 2020, CELL MOL IMMUNOL, V17, P178, DOI 10.1038/s41423-019-0199-z; Zhou J, 2019, IMMUNITY, V50, P403, DOI 10.1016/j.immuni.2018.12.024; Zingoni A, 2005, MOL IMMUNOL, V42, P451, DOI 10.1016/j.molimm.2004.07.025	42	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 31	2019	10								2561	10.3389/fimmu.2019.02561	http://dx.doi.org/10.3389/fimmu.2019.02561			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1KW	31736976	Green Published, gold			2022-12-18	WOS:000497344900001
J	Burns, DM; Ryan, GB; Harvey, CM; Nagy, E; Hughes, S; Murray, PG; Russell, NH; Fox, CP; Long, HM				Burns, David M.; Ryan, Gordon B.; Harvey, Caroline M.; Nagy, Eszter; Hughes, Simon; Murray, Paul G.; Russell, Nigel H.; Fox, Christopher P.; Long, Heather M.			Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease	FRONTIERS IN IMMUNOLOGY			English	Article						post-transplant lymphoproliferative disease; PTLD; Epstein-Barr virus; adoptive T-cell therapy; donor lymphocyte infusion; T-cells; flow cytometry; tetramers	ALLOGENEIC TRANSPLANTATION; ADOPTIVE IMMUNOTHERAPY; PREEMPTIVE RITUXIMAB; GENE-EXPRESSION; DISORDERS; INFECTION; THERAPY; RESPONSES; LATENT; RISK	Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) is a life-threatening complication of T-lymphocyte deplete allogeneic hematopoietic stem cell transplantation (allo-HSCT). For patients with PTLD refractory to Rituximab, donor lymphocyte infusion (DLI) is established as a successful option for salvage therapy. However, although in vivo lymphocyte expansion has been correlated with good clinical outcome following DLI, the specificity and functional characteristics of EBV-specific T-cell responses remain poorly characterized. Here we describe two patients with Rituximab-refractory PTLD complicating T-cell deplete allo-HSCT, both of whom were successfully rescued with 1 x 10(6)/Kg unselected stem cell donor-derived DLI. Prospective analyses revealed that complete clinical and radiological responses were associated with in vivo expansion of T and NK cells. Furthermore, EBV MHC tetramer, and interferon gamma analyses revealed a marked increase in EBV-specific T-cell frequency from 4 weeks after DLI. Reactivity was demonstrated against a range of EBV latent and lytic antigens, including those detected in tumor biopsy material. The immunodominant EBV-specific T cell response expanding in vivo following infusion matched the dominant response present in the DLI preparations prior to administration. Furthermore, differences in the repertoire of subdominant antigen-specific T-cells were also detected, suggesting that antigen-encounter in vivo can shape the immune response. These results demonstrate the value of prospectively studying in vivo T-cell responses, by facilitating the identification of important specificities required for clinical efficacy. Applying this approach on a larger scale promises to yield data which may be essential for the optimization of future adoptive immunotherapeutic strategies for PTLD.	[Burns, David M.; Ryan, Gordon B.; Nagy, Eszter; Murray, Paul G.; Long, Heather M.] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England; [Ryan, Gordon B.; Nagy, Eszter; Murray, Paul G.; Long, Heather M.] Univ Birmingham, Canc Immunol & Immunotherapy Ctr, Birmingham, W Midlands, England; [Harvey, Caroline M.; Russell, Nigel H.; Fox, Christopher P.] Nottingham Univ Hosp NHS Trust, Dept Clin Haematol, Nottingham, England; [Hughes, Simon] Nottingham Univ Hosp NHS Trust, Dept Radiol, Nottingham, England	University of Birmingham; University of Birmingham; Nottingham University Hospital NHS Trust; Nottingham University Hospital NHS Trust	Long, HM (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England.; Long, HM (corresponding author), Univ Birmingham, Canc Immunol & Immunotherapy Ctr, Birmingham, W Midlands, England.	h.m.long@bham.ac.uk		Fox, Christopher Paul/0000-0002-6322-9254	Bloodwise, UK [12014, 15021]	Bloodwise, UK	The authors would like to thank Bloodwise, UK (Project grants 12014 and 15021) for supporting this work.	Auger S, 2014, EUR J HAEMATOL, V92, P421, DOI 10.1111/ejh.12260; Benninger-Doring G, 1999, VIROLOGY, V264, P289, DOI 10.1006/viro.1999.9996; Bihl F, 2006, J IMMUNOL, V176, P4094, DOI 10.4049/jimmunol.176.7.4094; Bleakley M, 2014, BIOL BLOOD MARROW TR, V20, P705, DOI 10.1016/j.bbmt.2014.01.032; Bollard CM, 2012, NAT REV CLIN ONCOL, V9, P510, DOI 10.1038/nrclinonc.2012.111; Burns D, 2015, THESIS; Carpenter B, 2010, TRANSPLANTATION, V90, P564, DOI 10.1097/TP.0b013e3181e7a3bf; Cieri N, 2014, IMMUNOL REV, V257, P165, DOI 10.1111/imr.12130; Comoli P, 2007, AM J TRANSPLANT, V7, P1648, DOI 10.1111/j.1600-6143.2007.01823.x; De Pasquale MD, 2012, PEDIATRICS, V129, pE189, DOI 10.1542/peds.2011-0636; Doubrovina E, 2012, BLOOD, V119, P2644, DOI 10.1182/blood-2011-08-371971; Ferlazzo G, 2004, P NATL ACAD SCI USA, V101, P16606, DOI 10.1073/pnas.0407522101; Fox CP, 2014, BONE MARROW TRANSPL, V49, P280, DOI 10.1038/bmt.2013.170; Gustafsson A, 2000, BLOOD, V95, P807, DOI 10.1182/blood.V95.3.807.003k24_807_814; Haque T, 2007, BLOOD, V110, P1123, DOI 10.1182/blood-2006-12-063008; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; Heslop HE, 2009, BLOOD, V114, P4002, DOI 10.1182/blood-2009-07-143545; Hislop AD, 2002, J EXP MED, V195, P893, DOI 10.1084/jem.20011692; Hislop AD, 2007, ANNU REV IMMUNOL, V25, P587, DOI 10.1146/annurev.immunol.25.022106.141553; Hong GK, 2005, J VIROL, V79, P13993, DOI 10.1128/JVI.79.22.13993-14003.2005; Icheva V, 2013, J CLIN ONCOL, V31, P39, DOI 10.1200/JCO.2011.39.8495; Landgren O, 2009, BLOOD, V113, P4992, DOI 10.1182/blood-2008-09-178046; Leen A, 2001, J VIROL, V75, P8649, DOI 10.1128/JVI.75.18.8649-8659.2001; Leen AM, 2013, BLOOD, V121, P5113, DOI 10.1182/blood-2013-02-486324; Long HM, 2013, J EXP MED, V210, P933, DOI 10.1084/jem.20121437; Lucas KG, 1996, BLOOD, V87, P2594, DOI 10.1182/blood.V87.6.2594.bloodjournal8762594; Lunemann A, 2013, J IMMUNOL, V191, P4989, DOI 10.4049/jimmunol.1301046; McAulay KA, 2009, J IMMUNOL, V182, P3892, DOI 10.4049/jimmunol.0803572; Montes-Moreno S, 2012, MODERN PATHOL, V25, P968, DOI 10.1038/modpathol.2012.52; Moosmann A, 2010, BLOOD, V115, P2960, DOI 10.1182/blood-2009-08-236356; O'Reilly R J, 1996, Important Adv Oncol, P149; OUDEJANS JJ, 1995, AM J PATHOL, V147, P923; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Pappworth IY, 2007, J VIROL, V81, P474, DOI 10.1128/JVI.01777-06; Petropoulou AD, 2012, TRANSPLANTATION, V94, P879, DOI 10.1097/TP.0b013e3182664042; REA D, 1994, TRANSPLANTATION, V58, P317, DOI 10.1097/00007890-199408000-00012; Rickinson AB, 2006, FIELDS VIROLOGY; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Saulquin X, 2000, EUR J IMMUNOL, V30, P2531, DOI 10.1002/1521-4141(200009)30:9<2531::AID-IMMU2531>3.0.CO;2-O; Strowig T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040027; Styczynski J, 2009, TRANSPL INFECT DIS, V11, P383, DOI 10.1111/j.1399-3062.2009.00411.x; Styczynski J, 2016, HAEMATOLOGICA, V101, P803, DOI 10.3324/haematol.2016.144428; Styczynski J, 2013, CLIN INFECT DIS, V57, P794, DOI 10.1093/cid/cit391; Swerdlow SH, 2017, WHO CLASSIFICATION T; Taylor GS, 2015, ANNU REV IMMUNOL, V33, P787, DOI 10.1146/annurev-immunol-032414-112326; Teng YKO, 2008, ARTHRITIS RHEUM, V58, P634, DOI 10.1002/art.23298; Uhlin M, 2010, CANCER IMMUNOL IMMUN, V59, P473, DOI 10.1007/s00262-009-0789-1; van Esser JWJ, 2002, BLOOD, V99, P4364, DOI 10.1182/blood.V99.12.4364; Wagner HJ, 2004, BLOOD, V103, P3979, DOI 10.1182/blood-2003-12-4287; Williams LR, 2016, J VIROL, V90, P947, DOI 10.1128/JVI.01932-15	50	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 29	2019	10								2489	10.3389/fimmu.2019.02489	http://dx.doi.org/10.3389/fimmu.2019.02489			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1IK	31736946	Green Published, gold			2022-12-18	WOS:000497338500001
J	Pang, YP; Moura, MC; Thompson, GE; Nelson, DR; Hummel, AM; Jenne, DE; Emerling, D; Volkmuth, W; Robinson, WH; Specks, U				Pang, Yuan-Ping; Moura, Marta Casal; Thompson, Gwen E.; Nelson, Darlene R.; Hummel, Amber M.; Jenne, Dieter E.; Emerling, Daniel; Volkmuth, Wayne; Robinson, William H.; Specks, Ulrich			Remote Activation of a Latent Epitope in an Autoantigen Decoded With Simulated B-Factors	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmunity; autoantigen; antigenicity; antineutrophil cytoplasmic antibody; Proteinase 3; B-factor	ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; PROTEINASE-3 PR3; WEGENERS-GRANULOMATOSIS; NEUTROPHIL ELASTASE; MOLECULAR-DYNAMICS; CAPTURE-ELISA; RECOGNITION; REFINEMENT; INTERFERENCE; RESTRAINTS	Mutants of a catalytically inactive variant of Proteinase 3 (PR3)-iPR3-Val(103) possessing a Ser195Ala mutation relative to wild-type PR3-Val(103)-offer insights into how autoantigen PR3 interacts with antineutrophil cytoplasmic antibodies (ANCAs) in granulomatosis with polyangiitis (GPA) and whether such interactions can be interrupted. Here we report that iHm5-Val(103), a triple mutant of iPR3-Val(103), bound a monoclonal antibody (moANCA518) from a GPA patient on an epitope remote from the mutation sites, whereas the corresponding epitope of iPR3-Val(103) was latent to moANCA518. Simulated B-factor analysis revealed that the binding of moANCA518 to iHm5-Val(103) was due to increased main-chain flexibility of the latent epitope caused by remote mutations, suggesting rigidification of epitopes with therapeutics to alter pathogenic PR3 center dot ANCA interactions as new GPA treatments.	[Pang, Yuan-Ping] Mayo Clin, Comp Aided Mol Design Lab, Rochester, MN 55905 USA; [Moura, Marta Casal; Thompson, Gwen E.; Nelson, Darlene R.; Hummel, Amber M.; Specks, Ulrich] Mayo Clin, Thorac Dis Res Unit, Rochester, MN 55905 USA; [Jenne, Dieter E.] Helmholtz Zentrum Munchen, Comprehens Pneumol Ctr, Martinsried, Germany; [Jenne, Dieter E.] Max Planck Inst Neuroimmunol, Martinsried, Germany; [Emerling, Daniel; Volkmuth, Wayne] Atreca Inc, Redwood City, CA USA; [Robinson, William H.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA	Mayo Clinic; Mayo Clinic; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Stanford University	Pang, YP (corresponding author), Mayo Clin, Comp Aided Mol Design Lab, Rochester, MN 55905 USA.; Specks, U (corresponding author), Mayo Clin, Thorac Dis Res Unit, Rochester, MN 55905 USA.	pang@mayo.edu; specks.ulrich@mayo.edu	Jenne, Dieter Erich/AAP-1414-2020	Pang, Yuan-Ping/0000-0003-0838-2560; Robinson, William/0000-0003-4385-704X	US Army Research Office [W911NF-16-1-0264]; Connor Group Foundation; Mayo Foundation for Medical Education and Research; European Union's Horizon 2020 research and innovation program [668036]	US Army Research Office; Connor Group Foundation; Mayo Foundation for Medical Education and Research; European Union's Horizon 2020 research and innovation program	This work was supported by the US Army Research Office (W911NF-16-1-0264; to Y-PP), the Connor Group Foundation (to US), the Mayo Foundation for Medical Education and Research (to Y-PP and US), and the European Union's Horizon 2020 research and innovation program under grant agreement No. 668036 (RELENT; to DJ). Responsibility for the information and views in this study lies entirely with the authors.	Andraos J, 1996, J CHEM EDUC, V73, P150, DOI 10.1021/ed073p150; ARTYMIUK PJ, 1979, NATURE, V280, P563, DOI 10.1038/280563a0; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Capizzi SA, 2003, KIDNEY INT, V63, P756, DOI 10.1046/j.1523-1755.2003.00765.x; CSERNOK E, 1990, AM J PATHOL, V137, P1113; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Debye P, 1913, ANN PHYS-BERLIN, V43, P49; DeFalco J, 2018, CLIN IMMUNOL, V187, P37, DOI 10.1016/j.clim.2017.10.002; FAHEY JL, 1954, AM J MED, V17, P168, DOI 10.1016/0002-9343(54)90255-7; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; Finkielman JD, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.08.016; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; Garcia AE, 1997, PROTEINS, V29, P153; Gencik M, 2000, KIDNEY INT, V58, P2473, DOI 10.1046/j.1523-1755.2000.00430.x; Gross Wolfgang L., 1995, Current Opinion in Rheumatology, V7, P11; Hinkofer LC, 2013, J BIOL CHEM, V288, P26635, DOI 10.1074/jbc.M113.495770; JENNE DE, 1990, NATURE, V346, P520, DOI 10.1038/346520a0; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Joung IS, 2008, J PHYS CHEM B, V112, P9020, DOI 10.1021/jp8001614; KIDERA A, 1992, J MOL BIOL, V225, P457, DOI 10.1016/0022-2836(92)90932-A; Lee AS, 2005, J IMMUNOL METHODS, V307, P62, DOI 10.1016/j.jim.2005.09.004; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Morin S, 2011, PROG NUCL MAG RES SP, V59, P245, DOI 10.1016/j.pnmrs.2010.12.003; Oommen E, 2017, CLIN EXP RHEUMATOL, V35, pS98; Pang YP, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00161; Pang YP, 2017, BIOCHEM BIOPH RES CO, V492, P135, DOI 10.1016/j.bbrc.2017.08.010; Pang YP, 2016, PROTEINS, V84, P1490, DOI 10.1002/prot.25094; Pang Yuan-Ping, 2015, Biochem Biophys Rep, V4, P126, DOI 10.1016/j.bbrep.2015.08.023; Pang YP, 2015, BIOCHEM BIOPH RES CO, V458, P352, DOI 10.1016/j.bbrc.2015.01.115; Pang YP, 2015, BIOCHEM BIOPH RES CO, V457, P183, DOI 10.1016/j.bbrc.2014.12.084; Peikert T, 2008, ARTHRITIS RHEUM, V58, P1546, DOI 10.1002/art.23469; Shao JY, 2007, J CHEM THEORY COMPUT, V3, P2312, DOI 10.1021/ct700119m; Silva F, 2010, J AUTOIMMUN, V35, P299, DOI 10.1016/j.jaut.2010.06.021; Specks U, 1996, FEBS LETT, V390, P265, DOI 10.1016/0014-5793(96)00669-2; Specks U, 2000, ARTHRITIS RES, V2, P263, DOI 10.1186/ar99; Sun J, 1998, CLIN EXP IMMUNOL, V114, P320; Sun JY, 1998, J IMMUNOL METHODS, V211, P111, DOI 10.1016/S0022-1759(97)00203-2; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; Tan YC, 2014, ARTHRITIS RHEUMATOL, V66, P2706, DOI 10.1002/art.38754; Tan YC, 2014, CLIN IMMUNOL, V151, P55, DOI 10.1016/j.clim.2013.12.008; Thompson G, 2018, ARTHRITIS RHEUMATOL, V70; Travers TS, 2016, J IMMUNOL, V197, P1926, DOI 10.4049/jimmunol.1600162; Tronrud DE, 1996, J APPL CRYSTALLOGR, V29, P100, DOI 10.1107/S002188989501421X; Trueblood KN, 1996, ACTA CRYSTALLOGR A, V52, P770, DOI 10.1107/S0108767396005697; Van Der Geld YM, 1999, CLIN EXP IMMUNOL, V118, P487; Van Regenmortel MHV, 2002, J MOL RECOGNIT, V15, P240, DOI 10.1002/jmr.584; Waller I, 1923, Z PHYS, V17, P398, DOI 10.1007/BF01328696; Wegener F, 1936, VERHANDLUNGEN DTSCH, V29, P202; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; Wiesner O, 2005, FEBS LETT, V579, P5305, DOI 10.1016/j.febslet.2005.08.056; Wiesner O, 2004, ARTHRITIS RHEUM-US, V50, P2954, DOI 10.1002/art.20479; Willis BTM, 1975, THERMAL VIBRATIONS I; YU HA, 1985, ACTA CRYSTALLOGR B, V41, P191, DOI 10.1107/S0108768185001926	54	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 25	2019	10								2467	10.3389/fimmu.2019.02467	http://dx.doi.org/10.3389/fimmu.2019.02467			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JK3BY	31708920	Green Published, Green Submitted, gold			2022-12-18	WOS:000494721700001
J	Freund, C; Hofer, T				Freund, Christian; Hoefer, Thomas			A Missing Switch in Peptide Exchange for MHC Class II Molecules	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						MHC class II; HLA-DM; exchange catalyst; HLA-DO; switch	COMPLEX CLASS-II; HLA-DM; ANTIGEN; BINDING; EXPRESSION; PROTEASES; PROTEIN; CLIP		[Freund, Christian] Free Univ Berlin, Inst Chem & Biochem, Lab Prot Biochem, Berlin, Germany; [Hoefer, Thomas] Deutsch Krebsforschungszentrum, Div Theoret Syst Biol, Heidelberg, Germany	Free University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Freund, C (corresponding author), Free Univ Berlin, Inst Chem & Biochem, Lab Prot Biochem, Berlin, Germany.; Hofer, T (corresponding author), Deutsch Krebsforschungszentrum, Div Theoret Syst Biol, Heidelberg, Germany.	chfreund@zedat.fu-berlin.de; t.hoefer@dkfz-heidelberg.de	Höfer, Thomas/G-5665-2013	Höfer, Thomas/0000-0003-3560-8780	DFG [FR-1325/17-1, TRR186]	DFG(German Research Foundation (DFG))	CF was thankful to the DFG grants FR-1325/17-1 and TRR186).	Alvaro-Benito M, 2020, CELL MOL IMMUNOL, V17, P133, DOI 10.1038/s41423-018-0181-1; Alvaro-Benito M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00872; Alvaro-Benito M, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160165; Alvaro-Benito M, 2015, J IMMUNOL, V194, P803, DOI 10.4049/jimmunol.1401389; Bikoff EK, 2001, J IMMUNOL, V166, P5087, DOI 10.4049/jimmunol.166.8.5087; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Busch R, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/erm.2012.9; Casado P, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r37; Chapman HA, 1998, CURR OPIN IMMUNOL, V10, P93, DOI 10.1016/S0952-7915(98)80038-1; Chen XJ, 2002, J EXP MED, V195, P1053, DOI 10.1084/jem.20012066; Denzin LK, 2005, IMMUNOL REV, V207, P279, DOI 10.1111/j.0105-2896.2005.00302.x; Douek DC, 2000, IMMUNOLOGY, V99, P249, DOI 10.1046/j.1365-2567.2000.00940.x; Draghi NA, 2010, P NATL ACAD SCI USA, V107, P16607, DOI 10.1073/pnas.1004664107; Ewanchuk BW, 2018, FREE RADICAL BIO MED, V125, P53, DOI 10.1016/j.freeradbiomed.2018.03.040; Glazier KS, 2002, J EXP MED, V195, P1063, DOI 10.1084/jem.20012059; Guce AI, 2013, NAT STRUCT MOL BIOL, V20, P90, DOI 10.1038/nsmb.2460; Gunther S, 2010, P NATL ACAD SCI USA, V107, P22219, DOI 10.1073/pnas.1014708107; Hsing LC, 2005, IMMUNOL REV, V207, P229, DOI 10.1111/j.0105-2896.2005.00310.x; Jahnke M, 2013, EUR J IMMUNOL, V43, P1153, DOI 10.1002/eji.201243043; Jiang W, 2015, SCI REP-UK, V5, DOI 10.1038/srep17333; Jurewicz MM, 2019, IMMUNOGENETICS, V71, P171, DOI 10.1007/s00251-018-1095-x; Koonce CH, 2003, J IMMUNOL, V170, P3751, DOI 10.4049/jimmunol.170.7.3751; Machado Y, 2016, J ALLERGY CLIN IMMUN, V137, P1525, DOI 10.1016/j.jaci.2015.09.026; Macmillan H, 2014, J IMMUNOL, V193, P2641, DOI 10.4049/jimmunol.1400075; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; Morgan MAJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071974, 10.1371/journal.pone.0056738, 10.1371/journal.pone.0069936]; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; Nepal RM, 2008, J LEUKOCYTE BIOL, V84, P1011, DOI 10.1189/jlb.1207852; Poluektov YO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071228; Reed AM, 1997, J IMMUNOL, V159, P6260; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Rohn TA, 2004, NAT IMMUNOL, V5, P909, DOI 10.1038/ni1108; Ruckrich T, 2006, BIOL CHEM, V387, P1503, DOI 10.1515/BC.2006.188; Schlosshauer M, 2004, PROTEIN SCI, V13, P1660, DOI 10.1110/ps.03517304; Schlundt A, 2012, J MOL BIOL, V423, P294, DOI 10.1016/j.jmb.2012.07.008; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; Thanei S, 2017, BIOCHEM PHARMACOL, V146, P151, DOI 10.1016/j.bcp.2017.10.001; Tischer DK, 2019, ELIFE, V8, DOI 10.7554/eLife.42498; Unanue ER, 2016, ANNU REV IMMUNOL, V34, P265, DOI 10.1146/annurev-immunol-041015-055420; West LC, 2013, CURR OPIN IMMUNOL, V25, P103, DOI 10.1016/j.coi.2012.11.006; West LC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051343; Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292; Wieczorek M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13224; Yin LS, 2014, J IMMUNOL METHODS, V406, P21, DOI 10.1016/j.jim.2014.02.008; Yoon T, 2012, P NATL ACAD SCI USA, V109, P11276, DOI 10.1073/pnas.1113966109; Yousefi OS, 2019, ELIFE, V8, DOI 10.7554/eLife.42475; Zhou FF, 2006, BIOINFORMATICS, V22, P894, DOI 10.1093/bioinformatics/btl013; Zielinska DF, 2010, CELL, V141, P897, DOI 10.1016/j.cell.2010.04.012	48	2	2	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 23	2019	10								2513	10.3389/fimmu.2019.02513	http://dx.doi.org/10.3389/fimmu.2019.02513			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JK2CX	31708929	Green Published, gold			2022-12-18	WOS:000494655900001
J	Montfort, A; Colacios, C; Levade, T; Andrieu-Abadie, N; Meyer, N; Segui, B				Montfort, Anne; Colacios, Celine; Levade, Thierry; Andrieu-Abadie, Nathalie; Meyer, Nicolas; Segui, Bruno			The TNF Paradox in Cancer Progression and Immunotherapy (vol 10, 1818, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						tumor necrosis factor (TNF); PD-1; CTLA-4; melanoma; immune escape			[Montfort, Anne; Colacios, Celine; Levade, Thierry; Andrieu-Abadie, Nathalie; Meyer, Nicolas; Segui, Bruno] CRCT, INSERM, UMR 1037, Toulouse, France; [Colacios, Celine; Levade, Thierry; Meyer, Nicolas; Segui, Bruno] Univ Toulouse III Paul Sabatier, Toulouse, France; [Levade, Thierry] CHU Purpan, Inst Federatif Biol, Lab Biochim, Toulouse, France; [Meyer, Nicolas] Inst Univ Canc IUCT O, Dermatol, Toulouse, France; [Meyer, Nicolas] CHU Toulouse, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; CHU de Toulouse	Segui, B (corresponding author), CRCT, INSERM, UMR 1037, Toulouse, France.; Segui, B (corresponding author), Univ Toulouse III Paul Sabatier, Toulouse, France.	bruno.segui@inserm.fr		Montfort, Anne/0000-0002-2926-4902				Montfort A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01818	1	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2019	10								2515	10.3389/fimmu.2019.02515	http://dx.doi.org/10.3389/fimmu.2019.02515			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JJ8ZT	31695705	Green Published, gold			2022-12-18	WOS:000494441500001
J	Ubillos, I; Campo, JJ; Requena, P; Ome-Kaius, M; Hanieh, S; Rose, H; Samol, P; Barrios, D; Jimenez, A; Bardaji, A; Mueller, I; Menendez, C; Rogerson, S; Moncunill, G; Dobano, C				Ubillos, Itziar; Campo, Joseph J.; Requena, Pilar; Ome-Kaius, Maria; Hanieh, Sarah; Rose, Honor; Samol, Paula; Barrios, Diana; Jimenez, Alfons; Bardaji, Azucena; Mueller, Ivo; Menendez, Clara; Rogerson, Stephen; Moncunill, Gemma; Dobano, Carlota			Chronic Exposure to Malaria Is Associated with Inhibitory and Activation Markers on Atypical Memory B Cells and Marginal Zone-Like B Cells (vol 8, 966, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						chronic infection; malaria; tolerance; B cells; host-malaria interaction			[Ubillos, Itziar; Campo, Joseph J.; Requena, Pilar; Barrios, Diana; Jimenez, Alfons; Bardaji, Azucena; Menendez, Clara; Moncunill, Gemma; Dobano, Carlota] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain; [Campo, Joseph J.] Antigen Discovery Inc, Irvine, CA USA; [Requena, Pilar] Univ Granada, Fac Med, Granada, Spain; [Ome-Kaius, Maria; Hanieh, Sarah; Rose, Honor; Samol, Paula; Mueller, Ivo] Papua New Guinea Inst Med Res, Madang, Papua N Guinea; [Jimenez, Alfons] CIBER Epidemiol & Publ Hlth CIBERESP, Barcelona, Spain; [Mueller, Ivo] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Rogerson, Stephen] Univ Melbourne, Melbourne, Vic, Australia	ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; University of Granada; PNG Institute Of Medical Research; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Walter & Eliza Hall Institute; University of Melbourne	Dobano, C (corresponding author), Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain.	carlota.dobano@isglobal.org	Alonso, Azucena Bardají/V-5978-2018; JIMENEZ, ALFONS/L-2106-2019; Dobaño, Carlota/N-4119-2014; Requena, Pilar/B-1919-2017; Bardají, Azucena/AAE-9145-2019	Alonso, Azucena Bardají/0000-0002-5135-0540; JIMENEZ, ALFONS/0000-0003-0301-3344; Dobaño, Carlota/0000-0002-6751-4060; Requena, Pilar/0000-0002-2298-4085; 	Instituto de Salud Carlos III - FEDER funds/European Regional Development Fund (ERDF) [PI14/01422]; EU FP7 (PregVax, FP7/2007-2013 Grant) [201588]; Ministerio de Economia y Competitividad (National R&D Internationalization Program, EUROSALUD 2008) [EUS2009-03560]; Malaria in Pregnancy Consortium through the Bill & Melinda Gates Foundation [46099]; Sara Borrell-ISCIII fellowship [CD010/00156]; Ministerio de Economia y Competitividad [RYC-2008-02631]; EviMalaR; Agency for Management of University and Research Grants (AGAUR grant) [2014SGR991]	Instituto de Salud Carlos III - FEDER funds/European Regional Development Fund (ERDF); EU FP7 (PregVax, FP7/2007-2013 Grant); Ministerio de Economia y Competitividad (National R&D Internationalization Program, EUROSALUD 2008); Malaria in Pregnancy Consortium through the Bill & Melinda Gates Foundation; Sara Borrell-ISCIII fellowship; Ministerio de Economia y Competitividad(Spanish Government); EviMalaR; Agency for Management of University and Research Grants (AGAUR grant)	This work was funded by the Instituto de Salud Carlos III (grant number PI14/01422), cofunded by FEDER funds/European Regional Development Fund (ERDF), the EU FP7 (PregVax, FP7/2007-2013 Grant 201588), the Ministerio de Economia y Competitividad (National R&D Internationalization Program, EUROSALUD 2008, Grant EUS2009-03560), and the Malaria in Pregnancy Consortium through the Bill & Melinda Gates Foundation (Grant 46099). GM was recipient of a Sara Borrell-ISCIII fellowship (CD010/00156). CD was supported by a fellowship from the Ministerio de Economia y Competitividad (Grant RYC-2008-02631) and was affiliate of the EU FP7 Network of Excellence EviMalaR. IU received funds from EviMalaR and the Agency for Management of University and Research Grants (AGAUR grant number 2014SGR991) for doctoral studies. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya.	Ubillos I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00966	1	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 17	2019	10								2427	10.3389/fimmu.2019.02427	http://dx.doi.org/10.3389/fimmu.2019.02427			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1GC	31681313	Green Published, gold			2022-12-18	WOS:000497332500001
J	Liu, QQ; Ou, QF; Shen, L; Qiu, C; Zhang, BY; Zhang, WH; Shao, LY; Gao, Y; Chen, ZW				Liu, Qianqian; Ou, Qinfang; Shen, Lei; Qiu, Chao; Zhang, Bingyan; Zhang, Wenhong; Shao, Lingyun; Gao, Yan; Chen, Zheng W.			BATF Potentially Mediates Negative Regulation of PD-1/PD-Ls Pathway on T Cell Functions in Mycobacterium tuberculosis Infection	FRONTIERS IN IMMUNOLOGY			English	Article						BATF; tuberculosis; PD-1/PD-Ls pathway; T cell function; immune response	DYNAMIC CHANGES; PD-1; RESPONSES; MACROPHAGES; IMMUNOLOGY; PROTEIN	Background: Previously, we have found that blockade of PD-1/PD-Ls pathway could enhance CD4(+) T cells-mediated protective immunity in patients with active tuberculosis (ATB). However, the mechanism of PD-1/PD-Ls pathway involved in negative regulation of anti-TB immunity has been still unclear. Recently, the study of human immunodeficiency virus (HIV) infection demonstrated that PD-1 could induce the expression of basic leucine zipper ATF-like transcription factor (BATF) to inhibit CD8(+) T cell function. While the mechanism of immune regulation of BATF in Mycobacterium tuberculosis (M. tb) infection has not yet been elucidated. Methods: We enrolled 104 participants including ATB patients (n = 66), latent tuberculosis infection (LTBI) (n = 16) and healthy control (HC) (n = 22). The expressions of BATF in peripheral blood CD4(+) and CD8(+) T cells from enrolled subjects were determined using flow cytometry. Intervention with PD-1/PD-Ls pathway was performed by using blocking antibodies or human PD-L1 fusion protein. Silencing BATF in peripheral blood mononuclear cells (PBMCs) by electroporation with siRNA. Real-time quantitative PCR, CFSE dilution assay and enzyme linked immunosorbent assay (ELISA) were employed to test T cell functions after BATF knockdown. Results: The percentages of BATF(+) CD4(+) (P = 0.0003 and P < 0.0001, respectively) and BATF(+) CD8(+) (P = 0.0003 and P = 0.0003, respectively) cells were significantly increased in ATB patients compared with LTBI and HC. BATF-expressing PD-1(+) T cells in CD4(+) and CD8(+) T cells were much higher in ATB group than those in LTBI group (P = 0.0426 and 0.0104, respectively) and HC group (P = 0.0133 and 0.0340, respectively). There was a positive correlation between BATF expression and PD-1 expression in ATB patients (for CD4(+) T cells, r = 0.6761, P = 0.0158; for CD8(+) T cells, r = 0.6104, P = 0.0350). BATF knockdown could enhance IL-2 and IFN-gamma secretions (P = 0.0485 and 0.0473, respectively) and CD4(+) T cells proliferation (P = 0.0041) in vitro. Conclusions: In the context of tuberculosis, BATF mediates negative regulation of PD-1/PD-Ls pathway on T cell functions. BATF knockdown can improve cytokine secretion and cells proliferation in vitro.	[Liu, Qianqian; Zhang, Bingyan; Zhang, Wenhong; Shao, Lingyun; Gao, Yan] Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China; [Ou, Qinfang] Wuxi Infect Dis Hosp, Dept Pulm Dis, Wuxi, Jiangsu, Peoples R China; [Shen, Lei] Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Qiu, Chao] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Qiu, Chao; Zhang, Wenhong] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Key Lab Med Mol Virol,Minist Educ & Hlth, Shanghai, Peoples R China; [Chen, Zheng W.] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Ctr Primate Biomed Res, Chicago, IL 60612 USA	Fudan University; Fudan University; Fudan University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Shao, LY; Gao, Y (corresponding author), Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China.	lingyun26@fudan.edu.cn; yangao09@fudan.edu.cn	liu, qian/HDM-2936-2022		National Natural Science Foundation of China [81501359, 81671553, 81700009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The present study was partly supported by the National Natural Science Foundation of China (Nos. 81501359, 81671553, and 81700009).	Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Betz BC, 2010, J EXP MED, V207, P933, DOI 10.1084/jem.20091548; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Dheda K, 2010, RESPIROLOGY, V15, P433, DOI 10.1111/j.1440-1843.2010.01739.x; Dorsey MJ, 1995, ONCOGENE, V11, P2255; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Grusdat M, 2014, CELL DEATH DIFFER, V21, P1050, DOI 10.1038/cdd.2014.19; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Imai Y, 2015, J IMMUNOL, V195, P421, DOI 10.4049/jimmunol.1500448; Jurado JO, 2008, J IMMUNOL, V181, P116, DOI 10.4049/jimmunol.181.1.116; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Murphy TL, 2013, NAT REV IMMUNOL, V13, P499, DOI 10.1038/nri3470; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Qin XB, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1822-6; Quigley M, 2010, NAT MED, V16, P1147, DOI 10.1038/nm.2232; Roe JK, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87238; Roy S, 2015, J IMMUNOL, V194, P6035, DOI 10.4049/jimmunol.1402521; Rozot V, 2013, EUR J IMMUNOL, V43, P1568, DOI 10.1002/eji.201243262; Sakai S, 2010, INT IMMUNOL, V22, P915, DOI 10.1093/intimm/dxq446; Schmidt SCS, 2015, P NATL ACAD SCI USA, V112, P554, DOI 10.1073/pnas.1422580112; Schwander S, 2011, AM J RESP CRIT CARE, V183, P696, DOI 10.1164/rccm.201006-0963PP; Scott-Browne JP, 2016, IMMUNITY, V45, P1327, DOI 10.1016/j.immuni.2016.10.028; Shen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep38362; Shen L, 2016, TUBERCULOSIS, V101, P146, DOI 10.1016/j.tube.2016.10.001; Singh A, 2013, J INFECT DIS, V208, P603, DOI 10.1093/infdis/jit206; Sopel N, 2016, CYTOKINE GROWTH F R, V30, P39, DOI 10.1016/j.cytogfr.2016.03.004; Vesely PW, 2009, MUTAT RES-REV MUTAT, V682, P7, DOI 10.1016/j.mrrev.2009.01.001; Wang J, 2017, EUR J MED RES, V22, DOI 10.1186/s40001-016-0242-9; World Health Organization, 2017, GLOB TUB REP 2017; Xin G, 2015, CELL REP, V13, P1118, DOI 10.1016/j.celrep.2015.09.069	31	2	3	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2019	10								2430	10.3389/fimmu.2019.02430	http://dx.doi.org/10.3389/fimmu.2019.02430			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1DM	31681314	Green Published, gold			2022-12-18	WOS:000497325700001
J	Munck, NA; Roth, J; Sunderkotter, C; Ehrchen, J				Muenck, Niels-Arne; Roth, Johannes; Sunderkoetter, Cord; Ehrchen, Jan			Aryl Hydrocarbon Receptor-Signaling Regulates Early Leishmania major-Induced Cytokine Expression	FRONTIERS IN IMMUNOLOGY			English	Article						skin infection; leishmaniasis; AhR; macrophages; epidermis	NF-KAPPA-B; INTERFERON-GAMMA; TNF-ALPHA; MACROPHAGES; INFECTION; SUSCEPTIBILITY; RESISTANCE; MICE; DIFFERENTIATION; PROMASTIGOTES	The early inflammatory skin micromilieu affects resistance in experimental infection with Leishmania major. We pursue the concept that macrophages, which take up parasites during early infection, exert decisive influence on the inflammatory micromilieu after infection. In order to analyze their distinctive potential, we identified differentially regulated genes of murine granuloma macrophages (GM Phi) from resistant and susceptible mice after their infection with metacyclic Leishmania major. We found induction of several cytokines in GM Phi from both strains and a stronger upregulation of the transcription factor aryl hydrocarbon receptor (AhR) in GM Phi from resistant mice. Using both an AhR agonist and antagonist we demonstrated that AhR is involved in Leishmania-induced production of TNF in macrophages. In vivo, single local injection of an AhR agonist in early lesions of susceptible mice caused an increased induction of Tnf and other cytokines in the skin. Importantly, local agonist treatment led to a reduction of disease severity, reduced parasite loads and a weaker Th2 response. Our results demonstrate that local activation of AhR has a beneficial effect in experimental leishmaniasis.	[Muenck, Niels-Arne; Roth, Johannes] Univ Munster, Inst Immunol, Munster, Germany; [Muenck, Niels-Arne; Sunderkoetter, Cord] Univ Munster, Dept Translat Dermatoinfectiol, Munster, Germany; [Sunderkoetter, Cord; Ehrchen, Jan] Univ Munster, Dept Dermatol, Munster, Germany; [Sunderkoetter, Cord] Martin Luther Univ Halle Wittenberg, Dept Dermatol & Venereol, Halle, Germany	University of Munster; University of Munster; University of Munster; Martin Luther University Halle Wittenberg	Ehrchen, J (corresponding author), Univ Munster, Dept Dermatol, Munster, Germany.	jan.ehrchen@ukmuenster.de			Interdisziplinares Zentrum fur Klinische Forschung (IZKF) [EH111006]; Innovative medizinische Forschung (IMF) [Sun2/019/07]; German research foundation [DFG EH 397/2-1]	Interdisziplinares Zentrum fur Klinische Forschung (IZKF); Innovative medizinische Forschung (IMF); German research foundation(German Research Foundation (DFG))	Intramural funding was provided by the grants EH111006 and Sun2/019/07 by the intramural programs Interdisziplinares Zentrum fur Klinische Forschung (IZKF) and Innovative medizinische Forschung (IMF), respectively. Additional funding was provided by the German research foundation under grant no. DFG EH 397/2-1.	Belkaid Y, 1998, EUR J IMMUNOL, V28, P1389, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1389::AID-IMMU1389&gt;3.0.CO;2-1; Ben-Othman R, 2008, MOL IMMUNOL, V45, P3222, DOI 10.1016/j.molimm.2008.02.019; Ben-Othman R, 2009, MOL IMMUNOL, V46, P3438, DOI 10.1016/j.molimm.2009.05.337; Bessede A, 2014, NATURE, V511, P184, DOI 10.1038/nature13323; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; BOGDAN C, 1990, EUR J IMMUNOL, V20, P1131, DOI 10.1002/eji.1830200528; Bowers OJ, 2006, AM J TROP MED HYG, V75, P749, DOI 10.4269/ajtmh.2006.75.749; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; Cheon H, 2007, EXP MOL MED, V39, P524, DOI 10.1038/emm.2007.58; Climaco-Arvizu S, 2016, LIFE SCI, V155, P76, DOI 10.1016/j.lfs.2016.05.001; DeKrey GK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076259; Drevets DA, 2004, J IMMUNOL, V172, P4418, DOI 10.4049/jimmunol.172.7.4418; Ehrchen J, 2007, FASEB J, V21, P3208, DOI 10.1096/fj.06-7261com; Ehrchen J, 2007, BLOOD, V109, P1265, DOI 10.1182/blood-2006-02-001115; Ehrchen JM, 2008, INFECT IMMUN, V76, P4241, DOI 10.1128/IAI.01714-07; Ehrchen JM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02028; Ehrchen JM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000871; Elizondo G, 2011, INT J BIOL SCI, V7, P1220, DOI 10.7150/ijbs.7.1220; Filardy AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085715; Flaveny Colin A, 2009, Mol Cell Pharmacol, V1, P119; Fromm PD, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01520; Gregory DJ, 2008, EUR J IMMUNOL, V38, P1071, DOI 10.1002/eji.200737586; Gregory DJ, 2008, INFECT IMMUN, V76, P1186, DOI 10.1128/IAI.01320-07; Guizani-Tabbane L, 2004, INFECT IMMUN, V72, P2582, DOI 10.1128/IAI.72.5.2582-2589.2004; Halees AS, 2003, NUCLEIC ACIDS RES, V31, P3554, DOI 10.1093/nar/gkg549; Haverty PM, 2004, NUCLEIC ACIDS RES, V32, pW213, DOI 10.1093/nar/gkh402; Head JL, 2009, BIOCHEM PHARMACOL, V77, P642, DOI 10.1016/j.bcp.2008.10.031; Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029; Jin GB, 2010, TOXICOL SCI, V116, P514, DOI 10.1093/toxsci/kfq153; John Dominik, 2013, Methods Mol Biol, V961, P403, DOI 10.1007/978-1-62703-227-8_27; Kawajiri K, 2017, EXP ANIM TOKYO, V66, P75, DOI 10.1538/expanim.16-0092; Kimura A, 2009, J EXP MED, V206, P2027, DOI 10.1084/jem.20090560; Lapara NJ, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-8; LIEW FY, 1990, IMMUNOLOGY, V69, P570; Matsunawa M, 2009, TOXICOL SCI, V109, P50, DOI 10.1093/toxsci/kfp044; Phadnis-Moghe AS, 2016, TOXICOLOGY, V368, P172, DOI 10.1016/j.tox.2016.08.019; Rabhi I, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-723; Roebrock K, 2014, FASEB J, V28, P1724, DOI 10.1096/fj.13-233593; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sanchez Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/505694; Schleicher U, 2016, CELL REP, V15, P1062, DOI 10.1016/j.celrep.2016.04.001; Schonlau F, 2003, J LEUKOCYTE BIOL, V73, P564, DOI 10.1189/jlb.12011003; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Sekine H, 2009, MOL CELL BIOL, V29, P6391, DOI 10.1128/MCB.00337-09; Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656; SUNDERKOTTER C, 1993, J IMMUNOL, V151, P4891; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Vogel CFA, 2009, BIOCHEM PHARMACOL, V77, P734, DOI 10.1016/j.bcp.2008.09.036; von Stebut E, 2003, J EXP MED, V198, P191, DOI 10.1084/jem.20030159; Wilhelm P, 2001, J IMMUNOL, V166, P4012, DOI 10.4049/jimmunol.166.6.4012	50	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 15	2019	10								2442	10.3389/fimmu.2019.02442	http://dx.doi.org/10.3389/fimmu.2019.02442			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1EA	31749794	Green Published, gold			2022-12-18	WOS:000497327100001
J	Solodushko, V; Bitko, V; Barrington, R; Fouty, B				Solodushko, Victor; Bitko, Vira; Barrington, Robert; Fouty, Brian			A DNA Vaccine in Which the RSV-F Ectodomain Is Covalently Linked to the Burkholderia pseudomallei Antigens TssM and Hcp1 Augments the Humoral and Cytotoxic Response in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						DNA vaccine; RSV-F; melioidosis; antibody response; cytotoxicity	RESPIRATORY SYNCYTIAL-VIRUS; INFECTION; DEUBIQUITINASE; PROTEINS; EFFICACY; CELLS	DNA vaccines have great potential to control infectious disease, particularly those caused by intracellular organisms. They are inexpensive to produce and can be quickly modified to combat emerging infectious threats, but often fail to generate a strong immunologic response limiting enthusiasm for their use in humans and animals. To improve the immunogenic response, we developed a DNA vaccine in which the F protein ectodomain of Respiratory Syncytial Virus (RSV-F) was covalently linked to specific antigens of interest. The presence of the RSV-F ectodomain allowed secretion of the translated fusion product out of the originally transfected cells followed by its active binding to adjacent cells. This allowed the targeting of a greater number of cells than those originally transfected, enhancing both humoral and cytotoxic immune responses against the expressed antigen(s). We developed an engrafted mouse model that used antigen-expressing tumor cells to assess the in vivo cytotoxic immune response to specific antigens. We then used this model to demonstrate that a DNA vaccine in which the RSV-F ectodomain is fused to two antigens expressed by Burkholderia pseudomallei, the intracellular gram-negative organism that causes melioidosis, generated a stronger cytotoxic response than a DNA vaccine that lacked the RSV-F sequence while still generating a robust humoral response.	[Solodushko, Victor; Fouty, Brian] Univ S Alabama, Sch Med, Dept Pharmacol, Mobile, AL 36688 USA; [Solodushko, Victor; Barrington, Robert; Fouty, Brian] Univ S Alabama, Sch Med, Ctr Lung Biol, Mobile, AL 36688 USA; [Bitko, Vira] Emergent BioSolut, Gaithersburg, MD USA; [Barrington, Robert] Univ S Alabama, Sch Med, Dept Microbiol & Immunol, Mobile, AL USA; [Fouty, Brian] Univ S Alabama, Sch Med, Dept Internal Med, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama; University of South Alabama; University of South Alabama	Solodushko, V; Fouty, B (corresponding author), Univ S Alabama, Sch Med, Dept Pharmacol, Mobile, AL 36688 USA.; Solodushko, V; Fouty, B (corresponding author), Univ S Alabama, Sch Med, Ctr Lung Biol, Mobile, AL 36688 USA.; Fouty, B (corresponding author), Univ S Alabama, Sch Med, Dept Internal Med, Mobile, AL 36688 USA.	vsolodushko@southalabama.edu; bfouty@health.southalabama.edu		Solodushko, Victor/0000-0002-3137-8650	University of South Alabama College of Medicine Intramural Grants Program	University of South Alabama College of Medicine Intramural Grants Program	Funding for this project was provided in part by the University of South Alabama College of Medicine Intramural Grants Program.	Benoit TJ, 2015, MMWR SURVEILL SUMM, V64, P1; Bose S, 2015, VIROLOGY, V479, P518, DOI 10.1016/j.virol.2015.02.037; Burtnick MN, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00724-17; Burtnick MN, 2014, INFECT IMMUN, V82, P3214, DOI 10.1128/IAI.01739-14; Burtnick MN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076767; Burtnick MN, 2011, INFECT IMMUN, V79, P1512, DOI 10.1128/IAI.01218-10; Chaiwatpongsakorn S, 2011, J VIROL, V85, P3968, DOI 10.1128/JVI.01813-10; Chieng S, 2015, MICROB PATHOGENESIS, V79, P47, DOI 10.1016/j.micpath.2015.01.006; Cockburn IA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000877; Conlan JW, 2011, FUTURE MICROBIOL, V6, P391, DOI [10.2217/FMB.11.22, 10.2217/fmb.11.22]; Connolly SA, 2006, P NATL ACAD SCI USA, V103, P17903, DOI 10.1073/pnas.0608678103; Currie Bart J, 2008, Trans R Soc Trop Med Hyg, V102 Suppl 1, pS1, DOI 10.1016/S0035-9203(08)70002-6; DOMURAT F, 1985, J INFECT DIS, V152, P895, DOI 10.1093/infdis/152.5.895; Donnelly JJ, 2000, AM J RESP CRIT CARE, V162, pS190, DOI 10.1164/ajrccm.162.supplement_3.15tac10; Foong YC, 2014, RURAL REMOTE HEALTH, V14; Griffiths C, 2017, CLIN MICROBIOL REV, V30, P277, DOI 10.1128/CMR.00010-16; Griffiths KL, 2014, CURR OPIN IMMUNOL, V28, P58, DOI 10.1016/j.coi.2014.02.003; Grodeland G, 2016, J IMMUNOL, V197, P3575, DOI 10.4049/jimmunol.1600893; Gutirrez-Ortega A, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-127; Igietseme JU, 2011, EXPERT REV VACCINES, V10, P1585, DOI [10.1586/erv.11.139, 10.1586/ERV.11.139]; Karron RA, 1997, P NATL ACAD SCI USA, V94, P13961, DOI 10.1073/pnas.94.25.13961; Khan Kishwar Hayat, 2013, Germs, V3, P26, DOI 10.11599/germs.2013.1034; KRILOV LR, 1987, J GEN VIROL, V68, P1749, DOI 10.1099/0022-1317-68-6-1749; Manoury B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00368; McLellan JS, 2013, CURR TOP MICROBIOL, V372, P83, DOI 10.1007/978-3-642-38919-1_4; McLellan JS, 2011, J VIROL, V85, P7788, DOI 10.1128/JVI.00555-11; Pitt JM, 2013, MICROB PATHOGENESIS, V58, P2, DOI 10.1016/j.micpath.2012.12.002; Pollara J, 2011, CYTOM PART A, V79A, P603, DOI 10.1002/cyto.a.21084; Raiden S, 2017, J INFECT DIS, V215, P1049, DOI 10.1093/infdis/jix070; Reyes-Sandoval A, 2010, INFECT IMMUN, V78, P145, DOI 10.1128/IAI.00740-09; Ruiz-Arguello MB, 2002, VIROLOGY, V298, P317, DOI 10.1006/viro.2002.1497; Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/ERV.11.188, 10.1586/erv.11.188]; Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0; Shanks J, 2009, INFECT IMMUN, V77, P1636, DOI 10.1128/IAI.01339-08; Singh B, 2012, VACCINE, V30, P3834, DOI 10.1016/j.vaccine.2012.03.068; Smith EC, 2009, FEBS J, V276, P7217, DOI 10.1111/j.1742-4658.2009.07401.x; Solodushko V, 2014, GENE THER, V21, P1, DOI 10.1038/gt.2013.52; Tan KS, 2010, J IMMUNOL, V184, P5160, DOI 10.4049/jimmunol.0902663; Yunus AS, 2010, VIROLOGY, V396, P226, DOI 10.1016/j.virol.2009.10.040	39	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2019	10								2411	10.3389/fimmu.2019.02411	http://dx.doi.org/10.3389/fimmu.2019.02411			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1AX	31681300	gold, Green Published			2022-12-18	WOS:000497318900001
J	Zhang, F; Wang, LY; Niu, XF; Li, JS; Luo, J; Feng, YP; Yang, YJ; He, P; Fan, WX; Liang, RS; Zheng, ZQ; Pan, WQ; Li, CF; Tan, YJ; Yu, HJ; Chen, L; Li, PC				Zhang, Fan; Wang, Longyu; Niu, Xuefeng; Li, Jiashun; Luo, Jia; Feng, Yupeng; Yang, Yanjia; He, Ping; Fan, Wenxia; Liang, Renshan; Zheng, Zhiqiang; Pan, Weiqi; Li, Chufang; Tan, Yee Joo; Yu, Haijian; Chen, Ling; Li, Pingchao			Phenotypic Characterization of Chinese Rhesus Macaque Plasmablasts for Cloning Antigen-Specific Monoclonal Antibodies	FRONTIERS IN IMMUNOLOGY			English	Article						plasmablast; B cell; Chinese rhesus macaques; monoclonal antibodies; influenza virus; vaccination	B-CELLS; VIRUS; RESPONSES; IMMUNITY; SURVIVAL; BLIMP-1; PROTEIN; BLOOD	Rhesusmacaques (Macacamulatta) are used as a human-relevant animal species for the evaluation of vaccines and as a source for cloning monoclonal antibodies (mAbs) that are highly similar to human-derived antibodies. Although antibody-secreting plasmablasts in humans are well-defined and can be easily isolated for mAb cloning, it remains unclear whether the same phenotypic markers could be applied for isolating antibody-secreting plasmablasts from Chinese rhesus macaques. In this study, we evaluated a series of cell surface and intracellular markers and identified the phenotypic markers of plasmablasts in Chinese rhesus macaques as CD3(-)CD14(-)CD56(-)CD19(-)CD27(-)CD20(-/low)CD80(+) HLA-DR(+)CD95(+). After influenza virus vaccination, the plasmablasts in peripheral blood mononuclear cells (PBMCs) increased transiently, peaked at day 4-7 after booster vaccination and returned to nearly undetectable levels by day 14. Antigen-specific enzyme-linked immunosorbent spot (ELISPOT) assays confirmed that the majority of the plasmablasts could produce influenza virus-specific antibodies. These plasmablasts showed transcriptional characteristics similar to those of human plasmablasts. Using single-cell PCR for immunoglobulin heavy and light chains, most mAbs cloned from the CD3(-)CD14(-)CD56(-)CD19(-)CD27(-)CD20(-/low)CD80(+)HLA-DR(+)CD95(+) plasmablasts after vaccination exhibited specific binding to influenza virus. This study defined the phenotypic markers for isolating antibody-secreting plasmablasts from Chinese rhesus macaques, which has implications for efficient cloning of mAbs and for the evaluation of plasmablast response after vaccination or infection in Chinese rhesus macaques.	[Zhang, Fan; Wang, Longyu; Luo, Jia; Feng, Yupeng; He, Ping; Chen, Ling; Li, Pingchao] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, Guangdong Lab Computat Biomed, Guangzhou, Peoples R China; [Zhang, Fan; Wang, Longyu] Anhui Univ, Inst Phys Sci & Informat Technol, Hefei, Anhui, Peoples R China; [Niu, Xuefeng; Yang, Yanjia; Fan, Wenxia; Liang, Renshan; Pan, Weiqi; Li, Chufang; Chen, Ling] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China; [Li, Jiashun; Yu, Haijian] Huadu Peoples Hosp, Dept Resp Med, Guangzhou, Guangdong, Peoples R China; [Zheng, Zhiqiang; Tan, Yee Joo] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore; [Zheng, Zhiqiang; Tan, Yee Joo] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; State Key Laboratory of Respiratory Disease; Anhui University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Chen, L; Li, PC (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, Guangdong Lab Computat Biomed, Guangzhou, Peoples R China.; Chen, L (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.	chen_ling@gibh.ac.cn; li_pingchao@gibh.ac.cn		Tan, Yee-Joo/0000-0002-2278-4497; Zheng, Zhiqiang/0000-0003-1028-3246	Strategic Priority Research Program of Chinese Academy of Sciences [XDA/B29050701]; National Natural Science Foundation of China [81661148056, 81490530]; National Science and Technology Program of China [10600100000015001206, 2017ZX10204401, 2017ZX10301101-002]; Guangzhou Health Care and Cooperative Innovation Major Project [20160402011]; National Research Foundation, Singapore; National Natural Science Foundation of China under the NRF-NSFC [NRF2016NRF-NSFC002-016]	Strategic Priority Research Program of Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Program of China; Guangzhou Health Care and Cooperative Innovation Major Project; National Research Foundation, Singapore(National Research Foundation, Singapore); National Natural Science Foundation of China under the NRF-NSFC(National Natural Science Foundation of China (NSFC))	This work was supported by the Strategic Priority Research Program of Chinese Academy of Sciences (Grant No. XDA/B29050701). This work was also partly supported by grants from the National Natural Science Foundation of China (Grant Nos. 81661148056, 81490530), National Science and Technology Program of China (Grant Nos. 10600100000015001206, 2017ZX10204401, 2017ZX10301101-002), the Guangzhou Health Care and Cooperative Innovation Major Project (Grant No. 20160402011), the National Research Foundation, Singapore, and National Natural Science Foundation of China under the NRF-NSFC joint research grant call (Emerging Infectious Diseases) (Grant no. NRF2016NRF-NSFC002-016).	Corcoran LM, 2005, J EXP MED, V201, P1385, DOI 10.1084/jem.20042325; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Demberg T, 2014, CLIN IMMUNOL, V153, P264, DOI 10.1016/j.clim.2014.04.017; Doria-Rose NA, 2009, J VIROL, V83, P188, DOI 10.1128/JVI.01583-08; Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533; Geuijen CAW, 2005, J IMMUNOL METHODS, V302, P68, DOI 10.1016/j.jim.2005.04.016; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; Good-Jacobson KL, 2012, J IMMUNOL, V188, P4217, DOI 10.4049/jimmunol.1102885; Halliley JL, 2015, IMMUNITY, V43, P132, DOI 10.1016/j.immuni.2015.06.016; Hernandez RD, 2007, SCIENCE, V316, P240, DOI 10.1126/science.1140462; Hsu CH, 2003, LECT NOTES COMPUT SC, V2325, P197; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kong SY, 2016, P NATL ACAD SCI USA, V113, P10394, DOI 10.1073/pnas.1606742113; Li DY, 2011, AM J PRIMATOL, V73, P883, DOI 10.1002/ajp.20956; Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109; Lin ZH, 2014, NAT PROTOC, V9, P1563, DOI 10.1038/nprot.2014.104; Martinez-Murillo P, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00242; Medina LO, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02464; Meng WX, 2015, MABS-AUSTIN, V7, P707, DOI 10.1080/19420862.2015.1051440; Meng WX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066276; Niu XF, 2019, EMERG MICROBES INFEC, V8, P749, DOI 10.1080/22221751.2019.1614885; Pan WQ, 2014, ANTIVIR RES, V107, P1, DOI 10.1016/j.antiviral.2014.04.003; Pauthner MG, 2019, IMMUNITY, V50, P241, DOI 10.1016/j.immuni.2018.11.011; Peperzak V, 2013, NAT IMMUNOL, V14, P290, DOI 10.1038/ni.2527; Rossi SL, 2019, J INFECT DIS, V220, P735, DOI 10.1093/infdis/jiz202; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Silveira ELV, 2015, J IMMUNOL METHODS, V416, P69, DOI 10.1016/j.jim.2014.11.003; Stahl-Hennig C, 2007, J MED PRIMATOL, V36, P195, DOI 10.1111/j.1600-0684.2007.00237.x; Sun CJ, 2013, J VIROL, V87, P5669, DOI 10.1128/JVI.03247-12; Sundling C, 2012, J IMMUNOL METHODS, V386, P85, DOI 10.1016/j.jim.2012.09.003; Sundling C, 2010, J EXP MED, V207, P2003, DOI 10.1084/jem.20100025; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Vigdorovich V, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.42; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Zhang Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep25856; Zhao XL, 2017, CELL, V169, P891, DOI 10.1016/j.cell.2017.04.038	37	2	2	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 11	2019	10								2426	10.3389/fimmu.2019.02426	http://dx.doi.org/10.3389/fimmu.2019.02426			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JO1BI	31681312	Green Published, gold			2022-12-18	WOS:000497320000002
J	Hlavaty, SI; Chang, YM; Orth, RP; Goulian, M; Planet, PJ; Thamm, DH; Punt, JA; Garden, OA				Hlavaty, Sabina I.; Chang, Yu-Mei; Orth, Rachel P.; Goulian, Mark; Planet, Paul J.; Thamm, Douglas H.; Punt, Jennifer A.; Garden, Oliver A.			Bacterial Killing Activity of Polymorphonuclear Myeloid-Derived Suppressor Cells Isolated From Tumor-Bearing Dogs	FRONTIERS IN IMMUNOLOGY			English	Article						MDSC; PMN-MDSC; G-MDSC; canine; cancer; bactericidal; phagocytosis; reactive oxygen species	STAPHYLOCOCCUS-AUREUS; NEUTROPHILS; INFECTION	Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are implicated in the progression and outcome of a variety of pathological states, from cancer to infection. Our previous work has identified three antimicrobial peptides differentially expressed by PMN-MDSCs compared to conventional neutrophils isolated from dogs, mice, and human patients with cancer. We therefore hypothesized that PMN-MDSCs in dogs with cancer possess antimicrobial activity. In the current work, we observed that exposure of PMN-MDSCs to Gram-negative bacteria (Escherichia coli) increased the expression of reactive oxygen species by the PMN-MDSCs, indicating that they are capable of initiating an anti-microbial response. Electron microscopy revealed that the PMN-MDSCs phagocytosed Gram-negative and Gram-positive (Staphylococcus aureus) bacterial species. Lysis of bacteria within some of the PMN-MDSCs suggested bactericidal activity, which was confirmed by the recovery of significantly lower numbers of bacteria of both species following exposure to PMN-MDSCs isolated from tumor-bearing dogs. Our data therefore indicate that PMN-MDSCs isolated from dogs with cancer, in common with PMNs, have phagocytic and bactericidal activity. This nexus of immunosuppressive and antimicrobial activity reveals a hitherto unrecognized function of MDSCs.	[Hlavaty, Sabina I.; Garden, Oliver A.] Univ Penn, Sch Vet Med, Dept Clin Sci & Adv Med, Garden Immune Regulat Lab, Philadelphia, PA 19104 USA; [Chang, Yu-Mei] Royal Vet Coll, Res Support Off, London, England; [Orth, Rachel P.] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA; [Goulian, Mark] Univ Penn, Dept Biol, Sch Arts & Sci, Philadelphia, PA 19104 USA; [Planet, Paul J.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Planet, Paul J.] Childrens Hosp Philadelphia, Pediat Infect Dis Div, Philadelphia, PA 19104 USA; [Thamm, Douglas H.] Colorado State Univ, Dept Clin Sci, Flint Anim Canc Ctr, Ft Collins, CO 80523 USA; [Punt, Jennifer A.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of London; University of London Royal Veterinary College; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Colorado State University; University of Pennsylvania	Garden, OA (corresponding author), Univ Penn, Sch Vet Med, Dept Clin Sci & Adv Med, Garden Immune Regulat Lab, Philadelphia, PA 19104 USA.	ogarden@upenn.edu	Thamm, Douglas H/I-5976-2013	Thamm, Douglas H/0000-0002-8914-7767	Howard Hughes Medical Institute-Burroughs Wellcome Fund Medical Research Fellowship; UPenn's Center for Undergraduate Research Funds; Team Grant for Interdisciplinary Activities (TGIA); International Canine Health Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI070077, R21AI125814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080279] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T35OD010919] Funding Source: NIH RePORTER	Howard Hughes Medical Institute-Burroughs Wellcome Fund Medical Research Fellowship; UPenn's Center for Undergraduate Research Funds; Team Grant for Interdisciplinary Activities (TGIA); International Canine Health Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	SH was supported by the Howard Hughes Medical Institute-Burroughs Wellcome Fund Medical Research Fellowship. RO and JP were funded by UPenn's Center for Undergraduate Research Funds, with a Team Grant for Interdisciplinary Activities (TGIA). Work in the Garden Immune Regulation Laboratory was funded in part by an International Canine Health Award to OG from The Kennel Club (U.K.).	Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Chen Y, 2012, METHODS MOL BIOL, V844, P115, DOI 10.1007/978-1-61779-527-5_8; Condamine T, 2014, J CLIN INVEST, V124, P2626, DOI 10.1172/JCI74056; Goulart MR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40285-3; Groth C, 2019, BRIT J CANCER, V120, P16, DOI 10.1038/s41416-018-0333-1; Heim CE, 2014, J IMMUNOL, V192, P3778, DOI 10.4049/jimmunol.1303408; Irrazabal T, 2014, MOL CELL, V54, P309, DOI 10.1016/j.molcel.2014.03.039; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Leiber A, 2017, EUR J IMMUNOL, V47, P1009, DOI 10.1002/eji.201646621; Lu LC, 2019, J HEPATOCELL CARCINO, V6, P71, DOI 10.2147/JHC.S159693; Lu T, 2014, J INNATE IMMUN, V6, P639, DOI 10.1159/000360478; Ma J, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6319649; Pawelec G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01099; Pereira WF, 2011, J LEUKOCYTE BIOL, V90, P1191, DOI 10.1189/jlb.1110608; Periasamy S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005517; Poe SL, 2013, MUCOSAL IMMUNOL, V6, P189, DOI 10.1038/mi.2012.62; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Tebartz C, 2015, J IMMUNOL, V194, P1100, DOI 10.4049/jimmunol.1400196; Wang F, 2014, CANCER LETT, V345, P196, DOI 10.1016/j.canlet.2013.08.016; Youn JI, 2012, J LEUKOCYTE BIOL, V91, P167, DOI 10.1189/jlb.0311177; Zhou ZW, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00371	22	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 10	2019	10								2371	10.3389/fimmu.2019.02371	http://dx.doi.org/10.3389/fimmu.2019.02371			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JN8IB	31649676	Green Accepted, gold, Green Published			2022-12-18	WOS:000497134400001
J	Marzano, AV; Lipsker, D; Cugno, M				Marzano, Angelo V.; Lipsker, Dan; Cugno, Massimo			Editorial: Neutrophil-Mediated Skin Diseases: Immunology and Genetics	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neutrophil; skin-immunology; innate immunity; genetics; neutrophilic dermatoses (NDs); autoinflammation			[Marzano, Angelo V.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy; [Marzano, Angelo V.; Cugno, Massimo] Univ Milan, Dept Physiopathol & Transplantat, Milan, Italy; [Lipsker, Dan] Univ Strasbourg, Fac Med, Strasbourg, France; [Lipsker, Dan] Hop Univ, Clin Dermatol, Strasbourg, France; [Cugno, Massimo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Internal Med Unit, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; IRCCS Ca Granda Ospedale Maggiore Policlinico	Marzano, AV (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy.; Marzano, AV (corresponding author), Univ Milan, Dept Physiopathol & Transplantat, Milan, Italy.	angelo.marzano@unimi.it		Lipsker, Dan/0000-0003-4675-0336					0	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 9	2019	10								2377	10.3389/fimmu.2019.02377	http://dx.doi.org/10.3389/fimmu.2019.02377			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JN6DP	31649678	Green Published, gold			2022-12-18	WOS:000496986900002
J	Tentokam, BCN; Amaratunga, C; Alani, NAH; MacDonald, NJ; Narum, DL; Salinas, ND; Kwan, JL; Suon, S; Sreng, S; Pereira, DB; Tolia, NH; Fujiwara, RT; Bueno, LL; Duffy, PE; Coelho, CH				Tentokam, Bergeline C. Nguemwo; Amaratunga, Chanaki; Alani, Nada A. H.; MacDonald, Nicholas J.; Narum, David L.; Salinas, Nichole D.; Kwan, Jennifer L.; Suon, Seila; Sreng, Sokunthea; Pereira, Dhelio Batista; Tolia, Niraj H.; Fujiwara, Ricardo T.; Bueno, Lilian L.; Duffy, Patrick E.; Coelho, Camila H.			Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; Plasmodium vivax; Pvs230; transmission-blocking vaccine; seroreactivity	PLASMODIUM-VIVAX MALARIA; SEXUAL STAGE ANTIGENS; FALCIPARUM-MALARIA; IMMUNE-RESPONSES; CHILDREN; BINDING; PFS230; TRIAL; AGE	Plasmodium vivax malaria incidence has increased in Latin America and Asia and is responsible for nearly 74.1% of malaria cases in Latin America. Immune responses to P. vivax are less well characterized than those to P. falciparum, partly because P. vivax is more difficult to cultivate in the laboratory. While antibodies are known to play an important role in P. vivax disease control, few studies have evaluated responses to P. vivax sexual stage antigens. We collected sera or plasma samples from P. vivax-infected subjects from Brazil (n = 70) and Cambodia (n = 79) to assess antibody responses to domain 1 of the gametocyte/gamete stage protein Pvs230 (Pvs230D1M). We found that 27.1% (19/70) and 26.6% (21/79) of subjects from Brazil and Cambodia, respectively, presented with detectable antibody responses to Pvs230D1M antigen. The most frequent subclasses elicited in response to Pvs230D1M were IgG1 and IgG3. Although age did not correlate significantly with Pvs230D1M antibody levels overall, we observed significant differences between age strata. Hemoglobin concentration inversely correlated with Pvs230D1M antibody levels in Brazil, but not in Cambodia. Additionally, we analyzed the antibody response against Pfs230D1M, the P. falciparum ortholog of Pvs230D1M. We detected antibodies to Pfs230D1M in 7.2 and 16.5% of Brazilian and Cambodian P. vivax-infected subjects. Depletion of Pvs230D1M IgG did not impair the response to Pfs230D1M, suggesting pre-exposure to P. falciparum, or co-infection. We also analyzed IgG responses to sporozoite protein PvCSP (11.4 and 41.8% in Brazil and Cambodia, respectively) and to merozoite protein PvDBP-RII (67.1 and 48.1% in Brazil and Cambodia, respectively), whose titers also inversely correlated with hemoglobin concentration only in Brazil. These data establish patterns of seroreactivity to sexual stage Pvs230D1M and show similar antibody responses among P. vivax-infected subjects from regions of differing transmission intensity in Brazil and Cambodia.	[Tentokam, Bergeline C. Nguemwo; Alani, Nada A. H.; MacDonald, Nicholas J.; Narum, David L.; Salinas, Nichole D.; Tolia, Niraj H.; Duffy, Patrick E.; Coelho, Camila H.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Amaratunga, Chanaki] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD USA; [Kwan, Jennifer L.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Suon, Seila; Sreng, Sokunthea] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia; [Pereira, Dhelio Batista] Ctr Pesquisa Med Trop, Porto, Brazil; [Fujiwara, Ricardo T.; Bueno, Lilian L.] Univ Fed Minas Gerais, Dept Parasitol, Belo Horizonte, MG, Brazil	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Center Parasitology, Entomology & Malaria Control; Universidade Federal de Minas Gerais	Duffy, PE (corresponding author), NIAID, Lab Malaria Immunol & Vaccinol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	patrick.duffy@nih.gov	Bueno, Lilian/AAQ-1939-2020; Fujiwara, Ricardo Toshio/J-7579-2012; Pereira, Dhelio Batista/F-9312-2017	Bueno, Lilian/0000-0003-3510-4590; Fujiwara, Ricardo Toshio/0000-0002-4713-575X; Pereira, Dhelio Batista/0000-0002-7761-5498; Coelho, Camila/0000-0002-7885-9996; Salinas, Nichole/0000-0003-4105-3718	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)	This work was supported by the Intramural Research Program of the National Institute of Allergy and InfectiousDiseases, National Institutes of Health (NIH).	Alexandre MA, 2010, EMERG INFECT DIS, V16, P1611, DOI 10.3201/eid1610.100685; Barcus MJ, 2007, AM J TROP MED HYG, V77, P984, DOI 10.4269/ajtmh.2007.77.984; Batchelor JD, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003869; Batchelor JD, 2011, NAT STRUCT MOL BIOL, V18, P908, DOI 10.1038/nsmb.2088; BOUHAROUNTAYOUN H, 1992, MEM I OSWALDO CRUZ, V87, P229, DOI 10.1590/S0074-02761992000700038; BOUHAROUNTAYOUN H, 1992, INFECT IMMUN, V60, P1473, DOI 10.1128/IAI.60.4.1473-1481.1992; Bousema JT, 2007, PARASITE IMMUNOL, V29, P309, DOI 10.1111/j.1365-3024.2007.00948.x; Bousema T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014114; Canepa GE, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0065-5; Castro-Gomes T, 2014, INFECT IMMUN, V82, P3990, DOI 10.1128/IAI.01972-14; Chen E, 2016, P NATL ACAD SCI USA, V113, P6277, DOI 10.1073/pnas.1600488113; Coelho CH, 2019, TRENDS PARASITOL, V35, P483, DOI 10.1016/j.pt.2019.04.008; Coelho CH, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0035-3; Culleton R, 2009, J INFECT DIS, V200, P1465, DOI 10.1086/644510; Doi M, 2011, VACCINE, V29, P4308, DOI 10.1016/j.vaccine.2011.04.028; Drakeley CJ, 2006, PARASITE IMMUNOL, V28, P185, DOI 10.1111/j.1365-3024.2005.00818.x; Gansane A, 2013, MEM I OSWALDO CRUZ, V108, P644, DOI 10.1590/0074-0276108052013017; Genton B, 2008, PLOS MED, V5, P881, DOI 10.1371/journal.pmed.0050127; He X, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4357-9; Healer J, 1997, INFECT IMMUN, V65, P3017, DOI 10.1128/IAI.65.8.3017-3023.1997; Howes RE, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004222; Kochar DK, 2009, AM J TROP MED HYG, V80, P194, DOI 10.4269/ajtmh.2009.80.194; Li YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep18848; MacDonald NJ, 2016, J BIOL CHEM, V291, P19913, DOI 10.1074/jbc.M116.732305; Malkin EM, 2005, VACCINE, V23, P3131, DOI 10.1016/j.vaccine.2004.12.019; Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97; Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9; Naing C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003071; Ouedraogo AL, 2011, INFECT IMMUN, V79, P4957, DOI 10.1128/IAI.05288-11; Saavedra-Langer R, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2471-6; Sagara I, 2018, LANCET INFECT DIS, V18, P969, DOI 10.1016/S1473-3099(18)30344-X; Stanisic DI, 2009, INFECT IMMUN, V77, P1165, DOI 10.1128/IAI.01129-08; Tachibana M, 2012, VACCINE, V30, P1807, DOI 10.1016/j.vaccine.2012.01.003; Tachibana M, 2011, CLIN VACCINE IMMUNOL, V18, P1343, DOI 10.1128/CVI.05104-11; Twohig KA, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007140; Urusova D, 2019, NAT MICROBIOL, V4, P1486, DOI 10.1038/s41564-019-0461-2; Weaver R, 2016, SCI REP-UK, V6, DOI 10.1038/srep33094; World Health Organization, 2018, WORLD MALARIA REPORT; Wu YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002636	39	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2019	10								2295	10.3389/fimmu.2019.02295	http://dx.doi.org/10.3389/fimmu.2019.02295			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JN5ZY	31636633	Green Published, gold			2022-12-18	WOS:000496977400001
J	Hurst, TP; Magiorkinis, G				Hurst, Tara Patricia; Magiorkinis, Gkikas			Editorial: The Past and the Future of Human Immunity Under Viral Evolutionary Pressure	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						human viruses; endogenous retrovirus; immunity; evolution; disease			[Hurst, Tara Patricia] Birmingham City Univ, Sch Hlth Sci, Dept Life Sci, Birmingham, W Midlands, England; [Magiorkinis, Gkikas] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece	Birmingham City University; Athens Medical School; National & Kapodistrian University of Athens	Hurst, TP (corresponding author), Birmingham City Univ, Sch Hlth Sci, Dept Life Sci, Birmingham, W Midlands, England.; Magiorkinis, G (corresponding author), Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece.	tara.hurst@bcu.ac.uk; gkikasmag@gmail.com	Hurst, Tara/AAL-1296-2020	Hurst, Tara/0000-0001-5474-7132				Hurst T, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0242-4	1	2	2	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 2	2019	10								2340	10.3389/fimmu.2019.02340	http://dx.doi.org/10.3389/fimmu.2019.02340			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JN5YD	31632408	gold, Green Published			2022-12-18	WOS:000496972700001
J	Segelmark, M; Bjorck, L				Segelmark, Marten; Bjorck, Lars			Streptococcal Enzymes as Precision Tools Against Pathogenic IgG Autoantibodies in Small Vessel Vasculitis	FRONTIERS IN IMMUNOLOGY			English	Review						vasculitis; ANCA; Streptococcus pygenes; anti-GBM antibody disease; autoantibodies	ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; PLASMA-EXCHANGE; EXPERIMENTAL GLOMERULONEPHRITIS; GLYCAN HYDROLYSIS; ANTIBODIES; NEUTROPHILS; THERAPY; IDES; CLASSIFICATION; ENDOPEPTIDASE	In primary systemic small vessel vasculitis autoantibodies are common and seem to play an important role in the pathogenesis. Autoantibodies in vasculitis are preferentially directed against components of the immune system or directly against components of the vessel wall. Plasmapheresis is often applied in emergency situationists when the function of vital organs is jeopardized, the level of clinical evidence to apply such therapy, however, varies between low and non-existing. Plasmapheresis is a blunt and unspecific instrument that requires several sessions to achieve a substantial reduction of autoantibody levels. IdeS and EndoS are two relatively recently discovered enzymes produced by S. pyogenes, that have a remarkable capacity to degrade and disarm IgG. They have shown positive results in several in vivo models of autoimmunity, and treatment with IdeS has successfully been used to inactivate HLA alloantibodies in patients undergoing renal transplantation. Both IdeS and EndoS have the potential to become precision tools to replace plasmapheresis in the treatment of vasculitic emergencies and a clinical trial of IdeS in anti-GBM vasculitis is now ongoing.	[Segelmark, Marten] Lund Univ, Nephrol, Dept Clin Sci, Lund, Sweden; [Bjorck, Lars] Lund Univ, Infect Med, Dept Clin Sci, Lund, Sweden	Lund University; Lund University	Segelmark, M (corresponding author), Lund Univ, Nephrol, Dept Clin Sci, Lund, Sweden.	marten.segelmark@med.lu.se			Foundation of Knut and Alice Wallenberg; Foundation of Alfred Osterlund; Swedish Government Funds for Clinical Research (ALF); Medical Faculty of Lund University; Hansa Biopharma AB; Swedish Rheumatic Disease Foundation; Ingrid Asp Foundation; Skane University Hospital Funds	Foundation of Knut and Alice Wallenberg(Knut & Alice Wallenberg Foundation); Foundation of Alfred Osterlund; Swedish Government Funds for Clinical Research (ALF); Medical Faculty of Lund University; Hansa Biopharma AB; Swedish Rheumatic Disease Foundation; Ingrid Asp Foundation; Skane University Hospital Funds	LB's work was supported by the Foundations of Knut and Alice Wallenberg and Alfred Osterlund, the Swedish Government Funds for Clinical Research (ALF), the Medical Faculty of Lund University, and Hansa Biopharma AB. MS work was supported the Swedish Rheumatic Disease Foundation, Swedish Government Funds for Clinical Research (ALF), The Ingrid Asp Foundation, Hansa Biopharma AB, Skane University Hospital Funds.	Augusto JF, 2012, AM J KIDNEY DIS, V59, P663, DOI 10.1053/j.ajkd.2011.12.015; Black AK, 1999, CLIN DERMATOL, V17, P565, DOI 10.1016/S0738-081X(99)00062-0; BOLTON WK, 1984, J CLIN INVEST, V73, P1263, DOI 10.1172/JCI111328; Chen TK, 2014, SEMIN ARTHRITIS RHEU, V44, P198, DOI 10.1016/j.semarthrit.2014.03.008; Collin M, 2001, EMBO J, V20, P3046, DOI 10.1093/emboj/20.12.3046; Collin M, 2008, P NATL ACAD SCI USA, V105, P4265, DOI 10.1073/pnas.0711271105; Damoiseaux J, 2014, AUTOIMMUN REV, V13, P359, DOI 10.1016/j.autrev.2014.01.027; Elkon K, 2008, NAT CLIN PRACT RHEUM, V4, P491, DOI 10.1038/ncprheum0895; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Haury M, 1997, EUR J IMMUNOL, V27, P1557, DOI 10.1002/eji.1830270635; Heineke MH, 2017, AUTOIMMUN REV, V16, P1246, DOI 10.1016/j.autrev.2017.10.009; Hellmark T, 2014, J AUTOIMMUN, V48-49, P108, DOI 10.1016/j.jaut.2014.01.024; HOLMAN H. R., 1959, BULL NEW YORK ACAD MED, V35, P409; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; Jayne DRW, 2007, J AM SOC NEPHROL, V18, P2180, DOI 10.1681/ASN.2007010090; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Jin QY, 2018, J COMMUNITY HOSP INT, V8, P339, DOI 10.1080/20009666.2018.1536242; Johansson BP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001692; Jordan SC, 2017, NEW ENGL J MED, V377, P442, DOI 10.1056/NEJMoa1612567; Kallenberg CGM, 2016, CURR OPIN RHEUMATOL, V28, P8, DOI 10.1097/BOR.0000000000000233; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Leslie D, 2001, J CLIN INVEST, V108, P1417, DOI 10.1172/JCI14452; Lorant T, 2018, AM J TRANSPLANT, V18, P2752, DOI 10.1111/ajt.14733; Mahler M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00117; Marson P, 2018, TRANSFUS APHER SCI, V57, P639, DOI 10.1016/j.transci.2018.06.005; Mossberg M, 2018, SCAND J RHEUMATOL, V47, P295, DOI 10.1080/03009742.2017.1412497; Nagele EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060726; Nandakumar KS, 2007, ARTHRITIS RHEUM-US, V56, P3253, DOI 10.1002/art.22930; Ohlsson SM, 2014, CLIN EXP IMMUNOL, V176, P363, DOI 10.1111/cei.12301; Popat RJ, 2019, ANN RHEUM DIS, V78, P709, DOI 10.1136/annrheumdis-2018-214405; PUSEY CD, 1983, CLIN EXP IMMUNOL, V54, P697; PUSEY CD, 1983, INT J ARTIF ORGANS, V6, P15; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Segelmark M, 2019, NEPHROL DIAL TRANSPL, V34, P1826, DOI 10.1093/ndt/gfy327; Soveri I, 2019, KIDNEY INT, V96, P1234, DOI 10.1016/j.kint.2019.06.019; Szpirt WM, 2015, NEPHROL DIAL TRANSPL, V30, pi146, DOI 10.1093/ndt/gfv051; van Rossum AP, 2003, CLIN EXP RHEUMATOL, V21, pS64; van Timmeren MM, 2010, J AM SOC NEPHROL, V21, P1103, DOI 10.1681/ASN.2009090984; Vincents B, 2004, BIOCHEMISTRY-US, V43, P15540, DOI 10.1021/bi048284d; von Pawel-Rammingen U, 2002, EMBO J, V21, P1607, DOI 10.1093/emboj/21.7.1607; Weiner M, 2016, AUTOIMMUN REV, V15, P978, DOI 10.1016/j.autrev.2016.07.016; Winstedt L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132011; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Yang R, 2007, CLIN IMMUNOL, V124, P207, DOI 10.1016/j.clim.2007.05.001; Yang R, 2010, NEPHROL DIAL TRANSPL, V25, P2479, DOI 10.1093/ndt/gfq115	45	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2019	10								2165	10.3389/fimmu.2019.02165	http://dx.doi.org/10.3389/fimmu.2019.02165			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IZ6JJ	31616410	Green Published, gold			2022-12-18	WOS:000487187300001
J	Aris, M; Bravo, AI; Alvarez, HMG; Carri, I; Podaza, E; Blanco, PA; Rotondaro, C; Bentivegna, S; Nielsen, M; Barrio, MM; Mordoh, J				Aris, Mariana; Ines Bravo, Alicia; Garcia Alvarez, Heli Magali; Carri, Ibel; Podaza, Enrique; Alejandra Blanco, Paula; Rotondaro, Cecilia; Bentivegna, Sofia; Nielsen, Morten; Marcela Barrio, Maria; Mordoh, Jose			Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCR beta Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood	FRONTIERS IN IMMUNOLOGY			English	Article						cutaneous melanoma; CSF-470 vaccine; vaccination site; cutaneous metastasis; tumor infiltrating lymphocytes; TCR beta repertoire	METASTATIC MELANOMA; OPEN-LABEL; CELLS; DABRAFENIB; MULTICENTER; VEMURAFENIB; MONOTHERAPY; TRAMETINIB; EXPRESSION; GRANULOMAS	The CSF-470 cellular vaccine plus BCG and rhGM-CSF increased distant metastases-free survival in cutaneous melanoma patients stages IIB-IIC-III relative to medium dose IFN-alpha 2b (CASVAC-0401 study). Patient-045 developed a mature vaccination site (VAC-SITE) and a regional cutaneous metastasis (C-MTS), which were excised during the protocol, remaining disease-free 36 months from vaccination start. CDR3-TCR beta repertoire sequencing in PBMC and tissue samples, along with skin-DTH score and IFN-gamma ELISPOT assay, were performed to analyze the T-cell immune response dynamics throughout the immunization protocol. Histopathological analysis of the VAC-SITE revealed a highly-inflamed granulomatous structure encircled by CD11c(+) nested-clusters, brisk CD8(+) and scarce FOXP3(+), lymphocytes with numerous Langhans multinucleated-giant-cells and macrophages. A large tumor-regression area fulfilled the C-MTS with brisk lymphocyte infiltration, mainly composed of CD8(+)PD1(+) T-cells, CD20(+) B-cells, and scarce FOXP3(+) cells. Increasing DTH score and IFN-gamma ELISPOT assay signal against the CSF-470 vaccine-lysate was evidenced throughout immunization. TCR beta repertoire analysis revealed for the first time the presence of common clonotypes between a VAC-SITE and a C-MTS; most of them persisted in blood by the end of the immunization protocol. In vitro boost with vaccine-lysate revealed the expansion of persistent clones that infiltrated the VAC-SITE and/or the C-MTS; other persistent clones expanded in the patient's blood as well. We propose that expansion of such persistent clonotypes might derive from two different although complementary mechanisms: the proliferation of specific clones as well as the expansion of redundant clones, which increased the number of nucleotide rearrangements per clonotype, suggesting a functional antigenic selection. In this patient, immunization with the CSF-470 vaccine plus BCG and rhGM-CSF induced a T-cell repertoire at the VAC-SITE that was able to infiltrate an emerging C-MTS, which resulted in the expansion of a T-cell repertoire that persisted in blood by the end of the 2-year treatment.	[Aris, Mariana; Podaza, Enrique; Alejandra Blanco, Paula; Marcela Barrio, Maria; Mordoh, Jose] Ctr Invest Oncol Fdn Canc, Buenos Aires, DF, Argentina; [Ines Bravo, Alicia] Hosp Interzonal Gen Agudos Eva Peron, Unidad Inmunopatol, Buenos Aires, DF, Argentina; [Garcia Alvarez, Heli Magali; Carri, Ibel; Nielsen, Morten] UNSAM, IIBIO, Buenos Aires, DF, Argentina; [Rotondaro, Cecilia; Bentivegna, Sofia; Mordoh, Jose] Consejo Nacl Invest Cient & Tecn, IIBBA, Fdn Inst Leloir, Buenos Aires, DF, Argentina; [Nielsen, Morten] Tech Univ Denmark, Dept Hlth Technol, Lyngby, Denmark; [Mordoh, Jose] Inst Alexander Fleming, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Technical University of Denmark	Mordoh, J (corresponding author), Ctr Invest Oncol Fdn Canc, Buenos Aires, DF, Argentina.; Mordoh, J (corresponding author), Consejo Nacl Invest Cient & Tecn, IIBBA, Fdn Inst Leloir, Buenos Aires, DF, Argentina.; Mordoh, J (corresponding author), Inst Alexander Fleming, Buenos Aires, DF, Argentina.	jmordoh@leloir.org.ar	Podaza, Enrique/AAL-9286-2020; Nielsen, Morten/AAL-8700-2020	Podaza, Enrique/0000-0002-3078-9458; Nielsen, Morten/0000-0001-7885-4311; Aris, Mariana/0000-0002-9404-5845	CONICET; Instituto Nacional del Cancer-Ministerio de Salud de la Nacion Argentina (INC-MSal) INC III [IS001946]; Fundacion Sales; Fundacion Cancer; Fundacion Pedro F. Mosoteguy, Argentina; Laboratorio Pablo Cassara S.R.L.	CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Instituto Nacional del Cancer-Ministerio de Salud de la Nacion Argentina (INC-MSal) INC III; Fundacion Sales; Fundacion Cancer; Fundacion Pedro F. Mosoteguy, Argentina; Laboratorio Pablo Cassara S.R.L.	This work was supported by grants from CONICET, Instituto Nacional del Cancer-Ministerio de Salud de la Nacion Argentina (INC-MSal) INC III, IS001946, Fundacion Sales, Fundacion Cancer, Fundacion Pedro F. Mosoteguy, Argentina. The CASVAC0401 study was sponsored by Laboratorio Pablo Cassara S.R.L.	Aris M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00955; Aris M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00144; Arozarena I, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.09; Bajor DL, 2014, CANCER IMMUNOL RES, V2, P1051, DOI 10.1158/2326-6066.CIR-14-0154; Barrio MM, 2006, J IMMUNOTHER, V29, P444, DOI 10.1097/01.cji.0000208258.79005.5f; Byrd TF, 1998, CELL IMMUNOL, V188, P89, DOI 10.1006/cimm.1998.1352; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chapuis AG, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal2568; Chung DJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1372081; Corbiere V, 2011, CANCER RES, V71, P1253, DOI 10.1158/0008-5472.CAN-10-2693; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Gannon PO, 2017, CLIN CANCER RES, V23, P3285, DOI 10.1158/1078-0432.CCR-16-1708; Guirado E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00098; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hopkins AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122092; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Kawakami Y, 2000, J IMMUNOTHER, V23, P17, DOI 10.1097/00002371-200001000-00004; Kluger HM, 2015, CLIN CANCER RES, V21, P3052, DOI 10.1158/1078-0432.CCR-14-3073; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lay G, 2007, J PATHOL, V211, P76, DOI 10.1002/path.2092; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176; Mordoh J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00625; Pampena MB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02531; Pampena MB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01342; Parkhurst M, 2017, CLIN CANCER RES, V23, P2491, DOI 10.1158/1078-0432.CCR-16-2680; Plaza JA, 2010, AM J DERMATOPATH, V32, P129, DOI 10.1097/DAD.0b013e3181b34a19; Puissegur MP, 2007, J IMMUNOL, V178, P3161, DOI 10.4049/jimmunol.178.5.3161; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rosati E, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0379-9; Takeda K, 2018, CANCER IMMUNOL IMMUN, V67, P949, DOI 10.1007/s00262-018-2152-x; Tsuchiya N, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1346764; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ulrichs T, 2006, J PATHOL, V208, P261, DOI 10.1002/path.1906; Valmori D, 2002, J IMMUNOL, V168, P4231, DOI 10.4049/jimmunol.168.8.4231	39	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 18	2019	10								2213	10.3389/fimmu.2019.02213	http://dx.doi.org/10.3389/fimmu.2019.02213			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IY4VR	31620131	Green Published, gold			2022-12-18	WOS:000486391600001
J	del Fresno, C; Cueto, FJ; Sancho, D				del Fresno, Carlos; Cueto, Francisco J.; Sancho, David			A Proposal for Nomenclature in Myeloid C-Type Lectin Receptors	FRONTIERS IN IMMUNOLOGY			English	Review						lectin receptors; signaling; monocytes; macrophages; dendritic cells; innate immunity; nomenclature	CLEC9A(+) DENDRITIC CELLS; BIRBECK GRANULES; ANTIGENS; DNGR-1	Myeloid C-type lectin receptors (CLRs) comprise a family of receptors expressed by immune myeloid cells that share homologous C-type lectin domains. The implication of these CLRs in the regulation of homeostasis and activation of myeloid cells has generated a buoyant growth in the number of studies involving these receptors. Since their first description, diverse nomenclature has been used to refer to each of them, ranging from systematic classifications, such as gene name or cluster of differentiation, to non-systematic ones that include terminology based on gene expression patterns or function. In this review, we aim to summarize the different names used for the main myeloid CLRs and analyze which of them have been more frequently used in the literature. In addition, we have examined the evolution of the terminology applied to these myeloid CLRs over time. Based on this analysis, we propose a consensus alias for each of those myeloid CLRs. However, we acknowledge that systematicity is required beyond this terminology based on use frequency. Therefore, we have included gene names as the standardization tool to gather the maximum agreement. We suggest that a standard nomenclature consisting of both gene names and consensus alias should be included at least in scientific abstracts, which would help to identify relevant literature, saving time and effort and fostering the research in this field in a more systematic manner.	[del Fresno, Carlos; Cueto, Francisco J.; Sancho, David] CNIC, Immunobiol Lab, Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC)	del Fresno, C; Sancho, D (corresponding author), CNIC, Immunobiol Lab, Madrid, Spain.	carlos.delfresno@cnic.es; dsancho@cnic.es	Del Fresno, Carlos/ABD-7766-2020; Cueto, Francisco J/AGN-4489-2022; Sancho, David/D-3433-2009; Del Fresno Sánchez, CArlos/AAY-1525-2021	Del Fresno, Carlos/0000-0003-1771-7254; Cueto, Francisco J/0000-0002-7457-9583; Sancho, David/0000-0003-2890-3984; 	AECC Foundation [INVES192DELF]; CNIC; Ministerio de Ciencia, Innovacion e Universidades (MCIU) [SAF2016-79040-R]; Agencia Estatal de Investigacion; Fondo Europeo de Desarrollo Regional (FEDER); Immunothercan-CM from Comunidad de Madrid [B2017/BMD-3733]; FIS-Instituto de Salud Carlos III [RD16/0015/0018-REEM]; MICINN; FEDER; Acteria Foundation; Constantes y Vitales prize (Atresmedia); La Marato de TV3 Foundation [201723]; European Research Council (ERC) [725091]; European Commission [635122-PROCROP H2020]; MCIU; Pro-CNIC Foundation	AECC Foundation; CNIC; Ministerio de Ciencia, Innovacion e Universidades (MCIU); Agencia Estatal de Investigacion; Fondo Europeo de Desarrollo Regional (FEDER)(European CommissionSpanish Government); Immunothercan-CM from Comunidad de Madrid; FIS-Instituto de Salud Carlos III(Instituto de Salud Carlos III); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); FEDER(European Commission); Acteria Foundation; Constantes y Vitales prize (Atresmedia); La Marato de TV3 Foundation; European Research Council (ERC)(European Research Council (ERC)European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre); MCIU; Pro-CNIC Foundation	CF was supported by AECC Foundation (INVES192DELF). Work in the DS laboratory was funded by the CNIC and grant SAF2016-79040-R from Ministerio de Ciencia, Innovacion e Universidades (MCIU), Agencia Estatal de Investigacion and Fondo Europeo de Desarrollo Regional (FEDER); B2017/BMD-3733 Immunothercan-CM from Comunidad de Madrid; RD16/0015/0018-REEM from FIS-Instituto de Salud Carlos III, MICINN, and FEDER; Acteria Foundation; Constantes y Vitales prize (Atresmedia); La Marato de TV3 Foundation (201723); the European Research Council (ERC-2016-Consolidator Grant 725091); and the European Commission (635122-PROCROP H2020). The CNIC is supported by the MCIU and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505).	Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Barber N, 2009, FEBS LETT, V583, P1785, DOI 10.1016/j.febslet.2009.03.018; Clark G, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2015.38; Colonna M, 2000, EUR J IMMUNOL, V30, P697; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; del Fresno C, 2018, SCIENCE, V362, P351, DOI 10.1126/science.aan8423; del Fresno C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00804; Delvin E, 2016, FEBS J, V283, P3882, DOI [10.1111/febs.13918, DOI 10.1111/FEBS.13918]; Ecker Erika D, 2010, Evid Based Spine Care J, V1, P9, DOI 10.1055/s-0028-1100887; Engel P, 2015, J IMMUNOL, V195, P4555, DOI 10.4049/jimmunol.1502033; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gilfillan CB, 2018, J IMMUNOL, V200, P2978, DOI 10.4049/jimmunol.1701593; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kanazawa N, 2007, J DERMATOL SCI, V45, P77, DOI 10.1016/j.jdermsci.2006.09.001; Masumoto M, 1999, J IMMUNOL, V163, P5039; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mc Dermott R, 2002, MOL BIOL CELL, V13, P317, DOI 10.1091/mbc.01-06-0300; Piva L, 2012, J IMMUNOL, V189, P1128, DOI 10.4049/jimmunol.1201171; Rock J, 2007, EUR J IMMUNOL, V37, P3564, DOI 10.1002/eji.200737711; Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584; Sancho D, 2012, ANNU REV IMMUNOL, V30, P491, DOI 10.1146/annurev-immunol-031210-101352; Valladeau J, 2003, IMMUNOL RES, V28, P93, DOI 10.1385/IR:28:2:93; van Kooyk Y, 2013, MOL IMMUNOL, V55, P143, DOI 10.1016/j.molimm.2012.10.031; Zelenay S, 2012, J CLIN INVEST, V122, P1615, DOI 10.1172/JCI60644; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	25	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2019	10								2098	10.3389/fimmu.2019.02098	http://dx.doi.org/10.3389/fimmu.2019.02098			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IV8TJ	31555291	Green Published, gold			2022-12-18	WOS:000484537600001
J	Pean, P; Nouhin, J; Ratana, M; Madec, Y; Borand, L; Marcy, O; Laureillard, D; Fernandez, M; Barre-Sinoussi, F; Weiss, L; Scott-Algara, D				Pean, Polidy; Nouhin, Janin; Ratana, Meng; Madec, Yoann; Borand, Laurence; Marcy, Olivier; Laureillard, Didier; Fernandez, Marcelo; Barre-Sinoussi, Francoise; Weiss, Laurence; Scott-Algara, Daniel			High Activation of gamma delta T Cells and the gamma delta 2(pos) T-Cell Subset Is Associated With the Onset of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome, ANRS 12153 CAPRI NK	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; tuberculosis; immune reconstitution inflammatory syndrome; gamma delta T cells; invariant NKT cells	HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED PATIENTS; PERIPHERAL-BLOOD; RECEPTOR; LIGANDS; CYTOTOXICITY; LYMPHOCYTES; EXPRESSION; DISEASE	Background: Human Immunodeficiency Virus 1 (HIV-1) and Mycobacterium Tuberculosis (Mtb) co-infected patients are commonly at risk of immune reconstitution inflammatory syndrome (IRIS) when initiating antiretroviral treatment (ART). Evidence indicates that innate immunity plays a role in TB-IRIS. Here, we evaluate the phenotype of Gamma-delta (gamma delta) T cells and invariant Natural Killer (iNK) T cells in tuberculosis-associated IRIS. Methods: Forty-eight HIV+/TB+ patients (21 IRIS) and three control groups: HIV-/TB- (HD, n = 11), HIV+/TB- (n = 26), and HIV-/TB+ (n = 22) were studied. Samples were taken at ART initiation (week 2 of anti-tuberculosis treatment) and at the diagnosis of IRIS for HIV+/TB+; before ART for HIV+/TB-, and at week 2 of anti-tuberculosis treatment for HIV-/TB+ patients. gamma delta T cells and Invariant natural killer T (iNKT) cells were analyzed by flow cytometry. Results: Before ART, IRIS, and non-IRIS patients showed a similar proportion of gamma delta(pos) T and iNKT cells. HLA-DR on gamma delta(pos) T cells and delta 2(pos)gamma delta(pos) T cells was significantly higher in TB-IRIS vs. non-IRIS patients and controls (p < 0.0001). NKG2D expression on gamma delta(pos) T cells and the gamma 2(pos)gamma delta(pos) T cell subset was lower in HIV+/TB+ patients than controls. CD158a expression on gamma delta(pos) T cells was higher in TB-IRIS than non-IRIS (p = 0.02), HIV+/TB-, and HIV-/TB- patients. Conclusion: The higher activation of gamma delta T-pos cells and the gamma delta 2(pos)gamma delta(pos) T cell subset suggests that gamma delta T cells may play a role in the pathogenesis of TB-IRIS.	[Pean, Polidy; Ratana, Meng] Inst Pasteur Cambodge, Immunol Unit, Phnom Penh, Cambodia; [Nouhin, Janin] Inst Pasteur Cambodge, Virol Unit, Phnom Penh, Cambodia; [Madec, Yoann] Inst Pasteur, Unite Epidemiol Malad Emergentes, Paris, France; [Borand, Laurence] Inst Pasteur Cambodge, Epidemiol & Publ Hlth Unit, Phnom Penh, Cambodia; [Marcy, Olivier] Univ Bordeaux, Bordeaux Populat Hlth, Ctr Inserm U1219, Bordeaux, France; [Laureillard, Didier] Univ Hosp, Dept Infect & Trop Dis, Nimes, France; [Fernandez, Marcelo] Med Sans Frontieres, Geneva, Switzerland; [Barre-Sinoussi, Francoise] Inst Pasteur, Paris, France; [Weiss, Laurence] Hop Europeen Georges Pompidou, Serv Immunol Clin, Paris, France; [Weiss, Laurence] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Scott-Algara, Daniel] Inst Pasteur, Unite Biol Cellulaire Lymphocytes, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Universite de Montpellier; CHU de Nimes; Doctors Without Borders; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Pean, P (corresponding author), Inst Pasteur Cambodge, Immunol Unit, Phnom Penh, Cambodia.	polidy@pasteur-kh.org	pean, polidy/AAM-9582-2020; Nouhin, Janin/AAM-2322-2021; Scott, Daniel/AFK-5428-2022; Nouhin, Janin/AAS-6946-2020	pean, polidy/0000-0002-2252-9277; Nouhin, Janin/0000-0003-4985-8377; Nouhin, Janin/0000-0003-4985-8377	Association of the Pasteur Institute International Network (Pasteur-Fiocruz 2010); Pasteur Institute International Network/Dedonder-Clayton award	Association of the Pasteur Institute International Network (Pasteur-Fiocruz 2010); Pasteur Institute International Network/Dedonder-Clayton award	This work was supported by the Association of the Pasteur Institute International Network (Pasteur-Fiocruz 2010) and Pasteur Institute International Network/Dedonder-Clayton award.	Bachle SM, 2016, AIDS, V30, P1713, DOI 10.1097/QAD.0000000000001147; Baena A, 2009, TISSUE ANTIGENS, V74, P189, DOI 10.1111/j.1399-0039.2009.01301.x; Belkina AC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02783; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Berzins SP, 2011, NAT REV IMMUNOL, V11, P131, DOI 10.1038/nri2904; Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911; Bordon J, 2004, J INFECT DIS, V189, P1482, DOI 10.1086/382961; Bourgarit A, 2009, J IMMUNOL, V183, P3915, DOI 10.4049/jimmunol.0804020; Carrington M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007070; Carrington M, 2008, TRENDS MICROBIOL, V16, P620, DOI 10.1016/j.tim.2008.09.002; Carvalho ACC, 2002, THORAX, V57, P357, DOI 10.1136/thorax.57.4.357; Chaudhry S, 2013, AIDS, V27, P1557, DOI 10.1097/QAD.0b013e3283611888; Conradie F, 2011, JAIDS-J ACQ IMM DEF, V58, P309, DOI 10.1097/QAI.0b013e31822e0d15; Dolstra H, 2001, BONE MARROW TRANSPL, V27, P1087, DOI 10.1038/sj.bmt.1703043; Exley MA, 2008, EUR J IMMUNOL, V38, P1756, DOI 10.1002/eji.200737389; Fausther-Bovendoa H, 2008, AIDS, V22, P217, DOI 10.1097/QAD.0b013e3282f46e7c; Fernandez CS, 2014, IMMUNOL CELL BIOL, V92, P578, DOI 10.1038/icb.2014.25; Garand M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00257; Gaudieri S, 2005, GENES IMMUN, V6, P683, DOI 10.1038/sj.gene.6364256; Germain C, 2011, J BIOL CHEM, V286, P37964, DOI 10.1074/jbc.M111.285312; Haik J, 2016, ONCOTARGET, V7, P2220, DOI 10.18632/oncotarget.6789; Haridas V, 2015, AIDS, V29, P263, DOI 10.1097/QAD.0000000000000546; Hassan SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070063; Jiang YJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/863625; Kleinnijenhuis J, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/405310; Kosub DA, 2008, J VIROL, V82, P1155, DOI 10.1128/JVI.01275-07; Lai RPJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9451; Laureillard D, 2013, AIDS, V27, P2577, DOI 10.1097/01.aids.0000432456.14099.c7; Lawand M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00761; Lawn SD, 2009, AIDS, V23, P143, DOI 10.1097/QAD.0b013e32831d2a98; Luetkemeyer AF, 2014, JAIDS-J ACQ IMM DEF, V65, P423, DOI 10.1097/QAI.0000000000000030; Maggi L, 2010, EUR J IMMUNOL, V40, P2174, DOI 10.1002/eji.200940257; Maniar A, 2010, BLOOD, V116, P1726, DOI 10.1182/blood-2009-07-234211; Matusali G, 2013, FASEB J, V27, P2440, DOI 10.1096/fj.12-223057; Moll M, 2009, EUR J IMMUNOL, V39, P902, DOI 10.1002/eji.200838780; Montoya CJ, 2008, CLIN IMMUNOL, V127, P1, DOI 10.1016/j.clim.2007.12.006; Naidoo K, 2012, ANN INTERN MED, V157, P313, DOI 10.7326/0003-4819-157-5-201209040-00004; Naranbhai V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053251; Paquin-Proulx D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01394; Parasa VRR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037448; Pauza CD, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00687; Pean P, 2012, BLOOD, V119, P3315, DOI 10.1182/blood-2011-09-377523; Poggi A, 2004, BLOOD, V103, P2205, DOI 10.1182/blood-2003-08-2928; Ravimohan S, 2016, CLIN INFECT DIS, V62, P795, DOI 10.1093/cid/civ978; Ribeiro S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00015; Rincon-Orozco B, 2005, J IMMUNOL, V175, P2144, DOI 10.4049/jimmunol.175.4.2144; Rothchild AC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003805; Salih HR, 2008, FRONT BIOSCI, V13, P3448; Sandberg JK, 2004, P NATL ACAD SCI USA, V101, P7058, DOI 10.1073/pnas.0305986101; Shrestha N, 2005, ANN NY ACAD SCI, V1062, P79, DOI 10.1196/annals.1358.011; Snyder-Cappione JE, 2009, AIDS, V23, P1965, DOI 10.1097/QAD.0b013e32832b5134; Sullivan ZA, 2015, EBIOMEDICINE, V2, P334, DOI 10.1016/j.ebiom.2015.03.005; Sutherland JS, 2009, TUBERCULOSIS, V89, P398, DOI 10.1016/j.tube.2009.07.004; Szereday L, 2008, INT J TUBERC LUNG D, V12, P262; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Tan HY, 2016, J IMMUNOL, V196, P4052, DOI 10.4049/jimmunol.1502203; van der Vliet HJJ, 2006, J IMMUNOL, V177, P5775, DOI 10.4049/jimmunol.177.9.5775; van der Vliet HJJ, 2002, J IMMUNOL, V168, P1490, DOI 10.4049/jimmunol.168.3.1490; Vankayalapati R, 2005, J IMMUNOL, V175, P4611, DOI 10.4049/jimmunol.175.7.4611; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Walker NF, 2020, CLIN INFECT DIS, V70, P1865, DOI 10.1093/cid/ciz501; Walker NF, 2018, CURR OPIN HIV AIDS, V13, P512, DOI [10.1097/COH.0000000000000502, 10.1097/coh.0000000000000502]; Wilkinson KA, 2015, J IMMUNOL, V194, P1748, DOI 10.4049/jimmunol.1402105	63	2	3	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 27	2019	10								2018	10.3389/fimmu.2019.02018	http://dx.doi.org/10.3389/fimmu.2019.02018			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IT4GK	31507608	Green Published, gold			2022-12-18	WOS:000482818400002
J	Barham, MS; Abrahams, DA; Khayumbi, J; Ongalo, J; Tonui, J; Campbell, A; de Kock, M; Ouma, SG; Odhiambo, FH; Hanekom, WA; Gandhi, NR; Day, CL				Barham, Morgan S.; Abrahams, Deborah A.; Khayumbi, Jeremiah; Ongalo, Joshua; Tonui, Joan; Campbell, Angela; de Kock, Marwou; Ouma, Samuel Gurrion; Odhiambo, Felix Hayara; Hanekom, Willem A.; Gandhi, Neel R.; Day, Cheryl L.			HIV Infection Is Associated With Downregulation of BTLA Expression on Mycobacterium tuberculosis-Specific CD4T Cells in Active Tuberculosis Disease	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; Mycobacterium tuberculosis; LTBI; active TB disease; CD4T cell; BTLA; CTLA-4; PD-1	T-LYMPHOCYTE ATTENUATOR; B-LYMPHOCYTE; INHIBITORY RECEPTORS; EXHAUSTION; RESPONSES; PATHWAYS; CTLA-4; PD-1; INDIVIDUALS; DEPLETION	Nearly a quarter of the global population is infected with Mycobacterium tuberculosis (Mtb), with 10 million people developing active tuberculosis (TB) annually. Co-infection with human immunodeficiency virus (HIV) has long been recognized as a significant risk factor for progression to TB disease, yet the mechanisms whereby HIV impairs T cell-mediated control of Mtb infection remain poorly defined. We hypothesized that HIV infection may promote upregulation of inhibitory receptors on Mtb-specific CD4 T cells, a mechanism that has been associated with antigen-specific T cell dysfunction in chronic infections. Using cohorts of HIV-infected and HIV-uninfected individuals with latent Mtb infection (LTBI) and with active TB disease, we stimulated peripheral blood mononuclear cells (PBMC) for 6 hours with Mtb peptide pools and evaluated co-expression profiles of the inhibitory receptors BTLA, CTLA-4, and PD-1 on IFN-gamma(+)/TNF-alpha(+) Mtb-specific CD4 T cells. Mtb-specific CD4 T cells in all participant groups expressed predominately either one or no inhibitory receptors, unlike cytomegalovirus- and HIV-specific CD4 T cells circulating in the same individuals, which were predominately CTLA-4(+)PD-1(+). There were no significant differences in inhibitory receptor expression profiles of Mtb-specific CD4 T cells between HIV-uninfected and HIV-infected individuals with LTBI. Surprisingly, BTLA expression, both alone and in combination with CTLA-4 and PD-1, was markedly downregulated on Mtb-specific CD4 T cells in HIV-infected individuals with active TB. Together, these data provide novel evidence that the majority of Mtb-specific CD4T cells do not co-express multiple inhibitory receptors, regardless of HIV infection status; moreover, they highlight a previously unrecognized role of BTLA expression on Mtb-specific CD4T cells that could be further explored as a potential biomarker of Mtb infection status, particularly in people living with HIV, the population at greatest risk for development of active TB disease.	[Barham, Morgan S.; Day, Cheryl L.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA; [Abrahams, Deborah A.; de Kock, Marwou; Hanekom, Willem A.] Univ Cape Town, Sch Child & Adolescent Hlth, South African TB Vaccine Initiat, Inst Infect Dis & Mol Med, Cape Town, South Africa; [Khayumbi, Jeremiah; Ongalo, Joshua; Tonui, Joan; Ouma, Samuel Gurrion; Odhiambo, Felix Hayara] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya; [Campbell, Angela; Gandhi, Neel R.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Gandhi, Neel R.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA; [Day, Cheryl L.] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; [Hanekom, Willem A.] Bill & Melinda Gates Fdn, Seattle, WA USA	Emory University; University of Cape Town; Kenya Medical Research Institute; Emory University; Rollins School Public Health; Emory University; Emory University; Bill & Melinda Gates Foundation	Day, CL (corresponding author), Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.; Day, CL (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.	cday@emory.edu	Day, Cheryl L/J-9844-2012; Day, Cheryl/GQQ-9720-2022	Day, Cheryl L/0000-0002-6497-4846; Hanekom, Willem/0000-0003-3070-6154	National Institute of Allergy and Infectious Diseases at the National Institutes of Health [K24AI114444, U19AI111211, 3R01AI111948-03S1, 5R01AI083156, 5R01AI111948]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI111211, R01AI111948, K24AI114444] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by grants to CD from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (5R01AI083156, 5R01AI111948, U19AI111211). MB was supported by a Research Supplement to Promote Diversity in Health-Related Research from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (3R01AI111948-03S1). NG was supported by grants from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (K24AI114444, U19AI111211).	Amelio P, 2019, J VIROL, V93, DOI 10.1128/JVI.01728-18; [Anonymous], 2018, GLOBAL TUBERCULOSIS; Attanasio J, 2016, IMMUNITY, V44, P1052, DOI 10.1016/j.immuni.2016.04.022; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Borsuk S, 2009, TUBERCULOSIS, V89, P423, DOI 10.1016/j.tube.2009.07.003; Bunjun R, 2017, J INFECT DIS, V216, P1550, DOI 10.1093/infdis/jix529; Cho YS, 2012, PROTEOMICS, V12, P979, DOI 10.1002/pmic.201100544; Crawford A, 2014, IMMUNITY, V40, P289, DOI 10.1016/j.immuni.2014.01.005; Day CL, 2008, J INFECT DIS, V197, P990, DOI 10.1086/529048; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Day CL, 2017, J IMMUNOL, V199, P2069, DOI 10.4049/jimmunol.1700558; Day CL, 2011, J IMMUNOL, V187, P2222, DOI 10.4049/jimmunol.1101122; Deppong C, 2006, J IMMUNOL, V176, P3909, DOI 10.4049/jimmunol.176.7.3909; Doering TA, 2012, IMMUNITY, V37, P1130, DOI 10.1016/j.immuni.2012.08.021; Ernst JD, 2012, NAT REV IMMUNOL, V12, P581, DOI 10.1038/nri3259; Finak G, 2014, BIOSTATISTICS, V15, P87, DOI 10.1093/biostatistics/kxt024; Flynn R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077991; Geldmacher C, 2008, J INFECT DIS, V198, P1590, DOI 10.1086/593017; Geldmacher C, 2010, J EXP MED, V207, P2869, DOI 10.1084/jem.20100090; Gonzalez LC, 2005, P NATL ACAD SCI USA, V102, P1116, DOI 10.1073/pnas.0409071102; Han P, 2004, J IMMUNOL, V172, P5931, DOI 10.4049/jimmunol.172.10.5931; Harari A, 2006, IMMUNOL REV, V211, P236, DOI 10.1111/j.0105-2896.2006.00395.x; Horton KC, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002152, 10.1371/journal.pmed.1002119]; Hurchla MA, 2007, J IMMUNOL, V178, P6073, DOI 10.4049/jimmunol.178.10.6073; Jayaraman P, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005490; Kassu A, 2010, J IMMUNOL, V185, P3007, DOI 10.4049/jimmunol.1000156; Kaufmann DE, 2007, NAT IMMUNOL, V8, P1246, DOI 10.1038/ni1515; Kaufmann DE, 2009, J IMMUNOL, V182, P5891, DOI 10.4049/jimmunol.0803771; Kern F, 2000, EUR J IMMUNOL, V30, P1676, DOI 10.1002/1521-4141(200006)30:6<1676::AID-IMMU1676>3.0.CO;2-V; Kern F, 2002, J INFECT DIS, V185, P1709, DOI 10.1086/340637; Lawn SD, 2011, LANCET, V378, P57, DOI 10.1016/S0140-6736(10)62173-3; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Maecker HT, 2001, J IMMUNOL METHODS, V255, P27, DOI 10.1016/S0022-1759(01)00416-1; Murphy TL, 2010, ANNU REV IMMUNOL, V28, P389, DOI 10.1146/annurev-immunol-030409-101202; Odorizzi PM, 2012, J IMMUNOL, V188, P2957, DOI 10.4049/jimmunol.1100038; Piasecka B, 2018, P NATL ACAD SCI USA, V115, pE488, DOI 10.1073/pnas.1714765115; Pollock KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146905; Pollock KM, 2013, J INFECT DIS, V208, P952, DOI 10.1093/infdis/jit265; Porichis F, 2011, BLOOD, V118, P965, DOI 10.1182/blood-2010-12-328070; Qiu YQ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002984; Riou C, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00968; Riou C, 2016, TUBERCULOSIS, V101, P25, DOI 10.1016/j.tube.2016.07.018; Schmiedel BJ, 2018, CELL, V175, P1701, DOI 10.1016/j.cell.2018.10.022; Sedy JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/ni1144; Sterling TR, 2010, CLIN INFECT DIS, V50, pS223, DOI 10.1086/651495; Strickland N, 2017, J IMMUNOL, V199, P2440, DOI 10.4049/jimmunol.1700849; Teigler JE, 2017, J VIROL, V91, DOI 10.1128/JVI.01263-17; Watanabe N, 2003, NAT IMMUNOL, V4, P670, DOI 10.1038/ni944; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wong EA, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00426-18; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; Zhang BC, 2016, J BASIC MICROB, V56, P670, DOI 10.1002/jobm.201500751; Zhang Z, 2011, J INFECT DIS, V203, P1668, DOI 10.1093/infdis/jir165	55	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 21	2019	10								1983	10.3389/fimmu.2019.01983	http://dx.doi.org/10.3389/fimmu.2019.01983			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IS3HO	31497018	gold, Green Published			2022-12-18	WOS:000482044400001
J	Mvaya, L; Mwale, A; Hummel, A; Phiri, J; Kamng'ona, R; Mzinza, D; Chimbayo, E; Malamba, R; Kankwatira, A; Mwandumba, HC; Jambo, KC				Mvaya, Leonard; Mwale, Andrew; Hummel, Annemarie; Phiri, Joseph; Kamng'ona, Raphael; Mzinza, David; Chimbayo, Elizabeth; Malamba, Rose; Kankwatira, Anstead; Mwandumba, Henry C.; Jambo, Kondwani C.			Airway CD8(+)CD161(++)TCRv alpha 7.2(+) T Cell Depletion During Untreated HIV Infection Targets CD103 Expressing Cells	FRONTIERS IN IMMUNOLOGY			English	Article						airway; HIV; CD103; CD8T cell; adult	MAIT CELLS; HOST-DEFENSE; MUCOSAL; LYMPHOCYTES; RESPONSES; DECREASE; IMMUNITY; DEFINES; MOUSE	HIV-infected adults are at an increased risk to lower respiratory tract infections (LRTIs). CD8(+)CD161(++)TCRv alpha 7.2(+) T cells are an innate-like T cell subset that are thought to play an important role in early defense against pathogens in the respiratory tract. HIV infection leads to irreversible depletion of these cells in peripheral blood, however, its impact on this subset in the human airway is still unclear. Here, we show presence of CD103 expressing CD8(+)CD161(++)TCRv alpha 7.2(+) T cells in the airway that exhibited a distinct cytokine functional profile compared to their CD103(-) airway counterparts and those from peripheral blood. These CD103 expressing airway CD8(+)CD161(++)TCRv alpha 7.2(+) T cells were selectively depleted in untreated HIV-infected adults compared to healthy controls. Their frequency was positively correlated with frequency of airway CD4(+) T cells. Furthermore, the frequency of airway CD8(+)CD161(++)TCRv alpha 7.2(+) T cells was also inversely correlated with HIV plasma viral load, while suppressive antiretroviral therapy (ART) resulted in restoration of airway CD8(+)CD161(++)TCRv alpha 7.2(+) T cells. Our findings show that CD103 expressing airway CD8(+)CD161(++)TCRv alpha 7.2(+) T cells are functionally distinct and are preferentially depleted during untreated asymptomatic HIV infection. Depletion of CD103 expressing airway CD8(+)CD161(++)TCRv alpha 7.2(+) T cells, at a major portal of pathogen entry, could partly contribute to the increased propensity for opportunistic LRTIs observed in untreated HIV-infected adults.	[Mvaya, Leonard; Mwale, Andrew; Hummel, Annemarie; Phiri, Joseph; Kamng'ona, Raphael; Mzinza, David; Chimbayo, Elizabeth; Malamba, Rose; Kankwatira, Anstead; Mwandumba, Henry C.; Jambo, Kondwani C.] Univ Malawi, Malawi Liverpool Wellcome Trust Clin Res Programm, Coll Med, Blantyre, Malawi; [Mzinza, David; Mwandumba, Henry C.; Jambo, Kondwani C.] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England	University of Malawi; Liverpool School of Tropical Medicine	Jambo, KC (corresponding author), Univ Malawi, Malawi Liverpool Wellcome Trust Clin Res Programm, Coll Med, Blantyre, Malawi.; Jambo, KC (corresponding author), Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England.	kondwani.jambo@istmed.ac.uk		Mvaya, Leonard/0000-0002-5376-1706; Jambo, Kondwani/0000-0002-3195-2210; Mzinza, David/0000-0002-5999-8616	Wellcome (UK) [105831/Z/14/Z]; MRC (UK) [MR/P02056/1]; Bill and Melinda Gates Foundation [OPP1125279]; Wellcome	Wellcome (UK); MRC (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Wellcome	This work was funded by the Wellcome (UK) through an Intermediate Fellowship number 105831/Z/14/Z awarded to KJ. HM was supported by the MRC (UK) and the Bill and Melinda Gates Foundation through grant numbers MR/P02056/1 and OPP1125279, respectively. The Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) was supported by a strategic award from the Wellcome.	Archer NK, 2016, INFECT IMMUN, V84, P3575, DOI 10.1128/IAI.00596-16; Barathan M, 2016, EUR J CLIN INVEST, V46, P170, DOI 10.1111/eci.12581; Benito N, 2012, EUR RESPIR J, V39, P730, DOI 10.1183/09031936.00200210; Billerbeck E, 2010, P NATL ACAD SCI USA, V107, P3006, DOI 10.1073/pnas.0914839107; Booth JS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00466; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chen K, 2016, CELL HOST MICROBE, V20, P596, DOI 10.1016/j.chom.2016.10.003; Chen Z, 2017, MUCOSAL IMMUNOL, V10, P58, DOI 10.1038/mi.2016.39; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Chua WJ, 2012, INFECT IMMUN, V80, P3256, DOI 10.1128/IAI.00279-12; Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436; Cummins NW, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.77; Dias J, 2018, P NATL ACAD SCI USA, V115, pE11513, DOI 10.1073/pnas.1812273115; Fernandez CS, 2015, IMMUNOL CELL BIOL, V93, P177, DOI 10.1038/icb.2014.91; Gibbs A, 2017, MUCOSAL IMMUNOL, V10, P35, DOI 10.1038/mi.2016.30; Gold MC, 2015, IMMUNOL REV, V264, P154, DOI 10.1111/imr.12271; Gold MC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000407; Greathead L, 2014, AIDS, V28, P1690, DOI 10.1097/QAD.0000000000000351; Guglani L, 2010, CURR OPIN HIV AIDS, V5, P120, DOI 10.1097/COH.0b013e328335c2f6; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Jambo KC, 2014, MUCOSAL IMMUNOL, V7, P1116, DOI 10.1038/mi.2013.127; Jambo KC, 2014, AM J RESP CRIT CARE, V190, P938, DOI 10.1164/rccm.201405-0864OC; Jambo KC, 2011, THORAX, V66, P375, DOI 10.1136/thx.2010.153825; Jiang J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32320; Jiang J, 2014, AM J RESP CRIT CARE, V190, P329, DOI 10.1164/rccm.201401-0106OC; Kim CJ, 2012, MUCOSAL IMMUNOL, V5, P670, DOI 10.1038/mi.2012.72; Kurioka A, 2018, J INFECT DIS, V217, P988, DOI 10.1093/infdis/jix647; Kwon YS, 2015, TUBERCULOSIS, V95, P267, DOI 10.1016/j.tube.2015.03.004; Laidlaw BJ, 2014, IMMUNITY, V41, P633, DOI 10.1016/j.immuni.2014.09.007; Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890; Leeansyah E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005072; Leeansyah E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4143; Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429; Martin E, 2009, PLOS BIOL, V7, P525, DOI 10.1371/journal.pbio.1000054; Martinson Neil A, 2011, Proc Am Thorac Soc, V8, P288, DOI 10.1513/pats.201010-064WR; Meierovics A, 2013, P NATL ACAD SCI USA, V110, pE3119, DOI 10.1073/pnas.1302799110; Murray JF, 2005, INT J TUBERC LUNG D, V9, P826; Mwale A, 2017, WELLCOME OPEN RES, V2, P105; Popescu L, 2014, AM J RESP CRIT CARE, V190, P744, DOI 10.1164/rccm.201407-1226OC; Ringel Y, 2015, GUT MICROBES, V6, P173, DOI 10.1080/19490976.2015.1044711; Saeidi A, 2016, J LEUKOCYTE BIOL, V100, P305, DOI 10.1189/jlb.4RU0216-084R; Saeidi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124659; Sakala IG, 2015, J IMMUNOL, V195, P587, DOI 10.4049/jimmunol.1402545; Segal Leopoldo N, 2011, Proc Am Thorac Soc, V8, P282, DOI 10.1513/pats.201006-044WR; Sharma PK, 2015, IMMUNOLOGY, V145, P443, DOI 10.1111/imm.12461; Sobkowiak MJ, 2019, EUR J IMMUNOL, V49, P133, DOI 10.1002/eji.201847759; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Topham DJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00515; Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433; Twigg HL, 2017, TRANSL RES, V179, P97, DOI 10.1016/j.trsl.2016.07.008; Ussher JE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00450; Van Dyken SJ, 2016, NAT IMMUNOL, V17, P1381, DOI 10.1038/ni.3582; Vinton C, 2016, J VIROL, V90, P4520, DOI 10.1128/JVI.02876-15; Wong EB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083474; Yong YK, 2017, INNATE IMMUN-LONDON, V23, P459, DOI 10.1177/1753425917714854	55	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 21	2019	10								2003	10.3389/fimmu.2019.02003	http://dx.doi.org/10.3389/fimmu.2019.02003			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IS3IE	31497028	gold, Green Accepted, Green Published			2022-12-18	WOS:000482046100002
J	Melillo, D; Marino, R; Della Camera, G; Italiani, P; Boraschi, D				Melillo, Daniela; Marino, Rita; Della Camera, Giacomo; Italiani, Paola; Boraschi, Diana			Assessing Immunological Memory in the Solitary Ascidian Ciona robusta	FRONTIERS IN IMMUNOLOGY			English	Article						Ciona robusta; innate immunity; immunological memory; innate memory; immune priming	IMMUNE MEMORY; INVERTEBRATE CYTOKINES; COMPLEMENT-SYSTEM; INTESTINALIS; TUNICATE; INNATE; EXPRESSION; LPS; IDENTIFICATION; GENES	The immune defensive mechanisms active in the solitary ascidian Ciona robusta include phagocytic and encapsulating activity, largely brought about by phagocytic cells within the haemocyte population, the presence of complement components, which have been molecularly and functionally identified, and expression of a number of immune-related genes and pathways, identified by genome-based homology with vertebrate counterparts. Since C. robusta only displays highly conserved innate immune mechanisms, being devoid of an adaptive immune system, this organism is an excellent model for studying the features of innate memory, i.e., the capacity of the innate immune system to re-programming its responsiveness to potentially dangerous agents upon repeated exposure. In this study, we have developed an in vivo model for assessing the establishment and molecular/functional features of innate memory, by sequentially exposing C. robusta to a priming stimulus (microbial molecules), followed by a period of resting to return to basal conditions, and a challenge with microbial agents in homologous or cross-stimulation. The endpoints of immune activation were a functional activity (phagocytosis) and the molecular profiles of immune-related gene expression. The results show that exposure of C. robusta to microbial agents induces a reaction that primes animals for developing a different (expectedly more protective) response to subsequent challenges, showing the effective establishment of an immune memory. This immune memory relies on the modulation of a number of different mechanisms, some of which are priming-specific, others that are challenge-specific, and others that are non-specific, i.e., are common to all priming/challenge combinations (e.g., up-regulation of the Tnf and Lbp genes). Memory-dependent expression of the humoral immunity-related gene C3ar inversely correlates with memory-dependent variations of phagocytic rate, suggesting that complement activation and phagocytosis are alternative defensive mechanisms in C. robusta. Conversely, memory-dependent expression of the cellular immunity-related gene Cd36 directly correlates with variations of phagocytic rate, suggesting a direct involvement of this gene in the functional regulation of phagocytosis.	[Melillo, Daniela; Della Camera, Giacomo; Italiani, Paola; Boraschi, Diana] Natl Res Council CNR, Inst Biochem & Cell Biol IBBC, Naples, Italy; [Marino, Rita; Boraschi, Diana] Staz Zool Anton Dohrn, Biol & Evolut Marine Organisms BEOM, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica e Biologia Cellulare (IBBC-CNR); Stazione Zoologica Anton Dohrn di Napoli	Boraschi, D (corresponding author), Natl Res Council CNR, Inst Biochem & Cell Biol IBBC, Naples, Italy.; Boraschi, D (corresponding author), Staz Zool Anton Dohrn, Biol & Evolut Marine Organisms BEOM, Naples, Italy.	d.boraschi@ibp.cnr.it	Italiani, Paola/AAU-5841-2021; Boraschi, Diana/AAA-7171-2020	Boraschi, Diana/0000-0002-3953-4056	EUH2020 project PANDORA (Probing the safety of nano-objects by defining immune responses of environmental organisms) [GA 671881]; Italian Ministry of Education, University and Research (MIUR) [CNT01_00177_962865]; H2020 project ENDONANO (Quantitative detection of bacterial endotoxin by novel nanotechnological approaches) [GA 812661]; MIUR	EUH2020 project PANDORA (Probing the safety of nano-objects by defining immune responses of environmental organisms); Italian Ministry of Education, University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); H2020 project ENDONANO (Quantitative detection of bacterial endotoxin by novel nanotechnological approaches); MIUR(Ministry of Education, Universities and Research (MIUR))	DB was supported by the EUH2020 project PANDORA (Probing the safety of nano-objects by defining immune responses of environmental organisms; GA 671881), and the Cluster project Medintech (Converging technologies for increasing drug and vaccine safety; CNT01_00177_962865) of the Italian Ministry of Education, University and Research (MIUR). PI was supported by the H2020 project ENDONANO (Quantitative detection of bacterial endotoxin by novel nanotechnological approaches; GA 812661). DB and PI are supported by the MIUR Flagship InterOmics projects MEMORAT and MAME for studies on innate memory.	Amrhein V, 2019, NATURE, V567, P305, DOI 10.1038/d41586-019-00857-9; Azumi K, 2000, ZOOL SCI, V17, P625, DOI 10.2108/zsj.15.625; BECK G, 1993, CELL IMMUNOL, V146, P284, DOI 10.1006/cimm.1993.1027; BEESON PB, 1946, P SOC EXP BIOL MED, V61, P248; BISTONI F, 1986, INFECT IMMUN, V51, P668, DOI 10.1128/IAI.51.2.668-674.1986; Bonura A, 2009, MOL IMMUNOL, V46, P2389, DOI 10.1016/j.molimm.2009.04.035; Boraschi D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00799; Brunetti R, 2015, J ZOOL SYST EVOL RES, V53, P186, DOI 10.1111/jzs.12101; Cooper D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00539; Corbo JC, 2001, CELL, V106, P535, DOI 10.1016/S0092-8674(01)00481-0; DELEO G, 1981, ACTA ZOOL-STOCKHOLM, V62, P259; Di Bella MA, 2000, J INVERTEBR PATHOL, V76, P105, DOI 10.1006/jipa.2000.4959; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Giacomelli S, 2012, FISH SHELLFISH IMMUN, V33, P946, DOI 10.1016/j.fsi.2012.08.003; Gourbal B, 2018, IMMUNOL REV, V283, P21, DOI 10.1111/imr.12647; Hata S, 1998, COMP BIOCHEM PHYS B, V119, P769, DOI 10.1016/S0305-0491(98)00054-6; Hoshino Z., 1967, Publications of the Seto Marine Biological Laboratory, V15, P275; HOWARD JG, 1959, BRIT J EXP PATHOL, V40, P281; Lau CM, 2018, NAT IMMUNOL, V19, P963, DOI 10.1038/s41590-018-0176-1; Marino R, 2002, IMMUNOGENETICS, V53, P1055, DOI 10.1007/s00251-001-0421-9; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Melillo D, 2006, J IMMUNOL, V177, P4132, DOI 10.4049/jimmunol.177.6.4132; Melillo D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01915; Millar R.H., 1953, MEMOIRS TYPICAL BRIT, V35, P1; Milutinovic B, 2016, SEMIN IMMUNOL, V28, P328, DOI 10.1016/j.smim.2016.05.004; Netea MG, 2019, CELL HOST MICROBE, V25, P13, DOI 10.1016/j.chom.2018.12.006; Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006; Ottaviani E, 1996, ITAL J ZOOL, V63, P317, DOI 10.1080/11250009609356152; Ottaviani E, 2011, ISJ-INVERT SURVIV J, V8, P1; Parrinello N, 2008, CELL TISSUE RES, V334, P305, DOI 10.1007/s00441-008-0695-4; Parrinello N, 2010, CELL TISSUE RES, V341, P299, DOI 10.1007/s00441-010-0993-5; Pinto MR, 2007, ADV EXP MED BIOL, V598, P372; Pinto MR, 2003, J IMMUNOL, V171, P5521, DOI 10.4049/jimmunol.171.10.5521; RAFTOS DA, 1991, P NATL ACAD SCI USA, V88, P9518, DOI 10.1073/pnas.88.21.9518; Raftos DA, 2004, DEV COMP IMMUNOL, V28, P181, DOI 10.1016/S0145-305X(03)00136-8; Sasaki N, 2009, J BIOL CHEM, V284, P27336, DOI 10.1074/jbc.M109.032433; Satake H, 2019, CELL TISSUE RES, V377, P293, DOI 10.1007/s00441-019-03024-8; Skjoedt MO, 2010, DEV COMP IMMUNOL, V34, P59, DOI 10.1016/j.dci.2009.08.004; Soderhall K, 2010, INVERTEBRATE IMMUNIT, P316, DOI [10.1007/978-1-4419-8059-5, DOI 10.1007/978-1-4419-8059-5]; Terajima D, 2003, DNA RES, V10, P203, DOI 10.1093/dnares/10.5.203; Vizzini A, 2018, MOL IMMUNOL, V99, P66, DOI 10.1016/j.molimm.2018.04.009; Vizzini A, 2016, DEV COMP IMMUNOL, V55, P102, DOI 10.1016/j.dci.2015.10.013; Vizzini A, 2015, DEV COMP IMMUNOL, V48, P129, DOI 10.1016/j.dci.2014.09.014; Woodworth AM, 2017, ADV PROTEIN CHEM STR, V106, P43, DOI 10.1016/bs.apcsb.2016.09.002; WRIGHT RK, 1974, J INVERTEBR PATHOL, V24, P29, DOI 10.1016/0022-2011(74)90160-8; WRIGHT RK, 1975, AM ZOOL, V15, P21; WRIGHT RK, 1983, AM ZOOL, V23, P205; Yoshizaki FY, 2005, IMMUNOGENETICS, V56, P930, DOI 10.1007/s00251-004-0752-4; Zhang LJ, 2016, CURR BIOL, V26, pR14, DOI 10.1016/j.cub.2015.11.017	49	2	2	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 16	2019	10								1977	10.3389/fimmu.2019.01977	http://dx.doi.org/10.3389/fimmu.2019.01977			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IR5AS	31475017	gold, Green Published			2022-12-18	WOS:000481446000001
J	Peterson, TV; Jaiswal, MK; Beaman, KD; Reynolds, JM				Peterson, Theodore, V; Jaiswal, Mukesh K.; Beaman, Kenneth D.; Reynolds, Joseph M.			Conditional Deletion of the V-ATPase a2-Subunit Disrupts Intrathymic T Cell Development	FRONTIERS IN IMMUNOLOGY			English	Article						V-ATPase; thymocyte development; lymphopenia; a2V; Notch1; positive selection	BETA-SELECTION CHECKPOINT; ALPHA-BETA; VACUOLAR-ATPASE; PRE-TCR; NOTCH; TRAFFICKING; PROLIFERATION; INACTIVATION; NETWORKS; SURVIVAL	Proper orchestration of T lymphocyte development is critical, as T cells underlie nearly all responses of the adaptive immune system. Developing thymocytes differentiate in response to environmental cues carried from cell surface receptors to the nucleus, shaping a distinct transcriptional program that defines their developmental outcome. Our recent work has identified a previously undescribed role for the vacuolar ATPase (V-ATPase) in facilitating the development of murine thymocytes progressing toward the CD4(+) and CD8(+) alpha beta T cell lineages. Vav1(cre) recombinase-mediated deletion of the a2 isoform of the V-ATPase (a2V) in mouse hematopoietic cells leads to a specific and profound loss of peripheral CD4(+) and CD8(+) alpha beta T cells. Utilizing T cell-restricted Lck(cre) and CD4(cre) strains, we further traced this deficiency to the thymus and found that a2V plays a cell-intrinsic role throughout intrathymic development. Loss of a2V manifests as a partial obstruction in the double negative stage of T cell development, and later, a near complete failure of positive selection. These data deepen our understanding of the biological mechanisms that orchestrate T cell development and lend credence to the recent focus on V-ATPase as a potential chemotherapeutic target to combat proliferative potential in T cell lymphoblastic leukemias and autoimmune disease.	[Peterson, Theodore, V; Jaiswal, Mukesh K.; Beaman, Kenneth D.; Reynolds, Joseph M.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Ctr Canc Cell Biol Immunol & Infect, N Chicago, IL 60064 USA; [Reynolds, Joseph M.] Edward Hines Jr VA Hosp, Hines, IL 60141 USA	Chicago Medical School; Rosalind Franklin University Medical & Science; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Reynolds, JM (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Ctr Canc Cell Biol Immunol & Infect, N Chicago, IL 60064 USA.; Reynolds, JM (corresponding author), Edward Hines Jr VA Hosp, Hines, IL 60141 USA.	joseph.reynolds@rosalindfranklin.edu			Rosalind Franklin University of Medicine and Science	Rosalind Franklin University of Medicine and Science	This work was supported by institutional funding from Rosalind Franklin University of Medicine and Science.	Abu-Remaileh M, 2017, SCIENCE, V358, P807, DOI 10.1126/science.aan6298; Bagh MB, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14612; Bezbradica JS, 2005, P NATL ACAD SCI USA, V102, P5114, DOI 10.1073/pnas.0408449102; Billiard F, 2011, EUR J IMMUNOL, V41, P2207, DOI 10.1002/eji.201041343; Boudil A, 2015, NAT IMMUNOL, V16, P397, DOI 10.1038/ni.3122; Carpenter AC, 2010, NAT IMMUNOL, V11, P666, DOI 10.1038/ni.1887; Ciofani M, 2004, J IMMUNOL, V172, P5230, DOI 10.4049/jimmunol.172.9.5230; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Ciofani M, 2006, IMMUNITY, V25, P105, DOI 10.1016/j.immuni.2006.05.010; Del Real MM, 2013, DEVELOPMENT, V140, P1207, DOI 10.1242/dev.088559; Garbe AI, 2006, J EXP MED, V203, P1579, DOI 10.1084/jem.20060474; Gilman-Sachs A, 2015, J LEUKOCYTE BIOL, V97, P1121, DOI 10.1189/jlb.3A1214-620RR; Guillard M, 2009, BBA-MOL BASIS DIS, V1792, P903, DOI 10.1016/j.bbadis.2008.12.009; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; Hinton A, 2009, PFLUG ARCH EUR J PHY, V457, P589, DOI 10.1007/s00424-007-0382-4; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Jovic M, 2010, HISTOL HISTOPATHOL, V25, P99, DOI 10.14670/HH-25.99; Kreslavsky T, 2012, IMMUNITY, V37, P840, DOI 10.1016/j.immuni.2012.08.020; Krueger A, 2017, TRENDS IMMUNOL, V38, P128, DOI 10.1016/j.it.2016.10.007; Love PE, 2011, NAT REV IMMUNOL, V11, P469, DOI 10.1038/nri2989; Maillard I, 2006, J EXP MED, V203, P2239, DOI 10.1084/jem.20061020; Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015; Mingueneau M, 2013, NAT IMMUNOL, V14, P619, DOI 10.1038/ni.2590; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Ota K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070470; Pamarthy S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.347; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pereira P, 2012, J IMMUNOL, V188, P1600, DOI 10.4049/jimmunol.1102531; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rothenberg EV, 2016, ADV IMMUNOL, V129, P109, DOI 10.1016/bs.ai.2015.09.002; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Shah DK, 2014, J IMMUNOL, V192, P4017, DOI 10.4049/jimmunol.1302259; Shi JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046590; Shi JJ, 2011, BLOOD, V118, P2511, DOI 10.1182/blood-2011-04-346726; Siegemund S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124661; Sun-Wada GH, 2006, J CELL SCI, V119, P4531, DOI 10.1242/jcs.03234; Tagami S, 2008, MOL CELL BIOL, V28, P165, DOI 10.1128/MCB.00863-07; Trampont PC, 2010, NAT IMMUNOL, V11, P162, DOI 10.1038/ni.1830; Udono M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17342; Vaccari T, 2010, DEVELOPMENT, V137, P1825, DOI 10.1242/dev.045484; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Wolfer A, 2002, IMMUNITY, V16, P869, DOI 10.1016/S1074-7613(02)00330-8; Xiong JA, 2011, INT IMMUNOL, V23, P55, DOI 10.1093/intimm/dxq457; Yan Y, 2009, DEV CELL, V17, P387, DOI 10.1016/j.devcel.2009.07.001; Yang K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aas9818; Yui MA, 2014, NAT REV IMMUNOL, V14, P529, DOI 10.1038/nri3702; Zhang CS, 2014, CELL METAB, V20, P526, DOI 10.1016/j.cmet.2014.06.014	47	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2019	10								1911	10.3389/fimmu.2019.01911	http://dx.doi.org/10.3389/fimmu.2019.01911			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IQ1ZO	31456807	Green Published, gold			2022-12-18	WOS:000480549000002
J	Diedrichs, F; Stolk, M; Jurchott, K; Haag, M; Sittinger, M; Seifert, M				Diedrichs, Falk; Stolk, Meaghan; Juerchott, Karsten; Haag, Marion; Sittinger, Michael; Seifert, Martina			Enhanced Immunomodulation in Inflammatory Environments Favors Human Cardiac Mesenchymal Stromal-Like Cells for Allogeneic Cell Therapies	FRONTIERS IN IMMUNOLOGY			English	Article						cardiac-derived cells; immunogenicity; immunomodulation; inflammation; IFN gamma; IDO	ADHERENT PROLIFERATING CELLS; CARDIOSPHERE-DERIVED CELLS; STEM-CELLS; MYOCARDIAL-INFARCTION; ADIPOSE-TISSUE; INDOLEAMINE 2,3-DIOXYGENASE; ISCHEMIC CARDIOMYOPATHY; HEART REGENERATION; ATRIAL APPENDAGE; PROGENITOR CELLS	Rising numbers of patients with cardiovascular diseases and limited availability of donor hearts require new and improved therapy strategies. Human atrial appendage-derived cells (hAACs) are promising candidates for an allogeneic cell-based treatment. In this study, we evaluated their inductive and modulatory capacity regarding immune responses and underlying key mechanisms in vitro. For this, cryopreserved hAACs were either cultured in the presence of interferon-gamma (IFN gamma) or left unstimulated. The expression of characteristic mesenchymal stromal cell markers (CD29, CD44, CD73, CD105, CD166) was revealed by flow cytometry that also highlighted a predominant negativity for CD90. A low immunogeneic phenotype in an inflammatory milieu was shown by lacking expression of co-stimulatory molecules and upregulation of the inhibitory ligands PD-L1 and PD-L2, despite de novo expression of HLA-DR. Co-cultures of hAACs with allogeneic peripheral blood mononuclear cells, proved their low immunogeneic state by absence of induced T cell proliferation and activation. Additionally, elevated levels of IL-1 beta, IL-33, and IL-10 were detectable in those cell culture supernatants. Furthermore, the immunomodulatory potential of hAACs was assessed in co-cultures with alpha CD3/alpha CD28-activated peripheral blood mononuclear cells. Here, a strong inhibition of T cell proliferation and reduction of pro-inflammatory cytokines (IFN gamma, TNF alpha, TNF beta, IL-17A, IL-2) were observable after pre-stimulation of hAACs with IFN gamma. Transwell experiments confirmed that mostly soluble factors are responsible for these suppressive effects. We were able to identify indolamin-2,3-dioxygenase (IDO) as a potential key player through a genome-wide gene expression analysis and could demonstrate its involvement in the observed immunological responses. While the application of blocking antibodies against both PD-1 ligands did not affect the immunomodulation by hAACs, 1-methyl-L-tryptophan as specific inhibitor of IDO was able to restore proliferation and to lower apoptosis of T cells. In conclusion, hAACs represent a cardiac-derived mesenchymal stromal-like cell type with a high potential for the application in an allogeneic setting, since they do not trigger T cell responses and even increase their immunomodulatory potential in inflammatory environments.	[Diedrichs, Falk] Berlin Inst Hlth BIH, Berlin, Germany; [Diedrichs, Falk; Stolk, Meaghan; Juerchott, Karsten; Haag, Marion; Sittinger, Michael; Seifert, Martina] Charite Univ Med Berlin, BIH Ctr Regenerat Therapies BCRT, Berlin, Germany; [Diedrichs, Falk; Stolk, Meaghan; Juerchott, Karsten; Haag, Marion; Sittinger, Michael; Seifert, Martina] Free Univ Berlin, Berlin, Germany; [Diedrichs, Falk; Stolk, Meaghan; Juerchott, Karsten; Haag, Marion; Sittinger, Michael; Seifert, Martina] Humboldt Univ, Berlin, Germany; [Diedrichs, Falk; Stolk, Meaghan; Juerchott, Karsten; Haag, Marion; Sittinger, Michael; Seifert, Martina] Berlin Inst Hlth, Berlin, Germany; [Juerchott, Karsten; Seifert, Martina] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany; [Haag, Marion; Sittinger, Michael] Charite Univ Med Berlin, Tissue Engn Lab, Berlin, Germany	Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Seifert, M (corresponding author), Charite Univ Med Berlin, BIH Ctr Regenerat Therapies BCRT, Berlin, Germany.; Seifert, M (corresponding author), Free Univ Berlin, Berlin, Germany.; Seifert, M (corresponding author), Humboldt Univ, Berlin, Germany.; Seifert, M (corresponding author), Berlin Inst Hlth, Berlin, Germany.; Seifert, M (corresponding author), Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany.	martina.seifert@charite.de		Jurchott, Karsten/0000-0003-1589-0037; Diedrichs, Falk/0000-0002-4504-6016; , Martina/0000-0002-6372-9769	BCRT [Bundesministerium fur Bildung und Forschung (BMBF)] [13GW0099]; Berlin Institute of Health (BIH); DFG through the Berlin-Brandenburg School for Regenerative Therapies [GSC 203]	BCRT [Bundesministerium fur Bildung und Forschung (BMBF)](Federal Ministry of Education & Research (BMBF)); Berlin Institute of Health (BIH); DFG through the Berlin-Brandenburg School for Regenerative Therapies	This study was supported by the BCRT [Bundesministerium fur Bildung und Forschung (BMBF) grant (13GW0099)]. In part, the work was supported by the Berlin Institute of Health (BIH) with amedical doctoral research stipend and by DFG funding through the Berlin-Brandenburg School for Regenerative Therapies GSC 203 to FD.	Al-Daccak R, 2015, TISSUE ANTIGENS, V86, P155, DOI 10.1111/tan.12614; Altara R, 2018, CARDIOVASC RES, V114, P1578, DOI 10.1093/cvr/cvy166; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Berglund AK, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0742-8; Bolli R, 2011, LANCET, V378, P1847, DOI 10.1016/S0140-6736(11)61590-0; Bruno S, 2015, IMMUNOL LETT, V168, P154, DOI 10.1016/j.imlet.2015.06.007; Cahill TJ, 2017, NAT REV DRUG DISCOV, V16, P699, DOI 10.1038/nrd.2017.106; Campioni D, 2009, CYTOM PART B-CLIN CY, V76B, P225, DOI 10.1002/cyto.b.20461; Cheng K, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001260; Chiossone L, 2016, STEM CELLS, V34, P1909, DOI 10.1002/stem.2369; Chugh AR, 2012, CIRCULATION, V126, pS54, DOI 10.1161/CIRCULATIONAHA.112.092627; Clarkson MR, 2005, TRANSPLANTATION, V80, P555, DOI 10.1097/01.tp.0000168432.60022.99; Crisostomo V, 2015, EXPERT REV CARDIOVAS, V13, P285, DOI 10.1586/14779072.2015.1011621; Croitoru-Lamoury J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014698; Crop MJ, 2010, CLIN EXP IMMUNOL, V162, P474, DOI 10.1111/j.1365-2249.2010.04256.x; Dam N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01413; Davies LC, 2017, STEM CELLS, V35, P766, DOI 10.1002/stem.2509; de Witte SFH, 2018, STEM CELLS, V36, P602, DOI 10.1002/stem.2779; de Witte SFH, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0590-6; Dehne T, 2014, CELLS TISSUES ORGANS, V199, P24, DOI 10.1159/000362540; Detert S, 2018, J TISSUE ENG REGEN M, V12, pE1404, DOI 10.1002/term.2528; Di Trapani M, 2013, STEM CELLS DEV, V22, P2990, DOI 10.1089/scd.2013.0204; El Shafeey M, 2018, EUR J HEART FAIL, V20, P517; Fernandez-Aviles F, 2018, CIRC RES, V123, P579, DOI 10.1161/CIRCRESAHA.118.312823; Fernandez-Aviles F, 2017, EUR HEART J, V38, P2532, DOI 10.1093/eurheartj/ehx248; Francois M, 2012, MOL THER, V20, P187, DOI 10.1038/mt.2011.189; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gebler A, 2012, TRENDS MOL MED, V18, P128, DOI 10.1016/j.molmed.2011.10.004; Ghali R, 2018, HYPERTENSION, V72, P818, DOI 10.1161/HYPERTENSIONAHA.118.11157; Griesenauer B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00475; Groh ME, 2005, EXP HEMATOL, V33, P928, DOI 10.1016/j.exphem.2005.05.002; Guan QD, 2018, CYTOTHERAPY, V20, P639, DOI 10.1016/j.jcyt.2018.02.003; Haag M, 2013, J TISSUE ENG REGEN M, V7, P362, DOI 10.1002/term.531; Haag M, 2010, J CELL BIOCHEM, V109, P564, DOI 10.1002/jcb.22433; Hausenloy DJ, 2017, CARDIOVASC RES, V113, P564, DOI 10.1093/cvr/cvx049; Hogen R, 2017, CURR OPIN ORGAN TRAN, V22, P97, DOI 10.1097/MOT.0000000000000391; Hong J, 2016, CYTOTHERAPY, V18, P621, DOI 10.1016/j.jcyt.2016.01.009; Houtgraaf JH, 2012, J AM COLL CARDIOL, V59, P539, DOI 10.1016/j.jacc.2011.09.065; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Karantalis V, 2015, CIRC RES, V116, P1413, DOI 10.1161/CIRCRESAHA.116.303614; Kawka E, 2017, AM J PHYSIOL-RENAL, V313, pF1116, DOI 10.1152/ajprenal.00274.2017; Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004; Kim JY, 2018, J TISSUE ENG REGEN M, V12, pE1022, DOI 10.1002/term.2423; Kronsteiner B, 2011, STEM CELLS DEV, V20, P2115, DOI 10.1089/scd.2011.0031; Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552; Lauden L, 2013, CIRC RES, V112, P451, DOI 10.1161/CIRCRESAHA.112.276501; Li TS, 2012, J AM COLL CARDIOL, V59, P942, DOI 10.1016/j.jacc.2011.11.029; Li X., 2016, MATH PROBL ENG, V2016, P1, DOI DOI 10.1016/j.seppur.2016.01.021; Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709; Lilyanna S, 2013, TISSUE ENG PT A, V19, P1303, DOI 10.1089/ten.tea.2012.0407; Lohan P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01626; Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0; Malliaras K, 2011, BRIT MED BULL, V98, P161, DOI 10.1093/bmb/ldr018; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; Melief SM, 2013, STEM CELLS, V31, P1980, DOI 10.1002/stem.1432; Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51; Miteva K, 2016, STEM CELL TRANSL MED, V5, P1707, DOI 10.5966/sctm.2016-0031; Miteva K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028513; Najar M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050626; Nigro P, 2018, PHARMACOL RES, V127, P77, DOI 10.1016/j.phrs.2017.02.015; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Owens AT, 2016, CIRC RES, V118, P480, DOI 10.1161/CIRCRESAHA.115.306567; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Prabhu SD, 2016, CIRC RES, V119, P91, DOI 10.1161/CIRCRESAHA.116.303577; Reinisch A, 2009, BLOOD, V113, P6716, DOI 10.1182/blood-2008-09-181362; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rossini A, 2011, CARDIOVASC RES, V89, P650, DOI 10.1093/cvr/cvq290; Sattler S, 2017, NPJ REGEN MED, V2, DOI 10.1038/s41536-017-0022-3; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186; Selleri S, 2016, ONCOTARGET, V7, P30193, DOI 10.18632/oncotarget.8623; Sivanathan KN, 2014, STEM CELL REV REP, V10, P351, DOI 10.1007/s12015-014-9495-2; Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209; Souidi N, 2017, STEM CELLS, V35, P1233, DOI 10.1002/stem.2573; Stolk M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09875-x; Terasaki PI, 2005, CURR OPIN IMMUNOL, V17, P541, DOI 10.1016/j.coi.2005.07.018; Tipnis S, 2010, IMMUNOL CELL BIOL, V88, P795, DOI 10.1038/icb.2010.47; Tseliou E, 2013, J AM COLL CARDIOL, V61, P1108, DOI 10.1016/j.jacc.2012.10.052; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; van den Akker F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/181020; van den Akker F, 2013, BBA-GEN SUBJECTS, V1830, P2449, DOI 10.1016/j.bbagen.2012.08.026; Vizoso FJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091852; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang WB, 2015, STEM CELL REP, V5, P392, DOI 10.1016/j.stemcr.2015.07.013; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Ward MR, 2018, STEM CELL TRANSL MED, V7, P543, DOI 10.1002/sctm.17-0210; Wood Kathryn J, 2013, Methods Mol Biol, V1034, P71, DOI 10.1007/978-1-62703-493-7_3; Young PP, 2015, TRANSFUSION, V55, P441, DOI 10.1111/trf.12826; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhao JJ, 2014, MOL MED REP, V10, P1448, DOI 10.3892/mmr.2014.2378; Zheng GP, 2018, CELL TISSUE RES, V374, P1, DOI 10.1007/s00441-018-2871-5	91	2	2	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2019	10								1716	10.3389/fimmu.2019.01716	http://dx.doi.org/10.3389/fimmu.2019.01716			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IK7ES	31396228	Green Published, gold			2022-12-18	WOS:000476752300002
J	Key, PN; Germino, J; Yang, LP; Piersma, SJ; Tripathy, SK				Key, Phillip N.; Germino, Joe; Yang, Liping; Piersma, Sytse J.; Tripathy, Sandeep K.			Chronic Ly49H Receptor Engagement in vivo Decreases NK Cell Response to Stimulation Through ITAM-Dependent and Independent Pathways Both in vitro and in vivo	FRONTIERS IN IMMUNOLOGY			English	Article						NK cell; tolerance; activating receptor; signal transduction; ITAM; Ly49H; m157	MHC CLASS-I; NATURAL-KILLER-CELLS; SHED NKG2D LIGAND; ACTIVATION; CYTOTOXICITY; EXPRESSION; DNAM-1; RESPONSIVENESS; RECOGNITION; TOLERANCE	Natural killer (NK) cells play an important role in the innate immune response. The summation of activation and inhibitory signals delivered through cell surface membrane receptors determines NK cell function. However, the continuous engagement of an activating receptor on NK cells appears to render the cells hyporesponsive to stimulation through other unrelated activating receptors. The mechanism by which this takes place remains unclear. Herein we demonstrate that continuous in vivo engagement of the Ly49H receptor with its ligand, m157, results in Ly49H(+) NK cells that are hyporesponsive to further stimulation by other ITAM-dependent and independent receptors, while Ly49H-NK cells remain unaffected. The hyporesponsiveness of the NK cell correlates with the degree of Ly49H receptor downmodulation on its cell surface. We observe defects in calcium flux in the hyporesponsive NK cells following stimulation through the NK1.1 receptor. In addition, we observe differences in signaling molecules that play a role in calcium flux, including spleen tyrosine kinase (Syk) at baseline and phosphorylated phospholipase C gamma 2 (p-PLC gamma 2) at both baseline and following stimulation through NK1.1. We also demonstrate that various ITAM associated activation receptors, including Ly49H, remain associated with their respective adaptor molecules. With regard to in vivo NK cell function, we did not find differences in the formation of metastatic lung lesions following IV injection of B16 melanoma cells. However, we did observe defects in rejection of missing-self targets in vivo. The data suggest that continuous engagement of the Ly49H activating receptor on NK cells results in hyporesponsiveness of the NK cells to all of the ITAM-dependent and independent receptors we analyzed due to altered signaling pathways downstream of the receptor and adaptor molecule.	[Key, Phillip N.; Germino, Joe; Tripathy, Sandeep K.] Washington Univ, Sch Med, Dept Med, Div Gastroenterol, St Louis, MO 63110 USA; [Yang, Liping; Piersma, Sytse J.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Tripathy, SK (corresponding author), Washington Univ, Sch Med, Dept Med, Div Gastroenterol, St Louis, MO 63110 USA.	stripathy@wustl.edu		Germino, Joe/0000-0003-3939-3342; Piersma, Sytse/0000-0002-5379-3556	National Institutes of Health [R01 AI089870, RSG-15-181-01-LIB]; American Cancer Society; Washington University DDRCC [NIDDK P30 DK052574]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Washington University DDRCC; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grant R01 AI089870 and a Research scholar Grant, RSG-15-181-01-LIB from the American Cancer Society (to ST). The authors acknowledge support from the Washington University DDRCC (NIDDK P30 DK052574).	Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Abram Clare L, 2007, Sci STKE, V2007, pre2, DOI 10.1126/stke.3772007re2; Ballas ZK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065599; Bern MD, 2019, J EXP MED, V216, P99, DOI 10.1084/jem.20181076; Bolanos FD, 2011, J IMMUNOL, V186, P2765, DOI 10.4049/jimmunol.1003046; Brodin P, 2009, TRENDS IMMUNOL, V30, P143, DOI 10.1016/j.it.2009.01.006; Brodin P, 2009, BLOOD, V113, P2434, DOI 10.1182/blood-2008-05-156836; Caraux A, 2006, BLOOD, V107, P994, DOI 10.1182/blood-2005-06-2428; Carlsten M, 2010, LEUKEMIA, V24, P1607, DOI 10.1038/leu.2010.149; Carlsten M, 2009, J IMMUNOL, V183, P4921, DOI 10.4049/jimmunol.0901226; Chan CJ, 2010, J IMMUNOL, V184, P902, DOI 10.4049/jimmunol.0903225; Coudert JD, 2005, BLOOD, V106, P1711, DOI 10.1182/blood-2005-03-0918; Coudert JD, 2008, BLOOD, V111, P3571, DOI 10.1182/blood-2007-07-100057; Crane CA, 2014, P NATL ACAD SCI USA, V111, P12823, DOI 10.1073/pnas.1413933111; Deng WW, 2015, SCIENCE, V348, P136, DOI 10.1126/science.1258867; Easom NJW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01009; Fauriat C, 2010, BLOOD, V115, P1166, DOI 10.1182/blood-2009-09-245746; Garcia-Iglesias T, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-186; Garcia-Lora A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Hamerman Jessica A, 2006, Sci STKE, V2006, pre1, DOI 10.1126/stke.3202006re1; Inui M, 2009, P NATL ACAD SCI USA, V106, P4816, DOI 10.1073/pnas.0900463106; Joncker NT, 2009, J IMMUNOL, V182, P4572, DOI 10.4049/jimmunol.0803900; Jonsson AH, 2010, J IMMUNOL, V184, P3424, DOI 10.4049/jimmunol.0904057; Kadri N, 2015, IMMUNOL REV, V267, P167, DOI 10.1111/imr.12330; Kelley J, 2005, PLOS GENET, V1, P129, DOI 10.1371/journal.pgen.0010027; Kim S, 2002, NAT IMMUNOL, V3, P523, DOI 10.1038/ni796; Koch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01466; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Konjevic G, 2007, CLIN EXP METASTAS, V24, P1, DOI 10.1007/s10585-006-9043-9; Lakshmikanth T, 2009, J CLIN INVEST, V119, P1251, DOI 10.1172/JCI36022; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; McVicar DW, 1998, J BIOL CHEM, V273, P32934, DOI 10.1074/jbc.273.49.32934; Morgado S, 2011, J INNATE IMMUN, V3, P365, DOI 10.1159/000328505; Nakamura K, 2002, LIFE SCI, V70, P791, DOI 10.1016/S0024-3205(01)01454-0; Narni-Mancinelli E, 2015, CELL RES, V25, P651, DOI 10.1038/cr.2015.41; Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239; Parikh BA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005323; Pasquier B, 2005, IMMUNITY, V22, P31, DOI 10.1016/j.immuni.2004.11.017; Peng QS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000500; Pugh JL, 2018, J IMMUNOL, V200, P1146, DOI 10.4049/jimmunol.1700542; Rajasekaran K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00176; Saenz JB, 2016, METHODS MOL BIOL, V1422, P329, DOI 10.1007/978-1-4939-3603-8_28; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Steinle A, 2015, SCIENCE, V348, P45, DOI 10.1126/science.aaa9842; Sun JC, 2008, J EXP MED, V205, P1819, DOI 10.1084/jem.20072448; Tassi I, 2005, J IMMUNOL, V175, P749, DOI 10.4049/jimmunol.175.2.749; Tripathy SK, 2008, J EXP MED, V205, P1829, DOI 10.1084/jem.20072446; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Vugmeyster Y, 1998, P NATL ACAD SCI USA, V95, P12492, DOI 10.1073/pnas.95.21.12492; Wiemann K, 2005, J IMMUNOL, V175, P720, DOI 10.4049/jimmunol.175.2.720; Yu JH, 2013, TRENDS IMMUNOL, V34, P573, DOI 10.1016/j.it.2013.07.005	54	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2019	10								1692	10.3389/fimmu.2019.01692	http://dx.doi.org/10.3389/fimmu.2019.01692			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IK7EF	31396217	gold, Green Published			2022-12-18	WOS:000476750900001
J	McDaniel, MM; Ganusov, VV				McDaniel, Margaret M.; Ganusov, Vitaly V.			Estimating Residence Times of Lymphocytes in Ovine Lymph Nodes	FRONTIERS IN IMMUNOLOGY			English	Article						mathematical model; lymphocyte migration; lymph nodes; residence time; sheep	T-CELL MIGRATION; RECIRCULATING LYMPHOCYTES; EFFERENT LYMPH; MEMORY; NAIVE; SUBSETS; SPHINGOSINE-1-PHOSPHATE; IMMUNOTHERAPY; MECHANISMS; CHEMOKINES	The ability of lymphocytes to recirculate between blood and secondary lymphoid tissues such as lymph nodes (LNs) and spleen is well established. Sheep have been used as an experimental system to study lymphocyte recirculation for decades and multiple studies document accumulation and loss of intravenously (i.v.) transferred lymphocytes in efferent lymph of various ovine LNs. Yet, surprisingly little work has been done to accurately quantify the dynamics of lymphocyte exit from the LNs and to estimate the average residence times of lymphocytes in ovine LNs. In this work we developed a series of mathematical models based on fundamental principles of lymphocyte recirculation in the body under non-inflammatory (resting) conditions. Our analysis suggested that in sheep, recirculating lymphocytes spend on average 3 h in the spleen and 20 h in skin or gut-draining LNs with a distribution of residence times in LNs following a skewed gamma (lognormal-like) distribution. Our mathematical models also suggested an explanation for a puzzling observation of the long-term persistence of i.v. transferred lymphocytes in the efferent lymph of the prescapular LN (pLN); the model predicted that this is a natural consequence of long-term persistence of the transferred lymphocytes in circulation. We also found that lymphocytes isolated from the skin-draining pLN have a 2-fold increased entry rate into the pLN as opposed to the mesenteric (gut-draining) LN (mLN). Likewise, lymphocytes from mLN had a 3-fold increased entry rate into the mLN as opposed to entry rate into pLN. In contrast, these cannulation data could not be explained by preferential retention of cells in LNs of their origin. Taken together, our work illustrates the power of mathematical modeling in describing the kinetics of lymphocyte migration in sheep and provides quantitative estimates of lymphocyte residence times in ovine LNs.	[McDaniel, Margaret M.] Univ Texas Southwestern, Dept Immunol, Dallas, TX USA; [Ganusov, Vitaly V.] Univ Tennessee, Dept Math, Knoxville, TN 37996 USA; [Ganusov, Vitaly V.] Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville	Ganusov, VV (corresponding author), Univ Tennessee, Dept Math, Knoxville, TN 37996 USA.; Ganusov, VV (corresponding author), Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA.	vitaly.ganusov@gmail.com		McDaniel, Margaret/0000-0002-3986-459X	NIH [R01 GM118553]; University of Tennessee's Open Publishing Support Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM118553] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Tennessee's Open Publishing Support Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank the immunology community for discussion over this research, especially Michio Tomura, Gudrun Debes, and David Masopust. Two reviewers gave constructive suggestions on the previous version of the paper. This work was in part supported by the NIH grant (R01 GM118553) to VG. This manuscript has been released as a Pre-Print on BioRxiv at https://doi.org/10.1101/513176(61). Partial funding for open access to this research was provided by University of Tennessee's Open Publishing Support Fund.	Ahmed R, 1999, FUNDAMENTAL IMMUNOLO, P1295; Bimczok D, 2006, VET RES, V37, P325, DOI 10.1051/vetres:2006004; Brenner MK, 2010, CURR OPIN IMMUNOL, V22, P251, DOI 10.1016/j.coi.2010.01.020; Brinkman CC, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00241; Burnham K.P., 2002, MODEL SELECTION MULT, V2nd Edn, DOI 10.1007/b97636; CAHILL RNP, 1976, J EXP MED, V143, P870, DOI 10.1084/jem.143.4.870; Chiba K, 1998, J IMMUNOL, V160, P5037; CHIN W, 1980, GASTROENTEROLOGY, V79, P1231; Cyster JG, 2012, ANNU REV IMMUNOL, V30, P69, DOI 10.1146/annurev-immunol-020711-075011; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; DUIJVESTIJN A, 1989, IMMUNOL TODAY, V10, P23, DOI 10.1016/0167-5699(89)90061-3; Ebert LA, 2005, MOL IMMUNOL, V42, P799, DOI 10.1016/j.molimm.2004.06.040; Forster R, 2012, TRENDS IMMUNOL, V33, P271, DOI 10.1016/j.it.2012.02.007; FROST H, 1975, EUR J IMMUNOL, V5, P839, DOI 10.1002/eji.1830051208; Ganusov VV, 2007, TRENDS IMMUNOL, V28, P514, DOI 10.1016/j.it.2007.08.009; Ganusov VV, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003586; Ganusov VV, 2018, BIORXIV; GOWANS JL, 1957, BRIT J EXP PATHOL, V38, P67; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; Grebenciucova E, 2016, MULT SCLER RELAT DIS, V9, P158, DOI 10.1016/j.msard.2016.07.015; GRISCELLI C, 1969, J EXP MED, V130, P1427, DOI 10.1084/jem.130.6.1427; HALL JG, 1965, J EXP MED, V121, P901, DOI 10.1084/jem.121.6.901; HALL JG, 1967, Q J EXP PHYSIOL CMS, V52, P200, DOI 10.1113/expphysiol.1967.sp001902; HAMANN A, 1994, J IMMUNOL, V152, P3282; HANSARD SL, 1953, J ANIM SCI, V12, P402, DOI 10.2527/jas1953.122402x; HARP JA, 1990, VET IMMUNOL IMMUNOP, V24, P159, DOI 10.1016/0165-2427(90)90018-N; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Ikeda H, 2016, INT IMMUNOL, V28, P349, DOI 10.1093/intimm/dxw022; ISSEKUTZ TB, 1981, CLIN EXP IMMUNOL, V45, P604; Jenkins MK, 2012, J IMMUNOL, V188, P4135, DOI 10.4049/jimmunol.1102661; Kindt T.J., 2007, KUBY IMMUNOLOGY; Lefkovits I., 1997, IMMUNOLOGY METHODS M, V4; Lewis SM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau6085; MACKAY CR, 1992, EUR J IMMUNOL, V22, P887, DOI 10.1002/eji.1830220402; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MACKAY CR, 1988, J EXP MED, V167, P1755, DOI 10.1084/jem.167.6.1755; Mandl JN, 2012, P NATL ACAD SCI USA, V109, P18036, DOI 10.1073/pnas.1211717109; Marelli-Berg FM, 2010, IMMUNOLOGY, V130, P158, DOI 10.1111/j.1365-2567.2010.03278.x; Masopust D, 2010, J EXP MED, V207, P553, DOI 10.1084/jem.20090858; McDaniel MM, BIORXIV, DOI [10.1101/513176, DOI 10.1101/513176]; MIYASAKA M, 1986, IMMUNOL REV, V91, P87, DOI 10.1111/j.1600-065X.1986.tb01485.x; Murphy K., 2012, JANEWAYS IMMUNOBIOLO, V10th ed.; PABST R, 1987, AM REV RESPIR DIS, V136, P1213, DOI 10.1164/ajrccm/136.5.1213; Pabst R, 1988, Adv Exp Med Biol, V237, P553; PICKER LJ, 1990, J IMMUNOL, V145, P3247; REYNOLDS J, 1982, IMMUNOLOGY, V47, P415; Rose M, 1976, SUBJECT STRAIN BIBLI, V38, P475; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Schaerli P, 2005, IMMUNOL RES, V31, P57, DOI 10.1385/IR:31:1:57; SMITH ME, 1983, IMMUNOLOGY, V49, P83; Steiniger B, 1999, ADV ANAT EMBRYOL CEL; Textor J, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003752; Thomas N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045262; TREPEL F, 1974, KLIN WOCHENSCHR, V52, P511, DOI 10.1007/BF01468720; Van Rhijn I, 2007, J LEUKOCYTE BIOL, V81, P968, DOI 10.1189/jlb.0506331; Vrieling M, 2012, J IMMUNOL, V188, P578, DOI 10.4049/jimmunol.1101972; Westermann J, 2001, IMMUNOL REV, V184, P20, DOI 10.1034/j.1600-065x.2001.1840103.x; Williams MB, 1997, J IMMUNOL, V159, P1746; Winkelmann A, 2016, NAT REV NEUROL, V12, P217, DOI 10.1038/nrneurol.2016.21; Young AJ, 2000, J IMMUNOL, V165, P3168, DOI 10.4049/jimmunol.165.6.3168; Young AJ, 1999, SEMIN IMMUNOL, V11, P73, DOI 10.1006/smim.1999.0163	61	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2019	10								1492	10.3389/fimmu.2019.01492	http://dx.doi.org/10.3389/fimmu.2019.01492			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IJ3RW	31379805	Green Submitted, gold, Green Published			2022-12-18	WOS:000475823200001
J	Smith, AL; Scott, JNF; Boyes, J				Smith, Alastair L.; Scott, James N. F.; Boyes, Joan			The ESC: The Dangerous By-Product of V(D)J Recombination	FRONTIERS IN IMMUNOLOGY			English	Review						V(D)J recombination; RAG proteins; genome instability; leukemia; double strand breaks	RAG-MEDIATED RECOMBINATION; GENOMIC INSTABILITY; ACTIVE-SITE; DNA BREAKS; TRANSPOSITION; SIGNAL; PROTEINS; CLEAVAGE; REPAIR; EXPRESSION	V(D)J recombination generates antigen receptor diversity by mixing and matching individual variable (V), diversity (D), and joining (J) gene segments. An obligate by-product of many of these reactions is the excised signal circle (ESC), generated by excision of the DNA from between the gene segments. Initially, the ESC was believed to be inert and formed to protect the genome from reactive broken DNA ends but more recent work suggests that the ESC poses a substantial threat to genome stability. Crucially, the recombinase re-binds to the ESC, which can result in it being re-integrated back into the genome, to cause potentially oncogenic insertion events. In addition, very recently, the ESC/recombinase complex was found to catalyze breaks at recombination signal sequences (RSSs) throughout the genome, via a "cut-and-run" mechanism. Remarkably, the ESC/recombinase complex triggers these breaks at key leukemia driver genes, implying that this reaction could be a significant cause of lymphocyte genome instability. Here, we explore these alternate pathways and discuss their relative dangers to lymphocyte genome stability.	[Smith, Alastair L.; Scott, James N. F.; Boyes, Joan] Univ Leeds, Sch Mol & Cellular Biol, Fac Biol Sci, Leeds, W Yorkshire, England; [Smith, Alastair L.] Univ Oxford, John Radcliffe Hosp, MRC, Mol Haematol Unit,Weatherall Inst Mol Med, Oxford, England	University of Leeds; University of Oxford	Boyes, J (corresponding author), Univ Leeds, Sch Mol & Cellular Biol, Fac Biol Sci, Leeds, W Yorkshire, England.	j.m.boyes@leeds.ac.uk		Boyes, Joan/0000-0002-8705-9827	Bloodwise [15042]; National Center for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) [NC/K001639/1]	Bloodwise; National Center for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs)	We gratefully acknowledge support from Bloodwise (research grant: 15042) and the National Center for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs; studentship: NC/K001639/1). Bloodwise contribute to a fund for Open Access publication fees that is administered at the University of Leeds by the library.	Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Bashford-Rogers RJM, 2016, LEUKEMIA, V30, P2312, DOI 10.1038/leu.2016.142; Bettridge J, 2017, P NATL ACAD SCI USA, V114, P1904, DOI 10.1073/pnas.1615727114; BORIES JC, 1991, BLOOD, V78, P2053, DOI 10.1182/blood.V78.8.2053.bloodjournal7882053; Canela A, 2016, MOL CELL, V63, P898, DOI 10.1016/j.molcel.2016.06.034; Cui XP, 2007, P NATL ACAD SCI USA, V104, P17046, DOI 10.1073/pnas.0610928104; Curry JD, 2007, J EXP MED, V204, P2293, DOI 10.1084/jem.20070583; Dong Y, 2016, CLIN EXP IMMUNOL, V185, P320, DOI 10.1111/cei.12812; Elkin SK, 2003, EMBO J, V22, P1931, DOI 10.1093/emboj/cdg184; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Grundy GJ, 2010, P NATL ACAD SCI USA, V107, P22487, DOI 10.1073/pnas.1014958107; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Heinaniemi M, 2016, ELIFE, V5, DOI 10.7554/eLife.13087; Helmink BA, 2012, ANNU REV IMMUNOL, V30, P175, DOI 10.1146/annurev-immunol-030409-101320; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Hu JZ, 2016, NAT PROTOC, V11, P853, DOI 10.1038/nprot.2016.043; Jankovic M, 2004, ANNU REV IMMUNOL, V22, P485, DOI 10.1146/annurev.immunol.22.012703.104707; Jiang H, 2005, MOL CELL, V18, P699, DOI 10.1016/j.molcel.2005.05.011; Kapitonov VV, 2005, PLOS BIOL, V3, P998, DOI 10.1371/journal.pbio.0030181; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Kirkham CM, 2019, MOL CELL, V74, P584, DOI 10.1016/j.molcel.2019.02.025; Kong FK, 1999, P NATL ACAD SCI USA, V96, P1536, DOI 10.1073/pnas.96.4.1536; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Liu Y, 2007, IMMUNITY, V27, P561, DOI 10.1016/j.immuni.2007.09.005; Lu C, 2015, CELL REP, V10, P29, DOI 10.1016/j.celrep.2014.12.001; Maman Y, 2016, NUCLEIC ACIDS RES, V44, P9624, DOI 10.1093/nar/gkw633; Matthews AGW, 2007, NATURE, V450, P1106, DOI 10.1038/nature06431; Matthews AGW, 2009, ADV EXP MED BIOL, V650, P16; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Mensen A, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-188; Messier TL, 2006, HUM MUTAT, V27, DOI 10.1002/humu.9440; Messier TL, 2003, EMBO J, V22, P1381, DOI 10.1093/emboj/cdg137; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Neiditch MB, 2002, MOL CELL, V9, P871, DOI 10.1016/S1097-2765(02)00494-X; Papaemmanuil E, 2014, NAT GENET, V46, P116, DOI 10.1038/ng.2874; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Reddy YVR, 2006, GENE DEV, V20, P1575, DOI 10.1101/gad.1432706; Rommel PC, 2017, J EXP MED, V214, P815, DOI 10.1084/jem.20161638; Roth DB, 2003, NAT REV IMMUNOL, V3, P656, DOI 10.1038/nri1152; Roth DB, 1998, CELL, V94, P411, DOI 10.1016/S0092-8674(00)81580-9; Ru H, 2018, NAT STRUCT MOL BIOL, V25, P732, DOI 10.1038/s41594-018-0098-5; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; Schabla NM, 2018, J IMMUNOL, V201, P930, DOI 10.4049/jimmunol.1800054; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; Serana F, 2011, J CLIN IMMUNOL, V31, P540, DOI 10.1007/s10875-011-9526-6; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sodora DL, 2000, EUR J IMMUNOL, V30, P1145, DOI 10.1002/(SICI)1521-4141(200004)30:4<1145::AID-IMMU1145>3.0.CO;2-7; Swanson PC, 2004, J BIOL CHEM, V279, P4034, DOI 10.1074/jbc.M311100200; Swanson PC, 2002, MOL CELL BIOL, V22, P1340, DOI 10.1128/MCB.22.5.1340-1351.2002; Teng G, 2015, CELL, V162, P751, DOI 10.1016/j.cell.2015.07.009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Vanura K, 2007, PLOS BIOL, V5, P515, DOI 10.1371/journal.pbio.0050043; Zhang L, 2011, IMMUNITY, V34, P163, DOI 10.1016/j.immuni.2011.02.003; Zhang YH, 2019, NATURE, V569, P79, DOI 10.1038/s41586-019-1093-7; Zhou LQ, 2004, NATURE, V432, P995, DOI 10.1038/nature03157	59	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 4	2019	10								1572	10.3389/fimmu.2019.01572	http://dx.doi.org/10.3389/fimmu.2019.01572			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IH0US	31333681	Green Published, gold			2022-12-18	WOS:000474208700001
J	Castiglione, F; Ghersi, D; Celada, F				Castiglione, Filippo; Ghersi, Dario; Celada, Franco			Computer Modeling of Clonal Dominance: Memory-Anti-Naive and Its Curbing by Attrition	FRONTIERS IN IMMUNOLOGY			English	Article						computer modeling; IMMSIM; memory-anti-naive; attrition; CD8+response	IMMUNE-SYSTEM; HYPERSENSITIVITY; SIMULATION; NETWORK; GENE	Experimental and computational studies have revealed that T-cell cross-reactivity is a widespread phenomenon that can either be advantageous or detrimental to the host. In particular, detrimental effects can occur whenever the clonal dominance of memory cells is not justified by their infection-clearing capacity. Using an agent-based model of the immune system, we recently predicted the "memory anti-naive" phenomenon, which occurs when the secondary challenge is similar but not identical to the primary stimulation. In this case, the pre-existing memory cells formed during the primary infection may be rapidly deployed in spite of their low affinity and can actually prevent a potentially higher affinity naive response from emerging, resulting in impaired viral clearance. This finding allowed us to propose a mechanistic explanation for the concept of "antigenic sin" originally described in the context of the humoral response. However, the fact that antigenic sin is a relatively rare occurrence suggests the existence of evolutionary mechanisms that can mitigate the effect of the memory anti-naive phenomenon. In this study we use computer modeling to further elucidate clonal dominance and the memory anti-naive phenomenon, and to investigate a possible mitigating factor called attrition. Attrition has been described in the experimental and computational literature as a combination of competition for space and apoptosis of lymphocytes via typed interferon in the early stages of a viral infection. This study systematically explores the relationship between clonal dominance and the mechanism of attrition. Our results suggest that attrition can indeed mitigate the memory anti-naive effect by enabling the emergence of a diverse, higher affinity naive response against the secondary challenge. In conclusion, modeling attrition allows us to shed light on the nature of clonal interaction and dominance.	[Castiglione, Filippo] Natl Res Council Italy, Inst Appl Comp, Rome, Italy; [Ghersi, Dario] Univ Nebraska, Sch Interdisciplinary Informat, Coll Informat Sci & Technol, Omaha, NE 68182 USA; [Celada, Franco] NYU, Sch Med, New York, NY 10016 USA	Consiglio Nazionale delle Ricerche (CNR); University of Nebraska System; New York University	Celada, F (corresponding author), NYU, Sch Med, New York, NY 10016 USA.	franco.celada@nyumc.org	Castiglione, Filippo/B-1366-2010	Castiglione, Filippo/0000-0002-1442-3552	European Commission [600803]; H2020 Programme (iPC-Pediatric Cure) [826121]	European Commission(European CommissionEuropean Commission Joint Research Centre); H2020 Programme (iPC-Pediatric Cure)	This study is partially funded by the European Commission under the 7th Framework Programme (MISSION-T2D, No. 600803). Partial funding from the H2020 Programme (iPC-Pediatric Cure, No. 826121) is also acknowledged.	BRACK C, 1978, CELL, V15, P1, DOI 10.1016/0092-8674(78)90078-8; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; Burnet M, 1959, CLONAL SELECTION THE, DOI [10.5962/bhl.title.8281, DOI 10.5962/BHL.TITLE.8281]; Calcagno C, 2011, AUTOIMMUNITY, V44, P304, DOI 10.3109/08916934.2010.523220; Castiglione F, 2004, AIDS RES HUM RETROV, V20, P1314, DOI 10.1089/aid.2004.20.1314; Castiglione F, 2011, AUTOIMMUNITY, V44, P261, DOI 10.3109/08916934.2011.523272; Castiglione F, 2003, MATH COMP BIOL SER, P333; Castiglione F, 2007, BIOINFORMATICS, V23, P1371, DOI 10.1093/bioinformatics/btm044; CELADA F, 1992, IMMUNOL TODAY, V13, P56, DOI 10.1016/0167-5699(92)90135-T; Celada F, 1996, EUR J IMMUNOL, V26, P1350, DOI 10.1002/eji.1830260626; Cheng YM, 2009, VACCINE, V27, P833, DOI 10.1016/j.vaccine.2008.11.109; Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262; DESTGROTH SF, 1966, J EXP MED, V124, P331, DOI 10.1084/jem.124.3.331; FARMER JD, 1986, PHYSICA D, V22, P187, DOI 10.1016/0167-2789(86)90240-X; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Kohler B, 2000, VACCINE, V19, P862, DOI 10.1016/S0264-410X(00)00225-5; LANZAVECCHIA A, 1986, NATURE, V319, P778, DOI 10.1038/319778a0; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MORPURGO D, 1995, INT IMMUNOL, V7, P505, DOI 10.1093/intimm/7.4.505; NOSSAL GJV, 1980, P NATL ACAD SCI-BIOL, V77, P1602, DOI 10.1073/pnas.77.3.1602; Pappalardo F, 2005, BIOINFORMATICS, V21, P2891, DOI 10.1093/bioinformatics/bti426; Pearson YE, 2011, AUTOIMMUNITY, V44, P315, DOI 10.3109/08916934.2011.523275; Santoni D, 2008, BIOINFORMATICS, V24, P1374, DOI 10.1093/bioinformatics/btn135; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; SEIDEN PE, 1992, J THEOR BIOL, V158, P329, DOI 10.1016/S0022-5193(05)80737-4; Selin LK, 2011, AUTOIMMUNITY, V44, P328, DOI 10.3109/08916934.2011.523277; Selin LK, 2004, SEMIN IMMUNOL, V16, P335, DOI 10.1016/j.smim.2004.08.014; Von neumann J, 1966, THEORY SELF REPRODUC, V5, P3; Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x	31	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 3	2019	10								1513	10.3389/fimmu.2019.01513	http://dx.doi.org/10.3389/fimmu.2019.01513			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IG1PZ	31338096	Green Published, gold			2022-12-18	WOS:000473564800001
J	Luchini, LSG; Pidde, G; Squaiella-Baptistao, CC; Tambourgi, DV				Goncalves Luchini, Lygia Samartin; Pidde, Giselle; Squaiella-Baptistao, Carla Cristina; Tambourgi, Denise V.			Complement System Inhibition Modulates the Pro-Inflammatory Effects of a Snake Venom Metalloproteinase (vol 10, 1137, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						Bothrops pirajai; SVMP; complement system; whole blood model; compstatin			[Goncalves Luchini, Lygia Samartin; Pidde, Giselle; Squaiella-Baptistao, Carla Cristina; Tambourgi, Denise V.] Butantan Inst, Immunochem Lab, Sao Paulo, Brazil	Instituto Butantan	Tambourgi, DV (corresponding author), Butantan Inst, Immunochem Lab, Sao Paulo, Brazil.	denise.tambourgi@butantan.gov.br	Squaiella-Baptistão, Carla Cristina/K-2557-2013; Tambourgi, Denise Vilarinho/H-7114-2016	Tambourgi, Denise Vilarinho/0000-0003-1896-9074				Luchini LSG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01137	1	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 3	2019	10								1539	10.3389/fimmu.2019.01539	http://dx.doi.org/10.3389/fimmu.2019.01539			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IG1QI	31333670	Green Published, gold			2022-12-18	WOS:000473565900005
J	Kobets, T; Cepickova, M; Volkova, V; Sohrabi, Y; Havelkova, H; Svobodova, M; Demant, P; Lipoldova, M				Kobets, Tatyana; Cepickova, Marie; Volkova, Valeriya; Sohrabi, Yahya; Havelkova, Helena; Svobodova, Milena; Demant, Peter; Lipoldova, Marie			Novel Loci Controlling Parasite Load in Organs of Mice Infected With Leishmania major, Their Interactions and Sex Influence	FRONTIERS IN IMMUNOLOGY			English	Article						Leishmania major; visceral leishmaniasis; parasite load; PCR-ELISA; susceptibility to Infection; QTL; mouse model; sex influence	QUANTITATIVE TRAIT LOCI; CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; GENETIC-CONTROL; ACQUIRED-RESISTANCE; DONOVANI INFECTION; SUSCEPTIBILITY; EPIDEMIOLOGY; DISEASES; HETEROGENEITY	Leishmaniasis is a serious health problem in many countries, and continues expanding to new geographic areas including Europe and USA. This disease, caused by parasites of Leishmania spp. and transmitted by phiebotomine sand flies, causes up to 1.3 million new cases each year and despite efforts toward its functional dissection and treatment it causes 20-50 thousands deaths annually. Dependence of susceptibility to leishmaniasis on sex and host's genes was observed in humans and in mouse models. Several laboratories defined in mice a number of Lmr (Leishmania major response) genetic loci that control functional and pathological components of the response to and outcome of L. major infection. However, the development of its most aggressive form, visceral leishmaniasis, which is lethal if untreated, is not yet understood. Visceral leishmaniasis is caused by infection and inflammation of internal organs. Therefore, we analyzed the genetics of parasite load, spread to internal organs, and ensuing visceral pathology. Using a new PCR-based method of quantification of parasites in tissues we describe a network-like set of interacting genetic loci that control parasite load in different organs. Quantification of Leishmania parasites in lymph nodes, spleen and liver from infected F-2 hybrids between BALB/c and recombinant congenic strains CcS-9 and CcS-16 allowed us to map two novel parasite load controlling Leishmania major response loci, Lmr24 and Lmr27. We also detected parasite-controlling role of the previously described loci Lmr4, Lmr11, Lmr13, Lmr14, Lmr15, and Lmr25, and describe 8 genetic interactions between them. Lmr14, Lmr15, Lmr25, and Lmr27 controlled parasite load in liver and lymph nodes. In addition, Leishmania burden in lymph nodes but not liver was influenced by Lmr4 and Lmr24. In spleen, parasite load was controlled by Lmr11 and Lmr13. We detected a strong effect of sex on some of these genes. We also mapped additional genes controlling splenomegaly and hepatomegaly. This resulted in a systematized insight into genetic control of spread and load of Leishmania parasites and visceral pathology in the mammalian organism.	[Kobets, Tatyana; Cepickova, Marie; Volkova, Valeriya; Sohrabi, Yahya; Havelkova, Helena; Lipoldova, Marie] Acad Sci Czech Republ, Inst Mol Genet, Lab Mol & Cellular Immunol, Prague, Czech Republic; [Svobodova, Milena] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Demant, Peter] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Charles University Prague	Lipoldova, M (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Lab Mol & Cellular Immunol, Prague, Czech Republic.	lipoldova@img.cas.cz	Svobodová, Milena/E-1355-2011; Lipoldova, Marie/AAY-7358-2021; Lipoldova, Marie/G-4399-2014; Sohrabi, Yahya/AAK-2894-2021; Kobets, Tatyana/G-4402-2014	Svobodová, Milena/0000-0003-0281-6452; Lipoldova, Marie/0000-0002-2101-0334; Lipoldova, Marie/0000-0002-2101-0334; Kobets, Tatyana/0000-0003-0294-3638; Sohrabi, Yahya/0000-0001-5268-238X	Czech Science Foundation [GACR 14-30186S, GACR 16-22346S]; Academy of Sciences of the Czech Republic [RVO 68378050]; Ministry of Education, Youth, and Sports [LH12049]	Czech Science Foundation(Grant Agency of the Czech Republic); Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Ministry of Education, Youth, and Sports(Ministry of Education, Youth & Sports - Czech Republic)	This work was supported by the Czech Science Foundation (Grants GACR 14-30186S and GACR 16-22346S) the Academy of Sciences of the Czech Republic (RVO 68378050) and Ministry of Education, Youth, and Sports (grant LH12049).	Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P557; Badalova J, 2002, GENES IMMUN, V3, P187, DOI 10.1038/sj.gene.6363838; Baguet A, 2004, J EXP MED, V200, P1605, DOI 10.1084/jem.20040334; Bernin H, 2014, J INFECT DIS, V209, pS107, DOI 10.1093/infdis/jit610; Bettaieb J, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-386; BLACKWELL J, 1980, NATURE, V283, P72, DOI 10.1038/283072a0; Boivin GA, 2012, J IMMUNOL, V188, P3949, DOI 10.4049/jimmunol.1103320; BRADLEY DJ, 1979, CLIN EXP IMMUNOL, V37, P7; Butterfield RJ, 2003, GENETICS, V163, P1041; Carroll SF, 2008, GENES IMMUN, V9, P536, DOI 10.1038/gene.2008.48; Cato Andrew C B, 2002, Sci STKE, V2002, pre9, DOI 10.1126/stke.2002.138.re9; de Freitas EO, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00153; Demant P, 1996, SCIENCE, V274, P1392, DOI 10.1126/science.274.5291.1392; DETOLLA LJ, 1980, IMMUNOGENETICS, V10, P353, DOI 10.1007/BF01561585; Douvoyiannis M, 2014, CLIN INFECT DIS, V59, pE73, DOI 10.1093/cid/ciu386; Dujardin JC, 2008, EMERG INFECT DIS, V14, P1013, DOI 10.3201/eid1407.071589; Esch KJ, 2013, CLIN MICROBIOL REV, V26, P58, DOI 10.1128/CMR.00067-12; Fuentes N, 2018, BIOL SEX DIFFER, V9, DOI 10.1186/s13293-018-0177-7; Gandacu D, 2014, EMERG INFECT DIS, V20, P1605, DOI 10.3201/eid2010.140182; Ghorbani M, 2018, DRUG DES DEV THER, V12, P25, DOI 10.2147/DDDT.S146521; Gonzalez C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000585; Grekov I, 2011, J MICROBIOL METH, V87, P273, DOI 10.1016/j.mimet.2011.08.012; Guerra-Silveira F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062390; Harizanov R, 2013, Euro Surveill, V18, P20531, DOI 10.2807/1560-7917.ES2013.18.29.20531; Havelkova H, 2006, GENES IMMUN, V7, P220, DOI 10.1038/sj.gene.6364290; Hayes KS, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-193; Herrador Z, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003594; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Karamian M, 2007, PARASITOL RES, V101, P1431, DOI 10.1007/s00436-007-0649-x; KIRKPATRICK CE, 1982, INFECT IMMUN, V38, P1208, DOI 10.1128/IAI.38.3.1208-1216.1982; Kobets T, 2012, CURR MED CHEM, V19, P1443, DOI 10.2174/092986712799828300; Kobets T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001667; Kobets T, 2010, NAT PROTOC, V5, P1074, DOI 10.1038/nprot.2010.68; Kurey I, 2009, IMMUNOGENETICS, V61, P619, DOI 10.1007/s00251-009-0392-9; Lachaud L, 2013, Euro Surveill, V18, P20534, DOI 10.2807/1560-7917.ES2013.18.29.20534; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Layegh P, 2013, J INFECT DEV COUNTR, V7, P614, DOI 10.3855/jidc.2939; Leclercq V, 1996, J IMMUNOL, V157, P4537; Lipoldova M, 2000, GENES IMMUN, V1, P200, DOI 10.1038/sj.gene.6363660; Lipoldova M, 2006, NAT REV GENET, V7, P294, DOI 10.1038/nrg1832; Lipoldova M, 2002, IMMUNOGENETICS, V54, P174, DOI 10.1007/s00251-002-0439-7; Machado CM, 2009, REV INST MED TROP SP, V51, P309, DOI 10.1590/S0036-46652009000600002; McCall LI, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003053; McCormick H, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4350-x; McMahon-Pratt D, 2004, IMMUNOL REV, V201, P206, DOI 10.1111/j.0105-2896.2004.00190.x; Min-Oo G, 2008, GENES IMMUN, V9, P383, DOI 10.1038/sj.gene.6364450; Mortazavi H, 2015, IRAN J PARASITOL, V10, P296; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Pavli A, 2010, INT J INFECT DIS, V14, pE1032, DOI 10.1016/j.ijid.2010.06.019; Petersen CA, 2009, TOP COMPANION ANIM M, V24, P182, DOI 10.1053/j.tcam.2009.06.006; Picado A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087641; Ready PD, 2010, EUROSURVEILLANCE, V15, P29; Reithinger R, 2003, EMERG INFECT DIS, V9, P727; Rijal S, 2010, TROP MED INT HEALTH, V15, P21, DOI 10.1111/j.1365-3156.2010.02518.x; ROBERTS M, 1989, INFECT IMMUN, V57, P875, DOI 10.1128/IAI.57.3.875-881.1989; Rodriguez NE, 2018, AM J TROP MED HYG, V98, P142, DOI 10.4269/ajtmh.17-0563; Sakthianandeswaren A, 2009, TRENDS PARASITOL, V25, P383, DOI 10.1016/j.pt.2009.05.004; Sandanayaka R, 2014, TROP MED INT HEALTH, V19, P140, DOI 10.1111/tmi.12232; Schlagenhauf P, 2010, CLIN INFECT DIS, V50, P826, DOI 10.1086/650575; Sima M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001173; Slapnickova M, 2016, BIOL SEX DIFFER, V7, DOI 10.1186/s13293-016-0117-3; Snider H, 2009, NEUROIMMUNOMODULAT, V16, P106, DOI 10.1159/000180265; Soares L, 2014, TROP MED INT HEALTH, V19, P988, DOI 10.1111/tmi.12337; Sohrabi Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00130; Sohrabi Y, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002282; Spotin A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/913510; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; Talari Safar Ali, 2006, Korean Journal of Parasitology, V44, P355, DOI 10.3347/kjp.2006.44.4.355; Terrazas CA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/357106; The World Health Organization (WHO), 2017, INT NEGL TROP DIS GL; Torres-Guerrero Edoardo, 2017, F1000Res, V6, P750, DOI 10.12688/f1000research.11120.1; Varma N, 2010, INDIAN J HEMATOL BLO, V26, P78, DOI 10.1007/s12288-010-0027-1; Vladimirov V, 2003, INFECT IMMUN, V71, P2041, DOI 10.1128/IAI.71.4.2041-2046.2003; WHO, 2015, INV OV GLOB IMP NEGL; Wondimeneh Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/545393	77	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 7	2019	10								1083	10.3389/fimmu.2019.01083	http://dx.doi.org/10.3389/fimmu.2019.01083			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IC5EG	31231359	gold, Green Published			2022-12-18	WOS:000470989800001
J	Kaufmann, SHE				Kaufmann, Stefan H. E.			Corrigendum: Immunology's Coming of Age (vol 10, 684, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						antibody; cytokine; dendritic cell; immunology; lymphocyte; macrophage; phagocytosis; recombination			[Kaufmann, Stefan H. E.] Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany; [Kaufmann, Stefan H. E.] Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX 77843 USA	Max Planck Society; Texas A&M University System; Texas A&M University College Station	Kaufmann, SHE (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany.; Kaufmann, SHE (corresponding author), Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX 77843 USA.	Kaufmann@mpiib-berlin.mpg.de						Kaufmann SHE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00684	1	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 6	2019	10								1214	10.3389/fimmu.2019.01214	http://dx.doi.org/10.3389/fimmu.2019.01214			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IC5CK	31244830	Green Published, gold			2022-12-18	WOS:000470984800001
J	Kim, MS; Yi, EJ; Kim, YI; Kim, SH; Jung, YS; Kim, SR; Iwawaki, T; Ko, HJ; Chang, SY				Kim, Mee-Sun; Yi, Eun-Je; Kim, Young-In; Kim, So Hee; Jung, Yi-Sook; Kim, Seong-Ryeol; Iwawaki, Takao; Ko, Hyun-Jeong; Chang, Sun-Young			ERdj5 in Innate Immune Cells Is a Crucial Factor for the Mucosal Adjuvanticity of Cholera Toxin	FRONTIERS IN IMMUNOLOGY			English	Article						cholera toxin (CT); ERdj5; mucosal adjuvant; ER stress; dendrtic cells	STRUCTURAL BASIS; INDUCTION; PROTEIN; MACROPHAGES; IMMUNIZATION; ACTIVATION; RESPONSES; PROMOTES; SUBUNIT; VACCINE	Cholera toxin (CT) is one of most strong mucosal adjuvants, but it cannot be clinically used owing to its toxicity. The cytosolic A1 subunit of CT (CTA1) is the molecule responsible for its immunostimulatory activity, which increases the concentration of cyclic AMP and causes the induction of pro-inflammatory cytokines in innate immune cells. However, the importance of endoplasmic reticulum (ER) molecules involved in CTA1 retro-translocation to induce immune responses remained to be investigated. ERdj5 is an ER protein which is expected to transfer CTA1 to the Hrd1 complex for the retro-translocation of CTA1. In this study, we investigated the physiological relevance of ERdj5 in immune stimulation by CT. ERdj5-knockout (ERdj5 KO) mice had decreased production of antigen-specific IgG in the serum and IgA in the mucosal secretion after intranasal immunization with Ag and CT. Especially, IgG2c isotypes were specifically reduced in the absence of ERdj5. ERdj5 KO dendritic cells (DCs) failed to full activation with decreased expression of costimulatory molecules, such as MHC class II, CD80, and CD 86. In ERdj5 KO DCs, secretion of pro-inflammatory cytokines, such as IL-1 beta, TNF-alpha, and IL-6, was reduced. The cytokine signatures of several helper T cells were reduced in ERdj5 KO mice following intranasal CT immunization. The absence of ERdj5 affects the immunostimulatory properties of CT but does not affect the response to the CTB pentamer, the response to alum, total antibody production, or cytokine release from DCs exposed to CpG. Interestingly, CT enhanced the expression of ER stress proteins in ERdj5 KO innate immune cells. These results suggested that ERdj5 contributed as a decisive factor to the immunostimulatory capacity of CT via CTA1 retro-translocation.	[Kim, Mee-Sun; Yi, Eun-Je; Kim, Young-In; Kim, So Hee; Jung, Yi-Sook; Chang, Sun-Young] Ajou Univ, Coll Pharm, Suwon, South Korea; [Kim, Mee-Sun; Yi, Eun-Je; Kim, Young-In; Kim, So Hee; Jung, Yi-Sook; Chang, Sun-Young] Ajou Univ, RIPST, Suwon, South Korea; [Kim, Seong-Ryeol; Ko, Hyun-Jeong] Kangwon Natl Univ, Coll Pharm, Lab Microbiol & Immunol, Chuncheon Si, South Korea; [Iwawaki, Takao] Kanazawa Med Univ, Med Res Inst, Div Cell Med, Dept Life Sci, Uchinada, Ishikawa, Japan	Ajou University; Ajou University; Kangwon National University; Kanazawa Medical University	Chang, SY (corresponding author), Ajou Univ, Coll Pharm, Suwon, South Korea.; Chang, SY (corresponding author), Ajou Univ, RIPST, Suwon, South Korea.	sychang@ajou.ac.kr			Ajou University Research Fund (2016), Republic of Korea; National Research Foundation of Korea (NRF) - Ministry of Science, ICT and future Planning [NRF-2017R1A2B4002419]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI15C1980, HI17C0047]	Ajou University Research Fund (2016), Republic of Korea; National Research Foundation of Korea (NRF) - Ministry of Science, ICT and future Planning; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This study was supported by Ajou University Research Fund (2016), Republic of Korea; the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and future Planning (NRF-2017R1A2B4002419); and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI15C1980, HI17C0047).	BROMANDER A, 1991, J IMMUNOL, V146, P2908; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Datta SK, 2010, P NATL ACAD SCI USA, V107, P10638, DOI 10.1073/pnas.1002348107; Dixit G, 2008, EXP BIOL MED, V233, P163, DOI 10.3181/0705-RM-132; Eirini A, 2017, ANN RHEUM DIS, V76, pA91, DOI 10.1136/annrheumdis-2016-211055.38; GILL DM, 1975, J BIOL CHEM, V250, P6424; Givord C, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0058-4; Hagiwara M, 2011, MOL CELL, V41, P432, DOI 10.1016/j.molcel.2011.01.021; Helft J, 2015, IMMUNITY, V42, P1197, DOI 10.1016/j.immuni.2015.05.018; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; Hong EH, 2017, ONCOTARGET, V8, P41401, DOI 10.18632/oncotarget.17388; Hosoda A, 2010, BIOCHEM J, V425, P117, DOI 10.1042/BJ20091269; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Kim YG, 2017, IMMUNE NETW, V17, P20, DOI 10.4110/in.2017.17.1.20; Lavelle EC, 2003, J IMMUNOL, V171, P2384, DOI 10.4049/jimmunol.171.5.2384; Lavelle EC, 2004, J LEUKOCYTE BIOL, V75, P756, DOI 10.1189/jlb.1103534; Lee JB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005190; Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51; Lei H, 2011, CLIN VACCINE IMMUNOL, V18, P1046, DOI 10.1128/CVI.00050-11; Lowell GH, 1997, J INFECT DIS, V175, P292, DOI 10.1093/infdis/175.2.292; LYCKE N, 1986, IMMUNOLOGY, V59, P301; Mattsson J, 2015, MUCOSAL IMMUNOL, V8, P815, DOI 10.1038/mi.2014.111; MCGEE DW, 1993, INFECT IMMUN, V61, P4637, DOI 10.1128/IAI.61.11.4637-4644.1993; Morito D, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00048; O'Neal CJ, 2005, SCIENCE, V309, P1093, DOI 10.1126/science.1113398; Ross PJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003264; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Ushioda R, 2016, P NATL ACAD SCI USA, V113, pE6055, DOI 10.1073/pnas.1605818113; Williams JM, 2013, MOL BIOL CELL, V24, P785, DOI 10.1091/mbc.E12-07-0522; Wu HY, 1998, VACCINE, V16, P286, DOI 10.1016/S0264-410X(97)00168-0; ZHANG YH, 1988, J BIOL CHEM, V263, P6177; Zhou JY, 2010, BRIT J SURG, V97, P281, DOI 10.1002/bjs.6820	34	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 4	2019	10								1249	10.3389/fimmu.2019.01249	http://dx.doi.org/10.3389/fimmu.2019.01249			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IB3WA	31275300	Green Published, gold			2022-12-18	WOS:000470197000001
J	Romaniuk, DS; Postovskaya, AM; Khmelevskaya, AA; Malko, DB; Efimov, GA				Romaniuk, Dmitrii S.; Postovskaya, Anna M.; Khmelevskaya, Alexandra A.; Malko, Dmitry B.; Efimov, Grigory A.			Rapid Multiplex Genotyping of 20 HLA-A*02:01 Restricted Minor Histocompatibility Antigens	FRONTIERS IN IMMUNOLOGY			English	Article						multiplex qPCR; minor histocompatibility antigens; MiHA; SNP genotyping; allele-specific pri mer; AS-PCR; HSCT; AS-qPCR	MHC CLASS-I; T-CELLS; DIALLELIC GENE; GRAFT; IDENTIFICATION; IMMUNOTHERAPY; POLYMORPHISM; DISCOVERY; SNP	A subset of MHC-associated self-peptides presented by the recipient's cells and immunologically foreign to the donor can induce an allogeneic immune response after hematopoietic stem cell transplantation (HSCT). These immunogenic peptides originate from the genomic polymorphisms and are known as minor histocompatibility antigens (MiHA). MiHA mismatches trigger the post-transplant immune response, which could manifest in both the deleterious "graft-vs.-host" disease and the beneficial "graft-vs.-leukemia" effect. Importantly, some MiHAs are considered to be promising targets for posttransplant T-cell immunotherapy of hematopoietic malignancies. This creates a demand for a robust and fast approach to genotyping MiHA-encoding polymorphisms. We report a multiplex real-time PCR method for the genotyping of 20 polymorphisms that are encoding HLA-A*02:01 -restricted MiHAs. This method uses allele-specific primers and gene-specific hydrolysis probes. In 1 h it allows for the detection of MiHA mismatches in a donor-recipient pair without the need for electrophoresis, sequencing, or other time-consuming techniques. We validated the method with Sanger and NGS sequencing and demonstrated good performance over a wide range of DNA concentrations. We propose our protocol as a fast and accurate method of identifying mismatched MiHAs. The information on the MiHA mismatches is useful for studying the allogeneic immune response following HSCT and for selecting the targets for post-transplant T-cell therapy.	[Romaniuk, Dmitrii S.; Postovskaya, Anna M.; Khmelevskaya, Alexandra A.; Malko, Dmitry B.; Efimov, Grigory A.] Natl Res Ctr Hematol, Lab Transplantat Immunol, Moscow, Russia	Russian Academy of Medical Sciences; National Medical Research Center for Hematology	Efimov, GA (corresponding author), Natl Res Ctr Hematol, Lab Transplantat Immunol, Moscow, Russia.	efimov.g@blood.ru	Malko, Dmitry/B-9285-2016; Romaniuk, Dmitrii/D-6277-2017; Khmelevskaya, Alexandra/AAZ-8850-2020; Efimov, Grigory/AAH-4502-2021; Khmelevskaya, Alexandra/AAH-6721-2021	Malko, Dmitry/0000-0002-3278-3930; Romaniuk, Dmitrii/0000-0002-9423-1269; Khmelevskaya, Alexandra/0000-0003-2773-5608; Khmelevskaya, Alexandra/0000-0001-8399-4124; Efimov, Grigory/0000-0001-7129-6062	Russian Science Foundation [17-15-01512]; Russian Foundation for Basic Research [17-04-02186]	Russian Science Foundation(Russian Science Foundation (RSF)); Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR))	The work was supported by the Russian Science Foundation grant 17-15-01512. The bioinformatics was supported by the Russian Foundation for Basic Research project No. 17-04-02186. Authors would like to thank Vladimir V. Strelnikov and Alexander S. Tanas for help with performing the NGS, and Nadia A. Bykova, and Dasha Efimova for the critical reading of the manuscript.	Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Armistead PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023217; Bijen HM, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700250; Bleakley M, 2011, IMMUNOL CELL BIOL, V89, P396, DOI 10.1038/icb.2010.124; Brickner AG, 2001, J EXP MED, V193, P195, DOI 10.1084/jem.193.2.195; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Bykova NA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01819; D'Souza A, 2017, CURRENT EDITION INCL; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Dzierzak-Mietla M, 2012, BONE MARROW RES, DOI 10.1155/2012/257086; Falkenburg JHF, 2011, BIOL BLOOD MARROW TR, V17, pS33, DOI 10.1016/j.bbmt.2010.11.009; Feng X, 2008, TRENDS IMMUNOL, V29, P624, DOI 10.1016/j.it.2008.09.004; Gallardo D, 2017, BIOL BLOOD MARROW TR, V23, P2042, DOI 10.1016/j.bbmt.2017.08.003; Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166; Granados DP, 2016, LEUKEMIA, V30, P1344, DOI 10.1038/leu.2016.22; Griffioen M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00100; Hombrink P, 2015, CLIN CANCER RES, V21, P2177, DOI 10.1158/1078-0432.CCR-14-2188; Hombrink P, 2013, J IMMUNOL, V190, P3869, DOI 10.4049/jimmunol.1202351; Kamei M, 2009, BLOOD, V113, P5041, DOI 10.1182/blood-2008-07-171678; Kawase T, 2008, BLOOD, V111, P3286, DOI 10.1182/blood-2007-10-118950; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; Kim S, 2007, ANNU REV BIOMED ENG, V9, P289, DOI 10.1146/annurev.bioeng.9.060906.152037; Little S., 2001, CURRENT PROTOCOLS HU; Murata M, 2003, J EXP MED, V197, P1279, DOI 10.1084/jem.20030044; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Oostvogels R, 2013, LEUKEMIA, V27, P642, DOI 10.1038/leu.2012.277; Pierce RA, 2001, J IMMUNOL, V167, P3223, DOI 10.4049/jimmunol.167.6.3223; Rijke BC, 2005, J CLIN INVEST, V115, P3506, DOI 10.1172/JCI24832; Robinson JT, 2017, CANCER RES, V77, pE31, DOI 10.1158/0008-5472.CAN-17-0337; Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000; Slomka M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112316; Spierings E, 2003, BLOOD, V102, P621, DOI 10.1182/blood-2003-01-0260; Spierings Eric, 2007, Methods Mol Med, V134, P81; Spierings E, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000042; Stadhouders R, 2010, J MOL DIAGN, V12, P109, DOI 10.2353/jmoldx.2010.090035; SUDO T, 1995, J IMMUNOL, V155, P4749; Tykodi SS, 2008, CLIN CANCER RES, V14, P5260, DOI 10.1158/1078-0432.CCR-08-0028; van Bergen CAM, 2007, BLOOD, V109, P4089, DOI 10.1182/blood-2006-08-043935; van Bergen CAM, 2017, J CLIN INVEST, V127, P517, DOI 10.1172/JCI86175; Van Bergen CAM, 2010, CANCER RES, V70, P9073, DOI 10.1158/0008-5472.CAN-10-1832; van der Lee DI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162808; Wenandy L, 2009, LEUKEMIA, V23, P1926, DOI 10.1038/leu.2009.112; Wolfel C, 2008, CANCER IMMUNOL IMMUN, V57, P849, DOI 10.1007/s00262-007-0421-1	45	2	3	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 4	2019	10								1226	10.3389/fimmu.2019.01226	http://dx.doi.org/10.3389/fimmu.2019.01226			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IB3VU	31275297	Green Published, gold			2022-12-18	WOS:000470196400001
J	Lewis, DE; Lysaght, J; Wu, HZ				Lewis, Dorothy E.; Lysaght, Joanne; Wu, Huaizhu			Editorial: T Cell Alterations in Adipose Tissue During Obesity, HIV, and Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cells; obesity; cancer; HIV; inflammation	INSULIN-RESISTANCE; ACCUMULATION; INFLAMMATION; FAT; ACTIVATION; PLAYS; MICE		[Lewis, Dorothy E.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA; [Lysaght, Joanne] St James Hosp, Dept Surg, Trinity Translat Med Inst, Dublin, Ireland; [Wu, Huaizhu] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Trinity College Dublin; Baylor College of Medicine	Lewis, DE (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA.	Dorothy.e.lewis@uth.tmc.edu	Lysaght, Joanne/AAC-2399-2022	Lysaght, Joanne/0000-0003-3363-3763	National Institutes of Health [R01 HL098839]; American Heart Association [AHA16GRNT30410012]; American Diabetes Association [1-17-IBS-082]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); American Diabetes Association(American Diabetes Association)	Thanks to all those who submitted articles and to Pamela Love for edits. HW is supported by an National Institutes of Health grant (R01 HL098839), American Heart Association award (AHA16GRNT30410012), and American Diabetes Association award (1-17-IBS-082).	Bertola A, 2012, DIABETES, V61, P2238, DOI 10.2337/db11-1274; Caron-Debarle M, 2010, TRENDS MOL MED, V16, P218, DOI 10.1016/j.molmed.2010.03.002; Couturier J, 2018, CURR HIV-AIDS REP, V15, P60, DOI 10.1007/s11904-018-0378-z; Deng T, 2013, CELL METAB, V17, P411, DOI 10.1016/j.cmet.2013.02.009; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Jiang EL, 2014, ARTERIOSCL THROM VAS, V34, P34, DOI 10.1161/ATVBAHA.113.302077; Khan IM, 2015, INT J OBESITY, V39, P1607, DOI 10.1038/ijo.2015.104; Khan IM, 2014, ATHEROSCLEROSIS, V233, P419, DOI 10.1016/j.atherosclerosis.2014.01.011; Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Wang ZM, 2019, NAT MED, V25, P141, DOI 10.1038/s41591-018-0221-5; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; Wu HZ, 2007, CIRCULATION, V115, P1029, DOI 10.1161/CIRCULATIONAHA.106.638379; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	16	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 28	2019	10								1190	10.3389/fimmu.2019.01190	http://dx.doi.org/10.3389/fimmu.2019.01190			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IA0TI	31191549	Green Published, gold			2022-12-18	WOS:000469270000001
J	Sacre, S; Jaxa-Chamiec, A; Low, CMR; Chamberlain, G; Tralau-Stewart, C				Sacre, Sandra; Jaxa-Chamiec, Albert; Low, Caroline M. R.; Chamberlain, Giselle; Tralau-Stewart, Cathy			Structural Modification of the Antidepressant Mianserin Suggests That Its Anti-inflammatory Activity May Be Independent of 5-Hydroxytryptamine Receptors	FRONTIERS IN IMMUNOLOGY			English	Article						inflammation; toll-like receptor; rheumatoid arthritis; antidepressant; mianserin; macrophage; 5-hydroxytryptamine; tumor necrosis factor	TOLL-LIKE RECEPTORS; RHEUMATOID-ARTHRITIS; ANTAGONISTS; FLUOXETINE; DEPRESSION; BINDING	Antidepressants are increasingly recognized to have anti-inflammatory properties in addition to their ability to treat major depressive disorders. To explore if engagement of 5-hydroxytryptamine (5-HT) receptors was required for the anti-inflammatory effect of the tetracyclic antidepressant mianserin, a series of structural derivatives were generated with the aim of reducing 5-HT receptor binding. Primary human peripheral blood mononuclear cells were used to screen for anti-inflammatory activity. The lead compound demonstrated a significant loss in 5-HT receptor binding, as assessed by non-selective 5-HT binding of radio-labelled serotonin in rat cerebral cortex. However, it retained the ability to inhibit endosomal toll-like receptor 8 signaling in primary human macrophages and spontaneous cytokine production from human rheumatoid synovial tissue equivalent to that previously observed for mianserin. These data demonstrate that the anti-inflammatory mechanism of mianserin may be independent of 5-HT receptor activity. This research offers new insights into the mechanism and structural requirements for the anti-inflammatory action of mianserin.	[Sacre, Sandra; Chamberlain, Giselle] Univ Sussex, Brighton & Sussex Med Sch, Brighton, E Sussex, England; [Jaxa-Chamiec, Albert; Low, Caroline M. R.; Tralau-Stewart, Cathy] Imperial Coll Sci Technol & Med, Ctr Drug Discovery, London, England	University of Brighton; University of Sussex; Imperial College London	Sacre, S (corresponding author), Univ Sussex, Brighton & Sussex Med Sch, Brighton, E Sussex, England.	s.sacre@bsms.ac.uk	Sacre, Sandra/AAE-2297-2020	Sacre, Sandra/0000-0003-1665-1142	Imperial College London; Medical Research Council [G1001715]; Brighton and Sussex Medical School; MRC [G1001715] Funding Source: UKRI	Imperial College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Brighton and Sussex Medical School; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Imperial College London, the Medical Research Council (grant number G1001715) and Brighton and Sussex Medical School.	Abdel-Salam OME, 2004, PHARMACOL RES, V49, P119, DOI 10.1016/j.phrs.2003.07.016; Alzabin S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3875; Andres JI, 2002, BIOORG MED CHEM LETT, V12, P243, DOI 10.1016/S0960-894X(01)00721-1; BRENNAN FM, 1989, LANCET, V2, P244; BRENNAN FM, 1989, J AUTOIMMUN, V2, P177, DOI 10.1016/0896-8411(89)90129-7; Conti AC, 2004, MOL NEUROBIOL, V30, P143, DOI 10.1385/MN:30:2:143; Dahl J, 2014, PSYCHONEUROENDOCRINO, V45, P77, DOI 10.1016/j.psyneuen.2014.03.019; Ferreira PK, 2000, REGUL PEPTIDES, V89, P29, DOI 10.1016/S0167-0115(00)00094-X; Gibbard RJ, 2006, J BIOL CHEM, V281, P27503, DOI 10.1074/jbc.M605003200; Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121; Hutchinson MR, 2010, NEUROSCIENCE, V168, P551, DOI 10.1016/j.neuroscience.2010.03.067; Ishii N, 2014, J IMMUNOL, V193, P5118, DOI 10.4049/jimmunol.1401375; Kappelmann N, 2018, MOL PSYCHIATR, V23, P335, DOI 10.1038/mp.2016.167; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; LLOYD EJ, 1986, J MED CHEM, V29, P453, DOI 10.1021/jm00154a005; Lopez-Munoz F, 2009, CURR PHARM DESIGN, V15, P1563, DOI 10.2174/138161209788168001; Matcham F, 2013, RHEUMATOLOGY, V52, P2136, DOI 10.1093/rheumatology/ket169; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Obuchowicz E, 2006, INT J NEUROPSYCHOPH, V9, P27, DOI 10.1017/S146114570500547X; PEROUTKA SJ, 1979, MOL PHARMACOL, V16, P687; Sacre S, 2010, ARTHRITIS RHEUM-US, V62, P683, DOI 10.1002/art.27304; Sacre SM, 2008, J IMMUNOL, V181, P8002, DOI 10.4049/jimmunol.181.11.8002; SANDERSBUSH E, 1988, J PHARMACOL EXP THER, V247, P169; Schmidt FM, 2016, CURR NEUROPHARMACOL, V14, P674, DOI 10.2174/1570159X14666160115130414; Tynan RJ, 2012, BRAIN BEHAV IMMUN, V26, P469, DOI 10.1016/j.bbi.2011.12.011; Yang Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005	26	2	2	2	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2019	10								1167	10.3389/fimmu.2019.01167	http://dx.doi.org/10.3389/fimmu.2019.01167			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HZ6AR	31244825	Green Accepted, Green Published, gold			2022-12-18	WOS:000468934700001
J	Wium, M; Jonker, HI; Olivier, AJ; Belistedt, DU; Botes, A				Wium, Martha; Jonker, Hester Isabella; Olivier, Adriaan Jacobus; Belistedt, Dirk Uwe; Botes, Annelise			DNA Vaccines Against Mycoplasma Elicit Humoral Immune Responses in Ostriches	FRONTIERS IN IMMUNOLOGY			English	Article						ostrich; mycoplasma; DNA vaccine; OppA; antibody response	PLASMID DNA; OLIGOPEPTIDE PERMEASE; STRUTHIO-CAMELUS; VIRUS; OPPA; VACCINATION; EXPRESSION; PROTECTION; PROTEIN; GENE	In ostriches, the population densities resulting from intensive rearing increases susceptibility to pathogens such as mycoplasmas. In addition to good management practices, vaccination offers an attractive alternative for controlling mycoplasma infections in food animals, instead of using antibiotics, which often leave unacceptable residues. The use of live attenuated vaccines, however, carry the concern of reversion to virulence or genetic recombination with field strains. Currently there are no commercially available vaccines against ostrich-infecting mycoplasmas and this study therefore set out to develop and evaluate the use of a DNA vaccine against mycoplasma infections in ostriches using an OppA protein as antigen. To this end, the oppA gene of "Mycoplasma nasistruthionis sp. nov." str. Ms03 was cloned into two DNA vaccine expression vectors after codon correction by site-directed mutagenesis. Three-months-old ostriches were then vaccinated intramuscularly at different doses followed by a booster vaccination after 6 weeks. The ability of the DNA vaccines to elicit an anti-OppA antibody response was evaluated by ELISA using the recombinant OppA protein of Ms03 as coating antigen. A statistically significant anti-OppA antibody response could be detected after administration of a booster vaccination indicating that the OppA protein was successfully immunogenic. The responses were also both dose and vector dependent. In conclusion, the DNA vaccines were able to elicit an immune response in ostriches and can therefore be viewed as an option for the development of vaccines against mycoplasma infections.	[Wium, Martha; Jonker, Hester Isabella; Belistedt, Dirk Uwe; Botes, Annelise] Stellenbosch Univ, Dept Biochem, Stellenbosch, South Africa; [Olivier, Adriaan Jacobus] Klein Karoo Int, Oudtshoom, South Africa	Stellenbosch University	Botes, A (corresponding author), Stellenbosch Univ, Dept Biochem, Stellenbosch, South Africa.	annelise@sun.ac.za		Botes, Annelise/0000-0003-4373-2116; Wium, Martha/0000-0003-0527-1750	Technology and Human Resources for Industry Programme (THRIP), South Africa [TP50090719]; South African Ostrich Business Chamber	Technology and Human Resources for Industry Programme (THRIP), South Africa; South African Ostrich Business Chamber	This work was supported by The Technology and Human Resources for Industry Programme (THRIP), South Africa (Project reference TP50090719) and South African Ostrich Business Chamber.	Armour NK, 2013, AVIAN PATHOL, V42, P408, DOI 10.1080/03079457.2013.819486; Babiuk LA, 1999, VET IMMUNOL IMMUNOP, V72, P189, DOI 10.1016/S0165-2427(99)00132-4; Blignaut A, 2000, AVIAN DIS, V44, P390, DOI 10.2307/1592554; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Bonato M, 2009, BEHAV ECOL SOCIOBIOL, V64, P183, DOI 10.1007/s00265-009-0835-1; Botes A, 2005, VET MICROBIOL, V111, P159, DOI 10.1016/j.vetmic.2005.10.017; Botes A., 2005, Proceedings of the 3rd International Ratite Science Symposium of the World's Poultry Science Association (WPSA) and 12th World Ostrich Congress, Madrid, Spain, 14th-16th October, 2005, P211; Castellino F, 2009, EUR J IMMUNOL, V39, P2100, DOI 10.1002/eji.200939550; Chen YN, 2013, VET IMMUNOL IMMUNOP, V152, P359, DOI 10.1016/j.vetimm.2013.01.009; Citti C, 2013, TRENDS MICROBIOL, V21, P196, DOI 10.1016/j.tim.2013.01.003; Coban C, 2005, J LEUKOCYTE BIOL, V78, P647, DOI 10.1189/jlb.1104627; Combaz N, 2017, GEBURTSH FRAUENHEILK, V77, P1299, DOI 10.1055/s-0043-119687; Cupillard L, 2005, VACCINE, V23, P1910, DOI 10.1016/j.vaccine.2004.10.018; Darwish WS, 2013, JPN J VET RES, V61, pS13; Department of Agriculture Forestry & Fisheries (DAFF)., 2017, PROF S AFR OSTR MARK; Dunham SP, 2002, RES VET SCI, V73, P9, DOI 10.1016/S0034-5288(02)00032-2; El Gazzar M, 2011, AVIAN DIS, V55, P569, DOI 10.1637/9689-021711-Reg.1; Garmory HS, 2004, INFECT IMMUN, V72, P6757, DOI 10.1128/IAI.72.12.6757-6763.2004; Giese M, 1998, VIRUS GENES, V17, P219, DOI 10.1023/A:1008013720032; Grandi Guido, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-36; HEMPSTEAD PG, 1990, CAN J MICROBIOL, V36, P59, DOI 10.1139/m90-011; Hoffman LC, 2011, ANIM WELFARE SER, V11, P195, DOI 10.1007/978-3-642-19297-5_10; Hopfe M, 2004, J BACTERIOL, V186, P1021, DOI 10.1128/JB.186.4.1021-1028.2004; Huang J, 2018, VET MICROBIOL, V225, P40, DOI 10.1016/j.vetmic.2018.09.002; Jonker HI, 2017, THESIS; Kodihalli S, 1997, J VIROL, V71, P3391, DOI 10.1128/JVI.71.5.3391-3396.1997; Langer S., 2009, THESIS; Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x; Macedo N, 2016, RES VET SCI, V107, P62, DOI 10.1016/j.rvsc.2016.05.006; Malin AS, 2000, MICROBES INFECT, V2, P1677, DOI 10.1016/S1286-4579(00)01323-X; Maucksch C, 2009, J GENE MED, V11, P444, DOI 10.1002/jgm.1310; McCutchan TF, 2004, INFECT IMMUN, V72, P2248, DOI 10.1128/IAI.72.4.2248-2253.2004; Movahedi A, 2010, J MED MICROBIOL, V59, P353, DOI 10.1099/jmm.0.015842-0; Oshop GL, 2002, VET IMMUNOL IMMUNOP, V89, P1, DOI 10.1016/S0165-2427(02)00189-7; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; Robinson TJ, 1999, ANIM CONSERV, V2, P165, DOI 10.1111/j.1469-1795.1999.tb00062.x; Sarkander J, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.81; Scholtz A., 2014, OSTRICH MANUAL, P107; Shan S, 2016, ADV MICROBIOL, V6, P310, DOI DOI 10.4236/AIM.2016.64030; Sheets RL, 2006, TOXICOL SCI, V91, P610, DOI 10.1093/toxsci/kfj169; Smith JV, 2013, SYST BIOL, V62, P35, DOI 10.1093/sysbio/sys067; Stachyra A, 2019, POULTRY SCI, V98, P199, DOI 10.3382/ps/pey392; Tanabe M, 2006, INFECT IMMUN, V74, P3687, DOI 10.1128/IAI.01837-05; Triyatni M, 1998, J VIROL, V72, P84, DOI 10.1128/JVI.72.1.84-94.1998; Vanrompay D, 1999, CLIN EXP IMMUNOL, V118, P49; Verwoerd DJ, 2000, REV SCI TECH OIE, V19, P638, DOI 10.20506/rst.19.2.1235; Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213; Wium M., 2015, THESIS; Wium M, 2015, GENE, V558, P31, DOI 10.1016/j.gene.2014.12.036; Yan F, 2013, J VET SCI, V14, P53, DOI 10.4142/jvs.2013.14.1.53; Yang M, 2011, INFECT IMMUN, V79, P846, DOI 10.1128/IAI.00314-10; 2008, NAT REV GENET, V9, P776, DOI DOI 10.1038/NRG2432	52	2	2	3	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 14	2019	10								1061	10.3389/fimmu.2019.01061	http://dx.doi.org/10.3389/fimmu.2019.01061			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HY0ZZ	31139188	Green Published, gold			2022-12-18	WOS:000467844400001
J	Anzaghe, M; Resch, T; Schaser, E; Kronhart, S; Diez, C; Niles, MA; Korotkova, E; Schulke, S; Wolfheimer, S; Kreuz, D; Wingerter, M; Rodriguez, MMB; Waibler, Z				Anzaghe, Martina; Resch, Theresa; Schaser, Elea; Kronhart, Stefanie; Diez, Clara; Niles, Marc A.; Korotkova, Eugenia; Schuelke, Stefan; Wolfheimer, Sonja; Kreuz, Dorothea; Wingerter, Marion; Rodriguez, Maria Matilde Bartolome; Waibler, Zoe			Organ-Specific Expression of IL-1 Receptor Results in Severe Liver Injury in Type I Interferon Receptor Deficient Mice	FRONTIERS IN IMMUNOLOGY			English	Article						anti-inflammatory; poly(I:C); immune pathology; dysregulation; cytokines	POSITIVE FEEDBACK; VIRAL REPLICATION; MURINE MODEL; IMMUNE CELLS; INFLAMMATION; HEPATOCYTES; STEATOHEPATITIS; ACETAMINOPHEN; ANTAGONIST; MECHANISMS	Upon treatment with polyinosinic: polycytidylic acid [poly(I:C)], an artificial double-stranded RNA, type I interferon receptor-deficient (IFNAR(-/-)) mice develop severe liver injury seen by enhanced alanine aminotransferase (ALT) activity in the serum that is not observed in their wildtype (WT) counterparts. Recently, we showed that liver injury is mediated by an imbalanced expression of interleukin (IL)-1 beta and its receptor antagonist (IL1-RA) in the absence of type I IFN. Here we show that despite comparable expression levels of IL-1 beta in livers and spleens, spleens of poly(I: C)-treated IFNAR(-/-) mice show no signs of injury. In vitro analyses of hepatocytes and splenocytes revealed that poly(I:C) had no direct toxic effect on hepatocytes. Furthermore, expression levels of cytokines involved in other models for liver damage or protection such as interferon (IFN)-gamma, transforming growth factor (TGF)-beta, IL-6, IL-10, IL-17, and IL-22 were comparable for both organs in WT and IFNAR(-/-) mice upon treatment. Moreover, flow cytometric analyses showed that the composition of different immune cells in livers and spleens were not altered upon injection of poly(I: C). Finally, we demonstrated that the receptor binding IL-1 beta, IL1R1, is specifically expressed in livers but not spleens of WT and IFNAR(-/-) mice. Accordingly, mice double-deficient for IFNAR and IL1R1 developed no liver injury upon poly(I: C) treatment and showed ALT activities comparable to those of WT mice. Collectively, liver injury is mediated by the organ-specific expression of IL1R1 in the liver.	[Anzaghe, Martina; Resch, Theresa; Schaser, Elea; Kronhart, Stefanie; Diez, Clara; Niles, Marc A.; Korotkova, Eugenia; Waibler, Zoe] Paul Ehrlich Inst, Sect Prod Testing Immunol Biomed 3 1, Langen, Germany; [Schuelke, Stefan; Wolfheimer, Sonja] Paul Ehrlich Inst, Vice Presidents Res Grp Mol Allergol 1, Langen, Germany; [Kreuz, Dorothea] Paul Ehrlich Inst, Sect Morphol 3 3, Langen, Germany; [Wingerter, Marion] Paul Ehrlich Inst, Div Vet Med, Langen, Germany; [Rodriguez, Maria Matilde Bartolome] Univ Freiburg, Inst Internal Med, Freiburg, Germany	Paul Ehrlich Institute; Paul Ehrlich Institute; Paul Ehrlich Institute; Paul Ehrlich Institute; University of Freiburg	Waibler, Z (corresponding author), Paul Ehrlich Inst, Sect Prod Testing Immunol Biomed 3 1, Langen, Germany.	Zoe.Waibler@pei.de		Anzaghe, Martina/0000-0002-7983-3835; Niles, Marc/0000-0002-5791-1644	Deutsche Forschungsgemeinschaft [WA 2873/1-2]; BGAG Stiftung - Walter Hesselbach [BGAG 31993]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BGAG Stiftung - Walter Hesselbach	This work was supported by the Deutsche Forschungsgemeinschaft (WA 2873/1-2) and the BGAG Stiftung - Walter Hesselbach (BGAG 31993).	Chen K, 2017, J AUTOIMMUN, V83, P1, DOI 10.1016/j.jaut.2017.03.008; Cheng LL, 2009, HEPATOLOGY, V49, P215, DOI 10.1002/hep.22585; Conrad E, 2014, HEPATOLOGY, V59, P1555, DOI 10.1002/hep.26915; Detournay O, 2013, J INTERF CYTOK RES, V33, P746, DOI 10.1089/jir.2012.0130; Dong ZJ, 2007, CELL MOL IMMUNOL, V4, P241; Dong ZJ, 2004, J HEPATOL, V41, P966, DOI 10.1016/j.jhep.2004.08.021; Drebber U, 2006, J HEPATOL, V44, P879, DOI 10.1016/j.jhep.2006.02.006; Drucker C, 2010, J AUTOIMMUN, V34, P29, DOI 10.1016/j.jaut.2009.08.003; Fabregat I, 2016, FEBS J, V283, P2219, DOI 10.1111/febs.13665; Fang XF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010288; Feng DC, 2014, J IMMUNOL, V193, P2512, DOI 10.4049/jimmunol.1400588; Gaddi PJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042850; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gehrke N, 2018, J HEPATOL, V68, P986, DOI 10.1016/j.jhep.2018.01.008; Gewiese-Rabsch J, 2010, BBA-MOL BASIS DIS, V1802, P1054, DOI 10.1016/j.bbadis.2010.07.023; Glaccum MB, 1997, J IMMUNOL, V159, P3364; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Hu XY, 2005, J IMMUNOL, V175, P131, DOI 10.4049/jimmunol.175.1.131; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Khan HA, 2017, HEPATOB PANCREAT DIS, V16, P245, DOI 10.1016/S1499-3872(17)60014-6; Ki SH, 2010, HEPATOLOGY, V52, P1291, DOI 10.1002/hep.23837; Kim AR, 2019, FASEB J, V33, P5914, DOI 10.1096/fj.201801256RR; Knight B, 2007, J HEPATOL, V47, P826, DOI 10.1016/j.jhep.2007.06.022; Kumagai Y, 2009, J IMMUNOL, V182, P3960, DOI 10.4049/jimmunol.0804315; Kupke F, 2016, SCI REP-UK, V6, DOI 10.1038/srep37631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamy E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070846; Li J, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01528; Li SQ, 2015, J BIOCHEM MOL TOXIC, V29, P288, DOI 10.1002/jbt.21708; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Novobrantseva TI, 2005, J CLIN INVEST, V115, P3072, DOI 10.1172/JCI24798; Ochi M, 2004, HEPATOLOGY, V39, P1321, DOI 10.1002/hep.20204; Patel DN, 2007, J BIOL CHEM, V282, P27229, DOI 10.1074/jbc.M703250200; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Peters VA, 2013, BRAIN BEHAV IMMUN, V32, P1, DOI 10.1016/j.bbi.2012.11.006; Petrasek J, 2012, J CLIN INVEST, V122, P3476, DOI 10.1172/JCI60777; Petrasek J, 2011, HEPATOLOGY, V53, P649, DOI 10.1002/hep.24059; Qin SY, 2019, ADV CLIN EXP MED, V28, P765, DOI 10.17219/acem/94062; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Shen XD, 2009, HEPATOLOGY, V50, P1537, DOI 10.1002/hep.23153; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Tang-Feldman YJ, 2011, INFLAMM RES, V60, P233, DOI 10.1007/s00011-010-0259-4; Yang L, 2014, HEPATOLOGY, V59, P483, DOI 10.1002/hep.26698; Zamvil SS, 2003, NEURON, V38, P685, DOI 10.1016/S0896-6273(03)00326-X; Zhang Can, 2017, Shengwu Jiagong Guocheng, V15, P1, DOI 10.3969/j.issn.1672-3678.2017.06.001; 2011, GASTROENTEROLOGY, V140, P697, DOI DOI 10.1053/J.GASTRO.2010.08.020	49	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2019	10								1009	10.3389/fimmu.2019.01009	http://dx.doi.org/10.3389/fimmu.2019.01009			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HX5JP	31143178	Green Published, gold			2022-12-18	WOS:000467437600001
J	Silina, K; Kroeger, D				Silina, Karina; Kroeger, David			Immune Outposts on the Inflammatory Frontier: Tertiary Lymphoid Structures as Targets for Immunotherapy of Cancer and Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tertiary lymphoid structures; tertiary lymphoid organs; ectopic germinal centers; autoimmunity; transplantation; cancer microenvironment	B-CELLS; MANIPULATION; INFECTION		[Silina, Karina] Univ Zurich, Inst Expt Immunol, Zurich, Switzerland; [Kroeger, David] British Columbia Canc Agcy, Deeley Res Ctr, Victoria, BC, Canada	University of Zurich; British Columbia Cancer Agency	Silina, K (corresponding author), Univ Zurich, Inst Expt Immunol, Zurich, Switzerland.	silina@immunology.uzh.ch		Silina, Karina/0000-0003-3947-2710				Aloisi F, 2006, NAT REV IMMUNOL, V6, P205, DOI 10.1038/nri1786; Carragher DM, 2008, SEMIN IMMUNOL, V20, P26, DOI 10.1016/j.smim.2007.12.004; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101; Guy TV, 2016, CANCER IMMUNOL IMMUN, V65, P885, DOI 10.1007/s00262-016-1848-z; Neyt K, 2012, TRENDS IMMUNOL, V33, P297, DOI 10.1016/j.it.2012.04.006; Pitzalis C, 2014, NAT REV IMMUNOL, V14, P447, DOI 10.1038/nri3700; Sautes-Fridman C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00407; Silina K, 2014, CANCER IMMUNOL IMMUN, V63, P643, DOI 10.1007/s00262-014-1544-9; Vonderheide RH, 2017, CLIN CANCER RES, V23, P2640, DOI 10.1158/1078-0432.CCR-16-2569; Wada Y, 1998, HEPATOLOGY, V27, P407, DOI 10.1002/hep.510270214	12	2	2	3	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2019	10								993	10.3389/fimmu.2019.00993	http://dx.doi.org/10.3389/fimmu.2019.00993			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HX4AE	31130966	Green Published, gold			2022-12-18	WOS:000467336000003
J	Zhang, ZP; Mu, Y; Shan, L; Sun, D; Guo, WJ; Yu, ZP; Tan, R; Xu, SX; Yang, G				Zhang, Zepeng; Mu, Yuan; Shan, Lei; Sun, Di; Guo, Weijian; Yu, Zhenpeng; Tan, Ran; Xu, Shixia; Yang, Guang			Divergent Evolution of TRC Genes in Mammalian Niche Adaptation	FRONTIERS IN IMMUNOLOGY			English	Article						TRC genes; mammals; correlation; divergent evolution; niches	LIMITED MHC POLYMORPHISM; AMINO-ACID SITES; DELTA T-CELLS; FUNCTIONAL DIVERGENCE; COMPARATIVE BIOLOGY; PROVIDES INSIGHT; LOCUS; MODEL; PHYLOGENETICS; INFERENCE	Mammals inhabit a wide variety of ecological niches, which in turn can be affected by various ecological factors, especially in relation to immunity. The canonical TRC repertoire (TRAC, TRBC, TRGC, and TRDC) codes C regions of T cell receptor chains that form the primary antigen receptors involved in the activation of cellular immunity. At present, little is known about the correlation between the evolution of mammalian TRC genes and ecological factors. In this study, four types canonical of TRC genes were identified from 37 mammalian species. Phylogenetic comparative methods (phyANOVA and PGLS) and selective pressure analyses among different groups of ecological factors (habitat, diet, and sociality) were carried out. The results showed that habitat was the major ecological factor shaping mammalian TRC repertoires. Specifically, trade-off between TRGC numbers and positive selection of TRAC and the balanced evolutionary rates between TRAC and TRDC genes were speculated as two main mechanisms in adaption to habitat and sociality. Overall, our study suggested divergent mechanisms for the evolution of TRCs, prompting mammalian immunity adaptions within diverse niches.	[Zhang, Zepeng; Mu, Yuan; Shan, Lei; Sun, Di; Guo, Weijian; Yu, Zhenpeng; Tan, Ran; Xu, Shixia; Yang, Guang] Nanjing Normal Univ, Jiangsu Key Lab Biodivers & Biotechnol, Coll Life Sci, Nanjing, Jiangsu, Peoples R China	Nanjing Normal University	Xu, SX; Yang, G (corresponding author), Nanjing Normal Univ, Jiangsu Key Lab Biodivers & Biotechnol, Coll Life Sci, Nanjing, Jiangsu, Peoples R China.	xushixia78@163.com; gyang@njnu.edu.cn		Shan, Lei/0000-0002-4107-8061	National Key Programme of Research and Development, Ministry of Science and Technology [2016YFC0503200]; State Key Program of National Natural Science of China [31630071]; National Natural Science Foundation of China (NSFC) [31570379, 31772448]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Key Programme of Research and Development, Ministry of Science and Technology; State Key Program of National Natural Science of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by the National Key Programme of Research and Development, Ministry of Science and Technology (Grant number 2016YFC0503200 to GY and SX), the State Key Program of National Natural Science of China to GY (Grant Number 31630071); the National Natural Science Foundation of China (NSFC, Grant Numbers 31570379 and 31772448 to SX), the Priority Academic Program Development of Jiangsu Higher Education Institutions to GY and SX.	Alexander R.D., 1974, Annual Rev Ecol Syst, V5, P325, DOI 10.1146/annurev.es.05.110174.001545; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ayres DL, 2012, SYST BIOL, V61, P170, DOI [10.1093/sysbio/syr100, 10.1093/sysbio/sys029]; Babayan SA, 2011, ANN NY ACAD SCI, V1236, P17, DOI 10.1111/j.1749-6632.2011.06251.x; Baker JL, 2016, GENETICS, V203, P905, DOI 10.1534/genetics.115.183889; Bik EM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10516; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Braun BA, 2015, P NATL ACAD SCI USA, V112, P8036, DOI 10.1073/pnas.1501844112; Breaux B, 2018, DEV COMP IMMUNOL, V85, P71, DOI 10.1016/j.dci.2018.04.007; BURESI C, 1989, IMMUNOGENETICS, V29, P161, DOI 10.1007/BF00373641; Chien YH, 2014, ANNU REV IMMUNOL, V32, P121, DOI 10.1146/annurev-immunol-032713-120216; Connelley TK, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-994; Conrad ML, 2007, VET IMMUNOL IMMUNOP, V115, P346, DOI 10.1016/j.vetimm.2006.10.019; Hoang DT, 2018, MOL BIOL EVOL, V35, P518, DOI 10.1093/molbev/msx281; Flajnik MF, 2010, NAT REV GENET, V11, P47, DOI 10.1038/nrg2703; Fritz S., 2013, CAPER PACKAGE COMP A, V5, P1; Garland T, 1999, AM ZOOL, V39, P374; Gomez JMM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37796; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Harmon LJ, 2008, BIOINFORMATICS, V24, P129, DOI 10.1093/bioinformatics/btm538; Hedges SB, 2006, BIOINFORMATICS, V22, P2971, DOI 10.1093/bioinformatics/btl505; Hennessy MB, 2014, BRAIN BEHAV IMMUN, V37, P15, DOI 10.1016/j.bbi.2013.10.021; Holderness J, 2013, ANNU REV ANIM BIOSCI, V1, P99, DOI 10.1146/annurev-animal-031412-103639; IWASHIMA M, 1988, P NATL ACAD SCI USA, V85, P8161, DOI 10.1073/pnas.85.21.8161; Lang AS, 2009, FEMS MICROBIOL REV, V33, P295, DOI 10.1111/j.1574-6976.2008.00132.x; LEFRANC MP, 1989, EUR J IMMUNOL, V19, P989, DOI 10.1002/eji.1830190606; Lefranc MP, 2001, T CELL RECEPTOR FACT; Li LL, 2018, MOL IMMUNOL, V99, P75, DOI 10.1016/j.molimm.2018.04.011; Linguiti G, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2841-9; Litman GW, 2010, NAT REV IMMUNOL, V10, P543, DOI 10.1038/nri2807; LOEHLE C, 1995, ECOLOGY, V76, P326, DOI 10.2307/1941192; Luis AD, 2015, ECOL LETT, V18, P1153, DOI 10.1111/ele.12491; Massari S, 2009, MOL IMMUNOL, V46, P2728, DOI 10.1016/j.molimm.2009.05.008; Massari S, 2012, IMMUNOGENETICS, V64, P773, DOI 10.1007/s00251-012-0634-0; McCallum H, 2003, ECOL LETT, V6, P1062, DOI 10.1046/j.1461-0248.2003.00545.x; Murrell B, 2013, MOL BIOL EVOL, V30, P1196, DOI 10.1093/molbev/mst030; Nelson TM, 2015, MICROBIOL AUST, V36, P8, DOI 10.1071/MA15004; Nguyen Lam-Tung, 2015, Mol Biol Evol, V32, P268, DOI 10.1093/molbev/msu300; Nielsen MM, 2017, NAT REV IMMUNOL, V17, P733, DOI 10.1038/nri.2017.101; Nylander J., 2004, MRMODELTEST V2 PROGR; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Paradis E, 2004, BIOINFORMATICS, V20, P289, DOI 10.1093/bioinformatics/btg412; Parra ZE, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-111; Parra ZE, 2007, P NATL ACAD SCI USA, V104, P9776, DOI 10.1073/pnas.0609106104; Parra ZE, 2006, DEV COMP IMMUNOL, V30, P699, DOI 10.1016/j.dci.2005.10.002; Parra ZE, 2012, MOL BIOL EVOL, V29, P3205, DOI 10.1093/molbev/mss128; Pavlovich SS, 2018, CELL, V173, P1098, DOI 10.1016/j.cell.2018.03.070; Peterson AT, 1999, SCIENCE, V285, P1265, DOI 10.1126/science.285.5431.1265; Piccinni B, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1790-z; Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105; Posada D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Ranwez V, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-241; Revell LJ, 2012, METHODS ECOL EVOL, V3, P217, DOI 10.1111/j.2041-210X.2011.00169.x; Schowalter T, 2017, FORESTS, V8, DOI 10.3390/f8040097; Shen T, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-39; SLADE RW, 1992, P ROY SOC B-BIOL SCI, V249, P163, DOI 10.1098/rspb.1992.0099; Smith SM, 2017, HORMONE METABOLISM AND SIGNALING IN PLANTS, P1, DOI 10.1016/B978-0-12-811562-6.00001-3; Suttle CA, 2007, NAT REV MICROBIOL, V5, P801, DOI 10.1038/nrmicro1750; Symonds MR., 2014, MODERN PHYLOGENETIC, P105; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]; Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113; TROWSDALE J, 1989, IMMUNOGENETICS, V29, P19, DOI 10.1007/BF02341609; Wang LF, 2011, CURR OPIN VIROL, V1, P649, DOI 10.1016/j.coviro.2011.10.013; Wang XX, 2011, J IMMUNOL, V187, P5246, DOI 10.4049/jimmunol.1101113; Warren WC, 2008, NATURE, V453, P175, DOI 10.1038/nature06936; Weadick CJ, 2012, MOL BIOL EVOL, V29, P1297, DOI 10.1093/molbev/msr311; Xu SX, 2019, MOL IMMUNOL, V106, P135, DOI 10.1016/j.molimm.2018.12.022; Xu SX, 2010, J MOL EVOL, V71, P6, DOI 10.1007/s00239-010-9357-8; Yang ZH, 2005, MOL BIOL EVOL, V22, P1107, DOI 10.1093/molbev/msi097; Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088; Zhang GJ, 2013, SCIENCE, V339, P456, DOI 10.1126/science.1230835; Zhou P, 2016, P NATL ACAD SCI USA, V113, P2696, DOI 10.1073/pnas.1518240113; Zhou XM, 2012, SYST BIOL, V61, P150, DOI 10.1093/sysbio/syr089; 2018, J MOL EVOL, V86, P138, DOI DOI 10.1007/S00239-018-9832-1	75	2	2	2	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 24	2019	10								871	10.3389/fimmu.2019.00871	http://dx.doi.org/10.3389/fimmu.2019.00871			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HU6MT	31068942	Green Published, gold			2022-12-18	WOS:000465395400001
J	Liu, ZM; Cominelli, F; Di Martino, L; Liu, RF; Devireddy, N; Devireddy, LR; Wald, DN				Liu, Zhuoming; Cominelli, Fabio; Di Martino, Luca; Liu, Ruifu; Devireddy, Neha; Devireddy, Lax R.; Wald, David N.			Lipocalin 24p3 Induction in Colitis Adversely Affects Inflammation and Contributes to Mortality	FRONTIERS IN IMMUNOLOGY			English	Article						24p3; colitis; iron metabolism; PDGF; inflammatory bowel disease	GELATINASE-ASSOCIATED LIPOCALIN; INTESTINAL INFLAMMATION; COMMENSAL BACTERIA; EPITHELIAL-CELLS; MOUSE MODELS; EXPRESSION; IDENTIFICATION; RECOGNITION; HOMEOSTASIS; MICROBIOTA	Recognition of microorganism associated molecular patterns by epithelial cells elicits signaling cascades resulting in the production of host defense proteins. Lipocalin 24p3 is purported to be one such protein. 24p3 binds prokaryotic and eukaryotic siderophores and by sequestering iron laden bacterial siderophores it was believed to restrict bacterial replication. As such mice deficient for 24p3 are susceptible to systemic infections. However, it is not clear whether deficiency of 24p3 on the gut mucosa contributes to inflammation. In line with 24p3's function as a bacteriostat, it would be reasonable to assume that deficiencies in the control of intestinal flora from 24p3 absence play a role in inflammatory intestinal diseases. Surprisingly, we show 24p3 is a contributor of inflammation and 24p3 deficiency protects mice from dextran sodium sulfate (DSS)-induced colitis. 24p3 was found to be a negative regulator of platelet-derived growth factor (PDGF), which helps maintain the integrity of the gut mucosa. Neutralization of PDGF-BB abrogated resistance of 24p3 null mice to DSS confirming the direct link between 24p3 and PDGF-BB. Finally, iron handling in wild-type and 24p3-null mice upon DSS treatment also differed. In summary, differential iron levels and enhanced expression of PDGF-BB in 24p3 null mice confers resistance to DSS.	[Liu, Zhuoming; Liu, Ruifu; Devireddy, Lax R.; Wald, David N.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Cominelli, Fabio; Di Martino, Luca] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Devireddy, Neha] Beaumont High Sch, Shaker Hts, OH USA; [Wald, David N.] Univ Hosp Cleveland, Dept Pathol, Med Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Wald, DN (corresponding author), Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.; Wald, DN (corresponding author), Univ Hosp Cleveland, Dept Pathol, Med Ctr, Cleveland, OH 44106 USA.	david.wald@case.edu			NIH [P30CA043703, K1CA113838, R01DK081395]; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH P30CA043703, K1CA113838, and R01DK081395.	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Bachman MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000622; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Boismenu R, 2000, J LEUKOCYTE BIOL, V67, P267, DOI 10.1002/jlb.67.3.267; Borregaard N, 2006, BIOMETALS, V19, P211, DOI 10.1007/s10534-005-3251-7; Brestoff JR, 2013, NAT IMMUNOL, V14, P676, DOI 10.1038/ni.2640; Carlson M, 2002, GUT, V50, P501, DOI 10.1136/gut.50.4.501; Chassaing B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044328; Chelakkot C, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0126-x; Chu HT, 2013, NAT IMMUNOL, V14, P668, DOI 10.1038/ni.2635; Deschemin JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061050; Di Martino L, 2016, CANCER RES, V76, P6533, DOI 10.1158/0008-5472.CAN-16-0400; Drakesmith H, 2015, CELL METAB, V22, P777, DOI 10.1016/j.cmet.2015.09.006; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Fournier BM, 2012, MUCOSAL IMMUNOL, V5, P354, DOI 10.1038/mi.2012.24; Gallo RL, 2012, NAT REV IMMUNOL, V12, P503, DOI 10.1038/nri3228; Ganz T, 2012, BBA-MOL CELL RES, V1823, P1434, DOI 10.1016/j.bbamcr.2012.01.014; Guida C, 2015, BLOOD, V125, P2265, DOI 10.1182/blood-2014-08-595256; Guo H, 2012, ENDOCRINOLOGY, V153, P1183, DOI 10.1210/en.2011-1642; Holden VI, 2014, INFECT IMMUN, V82, P3826, DOI 10.1128/IAI.01849-14; Karlsson L, 2000, DEVELOPMENT, V127, P3457; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kitajima S, 1999, EXP ANIM TOKYO, V48, P137, DOI 10.1538/expanim.48.137; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KJELDSEN L, 1994, BLOOD, V83, P799; Kodani T, 2013, JOVE-J VIS EXP, DOI 10.3791/50843; Kundu P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003887; Laine VJO, 2000, INFECT IMMUN, V68, P87, DOI 10.1128/IAI.68.1.87-92.2000; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Liu ZH, 2014, AM J PHYSIOL-GASTR L, V307, pG1033, DOI 10.1152/ajpgi.00151.2014; Liu ZM, 2013, J IMMUNOL, V190, P4692, DOI 10.4049/jimmunol.1202411; Liu ZM, 2011, J BIOL CHEM, V286, P20606, DOI 10.1074/jbc.M110.216549; Matsuoka K, 2015, SEMIN IMMUNOPATHOL, V37, P47, DOI 10.1007/s00281-014-0454-4; Nelson AL, 2005, CELL MICROBIOL, V7, P1404, DOI 10.1111/j.1462-5822.2005.00566.x; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; Ohtsuka Y, 2003, PEDIATR RES, V53, P143, DOI 10.1203/01.PDR.0000041519.16507.06; Oikonomou KA, 2012, J GASTROENTEROL, V47, P519, DOI 10.1007/s00535-011-0516-5; Ostvik AE, 2013, CLIN EXP IMMUNOL, V173, P502, DOI 10.1111/cei.12136; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Seril DN, 2002, DIGEST DIS SCI, V47, P1266, DOI 10.1023/A:1015362228659; Shanmugam NKN, 2014, J IMMUNOL, V193, P1398, DOI 10.4049/jimmunol.1400278; Singh V, 2016, CELL MOL GASTROENTER, V2, P482, DOI 10.1016/j.jcmgh.2016.03.007; Steigedal M, 2014, J IMMUNOL, V193, P6081, DOI 10.4049/jimmunol.1401528; Suchodolski JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039333; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Wu H, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-96; Xiao X, 2017, ANNU REV NUTR, V37, P103, DOI 10.1146/annurev-nutr-071816-064559	49	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 17	2019	10								812	10.3389/fimmu.2019.00812	http://dx.doi.org/10.3389/fimmu.2019.00812			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HU1PT	31057545	gold, Green Published			2022-12-18	WOS:000465045000001
J	Wang, NH; Yigit, B; van der Poel, CE; Cuenca, M; Carroll, MC; Herzog, RW; Engel, P; Terhorst, C				Wang, Ninghai; Yigit, Burcu; van der Poel, Cees E.; Cuenca, Marta; Carroll, Michael C.; Herzog, Roland W.; Engel, Pablo; Terhorst, Cox			The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host Disease	FRONTIERS IN IMMUNOLOGY			English	Article						SLAMF3; cGVHD; B cells; autoreactive; alloimmunity	SYSTEMIC-LUPUS-ERYTHEMATOSUS; IFN-GAMMA RECEPTOR; HELPER T-CELLS; INTERFERON-GAMMA; IMMUNE-RESPONSES; GERMINAL-CENTERS; IL-21 RECEPTOR; LY9 CD229; AUTOIMMUNITY; INDUCTION	Absence of the mouse cell surface receptor SLAMF3 in SLAMF3(-/-) mice suggested that this receptor negatively regulates B cell homeostasis by modulating activation thresholds of B cell subsets. Here, we examine whether anti-SLAMF3 affects both B and T cell subsets during immune responses to haptenated ovalbumin [NP-OVA] and in the setting of chronic graft vs. host disease (cGVHD) induced by transferring B6.C-H2(bm12)/KhEg (bm12) CD4(+) T cells into B6 WT mice. We find that administering alpha SLAMF3 to NP-OVA immunized B6 mice primarily impairs antibody responses and Germinal center B cell [GC B] numbers, whilst CXCR5(+), PD-1(+), and ICOS+ T follicular helper (TFH) cells are not significantly affected. By contrast, administering alpha SLAMF3 markedly enhanced autoantibody production upon induction of cGVHD by the transfer of bm12 CD4(+) T cells into B6 recipients. Surprisingly, alpha SLAMF3 accelerated both the differentiation of GC B and donor-derived TFH cells initiated by cGVHD. The latter appeared to be induced by decreased numbers of donor-derived Treg and T follicular regulatory (TFR) cells. Collectively, these data show that control of anti-SLAMF3-induced signaling is requisite to prevent autoantibody responses during cGVHD, but reduces responses to foreign antigens.	[Wang, Ninghai; Yigit, Burcu; Terhorst, Cox] Harvard Med Sch, Div Immunol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [van der Poel, Cees E.; Carroll, Michael C.] Harvard Med Sch, Program Cellular & Mol Med, Boston Childrens Hosp, Boston, MA 02115 USA; [Cuenca, Marta; Herzog, Roland W.] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Engel, Pablo] Univ Barcelona, Immunol Unit, Dept Cell Biol Immunol & Neurosci, Med Sch, Barcelona, Spain	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Indiana University System; Indiana University Bloomington; University of Barcelona	Wang, NH; Terhorst, C (corresponding author), Harvard Med Sch, Div Immunol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.	nwang@bidmc.harvard.edu; cterhors@bidmc.harvard.edu	Engel, Pablo/R-5907-2019	Engel, Pablo/0000-0001-8410-252X	NIH [PO1-AI065687, PO1-DK43351, R01HL131093]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL131093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI065687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Grant support NIH PO1-AI065687 to CT and PE, NIH PO1-DK43351 to CT, and R01HL131093 to RH and CT.	Al-Shami A, 2004, J EXP MED, V200, P159, DOI 10.1084/jem.20031975; Bubier JA, 2009, P NATL ACAD SCI USA, V106, P1518, DOI 10.1073/pnas.0807309106; Choi YS, 2013, CURR OPIN IMMUNOL, V25, P366, DOI 10.1016/j.coi.2013.04.003; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Cohen Philip L, 2003, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1520s52; Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58; Cuenca M, 2016, J IMMUNOL, V196, P726, DOI 10.4049/jimmunol.1501266; de Salort J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00225; Dhaeze T, 2015, AUTOIMMUN REV, V14, P735, DOI 10.1016/j.autrev.2015.04.006; Dolff S, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3474; Domeier PP, 2016, J EXP MED, V213, P715, DOI 10.1084/jem.20151722; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; Good KL, 2006, J IMMUNOL, V177, P5236, DOI 10.4049/jimmunol.177.8.5236; Good-Jacobson KL, 2010, J IMMUNOL, V185, P3117, DOI 10.4049/jimmunol.1001155; Haas C, 1997, J IMMUNOL, V158, P5484; HANSEN TH, 1987, CRIT REV IMMUNOL, V7, P169; Hayashi T, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/461641; Jackson SW, 2016, J EXP MED, V213, P733, DOI 10.1084/jem.20151724; Keszei M, 2013, FASEB J, V27, P3123, DOI 10.1096/fj.12-226951; Keszei M, 2011, J EXP MED, V208, P811, DOI 10.1084/jem.20101653; La Cava Antonio, 2009, Discov Med, V8, P13; Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Ludwig-Portugall I, 2009, EUR J IMMUNOL, V39, P225, DOI 10.1002/eji.200838699; MacDonald KPA, 2017, BLOOD, V129, P13, DOI 10.1182/blood-2016-06-686618; McPhee CG, 2013, J IMMUNOL, V191, P4581, DOI 10.4049/jimmunol.1300439; MORRIS SC, 1990, CLIN IMMUNOL IMMUNOP, V57, P263, DOI 10.1016/0090-1229(90)90040-W; MORRIS SC, 1990, J EXP MED, V171, P503, DOI 10.1084/jem.171.2.503; Moudgil KD, 2011, J INTERF CYTOK RES, V31, P695, DOI 10.1089/jir.2011.0065; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Parrish-Novak J, 2002, J LEUKOCYTE BIOL, V72, P856; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Pollard KM, 2013, DISCOV MED, V16, P123; Romero X, 2005, J IMMUNOL, V174, P7033, DOI 10.4049/jimmunol.174.11.7033; Sage PT, 2015, CELL REP, V12, P163, DOI 10.1016/j.celrep.2015.06.015; Sage PT, 2015, TRENDS IMMUNOL, V36, P410, DOI 10.1016/j.it.2015.05.005; Sage PT, 2013, NAT IMMUNOL, V14, P152, DOI 10.1038/ni.2496; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Salek-Ardakani S, 2011, J IMMUNOL, V186, P5294, DOI 10.4049/jimmunol.1100406; Schwarting A, 1998, J IMMUNOL, V161, P494; Sintes J, 2013, J IMMUNOL, V190, P21, DOI 10.4049/jimmunol.1202435; Sweet RA, 2012, CURR OPIN IMMUNOL, V24, P658, DOI 10.1016/j.coi.2012.10.003; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927; Wang NH, 2016, CLIN IMMUNOL, V173, P19, DOI 10.1016/j.clim.2016.06.009; Wang NH, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00158; Wing JB, 2014, IMMUNITY, V41, P1013, DOI 10.1016/j.immuni.2014.12.006	47	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 17	2019	10								831	10.3389/fimmu.2019.00831	http://dx.doi.org/10.3389/fimmu.2019.00831			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HU1PX	31057553	Green Published, gold			2022-12-18	WOS:000465045400002
J	Varga, SM; Sant, AJ				Varga, Steven M.; Sant, Andrea J.			Editorial: Orchestration of an Immune Response to Respiratory Pathogens	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						influenza; T cells RSV; Tuberculosis; CD4 T cells; CD8 T cells	T-CELLS; PROTECTION; VACCINES		[Varga, Steven M.] Univ Iowa, Microbiol & Immunol, Iowa City, IA USA; [Sant, Andrea J.] David H Smith Ctr Vaccine Biol & Immunol, Microbiol & Immunol, Rochester, NY 14642 USA	University of Iowa	Sant, AJ (corresponding author), David H Smith Ctr Vaccine Biol & Immunol, Microbiol & Immunol, Rochester, NY 14642 USA.	andrea_sant@urmc.rochester.edu		Varga, Steven/0000-0001-7332-4290	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under CEIRS [HHSN272201400005C]	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under CEIRS	This work was supported in part with funds award to AS from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under CEIRS contract no. HHSN272201400005C.	Allie SR, 2017, CLIN SCI, V131, P1737, DOI 10.1042/CS20160259; Altenburg AF, 2015, VACCINE, V33, P500, DOI 10.1016/j.vaccine.2014.11.054; Andersen P, 2015, CURR OPIN IMMUNOL, V35, P55, DOI 10.1016/j.coi.2015.06.001; Arruvito L, 2015, CURR OPIN INFECT DIS, V28, P259, DOI 10.1097/QCO.0000000000000159; Barton AJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01839; Behr FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01770; Beverley PCL, 2014, MUCOSAL IMMUNOL, V7, P20, DOI 10.1038/mi.2013.99; Cauley LS, 2016, J LEUKOCYTE BIOL, V100, P905, DOI 10.1189/jlb.1MR0216-074R; Darton TC, 2015, LANCET INFECT DIS, V15, P840, DOI 10.1016/S1473-3099(15)00068-7; Devarajan P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00136; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Franz KM, 2017, MOL CELL, V66, P750, DOI 10.1016/j.molcel.2017.05.009; Gerlach C, 2015, CELL, V161, P702, DOI 10.1016/j.cell.2015.04.038; Grant EJ, 2016, CURR OPIN VIROL, V16, P132, DOI 10.1016/j.coviro.2016.01.016; Gray JI, 2018, IMMUNOLOGY, V154, P574, DOI 10.1111/imm.12929; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Mackay LK, 2017, TRENDS IMMUNOL, V38, P94, DOI 10.1016/j.it.2016.11.004; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Porter CK, 2017, VACCINE, V35, P6813, DOI 10.1016/j.vaccine.2017.05.068; Purwar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016245; Rivera A, 2016, NAT IMMUNOL, V17, P356, DOI 10.1038/ni.3375; Sant AJ, 2018, CURR OPIN IMMUNOL, V53, P13, DOI 10.1016/j.coi.2018.03.019; Schreiner D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02394; Soto JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02466; Steinbach K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02827; Steinert EM, 2015, CELL, V161, P737, DOI 10.1016/j.cell.2015.03.031; Thome JJC, 2014, CELL, V159, P814, DOI 10.1016/j.cell.2014.10.026; Turner DL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00331; Van Braeckel-Budimir N, 2017, IMMUNOL CELL BIOL, V95, P651, DOI 10.1038/icb.2017.32; Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820; Wissinger E, 2009, SEMIN IMMUNOL, V21, P147, DOI 10.1016/j.smim.2009.01.005	31	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 9	2019	10								690	10.3389/fimmu.2019.00690	http://dx.doi.org/10.3389/fimmu.2019.00690			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HS4GP	31024541	Green Published, gold			2022-12-18	WOS:000463820300001
J	Kotlan, B; Horvath, S; Eles, K; Ploter, VK; Naszados, G; Czirbesz, K; Blank, M; Farkas, E; Toth, L; Tovari, J; Szekacs, A; Shoenfeld, Y; Godeny, M; Kesler, M; Liszkay, G				Kotlan, Beatrix; Horvath, Szabolcs; Eles, Klara; Ploter, Vanda K.; Naszados, Gyorgy; Czirbesz, Katalin; Blank, Miri; Farkas, Emil; Toth, Laszlo; Tovari, Jozsef; Szekacs, Andras; Shoenfeld, Yehuda; Godeny, Maria; Kesler, Miklos; Liszkay, Gabriella			Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patient's Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor	FRONTIERS IN IMMUNOLOGY			English	Article						B lymphocytes; glycosphingolipids (GSLs); immune regulation; immunoglobulin; metastatic melanomas; natural antibody; tumor-associated antigen	MONOCLONAL-ANTIBODY; LYMPHOCYTES; GANGLIOSIDES; SURFACE; PHAGE; INHIBITION; CARCINOMAS; GENERATION; BINDING; GENES	There is far less information available about the tumor infiltrating B (TIL-B) cells, than about the tumor infiltrating T cells. We focused on discovering the features and potential role of B lymphocytes in solid tumors. Our project aimed to develop innovative strategies to define cancer membrane structures. We chose two solid tumor types, with variable to considerable B cell infiltration. The strategy we set up with invasive breast carcinoma, showing medullary features, has been introduced and standardized in metastatic melanoma. After detecting B lymphocytes by immunohistochemistry, VH-JH, V kappa-J kappa immunoglobulin rearranged V region genes were amplified by RT-PCR, from TIL-B cDNA. Immunoglobulin variable-region genes of interest were cloned, sequenced, and subjected to a comparative DNA analysis. Single-chain variable (scFv) antibody construction was performed in selected cases to generate a scFv library and to test tumor binding capacity. DNA sequence analysis revealed an overrepresented VH3-1 cluster, represented both in the breast cancer and the melanoma TIL-B immunoglobulin repertoire. We observed that our previously defined anti GD3 ganglioside-binder antibody-variable region genes were present in melanoma as well. Our antibody fragments showed binding potential to disialylated glycosphingolipids (GD3 ganglioside) and their O acetylated forms on melanoma cancer cells. We conclude that our results have a considerable tumor immunological impact, as they reveal the power of TIL-B cells to recognize strong tumor-associated glycosphingolipid structures on melanomas and other solid tumors. As tumor-derived gangliosides affect immune cell functions and reduce the B lymphocytes' antibody production, we suspect an important B lymphocyte and cancer cell crosstalk mechanism. We not only described the isolation and specificity testing of the tumor infiltrating B cells, but also showed the TIL-B cells' highly tumor-associated GD3 ganglioside-revealing potential in melanomas. The present data help to identify new cancer-associated biomarkers that may serve for novel cancer diagnostics. The two-direction regulation mechanism between immune B cells and the tumor could eventually be developed into an innovative cancer treatment strategy.	[Kotlan, Beatrix] Natl Inst Oncol, Mol Immunol & Toxicol, Budapest, Hungary; [Horvath, Szabolcs; Eles, Klara; Ploter, Vanda K.] Natl Inst Oncol, Ctr Surg & Mol Pathol, Budapest, Hungary; [Naszados, Gyorgy; Godeny, Maria] Natl Inst Oncol, Ctr Image Anal & Radiol Diagnost, Budapest, Hungary; [Czirbesz, Katalin; Liszkay, Gabriella] Natl Inst Oncol, Dept Oncodermatol, Budapest, Hungary; [Blank, Miri; Shoenfeld, Yehuda] Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Zabludowitz Ctr Autoimmune Dis, Tel Aviv, Israel; [Farkas, Emil; Toth, Laszlo] Natl Inst Oncol, Ctr Oncosurg, Budapest, Hungary; [Tovari, Jozsef] Natl Inst Oncol, Dept Expt Pharmacol, Budapest, Hungary; [Szekacs, Andras] Natl Agr Res & Innovat Ctr, Agroenvironm Res Inst, Budapest, Hungary; [Kesler, Miklos] Natl Inst Oncol, Budapest, Hungary; [Kesler, Miklos] Minist Human Capac, Budapest, Hungary	National Institute of Oncology Hungary; National Institute of Oncology Hungary; National Institute of Oncology Hungary; National Institute of Oncology Hungary; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; National Institute of Oncology Hungary; National Institute of Oncology Hungary; National Institute of Oncology Hungary	Kotlan, B (corresponding author), Natl Inst Oncol, Mol Immunol & Toxicol, Budapest, Hungary.	kotlanbea@gmail.com			Harry J. Lloyd Charitable Trust Melanoma Research Award, Fulbright [120610, 1214104]; National Scientific Research Fund of Hungary [OTKA K109865];  [OTKAT048933]	Harry J. Lloyd Charitable Trust Melanoma Research Award, Fulbright; National Scientific Research Fund of Hungary; 	BK received the following grants which supported the present work: OTKAT048933, Harry J. Lloyd Charitable Trust Melanoma Research Award, Fulbright: No120610, No1214104. An innovative collaborative research project grant by the National Scientific Research Fund of Hungary (OTKA K109865, 2013-2017) provided additional support.	Amos SM, 2011, BLOOD, V118, P499, DOI 10.1182/blood-2011-01-325266; Chammas R, 1999, CANCER RES, V59, P1337; CHAPMAN PB, 1990, J IMMUNOL, V145, P891; Coronella JA, 2001, CANCER RES, V61, P7889; Feldman SA, 2015, SEMIN ONCOL, V42, P626, DOI 10.1053/j.seminoncol.2015.05.005; Fox BA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-214; Garaud S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02660; Giovannone N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02839; Gruel Nadege, 2002, Methods Mol Biol, V193, P281; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; Hakomori S, 2001, ADV EXP MED BIOL, V491, P369; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95; Hansen MH, 2002, J IMMUNOL, V169, P2701, DOI 10.4049/jimmunol.169.5.2701; Hernandez AM, 2005, IMMUNOBIOLOGY, V210, P11, DOI 10.1016/j.imbio.2005.02.002; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Kieber-Emmons T, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00196; KIMATA H, 1994, BLOOD, V84, P1193, DOI 10.1182/blood.V84.4.1193.bloodjournal8441193; Kirkwood JM, 2000, CANCER, V88, P2693, DOI 10.1002/1097-0142(20000615)88:12<2693::AID-CNCR7>3.3.CO;2-V; Kotlan B, 2005, J IMMUNOL, V175, P2278, DOI 10.4049/jimmunol.175.4.2278; Kotlan B, 2000, DIS MARKERS, V16, P25, DOI 10.1155/2000/734293; Kotlan B, 1999, IMMUNOL LETT, V65, P143, DOI 10.1016/S0165-2478(98)00098-4; Kotlan Beatrix, 2016, Magy Onkol, V60, P64; Kotlan B, 2015, IMMUNOL RES, V61, P11, DOI 10.1007/s12026-014-8600-6; LADISCH S, 1983, CANCER RES, V43, P3808; LADISCH S, 1984, J CLIN INVEST, V74, P2074, DOI 10.1172/JCI111631; Ladjemi MZ, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00158; Lee HC, 2012, J IMMUNOL, V189, P3521, DOI 10.4049/jimmunol.1201256; Lopez-Requena A, 2009, OPEN IMMUNOL J, V2, P1, DOI [DOI 10.2174/1874226200902010001, 10. 2174/1874226200902010001]; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; Nelson BH, 2010, J IMMUNOL, V185, P4977, DOI 10.4049/jimmunol.1001323; O'Brien PM, 2001, CANCER IMMUNOL IMMUN, V50, P523, DOI 10.1007/s00262-001-0234-6; Ohmi Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206881; Ohyama C, 2008, INT J CLIN ONCOL, V13, P308, DOI 10.1007/s10147-008-0809-8; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Pavoni E, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-70; PUNT CJA, 1994, CANCER IMMUNOL IMMUN, V38, P225, DOI 10.1007/s002620050058; Ravindranath Mepur H, 2007, Future Oncol, V3, P201; Schauer R, 2009, CURR OPIN STRUC BIOL, V19, P507, DOI 10.1016/j.sbi.2009.06.003; Seledtsov VI, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00409; Shang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep15179; Shen M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00470; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Varki NM, 2007, LAB INVEST, V87, P851, DOI 10.1038/labinvest.3700656; Vazquez AMH, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00170	46	2	2	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 5	2019	10								650	10.3389/fimmu.2019.00650	http://dx.doi.org/10.3389/fimmu.2019.00650			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HS0QA	31024530	gold, Green Published			2022-12-18	WOS:000463564300001
J	Holmdahl, R; Nimmerjahn, F; Ludwig, RJ				Holmdahl, Rikard; Nimmerjahn, Falk; Ludwig, Ralf J.			Editorial: Autoantibodies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autoantibody; pemphigus; pemphigoid; arthritis; pathogenesis; biomarker; diagnos; treatment	SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTRAVENOUS IMMUNOGLOBULIN IVIG; ANTINUCLEAR ANTIBODIES; TOPICAL CORTICOSTEROIDS; EXPERIMENTAL-MODEL; ANTI-DESMOGLEIN; PEMPHIGUS; THERAPY; CELLS; SUSCEPTIBILITY		[Holmdahl, Rikard] Karolinska Inst, Sect Med Inflammat Res, Dept Med Biochem & Biophys, Stockholm, Sweden; [Nimmerjahn, Falk] Univ Erlangen Nurnberg, Inst Genet, Dept Biol, Erlangen, Germany; [Ludwig, Ralf J.] Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany; [Ludwig, Ralf J.] Univ Lubeck, Ctr Res Inflammat Skin, Lubeck, Germany	Karolinska Institutet; University of Erlangen Nuremberg; University of Lubeck; University of Lubeck	Holmdahl, R (corresponding author), Karolinska Inst, Sect Med Inflammat Res, Dept Med Biochem & Biophys, Stockholm, Sweden.; Nimmerjahn, F (corresponding author), Univ Erlangen Nurnberg, Inst Genet, Dept Biol, Erlangen, Germany.; Ludwig, RJ (corresponding author), Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany.; Ludwig, RJ (corresponding author), Univ Lubeck, Ctr Res Inflammat Skin, Lubeck, Germany.	Rikard.Holmdahl@ki.se; falk.nimmerjahn@fau.de; ralf.ludwig@uksh.de	Ludwig, Ralf/F-3996-2018; Holmdahl, Rikard/AAI-7682-2020	Ludwig, Ralf/0000-0002-1394-1737; 	Deutsche Forschungsgemeinschaft [KFO 303, EXC 306]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Dr. Yask Gupta (Lubeck Institute for Experimental Dermatology) for preparation of Figure 1. This word has been supported by the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Excellence Cluster Inflammation at Interfaces (EXC 306), all from the Deutsche Forschungsgemeinschaft.	Alexander T, 2015, ANN RHEUM DIS, V74, P1474, DOI 10.1136/annrheumdis-2014-206016; Amagai M, 2009, J AM ACAD DERMATOL, V60, P595, DOI 10.1016/j.jaad.2008.09.052; Aqel SI, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00236; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Benamu E, 2016, CURR OPIN INFECT DIS, V29, P319, DOI 10.1097/QCO.0000000000000279; Bolland S, 2002, J EXP MED, V195, P1167, DOI 10.1084/jem.20020165; Collin M, 2001, EMBO J, V20, P3046, DOI 10.1093/emboj/20.12.3046; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Ghodke-Puranik Y, 2015, J AUTOIMMUN, V64, P125, DOI 10.1016/j.jaut.2015.08.004; Hammers CM, 2016, ANNU REV PATHOL-MECH, V11, P175, DOI 10.1146/annurev-pathol-012615-044313; Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H; Hubner F, 2016, J INVEST DERMATOL, V136, P2495, DOI 10.1016/j.jid.2016.07.013; Ishii N, 2010, CLIN REV ALLERG IMMU, V38, P186, DOI 10.1007/s12016-009-8153-y; Iwata H, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0896-1; Joly P, 2002, NEW ENGL J MED, V346, P321, DOI 10.1056/NEJMoa011592; Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3; Joly P, 2009, J INVEST DERMATOL, V129, P1681, DOI 10.1038/jid.2008.412; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kasperkiewicz M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.26; Kim K, 2017, NAT REV RHEUMATOL, V13, P13, DOI 10.1038/nrrheum.2016.176; Koga H, 2019, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00362; Koga H, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00139; Lamberts A, 2019, ACTA DERM-VENEREOL, V99, P224, DOI 10.2340/00015555-3052; Lee JM, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00306; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Li N, 2005, J CLIN INVEST, V115, P3440, DOI 10.1172/JCI24394; Ludwig RJ, 2017, EXP DERMATOL, V26, P1179, DOI 10.1111/exd.13335; Ludwig RJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00603; Meroni PL, 2010, ANN RHEUM DIS, V69, P1420, DOI 10.1136/ard.2009.127100; Mihai S, 2007, J IMMUNOL, V178, P6514, DOI 10.4049/jimmunol.178.10.6514; Mimouni D, 2005, CLIN EXP IMMUNOL, V142, P426, DOI 10.1111/j.1365-2249.2005.02947.x; Mimouni D, 2010, CLIN EXP IMMUNOL, V162, P543, DOI 10.1111/j.1365-2249.2010.04265.x; Nemeth T, 2017, J INVEST DERMATOL, V137, P2131, DOI 10.1016/j.jid.2017.05.017; Nguyen VT, 1998, ARCH DERMATOL, V134, P971, DOI 10.1001/archderm.134.8.971; Pacheco-Tovar MG, 2009, J EUR ACAD DERMATOL, V23, P697, DOI 10.1111/j.1468-3083.2009.03162.x; Pisitkun P, 2006, SCIENCE, V312, P1669, DOI 10.1126/science.1124978; Planaguma J, 2015, BRAIN, V138, P94, DOI 10.1093/brain/awu310; Prussmann J, 2014, EXP DERMATOL, V23, P519, DOI 10.1111/exd.12445; Reichert JM, 2012, MABS-AUSTIN, V4, P413, DOI 10.4161/mabs.19931; Sajda T, 2016, P NATL ACAD SCI USA, V113, P1859, DOI 10.1073/pnas.1525448113; Satoh M, 2012, ARTHRITIS RHEUM-US, V64, P2319, DOI 10.1002/art.34380; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Schmidt E, 2009, AUTOIMMUN REV, V8, P533, DOI 10.1016/j.autrev.2009.01.011; Schwab I, 2014, EUR J IMMUNOL, V44, P1444, DOI 10.1002/eji.201344230; Schwab I, 2013, NAT REV IMMUNOL, V13, P176, DOI 10.1038/nri3401; Semchuk KM, 2007, J TOXICOL ENV HEAL A, V70, P638, DOI 10.1080/15287390600974593; Sinha AA, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00218; Sundberg JP, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035360; Tan EM, 1997, ARTHRITIS RHEUM-US, V40, P1601, DOI 10.1002/art.1780400909; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; Venkatesan A, 2017, ACS CHEM NEUROSCI, V8, P2586, DOI 10.1021/acschemneuro.7b00319; Vodo D, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00226; Voigt J, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/651058; Waisberg M, 2011, P NATL ACAD SCI USA, V108, P1122, DOI 10.1073/pnas.1017996108; Wegner J, 2017, ATHEROSCLEROSIS SUPP, V30, P264, DOI 10.1016/j.atherosclerosissup.2017.05.043; Willcocks LC, 2010, P NATL ACAD SCI USA, V107, P7881, DOI 10.1073/pnas.0915133107; Witte M, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00296; Yajima K, 2003, EUR J IMMUNOL, V33, P1020, DOI 10.1002/eji.200323794; Zong SH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00752; Zuber J, 2012, NAT REV NEPHROL, V8, P643, DOI 10.1038/nrneph.2012.214	60	2	2	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 2	2019	10								484	10.3389/fimmu.2019.00484	http://dx.doi.org/10.3389/fimmu.2019.00484			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HR3XQ	31001243	gold, Green Published			2022-12-18	WOS:000463076700001
J	Naidoo, KK; Ngubane, A; Gaza, P; Moodley, A; Ndung'u, T; Thobakgale, CF				Naidoo, Kewreshini K.; Ngubane, Ayanda; Gaza, Pedzisai; Moodley, Amber; Ndung'u, Thumbi; Thobakgale, Christina F.			Neutrophil Effector Functions Are Not Impaired in Duffy Antigen Receptor for Chemokines (DARC)-Null Black South Africans	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil; function; DARC; duffy; HIV-1	IMMUNODEFICIENCY-VIRUS TYPE-1; EXTRACELLULAR TRAPS; HIV; INFECTION; PHAGOCYTOSIS; CELLS; MACROPHAGES; PROGRESSION; INHIBITION; AMERICANS	Neutrophils are well-recognized for their pathogen killing mechanisms and disorders of neutrophil count and function are associated with recurrent infections. The Duffy Antigen Receptor for Chemokines (DARC)-null genotype is predominant in sub-Saharan African ancestry populations and is the major genetic determinant of benign ethnic neutropenia which has been associated with increased risk of Human Immunodeficiency Virus (HIV)-1 acquisition and mother-to-child transmission. However, the impact of DARC-null-linked neutropenia on HIV disease progression remains controversial. While the DARC-null genotype is associated with low numbers of circulating neutrophils, the effects of the polymorphism on neutrophil functions is unknown. We investigated the impact of the DARC-null trait and lower absolute neutrophil counts (ANCs) on key neutrophil effector functions [proteolytic activity within the phagosome following Fc receptor-mediated phagocytosis, reactive oxygen species (ROS) production, and neutrophil extracellular trap (NET) formation] in 20 HIV negative and 22 HIV-1 chronically infected black South Africans. Phagosome maturation was measured by flow cytometry following Fc-mediated uptake of IgG opsonized beads; ROS production was measured by chemi-luminescence after activation of neutrophils with phorbol 12-myristate 13-acetate (PMA). Activated neutrophils were also visualized by fluorescent microscopy for NET quantification. Study subjects were genotyped for the DARC trait using TaqMan allelic discrimination assays and ANCs were measured by full blood count. As expected, the DARC-null polymorphism was highly prevalent in our participant cohort (69%) and was strongly associated with lower ANCs in uninfected (p = 0.0007) and HIV-1 infected (p = 0.03) subjects. We observed enhanced proteolytic activity within the phagosome in the absence of DARC at 10min (p = 0.05 and p = 0.009) and 60min (p = 0.05 and p = 0.07) in uninfected and HIV-1 infected subjects, respectively. ROS was unaffected by DARC trait irrespective of HIV status. Furthermore, formation of NETs was reduced in neutrophils from DARC-null subjects (p = 0.04) following prolonged in vitro stimulation, but only in HIV-1 infected subjects. The data indicate differential neutrophil function in the absence of DARC that may be moderately modulated by HIV-1 infection but overall, the data suggest that DARC-null trait is not deleterious to neutrophil effector functions in African populations.	[Naidoo, Kewreshini K.; Ngubane, Ayanda; Gaza, Pedzisai; Ndung'u, Thumbi; Thobakgale, Christina F.] Univ KwaZulu Natal, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, Durban, South Africa; [Moodley, Amber] FRESH, Durban, South Africa; [Ndung'u, Thumbi] Univ KwaZulu Natal, Nelson R Mandela Sch Med, AHRI, Durban, South Africa; [Ndung'u, Thumbi] MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Ndung'u, Thumbi] Harvard Univ, Cambridge, MA 02138 USA; [Ndung'u, Thumbi] Max Planck Inst Infect Biol, Berlin, Germany; [Thobakgale, Christina F.] Univ Witwatersrand, Natl Inst Communicable Dis, Sch Pathol, Johannesburg, South Africa	University of Kwazulu Natal; Africa Health Research Institute; University of Kwazulu Natal; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Max Planck Society; National Institute for Communicable Diseases (NICD); University of Witwatersrand	Thobakgale, CF (corresponding author), Univ KwaZulu Natal, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, Durban, South Africa.; Thobakgale, CF (corresponding author), Univ Witwatersrand, Natl Inst Communicable Dis, Sch Pathol, Johannesburg, South Africa.	christina.thobakgale@wits.ac.za			South African Medical Research Council; Dan and Marjorie Sullivan Foundation; National Research Foundation (NRF) [RDYR14071576105]; U.S. National Institutes of Health [R37AI067073]; International AIDS Vaccine Initiative (IAVI) [UKZNRSA1001]; South African Research Chairs Initiative [64809]; Victor Daitz Foundation; Gilead Sciences, Inc. [00406]; Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [DEL-15-006]; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust [107752/Z/15/Z]; United Kingdom (UK) government; Victor Daitz information Gateway an initiative of the Victor Daitz foundation; University of KwaZulu-Natal; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI067073] Funding Source: NIH RePORTER	South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Dan and Marjorie Sullivan Foundation; National Research Foundation (NRF); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International AIDS Vaccine Initiative (IAVI); South African Research Chairs Initiative; Victor Daitz Foundation; Gilead Sciences, Inc.(Gilead Sciences); Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust(Wellcome TrustEuropean Commission); United Kingdom (UK) government; Victor Daitz information Gateway an initiative of the Victor Daitz foundation; University of KwaZulu-Natal; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the South African Medical Research Council, Dan and Marjorie Sullivan Foundation, the National Research Foundation (NRF; Grant#RDYR14071576105), U.S. National Institutes of Health (Grant#R37AI067073), and International AIDS Vaccine Initiative (IAVI, Grant#UKZNRSA1001). TN received funding from the South African Research Chairs Initiative (grant #64809), the Victor Daitz Foundation and Gilead Sciences, Inc. (Grant ID #00406). This work was also partially supported through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant #DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [Grant #107752/Z/15/Z] and the United Kingdom (UK) government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust, or the UK government. Open access publication of this article has been made possible through support from the Victor Daitz information Gateway an initiative of the Victor Daitz foundation and the University of KwaZulu-Natal.	BANDRES JC, 1993, J INFECT DIS, V168, P75, DOI 10.1093/infdis/168.1.75; Barnado A, 2016, J LEUKOCYTE BIOL, V99, P265, DOI 10.1189/jlb.5BT0615-234R; Barr FD, 2018, MUCOSAL IMMUNOL, V11, P1420, DOI 10.1038/s41385-018-0045-0; Bastian A, 2001, REGUL PEPTIDES, V101, P157, DOI 10.1016/S0167-0115(01)00282-8; Boxer LA, 2012, HEMATOL-AM SOC HEMAT, P174, DOI 10.1182/asheducation-2012.1.174; Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V., 2010, JOVE-J VIS EXP, V36, P1724, DOI [10.3791/1724, DOI 10.3791/1724/J0VE.C0M/VIDE0/1724]; Brinkmann V, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00413; CAMPBELL PA, 1990, CLIN EXP IMMUNOL, V79, P141; Casulli S, 2014, J INNATE IMMUN, V6, P13, DOI 10.1159/000353588; Charles BA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194400; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Dios PD, 2000, J INFECT DIS, V181, P1214, DOI 10.1086/315350; Donadieu J, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-26; Dong KL, 2018, LANCET HIV, V5, pE35, DOI 10.1016/S2352-3018(17)30146-7; Duchene J, 2017, NAT IMMUNOL, V18, P753, DOI 10.1038/ni.3763; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fujisawa H, 2001, MICROBIOL IMMUNOL, V45, P679, DOI 10.1111/j.1348-0421.2001.tb01302.x; He WJ, 2008, CELL HOST MICROBE, V4, P52, DOI 10.1016/j.chom.2008.06.002; Herant M, 2006, J CELL SCI, V119, P1903, DOI 10.1242/jcs.02876; Horne KC, 2009, CELL HOST MICROBE, V5, P415, DOI 10.1016/j.chom.2009.04.013; Howes RE, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1265; Hsieh MM, 2010, J CLIN ONCOL, V28, P1633, DOI 10.1200/JCO.2009.24.3881; Jenne CN, 2013, CELL HOST MICROBE, V13, P169, DOI 10.1016/j.chom.2013.01.005; Julg B, 2009, CELL HOST MICROBE, V5, P413, DOI 10.1016/j.chom.2009.04.009; Kedzierska K, 2002, J IMMUNOL, V168, P2895, DOI 10.4049/jimmunol.168.6.2895; Kourtis AP, 2012, NEW ENGL J MED, V367, P2260, DOI 10.1056/NEJMc1202292; Kulkarni H, 2009, BLOOD, V114, P2783, DOI 10.1182/blood-2009-04-215186; Lakshman R, 2001, J CLIN PATHOL, V54, P7, DOI 10.1136/jcp.54.1.7; Mastroianni CM, 1999, AIDS, V13, P883, DOI 10.1097/00002030-199905280-00003; Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023; Mazzolini J, 2010, BLOOD, V115, P4226, DOI 10.1182/blood-2009-12-259473; Michailidis C, 2012, CLIN EXP IMMUNOL, V167, P499, DOI 10.1111/j.1365-2249.2011.04526.x; Mocsai A, 2013, J EXP MED, V210, P1283, DOI 10.1084/jem.20122220; Munoz JF, 1999, J INFECT DIS, V180, P206, DOI 10.1086/314821; Nauseef WM, 2014, NAT IMMUNOL, V15, P602, DOI 10.1038/ni.2921; Ndung'u T, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau2798; Podinovskaia Maria, 2013, Curr Protoc Immunol, V102, DOI 10.1002/0471142735.im1434s102; Radebe M, 2011, J INFECT DIS, V204, P768, DOI 10.1093/infdis/jir394; Ramsuran V, 2011, CLIN INFECT DIS, V52, P1248, DOI 10.1093/cid/cir119; Reich D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000360; Schwartz R, 2010, BIOMED PHARMACOTHER, V64, P572, DOI 10.1016/j.biopha.2010.03.005; Shi X, 2014, INT REV IMMUNOL, V33, P511, DOI 10.3109/08830185.2014.893301; Thobakgale CF, 2014, CURR OPIN HEMATOL, V21, P50, DOI 10.1097/MOH.0000000000000007; Walley NM, 2009, CELL HOST MICROBE, V5, P408, DOI 10.1016/j.chom.2009.04.011; Yasin B, 2004, J VIROL, V78, P5147, DOI 10.1128/JVI.78.10.5147-5156.2004	47	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 26	2019	10								551	10.3389/fimmu.2019.00551	http://dx.doi.org/10.3389/fimmu.2019.00551			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HQ6PA	30972057	Green Published, gold			2022-12-18	WOS:000462538900001
J	Ban, Y; Dong, WJ; Zhang, LX; Zhou, T; Altiti, AS; Ali, K; Mootoo, DR; Blaho, VA; Hla, T; Ren, Y; Ma, XJ				Ban, Yi; Dong, Wenjuan; Zhang, Lixing; Zhou, Tian; Altiti, Ahmad S.; Ali, Khaleel; Mootoo, David R.; Blaho, Victoria A.; Hla, Timothy; Ren, Yi; Ma, Xiaojing			Abrogation of Endogenous Glycolipid Antigen Presentation on Myelin-Laden Macrophages by D-Sphingosine Ameliorates the Pathogenesis of Experimental Autoimmune Encephalomyelitis	FRONTIERS IN IMMUNOLOGY			English	Article						endogenous myelin-derived galcer; antigen presentation; IL-17; EAE progression; D-sphingosine	PROTECTS MICE; NKT CELLS; ALPHA; RECOGNITION; ACTIVATION; GENE; TH17; IDENTIFICATION; PHAGOCYTOSIS; EXPRESSION	Background: Although myelin is composed of mostly lipids, the pathological role of myelin lipids in demyelinating diseases remains elusive. The principal lipid of the myelin sheath is beta-galactosylceramide (beta-Galcer). Its alpha-anomer (alpha-Galcer) has been demonstrated to be antigenically presented by macrophages via CD1d, a MHC class I-like molecule. Myelin, which is mostly composed of beta-Galcer, has been long considered as an immunologically-inert neuron insulator, because the antigen-binding cleft of CD1d is highly alpha-form-restricted. Results: Here, we report that CD1d-mediated antigenic presentation of myelin-derived galactosylceramide (Mye-GalCer) by macrophages contributed significantly to the progression of experimental autoimmune encephalomyelitis (EAE). Surprisingly, this presentation was recognizable by alpha-Galcer:CD1d-specific antibody (clone L363), but incapable of triggering expansion of iNKT cells and production of iNKT signature cytokines (IFN gamma and IL-4). Likewise, a synthesized analog of Mye-Galcer, fluorinated alpha-C-GalCer (AA2), while being efficiently presented via CD1d on macrophages, failed to stimulate production of IFN gamma and IL-4. However, AA2 significantly exacerbated EAE progression. Further analyses revealed that the antigenic presentations of both Mye-GalCer and its analog (M2) in alpha-form via CD1d promoted IL-17 production from T cells, leading to elevated levels of IL-17 in EAE spinal cords and sera. The IL-17 neutralizing antibody significantly reduced the severity of EAE symptoms in AA2-treated mice. Furthermore, D-sphingosine, a lipid possessing the same hydrophobic base as ceramide but without a carbohydrate residue, efficiently blocked this glycolipid antigen presentation both in vitro and in spinal cords of EAE mice, and significantly decreased IL-17 and ameliorated the pathological symptoms. Conclusion: Our findings reveal a novel pathway from the presentation of Mye-GalCer to IL-17 production, and highlight the promising therapeutic potential of D-sphingosine for the human disorder of multiple sclerosis.	[Ban, Yi; Dong, Wenjuan; Ma, Xiaojing] Weill Cornell Med, Dept Microbiol & Immunol, New York, NY 10065 USA; [Zhang, Lixing; Ma, Xiaojing] Shanghai Jiao Tong Univ, Sheng Yushou Ctr Cell Biol, State Key Lab Microbial Metab, Shanghai, Peoples R China; [Zhou, Tian; Ren, Yi] Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA; [Zhou, Tian] Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Chongqing, Peoples R China; [Altiti, Ahmad S.; Ali, Khaleel; Mootoo, David R.] CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA; [Blaho, Victoria A.; Hla, Timothy] Weill Med Med, Ctr Vasc Biol, Dept Pathol & Lab Med, New York, NY USA; [Blaho, Victoria A.] Sanford Burnham Prepys Med Discovery Inst, La Jolla, CA USA	Cornell University; Shanghai Jiao Tong University; State University System of Florida; Florida State University; Chongqing University; City University of New York (CUNY) System; Hunter College (CUNY)	Ma, XJ (corresponding author), Weill Cornell Med, Dept Microbiol & Immunol, New York, NY 10065 USA.; Ma, XJ (corresponding author), Shanghai Jiao Tong Univ, Sheng Yushou Ctr Cell Biol, State Key Lab Microbial Metab, Shanghai, Peoples R China.; Ren, Y (corresponding author), Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA.	yi.ren@med.fsu.edu; xim2002@med.cornell.edu	Altiti, Ahmad/P-5706-2019; Hla, Timothy/G-5873-2012; Altiti, Ahmad/O-9262-2017	Hla, Timothy/0000-0001-8355-4065; Altiti, Ahmad/0000-0003-2946-4477; Ban, Yi/0000-0003-2467-001X	CTSC (Clinical and Translational Science Center of Weill Cornell Medicine) [5289990031]; National Science Foundation [CHE-1301330]; NIH-Clinical Translational Science Center Award [TR000457]; NIH-National Institute of Health Disparities [MD007599]; New Jersey Commission on Spinal Cord Research [CSCR13IRG006]; Ruth L. Kirschstein National Research Service Award from National Institute of healthy [5 T32 AI 7621-15]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000457, UL1TR002384] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R35HL135821] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007599] Funding Source: NIH RePORTER	CTSC (Clinical and Translational Science Center of Weill Cornell Medicine); National Science Foundation(National Science Foundation (NSF)); NIH-Clinical Translational Science Center Award; NIH-National Institute of Health Disparities; New Jersey Commission on Spinal Cord Research; Ruth L. Kirschstein National Research Service Award from National Institute of healthy(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by CTSC (Clinical and Translational Science Center of Weill Cornell Medicine) #5289990031 to XM National Science Foundation to DM (CHE-1301330). NIH-Clinical Translational Science Center Award to WCMC (TR000457), NIH-National Institute of Health Disparities to TH (MD007599), and New Jersey Commission on Spinal Cord Research (CSCR13IRG006) to YR. YB is the recipient of Ruth L. Kirschstein National Research Service Award from National Institute of healthy (5 T32 AI 7621-15).	Altiti AS, 2016, ORG LETT, V18, P4654, DOI 10.1021/acs.orglett.6b02284; Altiti AS, 2014, ORG LETT, V16, P1466, DOI 10.1021/ol5002686; Behar SM, 1999, J IMMUNOL, V162, P161; Blaho VA, 2015, NATURE, V523, P342, DOI 10.1038/nature14462; Bonder CS, 2009, BLOOD, V113, P2108, DOI 10.1182/blood-2008-07-166942; Boven LA, 2006, BRAIN, V129, P517, DOI 10.1093/brain/awh707; Coquet JM, 2008, P NATL ACAD SCI USA, V105, P11287, DOI 10.1073/pnas.0801631105; De Libero G, 2005, NAT REV IMMUNOL, V5, P485, DOI 10.1038/nri1631; DeGroot CJA, 1997, J NEUROPATH EXP NEUR, V56, P10, DOI 10.1097/00005072-199701000-00002; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Ferber IA, 1996, J IMMUNOL, V156, P5; Furlan R, 2003, EUR J IMMUNOL, V33, P1830, DOI 10.1002/eji.200323885; Haak S, 2009, J CLIN INVEST, V119, P61, DOI 10.1172/JCI35997; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; HIRANO K, 1985, J PHARM SCI, V74, P915, DOI 10.1002/jps.2600740902; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; ISSAZADEH S, 1995, J NEUROSCI RES, V40, P579, DOI 10.1002/jnr.490400503; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; Jahng AW, 2001, J EXP MED, V194, P1789, DOI 10.1084/jem.194.12.1789; Kain L, 2014, IMMUNITY, V41, P543, DOI 10.1016/j.immuni.2014.08.017; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Koch M, 2005, NAT IMMUNOL, V6, P819, DOI 10.1038/ni1225; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Kotter MR, 2006, J NEUROSCI, V26, P328, DOI 10.1523/JNEUROSCI.2615-05.2006; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Lairson LL, 2008, ANNU REV BIOCHEM, V77, P521, DOI 10.1146/annurev.biochem.76.061005.092322; Lampron A, 2015, J EXP MED, V212, P481, DOI 10.1084/jem.20141656; Lassmann H, 2004, TRENDS IMMUNOL, V25, P275, DOI 10.1016/j.it.2004.01.007; Liu MX, 2015, J BIOL CHEM, V290, P7861, DOI 10.1074/jbc.M114.631101; Liu Y, 2006, J NEUROSCI, V26, P12904, DOI 10.1523/JNEUROSCI.2531-06.2006; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lovett-Racke AE, 2011, BBA-MOL BASIS DIS, V1812, P246, DOI 10.1016/j.bbadis.2010.05.012; Patel O, 2011, J IMMUNOL, V187, P4705, DOI 10.4049/jimmunol.1100794; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Qian GC, 2010, CELL RES, V20, P480, DOI 10.1038/cr.2010.6; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Sun X, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009380; Tsai M, 2007, PHARM RES-DORDR, V24, P1691, DOI 10.1007/s11095-007-9298-0; van der Valk P, 2000, NEUROPATH APPL NEURO, V26, P2, DOI 10.1046/j.1365-2990.2000.00217.x; van der Vliet HJJ, 2001, J IMMUNOL METHODS, V247, P61, DOI 10.1016/S0022-1759(00)00272-6; van Rossum D, 2008, GLIA, V56, P271, DOI 10.1002/glia.20611; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; Vogel DYS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-35; Wang X, 2015, GLIA, V63, P635, DOI 10.1002/glia.22774; Yang YH, 2009, J EXP MED, V206, P1549, DOI 10.1084/jem.20082584; Yu ED, 2012, J BIOL CHEM, V287, P1269, DOI 10.1074/jbc.M111.308783; Yu KOA, 2007, J IMMUNOL METHODS, V323, P11, DOI 10.1016/j.jim.2007.03.006	52	2	2	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 19	2019	10								404	10.3389/fimmu.2019.00404	http://dx.doi.org/10.3389/fimmu.2019.00404			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HP3PG	30941120	Green Published, gold			2022-12-18	WOS:000461589000001
J	Lemarquis, AL; Theodors, F; Einaredottir, HK; Ludviksson, BR				Lemarquis, Andri L.; Theodors, Fannar; Einaredottir, Helga K.; Ludviksson, Bjorn R.			Mapping of Signaling Pathways Linked to sIgAD Reveals Impaired IL-21 Driven STAT3 B-Cell Activation	FRONTIERS IN IMMUNOLOGY			English	Article						selective IgA deficiency; IL-21; pSTAT3; phosphoflow; B cells; T cells; IgA	SELECTIVE IGA DEFICIENCY; GAMMA-CHAIN CYTOKINES; PHOSPHORYLATION; INTERLEUKIN-10; CLASSIFICATION	Objectives: It has recently been shown that individuals with selective IgA deficiency (sIgAD) have defective B cell responses both to T cell dependent and independent mimicking stimulations. The complex intracellular signaling pathways from different stimuli leading to IgA isotype switching have not been fully elucidated. Thus, the main objective of this study was to delineate these pathways and their potential role in the immunopathology linked to sIgAD. Materials and Methods: PBMCs from 10 individuals with sIgAD and 10 healthy controls (HC) were activated in vitro via either a T cell dependent or independent mimicking stimulation. Intracellular phosphorylation of pSTAT3, pSTAT5, pSTAT6, and as pERK1/2 was evaluated in T and B cells using phosphoflow cytometry. Results: By evaluating T cell dependent cytokine driven pathways linked to IgA isotype induction we identified a defect involving an IL-21 driven STAT3 activation isolated to B cells in sIgAD individuals. However, all other signaling pathways studied were found to be normal compared to HC. In T cell dependent cytokine driven stimulations linked to IgA isotype induction the following patterns emerged: (i) IL-10 led to significant STAT3 activation in both T- and B cells; (ii) IL-4 stimulation was predominantly confined to STAT6 activation in both T- and B cells, with some effects on STAT3 activation in T-cells; (iii) as expected, of tested stimuli, IL-2 alone activated STAT5 and some STAT3 activation though in both cases only in T-cells; (iv) IL-21 induced significant activation of STAT3 in both T- and B cells, with some effects on STAT5 activation in T-cells; and finally (v) synergistic effects were noted of IL-4H-IL-10 on STAT5 activation in T-cells, and possibly STAT6 in both T- and B cells. On the other hand, CPG induced T cell independent activation was confined to ERK1/2 activation in B cells. Conclusion: Our results indicate a diminished STAT3 phosphorylation following IL-21 stimulation solely in B cells from sIgAD individuals. This can represent aberrant germinal center reactions or developmental halt. Thus, our work provides further insight into the unraveling of the previously hypothesized role of IL-21 to reconstitute immunoglobulin production in primary antibody deficiencies.	[Lemarquis, Andri L.; Theodors, Fannar; Einaredottir, Helga K.; Ludviksson, Bjorn R.] Natl Univ Hosp Iceland, Landspitali, Dept Immunol, Reykjavik, Iceland; [Lemarquis, Andri L.; Theodors, Fannar; Ludviksson, Bjorn R.] Univ Iceland, Fac Med, Reykjavik, Iceland	Landspitali National University Hospital; University of Iceland	Lemarquis, AL; Ludviksson, BR (corresponding author), Natl Univ Hosp Iceland, Landspitali, Dept Immunol, Reykjavik, Iceland.; Lemarquis, AL; Ludviksson, BR (corresponding author), Univ Iceland, Fac Med, Reykjavik, Iceland.	andrileo@landspitali.is; bjornlud@landspitali.is	Lemarquis, Andri Leó/AAO-5044-2021; Lúðvíksson, Björn Rúnar/AFQ-7993-2022		Icelandic Research Fund; University hospital of Iceland research fund	Icelandic Research Fund; University hospital of Iceland research fund	We are grateful to the patients of this study and to the staff and the Icelandic Medical Research Center for blood sample collection and assistance with the patients. We thank the funding partners: The Icelandic Research Fund and The University hospital of Iceland research fund.	Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Alves NL, 2007, IMMUNOL LETT, V108, P113, DOI 10.1016/j.imlet.2006.11.006; Asano T, 2004, CLIN EXP IMMUNOL, V136, P284, DOI 10.1111/j.1365-2249.2004.02440.x; Borte S, 2009, BLOOD, V114, P4089, DOI 10.1182/blood-2009-02-207423; Borzutzky A, 2018, CLIN IMMUNOL, V197, P40, DOI 10.1016/j.clim.2018.08.008; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; BRIERE F, 1994, J CLIN INVEST, V94, P97, DOI 10.1172/JCI117354; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Degn SE, 2017, CELL, V170, P913, DOI 10.1016/j.cell.2017.07.026; GOSHEN E, 1989, J AUTOIMMUN, V2, P51, DOI 10.1016/0896-8411(89)90107-8; Haddad E, 2015, BLOOD, V125, P583, DOI 10.1182/blood-2014-11-610592; HAMMARSTROM L, 1985, LANCET, V1, P778; Hayashi K, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan4144; Hummelshoj L, 2006, CLIN EXP IMMUNOL, V144, P458, DOI 10.1111/j.1365-2249.2006.03096.x; Jorgensen GH, 2013, J CLIN IMMUNOL, V33, P742, DOI 10.1007/s10875-012-9858-x; Jorgensen GH, 2011, HUM IMMUNOL, V72, P166, DOI 10.1016/j.humimm.2010.10.014; Krutzik Peter O, 2011, Curr Protoc Cytom, VChapter 6, DOI 10.1002/0471142956.cy0631s55; Lemarquis AL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00909; LIBLAU RS, 1992, INT ARCH ALLERGY IMM, V99, P16, DOI 10.1159/000236330; Liu BS, 2013, J IMMUNOL, V191, P4086, DOI 10.4049/jimmunol.1300765; Marciano BE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00937; Marconi M, 1998, CLIN EXP IMMUNOL, V112, P528; Montag DT, 2006, CLIN IMMUNOL, V121, P215, DOI 10.1016/j.clim.2006.06.013; Pertovaara M, 2015, CLIN EXP IMMUNOL, V181, P29, DOI 10.1111/cei.12614; Pulliam SR, 2016, IMMUNOL LETT, V169, P61, DOI 10.1016/j.imlet.2015.11.007; Suzuki Hiroko, 2009, Allergology International, V58, P111, DOI 10.2332/allergolint.O-08-549; Takeuchi T, 2019, ANN RHEUM DIS, V78, P171, DOI 10.1136/annrheumdis-2018-213271; Wang N, 2012, CURR OPIN ALLERGY CL, V12, P602, DOI 10.1097/ACI.0b013e3283594219; Yazdani R, 2017, CLIN IMMUNOL, V175, P124, DOI 10.1016/j.clim.2016.09.009; ZIELEN S, 1993, LANCET, V342, P750, DOI 10.1016/0140-6736(93)91746-9	30	2	2	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 18	2019	10								403	10.3389/fimmu.2019.00403	http://dx.doi.org/10.3389/fimmu.2019.00403			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HP3LD	30936864	gold, Green Published			2022-12-18	WOS:000461577300001
J	Penin, I; Figueroa-Cabanas, ME; Guerrero-de la Rosa, F; Soto-Garcia, LA; Alvarez-Martinez, R; Flores-Moran, A; Acevedo-Whitehouse, K				Penin, Ignacio; Figueroa-Cabanas, Monica E.; Guerrero-de la Rosa, Fabiola; Soto-Garcia, Luis A.; Alvarez-Martinez, Roberto; Flores-Moran, Adriana; Acevedo-Whitehouse, Karina			Transcriptional Profiles of California Sea Lion Peripheral NK and CD+8 T Cells Reflect Ecological Regionalization and Infection by Oncogenic Viruses	FRONTIERS IN IMMUNOLOGY			English	Article						California sea lion; cytotoxicity; NK; CD8+ T cells; otarine gammaherpesvirus; sea lion papillomavirus	GULF-OF-CALIFORNIA; IN-VITRO EXPOSURE; ZALOPHUS-CALIFORNIANUS; ORGANOCHLORINE PESTICIDES; HUMAN-PAPILLOMAVIRUS; BAJA-CALIFORNIA; HIGH PREVALENCE; MARINE MAMMALS; BET; EXPRESSION	The California sea lion is one of the few wild mammals prone to develop cancer, particularly urogenital carcinoma (UGC), whose prevalence is currently estimated at 25% of dead adult sea lions stranded along the California coastline. Genetic factors, viruses and organochlorines have been identified as factors that increase the risk of occurrence of this pathology. Given that no cases of UGC have as yet been reported for the species along its distribution in Mexican waters, the potential relevance of contaminants for the development of urogenital carcinoma is highlighted even more as blubber levels of organochlorines are more than two orders of magnitude lower in the Gulf of California and Mexican Pacific than in California. In vitro studies have shown that organochlorines can modulate anti-viral and tumor-surveillance activities of NK and cytotoxic T-cells of marine mammals, but little is known about the activity of these effectors in live, free-living sea lions. Here, we examine leukocyte transcriptional profiles of free-ranging adult California sea lions for eight genes (Eomes, Granzyme B, Perforin, Ly49, STAT1, Tbx21, GATA3, and FoxP3) selected for their key role in anti-viral and tumor-surveillance, and investigate patterns of transcription that could be indicative of differences in ecological variables and exposure to two oncogenic viruses: sea lion type one gammaherpesvirus (OtHV-1) and sea lion papillomavirus type 1 (ZcPV-1) and systemic inflammation. We observed regional differences in the expression of genes related to Thl responses and immune modulation, and detected clear patterns of differential regulation of gene expression in sea lions infected by genital papillomavirus compared to those infected by genital gammaherpesvirus or for simultaneous infections, similar to what is known about herpesvirus and papillomavirus infections in humans. Our study is a first approach to profile the transcriptional patterns of key immune effectors of free-ranging California sea lions and their association with ecological regions and oncogenic viruses. The observed results add insight to our understanding of immune competence of marine mammals, and may help elucidate the marked difference in the number of cases of urogenital carcinoma in sea lions from US waters and other areas of their distribution.	[Penin, Ignacio; Figueroa-Cabanas, Monica E.; Guerrero-de la Rosa, Fabiola; Soto-Garcia, Luis A.; Alvarez-Martinez, Roberto; Flores-Moran, Adriana; Acevedo-Whitehouse, Karina] Autonomous Univ Queretaro, Sch Nat Sci, Unit Basic & Appl Microbiol, Santiago De Queretaro, Mexico; [Acevedo-Whitehouse, Karina] Marine Mammal Ctr, Sausalito, CA 94965 USA	Universidad Autonoma de Queretaro	Acevedo-Whitehouse, K (corresponding author), Autonomous Univ Queretaro, Sch Nat Sci, Unit Basic & Appl Microbiol, Santiago De Queretaro, Mexico.; Acevedo-Whitehouse, K (corresponding author), Marine Mammal Ctr, Sausalito, CA 94965 USA.	karina.acevedo.whitehouse@uaq.mx		Alvarez-Martinez, Roberto/0000-0002-0821-0067	CONACYT-Fronteras de la Ciencia [446]; CONACYT [298065, 287579]	CONACYT-Fronteras de la Ciencia; CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This study was funded by grant CONACYT-Fronteras de la Ciencia 446 awarded to KA-W.IP was funded by a CONACYT PhD studentship (298065). AF-M was funded by a CONACYT PhD studentship (287579).	Acevedo-Whitehouse K, 2003, NATURE, V422, P35, DOI 10.1038/422035a; Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Afonina IS, 2010, IMMUNOL REV, V235, P105, DOI 10.1111/j.0105-2896.2010.00908.x; Amirian ES, 2013, CANCER LETT, V336, P18, DOI 10.1016/j.canlet.2013.04.023; Aurioles-Gamboa D, 2017, MAR BIOL, V164, DOI 10.1007/s00227-017-3189-7; Avalos-Tellez R, 2016, J WILDLIFE DIS, V52, P199, DOI 10.7589/2015-06-133; Banuet-Martinez M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179359; Barragan-Vargas C, 2016, ROY SOC OPEN SCI, V3, DOI 10.1098/rsos.150419; Bartkowiak T, 2015, P NATL ACAD SCI USA, V112, pE5290, DOI 10.1073/pnas.1514418112; Bowen L, 2005, IMMUNOGENETICS, V56, P846, DOI 10.1007/s00251-004-0757-z; Bowen L, 2012, MOL ECOL RESOUR, V12, P67, DOI 10.1111/j.1755-0998.2011.03060.x; Browning HM, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0240; Buckles EL, 2006, J COMP PATHOL, V135, P183, DOI 10.1016/j.jcpa.2006.06.007; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chakir H, 2003, J IMMUNOL METHODS, V278, P157, DOI 10.1016/S0022-1759(03)00200-X; Choy JC, 2004, ARTERIOSCL THROM VAS, V24, P2245, DOI 10.1161/01.ATV.0000147162.51930.b7; De Guise S, 1998, J TOXICOL ENV HEAL A, V55, P479, DOI 10.1080/009841098158287; Del Toro L, 2006, ENVIRON POLLUT, V142, P83, DOI 10.1016/j.envpol.2005.09.019; Della Chiesa M, 2014, SEMIN IMMUNOL, V26, P152, DOI 10.1016/j.smim.2014.02.001; Deming AC, 2018, J WILDLIFE DIS, V54, P581, DOI 10.7589/2017-08-208; Desforges JPW, 2016, ENVIRON INT, V86, P126, DOI 10.1016/j.envint.2015.10.007; Di Santo JP, 2006, ANNU REV IMMUNOL, V24, P257, DOI 10.1146/annurev.immunol.24.021605.090700; Espinoza JL, 2016, SCI REP-UK, V6, DOI 10.1038/srep39231; Feng PH, 2013, CURR OPIN VIROL, V3, P285, DOI 10.1016/j.coviro.2013.05.011; Forget Patrice, 2017, BMC Res Notes, V10, P12, DOI 10.1186/s13104-016-2335-5; Garcia-Hernandez J, 2001, J ARID ENVIRON, V49, P65, DOI 10.1006/jare.2001.0836; Gotthardt D, 2016, FRONT IMMUNOL, V7, P694, DOI [DOI 10.3389/fimmu.2016.00694, DOI 10.3389/FIMMU.2016.00694]; Hammond JA, 2009, J IMMUNOL, V182, P3618, DOI 10.4049/jimmunol.0803026; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iwata S, 2017, IMMUNITY, V46, P983, DOI 10.1016/j.immuni.2017.05.005; Kao C, 2011, NAT IMMUNOL, V12, P663, DOI 10.1038/ni.2046; Kelso A, 2002, INT IMMUNOL, V14, P605, DOI 10.1093/intimm/dxf028; Knox JJ, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00217; Levin M, 2004, J TOXICOL ENV HEAL A, V67, P1517, DOI 10.1080/15287390490486761; Levin M, 2007, VET IMMUNOL IMMUNOP, V119, P269, DOI 10.1016/j.vetimm.2007.06.003; Lipscomb TP, 2000, VET PATHOL, V37, P609, DOI 10.1354/vp.37-6-609; Lluch-Cota SE, 2000, OCEANOL ACTA, V23, P731, DOI 10.1016/S0399-1784(00)00121-3; Lu L, 2017, NAT REV IMMUNOL, V17, P703, DOI 10.1038/nri.2017.75; MALDONADO JE, 1995, MAR MAMMAL SCI, V11, P46, DOI 10.1111/j.1748-7692.1995.tb00273.x; Martinet V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8089; Mercer F, 2009, ADV EXP MED BIOL, V665, P47; Miller CS, 2006, J CLIN MICROBIOL, V44, P2409, DOI 10.1128/JCM.00256-06; Mohl BS, 2016, MOL CELLS, V39, P286, DOI 10.14348/molcells.2016.0066; Montano-Frias JE, 2016, INFECT GENET EVOL, V42, P77, DOI 10.1016/j.meegid.2016.04.022; Mori C, 2006, J TOXICOL ENV HEAL A, V69, P283, DOI 10.1080/15287390500227472; Mori C, 2008, J TOXICOL ENV HEAL A, V71, P266, DOI 10.1080/15287390701612860; Murtagh F, 2014, J CLASSIF, V31, P274, DOI 10.1007/s00357-014-9161-z; Nino-Torres CA, 2009, ARCH ENVIRON CON TOX, V56, P350, DOI 10.1007/s00244-008-9181-y; Origoni M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/831907; Penin I, 2018, ENVIRON RES, V167, P708, DOI 10.1016/j.envres.2018.08.028; R Development Core Team, 2017, R LANG ENV STAT COMP; Randhawa N, 2015, ONE HEALTH, V1, P37, DOI 10.1016/j.onehlt.2015.08.003; Rehtanz M, 2012, VET MICROBIOL, V160, P297, DOI 10.1016/j.vetmic.2012.05.042; SANTAMARIADELANGEL E, 1994, J GEOPHYS RES-OCEANS, V99, P7411, DOI 10.1029/93JC02154; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schramm Y, 2009, MAR BIOL, V156, P1375, DOI 10.1007/s00227-009-1178-1; Shigehara K, 2014, J INFECT CHEMOTHER, V20, P741, DOI 10.1016/j.jiac.2014.08.033; SOKAL ROBERT R., 1962, TAXON, V11, P33, DOI 10.2307/1217208; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szteren D, 2011, CIENC MAR, V37, P349, DOI 10.7773/cm.v37i3.1818; Takemoto N, 2006, J IMMUNOL, V177, P7515, DOI 10.4049/jimmunol.177.11.7515; Turner M, 2011, ADV EXP MED BIOL, V780, P1, DOI 10.1007/978-1-4419-5632-3_1; Velez MM., 2012, THESIS; Vera-Massieu C, 2015, ROY SOC OPEN SCI, V2, DOI 10.1098/rsos.150108; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Wan YY, 2014, TRENDS IMMUNOL, V35, P233, DOI 10.1016/j.it.2014.04.002; Ward EJ, 2010, J APPL ECOL, V47, P47, DOI 10.1111/j.1365-2664.2009.01745.x; Ylitalo GM, 2005, MAR POLLUT BULL, V50, P30, DOI 10.1016/j.marpolbul.2004.08.005; Zhu JF, 2010, IMMUNOL REV, V238, P247, DOI 10.1111/j.1600-065X.2010.00951.x; Zuur Alain F., 2009, P1	70	2	3	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 12	2019	10								413	10.3389/fimmu.2019.00413	http://dx.doi.org/10.3389/fimmu.2019.00413			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HO6ZT	30915075	Green Published, gold			2022-12-18	WOS:000461084100001
J	Dios-Esponera, A; Melis, N; Subramanian, BC; Weigert, R; Samelson, LE				Dios-Esponera, Ana; Melis, Nicolas; Subramanian, Bhagawat C.; Weigert, Roberto; Samelson, Lawrence E.			Pak1 Kinase Promotes Activated T Cell Trafficking by Regulating the Expression of L-Selectin and	FRONTIERS IN IMMUNOLOGY			English	Article						Pak1 kinase; L-selectin; CCR7; lymph node trafficking; L-selectin shedding	FOXO TRANSCRIPTION FACTORS; SPLENIC WHITE PULP; MIGRATION; LYMPHOCYTES; CCR7; DIFFERENTIATION; MOLECULES; PATHWAYS; SURVIVAL; SLP-76	Normal function of the adaptive immune system requires trafficking of T cells between the blood and lymphoid organs. Lymphocyte homing to lymph nodes requires that they cross endothelial barriers present in blood vessels and lymphatics. This multi-step process requires a remodeling of the lymphocyte plasma membrane, which is mediated by the dynamic re-arrangement of the actin cytoskeleton. Pak1 plays a central role in cell morphology, adhesion and migration in various cell types. Here we demonstrate that Pak1 is required for activated CD4(+) T cell trafficking to lymph nodes. Pak1 deficiency in T cells causes a defect in the transcription of CCR7 and L-selectin, thereby altering lymphocyte trafficking. Additionally, we report an increase in L-selectin shedding in Pak1-deficient T cells, which correlates with a decrease in the recruitment of calmodulin to the cytoplasmic tail of L-selectin during T cell activation. Overall, our findings demonstrate that by regulating the expression of two major lymph node homing molecules, L-selectin and CCR7, Pak1 mediates activated CD4(+) T cell trafficking.	[Dios-Esponera, Ana; Melis, Nicolas; Subramanian, Bhagawat C.; Weigert, Roberto; Samelson, Lawrence E.] NCI, Lab Cellular & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Samelson, LE (corresponding author), NCI, Lab Cellular & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	samelsonl@helix.nih.gov		Melis, Nicolas/0000-0001-7456-6232; Subramanian, Bhagawat Chandrasekar/0000-0002-6976-7512	National Institutes of Health, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010304] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr. Carole A. Parent (University of Michigan) for discussions and review of the manuscript; Drs. Xin Wang and Ming Lei (Manchester University, U.K.) for providing Pak1ff mice; Devorah L. Gallardo for her help with tail injections and cardiac puncture; Wenmei Li for technical support; and Dr. John H. Kehrl and Dr. Chung Park (NIAID) for helpful advice on inguinal LN two-photon intravital microscopy. This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.	ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Bergmeier W, 2004, CIRC RES, V95, P677, DOI 10.1161/01.RES.0000143899.73453.11; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Chu PC, 2004, J IMMUNOL, V172, P7324, DOI 10.4049/jimmunol.172.12.7324; Estin ML, 2017, P NATL ACAD SCI USA, V114, pE2901, DOI 10.1073/pnas.1701886114; Fabre S, 2008, J IMMUNOL, V181, P2980, DOI 10.4049/jimmunol.181.5.2980; Faroudi M, 2010, BLOOD, V116, P5536, DOI 10.1182/blood-2010-08-299438; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Galkina E, 2003, J EXP MED, V198, P1323, DOI 10.1084/jem.20030485; Grailer JJ, 2009, J DERMATOL SCI, V56, P141, DOI 10.1016/j.jdermsci.2009.10.001; Guittard G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23549-2; Guittard G, 2015, EUR J IMMUNOL, V45, P2389, DOI 10.1002/eji.201445226; Harada Y, 2010, J EXP MED, V207, P1381, DOI 10.1084/jem.20100004; Hedrick SM, 2012, NAT REV IMMUNOL, V12, P649, DOI 10.1038/nri3278; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Jacobelli J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075151; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kerdiles YM, 2010, IMMUNITY, V33, P890, DOI 10.1016/j.immuni.2010.12.002; Kerdiles YM, 2009, NAT IMMUNOL, V10, P176, DOI 10.1038/ni.1689; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Liu W, 2011, CIRCULATION, V124, P2702, DOI 10.1161/CIRCULATIONAHA.111.048785; Liu Y, 2012, BLOOD, V119, P445, DOI 10.1182/blood-2011-07-368860; Masopust D, 2013, NAT REV IMMUNOL, V13, P309, DOI 10.1038/nri3442; Milberg O, 2017, J CELL BIOL, V216, P1925, DOI 10.1083/jcb.201612126; Nolte MA, 2002, IMMUNOLOGY, V106, P299, DOI 10.1046/j.1365-2567.2002.01443.x; Ouyang W, 2010, NAT IMMUNOL, V11, P618, DOI 10.1038/ni.1884; Park C, 2016, METHODS MOL BIOL, V1407, P195, DOI 10.1007/978-1-4939-3480-5_15; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Phee H, 2005, NAT IMMUNOL, V6, P608, DOI 10.1038/ni1199; Phee H, 2014, ELIFE, V3, DOI 10.7554/eLife.02270; Richards H, 2008, J IMMUNOL, V180, P198, DOI 10.4049/jimmunol.180.1.198; Rouquette-Jazdanian AK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131823; Rouquette-Jazdanian AK, 2012, MOL CELL, V48, P298, DOI 10.1016/j.molcel.2012.08.011; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sinclair LV, 2008, NAT IMMUNOL, V9, P513, DOI 10.1038/ni.1603; Smith CW, 2008, J ALLERGY CLIN IMMUN, V121, pS375, DOI 10.1016/j.jaci.2007.07.030; Tang MLK, 1998, J IMMUNOL, V160, P5113; Thelen M, 2008, NAT IMMUNOL, V9, P953, DOI 10.1038/ni.f.207; Unsoeld H, 2004, J IMMUNOL, V173, P3013, DOI 10.4049/jimmunol.173.5.3013; Vadlakonda L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00165; Venturi GM, 2003, IMMUNITY, V19, P713, DOI 10.1016/S1074-7613(03)00295-4; Venturi GM, 2007, J IMMUNOL, V178, P291, DOI 10.4049/jimmunol.178.1.291; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Zhang Q, 2014, J EXP MED, V211, P2549, DOI 10.1084/jem.20141307; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014	51	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2019	10								370	10.3389/fimmu.2019.00370	http://dx.doi.org/10.3389/fimmu.2019.00370			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HN6JV	30891040	Green Published, gold			2022-12-18	WOS:000460293200001
J	Manoury, B; De Berardinis, P				Manoury, Benedicte; De Berardinis, Piergiuseppe			Targeted Antigen Delivery: Bridging Innate and Adaptive Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						targeted delivery; dendritic cells; innate and adaptive immunity; pattern recognition receptors (PRR); immunotherapy			[Manoury, Benedicte] CNRS UMR8253, INSERM U1151, Inst Necker Enfants Malades, Paris, France; [De Berardinis, Piergiuseppe] CNR, Inst Prot Biochem, Naples, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	De Berardinis, P (corresponding author), CNR, Inst Prot Biochem, Naples, Italy.	p.deberardinis@ibp.cnr.it	De Berardinis, Piergiuseppe/AAX-1049-2020; De Berardinis, Piergiuseppe/HCI-0893-2022	De Berardinis, Piergiuseppe/0000-0001-6579-1729; 					0	2	2	5	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2019	10								368	10.3389/fimmu.2019.00368	http://dx.doi.org/10.3389/fimmu.2019.00368			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HN6JT	30891039	Green Published, gold			2022-12-18	WOS:000460293000003
J	Vojkovics, D; Kellermayer, Z; Gabris, F; Schippers, A; Wagner, N; Berta, G; Farkas, K; Balogh, P				Vojkovics, Dora; Kellermayer, Zoltan; Gabris, Fanni; Schippers, Angela; Wagner, Norbert; Berta, Gergely; Farkas, Kornelia; Balogh, Peter			Differential Effects of the Absence of Nkx2-3 and MAdCAM-1 on the Distribution of Intestinal Type 3 Innate Lymphoid Cells and Postnatal SILT Formation in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						NKX2-3; MAdCAM-1; ILC3; isolated lymphoid follicle; cryptopatch	TRANSCRIPTION FACTOR NKX2-3; EXPRESSION; FOLLICLES; CRYPTOPATCHES; GENERATION; MIGRATION; MULTIPLE; RECEPTOR; GENE	Seeding of leukocytes to developing lymphoid tissues in embryonic and early postnatal age and to the mucosa throughout adulthood depends on the interaction between endothelial MAdCAM-1 addressin and its cognate ligand alpha 4 beta 7 integrin. Nkx2-3 as a transcriptional regulator of MAdCAM-1 controls vascular patterning in visceral lymphoid tissues in mice, and has been identified as a susceptibility factor for inflammatory bowel diseases in humans, associated with lymphoid neogenesis in the inflamed intestines. The role of Nkx2-3 in the organogenesis of the solitary intestinal lymphoid tissues (SILTs) involving type 3 innate lymphoid cells (ILC3) is still unknown. Here we investigated the effect of Nkx2-3 on the postnatal distribution of intestinal ILC3s and the development of SILTs, comparing these to mice lacking MAdCAM-1, but preserving Nkx2-3. At 1 week of age small intestines (SI) contained significantly higher number of ILC3s relative to the colon, with a substantial reduction in MAdCAM-1(-/-) mice compared to C57BL/6 controls. One week later SI ILC3 number decreased in all genotypes, the number of colonic ILC3 of both Nkx2-3-deficient and Nkx2-3-heterozygous mice significantly increased. On the fourth postnatal week a further reduction of SI ILC3s was observed in both Nkx2-3-deficient and Nkx2-3-heterozygous mice, while in the colon the number of ILC3s showed a significant reduction in all genotypes. At 1 week of age only sporadic SILT components were present in all genotypes. By the second week mice deficient for either Nkx2-3 or MAdCAM-1 showed absence of SILT maturation compared to their relevant controls, lacking mature isolated lymphoid follicles (ILF). By the fourth week both Nkx2-3-deficient and Nkx2-3-heterozygous mice showed a similar distribution of ILFs relative to cryptopatches (CP), whereas in MAdCAM-1(-/-) mice CPs and immature ILFs were present, mature ILFs were scarce. Our data demonstrate that the complete absence of MAdCAM-1 partially impairs intestinal seeding of ILC3s and causes partial blockade of SILT maturation, without affecting peripheral lymph node development. In contrast, the inactivation of Nkx2-3 permits postnatal seeding, and its blocking effect on SILT maturation prevails at later stage, thus other adhesion molecules may compensate for the intestinal homing of ILC3s in the absence of MAdCAM-1.	[Vojkovics, Dora; Kellermayer, Zoltan; Gabris, Fanni; Balogh, Peter] Univ Pecs, Dept Immunol & Biotechnol, Clin Ctr, Pecs, Hungary; [Vojkovics, Dora; Kellermayer, Zoltan; Gabris, Fanni; Balogh, Peter] Univ Pecs, Lymphoid Organogenesis Res Grp, Szentagothai Res Ctr, Pecs, Hungary; [Schippers, Angela; Wagner, Norbert] Univ Hosp RWTH, Dept Pediat, Aachen, Germany; [Berta, Gergely] Univ Pecs, Med Sch, Dept Med Biol, Cent Electron Microscope Lab, Pecs, Hungary; [Farkas, Kornelia] Univ Pecs, Med Sch, Dept Bioanalyt, Pecs, Hungary	University of Pecs; University of Pecs; RWTH Aachen University; RWTH Aachen University Hospital; University of Pecs; University of Pecs	Balogh, P (corresponding author), Univ Pecs, Dept Immunol & Biotechnol, Clin Ctr, Pecs, Hungary.; Balogh, P (corresponding author), Univ Pecs, Lymphoid Organogenesis Res Grp, Szentagothai Res Ctr, Pecs, Hungary.	balogh.peter@pte.hu		Farkas, Nelli/0000-0002-5349-6527	New National Excellence Program of the Ministry of Human Capacities of Hungary [UNKP-17-4-I-PTE-83]; Faculty of Medicine, University of Pecs; Deutsche Forschungsgemeinschaft [SCHI 1170/2-1, WA 1127/4-1]; Hungarian Scientific Research Fund [OTKA K108429];  [PEPSYS-GINOP-2.3.2-15-2016-00050];  [EFOP-3.6.1-16-2016-00004]	New National Excellence Program of the Ministry of Human Capacities of Hungary; Faculty of Medicine, University of Pecs; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Hungarian Scientific Research Fund(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); ; 	ZK is supported by the UNKP-17-4-I-PTE-83 New National Excellence Program of the Ministry of Human Capacities of Hungary and the postdoctoral research grant of the Faculty of Medicine, University of Pecs. AS and NW are supported by the Deutsche Forschungsgemeinschaft (SCHI 1170/2-1 and WA 1127/4-1). PB is supported by the Hungarian Scientific Research Fund (OTKA K108429). This project is supported by PEPSYS-GINOP-2.3.2-15-2016-00050 and EFOP-3.6.1-16-2016-00004.	Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Brendolan A, 2007, BIOESSAYS, V29, P166, DOI 10.1002/bies.20528; Buettner M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00342; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; Czompoly T, 2011, J IMMUNOL, V186, P6981, DOI 10.4049/jimmunol.1003770; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Fisher SA, 2008, NAT GENET, V40, P710, DOI 10.1038/ng.145; Geremia A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01296; Hamada H, 2002, J IMMUNOL, V168, P57, DOI 10.4049/jimmunol.168.1.57; Hashi H, 2001, J IMMUNOL, V166, P3702, DOI 10.4049/jimmunol.166.6.3702; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Hsia LT, 2016, P NATL ACAD SCI USA, V113, pE2162, DOI 10.1073/pnas.1603534113; Ilvanov II, 2006, CURR TOP MICROBIOL, V308, P59; Kellermayer Z, 2019, J IMMUNOL, V202, P1833, DOI 10.4049/jimmunol.1801117; Kellermayer Z, 2017, IMMUNOL LETT, V189, P3, DOI 10.1016/j.imlet.2017.04.008; Kellermayer Z, 2014, J IMMUNOL, V193, P5284, DOI 10.4049/jimmunol.1402016; Knoop KA, 2011, AM J PATHOL, V179, P1861, DOI 10.1016/j.ajpath.2011.06.004; Mebius RE, 2003, NAT REV IMMUNOL, V3, P292, DOI 10.1038/nri1054; Mebius RE, 1996, P NATL ACAD SCI USA, V93, P11019, DOI 10.1073/pnas.93.20.11019; Pabst O, 2005, EUR J IMMUNOL, V35, P98, DOI 10.1002/eji.200425432; Pabst O, 1997, DEV DYNAM, V209, P29; Pabst O, 1999, DEVELOPMENT, V126, P2215; Pabst O, 2000, EMBO J, V19, P2015, DOI 10.1093/emboj/19.9.2015; Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Schippers A, 2009, GASTROENTEROLOGY, V137, P924, DOI 10.1053/j.gastro.2009.05.039; Tamboli CP, 2004, GUT, V53, P1, DOI 10.1136/gut.53.1.1; Wang CH, 2008, J IMMUNOL, V181, P4052, DOI 10.4049/jimmunol.181.6.4052; Wang CC, 2000, DEV BIOL, V224, P152, DOI 10.1006/dbio.2000.9749; Zundler S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00891	31	2	2	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2019	10								366	10.3389/fimmu.2019.00366	http://dx.doi.org/10.3389/fimmu.2019.00366			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HN6JT	30891037	Green Published, gold			2022-12-18	WOS:000460293000001
J	Trojnar, E; Jozsi, M; Szabo, Z; Reti, M; Farkas, P; Kelen, K; Reusz, GS; Szabo, AJ; Garam, N; Mikes, B; Sinkovits, G; Mezo, B; Csuka, D; Prohaszka, Z				Trojnar, Eszter; Jozsi, Mihaly; Szabo, Zsoka; Reti, Marienn; Farkas, Peter; Kelen, Kata; Reusz, George S.; Szabo, Attila J.; Garam, Nora; Mikes, Balint; Sinkovits, Gyorgy; Mezo, Blanka; Csuka, Dorottya; Prohaszka, Zoltan			Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies	FRONTIERS IN IMMUNOLOGY			English	Article						pentraxin-3; C-reactive protein; thrombotic microangiopathies; hemolytic uremic syndrome; thrombotic thrombocytopenic purpura; alternative pathway; complement consumption	C-REACTIVE PROTEIN; HEMOLYTIC-UREMIC SYNDROME; DISEASE-ACTIVITY; FACTOR-H; PTX3; ACTIVATION; INFLAMMATION; MARKER; REPERFUSION; LOCALIZES	Pentraxin-3 (PTX3) and C-reactive protein (CRP) have been shown to regulate complement activation in vitro, but their role has not been investigated in complement consumption in vivo. Thrombotic microangiopathies (TMA) are often accompanied by complement overactivation and consumption, therefore we analyzed the relation of the systemic pentraxin levels to the complement profile, laboratory parameters and clinical outcome of TMA patients. We determined the PTX3 and CRP levels, complement factor and activation product concentrations in blood samples of 171 subjects with the diagnosis of typical hemolytic uremic syndrome (STEC-HUS) (N = 34), atypical HUS (aHUS) (N = 44), secondary TMA (N = 63), thrombotic thrombocytopenic purpura (TTP) (N = 30) and 69 age-matched healthy individuals. Clinical data, blood count and chemistry were collected from medical records. To determine the in vitro effect of PTX3 on alternative pathway (AP) activation, sheep red blood cell-based hemolytic assay and AP activity ELISA were used. We found that PTX3 levels were elevated in the acute phase of STEC-HUS, aHUS and secondary TMA, whereas PTX3 elevation was exceptional is TTP. Conversely, a significantly higher median CRP was present in all patient groups compared to controls. PTX3, but not CRP was associated with signs of complement consumption in vivo, and PTX3 significantly decreased the AP hemolytic activity in vitro. Our results provide a detailed description of acute phase-TMA patients' complement profile linked to changes in the systemic pentraxin levels that may support further molecular studies on the function of PTX3 in disease pathogenesis and add to the laboratory assessment of complement consumption in TMA.	[Trojnar, Eszter; Farkas, Peter; Garam, Nora; Mikes, Balint; Sinkovits, Gyorgy; Mezo, Blanka; Csuka, Dorottya; Prohaszka, Zoltan] Hungarian Acad Sci, Res Lab, MTA SE Res Grp Immunol & Hematol, Dept Internal Med 3, Budapest, Hungary; [Trojnar, Eszter; Farkas, Peter; Garam, Nora; Mikes, Balint; Sinkovits, Gyorgy; Mezo, Blanka; Csuka, Dorottya; Prohaszka, Zoltan] Semmelweis Univ, Budapest, Hungary; [Jozsi, Mihaly; Szabo, Zsoka] Eotvos Lorand Univ, Complement Res Grp, Dept Immunol, Budapest, Hungary; [Reti, Marienn] Natl Inst Hematol & Infect Dis, Dept Haematol & Stem Cell Transplantat, Cent Hosp Southern Pest, Budapest, Hungary; [Kelen, Kata; Reusz, George S.; Szabo, Attila J.] Semmelweis Univ, Dept Pediat 1, Budapest, Hungary; [Szabo, Attila J.] MTA SE Pediat & Nephrol Res Grp, Budapest, Hungary	Hungarian Academy of Sciences; Semmelweis University; Eotvos Lorand University; Semmelweis University; Semmelweis University	Trojnar, E (corresponding author), Hungarian Acad Sci, Res Lab, MTA SE Res Grp Immunol & Hematol, Dept Internal Med 3, Budapest, Hungary.; Trojnar, E (corresponding author), Semmelweis Univ, Budapest, Hungary.	eszter.trojnar@gmail.com	Trojnar, Eszter/R-2833-2016; Jozsi, Mihaly/I-7872-2018; Csuka, Dorottya/F-2224-2010; Sinkovits, György/O-4613-2014	Trojnar, Eszter/0000-0002-3266-2477; Jozsi, Mihaly/0000-0002-5520-5535; Csuka, Dorottya/0000-0003-3610-9852; Sinkovits, György/0000-0002-5355-7318; Reti, Marienn/0000-0002-4682-5628; Reusz, Gyorgy/0000-0003-0396-043X	Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary; Human Capacities Grant Management Office [NTP-NFTO-18]; Hungarian Ministry of Human Capacities; National Research Fund (National Research, Development and Innovation Office) of Hungary [PD116119, K124549]; Hungarian Academy of Sciences [LP-2012/43]; Institutional Excellence Program of the Ministry of Human Capacities of Hungary;  [EFOP-3.6.3-VEKOP-16-2017-00009]	Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary; Human Capacities Grant Management Office; Hungarian Ministry of Human Capacities; National Research Fund (National Research, Development and Innovation Office) of Hungary; Hungarian Academy of Sciences(Hungarian Academy of Sciences); Institutional Excellence Program of the Ministry of Human Capacities of Hungary; 	The research was financed by the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the molecular biology thematic programme of Semmelweis University. ET received financial support from the NTP-NFTO-18 project by the Human Capacities Grant Management Office and the Hungarian Ministry of Human Capacities and the EFOP-3.6.3-VEKOP-16-2017-00009 grant. This work was partly supported by the grant of the National Research Fund (National Research, Development and Innovation Office) of Hungary, PD116119 to DC, and K124549 to GR. MJ was supported by the Hungarian Academy of Sciences (MTA Lendulet program, grant nr. LP-2012/43) and by the Institutional Excellence Program of the Ministry of Human Capacities of Hungary.	Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x; Bonacina F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/725102; Braunschweig A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023991; Daigo K, 2016, IMMUNOL REV, V274, P202, DOI 10.1111/imr.12476; de Bont CM, 2019, CELL MOL IMMUNOL, V16, P19, DOI 10.1038/s41423-018-0024-0; Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433; DELAMARCHE C, 1988, J IMMUNOL METHODS, V114, P101, DOI 10.1016/0022-1759(88)90160-3; Farkas P, 2017, IMMUNOBIOLOGY, V222, P119, DOI 10.1016/j.imbio.2016.10.014; FITZPATRICK MM, 1992, PEDIATR NEPHROL, V6, P50, DOI 10.1007/BF00856833; Fuchs TA, 2012, BLOOD, V120, P1157, DOI 10.1182/blood-2012-02-412197; Goldberg RJ, 2010, AM J KIDNEY DIS, V56, P1168, DOI 10.1053/j.ajkd.2010.06.006; He XL, 2007, AM J PHYSIOL-LUNG C, V292, pL1039, DOI 10.1152/ajplung.00490.2006; Hu CG, 2018, ONCOTARGET, V9, P5125, DOI 10.18632/oncotarget.23701; Hudzik B, 2013, J INTERF CYTOK RES, V33, P280, DOI 10.1089/jir.2012.0023; Inforzato A, 2013, SEMIN IMMUNOL, V25, P79, DOI 10.1016/j.smim.2013.05.002; Ishikawa N, 2000, PEDIATR INT, V42, P637, DOI 10.1046/j.1442-200x.2000.01309.x; Jaillon S, 2007, J EXP MED, V204, P793, DOI 10.1084/jem.20061301; Jokiranta TS, 2017, BLOOD, V129, P2847, DOI 10.1182/blood-2016-11-709865; Kavanagh D, 2013, SEMIN NEPHROL, V33, P508, DOI 10.1016/j.semnephrol.2013.08.003; Kocyigit I, 2014, J NEPHROL, V27, P181, DOI 10.1007/s40620-014-0045-4; Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357; Krzanowski M, 2017, POL ARCH INTERN MED, V127, P170, DOI 10.20452/pamw.3944; Kunes P, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/920517; Lech M, 2013, NEPHROL DIAL TRANSPL, V28, P803, DOI 10.1093/ndt/gfs448; Lech M, 2013, KIDNEY INT, V83, P647, DOI 10.1038/ki.2012.463; Lee YT, 2018, J INFECTION, V76, P1, DOI 10.1016/j.jinf.2017.10.016; Lin QH, 2013, HEART LUNG, V42, P139, DOI 10.1016/j.hrtlng.2012.11.005; Ma YJ, 2009, J BIOL CHEM, V284, P28263, DOI 10.1074/jbc.M109.009225; Ma YJ, 2011, J BIOL CHEM, V286, P3405, DOI 10.1074/jbc.M110.190637; Maekawa Yuichiro, 2011, Inflammation & Allergy Drug Targets, V10, P229; Maugeri N, 2011, J IMMUNOL, V187, P970, DOI 10.4049/jimmunol.1100261; Mikes B, 2014, THROMB RES, V133, P616, DOI 10.1016/j.thromres.2014.01.034; Nauta AJ, 2003, EUR J IMMUNOL, V33, P465, DOI 10.1002/immu.200310022; Noris M, 2012, NAT REV NEPHROL, V8, P622, DOI 10.1038/nrneph.2012.195; O'Flynn J, 2016, AM J PHYSIOL-RENAL, V310, pF1308, DOI 10.1152/ajprenal.00645.2014; Reti M, 2012, J THROMB HAEMOST, V10, P791, DOI 10.1111/j.1538-7836.2012.04674.x; ROTHER U, 1982, J IMMUNOL METHODS, V51, P101, DOI 10.1016/0022-1759(82)90386-6; Salio M, 2008, CIRCULATION, V117, P1055, DOI 10.1161/CIRCULATIONAHA.107.749234; Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612; Sjoberg B, 2014, CLIN KIDNEY J, V7, DOI 10.1093/ckj/sfu071; Souza DG, 2009, AM J PATHOL, V174, P1309, DOI 10.2353/ajpath.2009.080240; Souza DG, 2002, AM J PATHOL, V160, P1755, DOI 10.1016/S0002-9440(10)61122-4; Speeckaert MM, 2013, J CLIN IMMUNOL, V33, P881, DOI 10.1007/s10875-013-9879-0; Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754; Sun FF, 2018, CLIN RHEUMATOL, V37, P213, DOI 10.1007/s10067-017-3793-4; Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124; Trojnar E, 2018, MEMO-MAG EUR MED ONC, V11, P227, DOI 10.1007/s12254-017-0380-y; Trojnar E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00302; WALTERS MDS, 1989, PEDIATR NEPHROL, V3, P130, DOI 10.1007/BF00852893; Zhou Q, 2016, CHINESE MED J-PEKING, V129, P2589, DOI 10.4103/0366-6999.192785	50	2	2	0	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2019	10								240	10.3389/fimmu.2019.00240	http://dx.doi.org/10.3389/fimmu.2019.00240			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HM6SA	30858847	Green Published, gold			2022-12-18	WOS:000459606700001
J	Zhou, XJ; Verginis, P; Martinez, J; Radic, M				Zhou, Xu-jie; Verginis, Panayotis; Martinez, Jennifer; Radic, Marko			Editorial: Autophagy in Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						autophagy; autoimmunity; immunity; translational; human disease			[Zhou, Xu-jie] Peking Univ, Hosp 1, Renal Div, Beijing, Peoples R China; [Zhou, Xu-jie] Peking Univ, Inst Nephrol, Beijing, Peoples R China; [Zhou, Xu-jie] Minist Hlth China, Key Lab Renal Dis, Beijing, Peoples R China; [Zhou, Xu-jie] Peking Univ, Minist Educ, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing, Peoples R China; [Verginis, Panayotis] Acad Athens, Biomed Res Fdn, Athens, Greece; [Martinez, Jennifer] NIEHS, Durham, NC 27709 USA; [Radic, Marko] Univ Tennessee, Coll Med, Hlth Sci Ctr, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA	Peking University; Peking University; Peking University; Academy of Athens; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Tennessee System; University of Tennessee Health Science Center	Zhou, XJ (corresponding author), Peking Univ, Hosp 1, Renal Div, Beijing, Peoples R China.; Zhou, XJ (corresponding author), Peking Univ, Inst Nephrol, Beijing, Peoples R China.; Zhou, XJ (corresponding author), Minist Hlth China, Key Lab Renal Dis, Beijing, Peoples R China.; Zhou, XJ (corresponding author), Peking Univ, Minist Educ, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing, Peoples R China.; Verginis, P (corresponding author), Acad Athens, Biomed Res Fdn, Athens, Greece.; Martinez, J (corresponding author), NIEHS, Durham, NC 27709 USA.; Radic, M (corresponding author), Univ Tennessee, Coll Med, Hlth Sci Ctr, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA.	zhouxujie@bjmu.edu.cn; pverginis@bioacademy.gr; jennifer.martinez3@nih.gov; mradic@uthsc.edu	Zhou, Xu-jie/A-3740-2012	Zhou, Xu-jie/0000-0002-7215-707X; Radic, Marko/0000-0002-8004-282X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES103286] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))			0	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 25	2019	10								301	10.3389/fimmu.2019.00301	http://dx.doi.org/10.3389/fimmu.2019.00301			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HM6SO	30873167	Green Published, gold			2022-12-18	WOS:000459608100001
J	Zwick, M; Ulas, T; Cho, YL; Ried, C; Grosse, L; Simon, C; Bernhard, C; Busch, DH; Schultze, JL; Buchholz, VR; Stutte, S; Brocker, T				Zwick, Markus; Ulas, Thomas; Cho, Yi-Li; Ried, Christine; Grosse, Leonie; Simon, Charlotte; Bernhard, Caroline; Busch, Dirk H.; Schultze, Joachim L.; Buchholz, Veit R.; Stutte, Susanne; Brocker, Thomas			Expression of the Phosphatase Ppef2 Controls Survival and Function of CD8(+) Dendritic Cells	FRONTIERS IN IMMUNOLOGY			English	Article						apoptosis; CD8T cell priming; cross-presentation; dendritic cells; immune homeostasis; DC-maturation	ACTIVATION-INDUCED CYTOKINE; TUMOR-NECROSIS-FACTOR; STEADY-STATE; T-CELLS; RETINAL DEGENERATION; SIGNALING CONTROLS; GENE-EXPRESSION; KAPPA-B; APOPTOSIS; ANTIGEN	Apoptotic cell death of Dendritic cells (DCs) is critical for immune homeostasis. Although intrinsic mechanisms controlling DC death have not been fully characterized up to now, experimentally enforced inhibition of DC-death causes various autoimmune diseases in model systems. We have generated mice deficient for Protein Phosphatase with EF-Hands 2 (Ppef2), which is selectively expressed in CD8(+) DCs, but not in other related DC subtypes such as tissue CD103(+) DCs. Ppef2 is down-regulated rapidly upon maturation of DCs by toll-like receptor stimuli, but not upon triggering of CD40. Ppef2-deficient CD8(+) DCs accumulate the pro-apoptotic Bcl-2-like protein 11 (Bim) and show increased apoptosis and reduced competitve repopulation capacities. Furthermore, Ppef2(-/-) CD8(+) DCs have strongly diminished antigen presentation capacities in vivo, as CD8(+) T cells primed by Ppef2(-/-) CD8(+) DCs undergo reduced expansion. In conclusion, our data suggests that Ppef2 is crucial to support survival of immature CD8(+) DCs, while Ppef2 down-regulation during DC-maturation limits T cell responses.	[Zwick, Markus; Ried, Christine; Grosse, Leonie; Simon, Charlotte; Bernhard, Caroline; Stutte, Susanne; Brocker, Thomas] Ludwig Maximilians Univ Munchen, Inst Immunol, Fac Med, Biomed Ctr BMC, Planegg Martinsried, Germany; [Ulas, Thomas; Schultze, Joachim L.] Life & Med Sci Inst, Bonn, Germany; [Cho, Yi-Li; Busch, Dirk H.; Buchholz, Veit R.] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; [Schultze, Joachim L.] German Ctr Neurodegenerat Dis DZNE, PRECISE Platform Single Cell Genom & Epigen, Bonn, Germany; [Schultze, Joachim L.] Univ Bonn, Bonn, Germany	University of Munich; University of Bonn; Technical University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Bonn	Stutte, S; Brocker, T (corresponding author), Ludwig Maximilians Univ Munchen, Inst Immunol, Fac Med, Biomed Ctr BMC, Planegg Martinsried, Germany.	susanne.stutte@med.uni-muenchen.de; tbrocker@med.uni-muenchen.de	Buchholz, Veit R./AAF-6966-2021; Schultze, Joachim L./ABA-8176-2020	Buchholz, Veit R./0000-0003-0441-3913; Schultze, Joachim L./0000-0003-2812-9853; Brocker, Thomas/0000-0001-7060-5433	Deutsche Forschungsgemeinschaft [SFB 914 A06, SFB1054 B03, SFB1054 B09]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft SFB 914 A06 to SS and TB, SFB1054 B03 to TB and SFB1054 B09 to DB.	Andreeva AV, 2009, CELL MOL LIFE SCI, V66, P3103, DOI 10.1007/s00018-009-0110-7; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724; Birnberg T, 2008, IMMUNITY, V29, P986, DOI 10.1016/j.immuni.2008.10.012; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Caton ML, 2007, J EXP MED, V204, P1653, DOI 10.1084/jem.20062648; Chen M, 2006, SCIENCE, V311, P1160, DOI 10.1126/science.1122545; Chen M, 2007, BLOOD, V109, P4360, DOI 10.1182/blood-2006-11-056424; Daniels NJ, 2016, MUCOSAL IMMUNOL, V9, P229, DOI 10.1038/mi.2015.55; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Edelmann SL, 2011, BLOOD, V118, pE40, DOI 10.1182/blood-2011-03-342261; Eickhoff S, 2015, CELL, V162, P1322, DOI 10.1016/j.cell.2015.08.004; Gilbert RW, 2003, J CEREBR BLOOD F MET, V23, P1195, DOI 10.1097/01.WCB.0000088763.02615.79; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Hermans IF, 2000, J IMMUNOL, V164, P3095, DOI 10.4049/jimmunol.164.6.3095; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hou WS, 2004, NAT IMMUNOL, V5, P583, DOI 10.1038/ni1071; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; Kabashima K, 2005, IMMUNITY, V22, P439, DOI 10.1016/j.immuni.2005.02.007; Kushwah R, 2010, J IMMUNOL, V185, P795, DOI 10.4049/jimmunol.1000325; Kutuzov MA, 2002, BIOCHEM BIOPH RES CO, V293, P1047, DOI 10.1016/S0006-291X(02)00338-8; Kutuzov MA, 2010, INT J BIOCHEM CELL B, V42, P1816, DOI 10.1016/j.biocel.2010.07.014; Lattin Jane E, 2008, Immunome Res, V4, P5, DOI 10.1186/1745-7580-4-5; Lewis KL, 2011, IMMUNITY, V35, P780, DOI 10.1016/j.immuni.2011.08.013; Liu K, 2007, NAT IMMUNOL, V8, P578, DOI 10.1038/ni1462; Liu K, 2009, SCIENCE, V324, P392, DOI 10.1126/science.1170540; Lu E, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal5237; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Maillard I, 2005, ANNU REV IMMUNOL, V23, P945, DOI 10.1146/annurev.immunol.23.021704.115747; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Montini E, 1997, HUM MOL GENET, V6, P1137, DOI 10.1093/hmg/6.7.1137; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Murphy TL, 2016, ANNU REV IMMUNOL, V34, P93, DOI 10.1146/annurev-immunol-032713-120204; Naik SH, 2006, NAT IMMUNOL, V7, P663, DOI 10.1038/ni1340; NIKOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431, DOI 10.1002/eji.1830201111; Nopora A, 2002, J IMMUNOL, V169, P3006, DOI 10.4049/jimmunol.169.6.3006; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Sullivan BJ, 2002, J IMMUNOL, V168, P5491, DOI 10.4049/jimmunol.168.11.5491; Park D, 2006, NAT BIOTECHNOL, V24, P1581, DOI 10.1038/nbt1262; Prlic M, 2006, J EXP MED, V203, P2135, DOI 10.1084/jem.20060928; Ramulu P, 2001, MOL CELL BIOL, V21, P8605, DOI 10.1128/MCB.21.24.8605-8614.2001; Ramulu P, 2001, J BIOL CHEM, V276, P25127, DOI 10.1074/jbc.M011712200; Riepsaame J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00353; Riol-Blanco L, 2009, NAT IMMUNOL, V10, P753, DOI 10.1038/ni.1750; Sanchez PJ, 2007, J IMMUNOL, V178, P1564, DOI 10.4049/jimmunol.178.3.1564; Shutter JR, 2000, GENE DEV, V14, P1313; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Skokos D, 2007, J EXP MED, V204, P1525, DOI 10.1084/jem.20062305; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; Stranges PB, 2007, IMMUNITY, V26, P629, DOI 10.1016/j.immuni.2007.03.016; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Thompson S, 2011, J BIOL CHEM, V286, P19331, DOI 10.1074/jbc.M110.197707; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; Waskow C, 2008, NAT IMMUNOL, V9, P676, DOI 10.1038/ni.1615; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118	59	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 12	2019	10								222	10.3389/fimmu.2019.00222	http://dx.doi.org/10.3389/fimmu.2019.00222			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HL3BY	30809231	Green Published, gold, Green Accepted, Green Submitted			2022-12-18	WOS:000458587400001
J	Wendering, DJ; Amini, L; Schlickeiser, S; Reinke, P; Volk, HD; Schmueck-Henneresse, M				Wendering, Desiree J.; Amini, Leila; Schlickeiser, Stephan; Reinke, Petra; Volk, Hans-Dieter; Schmueck-Henneresse, Michael			The Value of a Rapid Test of Human Regulatory T Cell Function Needs to be Revised	FRONTIERS IN IMMUNOLOGY			English	Article						regulatory T cell functional assay; alpha CD3/28-coated microbeads; competitive CD3/CD28 binding; nullified Treg-mediated suppression; correlation between T cell-to-alpha CD3/CD28-coated microbead ratio; activation marker frequency on responder T cells		CD4(+)CD25(+)FoxP3(+) human regulatory T-CELLS (T-REG) are promising candidates for reshaping undesired immunity/inflammation by adoptive cell transfer, yet their application is strongly dependent on robust assays testing their functionality. Several studies along with first clinical data indicate T-REG to be auspicious to use for future cell therapies, e.g., to induce tolerance after solid organ transplantation. To this end, T-REG suppressive capacity has to be thoroughly evaluated prior to any therapeutic application. A 7 h-protocol for the assessment of T-REG function by suppression of the early activation markers CD154 and CD69 on CD4(+)CD25(-) responder T-CELLS (T-RESP) upon polyclonal stimulation via alpha CD3/28-coated activating microbeads has previously been published. Even though this assay has since been applied by various groups, the protocol comes with a critical pitfall, which is yet not corrected by the journal of its original publication. Our results demonstrate that the observed decrease in activation marker frequency on T-RESP is due to competition for alpha CD3/28-coated microbeads as opposed to a T-REG-attributable effect and therefore the protocol cannot further be used as a diagnostic test to assess suppressive TREG function.	[Wendering, Desiree J.; Amini, Leila; Schlickeiser, Stephan; Volk, Hans-Dieter; Schmueck-Henneresse, Michael] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany; [Wendering, Desiree J.; Amini, Leila; Reinke, Petra; Volk, Hans-Dieter; Schmueck-Henneresse, Michael] Charite Univ Med Berlin, Berlin Ctr Adv Therapies BeCAT, Berlin, Germany; [Wendering, Desiree J.; Amini, Leila; Schlickeiser, Stephan; Reinke, Petra; Volk, Hans-Dieter; Schmueck-Henneresse, Michael] Charite Univ Med Berlin, BIH, Ctr Regenerat Therapies B CRT, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schmueck-Henneresse, M (corresponding author), Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany.; Schmueck-Henneresse, M (corresponding author), Charite Univ Med Berlin, Berlin Ctr Adv Therapies BeCAT, Berlin, Germany.; Schmueck-Henneresse, M (corresponding author), Charite Univ Med Berlin, BIH, Ctr Regenerat Therapies B CRT, Berlin, Germany.	michael.schmueck-henneresse@charite.de	Amini, Leila/AAV-8042-2021; volk, hans-dieter/AAV-8053-2021	Amini, Leila/0000-0003-4855-5905; volk, hans-dieter/0000-0002-7743-6668; Schmueck-Henneresse, Michael/0000-0001-5964-9179; Reinke, Petra/0000-0003-0771-4375; Schlickeiser, Stephan/0000-0003-3142-2890; Wendering, Desiree Jacqueline/0000-0002-1399-787X	Deutsche Forschungsgemeinschaft (DFG) [SFB-TR36]; German Federal Ministry of Education and Research (Berlin-Brandenburg Center for Regenerative Therapies); German Research Foundation (DFG); Open Access Publication Fund of Charite-Universitatsmedizin Berlin	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (Berlin-Brandenburg Center for Regenerative Therapies); German Research Foundation (DFG)(German Research Foundation (DFG)); Open Access Publication Fund of Charite-Universitatsmedizin Berlin	The study was generously supported in parts by the Deutsche Forschungsgemeinschaft (DFG-SFB-TR36-project A3-H-DV, PR, and MS-H) and the German Federal Ministry of Education and Research (Berlin-Brandenburg Center for Regenerative Therapies grant-all authors). We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charite-Universitatsmedizin Berlin.	Brusko Todd M, 2007, Immunol Invest, V36, P607, DOI 10.1080/08820130701790368; Canavan JB, 2012, BLOOD, V119, pE57, DOI 10.1182/blood-2011-09-380048; Desreumaux P, 2012, GASTROENTEROLOGY, V143, P1207, DOI 10.1053/j.gastro.2012.07.116; Landwehr-Kenzel S, 2014, AM J TRANSPLANT, V14, P594, DOI 10.1111/ajt.12629; Noguchi K, 2012, J STAT SOFTW, V50, P1, DOI 10.18637/jss.v050.i12; Pedersen AE, 2015, IMMUNOPHARM IMMUNOT, V37, P63, DOI 10.3109/08923973.2014.977449; R.C. Team, 2017, R LANG ENV STAT COMP; Ruhnau J, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/2974605; Ruitenberg JJ, 2011, J IMMUNOL METHODS, V372, P95, DOI 10.1016/j.jim.2011.07.001; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Venken K, 2007, J IMMUNOL METHODS, V322, P1, DOI 10.1016/j.jim.2007.01.025	11	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 5	2019	10								150	10.3389/fimmu.2019.00150	http://dx.doi.org/10.3389/fimmu.2019.00150			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HK3GN	30804944	Green Published, gold			2022-12-18	WOS:000457801500002
J	de Souza, PRK; Ferreira, SS; Nunes, FPB; Casagrande, FB; Tessaro, FHG; Silva, MCF; Cruz, JWMC; Mamizuka, EM; Martins, JO				Knox de Souza, Paula R.; Ferreira, Sabrina S.; Nunes, Fernanda P. B.; Casagrande, Felipe B.; Tessaro, Fernando H. G.; Silva, Mariana C. F.; Miranda Costa Cruz, Jose Walber; Mamizuka, Elsa M.; Martins, Joilson O.			Cytokine and Adhesion Molecule Expression Induced by Different Strains of Staphylococcus aureus in Type 1 Diabetic Rats: Role of Insulin	FRONTIERS IN IMMUNOLOGY			English	Article						insulin; Staphylococcus aureus; diabetes mellitus; peritonitis; inflammation; cytokines; innate immune response	PHAGOCYTOSIS; INFLAMMATION; MIGRATION; PERITONITIS; NEUTROPHILS; MELLITUS; IMPROVES; SEPSIS; CELLS	Introduction: Staphylococcus aureus may provoke peritonitis and death, especially in immunocompromized individuals such as diabetic patients. We evaluated the role of insulin in S. aureus-induced peritoneal infection in diabetic and non-diabetic rats. Materials/Methods: Alloxan-diabetic male Wistar rats and their respective controls received intraperitoneal injections of different strains of S. aureus or sterile phosphate-buffered saline. After 3 days of infection, the first set of diabetic and non-diabetic rats received 4 and 1 IU, respectively, of neutral protamine Hagedorn insulin and were analyzed 8 h later. The second set of diabetic and non-diabetic rats received 4 and 1 IU, respectively, of insulin 2 h before intraperitoneal infection and a half dose of insulin at 5 p.m. for the next 2 days and were analyzed 16 h later. The following measurements were performed: (a) number of cells in the peritoneal lavage fluid (PeLF), white blood cell count, and blood glucose; (b) serum insulin and corticosterone; (c) cytokine levels in the PeLF; (d) expression of adhesion molecules in the vascular endothelium; and (e) microbicidal activity. Results: Diabetic rats showed an increased number of polymorphonuclear leukocytes (PMNs) and increased concentrations of CINC-1, IL-4, and IFN-gamma in the PeLF after infection with the ATCC 25923 or N315 alpha HL+ strain. The mesenteric expression of PECAM-1 was increased after infection with the N315 HLA(+) strain. ICAM-1 expression was increased with ATCC infection. Treatment of diabetic rats with a single dose of insulin restored CINC-1 levels in the PeLF for both strains; however, PMN migration, IL-4, and IFN-gamma were restored in rats infected with the ATCC strain, whereas the PeLF concentrations of CINC-2, IL-1 beta, and IL-4 were increased in N315-infected animals. Insulin restored PMN migration and CINC-2 levels in the PeLF in ATCC-infected rats. After multiple treatments with insulin, the levels of IL-1 beta, IL-6, and IFN-gamma were increased in the PeLF of diabetic rats after infection with either strain, and CINC-2 levels were restored in N315-infected animals. Conclusion: These results suggest that insulin distinctively modulates cytokine production or release, PMN leukocyte migration, and adhesion molecule expression during the course of peritonitis induced by different strains of S. aureus.	[Knox de Souza, Paula R.; Ferreira, Sabrina S.; Nunes, Fernanda P. B.; Casagrande, Felipe B.; Tessaro, Fernando H. G.; Silva, Mariana C. F.; Martins, Joilson O.] Univ Sao Paulo, Sch Pharmaceut Sci FCF, Dept Clin & Toxicol Anal, Lab Immunoendocrinol, Sao Paulo, Brazil; [Knox de Souza, Paula R.] Univ Paulista, Sao Paulo, Brazil; [Miranda Costa Cruz, Jose Walber] Univ Fed Sao Paulo, Dept Bioquim, Sao Paulo, Brazil; [Mamizuka, Elsa M.] Univ Sao Paulo, Sch Pharmaceut Sci FCF, Dept Clin & Toxicol Anal, Lab Microbiol, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Paulista; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo	Martins, JO (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci FCF, Dept Clin & Toxicol Anal, Lab Immunoendocrinol, Sao Paulo, Brazil.	martinsj@usp.br	Martins, Joilson O./G-4367-2011; Tessaro, Fernando/T-6377-2019	Martins, Joilson O./0000-0003-2630-7038; Ferreira, Sabrina/0000-0002-1779-8528; tessaro, fernando/0000-0002-0389-5976; Casagrande, Felipe/0000-0003-1117-4754	Sao Paulo Research Foundation (FAPESP) [2010/02272-0, 2012/06652-7, 2012/066177, 2014/05214-1, 2017/11540-7]; National Council for Technological and Scientific Development (CNPq; Projeto Universal 2013) [470523/2013-1, 301617/2016-3]; National Council for Technological and Scientific Development (CNPq; PQ-1D) [470523/2013-1, 301617/2016-3]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Pro-reitoria de Pesquisa da Universidade de Sao Paulo (PRP/USP, Projeto I); Pro-reitoria de Pesquisa da Universidade de Sao Paulo (PRP/USP, Novos Docentes)	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Council for Technological and Scientific Development (CNPq; Projeto Universal 2013)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); National Council for Technological and Scientific Development (CNPq; PQ-1D); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Pro-reitoria de Pesquisa da Universidade de Sao Paulo (PRP/USP, Projeto I); Pro-reitoria de Pesquisa da Universidade de Sao Paulo (PRP/USP, Novos Docentes)	The authors sincerely thank Irene M. Gouveia and Silene Migliorini for her expert technical help. The authors are supported by grants 2010/02272-0, 2012/06652-7, 2012/066177, 2014/05214-1, and 2017/11540-7 provided by the Sao Paulo Research Foundation (FAPESP); and grants 470523/2013-1 and 301617/2016-3 provided by the National Council for Technological and Scientific Development (CNPq; Projeto Universal 2013 and PQ-1D), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and Pro-reitoria de Pesquisa da Universidade de Sao Paulo (PRP/USP, Projeto I and Novos Docentes).	Alba-Loureiro TC, 2006, J ENDOCRINOL, V188, P295, DOI 10.1677/joe.1.06438; Alonzo F, 2013, NATURE, V493, P51, DOI 10.1038/nature11724; Anderson AS, 2012, HUM VACC IMMUNOTHER, V8, P1585, DOI 10.4161/hv.21872; Binesse J, 2015, INFECT IMMUN, V83, P2255, DOI 10.1128/IAI.02488-14; CALAME W, 1995, PERITON DIALYSIS INT, V15, P320; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; D'Ambrosio D, 2003, J IMMUNOL METHODS, V273, P3, DOI 10.1016/S0022-1759(02)00414-3; de Almeida LM, 2013, BRAZ J MICROBIOL, V44, P493, DOI 10.1590/S1517-83822013000200026; Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V; Dey S, 2015, J INFLAMM RES, V8, P29, DOI 10.2147/JIR.S76045; Di Petta A, 2011, INT J EXP PATHOL, V92, P392, DOI 10.1111/j.1365-2613.2011.00787.x; Fieren MWJA, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/976241; Geerlings SE, 1999, FEMS IMMUNOL MED MIC, V26, P259, DOI 10.1111/j.1574-695X.1999.tb01397.x; Govindarajulu S, 2010, PERITON DIALYSIS INT, V30, P311, DOI 10.3747/pdi.2008.00258; Greenlee-Wacker MC, 2014, J IMMUNOL, V192, P4709, DOI 10.4049/jimmunol.1302692; Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002; Hanke ML, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00062; Hanses F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023633; Hausmann MJ, 2000, KIDNEY INT, V57, P476, DOI 10.1046/j.1523-1755.2000.00867.x; Ip WKE, 2010, J IMMUNOL, V184, P7071, DOI 10.4049/jimmunol.1000110; Kumar S, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-9; Laval G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010284; Lawson C, 2009, PHARMACOL REP, V61, P22, DOI 10.1016/S1734-1140(09)70004-0; Lerco Mauro Masson, 2003, Acta Cir. Bras., V18, P132, DOI 10.1590/S0102-86502003000200010; Liu Y, 2004, J IMMUNOL, V172, P7, DOI 10.4049/jimmunol.172.1.7; Liu Y, 2018, NAT MICROBIOL, V3, P622, DOI 10.1038/s41564-018-0146-2; Martins JD, 2006, SHOCK, V25, P260, DOI 10.1097/01.shk.0000194042.18699.b4; Martins JO, 2009, SHOCK, V31, P404, DOI 10.1097/SHK.0b013e318186275e; Mauriello CT, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/762051; McLoughlin RM, 2008, J IMMUNOL, V181, P1323, DOI 10.4049/jimmunol.181.2.1323; Monecke S, 2007, CLIN MICROBIOL INFEC, V13, P236, DOI 10.1111/j.1469-0691.2006.01635.x; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Moutzouri AG, 2008, J INFECTION, V57, P147, DOI 10.1016/j.jinf.2008.04.004; Muller WA, 2009, CIRC RES, V105, P223, DOI 10.1161/CIRCRESAHA.109.200717; Nanra JS, 2013, HUM VACC IMMUNOTHER, V9, P480, DOI 10.4161/hv.23223; Netsvyetayeva I, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-128; Nielsen A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084992; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; Onogawa T, 2002, FEMS IMMUNOL MED MIC, V33, P15, DOI 10.1111/j.1574-695X.2002.tb00566.x; Osuchowski MF, 2018, SHOCK, V50, P377, DOI 10.1097/SHK.0000000000001212; Osuchowski MF, 2010, SHOCK, V34, P369, DOI 10.1097/SHK.0b013e3181dc40a8; Otto M, 2014, CURR OPIN MICROBIOL, V17, P32, DOI 10.1016/j.mib.2013.11.004; Panneerselvam S, 2003, CHEM-BIOL INTERACT, V145, P159, DOI 10.1016/S0009-2797(02)00254-5; Peleg AY, 2007, DIABETES-METAB RES, V23, P3, DOI 10.1002/dmrr.682; Pettersson US, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022480; Pongcharoen S, 2011, SE ASIAN J TROP MED, V42, P1197; Rauch S, 2012, INFECT IMMUN, V80, P3721, DOI 10.1128/IAI.00442-12; Rigby KM, 2012, SEMIN IMMUNOPATHOL, V34, P237, DOI 10.1007/s00281-011-0295-3; Scherr TD, 2015, MBIO, V6, DOI 10.1128/mBio.01021-15; Shibata F, 1996, CYTOKINE, V8, P222, DOI 10.1006/cyto.1996.0031; Slee AD, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-36; Spatz M, 2003, CELL IMMUNOL, V221, P15, DOI 10.1016/S0008-8749(03)00043-1; Stapels DAC, 2014, P NATL ACAD SCI USA, V111, P13187, DOI 10.1073/pnas.1407616111; Szeto CC, 2007, NEPHROL DIAL TRANSPL, V22, P1697, DOI 10.1093/ndt/gfl834; Thay B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054661; Watters C, 2014, INFECT IMMUN, V82, P92, DOI 10.1128/IAI.00651-13; Welten AGA, 2004, NEPHROL DIAL TRANSPL, V19, P831, DOI 10.1093/ndt/gfh024; Xiu F, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/486403; Yadav R, 2003, THROMB HAEMOSTASIS, V90, P598, DOI 10.1160/TH03-04-0220; Yano H, 2012, INFECT IMMUN, V80, P4409, DOI 10.1128/IAI.00787-12; Yung S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/484167; Zhang HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032746	62	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 17	2019	9								3165	10.3389/fimmu.2018.03165	http://dx.doi.org/10.3389/fimmu.2018.03165			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HH8BV	30705678	gold, Green Published			2022-12-18	WOS:000455957500001
J	Chen, YY; Xiao, JN; Li, Y; Xiao, YJ; Xiong, YQ; Liu, Y; Wang, SJ; Ji, P; Zhao, GP; Shen, H; Lu, SH; Fan, XY; Wang, Y				Chen, Yingying; Xiao, Jia-ni; Li, Yong; Xiao, Yang-jiong; Xiong, Yan-qing; Liu, Ying; Wang, Shu-jun; Ji, Ping; Zhao, Guo-ping; Shen, Hao; Lu, Shui-hua; Fan, Xiao-yong; Wang, Ying			Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against Mycobacterium tuberculosis Infection	FRONTIERS IN IMMUNOLOGY			English	Article						lipoprotein Z; tuberculosis; innate immunity; T cell immunity; immune protection	CD8(+) T-CELLS; ANTIGEN; VACCINE; IDENTIFICATION; PROTEINS; EFFICACY; AG85A; MODEL	Mycobacterial lipoproteins are considered to be involved in both virulence and immunoregulatory processes during Mycobacterium tuberculosis (M. tb) infection. In our previous investigations on the immunoreactivity of more than 30 M. tb proteins in active TB patients, we identified mycobacterial lipoprotein Z (LppZ) as one of the most immune dominant antigens. How LppZ triggers immune responses is still unclear. In this study, we analyzed LppZ-mediated innate and adaptive immunity using a murine air pouch model and an M. tb infection model, respectively. We found that LppZ could not only recruit inflammatory cells but also induce the production of proinflammatory cytokines inside the pouches. LppZ could also induce strong Th1 responses following immunization and confer protection against challenge with M. tb virulent strain H37Rv at a similar level to BCG vaccination but with less pathological damage in the lungs. Furthermore, we revealed the presence of LppZ-specific functional CD4(+) T cells in the lungs of the challenged mice that were capable of secreting double or triple cytokines, including IFN-gamma, IL-2, and TNF-alpha. Our study thus demonstrates that LppZ is of strong immunogenicity during M. tb infection in both humans and mice and has the ability to trigger effective innate and cellular immunity. Considering the limitations of candidate antigens in the pipeline of TB vaccine development, LppZ-mediated immune protection against M. tb challenge in the mouse model implies its potential application in vaccine development.	[Chen, Yingying; Xiao, Jia-ni; Li, Yong; Xiao, Yang-jiong; Liu, Ying; Wang, Shu-jun; Ji, Ping; Shen, Hao; Wang, Ying] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Microbiol & Immunol, Shanghai, Peoples R China; [Xiong, Yan-qing; Lu, Shui-hua; Fan, Xiao-yong] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Key Lab Med Mol Virol MOE MOH, Shanghai, Peoples R China; [Zhao, Guo-ping; Wang, Ying] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Hlth & Dis Genom, Shanghai, Peoples R China; [Shen, Hao] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Fan, Xiao-yong] Fudan Univ, Shanghai Emerging & Reemerging Infect Dis Inst, TB Ctr, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Fudan University; University of Pennsylvania; Pennsylvania Medicine; Fudan University	Wang, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Microbiol & Immunol, Shanghai, Peoples R China.; Fan, XY (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Key Lab Med Mol Virol MOE MOH, Shanghai, Peoples R China.; Wang, Y (corresponding author), Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Hlth & Dis Genom, Shanghai, Peoples R China.; Fan, XY (corresponding author), Fudan Univ, Shanghai Emerging & Reemerging Infect Dis Inst, TB Ctr, Shanghai, Peoples R China.	xyfan008@fudan.edu.cn; ywang@sibs.ac.cn	shen, hao/HGF-0551-2022; Xiao, Yangjiong/AAK-4706-2020; Xiao, Yangjiong/AAZ-3823-2020	Zhao, Guo-Ping/0000-0002-7621-6620	Chinese National Mega Science and Technology Program on Infectious Diseases [2018ZX10731301, 2018ZX10302301, 2013ZX10003007]; Shanghai Academic Research Leader Project [2018XD1403300]; National Natural Science Foundation of China [81501361, 81873868, 31771004]; Fundamental Research Funds for the Central Universities [17X100040012]; Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine [BXJ201803]	Chinese National Mega Science and Technology Program on Infectious Diseases; Shanghai Academic Research Leader Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine	This work was supported by grants from Chinese National Mega Science and Technology Program on Infectious Diseases (2018ZX10731301, 2018ZX10302301, and 2013ZX10003007), Shanghai Academic Research Leader Project (2018XD1403300), the National Natural Science Foundation of China (81501361, 81873868, and 31771004), the Fundamental Research Funds for the Central Universities (17X100040012) and Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine (BXJ201803).	Behar SM, 2013, ADV EXP MED BIOL, V783, P141, DOI 10.1007/978-1-4614-6111-1_8; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Bower MA, 2008, EXP PARASITOL, V118, P569, DOI 10.1016/j.exppara.2007.11.014; Clay H, 2008, IMMUNITY, V29, P283, DOI 10.1016/j.immuni.2008.06.011; COOPER AM, 1995, CURR OPIN IMMUNOL, V7, P512, DOI 10.1016/0952-7915(95)80096-4; Dalmia N, 2012, EXPERT REV VACCINES, V11, P1221, DOI [10.1586/erv.12.94, 10.1586/ERV.12.94]; de Souza GA, 2011, J PROTEOMICS, V75, P502, DOI 10.1016/j.jprot.2011.08.016; Fine PEM, 1998, NOVART FDN SYMP, V217, P57, DOI 10.1002/0470846526.ch5; Frick M., 2015, TUBERCULOSIS VACCINE; GARBE T, 1993, INFECT IMMUN, V61, P260, DOI 10.1128/IAI.61.1.260-267.1993; Gaur RL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004376; Gehring AJ, 2004, J IMMUNOL, V173, P2660, DOI 10.4049/jimmunol.173.4.2660; Hu ZD, 2017, MOL THER, V25, P1222, DOI 10.1016/j.ymthe.2017.02.018; HUYGEN K, 1992, INFECT IMMUN, V60, P2880, DOI 10.1128/IAI.60.7.2880-2886.1992; HUYGEN K, 1994, INFECT IMMUN, V62, P363, DOI 10.1128/IAI.62.2.363-370.1994; Jung YJ, 2002, INFECT IMMUN, V70, P6436, DOI 10.1128/IAI.70.11.6436-6443.2002; Kang H, 2014, IMMUNOLOGY, V143, P661, DOI 10.1111/imm.12348; Kong HM, 2014, HUM VACC IMMUNOTHER, V10, P378, DOI 10.4161/hv.27121; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; LAUNOIS P, 1994, INFECT IMMUN, V62, P3679, DOI 10.1128/IAI.62.9.3679-3687.1994; Leroux-Roels I, 2013, VACCINE, V31, P2196, DOI 10.1016/j.vaccine.2012.05.035; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Liu WB, 2017, INT IMMUNOPHARMACOL, V53, P83, DOI 10.1016/j.intimp.2017.10.015; Lopez M, 2003, J IMMUNOL, V170, P2409, DOI 10.4049/jimmunol.170.5.2409; Maione F, 2009, BIOCHEM PHARMACOL, V77, P878, DOI 10.1016/j.bcp.2008.11.011; Malen H, 2008, SCAND J IMMUNOL, V67, P245, DOI 10.1111/j.1365-3083.2007.02064.x; Malen H, 2007, PROTEOMICS, V7, P1702, DOI 10.1002/pmic.200600853; Nieuwenhuizen NE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00121; Cavalcanti YVN, 2012, PULM MED, V2012, DOI 10.1155/2012/745483; Ottenhoff THM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002607; Sanchez A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/950503; Sartain MJ, 2006, MOL CELL PROTEOMICS, V5, P2102, DOI 10.1074/mcp.M600089-MCP200; Schwander S, 2011, AM J RESP CRIT CARE, V183, P696, DOI 10.1164/rccm.201006-0963PP; Scriba TJ, 2010, EUR J IMMUNOL, V40, P279, DOI 10.1002/eji.200939754; Sethi D, 2016, J BIOL CHEM, V291, P2938, DOI 10.1074/jbc.M115.662593; Sutcliffe IC, 2004, FEMS MICROBIOL REV, V28, P645, DOI 10.1016/j.femsre.2004.06.002; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Tascon RE, 1998, INFECT IMMUN, V66, P830, DOI 10.1128/IAI.66.2.830-834.1998; Turner O, 2003, GRANULOMATOUS INFECT; Van der Meeren O, 2018, NEW ENGL J MED, V379, P1621, DOI 10.1056/NEJMoa1803484; Wang X, 2015, 3RD INTERNATIONAL CONFERENCE ON ADVANCED COMPOSITE MATERIALS AND MANUFACTURING ENGINEERING (CMME 2015), P10; Weiss G, 2015, IMMUNOL REV, V264, P182, DOI 10.1111/imr.12266; World Health Organization, 2017, GLOB TUB REP 2017; Wu CY, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002703; Xiao JN, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00495; Xiao YJ, 2016, J MOL MED, V94, P823, DOI 10.1007/s00109-016-1392-5; Xiong Y, 2005, J PROTEOME RES, V4, P855, DOI 10.1021/pr0500049; Yang XY, 2017, TUBERCULOSIS, V107, P119, DOI 10.1016/j.tube.2017.08.005; YOSHINO S, 1984, BRIT J EXP PATHOL, V65, P201	49	2	4	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 16	2019	9								3190	10.3389/fimmu.2018.03190	http://dx.doi.org/10.3389/fimmu.2018.03190			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HH5WH	30700988	gold, Green Published			2022-12-18	WOS:000455798700001
J	Maiden, MCJ				Maiden, Martin Christopher James			The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment	FRONTIERS IN IMMUNOLOGY			English	Review						Neisseria meningitidis; conjugate polysaccharide vaccines; outer membrane vesicle vaccines; population biology; herd immunity; efficacy	OUTER-MEMBRANE PROTEIN; HORIZONTAL GENETIC EXCHANGE; AFRICAN MENINGITIS BELT; NEISSERIA-MENINGITIDIS; SEROGROUP-B; CONJUGATE VACCINE; STRAIN COVERAGE; CARRIAGE; DISEASE; POPULATION	Since it became available as a routine tool in biology, the determination and analysis of nucleotide sequences has been applied to the design of vaccines and the investigation of their effectiveness. As vaccination is primarily concerned with the interaction of biological molecules with the immune system, the utility of sequence data is not immediately obvious and, indeed, nucleotide sequence data are most effective when used to complement more conventional immunological approaches. Here, the impact of sequencing on the field of vaccinology will be illustrated with reference to the development and implementation of vaccines against Neisseria meningitidis (the meningococcus) over the 30-year period from the late-1980s to the late-2010s. Nucleotide sequence-based studies have been important in the fight against this aggressive pathogen largely because of its high genetic and antigenic diversity, properties that were only fully appreciated because of sequence-based studies. Five aspects will be considered, the use of sequence data to: (i) discover vaccine antigens; (ii) assess the diversity and distribution of vaccine antigens; (iii) determine the evolutionary and population biology of the organism and their implications for immunization; and (iv) develop molecular approaches to investigate pre- and post-vaccine pathogen populations to assess vaccine impact. One of the great advantages of nucleotide sequence data has been its scalability, which has meant that increasingly large data sets have been available, which has proved invaluable in the investigation of an organism as diverse and enigmatic as the meningococcus.	[Maiden, Martin Christopher James] Univ Oxford, Dept Zool, Oxford, England	University of Oxford	Maiden, MCJ (corresponding author), Univ Oxford, Dept Zool, Oxford, England.	martin.maiden@zoo.ox.ac.uk	Maiden, Martin C J/C-5055-2014	Maiden, Martin C J/0000-0001-6321-5138	Alexander von Humboldt Stiftung; European Union [QLK2-CT-2001-01436, FP7-278864-2]; Wellcome Trust [047072/Z/96/B, 047072/Z/96/C, 062057/Z/00/Z, 081494/Z/06/Z, 087622/Z/08/A, 086546/Z/08/Z, 091634/Z/10/Z, 104992/Z/14/Z]; Meningitis Research Foundaton; UK Department of Health [PR-ST-0915-10015]; Oxford Martin School	Alexander von Humboldt Stiftung(Alexander von Humboldt Foundation); European Union(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Meningitis Research Foundaton; UK Department of Health; Oxford Martin School	During the earlier parts of this work (1988-1997) MM was employed by the UK National Health Service at the National Institute for Biological Standards and Control (NIBSC), he was funded for a sabbatical in the laboratory of Mark Achtman by the Alexander von Humboldt Stiftung (1996-7) from 1997 to 2015 he was Wellcome Trust Senior Fellow and from 2004-present Professor of Molecular Epidemiology and a Fellow of Hertford College at the University of Oxford. He is grateful to the European Union (especially grants QLK2-CT-2001-01436 and FP7-278864-2), the Wellcome Trust (especially grants: 047072/Z/96/B, 047072/Z/96/C, 062057/Z/00/Z, 081494/Z/06/Z, 087622/Z/08/A, 086546/Z/08/Z, 091634/Z/10/Z, and 104992/Z/14/Z), the Meningitis Research Foundaton, the UK Department of Health (especially contract PR-ST-0915-10015) and the Oxford Martin School for funding.	Aguilera JF, 2002, EMERG INFECT DIS, V8, P761, DOI 10.3201/eid0808.010422; Ali O, 2016, LANCET GLOB HEALTH, V4, pE989, DOI 10.1016/S2214-109X(16)30244-3; Ali O, 2015, J INFECT DIS, V212, P1298, DOI 10.1093/infdis/jiv211; Ali O, 2013, TROP MED INT HEALTH, V18, P968, DOI 10.1111/tmi.12125; Bambini S, 2014, CLIN VACCINE IMMUNOL, V21, P966, DOI 10.1128/CVI.00825-13; BARLOW AK, 1989, MOL MICROBIOL, V3, P131, DOI 10.1111/j.1365-2958.1989.tb01802.x; Bennett JS, 2014, J CLIN MICROBIOL, V52, P1375, DOI 10.1128/JCM.03529-13; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; Black S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003859; Bratcher HB, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1138; Brehony C, 2016, VACCINE, V34, P4690, DOI 10.1016/j.vaccine.2016.08.015; Brehony C, 2009, MICROBIOL-SGM, V155, P4155, DOI 10.1099/mic.0.027995-0; CAUGANT DA, 1992, EPIDEMIOL INFECT, V109, P241, DOI 10.1017/S0950268800050196; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; CAUGANT DA, 1988, INFECT IMMUN, V56, P2060, DOI 10.1128/IAI.56.8.2060-2068.1988; CAUGANT DA, 1987, INFECT IMMUN, V55, P1503, DOI 10.1128/IAI.55.6.1503-1512.1987; Chen WH, 2018, LANCET INFECT DIS, V18, P1088, DOI 10.1016/S1473-3099(18)30400-6; Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6; Daugla DM, 2014, LANCET, V383, P40, DOI 10.1016/S0140-6736(13)61612-8; Diallo K, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3789-0; Diallo K, 2016, J INFECTION, V72, P667, DOI 10.1016/j.jinf.2016.03.010; Donald RGK, 2017, HUM VACC IMMUNOTHER, V13, P255, DOI 10.1080/21645515.2017.1264750; Donnelly J, 2010, P NATL ACAD SCI USA, V107, P19490, DOI 10.1073/pnas.1013758107; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; Feavers IM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00566-16, 10.1128/cvi.00566-16]; FEAVERS IM, 1992, MOL MICROBIOL, V6, P489, DOI 10.1111/j.1365-2958.1992.tb01493.x; Feil E, 1996, J MOL EVOL, V43, P631, DOI 10.1007/BF02202111; FINNE J, 1983, LANCET, V2, P355; FRASCH CE, 1985, REV INFECT DIS, V7, P504; Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2; HALTER R, 1989, EMBO J, V8, P2737, DOI 10.1002/j.1460-2075.1989.tb08415.x; Harmsen D, 2001, J CLIN MICROBIOL, V39, P936, DOI 10.1128/JCM.39.3.936-942.2001; Harrison OB, 2013, EMERG INFECT DIS, V19, P566, DOI 10.3201/eid1904.111799; Harrison OB, 2009, J INFECT DIS, V200, P94, DOI 10.1086/599377; Hill DMC, 2015, LANCET INFECT DIS, V15, P1420, DOI 10.1016/S1473-3099(15)00267-4; Ibarz-Pavon AB, 2011, J INFECT DIS, V204, P1046, DOI 10.1093/infdis/jir466; Jolley KA, 2013, EUROSURVEILLANCE, V18, P41; Jolley KA, 2007, FEMS MICROBIOL REV, V31, P89, DOI 10.1111/j.1574-6976.2006.00057.x; Jolley KA, 2012, MICROBIOL-SGM, V158, P1005, DOI 10.1099/mic.0.055459-0; Jolley KA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-595; Kristiansen PA, 2013, CLIN INFECT DIS, V56, P354, DOI 10.1093/cid/cis892; Ladhani SN, 2016, ARCH DIS CHILD, V101, P91, DOI 10.1136/archdischild-2015-308928; Ladhani SN, 2015, CLIN INFECT DIS, V60, P578, DOI 10.1093/cid/ciu881; Lepeyssonnie L., 1963, B WHO S, V28, P53; Lucidarme J, 2015, J INFECTION, V71, P544, DOI 10.1016/j.jinf.2015.07.007; MacLennan J, 2006, EMERG INFECT DIS, V12, P950; Maiden MCJ, 2008, J INFECT DIS, V197, P737, DOI 10.1086/527401; Maiden MCJ, 2006, ANNU REV MICROBIOL, V60, P561, DOI 10.1146/annurev.micro.59.030804.121325; Maiden MCJ, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0147; Maiden MC, 2006, HDB MENINGOCOCCAL DI, P17, DOI DOI 10.1002/3527608508; MAIDEN MCJ, 1991, MOL MICROBIOL, V5, P727, DOI 10.1111/j.1365-2958.1991.tb00743.x; Maiden MCJ, 2002, LANCET, V359, P1829, DOI 10.1016/S0140-6736(02)08679-8; Maiden MCJ, 1999, LANCET, V354, P615, DOI 10.1016/S0140-6736(99)00252-4; Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911; Mayer LW, 2002, J INFECT DIS, V185, P1596, DOI 10.1086/340414; MCGUINNESS B, 1990, J EXP MED, V171, P1871, DOI 10.1084/jem.171.6.1871; McNeil LK, 2018, MBIO, V9, DOI 10.1128/mBio.00036-18; Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; OLYHOEK T, 1987, REV INFECT DIS, V9, P665; Oster P, 2005, VACCINE, V23, P2191, DOI 10.1016/j.vaccine.2005.01.063; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494; Poolman J T, 1986, Dev Biol Stand, V63, P147; POOLMAN JT, 1983, INFECT IMMUN, V40, P398, DOI 10.1128/IAI.40.1.398-406.1983; Rodrigues C, 2017, LANCET, V389, P85; Russell JE, 2004, EMERG INFECT DIS, V10, P674, DOI 10.3201/eid1004.030247; Saleem M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056746; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; Sierra GVG, 1991, NIPH ANN, V14, P95; SMITH JM, 1991, NATURE, V349, P29, DOI 10.1038/349029a0; Sow SO, 2011, NEW ENGL J MED, V364, P2293, DOI 10.1056/NEJMoa1003812; SPRATT BG, 1988, NATURE, V332, P173, DOI 10.1038/332173a0; SPRATT BG, 1989, P NATL ACAD SCI USA, V86, P8988, DOI 10.1073/pnas.86.22.8988; Taha MK, 2000, LANCET, V356, P2159, DOI 10.1016/S0140-6736(00)03502-9; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thompson EAL, 2003, MICROBIOL-SGM, V149, P1849, DOI 10.1099/mic.0.26131-0; Tiffay K, 2015, CLIN INFECT DIS, V61, pS396, DOI 10.1093/cid/civ594; Trotter CL, 2007, LANCET INFECT DIS, V7, P797, DOI 10.1016/S1473-3099(07)70288-8; Trotter CL, 2009, EXPERT REV VACCINES, V8, P851, DOI [10.1586/erv.09.48, 10.1586/ERV.09.48]; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1; Tzitzilonis C, 2006, PROTEINS, V62, P947, DOI 10.1002/prot.20800; vandenElsen JMH, 1997, PROTEINS, V29, P113; VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991; Vernikos G, 2014, PATHOG GLOB HEALTH, V108, P305, DOI 10.1179/2047773214Y.0000000162; Vogel U, 2013, LANCET INFECT DIS, V13, P416, DOI 10.1016/S1473-3099(13)70006-9; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320; WANG JF, 1992, INFECT IMMUN, V60, P5267, DOI 10.1128/IAI.60.12.5267-5282.1992; Zlotnick GW, 2015, HUM VACC IMMUNOTHER, V11, P5, DOI 10.4161/hv.34293	92	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 15	2019	9								3151	10.3389/fimmu.2018.03151	http://dx.doi.org/10.3389/fimmu.2018.03151			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HH4SO	30697213	Green Published, gold			2022-12-18	WOS:000455716000001
J	Rai, S; Espinoza, JL; Morita, Y; Tanaka, H; Matsumura, I				Rai, Shinya; Espinoza, J. Luis; Morita, Yasuyoshi; Tanaka, Hirokazu; Matsumura, Itaru			Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality	FRONTIERS IN IMMUNOLOGY			English	Article						eosinophilia; cytogenetic (CG) analyses; eosinophilic pneumonia; myelofibrosis; membranoproliferative glomerulonephritis (MPGN); myelodisdplastic/myeloproliferative disorders	WORLD-HEALTH-ORGANIZATION; MYELOID MALIGNANCIES; TRANSLOCATION; LEUKEMIA; CHROMOSOME-7	Myelodysplastic syndromes (MDS) are a heterogeneous group clonal disorders of hematopoietic stem cells (HSC) characterized by ineffective hematopoiesis that lead to variable grades of impaired blood cell production. Chromosomal aberrations are often detected in MDS patients and thus cytogenetic analysis is useful for the diagnosis of these disorders. Common recurring chromosomal defects, such as the -5/5q- and -7/7q- are relatively well characterized cytogenetic abnormalities in MDS, however, the biological significance of uncommon cytogenetic alterations is unknown. We report here, two cases of peripheral blood and bone marrow hypereosinophilia in patients with MDS harboring the unbalanced translocation der(1;7)(q10;p10), a poorly characterized cytogenetic abnormality that is found in certain myeloid malignancies, including MDS. The patients reported here presented hypereosinophilia that was refractory to steroids and cytotoxic therapy, leading to severe target tissue damage that ultimately resulted in fatal end-organ failure. Potential roles of the der(1 ;7)(q10;p10) aberrations in the pathogenesis of aggressive eosinophilia and disease prognosis are discussed here.	[Rai, Shinya; Espinoza, J. Luis; Morita, Yasuyoshi; Tanaka, Hirokazu; Matsumura, Itaru] Kindai Univ Hosp, Dept Hematol & Rheumatol, Fac Med, Osaka, Japan		Espinoza, JL (corresponding author), Kindai Univ Hosp, Dept Hematol & Rheumatol, Fac Med, Osaka, Japan.	luis@med.kindai.ac.jp						Bacher U, 2015, MEDITERR J HEMATOL I, V7, DOI 10.4084/MJHID.2015.034; Bain BJ, 2003, BRIT J HAEMATOL, V122, P173, DOI 10.1046/j.1365-2141.2003.04458.x; Bennett JM, 2018, LEUKEMIA RES, V71, P34, DOI 10.1016/j.leukres.2018.06.012; Butt NM, 2017, BRIT J HAEMATOL, V176, P553, DOI 10.1111/bjh.14488; Byun JM, 2016, ANN HEMATOL, V95, P1223, DOI 10.1007/s00277-016-2691-1; Caramazza D, 2010, EUR J HAEMATOL, V84, P191, DOI 10.1111/j.1600-0609.2009.01392.x; Davidovitz Y, 1997, CANCER GENET CYTOGEN, V97, P122, DOI 10.1016/S0165-4608(96)00391-3; Diny NL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00484; Dispenza MC, 2018, CURR HEMATOL MALIG R, V13, P191, DOI 10.1007/s11899-018-0448-8; Duployez N, 2016, EXPERT REV HEMATOL, V9, P1189, DOI 10.1080/17474086.2016.1257936; Gotlib J, 2017, AM J HEMATOL, V92, P1243, DOI 10.1002/ajh.24880; Gotlib J, 2015, AM J HEMATOL, V90, P1078, DOI 10.1002/ajh.24196; Haferlach T, 2019, PATHOBIOLOGY, V86, P24, DOI 10.1159/000488712; HORIIKE S, 1990, CANCER, V65, P1350, DOI 10.1002/1097-0142(19900315)65:6<1350::AID-CNCR2820650617>3.0.CO;2-J; Hussain FTN, 2012, AM J HEMATOL, V87, P684, DOI 10.1002/ajh.23230; Kahn JE, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00216; Kawankar N, 2011, HEMATOLOGY, V16, P131, DOI 10.1179/102453311X12940641877966; Khoury P, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00240; Matsushima T, 2003, BLOOD, V101, P3386, DOI 10.1182/blood-2002-03-0947; Nardi Valentina, 2016, Surg Pathol Clin, V9, P143, DOI 10.1016/j.path.2015.10.004; Pedersen B, 2000, AM J HEMATOL, V64, P161, DOI 10.1002/1096-8652(200007)64:3<161::AID-AJH4>3.0.CO;2-Q; Reiter A, 2017, BLOOD, V129, P704, DOI 10.1182/blood-2016-10-695973; Sanada M, 2007, LEUKEMIA, V21, P992, DOI 10.1038/sj.leu.2404619; Shallis RM, 2018, EUR J HAEMATOL, V101, P260, DOI 10.1111/ejh.13092; Shumilov E, 2018, BLOOD REV, V32, P508, DOI 10.1016/j.blre.2018.04.008; Slovak ML, 2009, CANCER GENET CYTOGEN, V193, P78, DOI 10.1016/j.cancergencyto.2009.04.013; Tang G, 2018, INT J LAB HEMATOL, V40, P385, DOI 10.1111/ijlh.12826; Vardiman JW, 2010, CHEM-BIOL INTERACT, V184, P16, DOI 10.1016/j.cbi.2009.10.009	28	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 9	2019	9								3031	10.3389/fimmu.2018.03031	http://dx.doi.org/10.3389/fimmu.2018.03031			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HG8XO	30687305	gold, Green Published			2022-12-18	WOS:000455290400001
J	Veremeyko, T; Yung, AWY; Anthony, DC; Strekalova, T; Ponomarev, ED				Veremeyko, Tatyana; Yung, Amanda W. Y.; Anthony, Daniel C.; Strekalova, Tatyana; Ponomarev, Eugene D.			Early Growth Response Gene-2 Is Essential for M1 and M2 Macrophage Activation and Plasticity by Modulation of the Transcription Factor CEBP beta (vol 9, 2515, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						CEBP beta; Egr2; M1/M2 balance; activation; inflammation; monocytes/macrophages; plasticity			[Veremeyko, Tatyana; Yung, Amanda W. Y.; Ponomarev, Eugene D.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China; [Anthony, Daniel C.] Univ Oxford, Dept Pharmacol, Oxford, England; [Strekalova, Tatyana] Maastricht Univ, Dept Neurosci, Maastricht, Netherlands; [Strekalova, Tatyana] Inst Gen Pathol & Pathophysiol, Moscow, Russia; [Strekalova, Tatyana] Sechenov First Moscow State Med Univ, Lab Psychiat Neurobiol, Inst Mol Med, Moscow, Russia; [Strekalova, Tatyana] Sechenov First Moscow State Med Univ, Dept Normal Physiol, Moscow, Russia; [Ponomarev, Eugene D.] Kunming Inst Zool Chinese Univ Hong Kong Joint La, Kunming, Yunnan, Peoples R China	Chinese University of Hong Kong; University of Oxford; Maastricht University; Russian Academy of Medical Sciences; Institute of General Pathology & Pathophysiology, RAMS; Sechenov First Moscow State Medical University; Sechenov First Moscow State Medical University	Ponomarev, ED (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.; Ponomarev, ED (corresponding author), Kunming Inst Zool Chinese Univ Hong Kong Joint La, Kunming, Yunnan, Peoples R China.	eponomarev@cuhk.edu.hk	Ponomarev, Eugene D./K-1546-2013; Anthony, Daniel/F-7765-2010	Ponomarev, Eugene D./0000-0002-0871-8522; Anthony, Daniel/0000-0003-1380-6655; Yung, Amanda WY/0000-0003-4265-9324				Veremeyko T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02515	1	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 13	2018	9								2923	10.3389/fimmu.2018.02923	http://dx.doi.org/10.3389/fimmu.2018.02923			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HE4HZ	30588236	gold, Green Published			2022-12-18	WOS:000453328200001
J	Petrovas, C; Velu, V				Petrovas, Constantinos; Velu, Vijayakumar			Editorial: Lymph Node T Cell Dynamics and Novel Strategies for HIV Cure	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HIV; lymph node; cure; T cells; follicular T helper cells	IMMUNODEFICIENCY-VIRUS-INFECTION; INDINAVIR		[Petrovas, Constantinos] NIAID, Tissue Anal Core, Immunol Lab, Vaccine Res Ctr,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Velu, Vijayakumar] Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University	Petrovas, C (corresponding author), NIAID, Tissue Anal Core, Immunol Lab, Vaccine Res Ctr,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.; Velu, V (corresponding author), Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.	petrovasc@mail.nih.gov; vvelu@emory.edu	Velu, Vijayakumar/I-7585-2019	Velu, Vijayakumar/0000-0003-4238-1924	Intramural Research Program of the Vaccine Research Center, NIAID, National Institutes of Health [OP1032325]; Bill and Melinda Gates Foundation; NIH [5U19AI109633]; Emory Center for AIDS Research Grant [P30 AI050409]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI109633, P30AI050409] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011132] Funding Source: NIH RePORTER	Intramural Research Program of the Vaccine Research Center, NIAID, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emory Center for AIDS Research Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by the Intramural Research Program of the Vaccine Research Center, NIAID, National Institutes of Health, a CAVD grant (#OP1032325) from the Bill and Melinda Gates Foundation, an NIH grant (5U19AI109633 to VV) and by Emory Center for AIDS Research Grant P30 AI050409.	Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106; Fukazawa Y, 2015, NAT MED, V21, P132, DOI 10.1038/nm.3781; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Perreau M, 2013, J EXP MED, V210, P143, DOI 10.1084/jem.20121932	5	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 12	2018	9								2950	10.3389/fimmu.2018.02950	http://dx.doi.org/10.3389/fimmu.2018.02950			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HE2JK	30619310	Green Published, gold			2022-12-18	WOS:000453102500001
J	Li, LZ; Liu, Y; Gorny, MK				Li, Liuzhe; Liu, Yan; Gorny, Miroslaw K.			Association of Diverse Genotypes and Phenotypes of Immune Cells and Immunoglobulins With the Course of HIV-1 Infection	FRONTIERS IN IMMUNOLOGY			English	Review						HIV-1; HIV-1 disease progression; immune cells; surface proteins; immunoglobulin; genotype; phenotype	NATURAL-KILLER-CELL; HLA CLASS-I; CD8(+) T-CELLS; IMMUNODEFICIENCY-VIRUS TYPE-1; LONG-TERM CONTROL; B-CELLS; LYMPHOCYTE RESPONSES; DISEASE PROGRESSION; OPPOSITE PATTERNS; GENETIC INFLUENCE	Disease progression among HIV-1-infected individuals varies widely, but the mechanisms underlying this variability remains unknown. Distinct disease outcomes are the consequences of many factors working in concert, including innate and adaptive immune responses, cell-mediated and humoral immunity, and both genetic and phenotypic factors. Current data suggest that these multifaceted aspects in infected individuals should be considered as a whole, rather than as separate unique elements, and that analyses must be performed in greater detail in order to meet the requirements of personalized medicine and guide optimal vaccine design. However, the wide adoption of antiretroviral therapy (ART) influences the implementation of systematic analyses of the HIV-1-infected population. Consequently, fewer data will be available for acquisition in the future, preventing the comprehensive investigations required to elucidate the underpinnings of variability in disease outcome. This review seeks to recapitulate the distinct genotypic and phenotypic features of the immune system, focusing in particular on comparing the surface proteins of immune cells among individuals with different HIV infection outcomes.	[Li, Liuzhe; Gorny, Miroslaw K.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Liu, Yan] Univ South China, Inst Pathogen Biol, Med Coll, Hengyang, Peoples R China	New York University; University of South China	Li, LZ (corresponding author), NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.	liuzhe.li@nyumc.org		Gorny, Miroslaw/0000-0002-2714-8780	National Institute of Allergy and Infectious Diseases (NIAID), National Instiutes of Health (NIH) [AI112546]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI112546] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), National Instiutes of Health (NIH); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The study was supported by grant AI112546 (MG) from the National Institute of Allergy and Infectious Diseases (NIAID), National Instiutes of Health (NIH).	Achord AP, 1996, PATHOBIOLOGY, V64, P204, DOI 10.1159/000164049; Aggarwal H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01697; Ahmad A, 2018, AIDS, V32, P1373, DOI 10.1097/QAD.0000000000001852; Airas L, 1996, BLOOD, V88, P1755, DOI 10.1182/blood.V88.5.1755.bloodjournal8851755; Alsahafi N, 2017, J VIROL, V91, DOI 10.1128/JVI.00109-17; Alter G, 2007, J EXP MED, V204, P3027, DOI 10.1084/jem.20070695; Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005; Ambada GN, 2017, IMMUNOLOGY, V151, P405, DOI 10.1111/imm.12738; Apps R, 2013, SCIENCE, V340, P87, DOI 10.1126/science.1232685; Bailey JR, 2008, J VIROL, V82, P7395, DOI 10.1128/JVI.00800-08; Benati D, 2016, J CLIN INVEST, V126, P2093, DOI 10.1172/JCI83792; Berger CT, 2011, J VIROL, V85, P9334, DOI 10.1128/JVI.00460-11; Blais ME, 2012, J IMMUNOL, V188, P4663, DOI 10.4049/jimmunol.1103472; Blais ME, 2011, IMMUNOLOGY, V133, P1, DOI 10.1111/j.1365-2567.2011.03422.x; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; Borinskaya SA, 2012, ACTA NATURAE, V4, P42, DOI 10.32607/20758251-2012-4-1-42-52; Boulet S, 2008, AIDS, V22, P595, DOI 10.1097/QAD.0b013e3282f56b23; Bowers E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081913; Buckheit RW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1697; Carriere M, 2014, J INFECT DIS, V209, P1321, DOI 10.1093/infdis/jit643; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Carrington M, 2012, ANNU REV MED, V63, P131, DOI 10.1146/annurev-med-062909-130018; Carrington M, 2008, TRENDS MICROBIOL, V16, P620, DOI 10.1016/j.tim.2008.09.002; Catano G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003636; Chaudhari DV, 2013, IMMUNOL LETT, V156, P1, DOI 10.1016/j.imlet.2013.09.002; Chen HB, 2012, NAT IMMUNOL, V13, P691, DOI 10.1038/ni.2342; Chikata T, 2018, J VIROL, V92, DOI 10.1128/JVI.01749-17; Chung AW, 2018, AIDS, V32, P1207, DOI 10.1097/QAD.0000000000001812; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Conter LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092009; Corrah TW, 2011, J VIROL, V85, P3367, DOI 10.1128/JVI.02276-10; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Deepe RN, 2012, HUM IMMUNOL, V73, P263, DOI 10.1016/j.humimm.2011.12.008; den Uyl D, 2004, AIDS REV, V6, P89; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dominguez-Molina B, 2017, CLIN INFECT DIS, V64, P621, DOI 10.1093/cid/ciw833; Eller MA, 2009, JAIDS-J ACQ IMM DEF, V51, P380, DOI 10.1097/QAI.0b013e3181aa256e; Elliott JM, 2011, TRENDS IMMUNOL, V32, P364, DOI 10.1016/j.it.2011.06.001; Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07; Farquhar C, 2004, AIDS RES HUM RETROV, V20, P692, DOI 10.1089/0889222041524616; Feger U, 2007, BLOOD, V110, P568, DOI 10.1182/blood-2006-11-057125; Fellay J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000791; Fogli M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000101; Forthal DN, 2007, J IMMUNOL, V179, P7916, DOI 10.4049/jimmunol.179.11.7916; French MA, 2013, AIDS, V27, P519, DOI 10.1097/QAD.0b013e32835cb720; Gao XJ, 2010, AIDS, V24, P1835, DOI 10.1097/QAD.0b013e32833c3219; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Gartland AJ, 2014, J VIROL, V88, P8242, DOI 10.1128/JVI.01164-14; Gonzalez N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193773; Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005; Gupta A, 2015, INT J IMMUNOGENET, V42, P270, DOI 10.1111/iji.12215; Harari A, 2004, EUR J IMMUNOL, V34, P3525, DOI 10.1002/eji.200425324; Hardie RA, 2008, AIDS, V22, P807, DOI 10.1097/QAD.0b013e3282f51b71; Hendel H, 1999, J IMMUNOL, V162, P6942; Hersperger AR, 2011, BLOOD, V117, P3799, DOI 10.1182/blood-2010-12-322727; Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917; Holtmeier Wolfgang, 2005, V86, P151, DOI 10.1159/000086659; Huang JH, 2009, J EXP MED, V206, P2959, DOI 10.1084/jem.20091386; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Hubert JB, 2000, AIDS, V14, P123, DOI 10.1097/00002030-200001280-00007; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Johansson SE, 2010, CLIN IMMUNOL, V134, P158, DOI 10.1016/j.clim.2009.10.001; Juarez-Molina CI, 2014, J VIROL, V88, P10392, DOI 10.1128/JVI.01162-14; Juarez-Molina CI, 2014, AIDS, V28, P1687, DOI 10.1097/QAD.0000000000000322; Juhasz E, 2012, PATHOL ONCOL RES, V18, P177, DOI 10.1007/s12253-011-9425-4; Kamya P, 2011, J VIROL, V85, P5949, DOI 10.1128/JVI.02652-10; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; Kaslow RA, 2001, J VIROL, V75, P8681, DOI 10.1128/JVI.75.18.8681-8689.2001; Kawashima Y, 2010, J VIROL, V84, P7151, DOI 10.1128/JVI.00171-10; Kim ES, 2017, J LEUKOCYTE BIOL, V101, P1263, DOI [10.1189/jlb.5a0816-346r, 10.1189/jlb.5A0816-346R]; Kloverpris HN, 2014, AIDS RES HUM RETROV, V30, P468, DOI [10.1089/AID.2013.0197, 10.1089/aid.2013.0197]; Koehler RN, 2010, J INFECT DIS, V202, P1562, DOI 10.1086/656913; Kosmrlj A, 2010, NATURE, V465, P350, DOI 10.1038/nature08997; Kottilil S, 2003, J INFECT DIS, V187, P1038, DOI 10.1086/368222; Kulkarni S, 2011, NATURE, V472, P495, DOI 10.1038/nature09914; Kulpa DA, 2011, IMMUNOLOGY, V134, P116, DOI 10.1111/j.1365-2567.2011.03474.x; Kwong PD, 2017, IMMUNOL REV, V275, P108, DOI 10.1111/imr.12480; Ladell K, 2013, IMMUNITY, V38, P425, DOI 10.1016/j.immuni.2012.11.021; Lai JI, 2014, J VIROL, V88, P2799, DOI 10.1128/JVI.03130-13; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lazaryan A, 2010, J VIROL, V84, P2610, DOI 10.1128/JVI.01962-09; Lefranc Marie-Paule, 2012, Methods Mol Biol, V882, P635, DOI 10.1007/978-1-61779-842-9_34; Leitman EM, 2017, J VIROL, V91, DOI 10.1128/JVI.00544-17; Leitman EM, 2016, AIDS, V30, P972, DOI 10.1097/QAD.0000000000001022; Leszczyszyn-Pynka M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127867; Li H, 2014, INFECT GENET EVOL, V24, P99, DOI 10.1016/j.meegid.2014.03.009; Lin ZS, 2016, CELL REP, V17, P2210, DOI 10.1016/j.celrep.2016.10.075; Long BR, 2008, J VIROL, V82, P4785, DOI 10.1128/JVI.02449-07; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243; Mann JK, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-100; Marras F, 2013, P NATL ACAD SCI USA, V110, P11970, DOI 10.1073/pnas.1302090110; Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Matthews PC, 2012, J VIROL, V86, P12643, DOI 10.1128/JVI.01381-12; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; McLaren PJ, 2012, HUM MOL GENET, V21, P4334, DOI 10.1093/hmg/dds226; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Mori M, 2018, JAIDS-J ACQ IMM DEF, V78, P356, DOI 10.1097/QAI.0000000000001676; Mori M, 2014, AIDS, V28, P959, DOI 10.1097/QAD.0000000000000206; Murakoshi H, 2015, J VIROL, V89, P5330, DOI 10.1128/JVI.00020-15; Nakayama EE, 2004, AIDS, V18, P729, DOI 10.1097/00002030-200403260-00003; Naruto T, 2012, J VIROL, V86, P10870, DOI 10.1128/JVI.00689-12; O'Connor GM, 2007, CLIN IMMUNOL, V124, P277, DOI 10.1016/j.clim.2007.05.016; Olvera A, 2014, AIDS, V28, P2323, DOI 10.1097/QAD.0000000000000403; Pandey JP, 2014, J VIROL, V88, P7117, DOI 10.1128/JVI.00726-14; Pandey JP, 2013, VIROLOGY, V441, P70, DOI 10.1016/j.virol.2013.03.007; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Poonia B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015562; Qidwai T, 2016, HUM IMMUNOL, V77, P961, DOI 10.1016/j.humimm.2016.06.010; Raghavan S, 2009, INT J IMMUNOGENET, V36, P129, DOI 10.1111/j.1744-313X.2009.00835.x; Rajapaksa US, 2012, P NATL ACAD SCI USA, V109, P13353, DOI 10.1073/pnas.1204199109; Rallon N, 2017, HIV MED, V18, P587, DOI 10.1111/hiv.12494; Ramsuran V, 2018, SCIENCE, V359, P86, DOI 10.1126/science.aam8825; Regateiro FS, 2013, CLIN EXP IMMUNOL, V171, P1, DOI 10.1111/j.1365-2249.2012.04623.x; Riedel DJ, 2009, AIDS, V23, P1955, DOI 10.1097/QAD.0b013e32832ff1ff; Rittiner JE, 2012, J BIOL CHEM, V287, P5301, DOI 10.1074/jbc.M111.291666; Sadanand S, 2018, AIDS, V32, P443, DOI 10.1097/QAD.0000000000001716; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Samie A, 2014, GENET MOL RES, V13, P7470, DOI 10.4238/2014.September.12.13; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Saze Z, 2013, BLOOD, V122, P9, DOI 10.1182/blood-2013-02-482406; Schellens IMM, 2014, JAIDS-J ACQ IMM DEF, V67, P236, DOI 10.1097/QAI.0000000000000324; Schena F, 2013, CELL REP, V3, P1824, DOI 10.1016/j.celrep.2013.05.022; Schuler PJ, 2013, AIDS, V27, P1545, DOI 10.1097/QAD.0b013e328360c7f3; Scott-Algara D, 2003, J IMMUNOL, V171, P5663, DOI 10.4049/jimmunol.171.11.5663; Selvaraj P, 2006, JAIDS-J ACQ IMM DEF, V43, P497, DOI 10.1097/01.qai.0000233312.36226.76; Shasha D, 2016, J LEUKOCYTE BIOL, V100, P1425, DOI 10.1189/jlb.4A0915-422R; Shepherd BL, 2015, AIDS RES HUM RETROV, V31, P504, DOI [10.1089/aid.2014.0338, 10.1089/AID.2014.0338]; Shrestha S, 2006, J INFECT DIS, V193, P16, DOI 10.1086/498532; Singh KK, 2003, J INFECT DIS, V188, P1461, DOI 10.1086/379038; Sivro A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam6354; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Streeck H, 2007, J VIROL, V81, P7725, DOI 10.1128/JVI.00708-07; Tang JM, 2002, J VIROL, V76, P8276, DOI 10.1128/JVI.76.16.8276-8284.2002; Thomas R, 2009, NAT GENET, V41, P1290, DOI 10.1038/ng.486; Thompson LF, 2013, J LEUKOCYTE BIOL, V94, P545, DOI 10.1189/jlb.0513245; Tiemessen CT, 2011, JAIDS-J ACQ IMM DEF, V57, P181, DOI 10.1097/QAI.0b013e3182174a76; Tjiam MC, 2017, JAIDS-J ACQ IMM DEF, V76, pE90, DOI 10.1097/QAI.0000000000001477; Tjiam MC, 2015, J IMMUNOL, V194, P5320, DOI 10.4049/jimmunol.1402918; Tomescu C, 2007, J IMMUNOL, V179, P2097, DOI 10.4049/jimmunol.179.4.2097; Tomescu C, 2012, AIDS, V26, P1869, DOI 10.1097/QAD.0b013e32835861b0; Toth I, 2013, J LEUKOCYTE BIOL, V94, P551, DOI 10.1189/jlb.0113018; van Bockel DJ, 2011, J IMMUNOL, V186, P359, DOI 10.4049/jimmunol.1001807; Vesa J, 2017, AIDS, V31, P1149, DOI 10.1097/QAD.0000000000001445; Vigano S, 2017, AIDS, V31, P207, DOI 10.1097/QAD.0000000000001326; Vingert B, 2012, J VIROL, V86, P10661, DOI 10.1128/JVI.00056-12; Weis JF, 2015, AIDS RES HUM RETROV, V31, P288, DOI [10.1089/aid.2014.0209, 10.1089/AID.2014.0209]; Willberg CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160293; Wright JK, 2012, J VIROL, V86, P3193, DOI 10.1128/JVI.06682-11; Yawata M, 2006, J EXP MED, V203, P633, DOI 10.1084/jem.20051884; Youngblood B, 2013, J IMMUNOL, V191, P540, DOI 10.4049/jimmunol.1203161; Zhang JY, 2007, BLOOD, V109, P4671, DOI 10.1182/blood-2006-09-044826; zur Wiesch JS, 2011, J VIROL, V85, P1287, DOI 10.1128/JVI.01758-10	159	2	3	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2018	9								2735	10.3389/fimmu.2018.02735	http://dx.doi.org/10.3389/fimmu.2018.02735			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HB7BZ	30534128	gold, Green Published			2022-12-18	WOS:000451232000001
J	King, LA; Lameris, R; de Gruijl, TD; van der Vliet, HJ				King, Lisa A.; Lameris, Roeland; de Gruijl, Tanja D.; van der Vliet, Hans J.			CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: alpha-Galactosylceramide and Beyond (vol 9, 1519, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						iNKT cells; CD1d; alpha-GalCer; glycolipids; cancer immunotherapy			[King, Lisa A.; Lameris, Roeland; de Gruijl, Tanja D.; van der Vliet, Hans J.] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; [King, Lisa A.; Lameris, Roeland; de Gruijl, Tanja D.; van der Vliet, Hans J.] Canc Ctr Amsterdam, Amsterdam, Netherlands; [van der Vliet, Hans J.] Lava Therapeut, Den Bosch, Netherlands	Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	van der Vliet, HJ (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands.; van der Vliet, HJ (corresponding author), Canc Ctr Amsterdam, Amsterdam, Netherlands.; van der Vliet, HJ (corresponding author), Lava Therapeut, Den Bosch, Netherlands.	jj.vandervliet@vumc.nl			Lava Therapeutics	Lava Therapeutics	LK and Rl are funded by Lava Therapeutics. HV acts as chief scientific officer of Lava Therapeutics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.	King LA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01519	1	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 20	2018	9								2606	10.3389/fimmu.2018.02606	http://dx.doi.org/10.3389/fimmu.2018.02606			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HB0FG	30519237	Green Published, gold			2022-12-18	WOS:000450687500001
J	Reddy, P; Zeiser, R				Reddy, Pavan; Zeiser, Robert			Editorial: Non-coding RNAs and Graft versus Host Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						GvHD; micro RNA; Inflammation; non-coding RNAs; T cell			[Reddy, Pavan] Univ Michigan, Comprehens Canc Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; [Zeiser, Robert] Albert Ludwigs Univ Freiburg, Freiburg Univ Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany	University of Michigan System; University of Michigan; University of Freiburg	Zeiser, R (corresponding author), Albert Ludwigs Univ Freiburg, Freiburg Univ Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany.	robert.zeiser@uniklinik-freiburg.de		Zeiser, Robert/0000-0001-6565-3393; Reddy, Pavan/0000-0001-7264-8429	ERC [681012]	ERC(European Research Council (ERC)European Commission)	This work was supported by ERC (grant number 681012) to RZ (GVHDCure).		0	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 20	2018	9								2713	10.3389/fimmu.2018.02713	http://dx.doi.org/10.3389/fimmu.2018.02713			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HB0GV	30524443	Green Published, gold			2022-12-18	WOS:000450692100002
J	Kumari, G; Gerasimova, T; Du, H; De, S; Wood, WH; Becker, KG; Sen, R				Kumari, Gita; Gerasimova, Tatiana; Du, Hansen; De, Supriyo; Wood, William H., III; Becker, Kevin G.; Sen, Ranjan			Misregulation of the IgH Locus in Thymocytes	FRONTIERS IN IMMUNOLOGY			English	Article						VDJ recombination; IgH locus; thymocytes; enhancer; chromatin; B cells	HEAVY-CHAIN GENE; T-CELL DEVELOPMENT; RECEPTOR ALPHA-ENHANCER; V(D)J RECOMBINATION; INTRONIC ENHANCER; B-CELLS; TARGETED DELETION; IMMUNOGLOBULIN; REARRANGEMENT; TRANSCRIPTION	Functional antigen receptor genes are assembled by somatic rearrangements that are largely lymphocyte lineage specific. The immunoglobulin heavy chain (IgH) gene locus is unique amongst the seven antigen receptor loci in undergoing partial gene rearrangements in the wrong lineage. Here we demonstrate that breakdown of lineage-specificity is associated with inappropriate activation of the Err, enhancer during T cell development by a different constellation of transcription factors than those used in developing B cells. This is reflected in reduced enhancer-induced epigenetic changes, eRNAs, formation of the RAG1 /2-rich recombination center, attenuated chromatin looping and markedly different utilization of D-H gene segments in CD4(+)CD8(+) (DP) thymocytes. Additionally, CTCF-dependent V-H locus compaction is disrupted in DP cells despite comparable transcription factor binding in both lineages. These observations identify multiple mechanisms that contribute to lineage-specific antigen receptor gene assembly.	[Kumari, Gita; Gerasimova, Tatiana; Du, Hansen; Sen, Ranjan] NIA, Lab Mol Biol & Immunol, Baltimore, MD 21224 USA; [De, Supriyo; Wood, William H., III; Becker, Kevin G.] NIA, Lab Genet & Genom, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sen, R (corresponding author), NIA, Lab Mol Biol & Immunol, Baltimore, MD 21224 USA.	senranja@grc.nia.nih.gov	De, Supriyo/Y-2492-2019	De, Supriyo/0000-0002-2075-7655	Intramural Research Program of the NIH, National Institute on Aging; NATIONAL INSTITUTE ON AGING [ZICAG000616] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported entirely by the Intramural Research Program of the NIH, National Institute on Aging.	Afshar R, 2006, J IMMUNOL, V176, P2439, DOI 10.4049/jimmunol.176.4.2439; Allman D, 2003, NAT IMMUNOL, V4, P168, DOI 10.1038/ni878; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bates JG, 2007, J EXP MED, V204, P3247, DOI 10.1084/jem.20071787; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; Bolland DJ, 2016, CELL REP, V15, P2475, DOI 10.1016/j.celrep.2016.05.020; Bories JC, 1996, P NATL ACAD SCI USA, V93, P7871, DOI 10.1073/pnas.93.15.7871; BORN W, 1988, J IMMUNOL, V140, P3228; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chakraborty T, 2007, MOL CELL, V27, P842, DOI 10.1016/j.molcel.2007.07.010; Chakraborty T, 2009, J EXP MED, V206, P1019, DOI 10.1084/jem.20081621; Choi NM, 2013, J IMMUNOL, V191, P2393, DOI 10.4049/jimmunol.1301279; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Degner SC, 2011, P NATL ACAD SCI USA, V108, P9566, DOI 10.1073/pnas.1019391108; Degner SC, 2009, J IMMUNOL, V182, P44, DOI 10.4049/jimmunol.182.1.44; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Fuxa M, 2004, GENE DEV, V18, P411, DOI 10.1101/gad.291504; Gerasimova T, 2015, GENE DEV, V29, P1683, DOI 10.1101/gad.263871.115; Guo CY, 2011, CELL, V147, P332, DOI 10.1016/j.cell.2011.08.049; Guo CG, 2011, NATURE, V477, P424, DOI 10.1038/nature10495; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Hsu LY, 2004, J EXP MED, V199, P825, DOI 10.1084/jem.20032249; Hu JZ, 2015, CELL, V163, P947, DOI 10.1016/j.cell.2015.10.016; Ji YH, 2010, CELL, V141, P419, DOI 10.1016/j.cell.2010.03.010; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kumari G, 2015, ADV IMMUNOL, V128, P41, DOI 10.1016/bs.ai.2015.08.001; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; LAUZURICA P, 1994, J EXP MED, V179, P1913, DOI 10.1084/jem.179.6.1913; Lin SG, 2016, P NATL ACAD SCI USA, V113, P7846, DOI 10.1073/pnas.1608649113; Liu HF, 2007, GENE DEV, V21, P1179, DOI 10.1101/gad.1529307; Loguercio S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00425; Montefiori L, 2016, CELL REP, V14, P896, DOI 10.1016/j.celrep.2015.12.083; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nikolajczyk BS, 1997, MOL CELL BIOL, V17, P3527, DOI 10.1128/MCB.17.7.3527; Nikolajczyk BS, 1999, COLD SPRING HARB SYM, V64, P99, DOI 10.1101/sqb.1999.64.99; Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108; Perlot T, 2005, P NATL ACAD SCI USA, V102, P14362, DOI 10.1073/pnas.0507090102; Qiu X, 2018, MOL CELL, V70, P21, DOI 10.1016/j.molcel.2018.02.020; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Revilla-i-Domingo R, 2012, EMBO J, V31, P3130, DOI 10.1038/emboj.2012.155; Roberts JL, 1997, J EXP MED, V185, P131, DOI 10.1084/jem.185.1.131; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Seitan VC, 2011, NATURE, V476, P467, DOI 10.1038/nature10312; Selimyan R, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001475; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; Spain LM, 1999, J IMMUNOL, V163, P2681; Subrahmanyam R, 2012, NAT IMMUNOL, V13, P1205, DOI 10.1038/ni.2447; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; Young MD, 2011, NUCLEIC ACIDS RES, V39, P7415, DOI 10.1093/nar/gkr416; Zhang JLA, 2012, CELL, V149, P467, DOI 10.1016/j.cell.2012.01.056	55	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 13	2018	9								2426	10.3389/fimmu.2018.02426	http://dx.doi.org/10.3389/fimmu.2018.02426			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HA1NF	30483245	Green Published, gold			2022-12-18	WOS:000449979400001
J	Parra, M; Yang, J; Weitner, M; Derrick, S; Yang, A; Schmidt, T; Singh, B; Moreno, A; Akkoyunlu, M				Parra, Marcela; Yang, Jiyeon; Weitner, Megan; Derrick, Steven; Yang, Amy; Schmidt, Thomas; Singh, Balwan; Moreno, Alberto; Akkoyunlu, Mustafa			TACI Contributes to Plasmodium yoelii Host Resistance by Controlling T Follicular Helper Cell Response and Germinal Center Formation	FRONTIERS IN IMMUNOLOGY			English	Article						Plasmodium yoelii; TACI; T follicular helper cell; Germinal center; B cell; antibody	CENTER B-CELLS; ANTIBODY-RESPONSES; MALARIA INFECTION; ACTIVATING FACTOR; BAFF-R; EXPRESSION; MICE; DEFICIENCY; SURVIVAL; LYMPHOCYTES	The delay in parasite-specific B cell development leaves people in malaria endemic areas vulnerable to repeated Plasmodium infections. Here, we investigated the role of transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI), a molecule involved in the generation of antigen-specific antibody secreting cells, in host response to non-lethal Plasmodium yoelii infection. We found that TACI deficiency not only resulted in higher peak parasitemia levels in P. yoelii challenged mice, but also led to a delay in parasite clearance and anti-P. yoelii Merozoite Surface Protein 1(C-terminal 19-kDa fragment [rMSP-1(19)]) protein and anti-rMSP-1(19) and anti-P. yoelii IgG antibody development. There was also a delay in the generation of splenic high affinity antibody secreting cells that recognize rMSP-1(19) protein as compared to wild-type mice. Interestingly, coinciding with the delay in parasite clearance there was a delay in the resolution of T follicular helper (T-FH) cell and germinal center (GC) B cell responses in TACI -/- mice. The persistence of TFH and GC B cells is likely a result of enhanced interaction between TFH and GC B cells because inducible costimulator ligand (ICOSL) expression was significantly higher on TACI -/- GC B cells than wild-type cells. The difference in the kinetics of GC reaction appeared to also impact the emergence of plasma cells (PC) because there was a delay in the generation of TACI -/- mice PC. Nevertheless, following the recovery from P. yoelii infection, TACI -/- and wild-typemice were both protected from a rechallenge infection. Establishment of protective B cell response was responsible for the resolution of parasitemia because B cells purified from recovered TACI -/- or wild-type mice were equally protective when introduced to naive wild-type mice prior to P. yoelii challenge. Thus, despite the increased susceptibility of TACI -/- mice to P. yoelii infection and a delay in the development of protective antibody levels, TACI -/- mice are able to clear the infection and resist rechallenge infection.	[Parra, Marcela; Yang, Jiyeon; Weitner, Megan; Derrick, Steven; Yang, Amy; Schmidt, Thomas; Akkoyunlu, Mustafa] US FDA, Div Bacterial Allergen & Parasit Dis, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA; [Singh, Balwan; Moreno, Alberto] Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA; [Moreno, Alberto] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA	US Food & Drug Administration (FDA); Emory University; Emory University	Akkoyunlu, M (corresponding author), US FDA, Div Bacterial Allergen & Parasit Dis, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.	Mustafa.Akkoyunlu@fda.hhs.gov	Akkoyunlu, Mustafa/I-5712-2012; Akkoyunlu, Mustafa/ABC-9013-2020	Akkoyunlu, Mustafa/0000-0001-9958-4031; Singh, Balwan/0000-0002-4699-2426; Moreno, Alberto/0000-0002-3031-7194	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011132] Funding Source: NIH RePORTER; NIH HHS [P51 OD011132] Funding Source: Medline	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Allman WR, 2015, P NATL ACAD SCI USA, V112, pE4094, DOI 10.1073/pnas.1421580112; Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874; Branch OH, 1998, AM J TROP MED HYG, V58, P211, DOI 10.4269/ajtmh.1998.58.211; Branch OH, 2000, J INFECT DIS, V181, P1746, DOI 10.1086/315424; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Coban C, 2010, EXPERT REV VACCINES, V9, P775, DOI 10.1586/ERV.10.60; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; D'Alessandro U, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-400; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Deenick EK, 2010, IMMUNITY, V33, P241, DOI 10.1016/j.immuni.2010.07.015; FAHEY JR, 1987, INFECT IMMUN, V55, P490, DOI 10.1128/IAI.55.2.490-493.1987; Gatto D, 2010, J ALLERGY CLIN IMMUN, V126, P898, DOI 10.1016/j.jaci.2010.09.007; Gowda NM, 2012, J IMMUNOL, V188, P5073, DOI 10.4049/jimmunol.1102143; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Hansen DS, 2017, INT J PARASITOL, V47, P105, DOI 10.1016/j.ijpara.2016.09.004; Ibison F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052939; JAYAWARDENA AN, 1978, IMMUNOLOGY, V34, P157; Kanswal S, 2008, J IMMUNOL, V181, P976, DOI 10.4049/jimmunol.181.2.976; Katsenelson N, 2007, EUR J IMMUNOL, V37, P1785, DOI 10.1002/eji.200636800; Kaur K, 2007, BLOOD, V110, P2948, DOI 10.1182/blood-2007-01-069245; Kerfoot SM, 2011, IMMUNITY, V34, P947, DOI 10.1016/j.immuni.2011.03.024; Krishnamurty AT, 2016, IMMUNITY, V45, P402, DOI 10.1016/j.immuni.2016.06.014; Kumsiri R, 2010, ACTA TROP, V116, P217, DOI 10.1016/j.actatropica.2010.08.012; Bao LQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064836; Langhorne J, 1998, P NATL ACAD SCI USA, V95, P1730, DOI 10.1073/pnas.95.4.1730; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Liu XQ, 2012, EUR J IMMUNOL, V42, P3291, DOI 10.1002/eji.201242689; Mackay F, 2002, NAT REV IMMUNOL, V2, P465, DOI 10.1038/nri844; Mantchev GT, 2007, J IMMUNOL, V179, P2282, DOI 10.4049/jimmunol.179.4.2282; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Nduati E, 2011, J INFECT DIS, V204, P962, DOI 10.1093/infdis/jir438; Ou XJ, 2012, P NATL ACAD SCI USA, V109, P15401, DOI 10.1073/pnas.1200386109; Parra M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066115; Parra M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028164; Perciani CT, 2007, J CLIN LAB ANAL, V21, P201, DOI 10.1002/jcla.20172; Portugal S, 2013, J IMMUNOL, V190, P3039, DOI 10.4049/jimmunol.1203067; Sage PT, 2016, IMMUNOL REV, V271, P246, DOI 10.1111/imr.12411; Scholzen A, 2014, J IMMUNOL, V192, P3719, DOI 10.4049/jimmunol.1302960; Singh B, 2010, VACCINE, V28, P2580, DOI 10.1016/j.vaccine.2010.01.019; Tongren JE, 2006, INFECT IMMUN, V74, P257, DOI 10.1128/IAI.74.1.257-264.2006; Tsuji S, 2014, J CLIN INVEST, V124, P4857, DOI 10.1172/JCI74428; Tsuji S, 2011, BLOOD, V118, P5832, DOI 10.1182/blood-2011-05-353961; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; vonderWeid T, 1996, J IMMUNOL, V156, P2510; WHO, 2016, HIGH RISK GROUPS MAL; WHO, 2015, WORLD MAL REP 2015; Wolf AI, 2011, J CLIN INVEST, V121, P3954, DOI 10.1172/JCI57362; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790	52	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 9	2018	9								2612	10.3389/fimmu.2018.02612	http://dx.doi.org/10.3389/fimmu.2018.02612			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GZ7JI	30473702	Green Published, gold			2022-12-18	WOS:000449654600001
J	Rodrigues-Santos, P; Lopez-Sejas, N; Almeida, JS; Ruzickova, L; Couceiro, P; Alves, V; Campos, C; Alonso, C; Tarazona, R; Freitas-Tavares, P; Solana, R; Santos-Rosa, M				Rodrigues-Santos, Paulo; Lopez-Sejas, Nelson; Almeida, Jani Sofia; Ruzickova, Lenka; Couceiro, Patricia; Alves, Vera; Campos, Carmen; Alonso, Corona; Tarazona, Raquel; Freitas-Tavares, Paulo; Solana, Rafael; Santos-Rosa, Manuel			Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors	FRONTIERS IN IMMUNOLOGY			English	Article						aging; CML; NK receptors; activation markers; differentiation markers; cytokines; NK cell subsets; tyrosine kinase inhibitors	CHRONIC MYELOGENOUS LEUKEMIA; NATURAL-KILLER-CELLS; ACTIVATING RECEPTORS; IMATINIB TREATMENT; IMMUNE-SYSTEM; BCR-ABL; EXPRESSION; IMMUNOSENESCENCE; SUBSETS; DISCONTINUATION	Natural killer (NK) cells are a very important component of the innate immune response involved in the lysis of virus infected and tumor cells. Aging has a profound impact in the frequency, phenotype and function of NK cells. Chronic Myeloid Leukemia (CML) is caused by the BCR-ABL gene formation encoding aberrant oncoprotein tyrosine kinase. Treatment with tyrosine kinase inhibitors (TKIs) induces durable deepmolecular response. The response to treatment and life expectancy is lower in older patients with chronic phase of CML than in younger patients. In this work we analyse NK cells from TKI-treated CML patients and healthy controls stratified according to age. We have analyzed the expression of NK receptors, activation markers, NK cell differentiation in CD56(bright) and CD56(dim) NK cell subsets and the expression of CD107a and IFN-gamma in NK cells stimulated with K562. Whereas significant differences on the phenotype and function of NK cells were found between middle-aged (35-65 years old) and elderly (older than 65) healthy individuals, NK cells from TKI-treated CML patients do not show significant differences related with age in most parameters studied, indicating that age is not a limitation of the NK cell recovery after treatment with TKI. Our results also revealed differences in the expression of NK receptors, activation markers and functional assays in NK cells from TKI-treated CML patients compared with age-matched healthy controls. These results highlight the relevance of NK cells in TKI-treated patients and the need of an extensive analysis of the effect of aging on NK cell phenotype and function in these patients in order to define new NK-cell based strategies directed to control CML progression and achieve long-term disease remission after TKI cessation.	[Rodrigues-Santos, Paulo; Alves, Vera; Santos-Rosa, Manuel] Univ Coimbra, Fac Med, Inst Immunol, Coimbra, Portugal; [Rodrigues-Santos, Paulo; Almeida, Jani Sofia; Couceiro, Patricia] Univ Coimbra, Ctr Neurosci & Cell Biol, Lab Immunol & Oncol, Coimbra, Portugal; [Rodrigues-Santos, Paulo; Almeida, Jani Sofia; Couceiro, Patricia; Alves, Vera; Santos-Rosa, Manuel] Univ Coimbra, Ctr Invest Environm Genet & Oncobiol CIMAGO, Fac Med, Coimbra, Portugal; [Lopez-Sejas, Nelson; Campos, Carmen; Alonso, Corona; Solana, Rafael] Univ Cordoba, Reina Sofia Univ Hosp, Inst Maimonides Invest Biomed Cordoba, Dept Immunol, Cordoba, Spain; [Ruzickova, Lenka; Freitas-Tavares, Paulo] Coimbra Hosp & Univ Ctr, Hematol Serv, Coimbra, Portugal; [Tarazona, Raquel] Univ Extremadura, Immunol Unit, Caceres, Spain	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidad de Cordoba; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidad de Extremadura	Campos, C; Solana, R (corresponding author), Univ Cordoba, Reina Sofia Univ Hosp, Inst Maimonides Invest Biomed Cordoba, Dept Immunol, Cordoba, Spain.	mccampos1977@gmail.com; rsolana@uco.es	Rodrigues Santos, Paulo/M-3314-2019; Alves, Vera/AAX-8195-2020; Solana, Rafael/R-9978-2019; Tavares, Paulo Freitas/V-8584-2019; Rodrigues Santos, Paulo/M-3175-2013; Almeida, Jani/AAE-7272-2022	Rodrigues Santos, Paulo/0000-0001-7519-1620; Solana, Rafael/0000-0001-8985-0295; Tavares, Paulo Freitas/0000-0001-7832-4134; Rodrigues Santos, Paulo/0000-0001-7519-1620; Alves, Vera/0000-0002-2625-1671; Alonso, Corona/0000-0001-6238-7632; Almeida, Jani/0000-0003-2024-0434; Tarazona, Raquel/0000-0002-2926-6377	FEDER Funds through the Operational Program Competitiveness Factors-COMPETE 2020; National Funds through the FCT-Foundation for Science and Technology [POCI-01-0145-FEDER-007440]; program Iberoamerica Scholarships; Spanish Ministry of Health [PI13/02691, PI16/01615]; Ministry of Economy and Competitiveness of Spain [SAF2017-87538-R]; Junta de Extremadura [IB16164, GR18085]; European Regional Development Funds (FEDER)	FEDER Funds through the Operational Program Competitiveness Factors-COMPETE 2020; National Funds through the FCT-Foundation for Science and Technology; program Iberoamerica Scholarships; Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Ministry of Economy and Competitiveness of Spain(Spanish Government); Junta de Extremadura; European Regional Development Funds (FEDER)(European Commission)	This work was supported by the FEDER Funds through the Operational Program Competitiveness Factors-COMPETE 2020 and by National Funds through the FCT-Foundation for Science and Technology within the framework of the Strategic Project with reference assigned by COMPETE: POCI-01-0145-FEDER-007440 (to PR-S and MS-R) and by the program Iberoamerica Scholarships. Santander Research Santander Universities 2016-2017 (to NL-S). This work also was supported by grants PI13/02691 and PI16/01615 (to RS and CA) from Spanish Ministry of Health, SAF2017-87538-R (to RT) from the Ministry of Economy and Competitiveness of Spain, IB16164 and GR18085 from Junta de Extremadura (to RT), cofinanced by European Regional Development Funds (FEDER).	Almeida-Oliveira A, 2011, HUM IMMUNOL, V72, P319, DOI 10.1016/j.humimm.2011.01.009; Bartel Y, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00362; Boissel N, 2006, J IMMUNOL, V176, P5108, DOI 10.4049/jimmunol.176.8.5108; Borrego F, 1999, EXP GERONTOL, V34, P253, DOI 10.1016/S0531-5565(98)00076-X; Camous X, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/195956; Campos C, 2015, BIOGERONTOLOGY, V16, P671, DOI 10.1007/s10522-015-9581-0; Campos C, 2014, IMMUNOL LETT, V162, P298, DOI 10.1016/j.imlet.2014.06.015; Campos C, 2014, EXP GERONTOL, V54, P130, DOI 10.1016/j.exger.2014.01.008; Champsaur M, 2010, IMMUNOL REV, V235, P267, DOI 10.1111/j.0105-2896.2010.00893.x; Chen CU, 2012, LEUKEMIA, V26, P465, DOI 10.1038/leu.2011.239; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Costello RT, 2012, IMMUNOLOGY, V135, P151, DOI 10.1111/j.1365-2567.2011.03521.x; Fauriat C, 2007, BLOOD, V109, P323, DOI 10.1182/blood-2005-08-027979; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Fu BQ, 2011, IMMUNOLOGY, V133, P350, DOI 10.1111/j.1365-2567.2011.03446.x; Fulop T, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00271; Gayoso I, 2011, J INNATE IMMUN, V3, P337, DOI 10.1159/000328005; Goldman JM, 2008, ACTA HAEMATOL-BASEL, V119, P212, DOI 10.1159/000140633; Gonzalez VD, 2009, J IMMUNOL, V183, P6612, DOI 10.4049/jimmunol.0901437; Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588; Grubeck-Loebenstein B, 2009, AGING CLIN EXP RES, V21, P201, DOI 10.1007/BF03324904; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; Hughes A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00469; Hughes A, 2017, BLOOD, V129, P1166, DOI 10.1182/blood-2016-10-745992; Ilander M, 2017, LEUKEMIA, V31, P1108, DOI 10.1038/leu.2016.360; Imagawa J, 2015, LANCET HAEMATOL, V2, pE528, DOI 10.1016/S2352-3026(15)00196-9; KANTARJIAN HM, 1987, SOUTHERN MED J, V80, P1228, DOI 10.1097/00007611-198710000-00007; Kiladjian JJ, 2006, LEUKEMIA, V20, P463, DOI 10.1038/sj.leu.2404080; Kumagai T, 2018, CANCER SCI, V109, P182, DOI 10.1111/cas.13430; Larbi A, 2008, PHYSIOLOGY, V23, P64, DOI 10.1152/physiol.00040.2007; Le Garff-Tavernier M, 2010, AGING CELL, V9, P527, DOI 10.1111/j.1474-9726.2010.00584.x; Lopez-Sejas N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00476; Pita-Lopez ML, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00616; Lutz CT, 2005, MECH AGEING DEV, V126, P722, DOI 10.1016/j.mad.2005.01.004; Mellqvist UH, 2000, BLOOD, V96, P1961, DOI 10.1182/blood.V96.5.1961.h8001961_1961_1968; Moretta L, 2014, INT ARCH ALLERGY IMM, V164, P253, DOI 10.1159/000365632; Moretta L, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00087; Nakajima H, 2002, J IMMUNOL, V168, P643, DOI 10.4049/jimmunol.168.2.643; Ouyang Q, 2007, ANN NY ACAD SCI, V1106, P240, DOI 10.1196/annals.1392.001; Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004; Phekoo KJ, 2006, HAEMATOLOGICA, V91, P1400; Pierson BA, 1996, BLOOD, V88, P2279, DOI 10.1182/blood.V88.6.2279.bloodjournal8862279; Pita-Lopez Maria Luisa, 2009, Immun Ageing, V6, P11, DOI 10.1186/1742-4933-6-11; Rodriguez J, 1998, J CLIN ONCOL, V16, P3782, DOI 10.1200/JCO.1998.16.12.3782; Rohrbacher M, 2009, LEUKEMIA, V23, P602, DOI 10.1038/leu.2008.245; Rohrbacher M, 2009, BEST PRACT RES CL HA, V22, P295, DOI 10.1016/j.beha.2009.07.007; Ross DM, 2014, BRIT J HAEMATOL, V166, P3, DOI 10.1111/bjh.12892; Sanchez-Correa B, 2016, CANCER IMMUNOL IMMUN, V65, P453, DOI 10.1007/s00262-015-1720-6; Sanchez-Correa B, 2011, CANCER IMMUNOL IMMUN, V60, P1195, DOI 10.1007/s00262-011-1050-2; Sanchez-Correa B, 2012, IMMUNOL CELL BIOL, V90, P109, DOI 10.1038/icb.2011.15; Saussele S, 2016, LEUKEMIA, V30, P1638, DOI 10.1038/leu.2016.115; Sconocchia G, 2005, BLOOD, V106, P3666, DOI 10.1182/blood-2005-02-0479; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; Solana R, 2014, CURR OPIN IMMUNOL, V29, P56, DOI 10.1016/j.coi.2014.04.002; Solana R, 2012, SEMIN IMMUNOL, V24, P331, DOI 10.1016/j.smim.2012.04.008; Spits H, 2016, NAT IMMUNOL, V17, P758, DOI 10.1038/ni.3482; Tarazona R, 2002, J CLIN IMMUNOL, V22, P176, DOI 10.1023/A:1015476114409; Weyand CM, 2014, CURR OPIN RHEUMATOL, V26, P93, DOI 10.1097/BOR.0000000000000011; Zhang JY, 2015, MATH IND, V6, P97, DOI 10.1007/978-4-431-54813-3_4	63	2	3	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 8	2018	9								2587	10.3389/fimmu.2018.02587	http://dx.doi.org/10.3389/fimmu.2018.02587			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GZ6HK	30487792	Green Published, gold			2022-12-18	WOS:000449535700001
J	Edwards, CL; de Oca, MM; Rivera, FD; Kumar, R; Ng, SS; Wang, YL; Amante, FH; Kometani, K; Kurosaki, T; Sidwell, T; Kallies, A; Engwerda, CR				Edwards, Chelsea L.; de Oca, Marcela Montes; Rivera, Fabian de Labastida; Kumar, Rajiv; Ng, Susanna S.; Wang, Yulin; Amante, Fiona H.; Kometani, Kohei; Kurosaki, Tomohiro; Sidwell, Tom; Kallies, Axel; Engwerda, Christian R.			The Role of BACH2 in T Cells in Experimental Malaria Caused by Plasmodium chabaudi chabaudi AS	FRONTIERS IN IMMUNOLOGY			English	Article						BACH2; malaria; protozoan; T cells; inflammation	NF-KAPPA-B; TRANSCRIPTION FACTOR BACH2; RHEUMATOID-ARTHRITIS; GAMMA-INTERFERON; DIFFERENTIATION; GENE; ACTIVATION; MECHANISMS; EXPRESSION; INFECTION	BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 2 (BACH2) is a transcription factor best known for its role in B cell development. More recently, it has been associated with T cell functions in inflammatory diseases, and has been proposed as a master transcriptional regulator within the T cell compartment. In this study, we employed T cell-specific Bach2-deficient (B6.Bach2(Delta T)) mice to examine the role of this transcription factor in CD4(+) T cell functions in vitro and in mice infected with Plasmodium chabaudi AS. We found that under CD4(+) T cell polarizing conditions in vitro, Th2, and Th17 helper cell subsets were more active in the absence of Bach2 expression. In mice infected with P. chabaudi AS, although the absence of Bach2 expression by T cells had no effect on blood parasitemia or disease pathology, we found reduced expansion of CD4(+) T cells in B6.Bach2(Delta T) mice, compared with littermate controls. Despite this reduction, we observed increased frequencies of Tbet(+) IFN gamma(+) CD4(+) (Th1) cells and IL-10-producing Th1 (Tr1) cells in mice lacking Bach2 expression by T cells. Studies in mixed bone marrow chimeric mice revealed T cell intrinsic effects of BACH2 on hematopoietic cell development, and in particular, the generation of CD4(+) and CD8(+) T cell subsets. Furthermore, T cell intrinsic BACH2 was needed for efficient expansion of CD4(+) T cells during experimental malaria in this immunological setting. We also examined the response of B6 center dot Bach2(Delta T) mice to a second protozoan parasitic challenge with Leishmania donovani and found similar effects on disease outcome and T cell responses. Together, our findings provide new insights into the role of BACH2 in CD4(+) T cell activation during experimental malaria, and highlight an important role for this transcription factor in the development and expansion of T cells under homeostatic conditions, as well as establishing the composition of the effector CD4(+) T cell compartment during infection.	[Edwards, Chelsea L.; de Oca, Marcela Montes; Rivera, Fabian de Labastida; Ng, Susanna S.; Wang, Yulin; Amante, Fiona H.; Engwerda, Christian R.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Edwards, Chelsea L.] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Kumar, Rajiv] Bananas Hindu Univ, Dept Biochem, Varanasi, Uttar Pradesh, India; [Ng, Susanna S.] Griffith Univ, Sch Nat Sci, Nathan, Qld, Australia; [Kometani, Kohei] RIKEN, Ctr Integrat Med Sci IMS, Lab Lymphocyte Differentiat, Kanagawa, Japan; [Kurosaki, Tomohiro] Osaka Univ, WPI Immunol Frontier Res Ctr, Lab Lymphocyte Differentiat, Osaka, Japan; [Sidwell, Tom; Kallies, Axel] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Sidwell, Tom; Kallies, Axel] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; Banaras Hindu University (BHU); Griffith University; RIKEN; Osaka University; University of Melbourne; Walter & Eliza Hall Institute	Engwerda, CR (corresponding author), QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.	christian.engwerda@qimr.edu.au	de Oca, Marcela Montes/AAN-8732-2020; Engwerda, Christian/I-3072-2015; Ng, Susanna S/L-9906-2014; Kumar, Rajiv/GSE-5530-2022	de Oca, Marcela Montes/0000-0003-1152-6158; Ng, Susanna S/0000-0002-8494-7722; Kumar, Rajiv/0000-0003-2338-1494; Kometani, Kohei/0000-0003-4281-4371; Kallies, Axel/0000-0002-6312-6968; Wang, Yulin/0000-0002-9976-5315; Engwerda, Christian/0000-0003-2813-4804	National Health and Medical Research Council of Australia; Indian government Department of Science and Technology (DST); Australian Post-graduate Awards through the University of Queensland, School of Medicine; Griffith University; Sylvia and Charles Viertel Fellowship	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Indian government Department of Science and Technology (DST); Australian Post-graduate Awards through the University of Queensland, School of Medicine; Griffith University(Griffith University); Sylvia and Charles Viertel Fellowship	This work was made possible through Queensland State Government funding. The research was supported by grants and fellowships from the National Health and Medical Research Council of Australia, as well as an Australian Post-graduate Awards through the University of Queensland, School of Medicine and Griffith University, a Sylvia and Charles Viertel Fellowship to AK and an INSPIRE Fellowship to RK provided by the Indian government Department of Science and Technology (DST).	Antignano F, 2014, J CLIN INVEST, V124, P1945, DOI 10.1172/JCI69592; Bankoti R, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/639304; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Bunn PT, 2014, J IMMUNOL, V192, P3709, DOI 10.4049/jimmunol.1300768; Burke TF, 2000, BIOCHEM BIOPH RES CO, V270, P1016, DOI 10.1006/bbrc.2000.2508; Chen SL, 2003, AM J PHYSIOL-ENDOC M, V284, pE1089, DOI 10.1152/ajpendo.00540.2002; Chen Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069126; Cimmino L, 2008, J IMMUNOL, V181, P2338, DOI 10.4049/jimmunol.181.4.2338; Couper KN, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000004; Cunningham AC, 2002, EXP MOL PATHOL, V72, P132, DOI 10.1006/exmp.2002.2418; de Oca MM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005398; Desmet C, 2005, AM J RESP CRIT CARE, V172, P671, DOI 10.1164/rccm.200410-1431OC; do Rosario APF, 2012, J IMMUNOL, V188, P1178, DOI 10.4049/jimmunol.1102755; Edwards CL, 2018, J INFECT DIS, V218, P1119, DOI 10.1093/infdis/jiy281; Engwerda CR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00498; Engwerda CR, 2000, IMMUNOL TODAY, V21, P73, DOI 10.1016/S0167-5699(99)01549-2; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Fischer A, 2000, CLIN EXP IMMUNOL, V122, P143, DOI 10.1046/j.1365-2249.2000.01359.x; Fletcher JM, 2010, CLIN EXP IMMUNOL, V162, P1, DOI 10.1111/j.1365-2249.2010.04143.x; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Han ZN, 1998, AUTOIMMUNITY, V28, P197, DOI 10.3109/08916939808995367; Hansen DS, 2017, INT J PARASITOL, V47, P105, DOI 10.1016/j.ijpara.2016.09.004; Haque A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001221; Heinemann C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4770; Hoppmann N, 2015, BRAIN, V138, P902, DOI 10.1093/brain/awu408; Hunter JE, 2016, ONCOGENE, V35, P3476, DOI 10.1038/onc.2015.399; Jagannathan P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003864; Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175; Kim EH, 2014, J IMMUNOL, V192, P985, DOI 10.4049/jimmunol.1302378; Kobayashi S, 2011, GENE CHROMOSOME CANC, V50, P207, DOI 10.1002/gcc.20845; Kuwahara M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12596; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Lesniewski ML, 2008, LEUKEMIA, V22, P2201, DOI 10.1038/leu.2008.234; Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531; Marroqui L, 2014, DIABETES, V63, P2516, DOI 10.2337/db13-1443; McAllister K, 2013, ARTHRITIS RHEUM-US, V65, P3058, DOI 10.1002/art.38183; MEDING SJ, 1990, INFECT IMMUN, V58, P3671, DOI 10.1128/IAI.58.11.3671-3678.1990; Muto A, 2004, NATURE, V429, P566, DOI 10.1038/nature02596; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Neumann C, 2014, J EXP MED, V211, P1807, DOI 10.1084/jem.20131548; Noori-Zadeh A, 2017, J NEUROL SCI, V375, P203, DOI 10.1016/j.jns.2017.01.060; Oakley MS, 2013, J IMMUNOL, V191, P4699, DOI 10.4049/jimmunol.1300396; Ochiai K, 2006, J BIOL CHEM, V281, P38226, DOI 10.1074/jbc.M607592200; Okamoto K, 1997, ARTHRITIS RHEUM, V40, P919, DOI 10.1002/art.1780400521; Okoye AA, 2013, IMMUNOL REV, V254, P54, DOI 10.1111/imr.12066; Quinn EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140049; Richer MJ, 2016, J IMMUNOL, V197, P1009, DOI 10.4049/jimmunol.1600847; Roychoudhuri R, 2016, NAT IMMUNOL, V17, P851, DOI 10.1038/ni.3441; Roychoudhuri R, 2016, J CLIN INVEST, V126, P599, DOI 10.1172/JCI82884; Roychoudhuri R, 2013, NATURE, V498, P506, DOI 10.1038/nature12199; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Stanley AC, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000028; Stephens R, 2012, TRENDS PARASITOL, V28, P73, DOI 10.1016/j.pt.2011.10.006; STERN JJ, 1988, J IMMUNOL, V140, P3971; Su Z, 2000, INFECT IMMUN, V68, P4399, DOI 10.1128/IAI.68.8.4399-4406.2000; Su Z, 2002, J INFECT DIS, V186, P1321, DOI 10.1086/344576; Sudarshan M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003366; Sudarshan M, 2011, J ANTIMICROB CHEMOTH, V66, P1751, DOI 10.1093/jac/dkr185; Tsukumo S, 2013, P NATL ACAD SCI USA, V110, P10735, DOI 10.1073/pnas.1306691110; Turkmen S, 2011, GENE CHROMOSOME CANC, V50, P389, DOI 10.1002/gcc.20863; Vahedi G, 2015, NATURE, V520, P558, DOI 10.1038/nature14154; Villegas-Mendez A, 2012, J IMMUNOL, V189, P968, DOI 10.4049/jimmunol.1200688	62	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 6	2018	9								2578	10.3389/fimmu.2018.02578	http://dx.doi.org/10.3389/fimmu.2018.02578			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GZ4BS	30459773	gold, Green Published			2022-12-18	WOS:000449337500001
J	Filaci, G; Fenoglio, D; Taramasso, L; Indiveri, F; Di Biagio, A				Filaci, Gilberto; Fenoglio, Daniela; Taramasso, Lucia; Indiveri, Francesco; Di Biagio, Antonio			Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; Treg; immune checkpoints; HIV vaccine; PD1	REGULATORY T-CELLS; INFECTION; CANCER; EXPRESSION; CD4(+); ACTIVATION; EXPANSION; RESPONSES; SUPPRESS; BLOCKADE	The pathogenesis of HIV immunodeficiency is mainly dependent on the cytopatic effects exerted by the virus against infected CD4+ T cells. However, CD4+ T cell loss cannot be the only pathogenic factor since severe opportunistic infections may develop in HIV infected patients with normal CD4+ T cell counts and since the recent START study indicated that absolute CD4+ T cell counts are not predictive for AIDS and non-AIDS events. Recently our group demonstrated that CD8+CD28-CD127lowCD39+ regulatory T lymphocytes, previously found highly concentrated within tumor microenvironment, circulate with elevated frequency in the peripheral blood of HIV infected patients. Here, we show that these cells, that at least in part are HIV specific, express the PD1 immune checkpoint. Based on these evidences and considerations, in this Perspective article we speculate on the opportunity to treat HIV infected patients with anti-PD1 immune checkpoint inhibitors as a way to counteract the T regulatory cell compartment and to unleash virus-specific immune responses. In order to potentiate the immune responses against HIV we also propose the potential utility to associate immune checkpoint inhibition with HIV-specific therapeutic vaccination, reminiscent of what currently applied in oncologic protocols. We suggest that such an innovative strategy could permit drug-sparing regimens and, perhaps, lead to eradication of the infection in some patients.	[Filaci, Gilberto; Fenoglio, Daniela; Indiveri, Francesco] Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy; [Filaci, Gilberto; Fenoglio, Daniela; Indiveri, Francesco] Univ Genoa, Dept Internal Med, Genoa, Italy; [Filaci, Gilberto; Fenoglio, Daniela] Osped Policlin San Martino, Biotherapy Unit, Genoa, Italy; [Taramasso, Lucia; Di Biagio, Antonio] Osped Policlin San Martino, Infect Dis Unit, Genoa, Italy	University of Genoa; University of Genoa	Filaci, G (corresponding author), Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy.; Filaci, G (corresponding author), Univ Genoa, Dept Internal Med, Genoa, Italy.; Filaci, G (corresponding author), Osped Policlin San Martino, Biotherapy Unit, Genoa, Italy.	gfilaci@unige.it	Fenoglio, Daniela/I-7220-2018; Di Biagio, Antonio/J-4901-2019; Taramasso, Lucia/J-3358-2019; Indiveri, Francesco/AAE-9086-2020	Fenoglio, Daniela/0000-0001-9532-6473; Di Biagio, Antonio/0000-0003-1436-5089; Taramasso, Lucia/0000-0002-6622-6358; 				Angin M, 2014, J INFECT DIS, V210, P899, DOI 10.1093/infdis/jiu188; Banga R, 2016, NAT MED, V22, P754, DOI 10.1038/nm.4113; Chevalier MF, 2013, BLOOD, V121, P29, DOI 10.1182/blood-2012-07-409755; Cockerham LR, 2014, AIDS, V28, P1749, DOI 10.1097/QAD.0000000000000314; Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407; Fauci AS, 2017, JAMA-J AM MED ASSOC, V318, P1535, DOI 10.1001/jama.2017.13505; Fenoglio D, 2018, J ALLERGY CLIN IMMUN, V141, P2220, DOI 10.1016/j.jaci.2017.08.021; Filaci G, 2004, HUM IMMUNOL, V65, P142, DOI 10.1016/j.humimm.2003.12.001; Filaci G, 2007, J IMMUNOL, V179, P4323, DOI 10.4049/jimmunol.179.7.4323; Filaci G, 2011, AUTOIMMUNITY, V44, P51, DOI 10.3109/08916931003782171; Finnefrock AC, 2009, J IMMUNOL, V182, P980, DOI 10.4049/jimmunol.182.2.980; Gay CL, 2017, J INFECT DIS, V215, P1725, DOI 10.1093/infdis/jix191; Gill AL, 2016, AIDS, V30, P2487, DOI 10.1097/QAD.0000000000001217; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Jiao YM, 2009, IMMUNOLOGY, V128, pe366, DOI 10.1111/j.1365-2567.2008.02978.x; Khagi Y, 2017, CANCER METAST REV, V36, P179, DOI 10.1007/s10555-016-9652-y; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Kinter AL, 2007, AIDS RES HUM RETROV, V23, P438, DOI 10.1089/aid.2006.0162; Klocke K, 2016, P NATL ACAD SCI USA, V113, pE2383, DOI 10.1073/pnas.1603892113; Koster BD, 2015, CURR OPIN ONCOL, V27, P482, DOI 10.1097/CCO.0000000000000221; Kyi C, 2014, FEBS LETT, V588, P368, DOI 10.1016/j.febslet.2013.10.015; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Mandalia S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029844; Mori S, 2009, INT J STD AIDS, V20, P662, DOI 10.1258/ijsa.2008.008428; Naidoo J, 2014, BRIT J CANCER, V111, P2214, DOI 10.1038/bjc.2014.348; Ndhlovu LC, 2008, J LEUKOCYTE BIOL, V83, P254, DOI 10.1189/jlb.0507281; Ostios-Garcia L, 2018, J THORAC ONCOL, V13, P1037, DOI 10.1016/j.jtho.2018.03.031; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Pantaleo G, 2016, CURR OPIN HIV AIDS, V11, P576, DOI 10.1097/COH.0000000000000324; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parodi A, 2013, CANCER IMMUNOL IMMUN, V62, P851, DOI 10.1007/s00262-013-1392-z; Perreau M, 2017, TRENDS MOL MED, V23, P945, DOI 10.1016/j.molmed.2017.08.006; Perreau M, 2013, J EXP MED, V210, P143, DOI 10.1084/jem.20121932; Phetsouphanh C, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00681; Rey D, 1999, EUR J CLIN MICROBIOL, V18, P137, DOI 10.1007/s100960050242; Veiga-Parga T, 2013, IMMUNOL REV, V255, P182, DOI 10.1111/imr.12085; Velu V, 2009, NATURE, V458, P206, DOI 10.1038/nature07662; Weiss L, 2004, BLOOD, V104, P3249, DOI 10.1182/blood-2004-01-0365; Whiteside TL, 2015, CANCER MICROENVIRON, V8, P201, DOI 10.1007/s12307-014-0159-1; Yamamoto T, 2011, BLOOD, V117, P4805, DOI 10.1182/blood-2010-11-317297; Zanetti M, 2017, NAT REV CLIN ONCOL, V14, P115, DOI 10.1038/nrclinonc.2016.67; Zhou JY, 2013, J CLIN INVEST, V123, P2629, DOI 10.1172/JCI64704; zur Wiesch JS, 2011, J VIROL, V85, P1287, DOI 10.1128/JVI.01758-10	43	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 23	2018	9								2447	10.3389/fimmu.2018.02447	http://dx.doi.org/10.3389/fimmu.2018.02447			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GX7RR	30459765	gold, Green Published			2022-12-18	WOS:000447973700001
J	Rajamanickam, A; Munisankar, S; Bhootra, Y; Dolla, C; Nutman, TB; Babu, S				Rajamanickam, Anuradha; Munisankar, Saravanan; Bhootra, Yukthi; Dolla, Chandrakumar; Nutman, Thomas B.; Babu, Subash			Elevated Systemic and Parasite-Antigen Stimulated Levels of Type III IFNs in a Chronic Helminth Infection and Reversal Following Anthelmintic Treatment	FRONTIERS IN IMMUNOLOGY			English	Article						Type III IFNs; DC subsets; IFN lambda-1; IFN lambda-2; IFN lambda-3; Strongyloides stercoralis; helminths	STRONGYLOIDES-STERCORALIS; INTERFERON-LAMBDA; IMMUNOMODULATION; RESPONSES; FILARIAL; BACTERIA; CELLS; IL-29	Type III IFNs are important players in immunity to viral and bacterial infections. However, their association with helminth infections has not been examined. To explore the association of Type III IFNs with Strongyloides stercoralis (Ss) infection, we examined the systemic levels of IFN lambda-1, IFN lambda-2 and IFN lambda-3, IL-10, and CXCL10/IP-10 in Ss infected (INF, n = 44), helminth-uninfected (UN, n = 44) and in post-treatment INF individuals. We also examined the levels of IFN lambda-1, IFN lambda-2 and IFN lambda-3, IL-10, and CXCL10/IP-10 in whole blood culture supernatants stimulated with Ss somatic antigens, or PPD or LPS. Finally, we performed correlations of systemic Type III IFN levels with absolute numbers of dendritic cell subsets. Ss infection is characterized by elevated systemic levels of IFN lambda-1, IFN lambda-2 and IFN lambda-3, IL-10, and CXCL10/IP-10 in comparison to UN individuals and a significant reduction following anthelmintic treatment. Ss infection is also characterized by elevated levels of unstimulated or Ss antigen stimulated levels of IFN lambda-1, IFN lambda-2 and IFN lambda-3, CXCL10/IP-10 and a significant reduction following treatment. In addition, Ss infection is characterized by increased numbers of plasmacytoid and myeloid dendritic cells in comparison to UN individuals, with a significant reduction following anthelmintic treatment of INF individuals. Finally, Ss infection exhibits a significant positive correlation between the systemic levels of IFN lambda-2 and IFN lambda-3 and the numbers of plasmacytoid dendritic cells. Thus, Ss infection is characterized by elevations in systemic and antigen-induced levels of Type III IFNs, which is positively associated with the numbers of plasmacytoid dendritic cells and reversed upon anthelmintic treatment.	[Rajamanickam, Anuradha; Munisankar, Saravanan; Bhootra, Yukthi; Babu, Subash] Natl Inst Hlth, NIRT, Int Ctr Excellence Res, Madras, Tamil Nadu, India; [Dolla, Chandrakumar] Natl Inst Res TB, Madras, Tamil Nadu, India; [Nutman, Thomas B.; Babu, Subash] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Babu, S (corresponding author), Natl Inst Hlth, NIRT, Int Ctr Excellence Res, Madras, Tamil Nadu, India.; Babu, S (corresponding author), NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.	sbabu@mail.nih.gov	Rajamanickam, Anuradha/AAV-3550-2020; Babu, Subash/GXG-4746-2022	Rajamanickam, Anuradha/0000-0002-8143-5502; 	Division of Intramural Research, NIAID, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001065] Funding Source: NIH RePORTER	Division of Intramural Research, NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by the Division of Intramural Research, NIAID, NIH.	Andreakos E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01232; Anuradha R, 2016, INFECT IMMUN, V84, P425, DOI 10.1128/IAI.01354-15; Anuradha R, 2015, J IMMUNOL, V195, P2241, DOI 10.4049/jimmunol.1500745; Bisoffi Z, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002640; Breloer M, 2017, PARASITOLOGY, V144, P295, DOI 10.1017/S0031182016000111; Buonfrate D, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003491; Durbin RK, 2013, IMMUNOL REV, V255, P25, DOI 10.1111/imr.12101; Dussurget O, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00050; Espinosa V, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5357; Gallagher G, 2010, J INTERF CYTOK RES, V30, P603, DOI 10.1089/jir.2010.0081; Goodridge HS, 2005, J IMMUNOL, V174, P284, DOI 10.4049/jimmunol.174.1.284; Jordan WJ, 2007, GENES IMMUN, V8, P13, DOI 10.1038/sj.gene.6364348; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Lasfar A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00598; Lazear HM, 2015, IMMUNITY, V43, P15, DOI 10.1016/j.immuni.2015.07.001; Lipner EM, 2006, AM J TROP MED HYG, V74, P841, DOI 10.4269/ajtmh.2006.74.841; McSorley HJ, 2013, INT J PARASITOL, V43, P301, DOI 10.1016/j.ijpara.2012.11.011; Megjugorac NJ, 2010, BLOOD, V115, P4185, DOI 10.1182/blood-2009-09-246157; Megjugorac NJ, 2009, J LEUKOCYTE BIOL, V86, P1359, DOI 10.1189/jlb.0509347; Nutman TB, 2017, PARASITOLOGY, V144, P263, DOI 10.1017/S0031182016000834; Odendall C, 2017, J IMMUNOL, V199, P3270, DOI 10.4049/jimmunol.1700250; Pekarek V, 2007, GENES IMMUN, V8, P177, DOI 10.1038/sj.gene.6364372; Pott J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00258; Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Srinivas S, 2008, IMMUNOLOGY, V125, P492, DOI 10.1111/j.1365-2567.2008.02862.x; Wack A, 2015, NAT IMMUNOL, V16, P802, DOI 10.1038/ni.3212; Waddell SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009753; Yin ZW, 2012, J IMMUNOL, V189, P2735, DOI 10.4049/jimmunol.1102038; Zanoni I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01661; Zhang SY, 2013, GASTROENTEROLOGY, V144, P414, DOI 10.1053/j.gastro.2012.10.034	32	2	3	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 23	2018	9								2353	10.3389/fimmu.2018.02353	http://dx.doi.org/10.3389/fimmu.2018.02353			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GX7QM	30405603	Green Accepted, Green Published, gold			2022-12-18	WOS:000447969800001
J	Hilger, N; Mueller, C; Stahl, L; Mueller, AM; Zoennchen, B; Dluczek, S; Halbich, C; Wickenhauser, C; Gerloff, D; Wurm, AA; Behre, G; Kretschmer, A; Fricke, S				Hilger, Nadja; Mueller, Claudia; Stahl, Lilly; Mueller, Anne M.; Zoennchen, Bianca; Dluczek, Sarah; Halbich, Christoph; Wickenhauser, Claudia; Gerloff, Dennis; Wurm, Alexander A.; Behre, Gerhard; Kretschmer, Anna; Fricke, Stephan			Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia	FRONTIERS IN IMMUNOLOGY			English	Article						anti-human CD4 antibody MAX.16H5; hematopoietic stem cell transplantation; graft-vs.-host disease; acute myeloid leukemia; 32D-FLT3(ITD); graft-vs.-leukemia; C3H/HeN	VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; T-CELLS; ALLOGENEIC TRANSPLANTATION; VIVO MODULATION; EX-VIVO; FLT3; CANCER; IMMUNOTHERAPY; AML	Despite the constant development of innovative therapeutic options for hematological malignancies, the gold-standard therapy regimen for curative treatment often includes allogeneic hematopoietic stem cell transplantation (HSCT). The graft-vs.-leukemia effect (GVL) is one of the main therapeutic goals that arises from HSCT. On the other hand, graft-vs.-host disease (GVHD) is still one of the main and most serious complications following allogeneic HSCT. In acute myeloid leukemia (AML), HSCT together with high-dose chemotherapy is used as a treatment option. An aggressive progression of the disease, a decreased response to treatment, and a poor prognosis are connected to internal tandem duplication (ITD) mutations in the Fms like tyrosine kinase 3 (FLT3) gene, which affects around 30% of AML patients. In this study, C3H/HeN mice received an allogeneic graft together with 32D-FLT3(ITD) AML cells to induce acute GVHD and GVL. It was examined if pre-incubation of the graft with the anti-human cluster of differentiation (CD) 4 antibody MAX.16H5 IgG(1) prevented the development of GVHD and whether the graft function was impaired. Animals receiving grafts pre-incubated with the antibody together with FLT3(ITD) AML cells survived significantly longer than mice receiving untreated grafts. The observed prolonged survival due to MAX.16H5 incubation of immune cell grafts prior to transplantation may allow an extended application of additional targeted strategies in the treatment of AML.	[Hilger, Nadja; Mueller, Claudia; Stahl, Lilly; Mueller, Anne M.; Zoennchen, Bianca; Dluczek, Sarah; Halbich, Christoph; Kretschmer, Anna; Fricke, Stephan] Fraunhofer Inst Cell Therapy & Immunol, Immune Tolerance, Immunol, Leipzig, Germany; [Hilger, Nadja] Univ Leipzig, Inst Clin Immunol, Leipzig, Germany; [Wickenhauser, Claudia] Halle Univ Hosp, Inst Pathol, Halle, Germany; [Gerloff, Dennis] Univ Hosp Halle, Dept Dermatol & Venereol, Halle, Germany; [Wurm, Alexander A.; Behre, Gerhard] Leipzig Univ Hosp, Div Hematol & Med Oncol, Leipzig, Germany	Fraunhofer Gesellschaft; Leipzig University; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Leipzig University	Hilger, N (corresponding author), Fraunhofer Inst Cell Therapy & Immunol, Immune Tolerance, Immunol, Leipzig, Germany.; Hilger, N (corresponding author), Univ Leipzig, Inst Clin Immunol, Leipzig, Germany.	nadja.hilger@izi.fraunhofer.de	Fricke, Stephan/AAF-1629-2021	Wurm, Alexander/0000-0003-0065-9481	German Federal Ministry of Education and Research (BMBF) [C4107]; Dr. Werner Jackstadt Stiftung; German society for hematology and medical oncology (DGHO)	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Dr. Werner Jackstadt Stiftung; German society for hematology and medical oncology (DGHO)	This study was supported by grants from Dr. Werner Jackstadt Stiftung and German society for hematology and medical oncology (DGHO, CH), German Federal Ministry of Education and Research (BMBF, C4107).	Abe BT, 2012, CANCER RES, V72, P4642, DOI 10.1158/0008-5472.CAN-11-3775; Apetoh L, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.998538; Appelbaum FR, 2001, NATURE, V411, P385, DOI 10.1038/35077251; Auletta JJ, 2015, STEM CELLS, V33, P601, DOI 10.1002/stem.1867; Barnes TA, 2017, BRIT J CANCER, V117, P451, DOI 10.1038/bjc.2017.220; Beitinjaneh A, 2010, LEUKEMIA RES, V34, P831, DOI 10.1016/j.leukres.2010.01.001; Bienz M, 2005, CLIN CANCER RES, V11, P1416, DOI 10.1158/1078-0432.CCR-04-1552; Chen FL, 2016, ONCOTARGET, V7, P47018, DOI 10.18632/oncotarget.10147; Chen Yun, 2017, Stem Cell Investig, V4, P48, DOI 10.21037/sci.2017.05.04; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; de Aquino MTP, 2015, IMMUNOL LETT, V166, P117, DOI 10.1016/j.imlet.2015.05.018; De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50; del Campo L, 2014, RADIOGRAPHICS, V34, P396, DOI 10.1148/rg.342135046; Dickinson AM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00496; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; European Medicines Agency, 2017, RYD MID; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Fox J., 2019, R COMPANION APPL REG, V3rd; Fricke S., 2015, ENTWICKLUNG PRAKLINI; Fricke S, 2014, CELL MOL LIFE SCI, V71, P2135, DOI 10.1007/s00018-013-1476-0; Fricke S, 2012, CYTOM PART A, V81A, P476, DOI 10.1002/cyto.a.22061; Gallogly MM, 2016, J BLOOD MED, V7, P73, DOI 10.2147/JBM.S100283; Gerloff D, 2015, LEUKEMIA, V29, P535, DOI 10.1038/leu.2014.231; Gerloff D, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.2438.2438; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Grafone T, 2012, ONCOL REV, V6, P64, DOI 10.4081/oncol.2012.e8; Greaves P, 2013, BLOOD, V121, P734, DOI 10.1182/blood-2012-10-385591; Hadrup S, 2013, CANCER MICROENVIRON, V6, P123, DOI 10.1007/s12307-012-0127-6; Heinrichs J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1146842; Helling B, 2015, IMMUNOL CELL BIOL, V93, P396, DOI 10.1038/icb.2014.102; Hilger N, 2016, CYTOM PART A, V89A, P803, DOI 10.1002/cyto.a.22930; HOROWITZ MM, 1990, BLOOD, V75, P555; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; Hothorn T, 2006, AM STAT, V60, P257, DOI 10.1198/000313006X118430; Hothorn T, 2008, J STAT SOFTW, V28, P1; Impola U, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00523; Jamani K, 2013, BONE MARROW TRANSPL, V48, P1359, DOI 10.1038/bmt.2013.59; Kadia TM, 2016, ANN ONCOL, V27, P770, DOI 10.1093/annonc/mdw015; Kanate Abraham S, 2014, World J Stem Cells, V6, P69, DOI 10.4252/wjsc.v6.i2.69; KERN DE, 1986, J IMMUNOL, V136, P4303; Levine JE, 2010, BIOL BLOOD MARROW TR, V16, P1693, DOI 10.1016/j.bbmt.2010.05.019; Li Pira G, 2016, BLOOD REV, V30, P297, DOI 10.1016/j.blre.2016.03.001; Loo DT, 2011, METHODS MOL BIOL, V682, P3, DOI 10.1007/978-1-60327-409-8_1; Magenau J, 2016, BRIT J HAEMATOL, V173, P190, DOI 10.1111/bjh.13959; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; Martin PJ, 2012, BIOL BLOOD MARROW TR, V18, P982, DOI 10.1016/j.bbmt.2012.04.006; Matthews K, 2009, HAEMATOL-HEMATOL J, V94, P956, DOI 10.3324/haematol.2008.003103; Midostaurin. US Food and Drug Administration, 2017, MID; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Muller-Tidow C, 2002, DEUT MED WOCHENSCHR, V127, P2195, DOI 10.1055/s-2002-34942; Nash RA, 1996, CURR OPIN IMMUNOL, V8, P674, DOI 10.1016/S0952-7915(96)80085-9; Nasilowska-Adamska B, 2016, EUR J HAEMATOL, V96, P236, DOI 10.1111/ejh.12575; Oelkrug C, 2014, INT J RADIAT BIOL, V90, P538, DOI 10.3109/09553002.2014.899443; Ogle D. H., 2018, FSA FISHERIES STOCK; Ottinger HD, 2003, BLOOD, V102, P1131, DOI 10.1182/blood-2002-09-2866; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Pratz KW, 2017, BLOOD, V129, P565, DOI 10.1182/blood-2016-09-693648; R Core Team, 2017, R LANG ENV STAT COMP; REPKE H, 1992, J IMMUNOL, V149, P1809; Rockova V, 2011, BLOOD, V118, P1069, DOI 10.1182/blood-2011-02-334748; Rollig C, 2018, AKUTE MYELOISCHE LEU; Schmid C, 2015, BLOOD, V126, P2062, DOI 10.1182/blood-2015-06-651562; Schmidt F, 2015, CYTOM PART A, V87A, P334, DOI 10.1002/cyto.a.22619; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schroeder MA, 2011, DIS MODEL MECH, V4, P318, DOI 10.1242/dmm.006668; Sengsayadeth SM, 2012, BONE MARROW TRANSPL, V47, P1535, DOI 10.1038/bmt.2012.88; Shulman HM, 2015, BIOL BLOOD MARROW TR, V21, P589, DOI 10.1016/j.bbmt.2014.12.031; Simonetta F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00465; Song Y, 2016, BONE MARROW TRANSPL, V51, P511, DOI 10.1038/bmt.2015.170; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Thibodeau J, 2012, ONCOIMMUNOLOGY, V1, P908, DOI 10.4161/onci.21205; Tschan-Plessl A, 2015, ANN HEMATOL, V94, P1899, DOI 10.1007/s00277-015-2461-5; Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004; Whitman SP, 2001, CANCER RES, V61, P7233; Zhou Y, 2018, EXP CELL RES, V362, P287, DOI 10.1016/j.yexcr.2017.11.029	78	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2018	9								2408	10.3389/fimmu.2018.02408	http://dx.doi.org/10.3389/fimmu.2018.02408			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GX6IV	30405611	gold, Green Published			2022-12-18	WOS:000447865500001
J	Schaefer, S; Hettinga, KA; Cullor, J; German, JB; Henrick, BM				Schaefer, Sara; Hettinga, Kasper Arthur; Cullor, James; German, J. Bruce; Henrick, Bethany M.			Use of UV Treated Milk Powder to Increase Vaccine Efficacy in the Elderly	FRONTIERS IN IMMUNOLOGY			English	Article						nutritional supplementation; dairy proteins; immune response; vaccines; UV-C treatment	TURBULENT-FLOW; CONSUMPTION; ASTHMA	Aging populations experience a decline in adaptive immune system function also known as immunosenesence. Protein nutrition has been shown to stimulate and strengthen the immune system, and such approaches are needed for this growing segment of the population. A controlled, randomized, double blind pilot study was conducted to compare two different protein sources (soy and dairy) as nutritional supplementation to enhance vaccine response. Our objective was to examine the immune stimulating effects of dairy protein subjected to ultraviolet radiation (UV-C) radiation treatment process instead of pasteurization. Participants were 21 healthy individuals over 60 years of age who consumed 6 g of the dairy protein or a comparison, soy iso flavone protein, twice a day for 8 weeks. DTaP vaccine administered at week 4. Non-parametric t-tests revealed a significant increase in Tetanus antibodies in the dairy group compared to the soy group at week 8. These findings suggest additional bene fits of UV-C treated unheated dairy protein as a solution to counteract immunosenescence, but warrant further study in elderly and other populations that might bene fit from immune system stimulation.	[Schaefer, Sara; Cullor, James; German, J. Bruce; Henrick, Bethany M.] Univ Calif Davis, Dept Food Sci & Technol, Foods Hlth Inst, Davis, CA 95616 USA; [Hettinga, Kasper Arthur] Wageningen Univ & Res, Wageningen, Netherlands; [Cullor, James] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA; [Henrick, Bethany M.] Univ Nebraska, Dept Food Sci & Technol, Lincoln, NE 68583 USA	University of California System; University of California Davis; Wageningen University & Research; University of California System; University of California Davis; University of Nebraska System; University of Nebraska Lincoln	Schaefer, S (corresponding author), Univ Calif Davis, Dept Food Sci & Technol, Foods Hlth Inst, Davis, CA 95616 USA.	seschaefer@ucdavis.edu	Henrick, Bethany M./N-5672-2018	Henrick, Bethany M./0000-0003-1883-6749	Tamarack Biotics, LLC.	Tamarack Biotics, LLC.	This work was supported by Tamarack Biotics, LLC., which is developing dairy food products using the UV-C treatment process described in this report.	Abbring S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01045; Ahluwalia N, 2004, J Nutr Health Aging, V8, P2; Alberini F, 2015, J FOOD ENG, V162, P63, DOI 10.1016/j.jfoodeng.2015.04.009; [Anonymous], 1988, B WORLD HEALTH ORGAN, V66, P421; [Anonymous], 2016, OFFICIAL METHODS ANA, V20th ed.; Archer DL, 2017, DOSSIER SUPPORT GENE; Braun-Fahrlander C, 2011, CLIN EXP ALLERGY, V41, P29, DOI 10.1111/j.1365-2222.2010.03665.x; Brick T, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090963; Brick T, 2016, J ALLERGY CLIN IMMUN, V137, P1699, DOI 10.1016/j.jaci.2015.10.042; Cappozzo JC, 2015, J DAIRY SCI, V98, P5068, DOI 10.3168/jds.2014-9190; CASTANEDA C, 1995, AM J CLIN NUTR, V62, P30, DOI 10.1093/ajcn/62.1.30; Center for Food Safety Applied Nutrition & FDA, 2002, FDA BACT AN MAN; Chandra RK, 2004, AGEING RES REV, V3, P91, DOI 10.1016/j.arr.2003.08.004; Crook JA, 2015, FOODBORNE PATHOG DIS, V12, P506, DOI 10.1089/fpd.2014.1843; Freeman SL, 2010, ANN NY ACAD SCI, V1190, P97, DOI 10.1111/j.1749-6632.2009.05264.x; Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001; Lluis A, 2014, J ALLERGY CLIN IMMUN, V133, P551, DOI 10.1016/j.jaci.2013.06.034; Loss G, 2015, J ALLERGY CLIN IMMUN, V135, P56, DOI 10.1016/j.jaci.2014.08.044; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Lutz HU, 2008, AUTOIMMUN REV, V7, P508, DOI 10.1016/j.autrev.2008.04.017; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; National Center for Health Statistics, 2017, DEATHS MORT; Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893, DOI 10.4049/jimmunol.168.11.5893; United States Public Health Service USPHS & FDA F. D. A, 2016, GRAD A PAST MILK ORD, P1; Weinberger B, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0107-2; Wyss AB, 2018, THORAX, V73, P279, DOI 10.1136/thoraxjnl-2017-210031	26	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 17	2018	9								2254	10.3389/fimmu.2018.02254	http://dx.doi.org/10.3389/fimmu.2018.02254			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GX1OQ	30386327	Green Published, gold			2022-12-18	WOS:000447487700001
J	Hughes, HR; Brockmeier, SL; Loving, CL				Hughes, Holly R.; Brockmeier, Susan L.; Loving, Crystal L.			Bordetella bronchiseptica Colonization Limits Efficacy, but Not Immunogenicity, of Live-Attenuated Influenza Virus Vaccine and Enhances Pathogenesis After Influenza Challenge	FRONTIERS IN IMMUNOLOGY			English	Article						influenza vaccine; vaccine; co-infection; efficacy; immunity	SECONDARY BACTERIAL-INFECTIONS; III SECRETION SYSTEM; A VIRUSES; RESPIRATORY-DISEASE; PASTEURELLA-MULTOCIDA; DERMONECROTIC TOXIN; UNITED-STATES; SWINE; PIGS; PROTECTION	Intranasally administered live-attenuated influenza virus (LAIV) vaccines provide significant protection against heterologous influenza A virus (IAV) challenge. However, LAIV administration can modify the bacterial microbiota in the upper respiratory tract, including alterations in species that cause pneumonia. We sought to evaluate the effect of Bordetella bronchiseptica colonization on LAIV immunogenicity and efficacy in swine, and the impact of LAIV and IAV challenge on B. bronchiseptica colonization and disease. LAIV immunogenicity was not significantly impacted by B. bronchiseptica colonization, but protective efficacy against heterologous IAV challenge in the upper respiratory tract was impaired. Titers of IAV in the nose and trachea of pigs that received LAIV were significantly reduced when compared to non-vaccinated, challenged controls, regardless of B. bronchiseptica infection. Pneumonia scores were higher in pigs colonized with B. bronchiseptica and challenged with IAV, but this was regardless of LAIV vaccination status. While LAIV vaccination provided significant protection against heterologous IAV challenge, the protection was not sterilizing and IAV replicated in the respiratory tract of all LAIV vaccinated pig. The interaction between IAV, B. bronchiseptica, and host led to development of acute-type B. bronchiseptica lesions in the lung. Thus, the data presented do not negate the efficacy of LAIV vaccination, but instead indicate that controlling B. bronchiseptica colonization in swine could limit the negative interaction between IAV and Bordetella on swine health.	[Hughes, Holly R.; Brockmeier, Susan L.; Loving, Crystal L.] ARS, Virus & Prion Dis Livestock Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA 50011 USA; [Loving, Crystal L.] ARS, Food Safety & Enter Pathogens Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA 50011 USA; [Hughes, Holly R.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA	United States Department of Agriculture (USDA); United States Department of Agriculture (USDA); Centers for Disease Control & Prevention - USA	Loving, CL (corresponding author), ARS, Virus & Prion Dis Livestock Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA 50011 USA.; Loving, CL (corresponding author), ARS, Food Safety & Enter Pathogens Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA 50011 USA.	crystal.loving@ars.usda.gov	huang, yee/Q-9528-2017		Boehringer-Ingelheim Vetmedica, Inc; USDA-Agricultural Research Service	Boehringer-Ingelheim Vetmedica, Inc(Boehringer Ingelheim); USDA-Agricultural Research Service(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	Funding for this work is provided in part by Boehringer-Ingelheim Vetmedica, Inc, and USDA-Agricultural Research Service.	Abe H, 2015, MICROBIOL IMMUNOL, V59, P249, DOI 10.1111/1348-0421.12247; Anderson TK, 2015, VIRUS RES, V201, P24, DOI 10.1016/j.virusres.2015.02.009; Bandyopadhyay A, 2012, BIOSYSTEMS, V110, P107, DOI 10.1016/j.biosystems.2012.08.004; Bone MA, 2017, P NATL ACAD SCI USA, V114, pE1519, DOI 10.1073/pnas.1609565114; Brockmeier SL, 2008, VET MICROBIOL, V128, P36, DOI 10.1016/j.vetmic.2007.09.025; Brockmeier SL, 2007, VET MICROBIOL, V125, P284, DOI 10.1016/j.vetmic.2007.05.022; Brockmeier S. L, 2002, POLYMICROBIAL DIS; Brockmeier SL, 2002, INFECT IMMUN, V70, P481, DOI 10.1128/IAI.70.2.481-490.2002; Ciacci-Zanella JR, 2010, J VET DIAGN INVEST, V22, P3, DOI 10.1177/104063871002200102; Coote JG, 2001, ADV MICROB PHYSIOL, V44, P141, DOI 10.1016/S0065-2911(01)44013-6; Esposito S, 2018, EUR J CLIN MICROBIOL, V37, P1, DOI 10.1007/s10096-017-3076-7; Gauger PC, 2012, VET PATHOL, V49, P900, DOI 10.1177/0300985812439724; Gauger PC, 2011, VACCINE, V29, P2712, DOI 10.1016/j.vaccine.2011.01.082; Gonyar LA, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00198-17; HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606; HARRIS DL, 1968, AM J VET RES, V29, P777; Hasan S, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00445-17; Hughes HR, 2015, CLIN VACCINE IMMUNOL, V22, P1109, DOI 10.1128/CVI.00358-15; Lorusso A, 2013, CURR TOP MICROBIOL, V370, P113, DOI 10.1007/82_2011_196; Lorusso A, 2011, J GEN VIROL, V92, P919, DOI 10.1099/vir.0.027557-0; Loving CL, 2013, J VIROL, V87, P9895, DOI 10.1128/JVI.01038-13; Loving CL, 2010, MICROB PATHOGENESIS, V49, P237, DOI 10.1016/j.micpath.2010.06.004; Masic A, 2010, VACCINE, V28, P7098, DOI 10.1016/j.vaccine.2010.08.003; Masic A, 2009, J VIROL, V83, P10198, DOI 10.1128/JVI.00926-09; Mattoo S, 2001, FRONT BIOSCI-LANDMRK, V6, pE168, DOI 10.2741/Mattoo; Mina MJ, 2015, J INFECT DIS, V212, P195, DOI 10.1093/infdis/jiu804; Mina MJ, 2014, MBIO, V5, DOI 10.1128/mBio.01040-13; Nelson MI, 2015, J VIROL, V89, P6218, DOI 10.1128/JVI.00459-15; Nelson MI, 2015, TRENDS MICROBIOL, V23, P142, DOI 10.1016/j.tim.2014.12.002; Nelson MI, 2012, J VIROL, V86, P8872, DOI 10.1128/JVI.00259-12; Nicholson TL, 2014, INFECT IMMUN, V82, P1092, DOI 10.1128/IAI.01115-13; Nicholson TL, 2009, INFECT IMMUN, V77, P2136, DOI 10.1128/IAI.01379-08; Pena L, 2011, J VIROL, V85, P456, DOI 10.1128/JVI.01503-10; Pilione MR, 2006, INFECT IMMUN, V74, P1043, DOI 10.1128/IAI.74.2.1043-1049.2006; Rajao DS, 2018, VIROLOGY, V518, P45, DOI 10.1016/j.virol.2018.02.006; REED L. J., 1938, AMER JOUR HYG, V27, P493; Richt JA, 2009, CURR TOP MICROBIOL, V333, P177, DOI 10.1007/978-3-540-92165-3_9; Robinson KM, 2015, CURR OPIN IMMUNOL, V34, P59, DOI 10.1016/j.coi.2015.02.002; Rose MA, 2012, EXPERT REV VACCINES, V11, P595, DOI [10.1586/erv.12.31, 10.1586/ERV.12.31]; Sandbulte MR, 2015, VACCINES-BASEL, V3, P22, DOI 10.3390/vaccines3010022; Sandbulte MR, 2014, VIROLOGY, V464, P45, DOI 10.1016/j.virol.2014.06.027; Scheller EV, 2015, MBIO, V6, DOI 10.1128/mBio.00500-15; Schulz BS, 2014, VET J, V201, P365, DOI 10.1016/j.tvjl.2014.04.019; Short KR, 2013, INFECT IMMUN, V81, P645, DOI 10.1128/IAI.01278-12; Shrivastava R, 2009, CURR OPIN MICROBIOL, V12, P88, DOI 10.1016/j.mib.2009.01.001; Siciliano NA, 2006, J IMMUNOL, V177, P7131, DOI 10.4049/jimmunol.177.10.7131; Smith AM, 2014, CURR TOP MICROBIOL, V385, P327, DOI 10.1007/82_2014_394; Sun K, 2011, J IMMUNOL, V186, P987, DOI 10.4049/jimmunol.1002664; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Teijaro JR, 2010, J VIROL, V84, P9217, DOI 10.1128/JVI.01069-10; Tessmer A, 2011, EUR RESPIR J, V38, P147, DOI 10.1183/09031936.00133510; Thors V, 2016, AM J RESP CRIT CARE, V193, P1401, DOI 10.1164/rccm.201510-2000OC; Vincent AL, 2012, J VIROL, V86, P10597, DOI 10.1128/JVI.01439-12; Vincent AL, 2008, ADV VIRUS RES, V72, P127, DOI 10.1016/S0065-3527(08)00403-X; Walia RR, 2019, INFLUENZA OTHER RESP, V13, P262, DOI 10.1111/irv.12559; Ward JI, 2005, NEW ENGL J MED, V353, P1555, DOI 10.1056/NEJMoa050824; Zens KD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85832; Zhang Q, 2014, SCAND J INFECT DIS, V46, P280, DOI 10.3109/00365548.2013.878034	58	2	2	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2018	9								2255	10.3389/fimmu.2018.02255	http://dx.doi.org/10.3389/fimmu.2018.02255			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GV7XA	30337924	Green Published, gold			2022-12-18	WOS:000446346200001
J	Ben-Shmuel, A; Joseph, N; Barda-Saad, M				Ben-Shmuel, Aviad; Joseph, Noah; Barda-Saad, Mira			Commentary: Integrins Modulate T Cell Receptor Signaling by Constraining Actin Flow at the Immunological Synapse	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mechanotransduction; cytoskeleton; NK cells; actin retrograde flow; SHP-1	ANTIGEN RECEPTOR; ACTIVATION; MECHANOTRANSDUCTION; POLYMERIZATION; MICROCLUSTERS; CYTOSKELETON; ZAP-70		[Ben-Shmuel, Aviad; Joseph, Noah; Barda-Saad, Mira] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel	Bar Ilan University	Barda-Saad, M (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel.	Mira.Barda-Saad@biu.ac.il			Israel Science Foundation [1503/08, 747/13]; Chief Scientist Office of the Ministry of Health [3-10151]; Taubenblatt Family Foundation Bio-Medicine excellence grant	Israel Science Foundation(Israel Science Foundation); Chief Scientist Office of the Ministry of Health; Taubenblatt Family Foundation Bio-Medicine excellence grant	This research was funded by the Israel Science Foundation grants no. 1503/08 and 747/13, grant no. 3-10151 from the Chief Scientist Office of the Ministry of Health, and a Taubenblatt Family Foundation Bio-Medicine excellence grant.	Babich A, 2012, J CELL BIOL, V197, P775, DOI 10.1083/jcb.201201018; Barda-Saad M, 2005, NAT IMMUNOL, V6, P80, DOI 10.1038/ni1143; Barr VA, 2006, TRAFFIC, V7, P1143, DOI 10.1111/j.1600-0854.2006.00464.x; Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Comrie WA, 2015, J CELL BIOL, V208, P475, DOI 10.1083/jcb.201406121; Dupre L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00586; Dustin ML, 2010, IMMUNOL REV, V235, P24, DOI 10.1111/j.0105-2896.2010.00904.x; Gomez TS, 2008, ADV IMMUNOL, V97, P1, DOI 10.1016/S0065-2776(08)00001-1; Hahn C, 2009, NAT REV MOL CELL BIO, V10, P53, DOI 10.1038/nrm2596; Hoffman BD, 2011, NATURE, V475, P316, DOI 10.1038/nature10316; Makino A, 2007, BIORHEOLOGY, V44, P221; Matalon O, 2018, EMBO J, V37, DOI 10.15252/embj.201696264; Matalon O, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad6182; Murugesan S, 2016, J CELL BIOL, V215, P383, DOI 10.1083/jcb.201603080; Nguyen K, 2008, IMMUNITY, V28, P810, DOI 10.1016/j.immuni.2008.04.019; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Smoligovets AA, 2012, J CELL SCI, V125, P735, DOI 10.1242/jcs.092825; Tolar P, 2017, NAT REV IMMUNOL, V17, P621, DOI 10.1038/nri.2017.67; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Weinbaum S, 2011, CELL MOL BIOENG, V4, P510, DOI 10.1007/s12195-011-0179-6	21	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 19	2018	9								2110	10.3389/fimmu.2018.02110	http://dx.doi.org/10.3389/fimmu.2018.02110			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GU1SK	30283450	Green Published, gold			2022-12-18	WOS:000445045900002
J	Ali, MN; Kasetty, G; Elven, M; Alyafei, S; Jovic, S; Egesten, A; Herwald, H; Schmidtchen, A; Papareddy, P				Ali, Mohamad N.; Kasetty, Gopinath; Elven, Malin; Alyafei, Saud; Jovic, Sandra; Egesten, Arne; Herwald, Heiko; Schmidtchen, Artur; Papareddy, Praveen			TFPI-2 Protects Against Gram-Negative Bacterial Infection	FRONTIERS IN IMMUNOLOGY			English	Article						TFPI-2; antimicrobial peptide; bacteria; complement; immunoglobulins; sepsis	HOST-DEFENSE PEPTIDES; FACTOR PATHWAY INHIBITOR-2; C-TERMINAL PEPTIDES; MOLECULAR-CLONING; LOCALIZATION; LIPOPOLYSACCHARIDE; PURIFICATION; COMPLEMENT; EXPRESSION; THROMBIN	Tissue factor pathway inhibitor-2 (TFPI-2) has previously been characterized as an endogenous anticoagulant. TFPI-2 is expressed in the vast majority of cells, mainly secreted into the extracellular matrix. Recently we reported that EDC34, a C-terminal peptide derived from TFPI-2, exerts a broad antimicrobial activity. In the present study, we describe a previously unknown antimicrobial mode of action for the human TFPI-2 C-terminal peptide EDC34, mediated via binding to immunoglobulins of the classes IgG, IgA, IgE, and IgM. In particular the interaction of EDC34 with the Fc part of IgG is of importance since this boosts interaction between the immunoglobulin and complement factor C1q. Moreover, we find that the binding increases the C1q engagement of the antigen-antibody interaction, leading to enhanced activation of the classical complement pathway during bacterial infection. In experimental murine models of infection and endotoxin challenge, we show that TFPI-2 is up-regulated in several organs, including the lung. Correspondingly, TFPI-2 -1- mice are more susceptible to pulmonary Pseudomonas aeruginosa bacterial infection. No anti-coagulant role of TFPI-2 was observed in these models in vivo. Furthermore, in vivo, the mouse TFPI-2-derived C-terminal peptide VKG24, a homolog to human EDC34 is protective against systemic Escherichia coli bacterial infection. Moreover, in sputum from cystic fibrosis patients TFPI-2 C-terminal fragments are generated and found associated with immunoglobulins. Together our data describe a previously unknown host defense mechanism and therapeutic importance of TFPI-2 against invading Gram-negative bacterial pathogens.	[Ali, Mohamad N.; Elven, Malin; Schmidtchen, Artur; Papareddy, Praveen] Lund Univ, Dept Clin Sci Lund, Div Dermatol & Venereol, Lund, Sweden; [Ali, Mohamad N.; Kasetty, Gopinath; Jovic, Sandra; Egesten, Arne] Lund Univ, Div Resp Med & Allergol, Dept Clin Sci Lund, Lund, Sweden; [Alyafei, Saud; Herwald, Heiko; Papareddy, Praveen] Lund Univ, Dept Clin Sci Lund, Div Infect Med, Lund, Sweden; [Schmidtchen, Artur] Nanyang Technol Univ, Dermatol, LKCMed, Singapore, Singapore; [Schmidtchen, Artur] Univ Copenhagen, Bispebjerg Hosp, Dept Biomed Sci, Copenhagen Wound Healing Ctr, Copenhagen, Denmark	Lund University; Lund University; Lund University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; University of Copenhagen; Bispebjerg Hospital	Papareddy, P (corresponding author), Lund Univ, Dept Clin Sci Lund, Div Dermatol & Venereol, Lund, Sweden.; Papareddy, P (corresponding author), Lund Univ, Dept Clin Sci Lund, Div Infect Med, Lund, Sweden.	praveen.papareddy@med.lu.se	Herwald, Heiko/AAN-3708-2021	Herwald, Heiko/0000-0002-8111-2842; Papareddy, Praveen/0000-0002-3872-478X	Alfred Osterlund Foundation; Crafoord Foundation; Welander-Finsen; Swedish Foundation for Strategic Research; Swedish Research Council [2012-1883]; Knut and Alice Wallenberg Foundation; The Swedish Government Funds for Clinical Research (ALF); Royal Physiographic Society in Lund	Alfred Osterlund Foundation; Crafoord Foundation; Welander-Finsen; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Research Council(Swedish Research CouncilEuropean Commission); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); The Swedish Government Funds for Clinical Research (ALF); Royal Physiographic Society in Lund	This work was supported by grants from the Alfred Osterlund Foundation, Crafoord Foundation, Welander-Finsen, the Swedish Foundation for Strategic Research, the Swedish Research Council (projects 2012-1883), the Knut and Alice Wallenberg Foundation, The Swedish Government Funds for Clinical Research (ALF), and the Royal Physiographic Society in Lund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson E, 2004, EUR J BIOCHEM, V271, P1219, DOI 10.1111/j.1432-1033.2004.04035.x; Andres MT, 2008, ANTIMICROB AGENTS CH, V52, P4081, DOI 10.1128/AAC.01597-07; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bistrian B, 2007, NUTR REV, V65, pS170, DOI 10.1301/nr.2007.dec.S170-S172; Bowdish DME, 2005, J LEUKOCYTE BIOL, V77, P451, DOI 10.1189/jlb.0704380; Charles A, 2001, IMMUNOBIOL IMMUNE SY, V5; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; Crawley JTB, 2002, ARTERIOSCL THROM VAS, V22, P218, DOI 10.1161/hq0102.101842; Dalby PA, 2000, PROTEIN SCI, V9, P2366, DOI 10.1017/S096183680000239X; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; Elsbach P, 2003, J CLIN INVEST, V111, P1643, DOI 10.1172/JCI200318761; Elvington M, 2012, BLOOD, V119, P6043, DOI 10.1182/blood-2011-10-383232; GANZ T, 1990, EUR J HAEMATOL, V44, P1; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; GERA JF, 1991, CELL IMMUNOL, V138, P108, DOI 10.1016/0008-8749(91)90136-Y; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Hansen FC, 2015, J IMMUNOL, V194, P5397, DOI 10.4049/jimmunol.1403009; Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403; Hong J, 2016, THROMB RES, V137, P148, DOI 10.1016/j.thromres.2015.11.010; Jiang ZQ, 2008, BIOPOLYMERS, V90, P369, DOI 10.1002/bip.20911; Kalle M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102577; Kalle M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051313; Kasetty G, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0750-3; Kasetty G, 2011, ANTIMICROB AGENTS CH, V55, P2880, DOI 10.1128/AAC.01515-10; Leem JY, 1996, J BIOL CHEM, V271, P13573, DOI 10.1074/jbc.271.23.13573; Liu YY, 1999, ARCH BIOCHEM BIOPHYS, V370, P112, DOI 10.1006/abbi.1999.1371; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Miriam F-F, 2010, BIOCHIM BIOPHYS ACTA, V1803, P3, DOI DOI 10.1016/J.BBAMCR.2009.07.004; Neduva V, 2005, PLOS BIOL, V3, P2090, DOI 10.1371/journal.pbio.0030405; Nijnik A, 2010, J IMMUNOL, V184, P2539, DOI 10.4049/jimmunol.0901813; Papareddy P, 2018, VIRULENCE, V9, P724, DOI 10.1080/21505594.2018.1441589; Papareddy P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003803; Papareddy P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052772; Papareddy P, 2010, J BIOL CHEM, V285, P28387, DOI 10.1074/jbc.M110.127019; PERKINS SJ, 1985, EUR J BIOCHEM, V147, P525; Rosenfeld Y, 2006, J BIOL CHEM, V281, P1636, DOI 10.1074/jbc.M504327200; Schuerholz T, 2012, CRIT CARE, V16, DOI 10.1186/cc11220; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Tan SH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-502; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; TYTLER EM, 1995, BIOCHEMISTRY-US, V34, P4393, DOI 10.1021/bi00013a031; Udagawa K, 2002, PLACENTA, V23, P145, DOI 10.1053/plac.2001.0774; van der Plas MJA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11567; Wiedemann U, 2004, J MOL BIOL, V343, P703, DOI 10.1016/j.jmb.2004.08.064; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; YASMEEN D, 1976, J IMMUNOL, V116, P518	50	2	2	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2018	9								2072	10.3389/fimmu.2018.02072	http://dx.doi.org/10.3389/fimmu.2018.02072			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GT2NE	30254643	Green Published, gold			2022-12-18	WOS:000444330600001
J	Koblischke, M; Stiasny, K; Aberle, SW; Malafa, S; Tsouchnikas, G; Schwaiger, J; Kundi, M; Heinz, FX; Aberle, JH				Koblischke, Maximilian; Stiasny, Karin; Aberle, Stephan W.; Malafa, Stefan; Tsouchnikas, Georgios; Schwaiger, Julia; Kundi, Michael; Heinz, Franz X.; Aberle, Judith H.			Structural Influence on the Dominance of Virus-Specific CD4 T Cell Epitopes in Zika Virus Infection (vol 9, 1196, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						Zika virus; flavivirus; CD4 T cell; immunodominance; epitope; Zika patients			[Koblischke, Maximilian; Stiasny, Karin; Aberle, Stephan W.; Malafa, Stefan; Tsouchnikas, Georgios; Schwaiger, Julia; Heinz, Franz X.; Aberle, Judith H.] Med Univ Vienna, Ctr Virol, Vienna, Austria; [Kundi, Michael] Med Univ Vienna, Ctr Publ Hlth, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Aberle, JH (corresponding author), Med Univ Vienna, Ctr Virol, Vienna, Austria.	judith.aberle@meduniwien.ac.at		Malafa, Stefan/0000-0002-0222-9832	Austrian Science Fund FWF [P 29881] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Koblischke M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01196	1	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2018	9								2083	10.3389/fimmu.2018.02083	http://dx.doi.org/10.3389/fimmu.2018.02083			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GT2NJ	30254648	Green Published, gold			2022-12-18	WOS:000444331200004
J	Roszik, J; Tanese, K; Ekmekcioglu, S				Roszik, Jason; Tanese, Keiji; Ekmekcioglu, Suhendan			Editorial: Targeting Metabolism in Cancer Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer; metabolism; immune cells; tumor microenvironment; immunotherapy	DORMANCY; CELLS		[Roszik, Jason; Ekmekcioglu, Suhendan] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Roszik, Jason] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Tanese, Keiji] Keio Univ, Dept Dermatol, Sch Med, Tokyo, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Keio University	Roszik, J; Ekmekcioglu, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA.; Roszik, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	jroszik@mdanderson.org; sekmekcioglu@mdanderson.org		Roszik, Jason/0000-0002-4561-6170				Godin-Ethier J, 2011, CLIN CANCER RES, V17, P6985, DOI 10.1158/1078-0432.CCR-11-1331; Hornyak L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00151; Liu YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15207; Lob S, 2009, CANCER IMMUNOL IMMUN, V58, P153, DOI 10.1007/s00262-008-0513-6; Szalmas A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00077	5	2	3	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 11	2018	9								2029	10.3389/fimmu.2018.02029	http://dx.doi.org/10.3389/fimmu.2018.02029			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GT2LU	30254633	Green Published, gold			2022-12-18	WOS:000444325900002
J	Zhang, XR; Huo, LN; Song, LL; Hu, ZQ; Wang, XR; Han, YH; Wang, Y; Xu, PP; Zhang, J; Hua, ZC				Zhang, Xuerui; Huo, Lina; Song, Lulu; Hu, Zhaoqing; Wang, Xinran; Han, Yuheng; Wang, Ying; Xu, Peipei; Zhang, Jing; Hua, Zi-Chun			Dominant Negative FADD/MORT1 Inhibits the Development of Intestinal Intraepithelial Lymphocytes With a Marked Defect on CD8 alpha alpha plus TCR gamma delta plus T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						FADD; mucosal immune system; gamma delta plus T-IELs; LPLs; DSS-induced colitis	DEATH DOMAIN FADD; MEDIATED APOPTOSIS; INTERFERING MUTANT; PROTEIN FADD; IN-VIVO; MICE; HOMEOSTASIS; GUT; INFLAMMATION; NECROPTOSIS	Intestinal intraepithelial lymphocytes (IELs) play a critical role in mucosal immune system, which differ from thymus-derived cells and develop locally in gut. Although the development of IELs has been studied in some detail, the molecular cues controlling their local development remain unclear. Here, we demonstrate that FADD, a classic adaptor protein required for death-receptor-induced apoptosis, is a critical regulator of the intestinal IEL development. The mice with a dominant negative mutant of FADD (FADD-DN) display an abnormal development of intestinal IELs with a marked reduction in the numbers of CD8 alpha alpha+TCR gamma delta(+) T cells. As a precursor for CD8 alpha alpha(+) development, lamina propria lymphocytes in lin-negative expression (lin(-) LPLs) were analyzed and the massive accumulation of IL-7R(-)lin(-) LPLs was observed in FADD-DN mice. As IL-7R is one of Notch1-target genes, we further observed that the level of Notch1 expression was lower in Lin(-) LPLs from FADD-DN mice compared with normal mice. The downregulation of Notch1 expression induced by FADD-DN overexpression was also confirmed in Jurkat T cells. Considering that IL-7 and its receptor IL7-R play a differentiation inducing role in the development of intestinal IELs, the influence of FADD via its DD domain on Notch1 expression might be a possible molecular signal involved in the early IELs development. In addition, loss of gamma delta T-IELs in FADD-DN mice aggravates DSS-induced colitis, suggesting that FADD is a relevant contribution to the field of mucosal immunology and intestinal homeostasis.	[Zhang, Xuerui; Huo, Lina; Song, Lulu; Hu, Zhaoqing; Wang, Xinran; Han, Yuheng; Wang, Ying; Zhang, Jing; Hua, Zi-Chun] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China; [Zhang, Xuerui; Wang, Ying; Zhang, Jing; Hua, Zi-Chun] Nanjing Univ, Changzhou High Tech Res Inst, Changzhou, Peoples R China; [Zhang, Xuerui; Wang, Ying; Zhang, Jing; Hua, Zi-Chun] Jiangsu Target Pharma Labs Inc, Changzhou, Peoples R China; [Xu, Peipei] Nanjing Univ, Drum Tower Hosp, Sch Med, Dept Hematol, Nanjing, Jiangsu, Peoples R China; [Hua, Zi-Chun] Nanjing Univ, Shenzhen Res Inst, Shenzhen, Peoples R China	Nanjing University; Nanjing University; Nanjing University; Nanjing University	Zhang, J; Hua, ZC (corresponding author), Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China.; Zhang, J; Hua, ZC (corresponding author), Nanjing Univ, Changzhou High Tech Res Inst, Changzhou, Peoples R China.; Zhang, J; Hua, ZC (corresponding author), Jiangsu Target Pharma Labs Inc, Changzhou, Peoples R China.; Hua, ZC (corresponding author), Nanjing Univ, Shenzhen Res Inst, Shenzhen, Peoples R China.	jzhang08@nju.edu.cn; zchua@nju.edu.cn	Hu, Zhaoqing/ABB-9344-2020		Chinese National Natural Sciences Foundation [81630092, 81773099, 81570790, 81573338]; National Key R&D Research Program by Ministry of Science and Technology [2017YFA0506002, 2017YFA0104301, 2016YFC0902700]; Shenzhen Science and Technology Innovation Committee [JCYJ20160331152141936]; Shenzhen Peacock Plan [KQTD20140630165057031]	Chinese National Natural Sciences Foundation(National Natural Science Foundation of China (NSFC)); National Key R&D Research Program by Ministry of Science and Technology; Shenzhen Science and Technology Innovation Committee; Shenzhen Peacock Plan	This study was supported in part by grants from the Chinese National Natural Sciences Foundation (81630092, 81773099, 81570790, 81573338), the National Key R&D Research Program by Ministry of Science and Technology (2017YFA0506002, 2017YFA0104301, 2016YFC0902700) and Shenzhen Science and Technology Innovation Committee (JCYJ20160331152141936), Shenzhen Peacock Plan (KQTD20140630165057031).	Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105; Bonnet MC, 2011, IMMUNITY, V35, P572, DOI 10.1016/j.immuni.2011.08.014; Cai YJ, 2012, INT J CLIN EXP PATHO, V5, P569; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; Cheroutre H, 2011, NAT REV IMMUNOL, V11, P445, DOI 10.1038/nri3007; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Delphine GG, 2003, J EXP MED, V197, P333, DOI [10.1084/jem.20021639, DOI 10.1084/JEM.20021639]; Dowling JP, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00012; Ettersperger J, 2016, IMMUNITY, V45, P610, DOI 10.1016/j.immuni.2016.07.018; Ford MS, 2006, J IMMUNOL, V177, P2803, DOI 10.4049/jimmunol.177.5.2803; Grunert M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.154; Guy-Grand D, 2002, CURR OPIN IMMUNOL, V14, P255, DOI 10.1016/S0952-7915(02)00330-8; Helgeland L, 1997, IMMUNOLOGY, V92, P447, DOI 10.1046/j.1365-2567.1997.00379.x; Herbrand H, 2011, DEVELOPMENTAL BIOLOGY OF PERIPHERAL LYMPHOID ORGANS, P107, DOI 10.1007/978-3-642-14429-5_10; Hoffmann JC, 2001, GUT, V48, P489, DOI 10.1136/gut.48.4.489; Inagaki-Ohara K, 2004, J IMMUNOL, V173, P1390, DOI 10.4049/jimmunol.173.2.1390; Ismail AS, 2011, P NATL ACAD SCI USA, V108, P8743, DOI 10.1073/pnas.1019574108; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Kikuchi M, 2012, J BIOL CHEM, V287, P41165, DOI 10.1074/jbc.M112.419747; Kuhl AA, 2007, J LEUKOCYTE BIOL, V81, P168, DOI 10.1189/jlb.1105696; Laky K, 1998, J IMMUNOL, V161, P707; Laky K, 1999, FASEB J, V13, pA622; Lambolez F, 2002, J EXP MED, V195, P437, DOI 10.1084/jem.20010798; Saiz ML, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01854; Lu JV, 2011, P NATL ACAD SCI USA, V108, P15312, DOI 10.1073/pnas.1102779108; Mallis RJ, 2015, P NATL ACAD SCI USA, V112, P8373, DOI 10.1073/pnas.1504971112; Meehan TF, 2014, MUCOSAL IMMUNOL, V7, P134, DOI 10.1038/mi.2013.32; Nanno M, 2007, IMMUNOL REV, V215, P103, DOI 10.1111/j.1600-065X.2006.00474.x; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Nogusa S, 2016, CELL HOST MICROBE, V20, P13, DOI 10.1016/j.chom.2016.05.011; Osborn SL, 2010, P NATL ACAD SCI USA, V107, P13034, DOI 10.1073/pnas.1005997107; Peaudecerf L, 2011, MUCOSAL IMMUNOL, V4, P93, DOI 10.1038/mi.2010.47; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Saito H, 1998, SCIENCE, V280, P275, DOI 10.1126/science.280.5361.275; Saran N, 2010, BLOOD, V115, P1137, DOI 10.1182/blood-2009-07-230821; Shitara S, 2013, J IMMUNOL, V190, P6173, DOI 10.4049/jimmunol.1202573; Suzuki H, 2002, DEV COMP IMMUNOL, V26, P589, DOI 10.1016/S0145-305X(02)00004-6; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang PX, 2017, NAT MED, V23, P439, DOI 10.1038/nm.4290; Wang XM, 2014, J EXP MED, V211, P2351, DOI 10.1084/jem.20140646; Wurbel MA, 2007, J IMMUNOL, V178, P7598, DOI 10.4049/jimmunol.178.12.7598; Zhang HB, 2011, NATURE, V471, P373, DOI 10.1038/nature09878; Zhang J, 2001, J BIOL CHEM, V276, P29815, DOI 10.1074/jbc.M103838200; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.198; Zhang XJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00388; Zhang YH, 2005, J IMMUNOL, V175, P3033, DOI 10.4049/jimmunol.175.5.3033	50	2	2	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 10	2018	9								2038	10.3389/fimmu.2018.02038	http://dx.doi.org/10.3389/fimmu.2018.02038			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GT0KH	30250469	Green Submitted, Green Published, gold			2022-12-18	WOS:000444127500001
J	Bevelacqua, JJ; Mortazavi, SMJ				Bevelacqua, Joseph J.; Mortazavi, S. M. J.			Commentary: Immune System Dysregulation During Spaceflight: Potential Countermeasures for Deep Space Exploration Missions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						space radiation; immune system; countermeasures; deep space missions; radioadaptation	RADIATION-HORMESIS; IN-VITRO		[Bevelacqua, Joseph J.] Bevelacqua Resources, Richland, WA USA; [Mortazavi, S. M. J.] Fox Chase Canc Ctr, Diagnost Imaging Dept, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Mortazavi, S. M. J.] Shiraz Univ Med Sci, INIRPRC, Shiraz, Iran	Fox Chase Cancer Center; Shiraz University of Medical Science	Mortazavi, SMJ (corresponding author), Fox Chase Canc Ctr, Diagnost Imaging Dept, 7701 Burholme Ave, Philadelphia, PA 19111 USA.; Mortazavi, SMJ (corresponding author), Shiraz Univ Med Sci, INIRPRC, Shiraz, Iran.	s.m.javad.mortazavi@fccc.edu	Mortazavi, SMJ/D-5830-2011	Mortazavi, SMJ/0000-0003-0139-2774				Austin AW, 2014, AVIAT SPACE ENVIR MD, V85, P912, DOI 10.3357/ASEM.3959.2014; Bevelacqua JJ, 2018, BRIT J ANAESTH, V120, P874, DOI 10.1016/j.bja.2017.12.015; Bevelacqua JJ, 2018, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01116; Bhattacharjee D, 2001, IN VIVO, V15, P87; Cortese Franco, 2018, Oncotarget, V9, P14692, DOI 10.18632/oncotarget.24461; Crucian BE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01437; Elmore E, 2011, RADIAT RES, V176, P291, DOI 10.1667/RR2646.1; Feinendegen LE, 2005, BRIT J RADIOL, V78, P3, DOI 10.1259/bjr/63353075; Huff J., 2016, EVIDENCE REPORT RISK; Mortazavi S, 2003, INT COSM RAY C; Mortazavi SMJ, 2018, HEALTH PHYS, V114, P344, DOI 10.1097/HP.0000000000000823; Mortazavi SMJ, 2014, DOSE-RESPONSE, V12, P233, DOI 10.2203/dose-response.12-055.Mortazavi; Mortazavi SMJ, 2013, INT J RADIAT RES, V11, P199; Mortazavi SMJ, 2013, TECHNOL HEALTH CARE, V21, P285, DOI 10.3233/THC-130732; Mortazavi SM, 2014, PHYS MED, V30, P97, DOI [10.1016/ j. ejmp. 2014.07.278, DOI 10.1016/J.EJMP.2014.07.278]; Mortazavi SMJ, 2003, ADV SPACE RES-SERIES, V31, P1543, DOI 10.1016/S0273-1177(03)00089-9; Rithidech KN, 2012, HEALTH PHYS, V102, P39, DOI 10.1097/HP.0b013e31822833af; Sato T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117020; Scott BR, 2014, J CELL COMMUN SIGNAL, V8, P341, DOI 10.1007/s12079-014-0250-x; Stowe RP, 2011, AVIAT SPACE ENVIR MD, V82, P627, DOI 10.3357/ASEM.2980.2011; Stowe RP, 1999, J LEUKOCYTE BIOL, V65, P179, DOI 10.1002/jlb.65.2.179	21	2	2	2	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 4	2018	9								2024	10.3389/fimmu.2018.02024	http://dx.doi.org/10.3389/fimmu.2018.02024			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GS4NL	30233600	Green Published, gold			2022-12-18	WOS:000443623300001
J	Michelucci, A; Mittelbronn, M; Gomez-Nicola, D				Michelucci, Alessandro; Mittelbronn, Michel; Gomez-Nicola, Diego			Microglia in Health and Disease: A Unique Immune Cell Population	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						microglia; ontogeny; inflammation; neurodegeneration; brain tumour			[Michelucci, Alessandro; Mittelbronn, Michel] Luxembourg Inst Hlth, Dept Oncol, NORLUX Neurooncol Lab, Luxembourg, Luxembourg; [Michelucci, Alessandro; Mittelbronn, Michel] Univ Luxembourg, Luxembourg Ctr Syst Biomed, Esch Sur Alzette, Luxembourg; [Mittelbronn, Michel] Luxembourg Ctr Neuropathol, Dudelange, Luxembourg; [Mittelbronn, Michel] Lab Natl Sante, Dudelange, Luxembourg; [Gomez-Nicola, Diego] Univ Southampton, Sch Biol Sci, Southampton, Hants, England	Luxembourg Institute of Health; University of Luxembourg; University of Southampton	Michelucci, A (corresponding author), Luxembourg Inst Hlth, Dept Oncol, NORLUX Neurooncol Lab, Luxembourg, Luxembourg.; Michelucci, A (corresponding author), Univ Luxembourg, Luxembourg Ctr Syst Biomed, Esch Sur Alzette, Luxembourg.	alessandro.michelucci@lih.lu	Gomez-Nicola, Diego/E-7728-2015	Gomez-Nicola, Diego/0000-0002-5316-2682; Mittelbronn, Michel/0000-0002-2998-052X; Michelucci, Alessandro/0000-0003-1230-061X	MRC [MR/P024572/1] Funding Source: UKRI; Medical Research Council [MR/P024572/1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Sousa C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00198	1	2	2	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 15	2018	9								1779	10.3389/fimmu.2018.01779	http://dx.doi.org/10.3389/fimmu.2018.01779			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GQ3WV	30158924	Green Published, gold, Green Accepted			2022-12-18	WOS:000441599400001
J	Song, L; Xiong, D; Song, HQ; Wu, LL; Zhang, MH; Kang, XL; Pan, ZM; Jiao, XA				Song, Li; Xiong, Dan; Song, Hongqin; Wu, Lili; Zhang, Meihua; Kang, Xilong; Pan, Zhiming; Jiao, Xinan			Mucosal and Systemic immune responses to influenza H7n9 Antigen HA1-2Co-Delivered intranasally With Flagellin or Polyethyleneimine in Mice and Chickens (vol 8, pg 326, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						avian influenza A (H7N9) virus; hemagglutinin globular head; flagellin; polyethyleneimine; mucosal subunit vaccine			[Song, Li; Xiong, Dan; Song, Hongqin; Wu, Lili; Zhang, Meihua; Kang, Xilong; Pan, Zhiming; Jiao, Xinan] Yangzhou Univ, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China; [Song, Li; Xiong, Dan; Song, Hongqin; Wu, Lili; Zhang, Meihua; Kang, Xilong; Pan, Zhiming; Jiao, Xinan] Yangzhou Univ, Jiangsu Key Lab Zoonosis, Yangzhou, Jiangsu, Peoples R China; [Song, Li; Xiong, Dan; Song, Hongqin; Wu, Lili; Zhang, Meihua; Kang, Xilong; Pan, Zhiming; Jiao, Xinan] Yangzhou Univ, Minist Agr China, Key Lab Prevent & Control Biol Hazard Factors Ani, Yangzhou, Jiangsu, Peoples R China; [Song, Li; Xiong, Dan; Song, Hongqin; Wu, Lili; Zhang, Meihua; Kang, Xilong; Pan, Zhiming; Jiao, Xinan] Yangzhou Univ, Minist Educ, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou, Jiangsu, Peoples R China	Yangzhou University; Yangzhou University; Ministry of Agriculture & Rural Affairs; Yangzhou University; Yangzhou University	Pan, ZM; Jiao, XA (corresponding author), Yangzhou Univ, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China.; Pan, ZM; Jiao, XA (corresponding author), Yangzhou Univ, Jiangsu Key Lab Zoonosis, Yangzhou, Jiangsu, Peoples R China.; Pan, ZM; Jiao, XA (corresponding author), Yangzhou Univ, Minist Agr China, Key Lab Prevent & Control Biol Hazard Factors Ani, Yangzhou, Jiangsu, Peoples R China.; Pan, ZM; Jiao, XA (corresponding author), Yangzhou Univ, Minist Educ, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou, Jiangsu, Peoples R China.	zmpan@yzu.edu.cn; jiao@yzu.edu.cn						Song L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00326	1	2	2	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 13	2018	9								1846	10.3389/fimmu.2018.01846	http://dx.doi.org/10.3389/fimmu.2018.01846			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GQ1TO	30131811	Green Published, gold			2022-12-18	WOS:000441423500001
J	Lee, SWL; Adriani, G; Ceccarello, E; Pavesi, A; Tan, AT; Bertoletti, A; Kamm, RD; Wong, SC				Lee, Sharon Wei Ling; Adriani, Giulia; Ceccarello, Erica; Pavesi, Andrea; Tan, Anthony Tanoto; Bertoletti, Antonio; Kamm, Roger Dale; Wong, Siew Cheng			Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model (vol 9, 416, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						microfluidics; monocytes; T cell receptor-redirected T cells; immunotherapy; immune checkpoint; PD-L1; tumor microenvironment			[Lee, Sharon Wei Ling; Adriani, Giulia; Kamm, Roger Dale] Singapore MIT Alliance Res & Technol, BioSyst & Micromech IRG, Singapore, Singapore; [Lee, Sharon Wei Ling; Ceccarello, Erica; Wong, Siew Cheng] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore; [Lee, Sharon Wei Ling; Wong, Siew Cheng] Agcy Sci Technol & Res, Singapore Immunol Network SIgN, Biomed Sci Inst, Singapore, Singapore; [Ceccarello, Erica; Pavesi, Andrea] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore, Singapore; [Tan, Anthony Tanoto; Bertoletti, Antonio] Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore, Singapore; [Kamm, Roger Dale] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Singapore-MIT Alliance for Research & Technology Centre (SMART); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Massachusetts Institute of Technology (MIT)	Kamm, RD (corresponding author), Singapore MIT Alliance Res & Technol, BioSyst & Micromech IRG, Singapore, Singapore.; Wong, SC (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.; Wong, SC (corresponding author), Agcy Sci Technol & Res, Singapore Immunol Network SIgN, Biomed Sci Inst, Singapore, Singapore.; Kamm, RD (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	rdkamm@mit.edu; wong_siew_cheng@immunol.a-star.edu.sg	Kamm, Roger D/I-7630-2012					Lee SWL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00416	1	2	2	4	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 24	2018	9								1719	10.3389/fimmu.2018.01719	http://dx.doi.org/10.3389/fimmu.2018.01719			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GO0EF	30083166	Green Published, gold			2022-12-18	WOS:000439593900001
J	Frisk, JMH; Kjellen, L; Melo, FR; Ohrvik, H; Pejler, G				Frisk, Jun Mei Hu; Kjellen, Lena; Melo, Fabio R.; Ohrvik, Helena; Pejler, Gunnar			Mitogen-Activated Protein Kinase Signaling Regulates Proteoglycan Composition of Mast Cell Secretory Granules	FRONTIERS IN IMMUNOLOGY			English	Article						mast cells; mitogen-activated protein kinase; MEK1/2; proteoglycans; heparin; chondroitin sulfate; tryptase; serglycin	FC-EPSILON-RI; SERGLYCIN PROTEOGLYCAN; MICE; EXPRESSION; RECEPTOR; PHOSPHORYLATION; TRANSCRIPTION; MATURATION; RESPONSES; PATHWAY	Mast cells (MCs) are characterized by an abundance of lysosome-like secretory granules filled with immunomodulatory compounds including histamine, cytokines, lysosomal hydrolases, MC-restricted proteases, and serglycin proteoglycans. The latter are essential for promoting the storage of other granule compounds and are built up of the serglycin core protein to which highly sulfated and thereby negatively charged glycosaminoglycan (GAG) side chains of heparin or chondroitin sulfate type are attached. In the search for mechanisms operating in regulating MC granule homeostasis, we here investigated the role of mitogen-activated protein kinase (MAPK) signaling. We show that inhibition of MEK1/2 (a MAPK kinase) leads to increased metachromatic staining of MC granules, indicative of increased proteoglycan content. Indeed, MEK1/2 inhibition caused a profound increase in the expression of the gene coding for the serglycin core protein and of genes coding for various enzymes involved in the biosynthesis/sulfation of the GAGs attached to the serglycin core protein. This was accompanied by corresponding increases in the levels of the respective GAGs. Deletion of the serglycin core protein abrogated the induction of enzymes operative in proteoglycan synthesis, indicating that availability of the serglycin proteoglycan core protein has a regulatory function impacting on the expression of the various serglycin-modifying enzymes. MEK1/2 inhibition also caused a substantial increase in the expression of granule-localized, proteoglycan-binding proteases. Altogether, this study identifies a novel role for MAPK signaling in regulating the content of secretory granules in MCs.	[Frisk, Jun Mei Hu; Kjellen, Lena; Melo, Fabio R.; Ohrvik, Helena; Pejler, Gunnar] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences	Pejler, G (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.; Pejler, G (corresponding author), Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden.	gunnar.pejler@imbim.uu.se	Melo, Fabio Rabelo/GQP-0844-2022		Swedish Heart and Lung Foundation; Swedish Research Council; Swedish Cancer Society; Knut and Alice Wallenberg Foundation	Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation)	This work was supported by grants from The Swedish Heart and Lung Foundation (GP), The Swedish Research Council (GP), The Swedish Cancer Society (GP), and The Knut and Alice Wallenberg Foundation.	Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; Akahoshi M, 2011, J CLIN INVEST, V121, P4180, DOI 10.1172/JCI46139; Alvarez-Errico D, 2009, IMMUNOL REV, V232, P195, DOI 10.1111/j.1600-065X.2009.00834.x; Azouz NP, 2014, DNA CELL BIOL, V33, P647, DOI 10.1089/dna.2014.2543; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; BURWEN SJ, 1982, TISSUE CELL, V14, P125, DOI 10.1016/0040-8166(82)90012-X; Dagalv A, 2011, J BIOL CHEM, V286, P44433, DOI 10.1074/jbc.M111.303891; Drube S, 2016, J IMMUNOL, V197, P3662, DOI 10.4049/jimmunol.1600658; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DVORAK AM, 1987, CELL IMMUNOL, V105, P199, DOI 10.1016/0008-8749(87)90068-2; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Frisk JMH, 2017, J IMMUNOL, V199, P4132, DOI 10.4049/jimmunol.1700786; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Gorzalczany Y, 2017, CANCER LETT, V397, P23, DOI 10.1016/j.canlet.2017.03.026; Grujic M, 2013, J IMMUNOL, V191, P3931, DOI 10.4049/jimmunol.1301441; Gurish MF, 2012, IMMUNITY, V37, P25, DOI 10.1016/j.immuni.2012.07.003; Henningsson F, 2006, FEBS J, V273, P4901, DOI 10.1111/j.1742-4658.2006.05489.x; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; Jippo T, 1997, BLOOD, V90, P2601, DOI 10.1182/blood.V90.7.2601.2601_2601_2608; Johnzon CF, 2016, AM J PATHOL, V186, P4, DOI 10.1016/j.ajpath.2015.06.024; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kolset SO, 2011, J IMMUNOL, V187, P4927, DOI 10.4049/jimmunol.1100806; Korpetinou A, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00327; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Martin-Avila A, 2016, J IMMUNOL, V196, P5075, DOI 10.4049/jimmunol.1501823; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Morii E, 2002, J BIOL CHEM, V277, P8566, DOI 10.1074/jbc.M110392200; Ringvall M, 2008, J ALLERGY CLIN IMMUN, V121, P1020, DOI 10.1016/j.jaci.2007.11.031; Ronnberg E, 2012, J HISTOCHEM CYTOCHEM, V60, P950, DOI 10.1369/0022155412458927; Ronnberg E, 2012, BIOL CHEM, V393, P107, DOI 10.1515/BC-2011-220; Ronnberg E, 2012, METHODS MOL BIOL, V836, P201, DOI 10.1007/978-1-61779-498-8_14; SLUTSKY B, 1987, EXP CELL RES, V168, P63, DOI 10.1016/0014-4827(87)90416-2; Song JS, 1999, J IMMUNOL, V163, P802; Song JS, 1996, J BIOL CHEM, V271, P26962, DOI 10.1074/jbc.271.43.26962; Suzuki H, 1997, J IMMUNOL, V159, P5881; Turski ML, 2012, MOL CELL BIOL, V32, P1284, DOI 10.1128/MCB.05722-11; Voehringer D, 2013, NAT REV IMMUNOL, V13, P362, DOI 10.1038/nri3427; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690	40	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 19	2018	9								1670	10.3389/fimmu.2018.01670	http://dx.doi.org/10.3389/fimmu.2018.01670			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GN6BD	30073001	gold, Green Published			2022-12-18	WOS:000439155000001
J	Mohammed, S; Harikumar, KB				Mohammed, Sabira; Harikumar, K. B.			Sphingosine 1-Phosphate: A Novel Target for Lung Disorders (vol 8, 296, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						FTY720; S1PR; asthma; lung diseases; sphingosine 1-phosphate; sphingosine kinase			[Mohammed, Sabira; Harikumar, K. B.] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram, Kerala, India; [Mohammed, Sabira] Manipal Acad Higher Educ, Manipal, Karnataka, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); Manipal Academy of Higher Education (MAHE)	Harikumar, KB (corresponding author), Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram, Kerala, India.	harikumar@rgcb.res.in	Harikumar, Kuzhuvelil/AAC-2407-2020	Harikumar, Kuzhuvelil/0000-0002-1763-4179; Jazir, Sabira Mohammed/0000-0002-0332-3660				Mohammed S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00296	1	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 17	2018	9								1628	10.3389/fimmu.2018.01628	http://dx.doi.org/10.3389/fimmu.2018.01628			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GN4BA	30050541	Green Published, gold			2022-12-18	WOS:000438956500001
J	Zhao, DQ; Liao, T; Li, SW; Zhang, YN; Zheng, HF; Zhou, J; Han, F; Dong, Y; Sun, QQ				Zhao, Daqiang; Liao, Tao; Li, Siwen; Zhang, Yannan; Zheng, Haofeng; Zhou, Jing; Han, Fei; Dong, Yu; Sun, Qiquan			Mouse Model Established by Early Renal Transplantation After Skin Allograft Sensitization Mimics Clinical Antibody-Mediated Rejection	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; antibody-mediated rejection; donor-specific antibody; animal model; mice	ACUTE HUMORAL REJECTION; DONOR-SPECIFIC ANTIBODY; CD4 T-CELLS; KIDNEY-TRANSPLANTATION; CELLULAR REJECTION; RECIPIENTS; BIOPSIES; BIOLOGY; INJURY	Antibody-mediated rejection (AMR) is the main barrier to renal graft survival, and mouse renal AMR models are important to study this process. Current mouse models are established by priming the recipient to donor skin for over 7 days before kidney transplantation. The robustness of AMR in these cases is too strong to mimic clinical AMR and it is unclear why altering the priming times ranging from 7 to 91 days fails to reduce the AMR potency in these models. In the present study, we found that the donor-recipient combination and skin graft size were determinants of donor-specific antibody (DSA) development patterns after skin transplantation. DSA-IgG was sustained for over 100 days after skin challenge, accounting for an identical AMR robustness upon different skin priming times over 7 days. However, decreasing the skin priming time within 7 days attenuated the robustness of subsequent renal allograft AMR in C3H to Balb/c mice. Four-day skin priming guaranteed that recipients develop acute renal AMR mixed with a high ratio of graft-infiltrating macrophages, renal grafts survived for a mean of 6.4 +/- 2.1 days, characterized by typical AMR histological changes, such as glomerulitis, peritubular capillary (PTC) dilation, and capillaritis, deposition of IgG and C3d in PTCs, but less prevalence of microthrombus, whereas the cellular rejection histological change of tubulitis was absent to mild. With this scheme, we also found that the renal AMR model can be developed using common mouse strains such as C57BL/6 and Balb/c, with mean prolonged renal graft survival times of 14.4 +/- 5.0 days. Finally, we proved that donor-matched skin challenge after kidney transplantation did not strongly affect DSA development and kidney graft outcome. These findings may facilitate an understanding and establishment of mouse renal allograft AMR models and promote AMR-associated studies.	[Zhao, Daqiang; Liao, Tao; Li, Siwen; Zhang, Yannan; Zheng, Haofeng; Han, Fei; Sun, Qiquan] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Surg, Div Kidney Transplantat, Guangzhou, Guangdong, Peoples R China; [Zhou, Jing] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Dong, Yu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Sun, QQ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Surg, Div Kidney Transplantat, Guangzhou, Guangdong, Peoples R China.	sunqiq@mail.sysu.edu.cn	zheng, hao/HHM-6949-2022	Sun, Qiquan/0000-0002-7296-316X	National Natural Science Foundation of China [81600586, 81470978]; New Teacher Fund of Ministry of Education, China [20130171120100]; Science and Technology [2014A030304020]; Bureau of TCM projects of Guangdong province [201607050495]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); New Teacher Fund of Ministry of Education, China; Science and Technology; Bureau of TCM projects of Guangdong province	We gratefully acknowledge the invaluable comments of Randhawa, Parmjeet Singh (Department of Pathology, Montefiore Hospital, University of Pittsburgh) on graft histology interpretation, and Khodor Abou Daya (STI, University of Pittsburgh) in language collation. This work was funded by the National Natural Science Foundation of China (Nos. 81600586, 81470978), New Teacher Fund of Ministry of Education, China (No. 20130171120100), and Science and Technology (No. 2014A030304020) and Bureau of TCM (No. 201607050495) projects of Guangdong province. Part of this work was presented at the 2017 American Transplant Congress in Chicago, IL, USA on 29 April-3 May, 2017.	Abe T, 2015, AM J TRANSPLANT, V15, P1192, DOI 10.1111/ajt.13150; Baldwin WM, 2016, CURR OPIN ORGAN TRAN, V21, P7, DOI 10.1097/MOT.0000000000000262; Baldwin WM, 2010, AM J TRANSPLANT, V10, P1135, DOI 10.1111/j.1600-6143.2010.03065.x; Bickerstaff AA, 2001, J IMMUNOL, V167, P4821, DOI 10.4049/jimmunol.167.9.4821; Bickerstaff A, 2008, AM J PATHOL, V173, P347, DOI 10.2353/ajpath.2008.070391; Bickerstaffa A, 2008, AM J TRANSPLANT, V8, P557, DOI 10.1111/j.1600-6143.2007.02125.x; Burghuber CK, 2016, AM J TRANSPLANT, V16, P1726, DOI 10.1111/ajt.13688; Chong AS, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015495; Davis S, 2017, TRANSPLANT REV-ORLAN, V31, P47, DOI 10.1016/j.trre.2016.10.004; Gaughan A, 2014, AM J TRANSPLANT, V14, P284, DOI 10.1111/ajt.12596; Ginevri F, 2012, AM J TRANSPLANT, V12, P3355, DOI 10.1111/j.1600-6143.2012.04251.x; Gorbacheva V, 2016, J AM SOC NEPHROL, V27, P3299, DOI 10.1681/ASN.2015080848; Halloran PF, 2014, KIDNEY INT, V85, P258, DOI 10.1038/ki.2013.300; Homs S, 2009, AM J TRANSPLANT, V9, P1230, DOI 10.1111/j.1600-6143.2009.02596.x; Huang G, 2014, AM J TRANSPLANT, V14, P1061, DOI 10.1111/ajt.12674; Kohei N, 2013, KIDNEY INT, V84, P722, DOI 10.1038/ki.2013.117; Kuo HH, 2015, J AM SOC NEPHROL, V26, P855, DOI 10.1681/ASN.2013121289; Kurosaki T, 2010, IMMUNOL REV, V237, P5, DOI 10.1111/j.1600-065X.2010.00946.x; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251; Lemke A, 2015, TRANSPL IMMUNOL, V33, P95, DOI 10.1016/j.trim.2015.08.003; Liao T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01334; Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107; Nasir S, 2009, ANN PLAS SURG, V62, P430, DOI 10.1097/SAP.0b013e3181877ad7; Oracki SA, 2010, IMMUNOL REV, V237, P140, DOI 10.1111/j.1600-065X.2010.00940.x; Pakyari M, 2016, WOUND REPAIR REGEN, V24, P695, DOI 10.1111/wrr.12445; Pouliquen Eric, 2015, F1000Prime Rep, V7, P51, DOI 10.12703/P7-51; Rother R P, 2008, Am J Transplant, V8, P1129, DOI 10.1111/j.1600-6143.2008.02222.x; Sis B, 2008, AM J KIDNEY DIS, V51, P127, DOI 10.1053/j.ajkd.2007.08.023; Sun Q, 2007, KIDNEY INT, V71, P24, DOI 10.1038/sj.ki.5001870; Tse GH, 2013, TRANSPL INT, V26, P1149, DOI 10.1111/tri.12129; Wang Jiao-Jing, 2009, J Vis Exp, DOI 10.3791/1150; Wiebe C, 2015, AM J TRANSPLANT, V15, P2921, DOI 10.1111/ajt.13347; Wu KY, 2016, CLIN TRANSPLANT, V30, P105, DOI 10.1111/ctr.12645; Xu L, 2014, CLIN TRANSPLANT, V28, P554, DOI 10.1111/ctr.12348; Yamamoto T, 2016, TRANSPLANTATION, V100, P2194, DOI 10.1097/TP.0000000000001012; Zhao DQ, 2018, AM J TRANSPLANT, V18, P1083, DOI 10.1111/ajt.14602	37	2	3	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 4	2018	9								1356	10.3389/fimmu.2018.01356	http://dx.doi.org/10.3389/fimmu.2018.01356			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GL6ND	30022978	Green Published, gold			2022-12-18	WOS:000437303000001
J	Lovewell, TRJ; McDonagh, AJG; Messenger, AG; Azzouz, M; Tazi-Ahnini, R				Lovewell, Thomas R. J.; McDonagh, Andrew J. G.; Messenger, Andrew G.; Azzouz, Mimoun; Tazi-Ahnini, Rachid			Meta-analysis of autoimmune regulator-regulated genes in human and Murine Models: a novel human Model Provides insights on the role of autoimmune regulator in regulating STAT1 and STAT1-regulated genes	FRONTIERS IN IMMUNOLOGY			English	Article						Aire gene; STAT1; auitoimmune polyglandular syndrome 1; tissue-restricted antigens; TEC1 A3 cells	THYMIC EPITHELIAL-CELLS; CANDIDIASIS-ECTODERMAL DYSTROPHY; POLYENDOCRINE SYNDROME TYPE-1; SYNDROME TYPE-I; CHRONIC MUCOCUTANEOUS CANDIDIASIS; PRIMARY SJOGRENS-SYNDROME; SORTING NEXIN 10; TRYPTOPHAN-HYDROXYLASE; ADDISONS-DISEASE; BINDING PROTEIN	Autoimmune regulator (AIRE) regulates promiscuous expression of tissue-restricted antigens in medullary epithelial cells (mTEC) of the thymus. To understand the diverse effects of AIRE, it is crucial to elucidate the molecular mechanisms underlying the process of AIRE-regulated gene expression. In this study, we generated a recombinant AIRE expression variant of the TEC 1A3 human cell line, TEC 1A3 AIRE(hi), to determine genes targeted by AIRE, and using microarray analysis, we identified 482 genes showing significant differential expression (P < 0.05; false discovery rate <5%), with 353 upregulated and 129 downregulated by AIRE expression. Microarray data were validated by quantitative PCR, confirming the differential expression of 12 known AIRE-regulated genes. Comparison of AIRE-dependent differential expression in our cell line model with murine datasets identified 447 conserved genes with a number of transcription regulatory interactions, forming several key nodes, including STAT1, which had over 30 interactions with other AIRE-regulated genes. As STAT1 mutations cause dominant chronic mucocutaneous candidiasis and decreased STAT1 levels in monocytes of autoimmune polyglandular syndrome 1 (APS-1) patients, it was important to further characterize AIRE-STAT1 interactions. TEC 1A3AIRE(hi) were treated with the STAT1 phosphorylation inhibitors fludarabine and LLL3 showed that phosphorylated STAT1 (p-STAT1) was not responsible for any of the observed differential expression. Moreover, treatment of TEC 1A3 AIRE(hi) with STAT1 shRNA did not induce any significant variation in the expression Cof unphosphorylated STAT1 (U-STAT1) downstream genes, suggesting that these genes were directly regulated by AIRE but not via U-STAT1. The novel model system we have developed provides potential opportunities for further analysis of the pathogenesis of (APS-1) and the wider roles of the AIRE gene.	[Lovewell, Thomas R. J.; Tazi-Ahnini, Rachid] Univ Sheffield, Med Sch, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England; [McDonagh, Andrew J. G.; Messenger, Andrew G.] Royal Hallamshire Hosp, Dept Dermatol, Sheffield, S Yorkshire, England; [Azzouz, Mimoun] Univ Sheffield, Med Sch, Dept Neurosci, Sheffield, S Yorkshire, England; [Lovewell, Thomas R. J.] Innovat Ctr, Sheffield, S Yorkshire, England	University of Sheffield; University of Sheffield; University of Sheffield	Tazi-Ahnini, R (corresponding author), Univ Sheffield, Med Sch, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.	r.taziahnini@shef.ac.uk	Messenger, Andrew/J-1240-2019; Azzouz, Mimoun/B-3979-2009	Messenger, Andrew/0000-0003-1424-8069; Azzouz, Mimoun/0000-0001-6564-5967; Shaw, Pamela/0000-0002-8925-2567	"L'Association Francaise Contre les Myopathies" [AFM 15536]; Sheffield Hospitals Charity; European Research Council grant [294745]; MRC DPFS Award [G1001492]	"L'Association Francaise Contre les Myopathies"(Association Francaise contre les Myopathies); Sheffield Hospitals Charity; European Research Council grant(European Research Council (ERC)); MRC DPFS Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Christophe Benoit and Mathis Diane for their critical review of an early version of the manuscript. We also thank Dr. Paul Heath for his help in analyzing microarray data. This work has been funded by "L'Association Francaise Contre les Myopathies" (AFM 15536) and The Sheffield Hospitals Charity. MA is supported by the European Research Council grant (ERC Advanced Award no. 294745) an MRC DPFS Award (G1001492).	Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Abramson J, 2016, IMMUNOL REV, V271, P127, DOI 10.1111/imr.12419; Abramson J, 2010, CELL, V140, P123, DOI 10.1016/j.cell.2009.12.030; Alimohammadi M, 2008, NEW ENGL J MED, V358, P1018, DOI 10.1056/NEJMoa0706487; Alimohammadi M, 2009, P NATL ACAD SCI USA, V106, P4396, DOI 10.1073/pnas.0809986106; Anderson MS, 2016, NAT REV IMMUNOL, V16, P247, DOI 10.1038/nri.2016.9; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bansal K, 2017, NAT IMMUNOL, V18, P263, DOI 10.1038/ni.3675; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Brozzetti A, 2015, J CLIN ENDOCR METAB, V100, P1941, DOI 10.1210/jc.2014-3571; Cervantes-Anaya N, 2017, TUMOR BIOL, V39, DOI [10.1177/1010428317695932, 10.1177/1010428317732181]; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Cheon H, 2009, P NATL ACAD SCI USA, V106, P9373, DOI 10.1073/pnas.0903487106; Danso-Abeam D, 2013, EUR J IMMUNOL, V43, P75, DOI 10.1002/eji.201242761; Derbinski J, 2005, J EXP MED, V202, P33, DOI 10.1084/jem.20050471; Derbinski J, 2008, P NATL ACAD SCI USA, V105, P657, DOI 10.1073/pnas.0707486105; Ekwall O, 1998, LANCET, V352, P279, DOI 10.1016/S0140-6736(97)11050-9; Ekwall O, 1999, LANCET, V354, P568, DOI 10.1016/S0140-6736(99)01989-3; FERNANDEZ E, 1994, BLOOD, V83, P3245; Fierabracci A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071106; Gavalas NG, 2007, J CLIN ENDOCR METAB, V92, P2107, DOI 10.1210/jc.2006-2466; Giraud M, 2012, P NATL ACAD SCI USA, V109, P535, DOI 10.1073/pnas.1119351109; Gotoh A, 2013, J BIOL CHEM, V288, P34699, DOI 10.1074/jbc.M113.513119; Guerau-De-Arellano M, 2008, P NATL ACAD SCI USA, V105, P14011, DOI 10.1073/pnas.0806616105; Halatsch ME, 2009, J NEUROSURG, V111, P211, DOI 10.3171/2008.9.JNS08551; Herzig Y, 2017, NAT IMMUNOL, V18, P161, DOI 10.1038/ni.3638; Howson JMM, 2009, GENES IMMUN, V10, pS74, DOI 10.1038/gene.2009.96; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Husebye ES, 2009, J INTERN MED, V265, P514, DOI 10.1111/j.1365-2796.2009.02090.x; Ilmarinen T, 2008, MOL IMMUNOL, V45, P1847, DOI 10.1016/j.molimm.2007.10.045; Johnnidis JB, 2005, P NATL ACAD SCI USA, V102, P7233, DOI 10.1073/pnas.0502670102; Kisand K, 2015, J CLIN IMMUNOL, V35, P463, DOI 10.1007/s10875-015-0176-y; Koh AS, 2010, P NATL ACAD SCI USA, V107, P13016, DOI 10.1073/pnas.1004436107; Kumar PG, 2001, J BIOL CHEM, V276, P41357, DOI 10.1074/jbc.M104898200; Laan M, 2009, J IMMUNOL, V183, P7682, DOI 10.4049/jimmunol.0804133; Landegren N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9186; Li HM, 2004, IMMUNITY, V21, P551, DOI 10.1016/j.immuni.2004.08.013; Liiv I, 2008, BBA-MOL CELL RES, V1783, P74, DOI 10.1016/j.bbamcr.2007.09.003; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lovewell T., 2008, THESIS; Lovewell T., 2011, EGYPT J MED HUM GENE, V12, P107, DOI [10.1016/j.ejmhg.2011.06.008, DOI 10.1016/J.EJMHG.2011.06.008]; Lundberg M, 2016, DIABETES, V65, P3104, DOI 10.2337/db16-0616; Macedo C, 2009, MOL IMMUNOL, V46, P3240, DOI 10.1016/j.molimm.2009.08.002; McDaniel P, 2009, MOL REPROD DEV, V76, P151, DOI 10.1002/mrd.20937; Meredith M, 2015, NAT IMMUNOL, V16, P942, DOI 10.1038/ni.3247; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Org T, 2009, HUM MOL GENET, V18, P4699, DOI 10.1093/hmg/ddp433; Oven I, 2007, MOL CELL BIOL, V27, P8815, DOI 10.1128/MCB.01085-07; Panarina M, 2014, SCAND J IMMUNOL, V80, P283, DOI 10.1111/sji.12204; Perniola R, 2000, EUR J ENDOCRINOL, V143, P497, DOI 10.1530/eje.0.1430497; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Pontynen N, 2006, J AUTOIMMUN, V27, P96, DOI 10.1016/j.jaut.2006.06.001; Ruan QG, 2007, J IMMUNOL, V178, P7173, DOI 10.4049/jimmunol.178.11.7173; Samano Eliana Sueco Tibana, 2004, Rev. Hosp. Clin., V59, P138, DOI 10.1590/S0041-87812004000300009; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Sato K, 2004, BIOCHEM BIOPH RES CO, V318, P935, DOI 10.1016/j.bbrc.2004.04.116; Satoh JI, 2013, GENE REGUL SYST BIO, V7, P41, DOI 10.4137/GRSB.S11433; Severin J, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r39; Shi XW, 2011, J INVEST DERMATOL, V131, P2401, DOI 10.1038/jid.2011.222; Shum AK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006998; Sillanpaa N, 2004, MOL IMMUNOL, V41, P1185, DOI 10.1016/j.molimm.2004.06.004; Sudzius G, 2014, RHEUMATOL INT, V34, P235, DOI 10.1007/s00296-013-2885-y; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Venanzi ES, 2008, P NATL ACAD SCI USA, V105, P15860, DOI 10.1073/pnas.0808070105; WINQVIST O, 1993, J CLIN INVEST, V92, P2377, DOI 10.1172/JCI116843; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507; Yang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078901; You Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20630; Zimmerman O, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00820	70	2	3	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 28	2018	9								1380	10.3389/fimmu.2018.01380	http://dx.doi.org/10.3389/fimmu.2018.01380			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GK9PZ	30002654	Green Published, Green Accepted, gold			2022-12-18	WOS:000436585300001
J	Keizer, MP; Kamp, A; van Mierlo, G; Kuijpers, TW; Wouters, D				Keizer, Mischa P.; Kamp, Angela; van Mierlo, Gerard; Kuijpers, Taco W.; Wouters, Diana			Substitution of Mannan-Binding Lectin (MBL)-Deficient Serum With Recombinant MBL Results in the Formation of New MBL/MBL-Associated Serine Protease Complexes	FRONTIERS IN IMMUNOLOGY			English	Article						recombinant MBL; MBL-associated serine protease; redistribution; mannan-binding lectin-MBL-associated serine protease complexes; size-exclusion chromatography	PATTERN-RECOGNITION MOLECULES; PHASE-I SAFETY; COMPLEMENT ACTIVATION; PATHWAY ACTIVATION; HUMAN PLASMA; OLIGOMERIC FORMS; MASP-1; POLYMORPHISMS; C1-INHIBITOR; CHILDREN	The lectin pathway (LP) of complement activation depends on the activation of the MBL-associated serine proteases (MASPs) circulating in complex with mannan-binding lectin (MBL). MBL deficiency is the most common complement deficiency and has been associated with several pathological conditions. As we had previously shown, plasma-derived MBL (pdMBL) contains pre-activated MASPs that upon in vivo pdMBL substitution results in restoration of MBL concentrations but no LP functionality due to immediate inactivation of pdMBL-MASP complexes upon infusion. In this study, we analyzed MBL-sufficient and -deficient serum by size-exclusion chromatography for complexes of LP activation. In both sera, we identified non-bound free forms of MASP-2 and to lesser extent MASP-1/3. After addition of recombinant MBL (rMBL) to MBL-deficient serum, these free MASPs were much less abundantly present, which is highly suggestive for the formation of high-molecular complexes that could still become activated upon subsequent ligand binding as shown by a restoration of C4-deposition of MBL-deficient serum. Ficolin (FCN)-associated MASPs have been described to redistribute to ligand-bound MBL, hereby forming new MBL/MASP complexes. However, reconstitution of MBL-deficient serum with rMBL did not change the relative size of the FCN molecules suggestive for a limited redistribution in fluid phase of already formed complexes. Our findings demonstrate that rMBL can associate with free non-bound MASPs in fluid phase while preserving full restoration of LP functionality. In contrast to pdMBL products containing pre-activated MASPs which become inactivated almost immediately, these current data provide a rationale for substitution studies using rMBL instead.	[Keizer, Mischa P.; Kamp, Angela; van Mierlo, Gerard; Wouters, Diana] Univ Amsterdam, Acad Med Ctr, Sanquin Blood Supply, Dept Immunopathol,Div Res & Landsteiner Lab, Amsterdam, Netherlands; [Keizer, Mischa P.; Kuijpers, Taco W.] Univ Amsterdam, AMC, Emma Childrens Hosp, Dept Pediat Hematol Immunol & Infect Dis, Amsterdam, Netherlands; [Kuijpers, Taco W.] Univ Amsterdam, Dept Blood Cell Res, Sanquin Blood Supply, Div Res & Landsteiner Lab AMC, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam	Keizer, MP (corresponding author), Univ Amsterdam, Acad Med Ctr, Sanquin Blood Supply, Dept Immunopathol,Div Res & Landsteiner Lab, Amsterdam, Netherlands.; Keizer, MP (corresponding author), Univ Amsterdam, AMC, Emma Childrens Hosp, Dept Pediat Hematol Immunol & Infect Dis, Amsterdam, Netherlands.	m.keizer@sanquin.nl			KiKa (stichting Kinderen Kankervrij) [41]	KiKa (stichting Kinderen Kankervrij)	This study was supported by a grant from KiKa (stichting Kinderen Kankervrij) (project 41).	Bos IGA, 2003, J BIOL CHEM, V278, P29463, DOI 10.1074/jbc.M302977200; Brouwer N, 2009, J IMMUNOL, V183, P3496, DOI 10.4049/jimmunol.0900445; Bultink IEM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2095; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; Degn SE, 2013, J IMMUNOL, V191, P1334, DOI 10.4049/jimmunol.1300780; Degn SE, 2012, J IMMUNOL, V189, P3957, DOI 10.4049/jimmunol.1201736; Degn SE, 2010, J IMMUNOL METHODS, V361, P37, DOI 10.1016/j.jim.2010.07.006; Dobo J, 2016, SCI REP-UK, V6, DOI 10.1038/srep31877; Dommett R, 2013, J PEDIAT HEMATOL ONC, V35, P69, DOI 10.1097/MPH.0b013e31827076e5; Frakking FNJ, 2006, EUR J CANCER, V42, P909, DOI 10.1016/j.ejca.2005.10.027; Haerynck F, 2012, HUM IMMUNOL, V73, P1175, DOI 10.1016/j.humimm.2012.08.010; Heja D, 2012, P NATL ACAD SCI USA, V109, P10498, DOI 10.1073/pnas.1202588109; Jensen PH, 2007, BBA-PROTEINS PROTEOM, V1774, P335, DOI 10.1016/j.bbapap.2006.12.008; Jensenius JC, 2003, BIOCHEM SOC T, V31, P763, DOI 10.1042/BST0310763; Keizer MP, 2014, MOL IMMUNOL, V61, P174, DOI 10.1016/j.molimm.2014.06.005; Keizer MP, 2014, MOL IMMUNOL, V58, P187, DOI 10.1016/j.molimm.2013.11.022; Kjaer TR, 2016, SCAND J IMMUNOL, V84, P12, DOI 10.1111/sji.12441; Kjaer TR, 2015, STRUCTURE, V23, P342, DOI 10.1016/j.str.2014.10.024; Lachmann PJ, 2010, J IMMUNOL METHODS, V352, P195, DOI 10.1016/j.jim.2009.11.003; Laursen I, 2003, BIOCHEM SOC T, V31, P758, DOI 10.1042/BST0310758; Megyeri M, 2014, MOL IMMUNOL, V59, P39, DOI 10.1016/j.molimm.2014.01.001; Mohamed WAW, 2012, J MATERN-FETAL NEO M, V25, P411, DOI 10.3109/14767058.2011.582903; Munthe-Fog L, 2007, SCAND J IMMUNOL, V65, P383, DOI 10.1111/j.1365-3083.2007.01915.x; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380; Parej K, 2014, MOL IMMUNOL, V59, P1, DOI 10.1016/j.molimm.2013.12.003; Petersen KA, 2006, J CLIN IMMUNOL, V26, P465, DOI 10.1007/s10875-006-9037-z; Rosbjerg A, 2014, J IMMUNOL, V192, P4352, DOI 10.4049/jimmunol.1303263; Sallenbach S, 2011, PEDIAT ALLERG IMM-UK, V22, P424, DOI 10.1111/j.1399-3038.2010.01104.x; Sorensen R, 2005, SPRINGER SEMIN IMMUN, V27, P299, DOI 10.1007/s00281-005-0006-z; Teillet F, 2005, J IMMUNOL, V174, P2870, DOI 10.4049/jimmunol.174.5.2870; Thiel S, 2009, J IMMUNOL, V182, P2939, DOI 10.4049/jimmunol.0802053; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; Troldborg A, 2017, CLIN EXP IMMUNOL, V188, P138, DOI 10.1111/cei.12909; Troldborg A, 2015, CLIN EXP IMMUNOL, V182, P132, DOI 10.1111/cei.12678; Valdimarsson H, 2004, SCAND J IMMUNOL, V59, P97, DOI 10.1111/j.0300-9475.2004.01357.x; Vorup-Jensen T, 2001, INT IMMUNOPHARMACOL, V1, P677, DOI 10.1016/S1567-5769(00)00052-7; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; WOLBINK GJ, 1993, J IMMUNOL METHODS, V163, P67, DOI 10.1016/0022-1759(93)90240-8	40	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 27	2018	9								1406	10.3389/fimmu.2018.01406	http://dx.doi.org/10.3389/fimmu.2018.01406			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GK8IS	29997613	gold, Green Published			2022-12-18	WOS:000436465900001
J	Baur, J; Otto, C; Steger, U; Klein-Hessling, S; Muhammad, K; Pusch, T; Murti, K; Wismer, R; Germer, CT; Klein, I; Muller, N; Serfling, E; Avots, A				Baur, Johannes; Otto, Christoph; Steger, Ulrich; Klein-Hessling, Stefan; Muhammad, Khalid; Pusch, Tobias; Murti, Krisna; Wismer, Rhoda; Germer, Christoph-Thomas; Klein, Ingo; Mueller, Nora; Serfling, Edgar; Avots, Andris			The Transcription Factor NFaTc1 Supports the Rejection of Heterotopic Heart Allografts	FRONTIERS IN IMMUNOLOGY			English	Article						NFATc1; transplantation; heterologous; CD8(+) T cells; ChIPseq; metabolism	REGULATORY T-CELLS; CHEMOKINE RECEPTOR CXCR3; KAPPA-B ACTIVATION; CARDIAC ALLOGRAFTS; NUCLEAR FACTOR; CYCLOSPORINE-A; IN-VIVO; MICE; EXPRESSION; INFLAMMATION	The immune suppressants cyclosporin A (CsA) and tacrolimus (FK506) are used worldwide in transplantation medicine to suppress graft rejection. Both CsA and FK506 inhibit the phosphatase calcineurin (CN) whose activity controls the immune receptor-mediated activation of lymphocytes. Downstream targets of CN in lymphocytes are the nuclear factors of activated T cells (NFATs). We show here that the activity of NFATc1, the most prominent NFAT factor in activated lymphocytes supports the acute rejection of heterotopic heart allografts. While ablation of NFATc1 in T cells prevented graft rejection, ectopic expression of inducible NFATc1/aA isoform led to rejection of heart allografts in recipient mice. Acceptance of transplanted hearts in mice bearing NFATc1-deficient T cells was accompanied by a reduction in number and cytotoxicity of graft infiltrating cells. In CD8(+) T cells, NFATc1 controls numerous intracellular signaling pathways that lead to the metabolic switch to aerobic glycolysis and the expression of numerous lymphokines, chemokines, and their receptors, including Cxcr3 that supports the rejection of allogeneic heart transplants. These findings favors NFATc1 as a molecular target for the development of new strategies to control the cytotoxicity of T cells upon organ transplantation.	[Baur, Johannes; Steger, Ulrich; Germer, Christoph-Thomas] Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Wurzburg, Germany; [Otto, Christoph] Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Expt Surg, Wurzburg, Germany; [Klein-Hessling, Stefan; Muhammad, Khalid; Pusch, Tobias; Murti, Krisna; Wismer, Rhoda; Serfling, Edgar; Avots, Andris] Julius Maximilians Univ Wurzburg, Inst Pathol, Dept Mol Pathol, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Klein, Ingo] Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Transplant & Hepatobiliary Surg, Wurzburg, Germany; [Mueller, Nora] Univ Wurzburg, Inst Virol & Immunobiol, Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg	Serfling, E; Avots, A (corresponding author), Julius Maximilians Univ Wurzburg, Inst Pathol, Dept Mol Pathol, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.	serfling.e@mail.uni-wuerzburg.de; andy_avots@hotmail.com	Muhammad, Khalid/AAY-7097-2020; Klein, Ingo/AAY-3371-2020; Murti, Krisna/AAC-5417-2021; Serfling, Edgar/X-7212-2019	Muhammad, Khalid/0000-0001-6488-1722; Klein, Ingo/0000-0003-1097-0986; 	Deutsche Forschungsgemeinschaft [TRR52]; Wilhelm-Sander foundation; Scheel foundation for Cancer Research; IZKF Wurzburg [D-235]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm-Sander foundation; Scheel foundation for Cancer Research; IZKF Wurzburg	This work was supported by the Deutsche Forschungsgemeinschaft, grant TRR52 (to ES and AA), the Wilhelm-Sander foundation (to ES and SK-H), the Scheel foundation for Cancer Research (to ES and AA) and the IZKF Wurzburg (D-235, to JB and AA).	Aliabadi A, 2012, CURR OPIN ORGAN TRAN, V17, P540, DOI 10.1097/MOT.0b013e328358000c; Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711; Alrefai H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11724; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Azzi JR, 2013, J IMMUNOL, V191, P5785, DOI 10.4049/jimmunol.1390055; Baumgart S, 2014, CANCER DISCOV, V4, P688, DOI 10.1158/2159-8290.CD-13-0593; Bopp T, 2005, J EXP MED, V201, P181, DOI 10.1084/jem.20041538; Busch R, 2016, EUR J IMMUNOL, V46, P634, DOI 10.1002/eji.201545925; Choi JM, 2012, IMMUNOL LETT, V143, P170, DOI 10.1016/j.imlet.2012.01.016; de Boer J, 2003, EUR J IMMUNOL, V33, P314, DOI 10.1002/immu.200310005; Delfs MW, 2001, TRANSPLANTATION, V71, P606, DOI 10.1097/00007890-200103150-00005; Ebert A, 2011, IMMUNITY, V34, P175, DOI 10.1016/j.immuni.2011.02.005; Finlay D, 2011, NAT REV IMMUNOL, V11, P109, DOI 10.1038/nri2888; Frischbutter S, 2011, EUR J IMMUNOL, V41, P2349, DOI 10.1002/eji.201041052; Gilot BJ, 2000, TRANSPLANTATION, V69, P639, DOI 10.1097/00007890-200002270-00028; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Hu JK, 2011, P NATL ACAD SCI USA, V108, pE118, DOI 10.1073/pnas.1101881108; Huser N, 2005, EUR J IMMUNOL, V35, P128, DOI 10.1002/eji.200324745; Jones ND, 1999, ANN SURG, V229, P570, DOI 10.1097/00000658-199904000-00018; Klein-Hessling S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00612-6; Klein-Hessling S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11841; Komarowska I, 2015, IMMUNITY, V42, P1087, DOI 10.1016/j.immuni.2015.05.014; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Lee CF, 2015, CELL REP, V13, P760, DOI 10.1016/j.celrep.2015.09.036; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Li HM, 2011, TRENDS CELL BIOL, V21, P91, DOI 10.1016/j.tcb.2010.09.011; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Maier S, 2001, NAT MED, V7, P557, DOI 10.1038/87880; Martinez GJ, 2015, IMMUNITY, V42, P265, DOI 10.1016/j.immuni.2015.01.006; Muhammad K, 2014, EUR J IMMUNOL, V44, P3392, DOI 10.1002/eji.201444756; O'Boyle G, 2011, TRANSPLANT REV-ORLAN, V25, P136, DOI 10.1016/j.trre.2010.10.005; Oh-hora M, 2013, IMMUNITY, V38, P881, DOI 10.1016/j.immuni.2013.02.008; Orosz CG, 1996, TRANSPLANTATION, V61, P783, DOI 10.1097/00007890-199603150-00019; Palkowitsch L, 2011, J BIOL CHEM, V286, P7522, DOI 10.1074/jbc.M110.155895; Reichel CA, 2006, J LEUKOCYTE BIOL, V79, P114, DOI 10.1189/jlb.0605337; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Schenk S, 2005, J IMMUNOL, V174, P3741, DOI 10.4049/jimmunol.174.6.3741; Serfling E, 2006, EUR J IMMUNOL, V36, P2837, DOI 10.1002/eji.200536618; Serfling E, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-16; Sharma Suveena, 2014, Curr Protoc Immunol, V105, DOI 10.1002/0471142735.im1034s105; Sieber M, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-25; Sitaru AG, 2002, HUM IMMUNOL, V63, P871, DOI 10.1016/S0198-8859(02)00452-4; Stinn JL, 1998, AM J PATHOL, V153, P1383, DOI 10.1016/S0002-9440(10)65725-2; Szot GL, 2001, AM J TRANSPLANT, V1, P38, DOI 10.1034/j.1600-6143.2001.010108.x; Ueno T, 2011, TRANSPLANTATION, V92, pE26, DOI 10.1097/TP.0b013e318228061c; Vaeth M, 2012, P NATL ACAD SCI USA, V109, P16258, DOI 10.1073/pnas.1203870109; Vaeth M, 2011, P NATL ACAD SCI USA, V108, P2480, DOI 10.1073/pnas.1009463108; WHITBY EH, 1990, IMMUNOLOGY, V69, P78; Wu J, 2017, IMMUNITY, V47, P1114, DOI 10.1016/j.immuni.2017.11.003; Zhang DJ, 2005, J IMMUNOL, V174, P6725, DOI 10.4049/jimmunol.174.11.6725; Zhou P, 2003, AM J TRANSPLANT, V3, P139, DOI 10.1034/j.1600-6143.2003.00033.x	53	2	3	2	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 12	2018	9								1338	10.3389/fimmu.2018.01338	http://dx.doi.org/10.3389/fimmu.2018.01338			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GJ0XB	29946322	Green Published, gold			2022-12-18	WOS:000434976700001
J	Shu, F; Shi, Y				Shu, Fei; Shi, Yan			Systematic Overview of Solid Particles and their Host Responses	FRONTIERS IN IMMUNOLOGY			English	Review						solid particle; host response; biological crystal; adjuvant; cell death	MONOSODIUM URATE CRYSTALS; NLRP3 INFLAMMASOME ACTIVATION; INDUCED NEUTROPHIL ACTIVATION; CALCIUM PYROPHOSPHATE DIHYDRATE; AMORPHOUS SILICA PARTICLES; INNATE IMMUNE ACTIVATION; NITRIC-OXIDE GENERATION; URIC-ACID CRYSTALS; NALP3 INFLAMMASOME; DENDRITIC CELLS	Crystalline/particulate substances trigger a plethora of signaling events in host cells. The most prominent consequence is the inflammatory reactions that underlie crystal arthropathies, such as gout and pseudogout. However, their impact on our health was underestimated. Recent work on the role of cholesterol crystal in the development of atherosclerosis and the harm of environmental particulates has set up new frontiers in our defense against their detrimental effects. On the other hand, in the last 100 years, crystalline/particulate substances have been used with increasing frequencies in our daily lives as a part of new industrial manufacturing and engineering. Importantly, they have become a tool in modern medicine, used as vaccine adjuvants and drug delivery vehicles. Their biological effects are also being dissected in great detail, particularly with regard to their inflammatory signaling pathways. Solid structure interaction with host cells is far from being uniform, with outcomes dependent on cell types and chemical/physical properties of the particles involved. In this review, we offer a systematic and broad outlook of this landscape and a sage analysis of the complex nature of this topic.	[Shu, Fei; Shi, Yan] Tsinghua Univ, Ctr Life Sci, Beijing Key Lab Immunol Res Chron Dis, Inst Immunol,Dept Basic Med Sci, Beijing, Peoples R China; [Shu, Fei] Peking Univ, Tsinghua Univ, Sch Life Sci, Natl Inst Biol Sci,Joint Grad Program, Beijing, Peoples R China; [Shi, Yan] Univ Calgary, Snyder Inst, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada	Tsinghua University; National Institute of Biological Sciences, Beijing; Peking University; Tsinghua University; University of Calgary	Shi, Y (corresponding author), Tsinghua Univ, Ctr Life Sci, Beijing Key Lab Immunol Res Chron Dis, Inst Immunol,Dept Basic Med Sci, Beijing, Peoples R China.; Shi, Y (corresponding author), Univ Calgary, Snyder Inst, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.	yanshi@biomed.tsinghua.edu.cn	Shi, Yan/Y-6642-2019		joint Peking-Tsinghua Center for Life Sciences; National Natural Science Foundation of China General Program [31370878]; Creative Research Groups Program [81621002]; National Institutes of Health [R01AI098995]; Natural Sciences and Engineering Research Council of Canada [RGPIN-355350/396037]; Canadian Institutes of Health Research [MOP-119295];  [31630023]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI098995] Funding Source: NIH RePORTER	joint Peking-Tsinghua Center for Life Sciences; National Natural Science Foundation of China General Program(National Natural Science Foundation of China (NSFC)); Creative Research Groups Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Ying Xu for the illustrations. This work was supported by the joint Peking-Tsinghua Center for Life Sciences and grants from the National Natural Science Foundation of China General Program (31370878), Key Program (31630023), and Creative Research Groups Program (81621002), National Institutes of Health (R01AI098995), Natural Sciences and Engineering Research Council of Canada (RGPIN-355350/396037), and Canadian Institutes of Health Research (MOP-119295) to YS.	Abela GS, 2010, J CLIN LIPIDOL, V4, P156, DOI 10.1016/j.jacl.2010.03.003; Abela GS, 2005, CLIN CARDIOL, V28, P413, DOI 10.1002/clc.4960280906; Apostolico JD, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1459394; Arts JHE, 2007, FOOD CHEM TOXICOL, V45, P1856, DOI 10.1016/j.fct.2007.04.001; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Barabe F, 1998, FASEB J, V12, P209, DOI 10.1096/fasebj.12.2.209; Baumer Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01186-z; Bezanilla F, 2008, NAT REV MOL CELL BIO, V9, P323, DOI 10.1038/nrm2376; Bjorkegren JLM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004201; Bollee G, 2012, CLIN J AM SOC NEPHRO, V7, P1521, DOI 10.2215/CJN.02320312; Braakhuis HM, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-18; Braydich-Stolle LK, 2009, J NANOPART RES, V11, P1361, DOI 10.1007/s11051-008-9523-8; Brojatsch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095032; Brown DI, 2009, FREE RADICAL BIO MED, V47, P1239, DOI 10.1016/j.freeradbiomed.2009.07.023; Brunner TJ, 2006, ENVIRON SCI TECHNOL, V40, P4374, DOI 10.1021/es052069i; Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016; CALA PM, 1977, J EXP ZOOL, V199, P339, DOI 10.1002/jez.1401990307; Cao ZW, 2016, INT J NANOMED, V11, P3331, DOI 10.2147/IJN.S106912; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105; Castranova V, 2004, FREE RADICAL BIO MED, V37, P916, DOI 10.1016/j.freeradbiomed.2004.05.032; Ceballos-Picot I, 2014, NUCLEOS NUCLEOT NUCL, V33, P241, DOI 10.1080/15257770.2013.853780; Chen CJ, 2006, J CLIN INVEST, V116, P2262, DOI 10.1172/JCI28075; CHERIAN PV, 1986, ULTRASTRUCT PATHOL, V10, P209, DOI 10.3109/01913128609032219; Chillaron J, 2010, NAT REV NEPHROL, V6, P424, DOI 10.1038/nrneph.2010.69; Cho WS, 2012, TOXICOL SCI, V126, P469, DOI 10.1093/toxsci/kfs006; Cho WS, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-27; Choi Angela O., 2007, Journal of Nanobiotechnology, V5, P1, DOI 10.1186/1477-3155-5-1; Choi HS, 2010, NAT BIOTECHNOL, V28, P1300, DOI 10.1038/nbt.1696; CHURG A, 1984, AM J PATHOL, V115, P437; Cimica V, 2017, CLIN IMMUNOL, V183, P99, DOI 10.1016/j.clim.2017.08.004; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; Costello JC, 2011, CONNECT TISSUE RES, V52, P139, DOI 10.3109/03008207.2010.491928; DAUT J, 1994, J CARDIOVASC ELECTR, V5, P154, DOI 10.1111/j.1540-8167.1994.tb01156.x; Davis SP, 2012, FASEB J, V26, P1119, DOI 10.1096/fj.11-196923; Deroost K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113519; Desai J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15106-0; Desai J, 2016, EUR J IMMUNOL, V46, P223, DOI 10.1002/eji.201545605; Desaulniers P, 2001, J LEUKOCYTE BIOL, V70, P659; Donaldson K, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-5; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510; Drescher D, 2011, ANAL BIOANAL CHEM, V400, P1367, DOI 10.1007/s00216-011-4893-7; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; DUNN JP, 1963, JAMA-J AM MED ASSOC, V185, P431, DOI 10.1001/jama.1963.03060060029012; Ea HK, 2005, ARTHRITIS RES THER, V7, pR915, DOI 10.1186/ar1763; Eguchi Y, 1997, CANCER RES, V57, P1835; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Evan AP, 2001, KIDNEY INT, V60, P910, DOI 10.1046/j.1523-1755.2001.060003910.x; Fahmy B, 2009, TOXICOL IN VITRO, V23, P1365, DOI 10.1016/j.tiv.2009.08.005; Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148; Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306; Flannagan RS, 2012, ANNU REV PATHOL-MECH, V7, P61, DOI 10.1146/annurev-pathol-011811-132445; Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Franklin BS, 2016, ANNU REV IMMUNOL, V34, P173, DOI 10.1146/annurev-immunol-041015-055539; Freigang S, 2013, NAT IMMUNOL, V14, P1045, DOI 10.1038/ni.2704; Freire J, 2013, NEOPLASIA, V15, P913, DOI 10.1593/neo.13310; Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111; Gagne F, 2014, BIOCHEMICAL ECOTOXICOLOGY: PRINCIPLES AND METHODS, P103, DOI 10.1016/B978-0-12-411604-7.00006-4; Gao N, 2000, J TOXICOL ENV HEAL A, V60, P153, DOI 10.1080/009841000156466; Gillrie MR, 2007, BLOOD, V110, P3426, DOI 10.1182/blood-2007-04-084582; Glenny AT, 1931, J PATHOL BACTERIOL, V34, P267, DOI 10.1002/path.1700340214; Gojova A, 2007, ENVIRON HEALTH PERSP, V115, P403, DOI 10.1289/ehp.8497; GOODGLICK LA, 1990, CANCER RES, V50, P5153; Griffith JW, 2009, J IMMUNOL, V183, P5208, DOI 10.4049/jimmunol.0713552; Gupta RK, 2000, METH MOLEC MED, V42, P65; HAMMERSCHMIDT DE, 1981, J LAB CLIN MED, V98, P68; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Hari A, 2014, SCI REP-UK, V4, DOI 10.1038/srep07281; Higo T, 2010, INFLAMM RES, V59, P71, DOI 10.1007/s00011-009-0073-z; HO M, 1989, PARASITE IMMUNOL, V11, P105, DOI 10.1111/j.1365-3024.1989.tb00652.x; Honarpisheh M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15804-9; Horie M, 2012, INHAL TOXICOL, V24, P391, DOI 10.3109/08958378.2012.682321; Horng T, 2014, TRENDS IMMUNOL, V35, P253, DOI 10.1016/j.it.2014.02.007; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Ichida K, 2012, INT J MOL SCI, V13, P15475, DOI 10.3390/ijms131115475; Jaramillo M, 2004, J IMMUNOL, V172, P3101, DOI 10.4049/jimmunol.172.5.3101; Jaramillo M, 2003, J IMMUNOL, V171, P4243, DOI 10.4049/jimmunol.171.8.4243; Jia G, 2005, ENVIRON SCI TECHNOL, V39, P1378, DOI 10.1021/es048729l; Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926; Joshi GN, 2013, APOPTOSIS, V18, P271, DOI 10.1007/s10495-012-0798-y; KAM M, 1992, FASEB J, V6, P2608, DOI 10.1096/fasebj.6.8.1592211; Kaminski MM, 2013, ARCH IMMUNOL THER EX, V61, P367, DOI 10.1007/s00005-013-0235-0; Kanevets U, 2009, J IMMUNOL, V182, P1912, DOI 10.4049/jimmunol.0803777; Katsnelson MA, 2015, J IMMUNOL, V194, P3937, DOI 10.4049/jimmunol.1402658; Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080; Khan SR, 2014, TRANSL ANDROL UROL, V3, P256, DOI 10.3978/j.issn.2223-4683.2014.06.04; Klonis N, 2010, BIOCHEMISTRY-US, V49, P6804, DOI 10.1021/bi100567j; Kono H, 2010, J CLIN INVEST, V120, P1939, DOI 10.1172/JCI40124; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; KOZIN F, 1980, J LAB CLIN MED, V95, P49; Kusaka T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092634; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Lammert F, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.24; Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588; Lee W, 2016, OCCUP ENVIRON MED, V73, P794, DOI 10.1136/oemed-2016-103552; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Lim RS, 2011, J LIPID RES, V52, P2177, DOI 10.1194/jlr.M018077; Lima H, 2013, CELL CYCLE, V12, P1868, DOI 10.4161/cc.24903; Lin Weisheng, 2008, Toxicological and Environmental Chemistry, V90, P983, DOI 10.1080/02772240701802559; Link A, 2012, J IMMUNOL, V188, P3724, DOI 10.4049/jimmunol.1103312; Liu LB, 2011, NAT MED, V17, P1010, DOI 10.1038/nm.2409; Liu W, 2010, NANOTOXICOLOGY, V4, P319, DOI 10.3109/17435390.2010.483745; Liu-Bryan R, 2005, J IMMUNOL, V174, P5016, DOI 10.4049/jimmunol.174.8.5016; MANDEL NS, 1984, ARTHRITIS RHEUM, V27, P789, DOI 10.1002/art.1780270710; Manke A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/942916; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Maschmann E, 1931, BER DTSCH CHEM GES, V64, P2174, DOI 10.1002/cber.19310640851; McCarthy GM, 2001, ANN RHEUM DIS, V60, P399, DOI 10.1136/ard.60.4.399; Mckee AS, 2008, INT IMMUNOL, V20, P659, DOI 10.1093/intimm/dxn025; Mckee AS, 2007, IMMUNITY, V27, P687, DOI 10.1016/j.immuni.2007.11.003; Mckee AS, 2013, P NATL ACAD SCI USA, V110, pE1122, DOI 10.1073/pnas.1300392110; Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164; McLaughlin JK, 1997, J TOXICOL ENV HEALTH, V50, P553, DOI 10.1080/009841097160267; Meissner F, 2008, NAT IMMUNOL, V9, P866, DOI 10.1038/ni.1633; Meissner F, 2010, BLOOD, V116, P1570, DOI 10.1182/blood-2010-01-264218; Menas AL, 2017, CHEMOSPHERE, V171, P671, DOI 10.1016/j.chemosphere.2016.12.105; Menu P, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.18; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005; Morishige T, 2010, PHARMAZIE, V65, P596, DOI 10.1691/ph.2010.9408; Morishige T, 2012, ARCH TOXICOL, V86, P1297, DOI 10.1007/s00204-012-0823-5; Morishige T, 2010, BIOMATERIALS, V31, P6833, DOI 10.1016/j.biomaterials.2010.05.036; Mulay SR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10274; Mulay SR, 2013, J CLIN INVEST, V123, P236, DOI 10.1172/JCI63679; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109; Murphy K., 2016, JANEWAYS IMMUNOBIOLO, DOI DOI 10.1201/9781315533247; Napierska D, 2009, SMALL, V5, P846, DOI 10.1002/smll.200800461; Nasr SH, 2010, NEPHROL DIAL TRANSPL, V25, P1909, DOI 10.1093/ndt/gfp711; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Neumann K, 2014, IMMUNITY, V40, P389, DOI 10.1016/j.immuni.2013.12.015; Newman ZL, 2009, INFECT IMMUN, V77, P4327, DOI 10.1128/IAI.00730-09; Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013; Nomura J, 2015, J IMMUNOL, V195, P5718, DOI 10.4049/jimmunol.1402512; Nuki G, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1906; OBRIEN AD, 1979, INFECT IMMUN, V25, P513, DOI 10.1128/IAI.25.2.513-520.1979; Olivier V, 2003, CELL BIOL TOXICOL, V19, P145, DOI 10.1023/A:1024723326036; Oliyier M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00025; Orlowski GM, 2017, J LEUKOCYTE BIOL, V102, P7, DOI 10.1189/jlb.3HI0316-152R; Orlowski GM, 2015, J IMMUNOL, V195, P1685, DOI 10.4049/jimmunol.1500509; Palomaki J, 2011, ACS NANO, V5, P6861, DOI 10.1021/nn200595c; Pandey AV, 1996, FEBS LETT, V393, P189, DOI 10.1016/0014-5793(96)00881-2; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; Pauluhn J, 2009, TOXICOL SCI, V109, P152, DOI 10.1093/toxsci/kfp046; Pavot V, 2014, NANOMEDICINE-UK, V9, P2703, DOI [10.2217/NNM.14.156, 10.2217/nnm.14.156]; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; PHU NH, 1995, T ROY SOC TROP MED H, V89, P200, DOI 10.1016/0035-9203(95)90496-4; PICHYANGKUL S, 1994, AM J TROP MED HYG, V51, P430, DOI 10.4269/ajtmh.1994.51.430; Popa-Nita O, 2007, J LEUKOCYTE BIOL, V82, P763, DOI 10.1189/jlb.0307174; Porter DW, 2013, TOXICOL SCI, V131, P179, DOI 10.1093/toxsci/kfs261; Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765; Raudales JLM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162865; Reisetter AC, 2011, J BIOL CHEM, V286, P21844, DOI 10.1074/jbc.M111.238519; Renwick LC, 2004, OCCUP ENVIRON MED, V61, P442, DOI 10.1136/oem.2003.008227; REUZEL PGJ, 1991, FOOD CHEM TOXICOL, V29, P341, DOI 10.1016/0278-6915(91)90205-L; Rice-Ficht AC, 2010, CURR OPIN MICROBIOL, V13, P106, DOI 10.1016/j.mib.2009.12.001; Rock KL, 2005, SPRINGER SEMIN IMMUN, V26, P231, DOI 10.1007/s00281-004-0173-3; Rosenthal AK, 2016, NEW ENGL J MED, V374, P2575, DOI 10.1056/NEJMra1511117; Roursgaard M, 2010, HUM EXP TOXICOL, V29, P915, DOI 10.1177/0960327110363329; Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238; RYAN LM, 1995, ANN RHEUM DIS, V54, P939, DOI 10.1136/ard.54.12.939; Samstad EO, 2014, J IMMUNOL, V192, P2837, DOI 10.4049/jimmunol.1302484; Sandberg WJ, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-32; Saquib Q, 2012, TOXICOL IN VITRO, V26, P351, DOI 10.1016/j.tiv.2011.12.011; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Schorn C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00277; SCHUMACHER R, 1989, SEMIN ARTHRITIS RHEU, V18, P81; Scott P, 2006, J IMMUNOL, V177, P6370, DOI 10.4049/jimmunol.177.9.6370; SHANBHAG AS, 1994, J BIOMED MATER RES, V28, P81, DOI 10.1002/jbm.820280111; Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shi Y, 2006, J IMMUNOL, V176, P3905, DOI 10.4049/jimmunol.176.7.3905; Shio MT, 2010, MICROBES INFECT, V12, P889, DOI 10.1016/j.micinf.2010.07.001; Shio MT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000559; Silva JM, 2014, NANOMEDICINE-UK, V9, P2639, DOI [10.2217/NNM.14.135, 10.2217/nnm.14.135]; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Sjogren U, 2002, J DENT RES, V81, P11, DOI 10.1177/154405910208100104; Slutter B, 2010, J CONTROL RELEASE, V143, P207, DOI 10.1016/j.jconrel.2010.01.007; Speiser DE, 2010, J IMMUNOTHER, V33, P848, DOI 10.1097/CJI.0b013e3181f1d614; STEENLAND K, 1995, AM J IND MED, V28, P603, DOI 10.1002/ajim.4700280505; Sun L, 2011, TOXICOL IN VITRO, V25, P1619, DOI 10.1016/j.tiv.2011.06.012; Sundelacruz S, 2009, STEM CELL REV REP, V5, P231, DOI 10.1007/s12015-009-9080-2; SWAN A, 1990, J RHEUMATOL, V17, P1346; Thibodeau M, 2003, TOXICOL SCI, V76, P91, DOI 10.1093/toxsci/kfg178; Thomasin C, 1996, J CONTROL RELEASE, V41, P131, DOI 10.1016/0168-3659(96)01363-6; Tomazic-Jezic VJ, 2001, J BIOMED MATER RES, V55, P523, DOI 10.1002/1097-4636(20010615)55:4<523::AID-JBM1045>3.0.CO;2-G; VALLYATHAN V, 1984, J TOXICOL ENV HEALTH, V14, P641, DOI 10.1080/15287398409530614; Wang YH, 2015, SCI REP-UK, V5, DOI 10.1038/srep16427; Warheit DB, 1995, SCAND J WORK ENV HEA, V21, P19; Wen YM, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.40; Wendorf J, 2008, HUM VACCINES, V4, P44, DOI 10.4161/hv.4.1.4886; West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975; WHITE RG, 1955, J EXP MED, V102, P73, DOI 10.1084/jem.102.1.73; WILCOX WR, 1975, ANN RHEUM DIS, V34, P332, DOI 10.1136/ard.34.4.332; Williams GR, 2014, J EXP MED, V211, P1019, DOI 10.1084/jem.20131768; Wottrich R, 2004, INT J HYG ENVIR HEAL, V207, P353, DOI 10.1078/1438-4639-00300; Wu XZ, 2010, J IMMUNOL, V184, P4338, DOI 10.4049/jimmunol.0903824; Yano E, 2001, AM J EPIDEMIOL, V154, P538, DOI 10.1093/aje/154.6.538; Yarahmadi Aliakbar, 2013, Tanaffos, V12, P34; Yaron JR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.277; Zhang Z, 2000, ENVIRON RES, V82, P245, DOI 10.1006/enrs.1999.4025; Zhao XX, 2013, ARCH TOXICOL, V87, P1037, DOI 10.1007/s00204-012-0827-1; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhou Y, 2015, SCIENCE, V349, P873, DOI 10.1126/science.aaa5619; [No title captured]	213	2	2	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 28	2018	9								1157	10.3389/fimmu.2018.01157	http://dx.doi.org/10.3389/fimmu.2018.01157			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GH1ZR	29892295	gold, Green Published			2022-12-18	WOS:000433201700001
J	Nagy, T; Katai, E; Fisi, V; Takacs, TT; Streda, A; Wittmann, I; Miseta, A				Nagy, Tamas; Katai, Emese; Fisi, Viktoria; Takacs, Tamas Tibor; Streda, Antal; Wittmann, Istvan; Miseta, Attila			Protein O-GlcNAc Modification Increases in White Blood Cells After a Single Bout of Physical Exercise	FRONTIERS IN IMMUNOLOGY			English	Article						exercise; O-GlcNAc; stress response; white blood cells; exercise immunology	KAPPA-B ACTIVATION; TRAUMA-HEMORRHAGE; MODERATE EXERCISE; GLCNACYLATION; STRESS; INFLAMMATION; EXPRESSION; TRANSFERASE; NUCLEAR; PHOSPHORYLATION	Background: Protein O-linked N-acetylglucosamine (O-GlcNAc) is a dynamic posttranslational modification influencing the function of many intracellular proteins. Recently it was revealed that O-GlcNAc regulation is modified under various stress states, including ischemia and oxidative stress. Aside from a few contradictory studies based on animal models, the effect of exercise on O-GlcNAc is unexplored. Purpose: To evaluate O-GlcNAc levels in white blood cells (WBC) of human volunteers following physical exercise. Methods: Young (age 30 +/- 5.2), healthy male volunteers (n = 6) were enlisted for the study. Blood parameters including metabolites, ions, "necro"-enzymes, and cell counts were measured before and after a single bout of exercise (2-mile run). From WBC samples, we performed western blots to detect O-GlcNAc modified proteins. The distribution of O-GlcNAc in WBC subpopulations was assessed by flow cytometry. Results: Elevation of serum lactic acid (increased from 1.3 +/- 0.4 to 6.9 +/- 1.7 mM), creatinine (from 77.5 +/- 6.3 U/L to 102.2 +/- 7.0 \g=m\M), and lactate dehydrogenase (from 318.5 +/- 26.2 to 380.5 +/- 33.2 U/L) confirmed the effect of exercise. WBC count also significantly increased (from 6.6 +/- 1.0 to 8.4 +/- 1.4 G/L). The level of O-GlcNAc modified proteins in WBCs showed significant elevation after exercise (85 +/- 51%, p < 0.05). Flow cytometry revealed that most of this change could be attributed to lymphocytes and monocytes. Conclusion: Our results indicate that short-term exercise impacts the O-GlcNAc status of WBCs. O-GlcNAc modification could be a natural process by which physical activity modulates the immune system. Further research could elucidate the role of O-GlcNAc during exercise and validate O-GlcNAc as a biomarker for fitness assessment.	[Nagy, Tamas; Katai, Emese; Fisi, Viktoria; Takacs, Tamas Tibor; Miseta, Attila] Univ Pecs, Med Sch, Dept Lab Med, Pecs, Hungary; [Nagy, Tamas] Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary; [Streda, Antal; Wittmann, Istvan] Univ Pecs, Med Sch, Dept Internal Med, Pecs, Hungary; [Streda, Antal; Wittmann, Istvan] Univ Pecs, Med Sch, Nephrol Ctr, Pecs, Hungary	University of Pecs; University of Pecs; University of Pecs; University of Pecs	Nagy, T (corresponding author), Univ Pecs, Med Sch, Dept Lab Med, Pecs, Hungary.; Nagy, T (corresponding author), Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary.	nagy.tamas@pte.hu	Nagy, Tamas/W-9340-2019; Fisi, Viktoria/AAF-2948-2022; Fisi, Viktoria/AFH-7514-2022	Nagy, Tamas/0000-0001-5437-1411; 	EU [2.3.2.-15-2016-00050, 2.3.3.-15-2016-00025]; Janos Szentagothai Research Centre, University of Pecs	EU(European Commission); Janos Szentagothai Research Centre, University of Pecs	This work was supported by the EU founded Hungarian projects GINOP under Grant number 2.3.2.-15-2016-00050 and 2.3.3.-15-2016-00025 and supported by Janos Szentagothai Research Centre, University of Pecs.	Accattato F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178900; Adams OP, 2013, DIABETES METAB SYNDR, V6, P113, DOI 10.2147/DMSO.S29222; Army US, 2012, ARM PHYS READ TRAIN; Barbieri Elena, 2012, J Signal Transduct, V2012, P982794, DOI 10.1155/2012/982794; Baudoin L, 2015, FRONT ENDOCRINOL, V5, DOI [10.3389/fendo.2016.00235, 10.3389/fendo.2014.00235]; Belke DD, 2011, J APPL PHYSIOL, V111, P157, DOI 10.1152/japplphysiol.00147.2011; Belotto MF, 2010, CLIN EXP IMMUNOL, V162, P237, DOI 10.1111/j.1365-2249.2010.04240.x; Bennett CE, 2013, LIFE SCI, V92, P657, DOI 10.1016/j.lfs.2012.09.007; Berzosa C, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/540458; Bowe DB, 2006, MOL CELL BIOL, V26, P8539, DOI 10.1128/MCB.01053-06; Buse MG, 2002, AM J PHYSIOL-ENDOC M, V283, pE241, DOI 10.1152/ajpendo.00060.2002; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Chatham JC, 2010, BBA-GEN SUBJECTS, V1800, P57, DOI 10.1016/j.bbagen.2009.07.004; Chen YX, 2006, CHEM BIOL, V13, P937, DOI 10.1016/j.chembiol.2006.06.017; Cox EJ, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-101; DALE G, 1987, BRIT MED J, V294, P939, DOI 10.1136/bmj.294.6577.939; Faude O, 2009, SPORTS MED, V39, P469, DOI 10.2165/00007256-200939060-00003; Gabriel HHW, 1998, CAN J PHYSIOL PHARM, V76, P512, DOI 10.1139/cjpp-76-5-512; Gjevestad GO, 2015, CURR CARDIOVASC RISK, V9, DOI 10.1007/s12170-015-0463-4; Gleeson M, 2007, J APPL PHYSIOL, V103, P693, DOI 10.1152/japplphysiol.00008.2007; Golks A, 2008, EMBO REP, V9, P748, DOI 10.1038/embor.2008.129; Golks A, 2007, EMBO J, V26, P4368, DOI 10.1038/sj.emboj.7601845; Gremeaux V, 2012, MATURITAS, V73, P312, DOI 10.1016/j.maturitas.2012.09.012; Hahne H, 2013, J PROTEOME RES, V12, P927, DOI 10.1021/pr300967y; Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511; Hawley JA, 2014, CELL, V159, P738, DOI 10.1016/j.cell.2014.10.029; Hilgers RHP, 2012, AM J PHYSIOL-HEART C, V303, pH513, DOI 10.1152/ajpheart.01175.2011; Hoffman NJ, 2015, CELL METAB, V22, P922, DOI 10.1016/j.cmet.2015.09.001; Hortemo KH, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12896; Huang JB, 2007, CELL IMMUNOL, V245, P1, DOI 10.1016/j.cellimm.2007.03.006; Jensen RV, 2013, SCAND CARDIOVASC J, V47, P168, DOI 10.3109/14017431.2012.756984; Johnson B, 2014, BBA-GEN SUBJECTS, V1840, P191, DOI 10.1016/j.bbagen.2013.09.011; Jones SP, 2008, CIRCULATION, V117, P1172, DOI 10.1161/CIRCULATIONAHA.107.730515; Kanwal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069150; Katai E, 2016, J CELL MOL MED, V20, P2269, DOI 10.1111/jcmm.12910; Kazemi Z, 2010, J BIOL CHEM, V285, P39096, DOI 10.1074/jbc.M110.131102; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KENNEY WL, 1995, J APPL PHYSIOL, V79, P1112, DOI 10.1152/jappl.1995.79.4.1112; Kessler HS, 2012, SPORTS MED, V42, P489, DOI 10.2165/11630910-000000000-00000; Kim BF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087913; Kneass ZT, 2005, J BIOL CHEM, V280, P14579, DOI 10.1074/jbc.M414066200; Kneass ZT, 2004, J BIOL CHEM, V279, P45759, DOI 10.1074/jbc.M407911200; Lawler JM, 2016, J PHYSIOL-LONDON, V594, P5161, DOI 10.1113/JP270656; Liu HT, 2014, CARDIOVASC RES, V103, P131, DOI 10.1093/cvr/cvu116; Lund PJ, 2016, J IMMUNOL, V197, P3086, DOI 10.4049/jimmunol.1502031; Madsen-Bouterse SA, 2008, CYTOM PART A, V73A, P667, DOI 10.1002/cyto.a.20569; Martinez MR, 2017, BIOCHEM SOC T, V45, P237, DOI 10.1042/BST20160153; McGinnis GR, 2015, AM J PHYSIOL-HEART C, V308, pH1423, DOI 10.1152/ajpheart.00850.2014; Medford HM, 2013, AM J PHYSIOL-HEART C, V305, pH114, DOI 10.1152/ajpheart.00135.2013; Milisav I, 2012, INT J MOL SCI, V13, P10771, DOI 10.3390/ijms130910771; Myslicki JP, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-96; Nagy T, 2006, AM J PHYSIOL-CELL PH, V290, pC57, DOI 10.1152/ajpcell.00263.2005; Nagy T, 2007, BIOCHEM MEDICA, V17, P162; Noble EG, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/836519; Not LG, 2010, CRIT CARE MED, V38, P562, DOI 10.1097/CCM.0b013e3181cb10b3; Olivier-Van Stichelen S, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00256; Ozaki H, 2016, MED HYPOTHESES, V88, P22, DOI 10.1016/j.mehy.2015.12.026; Park K, 2010, DIABETES, V59, P1845, DOI 10.2337/db09-1086; Pedersen BK, 2006, SCAND J MED SCI SPOR, V16, P3, DOI 10.1111/j.1600-0838.2006.00520.x; Peternelj TT, 2015, MOL CELL BIOCHEM, V400, P265, DOI 10.1007/s11010-014-2283-0; Sakharov DA, 2012, EUR J APPL PHYSIOL, V112, P963, DOI 10.1007/s00421-011-2048-3; Santos SA, 2016, J HUM NUTR DIET, V29, P516, DOI 10.1111/jhn.12361; Shek PN, 1998, CAN J PHYSIOL PHARM, V76, P589, DOI 10.1139/cjpp-76-5-589; Shephard RJ, 2010, EXERC IMMUNOL REV, V16, P194; SLOOT PMA, 1986, APPL OPTICS, V25, P3559, DOI 10.1364/AO.25.003559; Springhorn C, 2012, J CLIN ENDOCR METAB, V97, P4640, DOI 10.1210/jc.2012-2229; STEEL JM, 1987, BRIT MED J, V295, P1135, DOI 10.1136/bmj.295.6606.1135-c; Storey KB, 2013, COMP BIOCHEM PHYS A, V165, P417, DOI 10.1016/j.cbpa.2013.01.019; Taylor RP, 2008, J BIOL CHEM, V283, P6050, DOI 10.1074/jbc.M707328200; Vasconcellos F, 2014, SPORTS MED, V44, P1139, DOI 10.1007/s40279-014-0193-7; Xing DQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024021; Yang WH, 2008, P NATL ACAD SCI USA, V105, P17345, DOI 10.1073/pnas.0806198105; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zhang DM, 2015, INFLAMM RES, V64, P943, DOI 10.1007/s00011-015-0877-y; Zou LY, 2009, AM J PHYSIOL-HEART C, V296, pH515, DOI 10.1152/ajpheart.01025.2008	75	2	2	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2018	9								970	10.3389/fimmu.2018.00970	http://dx.doi.org/10.3389/fimmu.2018.00970			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GE6LD	29774032	Green Published, gold			2022-12-18	WOS:000431337100001
J	Sundqvist, KG				Sundqvist, Karl-Gosta			T Cell Co-Stimulation: Inhibition of Immunosuppression?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						co-stimulatory molecules; adhesion molecules; motility; cell surface receptor; shedding	RECEPTOR-RELATED PROTEIN-1; NF-KAPPA-B; ENDOGENOUS THROMBOSPONDIN-1; TGF-BETA; PLASMA-MEMBRANE; IN-VITRO; CD28; ADHESION; MOTILITY; MECHANISMS		[Sundqvist, Karl-Gosta] Karolinska Univ Hosp, Karolinska Inst, Clin Immunol & Transfus Med, Div Clin Immunol,Dept Lab Med, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Sundqvist, KG (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Clin Immunol & Transfus Med, Div Clin Immunol,Dept Lab Med, Stockholm, Sweden.	karl.sundqvist@sll.se			SCF project [1940]; SRC Project [20347]	SCF project; SRC Project	This work was supported by SCF project 1940 and SRC Project 20347.	Abraham M, 2008, J AUTOIMMUN, V30, P21, DOI 10.1016/j.jaut.2007.11.007; Azab AK, 2009, BLOOD, V114, P619, DOI 10.1182/blood-2009-01-199281; Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924; Bergstrom SE, 2015, IMMUNOLOGY, V144, P687, DOI 10.1111/imm.12424; Bergstrom SE, 2013, IMMUNOLOGY, V140, P441, DOI 10.1111/imm.12154; Boucher P, 2011, BIOCHEM PHARMACOL, V81, P1, DOI 10.1016/j.bcp.2010.09.018; Buckner JH, 2010, NAT REV IMMUNOL, V10, P849, DOI 10.1038/nri2889; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Clark RT, 2011, ASN NEURO, V3, P1, DOI 10.1042/AN20100027; Colombetti S, 2006, J IMMUNOL, V176, P2730, DOI 10.4049/jimmunol.176.5.2730; Eaton VL, 2008, AM J TRANSPLANT, V8, P507, DOI 10.1111/j.1600-6143.2007.02097.x; Forslow A, 2007, CELL MOL LIFE SCI, V64, P66, DOI 10.1007/s00018-006-6255-8; Forte D, 2017, ONCOTARGET, V8, P2261, DOI 10.18632/oncotarget.13664; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Garcon F, 2008, BLOOD, V111, P1464, DOI 10.1182/blood-2007-08-108050; Gonias SL, 2014, AM J PATHOL, V184, P18, DOI 10.1016/j.ajpath.2013.08.029; Hombach AA, 2007, J IMMUNOL, V179, P7924, DOI 10.4049/jimmunol.179.11.7924; Jedrychowski MP, 2010, J BIOL CHEM, V285, P104, DOI 10.1074/jbc.M109.040428; Jeon H, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-149; John AS, 2009, EXP MOL PATHOL, V87, P184, DOI 10.1016/j.yexmp.2009.09.002; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Levy R, 2016, P NATL ACAD SCI USA, V113, pE6437, DOI 10.1073/pnas.1603321113; Li SS, 2006, BLOOD, V108, P3112, DOI 10.1182/blood-2006-04-016832; Li SS, 2005, J IMMUNOL, V174, P654, DOI 10.4049/jimmunol.174.2.654; Li SS, 2002, EUR J IMMUNOL, V32, P1069, DOI 10.1002/1521-4141(200204)32:4<1069::AID-IMMU1069>3.0.CO;2-E; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Liu QA, 2010, J NEUROSCI, V30, P17068, DOI 10.1523/JNEUROSCI.4067-10.2010; Liu ZW, 2009, J IMMUNOL, V183, P3616, DOI 10.4049/jimmunol.0804336; Long SA, 2011, J IMMUNOL, V187, P2061, DOI 10.4049/jimmunol.1003224; Lu AL, 2011, AM J PATHOL, V178, P2573, DOI 10.1016/j.ajpath.2011.02.039; Luhder F, 2003, J EXP MED, V197, P955, DOI 10.1084/jem.20021024; Mantuano E, 2011, J NEUROSCI, V31, P13376, DOI 10.1523/JNEUROSCI.2850-11.2011; Mantuano E, 2010, J BIOL CHEM, V285, P14259, DOI 10.1074/jbc.M109.085126; Marinari B, 2002, EUR J IMMUNOL, V32, P447, DOI 10.1002/1521-4141(200202)32:2<447::AID-IMMU447>3.0.CO;2-5; Marinari B, 2004, P NATL ACAD SCI USA, V101, P6098, DOI 10.1073/pnas.0308688101; Panezai J, 2017, IMMUNOLOGY, V152, P308, DOI 10.1111/imm.12770; Patsoukis Nikolaos, 2016, Curr Trends Immunol, V17, P1; Raab M, 2001, IMMUNITY, V15, P921, DOI 10.1016/S1074-7613(01)00248-5; Resovi A, 2014, MATRIX BIOL, V37, P83, DOI 10.1016/j.matbio.2014.01.012; Riley JL, 2002, P NATL ACAD SCI USA, V99, P11790, DOI 10.1073/pnas.162359999; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Strazza M, 2015, J IMMUNOL, V194, P2871, DOI 10.4049/jimmunol.1401492; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Tacke M, 1997, EUR J IMMUNOL, V27, P239, DOI 10.1002/eji.1830270136; Talme T, 2014, IMMUNOLOGY, V142, P176, DOI 10.1111/imm.12229; Tavano R, 2004, J IMMUNOL, V173, P5392, DOI 10.4049/jimmunol.173.9.5392; Thaker YR, 2015, IMMUNOL LETT, V163, P113, DOI 10.1016/j.imlet.2014.10.020; Tran DQ, 2012, J MOL CELL BIOL, V4, P29, DOI 10.1093/jmcb/mjr033; Vicente-Manzanares M, 2003, J IMMUNOL, V171, P1023, DOI 10.4049/jimmunol.171.2.1023; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Zhang LJ, 2006, AUTOIMMUNITY, V39, P269, DOI 10.1080/08916930600753903	51	2	2	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2018	9								974	10.3389/fimmu.2018.00974	http://dx.doi.org/10.3389/fimmu.2018.00974			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GE6LG	29774033	Green Published, gold			2022-12-18	WOS:000431337400001
J	Pan, LL; Li, JH; Shamoon, M; Bhatia, M; Sun, J				Pan, Li-Long; Li, Jiahong; Shamoon, Muhammad; Bhatia, Madhav; Sun, Jia			Recent Advances on Nutrition in Treatment of Acute Pancreatitis (vol 8, 762, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						clinical management of acute pancreatitis; nutritional interventions; probiotics; prebiotics; vitamins; amino acids; omega-3 fatty acids			[Pan, Li-Long] Jiangnan Univ, Sch Med, Wuxi, Peoples R China; [Li, Jiahong; Shamoon, Muhammad; Sun, Jia] Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi, Peoples R China; [Li, Jiahong; Shamoon, Muhammad; Sun, Jia] Jiangnan Univ, Sch Food Sci & Technol, Nutr & Immunol Lab, Wuxi, Peoples R China; [Bhatia, Madhav] Univ Otago, Dept Pathol, Inflammat Res Grp, Christchurch, New Zealand	Jiangnan University; Jiangnan University; Jiangnan University; University of Otago	Sun, J (corresponding author), Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi, Peoples R China.; Sun, J (corresponding author), Jiangnan Univ, Sch Food Sci & Technol, Nutr & Immunol Lab, Wuxi, Peoples R China.	jiasun@jiangnan.edu.cn		Shamoon, Muhammad/0000-0003-0496-3544				Pan LL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00762	1	2	3	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 23	2018	9								849	10.3389/fimmu.2018.00849	http://dx.doi.org/10.3389/fimmu.2018.00849			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GD5TI	29719542	gold, Green Published			2022-12-18	WOS:000430569200001
J	Evering, TH; Tsuji, M				Evering, Teresa H.; Tsuji, Moriya			Human Immune System Mice for the Study of Human Immunodeficiency Virus-Type 1 Infection of the Central Nervous System	FRONTIERS IN IMMUNOLOGY			English	Review						human immunodeficiency virus; central nervous system; human immune system mice; myeloid cells; HIV-associated neurocognitive disorders	BROADLY NEUTRALIZING ANTIBODIES; ACTIVE ANTIRETROVIRAL THERAPY; PROGRESSIVE HIV-1 INFECTION; MOUSE MODELS; LYMPHOID DEVELOPMENT; CELL RECONSTITUTION; TRANSGENIC MICE; ANIMAL-MODELS; BRAIN-TISSUE; HUMAN-BLOOD	Immunodeficient mice transplanted with human cell populations or tissues, also known as human immune system (HIS) mice, have emerged as an important and versatile tool for the in vivo study of human immunodeficiency virus-type 1 (HIV-1) pathogenesis, treatment, and persistence in various biological compartments. Recent work in HIS mice has demonstrated their ability to recapitulate critical aspects of human immune responses to HIV-1 infection, and such studies have informed our knowledge of HIV-1 persistence and latency in the context of combination antiretroviral therapy. The central nervous system (CNS) is a unique, immunologically privileged compartment susceptible to HIV-1 infection, replication, and immune-mediated damage. The unique, neural, and glia-rich cellular composition of this compartment, as well as the important role of infiltrating cells of the myeloid lineage in HIV-1 seeding and replication makes its study of paramount importance, particularly in the context of HIV-1 cure research. Current work on the replication and persistence of HIV-1 in the CNS, as well as cells of the myeloid lineage thought to be important in HIV-1 infection of this compartment, has been aided by the expanded use of these HIS mouse models. In this review, we describe the major HIS mouse models currently in use for the study of HIV-1 neuropathogenesis, recent insights from the field, limitations of the available models, and promising advances in HIS mouse model development.	[Evering, Teresa H.; Tsuji, Moriya] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 1230 York Ave, New York, NY 10021 USA	Rockefeller University	Evering, TH (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 1230 York Ave, New York, NY 10021 USA.	tevering@adarc.org		Tsuji, Moriya/0000-0001-8587-277X	Mark S. Bertuch AIDS Research Fund [554400]; Leidos, Inc. [P010148091, P010173450]; Rockefeller University	Mark S. Bertuch AIDS Research Fund; Leidos, Inc.; Rockefeller University	This work was supported by the Mark S. Bertuch AIDS Research Fund (#554400), Leidos, Inc. (P010148091 and P010173450) and The Rockefeller University Bernard L. Schwartz Program for Physician Scientists.	Akkina R, 2016, AIDS RES HUM RETROV, V32, P109, DOI [10.1089/aid.2015.0258, 10.1089/AID.2015.0258]; [Anonymous], UNAIDS FACT SHEET NO; Arainga M, 2016, SCI REP-UK, V6, DOI 10.1038/srep23513; Baxter AE, 2014, CELL HOST MICROBE, V16, P711, DOI 10.1016/j.chom.2014.10.010; Boska MD, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-58; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Brainard DM, 2009, J VIROL, V83, P7305, DOI 10.1128/JVI.02207-08; Brehm MA, 2013, J INFECT DIS, V208, pS125, DOI 10.1093/infdis/jit319; Browning J, 1997, P NATL ACAD SCI USA, V94, P14637, DOI 10.1073/pnas.94.26.14637; BUDKA H, 1986, ACTA NEUROPATHOL, V69, P253, DOI 10.1007/BF00688301; Calantone N, 2014, IMMUNITY, V41, P493, DOI 10.1016/j.immuni.2014.08.014; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Chen QF, 2012, J IMMUNOL, V189, P5223, DOI 10.4049/jimmunol.1201789; Chen QF, 2009, P NATL ACAD SCI USA, V106, P21783, DOI 10.1073/pnas.0912274106; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Cook JE, 2005, ANN NEUROL, V57, P795, DOI 10.1002/ana.20479; Cook-Easterwood J, 2007, EXP NEUROL, V205, P506, DOI 10.1016/j.expneurol.2007.03.007; Dahiya S, 2013, ADV VIRUS RES, V87, P183, DOI 10.1016/B978-0-12-407698-3.00006-5; Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad; Dash PK, 2011, J NEUROSCI, V31, P3148, DOI 10.1523/JNEUROSCI.5473-10.2011; Denton PW, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0807-y; Denton PW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003872; Denton PW, 2012, J VIROL, V86, P630, DOI 10.1128/JVI.06120-11; Denton PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008829; Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Diskin R, 2013, J EXP MED, V210, P1235, DOI 10.1084/jem.20130221; Dudek TE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003984; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fitting S, 2013, BIOL PSYCHIAT, V73, P443, DOI 10.1016/j.biopsych.2012.09.026; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; FLOTTE TR, 1995, GENE THER, V2, P357; Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155; Gelman BB, 2018, J NEUROVIROL, V24, P146, DOI 10.1007/s13365-017-0601-5; Gelman BB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046178; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06; Gorantla S, 2012, TRENDS NEUROSCI, V35, P197, DOI 10.1016/j.tins.2011.12.006; Gorantla S, 2010, AM J PATHOL, V177, P2938, DOI 10.2353/ajpath.2010.100536; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Greenblatt MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044664; HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0; Hagberg L, 2000, J NEUROIMMUNOL, V102, P51, DOI 10.1016/S0165-5728(99)00150-2; Halper-Stromberg A, 2014, CELL, V158, P989, DOI 10.1016/j.cell.2014.07.043; Han XN, 2013, CELL STEM CELL, V12, P342, DOI 10.1016/j.stem.2012.12.015; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Harbison C, 2014, J NEUROVIROL, V20, P62, DOI 10.1007/s13365-013-0229-z; Hatziioannou T, 2012, NAT REV MICROBIOL, V10, P852, DOI 10.1038/nrmicro2911; Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; Honeycutt JB, 2017, NAT MED, V23, P638, DOI 10.1038/nm.4319; Honeycutt JB, 2016, J CLIN INVEST, V126, P1353, DOI 10.1172/JCI84456; Honeycutt JB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-121; Horwitz JA, 2013, P NATL ACAD SCI USA, V110, P16538, DOI 10.1073/pnas.1315295110; Hu Z, 2011, BLOOD, V118, P5938, DOI 10.1182/blood-2010-11-321414; Huang J, 2015, J IMMUNOL METHODS, V427, P42, DOI 10.1016/j.jim.2015.09.005; Huang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088205; Huntington ND, 2011, P NATL ACAD SCI USA, V108, P6217, DOI 10.1073/pnas.1019167108; Huntington ND, 2009, J EXP MED, V206, P25, DOI 10.1084/jem.20082013; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Jaeger LB, 2012, DIS MODEL MECH, V5, P313, DOI 10.1242/dmm.008763; Joseph SB, 2015, J NEUROVIROL, V21, P276, DOI 10.1007/s13365-014-0287-x; Karpel ME, 2015, CURR OPIN VIROL, V13, P75, DOI 10.1016/j.coviro.2015.05.002; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kim BO, 2003, AM J PATHOL, V162, P1693, DOI 10.1016/S0002-9440(10)64304-0; Kim J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01405; Kim KC, 2016, AIDS RES HUM RETROV, V32, P194, DOI [10.1089/AID.2015.0211, 10.1089/aid.2015.0211]; Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Koneru R, 2014, J NEUROVIROL, V20, P9, DOI 10.1007/s13365-013-0223-5; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; Kovarova M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005075; Lan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388; Lavender KJ, 2018, AIDS, V32, P1, DOI [10.1097/qad.0000000000001674, 10.1097/QAD.0000000000001674]; Lee MH, 2011, NEUROBIOL DIS, V41, P678, DOI 10.1016/j.nbd.2010.12.002; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; Li WZ, 2017, DIS MODEL MECH, V10, P1489, DOI 10.1242/dmm.031773; Li XM, 2016, VACCINE, V34, P4501, DOI 10.1016/j.vaccine.2016.08.006; Li Y, 2016, EUR J IMMUNOL, V46, P1291, DOI 10.1002/eji.201546132; Marsden MD, 2017, ANNU REV VIROL, V4, P393, DOI 10.1146/annurev-virology-101416-041703; Marsden MD, 2015, VIROLOGY, V479, P297, DOI 10.1016/j.virol.2015.01.017; Martinez-Torres F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108663; Masse-Ranson G, 2018, CURR OPIN HIV AIDS, V13, P143, DOI [10.1097/coh.0000000000000440, 10.1097/COH.0000000000000440]; McArthur JC, 2004, J NEUROIMMUNOL, V157, P3, DOI 10.1016/j.jneuroim.2004.08.042; Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431; Merino KM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01693; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORROW WJW, 1987, J GEN VIROL, V68, P2253, DOI 10.1099/0022-1317-68-8-2253; Mucke L, 1995, CURR TOP MICROBIOL, V202, P187; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; Nischang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038853; Nixon CC, 2017, J INFECT DIS, V215, pS142, DOI 10.1093/infdis/jiw637; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; Okamoto SI, 2007, CELL STEM CELL, V1, P230, DOI 10.1016/j.stem.2007.07.010; Olesen R, 2011, J REPROD IMMUNOL, V88, P195, DOI 10.1016/j.jri.2010.11.005; Persidsky Y, 1996, AM J PATHOL, V149, P1027; Persidsky Y, 1997, J NEUROVIROL, V3, P401, DOI 10.3109/13550289709031186; Persidsky Y, 2006, IMMUNOL REV, V213, P180, DOI 10.1111/j.1600-065X.2006.00440.x; Petite CK, 1986, J NEUROPATHOL EXP NE, V45, P635, DOI [10:1097/00005072-198611000-00003, DOI 10.1097/00005072-198611000-00003]; Pilcher CD, 2001, AIDS, V15, P837, DOI 10.1097/00002030-200105040-00004; Poluektova LY, 2002, J IMMUNOL, V168, P3941, DOI 10.4049/jimmunol.168.8.3941; Potash MJ, 2005, P NATL ACAD SCI USA, V102, P3760, DOI 10.1073/pnas.0500649102; Rongvaux A, 2013, ANNU REV IMMUNOL, V31, P635, DOI 10.1146/annurev-immunol-032712-095921; Saito A, 2016, J VIROL, V90, P6918, DOI 10.1128/JVI.00019-16; Saito Y, 2016, BLOOD, V128, P1829, DOI 10.1182/blood-2015-10-676452; Sanfilippo C, 2018, MOL NEUROBIOL, V55, P1905, DOI 10.1007/s12035-017-0460-3; Sango K, 2010, AIDS RES HUM RETROV, V26, P735, DOI 10.1089/aid.2009.0136; Sanna PP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175316; Saylor D, 2016, NAT REV NEUROL, V12, P234, DOI [10.1038/nrneurol.2016.27, 10.1038/nrneurol.2016.53]; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Seay K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063537; Sharma A, 2016, J VIROL, V90, P5068, DOI 10.1128/JVI.00259-16; SHIBATA R, 1991, J VIROL, V65, P3514, DOI 10.1128/JVI.65.7.3514-3520.1991; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Shultz LD, 2010, P NATL ACAD SCI USA, V107, P13022, DOI 10.1073/pnas.1000475107; Singh VB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10241-0; Spudich S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007120; Stevenson M, 2017, NAT MED, V23, P538, DOI 10.1038/nm.4337; Sun ZF, 2007, J EXP MED, V204, P705, DOI 10.1084/jem.20062411; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wahl A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002732; Wege AK, 2008, CURR TOP MICROBIOL, V324, P149; Williams KC, 2002, ANNU REV NEUROSCI, V25, P537, DOI 10.1146/annurev.neuro.25.112701.142822; Willinger T, 2011, P NATL ACAD SCI USA, V108, P2390, DOI 10.1073/pnas.1019682108; Windrem MS, 2014, J NEUROSCI, V34, P16153, DOI 10.1523/JNEUROSCI.1510-14.2014; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Wu XL, 2016, J NEUROIMMUNE PHARM, V11, P572, DOI 10.1007/s11481-016-9654-0; Zink MC, 1997, AM J PATHOL, V151, P793	136	2	2	3	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 4	2018	9								649	10.3389/fimmu.2018.00649	http://dx.doi.org/10.3389/fimmu.2018.00649			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GB6JJ	29670623	Green Published, gold			2022-12-18	WOS:000429175100001
J	Ghosn, S; Chamat, S; Prieur, E; Stephan, A; Druilhe, P; Bouharoun-Tayoun, H				Ghosn, Stephanie; Chamat, Soulaima; Prieur, Eric; Stephan, Antoine; Druilhe, Pierre; Bouharoun-Tayoun, Hasnaa			Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2r gamma Null Mouse Model	FRONTIERS IN IMMUNOLOGY			English	Article						humanized mouse model; vaccine development; Plasmodium falciparum; human spleen cells; malaria; immunogenicity; immunocompromised mice	PBL-SCID MICE; T-LYMPHOCYTE RESPONSES; LIVER-STAGE ANTIGEN; VERSUS-HOST-DISEASE; GAMMA-CHAIN GENE; PLASMODIUM-FALCIPARUM; SCID/BEIGE MICE; DENDRITIC CELLS; IN-VITRO; B-CELLS	The lack of preclinical models able to faithfully predict the immune responses which are later obtained in the clinic is a major hurdle for vaccines development as it increases markedly the delays and the costs required to perform clinical studies. We developed and evaluated the relevance to human immune responses of a novel humanized mouse model, humanized-spleen cells-NOD-SCID-gamma null (Hu-SPL-NSG), in which we grafted human spleen cells in immunodeficient NOD-SCID-IL-2r gamma null (NSG) mice. We selected the malaria vaccine candidate, Liver Stage Antigen 3-Full Length, because we had previously observed a major discrepancy between preclinical and clinical results, and compared its immunogenicity with that of a shorter form of the molecule, LSA3-729. NSG mice engrafted with human spleen lymphocytes were immunized with either LSA3-FL or LSA3-729, both adjuvanted with montanide ISA720. We found that the shorter LSA3-729 triggered the production of human antibodies and a T-helper-type 1 cellular immune response associated with protection whereas LSA3-FL did not. Results were consistent in five groups receiving lymphocytes from five distinct human donors. We identified antigenic regions in the full-length molecule, but not in the shorter version, which induced T-regulatory type of cellular responses. These regions had failed to be predicted by previous preclinical experiments in a wide range of animal models, including primates. Results were reproducible using spleen cells from all five human donors. The findings in the Hu-SPL-NSG model were similar to the results obtained using LSA3-FL in the clinic and hence could have been used to predict them. The model does not present graft versus host reaction, low survival of engrafted B lymphocytes and difficulty to raise primary immune responses, all limitations previously reported in humanized immune-compromised mice. Results also point to the shorter construct, LSA3-729 as a more efficient vaccine candidate. In summary, our findings indicate that the Hu-SPL-NSG model could be a relevant and cost-saving choice for early selection of vaccine candidates before clinical development, and deserves being further evaluated.	[Ghosn, Stephanie; Chamat, Soulaima; Bouharoun-Tayoun, Hasnaa] Lebanese Univ, Lab Immunol & Vector Born Dis, Fac Publ Hlth Fanar, Beirut, Lebanon; [Ghosn, Stephanie; Prieur, Eric; Druilhe, Pierre] Vac4All Initiat, Paris, France; [Chamat, Soulaima] Lebanese Univ, Fac Med, Hadath, Lebanon; [Stephan, Antoine] NOOTDT, Beirut, Lebanon	Lebanese University; Lebanese University	Bouharoun-Tayoun, H (corresponding author), Lebanese Univ, Lab Immunol & Vector Born Dis, Fac Publ Hlth Fanar, Beirut, Lebanon.	hbtayoun@ul.edu.lb			Lebanese University research program the Doctoral School of Science and Technologies of the Lebanese University; Vac-4-all Initiative	Lebanese University research program the Doctoral School of Science and Technologies of the Lebanese University; Vac-4-all Initiative	This project was supported by the Lebanese University research program the Doctoral School of Science and Technologies of the Lebanese University and by the Vac-4-all Initiative.	Akkina R, 2013, CURR OPIN IMMUNOL, V25, P403, DOI 10.1016/j.coi.2013.03.009; ALEGRE ML, 1994, J IMMUNOL, V153, P2738; Arias MA, 2011, VACCINE, V29, P1258, DOI 10.1016/j.vaccine.2010.11.084; Benmohamed L, 2000, VACCINE, V18, P2843, DOI 10.1016/S0264-410X(00)00068-2; BenMohamed L, 1997, EUR J IMMUNOL, V27, P1242, DOI 10.1002/eji.1830270528; Billerbeck E, 2013, J IMMUNOL, V191, P1753, DOI 10.4049/jimmunol.1201518; Biswas S, 2011, IMMUNOLOGY, V134, P419, DOI 10.1111/j.1365-2567.2011.03501.x; Bouharoun-Tayoun H, 2004, EXP PARASITOL, V108, P47, DOI 10.1016/j.exppara.2004.07.004; Brahimi K, 2001, INFECT IMMUN, V69, P3845, DOI 10.1128/IAI.69.6.3845-3952.2001; Brams P, 1998, J IMMUNOL, V160, P2051; Brehm MA, 2013, J INFECT DIS, V208, pS125, DOI 10.1093/infdis/jit319; Chamat S, 1999, J INFECT DIS, V180, P268, DOI 10.1086/314876; Daher LJ, 2010, INFECT IMMUN, V78, P477, DOI 10.1128/IAI.00941-08; Danner R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019826; Daubersies P, 2000, NAT MED, V6, P1258, DOI 10.1038/81366; Daubersies P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002659; Doolan DL, 2006, CURR MOL MED, V6, P169, DOI 10.2174/156652406776055249; Druilhe P., 1998, MALARIA PARASITE BIO; Druilhe P, 2007, CURR OPIN MICROBIOL, V10, P371, DOI 10.1016/j.mib.2007.07.009; Duan ZL, 2013, INT J ONCOL, V42, P1482, DOI 10.3892/ijo.2013.1834; Gomez CE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035485; Ernst W, 2016, COMP IMMUNOL MICROB, V49, P29, DOI 10.1016/j.cimid.2016.08.006; Esen M, 2009, VACCINE, V27, P6862, DOI 10.1016/j.vaccine.2009.09.011; Fassnacht M, 2005, CLIN CANCER RES, V11, P5566, DOI 10.1158/1078-0432.CCR-05-0699; Ferrara JLM, 2006, SEMIN HEMATOL, V43, P1, DOI 10.1053/j.seminhematol.2005.11.028; FERREIRA A, 1986, SCIENCE, V232, P881, DOI 10.1126/science.3085218; Fujiwara S, 2018, J CELL PHYSIOL, V233, P2889, DOI 10.1002/jcp.26022; Golovina TN, 2008, J IMMUNOL, V181, P2855, DOI 10.4049/jimmunol.181.4.2855; Houser KR, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-6; Ito R, 2018, J CELL PHYSIOL, V233, P3723, DOI 10.1002/jcp.26045; Junqueira C, 2011, P NATL ACAD SCI USA, V108, P19695, DOI 10.1073/pnas.1110030108; King MA, 2009, CLIN EXP IMMUNOL, V157, P104, DOI 10.1111/j.1365-2249.2009.03933.x; King M, 2008, CLIN IMMUNOL, V126, P303, DOI 10.1016/j.clim.2007.11.001; Lapenta C, 2005, INT IMMUNOL, V17, P469, DOI 10.1093/intimm/dxh226; Lapenta C, 2003, J EXP MED, V198, P361, DOI 10.1084/jem.20021924; Lapenta C, 2006, EUR J IMMUNOL, V36, P2046, DOI 10.1002/eji.200535579; Lee J, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-53; Marcheix B, 2005, TRANSPL P, V37, P2888, DOI 10.1016/j.transproceed.2005.05.031; Marcheix B, 2006, J HEART LUNG TRANSPL, V25, P675, DOI 10.1016/j.healun.2006.01.005; Marusic C, 2001, J VIROL, V75, P8434, DOI 10.1128/JVI.75.18.8434-8439.2001; MELLOUK S, 1987, J IMMUNOL, V139, P4192; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Mikkelsen TS, 2005, NATURE, V437, P69, DOI 10.1038/nature04072; Nervi B, 2007, EXP HEMATOL, V35, P1823, DOI 10.1016/j.exphem.2007.06.007; Perlaza BL, 2003, EUR J IMMUNOL, V33, P1321, DOI 10.1002/eji.200323339; Perlaza BL, 2001, EUR J IMMUNOL, V31, P2200, DOI 10.1002/1521-4141(200107)31:7&lt;2200::AID-IMMU2200&gt;3.0.CO;2-L; Perlaza BL, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-27; Ruiss R, 2011, J VIROL, V85, P13105, DOI 10.1128/JVI.05598-11; Sarkar S, 2011, MOL CELL BIOL, V31, P602, DOI 10.1128/MCB.00835-10; Sauzet JP, 2001, INFECT IMMUN, V69, P1202, DOI 10.1128/IAI.69.2.1202-1206.2001; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P10700, DOI 10.1073/pnas.91.22.10700; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Suzuki M, 2012, INT IMMUNOL, V24, P243, DOI 10.1093/intimm/dxs045; Thomsen M, 2005, TISSUE ANTIGENS, V66, P73, DOI 10.1111/j.1399-0039.2005.00409.x; Toure-Balde A, 2009, INFECT IMMUN, V77, P1189, DOI 10.1128/IAI.00780-07; van Rijn RS, 2003, BLOOD, V102, P2522, DOI 10.1182/blood-2002-10-3241; Watanabe Y, 2009, INT IMMUNOL, V21, P843, DOI 10.1093/intimm/dxp050; Yacoub-Youssef H, 2005, TRANSPL IMMUNOL, V15, P157, DOI 10.1016/j.trim.2005.07.002; Yoshida A, 2003, J VIROL, V77, P8719, DOI 10.1128/JVI.77.16.8719-8728.2003	59	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2018	9								601	10.3389/fimmu.2018.00601	http://dx.doi.org/10.3389/fimmu.2018.00601			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GA2WJ	29628927	gold, Green Published			2022-12-18	WOS:000428186800002
J	Brown, MA				Brown, Melissa A.			Studies of Mast Cells: Adventures in Serendipity	FRONTIERS IN IMMUNOLOGY			English	Review						IL-4; mast cells; experimental autoimmune encephalomyelitis/multiple sclerosis; sex-dependent response; IL-33/ST2; testosterone	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; INNATE LYMPHOID-CELLS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; STIMULATORY FACTOR-I; CYTOKINE GM-CSF; REGULATORY T-CELLS; MULTIPLE-SCLEROSIS; IMMUNE-RESPONSE; MENINGEAL INFLAMMATION	Like many of us who had the great fortune to work with Bill Paul, my science life was immeasurably altered by my interactions with him. Although intimidating at first because of his stature in the immunology world, it was soon clear that he not only truly cared about the specific research we were doing together, but he wished to convey to his trainees an approach to science that was open, always questioning, and infinitely fun. His enthusiasm was infectious and after my training with him, despite stresses due to funding and publishing hurdles, I never regretted the path I took. My research took a sharp turn from the studies of adaptive immunity I had planned on pursuing after my fellowship with Bill to a life long quest to understand the wonders of the mast cell, a relatively rare innate immune cell. This came about because Bill's curiosity and expectation of the unexpected allowed him to view, in retrospect, a rather mundane observation we made together involving a non-physiological transformed mast cell line as something that might be really interesting. I have never forgotten that lesson: Look at the data with an eye on the big picture. Sometimes the unexpected is more interesting than predicted results. His example in this regard was incredibly important when as an independent investigator a mistake in mouse sex determination led to unexpected and very confusing data. Yet, these data ultimately revealed a role for mast cells in male-specific protection in experimental autoimmune encephalomyelitis, the mouse model of multiple sclerosis. Bill's influence in immunology is far-reaching and will continue to be felt as those of us who train our own students and post-doctoral fellows pass on his wisdom and approach to scientific research.	[Brown, Melissa A.] Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Brown, MA (corresponding author), Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA.	m-brown12@northwestern.edu			NIH [R21 NS081598, RO1AI12829, RO1 NS047578]; National Multiple Sclerosis Society [RG3104B3/2, RG46845/1, RG-5281-A-3]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society)	This work was funded by the NIH R21 NS081598, RO1AI12829, RO1 NS047578 and the National Multiple Sclerosis Society RG3104B3/2, RG46845/1, and RG-5281-A-3.	Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Bebo BF, 1998, J NEUROIMMUNOL, V84, P122, DOI 10.1016/S0165-5728(97)00214-2; Bebo BF, 1999, J IMMUNOL, V162, P35; Bebo BF, 1998, J NEUROSCI RES, V52, P420, DOI 10.1002/(SICI)1097-4547(19980515)52:4<420::AID-JNR5>3.0.CO;2-B; Bot I, 2011, THROMB HAEMOSTASIS, V106, P820, DOI 10.1160/TH11-05-0291; BROWN MA, 1986, CELL IMMUNOL, V98, P538, DOI 10.1016/0008-8749(86)90313-8; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; Carlson T, 2008, J EXP MED, V205, P811, DOI 10.1084/jem.20072404; Christy AL, 2013, J AUTOIMMUN, V42, P50, DOI 10.1016/j.jaut.2012.11.003; Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027; Coussens LM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003285; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Croxford AL, 2015, IMMUNITY, V43, P502, DOI 10.1016/j.immuni.2015.08.010; CUA DJ, 1995, J IMMUNOL, V155, P4052; Dalal M, 1997, J IMMUNOL, V159, P3; DIETSCH GN, 1989, J IMMUNOL, V142, P1476; Dimitriadou V, 2000, INT J IMMUNOPHARMACO, V22, P673, DOI 10.1016/S0192-0561(00)00029-1; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Ehrlich P., 1878, BEITRAGE THEORIE PRA; El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Galli SJ, 2016, ALLERGOL INT, V65, P3, DOI 10.1016/j.alit.2015.09.002; Galli SJ, 2015, ADV IMMUNOL, V126, P45, DOI 10.1016/bs.ai.2014.11.002; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Haidl G, 2011, EXPERT REV CLIN IMMU, V7, P627, DOI [10.1586/eci.11.57, 10.1586/ECI.11.57]; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hatfield JK, 2015, CELL IMMUNOL, V297, P69, DOI 10.1016/j.cellimm.2015.06.006; Hendrix S, 2006, NEUROSCI LETT, V392, P174, DOI 10.1016/j.neulet.2005.09.029; Hershko AY, 2011, IMMUNITY, V35, P562, DOI 10.1016/j.immuni.2011.07.013; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; Kambayashi T, 2009, J IMMUNOL, V182, P4686, DOI 10.4049/jimmunol.0803180; KEEGAN AD, 1991, EMBO J, V10, P3675, DOI 10.1002/j.1460-2075.1991.tb04935.x; KITAMURA Y, 1978, BLOOD, V52, P447; Kurth F, 2014, NEUROIMAGE-CLIN, V4, P454, DOI 10.1016/j.nicl.2014.03.001; Kwong B, 2017, NAT IMMUNOL, V18, P1117, DOI 10.1038/ni.3816; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; Leveson-Gower DB, 2013, BLOOD, V122, P3659, DOI 10.1182/blood-2013-08-519157; Levy D, 2009, CURR PAIN HEADACHE R, V13, P237, DOI 10.1007/s11916-009-0040-y; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lotfi-Emran S, 2018, J ALLERGY CLIN IMMUN, V141, P311, DOI 10.1016/j.jaci.2017.02.048; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; Maltby S, 2009, BBA-REV CANCER, V1796, P19, DOI 10.1016/j.bbcan.2009.02.001; Mattila OS, 2011, STROKE, V42, P3600, DOI 10.1161/STROKEAHA.111.632224; Menzies FM, 2011, HUM REPROD UPDATE, V17, P383, DOI 10.1093/humupd/dmq053; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAGLE DL, 1995, HUM MOL GENET, V4, P2073, DOI 10.1093/hmg/4.11.2073; Nautiyal KM, 2008, P NATL ACAD SCI USA, V105, P18053, DOI 10.1073/pnas.0809479105; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; Nylander A, 2012, J CLIN INVEST, V122, P1180, DOI 10.1172/JCI58649; Odoardi F, 2012, NATURE, V488, P675, DOI 10.1038/nature11337; Papenfuss TL, 2004, J NEUROIMMUNOL, V150, P59, DOI 10.1016/j.jneuroim.2004.01.018; Piconese S, 2011, LAB INVEST, V91, P627, DOI 10.1038/labinvest.2011.3; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; Ponomarev ED, 2007, J IMMUNOL, V178, P39, DOI 10.4049/jimmunol.178.1.39; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Ransohoff RM, 2009, NATURE, V462, P41, DOI 10.1038/462041a; Robinson AP, 2014, HAND CLINIC, V122, P173, DOI 10.1016/B978-0-444-52001-2.00008-X; Rodewald HR, 2012, IMMUNITY, V37, P13, DOI 10.1016/j.immuni.2012.07.007; ROZNIECKI JJ, 1995, ANN NEUROL, V37, P63, DOI 10.1002/ana.410370112; Rumble JM, 2015, J EXP MED, V212, P23, DOI 10.1084/jem.20141015; Russi AE, 2018, P NATL ACAD SCI USA, V115, pE1520, DOI 10.1073/pnas.1710401115; Russi AE, 2016, J AUTOIMMUN, V73, P100, DOI 10.1016/j.jaut.2016.06.015; Russi AE, 2015, J IMMUNOL, V194, P5609, DOI 10.4049/jimmunol.1500068; Russi AE, 2015, TRANSL RES, V165, P255, DOI 10.1016/j.trsl.2014.08.005; Salamon P, 2017, CLIN EXP ALLERGY, V47, P1409, DOI 10.1111/cea.13027; Sayed BA, 2011, J IMMUNOL, V186, P3294, DOI 10.4049/jimmunol.1003574; Sayed BA, 2010, J IMMUNOL, V184, P6891, DOI 10.4049/jimmunol.1000126; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SEDER RA, 1991, INT ARCH ALLER A IMM, V94, P137, DOI 10.1159/000235345; Sicotte NL, 2007, ARCH NEUROL-CHICAGO, V64, P683, DOI 10.1001/archneur.64.5.683; Silva EZMD, 2014, J HISTOCHEM CYTOCHEM, V62, P698, DOI DOI 10.1369/0022155414545334; Taiwo OB, 2005, BRAIN RES, V1056, P76, DOI 10.1016/j.brainres.2005.07.022; Tellechea A, 2016, DIABETES, V65, P2006, DOI 10.2337/db15-0340; THEOHARIDES TC, 1993, NEUROSCIENCE, V57, P861, DOI 10.1016/0306-4522(93)90030-J; Torjesen PA, 2004, CLIN CHEM, V50, P678, DOI 10.1373/clinchem.2003.027565; TUOMISTO L, 1983, AGENTS ACTIONS, V13, P255, DOI 10.1007/BF01967346; Voskuhl RR, 2012, NAT REV NEUROL, V8, P255, DOI 10.1038/nrneurol.2012.43; Walker-Caulfield ME, 2015, J NEUROIMMUNOL, V278, P112, DOI 10.1016/j.jneuroim.2014.12.009; Whitacre CC, 2001, NAT IMMUNOL, V2, P777, DOI 10.1038/ni0901-777; Zhang J, 2012, BBA-MOL BASIS DIS, V1822, P14, DOI 10.1016/j.bbadis.2010.12.012; Zhu JF, 2010, IMMUNOL REV, V238, P247, DOI 10.1111/j.1600-065X.2010.00951.x	91	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 13	2018	9								520	10.3389/fimmu.2018.00520	http://dx.doi.org/10.3389/fimmu.2018.00520			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FZ0SA	29593744	gold, Green Published			2022-12-18	WOS:000427281300002
J	Narendra, SC; Chalise, JP; Biggs, S; Kalinke, U; Magnusson, M				Narendra, Sudeep Chenna; Chalise, Jaya Prakash; Biggs, Sophie; Kalinke, Ulrich; Magnusson, Mattias			Regulatory T-Cells Mediate IFN-alpha-Induced Resistance against Antigen-Induced Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						interferon-alpha; regulatory T-cells; experimental arthritis; indoleamine 2,3-dioxygenase; kynurenine	I INTERFERONS; INDOLEAMINE 2,3-DIOXYGENASE; RESPONSES; RECEPTOR; SUPPRESSION; TOLERANCE; PROTECTS; THERAPY; SYSTEM; MICE	Objective: CD4(+)FoxP3(+)CD25(+) regulatory T-cells (T-regs) are important for preventing tissue destruction. Here, we investigate the role of T-regs for protection against experimental arthritis by IFN-alpha. Methods: Arthritis was triggered by intra-articular injection of methylated bovine serum albumin (mBSA) in wild-type mice, Foxp3DTReGFP(+/-) mice [allowing selective depletion of T-regs by diphtheria toxin (DT)] and CD4-Cre(+/-) IFNA1R flox/flox mice (devoid of IFNAR signaling in T-cells) earlier immunized with mBSA, with or without treatment with IFN-alpha or the indoleamine 2,3-dioxygenase (IDO)-metabolite kynurenine. T-regs were depleted in DT-treated Foxp3DTReGFP(+/-) mice and enumerated by FoxP3 staining. Suppressive capacity of FACS-sorted CD25(+high)CD4(+) T-regs was tested in vivo by adoptive transfer and ex vivo in cocultures with antigen-stimulated CFSE-stained T-responder (CD25-CD4(+)) cells. IDO was inhibited by 1-methyl tryptophan. Results: Both control mice and mice devoid of IFNAR-signaling in T helper cells were protected from arthritis by IFN-alpha. Depletion of T-regs in the arthritis phase, but not at immunization, abolished the protective effect of IFN-alpha and kynurenine against arthritis. IFN-alpha increased the number of T-regs in ex vivo cultures upon antigen recall stimulation but not in naive cells. IFN-alpha also increased the suppressive capacity of T-regs against mBSA-induced T-responder cell proliferation ex vivo and against arthritis when adoptively transferred. The increased suppressive activity against proliferation conferred by IFN-alpha was clearly reduced by in vivo inhibition of IDO at immunization, which also abolished the protective effect of IFN-alpha against arthritis. Conclusion: By activating IDO during antigen sensitization, IFN-alpha activates T-regs, which prevent arthritis triggered by antigen rechallenge. This is one way by which IFN-alpha suppresses inflammation.	[Narendra, Sudeep Chenna; Biggs, Sophie; Magnusson, Mattias] Linkoping Univ, Div Rheumatol Autoimmun & Immune Regulat, Dept Clin & Expt Med, Linkoping, Sweden; [Chalise, Jaya Prakash] Osaka Univ, Immune Regulat, IFReC, Suita, Osaka, Japan; [Kalinke, Ulrich] Zentrum Expt & Klin Infekt Forsch, Twincore, Hannover, Germany	Linkoping University; Osaka University	Magnusson, M (corresponding author), Linkoping Univ, Div Rheumatol Autoimmun & Immune Regulat, Dept Clin & Expt Med, Linkoping, Sweden.	mattias.magnusson@liu.se	Chalise, Jaya Prakash/Z-1141-2019	Kalinke, Ulrich/0000-0003-0503-9564	Vetenskapsradet [521-2011-3095]; Reumatikerforbundet [R474951, R568881]; Ostergotland county hospital grant (ALF) [LIO-606871]	Vetenskapsradet(Swedish Research Council); Reumatikerforbundet; Ostergotland county hospital grant (ALF)	This work was supported by Vetenskapsradet 12-15 Dnr 521-2011-3095, Reumatikerforbundet R474951, Reumatikerforbundet R568881, and Ostergotland county hospital grant (ALF) LIO-606871.	Chalise JP, 2016, J IMMUNOL, V197, P3142, DOI 10.4049/jimmunol.1502125; Chalise JP, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4326; Chen W, 2008, J IMMUNOL, V181, P5396, DOI 10.4049/jimmunol.181.8.5396; de Andres C, 2007, J NEUROIMMUNOL, V182, P204, DOI 10.1016/j.jneuroim.2006.09.012; Golding A, 2010, IMMUNOLOGY, V131, P107, DOI 10.1111/j.1365-2567.2010.03280.x; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Hadaschik EN, 2015, HUM IMMUNOL, V76, P561, DOI 10.1016/j.humimm.2015.06.015; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Katakura K, 2005, J CLIN INVEST, V115, P695, DOI 10.1172/JCI200522996; Lahl K, 2011, METHODS MOL BIOL, V707, P157, DOI 10.1007/978-1-61737-979-6_10; Langhans B, 2017, J HEPATOL, V66, P888, DOI 10.1016/j.jhep.2016.12.019; Le Bon A, 2006, J IMMUNOL, V176, P4682, DOI 10.4049/jimmunol.176.8.4682; Lee SE, 2012, GASTROENTEROLOGY, V143, P145, DOI 10.1053/j.gastro.2012.03.042; Lippens C, 2016, J AUTOIMMUN, V75, P39, DOI 10.1016/j.jaut.2016.07.004; Metidji A, 2015, J IMMUNOL, V194, P4265, DOI 10.4049/jimmunol.1500036; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Munoz-Suano A, 2012, J AUTOIMMUN, V38, pJ103, DOI 10.1016/j.jaut.2011.09.007; Pace L, 2010, J IMMUNOL, V184, P5969, DOI 10.4049/jimmunol.0900526; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416; Piconese S, 2015, CYTOKINE GROWTH F R, V26, P133, DOI 10.1016/j.cytogfr.2014.10.012; Quah BJ, 2010, J VIS EXP, V44, DOI 10.3791/2259; Ronnblom L, 2011, SEMIN IMMUNOL, V23, P113, DOI 10.1016/j.smim.2011.01.009; Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464; Srivastava S, 2014, J EXP MED, V211, P961, DOI 10.1084/jem.20131556; Stephen-Victor E, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12746; Stubgen JP, 2009, J NEUROIMMUNOL, V212, P132, DOI 10.1016/j.jneuroim.2009.04.015; Trinchieri G, 2010, J EXP MED, V207, P2053, DOI 10.1084/jem.20101664; van den Berg Wim B., 2007, V136, P243; Venken K, 2007, J IMMUNOL METHODS, V322, P1, DOI 10.1016/j.jim.2007.01.025; Wang DC, 2016, J IMMUNOL, V197, P2992, DOI 10.4049/jimmunol.1500411; Yarilina A, 2007, J IMMUNOL, V178, P2204, DOI 10.4049/jimmunol.178.4.2204; Ying F, 2011, EUR J IMMUNOL, V41, P1687, DOI 10.1002/eji.201040956	33	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 19	2018	9								285	10.3389/fimmu.2018.00285	http://dx.doi.org/10.3389/fimmu.2018.00285			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FW6EW	29515584	Green Published, gold			2022-12-18	WOS:000425412000001
J	Khass, M; Blackburn, T; Elgavish, A; Burrows, PD; Schroeder, HW				Khass, Mohamed; Blackburn, Tessa; Elgavish, Ada; Burrows, Peter D.; Schroeder, Harry W., Jr.			In the Absence of Central pre-B Cell Receptor Selection, Peripheral Selection Attempts to Optimize the Antibody Repertoire by Enriching for CDR-H3 Y101	FRONTIERS IN IMMUNOLOGY			English	Article						antibody repertoire; B cell development; preBCR; CDR-H3; peripheral B cell subsets; BrdU incorporation; apoptosis	H READING FRAME; HEAVY-CHAIN; GENETIC-CONTROL; PROTEIN; MICE; SUFFICIENT; EXPRESSION; DIVERSITY; LAMBDA-5; SEQUENCE	Sequential developmental checkpoints are used to "optimize" the B cell antigen receptor repertoire by minimizing production of autoreactive or useless immunoglobulins and enriching for potentially protective antibodies. The first and apparently most impactful checkpoint requires mu HC to form a functional pre-B cell receptor (preBCR) by associating with surrogate light chain, which is composed of VpreB and lambda 5. Absence of any of the preBCR components causes a block in B cell development that is characterized by severe immature B cell lymphopenia. Previously, we showed that preBCR controls the amino acid content of the third complementary determining region of the H chain (CDR-H3) by using a VpreB amino acid motif (RDR) to select for tyrosine at CDR-H3 position 101 (Y101). In antibodies bound to antigen, Y101 is commonly in direct contact with the antigen, thus preBCR selection impacts the antigen binding characteristics of the repertoire. In this work, we sought to determine the forces that shape the peripheral B cell repertoire when it is denied preBCR selection. Using bromodeoxyuridine incorporation and evaluation of apoptosis, we found that in the absence of preBCR there is increased turnover of B cells due to increased apoptosis. CDR-H3 sequencing revealed that this is accompanied by adjustments to D-H identity, D-H reading frame, J(H), and CDR-H3 amino acid content. These adjustments in the periphery led to wild-type levels of CDR-H3 Y101 content among transitional (T1), mature recirculating, and marginal zone B cells. However, peripheral selection proved incomplete, with failure to restore Y101 levels in follicular B cells and increased production of dsDNA-binding IgM antibodies.	[Khass, Mohamed; Elgavish, Ada; Schroeder, Harry W., Jr.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Khass, Mohamed] Natl Res Ctr, Genet Engn & Biotechnol Div, Cairo, Egypt; [Blackburn, Tessa; Burrows, Peter D.; Schroeder, Harry W., Jr.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Egyptian Knowledge Bank (EKB); National Research Centre (NRC); University of Alabama System; University of Alabama Birmingham	Schroeder, HW (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.; Schroeder, HW (corresponding author), Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.	hschroeder@uabmc.edu		Schroeder, Harry/0000-0002-3767-6878	NIH [AI117703]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI117703] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank John F. Kearney, PhD, for helpful discussions. We thank Leticia Watkins, Cun Ren Liu and Yingxin Zhuang for expert technical assistance. This work was supported by NIH AI117703.	Allman D, 2001, J IMMUNOL, V167, P6834, DOI 10.4049/jimmunol.167.12.6834; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Capra J.D., 2002, THE ANTIBODIES, P43; Carey JB, 2008, J EXP MED, V205, P2043, DOI 10.1084/jem.20080559; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FRANCES V, 1994, EMBO J, V13, P5937, DOI 10.1002/j.1460-2075.1994.tb06939.x; GU H, 1991, IMMUNOL TODAY, V12, P420, DOI 10.1016/0167-5699(91)90146-K; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Hendriks RW, 2004, TRENDS IMMUNOL, V25, P249, DOI 10.1016/j.it.2004.02.011; ISENBERG DA, 1987, ANN RHEUM DIS, V46, P448, DOI 10.1136/ard.46.6.448; Ivanov II, 2005, J IMMUNOL, V174, P7773, DOI 10.4049/jimmunol.174.12.7773; Khass M, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf6628; Khass M, 2013, EUR J IMMUNOL, V43, P629, DOI 10.1002/eji.201242936; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Liu YJ, 1997, J EXP MED, V186, P625, DOI 10.1084/jem.186.5.625; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; Melchers F, 2015, J CLIN INVEST, V125, P2203, DOI 10.1172/JCI78083; NADEL B, 1995, J IMMUNOL, V155, P4322; Novobrantseva TI, 1999, J EXP MED, V189, P75, DOI 10.1084/jem.189.1.75; Nussenzweig MC, 1998, CELL, V95, P875, DOI 10.1016/S0092-8674(00)81711-0; Petro JB, 2002, J BIOL CHEM, V277, P48009, DOI 10.1074/jbc.M200305200; RADIC MZ, 1993, J IMMUNOL, V150, P4966; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rangel R, 2005, J BIOL CHEM, V280, P17807, DOI 10.1074/jbc.M409479200; Schelonka RL, 2005, J IMMUNOL, V175, P6624, DOI 10.4049/jimmunol.175.10.6624; Schelonka RL, 2007, EUR J IMMUNOL, V37, P1010, DOI 10.1002/eji.200636569; Schroeder HW, 2010, CRIT REV IMMUNOL, V30, P327; Schuh W, 2003, J IMMUNOL, V171, P3343, DOI 10.4049/jimmunol.171.7.3343; Silva-Sanchez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118171; Srivastava B, 2005, J EXP MED, V202, P1225, DOI 10.1084/jem.20051038; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; Trad A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00385; Vale AM, 2013, J EXP MED, V210, P875, DOI 10.1084/jem.20121861; Wang YG, 2016, IMMUNOGENETICS, V68, P145, DOI 10.1007/s00251-015-0890-x; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Zemlin M, 2005, MOL IMMUNOL, V42, P789, DOI 10.1016/j.molimm.2004.07.049; Zemlin M, 2008, J IMMUNOL, V181, P8416, DOI 10.4049/jimmunol.181.12.8416	41	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2018	9								120	10.3389/fimmu.2018.00120	http://dx.doi.org/10.3389/fimmu.2018.00120			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FV1TW	29472919	Green Published, gold			2022-12-18	WOS:000424348700001
J	Schaible, UE; Kaufmann, SHE				Schaible, Ulrich E.; Kaufmann, Stefan H. E.			Editorial: Reassessing Twenty Years of Vaccine Development against Tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccines; tuberculosis; immune protection; global health; pulmonary			[Schaible, Ulrich E.] Forschungszentrum Borstel, Dept Cellular Microbiol, Prior Program Area Infect, Borstel, Germany; [Kaufmann, Stefan H. E.] Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany	Forschungszentrum Borstel; Max Planck Society	Schaible, UE (corresponding author), Forschungszentrum Borstel, Dept Cellular Microbiol, Prior Program Area Infect, Borstel, Germany.	uschaible@fz-borstel.de						Bloemberg GV, 2015, NEW ENGL J MED, V373, P1986, DOI 10.1056/NEJMc1505196; Dheda K, 2017, LANCET RESP MED, V5, P291, DOI [10.1016/S2213-2600(17)30079-6, 10.1016/s2213-2600(17)30079-6]; G20 Leader's Declaration, 2017, SHAP INT WORLD HAMB; World Health Organization, 2017, GLOB TUB REP 2017	4	2	2	1	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 7	2018	9								180	10.3389/fimmu.2018.00180	http://dx.doi.org/10.3389/fimmu.2018.00180			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FV1VU	29467766	Green Published, gold			2022-12-18	WOS:000424353700001
J	Zhang, XY; Cui, JJ; Wu, YY; Wang, H; Wang, J; Qiu, YL; Mo, YJ; He, YJ; Zhang, XM; Yin, YB; Xu, WC				Zhang, Xinyuan; Cui, Jingjing; Wu, Yingying; Wang, Hong; Wang, Jian; Qiu, Yulan; Mo, Yunjun; He, Yujuan; Zhang, Xuemei; Yin, Yibing; Xu, Wenchun			Streptococcus pneumoniae Attenuated Strain SPY1 with an Artificial Mineral Shell Induces Humoral and Th17 Cellular Immunity and Protects Mice against Pneumococcal Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Streptococcus pneumoniae; live attenuated vaccine; biomineralization; thermal stability; immunogenicity	TLR2 AGONIST; VACCINE; MUCOSAL; DISEASE; COLONIZATION; IMMUNIZATION; ADJUVANT; CELLS; BIOMINERALIZATION; CLEARANCE	Streptococcus pneumoniae is a major pathogen leading to substantial morbidity and mortality in children under 5 years of age. Vaccination is an effective strategy to prevent S. pneumoniae infection. SPY1 is a pneumococcal vaccine candidate strain obtained in our previous study. To improve its stability and immunogencity, in this study, we constructed the SPY1 Delta lytA strain that lacks autolysin activity and was coated with an artificial exterior surface calcium phosphate shell by in situ mineralization. The resulting strain SPY1 Delta lytACaPi displayed enhanced thermal stability enabling storage at 37 degrees C for 1 week. Furthermore, mucosal and subcutaneous immunization with the SPY1 Delta lytACaPi strain induced better protective effects than SPY1 Delta lytA in anti-colonization after challenging with 19F and anti-invasion by D39 in mice. Subcutaneous immunization with SPY1 Delta lytACaPi elicited higher IgG level while mucosal immunization primarily elicited an immune response which is supposed to be related to Th17 cells. Taken together, the mineralized strain may be a promising candidate for an attenuated S. pneumoniae vaccine.	[Zhang, Xinyuan; Wu, Yingying; Wang, Hong; Wang, Jian; Qiu, Yulan; Mo, Yunjun; He, Yujuan; Zhang, Xuemei; Yin, Yibing; Xu, Wenchun] Chongqing Med Univ, Sch Lab Med, Minist Educ, Key Lab Lab Med Diagnost Designated, Chongqing, Peoples R China; [Cui, Jingjing] Chongqing Hosp Women & Children, Dept Clin Lab, Chongqing, Peoples R China	Chongqing Medical University	Xu, WC (corresponding author), Chongqing Med Univ, Sch Lab Med, Minist Educ, Key Lab Lab Med Diagnost Designated, Chongqing, Peoples R China.	100977@cqmu.edu.cn		Zhang, Xuemei/0000-0002-0326-9262	Natural Science Foundation of China [81671639, 31270984]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of China (No. 81671639 to WX and 31270984 to WX).	Albiger B, 2005, CELL MICROBIOL, V7, P1603, DOI 10.1111/j.1462-5822.2005.00578.x; [Anonymous], 2008, Wkly Epidemiol Rec, V83, P1; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Cao J, 2007, VACCINE, V25, P4996, DOI 10.1016/j.vaccine.2007.04.069; Cheng CM, 2011, VACCINE, V29, P6641, DOI 10.1016/j.vaccine.2011.06.105; CLAVERYS JP, 1995, GENE, V164, P123, DOI 10.1016/0378-1119(95)00485-O; Croucher NJ, 2011, SCIENCE, V331, P430, DOI 10.1126/science.1198545; Cruse G, 2010, J IMMUNOL, V184, P7108, DOI 10.4049/jimmunol.0900802; Feldman C, 2014, J INFECTION, V69, P309, DOI 10.1016/j.jinf.2014.06.006; Ferreira DM, 2008, CLIN VACCINE IMMUNOL, V15, P499, DOI 10.1128/CVI.00400-07; Hamm CE, 2003, NATURE, V421, P841, DOI 10.1038/nature01416; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002; He Q, 2000, CLIN DIAGN LAB IMMUN, V7, P899, DOI 10.1128/CDLI.7.6.899-903.2000; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101; Koedel U, 2003, J IMMUNOL, V170, P438, DOI 10.4049/jimmunol.170.1.438; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Malley R, 2012, P NATL ACAD SCI USA, V109, P3623, DOI 10.1073/pnas.1121383109; Mellroth P, 2012, J BIOL CHEM, V287, P11018, DOI 10.1074/jbc.M111.318584; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Roche AM, 2007, INFECT IMMUN, V75, P2469, DOI 10.1128/IAI.01972-06; Roy MD, 2008, ADV MATER, V20, P1830, DOI 10.1002/adma.200702322; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Tan ACL, 2012, MOL PHARMACEUT, V9, P2710, DOI 10.1021/mp300257x; Thanassi JA, 2002, NUCLEIC ACIDS RES, V30, P3152, DOI 10.1093/nar/gkf418; van Rossum AMC, 2005, INFECT IMMUN, V73, P7718, DOI 10.1128/IAI.73.11.7718-7726.2005; Wang B, 2008, ANGEW CHEM INT EDIT, V47, P3560, DOI 10.1002/anie.200704718; Wang GC, 2013, P NATL ACAD SCI USA, V110, P7619, DOI 10.1073/pnas.1300233110; Wang GC, 2012, ANGEW CHEM INT EDIT, V51, P10576, DOI 10.1002/anie.201206154; Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8; Wu KF, 2014, VACCINE, V32, P4179, DOI 10.1016/j.vaccine.2014.05.019; Xu XY, 2015, INFECT IMMUN, V83, P90, DOI 10.1128/IAI.02334-14; Yao HM, 2010, P NATL ACAD SCI USA, V107, P987, DOI 10.1073/pnas.0912988107; Zeng LB, 2015, VACCINE, V33, P1008, DOI 10.1016/j.vaccine.2015.01.013; Zhang JE, 2012, P NATL ACAD SCI USA, V109, P11981, DOI 10.1073/pnas.1206210109	37	2	3	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 11	2018	8								1983	10.3389/fimmu.2017.01983	http://dx.doi.org/10.3389/fimmu.2017.01983			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FS4UK		gold, Green Published			2022-12-18	WOS:000419788400001
J	Chartrand, K; Lebel, ME; Tarrab, E; Savard, P; Leclerc, D; Lamarre, A				Chartrand, Karine; Lebel, Marie-Eve; Tarrab, Esther; Savard, Pierre; Leclerc, Denis; Lamarre, Alain			Efficacy of a virus-Like Nanoparticle As Treatment for a Chronic Viral Infection Is Hindered by IRAK1 Regulation and Antibody Interference	FRONTIERS IN IMMUNOLOGY			English	Article						plasmacytoid dendritic cells; PapMV; interferon-alpha; IRAK1; Sca-1; antibodies; lymphocytic choriomeningitis virus clone 13	PLASMACYTOID DENDRITIC CELLS; PAPAYA MOSAIC-VIRUS; TOLL-LIKE RECEPTORS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PERSISTENT LCMV INFECTION; PAPMV VACCINE PLATFORM; CHRONIC HEPATITIS-B; SUBTYPES IN-VIVO; T-CELLS; INNATE IMMUNITY	Although vaccination has been an effective way of preventing infections ever since the eighteenth century, the generation of therapeutic vaccines and immunotherapies is still a work in progress. A number of challenges impede the development of these therapeutic approaches such as safety issues related to the administration of whole pathogens whether attenuated or inactivated. One safe alternative to classical vaccination methods gaining recognition is the use of nanoparticles, whether synthetic or naturally derived. We have recently demonstrated that the papaya mosaic virus (PapMV)-like nanoparticle can be used as a prophylactic vaccine against various viral and bacterial infections through the induction of protective humoral and cellular immune responses. Moreover, PapMV is also very efficient when used as an immune adjuvant in an immunotherapeutic setting at slowing down the growth of aggressive mouse melanoma tumors in a type I interferon (IFN-I)-dependent manner. In the present study, we were interested in exploiting the capacity of PapMV of inducing robust IFN-I production as treatment for the chronic viral infection model lymphocytic choriomeningitis virus (LCMV) clone 13 (Cl13). Treatment of LCMV Cl13-infected mice with two systemic administrations of PapMV was ineffective, as shown by the lack of changes in viral titers and immune response to LCMV following treatment. Moreover, IFN-alpha production following PapMV administration was almost completely abolished in LCMV-infected mice. To better isolate the mechanisms at play, we determined the influence of a pretreatment with PapMV on secondary PapMV administration, therefore eliminating potential variables emanating from the infection. Pretreatment with PapMV led to the same outcome as an LCMV infection in that IFN-alpha production following secondary PapMV immunization was abrogated for up to 50 days while immune activation was also dramatically impaired. We showed that two distinct and overlapping mechanisms were responsible for this outcome. While short-term inhibition was partially the result of interleukin-1 receptor-associated kinase 1 degradation, a crucial component of the toll-like receptor 7 signaling pathway, long-term inhibition was mainly due to interference by PapMV-specific antibodies. Thus, we identified a possible pitfall in the use of virus-like particles for the systemic treatment of chronic viral infections and discuss mitigating alternatives to circumvent these potential problems.	[Chartrand, Karine; Lebel, Marie-Eve; Tarrab, Esther; Lamarre, Alain] INRS, Immunovirol Lab, Inst Armand Frappier, Laval, PQ, Canada; [Savard, Pierre; Leclerc, Denis] Laval Univ, Dept Microbiol Infectiol & Immunol, Infect Dis Res Ctr, Quebec City, PQ, Canada	University of Quebec; Institut national de la recherche scientifique (INRS); Laval University	Lamarre, A (corresponding author), INRS, Immunovirol Lab, Inst Armand Frappier, Laval, PQ, Canada.	alain.lamarre@iaf.inrs.ca	Leclerc, Denis/P-1604-2019; Leclerc, Denis/AAG-6112-2019	savard, pierre/0000-0003-4134-0709	Canadian Institutes of Health Research [MOP-89833]; Jeanne and J.-Louis Levesque Chair in Immunovirology from the J.-Louis Levesque Foundation; Fonds de Recherche du Quebec - Sante	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Jeanne and J.-Louis Levesque Chair in Immunovirology from the J.-Louis Levesque Foundation; Fonds de Recherche du Quebec - Sante(Fonds de la Recherche en Sante du Quebec)	This work was financially supported by Canadian Institutes of Health Research Grant MOP-89833 and the Jeanne and J.-Louis Levesque Chair in Immunovirology from the J.-Louis Levesque Foundation. KC and M-EL acknowledge studentship support from the Fonds de Recherche du Quebec - Sante.	Abu Nahid M, 2016, J LEUKOCYTE BIOL, V100, P339, DOI 10.1189/jlb.2A0515-197R; Acosta-Ramirez E, 2008, IMMUNOLOGY, V124, P186, DOI 10.1111/j.1365-2567.2007.02753.x; Albrecht V, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-69; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Aul C, 1997, INTERFERONS, V1, P250; Babin C, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-10; Baccala R, 2012, J IMMUNOL, V189, P5976, DOI 10.4049/jimmunol.1201477; Barouch DH, 2004, J IMMUNOL, V172, P6290, DOI 10.4049/jimmunol.172.10.6290; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Bjoerck P, 2011, J IMMUNOL, V186, P1477, DOI 10.4049/jimmunol.1000454; Blasius AL, 2010, IMMUNITY, V32, P305, DOI 10.1016/j.immuni.2010.03.012; Borrow P, 2010, VIRUSES-BASEL, V2, P2443, DOI 10.3390/v2112443; Bourquin C, 2011, CANCER RES, V71, P5123, DOI 10.1158/0008-5472.CAN-10-3903; Carignan D, 2015, VACCINE, V33, P7245, DOI 10.1016/j.vaccine.2015.10.123; Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770; Cervantes-Barragan L, 2012, P NATL ACAD SCI USA, V109, P3012, DOI 10.1073/pnas.1117359109; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; Dalpke AH, 2005, IMMUNOLOGY, V116, P203, DOI 10.1111/j.1365-2567.2005.02211.x; Denis J, 2008, VACCINE, V26, P3395, DOI 10.1016/j.vaccine.2008.04.052; Denis J, 2007, VIROLOGY, V363, P59, DOI 10.1016/j.virol.2007.01.011; Fonteneau JF, 2003, BLOOD, V101, P3520, DOI 10.1182/blood-2002-10-3063; Fonteneau JF, 2004, J VIROL, V78, P5223, DOI 10.1128/JVI.78.10.5223-5232.2004; Gerlach N, 2009, EUR J IMMUNOL, V39, P136, DOI 10.1002/eji.200838311; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Hayashi T, 2009, P NATL ACAD SCI USA, V106, P2764, DOI 10.1073/pnas.0813037106; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Lacasse P, 2008, J VIROL, V82, P785, DOI 10.1128/JVI.01811-07; Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1; Lebel ME, 2017, J IMMUNOL, V198, P292, DOI 10.4049/jimmunol.1601271; Lebel ME, 2016, NANO LETT, V16, P1826, DOI 10.1021/acs.nanolett.5b04877; Lebel ME, 2015, VACCINES-BASEL, V3, P620, DOI 10.3390/vaccines3030620; Lebel ME, 2014, J IMMUNOL, V192, P1071, DOI 10.4049/jimmunol.1302030; Leclerc D, 2007, J VIROL, V81, P1319, DOI 10.1128/JVI.01720-06; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024; Liu YC, 2012, J IMMUNOL, V188, P1019, DOI 10.4049/jimmunol.1102181; Lund JM, 2006, J IMMUNOL, V177, P7510, DOI 10.4049/jimmunol.177.11.7510; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Mathieu C, 2013, NANOMED-NANOTECHNOL, V9, P839, DOI 10.1016/j.nano.2013.02.009; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Niederquell M, 2013, EUR J IMMUNOL, V43, P2993, DOI 10.1002/eji.201343498; Omatsu Y, 2005, J IMMUNOL, V174, P6657, DOI 10.4049/jimmunol.174.11.6657; Pelayo R, 2005, BLOOD, V105, P4407, DOI 10.1182/blood-2004-07-2529; Rioux G, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0200-2; Rioux G, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-19; Rioux G, 2012, FEBS J, V279, P2004, DOI 10.1111/j.1742-4658.2012.08583.x; Rodrigue-Gervais IG, 2007, J VIROL, V81, P5537, DOI 10.1128/JVI.01741-06; Sandler NG, 2014, NATURE, V511, P601, DOI 10.1038/nature13554; Santiago-Raber ML, 2003, J EXP MED, V197, P777, DOI 10.1084/jem.20021996; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Savard C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021522; Schwab N, 2010, J IMMUNOL, V184, P5368, DOI 10.4049/jimmunol.0903662; Siedlar M, 2004, J IMMUNOL, V173, P2736, DOI 10.4049/jimmunol.173.4.2736; Sleijfer S, 2005, PHARM WORLD SCI, V27, P423, DOI 10.1007/s11096-005-1319-7; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488; Sullivan BM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004588; Sumida SM, 2004, J VIROL, V78, P2666, DOI 10.1128/JVI.78.6.2666-2673.2004; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; Swiecki M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003728; Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020; Teijaro JR, 2013, SCIENCE, V340, P207, DOI 10.1126/science.1235214; Therien A, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0289-y; van Pesch V, 2004, J VIROL, V78, P8219, DOI 10.1128/JVI.78.15.8219-8228.2004; Villacres MC, 2008, J VIRAL HEPATITIS, V15, P137, DOI 10.1111/j.1365-2893.2007.00904.x; Wang YM, 2012, CELL HOST MICROBE, V11, P631, DOI 10.1016/j.chom.2012.05.003; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wilson EB, 2013, SCIENCE, V340, P202, DOI 10.1126/science.1235208; Xie Q, 2009, MICROBES INFECT, V11, P515, DOI 10.1016/j.micinf.2009.02.008; Xu N, 2012, INFLAMM RES, V61, P997, DOI 10.1007/s00011-012-0493-z; Yeow WS, 1998, J IMMUNOL, V160, P2932; Yoneyama H, 2005, J EXP MED, V202, P425, DOI 10.1084/jem.20041961; Yonkers NL, 2007, J IMMUNOL, V178, P4436, DOI 10.4049/jimmunol.178.7.4436; Zhang H, 2017, P NATL ACAD SCI USA, V114, P1988, DOI 10.1073/pnas.1610630114; Zhou SH, 2010, J VIROL, V84, P9452, DOI 10.1128/JVI.00155-10	78	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 4	2018	8								1885	10.3389/fimmu.2017.01885	http://dx.doi.org/10.3389/fimmu.2017.01885			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FR9AR		Green Published, gold			2022-12-18	WOS:000419366400001
J	Cserhalmi, M; Uzonyi, B; Merle, NS; Csuka, D; Meusburgers, E; Lhotta, K; Prohaszka, Z; Jozsi, M				Cserhalmi, Marcel; Uzonyi, Barbara; Merle, Nicolas S.; Csuka, Dorottya; Meusburgers, Edgar; Lhotta, Karl; Prohaszka, Zoltan; Jozsi, Mihaly			Functional Characterization of the Disease-associated N-Terminal complement Factor H Mutation W198R	FRONTIERS IN IMMUNOLOGY			English	Article						complement dysregulation; factor H; C3 glomerulopathy; atypical hemolytic uremic syndrome; mutation; kidney disease	HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; ANTI-FACTOR B; C3 GLOMERULOPATHY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; COFACTOR ACTIVITY; ALTERNATIVE PATHWAY; GENETIC-ANALYSIS; PROTEIN BETA-1H; AUTOANTIBODIES	Dysregulation of the complement alternative pathway is involved in the pathogenesis of several diseases, including the kidney diseases atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). In a patient, initially diagnosed with chronic glomerulonephritis, possibly C3G, and who 6 years later had an episode of aHUS, a heterozygous missense mutation leading to a tryptophan to arginine exchange (W198R) in the factor H (FH) complement control protein (CCP) 3 domain has previously been identified. The aim of this study was to clarify the functional relevance of this mutation. To this end, wild-type (FH1-4(WT)) and mutant (FH1-4(W198R)) CCPs 1-4 of FH were expressed as recombinant proteins. The FH1-4(W198R) mutant showed decreased C3b binding compared with FH1-4(WT). FH1-4(W198R) had reduced cofactor and decay accelerating activity compared with the wild-type protein. Hemolysis assays demonstrated impaired capacity of FH1-4(W198R) to protect rabbit erythrocytes from human complement-mediated lysis, and also to prevent lysis of sheep erythrocytes in human serum induced by a monoclonal antibody binding in FH CCP5 domain, compared with that of FH1-4(WT). Thus, the FH W198R exchange results in impaired complement alternative pathway regulation. The heterozygous nature of this mutation in the index patient may explain the manifestation of two diseases, likely due to different triggers leading to complement dysregulation in plasma or on cell surfaces.	[Cserhalmi, Marcel; Jozsi, Mihaly] Eotvos Lorand Univ, Dept Immunol, MTA ELTE Lendulet Complement Res Grp, Budapest, Hungary; [Uzonyi, Barbara] Eotvos Lorand Univ, Dept Immunol, MTA ELTE Immunol Res Grp, Budapest, Hungary; [Merle, Nicolas S.] INSERM, Complement & Dis Team, Cordeliers Res Ctr, UMRS 1138, Paris, France; [Csuka, Dorottya; Prohaszka, Zoltan] Semmelweis Univ, Dept Internal Med 3, Budapest, Hungary; [Meusburgers, Edgar; Lhotta, Karl] Acad Teaching Hosp Feldkirch, Dept Nephrol & Dialysis, Feldkirch, Austria; [Prohaszka, Zoltan] Semmelweis Univ, MTA SE Immunol & Hematol Res Grp, Budapest, Hungary	Eotvos Lorand University; Eotvos Lorand University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Semmelweis University; Semmelweis University	Jozsi, M (corresponding author), Eotvos Lorand Univ, Dept Immunol, MTA ELTE Lendulet Complement Res Grp, Budapest, Hungary.	mihaly.jozsi@ttk.elte.hu	Jozsi, Mihaly/I-7872-2018; Csuka, Dorottya/F-2224-2010; Uzonyi, Barbara/J-3973-2018; Prohaszka, Zoltan/F-2191-2010	Jozsi, Mihaly/0000-0002-5520-5535; Csuka, Dorottya/0000-0003-3610-9852; Uzonyi, Barbara/0000-0002-9680-1974; Prohaszka, Zoltan/0000-0003-1761-7982	Hungarian Academy of Sciences [LP2012-43, TKI2017-02064]; National Research Fund (NKFI) [PD116119]	Hungarian Academy of Sciences(Hungarian Academy of Sciences); National Research Fund (NKFI)	This work was supported by research grant no. LP2012-43 (to MJ) and TKI2017-02064 (to ZP) of the Hungarian Academy of Sciences, and PD116119 of the National Research Fund (NKFI) (to DC).	Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315; Abrera-Abeleda MA, 2011, J AM SOC NEPHROL, V22, P1551, DOI 10.1681/ASN.2010080795; Albuquerque JAT, 2012, J IMMUNOL, V189, P3242, DOI 10.4049/jimmunol.1201418; Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168; Blanc C, 2015, J IMMUNOL, V194, P5129, DOI 10.4049/jimmunol.1402770; Blanc C, 2012, J IMMUNOL, V189, P3528, DOI 10.4049/jimmunol.1200679; Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]; Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013; Castiblanco-Valencia MM, 2012, J INFECT DIS, V205, P995, DOI 10.1093/infdis/jir875; Chen Q, 2014, J CLIN INVEST, V124, P145, DOI 10.1172/JCI71866; Chen Q, 2011, NEW ENGL J MED, V365, P2340, DOI 10.1056/NEJMc1107484; Cooper M, 2004, NEPHROL DIAL TRANSPL, V19, P230, DOI 10.1093/ndt/gfg470; Dragon-Durey MA, 2009, J MED GENET, V46, P447, DOI 10.1136/jmg.2008.064766; Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380; Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7; Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066; Fakhouri F, 2017, LANCET, V390, P681, DOI 10.1016/S0140-6736(17)30062-4; Fakhouri F, 2010, NAT REV NEPHROL, V6, P494, DOI 10.1038/nrneph.2010.85; Falcao DA, 2008, SCAND J IMMUNOL, V68, P445, DOI 10.1111/j.1365-3083.2008.02152.x; Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8; Gnappi E, 2012, PEDIATR NEPHROL, V27, P1995, DOI 10.1007/s00467-012-2210-0; Goodship THJ, 2017, KIDNEY INT, V91, P539, DOI 10.1016/j.kint.2016.10.005; Goodship THJ, 2012, MOL IMMUNOL, V52, P200, DOI 10.1016/j.molimm.2012.05.009; GORDON DL, 1995, J IMMUNOL, V155, P348; Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471; Jokiranta TS, 1999, J IMMUNOL, V163, P4590; Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876; Jozsi M, 2014, IMMUNOL LETT, V160, P163, DOI 10.1016/j.imlet.2014.01.014; Kerr H, 2017, J BIOL CHEM, V292, P13345, DOI 10.1074/jbc.M117.795088; Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269; Malik TH, 2012, J AM SOC NEPHROL, V23, P1155, DOI 10.1681/ASN.2012020166; Marinozzi MC, 2017, J AM SOC NEPHROL, V28, P1603, DOI 10.1681/ASN.2016030343; Marinozzi MC, 2017, KIDNEY INT, V92, P1232, DOI 10.1016/j.kint.2017.04.017; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Nester CM, 2015, MOL IMMUNOL, V67, P31, DOI 10.1016/j.molimm.2015.03.246; Noris M, 2015, AM J KIDNEY DIS, V66, P359, DOI 10.1053/j.ajkd.2015.03.040; Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814; Nozal P, 2012, CLIN KIDNEY J, V5, P133, DOI 10.1093/ckj/sfs002; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4; Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839; Pickering M, 2011, CURR OPIN NEPHROL HY, V20, P271, DOI 10.1097/MNH.0b013e328345848b; Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117; Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003; Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63; Skerka C, 2009, MOL IMMUNOL, V46, P2801, DOI 10.1016/j.molimm.2009.05.018; Strobel S, 2010, MOL IMMUNOL, V47, P1476, DOI 10.1016/j.molimm.2010.02.002; Szarvas N, 2016, MOL IMMUNOL, V71, P10, DOI 10.1016/j.molimm.2016.01.003; Timmermans SAMEG, 2017, KIDNEY INT, V91, P1420, DOI 10.1016/j.kint.2016.12.009; Togarsimalemath SK, 2017, KIDNEY INT, V92, P876, DOI 10.1016/j.kint.2017.04.025; Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280; Tortajada A, 2012, KIDNEY INT, V81, P56, DOI 10.1038/ki.2011.291; Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289; van Doorn KJ, 2013, CLIN KIDNEY J, V6, P216, DOI 10.1093/ckj/sfs190; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; Wong EKS, 2014, J AM SOC NEPHROL, V25, P2425, DOI 10.1681/ASN.2013070732; Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755; Xiao X, 2016, MOL IMMUNOL, V77, P89, DOI 10.1016/j.molimm.2016.07.007; Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427; Zipfel PF, 2015, MOL IMMUNOL, V67, P21, DOI 10.1016/j.molimm.2015.03.012	63	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 13	2017	8								1800	10.3389/fimmu.2017.01800	http://dx.doi.org/10.3389/fimmu.2017.01800			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FP7JF	29321782	gold, Green Accepted, Green Published			2022-12-18	WOS:000417808700002
J	Arosa, FA				Arosa, Fernando A.			Editorial: On the origin and Function of Human NK-like Cd8+T Cells: Charting New territories	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						CD8+T cells; suppressor; regulatory; aging; cancer; infection; inflammation; homeostasis			[Arosa, Fernando A.] Univ Beira Interior, Hlth Sci Res Ctr, CICS, Fac Hlth Sci, Covilha, Portugal	Universidade da Beira Interior	Arosa, FA (corresponding author), Univ Beira Interior, Hlth Sci Res Ctr, CICS, Fac Hlth Sci, Covilha, Portugal.	arosa@fcsaude.ubi.pt	Arosa, Fernando A./E-5640-2010	Arosa, Fernando A./0000-0002-7209-4507	FEDER funds through the POCI-COMPETE-Program Competitiveness and Internationalization in Axis I-strengthening research, technological development, and innovation [007491]; FEDER funds [CENTRO-01-0145-FEDER-000013]; National Funds by FCT-Foundation for Science and Technology [UID/Multi/00709]	FEDER funds through the POCI-COMPETE-Program Competitiveness and Internationalization in Axis I-strengthening research, technological development, and innovation; FEDER funds(European Commission); National Funds by FCT-Foundation for Science and Technology	FAA was funded by FEDER funds through the POCI-COMPETE 2020-Program Competitiveness and Internationalization in Axis I-strengthening research, technological development, and innovation (Project No. 007491), through project CENTRO-01-0145-FEDER-000013, and National Funds by FCT-Foundation for Science and Technology (Project UID/Multi/00709).	Dutzan N, 2016, MUCOSAL IMMUNOL, V9, P1163, DOI 10.1038/mi.2015.136; Ramirez K, 2015, CELL IMMUNOL, V296, P57, DOI 10.1016/j.cellimm.2015.04.003; Smolders J, 2013, ACTA NEUROPATHOL, V126, P525, DOI 10.1007/s00401-013-1155-0; Thome JJC, 2015, TRENDS IMMUNOL, V36, P428, DOI 10.1016/j.it.2015.05.003; Vasanthakumar A, 2015, TRENDS IMMUNOL, V36, P756, DOI 10.1016/j.it.2015.10.002; Zaiss DMW, 2015, IMMUNITY, V42, P216, DOI 10.1016/j.immuni.2015.01.020	6	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2017	8								1588	10.3389/fimmu.2017.01588	http://dx.doi.org/10.3389/fimmu.2017.01588			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FM5PH	29187857	gold, Green Published			2022-12-18	WOS:000415087900001
J	Ha, JH; Kim, JE; Kim, YS				Ha, Ji-Hee; Kim, Jung-Eun; Kim, Yong-Sung			Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins (vol 7, 394, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						bispecific antibody; Fc engineering; heterodimeric Fc; Fc-fusion proteins; immunocytokines; antibody engineering			[Ha, Ji-Hee; Kim, Jung-Eun; Kim, Yong-Sung] Ajou Univ, Dept Mol Sci & Technol, Suwon, South Korea; [Kim, Yong-Sung] Ajou Univ, Dept Appl Chem & Biol Engn, Coll Engn, Suwon, South Korea	Ajou University; Ajou University	Kim, YS (corresponding author), Ajou Univ, Dept Mol Sci & Technol, Suwon, South Korea.; Kim, YS (corresponding author), Ajou Univ, Dept Appl Chem & Biol Engn, Coll Engn, Suwon, South Korea.	kimys@ajou.ac.kr						Ha JH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00394	1	2	2	1	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 13	2017	8								1582	10.3389/fimmu.2017.01582	http://dx.doi.org/10.3389/fimmu.2017.01582			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FM3MS	29151837	Green Published, gold			2022-12-18	WOS:000414910900001
J	Pampena, MB; Barrio, MM; Julia, EP; Blanco, PA; von Euw, EM; Mordoh, J; Levy, EM				Pampena, Maria B.; Barrio, Maria M.; Julia, Estefania P.; Blanco, Paula A.; von Euw, Erika M.; Mordoh, Jose; Mariel Levy, Estrella			Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy; melanoma vaccine; innate immunity; leukocyte recruitment; pro-inflammatory cytokines; bacillus Calmette-Guerin; adjuvants	NECROSIS-FACTOR-ALPHA; DENDRITIC CELLS; GM-CSF; CUTANEOUS MELANOMA; COMBINED NIVOLUMAB; GENE-EXPRESSION; LYMPH-NODES; NK CELLS; MONOCYTES; THERAPY	In a previous work, we showed that CSF-470 vaccine plus bacillus Calmette-Guerin (BCG) and granulocyte macrophage colony-stimulating factor (GM-CSF) as adjuvants resulted in a significant benefit in the distant metastasis-free survival when comparing vaccinated vs. IFN-alpha 2b-treated high-risk cutaneous melanoma patients in a Phase II study. Immune monitoring demonstrated an increase in anti-tumor innate and adaptive immunities of vaccinated patients, with a striking increase in IFN-gamma. secreting lymphocytes specific for melanoma antigens (Ags). In an effort to dissect the first steps of the immune response elicited by CSF-470 vaccine plus adjuvants, we evaluated, in an in vitro model, leukocyte migration, cytokine production, and monocyte phagocytosis of vaccine cells. Our results demonstrate that leukocytes recruitment, mostly from the innate immune system, is an early event after CSF-470 vaccine plus BCG plus GM-CSF interaction with immune cells, possibly explained by the high expression of CCL2/MCP-1 and other chemokines by vaccine cells. Early release of TNF-alpha and IL-1 beta pro-inflammatory cytokines and efficient tumor Ags phagocytosis by monocytes take place and would probably create a favorable context for Ag processing and presentation. Although the presence of the vaccine cells hampered cytokines production stimulated by BCG in a mechanism partially mediated by TGF-beta and IL-10, still significant levels of TNF-alpha and IL-1 beta could be detected. Thus, BCG was required to induce local inflammation in the presence of CSF-470 vaccine cells.	[Pampena, Maria B.; Barrio, Maria M.; Julia, Estefania P.; Blanco, Paula A.; Mordoh, Jose; Mariel Levy, Estrella] Ctr Invest Oncol Fdn Canc, Buenos Aires, DF, Argentina; [von Euw, Erika M.] UCLA JCCC Translat Oncol Res Labs, Los Angeles, CA USA; [Mordoh, Jose] Inst Med Especializado Alexander Fleming, Buenos Aires, DF, Argentina; [Mordoh, Jose] Fdn Inst Leloir, CONICET, IIBBA, Buenos Aires, DF, Argentina	UCLA Jonsson Comprehensive Cancer Center; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute	Levy, EM (corresponding author), Ctr Invest Oncol Fdn Canc, Buenos Aires, DF, Argentina.	estrellamlevy@yahoo.com.ar			CONICET; Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT); Instituto Nacional del Cancer - Ministerio de Salud de la Nacion Argentina (INC-MSal); Fundacion Sales; Fundacion Cancer; Fundacion Pedro F. Mosoteguy, Argentina	CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT)(ANPCyT); Instituto Nacional del Cancer - Ministerio de Salud de la Nacion Argentina (INC-MSal); Fundacion Sales; Fundacion Cancer; Fundacion Pedro F. Mosoteguy, Argentina	This work was supported by grants from CONICET, Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT), Instituto Nacional del Cancer - Ministerio de Salud de la Nacion Argentina (INC-MSal), Fundacion Sales, Fundacion Cancer, Fundacion Pedro F. Mosoteguy, Argentina. MB, JM, and EL are the members of CONICET. MP and EJ are the fellows from CONICET.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Aris M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00144; Aris M, 2012, J INVEST DERMATOL, V132, P365, DOI 10.1038/jid.2011.312; Banday AH, 2015, IMMUNOPHARM IMMUNOT, V37, P1, DOI 10.3109/08923973.2014.971963; Barrio MM, 2006, J IMMUNOTHER, V29, P444, DOI 10.1097/01.cji.0000208258.79005.5f; Bernardini G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00402; Brandau S, 2001, INT J CANCER, V92, P697, DOI 10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Distler JHW, 2008, ARTHRITIS RHEUM, V58, P2228, DOI 10.1002/art.23645; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dutton-Regester K, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00975.x; Guttlein LN, 2017, MOL CANCER RES, V15, P304, DOI 10.1158/1541-7786.MCR-16-0243-T; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Lameijer MA, 2013, EXPERT REV MOL DIAGN, V13, P567, DOI 10.1586/14737159.2013.819216; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Li Q, 2000, CLIN IMMUNOL, V94, P64, DOI 10.1006/clim.1999.4820; Mac Keon S, 2010, VACCINE, V28, P8162, DOI 10.1016/j.vaccine.2010.09.095; Mordoh J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00625; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Pardo E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177472; Pinheiro J., 2000, MIXED EFFECTS MODELS; Pizzurro GA, 2015, CANCER IMMUNOL IMMUN, V64, P1393, DOI 10.1007/s00262-015-1743-z; Pizzurro GA, 2013, CANCER IMMUNOL IMMUN, V62, P3, DOI 10.1007/s00262-012-1295-4; Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Robledo C, 2011, INFOSTAT VERS 2011 G, V8, P195; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Sawant KV, 2016, SCI REP-UK, V6, DOI 10.1038/srep33123; Seneschal J, 2012, IMMUNITY, V36, P873, DOI 10.1016/j.immuni.2012.03.018; Slingluff CL, 2008, J CLIN ONCOL, V26, P4973, DOI 10.1200/JCO.2008.17.3161; Sloot S, 2014, EXPERT OPIN PHARMACO, V15, P2629, DOI 10.1517/14656566.2014.967682; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Sziksz E, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/764641; Terando AM, 2007, VACCINE, V25, pB4, DOI 10.1016/j.vaccine.2007.06.033; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; Ushach I, 2016, J LEUKOCYTE BIOL, V100, P481, DOI 10.1189/jlb.3RU0316-144R; Van Acker HH, 2017, ONCOTARGET, V8, P13652, DOI 10.18632/oncotarget.14622; van de Laar L, 2012, BLOOD, V119, P3383, DOI 10.1182/blood-2011-11-370130; Von Euw EM, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-6; von Euw EM, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-19; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3; Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355; Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558; Zubieta MR, 2006, AM J PATHOL, V168, P1666, DOI 10.2353/ajpath.2006.050971	54	2	3	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 23	2017	8								1342	10.3389/fimmu.2017.01342	http://dx.doi.org/10.3389/fimmu.2017.01342			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FK3XW	29109725	Green Published, gold			2022-12-18	WOS:000413420700001
J	Zouikr, I; Hasegawa-Ishii, S; Shimada, A				Zouikr, Ihssane; Hasegawa-Ishii, Sanae; Shimada, Atsuyoshi			Editorial: Neuroimmune interface in Health and diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						neuron-glia interactions; amyotrophic lateral sclerosis; pain; BBB transport; mood disorders; neuroinflammation; HIV cure research; bone marrow-derived cells			[Zouikr, Ihssane] RIKEN BSI, Lab Mol Mech Thalamus Dev, Wako, Saitama, Japan; [Hasegawa-Ishii, Sanae] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA USA; [Shimada, Atsuyoshi] Kyorin Univ, Fac Hlth Sci, Tokyo, Japan	RIKEN; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Kyorin University	Zouikr, I (corresponding author), RIKEN BSI, Lab Mol Mech Thalamus Dev, Wako, Saitama, Japan.	ihssane.zouikr@riken.jp	Zouikr, Ihssane/X-9165-2019					BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; BESEDOVSKY H, 1983, SCIENCE, V221, P564, DOI 10.1126/science.6867729; Dantzer R, 2001, BRAIN BEHAV IMMUN, V15, P7, DOI 10.1006/brbi.2000.0613; Dantzer R, 2013, NEUROSCIENCE 21 CENT, P527; Palmer AM, 2010, NEUROBIOL DIS, V37, P3, DOI 10.1016/j.nbd.2009.07.029; SMITH EM, 1986, NATURE, V321, P881, DOI 10.1038/321881a0; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	7	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 23	2017	8								1315	10.3389/fimmu.2017.01315	http://dx.doi.org/10.3389/fimmu.2017.01315			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FK3XP	29109722	Green Published, gold			2022-12-18	WOS:000413419800001
J	Riehn, M; Cebula, M; Hauser, H; Wirth, D				Riehn, Mathias; Cebula, Marcin; Hauser, Hansjorg; Wirth, Dagmar			CpG-ODN Facilitates Effective Intratracheal Immunization and Recall of Memory against Neoantigen-Expressing Alveolar Cells	FRONTIERS IN IMMUNOLOGY			English	Article						neoantigen; cytotoxic T cells; tolerogenic; alveolar tract; immune modulation	TOLL-LIKE RECEPTORS; REGULATORY T-CELLS; DENDRITIC CELLS; IMMUNE-RESPONSES; MACROPHAGES CONTRIBUTE; PULMONARY-FIBROSIS; LUNG-CANCER; ANTIGEN; TOLERANCE; IMMUNOTHERAPY	Intrapulmonary immune reactions are impaired by the tolerogenic environment of the lung. This is manifested by the absence of effective endogenous T cell responses upon neoantigen expression. This tolerance is considered to contribute to lung cancer and inefficient immune therapeutic interventions. To investigate the mechanisms contributing to lung tolerance and to overcome these restrictions, we developed a transgenic mouse model with induction of a neoantigen (OVA) exclusively in alveolar type II epithelial cells. This model is characterized by the absence of functional endogenous T cell responses upon OVA neoantigen induction. Standard DNA and protein vaccination protocols resulted in the accumulation of high numbers of antigen-specific CD8 T cells in the lung. However, clearance of antigen-expressing cells was not achieved. To overcome this tolerance, we induced inflammatory conditions by coapplication of the TLR ligands LPS and CpG-ODN during intrapulmonary vaccinations. Both ligands induced high numbers of neoantigen-specific T cells in the lung. However, only coapplication of CpG-ODN was sufficient to establish functional cytotoxic responses resulting in the elimination of neoantigen presenting target cells. Remarkably, CpG-ODN was also crucial for functional memory responses upon re-induction of the neoantigen. The results highlight the need of TLR9 co-stimulation for overcoming tolerization, which might be a key factor for therapeutic interventions.	[Riehn, Mathias; Cebula, Marcin; Hauser, Hansjorg; Wirth, Dagmar] Helmholtz Ctr Infect Res, Res Grp Model Syst Infect & Immun, Braunschweig, Germany; [Wirth, Dagmar] Hannover Med Sch, Div Expt Hematol, Hannover, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School	Wirth, D (corresponding author), Helmholtz Ctr Infect Res, Res Grp Model Syst Infect & Immun, Braunschweig, Germany.; Wirth, D (corresponding author), Hannover Med Sch, Div Expt Hematol, Hannover, Germany.	dagmar.wirth@helmholtz-hzi.de	Cebula, Marcin/ABF-8802-2021	Cebula, Marcin/0000-0003-2649-1269; Riehn, Mathias/0000-0001-8737-5566	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [SFB900]; Cluster of Excellence REBIRTH (From Regenerative Biology to Reconstructive Therapy); HZI Grad School; Hannover Biomedical Research School (HBRS); Center for Infection Biology (ZIB); Helmholtz cross-program topic "Metabolic Dysfunction"	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); Cluster of Excellence REBIRTH (From Regenerative Biology to Reconstructive Therapy); HZI Grad School; Hannover Biomedical Research School (HBRS); Center for Infection Biology (ZIB); Helmholtz cross-program topic "Metabolic Dysfunction"	The work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) via the SFB900 (Chronic Infection) and the Cluster of Excellence REBIRTH (From Regenerative Biology to Reconstructive Therapy). This work was supported by the HZI Grad School, the Hannover Biomedical Research School (HBRS) and the Center for Infection Biology (ZIB). Further, we acknowledge support by a grant from the Helmholtz cross-program topic "Metabolic Dysfunction."	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Blaauboer SM, 2015, ELIFE, V4, DOI 10.7554/eLife.06670; Cebula M, 2017, MOL THER, V25, P2289, DOI 10.1016/j.ymthe.2017.06.018; Cebula M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068720; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Coleman MM, 2013, AM J RESP CELL MOL, V48, P773, DOI 10.1165/rcmb.2012-0263OC; Demedts IK, 2006, AM J RESP CELL MOL, V35, P387, DOI 10.1165/rcmb.2005-0382OC; Dowling JK, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.22; Duraiswamy J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25912; Duraiswamy J, 2013, CANCER RES, V73, P6900, DOI 10.1158/0008-5472.CAN-13-1550; Duraiswamy J, 2013, CANCER RES, V73, P3591, DOI 10.1158/0008-5472.CAN-12-4100; Enelow RI, 1996, J CLIN INVEST, V98, P914, DOI 10.1172/JCI118874; Gereke M, 2009, AM J RESP CRIT CARE, V179, P344, DOI 10.1164/rccm.200804-592OC; Giannakis M, 2016, CELL REP, V17, P1206, DOI 10.1016/j.celrep.2016.10.009; Hogaboam Cory M, 2012, Proc Am Thorac Soc, V9, P172, DOI 10.1513/pats.201201-002AW; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hoppstadter J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-124; Huang LR, 2013, NAT IMMUNOL, V14, P574, DOI 10.1038/ni.2573; Li LF, 2016, INT J CANCER, V139, P2261, DOI 10.1002/ijc.30289; Liu G, 2010, CLIN EXP IMMUNOL, V160, P168, DOI 10.1111/j.1365-2249.2010.04091.x; Liu WH, 2017, CELL MOL IMMUNOL, V14, P254, DOI 10.1038/cmi.2015.69; Mazza V, 2016, J THORAC DIS, V8, pE1348, DOI 10.21037/jtd.2016.10.99; McCoy KD, 1999, IMMUNOL CELL BIOL, V77, P1, DOI 10.1046/j.1440-1711.1999.00795.x; O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446; Ochel A, 2016, CELL MOL IMMUNOL, V13, P805, DOI 10.1038/cmi.2015.80; Ohyama K, 2017, INT J CANCER, V140, P370, DOI 10.1002/ijc.30455; Puttur F, 2016, CELL REP, V17, P1113, DOI 10.1016/j.celrep.2016.09.055; Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108; Sandhu U, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq868; Schmitz F, 2004, EUR J IMMUNOL, V34, P2863, DOI 10.1002/eji.200425228; Schneberger D, 2013, J ANAT, V222, P495, DOI 10.1111/joa.12039; Schulze K, 2017, NANOMED-NANOTECHNOL, V13, P2169, DOI 10.1016/j.nano.2017.05.012; Sharma SK, 2015, J IMMUNOL, V194, P5529, DOI 10.4049/jimmunol.1403215; Spies B, 2003, J IMMUNOL, V171, P5908, DOI 10.4049/jimmunol.171.11.5908; Steinbrink K, 2016, J IMMUNOL, V197, P1547; Tosiek MJ, 2012, AM J RESP CELL MOL, V47, P869, DOI 10.1165/rcmb.2011-0387OC; Tosiek MJ, 2011, J IMMUNOL, V186, P6106, DOI 10.4049/jimmunol.1000632; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Webster R, 2014, NAT REV DRUG DISCOV, V13, P883, DOI 10.1038/nrd4476; Workman CJ, 2002, J IMMUNOL, V169, P5392, DOI 10.4049/jimmunol.169.10.5392	41	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 2	2017	8								1201	10.3389/fimmu.2017.01201	http://dx.doi.org/10.3389/fimmu.2017.01201			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FI4SP	29038654	Green Published, gold			2022-12-18	WOS:000411966300001
J	Ghosh, S; Indracanti, N; Joshi, J; Indraganti, PK				Ghosh, Subhajit; Indracanti, Namita; Joshi, Jayadev; Indraganti, Prem Kumar			Rescuing Self: Transient Isolation and Autologous Transplantation of Bone Marrow Mitigates Radiation-Induced Hematopoietic Syndrome and Mortality in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						autologous bone marrow transfer; hematopoietic stem cells; homing; ionizing radiation; mitigation; hematopoietic syndrome	NONHUMAN PRIMATE MODEL; MESENCHYMAL STEM-CELLS; UMBILICAL-CORD BLOOD; IONIZING-RADIATION; NUCLEAR ACCIDENT; PROGENITOR CELLS; CD34(+) CELLS; IN-VIVO; IRRADIATED MICE; STROMAL CELLS	The inflamed bone marrow niche shortly after total body irradiation (TBI) is known to contribute to loss of hematopoietic stem cells in terms of their number and function. In this study, autologous bone marrow transfer (AL-BMT) was evaluated as a strategy for mitigating hematopoietic form of the acute radiation syndrome by timing the collection phase (2 h after irradiation) and reinfusion (24 h after irradiation) using mice as a model system. Collection of bone marrow (BM) cells (0.5 x 10(6) total marrow cells) 2 h after lethal TBI rescued different subclasses of hematopoietic stem and progenitor cells (HSPCs) from the detrimental inflammatory and damaging milieu in vivo. Cryopreservation of collected graft and its reinfusion 24 h after TBI significantly rescued mice from lethal effects of irradiation (65% survival against 0% in TBI group on day 30th) and hematopoietic depression. Transient hypometabolic state (HMS) induced 2 h after TBI effectively preserved the functional status of HSPCs and improved hematopoietic recovery even when BM was collected 8 h after TBI. Homing studies suggested that AL-BMT yielded similar percentages for different subsets of HSPCs when compared to syngeneic bone marrow transfer. The results suggest that the timing of collection, and reinfusion of graft is crucial for the success of AL-BMT.	[Ghosh, Subhajit; Indracanti, Namita; Joshi, Jayadev; Indraganti, Prem Kumar] Inst Nucl Med & Allied Sci, Div Radiat Biosci, Delhi, India; [Ghosh, Subhajit; Joshi, Jayadev] Univ Calcutta, SN Pradhan Ctr Neurosci, Kolkata, India	Defence Research & Development Organisation (DRDO); Institute of Nuclear Medicine & Allied Sciences (INMAS); University of Calcutta	Indraganti, PK (corresponding author), Inst Nucl Med & Allied Sci, Div Radiat Biosci, Delhi, India.	prem_indra@yahoo.co.in	Indraganti, Prem Kumar/AAF-5776-2020; Ghosh, Subhajit/AAJ-8326-2021; Joshi, Jayadev/AHD-1520-2022	Ghosh, Subhajit/0000-0002-5479-493X; 	Defence Research and Development Organization, Delhi, India	Defence Research and Development Organization, Delhi, India(Defence Research & Development Organisation (DRDO))	this study was supported by research funding from Defence Research and Development Organization, Delhi, India to PI.	Bai L, 2016, BONE MARROW TRANSPL, V51, P1631, DOI 10.1038/bmt.2016.236; BARANOV A, 1989, NEW ENGL J MED, V321, P205, DOI 10.1056/NEJM198907273210401; Bertho JM, 2005, RADIAT RES, V163, P557, DOI 10.1667/RR3352; Bertho JM, 2004, INT J RADIAT BIOL, V80, P73, DOI 10.1080/09553000310001642894; Bertho JM, 2002, J HEMATOTH STEM CELL, V11, P549, DOI 10.1089/15258160260091013; Berz D, 2007, AM J HEMATOL, V82, P463, DOI 10.1002/ajh.20707; BOGGS DR, 1984, AM J HEMATOL, V16, P277, DOI 10.1002/ajh.2830160309; Bouma HR, 2013, J LEUKOCYTE BIOL, V94, P431, DOI 10.1189/jlb.0611298; Camargo FD, 2006, BLOOD, V107, P501, DOI 10.1182/blood-2005-02-0655; Castelhano MV, 2013, TRANSFUS APHER SCI, V48, P241, DOI 10.1016/j.transci.2013.01.017; CHAMPLIN R, 1987, SEMIN HEMATOL, V24, P1; Chung YR, 2014, JOVE-J VIS EXP, DOI 10.3791/51660; Chute JP, 2004, EXP HEMATOL, V32, P308, DOI 10.1016/j.exphem.2003.12.002; COLE LJ, 1967, RADIAT RES, V32, P54, DOI 10.2307/3572306; Colvin GA, 2007, J CELL PHYSIOL, V211, P386, DOI 10.1002/jcp.20945; CRONKITE EP, 1993, EXP HEMATOL, V21, P823; Daniels IS, 2010, J BIOL CHEM, V285, P20716, DOI 10.1074/jbc.M109.090845; Densow D, 1997, STEM CELLS, V15, P287; Di Maggio FM, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0058-3; Drouet M, 1999, STEM CELLS, V17, P273, DOI 10.1002/stem.170273; Drouet M, 2005, BONE MARROW TRANSPL, V35, P1201, DOI 10.1038/sj.bmt.1704970; Duran-Struuck R, 2009, J AM ASSOC LAB ANIM, V48, P11; Fernandez-Garcia M, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0155-5; Fliedner TM, 2002, CANCER BIOTHER RADIO, V17, P405, DOI 10.1089/108497802760363204; Flynn DF, 2006, SURG CLIN N AM, V86, P601, DOI 10.1016/j.suc.2006.03.005; Frasca D, 2000, BONE MARROW TRANSPL, V25, P427, DOI 10.1038/sj.bmt.1702169; Fukumoto R, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0086-1; Gorbunov NV, 2000, RADIAT RES, V154, P73, DOI 10.1667/0033-7587(2000)154[0073:AOTNOS]2.0.CO;2; Heazlewood SY, 2014, ANN NY ACAD SCI, V1310, P119, DOI 10.1111/nyas.12329; Hoogstraten-Miller Shelley L, 2008, Curr Protoc Immunol, VChapter 1, DOI 10.1002/0471142735.im0112s82; Ishida T, 2017, STEM CELLS, V35, P989, DOI 10.1002/stem.2524; Ishida T, 2016, J EXP MED, V213, P1865, DOI 10.1084/jem.20151493; Jinka TR, 2015, ACS CHEM NEUROSCI, V6, P899, DOI 10.1021/acschemneuro.5b00056; Ketheesan N, 2004, TRANSFUS APHER SCI, V30, P47, DOI 10.1016/j.transci.2003.05.002; Kiang JG, 2016, HEALTH PHYS, V111, P198, DOI 10.1097/HP.0000000000000459; Kim K, 2009, CLIN CANCER RES, V15, P7238, DOI 10.1158/1078-0432.CCR-09-1964; Kovtonyuk LV, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00502; Krivokrysenko VI, 2012, J PHARMACOL EXP THER, V343, P497, DOI 10.1124/jpet.112.196071; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Mariani M, 2014, BLOOD TRANSFUS-ITALY, V12, P416, DOI 10.2450/2014.0198-13; Nagayama H, 2002, BONE MARROW TRANSPL, V29, P197, DOI 10.1038/sj.bmt.1703356; Norol F, 2003, BLOOD, V102, P4361, DOI 10.1182/blood-2003-03-0685; Norol F, 2000, BRIT J HAEMATOL, V109, P162, DOI 10.1046/j.1365-2141.2000.01995.x; Nunamaker EA, 2013, COMPARATIVE MED, V63, P22; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Palmer JL, 2011, J BURN CARE RES, V32, P317, DOI 10.1097/BCR.0b013e31820aafa9; Plett PA, 2012, HEALTH PHYS, V103, P343, DOI 10.1097/HP.0b013e3182667309; Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296; Rak J, 2017, BLOOD, V129, P950, DOI 10.1182/blood-2016-06-720649; Ratajczak MZ, 2016, STEM CELL REV REP, V12, P121, DOI 10.1007/s12015-015-9625-5; Reiffers J, 1999, LANCET, V354, P1092, DOI 10.1016/S0140-6736(99)03113-X; Rolls A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9516; Styczynski J, 2012, BLOOD, V119, P2935, DOI 10.1182/blood-2011-04-349688; Tanimoto T, 2011, LANCET, V377, P1489, DOI 10.1016/S0140-6736(11)60519-9; To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233; UNSGAARD B, 1961, ACTA RADIOL, V56, P296, DOI 10.3109/00016926109172824; Xu X, 2010, BIOTECHNOL PROGR, V26, P827, DOI 10.1002/btpr.368; Zhang M, 2012, CYTOKINE, V58, P169, DOI 10.1016/j.cyto.2011.12.023; Ziegler BL, 1998, INT J RADIAT ONCOL, V40, P1193, DOI 10.1016/S0360-3016(97)00945-0	59	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 25	2017	8								1180	10.3389/fimmu.2017.01180	http://dx.doi.org/10.3389/fimmu.2017.01180			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FI0FJ	28993772	Green Published, gold			2022-12-18	WOS:000411598700002
J	Gaillard, ME; Bottero, D; Zurita, ME; Carriquiriborde, F; Aispuro, PM; Bartel, E; Sabater-Mart-Nez, D; Bravo, MS; Castuma, C; Hozbor, DF				Emilia Gaillard, Maria; Bottero, Daniela; Eugenia Zurita, Maria; Carriquiriborde, Francisco; Martin Aispuro, Pablo; Bartel, Erika; Sabater-Martinez, David; Sol Bravo, Maria; Castuma, Celina; Flavia Hozbor, Daniela			Pertussis Maternal Immunization: Narrowing the Knowledge Gaps on the Duration of Transferred Protective Immunity and on Vaccination Frequency	FRONTIERS IN IMMUNOLOGY			English	Article						pertussis; Bordetella pertussis; pregnancy immunization; acellular vaccine; protection	INFANTS; DIPHTHERIA; TETANUS; PREGNANCY	Maternal safety through pertussis vaccination and subsequent maternal-fetal-antibody transfer are well documented, but information on infant protection from pertussis by such antibodies and by subsequent vaccinations is scarce. Since mice are used extensively for maternal-vaccination studies, we adopted that model to narrow those gaps in our understanding of maternal pertussis immunization. Accordingly, we vaccinated female mice with commercial acellular pertussis (aP) vaccine and measured offspring protection against Bordetella pertussis challenge and specific-antibody levels with or without revaccination. Maternal immunization protected the offspring against pertussis, with that immune protection transferred to the offspring lasting for several weeks, as evidenced by a reduction (4-5 logs, p < 0.001) in the colony-forming-units recovered from the lungs of 16-week-old offspring. Moreover, maternal-vaccination-acquired immunity from the first pregnancy still conferred protection to offspring up to the fourth pregnancy. Under the conditions of our experimental protocol, protection to offspring from the aP-induced immunity is transferred both transplacentally and through breastfeeding. Adoptive-transfer experiments demonstrated that transferred antibodies were more responsible for the protection detected in offspring than transferred whole spleen cells. In contrast to reported findings, the protection transferred was not lost after the vaccination of infant mice with the same or other vaccine preparations, and conversely, the immunity transferred from mothers did not interfere with the protection conferred by infant vaccination with the same or different vaccines. These results indicated that aP-vaccine immunization of pregnant female mice conferred protective immunity that is transferred both transplacentally and via offspring breastfeeding without compromising the protection boostered by subsequent infant vaccination. These results-though admittedly not necessarily immediately extrapolatable to humans-nevertheless enabled us to test hypotheses under controlled conditions through detailed sampling and data collection. These findings will hopefully refine hypotheses that can then be validated in subsequent human studies.	[Emilia Gaillard, Maria; Bottero, Daniela; Eugenia Zurita, Maria; Carriquiriborde, Francisco; Martin Aispuro, Pablo; Bartel, Erika; Sabater-Martinez, David; Sol Bravo, Maria; Castuma, Celina; Flavia Hozbor, Daniela] Univ Nacl La Plata, CONICET, Lab VacSal, IBBM,Fac Ciencias Exactas,CCT, La Plata, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata	Hozbor, DF (corresponding author), Univ Nacl La Plata, CONICET, Lab VacSal, IBBM,Fac Ciencias Exactas,CCT, La Plata, Buenos Aires, Argentina.	hozbor.daniela@gmail.com		Sabater Martinez, David/0000-0001-8113-8594; Hozbor, Daniela/0000-0001-6379-0482	ANCPyT [PICT 2014-3617, PICT 2012-2719]; CONICET; CICBA (Argentina)	ANCPyT; CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); CICBA (Argentina)	This work was supported by ANCPyT (PICT 2014-3617, PICT 2012-2719), CONICET, and CICBA (Argentina) grants to DH. DH, MG, and DB are members of the Scientific Career of CONICET. MZ, FC, PA, and EB are fellows from CONICET. DM and MB are fellows from ANPCyT and CC is a full-time Professor at Universidad Nacional de La Plata.	Amirthalingam G, 2016, CLIN INFECT DIS, V63, pS236, DOI 10.1093/cid/ciw559; Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1424; Asensio CJA, 2011, VACCINE, V29, P1649, DOI 10.1016/j.vaccine.2010.12.068; Bottero D, 2016, VACCINE, V34, P3303, DOI [10.1016/j.vaccine.2016.04.079, 10.1016/j.vaccine.2016.04.07]; Cherry JD, 2012, NEW ENGL J MED, V367, P785, DOI 10.1056/NEJMp1209051; Cherry JD, 1996, J INFECT DIS, V174, pS259, DOI 10.1093/infdis/174.Supplement_3.S259; de Voer RM, 2009, CLIN INFECT DIS, V49, P58, DOI 10.1086/599347; Donegan K, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4219; Eberhardt CS, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029629; Edwards KM, 2014, P NATL ACAD SCI USA, V111, P575, DOI 10.1073/pnas.1321360111; EDWARDS KM, 1990, PEDIATR CLIN N AM, V37, P549; Elahi S, 2006, INFECT IMMUN, V74, P2619, DOI 10.1128/IAI.74.5.2619-2627.2006; Elahi S, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.01063-16; Fallo AA, 2018, J PEDIAT INF DIS SOC, V7, P11, DOI 10.1093/jpids/piw069; Feunou PF, 2016, VACCINE, V34, P1062, DOI 10.1016/j.vaccine.2016.01.011; Hoang HTT, 2016, VACCINE, V34, P151, DOI 10.1016/j.vaccine.2015.10.098; He QS, 2008, FUTURE MICROBIOL, V3, P329, DOI 10.2217/17460913.3.3.329; Healy CM, 2016, HUM VACC IMMUNOTHER, V12, P1972, DOI 10.1080/21645515.2016.1171948; Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052; Klein NP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3326; Kuehn BM, 2012, JAMA-J AM MED ASSOC, V307, P1353, DOI 10.1001/jama.2012.367; Masseria C, 2017, PEDIATR INFECT DIS J, V36, pE54, DOI 10.1097/INF.0000000000001440; Mills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6; Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633; ODA M, 1983, J INFECT DIS, V148, P138, DOI 10.1093/infdis/148.1.138; Pentsuk N, 2009, BIRTH DEFECTS RES B, V86, P328, DOI 10.1002/bdrb.20201; Quinello C, 2010, SCAND J IMMUNOL, V72, P66, DOI 10.1111/j.1365-3083.2010.02410.x; Somerville RL, 2007, J PAEDIATR CHILD H, V43, P617, DOI 10.1111/j.1440-1754.2007.01154.x; Tan TN, 2015, PEDIATR INFECT DIS J, V34, pE222, DOI 10.1097/INF.0000000000000795; Tanaka M, 2003, JAMA-J AM MED ASSOC, V290, P2968, DOI 10.1001/jama.290.22.2968; Warfel JM, 2014, J INFECT DIS, V210, P604, DOI 10.1093/infdis/jiu090; WHO, 2016, VACCINE, V34, P1423, DOI 10.1016/j.vaccine.2015.10.136; Winter K, 2017, CLIN INFECT DIS, V64, P9, DOI 10.1093/cid/ciw633	33	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 6	2017	8								1099	10.3389/fimmu.2017.01099	http://dx.doi.org/10.3389/fimmu.2017.01099			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FG0QM	28932228	gold, Green Published			2022-12-18	WOS:000409469700001
J	Johannsen, H; Muppala, V; Groschel, C; Monecke, S; Elsner, L; Didie, M; Zimmermann, WH; Dressel, R				Johannsen, Hannah; Muppala, Vijayakumar; Groeschel, Carina; Monecke, Sebastian; Elsner, Leslie; Didie, Michael; Zimmermann, Wolfram-Hubertus; Dressel, Ralf			Immunological Properties of Murine Parthenogenetic Stem Cells and Their Differentiation Products	FRONTIERS IN IMMUNOLOGY			English	Article						pluripotent stem cells; natural killer cells; cytotoxic T lymphocytes; major histocompatibility complex class I molecules; natural killer receptor ligands; stem cell differentiation	NATURAL-KILLER-CELLS; INDUCED PLURIPOTENT; TERATOMA FORMATION; CLINICAL TRANSLATION; IMMUNE-RESPONSE; MOUSE EMBRYOS; HEART; TRANSPLANTATION; IMMUNOGENICITY; LINES	The perspective to transplant grafts derived from pluripotent stem cells has gained much attention in recent years. Parthenogenetic stem cells (PSCs) are an alternative pluripotent stem cell type that is attractive as source of grafts for allogeneic transplantations because most PSCs are haploidentical for the major histocompatibility complex (MHC). This reduced immunogenetic complexity of PSCs could tremendously simplify the search for MHC-matched allogeneic stem cells. In this study, we have characterized immunological properties of the MHC haploidentical PSC line A3 (H2(d/d)) and the heterologous PSC line A6 (H2(b'/b)). Both PSC lines largely lack MHC class I molecules, which present peptides to cytotoxic T lymphocytes (CTLs) and serve as ligands for inhibitory natural killer (NK) receptors. They express ligands for activating NK receptors, including the NKG2D ligand RAE-1, and the DNAM-1 ligands CD112 and CD155. Consequently, both PSC lines are highly susceptible to killing by IL-2-activated NK cells. In vitro-differentiated cells acquire resistance and downregulate ligands for activating NK receptors but fail to upregulate MHC class I molecules. The PSC line A6 and differentiated A6 cells are largely resistant to CTLs derived from T cell receptor transgenic OT-I mice after pulsing of the targets with the appropriate peptide. The high susceptibility to killing by activated NK cells may constitute a general feature of pluripotent stem cells as it has been also found with other pluripotent stem cell types. This activity potentially increases the safety of transplantations, if grafts contain traces of undifferentiated cells that could be tumorigenic in the recipient.	[Johannsen, Hannah; Groeschel, Carina; Monecke, Sebastian; Elsner, Leslie; Dressel, Ralf] Univ Med Ctr Gottingen, Inst Cellular & Mol Immunol, Gottingen, Germany; [Muppala, Vijayakumar; Didie, Michael; Zimmermann, Wolfram-Hubertus] Univ Med Ctr Gottingen, Inst Pharmacol & Toxicol, Gottingen, Germany; [Groeschel, Carina; Monecke, Sebastian; Didie, Michael; Zimmermann, Wolfram-Hubertus; Dressel, Ralf] DZHK German Ctr Cardiovasc Res, Partner Site Gottingen, Gottingen, Germany	University of Gottingen; University of Gottingen; German Centre for Cardiovascular Research	Dressel, R (corresponding author), Univ Med Ctr Gottingen, Inst Cellular & Mol Immunol, Gottingen, Germany.; Dressel, R (corresponding author), DZHK German Ctr Cardiovasc Res, Partner Site Gottingen, Gottingen, Germany.	rdresse@gwdg.de	Dressel, Ralf/R-7065-2016; Zimmermann, Wolfram-Hubertus H/I-6838-2012	Dressel, Ralf/0000-0002-1651-1214; Zimmermann, Wolfram-Hubertus H/0000-0003-1190-4040	DZHK (German Center for Cardiovascular Research); German Federal Ministry for Science and Education [BMBF FKZ 01GN081.9, 1.3GW0007A [CIRM-ET3]]; German Research Foundation [DUG ZI 708/10-1, SUB 937 TP18, SFB 1002 TPs C04, C05, IRTG 1618 RP12]; European Union EP7 CARE-MI; Fondation Leducq; NILI [U01HL099997]; Open Access Publication Funds of the Gottingen University	DZHK (German Center for Cardiovascular Research); German Federal Ministry for Science and Education; German Research Foundation(German Research Foundation (DFG)); European Union EP7 CARE-MI; Fondation Leducq(Leducq Foundation); NILI; Open Access Publication Funds of the Gottingen University	RD and W-HZ are supported by the DZHK (German Center for Cardiovascular Research), the German Federal Ministry for Science and Education (BMBF FKZ 01GN081.9 and 1.3GW0007A [CIRM-ET3]), the German Research Foundation (DUG ZI 708/10-1; SUB 937 TP18, SFB 1002 TPs C04, C05, IRTG 1618 RP12), the European Union EP7 CARE-MI, the Fondation Leducq, and the NILI (U01HL099997). We acknowledge support by the Open Access Publication Funds of the Gottingen University.	Abdullah Z, 2007, J IMMUNOL, V178, P3390, DOI 10.4049/jimmunol.178.6.3390; Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807; Bonde S, 2006, STEM CELLS, V24, P2192, DOI 10.1634/stemcells.2006-0022; Boukouaci W, 2014, CARDIOVASC RES, V104, P290, DOI 10.1093/cvr/cvu208; BROWER RC, 1994, MOL IMMUNOL, V31, P1285, DOI 10.1016/0161-5890(94)90079-5; Cibelli JB, 2002, SCIENCE, V295, P819, DOI 10.1126/science.1065637; de Almeida PE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4903; Didie M, 2013, J CLIN INVEST, V123, P1285, DOI 10.1172/JCI66854; Draper JS, 2002, J ANAT, V200, P249, DOI 10.1046/j.1469-7580.2002.00030.x; Dressel R, 2004, J BIOL CHEM, V279, P20200, DOI 10.1074/jbc.M313108200; Dressel R, 2011, SEMIN IMMUNOPATHOL, V33, P573, DOI 10.1007/s00281-011-0266-8; Dressel R, 2010, FASEB J, V24, P2164, DOI 10.1096/fj.09-134957; Dressel R, 2009, BIOL DIRECT, V4, DOI 10.1186/1745-6150-4-31; Dressel R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002622; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; Ebert AD, 2015, EMBO MOL MED, V7, P1090, DOI 10.15252/emmm.201504395; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Frenzel LP, 2009, STEM CELLS, V27, P307, DOI 10.1634/stemcells.2008-0528; Groschel C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00870; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; Guha P, 2013, CELL STEM CELL, V12, P407, DOI 10.1016/j.stem.2013.01.006; Han KH, 2011, TRANSPL IMMUNOL, V25, P7, DOI 10.1016/j.trim.2011.05.004; Hentze H, 2009, STEM CELL RES, V2, P198, DOI 10.1016/j.scr.2009.02.002; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hubscher D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00067; Ilic D, 2017, STEM CELLS, V35, P17, DOI 10.1002/stem.2450; Ilic D, 2015, BRIT MED BULL, V116, P19, DOI 10.1093/bmb/ldv045; Isernhagen A, 2015, EMBO MOL MED, V7, P1480, DOI 10.15252/emmm.201505246; Itakura G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116413; Kadri N, 2015, IMMUNOL REV, V267, P167, DOI 10.1111/imr.12330; Kim K, 2007, CELL STEM CELL, V1, P346, DOI 10.1016/j.stem.2007.07.001; Koch CA, 2008, STEM CELLS, V26, P89, DOI 10.1634/stemcells.2007-0151; Koch CA, 2006, J IMMUNOL, V177, P4803, DOI 10.4049/jimmunol.177.7.4803; Kofidis T, 2005, EUR J CARDIO-THORAC, V28, P461, DOI 10.1016/j.ejcts.2005.03.049; Kolossov E, 2006, J EXP MED, V203, P2315, DOI 10.1084/jem.20061469; Kruse V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125544; Lawrenz B, 2004, CYTOTHERAPY, V6, P212, DOI 10.1080/14653240410006031; Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Menasche P, 2015, EUR HEART J, V36, P2011, DOI 10.1093/eurheartj/ehv189; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Nakajima F, 2007, STEM CELLS, V25, P983, DOI 10.1634/stemcells.2006-0566; Neofytou E, 2015, J CLIN INVEST, V125, P2551, DOI 10.1172/JCI80575; Nussbaum J, 2007, FASEB J, V21, P1345, DOI 10.1096/fj.06-6769com; Perez-Cunningham J, 2014, TRANSPLANTATION, V97, P992, DOI 10.1097/TP.0000000000000063; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Revazova ES, 2007, CLONING STEM CELLS, V9, P432, DOI 10.1089/clo.2007.0033; Riegler J, 2015, CIRC RES, V117, P720, DOI 10.1161/CIRCRESAHA.115.306985; Robertson JA, 2010, J LAW MED ETHICS, V38, P191, DOI 10.1111/j.1748-720X.2010.00479.x; Robertson NJ, 2007, P NATL ACAD SCI USA, V104, P20920, DOI 10.1073/pnas.0710265105; Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3; Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2; Swijnenburg RJ, 2008, STEM CELLS DEV, V17, P1023, DOI 10.1089/scd.2008.0091; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tapia N, 2016, CELL STEM CELL, V19, P298, DOI 10.1016/j.stem.2016.06.017; Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0; Thies RS, 2015, DEVELOPMENT, V142, P3077, DOI [10.1242/dev.126482, 10.1242/dev.131250]; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tiburcy M, 2017, CIRCULATION, V135, P1832, DOI 10.1161/CIRCULATIONAHA.116.024145; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Wood KJ, 2016, TRENDS IMMUNOL, V37, P5, DOI 10.1016/j.it.2015.11.005; Yachimovich-Cohen N, 2010, J IMMUNOL, V184, P1300, DOI 10.4049/jimmunol.0804261; Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021; Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135	65	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 4	2017	8								924	10.3389/fimmu.2017.00924	http://dx.doi.org/10.3389/fimmu.2017.00924			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FC9IS	28824647	Green Published, gold			2022-12-18	WOS:000407155200002
J	Espinoza-Sanchez, NA; Chimal-Ramirez, GK; Mantilla, A; Fuentes-Panana, EM				Adriana Espinoza-Sanchez, Nancy; Karina Chimal-Ramirez, Gloria; Mantilla, Alejandra; Moises Fuentes-Panana, Ezequiel			IL-1 beta, IL-8, and Matrix Metalloproteinases-1, -2, and -10 Are enriched upon Monocyte-Breast Cancer Cell Cocultivation in a Matrigel-Based three-Dimensional System (vol 8, 205, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						breast cancer; monocytes; matrigel-based 3D culture; inflammation; IL-1 beta; IL-8; MMPs			[Adriana Espinoza-Sanchez, Nancy; Karina Chimal-Ramirez, Gloria; Moises Fuentes-Panana, Ezequiel] Hosp Infantil Mexico Dr Federico Gomez, Unidad Invest Virol & Canc, Ciudad De Mexico, Mexico; [Adriana Espinoza-Sanchez, Nancy] Univ Nacl Autonoma Mexico, Fac Med, Programa Doctorado Ciencias Biomed, Ciudad De Mexico, Mexico; [Mantilla, Alejandra] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo 21, Hosp Oncol, Dept Patol, Ciudad De Mexico, Mexico	Hospital Infantil de Mexico Federico Gomez; Universidad Nacional Autonoma de Mexico; Instituto Mexicano del Seguro Social	Fuentes-Panana, EM (corresponding author), Hosp Infantil Mexico Dr Federico Gomez, Unidad Invest Virol & Canc, Ciudad De Mexico, Mexico.	empanana@yahoo.com	Fuentes-Pananá, Ezequiel/AAI-2856-2020	Espinoza Sanchez, Nancy Adriana/0000-0002-4118-6521				Espinoza-Sanchez NA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00205	1	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2017	8								856	10.3389/fimmu.2017.00856	http://dx.doi.org/10.3389/fimmu.2017.00856			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FB9QV	28775725	gold, Green Published			2022-12-18	WOS:000406475000001
J	Bernelin-Cottet, C; Deloizy, C; Stanek, O; Barc, C; Bouguyon, E; Urien, C; Boulesteix, O; Pezant, J; Richard, CA; Moudjou, M; Da Costa, B; Jouneau, L; Chevalier, C; Leclerc, C; Sebo, P; Bertho, N; Schwartz-Cornil, I				Bernelin-Cottet, Cindy; Deloizy, Charlotte; Stanek, Ondrej; Barc, Celine; Bouguyon, Edwige; Urien, Celine; Boulesteix, Olivier; Pezant, Jeremy; Richard, Charles-Adrien; Moudjou, Mohammed; Da Costa, Bruno; Jouneau, Luc; Chevalier, Christophe; Leclerc, Claude; Sebo, Peter; Bertho, Nicolas; Schwartz-Cornil, Isabelle			A Universal influenza Vaccine Can Lead to Disease exacerbation or Viral Control Depending on Delivery Strategies (vol 7, 641, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						dendritic cells; swine; human; vaccines; routes of administration			[Bernelin-Cottet, Cindy; Deloizy, Charlotte; Bouguyon, Edwige; Urien, Celine; Richard, Charles-Adrien; Moudjou, Mohammed; Da Costa, Bruno; Jouneau, Luc; Chevalier, Christophe; Bertho, Nicolas; Schwartz-Cornil, Isabelle] Univ Paris Saclay, INRA, VIM, Jouy En Josas, France; [Stanek, Ondrej; Sebo, Peter] Czech Acad Sci, Vvi, Inst Microbiol, Prague, Czech Republic; [Barc, Celine; Boulesteix, Olivier; Pezant, Jeremy] INRA, Plateforme Infectiol Expt PFIE, UE1277, Nouzilly, France; [Leclerc, Claude] Inst Pasteur, Unite Regulat Immunitaire & Vaccinol, Equipe Labellisee Ligue Canc, Paris, France; [Leclerc, Claude] INSERM U1041, Unite Regulat Immunitaire & Vaccinol, Dept Immunol, Paris, France; [Bernelin-Cottet, Cindy] GenoSafe, Evry, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; INRAE; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Schwartz-Cornil, I (corresponding author), Univ Paris Saclay, INRA, VIM, Jouy En Josas, France.	isabelle.schwartz@inra.fr	Stanek, Ondrej/J-8407-2014; SEBO, Peter/F-7423-2011; Jouneau, Luc/AAC-4711-2020; Chevalier, Christophe/C-2575-2009; Chevalier, Christophe/AAK-4461-2020; BERTHO, Nicolas/B-8167-2019	SEBO, Peter/0000-0002-9755-7715; Chevalier, Christophe/0000-0003-3231-9027; BERTHO, Nicolas/0000-0002-6732-3483; Barc, Celine/0000-0002-5912-4652; RICHARD, Charles-Adrien/0000-0001-5306-2297				BERNELINCOTTET C, 2016, UNIVERSAL INFLUENZA, V7	1	2	2	1	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 18	2017	8								831	10.3389/fimmu.2017.00831	http://dx.doi.org/10.3389/fimmu.2017.00831			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FA7XJ	28740498	Green Published, Green Submitted, gold			2022-12-18	WOS:000405660400001
J	Schettini, JAD; Gomes, TV; Barreto, AKS; da Silva, CD; da Matta, M; Coutinho, ICN; de Oliveira, MDVC; Torres, LC				de Carvalho Schettini, Juliana Araujo; Gomes, Thomas Virgilio; Santos Barreto, Alexandra Karla; da Silva Junior, Claudeir Dias; da Matta, Marina; Neiva Coutinho, Isabela Cristina; Costa de Oliveira, Maria do Carmo Valgueiro; Torres, Leuridan Cavalcante			High Levels of CXCL8 and Low Levels of CXCL9 and CXCL 10 in Women with Material RhD Alloimmunization	FRONTIERS IN IMMUNOLOGY			English	Article						chemokines; pregnancy; inflammation; flow cytometry; Rh(o) antigen; genotyping techniques; hemolytic disease of the fetus and newborn	BLOOD-CELL ALLOIMMUNIZATION; PREECLAMPSIA; CHEMOKINES; DISEASE; RISK	Maternal RhD alloimmunization is an inflammatory response against protein antigens in fetal red blood cells (RBC). However, not all women become alloimmunized when exposed to RhD+ fetal RBC. Thus, this study aimed to evaluate levels of inflammatory chemokines in RhD(-)pregnant women with erythrocyte alloimmunization. CXCL8, CXCL9, CCL5, and CXCL10 levels were determined from cell culture supernatants by flow cytometry in 46 (30 non-alloimmunized RhD- and 16 previously alloimmunized RhD-) pregnant women. CXCL8 levels were significantly higher (P<0.004), and CXCL9 (P<0.008) and CXCL10 (P<0.003) levels were significantly lower in alloimmunized pregnant women. No significant difference in CCL5 levels was detected between the groups. Fetal RHD genotyping was performed in the alloimmunized RhD-group by real-time PCR. Anti-D alloantibody was detected in 10 mothers and anti-D and -C in six mothers. Twelve fetuses were RHD positive and four were RHD negative. Further studies of serum chemokines and placenta tissue could provide a better understanding of the cells involved in the pathogenesis of maternal erythrocyte alloimmunization.	[de Carvalho Schettini, Juliana Araujo; Gomes, Thomas Virgilio; Santos Barreto, Alexandra Karla; da Silva Junior, Claudeir Dias; da Matta, Marina] Inst Med Integral Prof Fernando Figueira IMIP, Translat Res Lab, Recife, PE, Brazil; [de Carvalho Schettini, Juliana Araujo; Neiva Coutinho, Isabela Cristina] Inst Med Integral Prof Fernando Figueira IMIP, Dept Obstet & Gynecol, Recife, PE, Brazil; [Costa de Oliveira, Maria do Carmo Valgueiro; Torres, Leuridan Cavalcante] Hematol & Hemotherapy Fdn Pernambuco HEMOPE, Recife, PE, Brazil	Instituto de Medicina Integral Professor Fernando Figueira (IMIP); Instituto de Medicina Integral Professor Fernando Figueira (IMIP)	Schettini, JAD (corresponding author), Inst Med Integral Prof Fernando Figueira IMIP, Translat Res Lab, Recife, PE, Brazil.; Schettini, JAD (corresponding author), Inst Med Integral Prof Fernando Figueira IMIP, Dept Obstet & Gynecol, Recife, PE, Brazil.	julianaschettini@yahoo.com.br	Torres, Leuridan Cavalcante/F-7187-2017		National Council for Scientific and Technological Development (CNPq) [473436/2011-6]; Research Foundation Support of Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) (FAPE/IMIP), Recife (PE), Brazil	National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Research Foundation Support of Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) (FAPE/IMIP), Recife (PE), Brazil	National Council for Scientific and Technological Development (CNPq)-Grant No. 473436/2011-6 and Research Foundation Support of Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) (FAPE/IMIP), Recife (PE), Brazil.	Amsalem H, 2014, J IMMUNOL, V193, P3070, DOI 10.4049/jimmunol.1303117; Antonelli A, 2014, AUTOIMMUN REV, V13, P272, DOI 10.1016/j.autrev.2013.10.010; Chitty LS, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5243; Christiansen OB, 2013, MOL IMMUNOL, V55, P8, DOI 10.1016/j.molimm.2012.08.025; Fasano RM, 2016, SEMIN FETAL NEONAT M, V21, P28, DOI 10.1016/j.siny.2015.10.006; Finning Kirstin, 2009, V496, P143, DOI 10.1007/978-1-59745-553-4_11; Fraccaroli L, 2009, HUM REPROD, V24, P166, DOI 10.1093/humrep/den344; Garraud O, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00534; Gibson DA, 2015, HUM REPROD, V30, P1290, DOI 10.1093/humrep/dev067; Gleissner CA, 2012, CURR VASC PHARMACOL, V10, P563; Kormoczi GF, 2014, TRANSFUS MED HEMOTH, V41, P446, DOI 10.1159/000369179; Liu XJ, 2015, EXP THER MED, V9, P1572, DOI 10.3892/etm.2015.2337; Mari G, 2015, AM J OBSTET GYNECOL, V212, P697, DOI 10.1016/j.ajog.2015.01.059; Matteocci A, 2014, VOX SANG, V106, P197, DOI 10.1111/vox.12086; Mehrad B, 2007, THROMB HAEMOSTASIS, V97, P755, DOI 10.1160/TH07-01-0040; OSMERS RGW, 1995, OBSTET GYNECOL, V86, P223, DOI 10.1016/0029-7844(95)93704-4; Park Dong-Wook, 2011, Clin Exp Reprod Med, V38, P179, DOI 10.5653/cerm.2011.38.4.179; Pinheiro MB, 2013, CYTOKINE, V62, P165, DOI 10.1016/j.cyto.2013.02.027; Polese B, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00106; Ryder AB, 2014, TRANSFUS MED HEMOTH, V41, P406, DOI 10.1159/000368995; Sykes L, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/967629; Vannuccini S, 2016, HUM REPROD UPDATE, V22, P104, DOI 10.1093/humupd/dmv044; Weiss G, 2009, REPROD SCI, V16, P216, DOI 10.1177/1933719108330087; Yazdanbakhsh K, 2012, BLOOD, V120, P528, DOI 10.1182/blood-2011-11-327361	24	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 3	2017	8								700	10.3389/fimmu.2017.00700	http://dx.doi.org/10.3389/fimmu.2017.00700			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EZ3BY	28717357	Green Published, gold			2022-12-18	WOS:000404586000001
J	Mehra, NK; Baranwal, AK; Tait, BD				Mehra, Narinder K.; Baranwal, Ajay Kumar; Tait, Brian D.			Editorial: antibody repertoire and Graft outcome following Solid organ transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						antibody; graft; organ transplantation; anti-HLA antibodies; sMICA			[Mehra, Narinder K.; Baranwal, Ajay Kumar] All India Inst Med Sci, New Delhi, India; [Tait, Brian D.] Australian Red Cross Blood Serv Australia, Melbourne, Vic, Australia	All India Institute of Medical Sciences (AIIMS) New Delhi; Australian Red Cross Blood Service	Mehra, NK (corresponding author), All India Inst Med Sci, New Delhi, India.	narin.mehra@gmail.com		Baranwal, Ajay/0000-0002-8916-3521	Indian Council of Medical Research (ICMR)	Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR))	The authors (NM and AB) thank the Indian Council of Medical Research (ICMR) for their financial support.		0	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 9	2017	8								648	10.3389/fimmu.2017.00648	http://dx.doi.org/10.3389/fimmu.2017.00648			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EX0KY	28649244	gold, Green Published			2022-12-18	WOS:000402910700001
J	Peng, SQ; Li, CY; Wang, XY; Liu, X; Han, C; Jin, T; Liu, SS; Zhang, XW; Zhang, HY; He, X; Xie, XC; Yu, XH; Wang, CY; Shan, L; Fan, CL; Shan, ZY; Teng, WP				Peng, Shiqiao; Li, Chenyan; Wang, Xinyi; Liu, Xin; Han, Cheng; Jin, Ting; Liu, Shanshan; Zhang, Xiaowen; Zhang, Hanyi; He, Xue; Xie, Xiaochen; Yu, Xiaohui; Wang, Chuyuan; Shan, Ling; Fan, Chenling; Shan, Zhongyan; Teng, Weiping			Corrigendum: Increased Toll-Like receptors Activity and TLR Ligands in Patients with Autoimmune Thyroid Diseases (vol 8, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						autoimmune thyroid disease; innate immunity; toll-like receptor; signaling; pathogenesis			[Peng, Shiqiao; Li, Chenyan; Wang, Xinyi; Liu, Xin; Han, Cheng; Jin, Ting; Liu, Shanshan; Zhang, Xiaowen; Zhang, Hanyi; He, Xue; Xie, Xiaochen; Yu, Xiaohui; Wang, Chuyuan; Shan, Ling; Fan, Chenling; Shan, Zhongyan; Teng, Weiping] China Med Univ, Affiliated Hosp 1, Liaoning Prov Key Lab Endocrine Dis, Dept Endocrinol & Metab,Inst Endocrinol, Shenyang, Liaoning, Peoples R China; [Li, Chenyan; Yu, Xiaohui; Wang, Chuyuan; Shan, Zhongyan; Teng, Weiping] China Med Univ, Dept Endocrinol & Metab, Hosp 1, Shenyang, Peoples R China; [Wang, Xinyi] China Med Univ, Dept Lab Med, Hosp 1, Shenyang, Peoples R China; [Liu, Xin] Qingdao Univ, Affiliated Hosp, Dept Intens Care Unit, Qingdao, Peoples R China; [Jin, Ting] Zhejiang Univ, Affiliated Sch Med, Sir Run Run Shaw Hosp, Dept Endocrinol, Hangzhou, Peoples R China; [Liu, Shanshan] Peoples Liberat Army 202 Hosp, Dept Emergency, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University; Qingdao University; Zhejiang University	Teng, WP (corresponding author), China Med Univ, Affiliated Hosp 1, Liaoning Prov Key Lab Endocrine Dis, Dept Endocrinol & Metab,Inst Endocrinol, Shenyang, Liaoning, Peoples R China.; Teng, WP (corresponding author), China Med Univ, Dept Endocrinol & Metab, Hosp 1, Shenyang, Peoples R China.	twp@vip.163.com	He, Xue/I-9721-2018; Wang, Xin/GYU-1129-2022; Wang, Xinyi/AAE-4342-2019; Zhang, Xiaowen/GZL-4194-2022	Han, Cheng/0000-0001-8553-4420; Zhang, Xiaowen/0000-0002-0072-2439				Peng SQ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00578	1	2	3	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 15	2017	8								551	10.3389/fimmu.2017.00551	http://dx.doi.org/10.3389/fimmu.2017.00551			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EU7BN	28515728	Green Published, gold			2022-12-18	WOS:000401189800001
J	Asensio, E; Lopez-Hoyos, M; Romon, I; Ontanon, J; Segundo, DS				Asensio, Esther; Lopez-Hoyos, Marcos; Romon, Inigo; Ontanon, Jesus; San Segundo, David			Assessment of Spanish Panel Reactive Antibody Calculator and Potential Usefulness	FRONTIERS IN IMMUNOLOGY			English	Article						anti-human leukocyte antigen antibodies; calculated panel reactive of antibody; kidney transplantation; highly sensitized patients; organ allocation; PATHI	SOLID-PHASE ASSAY; HLA ANTIBODIES; TRANSPLANTATION; ASSOCIATIONS; ANTIGENS; ALLELES	Background and objectives: The calculated panel reactive of antibodies (cPRAs) necessary for kidney donor-pair exchange and highly sensitized programs are estimated using different panel reactive antibody (PRA) calculators based on big enough samples in Eurotransplant (EUTR), United Network for Organ Sharing (UNOS), and Canadian Transplant Registry (CTR) websites. However, those calculators can vary depending on the ethnic they are applied. Here, we develop a PRA calculator used in the Spanish Program of Transplant Access for Highly Sensitized patients (PATHI) and validate it with EUTR, UNOS, and CTR calculators. Methods: The anti-human leukocyte antigen (HLA) antibody profile of 42 sensitized patients on waiting list was defined, and cPRA was calculated with different PRA calculators. Results: Despite different allelic frequencies derived from population differences in donor panel from each calculator, no differences in cPRA between the four calculators were observed. The PATHI calculator includes anti-DQA1 antibody profiles in cPRA calculation; however, no improvement in total cPRA calculation of highly sensitized patients was demonstrated. Interpretation and conclusion: The PATHI calculator provides cPRA results comparable with those from EUTR, UNOS, and CTR calculators and serves as a tool to develop valid calculators in geographical and ethnic areas different from Europe, USA, and Canada.	[Asensio, Esther; Lopez-Hoyos, Marcos; San Segundo, David] Marques Valdecilla Univ Hosp IDIVAL, Immunol Serv, Santander, Cantabria, Spain; [Asensio, Esther; Lopez-Hoyos, Marcos; Romon, Inigo; San Segundo, David] Marques Valdecilla Univ Hosp IDIVAL, Tissue Typing Lab, Santander, Cantabria, Spain; [Ontanon, Jesus] Univ Hosp Albacete, Immunol, Castilla La Mancha, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV)	Segundo, DS (corresponding author), Marques Valdecilla Univ Hosp IDIVAL, Immunol Serv, Santander, Cantabria, Spain.; Segundo, DS (corresponding author), Marques Valdecilla Univ Hosp IDIVAL, Tissue Typing Lab, Santander, Cantabria, Spain.	dsansegundo@humv.es	Romón, Iñigo/M-3497-2019	Romón, Iñigo/0000-0003-2428-4469; Ontanon Rodriguez, Jesus/0000-0002-2006-4357	Fondo de Investigaciones Sanitarias from ISCIII [PI1100990, PI1400378]	Fondo de Investigaciones Sanitarias from ISCIII	The work was partially supported by grants from the Fondo de Investigaciones Sanitarias (PI1100990 and PI1400378 from ISCIII).	Baxter-Lowe LA, 2014, AM J TRANSPLANT, V14, P1592, DOI 10.1111/ajt.12734; Ellis TM, 2012, HUM IMMUNOL, V73, P706, DOI 10.1016/j.humimm.2012.04.007; FERNANDEZVINA MA, 1991, IMMUNOGENETICS, V34, P299, DOI 10.1007/BF00211994; FERNANDEZVINA MA, 1994, HUM IMMUNOL, V39, P290, DOI 10.1016/0198-8859(94)90272-0; Ferrari-Lacraz S, 2012, TISSUE ANTIGENS, V79, P315, DOI 10.1111/j.1399-0039.2012.01853.x; Iyer HS, 2013, CURR OPIN NEPHROL HY, V22, P681, DOI 10.1097/MNH.0b013e328365b3b9; Klitz W, 2003, TISSUE ANTIGENS, V62, P296, DOI 10.1034/j.1399-0039.2003.00103.x; Picascia A, 2014, IMMUNOL LETT, V162, P181, DOI 10.1016/j.imlet.2014.08.014; Tambur AR, 2013, TRANSPLANTATION, V96, P1065, DOI 10.1097/TP.0b013e3182a452a5; Tinckam KJ, 2015, AM J TRANSPLANT, V15, P3194, DOI 10.1111/ajt.13355; Vina MAF, 2012, PHILOS T R SOC B, V367, P820, DOI 10.1098/rstb.2011.0320; ZACHARY AA, 1985, TRANSPLANTATION, V39, P316, DOI 10.1097/00007890-198503000-00024	12	2	3	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2017	8								540	10.3389/fimmu.2017.00540	http://dx.doi.org/10.3389/fimmu.2017.00540			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EU3RI	28553286	gold, Green Published			2022-12-18	WOS:000400948300001
J	Tan, Y; Tong, P; Wang, JY; Zhao, L; Li, J; Yu, Y; Chen, YH; Wang, J				Tan, Yue; Tong, Pei; Wang, Junyi; Zhao, Lei; Li, Jing; Yu, Yang; Chen, Ying-Hua; Wang, Ji			The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1	FRONTIERS IN IMMUNOLOGY			English	Article						C-C chemokine receptor type 5; membrane-proximal region; HIV-1; blocking antibody; HIV vaccine	IMMUNODEFICIENCY-VIRUS TYPE-1; AMINO-TERMINAL DOMAIN; LEUCINE-ZIPPER; N-TERMINUS; ENVELOPE GLYCOPROTEIN; BLOCKING ANTIBODIES; ANTI-HIV-1 ACTIVITY; EXTRACELLULAR LOOP; RESISTANT HIV-1; GP120 BINDING	The initial infection and transmission of HIV-1 requires C-C chemokine receptor type 5 (CCR5). Here, we report that the membrane-proximal region (MPR, aa 22-38) of CCR5 participates in the infection of HIV-1. First, MPR-specific antibodies elicited in mice dose-dependently inhibited the infection of CCR5-tropic HIV-1. Second, substituting MPR with the same region from other co-receptors significantly impaired HIV-1 infection, while the key residues identified by alanine scanning mutagenesis formed an exposed leucine zipper-like structure. Moreover, a peptide derived from MPR could block the infection of a number of HIV-1 strains only before the formation of gp41 six-helix bundle, coincide with the early interaction between CCR5 and the gp120 protein during HIV-1 infection. These promising results ensured the potential of this previously uncharacterized domain as a starting point for the development of antiviral drugs, blocking antibodies, and HIV vaccines.	[Tan, Yue; Tong, Pei; Wang, Junyi; Li, Jing; Yu, Yang; Chen, Ying-Hua; Wang, Ji] Tsinghua Univ, Beijing Key Lab Prot Therapeut, Sch Life Sci, Lab Immunol,Prot Sci Lab,Minist Educ, Beijing, Peoples R China; [Zhao, Lei] Tsinghua Univ, Key Lab Bioorgan Phosphorus Chem & Chem Biol, Minist Educ, Dept Chem, Beijing, Peoples R China; [Wang, Ji] Harvard Med Sch, Dept Dermatol, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02115 USA	Tsinghua University; Tsinghua University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Chen, YH; Wang, J (corresponding author), Tsinghua Univ, Beijing Key Lab Prot Therapeut, Sch Life Sci, Lab Immunol,Prot Sci Lab,Minist Educ, Beijing, Peoples R China.; Wang, J (corresponding author), Harvard Med Sch, Dept Dermatol, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02115 USA.	chenyh@mail.tsinghua.edu.cn; jwang10@mgh.harvard.edu	wang, junyi/GYA-3213-2022	Wang, Junyi/0000-0002-7525-430X	 [NSFC-81271823]		The authors thank Dr. Lu Lu at Fudan University for discussions and comment on the manuscript. This work was supported by the following grants NSFC-81271823 to Y-HC.	Arts EJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007161; Barassi C, 2004, BLOOD, V104, P2205, DOI 10.1182/blood-2004-06-2134; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bouhlal H, 2001, J IMMUNOL, V166, P7606, DOI 10.4049/jimmunol.166.12.7606; BUCKLAND R, 1992, J GEN VIROL, V73, P1703, DOI 10.1099/0022-1317-73-7-1703; Chackerian B, 1999, P NATL ACAD SCI USA, V96, P2373, DOI 10.1073/pnas.96.5.2373; Chain BM, 2008, VACCINE, V26, P5752, DOI 10.1016/j.vaccine.2008.08.025; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Cuevas JM, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002251; Devito C, 2000, AIDS, V14, P1917, DOI 10.1097/00002030-200009080-00006; Dogo-Isonagie C, 2012, J BIOL CHEM, V287, P15076, DOI 10.1074/jbc.M111.332361; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Duma L, 2007, J MOL BIOL, V365, P1063, DOI 10.1016/j.jmb.2006.10.040; El-Manzalawy Yasser, 2008, Comput Syst Bioinformatics Conf, V7, P121, DOI 10.1142/9781848162648_0011; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Garred P, 1997, LANCET, V349, P1884, DOI 10.1016/S0140-6736(05)63874-3; Geuenich S, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-27; Glass WG, 2005, J EXP MED, V202, P1087, DOI 10.1084/jem.20042530; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398; Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Ingallinella P, 2009, P NATL ACAD SCI USA, V106, P5801, DOI 10.1073/pnas.0901007106; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lim JK, 2008, J INFECT DIS, V197, P262, DOI 10.1086/524691; Lopalco L, 2000, J IMMUNOL, V164, P3426, DOI 10.4049/jimmunol.164.6.3426; Lopalco L, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S4; Lu L, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-104; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; Misumi S, 2006, J IMMUNOL, V176, P463, DOI 10.4049/jimmunol.176.1.463; Moncunill G, 2008, AIDS, V22, P23, DOI 10.1097/QAD.0b013e3282f303e6; Olson WC, 1999, J VIROL, V73, P4145, DOI 10.1128/JVI.73.5.4145-4155.1999; Pastori C, 2008, J VIROL, V82, P4125, DOI 10.1128/JVI.02232-07; Pastori C, 2006, BLOOD, V107, P4825, DOI 10.1182/blood-2005-06-2463; Pastori C, 2014, J VIROL, V88, P3623, DOI 10.1128/JVI.03663-13; Qin L, 2015, SCIENCE, V347, P1117, DOI 10.1126/science.1261064; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Sun Z. Z., 2016, IEEE T CIRCUITS SYST, VPP, P1, DOI DOI 10.1038/EMI.2016.86; Tan QX, 2013, SCIENCE, V341, P1387, DOI 10.1126/science.1241475; Tilton JC, 2010, J VIROL, V84, P10863, DOI 10.1128/JVI.01109-10; Tong P, 2013, J ANTIMICROB CHEMOTH, V68, P2533, DOI 10.1093/jac/dkt230; Trkola A, 2001, J VIROL, V75, P579, DOI 10.1128/JVI.75.2.579-588.2001; Walker DK, 2005, DRUG METAB DISPOS, V33, P587, DOI 10.1124/dmd.104.002626; Wang C, 2014, J ANTIMICROB CHEMOTH, V69, P1537, DOI 10.1093/jac/dku010; Wang J, 2015, P NATL ACAD SCI USA, V112, P5005, DOI 10.1073/pnas.1500408112; Wang J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5447; WANG JR, 2011, ELECTRON J QUAL THEO, P1, DOI DOI 10.1371/J0URNAL.P0NE.0018233; Wang Q, 2015, J VIROL, V89, P6960, DOI 10.1128/JVI.00791-15; Wexler-Cohen Y, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000509; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; Wilen CB, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006866; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Yao B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045152; Young JK, 1998, VIROLOGY, V243, P21, DOI 10.1006/viro.1998.9044; Yu XW, 2012, J VIROL, V86, P589, DOI 10.1128/JVI.05066-11; Zhou YH, 1998, J IMMUNOL, V160, P4018	63	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 24	2017	8								478	10.3389/fimmu.2017.00478	http://dx.doi.org/10.3389/fimmu.2017.00478			26	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EZ2RE	28484468	Green Published, gold			2022-12-18	WOS:000404556600001
J	Rodriguez-Frade, JM; Guedan, A; Lucas, P; Martinez-Munoz, L; Villares, R; Criado, G; Balomenos, D; Reyburn, HT; Mellado, M				Rodriguez-Frade, Jose M.; Guedan, Anabel; Lucas, Pilar; Martinez-Munoz, Laura; Villares, Ricardo; Criado, Gabriel; Balomenos, Dimitri; Reyburn, Hugh T.; Mellado, Mario			Use of Lentiviral Particles As a Cell Membrane-Based mFasL Delivery System for In Vivo Treatment of Inflammatory Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						FasL; lentiviral particles; apoptosis; caspases; rheumatoid arthritis	COLLAGEN-INDUCED ARTHRITIS; GPI-ANCHORED PROTEINS; FAS-LIGAND; RHEUMATOID-ARTHRITIS; DOWN-REGULATION; IMMUNE-SYSTEM; GENE-TRANSFER; APOPTOSIS; RECEPTOR; DEATH	During budding, lentiviral particles (LVP) incorporate cell membrane proteins in the viral envelope. We explored the possibility of harnessing this process to generate LVP-expressing membrane proteins of therapeutic interest and studied the potential of these tools to treat different pathologies. Fas-mediated apoptosis is central to the maintenance of T cell homeostasis and prevention of autoimmune processes. We prepared LVP that express murine FasL on their surface. Our data indicate that mFasL-bearing LVP induce caspase 3 and 9 processing, cytochrome C release, and significantly more cell death than control LVP in vitro. This cytotoxicity is blocked by the caspase inhibitor Z-VAD. Analysis of the application of these reagents for the treatment of inflammatory arthritis in vivo suggests that FasL-expressing LVP could be useful for therapy in autoimmune diseases such as rheumatoid arthritis, where there is an excess of Fas-expressing activated T cells in the joint. LVP could be a vehicle not only for mFasL but also for other membrane-bound proteins that maintain their native conformation and might mediate biological activities.	[Rodriguez-Frade, Jose M.; Guedan, Anabel; Lucas, Pilar; Martinez-Munoz, Laura; Villares, Ricardo; Balomenos, Dimitri; Reyburn, Hugh T.; Mellado, Mario] CSIC, Dept Immunol & Oncol, Ctr Nacl Biotecnol, Madrid, Spain; [Criado, Gabriel] Inst Invest Hosp 12 Octubre I 12, Inflammatory & Autoimmune Dis Grp, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Hospital Universitario 12 de Octubre	Mellado, M (corresponding author), CSIC, Dept Immunol & Oncol, Ctr Nacl Biotecnol, Madrid, Spain.	mmellado@cnb.csic.es	Mellado, Mario/M-9893-2014; Frade, Jose Miguel Rodriguez/K-4266-2014; Villares, Ricardo/AAA-7236-2020; Martínez-Muñoz, Laura/C-2719-2017; Balomenos, Dimitrios/I-3850-2015; Criado, Gabriel/J-1803-2019; Villares, Ricardo/AAN-3755-2021	Mellado, Mario/0000-0001-6325-1630; Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Martínez-Muñoz, Laura/0000-0003-3098-279X; Balomenos, Dimitrios/0000-0002-1252-0850; Criado, Gabriel/0000-0003-4824-0890; Villares, Ricardo/0000-0001-7562-6700; Guedan, Anabel/0000-0001-5732-4186	Spanish Ministry of Economy and Competitiveness [SAF 2014-53416-R, SAF 2014-58752-R]; RETICS Program of the Instituto de salud Carlos III [RD12/0009/009, RD16/0012/0006]; COMFUTURO program of the Fundacion General CSIC	Spanish Ministry of Economy and Competitiveness(Spanish Government); RETICS Program of the Instituto de salud Carlos III(Instituto de Salud Carlos III); COMFUTURO program of the Fundacion General CSIC	This work was supported in part by grants from the Spanish Ministry of Economy and Competitiveness (SAF 2014-53416-R to MM and SAF 2014-58752-R to HR) and the RETICS Program of the Instituto de salud Carlos III (RD12/0009/009 and RD16/0012/0006; RIER). LM-M is supported by the COMFUTURO program of the Fundacion General CSIC.	Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Akane K, 2016, P NATL ACAD SCI USA, V113, P2460, DOI 10.1073/pnas.1525098113; Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; Audo R, 2014, ARTHRITIS RHEUMATOL, V66, P3289, DOI 10.1002/art.38806; Azzouz M, 2004, J CLIN INVEST, V114, P1726, DOI 10.1172/JCI200422922; Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cary ZD, 2011, J VIROL, V85, P5708, DOI 10.1128/JVI.02393-10; Eisele G, 2011, NEURO-ONCOLOGY, V13, P155, DOI 10.1093/neuonc/noq176; Feng HP, 2004, J BIOMED BIOTECHNOL, P41; Franz JK, 2000, ARTHRITIS RHEUM, V43, P599, DOI 10.1002/1529-0131(200003)43:3<599::AID-ANR17>3.0.CO;2-T; Gasmi M, 1999, J VIROL, V73, P1828, DOI 10.1128/JVI.73.3.1828-1834.1999; Gutierrez del Arroyo A, 2000, ONCOGENE, V19, P3647, DOI [10.1038/sj.onc.1203662, DOI 10.1038/SJ.ONC.1203662]; Hacein-Bey-Abina S, 2014, NEW ENGL J MED, V371, P1407, DOI 10.1056/NEJMoa1404588; Hashimoto H, 1998, ARTHRITIS RHEUM, V41, P657, DOI 10.1002/1529-0131(199804)41:4<657::AID-ART12>3.3.CO;2-E; Hoffman TL, 2000, P NATL ACAD SCI USA, V97, P11215, DOI 10.1073/pnas.190274097; Houghton BC, 2015, CURR OPIN PHARMACOL, V24, P119, DOI 10.1016/j.coph.2015.08.007; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Inglis JJ, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2319; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kang TB, 2008, J IMMUNOL, V181, P2522, DOI 10.4049/jimmunol.181.4.2522; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kim SH, 2002, MOL THER, V6, P584, DOI 10.1006/mthe.2002.0712; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Kobayashi T, 2000, ARTHRITIS RHEUM, V43, P1106, DOI 10.1002/1529-0131(200005)43:5<1106::AID-ANR21>3.0.CO;2-F; Kreuwel HTC, 1999, J IMMUNOL, V163, P4335; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; Nayak S, 2010, GENE THER, V17, P295, DOI 10.1038/gt.2009.148; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Ogawa Y, 2001, J RHEUMATOL, V28, P950; Peng SL, 2006, RHEUMATOLOGY, V45, P26, DOI 10.1093/rheumatology/kei113; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; PILLEMER E, 1984, P NATL ACAD SCI-BIOL, V81, P4434, DOI 10.1073/pnas.81.14.4434; Rapp HT, 2004, ARTHRITIS RES THER, V6, pR404, DOI 10.1186/ar1205); Salmaso C, 2002, ANN NY ACAD SCI, V966, P496, DOI 10.1111/j.1749-6632.2002.tb04253.x; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Stassi G, 2000, NAT IMMUNOL, V1, P483, DOI 10.1038/82725; Stein CS, 2001, MOL THER, V3, P850, DOI 10.1006/mthe.2001.0325; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vega B, 2011, J LEUKOCYTE BIOL, V90, P399, DOI 10.1189/jlb.1010565; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; Zhang HD, 1997, J CLIN INVEST, V100, P1951, DOI 10.1172/JCI119726; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	55	2	3	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2017	8								460	10.3389/fimmu.2017.00460	http://dx.doi.org/10.3389/fimmu.2017.00460			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ES8WB	28484458	Green Published, gold			2022-12-18	WOS:000399836500002
J	Lozano, F; Martiinez-Florensa, M				Lozano, Francisco; Martinez-Florensa, Mario			Commentary: The Scavenger Receptor SSc5D Physically Interacts with Bacteria through the SRCR-Containing N-Terminal Domain	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						SSc5D; S5D-SRCRB; scavenger receptor cysteine-rich; bacterial binding; CD6	INDUCED SEPTIC SHOCK; CD6; ECTODOMAIN; EXPRESSION; PROTECTS		[Lozano, Francisco; Martinez-Florensa, Mario] IDIBAPS, Grp Immunoreceptors Sistema Innat & Adaptatiu, Barcelona, Spain; [Lozano, Francisco] Hosp Clin Barcelona, Servei Immunol, Barcelona, Spain; [Lozano, Francisco] Univ Barcelona, Fac Med, Dept Biomed, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona	Lozano, F (corresponding author), IDIBAPS, Grp Immunoreceptors Sistema Innat & Adaptatiu, Barcelona, Spain.; Lozano, F (corresponding author), Hosp Clin Barcelona, Servei Immunol, Barcelona, Spain.; Lozano, F (corresponding author), Univ Barcelona, Fac Med, Dept Biomed, Barcelona, Spain.	flozano@clinic.ub.es	LOZANO, FRANCISCO/AAB-7888-2019	LOZANO, FRANCISCO/0000-0003-1119-4368	Spanish Ministerio de Economia y Competitividad [SAF2013-46151-R]; Instituto de Salud Carlos III (ISCIII); European Development Regional Fund [RD12/0015/0018]	Spanish Ministerio de Economia y Competitividad(Spanish Government); Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); European Development Regional Fund(European Commission)	The work by FL and MM-F is supported by grants from the Spanish Ministerio de Economia y Competitividad (Plan Nacional de I+D+i, SAF2013-46151-R), Instituto de Salud Carlos III (ISCIII)-co-financed by European Development Regional Fund "A way to achieve Europe" ERDF (Spanish Network for Research in Infectious Diseases, REIPI, RD12/0015/0018).	Bessa Pereira C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00416; Chappell PE, 2015, STRUCTURE, V23, P1426, DOI 10.1016/j.str.2015.05.019; Martinez VG, 2014, CELL MOL IMMUNOL, V11, P343, DOI 10.1038/cmi.2014.12; Martinez-Florensa M, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01391-16; Martinez-Florensa M, 2014, J INFECT DIS, V209, P1077, DOI 10.1093/infdis/jit624; McAlister MSB, 1998, EUR J BIOCHEM, V257, P131, DOI 10.1046/j.1432-1327.1998.2570131.x; Miro-Julia C, 2014, TISSUE ANTIGENS, V83, P273, DOI 10.1111/tan.12330; Miro-Julia C, 2011, J IMMUNOL, V186, P2344, DOI 10.4049/jimmunol.1000840; Sarrias MR, 2007, P NATL ACAD SCI USA, V104, P11724, DOI 10.1073/pnas.0702815104; Sarrias MR, 2005, J BIOL CHEM, V280, P35391, DOI 10.1074/jbc.M505042200; Vera J, 2009, P NATL ACAD SCI USA, V106, P1506, DOI 10.1073/pnas.0805846106	11	2	3	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 28	2017	8								366	10.3389/fimmu.2017.00366	http://dx.doi.org/10.3389/fimmu.2017.00366			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EP6LI	28396672	Green Published, gold			2022-12-18	WOS:000397490600001
J	Nasi, A; Amu, S; Gothlin, M; Jansson, M; Nagy, N; Chiodi, F; Rethi, B				Nasi, Aikaterini; Amu, Sylvie; Gothlin, Marten; Jansson, Marianne; Nagy, Noemi; Chiodi, Francesca; Rethi, Bence			Dendritic Cell Response to HIV-1 Is Controlled by Differentiation Programs in the Cells and Strain-Specific Properties of the Virus	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; dendritic cell; cytokines; IL-12; infection	DC-SIGN; INFECTED-CELLS; T-CELLS; MATURATION; IMMUNITY; NEF; ACTIVATION; RESISTANCE; PROTEIN; GP120	Dendritic cells (DCs) are potent antigen-presenting cells that might play contradictory roles during HIV-1 infection, contributing not only to antiviral immunity but also to viral dissemination and immune evasion. Although DCs are characterized by enormous functional diversity, it has not been analyzed how differentially programmed DCs interact with HIV-1. We have previously described the reprogramming of DC development by endogenously produced lactic acid that accumulated in a cell culture density-dependent manner and provided a long-lasting anti-inflammatory signal to the cells. By exploiting this mechanism, we generated immunostimulatory DCs characterized by the production of TH1 polarizing and inflammatory mediators or, alternatively, suppressed DCs that produce IL-10 upon activation, and we tested the interaction of these DC types with different HIV-1 strains. Cytokine patterns were monitored in HIV-1-exposed DC cultures. Our results showed that DCs receiving suppressive developmental program strongly upregulated their capacity to produce the TH1 polarizing cytokine IL-12 and the inflammatory chemokines CCL2 and CCL7 upon interaction with HIV-1 strains IIIB and SF162. On the contrary, HIV-1 abolished cytokine production in the more inflammatory DC types. Preincubation of the cells with the HIV-1 proteins gp120 and Nef could inhibit IL-12 production irrespectively of the tested DC types, whereas MyD88-and TRIF-dependent signals stimulated IL-12 production in the suppressed DC type only. Rewiring of DC cytokines did not require DC infections or ligation of the HIV-1 receptor CD209. A third HIV-1 strain, BaL, could not modulate DC cytokines in a similar manner indicating that individual HIV-1 strains can differ in their capacity to influence DCs. Our results demonstrated that HIV-1 could not induce definite and invariable modulatory programs in DCs. Instead, interaction with the virus triggered different responses in different DC types. Thus, the outcome of DC-HIV-1 interactions might be highly variable, shaped by endogenous features of the cells and diversity of the virus.	[Nasi, Aikaterini; Amu, Sylvie; Gothlin, Marten; Jansson, Marianne; Nagy, Noemi; Chiodi, Francesca; Rethi, Bence] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Jansson, Marianne] Lund Univ, Dept Lab Med, Lund, Sweden; [Rethi, Bence] Karolinska Inst, Dept Med, Solna MedS, Stockholm, Sweden; [Rethi, Bence] Karolinska Univ Hosp, Stockholm, Sweden	Karolinska Institutet; Lund University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Rethi, B (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.; Rethi, B (corresponding author), Karolinska Inst, Dept Med, Solna MedS, Stockholm, Sweden.; Rethi, B (corresponding author), Karolinska Univ Hosp, Stockholm, Sweden.	bence.rethi@ki.se	Nagy, Noemi/J-2936-2012; Rethi, Bence/C-5770-2013	Amu, Sylvie/0000-0001-9593-7952; Jansson, Marianne/0000-0001-6536-8146; Nagy, Noemi/0000-0002-7800-3493; Chiodi, Francesca/0000-0002-1385-8343; Rethi, Bence/0000-0001-8220-5015	Onassis Foundation, Greece; Clas Groschinskys Minnesfond; Swedish Medical Research Council	Onassis Foundation, Greece; Clas Groschinskys Minnesfond; Swedish Medical Research Council(Swedish Medical Research Council (SMRC))	BR received a Senior Research Fellow position from Karolinska Institutet, and AN was supported by the Onassis Foundation, Greece. Our research was supported by the Clas Groschinskys Minnesfond and the Swedish Medical Research Council.	Abdi K, 2012, J IMMUNOL, V188, P5981, DOI 10.4049/jimmunol.1102868; Breckpot K, 2010, J VIROL, V84, P5627, DOI 10.1128/JVI.00014-10; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Campbell Tamika D, 2008, Ethn Dis, V18, pS2; Chattergoon MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004082; Chougnet C, 2006, J LEUKOCYTE BIOL, V80, P994, DOI 10.1189/jlb.0306135; Fantuzzi L, 2004, J VIROL, V78, P9763, DOI 10.1128/JVI.78.18.9763-9772.2004; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2009, FUTURE MICROBIOL, V4, P879, DOI 10.2217/FMB.09.51; Gringhuis SI, 2007, IMMUNITY, V26, P605, DOI 10.1016/j.immuni.2007.03.012; Gringhuis SI, 2010, NAT IMMUNOL, V11, P419, DOI 10.1038/ni.1858; Gringhuis SI, 2009, NAT IMMUNOL, V10, P1081, DOI 10.1038/ni.1778; Guo HT, 2014, J BIOL CHEM, V289, P21716, DOI 10.1074/jbc.M114.566620; Harman AN, 2006, J IMMUNOL, V177, P7103, DOI 10.4049/jimmunol.177.10.7103; Hertoghs N, 2015, J IMMUNOL, V194, P4431, DOI 10.4049/jimmunol.1403016; Huik K, 2013, INFECT GENET EVOL, V20, P78, DOI 10.1016/j.meegid.2013.08.008; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; Majumder B, 2005, J VIROL, V79, P7990, DOI 10.1128/JVI.79.13.7990-8003.2005; Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337; Martin-Gayo E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004930; Miller E, 2013, IMMUNOL REV, V254, P170, DOI 10.1111/imr.12082; Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Nasi A, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26744; Nasi A, 2013, J IMMUNOL, V191, P3090, DOI 10.4049/jimmunol.1300772; Quaranta MG, 2009, BIOFACTORS, V35, P169, DOI 10.1002/biof.28; Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170; Shan MM, 2007, PLOS PATHOG, V3, P1637, DOI 10.1371/journal.ppat.0030169; Sironi M, 2012, J IMMUNOL, V188, P818, DOI 10.4049/jimmunol.1102179; Smed-Sorensen A, 2004, BLOOD, V104, P2810, DOI 10.1182/blood-2003-07-2314; Smed-Sorensen A, 2005, J VIROL, V79, P8861, DOI 10.1128/JVI.79.14.8861-8869.2005; Wilflingseder D, 2004, J IMMUNOL, V173, P7497, DOI 10.4049/jimmunol.173.12.7497	32	2	3	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 13	2017	8								244	10.3389/fimmu.2017.00244	http://dx.doi.org/10.3389/fimmu.2017.00244			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EN2TZ	28348557	Green Published, gold			2022-12-18	WOS:000395864400001
J	Gregoriussen, AMM; Bohr, HG				Gregoriussen, Angelica Maria Mohr; Bohr, Henrik Georg			A Novel Model on DST-Induced Transplantation Tolerance by the Transfer of Self-Specific Donor tTregs to a Haplotype-Matched Organ Recipient	FRONTIERS IN IMMUNOLOGY			English	Article						Tregs; indirect alloantigen presentation; direct alloantigen presentation; MHC-II recruitment; DST; transplantation tolerance; haplotype-matched; self-tolerance	REGULATORY T-CELLS; PRETRANSPLANT BLOOD-TRANSFUSIONS; ANTIGEN-PRESENTING CELLS; CLASS-II; HISTORICAL-PERSPECTIVE; IMMUNE HOMEOSTASIS; GRAFT ACCEPTANCE; IN-VIVO; EXPRESSION; THYMUS	Donor-specific blood transfusion (DST) can lead to significant prolongation of allograft survival in experimental animal models and sometimes human recipients of solid organs. The mechanisms responsible for the beneficial effect on graft survival have been a topic of research and debate for decades and are not yet fully elucidated. Once we discover how the details of the mechanisms involved are linked, we could be within reach of a procedure making it possible to establish donor-specific tolerance with minimal or no immunosuppressive medication. Today, it is well established that CD4+Foxp3+ regulatory T cells (Tregs) are indispensable for maintaining immunological self-tolerance. A large number of animal studies have also shown that Tregs are essential for establishing and maintaining transplantation tolerance. In this paper, we present a hypothesis of one H2-haplotype-matched DST-induced transplantation tolerance (in mice). The formulated hypothesis is based on a re-interpretation of data from an immunogenetic experiment published by Niimi and colleagues in 2000. It is of importance that the naive recipient mice in this study were never immunosuppressed and were therefore fully immune competent during the course of tolerance induction. Based on the immunological status of the recipients, we suggest that one H2-haplotype-matched self-specific Tregs derived from the transfusion blood can be activated and multiply in the host by binding to antigen-presenting cells presenting allopeptides in their major histocompatibility complex (MHC) class II (MHC-II). We also suggest that the endothelial and epithelial cells within the solid organ allograft upregulate the expression of MHC-II and attract the expanded Treg population to suppress inflammation within the graft. We further suggest that this biological process, here termed MHC-II recruitment, is a vital survival mechanism for organs (or the organism in general) when attacked by an immune system.	[Gregoriussen, Angelica Maria Mohr] Univ Copenhagen, CPNSS, Copenhagen, Denmark; [Bohr, Henrik Georg] Tech Univ Denmark, Dept Chem, Lyngby, Denmark	University of Copenhagen; Technical University of Denmark	Gregoriussen, AMM (corresponding author), Univ Copenhagen, CPNSS, Copenhagen, Denmark.	ammgreg@gmail.com						Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444; Bushell A, 2003, TRANSPLANTATION, V76, P449, DOI 10.1097/01.TP.0000083043.84630.99; Caridade M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00378; Cobbold SP, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015545; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fu HM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4436; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Graca L, 2002, J EXP MED, V195, P1641, DOI 10.1084/jem.20012097; Graca L, 2004, P NATL ACAD SCI USA, V101, P10122, DOI 10.1073/pnas.0400084101; Gratz IK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00333; Gubser C, 2016, SCI REP-UK, V6, DOI 10.1038/srep25758; Hasegawa S, 1998, AM J PATHOL, V153, P69, DOI 10.1016/S0002-9440(10)65547-2; Herkel J, 2003, HEPATOLOGY, V37, P1079, DOI 10.1053/jhep.2003.50191; Herrera OB, 2004, J IMMUNOL, V173, P4828, DOI 10.4049/jimmunol.173.8.4828; Itoh M, 1999, J IMMUNOL, V162, P5317; Joffre O, 2008, NAT MED, V14, P88, DOI 10.1038/nm1688; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Kambayashi T, 2014, NAT REV IMMUNOL, V14, P719, DOI 10.1038/nri3754; Karim M, 2004, J IMMUNOL, V172, P923, DOI 10.4049/jimmunol.172.2.923; Kieback E, 2016, IMMUNITY, V44, P1114, DOI 10.1016/j.immuni.2016.04.018; Kingsley CI, 2007, TRANSPL INT, V20, P828, DOI 10.1111/j.1432-2277.2007.00533.x; Kishimoto K, 2004, J AM SOC NEPHROL, V15, P2423, DOI 10.1097/01.ASN.0000137883.20961.2D; Klein L, 2005, CURR TOP MICROBIOL, V293, P73, DOI 10.1007/3-540-27702-1_4; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Lechler RI, 2003, NAT REV IMMUNOL, V3, P147, DOI 10.1038/nri1002; Lerut J, 2006, AM J TRANSPLANT, V6, P1774, DOI 10.1111/j.1600-6143.2006.01396.x; Marti HP, 2006, TRANSPLANT INT, V19, P19, DOI 10.1111/j.1432-2277.2005.00233.x; Monguio-Tortajada M, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00416; Nagahama K, 2009, INT IMMUNOL, V21, P379, DOI 10.1093/intimm/dxp005; Niimi M, 2000, TRANSPLANTATION, V69, P411, DOI 10.1097/00007890-200002150-00018; Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010; OPELZ G, 1973, TRANSPLANT P, V5, P253; Opelz G, 1997, TRANSPLANTATION, V63, P964, DOI 10.1097/00007890-199704150-00010; Povoleri GAM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00169; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; Quezada SA, 2003, BLOOD, V102, P1920, DOI 10.1182/blood-2003-02-0586; Quiroga I, 2006, TRANSPLANTATION, V81, P1196, DOI 10.1097/01.tp.0000205788.05322.42; Rees LE, 2003, CLIN EXP IMMUNOL, V134, P497, DOI 10.1111/j.1365-2249.2003.02301.x; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Roelen DL, 2002, HUM IMMUNOL, V63, P902, DOI 10.1016/S0198-8859(02)00453-6; Rosenblum MD, 2011, NATURE, V480, P538, DOI 10.1038/nature10664; Sachs DH, 2003, J CLIN INVEST, V111, P1819, DOI 10.1172/JCI200318926; Safinia N, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00438; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; SALVATIERRA O, 1980, ANN SURG, V192, P543, DOI 10.1097/00000658-198010000-00012; Schmitt EG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00152; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; SHENGTANNER X, 1992, J EXP MED, V176, P407, DOI 10.1084/jem.176.2.407; Spoerl S, 2011, DISCOV MED, V11, P25; Starzl TE, 2004, P NATL ACAD SCI USA, V101, P14607, DOI 10.1073/pnas.0404829101; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Starzl TE, 2001, NAT REV IMMUNOL, V1, P233, DOI 10.1038/35105088; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; Strauss L, 2009, J IMMUNOL, V182, P1469, DOI 10.4049/jimmunol.182.3.1469; Thelemann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086844; Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473; Waanders M., 2009, CLIN IMMUNOLOGICAL A; Waanders MM, 2008, TRANSPLANTATION, V85, P1668, DOI 10.1097/TP.0b013e318170b8b4; Waanders MM, 2005, TRANSFUS MED REV, V19, P281, DOI 10.1016/j.tmrv.2005.04.002; Waldmann H, 2006, IMMUNOL REV, V212, P301, DOI 10.1111/j.0105-2896.2006.00406.x; Waldmann H, 2014, J CLIN INVEST, V124, P1439, DOI 10.1172/JCI67226; Walker LSK, 2013, J AUTOIMMUN, V45, P49, DOI 10.1016/j.jaut.2013.06.006; Watson CJE, 2012, BRIT J ANAESTH, V108, pI29, DOI 10.1093/bja/aer384; Wise MP, 1998, J IMMUNOL, V161, P5813; Wood KJ, 2012, TRANSPLANTATION, V93, P1, DOI 10.1097/TP.0b013e31823cab44; Yadav M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00232; Zheng SG, 2008, J IMMUNOL, V180, P7112, DOI 10.4049/jimmunol.180.11.7112	71	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 21	2017	8								9	10.3389/fimmu.2017.00009	http://dx.doi.org/10.3389/fimmu.2017.00009			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EL1ZN	28270810	Green Published, gold			2022-12-18	WOS:000394420000001
J	Li, L; Tao, YH; Feng, Z; Niu, Y; Tan, Q; Zheng, HW; Chen, QW; Tang, J; Zhang, Y; Zhu, G; Feng, H; Yang, YF; Chen, Z				Li Lin; Tao Yihao; Feng Zhou; Niu Yin; Tan Qiang; Zheng Haowen; Chen Qianwei; Tang Jun; Zhang Yuan; Zhu Gang; Feng Hua; Yang Yunfeng; Chen Zhi			Inflammatory Regulations by Driving Microglial M2 Polarization: Neuroprotective Effects of Cannabinoid Receptor-2 Activation in Intracerebral Hemorrhage	FRONTIERS IN IMMUNOLOGY			English	Article						intracerebral hemorrhage; cannabinoid receptor-2; neuroinflammation; microglial polarization; CREB	GERMINAL MATRIX HEMORRHAGE; TRAUMATIC BRAIN-INJURY; RAT MODEL; MICROGLIA/MACROPHAGE POLARIZATION; ALTERNATIVE ACTIVATION; NEUROLOGICAL DEFICITS; MACROPHAGE ACTIVATION; ISCHEMIC-INJURY; CB2 RECEPTORS; NEUROINFLAMMATION	The cannabinoid receptor-2 (CB2R) was initially thought to be the "peripheral cannabinoid receptor." Recent studies, however, have documented CB2R expression in the brain in both glial and neuronal cells, and increasing evidence suggests an important role for CB2R in the central nervous system inflammatory response. Intracerebral hemorrhage (ICH), which occurs when a diseased cerebral vessel ruptures, accounts for 10-15% of all strokes. Although surgical techniques have significantly advanced in the past two decades, ICH continues to have a high mortality rate. The aim of this study was to investigate the therapeutic effects of CB2R stimulation in acute phase after experimental ICH in rats and its related mechanisms. Data showed that stimulation of CB2R using a selective agonist, JWH133, ameliorated brain edema, brain damage, and neuron death and improved neurobehavioral outcomes in acute phase after ICH. The neuroprotective effects were prevented by SR144528, a selective CB2R inhibitor. Additionally, JWH133 suppressed neuroinflammation and upregulated the expression of microglial M2-associated marker in both gene and protein level. Furthermore, the expression of phosphorylated cAMP-dependent protein kinase (pPKA) and its downstream effector, cAMP-response element binding protein (CREB), were facilitated. Knockdown of CREB significantly inversed the increase of M2 polarization in microglia, indicating that the JWH133-mediated anti-inflammatory effects are closely associated with PKA/CREB signaling pathway. These findings demonstrated that CB2R stimulation significantly protected the brain damage and suppressed neuroinflammation by promoting the acquisition of microglial M2 phenotype in acute stage after ICH. Taken together, this study provided mechanism insight into neuroprotective effects by CB2R stimulation after ICH.	[Li Lin; Zhang Yuan] Nanchong Cent Hosp, Dept Neurosurg, Nanchong, Peoples R China; [Tao Yihao; Feng Zhou; Niu Yin; Tan Qiang; Chen Qianwei; Tang Jun; Zhu Gang; Feng Hua; Chen Zhi] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China; [Zheng Haowen] Affiliated Hosp Southwest Med Univ, Dept Neurosurg, Luzhou, Peoples R China; [Yang Yunfeng] Chinese Peoples Armed Police Forces, Sichuan Prov Corps Hosp, Dept Neurosurg, Leshan, Peoples R China	North Sichuan Medical University; Army Medical University	Chen, Z (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China.	zhichen@tmmu.edu.cn	zheng, hao/HHM-6949-2022; Feng, Hua/AAX-4121-2021	Feng, Hua/0000-0003-4489-9217	National Natural Science Foundation of China [81571130, 81271281, 81371440]; Science and Technology project of Nanchong [KY-15A0020]; National Key Basic Research Development Program (973 Program) of China [2014CB541606]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology project of Nanchong; National Key Basic Research Development Program (973 Program) of China	We gratefully thank Professor Guohua Xi for his generous suggestions regarding the experimental processes. This work was supported by Grant Nos. 81571130 (CZ), 81271281 (CZ), and 81371440 (YY) from the National Natural Science Foundation of China, the Science and Technology project of Nanchong (KY-15A0020), and Grant No. 2014CB541606 (FH) from the National Key Basic Research Development Program (973 Program) of China.	Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Borner C, 2009, J BIOL CHEM, V284, P35450, DOI 10.1074/jbc.M109.006338; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Chen QW, 2015, STROKE, V46, P2902, DOI 10.1161/STROKEAHA.115.009713; Chen QW, 2015, TRANSL STROKE RES, V6, P125, DOI 10.1007/s12975-014-0367-5; Chin KV, 2002, ANN NY ACAD SCI, V968, P49, DOI 10.1111/j.1749-6632.2002.tb04326.x; Choi IY, 2013, AM J PATHOL, V182, P928, DOI 10.1016/j.ajpath.2012.11.024; Ehrhart J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-29; Fernandez-Ruiz J, 2008, MOL CELL ENDOCRINOL, V286, pS91, DOI 10.1016/j.mce.2008.01.001; Fujii M, 2014, EXP NEUROL, V261, P396, DOI 10.1016/j.expneurol.2014.07.005; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Guo J, 2015, BRAIN RES, V1594, P115, DOI 10.1016/j.brainres.2014.10.046; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Li L, 2015, TRANSL STROKE RES, V6, P467, DOI 10.1007/s12975-015-0425-7; Liew HK, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-13; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Ofek O, 2011, J BONE MINER RES, V26, P308, DOI 10.1002/jbmr.228; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Tan Q, 2017, J NEUROSURG, V126, P548, DOI 10.3171/2016.1.JNS152287; Tang J, 2016, MOL NEUROBIOL, V53, P1935, DOI 10.1007/s12035-015-9154-x; Tang J, 2015, NEUROPHARMACOLOGY, V95, P424, DOI 10.1016/j.neuropharm.2015.04.028; Tao YH, 2016, BRAIN BEHAV IMMUN, V58, P118, DOI 10.1016/j.bbi.2016.05.020; Tao YH, 2015, BRAIN RES, V1602, P127, DOI 10.1016/j.brainres.2015.01.025; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wan S, 2016, TRANSL STROKE RES, V7, P478, DOI 10.1007/s12975-016-0472-8; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Zarruk JG, 2012, STROKE, V43, P211, DOI 10.1161/STROKEAHA.111.631044; Zhang Z, 2017, MOL NEUROBIOL, V54, P1874, DOI 10.1007/s12035-016-9785-6; Zhao H, 2015, TRANSL STROKE RES, V6, P407, DOI 10.1007/s12975-015-0428-4; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003	41	2	2	1	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 14	2017	8								112	10.3389/fimmu.2017.00112	http://dx.doi.org/10.3389/fimmu.2017.00112			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EK4RY		gold, Green Published			2022-12-18	WOS:000393915700001
J	Honke, N; Shaabani, N; Teijaro, JR; Christen, U; Hardt, C; Bezgovsek, J; Lang, PA; Lang, KS				Honke, Nadine; Shaabani, Namir; Teijaro, John R.; Christen, Urs; Hardt, Cornelia; Bezgovsek, Judith; Lang, Philipp A.; Lang, Karl S.			Presentation of Autoantigen in Peripheral Lymph Nodes Is Sufficient for Priming Autoreactive CD8(+) T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune diabetes; lymph nodes; LCMV; enforced viral replication; sphingosine-1-phosphate receptor	IN-VIVO DEPLETION; DENDRITIC CELLS; IMMUNE-RESPONSES; INDUCTION; MACROPHAGES; TOLERANCE; ANTIGEN; MICE; IMMUNODEFICIENCY; TRAFFICKING	Peripheral tolerance is an important mechanism by which the immune system can guarantee a second line of defense against autoreactive T and B cells. One autoimmune disease that is related to a break of peripheral tolerance is diabetes mellitus type 1. Using the RIP-GP mouse model, we analyzed the role of the spleen and lymph nodes (LNs) in priming CD8(+) T cells and breaking peripheral tolerance. We found that diabetes developed in splenectomized mice infected with the lymphocytic choriomeningitis virus (LCMV), a finding showing that the spleen was not necessary in generating autoimmunity. By contrast, the absence of LNs prevented the priming of LCMV-specific CD8+ T cells, and diabetes did not develop in these mice. Additionally, we found that dendritic cells are responsible for the distribution of virus in secondary lymphoid organs, when LCMV was administered intravenously. Preventing this distribution with the sphingosine-1-phosphate receptor antagonist FTY720 inhibits the transport of antigen to peripheral LNs and consequently prevented the onset of diabetes. However, in case of subcutaneous infection, administration of FTY720 could not inhibit the onset of diabetes because the viral antigen is already presented in the peripheral LNs. These findings demonstrate the importance of preventing the presence of antigen in LNs for maintaining tolerance.	[Honke, Nadine; Shaabani, Namir; Hardt, Cornelia; Bezgovsek, Judith; Lang, Karl S.] Univ Duisburg Essen, Fac Med, Inst Immunol, Essen, Germany; [Honke, Nadine; Shaabani, Namir; Lang, Philipp A.; Lang, Karl S.] Heinrich Heine Univ, Clin Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany; [Shaabani, Namir; Teijaro, John R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Christen, Urs] Goethe Univ Hosp Frankfurt, Pharmazentrum Frankfurt, Frankfurt, Germany; [Lang, Philipp A.] Heinrich Heine Univ Dusseldorf, Fac Med, Dept Mol Med 2, Dusseldorf, Germany	University of Duisburg Essen; Heinrich Heine University Dusseldorf; Scripps Research Institute; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Heinrich Heine University Dusseldorf	Honke, N; Shaabani, N (corresponding author), Univ Duisburg Essen, Fac Med, Inst Immunol, Essen, Germany.; Honke, N; Shaabani, N (corresponding author), Heinrich Heine Univ, Clin Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany.; Shaabani, N (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.	nadine_honke@yahoo.de; shaabani@scripps.edu		Lang, Karl/0000-0001-9783-7605; Christen, Urs/0000-0003-4165-7976; Honke, Nadine/0000-0002-2220-6806	Alexander von Humboldt Foundation [SKA-2008, SKA-2010]; Deutsche Forschungsgemeinschaft (DFG) [CRC974, CRC/TRR60, LA1419/5-1]	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This study was supported by the Alexander von Humboldt Foundation (SKA-2008 to KL and SKA-2010 to PL) and the Deutsche Forschungsgemeinschaft (DFG; CRC974, CRC/TRR60, and LA1419/5-1). The NIH Tetramer Core Facility provided the tetramer.	Ahmed SA, 2010, EUR J PEDIATR, V169, P315, DOI 10.1007/s00431-009-1030-0; AMLOT PL, 1985, LANCET, V1, P1008, DOI 10.1016/S0140-6736(85)91613-7; BARKER CF, 1968, J EXP MED, V128, P197, DOI 10.1084/jem.128.1.197; Boehm T, 2007, NAT IMMUNOL, V8, P131, DOI 10.1038/ni1435; Feder HM, 1999, NEW ENGL J MED, V341, P210, DOI 10.1056/NEJM199907153410317; Gagnerault MC, 2002, J EXP MED, V196, P369, DOI 10.1084/jem.20011353; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Honke N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003650; Honke N, 2012, NAT IMMUNOL, V13, P51, DOI 10.1038/ni.2169; Jeker LT, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007807; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Karrer U, 2000, EUR J IMMUNOL, V30, P2799, DOI 10.1002/1521-4141(200010)30:10<2799::AID-IMMU2799>3.0.CO;2-2; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; Lan YY, 2005, AM J TRANSPLANT, V5, P2649, DOI 10.1111/j.1600-6143.2005.01085.x; Lang KS, 2006, J CLIN INVEST, V116, P2456, DOI 10.1172/JCI28349; Lang PA, 2008, NAT MED, V14, P756, DOI 10.1038/nm1780; Ludewig B, 2000, EUR J IMMUNOL, V30, P185, DOI 10.1002/1521-4141(200001)30:1<185::AID-IMMU185>3.3.CO;2-C; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miyake Y, 2007, J CLIN INVEST, V117, P2268, DOI 10.1172/JCI31990; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Penaranda C, 2010, DIABETES, V59, P1461, DOI 10.2337/db09-1129; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Probst HC, 2005, CLIN EXP IMMUNOL, V141, P398, DOI 10.1111/j.1365-2249.2005.02868.x; Ravishankar B, 2012, P NATL ACAD SCI USA, V109, P3909, DOI 10.1073/pnas.1117736109; Shaabani N, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.350; Shinkura R, 1996, INT IMMUNOL, V8, P1067, DOI 10.1093/intimm/8.7.1067; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407	34	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 10	2017	8								113	10.3389/fimmu.2017.00113	http://dx.doi.org/10.3389/fimmu.2017.00113			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EK1VZ	28239381	Green Published, gold			2022-12-18	WOS:000393715200001
J	Chandran, PA; Heidu, S; Zelba, H; Schmid-Horch, B; Rammensee, HG; Pascolo, S; Gouttefangeas, C				Chandran, P. Anoop; Heidu, Sonja; Zelba, Henning; Schmid-Horch, Barbara; Rammensee, Hans-Georg; Pascolo, Steve; Gouttefangeas, Cecile			A Simple and Rapid Method for Quality Control of Major Histocompatibility Complex-Peptide Monomers by Flow Cytometry	FRONTIERS IN IMMUNOLOGY			English	Article						MHC-peptide monomers; multimers; antigen-specific T cells; quality control; UV-peptide exchange	CLASS-I MOLECULES; MONOCLONAL-ANTIBODY; T-CELLS; MHC MULTIMERS; HEAVY-CHAINS; ANTIGEN; EPITOPE; EXCHANGE; HLA-A2	Major histocompatibility complex (MHC) multimers are essential tools in T cell immunomonitoring, which are employed both in basic and clinical research, as well as for assessing clinical samples during therapy. The generation of MHC monomers loaded with synthetic peptides is an elaborate and time-consuming process. It would be beneficial to assess the quality of these monomers prior to downstream applications. In this technical note, we describe a novel flow cytometry-based, cell-free, quick, and robust assay to check the quality of MHC monomers directly after refolding or after long-term storage.	[Chandran, P. Anoop; Heidu, Sonja; Zelba, Henning; Rammensee, Hans-Georg; Gouttefangeas, Cecile] Eberhard Karls Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Tubingen, Germany; [Chandran, P. Anoop; Heidu, Sonja; Zelba, Henning; Rammensee, Hans-Georg; Gouttefangeas, Cecile] German Canc Consortium DKTK, German Canc Res Ctr DKFZ Partner Site Tuebinge, Partner Site Tuebingen, Tubingen, Germany; [Schmid-Horch, Barbara] Univ Hosp, Ctr Clin Transfus Med GmbH, Tubingen, Germany; [Pascolo, Steve] Univ Hosp, Dept Dermatol, Zurich, Switzerland	Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Zurich; University Zurich Hospital	Chandran, PA; Gouttefangeas, C (corresponding author), Eberhard Karls Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Tubingen, Germany.; Chandran, PA; Gouttefangeas, C (corresponding author), German Canc Consortium DKTK, German Canc Res Ctr DKFZ Partner Site Tuebinge, Partner Site Tuebingen, Tubingen, Germany.	chandran.anoop@ifiz.uni-tuebingen.de; cecile.gouttefangeas@uni-tuebingen.de			Deutsche Forschungsgemeinschaft [SFB685]; DKTK; ERC grant (Mutaediting); Wallace Coulter Foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DKTK; ERC grant (Mutaediting); Wallace Coulter Foundation	CG and PAC are supported by the Deutsche Forschungsgemeinschaft, SFB685 project Z05, H-GR by the DKTK, and the ERC grant (Mutaediting) and CG by the Wallace Coulter Foundation.	Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Andersen RS, 2012, NAT PROTOC, V7, P891, DOI 10.1038/nprot.2012.037; Barnes E, 2004, EUR J IMMUNOL, V34, P1570, DOI 10.1002/eji.200424898; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Blanchfield JL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00170; Chandran PA, 2018, CYTOM PART B-CLIN CY, V94, P342, DOI 10.1002/cyto.b.21397; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Hadrup SR, 2015, CYTOM PART A, V87A, P37, DOI 10.1002/cyto.a.22575; Hadrup SR, 2009, METHODS MOL BIOL, V524, P383, DOI 10.1007/978-1-59745-450-6_28; Hutter H, 1996, CELL TISSUE RES, V286, P439, DOI 10.1007/s004410050713; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; PARHAM P, 1979, J IMMUNOL, V123, P342; Peper JK, 2014, J IMMUNOL METHODS, V405, P192, DOI 10.1016/j.jim.2014.01.012; Perosa F, 2003, J IMMUNOL, V171, P1918, DOI 10.4049/jimmunol.171.4.1918; REBAI N, 1983, TISSUE ANTIGENS, V22, P107; Rodenko B, 2006, NAT PROTOC, V1, P1120, DOI 10.1038/nprot.2006.121; Seitz C, 1998, MOL IMMUNOL, V35, P819, DOI 10.1016/S0161-5890(98)00077-7; Shi Y, 1998, J IMMUNOL, V160, P4305; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; STAM NJ, 1986, J IMMUNOL, V137, P2299; Walter S, 2003, J IMMUNOL, V171, P4974, DOI 10.4049/jimmunol.171.10.4974; Wooldridge L, 2009, IMMUNOLOGY, V126, P147, DOI 10.1111/j.1365-2567.2008.02848.x	24	2	2	0	8	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 8	2017	8								96	10.3389/fimmu.2017.00096	http://dx.doi.org/10.3389/fimmu.2017.00096			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EJ8WG	28228758	gold, Green Published			2022-12-18	WOS:000393507100001
J	Bodor, J				Bodor, Josef			Editorial: The Molecular Mechanisms of Cyclic AMP in Regulation of Immunity and Tolerance	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cyclic AMP; inducible cAMP early repressor; interleukin-2; CD28-responsive element; conventional CD4(+) T cells; naturally occurring regulatory CD4(+) CD25(+) T cells; graft-versus-host disease	TRANSCRIPTIONAL REPRESSOR ICER; T-CELL FUNCTION; SUPPRESSION; IL-2; INDUCIBILITY; ATTENUATION; EXPRESSION; PROMOTER; BINDING; PROTEIN		[Bodor, Josef] BIOCEV, Vestec, Czech Republic; [Bodor, Josef] Johannes Gutenberg Univ Mainz, Inst Immunol, Mainz, Germany	Johannes Gutenberg University of Mainz	Bodor, J (corresponding author), BIOCEV, Vestec, Czech Republic.; Bodor, J (corresponding author), Johannes Gutenberg Univ Mainz, Inst Immunol, Mainz, Germany.	bodor@uni-mainz.de						Barabitskaja O, 2006, J LEUKOCYTE BIOL, V79, P378, DOI 10.1189/jlb.0505255; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; Bodor J, 2000, J LEUKOCYTE BIOL, V67, P774, DOI 10.1002/jlb.67.6.774; Bodor J, 2007, EUR J IMMUNOL, V37, P884, DOI 10.1002/eji.200636510; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Gogishvili T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004643; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Powell JD, 1999, J IMMUNOL, V163, P6631; Sumpter TL, 2008, J LEUKOCYTE BIOL, V83, P708, DOI 10.1189/jlb.0507321; Vaeth M, 2011, P NATL ACAD SCI USA, V108, P2480, DOI 10.1073/pnas.1009463108; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042	17	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 6	2017	8								76	10.3389/fimmu.2017.00076	http://dx.doi.org/10.3389/fimmu.2017.00076			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EJ7XW	28220119	Green Published, gold			2022-12-18	WOS:000393437000001
J	Detanico, T; Phillips, M; Wysocki, LJ				Detanico, Thiago; Phillips, Matthew; Wysocki, Lawrence J.			Functional Versatility of AGY Serine Codons in Immunoglobulin Variable Region Genes	FRONTIERS IN IMMUNOLOGY			English	Article						B cell; V-genes; somatic hypermutation; autoantibodies; antiviral immune response; autoimmunity; lupus erythematosus; systemic	COMPLEMENTARITY-DETERMINING REGION; NEUTRALIZING HIV-1 ANTIBODIES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-DNA AUTOANTIBODY; SINGLE-STRANDED-DNA; B-CELLS; SOMATIC HYPERMUTATION; HEAVY-CHAIN; AUTOIMMUNE ANTIBODIES; BOX PLOTS	In systemic autoimmunity, autoantibodies directed against nuclear antigens (Ags) often arise by somatic hypermutation (SHM) that converts AGT and AGC (AGY) Ser codons into Arg codons. This can occur by three different single-base changes. Curiously, AGY Ser codons are far more abundant in complementarity-determining regions (CDRs) of IgV-region genes than expected for random codon use or from species-specific codon frequency data. CDR AGY codons are also more abundant than TCN Ser codons. We show that these trends hold even in cartilaginous fishes. Because AGC is a preferred target for SHM by activation-induced cytidine deaminase, we asked whether the AGY abundance was solely due to a selection pressure to conserve high mutability in CDRs regardless of codon context but found that this was not the case. Instead, AGY triplets were selectively enriched in the Ser codon reading frame. Motivated by reports implicating a functional role for poly/autoreactive specificities in antiviral antibodies, we also analyzed mutations at AGY in antibodies directed against a number of different viruses and found that mutations producing Arg codons in antiviral antibodies were indeed frequent. Unexpectedly, however, we also found that AGY codons mutated often to encode nearly all of the amino acids that are reported to provide the most frequent contacts with Ag. In many cases, mutations producing codons for these alternative amino acids in antiviral antibodies were more frequent than those producing Arg codons. Mutations producing each of these key amino acids required only single-base changes in AGY. AGY is the only codon group in which two-thirds of random mutations generate codons for these key residues. Finally, by directly analyzing X-ray structures of immune complexes from the RCSB protein database, we found that Ag-contact residues generated via SHM occurred more often at AGY than at any other codon group. Thus, preservation of AGY codons in antibody genes appears to have been driven by their exceptional functional versatility, despite potential autoreactive consequences.	[Detanico, Thiago; Phillips, Matthew; Wysocki, Lawrence J.] Natl Jewish Hlth, Dept Biomed Res, Denver, CO 80206 USA; [Wysocki, Lawrence J.] Univ Colorado, Sch Med, Dept Immunol, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Detanico, T (corresponding author), Natl Jewish Hlth, Dept Biomed Res, Denver, CO 80206 USA.	detanicot@njhealth.org			National Institutes of Health [R01AI093822]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI093822] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by grant R01AI093822 from the National Institutes of Health.	Bonsignori M, 2014, J CLIN INVEST, V124, P1835, DOI 10.1172/JCI73441; Branden C, 1991, INTRO PROTEIN STRUCT, Vxv; CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; Chen Y, 2013, J IMMUNOL, V191, P1260, DOI 10.4049/jimmunol.1300770; Cooper MD, 2006, CELL, V124, P815, DOI 10.1016/j.cell.2006.02.001; Creighton T.E, 1993, PROTEINS STRUCTURES, Vxiii; Detanico T, 2015, J AUTOIMMUN, V58, P67, DOI 10.1016/j.jaut.2015.01.006; Doyle-Cooper C, 2013, J IMMUNOL, V191, P3186, DOI 10.4049/jimmunol.1301285; Goyenechea B, 1996, P NATL ACAD SCI USA, V93, P13979, DOI 10.1073/pnas.93.24.13979; Guo WZ, 2010, J EXP MED, V207, P2225, DOI 10.1084/jem.20092712; Guth AM, 2003, J IMMUNOL, V171, P6260, DOI 10.4049/jimmunol.171.11.6260; Haley J, 2004, MOL IMMUNOL, V40, P745, DOI 10.1016/j.molimm.2003.10.018; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Hsu E, 2006, IMMUNOL REV, V210, P8, DOI 10.1111/j.0105-2896.2006.00366.x; Jang YJ, 1998, MOL IMMUNOL, V35, P1207, DOI 10.1016/S0161-5890(98)00095-9; Jolly C J, 1996, Semin Immunol, V8, P159, DOI 10.1006/smim.1996.0020; Krishnan MR, 1996, J IMMUNOL, V157, P2430; Krzywinski M, 2014, NAT METHODS, V11, P119, DOI 10.1038/nmeth.2813; Lefranc MP, 1997, IMMUNOL TODAY, V18, P509, DOI 10.1016/S0167-5699(97)01163-8; Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109; Li ZD, 2000, EUR J IMMUNOL, V30, P2015, DOI 10.1002/1521-4141(200007)30:7<2015::AID-IMMU2015>3.0.CO;2-5; Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053; Liu MF, 2015, J VIROL, V89, P784, DOI 10.1128/JVI.02378-14; Mietzner B, 2008, P NATL ACAD SCI USA, V105, P9727, DOI 10.1073/pnas.0803644105; Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Raghunathan G, 2012, J MOL RECOGNIT, V25, P103, DOI 10.1002/jmr.2158; Rahman A, 2001, J MOL BIOL, V307, P149, DOI 10.1006/jmbi.2000.4491; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Schroeder K, 2013, AUTOIMMUNITY, V46, P121, DOI 10.3109/08916934.2012.748751; Shapiro GS, 2003, MOL IMMUNOL, V40, P287, DOI 10.1016/S0161-5890(03)00101-9; Shapiro GS, 2002, J IMMUNOL, V168, P2302, DOI 10.4049/jimmunol.168.5.2302; Shapiro GS, 2002, CRIT REV IMMUNOL, V22, P183; Silva-Sanchez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118171; Smith DS, 1996, J IMMUNOL, V156, P2642; Spitzer M, 2014, NAT METHODS, V11, P121, DOI 10.1038/nmeth.2811; Tanner JJ, 2001, J MOL BIOL, V314, P807, DOI 10.1006/jmbi.2001.5178; Tucker RM, 2004, ARTHRITIS RHEUM-US, V50, P3626, DOI 10.1002/art.20623; Verkoczy L, 2011, J IMMUNOL, V187, P3785, DOI 10.4049/jimmunol.1101633; Verkoczy L, 2010, P NATL ACAD SCI USA, V107, P181, DOI 10.1073/pnas.0912914107; WAGNER SD, 1995, NATURE, V376, P732, DOI 10.1038/376732a0; Wei LR, 2015, P NATL ACAD SCI USA, V112, pE728, DOI 10.1073/pnas.1500788112; Wellmann U, 2005, P NATL ACAD SCI USA, V102, P9258, DOI 10.1073/pnas.0500132102; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; Yang G, 2013, J EXP MED, V210, P241, DOI 10.1084/jem.20121977; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; Zhang J, 2008, MOL MED, V14, P675, DOI 10.2119/2008-00066.Zhang	50	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 22	2016	7								525	10.3389/fimmu.2016.00525	http://dx.doi.org/10.3389/fimmu.2016.00525			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EC4UJ	27920779	gold, Green Published			2022-12-18	WOS:000388129300001
J	Arciero, JC; Maturo, A; Arun, A; Oh, BC; Brandacher, G; Raimondi, G				Arciero, Julia C.; Maturo, Andrew; Arun, Anirudh; Oh, Byoung Chol; Brandacher, Gerald; Raimondi, Giorgio			Combining Theoretical and Experimental Techniques to Study Murine Heart Transplant Rejection	FRONTIERS IN IMMUNOLOGY			English	Article						mathematical model; transplant; rejection; immune response; antigen-presenting cells; T cells; cytokines	REGULATORY T-CELLS; CARDIAC ALLOGRAFT-REJECTION; SOLID-ORGAN TRANSPLANTATION; ACUTE INFLAMMATORY RESPONSE; REDUCED MATHEMATICAL-MODEL; IMMUNE-RESPONSE; IN-VIVO; MEDIATED SUPPRESSION; MONOCLONAL-ANTIBODY; SELF-RECOGNITION	The quality of life of organ transplant recipients is compromised by complications associated with life-long immunosuppression, such as hypertension, diabetes, opportunistic infections, and cancer. Moreover, the absence of established tolerance to the transplanted tissues causes limited long-term graft survival rates. Thus, there is a great medical need to understand the complex immune system interactions that lead to transplant rejection so that novel and effective strategies of intervention that redirect the system toward transplant acceptance (while preserving overall immune competence) can be identified. This study implements a systems biology approach in which an experimentally based mathematical model is used to predict how alterations in the immune response influence the rejection of mouse heart transplants. Five stages of conventional mouse heart transplantation are modeled using a system of 13 ordinary differential equations that tracks populations of both innate and adaptive immunity as well as proxies for pro- and anti-inflammatory factors within the graft and a representative draining lymph node. The model correctly reproduces known experimental outcomes, such as indefinite survival of the graft in the absence of CD4(+) T cells and quick rejection in the absence of CD8(+) T cells. The model predicts that decreasing the translocation rate of effector cells from the lymph node to the graft delays transplant rejection. Increasing the starting number of quiescent regulatory T cells in the model yields a significant but somewhat limited protective effect on graft survival. Surprisingly, the model shows that a delayed appearance of alloreactive T cells has an impact on graft survival that does not correlate linearly with the time delay. This computational model represents one of the first comprehensive approaches toward simulating the many interacting components of the immune system. Despite some limitations, the model provides important suggestions of experimental investigations that could improve the understanding of rejection. Overall, the systems biology approach used here is a first step in predicting treatments and interventions that can induce transplant tolerance while preserving the capacity of the immune system to protect against legitimate pathogens.	[Arciero, Julia C.; Maturo, Andrew] Indiana Univ Purdue Univ, Dept Math Sci, Indianapolis, IN 46202 USA; [Arun, Anirudh; Oh, Byoung Chol; Brandacher, Gerald; Raimondi, Giorgio] Johns Hopkins Sch Med, Dept Plast & Reconstruct Surg, Vascularized & Composite Allotransplantat Lab, Baltimore, MD 21205 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Johns Hopkins University; Johns Hopkins Medicine	Arciero, JC (corresponding author), Indiana Univ Purdue Univ, Dept Math Sci, Indianapolis, IN 46202 USA.; Raimondi, G (corresponding author), Johns Hopkins Sch Med, Dept Plast & Reconstruct Surg, Vascularized & Composite Allotransplantat Lab, Baltimore, MD 21205 USA.	jarciero@iupui.edu; g.raimondi@jhmi.edu		Brandacher, Gerald/0000-0001-7790-441X	Burroughs Wellcome Fund Collaborative Research Travel Grant [BWF 1014050]; IUPUI School of Science Institute for Mathematical Modeling and Computational Science Grant; National Institutes of Health [UL1TR000005];  [R21HL127355]	Burroughs Wellcome Fund Collaborative Research Travel Grant(Burroughs Wellcome Fund); IUPUI School of Science Institute for Mathematical Modeling and Computational Science Grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 	This work was supported by a Burroughs Wellcome Fund BWF 1014050 Collaborative Research Travel Grant (to JA), the IUPUI School of Science Institute for Mathematical Modeling and Computational Science Grant to Enhance Interdisciplinary Research and Education (iM2CS-GEIRE) award (to JA), a National Institutes of Health grant number UL1TR000005 in the form of a CTSI-PEIR (to GR), and grant number R21HL127355 (to GR).	Adams AB, 2005, J IMMUNOL, V174, P542, DOI 10.4049/jimmunol.174.1.542; An G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00561; Arciero JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010066; Bingaman AW, 2000, J IMMUNOL, V164, P3065, DOI 10.4049/jimmunol.164.6.3065; BRANDWOOD A, 1992, BIOMATERIALS, V13, P646, DOI 10.1016/0142-9612(92)90035-M; CAPLAN AL, 1983, HASTINGS CENT REP, V13, P23, DOI 10.2307/3560741; Caridade M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00378; Catron DM, 2004, IMMUNITY, V21, P341, DOI 10.1016/j.immuni.2004.08.007; Chalasani G, 2004, J IMMUNOL, V172, P7813, DOI 10.4049/jimmunol.172.12.7813; Chong AS, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a015495; Chong AS, 2012, NAT REV IMMUNOL, V12, P459, DOI 10.1038/nri3215; Dai ZH, 1999, CURR OPIN IMMUNOL, V11, P504, DOI 10.1016/S0952-7915(99)00008-4; Day J, 2006, J THEOR BIOL, V242, P237, DOI 10.1016/j.jtbi.2006.02.015; Day JD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00484; De Boer RJ, 2003, J IMMUNOL, V171, P3928, DOI 10.4049/jimmunol.171.8.3928; Doevendans PA, 1998, CARDIOVASC RES, V39, P34, DOI 10.1016/S0008-6363(98)00073-X; Filatenkov AA, 2005, J IMMUNOL, V174, P6909, DOI 10.4049/jimmunol.174.11.6909; Fu HM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4436; Giannoudis PV, 2008, J TRAUMA, V65, P646, DOI 10.1097/TA.0b013e3181820d48; Gratz IK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00333; Hancock WW, 2003, IMMUNOL REV, V196, P37, DOI 10.1046/j.1600-065X.2003.00084.x; Hancock WW, 2003, CURR OPIN IMMUNOL, V15, P479, DOI 10.1016/S0952-7915(03)00103-1; He G, 1999, TRANSPLANTATION, V67, P131, DOI 10.1097/00007890-199901150-00022; He HZ, 2002, TRANSPLANTATION, V73, P853, DOI 10.1097/00007890-200203270-00005; Heeger PS, 2003, AM J TRANSPLANT, V3, P525, DOI 10.1034/j.1600-6143.2003.00123.x; Joffre O, 2008, NAT MED, V14, P88, DOI 10.1038/nm1688; Kim PS, 2007, J THEOR BIOL, V246, P33, DOI 10.1016/j.jtbi.2006.12.012; Kim PS, 2009, METHOD ENZYMOL, V467, P79, DOI 10.1016/S0076-6879(09)67004-X; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirschner DE, 2007, IMMUNOL REV, V216, P93; Krieger NR, 1997, J HEART LUNG TRANSPL, V16, P263; Krieger NR, 1996, J EXP MED, V184, P2013, DOI 10.1084/jem.184.5.2013; Kronik N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015482; Lee HY, 2009, J VIROL, V83, P7151, DOI 10.1128/JVI.00098-09; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Leon K, 2000, J THEOR BIOL, V207, P231, DOI 10.1006/jtbi.2000.2169; Leon K, 1998, J THEOR BIOL, V193, P519, DOI 10.1006/jtbi.1998.0720; Leventhal J, 2013, TRANSPLANTATION, V95, P169, DOI 10.1097/TP.0b013e3182782fc1; Levisetti MG, 1997, J IMMUNOL, V159, P5187; Liang Y, 2007, TRANSPLANTATION, V84, P771, DOI 10.1097/01.tp.0000281384.24333.0b; Linderman JJ, 2010, J IMMUNOL, V184, P2873, DOI 10.4049/jimmunol.0903117; Malliaras K, 2013, EMBO MOL MED, V5, P191, DOI 10.1002/emmm.201201737; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mori DN, 2014, IMMUNOL REV, V258, P132, DOI 10.1111/imr.12146; Murray PJ, 2012, NAT IMMUNOL, V13, P916, DOI 10.1038/ni.2391; O'Gorman WE, 2009, J IMMUNOL, V183, P332, DOI 10.4049/jimmunol.0900691; Oberbarnscheidt MH, 2014, J CLIN INVEST, V124, P3579, DOI 10.1172/JCI74370; PEARSON TC, 1994, TRANSPLANTATION, V57, P1701, DOI 10.1097/00007890-199457120-00002; Pearson TC, 1997, TRANSPLANTATION, V63, P1463, DOI 10.1097/00007890-199705270-00016; Pietra BA, 2000, J CLIN INVEST, V106, P1003, DOI 10.1172/JCI10467; Raimondi G, 2010, J IMMUNOL, V184, P624, DOI 10.4049/jimmunol.0900936; Regoes RR, 2007, P NATL ACAD SCI USA, V104, P1599, DOI 10.1073/pnas.0508830104; Regoes RR, 2007, IMMUNOL CELL BIOL, V85, P274, DOI 10.1038/sj.icb.7100053; Reynolds A, 2006, J THEOR BIOL, V242, P220, DOI 10.1016/j.jtbi.2006.02.016; Riella LV, 2013, EXPERT OPIN BIOL TH, V13, P1557, DOI 10.1517/14712598.2013.845661; Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002; Sachs DH, 2011, SEMIN IMMUNOL, V23, P165, DOI 10.1016/j.smim.2011.07.001; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; Setoguchi K, 2011, AM J TRANSPLANT, V11, P923, DOI 10.1111/j.1600-6143.2011.03492.x; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Su CA, 2014, AM J TRANSPLANT, V14, P568, DOI 10.1111/ajt.12605; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Tanaka M, 2005, CIRCULATION, V112, pI105, DOI 10.1161/CIRCULATIONAHA.104.524777; Tang QZ, 2012, CURR OPIN ORGAN TRAN, V17, P349, DOI 10.1097/MOT.0b013e328355a992; Tchao NK, 2012, AM J TRANSPLANT, V12, P1079, DOI 10.1111/j.1600-6143.2012.04008.x; Tirziu D, 2010, CIRCULATION, V122, P928, DOI 10.1161/CIRCULATIONAHA.108.847731; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Turnquist HR, 2007, J IMMUNOL, V178, P7018, DOI 10.4049/jimmunol.178.11.7018; van der Net JB, 2016, TRANSPL INT, V29, P3, DOI 10.1111/tri.12608; van Maurik A, 2002, J IMMUNOL, V169, P5401; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vincenti F, 2011, NAT REV DRUG DISCOV, V10, P655, DOI 10.1038/nrd3536; Vu MD, 2004, J IMMUNOL, V173, P214, DOI 10.4049/jimmunol.173.1.214; Walsh PT, 2004, IMMUNITY, V20, P121, DOI 10.1016/S1074-7613(04)00024-X; Wang J, 2008, TRANSPL P, V40, P1612, DOI 10.1016/j.transproceed.2008.02.079; Wood KJ, 2012, NAT REV IMMUNOL, V12, P417, DOI 10.1038/nri3227; Wood KJ, 2012, TRANSPLANTATION, V93, P1, DOI 10.1097/TP.0b013e31823cab44; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Zecher D, 2012, TRANSPL IMMUNOL, V26, P113, DOI 10.1016/j.trim.2011.12.006; Zhang N, 2009, IMMUNITY, V30, P458, DOI 10.1016/j.immuni.2008.12.022	81	2	2	0	9	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 7	2016	7								448	10.3389/fimmu.2016.00448	http://dx.doi.org/10.3389/fimmu.2016.00448			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EA9YQ	27872621	gold, Green Published			2022-12-18	WOS:000387001000001
J	Londono-Renteria, B; Cardenas, JC; Troupin, A; Colpitts, TM				Londono-Renteria, Berlin; Cardenas, Jenny C.; Troupin, Andrea; Colpitts, Tonya M.			Natural Mosquito-Pathogen Hybrid IgG4 Antibodies in Vector-Borne Diseases: A Hypothesis	FRONTIERS IN IMMUNOLOGY			English	Article						IgG4; bi-specific; arthropod saliva; vector-borne diseases; malaria; dengue virus; mosquito	SALIVARY PROTEIN; CUTANEOUS LEISHMANIASIS; IMMUNE-RESPONSE; PLASMODIUM-FALCIPARUM; IMMUNOGLOBULIN G4; IGG4-RELATED LYMPHADENOPATHY; LUTZOMYIA-LONGIPALPIS; SUBCLASS DISTRIBUTION; PHLEBOTOMUS-PAPATASI; INFECTIOUS-DISEASES	Chronic exposure to antigens may favor the production of IgG4 antibodies over other antibody types. Recent studies have shown that up to a 30% of normal human IgG4 is bi-specific and is able to recognize two antigens of different nature. A requirement for this specificity is the presence of both eliciting antigens in the same time and at the same place where the immune response is induced. During transmission of most vector-borne diseases, the pathogen is delivered to the vertebrate host along with the arthropod saliva during blood feeding and previous studies have shown the existence of IgG4 antibodies against mosquito salivary allergens. However, there is very little ongoing research or information available regarding IgG4 bi-specificity with regard to infectious disease, particularly during immune responses to vector-borne diseases, such as malaria, filariasis, or dengue virus infection. Here, we provide background information and present our hypothesis that IgG4 may not only be a useful tool to measure exposure to infected mosquito bites, but that these bi-specific antibodies may also play an important role in modulation of the immune response against malaria and other vector-borne diseases in endemic settings.	[Londono-Renteria, Berlin; Troupin, Andrea; Colpitts, Tonya M.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Cardenas, Jenny C.] Hosp Los Patios, Clin Lab, Los Patios, Colombia	University of South Carolina System; University of South Carolina Columbia	Londono-Renteria, B (corresponding author), Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.	blondono@uscmed.sc.edu	Londono, Berlin/I-8830-2019	Londono, Berlin/0000-0001-5956-5274; Colpitts, Tonya/0000-0003-3915-1554	Universidad de Pamplona "50th anniversary Grant"	Universidad de Pamplona "50th anniversary Grant"	Universidad de Pamplona "50th anniversary Grant" (2010).	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Abbas A, 2005, BIOMED PHARMACOTHER, V59, P38, DOI 10.1016/j.biopha.2004.07.001; Abdeladhim M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001345; Adjobimey T, 2010, ANN TROP MED PARASIT, V104, P455, DOI 10.1179/136485910X12786389891407; Akue JP, 2002, AM J TROP MED HYG, V66, P245, DOI 10.4269/ajtmh.2002.66.245; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Ansari NA, 2008, PARASITE IMMUNOL, V30, P403, DOI 10.1111/j.1365-3024.2008.01036.x; Antonio-Nkondjio C, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-275; Banerjee K, 2010, AIDS RES HUM RETROV, V26, P445, DOI 10.1089/aid.2009.0223; Beeson JG, 2016, FEMS MICROBIOL REV, V40, P343, DOI 10.1093/femsre/fuw001; Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941; Bhowmick S, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-8; Biswas G, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0146; Bizzarro B, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-329; BOCTOR FN, 1989, J VIROL METHODS, V26, P305, DOI 10.1016/0166-0934(89)90112-2; Boppana VD, 2009, PARASITE IMMUNOL, V31, P287, DOI 10.1111/j.1365-3024.2009.01096.x; Boraschi D, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000255; BOUHAROUNTAYOUN H, 1992, INFECT IMMUN, V60, P1473, DOI 10.1128/IAI.60.4.1473-1481.1992; Brattig NW, 2010, PARASITOL RES, V107, P657, DOI 10.1007/s00436-010-1912-0; Briant L, 2014, VIROLOGY, V464, P26, DOI 10.1016/j.virol.2014.06.023; BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4; Carvalho AM, 2015, J INFECT DIS, V212, P157, DOI 10.1093/infdis/jiv020; Cavacini LA, 2003, AIDS RES HUM RETROV, V19, P785, DOI 10.1089/088922203769232584; Chisenhall DM, 2014, AM J TROP MED HYG, V90, P431, DOI 10.4269/ajtmh.13-0412; Choffnes ER, 2011, SCI APPL SYNTHETIC S; COBRA C, 1995, AM J EPIDEMIOL, V142, P1204, DOI 10.1093/oxfordjournals.aje.a117579; Colpitts TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024365; Conway MJ, 2014, J VIROL, V88, P164, DOI 10.1128/JVI.02235-13; Cu LW, 2015, AM J TROP MED HYG, V93, P57, DOI 10.4269/ajtmh.15-0007; da Matta VLR, 2000, J CLIN LAB ANAL, V14, P5, DOI 10.1002/(SICI)1098-2825(2000)14:1&lt;5::AID-JCLA2&gt;3.0.CO;2-F; Daeron M, 2008, IMMUNOL REV, V224, P11, DOI 10.1111/j.1600-065X.2008.00666.x; Dandapat M C, 1986, J Indian Med Assoc, V84, P210; Davies AM, 2014, J MOL BIOL, V426, P630, DOI 10.1016/j.jmb.2013.10.039; Davies AM, 2013, MOL IMMUNOL, V54, P1, DOI 10.1016/j.molimm.2012.10.029; de Martino M, 1999, ANN ALLERG ASTHMA IM, V83, P160, DOI 10.1016/S1081-1206(10)62629-4; de Moura TR, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000084; de Moura TR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002242; de Moura TR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000712; Di Lella F, 2006, INT J ORAL MAX SURG, V35, P870, DOI 10.1016/j.ijom.2006.02.015; DIAZ LA, 1989, J INVEST DERMATOL, V92, P4, DOI 10.1111/1523-1747.ep13070394; Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08; Douba MD, 2012, J EUR ACAD DERMATOL, V26, P1224, DOI 10.1111/j.1468-3083.2011.04266.x; Drame PM, 2010, AM J TROP MED HYG, V83, P115, DOI 10.4269/ajtmh.2010.09-0684; Epelboin L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-142; Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235; Franco-Paredes C, 2006, LANCET INFECT DIS, V6, P139, DOI 10.1016/S1473-3099(06)70410-8; Galatas B, 2016, TRENDS PARASITOL, V32, P296, DOI 10.1016/j.pt.2015.11.015; GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58; Geisberger R, 2006, IMMUNOLOGY, V118, P429, DOI 10.1111/j.1365-2567.2006.02386.x; Geraci NS, 2014, AM J TROP MED HYG, V90, P923, DOI 10.4269/ajtmh.13-0130; GLIGIC A, 1989, AM J TROP MED HYG, V41, P102, DOI 10.4269/ajtmh.1989.41.102; Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023; Gubler DJ, 1998, EMERG INFECT DIS, V4, P442, DOI 10.3201/eid0403.980326; GUTIERREZ Y, 1991, AM J TROP MED HYG, V45, P281, DOI 10.4269/ajtmh.1991.45.281; Hailu A, 2001, J INFECT DIS, V184, P112, DOI 10.1086/320994; HALDAR JP, 1983, INFECT IMMUN, V42, P702, DOI 10.1128/IAI.42.2.702-707.1983; HALL LR, 1995, J IMMUNOL, V155, P3501; Hemingway J, 2000, ANNU REV ENTOMOL, V45, P371, DOI 10.1146/annurev.ento.45.1.371; Hoerauf A, 2005, PARASITE IMMUNOL, V27, P417, DOI 10.1111/j.1365-3024.2005.00792.x; Hopp CS, 2015, ANN NY ACAD SCI, V1342, P37, DOI 10.1111/nyas.12661; Hotez PJ, 2009, LANCET, V373, P1570, DOI 10.1016/S0140-6736(09)60233-6; Howden BP, 2005, MED J AUSTRALIA, V182, P186, DOI 10.5694/j.1326-5377.2005.tb06652.x; HUSSAIN R, 1986, J IMMUNOL, V136, P1859; Hwang JK, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.MDNA3-0037-2014; James LK, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0600-2; Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351; KETTLEBOROUGH CA, 1993, EUR J IMMUNOL, V23, P206, DOI 10.1002/eji.1830230132; Kling JC, 2013, INT J PARASITOL, V43, P417, DOI 10.1016/j.ijpara.2013.02.001; Kontermann RE, 2015, DRUG DISCOV TODAY, V20, P838, DOI 10.1016/j.drudis.2015.02.008; Kuhn RJ, 2015, VIROLOGY, V479, P508, DOI 10.1016/j.virol.2015.03.025; KURNIAWAN A, 1993, J IMMUNOL, V150, P3941; Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205; Lawaly R, 2012, INFECT IMMUN, V80, P2240, DOI 10.1128/IAI.06414-11; Leitner WW, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00255; Leitner WW, 2011, EUR J IMMUNOL, V41, P3396, DOI 10.1002/eji.201190075; Li WL, 2014, J CLIN ENDOCR METAB, V99, pE1602, DOI 10.1210/jc.2013-4108; LIEVENS MM, 1989, J CLIN CHEM CLIN BIO, V27, P519; Lin JT, 2014, TRENDS PARASITOL, V30, P183, DOI 10.1016/j.pt.2014.02.004; Lindblade KA, 2013, EXPERT REV ANTI-INFE, V11, P623, DOI [10.1586/eri.13.45, 10.1586/ERI.13.45]; Lombardo F, 2009, INSECT BIOCHEM MOLEC, V39, P457, DOI 10.1016/j.ibmb.2009.04.006; Londono-Renteria B., 2014, AM J TROP MED HYG, V91, P1; Londono-Renteria B, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1160-3; Londono-Renteria B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081211; Londono-Renteria BL, 2010, J MED ENTOMOL, V47, P1156, DOI 10.1603/ME09240; LYAMUYA EF, 1994, E AFR MED J, V71, P24; Machain-Williams C, 2012, PARASITE IMMUNOL, V34, P15, DOI 10.1111/j.1365-3024.2011.01339.x; Marie A, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0599-y; Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226; Morrison J, 2012, VIRUSES-BASEL, V4, P397, DOI 10.3390/v4030397; MULLER F, 1989, CLIN EXP IMMUNOL, V78, P153; Mussi ADH, 2007, ACTA TROP, V104, P108, DOI 10.1016/j.actatropica.2007.07.011; Newby G, 2016, LANCET, V387, P1775, DOI 10.1016/S0140-6736(16)00230-0; Ockenfels B, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003197; Okorie PN, 2016, T ROY SOC TROP MED H, V110, P90, DOI 10.1093/trstmh/trv104; Otabil KB, 2015, J INFECT DEV COUNTR, V9, P456, DOI 10.3855/jidc.5346; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; Ozdemir Cevdet, 2008, Allergy Asthma Clin Immunol, V4, P106, DOI 10.1186/1710-1492-4-3-106; Palosuo K, 1997, INT ARCH ALLERGY IMM, V114, P367, DOI 10.1159/000237696; PANG T, 1987, BIOESSAYS, V6, P141, DOI 10.1002/bies.950060311; Patsatsi A, 2014, ACTA DERM-VENEREOL, V94, P203, DOI 10.2340/00015555-1666; Pfarr KM, 2009, PARASITE IMMUNOL, V31, P664, DOI 10.1111/j.1365-3024.2009.01133.x; Pinkevych M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002729; Poinsignon A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-198; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Qian Y, 2012, J IMMUNOL, V189, P1535, DOI 10.4049/jimmunol.1200842; Qureshi AA, 1996, AM J TROP MED HYG, V54, P665, DOI 10.4269/ajtmh.1996.54.665; Raux M, 2000, AIDS RES HUM RETROV, V16, P583, DOI 10.1089/088922200309007; Ready PD, 2014, CLIN EPIDEMIOL, V6, P147, DOI 10.2147/CLEP.S44267; Ready PD, 2013, ANNU REV ENTOMOL, V58, P227, DOI 10.1146/annurev-ento-120811-153557; Recker M, 2004, NATURE, V429, P555, DOI 10.1038/nature02486; REUNALA T, 1994, INT ARCH ALLERGY IMM, V104, P366, DOI 10.1159/000236693; RIBEIRO JMC, 1984, J EXP BIOL, V108, P1; Ribeiro JMC, 2010, INSECT BIOCHEM MOLEC, V40, P767, DOI 10.1016/j.ibmb.2010.08.002; Riethmuller Gert, 2012, Cancer Immun, V12, P12; RIHET P, 1992, EUR J IMMUNOL, V22, P2063, DOI 10.1002/eji.1830220816; Rispens T, 2013, MOL IMMUNOL, V53, P35, DOI 10.1016/j.molimm.2012.06.012; Rispens T, 2009, J IMMUNOL, V182, P4275, DOI 10.4049/jimmunol.0804338; Rizzo C, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0549-8; Rizzo C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096130; Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S003118200400681X; Sahu PK, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00075; Sarr JB, 2012, T ROY SOC TROP MED H, V106, P460, DOI 10.1016/j.trstmh.2012.05.006; Schmid MA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00647; Schneider BS, 2008, T ROY SOC TROP MED H, V102, P400, DOI 10.1016/j.trstmh.2008.01.024; Schuurman J, 1999, IMMUNOLOGY, V97, P693, DOI 10.1046/j.1365-2567.1999.00845.x; Shiny C, 2009, MICROBIOL IMMUNOL, V53, P685, DOI 10.1111/j.1348-0421.2009.00172.x; Silva LS, 2016, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00103; Takahashi E, 2012, VIRCHOWS ARCH, V460, P225, DOI 10.1007/s00428-011-1186-7; Takeuchi M, 2014, AM J SURG PATHOL, V38, P946, DOI 10.1097/PAS.0000000000000206; Tavares NM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001169; Teixeira C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002781; THEODOS CM, 1993, PARASITE IMMUNOL, V15, P481, DOI 10.1111/j.1365-3024.1993.tb00634.x; Titus RG, 2006, PARASITE IMMUNOL, V28, P131, DOI 10.1111/j.1365-3024.2006.00807.x; Tongren JE, 2005, INFECT IMMUN, V73, P8119, DOI 10.1128/IAI.73.12.8119-8129.2005; ULRICH M, 1995, CLIN EXP IMMUNOL, V100, P54; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415; Wada Y, 2013, MOD RHEUMATOL, V23, P597, DOI 10.1007/s10165-012-0695-9; Wan ZP, 2015, ELIFE, V4, DOI 10.7554/eLife.06925; Wang W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016527; Wang W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010879; Wassmer SC, 2015, AM J TROP MED HYG, V93, P42, DOI 10.4269/ajtmh.14-0841; WHO, 2013, WORLD MALARIA REPORT 2013, P1; WHO, 2009, WHO TECH REP SER, V958, P1; Wu XL, 2000, AIDS RES HUM RETROV, V16, P1423, DOI 10.1089/08892220050140973; Yang XY, 2015, ANAL BIOCHEM, V484, P173, DOI 10.1016/j.ab.2015.06.014; Young E, 2014, IMMUNOLOGY, V142, P406, DOI 10.1111/imm.12265; Zofou D, 2014, INFECT DIS POVERTY, V3, DOI 10.1186/2049-9957-3-1	149	2	3	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2016	7								380	10.3389/fimmu.2016.00380	http://dx.doi.org/10.3389/fimmu.2016.00380			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DX8AX	27746778	Green Published, gold			2022-12-18	WOS:000384611600001
J	Karantanos, T; Christofides, A; Bardhan, K; Li, LQ; Boussiotis, VA				Karantanos, Theodoros; Christofides, Anthos; Bardhan, Kankana; Li, Lequn; Boussiotis, Vassiliki A.			Regulation of T Cell Differentiation and Function by EZH2 (vol 7, pg 172, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						T cells; T cell differentiation; T cell activation; tumor immunity; EZH2			[Karantanos, Theodoros; Christofides, Anthos; Bardhan, Kankana; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Med Sch, Div Hematol Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Karantanos, Theodoros; Christofides, Anthos; Bardhan, Kankana; Li, Lequn; Boussiotis, Vassiliki A.] Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Karantanos, Theodoros] Boston Univ, Sch Med, Boston Med Ctr, Gen Internal Med Sect, Boston, MA 02118 USA; [Boussiotis, Vassiliki A.] Harvard Med Sch, Beth Israel Deaconess Canc Ctr, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston Medical Center; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Boussiotis, VA (corresponding author), Harvard Med Sch, Div Hematol Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.; Boussiotis, VA (corresponding author), Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.; Boussiotis, VA (corresponding author), Harvard Med Sch, Beth Israel Deaconess Canc Ctr, Boston, MA 02115 USA.	vboussio@bidmc.harvard.edu	KARANTANOS, THEODOROS/ABH-7600-2020	KARANTANOS, THEODOROS/0000-0002-6792-8298	NCI NIH HHS [R01 CA183605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA183605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Karantanos T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00172	1	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 14	2016	7								346	10.3389/fimmu.2016.00346	http://dx.doi.org/10.3389/fimmu.2016.00346			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DV6CC	27648006	gold, Green Submitted, Green Published			2022-12-18	WOS:000383017400001
J	Norton, TD; Miller, EA				Norton, Thomas D.; Miller, Elizabeth A.			Recent Advances in Lentiviral Vaccines for HIV-1 Infection (vol 7, 243, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						dendritic cells; lentiviral vectors; HIV-1; HIV-1 vaccines; SAMHD1; Vpx			[Norton, Thomas D.] NYU, Sch Med, Dept Med, Div Infect Dis, New York, NY 10003 USA; [Miller, Elizabeth A.] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA	New York University; Icahn School of Medicine at Mount Sinai	Miller, EA (corresponding author), Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA.	elizabeth.a.miller@mssm.edu						Di Nunzio F, 2012, VACCINE, V30, P2499, DOI 10.1016/j.vaccine.2012.01.089; Norton TD, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00243	2	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 14	2016	7								354	10.3389/fimmu.2016.00354	http://dx.doi.org/10.3389/fimmu.2016.00354			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DV6CE	27630642	Green Published, gold			2022-12-18	WOS:000383017600002
J	Kleiman, E; Salyakina, D; De Heusch, M; Hoek, KL; Llanes, JM; Castro, I; Wright, JA; Clark, ES; Dykxhoorn, DM; Capobianco, E; Takeda, A; McCormack, RM; Podack, ER; Renauld, JC; Khan, WN				Kleiman, Eden; Salyakina, Daria; De Heusch, Magali; Hoek, Kristen L.; Llanes, Joan M.; Castro, Iris; Wright, Jacqueline A.; Clark, Emily S.; Dykxhoorn, Derek M.; Capobianco, Enrico; Takeda, Akiko; McCormack, Ryan M.; Podack, Eckhard R.; Renauld, Jean-Christophe; Khan, Wasif N.			Distinct Transcriptomic Features Are Associated with Transitional and Mature B-Cell Populations in the Mouse Spleen (vol 6, 30, 2015)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Kleiman, Eden; Castro, Iris; Wright, Jacqueline A.; Clark, Emily S.; McCormack, Ryan M.; Podack, Eckhard R.; Khan, Wasif N.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Salyakina, Daria; Capobianco, Enrico] Univ Miami, Ctr Computat Sci, Miami, FL USA; [De Heusch, Magali; Renauld, Jean-Christophe] Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium; [De Heusch, Magali; Renauld, Jean-Christophe] Catholic Univ Louvain, de Duve Inst, Brussels, Belgium; [Hoek, Kristen L.; Llanes, Joan M.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Dykxhoorn, Derek M.] Univ Miami, Hussman Inst Human Genom, Miami, FL USA; [Takeda, Akiko] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA	University of Miami; University of Miami; Ludwig Institute for Cancer Research; Universite Catholique Louvain; Vanderbilt University; University of Miami; Washington University (WUSTL)	Khan, WN (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.	wnkhan@med.miami.edu	Clark, Emily/GVR-7159-2022; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131; Salyakina, Daria/0000-0003-3283-3691	NIAID NIH HHS [F31 AI106290] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI106290] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Kleiman E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00030	1	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 4	2016	7								267	10.3389/fimmu.2016.00267	http://dx.doi.org/10.3389/fimmu.2016.00267			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DQ3QX	27458457	Green Published, gold			2022-12-18	WOS:000379118100001
J	Blackwell, C				Blackwell, Caroline			Editorial: infection and inflammation: Potential triggers of Sudden infant deaths	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						sudden infant death; infection inflammation; cytokines; genetics; developmental stage			[Blackwell, Caroline] Univ Newcastle, Immunol & Microbiol, New Lambton, NSW, Australia	University of Newcastle	Blackwell, C (corresponding author), Univ Newcastle, Immunol & Microbiol, New Lambton, NSW, Australia.	Caroline.Blackwell@newcastle.edu.au						Froen JF, 2002, ARCH DIS CHILD-FETAL, V87, pF118, DOI 10.1136/fn.87.2.F118	1	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 30	2016	7								120	10.3389/fimmu.2016.00120	http://dx.doi.org/10.3389/fimmu.2016.00120			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DH7EY	27064382	Green Published, gold			2022-12-18	WOS:000372956100001
J	Kamimura, D; Atsumi, T; Stofkova, A; Nishikawa, N; Ohki, T; Suzuki, H; Katsunuma, K; Jiang, JJ; Bando, H; Meng, J; Sabharwal, L; Ogura, H; Hirano, T; Arima, Y; Murakami, M				Kamimura, Daisuke; Atsumi, Toru; Stofkova, Andrea; Nishikawa, Naoki; Ohki, Takuto; Suzuki, Hironao; Katsunuma, Kokichi; Jiang, Jing-jing; Bando, Hidenori; Meng, Jie; Sabharwal, Lavannya; Ogura, Hideki; Hirano, Toshio; Arima, Yasunobu; Murakami, Masaaki			Naive T Cell Homeostasis Regulated by Stress Responses and TCR Signaling	FRONTIERS IN IMMUNOLOGY			English	Review						T cell homeostasis; stress response; TCR signaling; naive T cells; mutagenesis	KDEL RECEPTOR; PROLIFERATION; SURVIVAL; KINASE; COMPETITION; AFFINITY; SPECIFICITY; MICE; IL-7	The survival of naive T cells is believed to require signals from TCR-pMHC interactions and cytokines such as IL-7. In contrast, signals that negatively impact naive T cell survival are less understood. We conducted a forward genetic screening of mice and found a mutant mouse line with reduced number of naive T cells (T-Red mice). T-Red mice have a point mutation in the Kdelr1 gene, and their naive T cells show enhanced integrated stress response (ISR), which eventually induces their apoptosis. Therefore, naive T cells require a KDEL receptor-mediated mechanism that efficiently relieves cellular stress for their survival in vivo. Interestingly, naive T cells expressing TCR with higher affinity/avidity to self-antigens survive in T-Red mice, suggesting the possible link between TCR-mediated survival and ISR-induced apoptosis. In this article, we discuss the regulation of naive T cell homeostasis, keeping special attention on the ISR and TCR signal.	[Kamimura, Daisuke; Atsumi, Toru; Stofkova, Andrea; Nishikawa, Naoki; Ohki, Takuto; Suzuki, Hironao; Jiang, Jing-jing; Bando, Hidenori; Meng, Jie; Sabharwal, Lavannya; Ogura, Hideki; Arima, Yasunobu; Murakami, Masaaki] Hokkaido Univ, Grad Sch Med, Inst Genom Med, Div Mol Neuroimmunol, Sapporo, Hokkaido, Japan; [Kamimura, Daisuke; Atsumi, Toru; Ohki, Takuto; Suzuki, Hironao; Katsunuma, Kokichi; Jiang, Jing-jing; Bando, Hidenori; Meng, Jie; Sabharwal, Lavannya; Ogura, Hideki; Arima, Yasunobu; Murakami, Masaaki] Osaka Univ, Grad Sch Frontier Biosci, WPI Immunol Frontier Res Ctr, Lab Dev Immunol, Suita, Osaka, Japan; [Kamimura, Daisuke; Atsumi, Toru; Ohki, Takuto; Suzuki, Hironao; Katsunuma, Kokichi; Jiang, Jing-jing; Bando, Hidenori; Meng, Jie; Sabharwal, Lavannya; Ogura, Hideki; Arima, Yasunobu; Murakami, Masaaki] Osaka Univ, Grad Sch Med, WPI Immunol Frontier Res Ctr, Lab Dev Immunol, Suita, Osaka, Japan; [Hirano, Toshio] Osaka Univ, Suita, Osaka, Japan	Hokkaido University; Osaka University; Osaka University; Osaka University	Murakami, M (corresponding author), Hokkaido Univ, Grad Sch Med, Inst Genom Med, Div Mol Neuroimmunol, Sapporo, Hokkaido, Japan.	murakami@igm.hokudai.ac.jp	Sabharwal, Lavannya/GRY-6912-2022; Stofkova, Andrea/GQZ-8090-2022	Stofkova, Andrea/0000-0002-6579-6578; , Masaaki/0000-0001-7159-7279; Kamimura, Daisuke/0000-0003-1022-4430	KAKENHI; Takeda Science Foundation; Institute for Fermentation Osaka; Mitsubishi Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Suzuken Memorial Foundation; Japan Prize Foundation; Ono Medical Research Foundation; Kanzawa Medical Research Foundation; Kishimoto Foundation; Nagao Takeshi Research Foundation; Tokyo Medical Research Foundation; JSPS; Grants-in-Aid for Scientific Research [15K15147] Funding Source: KAKEN	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Institute for Fermentation Osaka(Institute for Fermentation (IFO)); Mitsubishi Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Suzuken Memorial Foundation; Japan Prize Foundation(Japan Prize Foundation); Ono Medical Research Foundation; Kanzawa Medical Research Foundation(Kanzawa Medical Research Foundation); Kishimoto Foundation; Nagao Takeshi Research Foundation; Tokyo Medical Research Foundation; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank the excellent assistance by Ms. Chiemi Nakayama and Ms. Satomi Fukumoto (Hokkaido University, Sapporo, Japan). This work was supported by KAKENHI (DK, YA, TA, MM, and TH), Takeda Science Foundation (MM), Institute for Fermentation Osaka (MM), Mitsubishi Foundation (MM), Mochida Memorial Foundation for Medical and Pharmaceutical Research (DK), Suzuken Memorial Foundation (YA), Japan Prize Foundation (YA), Ono Medical Research Foundation (YA), Kanzawa Medical Research Foundation (YA), Kishimoto Foundation (YA), Nagao Takeshi Research Foundation (YA), Tokyo Medical Research Foundation (MM and YA), JSPS Postdoctoral Fellowship for Foreign Researchers (AS), the JST-CREST program (MM and TH), and the Osaka Foundation for the Promotion of Clinical Immunology (MM).	Capitani M, 2009, FEBS LETT, V583, P3863, DOI 10.1016/j.febslet.2009.10.053; Daniels MA, 2006, NATURE, V444, P724, DOI 10.1038/nature05269; den Braber I, 2012, IMMUNITY, V36, P288, DOI 10.1016/j.immuni.2012.02.006; Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018-012-1252-6; Fulton RB, 2015, NAT IMMUNOL, V16, P107, DOI 10.1038/ni.3043; Ge Q, 2004, P NATL ACAD SCI USA, V101, P3041, DOI 10.1073/pnas.0307339101; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hataye J, 2006, SCIENCE, V312, P114, DOI 10.1126/science.1124228; Kamimura D, 2016, INT IMMUNOL, V28, P117, DOI 10.1093/intimm/dxv059; Kamimura D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8474; Kieper WC, 2004, J IMMUNOL, V172, P40, DOI 10.4049/jimmunol.172.1.40; Kimura MY, 2013, NAT IMMUNOL, V14, P143, DOI 10.1038/ni.2494; King C, 2004, CELL, V117, P265, DOI 10.1016/S0092-8674(04)00335-6; Leitao C, 2009, J IMMUNOL, V182, P5232, DOI 10.4049/jimmunol.0804071; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Mandl JN, 2013, IMMUNITY, V38, P263, DOI 10.1016/j.immuni.2012.09.011; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Moses CT, 2003, P NATL ACAD SCI USA, V100, P1185, DOI 10.1073/pnas.0334572100; Ouyang WM, 2013, IMMUNITY, V39, P335, DOI 10.1016/j.immuni.2013.07.016; Papathanasiou P, 2005, ANNU REV GENET, V39, P241, DOI 10.1146/annurev.genet.39.110304.095817; Pulvirenti T, 2008, NAT CELL BIOL, V10, P912, DOI 10.1038/ncb1751; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Raykhel I, 2007, J CELL BIOL, V179, P1193, DOI 10.1083/jcb.200705180; Sawa S, 2006, J EXP MED, V203, P1459, DOI 10.1084/jem.20052187; Scheel AA, 1998, J BIOL CHEM, V273, P2467, DOI 10.1074/jbc.273.4.2467; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Sprent J, 2011, NAT IMMUNOL, V12, P478, DOI 10.1038/ni.2018; Stepanek O, 2014, CELL, V159, P333, DOI 10.1016/j.cell.2014.08.042; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Takada K, 2009, NAT REV IMMUNOL, V9, P823, DOI 10.1038/nri2657; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; Troy AE, 2003, J IMMUNOL, V170, P672, DOI 10.4049/jimmunol.170.2.672; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yamamoto K, 2003, J BIOL CHEM, V278, P34525, DOI 10.1074/jbc.M304188200; Zehn D, 2009, NATURE, V458, P211, DOI 10.1038/nature07657	40	2	2	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 17	2015	6								638	10.3389/fimmu.2015.00638	http://dx.doi.org/10.3389/fimmu.2015.00638			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CZ1CL	26734005	Green Published, gold			2022-12-18	WOS:000366843200001
J	Moser, B				Moser, Bernhard			Editorial: History of Chemoattractant Research	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						history; chemokines; chemoattractants; migration; immunity	AMINO-ACID SEQUENCE; CHEMOKINE RECEPTOR		[Moser, Bernhard] Cardiff Univ, Coll Biomed & Life Sci, Sch Med, Inst Infect & Immun, Cardiff, S Glam, Wales	Cardiff University	Moser, B (corresponding author), Cardiff Univ, Coll Biomed & Life Sci, Sch Med, Inst Infect & Immun, Cardiff, S Glam, Wales.	moserb@cardiff.ac.uk		Moser, Bernhard/0000-0002-4354-4572	Medical Research Council [MR/L018284/1] Funding Source: Medline; MRC [MR/L018284/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arenzana-Seisdedos F, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00256; Baggiolini M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00285; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Berger EA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00283; BURD PR, 1987, J IMMUNOL, V139, P3126; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; De Clercq E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00276; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Gerard NP, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00445; Graham GJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00280; Handel TM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00282; HERMODSON M, 1977, J BIOL CHEM, V252, P6276; Horuk R, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00279; Lusso P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00294; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MILLER MD, 1989, J IMMUNOL, V143, P2907; Moser B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00296; Murphy PM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00281; Nagasawa T, 2015, FRONT IMMUNOL, V6, DOI [10.3389/fimmu.2015.00301, 10.3389/fimmu.2014.00445]; OBARU K, 1986, J BIOCHEM-TOKYO, V99, P885, DOI 10.1093/oxfordjournals.jbchem.a135549; Parmentier M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00295; Proudfoot AEI, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00246; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Van Der Ryst E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00277; WALZ DA, 1977, THROMB RES, V11, P893, DOI 10.1016/0049-3848(77)90117-7; Williams TJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00084; Yoshimura T, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00278	29	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 26	2015	6								548	10.3389/fimmu.2015.00548	http://dx.doi.org/10.3389/fimmu.2015.00548			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CX9FK	26579123	gold, Green Published			2022-12-18	WOS:000366010200001
J	Stover, CM				Stover, Cordula M.			Editorial: Antimicrobial peptides and complement - maximising the inflammatory response	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						inflammation; complement; antimicrobial peptides; immune response; inflammatory response	ACTIVATION; CELLS		Univ Leicester, Coll Med Biol Sci & Psychol, Dept Infect Immun & Inflammat, Leicester, Leics, England	University of Leicester	Stover, CM (corresponding author), Univ Leicester, Coll Med Biol Sci & Psychol, Dept Infect Immun & Inflammat, Leicester, Leics, England.	cms13@le.ac.uk		Stover, Cordula/0000-0002-0125-4868				Al-Rayahi IAM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00002; Barchet W, 2006, BLOOD, V107, P1497, DOI 10.1182/blood-2005-07-2951; Buchmann K, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00459; Chehoud C, 2013, P NATL ACAD SCI USA, V110, P15061, DOI 10.1073/pnas.1307855110; Ferrer-Miralles N, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-101; Hussain M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00045; Kacprzyk L, 2007, BBA-BIOMEMBRANES, V1768, P2667, DOI 10.1016/j.bbamem.2007.06.020; Kenawy HI, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00215; Kopp ZA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00017; Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025; Machado LR, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00115; Martin L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00404; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Miajlovic H, 2014, FEMS MICROBIOL LETT, V354, P1, DOI 10.1111/1574-6968.12419; Rocha-Ferreira E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00056; Sahingur SE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00214; Stover CM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00024; Wan M, 2014, J LEUKOCYTE BIOL, V95, P971, DOI 10.1189/jlb.0513304; Wang ZP, 2011, INFECT IMMUN, V79, P606, DOI 10.1128/IAI.00254-10; Zimmer J, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00689	21	2	2	1	8	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2015	6								491	10.3389/fimmu.2015.00491	http://dx.doi.org/10.3389/fimmu.2015.00491			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CS2PP	26441995	Green Published, gold			2022-12-18	WOS:000361913700001
J	Wenzel, UA; Fernandez-Santoscoy, M; Tam, MA; Tegtmeyer, P; Wick, MJ				Wenzel, Ulf Alexander; Fernandez-Santoscoy, Maria; Tam, Miguel A.; Tegtmeyer, Pia; Wick, Mary Jo			Synergy between CD40 and MyD88 does not influence host survival to Salmonella infection	FRONTIERS IN IMMUNOLOGY			English	Article						dendritic cell; Salmonella; NF kappa B; MyD88; CD40	T-CELL RESPONSES; IN-VIVO REQUIRES; DENDRITIC CELLS; IMMUNE-RESPONSE; ANTIGEN PRESENTATION; ACTIVATION; COSTIMULATION; LIGATION; MONOCYTE; PATHWAY	Previous studies using purified toll-like receptor (TLR) ligands plus agonistic anti-CD40 antibodies showed that TLRs and CD40 can act synergistically on dendritic cells (DCs) to optimize T cell activation and Th1 differentiation. However, a synergistic effect of TLRs and CD40 during bacterial infection is not known. Here, we show that mice lacking the TLR adaptor MyD88 alone, or lacking both MyD88 and CD40 [double knockout (DKO) mice], are compromised in survival to Salmonella infection but have intact recruitment of neutrophils and inflammatory monocytes as well as unaltered abundance of DC subsets and DC activation in infected tissues. In contrast to infected wildtype and CD40(-/-) mice, both MyD88(-/-) mice and DKO mice lack detectable serum IFN-gamma and have elevated IL-10. A synergistic effect of TLRs and CD40 was revealed in co-culture experiments where 01-11 T cell proliferation was compromised when DKO DCs were pulsed with OVA protein and OVA(323-339) peptide, but not with heat-killed Salmonella expressing OVA (HKSOVA), relative to MyD88(-/-) DCs. By contrast, MyD88(-/-) or DKO DCs pulsed with any of the antigens had a similar ability to induce IFN-gamma that was lower than WT or CD40(-/-) DCs. DKO DCs pulsed with HKSOVA, but not with OVA or OVA(323-339), had increased IL-10 relative to MyD88(-/-) DCs. Finally, HKSHKSOVA-pulsed MyD88(-/-) and DKO DCs had similar and low induction of NF kappa B-dependent and independent genes upon co-culture with 01-11 cells. Overall, our data revealed that synergistic effects of CD40 and MyD88 do not influence host survival to Salmonella infection or serum levels of IFN-gamma or IL-10. However, synergistic effects of MyD88 and CD40 may be apparent on some (IL-10 production) but not all (01-11 proliferation and IFN-gamma production) DC functions and depend on the complexity of the antigen. Indeed, synergistic effects observed using purified ligands and well-defined antigens may not necessarily apply when complex antigens, such as live bacteria, challenge the immune system.	[Wenzel, Ulf Alexander; Fernandez-Santoscoy, Maria; Tegtmeyer, Pia; Wick, Mary Jo] Univ Gothenburg, Dept Microbiol & Immunol, Mucosal Immunobiol & Vaccine Ctr, Inst Biomed,Sahlgrenska Acad, S-40530 Gothenburg, Sweden; [Tam, Miguel A.] BioLegend, San Diego, CA USA; [Tegtmeyer, Pia] TWINCORE Ctr Expt & Clin Infect Res, Inst Expt Infect Res, Hannover, Germany	University of Gothenburg; Helmholtz Association; Helmholtz-Center for Infection Research	Wick, MJ (corresponding author), Univ Gothenburg, Dept Microbiol & Immunol, Box 435, S-40530 Gothenburg, Sweden.	mary-jo.wick@immuno.gu.se			Swedish Research Council [621-2110-5238]; Ruth and Richard Juhlin Foundation; Goljes Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Ruth and Richard Juhlin Foundation; Goljes Foundation	This work was funded by the Swedish Research Council (621-2110-5238), the Ruth and Richard Juhlin Foundation, and the Goljes Foundation.	Ahonen CL, 2004, J EXP MED, V199, P775, DOI 10.1084/jem.20031591; Ballesteros-Tato A, 2014, IMMUNITY, V41, P127, DOI 10.1016/j.immuni.2014.06.007; Bao S, 2000, IMMUNOLOGY, V99, P464, DOI 10.1046/j.1365-2567.2000.00955.x; Baruah P, 2009, BLOOD, V113, P3485, DOI 10.1182/blood-2008-06-164392; Bekiaris V, 2014, IMMUNOL REV, V260, P86, DOI 10.1111/imr.12194; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Edwards AD, 2002, J IMMUNOL, V169, P3652, DOI 10.4049/jimmunol.169.7.3652; Ferrer IR, 2011, P NATL ACAD SCI USA, V108, P20701, DOI 10.1073/pnas.1105500108; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; Gray CM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004557; Hawley KL, 2012, P NATL ACAD SCI USA, V109, P1228, DOI 10.1073/pnas.1112078109; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Krummen M, 2010, J LEUKOCYTE BIOL, V88, P189, DOI 10.1189/jlb.0408228; Lanzavecchia A, 2002, NAT REV IMMUNOL, V2, P982, DOI 10.1038/nri959; Lind EF, 2008, J IMMUNOL, V181, P354, DOI 10.4049/jimmunol.181.1.354; Luft T, 2004, BLOOD, V104, P1066, DOI 10.1182/blood-2003-12-4146; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; Martin S, 2010, J IMMUNOL, V185, P551, DOI 10.4049/jimmunol.0902206; Martin S, 2010, J IMMUNOL, V184, P5510, DOI 10.4049/jimmunol.0902762; Mittrucker HW, 2000, J LEUKOCYTE BIOL, V67, P457, DOI 10.1002/jlb.67.4.457; Pfaffl MW., 2006, REAL TIME PCR, P63; Ravindran R, 2005, J IMMUNOL, V175, P4603, DOI 10.4049/jimmunol.175.7.4603; Reynolds JM, 2013, TRENDS IMMUNOL, V34, P511, DOI 10.1016/j.it.2013.06.003; Rydstrom A, 2007, J IMMUNOL, V178, P5789, DOI 10.4049/jimmunol.178.9.5789; Rydstrom A, 2010, J LEUKOCYTE BIOL, V87, P823, DOI 10.1189/jlb.0909615; Rydstrom A, 2009, EUR J IMMUNOL, V39, P3019, DOI 10.1002/eji.200939483; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Seah SGK, 2013, J LEUKOCYTE BIOL, V93, P145, DOI 10.1189/jlb.0612266; Seya T, 2005, INT J BIOCHEM CELL B, V37, P524, DOI 10.1016/j.biocel.2004.07.018; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Sundquist M, 2005, J IMMUNOL, V175, P3287, DOI 10.4049/jimmunol.175.5.3287; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tam MA, 2008, IMMUNOL REV, V225, P140, DOI 10.1111/j.1600-065X.2008.00679.x; Warger T, 2006, BLOOD, V108, P544, DOI 10.1182/blood-2005-10-4015; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	39	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 14	2015	6								460	10.3389/fimmu.2015.00460	http://dx.doi.org/10.3389/fimmu.2015.00460			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CR8WL	26441965	Green Published, gold			2022-12-18	WOS:000361634800001
J	Dustin, LB; Trehanpati, N				Dustin, Lynn B.; Trehanpati, Nirupma			Editorial: Recent advances in HBV and HCV immunology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						hepatitis B virus; hepatitis C virus; vaccines; interferons; hepatocellular carcinoma	HEPATITIS-C VIRUS; NATURAL-HISTORY; T-CELLS; INFECTION; EPIDEMIOLOGY; OPPORTUNITIES; LIVER		[Dustin, Lynn B.] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Trehanpati, Nirupma] Inst Liver & Biliary Sci, New Delhi, India	University of Oxford; Institute of Liver & Biliary Sciences (ILBS)	Trehanpati, N (corresponding author), Inst Liver & Biliary Sci, New Delhi, India.	trehanpati@gmail.com	Dustin, Lynn B./G-5690-2011	Dustin, Lynn B./0000-0002-2619-1867				Abdel-Hakeem MS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00274; Cashman SB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00550; Cho H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00265; Gish RG, 2015, ANTIVIR RES, V121, P47, DOI 10.1016/j.antiviral.2015.06.008; Gogela NA, 2015, CURR HIV-AIDS REP, V12, P68, DOI 10.1007/s11904-014-0243-7; Hajarizadeh B, 2013, NAT REV GASTRO HEPAT, V10, P553, DOI 10.1038/nrgastro.2013.107; Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141; Laidlaw SM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00545; Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x; Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116; Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060; Rajoriya N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00400; Rehermann B, 2013, NAT MED, V19, P859, DOI 10.1038/nm.3251; Schuch A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00258; Sharman S, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00049; Sidharthan S, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00248; Sung PS, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00266; Thomson AW, 2010, NAT REV IMMUNOL, V10, P753, DOI 10.1038/nri2858; Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8; Webster DP, 2015, LANCET, V385, P1124, DOI [10.1016/S0140-6736(14)61932-2, 10.1016/S0140-6736(14)62401-6]	20	2	2	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 4	2015	6								453	10.3389/fimmu.2015.00453	http://dx.doi.org/10.3389/fimmu.2015.00453			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CR7QG	26388875	Green Published, gold			2022-12-18	WOS:000361544900001
J	Abrahimians, EM; Carlier, VA; Elst, LV; Saint-Remy, JMR				Abrahimians, Elin Malek; Carlier, Vincent A.; Elst, Luc Vander; Saint-Remy, Jean-Marie R.			MHC class II-restricted epitopes containing an oxidoreductase activity prompt CD4(+) T cells with apoptosis-inducing properties	FRONTIERS IN IMMUNOLOGY			English	Article						MHC class II epitopes; oxidoreductase activity; cytolytic CD4(+) T cells; apoptosis; immune suppression	IMMUNITY; EXPRESSION; MEMORY	Abrogating an unwanted immune response toward a specific antigen without compromising the entire immune system is a hoped-for goal in immunotherapy. Instead of manipulating dendritic cells and suppressive regulatory T cells, depleting effector T cells or blocking their co-stimulatory pathways, we describe a method to specifically inhibit the presentation of an antigen eliciting an unwanted immune reaction. Inclusion of an oxidoreductase motif within the flanking residues of MHC class II epitopes polarizes CD4(+) T cells to cytolytic cells capable of inducing apoptosis in antigen presenting cells (APCs) displaying cognate peptides through MHC class II molecules. This novel function results from an increased synapse formation between both cells. Moreover, these cells eliminate by apoptosis bystander CD4(+) T cells activated at the surface of the APC. We hypothesize that they would thereby block the recruitment of cells of alternative specificity for the same autoantigen or cells specific for another antigen associated with the pathology, providing a system by which response against multiple antigens linked with the same disease can be suppressed. These findings open the way toward a novel form of antigen-specific immunosuppression	[Abrahimians, Elin Malek; Carlier, Vincent A.; Elst, Luc Vander; Saint-Remy, Jean-Marie R.] Univ Leuven, Ctr Mol & Vasc Biol, Leuven, Belgium; [Abrahimians, Elin Malek; Carlier, Vincent A.; Elst, Luc Vander; Saint-Remy, Jean-Marie R.] ImCyse SA, Leuven, Belgium	KU Leuven	Saint-Remy, JMR (corresponding author), ImCyse, Bioincubator 2, Gaston Geenslaan 1, B-3001 Leuven, Belgium.	jean-marie.saint-remy@med.kuleuven.be						Adhikary D, 2006, J EXP MED, V203, P995, DOI 10.1084/jem.20051287; Akbari O, 2002, NAT REV IMMUNOL, V2, P629, DOI 10.1038/nm745; Anderson PO, 2006, EUR J IMMUNOL, V36, P1374, DOI 10.1002/eji.200635883; Anderson RP, 2013, CURR OPIN IMMUNOL, V25, P410, DOI 10.1016/j.coi.2013.02.004; Appay V, 2002, J IMMUNOL, V168, P5954, DOI 10.4049/jimmunol.168.11.5954; Bluestone JA, 2005, NAT REV IMMUNOL, V5, P343, DOI 10.1038/nri1574; Brown DM, 2010, CELL IMMUNOL, V262, P89, DOI 10.1016/j.cellimm.2010.02.008; Carlier VA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045366; Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X; Cheroutre H, 2013, SEMIN IMMUNOL, V25, P273, DOI 10.1016/j.smim.2013.10.022; Cobbold SP, 2006, EUR J IMMUNOL, V36, P1360, DOI 10.1002/eji.200636171; FEIGHERY C, 1979, J EXP MED, V149, P485, DOI 10.1084/jem.149.2.485; FLEISCHER B, 1984, NATURE, V308, P365, DOI 10.1038/308365a0; GROMKOWSKI SH, 1988, EUR J IMMUNOL, V18, P1385, DOI 10.1002/eji.1830180913; HAHN S, 1995, IMMUNOL REV, V146, P57, DOI 10.1111/j.1600-065X.1995.tb00684.x; Holland CJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00172; Janssens W, 2003, J IMMUNOL, V171, P4604, DOI 10.4049/jimmunol.171.9.4604; Knoechel B, 2006, J IMMUNOL, V176, P6473, DOI 10.4049/jimmunol.176.11.6473; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lovitch SB, 2006, J IMMUNOL, V176, P2958, DOI 10.4049/jimmunol.176.5.2958; Meyer Y, 2009, ANNU REV GENET, V43, P335, DOI 10.1146/annurev-genet-102108-134201; Nicholas D, 2011, DISCOV MED, V11, P293; Perez-Diez A, 2007, BLOOD, V109, P5346, DOI 10.1182/blood-2006-10-051318; Prasad S, 2012, J AUTOIMMUN, V39, P347, DOI 10.1016/j.jaut.2012.04.005; Purvis HA, 2010, BLOOD, V116, P4829, DOI 10.1182/blood-2010-03-272153; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Schmidt B, 2006, BIOCHEMISTRY-US, V45, P7429, DOI 10.1021/bi0603064; Schwertassek U, 2007, EMBO J, V26, P3086, DOI 10.1038/sj.emboj.7601746; Snow AL, 2010, IMMUNOL REV, V236, P68, DOI 10.1111/j.1600-065X.2010.00917.x; Soghoian DZ, 2010, EXPERT REV VACCINES, V9, P1453, DOI [10.1586/erv.10.132, 10.1586/ERV.10.132]; Swain SL, 2006, IMMUNOL REV, V211, P8, DOI 10.1111/j.0105-2896.2006.00388.x; TSUJI M, 1990, J EXP MED, V172, P1353, DOI 10.1084/jem.172.5.1353; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; von Herrath MG, 2003, NAT REV IMMUNOL, V3, P223, DOI 10.1038/nri1029; Woodland DL, 2001, IMMUNOL RES, V24, P53, DOI 10.1385/IR:24:1:53; Wu B, 2002, J IMMUNOL, V169, P2430, DOI 10.4049/jimmunol.169.5.2430	37	2	4	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2015	6								449	10.3389/fimmu.2015.00449	http://dx.doi.org/10.3389/fimmu.2015.00449			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CR3OV	26388872	Green Published, gold			2022-12-18	WOS:000361243700001
J	Farrugia, A; Visentini, M; Quinti, I				Farrugia, Albert; Visentini, Marcella; Quinti, Isabella			Editorial: Immunoglobulin therapy in the 21st century - the dark side of the moon	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunoglobulin G; immunedeficiency; dosage; safety; individualized medicine	SUBCUTANEOUS IMMUNOGLOBULIN; ANTIBODY DEFICIENCIES; REPLACEMENT; IVIG		[Farrugia, Albert] Univ Western Australia, Sch Sugery, Perth, WA 6009, Australia; [Visentini, Marcella; Quinti, Isabella] Univ Roma La Sapienza, Dept Mol Med, I-00185 Rome, Italy	University of Western Australia; Sapienza University Rome	Farrugia, A (corresponding author), Univ Western Australia, Sch Sugery, Perth, WA 6009, Australia.	albert.farrugia@uwa.edu.au	; VISENTINI, MARCELLA/K-4161-2016	Farrugia, Albert/0000-0003-0804-7463; VISENTINI, MARCELLA/0000-0002-4053-6091; Quinti, Isabella/0000-0002-3328-7584				Basta M, 2014, CLIN EXP IMMUNOL, V178, P87, DOI 10.1111/cei.12523; Benadiba J, 2015, TRANSFUSION, V55, P571, DOI 10.1111/trf.12897; BURNOUF T, 1995, J CHROMATOGR B, V664, P3, DOI 10.1016/0378-4347(94)00532-A; Compagno N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00626; Farrugia A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00665; Floyd Pink, 2015, BRAIN DAMAGE LYRICS; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Goldacker S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00675; Igarashi A, 2014, CLIN THER, V36, P1616, DOI 10.1016/j.clinthera.2014.08.007; Kerr J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00629; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Matucci A, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00690; Milito C, 2014, J CLIN IMMUNOL, V34, P813, DOI 10.1007/s10875-014-0081-9; Mitrevski M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00004; Nagelkerke SQ, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00674; Orange JS, 2012, CLIN EXP IMMUNOL, V169, P172, DOI 10.1111/j.1365-2249.2012.04594.x; Orange JS, 2010, CLIN IMMUNOL, V137, P21, DOI 10.1016/j.clim.2010.06.012; Paquin-Proulx D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00637; Peter JG, 2014, IMMUNOTHERAPY-UK, V6, P853, DOI [10.2217/IMT.14.54, 10.2217/imt.14.54]; Quinti I, 2015, TRANSFUSION, V55, P1067, DOI 10.1111/trf.12939; Quinti I, 2011, J CLIN IMMUNOL, V31, P315, DOI 10.1007/s10875-011-9511-0; Spath PJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00011; Tabolli S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00605; Wolf HM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00032	24	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 26	2015	6								436	10.3389/fimmu.2015.00436	http://dx.doi.org/10.3389/fimmu.2015.00436			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CQ1BG	26379671	gold, Green Published			2022-12-18	WOS:000360331700001
J	Toro, K; Voros, K; Meszner, Z; Varadi, A; Toth, A; Kovacs, K				Toero, Klara; Voeroes, Krisztina; Meszner, Zsofia; Varadi-T, Aletta; Toth, Adrienn; Kovacs, Katalin			Evidence for infection and inflammation in infant deaths in a country with historically low incidences of sudden infant death syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						sudden infant death syndrome; infant mortality; immunization; infection; inflammation	UNEXPECTED DEATH; SYNDROME SIDS; IMMUNIZATION; DIPHTHERIA; PERTUSSIS; POSITION; RISK	Total infant mortality in Hungary has been higher than other European countries; however, the reported incidence of sudden infant death syndrome (SIDS) has been lower. The low incidence of SIDS in Hungary has been supported by evidence obtained from the high rate of scene of death investigation and medico-legal autopsy mandatory since the 1950s. In this study, we compared the incidence of explained and unexplained infant deaths in Hungary for three periods: 1979-1989 when the incidence of SIDS was high in western Europe; 1990-1999 when the incidence of infant deaths was falling following introduction of the public health campaigns to reduce the risk factors associated with SIDS; and 2000-2012 to determine if introduction of Haemophilus influenzae type b or pneumococcal vaccines or introduction of an earlier immunization schedule during this period had an effect on SIDS. Explained infant deaths fell consistently during this period; however, SIDS rose during the second period when the incidence of SIDS was falling in other European countries. Evidence for infection and/or inflammation was observed for the majority of SIDS during each period. The results are discussed in relation to campaigns to reduce infant mortality in Hungary and the introduction of new vaccines and an earlier immunization schedule in 2006.	[Toero, Klara] Semmelweis Univ, Dept Forens & Insurance Med, H-1091 Budapest, Hungary; [Voeroes, Krisztina; Varadi-T, Aletta] Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1091 Budapest, Hungary; [Meszner, Zsofia] St Laszlo Hosp Infect Dis, Natl Inst Child Hlth, Budapest, Hungary; [Toth, Adrienn] Mil Hosp, Natl Hlth Ctr, Dept Pathol, Budapest, Hungary; [Kovacs, Katalin] Hungarian Demog Res Inst, Budapest, Hungary	Semmelweis University; Semmelweis University; Szent Laszlo Hospital	Toro, K (corresponding author), Semmelweis Univ, Dept Forens & Insurance Med, Ulloi Ut 93, H-1091 Budapest, Hungary.	toro.klara@med.semmelweis-univ.hu						BERRY PJ, 1992, J CLIN PATHOL, V45, P11; Blackwell CC, 2002, INT J MED MICROBIOL, V291, P561; Essery SD, 1999, FEMS IMMUNOL MED MIC, V25, P183, DOI 10.1111/j.1574-695X.1999.tb01342.x; Fleming PJ, 2001, BMJ-BRIT MED J, V322, P822, DOI 10.1136/bmj.322.7290.822; Foley B, 2013, INT SMOKING STAT; GILBERT R, 1992, ARCH DIS CHILD, V67, P171, DOI 10.1136/adc.67.2.171; Goldwater PN, 2009, ARCH DIS CHILD, V94, P303, DOI 10.1136/adc.2007.135939; Hakeem GF, 2015, WORLD J PEDIATR, V11, P41, DOI 10.1007/s12519-014-0530-9; Harrison LM, 1999, FEMS IMMUNOL MED MIC, V25, P29, DOI 10.1111/j.1574-695X.1999.tb01324.x; HOFFMAN HJ, 1987, PEDIATRICS, V79, P598; Lindgren C, 1997, EUR J PEDIATR, V156, P405, DOI 10.1007/s004310050626; MacDorman MF, 1997, AM J EPIDEMIOL, V146, P249, DOI 10.1093/oxfordjournals.aje.a009260; Rognum T, 2001, DEFINITION PATHOLOGI; Taylor JA, 1996, J PEDIATR-US, V128, P626, DOI 10.1016/S0022-3476(96)80126-0; Thayyil S, 2003, ARCH DIS CHILD, V88, P157, DOI 10.1136/adc.88.2.157; Toro K, 2004, FEMS IMMUNOL MED MIC, V42, P119, DOI 10.1016/j.femsim.2004.06.018; Vennemann M, 2006, ARCH DIS CHILD, V91, P324, DOI 10.1136/adc.2005.082172; Weber MA, 2008, LANCET, V371, P1848, DOI 10.1016/S0140-6736(08)60798-9	18	2	2	0	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 24	2015	6								389	10.3389/fimmu.2015.00389	http://dx.doi.org/10.3389/fimmu.2015.00389			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CQ1AV	26379661	Green Published, gold			2022-12-18	WOS:000360330600001
J	Smith, KA				Smith, Kendall Arthur			Commentary: The interleukin-2 T cell System: a new cell growth model	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						interleukin-2; T cell clones; IL-2 receptors; the quantal theory of immunity	QUANTAL THEORY		Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA.	kasmith@med.cornell.edu						BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; Chiodetti L, 2000, EUR J IMMUNOL, V30, P2157, DOI 10.1002/1521-4141(2000)30:8<2157::AID-IMMU2157>3.0.CO;2-#; Feinerman O, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.90; Huang J, 2013, IMMUNITY, V39, P846, DOI 10.1016/j.immuni.2013.08.036; Podtschaske M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000935; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; Smith K., 2010, THE QUANTAL THEORY O; Smith KA, 2006, CELL RES, V16, P11, DOI 10.1038/sj.cr.7310003; SMITH KA, 1983, J IMMUNOL, V131, P1808; Smith KA, 2008, J CLIN INVEST, V118, P3564, DOI 10.1172/JCI35819; Smith KA, 2008, IMMUNOL REV, V224, P124, DOI 10.1111/j.1600-065X.2008.00654.x; Smith Kendall A, 2004, Med Immunol, V3, P3, DOI 10.1186/1476-9433-3-3; Tkach KE, 2014, ELIFE, V3, DOI 10.7554/eLife.01944	14	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 10	2015	6								414	10.3389/fimmu.2015.00414	http://dx.doi.org/10.3389/fimmu.2015.00414			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CO9DF	26322046	Green Published, gold			2022-12-18	WOS:000359472100001
J	Stegall, MD; Borrows, R				Stegall, Mark D.; Borrows, Richard			Computational biology: modeling chronic renal allograft injury	FRONTIERS IN IMMUNOLOGY			English	Article						renal transplantation; computational biology; chronic renal allograft dysfunction; immunology; mathematical modeling	GENE-EXPRESSION; KIDNEY; TOLERANCE; SIGNATURE; PROFILES; DAMAGE	New approaches are needed to develop more effective interventions to prevent long-term rejection of organ allografts. Computational biology provides a powerful tool to assess the large amount of complex data that is generated in longitudinal studies in this area. This manuscript outlines how our two groups are using mathematical modeling to analyze predictors of graft loss using both clinical and experimental data and how we plan to expand this approach to investigate specific mechanisms of chronic renal allograft injury.	[Stegall, Mark D.] Mayo Clin, Dept Surg, von Liebig Transplant Ctr, Rochester, MN 55905 USA; [Borrows, Richard] Queen Elizabeth Hosp Ctr, Nephrol, Birmingham, W Midlands, England	Mayo Clinic	Stegall, MD (corresponding author), Mayo Clin, Dept Surg, von Liebig Transplant Ctr, 200 First St SW, Rochester, MN 55905 USA.	stegall.mark@mayo.edu	Stegall, Mark/AAX-6496-2020	Stegall, Mark/0000-0002-1392-0792				Anglicheau D, 2009, P NATL ACAD SCI USA, V106, P5330, DOI 10.1073/pnas.0813121106; Baron D, 2015, KIDNEY INT, V87, P984, DOI 10.1038/ki.2014.395; Bijkerk R, 2015, AM J TRANSPLANT, V15, P1081, DOI 10.1111/ajt.13072; Chen S, 2011, AM J TRANSPLANT, V11, P2057, DOI 10.1111/j.1600-6143.2011.03646.x; Cosio FG, 2005, AM J TRANSPLANT, V5, P2464, DOI 10.1111/j.1600-6143.2005.01050.x; Dorling A, 2012, AM J TRANSPLANT, V12, P545, DOI 10.1111/j.1600-6143.2011.03821.x; El-Zoghby ZM, 2009, AM J TRANSPLANT, V9, P527, DOI 10.1111/j.1600-6143.2008.02519.x; Ioannidis JPA, 2013, CLIN CHEM, V59, P202, DOI 10.1373/clinchem.2012.185801; Koch CA, 2004, J IMMUNOL, V172, P5143, DOI 10.4049/jimmunol.172.9.5143; Kurian SM, 2015, AM J TRANSPLANT, V15, P1605, DOI 10.1111/ajt.13145; Kurian SM, 2014, AM J TRANSPLANT, V14, P1164, DOI 10.1111/ajt.12671; Lamb KE, 2011, AM J TRANSPLANT, V11, P450, DOI 10.1111/j.1600-6143.2010.03283.x; Loupy A, 2014, J AM SOC NEPHROL, V25, P2267, DOI 10.1681/ASN.2013111149; Moreno-Gonzalez M, 2015, AM J TRANSPLANT, V15, P1, DOI [10.1111/ajt.13359, DOI 10.1111/AJT.13359]; Newell KA, 2010, J CLIN INVEST, V120, P1836, DOI 10.1172/JCI39933; Park WD, 2010, J AM SOC NEPHROL, V21, P1987, DOI 10.1681/ASN.2010010049; Roedder S, 2015, J AM SOC NEPHROL, V26, P2042, DOI 10.1681/ASN.2013111239; Roedder S, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001759; Shabir S, 2014, AM J KIDNEY DIS, V63, P643, DOI 10.1053/j.ajkd.2013.10.059; Sis B, 2009, AM J TRANSPLANT, V9, P2312, DOI 10.1111/j.1600-6143.2009.02761.x; Stegall MD, 2015, J AM SOC NEPHROL, V26, P20, DOI 10.1681/ASN.2014040378; Subpart H., ACCELERATE APPROVAL; Wolfe RA, 2008, AM J TRANSPLANT, V8, P997, DOI 10.1111/j.1600-6143.2008.02177.x	23	2	2	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 3	2015	6						1	4	385	10.3389/fimmu.2015.00385	http://dx.doi.org/10.3389/fimmu.2015.00385			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CO9BW	26284070	gold, Green Published			2022-12-18	WOS:000359468100001
J	Delovitch, TL				Delovitch, Terry L.			Imaging of NKT cell recirculation and tissue migration during antimicrobial immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						NKT cells; anti-microbial immunity; immunoregulation; in vivo imaging; immunotherapy	KILLER T-CELLS; EARLY-LIFE; DENDRITIC CELLS; INNATE-LIKE; INKT CELLS; ACTIVATION; DISTINCT; SELF; CD1D; MICROBIOTA		Univ Western Ontario, Dept Microbiol & Immunol, Robarts Res Inst, Lab Autoimmune Diabet, London, ON, Canada	Western University (University of Western Ontario)	Delovitch, TL (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, Robarts Res Inst, Lab Autoimmune Diabet, London, ON, Canada.	del@robarts.ca						Arrenberg P, 2010, P NATL ACAD SCI USA, V107, P10984, DOI 10.1073/pnas.1000576107; Arrenberg P, 2009, J CELL PHYSIOL, V218, P246, DOI 10.1002/jcp.21597; Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; Bousso P, 2008, NAT REV IMMUNOL, V8, P675, DOI 10.1038/nri2379; Bousso P, 2012, NAT REV IMMUNOL, V12, P858, DOI 10.1038/nri3342; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; Celli S, 2011, NAT MED, V17, P744, DOI 10.1038/nm.2376; Chang DH, 2005, J EXP MED, V201, P1503, DOI 10.1084/jem.20042592; Chiu YH, 1999, J EXP MED, V189, P103, DOI 10.1084/jem.189.1.103; Cohen NR, 2013, NAT IMMUNOL, V14, P90, DOI 10.1038/ni.2490; Crowe NY, 2003, J IMMUNOL, V171, P4020, DOI 10.4049/jimmunol.171.8.4020; Das R, 2010, IMMUNOL REV, V238, P195, DOI 10.1111/j.1600-065X.2010.00962.x; de Jong A, 2010, NAT IMMUNOL, V11, P1102, DOI 10.1038/ni.1956; Egen JG, 2011, IMMUNITY, V34, P807, DOI 10.1016/j.immuni.2011.03.022; Exley MA, 2001, J IMMUNOL, V167, P5531, DOI 10.4049/jimmunol.167.10.5531; Fife BT, 2009, NAT IMMUNOL, V10, P1185, DOI 10.1038/ni.1790; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Fuss IJ, 2001, J CLIN INVEST, V13, P1490; Geissmann F, 2005, PLOS BIOL, V3, P650, DOI 10.1371/journal.pbio.0030113; Germain RN, 2012, SCIENCE, V336, P1676, DOI 10.1126/science.1221063; Giaccone G, 2002, CLIN CANCER RES, V8, P3702; Girardi E, 2012, NAT IMMUNOL, V13, P851, DOI 10.1038/ni.2371; Godfrey DI, 2010, SEMIN IMMUNOL, V22, P61, DOI 10.1016/j.smim.2009.10.004; Godfrey DI, 2010, NAT IMMUNOL, V11, P197, DOI 10.1038/ni.1841; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Halder RC, 2007, J CLIN INVEST, V117, P2302, DOI 10.1172/JCI31602; Halder RC, 2007, NEUROCHEM RES, V32, P257, DOI 10.1007/s11064-006-9145-4; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Hugues S, 2004, NAT IMMUNOL, V5, P1235, DOI 10.1038/ni1134; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; Jahng AW, 2001, J EXP MED, V194, P1789, DOI 10.1084/jem.194.12.1789; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kumar V, 2014, IMMUNOLOGY, V142, P321, DOI 10.1111/imm.12247; Lawson V, 2012, IMMUNOLOGY, V137, P20, DOI 10.1111/j.1365-2567.2012.03612.x; Lee WY, 2008, J HEPATOL, V48, P504, DOI 10.1016/j.jhep.2007.12.005; Liao CM, 2013, INFLAMM BOWEL DIS, V19, P1330, DOI 10.1097/MIB.0b013e318280b1e3; Lindau D, 2012, IMMUNOLOGY, V137, P589, DOI 10.1111/imm.12036; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; Olszak T, 2014, NATURE, V509, P497, DOI 10.1038/nature13150; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Park SH, 2001, J EXP MED, V193, P893, DOI 10.1084/jem.193.8.893; Rhost S, 2012, SCAND J IMMUNOL, V76, P246, DOI 10.1111/j.1365-3083.2012.02750.x; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schneider H, 2006, SCIENCE, V313, P1972, DOI 10.1126/science.1131078; Simoni Y, 2013, CLIN EXP IMMUNOL, V171, P8, DOI 10.1111/j.1365-2249.2012.04625.x; Snyder-Cappione JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015412; Spada FM, 2000, J EXP MED, V191, P937, DOI 10.1084/jem.191.6.937; Thomas SY, 2011, J EXP MED, V208, P1179, DOI 10.1084/jem.20102630; Velazquez P, 2008, J IMMUNOL, V180, P2024, DOI 10.4049/jimmunol.180.4.2024; Viale Rachael, 2012, Current Immunology Reviews, V8, P287; Wen XS, 2013, P NATL ACAD SCI USA, V110, P2963, DOI 10.1073/pnas.1300200110; Wilson SB, 2003, NAT REV IMMUNOL, V3, P211, DOI 10.1038/nri1028; Wong CHY, 2013, IMMUNOL CELL BIOL, V91, P304, DOI 10.1038/icb.2013.6; Wong CHY, 2011, SCIENCE, V334, P101, DOI 10.1126/science.1210301; Zajonc DM, 2005, J EXP MED, V202, P1517, DOI 10.1084/jem.20051625; Zeissig S, 2007, AM J PHYSIOL-GASTR L, V293, pG1101, DOI 10.1152/ajpgi.00342.2007; Zeissig S, 2014, FEBS LETT, V588, P4188, DOI 10.1016/j.febslet.2014.06.042; Zeissig S, 2014, NAT IMMUNOL, V15, P307, DOI 10.1038/ni.2847; Zeissig S, 2013, CURR OPIN IMMUNOL, V25, P690, DOI 10.1016/j.coi.2013.09.012	65	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2015	6						1	5	356	10.3389/fimmu.2015.00356	http://dx.doi.org/10.3389/fimmu.2015.00356			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CO1YW	26236312	Green Published, gold			2022-12-18	WOS:000358953300001
J	Mol, M; Kosey, D; Singh, S				Mol, Milsee; Kosey, Dipali; Singh, Shailza			Nano-synthetic devices in leishmaniasis: a bioinformatics approach	FRONTIERS IN IMMUNOLOGY			English	Article						Leishmania; synthetic biology; nanotechnology; bioinformatics; nanodevices	DNA NANOTECHNOLOGY; DELIVERY; PROPULSION; TRANSPORT; DESIGN; CELLS	Synthetic biology is an investigative and constructive means of understanding the complexities of biology. Substantial progress in the fields has resulted in the creation of synthetic gene circuits, which when uploaded into the appropriate nanoliposomal vehicle, can be used for a tunable response in a cell. These tunable elements can be applied to treat diseased condition for a transition to a healthy state. Though in its nascent stage of development synthetic biology is beginning to use its constructs to bring engineering approaches into biomedicine for treatment of infectious disease leishmaniasis.	[Mol, Milsee; Kosey, Dipali; Singh, Shailza] Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Singh, S (corresponding author), Natl Ctr Cell Sci, NCCS Complex,SP Pune Univ Campus, Pune 411007, Maharashtra, India.	singhs@nccs.res.in			Department of Science and Technology, Ministry of Science and Technology, Government of India [SB/FT/LS400/2012]; Council of Scientific and Industrial Research, New Delhi	Department of Science and Technology, Ministry of Science and Technology, Government of India(Department of Science & Technology (India)); Council of Scientific and Industrial Research, New Delhi(Council of Scientific & Industrial Research (CSIR) - India)	The authors would like to thank Department of Science and Technology, Ministry of Science and Technology, Government of India for funding the work (SB/FT/LS400/2012). MM acknowledges the Senior Research Fellowship from Council of Scientific and Industrial Research, New Delhi. The authors would also like to thank the Director, National Centre for Cell Science (NCCS), Pune for supporting the Bioinformatics and High Performance Computing Facility at NCCS, Pune, India.	Afonin KA, 2015, ACS NANO, V9, P251, DOI 10.1021/nn504508s; Balasubramanian S, 2011, ANGEW CHEM INT EDIT, V50, P4161, DOI 10.1002/anie.201100115; Bewick S, 2009, WIRES NANOMED NANOBI, V1, P650, DOI 10.1002/wnan.61; Bruno JG, 2013, PHARMACEUTICALS, V6, P340, DOI 10.3390/ph6030340; Chen R, 2014, CURR OPIN BIOTECH, V28, P59, DOI 10.1016/j.copbio.2013.11.007; Chu TW, 2014, ACS NANO, V8, P719, DOI 10.1021/nn4053827; Delebecque CJ, 2011, SCIENCE, V333, P470, DOI 10.1126/science.1206938; Douglas SM, 2012, SCIENCE, V335, P831, DOI 10.1126/science.1214081; Gaheen S., 2013, COMPUT SCI DISCOVERY, V6; Geary C, 2014, SCIENCE, V345, P799, DOI 10.1126/science.1253920; Guo PX, 2012, NUCLEIC ACID THER, V22, P226, DOI 10.1089/nat.2012.0350; Jain K, 2014, CURR OPIN PHARMACOL, V15, P97, DOI 10.1016/j.coph.2014.01.006; Jungmann R, 2008, HFSP J, V2, P99, DOI 10.2976/1.2896331; Kaba SA, 2009, J IMMUNOL, V183, P7268, DOI 10.4049/jimmunol.0901957; Kagan Daniel, 2012, Angew Chem Int Ed Engl, V51, P7519, DOI 10.1002/anie.201201902; Kumar R, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.4; Liu XW, 2012, NANO LETT, V12, P4254, DOI 10.1021/nl301877k; MaHam A, 2009, SMALL, V5, P1706, DOI 10.1002/smll.200801602; Manesh KM, 2010, ACS NANO, V4, P1799, DOI 10.1021/nn1000468; MNneil SE, 2005, J LEUKOCYTE BIOL, V78, P585, DOI 10.1189/jlb.0205074; Mohri K, 2014, EUR J PHARM SCI, V58, P26, DOI 10.1016/j.ejps.2014.03.002; Nirujogi RS, 2014, J PROTEOMICS, V97, P48, DOI 10.1016/j.jprot.2013.04.021; Panneerselvam S, 2014, INT J MOL SCI, V15, P7158, DOI 10.3390/ijms15057158; Partha Roy, 2012, Journal of Cell and Animal Biology, V6, P78; Pouponneau P, 2014, ANN BIOMED ENG, V42, P929, DOI 10.1007/s10439-014-0972-1; Shapiro Bruce A., 2008, V474, P93, DOI 10.1007/978-1-59745-480-3_7; Shu D, 2011, NAT NANOTECHNOL, V6, P658, DOI [10.1038/NNANO.2011.105, 10.1038/nnano.2011.105]; Stephanopoulos N, 2015, NANO LETT, V15, P603, DOI 10.1021/nl504079q; Sundar S, 2010, J GLOB INFECT DIS, V2, P159, DOI 10.4103/0974-777X.62886; Thomas DG, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-2; Tokatlian T, 2010, WIRES NANOMED NANOBI, V2, P305, DOI 10.1002/wnan.81; Toumey C, 2013, NAT NANOTECHNOL, V8, P475, DOI 10.1038/nnano.2013.128; Wang DF, 2014, ANAL CHEM, V86, P1932, DOI 10.1021/ac403661z; Wang F, 2013, CURR OPIN BIOTECH, V24, P562, DOI 10.1016/j.copbio.2013.02.005; Wang J, 2012, ACS NANO, V6, P5745, DOI 10.1021/nn3028997; Wang X, 2014, INT J NANOMED, V9, P4899, DOI 10.2147/IJN.S69845; Zhang F, 2014, J AM CHEM SOC, V136, P11198, DOI 10.1021/ja505101a; Zhang L, 2010, ACS NANO, V4, P6228, DOI 10.1021/nn101861n; Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185	39	2	3	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 19	2015	6								323	10.3389/fimmu.2015.00323	http://dx.doi.org/10.3389/fimmu.2015.00323			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CL9DL	26150819	Green Published, gold			2022-12-18	WOS:000357275600001
J	Weiss, A; Stobo, JD				Weiss, Arthur; Stobo, John D.			The role of T3 surface molecules in the activation of human cells: a two-stimulus requirement for IL-2 production reflects events occurring at a pretranslational level	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cell; interleukin 2; Jurkat cells; immunology; T3 surface molecules	CYTOPLASMIC FREE CALCIUM; ANTIGEN RECEPTOR; T3-MOLECULAR COMPLEX; MONOCLONAL-ANTIBODY; PROTEIN-KINASE; LINE; RECOGNITION; BINDING; OKT3; GENE		[Weiss, Arthur] Univ Calif San Francisco, Howard Hughes Med Inst, Rosalind Russell Ephraim P Engleman Rheumatol Res, Dept Med, San Francisco, CA 94158 USA; [Stobo, John D.] Univ Calif, Off President, Oakland, CA USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Weiss, A (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Rosalind Russell Ephraim P Engleman Rheumatol Res, Dept Med, San Francisco, CA 94158 USA.	aweiss@medicine.ucst.edu						Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; ALLISON JP, 1982, J IMMUNOL, V129, P2293; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHANG TW, 1981, P NATL ACAD SCI-BIOL, V78, P1805, DOI 10.1073/pnas.78.3.1805; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; IMBODEN JB, 1985, J IMMUNOL, V134, P663; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MEUER SC, 1983, J EXP MED, V157, P705, DOI 10.1084/jem.157.2.705; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; WEISS A, 1986, J IMMUNOL, V137, P819; WEISS A, 1984, J IMMUNOL, V133, P123; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284	22	2	2	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2015	6								163	10.3389/fimmu.2015.00163	http://dx.doi.org/10.3389/fimmu.2015.00163			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI7HZ	25954271	Green Published, gold			2022-12-18	WOS:000354935200001
J	Filippi, CM				Filippi, Christophe M.			Toll-like receptor activation in immunity vs. tolerance	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						toll-like receptors; immune stimulation; immunoregulation; autoimmune diseases; cancer immunotherapy; infection; probiotics; microbiome			Novartis Res Fdn, Genom Inst, Immunol, San Diego, CA 92121 USA	Novartis	Filippi, CM (corresponding author), Novartis Res Fdn, Genom Inst, Immunol, San Diego, CA 92121 USA.	cfilippi@gnf.org						Burns EM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00135; Chandel HS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00220; de Kivit S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00060; Gulden E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00119; Kitazawa H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00201; Lu HL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00083; Nakamoto N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00221; Villena J, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00512; Yusuf N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00224; Zanin-Zhorov A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00211	10	2	2	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 2	2015	6								146	10.3389/fimmu.2015.00146	http://dx.doi.org/10.3389/fimmu.2015.00146			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI6VX	25883596	Green Published, gold			2022-12-18	WOS:000354903000001
J	Sautes-Fridman, C				Sautes-Fridman, Catherine			Tumor immunology, toward a success story?	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy; tumor microenvironment; immune escape; immune checkpoints; microbiota	CANCER		Ctr Rech Cordeliers, UMRS 1138, Dept Canc Immunol & Immunopathol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Sautes-Fridman, C (corresponding author), Ctr Rech Cordeliers, UMRS 1138, Dept Canc Immunol & Immunopathol, Paris, France.	catherine.fridman@crc.jussieu.fr		sautes-fridman, catherine/0000-0003-1735-8722				Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Wolchok JD, 2014, NATURE, V515, P496, DOI 10.1038/515496a	5	2	2	0	9	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 18	2015	6								65	10.3389/fimmu.2015.00065	http://dx.doi.org/10.3389/fimmu.2015.00065			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI5BM	25741340	Green Published, gold			2022-12-18	WOS:000354767900001
J	Kemper, C				Kemper, Claudia			Advances in bovine immunology - new tools and new insights to tackle old foes	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mastits; M. bovis; MAP; one health; immunobiotics; bovine immunology; pregnancy; miRNAs; tuberculosis	MACROPHAGE RESPONSE; INFECTION; MASTITIS		Kings Coll London, London WC2R 2LS, England	University of London; King's College London	Kemper, C (corresponding author), Kings Coll London, London WC2R 2LS, England.		Meade, Kieran G/HDN-5926-2022	Meade, Kieran G/0000-0002-3051-8586	Medical Research Council [G0701377] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Casey ME, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00023; Fair T, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00007; Kennedy AE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00564; Killick KE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00422; Lawless N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00611; McLoughlin KE, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00396; One Health Initiative, ONE HLTH IN WILL UN; Rue-Albrecht K, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00536; Schiller I, 2010, TRANSBOUND EMERG DIS, V57, P205, DOI 10.1111/j.1865-1682.2010.01148.x; Thompson-Crispi K, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00493; Viguier C, 2009, TRENDS BIOTECHNOL, V27, P486, DOI 10.1016/j.tibtech.2009.05.004; Villena J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00421; Wellenberg GJ, 2002, VET MICROBIOL, V88, P27, DOI 10.1016/S0378-1135(02)00098-6	13	2	2	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 17	2015	6								71	10.3389/fimmu.2015.00071	http://dx.doi.org/10.3389/fimmu.2015.00071			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI5BB	25741343	Green Published, gold			2022-12-18	WOS:000354766800001
J	Chaudhary, B; Elkord, E				Chaudhary, Belal; Elkord, Eyad			Downregulation of immunosuppressive environment in patients with chronic HBV hepatitis on maintained remission	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunosuppressive; Foxp3; PD1PD-L1; chronic HBV; downregulation	B-VIRUS INFECTION; T-CELLS; IMMUNE-RESPONSE; PATHWAY		[Chaudhary, Belal; Elkord, Eyad] United Arab Emirates Univ, Al Ain, U Arab Emirates; [Chaudhary, Belal; Elkord, Eyad] Univ Salford, Manchester, Lancs, England; [Chaudhary, Belal] Univ Cambridge, Cambridge, England; [Elkord, Eyad] Univ Manchester, Manchester, Lancs, England	United Arab Emirates University; University of Salford; University of Cambridge; University of Manchester	Elkord, E (corresponding author), United Arab Emirates Univ, Al Ain, U Arab Emirates.	e.elkord@salford.ac.uk	Elkord, Eyad/AAE-1136-2020	Elkord, Eyad/0000-0002-3868-0318; Chaudhary, Belal/0000-0002-3465-1886				Bertoletti A, 2006, J GEN VIROL, V87, P1439, DOI 10.1099/vir.0.81920-0; Chaudhary B, 2014, EXPERT OPIN BIOL TH, V14, P931, DOI 10.1517/14712598.2014.900539; Chen CJ, 2009, HEPATOLOGY, V49, pS72, DOI 10.1002/hep.22884; Chu CM, 2010, ANTIVIR THER, V15, P133, DOI 10.3851/IMP1497; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Ebinuma H, 2008, J VIROL, V82, P5043, DOI 10.1128/JVI.01548-07; El-Badawy O, 2012, HUM IMMUNOL, V73, P335, DOI 10.1016/j.humimm.2012.01.014; Fisicaro P, 2010, GASTROENTEROLOGY, V138, P682, DOI 10.1053/j.gastro.2009.09.052; Fletcher SP, 2013, SEMIN LIVER DIS, V33, P130, DOI 10.1055/s-0033-1345713; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Germanidis G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00207; Guicciardi ME, 2005, GUT, V54, P1024, DOI 10.1136/gut.2004.053850; Kassel R, 2009, HEPATOLOGY, V50, P1625, DOI 10.1002/hep.23173; Lehtimaki S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00294; Li FL, 2013, CELL MOL IMMUNOL, V10, P292, DOI 10.1038/cmi.2013.7; Li S, 2008, J VIROL, V82, P21, DOI 10.1128/JVI.01768-07; Manigold T, 2007, LANCET INFECT DIS, V7, P804, DOI 10.1016/S1473-3099(07)70289-X; Oo YH, 2013, J HEPATOL, V59, P1127, DOI 10.1016/j.jhep.2013.05.034; Speletas M, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/827565; Wang L, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0251-9; Wang L, 2014, J IMMUNOL METHODS, V407, P1, DOI 10.1016/j.jim.2014.04.004; Watanabe T, 2010, J VIRAL HEPATITIS, V17, P453, DOI 10.1111/j.1365-2893.2010.01313.x; Xu DP, 2006, J IMMUNOL, V177, P739, DOI 10.4049/jimmunol.177.1.739; Zhang HH, 2010, J VIRAL HEPATITIS, V17, P34, DOI 10.1111/j.1365-2893.2010.01269.x	24	2	2	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 11	2015	6								52	10.3389/fimmu.2015.00052	http://dx.doi.org/10.3389/fimmu.2015.00052			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI5AA	25717327	Green Published, gold			2022-12-18	WOS:000354763900001
J	Mehr, R				Mehr, Ramit			Immune system modeling and analysis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immune system; mathematical modeling; lymphocytes; repertoire; immunomics	AFFINITY MATURATION; SELECTION; VIRUS		Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Computat Immunol Lab, Ramat Gan, Israel	Bar Ilan University	Mehr, R (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Computat Immunol Lab, Ramat Gan, Israel.	ramit.mehr@biu.ac.il		Mehr, Ramit/0000-0002-4303-6834	BBSRC [BB/G023395/1, BB/F003811/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/G023395/1, BB/F003811/1] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alagha A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00426; Bocharov G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00264; Caridade M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00378; Carrillo-Bustamante P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00020; Castro M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00132; Chylek LA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00172; Collins AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00235; Fiala GJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00427; Gerdes S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00380; Gong C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00057; Hapuarachchi T, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00366; Jackson KJL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00263; Kepler TB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00170; Kessinger TA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00252; Leon K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00439; Liberman G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00274; Mamedov IZ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00456; Mehr R, 2012, IMMUNOL LETT, V148, P11, DOI 10.1016/j.imlet.2012.08.002; Michaeli M, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00264; Or-Guil M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00237; Rao XY, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00374; Reynolds J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00434; Schwartz GW, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00357; Shifrut E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00379; Six A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00413; Sun J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00038; Thomas-Vaslin V, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00300; Yaari G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00358; Yates AJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00013; Zarnitsyna VI, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00485	31	2	2	0	5	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 19	2014	5								644	10.3389/fimmu.2014.00644	http://dx.doi.org/10.3389/fimmu.2014.00644			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1XT	25566257	Green Published, gold			2022-12-18	WOS:000354539100001
J	Suslov, KV				Suslov, Konstantin V.			Neutralization-enhancing RF antibodies for HIV vaccines	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HIV; gp120 glycoprotein; neutralizing antibodies; rheumatoid factor; neutralization-enhancing RF antibodies; repeated immunization; microspheres; HIV vaccine	HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNOGLOBULIN-M IGM; RHEUMATOID-FACTOR; INFECTED INDIVIDUALS; IMMUNE-COMPLEXES; TYPE-1; ENHANCEMENT; IMMUNIZATIONS; VACCINATION; INDUCTION		Inst Immunol, Moscow, Russia	NRC Institute of Immunology FMBA of Russia	Suslov, KV (corresponding author), Inst Immunol, Moscow, Russia.	suslov_kv@mail.ru						ASHE WK, 1971, SCIENCE, V172, P176, DOI 10.1126/science.172.3979.176; BARTFELD H, 1969, ANN NY ACAD SCI, V168, P30, DOI 10.1111/j.1749-6632.1969.tb43092.x; Bonsignori M, 2012, TRENDS MICROBIOL, V20, P532, DOI 10.1016/j.tim.2012.08.011; CLARKSON AB, 1981, SCIENCE, V214, P186, DOI 10.1126/science.7025211; Cleland JL, 1999, TRENDS BIOTECHNOL, V17, P25, DOI 10.1016/S0167-7799(98)01272-4; Cleland JL, 1998, J PHARM SCI, V87, P1489, DOI 10.1021/js980263f; Douvas A, 1996, AIDS RES HUM RETROV, V12, P1509, DOI 10.1089/aid.1996.12.1509; Esbjornsson J, 2014, AIDS, V28, P949, DOI 10.1097/QAD.0000000000000101; GREEN TJ, 1984, INFECT IMMUN, V46, P668, DOI 10.1128/IAI.46.3.668-672.1984; Harada A, 2003, CHEM LETT, V32, P18, DOI 10.1246/cl.2003.18; HOMSY J, 1990, J VIROL, V64, P1437, DOI 10.1128/JVI.64.4.1437-1440.1990; JACKSON S, 1988, J CLIN IMMUNOL, V8, P390, DOI 10.1007/BF00917155; JARVIS JN, 1993, CLIN IMMUNOL IMMUNOP, V67, P50, DOI 10.1006/clin.1993.1044; JENDIS JB, 1988, AIDS, V2, P273, DOI 10.1097/00002030-198808000-00006; KHALIFE J, 1988, AIDS RES HUM RETROV, V4, P3, DOI 10.1089/aid.1988.4.3; KLINMAN DM, 1991, J EXP MED, V173, P881, DOI 10.1084/jem.173.4.881; Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012; Learn GH, 2002, J VIROL, V76, P11953, DOI 10.1128/JVI.76.23.11953-11959.2002; Margolin DH, 2006, J IMMUNOL, V177, P1108, DOI 10.4049/jimmunol.177.2.1108; McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011; Montefiori DC, 2012, J INFECT DIS, V206, P431, DOI 10.1093/infdis/jis367; NEMAZEE DA, 1985, J EXP MED, V161, P242, DOI 10.1084/jem.161.1.242; NEMAZEE DA, 1983, J EXP MED, V158, P529, DOI 10.1084/jem.158.2.529; NEMAZEE DA, 1982, P NATL ACAD SCI-BIOL, V79, P3828, DOI 10.1073/pnas.79.12.3828; PROCACCIA S, 1987, CLIN EXP IMMUNOL, V67, P236; Scarlatti G, 1996, IMMUNOL LETT, V51, P23, DOI 10.1016/0165-2478(96)02550-3; Stewart JJ, 1997, J IMMUNOL, V159, P1728; Suslov KV, 2010, IMMUNOL LETT, V128, P86, DOI 10.1016/j.imlet.2009.11.004; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Toran JL, 1999, EUR J IMMUNOL, V29, P2666, DOI 10.1002/(SICI)1521-4141(199909)29:09&lt;2666::AID-IMMU2666&gt;3.0.CO;2-Q; VANSNICK JL, 1978, EUR J IMMUNOL, V8, P279, DOI 10.1002/eji.1830080412; Wolbank S, 2003, J VIROL, V77, P4095, DOI 10.1128/JVI.77.7.4095-4103.2003; Wong G, 2014, VACCINE, V32, P5722, DOI 10.1016/j.vaccine.2014.08.028	34	2	3	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 16	2014	5								634	10.3389/fimmu.2014.00634	http://dx.doi.org/10.3389/fimmu.2014.00634			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1XF	25566247	Green Published, gold			2022-12-18	WOS:000354537700001
J	Al-Herz, W; Bousfiha, A; Casanova, JL; Chatila, T; Conley, ME; Cunningham-Rundlee, C; Etzioni, A; Franco, JL; Gaspar, HB; Holland, SM; Klein, C; Nonoyama, S; Ochs, HD; Oksenhendler, E; Picard, C; Puck, JM; Sullivan, K; Tang, MLK				Al-Herz, Waleed; Bousfiha, Aziz; Casanova, Jean-Laurent; Chatila, Talal; Conley, Mary Ellen; Cunningham-Rundlee, Charlotte; Etzioni, Amos; Franco, Jose Luis; Gaspar, H. Bobby; Holland, Steven M.; Klein, Christoph; Nonoyama, Shigeaki; Ochs, Hans D.; Oksenhendler, Erik; Picard, Capucine; Puck, Jennifer M.; Sullivan, Kate; Tang, Mimi L. K.			Primary immunodeficency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency (vol 5, 162,2014)	FRONTIERS IN IMMUNOLOGY			English	Correction						immunodeficiency; classification; gene defects; genotype; IUIS			[Al-Herz, Waleed] Kuwait Univ, Dept Pediat, Kuwait, Kuwait; [Al-Herz, Waleed] Al Sabah Hosp, Dept Pediat, Allergy & Clin Immunol Unit, Kuwait, Kuwait; [Bousfiha, Aziz] King Hassan II Univ, Ibn Rochd Med Sch, Casablanca Childrens Hosp, Clin Immunol Unit, Casablanca, Morocco; [Casanova, Jean-Laurent; Conley, Mary Ellen] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, New York, NY USA; [Casanova, Jean-Laurent; Picard, Capucine] Univ Paris 05, Necker Med Sch, Imagine Inst, INSERM,Necker Branch,Lab Human Genet Infect Dis,U, Paris, France; [Chatila, Talal] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Cunningham-Rundlee, Charlotte] Mt Sinai Sch Med, Dept Med & Pediat, New York, NY USA; [Franco, Jose Luis] Technion Israel Inst Technol, Meyer Childrens Hosp, Haifa, Israel; [Franco, Jose Luis] Univ Antioquia, Grp Primary Immunodeficiencies, Medellin, Colombia; [Gaspar, H. Bobby] UCL Inst Child Hlth, London, England; [Holland, Steven M.] NIAID, Lab Clin Infect Dis, Bethesda, MD 20892 USA; [Klein, Christoph] Univ Munich, Dr Von Hauner Childrens Hosp, Munich, Germany; [Nonoyama, Shigeaki] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Ochs, Hans D.] Univ Washington, Seattle Childrens Res Inst, Dept Pediat, Seattle, WA 98195 USA; [Oksenhendler, Erik] Hop St Louis, AP HP, Dept Clin Immunol, Paris, France; [Oksenhendler, Erik] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France; [Picard, Capucine] Hop Necker Enfants Malad, AP HP, CEDI, Paris, France; [Puck, Jennifer M.] Univ Calif San Francisco, Benioff Childrens Hosp, Dept Pediat, San Francisco, CA 94143 USA; [Sullivan, Kate] Childrens Hosp Philadelphia, Dept Pediat, Div Allergy Immunol, Philadelphia, PA 19104 USA; [Tang, Mimi L. K.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia	Kuwait University; Al Sabah Hospital; Hassan II University of Casablanca; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Boston Children's Hospital; Icahn School of Medicine at Mount Sinai; Rambam Health Care Campus; Technion Israel Institute of Technology; Universidad de Antioquia; University of London; University College London; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Munich; National Defense Medical College - Japan; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne	Gaspar, HB (corresponding author), UCL Inst Child Hlth, London, England.	h.gaspar@ucl.ac.uk	FRANCO, JOSE/AAK-1590-2020; Tang, Mimi/ABD-8350-2020	FRANCO, JOSE/0000-0001-5664-6415; Tang, Mimi/0000-0002-3839-5293; Casanova, Jean-Laurent/0000-0002-7782-4169				Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162	1	2	3	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2014	5								460	10.3389/fimmu.2014.00460	http://dx.doi.org/10.3389/fimmu.2014.00460			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI0TE		Green Published, gold			2022-12-18	WOS:000354450100001
J	Fraser, B; Maranchuk, RA; Foley, E				Fraser, Brittany; Maranchuk, Robert A.; Foley, Edan			A high-content RNAi screen identifies ubiquitin modifiers that regulate TNF-dependent nuclear accumulation of NF-kappa B	FRONTIERS IN IMMUNOLOGY			English	Article						TNF; ubiquitin; NF-kappa B; JNK; apoptosis; siRNA screen; high-content	CELL-DEATH; SIGNALING COMPLEX; ACTIVATION; PROTEIN; ALPHA; INFLAMMATION; PATHWAY; DEUBIQUITINATION; RECRUITMENT; INDUCTION	The mammalian tumor necrosis factor (TNF) cytokine is a central mediator of inflammatory events. Recent studies revealed a number of complex and sophisticated interactions between the TNF pathway and the enzymatic activities encoded by ubiquitin ligases and deubiquitylation enzymes. However, very little is known about the identity of the ubiquitin pathway members that control the extent of ubiquitylation in TNF responses. To address this deficit, we conducted an unbiased, high-content screen of the human ubiquitin pathway for gene products that control defining features of the cellular response to TNF In particular, we sought to identify ubiquitin modifying enzymes that alter the ability of TNF to regulate the nuclear accumulation of nuclear factor kappa B. In this screen, we identified and validated several novel regulators of the TNF pathway. We believe these regulators constitute potential targets for pharmacological interventions that manipulate INF-dependent inflammation.	[Fraser, Brittany; Maranchuk, Robert A.; Foley, Edan] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada; [Fraser, Brittany; Maranchuk, Robert A.; Foley, Edan] Univ Alberta, Inst Virol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Foley, E (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 6-71 HMRC, Edmonton, AB T6G 2S2, Canada.	efoley@ualberta.ca			Canadian Institutes of Health Research [MOP 77746]; Province of Alberta	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Province of Alberta	The research was funded by a grant from the Canadian Institutes of Health Research to Edan Foley (MOP 77746). Edan Foley holds a Canada Research Chair in Innate Immunity. The siRNA screen was conducted in the RNAi Core of the Faculty of Medicine and Dentistry and was made possible using equipment purchased through the Canada Foundation for Innovation and with matching funding from the Province of Alberta. We are grateful to Bart Hazes for assistance with calculating false discovery rates.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Bond D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000655; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Colleran A, 2013, P NATL ACAD SCI USA, V110, P618, DOI 10.1073/pnas.1208446110; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Echeverri CJ, 2006, NAT METHODS, V3, P777, DOI 10.1038/nmeth1006-777; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hao LH, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003235; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Jaattela M, 1996, J IMMUNOL, V156, P1166; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kurz T, 2005, NATURE, V435, P1257, DOI 10.1038/nature03662; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Tokunaga F, 2012, MICROBES INFECT, V14, P563, DOI 10.1016/j.micinf.2012.01.011; Tzimas C, 2006, CELL SIGNAL, V18, P83, DOI 10.1016/j.cellsig.2005.03.017; van Raam BJ, 2012, BBA-PROTEINS PROTEOM, V1824, P113, DOI 10.1016/j.bbapap.2011.06.005; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Wajant H, 2011, FEBS J, V278, P862, DOI 10.1111/j.1742-4658.2011.08015.x; Walczak H, 2011, IMMUNOL REV, V244, P9, DOI 10.1111/j.1600-065X.2011.01066.x; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Zaman MMU, 2013, MOL CELL BIOL, V33, P4971, DOI 10.1128/MCB.00465-13; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200	36	2	2	1	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2014	5								322	10.3389/fimmu.2014.00322	http://dx.doi.org/10.3389/fimmu.2014.00322			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH9SV	25071782	Green Published, gold			2022-12-18	WOS:000354377500001
J	Kurts, C				Kurts, Christian			Application of antigen cross-presentation research into patient care	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunotherapy; dendritic cell; cancer vaccines; clinical trial; virus infection; autoimmunity; T-cells	DENDRITIC CELLS		Univ Bonn, Bonn, Germany	University of Bonn	Kurts, C (corresponding author), Univ Bonn, Bonn, Germany.			Flinsenberg, Thijs/0000-0003-4268-3279; Boes, Marianne/0000-0003-2590-1692				Boltjes A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00131; Cohn L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00255; Everts B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00203; Fehres CM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00149; Hopp AK, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00055; Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171; Plantinga M, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00218; Platzer B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00140; Tullett KM, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00239; van Montfoort N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00182; Wimmers F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00165	11	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 17	2014	5								287	10.3389/fimmu.2014.00287	http://dx.doi.org/10.3389/fimmu.2014.00287			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH8JL	24987393	Green Published, gold			2022-12-18	WOS:000354282500001
J	Krzewski, K; Bryceson, YT				Krzewski, Konrad; Bryceson, Yenan T.			Molecular mechanisms regulating cytotoxic lymphocyte development and function, and their associations to human diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cytotoxicity; lytic granules; secretory lysosomes; perforin; granzyme; immunological synapse; hemophagocytic histiocytosis; immune therapy			[Krzewski, Konrad] NIAID, Receptor Cell Biol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA; [Bryceson, Yenan T.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Dis, Stockholm, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Karolinska Institutet; Karolinska University Hospital	Krzewski, K (corresponding author), NIAID, Receptor Cell Biol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA.	krzewskikj@niaid.nih.gov; yenan.bryceson@ki.se	Bryceson, Yenan T/D-2121-2018	Bryceson, Yenan T/0000-0002-7783-9934				Abeyweera TP, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00410; Baginska J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00490; Chijioke O, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00365; Della Chiesa M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00458; Galandrini R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00390; Ham H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00002; James AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00481; Jessen B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00448; Luetke-Eversloh M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00499; Muller ML, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00515; Nielsen CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00422; Olofsson PE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00080; Pattu V, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00411; Sieni E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00167; van der Sluijs P, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00359; Voskoboinik I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00441	16	2	2	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 11	2014	5								279	10.3389/fimmu.2014.00279	http://dx.doi.org/10.3389/fimmu.2014.00279			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH8IP	24966858	Green Published, gold			2022-12-18	WOS:000354280200001
J	Kubota, K; Iwabuchi, K				Kubota, Koichi; Iwabuchi, Kazuya			Pnenotypic changes in growth-arrested T cell hybrids: a possible avenue to produce functional T cell hybridoma	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						BW5147; cell growth-arrest; induction of differentiation; lymphocyte differentiation; reprograming; YACUT	EMBRYONIC STEM-CELLS; BACTERIAL-INFECTED MACROPHAGES; INNATE LYMPHOID-CELLS; NATURAL-KILLER-CELLS; IFN-GAMMA PRODUCTION; SOMATIC-CELLS; REPLACING FACTOR; GENE-EXPRESSION; ANTIGEN; DIFFERENTIATION		[Kubota, Koichi] Kitasato Univ, Sch Med, Dept Microbiol, Sagamihara, Kanagawa 228, Japan; [Iwabuchi, Kazuya] Kitasato Univ, Sch Med, Dept Immunol, Sagamihara, Kanagawa 228, Japan	Kitasato University; Kitasato University	Kubota, K (corresponding author), Kitasato Univ, Sch Med, Dept Microbiol, Sagamihara, Kanagawa 228, Japan.	koichi-tn@jcom.home.ne.jp	Kubota, Koichi/R-5818-2019		Grants-in-Aid for Scientific Research [25460502] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Ambrosi DJ, 2007, STEM CELLS, V25, P1104, DOI 10.1634/stemcells.2006-0532; Bartley MB, 2011, J IMMUNOL METHODS, V370, P35, DOI 10.1016/j.jim.2011.05.005; BEEZLEY BB, 1982, J IMMUNOL METHODS, V52, P269, DOI 10.1016/0022-1759(82)90001-1; Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; Berke G, 1997, HUM IMMUNOL, V54, P1, DOI 10.1016/S0198-8859(97)00009-8; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; Blomen VA, 2007, CELL MOL LIFE SCI, V64, P3084, DOI 10.1007/s00018-007-7271-z; BOSHART M, 1993, TRENDS GENET, V9, P240, DOI 10.1016/0168-9525(93)90088-Y; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; Foshay KM, 2012, MOL CELL, V46, P159, DOI 10.1016/j.molcel.2012.02.013; FOUGERE C, 1978, CELL, V15, P843, DOI 10.1016/0092-8674(78)90269-6; GOLDSBY RA, 1977, NATURE, V267, P707, DOI 10.1038/267707a0; GORDON S, 1994, LEGACY CELL FUSION; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; GU JJ, 1992, IMMUNOGENETICS, V36, P283; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; HAGIWARA H, 1988, J IMMUNOL, V140, P1561; HARRIS H, 1990, J CELL SCI, V97, P5; HAVRAN WL, 1987, NATURE, V325, P65, DOI 10.1038/325065a0; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; Kaneda R, 1997, IMMUNOL LETT, V55, P53, DOI 10.1016/S0165-2478(96)02683-1; KAPPLER J, 1983, CELL, V34, P727, DOI 10.1016/0092-8674(83)90529-9; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KAUFMANN Y, 1983, J IMMUNOL, V131, P50; KAUFMANN Y, 1981, P NATL ACAD SCI-BIOL, V78, P2502, DOI 10.1073/pnas.78.4.2502; KINASHI T, 1986, NATURE, V324, P70, DOI 10.1038/324070a0; Klein G., 1964, JNCI-J NATL CANCER I, V32, P547; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUBOTA K, 1990, INT J CANCER, V45, P540, DOI 10.1002/ijc.2910450328; KUBOTA K, 1994, J CELL SCI, V107, P2761; Kubota K, 1996, J IMMUNOL METHODS, V192, P137, DOI 10.1016/0022-1759(96)00030-0; Kubota K, 1997, CELL IMMUNOL, V181, P50, DOI 10.1006/cimm.1997.1195; Kubota K, 1999, IMMUNOLOGY, V96, P491; Kubota K, 2010, SCAND J IMMUNOL, V71, P199, DOI 10.1111/j.1365-3083.2009.02366.x; KUBOTA K, 1992, INT J CANCER, V51, P927, DOI 10.1002/ijc.2910510616; Kubota K, 1990, P JAP CANC ASS, V9, P163; Kubota K, 2006, J IMMUNOL, V176, P7576, DOI 10.4049/jimmunol.176.12.7576; Kubota K, 2014, INNATE IMMUN-LONDON, V20, P133, DOI 10.1177/1753425913485474; Kubota K, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00026; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Massa S, 2000, INT J BIOCHEM CELL B, V32, P23, DOI 10.1016/S1357-2725(99)00102-8; MELCHERS F, 1978, NATURE, V271, P9, DOI 10.1038/271009a0; NABHOLZ M, 1980, NATURE, V287, P437, DOI 10.1038/287437a0; NGUYEN TT, 1985, SOMAT CELL MOLEC GEN, V11, P593, DOI 10.1007/BF01534724; Palermo A, 2009, FASEB J, V23, P1431, DOI 10.1096/fj.08-122903; PEEHL DM, 1982, INT J CANCER, V30, P113, DOI 10.1002/ijc.2910300119; Probst AV, 2009, NAT REV MOL CELL BIO, V10, P192, DOI 10.1038/nrm2640; PURE E, 1981, J IMMUNOL, V127, P1953; Ramiscal RR, 2013, IMMUNOL REV, V252, P146, DOI 10.1111/imr.12031; Rankin L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00022; Ruddle N H, 1981, Prog Allergy, V29, P222; Russell SE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00246; SANDERSON S, 1994, INT IMMUNOL, V6, P369, DOI 10.1093/intimm/6.3.369; Serov OL, 2011, INT REV CEL MOL BIO, V291, P155, DOI 10.1016/B978-0-12-386035-4.00005-7; Singh N, 2011, METHODS MOL BIOL, V707, P39, DOI 10.1007/978-1-61737-979-6_3; SOMOZA C, 1989, EUR J IMMUNOL, V19, P1177, DOI 10.1002/eji.1830190704; Soza-Ried J, 2012, CURR OPIN GENET DEV, V22, P459, DOI 10.1016/j.gde.2012.07.005; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Sullivan S, 2006, CLONING STEM CELLS, V8, P174, DOI 10.1089/clo.2006.8.174; SZPIRER J, 1980, P NATL ACAD SCI-BIOL, V77, P6616, DOI 10.1073/pnas.77.11.6616; TAKATSU K, 1980, J IMMUNOL, V125, P2646; Terranova R, 2006, J CELL SCI, V119, P2065, DOI 10.1242/jcs.02945; Vahedi G, 2013, IMMUNOL REV, V252, P24, DOI 10.1111/imr.12037; WARREN DJ, 1985, IMMUNOLOGY, V54, P615; WHITE J, 1989, J IMMUNOL, V143, P1822; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229; Yusuf I, 2003, TRENDS IMMUNOL, V24, P380, DOI 10.1016/S1471-4906(03)00141-8; Zhang F, 2007, P NATL ACAD SCI USA, V104, P4395, DOI 10.1073/pnas.0700181104; Zhu JF, 2010, CELL RES, V20, P4, DOI 10.1038/cr.2009.138	71	2	2	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2014	5								229	10.3389/fimmu.2014.00229	http://dx.doi.org/10.3389/fimmu.2014.00229			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH7NK	24904579	Green Published, gold			2022-12-18	WOS:000354223400001
J	Yarkoni, S; Stein, J; Yaniv, I; Askenasy, N				Yarkoni, Shai; Stein, Jerry; Yaniv, Isaac; Askenasy, Nadir			Antigen-specific priming is dispensable in depletion of apoptosis-sensitive T cells for GvHD prophylaxis	FRONTIERS IN IMMUNOLOGY			English	Article						graft versus host disease; T cell depletion; apoptosis; Fas; TNF receptors; antigen-specific stimulation	VERSUS-HOST-DISEASE; UMBILICAL-CORD BLOOD; MINOR HISTOCOMPATIBILITY ANTIGENS; BONE-MARROW-TRANSPLANTATION; IN-VIVO; HEMATOPOIETIC PROGENITORS; SELECTIVE DEPLETION; MURINE ACUTE; FAS LIGAND; DENDRITIC CELLS	Prophylactic approaches to graft versus host disease (GvHD) have employed both phenotypic reduction of T cells and selective elimination of host-primed donor T cells in vitro and in vivo. An additional approach to GvHD prophylaxis by functional depletion of apoptosis-sensitive donor T cells without host-specific sensitization ex vivo showed remarkable reduction in GHD incidence and severity. We address the role and significance of antigen-specific sensitization of donor T cells and discuss the mechanisms of functional T cell purging by apoptosis for GvHD prevention. Host-specific sensitization is dispensable because migration is antigen-independent and donor T cell sensitization is mediated by multiple and redundant mechanisms of presentation of major and minor histocompatibility complex and tissue antigens by donor and host antigen-presenting cells. Our data suggest that potential murine and human GvH effectors reside within subsets of preactivated T cells susceptible to negative regulation by apoptosis prior to encounter of and sensitization to specific antigens.	[Yarkoni, Shai] Cellect Biomed, Kefar Sava, Israel; [Stein, Jerry; Yaniv, Isaac] Schneider Childrens Med Ctr Israel, Dept Pediat Hematol Oncol, Bone Marrow Transplant Unit, IL-49202 Petah Tiqwa, Israel; [Askenasy, Nadir] Schneider Childrens Med Ctr Israel, Ctr Stem Cell Res, Frankel Lab, IL-49202 Petah Tiqwa, Israel		Askenasy, N (corresponding author), Schneider Childrens Med Ctr Israel, Ctr Stem Cell Res, Frankel Lab, 14 Kaplan St, IL-49202 Petah Tiqwa, Israel.	anadir@012.net.il						Aggarwal S, 1997, J CLIN IMMUNOL, V17, P63, DOI 10.1023/A:1027340529644; Amir AL, 2011, BLOOD, V118, P6733, DOI 10.1182/blood-2011-05-354787; Anderson BE, 2003, J CLIN INVEST, V112, P101, DOI 10.1172/JCI200317601; Ash S, 2010, BRIT J CANCER, V103, P1597, DOI 10.1038/sj.bjc.6605924; Askenasy N, 2005, BLOOD, V105, P1396, DOI 10.1182/blood-2004-06-2364; Askenasy N, 2013, BIOL BLOOD MARROW TR, V19, P185, DOI 10.1016/j.bbmt.2012.10.004; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Bohana-Kashtan O, 2009, J IMMUNOL, V183, P696, DOI 10.4049/jimmunol.0800561; BROCHU S, 1995, J IMMUNOL, V155, P5104; CAVAZZANACALVO M, 1990, TRANSPLANTATION, V50, P1, DOI 10.1097/00007890-199007000-00001; CHAMPLIN R, 1990, BLOOD, V76, P418; Chen BJ, 2002, BLOOD, V99, P3083, DOI 10.1182/blood.V99.9.3083; Dickinson AM, 2002, NAT MED, V8, P410, DOI 10.1038/nm0402-410; Drobyski WR, 1998, J IMMUNOL, V161, P2610; Dutt S, 2007, J IMMUNOL, V179, P6547, DOI 10.4049/jimmunol.179.10.6547; Fehse B, 2000, BRIT J HAEMATOL, V109, P644, DOI 10.1046/j.1365-2141.2000.02074.x; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Friedman TM, 1998, J IMMUNOL, V161, P41; Georgantas RW, 2006, TRANSPLANTATION, V82, P471, DOI 10.1097/01.tp.0000229435.58898.c5; Giver CR, 2003, BIOL BLOOD MARROW TR, V9, P616, DOI 10.1016/S1083-8791(03)00229-5; Godfrey WR, 2004, BLOOD, V103, P1158, DOI 10.1182/blood-2003-04-1098; Guenechea G, 1999, BLOOD, V93, P1097, DOI 10.1182/blood.V93.3.1097.403k04_1097_1105; Hartwig UF, 2002, BLOOD, V99, P3041, DOI 10.1182/blood.V99.8.3041; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Jones SC, 2003, J CLIN INVEST, V112, P1880, DOI 10.1172/JCI200319427; Jung U, 2003, BLOOD, V102, P3439, DOI 10.1182/blood-2002-12-3936; Kaminitz A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021630; Kaminitz A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015684; Kanate Abraham Sebastian, 2011, Hematol Oncol Stem Cell Ther, V4, P149, DOI 10.5144/1658-3876.2011.149; Kim TD, 2008, BLOOD, V111, P2929, DOI 10.1182/blood-2007-06-096602; KORNGOLD R, 1990, J IMMUNOL, V145, P4079; KORNGOLD R, 1978, J EXP MED, V148, P1687; Lin SJ, 2005, AM J HEMATOL, V80, P106, DOI 10.1002/ajh.20431; Lin SJ, 2000, PEDIAT ALLERGY IMMUN, V20, P392, DOI [DOI 10.1111/J.1399-3038.2008.00790.X, 10.1111/j.1399-3038.2008.00790.x]; Liu DH, 2011, PEDIATR BLOOD CANCER, V57, P135, DOI 10.1002/pbc.23107; Martin PJ, 1999, BLOOD, V94, P2192, DOI 10.1182/blood.V94.7.2192.419a38_2192_2199; Matsue H, 2001, BLOOD, V98, P3465, DOI 10.1182/blood.V98.12.3465; Matte CC, 2004, NAT MED, V10, P987, DOI 10.1038/nm1089; Matte-Martone C, 2008, BLOOD, V111, P3884, DOI 10.1182/blood-2007-11-125294; MAYUMI H, 1987, TRANSPLANTATION, V44, P286, DOI 10.1097/00007890-198708000-00021; Mizrahi K, 2014, BONE MARROW TRANSPL, V49, P942, DOI 10.1038/bmt.2014.79; Mizrahi K, 2014, BONE MARROW TRANSPL, V49, P640, DOI 10.1038/bmt.2014.12; Mizrahi K, 2010, LEUKEMIA, V24, P1325, DOI 10.1038/leu.2010.97; Mizrahi K, 2014, STEM CELLS DEV, V23, P676, DOI 10.1089/scd.2013.0270; Mizrahi K, 2013, AM J STEM CELLS, V2, P155; Mizrahi K, 2013, STEM CELLS, V31, P156, DOI 10.1002/stem.1259; Morecki S, 2007, EXP HEMATOL, V35, P748, DOI 10.1016/j.exphem.2007.01.050; Murai M, 2003, NAT IMMUNOL, V4, P154, DOI 10.1038/ni879; Nagler A, 1998, TRANSPLANTATION, V66, P138, DOI 10.1097/00007890-199807150-00025; Panoskaltsis-Mortari A, 2004, BLOOD, V103, P3590, DOI 10.1182/blood-2003-08-2827; Pearl-Yafe M, 2007, STEM CELLS, V25, P3194, DOI 10.1634/stemcells.2007-0402; Pearl-Yafe M, 2010, STEM CELLS, V28, P1270, DOI 10.1002/stem.448; Rao SS, 1997, EXP HEMATOL, V25, P114; REISNER Y, 1995, IMMUNOL TODAY, V16, P437, DOI 10.1016/0167-5699(95)80021-2; Rocha V, 2000, NEW ENGL J MED, V342, P1846, DOI 10.1056/NEJM200006223422501; Samarasinghe S, 2010, BLOOD, V115, P396, DOI 10.1182/blood-2009-08-235895; Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Stanzani M, 2004, BLOOD, V103, P1140, DOI 10.1182/blood-06-2085; Teschner D, 2014, BONE MARROW TRANSPL, V49, P138, DOI 10.1038/bmt.2013.114; Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602-575; Tivol E, 2005, BLOOD, V105, P4885, DOI 10.1182/blood-2004-12-4980; Truitt RL, 1999, J IMMUNOL, V163, P5145; Vaclavkova P, 2006, BONE MARROW TRANSPL, V37, P559, DOI 10.1038/sj.bmt.1705286; Wang XN, 2000, TRANSPLANTATION, V70, P488, DOI 10.1097/00007890-200008150-00016; Yarkoni S, 2012, BIOL BLOOD MARROW TR, V18, P523, DOI 10.1016/j.bbmt.2011.11.016; Zhang Y, 2005, J IMMUNOL, V174, P3051, DOI 10.4049/jimmunol.174.5.3051; Zhang Y, 2004, BLOOD, V103, P3970, DOI 10.1182/blood-2003-09-3135	69	2	2	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2014	5								215	10.3389/fimmu.2014.00215	http://dx.doi.org/10.3389/fimmu.2014.00215			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH7MU	24904571	Green Published, gold			2022-12-18	WOS:000354221500001
J	Smith, KA				Smith, Kendall A.			Revisiting the first long-term culture of an antigen-specific cytotoxicT cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cytotoxicT-lymphocytes; lymphocyte-conditioned media	T-LYMPHOCYTE RESPONSE; IN-VITRO; POTENTIATION; SELECTION; MITOGENS		Cornell Univ, Div Immunol, Dept Med, Weill Med Coll, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Div Immunol, Dept Med, Weill Med Coll, New York, NY 10021 USA.	kasmith@med.cornell.edu						Bach F H, 1970, Cell Immunol, V1, P219, DOI 10.1016/0008-8749(70)90009-2; BAKER PE, 1979, J EXP MED, V149, P273, DOI 10.1084/jem.149.1.273; BENSASSON SZ, 1975, J EXP MED, V142, P90, DOI 10.1084/jem.142.1.90; CLINE MJ, 1974, NATURE, V248, P703, DOI 10.1038/248703a0; DENNERT G, 1976, J IMMUNOL, V116, P1601; Dutton R W, 1970, Cell Immunol, V1, P196, DOI 10.1016/0008-8749(70)90007-9; GERY I, 1972, J EXP MED, V136, P128, DOI 10.1084/jem.136.1.128; GERY I, 1972, J EXP MED, V136, P143, DOI 10.1084/jem.136.1.143; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GILLIS S, 1977, J EXP MED, V146, P468, DOI 10.1084/jem.146.2.468; GORDON J, 1965, NATURE, V208, P795, DOI 10.1038/208795a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOFFMANN M, 1971, SCIENCE, V172, P1047, DOI 10.1126/science.172.3987.1047; KASAKURA S, 1965, NATURE, V208, P794, DOI 10.1038/208794a0; MCDONALD HR, 1974, J EXP MED, V140, P718, DOI DOI 10.1084/JEM.140.3.718; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; SCHIMPL A, 1972, NATURE-NEW BIOL, V237, P15, DOI 10.1038/newbio237015a0; SVEDMYR E, 1975, SCAND J IMMUNOL, V4, P421, DOI 10.1111/j.1365-3083.1975.tb02647.x	18	2	2	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 5	2014	5								194	10.3389/fimmu.2014.00194	http://dx.doi.org/10.3389/fimmu.2014.00194			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH6HE	24829567	Green Published, gold			2022-12-18	WOS:000354136400003
J	Hargadon, KM; Bullock, TNJ				Hargadon, Kristian Michael; Bullock, Timothy N. J.			The role of tumor/dendritic cell interactions in the regulation of anti-tumor mmunity: the good, the bad, and the ugly	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tumor; dendritic cell; cancer immunotherapy; tumor immune evasion; cross-presentation; immune regulation			[Hargadon, Kristian Michael] Hampden Sydney Coll, Dept Biol, Hargadon Lab, Hampden Sydney, VA 23943 USA; [Bullock, Timothy N. J.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA	University of Virginia	Hargadon, KM (corresponding author), Hampden Sydney Coll, Dept Biol, Hargadon Lab, Hampden Sydney, VA 23943 USA.	khargadon@hsc.edu	Bullock, Timothy/AAA-4304-2021; Bullock, Timothy/AFL-5242-2022	Bullock, Timothy/0000-0001-6141-3261; 	NCI NIH HHS [R01 CA166458] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chmielewski M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00371; Dong H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00024; Dudek AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00438; Gallois A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00436; Goyne HE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00382; Hargadon KM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00192; Hosmalin A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00062; Ott PA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00346; Palombo F, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00503; Schiavoni G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00483; Schurch CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00496; Seliger B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00419; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Tesone AJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00435; Toubai T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00066; van de Ven R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00403; Vasaturo A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00417; Zinkemagel RM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00030	18	2	3	1	7	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 16	2014	5								178	10.3389/fimmu.2014.00178	http://dx.doi.org/10.3389/fimmu.2014.00178			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH5IP	24795721	Green Published, gold			2022-12-18	WOS:000354069200001
J	Hosmalin, A				Hosmalin, Anne			Mining the resource of cross-presentation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cross-presentation; dendritic cells; immunotherapy; tumors; HIV	ANTIGENS IN-VIVO; T-CELL IMMUNITY; DENDRITIC CELLS; DEATH		[Hosmalin, Anne] Inst Cochin, INSERM, U1016, Paris, France; [Hosmalin, Anne] CNRS, UMR8104, Paris, France; [Hosmalin, Anne] Univ Paris 05, Paris, France; [Hosmalin, Anne] Hop Cochin, AP HP, F-75674 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Hosmalin, A (corresponding author), Inst Cochin, INSERM, U1016, Paris, France.	anne.hosmalin@inserm.fr	Hosmalin, Anne/AAF-8561-2019	Hosmalin, Anne/0000-0001-9021-3488				Albert ML, 2004, NAT REV IMMUNOL, V4, P223, DOI 10.1038/nri11308; Beauvillain C, 2007, BLOOD, V110, P2965, DOI 10.1182/blood-2006-12-063826; Belz GT, 2005, J IMMUNOL, V175, P196, DOI 10.4049/jimmunol.175.1.196; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Goldszmid RS, 2003, J IMMUNOL, V171, P5940, DOI 10.4049/jimmunol.171.11.5940; Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545; Hoeffel G, 2007, IMMUNITY, V27, P481, DOI 10.1016/j.immuni.2007.07.021; HOSMALIN A, 1992, J IMMUNOL, V149, P1311; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Kerksiek KM, 2005, BLOOD, V105, P742, DOI 10.1182/blood-2004-05-1891; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Matheoud D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019104; Matheoud D, 2010, BLOOD, V115, P4412, DOI 10.1182/blood-2009-11-255935; Norbury CC, 2002, NAT IMMUNOL, V3, P265, DOI 10.1038/ni762; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Xu RH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000768; Zinkemagel RM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00030; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; Zinkernagel RM, 2002, EUR J IMMUNOL, V32, P2385, DOI 10.1002/1521-4141(200209)32:9<2385::AID-IMMU2385>3.0.CO;2-V	23	2	2	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 27	2014	5						1	2		10.3389/fimmu.2014.00062	http://dx.doi.org/10.3389/fimmu.2014.00062			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH5CW	24578703	Green Published, gold			2022-12-18	WOS:000354053100001
J	Ferrante, A				Ferrante, Andrea			Thermodynamics of peptide-MHC class II interactions: not all complexes are created equal	FRONTIERS IN IMMUNOLOGY			English	Review						antigen presentation; MHC class II; peptide binding; thermodynamics	INDUCED CONFORMATIONAL-CHANGE; HLA-DM; EPITOPE SELECTION; HYDROGEN-BONDS; ANCHOR INTERACTIONS; BINDING; MOLECULES; COOPERATIVITY; PREDICTION; STABILITY	The adaptive immune response begins when CD4+ T cells recognize antigenic peptides bound to class II molecules of the Major Histocompatibility Complex (MHCII). The interaction between peptides and MHCII has been historically interpreted as a rigid docking event. However, this model has been challenged by the evidence that conformational flexibility plays an important role in peptide-MHCII complex formation. Thermodynamic analysis of the binding reaction suggests a model of complexation in which the physical-chemical nature of the peptide determines the variability in flexibility of the substates in the peptide-MHC conformational ensemble. This review discusses our understanding of the correlation between thermodynamics of peptide binding and structural features of the resulting complex as well as their impact on HLA-DM activity and on our ability to predict MHCII-restricted epitopes.	[Ferrante, Andrea] Univ Alaska Fairbanks, Mol Immunol, Inst Arctic Biol, Fairbanks, AK USA	University of Alaska System; University of Alaska Fairbanks	Ferrante, A (corresponding author), Inst Arctic Biol, 902 North Koyukuk Dr,POB 757000, Fairbanks, AK 99775 USA.	aferrante@alaska.edu			NIH [R01AI63016]; National Institute of General Medical Sciences of the National Institutes of Health [P20GM103395]; National Institute of Allergy and Infectious Diseases [1R56AI098136]; Pfizer-sponsored Aspire Award [WS1907326]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Pfizer-sponsored Aspire Award	I wish to specially thank Dr. Jack Gorski for his remarkable mentorship and for his inspiring creative thinking. Funding for the research described here was provided by NIH grant R01AI63016 to Dr. Gorski. This work was supported by National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM103395, by the National Institute of Allergy and Infectious Diseases under Award Number 1R56AI098136, and by the Pfizer-sponsored Aspire Award Number WS1907326. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health or Pfizer. The author has no financial conflicts of interest.	Altuvia Y, 2004, METHODS, V34, P454, DOI 10.1016/j.ymeth.2004.06.008; Anders AK, 2011, NAT IMMUNOL, V12, P54, DOI 10.1038/ni.1967; Anderson MW, 2005, BIOCHEMISTRY-US, V44, P5617, DOI 10.1021/bi048675s; Bandyopadhyay A, 2008, MOL IMMUNOL, V45, P1248, DOI 10.1016/j.molimm.2007.09.011; Belmares MP, 2002, J IMMUNOL, V169, P5109, DOI 10.4049/jimmunol.169.9.5109; Carven GJ, 2005, BIOCHEMISTRY-US, V44, P13625, DOI 10.1021/bi050972p; Chou CL, 2000, J EXP MED, V192, P1697, DOI 10.1084/jem.192.12.1697; Davies MN, 2008, MOL IMMUNOL, V45, P1063, DOI 10.1016/j.molimm.2007.07.033; Elliott T, 2005, IMMUNOL REV, V207, P89, DOI 10.1111/j.0105-2896.2005.00311.x; Ferrante A, 2007, J IMMUNOL, V178, P7181, DOI 10.4049/jimmunol.178.11.7181; Ferrante A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00386; Ferrante A, 2012, J MOL BIOL, V417, P454, DOI 10.1016/j.jmb.2012.01.057; Ferrante A, 2010, J IMMUNOL, V184, P1153, DOI 10.4049/jimmunol.0902878; Ferrante A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003722; Guce AI, 2013, NAT STRUCT MOL BIOL, V20, P90, DOI 10.1038/nsmb.2460; HILL CM, 1994, J IMMUNOL, V152, P2890; HOROVITZ A, 1992, J MOL BIOL, V224, P733, DOI 10.1016/0022-2836(92)90557-Z; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; Hunter CA, 2003, CHEM BIOL, V10, P1023, DOI 10.1016/j.chembiol.2003.10.009; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; Joshi RV, 2000, BIOCHEMISTRY-US, V39, P3751, DOI 10.1021/bi9923656; Kasson PM, 2000, BIOCHEMISTRY-US, V39, P1048, DOI 10.1021/bi9921337; Leddon SA, 2010, CURR OPIN ORGAN TRAN, V15, P505, DOI 10.1097/MOT.0b013e32833bfc5c; Lin HH, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S12-S22; Marin-Esteban V, 2004, J BIOL CHEM, V279, P50684, DOI 10.1074/jbc.M407598200; McFarland BJ, 2005, J MOL BIOL, V350, P170, DOI 10.1016/j.jmb.2005.04.069; McFarland BJ, 2001, P NATL ACAD SCI USA, V98, P9231, DOI 10.1073/pnas.151131498; Narayan K, 2007, NAT IMMUNOL, V8, P92, DOI 10.1038/ni1414; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Nelson C A, 1999, Rev Immunogenet, V1, P47; Nelson CA, 1996, J IMMUNOL, V156, P176; Painter CA, 2011, P NATL ACAD SCI USA, V108, P19329, DOI 10.1073/pnas.1108074108; Painter CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002403; Pos W, 2012, CELL, V151, P1557, DOI 10.1016/j.cell.2012.11.025; Raddrizzani L, 1999, EUR J IMMUNOL, V29, P660, DOI 10.1002/(SICI)1521-4141(199902)29:02<660::AID-IMMU660>3.0.CO;2-I; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Reche PA, 2004, IMMUNOGENETICS, V56, P405, DOI 10.1007/s00251-004-0709-7; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SADEGHNASSERI S, 1992, IMMUNOL TODAY, V13, P43, DOI 10.1016/0167-5699(92)90131-P; Sant AJ, 1999, IMMUNOL REV, V172, P239, DOI 10.1111/j.1600-065X.1999.tb01369.x; Sato AK, 1999, HUM IMMUNOL, V60, P1227, DOI 10.1016/S0198-8859(99)00120-2; Sato AK, 2000, J BIOL CHEM, V275, P2165, DOI 10.1074/jbc.275.3.2165; Schneeweiss C, 2009, MOL IMMUNOL, V46, P2054, DOI 10.1016/j.molimm.2009.02.032; Schueler-Furman O, 2000, PROTEIN SCI, V9, P1838, DOI 10.1110/ps.9.9.1838; Sieker F, 2009, CURR PROTEIN PEPT SC, V10, P286, DOI 10.2174/138920309788452191; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Tobita T, 2003, IMMUNOL LETT, V85, P47, DOI 10.1016/S0165-2478(02)00206-7; Weaver JM, 2009, IMMUNOL RES, V45, P123, DOI 10.1007/s12026-009-8095-8; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; Yin LS, 2012, J IMMUNOL, V189, P3983, DOI 10.4049/jimmunol.1200626; Zarutskie JA, 1999, BIOCHEMISTRY-US, V38, P5878, DOI 10.1021/bi983048m; Zhou ZM, 2009, J IMMUNOL, V183, P4187, DOI 10.4049/jimmunol.0901663; Zhu SF, 2006, BIOINFORMATICS, V22, P1648, DOI 10.1093/bioinformatics/btl141	55	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								308	10.3389/fimmu.2013.00308	http://dx.doi.org/10.3389/fimmu.2013.00308			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	24101920	gold, Green Published			2022-12-18	WOS:000209374100302
J	Kurts, C				Kurts, Christian			Molecular and cell-biological mechanisms of antigen cross-presentation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									Univ Bonn, Inst Mol Med & Expt Immunol, Bonn, Germany	University of Bonn	Kurts, C (corresponding author), Univ Bonn, Inst Mol Med & Expt Immunol, Bonn, Germany.	churts@uni-bonn.de						Chopin M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00026; Compeer EB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00037; Harriff MJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00040; Kreer C, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00087; Kroczek RA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00014; Murshid A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00063; Neefjes J, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00031; Saveanu L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00057; Thacker RI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00041; Wagner CS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00138	10	2	2	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 51	10.3389/fimmu.2013.00051	http://dx.doi.org/10.3389/fimmu.2013.00051			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	23450983	Green Published, gold			2022-12-18	WOS:000209374100051
J	Murakami, M				Murakami, Masaaki			Tophaceous gout - even today	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						gout; gout suppressants; chronic disease; chronic pain; tophaceous gout			Osaka Univ, Suita, Osaka 565, Japan	Osaka University	Murakami, M (corresponding author), Osaka Univ, Suita, Osaka 565, Japan.								0	2	2	13	49	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 284	10.3389/fimmu.2013.00284	http://dx.doi.org/10.3389/fimmu.2013.00284			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	24069020	Green Published, gold			2022-12-18	WOS:000209374100279
J	Radic, M; Kaplan, MJ				Radic, Marko; Kaplan, Mariana J.			Extracellular chromatin traps interconnect cell biology, microbiology, and immunology	FRONTIERS IN IMMUNOLOGY			English	Editorial Material							NEUTROPHILS; PAD4		[Radic, Marko] Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA; [Kaplan, Mariana J.] Univ Michigan, Dept Internal Med, Div Rheumatol, Sch Med, Ann Arbor, MI 48109 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Michigan System; University of Michigan	Radic, M (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA.	mradic@uthsc.edu		Radic, Marko/0000-0002-8004-282X				Abdallah DSA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00382; Almyroudis NG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00045; Berger-Achituv S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00048; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00413; Brinkmann V, 2012, J CELL BIOL, V198, P773, DOI 10.1083/jcb.201203170; Cheng OZ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00001; Daigo K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00378; Darrah E, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00428; Goldmann O, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00420; Hahn S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00362; Hosseinzadeh A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00391; Kambas K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00385; Knight JS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00380; Leshner M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00307; Lu T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00365; Mohanan S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00067; Moorthy AN, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00056; Nakazawa D, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00333; Neeli I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00038; Parker H, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00424; Rohrbach AS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00360; Schorn C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00376	23	2	4	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								160	10.3389/fimmu.2013.00160	http://dx.doi.org/10.3389/fimmu.2013.00160			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	23805137	gold, Green Published			2022-12-18	WOS:000209374100156
J	Rao, XY; De Boer, RJ; van Baarle, D; Maiers, M; Kesmir, C				Rao, Xiangyu; De Boer, Rob J.; van Baarle, Debbie; Maiers, Martin; Kesmir, Can			Complementarity of binding motifs is a general property of HLA-A anc HLA-B molecules and does not seem to effect HLA haplotype composition	FRONTIERS IN IMMUNOLOGY			English	Article						haplotypes; HLA antigens; selection; genetic; peptide binding; bioinformatics; computational biology		Different human leukocyte antigen (HLA) haplotypes (i.e., the specific combinations of HLA-A, -B, -DR alleles inherited together from one parent) are observed in different frequencies in human populations. Some haplotypes, like HLA-A1-B8, are very frequent, reaching up to 10% in the Caucasian population, while others are very rare. Numerous studies have identified associations between HLA haplotypes and diseases, and differences in haplotype frequencies can in part be explained by these associations: the stronger the association with a severe (autoimmune) disease, the lower the expected HLA haplotype frequency. The peptide repertoires of the HLA molecules composing a haplotype can also influence the frequency of a haplotype. For example, it would seem advantageous to have HLA molecules with non-overlapping binding specificities within a haplotype, as individuals expressing such an haplotype would present a diverse set of peptides from viruses and pathogenic bacteria on the cell surface. To test this hypothesis, we collect the proteome data from a set of common viruses, and estimate the total ligand repertoire of HLA class I haplotypes (HLA-A-B) using in silico predictions. We compare the size of these repertoires to the HLA haplotype frequencies reported in the National Marrow Donor Program (NMDP). We find that in most HLA-A and HLA-B pairs have fairly distinct binding motifs, and that the observed haplotypes do not contain HLA-A and -B molecules with more distinct binding motifs than random HLA-A and HLA-B pairs. In addition, the population frequency of a haplotype is not correlated to the distinctness of its HLA-A and HLA-B peptide binding motifs. These results suggest that there is a not a strong selection pressure on the haplotype level favoring haplotypes having HLA molecules with distinct binding motifs, which would result the largest possible presented peptide repertoires in the context of infectious diseases.	[Rao, Xiangyu; De Boer, Rob J.; Kesmir, Can] Univ Utrecht, Theoret Biol & Bioinformat, NL-3584 CH Utrecht, Netherlands; [van Baarle, Debbie] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Immunol, Utrecht, Netherlands; [Maiers, Martin] Natl Marrow Donor Program, Minneapolis, MN USA	Utrecht University; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; National Marrow Donor Program	Kesmir, C (corresponding author), Univ Utrecht, Theoret Biol & Bioinformat, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	c.kesmir@uu.nl	Kesmir, Can/B-9410-2011; de Boer, Rob/B-6050-2011	de Boer, Rob/0000-0002-2130-691X; Maiers, Martin/0000-0002-0198-2064	University of Utrecht through a High Potential grant	University of Utrecht through a High Potential grant	This study was financially supported by the University of Utrecht through a High Potential grant. The funders had no role in study design, data collection, and analysis, decision to publish or preparation of the manuscript.	Albanidou-Farmaki E, 2008, INT J IMMUNOGENET, V35, P427, DOI 10.1111/j.1744-313X.2008.00801.x; Apanius V, 1997, CRIT REV IMMUNOL, V17, P179, DOI 10.1615/CritRevImmunol.v17.i2.40; Axelsson-Robertson R, 2010, IMMUNOLOGY, V129, P496, DOI 10.1111/j.1365-2567.2009.03201.x; BEGOVICH AB, 1992, J IMMUNOL, V148, P249; Bettencourt BF, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-68; Boehm T, 2006, TRENDS NEUROSCI, V29, P100, DOI 10.1016/j.tins.2005.11.006; Buus S, 2003, TISSUE ANTIGENS, V62, P378, DOI 10.1034/j.1399-0039.2003.00112.x; Capittini C, 2009, TISSUE ANTIGENS, V74, P156, DOI 10.1111/j.1399-0039.2009.01282.x; Carrington M, 1999, IMMUNOL REV, V167, P245, DOI 10.1111/j.1600-065X.1999.tb01397.x; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Castelli EC, 2010, TISSUE ANTIGENS, V76, P459, DOI 10.1111/j.1399-0039.2010.01539.x; Crawford DC, 2005, ANNU REV MED, V56, P303, DOI 10.1146/annurev.med.56.082103.104540; De Boer RJ, 2004, IMMUNOGENETICS, V55, P725, DOI 10.1007/s00251-003-0629-y; Douglas JA, 2001, NAT GENET, V28, P361, DOI 10.1038/ng582; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Frahm N, 2007, EUR J IMMUNOL, V37, P2419, DOI 10.1002/eji.200737365; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Kollman C, 2007, HUM IMMUNOL, V68, P950, DOI 10.1016/j.humimm.2007.10.009; LONG JC, 1995, AM J HUM GENET, V56, P799; MacNamara A, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000327; Madeleine MM, 2008, CANCER RES, V68, P3532, DOI 10.1158/0008-5472.CAN-07-6471; Maiers M, 2007, HUM IMMUNOL, V68, P779, DOI 10.1016/j.humimm.2007.04.005; Middleton D, 2003, TISSUE ANTIGENS, V61, P403, DOI 10.1034/j.1399-0039.2003.00062.x; Nakagawa M, 2007, J VIROL, V81, P1412, DOI 10.1128/JVI.01768-06; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Nielsen M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000796; Niu TH, 2004, GENET EPIDEMIOL, V27, P334, DOI 10.1002/gepi.20024; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; Rao XY, 2011, IMMUNOGENETICS, V63, P691, DOI 10.1007/s00251-011-0552-6; Smith WP, 2006, GENOMICS, V87, P561, DOI 10.1016/j.ygeno.2005.11.020; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659	31	2	2	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 374	10.3389/fimmu.2013.00374	http://dx.doi.org/10.3389/fimmu.2013.00374			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	24294213	gold, Green Published, Green Submitted			2022-12-18	WOS:000209374100365
J	Lambert, SE; Kinder, JM; Then, JE; Parliament, KN; Bruns, HA				Lambert, Sydney E.; Kinder, Jeremy M.; Then, Jenny E.; Parliament, Kelly N.; Bruns, Heather A.			Erythromycin treatment hinders the induction of oral tolerance to fed ovalbumin	FRONTIERS IN IMMUNOLOGY			English	Article						antibiotics; dendritic cells; Lactobacillus; probiotics; T regulatory cells; tolerance		The mucosal immune system is constantly exposed to antigen, whether it be food antigen, commensal bacteria, or harmful antigen. It is essential that the mucosal immune system can distinguish between harmful and non-harmful antigens, and initiate an active immune response to clear the harmful antigens, while initiating a suppressive immune response (tolerance) to non-harmful antigens. Oral tolerance is an immunologic hyporesponsiveness to an orally administered antigen and is important in preventing unnecessary gastrointestinal tract inflammation, which can result in a number of autoimmune and hypersensitivity diseases. Probiotics (beneficial intestinal bacteria), T regulatory cells, and dendritic cells (DCs) are all essential for generating tolerance. Antibiotics are commonly prescribed to fight infections and often necessary for maintaining health, but they can disrupt the normal intestinal probiotic populations. There is increasing epidemiologic evidence that suggests that antibiotic usage correlates with the development of atopic or irritable bowel disorders, which often result due to a breakdown in immune tolerance. This study investigated the effect of the antibiotic erythromycin on oral tolerance induction to ovalbumin. The results demonstrated that antibiotic treatment prior to exposure to fed antigen prevents tolerance to that antigen, which may be associated with a reduction in intestinal Lactobacillus populations. Furthermore, antibiotic treatment resulted in a significant decrease in the tolerogenic CD11c(+)/CD11b(+)/CD8 alpha(-) mesenteric lymph node DCs independent of tolerizing treatment. These results provide evidence that antibiotic treatment, potentially through its effects on tolerogenic DCs and intestinal microflora, may contribute to autoimmune and atopic disorders via a breakdown in tolerance and support prior epidemiologic studies correlating increased antibiotic usage with the development of these disorders.	[Lambert, Sydney E.; Kinder, Jeremy M.; Then, Jenny E.; Parliament, Kelly N.; Bruns, Heather A.] Ball State Univ, Dept Biol, Muncie, IN 47306 USA	Ball State University	Bruns, HA (corresponding author), Ball State Univ, Dept Biol, 2000 West Univ Ave CL 121, Muncie, IN 47306 USA.	habruns@bsu.edu		Kinder, Jeremy/0000-0001-5145-1344; Bruns, Heather/0000-0003-3168-3898	Ball State University's Department of Biology; Sponsored Programs Office	Ball State University's Department of Biology; Sponsored Programs Office	This work was supported by Ball State University's Department of Biology and Sponsored Programs Office. We would like to thank Susan A. McDowell and Jennifer A. Metzler for their critical review of this manuscript.	Alpan O, 2001, J IMMUNOL, V166, P4843, DOI 10.4049/jimmunol.166.8.4843; ANDREMONT A, 1983, J INFECT DIS, V148, P579, DOI 10.1093/infdis/148.3.579; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Brandtzaeg P, 2009, SCAND J IMMUNOL, V70, P505, DOI 10.1111/j.1365-3083.2009.02319.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Card T, 2004, GUT, V53, P246, DOI 10.1136/gut.2003.025239; Chahine BG, 2010, CURR OPIN ALLERGY CL, V10, P394, DOI 10.1097/ACI.0b013e32833982ab; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Chung Y, 2005, BLOOD, V106, P201, DOI 10.1182/blood-2004-11-4240; Di Giacinto C, 2005, J IMMUNOL, V174, P3237, DOI 10.4049/jimmunol.174.6.3237; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; FINEGOLD SM, 1970, AM J CLIN NUTR, V23, P1466; Foligne B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000313; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; FURRIE E, 1995, ADV EXP MED BIOL, V371, P1239; Hanaway P, 2006, ALTERN THER HEALTH M, V12, P52; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Hoban Daryl J, 2003, Clin Cornerstone, VSuppl 3, pS12; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ivanov II, 2011, CURR OPIN MICROBIOL, V14, P106, DOI 10.1016/j.mib.2010.12.003; Kunkel D, 2003, EUR J IMMUNOL, V33, P1292, DOI 10.1002/eji.200323383; Levy J, 2000, AM J GASTROENTEROL, V95, pS8, DOI 10.1016/S0002-9270(99)00808-4; Littman DR, 2011, CELL HOST MICROBE, V10, P311, DOI 10.1016/j.chom.2011.10.004; Livingston M, 2010, IMMUNOL CELL BIOL, V88, P99, DOI 10.1038/icb.2009.71; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; Milling S, 2010, IMMUNOL REV, V234, P259, DOI 10.1111/j.0105-2896.2009.00866.x; MOWAT AM, 1982, IMMUNOLOGY, V45, P105; Niess JH, 2006, CELL MICROBIOL, V8, P558, DOI 10.1111/j.1462-5822.2006.00694.x; Noverr MC, 2005, CLIN EXP ALLERGY, V35, P1511, DOI 10.1111/j.1365-2222.2005.02379.x; Ohkura N, 2010, SEMIN IMMUNOPATHOL, V32, P95, DOI 10.1007/s00281-010-0200-5; Pecquet S, 2004, ANN NY ACAD SCI, V1029, P374, DOI 10.1196/annals.1309.021; Prioult G, 2003, CLIN DIAGN LAB IMMUN, V10, P787, DOI 10.1128/CDLI.10.5.787-792.2003; Pronio A, 2008, INFLAMM BOWEL DIS, V14, P662, DOI 10.1002/ibd.20369; Roncarolo MG, 2001, J EXP MED, V193, pF5, DOI 10.1084/jem.193.2.F5; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Scott CL, 2011, TRENDS IMMUNOL, V32, P412, DOI 10.1016/j.it.2011.06.003; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Strobel S, 2006, CURR OPIN ALLERGY CL, V6, P207, DOI 10.1097/01.all.0000225162.98391.81; Tanaka K, 2004, HISTOL HISTOPATHOL, V19, P907, DOI 10.14670/HH-19.907; Tezuka H, 2010, IMMUNOL REV, V234, P247, DOI 10.1111/j.0105-2896.2009.00872.x; von der Weid T, 2001, CLIN DIAGN LAB IMMUN, V8, P695, DOI 10.1128/CDLI.8.4.695-701.2001; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016	50	2	2	0	0	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2012	3								203	10.3389/fimmu.2012.00203	http://dx.doi.org/10.3389/fimmu.2012.00203			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TQ	22826710	gold, Green Published			2022-12-18	WOS:000209501300199
J	Plichta, JK; Nienhouse, V; Radek, KA				Plichta, Jennifer K.; Nienhouse, Vanessa; Radek, Katherine A.			Integrating "omics" technologies to conceptualize dynamic antimicrobial peptide responses	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Plichta, Jennifer K.; Nienhouse, Vanessa; Radek, Katherine A.] Loyola Univ Hlth Syst, Burn & Shock Trauma Inst, Dept Surg, Maywood, IL 60153 USA	Loyola University Chicago	Radek, KA (corresponding author), Loyola Univ Hlth Syst, Burn & Shock Trauma Inst, Dept Surg, Maywood, IL 60153 USA.	kradek1@lumc.edu	Plichta, Jennifer K/L-5450-2016	Plichta, Jennifer K/0000-0002-7411-0558	NIAMS NIH HHS [R01 AR061497] Funding Source: Medline; NIGMS NIH HHS [T32 GM008750] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad A, 2012, CURR PROTEIN PEPT SC, V13, P211, DOI 10.2174/138920312800785076; Ali ASM, 2009, J UROLOGY, V182, P21, DOI 10.1016/j.juro.2009.02.124; Baltzer SA, 2011, J MOL MICROB BIOTECH, V20, P228, DOI 10.1159/000331009; BELL JD, 1991, BIOCHIM BIOPHYS ACTA, V1096, P101, DOI 10.1016/0925-4439(91)90046-C; Bhat S, 2007, CURR PROTEIN PEPT SC, V8, P506, DOI 10.2174/138920307782411428; Braff MH, 2007, J INFECT DIS, V195, P1365, DOI 10.1086/513277; Brahmachary M, 2004, NUCLEIC ACIDS RES, V32, pD586, DOI 10.1093/nar/gkh032; Chong KT, 2008, VIROLOGY, V380, P136, DOI 10.1016/j.virol.2008.07.024; Cole Alexander M, 2002, Am J Respir Med, V1, P249; Dong QF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019709; Fjell CD, 2007, BIOINFORMATICS, V23, P1148, DOI 10.1093/bioinformatics/btm068; FOXALL PJD, 1993, KIDNEY INT, V43, P234, DOI 10.1038/ki.1993.37; Hassan M, 2012, J APPL MICROBIOL, V113, P723, DOI 10.1111/j.1365-2672.2012.05338.x; Hermes O, 2011, BIOL CHEM, V392, P949, DOI 10.1515/BC.2011.092; Hirsch T, 2008, PROTEIN PEPTIDE LETT, V15, P238; Kesting MR, 2012, BIODRUGS, V26, P33, DOI 10.2165/11597570-000000000-00000; Kovach MA, 2012, J IMMUNOL, V189, P304, DOI 10.4049/jimmunol.1103196; Kumari S. R., 2012, PROTEIN PEPT LETT; Lai YP, 2010, J INVEST DERMATOL, V130, P2211, DOI 10.1038/jid.2010.123; Lai YP, 2009, TRENDS IMMUNOL, V30, P131, DOI 10.1016/j.it.2008.12.003; Lisitsyn NA, 2012, ANN CLIN MICROB ANTI, V11, DOI 10.1186/1476-0711-11-1; Micheel C., 2012, EVOLUTION TRANSLATIO; Murphy S. L., 2010, NATL VITAL STAT REPO, V60, P4; Nakatsuji T, 2012, J INVEST DERMATOL, V132, P887, DOI 10.1038/jid.2011.387; Nelson DE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014116; Nizet V, 2006, CURR ISSUES MOL BIOL, V8, P11; PAULING L, 1971, P NATL ACAD SCI USA, V68, P2374, DOI 10.1073/pnas.68.10.2374; Pedersen TX, 2003, ONCOGENE, V22, P3964, DOI 10.1038/sj.onc.1206614; Radek K, 2007, SEMIN IMMUNOPATHOL, V29, P27, DOI 10.1007/s00281-007-0064-5; Saemann MD, 2007, NEPHROL DIAL TRANSPL, V22, P347, DOI 10.1093/ndt/gfl590; Scharf S, 2012, EXP LUNG RES, V38, P100, DOI 10.3109/01902148.2011.652802; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Schluesener Hermann Josef, 2012, Front Biosci (Schol Ed), V4, P1375; Schroeder Jens-M., 2011, Allergology International, V60, P17, DOI 10.2332/allergolint.10-RAI-0292; Scola N, 2012, BRIT J DERMATOL, V167, P591, DOI 10.1111/j.1365-2133.2012.11110.x; Steinstraesser L, 2004, BURNS, V30, P619, DOI 10.1016/j.burns.2004.05.013; Steinstraesser L, 2011, IMMUNOBIOLOGY, V216, P322, DOI 10.1016/j.imbio.2010.07.003; Sundararajan VS, 2012, NUCLEIC ACIDS RES, V40, pD1108, DOI 10.1093/nar/gkr1063; Sweitzer SM, 2006, DIABETES EDUCATOR, V32, P197, DOI 10.1177/0145721706286897; Tecle T, 2010, INNATE IMMUN-LONDON, V16, P151, DOI 10.1177/1753425910365734; Torrent M, 2012, CURR DRUG TARGETS, V13, P1148, DOI 10.2174/138945012802002311; Wang GS, 2009, NUCLEIC ACIDS RES, V37, pD933, DOI 10.1093/nar/gkn823; Wang Z, 2004, NUCLEIC ACIDS RES, V32, pD590, DOI 10.1093/nar/gkh025; Williams WM, 2012, SCI WORLD J, DOI 10.1100/2012/905785; Wolfe AJ, 2012, J CLIN MICROBIOL, V50, P1376, DOI 10.1128/JCM.05852-11; Zasloff M, 2007, J AM SOC NEPHROL, V18, P2810, DOI 10.1681/ASN.2007050611; Zoetendal EG, 2006, MOL MICROBIOL, V59, P1639, DOI 10.1111/j.1365-2958.2006.05056.x	47	2	2	1	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2012	3								284	10.3389/fimmu.2012.00284	http://dx.doi.org/10.3389/fimmu.2012.00284			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TQ	23060875	Green Published, gold			2022-12-18	WOS:000209501300279
J	Sijts, AJ; van Eden, W				Sijts, Alice J.; van Eden, Willem			The tricky balancing act of using heat shock proteins for cross-presentation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material							ANTIGEN; MECHANISMS		[Sijts, Alice J.; van Eden, Willem] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Utrecht, Netherlands	Utrecht University	van Eden, W (corresponding author), Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Utrecht, Netherlands.	w.vaneden@uu.nl		van Eden, Willem/0000-0003-1272-704X; Sijts, Alice/0000-0003-3815-4788				Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Aldridge S, 2012, NAT BIOTECHNOL, V30, P124, DOI 10.1038/nbt0212-124c; Amigorena S, 2010, CURR OPIN IMMUNOL, V22, P109, DOI 10.1016/j.coi.2010.01.022; Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x; Kunisawa J, 2006, IMMUNITY, V24, P523, DOI 10.1016/j.immuni.2006.03.015; Murshid A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00063; Rock KL, 2005, IMMUNOL REV, V207, P166, DOI 10.1111/j.0105-2896.2005.00301.x; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; van Eden W, 2012, CELL STRESS CHAPERON, V17, P281, DOI 10.1007/s12192-011-0311-5	10	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2012	3								114	10.3389/fimmu.2012.00114	http://dx.doi.org/10.3389/fimmu.2012.00114			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TQ	22590470	Green Published, gold			2022-12-18	WOS:000209501300111
J	Miedema, F				Miedema, Frank			Grand Challenges in the immunology of HIV and AIDS	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Miedema, Frank] Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Miedema, F (corresponding author), Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands.	f.miedema@umcutrecht.nl						Autran B, 2008, AIDS, V22, P1313, DOI 10.1097/QAD.0b013e3282fdce94; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Betts M. R., 2006, HIV NONPROGRESSORS P; Bosinger SE, 2009, J CLIN INVEST, V119, P3556, DOI 10.1172/JCI40115; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Bunnik EM, 2010, NAT MED, V16, P995, DOI 10.1038/nm.2203; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Euler Z, 2010, J INFECT DIS, V201, P1045, DOI 10.1086/651144; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Fauci AS, 1996, ANN INTERN MED, V124, P654, DOI 10.7326/0003-4819-124-7-199604010-00006; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fischer W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012303; Frater AJ, 2007, J VIROL, V81, P6742, DOI 10.1128/JVI.00022-07; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Grossman Z, 2002, NAT MED, V8, P319, DOI 10.1038/nm0402-319; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Hardy AW, 2007, P NATL ACAD SCI USA, V104, P17453, DOI 10.1073/pnas.0707244104; Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Leslie AJ, 2006, CURR OPIN HIV AIDS, V1, P34, DOI 10.1097/01.COH.0000194102.28063.7c; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Meier A, 2007, J VIROL, V81, P8180, DOI 10.1128/JVI.00421-07; Miura T, 2010, J VIROL, V84, P7581, DOI 10.1128/JVI.00286-10; Navis M, 2007, J IMMUNOL, V179, P3133, DOI 10.4049/jimmunol.179.5.3133; Schellens IMM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002745; Sereti I, 2009, BLOOD, V113, P6304, DOI 10.1182/blood-2008-10-186601; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	41	2	2	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2011	2									10.3389/fimmu.2011.00020	http://dx.doi.org/10.3389/fimmu.2011.00020			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TR	22566810	Green Published, gold			2022-12-18	WOS:000209501400020
J	Reinherz, EL; Acuto, O				Reinherz, Ellis L.; Acuto, Oreste			Molecular T cell biology - basic and translational challenges in the twenty-first century	FRONTIERS IN IMMUNOLOGY			English	Editorial Material							RESTRICTED ANTIGEN RECEPTOR; BINDING PREDICTION SERVERS; CRYSTAL-STRUCTURE; ALPHA-SUBUNITS; BETA-SUBUNITS; COMPLEX; PROTEIN; CD3-EPSILON-GAMMA; RECOGNITION; PEPTIDES		[Reinherz, Ellis L.] Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; [Reinherz, Ellis L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Reinherz, Ellis L.] Harvard Univ, Harvard Fac Arts & Sci, Cambridge, MA 02138 USA; [Acuto, Oreste] Univ Oxford, Sir William Dunn Sch Pathol, Dept Pathol, T Cell Signalling Lab, Oxford OX1 3RE, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; University of Oxford	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu; oreste.acuto@path.ox.ac.uk			NIAID NIH HHS [R01 AI084785, U01 AI090043] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI090043, R01AI084785] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACUTO O, 1984, P NATL ACAD SCI-BIOL, V81, P3851, DOI 10.1073/pnas.81.12.3851; ACUTO O, 1983, J EXP MED, V158, P1368, DOI 10.1084/jem.158.4.1368; ACUTO O, 1983, CELL, V34, P717, DOI 10.1016/0092-8674(83)90528-7; Acuto O, 2008, NAT REV IMMUNOL, V8, P699, DOI 10.1038/nri2397; Allison JP, 2005, J IMMUNOL, V174, P1144; Arnett KL, 2004, P NATL ACAD SCI USA, V101, P16268, DOI 10.1073/pnas.0407359101; BAKER PE, 1979, J EXP MED, V149, P273, DOI 10.1084/jem.149.1.273; Bambini S, 2009, DRUG DISCOV TODAY, V14, P252, DOI 10.1016/j.drudis.2008.12.007; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Brockmeyer C., 2010, J BIOL CHEM; Call ME, 2006, CELL, V127, P355, DOI 10.1016/j.cell.2006.08.044; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; Debre P., 1998, L PASTEUR, P148; Dustin ML, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002311; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Fu G, 2009, NAT IMMUNOL, V10, P848, DOI 10.1038/ni.1766; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Johnson AL, 2009, NAT IMMUNOL, V10, P831, DOI 10.1038/ni.1769; JULIUS MH, 1972, P NATL ACAD SCI USA, V69, P1934, DOI 10.1073/pnas.69.7.1934; KAPPLER J, 1983, CELL, V35, P295, DOI 10.1016/0092-8674(83)90232-5; Kim ST, 2009, J BIOL CHEM, V284, P31028, DOI 10.1074/jbc.M109.052712; Kjer-Nielsen L, 2004, P NATL ACAD SCI USA, V101, P7675, DOI 10.1073/pnas.0402295101; Lemmel C, 2004, NAT BIOTECHNOL, V22, P450, DOI 10.1038/nbt947; Lesourne R, 2009, NAT IMMUNOL, V10, P840, DOI 10.1038/ni.1768; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Lin HH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-8; Lin HH, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S12-S22; Luber CA, 2010, IMMUNITY, V32, P279, DOI 10.1016/j.immuni.2010.01.013; Mayya V, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000007; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MEUER SC, 1983, J EXP MED, V157, P705, DOI 10.1084/jem.157.2.705; Milstein C, 1993, NOBEL LECT PHYSL MED, P248; Murphy K., 2007, JANEWAYS IMMUNOBIOLO; Nika K, 2010, IMMUNITY, V32, P766, DOI 10.1016/j.immuni.2010.05.011; Reche PA, 2005, NUCLEIC ACIDS RES, V33, pW138, DOI 10.1093/nar/gki357; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; Reinhold B, 2010, ANAL CHEM, V82, P9090, DOI 10.1021/ac102387t; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Schirle M, 2000, EUR J IMMUNOL, V30, P2216, DOI 10.1002/1521-4141(2000)30:18<2216::AID-IMMU2216>3.3.CO;2-F; Sitkovsky MV, 2009, TRENDS IMMUNOL, V30, P102, DOI 10.1016/j.it.2008.12.002; Sun ZYJ, 2004, P NATL ACAD SCI USA, V101, P16867, DOI 10.1073/pnas.0407576101; Sun ZYJ, 2001, CELL, V105, P913, DOI 10.1016/S0092-8674(01)00395-6; Tonegawa S, 1993, NOBEL LECT PHYSL MED, P381; Unanue ER, 2006, NAT IMMUNOL, V7, P1277, DOI 10.1038/ni1206-1277; Wang JH, 2002, MOL IMMUNOL, V38, P1039, DOI 10.1016/S0161-5890(02)00033-0; Weinzierl AO, 2007, MOL CELL PROTEOMICS, V6, P102, DOI 10.1074/mcp.M600310-MCP200; Weiss A, 2009, J IMMUNOL, V183, P4821, DOI 10.4049/jimmunol.0990083; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; Yu CI, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/548280; Zhang GL, 2011, J IMMUNOL METHODS, V374, P53, DOI 10.1016/j.jim.2010.11.009; Zinkernagel RM, 1997, SCAND J IMMUNOL, V46, P423, DOI 10.1046/j.1365-3083.1997.d01-161.x	59	2	2	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2011	2								3	10.3389/fimmu.2011.00003	http://dx.doi.org/10.3389/fimmu.2011.00003			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TR	22566794	gold, Green Published			2022-12-18	WOS:000209501400003
J	Silva, AS; Valencia, MMC; Cianciarullo, AM; Vasconcellos, SA; Barbosa, AS; Isaac, L				Silva, Aldacilene Souza; Castiblanco Valencia, Monica Marcela; Cianciarullo, Aurora Marques; Vasconcellos, Silvio Arruda; Barbosa, Angela Silva; Isaac, Lourdes			Interaction of human complement factor H variants Tyr(402) and His(402) with Leptospira spp.	FRONTIERS IN IMMUNOLOGY			English	Article						Leptospira; complement system; factor H; Y402H polymmphism	C-REACTIVE PROTEIN; BINDING PROTEIN; POLYMORPHISM; ACTIVATION; DOMAINS; SITE; C3B; IDENTIFICATION; LOCALIZATION; ALLOTYPE	Leptospirosis is a zoonosis caused by pathogenic bacteria from the genus Leptospira. The disease represents a serious public health problem in underdeveloped tropical countries. Leptospires infect hosts through small abrasions in the skin or mucous membranes and they rapidly disseminate to target organs. The capacity of some pathogenic leptospiral strains to acquire the negative complement regulators factor H (FH) and C4b binding protein correlates with their ability to survive in human serum. In this study we assessed the functional consequences of the age macular degeneration-associated polymorphism FH His(402) or FH Tyr(402) on FH Leptospira interactions. In binding assays using sub-saturating amounts of FH, the FH Tyr(402) variant interacted with all the strains tested more strongly than the FH His(402) variant. At higher concentrations, differences tended to disappear. We then compared cofactor activities displayed by FH His(402) and FHTyr(402) bound to the surface of L. mterrogans. Both variants exhibit similar activity as cofactors for Factor I-mediated cleavage of C3b, thus indicating that they do not differ in their capacity to regulate the complement cascade.	[Silva, Aldacilene Souza; Castiblanco Valencia, Monica Marcela; Isaac, Lourdes] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508900 Sao Paulo, Brazil; [Cianciarullo, Aurora Marques] Inst Butantan, Lab Genet, Sao Paulo, Brazil; [Vasconcellos, Silvio Arruda] Univ Sao Paulo, Fac Med Vet & Zootecnia, BR-05508900 Sao Paulo, Brazil; [Barbosa, Angela Silva] Inst Butantan, Lab Bacteriol, Sao Paulo, Brazil	Universidade de Sao Paulo; Instituto Butantan; Universidade de Sao Paulo; Instituto Butantan	Isaac, L (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, Av Prof Lineu Prestes 1730, BR-05508900 Sao Paulo, Brazil.	louisaac@icb.usp.br	Isaac, Lourdes/I-7186-2012; Barbosa, Angela S/I-3518-2013; Cianciarullo, Aurora M/B-5462-2016	Barbosa, Angela S/0000-0002-6458-9489; Cianciarullo, Aurora M/0000-0002-0676-9190; Isaac, Lourdes/0000-0002-7746-8942	FAPESP [09/05979-0, 09/1778-0, 10/50043-0]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	We thank Prof. Shaker Chuck Farah (Instituto de Quimica, Universidade de Sao Paulo, Brazil) for the critical review of the manuscript. This work has benefited from grants provided by FAPESP (09/05979-0; 09/1778-0; 10/50043-0).	Barbosa AS, 2010, INFECT IMMUN, V78, P3207, DOI 10.1128/IAI.00279-10; Barbosa AS, 2009, INFECT IMMUN, V77, P1137, DOI 10.1128/IAI.01310-08; Bharti AR, 2003, LANCET INFECT DIS, V3, P757, DOI 10.1016/S1473-3099(03)00830-2; Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Faine S, 1999, LEPTOSPIRA LEPTOSPIR, V2nd; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; GORDON DL, 1995, J IMMUNOL, V155, P348; Grosskinsky S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004858; Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Jarva H, 1999, J IMMUNOL, V163, P3957; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Meri T, 2005, MICROB PATHOGENESIS, V39, P139, DOI 10.1016/j.micpath.2005.07.003; Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7; Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297; Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Pappachan Joseph M, 2007, Indian J Med Sci, V61, P441; Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Sharma AK, 1997, INFECT IMMUN, V65, P484, DOI 10.1128/IAI.65.2.484-487.1997; Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200; Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012; Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x; Verma A, 2006, INFECT IMMUN, V74, P2659, DOI 10.1128/IAI.74.5.2659-2666.2006; Verma A, 2005, INFECT IMMUN, V73, P7259, DOI 10.1128/IAI.73.11.7259-7266.2005; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a; Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668; Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971; Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6	37	2	2	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2011	2								44	10.3389/fimmu.2011.00044	http://dx.doi.org/10.3389/fimmu.2011.00044			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TR	22566834	Green Published, gold			2022-12-18	WOS:000209501400044
J	Neuman, H; Arrouasse, J; Kedmi, M; Cerutti, A; Magri, G; Mehr, R				Neuman, Hadas; Arrouasse, Jessica; Kedmi, Meirav; Cerutti, Andrea; Magri, Giuliana; Mehr, Ramit			IgTreeZ, A Toolkit for Immunoglobulin Gene Lineage Tree-Based Analysis, Reveals CDR3s Are Crucial for Selection Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						antibody; B cell receptor (BCR); B cell repertoire; immunoglobulin; lineage tree; somatic hypermutation (SHM)	CELL; DIVERSIFICATION; IMMUNITY; SYSTEM; IG	Somatic hypermutation (SHM) is an important diversification mechanism that plays a part in the creation of immune memory. Immunoglobulin (Ig) variable region gene lineage trees were used over the last four decades to model SHM and the selection mechanisms operating on B cell clones. We hereby present IgTreeZ (Immunoglobulin Tree analyZer), a python-based tool that analyses many aspects of Ig gene lineage trees and their repertoires. Using simulations, we show that IgTreeZ can be reliably used for mutation and selection analyses. We used IgTreeZ on empirical data, found evidence for different mutation patterns in different B cell subpopulations, and gained insights into antigen-driven selection in corona virus disease 19 (COVID-19) patients. Most importantly, we show that including the CDR3 regions in selection analyses - which is only possible if these analyses are lineage tree-based - is crucial for obtaining correct results. Overall, we present a comprehensive lineage tree analysis tool that can reveal new biological insights into B cell repertoire dynamics.	[Neuman, Hadas; Arrouasse, Jessica; Kedmi, Meirav; Mehr, Ramit] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel; [Kedmi, Meirav] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Ramat Gan, Israel; [Kedmi, Meirav] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Cerutti, Andrea; Magri, Giuliana] Inst Hosp Mar Invest Med IMIM, Translat Clin Res Program, Barcelona, Spain; [Cerutti, Andrea] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain	Bar Ilan University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Institut Hospital del Mar d'Investigacions Mediques (IMIM); ICREA	Neuman, H; Mehr, R (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel.	hadas.doron@gmail.com; ramit.mehr@biu.ac.il						Barak M, 2008, J IMMUNOL METHODS, V338, P67, DOI 10.1016/j.jim.2008.06.006; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Corrie BD, 2018, IMMUNOL REV, V284, P24, DOI 10.1111/imr.12666; de Campos-Mata L, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1339; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Ellson J, 2004, MATH VIS, P127; Elsner RA, 2020, IMMUNITY, V53, P1136, DOI 10.1016/j.immuni.2020.11.006; Ghraichy M, 2021, ELIFE, V10, DOI [10.7554/eLife.73111, 10.7554/eLife.73111.sa1, 10.7554/eLife.73111.sa2]; Ghraichy M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01734; Giudicelli W, 2005, NUCLEIC ACIDS RES, V33, pD256, DOI 10.1093/nar/gki010; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; Hoehn KB, 2019, P NATL ACAD SCI USA, V116, P22664, DOI 10.1073/pnas.1906020116; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Khan T, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.144499; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lefranc MP, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0001-2012; Meng WZ, 2017, NAT BIOTECHNOL, V35, P879, DOI 10.1038/nbt.3942; Miao Y, 2019, NAT REV CLIN ONCOL, V16, P634, DOI 10.1038/s41571-019-0225-1; Montague Z, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109173; Pommie C, 2004, J MOL RECOGNIT, V17, P17, DOI 10.1002/jmr.647; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shahaf G, 2008, J THEOR BIOL, V255, P210, DOI 10.1016/j.jtbi.2008.08.005; Shannon M, 1999, J IMMUNOL, V162, P3950; Shemesh O, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627813; Tabibian-Keissar H, 2008, EUR J IMMUNOL, V38, P2600, DOI 10.1002/eji.200838333; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; Vander Heiden JA, 2014, BIOINFORMATICS, V30, P1930, DOI 10.1093/bioinformatics/btu138; Yaari G, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0242; Yaari G, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks457; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; Yermanos A, 2017, BIOINFORMATICS, V33, P3938, DOI 10.1093/bioinformatics/btx533; Zuckerman NS, 2010, INT IMMUNOL, V22, P875, DOI 10.1093/intimm/dxq441	34	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 26	2022	13								822834	10.3389/fimmu.2022.822834	http://dx.doi.org/10.3389/fimmu.2022.822834			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6C5KM	36389731	Green Published, gold			2022-12-18	WOS:000882053000001
J	Mukanova, S; Borissenko, A; Kim, A; Bolatbek, A; Abdrakhmanova, A; Vangelista, L; Sonnenberg-Riethmacher, E; Riethmacher, D				Mukanova, Saida; Borissenko, Anton; Kim, Alexey; Bolatbek, Aigerim; Abdrakhmanova, Ainur; Vangelista, Luca; Sonnenberg-Riethmacher, Eva; Riethmacher, Dieter			Role of periostin in inflammatory bowel disease development and synergistic effects mediated by the CCL5-CCR5 axis	FRONTIERS IN IMMUNOLOGY			English	Article						periostin (POSTN); CCL5-CCR5-signaling system; IBD; inflammatory bowel disease; inflammation; treatment option; chemically induced colitis	CHEMOKINE RECEPTOR CCR5; GENETICS; POTENT; MICE	Inflammatory bowel disease (IBD), comprising mainly Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract. In recent years, a wealth of data has been accumulated demonstrating the complex interplay of many different factors in the pathogenesis of IBD. Among these are factors impacting the epithelial barrier function, including vessel and extracellular matrix (ECM) formation, the gut microbiome (e.g., bacterial antigens), and, most importantly, the production of cytokines (pro- and anti-inflammatory) directly shaping the immune response. Patients failing to resolve the acute intestinal inflammation develop chronic inflammation. It has been shown that the expression of the matricellular protein periostin is enhanced during IBD and is one of the drivers of this disease. The C-C chemokine receptor 5 (CCR5) is engaged by the chemotactic mediators CCL3/MIP-1 alpha, CCL4/MIP-1 beta, and CCL5/RANTES. CCR5 blockade has been reported to ameliorate inflammation in a murine IBD model. Thus, both periostin and CCR5 are involved in the development of IBD. In this study, we investigated the potential crosstalk between the two signaling systems and tested a highly potent CCL5 derivative acting as a CCR5 antagonist in a murine model of IBD. We observed that the absence of periostin influences the CCR5-expressing cell population of the gut. Our data further support the notion that targeted modulation of the periostin and CCR5 signaling systems bears therapeutic potential for IBD.	[Mukanova, Saida; Borissenko, Anton; Bolatbek, Aigerim; Vangelista, Luca; Sonnenberg-Riethmacher, Eva; Riethmacher, Dieter] Nazarbayev Univ, Sch Med, Dept Biomed Sci, Astana, Kazakhstan; [Kim, Alexey; Abdrakhmanova, Ainur] Nazarbayev Univ, Sch Med, Astana, Kazakhstan; [Sonnenberg-Riethmacher, Eva; Riethmacher, Dieter] Univ Southampton, Sch Med, Dept Human Dev & Hlth, Southampton, England	Nazarbayev University; Nazarbayev University; University of Southampton	Sonnenberg-Riethmacher, E; Riethmacher, D (corresponding author), Nazarbayev Univ, Sch Med, Dept Biomed Sci, Astana, Kazakhstan.; Sonnenberg-Riethmacher, E; Riethmacher, D (corresponding author), Univ Southampton, Sch Med, Dept Human Dev & Hlth, Southampton, England.	eva.riethmacher@nu.edu.kz; dieter.riethmacher@nu.edu.kz			Nazarbayev University; Faculty Development Grants FDCRGP [090118FD5310, 021220FD2751, 110119FD4510, 021220FD2551]; Ministry of Health of the Republic of Kazakhstan [51760/PiPiPhi-M3 PK-19]	Nazarbayev University; Faculty Development Grants FDCRGP; Ministry of Health of the Republic of Kazakhstan(Government of the Republic of KazakhstanMinistry of Healthcare of the Republic of Kazakhstan)	This work was supported by grants from Nazarbayev University. In detail, these are Faculty Development Grants FDCRGP) to DR (090118FD5310, 021220FD2751), to ESR (110119FD4510) and to LV (021220FD2551). Additionally, this work was supported by the Ministry of Health of the Republic of Kazakhstan under the program-targeted funding of the Ageing and Healthy Lifespan research program (IRN: 51760/Pi Pi Phi-M3 PK-19).	Alatab S, 2020, LANCET GASTROENTEROL, V5, P17, DOI 10.1016/S2468-1253(19)30333-4; Amerzhanova Y, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.826418; Andres PG, 2000, J IMMUNOL, V164, P6303, DOI 10.4049/jimmunol.164.12.6303; Bain CC, 2014, NAT IMMUNOL, V15, P929, DOI 10.1038/ni.2967; Barmania F, 2013, APPL TRANSL GENOM, V2, P3, DOI 10.1016/j.atg.2013.05.004; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brodarac A., 2006, IMPAIRED TOOTH DEV P; Coelho T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85096-7; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; El Sayed S, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-021-04098-7; Gordon H, 2022, DIGEST DIS SCI, V67, P2444, DOI 10.1007/s10620-021-07080-5; Graham DB, 2020, NATURE, V578, P527, DOI 10.1038/s41586-020-2025-2; Hoersch S, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-30; Jain U, 2021, SCIENCE, V371, P1154, DOI 10.1126/science.abd0919; Kaplan GG, 2015, NAT REV GASTRO HEPAT, V12, P720, DOI 10.1038/nrgastro.2015.150; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kikuchi Y, 2008, J HISTOCHEM CYTOCHEM, V56, P753, DOI 10.1369/jhc.2008.951061; Koh SJ, 2019, CARCINOGENESIS, V40, P102, DOI 10.1093/carcin/bgy120; Koh SJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149652; Loddo I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00551; Mencarelli A, 2016, SCI REP-UK, V6, DOI 10.1038/srep30802; Mickael ME, 2020, AM J PATHOL, V190, P1984, DOI 10.1016/j.ajpath.2020.07.010; Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007; Paik D, 2022, NATURE, V603, P907, DOI 10.1038/s41586-022-04480-z; Ratajczak-Wielgomas K, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031240; Secchi M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20300-9; Sonnenberg-Riethmacher E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.722170; Sonnenberg-Riethmacher E, 2015, J CELL SCI, V128, P3345, DOI 10.1242/jcs.174177; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Uhlig HH, 2014, GASTROENTEROLOGY, V147, P990, DOI 10.1053/j.gastro.2014.07.023; Vangelista L, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01981; Zheng Y, 2017, IMMUNITY, V46, P1005, DOI 10.1016/j.immuni.2017.05.002	32	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 20	2022	13								956691	10.3389/fimmu.2022.956691	http://dx.doi.org/10.3389/fimmu.2022.956691			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5Z6OQ	36341422	Green Published, gold			2022-12-18	WOS:000880090800001
J	Patysheva, M; Frolova, A; Larionova, I; Afanas'ev, S; Tarasova, A; Cherdyntseva, N; Kzhyshkowska, J				Patysheva, Marina; Frolova, Anastasia; Larionova, Irina; Afanas'ev, Sergey; Tarasova, Anna; Cherdyntseva, Nadezhda; Kzhyshkowska, Julia			Monocyte programming by cancer therapy	FRONTIERS IN IMMUNOLOGY			English	Review						monocyte; anti-cancer treatment; surgery; chemotherapy; radiotherapy; immunotherapy; genotype	TUMOR-ASSOCIATED MACROPHAGES; CHEMOKINE RECEPTOR 2; TO-LYMPHOCYTE RATIO; CELL LUNG-CANCER; IONIZING-RADIATION; MYELOID CELLS; CHEMOATTRACTANT PROTEIN-1; MONOCLONAL-ANTIBODY; SUPPRESSOR-CELLS; DENDRITIC CELLS	Monocytes in peripheral blood circulation are the precursor of essential cells that control tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells (DCs) and myeloid-derive suppressor cells (MDSC). Monocytes-derived cells orchestrate immune reactions in tumor microenvironment that control disease outcome and efficiency of cancer therapy. Four major types of anti-cancer therapy, surgery, radiotherapy, chemotherapy, and most recent immunotherapy, affect tumor-associated macrophage (TAM) polarization and functions. TAMs can also decrease the efficiency of therapy in a tumor-specific way. Monocytes is a major source of TAMs, and are recruited to tumor mass from the blood circulation. However, the mechanisms of monocyte programming in circulation by different therapeutic onsets are only emerging. In our review, we present the state-of-the art about the effects of anti-cancer therapy on monocyte progenitors and their dedifferentiation, on the content of monocyte subpopulations and their transcriptional programs in the circulation, on their recruitment into tumor mass and their potential to give origin for TAMs in tumor-specific microenvironment. We have also summarized very limited available knowledge about genetics that can affect monocyte interaction with cancer therapy, and highlighted the perspectives for the therapeutic targeting of circulating monocytes in cancer patients. We summarized the knowledge about the mediators that affect monocytes fate in all four types of therapies, and we highlighted the perspectives for targeting monocytes to develop combined and minimally invasive anti-cancer therapeutic approaches.	[Patysheva, Marina; Frolova, Anastasia; Larionova, Irina; Afanas'ev, Sergey; Cherdyntseva, Nadezhda; Kzhyshkowska, Julia] Tomsk State Univ, Lab Translat Cellular & Mol Biomed, Tomsk, Russia; [Patysheva, Marina; Larionova, Irina] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Tumor Progress Biol, Tomsk, Russia; [Frolova, Anastasia; Cherdyntseva, Nadezhda] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Lab Mol Oncol & Immunol, Tomsk, Russia; [Larionova, Irina; Cherdyntseva, Nadezhda; Kzhyshkowska, Julia] Siberian State Med Univ, Lab Genet Technol, Tomsk, Russia; [Afanas'ev, Sergey; Tarasova, Anna] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Dept Abdominal Oncol, Tomsk, Russia; [Kzhyshkowska, Julia] Heidelberg Univ, Inst Transfus Med & Immunol, Inst Innate Immunosci MI3, Med Fac Mannheim, Mannheim, Germany; [Kzhyshkowska, Julia] German Red Cross Blood Serv Baden Wurttemberg Hess, Mannheim, Hessen, Germany	Tomsk State University; Russian Academy of Sciences; Tomsk National Research Medical Center; Cancer Research Institute of the RAS; Russian Academy of Sciences; Tomsk National Research Medical Center; Cancer Research Institute of the RAS; Siberian State Medical University; Russian Academy of Sciences; Tomsk National Research Medical Center; Cancer Research Institute of the RAS; Ruprecht Karls University Heidelberg	Kzhyshkowska, J (corresponding author), Tomsk State Univ, Lab Translat Cellular & Mol Biomed, Tomsk, Russia.; Kzhyshkowska, J (corresponding author), Siberian State Med Univ, Lab Genet Technol, Tomsk, Russia.; Kzhyshkowska, J (corresponding author), Heidelberg Univ, Inst Transfus Med & Immunol, Inst Innate Immunosci MI3, Med Fac Mannheim, Mannheim, Germany.; Kzhyshkowska, J (corresponding author), German Red Cross Blood Serv Baden Wurttemberg Hess, Mannheim, Hessen, Germany.	julia.kzhyshkowska@medma.uni-heidelberg.de			Ministry of Science and Higher Education of the Russian Federation;  [075-15-2021-1073]	Ministry of Science and Higher Education of the Russian Federation; 	Funding This research was funded state contract of the Ministry of Science and Higher Education of the Russian Federation "Genetic and epigenetic editing of tumor cells and microenvironment in order to block metastasis" o. 075-15-2021-1073.	Akeem S, 2019, ETHIOP J HEALTH SCI, V29, P195, DOI 10.4314/ejhs.v29i2.6; Alamilla-Presuel JC, 2022, INT J RADIAT BIOL, V98, P1301, DOI 10.1080/09553002.2022.2047825; Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4; Ando K, 2021, CANCER IMMUNOL IMMUN, V70, P337, DOI 10.1007/s00262-020-02686-6; ANDREESEN R, 1989, BLOOD, V74, P2150; Ao JY, 2017, MOL CANCER THER, V16, P1544, DOI 10.1158/1535-7163.MCT-16-0866; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arsenijevic N, 2005, J BUON, V10, P105; Attar R, 2010, IN VIVO, V24, P243; Banin-Hirata BK, 2016, CLIN EXP MED, V16, P139, DOI 10.1007/s10238-015-0342-9; Bauer M, 2011, P NATL ACAD SCI USA, V108, P21105, DOI 10.1073/pnas.1111919109; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Benna M, 2020, BRIT J RADIOL, V93, DOI 10.1259/bjr.20190147; Bennett S., 2014, CANADIAN SOC SURG ON; Berte N, 2021, DNA REPAIR, V98, DOI 10.1016/j.dnarep.2020.103037; Bianconi V, 2018, CURR OPIN HEMATOL, V25, P44, DOI 10.1097/MOH.0000000000000389; Bobdey S, 2017, INT ARCH OTORHINOLAR, V21, P21, DOI 10.1055/s-0036-1587318; Bodey B, 2004, IN VIVO, V18, P81; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Borlak J, 2016, ONCOTARGET, V7, P28059, DOI 10.18632/oncotarget.8574; Brana I, 2015, TARGET ONCOL, V10, P111, DOI 10.1007/s11523-014-0320-2; Braster R, 2014, METHODS, V65, P28, DOI 10.1016/j.ymeth.2013.06.020; Brooks N, 2012, INT J GYNECOL CANCER, V22, P1500, DOI 10.1097/IGC.0b013e3182249273; Brusa D, 2013, INT J UROL, V20, P971, DOI 10.1111/iju.12086; BUESCHER ES, 1984, BLOOD, V63, P1402; Burnette B, 2013, SEMIN RADIAT ONCOL, V23, P273, DOI 10.1016/j.semradonc.2013.05.009; CABIE A, 1992, CYTOKINE, V4, P576, DOI 10.1016/1043-4666(92)90022-J; Calabrese EJ, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/s41514-017-0013-z; Cao QZ, 2018, BIOMATERIALS, V152, P63, DOI 10.1016/j.biomaterials.2017.10.036; Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009; Chandra A, 2019, BONE, V120, P423, DOI 10.1016/j.bone.2018.12.006; Chen HM, 2015, CLIN CANCER RES, V21, P4073, DOI 10.1158/1078-0432.CCR-14-2742; Chen MK, 2011, ORAL ONCOL, V47, P577, DOI 10.1016/j.oraloncology.2011.04.008; Chen WK, 2015, INT J COLORECTAL DIS, V30, P475, DOI 10.1007/s00384-014-2098-1; Chen XJ, 2019, MOL CARCINOGEN, V58, P388, DOI 10.1002/mc.22936; Chen Z, 2021, IMMUNOL INVEST, V50, P461, DOI 10.1080/08820139.2020.1776726; Cherdyntseva NV, 2017, BYULLETEN SIB MED, V16, P61, DOI 10.20538/1682-0363-2017-4-61-74; Chin AL, 2018, ADV RADIAT ONCOL, V3, P297, DOI 10.1016/j.adro.2018.02.005; Chittezhath M, 2014, IMMUNITY, V41, P815, DOI 10.1016/j.immuni.2014.09.014; Choi YH, 2019, CANCER EPIDEM BIOMAR, V28, P1045, DOI [10.1158/1055-9965.EPI-18-1066, 10.1158/1055-9965.epi-18-1066]; Cittera E, 2007, J IMMUNOL, V178, P6616, DOI 10.4049/jimmunol.178.10.6616; Coates PJ, 2008, CANCER RES, V68, P450, DOI 10.1158/0008-5472.CAN-07-3050; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Coiffier B, 2008, BLOOD, V111, P1094, DOI 10.1182/blood-2007-09-111781; Costa S, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00587; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Deronic A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2481-0; Dijkgraaf EM, 2013, CANCER RES, V73, P2480, DOI 10.1158/0008-5472.CAN-12-3542; Ding KF, 2022, CANCER IMMUNOL RES, V10, DOI 10.1158/2326-6074.TUMIMM21-P016; Ding ZC, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594540; Duffy MJ, 2019, CLIN CHEM, V65, P1228, DOI 10.1373/clinchem.2019.303644; Eissler N, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1232222; El-Saghire H, 2013, INT J MOL MED, V32, P1407, DOI 10.3892/ijmm.2013.1514; Elasser D, 1996, BLOOD, V87, P3803, DOI 10.1182/blood.V87.9.3803.bloodjournal8793803; Elgstrom E, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317697550; Engblom C, 2016, NAT REV CANCER, V16, P447, DOI 10.1038/nrc.2016.54; Farkona S, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0623-5; Feng CS, 2021, GLAND SURG, V10, P1713, DOI 10.21037/gs-21-272; Feng PH, 2012, AM J RESP CRIT CARE, V186, P1025, DOI 10.1164/rccm.201204-0636OC; Fliedner TM, 2002, CANCER BIOTHER RADIO, V17, P405, DOI 10.1089/108497802760363204; Frey B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00231; Fu YJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1396-4; Galluzzi L, 2020, NAT REV CLIN ONCOL, V17, P725, DOI 10.1038/s41571-020-0413-z; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Garg S, 2010, RADIAT RES, V173, P469, DOI 10.1667/RR1742.1; Gebhardt C, 2015, CLIN CANCER RES, V21, P5453, DOI 10.1158/1078-0432.CCR-15-0676; Geller MA, 2010, INT J GYNECOL CANCER, V20, P918, DOI 10.1111/IGC.0b013e3181e5c442; Gessler P, 2005, J THORAC CARDIOV SUR, V130, P54, DOI 10.1016/j.jtcvs.2005.01.008; Cambui RAG, 2022, J CANCER RES CLIN, DOI 10.1007/s00432-022-04284-8; Grassberger C, 2019, NAT REV CLIN ONCOL, V16, P729, DOI 10.1038/s41571-019-0238-9; Green DS, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1569-5; Green DE, 2014, BONE, V63, P87, DOI 10.1016/j.bone.2014.02.018; Gren ST, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144351; Gubin MM, 2018, CELL, V175, P1014, DOI 10.1016/j.cell.2018.09.030; Hai Y, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4909-1; Hall EJ, 2007, LANCET ONCOL, V8, P369, DOI 10.1016/S1470-2045(07)70113-4; Hamm A, 2016, GUT, V65, P990, DOI 10.1136/gutjnl-2014-308988; Han SK, 2006, INT J RADIAT BIOL, V82, P686, DOI 10.1080/09553000600930699; Harrington NP, 1997, CLIN EXP IMMUNOL, V107, P417, DOI 10.1111/j.1365-2249.1997.272-ce1158.x; Hayashi T, 2017, ONCOTARGET, V8, P35255, DOI 10.18632/oncotarget.13052; Henze AT, 2016, J CLIN INVEST, V126, P3672, DOI 10.1172/JCI84427; Heylmann D, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81058-1; Heylmann D, 2014, BBA-REV CANCER, V1846, P121, DOI 10.1016/j.bbcan.2014.04.009; Hu XT, 2020, CANCER IMMUNOL IMMUN, V69, P2547, DOI 10.1007/s00262-020-02639-z; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Huang RX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0150-x; Hughes R, 2015, CANCER RES, V75, P3479, DOI 10.1158/0008-5472.CAN-14-3587; Jung KR, 2015, CANCER BIOL THER, V16, P1281, DOI 10.1080/15384047.2015.1056945; Kalbasi A, 2017, CLIN CANCER RES, V23, P137, DOI 10.1158/1078-0432.CCR-16-0870; Kang C, 2020, RADIAT ONCOL J, V38, P1, DOI 10.3857/roj.2019.00640; Kang JH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051086; Kapellos TS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02035; Kappler M, 2007, BBA-MOL CELL RES, V1773, P945, DOI 10.1016/j.bbamcr.2007.04.001; Katz MS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01171; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Kemp SB, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.202000935; Kiaie SH, 2021, ACTA PHARM SIN B, V11, P1083, DOI 10.1016/j.apsb.2020.12.011; Kioi M, 2009, INT J CANCER, V124, P1440, DOI 10.1002/ijc.24067; Kiss M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01399; Kitano S, 2014, CANCER IMMUNOL RES, V2, P812, DOI 10.1158/2326-6066.CIR-14-0013; Kolseth IBM, 2012, SCAND J CLIN LAB INV, V72, P593, DOI 10.3109/00365513.2012.721520; KOPROWSKI H, 1978, P NATL ACAD SCI USA, V75, P3405, DOI 10.1073/pnas.75.7.3405; Krieg C, 2018, NAT MED, V24, P144, DOI 10.1038/nm.4466; Krisnawan VE, 2020, CANCERS, V12, DOI 10.3390/cancers12102916; Kross KW, 2010, EUR ARCH OTO-RHINO-L, V267, P335, DOI 10.1007/s00405-009-1153-y; Kucukgergin C, 2012, GENE, V511, P7, DOI 10.1016/j.gene.2012.09.011; Kusmartsev S, 2002, CANCER IMMUNOL IMMUN, V51, P293, DOI 10.1007/s00262-002-0280-8; KWAN DK, 1978, RADIAT RES, V75, P556, DOI 10.2307/3574842; Kwiecien I, 2020, CANCERS, V12, DOI 10.3390/cancers12092513; Kzhyshkowska J, 2016, TRANSFUS MED HEMOTH, V43, P66, DOI 10.1159/000444943; Larionova I, 2022, J CANCER RES CLIN, V148, P1015, DOI 10.1007/s00432-022-03923-4; Larionova I, 2021, CANCERS, V13, DOI 10.3390/cancers13133253; Larionova I, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.566511; Larionova I, 2020, CANCERS, V12, DOI 10.3390/cancers12061411; Larionova I, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1596004; Larsson AM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49943-y; Lee J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627036; Leon-Mateos L, 2021, CLIN TRANSL ONCOL, V23, P434, DOI 10.1007/s12094-020-02442-3; Li KJ, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6157-4; Li M, 2020, J CONTROL RELEASE, V321, P23, DOI 10.1016/j.jconrel.2020.02.011; Li XH, 2018, RADIAT RES, V190, P612, DOI 10.1667/RR15087.1; Limagne E, 2019, CANCER IMMUNOL RES, V7, P1958, DOI 10.1158/2326-6066.CIR-19-0228; Lin CH, 2021, RADIOTHER ONCOL, V154, P76, DOI 10.1016/j.radonc.2020.09.012; Lin GN, 2014, TUMOR BIOL, V35, P10849, DOI 10.1007/s13277-014-2362-6; Linard C, 2004, INT J RADIAT ONCOL, V58, P427, DOI 10.1016/j.ijrobp.2003.09.039; Litviakov N, 2018, CANCER CHEMOTH PHARM, V82, P99, DOI 10.1007/s00280-018-3594-8; Liu L, 2018, CLIN CANCER RES, V24, P2370, DOI 10.1158/1078-0432.CCR-17-2545; Liu TF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1436922; Loberg RD, 2007, CANCER RES, V67, P9417, DOI 10.1158/0008-5472.CAN-07-1286; Loinard C, 2017, RADIAT RES, V187, P549, DOI 10.1667/RR14398.1; Lotfi N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58131-2; Lu C, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015876; Lv W, 2016, CANCER LETT, V375, P245, DOI 10.1016/j.canlet.2016.02.005; Ma WT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01140; Madsen DH, 2017, CELL REP, V21, P3662, DOI 10.1016/j.celrep.2017.12.011; Maeng HG, 2006, J RADIAT RES, V47, P9, DOI 10.1269/jrr.47.9; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; Hernandez CM, 2018, CLIN TRANSL ONCOL, V20, P476, DOI 10.1007/s12094-017-1732-0; Markham MJ, 2020, J CLIN ONCOL, V38, P1081, DOI 10.1200/JCO.19.03141; Massa C, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001261; Mengos AE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01147; Merah-Mourah F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61022-1; Meyer C, 2014, CANCER IMMUNOL IMMUN, V63, P247, DOI 10.1007/s00262-013-1508-5; Minard-Colin V, 2008, BLOOD, V112, P1205, DOI 10.1182/blood-2008-01-135160; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Mondini M, 2019, CANCER IMMUNOL RES, V7, P376, DOI 10.1158/2326-6066.CIR-18-0633; Moriyama Y, 2017, CLIN RESPIR J, V11, P453, DOI 10.1111/crj.12358; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Murphy FJ, 1996, IMMUNOLOGY, V89, P587, DOI 10.1046/j.1365-2567.1996.d01-788.x; NADLER LM, 1980, CANCER RES, V40, P3147; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Nockher WA, 1998, INFECT IMMUN, V66, P2782, DOI 10.1128/IAI.66.6.2782-2790.1998; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Olingy CE, 2019, J LEUKOCYTE BIOL, V106, P309, DOI 10.1002/JLB.4RI0818-311R; Ong SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01761; Ostrand-Rosenberg S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00215; Ouyang W, 2018, J CANCER RES THER, V14, pS565, DOI 10.4103/0973-1482.177502; Pan YC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013896; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parker JJ, 2013, CLIN IMMUNOL, V148, P44, DOI 10.1016/j.clim.2013.03.008; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Patysheva M., 2019, EXP ONCOL, DOI [10.32471/exp-oncology.2312-8852.vol-41-no-3.13597, DOI 10.32471/EXP-ONCOLOGY.2312-8852.VOL-41-NO-3.13597]; Patysheva M, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.800235; Peggs KS, 2008, IMMUNOL REV, V224, P141, DOI 10.1111/j.1600-065X.2008.00649.x; Peng Y, 2020, CANCER BIOL THER, V21, P189, DOI 10.1080/15384047.2019.1680057; Peters S, 2021, CANCER DISCOV, V11, P810, DOI 10.1158/2159-8290.CD-21-0124; Petroni G, 2021, CANCER CELL, V39, P310, DOI 10.1016/j.ccell.2020.11.009; Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637-012-9869-8; Pinto AT, 2016, SCI REP-UK, V6, DOI 10.1038/srep18765; PLOWMAN PN, 1983, INT J RADIAT ONCOL, V9, P829, DOI 10.1016/0360-3016(83)90008-1; Poon I, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.26312; Porrello A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04355-w; Przystal JM, 2021, CANCERS, V13, DOI 10.3390/cancers13102400; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Refae S, 2020, INVEST NEW DRUG, V38, P160, DOI 10.1007/s10637-019-00845-w; Reisz JA, 2014, ANTIOXID REDOX SIGN, V21, P260, DOI 10.1089/ars.2013.5489; Riemann D, 2020, CANCERS, V12, DOI 10.3390/cancers12102966; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rizzo A, 2022, EXPERT OPIN INV DRUG, V31, P549, DOI 10.1080/13543784.2022.2008354; Robinson A, 2021, TRENDS IMMUNOL, V42, P104, DOI 10.1016/j.it.2020.12.001; ROTMAN M, 1977, CANCER, V39, P744, DOI 10.1002/1097-0142(197702)39:2+<744::AID-CNCR2820390709>3.0.CO;2-R; Salas-Benito D, 2021, CANCER DISCOV, V11, P1353, DOI 10.1158/2159-8290.CD-20-1312; Schauer D, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1160185; Schauer D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044450; Schetters STT, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000588; Schirrmacher V, 2019, INT J ONCOL, V54, P407, DOI 10.3892/ijo.2018.4661; Sedykh SE, 2018, DRUG DES DEV THER, V12, P195, DOI 10.2147/DDDT.S151282; Sekine K, 2018, LUNG CANCER, V124, P179, DOI 10.1016/j.lungcan.2018.08.012; Shao YL, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20202613; Shimanuki Marie, 2018, Oncotarget, V9, P18970, DOI 10.18632/oncotarget.24863; Shin SC, 2010, BIOCHEM BIOPH RES CO, V397, P644, DOI 10.1016/j.bbrc.2010.05.121; Siamak S, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e14556; SMIT B, 1979, INT J RADIAT ONCOL, V5, P1841, DOI 10.1016/0360-3016(79)90569-8; Soeda A, 2009, JPN J CLIN ONCOL, V39, P797, DOI 10.1093/jjco/hyp112; Song Q, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2702719; Stakheyeva M, 2017, CURR PHARM DESIGN, V23, P4807, DOI 10.2174/1381612823666170714161703; Standish Leanna J, 2008, J Soc Integr Oncol, V6, P110; Steinberger KJ, 2020, J IMMUNOL, V205, P2301, DOI 10.4049/jimmunol.2000185; Stenzel AE, 2021, AM J REPROD IMMUNOL, V85, DOI 10.1111/aji.13343; Suwa T, 2021, EXP MOL MED, V53, P1029, DOI 10.1038/s12276-021-00640-9; Swierczak A, 2014, CANCER IMMUNOL RES, V2, P765, DOI 10.1158/2326-6066.CIR-13-0190; Tadmor T, 2015, MAYO CLIN PROC, V90, P756, DOI 10.1016/j.mayocp.2015.03.025; Takeuchi S, 2015, CANCER RES, V75, P2629, DOI 10.1158/0008-5472.CAN-14-2921; Talamantes S, 2020, CANCER MED-US, V9, P6954, DOI 10.1002/cam4.3358; Taylor PR, 2003, IMMUNITY, V19, P2, DOI 10.1016/S1074-7613(03)00178-X; Thomas J, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23137066; Tonouchi H, 2002, SCAND J GASTROENTERO, V37, P830, DOI 10.1080/713786535; Tsai CS, 2007, INT J RADIAT ONCOL, V68, P499, DOI 10.1016/j.ijrobp.2007.01.041; Tse KP, 2007, CLIN CANCER RES, V13, P6320, DOI 10.1158/1078-0432.CCR-07-1029; Uchida JJ, 2004, J EXP MED, V199, P1659, DOI 10.1084/jem.20040119; Urakawa S, 2019, CANCER IMMUNOL IMMUN, V68, P1341, DOI 10.1007/s00262-019-02366-0; Ushach I, 2016, J LEUKOCYTE BIOL, V100, P481, DOI 10.1189/jlb.3RU0316-144R; Valdes-Ferrada J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01413; Vempati P, 2020, INT J RADIAT ONCOL, V108, pE554; Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078; Wang J, 2017, ONCOTARGET, V8, P17050, DOI 10.18632/oncotarget.14991; Wang L, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102631; Wang ZB, 2016, ONCOTARGET, V7, P4760, DOI 10.18632/oncotarget.6734; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wu CJ, 2020, J IMMUNOL, V204, P212, DOI 10.4049/jimmunol.1900930; Wu HH, 2013, REPROD SCI, V20, P1175, DOI 10.1177/1933719113477481; Wu QJ, 2017, CELL DEATH DIFFER, V24, P1632, DOI 10.1038/cdd.2017.91; Xiang JD, 2017, TRANSL ONCOL, V10, P33, DOI 10.1016/j.tranon.2016.10.006; Xiong HZ, 2019, CANCER RES, V79, P1493, DOI 10.1158/0008-5472.CAN-18-3208; Xu BB, 2020, J CANCER, V11, P5078, DOI 10.7150/jca.44440; Xu JY, 2013, CANCER RES, V73, P2782, DOI 10.1158/0008-5472.CAN-12-3981; YANG FE, 1995, INT J RADIAT ONCOL, V33, P607, DOI 10.1016/0360-3016(95)00255-W; Yang S, 2022, BIOCHEM GENET, V60, P1159, DOI 10.1007/s10528-021-10145-9; Yoshida K, 2019, BRIT J HAEMATOL, V185, P107, DOI 10.1111/bjh.15750; Yoshino H, 2014, J RADIAT RES, V55, P876, DOI 10.1093/jrr/rru040; Zhang BK, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711571; Zhang W, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64579-z; Zhang XW, 2013, CANCER IMMUNOL IMMUN, V62, P563, DOI 10.1007/s00262-012-1361-y; Zhao KW, 2020, TRANSL CANCER RES, V9, P3842, DOI 10.21037/tcr-19-2849; Zhu X, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42781-y; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558; ZIEGLERHEITBROCK HWL, 1988, HYBRIDOMA, V7, P521, DOI 10.1089/hyb.1988.7.521; Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009; Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014; Zitvogel L, 2011, NAT REV CLIN ONCOL, V8, P151, DOI 10.1038/nrclinonc.2010.223; Zou Q, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-015-0339-9	243	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 20	2022	13								994319	10.3389/fimmu.2022.994319	http://dx.doi.org/10.3389/fimmu.2022.994319			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5Y7IZ	36341366	Green Published, gold			2022-12-18	WOS:000879455800001
J	Lin, JZ; Ma, JD; Yang, LJ; Zou, YW; Zhang, XP; Pan, J; Li, QH; Li, HG; Yang, ZH; Wu, T; Zhang, Q; Mo, YQ; Dai, L				Lin, Jian-Zi; Ma, Jian-Da; Yang, Li-Juan; Zou, Yao-Wei; Zhang, Xue-Pei; Pan, Jie; Li, Qian-Hua; Li, Hong-Gui; Yang, Ze-Hong; Wu, Tao; Zhang, Qian; Mo, Ying-Qian; Dai, Lie			Myokine myostatin is a novel predictor of one-year radiographic progression in patients with rheumatoid arthritis: A prospective cohort study	FRONTIERS IN IMMUNOLOGY			English	Article						rheumatoid arthritis; myostatin; myopenia; joint destruction; radiographic progression	BONE-FORMATION; DIFFERENTIATION; INHIBITION; DIAGNOSIS; CANCER	BackgroundAssociations between rheumatoid arthritis (RA) and reduced skeletal muscle have been studied, and we firstly reported myopenia independently predict one-year radiographic progression in RA. Myokine myostatin can negatively regulate skeletal muscle mass and promote osteoclast differentiation. However, there is no report about their relationships in RA patients. We firstly explored the relationship of serum myostatin and disease characteristics, as well as aggravated joint destruction during one-year follow-up. MethodsConsecutive RA patients were recruited from a real-world prospective cohort and completed at least one-year follow-up. Baseline serum level of myostatin was measured by enzyme-linked immunosorbent assay. Clinical data in RA patients as well as muscle index in both RA patients and healthy controls were collected. One-year radiographic progression as primary outcome was defined by a change in the total Sharp/van der Heijde modified score >= 0.5 units. ResultsTotally 344 RA patients (age 47.9 +/- 12.5 years, 84.0% female) and 118 healthy control subjects (age 42.8 +/- 11.3 years, 74.6% female) were recruited. Compared with healthy controls, RA patients showed a higher level of serum myostatin at baseline (3.241 +/- 1.679 ng/ml vs. 1.717 +/- 0.872 ng/ml, P<0.001), although lower appendicular skeletal muscle mass index (ASMI, 6.0 +/- 0.9 kg/m(2) vs. 6.5 +/- 1.0 kg/m(2), P<0.001). In RA patients, those with high myostatin level showed a higher rate of radiographic progression than low myostatin group (45.3% vs. 18.6%, P<0.001). Furtherly, RA patients were stratified into four subgroups according to serum myostatin and myopenia. Compared with other three subgroups, RA patients with high myostatin overlapping myopenia had the highest rate of radiographic progression (67.2% vs. 10.3%-31.4%, P<0.001), as well as the lowest proportion of remission and the highest rate of physical dysfunction during one-year follow-up. After adjustment for confounding factors, high serum myostatin (AOR=3.451, 95%CI: 2.016-5.905) and myopenia (AOR=2.387, 95%CI: 1.416-4.022) at baseline were risk factors for one-year radiographic progression, especially for those with high myostatin overlapping myopenia (AOR=10.425, 95%CI: 3.959-27.450) as the highest-risk individuals among four subgroups. Significant synergistic interaction effect was observed between high myostatin and myopenia on one-year radiographic progression (AP=66.3%, 95%CI: 43.2%-89.3%). ConclusionMyostatin is a novel predictor of aggravated joint destruction in RA patients which has synergistic interaction with myopenia for predicting value.	[Lin, Jian-Zi; Ma, Jian-Da; Yang, Li-Juan; Zou, Yao-Wei; Zhang, Xue-Pei; Pan, Jie; Li, Qian-Hua; Li, Hong-Gui; Wu, Tao; Zhang, Qian; Mo, Ying-Qian; Dai, Lie] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Rheumatol, Guangzhou, Peoples R China; [Yang, Ze-Hong] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Radiol, Guangzhou, Peoples R China; [Mo, Ying-Qian] Sun Yat Sen Univ, Mem Hosp, Shenshan Med Ctr, Dept Rheumatol, Shanwei, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Mo, YQ; Dai, L (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Rheumatol, Guangzhou, Peoples R China.; Mo, YQ (corresponding author), Sun Yat Sen Univ, Mem Hosp, Shenshan Med Ctr, Dept Rheumatol, Shanwei, Peoples R China.	moyingq@mail.sysu.edu.cn; dailie@mail.sysu.edu.cn			National Natural Science Foundation of China; Guangdong Basic and Applied Basic Research Foundation; China Postdoctoral Science Foundation; Guangdong Medical Scientific Research Foundation; Guangzhou Municipal Science and Technology Project;  [82171780];  [82101892];  [81971527];  [2022A1515010524];  [2020A1515110061];  [2019A1515011928];  [2021M703722];  [A2021065];  [202102010188]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Guangdong Medical Scientific Research Foundation; Guangzhou Municipal Science and Technology Project; ; ; ; ; ; ; ; ; 	Funding This work was supported by National Natural Science Foundation of China (grant no. 82171780, 82101892 and 81971527), Guangdong Basic and Applied Basic Research Foundation (grant no. 2022A1515010524, 2020A1515110061 and 2019A1515011928), Project funded by China Postdoctoral Science Foundation (grant no. 2021M703722), Guangdong Medical Scientific Research Foundation (grant no. A2021065), and Guangzhou Municipal Science and Technology Project (grant no. 202102010188).	Aletaha D, 2018, JAMA-J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103; Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; Arounleut P, 2013, EXP GERONTOL, V48, P898, DOI 10.1016/j.exger.2013.06.004; Arrieta H, 2019, GERONTOLOGY, V65, P229, DOI 10.1159/000494137; Baczek J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082401; Bialek P, 2014, BONE, V60, P162, DOI 10.1016/j.bone.2013.12.002; Chen LK, 2020, J AM MED DIR ASSOC, V21, P300, DOI 10.1016/j.jamda.2019.12.012; Cui YX, 2020, BIOFACTORS, DOI 10.1002/biof.1675; Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917; England BR, 2019, ARTHRIT CARE RES, V71, P1540, DOI 10.1002/acr.24042; Esposito Pasquale, 2022, Adv Clin Chem, V106, P181, DOI 10.1016/bs.acc.2021.09.006; Fennen M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-93599-6; Gomarasca M, 2020, ADV CLIN CHEM, V94, P155, DOI 10.1016/bs.acc.2019.07.010; Guo W, 2008, J BIOL CHEM, V283, P9136, DOI 10.1074/jbc.M708968200; Harish P, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00184; Hu SL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01747; Kendler KS, 2010, BRIT J PSYCHIAT, V197, P170, DOI 10.1192/bjp.bp.110.081331; Letarouilly JG, 2021, THER ADV MUSCULOSKEL, V13, DOI 10.1177/1759720X211015006; Lin JZ, 2019, J CACHEXIA SARCOPENI, V10, P355, DOI 10.1002/jcsm.12381; Lin JH, 2020, TOXINS, V12, DOI [10.3390/toxins12090572, 10.1177/1759720X20946220]; Loumaye A, 2015, J CLIN ENDOCR METAB, V100, P2030, DOI 10.1210/jc.2014-4318; Murillo-Saich JD, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000024186; Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105; Qin YW, 2017, J BIOL CHEM, V292, P11021, DOI 10.1074/jbc.M116.770941; Radner H, 2018, ANN RHEUM DIS, V77, P476, DOI 10.1136/annrheumdis-2017-212256; Rodriguez J, 2014, CELL MOL LIFE SCI, V71, P4361, DOI 10.1007/s00018-014-1689-x; Severinsen MCK, 2020, ENDOCR REV, V41, DOI 10.1210/endrev/bnaa016; Smith RC, 2013, CURR OPIN SUPPORT PA, V7, P352, DOI 10.1097/SPC.0000000000000013; Su CM, 2019, J CELL PHYSIOL, V234, P9793, DOI 10.1002/jcp.27665; Tay L, 2015, AGE, V37, DOI 10.1007/s11357-015-9860-3; van der Heijde D, 2000, J RHEUMATOL, V27, P261; Wagner KR, 2020, CURR OPIN NEUROL, V33, P621, DOI 10.1097/WCO.0000000000000853; Zhang XP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778480; Zhou HY, 2020, J CACHEXIA SARCOPENI, V11, P768, DOI 10.1002/jcsm.12542; Zhou YN, 2021, NEPHROL DIAL TRANSPL, V36, P95, DOI 10.1093/ndt/gfz210	36	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 18	2022	13								1005161	10.3389/fimmu.2022.1005161	http://dx.doi.org/10.3389/fimmu.2022.1005161			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5X2BK	36330524	Green Published			2022-12-18	WOS:000878409400001
J	Cai, JY; Hu, YY; Ye, Z; Ye, LG; Gao, L; Wang, YX; Sun, Q; Tong, S; Yang, JA; Chen, QX				Cai, Jiayang; Hu, Yuanyuan; Ye, Zhang; Ye, Liguo; Gao, Lun; Wang, Yixuan; Sun, Qian; Tong, Shiao; Yang, Ji'an; Chen, Qianxue			Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma	FRONTIERS IN IMMUNOLOGY			English	Article						Immunogenic cell death; lower-grade gliomas; prognosis; tumour microenvironment; immunotherapy	GENOMIC ANALYSIS; CANCER	Lower-grade glioma (LGG) is a common malignant primary tumour in the central nervous system, and most patients eventually develop highly aggressive gliomas despite comprehensive traditional treatment. Tumour molecular subtypes and prognostic biomarkers play a crucial role in LGG diagnosis and treatment. Therefore, the identification of novel biomarkers in LGG patients is crucial for predicting the prognosis of glioma. Immunogenic cell death (ICD) is defined as regulated cell death that is sufficient to activate the adaptive immune response of immunocompetent hosts. The combination of ICD and immunotherapy might exert a greater and more persistent antitumour effect in gliomas. In our study, we explored the expression, function, and genetic alterations of 34 ICD-related genes. Using 12 ICD-related genes, including IL17RA, IL1R1, EIF2AK3, CD4, PRF1, CXCR3, CD8A, BAX, PDIA3, CASP8, MYD88, and CASP1, we constructed and validated an ICD-related risk signature via least absolute shrinkage and selection operator (LASSO) Cox regression analysis. All the information was obtained from public databases, including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and the Chinese Glioma Genome Atlas (CGGA) databases. Our results revealed that ICD-high risk groups have a poor prognosis and might be more sensitive to immune checkpoint blockade (ICB) immunotherapy. In addition, ICD-high risk groups were associated with 1p19q noncodeletion, higher WHO grade, wild type IDH, and an immunosuppressive tumour microenvironment. We verified the prognostic value of 12 ICD-related genes in TCGA and CGGA databases. Immunohistochemistry was performed to verify the expression of several ICD-related genes at the protein level. Our study provides a novel and comprehensive perspective to elucidate the underlying mechanisms of LGG prognosis and direction for future individualized cancer immunotherapy.	[Cai, Jiayang; Ye, Zhang; Ye, Liguo; Gao, Lun; Wang, Yixuan; Sun, Qian; Tong, Shiao; Yang, Ji'an; Chen, Qianxue] Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan, Peoples R China; [Cai, Jiayang; Ye, Zhang; Ye, Liguo; Gao, Lun; Wang, Yixuan; Sun, Qian; Tong, Shiao; Yang, Ji'an; Chen, Qianxue] Wuhan Univ, Renmin Hosp, Cent Lab, Wuhan, Peoples R China; [Hu, Yuanyuan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Ophthalmol, Wuhan, Peoples R China	Wuhan University; Wuhan University; Huazhong University of Science & Technology	Yang, JA; Chen, QX (corresponding author), Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan, Peoples R China.; Yang, JA; Chen, QX (corresponding author), Wuhan Univ, Renmin Hosp, Cent Lab, Wuhan, Peoples R China.	jayang@whu.edu.cn; chenqx666@whu.edu.cn			National Natural Science Foundation of China; Natural Science Foundation of Hubei Province;  [82072764];  [2020CFB256]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province); ; 	Funding This work was supported by the National Natural Science Foundation of China (No. 82072764) and Natural Science Foundation of Hubei Province (No. 2020CFB256).	Ahmed A, 2020, MOL ONCOL, V14, P2994, DOI 10.1002/1878-0261.12851; Aponte-Lopez A, 2020, ADV EXP MED BIOL, V1273, P159, DOI 10.1007/978-3-030-49270-0_9; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Ballas ZK, 2018, J ALLERGY CLIN IMMUN, V142, P1752, DOI 10.1016/j.jaci.2018.10.021; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Davis BP, 2014, CANCER IMMUNOL RES, V2, P1, DOI 10.1158/2326-6066.CIR-13-0196; de Oca RM, 2021, MOL CANCER THER, V20, P1941, DOI 10.1158/1535-7163.MCT-21-0035; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Garg AD, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1069938; Guillerey C, 2020, ADV EXP MED BIOL, V1273, P69, DOI 10.1007/978-3-030-49270-0_4; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayes J, 2018, NEURO-ONCOLOGY, V20, P632, DOI 10.1093/neuonc/nox205; Hossain DMS, 2018, J CLIN INVEST, V128, P644, DOI 10.1172/JCI94586; Huang LP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12771-9; Jiang F, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.902143; Jongsma MLM, 2021, IMMUNITY, V54, P132, DOI 10.1016/j.immuni.2020.11.003; Karpel-Massler G, 2019, CNS DRUGS, V33, P1155, DOI 10.1007/s40263-019-00684-6; Kepp O, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1795995; Lamantia C, 2014, NEUROPHOTONICS, V1, DOI 10.1117/1.NPh.1.1.011014; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Wang X, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1085-3; Wierstra P, 2019, EJNMMI RADIOPHARM CH, V4, DOI 10.1186/s41181-019-0078-z; Xie W, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1656502; Xu SC, 2020, CANCER LETT, V476, P1, DOI 10.1016/j.canlet.2020.02.002; Yang Z, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03294-z; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang LY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00937; Zhang YA, 2016, EBIOMEDICINE, V13, P80, DOI 10.1016/j.ebiom.2016.10.040; Zhu H, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.759953	35	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 17	2022	13								1011757	10.3389/fimmu.2022.1011757	http://dx.doi.org/10.3389/fimmu.2022.1011757			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5W5WY	36325335	Green Published, gold			2022-12-18	WOS:000877985000001
J	Xiao, Q; Yu, FT; Yan, LT; Zhao, HX; Zhang, FJ				Xiao, Qing; Yu, Fengting; Yan, Liting; Zhao, Hongxin; Zhang, Fujie			Alterations in circulating markers in HIV/AIDS patients with poor immune reconstitution: Novel insights from microbial translocation and innate immunity	FRONTIERS IN IMMUNOLOGY			English	Review						human immunodeficiency virus (HIV); acquired immure deficiency syndrome (AIDS); poor immune reconstitution (PIR); plasma markers; fecal markers; innate immunity; microbial translocation	T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY; HIV-INFECTION; DISEASE PROGRESSION; HIV-1-INFECTED PATIENTS; SIGNIFICANT FIBROSIS; FECAL CALPROTECTIN; DENDRITIC CELLS; PLASMA-LEVELS; INTERLEUKIN-7	After long-term anti-retroviral therapy (ART) treatment, most human immunodeficiency virus (HIV)/Acquired Immure Deficiency Syndrome (AIDS) patients can achieve virological suppression and gradual recovery of CD4(+) T-lymphocyte (CD4(+) T cell) counts. However, some patients still fail to attain normal CD4(+) T cell counts; this group of patients are called immune non-responders (INRs), and these patients show severe immune dysfunction. The potential mechanism of poor immune reconstitution (PIR) remains unclear and the identification of uniform biomarkers to predict the occurrence of PIR is particularly vital. But limited information is available on the relationship between circulating markers of INRs and immune recovery. Hence, this review summarises alterations in the intestine microbiota and associated markers in the setting of PIR to better understand host-microbiota-metabolite interactions in HIV immune reconstitution and to identify biomarkers that can predict recovery of CD4(+) T cell counts in INRs.	[Xiao, Qing; Yu, Fengting; Zhao, Hongxin; Zhang, Fujie] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China; [Xiao, Qing; Yu, Fengting; Zhao, Hongxin; Zhang, Fujie] Capital Med Univ, Clin Ctr HIV AIDS, Beijing, Peoples R China; [Yan, Liting] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Infect Dis Dept, Chengdu, Peoples R China	Capital Medical University; Capital Medical University; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China	Zhang, FJ (corresponding author), Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China.; Zhang, FJ (corresponding author), Capital Med Univ, Clin Ctr HIV AIDS, Beijing, Peoples R China.	treatment@chinaaids.cn			Ministry of Science and Technology of China [2018ZX10302-102]; Beijing Municipal Administration of Hospitals' Ascent Plan [DFL20191802]; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX202126]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Beijing Municipal Administration of Hospitals' Ascent Plan; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support	This work was supported by the 13th Five-year Plan, Ministry of Science and Technology of China (2018ZX10302-102), Beijing Municipal Administration of Hospitals' Ascent Plan (DFL20191802), and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX202126). The funders had no role in study design, data collection, analysis, publication decisions, or manuscript preparation.	Abdel-Mohsen M, 2020, NAT MED, V26, P1339, DOI 10.1038/s41591-020-1022-1; Afonina IS, 2015, IMMUNITY, V42, P991, DOI 10.1016/j.immuni.2015.06.003; Ajello F, 2000, EUR J EPIDEMIOL, V16, P209, DOI 10.1023/A:1007632617516; ALEXANDER JW, 1991, ANN SURG, V213, P558, DOI 10.1097/00000658-199106000-00005; Allam O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194185; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anadol E, 2015, HEPATOLOGY, V61, P46, DOI 10.1002/hep.27369; Antonov A, 2014, ONCOTARGET, V5, P11004, DOI 10.18632/oncotarget.2668; Asahchop EL, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122450; Asahchop EL, 2016, AIDS, V30, P2021, DOI 10.1097/QAD.0000000000001160; Asmuth DM, 2015, AIDS, V29, P877, DOI 10.1097/QAD.0000000000000636; Bansal A, 2018, J CELL BIOL, V217, P2291, DOI 10.1083/jcb.201804161; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Berg Rodney D., 1995, Trends in Microbiology, V3, P149, DOI 10.1016/S0966-842X(00)88906-4; Biswas S, 2019, EBIOMEDICINE, V43, P307, DOI 10.1016/j.ebiom.2019.04.023; Boulassel M R, 2003, HIV Med, V4, P315, DOI 10.1046/j.1468-1293.2003.00165.x; Braun V, 2015, INT J MED MICROBIOL, V305, P238, DOI 10.1016/j.ijmm.2014.12.006; BUHL R, 1989, LANCET, V2, P1294; Burdo TH, 2011, J INFECT DIS, V204, P154, DOI 10.1093/infdis/jir214; Cassol E, 2010, J INFECT DIS, V202, P723, DOI 10.1086/655229; Cenderello G, 2016, EXPERT REV ANTI-INFE, V14, P29, DOI 10.1586/14787210.2016.1106937; Chen Z, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.888996; Chevalier MF, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003453; Chiappini E, 2003, JAIDS-J ACQ IMM DEF, V33, P601, DOI 10.1097/00126334-200308150-00008; Romero-Sanchez MC, 2012, J INFECTION, V65, P431, DOI 10.1016/j.jinf.2012.06.008; Correa R, 2003, J CLIN IMMUNOL, V23, P401, DOI 10.1023/A:1025325718213; d'Ettorre G, 2017, IMMUN INFLAMM DIS, V5, P244, DOI 10.1002/iid3.160; Dabritz J, 2014, WORLD J GASTROENTERO, V20, P363, DOI 10.3748/wjg.v20.i2.363; Dai XP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.799124; Deeks Steven G, 2009, Top HIV Med, V17, P118; Doitsh G, 2016, CELL HOST MICROBE, V19, P280, DOI 10.1016/j.chom.2016.02.012; Ducker GS, 2017, CELL METAB, V25, P27, DOI 10.1016/j.cmet.2016.08.009; Dunham RM, 2014, JAIDS-J ACQ IMM DEF, V65, P133, DOI 10.1097/01.qai.0000437172.08127.0b; Eller MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018779; Favre D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000632; Feinstein MJ, 2019, CIRCULATION, V140, pE98, DOI 10.1161/CIR.0000000000000695; Ferrari B, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI149571; Franco S, 2021, AIDS, V35, P1355, DOI 10.1097/QAD.0000000000002895; Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471-4906(01)02028-2; Fu YP, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5782927; Gaardbo JC, 2015, JAIDS-J ACQ IMM DEF, V70, P228, DOI 10.1097/QAI.0000000000000758; Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957; Gadaleta RM, 2011, GUT, V60, P463, DOI 10.1136/gut.2010.212159; Ghaffari G, 2004, PEDIATRICS, V114, pE604, DOI 10.1542/peds.2004-0274; Gioannini TL, 2007, IMMUNOL RES, V39, P249, DOI 10.1007/s12026-007-0069-0; Gomella LG, 2017, CAN J UROL, V24, P8693; Goulder PJ, 2016, NAT REV IMMUNOL, V16, P259, DOI 10.1038/nri.2016.19; Grasedieck S, 2013, BLOOD, V121, P4977, DOI 10.1182/blood-2013-01-480079; Hampel H, 2018, NAT REV NEUROL, V14, P639, DOI 10.1038/s41582-018-0079-7; Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; He BK, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0751-1; Head BM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226347; Hearps AC, 2014, CURR HIV-AIDS REP, V11, P20, DOI 10.1007/s11904-013-0190-8; Hestvik E, 2012, J PEDIATR GASTR NUTR, V54, P785, DOI 10.1097/MPG.0b013e318241a683; Hsue PY, 2019, NAT REV CARDIOL, V16, P745, DOI 10.1038/s41569-019-0219-9; Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Isgro A, 2002, AIDS, V16, P2231, DOI 10.1097/00002030-200211080-00020; Jasinska AJ, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00928-4; Jia W, 2018, NAT REV GASTRO HEPAT, V15, P111, DOI 10.1038/nrgastro.2017.119; Kelly CJ, 2015, CELL HOST MICROBE, V17, P662, DOI 10.1016/j.chom.2015.03.005; Kong DH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041057; Kroeze S, 2021, J INFECT DIS, V224, P673, DOI 10.1093/infdis/jiaa787; Kroeze S, 2019, J INFECT DIS, V220, P1029, DOI 10.1093/infdis/jiz252; Lee J, 2020, CIRC RES, V127, P453, DOI 10.1161/CIRCRESAHA.119.316448; Lee SC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32585-x; Leeansyah E, 2013, CURR OPIN HIV AIDS, V8, P117, DOI 10.1097/COH.0b013e32835c7134; Levring TB, 2012, SCI REP-UK, V2, DOI 10.1038/srep00266; Li F, 2012, BRAZ J INFECT DIS, V16, P9, DOI 10.1016/S1413-8670(12)70267-2; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Liovat AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046143; Lopes S, 2017, WORLD J GASTROENTERO, V23, P6482, DOI 10.3748/wjg.v23.i35.6482; Lu DF, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06491-z; Lu W, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01451; Lv JN, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.753044; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Ma EH, 2017, CELL METAB, V25, P345, DOI 10.1016/j.cmet.2016.12.011; Mait-Kaufman J, 2015, AIDS RES HUM RETROV, V31, P615, DOI [10.1089/aid.2014.0085, 10.1089/AID.2014.0085]; Marchetti G, 2011, AIDS, V25, P1385, DOI 10.1097/QAD.0b013e3283471d10; Marziali M, 2006, AIDS, V20, P2033, DOI 10.1097/01.aids.0000247588.69438.fd; Massanella M, 2010, AIDS, V24, P959, DOI 10.1097/QAD.0b013e328337b957; Mavigner M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007658; McKibben RA, 2015, J INFECT DIS, V211, P1219, DOI 10.1093/infdis/jiu594; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mendez-Lagares G, 2013, J INFECT DIS, V207, P1221, DOI 10.1093/infdis/jit025; Merlini E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00614; Merlini E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018580; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Moran CA, 2018, AIDS, V32, P999, DOI [10.1097/qad.0000000000001785, 10.1097/QAD.0000000000001785]; Mumolo MG, 2018, WORLD J GASTROENTERO, V24, P3681, DOI 10.3748/wjg.v24.i33.3681; Munshi SU, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095920; Nakanjako D, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-43; Napolitano LA, 2001, NAT MED, V7, P73, DOI 10.1038/83381; Narla V, 2018, JAIDS-J ACQ IMM DEF, V79, P644, DOI 10.1097/QAI.0000000000001851; Nganou-Makamdop K, 2021, CELL, V184, P3899, DOI 10.1016/j.cell.2021.05.023; Nowak P, 2015, AIDS, V29, P2409, DOI 10.1097/QAD.0000000000000869; Nystrom S., 2021, OPEN FORUM INFECT DI, V8, DOI [10.1093/ofid/ofab288, DOI 10.1093/OFID/OFAB288]; O'Meara T, 2019, JAIDS-J ACQ IMM DEF, V82, P514, DOI 10.1097/QAI.0000000000002187; Palmer CS, 2014, AIDS, V28, P297, DOI 10.1097/QAD.0000000000000128; Papanastasopoulou C, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22010; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00277; Park SH, 2011, CLIN BIOCHEM, V44, P1396, DOI 10.1016/j.clinbiochem.2011.08.1151; Pastor L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218000; Planas D, 2019, CURR OPIN HIV AIDS, V14, P85, DOI [10.1097/COH.0000000000000522, 10.1097/coh.0000000000000522]; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Qian S, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06525-6; Rajasuriar R, 2015, CURR OPIN HIV AIDS, V10, P35, DOI 10.1097/COH.0000000000000118; Rajasuriar R, 2010, J INFECT DIS, V202, P1254, DOI 10.1086/656369; Reid MJA, 2019, AIDS PATIENT CARE ST, V33, P299, DOI 10.1089/apc.2019.0032; Resino S, 2003, CLIN EXP IMMUNOL, V132, P105, DOI 10.1046/j.1365-2249.2003.02116.x; Rethi B, 2005, AIDS, V19, P2077, DOI 10.1097/01.aids.0000189848.75699.0f; Reynoso R, 2014, SCI REP-UK, V4, DOI 10.1038/srep05915; Rocafort M, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0687-5; Rousseau RK, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254149; Ruiz-Briseno MD, 2020, J INFLAMM-LOND, V17, DOI 10.1186/s12950-020-00262-4; Russler-Germain EV, 2017, MUCOSAL IMMUNOL, V10, P1375, DOI 10.1038/mi.2017.65; Russo E, 2022, WORLD J GASTROENTERO, V28, P635, DOI 10.3748/wjg.v28.i6.635; Sanchez JL, 2015, J INFECT DIS, V211, P1068, DOI 10.1093/infdis/jiu586; Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Schumacker PT, 2015, CANCER CELL, V27, P156, DOI 10.1016/j.ccell.2015.01.007; Scott NA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4755; Seven G, 2011, TURK J GASTROENTEROL, V22, P305, DOI 10.4318/tjg.2011.0217; Shive CL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.638010; Shukla S, 2021, CURR OPIN HIV AIDS, V16, P215, DOI 10.1097/COH.0000000000000692; Siberry GK, 2013, PEDIATR INFECT DIS J, V32, P1303, DOI 10.1097/INF.0000000000000080; Siedner MJ, 2018, J INFECT DIS, V218, P922, DOI 10.1093/infdis/jiy244; SPERDUTO AR, 1993, AIDS RES HUM RETROV, V9, P1277, DOI 10.1089/aid.1993.9.1277; Strugnell RA, 2010, NAT REV MICROBIOL, V8, P656, DOI 10.1038/nrmicro2384; Sundaravaradan V, 2006, P NATL ACAD SCI USA, V103, P11701, DOI 10.1073/pnas.0602185103; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Thorman J, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.01810-21; Tobolowsky FA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191606; Villar-Garcia J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173802; Watson WH, 2019, FREE RADICAL BIO MED, V143, P55, DOI 10.1016/j.freeradbiomed.2019.07.031; Wilmanski T, 2019, NAT BIOTECHNOL, V37, P1217, DOI 10.1038/s41587-019-0233-9; Wilson EMP, 2013, IMMUNOL REV, V254, P343, DOI 10.1111/imr.12064; Winston JA, 2020, GUT MICROBES, V11, P158, DOI 10.1080/19490976.2019.1674124; Wlodarska M, 2017, CELL HOST MICROBE, V22, P25, DOI 10.1016/j.chom.2017.06.007; Xie YR, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-020-02074-1; Yang XD, 2020, J LEUKOCYTE BIOL, V107, P597, DOI 10.1002/JLB.4MR1019-189R; Yap SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186000; Yaseen MM, 2018, ARCH VIROL, V163, P1, DOI 10.1007/s00705-017-3569-9; Zia K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77750-3; Ziegler TR, 2017, AIDS RES HUM RETROV, V33, P681, DOI [10.1089/aid.2015.0369, 10.1089/AID.2015.0369]	146	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 17	2022	13								1026070	10.3389/fimmu.2022.1026070	http://dx.doi.org/10.3389/fimmu.2022.1026070			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5W2WT	36325329	gold, Green Published			2022-12-18	WOS:000877781700001
J	Liu, P; Chen, SZ; Gao, XZ; Liang, H; Sun, DQ; Shi, BK; Zhang, QJ; Guo, H				Liu, Peng; Chen, Shouzhen; Gao, Xingzhe; Liang, Hao; Sun, Daqian; Shi, Benkang; Zhang, Qiujie; Guo, Hu			Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer	FRONTIERS IN IMMUNOLOGY			English	Article						sarcopenia; SII; BCG; Bacille Calmette-Guerin vaccine; NMIBC (non-muscle invasive bladder cancer); immunity	SKELETAL-MUSCLE; MITOMYCIN-C; RECURRENCE; METAANALYSIS; PROGRESSION; IMPACT; MODEL; MASS	BackgroundTo explore the prognostic significance of sarcopenia and systemic immune-inflammation index (SII) for response to intravesical Bacillus Calmette-Guerin (BCG) in patients with intermediate-, and high-risk non-muscle invasive bladder cancer (NMIBC). MethodsWe retrospectively analyzed 183 consecutive patients treated in Qilu hospital of Shandong University for a first diagnosis of intermediate and high risk NMIBC. Using computed tomography scans at the third lumbar vertebra level, we calculated skeletal muscle index (SMI). Sarcopenia was defined as SMI <43 cm(2)/m(2) for males with BMI < 25 kg/m(2), <53 cm(2)/m(2) for males with BMI >= 25 kg/m(2), and <41 cm(2)/m(2) for females. The response to intravesical BCG immunotherapy and relapse-free survival (RFS) were analyzed. ResultsCompared with BCG responders, BCG non-responders were associated with sarcopenia (P < 0.001), carcinoma in situ (P < 0.001), T1 stage (P < 0.001), multiple tumor (P < 0.001), tumor diameter >=3cm (P < 0.001), and have a significant increase of neutrophil-to-lymphocyte ratio (NLR) (P < 0.001), platelet to lymphocyte ratio (PLR) (P = 0.004), SII (P < 0.001). The area under the ROC curve (AUC) of the BMI, NLR, PLR, and SII for response to intravesical BCG immunotherapy were 0.425, 0.693, 0.631, and 0.702 respectively. Logistic regression analysis demonstrated that sarcopenia and SII were predictors of response to intravesical BCG immunotherapy. The Kaplan-Meier survival analysis showed that the RFS of patients with BCG response, lower SII and no sarcopenia was significantly increased compared with that of patients with BCG non-response, higher SII and sarcopenia, respectively. Subgroup analysis demonstrated that the RFS of patients with high SII and sarcopenia was significantly decreased compared with those with low SII and no sarcopenia in Ta stage subgroup, T1 stage subgroup, non-Cis subgroup, multiple tumor subgroup, single tumor subgroup, tumor diameter >= 3cm subgroup and tumor diameter<3cm subgroup, respectively (P < 0.05). However, there was no significant difference in RFS for patients in CIS subgroup (P > 0.05). Multivariate Cox analysis shown that sarcopenia (p=0.005) and high SII (p = 0.003) were significantly associated with poor RFS. ConclusionsBoth sarcopenia and high SII are useful predictors of response to intravesical BCG in intermediate- and high-risk NMIBC patients. Patients with intermediate- and high-risk NMIBC that had sarcopenia or high SII at diagnosis were associated with poor RFS, and the combination of sarcopenia and SII may be a better predictor of RFS.	[Liu, Peng; Chen, Shouzhen; Gao, Xingzhe; Liang, Hao; Sun, Daqian; Shi, Benkang; Zhang, Qiujie; Guo, Hu] Shandong Univ, Dept Urol Surg, Qilu Hosp, Jinan, Peoples R China	Shandong University	Zhang, QJ; Guo, H (corresponding author), Shandong Univ, Dept Urol Surg, Qilu Hosp, Jinan, Peoples R China.	18560082552@163.com; guohu97@sdu.edu.cn			Shandong Medical and Health Science and Technology Development Plan Project [2018WS333]; National Natural Science Foundation of China [81970661, 81900637]; Tai Shan Scholar Foundation [ts201511092]	Shandong Medical and Health Science and Technology Development Plan Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tai Shan Scholar Foundation	Shandong Medical and Health Science and Technology Development Plan Project (2018WS333), the National Natural Science Foundation of China (Grant No. 81970661; 81900637) and the Tai Shan Scholar Foundation to BS (ts201511092).	Babjuk M, 2022, EUR UROL, V81, P75, DOI 10.1016/j.eururo.2021.08.010; Bohle A, 2003, J UROLOGY, V169, P90, DOI 10.1016/S0022-5347(05)64043-8; Borges TC, 2021, CLIN NUTR, V40, P202, DOI 10.1016/j.clnu.2020.05.005; Busato WFS, 2016, CLIN GENITOURIN CANC, V14, P176, DOI 10.1016/j.clgc.2015.09.005; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; Cruz-Jentoft AJ, 2019, LANCET, V393, P2636, DOI 10.1016/S0140-6736(19)31138-9; Diakos CI, 2014, LANCET ONCOL, V15, pE493, DOI 10.1016/S1470-2045(14)70263-3; Feliciano EMC, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2319; Flint TR, 2016, CELL METAB, V24, P672, DOI 10.1016/j.cmet.2016.10.010; Fukushima H, 2017, EXPERT REV ANTICANC, V17, P455, DOI 10.1080/14737140.2017.1301209; Han RF, 2006, UROLOGY, V67, P1216, DOI 10.1016/j.urology.2005.12.014; Hirasawa Y, 2016, ANN SURG ONCOL, V23, pS1048, DOI 10.1245/s10434-016-5606-4; Ke ZB, 2021, CLIN NUTR, V40, P5792, DOI 10.1016/j.clnu.2021.10.019; Kurz E, 2022, CANCER CELL, V40, P720, DOI 10.1016/j.ccell.2022.05.006; Lenis AT, 2020, JAMA-J AM MED ASSOC, V324, P1980, DOI [10.1001/jama.2020.17601, 10.1001/jama.2020.17598]; Martin L, 2013, J CLIN ONCOL, V31, P1539, DOI 10.1200/JCO.2012.45.2722; Martini DJ, 2021, ONCOLOGIST, V26, P1017, DOI 10.1002/onco.13922; Mayr R, 2018, J CACHEXIA SARCOPENI, V9, P505, DOI 10.1002/jcsm.12279; Miyake M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3231-7; Nelke C, 2019, EBIOMEDICINE, V49, P381, DOI 10.1016/j.ebiom.2019.10.034; Nishikawa H, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103519; Pan LY, 2021, EXP GERONTOL, V154, DOI 10.1016/j.exger.2021.111544; Psutka SP, 2014, CANCER-AM CANCER SOC, V120, P2910, DOI 10.1002/cncr.28798; Saitoh-Maeda Y, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0279-2; Shelley MD, 2004, BJU INT, V93, P485, DOI 10.1111/j.1464-410X.2003.04655.x; Shelley MD, 2001, BJU INT, V88, P209, DOI 10.1046/j.1464-410x.2001.02306.x; Smith AB, 2014, J UROLOGY, V191, P1714, DOI 10.1016/j.juro.2013.12.047; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; van Rhijn BWG, 2009, EUR UROL, V56, P430, DOI 10.1016/j.eururo.2009.06.028; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326, DOI 10.1093/gerona/57.5.M326; Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961; Wilson D, 2017, AGEING RES REV, V36, P1, DOI 10.1016/j.arr.2017.01.006; Xylinas E, 2013, BRIT J CANCER, V109, P1460, DOI 10.1038/bjc.2013.372	33	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2022	13								1032907	10.3389/fimmu.2022.1032907	http://dx.doi.org/10.3389/fimmu.2022.1032907			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5R7IZ	36225922	gold, Green Published			2022-12-18	WOS:000874681100001
J	Zhao, X; Zhou, X; Sun, H; Shi, HX; Song, YP; Wang, Q; Zhang, GP; Xu, DK				Zhao, Xin; Zhou, Xing; Sun, Hui; Shi, Huixin; Song, Yiping; Wang, Qiang; Zhang, Guangping; Xu, Dake			3D printed Ti-5Cu alloy accelerates osteogenic differentiation of MC3T3-E1 cells by stimulating the M2 phenotype polarization of macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						3D printing technology; Ti-5Cu alloy; macrophage polarization; oncostatin M; osteogenic differentiation; bone immunomodulation	TI-CU ALLOYS; ONCOSTATIN M; BIOACTIVE GLASS; COPPER; ANTIBACTERIAL; CYTOKINES	Ti-5Cu alloy has been proved to have excellent mechanical properties and cell compatibility and has certain antibacterial properties due to the addition of Cu. However, there are few studies on the effects of Ti-5Cu alloy on macrophage polarization and immune-related bone formation. In this study, we prepared Ti-5Cu alloy by three-dimensional printing technology and found that Ti-5Cu alloy presented a much smoother surface compared with Ti. In addition, the CCK-8 results indicated the Ti-5Cu alloy had no cytotoxicity to RAW264.7 cells by co-culture. The results of inductively coupled plasma mass spectrometry showed that the concentration of Cu2+ was 0.133 mg/L after 7 days of co-culture, and the CCK-8 results proved that Cu2+ had no cytotoxicity to RAW264.7 at this concentration. Then, we studied the effects of Ti-5Cu alloy on macrophage polarization; it was shown that the Ti-5Cu alloy is more prone to modulate the RAW264.7 polarization towards the M2 phenotype and the conditioned medium derived from Ti-5Cu alloy significantly promoted the proliferation and osteogenic differentiation of MC3T3-E1 cells. However, when the expression of Oncostatin M (OSM) gene of RAW264.7 was knocked down, the osteogenic differentiation of MC3T3-E1 cells was decreased. This suggests that the OSM secreted by RAW264.7 co-cultured with Ti-5Cu alloy could accelerate the osteogenic differentiation of MC3T3-E1 cells by acting on OSMR/gp130 receptors.	[Zhao, Xin; Sun, Hui; Wang, Qiang] China Med Univ, Sch & Hosp Stomatol, Liaoning Prov Key Lab Oral Dis, Shenyang, Peoples R China; [Zhou, Xing; Xu, Dake] Northeastern Univ, Shenyang Natl Lab Mat Sci, Shenyang, Peoples R China; [Zhou, Xing; Xu, Dake] Northeastern Univ, Electrobiomat Inst, Key Lab Anisotropy & Texture Mat, Minist Educ, Shenyang, Peoples R China; [Shi, Huixin; Song, Yiping] China Med Univ, Dept Plast Surg, Hosp 1, Shenyang, Peoples R China; [Zhang, Guangping] China Med Univ, Dept Stomatol, Shengjing Hosp, Shenyang, Peoples R China	China Medical University; Northeastern University - China; Northeastern University - China; China Medical University; China Medical University	Wang, Q (corresponding author), China Med Univ, Sch & Hosp Stomatol, Liaoning Prov Key Lab Oral Dis, Shenyang, Peoples R China.; Zhang, GP (corresponding author), China Med Univ, Dept Stomatol, Shengjing Hosp, Shenyang, Peoples R China.	mfqwang@cmu.edu.cn; zhang_cmu@126.com			National Natural Science Foundation of China [51871050]; Natural Science Foundation Project of Liaoning Province [2020-MS-150, 2018225059]; Shenyang Science and Technology Funded Project [RC190290]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of Liaoning Province; Shenyang Science and Technology Funded Project	This work was supported by the National Natural Science Foundation of China (51871050), Natural Science Foundation Project of Liaoning Province (2020-MS-150, 2018225059), and Shenyang Science and Technology Funded Project (RC190290).	Arancibia S, 2016, NANOMEDICINE-UK, V11, P1237, DOI 10.2217/nnm.16.39; Bai B, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5600-6; Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756-3282(01)00638-X; Chen J, 2020, PFLUG ARCH EUR J PHY, V472, P1415, DOI 10.1007/s00424-020-02412-2; Chen L, 2021, BIOACT MATER, V6, P191, DOI 10.1016/j.bioactmat.2020.08.001; Chen SF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.634650; Chen ZT, 2018, BIOMATER SCI-UK, V6, P1007, DOI 10.1039/c7bm00869d; de Souza PPC, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063287; Diez-Tercero L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91070-0; Fan DY, 2022, RARE METALS, V41, P580, DOI 10.1007/s12598-021-01826-w; Fan YH, 2019, BIOMATERIALS, V204, P36, DOI 10.1016/j.biomaterials.2019.03.007; Feng XM, 2016, CYTOTECHNOLOGY, V68, P2699, DOI 10.1007/s10616-016-9995-9; Fowler L, 2019, MAT SCI ENG C-MATER, V97, P707, DOI 10.1016/j.msec.2018.12.050; Guihard P, 2015, AM J PATHOL, V185, P765, DOI 10.1016/j.ajpath.2014.11.008; Hamlet SM, 2019, CLIN ORAL IMPLAN RES, V30, P1085, DOI 10.1111/clr.13522; He C, 2016, AM J RESP CELL MOL, V55, P58, DOI 10.1165/rcmb.2015-0183OC; Hermanns HM, 2015, CYTOKINE GROWTH F R, V26, P545, DOI 10.1016/j.cytogfr.2015.07.006; Hirata E, 2016, NANOSCALE, V8, P14514, DOI 10.1039/c6nr02756c; Hordyjewska A, 2014, BIOMETALS, V27, P611, DOI 10.1007/s10534-014-9736-5; Horwood NJ, 2016, CLIN REV ALLERG IMMU, V51, P79, DOI 10.1007/s12016-015-8519-2; Hotchkiss KM, 2016, ACTA BIOMATER, V31, P425, DOI 10.1016/j.actbio.2015.12.003; Huang QL, 2019, ACTA BIOMATER, V100, P415, DOI 10.1016/j.actbio.2019.09.030; Jamalpoor Z, 2018, IRAN J ALLERGY ASTHM, V17, P398; Kang MY, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115627; Kardos J, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0277-3; Kim SG, 2020, MAX PLAST RECONSTR S, V42, DOI 10.1186/s40902-020-00249-4; Kosoff D, 2018, LAB CHIP, V18, P3011, DOI 10.1039/c8lc00431e; Kubin T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031811; Li J, 2020, REGEN BIOMATER, V7, P203, DOI 10.1093/rb/rbz053; Li PF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.700009; Li YD, 2020, CIRCULATION, V142, P967, DOI 10.1161/CIRCULATIONAHA.119.044484; Lin RC, 2019, THERANOSTICS, V9, P6300, DOI 10.7150/thno.36120; Liu H, 2022, BIOACT MATER, V8, P381, DOI 10.1016/j.bioactmat.2021.05.053; Liu J, 2014, MAT SCI ENG C-MATER, V35, P392, DOI 10.1016/j.msec.2013.11.028; Liu R, 2018, DENT MATER, V34, P1112, DOI 10.1016/j.dental.2018.04.007; Liu ZG, 2021, MATER DESIGN, V207, DOI 10.1016/j.matdes.2021.109831; Lokau J, 2019, ADV PROTEIN CHEM STR, V116, P283, DOI 10.1016/bs.apcsb.2018.11.007; Ma WH, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117139; Mahon OR, 2020, BIOMATERIALS, V239, DOI 10.1016/j.biomaterials.2020.119833; Maruyama M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00386; McWhorter FY, 2015, CELL MOL LIFE SCI, V72, P1303, DOI 10.1007/s00018-014-1796-8; Munoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999; Myint ZW, 2018, ANN HEMATOL, V97, P1527, DOI 10.1007/s00277-018-3407-5; Ni J, 2015, INT J MOL MED, V35, P1755, DOI 10.3892/ijmm.2015.2168; Pohanka M, 2019, BRATISL MED J, V120, P397, DOI 10.4149/BLL_2019_065; Sica A, 2015, CELL MOL LIFE SCI, V72, P4111, DOI 10.1007/s00018-015-1995-y; Tu CC, 2020, J FORMOS MED ASSOC, V119, P420, DOI 10.1016/j.jfma.2019.07.023; Wang JS, 2020, J IMMUNOL, V205, P968, DOI 10.4049/jimmunol.1901001; Wang LJ, 2020, KAOHSIUNG J MED SCI, V36, P775, DOI 10.1002/kjm2.12236; Wang WH, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2485959; Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9; Xu XC, 2018, ACS BIOMATER SCI ENG, V4, P3364, DOI 10.1021/acsbiomaterials.8b00736; Yi Z, 2022, MATER DESIGN, V213, DOI 10.1016/j.matdes.2021.110350; Zhang EL, 2016, BIOMED MATER, V11, DOI 10.1088/1748-6041/11/6/065001; Zhang EL, 2016, MAT SCI ENG C-MATER, V69, P760, DOI 10.1016/j.msec.2016.07.051; Zhang EL, 2016, MAT SCI ENG C-MATER, V69, P1210, DOI 10.1016/j.msec.2016.08.033; Zhang W, 2021, J MATER SCI TECHNOL, V88, P158, DOI 10.1016/j.jmst.2021.01.067; Zheng WB, 2018, MOL MED REP, V18, P2523, DOI 10.3892/mmr.2018.9261; Zhou PY, 2021, BIOACT MATER, V6, P810, DOI 10.1016/j.bioactmat.2020.09.018; Zhou X, 2021, J MATER RES TECHNOL, V14, P1459, DOI 10.1016/j.jmrt.2021.07.006; Zhou YH, 2018, J MATER CHEM B, V6, P3274, DOI 10.1039/c8tb00683k	61	1	1	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 7	2022	13								1001526	10.3389/fimmu.2022.1001526	http://dx.doi.org/10.3389/fimmu.2022.1001526			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5R7IE	36275667	Green Published, gold			2022-12-18	WOS:000874679000001
J	Banach, M; Harley, ITW; Getahun, A; Cambier, JC				Banach, Maureen; Harley, Isaac T. W.; Getahun, Andrew; Cambier, John C.			Comparative analysis of the repertoire of insulin-reactive B cells in type 1 diabetes-prone and resistant mice	FRONTIERS IN IMMUNOLOGY			English	Article						B cell receptor (BCR); immunoglobulin light chain; BCR affinity; non-obese diabetes (NOD) mice; insulin; type 1 diabetes (T1D)	NOD MICE; LYMPHOCYTES; ANERGY; ANTIBODIES; RECEPTORS; EDITORS; RISK	Seropositivity for autoantibodies against multiple islet antigens is associated with development of autoimmune type 1 diabetes (T1D), suggesting a role for B cells in disease. The importance of B cells in T1D is indicated by the effectiveness of B cell-therapies in mouse models and patients. B cells contribute to T1D by presenting islet antigens, including insulin, to diabetogenic T cells that kill pancreatic beta cells. The role of B cell receptor (BCR) affinity in T1D development is unclear. Here, we employed single cell RNA sequencing to define the relationship between BCR affinity for insulin and B cell phenotype during disease development. We utilized immunoglobulin (Ig) heavy chain (VH125) mouse models in which high-affinity insulin-reactive B cells (IBCs) were previously shown to be anergic in diabetes-resistant VH125.C57BL/6-H2g7 and activated in VH125. NOD mice developing disease. Here, high-affinity IBCs were found in the spleen of prediabetic VH125. NOD mice and exhibited marginal zone or follicular phenotypes. Ig light chains expressed by these B cells are unmutated and biased toward V kappa 4-74 and V kappa 4-57 usage. Receptors expressed by anergic high-affinity IBCs of diabetes-resistant VH125.C57BL/6-H2g7 are also unmutated; however, in this genetic background light chains are polymorphic relative to those of NOD. Light chains derived from NOD and C57BL/6-H2g7 genetic backgrounds conferred divergent kinetics of binding to insulin when paired with the VH125 heavy chain. These findings suggest that relaxation of tolerance mechanisms in the NOD mouse leads to accumulation and partial activation of B cells expressing germline encoded high-affinity BCRs that support development of autoimmunity.	[Banach, Maureen; Harley, Isaac T. W.; Getahun, Andrew; Cambier, John C.] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Anschutz Med Campus, Aurora, CO 80045 USA; [Harley, Isaac T. W.] Univ Colorado, Sch Med, Dept Med, Div Rheumatol, Anschutz Med Campus, Aurora, CO USA; [Harley, Isaac T. W.] Rocky Mt Reg Vet Affairs Med Ctr, Med Serv, Rheumatol Sect, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Cambier, JC (corresponding author), Univ Colorado, Sch Med, Dept Immunol & Microbiol, Anschutz Med Campus, Aurora, CO 80045 USA.	john.cambier@cuanschutz.edu			NIH [5T32AI007405]; Colorado Clinical and Translational Sciences Institute Pilot Grant Award [CO-M-21-51, 1R21AI149019, 5R01AI124487]; Rheumatology Research Foundation Scientist Development Award (ITWH)	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Colorado Clinical and Translational Sciences Institute Pilot Grant Award; Rheumatology Research Foundation Scientist Development Award (ITWH)	Funding Studies were funded by NIH Institutional T32 #5T32AI007405 (MB), Colorado Clinical and Translational Sciences Institute Pilot Grant Award #CO-M-21-51 (MB), R21 #1R21AI149019 (AG), R01 #5R01AI124487 (JCC), and Rheumatology Research Foundation Scientist Development Award (ITWH).	Acevedo-Suarez CA, 2005, J IMMUNOL, V174, P827, DOI 10.4049/jimmunol.174.2.827; Banach M, 2022, MAGNETOCHEMISTRY, V8, DOI 10.3390/magnetochemistry8020023; Bonami RH, 2015, J IMMUNOL, V195, P4730, DOI 10.4049/jimmunol.1500438; Dayan CM, 2021, SCIENCE, V373, P506, DOI 10.1126/science.abi4742; EWULONU UK, 1990, J IMMUNOL, V144, P3091; Felton JL, 2018, J IMMUNOL, V201, P861, DOI 10.4049/jimmunol.1701717; Fu Z, 2013, CURR DIABETES REV, V9, P25, DOI 10.2174/157339913804143225; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; Getahun A, 2022, IMMUNOL REV, V307, P27, DOI 10.1111/imr.13070; Getahun A, 2019, ANNU REV CELL DEV BI, V35, P337, DOI 10.1146/annurev-cellbio-100617-062518; Henry RA, 2010, IMMUNOGENETICS, V62, P507, DOI 10.1007/s00251-010-0457-9; Henry-Bonami RA, 2013, J IMMUNOL, V190, P5992, DOI 10.4049/jimmunol.1201359; Hu CY, 2007, J CLIN INVEST, V117, P3857, DOI 10.1172/JCI32405; Hulbert C, 2001, J IMMUNOL, V167, P5535, DOI 10.4049/jimmunol.167.10.5535; Kalinina O, 2014, J EXP MED, V211, P357, DOI 10.1084/jem.20122340; Kendall PL, 2007, J IMMUNOL, V178, P5643, DOI 10.4049/jimmunol.178.9.5643; Lee RD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27232-5; Leeth CM, 2016, DIABETES, V65, P1977, DOI 10.2337/db15-1606; Li H, 2001, IMMUNITY, V15, P947, DOI 10.1016/S1074-7613(01)00251-5; Li YV, 2014, ENDOCRINE, V45, P178, DOI 10.1007/s12020-013-0032-x; Marino E, 2012, DIABETES, V61, P2893, DOI 10.2337/db12-0006; Merrell KT, 2006, IMMUNITY, V25, P953, DOI 10.1016/j.immuni.2006.10.017; Minguet S, 2010, INT IMMUNOL, V22, P205, DOI 10.1093/intimm/dxp129; NELL LJ, 1992, BIOPOLYMERS, V32, P11, DOI 10.1002/bip.360320104; Noorchashm H, 1999, J IMMUNOL, V163, P743; Orban T, 2009, DIABETES CARE, V32, P2269, DOI 10.2337/dc09-0934; Packard TA, 2016, J CLIN MED, V5, DOI 10.3390/jcm5110098; Pelanda R, 2014, CURR OPIN IMMUNOL, V27, P53, DOI 10.1016/j.coi.2014.01.012; Pescovitz MD, 2009, NEW ENGL J MED, V361, P2143, DOI 10.1056/NEJMoa0904452; Rojas M, 2001, J IMMUNOL, V166, P3194, DOI 10.4049/jimmunol.166.5.3194; SCHROER JA, 1983, EUR J IMMUNOL, V13, P693, DOI 10.1002/eji.1830130902; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003; Silveira PA, 2002, EUR J IMMUNOL, V32, P3657, DOI 10.1002/1521-4141(200212)32:12<3657::AID-IMMU3657>3.0.CO;2-E; Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3; Smith MJ, 2018, DIABETOLOGIA, V61, P2621, DOI 10.1007/s00125-018-4730-z; Smith MJ, 2018, DIABETES, V67, P697, DOI 10.2337/db17-0937; Smith MJ, 2017, NAT REV NEPHROL, V13, P712, DOI 10.1038/nrneph.2017.138; Smith MJ, 2015, DIABETES, V64, P1703, DOI 10.2337/db13-1798; Stewart A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.602539; Stoeckius M, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1603-1; Thomas JW, 1996, J IMMUNOL, V157, P763; Wong FS, 2004, DIABETES, V53, P2581, DOI 10.2337/diabetes.53.10.2581; Xie Zhuorui, 2021, Curr Protoc, V1, pe90, DOI 10.1002/cpz1.90; Yoshida H, 2019, CELL, V176, P897, DOI 10.1016/j.cell.2018.12.036; Ziegler AG, 2013, JAMA-J AM MED ASSOC, V309, P2473, DOI 10.1001/jama.2013.6285; Zikherman J, 2012, NATURE, V489, P160, DOI 10.1038/nature11311	47	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2022	13								961209	10.3389/fimmu.2022.961209	http://dx.doi.org/10.3389/fimmu.2022.961209			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5O6RQ	36275764	Green Published, gold			2022-12-18	WOS:000872598300001
J	Kaminskiy, Y; Kuznetsova, V; Kudriaeva, A; Zmievskaya, E; Bulatov, E				Kaminskiy, Yaroslav; Kuznetsova, Varvara; Kudriaeva, Anna; Zmievskaya, Ekaterina; Bulatov, Emil			Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion	FRONTIERS IN IMMUNOLOGY			English	Review						FoxP1; T cell; Treg; quiescence; T cell differentiation; isoforms; antitumor; exhaustion	TRANSCRIPTION FACTOR FOXP1; FOLLICULAR-HELPER-CELLS; GENE-EXPRESSION; REGULATOR; LYMPHOMA; GENERATION; RESPONSES; VARIANT; BETA; LUNG	FOXP1 is ubiquitously expressed in the human body and is implicated in both physiological and pathological processes including cancer. However, despite its importance the role of FOXP1 in T-cells has not been extensively studied. Although relatively few phenotypic and mechanistic details are available, FOXP1 role in T-cell quiescence and differentiation of CD4+ subsets has recently been established. FOXP1 prevents spontaneous T-cell activation, preserves memory potential, and regulates the development of follicular helper and regulatory T-cells. Moreover, there is growing evidence that FOXP1 also regulates T-cell exhaustion. Altogether this makes FOXP1 a crucial and highly undervalued regulator of T-cell homeostasis. In this review, we discuss the biology of FOXP1 with a focus on discoveries made in T-cells in recent years.	[Kaminskiy, Yaroslav] Karolinska Inst, Dept Oncol & Pathol, SciLifeLab, Solna, Sweden; [Kaminskiy, Yaroslav; Kuznetsova, Varvara] Natl Res Ctr Hematol, Lab Transplantat Immunol, Moscow, Russia; [Kudriaeva, Anna; Bulatov, Emil] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Zmievskaya, Ekaterina; Bulatov, Emil] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia	Karolinska Institutet; SciLifeLab; Russian Academy of Medical Sciences; National Medical Research Center for Hematology; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Kazan Federal University	Bulatov, E (corresponding author), Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia.; Bulatov, E (corresponding author), Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia.	chembio.kazan@gmail.com			Ministry of Science and Higher Education of the Russian Federation;  [075-15-2020-795];  [13.1902.21.0027];  [RF-190220X0027]	Ministry of Science and Higher Education of the Russian Federation; ; ; 	Funding This research was funded by the Ministry of Science and Higher Education of the Russian Federation (grant agreement no. 075-15-2020-795, state contract no. 13.1902.21.0027 of 29.09.2020 unique project ID: RF-190220X0027).	Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Banham AH, 2001, CANCER RES, V61, P8820; Barrans SL, 2004, BLOOD, V104, P2933, DOI 10.1182/blood-2004-03-1209; Bi EG, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9741; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Brown PJ, 2016, LEUKEMIA, V30, P605, DOI 10.1038/leu.2015.299; Brown PJ, 2008, BLOOD, V111, P2816, DOI 10.1182/blood-2007-09-115113; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Choi EJ, 2016, ONCOTARGET, V7, P3496, DOI 10.18632/oncotarget.6510; Chokas AL, 2010, J BIOL CHEM, V285, P13304, DOI 10.1074/jbc.M109.088468; Chtanova T, 2004, J IMMUNOL, V173, P68, DOI 10.4049/jimmunol.173.1.68; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; De Silva P, 2019, EBIOMEDICINE, V39, P226, DOI 10.1016/j.ebiom.2018.11.066; Durek P, 2016, IMMUNITY, V45, P1148, DOI 10.1016/j.immuni.2016.10.022; Feng XM, 2011, NAT IMMUNOL, V12, P544, DOI 10.1038/ni.2034; Feng XM, 2010, BLOOD, V115, P510, DOI 10.1182/blood-2009-07-232694; Fujino N, 2012, RESPIR INVESTIG, V50, P110, DOI 10.1016/j.resinv.2012.07.002; Garaud S, 2017, EUR J IMMUNOL, V47, P168, DOI 10.1002/eji.201646373; Ghosh S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07018-y; Green MR, 2009, LEUKEMIA RES, V33, P1699, DOI 10.1016/j.leukres.2009.05.004; Han SL, 2009, DIGEST SURG, V26, P156, DOI 10.1159/000212058; Hu H, 2006, NAT IMMUNOL, V7, P819, DOI 10.1038/ni1358; Kim JH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1110-3; Konopacki C, 2019, NAT IMMUNOL, V20, P232, DOI 10.1038/s41590-018-0291-z; Kopelman NM, 2005, NAT GENET, V37, P588, DOI 10.1038/ng1575; Lefevre G, 2014, MEDICINE, V93, P255, DOI 10.1097/MD.0000000000000088; Li B, 2007, INT IMMUNOL, V19, P825, DOI 10.1093/intimm/dxm043; Li SR, 2004, MOL CELL BIOL, V24, P809, DOI 10.1128/MCB.24.2.809-822.2004; Liu XD, 2012, J EXP MED, V209, P1841, DOI 10.1084/jem.20120219; Lozano R, 2015, EUR J HUM GENET, V23, P1702, DOI 10.1038/ejhg.2015.66; Lu Y, 2012, J CLIN INVEST, V122, P4160, DOI 10.1172/JCI65459; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Ouyang WM, 2009, IMMUNITY, V30, P358, DOI 10.1016/j.immuni.2009.02.003; Purwar R, 2012, NAT MED, V18, P1248, DOI 10.1038/nm.2856; Rao RR, 2012, IMMUNITY, V36, P374, DOI 10.1016/j.immuni.2012.01.015; Ravoet M, 2009, BLOOD, V114, P2969, DOI 10.1182/blood-2008-08-175091; Ren JZ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000270; Rudra D, 2012, NAT IMMUNOL, V13, P1010, DOI 10.1038/ni.2402; Shi B, 2018, J IMMUNOL, V200, P586, DOI 10.4049/jimmunol.1701000; Shi C, 2008, BLOOD, V112, P4699, DOI 10.1182/blood-2008-01-137018; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Sollis E, 2016, HUM MOL GENET, V25, P546, DOI 10.1093/hmg/ddv495; Stephen TL, 2014, IMMUNITY, V41, P427, DOI 10.1016/j.immuni.2014.08.012; Tan AHM, 2006, J BIOL CHEM, V281, P28666, DOI 10.1074/jbc.M604081200; van Keimpema M, 2017, HAEMATOLOGICA, V102, P573, DOI 10.3324/haematol.2016.156455; Wang B, 2003, J BIOL CHEM, V278, P24259, DOI 10.1074/jbc.M207174200; Wang HK, 2014, NAT IMMUNOL, V15, P667, DOI 10.1038/ni.2890; Wang X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091501; Wei HR, 2016, J IMMUNOL, V196, P3537, DOI 10.4049/jimmunol.1501896; Xiao J, 2016, SCI REP-UK, V6, DOI 10.1038/srep30437; Xun XD, 2021, AM J TRANSL RES, V13, P4360; Yamada S, 2012, HUM PATHOL, V43, P1322, DOI 10.1016/j.humpath.2011.10.013; Yang CY, 2011, NAT IMMUNOL, V12, P1221, DOI 10.1038/ni.2158; Zhang M, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190061	54	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2022	13								971045	10.3389/fimmu.2022.971045	http://dx.doi.org/10.3389/fimmu.2022.971045			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5M7YE	36268015	gold, Green Published			2022-12-18	WOS:000871312100001
J	Li, JC; Reinke, S; Shen, Y; Schollmeyer, L; Liu, YC; Wang, ZX; Hardt, S; Hipfl, C; Hoffmann, U; Frischbutter, S; Chang, HD; Alexander, T; Perka, C; Radbruch, H; Qin, ZH; Radbruch, A; Dong, J				Li, Jinchan; Reinke, Simon; Shen, Yu; Schollmeyer, Lena; Liu, Yuk-Chien; Wang, Zixu; Hardt, Sebastian; Hipfl, Christian; Hoffmann, Ute; Frischbutter, Stefan; Chang, Hyun-Dong; Alexander, Tobias; Perka, Carsten; Radbruch, Helena; Qin, Zhihai; Radbruch, Andreas; Dong, Jun			A ubiquitous bone marrow reservoir of preexisting SARS-CoV-2-reactive memory CD4(+) T lymphocytes in unexposed individuals	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; cross-reactive; memory CD4(+) T lymphocytes; human bone marrow; peripheral blood; polyfunctional; tissue-resident memory T cells (Trm)	CELL MEMORY; IMMUNITY; REST	Circulating, blood-borne SARS-CoV-2-reactive memory T cells in persons so far unexposed to SARS-CoV-2 or the vaccines have been described in 20-100% of the adult population. They are credited with determining the efficacy of the immune response in COVID-19. Here, we demonstrate the presence of preexisting memory CD4(+) T cells reacting to peptides of the spike, membrane, or nucleocapsid proteins of SARS-CoV-2 in the bone marrow of all 17 persons investigated that had previously not been exposed to SARS-CoV-2 or one of the vaccines targeting it, with only 15 of these persons also having such cells detectable circulating in the blood. The preexisting SARS-CoV-2-reactive memory CD4(+) T cells of the bone marrow are abundant and polyfunctional, with the phenotype of central memory T cells. They are tissue-resident, at least in those persons who do not have such cells in the blood, and about 30% of them express CD69. Bone marrow resident SARS-CoV-2-reactive memory CD4(+) memory T cells are also abundant in vaccinated persons analyzed 10-168 days after 1 degrees-4 degrees vaccination. Apart from securing the bone marrow, preexisting cross-reactive memory CD4(+) T cells may play an important role in shaping the systemic immune response to SARS-CoV-2 and the vaccines, and contribute essentially to the rapid establishment of long-lasting immunity provided by memory plasma cells, already upon primary infection.	[Li, Jinchan; Shen, Yu; Schollmeyer, Lena; Liu, Yuk-Chien; Wang, Zixu; Hoffmann, Ute; Radbruch, Andreas; Dong, Jun] Deutsch Rheuma Forschungszentrum Julich Berlin DR, Inst Leibniz Assoc, Cell Biol, Berlin, Germany; [Reinke, Simon] Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany; [Reinke, Simon; Hardt, Sebastian; Hipfl, Christian; Frischbutter, Stefan; Alexander, Tobias; Perka, Carsten; Radbruch, Helena] Free Univ Berlin, Berlin, Germany; [Reinke, Simon; Hardt, Sebastian; Hipfl, Christian; Frischbutter, Stefan; Alexander, Tobias; Perka, Carsten; Radbruch, Andreas] Humboldt Univ, Berlin, Germany; [Reinke, Simon; Hardt, Sebastian; Hipfl, Christian; Frischbutter, Stefan; Alexander, Tobias; Perka, Carsten; Radbruch, Helena] Berlin Inst Hlth, Berlin, Germany; [Hardt, Sebastian; Hipfl, Christian; Perka, Carsten] Charite Univ Med Berlin, Ctr Musculoskeletal Surg, Berlin, Germany; [Hoffmann, Ute; Chang, Hyun-Dong] Deutsch Rheuma Forschungszentrum Julich Berlin DR, Inst Leibniz Assoc, Schwiete Lab Microbiota & Inflammat, Berlin, Germany; [Frischbutter, Stefan] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany; [Frischbutter, Stefan] Fraunhofer Inst Translat Med & Pharmacol ITMP, Allergol & Immunol, Berlin, Germany; [Alexander, Tobias] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany; [Radbruch, Helena] Charite Univ Med Berlin, Inst Neuropathol, Berlin, Germany; [Qin, Zhihai] Zhengzhou Univ, Med Res Ctr, Affiliated Hosp 1, Zhengzhou, Peoples R China	Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Zhengzhou University	Dong, J (corresponding author), Deutsch Rheuma Forschungszentrum Julich Berlin DR, Inst Leibniz Assoc, Cell Biol, Berlin, Germany.	dong@drfz.de			Deutsche Forschungsgemeinschft (DFG) [389687267]; Dr. Rolf M. Schwiete Foundation; Chinesisch-Deutsches Zentrum fuer Wissenschaftsfoerderung (CDZ) [C-0072]	Deutsche Forschungsgemeinschft (DFG)(German Research Foundation (DFG)); Dr. Rolf M. Schwiete Foundation; Chinesisch-Deutsches Zentrum fuer Wissenschaftsfoerderung (CDZ)	Chinesisch-Deutsches Zentrum fuer Wissenschaftsfoerderung (CDZ; DFG im Ausland) grant C-0072 (JD). Deutsche Forschungsgemeinschft (DFG) Project 389687267 (JD and AR). Leibniz science Campus Chronic Inflammation (www.chronische-entzuendung.org). HDC was supported by Dr. Rolf M. Schwiete Foundation.	A.Ades, 2020, medRxiv, DOI 10.1101/2020.11.02.20222778; Alp OS, 2015, EUR J IMMUNOL, V45, P975, DOI 10.1002/eji.201445295; Bacher P, 2020, IMMUNITY, V53, P1258, DOI 10.1016/j.immuni.2020.11.016; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Cendon C, 2022, EUR J IMMUNOL, V52, P737, DOI 10.1002/eji.202149726; Chang HD, 2021, EUR J IMMUNOL, V51, P1592, DOI 10.1002/eji.202049012; Chang HD, 2018, IMMUNOL REV, V283, P86, DOI 10.1111/imr.12656; Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293; Cossarizza A, 2021, EUR J IMMUNOL, V51, P2708, DOI 10.1002/eji.202170126; Di Rosa F, 2005, TRENDS IMMUNOL, V26, P360, DOI 10.1016/j.it.2005.04.011; Dykema AG, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146922; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Ferreira-Gomes M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22210-3; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Jameson SC, 2009, IMMUNITY, V31, P859, DOI 10.1016/j.immuni.2009.11.007; Jarjour NN, 2021, IMMUNITY, V54, P14, DOI 10.1016/j.immuni.2020.12.009; Kim W, 2022, NATURE, V604, P141, DOI 10.1038/s41586-022-04527-1; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Kundu Rhia, 2022, Nat Commun, V13, P80, DOI 10.1038/s41467-021-27674-x; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Loyal L, 2021, SCIENCE, V374, P171, DOI 10.1126/science.abh1823; Lu ZY, 2021, J INFECT DIS, V224, P2010, DOI 10.1093/infdis/jiab543; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; MCGREGOR DD, 1963, J EXP MED, V117, P303, DOI 10.1084/jem.117.2.303; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Mysore V, 2021, MED-CAMBRIDGE, V2, P1050, DOI 10.1016/j.medj.2021.08.004; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Okhrimenko A, 2014, P NATL ACAD SCI USA, V111, P9229, DOI 10.1073/pnas.1318731111; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Quiros-Fernandez I, 2021, EBIOMEDICINE, V72, DOI 10.1016/j.ebiom.2021.103610; Radbruch A, 2021, CSH PERSPECT BIOL, V13, DOI 10.1101/cshperspect.a038083; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Romero-Olmedo AJ, 2022, NAT MICROBIOL, V7, P195, DOI 10.1038/s41564-021-01046-z; Sagar M, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143380; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shinoda K, 2012, P NATL ACAD SCI USA, V109, P7409, DOI 10.1073/pnas.1118539109; Siracusa F, 2019, EUR J IMMUNOL, V49, P966, DOI 10.1002/eji.201847982; Snyder ME, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5581; Steiner S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.607918; Steinert EM, 2015, CELL, V161, P737, DOI 10.1016/j.cell.2015.03.031; Swadling L, 2022, NATURE, V601, DOI 10.1038/s41586-021-04186-8; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Tokoyoda K, 2009, IMMUNITY, V30, P721, DOI 10.1016/j.immuni.2009.03.015; TREPEL F, 1974, KLIN WOCHENSCHR, V52, P511, DOI 10.1007/BF01468720; Turner JS, 2021, NATURE, V595, P421, DOI 10.1038/s41586-021-03647-4; Wang WB, 2022, ADV SCI, V9, DOI 10.1002/advs.202103248; Witkowski M, 2021, NATURE, V600, P295, DOI 10.1038/s41586-021-04142-6; Zarnitsyna VI, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009468	56	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 4	2022	13								1004656	10.3389/fimmu.2022.1004656	http://dx.doi.org/10.3389/fimmu.2022.1004656			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5L6PD	36268016	Green Published, gold			2022-12-18	WOS:000870532600001
J	Liu, CL; Makrinioti, H; Saglani, S; Bowman, M; Lin, LL; Camargo, CA; Hasegawa, K; Zhu, ZZ				Liu, Conglin; Makrinioti, Heidi; Saglani, Sejal; Bowman, Michael; Lin, Lih-Ling; Camargo Jr, Carlos A.; Hasegawa, Kohei; Zhu, Zhaozhong			Microbial dysbiosis and childhood asthma development: Integrated role of the airway and gut microbiome, environmental exposures, and host metabolic and immune response	FRONTIERS IN IMMUNOLOGY			English	Review						microbial dysbiosis; airway microbiome; gut microbiome; immune mechanism; metabolic mechanism; childhood asthma	RESPIRATORY-INFECTION; COMMENSAL BACTERIA; INNATE IMMUNITY; RISK; DISEASE; ALLERGENS; INFANCY; MODELS; ATOPY; LUNG	Asthma is a chronic and heterogeneous respiratory disease with many risk factors that typically originate during early childhood. A complex interplay between environmental factors and genetic predisposition is considered to shape the lung and gut microbiome in early life. The growing literature has identified that changes in the relative abundance of microbes (microbial dysbiosis) and reduced microbial diversity, as triggers of the airway-gut axis crosstalk dysregulation, are associated with asthma development. There are several mechanisms underlying microbial dysbiosis to childhood asthma development pathways. For example, a bacterial infection in the airway of infants can lead to the activation and/or dysregulation of inflammatory pathways that contribute to bronchoconstriction and bronchial hyperresponsiveness. In addition, gut microbial dysbiosis in infancy can affect immune development and differentiation, resulting in a suboptimal balance between innate and adaptive immunity. This evolving dysregulation of secretion of pro-inflammatory mediators has been associated with persistent airway inflammation and subsequent asthma development. In this review, we examine current evidence around associations between the airway and gut microbial dysbiosis with childhood asthma development. More specifically, this review focuses on discussing the integrated roles of environmental exposures, host metabolic and immune responses, airway and gut microbial dysbiosis in driving childhood asthma development.	[Liu, Conglin; Bowman, Michael; Lin, Lih-Ling] Sanofi US, Immunol & Inflammat Res Therapeut Area, Cambridge, MA 02142 USA; [Makrinioti, Heidi] London Sch Paediat, London, England; [Saglani, Sejal] Imperial Coll, Natl Heart & Lung Inst, London, England; [Saglani, Sejal] Imperial Coll, Ctr Paediat & Child Hlth, London, England; [Camargo Jr, Carlos A.; Hasegawa, Kohei; Zhu, Zhaozhong] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA	Sanofi-Aventis; Imperial College London; Imperial College London; Harvard University; Harvard Medical School; Massachusetts General Hospital	Liu, CL (corresponding author), Sanofi US, Immunol & Inflammat Res Therapeut Area, Cambridge, MA 02142 USA.; Zhu, ZZ (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA.	conglin.liu@sanofi.com; zzhu5@mgh.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	National Institutes of Health [K01 AI-153558]; Massachusetts General Hospital Department of Emergency Medicine Fellowship/Eleanor and Miles Shore Faculty Development Awards Program; Harvard University William F. Milton Fund	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Massachusetts General Hospital Department of Emergency Medicine Fellowship/Eleanor and Miles Shore Faculty Development Awards Program; Harvard University William F. Milton Fund	This study was supported by the following grants: the National Institutes of Health: K01 AI-153558 (ZZ); Massachusetts General Hospital Department of Emergency Medicine Fellowship/Eleanor and Miles Shore Faculty Development Awards Program (ZZ); and the Harvard University William F. Milton Fund (ZZ).	Lira-Lucio JA, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8071059; Alnahas S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01562; Dang AT, 2019, MUCOSAL IMMUNOL, V12, P843, DOI 10.1038/s41385-019-0160-6; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Barcik W, 2020, IMMUNITY, V52, P241, DOI 10.1016/j.immuni.2020.01.007; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Borish L, 2008, ANN ALLERG ASTHMA IM, V101, P1, DOI 10.1016/S1081-1206(10)60826-5; Casaro MB, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01116-8; Chen JZ, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e15; Chung KF, 2017, J ALLERGY CLIN IMMUN, V139, P1071, DOI 10.1016/j.jaci.2017.02.004; Dasgupta S, 2014, CELL HOST MICROBE, V15, P413, DOI 10.1016/j.chom.2014.03.006; Depner M, 2020, NAT MED, V26, P1766, DOI 10.1038/s41591-020-1095-x; Dharmage SC, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00246; Diacovich L, 2010, NAT REV MICROBIOL, V8, P117, DOI 10.1038/nrmicro2295; Enaud R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00009; Essilfie AT, 2012, THORAX, V67, P588, DOI 10.1136/thoraxjnl-2011-200160; Ferreira MAR, 2019, AM J HUM GENET, V104, P665, DOI 10.1016/j.ajhg.2019.02.022; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Fujiogi M, 2022, THORAX, V77, P1059, DOI 10.1136/thorax-2022-219016; Glynn JR, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-00668-y; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Gubernatorova EO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.601842; Henrick BM, 2021, CELL, V184, P3884, DOI 10.1016/j.cell.2021.05.030; Hou KJ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00974-4; House JS, 2017, J ALLERGY CLIN IMMUN, V140, P249, DOI 10.1016/j.jaci.2016.09.036; Hu WB, 2021, J SCI FOOD AGR, V101, P5563, DOI 10.1002/jsfa.11207; Hufnagl K, 2020, SEMIN IMMUNOPATHOL, V42, P75, DOI 10.1007/s00281-019-00775-y; Johnson CC, 2021, J ALLERGY CLIN IMMUN, V148, P1270, DOI 10.1016/j.jaci.2021.04.027; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Khan R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01203; Koppe U, 2012, CELL MICROBIOL, V14, P460, DOI 10.1111/j.1462-5822.2011.01746.x; Lee-Sarwar K, 2022, J ALLERGY CLIN IMMUN, V150, P325, DOI 10.1016/j.jaci.2022.02.005; Lehtimaki J, 2021, J ALLERGY CLIN IMMUN, V148, P234, DOI 10.1016/j.jaci.2020.12.621; Levan SR, 2019, NAT MICROBIOL, V4, P1851, DOI 10.1038/s41564-019-0498-2; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Mansbach JM, 2020, J ALLERGY CLIN IMMUN, V145, P518, DOI 10.1016/j.jaci.2019.10.034; Miller RL, 2021, J ALLERGY CLIN IMMUN, V148, P1430, DOI 10.1016/j.jaci.2021.10.001; Paludan SR, 2021, NAT REV IMMUNOL, V21, P137, DOI 10.1038/s41577-020-0391-5; Parker D, 2011, AM J RESP CELL MOL, V45, P189, DOI 10.1165/rcmb.2011-0011RT; Patrick DM, 2020, LANCET RESP MED, V8, P1094, DOI 10.1016/S2213-2600(20)30052-7; Peng D, 2022, CELL IMMUNOL, V376, DOI 10.1016/j.cellimm.2022.104536; Peroni DG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00700; Pividori M, 2019, LANCET RESP MED, V7, P509, DOI 10.1016/S2213-2600(19)30055-4; Raita Y, 2022, EUR RESPIR J, V60, DOI 10.1183/13993003.02293-2021; Raita Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23859-6; Raita Y, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.665057; Raita Y, 2021, J ALLERGY CLIN IMMUN, V147, P2108, DOI 10.1016/j.jaci.2020.11.002; Rosas-Salazar Christian, 2022, J Allergy Clin Immunol, V150, P612, DOI 10.1016/j.jaci.2022.02.023; Roslund MI, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2578; Saglani S, 2007, CURR OPIN ALLERGY CL, V7, P83; Saglani S, 2019, AM J RESP CRIT CARE, V199, P414, DOI 10.1164/rccm.201810-1956CI; Segal LN, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.31, 10.1038/NMICROBIOL.2016.31]; Shimizu K, 2012, CLIN EXP ALLERGY, V42, P1273, DOI 10.1111/j.1365-2222.2012.04007.x; Smits HH, 2016, J ALLERGY CLIN IMMUN, V137, P690, DOI 10.1016/j.jaci.2016.01.004; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Stokholm J, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax9929; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Strieker Sonja, 2022, J Allergy Clin Immunol, V150, P1209, DOI 10.1016/j.jaci.2022.05.027; Subbarao P, 2009, CAN MED ASSOC J, V181, pE181, DOI 10.1503/cmaj.080612; Tang HHF, 2021, J ALLERGY CLIN IMMUN, V147, P781, DOI 10.1016/j.jaci.2020.08.026; Tang HHF, 2021, J ALLERGY CLIN IMMUN, V147, P1683, DOI 10.1016/j.jaci.2020.10.009; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; The Global Initiative for Asthma, 2022, 2022 GIN REP GLOB ST; Thorsen J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12989-7; Tlaskalova-Hogenova H, 2011, CELL MOL IMMUNOL, V8, P110, DOI 10.1038/cmi.2010.67; Toivonen L., 2020, Clinical Infectious Diseases, V72, P1546, DOI 10.1093/cid/ciaa262; Toivonen L, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-0421; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Winslow S, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.03312-2020; Yagi K, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.877771; Zhang DP, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00301; Zhu ZZ, 2022, J ALLERGY CLIN IMMUN, V150, P806, DOI 10.1016/j.jaci.2022.04.017; Zhu ZZ, 2022, J ALLERGY CLIN IMMUN, V149, P102, DOI 10.1016/j.jaci.2021.05.036; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V146, P327, DOI 10.1016/j.jaci.2020.06.001; Zhu ZZ, 2021, J ALLERGY CLIN IMMUN, V147, P796, DOI 10.1016/j.jaci.2020.07.004; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V145, P537, DOI 10.1016/j.jaci.2019.09.035; Zhu ZZ, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01507-2019; Zhu ZZ, 2019, EXPERT REV RESP MED, V13, P1135, DOI 10.1080/17476348.2019.1674650; Zhu ZZ, 2018, NAT GENET, V50, P857, DOI 10.1038/s41588-018-0121-0	84	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 30	2022	13								1028209	10.3389/fimmu.2022.1028209	http://dx.doi.org/10.3389/fimmu.2022.1028209			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5K0FV	36248891	gold, Green Published			2022-12-18	WOS:000869411400001
J	Schneider, F; Le Borgne, P; Herbrecht, JE; Danion, F; Solis, M; Helle, S; Betscha, C; Clere-Jehl, R; Lefebvre, F; Castelain, V; Goumon, Y; Metz-Boutigue, MH				Schneider, Francis; Le Borgne, Pierrick; Herbrecht, Jean-Etienne; Danion, Francois; Solis, Morgane; Helle, Sophie; Betscha, Cosette; Clere-Jehl, Raphael; Lefebvre, Francois; Castelain, Vincent; Goumon, Yannick; Metz-Boutigue, Marie-Helene			Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality	FRONTIERS IN IMMUNOLOGY			English	Article						Innate immunity; COVID; Catestatin; Chromogranin A; hypoxia; critically ill; nosocomial disease	RELEASE-INHIBITORY PEPTIDE; CHROMOGRANIN-A FRAGMENT; CATECHOLAMINE-RELEASE; PROTEOLYTIC CLEAVAGE; CYTOKINES; VARIANTS; SITES	IntroductionNeuroendocrine cells release Catestatin (CST) from Chromogranin A (CgA) to regulate stress responses. As regards COVID-19 patients (COVID+) requiring oxygen supply, to date nobody has studied CST as a potential mediator in the regulation of immunity. Patients & MethodsAdmission plasma CST and CgA - its precursor - concentrations were measured (ELISA test) in 73 COVID+ and 27 controls. Relationships with demographics, comorbidities, disease severity and outcomes were analysed (Mann-Whitney, Spearman correlation tests, ROC curves). ResultsAmong COVID+, 49 required ICU-admission (COVID+ICU+) and 24 standard hospitalization (COVID+ICU-). Controls were either healthy staff (COVID-ICU-, n=11) or COVID-ICU+ patients (n=16). Median plasma CST were higher in COVID+ than in controls (1.6 [1.02; 3.79] vs 0.87 [0.59; 2.21] ng/mL, p<0.03), with no difference between COVID+ and COVID-ICU+. There was no difference between groups in either CgA or CST/CgA ratios, but these parameters were lower in healthy controls (p<0.01). CST did not correlate with either hypoxia- or usual inflammation-related parameters. In-hospital mortality was similar whether COVID+ or not, but COVID+ had longer oxygen support and more complications (p<0.03). CST concentrations and the CST/CgA ratio were associated with in-hospital mortality (p<0.01) in COVID+, whereas CgA was not. CgA correlated with care-related infections (p<0.001). ConclusionRespiratory COVID patients release significant amounts of CST in the plasma making this protein widely available for the neural regulation of immunity. If confirmed prospectively, plasma CST will reliably help in predicting in-hospital mortality, whereas CgA will facilitate the detection of patients prone to care-related infections.	[Schneider, Francis; Herbrecht, Jean-Etienne; Clere-Jehl, Raphael; Castelain, Vincent] Hop Univ Strasbourg, Med Intens Reanimat, Hop Hautepierre, Federat Med Translat Strasbourg FMTS, Strasbourg, France; [Schneider, Francis; Le Borgne, Pierrick; Herbrecht, Jean-Etienne; Helle, Sophie; Betscha, Cosette; Clere-Jehl, Raphael; Castelain, Vincent; Metz-Boutigue, Marie-Helene] Unistra, Strasbourg, France; [Schneider, Francis; Solis, Morgane; Helle, Sophie; Betscha, Cosette; Metz-Boutigue, Marie-Helene] Federat Med Translat Strasbourg FMTS, INSERM, Unite Mixte Rech INSERM UMR 1121 Biomat & Bioingn, Strasbourg, France; [Le Borgne, Pierrick] Hop Univ Strasbourg, Federat Med Translat Strasbourg FMTS, Hop Hautepierre, Serv Accueil Urgences, Strasbourg, France; [Danion, Francois] Hop Univ Strasbourg, Nouvel Hop Civil, Malad Infect & Trop, Strasbourg, France; [Solis, Morgane] Hop Univ Strasbourg, Lab Virol, Federat Med Translat Strasbourg FMTS, Paculte Med, Strasbourg, France; [Lefebvre, Francois] Hop Univ Strasbourg, Unistra, Pole Sante Publ, Grp Methodes Recheche Clin GRMC, Strasbourg, France; [Goumon, Yannick] Unistra, Unite Propre Rech CNRS UPR 3212, Inst Neurosci Cellulaires & Integrat, CNRS, Strasbourg, France	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Metz-Boutigue, MH (corresponding author), Federat Med Translat Strasbourg FMTS, INSERM, Unite Mixte Rech INSERM UMR 1121 Biomat & Bioingn, Strasbourg, France.	marie-helene.metz@inserm.fr	; Danion, Francois/Q-2764-2017	Goumon, Yannick/0000-0003-4336-3437; Danion, Francois/0000-0003-3907-0658	University Hospital of Strasbourg; INSERM	University Hospital of Strasbourg; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	The authors thank the University Hospital of Strasbourg and the INSERM as sponsors. FS and M-HM-B thank also Drs Bernard Senger and Naji Kharouf for technical assistance in statistical analyses, and Sylvie L'Hotellier, MichelMasuccio and Ce ' line Picard for data collection, laboratory sampling and study materials provision, and the Association pour la Recherche en Re ' animation Me ' dicale, which generously sponsored part of the kits to perform dosages of chromogranin A.	Arias HR, 1998, BBA-REV BIOMEMBRANES, V1376, P173, DOI 10.1016/S0304-4157(98)00004-5; Aung G, 2011, IMMUNOLOGY, V132, P527, DOI 10.1111/j.1365-2567.2010.03395.x; Biswas N, 2008, ENDOCRINOLOGY, V149, P749, DOI 10.1210/en.2007-0838; Biswas N, 2009, ENDOCRINOLOGY, V150, P3547, DOI 10.1210/en.2008-1613; Blake KJ, 2019, TRENDS NEUROSCI, V42, P537, DOI 10.1016/j.tins.2019.05.005; Bourebaba Y, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111113; Briolat J, 2005, CELL MOL LIFE SCI, V62, P377, DOI 10.1007/s00018-004-4461-9; Crippa L, 2013, BLOOD, V121, P392, DOI 10.1182/blood-2012-05-430314; De Lorenzo R, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0267235; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; DRY KL, 1991, CIRC RES, V69, P466, DOI 10.1161/01.RES.69.2.466; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369; Izcovich A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241955; Janssen NAF, 2021, J INFECT DIS, V223, P1322, DOI 10.1093/infdis/jiab065; Kang Z, 2020, EUR RADIOL, V30, P4356, DOI 10.1007/s00330-020-06809-6; Kiranmayi M, 2016, HYPERTENSION, V68, P334, DOI 10.1161/HYPERTENSIONAHA.116.06568; Kojima M, 2018, THROMB HAEMOSTASIS, V118, P182, DOI 10.1160/TH17-05-0349; Labro G, 2022, INTENS CARE MED, V48, P876, DOI 10.1007/s00134-022-06721-1; Lee JC, 2003, BIOCHEMISTRY-US, V42, P6938, DOI 10.1021/bi0300433; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Mahata SK, 2000, MOL ENDOCRINOL, V14, P1525, DOI 10.1210/me.14.10.1525; Mahata SK, 2003, J BIOL CHEM, V278, P32058, DOI 10.1074/jbc.M305545200; Mahata SK, 1999, J BIOL CHEM, V274, P2920, DOI 10.1074/jbc.274.5.2920; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Mahata SK, 2010, REGUL PEPTIDES, V162, P33, DOI 10.1016/j.regpep.2010.01.006; Mancino D, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042066; Meyer NJ, 2021, LANCET, V398, P622, DOI 10.1016/S0140-6736(21)00439-6; Muntjewerff EM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02199; Parmer RJ, 2000, J CLIN INVEST, V106, P907, DOI 10.1172/JCI7394; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Piazza O, 2013, INT J IMMUNOPATH PH, V26, P383, DOI 10.1177/039463201302600211; Piotrowicz K, 2021, AGING CLIN EXP RES, V33, P2887, DOI 10.1007/s40520-021-01942-8; Rudolf R, 2019, NEUROSCI LETT, V711, DOI 10.1016/j.neulet.2019.134434; Sahu BS, 2012, J BIOL CHEM, V287, P43840, DOI 10.1074/jbc.M112.407916; Sahu BS, 2012, J CELL SCI, V125, P2323, DOI 10.1242/jcs.103176; Scavello F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94749-6; Schneider F, 2018, SHOCK, V49, P522, DOI 10.1097/SHK.0000000000001000; Shrivastava Shubham, 2021, Front Cell Infect Microbiol, V11, P751232, DOI 10.3389/fcimb.2021.751232; Silvin A, 2020, CELL, V182, P1401, DOI 10.1016/j.cell.2020.08.002; Simunovic M, 2019, PEDIATR DIABETES, V20, P549, DOI 10.1111/pedi.12825; Taupenot L, 2000, REGUL PEPTIDES, V95, P9, DOI 10.1016/S0167-0115(00)00135-X; Wargodsky R, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0261679; Wen G, 2004, AM J HUM GENET, V74, P197, DOI 10.1086/381399; Ying W, 2018, DIABETES, V67, P841, DOI 10.2337/db17-0788; Zhang D, 2008, CLIN CHEM, V54, P1497, DOI 10.1373/clinchem.2007.102442; Zhang D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004501	47	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2022	13								985472	10.3389/fimmu.2022.985472	http://dx.doi.org/10.3389/fimmu.2022.985472			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5I5YM	36248786	gold, Green Published			2022-12-18	WOS:000868431700001
J	Tang, XF; Deng, BL; Zang, AP; He, XW; Zhou, Y; Wang, DM; Li, D; Dai, XY; Chen, JQ; Zhang, XH; Liu, Y; Xu, YH; Chen, JJ; Zheng, WJ; Zhang, LD; Gao, CSC; Yang, HF; Li, B; Wang, XQ				Tang, Xiaofeng; Deng, Biaolong; Zang, Aiping; He, Xiaowen; Zhou, Ye; Wang, Daimeng; Li, Dan; Dai, Xueyu; Chen, Jieqiong; Zhang, Xuhua; Liu, Ye; Xu, Yonghua; Chen, Jingjing; Zheng, Weijie; Zhang, Luding; Gao, Constance; Yang, Huanfeng; Li, Bin; Wang, Xueqi			Characterization of age-related immune features after autologous NK cell infusion: Protocol for an open-label and randomized controlled trial	FRONTIERS IN IMMUNOLOGY			English	Article						aging; T-cell senescence; T-cell exhaustion; natural killer cells; SASP	T-CELLS; REPLICATIVE SENESCENCE; SECRETORY PHENOTYPE; PD-1 EXPRESSION; EXHAUSTION; CONSEQUENCES; ACTIVATION; INFECTION; EXPANSION; THERAPY	BackgroundAging is usually accompanied by functional declines of the immune system, especially in T-cell responses. However, little is known about ways to alleviate this. MethodsHere, 37 middle-aged healthy participants were recruited, among which 32 were intravenously administrated with expanded NK cells and 5 with normal saline. Then, we monitored changes of peripheral senescent and exhausted T cells within 4 weeks after infusion by flow cytometry, as well as serum levels of senescence-associated secretory phenotype (SASP)-related factors. In vitro co-culture assays were performed to study NK-mediated cytotoxic activity against senescent or exhausted T cells. Functional and phenotypic alteration of NK cells before and after expansion was finally characterized. ResultsAfter NK cell infusion, senescent CD28(-), CD57(+), CD28(-)CD57(+), and CD28(-)KLRG1(+) CD4(+) and CD8(+) T-cell populations decreased significantly, so did PD-1(+) and TIM-3(+) T cells. These changes were continuously observed for 4 weeks. Nevertheless, no significant changes were observed in the normal saline group. Moreover, SASP-related factors including IL-6, IL-8, IL-1 alpha, IL-17, MIP-1 alpha, MIP-1 beta, and MMP1 were significantly decreased after NK cell infusion. Further co-culture assays showed that expanded NK cells specifically and dramatically eliminated senescent CD4(+) T cells other than CD28(+)CD4(+) T cells. They also showed improved cytotoxic activity, with different expression patterns of activating and inhibitory receptors including NKG2C, NKG2A, KLRG1, LAG3, CD57, and TIM3. ConclusionOur findings imply that T-cell senescence and exhaustion is a reversible process in healthy individuals, and autologous NK cell administration can be introduced to alleviate the aging.	[Tang, Xiaofeng; Zhou, Ye; Liu, Ye; Xu, Yonghua; Chen, Jingjing; Zheng, Weijie; Zhang, Luding; Wang, Xueqi] Changzheng Hosp, Dept Blood Transfus, Shanghai, Peoples R China; [Deng, Biaolong; Li, Dan; Dai, Xueyu; Li, Bin] Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Dept Immunol & Microbiol, Sch Med, Shanghai, Peoples R China; [Zang, Aiping; He, Xiaowen; Wang, Daimeng; Zhang, Xuhua; Yang, Huanfeng] Origincell Technol Grp Co Ltd, Shanghai Origincell Med Technol Co Ltd, Shanghai, Peoples R China; [Chen, Jieqiong] Shanghai Affin Biopharmaceut Co Ltd, Dept Res & Dev, Shanghai, Peoples R China; [Gao, Constance] Northeastern Univ, Coll Sci, Dept Biol, Boston, MA USA	Naval Medical University; Chinese Academy of Sciences; Shanghai Jiao Tong University; Northeastern University	Wang, XQ (corresponding author), Changzheng Hosp, Dept Blood Transfus, Shanghai, Peoples R China.; Li, B (corresponding author), Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Dept Immunol & Microbiol, Sch Med, Shanghai, Peoples R China.; Yang, HF (corresponding author), Origincell Technol Grp Co Ltd, Shanghai Origincell Med Technol Co Ltd, Shanghai, Peoples R China.	heleny@origincell.com; binli@shsmu.edu.cn; xueqiniu_wang@163.com			National Natural Science Foundation of China [81470915]; Construction of Shanghai Innovation Center, National Human genetic resources sharing service platform; Cell Therapy Special Project of Shanghai Changzheng Hospital [CTSP201702]; Construction of Shanghai Innovation Center, National Human genetic resources sharing service platform [YCZYPT[2017]02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Construction of Shanghai Innovation Center, National Human genetic resources sharing service platform; Cell Therapy Special Project of Shanghai Changzheng Hospital; Construction of Shanghai Innovation Center, National Human genetic resources sharing service platform	This study was supported by National Natural Science Foundation of China, grant number 81470915; Construction of Shanghai Innovation Center, National Human genetic resources sharing service platform, project number YCZYPT[2017]02; Cell Therapy Special Project of Shanghai Changzheng Hospital, Number CTSP201702; and Scientific Collaborative Project between Shanghai Origincell Medical Technology and Institute Pasteur of Shanghai about Assessment of Immune System Status in Adults.	Antonangeli F, 2019, J LEUKOCYTE BIOL, V105, P1275, DOI 10.1002/JLB.MR0718-299R; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Camous X, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/195956; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Castelo-Branco C, 2014, GYNECOL ENDOCRINOL, V30, P16, DOI 10.3109/09513590.2013.852531; Chou JP, 2013, CURR PHARM DESIGN, V19, P1680; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Effros RB, 2005, IMMUNOL REV, V205, P147, DOI 10.1111/j.0105-2896.2005.00259.x; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823; Focosi D, 2010, J LEUKOCYTE BIOL, V87, P107, DOI 10.1189/jlb.0809566; Gounder SS, 2018, ANAL CELL PATHOL, V2018, DOI 10.1155/2018/7871814; Gurwitz JH, 2019, JAMA-J AM MED ASSOC, V321, P1567, DOI 10.1001/jama.2019.2633; Hazeldine J, 2013, AGEING RES REV, V12, P1069, DOI 10.1016/j.arr.2013.04.003; He J, 2016, NAT MED, V22, P991, DOI 10.1038/nm.4148; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kelesidis T, 2016, J INFECT DIS, V214, P748, DOI 10.1093/infdis/jiw253; Li J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687296; Lieberman NAP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00150; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Levy EM, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/676198; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Mittelbrunn M, 2021, NAT IMMUNOL, V22, P687, DOI 10.1038/s41590-021-00927-z; Montecino-Rodriguez E, 2013, J CLIN INVEST, V123, P958, DOI 10.1172/JCI64096; Muller-Durovic B, 2016, J IMMUNOL, V197, P2891, DOI 10.4049/jimmunol.1600590; Nielsen CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00422; Onyema OO, 2015, ANTICANCER RES, V35, P1481; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Prata Larissa G P Langhi, 2018, Semin Immunol, V40, P101275, DOI 10.1016/j.smim.2019.04.003; Provinciali M, 2013, CURR PHARM DESIGN, V19, P1699; Reiser J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8941260; Resino S, 2005, AIDS RES HUM RETROV, V21, P398, DOI 10.1089/aid.2005.21.398; Romee R, 2012, BLOOD, V120, P4751, DOI 10.1182/blood-2012-04-419283; Saez-Borderias A, 2009, J IMMUNOL, V182, P829, DOI 10.4049/jimmunol.182.2.829; Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4; Solana R, 1999, EXP GERONTOL, V34, P435, DOI 10.1016/S0531-5565(99)00008-X; Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098; Urbani S, 2006, J VIROL, V80, P11398, DOI 10.1128/JVI.01177-06; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112; Yang Y, 2020, MOL THER-METH CLIN D, V18, P428, DOI 10.1016/j.omtm.2020.06.014	48	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 29	2022	13								940577	10.3389/fimmu.2022.940577	http://dx.doi.org/10.3389/fimmu.2022.940577			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5K0UO	36248873	Green Published, gold			2022-12-18	WOS:000869449700001
J	Horckmans, M; Villamil, ED; Bianchini, M; De Roeck, L; Communi, D				Horckmans, Michael; Villamil, Esteban Diaz; Bianchini, Mariaelvy; De Roeck, Lucas; Communi, Didier			Central role of PD-L1 in cardioprotection resulting from P2Y(4) nucleotide receptor loss	FRONTIERS IN IMMUNOLOGY			English	Article						cardioprotection; cardiac adipose tissue; PD-L1; P2Y receptor; adiponectin; ischemia	REGULATORY T-CELLS; ADIPOSE-TISSUE; CARDIAC-FUNCTION; FAT; DIFFERENTIATION; MACROPHAGES; INFARCTION; PROTECTS	A better understanding of the immune function of pericardial adipose tissue is essential to adapt treatments after myocardial infarction. We showed previously that inactivation of mouse P2Y(4) nucleotide receptor induces adiponectin overexpression and protection against myocardial infarction. We investigated here the inflammatory state of pericardial adipose tissue in ischemic P2Y(4)-deficient mice. We demonstrated that P2Y(4)-deficient mice displayed adipocyte beiging with increased PD-L1 expression and a higher number of regulatory leukocytes in their pericardial adipose tissue after left anterior descending artery ligation, compared to wild type mice. Effectively, a higher level of anti-inflammatory M2c macrophages and regulatory T cells was observed in pericardial adipose tissue of P2Y(4) KO mice and correlated with reduced post-ischemic expansion of fat-associated lymphoid clusters. Interestingly, the anti-inflammatory effects observed in P2Y(4) KO mice, were no more observed in P2Y(4)/adiponectin double KO ischemic mice. Finally, the reduction of T cell infiltration and cardiac fibrosis observed in P2Y(4)-deficient heart was lost after injection of anti-PD-L1 blocking antibody in ischemic mice. The present study defines P2Y(4) as a regulator of PD-L1 and adiponectin, and as a potential target for anti-inflammatory therapies to improve myocardial infarction outcome. The combined effect of P2Y(4) loss on adipocyte beiging and regulatory leukocyte increase highlights this nucleotide receptor as an important player in post-ischemic cardiac response.	[Horckmans, Michael; Villamil, Esteban Diaz; De Roeck, Lucas; Communi, Didier] Free Univ Brussels, Inst Interdisciplinary Res, Inst Rech Interdisciplinaire Biol Humaine & Mol I, Brussels, Belgium; [Bianchini, Mariaelvy] Ludwig Maximilians Univ Munchen, Munich, Germany	Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Munich	Communi, D (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, Inst Rech Interdisciplinaire Biol Humaine & Mol I, Brussels, Belgium.	Didier.Communi@ulb.be	Bianchini, Mariaelvy/GZG-3300-2022	Bianchini, Mariaelvy/0000-0002-5549-4883	Research Project and Research Credit of the Fonds National de la Recherche Scientifique of Belgium [J.0060.18 CDR]; ATIMI (Attract Brains for Brussels, Belgium) grant of Innoviris Brussels [2019-BFB-106 ATIMI]; Fonds pour la Chirurgie Cardiaque [FCC489698]; Fund Lokumo, King Baudouin Foundation, Belgium [2017-B7131100-207336]; Fonds et Crdit d'Encouragement la Recherche; ATIMI (Attract Brains for Brussels, Belgium) grants of Innoviris Brussels; F.R.I.A., Fonds National de la Recherche Scientifique; U.L.B., Belgium	Research Project and Research Credit of the Fonds National de la Recherche Scientifique of Belgium; ATIMI (Attract Brains for Brussels, Belgium) grant of Innoviris Brussels; Fonds pour la Chirurgie Cardiaque; Fund Lokumo, King Baudouin Foundation, Belgium; Fonds et Crdit d'Encouragement la Recherche; ATIMI (Attract Brains for Brussels, Belgium) grants of Innoviris Brussels; F.R.I.A., Fonds National de la Recherche Scientifique; U.L.B., Belgium	This work was supported by Research Project and Research Credit of the Fonds National de la Recherche Scientifique of Belgium (J.0060.18 CDR grant), by an ATIMI (Attract Brains for Brussels, Belgium) grant of Innoviris Brussels (2019-BFB-106 ATIMI grants), by the Fonds pour la Chirurgie Cardiaque (FCC489698), by the Fund Lokumo, King Baudouin Foundation, Belgium (2017-B7131100-207336 grant), and by the Fonds et Credit d'Encouragement a la Recherche (F.E.R./C.E.R., Free University of Brussels (U.L.B.)). M. Horckmans was supported by ATIMI (Attract Brains for Brussels, Belgium) grants of Innoviris Brussels. EDV was supported by the F.R.I.A., Fonds National de la Recherche Scientifique, Communaute Francaise de Belgique, Belgium. LDR is supported by U.L.B., Belgium. DC is Senior Research Associate of the Fonds National de la Recherche Scientifique (F.N.R.S.), Communaute Francaise de Belgique. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammirati E, 2012, J AM HEART ASSOC, V1, P27, DOI 10.1161/JAHA.111.000125; Bai XW, 2010, EUR HEART J, V31, P489, DOI 10.1093/eurheartj/ehp568; Benezech C, 2015, NAT IMMUNOL, V16, P819, DOI 10.1038/ni.3215; Chen YQ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1392-9; Cipolletta D, 2014, IMMUNOLOGY, V142, P517, DOI 10.1111/imm.12262; Communi D, 1997, TRENDS PHARMACOL SCI, V18, P83, DOI 10.1016/S0165-6147(96)01035-8; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; Hoerter J, 2004, CIRCULATION, V110, P528, DOI 10.1161/01.CIR.0000137824.30476.0E; Horckmans M, 2018, CIRCULATION, V137, P948, DOI 10.1161/CIRCULATIONAHA.117.028833; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Horckmans M, 2015, J IMMUNOL, V194, P1874, DOI 10.4049/jimmunol.1401364; Ingram JR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00799-8; Kino T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145013; Lemaire A, 2017, STEM CELLS DEV, V26, P363, DOI 10.1089/scd.2016.0166; Liu J, 2022, CANCER GENE THER, DOI 10.1038/s41417-022-00510-0; Mandal P, 2011, J BIOL CHEM, V286, P13460, DOI 10.1074/jbc.M110.204644; Matarese G, 2010, TRENDS MOL MED, V16, P247, DOI 10.1016/j.molmed.2010.04.002; McLean DS, 2009, CLIN LIPIDOL, V4, P55, DOI 10.2217/17584299.4.1.55; Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Nagata H, 2016, STEM CELL TRANSL MED, V5, P141, DOI 10.5966/sctm.2015-0083; Ramos-Ramirez P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.677550; Schmidt A, 2016, IMMUNOL CELL BIOL, V94, P747, DOI 10.1038/icb.2016.34; Sckisel GD, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0235-4; Sicari R, 2011, J AM SOC ECHOCARDIOG, V24, P1156, DOI 10.1016/j.echo.2011.06.013; Srikakulapu P, 2020, ARTERIOSCL THROM VAS, V40, P1110, DOI 10.1161/ATVBAHA.119.312467; Tsang JYS, 2011, INT IMMUNOPHARMACOL, V11, P604, DOI 10.1016/j.intimp.2010.11.009; Walden TB, 2012, AM J PHYSIOL-ENDOC M, V302, pE19, DOI 10.1152/ajpendo.00249.2011; Wan E, 2013, CIRC RES, V113, P1004, DOI 10.1161/CIRCRESAHA.113.301198; Xia N, 2020, CIRCULATION, V142, P1956, DOI 10.1161/CIRCULATIONAHA.120.046789; Zeng Q, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02075	31	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2022	13								1006934	10.3389/fimmu.2022.1006934	http://dx.doi.org/10.3389/fimmu.2022.1006934			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5I6NY	36248854	Green Published, gold			2022-12-18	WOS:000868471900001
J	VanValkenburg, A; Kaipilyawar, V; Sarkar, S; Lakshminarayanan, S; Cintron, C; Babu, SP; Knudsen, S; Joseph, NM; Horsburgh, CR; Ellner, JJ; Narasimhan, PB; Johnson, WE; Hochberg, NS; Salgame, P				VanValkenburg, Arthur; Kaipilyawar, Vaishnavi; Sarkar, Sonali; Lakshminarayanan, Subitha; Cintron, Chelsie; Prakash Babu, Senbagavalli; Knudsen, Selby; Joseph, Noyal Mariya; Horsburgh, C. Robert; Ellner, Jerrold J.; Narasimhan, Prakash Babu; Johnson, W. Evan; Hochberg, Natasha S.; Salgame, Padmini			Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Article						tuberculosis; malnutrition; TB biomarkers; inflammation; immunoregulation	PROTEIN-CALORIE MALNUTRITION; INCIDENT TUBERCULOSIS; VITAMIN-A; RESPONSES; CELLS; CD7; SUSCEPTIBILITY; ASSOCIATION; CHILDREN; IMMUNITY	BackgroundMost individuals exposed to Mycobacterium tuberculosis (Mtb) develop latent tuberculosis infection (LTBI) and remain at risk for progressing to active tuberculosis disease (TB). Malnutrition is an important risk factor driving progression from LTBI to TB. However, the performance of blood-based TB risk signatures in malnourished individuals with LTBI remains unexplored. The aim of this study was to determine if malnourished and control individuals had differences in gene expression, immune pathways and TB risk signatures. MethodsWe utilized data from 50 tuberculin skin test positive household contacts of persons with TB - 18 malnourished participants (body mass index [BMI] < 18.5 kg/m2) and 32 controls (individuals with BMI >= 18.5 kg/m2). Whole blood RNA-sequencing was conducted to identify differentially expressed genes (DEGs). Ingenuity Pathway Analysis was applied to the DEGs to identify top canonical pathways and gene regulators. Gene enrichment methods were then employed to score the performance of published gene signatures associated with progression from LTBI to TB. ResultsMalnourished individuals had increased activation of inflammatory pathways, including pathways involved in neutrophil activation, T-cell activation and proinflammatory IL-1 and IL-6 cytokine signaling. Consistent with known association of inflammatory pathway activation with progression to TB disease, we found significantly increased expression of the RISK4 (area under the curve [AUC] = 0.734) and PREDICT29 (AUC = 0.736) progression signatures in malnourished individuals. ConclusionMalnourished individuals display a peripheral immune response profile reflective of increased inflammation and a concomitant increased expression of risk signatures predicting progression to TB. With validation in prospective clinical cohorts, TB risk biomarkers have the potential to identify malnourished LTBI for targeted therapy.	[VanValkenburg, Arthur; Johnson, W. Evan] Boston Univ, Sch Med, Div Computat Biomed, Boston, MA USA; [VanValkenburg, Arthur; Johnson, W. Evan] Boston Univ, Bioinformat Program, Boston, MA USA; [Kaipilyawar, Vaishnavi; Ellner, Jerrold J.; Salgame, Padmini] Rutgers New Jersey Med Sch, Ctr Emerging Pathogens, Dept Med, Newark, NJ 07103 USA; [Sarkar, Sonali; Lakshminarayanan, Subitha; Prakash Babu, Senbagavalli] Jawaharlal Inst Postgrad Med Educ & Res, Dept Prevent & Social Med, Pondicherry, India; [Cintron, Chelsie; Knudsen, Selby; Hochberg, Natasha S.] Boston Med Ctr, Dept Med, Boston, MA USA; [Joseph, Noyal Mariya] Jawaharlal Inst Postgrad Med Educ & Res, Dept Microbiol, Pondicherry, India; [Horsburgh, C. Robert; Hochberg, Natasha S.] Boston Univ, Sch Med, Sect Infect Dis, Boston, MA USA; [Horsburgh, C. Robert; Hochberg, Natasha S.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Narasimhan, Prakash Babu] Jawaharlal Inst Postgrad Med Educ & Res, Dept Clin Immunol, Pondicherry, India	Boston University; Boston University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Jawaharlal Institute of Postgraduate Medical Education & Research; Boston Medical Center; Jawaharlal Institute of Postgraduate Medical Education & Research; Boston University; Boston University; Jawaharlal Institute of Postgraduate Medical Education & Research	Salgame, P (corresponding author), Rutgers New Jersey Med Sch, Ctr Emerging Pathogens, Dept Med, Newark, NJ 07103 USA.	padmini.salgame@rutgers.edu		Narasimhan, Prakash babu/0000-0001-7111-7124	US Civilian Research & Development Foundation (CRDF Global) [USB-31150-XX-13]; National Science Foundation [OISE-9531011]; Government of India's (GOI) Department of Biotechnology (DBT); United States National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); Office of AIDS Research (OAR); Warren Alpert Foundation; Boston University School of Medicine; National Institutes of Health [R01GM127430, R21AI154387]; CRDF Global	US Civilian Research & Development Foundation (CRDF Global); National Science Foundation(National Science Foundation (NSF)); Government of India's (GOI) Department of Biotechnology (DBT); United States National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of AIDS Research (OAR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Warren Alpert Foundation; Boston University School of Medicine; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CRDF Global	This work was supported by Award No. USB-31150-XX-13 of the US Civilian Research & Development Foundation (CRDF Global) and the National Science Foundation under Cooperative Agreement No. OISE-9531011 with Federal funds from the Government of India's (GOI) Department of Biotechnology (DBT), the United States National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Office of AIDS Research (OAR), and distributed in part by CRDF Global; Warren Alpert Foundation; Boston University School of Medicine; and National Institutes of Health (R01GM127430 and R21AI154387). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the DBT, the NIH, or CRDF Global.	Abel L, 2018, LANCET INFECT DIS, V18, pE64, DOI 10.1016/S1473-3099(17)30623-0; Abel L, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0428; Aibana O, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002907; Aibana O, 2018, J NUTR, V148, P56, DOI 10.1093/jn/nxx006; Aibana O, 2017, CLIN INFECT DIS, V65, P900, DOI 10.1093/cid/cix476; Alcais A, 2005, J EXP MED, V202, P1617, DOI 10.1084/jem.20052302; Andrews S., 2010, FASTQC QUALITY CONTR; [Anonymous], 2021, WHO GLOBAL TUBERCULO; Anuradha R, 2016, CLIN VACCINE IMMUNOL, V23, P339, DOI 10.1128/CVI.00009-16; Azad AK, 2012, INFECT IMMUN, V80, P3343, DOI 10.1128/IAI.00443-12; Bal E, 2007, HUM MUTAT, V28, P703, DOI 10.1002/humu.20500; Bhargava Anurag, 2022, J Clin Tuberc Other Mycobact Dis, V27, P100309, DOI 10.1016/j.jctube.2022.100309; Blazek K, 2015, J EXP MED, V212, P845, DOI 10.1084/jem.20140995; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brandenburg J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00635; Broggi A, 2017, NAT IMMUNOL, V18, P1084, DOI 10.1038/ni.3821; Burl S, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012287, 10.1371/journal.pone.0018185]; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Chan J, 1996, P NATL ACAD SCI USA, V93, P14857, DOI 10.1073/pnas.93.25.14857; Chandrasekaran P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01316; Chatterjee S, 2018, CELL METAB, V27, P85, DOI 10.1016/j.cmet.2017.10.006; Chini C, 2019, BIOCHEM BIOPH RES CO, V513, P486, DOI 10.1016/j.bbrc.2019.03.199; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; George SJ, 2008, ARTERIOSCL THROM VAS, V28, P400, DOI 10.1161/ATVBAHA.107.160952; Hochberg NS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183195; Hogan KA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01187; Jiao L, 2022, INFECT GENET EVOL, V104, DOI 10.1016/j.meegid.2022.105352; Johnson WE, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-020-05598-z; Kar A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071716; Koethe JR, 2016, INT J TUBERC LUNG D, V20, P857, DOI 10.5588/ijtld.15.0936; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; Lee DM, 1996, INT IMMUNOL, V8, P1195, DOI 10.1093/intimm/8.8.1195; Leong S, 2020, TUBERCULOSIS, V120, DOI 10.1016/j.tube.2020.101898; Leong S, 2018, TUBERCULOSIS, V109, P41, DOI 10.1016/j.tube.2018.01.002; Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378; Mainali ES, 1998, INFECT IMMUN, V66, P927, DOI 10.1128/IAI.66.3.927-931.1998; Manicassamy S, 2010, SCIENCE, V329, P849, DOI 10.1126/science.1188510; Moller M, 2010, FEMS IMMUNOL MED MIC, V58, P3, DOI 10.1111/j.1574-695X.2009.00600.x; Nielsen NO, 2010, BRIT J NUTR, V104, P1487, DOI 10.1017/S0007114510002333; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Podell BK, 2022, CLIN INFECT DIS, DOI 10.1093/cid/ciac326; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Savino W, 2002, EUR J CLIN NUTR, V56, pS46, DOI 10.1038/sj.ejcn.1601485; Scriba TJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006687; Sepulveda RL, 1997, INT J TUBERC LUNG D, V1, P122; Shey MS, 2014, J IMMUNOL, V192, P4833, DOI 10.4049/jimmunol.1400062; Shivakoti R, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1150-3; Silva-Garcia O, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/310183; Sinha P, 2019, J INFECT DIS, V219, P1356, DOI 10.1093/infdis/jiy675; Stillwell R, 2001, IMMUNOL RES, V24, P31, DOI 10.1385/IR:24:1:31; Subrahmanyam G, 2003, EUR J IMMUNOL, V33, P46, DOI 10.1002/immu.200390006; Sudfeld CR, 2013, J INFECT DIS, V207, P378, DOI 10.1093/infdis/jis693; Suliman S, 2018, AM J RESP CRIT CARE, V197, P1198, DOI 10.1164/rccm.201711-2340OC; Sweeney TE, 2016, LANCET RESP MED, V4, P213, DOI 10.1016/S2213-2600(16)00048-5; Tenforde MW, 2017, JAIDS-J ACQ IMM DEF, V75, pE71, DOI 10.1097/QAI.0000000000001308; Thiele C, 2021, J STAT SOFTW, V98, DOI 10.18637/jss.v098.i11; Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; Whittaker E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00448; WHO, 2013, GROWTH REF DAT 5 19; WOLFEL T, 1993, INT J CANCER, V55, P237, DOI 10.1002/ijc.2910550212; World Health Organization, 2021, WHO CONS GUID TUB MO; Yang H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00484; Zaidi N, 2008, BIOCHEM BIOPH RES CO, V367, P517, DOI 10.1016/j.bbrc.2007.12.163; Zaiss DMW, 2015, IMMUNITY, V42, P216, DOI 10.1016/j.immuni.2015.01.020; Zak DE, 2016, LANCET, V387, P2312, DOI 10.1016/S0140-6736(15)01316-1; Zeng JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126014; Zhang YQ, 2020, NAR GENOM BIOINFORM, V2, DOI 10.1093/nargab/lqaa078	70	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 28	2022	13								1011166	10.3389/fimmu.2022.1011166	http://dx.doi.org/10.3389/fimmu.2022.1011166			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5I7FP	36248906	Green Published, gold			2022-12-18	WOS:000868518200001
J	Deng, LH; Harms, A; Ravens, S; Prinz, I; Tan, LK				Deng, Lihua; Harms, Anna; Ravens, Sarina; Prinz, Immo; Tan, Likai			Systematic pattern analyses of V delta 2(+) TCRs reveal that shared "public" V delta 2(+) gamma delta T cell clones are a consequence of rearrangement bias and a higher expansion status	FRONTIERS IN IMMUNOLOGY			English	Article						gamma delta TCR; V gamma 9V delta 2(+) T cells; TCR distance; TCR sequencing; TRD rearrangement	FETAL	Background V gamma 9V delta 2(+) T cells are a major innate T cell subset in human peripheral blood. Their V delta 2(+) VDJ-rearrangements are short and simple in the fetal thymus and gradually increase in diversity and CDR3 length along with development. So-called "public " versions of V delta 2(+) TCRs are shared among individuals of all ages. However, it is unclear whether such frequently occurring "public " V gamma 9V delta 2(+) T cell clones are derived from the fetal thymus and whether they are fitter to proliferate and persist than infrequent "private " clones. Methods Shared "public " V delta 2(+) TCRs were identified from V delta 2(+) TCR-repertoires collected from 89 individuals, including newborns (cord blood), infants, and adults (peripheral blood). Distance matrices of V delta 2(+) CDR3 were generated by TCRdist3 and then embedded into a UMAP for visualizing the heterogeneity of V delta 2(+) TCRs. Results V delta 2(+) CDR3 distance matrix embedded by UMAP revealed that the heterogeneity of V delta 2(+) TCRs is primarily determined by the J-usage and CDR3aa length, while age or publicity-specific motifs were not found. The most prevalent public V delta 2(+) TCRs showed germline-like rearrangement with low N-insertions. Age-related features were also identified. Public V delta 2(+) TRDJ1 TCRs from cord blood showed higher N-insertions and longer CDR3 lengths. Synonymous codons resulting from VDJ rearrangement also contribute to the generation of public V delta 2(+) TCRs. Each public TCR was always produced by multiple different transcripts, even with different D gene usage, and the publicity of V delta 2(+) TCRs was positively associated with expansion status. Conclusion To conclude, the heterogeneity of V delta 2(+) TCRs is mainly determined by TRDJ-usage and the length of CDR3aa sequences. Public V delta 2(+) TCRs result from germline-like rearrangement and synonymous codons, associated with a higher expansion status.	[Deng, Lihua; Prinz, Immo; Tan, Likai] Univ Med Ctr Hamburg Eppendorf, Inst Syst Immunol, Hamburg, Germany; [Harms, Anna; Ravens, Sarina; Prinz, Immo] Hannover Med Sch, Inst Immunol, Hannover, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School	Prinz, I; Tan, LK (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Syst Immunol, Hamburg, Germany.; Prinz, I (corresponding author), Hannover Med Sch, Inst Immunol, Hannover, Germany.	i.prinz@uke.de; l.tan@uke.de			Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) [395236335]; Germany's Excellence Strategy [390874280]	Deutsche Forschungsgemeinschaft (DFG; German Research Foundation)(German Research Foundation (DFG)); Germany's Excellence Strategy	This work was supported by the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) Research Unit FOR 2799 to SR and IP (Project ID 395236335) and under Germany's Excellence Strategy, EXC 2155 "RESIST," (Project ID 390874280) to IP and SR.	Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Conejo-Garcia JR, 2022, NAT CANCER, V3, P657, DOI 10.1038/s43018-022-00396-9; Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383; De Neuter N, 2018, IMMUNOGENETICS, V70, P159, DOI 10.1007/s00251-017-1023-5; DeWitt WS, 2018, J IMMUNOL, V201, P888, DOI 10.4049/jimmunol.1800186; Dimova T, 2015, P NATL ACAD SCI USA, V112, pE556, DOI 10.1073/pnas.1412058112; Fichtner AS, 2020, J LEUKOCYTE BIOL, V107, P1023, DOI 10.1002/JLB.1MA0120-427RR; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Haas JD, 2012, IMMUNITY, V37, P48, DOI 10.1016/j.immuni.2012.06.003; Holtmeier W, 1997, J IMMUNOL, V158, P5632; Huang H, 2020, NAT BIOTECHNOL, V38, P1194, DOI 10.1038/s41587-020-0505-4; Jin CC, 2019, CELL, V176, P998, DOI 10.1016/j.cell.2018.12.040; Karunakaran MM, 2020, IMMUNITY, V52, P487, DOI 10.1016/j.immuni.2020.02.014; Marcu-Malina V, 2011, BLOOD, V118, P50, DOI 10.1182/blood-2010-12-325993; Market E, 2003, PLOS BIOL, V1, P24, DOI 10.1371/journal.pbio.0000016; Mayer-Blackwell K, 2021, ELIFE, V10, DOI [10.7554/eLife.68605, 10.7554/eLife.68605.sa0, 10.7554/eLife.68605.sa1, 10.7554/eLife.68605.sa2]; Meysman P, 2019, BIOINFORMATICS, V35, P1461, DOI 10.1093/bioinformatics/bty821; Papadopoulou M, 2020, IMMUNOL REV, V298, P99, DOI 10.1111/imr.12926; Papadopoulou M, 2020, P NATL ACAD SCI USA, V117, P18638, DOI 10.1073/pnas.1922595117; Papadopoulou M, 2019, J IMMUNOL, V203, P1468, DOI 10.4049/jimmunol.1900592; Pogorelyy MV, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005572; Prinz I, 2013, EUR J IMMUNOL, V43, P1988, DOI 10.1002/eji.201343759; Ravens S, 2020, P NATL ACAD SCI USA, V117, P18649, DOI 10.1073/pnas.1922588117; Ravens S, 2017, NAT IMMUNOL, V18, P393, DOI 10.1038/ni.3686; Rigau M, 2020, SCIENCE, V367, P642, DOI 10.1126/science.aay5516; Shugay M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004503; SIEVERS F., 2020, BIOINFORMATICS, P227; Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Tan LK, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf0125; Tan LK, 2019, CELL REP, V27, P3657, DOI 10.1016/j.celrep.2019.05.064; Tareen A, 2020, BIOINFORMATICS, V36, P2272, DOI 10.1093/bioinformatics/btz921; Tieppo P, 2020, J EXP MED, V217, DOI 10.1084/jem.20190580; Yang YY, 2019, IMMUNITY, V50, P1043, DOI 10.1016/j.immuni.2019.02.016; Yuan L., 2022, BIORXIV, DOI [10.1101/2022.01.02.474068, DOI 10.1101/2022.01.02.474068]; Zhang H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24438-5	36	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 27	2022	13								960920	10.3389/fimmu.2022.960920	http://dx.doi.org/10.3389/fimmu.2022.960920			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5T0PF	36275749	Green Published, gold			2022-12-18	WOS:000875579400001
J	Wu, Y; Zhou, H; Wei, KH; Zhang, T; Che, YY; Nguyen, A; Pandita, S; Wan, X; Cui, XJ; Zhou, BX; Li, CY; Hao, P; Lei, HJ; Wang, L; Yang, XA; Liang, Y; Liu, JG; Wu, Y				Wu, Yu; Zhou, Hui; Wei, Kunhua; Zhang, Tao; Che, Yanyun; Nguyen, Audrey D.; Pandita, Sakshi; Wan, Xin; Cui, Xuejie; Zhou, Bingxue; Li, Caiyue; Hao, Ping; Lei, Hongjun; Wang, Lin; Yang, Xiaonan; Liang, Ying; Liu, Jiaguo; Wu, Yi			Structure of a new glycyrrhiza polysaccharide and its immunomodulatory activity	FRONTIERS IN IMMUNOLOGY			English	Article						glycyrrhiza polysaccharide; structural characterization; immunomodulatory activity; dendritic cells; toll-like receptor	LICORICE; IMMUNE	A component of licorice polysaccharide (GPS-1) was extracted from licorice, its primary structure was identified and characterized for the first time, and its immunomodulatory activity was studied. Crude licorice polysaccharide was isolated and purified by DEAE sepharose FF ion-exchange column chromatography and Chromdex 200 PG gel filtration column chromatography to obtain a purified Glycyrrhiza polysaccharide named GPS-1. NMR and methylation analysis revealed that GPS-1 is composed of homogalacturonan (HG)-type pectin with 4)-D-GalpA-(1 as the backbone. This study of GPS-1 also examined its significant role in regulating immune activity in vitro and in vivo. As a result, GPS-1 promoted the secretion of IFN-gamma and IL-4 in mice and increased the proportion of CD3(+)CD4(+) and CD3(+)CD8(+) T lymphocytes in their spleens. Dendritic cells (DCs) treated with GPS-1 showed promotion of DC maturation, antigen presentation, and phagocytic capacity. The results suggest that GPS-1 is a potential immunomodulator that stimulates the immune system by regulating multiple signaling pathways. Combined with our characterization of the primary structure of GPS-1, the present investigation provides the basis for future study of the form-function relationship of polysaccharides.	[Wu, Yu; Zhou, Hui; Wan, Xin; Cui, Xuejie; Zhou, Bingxue; Li, Caiyue; Hao, Ping; Lei, Hongjun; Liu, Jiaguo; Wu, Yi] Nanjing Agr Univ, Coll Vet Med, Joint Int Res Lab Anim Hlth & Food Safety, Minist Educ MOE, Nanjing, Peoples R China; [Wu, Yu; Zhou, Hui; Wan, Xin; Li, Caiyue; Hao, Ping; Lei, Hongjun; Liu, Jiaguo; Wu, Yi] Nanjing Agr Univ, Inst Tradit Chinese Vet Med, Coll Vet Med, Nanjing, Peoples R China; [Wei, Kunhua; Yang, Xiaonan; Liang, Ying] Guangxi Engn Res Ctr Tradit Chinese Med TCM Resour, Guangxi Key Lab Med Resources Protect & Genet Impr, Guangxi Bot Garden Med Plant, Nan Ning, Peoples R China; [Zhang, Tao] Beijing Univ Agr, Beijing Key Lab Tradit Chinese Vet Med, Beijing, Peoples R China; [Che, Yanyun] Yunnan Univ Chinese Med, Coll Pharmaceut Sci, Engn Lab Natl Healthcare Theories & Prod Yunnan Pr, Kunming, Peoples R China; [Nguyen, Audrey D.; Pandita, Sakshi] Univ Calif, Davis Med Ctr, Dept Biochem & Mol Med, Davis Med, Sacramento, CA USA; [Wang, Lin] Jiangsu Vocat Coll Agr & Forestry, Anim Sci & Vet Coll, Zhenjiang, Peoples R China	Nanjing Agricultural University; Nanjing Agricultural University; Beijing University of Agriculture; Yunnan University of Chinese Medicine; Jiangsu Vocational College of Agriculture & Forestry	Wu, Y (corresponding author), Nanjing Agr Univ, Coll Vet Med, Joint Int Res Lab Anim Hlth & Food Safety, Minist Educ MOE, Nanjing, Peoples R China.; Wu, Y (corresponding author), Nanjing Agr Univ, Inst Tradit Chinese Vet Med, Coll Vet Med, Nanjing, Peoples R China.	wuyi2001cn@163.com			National Natural Science Foundation of China (NSFC) [31872514, 32172900]; Open Project Program of Beijing Key Laboratory of 490 Traditional Chinese Veterinary Medicine at Beijing University of Agriculture [kftcvm202101]; Yunnan Provincial Science and Technology Department-Applied Basic Research Joint Special Funds of Yunnan University of Chinese Medicine [2018FF001 (-020), 2019FF002(-012)]; Guangxi Science and Technology Project [GuiKe ZY20198018, GuiKe AA18242040]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Open Project Program of Beijing Key Laboratory of 490 Traditional Chinese Veterinary Medicine at Beijing University of Agriculture; Yunnan Provincial Science and Technology Department-Applied Basic Research Joint Special Funds of Yunnan University of Chinese Medicine; Guangxi Science and Technology Project; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This research was financially supported by the National Natural Science Foundation of China (NSFC, Grant No. 31872514 and 32172900), the Open Project Program of Beijing Key Laboratory of 490 Traditional Chinese Veterinary Medicine at Beijing University of Agriculture (No. kftcvm202101), Yunnan Provincial Science and Technology Department-Applied Basic Research Joint Special Funds of Yunnan University of Chinese Medicine [2018FF001 (-020), 2019FF002(-012)], Guangxi Science and Technology Project (GuiKe ZY20198018, GuiKe AA18242040) and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). We appreciate the assistance from our distinguished colleagues in the Institute of Traditional Chinese Veterinary Medicine of Nanjing Agricultural University and the technological managers in Nanjing Super Biotech Co., Ltd.	Aipire A, 2020, PEERJ, V8, DOI [10.7717/peerj.8294, 10.7717/pearj.8294]; Arbelaez P, 2015, J CHROMATOGR A, V1408, P15, DOI 10.1016/j.chroma.2015.07.001; Chasan Achmet Imam, 2013, Methods Mol Biol, V960, P379, DOI 10.1007/978-1-62703-218-6_28; Cho BO, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12171; Cong Y., 2018, CHIN J TRADIT CHIN M, V36, P1044, DOI [10.13193/j.issn.1673-7717.2018.05.004, DOI 10.13193/J.ISSN.1673-7717.2018.05.004]; Hong YK, 2009, INT J BIOL MACROMOL, V45, P61, DOI 10.1016/j.ijbiomac.2009.04.001; Kubota A, 2018, J ETHNOPHARMACOL, V214, P240, DOI 10.1016/j.jep.2017.12.010; Li CX, 2022, J ANIM PHYSIOL AN N, DOI 10.1111/jpn.13692; Liu QQ, 2019, EXP THER MED, V18, P509, DOI 10.3892/etm.2019.7612; Lu YY, 2022, FOOD CHEM, V380, DOI 10.1016/j.foodchem.2022.132235; Makarova EN, 2020, CARBOHYD POLYM, V246, DOI 10.1016/j.carbpol.2020.116544; Mutaillifu P, 2020, INT J BIOL MACROMOL, V144, P751, DOI 10.1016/j.ijbiomac.2019.11.245; Nakamura T, 2016, EXP DERMATOL, V25, P299, DOI 10.1111/exd.12931; Ota M, 2022, J ETHNOPHARMACOL, V292, DOI 10.1016/j.jep.2022.115108; Pan LC, 2020, INT J BIOL MACROMOL, V155, P560, DOI 10.1016/j.ijbiomac.2020.03.192; Panda BC, 2015, CARBOHYD RES, V401, P24, DOI 10.1016/j.carres.2014.10.015; Pandiella-Alonso A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092661; Perrone P, 2002, PHYTOCHEMISTRY, V60, P67, DOI 10.1016/S0031-9422(02)00039-0; Petersen BO, 2008, CARBOHYD RES, V343, P2830, DOI 10.1016/j.carres.2008.08.016; Freitas CMP, 2021, COATINGS, V11, DOI 10.3390/coatings11080922; do Prado SBR, 2019, INT J BIOL MACROMOL, V126, P170, DOI 10.1016/j.ijbiomac.2018.12.191; Roman L, 2021, FOOD HYDROCOLLOID, V113, DOI 10.1016/j.foodhyd.2020.106476; Shakhmatov EG, 2020, CARBOHYD POLYM, V235, DOI 10.1016/j.carbpol.2020.115978; Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x; Sheng ZL, 2022, CARBOHYD POLYM, V278, DOI 10.1016/j.carbpol.2021.118939; Simayi Z, 2021, INT J BIOL MACROMOL, V183, P387, DOI 10.1016/j.ijbiomac.2021.04.099; Ul Ain N, 2022, MATERIALS, V15, DOI 10.3390/ma15103654; Wang XR, 2017, MICROB PATHOGENESIS, V109, P110, DOI 10.1016/j.micpath.2017.05.032; Wu DM, 2020, CRIT REV FOOD SCI, V60, P2938, DOI 10.1080/10408398.2019.1672037; Wu Y, 2017, INT J BIOL MACROMOL, V102, P68, DOI 10.1016/j.ijbiomac.2017.04.006; Wu Y, 2022, FRONT VET SCI, V9, DOI 10.3389/fvets.2022.891429; Wu Y, 2022, POULTRY SCI, V101, DOI 10.1016/j.psj.2021.101549; Yang JL, 2018, FOOD HYDROCOLLOID, V84, P481, DOI 10.1016/j.foodhyd.2018.06.022; Yang R, 2018, PAK J PHARM SCI, V31, P525; Zeng F, 2021, INT J BIOL MACROMOL, V187, P858, DOI 10.1016/j.ijbiomac.2021.07.179; Zeng G, 2015, TUMOR BIOL, V36, P6781, DOI 10.1007/s13277-015-3359-5; Zhang H, 2019, CARBOHYD POLYM, V219, P219, DOI 10.1016/j.carbpol.2019.05.019; Zhang XJ, 2020, INT J BIOL MACROMOL, V147, P1125, DOI 10.1016/j.ijbiomac.2019.10.081	38	1	1	9	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 27	2022	13								1007186	10.3389/fimmu.2022.1007186	http://dx.doi.org/10.3389/fimmu.2022.1007186			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5R5UO	36238291	Green Published, gold			2022-12-18	WOS:000874575600001
J	Zhou, SJ; Ren, F; Meng, XJ				Zhou, Shujie; Ren, Fei; Meng, Xiangjiao			Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy	FRONTIERS IN IMMUNOLOGY			English	Article						immune checkpoint inhibitors (ICIs); epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); brain metastases (BMs); efficacy; prognosis	CELL LUNG-CANCER; 1ST-LINE TREATMENT; ADENOCARCINOMA; MECHANISMS; DIAGNOSIS; SURVIVAL	BackgroundFew treatment options are available for brain metastases (BMs) in EGFR-mutant non-small cell lung cancer (NSCLC) that progress with prior EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. This study aimed to evaluate the efficacy of immune checkpoint inhibitor (ICI) therapy in these patients. MethodsNSCLC patients with confirmed sensitive EGFR mutations and BMs were retrospectively reviewed. All patients experienced failure of EGFR-TKI therapy and were divided into two cohorts based on subsequent treatment. Cohort 1 included patients who received ICI therapy, while cohort 2 included patients treated with chemotherapy. Overall and intracranial objective response rates (ORRs) were used to evaluate the treatment response. Overall and intacranial progression-free survival (PFS) were calculated by Kaplan-Meier analysis and compared with the log-rank test. Univariate and multivariate Cox analyses were used to identify prognostic factors. ResultsA total of 53 patients treated with ICI therapy and 40 patients treated with chemotherapy were included in cohorts 1 and 2, respectively. In cohort 1, the overall ORR was 20.8%, with a median overall PFS of 4.2 months. The median intracranial PFS was 5.1 months. Of the 38 patients with measurable intracranial lesions, the intracranial ORR was 21.0%. Patients who received ICI combined with chemotherapy had the highest intracranial ORR of 37.5%. Compared to patients treated with chemotherapy in cohort 2, patients receiving ICI combined with chemotherapy had both longer intracranial PFS (6.4 vs. 5.1 months, p = 0.110) and overall PFS (6.2 vs. 4.6 months, p = 0.054), and these differences approached statistical significance. Univariate and multivariate Cox analyses demonstrated that high disease burden (p = 0.019), prior third-generation EGFR-TKI therapy (p = 0.019), and a poor lung immune prognostic index (LIPI) (p = 0.012) were independent negative predicators of overall PFS and that multiple BMs were negatively correlated with intracranial PFS among patients treated with ICI therapy. ConclusionsOur results suggested that ICI combined with chemotherapy had potent intracranial efficacy and may be a promising treatment candidate in EGFR-mutant NSCLC patients with BMs for whom prior EGFR-TKI therapy failed.	[Zhou, Shujie; Meng, Xiangjiao] Shandong Univ, Shandong Canc Hosp & Inst, Cheeloo Coll Med, Jinan, Shandong, Peoples R China; [Zhou, Shujie; Ren, Fei; Meng, Xiangjiao] Shandong First Med Univ, Shandong Canc Hosp & Inst, Shandong Acad Med Sci, Dept Radiat Oncol, Jinan, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan	Meng, XJ (corresponding author), Shandong Univ, Shandong Canc Hosp & Inst, Cheeloo Coll Med, Jinan, Shandong, Peoples R China.; Meng, XJ (corresponding author), Shandong First Med Univ, Shandong Canc Hosp & Inst, Shandong Acad Med Sci, Dept Radiat Oncol, Jinan, Shandong, Peoples R China.	mengxiangjiao@126.com			National Natural Science Foundation of China [81972796, 82272845]; Natural Science Foundation of Shandong Province [ZR2019MH010, ZR2019MH289]; Beijing Bethune Charitable Foundation [flzh202107]; Wu Jieping Medical Foundation [320.6750.2020-12-10]; CSCO-Haosen Foundation [Y-HS202102-0089]; CSCO-Xinda Foundation [Y-XD202001-0008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Beijing Bethune Charitable Foundation; Wu Jieping Medical Foundation; CSCO-Haosen Foundation; CSCO-Xinda Foundation	The study was funded by National Natural Science Foundation of China (81972796 and 82272845), Natural Science Foundation of Shandong Province (ZR2019MH010 and ZR2019MH289), Beijing Bethune Charitable Foundation (flzh202107), Wu Jieping Medical Foundation (320.6750.2020-12-10), CSCO-Haosen Foundation (Y-HS202102-0089), and CSCO-Xinda Foundation (Y-XD202001-0008).	Ali A, 2013, CURR ONCOL, V20, pE300, DOI 10.3747/co.20.1481; Baek MY, 2018, KOREAN J INTERN MED, V33, P168, DOI 10.3904/kjim.2015.158; Bai ML, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.832419; Chu Xianjing, 2022, Front Immunol, V13, P875488, DOI 10.3389/fimmu.2022.875488; Eide IJZ, 2021, ACTA ONCOL, V60, P1565, DOI 10.1080/0284186X.2021.1973092; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gettinger S, 2016, J CLIN ONCOL, V34, P2980, DOI 10.1200/JCO.2016.66.9929; Goldberg SB, 2020, LANCET ONCOL, V21, P655, DOI 10.1016/S1470-2045(20)30111-X; Grant MJ, 2021, NAT REV CLIN ONCOL, V18, P625, DOI 10.1038/s41571-021-00520-1; Hendriks LEL, 2019, J THORAC ONCOL, V14, P1244, DOI 10.1016/j.jtho.2019.02.009; Hopkins AM, 2021, CANCERS, V13, DOI 10.3390/cancers13051176; Jiang T, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00751-9; Khan M, 2021, INT J GEN MED, V14, P8903, DOI 10.2147/IJGM.S333890; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Li LL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.697865; Lisberg A, 2018, J THORAC ONCOL, V13, P1138, DOI 10.1016/j.jtho.2018.03.035; Liu ST, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.639947; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Lu S, 2022, ANN ONCOL, V33, P112, DOI 10.1016/j.annonc.2021.10.007; Ma L, 2021, CANCER COMMUN, V41, P1314, DOI 10.1002/cac2.12229; Mansfield AS, 2016, ANN ONCOL, V27, P1953, DOI 10.1093/annonc/mdw289; Mazieres J, 2019, ANN ONCOL, V30, P1321, DOI 10.1093/annonc/mdz167; Mezquita L, 2018, JAMA ONCOL, V4, P351, DOI 10.1001/jamaoncol.2017.4771; POWELL S, 2019, ANN ONCOL, V30, P606, DOI DOI 10.1093/ANNONC/MDZ260.005; Reck M, 2020, ANN ONCOL, V31, pS837, DOI 10.1016/j.annonc.2020.08.1607; Shultz DB, 2020, J CLIN ONCOL, V38; Skribek M, 2020, CANCERS, V12, DOI 10.3390/cancers12123707; Soria JC, 2015, LANCET ONCOL, V16, P990, DOI 10.1016/S1470-2045(15)00121-7; Taggart D, 2018, P NATL ACAD SCI USA, V115, pE1540, DOI 10.1073/pnas.1714089115; Tan L, 2019, PATHOL ONCOL RES, V25, P791, DOI 10.1007/s12253-019-00598-0; Tseng YH, 2016, J CHEMOTHERAPY, V28, P50, DOI 10.1179/1973947815Y.0000000027; Villano JL, 2015, NEURO-ONCOLOGY, V17, P122, DOI 10.1093/neuonc/nou099; Wang BX, 2017, CLIN NEUROL NEUROSUR, V160, P96, DOI 10.1016/j.clineuro.2017.06.022; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Yang B, 2019, LUNG CANCER, V129, P28, DOI 10.1016/j.lungcan.2018.12.027; Yang XJ, 2022, J IMMUNOL RES, V2022, DOI 10.1155/2022/4518898; Zhou CC, 2021, J THORAC ONCOL, V16, P1501, DOI 10.1016/j.jtho.2021.04.011; Zhou J, 2018, BIOCHEM BIOPH RES CO, V498, P751, DOI 10.1016/j.bbrc.2018.03.053; Zhou SJ, 2021, CANCER LETT, V502, P166, DOI 10.1016/j.canlet.2020.12.043	41	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 27	2022	13								955944	10.3389/fimmu.2022.955944	http://dx.doi.org/10.3389/fimmu.2022.955944			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5R5TS	36238280	gold, Green Published			2022-12-18	WOS:000874573400001
J	Feng, SS; Liang, XS; Li, J; Wang, ZY; Zhang, H; Dai, ZY; Luo, P; Liu, ZQ; Zhang, J; Xiao, XX; Cheng, Q				Feng, Songshan; Liang, Xisong; Li, Jing; Wang, Zeyu; Zhang, Hao; Dai, Ziyu; Luo, Peng; Liu, Zaoqu; Zhang, Jian; Xiao, Xiaoxiong; Cheng, Quan			Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM	FRONTIERS IN IMMUNOLOGY			English	Article						immunogenic cell death; risk model; ferroptosis; prognosis; immunotherapy; glioblastoma	CANCER; DISCOVERY	Immunogenic cell death (ICD) is a type of cell death that leads to the regulation and activation of the immune response, which is marked by the exposure and delivery of damage-associated molecular patterns (DAMPs) in the tumor microenvironment. Accumulating evidence has revealed the significance of ICD-related genes in tumor progression and therapeutic response. In this study, we obtained two ICD-related clusters for glioblastoma (GBM) by applying consensus clustering, and further constructed a risk signature on account of the prognostic ICD genes. Based on the risk signature, we found that higher risk scores were associated with worse patient prognosis. Besides, the results illustrated that ferroptosis regulators/markers were highly enriched the high-risk group, and ferroptosis were correlated with cytokine signaling pathway and other immune-related pathways. We also discovered that high-risk scores were correlated to specific immune infiltration patterns and good response to immune checkpoint blockade (ICB) treatment. In conclusion, our study highlights the significance of ICD-related genes as prognostic biomarkers and immune response indicators in GBM. And the risk signature integrating prognostic genes possessed significant potential value to predict the prognosis of patients and the efficacy of ICB treatment.	[Feng, Songshan; Liang, Xisong; Wang, Zeyu; Zhang, Hao; Dai, Ziyu; Cheng, Quan] Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China; [Feng, Songshan; Cheng, Quan] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China; [Feng, Songshan] Cent South Univ, Xiangya Hosp, Xiangya Canc Ctr, Changsha, Peoples R China; [Feng, Songshan] Key Lab Mol Radiat Oncol Hunan Prov, Changsha, Peoples R China; [Li, Jing] Cent South Univ, Xiangya Hosp 2, Dept Rehabil, Changsha, Peoples R China; [Luo, Peng; Zhang, Jian] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China; [Liu, Zaoqu] Zhengzhou Univ, Hosp 1, Dept Intervent Radiol, Zhengzhou, Peoples R China; [Xiao, Xiaoxiong] Cent South Univ, Xiangya Hosp, Dept Thorac Surg, Changsha, Peoples R China; [Cheng, Quan] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University; Southern Medical University - China; Zhengzhou University; Central South University; Central South University	Cheng, Q (corresponding author), Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China.; Cheng, Q (corresponding author), Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.; Xiao, XX (corresponding author), Cent South Univ, Xiangya Hosp, Dept Thorac Surg, Changsha, Peoples R China.; Cheng, Q (corresponding author), Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Peoples R China.	xiaoxx1988@csu.edu.cn; chengquan@csu.edu.cn			National Natural Science Foundation of China; Hunan Provincial Natural Science Foundation of China; Hunan Provincial Health Committee Foundation of China; Natural Science Foundation General Program of Changsha City; Xiangya Hospital Central South University postdoctoral foundation;  [82102848];  [82073893];  [81703622];  [2020JJ8111];  [2022JJ20095];  [2022JJ40830];  [202204044869];  [kq2014290]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Hunan Provincial Health Committee Foundation of China; Natural Science Foundation General Program of Changsha City; Xiangya Hospital Central South University postdoctoral foundation; ; ; ; ; ; ; ; 	Funding This work was supported by the National Natural Science Foundation of China (NO.82102848, NO.82073893, NO.81703622); Hunan Provincial Natural Science Foundation of China (No.2020JJ8111, NO.2022JJ20095, 2022JJ40830); Hunan Provincial Health Committee Foundation of China (NO.202204044869); Natural Science Foundation General Program of Changsha City (kq2014290); and Xiangya Hospital Central South University postdoctoral foundation.	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Arrieta V, 2021, NEURO-ONCOLOGY, V23, P17, DOI 10.1038/s43018-021-00260-2; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Casili Giovanna, 2018, Oncotarget, V9, P37564, DOI 10.18632/oncotarget.26500; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen X, 2021, NAT REV CLIN ONCOL, V18, P280, DOI 10.1038/s41571-020-00462-0; Decraene B, 2022, GENES IMMUN, V23, P1, DOI 10.1038/s41435-021-00161-5; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Efimova I, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001369; Finotello F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0638-6; Formenti SC, 2018, NAT MED, V24, P1845, DOI 10.1038/s41591-018-0232-2; Fu JX, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-0721-z; Fucikova J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03221-2; Galluzzi L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000337; Garg AD, 2014, CELL DEATH DIFFER, V21, P26, DOI 10.1038/cdd.2013.48; Garg AD, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1386829; Garg AD, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1069938; Gong J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0316-z; Guo QL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.654388; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; HOERL AE, 1970, TECHNOMETRICS, V12, P69, DOI 10.2307/1267352; Jackson CM, 2019, NAT IMMUNOL, V20, P1100, DOI 10.1038/s41590-019-0433-y; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580-020-00324-8; Kepp O, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1637188; Kroemer G, 2022, NAT IMMUNOL, V23, P487, DOI 10.1038/s41590-022-01132-2; Lamano JB, 2019, CLIN CANCER RES, V25, P3643, DOI 10.1158/1078-0432.CCR-18-2402; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Liu TQ, 2022, NEURO-ONCOLOGY, V24, P1113, DOI 10.1093/neuonc/noac033; Luo X, 2021, CELL DEATH DIFFER, V28, P1971, DOI 10.1038/s41418-020-00719-2; McGrail DJ, 2020, CANCER CELL, V37, P371, DOI 10.1016/j.ccell.2020.01.011; Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487; Nagata S, 2017, NAT REV IMMUNOL, V17, P333, DOI 10.1038/nri.2016.153; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ostrom QT, 2019, NEURO-ONCOLOGY, V21, pV1, DOI 10.1093/neuonc/noz150; Racle J, 2017, ELIFE, V6, DOI 10.7554/eLife.26476; Reardon DA, 2020, JAMA ONCOL, V6, P1003, DOI 10.1001/jamaoncol.2020.1024; Schubert M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02391-6; Serrano-del Valle A, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00050; Shi L, 2022, FEBS J, V289, P3655, DOI 10.1111/febs.16034; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan AC, 2020, CA-CANCER J CLIN, V70, P299, DOI 10.3322/caac.21613; Tang DL, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2020.1862949; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Tewari R, 2012, J MOL MED, V90, P67, DOI 10.1007/s00109-011-0807-6; Vanmeerbeek I, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1703449; Wang WM, 2019, NATURE, V569, P270, DOI 10.1038/s41586-019-1170-y; Wang XW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.781466; Wen PY, 2016, NAT REV NEUROL, V12, P69, DOI 10.1038/nrneurol.2015.242; Xun Y, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01191-2; Yang KY, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01513-z; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhou N, 2020, DATABASE-OXFORD, DOI 10.1093/database/baaa021	58	1	1	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 26	2022	13								992855	10.3389/fimmu.2022.992855	http://dx.doi.org/10.3389/fimmu.2022.992855			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5I2GU	36248827	Green Published, gold			2022-12-18	WOS:000868182700001
J	Lu, GL; Baertsch, MA; Hickey, JW; Goltsev, Y; Rech, AJ; Mani, L; Forgo, E; Kong, C; Jiang, SZ; Nolan, GP; Rosenthal, EL				Lu, Guolan; Baertsch, Marc A.; Hickey, John W.; Goltsev, Yury; Rech, Andrew J.; Mani, Lucas; Forgo, Erna; Kong, Christina; Jiang, Sizun; Nolan, Garry P.; Rosenthal, Eben L.			A real-time GPU-accelerated parallelized image processor for large-scale multiplexed fluorescence microscopy data	FRONTIERS IN IMMUNOLOGY			English	Article						image processing; highly multiplexed imaging; CODEX imaging; image deconvolution; drift compensation; GPU acceleration; parallel computing; big data		Highly multiplexed, single-cell imaging has revolutionized our understanding of spatial cellular interactions associated with health and disease. With ever-increasing numbers of antigens, region sizes, and sample sizes, multiplexed fluorescence imaging experiments routinely produce terabytes of data. Fast and accurate processing of these large-scale, high-dimensional imaging data is essential to ensure reliable segmentation and identification of cell types and for characterization of cellular neighborhoods and inference of mechanistic insights. Here, we describe RAPID, a Real-time, GPU-Accelerated Parallelized Image processing software for large-scale multiplexed fluorescence microscopy Data. RAPID deconvolves large-scale, high-dimensional fluorescence imaging data, stitches and registers images with axial and lateral drift correction, and minimizes tissue autofluorescence such as that introduced by erythrocytes. Incorporation of an open source CUDA-driven, GPU-assisted deconvolution produced results similar to fee-based commercial software. RAPID reduces data processing time and artifacts and improves image contrast and signal-to-noise compared to our previous image processing pipeline, thus providing a useful tool for accurate and robust analysis of large-scale, multiplexed, fluorescence imaging data.	[Lu, Guolan; Mani, Lucas; Rosenthal, Eben L.] Stanford Univ, Sch Med, Dept Otolaryngol, Stanford, CA 94305 USA; [Lu, Guolan; Baertsch, Marc A.; Hickey, John W.; Goltsev, Yury; Rech, Andrew J.; Nolan, Garry P.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Lu, Guolan; Baertsch, Marc A.; Hickey, John W.; Goltsev, Yury; Rech, Andrew J.; Forgo, Erna; Kong, Christina; Nolan, Garry P.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Baertsch, Marc A.] Heidelberg Univ Hosp, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany; [Jiang, Sizun] Harvard Med Sch, Ctr Virol & Vaccine Res, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Rosenthal, Eben L.] Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nashville, CA 37235 USA	Stanford University; Stanford University; Stanford University; Ruprecht Karls University Heidelberg; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rosenthal, EL (corresponding author), Stanford Univ, Sch Med, Dept Otolaryngol, Stanford, CA 94305 USA.; Nolan, GP (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.; Nolan, GP (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.; Rosenthal, EL (corresponding author), Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nashville, CA 37235 USA.	gnolan@stanford.edu; elr@stanford.edu		Hickey, John/0000-0001-9961-7673	U.S. National Institutes of Health [5R01CA238686-02, 5R01CA239257-03, 5U54CA2 0997103]; Bill & Melinda Gates Foundation [INV-002704]; Stanford Molecular Imaging Scholars (SMIS) Program [NIH T32CA118681]; 2021 Stanford Cancer Institute (SCI) Innovation Award; National Cancer Institute [NIH K99CA267171]; Career Development Award of the International Myeloma Society; NIH T32 Fellowship [T32CA196585]; American Cancer Society -Roaring Fork Valley Postdoctoral Fellowship [PF-20-032-01-CSM]; Stanford Translational Research and Applied Medicine grant	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Stanford Molecular Imaging Scholars (SMIS) Program; 2021 Stanford Cancer Institute (SCI) Innovation Award; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Career Development Award of the International Myeloma Society; NIH T32 Fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society -Roaring Fork Valley Postdoctoral Fellowship(American Cancer Society); Stanford Translational Research and Applied Medicine grant	This work was supported by the U.S. National Institutes of Health (5R01CA238686-02, 5R01CA239257-03, 5U54CA2 0997103), and Bill & Melinda Gates Foundation INV-002704 (SJ & GPN). GL was supported by the Stanford Molecular Imaging Scholars (SMIS) Program (NIH T32CA118681), the 2021 Stanford Cancer Institute (SCI) Innovation Award, the Stanford Translational Research and Applied Medicine grant, and the National Cancer Institute (NIH K99CA267171). MB was funded by a Career Development Award of the International Myeloma Society. JH was supported by an NIH T32 Fellowship (T32CA196585), and an American Cancer Society -Roaring Fork Valley Postdoctoral Fellowship (PF-20-032-01-CSM).	Baertsch MA, 2022, TRENDS CANCER, V8, P164, DOI 10.1016/j.trecan.2021.11.004; Black S, 2021, NAT PROTOC, V16, P3802, DOI 10.1038/s41596-021-00556-8; Bruce MA, 2013, OPT EXPRESS, V21, P4766, DOI 10.1364/OE.21.004766; Chalfoun J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04567-y; Czech E, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3055-3; Davis AS, 2014, J HISTOCHEM CYTOCHEM, V62, P405, DOI 10.1369/0022155414531549; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; GROEN FCA, 1985, CYTOMETRY, V6, P81, DOI 10.1002/cyto.990060202; Hickey JW, 2022, NAT METHODS, V19, P284, DOI 10.1038/s41592-021-01316-y; Hickey JW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.727626; Ji AL, 2020, CELL, V182, P497, DOI 10.1016/j.cell.2020.05.039; Kennedy-Darling J, 2021, EUR J IMMUNOL, V51, P1262, DOI 10.1002/eji.202048891; Lee MY, 2022, BMC BIOINFORMATICS, V23, DOI 10.1186/s12859-022-04570-9; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Pertuz S, 2013, PATTERN RECOGN, V46, P1415, DOI 10.1016/j.patcog.2012.11.011; Phillips D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26974-6; Reddy BS, 1996, IEEE T IMAGE PROCESS, V5, P1266, DOI 10.1109/83.506761; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Sage D., 2021, MIJ RUNNING IMAGEJ F; Schapiro D, 2022, NAT METHODS, V19, P311, DOI 10.1038/s41592-021-01308-y; Schurch CM, 2020, CELL, V182, P1341, DOI 10.1016/j.cell.2020.07.005; Stringer C, 2021, NAT METHODS, V18, P100, DOI 10.1038/s41592-020-01018-x; Zuiderveld K., 1994, GRAPHICS GEMS, P474	24	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 23	2022	13								981825	10.3389/fimmu.2022.981825	http://dx.doi.org/10.3389/fimmu.2022.981825			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5S6KQ	36211386	Green Published, gold			2022-12-18	WOS:000875296700001
J	Cheng, LL; Li, HL; Zhan, HT; Liu, YM; Li, XM; Huang, Y; Wang, L; Zhang, FC; Li, YZ				Cheng, Linlin; Li, Haolong; Zhan, Haoting; Liu, Yongmei; Li, Xiaomeng; Huang, Yuan; Wang, Li; Zhang, Fengchun; Li, Yongzhe			Alterations of m6A RNA methylation regulators contribute to autophagy and immune infiltration in primary Sjogren's syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						primary Sjogren's syndrome; m6A; autophagy; immune microenvironment; GEO	CELLS	N6-methyladenosine (m6A) RNA modification is a new epigenetic regulation mechanism on eukaryotic mRNA. Few autoimmune diseases focused on the role of m6A in their pathogenies, and m6A modulation in the pathological process of primary Sjogren's syndrome (pSS) is still unknown. In this work, three microarray datasets of pSS patients were downloaded from the GEO database: datasets #1 and #2 from the whole peripheral blood (PB) samples, dataset #3 from the labial salivary gland tissue samples, as well as a PB cohort collected from our hospital. Six differentially expressed m6A regulators were identified by comparing the PB dataset #1 of pSS and healthy controls using the Wilcox test and logistic regression analysis. Among them, four (ALKBH5, RBMX, RBM15B, and YTHDF1) were confirmed as down-regulated in PB dataset #2 and in our PB cohort by RT-PCR, and four (ALKBH5, METTL3, RBM15B, and YTHDF1) were confirmed as down-regulated in the dataset #3 of the labial gland tissue. In addition, discrepantly expressed m6A regulators accompanied by diverse immunocytes, including dendritic cells (DCs), T cells, and CD56dim natural killer cells, and among the regulators, ALKBH5 and METTL3 were comprehensively linked with the infiltrated immune cells. Notably, the most enriched autophagy mechanism mediated by m6A was observed in pSS using functional annotation analysis. Ten hub genes were identified using a protein-protein interaction network, and their expression in PB dataset #2 and the expression of three genes (PIK3CA, STAT1, and MAPK3) in the labial gland tissue dataset #3 were confirmed. Our study provides evidence that m6A methylation is widely involved in the immune infiltration and autophagy of pSS, thus contributing to the pathogenesis of this disease and potentially representing a novel therapeutic target.	[Cheng, Linlin; Li, Haolong; Zhan, Haoting; Liu, Yongmei; Li, Xiaomeng; Huang, Yuan; Wang, Li; Zhang, Fengchun; Li, Yongzhe] Peking Union Med Coll Hosp, Chinese Acad Med Sci & Peking Union Med Coll, Dept Clin Lab, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China; [Li, Xiaomeng] Peking Union Med Coll Hosp, Dept Med Res Ctr, Chinese Acad Med Sci & Peking Union Med Coll, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Li, YZ (corresponding author), Peking Union Med Coll Hosp, Chinese Acad Med Sci & Peking Union Med Coll, Dept Clin Lab, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China.	yongzhelipumch@126.com			National Key Research and Development Program of China; National Natural Science Foundation of China; Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project;  [2018YFE0207300];  [81871302];  [ZK201000]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project; ; ; 	Funding This work was supported by the National Key Research and Development Program of China (2018YFE0207300), the National Natural Science Foundation of China (81871302), and Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project (No. ZK201000)	Alessandri C, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1385-y; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Barrera MJ, 2021, RHEUMATOLOGY, V60, P1951, DOI 10.1093/rheumatology/keaa670; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Chang GQ, 2020, CANCER CELL, V38, P857, DOI 10.1016/j.ccell.2020.10.004; Chen XC, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00661-x; Colafrancesco S, 2022, ARTHRITIS RHEUMATOL, V74, P654, DOI 10.1002/art.42018; Colafrancesco S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02317-6; Feng MD, 2021, BLOOD, V138, P71, DOI 10.1182/blood.2020009676; Han DL, 2019, NATURE, V566, P270, DOI 10.1038/s41586-019-0916-x; Hillen MR, 2019, RHEUMATOLOGY, V58, P2305, DOI 10.1093/rheumatology/kez195; Huang BX, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00415; Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li T, 2021, J INFLAMM RES, V14, P4245, DOI 10.2147/JIR.S327152; Liang DF, 2022, AUTOPHAGY, V18, P1318, DOI 10.1080/15548627.2021.1974175; Lin ZY, 2020, EMBO J, V39, DOI 10.15252/embj.2019103181; Liu Y, 2021, CELL METAB, V33, P1221, DOI 10.1016/j.cmet.2021.04.001; Luo Q, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5735279; Luo Q, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/8193895; Luo Q, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1298; Mariette X, 2018, NEW ENGL J MED, V378, P931, DOI 10.1056/NEJMcp1702514; Mingueneau M, 2016, J ALLERGY CLIN IMMUN, V137, P1809, DOI 10.1016/j.jaci.2016.01.024; Mo XB, 2019, J NEUROL, V266, P2699, DOI 10.1007/s00415-019-09476-w; Mo XB, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00299; Nie K, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.782636; Ozaki Y, 2010, CLIN EXP IMMUNOL, V159, P315, DOI 10.1111/j.1365-2249.2009.04071.x; Peng ZS, 2022, MOL THER, V30, P932, DOI 10.1016/j.ymthe.2021.09.016; Ramos-Casals M, 2012, BMJ-BRIT MED J, V344, DOI [10.1136/bmj.e3821, 10.1024/1661-8157/a001133]; Tu ZW, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00642; Tzioufas AG, 2012, J AUTOIMMUN, V39, P4, DOI 10.1016/j.jaut.2012.01.002; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Vogelsang P, 2010, ANN RHEUM DIS, V69, P1235, DOI 10.1136/ard.2009.118158; Wang HM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09903-6; Wang JH, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/3120391; Wang YM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.755691; Wardowska A, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14030218; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zhan HT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.794800; Zhang XQ, 2021, J CELL MOL MED, V25, P3634, DOI 10.1111/jcmm.16469; Zhou J, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg0470; Zhu HT, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1159-2	42	1	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2022	13								949206	10.3389/fimmu.2022.949206	http://dx.doi.org/10.3389/fimmu.2022.949206			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5P1MY	36203590	gold, Green Published			2022-12-18	WOS:000872924700001
J	Zhu, GS; Guo, M; Zhao, JX; Zhang, H; Wang, G; Chen, W				Zhu, Guangsu; Guo, Min; Zhao, Jianxin; Zhang, Hao; Wang, Gang; Chen, Wei			Bifidobacterium breve intervention combined with environmental enrichment alleviates cognitive impairment by regulating the gut microbiota and microbial metabolites in Alzheimer's disease mice	FRONTIERS IN IMMUNOLOGY			English	Article						Alzheimer's disease; Bifidobacterium breve; environmental enrichment; gut microbiota; acetate; tryptophan metabolism; gut-brain axis		Alzheimer's disease (AD) is characterized by behavioral and cognitive impairments and its increasing prevalence imposes a healthcare burden on society. To date, most intervention studies have only focused on a single AD-related factor and have yielded modest cognitive improvements. Here, we show that environmental enrichment (EE) training combined with Bifidobacterium breve CCFM1025 intervention significantly alleviated amyloid-beta (A beta)-induced cognitive impairment and inhibited neuroinflammation in mice. Moreover, we found that EE combined with B. breve CCFM1025 treatment restored AD-associated gut microbiota dysbiosis and reversed microbial metabolites changes. By integrating behavioral and neurological data with metabolomic profiles, we corroborated the microbiota-metabolite-brain interactions, with acetate and tryptophan metabolism as potential drivers. Taken together, our results provide a promising multidomain intervention strategy to prevent cognitive decline and delay the progression of AD through a combination of dietary microbiome-based approaches and lifestyle interventions.	[Zhu, Guangsu; Guo, Min; Zhao, Jianxin; Zhang, Hao; Wang, Gang; Chen, Wei] Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi, Peoples R China; [Zhu, Guangsu; Guo, Min; Zhao, Jianxin; Zhang, Hao; Wang, Gang; Chen, Wei] Jiangnan Univ, Sch Food Sci & Technol, Wuxi, Peoples R China; [Zhao, Jianxin; Zhang, Hao; Wang, Gang] Jiangnan Univ, Yangzhou Inst Food Biotechnol, Yangzhou, Peoples R China; [Zhang, Hao; Chen, Wei] Jiangnan Univ, Natl Engn Ctr Funct Food, Wuxi, Peoples R China	Jiangnan University; Jiangnan University; Jiangnan University; Jiangnan University	Wang, G (corresponding author), Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi, Peoples R China.; Wang, G (corresponding author), Jiangnan Univ, Sch Food Sci & Technol, Wuxi, Peoples R China.; Wang, G (corresponding author), Jiangnan Univ, Yangzhou Inst Food Biotechnol, Yangzhou, Peoples R China.	wanggang@jiangnan.edu.cn	Chen, Wei/GZK-7348-2022		National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities;  [31972052];  [32021005];  [31820103010];  [JUSRP22006];  [JUSRP51501]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); ; ; ; ; 	Funding This work was supported by the National Natural Science Foundation of China (No. 31972052, 32021005, 31820103010), the Fundamental Research Funds for the Central Universities (JUSRP22006, JUSRP51501).	Abraham D, 2019, EXP GERONTOL, V115, P122, DOI 10.1016/j.exger.2018.12.005; Boehme M., 2021, NAT AGING, V1, P666, DOI [https://doi.org/10.1038/s43587-021-00093-9, DOI 10.1038/S43587-021-00093-9, 10.1038/s43587-021-00093-9]; Choi SH, 2018, SCIENCE, V361, P991, DOI 10.1126/science.aan8821; Cryan JF, 2020, LANCET NEUROL, V19, P179, DOI 10.1016/S1474-4422(19)30356-4; Dinan TG, 2013, BIOL PSYCHIAT, V74, P720, DOI 10.1016/j.biopsych.2013.05.001; Erny D, 2021, CELL METAB, V33, P2260, DOI 10.1016/j.cmet.2021.10.010; Fischer A, 2016, NEUROIMAGE, V131, P42, DOI 10.1016/j.neuroimage.2015.11.039; Hertel J, 2019, CELL REP, V29, P1767, DOI 10.1016/j.celrep.2019.10.035; Kempermann G, 2019, NAT REV NEUROSCI, V20, P235, DOI 10.1038/s41583-019-0120-x; Kivipelto M, 2018, NAT REV NEUROL, V14, P653, DOI 10.1038/s41582-018-0070-3; Knox EG, 2022, MOL PSYCHIATR, V27, P2659, DOI 10.1038/s41380-022-01511-z; Ling ZX, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.634069; Lourenco MV, 2019, NAT MED, V25, P165, DOI 10.1038/s41591-018-0275-4; Lupori L, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2021.110212; Mars RAT, 2020, CELL, V182, P1460, DOI 10.1016/j.cell.2020.08.007; Morkl S, 2020, CURR NUTR REP, V9, P171, DOI 10.1007/s13668-020-00313-5; Morais LH, 2021, NAT REV MICROBIOL, V19, P241, DOI 10.1038/s41579-020-00460-0; Needham BD, 2020, NAT REV NEUROSCI, V21, P717, DOI 10.1038/s41583-020-00381-0; Scheltens P, 2021, LANCET, V397, P1577, DOI 10.1016/S0140-6736(20)32205-4; Shamsipour S, 2021, J MOL NEUROSCI, V71, P1495, DOI 10.1007/s12031-021-01812-y; Sztainberg Y, 2010, NAT PROTOC, V5, P1535, DOI 10.1038/nprot.2010.114; Teglas T, 2020, BIOGERONTOLOGY, V21, P807, DOI 10.1007/s10522-020-09895-7; Tian PJ, 2022, BRAIN BEHAV IMMUN, V100, P233, DOI 10.1016/j.bbi.2021.11.023; Tian PJ, 2021, MOL NUTR FOOD RES, V65, DOI 10.1002/mnfr.202000704; Tian PJ, 2020, NEUROBIOL STRESS, V12, DOI 10.1016/j.ynstr.2020.100216; Vogt NM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13601-y; Wang XY, 2019, CELL RES, V29, P787, DOI 10.1038/s41422-019-0216-x; Wrann CD, 2013, CELL METAB, V18, P649, DOI 10.1016/j.cmet.2013.09.008; Wu SC, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.650047; Xiao Y, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01108-8; Zheng X, 2022, CELL METAB, V34, P35, DOI 10.1016/j.cmet.2021.12.011; Zhu GS, 2022, NUTRIENTS, V14, DOI 10.3390/nu14040735; Zhu GS, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051602; Zhu GS, 2018, FOOD FUNCT, V9, P3509, DOI 10.1039/c8fo00100f	34	1	1	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2022	13								1013664	10.3389/fimmu.2022.1013664	http://dx.doi.org/10.3389/fimmu.2022.1013664			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5P1DA	36203603	Green Published, gold			2022-12-18	WOS:000872898900001
J	Boodhoo, N; Behboudi, S				Boodhoo, Nitish; Behboudi, Shahriar			Marek's disease virus-specific T cells proliferate, express antiviral cytokines but have impaired degranulation response	FRONTIERS IN IMMUNOLOGY			English	Article						T cells; genetic resistance; genetic susceptibility; Marek's disease virus; immunodominant epitopes	INDUCED IMMUNOSUPPRESSION; RELATIVE EFFICACY; GENE-EXPRESSION; B-HAPLOTYPE; CHICKENS; HERPESVIRUS; INFECTION; RESISTANCE; PERFORIN; STRAIN	The major histocompatibility complex (MHC) haplotype is one of the major determinants of genetic resistance and susceptibility of chickens to Marek's disease (MD) which is caused by an oncogenic herpesvirus; Marek's disease virus (MDV). To determine differential functional abilities of T cells associated with resistance and susceptibility to MD, we identified immunodominant CD4+TCRv beta 1 T cell epitopes within the pp38 antigen of MDV in B19 and B21 MHC haplotype chickens using an ex vivo ELISPOT assay for chicken IFN-gamma. These novel pp38 peptides were used to characterize differential functional abilities of T cells as associated with resistance and susceptibility to MD. The results demonstrated an upregulation of cytokines (IL-2, IL-4, IL-10) and lymphocyte lysis-related genes (perforin and granzyme B) in an antigen specific manner using RT-PCR. In the MD-resistant chickens (B21 MHC haplotype), antigen-specific and non-specific response was highly skewed towards Th2 response as defined by higher levels of IL-4 expression as well as lymphocyte lysis-related genes compared to that in the MD-susceptible chicken line (B19 MHC haplotype). Using CD107a degranulation assay, the results showed that MDV infection impairs cytotoxic function of T cells regardless of their genetic background. Taken together, the data demonstrate an association between type of T cell response to pp38 and resistance to the disease and will shed light on our understanding of immune response to this oncogenic herpesvirus and failure to induce sterile immunity.	[Boodhoo, Nitish; Behboudi, Shahriar] Pirbright Inst, Avian Immunol, Woking, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Behboudi, S (corresponding author), Pirbright Inst, Avian Immunol, Woking, England.	shahriar.behboudi@pirbright.ac.uk		behboudi, shahriar/0000-0001-6455-4086	 [BBS/E/I/00007039]		Funding The authors would like to acknowledge the Pirbright Flow Cytometry facility and support through the Core capability grant (BBS/E/I/00007039).	Aung S, 2000, J IMMUNOL, V164, P3487, DOI 10.4049/jimmunol.164.7.3487; BACON LD, 1994, AVIAN DIS, V38, P65, DOI 10.2307/1591838; BACON LD, 1993, AVIAN DIS, V37, P53, DOI 10.2307/1591457; Bertzbach LD, 2020, CANCERS, V12, DOI 10.3390/cancers12030647; Boodhoo N, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.784359; Boodhoo N, 2020, J VIROL, V94, DOI 10.1128/JVI.01001-20; Boodhoo N, 2020, J VIROL, V94, DOI 10.1128/JVI.01680-19; Boodhoo N, 2019, J VIROL, V93, DOI 10.1128/JVI.00352-19; Boodhoo N, 2016, VET RES, V47, DOI 10.1186/s13567-016-0404-3; Boodhoo N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150134; BRILES WE, 1983, SCIENCE, V219, P977, DOI 10.1126/science.6823560; Brisbin JT, 2010, CLIN VACCINE IMMUNOL, V17, P1337, DOI 10.1128/CVI.00143-10; Chen C L, 1990, Semin Immunol, V2, P79; CHEN CH, 1989, P NATL ACAD SCI USA, V86, P2351, DOI 10.1073/pnas.86.7.2351; Fabricant CG, 1999, AM HEART J, V138, pS465, DOI 10.1016/S0002-8703(99)70276-0; Gao L, 2019, J VIROL, V93, DOI 10.1128/JVI.01934-18; Gimeno IM, 2018, AVIAN DIS, V62, P272, DOI 10.1637/11841-041318-Review.1; Gimeno IM, 1999, AVIAN DIS, V43, P721, DOI 10.2307/1592741; Gurung A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006745; Heidari M, 2022, VACCINE-X, V10, DOI 10.1016/j.jvacx.2021.100128; Heidari M, 2010, VIRAL IMMUNOL, V23, P309, DOI 10.1089/vim.2009.0079; Holt D, 2011, CANCER IMMUNOL IMMUN, V60, P1577, DOI 10.1007/s00262-011-1064-9; Janas ML, 2005, J IMMUNOL, V175, P8003, DOI 10.4049/jimmunol.175.12.8003; Kamble N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.801781; Kaufman J, 2000, PHILOS T R SOC B, V355, P1077, DOI 10.1098/rstb.2000.0645; Li K, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007999; Li ZG, 2009, CELL MOL IMMUNOL, V6, P415, DOI 10.1038/cmi.2009.53; Markowski-Grimsrud CJ, 2003, IMMUNOLOGY, V109, P283, DOI 10.1046/j.1365-2567.2003.01643.x; Martinet L, 2010, BIOCHEM PHARMACOL, V80, P838, DOI 10.1016/j.bcp.2010.05.002; Matsuyama-Kato A, 2022, VIROLOGY, V568, P115, DOI 10.1016/j.virol.2022.01.012; Miller MM, 2016, POULTRY SCI, V95, P375, DOI 10.3382/ps/pev379; Nair V, 2013, AVIAN DIS, V57, P360, DOI 10.1637/10470-121712-Reg.1; Omar AR, 1997, IMMUNOLOGY, V90, P579, DOI 10.1046/j.1365-2567.1997.00211.x; Omar AR, 1998, VET IMMUNOL IMMUNOP, V62, P73, DOI 10.1016/S0165-2427(97)00159-1; Omar AR, 1996, VIROLOGY, V222, P87, DOI 10.1006/viro.1996.0400; Osterrieder N, 2006, NAT REV MICROBIOL, V4, P283, DOI 10.1038/nrmicro1382; Park A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01859; Pei JW, 2003, VIROLOGY, V306, P376, DOI 10.1016/S0042-6822(02)00059-4; Read AF, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002198; Sarson AJ, 2008, VIRAL IMMUNOL, V21, P267, DOI 10.1089/vim.2007.0094; SHARMA JM, 1975, CANCER RES, V35, P711; Sun GR, 2019, VET IMMUNOL IMMUNOP, V212, P15, DOI 10.1016/j.vetimm.2019.04.010; Takeuchi A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00194; Tregaskes CA, 2021, MOL IMMUNOL, V135, P12, DOI 10.1016/j.molimm.2021.03.019	44	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2022	13								973762	10.3389/fimmu.2022.973762	http://dx.doi.org/10.3389/fimmu.2022.973762			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	4Z5II	36189228	gold, Green Published			2022-12-18	WOS:000862241800001
J	Davoudian, S; Piovani, D; Desai, A; Mapelli, SN; Leone, R; Sironi, M; Valentino, S; Silva-Gomes, R; Stravalaci, M; Asgari, F; Madera, A; Piccinini, D; Fedeli, C; Comina, D; Bonovas, S; Voza, A; Mantovani, A; Bottazzi, B				Davoudian, Sadaf; Piovani, Daniele; Desai, Antonio; Mapelli, Sarah N.; Leone, Roberto; Sironi, Marina; Valentino, Sonia; Silva-Gomes, Rita; Stravalaci, Matteo; Asgari, Fatemeh; Madera, Alessandra; Piccinini, Daniele; Fedeli, Carlo; Comina, Denise; Bonovas, Stefanos; Voza, Antonio; Mantovani, Alberto; Bottazzi, Barbara			A cytokine/PTX3 prognostic index as a predictor of mortality in sepsis	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; biomarkers; cytokines; PTX3; disease severity	RECEPTOR-TYPE II; PATTERN-RECOGNITION MOLECULE; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE UNITS; INNATE IMMUNITY; IL-1 RECEPTOR; PLASMA-LEVELS; SEPTIC SHOCK; CIRCULATING LEVELS; INTERFERON-GAMMA	BackgroundEarly prognostic stratification of patients with sepsis is a difficult clinical challenge. Aim of this study was to evaluate novel molecules in association with clinical parameters as predictors of 90-days mortality in patients admitted with sepsis at Humanitas Research Hospital. MethodsPlasma samples were collected from 178 patients, diagnosed based on Sepsis-3 criteria, at admission to the Emergency Department and after 5 days of hospitalization. Levels of pentraxin 3 (PTX3), soluble IL-1 type 2 receptor (sIL-1R2), and of a panel of pro- and anti-inflammatory cytokines were measured by ELISA. Cox proportional-hazard models were used to evaluate predictors of 90-days mortality. ResultsCirculating levels of PTX3, sIL-1R2, IL-1 beta, IL-6, IL-8, IL-10, IL-18, IL-1ra, TNF-alpha increased significantly in sepsis patients on admission, with the highest levels measured in shock patients, and correlated with SOFA score (PTX3: r=0.44, p<0.0001; sIL-1R2: r=0.35, p<0.0001), as well as with 90-days mortality. After 5 days of hospitalization, PTX3 and cytokines, but not sIL-1R2 levels, decreased significantly, in parallel with a general improvement of clinical parameters. The combination of age, blood urea nitrogen, PTX3, IL-6 and IL-18, defined a prognostic index predicting 90-days mortality in Sepsis-3 patients and showing better apparent discrimination capacity than the SOFA score (AUC=0.863, 95% CI: 0.780-0.945 vs. AUC=0.727, 95% CI: 0.613-0.840; p=0.021 respectively). ConclusionThese data suggest that a prognostic index based on selected cytokines, PTX3 and clinical parameters, and hence easily adoptable in clinical practice, performs in predicting 90-days mortality better than SOFA. An independent validation is required.	[Davoudian, Sadaf; Mapelli, Sarah N.; Leone, Roberto; Sironi, Marina; Valentino, Sonia; Silva-Gomes, Rita; Stravalaci, Matteo; Asgari, Fatemeh; Mantovani, Alberto; Bottazzi, Barbara] IRCCS Humanitas Res Hosp, Dept Res Inflammat & Immunol, Milan, Italy; [Piovani, Daniele; Desai, Antonio; Madera, Alessandra; Piccinini, Daniele; Bonovas, Stefanos; Voza, Antonio; Mantovani, Alberto] Humanitas Univ, Dept Biomed Sci, Milan, Italy; [Desai, Antonio; Fedeli, Carlo; Comina, Denise; Voza, Antonio] IRCCS Humanitas Res Hosp, Dept Emergency, Milan, Italy; [Mantovani, Alberto] Queen Mary Univ London, William Harvey Res Inst, London, England	Humanitas University; University of London; Queen Mary University London	Mantovani, A; Bottazzi, B (corresponding author), IRCCS Humanitas Res Hosp, Dept Res Inflammat & Immunol, Milan, Italy.; Mantovani, A (corresponding author), Humanitas Univ, Dept Biomed Sci, Milan, Italy.; Mantovani, A (corresponding author), Queen Mary Univ London, William Harvey Res Inst, London, England.	Alberto.mantovani@humanitasresearch.it; barbara.bottazzi@humanitasresearch.it	Desai, Antonio/ABH-8942-2020; sironi, marina/AAB-5757-2020; mapelli, sarah natalia/AAC-6093-2022; Leone, Roberto/HGE-8714-2022; Valentino, Sonia/AAB-4066-2020; Voza, Antonio/AEW-4659-2022; Mantovani, Alberto/HCI-7449-2022	Desai, Antonio/0000-0003-4674-4905; sironi, marina/0000-0002-3342-1149; mapelli, sarah natalia/0000-0002-0129-2055; Leone, Roberto/0000-0003-4978-7847; Valentino, Sonia/0000-0001-8652-3168; Voza, Antonio/0000-0001-7309-6929; Mantovani, Alberto/0000-0001-5578-236X; Bonovas, Stefanos/0000-0001-6102-6579	European Sepsis Academy/Innovative Training Networks (ESA/ITN) from the European Commission (H2020-MSCA-ITN-2015) [676129]; Fundacao para a Ciencia e a Tecnologia (FCT) [PD/BD/114138/2016]; Associazione Italiana Ricerca sul Cancro (AIRC) [21147, 23465]	European Sepsis Academy/Innovative Training Networks (ESA/ITN) from the European Commission (H2020-MSCA-ITN-2015); Fundacao para a Ciencia e a Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	SD was supported by European Sepsis Academy/Innovative Training Networks (ESA/ITN) from the European Commission (H2020-MSCA-ITN-2015, Grant agreement Number: 676129). RS-G acknowledge financial support from Fundacao para a Ciencia e a Tecnologia (FCT) for Ph.D. grant PD/BD/114138/2016. This study has received funding from Associazione Italiana Ricerca sul Cancro (AIRC) [Special Program Metastatic disease: the key unmet need in oncology AIRC 5X1000 grant no 21147 and "Regulatory pathways of myeloid cells, inflammation and cancer" grant IG-2019 N. 23465].	AREND WP, 1994, J IMMUNOL, V153, P4766; Azzurri A, 2005, MICROBES INFECT, V7, P1, DOI 10.1016/j.micinf.2004.09.004; Bloos F, 2017, INTENS CARE MED, V43, P1602, DOI 10.1007/s00134-017-4782-4; Bonavia AS, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.940030; Bottazzi B, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.1.017006; Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305; Caironi P, 2017, EUR J CLIN INVEST, V47, P73, DOI 10.1111/eci.12704; Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2; Chen H, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11101906; Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8; D'Onofrio V, 2022, J INTENSIVE CARE, V10, DOI 10.1186/s40560-022-00602-x; De la Fuente M, 2015, CYTOKINE GROWTH F R, V26, P615, DOI 10.1016/j.cytogfr.2015.07.017; Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI [10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289; Doni A, 2015, J EXP MED, V212, P905, DOI 10.1084/jem.20141268; Eidt MV, 2016, CLIN CHIM ACTA, V453, P100, DOI 10.1016/j.cca.2015.12.009; Emmanuilidis K, 2002, SHOCK, V18, P301, DOI 10.1097/00024382-200210000-00002; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; Faix JD, 2013, CRIT REV CL LAB SCI, V50, P23, DOI 10.3109/10408363.2013.764490; Friedland JS, 1996, CRIT CARE MED, V24, P1775, DOI 10.1097/00003246-199611000-00003; Friedman G, 1997, J CRIT CARE, V12, P183, DOI 10.1016/S0883-9441(97)90030-7; Gao L, 2021, POSTGRAD MED, V133, P604, DOI 10.1080/00325481.2020.1823137; GARDLUND B, 1995, J INFECT DIS, V172, P296, DOI 10.1093/infdis/172.1.296; Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756; Garlanda C, 2018, PHYSIOL REV, V98, P623, DOI 10.1152/physrev.00016.2017; Garlanda C, 2013, SEMIN IMMUNOL, V25, P408, DOI 10.1016/j.smim.2013.10.019; Garlanda C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00180; GIRI JG, 1994, J IMMUNOL, V153, P5802; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; Grobmyer SR, 2000, J CLIN IMMUNOL, V20, P212, DOI 10.1023/A:1006641630904; Gronnesby J K, 1996, Lifetime Data Anal, V2, P315, DOI 10.1007/BF00127305; Gruyters I, 2022, ANAESTH INTENSIVE TH, V54, P3, DOI 10.5114/ait.2022.114048; HACK CE, 1989, BLOOD, V74, P1704; Hamed S, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2606-3; Henriquez-Camacho C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/547818; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hothorn T, 2003, COMPUT STAT DATA AN, V43, P121, DOI 10.1016/S0167-9473(02)00225-6; Jeannin P, 2005, IMMUNITY, V22, P551, DOI 10.1016/j.immuni.2005.03.008; Jiang Y, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0542-7; Jie HY, 2017, AM J MED SCI, V353, P242, DOI 10.1016/j.amjms.2017.01.003; Jouvenne P, 1998, ARTHRITIS RHEUM, V41, P1083, DOI 10.1002/1529-0131(199806)41:6<1083::AID-ART15>3.0.CO;2-9; Kamarudin AN, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0332-6; Kim H, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0252-y; Knoflach M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031474; Krychtiuk KA, 2018, CYTOKINE, V103, P109, DOI 10.1016/j.cyto.2017.09.017; Kumar S, 2019, BIOSENS BIOELECTRON, V124, P205, DOI 10.1016/j.bios.2018.10.034; Kyriakoudi A, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12010092; Kyriazopoulou E, 2022, ANTIBIOTICS-BASEL, V11, DOI 10.3390/antibiotics11030367; Kyriazopoulou E, 2021, CURR OPIN INFECT DIS, V34, P126, DOI 10.1097/QCO.0000000000000707; Lee YT, 2018, J INFECTION, V76, P1, DOI 10.1016/j.jinf.2017.10.016; Levy MM, 2018, CRIT CARE MED, V46, P997, DOI 10.1097/CCM.0000000000003119; Liu B, 2013, CRIT CARE, V17, DOI 10.1186/cc13070; Mairuhu ATA, 2005, J MED VIROL, V76, P547, DOI 10.1002/jmv.20397; Matsumoto H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32275-8; Mauri T, 2010, INTENS CARE MED, V36, P621, DOI 10.1007/s00134-010-1752-5; Mearelli F, 2018, CRIT CARE MED, V46, P1421, DOI 10.1097/CCM.0000000000003206; Mierzchala-Pasierb M, 2019, CYTOKINE, V120, P22, DOI 10.1016/j.cyto.2019.04.003; Molgora M, 2018, IMMUNOL REV, V281, P233, DOI 10.1111/imr.12609; Moons KGM, 2015, CLIN CHEM, V61, P565, DOI 10.1373/clinchem.2014.237883; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Muller B, 2002, J LEUKOCYTE BIOL, V72, P643; Muller B, 2001, CRIT CARE MED, V29, P1404, DOI 10.1097/00003246-200107000-00017; Niederman MS, 2008, CLIN INFECT DIS, V47, pS127, DOI 10.1086/591393; Niederman MS, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03736-w; Novick D, 2001, CYTOKINE, V14, P334, DOI 10.1006/cyto.2001.0914; Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59; Peters VA, 2013, BRAIN BEHAV IMMUN, V32, P1, DOI 10.1016/j.bbi.2012.11.006; Petrovic J, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5147364; Pierrakos C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02993-5; Pierrakos C, 2010, CRIT CARE, V14, DOI 10.1186/cc8872; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; Porte R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00794; PRUITT JH, 1995, SHOCK, V3, P235, DOI 10.1097/00024382-199504000-00001; Pruitt JH, 1996, BLOOD, V87, P3282; Ridker PM, 2020, EUR HEART J, V41, P2153, DOI 10.1093/eurheartj/ehz542; Rigato O, 2003, SHOCK, V19, P113, DOI 10.1097/00024382-200302000-00004; Royston P, 2008, MULTIVARIABLE MODEL; Rubio I, 2019, LANCET INFECT DIS, V19, pE422, DOI 10.1016/S1473-3099(19)30567-5; Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7; Saeed K, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2329-5; Seeley EJ, 2016, CLIN CHEST MED, V37, P181, DOI 10.1016/j.ccm.2016.01.015; Shukeri WFM, 2018, J CRIT CARE, V43, P163, DOI 10.1016/j.jcrc.2017.09.009; Simpson SQ, 2019, CRIT CARE MED, V47, P1656, DOI 10.1097/CCM.0000000000003983; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sinistro A, 2008, CLIN VACCINE IMMUNOL, V15, P1851, DOI 10.1128/CVI.00184-08; Slack JL, 2000, J BIOL CHEM, V275, P4670, DOI 10.1074/jbc.275.7.4670; So-Ngern A, 2019, INFECT CHEMOTHER, V51, P263, DOI 10.3947/ic.2019.51.3.263; Song J, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020495; Song J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4618-7; Teggert A, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11030286; Tschoeke SK, 2006, CRIT CARE MED, V34, P1225, DOI 10.1097/01.CCM.0000208356.05575.16; Uusitalo-Seppala R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053661; van der Poll T, 2008, LANCET INFECT DIS, V8, P32, DOI 10.1016/S1473-3099(07)70265-7; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; van Engelen TSR, 2018, CRIT CARE CLIN, V34, P139, DOI 10.1016/j.ccc.2017.08.010; vanderPoll T, 1997, J INFECT DIS, V175, P118, DOI 10.1093/infdis/175.1.118; vanDeuren M, 1997, BLOOD, V90, P1101, DOI 10.1182/blood.V90.3.1101.1101_1101_1108; Vega CA, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03048; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Walborn A, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620902849; Wang GB, 2022, CRIT CARE, V26, DOI 10.1186/s13054-022-04032-x; Ward NS., 2019, HUMANA PRESS, DOI [10.1007/978-3-319-48470-9, DOI 10.1007/978-3-319-48470-9]; Weighardt H, 2000, SURGERY, V127, P309, DOI 10.1067/msy.2000.104118; Xiao HY, 2006, INFECT IMMUN, V74, P5227, DOI 10.1128/IAI.01220-05	106	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2022	13								979232	10.3389/fimmu.2022.979232	http://dx.doi.org/10.3389/fimmu.2022.979232			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	4Z4PY	36189302	Green Published, gold			2022-12-18	WOS:000862194000001
J	Corona-Sanchez, EG; Martinez-Garcia, EA; Lujano-Benitez, AV; Pizano-Martinez, O; Guerra-Duran, IA; Chavarria-Avila, E; Aguilar-Vazquez, A; Martin-Marquez, BT; Arellano-Arteaga, KJ; Armendariz-Borunda, J; Perez-Vazquez, F; Garcia-De la Torre, I; Llamas-Garcia, A; Palacios-Zarate, BL; Toriz-Gonzalez, G; Vazquez-Del Mercado, M				Guadalupe Corona-Sanchez, Esther; Aurora Martinez-Garcia, Erika; Veronica Lujano-Benitez, Andrea; Pizano-Martinez, Oscar; Alejandra Guerra-Duran, Ivette; Chavarria-Avila, Efrain; Aguilar-Vazquez, Andrea; Teresita Martin-Marquez, Beatriz; Javier Arellano-Arteaga, Kevin; Armendariz-Borunda, Juan; Perez-Vazquez, Felipe; Garcia-De la Torre, Ignacio; Llamas-Garcia, Arcelia; Lucia Palacios-Zarate, Brenda; Toriz-Gonzalez, Guillermo; Vazquez-Del Mercado, Monica			Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?	FRONTIERS IN IMMUNOLOGY			English	Review						endoplasmic reticulum stress; idiopathic inflammatory myopathies; myositis specific antibodies; autophagy; myositis associated antibodies	UNFOLDED PROTEIN RESPONSE; SIGNAL RECOGNITION PROTEIN; RHEUMATOLOGY CLASSIFICATION CRITERIA; 2017 EUROPEAN LEAGUE; FACTOR-KAPPA-B; MHC CLASS-I; QUALITY-CONTROL; SKELETAL-MUSCLE; RHEUMATISM/AMERICAN COLLEGE; NASCENT PREPROLACTIN	Idiopathic inflammatory myopathies (IIMs) are a group of rare, acquired autoimmune diseases characterized by profound muscle weakness and immune cell invasion into non-necrotic muscle. They are related to the presence of antibodies known as myositis-specific antibodies and myositis-associated antibodies, which are associated with various IIM phenotypes and the clinical prognosis. The possibility of the participation of other pathological mechanisms involved in the inflammatory response in IIM has been proposed. Such mechanisms include the overexpression of major histocompatibility complex class I in myofibers, which correlates with the activation of stress responses of the endoplasmic reticulum (ER). Taking into account the importance of the ER for the maintenance of homeostasis of the musculoskeletal system in the regulation of proteins, there is probably a relationship between immunological and non-immunological processes and autoimmunity, and an example of this might be IIM. We propose that ER stress and its relief mechanisms could be related to inflammatory mechanisms triggering a humoral response in IIM, suggesting that ER stress might be related to the triggering of IIMs and their auto-antibodies' production.	[Guadalupe Corona-Sanchez, Esther; Aurora Martinez-Garcia, Erika; Veronica Lujano-Benitez, Andrea; Pizano-Martinez, Oscar; Alejandra Guerra-Duran, Ivette; Chavarria-Avila, Efrain; Aguilar-Vazquez, Andrea; Teresita Martin-Marquez, Beatriz; Vazquez-Del Mercado, Monica] Univ Guadalajara, Inst Invest Reumatol & Sistema Musculo Esquelet, Dept Biol Mol, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico; [Guadalupe Corona-Sanchez, Esther; Aurora Martinez-Garcia, Erika] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Fisiol, Guadalajara, Jalisco, Mexico; [Guadalupe Corona-Sanchez, Esther; Aurora Martinez-Garcia, Erika; Pizano-Martinez, Oscar; Teresita Martin-Marquez, Beatriz; Vazquez-Del Mercado, Monica] Univ Guadalajara, Cuerpo Acad UDG CA 703, Inmunol & Reumatol, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico; [Veronica Lujano-Benitez, Andrea; Aguilar-Vazquez, Andrea] Univ Guadalajara, Ctr Univ Ciencias Salud, Ciencias Biomed, Guadalajara, Jalisco, Mexico; [Pizano-Martinez, Oscar] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Morfol, Guadalajara, Jalisco, Mexico; [Chavarria-Avila, Efrain; Perez-Vazquez, Felipe] Univ Guadalajara, Dept Disciplinas Filosof Metodol & Instrumentales, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico; [Javier Arellano-Arteaga, Kevin] Consejo Nacl Ciencia & Tecnol CONACyT, Hosp Civil Guadalajara Dr Juan I Menchaca, Especialidad Med Interns, Padron Nacl Posgrad Calidad PNPC, Guadalajara, Jalisco, Mexico; [Armendariz-Borunda, Juan] Univ Guadalajara, Ctr Univ Ciencias Salud, Inst Biol Mol Med, Guadalajara, Jalisco, Mexico; [Armendariz-Borunda, Juan] Tecnol Monterrey, Escuela Med & Ciencias Salud, Zapopan, Mexico; [Garcia-De la Torre, Ignacio] Hosp Gen Occidente Seguro Social, Dept Inmunol & Reumatol, Guadalajara, Jalisco, Mexico; [Garcia-De la Torre, Ignacio] Univ Guadalajara, Guadalajara, Jalisco, Mexico; [Llamas-Garcia, Arcelia; Lucia Palacios-Zarate, Brenda; Vazquez-Del Mercado, Monica] Consejo Nacl Ciencia & Tecnol CONACyT, Padron Nacl Posgrad Calidad PNPC, Hosp Civil Guadalajara Dr Juan I Menchaca, Especialidad Reumatol, Guadalajara, Jalisco, Mexico; [Toriz-Gonzalez, Guillermo] Univ Guadalajara, Inst Transdisciplinar Invest & Serv ITRANS, Zapopan, Mexico	Universidad de Guadalajara; Universidad de Guadalajara; Universidad de Guadalajara; Universidad de Guadalajara; Universidad de Guadalajara; Universidad de Guadalajara; Universidad de Guadalajara; Tecnologico de Monterrey; Universidad de Guadalajara; Universidad de Guadalajara	Vazquez-Del Mercado, M (corresponding author), Univ Guadalajara, Inst Invest Reumatol & Sistema Musculo Esquelet, Dept Biol Mol, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico.; Vazquez-Del Mercado, M (corresponding author), Univ Guadalajara, Cuerpo Acad UDG CA 703, Inmunol & Reumatol, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico.; Vazquez-Del Mercado, M (corresponding author), Consejo Nacl Ciencia & Tecnol CONACyT, Padron Nacl Posgrad Calidad PNPC, Hosp Civil Guadalajara Dr Juan I Menchaca, Especialidad Reumatol, Guadalajara, Jalisco, Mexico.	dravme@hotmail.com	Pizano, Oscar/AGR-5765-2022; Vazquez-Del Mercado, Monica/F-5856-2017	Vazquez-Del Mercado, Monica/0000-0002-3823-4676; Perez-Vazquez, Felipe/0000-0003-0697-9371				Adams CJ, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00011; Adler BL, 2018, DISCOV MED, V25, P75; Adolf F, 2019, CELL REP, V26, P250, DOI 10.1016/j.celrep.2018.12.041; Agarraberes FA, 2001, BBA-BIOMEMBRANES, V1513, P1, DOI 10.1016/S0304-4157(01)00005-3; Aguilar-Vazquez A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672008; Allenbach Y, 2020, NAT REV RHEUMATOL, V16, P689, DOI 10.1038/s41584-020-00515-9; Amato AA, 2003, NEUROLOGY, V61, P288, DOI 10.1212/WNL.61.3.288; ARAHATA K, 1984, ANN NEUROL, V16, P193, DOI 10.1002/ana.410160206; Arana-Argaez VE, 2010, J BIOL CHEM, V285, P32824, DOI 10.1074/jbc.M110.121087; Arouche-Delaperche L, 2017, ANN NEUROL, V81, P538, DOI 10.1002/ana.24902; Balchin D, 2016, SCIENCE, V353, DOI 10.1126/science.aac4354; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Braakman I, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013201; Brandizzi F, 2013, NAT REV MOL CELL BIO, V14, P382, DOI 10.1038/nrm3588; Cai Y, 2016, AUTOPHAGY, V12, P225, DOI 10.1080/15548627.2015.1121360; Cao T, 2021, APPL MICROBIOL BIOT, V105, P4805, DOI 10.1007/s00253-021-11380-1; Cappelletti C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111490; Carrara M, 2013, INT J MOL SCI, V14, P6454, DOI 10.3390/ijms14036454; Ceribelli A, 2017, CLIN REV ALLERG IMMU, V52, P58, DOI 10.1007/s12016-016-8527-x; Chaudhari N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00213; Chen H, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1195; Chipurupalli S, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.758311; Coley W, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3791; Concha JSS, 2019, BRIT J DERMATOL, V180, P1001, DOI 10.1111/bjd.17536; Csala M, 2012, ANTIOXID REDOX SIGN, V16, P1100, DOI 10.1089/ars.2011.4227; da Costa CA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112495; Dalakas MC, 2015, NEW ENGL J MED, V372, P1734, DOI 10.1056/NEJMra1402225; Dalakas MC, 2003, LANCET, V362, P971, DOI 10.1016/S0140-6736(03)14368-1; Dalakas MC, 2006, NAT CLIN PRACT RHEUM, V2, P219, DOI 10.1038/ncprheum0140; Dalakas MC, 2006, NEUROLOGY, V66, pS33, DOI 10.1212/01.wnl.0000192129.65677.87; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Dudek J, 2015, J MOL BIOL, V427, P1159, DOI 10.1016/j.jmb.2014.06.011; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Ellgaard L, 2016, TRAFFIC, V17, P615, DOI 10.1111/tra.12392; Engin F, 2014, SCI REP-UK, V4, DOI 10.1038/srep04054; English AR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013227; Exeter D, 2010, SEMIN MUSCULOSKEL R, V14, P97, DOI 10.1055/s-0030-1253154; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Findlay AR, 2015, MUSCLE NERVE, V51, P638, DOI 10.1002/mus.24566; Fiorentino DF, 2013, ARTHRITIS RHEUM-US, V65, P2954, DOI 10.1002/art.38093; Fischer N, 2020, BRAIN PATHOL, V30, P261, DOI 10.1111/bpa.12772; Freret M, 2013, AM J PATHOL, V183, P893, DOI 10.1016/j.ajpath.2013.06.003; Friedman JR, 2011, TRENDS CELL BIOL, V21, P709, DOI 10.1016/j.tcb.2011.07.004; Frontera WR, 2015, CALCIFIED TISSUE INT, V96, P183, DOI 10.1007/s00223-014-9915-y; Galindo-Feria AS, 2022, BEST PRACT RES CL RH, V36, DOI 10.1016/j.berh.2022.101767; Gallo A, 2016, ANNU REV CELL DEV BI, V32, P279, DOI 10.1146/annurev-cellbio-111315-125024; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; Girolamo F, 2019, MUSCLE NERVE, V60, P315, DOI 10.1002/mus.26608; Gomez-Navarro N, 2016, J CELL BIOL, V215, P769, DOI 10.1083/jcb.201610031; Greenberg SA, 2019, NAT REV RHEUMATOL, V15, P257, DOI 10.1038/s41584-019-0186-x; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hebert DN, 2007, PHYSIOL REV, V87, P1377, DOI 10.1152/physrev.00050.2006; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; Helle SCJ, 2013, BBA-MOL CELL RES, V1833, P2526, DOI 10.1016/j.bbamcr.2013.01.028; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Henderson JM, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030625; Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z; Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017; Hillary RF, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0453-1; Hornung T, 2014, DRUGS, V74, P981, DOI 10.1007/s40265-014-0240-6; Hwang JW, 2018, TRENDS BIOCHEM SCI, V43, P593, DOI 10.1016/j.tibs.2018.06.005; Jain A, 2007, ARCH PATHOL LAB MED, V131, P1070; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kaneko M, 2003, BIOL PHARM BULL, V26, P931, DOI 10.1248/bpb.26.931; Karagoz GE, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a033886; Katsiougiannis S, 2015, CLIN EXP IMMUNOL, V181, P244, DOI 10.1111/cei.12638; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Kawasaki N, 2012, SCI REP-UK, V2, DOI 10.1038/srep00799; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Kohno K, 2010, J BIOCHEM, V147, P27, DOI 10.1093/jb/mvp196; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; Kurdi M, 2021, DEGENER NEUROL NEURO, V11, P61, DOI 10.2147/DNND.S340117; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; Lamark T, 2017, ESSAYS BIOCHEM, V61, P609, DOI 10.1042/EBC20170035; Lamark T, 2010, CURR OPIN CELL BIOL, V22, P192, DOI 10.1016/j.ceb.2009.11.002; Lamriben L, 2016, TRAFFIC, V17, P308, DOI 10.1111/tra.12358; Lanier LL, 1999, P NATL ACAD SCI USA, V96, P5343, DOI 10.1073/pnas.96.10.5343; Lee KH, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091057; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Lee YK, 1999, MOL BIOL CELL, V10, P2209, DOI 10.1091/mbc.10.7.2209; Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048; Li CL, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.627700; Loarce-Martos J, 2021, RHEUMATOLOGY, V60, P3398, DOI 10.1093/rheumatology/keaa801; Martinez ML, 2020, CURR OPIN RHEUMATOL, V32, P515, DOI 10.1097/BOR.0000000000000748; Lundberg I, 2000, ARTHRITIS RHEUM, V43, P336, DOI 10.1002/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V; Lundberg IE, 2016, J INTERN MED, V280, P39, DOI 10.1111/joim.12524; Lundberg IE, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00321-x; Lundberg IE, 2017, ARTHRITIS RHEUMATOL, V69, P2271, DOI 10.1002/art.40320; Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Ma X, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.791986; Ma X, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/s12872-021-01900-2; Malik A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00064; Mammen AL, 2011, NAT REV NEUROL, V7, P343, DOI 10.1038/nrneurol.2011.63; Mammen AL, 2011, ARTHRITIS RHEUM-US, V63, P713, DOI 10.1002/art.30156; Mari Muriel, 2011, F1000 Biol Rep, V3, P25, DOI 10.3410/B3-25; Mary C, 2010, RNA, V16, P969, DOI 10.1261/rna.2040410; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Mohassel Payam, 2018, J Neuromuscul Dis, V5, P11, DOI 10.3233/JND-170282; Momomura M, 2014, MOD RHEUMATOL, V24, P529, DOI 10.3109/14397595.2013.852852; Muro Y, 2016, CLIN REV ALLERG IMMU, V51, P293, DOI 10.1007/s12016-015-8496-5; Nagaraju K, 2005, ARTHRITIS RHEUM, V52, P1824, DOI 10.1002/art.21103; Nogalska A, 2010, AM J PATHOL, V177, P1377, DOI 10.2353/ajpath.2010.100050; Nyathi Y, 2013, BBA-MOL CELL RES, V1833, P2392, DOI 10.1016/j.bbamcr.2013.02.021; Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649; Oikawa Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231064; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; Parmar VM, 2012, ADV EXP MED BIOL, V738, P153, DOI 10.1007/978-1-4614-1680-7_10; Pinal-Fernandez I, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0732-6; Prell T, 2013, CELL CALCIUM, V54, P132, DOI 10.1016/j.ceca.2013.05.007; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Rassier DE, 2017, AM J PHYSIOL-CELL PH, V313, pC134, DOI 10.1152/ajpcell.00050.2017; Rayavarapu S, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044-5040-3-13; Rayavarapu S, 2012, CURR RHEUMATOL REP, V14, P238, DOI 10.1007/s11926-012-0247-5; REEVES WH, 1986, P NATL ACAD SCI USA, V83, P9507, DOI 10.1073/pnas.83.24.9507; Cruz PMR, 2014, NEUROMUSCULAR DISORD, V24, P1025, DOI 10.1016/j.nmd.2014.06.436; Rosen A, 2016, ANNU REV IMMUNOL, V34, P395, DOI 10.1146/annurev-immunol-032414-112205; Rothwell S, 2016, ANN RHEUM DIS, V75, P1558, DOI 10.1136/annrheumdis-2015-208119; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Ruggiano A, 2014, J CELL BIOL, V204, P868, DOI 10.1083/jcb.201312042; Saini I, 2016, RHEUMATOL INT, V36, P961, DOI 10.1007/s00296-016-3467-6; Saraogi I, 2011, TRAFFIC, V12, P535, DOI 10.1111/j.1600-0854.2011.01171.x; Satoh M, 2017, CLIN REV ALLERG IMMU, V52, P1, DOI 10.1007/s12016-015-8510-y; Schindler AJ, 2009, P NATL ACAD SCI USA, V106, P17775, DOI 10.1073/pnas.0910342106; Schmidt J, 2008, BRAIN, V131, P1228, DOI 10.1093/brain/awn053; Schwarz DS, 2016, CELL MOL LIFE SCI, V73, P79, DOI 10.1007/s00018-015-2052-6; Seifert U, 2010, CELL, V142, P613, DOI 10.1016/j.cell.2010.07.036; Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002; Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Sheshadri N, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04318-y; Simpson JC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062133; Sorrentino V, 2004, BBA-MOL CELL RES, V1742, P113, DOI 10.1016/j.bbamcr.2004.08.016; Stanley P, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005199; Tansley SL, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4198; Tawara N, 2017, ANN NEUROL, V81, P512, DOI 10.1002/ana.24919; Tiniakou E, 2017, CLIN REV ALLERG IMMU, V52, P20, DOI 10.1007/s12016-015-8511-x; Tirincsi A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010143; Tucci M, 2006, CLIN EXP IMMUNOL, V146, P21, DOI 10.1111/j.1365-2249.2006.03180.x; Unanue ER, 2014, DIABETES, V63, P48, DOI 10.2337/db13-1478; Uruha A, 2021, CURR RHEUMATOL REP, V23, DOI 10.1007/s11926-021-01017-7; Utz PJ, 1998, J BIOL CHEM, V273, P35362, DOI 10.1074/jbc.273.52.35362; Vattemi G, 2014, AUTOIMMUN HIGHLIGHTS, V5, P77, DOI 10.1007/s13317-014-0062-2; Vazquez-Del Mercado M, 2021, IMMUNOPHARM IMMUNOT, V43, P328, DOI 10.1080/08923973.2021.1910833; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang L, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-22-70; Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041; Wang P, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.648752; Wiendl H, 2003, HUM IMMUNOL, V64, P1050, DOI 10.1016/j.humimm.2003.07.001; Wild K, 2019, NUCLEIC ACIDS RES, V47, P3184, DOI 10.1093/nar/gky1324; Witkos TM, 2017, CURR OPIN CELL BIOL, V47, P16, DOI 10.1016/j.ceb.2017.02.003; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoo IS, 2019, J RHEUMAT DIS, V26, P165, DOI 10.4078/jrd.2019.26.3.165; Zhang H, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0536-7; Zheng DP, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0167-x	172	1	1	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2022	13								940122	10.3389/fimmu.2022.940122	http://dx.doi.org/10.3389/fimmu.2022.940122			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	4Z3ZS	36189221	Green Published, gold			2022-12-18	WOS:000862151800001
J	Huang, J; Wang, BJ; Tao, SY; Hu, YX; Wang, N; Zhang, QY; Wang, CH; Chen, C; Gao, BR; Cheng, XD; Li, YN				Huang, Jian; Wang, Bingjie; Tao, Shaoyi; Hu, Yuexia; Wang, Ning; Zhang, Qiaoyun; Wang, Chunhui; Chen, Chen; Gao, Bingren; Cheng, Xingdong; Li, Yongnan			D-tagatose protects against oleic acid-induced acute respiratory distress syndrome in rats by activating PTEN/PI3K/AKT pathway	FRONTIERS IN IMMUNOLOGY			English	Article						D-tagatose; acute respiratory distress syndrome; PTEN; PI3K; AKT pathway; oleic acid; alveolar	PULMONARY-FIBROSIS; LUNG; GROWTH; PTEN; PHOSPHATASE; MECHANISMS; APOPTOSIS	Acute respiratory distress syndrome (ARDS) is characterized by disruption of the alveolar-capillary barrier, resulting in severe alveolar edema and inflammation. D-tagatose (TAG) is a low-calorie fructose isomer with diverse biological activities whose role in ARDS has never been explored. We found that TAG protects lung tissues from injury in the oleic acid-induced rat model of ARDS. Seventeen male Sprague-Dawley rats were randomly assigned to 3 groups: Sham (n = 5), ARDS (n = 6), and TAG + ARDS (n = 6). The treatment groups were injected with oleic acid to induce ARDS, and the TAG + ARDS group was given TAG 3 days before the induction. After the treatments, the effect of TAG was evaluated by blood gas analysis and observing the gross and histological structure of the lung. The results showed that TAG significantly improved the oxygenation function, reduced the respiratory acidosis and the inflammatory response. TAG also improved the vascular permeability in ARDS rats and promoted the differentiation of alveolar type II cells, maintaining the stability of the alveolar structure. This protective effect of TAG on the lung may be achieved by activating the PTEN/PI3K/AKT pathway. Thus, TAG protects against oleic acid-induced ARDS in rats, suggesting a new clinical strategy for treating the condition.	[Huang, Jian; Zhang, Qiaoyun; Gao, Bingren; Cheng, Xingdong; Li, Yongnan] Lanzhou Univ, Hosp 2, Dept Cardiac Surg, Lanzhou, Peoples R China; [Wang, Bingjie; Hu, Yuexia; Wang, Ning; Wang, Chunhui; Chen, Chen] Anhui Med Univ, Dept Anesthesiol, Affiliated Hosp 4, Hefei, Peoples R China; [Tao, Shaoyi] Anhui Med Univ, Peoples Hosp Hefei 2, Dept Plast Repair Burn Surg Dermatol, Hefei Hosp, Hefei, Peoples R China; [Wang, Ning] Anhui Med Univ, Anhui Higher Educ Inst, Key Lab Anesthesiol & Perioperat Med, Hefei, Peoples R China	Lanzhou University; Anhui Medical University; Anhui Medical University; Anhui Medical University	Gao, BR; Cheng, XD; Li, YN (corresponding author), Lanzhou Univ, Hosp 2, Dept Cardiac Surg, Lanzhou, Peoples R China.			Li, Yongnan/0000-0003-0821-8875	Basic and Clinical Cooperative Research Promotion Program of Anhui Medical University [2020xkjT046]; Anhui Medical University [2019xkj144]; Open Research fund of Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University [MZKF202003]; Lanzhou Science and Technology Bureau, science and technology planning project of Lanzhou [2020-XG-59]	Basic and Clinical Cooperative Research Promotion Program of Anhui Medical University; Anhui Medical University; Open Research fund of Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University; Lanzhou Science and Technology Bureau, science and technology planning project of Lanzhou	This work was supported by the Basic and Clinical Cooperative Research Promotion Program of Anhui Medical University (2020xkjT046), the research fund of Anhui Medical University (2019xkj144), the Open Research fund of Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University (MZKF202003), Lanzhou Science and Technology Bureau, science and technology planning project of Lanzhou (2020-XG-59).	Bao SY, 2005, AM J PHYSIOL-LUNG C, V288, pL36, DOI 10.1152/ajplung.00309.2003; Bertelsen H, 1999, WORLD REV NUTR DIET, V85, P98; Chen JY, 2020, CELL RES, V30, P708, DOI 10.1038/s41422-020-0369-7; Dupuis J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242318; Durante M, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.650962; Goncalves-de-Albuquerque CF, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/260465; Guo Q, 2018, BIORESOURCE TECHNOL, V247, P940, DOI 10.1016/j.biortech.2017.09.187; Gupte VV, 2009, AM J RESP CRIT CARE, V180, P424, DOI 10.1164/rccm.200811-1794OC; Han XM, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9433; Hogan BLM, 2014, CELL STEM CELL, V15, P123, DOI 10.1016/j.stem.2014.07.012; Jiang P, 2020, AM J RESP CRIT CARE, V201, P1443, DOI 10.1164/rccm.201909-1726LE; Jiang ZL, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0707-6; Jung SY, 2014, EXP THER MED, V7, P587, DOI 10.3892/etm.2013.1451; Kumar KP, 2018, CELL TISSUE RES, V371, P551, DOI 10.1007/s00441-017-2753-2; Lai JP, 2007, BRIT J PHARMACOL, V152, P1172, DOI 10.1038/sj.bjp.0707501; Lai JP, 2009, BRIT J PHARMACOL, V156, P189, DOI 10.1111/j.1476-5381.2008.00020.x; Levin Gilbert V., 2002, Journal of Medicinal Food, V5, P23, DOI 10.1089/109662002753723197; Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0; Mendez MP, 2008, AM J PHYSIOL-LUNG C, V294, pL807, DOI 10.1152/ajplung.00398.2007; Meyer NJ, 2021, LANCET, V398, P622, DOI 10.1016/S0140-6736(21)00439-6; Peng LY, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01613; Potey PMD, 2019, J PATHOL, V247, P672, DOI 10.1002/path.5221; Riemondy KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123637; Rothberg AD, 2021, J MED CASE REP, V15, DOI 10.1186/s13256-021-03161-1; Scott BNV, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01274-2018; Silva JD, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.02978-2020; Tu KS, 2016, INT J ONCOL, V48, P965, DOI 10.3892/ijo.2015.3309; Wanarska M, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-113; Wu HJ, 2020, CELL, V180, P107, DOI 10.1016/j.cell.2019.11.027; Zhang J, 2017, CELL REP, V20, P549, DOI 10.1016/j.celrep.2017.06.054; Zhang QH, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9866	31	1	1	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2022	13								928312	10.3389/fimmu.2022.928312	http://dx.doi.org/10.3389/fimmu.2022.928312			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	4Z3ZE	36189316	Green Published, Green Submitted, gold			2022-12-18	WOS:000862150400001
J	Kong, JQ; Lu, SH; Zhang, L; Yao, YH; Zhang, J; Shen, ZF; Luo, ML; Liu, B; Zheng, JJ; Lin, TX				Kong, Jianqiu; Lu, Sihong; Zhang, Long; Yao, Yuhui; Zhang, Jie; Shen, Zefeng; Luo, Mingli; Liu, Bin; Zheng, Junjiong; Lin, Tianxin			m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent	FRONTIERS IN IMMUNOLOGY			English	Article						m6A methylation regulators; urothelial carcinoma; PD1; PDL1; prediction; outcome	PD-L1 EXPRESSION; CTLA-4 BLOCKADE; CANCER; CELLS; PROGNOSIS; NIVOLUMAB; ANTIBODY; SAFETY	PurposeImmune checkpoint blockade agents were shown to provide a survival advantage in urothelial carcinoma, while some patients got minimal benefit or side effects. Therefore, we aimed to investigate the prognostic value of m6A methylation regulators, and developed a nomogram for predicting the response to atezolizumab in urothelial carcinoma patients. MethodsA total of 298 advanced urothelial carcinoma patients with response data in the IMvigor210 cohort were included. Differential expressions of 23 m6A methylation regulators in different treatment outcomes were conducted. Subsequently, a gene signature was developed in the training set using the least absolute shrinkage and selection operator (LASSO) regression. Based on the multivariable logistic regression, a nomogram was constructed by incorporating the gene signature and independent clinicopathological predictors. The performance of the nomogram was assessed by its discrimination, calibration, and clinical utility with internal validation. ResultsSix m6A methylation regulators, including IGF2BP1, IGF2BP3, YTHDF2, HNRNPA2B1, FMR1, and FTO, were significantly differentially expressed between the responders and non-responders. These six regulators were also significantly correlated with the treatment outcomes. Based on the LASSO regression analysis, the gene signature consisting of two selected m6A methylation regulators (FMR1 and HNRNPA2B1) was constructed and showed favorable discrimination. The nomogram integrating the gene signature, TMB, and PD-L1 expression on immune cells, showed favorable calibration and discrimination in the training set (AUC 0.768), which was confirmed in the validation set (AUC 0.755). Decision curve analysis confirmed the potential clinical usefulness of the nomogram. ConclusionsThis study confirmed the prognostic value of FMR1 and HNRNPA2B1, and constructed a nomogram for individualized prediction of the response to atezolizumab in patients with urothelial carcinoma, which may aid in making treatment strategies.	[Kong, Jianqiu; Lu, Sihong; Yao, Yuhui; Zhang, Jie; Shen, Zefeng; Luo, Mingli; Zheng, Junjiong; Lin, Tianxin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Urol, Guangzhou, Peoples R China; [Zhang, Long] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pathol, Guangzhou, Peoples R China; [Liu, Bin] Univ Arizona, Coll Med Phoenix, Dept Internal Med, Phoenix, AZ 85004 USA; [Lin, Tianxin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China; [Lin, Tianxin] Sun Yat Sen Mem Hosp, Guangdong Prov Clin Res Ctr Urol Dis, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; University of Arizona; Sun Yat Sen University; Sun Yat Sen University	Zheng, JJ; Lin, TX (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Urol, Guangzhou, Peoples R China.; Liu, B (corresponding author), Univ Arizona, Coll Med Phoenix, Dept Internal Med, Phoenix, AZ 85004 USA.; Lin, TX (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China.; Lin, TX (corresponding author), Sun Yat Sen Mem Hosp, Guangdong Prov Clin Res Ctr Urol Dis, Guangzhou, Peoples R China.	lintx@mail.sysu.edu.cn; zhengjj59@mail.sysu.edu.cn; binliu3@arizona.edu		Zheng, Junjiong/0000-0003-3594-8961; Shen, Zefeng/0000-0002-4279-4879	China Postdoctoral Science Foundation; National Natural Science Foundation of China; Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme; Guangdong Provincial Clinical Research Center for Urological Diseases; GuangDong Basic and Applied Basic Research Foundation;  [2021TQ0387];  [2021M703709];  [2022M713625];  [81825016];  [2020B1111170006];  [2020A1515111119]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme; Guangdong Provincial Clinical Research Center for Urological Diseases; GuangDong Basic and Applied Basic Research Foundation; ; ; ; ; ; 	Funding This study was supported by the China Postdoctoral Science Foundation (Grant No. 2021TQ0387, 2021M703709, 2022M713625), the National Natural Science Foundation of China (Grant No. 81825016), Project Supported by Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme (for TL), Guangdong Provincial Clinical Research Center for Urological Diseases (2020B1111170006), the GuangDong Basic and Applied Basic Research Foundation (Grant No. 2020A1515111119).	Alarcon CR, 2015, CELL, V162, P1299, DOI 10.1016/j.cell.2015.08.011; Arguello AE, 2017, J AM CHEM SOC, V139, P17249, DOI 10.1021/jacs.7b09213; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chen CH, 2020, J CLIN INVEST, V130, P404, DOI 10.1172/JCI130892; Chen M, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20192892; Cheng MS, 2019, ONCOGENE, V38, P3667, DOI 10.1038/s41388-019-0683-z; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; Cong R, 2021, TRANSL ANDROL UROL, V10, P662, DOI 10.21037/tau-20-963; Darb-Esfahani S, 2016, ONCOTARGET, V7, P1486, DOI 10.18632/oncotarget.6429; Edens BM, 2019, CELL REP, V28, P845, DOI 10.1016/j.celrep.2019.06.072; Edupuganti RR, 2017, NAT STRUCT MOL BIOL, V24, P870, DOI 10.1038/nsmb.3462; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Gao Q, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8849218; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Hsu PJ, 2019, J BIOL CHEM, V294, P19889, DOI 10.1074/jbc.AC119.010078; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jiang FJ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01066-6; Jin H, 2019, EBIOMEDICINE, V47, P195, DOI 10.1016/j.ebiom.2019.07.068; Jin Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.637933; Khoja L, 2017, ANN ONCOL, V28, P2377, DOI 10.1093/annonc/mdx286; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Lee JS, 2019, JAMA ONCOL, V5, P1614, DOI 10.1001/jamaoncol.2019.2311; Lenis AT, 2020, JAMA-J AM MED ASSOC, V324, P1980, DOI [10.1001/jama.2020.17601, 10.1001/jama.2020.17598]; Li JH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00769; Li XC, 2021, TRANSL ANDROL UROL, V10, P3402, DOI 10.21037/tau-21-562; Liu X, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01412-9; Liu ZZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.735170; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Paramasivam A, 2020, CELL MOL IMMUNOL, V17, P550, DOI 10.1038/s41423-019-0307-0; Paramasivam A, 2020, CELL MOL IMMUNOL, V17, P668, DOI 10.1038/s41423-020-0387-x; Paramasivam A, 2020, HYPERTENS RES, V43, P153, DOI 10.1038/s41440-019-0338-z; Pauken KE, 2019, TRENDS IMMUNOL, V40, P511, DOI 10.1016/j.it.2019.04.002; Peggs KS, 2007, CANCER CELL, V12, P192, DOI 10.1016/j.ccr.2007.08.023; Pinello N, 2018, CANCER BIOL MED, V15, P323, DOI 10.20892/j.issn.2095-3941.2018.0365; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Shilts J, 2022, NATURE, V608, P397, DOI 10.1038/s41586-022-05028-x; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Tong JY, 2018, CELL RES, V28, P253, DOI 10.1038/cr.2018.7; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tregunna R, 2021, NAT REV UROL, V18, P383, DOI 10.1038/s41585-021-00489-7; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Wang P, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.540186; Webb JR, 2016, GYNECOL ONCOL, V141, P293, DOI 10.1016/j.ygyno.2016.03.008; Witjes JA, 2021, EUR UROL, V79, P82, DOI 10.1016/j.eururo.2020.03.055; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Worpenberg L, 2021, EMBO J, V40, DOI 10.15252/embj.2020104975; Wu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1014-2; Xu WH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.709579; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yuan F, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.798583; Zhang FR, 2018, HUM MOL GENET, V27, P3936, DOI 10.1093/hmg/ddy292; Zhao HY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.650023; Zhao RR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653711; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	63	1	1	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2022	13								1014861	10.3389/fimmu.2022.1014861	http://dx.doi.org/10.3389/fimmu.2022.1014861			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5B4UM	36189296	gold, Green Published			2022-12-18	WOS:000863566100001
